PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Lundy, J; Gearing, LJ; Gao, H; West, AC; McLeod, L; Deswaerte, V; Yu, L; Porazinski, S; Pajic, M; Hertzog, PJ; Croagh, D; Jenkins, BJ				Lundy, Joanne; Gearing, Linden J.; Gao, Hugh; West, Alison C.; McLeod, Louise; Deswaerte, Virginie; Yu, Liang; Porazinski, Sean; Pajic, Marina; Hertzog, Paul J.; Croagh, Daniel; Jenkins, Brendan J.			TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article							TOLL-LIKE RECEPTORS; STELLATE CELLS; DIFFERENTIAL EXPRESSION; CANCER; IMMUNOTHERAPY; INFLAMMATION; GEMCITABINE; CARCINOMA; CARCINOGENESIS; IDENTIFICATION	Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor prognosis, and is plagued by a paucity of targeted treatment options and tumour resistance to chemotherapeutics. The causal link between chronic inflammation and PDAC suggests that molecular regulators of the immune system promote disease pathogenesis and/or therapeutic resistance, yet their identity is unclear. Here, we couple endoscopic ultrasound-guided fine-needle aspiration, which captures tumour biopsies from all stages, with whole transcriptome profiling of PDAC patient primary tumours to reveal enrichment of the innate immune Toll-like receptor 2 (TLR2) molecular pathway. Augmented TLR2 expression associated with a 4-gene "TLR2 activation" signature, and was prognostic for survival and predictive for gemcitabine-based chemoresistance. Furthermore, antibody-mediated anti-TLR2 therapy suppressed the growth of human PDAC tumour xenografts, independent of a functional immune system. Our results support TLR2-based therapeutic targeting for precision medicine in PDAC, with further clinical utility that TLR2 activation is prognostic and predictive for chemoresponsiveness.	[Lundy, Joanne; Gearing, Linden J.; West, Alison C.; McLeod, Louise; Deswaerte, Virginie; Yu, Liang; Hertzog, Paul J.; Croagh, Daniel; Jenkins, Brendan J.] Hudson Inst Med Res, Ctr Innate Immun & Infect Dis, Clayton, Vic, Australia; [Lundy, Joanne; Gearing, Linden J.; West, Alison C.; McLeod, Louise; Deswaerte, Virginie; Yu, Liang; Hertzog, Paul J.; Jenkins, Brendan J.] Monash Univ, Dept Mol & Translat Sci, Fac Med Nursing & Hlth Sci, Clayton, Vic, Australia; [Gao, Hugh; Croagh, Daniel] Monash Univ, Sch Clin Sci Monash Hlth, Dept Surg, Clayton, Vic, Australia; [Porazinski, Sean; Pajic, Marina] Kinghorn Canc Ctr, Garvan Inst Med Res, Darlinghurst, NSW, Australia; [Porazinski, Sean; Pajic, Marina] Univ New South Wales, St Vincents Clin Sch, Fac Med, Darlinghurst, NSW, Australia	Hudson Institute of Medical Research; Monash University; Monash University; Garvan Institute of Medical Research; University of New South Wales Sydney	Jenkins, BJ (corresponding author), Hudson Inst Med Res, Ctr Innate Immun & Infect Dis, Clayton, Vic, Australia.; Jenkins, BJ (corresponding author), Monash Univ, Dept Mol & Translat Sci, Fac Med Nursing & Hlth Sci, Clayton, Vic, Australia.	Brendan.Jenkins@hudson.org.au	Hertzog, Paul/I-7053-2013; Porazinski, Sean/M-6973-2015	Hertzog, Paul/0000-0002-1373-8472; Porazinski, Sean/0000-0003-3804-1150; McLeod, Louise/0000-0002-7595-6432; Gearing, Linden/0000-0003-3508-3056; Lundy, Joanne/0000-0003-0210-4930	Avner Pancreatic Cancer Foundation; CASS Foundation; Operational Infrastructure Support Program by the Victorian Government of Australia; NHMRC Senior Medical Research Fellowship	Avner Pancreatic Cancer Foundation; CASS Foundation; Operational Infrastructure Support Program by the Victorian Government of Australia; NHMRC Senior Medical Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	We are grateful to Angela Vais (Monash Histology Platform, Melbourne, Australia) for immunohistochemistry and immunofluorescence expertise. We also thank Trevor Wilson and Jodee Gould from the MHTP Medical Genomics Facility (Melbourne, Australia) for providing technical expertise and assistance with the AmpliSeq transcriptomics studies, as well as Minoti Apte (University of New South Wales, Australia) for kindly providing human pancreatic stellate cells. We also thank the Australian Pancreatic Cancer Genome Initiative, supported by an Avner Pancreatic Cancer Foundation Grant, for the provision of biospecimens. This work was supported by research grants awarded by the Avner Pancreatic Cancer Foundation and CASS Foundation, as well as the Operational Infrastructure Support Program by the Victorian Government of Australia. BJJ is supported by an NHMRC Senior Medical Research Fellowship.	Aguirre AJ, 2017, CANCER CELL, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Amrutkar M, 2017, CANCERS, V9, DOI 10.3390/cancers9110157; Apte MV, 2013, GASTROENTEROLOGY, V144, P1210, DOI 10.1053/j.gastro.2012.11.037; Bachem MG, 1998, GASTROENTEROLOGY, V115, P421, DOI 10.1016/S0016-5085(98)70209-4; Berry W, 2018, CANCERS, V10, DOI 10.3390/cancers10020035; Berry W, 2017, INT J CANCER, V140, P2331, DOI 10.1002/ijc.30648; Biankin AV, 2011, HUM GENET, V130, P79, DOI 10.1007/s00439-011-1010-0; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Carbon S, 2017, NUCLEIC ACIDS RES, V45, pD331, DOI 10.1093/nar/gkw1108; Cebrian MJG, 2016, ANTICANCER RES, V36, P4381, DOI 10.21873/anticanres.10981; Chang JH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005541; Chantrill LA, 2015, CLIN CANCER RES, V21, P2029, DOI 10.1158/1078-0432.CCR-15-0426; Chen XL, 2019, EBIOMEDICINE, V40, P135, DOI 10.1016/j.ebiom.2018.12.016; Chou A, 2018, GUT, V67, P2142, DOI 10.1136/gutjnl-2017-315144; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Flo TH, 2001, J LEUKOCYTE BIOL, V69, P474; Foroutan M, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2435-4; Garcea G, 2011, WORLD J SURG, V35, P868, DOI 10.1007/s00268-011-0984-z; Gay NJ, 2014, NAT REV IMMUNOL, V14, P546, DOI 10.1038/nri3713; Geller LT, 2017, SCIENCE, V357, P1156, DOI 10.1126/science.aah5043; Grimmig T, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122060; Grimmig T, 2015, INT J ONCOL, V47, P857, DOI 10.3892/ijo.2015.3069; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Guerra C, 2011, CANCER CELL, V19, P728, DOI 10.1016/j.ccr.2011.05.011; Hamzah J, 2009, J IMMUNOL, V183, P1091, DOI 10.4049/jimmunol.0900736; Hao L, 2017, DIGEST LIVER DIS, V49, P1249, DOI 10.1016/j.dld.2017.07.001; Jheng HF, 2015, DIS MODEL MECH, V8, P1311, DOI 10.1242/dmm.019398; Kamisawa T, 2016, LANCET, V388, P73, DOI 10.1016/S0140-6736(16)00141-0; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kennedy CL, 2014, ONCOGENE, V33, P2540, DOI 10.1038/onc.2013.205; Knudsen ES, 2017, CLIN CANCER RES, V23, P4429, DOI 10.1158/1078-0432.CCR-17-0162; Lanki Mira A, 2018, Tumour Biol, V40, p1010428318801188, DOI 10.1177/1010428318801188; Leppanen J, 2017, VIRCHOWS ARCH, V470, P401, DOI 10.1007/s00428-017-2087-1; Li WL, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-2270-1; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Liu RJ, 2015, NUCLEIC ACIDS RES, V43, pE97, DOI 10.1093/nar/gkv412; Liu YD, 2019, INT J CANCER, V144, P3056, DOI 10.1002/ijc.32060; McCarthy DJ, 2009, BIOINFORMATICS, V25, P765, DOI 10.1093/bioinformatics/btp053; Nevala-Plagemann C, 2020, NAT REV CLIN ONCOL, V17, P108, DOI 10.1038/s41571-019-0281-6; Ochi A, 2012, J CLIN INVEST, V122, P4118, DOI 10.1172/JCI63606; Ochi A, 2012, J EXP MED, V209, P1671, DOI 10.1084/jem.20111706; Pearson Todd, 2008, Curr Protoc Immunol, VChapter 15, DOI 10.1002/0471142735.im1521s81; Pramanik KC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123890; Pratesi G, 2005, CANCER RES, V65, P6388, DOI 10.1158/0008-5472.CAN-05-0602; Principe DR, 2020, CANCER RES, V80, P3101, DOI 10.1158/0008-5472.CAN-19-2959; Pu N, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.10.91; Pushalkar S, 2018, CANCER DISCOV, V8, P403, DOI 10.1158/2159-8290.CD-17-1134; R Core Team, 2018, R LANGUAGE ENV STAT; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rosa R, 2011, CLIN CANCER RES, V17, P6531, DOI 10.1158/1078-0432.CCR-10-3376; Roshani R, 2014, CANCER LETT, V345, P157, DOI 10.1016/j.canlet.2013.07.014; Saad MI, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201809976; Schmidt J, 2007, BRIT J CANCER, V97, P598, DOI 10.1038/sj.bjc.6603903; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Sean D, 2007, BIOINFORMATICS, V23, P1846, DOI 10.1093/bioinformatics/btm254; Seya T, 2015, CANCER SCI, V106, P1659, DOI 10.1111/cas.12824; Sperb N, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155486; Steele CW, 2016, WORLD J GASTRO ONCOL, V8, P380, DOI 10.4251/wjgo.v8.i4.380; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun QQ, 2018, THERANOSTICS, V8, P5072, DOI 10.7150/thno.26546; Thind K, 2017, THER ADV GASTROENTER, V10, P168, DOI 10.1177/1756283X16667909; Torphy RJ, 2018, ANN GASTROENT SURG, V2, P274, DOI 10.1002/ags3.12176; Tye H, 2013, CANCER SCI, V104, P1139, DOI 10.1111/cas.12205; Tye H, 2012, CANCER CELL, V22, P466, DOI 10.1016/j.ccr.2012.08.010; Urban-Wojciuk Z, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02388; Vaz J, 2014, WORLD J GASTROENTERO, V20, P5808, DOI 10.3748/wjg.v20.i19.5808; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; West AC, 2017, ONCOGENE, V36, P5134, DOI 10.1038/onc.2017.121; West AC, 2015, CURR PHARM DESIGN, V21, P2968, DOI 10.2174/1381612821666150514104411; Witkiewicz AK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7744; Wolpin BM, 2014, NAT GENET, V46, P994, DOI 10.1038/ng.3052; Wu D, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks461; Xu CM, 2020, J ADV RES, V24, P139, DOI 10.1016/j.jare.2020.03.009; Zambirinis CP, 2015, J EXP MED, V212, P2077, DOI 10.1084/jem.20142162	77	5	5	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2021	40	41					6007	6022		10.1038/s41388-021-01992-2	http://dx.doi.org/10.1038/s41388-021-01992-2		AUG 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WH0WV	34400766				2022-12-17	WOS:000685396300002
J	Qiao, S; Lu, WH; Glorieux, C; Li, JJ; Zeng, PT; Meng, N; Zhang, HQ; Wen, SJ; Huang, P				Qiao, Shuang; Lu, Wenhua; Glorieux, Christophe; Li, Jiangjiang; Zeng, Peiting; Meng, Ning; Zhang, Huiqin; Wen, Shijun; Huang, Peng			Wild-type IDH2 protects nuclear DNA from oxidative damage and is a potential therapeutic target in colorectal cancer	ONCOGENE			English	Article							ISOCITRATE DEHYDROGENASE; CELLS; MITOCHONDRIA; MUTATIONS; PROMOTES; STRESS; APOPTOSIS; INVASION; GENES; ROS	Although the role of isocitrate dehydrogenase (IDH) mutation in promoting cancer development has been well-characterized, the impact of wild-type IDH on cancer cells remains unclear. Here we show that the wild-type isocitrate dehydrogenase 2 (IDH2) is highly expressed in colorectal cancer (CRC) cells, and plays an unexpected role in protecting the cancer cells from oxidative damage. Genetic abrogation of IDH2 in CRC cells leads to reactive oxygen species (ROS)-mediated DNA damage and an accumulation of 8-oxoguanine with DNA strand breaks, which activates DNA damage response (DDR) with elevated gamma H2AX and phosphorylation of ataxia telangiectasia-mutated (ATM) protein, leading to a partial cell cycle arrest and eventually cell senescence. Mechanistically, the suppression of IDH2 results in a reduction of the tricarboxylic acid (TCA) cycle activity due to a decrease in the conversion of isocitrate to alpha-ketoglutarate (alpha-KG) with a concurrent decrease in NADPH production, leading to ROS accumulation and oxidative DNA damage. Importantly, abrogation of IDH2 inhibits CRC cell growth in vitro and in vivo, and renders CRC cells more vulnerable to DNA-damaging drugs. Screening of an FDA-approved drug library has identified oxaliplatin as a compound highly effective against CRC cells when IDH2 was suppressed. Our study has uncovered an important role of the wild-type IDH2 in protecting DNA from oxidative damage, and provides a novel biochemical basis for developing metabolic intervention strategy for cancer treatment.	[Qiao, Shuang; Lu, Wenhua; Glorieux, Christophe; Li, Jiangjiang; Zeng, Peiting; Meng, Ning; Zhang, Huiqin; Wen, Shijun; Huang, Peng] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol Southern China, Canc Ctr, Guangzhou, Peoples R China; [Wen, Shijun; Huang, Peng] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou, Peoples R China; [Huang, Peng] Sun Yat Sen Univ, Metab Innovat Canc, Guangzhou, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Wen, SJ; Huang, P (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol Southern China, Canc Ctr, Guangzhou, Peoples R China.; Wen, SJ; Huang, P (corresponding author), Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou, Peoples R China.; Huang, P (corresponding author), Sun Yat Sen Univ, Metab Innovat Canc, Guangzhou, Peoples R China.	wenshj@sysucc.org.cn; huangpeng@sysucc.org.cn	; Wen, Shijun/Q-2571-2015	QIAO, Shuang/0000-0002-9095-4128; Wen, Shijun/0000-0002-9347-8243	National Key R&D Program of China [2020YFA0803300, 2018YFC0910203]; National Natural Science Foundation of China [81872440, 81672952]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We would like to thank Yanyu Zhang, Mingquan Zhang and Bing-ling Luo for technical assistance, Haijing Deng and Dr. Hui Zhang for helpful discussions. Some of the cartoons in this article were created using the drawing tools provided by BioRender (https://biorender.com).This work was support in part by grants from the National Key R&D Program of China (2020YFA0803300, 2018YFC0910203), and from the National Natural Science Foundation of China (81872440, 81672952).	Altenberg B, 2004, GENOMICS, V84, P1014, DOI 10.1016/j.ygeno.2004.08.010; Bergaggio E, 2019, CANCERS, V11, DOI 10.3390/cancers11040563; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Cha H, 2017, REDOX BIOL, V13, P32, DOI 10.1016/j.redox.2017.05.009; DALZIEL K, 1980, FEBS LETT, V117, pK45, DOI 10.1016/0014-5793(80)80569-2; Dang L, 2017, ANNU REV BIOCHEM, V86, P305, DOI 10.1146/annurev-biochem-061516-044732; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jezek P, 2020, ANTIOXID REDOX SIGN, V33, P903, DOI 10.1089/ars.2019.7902; King A, 2006, ONCOGENE, V25, P4675, DOI 10.1038/sj.onc.1209594; Klaunig JE, 2018, CURR PHARM DESIGN, V24, P4771, DOI 10.2174/1381612825666190215121712; Kong MJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0537-6; Li JJ, 2018, THERANOSTICS, V8, P4050, DOI 10.7150/thno.21524; Liu WR, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-32; Luo J, 2005, NEUROCHEM INT, V47, P449, DOI 10.1016/j.neuint.2005.07.002; Lv Q, 2012, EXP THER MED, V4, P801, DOI 10.3892/etm.2012.676; Matt S, 2016, CELL MOL LIFE SCI, V73, P2829, DOI 10.1007/s00018-016-2130-4; McBrayer SK, 2018, CELL, V175, P101, DOI 10.1016/j.cell.2018.08.038; Molenaar RJ, 2018, ONCOGENE, V37, P1949, DOI 10.1038/s41388-017-0077-z; Molenaar RJ, 2018, CLIN CANCER RES, V24, P1705, DOI 10.1158/1078-0432.CCR-17-2796; Molenaar RJ, 2015, CANCER RES, V75, P4790, DOI 10.1158/0008-5472.CAN-14-3603; Montalban-Bravo G, 2018, FUTURE ONCOL, V14, P979, DOI 10.2217/fon-2017-0523; Neuzil J, 2006, FEBS LETT, V580, P5125, DOI 10.1016/j.febslet.2006.05.072; Ott M, 2007, APOPTOSIS, V12, P913, DOI 10.1007/s10495-007-0756-2; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Salehi F, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32308-2; Short NJ, 2020, CANCER DISCOV, V10, P506, DOI 10.1158/2159-8290.CD-19-1011; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Sulkowski PL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2463; Tian GY, 2015, CELL PHYSIOL BIOCHEM, V37, P2405, DOI 10.1159/000438593; Torrens-Mas M, 2017, J CELL BIOCHEM, V118, P397, DOI 10.1002/jcb.25653; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Waitkus MS, 2018, CANCER CELL, V34, P186, DOI 10.1016/j.ccell.2018.04.011; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3; Wu DD, 2016, TUMOR BIOL, V37, P5225, DOI 10.1007/s13277-015-4358-2; Wu LL, 2004, CLIN CHIM ACTA, V339, P1, DOI 10.1016/j.cccn.2003.09.010; Yan H, 2009, CANCER RES, V69, P9157, DOI 10.1158/0008-5472.CAN-09-2650; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yang H, 2012, CLIN CANCER RES, V18, P5562, DOI 10.1158/1078-0432.CCR-12-1773; Yang YH, 2016, J CELL PHYSIOL, V231, P2570, DOI 10.1002/jcp.25349; Yen KE, 2010, ONCOGENE, V29, P6409, DOI 10.1038/onc.2010.444; Zhou LS, 2016, EMBO REP, V17, P811, DOI 10.15252/embr.201541643	47	5	5	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2021	40	39					5880	5892		10.1038/s41388-021-01968-2	http://dx.doi.org/10.1038/s41388-021-01968-2		AUG 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UZ8WB	34349242				2022-12-17	WOS:000681143600002
J	Garcia-Dominguez, DJ; Hajji, N; Sanchez-Molina, S; Figuerola-Bou, E; de Pablos, RM; Espinosa-Oliva, AM; Andres-Leon, E; Terron-Camero, LC; Flores-Campos, R; Pascual-Pasto, G; Robles, MJ; Carcaboso, AM; Mora, J; de Alava, E; Hontecillas-Prieto, L; Machado, I; Llombart-Bosch, A; Magagnoli, G; Scotlandi, K				Garcia-Dominguez, Daniel J.; Hajji, Nabil; Sanchez-Molina, Sara; Figuerola-Bou, Elisabet; de Pablos, Rocio M.; Espinosa-Oliva, Ana M.; Andres-Leon, Eduardo; Terron-Camero, Laura Carmen; Flores-Campos, Rocio; Pascual-Pasto, Guillem; Robles, Maria Jose; Carcaboso, Angel M.; Mora, Jaume; de Alava, Enrique; Hontecillas-Prieto, Lourdes; Machado, Isidro; Llombart-Bosch, Antonio; Magagnoli, Giovanna; Scotlandi, Katia			Selective inhibition of HDAC6 regulates expression of the oncogenic driver EWSR1-FLI1 through the EWSR1 promoter in Ewing sarcoma	ONCOGENE			English	Article							HISTONE DEACETYLASE 6; EWS-FLI1; SP1; OVEREXPRESSION; PROLIFERATION; TRANSCRIPTION; COMBINATION; MECHANISMS; REPRESSION; BORTEZOMIB	Ewing sarcoma (EWS) is an aggressive bone and soft tissue tumor of children and young adults in which the principal driver is a fusion gene, EWSR1-FLI1. Although the essential role of EWSR1-FLI1 protein in the regulation of oncogenesis, survival, and tumor progression processes has been described in-depth, little is known about the regulation of chimeric fusion-gene expression. Here, we demonstrate that the active nuclear HDAC6 in EWS modulates the acetylation status of specificity protein 1 (SP1), consequently regulating the SP1/P300 activator complex binding to EWSR1 and EWSR1-FLI1 promoters. Selective inhibition of HDAC6 impairs binding of the activator complex SP1/P300, thereby inducing EWSR1-FLI1 downregulation and significantly reducing its oncogenic functions. In addition, sensitivity of EWS cell lines to HDAC6 inhibition is higher than other tumor or non-tumor cell lines. High expression of HDAC6 in primary EWS tumor samples from patients correlates with a poor prognosis in two independent series accounting 279 patients. Notably, a combination treatment of a selective HDAC6 and doxorubicin (a DNA damage agent used as a standard therapy of EWS patients) dramatically inhibits tumor growth in two EWS murine xenograft models. These results could lead to suitable and promising therapeutic alternatives for patients with EWS.	[Garcia-Dominguez, Daniel J.; de Pablos, Rocio M.; Espinosa-Oliva, Ana M.; Flores-Campos, Rocio; Robles, Maria Jose; de Alava, Enrique; Hontecillas-Prieto, Lourdes] Univ Seville, CIBERONC, Inst Biomed Seville IBiS, Hosp Univ Virgen Rocio,CSIC, Seville, Spain; [Hajji, Nabil] Imperial Coll London, Div Brain Sci, London, England; [Sanchez-Molina, Sara; Figuerola-Bou, Elisabet; Mora, Jaume] Hosp St Joan Deu, Dev Tumour Biol Lab, Barcelona, Spain; [de Pablos, Rocio M.; Espinosa-Oliva, Ana M.] Univ Seville, Fac Pharm, Dept Biochem & Mol Biol, Seville, Spain; [Andres-Leon, Eduardo; Terron-Camero, Laura Carmen] Consejo Super Invest Cient IPBLN CSIC, Bioinformat Unit, Inst Parasitol & Biomed Lopez Neyra, Granada, Spain; [Pascual-Pasto, Guillem; Carcaboso, Angel M.] Hosp St Joan de Deu, Pediat Hematol & Oncol, Inst Recerca St Joan de Deu, Barcelona, Spain; [Robles, Maria Jose; de Alava, Enrique] Univ Seville, CIBERONC, Pathol Unit, Hosp Univ Virgen Rocio,CSIC, Seville, Spain; [Machado, Isidro] Inst Valenciano Oncol, Pathol Dept, Valencia, Spain; [Llombart-Bosch, Antonio] Univ Valencia, Pathol Dept, Valencia, Spain; [Magagnoli, Giovanna] IRCCS Ist Ortoped Rizzoli, Dept Pathol, Bologna, Italy; [Scotlandi, Katia] IRRCS Ist Ortoped Rizzoli, Expt Oncol Lab, Bologna, Italy; [de Alava, Enrique] Univ Seville, Sch Med, Dept Normal & Pathol Cytol & Histol, Seville, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital; Imperial College London; University of Barcelona; University of Sevilla; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); University of Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; Virgen del Rocio University Hospital; Instituto Valenciano De Oncologia; University of Valencia; University of Sevilla	Garcia-Dominguez, DJ; de Alava, E; Hontecillas-Prieto, L (corresponding author), Univ Seville, CIBERONC, Inst Biomed Seville IBiS, Hosp Univ Virgen Rocio,CSIC, Seville, Spain.; Hajji, N (corresponding author), Imperial Coll London, Div Brain Sci, London, England.; de Alava, E (corresponding author), Univ Seville, CIBERONC, Pathol Unit, Hosp Univ Virgen Rocio,CSIC, Seville, Spain.; de Alava, E (corresponding author), Univ Seville, Sch Med, Dept Normal & Pathol Cytol & Histol, Seville, Spain.	dgarcia-ibis@us.es; n.hajji@imperial.ac.uk; enrique.alava.sspa@juntadeandalucia.es; lhontecillas-ibis@us.es	Andrés-León., Eduardo/K-8944-2014; de Alava, Enrique/GOH-0368-2022; Garcia, Daniel Jose/B-5366-2016; Scotlandi, Katia/J-9009-2016; Sanchez-Molina, Sara/B-2148-2017; magagnoli, giovanna/D-1723-2019	Andrés-León., Eduardo/0000-0002-0621-9914; de Alava, Enrique/0000-0001-8400-046X; Garcia, Daniel Jose/0000-0001-8150-2747; Scotlandi, Katia/0000-0001-6114-9499; Carcaboso, Angel/0000-0002-8485-426X; Sanchez-Molina, Sara/0000-0002-1430-131X; Figuerola-Bou, Elisabet/0000-0002-6839-9586; Flores-Campos, Rocio/0000-0002-2563-4136; magagnoli, giovanna/0000-0002-6430-1318; Pascual-Pasto, Guillem/0000-0001-8537-261X; Hajji, Nabil/0000-0002-0695-920X	Asociacion Espanola Contra el Cancer (AECC); Ministry of Science of Spain-FEDER (CIBERONC) [PI1700464, PI2000003, RD06/0020/0059]; CIBERONC [CB16/12/00361]; Consejeria de Salud, Junta de Andalucia [PI-0197-2016, PI-0013-2018, ECAI F2-0012-2018]	Asociacion Espanola Contra el Cancer (AECC); Ministry of Science of Spain-FEDER (CIBERONC); CIBERONC; Consejeria de Salud, Junta de Andalucia(Junta de Andalucia)	Research in the E.D.A. lab is supported by Asociacion Espanola Contra el Cancer (AECC), the Ministry of Science of Spain-FEDER (CIBERONC, PI1700464, PI2000003, RD06/0020/0059)S. D.G.D. and L.H.P. are supported by CIBERONC (CB16/12/00361). D.G.D., M.J.R. and L.H.P. are PhD researchers funded by the Consejeria de Salud, Junta de Andalucia (PI-0197-2016, ECAI F2-0012-2018 and PI-0013-2018, respectively).	Abdul-Salam VB, 2020, NOVEL NUCLEAR ROLE H, DOI [DOI 10.1101/2020.11.02.356121V1, 10.1101/2020.11.02.356121v1]; Amengual JE, 2015, CLIN CANCER RES, V21, P4663, DOI 10.1158/1078-0432.CCR-14-3068; Azahri NSM, 2012, J CELL BIOCHEM, V113, P2597, DOI 10.1002/jcb.24135; Ban J, 2011, ONCOGENE, V30, P2173, DOI 10.1038/onc.2010.581; Beishline K, 2015, FEBS J, V282, P224, DOI 10.1111/febs.13148; Cao JL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0788-2; de Nigris F, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115605; Formisano L, 2015, J NEUROSCI, V35, P7332, DOI 10.1523/JNEUROSCI.2174-14.2015; Furumai R, 2002, CANCER RES, V62, P4916; Garcia-Dominguez DJ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234243; Garcia-Dominguez Daniel Jose, 2018, Oncotarget, V9, P31397, DOI 10.18632/oncotarget.25829; Giorgi C, 2015, ONCOTARGET, V6, P28895, DOI 10.18632/oncotarget.5000; Grunewald TGP, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0003-x; Herrero-Martin D, 2009, BRIT J CANCER, V101, P80, DOI 10.1038/sj.bjc.6605104; Hontecillas-Prieto L, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.578011; Huang PY, 2017, ONCOTARGET, V8, P2694, DOI 10.18632/oncotarget.13738; Hung JJ, 2006, MOL CELL BIOL, V26, P1770, DOI 10.1128/MCB.26.5.1770-1785.2006; Kanno K, 2012, ONCOL REP, V28, P867, DOI 10.3892/or.2012.1898; Keskin T, 2020, CELL REP, V30, P4567, DOI 10.1016/j.celrep.2019.12.053; Lee DH, 2018, INT J ONCOL, V53, P844, DOI 10.3892/ijo.2018.4405; Lee YS, 2008, CANCER RES, V68, P7561, DOI 10.1158/0008-5472.CAN-08-0188; Liu YJ, 2012, J BIOL CHEM, V287, P29168, DOI 10.1074/jbc.M112.371120; Llombart-Bosch A, 2009, VIRCHOWS ARCH, V455, P397, DOI 10.1007/s00428-009-0842-7; Machado I, 2018, VIRCHOWS ARCH, V472, P815, DOI 10.1007/s00428-018-2316-2; Mackintosh C, 2012, ONCOGENE, V31, P1287, DOI 10.1038/onc.2011.317; Martinez-Lage M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18875-x; Moller E, 2009, ONCOL REP, V21, P641, DOI 10.3892/or_00000267; Montoya C, 2020, ONCOL REP, V43, P1199, DOI 10.3892/or.2020.7489; Nacev BA, 2020, NAT REV CANCER, V20, P608, DOI 10.1038/s41568-020-0288-4; Negmeldin AT, 2017, ACS MED CHEM LETT, V8, P281, DOI 10.1021/acsmedchemlett.6b00124; Pattenden SG, 2016, P NATL ACAD SCI USA, V113, P3018, DOI 10.1073/pnas.1521827113; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Ray A, 2018, LEUKEMIA, V32, P843, DOI 10.1038/leu.2017.322; Riggi N, 2014, CANCER CELL, V26, P668, DOI 10.1016/j.ccell.2014.10.004; Sakimura R, 2005, INT J CANCER, V116, P784, DOI 10.1002/ijc.21069; Sanchez-Molina S, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba3058; Sankar S, 2013, ONCOGENE, V32, P5089, DOI 10.1038/onc.2012.525; Santo L, 2012, BLOOD, V119, P2579, DOI 10.1182/blood-2011-10-387365; Scotlandi K, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040968; Seidel C, 2015, EPIGENOMICS-UK, V7, P103, DOI [10.2217/EPI.14.69, 10.2217/epi.14.69]; Sun YJ, 2018, CURR TOP MED CHEM, V18, P2420, DOI 10.2174/1568026619666181210152115; Tang F, 2017, CANCER TREAT REV, V59, P33, DOI 10.1016/j.ctrv.2017.06.006; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Waby JS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-275; Wang XX, 2018, EUR J MED CHEM, V143, P1406, DOI 10.1016/j.ejmech.2017.10.040; Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049; Wang ZH, 2016, CANCER LETT, V379, P134, DOI 10.1016/j.canlet.2016.06.001; Yang CJ, 2015, ONCOTARGET, V6, P30263, DOI 10.18632/oncotarget.4749; Yee AJ, 2016, LANCET ONCOL, V17, P1569, DOI 10.1016/S1470-2045(16)30375-8; Zhang Y, 2008, MOL CELL BIOL, V28, P1688, DOI 10.1128/MCB.01154-06	50	5	5	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2021	40	39					5843	5853		10.1038/s41388-021-01974-4	http://dx.doi.org/10.1038/s41388-021-01974-4		AUG 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UZ8WB	34345016	Green Published, hybrid			2022-12-17	WOS:000681523500004
J	Fan, XY; Wang, YT; Jiang, TH; Liu, T; Jin, YL; Du, KL; Niu, YL; Zhang, CX; Liu, ZY; Lei, YL; Bu, YQ				Fan, Xiaoyan; Wang, Yitao; Jiang, Tinghui; Liu, Tao; Jin, Yuelei; Du, Kailong; Niu, Yulong; Zhang, Chunxue; Liu, Zhongyu; Lei, Yunlong; Bu, Youquan			B-Myb accelerates colorectal cancer progression through reciprocal feed-forward transactivation of E2F2	ONCOGENE			English	Article							TRANSCRIPTION FACTORS; HEPATOCELLULAR-CARCINOMA; GENE-EXPRESSION; CELL; PROLIFERATION; CONTRIBUTES; OVEREXPRESSION; ACTIVATION; CYCLIN-D1; FAMILY	B-Myb is an important transcription factor that plays a critical role in gene expression regulation and tumorigenesis. However, its functional implication in colorectal cancer remains elusive. In this study, we found that B-Myb was significantly upregulated at both mRNA and protein levels in colorectal cancer samples compared to non-tumor counterparts. B-Myb overexpression accelerated cell proliferation, cell cycle progression and cell motility in colorectal cancer cells, and promoted tumor growth in orthotopic nude mouse models in vivo. In contrast, B-Myb depletion inhibited these malignant phenotypes. Mechanistic investigations revealed that E2F2 was a novel transcriptional target of B-Myb and is essential to B-Myb-induced malignant phenotypes. Notably, B-Myb and E2F2 exhibited positive expression correlation, and interacted with each other in colorectal cancer cells. In addition to their autoregulatory mechanisms, B-Myb and E2F2 can also directly transactivate each other, thus constituting consolidated reciprocal feed-forward transactivation loops. Moreover, both B-Myb and E2F2 are required for the activation of ERK and AKT signaling pathways in colorectal cancer cells. Taken together, our data clarified a critical role for B-Myb in colorectal cancer and unraveled an exquisite mutual collaboration and reciprocal cross regulation between B-Myb and E2F2 that contribute to the malignant progression of human colorectal cancer.	[Fan, Xiaoyan; Wang, Yitao; Jiang, Tinghui; Liu, Tao; Jin, Yuelei; Du, Kailong; Zhang, Chunxue; Lei, Yunlong; Bu, Youquan] Chongqing Med Univ, Dept Biochem & Mol Biol, Coll Basic Med Sci, Chongqing 400016, Peoples R China; [Wang, Yitao; Jin, Yuelei; Niu, Yulong; Liu, Zhongyu; Lei, Yunlong; Bu, Youquan] Chongqing Med Univ, Canc Res Ctr, Mol Med, Chongqing 400016, Peoples R China; [Fan, Xiaoyan] Taizhou Univ, Taizhou Univ Hosp, Dermopath Res Inst, Taizhou, Peoples R China	Chongqing Medical University; Chongqing Medical University; Taizhou University	Lei, YL; Bu, YQ (corresponding author), Chongqing Med Univ, Dept Biochem & Mol Biol, Coll Basic Med Sci, Chongqing 400016, Peoples R China.; Lei, YL; Bu, YQ (corresponding author), Chongqing Med Univ, Canc Res Ctr, Mol Med, Chongqing 400016, Peoples R China.	leiyunlong@126.com; buyqcn@cqmu.edu.cn	Niu, Yulong/GQI-0688-2022	Niu, Yulong/0000-0002-1361-6272; yi tao, wang/0000-0002-1516-4548; Lei, Yunlong/0000-0002-7918-0221	National Natural Science Foundation of China [81672301, 81872014]; Basic Sciences and Advanced Technology Key Project of CQ CSTC [cstc2017jcyjBX0069]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Basic Sciences and Advanced Technology Key Project of CQ CSTC	This work was supported in part by grants-in-aid from the National Natural Science Foundation of China (No. 81672301 to YB and no. 81872014 to YL), the Basic Sciences and Advanced Technology Key Project of CQ CSTC (No. cstc2017jcyjBX0069). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank Prof. David P. Molloy for checking the language of our manuscript.	Bayley R, 2020, BBA-REV CANCER, V1874, DOI 10.1016/j.bbcan.2020.188407; Blais A, 2005, GENE DEV, V19, P1499, DOI 10.1101/gad.1325605; Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; Calvisi DF, 2011, HEPATOLOGY, V53, P1226, DOI 10.1002/hep.24174; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Cooper CS, 2006, LUNG CANCER, V54, P155, DOI 10.1016/j.lungcan.2006.07.005; Fan XY, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051479; Feng XF, 2017, ONCOTARGET, V8, P63605, DOI 10.18632/oncotarget.18868; Frau M, 2011, J HEPATOL, V55, P111, DOI 10.1016/j.jhep.2010.10.031; Huang CL, 2007, CLIN CANCER RES, V13, P6938, DOI 10.1158/1078-0432.CCR-07-1539; Ji Y, 2013, INT J BIOCHEM CELL B, V45, P645, DOI 10.1016/j.biocel.2012.12.002; Jiang M, 2016, MOL CELL BIOL, V36, P2945, DOI 10.1128/MCB.00370-16; Jin YL, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18060860; Joaquin M, 2003, CELL MOL LIFE SCI, V60, P2389, DOI 10.1007/s00018-003-3037-4; Kent LN, 2019, NAT REV CANCER, V19, P326, DOI 10.1038/s41568-019-0143-7; Kheirelseid EAH, 2013, J GASTROINTEST ONCOL, V4, P144, DOI 10.3978/j.issn.2078-6891.2013.010; Mega S, 2005, DIS ESOPHAGUS, V18, P109, DOI 10.1111/j.1442-2050.2005.00463.x; Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565; Mowla SN, 2014, AGING CELL, V13, P773, DOI 10.1111/acel.12242; Musa J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.244; Nientiedt M, 2021, J CANCER RES CLIN, V147, P129, DOI 10.1007/s00432-020-03392-7; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; O'Connell MJ, 2010, J CLIN ONCOL, V28, P3937, DOI 10.1200/JCO.2010.28.9538; Papetti M, 2011, AM J PHYSIOL-GASTR L, V301, pG508, DOI 10.1152/ajpgi.00066.2011; Reimer D, 2006, ANN NY ACAD SCI, V1091, P270, DOI 10.1196/annals.1378.073; Ren F, 2015, AM J CANCER RES, V5, P1542; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sandberg ML, 2005, DEV CELL, V8, P153, DOI 10.1016/j.devcel.2004.12.015; Scheijen B, 2004, J BIOL CHEM, V279, P10476, DOI 10.1074/jbc.M313682200; Sharma N, 2006, J BIOL CHEM, V281, P36124, DOI 10.1074/jbc.M604152200; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Thorner AR, 2009, ONCOGENE, V28, P742, DOI 10.1038/onc.2008.430; Timmers C, 2007, MOL CELL BIOL, V27, P65, DOI 10.1128/MCB.02147-06; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; Wang YT, 2015, BBA-GENE REGUL MECH, V1849, P1133, DOI 10.1016/j.bbagrm.2015.07.002; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Xanthoulis A, 2014, APPL IMMUNOHISTO M M, V22, P471, DOI 10.1097/PAI.0b013e3182598198; Xanthoulis A, 2013, WORLD J GASTROENTERO, V19, P3189, DOI 10.3748/wjg.v19.i21.3189; Zhou J, 2019, THERANOSTICS, V9, P5577, DOI 10.7150/thno.34663	39	5	5	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2021	40	37					5613	5625		10.1038/s41388-021-01961-9	http://dx.doi.org/10.1038/s41388-021-01961-9		JUL 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UR2PS	34316028	hybrid, Green Published			2022-12-17	WOS:000677949900001
J	Wang, J; Yan, HB; Zhang, Q; Liu, WY; Jiang, YH; Peng, G; Wu, FZ; Liu, X; Yang, PY; Liu, F				Wang, Jie; Yan, Hai-Bo; Zhang, Qian; Liu, Wei-Yan; Jiang, Ying-Hua; Peng, Gang; Wu, Fei-Zhen; Liu, Xin; Yang, Peng-Yuan; Liu, Feng			Enhancement of E-cadherin expression and processing and driving of cancer cell metastasis by ARID1A deficiency	ONCOGENE			English	Article							REMODELING GENE ARID1A; TUMOR-SUPPRESSOR; MUTATIONS; LANDSCAPE; INVASION; MIGRATION; CLEAVAGE; FRAGMENT; DOMAIN	The ARID1A gene, which encodes a subunit of the SWI/SNF chromatin remodeling complex, has been found to be frequently mutated in many human cancer types. However, the function and mechanism of ARID1A in cancer metastasis are still unclear. Here, we show that knockdown of ARID1A increases the ability of breast cancer cells to proliferate, migrate, invade, and metastasize in vivo. The ARID1A-related SWI/SNF complex binds to the second exon of CDH1 and negatively modulates the expression of E-cadherin/CDH1 by recruiting the transcriptional repressor ZEB2 to the CDH1 promoter and excluding the presence of RNA polymerase II. The silencing of CDH1 attenuated the migration, invasion, and metastasis of breast cancer cells in which ARID1A was silenced. ARID1A depletion increased the intracellular enzymatic processing of E-cadherin and the production of C-terminal fragment 2 (CTF2) of E-cadherin, which stabilized beta-catenin by competing for binding to the phosphorylation and degradation complex of beta-catenin. The matrix metalloproteinase inhibitor GM6001 inhibited the production of CTF2. In zebrafish and nude mice, ARID1A silencing or CTF2 overexpression activated beta-catenin signaling and promoted migration/invasion and metastasis of cancer cells in vivo. The inhibitors GM6001, BB94, and ICG-001 suppressed the migration and invasion of cancer cells with ARID1A-deficiency. Our findings provide novel insights into the mechanism of ARID1A metastasis and offer a scientific basis for targeted therapy of ARID1A-deficient cancer cells.	[Wang, Jie; Yan, Hai-Bo; Zhang, Qian; Liu, Wei-Yan; Jiang, Ying-Hua; Yang, Peng-Yuan; Liu, Feng] Fudan Univ, Minhang Hosp, Shanghai, Peoples R China; [Wang, Jie; Yan, Hai-Bo; Zhang, Qian; Liu, Wei-Yan; Jiang, Ying-Hua; Yang, Peng-Yuan; Liu, Feng] Fudan Univ, Int Colab Med Epigenet & Metab, Minist Sci & Technol, Inst Biomed Sci,Shanghai Key Lab Med Epigenet, Shanghai, Peoples R China; [Peng, Gang] Fudan Univ, Inst Brain Sci, Shanghai, Peoples R China; [Wu, Fei-Zhen; Yang, Peng-Yuan; Liu, Feng] Fudan Univ, Sch Basic Med Sci, Dept Syst Biol Med, Shanghai, Peoples R China; [Liu, Xin] Shanghai Univ Tradit Chinese Med, Shanghai Municipal Hosp Tradit Chinese Med, Dept Cent Lab Med, Shanghai, Peoples R China; [Yang, Peng-Yuan] Fudan Univ, Dept Chem, Shanghai, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University; Shanghai University of Traditional Chinese Medicine; Fudan University	Yang, PY; Liu, F (corresponding author), Fudan Univ, Minhang Hosp, Shanghai, Peoples R China.; Yang, PY; Liu, F (corresponding author), Fudan Univ, Int Colab Med Epigenet & Metab, Minist Sci & Technol, Inst Biomed Sci,Shanghai Key Lab Med Epigenet, Shanghai, Peoples R China.; Yang, PY; Liu, F (corresponding author), Fudan Univ, Sch Basic Med Sci, Dept Syst Biol Med, Shanghai, Peoples R China.; Yang, PY (corresponding author), Fudan Univ, Dept Chem, Shanghai, Peoples R China.	pyyang@fudan.edu.cn; liuf@fudan.edu.cn	Wu, Feizhen/AGR-5215-2022	Wang, Jie/0000-0002-4134-1624; peng, gang/0000-0001-6625-5426; LIU, Feng/0000-0003-1933-9437	National Natural Science Foundation of China (NSFC) [81572833, 22074020]; Chinese National Key Program on Basic Research Grant [2011CB910702, 2013CB911202]; Natural Science Foundation of Shanghai [14ZR1402100]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Chinese National Key Program on Basic Research Grant; Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai)	We acknowledge Yi-Yuan Ren, Jia-Hui Li, and Xiao-Qiang Chai for their helps in experiments. The work was supported by the National Natural Science Foundation of China (NSFC) (81572833, 22074020), Chinese National Key Program on Basic Research Grant (2011CB910702, 2013CB911202), and the Natural Science Foundation of Shanghai (14ZR1402100).	Berns K, 2016, CLIN CANCER RES, V22, P5238, DOI 10.1158/1078-0432.CCR-15-2996; Bitler BG, 2017, NAT CELL BIOL, V19, P962, DOI 10.1038/ncb3582; Chandler RL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7118; Cho HD, 2015, J BREAST CANCER, V18, P339, DOI 10.4048/jbc.2015.18.4.339; Fearon ER, 2003, CANCER CELL, V3, P307, DOI 10.1016/S1535-6108(03)00087-4; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Guan B, 2011, CANCER RES, V71, P6718, DOI 10.1158/0008-5472.CAN-11-1562; Guo X, 2018, ONCOGENE, V37, P5939, DOI 10.1038/s41388-018-0371-4; Helming KC, 2014, NAT MED, V20, P251, DOI 10.1038/nm.3480; Hu CB, 2018, J HEPATOL, V68, P465, DOI 10.1016/j.jhep.2017.10.028; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; Kim H, 2012, BBA-MOL BASIS DIS, V1822, P509, DOI 10.1016/j.bbadis.2011.12.015; Li C, 2017, NEOPLASMA, V64, P367, DOI 10.4149/neo_2017_307; Liang H, 2012, GENOME RES, V22, P2120, DOI 10.1101/gr.137596.112; Liang X, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-1007-x; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Marchio C, 2017, J PATHOL, V241, P405, DOI 10.1002/path.4837; Masliah-Planchon J, 2015, ANNU REV PATHOL-MECH, V10, P145, DOI 10.1146/annurev-pathol-012414-040445; Ng CKY, 2017, CLIN CANCER RES, V23, P3859, DOI 10.1158/1078-0432.CCR-16-2857; Noe V, 2001, J CELL SCI, V114, P111; Pinheiro H, 2012, HUM MOL GENET, V21, P4253, DOI 10.1093/hmg/dds248; Ryniers F, 2002, BIOL CHEM, V383, P159, DOI 10.1515/BC.2002.016; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Sanchez-Tillo E, 2011, AM J CANCER RES, V1, P897; Shen JF, 2015, CANCER DISCOV, V5, P752, DOI 10.1158/2159-8290.CD-14-0849; Simcha I, 2001, MOL BIOL CELL, V12, P1177, DOI 10.1091/mbc.12.4.1177; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Stewart DJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt356; Sun XX, 2016, CELL STEM CELL, V18, P456, DOI 10.1016/j.stem.2016.03.001; Svensson S, 2015, CLIN CANCER RES, V21, P3794, DOI 10.1158/1078-0432.CCR-15-0204; Tsurusaki Y, 2014, CLIN GENET, V85, P548, DOI 10.1111/cge.12225; Uncel M, 2019, EUR J BREAST HEALTH, V15, P125, DOI 10.5152/ejbh.2019.4677; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Cespedes MV, 2010, AM J PATHOL, V177, P2067, DOI 10.2353/ajpath.2010.100079; Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983; Williamson CT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13837; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Wu JN, 2013, CANCER DISCOV, V3, P35, DOI 10.1158/2159-8290.CD-12-0361; Xu GT, 2020, NAT GENET, V52, P198, DOI 10.1038/s41588-019-0554-0; Yan HB, 2014, CARCINOGENESIS, V35, P867, DOI 10.1093/carcin/bgt398; Zhang Q, 2016, ONCOTARGET, V7, P46127, DOI 10.18632/oncotarget.10060; Zhu M, 2019, CELL, V177, P608, DOI 10.1016/j.cell.2019.03.026	46	5	5	3	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2021	40	36					5468	5481		10.1038/s41388-021-01930-2	http://dx.doi.org/10.1038/s41388-021-01930-2		JUL 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO7MC	34290402				2022-12-17	WOS:000677857200003
J	Tang, J; Peng, WY; Feng, YX; Le, X; Wang, K; Xiang, Q; Li, LL; Wang, Y; Xu, C; Mu, JH; Xu, K; Ji, P; Tao, Q; Huang, AL; Deng, CX; Lin, Y; Xiang, TX				Tang, Jun; Peng, Weiyan; Feng, Yixiao; Le, Xin; Wang, Kang; Xiang, Qin; Li, Lili; Wang, Yan; Xu, Can; Mu, Junhao; Xu, Ke; Ji, Ping; Tao, Qian; Huang, Ailong; Deng, Chu-Xia; Lin, Yong; Xiang, Tingxiu			Cancer cells escape p53's tumor suppression through ablation of ZDHHC1-mediated p53 palmitoylation	ONCOGENE			English	Article							S-ACYLATION; PROTEIN; DNA; METHYLATION; ACETYLATION	The inactivation of tumor-suppressor genes contributes heavily to oncogenesis. The mutation of TP53 has been well-studied and recognized as a major factor in the development of tumors. Yet other means of p53 inactivation has not been well-elucidated. We previously identified a hypermethylated gene ZDHHC1 that suppresses tumor growth when the expression was restored, but the specific mechanism was yet to be found. The protein product of ZDHHC1 is an S-palmitoyltransferase and we have identified p53 as a substrate for ZDHHC1-mediated palmitoylation, specifically at the C135, C176, and C275 residues. The novel form of post-translational modification of p53 is required for the nuclear translocation of the tumor suppressor. p53 recruited DNMT3A to ZDHHC1 promoter and is responsible for the hypermethylation of ZDHHC1. The epigenetic feedback loop formed by ZDHHC1 and p53 sheds light on the inactivation of p53 without the presence of genetic mutations.	[Tang, Jun; Peng, Weiyan; Feng, Yixiao; Le, Xin; Wang, Kang; Xiang, Qin; Wang, Yan; Xu, Can; Mu, Junhao; Xu, Ke; Tao, Qian; Xiang, Tingxiu] Chongqing Med Univ, Affiliated Hosp 1, Chongqing Key Lab Mol Oncol & Epigenet, Chongqing, Peoples R China; [Li, Lili; Tao, Qian] Chinese Univ Hong Kong, Sir YK Pao Ctr Canc, Canc Epigenet Lab,Shatin, Dept Clin Oncol,State Key Lab Translat Oncol, Hong Kong, Peoples R China; [Li, Lili; Tao, Qian] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China; [Ji, Ping] Chongqing Med Univ, Affiliated Stomatol Hosp, Chongqing, Peoples R China; [Huang, Ailong] Chongqing Med Univ, Dept Infect Dis, MOE Key Lab Mol Biol Infect Dis, Chongqing, Peoples R China; [Deng, Chu-Xia] Univ Macau, Fac Hlth Sci, Macau, Peoples R China; [Lin, Yong] Lovelace Resp Res Inst, Albuquerque, NM USA	Chongqing Medical University; Chinese University of Hong Kong; Chinese University of Hong Kong; Chongqing Medical University; Chongqing Medical University; University of Macau; Lovelace Respiratory Research Institute	Xiang, TX (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Chongqing Key Lab Mol Oncol & Epigenet, Chongqing, Peoples R China.	xiangtx@cqmu.edu.cn	Li, Lili/Q-5750-2018	Li, Lili/0000-0002-0292-5889	National Natural Science Foundation of China [81872380, 81572769]; Natural Science Foundation of Chongqing [cstc2018jscx-mszdX0039]; Research Grants Council, University Grants Committee (HK) [14115920]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Chongqing(Natural Science Foundation of Chongqing); Research Grants Council, University Grants Committee (HK)	This study was supported by the National Natural Science Foundation of China (#81872380, #81572769), Natural Science Foundation of Chongqing (cstc2018jscx-mszdX0039), and Research Grants Council, University Grants Committee (HK) (#14115920).	Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Blanc Mathieu, 2015, F1000Res, V4, P261, DOI 10.12688/f1000research.6464.1; Brigidi GS, 2013, JOVE-J VIS EXP, DOI 10.3791/50031; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Brownlee C, 2019, CELL, V176, P805, DOI 10.1016/j.cell.2018.12.001; Cao N, 2016, BMC MOL BIOL, V17, DOI 10.1186/s12867-016-0065-9; Chamberlain LH, 2015, PHYSIOL REV, V95, P341, DOI 10.1152/physrev.00032.2014; Dai C, 2010, TRENDS MOL MED, V16, P528, DOI 10.1016/j.molmed.2010.09.002; Daniotti JL, 2017, TRAFFIC, V18, P699, DOI 10.1111/tra.12510; De I, 2018, EUR J CELL BIOL, V97, P319, DOI 10.1016/j.ejcb.2018.03.005; Drisdel RC, 2004, BIOTECHNIQUES, V36, P276, DOI 10.2144/04362RR02; Fraser NJ, 2020, BIOCHEM SOC T, V48, P281, DOI 10.1042/BST20190707; Gao HG, 1997, CARCINOGENESIS, V18, P473, DOI 10.1093/carcin/18.3.473; Gluck S, 2012, BREAST CANCER RES TR, V132, P781, DOI 10.1007/s10549-011-1412-7; Gnanapradeepan K, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00124; Goldfarb DS, 2004, TRENDS CELL BIOL, V14, P505, DOI 10.1016/j.tcb.2004.07.016; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Jung HY, 2007, J BIOL CHEM, V282, P35293, DOI 10.1074/jbc.M705181200; Ko PJ, 2018, EMBO REP, V19, DOI 10.15252/embr.201846666; Le X, 2020, THERANOSTICS, V10, P9495, DOI 10.7150/thno.45631; Leong WF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004135; Levine AJ, 2020, NAT REV CANCER, V20, P471, DOI 10.1038/s41568-020-0262-1; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Parks D, 1997, NUCLEIC ACIDS RES, V25, P1289, DOI 10.1093/nar/25.6.1289; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Resh MD, 2017, BIOCHEM SOC T, V45, P409, DOI 10.1042/BST20160233; Runkle KB, 2016, MOL CELL, V62, P385, DOI 10.1016/j.molcel.2016.04.003; Tabaczar S, 2017, EXP BIOL MED, V242, P1150, DOI 10.1177/1535370217707732; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Xiang TX, 2019, THERANOSTICS, V9, P8182, DOI 10.7150/thno.34983; Yao H, 2019, NAT BIOMED ENG, V3, P306, DOI 10.1038/s41551-019-0375-6; Yeste-Velasco M, 2014, J PATHOL, V232, P566, DOI 10.1002/path.4327; Zhang Y, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0459-2	35	5	5	6	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2021	40	35					5416	5426		10.1038/s41388-021-01949-5	http://dx.doi.org/10.1038/s41388-021-01949-5		JUL 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO0SJ	34282274	hybrid, Green Published			2022-12-17	WOS:000674560900001
J	Song, S; Fan, G; Li, Q; Su, Q; Zhang, XY; Xue, XF; Wang, ZM; Qian, CA; Jin, Z; Li, BZ; Zhuang, WZ				Song, Sha; Fan, Gao; Li, Qi; Su, Qi; Zhang, Xinyun; Xue, Xiaofeng; Wang, Zhiming; Qian, Chen'ao; Jin, Zhou; Li, Bingzong; Zhuang, Wenzhuo			IDH2 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in multiple myeloma	ONCOGENE			English	Article							M(6)A READER YTHDF2; ONCOMETABOLITE 2-HYDROXYGLUTARATE; REVEALS; HETEROGENEITY; TRANSCRIPTOME; INHIBITOR; MUTATIONS; PATTERNS; LEUKEMIA; CELLS	Epigenetic alterations have been previously shown to contribute to multiple myeloma (MM) pathogenesis via DNA methylations and histone modifications. RNA methylation, a novel epigenetic modification, is required for cancer cell survival, and targeting this pathway has been proposed as a new therapeutic strategy. The extent to the N6-methyladenosine (m6A)-regulatory pathway functions in MM remains unknown. Here, we show that an imbalance of RNA methylation may underlies the tumorigenesis of MM. Mechanistically, isocitrate dehydrogenase 2 (IDH2) is highly expressed in CD138(+) cells from MM and its levels appear a progressive increase in the progression of plasma cell dyscrasias. Downregulation of IDH2 increases global m6A RNA levels and reduces myeloma cell growth in vitro, decreases the burden of disease and prolongs overall survival in vivo. IDH2 regulates RNA methylation by activating the RNA demethylase FTO, which is an alpha-KG-dependent dioxygenase. Furthermore, IDH2-mediated FTO activation decreases the m6A level on WNT7B transcripts, then increases WNT7B expression and thus activated Wnt signaling pathway. Moreover, survival analysis indicates that the elevated expression of IDH2 predicts a poor prognosis. Higher expression of FTO is related to higher International Staging System (ISS) stage and higher Revised-ISS (R-ISS) stage of MM. Collectively, our studies reveal that IDH2 regulates global m6A RNA modification in MM via targeting RNA demethylases FTO. The imbalance of m6A methylation activates the Wnt signaling pathway by enhancing the WNT7B expression, and thus promoting tumorigenesis and progression of MM. IDH2 might be used as a therapeutic target and a possible prognostic factor for MM.	[Song, Sha; Fan, Gao; Su, Qi; Wang, Zhiming; Jin, Zhou; Zhuang, Wenzhuo] Soochow Univ, Sch Biol & Basic Med Sci, Dept Cell Biol, Suzhou, Peoples R China; [Song, Sha] Westlake Univ, Sch Life Sci, Hangzhou, Peoples R China; [Li, Qi; Zhang, Xinyun; Xue, Xiaofeng; Li, Bingzong] Soochow Univ, Affiliated Hosp 2, Dept Hematol, Suzhou, Peoples R China; [Qian, Chen'ao] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA	Soochow University - China; Westlake University; Soochow University - China; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zhuang, WZ (corresponding author), Soochow Univ, Sch Biol & Basic Med Sci, Dept Cell Biol, Suzhou, Peoples R China.; Li, BZ (corresponding author), Soochow Univ, Affiliated Hosp 2, Dept Hematol, Suzhou, Peoples R China.	lbzwz0907@hotmail.com; zhuangwenzhuo@suda.edu.cn	li, bing/GWQ-9617-2022; li, bz/GVR-7133-2022		Natural Science Foundation of Jiangsu Province China [BK20201408]; Clinical Key Diagnosis and Treatment Technologies in Suzhou City [LCZX201805]; Jiangsu Social Development Project-New Clinical Diagnosis and Treatment Technology [BE2019664]; Scientific and Technological Projects of People's Livelihood in Suzhou City [SS201856]; Fifth Phase of "333 High-level Talents Training Project" in Jiangsu Province [BRA2018138]; National Clinical Research Center for Hematologic Diseases	Natural Science Foundation of Jiangsu Province China(Natural Science Foundation of Jiangsu Province); Clinical Key Diagnosis and Treatment Technologies in Suzhou City; Jiangsu Social Development Project-New Clinical Diagnosis and Treatment Technology; Scientific and Technological Projects of People's Livelihood in Suzhou City; Fifth Phase of "333 High-level Talents Training Project" in Jiangsu Province; National Clinical Research Center for Hematologic Diseases	The research leading to these results has received funding from Natural Science Foundation of Jiangsu Province China (BK20201408), Clinical Key Diagnosis and Treatment Technologies in Suzhou City (LCZX201805), Jiangsu Social Development Project-New Clinical Diagnosis and Treatment Technology (BE2019664), Scientific and Technological Projects of People's Livelihood in Suzhou City (SS201856), The Fifth Phase of "333 High-level Talents Training Project" in Jiangsu Province (BRA2018138) and National Clinical Research Center for Hematologic Diseases.	Agnelli L, 2009, GENE CHROMOSOME CANC, V48, P603, DOI 10.1002/gcc.20668; Alzrigat M, 2018, SEMIN CANCER BIOL, V51, P101, DOI 10.1016/j.semcancer.2017.09.007; Amary MF, 2011, J PATHOL, V224, P334, DOI 10.1002/path.2913; Anderson NM, 2018, PROTEIN CELL, V9, P216, DOI 10.1007/s13238-017-0451-1; Bartosovic M, 2017, NUCLEIC ACIDS RES, V45, P11356, DOI 10.1093/nar/gkx778; Bianchi G, 2015, BLOOD, V125, P3049, DOI 10.1182/blood-2014-11-568881; Chng WJ, 2007, CANCER RES, V67, P2982, DOI 10.1158/0008-5472.CAN-06-4046; Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43; Danziger SA, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003323; Dimopoulos K, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.29; Gutierrez NC, 2007, LEUKEMIA, V21, P541, DOI 10.1038/sj.leu.2404520; Hausinger RP, 2004, CRIT REV BIOCHEM MOL, V39, P21, DOI 10.1080/10409230490440541; Herr CQ, 2018, TRENDS BIOCHEM SCI, V43, P517, DOI 10.1016/j.tibs.2018.04.002; Ivanova I, 2017, MOL CELL, V67, P1059, DOI 10.1016/j.molcel.2017.08.003; Kats LM, 2014, CELL STEM CELL, V14, P329, DOI 10.1016/j.stem.2013.12.016; Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746; Levin A, 2018, TRANSL RES, V201, P49, DOI 10.1016/j.trsl.2018.05.003; Li Zejuan, 2017, Cancer Cell, V31, P127, DOI 10.1016/j.ccell.2016.11.017; Li ZR, 2018, CELL RES, V28, P904, DOI 10.1038/s41422-018-0072-0; Lohr JG, 2014, CANCER CELL, V25, P91, DOI 10.1016/j.ccr.2013.12.015; Lopez-Corral L, 2014, HAEMATOLOGICA, V99, P1365, DOI 10.3324/haematol.2013.087809; Mattioli M, 2005, ONCOGENE, V24, P2461, DOI 10.1038/sj.onc.1208447; Mulligan G, 2007, BLOOD, V109, P3177, DOI 10.1182/blood-2006-09-044974; Palumbo A, 2015, J CLIN ONCOL, V33, P2863, DOI 10.1200/JCO.2015.61.2267; Pansuriya TC, 2011, NAT GENET, V43, P1256, DOI 10.1038/ng.1004; Paris J, 2019, CELL STEM CELL, V25, P137, DOI 10.1016/j.stem.2019.03.021; Repana D, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-018-1612-0; Shi HL, 2019, MOL CELL, V74, P640, DOI 10.1016/j.molcel.2019.04.025; Spaan I, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0615-3; Su R, 2018, CELL, V172, P90, DOI 10.1016/j.cell.2017.11.031; Szalat R, 2015, CURR OPIN GENET DEV, V30, P56, DOI 10.1016/j.gde.2015.03.008; van Andel H, 2019, LEUKEMIA, V33, P1063, DOI 10.1038/s41375-019-0404-1; van de Donk NWCJ, 2016, IMMUNOL REV, V270, P95, DOI 10.1111/imr.12389; Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039; Vu LP, 2019, CANCER DISCOV, V9, P25, DOI 10.1158/2159-8290.CD-18-0959; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Xie C, 2011, NUCLEIC ACIDS RES, V39, pW316, DOI 10.1093/nar/gkr483; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yang H, 2012, CLIN CANCER RES, V18, P5562, DOI 10.1158/1078-0432.CCR-12-1773; Zhao X, 2014, CELL RES, V24, P1403, DOI 10.1038/cr.2014.151; Zhou J, 2018, MOL CELL, V69, P636, DOI 10.1016/j.molcel.2018.01.019	42	5	5	4	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2021	40	35					5393	5402		10.1038/s41388-021-01939-7	http://dx.doi.org/10.1038/s41388-021-01939-7		JUL 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO0SJ	34274946				2022-12-17	WOS:000673748200001
J	Bi, O; Anene, CA; Nsengimana, J; Shelton, M; Roberts, W; Newton-Bishop, J; Boyne, JR				Bi, O.; Anene, C. A.; Nsengimana, J.; Shelton, M.; Roberts, W.; Newton-Bishop, J.; Boyne, J. R.			SFPQ promotes an oncogenic transcriptomic state in melanoma	ONCOGENE			English	Article							SPLICING-FACTOR; CANCER CELLS; RNA; BINDING; PROLIFERATION; PROGRESSION; LNCRNA; EXPRESSION; DYSREGULATION; TUMORIGENESIS	The multifunctional protein, splicing factor, proline- and glutamine-rich (SFPQ) has been implicated in numerous cancers often due to interaction with coding and non-coding RNAs, however, its role in melanoma remains unclear. We report that knockdown of SFPQ expression in melanoma cells decelerates several cancer-associated cell phenotypes, including cell growth, migration, epithelial to mesenchymal transition, apoptosis, and glycolysis. RIP-seq analysis revealed that the SFPQ-RNA interactome is reprogrammed in melanoma cells and specifically enriched with key melanoma-associated coding and long non-coding transcripts, including SOX10, AMIGO2 and LINC00511 and in most cases SFPQ is required for the efficient expression of these genes. Functional analysis of two SFPQ-enriched lncRNA, LINC00511 and LINC01234, demonstrated that these genes independently contribute to the melanoma phenotype and a more detailed analysis of LINC00511 indicated that this occurs in part via modulation of the miR-625-5p/PKM2 axis. Importantly, analysis of a large clinical cohort revealed that elevated expression of SFPQ in primary melanoma tumours may have utility as a prognostic biomarker. Together, these data suggest that SFPQ is an important driver of melanoma, likely due to SFPQ-RNA interactions promoting the expression of numerous oncogenic transcripts.	[Bi, O.; Shelton, M.; Boyne, J. R.] Univ Huddersfield, Sch Appl Sci, Huddersfield, W Yorkshire, England; [Anene, C. A.] Queen Mary Univ London, Barts Canc Inst, Ctr Canc Genom & Computat Biol, London, England; [Nsengimana, J.] Newcastle Univ, Fac Med Sci, Populat Hlth Sci Inst, Newcastle, England; [Roberts, W.] Leeds Beckett Univ, Sch Clin & Appl Sci, Leeds, W Yorkshire, England; [Newton-Bishop, J.] Univ Leeds, Sch Med, Leeds, W Yorkshire, England	University of Huddersfield; University of London; Queen Mary University London; Newcastle University - UK; Leeds Beckett University; University of Leeds	Boyne, JR (corresponding author), Univ Huddersfield, Sch Appl Sci, Huddersfield, W Yorkshire, England.	j.r.boyne@hud.ac.uk	Nsengimana, Jeremie/AGK-5625-2022; Boyne, James/AAU-6616-2021; Anene, Chinedu Anthony/AAI-7643-2021	Boyne, James/0000-0003-1219-6453; Anene, Chinedu Anthony/0000-0002-3591-3358; Newton-Bishop, Julia/0000-0001-9147-6802	British Skin Foundation award [030/s/18]; MRC award [MR/M019012/1]	British Skin Foundation award; MRC award(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The authors would like to thank Dr. M.J. Thornton and Dr. S. Sikkink for assistance with primary melanocyte cell culture and Prof. M. Dickman for providing the pSFPQ-FLAG construct. This work was funded by a personal scholarship to OB by Mr. Shaukat Ali, British Skin Foundation award to JRB (030/s/18) and MRC award MR/M019012/1 to JNB.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Akhbari P, 2018, J INVEST DERMATOL, V138, P2343, DOI 10.1016/j.jid.2018.03.1527; Anene C, 2018, BBA-MOL BASIS DIS, V1864, P2633, DOI 10.1016/j.bbadis.2018.04.013; Baquero-Perez B, 2019, ELIFE, V8, DOI 10.7554/eLife.47261; Bottini S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01126-x; Chai YQ, 2016, CANCER MED-US, V5, P1588, DOI 10.1002/cam4.710; Chen XE., 2020, BIOSCIENCE REP, V40, P40; Chen YH, 2020, MOL THER-NUCL ACIDS, V19, P168, DOI 10.1016/j.omtn.2019.10.035; Chen ZS, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-1070-0; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; de Silva HC, 2019, CELL MOL LIFE SCI, V76, P2015, DOI 10.1007/s00018-019-03033-4; Deng HH, 2019, AGING-US, V11, P5975, DOI 10.18632/aging.102156; Djulbegovic MB, 2020, INT J BIOL MACROMOL, V150, P1281, DOI 10.1016/j.ijbiomac.2019.10.139; Duan M, 2020, CANCER MANAG RES, V12, P2141, DOI 10.2147/CMAR.S229013; Fontanals-Cirera B, 2017, MOL CELL, V68, P731, DOI 10.1016/j.molcel.2017.11.004; Gao ZZ, 2019, RNA BIOL, V16, P940, DOI 10.1080/15476286.2019.1602436; Garbe C, 2009, CLIN DERMATOL, V27, P3, DOI 10.1016/j.clindermatol.2008.09.001; Ghosh Papia, 2009, Expert Rev Dermatol, V4, P131, DOI 10.1586/edm.09.2; Graf SA, 2014, J INVEST DERMATOL, V134, P2212, DOI 10.1038/jid.2014.128; Gu Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209338; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Hochberg-Laufer H, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008459; Hopkins TG, 2016, NUCLEIC ACIDS RES, V44, P1227, DOI 10.1093/nar/gkv1515; Hu L, 2018, ONCOL LETT, V16, P294, DOI 10.3892/ol.2018.8637; Hu YP, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1097-9; Hu ZX, 2020, HEPATOLOGY, V72, P548, DOI 10.1002/hep.31062; Hua JT, 2018, CELL, V174, P564, DOI 10.1016/j.cell.2018.06.014; Hui L, 2019, PEERJ, V7, DOI 10.7717/peerj.7456; Imamura K, 2014, MOL CELL, V53, P393, DOI 10.1016/j.molcel.2014.01.009; Jaafar L, 2017, NUCLEIC ACIDS RES, V45, P1848, DOI 10.1093/nar/gkw1209; Ji Q, 2014, BRIT J CANCER, V111, P736, DOI 10.1038/bjc.2014.383; Kaneko S, 2007, GENE DEV, V21, P1779, DOI 10.1101/gad.1565207; Ke YZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035678; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Li Y, 2018, ONCOTARGETS THER, V11, P1403, DOI 10.2147/OTT.S149511; Lin MG, 2018, EUR REV MED PHARMACO, V22, P3370, DOI 10.26355/eurrev_201806_15158; Lu J, 2018, J ALZHEIMERS DIS, V61, P1311, DOI 10.3233/JAD-170659; Luisier R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04373-8; Mitobe Y, 2020, CANCER RES, V80, P2230, DOI 10.1158/0008-5472.CAN-19-3095; Gallardo CM, 2019, NUCLEIC ACIDS RES, V47, P5381, DOI 10.1093/nar/gkz235; Muralidhar S, 2019, CANCER RES, V79, P5986, DOI 10.1158/0008-5472.CAN-18-3927; Nsengimana J, 2018, J CLIN INVEST, V128, P2048, DOI 10.1172/JCI95351; Pellarin I, 2020, ONCOGENE, V39, P4390, DOI 10.1038/s41388-020-1292-6; Perron G, 2018, CELL REP, V23, P1639, DOI 10.1016/j.celrep.2018.04.031; Qiu T, 2015, KAOHSIUNG J MED SCI, V31, P553, DOI 10.1016/j.kjms.2015.10.002; Rajesh C, 2011, NUCLEIC ACIDS RES, V39, P132, DOI 10.1093/nar/gkq738; Ren WQ, 2019, J CELL BIOCHEM, V120, P5417, DOI 10.1002/jcb.27820; Roeder C, 2005, ARCH DERMATOL RES, V296, P314, DOI 10.1007/s00403-004-0527-7; Ru Y, 2018, ONCOTARGETS THER, V11, P5695, DOI 10.2147/OTT.S163774; Shakhova O, 2012, NAT CELL BIOL, V14, P882, DOI 10.1038/ncb2535; Shao R, 2012, INT J CANCER, V130, P544, DOI 10.1002/ijc.26015; Snijders AP, 2015, RNA, V21, P347, DOI 10.1261/rna.045138.114; Sun CC, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2016.94; Takayama K, 2017, P NATL ACAD SCI USA, V114, P10461, DOI 10.1073/pnas.1706076114; Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Volders PJ, 2015, NUCLEIC ACIDS RES, V43, P4363, DOI 10.1093/nar/gkv295; Wang B, 2019, BIOCHEM BIOPH RES CO, V509, P143, DOI 10.1016/j.bbrc.2018.12.091; Wang D, 2016, BIOCHEM BIOPH RES CO, V473, P959, DOI 10.1016/j.bbrc.2016.03.161; Wang ZH, 2018, CANCER CELL, V33, P706, DOI 10.1016/j.ccell.2018.03.006; Wesley UV, 1999, J EXP MED, V190, P311, DOI 10.1084/jem.190.3.311; Williamson AJK, 2004, J BIOL CHEM, V279, P47912, DOI 10.1074/jbc.M409035200; Wu CF, 2013, J GENET GENOMICS, V40, P179, DOI 10.1016/j.jgg.2013.03.001; Xue JH, 2020, THORAC CANCER, V11, P2570, DOI 10.1111/1759-7714.13576; Zeng CW, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0884-z; Zhang GY, 2018, BIOMARKERS, V23, P435, DOI 10.1080/1354750X.2018.1443509; Zhang J, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1835-3; Zhao XH, 2018, J CELL MOL MED, V22, P655, DOI 10.1111/jcmm.13351; Zhu FY, 2019, EUR REV MED PHARMACO, V23, P8377, DOI 10.26355/eurrev_201910_19149; Zhu YH, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01223-w	70	5	5	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2021	40	33					5192	5203		10.1038/s41388-021-01912-4	http://dx.doi.org/10.1038/s41388-021-01912-4		JUL 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC8LP	34218270	hybrid, Green Accepted, Green Published			2022-12-17	WOS:000669300400003
J	Li, YY; Fei, H; Lin, QW; Liang, F; You, YA; Li, M; Wu, MY; Qu, Y; Li, PF; Yuan, Y; Chen, T; Jiang, H				Li, Yiying; Fei, He; Lin, Qiwang; Liang, Fan; You, Yanan; Li, Ming; Wu, Mengyao; Qu, Ying; Li, Pengfei; Yuan, Yan; Chen, Tong; Jiang, Hua			ZEB2 facilitates peritoneal metastasis by regulating the invasiveness and tumorigenesis of cancer stem-like cells in high-grade serous ovarian cancers	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; EXPRESSION; PROMOTES; HETEROGENEITY; INVASION	Peritoneal metastasis is a common issue in the progression of high-grade serous ovarian cancers (HGSOCs), yet the underlying mechanism remains unconfirmed. We demonstrated that ZEB2, the transcription factor of epithelial-mesenchymal transition (EMT), was upregulated in ascites cells from HGSOC patients and in CD133(+) cancer stem-like cells (CSLCs) from epithelial ovarian cancer (EOC) cell lines. SiRNA-mediated knockdown of ZEB2 in EOC cells decreased the percentage of CSLCs and reduced the colony forming potential, cell invasion capacity and expression of pluripotent genes Oct4 and Nanog. Inhibition of ZEB2 also induced cellular apoptosis and impacted the tumorigenicity of ovarian CSLCs. The mesenchymal markers N-cadherin and vimentin were downregulated, while the epithelial marker E-cadherin was upregulated after ZEB2 knockdown. MiR-200a, a molecule that downregulates ZEB2, had the opposite effect of ZEB2 expression in EOC-CSLCs. A retrospective study of 98 HGSOC patients on the relationship of ascites volume, pelvic and abdominal metastasis, International Federation of Gynecology and Obstetrics (FIGO) stage and the malignant involvement of abdominal organs and lymph nodes was performed. Patients with high expression of ZEB2 in tumour tissues had a higher metastasis rate and a poorer prognosis than those with low expression. The parameters of ZEB2 expression and ascites volume were strongly linked with the prognostic outcome of HGSOC patients and had higher hazard ratios. These findings illustrated that ZEB2 facilitates the invasive metastasis of EOC-CSLCs and can predict peritoneal metastasis and a poor prognosis in HGSOC patients.	[Li, Yiying; Fei, He; Lin, Qiwang; Liang, Fan; You, Yanan; Li, Ming; Jiang, Hua] Fudan Univ, Obstet & Gynecol Hosp, Dept Gynecol, Shanghai 200011, Peoples R China; [Li, Yiying] Nanchang Univ, Affiliated Hosp 1, Dept Gynecol, Nanchang 330006, Jiangxi, Peoples R China; [Fei, He] Fudan Univ, Shanghai Peoples Hosp 5, Dept Gynecol, Shanghai 200240, Peoples R China; [Wu, Mengyao; Qu, Ying; Li, Pengfei; Yuan, Yan; Chen, Tong] Fudan Univ, Huashan Hosp, Dept Hematol, Shanghai 200040, Peoples R China; [Jiang, Hua] Shanghai Key Lab Female Reprod Endocrine Related, Shanghai 200011, Peoples R China	Fudan University; Nanchang University; Fudan University; Fudan University	Jiang, H (corresponding author), Fudan Univ, Obstet & Gynecol Hosp, Dept Gynecol, Shanghai 200011, Peoples R China.; Chen, T (corresponding author), Fudan Univ, Huashan Hosp, Dept Hematol, Shanghai 200040, Peoples R China.; Jiang, H (corresponding author), Shanghai Key Lab Female Reprod Endocrine Related, Shanghai 200011, Peoples R China.	chentong@fudan.edu.cn; jianghua@fudan.edu.cn	Liang, Fan/HGA-0248-2022		National Natural Science Foundation of China [81870081]; Program for Outstanding Medical Academic Leader of Shanghai [2019LJ05]; Shanghai Collaborative Innovation Program on Regenerative Medicine and Stem Cell Research [2019CXJQ01]; Clinical Research Plan of Shanghai Hospital Development Center [SHDC2020CR1048B]; High-level Professional Physician Training Program of Minhang District [2020MZYS17]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Outstanding Medical Academic Leader of Shanghai; Shanghai Collaborative Innovation Program on Regenerative Medicine and Stem Cell Research; Clinical Research Plan of Shanghai Hospital Development Center; High-level Professional Physician Training Program of Minhang District	This study was supported by grants from the National Natural Science Foundation of China (81870081), the Program for Outstanding Medical Academic Leader of Shanghai (2019LJ05) and the Shanghai Collaborative Innovation Program on Regenerative Medicine and Stem Cell Research (2019CXJQ01) to TC, the Clinical Research Plan of Shanghai Hospital Development Center (SHDC2020CR1048B) to HJ and High-level Professional Physician Training Program of Minhang District (2020MZYS17) to HF.	Ahluwalia A, 2001, GYNECOL ONCOL, V82, P299, DOI 10.1006/gyno.2001.6284; Alberto-Aguilar DR, 2019, CANCER MICROENVIRON, V12, P181, DOI 10.1007/s12307-019-00227-z; Aslan B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8351; Baba T, 2009, ONCOGENE, V28, P209, DOI 10.1038/onc.2008.374; Choi PW, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061207; den Ouden Judith E, 2020, Oncotarget, V11, P4570, DOI 10.18632/oncotarget.27827; Gu SW, 2019, INT J CLIN EXP PATHO, V12, P2009; Han Q, 2019, INT J MOL MED, V44, P2245, DOI 10.3892/ijmm.2019.4361; Hooda J, 2019, CANCER RES, V79, P760, DOI 10.1158/0008-5472.CAN-18-2297; Hu YT, 2019, CANCER LETT, V457, P142, DOI 10.1016/j.canlet.2019.04.034; Ignacio RMC, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e29; Jiang H, 2012, MOL MED, V18, P1197, DOI 10.2119/molmed.2012.00075; Jolly MK, 2019, PHARMACOL THERAPEUT, V194, P161, DOI 10.1016/j.pharmthera.2018.09.007; Kim S, 2016, CANCER SCI, V107, P1173, DOI 10.1111/cas.12987; Kim S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31097-y; Kotrbova A, 2020, THERANOSTICS, V10, P537, DOI 10.7150/thno.37423; Liu CM, 2015, TUMOR BIOL, V36, P7213, DOI 10.1007/s13277-015-3437-8; Liu C, 2018, FUTURE ONCOL, V14, P2875, DOI 10.2217/fon-2018-0155; Loret N, 2019, CANCERS, V11, DOI 10.3390/cancers11060838; Lourenco AR, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14556-x; Lytle NK, 2018, NAT REV CANCER, V18, P669, DOI 10.1038/s41568-018-0056-x; Matte I, 2012, AM J CANCER RES, V2, P566; Mo LH, 2015, MOL CANCER THER, V14, P747, DOI 10.1158/1535-7163.MCT-14-0579; Moussa RA, 2019, WORLD J ONCOL, V10, P199, DOI 10.14740/wjon1234; Pakula M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010137; Saini U, 2017, ONCOGENE, V36, P168, DOI 10.1038/onc.2016.197; Scott CL, 2018, IMMUNITY, V49, P312, DOI 10.1016/j.immuni.2018.07.004; Shepherd TG, 2006, NAT PROTOC, V1, P2643, DOI 10.1038/nprot.2006.328; Shi J, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6321-x; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Song N, 2016, CELL PHYSIOL BIOCHEM, V38, P351, DOI 10.1159/000438635; Song Q, 2019, ONCOTARGETS THER, V12, P7387, DOI 10.2147/OTT.S218161; Torre LA, 2018, CA-CANCER J CLIN, V68, P284, DOI 10.3322/caac.21456; Tripathi S, 2020, ANNU REV BIOPHYS, V49, P1, DOI 10.1146/annurev-biophys-121219-081557; Webb TJ, 2012, CANCER RES, V72, P3744, DOI 10.1158/0008-5472.CAN-11-2695; Wu QG, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay9819; Yamanoi K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50794-w; Yan Z, 2017, INT J GYNECOL CANCER, V27, P1343, DOI 10.1097/IGC.0000000000001037; Yang D, 2013, CANCER CELL, V23, P186, DOI 10.1016/j.ccr.2012.12.020; Yang J, 2020, NAT REV MOL CELL BIO, V21, P341, DOI 10.1038/s41580-020-0237-9; Yeung KT, 2017, MOL ONCOL, V11, P28, DOI 10.1002/1878-0261.12017; YU DH, 1993, CANCER RES, V53, P891; Zhang YY, 2020, AM J REPROD IMMUNOL, V84, DOI 10.1111/aji.13251; Zhao YX, 2018, CELL CYCLE, V17, P250, DOI 10.1080/15384101.2017.1417708; Zheng TT, 2019, ONCOTARGETS THER, V12, P6145, DOI 10.2147/OTT.S209784	45	5	5	3	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2021	40	32					5131	5141		10.1038/s41388-021-01913-3	http://dx.doi.org/10.1038/s41388-021-01913-3		JUL 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA7OD	34211089	hybrid, Green Published			2022-12-17	WOS:000668832500002
J	Bi, XY; Lou, PB; Song, YL; Sheng, XL; Liu, RQ; Deng, M; Yang, X; Li, GL; Yuan, SK; Zhang, HL; Jiao, BW; Zhang, B; Xue, LX; Liu, ZH; Plikus, MV; Ren, FZ; Gao, S; Zhao, L; Yu, ZQ				Bi, Xueyun; Lou, Pengbo; Song, Yongli; Sheng, Xiaole; Liu, Ruiqi; Deng, Min; Yang, Xu; Li, Guilin; Yuan, Shukai; Zhang, Honglei; Jiao, Baowei; Zhang, Bing; Xue, Lixiang; Liu, Zhihua; Plikus, Maksim, V; Ren, Fazheng; Gao, Shan; Zhao, Li; Yu, Zhengquan			Msi1 promotes breast cancer metastasis by regulating invadopodia-mediated extracellular matrix degradation via the Timp3-Mmp9 pathway	ONCOGENE			English	Article							BINDING PROTEIN MUSASHI1; TISSUE INHIBITORS; RNA; METALLOPROTEINASES; INVASION; CORTACTIN; MIGRATION; CELLS; TRAFFICKING; ASSOCIATION	Metastasis is the main cause of death in breast cancer patients. The initial step of metastasis is invadopodia-mediated extracellular matrix (ECM) degradation, which enables local breast tumor cells to invade surrounding tissues. However, the molecular mechanism underlying invadopodia-mediated metastasis remains largely unknown. Here we found that the RNA-binding protein Musashi1 (Msi1) exhibited elevated expression in invasive breast tumors and promoted lung metastasis of mammary cancer cells. Suppression of Msi1 reduced invadopodia formation in mammary cancer cells. Furthermore, Msi1 deficiency decreased the expression and activity of Mmp9, an important enzyme in ECM degradation. Mechanistically, Msi1 directly suppressed Timp3, an endogenous inhibitor of Mmp9. In clinical breast cancer specimens, TIMP3 and MSI1 levels were significantly inversely correlated both in normal breast tissue and breast cancer tissues and associated with overall survival in breast cancer patients. Taken together, our findings demonstrate that the MSI1-TIMP3-MMP9 cascade is critical for invadopodia-mediated onset of metastasis in breast cancer, providing novel insights into a promising therapeutic strategy for breast cancer metastasis.	[Bi, Xueyun; Lou, Pengbo; Sheng, Xiaole; Liu, Ruiqi; Deng, Min; Yang, Xu; Li, Guilin; Yu, Zhengquan] China Agr Univ, Coll Biol Sci, Dept Nutr & Hlth, Key Lab Precis Nutr & Food Qual,Minist Educ, Beijing, Peoples R China; [Song, Yongli] Inner Mongolia Univ, State Key Lab Reprod Regulat & Breeding Grassland, Coll Life Sci, Hohhot, Peoples R China; [Song, Yongli] Inner Mongolia Univ, Res Ctr Anim Genet Resources Mongolia Plateau, Coll Life Sci, Hohhot, Peoples R China; [Yuan, Shukai; Zhao, Li] Tianjin Med Univ, Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc,Sch Basic Med Sci,Key Lab, Tianjins Clin Res Ctr Canc,Dept Biochem & Mol Bio, Tianjin, Peoples R China; [Zhang, Honglei] Yunnan Univ Chinese Med, Ctr Sci Res, Kunming, Yunnan, Peoples R China; [Jiao, Baowei] Chinese Acad Sci, Kunming Inst Zool, State Key Lab Genet Resources & Evolut, Kunming, Yunnan, Peoples R China; [Zhang, Bing] China Agr Univ, Coll Vet Med, Beijing, Peoples R China; [Xue, Lixiang] Peking Univ Third Hosp, Med Res Ctr, Dept Radiat Oncol, Beijing, Peoples R China; [Liu, Zhihua] Chinese Acad Med Sci, Natl Canc Ctr, State Key Lab Mol Oncol, Canc Hosp, Beijing, Peoples R China; [Plikus, Maksim, V] Univ Calif Irvine, Dept Dev & Cell Biol, Ctr Complex Biol Syst, Sue & Bill Gross Stem Cell Res Ctr, Irvine, CA 92717 USA; [Ren, Fazheng] China Agr Univ, Coll Food Sci & Nutr Engn, Dept Nutr & Hlth, Key Lab Precis Nutr & Food Qual,Minist Educ, Beijing, Peoples R China; [Gao, Shan] Chinese Acad Sci, Suzhou Inst Biomed Engn & Technol, CAS Key Lab Biomed Diagnost, Suzhou, Jiangsu, Peoples R China	China Agricultural University; Inner Mongolia University; Inner Mongolia University; Tianjin Medical University; Yunnan University of Chinese Medicine; Chinese Academy of Sciences; Kunming Institute of Zoology; China Agricultural University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; University of California System; University of California Irvine; China Agricultural University; Chinese Academy of Sciences; Suzhou Institute of Biomedical Engineering & Technology, CAS	Yu, ZQ (corresponding author), China Agr Univ, Coll Biol Sci, Dept Nutr & Hlth, Key Lab Precis Nutr & Food Qual,Minist Educ, Beijing, Peoples R China.; Zhao, L (corresponding author), Tianjin Med Univ, Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc,Sch Basic Med Sci,Key Lab, Tianjins Clin Res Ctr Canc,Dept Biochem & Mol Bio, Tianjin, Peoples R China.	shzhaoli@tmu.edu.cn; zyu@cau.edu.cn	邓, 敏/GRS-4423-2022	邓, 敏/0000-0002-0338-8253; JIAO, BAOWEI/0000-0001-8559-9160; Lou, Pengbo/0000-0002-7525-0173; Bi, Xueyun/0000-0002-0367-0590; Plikus, Maksim/0000-0002-8845-2559; Yuan, Shukai/0000-0003-0354-5113	National Natural Science Foundation of China [81772984, 81572614]; Beijing Nature Foundation Grant [5162018]; Major Project for Cultivation Technology [2016ZX08008001, 2014ZX08008001]; Basic Research Program [2019TC227, 2019TC088]; SKLAB Open Grant [2020SKLAB6-18]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Nature Foundation Grant; Major Project for Cultivation Technology; Basic Research Program; SKLAB Open Grant	This work is supported by the National Natural Science Foundation of China (Nos. 81772984, 81572614), Beijing Nature Foundation Grant (5162018), the Major Project for Cultivation Technology (2016ZX08008001, 2014ZX08008001), Basic Research Program (2019TC227, 2019TC088), and SKLAB Open Grant (2020SKLAB6-18). The authors thank the members of the laboratory animal center in China Agricultural University for their assistance in animal care.	Abreu RD, 2009, J BIOL CHEM, V284, P12125, DOI 10.1074/jbc.M809605200; Aktas B, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2333; Ala-Aho R, 2005, BIOCHIMIE, V87, P273, DOI 10.1016/j.biochi.2004.12.009; AnandApte B, 1996, BIOCHEM CELL BIOL, V74, P853, DOI 10.1139/o96-090; Artym Vira V., 2009, V522, P211, DOI 10.1007/978-1-59745-413-1_15; Ascano M, 2013, CURR OPIN GENET DEV, V23, P20, DOI 10.1016/j.gde.2013.01.003; Olivares-Urbano MA, 2020, J CELL MOL MED, V24, P139, DOI 10.1111/jcmm.14671; Ayala I, 2008, J CELL SCI, V121, P369, DOI 10.1242/jcs.008037; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; Brew K, 2010, BBA-MOL CELL RES, V1803, P55, DOI 10.1016/j.bbamcr.2010.01.003; Carman CV, 2007, IMMUNITY, V26, P784, DOI 10.1016/j.immuni.2007.04.015; Castagnino A, 2018, ONCOGENE, V37, P6425, DOI 10.1038/s41388-018-0422-x; Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741; Chen HY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09504-7; Cheung KJ, 2016, SCIENCE, V352, P167, DOI 10.1126/science.aaf6546; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; Clark ES, 2007, CANCER RES, V67, P4227, DOI 10.1158/0008-5472.CAN-06-3928; Courtneidge SA, 2005, COLD SH Q B, V70, P167, DOI 10.1101/sqb.2005.70.014; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Fehm T, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2349; Fox RG, 2016, NATURE, V534, P407, DOI 10.1038/nature17988; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Gong PJ, 2017, HUM PATHOL, V65, P53, DOI 10.1016/j.humpath.2016.12.026; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Henras AK, 2008, CELL MOL LIFE SCI, V65, P2334, DOI 10.1007/s00018-008-8027-0; Imai T, 2001, MOL CELL BIOL, V21, P3888, DOI 10.1128/MCB.21.12.3888-3900.2001; Jacob A, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00004; Kang MH, 2017, ONCOGENE, V36, P1745, DOI 10.1038/onc.2016.327; Katz Y, 2014, ELIFE, V3, DOI 10.7554/eLife.03915; Khokha R, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004333; Li M, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01587-x; Li N, 2015, CELL REP, V13, P2440, DOI 10.1016/j.celrep.2015.11.022; Li W, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0495-y; Lin JC, 2018, RADIOTHER ONCOL, V129, P352, DOI 10.1016/j.radonc.2018.09.014; Mehner C, 2014, ONCOTARGET, V5, P2736, DOI 10.18632/oncotarget.1932; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Nahas GR, 2016, FASEB J, V30, P149, DOI 10.1096/fj.15-278770; Okano H, 2002, J CELL SCI, V115, P1355; Oser M, 2009, J CELL BIOL, V186, P571, DOI 10.1083/jcb.200812176; Owyong M, 2019, LIFE SCI ALLIANCE, V2, DOI 10.26508/lsa.201800226; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; Paz H, 2014, ONCOGENE, V33, P4193, DOI 10.1038/onc.2013.393; Poincloux R, 2009, J CELL SCI, V122, P3015, DOI 10.1242/jcs.034561; Raimondi C, 2011, BREAST CANCER RES TR, V130, P449, DOI 10.1007/s10549-011-1373-x; Sanchez-Diaz PC, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-280; Schoumacher M, 2010, J CELL BIOL, V189, P541, DOI 10.1083/jcb.200909113; Shi JY, 2018, J INVEST DERMATOL, V138, P2253, DOI 10.1016/j.jid.2018.03.1521; Sun Y, 2015, ONCOL REP, V33, P338, DOI 10.3892/or.2014.3585; Tinhofer I, 2014, INT J RADIAT BIOL, V90, P622, DOI 10.3109/09553002.2014.886798; Vo DT, 2011, RNA BIOL, V8, P817, DOI 10.4161/rna.8.5.16041; Wang S, 2009, P NATL ACAD SCI USA, V106, P151, DOI 10.1073/pnas.0808703105; Wang XY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-221; Wang ZQ, 2017, DEV CELL, V43, P186, DOI 10.1016/j.devcel.2017.09.012; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Zhang Z, 2018, ARCH GYNECOL OBSTET, V297, P433, DOI 10.1007/s00404-017-4598-z	57	5	6	5	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2021	40	29					4832	4845		10.1038/s41388-021-01873-8	http://dx.doi.org/10.1038/s41388-021-01873-8		JUN 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR9TO	34155343				2022-12-17	WOS:000664006400002
J	Liu, Y; Nelson, MV; Bailey, C; Zhang, P; Zheng, P; Dome, JS; Liu, Y; Wang, Y				Liu, Yan; Nelson, Marie, V; Bailey, Christopher; Zhang, Peng; Zheng, Pan; Dome, Jeffrey S.; Liu, Yang; Wang, Yin			Targeting the HIF-1 alpha-IGFBP2 axis therapeutically reduces IGF1-AKT signaling and blocks the growth and metastasis of relapsed anaplastic Wilms tumor	ONCOGENE			English	Article							BINDING-PROTEIN 2; INDUCIBLE FACTOR 1-ALPHA; IGF-I RECEPTOR; GENE-EXPRESSION; BREAST-CANCER; STEM-CELLS; HYPOXIA; PTEN; SURVIVAL; IGFBP-2	For patients with anaplastic Wilms tumor (WiT), metastasis and recurrence are common, and prognosis is generally poor. Novel therapies are needed to improve outcomes for patients with this high-risk WiT. A potential contributor to WiT development is constitutive activation of AKT by insulin-like growth factor 1 (IGF1) and its receptor (IGF1R) signaling pathway, but the complete underlying mechanism remains unclear. Here, we demonstrate that the hypoxia-inducible factor 1 alpha (HIF-1 alpha)-IGF binding protein 2 (IGFBP2) axis and the tumor-specific IGF1A are key players for constitutive activation of IGF1-AKT signaling leading to the tumor malignancy. HIF-1 alpha and IGFBP2 are highly expressed in a majority of WiT patient samples. Deficiency of either HIF-1 alpha or IGFBP2 or IGF1 in the tumor cells significantly impairs tumor growth and nearly abrogates metastasis in xenografted mice. Pharmacologic targeting of HIF-1 alpha by echinomycin delivered via nanoliposomes can efficiently restrain growth and metastasis of patient-derived relapsed anaplastic WiT xenografts. Liposomal echinomycin is more potent and effective in inhibiting WiT growth than vincristine in an anaplastic WiT mouse model, and eliminates metastasis by suppressing HIF-1 alpha targets and the HIF-1 alpha-IGFBP2 axis, which governs IGF1-AKT signaling.	[Liu, Yan; Bailey, Christopher; Zhang, Peng; Zheng, Pan; Liu, Yang; Wang, Yin] Univ Maryland, Sch Med, Inst Human Virol, Div Canc & Immunol Res, Baltimore, MD 21201 USA; [Nelson, Marie, V; Dome, Jeffrey S.] Childrens Natl Hosp, Ctr Canc & Immunol Res, Washington, DC USA; [Zheng, Pan; Liu, Yang] OncoC4 Inc, Rockville, MD 20850 USA	University System of Maryland; University of Maryland Baltimore; Children's National Health System	Liu, Y; Liu, Y; Wang, Y (corresponding author), Univ Maryland, Sch Med, Inst Human Virol, Div Canc & Immunol Res, Baltimore, MD 21201 USA.; Liu, Y (corresponding author), OncoC4 Inc, Rockville, MD 20850 USA.	yanliu@ihv.umaryland.edu; ywang@ihv.umaryland.edu		Wang, Yin/0000-0002-4749-3768	National Institutes of Health National Cancer Institute [CA171972, CA183030, CA219150, CA227671]	National Institutes of Health National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the grants from the National Institutes of Health National Cancer Institute CA171972, CA183030 (Y.L.), and CA219150, CA227671 (Y.W.).	Alami J, 2003, INT J CANCER, V107, P365, DOI 10.1002/ijc.11429; Ambrosini-Spaltro A, 2011, APPL IMMUNOHISTO M M, V19, P318, DOI 10.1097/PAI.0b013e3128052936; Bailey CM, 2020, NANOMED-NANOTECHNOL, V29, DOI 10.1016/j.nano.2020.102278; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Barton ER, 2010, J APPL PHYSIOL, V108, P1069, DOI 10.1152/japplphysiol.01308.2009; Bielen A, 2012, P NATL ACAD SCI USA, V109, pE1267, DOI 10.1073/pnas.1105034109; Brahmkhatri VP, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/538019; Chekhonin VP, 2013, CURR CANCER DRUG TAR, V13, P423, DOI 10.2174/15680096113139990074; Chen XL, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-72; Dean SJR, 2014, AM J CLIN PATHOL, V141, P323, DOI 10.1309/AJCPR11DEAYPTUSL; Dome JS, 2015, J CLIN ONCOL, V33, P2999, DOI 10.1200/JCO.2015.62.1888; Dome JS, 2002, J PEDIAT HEMATOL ONC, V24, P192, DOI 10.1097/00043426-200203000-00007; Dungwa JV, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-390; Durzynska J, 2013, ENDOCRINOLOGY, V154, P1215, DOI 10.1210/en.2012-1992; Emerling BM, 2008, P NATL ACAD SCI USA, V105, P2622, DOI 10.1073/pnas.0706790105; Feldser D, 1999, CANCER RES, V59, P3915; Foulstone EJ, 2013, ENDOCRINOLOGY, V154, P1780, DOI 10.1210/en.2012-1970; Geller JI, 2016, UROL ONCOL-SEMIN ORI, V34, P50, DOI 10.1016/j.urolonc.2015.10.012; GERMAINLEE EL, 1992, BIOCHEM J, V281, P413, DOI 10.1042/bj2810413; HASELBACHER GK, 1987, P NATL ACAD SCI USA, V84, P1104, DOI 10.1073/pnas.84.4.1104; Hu QH, 2011, J CLIN INVEST, V121, P174, DOI 10.1172/JCI43772; Hua H, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00904-3; Huang YF, 2008, BRIT J CANCER, V99, P1096, DOI 10.1038/sj.bjc.6604661; Karth J, 2000, J PEDIATR SURG, V35, P1749, DOI 10.1053/jpsu.2000.19241; Kim YW, 2013, INT J ONCOL, V43, P539, DOI 10.3892/ijo.2013.1961; King ER, 2011, GYNECOL ONCOL, V123, P13, DOI 10.1016/j.ygyno.2011.06.016; Liou JM, 2010, J CLIN ENDOCR METAB, V95, P1717, DOI 10.1210/jc.2009-2668; Lu J, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0197-x; Mavinkurve-Groothuis AMC, 2015, PEDIATR BLOOD CANCER, V62, P598, DOI 10.1002/pbc.25357; Mireuta M, 2010, GROWTH FACTORS, V28, P243, DOI 10.3109/08977191003745472; Miyamoto S, 2007, CANCER SCI, V98, P685, DOI 10.1111/j.1349-7006.2007.00448.x; Newman B, 2012, CANCER RES, V72, P4551, DOI 10.1158/0008-5472.CAN-11-3600; Perks CM, 2007, ONCOGENE, V26, P5966, DOI 10.1038/sj.onc.1210397; Qiang L, 2012, CELL DEATH DIFFER, V19, P284, DOI 10.1038/cdd.2011.95; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; Rigiracciolo DC, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9041010; ROGHANI M, 1991, J CLIN ENDOCR METAB, V73, P658, DOI 10.1210/jcem-73-3-658; Sasso G, 2010, J PEDIAT HEMATOL ONC, V32, pE264, DOI 10.1097/MPH.0b013e3181e7931a; SCHILSKY RL, 1991, INVEST NEW DRUG, V9, P269; Sciarra A, 2010, EUR UROL, V58, P315, DOI 10.1016/j.eururo.2010.05.019; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; Semenza GL, 2011, NEW ENGL J MED, V365, P537, DOI [10.1056/NEJMra1011165, 10.1056/NEJMc1110602]; Shen XC, 2012, MOL CELL BIOL, V32, P4116, DOI 10.1128/MCB.01011-12; Shiratsuchi I, 2011, ANTICANCER RES, V31, P2541; Simpson A, 2017, TARGET ONCOL, V12, P571, DOI 10.1007/s11523-017-0514-5; VINCENT TS, 1994, PEDIATR PATHOL, V14, P723, DOI 10.3109/15513819409023344; Wamaitha SE, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14629-x; Wang HM, 2006, MODERN PATHOL, V19, P1149, DOI 10.1038/modpathol.3800637; Wang Y, 2020, ONCOGENE, V39, P3015, DOI 10.1038/s41388-020-1201-z; Wang Y, 2011, CELL STEM CELL, V8, P399, DOI 10.1016/j.stem.2011.02.006; Wegert J, 2017, J PATHOL CLIN RES, V3, P234, DOI 10.1002/cjp2.77; Wigerup C, 2016, PHARMACOL THERAPEUT, V164, P152, DOI 10.1016/j.pharmthera.2016.04.009; Yau SW, 2015, J CELL COMMUN SIGNAL, V9, P125, DOI 10.1007/s12079-015-0261-2; ZUMKELLER W, 1993, EUR J CANCER, V29A, P1973, DOI 10.1016/0959-8049(93)90455-O; Zundel W, 2000, GENE DEV, V14, P391	55	5	5	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2021	40	29					4809	4819		10.1038/s41388-021-01907-1	http://dx.doi.org/10.1038/s41388-021-01907-1		JUN 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR9TO	34155347	Green Accepted			2022-12-17	WOS:000664006700002
J	Zhang, JY; Liu, Y; Tan, JY; Zhang, YM; Wong, CW; Lin, ZQ; Liu, XC; Sander, M; Yan, XZ; Liang, LB; Song, DL; Dan, J; Zhou, YW; Cai, J; Lin, Y; Liang, JK; Hu, J; Yan, GM; Zhu, WB				Zhang, Jiayu; Liu, Ying; Tan, Jingyi; Zhang, Yanming; Wong, Chun-Wa; Lin, Ziqing; Liu, Xincheng; Sander, Max; Yan, Xiaozhi; Liang, Lebin; Song, Deli; Dan, Jia; Zhou, Yuwei; Cai, Jing; Lin, Yuan; Liang, Jiankai; Hu, Jun; Yan, Guangmei; Zhu, Wenbo			Necroptotic virotherapy of oncolytic alphavirus M1 cooperated with Doxorubicin displays promising therapeutic efficacy in TNBC	ONCOGENE			English	Article							CANCER STATISTICS; VIRUS; IDENTIFICATION; PATHWAYS	Triple-negative breast cancer (TNBC) is the most aggressive molecular subtype among breast tumors and remains a challenge even for the most current therapeutic regimes. Here, we demonstrate that oncolytic alphavirus M1 effectively kills both TNBC and non-TNBC. ER-stress and apoptosis pathways are responsible for the cell death in non-TNBC as reported in other cancer types, yet the cell death in TNBC does not depend on these pathways. Transcriptomic analysis reveals that the M1 virus activates necroptosis in TNBC, which can be pharmacologically blocked by necroptosis inhibitors. By screening a library of clinically available compounds commonly used for breast cancer treatment, we find that Doxorubicin enhances the oncolytic effect of the M1 virus by up to 100-fold specifically in TNBC in vitro, and significantly stalls the tumor growth of TNBC in vivo, through promoting intratumoral virus replication and further triggering apoptosis in addition to necroptosis. These findings reveal a novel antitumor mechanism and a new combination regimen of the M1 oncolytic virus in TNBC, and highlight a need to bridge molecular diagnosis with virotherapy.	[Zhang, Jiayu; Tan, Jingyi; Zhang, Yanming; Wong, Chun-Wa; Liu, Xincheng; Liang, Lebin; Song, Deli; Dan, Jia; Zhou, Yuwei; Cai, Jing; Lin, Yuan; Liang, Jiankai; Hu, Jun; Yan, Guangmei; Zhu, Wenbo] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Microbiol, Dept Pharmacol, Guangzhou 510080, Peoples R China; [Liu, Ying] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Infect Dis, 600 Tianhe Rd, Guangzhou 510630, Peoples R China; [Lin, Ziqing; Sander, Max; Yan, Xiaozhi] Guangzhou Virotech Pharmaceut Co Ltd, 3 Lanyue Rd,Sci Pk, Guangzhou 510663, Peoples R China	Sun Yat Sen University; Sun Yat Sen University	Zhu, WB (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Microbiol, Dept Pharmacol, Guangzhou 510080, Peoples R China.	zhuwenbo@mail.sysu.edu.cn		Wong, Chun-wa/0000-0003-3476-9283; zhang, Jiayu/0000-0003-1132-1101; Lin, Yuan/0000-0002-7152-0965	National Natural Science Foundation of China [81872886]; Fundamental Research Funds for the Central Universities [19ykpy36, 19ykpy166]; Guangdong Basic and Applied Basic Research Foundation [2020A1515011446]; Pioneering talents project of Guangzhou Development Zone, Guangdong Province [CY2018-012]; Leading Team for Entrepreneurship in Guangzhou, Guangdong Province [201809020004]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Guangdong Basic and Applied Basic Research Foundation; Pioneering talents project of Guangzhou Development Zone, Guangdong Province; Leading Team for Entrepreneurship in Guangzhou, Guangdong Province	We thank all authors who contributed to this work. This work was supported by the National Natural Science Foundation of China (No. 81872886), Fundamental Research Funds for the Central Universities (19ykpy36 and 19ykpy166), Guangdong Basic and Applied Basic Research Foundation (2020A1515011446), Pioneering talents project of Guangzhou Development Zone, Guangdong Province (CY2018-012), and Leading Team for Entrepreneurship in Guangzhou, Guangdong Province (201809020004).	Adair RA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003578; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Brown CM, 1998, TROP ANIM HEALTH PRO, V30, P241, DOI 10.1023/A:1005079229232; Budhwani M, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00322; Cai J, 2021, HUM GENE THER, V32, P138, DOI 10.1089/hum.2020.271; de Graaf JF, 2018, CYTOKINE GROWTH F R, V41, P28, DOI 10.1016/j.cytogfr.2018.03.006; Dent R, 2009, BREAST CANCER RES TR, V115, P423, DOI 10.1007/s10549-008-0086-2; DeSantis CE, 2017, CA-CANCER J CLIN, V67, P439, DOI 10.3322/caac.21412; Forrest RA, 2012, BIOCHEM PHARMACOL, V83, P1602, DOI 10.1016/j.bcp.2012.02.026; Garrido-Castro AC, 2019, CANCER DISCOV, V9, P176, DOI 10.1158/2159-8290.CD-18-1177; Gong YT, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1029-8; Goradel NH, 2021, CURR PROB CANCER, V45, DOI 10.1016/j.currproblcancer.2020.100639; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hu J, 2009, CELL CYCLE, V8, P3328, DOI 10.4161/cc.8.20.9832; Jensen EC, 2013, ANAT REC, V296, P378, DOI 10.1002/ar.22641; Kok F, 2020, MOL SYST BIOL, V16, DOI 10.15252/msb.20198955; Lawler SE, 2017, JAMA ONCOL, V3, P841, DOI 10.1001/jamaoncol.2016.2064; Lazear HM, 2019, IMMUNITY, V50, P907, DOI 10.1016/j.immuni.2019.03.025; Lin Y, 2014, P NATL ACAD SCI USA, V111, pE4504, DOI 10.1073/pnas.1408759111; Liu SZ, 2017, P NATL ACAD SCI USA, V114, pE7450, DOI 10.1073/pnas.1707531114; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Miest TS, 2014, NAT REV MICROBIOL, V12, P23, DOI 10.1038/nrmicro3140; Moskovskich A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46952-9; Muhuri M, 2021, HUM GENE THER, V32, P136, DOI 10.1089/hum.2021.29150.mmu; Pang BX, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2921; Poh A, 2016, CANCER DISCOV, V6, P6, DOI 10.1158/2159-8290.CD-NB2015-158; Pu ZQ, 2020, J CELL MOL MED, V24, P14171, DOI 10.1111/jcmm.16028; Rehman H, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0158-5; Reimand J, 2019, NAT PROTOC, V14, P482, DOI 10.1038/s41596-018-0103-9; Russell SJ, 2012, NAT BIOTECHNOL, V30, P658, DOI 10.1038/nbt.2287; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Silke J, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003845; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031; Tan YQ, 2018, HUM GENE THER, V29, P950, DOI 10.1089/hum.2017.055; Tanzer MC, 2016, CELL DEATH DIFFER, V23, P1185, DOI 10.1038/cdd.2015.169; Thorn CF, 2011, PHARMACOGENET GENOM, V21, P440, DOI 10.1097/FPC.0b013e32833ffb56; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Turnbull S, 2015, VIRUSES-BASEL, V7, P6291, DOI 10.3390/v7122938; Vanlangenakker N, 2011, CELL DEATH DIFFER, V18, P656, DOI 10.1038/cdd.2010.138; Wahba HA, 2015, CANCER BIOL MED, V12, P106, DOI 10.7497/j.issn.2095-3941.2015.0030; Wen JS, 2007, VIRUS GENES, V35, P597, DOI 10.1007/s11262-007-0110-3; Wen SH, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0625-9; Willson J, 2020, NAT REV MOL CELL BIO, V21, P63, DOI 10.1038/s41580-019-0201-8; WU J, 2020, CANCERS, V12; XIAO X, 2018, NAT COMMUN, V9; Yang F, 2014, BBA-REV CANCER, V1845, P84, DOI 10.1016/j.bbcan.2013.12.002; Yang F, 2013, CURR BIOL, V23, P782, DOI 10.1016/j.cub.2013.03.043; Zhang HP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam7996; Zhang HP, 2016, HUM GENE THER, V27, P700, DOI 10.1089/hum.2016.038; Zhang J, 2016, CELL MOL LIFE SCI, V73, P2153, DOI 10.1007/s00018-016-2190-5; Zhu WB, 2021, HUM GENE THER, V32, P158, DOI 10.1089/hum.2020.273	52	5	5	1	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2021	40	29					4783	4795		10.1038/s41388-021-01869-4	http://dx.doi.org/10.1038/s41388-021-01869-4		JUN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR9TO	34155344				2022-12-17	WOS:000664006400001
J	Pan, TH; Lin, SC; Lee, YC; Yu, GY; Song, JH; Pan, J; Titus, M; Satcher, RL; Panaretakis, T; Logothetis, C; Yu-Lee, L; Lin, SH				Pan, Tianhong; Lin, Song-Chang; Lee, Yu-Chen; Yu, Guoyu; Song, Jian H.; Pan, Jing; Titus, Mark; Satcher, Robert L.; Panaretakis, Theocharis; Logothetis, Christopher; Yu-Lee, Li-Yuan; Lin, Sue-Hwa			Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in bone	ONCOGENE			English	Article							ANDROGEN DEPRIVATION THERAPY; ADIPOCYTES; CELLS; GROWTH; RESISTANCE; LNCAP; MODEL; MICROENVIRONMENT; LOCALIZATION; METASTASIS	A fraction of patients undergoing androgen deprivation therapy (ADT) for advanced prostate cancer (PCa) will develop recurrent castrate-resistant PCa (CRPC) in bone. Strategies to prevent CRPC relapse in bone are lacking. Here we show that the cholesterol-lowering drugs statins decrease castration-induced bone marrow adiposity in the tumor microenvironment and reduce PCa progression in bone. Using primary bone marrow stromal cells (BMSC) and M2-10B4 cells, we showed that ADT increases bone marrow adiposity by enhancing BMSC-to-adipocyte transition in vitro. Knockdown of androgen receptor abrogated BMSC-to-adipocyte transition, suggesting an androgen receptor-dependent event. RNAseq analysis showed that androgens reduce the secretion of adipocyte hormones/cytokines including leptin during BMSC-to-adipocyte transition. Treatment of PCa C4-2b, C4-2B4, and PC3 cells with leptin led to an increase in cell cycle progression and nuclear Stat3. RNAseq analysis also showed that androgens inhibit cholesterol biosynthesis pathway, raising the possibility that inhibiting cholesterol biosynthesis may decrease BMSC-to-adipocyte transition. Indeed, statins decreased BMSC-to-adipocyte transition in vitro and castration-induced bone marrow adiposity in vivo. Statin pre-treatment reduced 22RV1 PCa progression in bone after ADT. Our findings with statin may provide one of the mechanisms to the clinical correlations that statin use in patients undergoing ADT seems to delay progression to "lethal" PCa.	[Pan, Tianhong; Satcher, Robert L.] Univ Texas MD Anderson Canc Ctr, Dept Orthoped Oncol, Houston, TX 77030 USA; [Lin, Song-Chang; Lee, Yu-Chen; Yu, Guoyu; Pan, Jing; Lin, Sue-Hwa] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Song, Jian H.; Titus, Mark; Panaretakis, Theocharis; Logothetis, Christopher; Lin, Sue-Hwa] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Yu-Lee, Li-Yuan] Baylor Coll Med, Dept Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Lin, SH (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA.; Lin, SH (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.	slin@mdanderson.org			NIH [CA174798, P50 CA140388, P30 CA016672]; Cancer Prevention and Research Institute of Texas [CPRIT RP150179, RP190252]; Prostate Cancer Foundation; University of Texas MD Anderson Moonshot Program	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institute of Texas; Prostate Cancer Foundation; University of Texas MD Anderson Moonshot Program	This work was supported by grants from the NIH (CA174798, P50 CA140388, P30 CA016672), Cancer Prevention and Research Institute of Texas (CPRIT RP150179, RP190252), the Prostate Cancer Foundation, and funds from The University of Texas MD Anderson Moonshot Program.	Abu EO, 1997, J CLIN ENDOCR METAB, V82, P3493, DOI 10.1210/jc.82.10.3493; Alfaqih MA, 2017, NAT REV UROL, V14, P107, DOI 10.1038/nrurol.2016.199; Azemawah V, 2019, CARDIOVASC DRUG THER, V33, P625, DOI 10.1007/s10557-019-06904-x; Caers J, 2007, LEUKEMIA, V21, P1580, DOI 10.1038/sj.leu.2404658; Calvi LM, 2015, BLOOD, V126, P2443, DOI 10.1182/blood-2015-07-533588; Crnalic S, 2010, ENDOCR-RELAT CANCER, V17, P885, DOI 10.1677/ERC-10-0059; Diedrich J, 2015, HORM MOL BIOL CLIN I, V21, P17, DOI 10.1515/hmbci-2014-0045; Diedrich JD, 2016, ONCOTARGET, V7, P64854, DOI 10.18632/oncotarget.11712; Gimble JM, 1996, BONE, V19, P421, DOI 10.1016/S8756-3282(96)00258-X; Gordon Jacob A, 2018, Oncotarget, V9, P19861, DOI 10.18632/oncotarget.24888; Goto T, 2011, BIOCHEM J, V438, P111, DOI 10.1042/BJ20101939; Hardaway AL, 2015, CLIN EXP METASTAS, V32, P353, DOI 10.1007/s10585-015-9714-5; Hardaway AL, 2014, CANCER METAST REV, V33, P527, DOI 10.1007/s10555-013-9484-y; Harshman LC, 2015, JAMA ONCOL, V1, P495, DOI 10.1001/jamaoncol.2015.0829; Herroon MK, 2013, ONCOTARGET, V4, P2108, DOI 10.18632/oncotarget.1482; Jiao SP, 2019, CELL, V179, P1177, DOI 10.1016/j.cell.2019.10.029; Laurent V, 2019, MOL CANCER RES, V17, P821, DOI 10.1158/1541-7786.MCR-18-0748; Laurent V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10230; Lee YC, 2015, CANCER RES, V75, P4949, DOI 10.1158/0008-5472.CAN-15-1215; Lee YC, 2013, MOL CANCER RES, V11, P405, DOI 10.1158/1541-7786.MCR-12-0551; Lin DS, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.510; Liu ZQ, 2015, ONCOTARGET, V6, P34329, DOI 10.18632/oncotarget.6020; Logothetis CJ, 2013, CANCER DISCOV, V3, P849, DOI 10.1158/2159-8290.CD-12-0460; Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528; Lucas-Herald AK, 2017, CLIN SCI, V131, P1405, DOI 10.1042/CS20170090; Mantalaris A, 2001, J PATHOL, V193, P361, DOI 10.1002/1096-9896(0000)9999:9999<::AID-PATH803>3.0.CO;2-W; Morris EV, 2018, J CELL PHYSIOL, V233, P9159, DOI 10.1002/jcp.26884; Ottewell PD, 2014, ENDOCR-RELAT CANCER, V21, P769, DOI 10.1530/ERC-14-0199; Platz EA, 2006, JNCI-J NATL CANCER I, V98, P1819, DOI 10.1093/jnci/djj499; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Sakaue-Sawano A, 2008, CELL, V132, P487, DOI 10.1016/j.cell.2007.12.033; Sato K, 2004, J HUM GENET, V49, P29, DOI 10.1007/s10038-003-0103-6; Sato S, 2008, CANCER SCI, V99, P316, DOI 10.1111/j.1349-7006.2007.00690.x; Saxena NK, 2007, J BIOL CHEM, V282, P13316, DOI 10.1074/jbc.M609798200; Sharifi N, 2010, ENDOCR-RELAT CANCER, V17, pR305, DOI 10.1677/ERC-10-0187; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; SUTHERLAND HJ, 1991, BLOOD, V78, P666, DOI 10.1182/blood.V78.3.666.bloodjournal783666; Tang KD, 2016, ONCOTARGET, V7, P4939, DOI 10.18632/oncotarget.6643; TAVASSOLI M, 1974, ARCH PATHOL, V98, P189; TAVASSOLI M, 1976, ACTA ANAT, V94, P65; Tencerova M, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00127; THALMANN GN, 1994, CANCER RES, V54, P2577; Thalmann GN, 2000, PROSTATE, V44, P91; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Wu TT, 1998, INT J CANCER, V77, P887, DOI 10.1002/(SICI)1097-0215(19980911)77:6<887::AID-IJC15>3.0.CO;2-Z; Xu LJ, 2018, PROSTATE, V78, P353, DOI 10.1002/pros.23479; Yu-Lee LY, 2018, CANCER RES, V78, P2911, DOI 10.1158/0008-5472.CAN-17-1051; Zhang YX, 2018, P NATL ACAD SCI USA, V115, pE6039, DOI 10.1073/pnas.1806366115	49	5	5	3	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2021	40	27					4592	4603		10.1038/s41388-021-01874-7	http://dx.doi.org/10.1038/s41388-021-01874-7		JUN 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TG4PV	34127814	Green Accepted			2022-12-17	WOS:000661408100002
J	Wang, SP; Cao, K; Liao, YT; Zhang, W; Zheng, JH; Li, XC; Huang, MT; Zhong, YH; Hu, X; Chen, D; Wang, YJ				Wang, Shouping; Cao, Kun; Liao, Yuting; Zhang, Wei; Zheng, Jihua; Li, Xiaocui; Huang, Mengting; Zhong, Yonghao; Hu, Xiao; Chen, De; Wang, Yanjie			CDCA2 protects against oxidative stress by promoting BRCA1-NRF2 signaling in hepatocellular carcinoma	ONCOGENE			English	Article							CELL-PROLIFERATION; GENE FAMILY; E3 LIGASE; CANCER; TRANSCRIPTION; NRF2; PATHWAY; EXPRESSION; MUTATIONS; APOPTOSIS	Hepatocellular carcinoma (HCC) patients mostly suffer from poor survival outcomes. It is necessary to identify effective therapeutic targets to improve prognosis for HCC patients. Here, we report a new factor, CDCA2, in promoting HCC development. CDCA2 amplification is an independent risk factor for the recurrence and survival of HCC patients, which is positively correlated with elevated level of alpha-fetoprotein (AFP), high histological grade, large tumor size, advanced TNM stage, and poor prognosis for HCC patients. In HCC cells, CDCA2 promotes cell growth and inhibits apoptosis. Mechanistically, CDCA2's transcription is activated through the binding of E2F2/E2F8 with its promoter. CDCA2 depletion contributes to the suppression of cell proliferation and induction of apoptosis due to reactive oxygen species (ROS)-mediated stress, which can be reversed by antioxidants N-acetyl cysteine (NAC) and glutathione (GSH). Interestingly, we found that CDCA2 triggers the BRCA1-NRF2 cascade, which elevates antioxidant response and attenuates ROS levels. In response to oxidative stress, CDCA2 promotes BRCA1's chromatin relocalization to NRF2, activating NRF2-driven downstream signaling (HO-1, TXNRD1, and NQO1), which then protects HCC cells against oxidative damage. In conclusion, our results reveal that CDCA2 is a prognostic biomarker for HCC patients, and present the E2F2/E2F8-CDCA2-BRCA1-NRF2-ROS signaling axis that have implications for HCC therapeutics.	[Wang, Shouping; Zhang, Wei; Li, Xiaocui; Huang, Mengting; Wang, Yanjie] Guangzhou Med Univ, Dept Anesthesiol, Affiliated Hosp 3, Guangzhou, Peoples R China; [Cao, Kun] Guangdong Med Univ, Inst Aging Res, Guangdong Prov Key Lab Med Mol Diagnost, Dongguan, Peoples R China; [Liao, Yuting; Zheng, Jihua] Gen Hosp Southern Theater Command, Dept Radiotherapy, Guangzhou, Peoples R China; [Zhong, Yonghao] Shenzhen Futian Dist, Dept Surg, Peoples Hosp 2, Shenzhen, Peoples R China; [Hu, Xiao] Second Peoples Hosp Guangdong Prov, Dept Surg, Guangzhou, Peoples R China; [Chen, De; Wang, Yanjie] Guangzhou Med Univ, Biomed Res Ctr, Affiliated Hosp 3, Guangzhou, Peoples R China	Guangzhou Medical University; Guangdong Medical University; Southern Theater Command General Hospital; Guangzhou Medical University	Wang, YJ (corresponding author), Guangzhou Med Univ, Dept Anesthesiol, Affiliated Hosp 3, Guangzhou, Peoples R China.; Chen, D; Wang, YJ (corresponding author), Guangzhou Med Univ, Biomed Res Ctr, Affiliated Hosp 3, Guangzhou, Peoples R China.	drchende@gzhmu.edu.cn; YanjieW@outlook.com			National Natural Science Foundation of China [82002104]; Science and technology project of Guangzhou [201707010379]; Natural Science Youth Project of the Third Affiliated Hospital of Guangzhou Medical University [2019Q07, 2019B06]; Guangdong Basic and Applied Basic Research Foundation [2019A1515110659]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and technology project of Guangzhou; Natural Science Youth Project of the Third Affiliated Hospital of Guangzhou Medical University; Guangdong Basic and Applied Basic Research Foundation	This work was supported by the National Natural Science Foundation of China (No. 81672393), Science and technology project of Guangzhou (No. 201707010379), Natural Science Youth Project of the Third Affiliated Hospital of Guangzhou Medical University (No. 2019Q07, 2019B06), the National Natural Science Foundation of China (82002104, to KC), Guangdong Basic and Applied Basic Research Foundation (2019A1515110659, to KC).	Bae I, 2004, CANCER RES, V64, P7893, DOI 10.1158/0008-5472.CAN-04-1119; Baiz D, 2014, WORLD J GASTROENTERO, V20, P795, DOI 10.3748/wjg.v20.i3.795; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cao L, 2007, CARCINOGENESIS, V28, P1401, DOI 10.1093/carcin/bgm060; Chen CX, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.01.99; Chen D, 2020, THERANOSTICS, V10, P8558, DOI 10.7150/thno.44873; Chen WM, 2009, MOL CELL, V34, P663, DOI 10.1016/j.molcel.2009.04.029; Chen XP, 2010, FREE RADICAL RES, V44, P587, DOI 10.3109/10715761003709802; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; El-Daher MT, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0061-y; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Gorbunova V, 2016, CELL, V165, P1312, DOI 10.1016/j.cell.2016.05.061; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Gorrini C, 2013, J EXP MED, V210, P1529, DOI 10.1084/jem.20121337; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hill SJ, 2014, GENE DEV, V28, P1957, DOI 10.1101/gad.241620.114; Huang GQ, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0770-y; Huang JZ, 2017, MOL CELL, V68, P171, DOI 10.1016/j.molcel.2017.09.015; Huang JZ, 2016, J PATHOL, V239, P186, DOI 10.1002/path.4716; Jeong Y, 2017, CANCER DISCOV, V7, P86, DOI 10.1158/2159-8290.CD-16-0127; Kim H, 2005, ONCOGENE, V24, P1252, DOI 10.1038/sj.onc.1208282; Le Gal K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad3740; Metallo CM, 2013, MOL CELL, V49, P388, DOI 10.1016/j.molcel.2013.01.018; Panieri E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.105; Thang PM, 2016, INT J ONCOL, V49, P1385, DOI 10.3892/ijo.2016.3649; Rezazadeh S, 2019, NUCLEIC ACIDS RES, V47, P7914, DOI 10.1093/nar/gkz528; Saha T, 2009, FEBS LETT, V583, P1535, DOI 10.1016/j.febslet.2009.04.005; Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025; Shen ZQ, 2018, ONCOTARGETS THER, V11, P891, DOI 10.2147/OTT.S154754; Shi R, 2017, ONCOTARGET, V8, P19768, DOI 10.18632/oncotarget.15519; Shibata T, 2008, P NATL ACAD SCI USA, V105, P13568, DOI 10.1073/pnas.0806268105; Subramanian A, 2007, BIOINFORMATICS, V23, P3251, DOI 10.1093/bioinformatics/btm369; Sugawara S, 2018, J HUM GENET, V63, P657, DOI 10.1038/s10038-018-0437-8; Sun XF, 2016, HEPATOLOGY, V63, P173, DOI 10.1002/hep.28251; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430; Teng YQ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06586-3; Uchida F, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-321; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Vagnarelli P, 2014, ADV EXP MED BIOL, V773, P401, DOI 10.1007/978-1-4899-8032-8_18; Wang H, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad6095; Wiel C, 2019, CELL, V178, P330, DOI 10.1016/j.cell.2019.06.005; Wu BW, 2020, J CANCER, V11, P5727, DOI 10.7150/jca.46554; Xanthoulis A, 2013, WORLD J GASTROENTERO, V19, P3189, DOI 10.3748/wjg.v19.i21.3189; Xu IMJ, 2016, P NATL ACAD SCI USA, V113, pE725, DOI 10.1073/pnas.1508779113; Xu YJ, 2018, MOL MED REP, V17, P1507, DOI 10.3892/mmr.2017.8095; Zhan L, 2014, CELL SIGNAL, V26, P1075, DOI 10.1016/j.cellsig.2014.01.008; Zhang YX, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00725; Zou YZ, 2020, AGING-US, V12, P25304, DOI 10.18632/aging.104131	49	5	5	6	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2021	40	25					4368	4383		10.1038/s41388-021-01855-w	http://dx.doi.org/10.1038/s41388-021-01855-w		JUN 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SY4AZ	34103686				2022-12-17	WOS:000659032900007
J	Wu, QY; Zhang, Y; An, HY; Sun, W; Wang, RZ; Liu, M; Zhang, KT				Wu, Quanyou; Zhang, Yuan; An, Haiyin; Sun, Wei; Wang, Ruozheng; Liu, Meng; Zhang, Kaitai			The landscape and biological relevance of aberrant alternative splicing events in esophageal squamous cell carcinoma	ONCOGENE			English	Article							GENE; TRANSCRIPTOME; ACCURATE; ISOFORMS; RATIO	Aberrant alternative splicing events (AASEs) are key biological processes for tumorigenesis and the rationale for designing splice-switching oligonucleotides (SSOs). However, the landscape of AASEs in esophageal squamous cell carcinoma (ESCC) remains unclear, which undermines the development of SSOs for ESCC. Here, we profiled AASEs based on 125 pairs of RNA-seq libraries. We identified 14,710 AASEs in ESCC, most of which (92.67%) affected coding genes. The first exon of transcripts was frequently changed in ESCC. We constructed a regulatory network where 74 RNA-binding proteins regulated 2142 AASEs. This network was enriched in apoptotic pathways and various adhesion/junction-related processes. Somatic mutations in ESCC regulating ASEs were mainly through trans-regulatory mode and were enriched in intron regions. Isoform switches of apoptotic genes and binding genes both tended to induce "noncoding transcripts" and "domain loss," disrupting the apoptotic and Hippo signaling pathways. All ESCC samples were grouped into three clusters with different AASEs patterns and the second cluster was identified as "cold tumor," with a low abundance of immune cells, activated immune pathways, and immunomodulators. Our work comprehensively profiled the landscape of AASEs in ESCC, revealed novel AASEs related to tumorigenesis and immune microenvironment, and suggested promising directions for designing SSOs for ESCC.	[Wu, Quanyou; Zhang, Kaitai] Chinese Acad Med Sci, State Key Lab Mol Oncol, Dept Etiol & Carcinogenesis, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China; [Wu, Quanyou; Zhang, Kaitai] Peking Union Med Coll, Beijing 100021, Peoples R China; [Zhang, Yuan; Sun, Wei; Wang, Ruozheng; Liu, Meng] Xinjiang Med Univ, Key Lab Oncol Xinjiang Uyghur Autonomous Reg, Affiliated Tumor Hosp, Urumqi, Xinjiang, Peoples R China; [An, Haiyin] Capital Med Univ, Beijing Chest Hosp, Beijing TB & Thorac Tumor Res Inst, Dept Med Oncol, Beijing 101149, Peoples R China; [Wang, Ruozheng; Liu, Meng] Chinese Acad Med Sci, Key Lab Canc Immunotherapy & Radiotherapy, Urumqi 830011, Xinjiang, Peoples R China; [Wang, Ruozheng; Liu, Meng] Xinjiang Med Univ, State Key Lab Pathogenesis Prevent & Treatment Hi, Urumqi 830011, Xinjiang, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Xinjiang Medical University; Capital Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Xinjiang Medical University	Zhang, KT (corresponding author), Chinese Acad Med Sci, State Key Lab Mol Oncol, Dept Etiol & Carcinogenesis, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China.; Zhang, KT (corresponding author), Peking Union Med Coll, Beijing 100021, Peoples R China.; Liu, M (corresponding author), Xinjiang Med Univ, Key Lab Oncol Xinjiang Uyghur Autonomous Reg, Affiliated Tumor Hosp, Urumqi, Xinjiang, Peoples R China.; Liu, M (corresponding author), Chinese Acad Med Sci, Key Lab Canc Immunotherapy & Radiotherapy, Urumqi 830011, Xinjiang, Peoples R China.; Liu, M (corresponding author), Xinjiang Med Univ, State Key Lab Pathogenesis Prevent & Treatment Hi, Urumqi 830011, Xinjiang, Peoples R China.	liuxiaomeng198154@163.com; zhangkt@cicams.ac.cn		Wu, Quanyou/0000-0002-3180-8606	Research Fund of Key Laboratory of Xinjiang oncology [2017D04006]	Research Fund of Key Laboratory of Xinjiang oncology	This research was supported by the Research Fund of Key Laboratory of Xinjiang oncology (Grant no. 2017D04006). Funders only provided funding and had no role in the study design, data collection, data analysis, interpretation, and writing of the report. The authors thank Dr Wen Zhang (Department of Immunology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China) for providing technical assistance.	Aigner P, 2019, BLOOD ADV, V3, P1989, DOI 10.1182/bloodadvances.2018026385; Akgul C, 2004, CELL MOL LIFE SCI, V61, P2189, DOI 10.1007/s00018-004-4001-7; Alipanahi B, 2015, NAT BIOTECHNOL, V33, P831, DOI 10.1038/nbt.3300; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Armenteros JJA, 2019, NAT BIOTECHNOL, V37, P420, DOI 10.1038/s41587-019-0036-z; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; BECHT E, 2016, GENOME BIOL, V17; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bonnal SC, 2020, NAT REV CLIN ONCOL, V17, P457, DOI 10.1038/s41571-020-0350-x; Brandt AC, 2020, P NATL ACAD SCI USA, V117, P3627, DOI 10.1073/pnas.1914153117; Chabot B, 2016, J CELL BIOL, V212, P13, DOI 10.1083/jcb.201510032; Crooke ST, 2018, CELL METAB, V27, P714, DOI 10.1016/j.cmet.2018.03.004; Desterro J, 2020, NAT REV DRUG DISCOV, V19, P112, DOI 10.1038/s41573-019-0042-3; FINOTELLO F, 2019, GENOME MED, V11; Frankiw L, 2019, NAT REV IMMUNOL, V19, P675, DOI 10.1038/s41577-019-0195-7; Garrido-Martin D, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20578-2; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Halloy F, 2020, NUCLEIC ACIDS RES, V48, P4658, DOI 10.1093/nar/gkaa229; Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111; Kang YJ, 2017, NUCLEIC ACIDS RES, V45, pW12, DOI 10.1093/nar/gkx428; Khorkova O, 2017, NAT BIOTECHNOL, V35, P249, DOI 10.1038/nbt.3784; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Klausen MS, 2019, PROTEINS, V87, P520, DOI 10.1002/prot.25674; Lagergren J, 2017, LANCET, V390, P2383, DOI 10.1016/S0140-6736(17)31462-9; Li B, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1028-7; Li L, 2020, BRIT J CANCER, V123, P1024, DOI 10.1038/s41416-020-0951-2; Li SL, 2019, HEPATOLOGY, V69, P359, DOI 10.1002/hep.30158; Liu M, 2020, EBIOMEDICINE, V57, DOI 10.1016/j.ebiom.2020.102831; Liu YE, 2019, PATHOL RES PRACT, V215, P272, DOI 10.1016/j.prp.2018.10.036; Lucena-Araujo AR, 2015, BLOOD, V126, P2302, DOI 10.1182/blood-2015-01-623330; Mao SS, 2019, CARCINOGENESIS, V40, P121, DOI 10.1093/carcin/bgy123; Marti, 2019, TAPPAS COMPREHENSIVE, DOI 10.1101/690743; Matlin AJ, 2005, NAT REV MOL CELL BIO, V6, P386, DOI 10.1038/nrm1645; Michaels WE, 2020, NUCLEIC ACIDS RES, V48, P7454, DOI 10.1093/nar/gkaa490; Mogilevsky M, 2018, NUCLEIC ACIDS RES, V46, P11396, DOI 10.1093/nar/gky921; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/nmeth.3337, 10.1038/NMETH.3337]; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Pertea M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/nbt.3122; Peterson RE, 2005, DEV DYNAM, V233, P811, DOI 10.1002/dvdy.20412; Racle J, 2017, ELIFE, V6, DOI 10.7554/eLife.26476; Rustgi AK, 2014, NEW ENGL J MED, V371, P2499, DOI 10.1056/NEJMra1314530; Ryan M, 2016, NUCLEIC ACIDS RES, V44, pD1018, DOI 10.1093/nar/gkv1288; Ryan MC, 2012, BIOINFORMATICS, V28, P2385, DOI 10.1093/bioinformatics/bts452; Shabalin AA, 2012, BIOINFORMATICS, V28, P1353, DOI 10.1093/bioinformatics/bts163; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Soliman MA, 2008, AGING CELL, V7, P783, DOI 10.1111/j.1474-9726.2008.00427.x; Sturm G, 2019, BIOINFORMATICS, V35, pI436, DOI 10.1093/bioinformatics/btz363; Thorsson V, 2018, IMMUNITY, V48, P812, DOI 10.1016/j.immuni.2018.03.023; Trincado JL, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1417-1; Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507; Vanharanta S, 2014, ELIFE, V3, DOI 10.7554/eLife.02734; Vitting-Seerup K, 2019, BIOINFORMATICS, V35, P4469, DOI 10.1093/bioinformatics/btz247; Wahl MC, 2009, CELL, V136, P701, DOI 10.1016/j.cell.2009.02.009; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wang LY, 2020, NUCLEIC ACIDS RES, V48, P5065, DOI 10.1093/nar/gkaa194; Warzecha CC, 2010, EMBO J, V29, P3286, DOI 10.1038/emboj.2010.195; Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170; Xie ZC, 2019, AM J TRANSL RES, V11, P4010; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118	60	5	5	3	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2021	40	24					4184	4197		10.1038/s41388-021-01849-8	http://dx.doi.org/10.1038/s41388-021-01849-8		JUN 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SU3OE	34079089				2022-12-17	WOS:000657217400005
J	Yang, X; Chen, Y; Zhou, Y; Wu, C; Li, Q; Wu, J; Hu, WW; Zhao, WQ; Wei, W; Wu, CP; Jiang, JT; Ji, M				Yang, Xin; Chen, Yan; Zhou, You; Wu, Chen; Li, Qing; Wu, Jun; Hu, Wen Wei; Zhao, Wei Qing; Wei, Wei; Wu, Chang Ping; Jiang, Jing Ting; Ji, Mei			GPC5 suppresses lung cancer progression and metastasis via intracellular CTDSP1/AhR/ARNT signaling axis and extracellular exosome secretion	ONCOGENE			English	Article							ANTITUMOR IMMUNITY; TUMOR-GROWTH; GLYPICAN-5; GENE; MICRORNAS; NICHE; MECHANISMS; TRANSITION; EXPRESSION; SMOKERS	Lung cancer is the leading cause of cancer-related death worldwide. Glypican-5 (GPC5) is a member of heparan sulfate proteoglycans, and its biological importance in initiation and progression of lung cancer remains controversial. In the present study, we revealed that GPC5 transcriptionally enhanced the expression of CTDSP1 (miR-26b host gene) via AhR-ARNT pathway, and such up-regulation of CTDSP1 intracellularly contributed to the inhibited proliferation of lung cancer cells. Moreover, exosomes derived from GPC5-overexpressing human lung cancer cells (GPC5-OE-derived exosomes) had an extracellular repressive effect on human lymphatic endothelial cells (hLECs), leading to decreased tube formation and migration. Comparison between GPC5-WT- and GPC5-OE-derived exosomes showed that miR-26b (embedded within introns of CTDSP1 gene) was significantly up-regulated in GPC5-OE-derived exosomes and critical to the influence on hLECs. On the mechanism, we demonstrated that miR-26b transferred into hLECs directly targeted to PTK2 3'-UTR and led to PTK2 down-regulation, resulting in defects in tube formation and migration of hLECs. By uncovering the regulation network among GPC5, miR-26b, miR-26b host gene (CTDSP1), and target gene (PTK2), our findings demonstrated that GPC5 functioned as a tumor suppressor in human lung cancer.	[Yang, Xin; Chen, Yan; Wu, Chen; Wu, Jun; Hu, Wen Wei; Zhao, Wei Qing; Wei, Wei; Wu, Chang Ping; Ji, Mei] Soochow Univ, Dept Oncol, Affiliated Hosp 3, Changzhou, Peoples R China; [Yang, Xin; Zhou, You; Jiang, Jing Ting] Jiangsu Engn Res Ctr Tumor Immunotherapy, Changzhou, Peoples R China; [Yang, Xin; Zhou, You; Jiang, Jing Ting] Soochow Univ, Inst Cell Therapy, Changzhou, Peoples R China; [Zhou, You; Jiang, Jing Ting] Soochow Univ, Affiliated Hosp 3, Dept Tumor Biol Treatment, Changzhou, Peoples R China; [Li, Qing] Soochow Univ, Affiliated Hosp 3, Dept Pathol, Changzhou, Peoples R China	Soochow University - China; Soochow University - China; Soochow University - China; Soochow University - China	Yang, X; Ji, M (corresponding author), Soochow Univ, Dept Oncol, Affiliated Hosp 3, Changzhou, Peoples R China.; Yang, X; Jiang, JT (corresponding author), Jiangsu Engn Res Ctr Tumor Immunotherapy, Changzhou, Peoples R China.; Yang, X; Jiang, JT (corresponding author), Soochow Univ, Inst Cell Therapy, Changzhou, Peoples R China.; Jiang, JT (corresponding author), Soochow Univ, Affiliated Hosp 3, Dept Tumor Biol Treatment, Changzhou, Peoples R China.	yangxindoctor@163.com; jiangjingting@suda.edu.cn; zlkjimei@163.com	Zhou, You/GMW-4434-2022		Natural Science Foundation of China [82072561]; Natural Science Youth Foundation of China [81501971, 31701111, 31700792]; China Postdoctoral Science Foundation [2018M630603]; Natural Science Youth Foundation of Jiangsu Province [BK20150252, BK20170295]; Human Resource Summit Grant of Jiangsu Province [WSW-142]; Youth Medical Professionals Foundation of Jiangsu Province [QNRC2016279]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Youth Foundation of China; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Natural Science Youth Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Human Resource Summit Grant of Jiangsu Province; Youth Medical Professionals Foundation of Jiangsu Province	This work was supported by grants from the Natural Science Foundation of China (82072561), the Natural Science Youth Foundation of China (81501971, 31701111, 31700792), Project funded by China Postdoctoral Science Foundation (2018M630603), the Natural Science Youth Foundation of Jiangsu Province (BK20150252, BK20170295), the Human Resource Summit Grant of Jiangsu Province (WSW-142), and the Youth Medical Professionals Foundation of Jiangsu Province (QNRC2016279).	Alitalo K, 2011, NAT MED, V17, P1371, DOI 10.1038/nm.2545; Ameres SL, 2007, CELL, V130, P101, DOI 10.1016/j.cell.2007.04.037; Bang C, 2014, J CLIN INVEST, V124, P2136, DOI 10.1172/JCI70577; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Broekman ML, 2018, NAT REV NEUROL, V14, P482, DOI 10.1038/s41582-018-0025-8; Butler JM, 2010, NAT REV CANCER, V10, P138, DOI 10.1038/nrc2791; Cao YH, 2005, NAT REV CANCER, V5, P735, DOI 10.1038/nrc1693; Chen G, 2018, NATURE, V560, P382, DOI 10.1038/s41586-018-0392-8; Chen Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11420; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Devarakonda S, 2015, LANCET ONCOL, V16, pE342, DOI 10.1016/S1470-2045(15)00077-7; Fong MY, 2015, NAT CELL BIOL, V17, P183, DOI 10.1038/ncb3094; Govindan R, 2012, CELL, V150, P1121, DOI 10.1016/j.cell.2012.08.024; Hirsch FR, 2017, LANCET, V389, P299, DOI 10.1016/S0140-6736(16)30958-8; Hulsmans M, 2013, CARDIOVASC RES, V100, P7, DOI 10.1093/cvr/cvt161; Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821; Kruspig B, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao2565; LeBleu VS, 2019, IMMUNITY, V50, P547, DOI 10.1016/j.immuni.2019.02.019; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li FC, 2011, J CELL BIOL, V192, P691, DOI 10.1083/jcb.201008087; Li YF, 2011, J THORAC ONCOL, V6, P2, DOI 10.1097/JTO.0b013e3181fd6b04; Li YF, 2010, LANCET ONCOL, V11, P321, DOI 10.1016/S1470-2045(10)70042-5; Li Y, 2013, ONCOL LETT, V6, P1565, DOI 10.3892/ol.2013.1622; Lito P, 2016, SCIENCE, V351, P604, DOI 10.1126/science.aad6204; Mallory AC, 2004, EMBO J, V23, P3356, DOI 10.1038/sj.emboj.7600340; Nishimura R, 2013, CANCER SCI, V104, P856, DOI 10.1111/cas.12173; Noone A, 2017, SEER CANC STAT REV C; Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796; Ovrevik J, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/s12964-014-0048-8; Poggio M, 2019, CELL, V177, P414, DOI 10.1016/j.cell.2019.02.016; Swanson HI, 2002, CHEM-BIOL INTERACT, V141, P63, DOI 10.1016/S0009-2797(02)00066-2; Tian YA, 2009, BIOCHEM PHARMACOL, V77, P670, DOI 10.1016/j.bcp.2008.10.023; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Veugelers M, 1997, GENOMICS, V40, P24, DOI 10.1006/geno.1996.4518; Wang SW, 2016, ONCOTARGET, V7, P79722, DOI 10.18632/oncotarget.12945; Wang Z, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1056-9; Williamson D, 2007, CANCER RES, V67, P57, DOI 10.1158/0008-5472.CAN-06-1650; Xu R, 2018, NAT REV CLIN ONCOL, V15, P617, DOI 10.1038/s41571-018-0036-9; Yang X, 2013, CANCER LETT, V341, P265, DOI 10.1016/j.canlet.2013.08.020; Yuan S, 2016, ONCOGENE, V35, P6120, DOI 10.1038/onc.2016.149; Zhang CW, 2016, TUMOR BIOL, V37, P6413, DOI 10.1007/s13277-015-4499-3; Zhang CW, 2011, MOL GENET METAB, V103, P104, DOI 10.1016/j.ymgme.2011.02.005; Zhang J, 2015, GENOM PROTEOM BIOINF, V13, P17, DOI 10.1016/j.gpb.2015.02.001; Zhang L, 2015, NATURE, V527, P100, DOI 10.1038/nature15376; Zhang YJ, 2010, MOL CELL, V39, P133, DOI 10.1016/j.molcel.2010.06.010; Zhu Y, 2012, NUCLEIC ACIDS RES, V40, P4615, DOI 10.1093/nar/gkr1278	48	5	5	1	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2021	40	25					4307	4323		10.1038/s41388-021-01837-y	http://dx.doi.org/10.1038/s41388-021-01837-y		JUN 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SY4AZ	34079082				2022-12-17	WOS:000657217400004
J	Guo, M; Goudarzi, KM; Abedi, S; Pieber, M; Sjoberg, E; Behnan, J; Zhang, XM; Harris, RA; Bartek, J; Lindstrom, MS; Nister, M; Hagerstrand, D				Guo, Min; Goudarzi, Kaveh M.; Abedi, Shiva; Pieber, Melanie; Sjoberg, Elin; Behnan, Jinan; Zhang, Xing-Mei; Harris, Robert A.; Bartek, Jiri; Lindstrom, Mikael S.; Nister, Monica; Hagerstrand, Daniel			SFRP2 induces a mesenchymal subtype transition by suppression of SOX2 in glioblastoma	ONCOGENE			English	Article							STEM-LIKE CELLS; GROWTH-FACTOR; INTRATUMORAL HETEROGENEITY; KINASE INHIBITOR; CONNECTIVITY MAP; TUMOR; EXPRESSION; EGFR; PROLIFERATION; AMPLIFICATION	Intratumoral heterogeneity is a characteristic of glioblastomas that contain an intermixture of cell populations displaying different glioblastoma subtype gene expression signatures. Proportions of these populations change during tumor evolution, but the occurrence and regulation of glioblastoma subtype transition is not well described. To identify regulators of glioblastoma subtypes we utilized a combination of in vitro experiments and in silico analyses, using experimentally generated as well as publicly available data. Through this combined approach SOX2 was identified to confer a proneural glioblastoma subtype gene expression signature. SFRP2 was subsequently identified as a SOX2-antagonist, able to induce a mesenchymal glioblastoma subtype signature. A subset of patient glioblastoma samples with high SFRP2 and low SOX2 expression was particularly enriched with mesenchymal subtype samples. Phenotypically, SFRP2 decreased tumor sphere formation, stemness as assessed by limiting dilution assay, and overall cell proliferation but increased cell motility, whereas SOX2 induced the opposite effects. Furthermore, an SFRP2/non-canonical-WNT/KLF4/PDGFR/phospho-AKT/SOX2 signaling axis was found to be involved in the mesenchymal transition. Analysis of human tumor tissue spatial gene expression patterns showed distinct expression of SFRP2- and SOX2-correlated genes in vascular and cellular areas, respectively. Finally, conditioned media from SFRP2 overexpressing cells increased CD206 on macrophages. Together, these findings present SFRP2 as a SOX2-antagonist with the capacity to induce a mesenchymal subtype transition in glioma cells located in vascular tumor areas, highlighting its role in glioblastoma tumor evolution and intratumoral heterogeneity.	[Guo, Min; Abedi, Shiva; Nister, Monica; Hagerstrand, Daniel] Karolinska Inst, Dept Oncol Pathol, BioClinicum, Solna, Sweden; [Guo, Min] Capital Med Univ, Beijing Tiantan Hosp, Dept Radiol, Beijing, Peoples R China; [Goudarzi, Kaveh M.] Karolinska Inst, Dept Oncol Pathol, Sci Life Lab, Solna, Sweden; [Pieber, Melanie; Zhang, Xing-Mei; Harris, Robert A.] Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Solna, Sweden; [Sjoberg, Elin] Uppsala Univ, Dept Immunol Genet & Pathol, Rudbeck Lab, Uppsala, Sweden; [Behnan, Jinan] Karolinska Inst, Dept Med Biochem & Biophys, Div Mol Neurobiol, Solna, Sweden; [Behnan, Jinan] Albert Einstein Coll Med, Dept Neurosurg, Bronx, NY 10467 USA; [Bartek, Jiri; Lindstrom, Mikael S.] Karolinska Inst, Dept Med Biochem & Biophys, Solna, Sweden; [Bartek, Jiri] Danish Canc Soc Res Ctr, Copenhagen, Denmark; [Hagerstrand, Daniel] Karolinska Inst, Dept Mol Med & Surg, BioClinicum, Solna, Sweden	Karolinska Institutet; Capital Medical University; Karolinska Institutet; Karolinska Institutet; Uppsala University; Karolinska Institutet; Yeshiva University; Albert Einstein College of Medicine; Karolinska Institutet; Danish Cancer Society; Karolinska Institutet	Guo, M (corresponding author), Karolinska Inst, Dept Oncol Pathol, BioClinicum, Solna, Sweden.; Guo, M (corresponding author), Capital Med Univ, Beijing Tiantan Hosp, Dept Radiol, Beijing, Peoples R China.	min.guo@ki.se	Hägerstrand, Daniel C/D-1584-2014; Hägerstrand, Daniel/AAH-3009-2019; Lindström, Mikael S/AAA-1451-2019; Sjöberg, Elin/AFQ-2245-2022	Hägerstrand, Daniel C/0000-0001-7270-0776; Hägerstrand, Daniel/0000-0001-7270-0776; Lindström, Mikael S/0000-0003-1148-8497; Harris, Robert/0000-0003-4990-509X; Behnan, Jinan/0000-0001-5780-0971	Chinese Scholarship Council; Karolinska Institutet KID funding; European Commission, Research Executive Agency Marie S.Curie Individual Fellowships, H2020MSCA-IF-2018 [844948]; Swedish Cancer Society [150733, CAN 2014/836, 160334, CAN 2017/737, 180538, 2019 190316Pj]; Swedish Research Council [VR-MH 2014-46602-117891-30, K201467X-15399-10-4, VR-MH 2018-02452]; King Gustaf V's Jubilee Foundation [164102]; The Cancer Society in Stockholm [2015151213, 2018-181223]; Swedish Childhood Cancer Foundation [PR2014-0021, PR 2017-0062]; Stockholm County Council (SLL); Magnus Bergvall's stiftelse	Chinese Scholarship Council(China Scholarship Council); Karolinska Institutet KID funding(Karolinska Institutet); European Commission, Research Executive Agency Marie S.Curie Individual Fellowships, H2020MSCA-IF-2018; Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); King Gustaf V's Jubilee Foundation; The Cancer Society in Stockholm; Swedish Childhood Cancer Foundation(European Commission); Stockholm County Council (SLL)(Stockholm County Council); Magnus Bergvall's stiftelse	MG: The Chinese Scholarship Council. KMG: Karolinska Institutet KID funding. JB: European Commission, Research Executive Agency Marie S.Curie Individual Fellowships, H2020MSCA-IF-2018 (Project: 844948). JB: The Swedish Cancer Society (JB, contract 150733); The Swedish Research Council (VR-MH 2014-46602-117891-30). MSL: Karolinska Institutet Funds; King Gustaf V's Jubilee Foundation (contract 164102). MN: Karolinska Institutet Funds; LA-private donations; The Swedish Cancer Society (CAN 2014/836, contract 160334, CAN 2017/737, contract 180538, and 2019 190316Pj); The Cancer Society in Stockholm (2015151213 and 2018-181223); The Swedish Research Council (K201467X-15399-10-4, VR-MH 2018-02452); The Swedish Childhood Cancer Foundation (PR2014-0021 and PR 2017-0062); Stockholm County Council (SLL). DH: Karolinska Institutet Funds; Magnus Bergvall's stiftelse; LA-private donations.	An ZJ, 2019, CELL REP, V29, P1986, DOI 10.1016/j.celrep.2019.10.026; Baer K, 2007, EXP NEUROL, V204, P828, DOI 10.1016/j.expneurol.2006.12.008; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Brinkmann EM, 2016, J BIOL CHEM, V291, P13730, DOI 10.1074/jbc.M116.733766; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Cheng L, 2013, CELL, V153, P139, DOI 10.1016/j.cell.2013.02.021; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cooper LAD, 2012, AM J PATHOL, V180, P2108, DOI 10.1016/j.ajpath.2012.01.040; Garros-Regulez L, 2016, EXPERT OPIN THER TAR, V20, P393, DOI 10.1517/14728222.2016.1151002; Goudarzi KM, 2018, CANCER RES, V78, P5901, DOI 10.1158/0008-5472.CAN-18-0320; Guo Min, 2020, Neurooncol Adv, V2, pvdaa061, DOI 10.1093/noajnl/vdaa061; Hagerstrand D, 2006, ONCOGENE, V25, P4913, DOI 10.1038/sj.onc.1209497; Hagerstrand D, 2011, NEURO-ONCOLOGY, V13, P1178, DOI 10.1093/neuonc/nor113; Han MZ, 2020, BRAIN, V143, P512, DOI 10.1093/brain/awz406; HERMANSON M, 1992, CANCER RES, V52, P3213; Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510; Jackson EL, 2006, NEURON, V51, P187, DOI 10.1016/j.neuron.2006.06.012; Jeong CH, 2010, STEM CELLS, V28, P2141, DOI 10.1002/stem.540; Kaffes I, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1655360; Kong WH, 2012, EVOL DEV, V14, P168, DOI 10.1111/j.1525-142X.2012.00533.x; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liu LJ, 2017, NAT CELL BIOL, V19, P177, DOI 10.1038/ncb3474; Marques S, 2016, SCIENCE, V352, P1326, DOI 10.1126/science.aaf6463; Meyer M, 2015, P NATL ACAD SCI USA, V112, P851, DOI 10.1073/pnas.1320611111; Minata M, 2019, CELL REP, V26, P1893, DOI 10.1016/j.celrep.2019.01.076; Neftel C, 2019, CELL, V178, P835, DOI 10.1016/j.cell.2019.06.024; Ozawa T, 2014, CANCER CELL, V26, P288, DOI 10.1016/j.ccr.2014.06.005; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Puchalski RB, 2018, SCIENCE, V360, P660, DOI 10.1126/science.aaf2666; Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500; Savary K, 2013, ONCOGENE, V32, P5409, DOI 10.1038/onc.2013.67; Segerman A, 2016, CELL REP, V17, P2994, DOI 10.1016/j.celrep.2016.11.056; Snuderl M, 2011, CANCER CELL, V20, P810, DOI 10.1016/j.ccr.2011.11.005; Sottoriva A, 2013, P NATL ACAD SCI USA, V110, P4009, DOI 10.1073/pnas.1219747110; Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049; Sun Y, 2016, ONCOGENE, V35, P4321, DOI 10.1038/onc.2015.494; Suva ML, 2014, CELL, V157, P580, DOI 10.1016/j.cell.2014.02.030; Szerlip NJ, 2012, P NATL ACAD SCI USA, V109, P3041, DOI 10.1073/pnas.1114033109; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Tang JM, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0074-2; Taylor TE, 2012, CURR CANCER DRUG TAR, V12, P197; Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wald JH, 2017, ONCOGENE, V36, P5158, DOI 10.1038/onc.2017.126; Wang QH, 2017, CANCER CELL, V32, P42, DOI 10.1016/j.ccell.2017.06.003; Wang Z, 2019, ONCOGENE, V38, P5250, DOI 10.1038/s41388-019-0790-x; Wurth R, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00144; Xie Y, 2015, EBIOMEDICINE, V2, P1351, DOI 10.1016/j.ebiom.2015.08.026; Zhao Z, 2021, GENOM PROTEOM BIOINF, V19, P1, DOI 10.1016/j.gpb.2020.10.005; Zheng B, 2009, J BIOL CHEM, V284, P22773, DOI 10.1074/jbc.M109.026989	52	5	5	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2021	40	32					5066	5080		10.1038/s41388-021-01825-2	http://dx.doi.org/10.1038/s41388-021-01825-2		MAY 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA7OD	34021259	hybrid, Green Published			2022-12-17	WOS:000652945900002
J	Lager, TW; Conner, C; Keating, CR; Warshaw, JN; Panopoulos, AD				Lager, Tyson W.; Conner, Clay; Keating, Claudia R.; Warshaw, Jane N.; Panopoulos, Athanasia D.			Cell surface GRP78 and Dermcidin cooperate to regulate breast cancer cell migration through Wnt signaling	ONCOGENE			English	Article							STEM-CELLS; COLOCALIZATION; GENE	The heat shock protein GRP78 typically resides in the endoplasmic reticulum in normal tissues, but it has been shown to be expressed on the cell surface of several cancer cells, and some stem cells, where it can act as a signaling molecule by not-yet-fully defined mechanisms. Although cell surface GRP78 (sGRP78) has emerged as an attractive chemotherapeutic target, understanding how sGRP78 is functioning in cancer has been complicated by the fact that sGRP78 can function in a cell-context dependent manner, with a diverse array of reported binding partners, to regulate a variety of cellular responses. We had previously shown that sGRP78 was important in regulating pluripotent stem cell (PSC) functions, and hypothesized that embryonic-like mechanisms of GRP78 were critical to regulating aggressive breast cancer cell functions. Here, using proteomics we identify Dermcidin (DCD) as a novel sGRP78 binding partner common to both PSCs and breast cancer cells. We show that GRP78 and DCD cooperate to regulate stem cell and cancer cell migration that is dependent on the cell surface functions of these proteins. Finally, we identify Wnt/beta-catenin signaling, a critical pathway in stem cell and cancer cell biology, as an important downstream intermediate in regulating this migration phenotype.	[Lager, Tyson W.; Conner, Clay; Keating, Claudia R.; Warshaw, Jane N.; Panopoulos, Athanasia D.] Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA; [Lager, Tyson W.; Conner, Clay; Panopoulos, Athanasia D.] Univ Notre Dame, Ctr Stem Cells & Regenerat Med, Notre Dame, IN 46556 USA; [Panopoulos, Athanasia D.] Univ Notre Dame, Harper Canc Res Inst, Notre Dame, IN 46556 USA; [Keating, Claudia R.] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA; [Warshaw, Jane N.] Univ Texas Southwestern Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA; [Warshaw, Jane N.] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA	University of Notre Dame; University of Notre Dame; University of Notre Dame; Loyola University Chicago; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Panopoulos, AD (corresponding author), Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA.; Panopoulos, AD (corresponding author), Univ Notre Dame, Ctr Stem Cells & Regenerat Med, Notre Dame, IN 46556 USA.; Panopoulos, AD (corresponding author), Univ Notre Dame, Harper Canc Res Inst, Notre Dame, IN 46556 USA.	apanopou@nd.edu	Keating, Charles/HGE-0760-2022	Lager, Tyson/0000-0002-4815-9761	American Cancer Society Research Scholar Grant [RSG-20-022-01-CDD]; Indiana Clinical and Translational Sciences Institute [UL1TR001108]; National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award [TL1TR001107]; Hiller Family Research Fellowship; Gallagher Family; Walther Cancer Foundation Advancing Basic Cancer grant	American Cancer Society Research Scholar Grant(American Cancer Society); Indiana Clinical and Translational Sciences Institute; National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award; Hiller Family Research Fellowship; Gallagher Family; Walther Cancer Foundation Advancing Basic Cancer grant	This work was supported in part by an American Cancer Society Research Scholar Grant (RSG-20-022-01-CDD), a Walther Cancer Foundation Advancing Basic Cancer grant, and by grant UL1TR001108 from the Indiana Clinical and Translational Sciences Institute (to ADP). CC was supported in part by grant TL1TR001107 from the National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award. CRK was supported in part through a Hiller Family Research Fellowship. We thank the members of the D'Souza-Schorey laboratory for kindly providing valuable advice for the TOPFlash assays; Drs. Michelle Joyce, Matthew Champion, and Bill Boggess of the Notre Dame Mass Spectrometry and Proteomics Facility for proteomics; and Dr. Sara Cole of the Optical Microscopy Core, Notre Dame Integrated Imaging Facility (NDIIF), for her microscopy assistance and expertise. We thank Drs. Jonathan Kelber and Peter Gray for valuable discussions, and three anonymous reviewers for their helpful comments. We are grateful to the Gallagher Family for their generous support of stem cell research at the University of Notre Dame.	Bancovik J, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1022-6; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Conner C, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60269-y; Davidson DJ, 2005, CANCER RES, V65, P4663, DOI 10.1158/0008-5472.CAN-04-3426; Dunn KW, 2011, AM J PHYSIOL-CELL PH, V300, pC723, DOI 10.1152/ajpcell.00462.2010; Holm F, 2015, P NATL ACAD SCI USA, V112, P15444, DOI 10.1073/pnas.1506943112; Kelber JA, 2009, ONCOGENE, V28, P2324, DOI 10.1038/onc.2009.97; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Lee AS, 2014, NAT REV CANCER, V14, P263, DOI 10.1038/nrc3701; Liu GH, 2011, NATURE, V472, P221, DOI 10.1038/nature09879; Malta TM, 2018, CELL, V173, P338, DOI 10.1016/j.cell.2018.03.034; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; Matsuda Y, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2317; Miharada K, 2011, CELL STEM CELL, V9, P330, DOI 10.1016/j.stem.2011.07.016; Mizuno H, 2010, P NATL ACAD SCI USA, V107, P22745, DOI 10.1073/pnas.1017001108; Panopoulos AD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019743; Porter D, 2003, P NATL ACAD SCI USA, V100, P10931, DOI 10.1073/pnas.1932980100; Schittek B, 2012, J INNATE IMMUN, V4, P349, DOI 10.1159/000336844; Spike BT, 2014, STEM CELL REP, V2, P427, DOI 10.1016/j.stemcr.2014.02.010; Stewart GD, 2008, CURR OPIN CLIN NUTR, V11, P208, DOI 10.1097/MCO.0b013e3282fb7b8d; Subik K, 2010, BREAST CANCER-BASIC, V4, P35; Tsai YL, 2018, P NATL ACAD SCI USA, V115, pE4245, DOI 10.1073/pnas.1714866115; Tsai YL, 2015, J BIOL CHEM, V290, P8049, DOI 10.1074/jbc.M114.618736; Tseng CC, 2019, LIFE SCI ALLIANCE, V2, DOI 10.26508/lsa.201900377; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304	27	5	5	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2021	40	23					4050	4059		10.1038/s41388-021-01821-6	http://dx.doi.org/10.1038/s41388-021-01821-6		MAY 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SQ8GV	33981001	Green Accepted			2022-12-17	WOS:000650166200001
J	Cronin, R; Brooke, GN; Prischi, F				Cronin, Ryan; Brooke, Greg N.; Prischi, Filippo			The role of the p90 ribosomal S6 kinase family in prostate cancer progression and therapy resistance	ONCOGENE			English	Review							EPIDERMAL-GROWTH-FACTOR; BOX-BINDING PROTEIN-1; ANDROGEN RECEPTOR; RSK FAMILY; POSTTRANSLATIONAL MODIFICATION; INTEGRIN ACTIVATION; BREAST-CANCER; TARGETING RSK; YB-1 YBX1; RAS-ERK	Prostate cancer (PCa) is the second most commonly occurring cancer in men, with over a million new cases every year worldwide. Tumor growth and disease progression is mainly dependent on the Androgen Receptor (AR), a ligand dependent transcription factor. Standard PCa therapeutic treatments include androgen-deprivation therapy and AR signaling inhibitors. Despite being successful in controlling the disease in the majority of men, the high frequency of disease progression to aggressive and therapy resistant stages (termed castrate resistant prostate cancer) has led to the search for new therapeutic targets. The p90 ribosomal S6 kinase (RSK1-4) family is a group of highly conserved Ser/Thr kinases that holds promise as a novel target. RSKs are effector kinases that lay downstream of the Ras/Raf/MEK/ERK signaling pathway, and aberrant activation or expression of RSKs has been reported in several malignancies, including PCa. Despite their structural similarities, RSK isoforms have been shown to perform nonredundant functions and target a wide range of substrates involved in regulation of transcription and translation. In this article we review the roles of the RSKs in proliferation and motility, cell cycle control and therapy resistance in PCa, highlighting the possible interplay between RSKs and AR in mediating disease progression. In addition, we summarize the current advances in RSK inhibitor development and discuss their potential clinical benefits.	[Cronin, Ryan; Brooke, Greg N.; Prischi, Filippo] Univ Essex, Sch Life Sci, Colchester, Essex, England	University of Essex	Brooke, GN; Prischi, F (corresponding author), Univ Essex, Sch Life Sci, Colchester, Essex, England.	gbrooke@essex.ac.uk; fprischi@essex.ac.uk	Prischi, Filippo/I-4844-2019	Prischi, Filippo/0000-0003-2107-938X; Brooke, Greg/0000-0003-4501-4134	Leverhulme Trust [RPG-2018-230]; Wellcome Trust [205767/Z/16/Z]; Rosetree Trust [M702]; Peter Nicholls scholarship	Leverhulme Trust(Leverhulme Trust); Wellcome Trust(Wellcome TrustEuropean Commission); Rosetree Trust(Rosetrees Trust); Peter Nicholls scholarship	FP acknowledges support from The Leverhulme Trust grant (RPG-2018-230) and The Wellcome Trust grant (205767/Z/16/Z). GB had funding from the Rosetree Trust (M702). RC was supported by a Peter Nicholls scholarship. All figures were created with Biorender.com.	Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; Aronchik I, 2014, MOL CANCER RES, V12, P803, DOI 10.1158/1541-7786.MCR-13-0595; Bennett NC, 2010, INT J BIOCHEM CELL B, V42, P813, DOI 10.1016/j.biocel.2009.11.013; Boutros R, 2007, NAT REV CANCER, V7, P495, DOI 10.1038/nrc2169; Boutros R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067822; Brooke GN, 2009, CURR GENOMICS, V10, P18, DOI 10.2174/138920209787581307; Campi R, 2019, EUR UROL FOCUS, V5, P1029, DOI 10.1016/j.euf.2018.04.001; Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10; Casalvieri KA, 2017, TRENDS CANCER, V3, P302, DOI 10.1016/j.trecan.2017.03.004; Chan HM, 2001, J CELL SCI, V114, P2363; Chao OSP, 2006, ONCOGENE, V25, P4458, DOI 10.1038/sj.onc.1209421; Chen C, 2013, P NATL ACAD SCI USA, V110, P20605, DOI 10.1073/pnas.1306328110; Chen L, 2016, MOL CANCER THER, V15, P2107, DOI 10.1158/1535-7163.MCT-16-0241; Cheng Y, 2017, MOLECULES, V22, DOI 10.3390/molecules22101551; Clark DE, 2005, CANCER RES, V65, P3108; Clarkl DE, 2001, EMBO J, V20, P3484, DOI 10.1093/emboj/20.13.3484; Cohen MS, 2005, SCIENCE, V308, P1318, DOI 10.1126/science1108367; Cuesta R, 2016, ONCOTARGET, V7, P27567, DOI 10.18632/oncotarget.8375; Cuzick J, 2014, LANCET ONCOL, V15, pE484, DOI 10.1016/S1470-2045(14)70211-6; Dart DA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071694; Doehn U, 2009, MOL CELL, V35, P511, DOI 10.1016/j.molcel.2009.08.002; Dolfini D, 2013, ONCOGENE, V32, P4189, DOI 10.1038/onc.2012.521; Dolfini D, 2013, CELL DEATH DIFFER, V20, P676, DOI 10.1038/cdd.2013.13; Dong J, 2019, MOL CANCER THER, V18, P39, DOI 10.1158/1535-7163.MCT-18-0432; Dummler BA, 2005, J BIOL CHEM, V280, P13304, DOI 10.1074/jbc.M408194200; Edgar AJ, 2014, BIOSCIENCE REP, V34, P28, DOI 10.1042/BSR20130094; Eisenmann KM, 2003, CANCER RES, V63, P8330; Eisinger-Mathason TSK, 2010, STEROIDS, V75, P191, DOI 10.1016/j.steroids.2009.12.010; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gandhi J, 2018, PROSTATE CANCER P D, V21, P22, DOI 10.1038/s41391-017-0023-8; Gawecka JE, 2012, J BIOL CHEM, V287, P43424, DOI 10.1074/jbc.M112.423046; Gilmore AP, 2002, J BIOL CHEM, V277, P27643, DOI 10.1074/jbc.M108863200; Gioeli D, 2012, MOL CELL ENDOCRINOL, V352, P70, DOI 10.1016/j.mce.2011.07.004; Gogl G, 2018, FEBS J, V285, P46, DOI 10.1111/febs.14311; Hatzivassiliou G, 2012, MOL CANCER THER, V11, P1143, DOI 10.1158/1535-7163.MCT-11-1010; Hawley RS, 1996, GENE DEV, V10, P2383, DOI 10.1101/gad.10.19.2383; Helsen C, 2014, MOL CELL ENDOCRINOL, V382, P97, DOI 10.1016/j.mce.2013.09.009; Huo H, 2019, ONCOL REP, V42, P2777, DOI 10.3892/or.2019.7328; Jackson SP, 2001, BIOCHEM SOC T, V29, P655, DOI 10.1042/BST0290655; Jakobsen NA, 2016, J CLIN UROL, V9, P3, DOI 10.1177/2051415816656121; Jin LT, 2013, MOL CELL BIOL, V33, P2574, DOI 10.1128/MCB.01677-12; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; Joo SS, 2009, J PINEAL RES, V47, P8, DOI 10.1111/j.1600-079X.2009.00682.x; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Katzenwadel A, 2015, CANCER LETT, V367, P12, DOI 10.1016/j.canlet.2015.06.021; Kim J, 2004, J CELL BIOCHEM, V93, P233, DOI 10.1002/jcb.20228; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Koryakina Y, 2014, ENDOCR-RELAT CANCER, V21, pT131, DOI 10.1530/ERC-13-0472; Lamont KR, 2010, ADV CANCER RES, V107, P137, DOI 10.1016/S0065-230X(10)07005-3; Lara R, 2013, CANCER RES, V73, P5301, DOI 10.1158/0008-5472.CAN-12-4448; Lavin MF, 2007, ONCOGENE, V26, P7749, DOI 10.1038/sj.onc.1210880; Law JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012661; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Li QY, 2019, ONCOTARGETS THER, V12, P5907, DOI 10.2147/OTT.S208988; Liao MM, 2001, METH MOL B, V176, P67; Lobrich M, 2007, NAT REV CANCER, V7, P861, DOI 10.1038/nrc2248; Ludwik KA, 2018, CANCER RES, V78, P2014, DOI 10.1158/0008-5472.CAN-17-2063; Ludwik KA, 2016, EXPERT OPIN THER PAT, V26, P1061, DOI 10.1080/13543776.2016.1212839; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Marinkovich MP, 2007, NAT REV CANCER, V7, P370, DOI 10.1038/nrc2089; Matsumoto T, 2013, ANNU REV PHYSIOL, V75, P201, DOI 10.1146/annurev-physiol-030212-183656; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Mei Y, 2020, J BIOCHEM, V167, P603, DOI 10.1093/jb/mvaa009; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; Miller CJ, 2018, TRENDS BIOCHEM SCI, V43, P380, DOI 10.1016/j.tibs.2018.02.009; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Nguyen TL, 2008, ANTI-CANCER AGENT ME, V8, P710, DOI 10.2174/187152008785914770; Packer JR, 2016, BBA-MOL CELL RES, V1863, P1238, DOI 10.1016/j.bbamcr.2016.02.016; Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822; Perez-Cornago A, 2017, BRIT J CANCER, V117, P1562, DOI 10.1038/bjc.2017.312; Pine Angela C, 2016, F1000Res, V5, DOI 10.12688/f1000research.8019.1; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Prabhu L, 2015, GENES DIS, V2, P240, DOI 10.1016/j.gendis.2015.05.001; Rana K, 2014, ASIAN J ANDROL, V16, P169, DOI 10.4103/1008-682X.122590; Roffe M, 2015, CELL SIGNAL, V27, P1630, DOI 10.1016/j.cellsig.2015.04.004; Romeo Y, 2013, ONCOGENE, V32, P2917, DOI 10.1038/onc.2012.312; Romeo Y, 2012, BIOCHEM J, V441, P553, DOI 10.1042/BJ20110289; Romeo Y, 2011, EXPERT OPIN THER TAR, V15, P5, DOI 10.1517/14728222.2010.531014; Rubin MA, 2011, J CLIN ONCOL, V29, P3659, DOI 10.1200/JCO.2011.35.1916; Santer FR, 2015, SEMIN CANCER BIOL, V35, P133, DOI 10.1016/j.semcancer.2015.08.005; Shi GX, 2018, P NATL ACAD SCI USA, V115, pE190, DOI 10.1073/pnas.1708584115; Shiota M, 2014, PROSTATE, V74, P959, DOI 10.1002/pros.22813; Shiota M, 2011, ENDOCR-RELAT CANCER, V18, P505, DOI 10.1530/ERC-11-0017; Smith JA, 2005, CANCER RES, V65, P1027; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; Subbiah V, 2020, TRENDS CANCER, V6, P797, DOI 10.1016/j.trecan.2020.05.009; Sulzmaier FJ, 2016, ONCOTARGET, V7, P79855, DOI 10.18632/oncotarget.13084; Sulzmaier FJ, 2013, CANCER RES, V73, P6099, DOI 10.1158/0008-5472.CAN-13-1087; Tan M H Eileen, 2015, Acta Pharmacol Sin, V36, P3, DOI 10.1038/aps.2014.18; van Royen ME, 2012, J CELL SCI, V125, P1970, DOI 10.1242/jcs.096792; Vial D, 2012, J BIOL CHEM, V287, P40371, DOI 10.1074/jbc.M112.389577; Wen SM, 2020, ASIAN J UROL, V7, P203, DOI 10.1016/j.ajur.2019.11.001; Wu CF, 2014, ONCOGENE, V33, P2385, DOI 10.1038/onc.2013.182; Yu G, 2015, MOL CANCER RES, V13, P348, DOI 10.1158/1541-7786.MCR-14-0384-T; Yu XZ, 2020, MOL CELL, V79, P812, DOI 10.1016/j.molcel.2020.06.031; Zarif JC, 2016, CELL SIGNAL, V28, P348, DOI 10.1016/j.cellsig.2016.01.013; Zaru R, 2007, NAT IMMUNOL, V8, P1227, DOI 10.1038/ni1517; Zoubeidi A, 2010, CANCER RES, V70, P2307, DOI 10.1158/0008-5472.CAN-09-3252	98	5	5	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2021	40	22					3775	3785		10.1038/s41388-021-01810-9	http://dx.doi.org/10.1038/s41388-021-01810-9		MAY 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SM7LL	33972681	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000648930100004
J	Ribeiro, IP; Esteves, L; Santos, A; Barroso, L; Marques, F; Caramelo, F; Melo, JB; Carreira, IM				Ribeiro, Ilda Patricia; Esteves, Luisa; Santos, Ana; Barroso, Leonor; Marques, Francisco; Caramelo, Francisco; Melo, Joana Barbosa; Carreira, Isabel Marques			A seven-gene signature to predict the prognosis of oral squamous cell carcinoma	ONCOGENE			English	Article							NECK-CANCER; HEAD; METASTASES; MANAGEMENT; EXPRESSION	The prognosis of oral squamous cell carcinoma (OSCC) patients remains poor without implemented biomarkers in the clinical routine practice to help in the patient's management. With this study we aimed to identify specific prognostic biomarkers for OSCC using a whole genome technology as well as to verify the clinical utility of a head and neck cancer-specific multiplex ligation-dependent probe amplification (MLPA) panel. A genomic characterization of tumor samples from 62 OSCC patients was performed using array comparative genomic hybridization (aCGH) and a more straightforward and cost-effective molecular technology, MLPA. The identification of a genomic signature and prognosis biomarkers was carried out by applying several statistical methods. With aCGH we observed that the chromosomes most commonly altered were 3p, 3q, 5q, 6p, 7q, 8p, 8q, 11q, 15q, 17q, and 18q. The MLPA results showed that the chromosomes with a higher frequency of alterations were 3p, 3q, 8p, 8q, and 11q. We identified a genomic signature with seven genes OCLN (3p21.31), CLDN16 (3q29), SCRIB (3q29), IKBKB (3q22.3), PAK2 (8q22.3), PIK3CB (3q28), and YWHAZ (8q24.3) that together allow to differentiate the patients that developed metastases or relapses after primary tumor treatment, with an overall accuracy of 79%. Amplification of PIK3CB as a predictor of metastases or relapses development was validated using TCGA data. This amplified gene showed a reduction in more than 5 years in the median survival of the patients. The identified biomarkers might have a significant impact in the patients' management and could leverage the OSCC precision medicine.	[Ribeiro, Ilda Patricia; Esteves, Luisa; Santos, Ana; Melo, Joana Barbosa; Carreira, Isabel Marques] Univ Coimbra, Cytogenet & Genom Lab, Inst Cellular & Mol Biol, Fac Med, Coimbra, Portugal; [Ribeiro, Ilda Patricia; Marques, Francisco; Caramelo, Francisco; Melo, Joana Barbosa; Carreira, Isabel Marques] Univ Coimbra, Coimbra Inst Clin & Biomed Res iCBR, Coimbra, Portugal; [Ribeiro, Ilda Patricia; Marques, Francisco; Caramelo, Francisco; Melo, Joana Barbosa; Carreira, Isabel Marques] Fac Med, Ctr Invest Environm Genet & Oncobiol CIMAGO, Coimbra, Portugal; [Ribeiro, Ilda Patricia; Melo, Joana Barbosa; Carreira, Isabel Marques] Univ Coimbra, Ctr Innovat Biomed & Biotechnol CIBB, Coimbra, Portugal; [Ribeiro, Ilda Patricia; Marques, Francisco; Melo, Joana Barbosa; Carreira, Isabel Marques] Clin Acad Ctr Coimbra CACC, Coimbra, Portugal; [Barroso, Leonor] Coimbra Hosp & Univ Ctr CHUC, EPE, Dept Maxillofacial Surg, Coimbra, Portugal; [Marques, Francisco] Univ Coimbra, Dept Dent, Fac Med, Coimbra, Portugal; [Marques, Francisco] Coimbra Hosp & Univ Ctr CHUC, EPE, Stomatol Unit, Coimbra, Portugal; [Caramelo, Francisco] Univ Coimbra, Lab Biostat & Med Informat, ICBR, Fac Med, Coimbra, Portugal	Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); Universidade de Coimbra; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); Universidade de Coimbra	Carreira, IM (corresponding author), Univ Coimbra, Cytogenet & Genom Lab, Inst Cellular & Mol Biol, Fac Med, Coimbra, Portugal.; Carreira, IM (corresponding author), Univ Coimbra, Coimbra Inst Clin & Biomed Res iCBR, Coimbra, Portugal.; Carreira, IM (corresponding author), Fac Med, Ctr Invest Environm Genet & Oncobiol CIMAGO, Coimbra, Portugal.; Carreira, IM (corresponding author), Univ Coimbra, Ctr Innovat Biomed & Biotechnol CIBB, Coimbra, Portugal.; Carreira, IM (corresponding author), Clin Acad Ctr Coimbra CACC, Coimbra, Portugal.	citogenetica@fmed.uc.pt	Melo, Joana B/AAY-8984-2020; Ribeiro, Ilda/K-6686-2014; Melo, Joana B/K-8347-2014; Carreira, Isabel M/C-7711-2018	Melo, Joana B/0000-0001-5049-2670; Ribeiro, Ilda/0000-0002-6096-8705; Melo, Joana B/0000-0001-5049-2670; Carreira, Isabel M/0000-0001-6842-1707	MRC-Holland	MRC-Holland	We thank MRC-Holland for the MLPA P428-B1 probe panel.	Al-Rawi N.H., 2014, J OROFACIAL SCI, V6, P99; Altman DG., 1991, PRACTICAL STAT MED R; Barrow J, 2011, NEURO-ONCOLOGY, V13, P212, DOI 10.1093/neuonc/noq158; Braakhuis BJM, 2005, ONCOLOGIST, V10, P493, DOI 10.1634/theoncologist.10-7-493; Chatterjee A, 2020, ORAL ONCOL, V104, DOI 10.1016/j.oraloncology.2020.104627; Gabusi A, 2020, VIRCHOWS ARCH, V476, P585, DOI 10.1007/s00428-019-02656-z; Gilyoma Japhet M, 2015, BMC Res Notes, V8, P772, DOI 10.1186/s13104-015-1773-9; Gupta A, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0887-0; Jeong S, 2013, RADIAT ONCOL J, V31, P206, DOI 10.3857/roj.2013.31.4.206; Jung AC, 2013, CLIN CANCER RES, V19, P4174, DOI 10.1158/1078-0432.CCR-12-3690; Kuo SJ, 2010, ONCOL REP, V24, P759, DOI 10.3892/or_00000918; LEEMANS CR, 1994, CANCER-AM CANCER SOC, V73, P187, DOI 10.1002/1097-0142(19940101)73:1<187::AID-CNCR2820730132>3.0.CO;2-J; LEEMANS CR, 1993, CANCER, V71, P452, DOI 10.1002/1097-0142(19930115)71:2<452::AID-CNCR2820710228>3.0.CO;2-B; Li Y, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00256; Lin WH, 2015, CANCER INFORM, V14, P15, DOI 10.4137/CIN.S18964; Lui VWY, 2013, CANCER DISCOV, V3, P761, DOI 10.1158/2159-8290.CD-13-0103; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; Nishimura Y, 2013, BRIT J CANCER, V108, P1324, DOI 10.1038/bjc.2013.65; Page A, 2017, GENES-BASEL, V8, DOI 10.3390/genes8120376; Pantvaidya G, 2020, ORAL ONCOL, V100, DOI 10.1016/j.oraloncology.2019.104476; Pierucci-Alves F, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.111.092262; RIBEIRO I, 2017, SCI REP-UK, V7; Ribeiro IP, 2016, MOL CYTOGENET, V9, DOI 10.1186/s13039-016-0293-1; Ribeiro IP, 2014, TUMOR BIOL, V35, P4687, DOI 10.1007/s13277-014-1614-9; Ribeiro IP, 2014, CELL ONCOL, V37, P29, DOI 10.1007/s13402-013-0161-5; Vincent-Chong VK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174865; Yang J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0954-x; Zhong L, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4806-7	28	5	5	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2021	40	22					3859	3869		10.1038/s41388-021-01806-5	http://dx.doi.org/10.1038/s41388-021-01806-5		MAY 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SM7LL	33972685				2022-12-17	WOS:000648930100002
J	Yusenko, MV; Trentmann, A; Casolari, DA; Ghani, LA; Lenz, M; Horn, M; Dorner, W; Klempnauer, S; Mootz, HD; Arteaga, MF; Mikesch, JH; Andrea, RJD; Gonda, TJ; Muller-Tidow, C; Schmidt, TJ; Klempnauer, KH				Yusenko, Maria V.; Trentmann, Amke; Casolari, Debora A.; Abdel Ghani, Luca; Lenz, Mairin; Horn, Melanie; Doerner, Wolfgang; Klempnauer, Stefan; Mootz, Henning D.; Arteaga, Maria Francisca; Mikesch, Jan-Henrik; Andrea, Richard J. D'; Gonda, Thomas J.; Mueller-Tidow, Carsten; Schmidt, Thomas J.; Klempnauer, Karl-Heinz			C/EBP beta is a MYB- and p300-cooperating pro-leukemogenic factor and promising drug target in acute myeloid leukemia	ONCOGENE			English	Article							DEPENDENT GENE-EXPRESSION; TRANSCRIPTION FACTOR MYB; V-MYB; NF-M; SYNERGISTIC ACTIVATION; SESQUITERPENE LACTONES; STEM-CELLS; C-MYB; DIFFERENTIATION; ENHANCER	Transcription factor MYB has recently emerged as a promising drug target for the treatment of acute myeloid leukemia (AML). Here, we have characterized a group of natural sesquiterpene lactones (STLs), previously shown to suppress MYB activity, for their potential to decrease AML cell proliferation. Unlike what was initially thought, these compounds inhibit MYB indirectly via its cooperation partner C/EBP beta. C/EBP beta-inhibitory STLs affect the expression of a large number of MYB-regulated genes, suggesting that the cooperation of MYB and C/EBP beta broadly shapes the transcriptional program of AML cells. We show that expression of GFI1, a direct MYB target gene, is controlled cooperatively by MYB, C/EBP beta, and co-activator p300, and is down-regulated by C/EBP beta-inhibitory STLs, exemplifying that they target the activity of composite MYB-C/EBP beta-p300 transcriptional modules. Ectopic expression of GFI1, a zinc-finger protein that is required for the maintenance of hematopoietic stem and progenitor cells, partially abrogated STL-induced myelomonocytic differentiation, implicating GFI1 as a relevant target of C/EBP beta-inhibitory STLs. Overall, our data identify C/EBP beta as a pro-leukemogenic factor in AML and suggest that targeting of C/EBP beta may have therapeutic potential against AML.	[Yusenko, Maria V.; Trentmann, Amke; Abdel Ghani, Luca; Doerner, Wolfgang; Mootz, Henning D.; Klempnauer, Karl-Heinz] Westfalische Wilhelms Univ, Inst Biochem, Munster, Germany; [Casolari, Debora A.; Andrea, Richard J. D'] SA Pathol, Ctr Canc Biol, Adelaide, SA, Australia; [Casolari, Debora A.; Andrea, Richard J. D'] Univ South Australia, Adelaide, SA, Australia; [Lenz, Mairin; Schmidt, Thomas J.] Westfalische Wilhelms Univ, Inst Pharmaceut Biol & Phytochem, Munster, Germany; [Horn, Melanie; Mueller-Tidow, Carsten] Univ Hosp Heidelberg, Dept Med 5, Hematol, Oncol,Rheumatol, Heidelberg, Germany; [Klempnauer, Stefan] Ruhr Univ, Dept Math, Bochum, Germany; [Arteaga, Maria Francisca; Mikesch, Jan-Henrik] Westfalische Wilhelms Univ, Univ Hosp, Dept Med Hematol & Oncol A, Munster, Germany; [Gonda, Thomas J.] Univ South Australia, Canc Res Inst, Adelaide, SA, Australia	University of Munster; Centre for Cancer Biology; SA Pathology; University of South Australia; University of Munster; Ruprecht Karls University Heidelberg; Ruhr University Bochum; University of Munster; University of South Australia	Klempnauer, KH (corresponding author), Westfalische Wilhelms Univ, Inst Biochem, Munster, Germany.	klempna@uni-muenster.de	Schmidt, Thomas J/M-1678-2016; Arteaga, Maria Francisca/GPS-7709-2022	Schmidt, Thomas J/0000-0003-2634-9705; Arteaga, Maria Francisca/0000-0003-3280-5113; Casolari, Debora/0000-0001-5072-0880	Deutsche Krebshilfe; Else Kroner-Fresenius Stiftung; Deutsche Jose Carreras Leukamie-Stiftung e.V	Deutsche Krebshilfe(Deutsche Krebshilfe); Else Kroner-Fresenius Stiftung; Deutsche Jose Carreras Leukamie-Stiftung e.V	We thank Bianca Berkenfeld, Stephanie Wulff, and Fredrick Hohn for expert technical assistance and help and the students Anna-Lena Feldberg and Lucas Forster for help in the initial pilot experiments. This work was supported by grants from the Deutsche Krebshilfe, the Else Kroner-Fresenius Stiftung and the Deutsche Jose Carreras Leukamie-Stiftung e.V. We also thank the Core Facility Genomics at the Medical Faculty of the University of Munster for performing next-generation-sequencing and preliminary data analysis.	Anastasov N, 2010, HAEMATOL-HEMATOL J, V95, P760, DOI 10.3324/haematol.2009.014050; Arteaga MF, 2013, CANCER CELL, V23, P376, DOI 10.1016/j.ccr.2013.02.014; Barth J, 2019, LEUKEMIA, V33, P1411, DOI 10.1038/s41375-018-0375-7; Bujnicki T, 2012, LEUKEMIA, V26, P615, DOI 10.1038/leu.2011.275; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Chayka O, 2005, MOL CELL BIOL, V25, P499, DOI 10.1128/MCB.25.1.499-511.2005; Clappier E, 2007, BLOOD, V110, P1251, DOI 10.1182/blood-2006-12-064683; Dohner H, 2015, NEW ENGL J MED, V373, P1136, DOI 10.1056/NEJMra1406184; Duprez E, 2003, EMBO J, V22, P5806, DOI 10.1093/emboj/cdg556; Galkina A, 2019, MOLECULES, V24, DOI 10.3390/molecules24061068; Hess JL, 2006, BLOOD, V108, P297, DOI 10.1182/blood-2005-12-5014; Hock H, 2004, NATURE, V431, P1002, DOI 10.1038/nature02994; HU YL, 1991, ONCOGENE, V6, P1549; Jakobs A, 2016, LEUKEMIA, V30, P1612, DOI 10.1038/leu.2016.16; Jakobs A, 2016, J BIOL CHEM, V291, P26098, DOI 10.1074/jbc.M116.748129; Jin SH, 2010, J CLIN INVEST, V120, P593, DOI 10.1172/JCI38030; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; Kim MH, 2009, PROSTATE, V69, P1435, DOI 10.1002/pros.20993; Lahortiga I, 2007, NAT GENET, V39, P593, DOI 10.1038/ng2025; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Liu X, 2015, MOL CANCER THER, V14, P1273, DOI 10.1158/1535-7163.MCT-15-0271; Lomenick Brett, 2011, Curr Protoc Chem Biol, V3, P163; Maiques-Diaz A, 2018, MOL CELL ONCOL, V5, DOI 10.1080/23723556.2018.1481813; Maiques-Diaz A, 2018, CELL REP, V22, P3641, DOI 10.1016/j.celrep.2018.03.012; Mandelbaum J, 2018, J EXP MED, V215, P2673, DOI 10.1084/jem.20180939; Mansour MR, 2014, SCIENCE, V346, P1373, DOI 10.1126/science.1259037; Mink S, 1996, MOL CELL BIOL, V16, P1316; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Muller C, 1995, EMBO J, V14, P6127, DOI 10.1002/j.1460-2075.1995.tb00303.x; Nerlov C, 2008, CURR OPIN CELL BIOL, V20, P180, DOI 10.1016/j.ceb.2008.02.002; Nerlov C, 2007, TRENDS CELL BIOL, V17, P318, DOI 10.1016/j.tcb.2007.07.004; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Pal R, 2009, BLOOD, V114, P3890, DOI 10.1182/blood-2009-01-201111; Plachetka A, 2008, MOL CELL BIOL, V28, P2102, DOI 10.1128/MCB.01943-07; Rahman S, 2017, BLOOD, V129, P3221, DOI 10.1182/blood-2016-09-742148; Ramaswamy K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02618-6; Ramsay RG, 2008, NAT REV CANCER, V8, P523, DOI 10.1038/nrc2439; Rask K, 2000, INT J CANCER, V86, P337, DOI 10.1002/(SICI)1097-0215(20000501)86:3<337::AID-IJC6>3.3.CO;2-V; Regalo G, 2006, J PATHOL, V210, P398, DOI 10.1002/path.2063; Roe JS, 2015, MOL CELL, V58, P1028, DOI 10.1016/j.molcel.2015.04.011; Schmidt TJ, 2014, ANTIMICROB AGENTS CH, V58, P325, DOI 10.1128/AAC.01263-13; Schomburg C, 2013, EUR J MED CHEM, V63, P313, DOI 10.1016/j.ejmech.2013.02.018; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; Sebastian T, 2006, CELL CYCLE, V5, P953, DOI 10.4161/cc.5.9.2733; Somervaille TCP, 2006, CANCER CELL, V10, P257, DOI 10.1016/j.ccr.2006.08.020; Somervaille TCP, 2009, CELL STEM CELL, V4, P129, DOI 10.1016/j.stem.2008.11.015; Sundfeldt K, 1999, BRIT J CANCER, V79, P1240, DOI 10.1038/sj.bjc.6690199; Uttarkar S, 2017, EXP HEMATOL, V47, P31, DOI 10.1016/j.exphem.2016.12.003; Uttarkar S, 2016, MOL CANCER THER, V15, P2905, DOI 10.1158/1535-7163.MCT-16-0185; Uttarkar S, 2016, BLOOD, V127, P1173, DOI 10.1182/blood-2015-09-668632; Uttarkar S, 2015, MOL CANCER THER, V14, P1276, DOI 10.1158/1535-7163.MCT-14-0662; van Bergen MGJM, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01027; van der Meer LT, 2010, LEUKEMIA, V24, P1834, DOI 10.1038/leu.2010.195; Walf-Vorderwulbecke V, 2018, LEUKEMIA, V32, P882, DOI 10.1038/leu.2017.317; Yusenko M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31620-1; Zeng H, 2004, EMBO J, V23, P4116, DOI 10.1038/sj.emboj.7600419; Zhao L, 2014, ONCOGENE, V33, P4442, DOI 10.1038/onc.2013.419; Zhao L, 2011, NUCLEIC ACIDS RES, V39, P4664, DOI 10.1093/nar/gkr024; Zuber J, 2011, GENE DEV, V25, P1628, DOI 10.1101/gad.17269211	60	5	5	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2021	40	29					4746	4758		10.1038/s41388-021-01800-x	http://dx.doi.org/10.1038/s41388-021-01800-x		MAY 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR9TO	33958723	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000648041500001
J	Wang, YY; Chen, YK; Lo, S; Chi, TC; Chen, YH; Hu, SCS; Chen, YW; Jiang, SS; Tsai, FY; Liu, WT; Li, RN; Hsieh, YC; Huang, CJ; Yuan, SSF				Wang, Yen-Yun; Chen, Yuk-Kwan; Lo, Steven; Chi, Tsung-Chen; Chen, Yi-Hua; Hu, Stephen Chu-Sung; Chen, Ya-Wen; Jiang, Shih Sheng; Tsai, Fang-Yu; Liu, Wangta; Li, Ruei-Nian; Hsieh, Ya-Ching; Huang, Chih-Jen; Yuan, Shyng-Shiou F.			MRE11 promotes oral cancer progression through RUNX2/CXCR4/AKT/FOXA2 signaling in a nuclease-independent manner	ONCOGENE			English	Article								MRE11, the nuclease component of RAD50/MRE11/NBS1 DNA repair complex which is essential for repair of DNA double-strand-breaks in normal cells, has recently garnered attention as a critical factor in solid tumor development. Herein we report the crucial role of MRE11 in oral cancer progression in a nuclease-independent manner and delineate its key downstream effectors including CXCR4. MRE11 expression in oral cancer samples was positively associated with tumor size, cancer stage and lymph node metastasis, and was predictive of poorer patient survival and radiotherapy resistance. MRE11 promoted cell proliferation/migration/invasion in a nuclease-independent manner but enhanced radioresistance via a nuclease-dependent pathway. The nuclease independent promotion of EMT and metastasis was mediated by RUNX2, CXCR4, AKT, and FOXA2, while CXCR4 neutralizing antibody mitigated these effects in vitro and in vivo. Collectively, MRE11 may serve as a crucial prognostic factor and therapeutic target in oral cancer, displaying dual nuclease dependent and independent roles that permit separate targeting of tumor vulnerabilities in oral cancer treatment.	[Wang, Yen-Yun; Chen, Yuk-Kwan] Kaohsiung Med Univ, Sch Dent, Coll Dent Med, Kaohsiung, Taiwan; [Wang, Yen-Yun; Chi, Tsung-Chen; Chen, Yi-Hua; Yuan, Shyng-Shiou F.] Kaohsiung Med Univ Hosp, Translat Res Ctr, Kaohsiung, Taiwan; [Wang, Yen-Yun; Yuan, Shyng-Shiou F.] Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung, Taiwan; [Wang, Yen-Yun; Chen, Yuk-Kwan; Liu, Wangta; Yuan, Shyng-Shiou F.] Kaohsiung Med Univ, Ctr Canc Res, Kaohsiung, Taiwan; [Chen, Yuk-Kwan] Kaohsiung Med Univ Hosp, Div Oral Pathol & Maxillofacial Radiol, Kaohsiung, Taiwan; [Chen, Yuk-Kwan] Kaohsiung Med Univ, Coll Dent Med, Oral & Maxillofacial Imaging Ctr, Kaohsiung, Taiwan; [Lo, Steven] Univ Glasgow, Coll Med Vet & Life Sci, Glasgow, Lanark, Scotland; [Hu, Stephen Chu-Sung] Kaohsiung Med Univ, Dept Dermatol, Coll Med, Kaohsiung, Taiwan; [Hu, Stephen Chu-Sung] Kaohsiung Med Univ Hosp, Dept Dermatol, Kaohsiung, Taiwan; [Chen, Ya-Wen; Jiang, Shih Sheng; Tsai, Fang-Yu] Natl Hlth Res Inst, Natl Inst Canc Res, Miaoli, Taiwan; [Liu, Wangta] Kaohsiung Med Univ, Dept Biotechnol, Coll Life Sci, Kaohsiung, Taiwan; [Li, Ruei-Nian] Kaohsiung Med Univ, Dept Biomed Sci & Environm Biol, Kaohsiung, Taiwan; [Hsieh, Ya-Ching] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland; [Huang, Chih-Jen] Kaohsiung Med Univ Hosp, Dept Radiat Oncol, Kaohsiung, Taiwan; [Huang, Chih-Jen] Kaohsiung Med Univ, Dept Radiat Oncol, Coll Med, Fac Med, Kaohsiung, Taiwan; [Yuan, Shyng-Shiou F.] Kaohsiung Med Univ Hosp, Dept Obstet & Gynecol, Kaohsiung, Taiwan; [Yuan, Shyng-Shiou F.] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung, Taiwan; [Yuan, Shyng-Shiou F.] Natl ChiaoTung Univ, Dept Biol Sci & Technol, Coll Biol Sci & Technol, Hsinchu, Taiwan; [Yuan, Shyng-Shiou F.] Natl Chiao Tung Univ, Ctr Intelligent Drug Syst & Smart Biodevices IDS2, Hsinchu, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; University of Glasgow; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; National Health Research Institutes - Taiwan; Kaohsiung Medical University; Kaohsiung Medical University; University of Glasgow; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Yuan, SSF (corresponding author), Kaohsiung Med Univ Hosp, Translat Res Ctr, Kaohsiung, Taiwan.; Yuan, SSF (corresponding author), Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung, Taiwan.; Yuan, SSF (corresponding author), Kaohsiung Med Univ, Ctr Canc Res, Kaohsiung, Taiwan.; Yuan, SSF (corresponding author), Kaohsiung Med Univ Hosp, Dept Obstet & Gynecol, Kaohsiung, Taiwan.; Yuan, SSF (corresponding author), Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung, Taiwan.; Yuan, SSF (corresponding author), Natl ChiaoTung Univ, Dept Biol Sci & Technol, Coll Biol Sci & Technol, Hsinchu, Taiwan.; Yuan, SSF (corresponding author), Natl Chiao Tung Univ, Ctr Intelligent Drug Syst & Smart Biodevices IDS2, Hsinchu, Taiwan.	yuanssf@ms33.hinet.net		Chen, Yi-Hua/0000-0002-4390-1090; Chen, Yuk-Kwan/0000-0001-6800-273X	Ministry of Health and Welfare of Taiwan [MOHW109-TDU-B-212-134016]; "Center For Intelligent Drug Systems and Smart Bio-devices (IDS2B)" from The Featured Areas Research Center Program within Ministry of Education in Taiwan; Kaohsiung Medical University Hospital [KMUH105-5R32, KMUH106-6R41, KMUH106-6R83, KMUH107-7R36]; Kaohsiung Medical University [KMU-DK108005]; Kaohsiung Medical University Research Center Grant (Center for Cancer Research) [KMU-TC108A04-0, KMU-TC108A04-1]; Ministry of Science and Technology, Taiwan [107-2314-B-037-097]; Taiwan Bioinformatics Institute Core Facility (National Core Facility Program for Biotechnology) [MOST 109-2319-B-400-001]	Ministry of Health and Welfare of Taiwan; "Center For Intelligent Drug Systems and Smart Bio-devices (IDS2B)" from The Featured Areas Research Center Program within Ministry of Education in Taiwan; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Research Center Grant (Center for Cancer Research); Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); Taiwan Bioinformatics Institute Core Facility (National Core Facility Program for Biotechnology)	This work was financially supported by grants from the Ministry of Health and Welfare (MOHW109-TDU-B-212-134016, Health and welfare surcharge of tobacco products) of Taiwan and from "Center For Intelligent Drug Systems and Smart Bio-devices (IDS2B)" from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education in Taiwan. This work was also supported by grants from the Kaohsiung Medical University Hospital (KMUH105-5R32, KMUH106-6R41, KMUH106-6R83, KMUH107-7R36), Kaohsiung Medical University (Research Center Grant KMU-DK108005), Kaohsiung Medical University Research Center Grant (Center for Cancer Research KMU-TC108A04-0, KMU-TC108A04-1), the Ministry of Science and Technology, Taiwan (grant number 107-2314-B-037-097), and Taiwan Bioinformatics Institute Core Facility (National Core Facility Program for Biotechnology, MOST 109-2319-B-400-001).	Balkwill F, 2004, SEMIN CANCER BIOL, V14, P171, DOI 10.1016/j.semcancer.2003.10.003; Herrero AB, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00098; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Chatterjee S, 2014, ADV CANCER RES, V124, P31, DOI 10.1016/B978-0-12-411638-2.00002-1; Chen C, 2013, P NATL ACAD SCI USA, V110, P20605, DOI 10.1073/pnas.1306328110; Chen TC, 2012, ORAL ONCOL, V48, P623, DOI 10.1016/j.oraloncology.2012.01.015; Cohen-Solal KA, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0404-3; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Ghani WMN, 2013, ASIAN PAC J CANCER P, V14, P1957, DOI 10.7314/APJCP.2013.14.3.1957; Guo ZJ, 2016, ONCOTARGET, V7, P20999, DOI 10.18632/oncotarget.8236; Gupta GP, 2013, MOL CELL, V52, P353, DOI 10.1016/j.molcel.2013.09.001; Gupta N, 2016, NEPAL J EPIDEMIOL, V6, P613, DOI 10.3126/nje.v6i4.17255; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Hill L, 2013, INT J CANCER, V132, P745, DOI 10.1002/ijc.27708; Huang CS, 2014, J AM SOC NEPHROL, V25, P1486, DOI 10.1681/ASN.2013070773; Huang YL, 2015, HUM MOL GENET, V24, P3506, DOI 10.1093/hmg/ddv102; Li ZG, 2017, CANCER RES, V77, P3169, DOI 10.1158/0008-5472.CAN-16-2787; Ma YX, 2019, AGING-US, V11, P3969, DOI 10.18632/aging.102032; Minchom A, 2018, THER ADV MED ONCOL, V10, DOI 10.1177/1758835918786658; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Nag S, 2014, CURR MED CHEM, V21, P553, DOI 10.2174/09298673113206660325; Pernas S, 2018, LANCET ONCOL, V19, P812, DOI 10.1016/S1470-2045(18)30147-5; Petrini JHJ, 1999, AM J HUM GENET, V64, P1264, DOI 10.1086/302391; Piscitello D, 2018, ONCOGENE, V37, P427, DOI 10.1038/onc.2017.340; Radisavljevic Z, 2013, J CELL PHYSIOL, V228, P522, DOI 10.1002/jcp.24167; Rishi L, 2014, BLOOD, V123, P2389, DOI 10.1182/blood-2013-07-511683; Rozengurt E, 2014, MOL CANCER THER, V13, P2477, DOI 10.1158/1535-7163.MCT-14-0330; Song Y, 2010, CANCER RES, V70, P2115, DOI 10.1158/0008-5472.CAN-09-2979; Spehalski E, 2017, CANCER RES, V77, P5327, DOI 10.1158/0008-5472.CAN-17-1355; Symington LS, 2016, CRIT REV BIOCHEM MOL, V51, P195, DOI 10.3109/10409238.2016.1172552; Tauchi H, 2002, NATURE, V420, P93, DOI 10.1038/nature01125; Taylor EM, 2016, FUTURE ONCOL, V12, P221, DOI 10.2217/fon.15.292; Uchida D, 2003, EXP CELL RES, V290, P289, DOI 10.1016/S0014-4827(03)00344-6; Vag T, 2018, EJNMMI RES, V8, DOI 10.1186/s13550-018-0442-0; Vanharanta S, 2013, CANCER DISCOV, V3, P1103, DOI 10.1158/2159-8290.CD-13-0481; Yuan SSF, 2012, JNCI-J NATL CANCER I, V104, P1485, DOI 10.1093/jnci/djs355; Zaidi SK, 2007, P NATL ACAD SCI USA, V104, P19861, DOI 10.1073/pnas.0709650104; Zhang Z, 2015, CANCER LETT, V361, P240, DOI 10.1016/j.canlet.2015.03.008; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	40	5	5	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2021	40	20					3510	3532		10.1038/s41388-021-01698-5	http://dx.doi.org/10.1038/s41388-021-01698-5		APR 2021	23	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE7RS	33927349	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000645517200002
J	Wu, SS; Liu, BD; Zhang, YH; Hong, RH; Liu, SH; Xiang, T; Tao, TY; Cai, JC; Wu, JH; Li, MF; Guan, HY				Wu, Shanshan; Liu, Bangdong; Zhang, Youhong; Hong, Ruohui; Liu, Shihua; Xiang, Tao; Tao, Tianyu; Cai, Junchao; Wu, Jueheng; Li, Mengfeng; Guan, Hongyu			Long non-coding RNA LEISA promotes progression of lung adenocarcinoma via enhancing interaction between STAT3 and IL-6 promoter	ONCOGENE			English	Article							CANCER; INFLAMMATION; TRANSCRIPTION; TARGETS; BIOLOGY; CELLS; PTEN; IL6	Long non-coding RNAs (lncRNAs) are emerging as a new class of regulators for a variety of biological processes and have been suggested to play pivotal roles in cancer development and progression. Our current study found that a lncRNA, designated enhancing IL-6/STAT3 signaling activation (LEISA, ENST00000603468), functioned as an oncogenic lncRNA in lung adenocarcinoma (LAD), a major form of non-small cell lung carcinoma, which is one of the most frequently diagnosed malignancies with high morbidity and mortality worldwide, and was involved in the regulation of STAT3 induced IL-6 transcription. Our data showed that LEISA was highly expressed in, and correlated with the clinical progression and prognosis of LAD. Ectopic expression of LEISA promoted the proliferation and suppressed apoptosis of LAD cells in vitro and in vivo. Mechanistically, we demonstrated that LEISA recruited STAT3 to bind the promoter of IL-6 and upregulated IL-6 expression. Taken together, our work identifies LEISA as a potential diagnostic biomarker and therapeutic target for LAD.	[Wu, Shanshan; Liu, Bangdong; Hong, Ruohui; Tao, Tianyu; Wu, Jueheng; Li, Mengfeng] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Microbiol, Guangzhou, Guangdong, Peoples R China; [Wu, Shanshan] Guangdong Med Univ, Sch Basic Med Sci, Dept Biol, Zhanjiang, Guangdong, Peoples R China; [Zhang, Youhong; Li, Mengfeng] Southern Med Univ, Sch Basic Med Sci, Guangzhou, Guangdong, Peoples R China; [Liu, Shihua] Sun Yat Sen Univ Canc Ctr, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China; [Xiang, Tao; Guan, Hongyu] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Endocrinol, Guangzhou, Guangdong, Peoples R China; [Cai, Junchao] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Immunol, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Guangdong Medical University; Southern Medical University - China; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Wu, JH; Li, MF (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Microbiol, Guangzhou, Guangdong, Peoples R China.; Li, MF (corresponding author), Southern Med Univ, Sch Basic Med Sci, Guangzhou, Guangdong, Peoples R China.; Guan, HY (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Endocrinol, Guangzhou, Guangdong, Peoples R China.	wujh@mail.sysu.edu.cn; limf@mail.sysu.edu.cn; ghongy@mail.sysu.edu.cn			National Key Research and Development Program of China [2017YFA0106300]; National Natural Science Foundation of China [81972170, 81820108025, 81621004, 81672296, 81922050, 81772473, 81802274]; Science and Technology Program of Guangzhou City [201803010039]; Guangdong MEPP Fund [GDOE [2019]A21]; Natural Science Foundation of Guangdong Province [2019A1515011174]; Fundamental Research Funds for the Central Universities [19ykpy162]	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Program of Guangzhou City; Guangdong MEPP Fund; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by the National Key Research and Development Program of China (2017YFA0106300) and the National Natural Science Foundation of China (81972170, 81820108025, 81621004, 81672296, 81922050, 81772473, 81802274); the Science and Technology Program of Guangzhou City (201803010039); the Guangdong MEPP Fund (NO. GDOE [2019]A21); the Natural Science Foundation of Guangdong Province (2019A1515011174); the Fundamental Research Funds for the Central Universities (19ykpy162).	Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Bhan A, 2017, CANCER RES, V77, P3965, DOI 10.1158/0008-5472.CAN-16-2634; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brichory FM, 2001, P NATL ACAD SCI USA, V98, P9824, DOI 10.1073/pnas.171320598; Cai JC, 2018, NAT CELL BIOL, V20, P465, DOI 10.1038/s41556-018-0065-8; Cai JC, 2013, CANCER RES, V73, P5402, DOI 10.1158/0008-5472.CAN-13-0297; Calabrese LH, 2014, NAT REV RHEUMATOL, V10, P720, DOI 10.1038/nrrheum.2014.127; Chang RX, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05852-8; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Deng SJ, 2019, CANCER RES, V79, P1398, DOI 10.1158/0008-5472.CAN-18-0419; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; Engreitz JM, 2016, NATURE, V539, P452, DOI 10.1038/nature20149; Ettinger DS, 2015, J NATL COMPR CANC NE, V13, P515, DOI 10.6004/jnccn.2015.0071; Fang LS, 2019, ONCOGENE, V38, P896, DOI 10.1038/s41388-018-0484-9; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Gong CG, 2011, NATURE, V470, P284, DOI 10.1038/nature09701; Guan HY, 2019, P NATL ACAD SCI USA, V116, P14019, DOI 10.1073/pnas.1900997116; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hess KR, 2006, CANCER, V106, P1624, DOI 10.1002/cncr.21778; Hung T, 2010, RNA BIOL, V7, P582, DOI 10.4161/rna.7.5.13216; Iioka H, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq1316; Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8; Jones SA, 2018, NAT REV IMMUNOL, V18, P773, DOI 10.1038/s41577-018-0066-7; Kang SJ, 2019, IMMUNITY, V50, P1007, DOI 10.1016/j.immuni.2019.03.026; Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011; Kung JTY, 2013, GENETICS, V193, P651, DOI 10.1534/genetics.112.146704; Lai F, 2013, NATURE, V494, P497, DOI 10.1038/nature11884; Lederle W, 2011, INT J CANCER, V128, P2803, DOI 10.1002/ijc.25621; Lee TI, 2006, NAT PROTOC, V1, P729, DOI 10.1038/nprot.2006.98; Liu WJ, 2020, PHARMACOL THERAPEUT, V206, DOI 10.1016/j.pharmthera.2019.107438; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Matsushita K, 2009, NATURE, V458, P1185, DOI 10.1038/nature07924; Peng WX, 2017, ONCOGENE, V36, P5661, DOI 10.1038/onc.2017.184; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Silva A, 2015, CANCERS, V7, P2169, DOI 10.3390/cancers7040884; Song LX, 2011, MOL CANCER THER, V10, P481, DOI 10.1158/1535-7163.MCT-10-0502; Tanaka T, 2014, CANCER IMMUNOL RES, V2, P288, DOI 10.1158/2326-6066.CIR-14-0022; Taniguchi K, 2014, SEMIN IMMUNOL, V26, P54, DOI 10.1016/j.smim.2014.01.001; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Uehata T, 2013, CELL, V153, P1036, DOI 10.1016/j.cell.2013.04.034; Vinocha A, 2018, J CANCER RES THER, V14, pS758, DOI 10.4103/0973-1482.183217; Wang JX, 2019, MOL ONCOL, V13, P2344, DOI 10.1002/1878-0261.12538; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wang X, 2016, J HEPATOL, V64, P1283, DOI 10.1016/j.jhep.2016.01.019; Wilusz JE, 2009, GENE DEV, V23, P1494, DOI 10.1101/gad.1800909; Xing YH, 2017, CELL, V169, P664, DOI 10.1016/j.cell.2017.04.011; Ying Z, 2017, J CLIN INVEST, V127, P1725, DOI 10.1172/JCI90439; Yoon S, 2012, ONCOGENE, V31, P3467, DOI 10.1038/onc.2011.517; Yoon S, 2010, AUTOPHAGY, V6, P1125, DOI 10.4161/auto.6.8.13547; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734	52	5	6	1	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2021	40	19					3449	3459		10.1038/s41388-021-01769-7	http://dx.doi.org/10.1038/s41388-021-01769-7		APR 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SB1JB	33859372				2022-12-17	WOS:000640485900001
J	Jung, HR; Oh, Y; Na, D; Min, S; Kang, J; Jang, D; Shin, S; Kim, J; Lee, SE; Jeong, EM; An, JY; Sung, CO; Lee, WS; Lee, C; Cho, SY				Jung, Hae Rim; Oh, Yumi; Na, Deukchae; Min, Seoyeon; Kang, Jinjoo; Jang, Dongjun; Shin, Seungjae; Kim, Jiwon; Lee, Sang Eun; Jeong, Eui Man; An, Joon Yong; Sung, Chang Ohk; Lee, Won-Suk; Lee, Charles; Cho, Sung-Yup			CRISPR screens identify a novel combination treatment targeting BCL-X-L and WNT signaling for KRAS/BRAF-mutated colorectal cancers	ONCOGENE			English	Article								Metastatic or recurrent colorectal cancer (CRC) patients require systemic chemotherapy, but the therapeutic options of targeted agents remain limited. CRC patients with KRAS or BRAF gene mutations exhibit a worse prognosis and are resistant to anti-EGFR treatment. Previous studies have shown that the expression of anti-apoptotic protein BCL-X-L is increased in CRC patients with KRAS/BRAF mutations, suggesting BCL-X-L as a therapeutic target for this subgroup. Here, we performed genome-wide CRISPR/Cas9 screens of cell lines with KRAS mutations to investigate the factors required for sensitivity to BCL-X-L inhibitor ABT-263 using single-guide RNAs (sgRNAs) that induce loss-of-function mutations. In the presence of ABT-263, sgRNAs targeting negative regulators of WNT signaling (resulting in WNT activation) were enriched, whereas sgRNAs targeting positive regulators of WNT signaling (resulting in WNT inhibition) were depleted in ABT-263-resistant cells. The activation of WNT signaling was highly associated with an increased expression ratio of anti- to pro-apoptotic BCL-2 family genes in CRC samples. Genetic and pharmacologic inhibition of WNT signaling using beta-catenin short hairpin RNA or TNIK inhibitor NCB-0846, respectively, augmented ABT-263-induced cell death in KRAS/BRAF-mutated cells. Inhibition of WNT signaling resulted in transcriptional repression of the anti-apoptotic BCL-2 family member, MCL1, via the functional inhibition of the beta-catenin-containing complex at the MCL1 promoter. In addition, the combination of ABT-263 and NCB-0846 exhibited synergistic effects in in vivo patient-derived xenograft (PDX) models with KRAS mutations. Our data provide a novel targeted combination treatment strategy for the CRC patient subgroup with KRAS or BRAF mutations.	[Jung, Hae Rim; Oh, Yumi] Seoul Natl Univ, Dept Biochem & Mol Biol, Coll Med, Seoul, South Korea; [Jung, Hae Rim; Oh, Yumi; Cho, Sung-Yup] Seoul Natl Univ, Med Res Ctr, Genom Med Inst, Coll Med, Seoul, South Korea; [Na, Deukchae] Ewha Womans Univ, Ewha Inst Convergence Med, Mokdong Hosp, Seoul, South Korea; [Min, Seoyeon; Kang, Jinjoo; Lee, Charles] Ewha Womans Univ, Dept Life Sci, Seoul, South Korea; [Jang, Dongjun; Shin, Seungjae; Kim, Jiwon; Lee, Sang Eun; Cho, Sung-Yup] Seoul Natl Univ, Dept Biomed Sci, Coll Med, Seoul, South Korea; [Jeong, Eui Man] Jeju Natl Univ, Coll Pharm, Dept Pharm, Jeju City, Jeju Special Se, South Korea; [Jeong, Eui Man] Jeju Natl Univ, Interdisciplinary Grad Program Adv Convergence Te, Jeju City, Jeju Special Se, South Korea; [Jeong, Eui Man] Jeju Natl Univ, Biohlth Mat Core Facil Ctr, Jeju City, Jeju Special Se, South Korea; [Jeong, Eui Man] Jeju Natl Univ, Pract Translat Res Ctr, Jeju City, Jeju Special Se, South Korea; [An, Joon Yong] Korea Univ, Coll Hlth Sci, Sch Biosyst & Biomed Sci, Seoul, South Korea; [Sung, Chang Ohk] Univ Ulsan, Asan Med Ctr, Dept Pathol, Coll Med, Seoul, South Korea; [Lee, Won-Suk] Gachon Univ, Gil Med Ctr, Dept Surg, Incheon, South Korea; [Lee, Charles] Jackson Lab Genom Med, Farmington, CT USA; [Cho, Sung-Yup] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Ewha Womans University; Ewha Womans University; Seoul National University (SNU); Jeju National University; Jeju National University; Jeju National University; Jeju National University; Korea University; University of Ulsan; Asan Medical Center; Gachon University; Jackson Laboratory; Seoul National University (SNU)	Cho, SY (corresponding author), Seoul Natl Univ, Med Res Ctr, Genom Med Inst, Coll Med, Seoul, South Korea.; Cho, SY (corresponding author), Seoul Natl Univ, Dept Biomed Sci, Coll Med, Seoul, South Korea.; Cho, SY (corresponding author), Seoul Natl Univ, Canc Res Inst, Seoul, South Korea.	csybio@snu.ac.kr		Sung, Chang Ohk/0000-0002-8567-456X; An, Joon-Yong/0000-0001-8839-6297	National Research Foundation of Korea (NRF) - Korea government (MSIP) [2017R1C1B2002183]; Bio & Medical Technology Development Program of the NRF - Ministry of Science ICT [2018M3A9F3056902, 2019M3E5D4066900]; Creative-Pioneering Researchers Program through Seoul National University [800-20200510]; Collaborative Research Program of SNU Boramae Medical Center [800-20200005]; Basic Medical Science from Seoul National University College of Medicine [800-20200005]	National Research Foundation of Korea (NRF) - Korea government (MSIP); Bio & Medical Technology Development Program of the NRF - Ministry of Science ICT; Creative-Pioneering Researchers Program through Seoul National University; Collaborative Research Program of SNU Boramae Medical Center; Basic Medical Science from Seoul National University College of Medicine	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (grant No. 2017R1C1B2002183); the Bio & Medical Technology Development Program of the NRF funded by the Ministry of Science & ICT (grant No. 2018M3A9F3056902 and 2019M3E5D4066900); Creative-Pioneering Researchers Program through Seoul National University (grant No. 800-20200510); and the Collaborative Research Program of SNU Boramae Medical Center and Basic Medical Science from Seoul National University College of Medicine (grant No. 800-20200005).	Bendell J, 2018, ANN ONCOL, V29, P123, DOI 10.1093/annonc/mdy208.003; Billard C, 2013, MOL CANCER THER, V12, P1691, DOI 10.1158/1535-7163.MCT-13-0058; Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101; Booy EP, 2011, ONCOGENE, V30, P2367, DOI 10.1038/onc.2010.616; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cho SY, 2017, MOL CANCER THER, V16, P2178, DOI 10.1158/1535-7163.MCT-16-0735; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007; Croce CM, 2016, CANCER RES, V76, P5914, DOI 10.1158/0008-5472.CAN-16-1248; DeStefanis RA, 2019, CURR COLORECT CANC R, V15, P61, DOI 10.1007/s11888-019-00430-6; Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786; Eguchi M, 2005, MED CHEM, V1, P467, DOI 10.2174/1573406054864098; Faber AC, 2014, CANCER DISCOV, V4, P42, DOI 10.1158/2159-8290.CD-13-0315; Gang EJ, 2014, ONCOGENE, V33, P2169, DOI 10.1038/onc.2013.169; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gui JH, 2011, HUM CELL, V24, P121, DOI 10.1007/s13577-011-0023-2; Halilovic E, 2010, CANCER RES, V70, P6804, DOI 10.1158/0008-5472.CAN-10-0409; Herbst A, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-74; Ho SY, 2015, BIOORG MED CHEM LETT, V25, P5472, DOI 10.1016/j.bmcl.2015.10.032; Hoeflich KP, 2012, CANCER RES, V72, P210, DOI 10.1158/0008-5472.CAN-11-1515; Holt SV, 2012, CANCER RES, V72, P1804, DOI 10.1158/0008-5472.CAN-11-1780; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Joung J, 2017, NAT PROTOC, V12, P828, DOI 10.1038/nprot.2017.016; Jung YS, 2020, EXP MOL MED, V52, P183, DOI 10.1038/s12276-020-0380-6; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; Krishnamurthy N, 2018, CANCER TREAT REV, V62, P50, DOI 10.1016/j.ctrv.2017.11.002; Li W, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0554-4; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Martini G, 2017, WORLD J GASTROENTERO, V23, P4675, DOI 10.3748/wjg.v23.i26.4675; Masuda M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12586; McBride A, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00192; Mills JR, 2008, P NATL ACAD SCI USA, V105, P10853, DOI 10.1073/pnas.0804821105; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Phipps AI, 2015, GASTROENTEROLOGY, V148, P77, DOI 10.1053/j.gastro.2014.09.038; Punt CJA, 2017, NAT REV CLIN ONCOL, V14, P235, DOI 10.1038/nrclinonc.2016.171; Schuijers J, 2015, CELL STEM CELL, V16, P158, DOI 10.1016/j.stem.2014.12.006; Senichkin VV, 2019, TRENDS CELL BIOL, V29, P549, DOI 10.1016/j.tcb.2019.03.004; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Shitashige M, 2010, CANCER RES, V70, P5024, DOI 10.1158/0008-5472.CAN-10-0306; Shkoda A, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001376; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Wang BB, 2019, NAT PROTOC, V14, P756, DOI 10.1038/s41596-018-0113-7; Wang L, 2020, ACS MED CHEM LETT, V11, P1829, DOI 10.1021/acsmedchemlett.9b00568; Yeung P., 2014, CANCER RES, V74, pS1907; Yoshida N, 2015, ANTICANCER RES, V35, P4403; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304	49	5	5	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2021	40	18					3287	3302		10.1038/s41388-021-01777-7	http://dx.doi.org/10.1038/s41388-021-01777-7		APR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE1MB	33846570				2022-12-17	WOS:000639635100005
J	Kakumani, PK; Guitart, T; Houle, F; Harvey, LM; Goyer, B; Germain, L; Gebauer, F; Simard, MJ				Kakumani, Pavan Kumar; Guitart, Tanit; Houle, Francois; Harvey, Louis-Mathieu; Goyer, Benjamin; Germain, Lucie; Gebauer, Fatima; Simard, Martin J.			CSDE1 attenuates microRNA-mediated silencing of PMEPA1 in melanoma	ONCOGENE			English	Article							RNA-BINDING PROTEINS; MESSENGER-RNA; TRANSLATIONAL REPRESSION; DROSOPHILA UNR; HUR; UPSTREAM; PHOSPHORYLATION; PROGRESSION; DOMAINS; TARGETS	MicroRNAs and RNA-binding proteins (RBPs) primarily target the 3 ' UTR of mRNAs to control their translation and stability. However, their co-regulatory effects on specific mRNAs in physiology and disease are yet to be fully explored. CSDE1 is an RBP that promotes metastasis in melanoma and mechanisms underlying its oncogenic activities need to be completely defined. Here we report that CSDE1 interacts with specific miRNA-induced silencing complexes (miRISC) in melanoma. We find an association of CSDE1 with AGO2, the essential component of miRISC, which is facilitated by target mRNAs and depends on the first cold shock domain of CSDE1. Both CSDE1 and AGO2 bind to 3 ' UTR of PMEPA1. CSDE1 counters AGO2 binding, leading to an increase of PMEPA1 expression. We also identify a miRNA, miR-129-5p, that represses PMEPA1 expression in melanoma. Collectively, our results show that PMEPA1 promotes tumorigenic traits and that CSDE1 along with miR-129-5p/AGO2 miRISC act antagonistically to fine-tune PMEPA1 expression toward the progression of melanoma.	[Kakumani, Pavan Kumar; Houle, Francois; Harvey, Louis-Mathieu; Simard, Martin J.] Univ Laval, Res Ctr, Oncol Div, CHU Quebec, Quebec City, PQ, Canada; [Kakumani, Pavan Kumar; Houle, Francois; Harvey, Louis-Mathieu; Simard, Martin J.] Univ Laval, Canc Res Ctr, Quebec City, PQ, Canada; [Guitart, Tanit; Gebauer, Fatima] Barcelona Inst Sci & Technol, Gene Regulat Stem Cells & Canc Programme, Ctr Genom Regulat CRG, Barcelona, Spain; [Goyer, Benjamin; Germain, Lucie] Univ Laval, Ctr Rech, Axe Med Regeneratrice, CHU Quebec Univ Laval, Quebec City, PQ, Canada; [Goyer, Benjamin; Germain, Lucie] Univ Laval, LOEX, Ctr Rech Organogenese Expt, Quebec City, PQ, Canada; [Goyer, Benjamin; Germain, Lucie] Univ Laval, Fac Med, Dept Chirurg, Quebec City, PQ, Canada; [Gebauer, Fatima] Univ Pompeu Fabra UPF, Barcelona, Spain	Laval University; Laval University; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Laval University; Laval University; Laval University; Pompeu Fabra University	Kakumani, PK; Simard, MJ (corresponding author), Univ Laval, Res Ctr, Oncol Div, CHU Quebec, Quebec City, PQ, Canada.; Kakumani, PK; Simard, MJ (corresponding author), Univ Laval, Canc Res Ctr, Quebec City, PQ, Canada.	pavan-kumar.kakumani@crchudequebec.ulaval.ca; Martin.Simard@crchudequebec.ulaval.ca	Kakumani, Pavan Kumar/AFH-9007-2022; Guitart, Tanit/G-9772-2015; Gebauer, Fatima/E-7725-2015	Kakumani, Pavan Kumar/0000-0002-8755-860X; Guitart, Tanit/0000-0003-2992-9895; Harvey, Louis-Mathieu/0000-0002-4745-7820; Gebauer, Fatima/0000-0001-7563-0013; Germain, Lucie/0000-0001-8883-6491; Simard, Martin/0000-0002-3189-9309	Canadian Institutes of Health Research (CIHR); Fonds de Recherche du Quebec-Sante (FRQ-S); CIHR [FDN-143213]; Spanish Ministry of Science and Innovation (MICINN) [PGC2018-099697-B-I00]; "la Caixa" Foundation [100010434, LCF/PR/HR17/52150016]; Catalan Government [2017SGR534]; Center of Excellence Severo Ochoa	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Fonds de Recherche du Quebec-Sante (FRQ-S); CIHR(Canadian Institutes of Health Research (CIHR)); Spanish Ministry of Science and Innovation (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); "la Caixa" Foundation(La Caixa Foundation); Catalan Government; Center of Excellence Severo Ochoa	The Canadian Institutes of Health Research (CIHR) supported this work. PKK and LMH are recipients of scholarship from Fonds de Recherche du Quebec-Sante (FRQ-S). MJS is a Research Chair from FRQ-S. LG was supported by the CIHR (FDN-143213). FG was supported by grants from the Spanish Ministry of Science and Innovation (MICINN, PGC2018-099697-B-I00), "la Caixa" Foundation (ID:100010434) under the agreement LCF/PR/HR17/52150016, the Catalan Government (2017SGR534) and the Center of Excellence Severo Ochoa.	Abaza I, 2006, GENE DEV, V20, P380, DOI 10.1101/gad.371906; Abaza I, 2008, RNA, V14, P482, DOI 10.1261/rna.802908; Abdelaziz M, 2019, J BIOCHEM, V165, P411, DOI 10.1093/jb/mvz022; Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Ahuja D, 2016, RNA BIOL, V13, P1152, DOI 10.1080/15476286.2016.1229734; Aksenenko M, 2019, BMC DERMATOL, V19, DOI 10.1186/s12895-018-0081-1; Amalia R, 2019, CELL SIGNAL, V59, P24, DOI 10.1016/j.cellsig.2019.03.016; Bhattacharyya SN, 2006, CELL, V125, P1111, DOI 10.1016/j.cell.2006.04.031; Bohn JA, 2018, NUCLEIC ACIDS RES, V46, P362, DOI 10.1093/nar/gkx1120; Bottini S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01126-x; Chang TC, 2004, GENE DEV, V18, P2010, DOI 10.1101/gad.1219104; Connerty P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010031; Cornelis S, 2005, NUCLEIC ACIDS RES, V33, P3095, DOI 10.1093/nar/gki611; Dinur M, 2006, MOL ENDOCRINOL, V20, P1652, DOI 10.1210/me.2005-0333; Dormoy-Raclet Virginie, 2005, RNA Biol, V2, pe27; Duncan K, 2006, GENE DEV, V20, P368, DOI 10.1101/gad.371406; Elatmani H, 2011, STEM CELLS, V29, P1504, DOI 10.1002/stem.712; Farazi TA, 2011, J PATHOL, V223, P102, DOI 10.1002/path.2806; Fattore L, 2019, CELL DEATH DIFFER, V26, P1267, DOI 10.1038/s41418-018-0205-5; Feng SJ, 2016, MOL MED REP, V13, P4030, DOI 10.3892/mmr.2016.5033; Fishbein L, 2017, CANCER CELL, V31, P181, DOI 10.1016/j.ccell.2017.01.001; Fournier PGJ, 2015, CANCER CELL, V27, P809, DOI 10.1016/j.ccell.2015.04.009; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Friend K, 2012, NAT STRUCT MOL BIOL, V19, P176, DOI 10.1038/nsmb.2214; Gebert LFR, 2019, NAT REV MOL CELL BIO, V20, P21, DOI 10.1038/s41580-018-0045-7; Golden RJ, 2017, NATURE, V542, P197, DOI 10.1038/nature21025; Goyer B, 2019, J TISSUE ENG REGEN M, V13, P2300, DOI 10.1002/term.2959; Hollmann NM, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107930; Huberdeau MQ, 2019, FEBS J, V286, P642, DOI 10.1111/febs.14666; Huberdeau MQ, 2017, EMBO J, V36, P2088, DOI 10.15252/embj.201696386; Iadevaia V, 2015, BIOMOLECULES, V5, P2207, DOI 10.3390/biom5042207; Jannot G, 2011, METHODS MOL BIOL, V725, P233, DOI 10.1007/978-1-61779-046-1_16; Ji JX, 2020, ONCOGENE, V39, P1125, DOI 10.1038/s41388-019-1050-9; Jiang Peng, 2012, Microrna, V1, P70; Jonas S, 2015, NAT REV GENET, V16, P421, DOI 10.1038/nrg3965; Kakumani PK, 2020, LIFE SCI ALLIANCE, V3, DOI 10.26508/lsa.201900632; Kamenska A, 2016, NUCLEIC ACIDS RES, V44, P6318, DOI 10.1093/nar/gkw565; Karginov FV, 2013, GENE DEV, V27, P1624, DOI 10.1101/gad.215939.113; Kaye JA, 2009, NEURON, V61, P57, DOI 10.1016/j.neuron.2008.11.012; Kedde M, 2007, CELL, V131, P1273, DOI 10.1016/j.cell.2007.11.034; Kedde M, 2010, NAT CELL BIOL, V12, P1014, DOI 10.1038/ncb2105; Keene JD, 2007, NAT REV GENET, V8, P533, DOI 10.1038/nrg2111; Kelly TJ, 2019, RNA, V25, P1291, DOI 10.1261/rna.071621.119; Kim HH, 2009, GENE DEV, V23, P1743, DOI 10.1101/gad.1812509; Kishore S, 2010, BRIEF FUNCT GENOMICS, V9, P391, DOI 10.1093/bfgp/elq028; Kundu P, 2012, NUCLEIC ACIDS RES, V40, P5088, DOI 10.1093/nar/gks148; Lee HJ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01744-5; Li G, 2019, ONCOL LETT, V17, P5777, DOI 10.3892/ol.2019.10241; Li YH, 2018, J MOL BIOL, V430, P285, DOI 10.1016/j.jmb.2017.12.006; Li ZZ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1923-4; Liu Q, 2018, BIOMED PHARMACOTHER, V105, P420, DOI 10.1016/j.biopha.2018.05.105; Ma LJ, 2019, J CELL BIOCHEM, V120, P7527, DOI 10.1002/jcb.28027; Martinez-Useros J, 2019, J CLIN MED, V8, DOI 10.3390/jcm8040560; Mihailovich M, 2010, BIOESSAYS, V32, P109, DOI 10.1002/bies.200900122; Militti C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5762; Mitchell SA, 2001, MOL CELL BIOL, V21, P3364, DOI 10.1128/MCB.21.10.3364-3374.2001; Nam JW, 2014, MOL CELL, V53, P1031, DOI 10.1016/j.molcel.2014.02.013; Peng Y, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2015.4; Pereira B, 2017, TRENDS CANCER, V3, P506, DOI 10.1016/j.trecan.2017.05.003; Qian H, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.28; Qiu ZS, 2019, ACTA BIOCH BIOPH SIN, V51, P997, DOI 10.1093/abbs/gmz096; Schadendorf D, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.3; Schepens B, 2007, EMBO J, V26, P158, DOI 10.1038/sj.emboj.7601468; Sternburg EL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33596-4; Nguyen TTV, 2014, CANCER SCI, V105, P334, DOI 10.1111/cas.12355; van Kouwenhove M, 2011, NAT REV CANCER, V11, P644, DOI 10.1038/nrc3107; Wan P, 2020, J CELL PHYSIOL, V235, P5689, DOI 10.1002/jcp.29501; Wang SC, 2019, PATHOL RES PRACT, V215, P676, DOI 10.1016/j.prp.2018.12.024; Wurth L, 2016, CANCER CELL, V30, P694, DOI 10.1016/j.ccell.2016.10.004; Xu Y, 2012, BRIT J CANCER, V106, P553, DOI 10.1038/bjc.2011.568; Xue YC, 2013, CELL, V152, P82, DOI 10.1016/j.cell.2012.11.045; Young LE, 2012, MOL CANCER RES, V10, P167, DOI 10.1158/1541-7786.MCR-11-0337	72	5	5	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2021	40	18					3231	3244		10.1038/s41388-021-01767-9	http://dx.doi.org/10.1038/s41388-021-01767-9		APR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE1MB	33833398				2022-12-17	WOS:000638023600002
J	Kim, ES; Nam, SM; Song, HK; Lee, S; Kim, K; Lim, HK; Lee, H; Kang, KT; Kwon, YJ; Chun, YJ; Park, SY; Jung, J; Moon, A				Kim, Eun-Sook; Nam, Su-Min; Song, Hye Kyung; Lee, Seungeun; Kim, Kyoungmee; Lim, Hyun Kyung; Lee, Hyunsook; Kang, Kyu-Tae; Kwon, Yeo-Jung; Chun, Young-Jin; Park, So Yeon; Jung, Joohee; Moon, Aree			CCL8 mediates crosstalk between endothelial colony forming cells and triple-negative breast cancer cells through IL-8, aggravating invasion and tumorigenicity	ONCOGENE			English	Article							NF-KAPPA-B; PROGENITOR CELLS; IN-VIVO; GENE-EXPRESSION; TUBE FORMATION; ANGIOGENESIS; METASTASIS; GROWTH; CD34; PROLIFERATION	Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer with a poor prognosis for which no effective therapeutic measures are currently available. The present study aimed to investigate whether interactions with endothelial colony-forming cells (ECFCs) promote aggressive progression of TNBC cells. Herein, using an indirect co-culture system, we showed that co-culture increased the invasive and migratory phenotypes of both MDA-MB-231 TNBC cells and ECFCs. Through a cytokine antibody array and RT-PCR analysis, we revealed that co-culture markedly induced secretion of the chemokine C-C motif ligand (CCL)8 from ECFCs and that of interleukin (IL)-8 from MDA-MB-231 cells. CCL8 was crucial for ECFC-induced IL-8 secretion and invasion of MDA-MB-231 cells as well as for MDA-MB-231-enhanced MMP-2 secretion and angiogenesis of ECFCs. We suggest c-Jun as a transcription factor for CCL8-induced IL-8 expression in MDA-MB-231 cells. IL-8 was important for co-culture-induced CCL8 and MMP-2 upregulation and invasion of ECFCs. Notably, our findings reveal a positive feedback loop between CCL8 and IL-8, which contributes to the aggressive phenotypes of both ECFC and TNBC cells. Using an MDA-MB-231 cell-based xenograft model, we show that tumor growth and metastasis are increased by co-injected ECFCs in vivo. Increased expression of IL-8 was observed in tissues with bone metastases in mice injected with conditioned media from co-cultured cells. High IL-8 levels are correlated with poor recurrence-free survival in TNBC patients. Together, these results suggest that CCL8 and IL-8 mediate the crosstalk between ECFCs and TNBC, leading to aggravation of tumorigenicity in TNBC.	[Kim, Eun-Sook; Nam, Su-Min; Lee, Seungeun; Kim, Kyoungmee; Lim, Hyun Kyung; Lee, Hyunsook; Kang, Kyu-Tae; Jung, Joohee; Moon, Aree] Duksung Womens Univ, Coll Pharm, Duksung Innovat Drug Ctr, Seoul, South Korea; [Song, Hye Kyung] Duksung Womens Univ, Coll Chem, Seoul, South Korea; [Kwon, Yeo-Jung; Chun, Young-Jin] Chung Ang Univ, Coll Pharm, Seoul, South Korea; [Park, So Yeon] Seoul Natl Univ, Bundang Hosp, Dept Pathol, Coll Med, Seongnam, South Korea	Duksung Women's University; Duksung Women's University; Chung Ang University; Seoul National University (SNU)	Jung, J; Moon, A (corresponding author), Duksung Womens Univ, Coll Pharm, Duksung Innovat Drug Ctr, Seoul, South Korea.	joohee@duksung.ac.kr; armoon@duksung.ac.kr		Park, So Yeon/0000-0002-0299-7268	National Research Foundation of Korea [2016R1A6A1A03007648, 2019R1A2C1009773]	National Research Foundation of Korea(National Research Foundation of Korea)	The present study was supported by the National Research Foundation of Korea (no. 2016R1A6A1A03007648 and no. 2019R1A2C1009773).	Afshar Moghaddam Noushin, 2015, Iran J Pathol, V10, P89; An GL, 2019, ONCOL REP, V42, P2499, DOI 10.3892/or.2019.7344; Andre F, 2012, ANN ONCOL, V23, P46, DOI 10.1093/annonc/mds195; Arnaoutova I, 2010, NAT PROTOC, V5, P628, DOI 10.1038/nprot.2010.6; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bettelli E, 2005, P NATL ACAD SCI USA, V102, P5138, DOI 10.1073/pnas.0501675102; Bianconi D, 2020, THER ADV MED ONCOL, V12, DOI 10.1177/1758835920928635; Cassetta L, 2019, CANCER CELL, V35, P588, DOI 10.1016/j.ccell.2019.02.009; CONNOLLY KM, 1993, J HISTOCHEM CYTOCHEM, V41, P1, DOI 10.1177/41.1.7678022; DELIA D, 1993, BLOOD, V81, P1001; Engels K, 1997, J PATHOL, V181, P207; Fadini GP, 2012, CIRC RES, V110, P624, DOI 10.1161/CIRCRESAHA.111.243386; Farmaki E, 2016, ONCOGENE, V35, P6309, DOI 10.1038/onc.2016.161; Finkenzeller G, 2009, CELL PROLIFERAT, V42, P498, DOI 10.1111/j.1365-2184.2009.00610.x; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fong YC, 2008, J BONE MINER RES, V23, P961, DOI [10.1359/jbmr.080206, 10.1359/JBMR.080206]; Freund A, 2003, ONCOGENE, V22, P256, DOI 10.1038/sj.onc.1206113; Gomez-Cuadrado L, 2017, DIS MODEL MECH, V10, P1061, DOI 10.1242/dmm.030403; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Halama N, 2016, CANCER CELL, V29, P587, DOI 10.1016/j.ccell.2016.03.005; Halvorsen EC, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1150398; Hoffmann OI, 2015, J BIOTECHNOL, V205, P14, DOI 10.1016/j.jbiotec.2015.02.029; Huang SY, 2002, AM J PATHOL, V161, P125, DOI 10.1016/S0002-9440(10)64164-8; Ingram DA, 2004, BLOOD, V104, P2752, DOI 10.1182/blood-2004-04-1396; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Khanjani S, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/504952; Khodarev NN, 2003, J CELL SCI, V116, P1013, DOI 10.1242/jcs.00281; Kivisto KT, 1995, BRIT J CLIN PHARMACO, V40, P523, DOI 10.1111/j.1365-2125.1995.tb05796.x; Kwon YH, 2012, BIOMOL THER, V20, P158, DOI 10.4062/biomolther.2012.20.2.158; Lambert E, 2004, CRIT REV ONCOL HEMAT, V49, P187, DOI 10.1016/j.critrevonc.2003.09.008; Le Bourhis X, 2010, BREAST CANCER RES TR, V120, P17, DOI 10.1007/s10549-009-0686-5; Lee HM, 2016, BIOMOL THER, V24, P62, DOI 10.4062/biomolther.2015.172; Lee H, 2018, KOREAN J PHYSIOL PHA, V22, P705, DOI 10.4196/kjpp.2018.22.6.705; Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369; Liu L, 2012, CARDIOVASC RES, V94, P3, DOI 10.1093/cvr/cvs108; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; McKenney JK, 2001, AM J SURG PATHOL, V25, P1167, DOI 10.1097/00000478-200109000-00007; Medrek C, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-306; Melero-Martin JM, 2008, CIRC RES, V103, P194, DOI 10.1161/CIRCRESAHA.108.178590; Melero-Martin JM, 2007, BLOOD, V109, P4761, DOI 10.1182/blood-2006-12-062471; Mencarelli A, 2013, TRANSL ONCOL, V6, P784, DOI 10.1593/tlo.13499; MIETTINEN M, 1994, MODERN PATHOL, V7, P82; Miller LJ, 1998, ANTICANCER RES, V18, P77; Neophytou C, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00031; Paschalaki KE, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00295; Riedlinger T, 2019, FASEB J, V33, P4188, DOI 10.1096/fj.201801638R; Rody A, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3035; Sato T, 2017, J CANCER, V8, P704, DOI 10.7150/jca.18027; Sicoli D, 2014, CANCER RES, V74, P7103, DOI 10.1158/0008-5472.CAN-14-0612; Singh JK, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3436; Smadja DM, 2010, ARTERIOSCL THROM VAS, V30, P2544, DOI 10.1161/ATVBAHA.110.213751; Snoussi K, 2006, HUM IMMUNOL, V67, P13, DOI 10.1016/j.humimm.2006.03.018; Snoussi K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-283; Song H, 2006, CANCER RES, V66, P10487, DOI 10.1158/0008-5472.CAN-06-1461; Sunaga N, 2014, BRIT J CANCER, V110, P2047, DOI 10.1038/bjc.2014.110; Tsutsui Shinichi, 2003, Breast Cancer, V10, P312, DOI 10.1007/BF02967651; Uzzan B, 2004, CANCER RES, V64, P2941, DOI 10.1158/0008-5472.CAN-03-1957; Vasudev NS, 2014, ANGIOGENESIS, V17, P471, DOI 10.1007/s10456-014-9420-y; Velasco-Velazquez M, 2012, CANCER RES, V72, P3839, DOI 10.1158/0008-5472.CAN-11-3917; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; Yin WJ, 2009, BREAST CANCER RES TR, V115, P325, DOI 10.1007/s10549-008-0096-0; Yuan A, 2002, J CLIN ONCOL, V20, P900, DOI 10.1200/JCO.20.4.900; Zhang WW, 2018, FASEB J, V32, P276, DOI 10.1096/fj.201700237RR; Zhang X, 2020, LAB INVEST, V100, P619, DOI 10.1038/s41374-019-0345-3; Zhao K, 2018, CARCINOGENESIS, V39, P588, DOI 10.1093/carcin/bgy007; Zheng HC, 2006, ANTICANCER RES, V26, P3579; Zhou J, 2018, CELL BIOL INT, V42, P365, DOI 10.1002/cbin.10909	67	5	5	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2021	40	18					3245	3259		10.1038/s41388-021-01758-w	http://dx.doi.org/10.1038/s41388-021-01758-w		APR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE1MB	33833397				2022-12-17	WOS:000638023600001
J	Qin, WR; Xu, GC; Tai, PWL; Wang, CM; Luo, L; Li, CJ; Hu, X; Xue, JX; Lu, Y; Zhou, Q; Wei, Q; Wen, TF; Hu, JK; Xiao, YY; Yang, L; Li, WM; Flotte, TR; Wei, YQ; Gao, GP				Qin, Wanru; Xu, Guangchao; Tai, Phillip W. L.; Wang, Chunmei; Luo, Li; Li, Chengjian; Hu, Xun; Xue, Jianxin; Lu, You; Zhou, Qiao; Wei, Qiang; Wen, Tianfu; Hu, Jiankun; Xiao, Yuanyuan; Yang, Li; Li, Weimin; Flotte, Terence R.; Wei, Yuquan; Gao, Guangping			Large-scale molecular epidemiological analysis of AAV in a cancer patient population	ONCOGENE			English	Article								Recombinant adeno-associated viruses (rAAVs) are well-established vectors for delivering therapeutic genes. However, previous reports have suggested that wild-type AAV is linked to hepatocellular carcinoma, raising concern with the safety of rAAVs. In addition, a recent long-term follow-up study in canines, which received rAAVs for factor VIII gene therapy, demonstrated vector integration into the genome of liver cells, reviving the uncertainty between AAV and cancer. To further explore this relationship, we performed large-scale molecular epidemiology of AAV in resected tumor samples and non-lesion tissues collected from 413 patients, reflecting nine carcinoma types: breast carcinoma, rectal cancer, pancreas carcinoma, brain tumor, hepatoid adenocarcinoma, hepatocellular carcinoma, gastric carcinoma, lung squamous, and adenocarcinoma. We found that over 80% of patients were AAV-positive among all nine types of carcinoma examined. Importantly, the AAV sequences detected in patient-matched tumor and adjacent non-lesion tissues showed no significant difference in incidence, abundance, and variation. In addition, no specific AAV sequences predominated in tumor samples. Our data shows that AAV genomes are equally abundant in tumors and adjacent normal tissues, but lack clonality. The finding critically adds to the epidemiological profile of AAV in humans, and provides insights that may assist rAAV-based clinical studies and gene therapy strategies.	[Qin, Wanru; Xu, Guangchao; Wang, Chunmei; Luo, Li; Xiao, Yuanyuan; Yang, Li; Li, Weimin; Wei, Yuquan] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China; [Xu, Guangchao; Tai, Phillip W. L.; Luo, Li; Flotte, Terence R.; Gao, Guangping] Univ Massachusetts, Sch Med, Horae Gene Therapy Ctr, Worcester, MA 01605 USA; [Xu, Guangchao; Tai, Phillip W. L.; Gao, Guangping] Univ Massachusetts, Sch Med, Microbiol & Physiol Syst, Worcester, MA 01605 USA; [Li, Chengjian] Fornax Biotech, Worcester, MA USA; [Hu, Xun] Sichuan Univ, West China Hosp, Biobank, Chengdu, Peoples R China; [Xue, Jianxin; Lu, You] Sichuan Univ, West China Hosp, Canc Ctr, Dept Thorac Oncol, Chengdu, Peoples R China; [Xue, Jianxin; Lu, You] Sichuan Univ, West China Hosp, Canc Ctr, State Key Lab Biotherapy, Chengdu, Peoples R China; [Zhou, Qiao] Sichuan Univ, West China Hosp, West China Med Sch, Pathol Dept, Chengdu, Peoples R China; [Zhou, Qiao] Sichuan Univ, West China Hosp, West China Med Sch, State Key Lab Biotherapy, Chengdu, Peoples R China; [Wei, Qiang] Sichuan Univ, West China Hosp, Inst Urol, Dept Urol, Chengdu, Peoples R China; [Wen, Tianfu] Sichuan Univ, West China Hosp, Dept Liver Surg, Chengdu, Peoples R China; [Hu, Jiankun] Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, Chengdu, Peoples R China; [Hu, Jiankun] Sichuan Univ, West China Hosp, Lab Gastr Canc, Chengdu, Peoples R China; [Flotte, Terence R.] Univ Massachusetts, Sch Med, Pediat, Worcester, MA 01605 USA	Sichuan University; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Sichuan University; Sichuan University; Sichuan University; Sichuan University; Sichuan University; Sichuan University; Sichuan University; Sichuan University; Sichuan University; University of Massachusetts System; University of Massachusetts Worcester	Wei, YQ (corresponding author), Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China.; Flotte, TR; Gao, GP (corresponding author), Univ Massachusetts, Sch Med, Horae Gene Therapy Ctr, Worcester, MA 01605 USA.; Gao, GP (corresponding author), Univ Massachusetts, Sch Med, Microbiol & Physiol Syst, Worcester, MA 01605 USA.; Flotte, TR (corresponding author), Univ Massachusetts, Sch Med, Pediat, Worcester, MA 01605 USA.	Terry.Flotte@umassmed.edu; yqwei@scu.edu.cn; guangping.gao@umassmed.edu		Xu, Guangchao/0000-0002-3806-2245; Tai, Phillip/0000-0001-7409-8344	University of Massachusetts Medical School; NIH [R01NS076991-01, P01AI100263-01, P01HL131471-02, R01AI121135, UG3HL147367-01, R01HL097088, U19AI149646-01]	University of Massachusetts Medical School; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by grants from the University of Massachusetts Medical School (an internal grant) and by the NIH (R01NS076991-01, P01AI100263-01, P01HL131471-02, R01AI121135, UG3HL147367-01, R01HL097088, and U19AI149646-01).	Afgan E, 2018, NUCLEIC ACIDS RES, V46, pW537, DOI 10.1093/nar/gky379; Berns KI, 2020, HUM GENE THER, V31, P518, DOI 10.1089/hum.2020.017; Berns KI, 2015, HUM GENE THER, V26, P779, DOI 10.1089/hum.2015.29014.kib; Boutin S, 2010, HUM GENE THER, V21, P704, DOI 10.1089/hum.2009.182; Buning H, 2015, MOL THER, V23, P1673, DOI 10.1038/mt.2015.182; Calcedo R, 2009, J INFECT DIS, V199, P381, DOI 10.1086/595830; Chandler RJ, 2016, MOL THER, V24, P198, DOI 10.1038/mt.2016.17; Chandler RJ, 2015, J CLIN INVEST, V125, P870, DOI 10.1172/JCI79213; Chen CL, 2005, J VIROL, V79, P14781, DOI 10.1128/JVI.79.23.14781-14792.2005; Donsante A, 2007, SCIENCE, V317, P477, DOI 10.1126/science.1142658; Duan DS, 1998, J VIROL, V72, P8568, DOI 10.1128/JVI.72.11.8568-8577.1998; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Gao GP, 2003, P NATL ACAD SCI USA, V100, P6081, DOI 10.1073/pnas.0937739100; Gil-Farina I, 2016, CURR OPIN VIROL, V21, P35, DOI 10.1016/j.coviro.2016.07.004; Halbert CL, 2006, HUM GENE THER, V17, P440, DOI 10.1089/hum.2006.17.440; Hanlon KS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12449-2; Huser D, 2017, J VIROL, V91, DOI 10.1128/JVI.02137-16; KOTIN RM, 1991, GENOMICS, V10, P831, DOI 10.1016/0888-7543(91)90470-Y; Kramer CJH, 2019, BREAST CANCER RES TR, V173, P55, DOI 10.1007/s10549-018-4987-4; La Bella T, 2020, GUT, V69, P737, DOI 10.1136/gutjnl-2019-318281; Li HJ, 2011, BLOOD, V117, P3311, DOI 10.1182/blood-2010-08-302729; Ling C, 2015, J INTEGR MED-JIM, V13, P341, DOI 10.1016/S2095-4964(15)60200-X; Liu Q, 2014, GENE THER, V21, P732, DOI 10.1038/gt.2014.47; Liu Q, 2013, J MED VIROL, V85, P1550, DOI 10.1002/jmv.23647; Logan GJ, 2017, NAT GENET, V49, P1267, DOI 10.1038/ng.3893; Mesker WE, 2007, CELL ONCOL, V29, P387; Miller DG, 2004, NAT GENET, V36, P767, DOI 10.1038/ng1380; Nakai H, 2003, MOL THER, V7, P101, DOI 10.1016/S1525-0016(02)00023-0; Nault JC, 2016, MOL THER, V24, P659, DOI 10.1038/mt.2016.47; Nault JC, 2015, NAT GENET, V47, P1187, DOI 10.1038/ng.3389; Nguyen GN, 2021, NAT BIOTECHNOL, V39, P47, DOI 10.1038/s41587-020-0741-7; Ogden PJ, 2019, SCIENCE, V366, P1139, DOI 10.1126/science.aaw2900; Pachori AS, 2004, BIOCHEM BIOPH RES CO, V313, P528, DOI 10.1016/j.bbrc.2003.11.140; Rosas LE, 2012, MOL THER, V20, P2098, DOI 10.1038/mt.2012.197; Schnepp BC, 2005, J VIROL, V79, P14793, DOI 10.1128/JVI.79.23.14793-14803.2005; Wang D, 2019, NAT REV DRUG DISCOV, V18, P358, DOI 10.1038/s41573-019-0012-9; Wang PR, 2012, P NATL ACAD SCI USA, V109, P11264, DOI 10.1073/pnas.1117032109; Zhong L, 2013, HUM GENE THER, V24, P520, DOI 10.1089/hum.2012.112	38	5	5	3	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2021	40	17					3060	3071		10.1038/s41388-021-01725-5	http://dx.doi.org/10.1038/s41388-021-01725-5		MAR 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RV2NJ	33782545	Green Accepted			2022-12-17	WOS:000634614900001
J	Ezrova, Z; Nahacka, Z; Stursa, J; Werner, L; Vlcak, E; Viziova, PK; Berridge, MV; Sedlacek, R; Zobalova, R; Rohlena, J; Boukalova, S; Neuzil, J				Ezrova, Zuzana; Nahacka, Zuzana; Stursa, Jan; Werner, Lukas; Vlcak, Erik; Kralova Viziova, Petra; Berridge, Michael V.; Sedlacek, Radislav; Zobalova, Renata; Rohlena, Jakub; Boukalova, Stepana; Neuzil, Jiri			SMAD4 loss limits the vulnerability of pancreatic cancer cells to complex I inhibition via promotion of mitophagy	ONCOGENE			English	Article								Pancreatic cancer is one of the deadliest forms of cancer, which is attributed to lack of effective treatment options and drug resistance. Mitochondrial inhibitors have emerged as a promising class of anticancer drugs, and several inhibitors of the electron transport chain (ETC) are being clinically evaluated. We hypothesized that resistance to ETC inhibitors from the biguanide class could be induced by inactivation of SMAD4, an important tumor suppressor involved in transforming growth factor beta (TGF beta) signaling, and associated with altered mitochondrial activity. Here we show that, paradoxically, both TGF beta-treatment and the loss of SMAD4, a downstream member of TGF beta signaling cascade, induce resistance to biguanides, decrease mitochondrial respiration, and fragment the mitochondrial network. Mechanistically, the resistance of SMAD4-deficient cells is mediated by increased mitophagic flux driven by MAPK/ERK signaling, whereas TGF beta-induced resistance is autophagy-independent and linked to epithelial-to-mesenchymal transition (EMT). Interestingly, mitochondria-targeted tamoxifen, a complex I inhibitor under clinical trial, overcomes resistance mediated by SMAD4-deficiency or TGF beta signaling. Our data point to differential mechanisms underlying the resistance to treatment in PDAC arising from TGF beta signaling and SMAD4 loss, respectively. The findings will help the development of mitochondria-targeted therapy for pancreatic cancer patients with SMAD4 as a plausible predictive marker.	[Ezrova, Zuzana; Nahacka, Zuzana; Stursa, Jan; Werner, Lukas; Zobalova, Renata; Rohlena, Jakub; Boukalova, Stepana; Neuzil, Jiri] Czech Acad Sci, Inst Biotechnol, Prague, Czech Republic; [Ezrova, Zuzana] Charles Univ Prague, Fac Sci, Prague, Czech Republic; [Vlcak, Erik] Czech Acad Sci, Inst Mol Genet, Prague, Czech Republic; [Kralova Viziova, Petra; Sedlacek, Radislav] Czech Acad Sci, Inst Mol Genet, Czech Ctr Phenogen, Prague, Czech Republic; [Berridge, Michael V.] Malaghan Inst Med Res, Wellington, New Zealand; [Neuzil, Jiri] Griffith Univ, Sch Med Sci, Southport, Qld, Australia	Czech Academy of Sciences; Institute of Biotechnology of the Czech Academy of Sciences; Charles University Prague; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Malaghan Institute; Victoria University Wellington; Griffith University	Boukalova, S; Neuzil, J (corresponding author), Czech Acad Sci, Inst Biotechnol, Prague, Czech Republic.; Neuzil, J (corresponding author), Griffith Univ, Sch Med Sci, Southport, Qld, Australia.	stepana.boukalova@ibt.cas.cz; j.neuzil@griffith.edu.au	WERNER, LUKÁŠ/AAL-7888-2021; Stursa, Jan/J-4255-2014; Rohlena, Jakub/H-6699-2014; Králová Viziová, Petra/AGJ-5763-2022; Boukalova, Stepana/H-2610-2014; Ezrova, Zuzana/W-3595-2017	Rohlena, Jakub/0000-0001-5427-6502; Boukalova, Stepana/0000-0002-6478-4604; Vlcak, Erik/0000-0003-4911-2380; Zobalova, Renata/0000-0002-9097-4700; Ezrova, Zuzana/0000-0002-4174-6066; Nahacka, Zuzana/0000-0003-0477-2764	Czech Health Research Council [NV16-31604A]; Czech Science Foundation [19-20553S, 20-18513S, 20-11724Y, 18-02550S]; Grant Agency of Charles University [GAUK1100217]; project International mobility grant of researchers of the Institute of Biotechnology CAS, v. v. i. from the ESF [CZ.02.2.69/0.0/0.0/16_027/0008353]; BIOCEV from the ERDF [CZ.1.05/1.1.00/02.0109]; Ministry of Education, Youth and Sports of the Czech Republic at the CZ-OPENSCREEN: National infrastructure for chemical biology [LO1220]; Czech-BioImaging large RI projects - (MEYS CR) [LM2015062, CZ.02.1.01/0.0/0.0/16_013/0001775]; program "Projects of Large Research, Development, and Innovations Infrastructures" [CESNET LM2015042]; Czech Academy of Sciences [RVO 68378050]; project of support program for large infrastructures for research, experimental development and innovation Czech Centre for Phenogenomics by MEYS CR [LM2018126]; MEYS; ESIF [CZ.02.1.01/0.0/0.0/16_013/0001789, CZ.02.1.01/0.0/0.0/18_046/0015861, CZ.1.05/2.1.00/19.0395];  [RVO: 86652036]	Czech Health Research Council; Czech Science Foundation(Grant Agency of the Czech Republic); Grant Agency of Charles University; project International mobility grant of researchers of the Institute of Biotechnology CAS, v. v. i. from the ESF; BIOCEV from the ERDF; Ministry of Education, Youth and Sports of the Czech Republic at the CZ-OPENSCREEN: National infrastructure for chemical biology; Czech-BioImaging large RI projects - (MEYS CR); program "Projects of Large Research, Development, and Innovations Infrastructures"; Czech Academy of Sciences(Czech Academy of Sciences); project of support program for large infrastructures for research, experimental development and innovation Czech Centre for Phenogenomics by MEYS CR; MEYS; ESIF; 	This work was supported by Czech Health Research Council grants (NV16-31604A) to JN, Czech Science Foundation grants (19-20553S, 20-18513S, 20-11724Y and 18-02550S), and Grant Agency of Charles University (GAUK1100217) to ZE. SB was supported by a project International mobility grant of researchers of the Institute of Biotechnology CAS, v. v. i. (CZ.02.2.69/0.0/0.0/16_027/0008353) from the ESF. Further support was provided by BIOCEV CZ.1.05/1.1.00/02.0109 from the ERDF, RVO: 86652036 and the Ministry of Education, Youth and Sports of the Czech Republic (LO1220) at the CZ-OPENSCREEN: National infrastructure for chemical biology. We acknowledge the Imaging Methods Core Facility at BIOCEV and Microscopy Centre -Electron Microscopy Core Facility, IMG AS CR, institutions supported by the Czech-BioImaging large RI projects (LM2015062 and CZ.02.1.01/0.0/0.0/16_013/0001775, funded by MEYS CR) for their support with obtaining scientific data presented in this paper. Access to computing and storage facilities owned by parties and projects contributing to the National Grid Infrastructure MetaCentrum provided under the program "Projects of Large Research, Development, and Innovations Infrastructures" (CESNET LM2015042), is greatly appreciated. Research data were collected in cooperation with the employees of the Czech Centre for Phenogenomics supported by the Czech Academy of Sciences RVO 68378050 and by the project of support program for large infrastructures for research, experimental development and innovation LM2018126 Czech Centre for Phenogenomics provided by MEYS CR. Further support was provided by MEYS and ESIF (CZ.02.1.01/0.0/0.0/16_013/0001789, CZ.02.1.01/0.0/0.0/18_046/0015861, and CZ.1.05/2.1.00/19.0395).	Arumugam T, 2009, CANCER RES, V69, P5820, DOI 10.1158/0008-5472.CAN-08-2819; Bajzikova M, 2019, CELL METAB, V29, P399, DOI 10.1016/j.cmet.2018.10.014; Basso D, 2017, ONCOTARGET, V8, P84928, DOI 10.18632/oncotarget.20863; Blackford A, 2009, CLIN CANCER RES, V15, P4674, DOI 10.1158/1078-0432.CCR-09-0227; Boukalova S, 2016, MOL CANCER THER, V15, P2875, DOI 10.1158/1535-7163.MCT-15-1021; Bridges HR, 2016, BMC BIOL, V14, DOI 10.1186/s12915-016-0287-9; Chae YK, 2016, ONCOTARGET, V7, P40767, DOI 10.18632/oncotarget.8194; Chen YW, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-181; Chen YH, 2020, J CELL PHYSIOL, V235, P1903, DOI 10.1002/jcp.29108; Cheng G, 2016, CANCER RES, V76, P3904, DOI 10.1158/0008-5472.CAN-15-2534; Colak S, 2017, TRENDS CANCER, V3, P56, DOI 10.1016/j.trecan.2016.11.008; Costanza B, 2019, INT J CANCER, V145, P1570, DOI 10.1002/ijc.32247; Cottet-Rousselle C, 2011, CYTOM PART A, V79A, P405, DOI 10.1002/cyto.a.21061; Dagda RK, 2008, AUTOPHAGY, V4, P770, DOI 10.4161/auto.6458; David CJ, 2016, CELL, V164, P1015, DOI 10.1016/j.cell.2016.01.009; Fullerton PT, 2015, MOL ENDOCRINOL, V29, P1440, DOI 10.1210/me.2015-1102; Georgakopoulos ND, 2017, NAT CHEM BIOL, V13, P136, DOI [10.1038/NCHEMBIO.2287, 10.1038/nchembio.2287]; Hernandez G, 2013, AUTOPHAGY, V9, P1852, DOI 10.4161/auto.26501; Hubackova S, 2019, CELL DEATH DIFFER, V26, P276, DOI 10.1038/s41418-018-0118-3; Katayama H, 2011, CHEM BIOL, V18, P1042, DOI 10.1016/j.chembiol.2011.05.013; Katsuno Y, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aau8544; Laker RC, 2014, J BIOL CHEM, V289, P12005, DOI 10.1074/jbc.M113.530527; Leone A, 2014, CANCER TREAT RES, V159, P355, DOI 10.1007/978-3-642-38007-5_21; Liang C, 2020, GUT, V69, P888, DOI 10.1136/gutjnl-2018-317163; Liang C, 2020, AUTOPHAGY, V16, P486, DOI 10.1080/15548627.2019.1628540; Mao L, 2017, ONCOL LETT, V14, P647, DOI 10.3892/ol.2017.6209; Molina JR, 2018, NAT MED, V24, P1036, DOI 10.1038/s41591-018-0052-4; Naguib A, 2018, CELL REP, V23, P58, DOI 10.1016/j.celrep.2018.03.032; Ozawa H, 2017, CLIN CANCER RES, V23, P5162, DOI 10.1158/1078-0432.CCR-16-1686; Papageorgis P, 2011, CANCER RES, V71, P998, DOI 10.1158/0008-5472.CAN-09-3269; Pecinova A, 2019, BIOFACTORS, V45, P703, DOI 10.1002/biof.1548; Rawla P, 2019, WORLD J ONCOL, V10, P10, DOI 10.14740/wjon1166; Rodriguez-Garcia A, 2017, FEBS J, V284, P3437, DOI 10.1111/febs.14201; Rohlenova K, 2017, ANTIOXID REDOX SIGN, V26, P84, DOI 10.1089/ars.2016.6677; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Shi S, 2015, CANCER LETT, V360, P227, DOI 10.1016/j.canlet.2015.02.014; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Sica V, 2020, INT J CANCER, V146, P10, DOI 10.1002/ijc.32616; Springer W, 2011, AUTOPHAGY, V7, P266, DOI 10.4161/auto.7.3.14348; Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350; Tan AS, 2015, CELL METAB, V21, P81, DOI 10.1016/j.cmet.2014.12.003; Tauber J, 2013, INT J BIOCHEM CELL B, V45, P593, DOI 10.1016/j.biocel.2012.11.019; Um JH, 2018, JOVE-J VIS EXP, DOI 10.3791/58099; Urra FA, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00118; Valente AJ, 2017, ACTA HISTOCHEM, V119, P315, DOI 10.1016/j.acthis.2017.03.001; Wang F, 2018, CLIN CANCER RES, V24, P3176, DOI 10.1158/1078-0432.CCR-17-3435; Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312; Wasserman I, 2019, CLIN CANCER RES, V25, P1948, DOI 10.1158/1078-0432.CCR-18-1726; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Xia X, 2015, TUMOR BIOL, V36, P111, DOI 10.1007/s13277-014-2883-z; Yalcin A, 2017, BIOCHEM BIOPH RES CO, V484, P687, DOI 10.1016/j.bbrc.2017.01.178; Zhang C, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0628-8; Zhang YE, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022129; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	54	5	5	2	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2021	40	14					2539	2552		10.1038/s41388-021-01726-4	http://dx.doi.org/10.1038/s41388-021-01726-4		MAR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK3YE	33686239				2022-12-17	WOS:000626396000002
J	Rawat, V; Malvi, P; Della Manna, D; Yang, ES; Bugide, S; Zhang, XC; Gupta, R; Wajapeyee, N				Rawat, Vipin; Malvi, Parmanand; Della Manna, Deborah; Yang, Eddy S.; Bugide, Suresh; Zhang, Xuchen; Gupta, Romi; Wajapeyee, Narendra			PSPH promotes melanoma growth and metastasis by metabolic deregulation-mediated transcriptional activation of NR4A1	ONCOGENE			English	Article								Metabolic deregulation, a hallmark of cancer, fuels cancer cell growth and metastasis. Here, we show that phosphoserine phosphatase (PSPH), an enzyme of the serine metabolism pathway, is upregulated in patient-derived melanoma samples. PSPH knockdown using short hairpin RNAs (shRNAs) blocks melanoma tumor growth and metastasis in both cell culture and mice. To elucidate the mechanism underlying PSPH action, we evaluated PSPH shRNA-expressing melanoma cells using global metabolomics and targeted mRNA expression profiling. Metabolomics analysis showed an increase in 2-hydroxyglutarate (2-HG) levels in PSPH knockdown cells. 2-HG inhibits the TET family of DNA demethylases and the Jumonji family of histone demethylases (KDM and JMJD), which is known to impact gene expression. Consistent with these data, PSPH knockdown in melanoma cells showed reduced DNA 5-hydroxymethylcytosine (5hmC) and increased histone H3K4me3 modifications. 2-HG treatment also inhibited melanoma growth. The nCounter PanCancer Pathways Panel-based mRNA expression profiling revealed attenuation of a number of cancer-promoting pathways upon PSPH knockdown. In particular, PSPH was necessary for nuclear receptor NR4A1 expression. Ectopic NR4A1 expression partly rescued the growth of melanoma cells expressing PSPH shRNA. Collectively, these results link PSPH to the facilitation of melanoma growth and metastasis through suppression of 2-HG and thus activation of pro-oncogenic gene expression.	[Rawat, Vipin; Malvi, Parmanand; Bugide, Suresh; Gupta, Romi; Wajapeyee, Narendra] Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; [Della Manna, Deborah; Yang, Eddy S.] Univ Alabama Birmingham, Dept Radiat Oncol, Birmingham, AL USA; [Zhang, Xuchen] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Yale University	Wajapeyee, N (corresponding author), Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA.	nwajapey@uab.edu	Bugide, Suresh/AAD-6053-2022; rawat, vipin/AAJ-3623-2021; zhang, xu/GYE-3558-2022	rawat, vipin/0000-0003-2070-2299; Wajapeyee, Narendra/0000-0003-3306-349X; Zhang, Xuchen/0000-0002-1484-4672; Gupta, Romi/0000-0001-5108-5962	NCATS NIH HHS [UL1 TR001863] Funding Source: Medline; NCI NIH HHS [R01 CA200919, R21 CA229927, R01 CA196566, R01 CA218008] Funding Source: Medline	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Amelio I, 2014, TRENDS BIOCHEM SCI, V39, P191, DOI 10.1016/j.tibs.2014.02.004; Bachelor MA, 2011, J DERMATOL SCI, V63, P164, DOI 10.1016/j.jdermsci.2011.06.001; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Cao LX, 2019, MOL CANCER THER, V18, P3, DOI 10.1158/1535-7163.MCT-18-0863; Chen JY, 2013, ONCOTARGET, V4, P2502, DOI 10.18632/oncotarget.1540; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43; DiNardo CD, 2018, NEW ENGL J MED, V378, P2386, DOI 10.1056/NEJMoa1716984; Fan J, 2015, ACS CHEM BIOL, V10, P510, DOI 10.1021/cb500683c; Fischer GM, 2018, PIGM CELL MELANOMA R, V31, P11, DOI 10.1111/pcmr.12661; Gao S, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0648-4; Hausinger RP, 2004, CRIT REV BIOCHEM MOL, V39, P21, DOI 10.1080/10409230490440541; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; Jin HO, 2019, ANTICANCER RES, V39, P6723, DOI 10.21873/anticanres.13887; Kakadia S, 2018, ONCOTARGETS THER, V11, P7095, DOI 10.2147/OTT.S182721; Kampen KR, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10508-2; Koo JS, 2015, AM J CLIN PATHOL, V143, P584, DOI 10.1309/AJCPXAYH10WENLTC; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Li SS, 2015, MOL CELL, V60, P408, DOI 10.1016/j.molcel.2015.09.024; Li XX, 2018, MOL CELL, V69, P480, DOI 10.1016/j.molcel.2018.01.001; Liao L, 2019, INT J BIOL SCI, V15, P183, DOI 10.7150/ijbs.29203; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Luke JJ, 2017, NAT REV CLIN ONCOL, V14, P463, DOI 10.1038/nrclinonc.2017.43; Mattaini KR, 2016, J CELL BIOL, V214, P248, DOI 10.1083/jcb.201604085; McCabe A, 2005, JNCI-J NATL CANCER I, V97, P1808, DOI 10.1093/jnci/dji427; Mullarky E, 2011, PIGM CELL MELANOMA R, V24, P1112, DOI 10.1111/j.1755-148X.2011.00919.x; Nowicki TS, 2018, CANCER J, V24, P47, DOI 10.1097/PPO.0000000000000303; Pacold ME, 2016, NAT CHEM BIOL, V12, P452, DOI [10.1038/NCHEMBIO.2070, 10.1038/nchembio.2070]; Park SM, 2019, MOL CELLS, V42, P604, DOI 10.14348/molcells.2019.0160; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Ratnikov BI, 2017, ONCOGENE, V36, P147, DOI 10.1038/onc.2016.198; Sato K, 2017, ANTICANCER RES, V37, P2365, DOI 10.21873/anticanres.11574; Song ZW, 2018, GENE, V642, P43, DOI 10.1016/j.gene.2017.11.014; Su R, 2018, CELL, V172, P90, DOI 10.1016/j.cell.2017.11.031; Sullivan MR, 2019, CELL METAB, V29, P1410, DOI 10.1016/j.cmet.2019.02.015; Tan EH, 2010, ANN ONCOL, V21, P217, DOI 10.1093/annonc/mdp520; Tsao H, 2012, GENE DEV, V26, P1131, DOI 10.1101/gad.191999.112; van Zijl F, 2011, MUTAT RES-REV MUTAT, V728, P23, DOI 10.1016/j.mrrev.2011.05.002; Wang CY, 2020, AM J CANCER RES, V10, P95; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yang M, 2016, NAT REV CANCER, V16, P650, DOI 10.1038/nrc.2016.81; Ye D, 2018, TRENDS CANCER, V4, P151, DOI 10.1016/j.trecan.2017.12.005; Zhan YY, 2012, NAT CHEM BIOL, V8, P897, DOI [10.1038/NCHEMBIO.1069, 10.1038/nchembio.1069]; Zhang BX, 2017, CELL REP, V19, P2289, DOI 10.1016/j.celrep.2017.05.067; Zhao GS, 1996, J BACTERIOL, V178, P232, DOI 10.1128/jb.178.1.232-239.1996	49	5	5	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2021	40	13					2448	2462		10.1038/s41388-021-01683-y	http://dx.doi.org/10.1038/s41388-021-01683-y		MAR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RH1BQ	33674745	Green Accepted			2022-12-17	WOS:000625607100002
J	Cheung, BB; Kleynhans, A; Mittra, R; Kim, PY; Holien, JK; Nagy, Z; Ciampa, OC; Seneviratne, JA; Mayoh, C; Raipuria, M; Gadde, S; Massudi, H; Wong, IPL; Tan, O; Gong, A; Suryano, A; Diakiw, SM; Liu, B; Arndt, GM; Liu, T; Kumar, N; Sangfelt, O; Zhu, SZ; Norris, MD; Haber, M; Carter, DR; Parker, MW; Marshall, GM				Cheung, Belamy B.; Kleynhans, Ane; Mittra, Rituparna; Kim, Patrick Y.; Holien, Jessica K.; Nagy, Zsuzsanna; Ciampa, Olivia C.; Seneviratne, Janith A.; Mayoh, Chelsea; Raipuria, Mukesh; Gadde, Satyanarayana; Massudi, Hassina; Wong, Iris Poh Ling; Tan, Owen; Gong, Andrew; Suryano, Aldwin; Diakiw, Sonya M.; Liu, Bing; Arndt, Greg M.; Liu, Tao; Kumar, Naresh; Sangfelt, Olle; Zhu, Shizhen; Norris, Murray D.; Haber, Michelle; Carter, Daniel R.; Parker, Michael W.; Marshall, Glenn M.			A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma	ONCOGENE			English	Article								Histone deacetylase (HDAC) inhibitors are effective in MYCN-driven cancers, because of a unique need for HDAC recruitment by the MYCN oncogenic signal. However, HDAC inhibitors are much more effective in combination with other anti-cancer agents. To identify novel compounds which act synergistically with HDAC inhibitor, such as suberanoyl hydroxamic acid (SAHA), we performed a cell-based, high-throughput drug screen of 10,560 small molecule compounds from a drug-like diversity library and identified a small molecule compound (SE486-11) which synergistically enhanced the cytotoxic effects of SAHA. Effects of drug combinations on cell viability, proliferation, apoptosis and colony forming were assessed in a panel of neuroblastoma cell lines. Treatment with SAHA and SE486-11 increased MYCN ubiquitination and degradation, and markedly inhibited tumorigenesis in neuroblastoma xenografts, and, MYCN transgenic zebrafish and mice. The combination reduced ubiquitin-specific protease 5 (USP5) levels and increased unanchored polyubiquitin chains. Overexpression of USP5 rescued neuroblastoma cells from the cytopathic effects of the combination and reduced unanchored polyubiquitin, suggesting USP5 is a therapeutic target of the combination. SAHA and SE486-11 directly bound to USP5 and the drug combination exhibited a 100-fold higher binding to USP5 than individual drugs alone in microscale thermophoresis assays. MYCN bound to the USP5 promoter and induced USP5 gene expression suggesting that USP5 and MYCN expression created a forward positive feedback loop in neuroblastoma cells. Thus, USP5 acts as an oncogenic cofactor with MYCN in neuroblastoma and the novel combination of HDAC inhibitor with SE486-11 represents a novel therapeutic approach for the treatment of MYCN-driven neuroblastoma.	[Cheung, Belamy B.; Kleynhans, Ane; Mittra, Rituparna; Kim, Patrick Y.; Nagy, Zsuzsanna; Ciampa, Olivia C.; Seneviratne, Janith A.; Mayoh, Chelsea; Raipuria, Mukesh; Gadde, Satyanarayana; Massudi, Hassina; Wong, Iris Poh Ling; Tan, Owen; Gong, Andrew; Suryano, Aldwin; Diakiw, Sonya M.; Liu, Bing; Arndt, Greg M.; Liu, Tao; Norris, Murray D.; Haber, Michelle; Carter, Daniel R.; Marshall, Glenn M.] UNSW Sydney, Childrens Canc Inst, Lowy Canc Res Ctr, Sydney, NSW, Australia; [Cheung, Belamy B.; Nagy, Zsuzsanna; Mayoh, Chelsea; Raipuria, Mukesh; Massudi, Hassina] UNSW Sydney, Sch Womens & Childrens Hlth, Sydney, NSW, Australia; [Holien, Jessica K.] St Vincents Inst Med Res, ACRF Rat Drug Discovery Ctr, Fitzroy, Vic, Australia; [Holien, Jessica K.; Parker, Michael W.] RMIT Univ, Sch Sci, Coll Sci Engn & Hlth, Melbourne, Vic, Australia; [Gadde, Satyanarayana; Kumar, Naresh] UNSW Sydney, Sch Chem, Sydney, NSW, Australia; [Sangfelt, Olle] Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden; [Zhu, Shizhen] Mayo Clin, Dept Biochem & Mol Biol, Canc Ctr, Rochester, MN USA; [Zhu, Shizhen] Mayo Clin, Dept Biochem & Mol Biol, Ctr Individualized Med, Rochester, MN USA; [Norris, Murray D.] Univ New South Wales, Ctr Childhood Canc Res Sydney, Sydney, NSW, Australia; [Carter, Daniel R.] Univ Technol Sydney, Sch Biomed Engn, Sydney, NSW, Australia; [Parker, Michael W.] Univ Melbourne, Bio21 Mol Sci & Biotechnol Inst, Parkville, Vic, Australia; [Marshall, Glenn M.] Sydney Childrens Hosp, Kids Canc Ctr, Randwick, NSW, Australia	Children's Cancer Institute; University of New South Wales Sydney; University of New South Wales Sydney; St. Vincent's Institute of Medical Research; Royal Melbourne Institute of Technology (RMIT); University of New South Wales Sydney; Karolinska Institutet; Mayo Clinic; Mayo Clinic; University of New South Wales Sydney; University of Technology Sydney; University of Melbourne	Cheung, BB; Marshall, GM (corresponding author), UNSW Sydney, Childrens Canc Inst, Lowy Canc Res Ctr, Sydney, NSW, Australia.; Cheung, BB (corresponding author), UNSW Sydney, Sch Womens & Childrens Hlth, Sydney, NSW, Australia.; Marshall, GM (corresponding author), Sydney Childrens Hosp, Kids Canc Ctr, Randwick, NSW, Australia.	bcheung@ccia.unsw.edu.au; g.marshall@unsw.edu.au	Parker, Michael W/F-9069-2013; Holien, Jess/V-7005-2019; Mayoh, Chelsea/AAE-7349-2021	Parker, Michael W/0000-0002-3101-1138; Holien, Jess/0000-0002-8735-2871; Mayoh, Chelsea/0000-0002-6398-3046; Cheung, Belamy/0000-0001-8784-860X; Liu, Tao/0000-0001-6244-7316; Haber, Michelle/0000-0003-2036-8817; Ciampa, Olivia/0000-0002-4073-6798; Carter, Daniel/0000-0002-8464-238X; Tan, Owen/0000-0002-0303-7138; Gadde, Satyanarayana/0000-0003-2910-6899; Seneviratne, Janith Ananda/0000-0003-0413-5829	National Health and Medical Research Council (NHMRC) Australia [APP1016699]; Cancer Institute NSW [10/TPG/1-13]; Cancer Council NSW [PG-11-06]; Australia Postgraduate Research Award, UNSW Sydney, Australia; Steven Walter Children's Cancer Foundation; NHMRC [APP1125171]; Neuroblastoma Australia [APP571073]; Cure Cancer Australia Foundation; Leukemia Foundation; Swedish Childhood Cancer Foundation; Swedish Cancer Society; Swedish Research Council; NHMRC Independent Research Institutes Infrastructure Support Scheme; Victorian State Government; ACRF Drug Discovery Centre; Children's Cancer Institute; Lowy Cancer Research Centre; UNSW Sydney; NSW, Australia [2052]	National Health and Medical Research Council (NHMRC) Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute NSW; Cancer Council NSW(Cancer Council New South Wales); Australia Postgraduate Research Award, UNSW Sydney, Australia; Steven Walter Children's Cancer Foundation; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Neuroblastoma Australia; Cure Cancer Australia Foundation; Leukemia Foundation; Swedish Childhood Cancer Foundation(European Commission); Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); NHMRC Independent Research Institutes Infrastructure Support Scheme(National Health and Medical Research Council (NHMRC) of Australia); Victorian State Government; ACRF Drug Discovery Centre; Children's Cancer Institute; Lowy Cancer Research Centre; UNSW Sydney; NSW, Australia	This work was supported by Program Grants (GMM, MDN, MH) from the National Health and Medical Research Council (NHMRC) Australia (APP1016699), Cancer Institute NSW (10/TPG/1-13), Cancer Council NSW (PG-11-06), and an Australia Postgraduate Research Award, UNSW Sydney, Australia (AK, SG). This work was also supported by the Steven Walter Children's Cancer Foundation, NHMRC (Project grant APP1125171 and Neuroblastoma Australia (GMM, BBC); (Project grant APP571073; Senior Principal Research Fellowship to MWP), Cure Cancer Australia Foundation, Leukemia Foundation and 5-point Foundation (Postdoctoral Fellowships to JKH). The Swedish Childhood Cancer Foundation, the Swedish Cancer Society, Swedish Research Council (OS, ASR). Infrastructure support from the NHMRC Independent Research Institutes Infrastructure Support Scheme and the Victorian State Government Operational Infrastructure Support Program to St Vincent's Institute are gratefully acknowledged, as is the support from the ACRF Drug Discovery Centre, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, NSW 2052, Australia. We would also like to thank Dr Shuai Li and Dr Cassie Flachs who helped on the zebrafish experiment of the project. The HA-tagged MYCN vector was kindly provided by Professor Wei Gu (Columbia University, New York).	Avvakumov GV, 2012, BIOCHEMISTRY-US, V51, P1188, DOI 10.1021/bi200854q; Carabet LA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010120; Carter DR, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab1803; Chen JB, 2013, J MED CHEM, V56, P3645, DOI 10.1021/jm400179b; Chen YH, 2016, EMBO J, V35, P668, DOI 10.15252/embj.201592810; Cheung BB, 2015, MOL ONCOL, V9, P1484, DOI 10.1016/j.molonc.2015.04.005; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dang M, 2016, DIS MODEL MECH, V9, P811, DOI 10.1242/dmm.024166; Davis Mindy I, 2015, Drug Target Rev, V2, P60; Dayal S, 2009, J BIOL CHEM, V284, P5030, DOI 10.1074/jbc.M805871200; Duvic M, 2007, BIOL-TARGETS THER, V1, P377; Fan YH, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.400; Fouladi M, 2010, J CLIN ONCOL, V28, P3623, DOI 10.1200/JCO.2009.25.9119; Gryder BE, 2012, FUTURE MED CHEM, V4, P505, DOI [10.4155/FMC.12.3, 10.4155/fmc.12.3]; Guo YF., 2020, SCI TRANSL MED, V12, P1; Gustafson WC, 2010, ONCOGENE, V29, P1249, DOI 10.1038/onc.2009.512; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Horiuchi D, 2012, J EXP MED, V209, P679, DOI 10.1084/jem.20111512; Khan O, 2012, IMMUNOL CELL BIOL, V90, P85, DOI 10.1038/icb.2011.100; Koach J, 2019, CANCER RES, V79, P5652, DOI 10.1158/0008-5472.CAN-19-1112; Kocak H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.84; Lindsey DF, 1998, J BIOL CHEM, V273, P29178, DOI 10.1074/jbc.273.44.29178; Ling D, 2012, EUR J CANCER, V48, P3278, DOI 10.1016/j.ejca.2012.02.067; Liu Y, 2017, ONCOTARGET, V8, P50655, DOI 10.18632/oncotarget.16901; Marshall GM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002135; Meyers RM, 2017, NAT GENET, V49, P1779, DOI 10.1038/ng.3984; Mueller S, 2011, CANCER LETT, V306, P223, DOI 10.1016/j.canlet.2011.03.010; Ortega-Atienza S, 2016, AM J PATHOL, V186, P2857, DOI 10.1016/j.ajpath.2016.06.022; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Reddy P, 2004, P NATL ACAD SCI USA, V101, P3921, DOI 10.1073/pnas.0400380101; Reyes-Turcu FE, 2006, CELL, V124, P1197, DOI 10.1016/j.cell.2006.02.038; Rouge L, 2016, STRUCTURE, V24, P1335, DOI 10.1016/j.str.2016.05.020; Ruiz-Perez MV, 2017, GENES-BASEL, V8, DOI 10.3390/genes8040113; Seto E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018713; Tavana O, 2016, NAT MED, V22, P1180, DOI 10.1038/nm.4180; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Whitfield JR, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00010; Williams RD, 2010, CLIN CANCER RES, V16, P2036, DOI 10.1158/1078-0432.CCR-09-2890; Zhang XL, 2017, CELL REP, V18, P2932, DOI 10.1016/j.celrep.2017.02.065; Zhang YJ, 2015, EPIGENOMICS-UK, V7, P5, DOI [10.2217/EPI.14.62, 10.2217/epi.14.62]	42	5	5	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2021	40	13					2367	2381		10.1038/s41388-021-01712-w	http://dx.doi.org/10.1038/s41388-021-01712-w		MAR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RH1BQ	33658627	Green Published, hybrid			2022-12-17	WOS:000625039900003
J	Fan, QH; Gong, TT; Zheng, CN; Ng, JMY; Chen, JQ; Myers, C; Hensley, H; Curran, T; Yang, ZJ				Fan, Qianhai; Gong, Tingting; Zheng, Chaonan; Ng, Jessica M. Y.; Chen, Jianquan; Myers, Cynthia; Hensley, Harvey; Curran, Tom; Yang, Zeng-jie			Statins repress hedgehog signaling in medulloblastoma with no bone toxicities	ONCOGENE			English	Article							SERUM CONCENTRATIONS; GROWTH-PLATE; CHOLESTEROL; REDUCTASE; PATHWAY; INHIBITORS; CHILDREN; CELLS; DIFFERENTIATION; CHONDROCYTES	The Hedgehog (Hh) pathway plays an indispensable role in bone development and genetic activation of the pathway results in medulloblastoma (MB), the most common malignant brain tumor in children. Inhibitors of Hh pathway (such as vismodegib and sonedigib), which are used to treat MB, cause irreversible defects in bone growth in young children. Cholesterol is required for the activation of the Hh pathway, and statins, inhibitors of cholesterol biosynthesis, suppress MB growth by repressing Hh signaling in tumor cells. Here, we investigate the role of cholesterol biosynthesis in the proliferation and Hh signaling in chondrocytes, and examine the bone development in mice after statin treatment. Statins significantly inhibited MB growth in young mice, but caused no defects in bone development. Conditional deletion of NADP steroid dehydrogenase-like (NSDHL), an enzyme necessary for cholesterol biosynthesis, suppressed cholesterol synthesis in chondrocytes, and disrupted the growth plate in mouse femur and tibia, indicating the important function of intracellular cholesterol in bone development. Hh pathway activation and the proliferation of chondrocytes were inhibited by statin treatment in vitro; however, statins did not impair bone growth in vivo due to insufficient penetration into the bone. Our studies reveal a critical role of cholesterol in bone development, and support the utilization of statins for treatment of MB as well as other Hh pathway-associated malignancies.	[Fan, Qianhai; Zheng, Chaonan] Soochow Univ, Coll Pharmaceut Sci, Pediat Canc Ctr, Suzhou 215007, Jiangsu, Peoples R China; [Fan, Qianhai; Yang, Zeng-jie] Temple Univ Hlth Syst, Fox Chase Canc Ctr, Canc Biol Program, Philadelphia, PA 19140 USA; [Gong, Tingting; Chen, Jianquan] Soochow Univ, Med Coll, Orthoped Inst, Suzhou 215007, Jiangsu, Peoples R China; [Ng, Jessica M. Y.; Curran, Tom] Childrens Mercy Kansas City, Childrens Res Inst, Kansas City, MO USA; [Myers, Cynthia] Temple Univ Hlth Syst, Fox Chase Canc Ctr, Organ Synth Facil, Philadelphia, PA USA; [Hensley, Harvey] Temple Univ Hlth Syst, Fox Chase Canc Ctr, Small Anim Imaging Facil, Philadelphia, PA USA	Soochow University - China; Fox Chase Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Soochow University - China; Children's Mercy Hospital; Fox Chase Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Fox Chase Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Yang, ZJ (corresponding author), Temple Univ Hlth Syst, Fox Chase Canc Ctr, Canc Biol Program, Philadelphia, PA 19140 USA.	zengjie.yang@fccc.edu	Curran, Thomas/AAE-7631-2019	Curran, Thomas/0000-0003-1444-7551	American Cancer Society [RSG1605301NEC]; American Brain Tumor Association [DG1900025]; PA CURE Health Research Fund [CURE 4100068716]; National Natural Science Foundation of China [81803616]; Natural Science Foundation of Jiangsu Higher Education Institutions [18KJB350010]	American Cancer Society(American Cancer Society); American Brain Tumor Association; PA CURE Health Research Fund; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Higher Education Institutions	We would like to thank Drs. Andrey Efimov, Kathy Cai, Dusica Cvetkovic, and James Oesterling for technical assistance; and Drs. Maike Sander, Joan Font-Burgada, and Sergei Grivenniko for providing transgenic mice. This research was supported by American Cancer Society (RSG1605301NEC to Z.-j.Y.), American Brain Tumor Association (DG1900025 to Z.-j.Y.), PA CURE Health Research Fund (CURE 4100068716 to Z.-j.Y.), National Natural Science Foundation of China (81803616 to C.Z.), and the Natural Science Foundation of Jiangsu Higher Education Institutions (18KJB350010 to C.Z.).	Atwood SX, 2015, CANCER CELL, V27, P342, DOI 10.1016/j.ccell.2015.02.002; Bosnakovski D, 2006, BIOTECHNOL BIOENG, V93, P1152, DOI 10.1002/bit.20828; Byrne EFX, 2016, NATURE, V535, P517, DOI 10.1038/nature18934; Cavalli FMG, 2017, CANCER CELL, V31, P737, DOI 10.1016/j.ccell.2017.05.005; Chan KA, 2000, LANCET, V355, P2185, DOI 10.1016/S0140-6736(00)02400-4; Cunningham D, 2015, HUM MOL GENET, V24, P2808, DOI 10.1093/hmg/ddv042; Curran T, 2018, OPEN BIOL, V8, DOI 10.1098/rsob.180098; DUGGAN DE, 1990, DRUG METAB REV, V22, P333, DOI 10.3109/03602539009041088; Gajjar A, 2013, CLIN CANCER RES, V19, P6305, DOI 10.1158/1078-0432.CCR-13-1425; Gofflot F, 2003, HUM MOL GENET, V12, P1187, DOI 10.1093/hmg/ddg129; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Gordon RE, 2018, CLIN CANCER RES, V24, P1375, DOI 10.1158/1078-0432.CCR-17-2923; Gosset M, 2008, NAT PROTOC, V3, P1253, DOI 10.1038/nprot.2008.95; Haraguchi R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235840; He LY, 2018, METHODS MOL BIOL, V1711, P351, DOI 10.1007/978-1-4939-7493-1_17; Hedger G, 2019, STRUCTURE, V27, P549, DOI 10.1016/j.str.2018.11.003; Hovestadt V, 2020, NAT REV CANCER, V20, P42, DOI 10.1038/s41568-019-0223-8; Huang PX, 2016, CELL, V166, P1176, DOI 10.1016/j.cell.2016.08.003; Ianevski A, 2020, NUCLEIC ACIDS RES, V48, pW488, DOI 10.1093/nar/gkaa216; Ianevski A, 2020, BIOINFORMATICS, V36, P2645, DOI 10.1093/bioinformatics/btaa102; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Kalliokoski A, 2009, BRIT J PHARMACOL, V158, P693, DOI 10.1111/j.1476-5381.2009.00430.x; Kan C, 2018, BONE, V109, P71, DOI 10.1016/j.bone.2017.06.014; Kantola T, 1998, CLIN PHARMACOL THER, V63, P397, DOI 10.1016/S0009-9236(98)90034-0; Kellick KA, 2014, J CLIN LIPIDOL, V8, pS30, DOI 10.1016/j.jacl.2014.02.010; Kieran MW, 2017, NEURO-ONCOLOGY, V19, P1542, DOI 10.1093/neuonc/nox109; Kimura H, 2008, CANCER CELL, V13, P249, DOI 10.1016/j.ccr.2008.01.027; Konig A, 2000, AM J MED GENET, V90, P339; Kopp JL, 2011, DEVELOPMENT, V138, P653, DOI 10.1242/dev.056499; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; Kusters DM, 2014, JAMA-J AM MED ASSOC, V312, P1055, DOI 10.1001/jama.2014.8892; LAUGHLIN RC, 1962, JAMA-J AM MED ASSOC, V181, P339, DOI 10.1001/jama.1962.03050300059020a; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; Lee Y, 2007, ONCOGENE, V26, P6442, DOI 10.1038/sj.onc.1210467; Lewis PM, 2001, CELL, V105, P599, DOI 10.1016/S0092-8674(01)00369-5; Lilja JJ, 1998, CLIN PHARMACOL THER, V64, P477, DOI 10.1016/S0009-9236(98)90130-8; Liu XY, 1999, NAT GENET, V22, P182, DOI 10.1038/9700; Long FX, 2001, DEVELOPMENT, V128, P5099; Luchetti G, 2016, ELIFE, V5, DOI 10.7554/eLife.20304; Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467; Maeda T, 2003, ENDOCRINOLOGY, V144, P681, DOI 10.1210/en.2002-220682; Maeda Y, 2007, P NATL ACAD SCI USA, V104, P6382, DOI 10.1073/pnas.0608449104; Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946; Myers BR, 2017, P NATL ACAD SCI USA, V114, pE11141, DOI 10.1073/pnas.1717891115; Ng JMY, 2011, NAT REV CANCER, V11, P493, DOI 10.1038/nrc3079; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Ohba S, 2016, J DEV BIOL, V4, DOI 10.3390/jdb4020020; Robinson GW, 2017, ONCOTARGET, V8, P69295, DOI 10.18632/oncotarget.20619; Rocha VZ, 2018, J CLIN LIPIDOL, V12, P12, DOI 10.1016/j.jacl.2017.11.007; Roth M, 2012, BRIT J PHARMACOL, V165, P1260, DOI 10.1111/j.1476-5381.2011.01724.x; ROUX C, 1980, J NUTR, V110, P2310, DOI 10.1093/jn/110.11.2310; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Schachter M, 2005, FUND CLIN PHARMACOL, V19, P117, DOI 10.1111/j.1472-8206.2004.00299.x; Schwalbe EC, 2017, LANCET ONCOL, V18, P958, DOI 10.1016/S1470-2045(17)30243-7; Sharpe HJ, 2015, CANCER CELL, V27, P327, DOI 10.1016/j.ccell.2015.02.001; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; Suzuki A, 2020, BONE RES, V8, DOI 10.1038/s41413-019-0078-3; Thompson MC, 2006, J CLIN ONCOL, V24, P1924, DOI 10.1200/JCO.2005.04.4974; Tsushima H, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.162396; Wang PS, 2000, JAMA-J AM MED ASSOC, V283, P3211, DOI 10.1001/jama.283.24.3211; Wu SF, 2004, J BIOL CHEM, V279, P4642, DOI 10.1074/jbc.M305518200; Xu RS, 2018, BONE RES, V6, DOI 10.1038/s41413-018-0034-7; Yadav B, 2015, COMPUT STRUCT BIOTEC, V13, P504, DOI 10.1016/j.csbj.2015.09.001; Yang J, 2015, INT J ORAL SCI, V7, P73, DOI 10.1038/ijos.2015.14; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003	65	5	5	3	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2258	2272		10.1038/s41388-021-01701-z	http://dx.doi.org/10.1038/s41388-021-01701-z		MAR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33649536				2022-12-17	WOS:000623739900007
J	Milewski, D; Shukla, S; Gryder, BE; Pradhan, A; Donovan, J; Sudha, P; Vallabh, S; Pyros, A; Xu, Y; Barski, A; Szabo, S; Turpin, B; Pressey, JG; Millay, DP; Khan, J; Kalinichenko, VV; Kalin, TV				Milewski, David; Shukla, Samriddhi; Gryder, Berkley E.; Pradhan, Arun; Donovan, Johnny; Sudha, Parvathi; Vallabh, Sushmitha; Pyros, Athena; Xu, Yan; Barski, Artem; Szabo, Sara; Turpin, Brian; Pressey, Joseph G.; Millay, Douglas P.; Khan, Javed; Kalinichenko, Vladimir V.; Kalin, Tanya, V			FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma	ONCOGENE			English	Article							TRANSCRIPTION FACTOR FOXF1; TRANS-RETINOIC ACID; ALVEOLAR RHABDOMYOSARCOMA; RESPONSE FACTOR; PHASE-2 TRIAL; GROWTH-FACTOR; FUSION GENE; EXPRESSION; IDENTIFICATION; DIFFERENTIATION	The PAX3-FOXO1 fusion protein is the key oncogenic driver in fusion positive rhabdomyosarcoma (FP-RMS), an aggressive soft tissue malignancy with a particularly poor prognosis. Identifying key downstream targets of PAX3-FOXO1 will provide new therapeutic opportunities for treatment of FP-RMS. Herein, we demonstrate that Forkhead Box F1 (FOXF1) transcription factor is uniquely expressed in FP-RMS and is required for FP-RMS tumorigenesis. The PAX3-FOXO1 directly binds to FOXF1 enhancers and induces FOXF1 gene expression. CRISPR/Cas9 mediated inactivation of either FOXF1 coding sequence or FOXF1 enhancers suppresses FP-RMS tumorigenesis even in the presence of PAX3-FOXO1 oncogene. Knockdown or genetic knockout of FOXF1 induces myogenic differentiation in PAX3-FOXO1-positive FP-RMS. Over-expression of FOXF1 decreases myogenic differentiation in primary human myoblasts. In FP-RMS tumor cells, FOXF1 protein binds chromatin near enhancers associated with FP-RMS gene signature. FOXF1 cooperates with PAX3-FOXO1 and E-box transcription factors MYOD1 and MYOG to regulate FP-RMS-specific gene expression. Altogether, FOXF1 functions downstream of PAX3-FOXO1 to promote FP-RMS tumorigenesis.	[Milewski, David; Shukla, Samriddhi; Pradhan, Arun; Donovan, Johnny; Sudha, Parvathi; Pyros, Athena; Xu, Yan; Kalinichenko, Vladimir V.; Kalin, Tanya, V] Cincinnati Childrens Hosp Med Ctr, Div Pulm Biol, Perinatal Inst, Cincinnati, OH 45229 USA; [Milewski, David; Gryder, Berkley E.; Khan, Javed] NCI, Genet Branch, NIH, Bethesda, MD 20892 USA; [Vallabh, Sushmitha; Barski, Artem] Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH USA; [Xu, Yan; Barski, Artem; Szabo, Sara; Turpin, Brian; Pressey, Joseph G.; Millay, Douglas P.; Kalinichenko, Vladimir V.; Kalin, Tanya, V] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45221 USA; [Barski, Artem] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH USA; [Szabo, Sara] Cincinnati Childrens Hosp Med Ctr, Dept Pathol, Cincinnati, OH USA; [Turpin, Brian; Pressey, Joseph G.] Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Cincinnati, OH USA; [Millay, Douglas P.] Cincinnati Childrens Hosp Med Ctr, Div Mol Cardiovasc Biol, Cincinnati, OH USA; [Kalinichenko, Vladimir V.] Cincinnati Childrens Hosp Med Ctr, Ctr Lung Regenerat Med, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center	Kalin, TV (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Pulm Biol, Perinatal Inst, Cincinnati, OH 45229 USA.; Kalin, TV (corresponding author), Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45221 USA.	tatiana.kalin@cchmc.org	Milewski, David/GPF-5870-2022; Shukla, Samriddhi/AAF-1876-2021	Milewski, David/0000-0002-9778-8548; Shukla, Samriddhi/0000-0002-3771-4184; Pressey, Joseph/0000-0003-1816-3281; Barski, Artem/0000-0002-1861-5316; Szabo, Sara/0000-0002-6212-7264	NIH [R01 CA142724, R01 HL132849, R01 HL141174]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Tien Le for technical assistance. This work was supported by the NIH grants R01 CA142724 (TVK), R01 HL132849 (TVK), R01 HL141174 (VVK).	Alaggio R, 2016, AM J SURG PATHOL, V40, P224, DOI 10.1097/PAS.0000000000000538; Black M, 2020, MOL BIOL CELL, V31, P1411, DOI 10.1091/mbc.E19-07-0413; Black M, 2018, CELL REP, V23, P442, DOI 10.1016/j.celrep.2018.03.067; Bolte C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11175-3; Bolte C, 2015, J BIOL CHEM, V290, P7563, DOI 10.1074/jbc.M114.609487; Brewster AM, 2007, J CLIN ONCOL, V25, P1974, DOI 10.1200/JCO.2006.05.9873; Cai YQ, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad1899; Cai YQ, 2013, J BIOL CHEM, V288, P22527, DOI 10.1074/jbc.M113.455089; Cairns J, 2018, EMBO REP, V19, DOI 10.15252/embr.201744767; Cao LA, 2010, CANCER RES, V70, P6497, DOI 10.1158/0008-5472.CAN-10-0582; Chen L, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005075; Chen X, 2013, CANCER CELL, V24, P710, DOI 10.1016/j.ccr.2013.11.002; Cheng XH, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004656; DAMORE ESG, 1994, MODERN PATHOL, V7, P69; Davicioni E, 2006, CANCER RES, V66, P6936, DOI 10.1158/0008-5472.CAN-05-4578; Davicioni E, 2009, AM J PATHOL, V174, P550, DOI 10.2353/ajpath.2009.080631; Dias P, 2000, AM J PATHOL, V156, P399, DOI 10.1016/S0002-9440(10)64743-8; Ebauer M, 2007, ONCOGENE, V26, P7267, DOI 10.1038/sj.onc.1210525; Feng YF, 2013, EXP CELL RES, V319, P1124, DOI 10.1016/j.yexcr.2013.02.009; Goda C, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008692; Gryder BE, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101103; Gryder BE, 2020, NAT PROTOC, V15, P1209, DOI 10.1038/s41596-019-0285-9; Gryder BE, 2019, NAT GENET, V51, P1714, DOI 10.1038/s41588-019-0534-4; Gryder BE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11046-7; Gryder BE, 2017, CANCER DISCOV, V7, P884, DOI 10.1158/2159-8290.CD-16-1297; Hakozaki M, 2013, HUM CELL, V26, P149, DOI 10.1007/s13577-013-0067-6; Hinson ARP, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00183; Hoggatt AM, 2013, J BIOL CHEM, V288, P28477, DOI 10.1074/jbc.M113.478974; Iland HJ, 2012, BLOOD, V120, P1570, DOI 10.1182/blood-2012-02-410746; Jothi M, 2012, CELL CYCLE, V11, P895, DOI 10.4161/cc.11.5.19346; Kalin TV, 2008, AM J RESP CELL MOL, V39, P390, DOI 10.1165/rcmb.2008-0044OC; Kalinichenko VV, 2002, J BIOL CHEM, V277, P12369, DOI 10.1074/jbc.M112162200; Kartashov AV, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0720-3; Kikuchi K, 2008, BIOCHEM BIOPH RES CO, V365, P568, DOI 10.1016/j.bbrc.2007.11.017; Lae M, 2007, J PATHOL, V212, P143, DOI 10.1002/path.2170; Liu QC, 2012, J MOL CELL BIOL, V4, P386, DOI 10.1093/jmcb/mjs045; Lo PK, 2010, CANCER RES, V70, P6047, DOI 10.1158/0008-5472.CAN-10-1576; Machanick P, 2011, BIOINFORMATICS, V27, P1696, DOI 10.1093/bioinformatics/btr189; Mahlapuu M, 2001, DEVELOPMENT, V128, P155; Mehner C, 2014, MOL CANCER RES, V12, P1430, DOI 10.1158/1541-7786.MCR-13-0557-T; Mercado GE, 2008, GENE CHROMOSOME CANC, V47, P510, DOI 10.1002/gcc.20554; Milewski D, 2017, ONCOGENE, V36, P850, DOI 10.1038/onc.2016.254; Milewski D, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007097; Nilsson G, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2196-2; Ognjanovic S, 2009, CANCER-AM CANCER SOC, V115, P4218, DOI 10.1002/cncr.24465; Otabe O, 2017, ONCOL REP, V37, P98, DOI 10.3892/or.2016.5213; Pappo AS, 2014, CANCER-AM CANCER SOC, V120, P2448, DOI 10.1002/cncr.28728; Pradhan A, 2019, AM J RESP CRIT CARE, V200, P1045, DOI 10.1164/rccm.201810-1897OC; Rekhi B, 2018, ANN DIAGN PATHOL, V36, P50, DOI 10.1016/j.anndiagpath.2018.07.002; Ren XM, 2019, AM J RESP CRIT CARE, V200, P1164, DOI 10.1164/rccm.201812-2312OC; Ren XM, 2014, CIRC RES, V115, P709, DOI 10.1161/CIRCRESAHA.115.304382; Ren XM, 2010, MOL CELL BIOL, V30, P5381, DOI 10.1128/MCB.00876-10; Robinson JT, 2018, CELL SYST, V6, P256, DOI 10.1016/j.cels.2018.01.001; Rudzinski ER, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26645; Schoffski P, 2013, EUR J CANCER, V49, P3219, DOI 10.1016/j.ejca.2013.06.010; Schoffski P, 2018, EUR J CANCER, V94, P156, DOI 10.1016/j.ejca.2018.02.011; Shao Z, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-3-r16; Shern JF, 2014, CANCER DISCOV, V4, P216, DOI 10.1158/2159-8290.CD-13-0639; Skrzypek K, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0693-8; Smith LM, 2002, MED PEDIATR ONCOL, V38, P398, DOI 10.1002/mpo.10060; Sorensen PHB, 2002, J CLIN ONCOL, V20, P2672, DOI 10.1200/JCO.2002.03.137; Stewart E, 2018, CANCER CELL, V34, P411, DOI 10.1016/j.ccell.2018.07.012; STRATTON MR, 1989, CANCER RES, V49, P6324; Sun LF, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aai8583; Sun WY, 2015, MODERN PATHOL, V28, P1214, DOI 10.1038/modpathol.2015.82; Szafranski P, 2014, AM J MED GENET A, V164, P2013, DOI 10.1002/ajmg.a.36606; Taulli R, 2006, CANCER RES, V66, P4742, DOI 10.1158/0008-5472.CAN-05-4292; Taylor AC, 2000, MED PEDIATR ONCOL, V35, P96, DOI 10.1002/1096-911X(200008)35:2<96::AID-MPO2>3.0.CO;2-Z; Taylor JG, 2009, J CLIN INVEST, V119, P3395, DOI 10.1172/JCI39703; Tenente IM, 2017, ELIFE, V6, DOI 10.7554/eLife.19214; Thakore PI, 2015, NAT METHODS, V12, P1143, DOI 10.1038/nmeth.3630; Ustiyan V, 2018, DEV BIOL, V443, P50, DOI 10.1016/j.ydbio.2018.08.011; Ustiyan V, 2012, DEV BIOL, V370, P198, DOI 10.1016/j.ydbio.2012.07.028; Vallabh S, 2018, METHODS MOL BIOL, V1783, P343, DOI 10.1007/978-1-4939-7834-2_17; Wachtel M, 2004, CANCER RES, V64, P5539, DOI 10.1158/0008-5472.CAN-04-0844; Wang SY, 2018, NEOPLASIA, V20, P996, DOI 10.1016/j.neo.2018.08.004; Williamson D, 2005, J CLIN ONCOL, V23, P880, DOI 10.1200/JCO.2005.11.078; Williamson D, 2010, J CLIN ONCOL, V28, P2151, DOI 10.1200/JCO.2009.26.3814; Zhang Y, 2013, J HEPATOL, V59, P1255, DOI 10.1016/j.jhep.2013.07.009; Zhao ZH, 2015, INT J CLIN EXP PATHO, V8, P13814	80	5	6	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2182	2199		10.1038/s41388-021-01694-9	http://dx.doi.org/10.1038/s41388-021-01694-9		FEB 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33627785	Green Accepted			2022-12-17	WOS:000621289100004
J	Schafer, A; Haenig, B; Erupathil, J; Strickner, P; Sabato, D; Welford, RWD; Klaeyle, L; Simon, E; Krepler, C; Brafford, P; Xiao, M; Herlyn, M; Gstaiger, M; Lehembre, F; Renz, I				Schaefer, Alexander; Haenig, Benedicte; Erupathil, Julie; Strickner, Panja; Sabato, Daniela; Welford, Richard W. D.; Klaeyle, Lheanna; Simon, Elise; Krepler, Clemens; Brafford, Patricia; Xiao, Min; Herlyn, Meenhard; Gstaiger, Matthias; Lehembre, Francois; Renz, Imke			Inhibition of endothelin-B receptor signaling synergizes with MAPK pathway inhibitors in BRAF mutated melanoma	ONCOGENE			English	Article							METASTATIC MELANOMA; CONFERS RESISTANCE; CELLS; EXPRESSION; APOPTOSIS; ANTAGONIST; SURVIVAL; BEHAVIOR; THERAPY; GROWTH	The clinical benefit of MAPK pathway inhibition in melanoma patients carrying BRAF mutations is temporal. After the initial response to treatment, the majority of tumors will develop resistance and patients will relapse. Here we demonstrate that the endothelin-endothelin receptor B (ETBR) signaling pathway confers resistance to MAPK pathway inhibitors in BRAF mutated melanoma. MAPK blockade, in addition to being anti-proliferative, induces a phenotypic change which is characterized by increased expression of melanocyte-specific genes including ETBR. In the presence of MAPK inhibitors, activation of ETBR by endothelin enables the sustained proliferation of melanoma cells. In mouse models of melanoma, including patient-derived xenograft models, concurrent inhibition of the MAPK pathway and ETBR signaling resulted in a more effective anti-tumor response compared to MAPK pathway inhibition alone. The combination treatment significantly reduced tumor growth and prolonged survival compared to therapies with MAPK pathway inhibitors alone. The phosphoproteomic analysis revealed that ETBR signaling did not induce resistance towards MAPK pathway inhibitors by restoring MAPK activity, but instead via multiple alternative signaling pathways downstream of the small G proteins GNAq/11. Together these data indicate that a combination of MAPK pathway inhibitors with ETBR antagonists could have a synergistically beneficial effect in melanoma patients with hyperactivated MAPK signaling pathways.	[Schaefer, Alexander; Gstaiger, Matthias] Swiss Fed Inst Technol, Inst Mol Syst Biol, Dept Biol, Otto Stern Weg 3, CH-8093 Zurich, Switzerland; [Haenig, Benedicte; Erupathil, Julie; Strickner, Panja; Sabato, Daniela; Welford, Richard W. D.; Klaeyle, Lheanna; Simon, Elise; Lehembre, Francois; Renz, Imke] Idorsia Pharmaceut Ltd, Drug Discovery Biol, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland; [Krepler, Clemens; Brafford, Patricia; Xiao, Min; Herlyn, Meenhard] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program & Melanoma Res, 3601 Spruce St, Philadelphia, PA 19104 USA; [Schaefer, Alexander] Swiss BioQuant AG, CH-4153 Reinach, Switzerland; [Simon, Elise] Novartis Inst BioMed Res, CH-4002 Basel, Switzerland; [Krepler, Clemens] Merck, N Wales, PA 19454 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; Idorsia Pharmaceuticals Ltd; The Wistar Institute; Novartis	Renz, I (corresponding author), Idorsia Pharmaceut Ltd, Drug Discovery Biol, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland.	imke.renz@idorsia.com			Idorsia Pharmaceuticals Ltd.	Idorsia Pharmaceuticals Ltd.	The study was funded by Idorsia Pharmaceuticals Ltd.	Asundi J, 2014, MOL CANCER THER, V13, P1599, DOI 10.1158/1535-7163.MCT-13-0446; Asundi J, 2011, CLIN CANCER RES, V17, P965, DOI 10.1158/1078-0432.CCR-10-2340; Bagnato A, 2004, CANCER RES, V64, P1436, DOI 10.1158/0008-5472.CAN-03-2344; Barton M, 2008, CAN J PHYSIOL PHARM, V86, P485, DOI 10.1139/Y08-059; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Borrull A, 2016, MABS-AUSTIN, V8, P1371, DOI 10.1080/19420862.2016.1208865; Chiriboga L, 2016, MELANOMA RES, V26, P236, DOI 10.1097/CMR.0000000000000235; Christensen C, 2005, ONCOGENE, V24, P6292, DOI 10.1038/sj.onc.1208758; Demunter A, 2001, VIRCHOWS ARCH, V438, P485, DOI 10.1007/s004280000362; Faiao-Flores F, 2019, CLIN CANCER RES, V25, P5686, DOI 10.1158/1078-0432.CCR-18-3382; Haq R, 2013, P NATL ACAD SCI USA, V110, P4321, DOI 10.1073/pnas.1205575110; Hoek KS, 2008, PIGM CELL MELANOMA R, V21, P665, DOI 10.1111/j.1755-148X.2008.00505.x; Hugo W, 2015, CELL, V162, P1271, DOI 10.1016/j.cell.2015.07.061; Jankov RP, 2006, PEDIATR RES, V60, P245, DOI 10.1203/01.pdr.0000233056.37254.0b; Johannessen CM, 2013, NATURE, V504, P138, DOI 10.1038/nature12688; Johnson DB, 2015, EUR J CANCER, V51, P2792, DOI 10.1016/j.ejca.2015.08.022; Kakadia S, 2018, ONCOTARGETS THER, V11, P7095, DOI 10.2147/OTT.S182721; Kefford R, 2007, INVEST NEW DRUG, V25, P247, DOI 10.1007/s10637-006-9014-7; Kefford RF, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-69; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Lahav R, 2004, CANCER RES, V64, P8945, DOI 10.1158/0008-5472.CAN-04-1510; Lahav R, 1999, P NATL ACAD SCI USA, V96, P11496, DOI 10.1073/pnas.96.20.11496; Lin NX, 2007, J HUAZHONG U SCI-MED, V27, P611, DOI 10.1007/s11596-007-0535-x; Luebker SA, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00268; Maffei R, 2017, ONCOTARGET, V8, P90013, DOI 10.18632/oncotarget.21341; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Nelson JB, 2005, NEOPLASIA, V7, P631, DOI 10.1593/neo.04787; Paulitschke V, 2019, EMBO J, V38, DOI 10.15252/embj.201695874; Rosano L, 2004, J CARDIOVASC PHARM, V44, pS136, DOI 10.1097/01.fjc.0000166247.35992.dd; Rosano L, 2013, NAT REV CANCER, V13, P637, DOI 10.1038/nrc3546; Sandhu S, 2020, INVEST NEW DRUG, V38, P844, DOI 10.1007/s10637-019-00832-1; Sato-Jin K, 2008, FASEB J, V22, P1155, DOI 10.1096/fj.07-9080com; Schafer A, 2019, MOL SYST BIOL, V15, DOI 10.15252/msb.20198828; Schorlemmer A, 2008, TRENDS CARDIOVAS MED, V18, P233, DOI 10.1016/j.tcm.2008.11.005; Shoushtari AN, 2014, MELANOMA RES, V24, P525, DOI 10.1097/CMR.0000000000000121; Smith MP, 2017, EMBO MOL MED, V9, P1011, DOI 10.15252/emmm.201607156; Smith MP, 2016, CANCER CELL, V29, P270, DOI 10.1016/j.ccell.2016.02.003; Spinella F, 2007, CANCER RES, V67, P1725, DOI 10.1158/0008-5472.CAN-06-2606; Tang L, 2008, J CUTAN MED SURG, V12, P64, DOI 10.2310/7750.2008.06164; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Wu-Wong JR, 2002, CLIN SCI, V103, p107S, DOI 10.1042/CS103S107S; Xing F, 2012, ONCOGENE, V31, P446, DOI 10.1038/onc.2011.250; YOHN JJ, 1994, BIOCHEM BIOPH RES CO, V201, P449, DOI 10.1006/bbrc.1994.1722	44	5	5	1	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1659	1673		10.1038/s41388-020-01628-x	http://dx.doi.org/10.1038/s41388-020-01628-x		JAN 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33500549				2022-12-17	WOS:000611934200001
J	Vareslija, D; Ward, E; Purcell, SP; Cosgrove, NS; Cocchiglia, S; O'Halloran, PJ; Charmsaz, S; Bane, FT; Brett, FM; Farrell, M; Cryan, J; Beausang, A; Hudson, L; Turnbul, AK; Dixon, JM; Hill, ADK; Priedigkeit, N; Oesterreich, S; Lee, AV; Sims, AH; Redmond, AM; Carroll, JS; Young, LS				Vareslija, Damir; Ward, Elspeth; Purcell, Siobhan P.; Cosgrove, Nicola S.; Cocchiglia, Sinead; O'Halloran, Philip J.; Charmsaz, Sara; Bane, Fiona T.; Brett, Francesca M.; Farrell, Michael; Cryan, Jane; Beausang, Alan; Hudson, Lance; Turnbul, Arran K.; Dixon, J. Michael; Hill, Arnold D. K.; Priedigkeit, Nolan; Oesterreich, Steffi; Lee, Adrian V.; Sims, Andrew H.; Redmond, Aisling M.; Carroll, Jason S.; Young, Leonie S.			Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotype	ONCOGENE			English	Article							STEROID-RECEPTOR; PROTEIN COMPLEX; ALPHA; COACTIVATORS; RESISTANCE; EXPRESSION; TRANSCRIPTION; MECHANISMS; MUTATIONS; THERAPY	Steroid regulated cancer cells use nuclear receptors and associated regulatory proteins to orchestrate transcriptional networks to drive disease progression. In primary breast cancer, the coactivator AIB1 promotes estrogen receptor (ER) transcriptional activity to enhance cell proliferation. The function of the coactivator in ER+ metastasis however is not established. Here we describe AIB1 as a survival factor, regulator of pro-metastatic transcriptional pathways and a promising actionable target. Genomic alterations and functional expression of AIB1 associated with reduced disease-free survival in patients and enhanced metastatic capacity in novel CDX and PDX ex-vivo models of ER+ metastatic disease. Comparative analysis of the AIB1 interactome with complementary RNAseq characterized AIB1 as a transcriptional repressor. Specifically, we report that AIB1 interacts with MTA2 to form a repressive complex, inhibiting CDH1 (encoding E-cadherin) to promote EMT and drive progression. We further report that pharmacological and genetic inhibition of AIB1 demonstrates significant anti-proliferative activity in patient-derived models establishing AIB1 as a viable strategy to target endocrine resistant metastasis. This work defines a novel role for AIB1 in the regulation of EMT through transcriptional repression in advanced cancer cells with a considerable implication for prognosis and therapeutic interventions.	[Vareslija, Damir; Ward, Elspeth; Purcell, Siobhan P.; Cosgrove, Nicola S.; Cocchiglia, Sinead; Charmsaz, Sara; Bane, Fiona T.; Hudson, Lance; Hill, Arnold D. K.; Young, Leonie S.] Royal Coll Surgeons Ireland, Dept Surg, Endocrine Oncol Res Grp, Dublin, Ireland; [O'Halloran, Philip J.] Beaumont Hosp, Dept Neurosurg, Natl Neurosurg Ctr, Dublin, Ireland; [Brett, Francesca M.; Farrell, Michael; Cryan, Jane; Beausang, Alan] Beaumont Hosp, Dept Neuropathol, Natl Neurosurg Ctr, Dublin, Ireland; [Turnbul, Arran K.; Dixon, J. Michael] Breast Canc Now Res Labs, Edinburgh EH4 2XU, Midlothian, Scotland; [Priedigkeit, Nolan; Oesterreich, Steffi; Lee, Adrian V.] Univ Pittsburgh, Univ Pittsburgh Canc Inst, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA; [Oesterreich, Steffi; Lee, Adrian V.] Univ Pittsburgh, Univ Pittsburgh Canc Inst, Magee Womens Res Inst, Dept Womens Canc Res Ctr, Pittsburgh, PA USA; [Lee, Adrian V.] Univ Pittsburgh, Dept Human Genet, Univ Pittsburgh Canc Inst, Pittsburgh, PA USA; [Sims, Andrew H.] Univ Edinburgh, MRC Inst Genet & Mol Med, Western Gen Hosp, Appl Bioinformat Canc Grp,Canc Res UK Ctr, Edinburgh, Midlothian, Scotland; [Redmond, Aisling M.; Carroll, Jason S.] Univ Cambridge, Canc Res UK Cambridge Inst, Li Ka Shing Ctr, Cambridge CB2 0RE, England	Royal College of Surgeons - Ireland; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Edinburgh; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Vareslija, D; Young, LS (corresponding author), Royal Coll Surgeons Ireland, Dept Surg, Endocrine Oncol Res Grp, Dublin, Ireland.	damirvareslija@rcsi.ie; lyoung@rcsi.ie		Ward, Elspeth/0000-0002-7530-2279; O'Halloran, Philip J/0000-0001-9175-8682; Carroll, Jason/0000-0003-3643-0080; Vareslija, Damir/0000-0003-1000-0357; Brett, Francesca/0000-0002-7453-4027; Cosgrove, Nicola/0000-0002-8296-115X	Breast Cancer Ireland [GR 14-0883]; Irish Cancer Society Collaborative Cancer Research Centre grant [CCRC13GAL]; Breast Cancer NOW grant [2018JulPR1094, 2019AugSF1310]; Irish Cancer Society Research Fellowship [STB19VAR]; Walk the Walk	Breast Cancer Ireland; Irish Cancer Society Collaborative Cancer Research Centre grant; Breast Cancer NOW grant; Irish Cancer Society Research Fellowship; Walk the Walk	We would like to acknowledge Robert Bagnall for his technical assistance in performing protein characterization experiments in this manuscript. We would like to acknowledge Aisling Hegarty for her tissue bank and database curation. We are thankful to the patients who generously provided tumor tissue for our studies and to the surgical, pathology and tissue bank colleagues for their substantial assistance and support. We kindly acknowledge the funding support from Breast Cancer Ireland (GR 14-0883)(LY),the Irish Cancer Society Collaborative Cancer Research Centre grant, (CCRC13GAL)(LY) and Breast Cancer NOW grant, 2018JulPR1094 (LY, DV). This work is supported by Irish Cancer Society Research Fellowship STB19VAR (DV). This work is supported by funding from Breast Cancer Now Grant, 2019AugSF1310 with the generous support of Walk the Walk (DV).	Alkner S, 2017, BREAST CANCER RES TR, V166, P481, DOI 10.1007/s10549-017-4416-0; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Arnedos M, 2014, ANN ONCOL, V25, P605, DOI 10.1093/annonc/mdt575; Browne AL, 2018, ONCOGENE, V37, P2008, DOI 10.1038/s41388-017-0042-x; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Covington KR, 2013, BREAST CANCER RES TR, V141, P375, DOI 10.1007/s10549-013-2709-5; DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454; Foulds CE, 2013, MOL CELL, V51, P185, DOI 10.1016/j.molcel.2013.06.007; Fu JJ, 2012, INT J BIOL SCI, V8, P522, DOI 10.7150/ijbs.4164; Fu JJ, 2011, CELL RES, V21, P275, DOI 10.1038/cr.2010.118; Gao ZG, 2005, J BIOL CHEM, V280, P21091, DOI 10.1074/jbc.M500754200; Garee JP, 2014, MOL ENDOCRINOL, V28, P846, DOI 10.1210/me.2013-1379; Gates LA, 2018, ONCOGENE, V37, P4581, DOI 10.1038/s41388-018-0284-2; Giltnane JM, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai7993; Groner AC, 2017, J CLIN INVEST, V127, P1126, DOI 10.1172/JCI88885; Guo S, 2014, INT J CLIN ONCOL, V19, P319, DOI 10.1007/s10147-013-0549-2; Hanker AB, 2020, CANCER CELL, V37, P496, DOI 10.1016/j.ccell.2020.03.009; Jansen MPHM, 2013, CANCER RES, V73, P6632, DOI 10.1158/0008-5472.CAN-13-0704; Jeselsohn R, 2018, CANCER CELL, V33, P173, DOI 10.1016/j.ccell.2018.01.004; Jeselsohn R, 2014, CLIN CANCER RES, V20, P1757, DOI 10.1158/1078-0432.CCR-13-2332; Karmakar S, 2010, MOL ENDOCRINOL, V24, P1187, DOI 10.1210/me.2009-0480; Lefebvre C, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002201; Ma CX, 2015, NAT REV CANCER, V15, P261, DOI 10.1038/nrc3920; McBryan J, 2015, CLIN CANCER RES, V21, P5371, DOI 10.1158/1078-0432.CCR-14-2155; Mei SL, 2017, NUCLEIC ACIDS RES, V45, pD658, DOI 10.1093/nar/gkw983; Mohammed H, 2013, CELL REP, V3, P342, DOI 10.1016/j.celrep.2013.01.010; Naeem H, 2007, MOL CELL BIOL, V27, P120, DOI 10.1128/MCB.00815-06; Nguyen VTM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10044; O'Hara J, 2012, CLIN CANCER RES, V18, P3305, DOI 10.1158/1078-0432.CCR-11-3300; Oesterreich S, 2003, CANCER RES, V63, P5203; Padmanaban V, 2019, NATURE, V573, P439, DOI 10.1038/s41586-019-1526-3; Priedigkeit N, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.95703; Priedigkeit N, 2017, JAMA ONCOL, V3, P666, DOI 10.1001/jamaoncol.2016.5630; Qin L, 2008, MOL CELL BIOL, V28, P5937, DOI 10.1128/MCB.00579-08; Rohira AD, 2017, CANCER RES, V77, P4293, DOI 10.1158/0008-5472.CAN-16-2982; Shafi AA, 2018, EUR UROL ONCOL, V1, P325, DOI 10.1016/j.euo.2018.04.019; Siegel MB, 2018, J CLIN INVEST, V128, P1371, DOI 10.1172/JCI96153; Torres-Arzayus MI, 2010, CANCER RES, V70, P4102, DOI 10.1158/0008-5472.CAN-09-4080; Uhlenhaut NH, 2013, MOL CELL, V49, P158, DOI 10.1016/j.molcel.2012.10.013; Vareslija D, 2019, JNCI-J NATL CANCER I, V111, P388, DOI 10.1093/jnci/djy110; Vareslija D, 2017, METHODS MOL BIOL, V1501, P327, DOI 10.1007/978-1-4939-6475-8_17; Vareslija D, 2016, CLIN CANCER RES, V22, P2765, DOI 10.1158/1078-0432.CCR-15-1583; Walsh CA, 2014, CANCER RES, V74, P2533, DOI 10.1158/0008-5472.CAN-13-2133; Wang L, 2016, HORM CANCER-US, V7, P229, DOI 10.1007/s12672-016-0261-6; Wang L, 2015, CANCER CELL, V28, P240, DOI 10.1016/j.ccell.2015.07.005; Ward E, 2018, CLIN CANCER RES, V24, P3692, DOI 10.1158/1078-0432.CCR-17-2615; Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695; Yan J, 2008, CANCER RES, V68, P5460, DOI 10.1158/0008-5472.CAN-08-0955; Yi P, 2017, MOL CELL, V67, P733, DOI 10.1016/j.molcel.2017.07.026; Zwart W, 2016, CLIN CANCER RES, V22, P479, DOI 10.1158/1078-0432.CCR-14-3277	50	5	6	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2021	40	7					1318	1331		10.1038/s41388-020-01606-3	http://dx.doi.org/10.1038/s41388-020-01606-3		JAN 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QK0LS	33420368	Green Published, hybrid			2022-12-17	WOS:000607346000008
J	Sari, IN; Yang, YG; Wijaya, YT; Jun, N; Lee, S; Kim, KS; Bajaj, J; Oehler, VG; Kim, SH; Choi, SY; Park, SH; Kim, DW; Reya, T; Han, J; Kwon, HY				Sari, Ita Novita; Yang, Ying-Gui; Wijaya, Yoseph Toni; Jun, Nayoung; Lee, Sanghyun; Kim, Kwang Seock; Bajaj, Jeevisha; Oehler, Vivian G.; Kim, Soo-Hyun; Choi, Soo-Young; Park, Sa-Hee; Kim, Dong-Wook; Reya, Tannishtha; Han, Jaeseok; Kwon, Hyog Young			AMD1 is required for the maintenance of leukemic stem cells and promotes chronic myeloid leukemic growth	ONCOGENE			English	Article							POLYAMINE BIOSYNTHESIS INHIBITOR; PHASE-II TRIAL; GENE-EXPRESSION; ESCHERICHIA-COLI; CANCER; METABOLISM; SPERMINE; SAM486A; STRESS; TARGETS	Polyamines are critical elements in mammals, but it remains unknown whether adenosyl methionine decarboxylase (AMD1), a rate-limiting enzyme in polyamine synthesis, is required for myeloid leukemia. Here, we found that leukemic stem cells (LSCs) were highly differentiated, and leukemia progression was severely impaired in the absence of AMD1 in vivo. AMD1 was highly upregulated as chronic myeloid leukemia (CML) progressed from the chronic phase to the blast crisis phase, and was associated with the poor prognosis of CML patients. In addition, the pharmacological inhibition of AMD1 by AO476 treatment resulted in a robust reduction of the progression of leukemic cells both in vitro and in vivo. Mechanistically, AMD1 depletion induced loss of mitochondrial membrane potential and accumulation of reactive oxygen species (ROS), resulting in the differentiation of LSCs via oxidative stress and aberrant activation of unfolded protein response (UPR) pathway, which was partially rescued by the addition of polyamine. These results indicate that AMD1 is an essential element in the progression of myeloid leukemia and could be an attractive target for the treatment of the disease.	[Sari, Ita Novita; Yang, Ying-Gui; Wijaya, Yoseph Toni; Jun, Nayoung; Lee, Sanghyun; Kim, Kwang Seock; Han, Jaeseok; Kwon, Hyog Young] Soonchunhyang Univ, Soonchunhyang Inst Medibio Sci, Cheonan, South Korea; [Yang, Ying-Gui] Southern Med Univ, Shenzhen Hosp, Clin Innovat & Res Ctr CIRC, Shenzhen Key Lab Viral Oncol, Shenzhen, Peoples R China; [Bajaj, Jeevisha; Reya, Tannishtha] Univ Calif San Diego, Sch Med, Dept Pharmacol, La Jolla, CA 92093 USA; [Bajaj, Jeevisha; Reya, Tannishtha] Sanford Consortium Regenerat Med, La Jolla, CA USA; [Oehler, Vivian G.] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA; [Kim, Soo-Hyun; Choi, Soo-Young; Park, Sa-Hee; Kim, Dong-Wook] Catholic Univ Korea, Catholic Leukemia Res Inst, Seoul, South Korea; [Kim, Dong-Wook] Catholic Univ Korea, Seoul St Marys Hosp, Dept Hematol, Seoul, South Korea; [Reya, Tannishtha] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Soonchunhyang University; Southern Medical University - China; University of California System; University of California San Diego; Fred Hutchinson Cancer Center; Catholic University of Korea; Catholic University of Korea; Seoul St. Mary's Hospital; Duke University	Kwon, HY (corresponding author), Soonchunhyang Univ, Soonchunhyang Inst Medibio Sci, Cheonan, South Korea.	hykwon@sch.ac.kr		Sari, Ita Novita/0000-0001-9475-7992; Wijaya, Yoseph Toni/0000-0003-3002-8592; KIM, Kwang Seock/0000-0002-3329-1225	National Research Foundation of Korea [NRF-2020R1A2C1003791, NRF-2019R1A5A8083404]; Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHID) - Ministry of Health & Welfare, Republic of Korea [HI15C1647]; Global Research Development Center [NRF-2016K1A4A3914725]	National Research Foundation of Korea(National Research Foundation of Korea); Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHID) - Ministry of Health & Welfare, Republic of Korea; Global Research Development Center	This work was supported by the National Research Foundation of Korea (NRF-2020R1A2C1003791 and NRF-2019R1A5A8083404), the grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHID), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI15C1647) and Global Research Development Center (NRF-2016K1A4A3914725).	Abreu RD, 2009, J BIOL CHEM, V284, P12125, DOI 10.1074/jbc.M809605200; Agostinelli E, 2007, AMINO ACIDS, V33, P175, DOI 10.1007/s00726-007-0510-7; Basuroy UK, 2006, J BIOCHEM, V139, P27, DOI 10.1093/jb/mvj022; Battelli C, 2006, MOL CELL NEUROSCI, V31, P85, DOI 10.1016/j.mcn.2005.09.003; Ferreira AMC, 2016, J CHROMATOGR A, V1444, P32, DOI 10.1016/j.chroma.2016.03.054; Casero RA, 2007, NAT REV DRUG DISCOV, V6, P373, DOI 10.1038/nrd2243; Das KC, 2004, MOL CELL BIOCHEM, V262, P127, DOI 10.1023/B:MCBI.0000038227.91813.79; delaVega AL, 1996, J BACTERIOL, V178, P3715, DOI 10.1128/jb.178.13.3715-3721.1996; Fujisawa S, 2005, ANTICANCER RES, V25, P965; Gamble LD, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00162; Gerner EW, 2004, NAT REV CANCER, V4, P781, DOI 10.1038/nrc1454; Gugliucci A, 2004, CLIN CHIM ACTA, V344, P23, DOI 10.1016/j.cccn.2004.02.022; Imai T, 2001, MOL CELL BIOL, V21, P3888, DOI 10.1128/MCB.21.12.3888-3900.2001; Ito T, 2010, NATURE, V466, P765, DOI 10.1038/nature09171; Ji AR, 2010, EXP MOL MED, V42, P175, DOI 10.3858/emm.2010.42.3.018; Jung IL, 2003, BIOCHEM BIOPH RES CO, V301, P915, DOI 10.1016/S0006-291X(03)00064-0; Kabbarah O, 2003, AM J PATHOL, V162, P755, DOI 10.1016/S0002-9440(10)63872-2; Kim JS, 2006, ENVIRON TOXICOL PHAR, V22, P160, DOI 10.1016/j.etap.2006.02.003; Kwon HY, 2015, CELL STEM CELL, V17, P152, DOI 10.1016/j.stem.2015.06.006; Larque E, 2007, NUTRITION, V23, P87, DOI 10.1016/j.nut.2006.09.006; Liao CZ, 2015, SCI REP-UK, V5, DOI 10.1038/srep10754; Luo M, 2018, CELL METAB, V28, P69, DOI 10.1016/j.cmet.2018.06.006; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; McStay GP, 2002, BIOCHEM J, V367, P541, DOI 10.1042/BJ20011672; Millward MJ, 2005, INVEST NEW DRUG, V23, P253, DOI 10.1007/s10637-005-6734-z; MUSCARI C, 1995, MOL CELL BIOCHEM, V144, P125, DOI 10.1007/BF00944391; Paridaens R, 2000, BRIT J CANCER, V83, P594, DOI 10.1054/bjoc.2000.1305; Park SM, 2014, J EXP MED, V211, P71, DOI 10.1084/jem.20130736; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; Pegg AE, 2009, IUBMB LIFE, V61, P880, DOI 10.1002/iub.230; Pless M, 2004, CLIN CANCER RES, V10, P1299, DOI 10.1158/1078-0432.CCR-0977-03; Radich JP, 2006, P NATL ACAD SCI USA, V103, P2794, DOI 10.1073/pnas.0510423103; Rider JE, 2007, AMINO ACIDS, V33, P231, DOI 10.1007/s00726-007-0513-4; RUSSELL DH, 1971, NATURE-NEW BIOL, V233, P144, DOI 10.1038/newbio233144a0; Sagor GHM, 2013, TRANSGENIC RES, V22, P595, DOI 10.1007/s11248-012-9666-3; Sava IG, 2006, FREE RADICAL BIO MED, V41, P1272, DOI 10.1016/j.freeradbiomed.2006.07.008; Scuoppo C, 2012, NATURE, V487, P244, DOI 10.1038/nature11126; Segawa T, 2002, ONCOGENE, V21, P8749, DOI 10.1038/sj.onc.1205992; Seiler N, 1996, INT J BIOCHEM CELL B, V28, P843, DOI 10.1016/1357-2725(96)00021-0; SIMON MS, 1990, INVEST NEW DRUG, V8, pS79; Siu LL, 2002, CLIN CANCER RES, V8, P2157; Soda K, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-95; SOHAL RS, 1986, ADV FREE RADICAL BIO, V2, P117, DOI 10.1016/S8755-9668(86)80026-6; Stewart TM, 2018, J BIOL CHEM, V293, P18736, DOI 10.1074/jbc.TM118.003337; TIBURCIO AF, 1994, BIOCHEM SOC T, V22, pS455, DOI 10.1042/bst022455s; Tkachenko AG, 2003, BIOCHEMISTRY-MOSCOW+, V68, P850, DOI 10.1023/A:1025790729797; Urdiales JL, 2001, EUR J GASTROEN HEPAT, V13, P1015, DOI 10.1097/00042737-200109000-00003; van Zuylen L, 2004, CLIN CANCER RES, V10, P1949, DOI 10.1158/1078-0432.CCR-02-0995; Vu LP, 2017, NAT GENET, V49, P866, DOI 10.1038/ng.3854; Walker JA, 2017, JAIDS-J ACQ IMM DEF, V74, P583, DOI 10.1097/QAI.0000000000001297; Xu LJ, 2020, CARCINOGENESIS, V41, P214, DOI 10.1093/carcin/bgz098; Zimdahl B, 2014, NAT GENET, V46, P245, DOI 10.1038/ng.2889	52	5	5	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					603	617		10.1038/s41388-020-01547-x	http://dx.doi.org/10.1038/s41388-020-01547-x		NOV 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33203990				2022-12-17	WOS:000590200200001
J	Wang, XG; Song, YQ; Chen, W; Ding, N; Liu, WP; Xie, Y; Wang, YN; Zhu, J; Zeng, CQ				Wang, Xiaogan; Song, Yuqin; Chen, Wei; Ding, Ning; Liu, Weiping; Xie, Yan; Wang, Yinan; Zhu, Jun; Zeng, Changqing			Germline variants of DNA repair genes in early onset mantle cell lymphoma	ONCOGENE			English	Article							NON-HODGKINS-LYMPHOMA; MICROSATELLITE INSTABILITY; MOLECULAR PATHOGENESIS; CANCER; EXPRESSION; ASSOCIATION; DEFICIENCY; SIGNATURES; ALIGNMENT; PATIENT	Although somatic mutations of DNA repair genes are frequent in mantle cell lymphoma (MCL), our understanding of their germline defects is limited. In a Chinese family with maternal Lynch syndrome and paternal B cell non-Hodgkin lymphoma, one sibling developed both Lynch syndrome and MCL. Lynch syndrome is caused by heterozygous mutations in mismatch repair (MMR) genes. To understand the genetic predispositions in the family, we performed exome sequencing and analyses of affected individuals and their tumor samples. A novel germline indel, MLH1 Gly101fsX1, was identified as the cause of Lynch syndrome, and unstable microsatellite loci and mutational signatures as evidence of defective MMR were revealed in the MCL sample. Furthermore, we included additional 15 MCL patients with early onset, and found by exome sequencing that 11 patients carried heterozygous germline variants of 20 DNA repair genes, including MSH2 in MMR. In the MCL with MSH2 Arg359fsX16, unstable microsatellite loci and defective MMR signatures were also found. In addition, five patients also had heterozygous germline variants of genes involved in B cell functions. Thus, our study found germline variants of genes in single-strand break repair, double-strand break repair, and Fanconi anemia pathway in early onset MCL; and for the first time we identified germline defects of MMR in two MCLs.	[Wang, Xiaogan; Song, Yuqin; Ding, Ning; Liu, Weiping; Xie, Yan; Zhu, Jun] Peking Univ Canc Hosp & Inst, Minist Educ, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China; [Wang, Xiaogan; Chen, Wei; Zeng, Changqing] Chinese Acad Sci, Beijing Inst Genom, CAS Key Lab Genom & Precis Med, Beijing, Peoples R China; [Chen, Wei; Zeng, Changqing] China Natl Ctr Bioinformat, Beijing, Peoples R China; [Wang, Yinan] Hebei Tangshan Peoples Hosp, Tangshan, Hebei, Peoples R China; [Zeng, Changqing] Univ Chinese Acad Sci, Beijing, Peoples R China	Chinese Academy of Sciences; Beijing Institute of Genomics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Zhu, J (corresponding author), Peking Univ Canc Hosp & Inst, Minist Educ, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China.; Zeng, CQ (corresponding author), Chinese Acad Sci, Beijing Inst Genom, CAS Key Lab Genom & Precis Med, Beijing, Peoples R China.; Zeng, CQ (corresponding author), China Natl Ctr Bioinformat, Beijing, Peoples R China.; Zeng, CQ (corresponding author), Univ Chinese Acad Sci, Beijing, Peoples R China.	zhu-jun2017@outlook.com; czeng@big.ac.cn			Key Research Program of the Chinese Academy of Sciences [KJZD-EWL06-2]; National Natural Science Foundation of China [81972807, 81670187, 81470368]; National High Technology Research and Development Program (863 Program) of China [2012AA022502]; Beijing Natural Science Foundation [7202025]; China Postdoctoral Science Foundation [2013M541009]	Key Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High Technology Research and Development Program (863 Program) of China(National High Technology Research and Development Program of China); Beijing Natural Science Foundation(Beijing Natural Science Foundation); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by grants from the Key Research Program of the Chinese Academy of Sciences (KJZD-EWL06-2) (CZ), the National Natural Science Foundation of China (81972807, 81670187 and 81470368) (YS and JZ), the National High Technology Research and Development Program (863 Program) of China (2012AA022502) (CZ), the Beijing Natural Science Foundation (7202025) (YS), and the China Postdoctoral Science Foundation (2013M541009) (XW). We thank Sheng Li for the help in the interview of relatives of the family and collection of their samples. We are grateful to Yunfei Shi for pathological review. Further thanks are due to Wen Zheng, Ningjing Lin, Meifeng Tu, Xiaopei Wang, Lingyan Ping, Zhitao Ying, Lijuan Deng, Chen Zhang, Tingting Du, Meng Wu, Xin Len, and Feier Feng for their help in collection of clinical information. We are grateful to Caixia Guo for advice and help in revision.	Adzhubei Ivan, 2013, Curr Protoc Hum Genet, VChapter 7, DOI 10.1002/0471142905.hg0720s76; Alexandrov LB, 2020, NATURE, V578, P94, DOI 10.1038/s41586-020-1943-3; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Blokzijl F, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0539-0; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cheah CY, 2016, J CLIN ONCOL, V34, P1256, DOI 10.1200/JCO.2015.63.5904; Cheah CY, 2015, J CLIN PATHOL, V68, P755, DOI 10.1136/jclinpath-2015-203039; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cuceu C, 2018, CANCERS, V10, DOI 10.3390/cancers10070233; de Miranda NFCC, 2013, J EXP MED, V210, P1729, DOI 10.1084/jem.20122842; Degroote A, 2013, LEUKEMIA LYMPHOMA, V54, P812, DOI 10.3109/10428194.2012.723211; Dreyling M, 2017, ANN ONCOL, V28, P62, DOI [10.1093/annonc/mdx289, 10.1093/annonc/mdx223]; Du ZL, 2019, GENOM PROTEOM BIOINF, V17, P229, DOI 10.1016/j.gpb.2019.07.002; Elenitoba-Johnson KSJ, 2018, ANNU REV PATHOL-MECH, V13, P193, DOI 10.1146/annurev-pathol-020117-043803; Ferrari Vittorio, 1999, Recenti Progressi in Medicina, V90, P81; Hirano K, 2002, DIS COLON RECTUM, V45, P273, DOI 10.1007/s10350-004-6161-9; Huet S, 2018, NAT REV CANCER, V18, P224, DOI 10.1038/nrc.2017.127; Jares P, 2007, NAT REV CANCER, V7, P750, DOI 10.1038/nrc2230; Kim D, 2019, NAT BIOTECHNOL, V37, P907, DOI 10.1038/s41587-019-0201-4; Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892; Kotoula V, 2002, LEUKEMIA LYMPHOMA, V43, P393, DOI 10.1080/10428190290006215; Kratz CP, 2008, LEUKEMIA, V22, P1078, DOI 10.1038/sj.leu.2405008; Krueger S, 2008, EUR J HUM GENET, V16, P62, DOI 10.1038/sj.ejhg.5201923; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Lindsley AW, 2016, J ALLERGY CLIN IMMUN, V137, P179, DOI 10.1016/j.jaci.2015.06.002; Lynch HT, 2015, NAT REV CANCER, V15, P181, DOI 10.1038/nrc3878; Moffitt AB, 2017, J CLIN ONCOL, V35, P955, DOI 10.1200/JCO.2016.71.7603; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; Ortega-Molina A, 2015, NAT MED, V21, P1199, DOI 10.1038/nm.3943; Perez-Galan P, 2011, BLOOD, V117, P26, DOI 10.1182/blood-2010-04-189977; Pineda M, 2008, GENE CHROMOSOME CANC, V47, P326, DOI 10.1002/gcc.20536; Puente XS, 2018, BLOOD, V131, P2283, DOI 10.1182/blood-2017-10-764373; Rao RC, 2015, NAT REV CANCER, V15, P334, DOI 10.1038/nrc3929; Renkonen E, 2003, J CLIN ONCOL, V21, P3629, DOI 10.1200/JCO.2003.03.181; Ripperger T, 2016, EUR J MED GENET, V59, P133, DOI 10.1016/j.ejmg.2015.12.014; Ripperger T, 2010, HAEMATOL-HEMATOL J, V95, P841, DOI 10.3324/haematol.2009.015503; Rosty C, 2000, MODERN PATHOL, V13, P586, DOI 10.1038/modpathol.3880100; Salipante SJ, 2014, CLIN CHEM, V60, P1192, DOI 10.1373/clinchem.2014.223677; Sanz-Vaque L, 2001, HAEMATOLOGICA, V86, P181; Saunders CT, 2012, BIOINFORMATICS, V28, P1811, DOI 10.1093/bioinformatics/bts271; Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810-575; Smedby Karin E., 2014, Journal of the National Cancer Institute Monographs, P76, DOI 10.1093/jncimonographs/lgu007; Sud A, 2019, BLOOD, V132, P960, DOI 10.1182/blood.2019001362; Supek F, 2015, NATURE, V521, P81, DOI 10.1038/nature14173; Taylor J, 2017, BLOOD, V130, P410, DOI 10.1182/blood-2017-02-734541; Teruya-Feldstein J, 2002, LEUKEMIA LYMPHOMA, V43, P1619, DOI 10.1080/1042819021000002956; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Tian T, 2020, LAB INVEST, V100, P1397, DOI 10.1002/cam4.2870; Vogt N, 2017, LEUKEMIA LYMPHOMA, V58, P1530, DOI 10.1080/10428194.2016.1248965; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Zhang JY, 2015, NAT MED, V21, P1190, DOI 10.1038/nm.3940	51	5	5	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					551	563		10.1038/s41388-020-01542-2	http://dx.doi.org/10.1038/s41388-020-01542-2		NOV 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33191405				2022-12-17	WOS:000589571100001
J	Beck, M; Baranger, M; Moufok-Sadoun, A; Bersuder, E; Hinkel, I; Mellitzer, G; Martin, E; Marisa, L; Duluc, I; de Reynies, A; Gaiddon, C; Freund, JN; Gross, I				Beck, Marine; Baranger, Mathilde; Moufok-Sadoun, Ahlam; Bersuder, Emilie; Hinkel, Isabelle; Mellitzer, Georg; Martin, Elisabeth; Marisa, Laetitia; Duluc, Isabelle; de Reynies, Aurelien; Gaiddon, Christian; Freund, Jean-Noel; Gross, Isabelle			The atypical cadherin MUCDHL antagonizes colon cancer formation and inhibits oncogenic signaling through multiple mechanisms	ONCOGENE			English	Article							MU-PROTOCADHERIN; EXPRESSION; MOUSE; GENE; PATHWAY; GROWTH; MODEL	Cadherins form a large and pleiotropic superfamily of membranous proteins sharing Ca2+-binding repeats. While the importance of classic cadherins such as E- or N-cadherin for tumorigenesis is acknowledged, there is much less information about other cadherins that are merely considered as tissue-specific adhesion molecules. Here, we focused on the atypical cadherin MUCDHL that stood out for its unusual features and unique function in the gut. Analyses of transcriptomic data sets (n > 250) established that MUCDHL mRNA levels are down-regulated in colorectal tumors. Importantly, the decrease of MUCDHL expression is more pronounced in the worst-prognosis subset of tumors and is associated with decreased survival. Molecular characterization of the tumors indicated a negative correlation with proliferation-related processes (e.g., nucleic acid metabolism, DNA replication). Functional genomic studies showed that the loss of MUCDHL enhanced tumor incidence and burden in intestinal tumor-prone mice. Extensive structure/function analyses revealed that the mode of action of MUCDHL goes beyond membrane sequestration of ss-catenin and targets through its extracellular domain key oncogenic signaling pathways (e.g., EGFR, AKT). Beyond MUCDHL, this study illustrates how the loss of a gene critical for the morphological and functional features of mature cells contributes to tumorigenesis by dysregulating oncogenic pathways.	[Beck, Marine; Baranger, Mathilde; Moufok-Sadoun, Ahlam; Bersuder, Emilie; Hinkel, Isabelle; Mellitzer, Georg; Martin, Elisabeth; Duluc, Isabelle; Gaiddon, Christian; Freund, Jean-Noel; Gross, Isabelle] Univ Strasbourg, INSERM, IRFAC, UMR S1113, F-67200 Strasbourg, France; [Marisa, Laetitia; de Reynies, Aurelien] Ligue Natl Canc, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Gross, I (corresponding author), Univ Strasbourg, INSERM, IRFAC, UMR S1113, F-67200 Strasbourg, France.	isabelle.gross@unistra.fr	Freund, Jean-Noel/R-4383-2016; Gross, Isabelle/P-9859-2019; Georg, Mellitzer/R-4180-2016; DULUC, Isabelle/AAA-7062-2022; Gaiddon, Christian/F-7321-2012	Freund, Jean-Noel/0000-0002-0971-3774; Gross, Isabelle/0000-0002-2783-8773; Georg, Mellitzer/0000-0003-4467-0789; DULUC, Isabelle/0000-0001-8396-6385; Gaiddon, Christian/0000-0003-4315-3851	INSERM; Fondation ARC [SFI20101201854]; La Ligue Contre Le Cancer [Haute-Marne 2013, Haut-Rhin 2016]	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Fondation ARC; La Ligue Contre Le Cancer(Ligue nationale contre le cancer)	This work was supported by the financial support of INSERM (2013-2019), Fondation ARC (#SFI20101201854), and La Ligue Contre Le Cancer (Haute-Marne 2013, Haut-Rhin 2016); MBe, MBa, EB, AMS, and IH were fellows of the French government (Ministere de l'Enseignement Superieur et de la Recherche). MBe and MBawere also fellows of Fondation ARC, and EB of the FRM.	Balbinot C, 2018, J EXP MED, V215, P911, DOI 10.1084/jem.20170934; Basu Sayon, 2016, F1000Res, V5, DOI 10.12688/f1000research.7579.1; Blasius FM, 2017, ONCOTARGET, V8, P75076, DOI 10.18632/oncotarget.20507; Borowicz S, 2014, JOVE-J VIS EXP, DOI 10.3791/51998; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; CHANTRET I, 1994, J CELL SCI, V107, P213; Colnot S, 2004, LAB INVEST, V84, P1619, DOI 10.1038/labinvest.3700180; Crawley SW, 2014, CELL, V157, P433, DOI 10.1016/j.cell.2014.01.067; Danielsen SA, 2015, BBA-REV CANCER, V1855, P104, DOI 10.1016/j.bbcan.2014.09.008; Ding X, 2020, IRISH J MED SCI, V189, P439, DOI 10.1007/s11845-019-02092-7; Fichera A, 2007, CANCER RES, V67, P827, DOI 10.1158/0008-5472.CAN-05-3343; Gehart H, 2019, NAT REV GASTRO HEPAT, V16, P19, DOI 10.1038/s41575-018-0081-y; Goldberg M, 2000, J BIOL CHEM, V275, P24622, DOI 10.1074/jbc.M000234200; Goldberg M, 2002, AM J PHYSIOL-RENAL, V283, pF454, DOI 10.1152/ajprenal.00012.2002; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Gul IS, 2017, EXP CELL RES, V358, P3, DOI 10.1016/j.yexcr.2017.03.001; Hinkel I, 2012, GASTROENTEROLOGY, V142, P875, DOI 10.1053/j.gastro.2011.12.037; Hu TH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-236; Hughes LAE, 2017, CURR COLORECT CANC R, V13, P455, DOI 10.1007/s11888-017-0395-0; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lee CH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-64; Losi L, 2011, HUM PATHOL, V42, P960, DOI 10.1016/j.humpath.2010.10.009; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453; Markowitz SD, 2002, CANCER CELL, V1, P233, DOI 10.1016/S1535-6108(02)00053-3; Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169; Mateusz B, 2015, GASTROENT RES PRACT, V2015, DOI 10.1155/2015/317093; Mazzolini R, 2012, P NATL ACAD SCI USA, V109, P1530, DOI 10.1073/pnas.1108411109; McCubrey JA, 2014, ONCOTARGET, V5, P2881, DOI 10.18632/oncotarget.2037; Montorsi L, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.163; Moulton DE, 2004, PEDIATR RES, V55, P927, DOI 10.1203/01.PDR.0000125260.46861.32; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Novellasdemunt L, 2015, AM J PHYSIOL-CELL PH, V309, pC511, DOI 10.1152/ajpcell.00117.2015; O'Connell MJ, 2010, J CLIN ONCOL, V28, P3937, DOI 10.1200/JCO.2010.28.9538; Parenti S, 2009, ALIMENT PHARM THER, V31, P108, DOI 10.1111/j.1365-2036.2009.04149.x; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Shih LM, 2001, P NATL ACAD SCI USA, V98, P2640, DOI 10.1073/pnas.051629398; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; van Roy F, 2014, NAT REV CANCER, V14, P121, DOI 10.1038/nrc3647	40	5	5	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					522	535		10.1038/s41388-020-01546-y	http://dx.doi.org/10.1038/s41388-020-01546-y		NOV 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33188295	Green Submitted			2022-12-17	WOS:000589573800002
J	Chen, J; Xuan, ZF; Song, WF; Han, WL; Chen, H; Du, YH; Xie, HY; Zhao, YC; Zheng, SS; Song, PH				Chen, Jun; Xuan, Zefeng; Song, Wenfeng; Han, Weili; Chen, Hao; Du, Yehui; Xie, Haiyang; Zhao, Yongchao; Zheng, Shusen; Song, Penghong			EAG1 enhances hepatocellular carcinoma proliferation by modulating SKP2 and metastasis through pseudopod formation	ONCOGENE			English	Article							UBIQUITIN; ASTEMIZOLE; PATHWAY; INVOLVEMENT; PROGRESSION; EXPRESSION; CHANNELS	Ether-a-go-go-1 (EAG1), one of the potassium channels, is involved in various physiological processes and plays an important role in the tumorigenesis of many kinds of cancer. EAG1 is highly expressed in hepatocarcinoma cells and is closely related to clinical prognosis, but the molecular mechanism remains elusive. In this study, we verified that EAG1 promotes the proliferation of hepatocellular carcinoma (HCC) both in vitro and in vivo. It promotes cell cycle progression by inhibiting the ubiquitination of SKP2. In addition, EAG1 promotes the migration and invasion of HCC by promoting cell pseudopod formation. Furthermore, in a high-pressure plasmid-injected mouse liver orthotopic carcinoma model, astemizole, an EAG family blocker, can significantly inhibit the formation of liver cancer. Meanwhile, liver-specific EAG1 knockout mice show resistance to hepatocarcinogenesis. This research demonstrated that EAG1 plays an important role in the progression of HCC, and could be a potential therapeutic target for HCC.	[Chen, Jun; Xuan, Zefeng; Song, Wenfeng; Chen, Hao; Xie, Haiyang; Zheng, Shusen; Song, Penghong] Zhejiang Univ, Sch Med, Div Hepatobiliary & Pancreat Surg, Dept Surg,Affiliated Hosp 1, Hangzhou, Peoples R China; [Chen, Jun; Xuan, Zefeng; Song, Wenfeng; Chen, Hao; Xie, Haiyang; Zhao, Yongchao; Zheng, Shusen; Song, Penghong] NHC Key Lab Combined Multiorgan Transplantat, Hangzhou, Peoples R China; [Chen, Jun; Xuan, Zefeng; Song, Wenfeng; Chen, Hao; Xie, Haiyang; Zheng, Shusen; Song, Penghong] Chinese Acad Med Sci, Key Lab Diag & Treatment Organ Transplantat, Res Unit Collaborat Diag & Treatment Hepatobiliar, 2019RU019, Hangzhou, Peoples R China; [Chen, Jun; Xuan, Zefeng; Song, Wenfeng; Chen, Hao; Xie, Haiyang; Zheng, Shusen; Song, Penghong] Res Ctr Diag & Treatment Hepatobiliary Dis, Key Lab Organ Transplantat, Hangzhou 310003, Zhejiang, Peoples R China; [Chen, Jun; Han, Weili; Chen, Hao] Zhejiang Univ, Sch Med, Dept Lung Transplantat, Affiliated Hosp 1, Hangzhou, Peoples R China; [Xuan, Zefeng] Zhejiang Univ, Sch Med, Div Breast Surg, Dept Surg,Affiliated Hosp 1, Hangzhou, Peoples R China; [Du, Yehui] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Thyroid Dis Diag & Treatment Ctr, Hangzhou, Peoples R China; [Zhao, Yongchao] Zhejiang Univ, Sch Med, Inst Translat Med, Hangzhou 310029, Peoples R China	Zhejiang University; Chinese Academy of Medical Sciences - Peking Union Medical College; Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University	Zheng, SS; Song, PH (corresponding author), Zhejiang Univ, Sch Med, Div Hepatobiliary & Pancreat Surg, Dept Surg,Affiliated Hosp 1, Hangzhou, Peoples R China.; Zheng, SS; Song, PH (corresponding author), NHC Key Lab Combined Multiorgan Transplantat, Hangzhou, Peoples R China.; Zheng, SS; Song, PH (corresponding author), Chinese Acad Med Sci, Key Lab Diag & Treatment Organ Transplantat, Res Unit Collaborat Diag & Treatment Hepatobiliar, 2019RU019, Hangzhou, Peoples R China.; Zheng, SS; Song, PH (corresponding author), Res Ctr Diag & Treatment Hepatobiliary Dis, Key Lab Organ Transplantat, Hangzhou 310003, Zhejiang, Peoples R China.	shusenzheng@zju.edu.cn; songpenghong@zju.edu.cn			National Natural Science Foundation of China [81272675, 81870434]; Key Research and Development Plan of Zhejiang Province [2020C04003]; National ST Major Project [2017ZX10203205]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Research and Development Plan of Zhejiang Province; National ST Major Project	This work was supported by the National Natural Science Foundation of China (81272675 and 81870434) to PS, the Key Research and Development Plan of Zhejiang Province (2020C04003) to PS, the National S&T Major Project (2017ZX10203205) to SZ.	Bertuccio P, 2017, J HEPATOL, V67, P302, DOI 10.1016/j.jhep.2017.03.011; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Calvisi DF, 2011, GASTROENTEROLOGY, V140, P1071, DOI 10.1053/j.gastro.2010.12.006; Chen TP, 2007, GYNECOL ONCOL, V104, P516, DOI 10.1016/j.ygyno.2006.09.015; Chen X, 2014, AM J PATHOL, V184, P912, DOI 10.1016/j.ajpath.2013.12.002; Chavez-Lopez MD, 2015, TUMOR BIOL, V36, P6149, DOI 10.1007/s13277-015-3299-0; Chavez-Lopez MD, 2014, INT J GYNECOL CANCER, V24, P824, DOI 10.1097/IGC.0000000000000151; Diaz L, 2009, CANCER RES, V69, P3300, DOI 10.1158/0008-5472.CAN-08-2036; El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061; Garcia-Quiroz J, 2011, ANTI-CANCER AGENT ME, V11, P307, DOI 10.2174/187152011795347513; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Guo XC, 2017, GENE DEV, V31, P247, DOI 10.1101/gad.294348.116; Haitin Y, 2013, NATURE, V501, P444, DOI 10.1038/nature12487; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Liu GX, 2015, INT J CLIN EXP PATHO, V8, P15093; Liu YT, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0462-3; Mukhopadhyay D, 2007, SCIENCE, V315, P201, DOI 10.1126/science.1127085; Nakayama KI, 2005, SEMIN CELL DEV BIOL, V16, P323, DOI 10.1016/j.semcdb.2005.02.010; Pardo LA, 2014, NAT REV CANCER, V14, P39, DOI 10.1038/nrc3635; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; SHETERLINE P, 1995, PROTEIN PROFILE, V2, P1; Signoretti S, 2016, J CLIN INVEST, V126, P4387, DOI 10.1172/JCI90690; Stotz M, 2015, ANTICANCER RES, V35, P5737; Uddin S, 2016, SEMIN CANCER BIOL, V36, P18, DOI 10.1016/j.semcancer.2015.09.008; Vaiana SM, 2001, J BIOL PHYS, V27, P133, DOI 10.1023/A:1013146530021; Wang XZ, 2017, J MEMBRANE BIOL, V250, P123, DOI 10.1007/s00232-016-9944-8; Wei Z, 2013, CELL SIGNAL, V25, P931, DOI 10.1016/j.cellsig.2013.01.011; Wickenden AD, 2002, PHARMACOL THERAPEUT, V94, P157, DOI 10.1016/S0163-7258(02)00201-2; Yang JD, 2010, NAT REV GASTRO HEPAT, V7, P448, DOI 10.1038/nrgastro.2010.100; Yoshida Y, 2012, ONCOGENE, V31, P4128, DOI 10.1038/onc.2011.570; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	34	5	5	3	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					163	176		10.1038/s41388-020-01522-6	http://dx.doi.org/10.1038/s41388-020-01522-6		OCT 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33097858				2022-12-17	WOS:000582109600001
J	Eustace, NJ; Anderson, JC; Warram, JM; Widden, HN; Pedersen, RT; Alrefai, H; Patel, Z; Hicks, PH; Placzek, WJ; Gillespie, GY; Hjelmeland, AB; Willey, CD				Eustace, Nicholas J.; Anderson, Joshua C.; Warram, Jason M.; Widden, Hayley N.; Pedersen, Rune T.; Alrefai, Hasan; Patel, Zeel; Hicks, Patricia H.; Placzek, William J.; Gillespie, G. Yancey; Hjelmeland, Anita B.; Willey, Christopher D.			A cell-penetrating MARCKS mimetic selectively triggers cytolytic death in glioblastoma	ONCOGENE			English	Article							PI3K PATHWAY; RADIATION SENSITIVITY; MOLECULAR-MECHANISMS; CANCER; RESISTANCE; PHOSPHORYLATION; APOPTOSIS; PEPTIDE; CALCIUM; GROWTH	Glioblastoma (GBM) is an aggressive malignancy with limited effectiveness of standard of care therapies including surgery, radiation, and temozolomide chemotherapy necessitating novel therapeutics. Unfortunately, GBMs also harbor several signaling alterations that protect them from traditional therapies that rely on apoptotic programmed cell death. Because almost all GBM tumors have dysregulated phosphoinositide signaling as part of that process, we hypothesized that peptide mimetics derived from the phospholipid binding domain of Myristoylated alanine-rich C-kinase substrate (MARCKS) could serve as a novel GBM therapeutic. Using molecularly classified patient-derived xenograft (PDX) lines, cultured in stem-cell conditions, we demonstrate that cell permeable MARCKS effector domain (ED) peptides potently target all GBM molecular classes while sparing normal human astrocytes. Cell death mechanistic testing revealed that these peptides produce rapid cytotoxicity in GBM that overcomes caspase inhibition. Moreover, we identify a GBM-selective cytolytic death mechanism involving plasma membrane targeting and intracellular calcium accumulation. Despite limited relative partitioning to the brain, tail-vein peptide injection revealed tumor targeting in intracranially implanted GBM PDX. These results indicate that MARCKS ED peptide therapeutics may overcome traditional GBM resistance mechanisms, supporting further development of similar agents.	[Eustace, Nicholas J.; Anderson, Joshua C.; Alrefai, Hasan; Patel, Zeel; Hicks, Patricia H.; Willey, Christopher D.] Univ Alabama Birmingham, Dept Radiat Oncol, Birmingham, AL 35294 USA; [Warram, Jason M.] Univ Alabama Birmingham, Dept Otolaryngol, Birmingham, AL USA; [Widden, Hayley N.; Placzek, William J.] Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL USA; [Pedersen, Rune T.] ChemoMetec, DK-3450 Allerod, Denmark; [Gillespie, G. Yancey] Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL USA; [Hjelmeland, Anita B.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Willey, CD (corresponding author), Univ Alabama Birmingham, Dept Radiat Oncol, Birmingham, AL 35294 USA.	cwilley@uabmc.edu		Eustace, Nicholas/0000-0002-2483-7863; Placzek, William/0000-0003-4096-8617; Alrefai, Hasan/0000-0002-7240-8748; Gillespie, George/0000-0001-6436-9542; Anderson, Joshua/0000-0002-6977-9054; Pedersen, Rune Troelsgaard/0000-0002-0655-1351	National Institutes of Health (UAB MSTP training Grant) [T32GM008361]; National Institutes of Health (UAB Training Program in Brain Tumor Biology) [T32NS048039]; American Cancer Society [RSG-14-071-01-TBG]; UAB Physician Scientist Training Program Medical Student Summer Research Training Program; UAB Department of Radiation Oncology	National Institutes of Health (UAB MSTP training Grant)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health (UAB Training Program in Brain Tumor Biology)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); UAB Physician Scientist Training Program Medical Student Summer Research Training Program; UAB Department of Radiation Oncology	This work was supported by funding from the National Institutes of Health (the UAB MSTP training Grant: T32GM008361 and the UAB Training Program in Brain Tumor Biology: T32NS048039), the American Cancer Society RSG-14-071-01-TBG, the UAB Physician Scientist Training Program Medical Student Summer Research Training Program, and an intramural research grant from the UAB Department of Radiation Oncology.	Arbuzova A, 2002, BIOCHEM J, V362, P1, DOI 10.1042/0264-6021:3620001; Babiychuk EB, 2011, CELL DEATH DIFFER, V18, P80, DOI 10.1038/cdd.2010.81; Birge RB, 2016, CELL DEATH DIFFER, V23, P962, DOI 10.1038/cdd.2016.11; Boohaker RJ, 2012, CURR MED CHEM, V19, P3794; Brudvig JJ, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00407; Castellano Esther, 2011, Genes Cancer, V2, P261, DOI 10.1177/1947601911408079; Chaitanya GV, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-31; Chang L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.407; Chen CH, 2017, ONCOGENE, V36, P3588, DOI 10.1038/onc.2016.510; Chen CH, 2014, AM J RESP CRIT CARE, V190, P1127, DOI 10.1164/rccm.201408-1505OC; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Collatz MB, 1997, CELL CALCIUM, V21, P453, DOI 10.1016/S0143-4160(97)90056-7; Dasari S, 2014, EUR J PHARMACOL, V740, P364, DOI 10.1016/j.ejphar.2014.07.025; de Boer E, 2016, MOL IMAGING BIOL, V18, P232, DOI 10.1007/s11307-015-0892-y; Denley A, 2009, MOL CANCER RES, V7, P1132, DOI 10.1158/1541-7786.MCR-09-0068; Dinca A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020263; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Fong LWR, 2017, CANCER METAST REV, V36, P737, DOI 10.1007/s10555-017-9709-6; Fruman DA, 2017, CELL, V170, P605, DOI 10.1016/j.cell.2017.07.029; Fulda S, 2009, INT J CANCER, V124, P511, DOI 10.1002/ijc.24064; Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4; Gimple RC, 2019, CANCER DISCOV, V9, P1248, DOI 10.1158/2159-8290.CD-19-0061; Groothuis DR, 2000, NEURO-ONCOLOGY, V2, P45, DOI 10.1093/neuonc/2.1.45; Haar CP, 2012, NEUROCHEM RES, V37, P1192, DOI 10.1007/s11064-011-0701-1; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Iqbal S, 2020, ACS CHEM NEUROSCI, V11, P1944, DOI 10.1021/acschemneuro.0c00139; Jarboe JS, 2012, CLIN CANCER RES, V18, P3030, DOI 10.1158/1078-0432.CCR-11-3091; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; Kastelowitz N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04494-y; Keoni Chanel Li, 2015, J Cell Death, V8, P1, DOI 10.4137/JCD.S23844; Kepp O, 2009, APOPTOSIS, V14, P364, DOI 10.1007/s10495-008-0303-9; Krakstad C, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-135; Langhans J, 2017, ONCOGENESIS, V6, DOI 10.1038/s41389-017-0004-8; Li XM, 2016, ONCOTARGET, V7, P33440, DOI [10.18632/oncotarget.7961, 10.18632/oncotarget.6497]; Micallef J, 2009, CANCER RES, V69, P7548, DOI 10.1158/0008-5472.CAN-08-4783; Morton LA, 2013, ACS CHEM BIOL, V8, P218, DOI 10.1021/cb300429e; Nichol D, 2015, NEURO-ONCOLOGY, V17, P1183, DOI 10.1093/neuonc/nov124; Panzarini E, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.51; Rohrbach TD, 2017, ONCOL LETT, V13, P1216, DOI 10.3892/ol.2016.5550; Rohrbach TD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140870; Sarkaria JN, 2006, CLIN CANCER RES, V12, P2264, DOI 10.1158/1078-0432.CCR-05-2510; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Tanabe A, 2006, BIOCHEM BIOPH RES CO, V345, P156, DOI 10.1016/j.bbrc.2006.04.082; Tchoghandjian A, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.214; Toulany M, 2015, SEMIN CANCER BIOL, V35, P180, DOI 10.1016/j.semcancer.2015.07.003; Vadlakondalf L, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00085; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wen PY, 2012, NEURO-ONCOLOGY, V14, P819, DOI 10.1093/neuonc/nos117; Wijaya J, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122544; Willey CD, 2015, SEMIN RADIAT ONCOL, V25, P273, DOI 10.1016/j.semradonc.2015.05.008; Wlodkowic D, 2011, METHOD CELL BIOL, V103, P55, DOI 10.1016/B978-0-12-385493-3.00004-8; Zhivotovsky B, 2011, CELL CALCIUM, V50, P211, DOI 10.1016/j.ceca.2011.03.003	53	5	5	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2020	39	46					6961	6974		10.1038/s41388-020-01511-9	http://dx.doi.org/10.1038/s41388-020-01511-9		OCT 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OQ9FF	33077834	Green Accepted			2022-12-17	WOS:000579741400002
J	Broggini, T; Piffko, A; Hoffmann, CJ; Ghori, A; Harms, C; Adams, RH; Vajkoczy, P; Czabanka, M				Broggini, Thomas; Piffko, Andras; Hoffmann, Christian J.; Ghori, Adnan; Harms, Christoph; Adams, Ralf H.; Vajkoczy, Peter; Czabanka, Marcus			Ephrin-B2-EphB4 communication mediates tumor-endothelial cell interactions during hematogenous spread to spinal bone in a melanoma metastasis model	ONCOGENE			English	Article							EPHB4 RECEPTOR; IN-VIVO; EPHRIN; PROLIFERATION; ANGIOGENESIS; ENDOCYTOSIS; MECHANISMS; MIGRATION; PROMOTES; ADHESION	Metastases account for the majority of cancer deaths. Bone represents one of the most common sites of distant metastases, and spinal bone metastasis is the most common source of neurological morbidity in cancer patients. During metastatic seeding of cancer cells, endothelial-tumor cell interactions govern extravasation to the bone and potentially represent one of the first points of action for antimetastatic treatment. The ephrin-B2-EphB4 pathway controls cellular interactions by inducing repulsive or adhesive properties, depending on forward or reverse signaling. Here, we report that in an in vivo metastatic melanoma model, ephrin-B2-mediated activation of EphB4 induces tumor cell repulsion from bone endothelium, translating in reduced spinal bone metastatic loci and improved neurological function. Selective ephrin-B2 depletion in endothelial cells or EphB4 inhibition increases bone metastasis and shortens the time window to hind-limb locomotion deficit from spinal cord compression. EphB4 overexpression in melanoma cells ameliorates the metastatic phenotype and improves neurological outcome. Timely harvesting of bone tissue after tumor cell injection and intravital bone microscopy revealed less tumor cells attached to ephrin-B2-positive endothelial cells. These results suggest that ephrin-B2-EphB4 communication influences bone metastasis formation by altering melanoma cell repulsion/adhesion to bone endothelial cells, and represents a molecular target for therapeutic intervention.	[Broggini, Thomas; Piffko, Andras; Ghori, Adnan; Vajkoczy, Peter; Czabanka, Marcus] Univ Med Charite, Dept Neurosurg, D-10117 Berlin, Germany; [Broggini, Thomas] Univ Calif San Diego, Dept Phys, 9500 Gilman Dr, La Jolla, CA 92093 USA; [Piffko, Andras] Univ Med Ctr Hamburg Eppendorf, Dept Neurosurg, Martinistr 52, D-20246 Hamburg, Germany; [Hoffmann, Christian J.; Harms, Christoph] Univ Med Charite, Ctr Stroke Res Berlin, Dept Expt Neurol, D-10117 Berlin, Germany; [Adams, Ralf H.] Max Planck Inst Mol Biomed, Dept Tissue Morphogenesis, D-48149 Munster, Germany; [Adams, Ralf H.] Univ Munster, Fac Med, D-48149 Munster, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of California System; University of California San Diego; University of Hamburg; University Medical Center Hamburg-Eppendorf; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Max Planck Society; University of Munster	Czabanka, M (corresponding author), Univ Med Charite, Dept Neurosurg, D-10117 Berlin, Germany.	marcus.czabanka@charite.de	Harms, Christoph/AAD-7895-2021	Harms, Christoph/0000-0002-2063-2860; Piffko, Andras/0000-0001-5300-6594; Adams, Ralf/0000-0003-3031-7677; Hoffmann, Christian Johannes/0000-0003-0861-2418; Ghori, Adnan/0000-0003-0921-1683	German research foundation [DFG GEPRIS: 267716524]; DFG Forschergruppe [FOR2325]; Berliner Krebsgesellschaft e.V.; Early/Advanced Postdoc Mobility fellowship from the Swiss National Science Foundation; Volkswagen Foundation; Charite Foundation; Clinical Fellow Program of the Berlin Institue of Health	German research foundation(German Research Foundation (DFG)); DFG Forschergruppe(German Research Foundation (DFG)); Berliner Krebsgesellschaft e.V.; Early/Advanced Postdoc Mobility fellowship from the Swiss National Science Foundation(Swiss National Science Foundation (SNSF)); Volkswagen Foundation(Volkswagen); Charite Foundation; Clinical Fellow Program of the Berlin Institue of Health	Basic components of the cartoon are provided by Servier Medical Art. This work was supported by the German research foundation (DFG GEPRIS: 267716524) and the FOR2325 DFG Forschergruppe. TB was a doctoral student of the Charite Medical Neuroscience, NeuroCure cluster of excellence graduate school, received the Ernst von Leyden fellowship from the "Berliner Krebsgesellschaft e.V.," and the Early/Advanced Postdoc Mobility fellowship from the Swiss National Science Foundation. MC was part of the Friedrich C. Luft Clinical Scientist Pilot Program funded by the Volkswagen Foundation and the Charite Foundation and the Clinical Fellow Program of the Berlin Institue of Health. The funding sources had no involvement in study design; in the collection, analysis, and interpretation of the data; in the writing of the report; in the decision to submit the paper for publication.	Adams RH, 2000, TRENDS CARDIOVAS MED, V10, P183, DOI 10.1016/S1050-1738(00)00046-3; ARGUELLO F, 1988, CANCER RES, V48, P6876; Azab F, 2012, CLIN CANCER RES, V18, P91, DOI 10.1158/1078-0432.CCR-11-0111; Bayerl SH, 2016, GLIA, V64, P1210, DOI 10.1002/glia.22994; Bochenek ML, 2010, J CELL SCI, V123, P1235, DOI 10.1242/jcs.061903; Broggini T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162540; Broggini T, 2016, CANCER LETT, V380, P568, DOI 10.1016/j.canlet.2015.06.026; Broggini T, 2015, EUR SPINE J, V24, P2173, DOI 10.1007/s00586-015-3811-7; Chen YN, 2019, SEMIN CANCER BIOL, V56, P37, DOI 10.1016/j.semcancer.2017.10.002; Erber R, 2006, EMBO J, V25, P628, DOI 10.1038/sj.emboj.7600949; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; Foster KE, 2010, P NATL ACAD SCI USA, V107, P13414, DOI 10.1073/pnas.1003747107; Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304; Heroult M, 2006, EXP CELL RES, V312, P642, DOI 10.1016/j.yexcr.2005.10.028; Heroult M, 2010, MOL CANCER RES, V8, P1297, DOI 10.1158/1541-7786.MCR-09-0453; Holmberg J, 2006, CELL, V125, P1151, DOI 10.1016/j.cell.2006.04.030; Huehnchen P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076772; Kania A, 2016, NAT REV MOL CELL BIO, V17, P240, DOI 10.1038/nrm.2015.16; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Kusumbe AP, 2015, NAT PROTOC, V10, P1904, DOI 10.1038/nprot.2015.125; Kwak H, 2016, J CLIN INVEST, V126, P4554, DOI 10.1172/JCI87848; Laurent C, 2011, CANCER RES, V71, P666, DOI 10.1158/0008-5472.CAN-10-0605; Lin SC, 2017, DEV CELL, V41, P467, DOI 10.1016/j.devcel.2017.05.005; Macedo F, 2017, ONCOL REV, V11, P43, DOI 10.4081/oncol.2017.321; Marston DJ, 2003, NAT CELL BIOL, V5, P879, DOI 10.1038/ncb1044; Martiny-Baron G, 2010, ANGIOGENESIS, V13, P259, DOI 10.1007/s10456-010-9183-z; Matsuo K, 2012, CELL ADHES MIGR, V6, P148, DOI 10.4161/cam.20888; Noren NK, 2007, CANCER RES, V67, P3994, DOI 10.1158/0008-5472.CAN-07-0525; Nunan R, 2015, CELL REP, V13, P1380, DOI 10.1016/j.celrep.2015.09.085; Onken J, 2016, ONCOTARGET, V7, P9876, DOI 10.18632/oncotarget.7130; Patchell RA, 2005, LANCET, V366, P643, DOI 10.1016/S0140-6736(05)66954-1; Pennisi A, 2009, BLOOD, V114, P1803, DOI 10.1182/blood-2009-01-201954; Pitulescu ME, 2010, GENE DEV, V24, P2480, DOI 10.1101/gad.1973910; Sawamiphak S, 2010, NATURE, V465, P487, DOI 10.1038/nature08995; Schott AF, 2016, BREAST CANCER RES TR, V159, P87, DOI 10.1007/s10549-016-3911-z; Wang YD, 2010, NATURE, V465, P483, DOI 10.1038/nature09002; Weichselbaum RR, 2011, NAT REV CLIN ONCOL, V8, P378, DOI 10.1038/nrclinonc.2011.44; Xu R, 2018, NAT MED, V24, P823, DOI 10.1038/s41591-018-0020-z; Yang NY, 2010, PIGM CELL MELANOMA R, V23, P684, DOI 10.1111/j.1755-148X.2010.00745.x; Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012; Zimmer M, 2003, NAT CELL BIOL, V5, P869, DOI 10.1038/ncb1045	41	5	5	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2020	39	47					7063	7075		10.1038/s41388-020-01473-y	http://dx.doi.org/10.1038/s41388-020-01473-y		SEP 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OT7KA	32989254				2022-12-17	WOS:000573446900006
J	Ochieng, JK; Kundu, ST; Bajaj, R; Rodriguez, BL; Fradette, JJ; Gibbons, DL				Ochieng, Joshua Kapere; Kundu, Samrat T.; Bajaj, Rakhee; Rodriguez, B. Leticia; Fradette, Jared J.; Gibbons, Don L.			MBIP (MAP3K12 binding inhibitory protein) drives NSCLC metastasis by JNK-dependent activation of MMPs	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; OVARIAN-CANCER CELLS; MATRIX METALLOPROTEINASES; LUNG-CANCER; ACETYLTRANSFERASE COMPLEX; PROMOTES INVASION; EXPRESSION; PATHWAY; GENOME; TARGET	Metastasis is the cause for 90% of cancer-related mortalities. Identification of genetic drivers promoting dissemination of tumor cells may provide opportunities for novel therapeutic strategies. We previously reported an in vivo gain-of-function screen that identified similar to 30 genes with a functional role in metastasis promotion and characterized detailed mechanistic functions of two hits. In this study, we characterized the contribution of one of the identified genes, MBIP (MAP3K12 binding inhibitory protein), towards driving tumor invasion and metastasis. We demonstrate that expression of MBIP significantly enhances the cellular proliferation, migration and invasion of NSCLC cells in vitro and metastasis in vivo. We functionally characterized that MBIP mediates activation of the JNK pathway and induces expression of matrix metalloproteinases (MMPs), which are necessary for the invasive and metastatic phenotype. Our findings establish a novel mechanistic role of MBIP as a driver of NSCLC progression and metastasis.	[Ochieng, Joshua Kapere; Kundu, Samrat T.; Bajaj, Rakhee; Rodriguez, B. Leticia; Fradette, Jared J.; Gibbons, Don L.] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA; [Gibbons, Don L.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kundu, ST; Gibbons, DL (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.; Gibbons, DL (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	skundu@mdanderson.org; dlgibbon@mdanderson.org		Fradette, Jared/0000-0001-6712-2860; Gibbons, Don/0000-0003-2362-3094; Kundu, Samrat/0000-0002-0117-6986; Bajaj, Rakhee/0000-0002-9990-1655; Kapere Ochieng, Joshua/0000-0001-5082-3353	DoD CDMRP Lung cancer research award [W81XWH-12-16294]; NIH/NCIK [K08 CA151651]; Jeane F Shelby Scholarship Fund; University of Texas MD Anderson Lung Cancer Moon Shots Program	DoD CDMRP Lung cancer research award; NIH/NCIK; Jeane F Shelby Scholarship Fund; University of Texas MD Anderson Lung Cancer Moon Shots Program	This work was supported by the DoD CDMRP Lung cancer research award W81XWH-12-16294 and NIH/NCIK K08 CA151651. DLG is an R. Lee Clark Fellow of the University of Texas MD Anderson Cancer Center, supported by the Jeane F Shelby Scholarship Fund. The work was also supported by the generous philanthropic contributions to The University of Texas MD Anderson Lung Cancer Moon Shots Program. We would like to thank Dr. Ignacio Wistuba's lab for technical support, Jared Fredette and Laura Gibson for technical assistance and the UTMDACC Department of Veterinary Medicine Facility.	Ahn YH, 2012, J CLIN INVEST, V122, P3170, DOI 10.1172/JCI63608; Bajaj R, 2020, ONCOGENE, V39, P5979, DOI 10.1038/s41388-020-01410-z; Basu S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123979; Cheng CY, 2012, STEM CELL RES, V9, P9, DOI 10.1016/j.scr.2012.02.005; Choi Y, 2016, WORLD J GASTROENTERO, V22, P9141, DOI 10.3748/wjg.v22.i41.9141; Conlon GA, 2019, J PATHOL, V247, P629, DOI 10.1002/path.5225; Fukuyama K, 2000, J BIOL CHEM, V275, P21247, DOI 10.1074/jbc.M001488200; Gazon H, 2018, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02686; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Gibbons DL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005401; Grzeskowiak CL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04572-3; Guelman S, 2009, MOL CELL BIOL, V29, P1176, DOI 10.1128/MCB.01599-08; Harris T, 2011, CLIN CANCER RES, V17, P690, DOI 10.1158/1078-0432.CCR-10-1892; He WL, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4317-6; Inoue H, 2001, EMBO J, V20, P5421, DOI 10.1093/emboj/20.19.5421; Ispanovic E, 2006, AM J PHYSIOL-CELL PH, V291, pC579, DOI 10.1152/ajpcell.00300.2005; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Jendrzejewski J, 2016, THYROID, V26, P1276, DOI 10.1089/thy.2015.0665; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kenny HA, 2008, J CLIN INVEST, V118, P1367, DOI 10.1172/JCI33775; Konen JM, 2019, CANCERS, V11, DOI 10.3390/cancers11040462; Lee YH, 2014, TUMOR BIOL, V35, P7699, DOI 10.1007/s13277-014-2027-5; Levin PA, 2016, J THORAC ONCOL, V11, P1357, DOI 10.1016/j.jtho.2016.04.015; Li M, 2018, CHIN J INTEGR MED, V24, P40, DOI 10.1007/s11655-017-2805-1; Liotta L A, 1990, Semin Cancer Biol, V1, P99; Liu D, 2007, LUNG CANCER, V58, P384, DOI 10.1016/j.lungcan.2007.07.005; Martinotti S, 2020, METHODS MOL BIOL, V2109, P225, DOI 10.1007/7651_2019_259; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; MCDONNELL S, 1991, MOL CARCINOGEN, V4, P527, DOI 10.1002/mc.2940040617; Naglich JG, 2001, CANCER RES, V61, P8480; Olaussen KA, 2006, NEW ENGL J MED, V355, P983, DOI 10.1056/NEJMoa060570; Peng DH, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaq1238; Sathyanesan A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05656-w; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sporn MB, 1996, LANCET, V347, P1377, DOI 10.1016/S0140-6736(96)91015-6; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Stanciu AE, 2017, CLIN LAB, V63, P1613, DOI 10.7754/Clin.Lab.2017.170339; Suganuma T, 2008, NAT STRUCT MOL BIOL, V15, P364, DOI 10.1038/nsmb.1397; Suganuma T, 2010, CELL, V142, P726, DOI 10.1016/j.cell.2010.07.045; Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019; Sulminoe A, 2007, LEUKEMIA RES, V31, P1437, DOI 10.1016/j.leukres.2007.01.015; Vincenti M P, 2001, Methods Mol Biol, V151, P121; Wang FQ, 2005, INT J CANCER, V114, P19, DOI 10.1002/ijc.20697; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Zappa C, 2016, TRANSL LUNG CANCER R, V5, P288, DOI 10.21037/tlcr.2016.06.07; Zheng S, 2007, ONCOGENE, V26, P6896, DOI 10.1038/sj.onc.1210493; Zhu J, 2019, AM J TRANSL RES, V11, P3862	47	5	5	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2020	39	43					6719	6732		10.1038/s41388-020-01463-0	http://dx.doi.org/10.1038/s41388-020-01463-0		SEP 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OF2UT	32963352	Green Accepted			2022-12-17	WOS:000572030400003
J	Wang, XY; Wendel, JRH; Emerson, RE; Broaddus, RR; Creighton, CJ; Rusch, DB; Buechlein, A; DeMayo, FJ; Lydon, JP; Hawkins, SM				Wang, Xiyin; Wendel, Jillian R. H.; Emerson, Robert E.; Broaddus, Russell R.; Creighton, Chad J.; Rusch, Douglas B.; Buechlein, Aaron; DeMayo, Francesco J.; Lydon, John P.; Hawkins, Shannon M.			PtenandDicer1loss in the mouse uterus causes poorly differentiated endometrial adenocarcinoma	ONCOGENE			English	Article							DICER1 HOTSPOT MUTATIONS; EPHA2 OVEREXPRESSION; OVARIAN-CANCER; CARCINOMA; EXPRESSION; PTEN; TUMORS; RECOMMENDATIONS; IDENTIFICATION; RECURRENCE	Endometrial cancer remains the most common gynecological malignancy in the United States. While the loss of the tumor suppressor,PTEN(phosphatase and tensin homolog), is well studied in endometrial cancer, recent studies suggest thatDICER1, the endoribonuclease responsible for miRNA genesis, also plays a significant role in endometrial adenocarcinoma. Conditional uterine deletion ofDicer1andPtenin mice resulted in poorly differentiated endometrial adenocarcinomas, which expressed Napsin A and HNF1B (hepatocyte nuclear factor 1 homeobox B), markers of clear-cell adenocarcinoma. Adenocarcinomas were hormone-independent. Treatment with progesterone did not mitigate poorly differentiated adenocarcinoma, nor did it affect adnexal metastasis. Transcriptomic analyses ofDICER1deleted uteri or Ishikawa cells revealed unique transcriptomic profiles and global miRNA downregulation. Computational integration of miRNA with mRNA targets revealed deregulated let-7 and miR-16 target genes, similar to published humanDICER1-mutant endometrial cancers from TCGA (The Cancer Genome Atlas). Similar to human endometrial cancers, tumors exhibited dysregulation of ephrin-receptor signaling and transforming growth factor-beta signaling pathways. LIM kinase 2 (LIMK2), an essential molecule in p21 signal transduction, was significantly upregulated and represents a novel mechanism for hormone-independent pathogenesis of endometrial adenocarcinoma. This preclinical mouse model represents the first genetically engineered mouse model of poorly differentiated endometrial adenocarcinoma.	[Wang, Xiyin; Wendel, Jillian R. H.; Hawkins, Shannon M.] Indiana Univ Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA; [Emerson, Robert E.] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA; [Broaddus, Russell R.] Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC 27515 USA; [Creighton, Chad J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Rusch, Douglas B.; Buechlein, Aaron] Indiana Univ, Ctr Genom & Bioinformat, Bloomington, IN USA; [DeMayo, Francesco J.] Natl Inst Environm Hlth Sci, Res Triangle Pk, NC USA; [Lydon, John P.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Baylor College of Medicine; Indiana University System; Indiana University Bloomington; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Baylor College of Medicine	Hawkins, SM (corresponding author), Indiana Univ Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA.	shhawkin@iu.edu	; Hawkins, Shannon/B-7095-2015	Wang, Xiyin/0000-0002-3642-9373; Hawkins, Shannon/0000-0002-0727-3971	Indiana Clinical Translational Sciences Institute - National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award [UL1TR002529]; Uterine SPORE Career Development Award from MD Anderson Cancer Center [P50-CA098258]; Intramural Research Program of the National Institute of Environmental Health Sciences [Z1AES103311-01]	Indiana Clinical Translational Sciences Institute - National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award; Uterine SPORE Career Development Award from MD Anderson Cancer Center; Intramural Research Program of the National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We acknowledge the Indiana Center for Musculoskeletal Health Histology Core at Indiana University School of Medicine and the Human Tissue and Acquisition and Pathology Core at the Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine for histology services; the Center for Genomics and Bioinformatics for RNA sequencing, and the Center for Medical Genomics for RNA quality control analysis. We appreciate Dr. Ken Nephew for thoughtful review and comments. These studies were supported by the Indiana Clinical Translational Sciences Institute funded, in part, by Award Number UL1TR002529 from the National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. These studies were supported by a Uterine SPORE Career Development Award from MD Anderson Cancer Center P50-CA098258 (to SMH) and the Intramural Research Program of the National Institute of Environmental Health Sciences supported FJD: Project Z1AES103311-01.	Aghajanova L, 2009, ENDOCRINOLOGY, V150, P3863, DOI 10.1210/en.2009-0008; Al-Maghrabi JA, 2017, APPL IMMUNOHISTO M M, V25, P632, DOI 10.1097/PAI.0000000000000350; Dosil MA, 2017, J PATHOL, V242, P152, DOI 10.1002/path.4896; Anglesio MS, 2013, J PATHOL, V229, P400, DOI 10.1002/path.4135; Bailey MH, 2018, CELL, V174, P1034, DOI 10.1016/j.cell.2018.07.034; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bean GR, 2019, MODERN PATHOL, V32, P280, DOI 10.1038/s41379-018-0132-5; Bian Y, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010236; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen JM, 2015, J PATHOL, V237, P215, DOI 10.1002/path.4569; Chou CH, 2018, NUCLEIC ACIDS RES, V46, pD296, DOI 10.1093/nar/gkx1067; Clarke MA, 2019, J CLIN ONCOL, V37, P1895, DOI 10.1200/JCO.19.00151; Creasman WT, 2006, INT J GYNECOL OBSTET, V95, pS105, DOI 10.1016/S0020-7292(06)60031-3; Creighton CJ, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-4-r28; Creutzberg CL, 2000, LANCET, V355, P1404, DOI 10.1016/S0140-6736(00)02139-5; Daikoku T, 2008, CANCER RES, V68, P5619, DOI 10.1158/0008-5472.CAN-08-1274; de Kock L, 2020, MODERN PATHOL, V33, P1207, DOI 10.1038/s41379-019-0436-0; DeLair DF, 2017, J PATHOL, V243, P230, DOI 10.1002/path.4947; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gennarino VA, 2009, GENOME RES, V19, P481, DOI 10.1101/gr.084129.108; Gordon LB., 1993, GENEREVIEWS; Gurtan AM, 2012, RNA, V18, P1116, DOI 10.1261/rna.032680.112; Han GM, 2013, MODERN PATHOL, V26, P1594, DOI 10.1038/modpathol.2013.102; Hawkins SM, 2012, MOL ENDOCRINOL, V26, P1552, DOI 10.1210/me.2012-1042; Hawkins SM, 2011, MOL ENDOCRINOL, V25, P821, DOI 10.1210/me.2010-0371; Heravi-Moussavi A, 2012, NEW ENGL J MED, V366, P234, DOI 10.1056/NEJMoa1102903; Hoadley KA, 2018, CELL, V173, P291, DOI 10.1016/j.cell.2018.03.022; Hsu SD, 2011, NUCLEIC ACIDS RES, V39, pD163, DOI 10.1093/nar/gkq1107; Huang EY, 2015, FUTURE ONCOL, V11, P2351, DOI 10.2217/fon.15.101; Huang HY, 2020, NUCLEIC ACIDS RES, V48, pD148, DOI 10.1093/nar/gkz896; Hussain NK, 2015, P NATL ACAD SCI USA, V112, pE5883, DOI 10.1073/pnas.1518382112; Ihira K, 2017, ONCOTARGET, V8, P13509, DOI 10.18632/oncotarget.14586; Ikeda Y, 2015, BRIT J CANCER, V113, P1477, DOI 10.1038/bjc.2015.369; Jeong JW, 2005, ENDOCRINOLOGY, V146, P3490, DOI 10.1210/en.2005-0016; Ji H, 2011, PROTEOMICS, V11, P4029, DOI 10.1002/pmic.201100102; Kamat AA, 2009, CANCER-AM CANCER SOC, V115, P2684, DOI 10.1002/cncr.24335; Kim J, 2012, P NATL ACAD SCI USA, V109, P3921, DOI 10.1073/pnas.1117135109; Kriseman M, 2019, P NATL ACAD SCI USA, V116, P3873, DOI 10.1073/pnas.1806862116; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; KURMAN RJ, 1982, CANCER, V49, P2547, DOI 10.1002/1097-0142(19820615)49:12<2547::AID-CNCR2820491224>3.0.CO;2-0; Le Gallo M, 2017, CANCER-AM CANCER SOC, V123, P3261, DOI 10.1002/cncr.30745; Lim D, 2015, AM J SURG PATHOL, V39, P1061, DOI 10.1097/PAS.0000000000000436; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mashiach-Farkash E, 2012, ONCOTARGET, V3, P629; Merritt WM, 2010, CANCER BIOL THER, V10, P1306, DOI 10.4161/cbt.10.12.13582; Monsivais D, 2019, P NATL ACAD SCI USA, V116, P3883, DOI 10.1073/pnas.1806838116; MORROW CP, 1991, GYNECOL ONCOL, V40, P55, DOI 10.1016/0090-8258(91)90086-K; Munson PB, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48133-0; Murali R, 2019, INT J GYNECOL PATHOL, V38, pS40, DOI 10.1097/PGP.0000000000000491; Nikhil K, 2019, CANCER LETT, V448, P182, DOI 10.1016/j.canlet.2019.01.035; Pandita P, 2019, CANCERS, V11, DOI 10.3390/cancers11111665; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schultz KAP, 2017, CLIN CANCER RES, V23, pE76, DOI 10.1158/1078-0432.CCR-17-0629; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21601, 10.3322/caac.21590]; Soslow RA, 2019, INT J GYNECOL PATHOL, V38, pS64, DOI 10.1097/PGP.0000000000000518; Soyal SM, 2005, GENESIS, V41, P58, DOI 10.1002/gene.20098; Tashiro H, 1997, CANCER RES, V57, P3935; Torres A, 2011, TUMOR BIOL, V32, P769, DOI 10.1007/s13277-011-0179-0; Ullman-Cullere MH, 1999, LAB ANIM SCI, V49, P319; van der Horst PH, 2014, INT J CANCER, V135, P1028, DOI 10.1002/ijc.28746; Vedanayagam J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11610-1; Versluis MA, 2015, BRIT J CANCER, V113, P786, DOI 10.1038/bjc.2015.268; Vogel TJ, 2015, J GYNECOL ONCOL, V26, P25, DOI 10.3802/jgo.2015.26.1.25; Wang J, 2017, NUCLEIC ACIDS RES, V45, pW130, DOI 10.1093/nar/gkx356; Wang XJ, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317695967; Wang XY, 2017, GYNECOL ONCOL, V147, P481, DOI 10.1016/j.ygyno.2017.08.027; Wang XY, 2016, BIOL REPROD, V94, DOI 10.1095/biolreprod.115.133637; Wang YM, 2015, NEOPLASIA, V17, P650, DOI 10.1016/j.neo.2015.08.003; Wang YM, 2010, TECHNOL CANCER RES T, V9, P179, DOI 10.1177/153303461000900207; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333; Zhang B, 2014, ONCOGENE, V33, P3099, DOI 10.1038/onc.2013.281; Zighelboim I, 2011, CANCER-AM CANCER SOC, V117, P1446, DOI 10.1002/cncr.25665; Zorn KK, 2005, CLIN CANCER RES, V11, P6422, DOI 10.1158/1078-0432.CCR-05-0508	75	5	5	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2020	39	40					6286	6299		10.1038/s41388-020-01434-5	http://dx.doi.org/10.1038/s41388-020-01434-5		AUG 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NV5JK	32843721	Green Accepted, Green Submitted			2022-12-17	WOS:000562669100002
J	Lin, BY; Li, YX; Wang, TP; Qiu, YM; Chen, ZZ; Zhao, K; Lu, N				Lin, Binyan; Li, Yongxu; Wang, Tiepeng; Qiu, Yangmin; Chen, Zhenzhong; Zhao, Kai; Lu, Na			CRMP2 is a therapeutic target that suppresses the aggressiveness of breast cancer cells by stabilizing RECK	ONCOGENE			English	Article							NF-KAPPA-B; METASTASIS; VARIANCE; EMT	Metastatic breast cancer is characterized by high mortality and limited therapeutic target. During tumor metastasis, cytoskeletal reorganization is one of the key steps in the migration and invasion of breast cancer cells. Collapsin response mediator protein 2 (CRMP2) is a cytosolic phosphoprotein that plays an important role in regulating cytoskeletal dynamics. Previous researches have reported that altered CRMP2 expression is associated with breast cancer progression, but the underlying mechanism remains poorly understood. Here, we show that CRMP2 expression is reduced in various subtypes of breast cancers and negatively correlated with lymphatic metastasis. Overexpression of CRMP2 significantly inhibits invasion and stemness in breast cancer cells, while downregulation of CRMP2 promotes cell invasion, which is not required for tubulin polymerization. Mechanistic studies demonstrate that CRMP2 interacts with RECK, prevents RECK degradation, which, in turn, blocks NF-kappa B and Wnt signaling pathways. Furthermore, we find that phosphorylation of CRMP2 at T514 and S522 remarkably abolishes its functions to bind with RECK and to inhibit cell invasion. Pharmacologic rescue of CRMP2 expression suppressed breast cancer metastasis in vitro and in vivo and stimulated a synergetic effect with FN-1501 that induces CRMP2 dephosphorylation. Collectively, this study highlights the potential of CRMP2 as a therapeutic target in breast cancer metastasis and reveals a distinct mechanism of CRMP2.	[Lin, Binyan; Li, Yongxu; Wang, Tiepeng; Qiu, Yangmin; Chen, Zhenzhong; Zhao, Kai; Lu, Na] China Pharmaceut Univ, State Key Lab Nat Med, Jiangsu Key Lab Carcinogenesis & Intervent, Dept Physiol,Sch Basic Med & Clin Pharm, 24 Tongjiaxiang, Nanjing 210009, Peoples R China; [Lin, Binyan] Nanjing Univ Chinese Med, Sch Pharm, Xianlin Ave 138, Nanjing 210023, Peoples R China	China Pharmaceutical University; Nanjing University of Chinese Medicine	Zhao, K; Lu, N (corresponding author), China Pharmaceut Univ, State Key Lab Nat Med, Jiangsu Key Lab Carcinogenesis & Intervent, Dept Physiol,Sch Basic Med & Clin Pharm, 24 Tongjiaxiang, Nanjing 210009, Peoples R China.	cpuzhaokai@163.com; nalu@cpu.edu.com		Qiu, Yangmin/0000-0001-6039-7909; Wang, Tiepeng/0000-0002-0691-2882; Zhao, Kai/0000-0002-4492-6185	National Natural Science Foundation of China [81872899, 81903625]; National Science & Technology Major Project [2017ZX09101003-005023, 2017ZX09301014, 2018ZX09711001-003-007]; Social Development Project of Jiangsu Provincial Science and Technology Department [BE2018711]; Natural Science Foundation of Jiangsu Province [BK20190563]; "Double First-Class" University project [CPU2018GY17]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science & Technology Major Project; Social Development Project of Jiangsu Provincial Science and Technology Department; Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); "Double First-Class" University project	This work was supported by the National Natural Science Foundation of China (Nos. 81872899 and 81903625), the National Science & Technology Major Project (Nos. 2017ZX09101003-005023, 2017ZX09301014, and 2018ZX09711001-003-007), Social Development Project of Jiangsu Provincial Science and Technology Department (BE2018711), Natural Science Foundation of Jiangsu Province (BK20190563), and the "Double First-Class" University project (CPU2018GY17).	Abe H, 2018, SCIENCE, V360, P50, DOI 10.1126/science.aao2300; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Armstrong RA, 2002, OPHTHAL PHYSL OPT, V22, P248, DOI 10.1046/j.1475-1313.2002.00020.x; Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Deng J, 2004, MOL CARCINOGEN, V39, P139, DOI 10.1002/mc.10169; DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600-065X.2012.01099.x; Duciel L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39643-y; Farago M, 2005, CANCER RES, V65, P5792, DOI 10.1158/0008-5472.CAN-05-1021; Fife CM, 2014, BRIT J PHARMACOL, V171, P5507, DOI 10.1111/bph.12704; Geng SQ, 2014, CANCER LETT, V349, P1, DOI 10.1016/j.canlet.2014.03.036; Grant NJ, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1691-1; Huang RYJ, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.442; Kawai T, 2008, ANN NY ACAD SCI, V1143, P1, DOI 10.1196/annals.1443.020; Ma B, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00378; Matsunuma R, 2018, P NATL ACAD SCI USA, V115, pE11978, DOI 10.1073/pnas.1810598115; Matsuzaki T, 2018, BIOL OPEN, V7, DOI 10.1242/bio.033985; McDonald ES, 2016, J NUCL MED, V57, p9S, DOI 10.2967/jnumed.115.157834; Mishra P, 2019, ANN CARD ANAESTH, V22, P407, DOI 10.4103/aca.ACA_94_19; Moutal A, 2019, MOL NEUROBIOL, V56, P6736, DOI 10.1007/s12035-019-1568-4; Moutal A, 2018, MOL NEUROBIOL, V55, P4403, DOI 10.1007/s12035-017-0653-9; Oliemuller E, 2013, INT J CANCER, V132, P1986, DOI 10.1002/ijc.27881; Pastushenko I, 2019, TRENDS CELL BIOL, V29, P212, DOI 10.1016/j.tcb.2018.12.001; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Quach TT, 2015, MOL PSYCHIATR, V20, P1037, DOI 10.1038/mp.2015.77; Schlenker E, 2016, METHODS MOL BIOL, V1366, P271, DOI 10.1007/978-1-4939-3127-9_21; Schmidt EF, 2007, ADV EXP MED BIOL, V600, P1; Shih JY, 2001, JNCI-J NATL CANCER I, V93, P1392, DOI 10.1093/jnci/93.18.1392; Shih YW, 2010, CELL BIOCHEM BIOPHYS, V58, P31, DOI 10.1007/s12013-010-9091-2; Shimada K, 2014, BREAST CANCER-TOKYO, V21, P715, DOI 10.1007/s12282-013-0447-5; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Walsh LA, 2015, ONCOGENE, V34, P2189, DOI 10.1038/onc.2014.175; Wang Y, 2018, J MED CHEM, V61, P1499, DOI 10.1021/acs.jmedchem.7b01261; Wilson SM, 2012, NEUROSCIENCE, V210, P451, DOI 10.1016/j.neuroscience.2012.02.038; Wu YY, 2012, MOL CANCER RES, V10, P1597, DOI 10.1158/1541-7786.MCR-12-0155-T; Yan W, 2018, CELL PHYSIOL BIOCHEM, V47, P489, DOI 10.1159/000489983; Zardavas D, 2013, NAT REV CLIN ONCOL, V10, P191, DOI 10.1038/nrclinonc.2013.29; Zheng YR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04954-7	39	5	5	2	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2020	39	37					6024	6040		10.1038/s41388-020-01412-x	http://dx.doi.org/10.1038/s41388-020-01412-x		AUG 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NM2OY	32778769				2022-12-17	WOS:000558201400001
J	Roh, JI; Lee, J; Sung, YH; Oh, J; Hyeon, D; Kim, Y; Lee, S; Devkota, S; Kim, HJ; Park, B; Nam, T; Song, Y; Kim, Y; Hwang, D; Lee, HW				Roh, Jae-il; Lee, Jaehoon; Sung, Young-Hoon; Oh, Jahyun; Hyeon, Do Young; Kim, Yujin; Lee, Seungeon; Devkota, Sushil; Kim, Hye Jeong; Park, Bomin; Nam, Taewook; Song, Yaechan; Kim, Yonghwan; Hwang, Daehee; Lee, Han-Woong			Impaired AKT signaling and lung tumorigenesis by PIERCE1 ablation in KRAS-mutant non-small cell lung cancer	ONCOGENE			English	Article							ER STRESS; PI3K/AKT/MTOR PATHWAY; INDUCIBLE GENE; ACTIVATION; EXPRESSION; SURVIVAL; PHOSPHORYLATION; PROLIFERATION; METABOLISM; INHIBITORS	KRAS-mutant non-small cell lung cancer (NSCLC) is a major lung cancer subtype that leads to many cancer-related deaths worldwide. Although numerous studies on KRAS-mutant type NSCLC have been conducted, new oncogenic or tumor suppressive genes need to be detected because a large proportion of NSCLC patients does not respond to currently used therapeutics. Here, we show the tumor-promoting function of a cell cycle-related protein, PIERCE1, in KRAS-mutant NSCLC. Mechanistically, PIERCE1 depletion inhibits cell growth and AKT phosphorylation (pAKT) at S473, which is particularly observed in KRAS-mutant lung cancers. Analyses of AKT-related genes using microarray, immunoblotting, and real-time quantitative PCR indicated that PIERCE1 negatively regulates the gene expression of the AKT suppressor, TRIB3, through the CHOP pathway, which is a key regulatory pathway for TRIB3 expression. Similarly, in vivo analyses of PIERCE1 depletion in the KRAS mutation-related lung cancer mouse models revealed the suppressive effect of PIERCE1 knockout in urethane- and KRAS(G12D)-induced lung tumorigenesis with decreased pAKT levels observed in the tumors. Tissue microarrays of human lung cancers indicated the expression of PIERCE1 in 83% of lung cancers and its correlation with pAKT expression. Thus, we illustrate how PIERCE1 depletion may serve as a therapeutic strategy against KRAS-mutant NSCLC and propose the clinical benefit of PIERCE1.	[Roh, Jae-il; Lee, Jaehoon; Oh, Jahyun; Kim, Yujin; Lee, Seungeon; Kim, Hye Jeong; Park, Bomin; Nam, Taewook; Song, Yaechan; Lee, Han-Woong] Yonsei Univ, Dept Biochem, Coll Life Sci & Biotechnol, Seoul, South Korea; [Sung, Young-Hoon] Univ Ulsan, Coll Med, Dept Convergence Med, Seoul, South Korea; [Hyeon, Do Young; Hwang, Daehee] Seoul Natl Univ, Dept Biol Sci, Seoul, South Korea; [Devkota, Sushil] Univ Calif San Diego, Dept Cell & Dev Biol, San Diego, CA 92093 USA; [Kim, Yonghwan] Sookmyung Womens Univ, Dept Life Syst, Seoul, South Korea	Yonsei University; University of Ulsan; Seoul National University (SNU); University of California System; University of California San Diego; Sookmyung Women's University	Lee, HW (corresponding author), Yonsei Univ, Dept Biochem, Coll Life Sci & Biotechnol, Seoul, South Korea.	hwl@yonsei.ac.kr			National Research Foundation of the Republic of Korea [2018R1A2A1A05022746, 2017R1A4A1015328]; Brain Korea 21 (BK21) PLUS program	National Research Foundation of the Republic of Korea(National Research Foundation of Korea); Brain Korea 21 (BK21) PLUS program	This work was supported by the National Research Foundation of the Republic of Korea (grants 2018R1A2A1A05022746 and 2017R1A4A1015328) and in part by Brain Korea 21 (BK21) PLUS program.	Abeyrathna P, 2015, VASC PHARMACOL, V74, P38, DOI 10.1016/j.vph.2015.05.008; Barkauskas CE, 2017, DEVELOPMENT, V144, P986, DOI 10.1242/dev.140103; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Bitting RL, 2013, ENDOCR-RELAT CANCER, V20, pR83, DOI 10.1530/ERC-12-0394; Bittner N, 2014, PATHOL ONCOL RES, V20, P11, DOI 10.1007/s12253-013-9719-9; Carew JS, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.259; Chia S, 2015, CURR ONCOL, V22, P33, DOI 10.3747/co.22.2393; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Daga Aditi, 2015, Asian Pac J Cancer Prev, V16, P4147; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Erazo T, 2016, CLIN CANCER RES, V22, P2508, DOI 10.1158/1078-0432.CCR-15-1808; Eser S, 2014, BRIT J CANCER, V111, P817, DOI 10.1038/bjc.2014.215; Furic L, 2010, P NATL ACAD SCI USA, V107, P14134, DOI 10.1073/pnas.1005320107; Gangloff YG, 2004, MOL CELL BIOL, V24, P9508, DOI 10.1128/MCB.24.21.9508-9516.2004; Ghosh AP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039586; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Hung JY, 2010, LUNG CANCER, V68, P355, DOI 10.1016/j.lungcan.2009.07.017; Iurlaro R, 2016, FEBS J, V283, P2640, DOI 10.1111/febs.13598; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kim JY, 2016, MOL CANCER RES, V14, P1019, DOI 10.1158/1541-7786.MCR-15-0506; Lanczky A, 2016, BREAST CANCER RES TR, V160, P439, DOI 10.1007/s10549-016-4013-7; Lawlor MA, 2001, J CELL SCI, V114, P2903; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; Ord D, 2016, BBA-MOL CELL RES, V1863, P2668, DOI 10.1016/j.bbamcr.2016.08.003; Ord T, 2017, CURR PROTEIN PEPT SC, V18, P819, DOI 10.2174/1389203718666170406124547; Ramadori G, 2015, CELL METAB, V21, P117, DOI 10.1016/j.cmet.2014.11.020; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Rock JR, 2011, P NATL ACAD SCI USA, V108, pE1475, DOI 10.1073/pnas.1117988108; Roh JI, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193182; Roman M, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0789-x; Salazar M, 2015, CELL DEATH DIFFER, V22, P131, DOI 10.1038/cdd.2014.133; Salazar M, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.980134; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; SPERANZA G, 2012, J CLIN ONCOL S, V30; Stathopoulos GT, 2007, P NATL ACAD SCI USA, V104, P18514, DOI 10.1073/pnas.0705316104; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sung YH, 2007, MOL CELLS, V24, P409; Sung YH, 2016, SCI REP-UK, V6, DOI 10.1038/srep27932; Sung YH, 2010, CANCER RES, V70, P10454, DOI 10.1158/0008-5472.CAN-10-0031; Tomasini P, 2016, ONCOLOGIST, V21, P1450, DOI 10.1634/theoncologist.2015-0084; Toschi A, 2009, MOL CELL BIOL, V29, P1411, DOI 10.1128/MCB.00782-08; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Walter DM, 2019, NATURE, V569, P423, DOI 10.1038/s41586-019-1172-9; Wang R, 2015, ONCOTARGET, V6, P34300, DOI 10.18632/oncotarget.5549; Wang Z, 2015, ONCOGENE, V34, P4975, DOI 10.1038/onc.2014.426; Westcott PMK, 2015, NATURE, V517, P489, DOI 10.1038/nature13898; Wu KH, 2012, INT J MOL SCI, V13, P11471, DOI 10.3390/ijms130911471; Yu JSL, 2016, DEVELOPMENT, V143, P3050, DOI 10.1242/dev.137075; Zappa C, 2016, TRANSL LUNG CANCER R, V5, P288, DOI 10.21037/tlcr.2016.06.07; Zhang C, 2017, PLOS ONE, V12	55	5	5	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2020	39	36					5876	5887		10.1038/s41388-020-01399-5	http://dx.doi.org/10.1038/s41388-020-01399-5		JUL 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NJ1HO	32728173	hybrid, Green Published			2022-12-17	WOS:000553757600001
J	Lundberg, A; Lindstrom, LS; Parker, JS; Loverli, E; Perou, CM; Bergh, J; Tobin, NP				Lundberg, Arian; Lindstrom, Linda S.; Parker, Joel S.; Loverli, Elinor; Perou, Charles M.; Bergh, Jonas; Tobin, Nicholas P.			A pan-cancer analysis of the frequency of DNA alterations across cell cycle activity levels	ONCOGENE			English	Article							GENE-EXPRESSION SIGNATURES; MOLECULAR CLASSIFICATION; DIVISION CYCLE; RESOURCE	Pan-cancer genomic analyses based on the magnitude of pathway activity are currently lacking. Focusing on the cell cycle, we examined the DNA mutations and chromosome arm-level aneuploidy within tumours with low, intermediate and high cell-cycle activity in 9515 pan-cancer patients with 32 different tumour types. Boxplots showed that cell-cycle activity varied broadly across and within all cancers.TP53andPIK3CAmutations were common in all cell cycle score (CCS) tertiles but with increasing frequency as cell-cycle activity levels increased (P < 0.001). Mutations inBRAFand gains in 16p were less frequent in CCS High tumours (P < 0.001). In Kaplan-Meier analysis, patients whose tumours were CCS Low had a longer Progression Free Interval (PFI) relative to Intermediate or High (P < 0.001) and this significance remained in multivariable analysis (CCS Intermediate: HR = 1.37; 95% CI 1.17-1.60, CCS High: 1.54; 1.29-1.84, CCS Low = Ref). These results demonstrate that whilst similar DNA alterations can be found at all cell-cycle activity levels, some notable exceptions exist. Moreover, independent prognostic information can be derived on a pan-cancer level from a simple measure of cell-cycle activity.	[Lundberg, Arian; Loverli, Elinor; Bergh, Jonas; Tobin, Nicholas P.] Karolinska Inst, Dept Oncol & Pathol, Stockholm, Sweden; [Lundberg, Arian; Lindstrom, Linda S.; Loverli, Elinor; Bergh, Jonas; Tobin, Nicholas P.] Univ Hosp, Stockholm, Sweden; [Lundberg, Arian] Stanford Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA; [Lindstrom, Linda S.] Karolinska Inst, Dept Biosci & Nutr, Stockholm, Sweden; [Parker, Joel S.; Perou, Charles M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Genet, Chapel Hill, NC 27515 USA; [Perou, Charles M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pathol & Lab Med, Chapel Hill, NC 27515 USA; [Bergh, Jonas] Univ Oxford, Dept Publ Hlth, Oxford, England	Karolinska Institutet; Stanford University; Karolinska Institutet; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Oxford	Tobin, NP (corresponding author), Karolinska Inst, Dept Oncol & Pathol, Stockholm, Sweden.; Tobin, NP (corresponding author), Univ Hosp, Stockholm, Sweden.	nick.tobin@ki.se	Lundberg, Arian/AAD-2244-2022; Lundberg, Arian/AAX-7213-2021; Perou, Charles M/H-9934-2014	Lundberg, Arian/0000-0002-6630-2787; Perou, Charles M/0000-0001-9827-2247; Bergh, Jonas/0000-0001-5526-1847; Tobin, Nicholas/0000-0003-2343-9772	Iris, Stig och Gerry Castenbacks Stiftelse for cancer research; King Gustaf V Jubilee Foundation; BRECT; Swedish Cancer Society; Cancer Society in Stockholm Personalised Cancer Medicine (PCM); Swedish Breast Cancer Association (BRO); Swedish Research Council; NCI Breast SPORE program [P50-CA58223-09A1]; Susan G. Komen [SAC-160074]; Breast Cancer Research Foundation;  [R01-CA195754-01]	Iris, Stig och Gerry Castenbacks Stiftelse for cancer research; King Gustaf V Jubilee Foundation; BRECT; Swedish Cancer Society(Swedish Cancer Society); Cancer Society in Stockholm Personalised Cancer Medicine (PCM); Swedish Breast Cancer Association (BRO); Swedish Research Council(Swedish Research CouncilEuropean Commission); NCI Breast SPORE program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G. Komen(Susan G. Komen Breast Cancer Foundation); Breast Cancer Research Foundation; 	This work was supported by the Iris, Stig och Gerry Castenbacks Stiftelse for cancer research (to NPT), the King Gustaf V Jubilee Foundation (NPT and JB), BRECT, the Swedish Cancer Society, the Cancer Society in Stockholm Personalised Cancer Medicine (PCM), the King Gustaf V Jubilee Foundation, the Swedish Breast Cancer Association (BRO) and the Swedish Research Council (J. Bergh). CMP was supported by funds from the NCI Breast SPORE program (P50-CA58223-09A1), by R01-CA195754-01, by the Susan G. Komen (SAC-160074) and the Breast Cancer Research Foundation.	Asp M, 2020, BIOESSAYS, V42, DOI 10.1002/bies.201900221; Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Chen JD, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026104; Desmedt C, 2008, CLIN CANCER RES, V14, P5158, DOI 10.1158/1078-0432.CCR-07-4756; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; Gray KA, 2015, NUCLEIC ACIDS RES, V43, pD1079, DOI 10.1093/nar/gku1071; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; Hoadley KA, 2018, CELL, V173, P291, DOI 10.1016/j.cell.2018.03.022; Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049; Kanehisa M, 2016, NUCLEIC ACIDS RES, V44, pD457, DOI 10.1093/nar/gkv1070; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Lundberg A, 2017, CLIN CANCER RES, V23, P7512, DOI 10.1158/1078-0432.CCR-17-1535; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Santos A, 2015, NUCLEIC ACIDS RES, V43, pD1140, DOI 10.1093/nar/gku1092; Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289; Sparano JA, 2019, NEW ENGL J MED, V380, P2395, DOI 10.1056/NEJMoa1904819; Taylor AM, 2018, CANCER CELL, V33, P676, DOI 10.1016/j.ccell.2018.03.007; Team RC., 2022, R LANG ENV STAT COMP; Tobin NP, 2017, CLIN CANCER RES, V23, P7225, DOI 10.1158/1078-0432.CCR-17-2301; Tobin NP, 2014, MOL ONCOL, V8, P741, DOI 10.1016/j.molonc.2014.02.007; Turner NC, 2019, J CLIN ONCOL, V37, P1169, DOI 10.1200/JCO.18.00925	27	5	5	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2020	39	32					5430	5440		10.1038/s41388-020-1367-4	http://dx.doi.org/10.1038/s41388-020-1367-4		JUN 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW4DS	32581248	Green Submitted, Green Accepted			2022-12-17	WOS:000543161100001
J	Frangez, Z; Fernandez-Marrero, Y; Stojkov, D; Jafari, SMS; Hunger, RE; Djonov, V; Riether, C; Simon, HU				Frangez, Ziva; Fernandez-Marrero, Yuniel; Stojkov, Darko; Jafari, S. Morteza Seyed; Hunger, Robert E.; Djonov, Valentin; Riether, Carsten; Simon, Hans-Uwe			BIF-1 inhibits both mitochondrial and glycolytic ATP production: its downregulation promotes melanoma growth	ONCOGENE			English	Article							INTERACTING FACTOR-I; BAX; METABOLISM; PROTEIN; DOMAIN; EXPRESSION; GENERATION; CURVATURE; MEMBRANES; METFORMIN	Endophilin B1, also known as BAX-interacting protein 1 (BIF-1), is part of the endophilin B protein family, and is a multifunctional protein involved in the regulation of apoptosis, autophagy, and mitochondrial morphology. The role of BIF-1 in cancer is controversial since previous reports indicated to both tumor-promoting and tumor-suppressive roles, perhaps depending on the cancer cell type. In the present study, we report that BIF-1 is significantly downregulated in both primary and metastatic melanomas, and that patients with high levels of BIF-1 expression exhibited a better overall survival. Depleting BIF-1 using CRISPR/Cas9 technology in melanoma cells resulted in higher proliferation rates both in vitro and in vivo, a finding that was associated with increased ATP production, metabolic acidification, and mitochondrial respiration. We also observed mitochondrial hyperpolarization, but no increase in the mitochondrial content of BIF-1-knockout melanoma cells. In contrast, such knockout melanoma cells were equally sensitive to anticancer drug- or UV irradiation-induced cell death, and exhibited similar autophagic activities as compared with control cells. Taken together, it appears that downregulation of BIF-1 contributes to tumorigenesis in cutaneous melanoma by upregulating mitochondrial respiration and metabolism, independent of its effect on apoptosis and autophagy.	[Frangez, Ziva; Fernandez-Marrero, Yuniel; Stojkov, Darko; Simon, Hans-Uwe] Univ Bern, Inst Pharmacol, Bern, Switzerland; [Jafari, S. Morteza Seyed; Hunger, Robert E.] Univ Bern, Bern Univ Hosp, Dept Dermatol, Inselspital, Bern, Switzerland; [Djonov, Valentin] Univ Bern, Inst Anat, Bern, Switzerland; [Riether, Carsten] Univ Bern, Dept Biomed Res, Tumor Immunol, Bern, Switzerland; [Riether, Carsten] Univ Bern, Bern Univ Hosp, Dept Med Oncol, Inselspital, Bern, Switzerland; [Simon, Hans-Uwe] Sechenov Univ, Dept Clin Immunol & Allergol, Moscow, Russia	University of Bern; University of Bern; University Hospital of Bern; University of Bern; University of Bern; University of Bern; University Hospital of Bern; Sechenov First Moscow State Medical University	Simon, HU (corresponding author), Univ Bern, Inst Pharmacol, Bern, Switzerland.; Simon, HU (corresponding author), Sechenov Univ, Dept Clin Immunol & Allergol, Moscow, Russia.	hus@pki.unibe.ch	Jafari, S. Morteza Seyed/AAV-9160-2020; Simon, Hans-Uwe/AAU-7410-2020; Riether, Carsten/ABC-7699-2021; Riether, Carsten/K-8603-2013	Jafari, S. Morteza Seyed/0000-0002-6466-2199; Simon, Hans-Uwe/0000-0002-9404-7736; Riether, Carsten/0000-0001-7512-513X; Riether, Carsten/0000-0001-7512-513X; Frangez, Ziva/0000-0002-9164-7656	Swiss National Science Foundation [310030_184816]; European Union [642295]; Microscopy Imaging Center of the University of Bern	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); European Union(European Commission); Microscopy Imaging Center of the University of Bern	This work was supported by the Swiss National Science Foundation (310030_184816 to H.U.S.) and the European Union Horizon 2020 Research and Innovation Program (Marie Sklodowska-Curie grant No. 642295; MEL-PLEX). Z.F. is a PhD student of the Graduate School of Cellular and Biomedical Sciences of the University of Bern. Images were acquired on equipment supported by the Microscopy Imaging Center of the University of Bern.	Amini P, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05387-y; Bankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5; Coppola D, 2008, CANCER-AM CANCER SOC, V113, P2665, DOI 10.1002/cncr.23892; Cuddeback SM, 2001, J BIOL CHEM, V276, P20559, DOI 10.1074/jbc.M101527200; Diepart C, 2012, CANCER RES, V72, P482, DOI 10.1158/0008-5472.CAN-11-1755; El-Mir MY, 2000, J BIOL CHEM, V275, P223, DOI 10.1074/jbc.275.1.223; Fan RG, 2012, ONCOL LETT, V3, P851, DOI 10.3892/ol.2012.562; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; Giachino C, 1997, GENOMICS, V41, P427, DOI 10.1006/geno.1997.4645; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huttner WB, 2000, CURR OPIN NEUROBIOL, V10, P543, DOI 10.1016/S0959-4388(00)00126-4; Jiao L, 2018, AUTOPHAGY, V14, P671, DOI 10.1080/15548627.2017.1381804; Karbowski M, 2004, J CELL BIOL, V166, P1027, DOI 10.1083/jcb.200407046; Kim SY, 2008, PATHOLOGY, V40, P553, DOI 10.1080/00313020802320440; Kjaerulff O, 2011, CELL BIOCHEM BIOPHYS, V60, P137, DOI 10.1007/s12013-010-9137-5; Koritzinsky M, 2015, INT J RADIAT ONCOL, V93, P454, DOI 10.1016/j.ijrobp.2015.06.003; Liu H, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005864; Loll PJ, 2008, ACTA CRYSTALLOGR F, V64, P243, DOI 10.1107/S1744309108007574; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Masuda M, 2006, EMBO J, V25, P2889, DOI 10.1038/sj.emboj.7601176; Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314; Mishra P, 2016, J CELL BIOL, V212, P379, DOI 10.1083/jcb.201511036; Moreno-Sanchez R, 2007, FEBS J, V274, P1393, DOI 10.1111/j.1742-4658.2007.05686.x; Pierrat B, 2001, GENOMICS, V71, P222, DOI 10.1006/geno.2000.6378; Rozman S, 2015, CELL DEATH DIFFER, V22, P445, DOI 10.1038/cdd.2014.169; Schlauder SM, 2009, J CUTAN PATHOL, V36, P21, DOI 10.1111/j.1600-0560.2007.00945.x; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Simon N, 1998, FEBS LETT, V435, P25, DOI 10.1016/S0014-5793(98)01033-3; Takahashi Y, 2005, MOL CELL BIOL, V25, P9369, DOI 10.1128/MCB.25.21.9369-9382.2005; Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634; Takahashi Y, 2011, AUTOPHAGY, V7, P61, DOI 10.4161/auto.7.1.14015; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang DB, 2014, J NEUROSCI, V34, P2674, DOI 10.1523/JNEUROSCI.4074-13.2014; Weinberg SE, 2015, NAT CHEM BIOL, V11, P9, DOI 10.1038/nchembio.1712; Wheaton WW, 2014, ELIFE, V3, DOI 10.7554/eLife.02242; Xu L, 2016, ONCOL REP, V36, P3513, DOI 10.3892/or.2016.5172; Yamaguchi H, 2008, J BIOL CHEM, V283, P19112, DOI 10.1074/jbc.M709882200; Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014; Zannella VE, 2013, CLIN CANCER RES, V19, P6741, DOI 10.1158/1078-0432.CCR-13-1787	39	5	6	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 25	2020	39	26					4944	4955		10.1038/s41388-020-1339-8	http://dx.doi.org/10.1038/s41388-020-1339-8		JUN 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MQ2YO	32493957				2022-12-17	WOS:000537926600001
J	Al-Zahrani, KN; Abou-Hamad, J; Cook, DP; Prycel, BR; Hodgins, JJ; Labreche, C; Robineau-Charette, P; de Souza, CT; Bell, JC; Auer, RC; Ardolino, M; Vanderhyden, BC; Sabourin, LA				Al-Zahrani, Khalid N.; Abou-Hamad, John; Cook, David P.; Prycel, Benjamin R.; Hodgins, Jonathan J.; Labreche, Cedrik; Robineau-Charette, Pascale; de Souza, Christiano T.; Bell, John C.; Auer, Rebecca C.; Ardolino, Michele; Vanderhyden, Barbara C.; Sabourin, Luc A.			Loss of the Ste20-like kinase induces a basal/stem-like phenotype in HER2-positive breast cancers	ONCOGENE			English	Article							MOUSE MODELS; SLK; ACTIVATION; CELLS; EXPRESSION; SOX10	HER2 is overexpressed in 20-30% of all breast cancers and is associated with an invasive disease and poor clinical outcome. The Ste20-like kinase (SLK) is activated downstream of HER2/Neu and is required for efficient epithelial-to-mesenchymal transition, cell cycle progression, and migration in the mammary epithelium. Here we show that loss of SLK in a murine model of HER2/Neu-positive breast cancers significantly accelerates tumor onset and decreases overall survival. Transcriptional profiling of SLK knockout HER2/Neu-derived tumor cells revealed a strong induction in the triple-negative breast cancer marker, Sox10, accompanied by an increase in mammary stem/progenitor activity. Similarly, we demonstrate that SLK and Sox10 expression are inversely correlated in patient samples, with the loss of SLK and acquisition of Sox10 marking the triple-negative subtype. Furthermore, pharmacological inhibition of AKT reduces SLK-null tumor growth in vivo and is rescued by ectopic Sox10 expression, suggesting that Sox10 is a critical regulator of tumor growth downstream of SLK/AKT. These findings highlight a role for SLK in negatively regulating HER2-induced mammary tumorigenesis and provide mechanistic insight into the regulation of Sox10 expression in breast cancer.	[Al-Zahrani, Khalid N.; Abou-Hamad, John; Cook, David P.; Prycel, Benjamin R.; Hodgins, Jonathan J.; Labreche, Cedrik; Robineau-Charette, Pascale; de Souza, Christiano T.; Bell, John C.; Auer, Rebecca C.; Ardolino, Michele; Vanderhyden, Barbara C.; Sabourin, Luc A.] Ottawa Hosp Res Inst, Ctr Canc Therapeut, Ottawa, ON K1H 8L6, Canada; [Al-Zahrani, Khalid N.; Abou-Hamad, John; Cook, David P.; Prycel, Benjamin R.; Labreche, Cedrik; Robineau-Charette, Pascale; Vanderhyden, Barbara C.; Sabourin, Luc A.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; [Hodgins, Jonathan J.; Bell, John C.; Auer, Rebecca C.; Ardolino, Michele] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada; [Auer, Rebecca C.] Univ Ottawa, Dept Surg, Ottawa, ON K1H 8M5, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; University of Ottawa	Sabourin, LA (corresponding author), Ottawa Hosp Res Inst, Ctr Canc Therapeut, Ottawa, ON K1H 8L6, Canada.; Sabourin, LA (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada.	lsabourin@ohri.ca		Al-Zahrani, Khalid/0000-0001-5771-7537; Ardolino, Michele/0000-0003-4114-0985; Cook, David/0000-0001-7639-6724; Abou-Hamad, John/0000-0003-0138-1821	Canadian Breast Cancer Foundation; Canadian Institutes of Health Research; Ontario Graduate Scholarship; Cancer Research Society; Canadian Cancer Society Research Institute	Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Ontario Graduate Scholarship(Ontario Graduate Scholarship); Cancer Research Society; Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS))	KNA-Z and BRP are funded by the Canadian Breast Cancer Foundation. JA-H, JJH, and DPC are funded by scholarships from the Canadian Institutes of Health Research. PR-C is funded by an Ontario Graduate Scholarship. This study was supported by grants from the Canadian Breast Cancer Foundation, the Cancer Research Society, the Canadian Institutes of Health Research and the Canadian Cancer Society Research Institute. This work was also supported in part by a generous donation from Mr Eugene Tasse.	Al-Zahrani Khalid N, 2018, Oncotarget, V9, P33348, DOI 10.18632/oncotarget.26072; Al-Zahrani KN, 2013, CELL ADHES MIGR, V7, P1, DOI 10.4161/cam.22495; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Burnett JP, 2015, SCI REP-UK, V5, DOI 10.1038/srep15821; Chan CT, 2005, BREAST CANCER RES TR, V91, P187, DOI 10.1007/s10549-004-7715-1; Chen ZY, 2014, DEVELOPMENT, V141, P2691, DOI 10.1242/dev.108944; Cimino-Mathews A, 2013, HUM PATHOL, V44, P959, DOI 10.1016/j.humpath.2012.09.005; Conway J, 2017, ONCOTARGET, V8, P98745, DOI 10.18632/oncotarget.21928; Cossu-Rocca P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141763; Costa RLB, 2018, BREAST CANCER RES TR, V169, P397, DOI 10.1007/s10549-018-4697-y; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; Dillon RL, 2009, CANCER RES, V69, P5057, DOI 10.1158/0008-5472.CAN-08-4287; Dravis C, 2018, CANCER CELL, V34, P466, DOI 10.1016/j.ccell.2018.08.001; Dravis C, 2015, CELL REP, V12, P2035, DOI 10.1016/j.celrep.2015.08.040; Guilluy C, 2008, CIRC RES, V102, P1265, DOI 10.1161/CIRCRESAHA.107.164764; Gullick WJ, 1998, BREAST CANCER RES TR, V52, P43, DOI 10.1023/A:1006107016969; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Hirschmann-Jax C, 2004, P NATL ACAD SCI USA, V101, P14228, DOI 10.1073/pnas.0400067101; Hutchinson JN, 2004, CANCER RES, V64, P3171, DOI 10.1158/0008-5472.CAN-03-3465; Kim SB, 2017, LANCET ONCOL, V18, P1360, DOI 10.1016/S1470-2045(17)30450-3; Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014; Liu H, 2018, CANCER DISCOV, V8, P354, DOI 10.1158/2159-8290.CD-17-0679; MANSOUR EG, 1994, CANCER, V74, P381, DOI 10.1002/cncr.2820741326; Menard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E; Neuzil J, 2007, BIOCHEM BIOPH RES CO, V355, P855, DOI 10.1016/j.bbrc.2007.01.159; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pryce BR, 2017, SKELET MUSCLE, V7, DOI 10.1186/s13395-016-0119-1; Roovers K, 2009, ONCOGENE, V28, P2839, DOI 10.1038/onc.2009.146; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Ursini-Siegel J, 2008, EMBO J, V27, P910, DOI 10.1038/emboj.2008.22; Wang K, 2018, NEOPLASMA, V65, P185, DOI 10.4149/neo_2018_170318N193; Wisinski KB, 2016, CLIN CANCER RES, V22, P2659, DOI 10.1158/1078-0432.CCR-15-2365; Wolff AC, 2007, ARCH PATHOL LAB MED, V131, P18, DOI 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2; Zuo Y, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-0966-2	35	5	5	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	23					4592	4602		10.1038/s41388-020-1315-3	http://dx.doi.org/10.1038/s41388-020-1315-3		MAY 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LU5ZF	32393835				2022-12-17	WOS:000531771800001
J	Feng, JB; Zhang, Y; Ren, X; Li, D; Fu, HJ; Liu, CH; Zhou, W; Liu, Q; Liu, Q; Wu, MH				Feng, Jianbo; Zhang, Yan; Ren, Xing; Li, Di; Fu, Haijuan; Liu, Changhong; Zhou, Wen; Liu, Qing; Liu, Qiang; Wu, Minghua			Leucine-rich repeat containing 4 act as an autophagy inhibitor that restores sensitivity of glioblastoma to temozolomide	ONCOGENE			English	Article							COLORECTAL-CANCER; GLIOMA-CELLS; BETA-TRCP; RESISTANCE; MTOR; CHEMORESISTANCE; PROLIFERATION; EXPRESSION; APOPTOSIS; CYTOKINE	Temozolomide (TMZ) insensitivity and resistance are major causes of treatment failure and poor prognosis for GBM patients. Here, we identify LRRC4 as a novel autophagy inhibitor that restores the sensitivity of GBMs to TMZ. LRRC4 was associated with the DEPTOR/mTOR complex, and this interaction resulted in autophagy inhibition. Further investigation demonstrated that the PDZ binding domain of LRRC4 binds to the PDZ domain of DEPTOR. This binding decreases the half-life of DEPTOR via ubiquitination, thus inhibiting GBM cell autophagy and increasing the TMZ treatment response of GBM. Combined LRRC4 expression and TMZ treatment prolonged the survival of mice with tumour xenografts. Furthermore, the levels of LRRC4, DEPTOR and autophagy are clinically relevant for GBM, indicating that LRRC4 is likely to have significant potential as a therapeutic marker and target for TMZ treatment in glioma patients.	[Feng, Jianbo; Zhang, Yan; Ren, Xing; Li, Di; Fu, Haijuan; Liu, Changhong; Wu, Minghua] Cent South Univ, Hunan Prov Tumor Hosp, Changsha 410006, Hunan, Peoples R China; [Feng, Jianbo; Zhang, Yan; Ren, Xing; Li, Di; Fu, Haijuan; Liu, Changhong; Wu, Minghua] Cent South Univ, Xiangya Med Sch, Affiliated Tumor Hosp, Changsha 410006, Hunan, Peoples R China; [Feng, Jianbo; Zhang, Yan; Ren, Xing; Li, Di; Fu, Haijuan; Liu, Changhong; Zhou, Wen; Wu, Minghua] Cent South Univ, Canc Res Inst, Sch Basic Med Sci, Changsha 410078, Hunan, Peoples R China; [Feng, Jianbo; Zhang, Yan; Ren, Xing; Li, Di; Fu, Haijuan; Liu, Changhong; Zhou, Wen; Wu, Minghua] Minist Educ, Key Lab Carcinogenesis & Canc Invas, Changsha 410078, Hunan, Peoples R China; [Feng, Jianbo; Zhang, Yan; Ren, Xing; Li, Di; Fu, Haijuan; Liu, Changhong; Zhou, Wen; Wu, Minghua] Minist Hlth, Key Lab Carcinogenesis, Changsha 410078, Hunan, Peoples R China; [Liu, Changhong] Shandong Univ, Hosp 2, Inst Med Sci, Jinan 250033, Shandong, Peoples R China; [Liu, Qing] Cent South Univ, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China; [Liu, Qiang] Cent South Univ, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China	Central South University; Central South University; Central South University; Shandong University; Central South University; Central South University	Wu, MH (corresponding author), Cent South Univ, Hunan Prov Tumor Hosp, Changsha 410006, Hunan, Peoples R China.; Wu, MH (corresponding author), Cent South Univ, Xiangya Med Sch, Affiliated Tumor Hosp, Changsha 410006, Hunan, Peoples R China.; Wu, MH (corresponding author), Cent South Univ, Canc Res Inst, Sch Basic Med Sci, Changsha 410078, Hunan, Peoples R China.; Wu, MH (corresponding author), Minist Educ, Key Lab Carcinogenesis & Canc Invas, Changsha 410078, Hunan, Peoples R China.; Wu, MH (corresponding author), Minist Hlth, Key Lab Carcinogenesis, Changsha 410078, Hunan, Peoples R China.	wuminghua554@aliyun.com			National Natural Science Foundation of China [81874150]; Graduate Student Research Innovation Project in Hunan Province [2019zzts084]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Graduate Student Research Innovation Project in Hunan Province	This works was supported by the National Natural Science Foundation of China (Grant No. 81874150) and Graduate Student Research Innovation Project in Hunan Province (2019zzts084).	Catena V, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0484-y; Chin SF, 2007, ONCOGENE, V26, P1959, DOI 10.1038/sj.onc.1209985; Cosin-Roger J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00213-3; Duan SS, 2011, MOL CELL, V44, P317, DOI 10.1016/j.molcel.2011.09.005; Dunlop EA, 2014, SEMIN CELL DEV BIOL, V36, P121, DOI 10.1016/j.semcdb.2014.08.006; Dunn GP, 2012, GENE DEV, V26, P756, DOI 10.1101/gad.187922.112; Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007; Ghavami S, 2014, PROG NEUROBIOL, V112, P24, DOI 10.1016/j.pneurobio.2013.10.004; Guo JY, 2013, CELL, V155, P1216, DOI 10.1016/j.cell.2013.11.019; Hale AN, 2013, AUTOPHAGY, V9, P951, DOI 10.4161/auto.24273; Hombach-Klonisch S, 2018, PHARMACOL THERAPEUT, V184, P13, DOI 10.1016/j.pharmthera.2017.10.017; Hori YS, 2015, J NEURO-ONCOL, V122, P11, DOI 10.1007/s11060-014-1686-9; Huang J, 2011, ANTIOXID REDOX SIGN, V14, P2215, DOI 10.1089/ars.2010.3554; Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161; Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487; Kim S, 2006, NAT NEUROSCI, V9, P1294, DOI 10.1038/nn1763; Li PY, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01748; Li PY, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-266; Masui K, 2012, NEUROPATH APPL NEURO, V38, P271, DOI 10.1111/j.1365-2990.2011.01238.x; Menzies FM, 2017, NEURON, V93, P1015, DOI 10.1016/j.neuron.2017.01.022; Minghua W, 2010, J CELL BIOCHEM, V103, P245; Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751; Murat A, 2008, J CLIN ONCOL, V26, P3015, DOI 10.1200/JCO.2007.15.7164; Nanegrungsunk D, 2015, NEUROL RES, V37, P167, DOI 10.1179/1743132814Y.0000000423; Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Soto F, 2018, ELIFE, V7, DOI 10.7554/eLife.30388; Um SM, 2018, CELL REP, V23, P3839, DOI 10.1016/j.celrep.2018.05.087; Wang JR, 2002, PROG BIOCHEM BIOPHYS, V29, P233; Wang QD, 2018, CANCER RES, V78, P3163, DOI 10.1158/0008-5472.CAN-17-3107; Wang ZY, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0355-1; Wang ZW, 2012, NEOPLASIA, V14, P368, DOI 10.1593/neo.12542; White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262; Wick W, 2014, CANCER DISCOV, V4, P1120, DOI 10.1158/2159-8290.CD-14-0918; Woo J, 2009, NAT NEUROSCI, V12, P428, DOI 10.1038/nn.2279; Wu MH, 2008, J CELL PHYSIOL, V214, P65, DOI 10.1002/jcp.21163; Wu MH, 2006, MOL BIOL CELL, V17, P3534, DOI 10.1091/mbc.E05-11-1082; Xu G, 2015, J NEUROSCI, V35, P7153, DOI 10.1523/JNEUROSCI.4726-14.2015; Yan YL, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0303-5; Yang ZNJ, 2011, CANCER BIOL THER, V11, P169, DOI 10.4161/cbt.11.2.14663; Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008; Yu TF, 2018, CANCER LETT, V433, P210, DOI 10.1016/j.canlet.2018.06.041; Zanotto-Filho A, 2015, CANCER LETT, V358, P220, DOI 10.1016/j.canlet.2014.12.044; Zhang W, 2008, GENES BRAIN BEHAV, V7, P385, DOI 10.1111/j.1601-183X.2007.00361.x; Zhao YC, 2011, MOL CELL, V44, P304, DOI 10.1016/j.molcel.2011.08.029; Zhou WC, 2017, CELL STEM CELL, V21, P591, DOI 10.1016/j.stem.2017.10.002	48	5	5	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	23					4551	4566		10.1038/s41388-020-1312-6	http://dx.doi.org/10.1038/s41388-020-1312-6		MAY 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LU5ZF	32372061	Green Published, hybrid			2022-12-17	WOS:000530617200002
J	Rao, HY; Li, XF; Liu, M; Liu, J; Li, XX; Xu, J; Li, L; Gao, WQ				Rao, Hanyu; Li, Xuefeng; Liu, Min; Liu, Jing; Li, Xiaoxue; Xu, Jin; Li, Li; Gao, Wei-Qiang			Di-Ras2 promotes renal cell carcinoma formation by activating the mitogen-activated protein kinase pathway in the absence of von Hippel-Lindau protein	ONCOGENE			English	Article							COMPREHENSIVE MOLECULAR CHARACTERIZATION; TUMOR-SUPPRESSOR; SIGNALING PATHWAYS; UBIQUITINATION; RAS; VHL; INHIBITION; LANDSCAPE; NECROSIS; DRIVER	Clear cell renal cell carcinoma (ccRCC) is one of the most common and lethal human urological malignancies in the world. One of the pathological drivers for ccRCC is the Ras family of small GTPases that function as "molecular switches" in many diseases including ccRCC. Among the GTPases in the Di-Ras family, DIRAS2 gene encodes a GTPase that shares 60% homology to Ras and Rap. Yet little is known about the biological function(s) of Di-Ras2 or how its activities are regulated. In this study, we focused on Di-Ras2, and determined its functions and underlying mechanism during formation of ccRCC. We found that Di-Ras2 was upregulated in ccRCC, and promoted the proliferation, migration and invasion of human ccRCC cells in the absence of von Hippel-Lindau protein (pVHL). Mechanistically, Di-Ras2 induces and regulates ccRCC formation by modulating phosphorylation of the downstream effectors and activating the Ras/mitogen-activated protein kinase (MAPK) signaling pathway. Moreover, Di-Ras2 interacts with E3 ubiquitin ligase, pVHL, which facilitates the ubiquitination and degradation of Di-Ras2. Together, these results indicate a potential function of Di-Ras2 as an oncogene in ccRCC, and these data provide a new perspective of the relationship between pVHL and the MAPK pathway in ccRCC tumorigenesis.	[Rao, Hanyu; Li, Xuefeng; Liu, Min; Liu, Jing; Li, Xiaoxue; Li, Li; Gao, Wei-Qiang] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Renji Med X Clin Stem Cell Res Ctr, Ren Ji Hosp,Sch Med, Shanghai 200127, Peoples R China; [Rao, Hanyu; Li, Xuefeng; Liu, Min; Liu, Jing; Li, Xiaoxue; Xu, Jin; Li, Li; Gao, Wei-Qiang] Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai 200127, Peoples R China; [Rao, Hanyu; Liu, Min; Liu, Jing; Li, Xiaoxue; Xu, Jin; Li, Li; Gao, Wei-Qiang] Shanghai Jiao Tong Univ, Med X Res Inst, Shanghai, Peoples R China; [Li, Xuefeng] Univ South China, Affiliated Hosp 1, Dept Med Oncol, Hengyang 421001, Hunan, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; University of South China	Li, L; Gao, WQ (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Renji Med X Clin Stem Cell Res Ctr, Ren Ji Hosp,Sch Med, Shanghai 200127, Peoples R China.; Li, L; Gao, WQ (corresponding author), Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai 200127, Peoples R China.; Li, L; Gao, WQ (corresponding author), Shanghai Jiao Tong Univ, Med X Res Inst, Shanghai, Peoples R China.	lil@sjtu.edu.cn; gao.weiqiang@sjtu.edu.cn	Gao, Wei/GXH-0380-2022	Li, Li/0000-0003-2342-3658				Alonso-Gordoa T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081901; Alt AL, 2011, CANCER-AM CANCER SOC, V117, P2873, DOI 10.1002/cncr.25836; Aoki Y, 2008, HUM MUTAT, V29, P992, DOI 10.1002/humu.20748; Banumathy G, 2010, CANCER BIOL THER, V10, P658, DOI 10.4161/cbt.10.7.13247; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Brinkmann K, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00098; Brodaczewska KK, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0565-8; Chitalia VC, 2008, NAT CELL BIOL, V10, P1208, DOI 10.1038/ncb1781; Chittiboina Prashant, 2015, Handb Clin Neurol, V132, P139, DOI 10.1016/B978-0-444-62702-5.00010-X; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Davis CF, 2014, CANCER CELL, V26, P319, DOI 10.1016/j.ccr.2014.07.014; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Dushukyan N, 2017, CELL REP, V21, P1883, DOI 10.1016/j.celrep.2017.10.074; Elbanna M, 2020, MOL CANCER THER, V19, P147, DOI 10.1158/1535-7163.MCT-18-1202; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Foster SA, 2016, MOL CELL, V64, P854, DOI 10.1016/j.molcel.2016.11.024; Gasper Raphael, 2010, Small GTPases, V1, P133, DOI 10.4161/sgtp.1.3.14742; Hasanov E, 2017, ONCOGENE, V36, P3450, DOI 10.1038/onc.2016.495; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Hsieh JJ, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.9; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Kontani K, 2002, J BIOL CHEM, V277, P41070, DOI 10.1074/jbc.M202150200; Kulbe H, 2007, CANCER RES, V67, P585, DOI 10.1158/0008-5472.CAN-06-2941; Kuznetsova AV, 2003, P NATL ACAD SCI USA, V100, P2706, DOI 10.1073/pnas.0436037100; Li Q, 2018, IMMUNITY, V48, P258, DOI 10.1016/j.immuni.2017.12.013; Linehan WM, 2016, NEW ENGL J MED, V374, P135, DOI 10.1056/NEJMoa1505917; Maniaci C, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00954-1; Moch H, 2016, EUR UROL, V70, P93, DOI 10.1016/j.eururo.2016.02.029; Morris MR, 2017, NAT REV NEPHROL, V13, P47, DOI 10.1038/nrneph.2016.168; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Ogita Y, 2015, J BIOL CHEM, V290, P20245, DOI 10.1074/jbc.M115.637769; Okuda H, 2001, J BIOL CHEM, V276, P43611, DOI 10.1074/jbc.M107880200; Paik PK, 2011, J CLIN ONCOL, V29, P2046, DOI 10.1200/JCO.2010.33.1280; Rini BI, 2009, LANCET, V373, P1119, DOI 10.1016/S0140-6736(09)60229-4; Ritt DA, 2016, MOL CELL, V64, P875, DOI 10.1016/j.molcel.2016.10.029; Robinson CM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21524-5; Schermer B, 2006, J CELL BIOL, V175, P547, DOI 10.1083/jcb.200605092; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Stadler WM, 2005, CANCER-AM CANCER SOC, V104, P2323, DOI 10.1002/cncr.21453; Tang XH, 2016, CANCER RES, V76, P1892, DOI 10.1158/0008-5472.CAN-15-2328; Tidyman WE, 2009, CURR OPIN GENET DEV, V19, P230, DOI 10.1016/j.gde.2009.04.001; Tu YQ, 2012, INT J CLIN EXP PATHO, V5, P726; Wu XF, 2016, OPEN MED-WARSAW, V11, P226, DOI 10.1515/med-2016-0043; Yang L, 2018, AM J MED SCI, V355, P368, DOI 10.1016/j.amjms.2017.12.012; Zeng LL, 2013, CANCER RES, V73, P5371, DOI 10.1158/0008-5472.CAN-12-4707; Zhang J, 2018, SCIENCE, V361, P290, DOI 10.1126/science.aap8411; Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725	48	5	5	2	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	19					3853	3866		10.1038/s41388-020-1247-y	http://dx.doi.org/10.1038/s41388-020-1247-y			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LK4OF	32161311				2022-12-17	WOS:000530841700005
J	Li, MC; Nopparat, J; Aguilar, BJ; Chen, YH; Zhang, J; Du, J; Ai, X; Luo, Y; Jiang, YG; Boykin, C; Lu, Q				Li, Mingchuan; Nopparat, Jongdee; Aguilar, Byron J.; Chen, Yan-hua; Zhang, Jiao; Du, Jie; Ai, Xin; Luo, Yong; Jiang, Yongguang; Boykin, Christi; Lu, Qun			Intratumor delta-catenin heterogeneity driven by genomic rearrangement dictates growth factor dependent prostate cancer progression	ONCOGENE			English	Article							ARMADILLO PROTEIN; E-CADHERIN; EXPRESSION; REDISTRIBUTION; IDENTIFICATION; P120-CATENIN; P190RHOGEF; CHALLENGES; INVASION; HYPOXIA	Only a small number of genes are bona fide oncogenes and tumor suppressors such as Ras, Myc, beta-catenin, p53, and APC. However, targeting these cancer drivers frequently fail to demonstrate sustained cancer remission. Tumor heterogeneity and evolution contribute to cancer resistance and pose challenges for cancer therapy due to differential genomic rearrangement and expression driving distinct tumor responses to treatments. Here we report that intratumor heterogeneity of Wnt/beta-catenin modulator delta-catenin controls individual cell behavior to promote cancer. The differential intratumor subcellular localization of delta-catenin mirrors its compartmentalization in prostate cancer xenograft cultures as result of mutation-rendered delta-catenin truncations. Wild-type and delta-catenin mutants displayed distinct protein interactomes that highlight rewiring of signal networks. Localization specific delta-catenin mutants influenced p120(ctn)-dependent Rho GTPase phosphorylation and shifted cells towards differential bFGF-responsive growth and motility, a known signal to bypass androgen receptor dependence. Mutant delta-catenin promoted Myc-induced prostate tumorigenesis while increasing bFGF-p38 MAP kinase signaling, beta-catenin-HIF-1 alpha expression, and the nuclear size. Therefore, intratumor delta-catenin heterogeneity originated from genetic remodeling promotes prostate cancer expansion towards androgen independent signaling, supporting a neomorphism model paradigm for targeting tumor progression.	[Li, Mingchuan; Nopparat, Jongdee; Aguilar, Byron J.; Chen, Yan-hua; Zhang, Jiao; Boykin, Christi; Lu, Qun] East Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, Greenville, NC 27834 USA; [Li, Mingchuan; Luo, Yong; Jiang, Yongguang] Capital Med Univ, Beijing An Zhen Hosp, Dept Urol Surg, Beijing 100029, Peoples R China; [Nopparat, Jongdee] Prince Songkla Univ, Dept Anat, Hat Yai 90110, Thailand; [Du, Jie] Capital Med Univ, Beijing An Zhen Hosp, Beijing Inst Heart Lung & Blood Vessel Dis, Beijing 100029, Peoples R China; [Ai, Xin] Peoples Liberat Army Gen Hosp, Med Ctr 7, Dept Urol, Beijing 100029, Peoples R China; [Lu, Qun] East Carolina Univ, Brody Sch Med, Harriet & John Wooten Lab Alzheimers & Neurodegen, Greenville, NC 27834 USA	University of North Carolina; East Carolina University; Capital Medical University; Prince of Songkla University; Capital Medical University; Chinese People's Liberation Army General Hospital; University of North Carolina; East Carolina University	Lu, Q (corresponding author), East Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, Greenville, NC 27834 USA.; Lu, Q (corresponding author), East Carolina Univ, Brody Sch Med, Harriet & John Wooten Lab Alzheimers & Neurodegen, Greenville, NC 27834 USA.	luq@ecu.edu	, Proteomics Core UNC/AAH-3777-2022; Nopparat, Jongdee/AAX-1690-2020; , Proteomics Core UNC/AFQ-7201-2022	Nopparat, Jongdee/0000-0003-3532-1405; 	USA National Cancer Institute [CA111891, CA165202, P30 CA016086]; Harriet and John Wooten Foundation for Alzheimer's and Neurodegenerative Diseases Research; Chinese Beijing Natural Science Foundation [7172068]	USA National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Harriet and John Wooten Foundation for Alzheimer's and Neurodegenerative Diseases Research; Chinese Beijing Natural Science Foundation(Beijing Natural Science Foundation)	We thank George W. Lanford and William Guiler for technical assistance. This work was supported in part by grants from USA National Cancer Institute CA111891 (QL), CA165202 (QL), the Harriet and John Wooten Foundation for Alzheimer's and Neurodegenerative Diseases Research (QL), and Chinese Beijing Natural Science Foundation 7172068 (YGJ). This research is based in part upon work conducted using the UNC Proteomics Core Facility, which is supported in part by USA National Cancer Institute P30 CA016086 Cancer Center Core Support Grant to the UNC Lineberger Comprehensive Cancer Center.	Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]; Bensinger SJ, 2012, SEMIN CELL DEV BIOL, V23, P352, DOI 10.1016/j.semcdb.2012.02.003; Bluemn EG, 2017, CANCER CELL, V32, P474, DOI 10.1016/j.ccell.2017.09.003; Chaffer CL, 2016, CANCER METAST REV, V35, P645, DOI 10.1007/s10555-016-9648-7; Dang CV, 2008, NAT REV CANCER, V8, P51, DOI 10.1038/nrc2274; DeBusk LM, 2010, J EXP MED, V207, P669, DOI 10.1084/jem.2009109722610c; Dohn MR, 2009, J CELL BIOL, V184, P437, DOI 10.1083/jcb.200807096; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Fang YY, 2012, J CANCER RES CLIN, V138, P1769, DOI 10.1007/s00432-012-1257-4; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang F, 2018, ONCOL REP, V39, P809, DOI 10.3892/or.2017.6140; Ip CKM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06949-w; Israely I, 2004, CURR BIOL, V14, P1657, DOI 10.1016/j.cub.2004.08.065; Iwata T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009427; Jones SB, 2004, J NEUROSCI, V24, P8510, DOI 10.1523/JNEUROSCI.1264-04.2004; Jones SB, 2002, NEUROSCIENCE, V115, P1009, DOI 10.1016/S0306-4522(02)00532-8; Kim H, 2008, J BIOL CHEM, V283, P977, DOI 10.1074/jbc.M707158200; Kim H, 2012, BBA-MOL BASIS DIS, V1822, P509, DOI 10.1016/j.bbadis.2011.12.015; Kim H, 2008, BIOCHEM BIOPH RES CO, V377, P636, DOI 10.1016/j.bbrc.2008.10.030; Kim K, 2002, EXP CELL RES, V275, P171, DOI 10.1006/excr.2002.5503; Kosik KS, 2005, TRENDS CELL BIOL, V15, P172, DOI 10.1016/j.tcb.2005.01.004; Liu Y, 2009, CANCER SCI, V100, P441, DOI 10.1111/j.1349-7006.2008.01067.x; Lu Q, 2005, HUM PATHOL, V36, P1037, DOI 10.1016/j.humpath.2005.07.012; Lu Q, 1999, J CELL BIOL, V144, P519, DOI 10.1083/jcb.144.3.519; Lu Q, 2016, HUM GENET, V135, P1107, DOI 10.1007/s00439-016-1705-3; Lu Q, 2010, J PATHOL, V222, P119, DOI 10.1002/path.2755; Maere S, 2005, BIOINFORMATICS, V21, P3448, DOI 10.1093/bioinformatics/bti551; McCrea PD, 2007, BBA-MOL CELL RES, V1773, P17, DOI 10.1016/j.bbamcr.2006.06.009; Nopparat J, 2015, ONCOGENE, V34, P1542, DOI 10.1038/onc.2014.89; Olson Michael F, 2018, Small GTPases, V9, P203, DOI 10.1080/21541248.2016.1218407; Paffenholz R, 1997, DIFFERENTIATION, V61, P293, DOI 10.1046/j.1432-0436.1997.6150293.x; Patiar S, 2006, ENDOCR-RELAT CANCER, V13, pS61, DOI 10.1677/erc.1.01290; Podar K, 2010, CELL CYCLE, V9, P1722, DOI 10.4161/cc.9.9.11358; Poon E, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001173; Powis G, 2004, MOL CANCER THER, V3, P647; Suhovskih AV, 2017, CELL ADHES MIGR, V11, P39, DOI 10.1080/19336918.2016.1182292; Swanton C, 2012, CANCER RES, V72, P4875, DOI 10.1158/0008-5472.CAN-12-2217; Tai S, 2011, PROSTATE, V71, P1668, DOI 10.1002/pros.21383; Takiar V, 2017, ONCOGENE, V36, P1607, DOI 10.1038/onc.2016.312; Viswanathan SR, 2018, NAT GENET, V50, P937, DOI 10.1038/s41588-018-0155-3; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Wolf A, 2006, NAT CELL BIOL, V8, P1432, DOI 10.1038/ncb1504; Wu YM, 2018, CELL, V173, P1770, DOI 10.1016/j.cell.2018.04.034; Yanagisawa M, 2008, J BIOL CHEM, V283, P18344, DOI 10.1074/jbc.M801192200; Zeng Y, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-19; Zhang GA, 2006, PROTEOMICS, V6, P571, DOI 10.1002/pmic.200500267; Zhang J, 2010, FUTURE ONCOL, V6, P587, DOI [10.2217/fon.10.15, 10.2217/FON.10.15]; Zhang J, 2008, DEVELOPMENT, V135, P3611, DOI 10.1242/dev.025361; Zhang Y, 2018, FRONT MED-PRC, V12, P361, DOI 10.1007/s11684-018-0656-6; Zheng JY, 2003, J MEMBRANE BIOL, V194, P187, DOI 10.1007/s00232-003-2038-4	51	5	5	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	22					4358	4374		10.1038/s41388-020-1281-9	http://dx.doi.org/10.1038/s41388-020-1281-9		APR 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LR9IT	32313227				2022-12-17	WOS:000527509300002
J	Kim, M; Morales, LD; Lee, CJ; Olivarez, SA; Kim, WJ; Hernandez, J; Mummidi, S; Jenkinson, C; Tsin, AT; Jang, IS; Slaga, TJ; Kim, DJ				Kim, Mihwa; Morales, Liza D.; Lee, Cheol Jung; Olivarez, Serena A.; Kim, Woo Jin; Hernandez, Joselin; Mummidi, Srinivas; Jenkinson, Christopher; Tsin, Andrew T.; Jang, Ik-Soon; Slaga, Thomas J.; Kim, Dae Joon			Overexpression of TC-PTP in murine epidermis attenuates skin tumor formation	ONCOGENE			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; KERATINOCYTE SURVIVAL; CELL-CYCLE; ACTIVATION; STAT3; CARCINOGENESIS; EXPRESSION; APOPTOSIS; VARIANTS; PATHWAY	T-cell protein tyrosine phosphatase (TC-PTP), encoded by Ptpn2, has been shown to function as a tumor suppressor during skin carcinogenesis. In the current study, we generated a novel epidermal-specific TC-PTP-overexpressing (K5HA.Ptpn2) mouse model to show that TC-PTP contributes to the attenuation of chemically induced skin carcinogenesis through the synergistic regulation of STAT1, STAT3, STAT5, and PI3K/AKT signaling. We found overexpression of TC-PTP increased epidermal sensitivity to DMBA-induced apoptosis and it decreased TPA-mediated hyperproliferation, coinciding with reduced epidermal thickness. Inhibition of STAT1, STAT3, STAT5, or AKT reversed the effects of TC-PTP overexpression on epidermal survival and proliferation. Mice overexpressing TC-PTP in the epidermis developed significantly reduced numbers of tumors during skin carcinogenesis and presented a prolonged latency of tumor initiation. Examination of human papillomas and squamous cell carcinomas (SCCs) revealed that TC-PTP expression was significantly reduced and TC-PTP expression was inversely correlated with the increased grade of SCCs. Our findings demonstrate that TC-PTP is a potential therapeutic target for the prevention of human skin cancer given that it is a major negative regulator of oncogenic signaling.	[Kim, Mihwa; Lee, Cheol Jung; Olivarez, Serena A.; Tsin, Andrew T.; Kim, Dae Joon] Univ Texas Rio Grande Valley, Sch Med, Dept Mol Sci, Edinburg, TX 78541 USA; [Morales, Liza D.; Hernandez, Joselin; Mummidi, Srinivas; Jenkinson, Christopher; Kim, Dae Joon] Univ Texas Rio Grande Valley, Sch Med, Dept Human Genet, Edinburg, TX 78541 USA; [Kim, Woo Jin] Univ Texas Rio Grande Valley, Sch Math & Stat Sci, Coll Sci, Edinburg, TX USA; [Jang, Ik-Soon] Korea Basic Sci Inst, Div Bioconvergence Anal, Daejeon 305333, South Korea; [Slaga, Thomas J.] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Dept Pharmacol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Rio Grande Valley; University of Texas System; University of Texas Rio Grande Valley; University of Texas System; University of Texas Rio Grande Valley; Korea Basic Science Institute (KBSI); University of Texas System; University of Texas Health San Antonio	Kim, DJ (corresponding author), Univ Texas Rio Grande Valley, Sch Med, Dept Mol Sci, Edinburg, TX 78541 USA.; Kim, DJ (corresponding author), Univ Texas Rio Grande Valley, Sch Med, Dept Human Genet, Edinburg, TX 78541 USA.	dae.kim@utrgv.edu	Kim, Mihwa/AAN-5784-2020	Hernandez Ruiz, Joselin/0000-0002-0571-2563; KIM, DAE/0000-0002-7977-9955; Morales, Liza/0000-0003-1056-9121	NIH/NIEHS [ES022250]; NIH/NIAID [AI119131]	NIH/NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank H. Lee for technical assistance. This work was supported by NIH/NIEHS ES022250 (to D.J. Kim) and NIH/NIAID AI119131 (to S. Mummidi).	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Agrawal S, 2002, MOL CELL BIOL, V22, P1981, DOI 10.1128/MCB.22.7.1981-1992.2002; Baek M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0781-9; Bourdeau A, 2005, CURR OPIN CELL BIOL, V17, P203, DOI 10.1016/j.ceb.2005.02.001; Bozeman R, 2015, MOL CARCINOGEN, V54, P642, DOI 10.1002/mc.22132; Casaletto JB, 2012, NAT REV CANCER, V12, P386, DOI 10.1038/nrc3277; Chan KS, 2004, CANCER RES, V64, P2382, DOI 10.1158/0008-5472.CAN-03-3197; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; Cuppen E, 1999, J CELL SCI, V112, P3299; DeVries TA, 2004, J BIOL CHEM, V279, P45603, DOI 10.1074/jbc.M407448200; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3; Dube N, 2005, BBA-PROTEINS PROTEOM, V1754, P108, DOI 10.1016/j.bbapap.2005.07.030; Hendriks WJAJ, 2008, FEBS J, V275, P816, DOI 10.1111/j.1742-4658.2008.06249.x; Hendriks WJAJ, 2013, BBA-MOL BASIS DIS, V1832, P1673, DOI 10.1016/j.bbadis.2013.05.022; HENNINGS H, 1993, CARCINOGENESIS, V14, P2353, DOI 10.1093/carcin/14.11.2353; Hunter T, 2009, CURR OPIN CELL BIOL, V21, P140, DOI 10.1016/j.ceb.2009.01.028; Kamatkar S, 1996, J BIOL CHEM, V271, P26755, DOI 10.1074/jbc.271.43.26755; Karlsson E, 2015, BREAST CANCER RES TR, V153, P31, DOI 10.1007/s10549-015-3516-y; Kim DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010290; Kim M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092708; Kim M, 2017, ONCOTARGET, V8, P90674, DOI 10.18632/oncotarget.21794; Kleppe M, 2010, NAT GENET, V42, P530, DOI 10.1038/ng.587; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Lee CF, 2009, WORLD J GASTROENTERO, V15, P356, DOI 10.3748/wjg.15.356; Lee H, 2017, SCI REP-UK, V7, DOI 10.1038/srep45077; Lee H, 2015, J BIOL CHEM, V290, P13, DOI 10.1074/jbc.M114.611681; Lim WA, 2010, CELL, V142, P661, DOI 10.1016/j.cell.2010.08.023; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Manguso RT, 2017, NATURE, V547, P413, DOI 10.1038/nature23270; Martini M, 2014, ANN MED, V46, P372, DOI 10.3109/07853890.2014.912836; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; Shields BJ, 2013, MOL CELL BIOL, V33, P557, DOI 10.1128/MCB.01016-12; TILLMANN U, 1994, MOL CELL BIOL, V14, P3030, DOI 10.1128/MCB.14.5.3030; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xu D, 2008, FRONT BIOSCI-LANDMRK, V13, P4925, DOI 10.2741/3051; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zimmerman MA, 2012, CANCER RES, V72, P4724, DOI 10.1158/0008-5472.CAN-12-1347	38	5	5	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	21					4241	4256		10.1038/s41388-020-1282-8	http://dx.doi.org/10.1038/s41388-020-1282-8		APR 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LQ2DH	32286519	Green Submitted, Green Accepted			2022-12-17	WOS:000526237900004
J	Federico, MB; Siri, SO; Calzetta, NL; Paviolo, NS; de la Vega, MB; Martino, J; Campana, MC; Wiesmuller, L; Gottifredi, V				Federico, Maria Belen; Siri, Sebastian Omar; Calzetta, Nicolas Luis; Paviolo, Natalia Soledad; de la Vega, Maria Belen; Martino, Julieta; Campana, Maria Carolina; Wiesmueller, Lisa; Gottifredi, Vanesa			Unscheduled MRE11 activity triggers cell death but not chromosome instability in polymerase eta-depleted cells subjected to UV irradiation	ONCOGENE			English	Article							XERODERMA-PIGMENTOSUM VARIANT; STALLED REPLICATION FORKS; TRANSLESION DNA-SYNTHESIS; DAMAGE TOLERANCE; STRUCTURAL BASIS; REPAIR; CISPLATIN; BREAK; SURVIVAL; PATHWAY	The elimination of DNA polymerase eta (pol eta) causes discontinuous DNA elongation and fork stalling in UV-irradiated cells. Such alterations in DNA replication are followed by S-phase arrest, DNA double-strand break (DSB) accumulation, and cell death. However, their molecular triggers and the relative timing of these events have not been fully elucidated. Here, we report that DSBs accumulate relatively early after UV irradiation in pol eta-depleted cells. Despite the availability of repair pathways, DSBs persist and chromosome instability (CIN) is not detectable. Later on cells with pan-nuclear gamma H2AX and massive exposure of template single-stranded DNA (ssDNA), which indicate severe replication stress, accumulate and such events are followed by cell death. Reinforcing the causal link between the accumulation of pan-nuclear ssDNA/gamma H2AX signals and cell death, downregulation of RPA increased both replication stress and the cell death of pol eta-deficient cells. Remarkably, DSBs, pan-nuclear ssDNA/gamma H2AX, S-phase arrest, and cell death are all attenuated by MRE11 nuclease knockdown. Such results suggest that unscheduled MRE11-dependent activities at replicating DNA selectively trigger cell death, but not CIN. Together these results show that pol eta-depletion promotes a type of cell death that may be attractive as a therapeutic tool because of the lack of CIN.	[Federico, Maria Belen; Siri, Sebastian Omar; Calzetta, Nicolas Luis; Paviolo, Natalia Soledad; de la Vega, Maria Belen; Martino, Julieta; Campana, Maria Carolina; Gottifredi, Vanesa] Consejo Nacl Invest Cient & Tecn, Cell Cycle & Genom Stabil Lab, Fdn Inst Leloir, Ave Patricias Argentinas 435, Buenos Aires, DF, Argentina; [Wiesmueller, Lisa] Ulm Univ, Dept Obstet & Gynecol, D-89075 Ulm, Germany	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Leloir Institute; Ulm University	Gottifredi, V (corresponding author), Consejo Nacl Invest Cient & Tecn, Cell Cycle & Genom Stabil Lab, Fdn Inst Leloir, Ave Patricias Argentinas 435, Buenos Aires, DF, Argentina.	vgottifredi@leloir.org.ar		Gottifredi, Vanesa/0000-0001-9656-5951; Calzetta, Nicolas Luis/0000-0002-5790-0515; Martino, Julieta/0000-0001-9880-2682	Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT) [PICT 2015-1217]; Instituto Nacional del Cancer (INC)-"Asistencia Financiera a proyectos de investigacion de cancer de origen nacional III; German Cancer Aid, Priority Program "Translational Oncology" [70112504]; Deutsche Forschungsgemeinschaft (DFG); CONICET; ANPCyT; Alexander von Humboldt Foundation	Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT)(ANPCyT); Instituto Nacional del Cancer (INC)-"Asistencia Financiera a proyectos de investigacion de cancer de origen nacional III; German Cancer Aid, Priority Program "Translational Oncology"; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); CONICET(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); ANPCyT(ANPCyT); Alexander von Humboldt Foundation(Alexander von Humboldt Foundation)	We would like to thank Professors AR Lehmann (University of Sussex), for the gift of XPV cells. We also thank Carlos Menck at the University of Sao Paolo and all the members of the Gottifredi laboratory for fruitful discussions. The excellent support of Andres H. Rossi and Anabel Alvarez Julia in the microscopy and tissue cultures facilities is acknowledged. This work was supported by grants from the Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT) grant number PICT 2015-1217, Instituto Nacional del Cancer (INC)-"Asistencia Financiera a proyectos de investigacion de cancer de origen nacional III to VG and the German Cancer Aid, Priority Program "Translational Oncology" 70112504 and by the Deutsche Forschungsgemeinschaft (DFG, Research Training Group 2544) to LW. MBF, SOS, NLC, NSP, JM, and MBdlV were supported by fellowships from CONICET and ANPCyT. VG is a researcher from CONICET and was supported by the Friedrich Wilhelm Bessel from Alexander von Humboldt Foundation.	Albertella MR, 2005, CANCER RES, V65, P9799, DOI 10.1158/0008-5472.CAN-05-1095; Alt A, 2007, SCIENCE, V318, P967, DOI 10.1126/science.1148242; Ashworth A, 2018, NAT REV CLIN ONCOL, V15, P564, DOI 10.1038/s41571-018-0055-6; Barnes RP, 2018, CANCER RES, V78, P6549, DOI 10.1158/0008-5472.CAN-17-3931; Federico MB, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005792; Vallerga MB, 2015, P NATL ACAD SCI USA, V112, pE6624, DOI 10.1073/pnas.1508543112; Bertolin AP, 2015, DNA REPAIR, V32, P158, DOI 10.1016/j.dnarep.2015.04.027; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Bryant PE, 2004, RADIOTHER ONCOL, V72, P251, DOI 10.1016/j.radonc.2004.07.005; Buisson R, 2015, MOL CELL, V59, P1011, DOI 10.1016/j.molcel.2015.07.029; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Ceppi P, 2009, CLIN CANCER RES, V15, P1039, DOI 10.1158/1078-0432.CCR-08-1227; Chen YW, 2006, MOL CANCER RES, V4, P257, DOI 10.1158/1541-7786.MCR-05-0118; Cleaver JE, 1999, CANCER RES, V59, P1102; Cruet-Hennequart S, 2006, DNA REPAIR, V5, P491, DOI 10.1016/j.dnarep.2006.01.008; Cruet-Hennequart S, 2010, SUBCELL BIOCHEM, V50, P189, DOI 10.1007/978-90-481-3471-7_10; Deniz M, 2013, MUTAT RES-FUND MOL M, V743, P132, DOI 10.1016/j.mrfmmm.2013.03.009; Despras E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13326; Despras E, 2010, HUM MOL GENET, V19, P1690, DOI 10.1093/hmg/ddq046; Eckert Kristin A, 2019, Oncotarget, V10, P620, DOI 10.18632/oncotarget.26572; Elvers I, 2011, NUCLEIC ACIDS RES, V39, P7049, DOI 10.1093/nar/gkr420; EVENO E, 1995, CANCER RES, V55, P4325; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Gonzalez Besteiro MA, 2019, EMBO J, V38, DOI 10.15252/embj.2018101284; Gueranger Q, 2008, DNA REPAIR, V7, P1551, DOI 10.1016/j.dnarep.2008.05.012; Gursoy-Yuzugullu O, 2016, J MOL BIOL, V428, P1846, DOI 10.1016/j.jmb.2015.11.021; Hamppa S, 2016, P NATL ACAD SCI USA, V113, pE4311, DOI 10.1073/pnas.1605828113; Hashimoto Y, 2012, NAT STRUCT MOL BIOL, V19, P17, DOI 10.1038/nsmb.2177; Helleday T, 2011, MOL ONCOL, V5, P387, DOI 10.1016/j.molonc.2011.07.001; Hendel A, 2008, DNA REPAIR, V7, P1636, DOI 10.1016/j.dnarep.2008.06.008; Ireno IC, 2014, CARCINOGENESIS, V35, P2273, DOI 10.1093/carcin/bgu160; Jansen JG, 2014, NUCLEIC ACIDS RES, V42, P11071, DOI 10.1093/nar/gku779; Jeggo PA, 2014, EXP CELL RES, V329, P69, DOI 10.1016/j.yexcr.2014.09.023; Kannouche P, 2001, GENE DEV, V15, P158, DOI 10.1101/gad.187501; Kannouche P, 2003, BIOCHIMIE, V85, P1123, DOI 10.1016/j.biochi.2003.10.009; Lemacon D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01180-5; Lerner LK, 2017, NUCLEIC ACIDS RES, V45, P1270, DOI 10.1093/nar/gkw1196; Limoli CL, 2002, P NATL ACAD SCI USA, V99, P233, DOI 10.1073/pnas.231611798; Limoli CL, 2000, P NATL ACAD SCI USA, V97, P7939, DOI 10.1073/pnas.130182897; Mah LJ, 2010, LEUKEMIA, V24, P679, DOI 10.1038/leu.2010.6; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; McIlwraith MJ, 2005, MOL CELL, V20, P783, DOI 10.1016/j.molcel.2005.10.001; Mouron S, 2013, NAT STRUCT MOL BIOL, V20, P1383, DOI 10.1038/nsmb.2719; Murfuni I, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003910; Ochs F, 2016, NAT STRUCT MOL BIOL, V23, P714, DOI 10.1038/nsmb.3251; Panier S, 2014, NAT REV MOL CELL BIO, V15, P7, DOI 10.1038/nrm3719; Paull TT, 2018, MOL CELL, V71, P419, DOI 10.1016/j.molcel.2018.06.033; Pellegrino S, 2017, CELL REP, V19, P1819, DOI 10.1016/j.celrep.2017.05.016; Petermann E, 2010, MOL CELL, V37, P492, DOI 10.1016/j.molcel.2010.01.021; Quinet A, 2016, NUCLEIC ACIDS RES, V44, P5717, DOI 10.1093/nar/gkw280; Quinet A, 2014, DNA REPAIR, V14, P27, DOI 10.1016/j.dnarep.2013.12.005; Roerink SF, 2014, GENOME RES, V24, P954, DOI 10.1101/gr.170431.113; Schlacher K, 2012, CANCER CELL, V22, P106, DOI 10.1016/j.ccr.2012.05.015; Schlacher K, 2011, CELL, V145, P529, DOI 10.1016/j.cell.2011.03.041; Paviolo NS, 2020, GENET MOL BIOL, V43, DOI [10.1590/1678-4685-gmb-2019-0070, 10.1590/1678-4685-GMB-2019-0070]; Spivak G, 2015, DNA REPAIR, V36, P13, DOI 10.1016/j.dnarep.2015.09.003; Stary A, 2003, J BIOL CHEM, V278, P18767, DOI 10.1074/jbc.M211838200; Syed A, 2018, ANNU REV BIOCHEM, V87, P263, DOI 10.1146/annurev-biochem-062917-012415; Teng KY, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-126; Toledo LI, 2013, CELL, V155, P1088, DOI 10.1016/j.cell.2013.10.043; Ummat A, 2012, NAT STRUCT MOL BIOL, V19, P628, DOI 10.1038/nsmb.2295; Villafanez F, 2019, ONCOGENE, V38, P4310, DOI 10.1038/s41388-019-0724-7; Xu XY, 2013, P NATL ACAD SCI USA, V110, P18638, DOI 10.1073/pnas.1303958110; Yang Y, 2018, CELL CYCLE, V17, P833, DOI 10.1080/15384101.2018.1456296; Yoon JH, 2019, CELL, V176, P1295, DOI 10.1016/j.cell.2019.01.023; Zellweger R, 2015, J CELL BIOL, V208, P563, DOI 10.1083/jcb.201406099; Zhang F, 2009, ANNU REV GENOM HUM G, V10, P451, DOI 10.1146/annurev.genom.9.081307.164217; Zhao Y, 2012, P NATL ACAD SCI USA, V109, P7269, DOI 10.1073/pnas.1202681109; Ziv O, 2009, P NATL ACAD SCI USA, V106, P11552, DOI 10.1073/pnas.0812548106	70	5	5	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	19					3952	3964		10.1038/s41388-020-1265-9	http://dx.doi.org/10.1038/s41388-020-1265-9		MAR 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LK4OF	32203168				2022-12-17	WOS:000521527500003
J	Ma, XJ; Lu, JY; Moraru, A; Teleman, AA; Fang, JN; Qiu, Y; Liu, P; Xu, T				Ma, Xianjue; Lu, Jin-Yu; Moraru, Alexandra; Teleman, Aurelio A.; Fang, Jinan; Qiu, Yue; Liu, Peng; Xu, Tian			A novel regulator of ER Ca2+ drives Hippo-mediated tumorigenesis	ONCOGENE			English	Article							CELL-PROLIFERATION; DROSOPHILA HOMOLOG; SIGNALING PATHWAY; TUMOR-GROWTH; PROMOTES APOPTOSIS; JNK ACTIVATION; POSH; PROTEIN; CANCER; INVASION	Calcium ion (Ca2+) is a versatile second messenger that regulates various cellular and physiological functions. However, the in vivo molecular mechanisms by which Ca2+ alterations contribute to tumor growth remain poorly explored. Here we show that Emei is a novel ER Ca2+ regulator that synergizes with Ras(V12) to induce tumor growth via JNK-mediated Hippo signaling. Emei disruption reduces ER Ca2+ level and subsequently leads to JNK activation and Hippo inactivation. Importantly, genetically increasing cytosolic Ca2+ concentration cooperates with Ras(V12) to drive tumor growth via inactivating the Hippo pathway. Finally, we identify POSH as a crucial link that bridges cytosolic Ca2+ alteration with JNK activation and Hippo-mediated tumor growth. Together, our findings provide a novel mechanism of tumor growth that acts through intracellular Ca2+ levels to modulate JNK-mediated Hippo signaling.	[Ma, Xianjue; Fang, Jinan; Qiu, Yue; Liu, Peng; Xu, Tian] Westlake Univ, Sch Life Sci, Hangzhou, Peoples R China; [Ma, Xianjue; Lu, Jin-Yu; Xu, Tian] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; [Moraru, Alexandra; Teleman, Aurelio A.] German Canc Res Ctr, Heidelberg, Germany; [Teleman, Aurelio A.] Heidelberg Univ, D-69120 Heidelberg, Germany; [Teleman, Aurelio A.] Heidelberg Univ, CellNetworks Cluster Excellence, Heidelberg, Germany; [Lu, Jin-Yu] Baylor Coll Med, Hematol & Oncol, Houston, TX 77030 USA	Westlake University; Yale University; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Baylor College of Medicine	Ma, XJ; Xu, T (corresponding author), Westlake Univ, Sch Life Sci, Hangzhou, Peoples R China.; Ma, XJ; Xu, T (corresponding author), Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA.	maxianjue@westlake.edu.cn; xutian@westlake.edu.cn	Teleman, Aurelio A/E-6864-2013; Teleman, Aurelio/V-8470-2019	Teleman, Aurelio A/0000-0002-4237-9368; Teleman, Aurelio/0000-0002-4237-9368; Ma, Xianjue/0000-0003-4360-3947	Natural Science Foundation of China [31601024]; NIH [R01CA069408]; American Cancer Society; NCI-NRSA [F32CA132311]; Westlake University	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NCI-NRSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Westlake University	We are thankful for Bloomington, VDRC and DGRC stock centers for providing fly stocks, Lei Xue for comments. This research was supported in part by Natural Science Foundation of China Grants 31601024 to XM. Work in the Xu lab was supported by NIH grant R01CA069408. J-Y Lu was supported by American Cancer Society, and NCI-NRSA (F32CA132311) postdoctoral fellowships. XM and TX are supported by Westlake University.	Bustos G, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00199; Cho E, 2006, NAT GENET, V38, P1142, DOI 10.1038/ng1887; Cong B, 2018, ONCOGENE, V37, P3088, DOI 10.1038/s41388-018-0201-8; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Enomoto M, 2018, ADV EXP MED BIOL, V1076, P173, DOI 10.1007/978-981-13-0529-0_10; Feng MY, 2010, CELL, V143, P84, DOI 10.1016/j.cell.2010.08.040; Giorgi C, 2018, TRENDS CELL BIOL, V28, P258, DOI 10.1016/j.tcb.2018.01.002; Groenendyk J, 2013, ANNU REV PHYSIOL, V75, P49, DOI 10.1146/annurev-physiol-030212-183707; Hamaratoglu F, 2006, NAT CELL BIOL, V8, P27, DOI 10.1038/ncb1339; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Igaki T, 2002, EMBO J, V21, P3009, DOI 10.1093/emboj/cdf306; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kukekov NV, 2006, J BIOL CHEM, V281, P15517, DOI 10.1074/jbc.M601056200; Lee TM, 2001, TRENDS NEUROSCI, V24, P251, DOI 10.1016/S0166-2236(00)01791-4; Ma X, 2017, ONCOGENE, V36, P3159, DOI 10.1038/onc.2016.463; Ma X, 2016, ONCOGENE, V35, P846, DOI 10.1038/onc.2015.137; Ma X, 2014, CELL DEATH DIFFER, V21, P407, DOI 10.1038/cdd.2013.154; Ma XJ, 2018, P NATL ACAD SCI USA, V115, P2150, DOI 10.1073/pnas.1715165115; Ma XJ, 2017, CELL REP, V19, P2657, DOI 10.1016/j.celrep.2017.05.092; Ma XJ, 2017, P NATL ACAD SCI USA, V114, P1934, DOI 10.1073/pnas.1621359114; Ma XJ, 2015, P NATL ACAD SCI USA, V112, P1065, DOI 10.1073/pnas.1415020112; McAndrew D, 2011, MOL CANCER THER, V10, P448, DOI 10.1158/1535-7163.MCT-10-0923; McEwen DG, 2005, DEVELOPMENT, V132, P3935, DOI 10.1242/dev.01949; Mirzoyan Z, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00051; Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638; Monteith GR, 2017, NAT REV CANCER, V17, P367, DOI 10.1038/nrc.2017.18; Moraru A, 2017, DEV CELL, V41, P450, DOI 10.1016/j.devcel.2017.05.001; Moreno E, 2002, CURR BIOL, V12, P1263, DOI 10.1016/S0960-9822(02)00954-5; Neto-Silva RM, 2010, DEV CELL, V19, P507, DOI 10.1016/j.devcel.2010.09.009; Oh H, 2008, DEVELOPMENT, V135, P1081, DOI 10.1242/dev.015255; Ohsawa S, 2014, J BIOCHEM, V156, P129, DOI 10.1093/jb/mvu045; Ohsawa S, 2012, NATURE, V490, P547, DOI 10.1038/nature11452; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Pan DJ, 2007, GENE DEV, V21, P886, DOI 10.1101/gad.1536007; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Prasad V, 2005, CANCER RES, V65, P8655, DOI 10.1158/0008-5472.CAN-05-0026; Roderick HL, 2008, NAT REV CANCER, V8, P361, DOI 10.1038/nrc2374; Ryoo HD, 2007, EMBO J, V26, P242, DOI 10.1038/sj.emboj.7601477; Shibao K, 2010, CELL CALCIUM, V48, P315, DOI 10.1016/j.ceca.2010.09.005; Srivastava A, 2007, P NATL ACAD SCI USA, V104, P2721, DOI 10.1073/pnas.0611666104; Sun GP, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004324; Tsuda M, 2006, FEBS LETT, V580, P3296, DOI 10.1016/j.febslet.2006.05.005; Tuvia S, 2007, J CELL BIOL, V177, P51, DOI 10.1083/jcb.200611036; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; Uhlirova M, 2006, EMBO J, V25, P5294, DOI 10.1038/sj.emboj.7601401; Wu M, 2010, NATURE, V463, P545, DOI 10.1038/nature08702; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; XU TA, 1995, DEVELOPMENT, V121, P1053; Xu ZH, 2005, MOL CELL BIOL, V25, P9949, DOI 10.1128/MCB.25.22.9949-9959.2005; Xu ZH, 2003, EMBO J, V22, P252, DOI 10.1093/emboj/cdg021; Zhu H, 2014, ONCOTARGET, V5, P3455, DOI 10.18632/oncotarget.1903; Ziosi M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001140	54	5	5	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1378	1387		10.1038/s41388-019-1076-z	http://dx.doi.org/10.1038/s41388-019-1076-z			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31649333				2022-12-17	WOS:000526714600015
J	Ran, R; Harrison, H; Ariffin, NS; Ayubi, R; Pegg, HJ; Deng, WS; Mastro, A; Ottewell, PD; Mason, SM; Blyth, K; Holen, I; Shore, P				Ran, Ran; Harrison, Hannah; Ariffin, Nur Syamimi; Ayubi, Rahna; Pegg, Henry J.; Deng, Wensheng; Mastro, Andrea; Ottewell, Penny D.; Mason, Susan M.; Blyth, Karen; Holen, Ingunn; Shore, Paul			A role for CBF beta in maintaining the metastatic phenotype of breast cancer cells	ONCOGENE			English	Article							RUNX FAMILY; STEM-CELLS; EXPRESSION; PLASTICITY; MORPHOGENESIS; EMT	Epithelial to mesenchymal transition (EMT) is a dynamic process that drives cancer cell plasticity and is thought to play a major role in metastasis. Here we show, using MDA-MB-231 cells as a model, that the plasticity of at least some metastatic breast cancer cells is dependent on the transcriptional co-regulator CBF beta. We demonstrate that CBF beta is essential to maintain the mesenchymal phenotype of triple-negative breast cancer cells and that CBF beta-depleted cells undergo a mesenchymal to epithelial transition (MET) and re-organise into acini-like structures, reminiscent of those formed by epithelial breast cells. We subsequently show, using an inducible CBF beta system, that the MET can be reversed, thus demonstrating the plasticity of CBF beta-mediated EMT. Moreover, the MET can be reversed by expression of the EMT transcription factor Slug whose expression is dependent on CBF beta. Finally, we demonstrate that loss of CBF beta inhibits the ability of metastatic breast cancer cells to invade bone cell cultures and suppresses their ability to form bone metastases in vivo. Together our findings demonstrate that CBF beta can determine the plasticity of the metastatic cancer cell phenotype, suggesting that its regulation in different micro-environments may play a key role in the establishment of metastatic tumours.	[Ran, Ran; Harrison, Hannah; Ariffin, Nur Syamimi; Ayubi, Rahna; Pegg, Henry J.; Shore, Paul] Univ Manchester, Fac Biol Med & Hlth, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England; [Deng, Wensheng] Wuhan Univ Sci & Technol, Jishi Rd, Wuhan 430065, Hubei, Peoples R China; [Mastro, Andrea] Penn State Univ, 428 South Frear Lab,Univ Pk, Philadelphia, PA 16802 USA; [Ottewell, Penny D.; Holen, Ingunn] Univ Sheffield, Dept Oncol & Metab, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England; [Mason, Susan M.; Blyth, Karen] CRUK Beatson Inst, Garscube Estate, Glasgow G61 1BD, Lanark, Scotland; [Blyth, Karen] Univ Glasgow, Inst Canc Sci, Glasgow G61 1QH, Lanark, Scotland	University of Manchester; Wuhan University of Science & Technology; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; University of Sheffield; Beatson Institute; University of Glasgow	Shore, P (corresponding author), Univ Manchester, Fac Biol Med & Hlth, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.; Holen, I (corresponding author), Univ Sheffield, Dept Oncol & Metab, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.	i.holen@sheffield.ac.uk; paul.shore@manchester.ac.uk	Ariffin, Nur Syamimi/AAJ-3580-2020	Ariffin, Nur Syamimi/0000-0002-4183-8147; Shore, Paul/0000-0002-1832-5976; Holen, Ingunn/0000-0002-8759-6913; Ottewell, Penelope/0000-0002-4826-0771	Breast Cancer Now [PR018]; Cancer Research UK PhD Studentship; BBSRC PhD studentship; Manchester Alumni fund	Breast Cancer Now; Cancer Research UK PhD Studentship(Cancer Research UK); BBSRC PhD studentship(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Manchester Alumni fund	The work was funded by Breast Cancer Now (2013 May PR018; PS, IH and HH), a Cancer Research UK PhD Studentship (PS and HP), a BBSRC PhD studentship and the Manchester Alumni fund.	Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154; Bianchini G, 2016, NAT REV CLIN ONCOL, V13, P674, DOI 10.1038/nrclinonc.2016.66; Browne G, 2016, TUMOR BIOL, V37, P8825, DOI 10.1007/s13277-015-4710-6; Browne G, 2015, J CELL PHYSIOL, V230, P2522, DOI 10.1002/jcp.24989; Chaffer CL, 2016, CANCER METAST REV, V35, P645, DOI 10.1007/s10555-016-9648-7; Chimge NO, 2013, ONCOGENE, V32, P2121, DOI 10.1038/onc.2012.328; Chimge NO, 2017, CELL CYCLE, V16, P312, DOI 10.1080/15384101.2016.1237325; Chimge NO, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3073; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Deng WS, 2012, P NATL ACAD SCI USA, V109, P1524, DOI 10.1073/pnas.1107879109; Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143; Ferrari N, 2015, SCI REP-UK, V5, DOI 10.1038/srep15658; Ferreira NC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084531; Harrison H, 2010, CANCER RES, V70, P709, DOI 10.1158/0008-5472.CAN-09-1681; Holen I, 2016, ONCOTARGET, V7, P75571, DOI 10.18632/oncotarget.12289; Hong D, 2017, ONCOTARGET, V8, P17610, DOI 10.18632/oncotarget.15381; Illendula A, 2016, EBIOMEDICINE, V8, P117, DOI 10.1016/j.ebiom.2016.04.032; Ingthorsson S, 2016, J MAMMARY GLAND BIOL, V21, P139, DOI 10.1007/s10911-016-9366-3; Ito Y, 2015, NAT REV CANCER, V15, P81, DOI 10.1038/nrc3877; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Kim DH, 2018, J CLIN MED, V7, DOI 10.3390/jcm7010001; Kulkarni Madhura, 2018, Oncotarget, V9, P14175, DOI 10.18632/oncotarget.24419; Luo M, 2015, CURR PHARM DESIGN, V21, P1301, DOI 10.2174/1381612821666141211120604; Mastro AM, 2009, CANCER RES, V69, P4097, DOI 10.1158/0008-5472.CAN-08-4437; McDonald L, 2014, DIS MODEL MECH, V7, P525, DOI 10.1242/dmm.015040; Mendoza-Villanueva D, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3048; Mendoza-Villanueva D, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-171; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Pratap J, 2011, BONE, V48, P30, DOI 10.1016/j.bone.2010.05.035; Pratap J, 2009, CANCER RES, V69, P6807, DOI 10.1158/0008-5472.CAN-09-1471; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rooney N, 2017, ADV EXP MED BIOL, V962, P353, DOI 10.1007/978-981-10-3233-2_22; Shaw FL, 2012, J MAMMARY GLAND BIOL, V17, P111, DOI 10.1007/s10911-012-9255-3; Shore P, 2005, J CELL BIOCHEM, V96, P484, DOI 10.1002/jcb.20557; Shore P, 2002, NUCLEIC ACIDS RES, V30, P1767, DOI 10.1093/nar/30.8.1767; Tahirov TH, 2017, ADV EXP MED BIOL, V962, P21, DOI 10.1007/978-981-10-3233-2_2; van Bragt MPA, 2014, ELIFE, V3, DOI 10.7554/eLife.03881; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Zhu YY, 2014, CLIN TRANSL MED, V3, DOI 10.1186/s40169-014-0032-3	39	5	5	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	12					2624	2637		10.1038/s41388-020-1170-2	http://dx.doi.org/10.1038/s41388-020-1170-2		JAN 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KW4HU	32005976	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000510346700003
J	Ko, TY; Sharma, R; Li, SS				Ko, Tengyu; Sharma, Rahul; Li, Shisheng			Genome-wide screening identifies novel genes implicated in cellular sensitivity to BRAF(V600E) expression	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; SYRUP-URINE-DISEASE; RECEPTOR SIGNALS; PROTEIN; P53; ACTIVATION; GPR4; BRAF; MECHANISMS; MUTATIONS	The V600E mutation of BRAF (BRAF(V600E)), which constitutively activates the ERK/MAPK signaling pathway, is frequently found in melanoma and other cancers. Like most other oncogenes, BRAF(V600E) causes oncogenic stress to normal cells, leading to growth arrest (senescence) or apoptosis. Through genome-wide screening, we identified genes implicated in sensitivity of human skin melanocytes and fibroblasts to BRAF(V600E) overexpression. Among the identified genes shared by the two cell types are proto-oncogenes ERK2, a component of the ERK/MAPK pathway, and VAV1, a guanine nucleotide exchange factor for Rho family GTPases that also activates the ERK/MAPK pathway. CDKN1A, which has been known to promote senescence of fibroblasts but not melanocytes, is implicated in sensitivity of the fibroblasts but not the melanocytes to BRAF(V600E) overexpression. Disruptions of GPR4, a pH-sensing G-protein coupled receptor, and DBT, a subunit of the branched chain alpha-keto acid dehydrogenase that is required for the second and rate-limiting step of branched amino acid catabolism and implicated in maple syrup urine disease, are the most highly selected in the melanocytes upon BRAF(V600E) overexpression. Disruption of DBT severely attenuates ERK/MAPK signaling, p53 activation, and apoptosis in melanocytes, at least in part due to accumulation of branched chain alpha-keto acids. The expression level of BRAF positively correlates with that of DBT in all cancer types and with that of GPR4 in most cancer types. Overexpression of DBT kills all four melanoma cell lines tested regardless of the presence of BRAF(V600E) mutation. Our findings shed new lights on regulations of oncogenic stress signaling and may be informative for development of novel cancer treatment strategies.	[Ko, Tengyu; Li, Shisheng] Louisiana State Univ, Sch Vet Med, Dept Comparat Biomed Sci, Baton Rouge, LA 70803 USA; [Sharma, Rahul] Louisiana State Univ, Lab Res Branch, Natl Hansens Dis Program, 3519E Sch Vet Med, Baton Rouge, LA 70803 USA; [Sharma, Rahul] NuProbe Inc, Cambridge, MA 02140 USA	Louisiana State University School of Veterinary Medicine; Louisiana State University System; Louisiana State University; Louisiana State University System; Louisiana State University	Li, SS (corresponding author), Louisiana State Univ, Sch Vet Med, Dept Comparat Biomed Sci, Baton Rouge, LA 70803 USA.	shli@lsu.edu			National Science Foundation [MCB-1615550]	National Science Foundation(National Science Foundation (NSF))	We are deeply in debt to Elena Sviderskaya and Philip Goff at Wellcome Trust Functional Genomics Cell Bank for supplying human melanocyte and melanoma cell lines. We also thank Mary Price at the Cell Analysis Core Facility, Louisiana Cancer Research Center for flow cytometry analysis, cell sorting and single cell deposition, and Dr Luan Vu at our department for analysis and graphic preparation of flow cytometry data. This study was supported by the National Science Foundation (MCB-1615550 to SL).	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Bandyopadhyay D, 2000, ANN NY ACAD SCI, V908, P71; Bansal R, 2010, CELL CYCLE, V9, P2782, DOI 10.4161/cc.9.14.12251; Bektas M, 2003, BIOCHEMISTRY-US, V42, P12181, DOI 10.1021/bi035051y; Blackburn PR, 2017, APPL CLIN GENET, V10, P57, DOI 10.2147/TACG.S125962; Brennan DF, 2011, NATURE, V472, P366, DOI 10.1038/nature09860; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Caloca MJ, 2003, EMBO J, V22, P3326, DOI 10.1093/emboj/cdg316; Carpenter K, 2015, NUTR HEALTH SER, P145, DOI 10.1007/978-1-4939-1923-9_12; Castellone RD, 2011, CANCER LETT, V312, P197, DOI 10.1016/j.canlet.2011.08.013; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Childs BG, 2014, EMBO REP, V15, P1139, DOI 10.15252/embr.201439245; Cole JT, 2015, NUTR HEALTH SER, P13, DOI 10.1007/978-1-4939-1923-9_2; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Dankner M, 2018, ONCOGENE, V37, P3183, DOI 10.1038/s41388-018-0171-x; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Deschenes-Simard X, 2013, GENE DEV, V27, P900, DOI 10.1101/gad.203984.112; Dhanasekaran DN, 2007, ONCOGENE, V26, P3185, DOI 10.1038/sj.onc.1210411; Dong B, 2017, BIOCHEM J, V474, P4065, DOI 10.1042/BCJ20170676; Dong L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020278; Fukuda H, 2016, ACS MED CHEM LETT, V7, P493, DOI 10.1021/acsmedchemlett.6b00014; Galanos P, 2016, NAT CELL BIOL, V18, P777, DOI 10.1038/ncb3378; Georgakilas AG, 2017, TRENDS MOL MED, V23, P310, DOI 10.1016/j.molmed.2017.02.001; Goldman M., 2019, UCSC XENA PLATFORM P; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Gray-Schopfer VC, 2006, BRIT J CANCER, V95, P496, DOI 10.1038/sj.bjc.6603283; Hedman AC, 2015, EMBO REP, V16, P427, DOI 10.15252/embr.201439834; Hernandez B, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020394; Hernandez-Segura A, 2018, TRENDS CELL BIOL, V28, P436, DOI 10.1016/j.tcb.2018.02.001; Holecek M, 2018, NUTR METAB, V15, DOI 10.1186/s12986-018-0271-1; Kakadia S, 2018, ONCOTARGETS THER, V11, P7095, DOI 10.2147/OTT.S182721; Kidger AM, 2016, SEMIN CELL DEV BIOL, V50, P125, DOI 10.1016/j.semcdb.2016.01.009; Kong BY, 2016, MELANOMA MANAG, V3, P33, DOI 10.2217/mmt.15.38; Kotsantis P, 2018, CANCER DISCOV, V8, P537, DOI 10.1158/2159-8290.CD-17-1461; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Labazi M, 2003, ESSAYS BIOCHEM, V39, P89, DOI 10.1042/bse0390089; Lake D, 2016, CELL MOL LIFE SCI, V73, P4397, DOI 10.1007/s00018-016-2297-8; Lee EYHP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003236; Li W, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0843-6; Li W, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0554-4; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; McDuff FKE, 2011, CELL SIGNAL, V23, P6, DOI 10.1016/j.cellsig.2010.07.004; Melnikova VO, 2003, ONCOGENE, V22, P5958, DOI 10.1038/sj.onc.1206595; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Reynolds LF, 2004, J BIOL CHEM, V279, P18239, DOI 10.1074/jbc.M400257200; Sambrook J, 2006, CSH PROTOC, V1, P3871; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Scott MC, 2002, J CELL SCI, V115, P2349; Shamma A, 2009, CANCER CELL, V15, P255, DOI 10.1016/j.ccr.2009.03.001; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Shortt J, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a009829; Sin WC, 2004, ONCOGENE, V23, P6299, DOI 10.1038/sj.onc.1207838; SURH CD, 1989, HEPATOLOGY, V9, P63, DOI 10.1002/hep.1840090110; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tomczak Katarzyna, 2015, Contemp Oncol (Pozn), V19, pA68, DOI 10.5114/wo.2014.47136; Tsuruta M, 1998, J HUM GENET, V43, P91, DOI 10.1007/s100380050047; Vredeveld LCW, 2012, GENE DEV, V26, P1055, DOI 10.1101/gad.187252.112; Wellbrock C, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00033; Wilsbacher JL, 2006, CELL COMMUN SIGNAL, V4; Wyder L, 2011, ANGIOGENESIS, V14, P533, DOI 10.1007/s10456-011-9238-9; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	66	5	6	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					723	738		10.1038/s41388-019-1022-0	http://dx.doi.org/10.1038/s41388-019-1022-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31548614				2022-12-17	WOS:000509197200001
J	Fotouhi, O; Kjellin, H; Juhlin, CC; Pan, YB; Vesterlund, M; Ghaderi, M; Yousef, A; Andersson-Sand, H; Kharaziha, P; Caramuta, S; Kjellman, M; Zedenius, J; Larsson, C; Orre, LM				Fotouhi, Omid; Kjellin, Hanna; Juhlin, C. Christofer; Pan, Yanbo; Vesterlund, Mattias; Ghaderi, Mehran; Yousef, Abdelhamid; Andersson-Sand, Hillevi; Kharaziha, Pedram; Caramuta, Stefano; Kjellman, Magnus; Zedenius, Jan; Larsson, Catharina; Orre, Lukas M.			Proteomics identifies neddylation as a potential therapy target in small intestinal neuroendocrine tumors	ONCOGENE			English	Article							NEDD8-ACTIVATING ENZYME-INHIBITOR; PEVONEDISTAT TAK-924/MLN4924; RBX1 EXPRESSION; HUMAN CANCER; PHASE-I; NEDD8; P27(KIP1); CULLIN; DEGRADATION; SUPPRESSOR	Patients with small intestinal neuroendocrine tumors (SI-NETs) frequently develop spread disease; however, the underlying molecular mechanisms of disease progression are not known and effective preventive treatment strategies are lacking. Here, protein expression profiling was performed by HiRIEF-LC-MS in 14 primary SI-NETs from patients with and without liver metastases detected at the time of surgery and initial treatment. Among differentially expressed proteins, overexpression of the ubiquitin-like protein NEDD8 was identified in samples from patients with liver metastasis. Further, NEDD8 correlation analysis indicated co-expression with RBX1, a key component in cullin-RING ubiquitin ligases (CRLs). In vitro inhibition of neddylation with the therapeutic agent pevonedistat (MLN4924) resulted in a dramatic decrease of proliferation in SI-NET cell lines. Subsequent mass spectrometry-based proteomics analysis of pevonedistat effects and effects of the proteasome inhibitor bortezomib revealed stabilization of multiple targets of CRLs including p27, an established tumor suppressor in SI-NET. Silencing of NEDD8 and RBX1 using siRNA resulted in a stabilization of p27, suggesting that the cellular levels of NEDD8 and RBX1 affect CRL activity. Inhibition of CRL activity, by either NEDD8/RBX1 silencing or pevonedistat treatment of cells resulted in induction of apoptosis that could be partially rescued by siRNA-based silencing of p27. Differential expression of both p27 and NEDD8 was confirmed in a second cohort of SI-NET using immunohistochemistry. Collectively, these findings suggest a role for CRLs and the ubiquitin proteasome system in suppression of p27 in SI-NET, and inhibition of neddylation as a putative therapeutic strategy in SI-NET.	[Fotouhi, Omid; Juhlin, C. Christofer; Pan, Yanbo; Vesterlund, Mattias; Ghaderi, Mehran; Larsson, Catharina; Orre, Lukas M.] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden; [Kjellin, Hanna; Kjellman, Magnus; Zedenius, Jan] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden; [Juhlin, C. Christofer] Karolinska Univ Hosp Solna, Dept Pathol & Cytol, Stockholm, Sweden; [Pan, Yanbo; Vesterlund, Mattias; Andersson-Sand, Hillevi; Orre, Lukas M.] SciLifeLab, Stockholm, Sweden; [Yousef, Abdelhamid] Univ Cambridge, Dept Pharmacol, Cambridge, England; [Kharaziha, Pedram] Linkoping Univ Hosp, Dept Clin Genet, Linkoping, Sweden; [Caramuta, Stefano] Uppsala Univ, Uppsala Clin Res Ctr, Uppsala, Sweden; [Kjellman, Magnus; Zedenius, Jan] Karolinska Univ Hosp Solna, Dept Breast Endocrine Tumours & Sarcoma, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; SciLifeLab; University of Cambridge; Linkoping University; Uppsala University; Karolinska Institutet; Karolinska University Hospital	Larsson, C; Orre, LM (corresponding author), Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.; Orre, LM (corresponding author), SciLifeLab, Stockholm, Sweden.	catharina.larsson@ki.se; lukas.orre@ki.se	Vesterlund, Mattias/AAX-8014-2021; Juhlin, Carl Christofer/C-1125-2016; Pan, Yanbo/G-9371-2016; Ghaderi, Mehran/AAB-7416-2021	Juhlin, Carl Christofer/0000-0002-5945-9081; Pan, Yanbo/0000-0001-9442-7782; Vesterlund, Mattias/0000-0001-9471-6592; Orre, Lukas/0000-0002-0384-1003	Novartis; Swedish Research Council; Swedish Cancer Society; Cancer Society in Stockholm; Gustav V Jubilee Foundation; Stockholm County Council; Karolinska Institutet	Novartis(Novartis); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Cancer Society in Stockholm; Gustav V Jubilee Foundation; Stockholm County Council(Stockholm County Council); Karolinska Institutet(Karolinska Institutet)	The study was supported by grants from Novartis, the Swedish Research Council, the Swedish Cancer Society, the Cancer Society in Stockholm, the Gustav V Jubilee Foundation, Stockholm County Council, and Karolinska Institutet. Mass spectrometry-based proteomics analysis was performed at the Clinical Proteomics Mass Spectrometry facility located at SciLifeLab in Solna, Sweden.	Bhatia S, 2016, INVEST NEW DRUG, V34, P439, DOI 10.1007/s10637-016-0348-5; Branca RMM, 2014, NAT METHODS, V11, P59, DOI [10.1038/NMETH.2732, 10.1038/nmeth.2732]; Brownell JE, 2010, MOL CELL, V37, P102, DOI 10.1016/j.molcel.2009.12.024; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Cunningham JL, 2011, EUR J CLIN INVEST, V41, P1353, DOI 10.1111/j.1365-2362.2011.02537.x; Duda DM, 2008, CELL, V134, P995, DOI 10.1016/j.cell.2008.07.022; Edfeldt K, 2017, NEUROENDOCRINOLOGY, V105, P170, DOI 10.1159/000452891; Emanuele MJ, 2011, CELL, V147, P459, DOI 10.1016/j.cell.2011.09.019; Enchev RI, 2015, NAT REV MOL CELL BIO, V16, P30, DOI 10.1038/nrm3919; Fotouhi O, 2016, J CLIN ENDOCR METAB, V101, P3616, DOI 10.1210/jc.2016-2028; Francis JM, 2013, NAT GENET, V45, P1483, DOI 10.1038/ng.2821; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Galvan JA, 2013, AM J CLIN PATHOL, V140, P61, DOI 10.1309/AJCPIV40ISTBXRAX; Gao H, 2004, P NATL ACAD SCI USA, V101, P17204, DOI 10.1073/pnas.0407693101; Gao J, 2009, GLIA, V57, P989, DOI 10.1002/glia.20823; Hashemi J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-505; Karpathakis A, 2016, CLIN CANCER RES, V22, P250, DOI 10.1158/1078-0432.CCR-15-0373; Klimstra, 2010, WHO CLASSIFICATION T, P102; Kytola S, 2001, AM J PATHOL, V158, P1803, DOI 10.1016/S0002-9440(10)64136-3; Lee J, 2009, EXP MOL MED, V41, P765, DOI 10.3858/emm.2009.41.11.102; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Migita K, 2014, GASTRIC CANCER, V17, P601, DOI 10.1007/s10120-013-0318-y; Muraoka RS, 2002, MOL CELL BIOL, V22, P2204, DOI 10.1128/MCB.22.7.2204-2219.2002; Nieser M, 2017, NEUROENDOCRINOLOGY, V104, P302, DOI 10.1159/000446917; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pan ZQ, 2004, ONCOGENE, V23, P1985, DOI 10.1038/sj.onc.1207414; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; Ritz C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0146021; Salon C, 2007, J PATHOL, V213, P303, DOI 10.1002/path.2223; Sarantopoulos J, 2016, CLIN CANCER RES, V22, P847, DOI 10.1158/1078-0432.CCR-15-1338; Shah JJ, 2016, CLIN CANCER RES, V22, P34, DOI 10.1158/1078-0432.CCR-15-1237; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Stalberg P, 2016, J INTERN MED, V280, P584, DOI 10.1111/joim.12526; Swords RT, 2018, BLOOD, V131, P1415, DOI 10.1182/blood-2017-09-805895; Tian DW, 2019, CANCER SCI, V110, P458, DOI 10.1111/cas.13865; Wang W, 2013, J SURG ONCOL, V107, P758, DOI 10.1002/jso.23317; Watson IR, 2011, CANCER CELL, V19, P168, DOI 10.1016/j.ccr.2011.01.002; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Xie P, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.195; Xing R, 2016, SURG ONCOL, V25, P147, DOI 10.1016/j.suronc.2016.05.006; Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111; Yu J, 2018, CANC MED; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhou LS, 2018, CELL SIGNAL, V44, P92, DOI 10.1016/j.cellsig.2018.01.009; Zhou Y, 2017, ONCOGENE, V36, P731, DOI 10.1038/onc.2016.242	47	5	6	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2019	38	43					6881	6897		10.1038/s41388-019-0938-8	http://dx.doi.org/10.1038/s41388-019-0938-8			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JH4GX	31406256	Green Published, hybrid			2022-12-17	WOS:000492728000001
J	He, YF; Johnson, DT; Yang, JS; Wu, HQ; You, S; Yoon, J; Lee, DH; Kim, WK; Aldahl, J; Le, V; Hooker, E; Yu, EJ; Geradts, J; Cardiff, RD; Sun, ZJ				He, Yongfeng; Johnson, Daniel T.; Yang, Julie S.; Wu, Huiqing; You, Sungyong; Yoon, Junhee; Lee, Dong-Hoon; Kim, Won Kyung; Aldahl, Joseph; Le, Vien; Hooker, Erika; Yu, Eun-Jeong; Geradts, Joseph; Cardiff, Robert D.; Sun, Zijie			Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; RB DEFICIENCY; CHIP-SEQ; CANCER; P53; GENE; DATABASE; EXPRESSION; STEM; RESISTANCE	Recent genome analysis of human prostate cancers demonstrated that both AR gene amplification and TP53 mutation are among the most frequently observed alterations in advanced prostate cancer. However, the biological role of these dual genetic alterations in prostate tumorigenesis is largely unknown. In addition, there are no biologically relevant models that can be used to assess the molecular mechanisms for these genetic abnormalities. Here, we report a novel mouse model, in which elevated transgenic AR expression and Trp53 deletion occur simultaneously in mouse prostatic epithelium to mimic human prostate cancer cells. These compound mice developed an earlier onset of high-grade prostatic intraepithelial neoplasia and accelerated prostate tumors in comparison with mice harboring only the AR transgene. Histological analysis showed prostatic sarcomatoid and basaloid carcinomas with massive squamous differentiation in the above compound mice. RNA-sequencing analyses identified a robust enrichment of the signature genes for human prostatic basal cell carcinomas in the above prostate tumors. Master regulator analysis revealed SOX2 as a transcriptional regulator in prostatic basal cell tumors. Elevated expression of SOX2 and its downstream target genes were detected in prostatic tumors of the compound mice. Chromatin immunoprecipitation analyses implicate a coregulatory role of AR and SOX2 in the expression of prostatic basal cell signature genes. Our data demonstrate a critical role of SOX2 in prostate tumorigenesis and provide mechanistic insight into prostate tumor aggressiveness and progression mediated by aberrant AR and p53 signaling pathways.	[He, Yongfeng; Yang, Julie S.; Lee, Dong-Hoon; Kim, Won Kyung; Aldahl, Joseph; Le, Vien; Hooker, Erika; Yu, Eun-Jeong; Sun, Zijie] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA 91010 USA; [He, Yongfeng; Johnson, Daniel T.; Hooker, Erika; Yu, Eun-Jeong; Sun, Zijie] Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA; [Wu, Huiqing] City Hope Natl Med Ctr, Beckman Res Inst, Dept Pathol, Duarte, CA 91010 USA; [You, Sungyong; Yoon, Junhee] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Surg, Div Canc Biol & Therapeut, Los Angeles, CA 90048 USA; [Geradts, Joseph] City Hope Natl Med Ctr, Beckman Res Inst, Dept Populat Sci, Duarte, CA 91010 USA; [Cardiff, Robert D.] Univ Calif Davis, Ctr Comparat Med, 4115 Primate Res Dr, Davis, CA 95616 USA	City of Hope; Beckman Research Institute of City of Hope; Stanford University; City of Hope; Beckman Research Institute of City of Hope; Cedars Sinai Medical Center; City of Hope; Beckman Research Institute of City of Hope; University of California System; University of California Davis	Sun, ZJ (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA 91010 USA.; Sun, ZJ (corresponding author), Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA.	zjsun@coh.org	You, Sungyong/AAJ-7372-2020; le, vien/GWV-7308-2022; He, Yongfeng/AAR-8257-2020	You, Sungyong/0000-0003-3513-1783; Johnson, Daniel/0000-0003-4669-037X; Hooker, Erika/0000-0002-4515-4041	Public Health Service grants [R01CA070297, R01CA166894, R21CA190021, R01DK104941]; NATIONAL CANCER INSTITUTE [R01CA166894, R01CA070297, R21CA190021] Funding Source: NIH RePORTER	Public Health Service grants(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Public Health Service grants, R01CA070297, R01CA166894, R21CA190021, and R01DK104941.	Aggarwal R, 2018, J CLIN ONCOL, V36, P2492, DOI 10.1200/JCO.2017.77.6880; BOOKSTEIN R, 1993, CANCER RES, V53, P3369; Cahan P, 2014, CELL, V158, P903, DOI 10.1016/j.cell.2014.07.020; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chamarthy Murthy R., 2011, Yale Journal of Biology and Medicine, V84, P391; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen L, 2011, BIOINFORMATICS, V27, P1447, DOI 10.1093/bioinformatics/btr156; Chen Y, 2013, NAT MED, V19, P1023, DOI 10.1038/nm.3216; Esposito S, 2015, ONCOTARGET, V6, P17121, DOI 10.18632/oncotarget.2736; Ewels P, 2016, BIOINFORMATICS, V32, P3047, DOI 10.1093/bioinformatics/btw354; Frohwitter G, 2016, ONCOL LETT, V12, P107, DOI 10.3892/ol.2016.4588; Grieshammer U, 2008, GENESIS, V46, P69, DOI 10.1002/dvg.20366; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Huggins C, 2002, J UROLOGY, V168, P9, DOI 10.1016/S0022-5347(05)64820-3; Ittmann M, 2013, CANCER RES, V73, P2718, DOI 10.1158/0008-5472.CAN-12-4213; Johnson DT, 2013, J BIOL CHEM, V288, P3727, DOI 10.1074/jbc.M112.417568; Kleihues P, 1997, AM J PATHOL, V150, P1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koivisto P, 1997, CANCER RES, V57, P314; Kwak MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053476; KYPRIANOU N, 1988, ENDOCRINOLOGY, V122, P552, DOI 10.1210/endo-122-2-552; Lachmann A, 2010, BIOINFORMATICS, V26, P2438, DOI 10.1093/bioinformatics/btq466; Lee J, 2007, NUCLEIC ACIDS RES, V35, P4523, DOI 10.1093/nar/gkm476; Lee SH, 2016, ONCOGENE, V35, P702, DOI 10.1038/onc.2015.117; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Linhart C, 2008, GENOME RES, V18, P1180, DOI 10.1101/gr.076117.108; Matusik RJ, 2008, DIFFERENTIATION, V76, P682, DOI 10.1111/j.1432-0436.2008.00276.x; Mollaoglu G, 2018, IMMUNITY, V49, P764, DOI 10.1016/j.immuni.2018.09.020; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Quigley DA, 2018, CELL, V174, P758, DOI 10.1016/j.cell.2018.06.039; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Sarkar A, 2013, CELL STEM CELL, V12, P15, DOI 10.1016/j.stem.2012.12.007; Smith BA, 2015, P NATL ACAD SCI USA, V112, pE6544, DOI 10.1073/pnas.1518007112; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Stoyanova T, 2013, P NATL ACAD SCI USA, V110, P20111, DOI 10.1073/pnas.1320565110; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takeda DY, 2018, CELL, V174, P422, DOI 10.1016/j.cell.2018.05.037; VOELLER HJ, 1994, J UROLOGY, V151, P492; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wyce A, 2010, MOL ENDOCRINOL, V24, P1665, DOI 10.1210/me.2010-0138; Yang JH, 2013, NUCLEIC ACIDS RES, V41, pD177, DOI 10.1093/nar/gks1060; You SY, 2016, CANCER RES, V76, P4948, DOI 10.1158/0008-5472.CAN-16-0902; You S, 2014, P NATL ACAD SCI USA, V111, P550, DOI 10.1073/pnas.1311239111; Zhao SG, 2017, JAMA ONCOL, V3, P1663, DOI 10.1001/jamaoncol.2017.0751; Zhou ZX, 2007, CANCER RES, V67, P5683, DOI 10.1158/0008-5472.CAN-07-0768; Zhou ZX, 2006, CANCER RES, V66, P7889, DOI 10.1158/0008-5472.CAN-06-0486; Zhu CF, 2011, J BIOL CHEM, V286, P33478, DOI 10.1074/jbc.M111.269894	49	5	5	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2019	38	38					6507	6520		10.1038/s41388-019-0901-8	http://dx.doi.org/10.1038/s41388-019-0901-8			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IY7XR	31358900	Green Submitted, Green Accepted			2022-12-17	WOS:000486609000003
J	Yao, S; Huang, HY; Han, XK; Ye, Y; Qin, Z; Zhao, GX; Li, FM; Hu, GH; Hu, L; Ji, HB				Yao, Shun; Huang, Hsin-Yi; Han, Xiangkun; Ye, Yi; Qin, Zhen; Zhao, Gaoxiang; Li, Fuming; Hu, Guohong; Hu, Liang; Ji, Hongbin			Keratin 14-high subpopulation mediates lung cancer metastasis potentially through Gkn1 upregulation	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMAS; 1 INDUCES SENESCENCE; K-RAS ONCOGENE; SIGNALING PATHWAY; MESENCHYMAL TRANSITION; MOLECULAR SWITCH; GENE-EXPRESSION; GASTRIC-MUCOSA; PROTEIN; DIFFERENTIATION	Metastasis is the leading cause of lung cancer-related death. Elucidating the metastasis process can provide new avenues to inhibit this malignant behavior of cancer cells. Here we found that human lung cancers with high Keratin 14 (K14) expression were associated with nodal metastasis and poor survival. Using the Kras(G12D)/Trp53(L/L) lung cancer mouse model, we confirmed that K14-high cancer cells harbored increased metastatic potential. Mechanistic investigation revealed that Gastrokine 1 (Gknl) expression positively correlated with K14 level, cancer metastasis, and poor patient survival. Importantly, ectopic expression of Gknl enhanced the metastatic capability of K14-low cells in vitro and in vivo, whereas knockdown of Gknl did the opposite, indicating the importance of Gknl in mediating the metastasis of K14-high cells. Further study demonstrated that Gknl expression conferred K14-high cells resistance to anoikis, which is critical for cancer metastasis. Collectively, our findings demonstrate that K14-high cells contribute to lung cancer metastasis potentially through inhibition of anoikis via upregulation of Gknl.	[Yao, Shun; Huang, Hsin-Yi; Han, Xiangkun; Ye, Yi; Qin, Zhen; Zhao, Gaoxiang; Li, Fuming; Hu, Liang; Ji, Hongbin] Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, State Key Lab Cell Biol, Shanghai 200031, Peoples R China; [Yao, Shun; Huang, Hsin-Yi; Han, Xiangkun; Ye, Yi; Qin, Zhen; Zhao, Gaoxiang; Li, Fuming; Hu, Liang; Ji, Hongbin] Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, Innovat Ctr Cell Signaling Network, Shanghai 200031, Peoples R China; [Yao, Shun; Huang, Hsin-Yi; Han, Xiangkun; Ye, Yi; Qin, Zhen; Zhao, Gaoxiang; Li, Fuming; Hu, Liang; Ji, Hongbin] Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, CAS Ctr Excellence Mol Cell Sci, Shanghai 200031, Peoples R China; [Yao, Shun; Qin, Zhen; Ji, Hongbin] Univ Chinese Acad Sci, Beijing 100049, Peoples R China; [Ye, Yi; Ji, Hongbin] Shanghai Tech Univ, Sch Life Sci & Technol, Shanghai 200120, Peoples R China; [Hu, Guohong] Chinese Acad Sci, Inst Hlth Sci, Shanghai Inst Biol Sci, Key Lab Stem Cell Biol, Shanghai 200031, Peoples R China; [Hu, Guohong] Shanghai Jiao Tong Univ, Sch Med, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; ShanghaiTech University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University	Hu, L; Ji, HB (corresponding author), Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, State Key Lab Cell Biol, Shanghai 200031, Peoples R China.; Hu, L; Ji, HB (corresponding author), Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, Innovat Ctr Cell Signaling Network, Shanghai 200031, Peoples R China.; Hu, L; Ji, HB (corresponding author), Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, CAS Ctr Excellence Mol Cell Sci, Shanghai 200031, Peoples R China.; Ji, HB (corresponding author), Univ Chinese Acad Sci, Beijing 100049, Peoples R China.; Ji, HB (corresponding author), Shanghai Tech Univ, Sch Life Sci & Technol, Shanghai 200120, Peoples R China.	liang.hu@sibcb.ac.cn; hbji@sibcb.ac.cn	; ji, hong bin/I-5625-2017	Hu, Guohong/0000-0002-2980-5166; Huang, Hsinyi/0000-0003-1217-4131; ji, hong bin/0000-0003-0891-6390	National Basic Research Program of China [2017YFA0505501]; Strategic Priority Research Program of the Chinese Academy of Sciences [XDB19020201]; National Natural Science Foundation of China [81430066, 91731314, 31621003, 81872312, 81871875, 81802279]; China Postdoctoral Science Foundation [2016M601667]	National Basic Research Program of China(National Basic Research Program of China); Strategic Priority Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	The authors thank Dr. Tyler Jacks and Dr. KwokKin Wong for kindly providing the Kras<SUP>G12D</SUP>/Trp53<SUP>L/L</SUP> mice. We are grateful to Dr. Luonan Chen, Ying Tang, and Zaoyuan Fang for providing bioinformatic supports. We thank Dr. Lin He for critical review of the manuscript. This work was supported by the National Basic Research Program of China (Grant 2017YFA0505501), Strategic Priority Research Program of the Chinese Academy of Sciences (Grant XDB19020201), the National Natural Science Foundation of China (Grants 81430066, 91731314, 31621003, 81872312, 81871875 and 81802279), and the China Postdoctoral Science Foundation (2016M601667).	Aceto N, 2014, CELL, V158, P1110, DOI 10.1016/j.cell.2014.07.013; Almendro V, 2013, ANNU REV PATHOL-MECH, V8, P277, DOI 10.1146/annurev-pathol-020712-163923; Banyard J, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-387; Bao LM, 2016, CELL BIOL TOXICOL, V32, P419, DOI 10.1007/s10565-016-9343-z; Barcelos ACN, 2009, J CUTAN PATHOL, V36, P647, DOI 10.1111/j.1600-0560.2008.01127.x; Boone J, 2008, VIRCHOWS ARCH, V452, P507, DOI 10.1007/s00428-008-0602-0; Brady JJ, 2016, CANCER CELL, V29, P697, DOI 10.1016/j.ccell.2016.03.003; Camolotto SA, 2018, ELIFE, V7, DOI 10.7554/eLife.38579; Carrington EM, 2017, CELL DEATH DIFFER, V24, P878, DOI 10.1038/cdd.2017.30; Chen PL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125490; Chen Y, 2011, ONCOLOGY-BASEL, V80, P333, DOI 10.1159/000329098; Cheung KJ, 2016, P NATL ACAD SCI USA, V113, pE854, DOI 10.1073/pnas.1508541113; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Choi KH, 2010, CANCER RES TREAT, V42, P107, DOI 10.4143/crt.2010.42.2.107; Chu PG, 2002, HISTOPATHOLOGY, V40, P403, DOI 10.1046/j.1365-2559.2002.01387.x; Chu PG, 2001, HISTOPATHOLOGY, V39, P9, DOI 10.1046/j.1365-2559.2001.01105.x; Chuang CH, 2017, NAT MED, V23, P291, DOI 10.1038/nm.4285; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Dhanda J, 2014, BRIT J CANCER, V111, P2114, DOI 10.1038/bjc.2014.500; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Doerks T, 2002, GENOME RES, V12, P47, DOI 10.1101/gr.203201; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Gu Y, 2012, ONCOGENE, V31, P469, DOI 10.1038/onc.2011.247; Guo XY, 2014, WORLD J GASTROENTERO, V20, P16702, DOI 10.3748/wjg.v20.i44.16702; Han CP, 2009, MODERN PATHOL, V22, P797, DOI 10.1038/modpathol.2009.31; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kim BG, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3203; Kim YN, 2012, INT J CELL BIOL, V2012, DOI DOI 10.1155/2012/306879; Kong HK, 2012, J BIOL CHEM, V287, P38889, DOI 10.1074/jbc.M112.394270; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Kouwenhoven EN, 2015, EMBO REP, V16, P863, DOI 10.15252/embr.201439941; LACY ER, 1993, J CLIN GASTROENTEROL, V17, pS125, DOI 10.1097/00004836-199312001-00023; Lyda MH, 2000, HUM PATHOL, V31, P980, DOI 10.1053/hupa.2000.9076; Martin TE, 2003, AM J PHYSIOL-GASTR L, V285, pG332, DOI 10.1152/ajpgi.00453.2002; Martini M, 2014, ANN MED, V46, P372, DOI 10.3109/07853890.2014.912836; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; Mazzoccoli G, 2012, J CANCER RES CLIN, V138, P501, DOI 10.1007/s00432-011-1126-6; Moquet-Torcy G, 2014, NUCLEIC ACIDS RES, V42, P11011, DOI 10.1093/nar/gku814; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; O'Gorman DM, 2001, LEUKEMIA, V15, P21, DOI 10.1038/sj.leu.2401998; Offield MF, 1996, DEVELOPMENT, V122, P983; Oien KA, 2004, J PATHOL, V203, P789, DOI 10.1002/path.1583; Ooi AT, 2010, CANCER RES, V70, P6639, DOI 10.1158/0008-5472.CAN-10-0455; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026; Portt L, 2011, BBA-MOL CELL RES, V1813, P238, DOI 10.1016/j.bbamcr.2010.10.010; Quemener C, 2007, CANCER RES, V67, P9, DOI 10.1158/0008-5472.CAN-06-2448; Rippa E, 2011, J CELL PHYSIOL, V226, P2571, DOI 10.1002/jcp.22601; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; RODENHUIS S, 1988, CANCER RES, V48, P5738; Russo C, 2018, P NATL ACAD SCI USA, V115, pE906, DOI 10.1073/pnas.1713773115; Sakai Y, 2013, INT J SURG PATHOL, V21, P476, DOI 10.1177/1066896913489345; Schmidt M, 2002, BRIT J CANCER, V87, P924, DOI 10.1038/sj.bjc.6600566; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Simone TM, 2014, ADV WOUND CARE, V3, P281, DOI 10.1089/wound.2013.0512; Snyder EL, 2013, MOL CELL, V50, P185, DOI 10.1016/j.molcel.2013.02.018; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Tang L, 2013, CLIN CANCER RES, V19, P2014, DOI 10.1158/1078-0432.CCR-12-0349; Toback FG, 2003, AM J PHYSIOL-GASTR L, V285, pG344, DOI 10.1152/ajpgi.00455.2002; Tuveson DA, 1999, ONCOGENE, V18, P5318, DOI 10.1038/sj.onc.1203107; van Dorst EBL, 1998, J CLIN PATHOL, V51, P679, DOI 10.1136/jcp.51.9.679; Walia V, 2012, ONCOGENE, V31, P2237, DOI 10.1038/onc.2011.392; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Winslow MM, 2011, NATURE, V473, P101, DOI 10.1038/nature09881; Woolf PJ, 2009, LUNG CANCER METASTASIS: NOVEL BIOLOGICAL MECHANISMS AND IMPACT ON CLINICAL PRACTICE, P383, DOI 10.1007/978-1-4419-0772-1_17; Xing R, 2012, GUT, V61, P43, DOI 10.1136/gut.2010.230623; Yoon JH, 2014, J GASTRIC CANCER, V14, P147, DOI 10.5230/jgc.2014.14.3.147; Yoon JH, 2014, ONCOTARGET, V5, P11695, DOI 10.18632/oncotarget.2586; Yoon JH, 2013, J CELL BIOCHEM, V114, P1800, DOI 10.1002/jcb.24524; Yoon JH, 2011, J CANCER RES CLIN, V137, P1697, DOI 10.1007/s00432-011-1051-8; Yoon JH, 2011, J PATHOL, V223, P618, DOI 10.1002/path.2838; Yu XM, 2016, CLIN CANCER RES, V22, P3582, DOI 10.1158/1078-0432.CCR-15-1749; Zhang S, 2015, DIS MARKERS, V2015, DOI 10.1155/2015/824304; Zheng YB, 2016, ONCOTARGET, V7, P62159, DOI 10.18632/oncotarget.11398	80	5	5	2	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2019	38	36					6354	6369		10.1038/s41388-019-0889-0	http://dx.doi.org/10.1038/s41388-019-0889-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IX6EX	31320708				2022-12-17	WOS:000485776800003
J	Tassone, E; Bradaschia-Correa, V; Xiong, XZ; Sastre-Perona, A; Josephson, AM; Khodadadi-Jamayran, A; Melamed, J; Bu, L; Kahler, DJ; Ossowski, L; Leucht, P; Schober, M; Wilson, EL				Tassone, Evelyne; Bradaschia-Correa, Vivian; Xiong, Xiaozhong; Sastre-Perona, Ana; Josephson, Anne Marie; Khodadadi-Jamayran, Alireza; Melamed, Jonathan; Bu, Lei; Kahler, David J.; Ossowski, Liliana; Leucht, Philipp; Schober, Markus; Wilson, Elaine L.			KLF4 as a rheostat of osteolysis and osteogenesis in prostate tumors in the bone	ONCOGENE			English	Article							MARROW MICROENVIRONMENT; TNF-ALPHA; CANCER; GENE; EXPRESSION; GROWTH; CELLS; DIFFERENTIATION; METASTASIS; SUPPRESSOR	We previously showed that KLF4, a gene highly expressed in murine prostate stem cells, blocks the progression of indolent intraepithelial prostatic lesions into aggressive and rapidly growing tumors. Here, we show that the anti-tumorigenic effect of KLF4 extends to PC3 human prostate cancer cells growing in the bone. We compared KLF4 null cells with cells transduced with a DOX-inducible KLF4 expression system, and find KLF4 function inhibits PC3 growth in monolayer and soft agar cultures. Furthermore, KLF4 null cells proliferate rapidly, forming large, invasive, and osteolytic tumors when injected into mouse femurs, whereas KLF4 re-expression immediately after their intra-femoral inoculation blocks tumor development and preserves a normal bone architecture. KLF4 re-expression in established KLF4 null bone tumors inhibits their osteolytic effects, preventing bone fractures and inducing an osteogenic response with new bone formation. In addition to these profound biological changes, KLF4 also induces a transcriptional shift from an osteolytic program in KLF4 null cells to an osteogenic program. Importantly, bioinformatic analysis shows that genes regulated by KLF4 overlap significantly with those expressed in metastatic prostate cancer patients and in three individual cohorts with bone metastases, strengthening the clinical relevance of the findings in our xenograft model.	[Tassone, Evelyne; Bradaschia-Correa, Vivian; Xiong, Xiaozhong; Josephson, Anne Marie; Leucht, Philipp; Schober, Markus; Wilson, Elaine L.] NYU, Dept Cell Biol, Sch Med, New York, NY 10016 USA; [Bradaschia-Correa, Vivian; Josephson, Anne Marie; Leucht, Philipp] NYU, Dept Orthoped Surg, Sch Med, New York, NY 10016 USA; [Sastre-Perona, Ana; Schober, Markus] NYU, Ronald O Perelman Dept Dermatol, Sch Med, New York, NY 10016 USA; [Khodadadi-Jamayran, Alireza; Melamed, Jonathan] NYU, Dept Pathol, Sch Med, New York, NY 10016 USA; [Khodadadi-Jamayran, Alireza] NYU, Appl Bioinformat Labs, Sch Med, New York, NY 10016 USA; [Bu, Lei] NYU, Dept Med, Sch Med, New York, NY 10016 USA; [Kahler, David J.] NYU, High Throughput Biol Lab, Sch Med, New York, NY 10016 USA; [Ossowski, Liliana] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; [Wilson, Elaine L.] NYU, Dept Urol, Sch Med, New York, NY 10016 USA	New York University; New York University; New York University; New York University; New York University; New York University; New York University; Icahn School of Medicine at Mount Sinai; New York University	Schober, M; Wilson, EL (corresponding author), NYU, Dept Cell Biol, Sch Med, New York, NY 10016 USA.; Schober, M (corresponding author), NYU, Ronald O Perelman Dept Dermatol, Sch Med, New York, NY 10016 USA.; Wilson, EL (corresponding author), NYU, Dept Urol, Sch Med, New York, NY 10016 USA.	markus.schober@nyumc.org; elaine.wilson@nyumc.org	Melamed, Jonathan/AAV-3769-2020; Sastre-Perona, Ana/AAC-1202-2021	Melamed, Jonathan/0000-0003-2844-7990; BU, LEI/0000-0003-4476-2157; Khodadadi-Jamayran, Alireza/0000-0003-2495-7504; Tassone, Evelyne/0000-0003-0631-007X; Leucht, Philipp/0000-0002-8409-8513; Kahler, David/0000-0002-7144-2215	NIH [S10 OD010751, R01CA132641, R01AG056169, K08AR069099, R01CA181111, T32CA009161, T32AR064184]; American Cancer Society [RSG-16-033-01-DDC]; Department of Urology; Kimmel Center for Stem Cell Biology; Perlmutter Cancer Center [P30CA016087]; NYSTEM [C026719]; NATIONAL CANCER INSTITUTE [R01CA132641, R01CA181111, T32CA009161, P30CA016087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR069099, T32AR064184] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG056169] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Department of Urology; Kimmel Center for Stem Cell Biology; Perlmutter Cancer Center; NYSTEM; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Dr. E. Hernando-Monge (NYU School of Medicine) for the GFP-luciferase plasmid (BLIV513PA-1) and Drs. S. Logan and M. Garabedian (NYU School of Medicine) for helpful discussions. This study was supported by the NIH (R01CA132641 to E.L.W., R01AG056169 and K08AR069099 to P.L., R01CA181111 to M.S., T32CA009161 and T32AR064184 to A.S-P.), the American Cancer Society (RSG-16-033-01-DDC to M. S.), the Department of Urology and the Kimmel Center for Stem Cell Biology. Core funding (Applied Bioinformatics Laboratories, Genome Technology Center, High Throughput Biology Laboratory, Experimental Pathology Research Laboratory, Micro-CT) is partially supported by the Perlmutter Cancer Center (P30CA016087), NYSTEM (contract C026719), and NIH (S10 OD010751).	Anders Simon, 2010, Genome Biol, V11, pR106, DOI 10.1186/gb-2010-11-10-r106; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Armstrong AP, 2008, PROSTATE, V68, P92, DOI 10.1002/pros.20678; Barba M, 2012, J BIOMED BIOTECHNOL, V2012, P1; Body JJ, 2015, NAT REV UROL, V12, P340, DOI 10.1038/nrurol.2015.90; Borowicz S, 2014, JOVE-J VIS EXP, DOI 10.3791/51998; Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Chen XM, 2003, J MOL BIOL, V326, P665, DOI 10.1016/S0022-2836(02)01449-3; Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Fradet A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075092; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200; Ghaleb AM, 2017, GENE, V611, P27, DOI 10.1016/j.gene.2017.02.025; Gooding S, 2016, CURR OPIN PHARMACOL, V28, P43, DOI 10.1016/j.coph.2016.02.013; Hockemeyer D, 2008, CELL STEM CELL, V3, P346, DOI 10.1016/j.stem.2008.08.014; Hopkins DR, 2007, MATRIX BIOL, V26, P508, DOI 10.1016/j.matbio.2007.05.004; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kudo O, 2002, J PATHOL, V198, P220, DOI 10.1002/path.1190; Kumar A, 2016, NAT MED, V22, P369, DOI 10.1038/nm.4053; Lee HL, 2010, EXP MOL MED, V42, P437, DOI 10.3858/emm.2010.42.6.045; LeRoy BE, 2006, PROSTATE, V66, P1213, DOI 10.1002/pros.20408; Leucht P, 2007, BONE, V40, P919, DOI 10.1016/j.bone.2006.10.027; Li ZG, 2008, J CLIN INVEST, V118, P2697, DOI 10.1172/JCI33093; Liu YN, 2012, MOL CELL BIOL, V32, P941, DOI 10.1128/MCB.06306-11; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Morcos MW, 2018, BONE JOINT RES, V7, P397, DOI 10.1302/2046-3758.76.BJR-2017-0140.R2; Nandana S, 2017, CANCER RES, V77, P1331, DOI 10.1158/0008-5472.CAN-16-0497; Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00048; Park SH, 2018, CALCIFIED TISSUE INT, V102, P152, DOI 10.1007/s00223-017-0350-8; Quigley DA, 2018, CELL, V174, P758, DOI 10.1016/j.cell.2018.06.039; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Rowland BD, 2006, NAT REV CANCER, V6, P11, DOI 10.1038/nrc1780; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Rucci N, 2009, J CELL BIOL, V187, P669, DOI 10.1083/jcb.200906014; Sanchez-Sweatman Otto H., 1998, Invasion and Metastasis, V18, P297, DOI 10.1159/000024522; Sastre-Perona A, 2019, CELL STEM CELL, V24, P390, DOI 10.1016/j.stem.2019.01.003; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Sims NA, 2016, INT J BIOCHEM CELL B, V79, P14, DOI 10.1016/j.biocel.2016.08.003; Siu MK, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.79; Sottnik JL, 2013, CURR MOL MED, V13, P626; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tetreault MP, 2013, NAT REV CANCER, V13, P701, DOI 10.1038/nrc3582; Tsuji T, 2008, BIOCHEM BIOPH RES CO, V376, P186, DOI 10.1016/j.bbrc.2008.08.139; Uchimura T, 2017, DEVELOPMENT, V144, P3533, DOI 10.1242/dev.155598; Vela I, 2007, BJU INT, V99, P735, DOI 10.1111/j.1464-410X.2006.06670.x; Wang J, 2010, CANCER RES, V70, P10182, DOI 10.1158/0008-5472.CAN-10-2414; Wei DY, 2005, CANCER RES, V65, P2746, DOI 10.1158/0008-5472.CAN-04-3619; Wu JB, 2017, CANCER CELL, V31, P368, DOI 10.1016/j.ccell.2017.02.003; Xiong XZ, 2018, CELL REP, V25, P3006, DOI 10.1016/j.celrep.2018.11.065; Yoshida T, 2012, J BIOL CHEM, V287, P25706, DOI 10.1074/jbc.M112.361360; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067	61	5	6	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2019	38	29					5766	5777		10.1038/s41388-019-0841-3	http://dx.doi.org/10.1038/s41388-019-0841-3			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IQ4WS	31239516	Green Accepted, Green Published			2022-12-17	WOS:000480752800002
J	Kresinsky, A; Schnoder, TM; Jacobsen, ID; Rauner, M; Hofbauer, LC; Ast, V; Konig, R; Hoffmann, B; Svensson, CM; Figge, MT; Hilger, I; Heidel, FH; Bohmer, FD; Muller, JP				Kresinsky, Anne; Schnoeder, Tina M.; Jacobsen, Ilse D.; Rauner, Martina; Hofbauer, Lorenz C.; Ast, Volker; Koenig, Rainer; Hoffmann, Bianca; Svensson, Carl-Magnus; Figge, Marc Thilo; Hilger, Ingrid; Heidel, Florian H.; Boehmer, Frank-D.; Mueller, Joerg P.			Lack of CD45 in FLT3-ITD mice results in a myeloproliferative phenotype, cortical porosity, and ectopic bone formation	ONCOGENE			English	Article							INTERNAL TANDEM DUPLICATION; ACUTE MYELOID-LEUKEMIA; PROTEIN-TYROSINE PHOSPHATASES; CELL-TRANSFORMATION; STEM-CELLS; B-CELL; MUTATIONS; DISEASE; LIGAND; PROGENITORS	The receptor tyrosine kinase FLT3 is expressed in myeloid and lymphoid progenitor cells. Activating mutations in FLT3 occur in 25-30% of acute myeloid leukaemia (AML) patients. Most common are internal tandem duplications of sequence (ITD) leading to constitutive FLT3-ITD kinase activity with an altered signalling quality promoting leukaemic cell transformation. Here, we observed the attenuating role of the receptor-like protein tyrosine phosphatase (RPTP) CD45/Ptprc in FLT3 signalling in vivo. Low level expression of this abundant RPTP correlates with a poor prognosis of FLT3-ITD-positive AML patients. To get a further insight into the regulatory role of Ptprc in FLT3-ITD activity in vivo, Ptprc knockout mice were bred with FLT3-ITD knock-in mice. Inactivation of the Ptprc gene in FLT3-ITD mice resulted in a drastically shortened life span and development of severe monocytosis, a block in B-cell development and anaemia. The myeloproliferative phenotype was associated with extramedullary haematopoiesis, splenohepatomegaly and severe alterations of organ structures. The phenotypic alterations were associated with increased transforming signalling of FLT3-ITD, including activation of its downstream target STAT5. These data reveal the capacity of Ptprc for the regulation of FLT3-ITD signalling activity in vivo. In addition, histopathology and computed tomography (CT) revealed an unexpected bone phenotype; the FLT3-ITD Ptprc(-/-) mice, but none of the controls, showed pronounced alterations in bone morphology and, in part, apparent features of osteoporosis. In the spleen, ectopic bone formation was observed. The observed bone phenotypes suggest a previously unappreciated capacity of FLT3-ITD (and presumably FLT3) to regulate bone development/remodelling, which is under negative control of CD45/Ptprc.	[Kresinsky, Anne; Boehmer, Frank-D.; Mueller, Joerg P.] Jena Univ Hosp, CMB, Inst Mol Cell Biol, Jena, Germany; [Schnoeder, Tina M.; Heidel, Florian H.] Jena Univ Hosp, Dept Haematol & Oncol, Internal Med 2, Jena, Germany; [Jacobsen, Ilse D.] Hans Knoell Inst, Leibniz Inst Nat Prod Res & Infect Biol, Res Grp Microbial Immunol, Jena, Germany; [Rauner, Martina; Hofbauer, Lorenz C.] Tech Univ Dresden, Dept Med 3, Dresden, Germany; [Rauner, Martina; Hofbauer, Lorenz C.] Tech Univ Dresden, Ctr Hlth Aging, Dresden, Germany; [Ast, Volker; Koenig, Rainer] Hans Knoell Inst, Leibniz Inst Nat Prod Res & Infect Biol, Network Modelling, Jena, Germany; [Ast, Volker; Koenig, Rainer] Jena Univ Hosp, CSCC, Integrated Res & Treatment Ctr, Klinikum 1, D-07747 Jena, Germany; [Hoffmann, Bianca; Svensson, Carl-Magnus; Figge, Marc Thilo] Hans Knoell Inst, Leibniz Inst Nat Prod Res & Infect Biol, Appl Syst Biol, Jena, Germany; [Figge, Marc Thilo] Friedrich Schiller Univ Jena, Fac Biol Sci, Jena, Germany; [Hilger, Ingrid] Jena Univ Hosp, Inst Diagnost & Intervent Radiol, Jena, Germany	Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Hans Knoll Institute (HKI); Technische Universitat Dresden; Technische Universitat Dresden; Hans Knoll Institute (HKI); Friedrich Schiller University of Jena; Hans Knoll Institute (HKI); Friedrich Schiller University of Jena; Friedrich Schiller University of Jena	Muller, JP (corresponding author), Jena Univ Hosp, CMB, Inst Mol Cell Biol, Jena, Germany.	joerg.mueller2@med.uni-jena.de		Heidel, Florian/0000-0003-2438-1955	Deutsche Forschungsgemeinschaft [Mu955/11-1]; Federal Ministry of Education and Research (BMBF), Germany, CancerTelSys [FKZ 01ZX1302B, 01ZX1602B]; IFB/CSCC [01EO1002, 01EO1502]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Federal Ministry of Education and Research (BMBF), Germany, CancerTelSys; IFB/CSCC	We are thankful to Jorg Cammenga (Lund University, Sweden) for kindly providing FLT3-ITD mice and Klaus Metzeler for providing array data. The work was supported by Deutsche Forschungsgemeinschaft (grant Mu955/11-1), the Federal Ministry of Education and Research (BMBF), Germany, CancerTelSys (FKZ 01ZX1302B, 01ZX1602B) and IFB/CSCC (01EO1002, 01EO1502).	Alexander DR, 2000, SEMIN IMMUNOL, V12, P349, DOI 10.1006/smim.2000.0218; Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Arora D, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-19; Arora D, 2011, J BIOL CHEM, V286, P10918, DOI 10.1074/jbc.M110.205021; Bohmer F, 2013, FEBS J, V280, P413, DOI 10.1111/j.1742-4658.2012.08655.x; Choudhary C, 2009, MOL CELL, V36, P326, DOI 10.1016/j.molcel.2009.09.019; DeFranco AL, 1998, SEMIN IMMUNOL, V10, P299, DOI 10.1006/smim.1998.0122; Ebeling PR, 1999, J BONE MINER RES, V14, P342, DOI 10.1359/jbmr.1999.14.3.342; Pinheiro RF, 2007, LEUKEMIA RES, V31, P1015, DOI 10.1016/j.leukres.2006.09.018; Frohling S, 2007, CANCER CELL, V12, P501, DOI 10.1016/j.ccr.2007.11.005; GABBIANELLI M, 1995, BLOOD, V86, P1661, DOI 10.1182/blood.V86.5.1661.bloodjournal8651661; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Godfrey R, 2012, BLOOD, V119, P4499, DOI 10.1182/blood-2011-02-336446; Hayakawa F, 2000, ONCOGENE, V19, P624, DOI 10.1038/sj.onc.1203354; Hendriks WJAJ, 2013, BBA-MOL BASIS DIS, V1832, P1673, DOI 10.1016/j.bbadis.2013.05.022; Jayavelu AK, 2016, LEUKEMIA, V30, P473, DOI 10.1038/leu.2015.234; Kelly LM, 2002, BLOOD, V99, P310, DOI 10.1182/blood.V99.1.310; Lacombe F, 1997, LEUKEMIA, V11, P1878, DOI 10.1038/sj.leu.2400847; Lee BH, 2007, CANCER CELL, V12, P367, DOI 10.1016/j.ccr.2007.08.031; Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047; Li L, 2008, BLOOD, V111, P3849, DOI 10.1182/blood-2007-08-109942; Li L, 2011, BLOOD, V118, P4935, DOI 10.1182/blood-2011-01-328096; Mizuki M, 2000, BLOOD, V96, P3907, DOI 10.1182/blood.V96.12.3907; Ostman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837; Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192; Pyzer AR, 2017, BLOOD, V129, P1791, DOI 10.1182/blood-2016-07-730614; Rasko JEJ, 1995, LEUKEMIA, V9, P2058; Rusten LS, 1996, BLOOD, V87, P1317, DOI 10.1182/blood.V87.4.1317.bloodjournal8741317; Sallmyr A, 2008, BLOOD, V111, P3173, DOI 10.1182/blood-2007-05-092510; Schmidt-Arras DE, 2005, MOL CELL BIOL, V25, P3690, DOI 10.1128/MCB.25.9.3690-3703.2005; Schulte C, 2000, OSTEOPOROSIS INT, V11, P344, DOI 10.1007/s001980070124; Shivtiel S, 2008, J EXP MED, V205, P2381, DOI 10.1084/jem.20080072; Stirewalt DL, 2003, NAT REV CANCER, V3, P650, DOI 10.1038/nrc1169; Verhaak RGW, 2009, HAEMATOL-HEMATOL J, V94, P131, DOI 10.3324/haematol.13299; Voronov I, 2016, J LEUKOCYTE BIOL, V99, P401, DOI 10.1189/jlb.3CE0915-445RR; Zhu JW, 2008, IMMUNITY, V28, P183, DOI 10.1016/j.immuni.2007.11.024	36	5	5	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4773	4787		10.1038/s41388-019-0757-y	http://dx.doi.org/10.1038/s41388-019-0757-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30820040				2022-12-17	WOS:000471160500009
J	Vazquez-Dominguez, I; Gonzalez-Sanchez, L; Lopez-Nieva, P; Fernandez-Navarro, P; Villa-Morales, M; Cobos-Fernandez, MA; Sastre, I; Fraga, MF; Fernandez, AF; Malumbres, M; Salazar-Roa, M; Grana-Castro, O; Santos, J; Llamas, P; Lopez-Lorenzo, JL; Fernandez-Piqueras, J				Vazquez-Dominguez, Irene; Gonzalez-Sanchez, Laura; Lopez-Nieva, Pilar; Fernandez-Navarro, Pablo; Villa-Morales, Maria; Cobos-Fernandez, Maria A.; Sastre, Isabel; Fraga, Mario F.; Fernandez, Agustin F.; Malumbres, Marcos; Salazar-Roa, Maria; Grana-Castro, Osvaldo; Santos, Javier; Llamas, Pilar; Lopez-Lorenzo, Jose L.; Fernandez-Piqueras, Jose			Downregulation of specific FBXW7 isoforms with differential effects in T-cell lymphoblastic lymphoma	ONCOGENE			English	Article							FBW7 UBIQUITIN LIGASE; TUMOR-SUPPRESSOR; STEM-CELLS; BETA-FORM; CYCLIN-E; LEUKEMIA; MUTATIONS; NOTCH1; EXPRESSION; CHILDHOOD	FBXW7 is a driver gene in T-cell lymphoblastic neoplasia acting through proteasome degradation of key proto-oncogenes. FBXW7 encodes three isoforms, alpha, beta and gamma, which differ only in the N-terminus. In this work, massive sequencing revealed significant downregulation of FBXW7 in a panel of primary T-cell lymphoblastic lymphomas characterised by the absence of mutations in its sequence. We observed that decreased expression mainly affected the FBXW7 beta isoform and to a lesser extent FBXW7 alpha and may be attributed to the combined effect of epigenetic changes, alteration of upstream factors and upregulation of miRNAs. Transient transfections with miRNA mimics in selected cell lines resulted in a significant decrease of total FBXW7 expression and its different isoforms separately, with the consequent increment of critical substrates and the stimulation of cell proliferation. Transient inhibition of endogenous miRNAs in a T-cell lymphoblastic-derived cell line (SUP-T1) was capable of reversing these proliferative effects. Finally, we show how FBXW7 isoforms display different roles within the cell. Simultaneous downregulation of the alpha and gamma isoforms modulates the amount of CCNE1, whilst the beta-isoform alone was found to have a prominent role in modulating the amount of c-MYC. Our data also revealed that downregulation of all isoforms is a sine qua non condition to induce a proliferative pattern in our cell model system. Taking these data into account, potential new treatments to reverse downregulation of all or a specific FBXW7 isoform may be an effective strategy to counteract the proliferative capacity of these tumour cells.	[Vazquez-Dominguez, Irene; Gonzalez-Sanchez, Laura; Lopez-Nieva, Pilar; Villa-Morales, Maria; Cobos-Fernandez, Maria A.; Sastre, Isabel; Santos, Javier; Fernandez-Piqueras, Jose] UAM, CSIC, CBMSO, Madrid, Spain; [Vazquez-Dominguez, Irene; Gonzalez-Sanchez, Laura; Lopez-Nieva, Pilar; Villa-Morales, Maria; Cobos-Fernandez, Maria A.; Santos, Javier; Llamas, Pilar; Lopez-Lorenzo, Jose L.; Fernandez-Piqueras, Jose] IIS Fdn Jimenez Diaz, Madrid, Spain; [Gonzalez-Sanchez, Laura; Lopez-Nieva, Pilar; Villa-Morales, Maria; Santos, Javier; Fernandez-Piqueras, Jose] Consorcio Invest Biomed Enfermedades Raras CIBERE, Madrid, Spain; [Fernandez-Navarro, Pablo] Inst Salud Carlos III, Ctr Nacl Epidemiol, Unidad Epidemiol Ambiental & Canc, Madrid, Spain; [Fernandez-Navarro, Pablo] Consorcio Invest Biomed Epidemiol & Salud Publ CI, Madrid, Spain; [Fraga, Mario F.] Univ Oviedo Principado Asturias, CSIC, CINN, Oviedo, Spain; [Fernandez, Agustin F.] Inst Invest Sanitaria Principado Asturias ISPA HU, Fdn Invest Biosanitaria Asturias FINBA, Unidad Epigenet Canc, IUOPA, Oviedo, Spain; [Malumbres, Marcos; Salazar-Roa, Maria] CNIO, Grp Div Celular & Canc, Madrid, Spain; [Grana-Castro, Osvaldo] CNIO, Unidad Bioinformat Biol Estruct & Biocomputac, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Fundacion Jimenez Diaz; Instituto de Salud Carlos III; Centro Nacional de Epidemiologia (CNE); CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion en Nanomateriales y Nanotecnologia (CINN); University of Oviedo; Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO)	Fernandez-Piqueras, J (corresponding author), UAM, CSIC, CBMSO, Madrid, Spain.; Fernandez-Piqueras, J (corresponding author), IIS Fdn Jimenez Diaz, Madrid, Spain.; Fernandez-Piqueras, J (corresponding author), Consorcio Invest Biomed Enfermedades Raras CIBERE, Madrid, Spain.	jfpiqueras@cbm.csic.es	Domínguez, Irene Vázquez/R-4512-2018; Fraga, Mario F/H-7824-2017; Fernandez, Agustin F./N-7302-2014; Santos, Javier/ABF-5755-2021; VILLA-MORALES, MARIA C./H-8797-2015; Malumbres, Marcos/E-8834-2011	Domínguez, Irene Vázquez/0000-0001-9753-521X; Fraga, Mario F/0000-0001-8450-2603; Fernandez, Agustin F./0000-0002-3792-4085; Santos, Javier/0000-0002-4168-6251; VILLA-MORALES, MARIA C./0000-0001-7906-0169; Malumbres, Marcos/0000-0002-0829-6315; Grana-Castro, Osvaldo/0000-0003-1615-4242; Llamas Sillero, Pilar/0000-0002-8552-3219; Gonzalez-Sanchez, Laura/0000-0002-4749-2423	Spanish Ministry of Economy and Competitiveness [SAF2015-70561-R, BES-2013-065740]; Autonomous Community of Madrid, Spain [B2017/BMD-3778]; Spanish Association against Cancer (AECC, 2018) [PROYE18054PIRI]; Instituto de Salud Carlos III (ISCIII) [ACCI-CIBERER-17]; Fundacion Ramon Areces; Banco de Santander	Spanish Ministry of Economy and Competitiveness(Spanish Government); Autonomous Community of Madrid, Spain; Spanish Association against Cancer (AECC, 2018); Instituto de Salud Carlos III (ISCIII)(Instituto de Salud Carlos IIIEuropean Commission); Fundacion Ramon Areces; Banco de Santander	Spanish Ministry of Economy and Competitiveness (SAF2015-70561-R; MINECO/FEDER, EU; BES-2013-065740); the Autonomous Community of Madrid, Spain (B2017/BMD-3778; LINFOMAS-CM); the Spanish Association against Cancer (AECC, 2018; PROYE18054PIRI) and the Instituto de Salud Carlos III (ISCIII) (ACCI-CIBERER-17). Institutional grants from the Fundacion Ramon Areces and Banco de Santander to the CBMSO are also acknowledged.	Aifantis I, 2008, NAT REV IMMUNOL, V8, P380, DOI 10.1038/nri2304; Akhoondi S, 2007, CANCER RES, V67, P9006, DOI 10.1158/0008-5472.CAN-07-1320; Akhoondi S, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2788; Andres-Leon E, 2015, MIRGATE CURATED DATA, V2015; Atak ZK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038463; Balamurugan K, 2010, EMBO J, V29, P4106, DOI 10.1038/emboj.2010.280; Baldus CD, 2009, HAEMATOL-HEMATOL J, V94, P1383, DOI 10.3324/haematol.2008.005272; Bonn BR, 2013, BLOOD, V121, P3153, DOI 10.1182/blood-2012-12-474148; Burkhardt B, 2010, BRIT J HAEMATOL, V149, P653, DOI 10.1111/j.1365-2141.2009.08006.x; Callens C, 2012, J CLIN ONCOL, V30, P1966, DOI 10.1200/JCO.2011.39.7661; Cheng YB, 2013, J INVEST DERMATOL, V133, P1794, DOI 10.1038/jid.2013.58; Correia NC, 2013, LEUKEMIA, V27, P1603, DOI 10.1038/leu.2013.63; Crusio KM, 2010, ONCOGENE, V29, P4865, DOI 10.1038/onc.2010.222; Davis RJ, 2014, CANCER CELL, V26, P455, DOI 10.1016/j.ccell.2014.09.013; de Leval L, 2009, CRIT REV ONCOL HEMAT, V72, P125, DOI 10.1016/j.critrevonc.2009.01.002; Feng DD, 2011, J CELL MOL MED, V15, P2164, DOI 10.1111/j.1582-4934.2010.01213.x; Gedman AL, 2009, LEUKEMIA, V23, P1417, DOI 10.1038/leu.2009.64; Grinkevich VV, 2009, CANCER CELL, V15, P441, DOI 10.1016/j.ccr.2009.03.021; Gu Z, 2008, GENES GENET SYST, V83, P347, DOI 10.1266/ggs.83.347; Gu ZD, 2008, BIOCHEM BIOPH RES CO, V377, P685, DOI 10.1016/j.bbrc.2008.10.047; Guo DM, 2009, LEUKEMIA RES, V33, P678, DOI 10.1016/j.leukres.2008.10.026; Ho MS, 2006, J BIOMED SCI, V13, P181, DOI 10.1007/s11373-005-9058-2; Hu JP, 2017, ONCOTARGETS THER, V10, P3709, DOI 10.2147/OTT.S141652; Huang HS, 2014, ONCOTARGET, V5, P493, DOI 10.18632/oncotarget.1643; Jin HY, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00340; Katt ME, 2016, FRONT BIOENG BIOTECH, V4, DOI 10.3389/fbioe.2016.00012; Khoury MP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000927; Kimura T, 2003, CANCER SCI, V94, P431, DOI 10.1111/j.1349-7006.2003.tb01460.x; King B, 2013, CELL, V153, P1552, DOI 10.1016/j.cell.2013.05.041; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Kourtis N, 2015, NAT CELL BIOL, V17, P322, DOI 10.1038/ncb3121; Kumar V, 2014, LEUKEMIA, V28, P2324, DOI 10.1038/leu.2014.133; Lai EC, 2015, RNA, V21, P675, DOI 10.1261/rna.051193.115; Malyukova A, 2007, CANCER RES, V67, P5611, DOI 10.1158/0008-5472.CAN-06-4381; Mansour MR, 2013, J EXP MED, V210, P1545, DOI 10.1084/jem.20122516; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Matsuoka S, 2008, GENE DEV, V22, P986, DOI 10.1101/gad.1621808; Mavrakis KJ, 2011, NAT GENET, V43, P673, DOI 10.1038/ng.858; Mullokandov G, 2012, NAT METHODS, V9, P840, DOI [10.1038/NMETH.2078, 10.1038/nmeth.2078]; Mussolin L, 2014, LEUKEMIA, V28, P1909, DOI 10.1038/leu.2014.134; Neumann M, 2015, ONCOTARGET, V6, P2754, DOI 10.18632/oncotarget.2218; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Onoyama I, 2007, J EXP MED, V204, P2875, DOI 10.1084/jem.20062299; Park MJ, 2009, BRIT J HAEMATOL, V145, P198, DOI 10.1111/j.1365-2141.2009.07607.x; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Rocher-Ros V, 2010, ONCOGENE, V29, P2950, DOI 10.1038/onc.2010.57; Sancho R, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001586; Sionov RV, 2013, CELL CYCLE, V12, P3547, DOI 10.4161/cc.26591; Spruck CH, 2002, CANCER RES, V62, P4535; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Thompson BJ, 2007, J EXP MED, V204, P1825, DOI 10.1084/jem.20070872; Trausch-Azar JS, 2015, J CELL PHYSIOL, V230, P842, DOI 10.1002/jcp.24812; Tremblay CS, 2014, CURR OPIN HEMATOL, V21, P320, DOI 10.1097/MOH.0000000000000058; van Drogen F, 2006, MOL CELL, V23, P37, DOI 10.1016/j.molcel.2006.05.020; Van Vlierberghe P, 2012, J CLIN INVEST, V122, P3398, DOI 10.1172/JCI61269; Wang LX, 2014, ONCOTARGET, V5, P2000, DOI 10.18632/oncotarget.1859; Wei XF, 2015, ONCOTARGET, V6, P18389, DOI 10.18632/oncotarget.4089; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Xu WS, 2016, SEMIN CANCER BIOL, V36, P62, DOI 10.1016/j.semcancer.2015.09.005; Yumimoto K, 2015, J CLIN INVEST, V125, P621, DOI 10.1172/JCI78782; Zhou ZY, 2015, ONCOL REP, V34, P2215, DOI 10.3892/or.2015.4227	63	5	5	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4620	4636		10.1038/s41388-019-0746-1	http://dx.doi.org/10.1038/s41388-019-0746-1			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30742097				2022-12-17	WOS:000470240300013
J	Wang, MX; Ferreira, RB; Law, ME; Davis, BJ; Yaaghubi, E; Ghilardi, AF; Sharma, A; Avery, BA; Rodriguez, E; Chiang, CW; Narayan, S; Heldermon, CD; Castellano, RK; Law, BK				Wang, Mengxiong; Ferreira, Renan B.; Law, Mary E.; Davis, Bradley J.; Yaaghubi, Elham; Ghilardi, Amanda F.; Sharma, Abhisheak; Avery, Bonnie A.; Rodriguez, Edgardo; Chiang, Chi-Wu; Narayan, Satya; Heldermon, Coy D.; Castellano, Ronald K.; Law, Brian K.			A novel proteotoxic combination therapy for EGFR+ and HER2+cancers	ONCOGENE			English	Article							UNFOLDED PROTEIN RESPONSE; CYCLOSPORINE-A; EXTRACELLULAR REGION; ORGANIC DISULFIDES; CRYSTAL-STRUCTURE; ER STRESS; CANCER; GROWTH; CELLS; SUBSTANCES	While HER2 and EGFR are overexpressed in breast cancers and multiple other types of tumors, the use of EGFR and/or HER2 inhibitors have failed to cure many cancer patients, largely because cancers acquire resistance to HER2/EGFR-specific drugs. Cancers that overexpress the HER-family proteins EGFR, HER2, and HER3 are uniquely sensitive to agents that disrupt HER2 and EGFR protein folding. We previously showed that disruption of disulfide bond formation by Disulfide Disrupting Agents (DDAs) kills HER2/EGFR overexpressing cells through multiple mechanisms. Herein, we show that interference with proline isomerization in HER2/EGFR overexpressing cells also induces cancer cell death. The peptidyl-prolyl isomerase inhibitor Cyclosporine A (CsA) selectively kills EGFR+ or HER2+ breast cancer cells in vitro by activating caspase-dependent apoptotic pathways. Further, CsA synergizes with the DDA tcyDTDO to kill HER2/EGFR overexpressing cells in vitro and the two agents cooperate to kill HER2+ tumors in vivo. There is a critical need for novel strategies to target HER2+ and EGFR+ cancers that are resistant to currently available mechanism-based agents. Drugs that target HER2/EGFR protein folding, including DDAs and CsA, have the potential to kill cancers that overexpress EGFR or HER2 through the induction of proteostatic synthetic lethality.	[Wang, Mengxiong; Law, Mary E.; Davis, Bradley J.; Rodriguez, Edgardo; Law, Brian K.] Univ Florida, Dept Pharmacol, Gainesville, FL 32610 USA; [Ferreira, Renan B.; Yaaghubi, Elham; Ghilardi, Amanda F.; Castellano, Ronald K.] Univ Florida, Dept Chem, Gainesville, FL 32611 USA; [Sharma, Abhisheak; Avery, Bonnie A.] Univ Florida, Dept Pharmaceut, Gainesville, FL 32610 USA; [Chiang, Chi-Wu] Natl Cheng Kung Univ, Coll Med, Inst Mol Med, Tainan, Taiwan; [Chiang, Chi-Wu] Natl Cheng Kung Univ, Ctr Infect Dis & Signaling Res, Tainan, Taiwan; [Narayan, Satya] Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; [Narayan, Satya; Heldermon, Coy D.; Castellano, Ronald K.; Law, Brian K.] Univ Florida, UF Hlth Canc Ctr, Gainesville, FL 32610 USA; [Heldermon, Coy D.] Univ Florida, Dept Med, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; National Cheng Kung University; National Cheng Kung University; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Law, BK (corresponding author), Univ Florida, Dept Pharmacol, Gainesville, FL 32610 USA.; Castellano, RK (corresponding author), Univ Florida, Dept Chem, Gainesville, FL 32611 USA.; Castellano, RK; Law, BK (corresponding author), Univ Florida, UF Hlth Canc Ctr, Gainesville, FL 32610 USA.	castellano@chem.ufl.edu; bklaw@ufl.edu	Ferreira, Renan/O-4919-2019; Sharma, Abhisheak/H-9327-2019; Sharma, Abhisheak/V-8401-2017; Castellano, Ronald/AAY-3252-2020	Ferreira, Renan/0000-0001-5205-659X; Sharma, Abhisheak/0000-0003-0553-4039; Castellano, Ronald/0000-0003-4322-9932; Wang, Mengxiong/0000-0002-8290-151X; Yaaghubi, Elham/0000-0003-1821-1052; Heldermon, Coy/0000-0002-2148-2868	Office of the Assistant Secretary of Defense for Health Affairs through the Breast Cancer Research Program [W81XWH-15-1-0199, W81XWH-15-1-0200]; Florida Breast Cancer Foundation; Ocala Royal Dames for Cancer Research; Florida Department of Health Bankhead-Coley Program [4BF03]; UF-Health Cancer Center pilot project award; University of Florida; Collaboration of Scientists for Critical Research in Biomedicine (CSCRB, Inc.)	Office of the Assistant Secretary of Defense for Health Affairs through the Breast Cancer Research Program; Florida Breast Cancer Foundation; Ocala Royal Dames for Cancer Research; Florida Department of Health Bankhead-Coley Program; UF-Health Cancer Center pilot project award; University of Florida(University of Florida); Collaboration of Scientists for Critical Research in Biomedicine (CSCRB, Inc.)	This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Breast Cancer Research Program under Award Nos. W81XWH-15-1-0199 (BL) and W81XWH-15-1-0200 (RC). These studies were supported in part by grants from the Florida Breast Cancer Foundation (BL and RC), The Ocala Royal Dames for Cancer Research (BL), the Florida Department of Health Bankhead-Coley Program (4BF03, BL), the Collaboration of Scientists for Critical Research in Biomedicine (CSCRB, Inc., BL), and a UF-Health Cancer Center pilot project award (BL, RC, and CH). RF is grateful to the University of Florida for a Graduate School Fellowship.	Ahmed-Belkacem A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12777; Anderson DJ, 2015, CANCER CELL, V28, P653, DOI 10.1016/j.ccell.2015.10.002; BASS SW, 1980, J ORG CHEM, V45, P710, DOI 10.1021/jo01292a032; Chlebowski RT, 2013, JNCI-J NATL CANCER I, V105, P526, DOI 10.1093/jnci/djt043; Cho HS, 2002, SCIENCE, V297, P1330, DOI 10.1126/science.1074611; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Ciechomska IA, 2013, ONCOGENE, V32, P1518, DOI 10.1038/onc.2012.174; DeRose Yoko S, 2013, Curr Protoc Pharmacol, VChapter 14, DOI 10.1002/0471141755.ph1423s60; Dunyak BM, 2016, J MED CHEM, V59, P9622, DOI 10.1021/acs.jmedchem.6b00411; Erdogan E, 2006, J BIOL CHEM, V281, P28450, DOI 10.1074/jbc.M606054200; Feng XL, 2014, EXP HEMATOL, V42, P172, DOI 10.1016/j.exphem.2013.11.010; Ferreira RB, 2017, ONCOTARGET, V8, P28971, DOI 10.18632/oncotarget.15952; Ferreira RB, 2015, ONCOTARGET, V6, P10445, DOI 10.18632/oncotarget.3398; FIELD L, 1972, J MED CHEM, V15, P312, DOI 10.1021/jm00273a024; Garg AD, 2014, PHOTOCH PHOTOBIO SCI, V13, P474, DOI 10.1039/c3pp50333j; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; GOETHALS EJ, 1969, B SOC CHIM BELG, V78, P191; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hartman DA, 2003, CURR PROTOC PHARM, V7, P6; Hysing Jan, 2011, Tidsskr Nor Laegeforen, V131, P2239, DOI 10.4045/tidsskr.10.0862; IYER RP, 1990, J AM CHEM SOC, V112, P1253, DOI 10.1021/ja00159a059; KALLIONIEMI OP, 1992, P NATL ACAD SCI USA, V89, P5321, DOI 10.1073/pnas.89.12.5321; Kopper L, 2008, PATHOL ONCOL RES, V14, P1, DOI 10.1007/s12253-008-9018-z; Law BK, 2000, J BIOL CHEM, V275, P38261, DOI 10.1074/jbc.M005545200; Law ME, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0741-1; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Liu XF, 2012, AM J PATHOL, V180, P599, DOI 10.1016/j.ajpath.2011.10.036; Neckers L, 2000, Breast Dis, V11, P49; Ni SS, 2009, J MED CHEM, V52, P5295, DOI 10.1021/jm9008295; Obeng EA, 2006, BLOOD, V107, P4907, DOI 10.1182/blood-2005-08-3531; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Robinson PJ, 2017, J BIOL CHEM, V292, P6978, DOI 10.1074/jbc.M117.780742; SHIMIZU T, 1989, IMMUNOBIOLOGY, V178, P401, DOI 10.1016/S0171-2985(89)80062-2; Singh N, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa6922; SRIVASTAVA PK, 1972, J ORG CHEM, V37, P4196, DOI 10.1021/jo00798a055; Stocki P, 2014, J BIOL CHEM, V289, P23086, DOI 10.1074/jbc.M114.570911; Takenokuchi M, 2015, ANTICANCER RES, V35, P3307; Theuerkorn M, 2011, CURR OPIN PHARMACOL, V11, P281, DOI 10.1016/j.coph.2011.03.007; Vekaria PH, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00181; Wang MX, 2018, CRIT REV ONCOL HEMAT, V127, P66, DOI 10.1016/j.critrevonc.2018.05.003; Werneck MBF, 2012, CELL CYCLE, V11, P3997, DOI 10.4161/cc.22222	43	5	5	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4264	4282		10.1038/s41388-019-0717-6	http://dx.doi.org/10.1038/s41388-019-0717-6			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30718919				2022-12-17	WOS:000469339100005
J	Molenaar, RJ; Maciejewski, JP; Wilmink, JW; van Noorden, CJF				Molenaar, Remco J.; Maciejewski, Jaroslaw P.; Wilmink, Johanna W.; van Noorden, Cornelis J. F.			Wild-type and mutated IDH1/2 enzymes and therapy responses (vol 37, pg 1949, 2018)	ONCOGENE			English	Correction									[Molenaar, Remco J.; van Noorden, Cornelis J. F.] Acad Med Ctr, Canc Ctr Amsterdam, Dept Med Biol, Amsterdam, Netherlands; [Molenaar, Remco J.; Wilmink, Johanna W.] Acad Med Ctr, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam, Netherlands; [Molenaar, Remco J.; Maciejewski, Jaroslaw P.] Cleveland Clin, Dept Translat Hematol & Oncol Res, Cleveland, OH 44106 USA	University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Cleveland Clinic Foundation	Molenaar, RJ (corresponding author), Acad Med Ctr, Canc Ctr Amsterdam, Dept Med Biol, Amsterdam, Netherlands.; Molenaar, RJ (corresponding author), Acad Med Ctr, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam, Netherlands.; Molenaar, RJ (corresponding author), Cleveland Clin, Dept Translat Hematol & Oncol Res, Cleveland, OH 44106 USA.	r.j.molenaar@amc.nl						Molenaar RJ, 2018, ONCOGENE, V37, P1949, DOI 10.1038/s41388-017-0077-z	1	5	5	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2018	37	43					5810	5810		10.1038/s41388-018-0455-1	http://dx.doi.org/10.1038/s41388-018-0455-1			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY1KL	30140044	Green Published, hybrid			2022-12-17	WOS:000448288200008
J	Acosta, J; Wang, W; Feldser, DM				Acosta, Jonuelle; Wang, Walter; Feldser, David M.			Off and back-on again: a tumor suppressor's tale	ONCOGENE			English	Review							CONDITIONAL RNA INTERFERENCE; CRE RECOMBINASE ACTIVITY; IN-VIVO; P53 RESTORATION; TRANSGENIC MICE; GENE-EXPRESSION; CANCER; MOUSE; CRISPR; CELLS	Tumor suppressor genes play critical roles orchestrating anti-cancer programs that are both context dependent and mechanistically diverse. Beyond canonical tumor suppressive programs that control cell division, cell death, and genome stability, unexpected tumor suppressor gene activities that regulate metabolism, immune surveillance, the epigenetic landscape, and others have recently emerged. This diversity underscores the important roles these genes play in maintaining cellular homeostasis to suppress cancer initiation and progression, but also highlights a tremendous challenge in discerning precise context-specific programs of tumor suppression controlled by a given tumor suppressor. Fortunately, the rapid sophistication of genetically engineered mouse models of cancer has begun to shed light on these context-dependent tumor suppressor activities. By using techniques that not only toggle "off" tumor suppressor genes in nascent tumors, but also facilitate the timely restoration of gene function "back-on again" in disease specific contexts, precise mechanisms of tumor suppression can be revealed in an unbiased manner. This review discusses the development and implementation of genetic systems designed to toggle tumor suppressor genes off and back-on again and their potential to uncover the tumor suppressor's tale.	[Acosta, Jonuelle; Feldser, David M.] Univ Penn, Perelman Sch Med, Biomed Grad Studies Program Cellular & Mol Biol, 421 Curie Blvd,751 BRB 2-3, Philadelphia, PA 19104 USA; [Wang, Walter] Univ Penn, Sch Arts & Sci, Vagelos Scholars Program, 421 Curie Blvd,751 BRB 2-3, Philadelphia, PA 19104 USA; [Feldser, David M.] Univ Penn, Dept Canc Biol, 421 Curie Blvd,751 BRB 2-3, Philadelphia, PA 19104 USA; [Feldser, David M.] Univ Penn, Abramson Family Canc Res Inst, 421 Curie Blvd,751 BRB 2-3, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Feldser, DM (corresponding author), Univ Penn, Perelman Sch Med, Biomed Grad Studies Program Cellular & Mol Biol, 421 Curie Blvd,751 BRB 2-3, Philadelphia, PA 19104 USA.; Feldser, DM (corresponding author), Univ Penn, Dept Canc Biol, 421 Curie Blvd,751 BRB 2-3, Philadelphia, PA 19104 USA.; Feldser, DM (corresponding author), Univ Penn, Abramson Family Canc Res Inst, 421 Curie Blvd,751 BRB 2-3, Philadelphia, PA 19104 USA.	dfeldser@upenn.edu		Wang, Walter/0000-0003-1054-4688; Feldser, David/0000-0001-5975-864X	American Lung Association [LCD-400095]; NIH [CA193602, CA205340]; Penn Medicine's Abramson Cancer Center [P30-CA016520]; NATIONAL CANCER INSTITUTE [R01CA193602, R00CA158581, P30CA016520, R21CA205340] Funding Source: NIH RePORTER	American Lung Association; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Penn Medicine's Abramson Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Junwei Shi, Donita Brady, and the entire Feldser Laboratory for critical review of this manuscript. D.F. is the Alan Steinberg Scholar in Cancer Research, and a Richard A. "Buz" Cooper Scholar of the Abramson Cancer Center. Work in the Feldser Laboratory is supported by grants from the American Lung Association LCD-400095, NIH CA193602, CA205340, and also by Penn Medicine's Abramson Cancer Center core grant P30-CA016520.	Abudayyeh OO, 2017, NATURE, V550, P280, DOI 10.1038/nature24049; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Aubrey BJ, 2015, CELL REP, V10, P1422, DOI 10.1016/j.celrep.2015.02.002; Beard C, 2006, GENESIS, V44, P23, DOI 10.1002/gene.20180; Birling Marie-Christine, 2009, Methods Mol Biol, V561, P245, DOI 10.1007/978-1-60327-019-9_16; Buskirk AR, 2004, P NATL ACAD SCI USA, V101, P10505, DOI 10.1073/pnas.0402762101; Cao J, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw660; Christophorou MA, 2005, NAT GENET, V37, P718, DOI 10.1038/ng1572; Cox DBT, 2017, SCIENCE, V358, P1019, DOI 10.1126/science.aaq0180; Davis KM, 2015, NAT CHEM BIOL, V11, P316, DOI [10.1038/nchembio.1793, 10.1038/NCHEMBIO.1793]; Direnzo D, 2012, GASTROENTEROLOGY, V143, P469, DOI 10.1053/j.gastro.2012.04.011; Dominguez AA, 2016, NAT REV MOL CELL BIO, V17, DOI 10.1038/nrm.2015.2; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Doudna JA, 2014, SCIENCE, V346, P1077, DOI 10.1126/science.1258096; Dow LE, 2015, CELL, V161, P1539, DOI 10.1016/j.cell.2015.05.033; Dow LE, 2015, NAT BIOTECHNOL, V33, P390, DOI 10.1038/nbt.3155; Dow LE, 2012, NAT PROTOC, V7, P374, DOI 10.1038/nprot.2011.446; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Echeverri CJ, 2006, NAT METHODS, V3, P777, DOI 10.1038/nmeth1006-777; Feil R, 1997, BIOCHEM BIOPH RES CO, V237, P752, DOI 10.1006/bbrc.1997.7124; Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535; Fuhrmann-Benzakein E, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.23.e99; Gilbert LA, 2014, CELL, V159, P647, DOI 10.1016/j.cell.2014.09.029; Gilbert LA, 2013, CELL, V154, P442, DOI 10.1016/j.cell.2013.06.044; Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Hsu PD, 2014, CELL, V157, P1262, DOI 10.1016/j.cell.2014.05.010; Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson AL, 2006, RNA, V12, P1179, DOI 10.1261/rna.25706; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Junttila MR, 2010, NATURE, V468, P567, DOI 10.1038/nature09526; Kaelin WG, 2012, SCIENCE, V337, P421, DOI 10.1126/science.1225787; Katoh Y, 2017, MOL BIOL CELL, V28, P898, DOI 10.1091/mbc.E17-01-0051; Kellendonk C, 1996, NUCLEIC ACIDS RES, V24, P1404, DOI 10.1093/nar/24.8.1404; Lao ZM, 2012, CELL REP, V2, P386, DOI 10.1016/j.celrep.2012.07.004; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lu J, 2018, NUCLEIC ACIDS RES, V46, DOI 10.1093/nar/gkx1222; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; Meerbrey KL, 2011, P NATL ACAD SCI USA, V108, P3665, DOI 10.1073/pnas.1019736108; Miething C, 2014, NATURE, V510, P402, DOI 10.1038/nature13239; Murugan K, 2017, MOL CELL, V68, P15, DOI 10.1016/j.molcel.2017.09.007; Nguyen DP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12009; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Premsrirut Prem K, 2013, Cold Spring Harb Protoc, V2013, P835, DOI 10.1101/pdb.prot077057; Premsrirut PK, 2011, CELL, V145, P145, DOI 10.1016/j.cell.2011.03.012; Qi LS, 2013, CELL, V152, P1173, DOI 10.1016/j.cell.2013.02.022; Robles-Oteiza C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9783; Sakuma T, 2016, NAT PROTOC, V11, P118, DOI 10.1038/nprot.2015.140; Selivanova G, 2010, SEMIN CANCER BIOL, V20, P46, DOI 10.1016/j.semcancer.2010.02.006; Shchors K, 2013, P NATL ACAD SCI USA, V110, pE1480, DOI 10.1073/pnas.1219142110; Shin KJ, 2006, P NATL ACAD SCI USA, V103, P13759, DOI 10.1073/pnas.0606179103; Suzuki K, 2016, NATURE, V540, P144, DOI 10.1038/nature20565; Swisher SG, 2003, CLIN CANCER RES, V9, P93; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Weinmann L, 2008, CELL DEATH DIFFER, V15, P718, DOI 10.1038/sj.cdd.4402301; Whitfield Jonathan, 2015, Cold Spring Harb Protoc, V2015, P227, DOI 10.1101/pdb.top069815; Wiznerowicz M, 2006, NAT METHODS, V3, P682, DOI 10.1038/NMETH914; Wunderlich FT, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.10.e47; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yoshimi K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10431; Zuber J, 2011, NAT BIOTECHNOL, V29, P79, DOI 10.1038/nbt.1720	64	5	5	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	23					3058	3069		10.1038/s41388-018-0186-3	http://dx.doi.org/10.1038/s41388-018-0186-3			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GI6VO	29540833	Green Accepted			2022-12-17	WOS:000434641400002
J	Aira, LE; Villa, E; Colosetti, P; Gamas, P; Signetti, L; Obba, S; Proics, E; Gautier, F; Bailly-Maitre, B; Lacquel, A; Robert, G; Luciano, F; Juin, PP; Ricci, JE; Auberger, P; Marchetti, S				Aira, Lazaro E.; Villa, Elodie; Colosetti, Pascal; Gamas, Parvati; Signetti, Laurie; Obba, Sandrine; Proics, Emma; Gautier, Fabien; Bailly-Maitre, Beatrice; Lacquel, Arnaud; Robert, Guillaume; Luciano, Frederic; Juin, Philippe P.; Ricci, Jean-Ehrland; Auberger, Patrick; Marchetti, Sandrine			The oncogenic tyrosine kinase Lyn impairs the pro-apoptotic function of Bim	ONCOGENE			English	Article							FAMILY-MEMBER BIM; BCL-2 FAMILY; CELL-DEATH; B-CELLS; PHOSPHORYLATION; PROTEIN; HOMEOSTASIS; RESISTANCE; IMATINIB; PATHWAY	Phosphorylation of Ser/Thr residues is a well-established modulating mechanism of the pro-apoptotic function of the BH3-only protein Bim. However, nothing is known about the putative tyrosine phosphorylation of this Bcl-2 family member and its potential impact on Bim function and subsequent Bax/Bak-mediated cytochrome c release and apoptosis. As we have previously shown that the tyrosine kinase Lyn could behave as an anti-apoptotic molecule, we investigated whether this Src family member could directly regulate the pro-apoptotic function of Bim. In the present study, we show that Bim is phosphorylated onto tyrosine residues 92 and 161 by Lyn, which results in an inhibition of its pro-apoptotic function. Mechanistically, we show that Lyn-dependent tyrosine phosphorylation of Bim increases its interaction with anti-apoptotic members such as Bcl-xL, therefore limiting mitochondrial outer membrane permeabilization and subsequent apoptosis. Collectively, our data uncover one molecular mechanism through which the oncogenic tyrosine kinase Lyn negatively regulates the mitochondrial apoptotic pathway, which may contribute to the transformation and/or the chemotherapeutic resistance of cancer cells.	[Aira, Lazaro E.; Villa, Elodie; Colosetti, Pascal; Gamas, Parvati; Signetti, Laurie; Obba, Sandrine; Proics, Emma; Bailly-Maitre, Beatrice; Lacquel, Arnaud; Robert, Guillaume; Luciano, Frederic; Ricci, Jean-Ehrland; Auberger, Patrick; Marchetti, Sandrine] Univ Cote dAzur, INSERM, C3M, Nice, France; [Gautier, Fabien; Juin, Philippe P.] Univ Nantes, Univ Angers, Inst Rech Sante, INSERM,CRCINA,UMR 1232, 8 Quai Moncousu,BP 70721, F-44007 Nantes 1, France; [Gautier, Fabien; Juin, Philippe P.] Inst Cancerol Ouest, Bvd J Monod,Site Rene Gauducheau, F-44805 St Herblain, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Universite d'Angers; UNICANCER; Institut de Cancerologie de l'Ouest (ICO)	Marchetti, S (corresponding author), Univ Cote dAzur, INSERM, C3M, Nice, France.	marchett@unice.fr	AUBERGER, Patrick/G-1491-2013; Ricci, Jean Ehrland/I-7117-2016; robert, guillaume/O-1935-2017; Jacquel, Arnaud/O-1928-2017; Colosetti, Pascal/ABH-4585-2020; Jacquel, Arnaud/AAJ-4760-2021; Marchetti, Sandrine/P-6479-2016; luciano, frederic/P-6264-2016; RICCI, Jean Ehrland/AAS-4379-2020; JUIN, Philippe/Q-1338-2019; JUIN, Philippe P/H-3636-2014; Carmen, Team2/Y-7383-2019	AUBERGER, Patrick/0000-0002-2481-8275; Ricci, Jean Ehrland/0000-0003-1585-8117; robert, guillaume/0000-0002-6350-2222; Jacquel, Arnaud/0000-0001-5062-8048; Jacquel, Arnaud/0000-0001-5062-8048; Marchetti, Sandrine/0000-0001-8326-5730; luciano, frederic/0000-0001-9253-4998; RICCI, Jean Ehrland/0000-0003-1585-8117; JUIN, Philippe/0000-0002-4997-3888; JUIN, Philippe P/0000-0002-4997-3888; Carmen, Team2/0000-0001-9867-5724; Lab, Carmen/0000-0002-5935-3236; Colosetti, Pascal/0000-0002-5848-6053; Bailly-Maitre, Beatrice/0000-0002-8389-8498	Fondation ARC pour la Recherche sur le Cancer [PJA 20131200392, PGA1RF201702053889]; Fondation pour la Recherche Medicale [DMP20101120387]; INSERM; Ministere de la Recherche; University of Nice-Sophia-Antipolis; French Government (National Research Agency, ANR) through the "Investments for the Future" LABEX SIGNALIFE [ANR-11-LABX-0028-01]; Conseil general des AM et de la region PACA et Corse	Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Ministere de la Recherche(Ministry of Science and Innovation, Spain (MICINN)Ministry of Research, France); University of Nice-Sophia-Antipolis; French Government (National Research Agency, ANR) through the "Investments for the Future" LABEX SIGNALIFE(French National Research Agency (ANR)); Conseil general des AM et de la region PACA et Corse	This work was supported by grants from the Fondation ARC pour la Recherche sur le Cancer (#PJA 20131200392 and #PGA1RF201702053889), the Fondation pour la Recherche Medicale (DMP20101120387), the INSERM, the Ministere de la Recherche, and the University of Nice-Sophia-Antipolis. This work and LEA were funded by the French Government (National Research Agency, ANR) through the "Investments for the Future" LABEX SIGNALIFE: program reference #ANR-11-LABX-0028-01. We thank Frederic Larbret for technical support for FACS sorting. We thank Dr. Simon Cook for GST-Bim constructs, Dr. Andreas Villunger for kindly providing the WEHI-231 cell line, Dr. David Rubinsztein for the plasmid encoding human BimEL, and Drs. Doug Green and Stephen Tait for HeLa cells stably expressing Smac-GFP. We thank Drs. Eric Eldering and Fabio Brocco for insights and helpful discussion. We thank the Conseil general des AM et de la region PACA et Corse for its financial support.	Ban T, 2016, IMMUNITY, V45, P319, DOI 10.1016/j.immuni.2016.07.015; Belloc F, 2007, CANCER BIOL THER, V6, P912, DOI 10.4161/cbt.6.6.4101; Bian YY, 2016, NAT CHEM BIOL, V12, P959, DOI [10.1038/nchembio.2178, 10.1038/NCHEMBIO.2178]; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Carpenter RL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078836; Chen WS, 1999, INT J CANCER, V83, P579, DOI 10.1002/(SICI)1097-0215(19991126)83:5<579::AID-IJC1>3.0.CO;2-R; Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025; Clybouw C, 2012, CELL DEATH DIFFER, V19, P1060, DOI 10.1038/cdd.2011.198; Contri A, 2005, J CLIN INVEST, V115, P369, DOI 10.1172/JC1200522094; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Enders A, 2003, J EXP MED, V198, P1119, DOI 10.1084/jem.20030411; Fox JL, 2010, EMBO J, V29, P3853, DOI 10.1038/emboj.2010.244; Gamas P, 2009, LEUKEMIA, V23, P1500, DOI 10.1038/leu.2009.60; Gogada R, 2013, J BIOL CHEM, V288, P368, DOI 10.1074/jbc.M112.386102; Goldenberg-Furmanov M, 2004, CANCER RES, V64, P1058, DOI 10.1158/0008-5472.CAN-03-2420; GREEN DR, 2015, COLD SPRING HARB PER, V7, DOI DOI 10.1101/CSHPERSPECT.A006080; Gross AJ, 2011, EUR J IMMUNOL, V41, P3645, DOI 10.1002/eji.201141708; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harder KW, 2001, IMMUNITY, V15, P603, DOI 10.1016/S1074-7613(01)00208-4; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; Hubner A, 2008, MOL CELL, V30, P415, DOI 10.1016/j.molcel.2008.03.025; Ingley E, 2008, BBA-PROTEINS PROTEOM, V1784, P56, DOI 10.1016/j.bbapap.2007.08.012; Ingley E, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-21; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Kuroda J, 2006, P NATL ACAD SCI USA, V103, P14907, DOI 10.1073/pnas.0606176103; Leonard JT, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf5309; Ley R, 2004, J BIOL CHEM, V279, P8837, DOI 10.1074/jbc.M311578200; Lopez J, 2012, CELL DEATH DIFFER, V19, P1459, DOI 10.1038/cdd.2012.21; Luciano F, 2003, FASEB J, V17, P711, DOI 10.1096/fj.02-0716fje; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Luciano F, 2001, ONCOGENE, V20, P4935, DOI 10.1038/sj.onc.1204661; Luo SQ, 2012, MOL CELL, V47, P359, DOI 10.1016/j.molcel.2012.05.040; Mahon FX, 2008, CANCER RES, V68, P9809, DOI 10.1158/0008-5472.CAN-08-1008; Mertins P, 2016, NATURE, V534, P55, DOI 10.1038/nature18003; Mestre-Escorihuela C, 2007, BLOOD, V109, P271, DOI 10.1182/blood-2006-06-026500; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Pecot J, 2016, CELL REP, V17, P3347, DOI 10.1016/j.celrep.2016.11.064; Pinon JD, 2008, ONCOGENE, V27, pS41, DOI 10.1038/onc.2009.42; Ptasznik A, 2004, NAT MED, V10, P1187, DOI 10.1038/nm1127; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Ricci JE, 2001, FASEB J, V15, P1777, DOI 10.1096/fj.00-0665fje; Rooswinkel RW, 2014, BLOOD, V123, P2806, DOI 10.1182/blood-2013-08-519470; Scapini P, 2009, IMMUNOL REV, V228, P23, DOI 10.1111/j.1600-065X.2008.00758.x; Sionov RV, 2015, ONCOTARGET, V6, P23058, DOI 10.18632/oncotarget.5492; Tait SWG, 2010, DEV CELL, V18, P802, DOI [10.1016/j.devce1.2010.03.014, 10.1016/j.devcel.2010.03.014]; Tauzin S, 2008, BLOOD, V111, P2310, DOI 10.1182/blood-2007-05-090985; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Zonta F, 2014, BLOOD, V123, P875, DOI 10.1182/blood-2013-02-485540	52	5	5	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	16					2122	2136		10.1038/s41388-017-0112-0	http://dx.doi.org/10.1038/s41388-017-0112-0			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GD5ZV	29391601				2022-12-17	WOS:000430589000004
J	Simond, AM; Rao, T; Zuo, D; Zhao, JJ; Muller, WJ				Simond, A. M.; Rao, T.; Zuo, D.; Zhao, J. J.; Muller, W. J.			ErbB2-positive mammary tumors can escape PI3K-p110 alpha loss through downregulation of the Pten tumor suppressor	ONCOGENE			English	Article							PHOSPHOINOSITIDE 3-KINASE PATHWAY; BREAST-CANCER; PHOSPHATIDYLINOSITOL 3-KINASE; CATALYTIC SUBUNIT; HIGH-FREQUENCY; PIK3CA GENE; ISOFORM; PI3K; P110-BETA; P110-ALPHA	Breast cancer is the most common cancer among women and 30% of patients will be diagnosed with an ErbB2-positive tumor. Forty percent of ErbB2-positive breast tumors have an activating mutation in p110 alpha, a catalytic subunit of phosphoinositide 3-kinase. Clinical and experimental data show that breast tumors treated with a p110 alpha-specific inhibitor often circumvent inhibition and resume growth. To understand this mechanism of resistance, we crossed a p110 alpha conditional (p110 alpha(flx/flx)) mouse model with mice that overexpress the ErbB2/Neu-IRES-Cre transgene (NIC) specifically in the mammary epithelium. Although mammary-specific deletion of p110 alpha dramatically delays tumor onset, tumors eventually arise and are dependent on p110 beta. Through biochemical analyses we find that a proportion of p110 alpha-deficient tumors (23%) display downregulation of the Pten tumor suppressor. We further demonstrate that loss of one allele of PTEN is sufficient to shift isoform dependency from p110 alpha to p110 beta in vivo. These results provide insight into the molecular mechanism by which ErbB2-positive breast cancer escapes p110 alpha inhibition.	[Simond, A. M.; Rao, T.; Zuo, D.; Muller, W. J.] McGill Univ, Rosalind & Morris Goodman Canc Res Ctr, Dept Biochem, Room 516,1160 Pine Ave West, Montreal, PQ H3A 1A3, Canada; [Zhao, J. J.] Harvard Med Sch, Dana Farber Canc Inst, Dept Canc Biol, Pathol, Boston, MA USA	McGill University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Muller, WJ (corresponding author), McGill Univ, Rosalind & Morris Goodman Canc Res Ctr, Dept Biochem, Room 516,1160 Pine Ave West, Montreal, PQ H3A 1A3, Canada.	william.muller@mcgill.ca			Canadian Institutes of Health Research (CIHR) [MOP-133706, FDN-148373]; Terry Fox team [RI X-242115]; CRC Chair in Molecular Oncology; Roland and Marcel Gosselin Fellowship; National Institutes of Health (NIH) [P50 CA168504, CA187918-02, R35 CA210057, CA172461]; Breast Cancer Research Foundation; NATIONAL CANCER INSTITUTE [P50CA168504, R01CA187918, R35CA210057, R01CA172461] Funding Source: NIH RePORTER	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Terry Fox team; CRC Chair in Molecular Oncology; Roland and Marcel Gosselin Fellowship; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Breast Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Cynthia Lavoie for assistance with the GDC-0941 drug trial and Vasilios Papavasiliou for mammary fat pad injections and transplants; Colin Ratcliffe for technical support with the Metamorph software; Chen Ling for editorial assistance and all the students in the Muller laboratory for their constant feedback and support. Our work is supported by the Canadian Institutes of Health Research (CIHR): MOP-133706 (WJM), FDN-148373 (WJM), Terry Fox team program grant: RI X-242115 (WJM). WJM is supported by CRC Chair in Molecular Oncology. National Institutes of Health (NIH): P50 CA168504 (JJZ), CA187918-02 (JJZ), R35 CA210057 (JJZ), CA172461 (JJZ) and Breast Cancer Research Foundation (JJZ), Roland and Marcel Gosselin Fellowship (AMS).	Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; Beeton CA, 2000, BIOCHEM J, V350, P353, DOI 10.1042/0264-6021:3500353; Bellacosa A, 2005, WOM ONCOL REV, V5, P223; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; Cheng H, 2015, ONCOGENE, V74, P15; Costa C, 2015, CANCER CELL, V27, P97, DOI 10.1016/j.ccell.2014.11.007; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; Dbouk Hashem A, 2015, Postdoc J, V3, P71; Dbouk HA, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003264; Dbouk HA, 2010, ONCOTARGET, V1, P729; Dourdin N, 2008, CANCER RES, V68, P2122, DOI 10.1158/0008-5472.CAN-07-5727; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Folkes AJ, 2008, J MED CHEM, V51, P5522, DOI 10.1021/jm800295d; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Geering B, 2007, P NATL ACAD SCI USA, V104, P7809, DOI 10.1073/pnas.0700373104; Hernandez-Aya LF, 2011, ONCOLOGIST, V16, P404, DOI 10.1634/theoncologist.2010-0402; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; Jackson SP, 2005, NAT MED, V11, P507, DOI 10.1038/nm1232; Juric D, 2015, NATURE, V518, P240, DOI 10.1038/nature13948; Karakas B, 2006, BRIT J CANCER, V94, P455, DOI 10.1038/sj.bjc.6602970; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Martin V, 2010, BLOOD, V115, P2008, DOI 10.1182/blood-2009-04-217224; Meier TI, 2004, PROTEIN EXPRES PURIF, V35, P218, DOI 10.1016/j.pep.2003.12.010; Mellor P, 2012, BIOCHEM J, V441, P23, DOI 10.1042/BJ20111164; Ni J, 2012, CANCER DISCOV, V2, P425, DOI 10.1158/2159-8290.CD-12-0003; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Schmit F, 2014, P NATL ACAD SCI USA, V111, P6395, DOI 10.1073/pnas.1323004111; Schoenwaelder SM, 2010, J BIOL CHEM, V285, P2886, DOI 10.1074/jbc.M109.029132; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Thorpe LM, 2015, NAT REV CANCER, V15, P7, DOI 10.1038/nrc3860; Torbett NE, 2008, BIOCHEM J, V415, P97, DOI 10.1042/BJ20080639; Ursini-Siegel J, 2008, EMBO J, V27, P910, DOI 10.1038/emboj.2008.22; Utermark T, 2012, GENE DEV, V26, P1573, DOI 10.1101/gad.191973.112; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882; Wang Q, 2016, ONCOGENE, V35, P3607, DOI 10.1038/onc.2015.406; Wee S, 2008, P NATL ACAD SCI USA, V105, P13057, DOI 10.1073/pnas.0802655105; Zhao JJ, 2006, P NATL ACAD SCI USA, V103, P16296, DOI 10.1073/pnas.0607899103	43	5	5	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2017	36	43					6059	6066		10.1038/onc.2017.264	http://dx.doi.org/10.1038/onc.2017.264			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK9OT	28783168	Green Submitted, Green Accepted			2022-12-17	WOS:000413841400014
J	Kao, SH; Wang, WL; Chen, CY; Chang, YL; Wu, YY; Wang, YT; Wang, SP; Nesvizhskii, AI; Chen, YJ; Hong, TM; Yang, PC				Kao, S-H; Wang, W-L; Chen, C-Y; Chang, Y-L; Wu, Y-Y; Wang, Y-T; Wang, S-P; Nesvizhskii, A. I.; Chen, Y-J; Hong, T-M; Yang, P-C			GSK3 beta controls epithelial-mesenchymal transition and tumor metastasis by CHIP-mediated degradation of Slug (vol 33, pg 3172, 2013)	ONCOGENE			English	Correction																		Kao SH, 2014, ONCOGENE, V33, P3172, DOI 10.1038/onc.2013.279	1	5	5	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5916	5916		10.1038/onc.2017.302	http://dx.doi.org/10.1038/onc.2017.302			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28869596	Bronze			2022-12-17	WOS:000413292900015
J	Jen, J; Lin, LL; Lo, FY; Chen, HT; Liao, SY; Tang, YA; Su, WC; Salgia, R; Hsu, CL; Huang, HC; Juan, HF; Wang, YC				Jen, J.; Lin, L-L; Lo, F-Y; Chen, H-T; Liao, S-Y; Tang, Y-A; Su, W-C; Salgia, R.; Hsu, C-L; Huang, H-C; Juan, H-F; Wang, Y-C			Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer (vol 35, pg 2357, 2016)	ONCOGENE			English	Correction													; Huang, Hsuan-Cheng/C-7266-2011	Lin, Li-Ling/0000-0001-9891-5900; Huang, Hsuan-Cheng/0000-0002-3386-0934				Jen J, 2016, ONCOGENE, V35, P2357, DOI 10.1038/onc.2015.296	1	5	5	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2017	36	36					5219	5219		10.1038/onc.2017.203	http://dx.doi.org/10.1038/onc.2017.203			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF9XD	28628114	hybrid, Green Published			2022-12-17	WOS:000409371100013
J	Taylor, E; Alqadri, N; Dodgson, L; Mason, D; Lyulcheva, E; Messina, G; Bennett, D				Taylor, E.; Alqadri, N.; Dodgson, L.; Mason, D.; Lyulcheva, E.; Messina, G.; Bennett, D.			MRL proteins cooperate with activated Ras in glia to drive distinct oncogenic outcomes	ONCOGENE			English	Article							SERUM RESPONSE FACTOR; ACTIN-FILAMENT TURNOVER; CENTRAL-NERVOUS-SYSTEM; CELL-MIGRATION; DROSOPHILA; JNK; EXPRESSION; DYNAMICS; CANCER; GENE	The Mig10/RIAM/Lpd (MRL) adapter protein Lpd regulates actin dynamics through interactions with Scar/WAVE and Ena/VASP proteins to promote the formation of cellular protrusions and to stimulate invasive migration. However, the ability of MRL proteins to interact with multiple actin regulators and to promote serum response factor (SRF) signalling has raised the question of whether MRL proteins employ alternative downstream mechanisms to drive oncogenic processes in a context-dependent manner. Here, using a Drosophila model, we show that overexpression of either human Lpd or its Drosophila orthologue Pico can promote growth and invasion of Ras(V12)-induced cell tumours in the brain. Notably, effects were restricted to two populations of Repo-positive glial cells: an invasive population, characterized by JNK-dependent elevation of Mmp1 expression, and a hyperproliferative population lacking elevated JNK signalling. JNK activation was not triggered by reactive immune cell signalling, implicating the involvement of an intrinsic stress response. The ability to promote dissemination of Ras(V12)-induced tumours was shared by a subset of actin regulators, including, most prominently, Chicadee/Profilin, which directly interacts with Pico, and, Mal, a cofactor for serum response factor that responds to changes in G:F actin dynamics. Suppression of Mal activity partially abrogated the ability of pico to promote invasion of Ras(V12) tumours. Furthermore, we found that larval glia are enriched for serum response factor expression, explaining the apparent sensitivity of glial cells to Pico/Ras(V12) overexpression. Taken together, our findings indicate that MRL proteins cooperate with oncogenic Ras to promote formation of glial tumours, and that, in this context, Mal/serum response factor activation is rate-limiting for tumour dissemination.	[Taylor, E.; Alqadri, N.; Dodgson, L.; Lyulcheva, E.; Messina, G.; Bennett, D.] Univ Liverpool, Inst Integrat Biol, Dept Biochem, Crown St, Liverpool L69 7ZB, Merseyside, England; [Dodgson, L.; Mason, D.; Bennett, D.] Univ Liverpool, Ctr Cell Imaging, Biosci Bldg, Liverpool, Merseyside, England; [Taylor, E.] Liverpool Womens NHS Fdn Trust, Crown St, Liverpool L8 7SS, Merseyside, England; [Dodgson, L.; Lyulcheva, E.] Salford Royal NHS Fdn Trust, Salford M6 8HD, Lancs, England	University of Liverpool; University of Liverpool; Salford Royal NHS Foundation Trust	Bennett, D (corresponding author), Univ Liverpool, Inst Integrat Biol, Dept Biochem, Crown St, Liverpool L69 7ZB, Merseyside, England.	daimark.bennett@liverpool.ac.uk	Messina, Giovanni/AAE-8668-2022; Bennett, Daimark/E-2701-2014	Messina, Giovanni/0000-0002-0011-867X; Bennett, Daimark/0000-0002-0014-2290; Mason, David/0000-0002-8773-5274; Messina, Giovanni/0000-0002-7597-4972; Alqadri, Nada/0000-0003-3607-2359	BBSRC [BB/L014947/1, BB/M012441/1]; MRC [MR/K015931/1]; CRUK [C20691/A11834]; Biotechnology and Biological Sciences Research Council [BB/L014947/1] Funding Source: researchfish; Medical Research Council [MR/K015931/1] Funding Source: researchfish	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); CRUK(Cancer Research UK); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank the Bloomington Stock Centre, Zhe Han, Julian Ng, Pernille Rorth, Eyal Schejter, Marcos Vidal, Sanjai Patel and the Manchester Fly Facility for Drosophila strains, B Altenhein, I Ando, the Developmental Studies Hybridoma Bank, S Baumgartner and Manzoor Bhat for antibodies, Marco Marcello in the Liverpool Centre for Cell Imaging for assistance with image acquisition, Chris Lofthouse for artwork, and Mirel Lucaci for technical assistance. This work was supported by grants from BBSRC (BB/L014947/1, BB/M012441/1), MRC (MR/K015931/1) and CRUK (C20691/A11834).	Allan C, 2012, NAT METHODS, V9, P245, DOI [10.1038/NMETH.1896, 10.1038/nmeth.1896]; Andersen DS, 2015, NATURE, V522, P482, DOI 10.1038/nature14298; Balcer HI, 2003, CURR BIOL, V13, P2159, DOI 10.1016/j.cub.2003.11.051; Bazigou E, 2007, CELL, V128, P961, DOI 10.1016/j.cell.2007.02.024; Bennett D, 2015, OCUL ONCOL PATHOL, V1, P190, DOI 10.1159/000370155; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bravo-Cordero JJ, 2012, CURR OPIN CELL BIOL, V24, P277, DOI 10.1016/j.ceb.2011.12.004; Brumby AM, 2005, NAT REV CANCER, V5, P626, DOI 10.1038/nrc1671; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Carmona G, 2016, ONCOGENE, V35, P5155, DOI 10.1038/onc.2016.47; Choi C, 2014, ONCOGENE, V33, P3668, DOI 10.1038/onc.2013.341; Chotard C, 2005, NEURON, V48, P237, DOI 10.1016/j.neuron.2005.09.019; Chuang HN, 2013, GLIA, V61, P1331, DOI 10.1002/glia.22518; Ciurciu A, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003885; Cordero JB, 2010, DEV CELL, V18, P999, DOI 10.1016/j.devcel.2010.05.014; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Didry D, 1998, J BIOL CHEM, V273, P25602, DOI 10.1074/jbc.273.40.25602; Donlea JM, 2009, SCIENCE, V324, P105, DOI 10.1126/science.1166657; Esnault C, 2014, GENE DEV, V28, P943, DOI 10.1101/gad.239327.114; Fernandez BG, 2014, ONCOGENE, V33, P2027, DOI 10.1038/onc.2013.155; Friese MA, 2004, ONKOLOGIE, V27, P487, DOI 10.1159/000080371; Ginestier C, 2006, CLIN CANCER RES, V12, P4533, DOI 10.1158/1078-0432.CCR-05-2339; Grosse R, 2003, EMBO J, V22, P3050, DOI 10.1093/emboj/cdg287; Han Z, 2004, P NATL ACAD SCI USA, V101, P12567, DOI 10.1073/pnas.0405085101; Hansen SD, 2015, ELIFE, V4, DOI 10.7554/eLife.06585; Krause M, 2004, DEV CELL, V7, P571, DOI 10.1016/j.devcel.2004.07.024; Krause M, 2014, NAT REV MOL CELL BIO, V15, P577, DOI 10.1038/nrm3861; Kulshammer E, 2013, J CELL SCI, V126, P927, DOI 10.1242/jcs.114462; Kurucz E, 2007, CURR BIOL, V17, P649, DOI 10.1016/j.cub.2007.02.041; Lafuente EM, 2004, DEV CELL, V7, P585, DOI 10.1016/j.devcel.2004.07.021; Law AL, 2013, J CELL BIOL, V203, P673, DOI 10.1083/jcb.201304051; Logan MA, 2007, NEURON GLIA BIOL, V3, P63, DOI [10.1017/S1740925X0700049X, 10.1017/S1740925X07000646]; Lyulcheva E, 2008, DEV CELL, V15, P680, DOI 10.1016/j.devcel.2008.09.020; MacDonald JM, 2013, CELL DEATH DIFFER, V20, P1140, DOI 10.1038/cdd.2013.30; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Nawaz S, 2015, DEV CELL, V34, P139, DOI 10.1016/j.devcel.2015.05.013; Ohayon D, 2009, EMBO J, V28, P3228, DOI 10.1038/emboj.2009.247; Olson EN, 2010, NAT REV MOL CELL BIO, V11, P353, DOI 10.1038/nrm2890; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Petryszak R, 2016, NUCLEIC ACIDS RES, V44, pD746, DOI 10.1093/nar/gkv1045; Pinheiro EM, 2011, NAT CELL BIOL, V13, P989, DOI 10.1038/ncb2292; Read RD, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000374; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Rudrapatna VA, 2014, ONCOGENE, V33, P2801, DOI 10.1038/onc.2013.232; Salvany L, 2014, GENE DEV, V28, P1048, DOI 10.1101/gad.237743.114; Shekhar S, 2016, J CELL SCI, V129, P1085, DOI 10.1242/jcs.179994; Shklover J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.27; Skau CT, 2015, ANNU REV BIOPHYS, V44, P285, DOI 10.1146/annurev-biophys-060414-034308; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Srivastava A, 2007, P NATL ACAD SCI USA, V104, P2721, DOI 10.1073/pnas.0611666104; Stevenson RP, 2012, J CELL SCI, V125, P1073, DOI 10.1242/jcs.093799; Thran J, 2013, CURR BIOL, V23, P1756, DOI 10.1016/j.cub.2013.07.034; Uhlirova M, 2006, EMBO J, V25, P5294, DOI 10.1038/sj.emboj.7601401; Vartiainen MK, 2007, SCIENCE, V316, P1749, DOI 10.1126/science.1141084; Wu Y, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471-213X-9-53; Ziv-Av A, 2011, CELL SIGNAL, V23, P1936, DOI 10.1016/j.cellsig.2011.07.001	56	5	5	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4311	4322		10.1038/onc.2017.68	http://dx.doi.org/10.1038/onc.2017.68			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	28346426	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000406360600008
J	Suklabaidya, S; Dash, P; Senapati, S				Suklabaidya, S.; Dash, P.; Senapati, S.			Pancreatic fibroblast exosomes regulate survival of cancer cells	ONCOGENE			English	Letter							MESENCHYMAL STROMAL CELLS; GEMCITABINE; DRUG		[Suklabaidya, S.; Dash, P.; Senapati, S.] Inst Life Sci, Dept Translat Res, Tumor Microenvironm & Anim Models Lab, Bhubaneswar, Odisha, India; [Suklabaidya, S.] Manipal Univ, Manipal, Karnataka, India	Department of Biotechnology (DBT) India; Institute of Life Sciences India (ILS); Manipal Academy of Higher Education (MAHE)	Senapati, S (corresponding author), Inst Life Sci, Dept Translat Res, Tumor Microenvironm & Anim Models Lab, Bhubaneswar, Odisha, India.	drsantibhusan@yahoo.com	Suklabaidya, Sujit/AAF-2798-2021	Suklabaidya, Sujit/0000-0002-6460-6410; Dash, Pujarini/0000-0002-5221-011X; Senapati, Shantibhusan/0000-0001-7108-8255				Arora S, 2013, J BIOL CHEM, V288, P21197, DOI 10.1074/jbc.M113.484576; Bonomi A, 2015, CYTOTHERAPY, V17, P1687, DOI 10.1016/j.jcyt.2015.09.005; Namba T, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.172; Pascucci L, 2014, J CONTROL RELEASE, V192, P262, DOI 10.1016/j.jconrel.2014.07.042; Richards KE, 2017, ONCOGENE, V36, P1770, DOI 10.1038/onc.2016.353; Xu X, 2015, MEDIAT INFLAMM, V2015, DOI [10.1155/2015/380218, 10.1155/2015/810798]	6	5	5	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3648	3649		10.1038/onc.2016.528	http://dx.doi.org/10.1038/onc.2016.528			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28166198				2022-12-17	WOS:000403878600014
J	Uo, T; Dvinge, H; Sprenger, CC; Bradley, RK; Nelson, PS; Plymate, SR				Uo, T.; Dvinge, H.; Sprenger, C. C.; Bradley, R. K.; Nelson, P. S.; Plymate, S. R.			Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain	ONCOGENE			English	Article							HEAT-SHOCK PROTEIN; PROSTATE-CANCER; GLUCOCORTICOID-RECEPTOR; NUCLEAR-LOCALIZATION; INCREASED SURVIVAL; RESISTANCE; ENZALUTAMIDE; ABIRATERONE; ACTIVATION; EXPRESSION	The presence of intact ligand-binding domain (LBD) ensures the strict androgen-dependent regulation of androgen receptor (AR): binding of androgen induces structural reorganization of LBD resulting in release of AR from HSP90, suppression of nuclear export which otherwise dominates over import and nuclear translocation of AR as a transcription factor. Thus, loss or defects of the LBD abolish constraint from un-liganded LBD as exemplified by constitutively active AR variants (AR-Vs), which are associated with emerging resistance mechanism to anti-AR therapy in castration-resistant prostate cancer (mCRPC). Recent analysis of the AR splicing landscapes revealed mCRPC harboring multiple AR-Vs with diverse patterns of inclusion/exclusion of exons (exons 4-8) corresponding to LBD to produce namely exon-skipping variants. In silico construction for these AR-Vs revealed four novel AR-Vs having unique features: Exclusion of specified exons introduces a frameshift in variants v5es, v6es and v7es. ARv56es maintains the reading frame resulting in the inclusion of the C-terminal half of the LBD. We systematically characterized these AR-Vs regarding their subcellular localization, affinity for HSP90 and transactivation capability. Notably, ARv5es was free from HSP90, exclusively nuclear, and constitutively active similarly as previously reported for v567es. In contrast, v6es and v7es were similar in that they are cytoplasmic, transcriptionally inactive and bind HSP90, ARv56es was present in both nucleus and cytoplasm, does not bind HSP90 and is transcriptionally inactive. Converting these transcriptionally inactive AR-Vs into active forms, we identified the two separate elements that allosterically suppress otherwise constitutively active AR-Vs; one in exon 5 for v6es and v7es and the other in exon 8 for v56es. Our findings identify a novel constitutively active AR-V, ARv5es and establish a method to predict potential activities of AR-Vs carrying impaired LBD.	[Uo, T.; Dvinge, H.; Plymate, S. R.] Univ Washington, Dept Med, Harborview Res & Training Bldg,Box 359625,325 9th, Seattle, WA 98195 USA; [Dvinge, H.; Bradley, R. K.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Computat Biol Program, 1124 Columbia St, Seattle, WA 98104 USA; [Dvinge, H.; Bradley, R. K.] Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1124 Columbia St, Seattle, WA 98104 USA; [Nelson, P. S.] Fred Hutchinson Canc Res Ctr, Human Biol Div, 1124 Columbia St, Seattle, WA 98104 USA	Harborview Medical Center; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center	Plymate, SR (corresponding author), Univ Washington, Dept Med, Harborview Res & Training Bldg,Box 359625,325 9th, Seattle, WA 98195 USA.	splymate@u.washington.edu		Bradley, Robert/0000-0002-8046-1063; Dvinge, Heidi/0000-0003-1741-0738	Department of Defense [W81XWH-12-PCRP-TIA]; Veterans Affairs Research Program; National Cancer of Institute [P01CA163227, P50 CA 097186]; NATIONAL CANCER INSTITUTE [P50CA097186, P01CA163227] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [S10OD020069] Funding Source: NIH RePORTER; Veterans Affairs [I01BX003324] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); Veterans Affairs Research Program; National Cancer of Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veterans Affairs(US Department of Veterans Affairs)	This work was supported by the Department of Defense (W81XWH-12-PCRP-TIA), Veterans Affairs Research Program (to SRP) and National Cancer of Institute (P01CA163227, P50 CA 097186) (to SRP and PSN).	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; An J, 2014, CELL REP, V6, P657, DOI 10.1016/j.celrep.2014.01.013; Antonarakis ES, 2015, JAMA ONCOL, V1, P582, DOI 10.1001/jamaoncol.2015.1341; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Attard G, 2016, LANCET, V387, P70, DOI 10.1016/S0140-6736(14)61947-4; Cao B, 2014, ONCOTARGET, V5, P1646, DOI 10.18632/oncotarget.1802; Centenera MM, 2008, MOL ENDOCRINOL, V22, P2373, DOI 10.1210/me.2008-0017; Ceraline J, 2004, INT J CANCER, V108, P152, DOI 10.1002/ijc.11404; Chan SC, 2012, J BIOL CHEM, V287, P19736, DOI 10.1074/jbc.M112.352930; Claessens Frank, 2008, Nucl Recept Signal, V6, pe008, DOI 10.1621/nrs.06008; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; Darshan MS, 2011, CANCER RES, V71, P6019, DOI 10.1158/0008-5472.CAN-11-1417; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Dehm SM, 2006, J BIOL CHEM, V281, P27882, DOI 10.1074/jbc.M605002200; Dehm SM, 2011, ENDOCR-RELAT CANCER, V18, pR183, DOI 10.1530/ERC-11-0141; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Ferraldeschi R, 2015, ONCOGENE, V34, P1745, DOI 10.1038/onc.2014.115; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gardner LB, 2010, MOL CANCER RES, V8, P295, DOI 10.1158/1541-7786.MCR-09-0502; Gillis JL, 2013, ONCOTARGET, V4, P691, DOI 10.18632/oncotarget.975; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Helsen C, 2012, MOL CELL BIOL, V32, P3033, DOI 10.1128/MCB.00151-12; Hornberg E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019059; Hu R, 2011, PROSTATE, V71, P1656, DOI 10.1002/pros.21382; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Li Y, 2012, ONCOGENE, V31, P4759, DOI 10.1038/onc.2011.637; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Li YM, 2011, CANCER RES, V71, P2108, DOI 10.1158/0008-5472.CAN-10-1998; Liu LL, 2014, ONCOGENE, V33, P3140, DOI 10.1038/onc.2013.284; Lu CX, 2013, TRANSL ANDROL UROL, V2, P178, DOI 10.3978/j.issn.2223-4683.2013.09.08; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; MARIVOET S, 1992, MOL CELL ENDOCRINOL, V88, P165, DOI 10.1016/0303-7207(92)90021-W; Mostaghel EA, 2014, CLIN CANCER RES, V20, P791, DOI 10.1158/1078-0432.CCR-12-3601; Myung JK, 2013, J CLIN INVEST, V123, P2948, DOI 10.1172/JCI66398; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Saporita AJ, 2003, J BIOL CHEM, V278, P41998, DOI 10.1074/jbc.M302460200; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Sprenger CCT, 2014, HORM CANCER-US, V5, P207, DOI 10.1007/s12672-014-0177-y; Steinkamp MP, 2009, CANCER RES, V69, P4434, DOI 10.1158/0008-5472.CAN-08-3605; Storer CL, 2011, TRENDS ENDOCRIN MET, V22, P481, DOI 10.1016/j.tem.2011.08.001; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; TAKAHASHI H, 1995, CANCER RES, V55, P1621; Tan MHE, 2015, ACTA PHARMACOL SIN, V36, P3, DOI 10.1038/aps.2014.18; Thadani-Mulero M, 2014, CANCER RES, V74, P2270, DOI 10.1158/0008-5472.CAN-13-2876; van Soest RJ, 2013, EUR J CANCER, V49, P3821, DOI 10.1016/j.ejca.2013.09.026; Wang D, 2015, MOL ENDOCRINOL, V29, P1731, DOI 10.1210/me.2015-1112; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; WEN W, 1994, J BIOL CHEM, V269, P32214; Xu D, 2015, CANCER RES, V75, P3663, DOI 10.1158/0008-5472.CAN-15-0381; Yang X, 2011, J BIOL CHEM, V286, P36152, DOI 10.1074/jbc.M111.265124; Zhang GY, 2015, ONCOTARGET, V6, P23358, DOI 10.18632/oncotarget.4396; Zhang JF, 2000, ENDOCRINOLOGY, V141, P4698, DOI 10.1210/en.141.12.4698	58	5	5	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2017	36	10					1440	1450		10.1038/onc.2016.313	http://dx.doi.org/10.1038/onc.2016.313			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2TG	27694897	Green Accepted, hybrid, Green Published			2022-12-17	WOS:000395862500012
J	Gallastegui, E; Bicer, A; Orlando, S; Besson, A; Pujol, MJ; Bachs, O				Gallastegui, E.; Bicer, A.; Orlando, S.; Besson, A.; Pujol, M. J.; Bachs, O.			p27(Kip1) represses the Pitx2-mediated expression of p21(Cip1) and regulates DNA replication during cell cycle progression	ONCOGENE			English	Article							CDK INHIBITORS; PITX2; ACTIVATION; P21; DIFFERENTIATION; PROLIFERATION; REQUIREMENT; QUIESCENCE; RELEVANCE; MIGRATION	The tumor suppressor p21 regulates cell cycle progression and peaks at mid/late G1. However, the mechanisms regulating its expression during cell cycle are poorly understood. We found that embryonic fibroblasts from p27 null mice at early passages progress slowly through the cell cycle. These cells present an elevated basal expression of p21 suggesting that p27 participates to its repression. Mechanistically, we found that p27 represses the expression of Pitx2 (an activator of p21 expression) by associating with the ASE- regulatory region of this gene together with an E2F4 repressive complex. Furthermore, we found that Pitx2 binds to the p21 promoter and induces its transcription. Finally, silencing Pitx2 or p21 in proliferating cells accelerates DNA replication and cell cycle progression. Collectively, these results demonstrate an unprecedented connection between p27, Pitx2 and p21 relevant for the regulation of cell cycle progression and cancer and for understanding human pathologies associated with p27 germline mutations.	[Gallastegui, E.; Bicer, A.; Orlando, S.; Pujol, M. J.; Bachs, O.] Univ Barcelona, IDIBAPS, Dept Cell Biol Immunol & Neurosci, Barcelona, Spain; [Besson, A.] INSERM, UMR1037, Canc Res Ctr Toulouse, Toulouse, France; [Besson, A.] Univ Toulouse, Toulouse, France; [Besson, A.] CNRS ERL5294, Toulouse, France	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB)	Bachs, O (corresponding author), Univ Barcelona, Biomed, Casanova 143, E-08036 Barcelona, Spain.	obachs@ub.edu	Besson, Arnaud/J-6254-2014; Bicer, Atilla/AAA-6738-2019; Orlando, Serena/AAA-7963-2019	Besson, Arnaud/0000-0002-9599-3943; Bicer, Atilla/0000-0003-4032-6534; Gallastegui Calvache, Edurne/0000-0003-0768-8648	Ministerio de Economia y Competitividad (MINECO) [SAF2012-38078]; Instituto de Salud Carlos III [RD12/0036/0054]; Fondation ARC pour la Recherche sur le Cancer; Ligue Nationale Contre le Cancer; Institut National du Cancer	Ministerio de Economia y Competitividad (MINECO); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Institut National du Cancer(Institut National du Cancer (INCA) France)	We would like to thank to Dr Hiroshi Hamada, Dr Chrissa Kioussi, Dr Charles P Emerson and Dr Nobuko Hagiwara for the kind gift of Pitx2-ASE luciferase vector, the expression vector for Pitx2, the expression vector for Zic1 and the expression vector for Sox6, respectively. This work was supported by grants from the Ministerio de Economia y Competitividad (MINECO) SAF2012-38078 and from the Instituto de Salud Carlos III RD12/0036/0054. AB is supported by grants from the Fondation ARC pour la Recherche sur le Cancer, Ligue Nationale Contre le Cancer and Institut National du Cancer. The data set has been deposited in ArrayExpress accession number E-MTAB-2790.	Aguilera C, 2004, P NATL ACAD SCI USA, V101, P16537, DOI 10.1073/pnas.0404429101; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Cao HJ, 2010, DEV BIOL, V347, P289, DOI 10.1016/j.ydbio.2010.08.031; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; de la Grange P, 2005, NUCLEIC ACIDS RES, V33, P4276, DOI 10.1093/nar/gki738; de la Grange P, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-180; Dickson DW, 2009, LANCET NEUROL, V8, P1150, DOI 10.1016/S1474-4422(09)70238-8; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; Fung FKC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037076; Gage PJ, 1999, DEVELOPMENT, V126, P4643; Gallastegui E, 2011, J VIROL, V85, P3187, DOI 10.1128/JVI.01920-10; Heldring N, 2012, CNS NEUROL DISORD-DR, V11, P884, DOI 10.2174/1871527311201070884; Henley SA, 2012, CELL DIV, V7, DOI 10.1186/1747-1028-7-10; Houtmeyers R, 2013, CELL MOL LIFE SCI, V70, P3791, DOI 10.1007/s00018-013-1285-5; Huang Y, 2010, CELL CYCLE, V9, P1333, DOI 10.4161/cc.9.7.11126; Jaime M, 2002, HEPATOLOGY, V35, P1063, DOI 10.1053/jhep.2002.32678; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; Kwon YH, 2002, J BIOL CHEM, V277, P41417, DOI 10.1074/jbc.M203388200; Li H, 2012, CELL STEM CELL, V11, P845, DOI 10.1016/j.stem.2012.09.014; Lim SH, 2013, DEVELOPMENT, V140, P3079, DOI 10.1242/dev.091744; Liu Y, 2013, MOL CELL BIOCHEM, V384, P221, DOI 10.1007/s11010-013-1801-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Malumbres M, 2011, PHYSIOL REV, V91, P973, DOI 10.1152/physrev.00025.2010; Meeh PF, 2009, NEOPLASIA, V11, P1074, DOI 10.1593/neo.09808; Montavon T, 2014, SEMIN CELL DEV BIOL, V34, P76, DOI 10.1016/j.semcdb.2014.06.005; Moreno CS, 2005, CANCER RES, V65, P10214, DOI 10.1158/0008-5472.CAN-05-0884; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nguyen L, 2006, GENE DEV, V20, P1511, DOI 10.1101/gad.377106; Orlando S, 2015, NUCLEIC ACIDS RES, V43, P6860, DOI 10.1093/nar/gkv593; Pippa R, 2012, ONCOGENE, V31, P4207, DOI 10.1038/onc.2011.582; SALA A, 1994, CANCER RES, V54, P1402; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shiratori H, 2001, MOL CELL, V7, P137, DOI 10.1016/S1097-2765(01)00162-9; Spencer SL, 2013, CELL, V155, P369, DOI 10.1016/j.cell.2013.08.062; Starostina NG, 2012, TRENDS CELL BIOL, V22, P33, DOI 10.1016/j.tcb.2011.10.004	37	5	6	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	2017	36	3					350	361		10.1038/onc.2016.200	http://dx.doi.org/10.1038/onc.2016.200			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IB	27270438				2022-12-17	WOS:000394166000005
J	Sankar, S; Bell, R; Stephens, B; Zhuo, R; Sharma, S; Bearss, DJ; Lessnick, SL				Sankar, S.; Bell, R.; Stephens, B.; Zhuo, R.; Sharma, S.; Bearss, D. J.; Lessnick, S. L.			Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma (vol 32, pg 5089, 2012)	ONCOGENE			English	Correction														Bearss, David/0000-0002-4458-826X				Sankar S, 2013, ONCOGENE, V32, P5089, DOI 10.1038/onc.2012.525	1	5	5	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2016	35	47					6155	6156		10.1038/onc.2016.142	http://dx.doi.org/10.1038/onc.2016.142			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CE	27345405	Bronze			2022-12-17	WOS:000388509800012
J	Cross, AM; Wilson, AL; Guerrero, MS; Thomas, KS; Bachir, AI; Kubow, KE; Horwitz, AR; Bouton, AH				Cross, A. M.; Wilson, A. L.; Guerrero, M. S.; Thomas, K. S.; Bachir, A. I.; Kubow, K. E.; Horwitz, A. R.; Bouton, A. H.			Breast cancer antiestrogen resistance 3-p130(Cas) interactions promote adhesion disassembly and invasion in breast cancer cells	ONCOGENE			English	Article							MIGRATION; INTEGRIN; BCAR3; CAS; AND-34/BCAR3; ACTIVATION; EXPRESSION; FAMILY; ASSOCIATION; INDUCTION	Adhesion turnover is critical for cell motility and invasion. We previously demonstrated that the adaptor molecule breast cancer antiestrogen resistance 3 (BCAR3) promotes adhesion disassembly and breast tumor cell invasion. One of two established binding partners of BCAR3 is the adaptor molecule, p130(Cas). In this study, we sought to determine whether signaling through the BCAR3-Cas complex was responsible for the cellular functions of BCAR3. We show that the entire pool of BCAR3 is in complex with Cas in invasive breast tumor cells and that these proteins colocalize in dynamic cellular adhesions. Although accumulation of BCAR3 in adhesions did not require Cas binding, a direct interaction between BCAR3 and Cas was necessary for efficient dissociation of BCAR3 from adhesions. The dissociation rates of Cas and two other adhesion molecules, a-actinin and talin, were also significantly slower in the presence of a Cas-binding mutant of BCAR3, suggesting that turnover of the entire adhesion complex was delayed under these conditions. As was the case for adhesion turnover, BCAR3-Cas interactions were found to be important for BCAR3-mediated breast tumor cell chemotaxis toward serum and invasion in Matrigel. Previous work demonstrated that BCAR3 is a potent activator of Rac1, which in turn is an important regulator of adhesion dynamics and invasion. However, in contrast to wild-type BCAR3, ectopic expression of the Cas-binding mutant of BCAR3 failed to induce Rac1 activity in breast cancer cells. Together, these data show that the ability of BCAR3 to promote adhesion disassembly, tumor cell migration and invasion, and Rac1 activity is dependent on its ability to bind to Cas. The activity of BCAR3-Cas complexes as a functional unit in breast cancer is further supported by the co-expression of these molecules in multiple subtypes of human breast tumors.	[Cross, A. M.; Wilson, A. L.; Thomas, K. S.; Bouton, A. H.] Univ Virginia, Sch Med, Dept Microbiol Immunol & Canc Biol, Box 800734, Charlottesville, VA 22908 USA; [Guerrero, M. S.] Fujifilm Diosynth Biotechnol USA Inc, Cary, NC USA; [Bachir, A. I.; Horwitz, A. R.] Univ Virginia, Sch Med, Dept Cell Biol, Charlottesville, VA 22908 USA; [Kubow, K. E.] James Madison Univ, Dept Biol, Harrisonburg, VA 22807 USA	University of Virginia; Fujifilm Corporation; University of Virginia; James Madison University	Bouton, AH (corresponding author), Univ Virginia, Sch Med, Dept Microbiol Immunol & Canc Biol, Box 800734, Charlottesville, VA 22908 USA.	ahb8y@virginia.edu		Kubow, Kristopher/0000-0003-0259-882X	NIH [5 T32 CA009109, 1 R01 CA096846, 1 F31 CA165703, 1 F31 CA130168, GM023244]; Department of Defense Breast Cancer Research Program [BC141713]; American Cancer Society [PF-12-136-01-CSM]; Women's Oncology Research Fund; NCI Cancer Center Support Grant from the UVA Cancer Center [P30 CA44579]; NATIONAL CANCER INSTITUTE [P30CA044579, F31CA165703, T32CA009109, F31CA130168, R01CA096846] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023244, R37GM023244] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Breast Cancer Research Program(United States Department of Defense); American Cancer Society(American Cancer Society); Women's Oncology Research Fund; NCI Cancer Center Support Grant from the UVA Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Jessica Zareno for technical assistance with TIRF microscopy and Dr Kristen Atkins for identification and pathological assessment of human breast tumor samples. This work was supported by grants from the NIH (5 T32 CA009109 (ALW, AMC), 1 R01 CA096846 (AHB), 1 F31 CA165703 (ALW), 1 F31 CA130168 (MSG) and GM023244 (ARH)); the Department of Defense Breast Cancer Research Program (BC141713 to AHB); the American Cancer Society (PF-12-136-01-CSM to KEK); and the Women's Oncology Research Fund and NCI Cancer Center Support Grant P30 CA44579 from the UVA Cancer Center. Breast tumor samples were obtained from the UVA tumor bank and stained by the Biorepository and Tissue Research Facility (BTRF).	Akakura S, 2005, J CELL PHYSIOL, V204, P344, DOI 10.1002/jcp.20288; Borre PV, 2011, CELL SIGNAL, V23, P1030, DOI 10.1016/j.cellsig.2011.01.018; Bouton AH, 1997, HYBRIDOMA, V16, P403, DOI 10.1089/hyb.1997.16.403; Broussard JA, 2008, CURR OPIN CELL BIOL, V20, P85, DOI 10.1016/j.ceb.2007.10.009; Cabodi S, 2010, NAT REV CANCER, V10, P858, DOI 10.1038/nrc2967; Cai DP, 1999, J IMMUNOL, V163, P2104; Harunaga JS, 2011, MATRIX BIOL, V30, P363, DOI 10.1016/j.matbio.2011.06.001; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Lu YM, 1999, J BIOL CHEM, V274, P10047, DOI 10.1074/jbc.274.15.10047; Mace PD, 2011, NAT STRUCT MOL BIOL, V18, P1381, DOI 10.1038/nsmb.2152; Near RI, 2007, J CELL PHYSIOL, V212, P655, DOI 10.1002/jcp.21059; Near RI, 2009, MOL VIS, V15, P685; Parsons JT, 2010, NAT REV MOL CELL BIO, V11, P633, DOI 10.1038/nrm2957; Petrie RJ, 2012, J CELL SCI, V125, P5917, DOI 10.1242/jcs.093732; Riggins RB, 2003, J BIOL CHEM, V278, P28264, DOI 10.1074/jbc.M303535200; Schrecengost RS, 2007, CANCER RES, V67, P6174, DOI 10.1158/0008-5472.CAN-06-3455; Schuh NR, 2010, J BIOL CHEM, V285, P2309, DOI 10.1074/jbc.M109.046631; Sun GB, 2012, MOL CELL BIOL, V32, P3776, DOI 10.1128/MCB.00214-12; Vervoort VS, 2007, GENE, V391, P161, DOI 10.1016/j.gene.2006.12.016; Wallez Y, 2014, J BIOL CHEM, V289, P10431, DOI 10.1074/jbc.M113.541839; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wilson AL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065678; Yamazaki D, 2009, ONCOGENE, V28, P1570, DOI 10.1038/onc.2009.2	24	5	5	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2016	35	45					5850	5859		10.1038/onc.2016.123	http://dx.doi.org/10.1038/onc.2016.123			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EB7IR	27109104	Green Accepted			2022-12-17	WOS:000387560800004
J	Wells, JE; Howlett, M; Halse, HM; Heng, J; Ford, J; Cheung, LC; Samuels, AL; Crook, M; Charles, AK; Cole, CH; Kees, UR				Wells, J. E.; Howlett, M.; Halse, H. M.; Heng, J.; Ford, J.; Cheung, L. C.; Samuels, A. L.; Crook, M.; Charles, A. K.; Cole, C. H.; Kees, U. R.			High expression of connective tissue growth factor accelerates dissemination of leukaemia	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; MINIMAL RESIDUAL DISEASE; MARROW STROMAL CELLS; HUMAN-BONE-MARROW; EXTRACELLULAR-MATRIX; TUMOR-GROWTH; CLINICAL-SIGNIFICANCE; MOUSE MODEL; FACTOR CTGF; IN-VITRO	To improve treatment of acute lymphoblastic leukaemia (ALL), a better understanding of disease development is needed to tailor new therapies. Connective tissue growth factor (CTGF/CCN2) is highly expressed in leukaemia cells from the majority of paediatric patients with B-lineage ALL (pre-B ALL). CTGF is a matricellular protein and plays a role in aggressive cancers. Here we have genetically engineered leukaemia cells to modulate CTGF expression levels. Elevated CTGF levels accelerated disease dissemination and reduced survival in NOD/SCID mice. In vitro studies showed that CTGF protein induces stromal cell proliferation, promotes adhesion of leukaemia cells to stromal cells and leads to overexpression of genes associated with cell cycle and synthesis of extracellular matrix (ECM). Corresponding data from our leukaemia xenograft models demonstrated that CTGF leads to increased proliferation of non-leukaemia cells and deposition of ECM in the bone marrow. We document for the first time a functional role of CTGF in altering disease progression in a lymphoid malignancy. The findings provide support for targeting the bone marrow microenvironment in aggressive forms of leukaemia.	[Wells, J. E.; Howlett, M.; Halse, H. M.; Heng, J.; Ford, J.; Cheung, L. C.; Samuels, A. L.; Kees, U. R.] Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia; [Wells, J. E.; Cole, C. H.; Kees, U. R.] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA, Australia; [Crook, M.; Charles, A. K.; Cole, C. H.] Princess Margaret Hosp Children, Perth, WA, Australia	Telethon Kids Institute; University of Western Australia; University of Western Australia; University of Western Australia	Kees, UR (corresponding author), Telethon Kids Inst, Head Childrens Leukaemia & Canc Div, POB 855,West Perth, Perth, WA 6872, Australia.	ursula.kees@telethonkids.org.au	Cheung, Laurence/R-9932-2017; Cheung, Laurence/HGU-5859-2022	Cheung, Laurence/0000-0001-6298-5288; Cheung, Laurence/0000-0001-6298-5288; Howlett, Meegan/0000-0003-4332-6572				Aikawa T, 2006, MOL CANCER THER, V5, P1108, DOI 10.1158/1535-7163.MCT-05-0516; Barkan D, 2010, CANCER RES, V70, P5706, DOI 10.1158/0008-5472.CAN-09-2356; Bennewith KL, 2009, CANCER RES, V69, P775, DOI 10.1158/0008-5472.CAN-08-0987; BENTLEY SA, 1981, BRIT J HAEMATOL, V48, P287, DOI 10.1111/j.1365-2141.1981.tb08462.x; Biondi A, 2012, LANCET ONCOL, V13, P936, DOI 10.1016/S1470-2045(12)70377-7; Boag JM, 2006, LEUKEMIA, V20, P1731, DOI 10.1038/sj.leu.2404365; Boag JM, 2007, BRIT J HAEMATOL, V138, P740, DOI 10.1111/j.1365-2141.2007.06739.x; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Boyerinas B, 2013, BLOOD, V121, P4821, DOI 10.1182/blood-2012-12-475483; Capparelli C, 2012, CELL CYCLE, V11, P2272, DOI 10.4161/cc.20717; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Cheung LC, 2014, HAEMATOLOGICA, V99, P1149, DOI 10.3324/haematol.2013.102327; Cichon MA, 2014, CELL ADHES MIGR, V8, P588, DOI 10.4161/19336918.2014.972788; Conter V, 2010, BLOOD, V115, P3206, DOI 10.1182/blood-2009-10-248146; Cox TR, 2013, CANCER RES, V73, P1721, DOI 10.1158/0008-5472.CAN-12-2233; Duan CW, 2014, CANCER CELL, V25, P778, DOI 10.1016/j.ccr.2014.04.015; Dworzak MN, 2002, BLOOD, V99, P1952, DOI 10.1182/blood.V99.6.1952; Finger EC, 2014, ONCOGENE, V33, P1093, DOI 10.1038/onc.2013.47; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Fujii M, 2012, CELL CYCLE, V11, P3373, DOI 10.4161/cc.21397; GORDON MY, 1988, BRIT J HAEMATOL, V70, P1, DOI 10.1111/j.1365-2141.1988.tb02425.x; Ijichi H, 2011, J CLIN INVEST, V121, P4106, DOI 10.1172/JCI42754; Jun JI, 2011, NAT REV DRUG DISCOV, V10, P945, DOI 10.1038/nrd3599; Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413; Kang HN, 2010, BLOOD, V115, P1394, DOI 10.1182/blood-2009-05-218560; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; KEES UR, 1987, LEUKEMIA RES, V11, P489, DOI 10.1016/0145-2126(87)90082-8; Khan RB, 2014, J CANCER SURVIV, V8, P688, DOI 10.1007/s11764-014-0375-1; Kim SK, 2014, MOL ONCOL, V8, P1653, DOI 10.1016/j.molonc.2014.06.016; Kuter DJ, 2007, BRIT J HAEMATOL, V139, P351, DOI 10.1111/j.1365-2141.2007.06807.x; Leask A, 2006, J CELL SCI, V119, P4803, DOI 10.1242/jcs.03270; Lu HB, 2014, ANN HEMATOL, V93, P485, DOI 10.1007/s00277-013-1939-2; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; MANABE A, 1994, BLOOD, V83, P758; Mayorca-Guiliani A, 2013, ONCOTARGETS THER, V6, P1729, DOI 10.2147/OTT.S38110; Neesse A, 2013, P NATL ACAD SCI USA, V110, P12325, DOI 10.1073/pnas.1300415110; Nishida T, 2000, J CELL PHYSIOL, V184, P197, DOI 10.1002/1097-4652(200008)184:2<197::AID-JCP7>3.0.CO;2-R; Noren-Nystrom U, 2008, LEUKEMIA, V22, P504, DOI 10.1038/sj.leu.2405072; Payne SL, 2007, J CELL BIOCHEM, V101, P1338, DOI 10.1002/jcb.21371; Pui CH, 2014, LEUKEMIA, V28, P2336, DOI 10.1038/leu.2014.142; Safadi FF, 2003, J CELL PHYSIOL, V196, P51, DOI 10.1002/jcp.10319; Sala-Torra O, 2007, BLOOD, V109, P3080, DOI 10.1182/blood-2006-06-031096; SANERKIN NG, 1964, J CLIN PATHOL, V17, P541, DOI 10.1136/jcp.17.5.541; Schultz KR, 2009, J CLIN ONCOL, V27, P5175, DOI 10.1200/JCO.2008.21.2514; SHIMIZU Y, 1991, FASEB J, V5, P2292, DOI 10.1096/fasebj.5.9.1860621; Sison EAR, 2011, EXPERT REV HEMATOL, V4, P271, DOI [10.1586/ehm.11.30, 10.1586/EHM.11.30]; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; Stow P, 2010, BLOOD, V115, P4657, DOI 10.1182/blood-2009-11-253435; Tesfai Y, 2012, LEUKEMIA RES, V36, P299, DOI 10.1016/j.leukres.2011.08.001; Vorwerk P, 2000, BRIT J CANCER, V83, P756, DOI 10.1054/bjoc.2000.1364; Welch MD, 2013, BRIT J HAEMATOL, V162, P537, DOI 10.1111/bjh.12417; Wells JE, 2015, INT J CANCER, V137, P504, DOI 10.1002/ijc.28972; WICKRAMASINGHE SN, 1991, CLIN LAB HAEMATOL, V13, P263; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zombori L, 2013, PEDIATR RHEUMATOL, V11, DOI 10.1186/1546-0096-11-20	55	5	6	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2016	35	35					4591	4600		10.1038/onc.2015.525	http://dx.doi.org/10.1038/onc.2015.525			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU6PE	26804166				2022-12-17	WOS:000382336300005
J	De Donatis, GM; Le Pape, E; Pierron, A; Cheli, Y; Hofman, V; Hofman, P; Allegra, M; Zahaf, K; Bahadoran, P; Rocchi, S; Bertolotto, C; Ballotti, R; Passeron, T				De Donatis, G. M.; Le Pape, E.; Pierron, A.; Cheli, Y.; Hofman, V.; Hofman, P.; Allegra, M.; Zahaf, K.; Bahadoran, P.; Rocchi, S.; Bertolotto, C.; Ballotti, R.; Passeron, T.			NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2 (vol 35, pg 2735, 2016)	ONCOGENE			English	Correction													Hofman, Paul/P-7654-2018; Rocchi, Stephane/O-4152-2016; Cheli, Yann/O-5783-2016; Bertolotto, Corine/AAF-6634-2021	Hofman, Paul/0000-0003-0431-9353; Rocchi, Stephane/0000-0002-0943-1304; Cheli, Yann/0000-0001-9839-4332; Bertolotto, Corine/0000-0001-6971-7753; Bahadoran, Philippe/0000-0002-2481-0556; BALLOTTI, Robert/0000-0002-7322-4908; Passeron, Thierry/0000-0002-0797-6570				De Donatis GM, 2016, ONCOGENE, V35, P2735, DOI 10.1038/onc.2015.331	1	5	5	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2016	35	21					2813	2813		10.1038/onc.2015.468	http://dx.doi.org/10.1038/onc.2015.468			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MJ	27225420	Bronze			2022-12-17	WOS:000377472700014
J	Morrison, MM; Williams, MM; Vaught, DB; Hicks, D; Lim, J; McKernan, C; Aurisicchio, L; Cennaro, G; Simion, C; Sweeney, C; Cook, RS				Morrison, M. M.; Williams, M. M.; Vaught, D. B.; Hicks, D.; Lim, J.; McKernan, C.; Aurisicchio, L.; Cennaro, G.; Simion, C.; Sweeney, C.; Cook, R. S.			Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth (vol 35, pg 1143, 2016)	ONCOGENE			English	Correction									[Cennaro, G.] IRCCS Natl Canc Inst G Pascale, Via Mariano Semmola, I-83131 Naples, Italy; [Aurisicchio, L.] Takis Biotech, Via Castel Romano 100, I-00128 Rome, Italy	IRCCS Fondazione Pascale			Williams, Michelle/AAI-2839-2020; Ciliberto, Gennaro/J-4131-2017	Williams, Michelle/0000-0002-7063-9147; Ciliberto, Gennaro/0000-0003-2851-8605				Morrison MM, 2016, ONCOGENE, V35, P1143, DOI 10.1038/onc.2015.169	1	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1206	1206		10.1038/onc.2015.418	http://dx.doi.org/10.1038/onc.2015.418			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	26935538	Bronze			2022-12-17	WOS:000371351700015
J	Yoo, BH; Masson, O; Li, Y; Khan, IA; Gowda, PS; Rosen, KV				Yoo, B. H.; Masson, O.; Li, Y.; Khan, I. A.; Gowda, P. S.; Rosen, K. V.			Anoikis of colon carcinoma cells triggered by beta-catenin loss can be enhanced by tumor necrosis factor receptor 1 antagonists	ONCOGENE			English	Article							NF-KAPPA-B; INTESTINAL EPITHELIAL-CELLS; DOWN-REGULATION; GROWTH-FACTOR; INDUCED RESISTANCE; APC MUTATIONS; UP-REGULATION; TNF RECEPTOR; IN-VIVO; APOPTOSIS	Detachment of non-malignant epithelial cells from the extracellular matrix causes their apoptosis, a phenomenon called anoikis. By contrast, carcinoma cells are anoikis-resistant, and this resistance is thought to be critical for tumor progression. Many oncogenes trigger not only anti-but also pr-apoptotic signals. The proapoptotic events represent an aspect of a phenomenon called oncogenic stress, which acts as a safeguard mechanism blocking tumor initiation. In cells that become malignant, oncogene-induced antiapoptotic signals outbalance the proapoptotic ones. It is now thought that treatments blocking the antiapoptotic events but preserving the proapoptotic signals can be particularly effective in killing tumor cells. Whether or not oncogenes induce any proanoikis signals that can be used for enhancing the efficiency of approaches aimed at triggering anoikis of cancer cells has never been explored. beta-Catenin is a major oncoprotein that is often activated in colorectal cancer and promotes tumor progression via mechanisms that are understood only in part. We found here that beta-catenin triggers both anti-and proanoikis signals in colon cancer cells. We observed that the antianoikis signals prevail and the cells become anoikis-resistant. We further established that one proanoikis signal in these cells is triggered by beta-catenin-induced downregulation of an apoptosis inhibitor tumor necrosis factor receptor 1 (TNFR1) and subsequent reduction of the activity of a transcription factor NF-kappa B (nuclear factor-kappa B), a mediator of TNFR1 signaling. We also found that the effect of beta-catenin on TNFR1 requires the presence of transcription factor TCF1, a beta-catenin effector. We demonstrated that ablation of beta-catenin in colon cancer cells triggers their anoikis and that this anoikis is enhanced even further if low TNFR1 or NF-kappa B activity is artificially preserved in the beta-catenin-deprived cells. Thus, inhibition of TNFR1 or NF-kappa B activity can be expected to enhance the efficiency of approaches aimed at blocking beta-catenin-driven anoikis resistance of colon carcinoma cells.	Dalhousie Univ, Dept Pediat, Halifax, NS B3H 3J5, Canada; Dalhousie Univ, Dept Biochem, Halifax, NS B3H 3J5, Canada; Dalhousie Univ, Dept Mol Biol, Halifax, NS B3H 3J5, Canada	Dalhousie University; Dalhousie University; Dalhousie University	Rosen, KV (corresponding author), Atlantic Res Ctr, Room C-304,CRC,5849 Univ Ave,POB 15000, Halifax, NS B3H 4R2, Canada.	kirill.rosen@dal.ca		Rosen, Kirill/0000-0002-4317-9907	Canadian Institutes of Health Research/Nova Scotia Regional Partnership Program (CIHR/NS RPP) [125109]; IWK Health Centre	Canadian Institutes of Health Research/Nova Scotia Regional Partnership Program (CIHR/NS RPP)(Canadian Institutes of Health Research (CIHR)); IWK Health Centre	This study was supported by the Canadian Institutes of Health Research/Nova Scotia Regional Partnership Program (CIHR/NS RPP) Grant 125109 held by KR. KR was a recipient of the CIHR/NS RPP New Investigator Salary award. YL and PSG were recipients of the IWK Health Centre Post Doctoral Fellowship. BHY was a recipient of the IWK Health Centre Research Associateship.	Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Anson M, 2012, J CLIN INVEST, V122, P586, DOI 10.1172/JCI43937; Au PYB, 2005, ONCOGENE, V24, P3196, DOI 10.1038/sj.onc.1208516; Balint K, 2005, J CLIN INVEST, V115, P3166, DOI 10.1172/JCI25001; Berezovskaya O, 2005, CANCER RES, V65, P2378, DOI 10.1158/0008-5472.CAN-04-2649; Blattner C, 2000, MOL CELL BIOL, V20, P3616, DOI 10.1128/MCB.20.10.3616-3625.2000; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Brasse-Lagnel C, 2007, FEBS J, V274, P5250, DOI 10.1111/j.1742-4658.2007.06047.x; Cohen-Lahav M, 2006, NEPHROL DIAL TRANSPL, V21, P889, DOI 10.1093/ndt/gfi254; Coll ML, 2002, ONCOGENE, V21, P2908, DOI 10.1038/sj.onc.1205388; DECOSTER E, 1995, J BIOL CHEM, V270, P18473, DOI 10.1074/jbc.270.31.18473; Delage B, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.83; Derouet M, 2007, NEOPLASIA, V9, P536, DOI 10.1593/neo.07217; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Duxbury MS, 2004, ONCOGENE, V23, P465, DOI 10.1038/sj.onc.1207036; Duxbury MS, 2004, ONCOGENE, V23, P1448, DOI 10.1038/sj.onc.1207247; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Frankel A, 2001, CANCER RES, V61, P4837; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Haenssen KK, 2010, J CELL SCI, V123, P1373, DOI 10.1242/jcs.050906; Haigis KM, 2011, NAT GENET, V43, P177, DOI 10.1038/ng0311-177; Handeli S, 2008, MOL CANCER THER, V7, P521, DOI 10.1158/1535-7163.MCT-07-2063; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hsu DK, 1996, AM J PATHOL, V148, P1661; Jacks T, 2002, CELL, V111, P923, DOI 10.1016/S0092-8674(02)01229-1; Jamora C, 2003, NATURE, V422, P317, DOI 10.1038/nature01458; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Jiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Jobin C, 1998, J IMMUNOL, V160, P410; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Kaltschmidt B, 2006, MOL CELL BIOL, V26, P2936, DOI 10.1128/MCB.26.8.2936-2946.2006; KEMPER O, 1993, GENE, V134, P209, DOI 10.1016/0378-1119(93)90095-K; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kim HJ, 2006, CELL DEATH DIFFER, V13, P738, DOI 10.1038/sj.cdd.4401877; Kim HRC, 1999, CANCER RES, V59, P4148; Kitamura T, 2005, AM J PHYSIOL-CELL PH, V289, pC82, DOI 10.1152/ajpcell.00486.2004; Kohler EM, 2009, HUM MOL GENET, V18, P213, DOI 10.1093/hmg/ddn338; Kontermann RE, 2008, J IMMUNOTHER, V31, P225, DOI 10.1097/CJI.0b013e31816a88f9; Kumler I, 2014, CANCER TREAT REV, V40, P259, DOI 10.1016/j.ctrv.2013.09.002; Lei QB, 2006, DEV CELL, V11, P325, DOI 10.1016/j.devcel.2006.06.013; Li HB, 2009, J BIOL CHEM, V284, P2012, DOI 10.1074/jbc.M805612200; Lim KH, 2005, CANCER CELL, V7, P533, DOI 10.1016/j.ccr.2005.04.030; Liu YC, 1996, EXP CELL RES, V228, P206, DOI 10.1006/excr.1996.0318; Liu Z, 2006, ONCOGENE, V25, P7680, DOI 10.1038/sj.onc.1209753; Liu ZP, 2005, J BIOL CHEM, V280, P37383, DOI 10.1074/jbc.M503724200; LJUBIMOV AV, 1992, INT J CANCER, V50, P562, DOI 10.1002/ijc.2910500412; Lobito AA, 2006, BLOOD, V108, P1320, DOI 10.1182/blood-2005-11-006783; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Mahon PC, 2007, CANCER RES, V67, P6786, DOI 10.1158/0008-5472.CAN-07-0440; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587; Ratti M, 2014, ANTI-CANCER DRUG, V25, P127, DOI 10.1097/CAD.0000000000000035; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Rosen K, 2002, J BIOL CHEM, V277, P46123, DOI 10.1074/jbc.M207883200; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Scotlandi K, 2002, CANCER GENE THER, V9, P296, DOI 10.1038/sj.cgt.7700442; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Sharma SV, 2006, CANCER CELL, V10, P425, DOI 10.1016/j.ccr.2006.09.014; Shin HM, 2004, FEBS LETT, V571, P50, DOI 10.1016/j.febslet.2004.06.056; Stein U, 2006, GASTROENTEROLOGY, V131, P1486, DOI 10.1053/j.gastro.2006.08.041; Tulchinsky E, 1997, J BIOL CHEM, V272, P4828, DOI 10.1074/jbc.272.8.4828; Van Herreweghe F, 2010, CELL MOL LIFE SCI, V67, P1567, DOI 10.1007/s00018-010-0283-0; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Yan SR, 2005, ONCOGENE, V24, P6482, DOI 10.1038/sj.onc.1208810; Yoo BH, 2012, INT J CANCER, V131, P357, DOI 10.1002/ijc.26368; Yoshimura H, 2003, ANTICANCER RES, V23, P85; Yun K, 2009, J IMMUNOL, V183, P5129, DOI 10.4049/jimmunol.0802744	77	5	5	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2015	34	38					4939	4951		10.1038/onc.2014.415	http://dx.doi.org/10.1038/onc.2014.415			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9QZ	25531320				2022-12-17	WOS:000361693000004
J	Castillo-Lluva, S; Hontecillas-Prieto, L; Blanco-Gomez, A; Saez-Freire, MD; Garcia-Cenador, B; Garcia-Criado, J; Perez-Andres, M; Orfao, A; Canamero, M; Mao, JH; Gridley, T; Castellanos-Martin, A; Perez-Losada, J				Castillo-Lluva, S.; Hontecillas-Prieto, L.; Blanco-Gomez, A.; del Mar Saez-Freire, M.; Garcia-Cenador, B.; Garcia-Criado, J.; Perez-Andres, M.; Orfao, A.; Canamero, M.; Mao, J. H.; Gridley, T.; Castellanos-Martin, A.; Perez-Losada, J.			A new role of SNAI2 in postlactational involution of the mammary gland links it to luminal breast cancer development (vol 34, pg 4777, 2015)	ONCOGENE			English	Correction													Pérez-Losada, Jesús/A-5883-2019; /AAI-3238-2021; CASTILLO-LLUVA, SONIA/AAA-1776-2020; Blanco-Gomez, Adrian/GPK-8337-2022; Perez-Andres, Martin/B-3692-2019; Castellanos, Andres/F-3302-2016	Pérez-Losada, Jesús/0000-0003-2400-624X; Perez-Andres, Martin/0000-0003-4599-0776; Castellanos, Andres/0000-0003-2864-7271; Blanco Gomez, Adrian/0000-0002-1956-088X				Castillo-Lluva S, 2015, ONCOGENE, V34, P4777, DOI 10.1038/onc.2015.224	1	5	5	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2015	34	36					4797	4798		10.1038/onc.2015.322	http://dx.doi.org/10.1038/onc.2015.322			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CQ9JU	26333823	Bronze			2022-12-17	WOS:000360931500013
J	Fuchs, D; Metzig, M; Bickeboller, M; Brandel, C; Roth, W				Fuchs, D.; Metzig, M.; Bickeboeller, M.; Brandel, C.; Roth, W.			The G beta 5 protein regulates sensitivity to TRAIL-induced cell death in colon carcinoma	ONCOGENE			English	Article							NF-KAPPA-B; X-LINKED INHIBITOR; SMALL-MOLECULE DISRUPTION; GROWTH-FACTOR RECEPTOR; BETA-GAMMA SUBUNITS; NUCLEAR-LOCALIZATION; APOPTOSIS PROTEIN; CANCER-CELLS; COUPLED RECEPTORS; ADENYLYL-CYCLASE	Aberrant signaling via G protein-coupled receptors (GPCRs) is implicated in numerous diseases including colon cancer. The heterotrimeric G proteins transduce signals from GPCRs to various effectors. So far, the G protein subunit G beta 5 has not been studied in the context of cancer. Here we demonstrate that G beta 5 protects colon carcinoma cells from apoptosis induced by the death ligand TRAIL via different routes. The G beta 5 protein (i) causes a decrease in the cell surface expression of the TRAIL-R2 death receptor, (ii) induces the expression of the anti-apoptotic protein XIAP and (iii) activates the NF-kappa B signaling pathway. The intrinsic resistance to TRAIL-triggered apoptosis of colon cancer cells is overcome by antagonization of G beta 5. Based on these results, targeting of G proteins emerges as a novel therapeutic approach in the experimental treatment of colon cancer.	[Fuchs, D.; Metzig, M.; Bickeboeller, M.; Brandel, C.; Roth, W.] German Canc Res Ctr, Mol Tumor Pathol, D-69120 Heidelberg, Germany; [Metzig, M.; Roth, W.] Heidelberg Univ, Inst Pathol, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Roth, W (corresponding author), German Canc Res Ctr, Mol Tumor Pathol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	W.Roth@dkfz.de			Else Kroner-Fresenius Foundation [2012_A20]	Else Kroner-Fresenius Foundation	We thank William F Simonds (National Institute of Diabetes and Digestive and Kidney Diseases, USA) for providing pcDNA3-G beta 5-HA and Muxiang Zhou (Emory University School of Medicine, USA) for providing pc-cmv-I kappa B-am. This study was supported by a grant from the Else Kroner-Fresenius Foundation (2012_A20).	Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Baselga J, 2005, J CLIN ONCOL, V23, P2445, DOI 10.1200/JCO.2005.11.890; Bayewitch ML, 1998, FASEB J, V12, P1019, DOI 10.1096/fasebj.12.11.1019; Bayewitch ML, 1998, J BIOL CHEM, V273, P2273, DOI 10.1074/jbc.273.4.2273; Behrens J, 2004, INT J DEV BIOL, V48, P477, DOI 10.1387/ijdb.041815jb; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Bernard D, 2001, J BIOL CHEM, V276, P27322, DOI 10.1074/jbc.M011183200; Bhola NE, 2008, FRONT BIOSCI-LANDMRK, V13, P1857, DOI 10.2741/2805; Bonacci TM, 2006, SCIENCE, V312, P443, DOI 10.1126/science.1120378; Bookout AL, 2003, J BIOL CHEM, V278, P37569, DOI 10.1074/jbc.M306276200; Braeuer SJ, 2006, MOL CANCER RES, V4, P715, DOI 10.1158/1541-7786.MCR-05-0231; Burstein E, 2004, EMBO J, V23, P244, DOI 10.1038/sj.emboj.7600031; Cabrera-Vera TM, 2003, ENDOCR REV, V24, P765, DOI 10.1210/er.2000-0026; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; Casey LM, 2010, CIRC RES, V107, P532, DOI 10.1161/CIRCRESAHA.110.217075; Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Drenan RM, 2005, J CELL BIOL, V169, P623, DOI 10.1083/jcb.200502007; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Fassl A, 2012, ONCOGENE, V31, P4698, DOI 10.1038/onc.2011.615; Frieze DA, 2006, ANN PHARMACOTHER, V40, P241, DOI 10.1345/aph.1G191; Galban S, 2010, CELL DEATH DIFFER, V17, P54, DOI 10.1038/cdd.2009.81; Gutkind J S, 2000, Sci STKE, V2000, pre1, DOI 10.1126/stke.2000.40.re1; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Hepler John R, 2005, Sci STKE, V2005, ppe38, DOI 10.1126/stke.2942005pe38; Hintersteiner M, 2010, ACS CHEM BIOL, V5, P967, DOI 10.1021/cb100094k; Hofer-Warbinek R, 2000, J BIOL CHEM, V275, P22064, DOI 10.1074/jbc.M910346199; Holubec L, 2012, ANTICANCER RES, V32, P4007; Hull MA, 2004, MOL CANCER THER, V3, P1031; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; Karashima T, 2003, CLIN CANCER RES, V9, P2786; Kau TR, 2004, NAT REV CANCER, V4, P106, DOI 10.1038/nrc1274; Khan SM, 2013, PHARMACOL REV, V65, P545, DOI 10.1124/pr.111.005603; Kim EH, 2005, ONCOGENE, V24, P838, DOI 10.1038/sj.onc.1208241; Kim TH, 2005, ONCOGENE, V24, P597, DOI 10.1038/sj.onc.1208237; Kojima Y, 2011, J BIOL CHEM, V286, P43383, DOI 10.1074/jbc.M111.309377; Krispel CM, 2003, J NEUROSCI, V23, P6965, DOI 10.1523/JNEUROSCI.23-18-06965.2003; Lehmann DM, 2008, MOL PHARMACOL, V73, P410, DOI 10.1124/mol.107.041780; Leithner K, 2009, LUNG CANCER, V65, P98, DOI 10.1016/j.lungcan.2008.10.015; Liang JJ, 1998, J NEUROCHEM, V71, P345; Lin-Lee YC, 2006, J BIOL CHEM, V281, P18878, DOI 10.1074/jbc.M513315200; Lu M, 2007, MOL CELL, V26, P689, DOI 10.1016/j.molcel.2007.05.006; McClanahan T, 2006, CANCER BIOL THER, V5, P419, DOI 10.4161/cbt.5.4.2521; McManus DC, 2004, ONCOGENE, V23, P8105, DOI 10.1038/sj.onc.1207967; Rojkova AM, 2003, J BIOL CHEM, V278, P12507, DOI 10.1074/jbc.M207302200; Roman DL, 2011, J MED CHEM, V54, P7433, DOI 10.1021/jm101572n; Rosato R, 2004, LEUKEMIA, V18, P1780, DOI 10.1038/sj.leu.2403491; Saif MW, 2010, EXPERT OPIN INV DRUG, V19, P357, DOI 10.1517/13543781003593962; Sakamoto K, 2010, EXPERT OPIN THER TAR, V14, P593, DOI 10.1517/14728221003769903; Schimmer AD, 2009, J CLIN ONCOL, V27, P4741, DOI 10.1200/JCO.2009.21.8172; Shirley S, 2011, RECENT PAT ANTI-CANC, V6, P311, DOI 10.2174/157489211796957757; Slepak VZ, 2009, PROG MOL BIOL TRANSL, V86, P157, DOI 10.1016/S1877-1173(09)86006-7; Smirnov AS, 2001, CELL DEATH DIFFER, V8, P621, DOI 10.1038/sj.cdd.4400853; Smrcka AV, 2013, TRENDS PHARMACOL SCI, V34, P290, DOI 10.1016/j.tips.2013.02.006; Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661; Sorokin AV, 2007, BIOCHEMISTRY-MOSCOW+, V72, P1439, DOI 10.1134/S0006297907130032; Straszewski-Chavez SL, 2010, BIOL REPROD, V82, P146, DOI 10.1095/biolreprod.109.078972; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; Vogelzang NJ, 2004, CANCER, V100, P65, DOI 10.1002/cncr.11867; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zhang JH, 2001, J BIOL CHEM, V276, P10284, DOI 10.1074/jbc.M009247200; Zhang JH, 2011, J NEUROCHEM, V119, P544, DOI 10.1111/j.1471-4159.2011.07457.x; Zhang YQ, 2008, MOL CANCER RES, V6, P1861, DOI 10.1158/1541-7786.MCR-08-0313	68	5	5	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2015	34	21					2753	2763		10.1038/onc.2014.213	http://dx.doi.org/10.1038/onc.2014.213			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI7XN	25043307				2022-12-17	WOS:000354979500008
J	Fan, D; Zhou, X; Li, Z; Li, ZQ; Duan, C; Liu, T; Zhang, F; Huang, Y; Zhang, Y; Gao, F; Guo, Y; Gupta, R; Chen, G; Enver, T; Tang, J; Hong, D				Fan, D.; Zhou, X.; Li, Z.; Li, Z-Q; Duan, C.; Liu, T.; Zhang, F.; Huang, Y.; Zhang, Y.; Gao, F.; Guo, Y.; Gupta, R.; Chen, G.; Enver, T.; Tang, J.; Hong, D.			Stem cell programs are retained in human leukemic lymphoblasts	ONCOGENE			English	Article							HUMAN HEMATOPOIETIC STEM; ACUTE MYELOID-LEUKEMIA; SELF-RENEWAL; BONE-MARROW; GENE; TRANSPLANTATION; EXPANSION; CAPACITY; LINEAGE; BMI-1	Leukemic lymphoblasts within different immunophenotypic populations possess stem cell properties. However, whether or not the self-renewal program is retained from stem cells or conferred on progenitors by leukemogenic molecules remains unknown. We have addressed the issue in the context of TEL-AML1-associated acute lymphoblastic leukemia (ALL) by profiling a refined program edited from genes essential for self-renewal of hematopoietic stem cells and B-cell development. Bioinformatic analysis shows that ALL populations are loosely clustered and close to the normal population that contains stem and primitive progenitor cells. This finding indicates that immunophenotypes do not reflect maturation stages in ALL and that the self-renewal program may be retained from stem cells. Results of assessing 'first hit' function of TEL-AML1 in different populations of normal cells demonstrate the molecular model. Therefore, the current study shows a leukemogenic scenario of human ALL in which programs of stem cells are sustained in distinct fractions by leukemogenic mutations.	[Fan, D.; Zhang, F.; Tang, J.; Hong, D.] Shanghai Jiao Tong Univ, Dept Pediat Hematol & Oncol, Shanghai Childrens Med Ctr, Key Lab Pediat Hematol & Oncol,Minist Hlth,Sch Me, Shanghai 200030, Peoples R China; [Zhou, X.; Li, Z-Q; Huang, Y.; Chen, G.; Hong, D.] SJTU SM, Dept Pathophysiol, Minist Educ, Key Lab Cell Differentiat & Apoptosis Natl, Shanghai, Peoples R China; [Li, Z.; Duan, C.; Liu, T.] SJTU SM, Ruijin Hosp, Shanghai, Peoples R China; [Zhang, Y.; Gao, F.] Shanghai Cord Blood Bank, Shanghai, Peoples R China; [Guo, Y.; Gupta, R.; Enver, T.] UCL, UCL Canc Inst, Stem Cell Lab, London, England	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; University of London; University College London	Tang, J (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Childrens Med Ctr, Dept Pediat Hematol & Oncol, Shanghai 200030, Peoples R China.	yantfk@gmail.com; dlhong@sjtu.edu.cn	Zhang, Fang/HHN-2153-2022	Gupta, Rajeev/0000-0001-9573-0505; chen, guo qiang/0000-0003-4936-2363; Hong, Dengli/0000-0001-5251-0297; Liu, Tianhui/0000-0002-9301-641X; Guo, Yanping/0000-0001-6217-7133	National Natural Science Foundation of China (NSFC) [90919055, 81120108006]; National Basic Research Program of China [2012CB967000]; Shanghai Pujiang Program [10PJ1406500]; Cancer Research UK [12796] Funding Source: researchfish; Medical Research Council [G1000801g, MC_U137973817, MC_qA137913] Funding Source: researchfish; Great Ormond Street Hospital Childrens Charity [W1062] Funding Source: researchfish; MRC [MC_qA137913, MC_U137973817] Funding Source: UKRI	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China(National Basic Research Program of China); Shanghai Pujiang Program(Shanghai Pujiang Program); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Great Ormond Street Hospital Childrens Charity; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank T Tanaka for providing hybridoma TM-beta 1; and Chenzhi Guo for technical help in flow sorting. This work was supported by grants from the National Natural Science Foundation of China (NSFC, 90919055 and 81120108006), the National Basic Research Program of China (2012CB967000) and the Shanghai Pujiang Program (10PJ1406500).	Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Castor A, 2005, NAT MED, V11, P630, DOI 10.1038/nm1253; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Ding L, 2013, NATURE, V495, P231, DOI 10.1038/nature11885; Dorrell C, 2000, BLOOD, V95, P102; Enver T, 1998, CELL, V94, P9, DOI 10.1016/S0092-8674(00)81215-5; Eppert K, 2011, NAT MED, V17, P1086, DOI 10.1038/nm.2415; Ford AM, 2009, J CLIN INVEST, V119, P826, DOI 10.1172/JCI36428; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Ghia P, 1998, IMMUNOL TODAY, V19, P480, DOI 10.1016/S0167-5699(98)01330-9; Goardon N, 2011, CANCER CELL, V19, P138, DOI 10.1016/j.ccr.2010.12.012; GREAVES MF, 1993, BRIT J CANCER, V67, P413, DOI 10.1038/bjc.1993.81; Greenbaum A, 2013, NATURE, V495, P227, DOI 10.1038/nature11926; Gupta R, 2007, SCIENCE, V316, P590, DOI 10.1126/science.1136031; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hong DL, 2008, SCIENCE, V319, P336, DOI 10.1126/science.1150648; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; Hystad ME, 2007, J IMMUNOL, V179, P3662, DOI 10.4049/jimmunol.179.6.3662; Kong Y, 2008, LEUKEMIA, V22, P1207, DOI 10.1038/leu.2008.83; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; le Viseur C, 2008, CANCER CELL, V14, P47, DOI 10.1016/j.ccr.2008.05.015; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Lin YC, 2010, NAT IMMUNOL, V11, P635, DOI 10.1038/ni.1891; McKenzie JL, 2005, BLOOD, V106, P1259, DOI 10.1182/blood-2005-03-1081; Notta F, 2011, SCIENCE, V333, P218, DOI 10.1126/science.1201219; Orkin SH, 2008, CELL, V132, P631, DOI 10.1016/j.cell.2008.01.025; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Piacibello W, 1999, BLOOD, V93, P3736, DOI 10.1182/blood.V93.11.3736.411k01_3736_3749; Pina C, 2007, ONCOGENE, V26, P6750, DOI 10.1038/sj.onc.1210759; Schindler JW, 2009, CELL STEM CELL, V5, P43, DOI 10.1016/j.stem.2009.04.019; Tsuzuki S, 2013, STEM CELLS, V31, P236, DOI 10.1002/stem.1277; Zelent A, 2004, ONCOGENE, V23, P4275, DOI 10.1038/sj.onc.1207672; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747	34	5	7	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2015	34	16					2083	2093		10.1038/onc.2014.148	http://dx.doi.org/10.1038/onc.2014.148			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG3IL	24909160				2022-12-17	WOS:000353173400008
J	Sanchez-Perez, T; Medema, RH; Lopez-Rivas, A				Sanchez-Perez, T.; Medema, R. H.; Lopez-Rivas, A.			Delaying mitotic exit downregulates FLIP expression and strongly sensitizes tumor cells to TRAIL	ONCOGENE			English	Article						mitotic exit; TRAIL; FLIP; apoptosis; tumor cells	SPINDLE CHECKPOINT; INDUCED APOPTOSIS; CANCER-CELLS; CYCLIN-B; ANAPHASE; RECEPTOR; PHOSPHORYLATION; DEGRADATION; MITOSIS; ARREST	Many of the current antitumor therapeutic strategies are based on the perturbation of the cell cycle, especially during mitosis. Antimitotic drugs trigger mitotic checkpoint activation, mitotic arrest and eventually cell death. However, mitotic slippage represents a major mechanism of resistance to these treatments. In an attempt to circumvent the process of slippage, targeting mitotic exit has been proposed as a better strategy to kill tumor cells. In this study, we show that treatments that induce mitotic checkpoint activation and mitotic arrest downregulate FLICE-like inhibitory protein (FLIP) levels and sensitize several tumor cell lines to TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis. Interestingly, we also demonstrate that in absence of mitotic checkpoint activation, mitotic arrest induced either by Cdc20 knockdown or overexpression of nondegradable cyclin B is sufficient to induce both FLIP downregulation and sensitivity to TRAIL. In summary, our data suggest that a combination of antimitotic drugs targeting cyclin B degradation and TRAIL might prevent mitotic slippage and allow tumor cells to reach the threshold for apoptosis induction, thereby facilitating tumor suppression.	[Sanchez-Perez, T.; Lopez-Rivas, A.] CSIC, Ctr Andaluz Biol Mol & Med Regenerat CABIMER, Seville 41092, Spain; [Sanchez-Perez, T.; Medema, R. H.] Netherlands Canc Inst, Div Cell Biol, Amsterdam, Netherlands	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; University of Sevilla; CSIC - Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER); Netherlands Cancer Institute	Lopez-Rivas, A (corresponding author), CSIC, Ctr Andaluz Biol Mol & Med Regenerat CABIMER, Aven Amer Vespucio S-N, Seville 41092, Spain.	abelardo.lopez@cabimer.es	Lopez-Rivas, Abelardo/E-5115-2015	Lopez-Rivas, Abelardo/0000-0002-9351-9690; Medema, Rene/0000-0002-6754-0381	Ministerio de Ciencia e Innovacion [SAF2009-07163, SAF2012-32824]; Red Tematica de Investigacion Cooperativa en Cancer (RTICC) [RD06/0020/0068, RD12/0036/0026]; European Community through the regional development funding program (FEDER); Junta de Andalucia [P09-CVI-4497]; Ministerio de Economia y Competitividad (MINECO)	Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Red Tematica de Investigacion Cooperativa en Cancer (RTICC)(European Commission); European Community through the regional development funding program (FEDER); Junta de Andalucia(Junta de Andalucia); Ministerio de Economia y Competitividad (MINECO)(Spanish Government)	This work was supported by grants SAF2009-07163 and SAF2012-32824 from Ministerio de Ciencia e Innovacion, Red Tematica de Investigacion Cooperativa en Cancer (RTICC: RD06/0020/0068 and RD12/0036/0026), the European Community through the regional development funding program (FEDER) and Junta de Andalucia (P09-CVI-4497) to AL-R. TS-P was supported by contracts from Ministerio de Economia y Competitividad (MINECO). We are grateful to Aniek Janssen, Monica Alvarez and Martin Vromans for providing helpful advice and discussions. We also thank FJ Fernandez-Farran for excellent technical assistance.	Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Allan LA, 2007, MOL CELL, V26, P301, DOI 10.1016/j.molcel.2007.03.019; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 2008, NAT REV DRUG DISCOV, V7, P1001, DOI 10.1038/nrd2637; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Chang DC, 2003, J BIOL CHEM, V278, P37865, DOI 10.1074/jbc.M306376200; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; Griffith TS, 1998, J IMMUNOL, V161, P2833; Grosse-Wilde A, 2008, J CLIN INVEST, V118, P100, DOI 10.1172/JCI33061; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harley ME, 2010, EMBO J, V29, P2407, DOI 10.1038/emboj.2010.112; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; Huang HC, 2009, CANCER CELL, V16, P347, DOI 10.1016/j.ccr.2009.08.020; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Janssen A, 2011, ONCOGENE, V30, P2799, DOI 10.1038/onc.2011.30; Jordan MA, 1996, CANCER RES, V56, P816; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Manchado E, 2010, CANCER CELL, V18, P641, DOI 10.1016/j.ccr.2010.10.028; Matthess Y, 2010, MOL CELL BIOL, V30, P5726, DOI 10.1128/MCB.00731-10; Palacios C, 2006, CANCER RES, V66, P8858, DOI 10.1158/0008-5472.CAN-06-0808; Piao XH, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003558; Pyronnet S, 2001, GENE DEV, V15, P2083, DOI 10.1101/gad.889201; Rath O, 2012, NAT REV CANCER, V12, P527, DOI 10.1038/nrc3310; Ruiz-Ruiz C, 2002, BIOCHEM J, V365, P825, DOI 10.1042/BJ20020184; Sanchez-Perez T, 2010, CELL DEATH DIFFER, V17, P883, DOI 10.1038/cdd.2009.176; Santaguida S, 2010, J CELL BIOL, V190, P73, DOI 10.1083/jcb.201001036; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Terrano DT, 2010, MOL CELL BIOL, V30, P640, DOI 10.1128/MCB.00882-09; Tighe A, 2008, J CELL BIOL, V181, P893, DOI 10.1083/jcb.200712028; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wasch R, 2002, NATURE, V418, P556, DOI 10.1038/nature00856; Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011; Wertz IE, 2011, NATURE, V471, P110, DOI 10.1038/nature09779; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zeng X, 2010, CANCER CELL, V18, P382, DOI 10.1016/j.ccr.2010.08.010; Zhang XD, 1999, CANCER RES, V59, P2747	40	5	5	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2015	34	5					661	669		10.1038/onc.2013.601	http://dx.doi.org/10.1038/onc.2013.601			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DD	24488010				2022-12-17	WOS:000348853500013
J	Kalakonda, S; Nallar, SC; Lindner, DJ; Sun, P; Lorenz, RR; Lamarre, E; Reddy, SP; Kalvakolanu, DV				Kalakonda, S.; Nallar, S. C.; Lindner, D. J.; Sun, P.; Lorenz, R. R.; Lamarre, E.; Reddy, S. P.; Kalvakolanu, D. V.			GRIM-19 mutations fail to inhibit v-Src-induced oncogenesis	ONCOGENE			English	Article						tyrosine kinases; tumor suppression; cytoskeleton; metastasis; cytokines	SQUAMOUS-CELL CARCINOMA; REGULATORY GENE-PRODUCT; C-SRC; RETINOIC ACID; BONE METASTASIS; FAMILY KINASES; TUMOR-CELLS; COMPLEX-I; CANCER; CORTACTIN	The non-receptor tyrosine kinase Src is a major player in multiple physiological responses including growth, survival and differentiation. Overexpression and/or oncogenic mutation in the Src gene have been documented in human tumors. The v-Src protein is an oncogenic mutant of Src, which promotes cell survival, migration, invasion and division. GRIM-19 is an antioncogene isolated using a genome-wide knockdown screen. Genes associated with Retinoid-IFN-induced Mortality (GRIM)-19 binds to transcription factor STAT3 and ablates its pro-oncogenic effects while v-Src activates STAT3 to promote its oncogenic effects. However, we found that GRIM-19 inhibits the pro-oncogenic effects of v-Src independently of STAT3. Here, we report the identification of functionally inactivating GRIM-19 mutations in a set of head and neck cancer patients. While wild-type GRIM-19 strongly ablated v-Src-induced cell migration, cytoskeletal remodeling and tumor metastasis, the tumor-derived mutants ((LP)-P-71, (LP)-P-91 and A(95)T) did not. These mutants were also incapable of inhibiting the drug resistance of v-Src-transformed cells. v-Src downregulated the expression of Pag1, a lipid raft-associated inhibitor of Src, which was restored by wild-type GRIM-19. The tumor-derived mutant GRIM-19 proteins failed to upregulate Pag1. These studies show a novel mechanism that deregulates Src activity in cancer cells.	[Kalakonda, S.; Nallar, S. C.; Sun, P.; Kalvakolanu, D. V.] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Program Oncol,Greenebaum Canc Ctr, Baltimore, MD 21201 USA; [Lindner, D. J.] Taussig Canc Ctr, Cleveland, OH USA; [Lorenz, R. R.; Lamarre, E.] Cleveland Clin Fdn, Head & Neck Inst, Cleveland, OH 44195 USA; [Reddy, S. P.] Univ Illinois, Coll Med, Dept Pediat, Chicago, IL USA	University System of Maryland; University of Maryland Baltimore; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kalvakolanu, DV (corresponding author), Univ Maryland, Sch Med, Dept Microbiol & Immunol, Program Oncol,Greenebaum Canc Ctr, 660 West Redwood St,Howard Hall Room 324, Baltimore, MD 21201 USA.	dkalvako@umaryland.edu	Lindner, Daniel/ABB-5440-2020		National Institutes of Health [CA105005]; University of Maryland Greenebaum Cancer Center; NATIONAL CANCER INSTITUTE [R01CA105005] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Maryland Greenebaum Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Michael Kahn (University of California at Los Angeles, CA) for lentiviral luciferase (pCCL-c-MNDU3c-Luc) vector. This study is supported by the National Institutes of Health grant CA105005 and an intramural award from the Cigarette restitution funds of the University of Maryland Greenebaum Cancer Center to DVK.	Alchanati I, 2006, ONCOGENE, V25, P7138, DOI 10.1038/sj.onc.1209708; Angell JE, 2000, J BIOL CHEM, V275, P33416, DOI 10.1074/jbc.M003929200; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Buday L, 2007, BBA-REV CANCER, V1775, P263, DOI 10.1016/j.bbcan.2006.12.002; Byers LA, 2009, CLIN CANCER RES, V15, P6852, DOI 10.1158/1078-0432.CCR-09-0767; Chen JYF, 2008, NEOPLASIA, V10, P1393, DOI 10.1593/neo.08854; Fearnley IM, 2001, J BIOL CHEM, V276, P38345, DOI 10.1074/jbc.C100444200; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Giannoni E, 2010, FREE RADICAL BIO MED, V49, P516, DOI 10.1016/j.freeradbiomed.2010.04.025; Gong Long-Bo, 2007, Ai Zheng, V26, P683; Hofman ER, 1998, MOL CELL BIOL, V18, P6493, DOI 10.1128/MCB.18.11.6493; Huang GC, 2004, MOL CELL BIOL, V24, P8447, DOI 10.1128/MCB.24.19.8447-8456.2004; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jiang LQ, 2006, ONCOGENE, V25, P5495, DOI 10.1038/sj.onc.1209554; Kalakonda S, 2007, AM J PATHOL, V171, P1352, DOI 10.2353/ajpath.2007.070241; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Koppikar P, 2008, CLIN CANCER RES, V14, P4284, DOI 10.1158/1078-0432.CCR-07-5226; Li XH, 2008, INT J ONCOL, V33, P69; Li YS, 2001, CANCER RES, V61, P6906; Lindner DJ, 1997, CLIN CANCER RES, V3, P931; Liu Yan-bo, 2011, Zhonghua Nan Ke Xue, V17, P21; Lufei CC, 2003, EMBO J, V22, P1325, DOI 10.1093/emboj/cdg135; MATSOUKA PT, 1989, MOL ENDOCRINOL, V3, P1845, DOI 10.1210/mend-3-11-1845; Mazurek S, 2011, INT J BIOCHEM CELL B, V43, P969, DOI 10.1016/j.biocel.2010.02.005; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; Oneyama C, 2008, MOL CELL, V30, P426, DOI 10.1016/j.molcel.2008.03.026; Patel AS, 1998, ONCOGENE, V16, P3227, DOI 10.1038/sj.onc.1201850; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025; Stark GR, 2012, IMMUNITY, V36, P503, DOI 10.1016/j.immuni.2012.03.013; Sun P, 2009, ONCOGENE, V28, P1339, DOI 10.1038/onc.2008.480; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; Suzuki K, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.195362; Theocharis S, 2012, J CANCER RES CLIN, V138, P1369, DOI 10.1007/s00432-012-1215-1; Valle Casuso JC, 2012, PLOS ONE, V7; van Oijen MGCT, 1998, J ORAL PATHOL MED, V27, P147; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; WHITE MK, 1991, MOL CELL BIOL, V11, P4448, DOI 10.1128/MCB.11.9.4448; Yamada S, 2010, PATHOL ONCOL RES, V16, P523, DOI 10.1007/s12253-009-9245-y; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang J, 2003, P NATL ACAD SCI USA, V100, P9342, DOI 10.1073/pnas.1633516100; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017; Zhang YM, 2011, CANCER SCI, V102, P1991, DOI 10.1111/j.1349-7006.2011.02059.x; Zhou Ai-Min, 2009, Ai Zheng, V28, P431; Zhou Y, 2009, J INTERF CYTOK RES, V29, P695, DOI 10.1089/jir.2009.0003	47	5	5	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2014	33	24					3195	3204		10.1038/onc.2013.271	http://dx.doi.org/10.1038/onc.2013.271			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK4QU	23851499	Green Accepted			2022-12-17	WOS:000338410000012
J	Alfonso-Perez, T; Dominguez-Sanchez, MS; Garcia-Dominguez, M; Reyes, JC				Alfonso-Perez, T.; Dominguez-Sanchez, M. S.; Garcia-Dominguez, M.; Reyes, J. C.			Cytoplasmic interaction of the tumour suppressor protein hSNF5 with dynamin-2 controls endocytosis	ONCOGENE			English	Article						rhabdoid tumours; nucleocytoplasmic shuttling; chromatin remodelling; endocytosis	CLATHRIN-MEDIATED ENDOCYTOSIS; CRYSTAL-STRUCTURE; TRANSCRIPTION FACTOR; SH3 DOMAIN; CELLS; CANCER; GTPASE; INI1/HSNF5; COMPLEX; TUMORIGENESIS	Human SNF5 (hSNF5; INI1, SMARCB1 or BAF47) is a component of the human SWI/SNF chromatin remodelling complex and a tumour suppressor mutated in rhabdoid tumours. It also associates with the integrase of the human immunodeficiency virus (HIV)-1. We show by fluorescence loss in photobleaching that hSNF5 is constantly shuttling between the nucleus and the cytoplasm, raising the question of what the role of hSNF5 is in the cytoplasm. Here, we demonstrate that hSNF5 directly interacts with the GTPase dynamin-2 (DNM2) in the cytoplasm. DNM2 is a large GTPase involved in endocytosis and vesicle dynamics, which has been related to HIV-1 internalization. We show that hSNF5 colocalizes with DNM2 in endocytic vesicles. Depletion of hSNF5, but not of other components of the SWI/SNF complex, destabilizes DNM2 and impairs DNM2-dependent endocytosis. Furthermore, we show that hSNF5 inhibits assembly-stimulated DNM2 GTPase activity but not basal GTPase activity in vitro. Altogether, these results indicate that hSNF5 affects both the stability and the activity of DNM2, uncovering an unexpected role of hSNF5 in modulating endocytosis, and open new perspectives in understanding the role of hSNF5 in tumour genesis.	[Alfonso-Perez, T.; Dominguez-Sanchez, M. S.; Reyes, J. C.] CSIC, Ctr Andaluz Biol Mol & Med Regenerat CABIMER, Dept Mol Biol, Seville 41092, Spain; [Garcia-Dominguez, M.] CSIC, Ctr Andaluz Biol Mol & Med Regenerat CABIMER, Stem Cells Dept, Seville 41092, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; University of Sevilla; CSIC - Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER); Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; University of Sevilla; CSIC - Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER)	Reyes, JC (corresponding author), CSIC, Ctr Andaluz Biol Mol & Med Regenerat CABIMER, Dept Mol Biol, Av Amer Vespucio, Seville 41092, Spain.	mario.garcia@cabimer.es; jose.reyes@cabimer.es	Reyes, Jose C/K-3699-2014; Alfonso-Perez, Tatiana/Q-9269-2016; Garcia-Dominguez, Mario/K-3674-2014	Reyes, Jose C/0000-0002-8042-5142; Garcia-Dominguez, Mario/0000-0003-2211-8731	Spanish Ministerio de Economia y Competitividad [BFU2011-23442, CSD2006-00049]; Junta de Andalucia and Fundacion Ramon Areces [P06-CVI-4844]	Spanish Ministerio de Economia y Competitividad(Spanish Government); Junta de Andalucia and Fundacion Ramon Areces(Junta de Andalucia)	We thank C Muchardt, M Yaniv, SL Schmid and MA McNiven for providing plasmids, and P Dominguez for microscopy technical support. This work was supported by Grants BFU2011-23442 and CSD2006-00049 from the Spanish Ministerio de Economia y Competitividad, P06-CVI-4844 from Junta de Andalucia and Fundacion Ramon Areces.	Bukrinsky M, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-49; Cao H, 2007, J CELL SCI, V120, P4167, DOI 10.1242/jcs.010686; Ceballos-Chavez M, 2012, P NATL ACAD SCI USA, V109, P8085, DOI 10.1073/pnas.1121522109; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; Craig E, 2002, EMBO J, V21, P31, DOI 10.1093/emboj/21.1.31; Das S, 2009, J BIOL CHEM, V284, P19903, DOI 10.1074/jbc.M808141200; Deitcher D, 2001, TRENDS NEUROSCI, V24, P625, DOI 10.1016/S0166-2236(00)01927-5; Dundr M, 2003, CURR PROTOC CELL BIO; Faelber K, 2011, NATURE, V477, P556, DOI 10.1038/nature10369; Ferguson SM, 2012, NAT REV MOL CELL BIO, V13, P75, DOI 10.1038/nrm3266; Ford MGJ, 2011, NATURE, V477, P561, DOI 10.1038/nature10441; Formstecher E, 2005, GENOME RES, V15, P376, DOI 10.1101/gr.2659105; Giebel B, 2006, CURR BIOL, V16, pR91, DOI 10.1016/j.cub.2006.01.022; Giudicelli F, 2003, DEV BIOL, V253, P150, DOI 10.1006/dbio.2002.0864; Goodwin JS, 2005, METHODS, V37, P154, DOI 10.1016/j.ymeth.2005.05.013; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; Hargreaves DC, 2011, CELL RES, V21, P396, DOI 10.1038/cr.2011.32; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Joshi S, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-78; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Koster M, 2005, CURR OPIN BIOTECH, V16, P28, DOI 10.1016/j.copbio.2004.11.002; Lanzetti L, 2008, TRAFFIC, V9, P2011, DOI 10.1111/j.1600-0854.2008.00816.x; Leonard M, 2005, METHOD ENZYMOL, V404, P490, DOI 10.1016/S0076-6879(05)04043-7; Liu YW, 2008, MOL BIOL CELL, V19, P5347, DOI 10.1091/mbc.E08-08-0890; McKenna ES, 2012, CELL CYCLE, V11, P1956, DOI 10.4161/cc.20280; McMahon HT, 2011, NAT REV MOL CELL BIO, V12, P517, DOI 10.1038/nrm3151; Miyauchi K, 2009, CELL, V137, P433, DOI 10.1016/j.cell.2009.02.046; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; Narayanan R, 2005, J CELL BIOL, V169, P117, DOI 10.1083/jcb.200502042; Newmyer SL, 2003, DEV CELL, V4, P929, DOI 10.1016/S1534-5807(03)00157-6; Owen DJ, 1998, EMBO J, V17, P5273, DOI 10.1093/emboj/17.18.5273; Pant S, 2009, NAT CELL BIOL, V11, P1399, DOI 10.1038/ncb1986; PEARSE BMF, 1982, P NATL ACAD SCI-BIOL, V79, P451, DOI 10.1073/pnas.79.2.451; Roberts CWM, 2009, CANCER BIOL THER, V8, P412, DOI 10.4161/cbt.8.5.8019; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Snapp Erik L, 2003, Curr Protoc Cell Biol, VChapter 21, DOI 10.1002/0471143030.cb2101s19; Soulet F, 2005, MOL BIOL CELL, V16, P2058, DOI 10.1091/mbc.E04-11-1016; Stojanova A, 2009, BIOCHEM CELL BIOL, V87, P163, DOI 10.1139/O08-113; Thompson HM, 2002, CURR BIOL, V12, P2111, DOI 10.1016/S0960-9822(02)01390-8; Treich I, 1997, MOL CELL BIOL, V17, P1768, DOI 10.1128/MCB.17.4.1768; TUMA PL, 1995, J BIOL CHEM, V270, P26707, DOI 10.1074/jbc.270.44.26707; Turelli P, 2001, MOL CELL, V7, P1245, DOI 10.1016/S1097-2765(01)00255-6; Vachtenheim J, 2010, BIOCHEM BIOPH RES CO, V392, P454, DOI 10.1016/j.bbrc.2010.01.048; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vries RGJ, 2005, GENE DEV, V19, P665, DOI 10.1101/gad.335805; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068	51	5	5	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2014	33	23					3064	3074		10.1038/onc.2013.276	http://dx.doi.org/10.1038/onc.2013.276			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EL	23851497				2022-12-17	WOS:000337232200013
J	Hemler, ME; Hoff, J; Li, Q; Yang, XH				Hemler, M. E.; Hoff, J.; Li, Q.; Yang, X. H.			Renal disease appears not to affect carcinogenesis in CD151-null mice	ONCOGENE			English	Letter							TETRASPANIN CD151; DELETION		[Hemler, M. E.; Li, Q.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Hoff, J.; Yang, X. H.] Univ Kentucky, Albert B Chandler Med Ctr, Lexington, KY 40536 USA	Harvard University; Dana-Farber Cancer Institute; University of Kentucky	Hemler, ME (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.	Martin_Hemler@dfci.harvard.edu; xiuwei-yang@uky.edu	Li, Qinglin/K-2570-2015	Li, Qinglin/0000-0002-4125-1944				Baleato RM, 2008, AM J PATHOL, V173, P927, DOI 10.2353/ajpath.2008.071149; Deng XY, 2012, NEOPLASIA, V14, P678, DOI 10.1593/neo.12922; HENNINGS H, 1993, CARCINOGENESIS, V14, P2353, DOI 10.1093/carcin/14.11.2353; Li Q, 2013, ONCOGENE, V32, P1772, DOI 10.1038/onc.2012.205; Sachs N, 2006, J CELL BIOL, V175, P33, DOI 10.1083/jcb.200603073; Takeda Y, 2007, BLOOD, V109, P1524, DOI 10.1182/blood-2006-08-041970	6	5	5	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2013	32	37					4458	4458		10.1038/onc.2013.79	http://dx.doi.org/10.1038/onc.2013.79			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23503459				2022-12-17	WOS:000324404200015
J	Shi, Y; Chen, J; Li, Z; Zhang, Z; Yu, H; Sun, K; Wang, X; Song, X; Wang, Y; Zhen, Y; Yang, T; Lou, K; Zhang, Y; Zhang, G; Hu, Y; Ji, J; Hui, R				Shi, Y.; Chen, J.; Li, Z.; Zhang, Z.; Yu, H.; Sun, K.; Wang, X.; Song, X.; Wang, Y.; Zhen, Y.; Yang, T.; Lou, K.; Zhang, Y.; Zhang, G.; Hu, Y.; Ji, J.; Hui, R.			C10ORF97 is a novel tumor-suppressor gene of non-small-cell lung cancer and a functional variant of this gene increases the risk of non-small-cell lung cancer	ONCOGENE			English	Article						C10ORF97; tumor suppressor; non-small-cell lung cancer; genetic variant	DEPENDENT-KINASE INHIBITOR; DOMAIN-BINDING PROTEIN-1; REDUCED EXPRESSION; INVERSE EXPRESSION; COP9 SIGNALOSOME; JAB1 EXPRESSION; POOR-PROGNOSIS; P27(KIP1); P27; DEREGULATION	In an earlier study we showed that C10ORF97 (chromosome-10, open reading frame-97) was expressed in almost all of the tissues and cell lines tested, and that it inhibited the growth of seven tumor cell lines, including two lung carcinoma cell lines (A549 and PG). Here, we show that C10ORF97 is downregulated in non-small-cell lung cancer (NSCLC) tissue compared with normal lung tissue. Overexpression of C10ORF97 significantly suppressed human lung carcinoma A549 cell growth (proliferation and anchorage-independent growth in soft agar) and motility (migration and adhesion). This tumor-suppressive function of C10ORF97 was also verified in vivo. We further found that C10ORF97 caused G(1) arrest of A549 cells and modulated the expression level of several cell-cycle regulators (such as CDK2, cyclin-E and p27). These effects of C10ORF97 were mediated by physical association between C10ORF97 and Jun-activating domain-binding protein-1 (JAB1), and blocking of JAB1-mediated translocation of p27 from the nucleus to the cytoplasm. Together, these results indicated that C10ORF97 functions as a novel tumor suppressor by modulating several key G(1)/S-regulatory proteins by interacting with JAB1. These findings led us to hypothesize that a single-nucleotide polymorphism (SNP) in the C10ORF97 gene that affects its expression might be associated with susceptibility to NSCLC. SNP216 C > T (rs2297882) in the C10ORF97 Kozak sequence was identified, and allele T of SNP216 suppressed C10ORF97 expression in vitro and in vivo. Furthermore, the TT genotype of SNP216 was associated with an increased risk of NSCLC (adjusted odds ratio = 1.73 (95% confidence interval: 1.33-2.25), P = 4.6 x 10(-5)). These data indicated that C10ORF97 is a tumor suppressor of NSCLC progression and C10ORF97-SNP216 may serve as a predictor of NSCLC. Oncogene (2011) 30, 4107-4117; doi:10.1038/onc.2011.116; published online 18 April 2011	[Li, Z.; Zhang, G.; Hu, Y.; Ji, J.] Peking Univ, Canc Hosp & Inst, Minist Educ, Dept Surg,Key Lab Carcinogenesis & Translat Res, Beijing 100042, Peoples R China; [Shi, Y.; Zhang, Z.; Yu, H.; Sun, K.; Wang, X.; Song, X.; Wang, Y.; Zhen, Y.; Yang, T.; Lou, K.; Zhang, Y.; Hui, R.] Chinese Acad Med Sci, Peking Union Med Coll, Key Lab Clin Cardiovasc Genet, Sino German Lab Mol Med,Fuwai Hosp,Minist Educ, Beijing 100037, Peoples R China; [Shi, Y.] Sichuan Acad Med Sci, Sichuan Prov Key Lab Human Dis Gene Study, Chengdu, Peoples R China; [Shi, Y.] Sichuan Prov Peoples Hosp, Chengdu, Peoples R China	Peking University; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Peking Union Medical College; Sichuan Provincial People's Hospital; Sichuan Provincial People's Hospital	Ji, J (corresponding author), Peking Univ, Canc Hosp & Inst, Minist Educ, Dept Surg,Key Lab Carcinogenesis & Translat Res, 52 Fucheng Rd, Beijing 100042, Peoples R China.	jiafuj@hotmail.com; huirutai@sglab.org	Zhang, Zhen/F-8561-2011; Wang, Weili/D-1546-2011; wang, yibo/A-6484-2013	wang, yibo/0000-0001-9984-581X	National High Technology Research and Development Program of China (863 Program) [2006AA02Z477]; National Natural Science Foundation of China [30500199, 30900809]; Foundation of Beijing Municipal Committee of Science and Technology [D0905001040631]	National High Technology Research and Development Program of China (863 Program)(National High Technology Research and Development Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Foundation of Beijing Municipal Committee of Science and Technology	We thank Professor Gu Xiaocheng and Zheng Xiaofeng (Department of Biochemistry and Molecular Biology, College of Life Sciences, Peking University, Beijing, China) for preparation and purification of the C10ORF97 protein. Sources of support: This study was supported by the National High Technology Research and Development Program of China (863 Program, No. 2006AA02Z477 to RH), the National Natural Science Foundation of China (No. 30500199 to JC and No. 30900809 to YS) and the Foundation of Beijing Municipal Committee of Science and Technology (No. D0905001040631 to JJ).	Blain SW, 2003, CANCER CELL, V3, P111, DOI 10.1016/S1535-6108(03)00026-6; Bloom J, 2007, NAT REV MOL CELL BIO, V8, P149, DOI 10.1038/nrm2105; Catzavelos C, 1999, CANCER RES, V59, P684; Chamovitz DA, 2001, EMBO REP, V2, P96, DOI 10.1093/embo-reports/kve028; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Esposito V, 1997, CANCER RES, V57, P3381; Frolova N, 2009, TUMOR BIOL, V30, P148, DOI 10.1159/000228908; Govindan R, 2006, J CLIN ONCOL, V24, P4539, DOI 10.1200/JCO.2005.04.4859; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hoffman PC, 2000, LANCET, V355, P479, DOI 10.1016/S0140-6736(00)82038-3; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Korbonits M, 2002, J CLIN ENDOCR METAB, V87, P2635, DOI 10.1210/jc.87.6.2635; Kouvaraki MA, 2003, CANCER RES, V63, P2977; Liu BH, 2002, BIOCHEM BIOPH RES CO, V293, P1396, DOI 10.1016/S0006-291X(02)00379-0; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Malumbres M, 2007, CURR OPIN GENET DEV, V17, P60, DOI 10.1016/j.gde.2006.12.008; Masciullo V, 2003, CLIN CANCER RES, V9, P5332; Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094; Meyerson M, 2004, SEMIN ONCOL, V31, P4, DOI 10.1053/j.seminoncol.2003.12.009; Osoegawa A, 2006, CANCER, V107, P154, DOI 10.1002/cncr.21961; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Rassidakis GZ, 2003, CLIN CANCER RES, V9, P1121; Sato M, 2007, J THORAC ONCOL, V2, P327, DOI 10.1097/01.JTO.0000263718.69320.4c; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shintani S, 2003, ONCOLOGY-BASEL, V65, P355, DOI 10.1159/000074649; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Sui L, 2001, CLIN CANCER RES, V7, P4130; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Tsukamoto S, 2001, LUNG CANCER-J IASLC, V34, P83, DOI 10.1016/S0169-5002(01)00216-1; Viglietto G, 2002, CELL CYCLE, V1, P394, DOI 10.4161/cc.1.6.263; Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558; Wu FY, 2006, CANCER RES, V66, P2162, DOI 10.1158/0008-5472.CAN-05-3304	36	5	7	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	39					4107	4117		10.1038/onc.2011.116	http://dx.doi.org/10.1038/onc.2011.116			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	826ME	21499297				2022-12-17	WOS:000295357500006
J	Belloni, E; Veronesi, G; Micucci, C; Javan, S; Minardi, SP; Venturini, E; Maisonneuve, P; Volorio, S; Riboni, M; Bellomi, M; Scanagatta, P; Taliento, G; Pelosi, G; Pece, S; Spaggiari, L; Pelicci, PG				Belloni, E.; Veronesi, G.; Micucci, C.; Javan, S.; Minardi, S. P.; Venturini, E.; Maisonneuve, P.; Volorio, S.; Riboni, M.; Bellomi, M.; Scanagatta, P.; Taliento, G.; Pelosi, G.; Pece, S.; Spaggiari, L.; Pelicci, P. G.			Genomic characterization of asymptomatic CT-detected lung cancers	ONCOGENE			English	Article						whole genome analysis; early diagnosis; cancer	SPIRAL COMPUTED-TOMOGRAPHY; ARYL-HYDROCARBON RECEPTOR; BASE-LINE; INDOLEAMINE 2,3-DIOXYGENASE; MOLECULAR-ORIGINS; ADENOCARCINOMA; EPIDEMIC; SMOKERS; NODULES; DNA	Computed tomography (CT) screening of lung cancer allows the detection of early tumors. The objective of our study was to verify whether initial asymptomatic lung cancers, identified by high-resolution low-dose CT (LD-CT) on a high-risk population, show genetic abnormalities that could be indicative of the early events of lung carcinogenesis. We analyzed 78 tumor samples: 21 (pilot population) from heavy smokers with asymptomatic non-screening detected early-stage lung cancers and 57 from 5203 asymptomatic heavy smoker volunteers, who underwent a LD-CT screening study. During surgical resection of the detected tumors, tissue samples were collected and short-term cultures were started for karyotype evaluation. Samples were classified according to the normal (NK) or aneuploid (AK) karyotype. The NK samples were further analyzed by the Affymetrix single-nucleotide polymorphisms (SNPs) technology. Metaphase spreads were obtained in 73.0% of the selected samples: 80.7% showed an AK. A statistically significant correlation was found between presence of vascular invasion and abnormal karyotype. A total of 10 NK samples were suitable for SNPs analysis. Subtle genomic alterations were found in eight tumors, the remaining two showing no evidence to date of chromosomal aberrations anywhere in the genome. Two common regions of amplification were identified at 5p and 8p11. Mutation analysis by direct sequencing was conducted for the K-RAS, TP53 and EGFR genes, confirming data already described for heavy smokers. We show that: (i) the majority of screening-detected tumors are aneuploid; (ii) early-stage tumors tend to harbor a less abnormal karyotype; (iii) whole genome analysis of NK tumors allows for the detection of common regions of copy number variation (such as amplifications at 5p and 8p11), highlighting genes that might be considered candidate markers of early events in lung carcinogenesis. Oncogene (2011) 30, 1117-1126; doi:10.1038/onc.2010.478; published online 25 October 2010	[Belloni, E.; Micucci, C.; Javan, S.; Volorio, S.; Riboni, M.; Pece, S.; Pelicci, P. G.] European Inst Oncol, Dept Expt Oncol, I-20139 Milan, Italy; [Veronesi, G.; Scanagatta, P.; Taliento, G.; Spaggiari, L.] European Inst Oncol, Div Thorac Surg, I-20141 Milan, Italy; [Minardi, S. P.; Venturini, E.; Volorio, S.; Riboni, M.] Cogentech, Milan, Italy; [Maisonneuve, P.] European Inst Oncol, Div Epidemiol & Biostat, Milan, Italy; [Bellomi, M.] European Inst Oncol, Div Radiol, Milan, Italy; [Pelosi, G.] European Inst Oncol, Div Pathol, Milan, Italy; [Pece, S.; Spaggiari, L.; Pelicci, P. G.] Univ Milan, Milan, Italy	IRCCS European Institute of Oncology (IEO); IRCCS European Institute of Oncology (IEO); IRCCS European Institute of Oncology (IEO); IRCCS European Institute of Oncology (IEO); IRCCS European Institute of Oncology (IEO); University of Milan	Belloni, E (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Adamello 16, I-20139 Milan, Italy.	elena.belloni@ifom-ieo-campus.it; giulia.veronesi@ieo.it	Pelicci, Pier Giuseppe/AAL-6572-2020; Maisonneuve, Patrick/U-9789-2018; Pece, Salvatore/B-9609-2013; Bellomi, Massimo/AAM-4352-2020; Scanagatta, Paolo/AAX-3226-2020; belloni, elena/H-9909-2013; Veronesi, Giulia/AAA-6327-2021; Spaggiari, Lorenzo/G-7915-2012; Scanagatta, Paolo/I-1215-2013; Pelosi, Giuseppe/F-5073-2012	Maisonneuve, Patrick/0000-0002-5309-4704; Pece, Salvatore/0000-0003-1764-3929; Scanagatta, Paolo/0000-0002-1619-6453; Veronesi, Giulia/0000-0001-9032-1278; Scanagatta, Paolo/0000-0002-1619-6453; Belloni, Elena/0000-0003-3214-0780; Pelosi, Giuseppe/0000-0003-4725-4692; Minardi, Simone Paolo/0000-0001-7303-3821; Spaggiari, Lorenzo/0000-0002-1068-3541	AIRC (Associazione Italiana per la Ricerca sul Cancro); FUV (Fondazione Umberto Veronesi); Eredita' Benilde Viotti	AIRC (Associazione Italiana per la Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro); FUV (Fondazione Umberto Veronesi)(Fondazione Umberto Veronesi); Eredita' Benilde Viotti	This study was supported by AIRC (Associazione Italiana per la Ricerca sul Cancro), FUV (Fondazione Umberto Veronesi) and Eredita' Benilde Viotti. We would like to thank Daniela Brambilla, Raffaella Bertolotti and Giovanna Ciambrone for data managing; Antonio De Vito and Loris Bernard for technical assistance; the Real Time PCR Service at the IFOM-IEO campus for TaqMan assays; Marco Bianchi, Giovanna Maria Jodice, Paolo Nuciforo and the Molecular Pathology Unit at IFOM for samples characterization; Elvira Gerbino for samples preparation; the staff of the IEO Thoracic Surgery and Radiology Departments for clinical assistance; Paola Dalton for manuscript editing; Francesca Toffalorio for helpful discussion.	Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bianchi F, 2004, CLIN CANCER RES, V10, P6023, DOI 10.1158/1078-0432.CCR-04-0619; Diederich S, 2004, EUR RADIOL, V14, P691, DOI 10.1007/s00330-003-2200-5; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Ebi H, 2009, ONCOGENE, V28, P3371, DOI 10.1038/onc.2009.201; Enstrom JE, 1999, EPIDEMIOLOGY, V10, P500, DOI 10.1097/00001648-199909000-00007; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Henschke CI, 1999, LANCET, V354, P99, DOI 10.1016/S0140-6736(99)06093-6; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Horner MJ, 2009, SEER CANC STAT REV 1; Humphrey LL, 2004, ANN INTERN MED, V140, P740, DOI 10.7326/0003-4819-140-9-200405040-00015; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Metz R, 2007, CANCER RES, V67, P7082, DOI 10.1158/0008-5472.CAN-07-1872; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Mitsuuchi Y, 2002, AM J MED GENET, V115, P183, DOI 10.1002/ajmg.10692; Mulshine JL, 2005, NEW ENGL J MED, V352, P2714, DOI 10.1056/NEJMcp042630; Nannya Y, 2005, CANCER RES, V65, P6071, DOI 10.1158/0008-5472.CAN-05-0465; Nguyen-Khac F, 2006, ONCOGENE, V25, P4840, DOI 10.1038/sj.onc.1209503; Patel JD, 2004, JAMA-J AM MED ASSOC, V291, P1763, DOI 10.1001/jama.291.14.1763; Pelosi G, 2008, LUNG CANCER, V62, P202, DOI 10.1016/j.lungcan.2008.03.012; Proctor RN, 2001, NAT REV CANCER, V1, P82, DOI 10.1038/35094091; Puppala D, 2007, CARCINOGENESIS, V28, P639, DOI 10.1093/carcin/bgl169; Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486; Sun S, 2007, NAT REV CANCER, V7, P778, DOI 10.1038/nrc2190; Tonon G, 2005, P NATL ACAD SCI USA, V102, P9625, DOI 10.1073/pnas.0504126102; Uyttenhove C, 2003, NAT MED, V9, P1269, DOI 10.1038/nm934; Veronesi G, 2008, LUNG CANCER, V61, P340, DOI 10.1016/j.lungcan.2008.01.001; Veronesi G, 2007, ANN THORAC SURG, V84, P959, DOI 10.1016/j.athoracsur.2007.04.058; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Zhao XJ, 2005, CANCER RES, V65, P5561, DOI 10.1158/0008-5472.CAN-04-4603; Zudaire E, 2008, J CLIN INVEST, V118, P640, DOI 10.1172/JCI30024	31	5	5	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	9					1117	1126		10.1038/onc.2010.478	http://dx.doi.org/10.1038/onc.2010.478			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729PX	20972464				2022-12-17	WOS:000287964100010
J	Schmidt, C; Bloomston, M; Shah, MH				Schmidt, C.; Bloomston, M.; Shah, M. H.			Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapies	ONCOGENE			English	Review						neuroendocrine tumors; somatostatin; chemoembolization	PHASE-II TRIAL; HEPATIC METASTASES; RADIONUCLIDE THERAPY; INTERFERON-ALPHA; CARCINOID-TUMORS; ENDOCRINE TUMORS; CLINICAL-TRIAL; EFFICACY; CHEMOEMBOLIZATION; COMBINATION	Neuroendocrine tumors (NETs) are a complex group of malignancies with variable prognosis and response to treatment. For pancreatic neuroendocrine and carcinoid tumors, traditional cytotoxic chemotherapies have demonstrated minimal activity. Current approaches for treatment of metastatic disease use a combination of loco-regional and targeted biological therapies. Clinical trials remain critical for evaluation of new and promising therapeutic options for patients with NETs. Oncogene (2011) 30, 1497-1505; doi: 10.1038/onc.2010.548; published online 6 December 2010	[Shah, M. H.] Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; [Schmidt, C.; Bloomston, M.] Ohio State Univ, Dept Surg, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Shah, MH (corresponding author), Ohio State Univ, Dept Internal Med, A438 Starling Loving Hall,320 W 10th Ave, Columbus, OH 43210 USA.	manisha.shah@osumc.edu	Schmidt, Carl/E-4039-2011		NCI NIH HHS [K12 CA133250] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K12CA133250] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agaram NP, 2007, CLIN CANCER RES, V13, P170, DOI 10.1158/1078-0432.CCR-06-1508; Ansell SM, 2001, CANCER-AM CANCER SOC, V91, P1543, DOI 10.1002/1097-0142(20010415)91:8<1543::AID-CNCR1163>3.0.CO;2-N; Anthony LB, 2002, SEMIN NUCL MED, V32, P123, DOI 10.1053/snuc.2002.31769; Asnacios A, 2008, J CLIN ONCOL, V26, P963, DOI 10.1200/JCO.2007.12.7431; Bajetta E, 2002, ANN ONCOL, V13, P614, DOI 10.1093/annonc/mdf064; Berkovic MC, 2007, COLLEGIUM ANTROPOL, V31, P531; Bloomston M, 2007, J GASTROINTEST SURG, V11, P264, DOI 10.1007/s11605-007-0089-z; Bushnell DL, 2010, J CLIN ONCOL, V28, P1652, DOI 10.1200/JCO.2009.22.8585; Calhoun K, 2003, AM J SURG, V186, P28, DOI 10.1016/S0002-9610(03)00115-6; Delpassand ES, 2008, CANCER BIOTHER RADIO, V23, P292, DOI 10.1089/cbr.2007.0448; Duran I, 2006, BRIT J CANCER, V95, P1148, DOI 10.1038/sj.bjc.6603419; Faiss S, 2003, J CLIN ONCOL, V21, P2689, DOI 10.1200/JCO.2003.12.142; Fjallskog MLH, 2001, CANCER, V92, P1101, DOI 10.1002/1097-0142(20010901)92:5<1101::AID-CNCR1426>3.0.CO;2-V; Forrer F, 2006, ANTICANCER RES, V26, P703; Grover AC, 2004, SURGERY, V136, P1176, DOI 10.1016/j.surg.2004.06.044; Hodul Pamela J, 2008, Cancer Control, V15, P314; Kaubisch A, 2004, CANCER CHEMOTH PHARM, V53, P337, DOI 10.1007/s00280-003-0727-4; Kennedy AS, 2008, AM J CLIN ONCOL-CANC, V31, P271, DOI 10.1097/COC.0b013e31815e4557; Kiely JM, 2006, J VASC INTERV RADIOL, V17, P47, DOI 10.1097/01.RVI.0000195074.43474.2F; Kolby L, 2003, BRIT J SURG, V90, P687, DOI 10.1002/bjs.4149; KRENNING EP, 1993, EUR J NUCL MED, V20, P716, DOI 10.1007/BF00181765; Krug LM, 2005, CANCER, V103, P2128, DOI 10.1002/cncr.21000; Kulke MH, 2008, J CLIN ONCOL, V26, P3403, DOI 10.1200/JCO.2007.15.9020; Kulke MH, 2006, J CLIN ONCOL, V24, P3555, DOI 10.1200/JCO.2006.05.6762; Kulke MH, 2006, DIGEST DIS SCI, V51, P1033, DOI 10.1007/s10620-006-8001-3; Kulke MH, 2009, CLIN CANCER RES, V15, P338, DOI 10.1158/1078-0432.CCR-08-1476; Kulke MH, 2006, J CLIN ONCOL, V24, P401, DOI 10.1200/JCO.2005.03.6046; Kulke MH, 2004, CANCER INVEST, V22, P353, DOI 10.1081/CNV-200029058; Kulke MH, 2004, CANCER, V101, P934, DOI 10.1002/cncr.20466; Kwekkeboom DJ, 2008, J CLIN ONCOL, V26, P2124, DOI 10.1200/JCO.2007.15.2553; Le Treut YP, 2008, AM J TRANSPLANT, V8, P1205, DOI 10.1111/j.1600-6143.2008.02233.x; Modlin IM, 2005, GASTROENTEROLOGY, V128, P1717, DOI 10.1053/j.gastro.2005.03.038; Osborne DA, 2006, ANN SURG ONCOL, V13, P572, DOI 10.1245/ASO.2006.03.071; Pavel Marianne E, 2005, Int J Gastrointest Cancer, V35, P179, DOI 10.1385/IJGC:35:3:179; Pavel ME, 2006, J INTERF CYTOK RES, V26, P8, DOI 10.1089/jir.2006.26.8; QUE FG, 1995, AM J SURG, V169, P36, DOI 10.1016/S0002-9610(99)80107-X; Reidy DL, 2009, NAT CLIN PRACT ONCOL, V6, P143, DOI 10.1038/ncponc1326; Rindi G, 2007, VIRCHOWS ARCH, V451, P757, DOI 10.1007/s00428-007-0452-1; Rindi G, 2006, VIRCHOWS ARCH, V449, P395, DOI 10.1007/s00428-006-0250-1; Rinke A, 2009, J CLIN ONCOL, V27, P4656, DOI 10.1200/JCO.2009.22.8510; Ruszniewski P, 2004, NEUROENDOCRINOLOGY, V80, P244, DOI 10.1159/000082875; Shah MH, 2006, CLIN CANCER RES, V12, P3997, DOI 10.1158/1078-0432.CCR-05-2689; Shah MH, 2004, CLIN CANCER RES, V10, P6111, DOI 10.1158/1078-0432.CCR-04-0422; SOLCIA E, 2000, WHO INT HISTOLOGIC C; Stuart K, 2004, INVEST NEW DRUG, V22, P75, DOI 10.1023/B:DRUG.0000006177.46798.1f; Sun WJ, 2005, J CLIN ONCOL, V23, P4897, DOI 10.1200/JCO.2005.03.616; Touzios JG, 2005, ANN SURG, V241, P776, DOI 10.1097/01.sla.0000161981.58631.ab; Varker KA, 2008, CANCER CHEMOTH PHARM, V61, P661, DOI 10.1007/s00280-007-0521-9; Varker KA, 2007, J GASTROINTEST SURG, V11, P1680, DOI 10.1007/s11605-007-0235-7; Vinik AI, 2009, PANCREAS, V38, P876, DOI 10.1097/MPA.0b013e3181bc0e77; Yao JC, 2008, J CLIN ONCOL, V26, P4311, DOI 10.1200/JCO.2008.16.7858; Yao JC, 2008, J CLIN ONCOL, V26, P1316, DOI 10.1200/JCO.2007.13.6374; Yao JC, 2007, CLIN CANCER RES, V13, P234, DOI 10.1158/1078-0432.CCR-06-1618	53	5	5	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	13					1497	1505		10.1038/onc.2010.548	http://dx.doi.org/10.1038/onc.2010.548			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	743DU	21132004	Green Accepted			2022-12-17	WOS:000288998300001
J	Lizardi, PM				Lizardi, P. M.			As we bring demethylating drugs to the clinic, we better know the DICE being cast	ONCOGENE			English	Editorial Material							ELEMENTS; CELLS; TRANSCRIPTOME; PROMOTER		Yale Univ, Sch Med, Dept Pathol, Interdept Computat Biol & Bioinformat Program, New Haven, CT 06520 USA	Yale University	Lizardi, PM (corresponding author), Yale Univ, Sch Med, Dept Pathol, Interdept Computat Biol & Bioinformat Program, 310 Cedar St, New Haven, CT 06520 USA.	paul.lizardi@mac.com						Apostolou E, 2008, CELL, V134, P85, DOI 10.1016/j.cell.2008.05.052; Comfort NC, 2001, ENDEAVOUR, V25, P127, DOI 10.1016/S0160-9327(00)01370-3; Faulkner GJ, 2009, NAT GENET, V41, P563, DOI 10.1038/ng.368; Lamprecht B, 2010, NAT MED, V16, P571, DOI 10.1038/nm.2129; Penzkofer T, 2005, NUCLEIC ACIDS RES, V33, pD498, DOI 10.1093/nar/gki044; Rangwala SH, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-9-r100; Roman-Gomez J, 2005, ONCOGENE, V24, P7213, DOI 10.1038/sj.onc.1208866; Saito Y, 2009, ONCOGENE, V28, P2738, DOI 10.1038/onc.2009.140; Speek M, 2001, MOL CELL BIOL, V21, P1973, DOI 10.1128/MCB.21.6.1973-1985.2001; Szpakowski S, 2009, GENE, V448, P151, DOI 10.1016/j.gene.2009.08.006; Weber B, 2010, ONCOGENE, V29, P5775, DOI 10.1038/onc.2010.227; Wolff EM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000917	12	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2010	29	43					5772	5774		10.1038/onc.2010.372	http://dx.doi.org/10.1038/onc.2010.372			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	672LY	20729909				2022-12-17	WOS:000283586200002
J	Santos, J; Gonzalez-Sanchez, L; Villa-Morales, M; Ors, I; Lopez-Nieva, P; Vaquero, C; Gonzalez-Gugel, E; Fernandez-Navarro, P; Roncero, AM; Guenet, JL; Montagutelli, X; Fernandez-Piqueras, J				Santos, J.; Gonzalez-Sanchez, L.; Villa-Morales, M.; Ors, I.; Lopez-Nieva, P.; Vaquero, C.; Gonzalez-Gugel, E.; Fernandez-Navarro, P.; Roncero, A. M.; Guenet, J-L; Montagutelli, X.; Fernandez-Piqueras, J.			The stromal gene encoding the CD274 antigen as a genetic modifier controlling survival of mice with gamma-radiation-induced T-cell lymphoblastic lymphomas	ONCOGENE			English	Article						T-cell lymphoblastic lymphoma; gamma-irradiation; survival; thymus stroma; Cd274 gene	RECOMBINANT CONGENIC STRAINS; INDUCED THYMIC LYMPHOMAS; NON-HODGKINS-LYMPHOMA; TUMOR-SUSCEPTIBILITY; POSITIVE SELECTION; POTENTIAL MECHANISM; BREAST-CANCER; MOUSE MODELS; BONE-MARROW; B7-H1	Using an inter-specific subcongenic strain, Nested Recombinant Haplotype 3 (NRH3), generated between two mouse strains showing extreme differences in gamma-radiation-induced thymic lymphoma susceptibility (SEG/Pas and C57BL/6J), we have identified a critical region on chromosome 19 that regulates survival of mice suffering from T-cell lymphoblastic lymphomas. Mapped on this region, the gene encoding the Cd274 ligand is able to trigger an inhibitory effect that modulates T-cell receptor (TCR) signalling and affects thymocyte maturation. Interestingly, this gene shows differential expression between thymic stromal cells from both strains in early response to a single sublethal c-ray dose, but is inhibited in T-cell lymphoblastic lymphomas. Furthermore, we have identified several polymorphisms in the complementary DNA sequence of this gene that affect the affinity for its Cd279 receptor and are able to induce a differential rate of thymocyte apoptosis. Taken together, our data are consistent with Cd274 acting as a genetic modifier that influences the survival of c-radiation-induced T-cell lymphoma-bearing mice. The data similarly support the idea of a co-evolution of tumour cells and associated stromal cells to generate a favourable microenvironment for T-cell lymphoma growth. Oncogene (2010) 29, 5265-5273; doi:10.1038/onc.2010.280; published online 19 July 2010	[Santos, J.; Gonzalez-Sanchez, L.; Villa-Morales, M.; Ors, I.; Vaquero, C.; Gonzalez-Gugel, E.; Roncero, A. M.; Fernandez-Piqueras, J.] Univ Autonoma Madrid, CSIC, Dept Biol Celular & Inmunol, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; [Santos, J.; Gonzalez-Sanchez, L.; Villa-Morales, M.; Ors, I.; Vaquero, C.; Gonzalez-Gugel, E.; Fernandez-Piqueras, J.] MICINN, ISCIII, Madrid, Spain; [Lopez-Nieva, P.] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona, Catalonia, Spain; [Fernandez-Navarro, P.] Inst Salud Carlos III, Area Epidemiol Ambiental & Canc, Ctr Nacl Epidemiol, Madrid, Spain; [Fernandez-Navarro, P.] Minist Sanidad & Consumo, Madrid, Spain; [Guenet, J-L; Montagutelli, X.] Inst Pasteur, Unite Genet Mammiferes, F-75724 Paris, France	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Instituto de Salud Carlos III; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Instituto de Salud Carlos III; Centro Nacional de Epidemiologia (CNE); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Fernandez-Piqueras, J (corresponding author), Univ Autonoma Madrid, CSIC, Dept Biol Celular & Inmunol, Ctr Biol Mol Severo Ochoa, Nicolas Cabrera 1, E-28049 Madrid, Spain.	jfpiqueras@cbm.uam.es	Santos, Javier/ABF-5755-2021; Navarro, Pablo Fernandez/E-8893-2018; VILLA-MORALES, MARIA C./H-8797-2015; Nieva, Pilar López/R-9516-2019	Santos, Javier/0000-0002-4168-6251; Navarro, Pablo Fernandez/0000-0001-9427-2581; VILLA-MORALES, MARIA C./0000-0001-7906-0169; Nieva, Pilar López/0000-0001-6369-2444; Gonzalez-Sanchez, Laura/0000-0002-4749-2423; RONCERO SANCHEZ, ANA MARIA/0000-0002-2542-9028	European Commission [FI6R-CT2003-508842]; Spanish Ministry of Education and Science [SAF-2006-09437, SAF2009-11426]	European Commission(European CommissionEuropean Commission Joint Research Centre); Spanish Ministry of Education and Science(Spanish Government)	This work was supported by the European Commission contract number FI6R-CT2003-508842 to JS and by the Spanish Ministry of Education and Science contract number SAF-2006-09437 and SAF2009-11426 to JFP. We thank Arturo Morales for the critical reading of the paper.	Aifantis I, 2008, NAT REV IMMUNOL, V8, P380, DOI 10.1038/nri2304; Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Anderson G, 2001, NAT REV IMMUNOL, V1, P31, DOI 10.1038/35095500; Balmain A, 2002, CELL, V108, P145, DOI 10.1016/S0092-8674(02)00622-0; Bian YS, 2007, HUM MOL GENET, V16, P3128, DOI 10.1093/hmg/ddm274; Blank C, 2007, CANCER IMMUNOL IMMUN, V56, P739, DOI 10.1007/s00262-006-0272-1; BRATHWAITE O, 1992, CANCER RES, V52, P3791; Burgio G, 2007, GENETICS, V177, P2321, DOI 10.1534/genetics.107.078006; Cormier RT, 2000, ONCOGENE, V19, P3182, DOI 10.1038/sj.onc.1203646; DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; DIAMOND LE, 1988, IMMUNOGENETICS, V28, P71, DOI 10.1007/BF00346154; Dong HD, 1999, NAT MED, V5, P1365; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Elahi E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004388; Gray DHD, 2002, J IMMUNOL METHODS, V260, P15, DOI 10.1016/S0022-1759(01)00493-8; Hamanishi J, 2007, P NATL ACAD SCI USA, V104, P3360, DOI 10.1073/pnas.0611533104; Hare KJ, 1999, J IMMUNOL, V162, P3978; Inman BA, 2007, CANCER-AM CANCER SOC, V109, P1499, DOI 10.1002/cncr.22588; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Jawad M, 2007, BLOOD CELL MOL DIS, V38, P69, DOI 10.1016/j.bcmd.2006.10.009; Keir ME, 2005, J IMMUNOL, V175, P7372, DOI 10.4049/jimmunol.175.11.7372; Kodama Y, 2004, CARCINOGENESIS, V25, P143, DOI 10.1093/carcin/bgg177; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; Lenz G, 2008, NEW ENGL J MED, V359, P2313, DOI 10.1056/NEJMoa0802885; Liang SC, 2003, EUR J IMMUNOL, V33, P2706, DOI 10.1002/eji.200324228; Lwin T, 2007, LEUKEMIA, V21, P1521, DOI 10.1038/sj.leu.2404723; Mao JH, 2003, CURR OPIN GENET DEV, V13, P14, DOI 10.1016/S0959-437X(03)00005-4; Marzec M, 2008, P NATL ACAD SCI USA, V105, P20852, DOI 10.1073/pnas.0810958105; Matin A, 1999, NAT GENET, V23, P237, DOI 10.1038/13874; Mori N, 2000, J RADIAT RES, V41, P367, DOI 10.1269/jrr.41.367; Muhlbauer M, 2006, J HEPATOL, V45, P520, DOI 10.1016/j.jhep.2006.05.007; Nishimura H, 2000, J EXP MED, V191, P891, DOI 10.1084/jem.191.5.891; Nomi T, 2007, CLIN CANCER RES, V13, P2151, DOI 10.1158/1078-0432.CCR-06-2746; Ochiai Y, 2003, ONCOGENE, V22, P1098, DOI 10.1038/sj.onc.1206202; Ogawa K, 2007, CANCER RES, V67, P4016, DOI 10.1158/0008-5472.CAN-06-4498; Oka S, 1999, J VET MED SCI, V61, P709, DOI 10.1292/jvms.61.709; Patocs A, 2007, NEW ENGL J MED, V357, P2543, DOI 10.1056/NEJMoa071825; Pelham RJ, 2006, P NATL ACAD SCI USA, V103, P19848, DOI 10.1073/pnas.0609635104; Saito Y, 2001, ONCOGENE, V20, P5243, DOI 10.1038/sj.onc.1204675; Sandlund JT, 1996, NEW ENGL J MED, V334, P1238, DOI 10.1056/NEJM199605093341906; Santos J, 2002, ONCOGENE, V21, P6680, DOI 10.1038/sj.onc.1205846; Santos J, 2001, ONCOGENE, V20, P2186, DOI 10.1038/sj.onc.1204297; Santos J, 2009, CANCER RES, V69, P2577, DOI 10.1158/0008-5472.CAN-08-1821; Villa-Morales M, 2006, ONCOGENE, V25, P2022, DOI 10.1038/sj.onc.1209234; Villa-Morales M, 2007, CANCER RES, V67, P5107, DOI 10.1158/0008-5472.CAN-06-4006; Wang M, 2003, CANCER RES, V63, P3317; Wang SD, 2003, J EXP MED, V197, P1083, DOI 10.1084/jem.20021752; Wintterle S, 2003, CANCER RES, V63, P7462	48	5	7	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	38					5265	5273		10.1038/onc.2010.280	http://dx.doi.org/10.1038/onc.2010.280			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	653KE	20639904				2022-12-17	WOS:000282089100005
J	Ndisang, D; Khan, A; Lorenzato, F; Sindos, M; Singer, A; Latchman, DS				Ndisang, D.; Khan, A.; Lorenzato, F.; Sindos, M.; Singer, A.; Latchman, D. S.			The cellular transcription factor Brn-3a and the smoking-related substance nicotine interact to regulate the activity of the HPV URR in the cervix	ONCOGENE			English	Article						Brn-3a cellular transactivator; nicotine; environmental smoking-related substance; HPV variants; cervical intraepithelial neoplasia	HUMAN-PAPILLOMAVIRUS; INTRAEPITHELIAL NEOPLASIA; GENE-EXPRESSION; CANCER CELLS; FACTOR PLAYS; NONSMOKERS; PROMOTER; SMOKERS; GROWTH; SMEARS	The cellular transcription factor Brn-3a differentially regulates different human papilloma virus (HPV)-16 variants that are associated with different risks of progression to cervical carcinoma in infected humans. The upstream regulatory regions (URRs) of high- and intermediate-risk HPV-16 variants are activated by the cellular transcription factor Brn-3a, whereas the URR of a low-risk HPV-16 variant is not. In this study, we show in transfection assays that Brn-3a and the smoking-related substance nicotine produce stronger responsiveness of the URR of the low- and high-risk variants than with either factor alone, but not the intermediate-risk variant. We determined that this synergistic activity of Brn-3a/nicotine is due to two nucleotide differences in the URR, crucial for oncogenic E6/E7 transactivation. Mutant constructs in which the nucleotide residues were substituted alter Brn-3a/nicotine responsiveness. Importantly, women smokers with high levels of Brn-3a infected with low- or high-risk HPV-16 variants have augmented E6 levels, and were more frequently diagnosed with higher grades of cervical intraepithelial neoplasia (CIN) and cancer, as compared with non-smokers who were infected with similar variants and expressed similar levels of Brn-3a. Therefore, this study defines the specific interplay between the cellular transactivator Brn-3a, the environmental smoking-related substance nicotine and specific HPV variants in cervical carcinogenesis, and thus helps to explain why some women are susceptible to rapid CIN progression and cancer and others are not. Oncogene (2010) 29, 2701-2711; doi:10.1038/onc.2010.33; published online 1 March 2010	[Ndisang, D.; Khan, A.; Sindos, M.; Latchman, D. S.] UCL, Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EH, England; [Lorenzato, F.] Whittington Hosp, Dept Womens & Childrens Hlth, London N19 5NF, England; [Latchman, D. S.] Univ London, London, England	University of London; University College London; University of London; University College London; University of London	Ndisang, D (corresponding author), UCL, Inst Child Hlth, Med Mol Biol Unit, 30 Guilford St,Guilford St, London WC1N 1EH, England.	d.ndisang@ich.ucl.ac.uk			Association for International Cancer Research (AICR)	Association for International Cancer Research (AICR)	This study was funded by the Association for International Cancer Research (AICR).	ANTHONY SG, 2006, CANCER EPIDEM BIOMAR, V15, P2141; Bible JM, 2000, J GEN VIROL, V81, P1517, DOI 10.1099/0022-1317-81-6-1517; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BURGHARDT E, 1991, CANCER-AM CANCER SOC, V67, P1037, DOI 10.1002/1097-0142(19910215)67:4<1037::AID-CNCR2820670429>3.0.CO;2-2; COX MF, 1986, LANCET, V2, P157; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; Dasgupta P, 2006, P NATL ACAD SCI USA, V103, P6332, DOI 10.1073/pnas.0509313103; Dasgupta P, 2006, J CLIN INVEST, V116, P2208, DOI 10.1172/JCI28164; Harkness PC, 2002, J NEUROSCI, V22, P10172; HELLBERG D, 1988, AM J OBSTET GYNECOL, V158, P910, DOI 10.1016/0002-9378(88)90093-2; Lane D, 2005, AM J REPROD IMMUNOL, V53, P153, DOI 10.1111/j.1600-0897.2005.00259.x; Lee SA, 2005, CANCER RES, V65, P3072, DOI 10.1158/0008-5472.CAN-04-2865; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; MCCANN MF, 1992, CANCER EPIDEM BIOMAR, V1, P125; Miller AB, 2001, LANCET, V357, P1816, DOI 10.1016/S0140-6736(00)05008-X; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; MORRIS PJ, 1993, NUCLEIC ACIDS RES, V21, P1019, DOI 10.1093/nar/21.4.1019; Ndisang D, 2006, ONCOGENE, V25, P51, DOI 10.1038/sj.onc.1209006; Ndisang D, 2006, GYNECOL ONCOL, V100, P89, DOI 10.1016/j.ygyno.2005.07.109; Ndisang D, 1999, J BIOL CHEM, V274, P28521, DOI 10.1074/jbc.274.40.28521; Ndisang D, 2000, CLIN SCI, V98, P601, DOI 10.1042/CS19990350; Ndisang D, 2001, ONCOGENE, V20, P4899, DOI 10.1038/sj.onc.1204634; Prokopczyk B, 1997, J NATL CANCER I, V89, P868, DOI 10.1093/jnci/89.12.868; Sindos M, 2003, GYNECOL ONCOL, V90, P366, DOI 10.1016/S0090-8258(03)00261-0; Sindos M, 2003, INT J GYNECOL CANCER, V13, P515, DOI 10.1046/j.1525-1438.2003.13303.x; Tsai HT, 2007, GYNECOL ONCOL, V105, P181, DOI 10.1016/j.ygyno.2006.11.012; zur Hausen H, 2009, VIROLOGY, V392, P1, DOI 10.1016/j.virol.2009.06.001	27	5	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	2010	29	18					2701	2711		10.1038/onc.2010.33	http://dx.doi.org/10.1038/onc.2010.33			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	20190800				2022-12-17	WOS:000277354600010
J	Clybouw, C; El Mchichi, B; Hadji, A; Portier, A; Auffredou, MT; Arnoult, D; Leca, G; Vazquez, A				Clybouw, C.; El Mchichi, B.; Hadji, A.; Portier, A.; Auffredou, M. T.; Arnoult, D.; Leca, G.; Vazquez, A.			TGF beta-mediated apoptosis of Burkitt's lymphoma BL41 cells is associated with the relocation of mitochondrial BimEL	ONCOGENE			English	Article						Bim; TGF beta; mitochondrial delocalization; apoptosis; lymphoma	BCL-2 FAMILY-MEMBER; HUMAN B-CELLS; BH3-ONLY PROTEINS; P38 MAPK; CASPASE-8 ACTIVATION; DEPENDENT APOPTOSIS; BH3 DOMAINS; T-CELLS; MCL-1; PHOSPHORYLATION	In this study, we showed that the transforming growth factor beta ( TGF beta)-mediated apoptosis of Burkitt's lymphoma BL41 cells is dependent on the BH3-only protein Bim. In contrast to what has been observed with other cell types, TGFb activation did not promote Bim upregulation in BL41 cells, but instead resulted in Bim release from the mitochondria. Indeed, Bim levels were high in healthy BL41 cells, in which they dimerized with the Bcl-2-like protein Mcl-1 at the mitochondrial surface. In healthy and TGF beta-activated BL41 cells, unlike in epithelial cells or hepatocytes, Bim did not associate with Bcl-2 or Bcl-xL. TGFb activation of BL41 cells triggered the p38-dependent activation of caspase-8, causing the cleavage of Mcl-1 and the transfer of Bim from the mitochondria to the cytoskeleton. In addition to mitochondrial activation, this relocation of Bim may facilitate the complete demise of a cell death that is beyond the commitment point to apoptosis and may represent a hallmark of the TGF beta-mediated apoptosis of human lymphoma B cells.	[Clybouw, C.; El Mchichi, B.; Hadji, A.; Portier, A.; Auffredou, M. T.; Arnoult, D.; Leca, G.; Vazquez, A.] Univ Paris Sud, Hop Paul Brousse, INSERM, U542, F-94807 Villejuif, Val De Marne, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Vazquez, A (corresponding author), Univ Paris Sud, Hop Paul Brousse, INSERM, U542, Batiment,Lavoisier,14 Ave Paul Vaillant Couturier, F-94807 Villejuif, Val De Marne, France.	vazquez@vjf.inserm.fr	Arnoult, Damien/R-2032-2018					Alvarado-Kristensson M, 2004, J EXP MED, V199, P449, DOI 10.1084/jem.20031771; Bingle CD, 2000, J BIOL CHEM, V275, P22136, DOI 10.1074/jbc.M909572199; Bouillet P, 2001, DEV CELL, V1, P645, DOI 10.1016/S1534-5807(01)00083-1; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Cai BB, 2006, J BIOL CHEM, V281, P25215, DOI 10.1074/jbc.M512627200; CHAOUCHI N, 1995, ONCOGENE, V11, P1615; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Choi WS, 2004, J BIOL CHEM, V279, P20451, DOI 10.1074/jbc.M311164200; Clybouw C, 2005, J IMMUNOL, V175, P2968, DOI 10.4049/jimmunol.175.5.2968; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Domina AM, 2004, ONCOGENE, V23, P5301, DOI 10.1038/sj.onc.1207692; El Mchichi B, 2007, CELL DEATH DIFFER, V14, P1826, DOI 10.1038/sj.cdd.4402187; Ewings KE, 2007, EMBO J, V26, P2856, DOI 10.1038/sj.emboj.7601723; Gomez-Bougie P, 2004, EUR J IMMUNOL, V34, P3156, DOI 10.1002/eji.200424981; Gomez-Bougie P, 2005, EUR J IMMUNOL, V35, P971, DOI 10.1002/eji.200425878; Han J, 2006, J BIOL CHEM, V281, P10153, DOI 10.1074/jbc.M510349200; Han J, 2004, J BIOL CHEM, V279, P22020, DOI 10.1074/jbc.M313234200; Herrant M, 2004, ONCOGENE, V23, P7863, DOI 10.1038/sj.onc.1208069; Herrant M, 2002, ONCOGENE, V21, P4957, DOI 10.1038/sj.onc.1205689; Hildeman DA, 2002, IMMUNITY, V16, P759, DOI 10.1016/S1074-7613(02)00322-9; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kobayashi S, 2007, J BIOL CHEM, V282, P18407, DOI 10.1074/jbc.M610010200; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Ley R, 2004, J BIOL CHEM, V279, P8837, DOI 10.1074/jbc.M311578200; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; MAURER F, 1906, HDB VERGLEICHENDEN 1, V3, P1; Michels J, 2004, ONCOGENE, V23, P4818, DOI 10.1038/sj.onc.1207648; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; Mouhamad S, 2004, J IMMUNOL, V172, P2084, DOI 10.4049/jimmunol.172.4.2084; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Ohgushi M, 2005, MOL CELL BIOL, V25, P10017, DOI 10.1128/MCB.25.22.10017-10028.2005; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Park HJ, 2002, HEPATOLOGY, V35, P1360, DOI 10.1053/jhep.2002.33205; Park MT, 2003, J BIOL CHEM, V278, P50624, DOI 10.1074/jbc.M309011200; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj/cdd/4400998; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Ramjaun AR, 2007, ONCOGENE, V26, P970, DOI 10.1038/sj.onc.1209852; Schrantz N, 2001, MOL BIOL CELL, V12, P3139, DOI 10.1091/mbc.12.10.3139; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Wildey GM, 2003, J BIOL CHEM, V278, P18069, DOI 10.1074/jbc.M211958200; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zhu YN, 2004, P NATL ACAD SCI USA, V101, P7681, DOI 10.1073/pnas.0402293101	55	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	24					3446	3456		10.1038/sj.onc.1211009	http://dx.doi.org/10.1038/sj.onc.1211009			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193085				2022-12-17	WOS:000256309900009
J	Rao, PR; Makhijani, K; Shashidhara, LS				Rao, P. R.; Makhijani, K.; Shashidhara, L. S.			Human APC sequesters beta-catenin even in the absence of GSK-3 beta in a Drosophila model	ONCOGENE			English	Article						colon cancer; adenomatous polyposis coli; Shaggy/GSK-3 beta; Armadillo; Wnt; wingless	HOMEOTIC GENE; PHOSPHORYLATION; EXPRESSION; BINDING; COMPLEX	There have been conflicting reports on the requirement of GSK- 3 beta- mediated phosphorylation of the tumor suppressor adenomatous polyposis coli ( APC) vis-a-vis its ability to bind and degrade beta- catenin. Using a unique combination of loss of function for Shaggy/ GSK- 3 beta and a gain of function for human APC in Drosophila, we show that misexpressed human APC ( hAPC) can still sequester Armadillo/beta- catenin. In addition, human APC could suppress gain of Wnt/ Wingless phenotypes associated with loss of Shaggy/ GSK- 3 beta activity, suggesting that sequestered Armadillo/beta- catenin is non- functional. Based on these studies, we propose that binding per se of b- catenin by APC does not require phosphorylation by GSK- 3 beta.	[Rao, P. R.; Makhijani, K.; Shashidhara, L. S.] Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Rao, PR (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	prashanth21676@gmail.com		Rao, Prashanth Ramesh/0000-0002-6877-6214; , Kalpana/0000-0001-7795-891X				Bajpai R, 2004, DEVELOPMENT, V131, P1007, DOI 10.1242/dev.00980; Bhandari P, 2001, ONCOGENE, V20, P6871, DOI 10.1038/sj.onc.1204849; BRAND AH, 1993, DEVELOPMENT, V118, P401; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Liu J, 2006, J MOL BIOL, V360, P133, DOI 10.1016/j.jmb.2006.04.064; Mohit P, 2003, DEVELOPMENT, V130, P1537, DOI 10.1242/dev.00393; Neumann CJ, 1997, DEVELOPMENT, V124, P871; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PERRIMON N, 1989, DEV BIOL, V135, P287, DOI 10.1016/0012-1606(89)90180-2; Rubinfeld B, 2001, J BIOL CHEM, V276, P39037, DOI 10.1074/jbc.M105148200; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Seo E, 2007, BIOCHEM BIOPH RES CO, V357, P81, DOI 10.1016/j.bbrc.2007.03.117; Shashidhara LS, 1999, DEV BIOL, V212, P491, DOI 10.1006/dbio.1999.9341; SIMMONDS AJ, 1995, NATURE, V376, P424, DOI 10.1038/376424a0; von Kries JP, 2000, NAT STRUCT BIOL, V7, P800; Xing Y, 2004, MOL CELL, V15, P523, DOI 10.1016/j.molcel.2004.08.001; XU T, 1993, DEVELOPMENT, V117, P1223; Zilian O, 1999, DEVELOPMENT, V126, P5409	19	5	5	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2488	2493		10.1038/sj.onc.1210890	http://dx.doi.org/10.1038/sj.onc.1210890			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17968317				2022-12-17	WOS:000254844900013
J	Demichelis, F; Fall, K; Perner, S; Andren, O; Schmidt, F; Setlur, SR; Hoshida, Y; Mosquera, JM; Pawitan, Y; Lee, C; Adami, HO; Mucci, LA; Kantoff, PW; Andersson, SO; Chinnaiyan, AM; Johansson, JE; Rubin, MA				Demichelis, F.; Fall, K.; Perner, S.; Andren, O.; Schmidt, F.; Setlur, S. R.; Hoshida, Y.; Mosquera, J-M; Pawitan, Y.; Lee, C.; Adami, H-O; Mucci, L. A.; Kantoff, P. W.; Andersson, S-O; Chinnaiyan, A. M.; Johansson, J-E; Rubin, M. A.			TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort (vol 26, pg 4596, 2007)	ONCOGENE			English	Correction													Fall, Katja/AAE-1876-2021	Fall, Katja/0000-0002-3649-2639; Kantoff, Philip/0000-0001-7275-0597; Rubin, Mark/0000-0002-8321-9950				Demichelis F, 2007, ONCOGENE, V26, P4596, DOI 10.1038/sj.onc.1210237	1	5	5	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	38					5692	5692		10.1038/sj.onc.1210630	http://dx.doi.org/10.1038/sj.onc.1210630			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS		Bronze			2022-12-17	WOS:000248801900017
J	Thirunarayanan, N; Cifire, F; Fichtner, I; Posner, S; Benga, J; Relterer, P; Krernmer, E; Koble, K; Lipp, M				Thirunarayanan, N.; Cifire, F.; Fichtner, I.; Posner, S.; Benga, J.; Relterer, P.; Krernmer, E.; Koeble, K.; Lipp, M.			Enhanced tumorigenicity of fibroblasts transformed with human herpesvirus 8 chemokine receptor vGPCR by successive passage in nude and immunocompetent mice	ONCOGENE			English	Article						chemokine receptor; vGPCR; Kaposi's sarcoma; animal model; HHV-8	PROTEIN-COUPLED RECEPTOR; SARCOMA-ASSOCIATED HERPESVIRUS; ENDOTHELIAL GROWTH-FACTOR; KAPOSIS-SARCOMA; MAMMALIAN-CELLS; EXPRESSION; ACTIVATION; INFECTION; ORF74; MODEL	The human herpes virus 8 (HHV-8)-encoded G protein-coupled chemokine receptor (vGPCR) has been implicated in the pathogenesis of Kaposi's sarcoma (KS), particularly because of its high constitutive signaling activity. Here, we used retroviral transduction to generate vGPCR-expressing 3T3 fibroblasts that are tumorigenic in nude mice, but as expected fail to induce tumors in their immunocompetent counterparts. However, tumor fragments obtained from nude mice grow progressively in immunocompetent BALB/c mice. Unexpectedly, vGPCR-expressing cells established from grafted tumor fragments gave rise to tumors in immunocompetent mice. These tumors exhibit a striking histological resemblance to KS including plump spindle cell morphology, a high degree of vascularization and brisk mitotic activity. High expression of vGPCR was confirmed in the cell lines and tumors using a newly developed vGPCR-specific monoclonal antibody. Finally, short interfering RNA directed at vGPCR abrogated or significantly delayed tumorigenesis in mice, demonstrating that the tumor development is specifically driven by vGPCR. This novel model for vGPCR-mediated oncogenesis will contribute to our understanding of the role of vGPCR in the pathogenesis of HHV-8 and may even be important in identifying critical molecular and epigenetic changes during tumor progression in vivo.	Max Delbruck Ctr Mol Med, Dept Tumor Genet & Immunogenet, D-13125 Berlin, Germany; Max Delbruck Ctr Mol Med, Dept Expt Pharmacol, D-13125 Berlin, Germany; GSF Munich, Res Ctr, Inst Mol Immunol, Munich, Germany; Univ Klinikum Charite, Inst Pathol, Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Lipp, M (corresponding author), Max Delbruck Ctr Mol Med, Dept Tumor Genet & Immunogenet, Robert Rossle Str 10, D-13125 Berlin, Germany.	mLIPP@mdc-berlin.de	Lipp, Martin/G-2235-2010	Lipp, Martin/0000-0002-0087-2672				Akula SM, 2003, J VIROL, V77, P7978, DOI 10.1128/JVI.77.14.7978-7990.2003; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 2003, CANCER CELL, V3, P131, DOI 10.1016/S1535-6108(03)00024-2; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Brekken RA, 2001, J CONTROL RELEASE, V74, P173, DOI 10.1016/S0168-3659(01)00333-9; Cerimele F, 2001, J VIROL, V75, P2435, DOI 10.1128/JVI.75.5.2435-2443.2001; Cesarman E, 2000, J EXP MED, V191, P417, DOI 10.1084/jem.191.3.417; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chiou CJ, 2002, J VIROL, V76, P3421, DOI 10.1128/JVI.76.7.3421-3439.2002; EMRICH T, 1993, BIOCHEM BIOPH RES CO, V197, P214, DOI 10.1006/bbrc.1993.2463; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Forster R, 1998, J IMMUNOL, V160, P1522; Gallo RC, 1998, SCIENCE, V282, P1837, DOI 10.1126/science.282.5395.1837; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; Guo HG, 2003, J VIROL, V77, P2631, DOI 10.1128/JVI.77.4.2631-2639.2003; Holst PJ, 2001, J CLIN INVEST, V108, P1789, DOI 10.1172/JCI13622; Hopken UE, 2004, EUR J IMMUNOL, V34, P461, DOI 10.1002/eji.200324690; Jensen KK, 2005, J IMMUNOL, V174, P3686, DOI 10.4049/jimmunol.174.6.3686; KAAYA EE, 1995, J ACQ IMMUN DEF SYND, V10, P295; Kirshner JR, 1999, J VIROL, V73, P6006, DOI 10.1128/JVI.73.7.6006-6014.1999; Kolble K, 1999, LAB INVEST, V79, P1145; Monini P, 1999, BLOOD, V93, P4044; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Muller G, 2001, BIOL CHEM, V382, P1387, DOI 10.1515/BC.2001.171; Ochsenbein AF, 1999, P NATL ACAD SCI USA, V96, P2233, DOI 10.1073/pnas.96.5.2233; Ochsenbein AF, 2001, NATURE, V411, P1058, DOI 10.1038/35082583; Pati S, 2001, J VIROL, V75, P8660, DOI 10.1128/JVI.75.18.8660-8673.2001; QIN ZH, 1995, CANCER RES, V55, P4747; Quan N, 1999, CANCER RES, V59, P1080; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Samaniego F, 2002, CELL GROWTH DIFFER, V13, P387; Skobe M, 1999, J INVEST DERMATOL, V113, P1047, DOI 10.1046/j.1523-1747.1999.00798.x; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445	34	5	5	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	39					5702	5712		10.1038/sj.onc.1210357	http://dx.doi.org/10.1038/sj.onc.1210357			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17353903				2022-12-17	WOS:000248885100002
J	Mateos, S; Amarir, S; Laugier, D; Marx, M; Calothy, G				Mateos, S.; Amarir, S.; Laugier, D.; Marx, M.; Calothy, G.			Stable expression of intracellular Notch suppresses v-Src-induced transformation in avian neural cells	ONCOGENE			English	Article						cell transformation; differentiation; Src; Notch; tumor suppressor; paracrine activity	RETINAL PROGENITOR CELLS; QUAIL NEURORETINA CELLS; PROTEIN-KINASE; CHICK-EMBRYO; NEOPLASTIC TRANSFORMATION; TRANSCRIPTION FACTOR; VIRAL ONCOGENES; GROWTH ARREST; CANCER CELLS; CYCLE ARREST	Understanding how disruption of differentiation contributes to the cancer cell phenotype is required to identify alterations essential for malignant transformation and provide experimental basis for their correction. We investigated whether primary quail neuroretina cells, transformed by a conditional v-Src mutant (QNR/v-src(ts)), could revert to a normal phenotype, in response to the stable expression of constitutively active Notch1 intracellular domain (ICN). This model system was chosen because Notch signaling plays an instructive role in cell fate determination during NR development, and because the intrinsic capacity of QNR cultures to differentiate is blocked by v-Src.We report that stable ICN expression results in suppression of QNR/v-src(ts) cell transformation in the presence of an active oncoprotein. This phenotypic reversion coincides with a major switch in cell identity, as these undifferentiated cells acquire glial differentiation traits. Both changes appear to be mediated by CBF, a transcription factor that binds to ICN and activates target genes. Cells restored to a normal and differentiated phenotype have undergone changes in the functioning of signaling effectors, essentially regulating cell morphology and cytoskeleton organization. This dominant interference may be partially mediated by an autocrine/paracrine mechanism, as revertant cells secrete a factor(s), which inhibits transformation properties of QNR/v-src(ts) cells.	Ctr Univ Paris Sud, Inst CURIE, CNTS, UMR 146, F-91405 Orsay, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Calothy, G (corresponding author), Ctr Univ Paris Sud, Inst CURIE, CNTS, UMR 146, F-91405 Orsay, France.	georges.calothy@curie.u-psud.fr						ADLER V, 1992, J BIOL CHEM, V267, P17001; ALVAREZBUYLLA A, 1987, J COMP NEUROL, V264, P159, DOI 10.1002/cne.902640203; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Aouacheria A, 2002, ONCOGENE, V21, P1171, DOI 10.1038/sj.onc.1205170; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bao ZZ, 1997, J NEUROSCI, V17, P1425; BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BeleckyAdams T, 1997, INVEST OPHTH VIS SCI, V38, P1293; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bernardos RL, 2005, DEV BIOL, V278, P381, DOI 10.1016/j.ydbio.2004.11.018; Berset T, 2001, SCIENCE, V291, P1055, DOI 10.1126/science.1055642; BINDER LI, 1986, ANN NY ACAD SCI, V466, P145, DOI 10.1111/j.1749-6632.1986.tb38392.x; Bissell MJ, 2005, CANCER CELL, V7, P17, DOI 10.1016/j.ccr.2004.12.013; Bocchetta M, 2003, ONCOGENE, V22, P81, DOI 10.1038/sj.onc.1206097; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Burmeister M, 1996, NAT GENET, V12, P376, DOI 10.1038/ng0496-376; CALOTHY G, 1980, COLD SPRING HARB SYM, V44, P983, DOI 10.1101/SQB.1980.044.01.106; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Chen CB, 2002, DEVELOPMENT, V129, P2401; Chen CMA, 2000, MECH DEVELOP, V90, P293; COMBES PC, 1977, CELL TISSUE RES, V185, P159; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; Douer D, 2002, INT J HEMATOL, V76, P179, DOI 10.1007/BF03165115; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; Faigle R, 2004, MOL CELL BIOL, V24, P280, DOI 10.1128/MCB.24.1.280-293.2004; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; Fincham VJ, 1999, J CELL SCI, V112, P947; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Furukawa T, 2000, NEURON, V26, P383, DOI 10.1016/S0896-6273(00)81171-X; Galy A, 2002, DEV BIOL, V248, P251, DOI 10.1006/dbio.2002.0736; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; GUERMAH M, 1990, MOL CELL BIOL, V10, P3584, DOI 10.1128/MCB.10.7.3584; GUERMAH M, 1991, P NATL ACAD SCI USA, V88, P4503, DOI 10.1073/pnas.88.10.4503; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hansen LA, 2000, CARCINOGENESIS, V21, P1271, DOI 10.1093/carcin/21.7.1271; Henrique D, 1997, CURR BIOL, V7, P661, DOI 10.1016/S0960-9822(06)00293-4; Huang C, 2004, CELL CYCLE, V3, P4, DOI 10.4161/cc.3.1.601; Huang S, 2003, MOL CELL, V11, P1491, DOI 10.1016/S1097-2765(03)00180-1; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jean D, 1998, MECH DEVELOP, V76, P3, DOI 10.1016/S0925-4773(98)00117-8; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; KAHN P, 1984, P NATL ACAD SCI-BIOL, V81, P7122, DOI 10.1073/pnas.81.22.7122; KAWAI S, 1971, VIROLOGY, V46, P470, DOI 10.1016/0042-6822(71)90047-X; Kim JW, 2005, P NATL ACAD SCI USA, V102, P14308, DOI 10.1073/pnas.0501600102; Kopan R, 1996, CURR OPIN NEUROBIOL, V6, P594, DOI 10.1016/S0959-4388(96)80090-0; Kopan R, 2002, J CELL SCI, V115, P1095; LAYER PG, 1989, CELL TISSUE RES, V258, P233; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Marquardt T, 2002, TRENDS NEUROSCI, V25, P32, DOI 10.1016/S0166-2236(00)02028-2; Marquardt T, 2001, CELL, V105, P43, DOI 10.1016/S0092-8674(01)00295-1; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; MARX M, 1988, J VIROL, V62, P4627, DOI 10.1128/JVI.62.12.4627-4633.1988; Mateos S, 2003, ONCOGENE, V22, P740, DOI 10.1038/sj.onc.1206213; Mayer T, 1999, ONCOGENE, V18, P2117, DOI 10.1038/sj.onc.1202537; Mey J, 2000, BRAIN RES REV, V32, P343, DOI 10.1016/S0165-0173(99)00022-3; Morimura T, 2000, J BIOL CHEM, V275, P36523, DOI 10.1074/jbc.M006415200; Nguyen BC, 2006, GENE DEV, V20, P1028, DOI 10.1101/gad.1406006; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; OKADA TS, 1983, CELL DIFFER DEV, V12, P85, DOI 10.1016/0045-6039(83)90060-X; Oren A, 1999, MOL CELL BIOL, V19, P1742; Pawlak G, 2002, J BIOL CHEM, V277, P26927, DOI 10.1074/jbc.M202261200; Perron M, 2000, CELL MOL LIFE SCI, V57, P215, DOI 10.1007/PL00000685; PESSAC B, 1983, NATURE, V302, P616, DOI 10.1038/302616a0; PESSAC B, 1974, SCIENCE, V185, P709, DOI 10.1126/science.185.4152.709; Peyssonnaux C, 2000, MOL CELL BIOL, V20, P7068, DOI 10.1128/MCB.20.19.7068-7079.2000; POUPONNOT C, 1995, MOL CELL BIOL, V15, P5563; Prada FA, 1995, GLIA, V15, P389, DOI 10.1002/glia.440150404; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Rohn JL, 1996, J VIROL, V70, P8071, DOI 10.1128/JVI.70.11.8071-8080.1996; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; Souopgui J, 2002, EMBO J, V21, P6429, DOI 10.1093/emboj/cdf644; Spira AI, 2003, CURR OPIN PHARMACOL, V3, P338, DOI 10.1016/S1471-4892(03)00081-X; Sriuranpong V, 2001, CANCER RES, V61, P3200; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Tanaka M, 1999, J NEUROBIOL, V41, P524, DOI 10.1002/(SICI)1097-4695(199912)41:4<524::AID-NEU8>3.3.CO;2-9; TROTTER J, 1989, ONCOGENE, V4, P457; Vadlamudi RK, 2005, ONCOGENE, V24, P4591, DOI 10.1038/sj.onc.1208672; Wakamatsu Y, 2000, DEVELOPMENT, V127, P2811; Waltzer L, 1995, NUCLEIC ACIDS RES, V23, P4939, DOI 10.1093/nar/23.24.4939; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Xia Y, 2004, TRENDS CELL BIOL, V14, P94, DOI 10.1016/j.tcb.2003.12.005; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	85	5	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2007	26	23					3338	3351		10.1038/sj.onc.1210124	http://dx.doi.org/10.1038/sj.onc.1210124			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17146440				2022-12-17	WOS:000246579600004
J	Wong, KK; Maser, RS; Sahin, E; Bailey, ST; Xia, H; Ji, H; McNamara, K; Naylor, M; Bronson, RT; Ghosh, S; Welsh, R; DePinho, RA				Wong, K-K; Maser, R. S.; Sahin, E.; Bailey, S. T.; Xia, H.; Ji, H.; McNamara, K.; Naylor, M.; Bronson, R. T.; Ghosh, S.; Welsh, R.; DePinho, R. A.			Diminished lifespan and acute stress-induced death in DNA-PKcs-deficient mice with limiting telomeres	ONCOGENE			English	Article						DNAPKcs; telomere; telomerase; stress; aging; cytokines	NF-KAPPA-B; ACTIVATION; REPAIR; AGE; KU; RESTRICTION; MAINTENANCE; DYSFUNCTION; IMMUNITY; LACKING	An adequate and appropriate response to physiological and pathophysiological stresses is critical for long-term homeostasis and viability of the aging organism. Previous work has pointed to the immune system, telomeres and DNA repair pathways as important and distinct determinants of a normal healthy lifespan. In this study, we explored the genetic interactions of telomeres and DNA-PKcs, a protein involved in non-homologous end-joining (NHEJ) and immune responses, in the context of a key aspect of aging and lifespan - the capacity to mount an acute and appropriate immune-mediated stress response. We observed that the combination of DNA-PKcs deficiency and telomere dysfunction resulted in a shortened lifespan that was reduced further following viral infection or experimental activation of the innate immune response. Analysis of the innate immune response in the DNA-PKcs-deficient mice with short dysfunctional telomeres revealed high basal serum levels of tumor necrosis factor alpha (TNF alpha) and hyper-active cytokine responses upon challenge with polyinosinic-polycytidylic acid (poly-IC). We further show that serum cytokine levels become elevated in telomere dysfunctional mice as a function of age. These results raise speculation that these genetic factors may contribute to misdirected immune responses of the aged under conditions of acute and chronic stress.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA; Harvard Univ, Sch Med, Dept Genet & Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA; Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01605 USA; Dana Farber Canc Inst, Ctr Appl Canc Sci, Boston, MA 02115 USA; Dana Farber Canc Inst, Belfer Fdn Inst Innovat Canc Sci, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Yale University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Yale University; Yale University; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute	DePinho, RA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St,M413, Boston, MA 02115 USA.	ron_depinho@dfci.harvard.edu	Bailey, Shannon/B-8045-2014; Maser, Richard/B-2970-2012	DePinho, Ronald/0000-0002-5625-577X	NATIONAL CANCER INSTITUTE [P01CA095616, R01CA034461, U01CA084313, R01CA084628] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG024004] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA84313, P01 CA95616, R01 CA84628, CA34461] Funding Source: Medline; NIA NIH HHS [K08 AG2400401] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Bruunsgaard H, 2003, AM J MED, V115, P278, DOI 10.1016/S0002-9343(03)00329-2; Bruunsgaard H, 2003, IMMUNOL ALLERGY CLIN, V23, P15, DOI 10.1016/S0889-8561(02)00056-5; Chu WM, 2000, CELL, V103, P909, DOI 10.1016/S0092-8674(00)00194-X; DAYNES RA, 1993, J IMMUNOL, V150, P5219; ERSHLER WB, 1993, LYMPHOKINE CYTOK RES, V12, P225; Espejel S, 2004, J CELL BIOL, V167, P627, DOI 10.1083/jcb.200407178; Espejel S, 2002, EMBO J, V21, P6275, DOI 10.1093/emboj/cdf593; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Hasty P, 2003, SCIENCE, V299, P1355, DOI 10.1126/science.1079161; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Karpova AY, 2002, P NATL ACAD SCI USA, V99, P2818, DOI 10.1073/pnas.052713899; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; Maser RS, 2004, DNA REPAIR, V3, P979, DOI 10.1016/j.dnarep.2004.05.009; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Salminen A, 1997, BIOCHEM BIOPH RES CO, V238, P712, DOI 10.1006/bbrc.1997.7371; Smogorzewska A, 2002, CURR BIOL, V12, P1635, DOI 10.1016/S0960-9822(02)01179-X; Um JH, 2003, MECH AGEING DEV, V124, P967, DOI 10.1016/S0047-6374(03)00169-6; WOLLSCHEIDLENGE.E, 2004, SCI AGING KNOWL ENV, pPE2; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Wong KK, 2003, NATURE, V421, P643, DOI 10.1038/nature01385	24	5	6	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2007	26	20					2815	2821		10.1038/sj.onc.1210099	http://dx.doi.org/10.1038/sj.onc.1210099			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17072335				2022-12-17	WOS:000246210800001
J	Bonavida, B				Bonavida, B.			Preface: antibody therapies for cancer - Introduction	ONCOGENE			English	Editorial Material							MONOCLONAL-ANTIBODIES; LYMPHOMA		Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Bonavida, B (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90024 USA.							BEHRING EK, 1890, DEUT MED WOCHENSCHR, V14, P1113; Booy EP, 2006, ARCH IMMUNOL THER EX, V54, P85, DOI 10.1007/s00005-006-0011-5; EDELMAN GM, 1968, BIOCHEMISTRY-US, V7, P1950, DOI 10.1021/bi00845a045; Ehrlich P., 1900, P R SOC            B, V66, P424, DOI DOI 10.1098/RSPL.1899.0121; KOHLER G, 1975, NATURE, V256, P497; MILLER RA, 1982, NEW ENGL J MED, V306, P517, DOI 10.1056/NEJM198203043060906; NADLER LM, 1980, CANCER RES, V40, P3147; PORTER RR, 1967, SCI AM, V217, P81, DOI 10.1038/scientificamerican1067-81; RITZ J, 1982, BLOOD, V59, P1; Stern M, 2005, CRIT REV ONCOL HEMAT, V54, P11, DOI 10.1016/j.critrevonc.2004.10.011	10	5	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2007	26	25					3592	3593		10.1038/sj.onc.1210369	http://dx.doi.org/10.1038/sj.onc.1210369			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530012				2022-12-17	WOS:000246816100001
J	Nieto, M; Barradas, M; Criado, LM; Flores, JM; Serrano, M; Llano, E				Nieto, M.; Barradas, M.; Criado, L. M.; Flores, J. M.; Serrano, M.; Llano, E.			Normal cellular senescence and cancer susceptibility in mice genetically deficient in Ras-induced senescence-1 (Ris1)	ONCOGENE			English	Article						Ris1; Ras; senescence; tumor suppression; mouse models	ONCOGENIC RAS; TUMOR SUPPRESSION; CARCINOGENESIS; IDENTIFICATION; TUMORIGENESIS; GENES; P53	Oncogenic Ras triggers a permanent cell-cycle arrest known as oncogene-induced senescence (OIS) that constitutes a relevant tumor suppressor mechanism. Ris1 (Ras-induced senescence-1) is a novel gene that was identified in a screen as specifically upregulated during Ras-induced senescence, and that is located at a chromosomal region, 3p21.3, frequently lost in human cancer. Moreover, Ris1 is highly conserved in vertebrates, does not present paralogs, and its sequence does not reveal similarities with other proteins or domains. To analyse the physiological function of Ris1 and test its putative role as a tumor suppressor gene, we have generated mutant mice deficient for this gene. Ris1-null mice are viable, fertile, develop normally and do not display any obvious abnormalities. Of relevance, Ris1-deficient mice had a normal lifespan and did not exhibit predisposition to spontaneous tumors or to tumors induced by chemical carcinogens. Finally, Ris1-deficient embryonic fibroblasts were indistinguishable from wild-type cells regarding their proliferation properties, immortalization, senescence and oncogenic transformation. These findings do not support a role of Ris1 in tumor suppression or in OIS.	Spanish Natl Canc Ctr, Dept Mol Oncol, CNIO, E-28029 Madrid, Spain; Spanish Natl Canc Ctr, Tumor Suppress Grp, CNIO, E-28029 Madrid, Spain; Univ Complutense, Sch Vet, Dept Anim Surg & Med, E-28040 Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Complutense University of Madrid	Serrano, M (corresponding author), Spanish Natl Canc Ctr, Dept Mol Oncol, CNIO, 3 Melchor Fernandez Almagro St, E-28029 Madrid, Spain.	mserrano@cnio.es	Llano, Elena/K-1723-2014; Serrano, Manuel/H-2634-2015; Llano, Elena/AAS-5517-2021	Llano, Elena/0000-0002-2626-5723; Serrano, Manuel/0000-0001-7177-9312; Llano, Elena/0000-0002-2626-5723				Barradas M, 2002, EXP CELL RES, V273, P127, DOI 10.1006/excr.2001.5434; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Hama T, 2001, J BIOL CHEM, V276, P31929, DOI 10.1074/jbc.M100617200; Imreh S, 2003, GENE CHROMOSOME CANC, V38, P307, DOI 10.1002/gcc.10271; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Palmero I, 2001, METHOD ENZYMOL, V333, P247; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Petursdottir TE, 2004, GENE CHROMOSOME CANC, V41, P232, DOI 10.1002/gcc.20072; Qin ZH, 2002, J EXP MED, V195, P1479, DOI 10.1084/jem.20011887; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Silva J, 2006, MUTAT RES-FUND MOL M, V594, P78, DOI 10.1016/j.mrfmmm.2005.07.017; van der Weyden L, 2005, MOL CELL BIOL, V25, P8356, DOI 10.1128/MCB.25.18.8356-8367.2005; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; Xiang RH, 2002, CANCER RES, V62, P2637	21	5	6	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1673	1680		10.1038/sj.onc.1209978	http://dx.doi.org/10.1038/sj.onc.1209978			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16964279				2022-12-17	WOS:000244955600001
J	Schmitz, I; Meyer, C; Schulze-Osthoff, K				Schmitz, I.; Meyer, C.; Schulze-Osthoff, K.			CD95 ligand mediates T-cell receptor-induced apoptosis of a CD4(+) CD8(+) double positive thymic lymphoma	ONCOGENE			English	Article						apoptosis; caspase; CD95; thymic lymphoma; thymus	NEGATIVE SELECTION; THYMOCYTE DEVELOPMENT; CASPASE INHIBITOR; C-FLIPSHORT; IN-VITRO; KAPPA-B; ACTIVATION; DEATH; MICE; GENES	Tumors in the thymus can be of different cellular origin. Among the most common tumors are thymoma and lymphoma, which are derived from transformed thymic epithelial cells and transformed lymphocytes, respectively. Thymic lymphoma and their response to apoptotic stimuli are poorly characterized. Here, we analyse apoptosis events in the thymic lymphoma cell line Thy278, which expresses cell surface antigens characteristic of immature double positive thymocytes. Upon T-cell receptor (TCR)/CD3 stimulation, Thy278 cells die by apoptosis, similar as primary thymocytes during negative selection. Caspases are crucial for deletion of both Thy278cells and normal thymocytes. Moreover, we show that deletion of primary thymocytes and Thy278 cells upon CD3 stimulation is considerably impaired by neutralizing CD95L antibody. Thus, our results not only demonstrate that TCR-induced apoptosis is still functional in transformed thymocytes, but also suggest that Thy278 cells are a helpful model for the molecular analysis of negative selection.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Schmitz, I (corresponding author), Univ Dusseldorf, Inst Mol Med, Univ Str 1,Bldg 23-12, D-40225 Dusseldorf, Germany.	ingo-schmitz@uni-duesseldorf.de	Schulze-Osthoff, Klaus/N-9025-2013; Schmitz, Ingo/G-2093-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Schmitz, Ingo/0000-0002-5360-0419				AISENBERG AC, 1993, J CLIN ONCOL, V11, P2291, DOI 10.1200/JCO.1993.11.12.2291; Alam A, 1997, J EXP MED, V186, P1503, DOI 10.1084/jem.186.9.1503; BERG LJ, 1988, MOL CELL BIOL, V8, P5459, DOI 10.1128/MCB.8.12.5459; BOEHM T, 1989, FASEB J, V3, P2344, DOI 10.1096/fasebj.3.12.2676678; Caserta TM, 2003, APOPTOSIS, V8, P345, DOI 10.1023/A:1024116916932; Castro JE, 1996, IMMUNITY, V5, P617, DOI 10.1016/S1074-7613(00)80275-7; CHAHINIAN AP, 2003, CANC MED, V2, P1467; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Clayton LK, 1997, EMBO J, V16, P2282, DOI 10.1093/emboj/16.9.2282; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; Doerfler P, 2000, J IMMUNOL, V164, P4071, DOI 10.4049/jimmunol.164.8.4071; Fernandez E, 2000, BLOOD, V95, P1356, DOI 10.1182/blood.V95.4.1356.004k23_1356_1361; Fischer U, 2005, PHARMACOL REV, V57, P187, DOI 10.1124/pr.57.2.6; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Geisler C, 2004, CRIT REV IMMUNOL, V24, P67; GROVES T, 1995, J IMMUNOL, V154, P5011; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Izquierdo M, 1999, EMBO J, V18, P156, DOI 10.1093/emboj/18.1.156; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; KAYE J, 1992, CELL, V71, P423, DOI 10.1016/0092-8674(92)90512-B; Kirchhoff S, 2000, EUR J IMMUNOL, V30, P2765, DOI 10.1002/1521-4141(200010)30:10<2765::AID-IMMU2765>3.0.CO;2-W; Kovalik JP, 1996, J IMMUNOL, V157, P5290; Legembre P, 2004, EMBO REP, V5, P1084, DOI 10.1038/sj.embor.7400280; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Maeda T, 1999, J EXP MED, V189, P1063, DOI 10.1084/jem.189.7.1063; Martin DA, 1999, P NATL ACAD SCI USA, V96, P4552, DOI 10.1073/pnas.96.8.4552; Matiba B, 1997, Semin Immunol, V9, P59, DOI 10.1006/smim.1996.0054; Moulian N, 1998, SEMIN IMMUNOL, V10, P449, DOI 10.1006/smim.1998.0155; Muschen M, 2002, TRENDS IMMUNOL, V23, P75, DOI 10.1016/S1471-4906(01)02115-9; NAMBA T, 1978, MEDICINE, V57, P411, DOI 10.1097/00005792-197809000-00002; Nishida T, 2004, J IMMUNOL, V172, P6634, DOI 10.4049/jimmunol.172.11.6634; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; RATHMELL JC, 2002, CELL S, V109, P97; Reichmann E, 2002, SEMIN CANCER BIOL, V12, P309, DOI 10.1016/S1044-579X(02)00017-2; ROSAI J, 1976, ATLAS TUMOR PATHOLOG; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sasada T, 2001, J IMMUNOL, V166, P2394, DOI 10.4049/jimmunol.166.4.2394; Schmitz I, 2004, J IMMUNOL, V172, P2194, DOI 10.4049/jimmunol.172.4.2194; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; SIDMAN CL, 1992, EUR J IMMUNOL, V22, P499, DOI 10.1002/eji.1830220231; Sohn D, 2006, MOL CELL BIOL, V26, P1967, DOI 10.1128/MCB.26.5.1967-1978.2006; Starr TK, 2003, ANNU REV IMMUNOL, V21, P139, DOI 10.1146/annurev.immunol.21.120601.141107; Venanzi ES, 2004, CURR OPIN IMMUNOL, V16, P197, DOI 10.1016/j.coi.2004.01.008; WADSWORTH S, 1990, EUR J IMMUNOL, V20, P723, DOI 10.1002/eji.1830200403; Yefenof E, 1999, ADV IMMUNOL, V73, P511, DOI 10.1016/S0065-2776(08)60792-0	49	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2006	25	58					7587	7596		10.1038/sj.onc.1209741	http://dx.doi.org/10.1038/sj.onc.1209741			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	16767155				2022-12-17	WOS:000242655500004
J	Zhang, L; D'Costa, J; Kummalue, T; Civin, CI; Friedman, AD				Zhang, L.; D'Costa, J.; Kummalue, T.; Civin, C. I.; Friedman, A. D.			Identification of a region on the outer surface of the CBF beta-SMMHC myeloid oncoprotein assembly competence domain critical for multimerization	ONCOGENE			English	Article						CBF beta-SMMHC; myosin; ACD; proliferation; RUNX1	MYOSIN HEAVY-CHAIN; COILED-COIL ROD; CELL-CYCLE; TRANSCRIPTION FACTOR; GENE CBFB-MYH11; FUSION GENE; LEUKEMIA; BINDING; PROLIFERATION; HEMATOPOIESIS	In the core binding factor (CBF) beta-smooth muscle myosin heavy chain (SMMHC) acute myeloid leukemia (AML) oncoprotein, CBF beta lies N-terminal to the alpha-helical rod domain of SMMHC. Deletion of the SMMHC assembly competence domain (ACD), conserved among skeletal, smooth and nonmuscle myosins, prevents multimerization, inhibition of CBF and inhibition of cell proliferation. To de. ne the amino acids critical for ACD function, three outer surface residues of ACD helices A-D, the subsequent helices E-H or the more N-terminal X or Z helices were now mutated. Variants were assessed for multimerization in low ionic strength in vitro and for nuclear localization as a measure of in vivo multimerization. Mutation of individual helices C-H reduced multimerization, with alteration of the outer surface of helices D or E having the greatest effect. The ability of these SMMHC variants to slow murine myeloid progenitor proliferation largely paralleled their effects on multimerization. Divergence at the boundaries of the ACD may reflect quantitative differences between in vitro and in vivo filament assembly. Each helix mutant retained the ability to bind the mSin3A corepressor. Agents interacting with the outer surface of the CBF beta-SMMHC ACD that prevent multimerization may be effective as novel therapeutics in AML.	Johns Hopkins Univ, Div Pediat Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Div Immunol & Hematopoiesis, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins University	Friedman, AD (corresponding author), Johns Hopkins Univ, Div Pediat Oncol, Canc Res Bldg,Room 253,1650 Orleans St, Baltimore, MD 21231 USA.	afriedm2@jhmi.edu			NATIONAL CANCER INSTITUTE [R01CA098805] Funding Source: NIH RePORTER; NCI NIH HHS [CA070970, CA098805] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATKINSON SJ, 1991, J CELL SCI, V99, P823; Bernardin F, 2002, ONCOGENE, V21, P3247, DOI 10.1038/sj.onc.1205447; Bernardin-Fried F, 2004, J BIOL CHEM, V279, P15678, DOI 10.1074/jbc.M310023200; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Cao WS, 1998, J BIOL CHEM, V273, P31534, DOI 10.1074/jbc.273.47.31534; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Cohen C, 1998, J STRUCT BIOL, V122, P180, DOI 10.1006/jsbi.1998.3983; D'Costa J, 2005, LEUKEMIA, V19, P921, DOI 10.1038/sj.leu.2403755; Durst KL, 2003, MOL CELL BIOL, V23, P607, DOI 10.1128/MCB.23.2.607-619.2003; FINER MH, 1994, BLOOD, V83, P43; Friedman AD, 1999, LEUKEMIA, V13, P1932, DOI 10.1038/sj.leu.2401590; Hoppe PE, 1996, J CELL BIOL, V135, P371, DOI 10.1083/jcb.135.2.371; Kummalue T, 2002, MOL CELL BIOL, V22, P8278, DOI 10.1128/MCB.22.23.8278-8291.2002; Landrette SF, 2005, BLOOD, V105, P2900, DOI 10.1182/blood-2004-09-3630; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Liu PP, 1996, GENE CHROMOSOME CANC, V16, P77, DOI 10.1002/(SICI)1098-2264(199606)16:2<77::AID-GCC1>3.0.CO;2-#; Lou JR, 2000, ONCOGENE, V19, P2695, DOI 10.1038/sj.onc.1203588; Moreno-Miralles I, 2005, J BIOL CHEM, V280, P40097, DOI 10.1074/jbc.M506855200; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nakasawa T, 2005, BIOCHEMISTRY-US, V44, P174, DOI 10.1021/bi048807h; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Sohn RL, 1997, J MOL BIOL, V266, P317, DOI 10.1006/jmbi.1996.0790; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Yang YD, 2002, CANCER RES, V62, P2232; Yoshida N, 2005, MOL CELL BIOL, V25, P1003, DOI 10.1128/MCB.25.3.1003-1012.2005	29	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	55					7289	7296		10.1038/sj.onc.1209725	http://dx.doi.org/10.1038/sj.onc.1209725			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16767164				2022-12-17	WOS:000242244700007
J	Sasaki, M; Sugimoto, K; Tamayose, K; Ando, M; Tanaka, Y; Oshimi, K				Sasaki, M.; Sugimoto, K.; Tamayose, K.; Ando, M.; Tanaka, Y.; Oshimi, K.			Spindle checkpoint protein Bub1 corrects mitotic aberrancy induced by human T-cell leukemia virus type I Tax	ONCOGENE			English	Article						spindle checkpoint; chromosomal instability; Bub1; Tax; mitotic lobulation	MUTATION ANALYSIS; CANCER; GENE; LYMPHOMA; HBUB1; TRANSFORMATION; LOCALIZATION; ONCOPROTEIN; MICRONUCLEI; EXPRESSION	Bub1 is a component of the mitotic spindle checkpoint apparatus. Abnormality of this apparatus is known to cause multinuclei formation, a hallmark of chromosomal instability ( CIN). A549, aneuploid cell line, aberrantly passed through the mitotic phase and became multinuclei morphology in the presence of nocodazole. Time-lapse videomicroscopy showed unreported bizarre morphology, which we named 'mitotic lobulation' in A549 cells just before the exit from mitosis and multinuclei formation. External expression of wild-type Bub1-EGFP clearly suppressed the multinuclei formation by retaining A549 cells at the mitotic phase during 48 h of time-lapse observation. This suppressive effect on mitotic aberrancy should not be mere restoration of normal Bub1 function, because A549 cells express proper amount of Bub1, which distributed cytoplasm during interphase and concentrated at kinetochore in metaphase. Furthermore, external expression of wild-type Bub1-EGFP suppressed multinuclei formation induced by Tax both in A549 and HeLa cells. Tax is known to induce mitotic abnormality by binding and inactivating Mad1. These observations, therefore, suggest functional redundancy between Bub1 and other mitotic checkpoint protein( s) and a possibility of correction of mitotic aberrancy by external Bub1 expression.	Juntendo Univ, Sch Med, Dept Internal Med, Div Hematol,Bunkyo Ku, Tokyo 1138421, Japan; Univ Ryukyus, Grad Sch Med, Dept Immunol, Nishihara, Okinawa, Japan	Juntendo University; University of the Ryukyus	Sugimoto, K (corresponding author), Juntendo Univ, Sch Med, Dept Internal Med, Div Hematol,Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	ksugimot@med.juntendo.ac.jp	Pillay, Nischalan/F-9536-2012					Bahar R, 2002, J BIOL CHEM, V277, P40012, DOI 10.1074/jbc.M205345200; Burton M, 2000, J VIROL, V74, P2351, DOI 10.1128/JVI.74.5.2351-2364.2000; Cahill DP, 1999, GENOMICS, V58, P181, DOI 10.1006/geno.1999.5831; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen JG, 2002, CANCER RES, V62, P1935; Hempen PM, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9120; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Isaka T, 2003, J HISTOCHEM CYTOCHEM, V51, P1343, DOI 10.1177/002215540305101011; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; KAMADA N, 1992, CANCER RES, V52, P1481; KIKUCHI M, 1986, HEMATOL ONCOL, V4, P67, DOI 10.1002/hon.2900040109; Knecht H, 1996, ONCOGENE, V13, P947; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Ohshima K, 2000, CANCER LETT, V158, P141, DOI 10.1016/S0304-3835(00)00512-7; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Ru HY, 2002, ONCOGENE, V21, P4673, DOI 10.1038/sj.onc.1205585; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; Shimura M, 1999, FASEB J, V13, P621, DOI 10.1096/fasebj.13.6.621; TAGUCHI H, 1993, CANCER, V71, P133, DOI 10.1002/1097-0142(19930101)71:1<133::AID-CNCR2820710121>3.0.CO;2-G; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TANAKA Y, 1990, JPN J CANCER RES, V81, P225, DOI 10.1111/j.1349-7006.1990.tb02554.x; Tashiro S, 1996, ONCOGENE, V12, P2165; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; Yamaguchi K, 1999, CANCER LETT, V139, P183, DOI 10.1016/S0304-3835(99)00035-X; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4	33	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3621	3627		10.1038/sj.onc.1209404	http://dx.doi.org/10.1038/sj.onc.1209404			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16449967				2022-12-17	WOS:000238448300001
J	Isachenko, N; Dyakova, N; Aushev, V; Chepurnych, T; Gurova, K; Tatosyan, A				Isachenko, N; Dyakova, N; Aushev, V; Chepurnych, T; Gurova, K; Tatosyan, A			High expression of shMDG1 gene is associated with low metastatic potential of tumor cells	ONCOGENE			English	Article						shMDG1; metastasis; v-src transformation; chaperones; glycosylation	ROUS-SARCOMA VIRUS; IN-VITRO; CHROMOSOME; CANCER; OLIGOSACCHARIDES; DIFFERENTIATION; IDENTIFICATION; GLYCOPEPTIDES; STRESS; MDG1	Metastasis is the primary cause of mortality associated with cancer. Molecular mechanisms leading to metastatic spread are poorly studied. To get a better understanding of this process, we compared the gene expression pattern of two isogenic cell lines, HET-SR and HET-SR1 (Rous Sarcoma Virus-transformed embryo hamster fibroblasts) with different metastatic activity using the differential display technique. A novel cDNA of hamster gene shMDG1 (Syrian hamster homologue of microvascular differentiation gene 1), which had 94% homology with rat MDG1 gene, was identified. Expression of shMDG1 was increased in low metastatic HET-SR cell line in comparison to high metastatic HET-SR1. Sequence analysis of the ORF of shMDG1 gene showed that it belongs to the DnaJ/heat-shock proteins of 40 kDa (HSP40) chaperones family, considered to function as a cochaperone of HSP70 family. In order to confirm involvement of shMDG1 in metastasis, we injected parental and shMDG1 overexpressed cells into animals. We showed that overexpression of the shMDG1 gene significantly diminished the metastatic activity of both HET-SR and HET-SR1 cells. The shMDG1-induced repression of metastasis was not connected with alterations in cell proliferation and motility in vitro, but correlated well with a decrease in content of the Asn-linked beta 1-6 branched oligosaccharides on cell surface.	Canc Res Ctr, Inst Carcinogenesis, Viral & Cellular Oncogenes Lab, Moscow 115478, Russia; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Genet, Cleveland, OH USA	Cleveland Clinic Foundation	Isachenko, N (corresponding author), Canc Res Ctr, Inst Carcinogenesis, Viral & Cellular Oncogenes Lab, Kashirskoye Sh 24, Moscow 115478, Russia.	isachenko@crc.umos.ru	Aushev, Vasily N./A-7209-2008	Aushev, Vasily N./0000-0001-8003-358X				Blomer U, 1997, J VIROL, V71, P6641; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; CHEPURNYKH TV, 2000, CELL MOL BIOL, V34, P907; DEICHMAN GI, 1989, INT J CANCER, V44, P908, DOI 10.1002/ijc.2910440527; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; Dichamp C, 2004, J NEURO-ONCOL, V67, P281, DOI 10.1023/B:NEON.0000024218.68120.8d; GU JG, 1993, J BIOCHEM, V113, P614, DOI 10.1093/oxfordjournals.jbchem.a124091; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MORIMOTO RI, 1991, CANCER CELL-MON REV, V3, P295; NICOLSON G L, 1991, Current Opinion in Oncology, V3, P75, DOI 10.1097/00001622-199102000-00012; Ohtsuka K, 2000, INT J HYPERTHER, V16, P231, DOI 10.1080/026567300285259; OSAWA T, 1987, ANNU REV BIOCHEM, V56, P21, DOI 10.1146/annurev.biochem.56.1.21; PIERCE M, 1986, J BIOL CHEM, V261, P772; Prols F, 2001, EXP CELL RES, V269, P42, DOI 10.1006/excr.2001.5294; Prols F, 1997, CYTOGENET CELL GENET, V79, P149, DOI 10.1159/000134706; Shen Y, 2002, J BIOL CHEM, V277, P15947, DOI 10.1074/jbc.M112214200; Tatosyan A, 1996, VIROLOGY, V216, P347, DOI 10.1006/viro.1996.0070; Thorstensen L, 2001, SCAND J GASTROENTERO, V36, P1327; Welch WJ, 1990, STRESS PROTEINS BIOL, P223; YOCHEM J, 1978, MOL GEN GENET, V4, P9	22	5	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2006	25	2					317	322		10.1038/sj.onc.1209022	http://dx.doi.org/10.1038/sj.onc.1209022			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16205647				2022-12-17	WOS:000234583600017
J	Gespach, C				Gespach, C			Crosstalk between the cell cycle regulator Cdk2 and the Cdx2 tumor suppressor at the proliferation-differentiation interface	ONCOGENE			English	Editorial Material									Univ Paris 06, INSERM U673, Hop St Antoine, F-75571 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Gespach, C (corresponding author), Univ Paris 06, INSERM U673, Hop St Antoine, 12 Rue Cuvier, F-75571 Paris, France.	christian.gespach@st-antoine.inserm.fr						Boulanger J, 2005, J BIOL CHEM, V280, P18095, DOI 10.1074/jbc.M502184200; GROSS I, 2005, ONCOGENE        0718; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659	4	5	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 1	2005	24	54					7953	7954		10.1038/sj.onc.1209084	http://dx.doi.org/10.1038/sj.onc.1209084			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16170344				2022-12-17	WOS:000233656600001
J	Zhang, LL; Shimizu, S; Tsujimoto, Y				Zhang, LL; Shimizu, S; Tsujimoto, Y			Two distinct Fas-activated signaling pathways revealed by an antitumor drug D609	ONCOGENE			English	Article						apoptosis; Bak; Bax; mitochondria; Fas	CYTOCHROME-C RELEASE; OUTER MITOCHONDRIAL-MEMBRANE; NECROSIS-FACTOR RECEPTOR; PHOSPHOLIPASE-C; CELL-DEATH; ACIDIC SPHINGOMYELINASE; CONFORMATIONAL-CHANGE; KINASE ACTIVATION; APOPTOSIS; BAX	During the process of death receptor-mediated apoptosis, Bid is cleaved by activated caspase-8, and then cleaved Bid conveys apoptotic signals to the mitochondria by activating Bax/Bak. In the present study, we found that D609 (an antitumor drug with multiple activities) blocks Fas-induced apoptosis. D609 did not interfere with activation of caspase-8 and cleavage of Bid, whereas it blocked cytochrome c release from the mitochondria by inhibiting the activation of Bax and Bak. D609 had no protective effect against apoptosis of SKW6.4 cells, which are typical type I cells. Studies using permeabilized cells revealed that in addition to activation of caspase-8, Fas activated a distinct and D609-sensitive signaling pathway that transmitted signal(s) sensitizing the mitochondria to apoptotic stimuli, and that D609 itself promoted mitochondrial resistance to apoptotic stimuli.	Osaka Univ, Sch Med, Dept Postgenom & Dis,Lab Mol Genet, Japan Sci & Technol Corp,SORST, Suita, Osaka 5650871, Japan	Japan Science & Technology Agency (JST); Osaka University	Tsujimoto, Y (corresponding author), Osaka Univ, Sch Med, Dept Postgenom & Dis,Lab Mol Genet, Japan Sci & Technol Corp,SORST, Rm B8,2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	tsujimot@gene.med.osaka-u.ac.jp						AMTMANN E, 1987, CANCER LETT, V35, P237, DOI 10.1016/0304-3835(87)90125-X; Amtmann E, 1996, DRUG EXP CLIN RES, V22, P287; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Boesen-de Cock JGR, 1999, J BIOL CHEM, V274, P14255, DOI 10.1074/jbc.274.20.14255; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Desbarats J, 2003, NAT CELL BIOL, V5, P118, DOI 10.1038/ncb916; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; Epand RF, 2002, J BIOL CHEM, V277, P32632, DOI 10.1074/jbc.M202396200; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lambert C, 2003, APOPTOSIS, V8, P551, DOI 10.1023/A:1026113222478; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li YH, 1998, P NATL ACAD SCI USA, V95, P7748, DOI 10.1073/pnas.95.13.7748; Lin T, 2000, J BIOL CHEM, V275, P8657, DOI 10.1074/jbc.275.12.8657; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Machleidt T, 1996, J EXP MED, V184, P725, DOI 10.1084/jem.184.2.725; Matsko CM, 2001, BIOCHEM BIOPH RES CO, V287, P1112, DOI 10.1006/bbrc.2001.5696; Nomura M, 1999, CANCER RES, V59, P5542; Paris F, 2001, J BIOL CHEM, V276, P8297, DOI 10.1074/jbc.M008732200; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Shinohara H, 2000, CANCER RES, V60, P1766; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zhang LL, 2004, J BIOL CHEM, V279, P33865, DOI 10.1074/jbc.M403499200; Zhou DH, 2001, J PHARMACOL EXP THER, V298, P103	43	5	8	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					2954	2962		10.1038/sj.onc.1208388	http://dx.doi.org/10.1038/sj.onc.1208388			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15846303				2022-12-17	WOS:000228649500004
J	Pedigo, NG; Zhang, HX; Bruno, MEC; Kaetzel, CS; Dugan, AR; Shanehsaz, P; Hennigan, RF; Xing, ZL; Koszewski, NJ; Kaetzel, DM				Pedigo, NG; Zhang, HX; Bruno, MEC; Kaetzel, CS; Dugan, AR; Shanehsaz, P; Hennigan, RF; Xing, ZL; Koszewski, NJ; Kaetzel, DM			A 5 '-distal enhanceosome in the PDGF-A gene is activated in choriocarcinoma cells via ligand-independent binding of vitamin D receptor and constitutive jun kinase signaling	ONCOGENE			English	Article						platelet-derived growth factor; transcription; enhancer; vitamin D receptor; jun kinase; enhanceosome	GROWTH-FACTOR; CHAIN GENE; DNA-BINDING; C-JUN; TRANSCRIPTION; PROMOTER; EXPRESSION; INDUCTION; PROTEIN; REQUIRES	Overexpression of platelet-derived growth factor A-chain ( PDGF-A) is clearly linked to autocrine and paracrine stimulation of malignant growth in many human cancers. We have shown previously that PDGF-A overexpression in choriocarcinoma, hepatoma and lung carcinoma cell lines is driven by the activity of a 66 bp enhancer element (ACE66) located approximately 7kb upstream of the PDGF-A transcription start site. In this study, the ACE66 element is shown to be activated in JEG-3 choriocarcinoma cells through synergistic interactions between consensus DNA motifs for binding of vitamin D receptor, AP1 and ELK1. Binding of the vitamin D/retinoid-X receptor (VDR/RXR alpha) heterodimer to the ACE66 element was reconstituted in vitro with recombinant VDR/RXR alpha and with JEG-3 nuclear extract, and was verified in living JEG-3 cells by chromatin immunoprecipitation analysis. Transcriptional activity of the ACE66 element, as well as occupancy of the element by VDR/RXRa, was shown to be independent of stimulation with the hormonal VDR ligand, 1,25-dihydroxyvitamin D-3. The jun kinase pathway of mitogen-activated protein kinase (MAPK) signaling was shown to activate the ACE66 enhancer, most likely through activation of factors binding to the AP1 element. These results identify a novel mechanism of transcriptional enhancement involving ligand-independent activity of the VDR/RXR heterodimer and MAPK signaling pathways that appears to play an important role in the overexpression of PDGF in many different settings of human malignancy.	Univ Kentucky, Coll Med, Chandler Med Ctr, Dept Mol & Biomed Pharmacol, Lexington, KY 40536 USA; Univ Kentucky, Coll Med, Dept Microbiol Mol Genet & Immunol, Lexington, KY 40536 USA; Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA; Univ Kentucky, Coll Med, Dept Internal Med, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University System of Ohio; University of Cincinnati; University of Kentucky	Kaetzel, DM (corresponding author), Univ Kentucky, Coll Med, Chandler Med Ctr, Dept Mol & Biomed Pharmacol, MS-305, Lexington, KY 40536 USA.	dmkaetz@uky.edu		Kaetzel, Charlotte/0000-0001-7546-0085	NATIONAL CANCER INSTITUTE [R01CA083237] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062877] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045518] Funding Source: NIH RePORTER; NCI NIH HHS [CA83237] Funding Source: Medline; NHLBI NIH HHS [HL62877] Funding Source: Medline; NIDDK NIH HHS [DK45518] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BHANDARI B, 1995, J BIOL CHEM, V270, P5541, DOI 10.1074/jbc.270.10.5541; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; Brown AJ, 1999, AM J PHYSIOL-RENAL, V277, pF157, DOI 10.1152/ajprenal.1999.277.2.F157; BROWN PH, 1993, ONCOGENE, V8, P877; BUNING H, 1995, NUCLEIC ACIDS RES, V23, P1443, DOI 10.1093/nar/23.8.1443; Day FL, 1999, J BIOL CHEM, V274, P23726, DOI 10.1074/jbc.274.34.23726; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; Hakim I, 2003, J CELL BIOCHEM, V88, P986, DOI 10.1002/jcb.10453; Hart LL, 2002, BIOCHEM CELL BIOL, V80, P335, DOI 10.1139/O02-038; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Hennigan RF, 2001, MOL BIOL CELL, V12, P2352, DOI 10.1091/mbc.12.8.2352; Kaetzel DM, 2003, CYTOKINE GROWTH F R, V14, P427, DOI 10.1016/S1359-6101(03)00051-0; KAETZEL DM, 1994, BIOCHEM J, V301, P321, DOI 10.1042/bj3010321; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; Khachigian LM, 1999, CIRC RES, V84, P1258, DOI 10.1161/01.RES.84.11.1258; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1997, CIRC RES, V81, P457, DOI 10.1161/01.RES.81.4.457; Koszewski NJ, 1998, ARCH BIOCHEM BIOPHYS, V349, P388, DOI 10.1006/abbi.1997.0481; Koszewski NJ, 1996, J STEROID BIOCHEM, V59, P377, DOI 10.1016/S0960-0760(96)00127-6; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Lemon BD, 1999, CURR OPIN GENET DEV, V9, P499, DOI 10.1016/S0959-437X(99)00010-6; LIN XH, 1992, J BIOL CHEM, V267, P25614; Liu SM, 1996, MOL ENDOCRINOL, V10, P206, DOI 10.1210/me.10.2.206; Ma DQ, 2002, J BIOL CHEM, V277, P1560, DOI 10.1074/jbc.M108359200; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Maul RS, 1998, J BIOL CHEM, V273, P33239, DOI 10.1074/jbc.273.50.33239; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; MULKINS MA, 1983, J BIOL CHEM, V258, P6219; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Pedigo N, 2003, GROWTH FACTORS, V21, P151, DOI 10.1080/08977190310001636595; Pietras K, 2003, CANCER CELL, V3, P439, DOI 10.1016/S1535-6108(03)00089-8; PIKE JW, 1980, LIFE SCI, V26, P407, DOI 10.1016/0024-3205(80)90158-7; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rafty LA, 2002, EMBO J, V21, P334, DOI 10.1093/emboj/21.3.334; Silverman ES, 1999, AM J PATHOL, V155, P1311, DOI 10.1016/S0002-9440(10)65233-9; Silverman ES, 1997, AM J PHYSIOL-HEART C, V273, pH1415, DOI 10.1152/ajpheart.1997.273.3.H1415; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMITH CL, 1991, MOL ENDOCRINOL, V5, P867, DOI 10.1210/mend-5-6-867; Sun TJ, 1998, ENDOCRINOLOGY, V139, P1684, DOI 10.1210/en.139.4.1684; Tanamura A, 1995, J Obstet Gynaecol (Tokyo 1995), V21, P631; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Tolon RM, 2000, MOL CELL BIOL, V20, P8793, DOI 10.1128/MCB.20.23.8793-8802.2000; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WANG ZY, 1992, J BIOL CHEM, V267, P21999; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5	53	5	5	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2654	2666		10.1038/sj.onc.1208336	http://dx.doi.org/10.1038/sj.onc.1208336			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15829977				2022-12-17	WOS:000228356700007
J	Andrique, T; Ayrault, O; Larsen, CJ; Seite, P				Andrique, T; Ayrault, O; Larsen, CJ; Seite, P			In vitro and in vivo analysis of the interaction between 5.8S rRNA and ARF protein reveal a new difference between murine p19(ARF) and human p14(ARF)	ONCOGENE			English	Article						p14(ARF); p19(ARF); 5.8s; chip-RNA	TUMOR-SUPPRESSOR; B23	Both human and murine ARF proteins have been recently reported to impair rRNA maturation and ribosomes biogenesis through a p53-independent pathway. A specific interaction has been established between 5.8S rRNA and the murine p19(ARF) specie. We report here, by use of both in vitro and ChIP-RNA assays, the absence of any interaction between the human p14(ARF) and the homologous 5.8S rRNA. Our data are not consistent with the involvement of a 5.8S-p14(ARF) complex in ribosome biogenesis in man. Rather they suggest that the human protein does not require such an interaction to achieve a similar function. This result is a new argument in favour of functional differences between human and murine ARF proteins.	Oncol Mol Lab, EA 3805, Pole Biol Sante, F-86022 Poitiers, France	Universite de Poitiers	Seite, P (corresponding author), Oncol Mol Lab, EA 3805, Pole Biol Sante, 40 Ave Recteur Pineau, F-86022 Poitiers, France.	paule.seite@univ-poitiers.fr		Seite, Paule/0000-0002-7809-7610; Andrique, Laetitia/0000-0001-7840-8135				Ayrault O, 2004, ONCOGENE, V23, P8097, DOI 10.1038/sj.onc.1207968; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; Olivier A, 2003, ONCOGENE, V22, P1945, DOI 10.1038/sj.onc.1206214; QUELLE DE, 1995, CELL, V83, P993; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Wadhwa R, 2002, J BIOL CHEM, V277, P36665, DOI 10.1074/jbc.M203222200; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300	16	5	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2580	2584		10.1038/sj/onc.1208457	http://dx.doi.org/10.1038/sj/onc.1208457			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735732				2022-12-17	WOS:000228180600016
J	Kucharczak, J; Simmons, MJ; Fan, YJ; Gelinas, C				Kucharczak, J; Simmons, MJ; Fan, YJ; Gelinas, C			To be, or not to be: NF-kappa B is the answer - role of Rel/NF-kappa B in the regulation of apoptosis	ONCOGENE			English	Correction																		Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230	1	5	6	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	2004	23	54					8858	8858		10.1038/sj.onc.1207744	http://dx.doi.org/10.1038/sj.onc.1207744			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ		Bronze			2022-12-17	WOS:000225165100019
J	Shi, SL; Noda, M; Kitayama, H				Shi, SL; Noda, M; Kitayama, H			Rap1 mutants with increased affinity for the guanine-nucleotide exchange factor C3G	ONCOGENE			English	Article						Rap1; C3G; dominant inhibitory mutant; random mutagenesis	SIGNAL-TRANSDUCTION; MAP KINASE; RAS; PROTEIN; ACTIVATION; GENE; GTPASE; CRK; ASSOCIATION; ADHESION	The mutant of Ras protein with serine to asparagine mutation at residue 17 (Ras-17N) is known to interfere with the signaling function of the wild-type Ras protein by sequestering its guanine-nucleotide exchange factors ( GEFs). The similar mutant of another Ras family protein Rap1 (Rap1-17N) fails to effectively interfere with the interaction between the wild-type Rap1 and one of its GEFs, C3G, in vitro. In the present study, we have attempted to isolate Rap1 mutants with increased affinity for C3G using random mutagenesis and yeast two-hybrid screening. Based on the pattern of mutations found among these mutants, we could design a potent C3G-binder, named Rap1-AGE, harboring mutations in three sites (17A, 29G, and 117E). The association of Rap1-AGE with C3G in the cells was confirmed by co-immunoprecipitation experiments. The ability of Rap1-AGE to inhibit C3G-mediated Rap1-activation and cell spreading was also demonstrated. On the other hand, Rap1 activation mediated by two other GEFs, Epac and smgGDS, was not inhibited by Rap1-AGE. These results suggest that Rap1-AGE acts as a dominant interfering factor against C3G and serves as a useful tool in analyzing the roles of C3G-Rap1 signaling pathway in various biological processes.	Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Kitayama, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	hkitayam@virus.kyoto-u.ac.jp						BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; CHEN SY, 1994, ONCOGENE, V9, P2691; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Imamura Y, 2004, NEUROSCIENCE, V127, P973, DOI 10.1016/j.neuroscience.2004.05.051; Imamura Y, 2003, NEUROREPORT, V14, P1203, DOI 10.1097/00001756-200307010-00003; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kinbara K, 2003, NAT REV MOL CELL BIO, V4, P767, DOI 10.1038/nrm1229; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Serebriiskii I, 1997, ONCOGENE, V15, P1043, DOI 10.1038/sj.onc.1201268; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Stork PJS, 2003, TRENDS BIOCHEM SCI, V28, P267, DOI 10.1016/S0968-0004(03)00087-2; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; van den Berghe N, 1999, J BIOL CHEM, V274, P11078, DOI 10.1074/jbc.274.16.11078; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Voss AK, 2003, DEVELOPMENT, V130, P355, DOI 10.1242/dev.00217; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	48	5	5	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8711	8719		10.1038/sj.onc.1208132	http://dx.doi.org/10.1038/sj.onc.1208132			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15480424	Green Submitted			2022-12-17	WOS:000225165100001
J	Downward, J				Downward, J			RNA interference-based functional genomics in cancer research - an introduction	ONCOGENE			English	Editorial Material									Canc Res UK London Res Inst, London WC2A 3PX, England	Cancer Research UK	Downward, J (corresponding author), Canc Res UK London Res Inst, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729				Baum B, 2004, ONCOGENE, V23, P8336, DOI 10.1038/sj.onc.1208009; Dasgupta R, 2004, ONCOGENE, V23, P8359, DOI 10.1038/sj.onc.1208028; Downward J, 2004, ONCOGENE, V23, P8376, DOI 10.1038/sj.onc.1208073; Fraser A, 2004, ONCOGENE, V23, P8346, DOI 10.1038/sj.onc.1208044; Poulin G, 2004, ONCOGENE, V23, P8340, DOI 10.1038/sj.onc.1208010; Sachse C, 2004, ONCOGENE, V23, P8384, DOI 10.1038/sj.onc.1208072; Silva J, 2004, ONCOGENE, V23, P8401, DOI 10.1038/sj.onc.1208176; van Haaften G, 2004, ONCOGENE, V23, P8366, DOI 10.1038/sj.onc.1208011; Vanhecke D, 2004, ONCOGENE, V23, P8353, DOI 10.1038/sj.onc.1208027; Willingham AT, 2004, ONCOGENE, V23, P8392, DOI 10.1038/sj.onc.1208217	10	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2004	23	51					8334	8335		10.1038/sj.onc.1208121	http://dx.doi.org/10.1038/sj.onc.1208121			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867BA	15517012				2022-12-17	WOS:000224815900001
J	Wodarz, D				Wodarz, D			Checkpoint genes, ageing, and the development of cancer	ONCOGENE			English	Article						mathematical; computational; p53	STROMAL CELLS; TUMOR-GROWTH; P53; APOPTOSIS; PROGRESSION; SENESCENCE; DEATH; LIFE; MICE	Mathematical models are used to examine the relationship between checkpoint competence, ageing, and the development of cancer. The models take into account the dynamics of healthy tissue, the dynamics of initial tumor growth, and the interactions between healthy tissue and tumor cells. Two types of behavior are found. (i) A reduction of checkpoint competence results in reduced ageing of tissue, but in faster development and progression of tumors. (ii) Reduced checkpoint competence results both in reduced ageing of tissue, and in a reduced incidence of tumors. The tumors which do become established, however, are predicted to progress at an accelerated rate. The models define the conditions under which this counter-intuitive finding is observed. One reason could be the relationship between checkpoint activity and the ability of the tissue environment to exert inhibitory effects on tumor cells. Checkpoints induce senescence in tissue cells, and this compromises their ability to suppress tumor growth. Reduced checkpoint competence leads to reduced tissue senescence, and this results in higher amounts of tumor inhibition. The theoretical work is discussed with respect to data from p53 mutant mice, which show both types of relationships suggested by the models. The models help to identify differences in the experimental protocols which could explain the seemingly contradictory observations.	Univ Calif Irvine, Dept Ecol & Evolut, Irvine, CA 92697 USA; Inst Adv Study, Princeton, NJ 08540 USA	University of California System; University of California Irvine; Institute for Advanced Study - USA	Wodarz, D (corresponding author), Univ Calif Irvine, Dept Ecol & Evolut, Steinhaus Hall, Irvine, CA 92697 USA.	dwodarz@uci.edu						Bayko L, 1998, Angiogenesis, V2, P203, DOI 10.1023/A:1009275307663; Blagosklonny MV, 2002, INT J CANCER, V98, P161, DOI 10.1002/ijc.10158; Campisi J, 2003, NAT REV CANCER, V3, P339, DOI 10.1038/nrc1073; Campisi Judith, 2001, ScientificWorldJournal, V1, P65, DOI 10.1100/tsw.2001.106; Camplejohn RS, 2003, BRIT J CANCER, V88, P487, DOI 10.1038/sj.bjc.6600767; Chavez-Reyes A, 2003, CANCER RES, V63, P8664; Cunha GR, 2002, DIFFERENTIATION, V70, P469, DOI 10.1046/j.1432-0436.2002.700901.x; Donehower LA, 2002, J CELL PHYSIOL, V192, P23, DOI 10.1002/jcp.10104; Evans SC, 1997, MOL MED TODAY, V3, P390, DOI 10.1016/S1357-4310(97)01105-2; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Folkman J, 2004, NATURE, V427, P787, DOI 10.1038/427787a; Gilhar A, 2004, BRIT J DERMATOL, V150, P56, DOI 10.1111/j.1365-2133.2004.05715.x; Guba M, 2001, CANCER RES, V61, P5575; Hahnfeldt P, 1999, CANCER RES, V59, P4770; Hasty P, 2003, SCIENCE, V299, P1355, DOI 10.1126/science.1079161; Hsu MY, 2002, DIFFERENTIATION, V70, P522, DOI 10.1046/j.1432-0436.2002.700906.x; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; Jansen-Durr Pidder, 2002, TheScientificWorldJOURNAL, V2, P943; Kahlem P, 2004, J CLIN INVEST, V113, P169, DOI 10.1172/JCI200420784; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Kirkwood TBL, 2002, BIOESSAYS, V24, P577, DOI 10.1002/bies.10111; Komarova NL, 2003, CANCER RES, V63, P6635; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Mueller MM, 2002, DIFFERENTIATION, V70, P486, DOI 10.1046/j.1432-0436.2002.700903.x; Offer H, 2002, CARCINOGENESIS, V23, P1025, DOI 10.1093/carcin/23.6.1025; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Tlsty TD, 2001, SEMIN CANCER BIOL, V11, P97, DOI 10.1006/scbi.2000.0361; Tlsty TD, 2001, CURR OPIN GENET DEV, V11, P54, DOI 10.1016/S0959-437X(00)00156-8; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675	34	5	5	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7799	7809		10.1038/sj.onc.1207833	http://dx.doi.org/10.1038/sj.onc.1207833			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15361848				2022-12-17	WOS:000224331600006
J	Sandercock, LE; Kwok, MCH; Luchman, HA; Mark, SC; Giesbrecht, JL; Samson, LD; Jirik, FR				Sandercock, LE; Kwok, MCH; Luchman, HA; Mark, SC; Giesbrecht, JL; Samson, LD; Jirik, FR			Mutational-reporter transgenes rescued from mice lacking either Mgmt, or both Mgmt and Msh6 suggest that O(6-)alkylguanine-induced miscoding does not contribute to the spontaneous mutational spectrum	ONCOGENE			English	Article						Mgmt; Msh6; lacI; DNA mismatch repair; transgenic shuttle-phage; O-6 -alkylguanine; liver; small intestine; Big Blue (TM)	DNA-REPAIR METHYLTRANSFERASE; ELEVATED MUTANT FREQUENCIES; ESCHERICHIA-COLI; MISMATCH-REPAIR; LIPID-PEROXIDATION; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; NITRIC-OXIDE; ALKYLATION SENSITIVITY; INDUCED TUMORIGENESIS; METHYLATING AGENT	O-6-methylguanine methyltransferase, Mgmt, constitutes the first line of defense against O-6-alkylguanine, which can result in G: C to A: T transitions upon DNA replication. Mgmt has been found in organisms as diverse as archaebacteria and mammals. This evolutionary conservation suggests that all organisms may be exposed to either endogenous or environmental alkylating agents. We thus hypothesized that tissues of Mgmt(-/-) mice would exhibit elevated mutant frequencies. Employing the Big Blue(TM) transgenic system, we evaluated lacI mutants rescued from liver and small intestinal DNA of young Mgmt(-/-) mice. Interestingly, while there was a small difference between Mgmt(-/-) mice and controls with respect to lacI mutant frequency, no differences attributable to Mgmt deficiency were apparent in the mutational spectra. Although mutations stemming from O-6-guanine alkylations would be predicted to be cumulative, we found no evidence of an Mgmt-dependent alteration in mutation spectrum in DNA samples from 12 month-old mice. To optimize our ability to detect mutations resulting from O-6-alkylguanine-induced G: T mismatches, mice with combined deficiencies of Mgmt and the DNA mismatch repair molecule, Msh6, were analysed. In spite of this strategy, we observed no significant differences between Mgmt(-/-) Msh6(-/-) and Msh6(-/-) mouse lacI mutations, except for a trend towards a greater percentage (of total transitions) of G: C to A: T changes in Mgmt(-/-) Msh6(-/-) livers. Therefore, despite the striking evolutionary conservation of Mgmt, deficiency of this gene did not significantly impact the spontaneous laeI mutational spectrum in vivo.	Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; MIT, Biol Engn Div, Cambridge, MA 02139 USA; MIT, Ctr Environm Hlth Sci, Cambridge, MA 02139 USA	University of Calgary; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Jirik, FR (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada.	jirik@ucalgary.ca			NATIONAL CANCER INSTITUTE [R01CA149261, R01CA075576, R01CA055042] Funding Source: NIH RePORTER; NCI NIH HHS [CA55042, R01 CA149261, CA75576] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS WT, 1987, J MOL BIOL, V194, P391, DOI 10.1016/0022-2836(87)90669-3; Allay E, 1999, ONCOGENE, V18, P3783, DOI 10.1038/sj.onc.1202697; Allay E, 1997, ONCOGENE, V15, P2127, DOI 10.1038/sj.onc.1201384; Andrew SE, 1996, MUTAT RES-FUND MOL M, V357, P57, DOI 10.1016/0027-5107(96)00080-2; Andrew SE, 2000, CARCINOGENESIS, V21, P1291, DOI 10.1093/carcin/21.7.1291; Andrew SE, 1997, ONCOGENE, V15, P123, DOI 10.1038/sj.onc.1201180; Andrew SE, 1998, P NATL ACAD SCI USA, V95, P1126, DOI 10.1073/pnas.95.3.1126; Arrault X, 2002, MUTAGENESIS, V17, P353, DOI 10.1093/mutage/17.4.353; Baross-Francis A, 2001, ONCOGENE, V20, P619, DOI 10.1038/sj.onc.1204138; Bawa S, 1999, MUTAT RES-FUND MOL M, V430, P99, DOI 10.1016/S0027-5107(99)00163-3; Benjamin N, 2000, ANN ZOOTECH, V49, P207, DOI 10.1051/animres:2000118; Bignami M, 2000, MUTAT RES-REV MUTAT, V462, P71, DOI 10.1016/S1383-5742(00)00016-8; Cariello NF, 1996, ENVIRON MOL MUTAGEN, V28, P397, DOI 10.1002/(SICI)1098-2280(1996)28:4<397::AID-EM14>3.0.CO;2-A; Cariello NF, 1997, NUCLEIC ACIDS RES, V25, P136, DOI 10.1093/nar/25.1.136; Chung FL, 1996, CARCINOGENESIS, V17, P2105, DOI 10.1093/carcin/17.10.2105; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; de Boer JG, 1998, MUTAGENESIS, V13, P109; DYCAICO MJ, 1994, MUTAT RES, V307, P461, DOI 10.1016/0027-5107(94)90257-7; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Espey MG, 2002, ANN NY ACAD SCI, V962, P195, DOI 10.1111/j.1749-6632.2002.tb04068.x; Georgiadis P, 2000, CANCER EPIDEM BIOMAR, V9, P299; Gerson SL, 2002, J CLIN ONCOL, V20, P2388, DOI 10.1200/JCO.2002.06.110; GERSON SL, 1986, CARCINOGENESIS, V7, P745, DOI 10.1093/carcin/7.5.745; Glassner BJ, 1999, MUTAGENESIS, V14, P339, DOI 10.1093/mutage/14.3.339; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Hill KA, 2004, ENVIRON MOL MUTAGEN, V43, P110, DOI 10.1002/em.20004; HOGG N, 1993, FEBS LETT, V326, P199, DOI 10.1016/0014-5793(93)81790-7; Ishikawa T, 2001, MUTAT RES-FUND MOL M, V477, P41, DOI 10.1016/S0027-5107(01)00094-X; Iwakuma T, 1997, CARCINOGENESIS, V18, P1631, DOI 10.1093/carcin/18.8.1631; Jansen M, 2001, EUR J HAEMATOL, V67, P2, DOI 10.1034/j.1600-0609.2001.067001002.x; Janssen K, 2001, ARCH TOXICOL, V75, P306, DOI 10.1007/s002040100226; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; Kaina B, 2001, PROG NUCLEIC ACID RE, V68, P41; Kawate H, 2000, CARCINOGENESIS, V21, P301, DOI 10.1093/carcin/21.2.301; Kawate H, 1998, P NATL ACAD SCI USA, V95, P5116, DOI 10.1073/pnas.95.9.5116; KLEIN JC, 1990, NUCLEIC ACIDS RES, V18, P4131, DOI 10.1093/nar/18.14.4131; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MACKAY WJ, 1994, J BACTERIOL, V176, P3224, DOI 10.1128/jb.176.11.3224-3230.1994; Major G N, 1998, J Hepatobiliary Pancreat Surg, V5, P355, DOI 10.1007/s005340050059; Mark SC, 2002, ONCOGENE, V21, P7126, DOI 10.1038/sj.onc.1205861; Marnett LJ, 2000, CARCINOGENESIS, V21, P361, DOI 10.1093/carcin/21.3.361; MINNICK DT, 1993, CANCER RES, V53, P997; MIRSALIS JC, 1993, MUTAGENESIS, V8, P265, DOI 10.1093/mutage/8.3.265; Mostafa MH, 1999, CLIN MICROBIOL REV, V12, P97, DOI 10.1128/CMR.12.1.97; Mukai T, 2002, ONCOGENE, V21, P9033, DOI 10.1038/sj.onc.1206095; Nair J, 1999, MUTAT RES-FUND MOL M, V424, P59, DOI 10.1016/S0027-5107(99)00008-1; Nair J, 1998, CANCER EPIDEM BIOMAR, V7, P435; Nair J, 1998, CARCINOGENESIS, V19, P2081, DOI 10.1093/carcin/19.12.2081; NAKATSURU Y, 1993, P NATL ACAD SCI USA, V90, P6468, DOI 10.1073/pnas.90.14.6468; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; Pauly GT, 2001, CHEM RES TOXICOL, V14, P894, DOI 10.1021/tx010032f; Pegg AE, 2000, MUTAT RES-REV MUTAT, V462, P83, DOI 10.1016/S1383-5742(00)00017-X; Posnick LM, 1999, J BACTERIOL, V181, P6756, DOI 10.1128/JB.181.21.6756-6762.1999; PROVOST GS, 1993, MUTAT RES, V288, P133; Quillardet P, 2000, MUTAT RES-GEN TOX EN, V470, P177, DOI 10.1016/S1383-5718(00)00103-0; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; REBECK GW, 1991, J BACTERIOL, V173, P2068, DOI 10.1128/jb.173.6.2068-2076.1991; Reese JS, 2001, ONCOGENE, V20, P5258, DOI 10.1038/sj.onc.1204700; Rogozin IB, 2001, HUM MUTAT, V17, P83, DOI 10.1002/1098-1004(200102)17:2<83::AID-HUMU1>3.0.CO;2-E; Roth RB, 2000, MUTAT RES-REV MUTAT, V462, P107, DOI 10.1016/S1383-5742(00)00021-1; Sakumi K, 1997, CANCER RES, V57, P2415; Sedgwick B, 1997, CARCINOGENESIS, V18, P1561, DOI 10.1093/carcin/18.8.1561; Singer B, 1997, CHEM RES TOXICOL, V10, P713, DOI 10.1021/tx970011e; Stuart GR, 2000, GENETICS, V154, P1291; Taverna P, 1996, J BACTERIOL, V178, P5105, DOI 10.1128/jb.178.17.5105-5111.1996; Tsuzuki T, 1996, CARCINOGENESIS, V17, P1215, DOI 10.1093/carcin/17.6.1215; VACA CE, 1988, MUTAT RES, V195, P137, DOI 10.1016/0165-1110(88)90022-X; Vidal A, 1998, MUTAGENESIS, V13, P367, DOI 10.1093/mutage/13.4.367; Virag L, 2003, TOXICOL LETT, V140, P113, DOI 10.1016/S0378-4274(02)00508-8; Walter CA, 2001, ANN NY ACAD SCI, V928, P132; Wei K, 2002, TRENDS MOL MED, V8, P346, DOI 10.1016/S1471-4914(02)02359-6; WEI X, 1993, P NATL ACAD SCI USA, V90, P2117, DOI 10.1073/pnas.90.6.2117; Zhou ZQ, 2001, P NATL ACAD SCI USA, V98, P12566, DOI 10.1073/pnas.221232998	73	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5931	5940		10.1038/sj.onc.1207791	http://dx.doi.org/10.1038/sj.onc.1207791			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208683				2022-12-17	WOS:000222941100007
J	Candeias, SM; Mancini, SJC; Touvrey, C; Borel, E; Jouvin-Marche, E; Marche, PN				Candeias, SM; Mancini, SJC; Touvrey, C; Borel, E; Jouvin-Marche, E; Marche, PN			p53-dependent and p53-independent pathways for radiation-induced immature thymocyte differentiation	ONCOGENE			English	Article						p53; ionizing radiation; T lymphocyte survival; differentiation; DNA-PK	DEPENDENT PROTEIN-KINASE; T-CELL RECEPTOR; TCRA GENE REARRANGEMENT; DNA-DAMAGE; PRE-TCR; V(D)J RECOMBINATION; TRANSCRIPTIONAL REPRESSION; MOUSE THYMOCYTES; DEFICIENT MICE; SCID MICE	The pre-T-cell receptor (TCR) delivers essential survival/differentiation signals to the developing thymocytes. Severe combined immunodeficient (SCID) and recombination-activating gene (RAG)-deficient mice are unable to assemble antigen receptor genes, and therefore cannot express a pre-TCR. Consequently, T lymphocyte differentiation is arrested at an early stage in the thymus of these animals, and immature thymocytes are eliminated through apoptotic processes. This maturation arrest can be relieved and thymocyte differentiation rescued after the exposure of these mice to whole-body gamma-irradiation. Whereas the promotion of immature thymocyte survival/differentiation was shown to require p53 activity in irradiated SCID mice, it was suggested, on the other hand, that p53 activation prevents immature thymocytes survival/differentiation in irradiated RAG-deficient mice. However, SCID mice have impaired responses to ionizing radiation. In this paper, we analysed p53 requirement in radiation-induced thymocyte differentiation in CD3epsilon(Delta5/Delta5) mice, where pre-TCR deficiency also results in an early block of lymphocyte development. Our results show at the cellular and molecular levels that, in this DNA repair-proficient model, irradiation-induced thymocyte differentiation proceeds either by a p53-dependent or by a p53-independent pathway, which differ in their sensitivity to the radiation dose delivered.	Univ Grenoble 1, Dept Reponse & Dynam Cellulaire, Commissariat Energie Atom Grenoble, Lab Immunochim,INSERM,U548, F-38054 Grenoble, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Candeias, SM (corresponding author), Univ Grenoble 1, Dept Reponse & Dynam Cellulaire, Commissariat Energie Atom Grenoble, Lab Immunochim,INSERM,U548, 17 Rue Martyrs, F-38054 Grenoble, France.	immuno@dsvsud.cea.fr	Mancini, Stéphane J/R-4109-2016; JOUVIN MARCHE, Evelyne/L-8648-2013; Marche, Patrice N/K-5060-2013; TOUVREY, Cedric/G-4126-2011	Mancini, Stéphane J/0000-0001-9255-4606; JOUVIN MARCHE, Evelyne/0000-0001-8616-138X; Marche, Patrice N/0000-0002-8930-9340; Borel Meneroud, eve/0000-0002-9638-578X; Candeias, Serge/0000-0003-2257-5529				Araki R, 1997, P NATL ACAD SCI USA, V94, P2438, DOI 10.1073/pnas.94.6.2438; Bogue MA, 1996, GENE DEV, V10, P553, DOI 10.1101/gad.10.5.553; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Candeias SM, 1997, BIOCHIMIE, V79, P607, DOI 10.1016/S0300-9084(97)82010-X; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; Danska JS, 1996, MOL CELL BIOL, V16, P5507; DeJarnette JB, 1998, P NATL ACAD SCI USA, V95, P14909, DOI 10.1073/pnas.95.25.14909; Di JA, 1996, J EXP MED, V183, P1923, DOI 10.1084/jem.183.4.1923; Gallagher M, 1998, EUR J IMMUNOL, V28, P3878, DOI 10.1002/(SICI)1521-4141(199811)28:11&lt;3878::AID-IMMU3878&gt;3.0.CO;2-C; GUIDOS CJ, 1995, J EXP MED, V181, P1187, DOI 10.1084/jem.181.3.1187; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Haks MC, 1999, IMMUNITY, V11, P91, DOI 10.1016/S1074-7613(00)80084-9; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; HUGO P, 1991, EUR J IMMUNOL, V21, P835, DOI 10.1002/eji.1830210346; Jhappan C, 2000, MOL CELL BIOL, V20, P4075, DOI 10.1128/MCB.20.11.4075-4083.2000; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALISSEN M, 1995, EMBO J, V14, P4641, DOI 10.1002/j.1460-2075.1995.tb00146.x; Mancini S, 1999, J IMMUNOL, V163, P6053; Mancini SJC, 2001, J IMMUNOL, V167, P4485, DOI 10.4049/jimmunol.167.8.4485; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MURPHY WJ, 1994, J IMMUNOL, V153, P1004; Nacht M, 1998, CELL GROWTH DIFFER, V9, P131; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Newton K, 2000, EMBO J, V19, P931, DOI 10.1093/emboj/19.5.931; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; von Boehmer H, 1999, CURR OPIN IMMUNOL, V11, P135, DOI 10.1016/S0952-7915(99)80024-7; Wang BP, 1998, J EXP MED, V188, P1375, DOI 10.1084/jem.188.7.1375; Wang BP, 1999, J IMMUNOL, V162, P88; Zhao RB, 2000, GENE DEV, V14, P981; ZUNIGAPFLUCKER JC, 1994, J EXP MED, V180, P1517, DOI 10.1084/jem.180.4.1517	38	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1922	1929		10.1038/sj.onc.1207320	http://dx.doi.org/10.1038/sj.onc.1207320			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14755249				2022-12-17	WOS:000220129500014
J	Fukao, T; Chen, P; Ren, J; Kaneko, H; Zhang, GX; Kondo, M; Yamamoto, K; Furuichi, Y; Takeda, S; Kondo, N; Lavin, MF				Fukao, T; Chen, P; Ren, J; Kaneko, H; Zhang, GX; Kondo, M; Yamamoto, K; Furuichi, Y; Takeda, S; Kondo, N; Lavin, MF			Disruption of the BLM gene in ATM-null DT40 cells does not exacerbate either phenotype	ONCOGENE			English	Article						ataxia-telangiectasia; Bloom syndrome; DNA damage; DT40 cells; gene disruption	BLOOMS-SYNDROME GENE; DOUBLE-STRAND BREAKS; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; DNA-DAMAGE; DEPENDENT PHOSPHORYLATION; RECOMBINATIONAL REPAIR; GENOMIC INSTABILITY; SYNDROME PROTEIN; S-PHASE	Bloom syndrome and ataxia-telangiectasia are autosomal recessive human disorders characterized by immunodeficiency, genome instability and predisposition to develop cancer. Recent data reveal that the products of these two genes, BLM and ATM, interact and function together in recognizing abnormal DNA structures. To investigate the function of these two molecules in DNA damage recognition, we generated double knockouts of ATM(-/-) BLM-/- in the DT40 chicken B-lymphocyte cell line. The double mutant cells were viable and exhibited a variety of characteristics of both ATM(-/-) and BLM-/- cells. There was no evidence for exacerbation of either phenotype; however, the more extreme radiosensitivity seen in ATM(-/-) and the elevated sister chromatid exchange seen in BLM-/- cells were retained in the double mutants. These results suggest that ATM and BLM have largely distinct roles in recognizing different forms of damage in DNA, but are also compatible with partially overlapping functions in recognizing breaks in radiation-damaged DNA.	Royal Brisbane Hosp, Res Unit, Queensland Canc Fund, Queensland Inst Med Res, Herston, Qld 4029, Australia; Gifu Univ, Sch Med, Dept Pediat, Gifu 5008076, Japan; Shandong Univ, Sch Med, Dept Haematol & Oncol, Shandong, Peoples R China; Kanazawa Univ, Canc Res Inst, Dept Mol Pathol, Kanazawa, Ishikawa 9200934, Japan; GeneCare Res Inst, Kamakura, Kanagawa 2470063, Japan; Kyoto Univ, Dept Radiat Genet, Kyoto 6068501, Japan; Univ Queensland, Royal Brisbane Hosp, Dept Surg, Brisbane, Qld 4072, Australia	Cancer Council Queensland; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Gifu University; Shandong University; Kanazawa University; Kyoto University; Royal Brisbane & Women's Hospital; University of Queensland	Lavin, MF (corresponding author), Royal Brisbane Hosp, Res Unit, Queensland Canc Fund, Queensland Inst Med Res, Herston, Qld 4029, Australia.	martinL@qimr.edu.au	Lavin, Martin F/F-5961-2014	Lavin, Martin F/0000-0002-5940-4769; Takeda, Shunichi/0000-0002-7924-7991				Ababou M, 2000, ONCOGENE, V19, P5955, DOI 10.1038/sj.onc.1204003; Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; ARLETT CF, 1979, ACTA BIOL MED GER, V38, P1277; AURIAS A, 1980, MUTAT RES, V69, P369, DOI 10.1016/0027-5107(80)90101-3; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BEAMISH H, 2002, J BIOL CHEM; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; CHAGANTI RS, 1974, P NATL ACAD SCI USA, V71, P4508, DOI 10.1073/pnas.71.11.4508; Chen P, 1999, ONCOGENE, V18, P249, DOI 10.1038/sj.onc.1202257; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; Chester N, 1998, GENE DEV, V12, P3382, DOI 10.1101/gad.12.21.3382; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; Dutertre S, 2000, ONCOGENE, V19, P2731, DOI 10.1038/sj.onc.1203595; Ellis NA, 1999, AM J HUM GENET, V65, P1368, DOI 10.1086/302616; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; Franchitto A, 2002, J CELL BIOL, V157, P19, DOI 10.1083/jcb.200110009; Fukao T, 1999, BLOOD, V94, P1998; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gaymes TJ, 2002, ONCOGENE, V21, P2525, DOI 10.1038/sj.onc.1205331; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Gueven N, 2001, J BIOL CHEM, V276, P8884, DOI 10.1074/jbc.M006190200; HAND R, 1975, P NATL ACAD SCI USA, V72, P758, DOI 10.1073/pnas.72.2.758; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; Imamura O, 2001, ONCOGENE, V20, P1143, DOI 10.1038/sj.onc.1204195; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Kozlov S, 2003, J BIOL CHEM, V278, P9309, DOI 10.1074/jbc.M300003200; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LAVIN MF, 2003, IN PRESS IMMUNOLOGIC; Lim J, 2000, MOL CELL BIOCHEM, V212, P51, DOI 10.1023/A:1007148719497; LONN U, 1990, CANCER RES, V50, P3141; Luo CM, 1996, J BIOL CHEM, V271, P4497; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Morrison C, 2000, EMBO J, V19, P463, DOI 10.1093/emboj/19.3.463; PANDITA TK, 1994, MUTAT RES, V310, P1013; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Takao N, 1999, ONCOGENE, V18, P7002, DOI 10.1038/sj.onc.1203172; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; TAYLOR AMR, 1976, BRIT J RADIOL, V49, P561; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Wang Y, 2000, GENE DEV, V14, P927; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; ZAMPETTIBOSSELER F, 1981, INT J RADIAT BIOL, V39, P547, DOI 10.1080/09553008114550651; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	60	5	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1498	1506		10.1038/sj.onc.1207276	http://dx.doi.org/10.1038/sj.onc.1207276			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14985700				2022-12-17	WOS:000189219500002
J	Serresi, M; Piccinini, G; Pierpaoli, E; Fazioli, F				Serresi, M; Piccinini, G; Pierpaoli, E; Fazioli, F			A ligand-inducible anaplastic lymphoma kinase chimera is endocytosis impaired	ONCOGENE			English	Article						internalization; EGFR-ALK chimera; downregulation; receptor degradation	EPIDERMAL-GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; MOLECULAR CHARACTERIZATION; ERBB RECEPTORS; C-CBL; ALK; PROTEIN; GENE; ACTIVATION; PHOSPHORYLATION	Ligand-induced membrane trafficking of the anaplastic lymphoma kinase (ALK) was studied using a chimeric receptor in which the extracellular and transmembrane domain of ALK was substituted for the corresponding regions of epidermal growth factor receptor (EGFR). Wild-type EGFR, EGFR/ALK and an EGFR/ALK kinase negative mutant were independently expressed in mouse NR6 fibroblasts. The capacity of EGFR/ALK to mediate [I-125]-EGF internalization, receptor degradation and downregulation, which has never been previously described, was assayed. The rate of [I-125]-EGF-induced internalization mediated by the cytoplasmic domain of ALK was reduced several fold compared with the wildtype EGFR. The low rate of EGF internalization promoted by EGFR/ALK correlated with an impaired degradation and downregulation of the receptor and indicate that ALK is not subject to traditional mechanisms used to regulate receptor tyrosine kinase function. Accordingly, ALK-activated intracellular domain does not associate in vivo with c-cbl and does not undergo ligand-mediated ubiquitination. The current study provides new insight into the function and regulation of ALK suggesting that the relative long membrane residence of activated ALK might confers a more potent and prolonged signaling activity. Indeed NR6-EGFR/ALK cells exhibited a similar to3-fold increase in a maximal mitogenic response than NR6-EGFR.	Univ Ancona, Inst Clin Med, Cellular & Mol Biol Lab, I-60020 Ancona, Italy	Marche Polytechnic University	Fazioli, F (corresponding author), Univ Ancona, Inst Clin Med, Cellular & Mol Biol Lab, Via Tronto 10-A, I-60020 Ancona, Italy.	fazioli@mta01.univpm.it	Pierpaoli, Elisa/J-5996-2016	Pierpaoli, Elisa/0000-0003-4612-7317				Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Baulida J, 1996, J BIOL CHEM, V271, P5251; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Falini B, 1998, AM J PATHOL, V153, P875, DOI 10.1016/S0002-9440(10)65629-5; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Hernandez L, 1999, BLOOD, V94, P3265; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Kholodenko BN, 2002, TRENDS CELL BIOL, V12, P173, DOI 10.1016/S0962-8924(02)02251-1; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lamant L, 1999, BLOOD, V93, P3088; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; LONARDO F, 1990, New Biologist, V2, P992; LUND KA, 1990, J BIOL CHEM, V265, P15713; Ma ZG, 2000, BLOOD, V95, P2144, DOI 10.1182/blood.V95.6.2144; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Miyake I, 2002, ONCOGENE, V21, P5823, DOI 10.1038/sj.onc.1205735; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; Pandit SD, 1997, J BIOL CHEM, V272, P2199; Piccinini G, 2002, J BIOL CHEM, V277, P22231, DOI 10.1074/jbc.M111145200; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Slupianek A, 2001, CANCER RES, V61, P2194; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1993, ONCOGENE, V8, P3021; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; Souttou B, 2001, J BIOL CHEM, V276, P9526, DOI 10.1074/jbc.M007333200; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Tort F, 2001, LAB INVEST, V81, P419, DOI 10.1038/labinvest.3780249; Touriol C, 2000, BLOOD, V95, P3204, DOI 10.1182/blood.V95.10.3204.010k04_3204_3207; Trinei M, 2000, CANCER RES, V60, P793; Waterman H, 1998, J BIOL CHEM, V273, P13819, DOI 10.1074/jbc.273.22.13819; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; WATERS CM, 1992, J CELL PHYSIOL, V152, P253, DOI 10.1002/jcp.1041520206; Weber D, 2000, CANCER RES, V60, P5284; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; WILEY HS, 1991, J BIOL CHEM, V266, P11083	49	5	5	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1098	1108		10.1038/sj.onc.1207227	http://dx.doi.org/10.1038/sj.onc.1207227			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14691459				2022-12-17	WOS:000188749900008
J	Sutherland, LC; Lerman, M; Williams, GT; Miller, BA				Sutherland, LC; Lerman, M; Williams, GT; Miller, BA			LUCA-15 suppresses CD95-mediated apoptosis in Jurkat T cells (vol 20, pg 2713, 2001)	ONCOGENE			English	Correction													Williams, Gwyn/GQY-7555-2022					Sutherland LC, 2001, ONCOGENE, V20, P2713, DOI 10.1038/sj.onc.1204371	1	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	2004	23	2					629	629		10.1038/sj.onc.1207349	http://dx.doi.org/10.1038/sj.onc.1207349			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH		Bronze			2022-12-17	WOS:000188098300035
J	Dunn, JR; Risk, JM; Langan, JE; Marlee, D; Ellis, A; Campbell, F; Watson, AJM; Field, JK				Dunn, JR; Risk, JM; Langan, JE; Marlee, D; Ellis, A; Campbell, F; Watson, AJM; Field, JK			Physical and transcript map of the minimally deleted region III on 17p implicated in the early development of Barrett's oesophageal adenocarcinoma	ONCOGENE			English	Article						chromosome 17; Barrett's oesophageal adenocarcinoma; transcript map; tumour suppressor gene; gene prediction programmes	CANDIDATE TUMOR-SUPPRESSOR; TARGET SITES; GENE; EXPRESSION; HETEROZYGOSITY; IDENTIFICATION; CHROMOSOME-17; DISCOVERY	Allelic imbalance (AI) studies on chromosome 17 (C17) in Barrett's oesophageal adenocarcinoma (BOA) tumours strongly suggest that a minimally deleted region on C17p harbours a BOA-associated gene with tumour suppressor function. This deleted region, designated minimal region III (MRIII), lies between the two microsatellite markers D17S1852 and D17S954. Computational sequence analysis techniques, BLAST and NIX, were used to assemble a physical map of MRIII, consisting of three overlapping bacterial artificial chromosome (BAC) clones, 297N7, 963H4 and 795F17, from the RPCI-11 library. The 270 kb genomic sequence of MRIII was analysed using the computational gene prediction methods NIX and TAP to identify putative BOA genes. A transcript map of MRIII has been generated and contains 25 candidate BOA genes, four of which are the named genes MYH3, SCO1, x006 and MAGOH-LIKE. The other candidates consist of seven genes predicted by TAP with associated ESTs identified by NIX, two genes predicted by TAP alone and 12 genes/ESTs (or pairs of ESTs) identified by NIX alone. No disease-specific mutations were identified in x006 or MAGOH-LIKE, although expression analysis of these genes suggests that they may show alternative splicing or be altered epigenetically or in regulatory regions in oesophageal cancer.	Univ Liverpool, Roy Castle Int Ctr Lung Canc Res, Liverpool L3 9TA, Merseyside, England; Univ Liverpool, Mol Genet & Oncol Grp, Liverpool L69 3BX, Merseyside, England; Royal Liverpool Univ Hosp, Dept Gastroenterol, Liverpool L69 3BX, Merseyside, England; Royal Liverpool Univ Hosp, Dept Pathol, Liverpool, Merseyside, England; Royal Liverpool Univ Hosp, Dept Med, Liverpool, Merseyside, England	University of Liverpool; University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Field, JK (corresponding author), Univ Liverpool, Roy Castle Int Ctr Lung Canc Res, Liverpool L3 9TA, Merseyside, England.	J.K.Field@liv.ac.uk	Field, John K./AAD-5674-2020	Field, John K./0000-0003-3951-6365				Bruening W, 1999, CANCER RES, V59, P4973; Dolan K, 1998, BRIT J CANCER, V78, P950, DOI 10.1038/bjc.1998.607; Dunn J, 1999, ONCOGENE, V18, P987, DOI 10.1038/sj.onc.1202371; Dunn JR, 2000, CLIN CANCER RES, V6, P4033; GISH W, 1996, WU BLASTN2; Harada H, 2001, J HUM GENET, V46, P90, DOI 10.1007/s100380170115; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; Holscher AH, 1997, BRIT J SURG, V84, P1470, DOI 10.1111/j.1365-2168.1997.02800.x; Huang J, 2000, CARCINOGENESIS, V21, P2019, DOI 10.1093/carcin/21.11.2019; Kan ZY, 2001, GENOME RES, V11, P889, DOI 10.1101/gr.155001; Marchese A, 1999, GENOMICS, V56, P12, DOI 10.1006/geno.1998.5655; Monaco C, 1997, GENOMICS, V46, P217, DOI 10.1006/geno.1997.5036; Nishiwaki T, 2000, GENE CHROMOSOME CANC, V27, P169, DOI 10.1002/(SICI)1098-2264(200002)27:2<169::AID-GCC8>3.3.CO;2-D; Osoegawa K, 2001, GENOME RES, V11, P483, DOI 10.1101/gr.169601; Phillips NJ, 1996, CANCER RES, V56, P606; RANKIN SC, 2000, OESOPHAGEAL CANC STA; RISK JM, 1994, NAT GENET, V8, P319, DOI 10.1038/ng1294-319; Russell SEH, 2000, CANCER RES, V60, P4729; Schultz DC, 1996, CANCER RES, V56, P1997; Soenen V, 1998, BLOOD, V91, P1008, DOI 10.1182/blood.V91.3.1008.1008_1008_1015; Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Wittenberger T, 2001, J MOL BIOL, V307, P799, DOI 10.1006/jmbi.2001.4520; Yamato T, 1999, CYTOGENET CELL GENET, V87, P291, DOI 10.1159/000015452; Zhao XF, 1998, GENOMICS, V47, P319, DOI 10.1006/geno.1997.5126	25	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2003	22	26					4134	4142		10.1038/sj.onc.1206466	http://dx.doi.org/10.1038/sj.onc.1206466			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821948				2022-12-17	WOS:000183707600017
J	Graham, LJ; Veri, MC; DeBell, KE; Noviello, C; Rawat, R; Jen, S; Bonvini, E; Rellahan, B				Graham, LJ; Veri, MC; DeBell, KE; Noviello, C; Rawat, R; Jen, S; Bonvini, E; Rellahan, B			70Z/3 Cbl induces PLC gamma 1 activation in T lymphocytes via an alternate Lat- and Slp-76-independent signaling mechanism	ONCOGENE			English	Article						T lymphocytes; T-cell receptor; signal transduction; PLC gamma 1; c-Cbl	PHOSPHOTYROSINE-BINDING DOMAIN; EPIDERMAL GROWTH-FACTOR; PHOSPHOLIPASE C-GAMMA-1 PLC-GAMMA-1; TEC FAMILY KINASES; CELL RECEPTOR; C-CBL; TYROSINE PHOSPHORYLATION; NEGATIVE REGULATOR; SH2 DOMAIN; ZAP-70	The oncoprotein 70Z/3 Cbl signals in an autonomous fashion or through blockade of endogenous c-Cbl, a negative regulator of signaling. The mechanism of 70Z/3 Cbl-induced signaling was investigated by comparing the molecular requirements for 70Z/3 Cbl- and TCR-induced phospholipase Cgamma1 (PLCgamma1) activation. 70Z/3 Cbl-induced PLCgamma1 tyrosine phosphorylation required, in addition to the PLCgamma1 N-terminal SH2 domain, the C-terminal SH2 and SH3 domains that were dispensable for TCR-induced phosphorylation. Deletion of the leucine zipper of 70Z/3 Cbl did not eliminate 70Z/3 Cbl-induced PLCgamma1 phosphorylation, suggesting that blockage of c-Cbl via dimerization with 70Z/3 Cbl cannot fully explain 70Z/3 Cbl activating characteristics. The complete elimination of PLCgamma1 phosphorylation required deleting the SH3 domain-binding region of 70Z/3 Cbl, consistent with 70Z/3 Cbl binding the PLCgamma1 SH3 domain. 70Z/3 Cbl-induced PLCgamma1 phosphorylation required Zap-70, as for the TCR, and the tyrosine kinase binding domain of 70Z/3 Cbl, which binds Zap-70, but did not require PLCgamma1 binding to Lat, a crucial interaction in TCR-induced PLCgamma1 phosphorylation. Furthermore, 70Z/3 Cbl-induced activation of NFAT, a PLCgamma1/Ca2+-dependent transcriptional event, required Zap-70, but was independent of Slp-76, an adapter required for TCR-induced NFAT activation. These results suggest that 70Z/3 Cbl and PLCgamma1 form a TCR-, Lat- and Slp-76-independent complex that leads to PLCgamma1 phosphorylation and activation.	US FDA, Ctr Biol Evaluat & Res, Div Monoc Antibodies, Immunobiol Lab, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA)	Bonvini, E (corresponding author), HFM-564,29B-3NN10,8800 Rockville Pike, Bethesda, MD 20892 USA.							ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Bartkiewicz M, 1999, J BIOL CHEM, V274, P30887, DOI 10.1074/jbc.274.43.30887; Boerth NJ, 2000, J EXP MED, V192, P1047, DOI 10.1084/jem.192.7.1047; Bunnell SC, 1996, J BIOL CHEM, V271, P25646, DOI 10.1074/jbc.271.41.25646; Chang JS, 1997, CANCER RES, V57, P5465; DeBell KE, 1999, MOL CELL BIOL, V19, P7388; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Graham LJ, 1998, BIOCHEM BIOPH RES CO, V249, P537, DOI 10.1006/bbrc.1998.9177; Graham LJ, 2000, FEBS LETT, V470, P273, DOI 10.1016/S0014-5793(00)01341-7; Irvin BJ, 2000, MOL CELL BIOL, V20, P9149, DOI 10.1128/MCB.20.24.9149-9161.2000; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JOHNSON MD, 1994, HUM PATHOL, V25, P146, DOI 10.1016/0046-8177(94)90270-4; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; LEE SJ, 1995, J BIOL CHEM, V270, P16378, DOI 10.1074/jbc.270.27.16378; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; NOH DY, 1994, CANCER, V73, P36, DOI 10.1002/1097-0142(19940101)73:1<36::AID-CNCR2820730108>3.0.CO;2-5; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Rellahan BL, 1997, J BIOL CHEM, V272, P30806, DOI 10.1074/jbc.272.49.30806; RELLAHAN BL, 1994, J EXP MED, V180, P1529, DOI 10.1084/jem.180.4.1529; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Sawasdikosol S, 2000, BBA-REV CANCER, V1471, pM1, DOI 10.1016/S0304-419X(00)00013-5; Schaeffer EM, 2000, CURR OPIN IMMUNOL, V12, P282, DOI 10.1016/S0952-7915(00)00088-1; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Shan XC, 1999, J BIOL CHEM, V274, P29323, DOI 10.1074/jbc.274.41.29323; Smith MR, 1998, CARCINOGENESIS, V19, P177, DOI 10.1093/carcin/19.1.177; Stoica B, 1998, J IMMUNOL, V160, P1059; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; Tsygankov AY, 2001, ONCOGENE, V20, P6382, DOI 10.1038/sj.onc.1204781; van Leeuwen JEM, 1999, MOL CELL BIOL, V19, P6652; van Leeuwen JEM, 1999, J BIOL CHEM, V274, P5153, DOI 10.1074/jbc.274.8.5153; Veri MC, 2001, MOL CELL BIOL, V21, P6939, DOI 10.1128/MCB.21.20.6939-6950.2001; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Williams BL, 1999, EMBO J, V18, P1832, DOI 10.1093/emboj/18.7.1832; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Yablonski D, 2001, MOL CELL BIOL, V21, P4208, DOI 10.1128/MCB.21.13.4208-4218.2001; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yasuda T, 2000, J EXP MED, V191, P641, DOI 10.1084/jem.191.4.641; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhang ZH, 1999, J BIOL CHEM, V274, P4883, DOI 10.1074/jbc.274.8.4883; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	50	5	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2003	22	16					2493	2503		10.1038/sj.onc.1206318	http://dx.doi.org/10.1038/sj.onc.1206318			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717426				2022-12-17	WOS:000182383500012
J	Cariati, R; Zancai, P; Righetti, E; Rizzo, S; De Rossi, A; Boiocchi, M; Dolcetti, R				Cariati, R; Zancai, P; Righetti, E; Rizzo, S; De Rossi, A; Boiocchi, M; Dolcetti, R			Inhibition of oxidative phosphorylation underlies the antiproliferative and proapoptotic effects of mofarotene (Ro 40-8757) in Burkitt's lymphoma cells	ONCOGENE			English	Article						Burkitt's lymphoma; retinoids; Ro 40-8757; Epstein-Barr virus; reactive oxygen species; oxidative phosphorylation	COMPLEX I; AROTINOID RO-40-8757; APOPTOSIS; CANCER; BIOLOGY; BCL-2; EXPRESSION; INDUCTION; THERAPY; VITRO	In the search for retinoids active against Burkitt's lymphoma (BL), we found that the arotinoid mofarotene (Ro 40-8757) induced strong antiproliferative and apoptotic responses in most established BL cell lines as well as in primary BL cells. Ro 40-8757-induced apoptosis is associated with mitochondrial membrane depolarization, activation of caspase-3 and -9, and enhanced production of reactive oxygen species. These effects were related to a transient drop in intracellular ATP content, probably favored by a downregulation of NADH dehydrogenase subunit-1, a component of the mitochondrial respiratory chain (MRC) Complex I. Inhibition of MRC with thenoyltrifluoroacetone suppressed both the ATP recovery and apoptosis, confirming that the effects of Ro 40-8757 are mediated by changes in mitochondrial function. Compared to EBV-negative lines, EBV-carrying BLs were more resistant to Ro 40-8757-induced apoptosis. EBV infection and ectopic LMP-1 expression increased the resistance of BL cells to Ro 40-8757-induced apoptosis, probably through bcl-2 upregulation. Finally, we also show that 2-methoxyoestradiol, an inhibitor of the scavenger enzymes superoxide dismutases, enhanced Ro 40-8757-mediated apoptosis. These findings provide the rationale for evaluating the clinical efficacy of Ro 40-8757 in BL patients and suggest that the combination of Ro 40-8757 with inhibitors of scavenger enzymes may be a promising therapeutic approach for this aggressive lymphoma.	Ctr Riferimento Oncol, Div Expt Oncol 1, IRCCS, Natl Canc Inst,Dept Pre Clin & Epidemiol Res, I-33081 Aviano, PN, Italy; AIDS Reference Ctr, Dept Oncol & Surg Sci, Padua, Italy	IRCCS Aviano (CRO); IRCCS Istituto Oncologico Veneto (IOV)	Boiocchi, M (corresponding author), Ctr Riferimento Oncol, Div Expt Oncol 1, IRCCS, Natl Canc Inst,Dept Pre Clin & Epidemiol Res, Via Pedemontana Occidentale 12, I-33081 Aviano, PN, Italy.	mboiocchi@cro.it	Rizzo, Silvana/AAW-1132-2020; Dolcetti, Riccardo/O-3832-2015; De Rossi, Anita/Q-4845-2019; De Rossi, A./L-3128-2015	Rizzo, Silvana/0000-0002-7156-1783; Dolcetti, Riccardo/0000-0003-1625-9853; De Rossi, Anita/0000-0001-6435-7509; De Rossi, A./0000-0001-6435-7509				Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Cariati R, 2000, INT J CANCER, V86, P375, DOI 10.1002/(SICI)1097-0215(20000501)86:3<375::AID-IJC12>3.0.CO;2-Z; CASTLEBERRY RP, 1994, NEW ENGL J MED, V331, P1680, DOI 10.1056/NEJM199412223312503; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; ELIASON JF, 1993, BRIT J CANCER, V67, P1293, DOI 10.1038/bjc.1993.240; ELIASON JF, 1995, BLOOD, V86, P4516, DOI 10.1182/blood.V86.12.4516.bloodjournal86124516; ELIASON JF, 1994, INT J CANCER, V57, P192, DOI 10.1002/ijc.2910570211; FalK MH, 1998, INT J CANCER, V75, P620, DOI 10.1002/(SICI)1097-0215(19980209)75:4<620::AID-IJC21>3.0.CO;2-B; Fenaux P, 1997, SEMIN ONCOL, V24, P92; FRENCH LE, 1994, LANCET, V344, P686, DOI 10.1016/S0140-6736(94)92122-9; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; HARTMANN D, 1993, RETINOIDS PROGR RES, P491; Hecht JL, 2000, J CLIN ONCOL, V18, P3707, DOI 10.1200/JCO.2000.18.21.3707; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Higuchi M, 1998, ONCOGENE, V17, P2515, DOI 10.1038/sj.onc.1202485; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; KNOWLES DM, 1988, ANN INTERN MED, V108, P744, DOI 10.7326/0003-4819-108-5-744; Komano J, 1999, J VIROL, V73, P9827, DOI 10.1128/JVI.73.12.9827-9831.1999; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Louvet C, 1996, BRIT J CANCER, V74, P394, DOI 10.1038/bjc.1996.371; Marton A, 1997, EUR J BIOCHEM, V250, P467, DOI 10.1111/j.1432-1033.1997.0467a.x; Morrison VA, 1999, SEMIN ONCOL, V26, P84; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; OHNO R, 1994, LEUKEMIA LYMPHOMA, V14, P401, DOI 10.3109/10428199409049696; Pettus EH, 2000, J NEUROCHEM, V75, P383, DOI 10.1046/j.1471-4159.2000.0750383.x; Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798; Pomponi F, 1996, BLOOD, V88, P3147, DOI 10.1182/blood.V88.8.3147.bloodjournal8883147; PRYOR WA, 1982, ANN NY ACAD SCI, V393, P1, DOI 10.1111/j.1749-6632.1982.tb31228.x; Richter C, 1996, FEBS LETT, V378, P107, DOI 10.1016/0014-5793(95)01431-4; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Ruf IK, 2000, J VIROL, V74, P10223, DOI 10.1128/JVI.74.21.10223-10228.2000; Schweizer M., 1997, OXIDATIVE STRESS MOL, P169; Seaton TA, 1998, BRAIN RES, V809, P12, DOI 10.1016/S0006-8993(98)00790-2; SLATER AFG, 1995, BBA-MOL BASIS DIS, V1271, P59, DOI 10.1016/0925-4439(95)00010-2; TEELMANN K, 1993, CANCER RES, V53, P2319; UCHIDA T, 1994, INT J CANCER, V58, P891, DOI 10.1002/ijc.2910580624; WHITE L, 1992, CRIT REV ONCOL HEMAT, V13, P55, DOI 10.1016/1040-8428(92)90016-J; Xu JW, 2000, J IMMUNOL, V164, P2815, DOI 10.4049/jimmunol.164.5.2815	40	5	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2003	22	6					906	918		10.1038/sj.onc.1206060	http://dx.doi.org/10.1038/sj.onc.1206060			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584570				2022-12-17	WOS:000180864300013
J	Miranda, C; Zanotti, G; Pagliardinil, S; Ponzetto, C; Pierotti, MA; Greco, A				Miranda, C; Zanotti, G; Pagliardinil, S; Ponzetto, C; Pierotti, MA; Greco, A			Gain of function mutations of RTK conserved residues display differential effects on NTRK1 kinase activity	ONCOGENE			English	Article						tyrosine kinase receptors; NTRK1; oncogenic; activation	RECEPTOR TYROSINE KINASE; NERVE GROWTH-FACTOR; LIGAND-INDEPENDENT ACTIVATION; PROTOONCOGENE C-KIT; CONGENITAL INSENSITIVITY; POINT MUTATION; DOMAIN; CELLS; TRK; IDENTIFICATION	Activation of tyrosine kinase receptors is associated with human tumors. Tumorigenic versions of several RTKs, such as Ret, Kit and Met carry activating mutations at highly conserved residues of the tyrosine kinase domain. We have investigated the effect of some of these mutations on the NTRK1/NGF receptor, for which no naturally occurring activating point mutations have been so far detected. We introduced the following mutations in NTRK1 tyrosine kinase domain: (i) D668N equivalent to Met D1246N associated to HPRC; (ii) D668V modelled on Kit D816V found in mastocytosis; (iii) M688T corresponding to Ret M918T associated to the cancer syndrome MEN2B. The Met-like mutation rendered the NTRK1 receptor more responsive to ligand, as observed for the corresponding mutation in Met. On the contrary the Kit-like D668V resulted as neutral mutation. Surprisingly, the MEN213-like M688T completely abrogated NTRK1 receptor activity, resulting as a loss of function mutation. Our results show that the mutations tested, although involving conserved amino acids in highly homologous regions, exert distinct effects in different receptors, and suggest a very peculiar auto-inhibitory mechanism for NTRK1.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Univ Padua, Dept Organ Chem, I-35131 Padua, Italy; Univ Turin, Dept Anat & Pharmacol, I-10126 Turin, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Padua; University of Turin	Greco, A (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.		Pierotti, Marco Alessandro/AAC-4728-2022; Greco, Angela/C-1953-2017	Pierotti, Marco Alessandro/0000-0002-7431-8332; Greco, Angela/0000-0003-2994-0349; Zanotti, Giuseppe/0000-0002-0945-6501				CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; Cunningham ME, 1998, EMBO J, V17, P7282, DOI 10.1093/emboj/17.24.7282; Descamps S, 1998, J BIOL CHEM, V273, P16659, DOI 10.1074/jbc.273.27.16659; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GRECO A, 1995, MOL CELL BIOL, V15, P6118; Greco A, 2000, J CELL PHYSIOL, V182, P127, DOI 10.1002/(SICI)1097-4652(200001)182:1<127::AID-JCP14>3.0.CO;2-0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Indo Y, 2001, HUM MUTAT, V18, P462, DOI 10.1002/humu.1224; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Maritano D, 2000, ONCOGENE, V19, P1354, DOI 10.1038/sj.onc.1203431; Miknyoczki SJ, 1999, INT J CANCER, V81, P417, DOI 10.1002/(SICI)1097-0215(19990505)81:3<417::AID-IJC16>3.0.CO;2-6; Miranda C, 2002, J BIOL CHEM, V277, P6455, DOI 10.1074/jbc.M110016200; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; Reuther GW, 2000, MOL CELL BIOL, V20, P8655, DOI 10.1128/MCB.20.23.8655-8666.2000; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Tagliabue E, 1999, INT J BIOL MARKER, V14, P68, DOI 10.1177/172460089901400203; Till JH, 2001, J BIOL CHEM, V276, P10049, DOI 10.1074/jbc.M010161200; TSUJIMURA T, 1994, BLOOD, V83, P2619; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; Weeraratna AT, 2001, CLIN CANCER RES, V7, P2237	24	5	5	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8334	8339		10.1038/sj.onc.1206052	http://dx.doi.org/10.1038/sj.onc.1206052			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447696				2022-12-17	WOS:000179323900011
J	Zambrano, A; Villarreal, LP				Zambrano, A; Villarreal, LP			A monoclonal antibody specific for BK virus large T-antigen (clone BK.T-1) also binds the human Ku autoantigen	ONCOGENE			English	Article						BK virus; large T antigen; Ku proteins; antibodies	DNA; INFECTION; GROWTH; P70	A monoclonal antibody directed against the BK virus large T-antigen (clone BK.T-1) has previously been used to evaluate BKV-T antigen (BKV-TAg) expression. However, our experience showed a consistent reactivity to uninfected human, but not rodent cells and tissues. Using immunoprecipitation, Western analysis, amino acid sequencing and end-point dilution analysis, we analysed the BK.T-1 antibody reactivity and identified the bound cellular protein. The results clearly show that the antibody recognizes the large subunit (Ku86) of the Ku autoantigen, the regulatory component of the DNA-PKcs. We also demonstrated that the antibody retained its original reactivity in BKV-TAg transformed hamster kidney cells. The cross-reaction of the BK.T-1 antibody suggests a possible similarity between BKV-TAg and Ku86, but makes the antibody unsuitable for studies of BKV large T-antigen in the human cells.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Villarreal, LP (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Room 3232, Irvine, CA 92697 USA.	lpvillar@uci.edu	Zambrano, Alberto/A-1580-2013; Zambrano, Alberto/Q-6188-2019	Zambrano, Alberto/0000-0001-5677-2999; Zambrano, Alberto/0000-0001-5677-2999				CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Flaegstad T, 1999, CANCER RES, V59, P1160; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Imperiale MJ, 2000, VIROLOGY, V267, P1, DOI 10.1006/viro.1999.0092; Jin SF, 1997, EMBO J, V16, P6874, DOI 10.1093/emboj/16.22.6874; LEROMANCER M, 1994, J BIOL CHEM, V269, P17464; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; MARSHALL J, 1991, ONCOGENE, V6, P1673; MENEGUZZI G, 1981, VIROLOGY, V111, P139, DOI 10.1016/0042-6822(81)90660-7; MESSIER H, 1993, P NATL ACAD SCI USA, V90, P2685, DOI 10.1073/pnas.90.7.2685; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Ochem AE, 1997, J BIOL CHEM, V272, P29919, DOI 10.1074/jbc.272.47.29919; SHINOHARA T, 1993, J MED VIROL, V41, P301, DOI 10.1002/jmv.1890410408; SIMMONS DT, 1978, VIROLOGY, V85, P137, DOI 10.1016/0042-6822(78)90418-X; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	16	5	5	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5725	5732		10.1038/sj.onc.1205692	http://dx.doi.org/10.1038/sj.onc.1205692			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173042				2022-12-17	WOS:000177463400007
J	Aiba-Masago, S; Liu, XB; Masago, R; Vela-Roch, N; Jimenez, F; Lau, CMA; Frohlich, VC; Talal, N; Dang, H				Aiba-Masago, S; Liu, XB; Masago, R; Vela-Roch, N; Jimenez, F; Lau, CMA; Frohlich, VC; Talal, N; Dang, H			Bax gene expression alters Ca2+ signal transduction without affecting apoptosis in an epithelial cell fine	ONCOGENE			English	Article						calcium; Bcl-2 family; oxidative stress; glutathione; muscarinic receptor	CYTOCHROME-C RELEASE; GLUTATHIONE DEPLETION; SJOGRENS-SYNDROME; REDOX REGULATION; BCL-2; CALCIUM; DEATH; OVEREXPRESSION; BCL-X(L); ALPHA	Bax is an oncogene that has proapoptotic properties but not all cells that express Bax undergo apoptosis. Bax may have a function unrelated to apoptosis. To elucidate the role of Bax in cell signaling, an epithelial cell line called SMG-C6 was transfected with the human bax gene. Stable transfectants were studied for their response to carbachol, a muscarinic receptor agonist, by measuring the increase in intracellular free Ca2+ and Ca2+ influx. Carbachol-mediated release of Call from intracellular stores was significantly higher in Bax transfectants compared to control transfectants (empty vector). Ca2+ influx was also increased in Bax transfectants. Bax had no affect on the storage operated channels. However, the concentration of Ca2+d in the intracellular stores (i.e., mitochondria and granules) was 40-50% lower in the Bax transfectants. There was no significant difference in thapsigargin-mediated apoptosis in Bax transfectants compared to wild-type and control transfectants. Measurement of glutathione was reduced in the Bax transfectant. Restoration of glutathione levels with glutathione monoethyl ester partially normalized Ca2+ mobilization and storage capacity in the mitochondria to control levels. This study shows that subapoptotic levels of Bax can reduce Ca2+ content in intracellular stores and Ca2+ homeostasis. Bax may mediate these effects by reducing the levels of antioxidants resulting in mild oxidative stress.	Univ Texas, Hlth Sci Ctr, Dept Community Dent, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Harcourt Brace Educ Measurement, San Antonio, TX 78204 USA; Columbia Univ, Coll Phys & Surg, New York, NY 10019 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Columbia University	Dang, H (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Community Dent, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	dang@uthscsa.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012203] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE12203] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Azhar G, 1999, MECH AGEING DEV, V112, P5, DOI 10.1016/S0047-6374(99)00048-2; Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bojes HK, 1997, BIOCHEM J, V325, P315, DOI 10.1042/bj3250315; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; BUTTKE TM, 1995, FREE RADICAL RES, V22, P389, DOI 10.3109/10715769509147548; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Ghibelli L, 1999, FASEB J, V13, P2031, DOI 10.1096/fasebj.13.14.2031; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hehner SP, 2000, J IMMUNOL, V165, P4319, DOI 10.4049/jimmunol.165.8.4319; Ichimiya M, 1998, AM J PHYSIOL-CELL PH, V275, pC832, DOI 10.1152/ajpcell.1998.275.3.C832; Kampranis SC, 2000, J BIOL CHEM, V275, P29207, DOI 10.1074/jbc.M002359200; Kong LP, 1998, CLIN IMMUNOL IMMUNOP, V88, P133, DOI 10.1006/clin.1998.4556; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; Masago R, 2001, ARTHRITIS RHEUM, V44, P693, DOI 10.1002/1529-0131(200103)44:3<693::AID-ANR119>3.0.CO;2-7; McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775, DOI 10.1002/jlb.59.6.775; Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Naarala J, 1997, LIFE SCI, V60, P1905, DOI 10.1016/S0024-3205(97)00152-5; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NUTT LK, 2002, IN PRESS J BIOL CHEM; Ohlsson M, 2001, LAB INVEST, V81, P95, DOI 10.1038/labinvest.3780215; Olive M, 1999, J NEUROL SCI, V164, P76, DOI 10.1016/S0022-510X(99)00041-6; Penault-Llorca F, 1998, PATHOL RES PRACT, V194, P457, DOI 10.1016/S0344-0338(98)80114-3; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Polihronis M, 1998, CLIN EXP IMMUNOL, V114, P485; Quissell D O, 1997, In Vitro Cell Dev Biol Anim, V33, P164; STAAL FJT, 1994, P NATL ACAD SCI USA, V91, P3619, DOI 10.1073/pnas.91.9.3619; Wang H, 2000, FREE RADICAL BIO MED, V28, P1222, DOI 10.1016/S0891-5849(00)00241-0; Wei HF, 1998, J NEUROCHEM, V70, P2305; Zhang GH, 1997, P SOC EXP BIOL MED, V216, P117; Zhou YP, 2000, AM J PHYSIOL-ENDOC M, V278, pE340, DOI 10.1152/ajpendo.2000.278.2.E340	36	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2762	2767		10.1038/sj.onc.1205369	http://dx.doi.org/10.1038/sj.onc.1205369			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965549				2022-12-17	WOS:000174996500016
J	Liu, YZ; Hiraiwa, Y; Liu, EB; Kurata, H; Thant, AA; Matsuda, S; Hamaguchi, M				Liu, YZ; Hiraiwa, Y; Liu, EB; Kurata, H; Thant, AA; Matsuda, S; Hamaguchi, M			Suppression of cell spreading by v-Crk requires Ras-MPK-MAP kinase signaling	ONCOGENE			English	Article						v-Crk; Ras; MAP kinase; cell spreading; integrin	PROTEIN; TRANSFORMATION; PATHWAY; ACTIVATION; TRANSDUCTION; FIBROBLASTS; INTEGRINS; ADHESION	We investigated the attachment and spreading of v-Crk-transformed cells, v-Crk3Y1, on fibronectin. Transformation-by v-Crk virtually suppressed the spreading, but not the attachment, of cells on fibronectin. This suppression of cell spreading was not correlated with the suppression of integrin alpha5 and beta1 expression. However, the spreading of v-Crk3Y1 on fibronectin was dramatically restored by either expression of dominant-negative Ras or treatment with manumycin A, a Ras farnesyltransferase inhibitor. Moreover, both expression of dominant-negative MEK1 and treatment of cells with U0126, a MEK1 inhibitor, restored the cell spreading of v-Crk3Y1. In contrast, neither treatment with LY294002, a PI3K inhibitor, nor expression of dominant-negative C3G showed no effect on cell spreading on fibronectin. Taken together, our results suggest that, among multiple signaling pathways activated by v-Crk, the Ras-MEK1-MAP kinase cascade plays a pivotal role in the suppression of cell spreading on fibronectin, but C3G and the PI3 kinase do not.	Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University	Hamaguchi, M (corresponding author), Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.							ADAMS SL, 1977, P NATL ACAD SCI USA, V74, P3399, DOI 10.1073/pnas.74.8.3399; Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Greulich H, 1996, CELL GROWTH DIFFER, V7, P1443; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Kurata H, 2000, EXP CELL RES, V254, P180, DOI 10.1006/excr.1999.4738; Liu EB, 2000, CANCER RES, V60, P2361; Liu F, 1998, MOL CELL BIOL, V18, P250, DOI 10.1128/MCB.18.1.250; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; NIGG EA, 1986, VIROLOGY, V151, P50, DOI 10.1016/0042-6822(86)90103-0; OLDEN K, 1977, CELL, V11, P957, DOI 10.1016/0092-8674(77)90307-5; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356	21	5	5	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5908	5912		10.1038/sj.onc.1204738	http://dx.doi.org/10.1038/sj.onc.1204738			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593397				2022-12-17	WOS:000171037200015
J	Michalowski, J; Seavey, SE; Mendrysa, SM; Perry, ME				Michalowski, J; Seavey, SE; Mendrysa, SM; Perry, ME			Defects in transcription coupled repair interfere with expression of p90(MDM2) in response to ultraviolet light	ONCOGENE			English	Article						p53; MDM2; ultraviolet; transcription	RNA-POLYMERASE-II; WILD-TYPE P53; NUCLEOTIDE EXCISION-REPAIR; XERODERMA-PIGMENTOSUM; DNA-DAMAGE; UV IRRADIATION; MDM2 GENE; COCKAYNES-SYNDROME; PYRIMIDINE DIMERS; FEEDBACK LOOP	Ultraviolet (UV) irradiation transiently stabilizes p53 through a mechanism that may require a decrease in the activity of the ubiquitin ligase, p90(MDM2). Conversely, the recovery of low levels of p53 following UV exposure may depend on an increase in p90(MDM2). The level of p90(MDM2) is increased by UV light following the p53-dependent induction of an internal mdm2 promoter, P2. If this induction of mdm2 were critical for the recovery of low levels of p53 following UV exposure, defects in mdm2's transcription would result in a prolonged increase in p53. Cells defective in transcription coupled repair (TCR) maintain high levels of p53 for a prolonged period following UV exposure. Such cells also have defects in general transcription after UV irradiation. We investigated whether TCR-deficient cells express diminished levels of mdm2 mRNA and p90(MDM2) following UV exposure. We found that transcription of mdm2 was reduced in TCR-deficient cells. The uninducible mdm2 promoter, P1, was more sensitive to the inhibitory effects of UV irradiation than the P2 promoter. The decrease in transcription from the P1 promoter was sufficient to reduce the level of p90(MDM2) and correlated with a prolonged increase in p53. Thus, p53-independent transcription of mdm2 appears critical to p53's regulation.	Univ Wisconsin, Sch Med, Dept Oncol, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Perry, ME (corresponding author), Univ Wisconsin, Sch Med, Dept Oncol, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.				NCI NIH HHS [CA-07175, CA-09135, CA-70781] Funding Source: Medline; NIGMS NIH HHS [GM-07215] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009135, R01CA070781, R29CA070781, P30CA007175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMS PJ, 1995, MUTAT RES-DNA REPAIR, V336, P169, DOI 10.1016/0921-8777(94)00049-C; Bar-Or RL, 2000, P NATL ACAD SCI USA, V97, P11250, DOI 10.1073/pnas.210171597; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Blaydes JP, 1998, ONCOGENE, V16, P3317, DOI 10.1038/sj.onc.1201880; Brown CY, 1999, ONCOGENE, V18, P5631, DOI 10.1038/sj.onc.1202949; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; Dumaz N, 1997, MOL CARCINOGEN, V20, P340, DOI 10.1002/(SICI)1098-2744(199712)20:4<340::AID-MC3>3.0.CO;2-N; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Ganesan AK, 1999, MUTAT RES-DNA REPAIR, V433, P117, DOI 10.1016/S0921-8777(98)00070-6; Geyer RK, 2000, CELL GROWTH DIFFER, V11, P149; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Huang JH, 1998, ONCOGENE, V17, P401, DOI 10.1038/sj.onc.1201951; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Jiang WD, 1999, ONCOGENE, V18, P4247, DOI 10.1038/sj.onc.1202789; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; JUVEN T, 1993, ONCOGENE, V8, P3411; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Landers JE, 1997, CANCER RES, V57, P3562; LI G, 1995, CANCER RES, V55, P2070; Ljungman M, 1996, ONCOGENE, V13, P823; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MAYNE LV, 1982, CANCER RES, V42, P1473; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Rockx DAP, 2000, P NATL ACAD SCI USA, V97, P10503, DOI 10.1073/pnas.180169797; Saucedo LJ, 1999, J BIOL CHEM, V274, P8161, DOI 10.1074/jbc.274.12.8161; Saucedo LJ, 1998, CELL GROWTH DIFFER, V9, P119; Seavey SE, 1999, J VIROL, V73, P7590, DOI 10.1128/JVI.73.9.7590-7598.1999; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; van Hoffen A, 1999, NUCLEIC ACIDS RES, V27, P2898, DOI 10.1093/nar/27.14.2898; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; Zhu QZ, 2000, MOL CARCINOGEN, V28, P215; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	46	5	5	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5856	5864		10.1038/sj.onc.1204721	http://dx.doi.org/10.1038/sj.onc.1204721			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593391				2022-12-17	WOS:000171037200009
J	VanHouten, JN; Asch, HL; Asch, BB				VanHouten, JN; Asch, HL; Asch, BB			Cloning and characterization of ectopically expressed transcripts for the actin-binding protein MIPP in mouse mammary carcinomas	ONCOGENE			English	Article						MIPP; mammary; cancer; endoplasmic reticulum; actin; kelch	ENDOPLASMIC-RETICULUM; DROSOPHILA KELCH; GENE; MICROTUBULE; CYTOSKELETON; OUTGROWTHS; FILAMENTS; COMPLEX; ENCODES; DOMAIN	Mipp is a kelch-related, placental-specific gene that is ectopically expressed in many BALB/c mouse mammary carcinomas of various etiologies. The Kelch family encompasses proteins that are emerging as key links between microfilaments and a variety of cellular structures and functions. Mouse mammary tumors express two mipp transcripts (2.2 and 5.6 kb). We cloned the 2.2 kb mipp mRNA and analysed the product of its 1.7 kb ORE The 584 residue MIPP protein has an N-terminal BTB domain and six C-terminal tandem Kelch repeats. Despite expression of two mipp RNAs, only a single MIPP protein is expressed in mammary tumors. MIPP protein binds to microfilaments in vitro and co-immunoprecipitates with actin. MIPP co-localized with concanavalin A at the endoplasmic reticulum, suggesting that MIPP might mediate interactions between microtubules and actin filaments. Because MIPP expression is widespread in mouse mammary tumors, it might contribute to tumorigenesis. Although MIPP had little effect on the growth rate of human breast cell lines following transfection, it greatly reduced the formation of duct-like structures on reconstituted basement membrane. Our results suggest that MIPP could contribute to malignant progression in the mouse mammary epithelial cells by perverting their response to cues from the extracellular matrix.	Roswell Pk Canc Inst Corp, Div Expt Pathol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	VanHouten, JN (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Div Endocrinol & Metab, New Haven, CT 06520 USA.				NATIONAL CANCER INSTITUTE [R01CA062014, P30CA016056, R01CA072768] Funding Source: NIH RePORTER; NCI NIH HHS [CA62014, CA16056, CA72768] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; BORK P, 1994, J MOL BIOL, V236, P1277, DOI 10.1016/0022-2836(94)90056-6; Callebaut I, 1998, CELL MOL LIFE SCI, V54, P880, DOI 10.1007/s000180050216; CARDIFF RD, 1988, ANTICANCER RES, V8, P925; CARRAWAY KL, 1992, CYTOSKELETON PRACTIC; CHANGYEH A, 1993, P NATL ACAD SCI USA, V90, P292, DOI 10.1073/pnas.90.1.292; CHANGYEH A, 1991, NUCLEIC ACIDS RES, V19, P3667, DOI 10.1093/nar/19.13.3667; Eichinger L, 1996, EMBO J, V15, P5547, DOI 10.1002/j.1460-2075.1996.tb00939.x; Goode BL, 2000, CURR OPIN CELL BIOL, V12, P63, DOI 10.1016/S0955-0674(99)00058-7; GOULD MN, 1995, SEMIN CANCER BIOL, V6, P147, DOI 10.1006/scbi.1995.0023; Gregory RB, 1999, BIOCHEM J, V341, P401, DOI 10.1042/0264-6021:3410401; Hernandez MC, 1997, J NEUROSCI, V17, P3038; Horton Paul, 1997, INTELLIGENT SYSTEMS, V5, P147; Kim IF, 1999, GENE, V228, P73, DOI 10.1016/S0378-1119(99)00006-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUEDERS KK, 1977, CELL, V12, P963, DOI 10.1016/0092-8674(77)90161-1; Mata J, 1997, CELL, V89, P939, DOI 10.1016/S0092-8674(00)80279-2; MEDINA D, 1993, CARCINOGENESIS, V14, P25, DOI 10.1093/carcin/14.1.25; MEDINA D, 1993, CANCER RES, V53, P663; MEDINA D, 1988, CARCINOGENESIS, V9, P1113, DOI 10.1093/carcin/9.7.1113; Medina D, 1996, J MAMMARY GLAND BIOL, V1, P3, DOI 10.1007/BF02096298; Prinz WA, 2000, J CELL BIOL, V150, P461, DOI 10.1083/jcb.150.3.461; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; Robinson DN, 1997, J CELL BIOL, V138, P799, DOI 10.1083/jcb.138.4.799; Sanders MC, 1996, J BIOL CHEM, V271, P2651, DOI 10.1074/jbc.271.5.2651; SCHMID MF, 1994, J CELL BIOL, V124, P341, DOI 10.1083/jcb.124.3.341; Schmucker B, 1997, EUR J CELL BIOL, V72, P46; SELDEN SC, 1986, ANN NY ACAD SCI, V466, P803, DOI 10.1111/j.1749-6632.1986.tb38464.x; Soltysik-Espanola M, 1999, MOL BIOL CELL, V10, P2361, DOI 10.1091/mbc.10.7.2361; Tabb JS, 1998, J CELL SCI, V111, P3221; TERASAKI M, 1990, CELL MOTIL CYTOSKEL, V15, P71, DOI 10.1002/cm.970150203; VanHouten JN, 1996, ONCOGENE, V12, P2241; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8; WOOD JG, 1981, J NEUROCYTOL, V10, P149, DOI 10.1007/BF01181750; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9	35	5	6	1	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5366	5372		10.1038/sj.onc.1204701	http://dx.doi.org/10.1038/sj.onc.1204701			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536049				2022-12-17	WOS:000170575500012
J	Yolcu, E; Sayan, BS; Yagci, T; Cetin-Atalay, R; Soussi, T; Yurdusev, N; Ozturk, M				Yolcu, E; Sayan, BS; Yagci, T; Cetin-Atalay, R; Soussi, T; Yurdusev, N; Ozturk, M			A monoclonal antibody against DNA binding helix of p53 protein	ONCOGENE			English	Article						p53; hybridoma; DNA binding helix	MUTATIONS; MUTANTS; REGION; CANCER; CELLS	Three monoclonal antibodies (Mabs) were generated against p53 DNA-binding core domain. When tested by immunoprecipitation, Western blot and immunofluorescence techniques, Mab 9E4, as well as 7D3 and 6B10 reacted with both wild-type and various mutant p53 proteins. The epitopes recognized by Mabs 7D3, 9E4 and 6B10 were located respectively within the amino acid residues 211-220, 281-290 and 291-300 of human p53 protein. The epitope recognized by 9E4 Mab coincides with helix 2, also called p53 DNA binding helix, which allows the direct contact of the protein with its target DNA sequences. This antibody may be useful to study transcription-dependent and transcription-independent activities of wild-type and mutant p53 proteins.	Bilkent Univ, Dept Mol Biol & Genet, TR-06533 Ankara, Turkey; Bilkent Univ, BilGen Genet & Biotechnol Ctr, TR-06533 Ankara, Turkey; TUBITAK MRC, Res Inst Genet Engn & Biotechnol, Dept Mol Oncol, Gebze, Kocaeli, Turkey; Inst Curie, Paris, France	Ihsan Dogramaci Bilkent University; Ihsan Dogramaci Bilkent University; Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Ozturk, M (corresponding author), Bilkent Univ, Dept Mol Biol & Genet, TR-06533 Ankara, Turkey.		OZTURK, MEHMET/AAS-7241-2021; ozturk, mehmet/G-3330-2014; Cetin-Atalay, Rengul/O-9826-2014; Cetin-Atalay, Rengul/F-5780-2013	OZTURK, MEHMET/0000-0002-6092-9706; Cetin-Atalay, Rengul/0000-0003-2408-6606; Cetin-Atalay, Rengul/0000-0003-2408-6606; soussi, thierry/0000-0001-8184-3293				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cohen PA, 1998, ONCOGENE, V17, P2445, DOI 10.1038/sj.onc.1202190; de Fromentel CC, 1999, ONCOGENE, V18, P551, DOI 10.1038/sj.onc.1202338; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; LEGROS Y, 1994, ONCOGENE, V9, P3689; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A	15	5	6	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 15	2001	20	11					1398	1401		10.1038/sj.onc.1204240	http://dx.doi.org/10.1038/sj.onc.1204240			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313883	Green Published			2022-12-17	WOS:000167495000013
J	Braliou, GG; Ciana, P; Klaassen, W; Gandrillon, O; Stunnenberg, HG				Braliou, GG; Ciana, P; Klaassen, W; Gandrillon, O; Stunnenberg, HG			The v-ErbA oncoprotein quenches the activity of an erythroid-specific enhancer	ONCOGENE			English	Article						v-ErbA; thyroid hormone; repression; erythroid enhancer; carbonic anhydrase II; GATA-sites	THYROID-HORMONE RECEPTOR; RETINOIC ACID RECEPTOR; DNA-BINDING SPECIFICITY; BETA-GLOBIN GENE; TRANSCRIPTIONAL REPRESSION; C-ERBA; DEPENDENT TRANSACTIVATION; CELL-DIFFERENTIATION; HISTONE DEACETYLASE; ONCOGENE PRODUCT	v-ErbA is a mutated variant of thyroid hormone receptor (TR alpha /NR1A1) borne by the Avian Erythroblastosis virus causing erythroleukemia. TR alpha is known to activate transcription of specific genes in the presence of its cognate ligand, T3 hormone, while in its absence it represses it, v-ErbA is unable to bind ligand, and hence is thought to contribute to leukemogenesis by actively repressing erythroid-specific genes such as the carbonic anhydrase II gene (CA II). In the prevailing model, v-ErbA occludes liganded TR from binding to its cognate elements and constitutively interacts with the corepressors NCoR/ SMRT. We previously identified a v-ErbA responsive element (VRE) within a DNase I hypersensitive region (HS2) located in the second intron of the CA II gene. We now show that HS2 fulfils all the requirements for a genuine enhancer that functions independent of its orientation and position with a profound erythroid-specific activity in normal erythroid progenitors (T2ECs) and in leukemic erythroid cell lines. We find that the HS2 enhancer activity is governed by two adjacent GATA-factor binding sites. v-ErbA as well as unliganded TR prevent HS2 activity by nullifying the positive function of factors bound to GATA-sites. However, v-ErbA, in contrast to TR, does not convey active repression to silence the transcriptional activity intrinsic to a heterologous tk promoter. We propose that depending on the sequence and context of the binding site, v-ErbA contributes to leukomogenesis by occluding liganded TR as well as unliganded TR thereby preventing activation or repression, respectively.	Univ Nijmegen, NCMLS, Dept Mol Biol, NL-6500 HB Nijmegen, Netherlands; Univ Lyon 1, CNRS, UMR 5534, Ctr Genet Mol & Cellulaire, F-69622 Villeurbanne, France	Radboud University Nijmegen; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Stunnenberg, HG (corresponding author), Univ Nijmegen, NCMLS, Dept Mol Biol, Geert Groote Pl 26,POB 9101, NL-6500 HB Nijmegen, Netherlands.		Stunnenberg, Hendrik G./D-6875-2012; Ciana, Paolo/F-9224-2012	Stunnenberg, Hendrik G./0000-0002-0066-1576; CIANA, PAOLO/0000-0001-5771-5638				ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Auwerx J, 1999, CELL, V97, P161; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; Bauer A, 1997, ONCOGENE, V15, P701, DOI 10.1038/sj.onc.1201208; Bauer A, 1998, EMBO J, V17, P4291, DOI 10.1093/emboj/17.15.4291; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; Beug H, 1996, BBA-REV CANCER, V1288, pM35, DOI 10.1016/S0304-419X(96)00032-7; BOUCHER P, 1988, J VIROL, V62, P534, DOI 10.1128/JVI.62.2.534-544.1988; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CASINI T, 1995, ONCOGENE, V11, P1019; CEREGHINI S, 1984, EMBO J, V3, P1243, DOI 10.1002/j.1460-2075.1984.tb01959.x; CHANG TJ, 1993, MOL ENDOCRINOL, V7, P528, DOI 10.1210/me.7.4.528; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; Ciana P, 1998, EMBO J, V17, P7382, DOI 10.1093/emboj/17.24.7382; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DEMAGISTRIS L, 1988, NUCLEIC ACIDS RES, V16, P3141, DOI 10.1093/nar/16.8.3141; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; EMERSON BM, 1987, P NATL ACAD SCI USA, V84, P4786, DOI 10.1073/pnas.84.14.4786; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Fondell JD, 1996, MOL CELL BIOL, V16, P281; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; Gandrillon O, 1999, EMBO J, V18, P2764, DOI 10.1093/emboj/18.10.2764; GANDRILLON O, 1994, ONCOGENE, V9, P749; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Glass CK, 2000, GENE DEV, V14, P121; Goldhirsch A, 1996, SEMIN ONCOL, V23, P494; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; INNIS JW, 1983, MOL CELL BIOL, V3, P2203, DOI 10.1128/MCB.3.12.2203; Jenuwein T, 1997, NATURE, V385, P269, DOI 10.1038/385269a0; JEONG SW, 1994, NUCLEIC ACIDS RES, V22, P370, DOI 10.1093/nar/22.3.370; Judelson C, 1996, J BIOL CHEM, V271, P10800, DOI 10.1074/jbc.271.18.10800; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; NELSON CC, 1994, MOL ENDOCRINOL, V8, P829, DOI 10.1210/me.8.7.829; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Olson DP, 1998, J BIOL CHEM, V273, P3375, DOI 10.1074/jbc.273.6.3375; PAIN B, 1990, New Biologist, V2, P284; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; RASCLE A, 1994, ONCOGENE, V9, P2853; REEVES R, 1985, NUCLEIC ACIDS RES, V13, P3599, DOI 10.1093/nar/13.10.3599; Renaud JP, 2000, MOL ENDOCRINOL, V14, P700, DOI 10.1210/me.14.5.700; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SCHROEDER C, 1992, ONCOGENE, V7, P217; Seraphin B, 1996, NUCLEIC ACIDS RES, V24, P3276, DOI 10.1093/nar/24.16.3276; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; Stunnenberg HG, 1999, BBA-REV CANCER, V1423, pF15, DOI 10.1016/S0304-419X(98)00036-5; STUNNENBERG HG, 1988, NUCLEIC ACIDS RES, V16, P2431, DOI 10.1093/nar/16.6.2431; SUBAUSTE JS, 1995, J BIOL CHEM, V270, P7957, DOI 10.1074/jbc.270.14.7957; Subauste JS, 1998, MOL ENDOCRINOL, V12, P1380, DOI 10.1210/me.12.9.1380; Thormeyer D, 1999, INT J MOL MED, V4, P351; Urnov FD, 2000, EMBO J, V19, P4074, DOI 10.1093/emboj/19.15.4074; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; Wahlstrom GM, 1996, ONCOGENE, V13, P843; Wahlstrom GM, 1998, MOL ENDOCRINOL, V12, P645, DOI 10.1210/me.12.5.645; Wang GF, 1998, MOL CELL BIOL, V18, P6023, DOI 10.1128/MCB.18.10.6023; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Wolff L, 1997, BBA-REV CANCER, V1332, pF67, DOI 10.1016/S0304-419X(97)00006-1; Wong JM, 1998, EMBO J, V17, P520, DOI 10.1093/emboj/17.2.520; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; Zhang JS, 1999, MOL CELL BIOL, V19, P6448	69	5	5	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 15	2001	20	7					775	787		10.1038/sj.onc.1204159	http://dx.doi.org/10.1038/sj.onc.1204159			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314012	Green Published, Bronze			2022-12-17	WOS:000166924400001
J	May, P; May, E				May, P; May, E			Twenty years of p53 research: structural and functional aspects of the p53 protein (vol 18, pg 7621, 1999)	ONCOGENE			English	Correction																		May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285	1	5	5	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 23	2000	19	13					1734	1734						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG					2022-12-17	WOS:000086083800015
J	Coutts, M; Zou, XM; Calame, K				Coutts, M; Zou, XM; Calame, K			v-Abl utilizes multiple mechanisms to drive G1/S progression in fibroblasts	ONCOGENE			English	Article						v-Abl; cell cycle; p27; E2F	CDK INHIBITOR P27(KIP1); CELL-CYCLE PROGRESSION; C-MYC TRANSCRIPTION; RESTRICTION POINT; TYROSINE KINASE; DEPENDENT KINASES; GROWTH; PROTEIN; ARREST; PHOSPHORYLATION	Transformation of 3T3 fibroblasts by the v-Abl tyrosine kinase replaces mitogenic and adhesion signals normally required for cell cycle progression. A 3T3 cell line conditionally transformed with v-Abl has been used to study v-Abl's effects on cell cycle in the context of either serum depletion or absence of adhesion signals. We show that E2F-dependent mRNAs, encoding proteins required for cell cycle progression, are induced by v-Abl, In addition, we identify two previously unknown targets of v-Abl signaling: (1) cyclin D1 and D2 mRNAs are induced upon v-Abl activation; and (2) the CDK inhibitor p27 is decreased upon v-Abl activation.	Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Columbia University; Columbia University	Calame, K (corresponding author), Columbia Univ Coll Phys & Surg, Dept Microbiol, 701 W 168th St,HHSC 1202, New York, NY 10032 USA.							Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BirchenallRoberts MC, 1997, J BIOL CHEM, V272, P8905; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHEN YY, 1992, P NATL ACAD SCI USA, V89, P6683, DOI 10.1073/pnas.89.15.6683; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DelSal G, 1996, CRIT REV ONCOGENESIS, V7, P127, DOI 10.1615/CritRevOncog.v7.i1-2.80; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; Harper JW, 1997, CANCER SURV, V29, P91; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Phelps DE, 1997, METHOD ENZYMOL, V283, P194; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; QUELLE DE, 1995, ONCOGENE, V11, P635; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Sheaff RJ, 1997, METHOD ENZYMOL, V283, P173; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Weissinger EM, 1997, MOL CELL BIOL, V17, P3229, DOI 10.1128/MCB.17.6.3229; WONG KK, 1995, MOL CELL BIOL, V15, P6535; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; Zou XM, 1997, GENE DEV, V11, P654, DOI 10.1101/gad.11.5.654	42	5	6	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 10	2000	19	6					801	809		10.1038/sj.onc.1203398	http://dx.doi.org/10.1038/sj.onc.1203398			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698498				2022-12-17	WOS:000085192100010
J	Tortola, S; Marcuello, E; Risques, RA; Gonzalez, S; Aiza, G; Capella, G; Peinado, MA				Tortola, S; Marcuello, E; Risques, RA; Gonzalez, S; Aiza, G; Capella, G; Peinado, MA			Overall deregulation in gene expression as a novel indicator of tumor aggressiveness in colorectal cancer	ONCOGENE			English	Article						RNA differential display; genetic instability; prognostic assessment	ARBITRARILY PRIMED-PCR; DNA METHYLATION; RNA; INSTABILITY; COLON; HYBRIDIZATION; CARCINOMAS; SEQUENCES; MECHANISM; CELLS	Malignant transformation of the cell is accompanied and characterized by disruption of genetic material and aberrant expression of multiple genes. Systematic analysis of differential gene expression in human tumor samples may provide an estimate of the degree of genetic and epigenetic deregulation in neoplastic cells. We have assessed, by means of a RNA differential display technique, the overall gene expression deregulation in a prospectively collected series of 68 human colorectal carcinomas. An index of differential expression has been calculated for each case. A similar proportion of the displayed sequences (23%) was under- and over-represented in the tumor in respect of the normal tissue. An increased variation in the expression profile was observed in advanced Dukes' stages (P<0.02) and correlated with lymph node invasion (P<0.05). Furthermore, a diminished overall survival was associated to increased rates of deregulation (Log-rank, P<0.02) and especially down-regulation (P<0.001), When Cox multivariate analysis was performed in front of Dukes' stage, both indexes of differential expression were independent indicators of a worse outcome (P=0.05 and P<0.01 respectively). We conclude that estimation of the fraction of differentially displayed tags by RNA fingerprinting ma!: have relevant applications in the prognostic assessment of colorectal cancer.	Hosp Duran & Reynals, Dept Canc & Metastasis, Inst Recerca Oncol, Lhospitalet De Llobregat 08025, Barcelona, Spain; Hosp Santa Creu & St Pau, Serv Oncol, Barcelona, Spain; Hosp Santa Creu & St Pau, Lab Invest Gastrointestinal, Barcelona, Spain; Inst Catala Oncol, Lhospitalet De Llobregat 08907, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; Hospital of Santa Creu i Sant Pau; Hospital of Santa Creu i Sant Pau; Catalan Institute of Oncology	Peinado, MA (corresponding author), Hosp Duran & Reynals, Dept Canc & Metastasis, Inst Recerca Oncol, Autovia Castelldefels Km 2,7, Lhospitalet De Llobregat 08025, Barcelona, Spain.		Peinado, Miguel A./A-5591-2008; Capella, Gabriel/I-1879-2015; Gonzalez, Sara/D-8427-2019	Peinado, Miguel A./0000-0002-4090-793X; Capella, Gabriel/0000-0002-4669-7320; Gonzalez, Sara/0000-0002-7765-1325				Arribas R, 1997, J CLIN ONCOL, V15, P3230, DOI 10.1200/JCO.1997.15.10.3230; Baylin SB, 1997, SCIENCE, V277, P1948, DOI 10.1126/science.277.5334.1948; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; DELATTRE O, 1989, LANCET, V2, P353; Dutrillaux B, 1995, ADV CANCER RES, V67, P59, DOI 10.1016/S0065-230X(08)60710-1; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jones PA, 1997, P NATL ACAD SCI USA, V94, P2103, DOI 10.1073/pnas.94.6.2103; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; KIM HG, 1994, AM J PATHOL, V145, P148; KOKAL W, 1986, JAMA-J AM MED ASSOC, V255, P3123, DOI 10.1001/jama.255.22.3123; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Ricote M, 1997, MUTAT RES-FUND MOL M, V374, P153, DOI 10.1016/S0027-5107(97)00002-X; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; SCHLEGEL J, 1995, CANCER RES, V55, P6002; Scicchitano David A., 1997, Environmental Health Perspectives, V105, P145, DOI 10.2307/3433403; THEIN SL, 1987, BRIT J CANCER, V55, P353, DOI 10.1038/bjc.1987.71; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMAS JH, 1995, P NATL ACAD SCI USA, V92, P480, DOI 10.1073/pnas.92.2.480; Tortola S, 1998, LAB INVEST, V78, P309; Versteeg R, 1997, AM J HUM GENET, V60, P751; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WELSH J, 1992, NUCLEIC ACIDS RES, V20, P4965, DOI 10.1093/nar/20.19.4965	25	5	5	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 29	1999	18	30					4383	4387		10.1038/sj.onc.1202757	http://dx.doi.org/10.1038/sj.onc.1202757			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439046				2022-12-17	WOS:000081732700011
J	Uden, M; Morley, GM; Dibb, NJ				Uden, M; Morley, GM; Dibb, NJ			Evidence that downregulation of the M-CSF receptor is not dependent upon receptor kinase activity	ONCOGENE			English	Article						CSF-1; downregulation; fms; M-CSF; receptor	STIMULATING FACTOR-I; GROWTH-FACTOR RECEPTOR; PROTO-ONCOGENE PRODUCT; INSULIN-RECEPTOR; C-FMS; DOWN-REGULATION; POINT MUTATION; BETA-RECEPTOR; INTERNALIZATION; LIGAND	The downregulation of tyrosine kinase receptors attenuates signalling and is thought to be dependent upon intrinsic receptor kinase activity, largely because downregulation is inhibited by a kinase-inactivating mutation of an invariant lysine residue of the receptors for EGF, insulin, M-CSF and PDGF. We confirmed that this mutation inhibited the degradation of the M-CSF receptor. However, two different kinase inactivating mutations of the invariant amino acids Gly 591 and cia 633 did not prevent IM-CSF-induced receptor degradation, so demonstrating that receptor kinase activity is not essential for this process, Three other kinase-inactivating mutations were found to cause constitutive receptor degradation in the absence of M-CSF, most probably by disrupting the structure of the activating loop of the kinase domain. It is known that extensive movement of the A-loop is necessary for kinase activation and is normally induced by ligand-binding. It is therefore suggested that some aspect or consequence of the change in structure of the A-loop caused by ligand binding also activates receptor downregulation, so ensuring that downregulation is coupled to but is not necessarily dependent upon receptor kinase activity.	Hammersmith Hosp, Imperial Coll, Sch Med, Div Pediat,Cell Signalling Unit, London W12 0NN, England	Imperial College London	Dibb, NJ (corresponding author), Hammersmith Hosp, Imperial Coll, Sch Med, Div Pediat,Cell Signalling Unit, Du Cane Rd, London W12 0NN, England.							BACKER JM, 1989, P NATL ACAD SCI USA, V86, P3209, DOI 10.1073/pnas.86.9.3209; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; CARPENTIER JL, 1994, DIABETOLOGIA, V37, pS117, DOI 10.1007/BF00400835; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; Dibb NJ, 1990, GROWTH FACTORS, V2, P301, DOI 10.3109/08977199009078018; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; FORMISANO P, 1994, J BIOL CHEM, V269, P16242; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GLENNEY JR, 1988, CELL, V52, P657; GLOVER HR, 1995, ONCOGENE, V11, P1347; HALENBECK R, 1989, BIO-TECHNOL, V7, P710, DOI 10.1038/nbt0789-710; HARI J, 1987, J BIOL CHEM, V262, P15341; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; IMAMURA T, 1994, J BIOL CHEM, V269, P31019; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Krook A, 1996, BAILLIERE CLIN ENDOC, V10, P97, DOI 10.1016/S0950-351X(96)80330-2; LADNER MB, 1987, EMBO J, V6, P2693, DOI 10.1002/j.1460-2075.1987.tb02561.x; LIVNEH E, 1987, EMBO J, V6, P2669, DOI 10.1002/j.1460-2075.1987.tb02558.x; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; MORI S, 1993, J BIOL CHEM, V268, P577; MYLES GM, 1994, MOL CELL BIOL, V14, P4843, DOI 10.1128/MCB.14.7.4843; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; Seaman MNJ, 1996, CURR OPIN CELL BIOL, V8, P549, DOI 10.1016/S0955-0674(96)80034-2; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cellbio.8.1.429; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263	38	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3846	3851		10.1038/sj.onc.1202743	http://dx.doi.org/10.1038/sj.onc.1202743			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445847				2022-12-17	WOS:000081171700005
J	Yin, J; Harpaz, N; Souza, RF; Zou, TT; Kong, DH; Wang, SN; Leytin, AL; Medalie, NS; Smolinski, KN; Abraham, JM; Fleisher, AS; Meltzer, SJ				Yin, J; Harpaz, N; Souza, RF; Zou, TT; Kong, DH; Wang, SN; Leytin, AL; Medalie, NS; Smolinski, KN; Abraham, JM; Fleisher, AS; Meltzer, SJ			Low prevalence of the APC I1307K sequence in Jewish and non-Jewish patients with inflammatory bowel disease	ONCOGENE			English	Article						APC gene; I1307K sequence; inflammatory bowel disease; colorectal carcinoma; cancer genetics; Jewish	COLORECTAL-CANCER; ASHKENAZI JEWS; RISK; BREAST	A germline sequence alteration at codon 1307 of the APC gene (I1307K) has been reported in 6-7% of the Ashkenazi Jewish population in the United States. This alteration is believed to predispose the APC gene to a secondary mutation at the same locus, resulting in an increased risk of colorectal carcinoma. There is an increased risk of colorectal carcinoma in patients with inflammatory bowel disease (IBD), a relatively large proportion of whom are Ashkenazi Jews. We therefore sought to determine whether the I1307K sequence variant occurred in the germline DNA of IBD patients. To our surprise, we found this sequence in only two of 267 patients with IBD (0.7%), occurring in only 1.5% of Jewish IBD patients. The I1307K sequence variant was not found in 67 patients with esophageal cancer, 53 patients with gastric carcinoma (13 MSI-H and 44 MSI-negative), or ten patients with sporadic MSI-H colon cancer. These findings suggest that the I1307K sequence is relatively rare in the germline of Jewish as well as non-Jewish IBD patients. It does not appear to contribute to the increased colorectal cancer risk present in these patients.	Univ Maryland, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21201 USA; Baltimore VA Hosp, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Mol Biol Grad Program, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; NYU, Mt Sinai Sch Med, Dept Pathol, New York, NY USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Icahn School of Medicine at Mount Sinai; New York University	Meltzer, SJ (corresponding author), Univ Maryland, Sch Med, Dept Med, Div Gastroenterol, N3W62,22 S Greene St, Baltimore, MD 21201 USA.		Harpaz, Noam/L-3411-2017	Harpaz, Noam/0000-0003-4923-2200	NATIONAL CANCER INSTITUTE [R01CA077057, R01CA078843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047717] Funding Source: NIH RePORTER; NCI NIH HHS [CA78843, CA77057] Funding Source: Medline; NIDDK NIH HHS [DK47717] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abrahamson J, 1998, CANCER RES, V58, P2919; Asaka M, 1997, GASTROENTEROLOGY, V113, pS56, DOI 10.1016/S0016-5085(97)80013-3; CHO KR, 1992, J CELL BIOCHEM, P137; EKBOM A, 1992, GASTROENTEROLOGY, V103, P954, DOI 10.1016/0016-5085(92)90029-X; Harpaz N, 1996, SEMIN DIAGN PATHOL, V13, P339; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Lothe RA, 1998, CANCER RES, V58, P2923; LOWENFELS AB, 1993, NEW ENGL J MED, V328, P1433, DOI 10.1056/NEJM199305203282001; NUGENT FW, 1991, GASTROENTEROLOGY, V100, P1241, DOI 10.1016/0016-5085(91)70010-U; Petrukhin L, 1997, CANCER RES, V57, P5480; ROTH MP, 1989, GASTROENTEROLOGY, V96, P1016, DOI 10.1016/0016-5085(89)91618-1; Rozen P, 1999, GASTROENTEROLOGY, V116, P54, DOI 10.1016/S0016-5085(99)70228-3; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; ZLOTOGORA J, 1991, DIGEST DIS SCI, V36, P471, DOI 10.1007/BF01298876	14	5	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	1999	18	26					3902	3904		10.1038/sj.onc.1202638	http://dx.doi.org/10.1038/sj.onc.1202638			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445854				2022-12-17	WOS:000081171700012
J	Kim, JJ; Schoemaker, H				Kim, JJ; Schoemaker, H			Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine (vol 17, pg 3125, 1998)	ONCOGENE			English	Correction																		Kim JJ, 1998, ONCOGENE, V17, P3125, DOI 10.1038/sj.onc.1201736	1	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	1999	18	14					2411	2411						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT					2022-12-17	WOS:000079595500015
J	Mary, MN; Venot, C; de Fromentel, CC; Debussche, L; Conseiller, E; Cochet, O; Gruel, N; Teillaud, JL; Schweighoffer, F; Tocque, B; Bracco, L				Mary, MN; Venot, C; de Fromentel, CC; Debussche, L; Conseiller, E; Cochet, O; Gruel, N; Teillaud, JL; Schweighoffer, F; Tocque, B; Bracco, L			A tumor specific single chain antibody dependent gene expression system	ONCOGENE			English	Article						gene expression; gene therapy; scFv; p53	PHAGE DISPLAY LIBRARY; INTRACELLULAR IMMUNIZATION; HIV-1 INFECTION; 2-HYBRID SYSTEM; FV-FRAGMENTS; EGF RECEPTOR; P53; CELLS; PROMOTERS; DOMAIN	The design of conditional gene expression systems restricted to given tissues or cellular types is an important issue of gene therapy. Systems based on the targeting of molecules characteristic of the pathological state of tissues would be of interest. We have developed a synthetic transcription factor by fusing a single chain antibody (scFv) directed against p53 with the bacterial tetracycline repressor as a DNA binding domain. This hybrid protein binds to p53 and can interact with a synthetic promoter containing tetracycline-operator sequences. Gene expression can now be specifically achieved in tumor cells harboring an endogenous mutant p53 but not in a wild-type p53 containing tumor cell line or in a non-transformed cell line, Thus, a functional transactivator centered on single chain antibodies can be expressed intracellularly and induce gene expression in a scFv-mediated specific manner. This novel class of transcriptional transactivators could be referred as 'trabodies' for transcription-activating-antibodies. The trabodies technology could be useful to any cell type in which a disease related protein could be the target of specific antibodies.	Rhone Poulenc Rorer SA, Gene Med Dept, F-94403 Vitry, France; INSERM, U255, Lab Biotechnol Anticorps, F-75005 Paris, France; INSERM, U255, Inst Curie, F-75005 Paris, France	Sanofi-Aventis; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Bracco, L (corresponding author), ExonHit Therapeut SA, 65 Blvd Massena, F-75013 Paris, France.		de Fromentel, Claude Caron/Y-9715-2019	de Fromentel, Claude Caron/0000-0001-7566-3958; Teillaud, Jean-Luc/0000-0003-4442-9565				ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BIOCCA S, 1994, BIO-TECHNOL, V12, P396, DOI 10.1038/nbt0494-396; BYK G, Patent No. 9625508; Chen JD, 1996, HUM GENE THER, V7, P1515, DOI 10.1089/hum.1996.7.13-1515; CHEN X, 1995, NAT STRUCT BIOL, V2, P2; COCHET O, 1998, IN PRESS CANC RES; DaCosta LT, 1996, P NATL ACAD SCI USA, V93, P4192, DOI 10.1073/pnas.93.9.4192; deKruif J, 1996, J BIOL CHEM, V271, P7630, DOI 10.1074/jbc.271.13.7630; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; Hu SZ, 1996, CANCER RES, V56, P3055; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; Jannot CB, 1996, ONCOGENE, V13, P275; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; Luo Y, 1997, BIOTECHNIQUES, V22, P350, DOI 10.2144/97222pf02; MHASHILKAR AM, 1995, EMBO J, V14, P1542, DOI 10.1002/j.1460-2075.1995.tb07140.x; MORITZ D, 1995, GENE THER, V2, P539; Nilson BHK, 1996, GENE THER, V3, P280; PACK P, 1992, BIOCHEMISTRY-US, V31, P1579, DOI 10.1021/bi00121a001; Persic L, 1997, GENE, V187, P9, DOI 10.1016/S0378-1119(96)00628-2; Persic L, 1997, GENE, V187, P1, DOI 10.1016/S0378-1119(96)00627-0; Pilkington GR, 1996, MOL IMMUNOL, V33, P439, DOI 10.1016/0161-5890(95)00153-0; REIHSAUS E, 1990, ONCOGENE, V5, P137; RICHARDSON JH, 1995, P NATL ACAD SCI USA, V92, P3137, DOI 10.1073/pnas.92.8.3137; RICHARDSON JH, 1995, TRENDS BIOTECHNOL, V13, P306, DOI 10.1016/S0167-7799(00)88970-2; Schmidt M, 1996, INT J CANCER, V65, P538, DOI 10.1002/(SICI)1097-0215(19960208)65:4<538::AID-IJC24>3.0.CO;2-4; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; WELS W, 1995, INT J CANCER, V60, P137, DOI 10.1002/ijc.2910600120	36	5	7	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					559	564		10.1038/sj.onc.1202377	http://dx.doi.org/10.1038/sj.onc.1202377			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927213				2022-12-17	WOS:000078166500029
J	Hilbert, DM; Theisen, PW; Rudikoff, EK; Bauer, SR				Hilbert, DM; Theisen, PW; Rudikoff, EK; Bauer, SR			Interaction of abl and raf with IL-7 signaling pathway and transformation of pre-B cells from resistant mice	ONCOGENE			English	Article						pre-B lymphomagenesis; JAK-STAT signaling; raf/myc retrovirus; abl/myc retrovirus; IL-7 signal transduction	T-CELLS; MURINE PLASMACYTOMAGENESIS; LEUKEMIA-VIRUS; MYC ONCOGENES; V-ABL; EXPRESSION; ABROGATION; MOUSE; DEPENDENCE; RETROVIRUS	After in vivo inoculation with abl/myc- and raf/myc-containing retroviruses, BALB/c mice predominantly develop late stage B cell tumors (plasmacytomas) and less frequently develop earlier B-lineage tumors while DBA/2 mice do not develop B-lineage tumors. We have investigated the in vitro tumorigenic potential of these viruses using cultured normal pre-B cell lymphocytes from both BALB/c and DBA/2 mice. Interestingly, both viruses infect cultured pre-B lymphocytes from both mouse strains. Following infection, IL-7 dependent pre-B cells become independent of normal in vitro growth requirements within 24 h and can rapidly form in vivo pre-B lymphomas in both mouse strains, Mechanisms mediating loss of IL-7 dependence are different depending on whether the I nf or abl gene is present in myc-containing viruses. IL-7 JAK-STAT signaling is constitutively active in abl/myc induced pre-B cell tumors, In contrast, IL-7 JAK-STAT signaling is not constitutive in raf/myc induced pre-B cell tumors, demonstrating that subversion of this component of IL-7 signal transduction is not obligatory for pre-B cell transformation or loss of IL-7 dependence.	US FDA, Mol Immunol Lab, Ctr Biol Evaluat & Res, Div Cellular & Gene Therapies, Rockville, MD 20852 USA; NCI, Genet Lab, NIH, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bauer, SR (corresponding author), US FDA, Mol Immunol Lab, Ctr Biol Evaluat & Res, Div Cellular & Gene Therapies, Bldg 29B,2E16 HFM-521,1401 Rockville Pike, Rockville, MD 20852 USA.		Bauer, Steven/G-5559-2012	Bauer, Steven/0000-0003-2831-846X				ANDERSON PN, 1969, NATURE, V222, P994, DOI 10.1038/222994a0; ANDERSON SM, 1990, ONCOGENE, V5, P317; BENDER TP, 1987, J IMMUNOL, V139, P3822; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Corcoran AE, 1996, EMBO J, V15, P1924, DOI 10.1002/j.1460-2075.1996.tb00543.x; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DEAN M, 1987, ONCOGENE RES, V1, P279; GHIA P, 1995, EUR J IMMUNOL, V25, P3108, DOI 10.1002/eji.1830251118; HILBERT DM, 1993, ONCOGENE, V8, P1993; HILBERT DM, 1995, P NATL ACAD SCI USA, V92, P649, DOI 10.1073/pnas.92.3.649; Hilbert DM, 1996, IMMUNITY, V5, P81, DOI 10.1016/S1074-7613(00)80312-X; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LANEUVILLE P, 1992, BLOOD, V80, P1788; LARGAESPADA DA, 1992, ONCOGENE, V7, P811; LIN AY, 1996, NEOPLASTIC DIS BLOOD; MCCUBREY JA, 1993, ONCOGENE, V8, P2905; MERWIN RM, 1959, P SOC EXP BIOL MED, V101, P437; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; OKABE T, 1992, EUR J IMMUNOL, V22, P31, DOI 10.1002/eji.1830220106; POPLACK DG, 1989, CANC PRINCIPLES PRAC, P1671; Potter M, 1995, Curr Top Microbiol Immunol, V194, P83; POTTER M, 1962, NATURE, V193, P1086, DOI 10.1038/1931086a0; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; ROLINK A, 1993, ADV IMMUNOL, V53, P123, DOI 10.1016/S0065-2776(08)60499-X; ROLINK A, 1993, BLOOD, V81, P2290; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROLINK A, 1991, BIOCHEM SOC T, V19, P275, DOI 10.1042/bst0190275; ROSE FV, 1992, VIROLOGY, V188, P650, DOI 10.1016/0042-6822(92)90519-U; ROSENBERG N, 1982, CURR TOP MICROBIOL, V101, P95; Sambrook J., 1989, MOL CLONING; SCHEUERMANN RH, 1993, METHOD ENZYMOL, V218, P446; SILVA S, 1991, INT J CANCER, V49, P224, DOI 10.1002/ijc.2910490214; Smith MR, 1996, CURR PROB CANCER, V20, P6, DOI 10.1016/S0147-0272(96)80303-5; TROPPMAIR J, 1989, P NATL ACAD SCI USA, V86, P9941, DOI 10.1073/pnas.86.24.9941; WEISSINGER EM, 1993, MOL CELL BIOL, V13, P2578, DOI 10.1128/MCB.13.4.2578; WHITLOCK CA, 1981, J VIROL, V40, P577, DOI 10.1128/JVI.40.2.577-584.1981; WIERNIK PH, 1996, NEOPLASTIC DIS BLOOD	38	5	5	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2125	2135		10.1038/sj.onc.1202134	http://dx.doi.org/10.1038/sj.onc.1202134			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798684				2022-12-17	WOS:000076540900012
J	Oliveira, MLS; Roberts, TM; Druker, BJ; Armelin, MCS				Oliveira, MLS; Roberts, TM; Druker, BJ; Armelin, MCS			Mapping of polyomavirus middle T domain that is responsible for AP-1 activation	ONCOGENE			English	Article						polyomavirus; middle T antigen; cell transformation; AP-1 activation; phosphatidylinositol-3 kinase	PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; SIZED TUMOR-ANTIGEN; RECOMBINANT RETROVIRUSES; CELL-TRANSFORMATION; PROTEIN-KINASES; INTACT-CELLS; WILD-TYPE; C-FOS; JUN; EXPRESSION	Cell transformation by Polyomavirus middle T (MT) oncoprotein involves binding and activation of several cytoplasmic proteins that participate in growth factors-induced mitogenic signal transduction to the nucleus. We have previously reported that the AP-I transcriptional complex is a target for MT during cell transformation. To analyse the interactions between MT and cellular proteins that are required for constitutive AP-1 activation, we compared wild type and transformation-defective MT mutant cell lines. High AP-1 activity, assessed by gel mobility shift assays, displayed by MT-overexpressing cells, is dependent on MT binding to phosphatidylinositol-3 kinase (PI3K). Treatment with wortmannin (a specific PI3K inhibitor) leads to decreased AP-I activity. Supershift and Western blot analysis with specific antisera, indicate that JunB and cJun, but not cFos or FosB are present in the AP-1 complex. The results confirm the AP-1 complex as a downstream MT target and indicate that AP-1 activation may not be sufficient for cell transformation, since two transformation-defective MT mutants (250phe and MT322) display high AP-1 activity.	Univ Sao Paulo, Inst Quim, BR-05599970 Sao Paulo, SP, Brazil; Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Cellular & Mol Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA	Universidade de Sao Paulo; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Oregon Health & Science University	Armelin, MCS (corresponding author), Univ Sao Paulo, Inst Quim, CP 26077, BR-05599970 Sao Paulo, SP, Brazil.		Oliveira, Maria Leonor S/F-4988-2012	Oliveira, Maria Leonor/0000-0003-4849-3062; Druker, Brian/0000-0001-8331-8206				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Armelin MCS, 1996, BRAZ J MED BIOL RES, V29, P1133; ARMELIN MCS, 1985, COLD SPRING HARBOR C, V3, P195; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOLENJB, 1994, CELL, V38, P767; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; CARMICHAEL G, 1984, P NATL ACAD SCI-BIOL, V81, P679, DOI 10.1073/pnas.81.3.679; CHERINGTON V, 1986, P NATL ACAD SCI USA, V83, P4307, DOI 10.1073/pnas.83.12.4307; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; Dahl J, 1996, MOL CELL BIOL, V16, P2728; DEGROOT RP, 1992, ONCOGENE, V7, P841; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DRUKER BJ, 1990, J VIROL, V64, P4454, DOI 10.1128/JVI.64.9.4454-4461.1990; DRUKER BJ, 1992, J VIROL, V66, P5770, DOI 10.1128/JVI.66.10.5770-5776.1992; DRUKER BJ, 1992, NUCLEIC ACIDS RES, V19, P6855; Dunant NM, 1996, J VIROL, V70, P1323, DOI 10.1128/JVI.70.3.1323-1330.1996; GLENN GM, 1993, J VIROL, V67, P1945, DOI 10.1128/JVI.67.4.1945-1952.1993; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LING LE, 1992, J VIROL, V66, P1702, DOI 10.1128/JVI.66.3.1702-1708.1992; MARKLAND W, 1987, BIOCHIM BIOPHYS ACTA, V907, P299, DOI 10.1016/0304-419X(87)90011-4; MARRA F, 1995, FEBS LETT, V376, P141, DOI 10.1016/0014-5793(95)01261-0; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORGAN WC, 1988, J VIROL, V62, P3407, DOI 10.1128/JVI.62.9.3407-3414.1988; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; PALLAS DC, 1988, J VIROL, V62, P3934, DOI 10.1128/JVI.62.11.3934-3940.1988; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; POWIS G, 1994, CANCER RES, V54, P2419; RAMEH LE, 1991, ONCOGENE, V6, P1049; RAMEH LE, 1992, MOL CELL BIOL, V12, P4612, DOI 10.1128/MCB.12.10.4612; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SCHLEGEL R, 1978, CELL, V14, P587, DOI 10.1016/0092-8674(78)90244-1; SCHONTHAL A, 1992, P NATL ACAD SCI USA, V89, P4972, DOI 10.1073/pnas.89.11.4972; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SRINIVAS S, 1994, P NATL ACAD SCI USA, V91, P10064, DOI 10.1073/pnas.91.21.10064; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; THOMAS JE, 1993, ONCOGENE, V8, P2521; ULUG ET, 1990, J VIROL, V64, P3895, DOI 10.1128/JVI.64.8.3895-3904.1990; URICH M, 1995, J BIOL CHEM, V270, P29286, DOI 10.1074/jbc.270.49.29286; Urich M, 1997, ONCOGENE, V14, P1235, DOI 10.1038/sj.onc.1200982; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0	51	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					2975	2982		10.1038/sj.onc.1201841	http://dx.doi.org/10.1038/sj.onc.1201841			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662329				2022-12-17	WOS:000074125300003
J	Martinelli, R; Blandino, G; Scardigli, R; Crescenzi, M; Lombardi, D; Sacchi, A; Soddu, S				Martinelli, R; Blandino, G; Scardigli, R; Crescenzi, M; Lombardi, D; Sacchi, A; Soddu, S			Oncogenes belonging to the CSF-1 transduction pathway direct p53 tumor suppressor effects to monocytic differentiation in 32D cells	ONCOGENE			English	Article						differentiation; tumor suppression; cellular environment	GRANULOCYTIC DIFFERENTIATION; LINE; PROLIFERATION; APOPTOSIS; GROWTH; MACROPHAGE; RECEPTOR; BLOCKS	Expression of exogenous wt-p53 in different tumor cell lines can induce growth arrest, apoptosis, or differentiation. Several experimental works have highlighted the relevance of cellular context in the determination of p53-mediated final outcomes. We recently observed that these diverse wt-p53 effects can also be induced by overexpressing wt-p53 in a single cell type-the 32D myeloid progenitors-transformed with different activated oncogenes. Here we show that 32D cells transformed with two different oncogenes, v-src or c-fms [S301,F969], both belonging to the CSF-1 transduction pathway, respond to exogenous wt-p53 expression with the same final outcome-monocytic differentiation. This result is particularly significant since 32D cells do not spontaneously express the CSF-1 receptor, whereas they undergo granulocytic differentiation upon G-CSF stimulation. These data strongly support the idea that wt-p53 suppressing effects result from interactions between p53 activity and the signaling pathways activated in different transformed cells.	CRS,REGINA ELENA CANC INST,MOL ONCOGENESIS LAB,I-00158 ROME,ITALY; UNIV AQUILA,DEPT EXPT MED,I-67100 LAQUILA,ITALY	University of L'Aquila			Blandino, Giovanni/B-1137-2013; Soddu, Silvia/ABH-6774-2020; Soddu, Silvia/K-2467-2018; Crescenzi, Marco/J-3603-2018	Blandino, Giovanni/0000-0002-6970-2241; Soddu, Silvia/0000-0001-8526-0044; Soddu, Silvia/0000-0001-8526-0044; Crescenzi, Marco/0000-0003-0156-1494; Scardigli, Raffaella/0000-0003-1369-0496				ANDERSON SM, 1990, ONCOGENE, V5, P317; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BLANDINO G, 1995, ONCOGENE, V10, P731; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GREENBERGER JS, 1983, FED PROC, V42, P2762; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; HUME DA, 1983, J EXP MED, V158, P1522, DOI 10.1084/jem.158.5.1522; KRUGER A, 1991, ONCOGENE, V6, P245; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; MAVILIO F, 1989, ONCOGENE, V4, P301; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; PIERCE JH, 1990, P NATL ACAD SCI USA, V87, P5613, DOI 10.1073/pnas.87.15.5613; ROVERA G, 1987, ONCOGENE, V1, P29; Soddu S, 1996, MOL CELL BIOL, V16, P487; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; VALTIERI M, 1987, J IMMUNOL, V138, P3829	24	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					607	611		10.1038/sj.onc.1201218	http://dx.doi.org/10.1038/sj.onc.1201218			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247315				2022-12-17	WOS:A1997XN25500013
J	Colley, SM; Tilbrook, PA; Klinken, SP				Colley, SM; Tilbrook, PA; Klinken, SP			Increased transcription of the E mu-myc transgene and mRNA stabilisation produce only a modest elevation in Myc protein	ONCOGENE			English	Article						E mu-myc transgene; mRNA stabilisation; transcription; Myc protein	MESSENGER-RNA STABILITY; 5' NONCODING REGION; C-MYC; CHROMOSOME-TRANSLOCATION; IMMUNOGLOBULIN ENHANCER; MURINE PLASMACYTOMA; NEOPLASTIC-CELLS; GENE-EXPRESSION; ONCOGENE; TRANSLATION	Mice bearing the E mu-myc transgene, which Links the immunoglobulin heavy chain enhancer (E mu) with c-myc, are predisposed to developing B cell lymphomas, Several B lineage cell lines have been isolated from these animals, and some have been converted to macrophages following infection with v-raf. In this study we compared the regulation of myc expression in E mu-myc B lymphoma lines, their macrophage counterparts and other non-myc transformed B cell lines, Nuclear run-on analyses demonstrated that transcription of the transgene was elevated in E mu-myc B cell lines, Moreover, the presence of a 600 bp phi X174 marker in the 3' end of the transgene produced a marked stabilisation of this RNA species, Consequently, steady state myc mRNA levels in the E mu-myc B lymphoma cells were tenfold higher than the macrophage derivatives and non-myc transformed B Lineage lines, Despite the considerable difference in myc RNA levels, the E mu-myc B cell Lines contained only 30-50% more Myc protein than the other cell lines, This discrepancy between RNA and protein content was not due to increased degradation of the protein as the half life was normal in the transgenic cell lines, These results indicate that both E mu and phi X174 sequences influence transgenic myc expression and that protein levels do not correlate with RNA content in E mu-myc cell lines.	UNIV WESTERN AUSTRALIA, DEPT BIOCHEM, LAB CANC MED, ROYAL PERTH HOSP, NEDLANDS, WA 6001, AUSTRALIA	Royal Perth Hospital; University of Western Australia				Colley, Shane/0000-0002-5792-7005				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; AGHIB DF, 1990, ONCOGENE, V5, P707; ALEXANDER WS, 1987, MOL CELL BIOL, V7, P1436, DOI 10.1128/MCB.7.4.1436; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BAUER SR, 1989, ONCOGENE, V4, P615; BONNIEU A, 1988, ONCOGENE RES, V3, P155; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLE MD, 1990, ENZYME, V44, P167, DOI 10.1159/000468755; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CORCORAN LM, 1985, CELL, V40, P71, DOI 10.1016/0092-8674(85)90310-1; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GOODALL GJ, 1990, METHOD ENZYMOL, V181, P148; GOUGH NM, 1980, P NATL ACAD SCI-BIOL, V77, P554, DOI 10.1073/pnas.77.1.554; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HOLLIS GF, 1988, MOL CELL BIOL, V8, P124, DOI 10.1128/MCB.8.1.124; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; LAIRDOFFRINGA IA, 1990, MOL CELL BIOL, V10, P6132, DOI 10.1128/MCB.10.12.6132; LAIRDOFFRINGA IA, 1992, BIOESSAYS, V14, P119, DOI 10.1002/bies.950140209; LANGDON WY, 1988, ONCOGENE RES, V3, P271; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LAZARUS P, 1988, ONCOGENE, V3, P517; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PERSSON H, 1985, MOL CELL BIOL, V5, P2903, DOI 10.1128/MCB.5.11.2903; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STANTON LW, 1984, P NATL ACAD SCI-BIOL, V81, P829, DOI 10.1073/pnas.81.3.829; Tilbrook PA, 1996, J BIOL CHEM, V271, P3453; WINGROVE TG, 1988, J BIOL CHEM, V263, P8918	39	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	1997	14	22					2735	2739		10.1038/sj.onc.1201113	http://dx.doi.org/10.1038/sj.onc.1201113			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XB978	9178772				2022-12-17	WOS:A1997XB97800013
J	Altabef, M; Garcia, M; VariorKrishnan, G; Samarut, J				Altabef, M; Garcia, M; VariorKrishnan, G; Samarut, J			A truncated RAR alpha co-operates with the v-erbB oncogene to transform early haematopoietic progenitors in vitro and in vivo	ONCOGENE			English	Article						nuclear hormone receptor; leukaemic transformation; haematopoietic differentiation	RETINOIC ACID RECEPTOR; ACUTE PROMYELOCYTIC LEUKEMIA; DOMINANT-NEGATIVE ACTIVITY; HEPATOCELLULAR-CARCINOMA; TRANSCRIPTION FACTOR; HORMONE RECEPTORS; CELLS-INVITRO; TARGET-CELLS; VIRUS; GENE	We have shown recently that a retrovirus vector expressing a natural mutant form of the PML-RAR alpha protein characteristic of human acute promyelocytic leukaemia can transform early chicken hematopoietic progenitors (Altabef et al., 1996). Neither truncated PML nor truncated RAR alpha alone could induce transformation which suggest that the two domains should co-operate for the oncogenicity of the fusion product. To further investigate the mechanisms of this co-operation, we have tested whether a truncated RAR alpha could co-operate with the v-erbB oncogene. This oncogene has previously been shown to co-operate with the rearranged thyroid hormone receptor, v-erbA, to transform erythrocytic progenitors. We show that v-erbB and a truncated RAR alpha co-operate when expressed simultaneously as independent products to transform very early chicken haematopoietic cells close to pluripotent stage. In addition, we show that v-erbB alters transcriptional abilities of RAR alpha by both enhancing its effects on RARE and reducing those on AP-1. Therefore, RAR alpha is able to co-operate with different kinds of proteins to induce transformation of early haematopoietic cells. This strongly suggests that RAR alpha are involved in the differentiation commitment of early haematopoietic progenitors during the normal process of haematopoietic differentiation. These data bring new insights in the mechanisms of oncogenic transformation by rearranged RAR alpha.	ECOLE NORMALE SUPER LYON,BIOL CELLULAIRE & MOL LAB,UMR49 CNRS,INRA,LAB ASSOCIE 913,F-69364 LYON 07,FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON); INRAE			Samarut, Jacques/AAD-2587-2019					ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; ALLENBY G, 1994, J BIOL CHEM, V269, P16689; ALTABEF M, 1996, EMBO J, V15, P270; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CHAMBON P, 1993, GENE, V135, P223, DOI 10.1016/0378-1119(93)90069-F; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DOUCAS V, 1993, P NATL ACAD SCI USA, V90, P9345, DOI 10.1073/pnas.90.20.9345; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GANDRILLON O, 1995, INT J ONCOL, V6, P215; GARCIA M, 1993, P NATL ACAD SCI USA, V90, P89, DOI 10.1073/pnas.90.1.89; GARCIA M, 1990, J VIROL, V64, P4684, DOI 10.1128/JVI.64.10.4684-4690.1990; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GUDAS LJ, 1994, J BIOL CHEM, V269, P15399; HERMANN T, 1993, ONCOGENE, V8, P55; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCNAGNY KM, 1992, LEUKEMIA, V6, P975; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NICOLSON RC, 1990, EMBO J, V9, P4443; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; SAMARUT J, 1982, CELL, V28, P921, DOI 10.1016/0092-8674(82)90071-X; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TSAI S, 1992, GENE DEV, V6, P2258, DOI 10.1101/gad.6.12a.2258; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; YANGYEN HF, 1991, NEW BIOL, V3, P1206	43	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 27	1997	14	12					1471	1479		10.1038/sj.onc.1200984	http://dx.doi.org/10.1038/sj.onc.1200984			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136991				2022-12-17	WOS:A1997WT58400010
J	Stiegler, P; Schuchner, S; Lestou, V; Wintersberger, E				Stiegler, P; Schuchner, S; Lestou, V; Wintersberger, E			Polyomavirus large T antigen-dependent DNA amplification	ONCOGENE			English	Article						DNA amplification; tumor viruses; cell cycle; checkpoint; tumorsuppressors	CELL-CYCLE CONTROL; SV40-TRANSFORMED HUMAN-CELLS; CHINESE-HAMSTER CELLS; WILD-TYPE P53; GENE AMPLIFICATION; GROWTH ARREST; RETINOBLASTOMA PROTEIN; GENOMIC INSTABILITY; HUMAN FIBROBLASTS; ADENOVIRUS E1A	DNA amplification is a readily measurable indicator for genome destabilization. Contrary to normal senescing cells, those of most immortal or transformed cell lines are karyotypically unstable and permissive for amplification. Permissivity for amplification can be generated by gene products of several DNA tumor viruses whereby their interaction with the tumorsuppressor protein p53 is important. p53 is the major protein involved in check point control of DNA damage. Polyomavirus large T antigen is also involved in immortalization and transformation of cells but it does not interact with p53. We, therefore, examined whether this protein could still make the non-permissive cell line REF52 permissive for gene amplification. To this end REF52 cell lines were constructed which conditionally expressed the wild type polyomavirus large T antigen or a mutant form unable to bind the retinoblastoma protein. Using the inhibitor of de novo pyrimidine biosynthesis, phosphonoacetyl-L-aspartate (PALA), as selective agent we found that PALA resistant cells arise with a frequency of about 5x10(-5) and that the interaction of polyomavirus large T protein with the retinoblastoma protein or another related pocket protein is important for this to occur. PALA resistant cells have an increased number of chromosomes and dicentric chromosomes which are considered as starting point for DNA structures characteristic for amplified DNA. Such structures were indeed found with the help of fluorescence in situ hybridization. PALA resistant cells appear normal with respect to p53. Our data indicate that PALA induces a G(1) block which can be partially overcome by polyomavirus large T protein by its interaction with E2F-pocket protein complexes providing further evidence that these complexes are downstream targets of p53.	UNIV VIENNA, VIENNA BIOCTR, INST MOL BIOL, VIENNA, AUSTRIA; ST ANNA CHILDRENS HOSP, A-1090 VIENNA, AUSTRIA	University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); Saint Anna Children's Hospital								ADAMCZEWSKI JP, 1993, J VIROL, V67, P6551, DOI 10.1128/JVI.67.11.6551-6557.1993; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DAVIDSON JN, 1990, DNA CELL BIOL, V9, P667, DOI 10.1089/dna.1990.9.667; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; GANNON JV, 1991, NATURE, V349, P802; HAMLIN JL, 1991, PROG NUCLEIC ACID RE, V41, P203; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HICKMAN ES, 1994, ONCOGENE, V9, P2177; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; ISHIZAKA Y, 1995, P NATL ACAD SCI USA, V92, P3224, DOI 10.1073/pnas.92.8.3224; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; KOUZARIDES T, 1995, TRENDS CELL BIOL, V5, P448, DOI 10.1016/S0962-8924(00)89109-6; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE WH, 1994, COLD SPRING HARB SYM, V59, P97, DOI 10.1101/SQB.1994.059.01.013; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MUDRAK I, 1994, MOL CELL BIOL, V14, P1886, DOI 10.1128/MCB.14.3.1886; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; OGRIS E, 1992, J VIROL, V66, P53, DOI 10.1128/JVI.66.1.53-61.1992; OTTO E, 1989, J BIOL CHEM, V264, P3390; PALLAS DC, 1986, J VIROL, V60, P1075, DOI 10.1128/JVI.60.3.1075-1084.1986; PERRY ME, 1992, P NATL ACAD SCI USA, V89, P8112, DOI 10.1073/pnas.89.17.8112; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; Poupon MF, 1996, MOL BIOL CELL, V7, P345, DOI 10.1091/mbc.7.3.345; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; RUBELJ I, 1994, EXP CELL RES, V211, P82, DOI 10.1006/excr.1994.1062; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SMITH KA, 1990, CELL, V63, P1219, DOI 10.1016/0092-8674(90)90417-D; STARK GR, 1993, ADV CANCER RES, V61, P87, DOI 10.1016/S0065-230X(08)60956-2; SZEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320; Thomas RC, 1996, EXP CELL RES, V223, P227, DOI 10.1006/excr.1996.0076; TLSTY TD, 1990, P NATL ACAD SCI USA, V87, P3132, DOI 10.1073/pnas.87.8.3132; TLSTY TD, 1989, P NATL ACAD SCI USA, V86, P9441, DOI 10.1073/pnas.86.23.9441; TOLEDO F, 1993, CURR BIOL, V3, P255, DOI 10.1016/0960-9822(93)90175-N; VOUSDEN KH, 1993, ONCOGENE, V8, P1697; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; WINTERSBERGER E, 1994, CHROMOSOMA, V103, P73, DOI 10.1007/BF00352315; WOODS C, 1994, ONCOGENE, V9, P2943; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZERFASS K, 1995, J GEN VIROL, V76, P1815, DOI 10.1099/0022-1317-76-7-1815; ZHU XL, 1995, MOL CELL BIOL, V15, P5017	59	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	1997	14	8					987	995		10.1038/sj.onc.1200904	http://dx.doi.org/10.1038/sj.onc.1200904			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050998				2022-12-17	WOS:A1997WK34400012
J	Stoppler, H; Koval, D; Schlegel, R				Stoppler, H; Koval, D; Schlegel, R			The serine protease inhibitors TLCK and TPCK inhibit the in vitro immortalization of primary human keratinocytes by HPV-18 DNA	ONCOGENE			English	Article						HPV-immortalization; E7-Rb binding; serine protease inhibitors (TLCK/TPCK)	HUMAN PAPILLOMAVIRUS TYPE-16; LYSINE CHLOROMETHYL KETONE; RAT EMBRYO FIBROBLASTS; CATALYTIC SUBUNIT; TRANSFORMING GENE; E6 ONCOPROTEIN; KINASE-C; E7 GENE; HA-RAS; CELLS	The human papillomaviruses (HPV) which are commonly found in anogenital malignancies express viral E7 oncoprotein which possesses both immortalizing and transforming activities. The E7 protein forms a complex with the cellular tumor suppressor protein Rb and alters its interaction with transcription factor E2F, presumably interfering with cell cycle control and contributing to cellular transformation/immortalization. We demonstrated earlier that the serine protease inhibitors tosyl-L-phenylalanine chloromethyl ketone (TPCK) and tosyl-L-lysine chloromethyl ketone (TLCK) modified the HPV type 18 E7 protein in cell extracts as well as in Living cells and abrogated its ability to form a complex with Rb. In the present study we evaluated the effect of TLCK or TPCK treatment on the immortalization of primary keratinocytes by transfected HPV-18 DNA. Supplementing the medium of primary foreskin keratinocytes with TLCK or TPCK during their immortalization with HPV 18 DNA demonstrated that either TLCK (5-10 mu M) or TPCK (0.25 mu M) could inhibit cellular immortalization by 50-100% without altering keratinocyte proliferation, suggesting that the topical application of these reagents in ripe could significantly interfere with HPV-mediated cellular transformation.	GEORGETOWN UNIV, MED CTR, DEPT PATHOL, MOL PATHOBIOL PROGRAM, WASHINGTON, DC 20007 USA	Georgetown University								BARBOSA MS, 1989, ONCOGENE, V4, P1529; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; CHESTERS PM, 1989, J GEN VIROL, V70, P353, DOI 10.1099/0022-1317-70-2-353; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HAUSEN HZ, 1988, MOL CARCINOGEN, V1, P147, DOI 10.1002/mc.2940010302; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KANDA T, 1988, VIROLOGY, V165, P321, DOI 10.1016/0042-6822(88)90694-0; KINZEL V, 1980, BIOCHEM BIOPH RES CO, V93, P349, DOI 10.1016/0006-291X(80)91083-9; KUPFER A, 1979, P NATL ACAD SCI USA, V76, P3073, DOI 10.1073/pnas.76.7.3073; LALOU CI, 1993, BIOCHIMIE, V75, P443, DOI 10.1016/0300-9084(93)90109-6; LIU ZJ, 1994, VIROLOGY, V201, P388, DOI 10.1006/viro.1994.1306; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MUNGER K, 1989, J VIROL, V63, P4417; PEACOCK JW, 1990, ONCOGENE, V5, P1769; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; SCHNEBLI HP, 1972, P NATL ACAD SCI USA, V69, P3825, DOI 10.1073/pnas.69.12.3825; SCHOELLMANN G, 1963, BIOCHEMISTRY-US, V2, P252, DOI 10.1021/bi00902a008; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SHAW E, 1970, PHYSIOL REV, V50, P244, DOI 10.1152/physrev.1970.50.2.244; SOLOMON DH, 1985, FEBS LETT, V190, P342, DOI 10.1016/0014-5793(85)81315-6; Stoppler H, 1996, VIROLOGY, V217, P542, DOI 10.1006/viro.1996.0149; STOPPLER H, 1994, INTERVIROLOGY, V37, P168; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STOREY A, 1993, ONCOGENE, V8, P919; TANAKA A, 1989, J VIROL, V63, P1465, DOI 10.1128/JVI.63.3.1465-1469.1989; TROLL W, 1970, SCIENCE, V169, P1211, DOI 10.1126/science.169.3951.1211; VILLA LL, 1991, VIROLOGY, V181, P374; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167	36	5	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1545	1548						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875993				2022-12-17	WOS:A1996VL38400020
J	Hawker, KL; Vass, JK; Ozanne, BW				Hawker, KL; Vass, JK; Ozanne, BW			Isolation of novel, transcriptionally active AP-1 binding sites: Implications for cellular transformation	ONCOGENE			English	Article						c-fos; v-fos; transformation; AP-1	C-FOS; GROWTH-FACTOR; PHYSICAL ASSOCIATION; JUN ONCOGENE; V-JUN; DNA; GENE; PROTEIN; TRANSACTIVATION; COMPLEXES	Increased AP-1 DNA-binding activity, in the context of TRE-binding, is not a consequence of Fos transformation. In this report we investigate the possibility of a change in binding site preference by vFosAP-1 compared with AP-1 from an untransformed cell. Fos binding sites mere immunoselected from random sequence oligonucleotides using a pan Fos anti-serum with nuclear protein from quiescent FBRp75(v-fos)-transformed (FBR) and normal (208F) rat fibroblasts. The selected oligonucleotides were aligned by computer and a consensus described for the sequences bound by AP-1 from the two cell lines. The vFos binding site is shown to be a consensus TRE, whereas the sequence ACCACATC is described as the cellular Fos protein family consensus. We demonstrate that sequences differing from the TRE consensus can bind AP-1 and direct transcription. AP-1 DNA-binding activity differs between normal and transformed cells with several of the selected oligonucleotides. These sequences also demonstrate differential transcriptional activation between normal and transformed cells. In particular, the 208F consensus has no transcriptional activity in FBR cells. Further, EGF differentially influences the transcriptional activity of the oligonucleotides in 208F and FBR cells. Our results suggest that AP-1 may change its preferred binding site depending on the proteins available at any given time, the sequences flanking a non-consensus TRE or even the environment in which the cell exists. These differences in binding site preference and transcriptional activation may result in the increased transforming ability. of the v-fos oncogene compared with the c-fos proto-oncogene and may extend the potential target genes beyond those with an AP-1 consensus binding site.	BEATSON INST CANC RES,CRC,BEATSON LABS,GLASGOW G61 1BD,LANARK,SCOTLAND	Beatson Institute								ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BOHMAN D, 1989, CELL, V52, P705; CARICASOLE A, 1993, NUCLEIC ACIDS RES, V21, P1873, DOI 10.1093/nar/21.8.1873; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; CHUI R, 1988, CELL, V54, P541; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; FELTS SJ, 1995, BIOCHEMISTRY-US, V34, P12355, DOI 10.1021/bi00038a032; FINKEL MP, 1975, FRONTIERS RADIATION, V10, P28; FRAME MC, 1991, ONCOGENE, V6, P205; GOLDBERG Y, 1994, J BIOL CHEM, V269, P16566; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; GROSKOPF JC, 1994, MOL CELL BIOL, V14, P6013, DOI 10.1128/MCB.14.9.6013; HADMAN M, 1993, ONCOGENE, V8, P1895; HAWKER KL, 1993, J VIROL, V67, P5487, DOI 10.1128/JVI.67.9.5487-5495.1993; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; HERTZ GZ, 1990, COMPUT APPL BIOSCI, V6, P81; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JOOSS K, 1992, ONCOGENE, V7, P1933; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kataoka K, 1996, ONCOGENE, V12, P53; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KERPPOLA TK, 1994, ONCOGENE, V9, P3149; KIZAKAKONDOH S, 1992, MOL CELL BIOL, V12, P5078, DOI 10.1128/MCB.12.11.5078; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KRAMER B, 1995, J BIOL CHEM, V270, P6577; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCIBELLO FC, 1991, NEW BIOL, V3, P671; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; MORGAN IM, 1993, ONCOGENE, V8, P1135; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; MULLER U, 1992, J VIROL, V66, P5867; NEUBERG M, 1991, ONCOGENE, V6, P1325; OEHLER T, 1993, ONCOGENE, V8, P1141; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; Ransone Lynn J., 1993, Gene Expression, V3, P37; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1991, ONCOGENE, V6, P553; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429	56	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					283	292						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710367				2022-12-17	WOS:A1996VA25200007
J	RiveroLezcano, OM; Marcilla, A; Robbins, KC				RiveroLezcano, OM; Marcilla, A; Robbins, KC			Mutations in the non-catalytic domains of Fyn and Fgr tyrosine kinases reveal differences in mechanisms of their regulation	ONCOGENE			English	Article						Fyn; Fgr; tyrosine kinase; mutation; SH2 and SH3 domains	PROTEIN-KINASES; SH2 DOMAIN; C-SRC; GENE; PROTOONCOGENE; ACTIVATION; P60C-SRC; BINDING	Non-catalytic domains of tyrosine kinases from the Src family are believed to be regulated intra- and intermolecularly through protein-protein interactions. We have deleted the SH2 and SH3 domains from Fyn and Fgr and have generated two point mutations in residues completely conserved in all members of the Src family. The dramatically different biological effects of these mutations suggest that non-catalytic domains regulate Src family kinase activities through distinctly different mechanisms.	NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			marcilla, antonio/F-9996-2010; Rivero-Lezcano, Octavio Miguel/J-9089-2015	marcilla, antonio/0000-0003-0004-0531; Rivero-Lezcano, Octavio Miguel/0000-0002-8793-0731				ABRAMS CS, 1995, J BIOL CHEM, V270, P333, DOI 10.1074/jbc.270.1.333; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BOEUF H, 1995, ONCOGENE, V10, P433; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHANG CM, 1995, P NATL ACAD SCI USA, V92, P3928, DOI 10.1073/pnas.92.9.3928; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1984, J BIOL CHEM, V259, P7835; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; RIVEROLEZCANO OM, 1994, FEBS LETT, V338, P183, DOI 10.1016/0014-5793(94)80361-7; ROBBINS KC, 1985, EMBO J, V4, P1783, DOI 10.1002/j.1460-2075.1985.tb03851.x; SARTOR O, 1992, J BIOL CHEM, V267, P3460; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; VEILLETTE A, 1992, ONCOGENE, V7, P971; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417	20	5	5	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2675	2679						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545125				2022-12-17	WOS:A1995TP18800024
J	WU, LW; HACKETT, PB				WU, LW; HACKETT, PB			DEVELOPMENT OF CELLULAR-RESISTANCE TO PP60(V-SRC) KINASE-INDUCED CELL-DEATH	ONCOGENE			English	Article						CYTOTOXICITY; PP60(V-SRC) OVEREXPRESSION; TYROSINE KINASE	ROUS-SARCOMA VIRUS; PROTEIN-TYROSINE PHOSPHATASES; HEAT-SHOCK; V-SRC; GENE-EXPRESSION; C-SRC; TRANSFORMING GENE; MAMMALIAN-CELLS; PHOSPHORYLATION; FIBROBLASTS	The v-src gene of Rous sarcoma virus (RSV) encodes pp60(v-src) a tyrosine kinase that can initiate cellular transformation. High levels of v-src gene expression can either be cytotoxic or the cause of altered expression of cellular genes, Examination of cytotoxic thresholds is difficult because cells expressing high levels of a cytotoxic oncogene will die. To evaluate quantitatively the cytotoxicity of pp60(v-src) on growth, we amplified two different v-src genes, under the control of the human hsp70B heat shock promoter to establish cell clones with varying copy numbers of the heat-inducible v-src gene. The viability of cell lines over a prolonged period of time depended on the particular src gene, the expression of v-src mRNA, synthesis of the pp60(v-src) protein and, most importantly, the tyrosine kinase activity of the pp60(v-src) protein. We found a relatively sharp threshold in v-src-encoded tyrosine kinase activity above which cell viability rapidly declines. However, over time, tyrosine kinase activity was exponentially suppressed at about a 10-fold higher rate than pp60(v-src) protein during passage. Our results indicate that homeostasis: of tyrosine phosphorylation is important for cell viability, that perturbation of this balance results in cell mortality, and that cells can evolve to accommodate overexpression of oncogene by downregulating the level of tyrosine kinase activity.	UNIV MINNESOTA, DEPT GENET & CELL BIOL, ST PAUL, MN 55108 USA; UNIV MINNESOTA, INST HUMAN GENET, ST PAUL, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NCI NIH HHS [R01 CA 1983881] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELGHANY M, 1990, P NATL ACAD SCI USA, V87, P7061, DOI 10.1073/pnas.87.18.7061; ANTCZAK M, 1990, J VIROL, V64, P1451, DOI 10.1128/JVI.64.4.1451-1458.1990; APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; ASHBURNER M, 1979, CELL, V17, P241, DOI 10.1016/0092-8674(79)90150-8; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; BISHOP JM, 1982, RNA TUMOR VIRUS MOL, P1001; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; BRUGGE JS, 1987, MOL CELL BIOL, V7, P2180, DOI 10.1128/MCB.7.6.2180; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COURTNEIDGE SA, 1980, P NATL ACAD SCI-BIOL, V77, P3783, DOI 10.1073/pnas.77.7.3783; COURTNEIDGE SA, 1994, SEMIN CANCER BIOL, V5, P239; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DEHBI M, 1992, MOL CELL BIOL, V12, P1490, DOI 10.1128/MCB.12.4.1490; DEWEY WC, 1971, INT J RADIAT BIOL RE, V20, P505, DOI 10.1080/09553007114551421; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FORNACE AJ, 1989, EXP CELL RES, V182, P61, DOI 10.1016/0014-4827(89)90279-6; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HOSKINS JM, 1956, EXP CELL RES, V11, P297, DOI 10.1016/0014-4827(56)90105-7; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JACKS CM, 1988, NUCLEIC ACIDS RES, V16, P10751, DOI 10.1093/nar/16.22.10751; JAKOBOVITS EB, 1984, CELL, V38, P757, DOI 10.1016/0092-8674(84)90271-X; JEHN B, 1992, MOL CELL BIOL, V12, P3890, DOI 10.1128/MCB.12.9.3890; JOHNSTON RN, 1988, SCIENCE, V242, P1551, DOI 10.1126/science.3201244; KAMMANN M, 1989, NUCLEIC ACIDS RES, V17, P5404, DOI 10.1093/nar/17.13.5404; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KATAGIRI T, 1989, P NATL ACAD SCI USA, V86, P10064, DOI 10.1073/pnas.86.24.10064; KAUFMAN RJ, 1987, EMBO J, V6, P187, DOI 10.1002/j.1460-2075.1987.tb04737.x; KAUFMAN RJ, 1985, MOL CELL BIOL, V5, P1750, DOI 10.1128/MCB.5.7.1750; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; LI GC, 1983, J CELL PHYSIOL, V115, P116, DOI 10.1002/jcp.1041150203; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LIU ZJ, 1989, NUCLEIC ACIDS RES, V17, P3986, DOI 10.1093/nar/17.10.3986; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MOUSTAKAS A, 1993, J VIROL, V67, P4337, DOI 10.1128/JVI.67.7.4337-4349.1993; NELSON RL, 1984, MOL CELL BIOL, V4, P1003, DOI 10.1128/MCB.4.6.1003; OZAKI T, 1993, P NATL ACAD SCI USA, V90, P2593, DOI 10.1073/pnas.90.7.2593; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PETERSEN RB, 1989, J VIROL, V63, P4787, DOI 10.1128/JVI.63.11.4787-4796.1989; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SCHLESINGER MJ, 1989, STRESS INDUCED PROTE, P137; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STOLTZFUS CM, 1987, J VIROL, V61, P3401, DOI 10.1128/JVI.61.11.3401-3409.1987; TARPLEY WG, 1984, MOL CELL BIOL, V4, P2653, DOI 10.1128/MCB.4.12.2653; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VOELLMY R, 1985, P NATL ACAD SCI USA, V82, P4949, DOI 10.1073/pnas.82.15.4949; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WARREN SL, 1988, MOL CELL BIOL, V8, P632, DOI 10.1128/MCB.8.2.632; WASILENKO WJ, 1990, MOL CELL BIOL, V10, P1254, DOI 10.1128/MCB.10.3.1254; WATANABE SM, 1983, J VIROL, V45, P1028, DOI 10.1128/JVI.45.3.1028-1036.1983; WILSON C, 1990, ANNU REV CELL BIOL, V6, P679, DOI 10.1146/annurev.cb.06.110190.003335; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; WU LW, 1993, THESIS U MINNESOTA; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	69	5	5	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1459	1468						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478570				2022-12-17	WOS:A1995TC53500004
J	LARMINAT, F; BEECHAM, EJ; LINK, CJ; MAY, A; BOHR, VA				LARMINAT, F; BEECHAM, EJ; LINK, CJ; MAY, A; BOHR, VA			DNA-REPAIR IN THE ENDOGENOUS AND EPISOMAL AMPLIFIED C-MYC ONCOGENE LOCI IN HUMAN TUMOR-CELLS	ONCOGENE			English	Article						DNA REPAIR; C-MYC ONCOGENE; DOUBLE-MINUTE CHROMOSOME	COMPLEMENTATION GROUP-C; HOMOGENEOUSLY STAINING REGIONS; DIHYDROFOLATE-REDUCTASE GENE; HUMAN-COLON CARCINOMA; MATRIX ASSOCIATED DNA; ULTRAVIOLET-LIGHT; DOUBLE MINUTES; TRANSCRIPTION; AMPLIFICATION; FIBROBLASTS	We have studied the repair of u.v.-induced cyclobutane pyrimidine diners (CPDs) in amplified c-myr: oncogene loci in human colon cancer cells to better understand the relationship between chromatin structure, transcription and DNA repair. To assess the variation in DNA repair in the same gene whether located in a chromosomal site or in a extra-chromosomal site, we have quantitated the efficiency of excision repair after u.v. exposure in the endogenous and episomal c-myc genes isolated from COLO320HSR and DM cells. In the HSR cells, c-myc is localized in a homogeneously staining region (HSR), and in the DM cells, the gene is localized in double minute chromosomes (DM). Our results indicate that the repair is less efficient in c-myc amplicons organized as double minute chromosomes than in the endogenous c-myc amplicons, The episomal gene is not repaired with the same efficiency as when it is intrachromosomal. This may reflect differences in chromatin structure. An advantage of this biological system is that the cells possess two different alleles of the c-myc gene, one that is active and another which is inactive. We have studied the relationship between DNA repair and transcriptional activity in the c-myc locus by measuring the efficiency of excision repair after u.v. exposure in the normal and rearranged alleles of the c-myc gene. Surprisingly, the c-myc gene is repaired with similar efficiency in the highly transcribed allele as in the poorly expressed allele. However, u.v. damage is selectively removed from the transcribed strand of the active c-myc allele, but DNA repair is not strand specific in the non-expressed c-myc allele.	NIA, MOLEC GENET LAB, BALTIMORE, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)			Bohr, Vilhelm/AAP-5931-2020					ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BEECHAM EJ, 1991, MOL CELL BIOL, V11, P3095, DOI 10.1128/MCB.11.6.3095; BIANCHI NO, 1991, DNA CELL BIOL, V10, P125, DOI 10.1089/dna.1991.10.125; Biedler JL, 1983, ADV CELL NEUROBIOL, V4, P268; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOHR VA, 1986, J BIOL CHEM, V261, P6666; BOHR VA, 1991, CARCINOGENESIS, V12, P1983, DOI 10.1093/carcin/12.11.1983; BOHR VA, 1988, DNA REPAIR LABORATOR, P347; BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; CLEAVER JE, 1983, J MOL BIOL, V170, P305, DOI 10.1016/S0022-2836(83)80150-8; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; COWELL JK, 1982, ANNU REV GENET, V16, P21, DOI 10.1146/annurev.ge.16.120182.000321; DESALUM SB, 1984, CANCER GENET CYTOGEN, V11, P53, DOI 10.1016/0165-4608(84)90098-0; HAHN PJ, 1993, BIOESSAYS, V15, P477, DOI 10.1002/bies.950150707; KANTOR GJ, 1990, MUTAT RES, V235, P171, DOI 10.1016/0921-8777(90)90071-C; MADHANI HD, 1986, CELL, V45, P417, DOI 10.1016/0092-8674(86)90327-2; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MITCHELL DL, 1994, PHOTOCHEM PHOTOBIOL, V60, P221, DOI 10.1111/j.1751-1097.1994.tb05094.x; MULLENDERS LHF, 1988, NUCLEIC ACIDS RES, V16, P10607, DOI 10.1093/nar/16.22.10607; MULLENDERS LHF, 1984, MUTAT RES, V141, P75, DOI 10.1016/0165-7992(84)90014-9; QUINN LA, 1979, CANCER RES, V39, P4914; RONAI ZA, 1988, ONCOGENE, V2, P201; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHIMKE RT, 1982, GENE AMPLIFICATION, P317; SCHWAB M, 1986, MOL CELL BIOL, V6, P2752, DOI 10.1128/MCB.6.7.2752; SHTIVELMAN E, 1989, MOL CELL BIOL, V9, P1148, DOI 10.1128/MCB.9.3.1148; SHTIVELMAN E, 1990, MOL CELL BIOL, V10, P1835, DOI 10.1128/MCB.10.4.1835; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; VANDEVANTER DR, 1993, GENE CHROMOSOME CANC, V6, P190, DOI 10.1002/gcc.2870060310; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; YANG JK, 1984, J MOL BIOL, V176, P169, DOI 10.1016/0022-2836(84)90419-4	36	5	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1639	1645						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731719				2022-12-17	WOS:A1995QU68100021
J	YANG, JJ; KANG, JS; KRAUSS, RS				YANG, JJ; KANG, JS; KRAUSS, RS			TRANSFORMATION-RESTORING FACTOR - A LOW-MOLECULAR-WEIGHT SECRETED FACTOR REQUIRED FOR ANCHORAGE-INDEPENDENT GROWTH OF ONCOGENE-RESISTANT MUTANT-CELL LINES	ONCOGENE			English	Article						CELLULAR TRANSFORMATION; GENETIC REVERTANT; RAS ONCOGENE; GROWTH FACTORS; SIGNAL TRANSDUCTION	ACTIVATED PROTEIN-KINASE; H-RAS ONCOGENE; SIGNAL-TRANSDUCTION; MAP KINASES; NUDE MICE; PHOSPHORYLATION; TUMORIGENICITY; FIBROBLASTS; EXPRESSION; REVERTANTS	We have previously described two independent mutant rat fibroblast cell lines that fail to form colonies in soft agar when infected with a v-H-ras-expressing retrovirus, yet still undergo transformation-related morphological alterations in response to this oncogene, We report here that conditioned medium (CM) from non-transformed rat fibroblasts contains an activity that specifically corrects this defect in the mutant cell lines, rendering them capable of anchorage-independent growth in response to uas, The major activity in CM, designated transformation-restoring factor (TRF), is similar to 1300 molecular weight, lipid insoluble, and heat, protease, acid and base stable, Latent activity, distinct from TRF, is also present in CM; several lines of evidence indicate that transforming growth factor (TGF) beta is responsible for this activity, TRF, however, cannot substitute for TGF beta in the phenotypic transformation of NRK cells, TRF activity is decreased in CM of control cells transformed by uas and this response to ras is retained by the mutant cell lines, We propose that whereas wild-type cells transformed by ras may constitutively activate a TRF-regulated pathway, thus becoming independent of TRF for growth in soft agar, these mutants have acquired dependence on an exogenous supply of TRF for this aspect of the transformed phenotype, Cellular activities regulated, directly or indirectly, by TRF may be effecters of the anchorge-independent growth property that is a hallmark of transformed rodent fibroblasts.	MT SINAI SCH MED, DEPT BIOCHEM, NEW YORK, NY 10029 USA	Icahn School of Medicine at Mount Sinai					NATIONAL CANCER INSTITUTE [R01CA059474, R29CA059474] Funding Source: NIH RePORTER; NCI NIH HHS [CA59474] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANZANO MA, 1983, P NATL ACAD SCI-BIOL, V80, P6264, DOI 10.1073/pnas.80.20.6264; ANZANO MA, 1982, CANCER RES, V42, P4776; BARRETT JC, 1978, P NATL ACAD SCI USA, V75, P3761, DOI 10.1073/pnas.75.8.3761; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COLBURN NH, 1978, CANCER RES, V38, P624; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; EAGLE H, 1960, P NATL ACAD SCI USA, V46, P427, DOI 10.1073/pnas.46.4.427; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMMERSAMPT JH, 1993, CELL, V75, P1129, DOI 10.1016/0092-8674(93)90322-H; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GWATKIN RB, 1960, NATURE, V186, P984, DOI 10.1038/186984a0; HAN EKH, 1993, J CELL BIOL, V122, P461, DOI 10.1083/jcb.122.2.461; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; HSIAO WLW, 1987, MOL CELL BIOL, V7, P3380, DOI 10.1128/MCB.7.10.3380; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAUSS RS, 1992, MOL CELL BIOL, V12, P3117, DOI 10.1128/MCB.12.7.3117; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; PICKART L, 1973, NATURE-NEW BIOL, V243, P85; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SETH A, 1992, J BIOL CHEM, V267, P24796; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; SHODELL M, 1973, NATURE-NEW BIOL, V243, P83; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	35	5	5	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1291	1299						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731679				2022-12-17	WOS:A1995QR65100005
J	BOEUF, H; MURPHY, J; BIBBINS, KB; VARMUS, HE				BOEUF, H; MURPHY, J; BIBBINS, KB; VARMUS, HE			BINDING IN-VITRO OF PHOSPHOTYROSINE-CONTAINING PROTEINS TO PP60(C-SRC) SH2 DOMAIN DOES NOT CORRELATE WITH CEF CELL-TRANSFORMATION	ONCOGENE			English	Article						SH2; SH3; SRC; TRANSFORMATION; PHOSPHOTYROSINE	GTPASE-ACTIVATING PROTEIN; GROWTH-FACTOR RECEPTORS; SRC HOMOLOGY REGION-2; C-SRC; V-SRC; SIGNAL TRANSDUCTION; PP60(SRC) SUBSTRATE; DEPENDENT MANNER; TYROSINE KINASE; HIGH-AFFINITY	We have previously described pp60(c-src) SH2 mutants that are host-range-dependent for cell transformation; most of these mutants can transform CEF cells but not NIH3T3 cells, and others transform NM3T3 cells more efficiently than CEF (Hirai and Varmus, 1990c). In an attempt to understand the molecular basis of these phenotypes, we analysed the ability of mutant SH2 domains in GST fusion-proteins to bind to tyrosine phosphorylated proteins in lysates from CEF and NIH3T3 cells. The relative affinity of mutated versions of the SH2 domain for phosphotyrosine-containing proteins from CEF and NM3T3 cells was compared with the relative ability of the mutant Src proteins to transform the two cell types. While the affinity of the SH2 domain for phosphotyrosine-containing proteins was closely correlated with transformation in NIH3T3 cells, there was no correlation between phosphotyrosine binding and transformation of CEF cells, and none of the host range mutant SH2 domains showed significant differences in their ability to bind phosphotyrosine-containing proteins from lysates from either cell type. In addition, the SH3 domain was shown to augment the capacity of mutant SH2 domain to bind phosphotyrosine-containing proteins.	CU, STRASBOURG, FRANCE; CHIRON CORP, DEPT VIROL, EMERYVILLE, CA 94608 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; NIH, BETHESDA, MD 20892 USA	Novartis; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA	BOEUF, H (corresponding author), IGBMC, BP 163, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE.							ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BOLEN JB, 1993, ONCOGENE, V8, P2025; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BROTT BK, 1991, MOL CELL BIOL, V11, P5059, DOI 10.1128/MCB.11.10.5059; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, GENE DEV, V4, P2342, DOI 10.1101/gad.4.12b.2342; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIEBL EC, 1992, J VIROL, V66, P4315, DOI 10.1128/JVI.66.7.4315-4324.1992; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACAULEY A, 1989, MOL CELL BIOL, V9, P2648, DOI 10.1128/MCB.9.6.2648; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEELE RE, 1992, TRENDS BIOCHEM SCI, V17, P205, DOI 10.1016/0968-0004(92)90375-J; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; VERDERAME MF, 1994, ONCOGENE, V9, P175; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	57	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	1995	10	3					433	438						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7531318				2022-12-17	WOS:A1995QF64800003
J	SCHUUR, ER; RABINOVICH, JM; BALUDA, MA				SCHUUR, ER; RABINOVICH, JM; BALUDA, MA			DISTRIBUTION OF ALTERNATIVELY SPLICED CHICKEN C-MYB EXON 9A AMONG HEMATOPOIETIC TISSUES	ONCOGENE			English	Note							AVIAN-MYELOBLASTOSIS VIRUS; DIFFERENTIAL EXPRESSION; CELLS; GENE; IDENTIFICATION; PROTOONCOGENE; TRANSCRIPTS; ONCOGENES	The role of the c-myb proto-oncogene in cellular differentiation may be regulated in part by alternative splicing of its mRNAs. Previously, two forms of alternative splicing of the chicken c-myb gene between exons 9 and 10 were described: one form utilizes the entire 360 base pair (bp) exon 9A while a second form utilizes exon 9A' which consists of the 3' 150 bp of exon 9A. In this study the distribution among chicken hematopoietic tissues of these two forms of alternative splicing was determined by Northern blot analysis using a probe specific for exon 9A. RNA species of 4.2 kilobases (kb) and 4.4 kb which contain exon 9A' or exon 9A, respectively, were detected in each tissue tested. Quantitative analysis of the major 4.0 kb c-myb species and the c-myb species containing exon 9A and exon 9A' revealed that cells from yolk sac contained both the highest absolute and the highest relative levels of alternatively spliced c-myb mRNA, presumably because of the preponderance of immature erythroid cells in these preparations.	UNIV CALIF LOS ANGELES, SCH MED, DEPT PATHOL & LAB MED, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	SCHUUR, ER (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA010197] Funding Source: NIH RePORTER; NCI NIH HHS [CA 10197] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENDER TP, 1987, J IMMUNOL, V139, P3822; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; DASGUPTA P, 1989, ONCOGENE, V4, P1419; DUDEK H, 1989, ONCOGENE, V4, P1061; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; GARCIA A, 1991, ONCOGENE, V6, P265; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GONDA TJ, 1983, J VIROL, V46, P212, DOI 10.1128/JVI.46.1.212-220.1983; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; KIM WK, 1989, MOL CELL BIOL, V9, P3771, DOI 10.1128/MCB.9.9.3771; KIM WK, 1988, ONCOGENE RES, V3, P147; Lipsick J S, 1986, Gene Amplif Anal, V4, P73; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; ROMANOFF AL, 1960, AVIAN EMBRYO, P575; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHUUR ER, 1993, ONCOGENE, V8, P1839; SCHUUR ER, 1991, ONCOGENE, V6, P1409; SCHUUR ER, 1991, ONCOGENE, V6, P1923; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WESTIN EH, 1990, ONCOGENE, V5, P1117; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194	27	5	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3363	3365						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936662				2022-12-17	WOS:A1994PM65800031
J	ANAND, R; WILKINSON, JM; KELLIE, S				ANAND, R; WILKINSON, JM; KELLIE, S			LOCALIZATION OF PP60(C-SRC) TO THE SURFACE-MEMBRANE OF HUMAN PLATELETS	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASES; EXPRESS HIGH-LEVELS; INTRACELLULAR MEMBRANES; GLYCOPROTEIN-IIB; ARACHIDONIC-ACID; PHORBOL ESTERS; SRC PROTEIN; PP60C-SRC; PHOSPHORYLATION; LOCALIZATION	In platelets, pp60c-src has been variously localised to cytosol, dense bodies, or plasma membrane and surface-connected canalicular membranes. We have investigated the localisation of pp60c-src in highly purified human platelet subcellular fractions isolated using density gradient centrifugation and continuous flow electrophoresis followed by quantitative immunoblotting. We have obtained fractions enriched in surface membranes and alpha granule membranes as assessed by the presence of the marker proteins gpIb, gpIIb, thrombospondin, fibrinogen and fibronectin. Quantitative immunoblotting demonstrated that most of the cellular pp60c-src co-purified with markers for surface membrane components and that unlike the situation in fibroblasts, platelet pp60c-src did not associate with non-granule intracellular membranes such as Golgi, endoplasmic reticulum and endosomes. A small subpopulation of the total cellular pp60c-src co-purified with granule components or dense body markers, however this occurred in proportion to the presence of surface membrane markers. Our results demonstrate that the majority of platelet pp60c-src is located on the cytoplasmic face of the plasma membrane in human platelets.	LITTLEMORE HOSP,YAMANOUCHI RES INST,OXFORD OX4 4XN,ENGLAND; ST BARTHOLOMEWS HOSP,COLL MED,WILLIAM HARVEY RES INST,DEPT BIOCHEM PHARMACOL,LONDON EC1,ENGLAND				Kellie, Stuart/A-6036-2010	Kellie, Stuart/0000-0002-8163-1474				AAKHUS AM, 1992, THROMB HAEMOSTASIS, V67, P252; AUTHI KS, 1985, BIOCHEM J, V230, P274; Brass L F, 1991, Prog Hemost Thromb, V10, P127; CALVETE JJ, 1989, BIOCHEM J, V261, P551, DOI 10.1042/bj2610551; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; COUSSENS PM, 1985, MOL CELL BIOL, V5, P2753, DOI 10.1128/MCB.5.10.2753; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DHAR A, 1991, J BIOL CHEM, V266, P18797; ELMORE MA, 1990, FEBS LETT, V269, P283, DOI 10.1016/0014-5793(90)81177-P; FEDER D, 1991, J BIOL CHEM, V266, P19040; FEDER D, 1990, J BIOL CHEM, V265, P8205; FERRELL JE, 1990, ONCOGENE, V5, P1033; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; GOGSTAD GO, 1981, BIOCHIM BIOPHYS ACTA, V670, P150, DOI 10.1016/0005-2795(81)90003-9; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; HACK N, 1984, BIOCHEM J, V222, P235, DOI 10.1042/bj2220235; HACK N, 1986, BIOCHEM J, V233, P661, DOI 10.1042/bj2330661; HALENDA SP, 1985, J BIOL CHEM, V260, P2484; HORAK ID, 1990, ONCOGENE, V5, P597; HORNBY EJ, 1991, BRIT J HAEMATOL, V79, P277, DOI 10.1111/j.1365-2141.1991.tb04533.x; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KELLIE S, 1987, FEBS LETT, V213, P428, DOI 10.1016/0014-5793(87)81536-3; KNIGHT DE, 1980, THROMB RES, V20, P437, DOI 10.1016/0049-3848(80)90282-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MENASHI S, 1981, J BIOL CHEM, V256, P4095; MURPHY CT, 1991, BIOCHIM BIOPHYS ACTA, V1133, P46, DOI 10.1016/0167-4889(91)90240-X; MURPHY CT, 1991, BIOCHEM J, V278, P255, DOI 10.1042/bj2780255; PARSONS SJ, 1986, BIOCHEM BIOPH RES CO, V134, P736, DOI 10.1016/S0006-291X(86)80482-X; POLL C, 1986, BIOCHIM BIOPHYS ACTA, V886, P434, DOI 10.1016/0167-4889(86)90179-5; REDMOND T, 1992, CELL GROWTH DIFFER, V3, P567; RENDU F, 1989, BLOOD, V73, P1545; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; WELHAM MJ, 1988, J VIROL, V62, P1898, DOI 10.1128/JVI.62.6.1898-1906.1988	39	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3013	3020						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	7692371				2022-12-17	WOS:A1993MC09300015
J	FRITSCHE				FRITSCHE			INDUCTION OF NUCLEAR ACCUMULATION OF THE TUMOR-SUPPRESSOR PROTEIN P53 BY DNA-DAMAGING AGENTS (VOL 8, PG 307, 1993)	ONCOGENE			English	Correction, Addition																		FRITSCHE, 1993, ONCOGENE, V8, P307	1	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2605	2605						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368					2022-12-17	WOS:A1993LT36800034
J	GOUTEBROZE, L; SAINTANDRE, CD; SCHERNECK, S; FEUNTEUN, J				GOUTEBROZE, L; SAINTANDRE, CD; SCHERNECK, S; FEUNTEUN, J			MUTATIONS WITHIN THE HAMSTER POLYOMAVIRUS LARGE T-ANTIGEN DOMAIN INVOLVED IN PRB-BINDING IMPAIR VIRUS PRODUCTIVE CYCLE AND IMMORTALIZATION CAPACITY	ONCOGENE			English	Article							TUMOR-ANTIGEN; RETINOBLASTOMA PROTEIN; KINASE-ACTIVITY; TRANSFORMATION; ASSOCIATION; GENE; IDENTIFICATION; PHOSPHATASE-2A; PAPOVAVIRUS; COMPLEXES	Hamster polyomavirus (HaPV) causes lymphoma and leukemia when injected into newborn Syrian hamsters and achieves full transformation of rodent fibroblasts in vitro. It offers a comprehensive model to study at a molecular level the contributions of the viral oncogenes to neoplastic transformation in vitro and in the animal. We have investigated the ability of HaPV large T antigen to form a complex with the product of the retinoblastoma gene (pRb) in vitro. In this report, we demonstrate that HaPV large T antigen can indeed complex the pRb polypeptide. In order to investigate to what extent this interaction might contribute to tumor induction by the virus, we have introduced two different point mutations within the putative pRb-binding sequence of large T antigen, and as a preliminary to in vivo experiments we have studied their effects in vitro on some biological activities relevant to tumor induction. We show that the substitution (Glu-134-->Lys) obliterates pRb binding, suggesting that Glu-134 participates in the interaction between pRb and large T antigen, whereas the substitution (Glu-135-->Lys) has no effect. The Lys-134 mutation is strongly deleterious to the immortalization capacity of the viral genome, whereas the Lys-135 mutation has no effect. Neither of the two mutations affects the capacity of the viral genome to induce foci formation in the rat established cell line F111. These results indicate that the interaction between large T and pRb is required in the immortalization process but irrelevant to transformation. Both mutants show at least partial impairment of replication and productive cycle.	INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,URA 1158,F-94805 VILLEJUIF,FRANCE; MAX DELBRUCK CENTRUM MOLEC MED TUMORIGENET,O-1115 BERLIN,GERMANY	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Helmholtz Association; Max Delbruck Center for Molecular Medicine			Goutebroze, Laurence/H-3543-2016; Feunteun, Jean/AAZ-1267-2020	Goutebroze, laurence/0000-0002-8712-000X; Feunteun, Jean/0000-0003-1212-9189				BASTIEN C, 1988, ONCOGENE, V2, P129; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1991, J VIROL, V65, P3301, DOI 10.1128/JVI.65.6.3301-3308.1991; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DELMAS V, 1985, EMBO J, V4, P1279, DOI 10.1002/j.1460-2075.1985.tb03773.x; DELMAS V, 1992, ONCOGENE, V7, P295; DIAMANDOPOULOS GT, 1972, SCIENCE, V176, P173, DOI 10.1126/science.176.4031.173; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; GOUTEBROZE L, 1992, J VIROL, V66, P2495, DOI 10.1128/JVI.66.4.2495-2504.1992; GRAFFI A, 1969, P NATL ACAD SCI USA, V64, P1172, DOI 10.1073/pnas.64.4.1172; GRAFFI A, 1968, J NATL CANCER I, V40, P867; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LEWIS AM, 1979, J NATL CANCER I, V63, P695, DOI 10.1093/jnci/63.3.695; NORKIN LC, 1982, MICROBIOL REV, V46, P384, DOI 10.1128/MMBR.46.4.384-425.1982; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; SAINTANDRE CD, 1990, VIROLOGY, V177, P532; SALZMAN NP, 1986, VIRUSES PAPOVAVIRIDA, P1; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; ZHU J, 1991, J VIROL, V65, P6782	28	5	5	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					685	693						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8382359				2022-12-17	WOS:A1993KN00800020
J	CASES, S; DAUTRY, F				CASES, S; DAUTRY, F			INACTIVATION OF THE MURINE N-RAS GENE BY GENE TARGETING	ONCOGENE			English	Note							EMBRYONIC STEM-CELLS; HOMOLOGOUS RECOMBINATION; SIGNAL TRANSDUCTION; MUTATION; MICE; ORGANIZATION; EXPRESSION; PROTEIN; GROWTH; LOCUS	The mammalian ras genes have been implicated in the genesis of a wide variety of tumors. Although it is likely that they play an essential role in signal transduction, their specific function is still unknown. To initiate a genetic analysis of the ras genes in mammals we inactivated the N-ras gene in murine embryonic stem cells by gene targeting. The frequency of integration at the N-ras locus of our targeting vector being low (of the order of 1/5000 transfectants), we used a positive/negative selection followed by an analysis of individual colonies in order to minimize the in vitro manipulation of the embryonic stem cells. Using this approach, we isolated two clones of ES cells with one inactivated N-ras allele. These cells have no distinctive phenotype either in vitro or in vivo in chimeric mice.	INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,UA 1158,F-94805 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy								BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOS JL, 1989, CANCER RES, V49, P4682; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHANG HY, 1987, ONCOGENE RES, V1, P129; CHARDIN P, 1991, CANCER CELL-MON REV, V3, P117; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHESA PG, 1987, P NATL ACAD SCI USA, V84, P3234, DOI 10.1073/pnas.84.10.3234; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOULD B, 1988, CELL, V53, P753; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; JEFFERS M, 1990, NUCLEIC ACIDS RES, V18, P4891; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KIM HS, 1988, NUCLEIC ACIDS RES, V16, P8887, DOI 10.1093/nar/16.18.8887; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NICOLAIEW N, 1991, ONCOGENE, V6, P721; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; STERNBERG PW, 1991, TRENDS GENET, V7, P366, DOI 10.1016/0168-9525(91)90257-Q; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0	30	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2525	2528						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461656				2022-12-17	WOS:A1992KA85600019
J	MERZAK, A; DOOGHE, Y; PIRONIN, M; PERBAL, B; VIGIER, P				MERZAK, A; DOOGHE, Y; PIRONIN, M; PERBAL, B; VIGIER, P			COOPERATION BETWEEN THE H-RAS ONCOGENE AND A TRUNCATED DERIVATIVE OF THE V-MYB ONCOGENE IN TRANSFORMATION OF HAMSTER-EMBRYO FIBROBLASTS	ONCOGENE			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; C-MYB; MONOCLONAL-ANTIBODIES; FUNCTIONAL DOMAINS; COLONY FORMATION; CELLS; DNA; PRODUCT; SEQUENCES; PROTEIN	The ras oncogenes alone fully transform established (immortalized) rodent fibroblasts in a few days, but generally transform early-passage fibroblasts only partially, unless their action is complemented by that of a nuclear, immortalizing, oncogene. Here we show that transfection of second-passage Syrian hamster embryo fibroblasts (HEFs) by the EJ-H-ras oncogene coupled to the neo gene, followed by selection with G418, gives rise to apparently normal, or only slightly transformed, clonal colonies, only a few of which become established. The study of two established clonal fines showed that they acquired only after some weeks, and stepwise, the main characteristics of full neoplastic transformation, i.e. anchorage independence, reduced requirement for serum growth factors and tumorigenicity. Later both clonal lines became increasingly tumorigenic and completely independent of exogenous growth and attachment factors, without increase in the expression of the H-ras oncogene. Transfection of one of the clones, early after its isolation, with a truncated derivative of the nuclear v-myb oncogene devoid of its transcriptional negative regulatory domain and able to partially transform chicken embryo fibroblasts [(myb(KXANM)] gave rise to more transformed cells, expressing both EJ-H-ras and myb(KXANM), which became tumorigenic earlier than the controls and remained more tumorigenic later on. With more efficient transfection techniques, numerous foci of fully transformed cells were subsequently obtained, in a few days, in cultures transfected sequentially with EJ-H-ras(neo) and myb(KXANM) and in cultures co-transfected with the two oncogenes. Highly tumorigenic, serum-independent and immortalized clones expressing both oncogenes were obtained from these cultures. Hence, the truncated myb(KXANM) oncogene accelerates the stepwise transformation of unestablished HEFs by the EJ-HH-ras oncogene and, together with this oncogene, fully transforms these same cells in a single step. The two oncogenes acting in cooperation also induce cell immortalization, but myb(KXANM), by itself, is not an immortalizing oncogene. No cooperation was observed between EJ-H-ras(neo) and the unaltered v-myb oncogene.	CTR UNIV ORSAY,INST CURIE,BIOL SECT,BATIMENT 110,F-91405 ORSAY,FRANCE; UNIV PARIS 07,F-75221 PARIS 05,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite			MERZAK, Abderrahim/AAW-9746-2021	MERZAK, Abderrahim/0000-0002-7269-2224				ANTCZAK M, 1990, J VIROL, V64, P1451, DOI 10.1128/JVI.64.4.1451-1458.1990; BADING H, 1989, ONCOGENE, V4, P33; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BART LMC, 1991, CANCER RES, V51, P1177; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1985, MOL CELL BIOL, V5, P3017, DOI 10.1128/MCB.5.11.3017; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; DOOLEY S, 1989, Methods in Molecular and Cellular Biology, V1, P95; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KRYCEVEMARTINERIE C, 1987, FEBS LETT, V214, P81, DOI 10.1016/0014-5793(87)80017-0; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LIPSICK JS, 1984, CANCER CELLS, V2, P143; MARTINERIE C, 1987, NUCLEIC ACIDS RES, V15, P1329, DOI 10.1093/nar/15.3.1329; MCCLURE DB, 1983, CELL, V32, P999, DOI 10.1016/0092-8674(83)90084-3; MERZAK A, 1991, ONCOGENE, V7, P535; PERBAL B, 1986, BIOCHIMIE, V68, P969, DOI 10.1016/S0300-9084(86)80040-2; Perbal B., 1988, PRACTICAL GUIDE MOL; PIRONIN M, 1992, INT J CANCER, V52, P1; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHWARTZ SA, 1988, CANCER RES, V48, P3470; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SORET J, 1985, J VIROL, V55, P193, DOI 10.1128/JVI.55.1.193-205.1985; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WEINBERG RA, 1989, CANCER RES, V49, P3713; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541	36	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2031	2039						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408144				2022-12-17	WOS:A1992JP42400018
J	OHUCHI, T; KURITA, Y; SASAI, H; MIYOSHI, J; NOMURA, T; TOYOSHIMA, K				OHUCHI, T; KURITA, Y; SASAI, H; MIYOSHI, J; NOMURA, T; TOYOSHIMA, K			ONCOGENIC ACTIVATION OF MURINE MOS PROTEIN-KINASE BY DNA REARRANGEMENT OF ITS N-TERMINAL CODING REGION	ONCOGENE			English	Article							C-MOS; SARCOMA-VIRUS; SEQUENCE; PRODUCT; MATURATION; VECTORS; CLONING; GENOME; GENES; EGGS	An activated c-mos oncogene was detected by DNA transfection assay of hamster SHOK cells with DNAs from X-ray-induced mouse osteosarcoma. It was molecularly cloned by the cosmid rescue method and found to form transformed foci of SHOK cells. Genomic DNA sequencing revealed that in this oncogene the N-terminal coding region of the mouse proto-mos gene was deleted and replaced by a hamster-derived sequence in the primary transformant, suggesting that activation was due to the rearrangement during transfection. The gene product was about 37 kDa and was immunoprecipitated with anti-mos antibody from a lysate of a SHOK cell transfectant. This truncated mos (t-mos) gene transformed SHOK cells more effectively than v-mos. A chimeric gene construct of this hamster-derived upstream sequence and normal mouse c-mos also transformed SHOK cells at a lower level, whereas neither t-mos nor the chimeric c-mos gene transformed NIH3T3 cells appreciably. The high transforming efficiency of t-mos in SHOK cells was due not only to truncation of the coding region but also to its integration under a putative promoter sequence derived from the hamster genome. This is the first report of detection of an activated c-mos gene by DNA transfection assay.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT ONCOGENE RES,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,DEPT RADIAT BIOL,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University								BASU M, 1984, NATURE, V311, P477, DOI 10.1038/311477a0; BLAIR DG, 1986, CELL, V46, P785, DOI 10.1016/0092-8674(86)90354-5; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; BOLD RJ, 1985, MOL CELL BIOL, V5, P3131, DOI 10.1128/MCB.5.11.3131; BRADY G, 1984, GENE, V27, P223, DOI 10.1016/0378-1119(84)90143-4; CANAANI E, 1983, P NATL ACAD SCI-BIOL, V80, P7118, DOI 10.1073/pnas.80.23.7118; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COHEN JB, 1983, NATURE, V306, P797, DOI 10.1038/306797a0; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FUJIMOTO S, 1985, P NATL ACAD SCI USA, V82, P2072, DOI 10.1073/pnas.82.7.2072; GERBAUD C, 1981, CURR GENET, V3, P173, DOI 10.1007/BF00429819; HIGASHI T, 1990, P NATL ACAD SCI USA, V87, P2409, DOI 10.1073/pnas.87.7.2409; Maniatis T, 1989, DECONTAMINATION DILU; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MIYOSHI J, 1991, IN PRESS MOL CELL BI; MOLONEY JOHN B., 1966, NAT CANCER INST MONOGR, V22, P139; NAHARRO G, 1983, J VIROL, V47, P611, DOI 10.1128/JVI.47.3.611-619.1983; NOMURA T, 1982, NATURE, V296, P575, DOI 10.1038/296575a0; OKAZAKI K, 1991, JPN J CANCER RES, V82, P250, DOI 10.1111/j.1349-7006.1991.tb01837.x; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PAPKOFF J, 1981, CELL, V27, P109, DOI 10.1016/0092-8674(81)90365-2; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0	27	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					331	338						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1532243				2022-12-17	WOS:A1992HG98200019
J	SCHAFER, R; NIRKKO, AC; AMBUHL, PM; GRZESCHIK, KH; SCHWARTEWALDHOFF, I				SCHAFER, R; NIRKKO, AC; AMBUHL, PM; GRZESCHIK, KH; SCHWARTEWALDHOFF, I			EVIDENCE FOR HUMAN DNA-MEDIATED TRANSFER OF THE SUPPRESSED PHENOTYPE INTO MALIGNANT CHINESE-HAMSTER CELLS	ONCOGENE			English	Article							DIPLOID MOUSE FIBROBLASTS; HA-RAS ONCOGENE; TRANSFORMED PHENOTYPE; GENETIC-ANALYSIS; RB GENE; TUMOR SUPPRESSION; PARTIAL REVERSION; CARCINOMA-CELLS; TRANSGENIC MICE; SRC GENE	Genetic suppression of the neoplastic phenotype has been demonstrated in somatic cell hybrids between tumor and normal cells. Suppression in whole-cell and microcell hybrids cannot, as yet, be attributed to specific elements defined at the molecular level. To identify a gene capable of suppressing the neoplastic phenotype, we have introduced DNA of normal human cells into tumorigenic Chinese hamster Wg3-h-o cells. Primary and secondary transfectants which exhibit the suppressed phenotype similar to Wg3-h-o x embryonic fibroblast hybrids were selected. The cells require serum growth factors and anchorage for proliferation in vitro and show a reduced tumorigenicity in nude mice. Transferred human DNA segments were molecularly cloned from a secondary transfectant. Indirect evidence suggests that the cloned human DNA is associated with the expression of the suppressed phenotype.	UNIV MARBURG,INST HUMAN GENET,W-3550 MARBURG,GERMANY	Philipps University Marburg	SCHAFER, R (corresponding author), UNIV ZURICH,INST PATHOL,DIV CANC RES,SCHMELZBERGSTR 12,CH-8091 ZURICH,SWITZERLAND.							BAKER RF, 1983, P NATL ACAD SCI-BIOL, V80, P1174, DOI 10.1073/pnas.80.5.1174; BARDWELL L, 1989, MUTAGENESIS, V4, P245, DOI 10.1093/mutage/4.4.245; BECHER R, 1983, CANCER GENET CYTOGEN, V9, P173, DOI 10.1016/0165-4608(83)90038-9; BENEDICT WF, 1984, CANCER RES, V44, P3471; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLAIR DG, 1982, SCIENCE, V218, P1122, DOI 10.1126/science.6293052; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHOMCZYNSKI P, 1984, BIOCHEM BIOPH RES CO, V122, P340, DOI 10.1016/0006-291X(84)90480-7; CRAIG RW, 1985, P NATL ACAD SCI USA, V82, P2062, DOI 10.1073/pnas.82.7.2062; CULINE S, 1989, INT J CANCER, V44, P990; DIAMANTIS ID, 1989, P NATL ACAD SCI USA, V86, P9299, DOI 10.1073/pnas.86.23.9299; DUIGOU GJ, 1990, MOL CELL BIOL, V10, P2027, DOI 10.1128/MCB.10.5.2027; DYSON PJ, 1982, CELL, V30, P491, DOI 10.1016/0092-8674(82)90246-X; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GEISER AG, 1986, P NATL ACAD SCI USA, V83, P5209, DOI 10.1073/pnas.83.14.5209; GRIEGEL S, 1986, INT J CANCER, V38, P697, DOI 10.1002/ijc.2910380513; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HOHN B, 1980, GENE, V11, P291, DOI 10.1016/0378-1119(80)90069-4; HOWELL N, 1981, CYTOGENET CELL GENET, V31, P214, DOI 10.1159/000131651; HSU TC, 1964, J NATL CANCER I, V32, P857; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Iten E, 1989, Recent Results Cancer Res, V113, P78; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLINGER HP, 1983, JNCI-J NATL CANCER I, V71, P559; KOZAK CA, 1977, EXP CELL RES, V105, P109, DOI 10.1016/0014-4827(77)90156-2; KUZUMAKI N, 1989, MOL CELL BIOL, V9, P2258, DOI 10.1128/MCB.9.5.2258; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; MARSHALL CJ, 1980, EXP CELL RES, V127, P373, DOI 10.1016/0014-4827(80)90442-5; MIKKELSEN T, 1990, CELL GROWTH DIFFER, V1, P201; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; OSHIMURA M, 1989, P AM ASSOC CANC RES, V30, P786; PADMANABHAN R, 1987, MOL CELL BIOL, V7, P1894, DOI 10.1128/MCB.7.5.1894; PATERSON H, 1987, CELL, V51, P803, DOI 10.1016/0092-8674(87)90103-6; PATTENGALE PK, 1989, AM J PATHOL, V135, P39; PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3; PIZON V, 1988, ONCOGENE, V3, P201; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; RUSSELL WC, 1975, NATURE, V253, P461, DOI 10.1038/253461a0; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SCHAEFER R, 1988, P NATL ACAD SCI USA, V85, P1590, DOI 10.1073/pnas.85.5.1590; SCHAFER R, 1981, CANCER RES, V41, P1214; SCHAFER R, 1983, CANCER RES, V43, P2240; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SRIVATSAN ES, 1986, CANCER RES, V46, P6174; STENMAN G, 1987, P NATL ACAD SCI USA, V84, P9099, DOI 10.1073/pnas.84.24.9099; STOLER A, 1985, P NATL ACAD SCI USA, V82, P570, DOI 10.1073/pnas.82.2.570; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TRENT JM, 1981, CANCER GENET CYTOGEN, V3, P279, DOI 10.1016/0165-4608(81)90037-6; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WEINBERG RA, 1989, CANCER RES, V49, P3713; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	56	5	5	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2221	2228						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766670				2022-12-17	WOS:A1991GX73500007
J	SCHUUR, ER; BALUDA, MA				SCHUUR, ER; BALUDA, MA			EXPRESSION OF MYB PROTEINS IN AVIAN HEMATOPOIETIC TISSUES	ONCOGENE			English	Article							HUMAN C-MYB; MYELOBLASTOSIS VIRUS; V-MYB; TRANSFORMING GENE; NUCLEOTIDE-SEQUENCE; PROTO-ONCOGENE; CHICKEN DNA; DIFFERENTIAL EXPRESSION; STRUCTURAL ORGANIZATION; MYELOID-LEUKEMIA	MYB gene products are thought to be regulators of cellular replication and of differentiation. The major product of the avian MYB gene is a 75 kDa nuclear phosphoprotein which can activate transcription. A minor 89 kDa MYB protein of unknown function has also been described in murine and human cells. Additional heterogeneity at the level of MYB RNA which could affect the structure of MYB proteins has been described in several species. Such heterogeneity could explain the diverse effects of the MYB gene. To investigate the possible existence of heterogeneous and/or cell lineage-specific MYB proteins, five different avian hematopoietic tissues (bone marrow, bursa of Fabricius, embryonic spleen, thymus and yolk sac) were examined by immunoprecipitation with several MYB-specific antisera and SDS-PAGE analysis. In all five tissues there was a 75 kDa protein of uniform size which varied in abundance in a tissue-specific manner paralleling that observed for the 4.0 kb MYB RNA. A less abundant 89 kDa protein was also detected by several antisera in bone marrow, spleen, thymus and yolk sac but not in bursa. This 89 kDa MYB protein appears to be analogous to the 89 kDa MYB protein encoded by a minor but larger (360 nucleotides) MYB mRNA in murine and human cells. Immunoprecipitation of MYB proteins with an antiserum specific for exons 8 and 9 revealed a 74 kDa protein which coprecipitated and appeared to be complexed with p75 in normal hematopoietic cells and with the 48 kDa product of v-myb in leukemic cells.	UNIV CALIF LOS ANGELES,SCH MED,MED LAB,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,JONNSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BALUDA MA, 1961, VIROLOGY, V15, P185, DOI 10.1016/0042-6822(61)90234-3; BALUDA MA, 1990, ONCOGENESIS ONCOGENE, P131; BENDER TP, 1987, J IMMUNOL, V139, P3822; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1983, P NATL ACAD SCI-BIOL, V80, P2834, DOI 10.1073/pnas.80.10.2834; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; DASGUPTA P, 1989, ONCOGENE, V4, P1419; DAVIS JN, 1990, ONCOGENE, V5, P1109; DUDEK H, 1989, ONCOGENE, V4, P1061; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; GARCIA A, 1991, IN PRESS ONCOGENE; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; HAHN SL, 1989, MOL CELL BIOL, V9, P837, DOI 10.1128/MCB.9.2.837; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KIM WK, 1989, MOL CELL BIOL, V9, P3771, DOI 10.1128/MCB.9.9.3771; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; Lipsick J S, 1986, Gene Amplif Anal, V4, P73; LIPSICK JS, 1987, J VIROL, V61, P3284, DOI 10.1128/JVI.61.10.3284-3287.1987; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; Moscovici C., 1973, Methods Cell Biol, V7, P313; NUNN MF, 1985, VIROLOGY, V139, P330; PERBAL B, 1983, J VIROL, V45, P925, DOI 10.1128/JVI.45.3.925-940.1983; PERBAL B, 1982, J VIROL, V44, P586, DOI 10.1128/JVI.44.2.586-594.1982; PERBAL B, 1982, J VIROL, V41, P250, DOI 10.1128/JVI.41.1.250-257.1982; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; RUSHLOW KE, 1982, SCIENCE, V216, P1421, DOI 10.1126/science.6283631; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SORET J, 1988, FEBS LETT, V232, P227, DOI 10.1016/0014-5793(88)80422-8; SORET J, 1990, FEBS LETT, V263, P254, DOI 10.1016/0014-5793(90)81387-4; SOUZA LM, 1980, P NATL ACAD SCI-BIOL, V77, P5177, DOI 10.1073/pnas.77.9.5177; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; VELLARD M, 1991, ONCOGENE, V6, P505; WATSON RJ, 1987, EMBO J, V6, P1643, DOI 10.1002/j.1460-2075.1987.tb02413.x; WESTIN EH, 1990, ONCOGENE, V5, P1117; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	57	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1923	1929						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923515				2022-12-17	WOS:A1991GX11800029
J	WEBER, JM; SIRCAR, S; RODRIGUES, M; CAI, FX; HORVATH, J				WEBER, JM; SIRCAR, S; RODRIGUES, M; CAI, FX; HORVATH, J			DOMINANT SUPPRESSION OF ADENOVIRUS MEDIATED TRANSFORMATION AND INSUFFICIENCY OF P105RB BINDING AS A CONDITION FOR ONCOGENIC TRANSFORMATION	ONCOGENE			English	Article							LARGE T-ANTIGENS; RAT-CELLS; METHYLGLYOXAL BIS(GUANYLHYDRAZONE); RETINOBLASTOMA PROTEIN; GENE-PRODUCT; E1A PROTEINS; VIRUS; INTEGRATION; RESISTANT; RETRANSFORMATION	An adenovirus-specific transformation resistant cell line (G2) expressing biologically active E1a proteins and originally isolated as a revertant from Ad2-transformed rat cells (F4), was shown to form stable Rb-E1a and 300K-E1a complexes in immunoprecipitation experiments. Consistent with the transformation resistant phenotype, cell hybrids between G2 and F4 were all nontumorigenic. Retrovirus insertion mutagenesis resulted in tumorigenic cell lines and identified a common locus responsible for the E1a-specific dominant tumor suppressor phenotype of G2 cells.			WEBER, JM (corresponding author), UNIV SHERBROOKE,FAC MED,DEPT MICROBIOL,SHERBROOKE J1H 5N4,QUEBEC,CANADA.							ARMENTANO D, 1987, J VIROL, V61, P1647, DOI 10.1128/JVI.61.5.1647-1650.1987; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CRAIG RW, 1985, P NATL ACAD SCI USA, V82, P2062, DOI 10.1073/pnas.82.7.2062; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GARDELLA T, 1984, J VIROL, V50, P248, DOI 10.1128/JVI.50.1.248-254.1984; HEATON MA, 1988, J CELL PHYSIOL, V136, P133, DOI 10.1002/jcp.1041360117; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LOHUIZEN M, 1989, EMBO J, V8, P133; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; RODRIGUES M, 1989, VIRUS RES, V15, P231; RYAN KW, 1985, MOL CELL BIOL, V5, P3577, DOI 10.1128/MCB.5.12.3577; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SCHAEFER R, 1988, P NATL ACAD SCI USA, V85, P1590, DOI 10.1073/pnas.85.5.1590; SEIF R, 1977, J VIROL, V24, P721, DOI 10.1128/JVI.24.3.721-728.1977; SHIH CC, 1988, CELL, V53, P531, DOI 10.1016/0092-8674(88)90569-7; SIRCAR S, 1987, CANCER RES, V47, P1339; SIRCAR S, 1988, ONCOGENE, V3, P725; SUGIYAMA A, 1989, P NATL ACAD SCI USA, V86, P9144, DOI 10.1073/pnas.86.23.9144; WEBER JM, 1990, J GEN VIROL, V71, P585, DOI 10.1099/0022-1317-71-3-585; WEBER JM, 1989, CANCER RES, V49, P5779; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	31	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					989	993						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1648705				2022-12-17	WOS:A1991GU62200013
J	KASHISHIAN, A; MACAULEY, A; COOPER, JA				KASHISHIAN, A; MACAULEY, A; COOPER, JA			PROPERTIES OF TRIPARTITE CHIMERAS BETWEEN SRC AND LCK	ONCOGENE			English	Article									FRED HUTCHINSON CANC RES CTR, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA	Fred Hutchinson Cancer Center					NCI NIH HHS [CA-41072] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041072, R37CA041072] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BRUGGE JS, 1984, J BIOL CHEM, V259, P4550; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CASNELLIE JE, 1982, J BIOL CHEM, V257, P3877; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HURLEY TR, 1989, ONCOGENE, V4, P265; JOVE R, 1989, ONCOGENE RES, V5, P49; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LEVINSON AD, 1981, P NATL ACAD SCI-BIOL, V78, P1624, DOI 10.1073/pnas.78.3.1624; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; LOUIE RR, 1988, J VIROL, V62, P4673, DOI 10.1128/JVI.62.12.4673-4679.1988; MACAULEY A, 1988, MOL CELL BIOL, V8, P3560, DOI 10.1128/MCB.8.8.3560; MACAULEY A, 1989, MOL CELL BIOL, V9, P2648, DOI 10.1128/MCB.9.6.2648; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MILLER AD, 1986, SOMAT CELL MOLEC GEN, V12, P175, DOI 10.1007/BF01560664; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PARSONS SJ, 1986, J VIROL, V59, P755, DOI 10.1128/JVI.59.3.755-758.1986; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Potts W M, 1988, Oncogene Res, V3, P343; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; SATO M, 1989, J VIROL, V63, P683, DOI 10.1128/JVI.63.2.683-688.1989; SEFTON BM, 1982, J VIROL, V41, P813, DOI 10.1128/JVI.41.3.813-820.1982; SEFTON BM, 1978, J VIROL, V28, P957, DOI 10.1128/JVI.28.3.957-971.1978; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013	40	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1990	5	10					1463	1470						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK502	2250908				2022-12-17	WOS:A1990EK50200004
J	MISCHAK, H; KOLCH, W; HOFER, F; WEISSINGER, E; GESSL, A; DAVIDSON, WF; AIELLO, FB; BLAAS, D; RAPP, UR				MISCHAK, H; KOLCH, W; HOFER, F; WEISSINGER, E; GESSL, A; DAVIDSON, WF; AIELLO, FB; BLAAS, D; RAPP, UR			A RAF/MYC VIRUS IMMORTALIZED MACROPHAGE CELL-LINE WHICH SUPPORTS THE GROWTH OF B-CELL AND B-CELL HYBRIDOMAS	ONCOGENE			English	Article									NCI, FREDERICK CANC RES FACIL, VIRAL CARCINOGENESIS LAB, FREDERICK, MD 21701 USA; INST BIOCHEM, A-1090 VIENNA, AUSTRIA; INST EXPTL PATHOL, A-1090 VIENNA, AUSTRIA; NCI, FREDERICK CANC RES FACIL, PROGRAM RESOURCES INC, BIOL CARCINOGENESIS & DEV PROGRAM, FREDERICK, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	MISCHAK, H (corresponding author), NCI, GENET LAB, BLDG 37, BETHESDA, MD 20892 USA.		Mischak, Harald/E-8685-2011; Kolch, Walter/ABF-2102-2021	Kolch, Walter/0000-0001-5777-5016; Mischak, Harald/0000-0003-0323-0306				Aarden L, 1985, LYMPHOKINES, V10, P175; AIELLO FB, 1990, J IMMUNOL, V144, P2572; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BOLDICKE T, 1988, EUR J BIOCHEM, V175, P259, DOI 10.1111/j.1432-1033.1988.tb14191.x; CHIPLUNKAR S, 1986, J IMMUNOL, V137, P3748; CLEVELAND JL, 1986, CURR TOP MICROBIOL, V132, P44; DAHMUS ME, 1988, MOL IMMUNOL, V25, P997, DOI 10.1016/0161-5890(88)90006-5; DAVIDSON WF, 1988, J EXP MED, V168, P389, DOI 10.1084/jem.168.1.389; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HOLLEY RW, 1983, CELL BIOL INT REP, V7, P141, DOI 10.1016/0309-1651(83)90027-9; HOLMES KL, 1986, J EXP MED, V164, P443, DOI 10.1084/jem.164.2.443; KAYE J, 1984, J IMMUNOL, V133, P1339; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KLINKEN SP, 1989, J VIROL, V63, P1489, DOI 10.1128/JVI.63.3.1489-1492.1989; KOLCH W, 1990, IN PRESS CRC REV CAN; KOLCH W, 1990, IN PRESS ONCOGENE; KUNIMOTO DY, 1989, J IMMUNOL, V143, P2230; LANE RD, 1988, HYBRIDOMA, V7, P289, DOI 10.1089/hyb.1988.7.289; Maniatis T., 1982, MOL CLONING; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MISCHAK H, 1989, BIOCHIM BIOPHYS ACTA, V990, P1, DOI 10.1016/S0304-4165(89)80003-0; MIZEL SB, 1978, J IMMUNOL, V120, P1497; MOLLER SA, 1985, J IMMUNOL METHODS, V79, P195, DOI 10.1016/0022-1759(85)90099-7; MORSE HC, 1988, CELLULAR ONCOGENE AC, P335; NOELLE R, 1984, P NATL ACAD SCI-BIOL, V81, P6149, DOI 10.1073/pnas.81.19.6149; NORDAN RP, 1986, SCIENCE, V233, P566, DOI 10.1126/science.3726549; PIKE BL, 1985, P NATL ACAD SCI USA, V82, P8153, DOI 10.1073/pnas.82.23.8153; PRINCIPATO M, 1988, CURR TOP MICROBIOL, V141, P31; PRINCIPATO M, 1990, IN PRESS MOL CELL BI; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; RAPP UR, 1988, HDB ONCOGENES, P213; RAPP UR, 1986, RETROVIRUSES HUMAN P, P449; ROBERSON SM, 1988, CELL IMMUNOL, V116, P341, DOI 10.1016/0008-8749(88)90236-5; SIRAGANIAN RP, 1983, METHOD ENZYMOL, V92, P17; SUDA T, 1989, J IMMUNOL METHODS, V120, P173, DOI 10.1016/0022-1759(89)90239-1; TREANOR J, 1988, P NATL ACAD SCI USA, V85, P3613, DOI 10.1073/pnas.85.10.3613; VANDAMME J, 1987, J EXP MED, V165, P914, DOI 10.1084/jem.165.3.914; VANNESS J, 1984, P NATL ACAD SCI-BIOL, V81, P7897; WONG GG, 1988, IMMUNOL TODAY, V9, P137, DOI 10.1016/0167-5699(88)91200-5	40	5	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1990	5	9					1377	1382						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	2216460				2022-12-17	WOS:A1990EC24100015
J	TARAKHOVSKY, AM; RESNIKOV, M; ZAICHUK, T; TUGUSHEVA, MV; BUTENKO, ZA; PRASSOLOV, VS				TARAKHOVSKY, AM; RESNIKOV, M; ZAICHUK, T; TUGUSHEVA, MV; BUTENKO, ZA; PRASSOLOV, VS			POLYMORPHIC CHANGES OF CELL PHENOTYPE CAUSED BY ELEVATED EXPRESSION OF AN EXOGENOUS NEU PROTOONCOGENE	ONCOGENE			English	Article									ACAD SCI USSR,INST MOLEC BIOL,MOSCOW V-71,USSR		TARAKHOVSKY, AM (corresponding author), ACAD SCI UKSSR,INST ONCOL PROBLEMS,DEPT LEUKEMIAGENESIS,VASILKOVSKAYA 45,KIEV 252022,UKRAINE,USSR.							ADAMSON ED, 1981, MOL CELL BIOCHEM, V34, P129, DOI 10.1007/BF02359619; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Cowley GO, 1984, CANCER CELL, V1, P5; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GURROFF G, 1988, GROWTH MATURATION FA; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; Maniatis T., 1982, MOL CLONING; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARTIN GS, 1971, P NATL ACAD SCI USA, V68, P2739, DOI 10.1073/pnas.68.11.2739; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3; PRASOLOV VS, 1988, DOKL AKAD NAUK SSSR+, V300, P1498; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SEMBA K, 1985, SCIENCE, V85, P6479; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH JJ, 1987, P NATL ACAD SCI USA, V84, P7567, DOI 10.1073/pnas.84.21.7567; STERN DF, 1987, SCIENCE, V235, P321, DOI 10.1126/science.3492043; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAMAZAKI H, 1988, MOL CELL BIOL, V8, P1816, DOI 10.1128/MCB.8.4.1816	38	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					405	410						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	1969137				2022-12-17	WOS:A1990CW41500019
J	MOWAT, M; SAUDER, M; PEREIRA, D				MOWAT, M; SAUDER, M; PEREIRA, D			THE ACTIVATED FORM OF P53 IS NOT A TRANSACTIVATOR OF THE INTRACISTERNAL-A PARTICLE LONG TERMINAL REPEAT PROMOTER	ONCOGENE			English	Note									UNIV MANITOBA,DEPT PHYSIOL,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba	MOWAT, M (corresponding author), MANITOBA INST CELL BIOL,100 OLIVIA ST,WINNIPEG R3E 0V9,MANITOBA,CANADA.							BEGEMANN M, 1988, MOL CARCINOGEN, V1, P196, DOI 10.1002/mc.2940010308; BENCHIMOL S, 1989, IN PRESS CANCER CELL, V7; BENDAVID Y, 1988, ONCOGENE, V3, P179; BRAITHWAITE A, 1987, NATURE, V329, P456; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1988, ONCOGENE, V3, P313; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FLANAGAN JR, 1989, MOL CELL BIOL, V9, P739, DOI 10.1128/MCB.9.2.739; Gai X X, 1988, Oncogene Res, V3, P377; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HICKS GG, 1988, J VIROL, V62, P4752, DOI 10.1128/JVI.62.12.4752-4755.1988; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, ONCOGENE HDB, P403; KACZMAREK L, 1986, EXP CELL RES, V162, P268, DOI 10.1016/0014-4827(86)90445-3; KINGSTON RE, 1985, CELL, V41, P3, DOI 10.1016/0092-8674(85)90049-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LURIA S, 1986, J VIROL, V57, P998, DOI 10.1128/JVI.57.3.998-1003.1986; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1988, ONCOGENE, V2, P621; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PINHASI O, 1984, MOL CELL BIOL, V4, P2180, DOI 10.1128/MCB.4.10.2180; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROSVINSKI B, 1987, MOL CELL BIOL, V7, P847; ROVINSKI B, 1988, ONCOGENE, V2, P445; SHOHAT O, 1987, ONCOGENE, V1, P277; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SOLAZZO M, 1989, EUR J IMMUNOL, V19, P453; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STURZBECHER HW, 1988, ONCOGENE, V3, P405; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; TACK LC, 1989, J VIROL, V63, P1310, DOI 10.1128/JVI.63.3.1310-1317.1989; VARMUS HE, 1987, SCIENCE, V238, P1337, DOI 10.1126/science.2825348; WOLF D, 1984, MOL CELL BIOL, V4, P1402, DOI 10.1128/MCB.4.7.1402; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790	47	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1990	5	2					241	244						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU029	2138726				2022-12-17	WOS:A1990CU02900012
J	NASI, S; SIRINIAN, MI; PANETTA, G; MARCHETTI, A; JUCKER, R				NASI, S; SIRINIAN, MI; PANETTA, G; MARCHETTI, A; JUCKER, R			INDUCTION OF THE NEOPLASTIC PHENOTYPE OF EBV-ESTABLISHED LYMPHOCYTES-B BY THE HUMAN HA-RAS ONCOGENE	ONCOGENE			English	Article											NASI, S (corresponding author), UNIV LA SAPIENZA,DIPARTIMENTO GENET & BIOL MOLEC,CNR,CTR STUDIO ACIDI NUCL,P A MORO 5,I-00185 ROME,ITALY.		Marchetti, Alessandra/AAD-5498-2019	MARCHETTI, ALESSANDRA/0000-0001-9706-848X				Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BENEDICT WF, 1987, ADV VIRAL ONCOL, V7, P19; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; CICHUTEK K, 1986, P NATL ACAD SCI USA, V83, P2340, DOI 10.1073/pnas.83.8.2340; DETHE G, 1970, INT J CANCER, V6, P189, DOI 10.1002/ijc.2910060206; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FISCHERFANTUZZI L, 1987, ONCOGENE RES, V1, P229; FOON KA, 1986, BLOOD, V68, P1; GORDON J, 1985, INT J CANCER, V35, P251, DOI 10.1002/ijc.2910350218; GREAVES MF, 1986, BLOOD, V67, P1; HALUSKA FG, 1986, NATURE, V324, P158, DOI 10.1038/324158a0; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLEIN G, 1985, IMMUNOL TODAY, V6, P208, DOI 10.1016/0167-5699(85)90036-2; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MORSE B, 1989, MOL CELL BIOL, V9, P74, DOI 10.1128/MCB.9.1.74; NILSSON K, 1977, INT J CANCER, V19, P337, DOI 10.1002/ijc.2910190309; NILSSON K, 1982, ADV CANCER RES, V37, P319, DOI 10.1016/S0065-230X(08)60886-6; PATERSON H, 1987, CELL, V51, P803, DOI 10.1016/0092-8674(87)90103-6; PIERCE JH, 1982, J EXP MED, V156, P873, DOI 10.1084/jem.156.3.873; PULCIANI S, 1982, P NATL ACAD SCI-BIOL, V79, P2845, DOI 10.1073/pnas.79.9.2845; PULVERTA.RJ, 1965, J CLIN PATHOL, V18, P261, DOI 10.1136/jcp.18.3.261; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RAGONA G, 1986, CELL BIOL INT REP, V10, P315, DOI 10.1016/0309-1651(86)90002-0; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SEREMETIS S, 1989, SCIENCE, V243, P660, DOI 10.1126/science.2536954; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STANBRIDGE EJ, 1982, SCIENCE, V215, P252, DOI 10.1126/science.7053574; STEVENSON M, 1986, MOL CELL BIOL, V6, P3410, DOI 10.1128/MCB.6.10.3410; SULLIVAN NF, 1986, CANCER RES, V46, P6427; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WINTER E, 1986, MOL CELL BIOL, V6, P2562, DOI 10.1128/MCB.6.7.2562; ZIEGLER JL, 1984, NEW ENGL J MED, V311, P565, DOI 10.1056/NEJM198408303110904	49	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1990	5	1					117	122						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM620	2157177				2022-12-17	WOS:A1990CM62000016
J	NATESAN, S; QUINN, EM; BENTLEY, MM				NATESAN, S; QUINN, EM; BENTLEY, MM			THE EXPRESSION OF SEQUENCES SIMILAR TO THE HUMAN C-ERB-A ONCOGENE ARE REGULATED IN A TISSUE AND STAGE SPECIFIC MANNER IN DROSOPHILA-MELANOGASTER	ONCOGENE			English	Article											NATESAN, S (corresponding author), UNIV CALGARY,DEPT BIOL SCI,CALGARY T2N 1N4,ALBERTA,CANADA.							ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BENDER W, 1987, CELL, V50, P519, DOI 10.1016/0092-8674(87)90023-7; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREEN S, 1986, NATURE, V324, P615, DOI 10.1038/324615a0; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUMAR V, 1988, CELL, V51, P469; Maniatis T, 1982, MOL CLONING LABORATO, P194; MASCHAT F, 1986, EMBO J, V5, P583, DOI 10.1002/j.1460-2075.1986.tb04250.x; NAKANISHI Y, 1983, P NATL ACAD SCI-BIOL, V80, P2971, DOI 10.1073/pnas.80.10.2971; SHILO B, 1981, P NATL ACAD SCI USA, V74, P5463; SHILO BZ, 1987, TRENDS GENET, V3, P69, DOI 10.1016/0168-9525(87)90178-8; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; WEINBERGER C, 1985, NATURE, V318, P670, DOI 10.1038/318670a0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0	20	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1989	4	11					1397	1401						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2478942				2022-12-17	WOS:A1989AX65900018
J	STETTER, G; MONTENARH, M				STETTER, G; MONTENARH, M			COMPLEX INTERACTION OF SV40 LARGE T-ANTIGEN WITH THE CONTROL REGION ON THE SV40-DNA	ONCOGENE			English	Article									UNIV ULM,DEPT BIOCHEM,POB 4066,D-7900 ULM,FED REP GER	Ulm University			Montenarh, Mathias/AAB-6689-2020					ALWINE JC, 1977, J VIROL, V24, P22, DOI 10.1128/JVI.24.1.22-27.1977; BENOIST C, 1981, NATURE, V290, P304, DOI 10.1038/290304a0; BRADY J, 1985, P NATL ACAD SCI USA, V82, P7299, DOI 10.1073/pnas.82.21.7299; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; DEB S, 1987, J VIROL, V61, P2143, DOI 10.1128/JVI.61.7.2143-2149.1987; DIMAIO D, 1982, J MOL BIOL, V156, P531, DOI 10.1016/0022-2836(82)90265-0; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; HANSEN U, 1981, CELL, V27, P603, DOI 10.1016/0092-8674(81)90402-5; KELLER JM, 1985, MOL CELL BIOL, V5, P1859, DOI 10.1128/MCB.5.8.1859; MONTENARH M, 1987, FEBS LETT, V204, P51; MULLER D, 1987, VIROLOGY, V161, P81, DOI 10.1016/0042-6822(87)90173-5; MYERS RM, 1980, P NATL ACAD SCI-BIOL, V77, P6491, DOI 10.1073/pnas.77.11.6491; MYERS RM, 1981, CELL, V25, P373, DOI 10.1016/0092-8674(81)90056-8; RIO D, 1980, P NATL ACAD SCI-BIOL, V77, P5706, DOI 10.1073/pnas.77.10.5706; RIO DC, 1983, CELL, V32, P1227, DOI 10.1016/0092-8674(83)90305-7; RUNZLER R, 1987, J VIROL, V61, P2076, DOI 10.1128/JVI.61.7.2076-2083.1987; RYDER K, 1985, CELL, V42, P539, DOI 10.1016/0092-8674(85)90111-4; SCHURMANN C, 1985, VIROLOGY, V146, P1, DOI 10.1016/0042-6822(85)90047-9; SHORTLE DR, 1979, P NATL ACAD SCI USA, V76, P6128, DOI 10.1073/pnas.76.12.6128; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; STETTER G, 1988, VIROLOGY, V164, P309, DOI 10.1016/0042-6822(88)90543-0; TEGTMEYER P, 1975, J VIROL, V15, P613, DOI 10.1128/JVI.15.3.613-618.1975; TOOZE J, 1981, DNA TUMOUR VIRUSES; WACHTER M, 1985, J VIROL, V56, P520, DOI 10.1128/JVI.56.2.520-526.1985; WIEKOWSKI M, 1987, J VIROL, V61, P411, DOI 10.1128/JVI.61.2.411-418.1987; WILSON VG, 1982, J VIROL, V44, P458, DOI 10.1128/JVI.44.2.458-466.1982	27	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1989	4	11					1353	1357						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2554237				2022-12-17	WOS:A1989AX65900012
J	VERMA, RS; MACERA, MJ; BENN, P; GROFFEN, J				VERMA, RS; MACERA, MJ; BENN, P; GROFFEN, J			MOLECULAR CHARACTERIZATION OF VARIANT TRANSLOCATIONS IN CHRONIC MYELOGENOUS LEUKEMIA	ONCOGENE			English	Note									LIFECODES CORP,VALHALLA,NY; CHILDRENS HOSP,LOS ANGELES,CA 90027	Children's Hospital Los Angeles	VERMA, RS (corresponding author), SUNY HLTH SCI CTR,LONG ISL COLL HOSP,340 HENRY ST,BROOKLYN,NY 11201, USA.		Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273				ALIMENA G, 1987, CANCER GENET CYTOGEN, V27, P21, DOI 10.1016/0165-4608(87)90255-X; ANDREWS DF, 1987, LEUKEMIA, V1, P718; Bartram C R, 1985, Haematol Blood Transfus, V29, P150; BARTRAM CR, 1988, LEUKEMIA, V2, P63; BARTRAM CR, 1985, J EXP MED, V162, P2175, DOI 10.1084/jem.162.6.2175; BARTRAM CR, 1985, EMBO J, V4, P683, DOI 10.1002/j.1460-2075.1985.tb03683.x; BENBASSAT I, 1988, LEUKEMIA, V2, P704; BENN P A, 1988, Journal of Tumor Marker Oncology, V3, P101; BERNSTEIN R, 1988, SEMIN HEMATOL, V25, P20; BLENNERHASSETT GT, 1988, LEUKEMIA, V2, P648; BOTTI AC, 1988, CANCER GENET CYTOGEN, V35, P51, DOI 10.1016/0165-4608(88)90121-5; Canaani E, 1985, Haematol Blood Transfus, V29, P154; CHAMPLIN RE, 1985, BLOOD, V65, P1039; CHAMPLIN RE, 1985, LEUKEMIA RECENT ADV, P651; CHEN SJ, 1988, LEUKEMIA, V2, P634; COLLINS SJ, 1989, BLOOD, V73, P1028; CROCE CM, 1987, P NATL ACAD SCI USA, V84, P7174, DOI 10.1073/pnas.84.20.7174; DREAZEN O, 1988, SEMIN HEMATOL, V25, P35; DREAZEN O, 1988, BLOOD, V71, P797; EISENBERG A, 1988, LEUKEMIA, V2, P642; GALE RP, 1985, BRIT J HAEMATOL, V60, P395, DOI 10.1111/j.1365-2141.1985.tb07436.x; GERHARD DS, 1981, P NATL ACAD SCI-BIOL, V78, P3755, DOI 10.1073/pnas.78.6.3755; GOLDMAN JM, 1987, BRIT J HAEMATOL, V66, P435, DOI 10.1111/j.1365-2141.1987.tb01323.x; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GROFFEN J, 1987, ADV VIRAL ONCOL, V7, P77; HAGEMEIJER A, 1984, CANCER GENET CYTOGEN, V13, P1, DOI 10.1016/0165-4608(84)90083-9; Heim S, 1987, ADV VIRAL ONCOL, V7, P53; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HURET JL, 1987, ANN GENET-PARIS, V30, P175; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LATT SA, 1983, J VIROL, V45, P1195, DOI 10.1128/JVI.45.3.1195-1199.1983; LEIBOWITZ D, 1985, BLOOD, V66, P243; LEMAISTRE A, 1989, BLOOD, V73, P889; LIFSHITZ B, 1988, ONCOGENE, V2, P113; Maniatis T., 1982, MOL CLONING; MASERATI E, 1988, HUM GENET, V78, P248, DOI 10.1007/BF00291671; MILLS KI, 1988, BLOOD, V72, P1237; MIURA I, 1988, CANCER GENET CYTOGEN, V34, P53, DOI 10.1016/0165-4608(88)90168-9; MORRIS CM, 1986, NATURE, V320, P281, DOI 10.1038/320281a0; OHYASHIKI JH, 1988, CANCER GENET CYTOGEN, V35, P151, DOI 10.1016/0165-4608(88)90236-1; PALKA G, 1988, ANN GENET-PARIS, V31, P190; PRZEPIORKA D, 1988, CANCER GENET CYTOGEN, V36, P117, DOI 10.1016/0165-4608(88)90081-7; PUGH WC, 1985, BRIT J HAEMATOL, V60, P457, DOI 10.1111/j.1365-2141.1985.tb07443.x; ROSSON D, 1988, MUTAT RES, V195, P231, DOI 10.1016/0165-1110(88)90002-4; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SOKAL JE, 1988, SEMIN HEMATOL, V25, P49; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAM K, 1985, NEW ENGL J MED, V313, P1429, DOI 10.1056/NEJM198512053132301; STRIFE A, 1988, SEMIN HEMATOL, V25, P1; SZABO P, 1988, MOL BIOL MED, V5, P139; VANDERPLAS DC, 1989, BLOOD, V73, P1038; VERMA RS, 1987, LEUKEMIA RES, V11, P833, DOI 10.1016/0145-2126(87)90068-3; VERMA RS, 1985, BLUT, V50, P129, DOI 10.1007/BF00320068; VERMA RS, 1989, HUMAN CHROMOSOMES MA; VERMA RS, 1988, IN VIVO, V2, P257; WEINSTEIN ME, 1988, CANCER GENET CYTOGEN, V55, P223; YOFFE G, 1987, EXP HEMATOL, V15, P725; YOUNG BD, 1988, BRIT J CANCER, V58, P58; Yunis J J, 1986, Important Adv Oncol, P93	59	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1989	4	9					1145	1148						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2674857				2022-12-17	WOS:A1989AM53100015
J	TRENCH, GC; SOUTHALL, M; SMITH, P; KIDSON, C				TRENCH, GC; SOUTHALL, M; SMITH, P; KIDSON, C			ALLELIC VARIATION OF THE C-RAF-1 PROTO-ONCOGENE IN HUMAN LYMPHOMA AND LEUKEMIA	ONCOGENE			English	Article											TRENCH, GC (corresponding author), QUEENSLAND INST MED RES,BRAMSTON TERRACE,HERSTON,QLD 4006,AUSTRALIA.							BERARD CW, 1981, ANN INTERN MED, V94, P218, DOI 10.7326/0003-4819-94-2-218; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CHENEVIXTRENCH G, 1987, LEUKEMIA, V1, P82; CLEVELAND JL, 1986, J CELL BIOCHEM, V30, P195, DOI 10.1002/jcb.240300303; COLL J, 1983, EMBO J, V2, P2189, DOI 10.1002/j.1460-2075.1983.tb01722.x; COX DW, 1987, AM J HUM GENET, V41, P891; HAYWARD NK, 1988, HUM GENET, V78, P115, DOI 10.1007/BF00278178; JACK AS, 1986, J PATHOL, V149, P25, DOI 10.1002/path.1711490107; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; KRONTIRIS TG, 1985, NATURE, V313, P369, DOI 10.1038/313369a0; Maniatis T., 1982, MOL CLONING; MCKEITHAN TW, 1986, P NATL ACAD SCI USA, V83, P6636, DOI 10.1073/pnas.83.17.6636; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; PETO TEA, 1988, AM J HUM GENET, V42, P615; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; TAHIRA T, 1987, NUCLEIC ACIDS RES, V15, P4809, DOI 10.1093/nar/15.12.4809; THEIN SL, 1986, NATURE, V321, P84, DOI 10.1038/321084a0	19	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1989	4	4					507	510						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5677	2566145				2022-12-17	WOS:A1989U567700016
J	KAPPES, B; ZIEMIECKI, A; MULLER, RG; THEILEN, GH; BAUER, H; BARNEKOW, A				KAPPES, B; ZIEMIECKI, A; MULLER, RG; THEILEN, GH; BAUER, H; BARNEKOW, A			THE TP1 ISOLATE OF FELINE SARCOMA-VIRUS ENCODES A FGR-RELATED ONCOGENE LACKING GAMMA-ACTIN SEQUENCES	ONCOGENE			English	Article									UNIV GIESSEN,INST MED VIROL,FRANKFURTER STR 107,D-6300 GIESSEN,FED REP GER; UNIV BERN,TIEFENAU HOSP,INST CLIN & EXPTL CANC RES,CH-3004 BERN,SWITZERLAND; UNIV CALIF DAVIS,DEPT VET SURG,DAVIS,CA 95616; UNIV CALIF DAVIS,CTR COMPARAT CANC,DAVIS,CA 95616	Justus Liebig University Giessen; University of Bern; University of California System; University of California Davis; University of California System; University of California Davis								ADKINS B, 1982, J VIROL, V43, P448, DOI 10.1128/JVI.43.2.448-455.1982; BARBACID M, 1980, P NATL ACAD SCI-BIOL, V77, P5158, DOI 10.1073/pnas.77.9.5158; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BESMER P, 1983, NATURE, V303, P825, DOI 10.1038/303825a0; BESMER P, 1986, J VIROL, V60, P194, DOI 10.1128/JVI.60.1.194-203.1986; BESMER P, 1983, J VIROL, V46, P606, DOI 10.1128/JVI.46.2.606-613.1983; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1988, IN PRESS PEPTIDES PR; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; DONNER L, 1982, J VIROL, V41, P489, DOI 10.1128/JVI.41.2.489-500.1982; ELDER JH, 1983, J VIROL, V46, P871, DOI 10.1128/JVI.46.3.871-880.1983; FEDELE LA, 1981, P NATL ACAD SCI-BIOL, V78, P4036, DOI 10.1073/pnas.78.7.4036; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; GARDNER MB, 1970, NATURE, V226, P807, DOI 10.1038/226807a0; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GUILHOT S, 1987, VIROLOGY, V161, P252, DOI 10.1016/0042-6822(87)90194-2; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAMPE A, 1982, CELL, V30, P775, DOI 10.1016/0092-8674(82)90282-3; HENDERSON IC, 1974, VIROLOGY, V60, P282, DOI 10.1016/0042-6822(74)90386-9; HOHN B, 1977, P NATL ACAD SCI USA, V74, P3259, DOI 10.1073/pnas.74.8.3259; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IKAWA S, 1986, MOL CELL BIOL, V6, P2420, DOI 10.1128/MCB.6.7.2420; IRGENS K, 1973, CR ACAD SCI D NAT, V276, P1783; JOVE R, 1986, J VIROL, V60, P840, DOI 10.1128/JVI.60.3.840-848.1986; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPREVOTTE I, 1984, J VIROL, V50, P884, DOI 10.1128/JVI.50.3.884-894.1984; LIPSICH LA, 1982, MOL CELL BIOL, V2, P875, DOI 10.1128/MCB.2.7.875; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1989, IN PRESS MOL CELL BI; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCDONOUGH SK, 1971, CANCER RES, V31, P953; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; NAHARRO G, 1983, J VIROL, V47, P611, DOI 10.1128/JVI.47.3.611-619.1983; NAHARRO G, 1983, VIROLOGY, V125, P502, DOI 10.1016/0042-6822(83)90223-4; NECKAMEYER WS, 1985, J VIROL, V53, P879, DOI 10.1128/JVI.53.3.879-884.1985; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; OPPERMANN H, 1981, VIROLOGY, V113, P736, DOI 10.1016/0042-6822(81)90202-6; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RASHEED S, 1982, VIROLOGY, V117, P238, DOI 10.1016/0042-6822(82)90522-0; RAYMOND VW, 1987, VIROLOGY, V160, P400, DOI 10.1016/0042-6822(87)90011-0; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUH S, 1985, J BIOL CHEM, V260, P4292; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SEFTON BM, 1986, CURR TOP MICROBIOL, V123, P39; SHERR CJ, 1980, J VIROL, V34, P200, DOI 10.1128/JVI.34.1.200-212.1980; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHUNTARO I, 1986, JPN J CANCER RES, V77, P611; SNYDER HW, 1984, VIROLOGY, V132, P205, DOI 10.1016/0042-6822(84)90104-1; SNYDER SP, 1969, NATURE, V221, P1074, DOI 10.1038/2211074a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TAKEYA T, 1982, J VIROL, V44, P12, DOI 10.1128/JVI.44.1.12-18.1982; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDEVEN WJM, 1980, VIROLOGY, V101, P185, DOI 10.1016/0042-6822(80)90495-X; VENNSTROM B, 1980, J VIROL, V36, P575; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; ZIEMIECKI A, 1984, VIROLOGY, V138, P324, DOI 10.1016/0042-6822(84)90355-6; ZIEMIECKI A, 1986, VIROLOGY, V151, P265, DOI 10.1016/0042-6822(86)90048-6; ZIEMIECKI A, 1986, BIOCHEM BIOPH RES CO, V138, P1298, DOI 10.1016/S0006-291X(86)80424-7	79	5	5	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1989	4	3					363	372						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5676	2539576				2022-12-17	WOS:A1989U567600013
J	DEDIEU, JF; GAZIN, C; RIGOLET, M; GALIBERT, F				DEDIEU, JF; GAZIN, C; RIGOLET, M; GALIBERT, F			EVOLUTIONARY CONSERVATION OF THE PRODUCT OF HUMAN C-MYC EXON-1 AND ITS INDUCIBLE EXPRESSION IN A MURINE CELL-LINE	ONCOGENE			English	Article											DEDIEU, JF (corresponding author), HOP ST LOUIS,CTR HAYEM,HEMATOL EXPTL LAB,CNRS,2 PL DR FOURNIER,F-75475 PARIS 10,FRANCE.							ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7978; COLBEREGARAPIN F, 1979, P NATL ACAD SCI USA, V76, P3755, DOI 10.1073/pnas.76.8.3755; COLBY WW, 1983, NATURE, V301, P722, DOI 10.1038/301722a0; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; FASEL N, 1982, EMBO J, V1, P3, DOI 10.1002/j.1460-2075.1982.tb01115.x; FINVER SN, 1988, P NATL ACAD SCI USA, V85, P3052, DOI 10.1073/pnas.85.9.3052; FORNSTEDT N, 1984, FEBS LETT, V177, P195, DOI 10.1016/0014-5793(84)81282-X; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GAZIN C, 1986, EMBO J, V5, P2241, DOI 10.1002/j.1460-2075.1986.tb04491.x; GEYSEN HM, 1985, P NATL ACAD SCI USA, V82, P178, DOI 10.1073/pnas.82.1.178; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Griffin B., 1981, DNA TUMOR VIRUSES, P61; GUTIERREZ C, 1987, MOL CELL BIOL, V7, P4594, DOI 10.1128/MCB.7.12.4594; HARRIS LJ, 1982, P NATL ACAD SCI-BIOL, V79, P4175, DOI 10.1073/pnas.79.13.4175; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LINIAL M, 1985, P NATL ACAD SCI USA, V82, P53, DOI 10.1073/pnas.82.1.53; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; Maniatis T., 1982, MOL CLONING; MAXAM AM, 1980, METHODS ENZYMOLOGY 1, V65; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; SHIH CK, 1984, P NATL ACAD SCI-BIOL, V81, P4697, DOI 10.1073/pnas.81.15.4697; SHOWE LC, 1987, P NATL ACAD SCI USA, V84, P2824, DOI 10.1073/pnas.84.9.2824; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STUDZINSKI GP, 1986, SCIENCE, V234, P467, DOI 10.1126/science.3532322; VANBENEDEN RJ, 1986, P NATL ACAD SCI USA, V83, P3698; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x	46	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					523	529						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	3078958				2022-12-17	WOS:A1988R516300006
J	DONIGER, J				DONIGER, J			DIFFERENTIAL CONSERVATION OF NONCODING REGIONS WITHIN HUMAN AND GUINEA-PIG N-RAS GENES	ONCOGENE			English	Note											DONIGER, J (corresponding author), NATL CANC INST,DIV CANC ETIOL,BIOL LAB,BLDG 37,ROOM 2A19,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; DONIGER J, 1987, J BIOL CHEM, V262, P3813; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; EVA A, 1983, P NATL ACAD SCI-BIOL, V80, P4926, DOI 10.1073/pnas.80.16.4926; EVANS CH, 1975, CANCER RES, V35, P1035; GONZALEZ FJ, 1985, J BIOL CHEM, V260, P5040; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HART RP, 1985, MOL CELL BIOL, V5, P2975, DOI 10.1128/MCB.5.11.2975; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; LARHAMMAR D, 1983, CELL, V34, P179, DOI 10.1016/0092-8674(83)90148-4; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MIYATA T, 1981, P NATL ACAD SCI-BIOL, V78, P450, DOI 10.1073/pnas.78.1.450; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; ROMEROHERRERA AE, 1973, NATURE, V246, P389, DOI 10.1038/246389a0; SANGER F, 1978, FEBS LETT, V87, P107, DOI 10.1016/0014-5793(78)80145-8; SCHOENIGER LO, 1986, MOL CELL BIOL, V6, P1508, DOI 10.1128/MCB.6.5.1508; SOGAWA K, 1985, J BIOL CHEM, V260, P5026; SUKUMAR S, 1984, SCIENCE, V223, P1197, DOI 10.1126/science.6322298; TAKAHASHI K, 1986, NATURE, V319, P121, DOI 10.1038/319121a0; YAFFE D, 1985, NUCLEIC ACIDS RES, V13, P3723, DOI 10.1093/nar/13.10.3723; YOUNG HA, 1980, VIROLOGY, V107, P89, DOI 10.1016/0042-6822(80)90275-5	23	5	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	1	3					331	334						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J9705	3133626				2022-12-17	WOS:A1987J970500016
J	FERRE, F; MARTIN, P; LAGROU, C; RAES, MB; GHYSDAEL, J; SAULE, S; STEHELIN, D				FERRE, F; MARTIN, P; LAGROU, C; RAES, MB; GHYSDAEL, J; SAULE, S; STEHELIN, D			THE HUMAN-C-MYC EXON-1 PRODUCT - PREPARATION OF ANTISERA AND ANALYSIS OF ITS EXPRESSION	ONCOGENE			English	Article									INST PASTEUR, INSERM, U186, CNRS, UNITE 041160, 1 RUE CALMETTE, F-59019 LILLE, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			GHYSDAEL, Jacques/F-3377-2013					BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; COLL J, 1983, EMBO J, V2, P2189, DOI 10.1002/j.1460-2075.1983.tb01722.x; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GAZIN C, 1986, EMBO J, V5, P2241, DOI 10.1002/j.1460-2075.1986.tb04491.x; GHYSDAEL J, 1981, VIROLOGY, V111, P386, DOI 10.1016/0042-6822(81)90342-1; GHYSDAEL J, 1979, J VIROL, V29, P1087, DOI 10.1128/JVI.29.3.1087-1098.1979; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINIAL M, 1985, P NATL ACAD SCI USA, V82, P53, DOI 10.1073/pnas.82.1.53; MARTIN P, 1986, EMBO J, V5, P1529, DOI 10.1002/j.1460-2075.1986.tb04393.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; REMAUT E, 1981, GENE, V15, P81, DOI 10.1016/0378-1119(81)90106-2; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; TAUB R, 1984, CELL, V37, P511, DOI 10.1016/0092-8674(84)90381-7; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448	24	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene		1987	1	4					387	393						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	K7483	3330782				2022-12-17	WOS:A1987K748300007
J	WODNARFILIPOWICZ, A; SENN, HP; JIRICNY, J; SIGNER, E; MORONI, C				WODNARFILIPOWICZ, A; SENN, HP; JIRICNY, J; SIGNER, E; MORONI, C			GLYCINE-CYSTEINE SUBSTITUTION AT CODON-13 OF THE N-RAS-PROTO-ONCOGENE IN A HUMAN T-CELL NON-HODGKINS-LYMPHOMA	ONCOGENE			English	Note									FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND; UNIV BASEL,CHILDRENS HOSP,CH-4058 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research; University of Basel								BALMAIN A, 1985, BRIT J CANCER, V51, P1, DOI 10.1038/bjc.1985.1; BARBACID M, 1986, TRENDS GENET, V2, P188, DOI 10.1016/0168-9525(86)90222-2; BLAIR DG, 1982, SCIENCE, V218, P1122, DOI 10.1126/science.6293052; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BOS JL, 1986, NUCLEIC ACIDS RES, V14, P1209, DOI 10.1093/nar/14.3.1209; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; CHARDIN P, 1985, INT J CANCER, V35, P647, DOI 10.1002/ijc.2910350513; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; EVA A, 1983, P NATL ACAD SCI-BIOL, V80, P4926, DOI 10.1073/pnas.80.16.4926; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJITA J, 1984, NATURE, V309, P464, DOI 10.1038/309464a0; GAMBKE C, 1984, NATURE, V307, P476, DOI 10.1038/307476a0; GAMBKE C, 1985, P NATL ACAD SCI USA, V82, P879, DOI 10.1073/pnas.82.3.879; GIBBS JB, 1985, TRENDS BIOCHEM SCI, V10, P350, DOI 10.1016/0968-0004(85)90110-0; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; JANSSEN JWG, 1985, CANCER RES, V45, P3262; LEVINSON AD, 1986, TRENDS GENET, V2, P81, DOI 10.1016/0168-9525(86)90184-8; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; NEEDLEMAN SW, 1986, BLOOD, V67, P753; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; SCHWAB M, 1985, TRENDS GENET, V1, P271, DOI 10.1016/0168-9525(85)90103-9; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SEKIYA T, 1984, P NATL ACAD SCI-BIOL, V81, P4771, DOI 10.1073/pnas.81.15.4771; SENN HP, 1987, IN PRESS INT J CANCE; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH GE, 1980, ANAL BIOCHEM, V109, P123, DOI 10.1016/0003-2697(80)90019-6; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P, 1982, EUKARYOTIC VIRAL VEC, P41; SOUYRI M, 1983, P NATL ACAD SCI-BIOL, V80, P6676, DOI 10.1073/pnas.80.21.6676; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TOPAL MD, 1986, J BIOL CHEM, V261, P9879; WEISS RA, 1984, LANCET, V2, P1138; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	39	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	1	4					457	461						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	K7483	3330790				2022-12-17	WOS:A1987K748300018
J	Lu, XY; Wang, J; Wang, W; Lu, CF; Qu, TY; He, XZ; Liu, XY; Guo, RH; Zhang, EB				Lu, Xiyi; Wang, Jing; Wang, Wei; Lu, Chenfei; Qu, Tianyu; He, Xuezhi; Liu, Xinyin; Guo, Renhua; Zhang, Erbao			Copy number amplification and SP1-activated lncRNA MELTF-AS1 regulates tumorigenesis by driving phase separation of YBX1 to activate ANXA8 in non-small cell lung cancer	ONCOGENE			English	Article							BOX BINDING-PROTEIN; NONCODING RNAS; EXPRESSION; TRANSCRIPTION; PROGRESSION; PROMOTES; YB-1; SP1; METASTASIS; RESISTANCE	Long non-coding RNAs (lncRNAs) are reported to play key roles in tumorigenesis. However, the mechanisms underlying lncRNA-mediated regulation of RNA-binding protein phase separation in tumorigenesis have not been completely elucidated. In this study, an oncogenic lncRNA MELTF-AS1 was identified using systematic data analysis, screening, and verification. MELTF-AS1 was markedly upregulated in non-small cell lung cancer (NSCLC). High MELTF-AS1 levels were associated with advanced tumor-node-metastasis stage (TNM), high tumor size, and decreased survival time. Functionally, MELTF-AS1 regulated cell proliferation and metastasis in vitro and in vivo. RNA sequencing analysis revealed that MELTF-AS1 knockdown specifically modulated genes associated with cell proliferation, apoptosis, and migration. Mechanistically, at the genome level, copy number amplification promoted MELTF-AS1 expression. At the transcriptional level, the transcription factor SP1 directly activated MELTF-AS1 transcription by binding to its promoter. Furthermore, MELTF-AS1 could directly bind and drive the phase separation of YBX1, which was an RNA-binding protein and involved in tumorigenesis, thus activating ANXA8 transcription and promoting tumorigenesis of NSCLC. Aberrant activation of ANXA8 and promotion of tumorigenesis have been found in a variety of tumors. These novel findings demonstrated the critical role of MELTF-AS1-driven phase separation-mediated transcriptional regulation and provided a potential novel diagnostic and therapeutic target for NSCLC.	[Lu, Xiyi; Qu, Tianyu; Liu, Xinyin; Guo, Renhua] Nanjing Med Univ, Dept Oncol, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China; [Wang, Jing; He, Xuezhi] Nanjing Med Univ, Res Ctr Bone & Stem Cells, Dept Anat Histol & Embryol, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China; [Wang, Wei] Nanjing Med Univ, Dept Thorac Surg, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China; [Lu, Chenfei] Yangzhou Univ, Dept Clin Med, Med Coll, Yangzhou, Jiangsu, Peoples R China; [Zhang, Erbao] Nanjing Med Univ, Ctr Global Hlth, Sch Publ Hlth, Dept Epidemiol, Nanjing 211166, Peoples R China; [Zhang, Erbao] Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 211166, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Yangzhou University; Nanjing Medical University; Nanjing Medical University	Guo, RH (corresponding author), Nanjing Med Univ, Dept Oncol, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China.; Zhang, EB (corresponding author), Nanjing Med Univ, Ctr Global Hlth, Sch Publ Hlth, Dept Epidemiol, Nanjing 211166, Peoples R China.; Zhang, EB (corresponding author), Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 211166, Jiangsu, Peoples R China.	rhguo@njmu.edu.cn; erbaozhang@njmu.edu.cn		Guo, Renhua/0000-0003-4475-8617; Qu, Tianyu/0000-0002-4242-0615; Lu, Xiyi/0000-0003-2204-2052; zhang, erbao/0000-0002-5752-7976	National Natural Science Foundation of China [82172992, 81972188, 82103133]; Natural Science Foundation of Jiangsu Province [BK20211253, BK20210973]; China Postdoctoral Science Foundation [2020M671395]; Medical Important Talents [ZDRCA2016024]; Program for Innovative Research Team of Nanjing Medical University [JX102GSP201727]; Wu Jie-ping Foundation [320.6799.15032]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Medical Important Talents; Program for Innovative Research Team of Nanjing Medical University; Wu Jie-ping Foundation	This work was supported by the National Natural Science Foundation of China [82172992, 81972188 and 82103133], Natural Science Foundation of Jiangsu Province [BK20211253 and BK20210973], China Postdoctoral Science Foundation (2020M671395), the Medical Important Talents [ZDRCA2016024], the Program for Innovative Research Team of Nanjing Medical University [JX102GSP201727], and the Wu Jie-ping Foundation [320.6799.15032].	Alberti S, 2019, ANNU REV GENET, V53, P171, DOI 10.1146/annurev-genet-112618-043527; Banani SF, 2017, NAT REV MOL CELL BIO, V18, P285, DOI 10.1038/nrm.2017.7; Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Boija A, 2021, CANCER CELL, V39, P174, DOI 10.1016/j.ccell.2020.12.003; Boija A, 2018, CELL, V175, P1842, DOI 10.1016/j.cell.2018.10.042; Camps C, 2009, CLIN LUNG CANCER, V10, P83, DOI 10.3816/CLC.2009.n.010; Chen ZR, 2016, J CLIN INVEST, V126, P2267, DOI 10.1172/JCI85250; Deng SJ, 2018, ONCOGENE, V37, P5811, DOI 10.1038/s41388-018-0382-1; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017; Flippot R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08363-6; Goodarzi H, 2015, CELL, V161, P790, DOI 10.1016/j.cell.2015.02.053; Gutschner T, 2013, CANCER RES, V73, P1180, DOI 10.1158/0008-5472.CAN-12-2850; Hata H, 2014, MOL CARCINOGEN, V53, P181, DOI 10.1002/mc.21961; Imada K, 2013, CLIN CANCER RES, V19, P4638, DOI 10.1158/1078-0432.CCR-12-3705; Jiang S, 2020, ELIFE, V9, DOI 10.7554/eLife.60264; Jungert K, 2007, CANCER RES, V67, P1563, DOI 10.1158/0008-5472.CAN-06-1670; Kosnopfel C, 2014, EUR J CELL BIOL, V93, P61, DOI 10.1016/j.ejcb.2013.11.007; La-Touche S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146740; Li CL, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12632; Li D, 2017, HEPATOLOGY, V65, P1612, DOI 10.1002/hep.29010; Li J, 2015, CANCER RES, V75, P3728, DOI 10.1158/0008-5472.CAN-15-0273; Li L, 2010, ANN ANAT, V192, P275, DOI 10.1016/j.aanat.2010.07.010; Lin CR, 2018, TRENDS CELL BIOL, V28, P287, DOI 10.1016/j.tcb.2017.11.008; Lin M, 2006, ONCOGENE, V25, P1424, DOI 10.1038/sj.onc.1209166; Liu K, 2019, EUR REV MED PHARMACO, V23, P5884, DOI 10.26355/eurrev_201907_18333; Liu XY, 2019, MOL THER-NUCL ACIDS, V16, P155, DOI 10.1016/j.omtn.2019.02.010; Liu Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep14082; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Munschauer M, 2018, NATURE, V561, P132, DOI 10.1038/s41586-018-0453-z; Petrelli NJ, 2009, J CLIN ONCOL, V27, P6052, DOI 10.1200/JCO.2009.26.6171; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Ricciotti RW, 2017, CANCER GENET-NY, V218, P69, DOI 10.1016/j.cancergen.2017.09.005; Roden C, 2021, NAT REV MOL CELL BIO, V22, P183, DOI 10.1038/s41580-020-0264-6; Sabari BR, 2018, SCIENCE, V361, DOI 10.1126/science.aar3958; SARKAR A, 1994, BLOOD, V84, P279; SCHIMKE RT, 1990, CANCER CELL-MON REV, V2, P149; Shibahara K, 2001, CLIN CANCER RES, V7, P3151; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Song J, 2007, CLIN CANCER RES, V13, P6842, DOI 10.1158/1078-0432.CCR-07-0569; Stein T, 2005, CLIN CANCER RES, V11, P6872, DOI 10.1158/1078-0432.CCR-05-0547; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Wei YP, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109890; Wierstra I, 2008, BIOCHEM BIOPH RES CO, V372, P1, DOI 10.1016/j.bbrc.2008.03.074; Wu M, 2021, SCIENCE, V373, P547, DOI 10.1126/science.abf6582; Yan XD, 2010, CANCER RES, V70, P1616, DOI 10.1158/0008-5472.CAN-09-3215; Yang F, 2017, CANCER RES, V77, P5543, DOI 10.1158/0008-5472.CAN-17-1375; Yin DD, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0836-7; Yu XX, 2005, HEPATOLOGY, V42, P362, DOI 10.1002/hep.20783; Zhang EB, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1523-0; Zhang EB, 2017, NUCLEIC ACIDS RES, V45, P3086, DOI 10.1093/nar/gkw1247	55	4	4	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2022	41	23					3222	3238		10.1038/s41388-022-02292-z	http://dx.doi.org/10.1038/s41388-022-02292-z		MAY 2022	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1V0EG	35508543				2022-12-17	WOS:000790621800003
J	Lv, Y; Tang, WT; Zhang, ZY; Lin, Q; Luo, YX; Zheng, P; Li, K; Jia, XN; Pang, YZ; Ji, ML; Feng, QY; He, GD; Wang, YX; Xu, JM				Lv Yang; Tang WenTao; Zhang ZhiYuan; Lin Qi; Luo YuXiang; Zheng Peng; Li Ke; Jia XiaoNa; Pang YuZhi; Ji MeiLing; Feng QingYang; He GuoDong; Wang YueXiang; Xu JianMin			Cullin-9/p53 mediates HNRNPC degradation to inhibit erastin-induced ferroptosis and is blocked by MDM2 inhibition in colorectal cancer	ONCOGENE			English	Article							CELL-DEATH; VULNERABILITY; STATISTICS; SUBTYPES; COMPLEX; PARC; KRAS	Colorectal cancer (CRC) is the leading cause of cancer associated death worldwide. Ferroptosis is a newly defined form of regulated cell death characterized by the accumulation of lipid hydroperoxides and exerts an increased attention for cancer treatment. However, little is known about ferroptosis in CRC. In this study, through whole genome sequencing and external differential differentiated expression analysis, we identify CUL9 as a novel important modulator for ferroptosis in CRC. Here we demonstrated that CUL9 can binds p53 to ubiquitylate heterogeneous nuclear ribonucleoprotein C for degradation. Overexpression of CUL9 increases resistance to erastin-induced ferroptosis. Then, we discovered this resistance was mediated by CUL9-HNRNPC-MATE1 negative loop, which can provide us with a novel target to overcome drug resistance to ferroptosis activators. Finally, we found that targeting MDM2 was developed as an effective strategy to destroy precious drug-resistant CRC cells.	[Lv Yang; Tang WenTao; Zhang ZhiYuan; Lin Qi; Zheng Peng; Ji MeiLing; Feng QingYang; He GuoDong; Xu JianMin] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai, Peoples R China; [Lv Yang; Tang WenTao; Zhang ZhiYuan; Lin Qi; Zheng Peng; Ji MeiLing; Feng QingYang; He GuoDong; Xu JianMin] Fudan Univ, Zhongshan Hosp, Canc Ctr, Shanghai, Peoples R China; [Tang WenTao; Zhang ZhiYuan; Lin Qi; Zheng Peng; Ji MeiLing; Feng QingYang; He GuoDong; Xu JianMin] Shanghai Engn Res Ctr Colorectal Canc Minimally I, Shanghai, Peoples R China; [Luo YuXiang; Li Ke; Jia XiaoNa; Pang YuZhi; Wang YueXiang] Chinese Acad Sci, Univ Chinese Acad Sci, Shanghai Inst Nutr & Hlth, CAS Key Lab Tissue Microenvironm & Tumor, Shanghai, Peoples R China	Fudan University; Fudan University; Chinese Academy of Sciences; Shanghai Institute of Nutrition & Health, CAS; University of Chinese Academy of Sciences, CAS	Xu, JM (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai, Peoples R China.; Xu, JM (corresponding author), Fudan Univ, Zhongshan Hosp, Canc Ctr, Shanghai, Peoples R China.; Xu, JM (corresponding author), Shanghai Engn Res Ctr Colorectal Canc Minimally I, Shanghai, Peoples R China.; Wang, YX (corresponding author), Chinese Acad Sci, Univ Chinese Acad Sci, Shanghai Inst Nutr & Hlth, CAS Key Lab Tissue Microenvironm & Tumor, Shanghai, Peoples R China.	yxwang76@sibs.ac.cn; xujmin@aliyun.com	Wang, Yuexiang/GNH-5248-2022; zhang, zhiyuan/GRS-2141-2022	Zhang, Zhiyuan/0000-0003-0336-7783	National Natural Science Foundation of China [81602040, 81903067, 82072678, 81402341]; Clinical science and technology innovation project of Shanghai [SHDC12016104]; Shanghai Science and Technology Committee Project [17411951300, 18140903200, 19511121300]; Youth fund of Zhongshan Hospital [2019ZSQN28]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Clinical science and technology innovation project of Shanghai; Shanghai Science and Technology Committee Project(Shanghai Science & Technology Committee); Youth fund of Zhongshan Hospital	This work was supported by National Natural Science Foundation of China (Grant No. 81602040, 81903067, 82072678 and 81402341), Clinical science and technology innovation project of Shanghai (SHDC12016104), Shanghai Science and Technology Committee Project (17411951300, 18140903200 and 19511121300) and Youth fund of Zhongshan Hospital (2019ZSQN28). The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data and in the writing of the paper.	Aldrovandi M, 2020, CELL RES, V30, P1061, DOI 10.1038/s41422-020-00434-0; AMOR B, 1984, ANN INTERN MED, V101, P878, DOI 10.7326/0003-4819-101-6-878_1; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chen Y, 2019, CELL SIGNAL, V63, DOI 10.1016/j.cellsig.2019.109384; Conrad M, 2016, NAT REV DRUG DISCOV, V15, P348, DOI 10.1038/nrd.2015.6; De Roock W, 2011, LANCET ONCOL, V12, P594, DOI 10.1016/S1470-2045(10)70209-6; Fang XX, 2019, P NATL ACAD SCI USA, V116, P2672, DOI 10.1073/pnas.1821022116; Gama V, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005309; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Giordano G, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-1019-5; Guo JP, 2018, CANCER RES TREAT, V50, P445, DOI 10.4143/crt.2016.572; Hassannia B, 2019, CANCER CELL, V35, P830, DOI 10.1016/j.ccell.2019.04.002; Hattori K, 2017, EMBO REP, V18, P2067, DOI 10.15252/embr.201744228; Ishizawa J, 2019, CANCER CELL, V35, P721, DOI 10.1016/j.ccell.2019.03.014; Jiang L, 2015, NATURE, V520, P57, DOI 10.1038/nature14344; Jiang XJ, 2021, NAT REV MOL CELL BIO, V22, P266, DOI 10.1038/s41580-020-00324-8; Khan OM, 2018, J CLIN INVEST, V128, P1326, DOI 10.1172/JCI97325; Kunii A, 2018, CRISPR J, V1, P337, DOI 10.1089/crispr.2018.0009; Lal N, 2018, CLIN CANCER RES, V24, P224, DOI 10.1158/1078-0432.CCR-17-1090; Li ZJ, 2014, MOL CELL, V54, P805, DOI 10.1016/j.molcel.2014.03.046; Liu Y, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.596679; Liu YH, 2015, NATURE, V520, P697, DOI 10.1038/nature14418; Lopez J, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005619; Loree JM, 2018, JNCI-J NATL CANCER I, V110, P1409, DOI 10.1093/jnci/djy067; Louandre C, 2013, INT J CANCER, V133, P1732, DOI 10.1002/ijc.28159; Lu B, 2018, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00992; Maldonado EN, 2013, J BIOL CHEM, V288, P11920, DOI 10.1074/jbc.M112.433847; Mou YH, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0720-y; Nagpal A, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1177-1; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Oliphant R, 2013, BRIT J SURG, V100, P1388, DOI 10.1002/bjs.9227; Rink Jonathan S, 2020, J Biol Chem, V296, P100100, DOI 10.1074/jbc.RA120.014888; Santos C, 2018, ANN ONCOL, V29, P1340, DOI 10.1093/annonc/mdy132; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Toyokuni S, 2020, CANCER SCI, V111, P2665, DOI 10.1111/cas.14496; Tsoi J, 2018, CANCER CELL, V33, P890, DOI 10.1016/j.ccell.2018.03.017; Xie YC, 2017, CELL REP, V20, P1692, DOI 10.1016/j.celrep.2017.07.055; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010; Yang YT, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15883-9; Yu Y, 2015, MOL CELL ONCOL, V2, DOI 10.1080/23723556.2015.1054549; Zhang X, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101211; Zhao J, 2008, SCIENCE, V322, P750, DOI 10.1126/science.1163045; Zheng P, 2018, J ONCOL, V2018, DOI 10.1155/2018/5072987; Zheng YY, 2018, NUCLEIC ACIDS RES, V46, pD139, DOI 10.1093/nar/gkx895	44	4	4	7	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2022	41	23					3210	3221		10.1038/s41388-022-02284-z	http://dx.doi.org/10.1038/s41388-022-02284-z		MAY 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1V0EG	35505093				2022-12-17	WOS:000790289600002
J	Liu, ZL; Liu, JL; Chen, TL; Wang, Y; Shi, AD; Li, KS; Li, XY; Qiu, B; Zheng, LJ; Zhao, LM; Shu, LZ; Lian, S; Huang, SH; Zhang, ZL; Xu, YF				Liu, Zengli; Liu, Jialiang; Chen, Tianli; Wang, Yue; Shi, Anda; Li, Kangshuai; Li, Xingyong; Qiu, Bo; Zheng, Lijie; Zhao, Liming; Shu, Lizhuang; Lian, Shuo; Huang, Shaohui; Zhang, Zongli; Xu, Yunfei			Wnt-TCF7-SOX9 axis promotes cholangiocarcinoma proliferation and pemigatinib resistance in a FGF7-FGFR2 autocrine pathway	ONCOGENE			English	Article							BETA-CATENIN; INVASION; TARGETS; GROWTH; CANCER; SOX9	Cholangiocarcinoma (CCA) is a type of highly malignant tumor originating from bile ducts. The prognosis of CCA is poor and the treatment options are limited. The biomarker study of CCA has made little progresses in recent years because of the difficulty to obtain CCA specimens. SOX9 is an important regulator of cholangiocyte proliferation and differentiation. We performed mRNA sequencing of CCA, retrieved TCGA data, and detected SOX9 expression in a large CCA cohort. With WNT3A stimulation, SOX9 expression and transcription was elevated by TCF7. Moreover, SOX9 was substantially up-regulated in CCA tissues and was identified as a prognostic biomarker of CCA. With mRNA sequencing and in vitro/vivo validation, we demonstrated that SOX9 enhanced the transcription and expression of FGF7 and FGFR2. FGF7 was significantly up-regulated in the bile and serum of CCA patients, and may promote CCA proliferation by activating FGFR2 in an autocrine pathway. co-expression of FGF7 and FGFR2 was a more sensitive marker for poor prognosis. SOX9-induced overexpression of FGF7 and FGFR2 was the key reason of SOX9-involved pemigatinib resistance. In conclusion, SOX9 and FGF7 were prognostic biomarkers of CCA. WNT3A-TCF7-SOX9 axis could induce pemigatinib resistance in two independent pathways: (1)SOX9 directly promotes FGFR2 transcription and expression; (2)SOX9 elevates FGF7 expression, which could be secreted from CCA cells and activates FGFR2 phosphorylation in an autocrine pathway.	[Liu, Zengli; Liu, Jialiang; Chen, Tianli; Wang, Yue; Shi, Anda; Li, Kangshuai; Qiu, Bo; Zheng, Lijie; Zhao, Liming; Shu, Lizhuang; Lian, Shuo; Huang, Shaohui; Zhang, Zongli; Xu, Yunfei] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Gen Surg, Jinan 250012, Shandong, Peoples R China; [Li, Xingyong] Shandong Univ, Shandong Prov Hosp 3, Cheeloo Coll Med, Dept Hepatobiliary Surg, Jinan 250012, Shandong, Peoples R China	Shandong University; Shandong University	Zhang, ZL; Xu, YF (corresponding author), Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Gen Surg, Jinan 250012, Shandong, Peoples R China.	zzlzzl1900@163.com; xuyunfei1988@126.com			Shandong University Multidisciplinary Research and Innovation Team of Young Scholars [2020QNQT002]; Shandong Province Key RD Program [,2021CXGC011105]; National Natural Science Foundation of China [82072676, 82172791]; China Postdoctoral Science Foundation [2020M682190, 2020M682195]; Clinical Research Foundation of Shandong University [2020SDUCRCA018]; Natural Science Foundation of Shandong Province [ZR2019MH008]; Jinan City Science and Technology Development Program [201805017, 201805013]; Clinical Research Innovation Fund Project [CXPJJH11800001-2018240]; Hengrui Hepatobiliary and Pancreatic Foundation; Key Research and Development Program of Shandong Province [2019GSF108254]; Beijing Medical Award Foundation [YXJL-2020-0785-0967, YXJL-2020-0785-0968]	Shandong University Multidisciplinary Research and Innovation Team of Young Scholars; Shandong Province Key RD Program; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Clinical Research Foundation of Shandong University; Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Jinan City Science and Technology Development Program; Clinical Research Innovation Fund Project; Hengrui Hepatobiliary and Pancreatic Foundation; Key Research and Development Program of Shandong Province; Beijing Medical Award Foundation	Our study was supported by Shandong University Multidisciplinary Research and Innovation Team of Young Scholars (Grant No. 2020QNQT002), Shandong Province Key R&D Program(Major Scientific Innovation Projects,2021CXGC011105), National Natural Science Foundation of China (Grant No. 82072676, 82172791), China Postdoctoral Science Foundation (Grant No. 2020M682190, 2020M682195), Clinical Research Foundation of Shandong University (Grant No. 2020SDUCRCA018), Natural Science Foundation of Shandong Province (ZR2019MH008), Jinan City Science and Technology Development Program (Grant No. 201805017, 201805013), Clinical Research Innovation Fund Project(CXPJJH11800001-2018240), Hengrui Hepatobiliary and Pancreatic Foundation (Grant No.Y-2017-144), Key Research and Development Program of Shandong Province (Grant No. 2019GSF108254), Beijing Medical Award Foundation (YXJL-2020-0785-0967, YXJL-2020-0785-0968).	Abou-Alfa GK, 2020, LANCET ONCOL, V21, P671, DOI 10.1016/S1470-2045(20)30109-1; Andersen JB, 2012, GASTROENTEROLOGY, V142, P1021, DOI 10.1053/j.gastro.2011.12.005; Antoniou A, 2009, GASTROENTEROLOGY, V136, P2325, DOI 10.1053/j.gastro.2009.02.051; Chamorro MN, 2005, EMBO J, V24, P73, DOI 10.1038/sj.emboj.7600460; Chen TL, 2021, ONCOGENE, V40, P4941, DOI 10.1038/s41388-021-01850-1; Chen TL, 2021, MOL THER, V29, P2134, DOI 10.1016/j.ymthe.2021.02.017; Davis K, 1990, Int J Technol Assess Health Care, V6, P203; Fan EW, 2015, J UROLOGY, V194, P223, DOI 10.1016/j.juro.2015.01.073; Goyal L, 2021, CANCER TREAT REV, V95, DOI 10.1016/j.ctrv.2021.102170; Hoy SM, 2020, DRUGS, V80, P923, DOI 10.1007/s40265-020-01330-y; Huang TT, 2017, INT J ONCOL, V50, P1501, DOI 10.3892/ijo.2017.3927; Katoh M, 2014, MED RES REV, V34, P280, DOI 10.1002/med.21288; Kawaguchi Y, 2013, J CLIN INVEST, V123, P1881, DOI 10.1172/JCI66022; Lau WM, 2018, MOL CANCER THER, V17, P232, DOI 10.1158/1535-7163.MCT-17-0367; Li ZP, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01890-1; Liu PCC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231877; Liu ZL, 2019, EBIOMEDICINE, V45, P181, DOI 10.1016/j.ebiom.2019.06.023; Pai R, 2008, CANCER RES, V68, P5086, DOI 10.1158/0008-5472.CAN-07-2325; Poncy A, 2015, DEV BIOL, V404, P136, DOI 10.1016/j.ydbio.2015.05.012; Qiu B, 2019, EBIOMEDICINE, V50, P166, DOI 10.1016/j.ebiom.2019.11.021; Rizvi S, 2018, NAT REV CLIN ONCOL, V15, P95, DOI 10.1038/nrclinonc.2017.157; Ropiquet F, 1999, INT J CANCER, V82, P237, DOI 10.1002/(SICI)1097-0215(19990719)82:2<237::AID-IJC14>3.0.CO;2-Q; Sarabipour S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10262; Shimokawa T, 2003, CANCER RES, V63, P6116; Silverman IM, 2021, CANCER DISCOV, V11, P326, DOI 10.1158/2159-8290.CD-20-0766; Sun RQ, 2019, EBIOMEDICINE, V47, P142, DOI 10.1016/j.ebiom.2019.08.062; Valle JW, 2021, LANCET, V397, P428, DOI 10.1016/S0140-6736(21)00153-7; Xie YL, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00222-7; Xu YF, 2019, ONCOGENE, V38, P868, DOI 10.1038/s41388-018-0485-8; Xu YF, 2014, BIOCHEM BIOPH RES CO, V446, P54, DOI 10.1016/j.bbrc.2014.02.050; Yuan XD, 2018, BRIT J CANCER, V119, P1358, DOI 10.1038/s41416-018-0338-9	31	4	4	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2022	41	20					2885	2896		10.1038/s41388-022-02313-x	http://dx.doi.org/10.1038/s41388-022-02313-x		APR 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1F4TJ	35428876				2022-12-17	WOS:000782705700001
J	Tan, Z; Shi, S; Xu, J; Liu, XM; Lei, YB; Zhang, B; Hua, J; Meng, QC; Wang, W; Yu, XJ; Liang, C				Tan, Zhen; Shi, Si; Xu, Jin; Liu, Xiaomeng; Lei, Yubin; Zhang, Bo; Hua, Jie; Meng, Qingcai; Wang, Wei; Yu, Xianjun; Liang, Chen			RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m(6)A-YTHDF2-dependent manner	ONCOGENE			English	Article							GROWTH-FACTOR-C; OBESITY	RNA N6-methyladenosine (m(6)A) is an emerging regulator of mRNA modifications and represents a novel player in tumorigenesis. Although it has functional significance in both pathological and physiological processes, the role of m(6)A modification in pancreatic ductal cancer (PDAC) remains elusive. Here, we showed that high fat mass and obesity-associated gene (FTO) expression was associated with a poor prognosis in PDAC patients and that suppression of FTO expression inhibited cell proliferation. Here, m(6)A sequencing (m(6)A-seq) was performed to screen genes targeted by FTO. The effects of FTO stimulation on the biological characteristics of pancreatic cancer cells, including proliferation and colony formation, were investigated in vitro and in vivo. The results indicate that FTO directly targets platelet-derived growth factor C (PDGFC) and stabilizes its mRNA expression in an m(6)A-YTHDF2-dependent manner. m(6)A-methylated RNA immunoprecipitation-qPCR (MeRIP-qPCR), RNA immunoprecipitation (RIP), and luciferase reporter assays were employed to validate the specific binding of FTO to PDGFC. PDGFC upregulation led to reactivation of the Akt signaling pathway, promoting cell growth. Overall, our study reveals that FTO downregulation leads to increased m(6)A modifications in the 3MODIFIER LETTER PRIME UTR of PDGFC and then modulates the degradation of its transcriptional level in an m(6)A-YTHDF2-dependent manner, highlighting a potential therapeutic target for PDAC treatment and prognostic prediction.	[Tan, Zhen; Shi, Si; Xu, Jin; Liu, Xiaomeng; Lei, Yubin; Zhang, Bo; Hua, Jie; Meng, Qingcai; Wang, Wei; Yu, Xianjun; Liang, Chen] Fudan Univ, Dept Pancreat Surg, Shanghai Canc Ctr, Shanghai 200032, Peoples R China; [Tan, Zhen; Shi, Si; Xu, Jin; Liu, Xiaomeng; Lei, Yubin; Zhang, Bo; Hua, Jie; Meng, Qingcai; Wang, Wei; Yu, Xianjun; Liang, Chen] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Tan, Zhen; Shi, Si; Xu, Jin; Liu, Xiaomeng; Lei, Yubin; Zhang, Bo; Hua, Jie; Meng, Qingcai; Wang, Wei; Yu, Xianjun; Liang, Chen] Shanghai Pancreat Canc Inst, Shanghai 200032, Peoples R China; [Tan, Zhen; Shi, Si; Xu, Jin; Liu, Xiaomeng; Lei, Yubin; Zhang, Bo; Hua, Jie; Meng, Qingcai; Wang, Wei; Yu, Xianjun; Liang, Chen] Fudan Univ, Pancreat Canc Inst, Shanghai 200032, Peoples R China	Fudan University; Fudan University; Fudan University	Wang, W; Yu, XJ; Liang, C (corresponding author), Fudan Univ, Dept Pancreat Surg, Shanghai Canc Ctr, Shanghai 200032, Peoples R China.; Wang, W; Yu, XJ; Liang, C (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.; Wang, W; Yu, XJ; Liang, C (corresponding author), Shanghai Pancreat Canc Inst, Shanghai 200032, Peoples R China.; Wang, W; Yu, XJ; Liang, C (corresponding author), Fudan Univ, Pancreat Canc Inst, Shanghai 200032, Peoples R China.	wangwei@fudanpci.org; yuxianjun@fudanpci.org; liangchen@fudanpci.org			National Natural Science Foundation of China [81802352, 81902428, 82002541, U21A20374]; Shanghai Municipal Science and Technology Major Project [21JC1401500]; Scientific Innovation Project of Shanghai Education Committee [2019-01-07-00-07-E00057]; Clinical Research Plan of Shanghai Hospital Development Center [SHDC2020CR1006A]; Shanghai Sailing Program [19YF1409400]; Xuhui District Artificial Intelligence Medical Hospital Cooperation Project [2021-011]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Science and Technology Major Project; Scientific Innovation Project of Shanghai Education Committee; Clinical Research Plan of Shanghai Hospital Development Center; Shanghai Sailing Program; Xuhui District Artificial Intelligence Medical Hospital Cooperation Project	This study was jointly funded by the National Natural Science Foundation of China (No. 81802352, 81902428, 82002541 and U21A20374), Shanghai Municipal Science and Technology Major Project (21JC1401500), Scientific Innovation Project of Shanghai Education Committee (2019-01-07-00-07-E00057), Clinical Research Plan of Shanghai Hospital Development Center (SHDC2020CR1006A), and Xuhui District Artificial Intelligence Medical Hospital Cooperation Project (2021-011), the Shanghai Sailing Program (No. 19YF1409400).	Anderson AC, 2011, DRUG DISCOV TODAY, V16, P755, DOI 10.1016/j.drudis.2011.07.001; Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Cao YH, 2013, TRENDS MOL MED, V19, P460, DOI 10.1016/j.molmed.2013.05.002; Chen JL, 2019, J CANCER RES CLIN, V145, P19, DOI 10.1007/s00432-018-2796-0; Cho YS, 2009, NAT GENET, V41, P527, DOI 10.1038/ng.357; Christenson ES, 2020, LANCET ONCOL, V21, pE135, DOI 10.1016/S1470-2045(19)30795-8; Cui Q, 2017, CELL REP, V18, P2622, DOI 10.1016/j.celrep.2017.02.059; Deng XL, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00396; Dina C, 2007, NAT GENET, V39, P724, DOI 10.1038/ng2048; Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; Fu Y, 2014, NAT REV GENET, V15, P293, DOI 10.1038/nrg3724; Grossberg AJ, 2020, CA-CANCER J CLIN, V70, P375, DOI 10.3322/caac.21626; He CA, 2010, NAT CHEM BIOL, V6, P863, DOI 10.1038/nchembio.482; He LE, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1109-9; Hirayama M, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.03.028; Huang XY, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12464; Huang Y, 2019, CANCER CELL, V35, P677, DOI 10.1016/j.ccell.2019.03.006; Jia GF, 2011, NAT CHEM BIOL, V7, P885, DOI [10.1038/NCHEMBIO.687, 10.1038/nchembio.687]; Kramer F, 2020, HAEMATOLOGICA, V105, P2083, DOI 10.3324/haematol.2019.226332; Lei H, 2008, EXP EYE RES, V86, P711, DOI 10.1016/j.exer.2007.08.007; Li Q, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-020-00453-8; Li Zejuan, 2017, Cancer Cell, V31, P127, DOI 10.1016/j.ccell.2016.11.017; Liang C, 2020, GUT, V69, P888, DOI 10.1136/gutjnl-2018-317163; Liu J, 2018, NAT CELL BIOL, V20, P1074, DOI 10.1038/s41556-018-0174-4; Liu T, 2020, J CELL PHYSIOL, V235, P548, DOI 10.1002/jcp.28994; Lurie G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016756; Mizrahi JD, 2020, LANCET, V395, P2008, DOI 10.1016/S0140-6736(20)30974-0; Niu Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1004-4; Pietras K, 2002, CANCER RES, V62, P5476; Reigstad LJ, 2003, J BIOL CHEM, V278, P17114, DOI 10.1074/jbc.M301728200; Salgado-Montilla Jeannette L, 2017, Arch Cancer Res, V5, DOI 10.21767/2254-6081.1000148; Shi HL, 2019, MOL CELL, V74, P640, DOI 10.1016/j.molcel.2019.04.025; Son D, 2014, J BIOL CHEM, V289, P6225, DOI 10.1074/jbc.M113.508994; Su R, 2018, CELL, V172, P90, DOI 10.1016/j.cell.2017.11.031; Tang XD, 2019, ONCOL LETT, V17, P2473, DOI 10.3892/ol.2018.9873; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vu LP, 2017, NAT MED, V23, P1369, DOI 10.1038/nm.4416; Wang TY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01204-7; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Yang S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10669-0; Zaccara S, 2019, NAT REV MOL CELL BIO, V20, P608, DOI 10.1038/s41580-019-0168-5; Zhao BXS, 2017, NAT REV MOL CELL BIO, V18, P31, DOI 10.1038/nrm.2016.132; Zhao X, 2014, CELL RES, V24, P1403, DOI 10.1038/cr.2014.151; Zhou ZJ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01216-3	44	4	4	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2022	41	20					2860	2872		10.1038/s41388-022-02306-w	http://dx.doi.org/10.1038/s41388-022-02306-w		APR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1F4TJ	35422475	hybrid, Green Published			2022-12-17	WOS:000782543300001
J	Iida, T; Mizutani, Y; Esaki, N; Ponik, SM; Burkel, BM; Weng, L; Kuwata, K; Masamune, A; Ishihara, S; Haga, H; Kataoka, K; Mii, S; Shiraki, Y; Ishikawa, T; Ohno, E; Kawashima, H; Hirooka, Y; Fujishiro, M; Takahashi, M; Enomoto, A				Iida, Tadashi; Mizutani, Yasuyuki; Esaki, Nobutoshi; Ponik, Suzanne M.; Burkel, Brian M.; Weng, Liang; Kuwata, Keiko; Masamune, Atsushi; Ishihara, Seiichiro; Haga, Hisashi; Kataoka, Kunio; Mii, Shinji; Shiraki, Yukihiro; Ishikawa, Takuya; Ohno, Eizaburo; Kawashima, Hiroki; Hirooka, Yoshiki; Fujishiro, Mitsuhiro; Takahashi, Masahide; Enomoto, Atsushi			Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics	ONCOGENE			English	Article							CARCINOMA-ASSOCIATED FIBROBLASTS; DUCTAL ADENOCARCINOMA; TUMOR; MYOFIBROBLASTS; AM80; IMMUNOSUPPRESSION; INHIBITION; FIBROSIS; FAMILY; ROLES	Previous therapeutic attempts to deplete cancer-associated fibroblasts (CAFs) or inhibit their proliferation in pancreatic ductal adenocarcinoma (PDAC) were not successful in mice or patients. Thus, CAFs may be tumor suppressive or heterogeneous, with distinct cancer-restraining and -promoting CAFs (rCAFs and pCAFs, respectively). Here, we showed that induced expression of the glycosylphosphatidylinositol-anchored protein Meflin, a rCAF-specific marker, in CAFs by genetic and pharmacological approaches improved the chemosensitivity of mouse PDAC. A chemical library screen identified Am80, a synthetic, nonnatural retinoid, as a reagent that effectively induced Meflin expression in CAFs. Am80 administration improved the sensitivity of PDAC to chemotherapeutics, accompanied by increases in tumor vessel area and intratumoral drug delivery. Mechanistically, Meflin was involved in the suppression of tissue stiffening by interacting with lysyl oxidase to inhibit its collagen crosslinking activity. These data suggested that modulation of CAF heterogeneity may represent a strategy for PDAC treatment.	[Iida, Tadashi; Mizutani, Yasuyuki; Esaki, Nobutoshi; Kataoka, Kunio; Mii, Shinji; Shiraki, Yukihiro; Enomoto, Atsushi] Nagoya Univ, Dept Pathol, Grad Sch Med, Nagoya, Aichi, Japan; [Iida, Tadashi; Mizutani, Yasuyuki; Kataoka, Kunio; Ishikawa, Takuya; Ohno, Eizaburo; Kawashima, Hiroki; Fujishiro, Mitsuhiro] Nagoya Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, Nagoya, Aichi, Japan; [Ponik, Suzanne M.; Burkel, Brian M.] Univ Wisconsin, Dept Cell & Regenerat Biol, Madison, WI USA; [Weng, Liang] Cent South Univ, Xiangya Hosp, Xiangya Canc Ctr, Dept Oncol, Changsha, Peoples R China; [Kuwata, Keiko] Nagoya Univ, Inst Transformat Biomol, Nagoya, Japan; [Masamune, Atsushi] Tohoku Univ, Div Gastroenterol, Grad Sch Med, Sendai, Miyagi, Japan; [Ishihara, Seiichiro; Haga, Hisashi] Hokkaido Univ, Fac Adv Life Sci, Sapporo, Hokkaido, Japan; [Kawashima, Hiroki] Nagoya Univ Hosp, Dept Endoscopy, Nagoya, Aichi, Japan; [Hirooka, Yoshiki] Fujita Hlth Univ, Dept Gastroenterol & Hepatol, Toyoake, Aichi, Japan; [Takahashi, Masahide] Fujita Hlth Univ, Int Ctr Cell & Gene Therapy, Toyoake, Aichi, Japan; [Takahashi, Masahide] Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Tokyo, Japan	Nagoya University; Nagoya University; University of Wisconsin System; University of Wisconsin Madison; Central South University; Nagoya University; Tohoku University; Hokkaido University; Nagoya University; Fujita Health University; Fujita Health University; University of Tokyo	Enomoto, A (corresponding author), Nagoya Univ, Dept Pathol, Grad Sch Med, Nagoya, Aichi, Japan.	enomoto@iar.nagoya-u.ac.jp	Mii, Shinji/I-7480-2014; Shiraki, Yukihiro/AIA-7918-2022	Mii, Shinji/0000-0001-8266-3235; Shiraki, Yukihiro/0000-0003-3666-0556	Ministry of Education, Culture, Sports, Science and Technology of Japan [18H02638, 20H03467]; Nagoya University Hospital Funding for Clinical Research; MED-CREST (Japan Agency for Medical Research and Development, Core Research for Evolutional Science and Technology) [JP20gm0810007h0105, JP20gm1210009s0102]; Project for Cancer Research and Therapeutic Evolution (P-CREATE) from AMED [JP20cm0106377h0001, JP21cm0106704h0002]	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Nagoya University Hospital Funding for Clinical Research; MED-CREST (Japan Agency for Medical Research and Development, Core Research for Evolutional Science and Technology); Project for Cancer Research and Therapeutic Evolution (P-CREATE) from AMED	We thank David Tuveson (Cold Spring Harbor Laboratory) and Chang-il Hwang (UC Davis College of Biological Sciences) for providing the mouse PDAC cell line mT5; Kohji Kusano (ID Pharma Co., Ltd.) for generating recombinant Sendai virus; Shuzo Watanabe, Kaoru Shimada (RaQualia Pharma Inc.), and Hisao Ekimoto (TMRC Co., Ltd) for helpful discussions on Am80; Kentaro Taki (Nagoya University) for help with mass spectrometry; and Kozo Uchiyama and Kaori Ushida (Nagoya University) for technical assistance. This work was supported by a Grant-in-Aid for Scientific Research (B) (grant nos. 18H02638 to AE and 20H03467 to MT) commissioned by the Ministry of Education, Culture, Sports, Science and Technology of Japan; Nagoya University Hospital Funding for Clinical Research (to AE); AMED-CREST (Japan Agency for Medical Research and Development, Core Research for Evolutional Science and Technology; grant nos. JP20gm0810007h0105 and JP20gm1210009s0102 to AE); and the Project for Cancer Research and Therapeutic Evolution (P-CREATE) from AMED (grant nos. JP20cm0106377h0001 to AE and JP21cm0106704h0002 to YM).	Apte MV, 2004, PANCREAS, V29, P179, DOI 10.1097/00006676-200410000-00002; Barker HE, 2012, NAT REV CANCER, V12, P540, DOI 10.1038/nrc3319; Bhattacharjee S, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI146987; Biffi G, 2019, CANCER DISCOV, V9, P282, DOI 10.1158/2159-8290.CD-18-0710; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chen Y, 2021, CANCER CELL, V39, P548, DOI 10.1016/j.ccell.2021.02.007; Chronopoulos A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12630; Elyada E, 2019, CANCER DISCOV, V9, P1102, DOI 10.1158/2159-8290.CD-19-0094; Gieniec KA, 2019, BRIT J CANCER, V121, P293, DOI 10.1038/s41416-019-0509-3; Gonzalez H, 2018, GENE DEV, V32, P1267, DOI 10.1101/gad.314617.118; Hara A, 2021, GENES CELLS, V26, P495, DOI 10.1111/gtc.12855; Hara A, 2019, CIRC RES, V125, P414, DOI 10.1161/CIRCRESAHA.119.314806; HASHIMOTO Y, 1990, BIOCHEM BIOPH RES CO, V166, P1300, DOI 10.1016/0006-291X(90)91007-F; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Ishii G, 2016, ADV DRUG DELIVER REV, V99, P186, DOI 10.1016/j.addr.2015.07.007; Kagechika H, 2002, CURR MED CHEM, V9, P591, DOI 10.2174/0929867024606975; KAGECHIKA H, 1984, CHEM PHARM BULL, V32, P4209; Klemann C, 2009, AM J PATHOL, V174, P2234, DOI 10.2353/ajpath.2009.081084; Kobayashi H, 2021, GASTROENTEROLOGY, V160, P1224, DOI 10.1053/j.gastro.2020.11.011; Kobayashi H, 2019, NAT REV GASTRO HEPAT, V16, P282, DOI 10.1038/s41575-019-0115-0; Kocher HM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18636-w; Le Calve B, 2016, ONCOTARGET, V7, P32100, DOI 10.18632/oncotarget.8527; Lee JJ, 2014, P NATL ACAD SCI USA, V111, pE3091, DOI 10.1073/pnas.1411679111; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Maeda K, 2016, SCI REP-UK, V6, DOI 10.1038/srep22288; Mezawa Y, 2016, CELL TISSUE RES, V365, P675, DOI 10.1007/s00441-016-2471-1; Miyai Y, 2020, CANCER SCI, V111, P1047, DOI 10.1111/cas.14346; Mizutani Y, 2019, CANCER RES, V79, P5367, DOI 10.1158/0008-5472.CAN-19-0454; Nagathihalli NS, 2016, ONCOTARGET, V7, P65982, DOI 10.18632/oncotarget.11786; Neesse A, 2019, GUT, V68, P159, DOI 10.1136/gutjnl-2018-316451; Neuzillet C, 2019, J PATHOL, V248, P51, DOI 10.1002/path.5224; Ohlund D, 2014, J EXP MED, V211, P1503, DOI 10.1084/jem.20140692; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Ohlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Pure E, 2018, ONCOGENE, V37, P4343, DOI 10.1038/s41388-018-0275-3; Quante M, 2011, CANCER CELL, V19, P257, DOI 10.1016/j.ccr.2011.01.020; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Sanda T, 2005, LEUKEMIA, V19, P901, DOI 10.1038/sj.leu.2403754; Sherman MH, 2014, CELL, V159, P80, DOI 10.1016/j.cell.2014.08.007; Shi Y, 2019, NATURE, V569, P131, DOI 10.1038/s41586-019-1130-6; Takahashi M, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.749924; Tebben PJ, 2016, ENDOCR REV, V37, P521, DOI 10.1210/er.2016-1070; Tobita T, 1997, BLOOD, V90, P967, DOI 10.1182/blood.V90.3.967.967_967_973; Waghray M, 2016, CANCER DISCOV, V6, P886, DOI 10.1158/2159-8290.CD-15-0947; Xu JZ, 2020, EMBO J, V39, DOI 10.15252/embj.2019103255; Yang XG, 2016, CANCER RES, V76, P4124, DOI 10.1158/0008-5472.CAN-15-2973; Zhang DX, 2018, CANCER RES, V78, P1700, DOI 10.1158/0008-5472.CAN-17-1366; Zhang K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07638-4	51	4	4	6	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2022	41	19					2764	2777		10.1038/s41388-022-02288-9	http://dx.doi.org/10.1038/s41388-022-02288-9		APR 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1A5QI	35414659				2022-12-17	WOS:000781960100001
J	Bertolini, I; Perego, M; Ghosh, JC; Kossenkov, AV; Altieri, DC				Bertolini, Irene; Perego, Michela; Ghosh, Jagadish C.; Kossenkov, Andrew, V; Altieri, Dario C.			NF kappa B activation by hypoxic small extracellular vesicles drives oncogenic reprogramming in a breast cancer microenvironment	ONCOGENE			English	Article							INTEGRIN	Small extracellular vesicles (sEV) contribute to the crosstalk between tumor cells and stroma, but the underlying signals are elusive. Here, we show that sEV generated by breast cancer cells in hypoxic (sEV(HYP)), but not normoxic (sEV(NORM)) conditions activate NF kappa B in recipient normal mammary epithelial cells. This increases the production and release of inflammatory cytokines, promotes mitochondrial dynamics leading to heightened cell motility and disrupts 3D mammary acini architecture with aberrant cell proliferation, reduced apoptosis and EMT. Mechanistically, Integrin-Linked Kinase packaged in sEV(HYP) via HIF1 alpha is sufficient to activate NF kappa B in the normal mammary epithelium, in vivo. Therefore, sEV(HYP) activation of NF kappa B drives multiple oncogenic steps of inflammation, mitochondrial dynamics, and mammary gland morphogenesis in a breast cancer microenvironment.	[Bertolini, Irene; Perego, Michela; Ghosh, Jagadish C.; Altieri, Dario C.] Wistar Inst Anat & Biol, Immunol Microenvironm & Metastasis Program, Philadelphia, PA 19104 USA; [Kossenkov, Andrew, V] Wistar Inst Anat & Biol, Bioinformat Shared Resource, Philadelphia, PA 19104 USA; [Kossenkov, Andrew, V] Wistar Inst Anat & Biol, Gene Express & Regulat Program, Philadelphia, PA 19104 USA	The Wistar Institute; The Wistar Institute; The Wistar Institute	Altieri, DC (corresponding author), Wistar Inst Anat & Biol, Immunol Microenvironm & Metastasis Program, Philadelphia, PA 19104 USA.	daltieri@wistar.org		ALTIERI, DARIO C/0000-0002-0617-3469	National Institutes of Health (NIH) [P01 CA140043, R35 CA220446, R50 CA211199]; Mary Kay Foundation	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mary Kay Foundation	We thank James Hayden and Frederick Keeney of the Wistar Imaging Core Shared Resource for assistance with time-lapse videomicroscopy and Sudheer Mulugu of the Electron Microscopy Resource Lab, Perelman School of Medicine, University of Pennsylvania for cryo-electron microscopy. This work was supported by National Institutes of Health (NIH) grants P01 CA140043, R35 CA220446 (D.C.A.), R50 CA211199 (A.V.K.) and an award from the Mary Kay Foundation (D.C.A.).	Baram T, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.614468; Bertolini I, 2020, DEV CELL, V55, P163, DOI 10.1016/j.devcel.2020.07.014; Caino MC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13730; Chen F, 2019, NAT CELL BIOL, V21, P498, DOI 10.1038/s41556-019-0299-0; Curtius K, 2018, NAT REV CANCER, V18, P19, DOI 10.1038/nrc.2017.102; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Jaiswal R, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00125; Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977; Lucien F, 2019, BIOCHEM SOC T, V47, P273, DOI 10.1042/BST20180253; Ma YF, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.606906; Marar C, 2021, NAT IMMUNOL, V22, P560, DOI 10.1038/s41590-021-00899-0; Sansone P, 2017, P NATL ACAD SCI USA, V114, pE9066, DOI 10.1073/pnas.1704862114; Singh A, 2016, MOL CANCER RES, V14, P1136, DOI 10.1158/1541-7786.MCR-16-0058; Sung BH, 2021, DEV CELL, V56, P1861, DOI 10.1016/j.devcel.2021.03.020; Sung BH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15747-2; Vaynberg J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06906-7; You SX, 2019, P NATL ACAD SCI USA, V116, P24012, DOI 10.1073/pnas.1909243116; Zhao LJ, 2021, EMBO REP, V22, DOI 10.15252/embr.202050922	18	4	4	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2022	41	17					2520	2525		10.1038/s41388-022-02280-3	http://dx.doi.org/10.1038/s41388-022-02280-3		MAR 2022	6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0R6YF	35354906	Green Accepted			2022-12-17	WOS:000775854600002
J	Ikeuchi, H; Hirose, T; Ikegami, M; Takamochi, K; Suzuki, K; Mano, H; Kohsaka, S				Ikeuchi, Hiroshi; Hirose, Takeshi; Ikegami, Masachika; Takamochi, Kazuya; Suzuki, Kenji; Mano, Hiroyuki; Kohsaka, Shinji			Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model	ONCOGENE			English	Article							CELL LUNG-CANCER; OPEN-LABEL; 1ST-LINE TREATMENT; OSIMERTINIB; MUTATIONS; AFATINIB; T790M; ADENOCARCINOMA; GEFITINIB; MULTICENTER	The development of tyrosine kinase inhibitors (TKIs) has improved the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. The current research priority is to provide viable treatments for patients who have drug-resistant EGFR mutations. We evaluated the drug sensitivity of various EGFR mutants to monotherapies and combination therapies of EGFR-TKIs. In vitro, the transforming potential and drug sensitivity of 357 EGFR variants were assessed. In vivo, we tested the sensitivity of EGFR variants to different regimens of EGFR-TKIs by examining changes in the proportion of each variant within the tumor. Out of 357 variants thoroughly examined for transforming activities, 144 (40.3%) and 282 (79.0%) transformed 3T3 and Ba/F3 cells, respectively. Among the latter variants, 50 (17.7%) were found to be resistant or only partly resistant to osimertinib or afatinib. Four of 25 afatinib-resistant variants (16%) were sensitive to osimertinib, whereas 25 of 46 osimertinib-resistant variants (54.3%) were sensitive to afatinib. Despite the lack of a synergistic impact, TKI combination treatment effectively reduced in vivo the heterogeneous tumors composed of 3T3 cells with different EGFR variants. Regimens starting with afatinib and subsequently switched to osimertinib suppressed tumor development more efficiently than the opposite combination. Combination EGFR-TKI treatment may decrease tumor growth and prevent the development of resistant variants. This work created an experimental model of a heterogeneous tumor to find the best combination therapy regimen and proposes a basic notion of EGFR-TKI combination therapy to enhance the prognosis of NSCLC patients.	[Ikeuchi, Hiroshi; Hirose, Takeshi; Ikegami, Masachika; Mano, Hiroyuki; Kohsaka, Shinji] Natl Canc Ctr, Div Cellular Signaling, Res Inst, Tokyo 1040045, Japan; [Ikeuchi, Hiroshi; Takamochi, Kazuya; Suzuki, Kenji] Juntendo Univ, Dept Gen Thorac Surg, Sch Med, Tokyo 1138431, Japan; [Ikegami, Masachika] Komagome Hosp, Dept Musculoskeletal Oncol, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo 1138677, Japan	National Cancer Center - Japan; Juntendo University; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital	Kohsaka, S (corresponding author), Natl Canc Ctr, Div Cellular Signaling, Res Inst, Tokyo 1040045, Japan.	skohsaka@ncc.go.jp		Hirose, Takeshi/0000-0003-1588-9757	Practical Research for Innovative Cancer Control [JP20ck0106536]; Japan Agency for Medical Research and Development (AMED); Boehringer Ingelheim	Practical Research for Innovative Cancer Control; Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Boehringer Ingelheim(Boehringer Ingelheim)	This study was financially supported in part through grants from the Practical Research for Innovative Cancer Control under Grant Number JP20ck0106536 from the Japan Agency for Medical Research and Development (AMED). This work was also supported in part by a grant from Boehringer Ingelheim.	Akagi T, 2003, P NATL ACAD SCI USA, V100, P13567, DOI 10.1073/pnas.1834876100; Alvarez A, 2014, JOVE-J VIS EXP, DOI 10.3791/51742; Arulananda S, 2017, J THORAC ONCOL, V12, P1728, DOI 10.1016/j.jtho.2017.08.006; Beau-Faller M, 2014, ANN ONCOL, V25, P126, DOI 10.1093/annonc/mdt418; Berger AH, 2016, CANCER CELL, V30, P214, DOI 10.1016/j.ccell.2016.06.022; Blasi M, 2021, CASE REP ONCOL, V14, P477, DOI 10.1159/000513904; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Castellano GM, 2019, J THORAC ONCOL, V14, P1982, DOI 10.1016/j.jtho.2019.06.015; Cho JH, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.00931; Neto JMF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16952-9; Gu JJ, 2020, CANCER-AM CANCER SOC, V126, P3788, DOI 10.1002/cncr.32996; He LY, 2018, METHODS MOL BIOL, V1711, P351, DOI 10.1007/978-1-4939-7493-1_17; Hirose T, 2021, LUNG CANCER, V152, P135, DOI 10.1016/j.lungcan.2020.12.023; Ho CC, 2017, J THORAC ONCOL, V12, P567, DOI 10.1016/j.jtho.2016.11.2231; Kohno T, 2015, TRANSL LUNG CANCER R, V4, P156, DOI 10.3978/j.issn.2218-6751.2014.11.11; Kohsaka S, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan6566; La Monica S, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0653-7; Leonetti A, 2019, BRIT J CANCER, V121, P725, DOI 10.1038/s41416-019-0573-8; Li TH, 2013, J CLIN ONCOL, V31, P1039, DOI 10.1200/JCO.2012.45.3753; Li X, 2018, CANCER LETT, V418, P1, DOI 10.1016/j.canlet.2018.01.005; Liu YT, 2018, LUNG CANCER, V118, P1, DOI 10.1016/j.lungcan.2018.01.015; Masuda T, 2020, THORAC CANCER, V11, P2351, DOI 10.1111/1759-7714.13532; Murtuza A, 2019, CANCER RES, V79, P689, DOI 10.1158/0008-5472.CAN-18-1281; Nasu S, 2018, INTERNAL MED, V57, P3643, DOI 10.2169/internalmedicine.0923-18; Ou SHI, 2019, LUNG CANCER, V138, P141, DOI 10.1016/j.lungcan.2019.08.013; Park K, 2016, LANCET ONCOL, V17, P577, DOI 10.1016/S1470-2045(16)30033-X; Passaro A, 2021, J THORAC ONCOL, V16, P764, DOI 10.1016/j.jtho.2020.12.002; Piper-Vallillo AJ, 2020, J CLIN ONCOL, V38, P2926, DOI 10.1200/JCO.19.03123; Qin Q, 2020, THORAC CANCER, V11, P2389, DOI 10.1111/1759-7714.13521; Ramalingam SS, 2020, NEW ENGL J MED, V382, P41, DOI 10.1056/NEJMoa1913662; Robichaux JP, 2021, NATURE, V597, P732, DOI 10.1038/s41586-021-03898-1; Sequist LV, 2020, LANCET ONCOL, V21, P373, DOI 10.1016/S1470-2045(19)30785-5; Sequist LV, 2013, J CLIN ONCOL, V31, P3327, DOI 10.1200/JCO.2012.44.2806; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Starrett JH, 2020, CANCER RES, V80, P2017, DOI 10.1158/0008-5472.CAN-19-3819; Subbiah V, 2020, TRENDS CANCER, V6, P797, DOI 10.1016/j.trecan.2020.05.009; Tian YQ, 2016, ONCOL RES, V24, P295, DOI 10.3727/096504016X14648701447814; Tu HY, 2017, LUNG CANCER, V114, P96, DOI 10.1016/j.lungcan.2017.11.005; Uchibori K, 2018, J THORAC ONCOL, V13, P915, DOI 10.1016/j.jtho.2018.04.005; Wang Z, 2017, J THORAC ONCOL, V12, P1723, DOI 10.1016/j.jtho.2017.06.017; Watanabe H, 2021, CANCER SCI, V112, P1853, DOI 10.1111/cas.14801; Watanabe-Smith K, 2017, ONCOTARGET, V8, P12596, DOI 10.18632/oncotarget.15392; Wu YL, 2017, LANCET ONCOL, V18, P1454, DOI 10.1016/S1470-2045(17)30608-3; Wu YL, 2014, LANCET ONCOL, V15, P213, DOI 10.1016/S1470-2045(13)70604-1; Xu L, 2012, CANCER RES, V72, P3302, DOI 10.1158/0008-5472.CAN-11-3720; Yang JCH, 2020, J THORAC ONCOL, V15, P803, DOI 10.1016/j.jtho.2019.12.126; Zhang TL, 2019, TRANSL LUNG CANCER R, V8, P302, DOI 10.21037/tlcr.2019.04.12	47	4	4	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2022	41	17					2470	2479		10.1038/s41388-022-02263-4	http://dx.doi.org/10.1038/s41388-022-02263-4		MAR 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0R6YF	35304574	hybrid, Green Published			2022-12-17	WOS:000770512400001
J	Zhang, X; Zheng, SY; Hu, CH; Li, GL; Lin, HC; Xia, RP; Ye, YC; He, RH; Li, ZH; Lin, Q; Chen, RF; Zhou, QB				Zhang, Xiang; Zheng, Shangyou; Hu, Chonghui; Li, Guolin; Lin, Hongcao; Xia, Renpeng; Ye, Yuancheng; He, Rihua; Li, Zhihua; Lin, Qing; Chen, Rufu; Zhou, Quanbo			Cancer-associated fibroblast-induced lncRNA UPK1A-AS1 confers platinum resistance in pancreatic cancer via efficient double-strand break repair	ONCOGENE			English	Article							CISPLATIN RESISTANCE; TUMOR; CHEMORESISTANCE; CELLS; CHEMOTHERAPY; INHIBITION; EXPRESSION; PATHWAY; END	The tumor stroma of pancreatic ductal adenocarcinoma (PDAC) is characterized by an abundant and heterogeneous population of cancer-associated fibroblasts (CAFs), which are critically involved in chemoresistance. However, the underlying mechanism of CAFs in chemoresistance is unclear. Here, we show that CAF(R), a CAF subset derived from platinum-resistant PDAC patients, assumes an iCAF phenotype and produces more IL8 than CAF(S) isolated from platinum-sensitive PDAC patients. CAF(R)-derived IL8 promotes oxaliplatin chemoresistance in PDAC. Based on long noncoding RNA (lncRNA) profiling in tumor cells incubated with CAF-CM, we found that UPK1A-AS1, whose expression is directly induced by IL8/NF-kappa B signaling, functions as a chemoresistance-promoting lncRNA and is critical for active IL8-induced oxaliplatin resistance. Impressively, blocking the activation of UPK1A-AS1 expression increases the oxaliplatin sensitivity of tumor cells in vivo. Mechanistically, UPK1A-AS1 strengthens the interaction between Ku70 and Ku80 to facilitate nonhomologous end joining (NHEJ), thereby enhancing DNA double-strand break (DSB) repair. Clinically, UPK1A-AS1 expression is positively correlated with IL8 expression, a poor chemotherapeutic response and a shorter progression-free survival (PFS) time in advanced PDAC patients. Collectively, our study reveals a lncRNA-mediated mechanism of CAF-derived paracrine IL8-dependent oxaliplatin resistance and highlights UPK1A-AS1 as a potential therapeutic target.	[Zhang, Xiang; Li, Zhihua; Zhou, Quanbo] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Guangdong, Peoples R China; [Zhang, Xiang; Zhou, Quanbo] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Pancreatobiliary Surg, Guangzhou 510120, Guangdong, Peoples R China; [Zheng, Shangyou; Hu, Chonghui; Xia, Renpeng; Ye, Yuancheng; He, Rihua; Lin, Qing; Chen, Rufu] Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Pancreas Ctr, Dept Gen Surg, Guangzhou 510080, Guangdong, Peoples R China; [Zheng, Shangyou; Ye, Yuancheng; Lin, Qing; Chen, Rufu] Southern Med Univ, Sch Clin Med 2, Guangzhou 510515, Guangdong, Peoples R China; [Hu, Chonghui; Chen, Rufu] Guangdong Cardiovasc Inst, Guangzhou 510080, Guangdong, Peoples R China; [Li, Guolin] Sun Yat Sen Univ, Dept Hepatobiliary Pancreat & Splen Surg, Affiliated Hosp 6, Guangzhou 510655, Guangdong, Peoples R China; [Lin, Hongcao] Sun Yat Sen Univ, Gen Surg Shenshan Med Ctr, Mem Hosp, Shanwei 516600, Guangdong, Peoples R China; [Xia, Renpeng] Hunan Childrens Hosp, Dept Neonatal Gen Surg, Changsha 410007, Hunan, Peoples R China; [Li, Zhihua] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Oncol, Guangzhou 510120, Guangdong, Peoples R China; [Lin, Qing; Chen, Rufu] South China Univ Technol, Sch Med, Guangzhou 510006, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Southern Medical University - China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; South China University of Technology	Zhou, QB (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Guangdong, Peoples R China.; Zhou, QB (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Pancreatobiliary Surg, Guangzhou 510120, Guangdong, Peoples R China.; Lin, Q; Chen, RF (corresponding author), Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Pancreas Ctr, Dept Gen Surg, Guangzhou 510080, Guangdong, Peoples R China.; Lin, Q; Chen, RF (corresponding author), Southern Med Univ, Sch Clin Med 2, Guangzhou 510515, Guangdong, Peoples R China.; Chen, RF (corresponding author), Guangdong Cardiovasc Inst, Guangzhou 510080, Guangdong, Peoples R China.; Lin, Q; Chen, RF (corresponding author), South China Univ Technol, Sch Med, Guangzhou 510006, Guangdong, Peoples R China.	gzhorse@163.com; chenrufu@mail.sysu.edu; zhouqbo@mail.sysu.edu.cn		Zhang, Xiang/0000-0002-7144-1933	National Natural Science Foundation of China [82073149, 81871945, 82072639]; Guangdong Science and Technology Department [2020B1212060018]; National Key R&D Program of China [2017YFC1308600]; Special Fund of "Dengfeng Plan" of Guangdong Provincial People's Hospital, China [KJ012019509, DFJH2020027]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Science and Technology Department; National Key R&D Program of China; Special Fund of "Dengfeng Plan" of Guangdong Provincial People's Hospital, China	This study was supported by grants from the National Natural Science Foundation of China (grant number 82073149, 81871945, 82072639), the Guangdong Science and Technology Department (grant number 2021A1515011089), and the National Key R&D Program of China (grant number 2017YFC1308600), the Special Fund of "Dengfeng Plan" of Guangdong Provincial People's Hospital, China (KJ012019509, DFJH2020027), the Guangdong Science and Technology Department (grant number 2020B1212060018).	Biffi G, 2021, PHYSIOL REV, V101, P147, DOI 10.1152/physrev.00048.2019; Biffi G, 2019, CANCER DISCOV, V9, P282, DOI 10.1158/2159-8290.CD-18-0710; Byun Y, 2020, MOL CELLS, V43, P975, DOI 10.14348/molcells.2020.0126; Causse SZ, 2019, ONCOGENE, V38, P2767, DOI 10.1038/s41388-018-0616-2; Ding J, 2020, HEPATOLOGY, V72, P1666, DOI 10.1002/hep.31195; Dominguez CX, 2020, CANCER DISCOV, V10, P232, DOI 10.1158/2159-8290.CD-19-0644; Downs JA, 2004, NAT REV MOL CELL BIO, V5, P367, DOI 10.1038/nrm1367; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Elyada E, 2019, CANCER DISCOV, V9, P1102, DOI 10.1158/2159-8290.CD-19-0094; Fan LL, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2405-4; Fell VL, 2015, MUTAT RES-REV MUTAT, V763, P15, DOI 10.1016/j.mrrev.2014.06.002; Feng HR, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03111-7; Golan T, 2014, BRIT J CANCER, V111, P1132, DOI 10.1038/bjc.2014.418; Golan T, 2019, NEW ENGL J MED, V381, P317, DOI 10.1056/NEJMoa1903387; Grossberg AJ, 2020, CA-CANCER J CLIN, V70, P375, DOI 10.3322/caac.21626; Diaz-Maroto NG, 2019, CLIN CANCER RES, V25, P4466, DOI 10.1158/1078-0432.CCR-18-3957; Guo XF, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01196-4; Haemmig S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaw1868; Ham IH, 2021, CANCERS, V13, DOI 10.3390/cancers13051172; Hato SV, 2014, CLIN CANCER RES, V20, P2831, DOI 10.1158/1078-0432.CCR-13-3141; Hirata E, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a026781; Ho WJ, 2020, NAT REV CLIN ONCOL, V17, P527, DOI 10.1038/s41571-020-0363-5; Hosein AN, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.129212; Hustinx SR, 2005, CANCER BIOL THER, V4, P83, DOI 10.4161/cbt.4.1.1380; Kobayashi H, 2019, NAT REV GASTRO HEPAT, V16, P282, DOI 10.1038/s41575-019-0115-0; Li BR, 2021, ONCOGENE, V40, P4686, DOI 10.1038/s41388-021-01870-x; Liu BD, 2015, CANCER CELL, V27, P370, DOI 10.1016/j.ccell.2015.02.004; Melisi D, 2011, JNCI-J NATL CANCER I, V103, P1190, DOI 10.1093/jnci/djr243; Milosevic V, 2020, INT J CANCER, V146, P192, DOI 10.1002/ijc.32419; Moffitt RA, 2015, NAT GENET, V47, P1168, DOI 10.1038/ng.3398; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Ohlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024; Ohuchida K, 2004, CANCER RES, V64, P3215, DOI 10.1158/0008-5472.CAN-03-2464; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Park W, 2021, JAMA-J AM MED ASSOC, V326, P851, DOI 10.1001/jama.2021.13027; Reiss KA, 2021, J CLIN ONCOL, V39, P2497, DOI 10.1200/JCO.21.00003; Sakai W, 2008, NATURE, V451, P1116, DOI 10.1038/nature06633; Srivastava M, 2012, CELL, V151, P1474, DOI 10.1016/j.cell.2012.11.054; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Su D, 2020, THERANOSTICS, V10, P5029, DOI 10.7150/thno.42440; Su SC, 2018, CELL, V172, P841, DOI 10.1016/j.cell.2018.01.009; Thakur B, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0636-8; Thapar R, 2021, NUCLEIC ACIDS RES, V49, DOI 10.1093/nar/gkaa1233; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Unfried JP, 2021, CANCER RES, V81, P4910, DOI 10.1158/0008-5472.CAN-21-0463; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Wang BS, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01684-x; Wang D, 2020, CELL DEATH DIFFER, V27, P3337, DOI 10.1038/s41418-020-0581-5; Wang W., 2021, NAT COMMUN, V12; Wang WM, 2016, CELL, V165, P1092, DOI 10.1016/j.cell.2016.04.009; Wattenberg MM, 2020, BRIT J CANCER, V122, P333, DOI 10.1038/s41416-019-0582-7; Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843; Wei LS, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03574-2; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Xie WK, 2022, SEMIN CANCER BIOL, V83, P303, DOI 10.1016/j.semcancer.2020.11.004; Yin F, 2020, ONCOTARGETS THER, V13, P2689, DOI 10.2147/OTT.S234924; Zhai J, 2019, CANCER LETT, V454, P37, DOI 10.1016/j.canlet.2019.04.002; Zhang DY, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01748-y; Zhao BL, 2020, NAT REV MOL CELL BIO, V21, P765, DOI 10.1038/s41580-020-00297-8; Zhu YX, 2020, CELL MOL GASTROENTER, V10, P811, DOI 10.1016/j.jcmgh.2020.06.009	60	4	4	5	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2022	41	16					2372	2389		10.1038/s41388-022-02253-6	http://dx.doi.org/10.1038/s41388-022-02253-6		MAR 2022	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0N1NW	35264742	Green Published, hybrid			2022-12-17	WOS:000766524200001
J	Park, YL; Kim, HP; Ock, CY; Min, DW; Kang, JK; Lim, YJ; Song, SH; Han, SW; Kim, TY				Park, Ye-Lim; Kim, Hwang-Phill; Ock, Chan-Young; Min, Dong-Wook; Kang, Jun Kyu; Lim, Yoo Joo; Song, Sang-Hyun; Han, Sae-Won; Kim, Tae-You			EMT-mediated regulation of CXCL1/5 for resistance to anti-EGFR therapy in colorectal cancer	ONCOGENE			English	Article							NF-KAPPA-B; CETUXIMAB RESISTANCE; TUMOR HETEROGENEITY; MUTATIONS; ACTIVATION; EXPRESSION; CYTOKINES; GROWTH; TRANSACTIVATION; CHEMOTHERAPY	The emergence of RAS/RAF mutant clone is the main feature of EGFR inhibitor resistance in KRAS wild-type colon cancer. However, its molecular mechanism is thought to be multifactorial, mainly due to cellular heterogeneity. In order to better understand the resistance mechanism in a single clone level, we successfully isolated nine cells with cetuximab-resistant (CR) clonality from in vitro system. All CR cells harbored either KRAS or BRAF mutations. Characteristically, these cells showed a higher EMT (Epithelial to mesenchymal transition) signature, showing increased EMT markers such as SNAI2. Moreover, the expression level of CXCL1/5, a secreted protein, was significantly higher in CR cells compared to the parental cells. In these CR cells, CXCL1/5 expression was coordinately regulated by SNAI2/NFKB and transactivated EGFR through CXCR/MMPI/EGF axis via autocrine singling. We also observed that combined cetuximab/MEK inhibitor not only showed growth inhibition but also reduced the secreted amounts of CXCL1/5. We further found that serum CXCL1/5 level was positively correlated with the presence of RAS/RAF mutation in colon cancer patients during cetuximab therapy, suggesting its role as a biomarker. These data indicated that the application of serum CXCL1/5 could be a potential serologic biomarker for predicting resistance to EGFR therapy in colorectal cancer.	[Park, Ye-Lim; Kim, Hwang-Phill; Kang, Jun Kyu; Kim, Tae-You] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Sci, Seoul, South Korea; [Park, Ye-Lim; Kim, Hwang-Phill; Min, Dong-Wook; Kang, Jun Kyu; Song, Sang-Hyun; Han, Sae-Won; Kim, Tae-You] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea; [Kim, Hwang-Phill] IMBDx Inc, Seoul, South Korea; [Ock, Chan-Young; Lim, Yoo Joo; Han, Sae-Won; Kim, Tae-You] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital	Park, YL; Kim, TY (corresponding author), Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Sci, Seoul, South Korea.; Park, YL; Kim, TY (corresponding author), Seoul Natl Univ, Canc Res Inst, Seoul, South Korea.; Kim, TY (corresponding author), Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea.	yelim_park@snu.ac.kr; kimty@snu.ac.kr		PARK, YE-LIM/0000-0002-3043-9984; Lim, Yoojoo/0000-0002-4181-2916	Korea Health Technology R&D Project through the Korea Health Industry Development Institute - Ministry of Health Welfare [HI14C1277, HI13C2096]; Ministry of Science, ICT & Future Planning [2016M3A9B6026918, 2018R1C1B6005264]; National Research Foundation of Korea [2017M3C9A5029978]; Bio & Medical Technology Development Program of the National Research Foundation (NRF) - Ministry of Science ICT [NRF-2017M3A9A7050610]	Korea Health Technology R&D Project through the Korea Health Industry Development Institute - Ministry of Health Welfare; Ministry of Science, ICT & Future Planning(Ministry of Science, ICT & Future Planning, Republic of Korea); National Research Foundation of Korea(National Research Foundation of Korea); Bio & Medical Technology Development Program of the National Research Foundation (NRF) - Ministry of Science ICT(National Research Foundation of KoreaMinistry of Science, ICT & Future Planning, Republic of Korea)	We thank H. Nikki March, Ph.D., from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript. The authors are grateful to all members of our group for their helpful advice. This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare (HI14C1277, HI13C2096), by the Ministry of Science, ICT & Future Planning (2016M3A9B6026918, 2018R1C1B6005264), and by the National Research Foundation of Korea (2017M3C9A5029978), and by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Ministry of Science & ICT (NRF-2017M3A9A7050610).	Arena S, 2015, CLIN CANCER RES, V21, P2157, DOI 10.1158/1078-0432.CCR-14-2821; Bolitho C, 2010, ENDOCR-RELAT CANCER, V17, P929, DOI 10.1677/ERC-10-0107; Bommarito A, 2011, ENDOCR-RELAT CANCER, V18, P669, DOI 10.1530/ERC-11-0076; Burke SJ, 2014, AM J PHYSIOL-ENDOC M, V306, pE131, DOI 10.1152/ajpendo.00347.2013; Chen C, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1431-6; Choi YH, 2019, MOL CELLS, V42, P189, DOI 10.14348/molcells.2019.2446; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; Cremolini C, 2015, NAT REV CLIN ONCOL, V12, P607, DOI 10.1038/nrclinonc.2015.129; Dagogo-Jack I, 2018, NAT REV CLIN ONCOL, V15, P81, DOI 10.1038/nrclinonc.2017.166; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252; Girbl T, 2018, IMMUNITY, V49, P1062, DOI 10.1016/j.immuni.2018.09.018; Goldman SL, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00008; Grepin R, 2014, CANCER RES, V74, P873, DOI 10.1158/0008-5472.CAN-13-1267; Grisanti LA, 2017, J CARDIOVASC PHARM, V70, P3, DOI 10.1097/FJC.0000000000000462; Hensley CT, 2016, CELL, V164, P681, DOI 10.1016/j.cell.2015.12.034; Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86; Hsu HC, 2016, ONCOTARGET, V7, P22257, DOI 10.18632/oncotarget.8076; Hu BW, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0562-7; Jones VS, 2016, BBA-REV CANCER, V1865, P255, DOI 10.1016/j.bbcan.2016.03.005; Kogan-Sakin I, 2009, CARCINOGENESIS, V30, P698, DOI 10.1093/carcin/bgp043; Kuo PL, 2012, CARCINOGENESIS, V33, P2477, DOI 10.1093/carcin/bgs299; Lawson DA, 2018, NAT CELL BIOL, V20, P1349, DOI 10.1038/s41556-018-0236-7; Ling JH, 2012, CANCER CELL, V21, P105, DOI 10.1016/j.ccr.2011.12.006; Mangahas CR, 2005, J INVEST DERMATOL, V125, P307, DOI 10.1111/j.0022-202X.2005.23820.x; MILNE GWA, 1994, J CHEM INF COMP SCI, V34, P1219, DOI 10.1021/ci00021a032; Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462; Misale S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007947; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Mishra J, 2013, CRIT REV ONCOL HEMAT, V86, P232, DOI 10.1016/j.critrevonc.2012.09.014; Mizumoto Y, 2011, CLIN CANCER RES, V17, P1341, DOI 10.1158/1078-0432.CCR-10-2291; Nolen BM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2096; Park MH, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5020015; Park YL, 2019, INT J CANCER, V144, P389, DOI 10.1002/ijc.31662; Pommier AJC, 2014, BRIT J CANCER, V111, P1590, DOI 10.1038/bjc.2014.436; Ramesh G, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/480739; Saunders NA, 2012, EMBO MOL MED, V4, P675, DOI 10.1002/emmm.201101131; Shaw VE, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-114; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Sokol CL, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016303; Song SH, 2007, MOL CELL, V28, P810, DOI 10.1016/j.molcel.2007.09.025; Spaks A, 2017, J THORAC DIS, V9, pS164, DOI 10.21037/jtd.2017.03.61; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Susek KH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02159; Taylor SC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02217-x; Turner MD, 2014, BBA-MOL CELL RES, V1843, P2563, DOI 10.1016/j.bbamcr.2014.05.014; van Brummelen EMJ, 2017, ONCOLOGIST, V22, P864, DOI 10.1634/theoncologist.2017-0031; Wang ZX, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010095; Xia YF, 2014, CANCER IMMUNOL RES, V2, P823, DOI 10.1158/2326-6066.CIR-14-0112; Xu JM, 2017, CLIN CANCER RES, V23, P4602, DOI 10.1158/1078-0432.CCR-16-2738; Yako YY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154016; Yamazaki N, 2017, CANCER SCI, V108, P1022, DOI 10.1111/cas.13226; Yuan M, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/6530410; Yun J, 2016, NUCLEIC ACIDS RES, V44, P558, DOI 10.1093/nar/gkv933; Zhao B, 2017, ONCOTARGET, V8, P3980, DOI 10.18632/oncotarget.14012	55	4	4	3	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2022	41	14					2026	2038		10.1038/s41388-021-01920-4	http://dx.doi.org/10.1038/s41388-021-01920-4		FEB 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0F2FY	35173310				2022-12-17	WOS:000756457400003
J	Rao, VS; Gu, QY; Tzschentke, S; Lin, KL; Ganig, N; Thepkaysone, ML; Wong, FC; Polster, H; Seifert, L; Seifert, AM; Buck, N; Riediger, C; Weisse, J; Gutschner, T; Michen, S; Temme, A; Schneider, M; Baenke, F; Weitz, J; Kahlert, C				Rao, Venkatesh Sadananda; Gu, Qianyu; Tzschentke, Sandra; Lin, Kuailu; Ganig, Nicole; Thepkaysone, May-Linn; Wong, Fang Cheng; Polster, Heike; Seifert, Lena; Seifert, Adrian M.; Buck, Nathalie; Riediger, Carina; Weisse, Jonas; Gutschner, Tony; Michen, Susanne; Temme, Achim; Schneider, Martin; Baenke, Franziska; Weitz, Juergen; Kahlert, Christoph			Extravesicular TIMP-1 is a non-invasive independent prognostic marker and potential therapeutic target in colorectal liver metastases	ONCOGENE			English	Article							TISSUE INHIBITOR; EXTRACELLULAR VESICLES; CANCER; MATRIX; METALLOPROTEINASES-1; PLASMA; NICHE	Molecular reprogramming of stromal microarchitecture by tumour-derived extracellular vesicles (EVs) is proposed to favour pre-metastatic niche formation. We elucidated the role of extravesicular tissue inhibitor of matrix metalloproteinase-1 (TIMP1(EV)) in pro-invasive extracellular matrix (ECM) remodelling of the liver microenvironment to aid tumour progression in colorectal cancer (CRC). Immunohistochemistry analysis revealed a high expression of stromal TIMP1 in the invasion front that was associated with poor progression-free survival in patients with colorectal liver metastases. Molecular analysis identified TIMP1(EV) enrichment in CRC-EVs as a major factor in the induction of TIMP1 upregulation in recipient fibroblasts. Mechanistically, we proved that EV-mediated TIMP1 upregulation in recipient fibroblasts induced ECM remodelling. This effect was recapitulated by human serum-derived EVs providing strong evidence that CRC release active EVs into the blood circulation of patients for the horizontal transfer of malignant traits to recipient cells. Moreover, EV-associated TIMP1 binds to HSP90AA, a heat-shock protein, and the inhibition of HSP90AA on human-derived serum EVs attenuates TIMP1(EV)-mediated ECM remodelling, rendering EV-associated TIMP1 a potential therapeutic target. Eventually, in accordance with REMARK guidelines, we demonstrated in three independent cohorts that EV-bound TIMP1 is a robust circulating biomarker for a non-invasive, preoperative risk stratification in patients with colorectal liver metastases.	[Rao, Venkatesh Sadananda; Gu, Qianyu; Lin, Kuailu; Ganig, Nicole; Thepkaysone, May-Linn; Wong, Fang Cheng; Polster, Heike; Seifert, Lena; Seifert, Adrian M.; Buck, Nathalie; Riediger, Carina; Baenke, Franziska; Weitz, Juergen; Kahlert, Christoph] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Visceral Thorac & Vasc Surg, Dresden, Germany; [Tzschentke, Sandra] Goethe Univ, Univ Hosp Frankfurt, Dept Med Haematol Oncol, Frankfurt, Germany; [Seifert, Lena; Seifert, Adrian M.; Weitz, Juergen; Kahlert, Christoph] German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany; [Seifert, Lena; Seifert, Adrian M.; Weitz, Juergen; Kahlert, Christoph] Natl Ctr Tumor Dis, Partner Site Dresden, Heidelberg, Germany; [Weisse, Jonas; Gutschner, Tony] Martin Luther Univ Halle Wittenberg, Med Fac, Jr Res Grp RNA Biol & Pathogenesis, Halle An Der Saale, Germany; [Michen, Susanne; Temme, Achim] Tech Univ Dresden, Dept Neurosurg, Sect Expt Neurosurg & Tumour Immunol, Univ Hosp Carl Gustav Carus, Dresden, Germany; [Schneider, Martin] Univ Hosp Heidelberg, Dept Gen Visceral & Transplantat Surg, Heidelberg, Germany	Technische Universitat Dresden; Carl Gustav Carus University Hospital; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Martin Luther University Halle Wittenberg; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Ruprecht Karls University Heidelberg	Kahlert, C (corresponding author), Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Visceral Thorac & Vasc Surg, Dresden, Germany.; Kahlert, C (corresponding author), German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany.	Christoph.Kahlert@uniklinikum-dresden.de	Seifert, Adrian M./AAL-3453-2021	Seifert, Adrian M./0000-0002-5329-3164	Roland-Ernst-Foundation, Dresden [5/15]; Deutsche Forschungsgemeinschaft (DFG) [KA 3511/3-1]	Roland-Ernst-Foundation, Dresden; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	The authors thank all the patients and their families for agreeing to the use of their samples. We also thank the surgeons of the VTG department who performed the surgeries. Special thanks to Falk Zakrewski for his assistance with the digital slide scanner. This work was funded by the Roland-Ernst-Foundation, Dresden (project no. 5/15) and Deutsche Forschungsgemeinschaft (DFG) (KA 3511/3-1).	Aaberg-Jessen C, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4179-y; Abdouh M, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0587-0; Angioni R, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1757900; Atai NA, 2013, J NEURO-ONCOL, V115, P343, DOI 10.1007/s11060-013-1235-y; Baker-Williams AJ, 2019, CELL REP, V28, P1894, DOI 10.1016/j.celrep.2019.07.045; Bockelman C, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4589-x; Dechene A, 2010, HEPATOLOGY, V52, P1008, DOI 10.1002/hep.23754; Engstrand J, 2018, BMC CANCER, V18, DOI 10.1186/s12885-017-3925-x; Forte D, 2017, ONCOTARGET, V8, P2261, DOI 10.18632/oncotarget.13664; Franzen CA, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/619829; Galindo-Hernandez O, 2013, ARCH MED RES, V44, P208, DOI 10.1016/j.arcmed.2013.03.002; Gong YX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077366; Han L, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0980-8; Hanamura N, 1997, INT J CANCER, V73, P10, DOI 10.1002/(SICI)1097-0215(19970926)73:1<10::AID-IJC2>3.0.CO;2-4; Holten-Andersen MN, 2005, INT J CANCER, V113, P198, DOI 10.1002/ijc.20566; Huang T, 2019, INT J BIOL SCI, V15, P1, DOI 10.7150/ijbs.27796; Kahlert C, 2008, ANTICANCER RES, V28, P1459; Kaushik S, 2016, CANCER METAST REV, V35, P655, DOI 10.1007/s10555-016-9650-0; Kim H, 2019, PROTEOME SCI, V17, DOI 10.1186/s12953-019-0154-z; Kopitz C, 2007, CANCER RES, V67, P8615, DOI 10.1158/0008-5472.CAN-07-0232; Kur P, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17082620; Lachowski D, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43759-6; Lee JH, 2011, J GASTROINTEST LIVER, V20, P287; Liu LX, 2003, WORLD J GASTROENTERO, V9, P193, DOI 10.3748/wjg.v9.i2.193; McShane LM, 2005, BRIT J CANCER, V93, P387, DOI 10.1038/sj.bjc.6602678; Park HK, 2020, EXP MOL MED, V52, P79, DOI 10.1038/s12276-019-0360-x; Pretzsch E, 2019, J ONCOL, V2019, DOI 10.1155/2019/7407190; Psaila B, 2009, NAT REV CANCER, V9, P285, DOI 10.1038/nrc2621; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Ries C, 2014, CELL MOL LIFE SCI, V71, P659, DOI 10.1007/s00018-013-1457-3; Robinson BK, 2016, BIOL OPEN, V5, P875, DOI 10.1242/bio.017632; Seubert B, 2015, HEPATOLOGY, V61, P238, DOI 10.1002/hep.27378; Sontake V, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91454; Takawale A, 2017, HYPERTENSION, V69, P1092, DOI 10.1161/HYPERTENSIONAHA.117.09045; Terpos E, 2010, LEUKEMIA RES, V34, P399, DOI 10.1016/j.leukres.2009.08.035; Thery C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750; Tommelein J, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00063; Vong Sylvia, 2011, Genes Cancer, V2, P1139, DOI 10.1177/1947601911423940; Weidle UH, 2017, CANCER GENOM PROTEOM, V14, P1, DOI 10.21873/cgp.20015; Wendler F, 2017, ONCOGENE, V36, P877, DOI 10.1038/onc.2016.253; Wurtz SO, 2008, MOL CELL PROTEOMICS, V7, P424, DOI 10.1074/mcp.M700305-MCP200; Xu R, 2018, NAT REV CLIN ONCOL, V15, P617, DOI 10.1038/s41571-018-0036-9	42	4	4	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2022	41	12					1809	1820		10.1038/s41388-022-02218-9	http://dx.doi.org/10.1038/s41388-022-02218-9		FEB 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV6UV	35140332	Green Published, hybrid			2022-12-17	WOS:000753256900002
J	Liao, CG; Liang, XH; Ke, Y; Yao, L; Liu, M; Liu, ZK; He, L; Guo, YX; Bian, HJ; Chen, ZN; Kong, LM				Liao, Cheng-Gong; Liang, Xiao-Hua; Ke, Yuan; Yao, Li; Liu, Man; Liu, Ze-Kun; He, Lin; Guo, Yi-Xiao; Bian, Huijie; Chen, Zhi-Nan; Kong, Ling-Min			Active demethylation upregulates CD147 expression promoting non-small cell lung cancer invasion and metastasis	ONCOGENE			English	Article							TARGETED DNA DEMETHYLATION; 5-HYDROXYMETHYLCYTOSINE SIGNATURES; BONE METASTASIS; POOR-PROGNOSIS; 5-METHYLCYTOSINE; HYPOMETHYLATION; PROLIFERATION; RECRUITMENT; METHYLATION; MECHANISMS	Non-small cell lung cancer (NSCLC) is a fatal disease, and its metastatic process is poorly understood. Although aberrant methylation is involved in tumor progression, the mechanisms underlying dynamic DNA methylation remain to be elucidated. It is significant to study the molecular mechanism of NSCLC metastasis and identify new biomarkers for NSCLC early diagnosis. Here, we performed MeDIP-seq and hMeDIP-seq analyses to detect the genes regulated by dynamic DNA methylation. Comparison of the 5mC and 5hmC sites revealed that the CD147 gene underwent active demethylation in NSCLC tissues compared with normal tissues, and this demethylation upregulated CD147 expression. Significantly high levels of CD147 expression and low levels of promoter methylation were observed in NSCLC tissues. Then, we identified the CD147 promoter as a target of KLF6, MeCP2, and DNMT3A. Treatment of cells with TGF-beta triggered active demethylation involving loss of KLF6/MeCP2/DNMT3A and recruitment of Sp1, Tet1, TDG, and SMAD2/3 transcription complexes. A dCas9-SunTag-DNMAT3A-sgCD147-targeted methylation system was constructed to reverse CD147 expression. The targeted methylation system downregulated CD147 expression and inhibited NSCLC proliferation and metastasis in vitro and in vivo. Accordingly, we used cfDNA to detect the levels of CD147 methylation in NSCLC tissues and found that the CD147 methylation levels exhibited an inverse relationship with tumor size, lymphatic metastasis, and TNM stage. In conclusion, this study clarified the mechanism of active demethylation of CD147 and suggested that the targeted methylation of CD147 could inhibit NSCLC invasion and metastasis, providing a highly promising therapeutic target for NSCLC.	[Liao, Cheng-Gong; Ke, Yuan] Fourth Mil Med Univ, Tangdu Hosp, Dept Oncol, Xian 710038, Peoples R China; [Liang, Xiao-Hua] Fourth Mil Med Univ, Tangdu Hosp, Dept Thorac Surg, Xian 710038, Peoples R China; [Yao, Li] Northwest Univ, Dept Pathol, Xian 3 Hosp, Affiliated Hosp, Xian 710018, Peoples R China; [Liu, Man; Liu, Ze-Kun; He, Lin; Guo, Yi-Xiao; Bian, Huijie; Chen, Zhi-Nan; Kong, Ling-Min] Fourth Mil Med Univ, Natl Translat Sci Ctr Mol Med, Dept Cell Biol, Xian 710032, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; Northwest University Xi'an; Air Force Military Medical University	Bian, HJ; Chen, ZN; Kong, LM (corresponding author), Fourth Mil Med Univ, Natl Translat Sci Ctr Mol Med, Dept Cell Biol, Xian 710032, Peoples R China.	hjbian@fmmu.edu.cn; znchen@fmmu.edu.cn; konglingmin81@163.com		Chen, Zhi-Nan/0000-0001-5512-4623; Cheng-Gong, Liao/0000-0002-7624-0196	Basic Research Plan of Natural Science in Shaanxi Province [2020JM-326]; National Natural Science Foundation of China [8217111294]; Social Talent Fund Supporting Scheme of Tangdu Hospital [2021SHRC001]; National Key Research [2018YFA0109000]; Development Program of China [2019YFC1316303]	Basic Research Plan of Natural Science in Shaanxi Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Social Talent Fund Supporting Scheme of Tangdu Hospital; National Key Research; Development Program of China	This study was supported by grants from the Basic Research Plan of Natural Science in Shaanxi Province (2020JM-326), the National Natural Science Foundation of China (8217111294), the Social Talent Fund Supporting Scheme of Tangdu Hospital (2021SHRC001), the National Key Research (2018YFA0109000) and the Development Program of China (2019YFC1316303).	Anton T, 2017, NUCLEUS-PHILA, V8, P279, DOI 10.1080/19491034.2017.1292194; CHEN Z-N, 1992, Zhonghua Zhongliu Zazhi, V14, P9; Cortellino S, 2011, CELL, V146, P67, DOI 10.1016/j.cell.2011.06.020; Duruisseaux M, 2018, SEMIN CANCER BIOL, V51, P116, DOI 10.1016/j.semcancer.2017.09.005; Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI 10.2217/EPI.09.33; Escudero L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19175-0; Fei F, 2014, ANN SURG ONCOL, V21, P4359, DOI 10.1245/s10434-014-3816-1; Ge JP, 2016, SCI REP-UK, V6, DOI 10.1038/srep19366; Goulet CR, 2021, ADV EXP MED BIOL, V1270, P89, DOI 10.1007/978-3-030-47189-7_6; Guler GD, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18965-w; Hashimoto H, 2012, NUCLEIC ACIDS RES, V40, P4841, DOI 10.1093/nar/gks155; Hassan HM, 2017, CELL REP, V19, P1685, DOI 10.1016/j.celrep.2017.05.007; He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944; Hervouet E, 2009, EPIGENETICS-US, V4, P487, DOI 10.4161/epi.4.7.9883; Huang YH, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1248-5; Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597; Jeschke J, 2017, J CLIN INVEST, V127, P3090, DOI 10.1172/JCI91095; Jin L, 2012, CELL RES, V22, P1356, DOI 10.1038/cr.2012.90; Kidder BL, 2011, NAT IMMUNOL, V12, P918, DOI 10.1038/ni.2117; Kim BN, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67325-7; Kinnaird A, 2016, NAT REV CANCER, V16, P694, DOI 10.1038/nrc.2016.82; Kohli RM, 2013, NATURE, V502, P472, DOI 10.1038/nature12750; Kong LM, 2016, ONCOTARGET, V7, P27975, DOI 10.18632/oncotarget.8564; Kong LM, 2014, CANCER RES, V74, P3764, DOI 10.1158/0008-5472.CAN-13-3555; Kong LM, 2011, J CELL MOL MED, V15, P1415, DOI 10.1111/j.1582-4934.2010.01124.x; Ku XM, 2007, SCAND J IMMUNOL, V65, P435, DOI 10.1111/j.1365-3083.2007.01930.x; Li HY, 2015, SCI REP-UK, V5, DOI 10.1038/srep16552; Li WS, 2017, CELL RES, V27, P1243, DOI 10.1038/cr.2017.121; Li Y, 2009, HISTOPATHOLOGY, V54, P677, DOI 10.1111/j.1365-2559.2009.03280.x; Liao CG, 2011, MOL CELL BIOL, V31, P2591, DOI 10.1128/MCB.05160-11; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maeder ML, 2013, NAT BIOTECHNOL, V31, P1137, DOI 10.1038/nbt.2726; McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084; Moreira EA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12861; Morita S, 2016, NAT BIOTECHNOL, V34, P1060, DOI 10.1038/nbt.3658; Murata M, 2009, HEPATOLOGY, V49, P1203, DOI 10.1002/hep.22765; O'Leary K, 2018, CURR CANCER DRUG TAR, V18, P89, DOI 10.2174/1568009617666170203162556; Park PJ, 2009, NAT REV GENET, V10, P669, DOI 10.1038/nrg2641; Pflueger C, 2018, GENOME RES, V28, P1193, DOI 10.1101/gr.233049.117; Porteus MH, 2005, NAT BIOTECHNOL, V23, P967, DOI 10.1038/nbt1125; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Song CX, 2017, CELL RES, V27, P1231, DOI 10.1038/cr.2017.106; Stevens LE., 2018, JOVE-J VIS EXP, V136, P56650; Strauss A, 2013, MOL PLANT, V6, P1384, DOI 10.1093/mp/sst075; Thillainadesan G, 2012, MOL CELL, V46, P636, DOI 10.1016/j.molcel.2012.03.027; Tseng HC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18444-2; Wan JCM, 2017, NAT REV CANCER, V17, P223, DOI 10.1038/nrc.2017.7; Wang H, 2017, FUTURE ONCOL, V13, P695, DOI 10.2217/fon-2016-0237; Wang K, 2021, CELL METAB, V33, P160, DOI 10.1016/j.cmet.2020.12.010; Wang Q, 2019, CANCER LETT, V448, P132, DOI 10.1016/j.canlet.2019.01.040; Wang SJ, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01647-2; Warton K, 2016, ENDOCR-RELAT CANCER, V23, pR157, DOI 10.1530/ERC-15-0369; Wu H, 2011, GENE DEV, V25, P2436, DOI 10.1101/gad.179184.111; Wu J, 2016, ONCOGENE, V35, P5468, DOI 10.1038/onc.2016.89; Wu J, 2011, ONCOGENE, V30, P4410, DOI 10.1038/onc.2011.149; Zhang JN, 2020, INT J GEN MED, V13, P1115, DOI 10.2147/IJGM.S279023; Zhang RY, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00233	57	4	4	3	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2022	41	12					1780	1794		10.1038/s41388-022-02213-0	http://dx.doi.org/10.1038/s41388-022-02213-0		FEB 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV6UV	35132181	Green Published, hybrid			2022-12-17	WOS:000752288100001
J	Jin, Y; Pan, YM; Zheng, S; Liu, Y; Xu, J; Peng, YZ; Zhang, ZM; Wang, YD; Xiong, YL; Xu, L; Mu, KY; Chen, SW; Zheng, F; Yuan, Y; Fu, J				Jin, Ying; Pan, Yamu; Zheng, Shuang; Liu, Yao; Xu, Jie; Peng, Yazhi; Zhang, Zemei; Wang, Yadong; Xiong, Yulian; Xu, Lei; Mu, Kaiyu; Chen, Suwen; Zheng, Fei; Yuan, Ye; Fu, Jian			Inactivation of EGLN3 hydroxylase facilitates Erk3 degradation via autophagy and impedes lung cancer growth	ONCOGENE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; NF-KAPPA-B; PROLYL HYDROXYLASE; INDEPENDENT INHIBITION; PYRUVATE-KINASE; PROMOTES; HYPOXIA; PHD3; HIF; DIFFERENTIATION	EGLN3 is critically important for growth of various cancers including lung cancer. However, virtually nothing is known about the role and mechanism for EGLN3 hydroxylase activity in cancers. EGLN3 catalyzes the hydroxylation of extracellular signal-regulated kinase 3 (Erk3), a potent driver of cancers. The role and mechanism for EGLN3-induced stabilization of Erk3 remain to be defined. Here, we show that Erk3 interacts with heat shock cognate protein of 70 kDa (HSC70) and lysosome-associated membrane protein type 2 A (LAMP2A), two core components of chaperone-mediated autophagy (CMA). As a consequence, Erk3 is degraded by the CMA-lysosome pathway. EGLN3-catalyzed hydroxylation antagonizes CMA-dependent destruction of Erk3. Mechanistically, hydroxylation blunts the interaction of Erk3 with LAMP2A, thereby blocking lysosomal decay of Erk3. EGLN3 inactivation inhibits macrophage migration, efferocytosis, and M2 polarization. Studies using EGLN3 catalytically inactive knock-in mice indicate that inactivation of EGLN3 hydroxylase in host cells ameliorates LLC cancer growth through reprogramming the tumor microenvironment (TME). Adoptive transfer of macrophages with inactivated EGLN3 restrains tumor growth by mounting anti-tumor immunity and restricting angiogenesis. Administration of EGLN3 hydroxylase pharmacologic inhibitor to mice bearing LLC carcinoma impedes cancer growth by targeting the TME. LLC cells harboring inactivated EGLN3 exhibit reduced tumor burden via mitigating immunosuppressive milieu and inducing cancer senescence. This study provides novel insights into the role of CMA in regulating Erk3 stability and the mechanism behind EGLN3-enhanced stability of Erk3. This work demonstrates that inactivation of EGLN3 in malignant and stromal cells suppresses tumor by orchestrating reciprocal interplays between cancer cells and the TME. This work sheds new light on the role and mechanism for EGLN3 catalytic activity in regulating cancer growth. Manipulating EGLN3 activity holds promise for cancer treatment.	[Jin, Ying; Pan, Yamu; Zheng, Shuang; Liu, Yao; Xu, Jie; Peng, Yazhi; Zhang, Zemei; Wang, Yadong; Xiong, Yulian; Xu, Lei; Mu, Kaiyu; Chen, Suwen; Zheng, Fei; Yuan, Ye; Fu, Jian] Hubei Univ Med, Lab Inflammat & Vasc Biol, Inst Clin Med, Renmin Hosp, Shiyan, Hubei, Peoples R China; [Jin, Ying; Pan, Yamu; Zheng, Shuang; Liu, Yao; Xu, Jie; Peng, Yazhi; Zhang, Zemei; Wang, Yadong; Xiong, Yulian; Xu, Lei; Mu, Kaiyu; Chen, Suwen; Zheng, Fei; Yuan, Ye; Fu, Jian] Hubei Univ Med, Dept Cardiol, Renmin Hosp, Shiyan, Hubei, Peoples R China; [Jin, Ying; Fu, Jian] Univ Rochester, Sch Med & Dent, Aab Cardiovasc Res Inst, Rochester, NY 14627 USA; [Jin, Ying; Fu, Jian] Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14627 USA; [Zheng, Shuang] Hubei Univ Med, Renmin Hosp, Dept Ultrasound, Shiyan, Hubei, Peoples R China; [Zhang, Zemei] Jinzhou Med Univ, Grad Sch, Jinzhou, Liaoning, Peoples R China	Hubei University of Medicine; Hubei University of Medicine; University of Rochester; University of Rochester; Hubei University of Medicine; Jinzhou Medical University	Jin, Y; Fu, J (corresponding author), Hubei Univ Med, Lab Inflammat & Vasc Biol, Inst Clin Med, Renmin Hosp, Shiyan, Hubei, Peoples R China.; Jin, Y; Fu, J (corresponding author), Hubei Univ Med, Dept Cardiol, Renmin Hosp, Shiyan, Hubei, Peoples R China.; Jin, Y; Fu, J (corresponding author), Univ Rochester, Sch Med & Dent, Aab Cardiovasc Res Inst, Rochester, NY 14627 USA.; Jin, Y; Fu, J (corresponding author), Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14627 USA.	jdyj0001@163.com; jianfu0326@163.com		Jin, Ying/0000-0002-8811-2204	National Natural Science Foundation of China [81872381]; Health Commission of Hubei Province Scientific Research Projects [WJ2019Z003, WJ2019M047]; Hubei University of Medicine; Hubei University of Medicine Renmin Hospital	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Health Commission of Hubei Province Scientific Research Projects; Hubei University of Medicine; Hubei University of Medicine Renmin Hospital	This work was funded by grants from the National Natural Science Foundation of China (81872381) and from the Health Commission of Hubei Province Scientific Research Projects (WJ2019Z003 and WJ2019M047) to Fu and Jin. This work was also supported by startup funds from the Hubei University of Medicine and the Hubei University of Medicine Renmin Hospital to Fu and Jin.	Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bogucka K, 2021, CANCER GENE THER, V28, P359, DOI 10.1038/s41417-020-00245-w; Carey KL, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108371; Casazza A, 2013, CANCER CELL, V24, P695, DOI 10.1016/j.ccr.2013.11.007; Cassetta L, 2018, NAT REV DRUG DISCOV, V17, P887, DOI 10.1038/nrd.2018.169; Cerezo-Wallis D, 2020, NAT MED, V26, DOI 10.1038/s41591-020-1073-3; Chen SW, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.015513; Childs BG, 2014, EMBO REP, V15, P1139, DOI 10.15252/embr.201439245; Conway EM, 2016, AM J RESP CRIT CARE, V193, P116, DOI 10.1164/rccm.201508-1545CI; Cortes M, 2017, EMBO J, V36, P3336, DOI 10.15252/embj.201797345; Coulombe P, 2003, MOL CELL BIOL, V23, P4542, DOI 10.1128/MCB.23.13.4542-4558.2003; Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501; Dopeso H, 2018, CANCER RES, V78, P1805, DOI 10.1158/0008-5472.CAN-17-1346; Elkhadragy L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21114044; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937; Ferreira JV, 2013, AUTOPHAGY, V9, P1349, DOI 10.4161/auto.25190; Franklin RA, 2016, TRENDS CANCER, V2, P20, DOI 10.1016/j.trecan.2015.11.004; Fu J, 2003, J BIOL CHEM, V278, P52660, DOI 10.1074/jbc.M308036200; Fu J, 2007, J BIOL CHEM, V282, P12410, DOI 10.1074/jbc.M608748200; Fu J, 2016, CELL SIGNAL, V28, P72, DOI 10.1016/j.cellsig.2015.11.011; Fu J, 2013, MOL CELL BIOL, V33, P3050, DOI 10.1128/MCB.00273-13; Fu J, 2010, J BIOL CHEM, V285, P8927, DOI 10.1074/jbc.M109.078600; German NJ, 2016, MOL CELL, V63, P1006, DOI 10.1016/j.molcel.2016.08.014; Gonda TA, 2020, CANCER RES, V80, P4754, DOI 10.1158/0008-5472.CAN-20-0285; Gonzalez-Rodriguez P, 2021, AUTOPHAGY, V17, P1259, DOI 10.1080/15548627.2020.1816664; Gregory CD, 2011, J PATHOL, V223, P177, DOI 10.1002/path.2792; He SH, 2017, CELL, V169, P1000, DOI 10.1016/j.cell.2017.05.015; Henze AT, 2016, J CLIN INVEST, V126, P3672, DOI 10.1172/JCI84427; Henze AT, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6582; Hogel H, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0410-5; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kaneda MM, 2016, NATURE, V539, P437, DOI 10.1038/nature19834; Kaushik S, 2018, NAT REV MOL CELL BIO, V19, P365, DOI 10.1038/s41580-018-0001-6; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Long WW, 2012, J CLIN INVEST, V122, P1869, DOI 10.1172/JCI61492; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025; Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217; Miikkulainen P, 2017, CANCER METAB, V5, DOI 10.1186/s40170-017-0167-y; Rodriguez J, 2018, CELL REP, V24, P1316, DOI 10.1016/j.celrep.2018.06.108; Rodriguez J, 2016, CELL REP, V14, P2745, DOI 10.1016/j.celrep.2016.02.043; Roy S, 2018, CANCER RES, V78, P5600, DOI 10.1158/0008-5472.CAN-18-0562; Schodel J, 2019, NAT REV NEPHROL, V15, P641, DOI 10.1038/s41581-019-0182-z; Semenza GL, 2014, ANNU REV PATHOL-MECH, V9, P47, DOI 10.1146/annurev-pathol-012513-104720; Sounni NE, 2013, CLIN CHEM, V59, P85, DOI 10.1373/clinchem.2012.185363; Tan BH, 2018, CANCER RES, V78, P4929, DOI 10.1158/0008-5472.CAN-18-0152; Valkenburg KC, 2018, NAT REV CLIN ONCOL, V15, P366, DOI 10.1038/s41571-018-0007-1; Wang Wei, 2018, Cancer Cell, V34, P757, DOI 10.1016/j.ccell.2018.10.006; Wang W, 2014, J CELL PHYSIOL, V229, P1529, DOI 10.1002/jcp.24596; Wang YS, 2020, EMBO REP, V21, DOI 10.15252/embr.201948335; Xie L, 2012, J CLIN INVEST, V122, P2827, DOI 10.1172/JCI62374; Xu YM, 2019, J BIOL CHEM, V294, P9949, DOI 10.1074/jbc.RA118.007181; Xue J, 2010, GASTROENTEROLOGY, V138, P606, DOI 10.1053/j.gastro.2009.09.049; Yang M, 2018, CANCER RES, V78, P5492, DOI 10.1158/0008-5472.CAN-18-1367	55	4	4	3	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2022	41	12					1752	1766		10.1038/s41388-022-02203-2	http://dx.doi.org/10.1038/s41388-022-02203-2		FEB 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV6UV	35124697	hybrid, Green Published			2022-12-17	WOS:000751597800001
J	Frank, DN; Qiu, Y; Cao, Y; Zhang, SG; Lu, L; Kofonow, JM; Robertson, CE; Liu, YQ; Wang, HB; Levens, CL; Kuhn, KA; Song, J; Ramakrishnan, VR; Lu, SL				Frank, Daniel N.; Qiu, Yue; Cao, Yu; Zhang, Shuguang; Lu, Ling; Kofonow, Jennifer M.; Robertson, Charles E.; Liu, Yanqiu; Wang, Haibo; Levens, Cassandra L.; Kuhn, Kristine A.; Song, John; Ramakrishnan, Vijay R.; Lu, Shi-Long			A dysbiotic microbiome promotes head and neck squamous cell carcinoma	ONCOGENE			English	Article							ARYL-HYDROCARBON RECEPTOR; GUT MICROBIOTA; ORAL-CANCER; TRYPTOPHAN; ASSOCIATION; METABOLITES; ACTIVATION; DIVERSITY; EFFICACY; MODELS	Recent studies have reported dysbiotic oral microbiota and tumor-resident bacteria in human head and neck squamous cell carcinoma (HNSCC). We aimed to identify and validate oral microbial signatures in treatment-naive HNSCC patients compared with healthy control subjects. We confirm earlier reports that the relative abundances of Lactobacillus spp. and Neisseria spp. are elevated and diminished, respectively, in human HNSCC. In parallel, we examined the disease-modifying effects of microbiota in HNSCC, through both antibiotic depletion of microbiota in an induced HNSCC mouse model (4-Nitroquinoline 1-oxide, 4NQO) and reconstitution of tumor-associated microbiota in a germ-free orthotopic mouse model. We demonstrate that depletion of microbiota delays oral tumorigenesis, while microbiota transfer from mice with oral cancer accelerates tumorigenesis. Enrichment of Lactobacillus spp. was also observed in murine HNSCC, and activation of the aryl-hydrocarbon receptor was documented in both murine and human tumors. Together, our findings support the hypothesis that dysbiosis promotes HNSCC development.	[Frank, Daniel N.; Kofonow, Jennifer M.; Robertson, Charles E.] Univ Colorado, Dept Med, Div Infect Dis, Anschutz Med Ctr, Aurora, CO 80045 USA; [Qiu, Yue; Cao, Yu; Zhang, Shuguang; Lu, Ling; Liu, Yanqiu; Wang, Haibo; Song, John; Ramakrishnan, Vijay R.; Lu, Shi-Long] Univ Colorado, Dept Otolaryngol Head & Neck Surg, Anschutz Med Ctr, Aurora, CO 80045 USA; [Qiu, Yue] China Med Univ, Coll Basic Med Sci, Dept Immunol, Shenyang 110122, Peoples R China; [Cao, Yu] China Med Univ, Univ Hosp 1, Dept Surg Oncol, Shenyang 110122, Peoples R China; [Levens, Cassandra L.; Kuhn, Kristine A.] Univ Colorado, Dept Med, Div Rheumatol, Anschutz Med Ctr, Aurora, CO USA; [Levens, Cassandra L.; Kuhn, Kristine A.] Univ Colorado, Dept Med, Mucosal Inflammat Program, Anschutz Med Ctr, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; China Medical University; China Medical University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Frank, DN (corresponding author), Univ Colorado, Dept Med, Div Infect Dis, Anschutz Med Ctr, Aurora, CO 80045 USA.; Lu, SL (corresponding author), Univ Colorado, Dept Otolaryngol Head & Neck Surg, Anschutz Med Ctr, Aurora, CO 80045 USA.	daniel.frank@cuanschutz.edu; shi-long.lu@cuanschutz.edu			NIH-NIDCR [R56 DE028959]; NIH-NIAMS [R01 AR075033]; Cancer League of Colorado; Golfers Against Cancer; University of Colorado Cancer Center; University of Colorado GI and Liver Innate Immunity Program; NIH-NIDCD [K23 DC014747]	NIH-NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIH-NIAMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Cancer League of Colorado; Golfers Against Cancer; University of Colorado Cancer Center; University of Colorado GI and Liver Innate Immunity Program; NIH-NIDCD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This work was funded by grants from NIH-NIDCR (R56 DE028959; SLL & DNF), NIH-NIAMS (R01 AR075033; KAK), the Cancer League of Colorado (SLL & DNF), Golfers Against Cancer (SLL & DNF), and the University of Colorado Cancer Center (SLL & DNF). DNF, CER, and JMK were supported in part by the University of Colorado GI and Liver Innate Immunity Program. VRR was supported in part by a Career Development Grant from the University of Colorado Cancer Center and NIH-NIDCD K23 DC014747 (VRR). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding organizations.	Al-hebshi NN, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02079-3; Alexeev EE, 2018, AM J PATHOL, V188, P1183, DOI 10.1016/j.ajpath.2018.01.011; Alfano M, 2016, NAT REV UROL, V13, P77, DOI 10.1038/nrurol.2015.292; Anderson MJ, 2011, ECOL LETT, V14, P19, DOI 10.1111/j.1461-0248.2010.01552.x; Andreeva NV, 2020, CURR OPIN MICROBIOL, V56, P118, DOI 10.1016/j.mib.2020.09.001; Bebek G, 2012, HUM MOL GENET, V21, P1557, DOI 10.1093/hmg/ddr593; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blaser MJ, 2008, CANCER PREV RES, V1, P15, DOI 10.1158/1940-6207.CAPR-08-0024; Brennan CA, 2016, ANNU REV MICROBIOL, V70, P395, DOI 10.1146/annurev-micro-102215-095513; BUCKLAND ST, 1993, J APPL ECOL, V30, P478, DOI 10.2307/2404188; Bultman SJ, 2014, CARCINOGENESIS, V35, P249, DOI 10.1093/carcin/bgt392; Cao KAL, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-253; Cervantes-Barragan L, 2017, SCIENCE, V357, P806, DOI 10.1126/science.aah5825; Chang H, 2006, TOXICOL SCI, V89, P205, DOI 10.1093/toxsci/kfj025; Chen X, 2020, MOL ONCOL, V14, P139, DOI 10.1002/1878-0261.12584; Chow LQM, 2020, NEW ENGL J MED, V382, P60, DOI 10.1056/NEJMra1715715; Cullin N, 2021, CANCER CELL, V39, P1317, DOI 10.1016/j.ccell.2021.08.006; Daniel CR, 2019, TRENDS CANCER, V5, P521, DOI 10.1016/j.trecan.2019.07.003; Du L, 2016, ONCOGENE, V35, P4641, DOI 10.1038/onc.2016.1; Elinav E, 2019, NAT REV CANCER, V19, P371, DOI 10.1038/s41568-019-0155-3; Fan XZ, 2018, GUT, V67, P120, DOI 10.1136/gutjnl-2016-312580; Fernandes AD, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-15; Fernandes AD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067019; Fox J., 2011, R COMPANION APPL REG, V2; Frank DN, 2021, J MED GENET, V58, P442, DOI 10.1136/jmedgenet-2020-106844; Frank DN, 2012, JAIDS-J ACQ IMM DEF, V60, P299, DOI 10.1097/QAI.0b013e31824e4bdb; Frank JA, 2008, APPL ENVIRON MICROB, V74, P2461, DOI 10.1128/AEM.02272-07; Frankel AE, 2017, NEOPLASIA, V19, P848, DOI 10.1016/j.neo.2017.08.004; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Ganly I, 2019, INT J CANCER, V145, P775, DOI 10.1002/ijc.32152; Gholizadeh P, 2016, BIOMED PHARMACOTHER, V84, P552, DOI 10.1016/j.biopha.2016.09.082; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Gopalakrishnan V, 2018, CANCER CELL, V33, P570, DOI 10.1016/j.ccell.2018.03.015; Guerrero-Preston R, 2017, ONCOTARGET, V8, P110931, DOI 10.18632/oncotarget.20677; Guerrero-Preston R, 2016, ONCOTARGET, V7, P51320, DOI 10.18632/oncotarget.9710; Hayes RB, 2018, JAMA ONCOL, V4, P358, DOI 10.1001/jamaoncol.2017.4777; Healy CM, 2019, ORAL ONCOL, V89, P30, DOI 10.1016/j.oraloncology.2018.12.003; Helmink BA, 2019, NAT MED, V25, P377, DOI 10.1038/s41591-019-0377-7; Hold GL, 2015, NAT REV GASTRO HEPAT, V12, P128, DOI 10.1038/nrgastro.2015.25; Hooper SJ, 2006, J CLIN MICROBIOL, V44, P1719, DOI 10.1128/JCM.44.5.1719-1725.2006; Hooper SJ, 2009, HEAD NECK-J SCI SPEC, V31, P1228, DOI 10.1002/hed.21140; Jenkinson HF, 2005, TRENDS MICROBIOL, V13, P589, DOI 10.1016/j.tim.2005.09.006; Jin UH, 2014, MOL PHARMACOL, V85, P777, DOI 10.1124/mol.113.091165; Lamas B, 2016, NAT MED, V22, P598, DOI 10.1038/nm.4102; Lanis JM, 2017, MUCOSAL IMMUNOL, V10, P1133, DOI 10.1038/mi.2016.133; Liu YY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15207; Mager DL, 2003, J CLIN PERIODONTOL, V30, P644, DOI 10.1034/j.1600-051X.2003.00376.x; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; Nadkarni MA, 2002, MICROBIOL-SGM, V148, P257, DOI 10.1099/00221287-148-1-257; Neville BW, 2002, CA-CANCER J CLIN, V52, P195, DOI 10.3322/canjclin.52.4.195; Ohtani N, 2015, SEMIN IMMUNOPATHOL, V37, P65, DOI 10.1007/s00281-014-0457-1; Oksanen J., 2020, VEGAN COMMUNITY ECOL; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Pfister DG, 2020, J NATL COMPR CANC NE, V18, P873, DOI 10.6004/jnccn.2020.0031; Plottel CS, 2011, CELL HOST MICROBE, V10, P324, DOI 10.1016/j.chom.2011.10.003; Pruesse E, 2007, NUCLEIC ACIDS RES, V35, P7188, DOI 10.1093/nar/gkm864; Pruesse E, 2012, BIOINFORMATICS, V28, P1823, DOI 10.1093/bioinformatics/bts252; Pushalkar S, 2011, FEMS IMMUNOL MED MIC, V61, P269, DOI 10.1111/j.1574-695X.2010.00773.x; Quast Christian, 2013, Nucleic Acids Res, V41, pD590, DOI 10.1093/nar/gks1219; Quintana FJ, 2013, PHARMACOL REV, V65, P1148, DOI 10.1124/pr.113.007823; Quintana FJ, 2013, IMMUNOLOGY, V138, P183, DOI 10.1111/imm.12046; R Core Team, 2019, R LANG ENV STAT COMP; Roager HM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05470-4; Robertson CE, 2013, BIOINFORMATICS, V29, P3100, DOI 10.1093/bioinformatics/btt526; Rohart F, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005752; Rothhammer V, 2016, NAT MED, V22, P586, DOI 10.1038/nm.4106; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Schwabe RF, 2013, NAT REV CANCER, V13, P800, DOI 10.1038/nrc3610; Sfanos KS, 2018, NAT REV UROL, V15, P11, DOI 10.1038/nrurol.2017.167; Shay Elizabeth, 2020, Oncotarget, V11, P2375, DOI 10.18632/oncotarget.27629; Stanford EA, 2016, MOL CANCER RES, V14, P696, DOI 10.1158/1541-7786.MCR-16-0069; Stange J, 2013, SEMIN IMMUNOPATHOL, V35, P645, DOI 10.1007/s00281-013-0389-1; Statnikov A, 2013, MICROBIOME, V1, DOI 10.1186/2049-2618-1-11; Stockinger B, 2014, ANNU REV IMMUNOL, V32, P403, DOI 10.1146/annurev-immunol-032713-120245; Stockinger B, 2011, SEMIN IMMUNOL, V23, P99, DOI 10.1016/j.smim.2011.01.008; Vickery TW., 2020, PROSTAGLANDINS LEUKO, V164; Vitale-Cross L, 2009, CANCER PREV RES, V2, P419, DOI 10.1158/1940-6207.CAPR-09-0058; Wie SM, 2017, MOL CANCER THER, V16, P1989, DOI 10.1158/1535-7163.MCT-17-0267; Wolf A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06361-2; Yu GQ, 2014, CANCER EPIDEM BIOMAR, V23, P735, DOI 10.1158/1055-9965.EPI-13-0855; Yu LX, 2017, NAT REV GASTRO HEPAT, V14, P527, DOI 10.1038/nrgastro.2017.72; Zelante T, 2013, IMMUNITY, V39, P372, DOI 10.1016/j.immuni.2013.08.003; Zhang L, 2007, ORAL ONCOL, V43, P693, DOI 10.1016/j.oraloncology.2006.08.008; Zitvogel L, 2018, SCIENCE, V359, P1366, DOI 10.1126/science.aar6918	84	4	4	9	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2022	41	9					1269	1280		10.1038/s41388-021-02137-1	http://dx.doi.org/10.1038/s41388-021-02137-1		JAN 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZI1MQ	35087236	Green Accepted			2022-12-17	WOS:000749068000001
J	Hua, Z; Wei, RF; Guo, MJ; Lin, ZG; Yu, XC; Li, XY; Gu, CY; Yang, Y				Hua, Zhen; Wei, Rongfang; Guo, Mengjie; Lin, Zigen; Yu, Xichao; Li, Xinying; Gu, Chunyan; Yang, Ye			YTHDF2 promotes multiple myeloma cell proliferation via STAT5A/MAP2K2/p-ERK axis	ONCOGENE			English	Article							MOLECULAR CLASSIFICATION; PROTEASOME INHIBITORS; CANCER; HETEROGENEITY; STAT5; MEK	Multiple myeloma (MM) is still incurable partially due to lacking effective therapeutic targets. Aberrant N6-methyladenosine (m6A) RNA modification plays a vital role in many cancers, however few researches are executed in MM. We first screened the m6A-related genes in MM patient cohorts and correlated these genes with patient outcomes. We found that YTHDF2, a well-recognized m6A reader, was increased in MM patients and associated with poor outcomes. Decreased YTHDF2 expression hampered MM cell proliferation in vitro and in vivo, while enforced YTHDF2 expression reversed those effects. The analyses of m6A-RIP-seq and RIP-PCR indicated that STAT5A was the downstream target of YTHDF2, which was binding to the m6A modification site of STAT5A to promote its mRNA degradation. ChIP-seq and PCR assays revealed that STAT5A suppressed MM cell proliferation by occupying the transcription site of MAP2K2 to decrease ERK phosphorylation. In addition, we confirmed that YTHDF2 mediated the unphosphorylated form of STAT5A to inhibit the expression of MAP2K2/p-ERK. In conclusion, our study highlights that YTHDF2/STAT5A/MAP2K2/p-ERK axis plays a key role in MM proliferation and targeting YTHDF2 may be a promising therapeutic strategy.	[Hua, Zhen; Guo, Mengjie; Gu, Chunyan] Nanjing Univ Chinese Med, Nanjing Hosp Chinese Med, Nanjing, Peoples R China; [Hua, Zhen; Wei, Rongfang; Guo, Mengjie; Lin, Zigen; Yu, Xichao; Li, Xinying; Gu, Chunyan; Yang, Ye] Nanjing Univ Chinese Med, Sch Med & Holist Integrat Med, Nanjing, Peoples R China	Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine	Gu, CY (corresponding author), Nanjing Univ Chinese Med, Nanjing Hosp Chinese Med, Nanjing, Peoples R China.; Gu, CY; Yang, Y (corresponding author), Nanjing Univ Chinese Med, Sch Med & Holist Integrat Med, Nanjing, Peoples R China.	guchunyan@njucm.edu.cn; yangye876@sina.com	yang, yang/GWB-9426-2022; YANG, YE/F-4987-2015	Lin, Zigen/0000-0001-7323-4279; Xichao, YU/0000-0003-2694-1389; YANG, YE/0000-0003-0228-5102; Li, Xinying/0000-0002-1162-2556; Hua, Zoe/0000-0002-7672-2929; Gu, Chunyan/0000-0001-7408-8840; Wei, Rongfang/0000-0002-7654-7251	National Natural Science Foundation of China [81970196, 82073885, 82003832]; Natural Science Foundation of Jiangsu Province [BK20200097]; Jiangsu Postgraduate Research and Practice Innovation Program [KYCX21_1769]; Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine)	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Jiangsu Postgraduate Research and Practice Innovation Program; Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine)	This work was supported by National Natural Science Foundation of China 81970196 (to CG), 82073885 (to YY), 82003832 (to MG); Natural Science Foundation of Jiangsu Province BK20200097 (to CG); Jiangsu Postgraduate Research and Practice Innovation Program KYCX21_1769 (to RW); A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine).	Bach C, 2019, ONCOL RES TREAT, V42, P123; Bai H, 2021, CURR RES TRANSL MED, V69, DOI 10.1016/j.retram.2021.103288; Bakhoum SF, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a029611; Bianchi G, 2014, CA-CANCER J CLIN, V64, P422, DOI 10.3322/caac.21252; Bolli N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms3997; Brioli A, 2014, BRIT J HAEMATOL, V165, P441, DOI 10.1111/bjh.12805; Brown S, 2021, CL LYMPH MYELOM LEUK, V21, P154, DOI 10.1016/j.clml.2020.11.019; Broyl A, 2010, BLOOD, V116, P2543, DOI 10.1182/blood-2009-12-261032; Cardona-Benavides IJ, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10020336; Chang YZ, 2021, CANCER LETT, V511, P36, DOI 10.1016/j.canlet.2021.04.020; Chen B, 2019, MOL BIOL REP, V46, P2567, DOI 10.1007/s11033-019-04655-4; Chen Y, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01207-4; CIMINO G, 1990, BRIT J HAEMATOL, V75, P373, DOI 10.1111/j.1365-2141.1990.tb04351.x; Cui XC, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12768; Dimopoulos K, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.29; Dominissini D, 2012, NATURE, V485, P201, DOI 10.1038/nature11112; Du H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12626; du Pont SR, 2017, J CLIN ONCOL, V35, P963, DOI 10.1200/JCO.2016.70.6705; Furigo IC, 2018, BRAIN STRUCT FUNCT, V223, P2229, DOI 10.1007/s00429-018-1627-z; Gu CY, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01380-0; He LE, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1109-9; Heuck CJ, 2016, LEUKEMIA, V30, P976, DOI 10.1038/leu.2015.208; Hu BB, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1099-7; Hu XY, 2013, P NATL ACAD SCI USA, V110, P10213, DOI 10.1073/pnas.1221243110; Huang T, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2235-4; Jiang FJ, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01066-6; Kimura A, 2010, J BIOL CHEM, V285, P32704, DOI 10.1074/jbc.M110.141804; Lauta VM, 2003, CANCER, V97, P2440, DOI 10.1002/cncr.11072; Li WX, 2008, TRENDS CELL BIOL, V18, P545, DOI 10.1016/j.tcb.2008.08.008; Li ZR, 2018, CELL RES, V28, P904, DOI 10.1038/s41422-018-0072-0; Liao W, 2013, IMMUNITY, V38, P13, DOI 10.1016/j.immuni.2013.01.004; Liu Y, 2021, CELL METAB, V33, P1221, DOI 10.1016/j.cmet.2021.04.001; Lohr JG, 2014, CANCER CELL, V25, P91, DOI 10.1016/j.ccr.2013.12.015; Manasanch EE, 2017, NAT REV CLIN ONCOL, V14, P417, DOI [10.1038/nrclinonc.2016.206, 10.1007/s12079-011-0121-7]; McClure JJ, 2018, ADV CANCER RES, V138, P183, DOI 10.1016/bs.acr.2018.02.006; Meyer KD, 2012, CELL, V149, P1635, DOI 10.1016/j.cell.2012.05.003; Neuse CJ, 2020, LEUKEMIA, V34, P2887, DOI 10.1038/s41375-020-0921-y; Neuzillet C, 2014, PHARMACOL THERAPEUT, V141, P160, DOI 10.1016/j.pharmthera.2013.10.001; Peng Y, 2020, LIFE SCI, V249, DOI 10.1016/j.lfs.2020.117503; Rajkumar SV, 2016, AM J HEMATOL, V91, P720, DOI 10.1002/ajh.24402; Rajkumar SV, 2009, CURR PROB CANCER, V33, P7, DOI 10.1016/j.currproblcancer.2009.01.001; Rani A, 2016, J INTERF CYTOK RES, V36, P226, DOI 10.1089/jir.2015.0054; Ri M, 2016, INT J HEMATOL, V104, P273, DOI 10.1007/s12185-016-2016-0; Rollig C, 2015, LANCET, V385, P2197, DOI 10.1016/S0140-6736(14)60493-1; Shen XT, 2020, CANCER BIOL MED, V17, P937, DOI 10.20892/j.issn.2095-3941.2020.0402; Shen XD, 2021, FRONT GENET, V11, DOI 10.3389/fgene.2020.592042; Sheng H, 2020, CARCINOGENESIS, V41, P541, DOI 10.1093/carcin/bgz152; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Song P, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01244-z; Song S, 2021, ONCOGENE, V40, P5393, DOI 10.1038/s41388-021-01939-7; Sonneveld P, 2016, BLOOD, V127, P2955, DOI 10.1182/blood-2016-01-631200; Sun T, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108613; Surbek M, 2021, CYTOKINE, V139, DOI 10.1016/j.cyto.2020.155392; Tang XZ, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00746-6; Teras LR, 2016, CA-CANCER J CLIN, V66, P443, DOI 10.3322/caac.21357; van Nieuwenhuijzen N, 2018, CANCER RES, V78, P2449, DOI 10.1158/0008-5472.CAN-17-3115; Wang TY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01204-7; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Wei RF, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01501; Wu CJ, 2020, CANCERS, V12, DOI 10.3390/cancers12010024; Xu J, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.36; Xu Y, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.561703; Zhan F, 2006, BLOOD, V108, P2020, DOI 10.1182/blood-2005-11-013458; Zhang L, 2021, RNA BIOL, V18, P1265, DOI 10.1080/15476286.2020.1841458; Zhao ZJ, 2018, ACTA PHARM SIN B, V8, P539, DOI 10.1016/j.apsb.2018.03.001; Zhong L, 2019, CANCER LETT, V442, P252, DOI 10.1016/j.canlet.2018.11.006; Zhu HL, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.714267; Zhuang JL, 2019, BLOOD, V133, P1572, DOI 10.1182/blood-2018-06-859686	68	4	4	4	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2022	41	10					1482	1491		10.1038/s41388-022-02191-3	http://dx.doi.org/10.1038/s41388-022-02191-3		JAN 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN2JO	35075244				2022-12-17	WOS:000746328800002
J	Avalle, L; Raggi, L; Monteleone, E; Savino, A; Viavattene, D; Statello, L; Camperi, A; Stabile, SA; Salemme, V; De Marzo, N; Marino, F; Guglielmi, C; Lobascio, A; Zanini, C; Forni, M; Incarnato, D; Defilippi, P; Oliviero, S; Poli, V				Avalle, Lidia; Raggi, Laura; Monteleone, Emanuele; Savino, Aurora; Viavattene, Daniele; Statello, Luisa; Camperi, Andrea; Stabile, Simona Aversano; Salemme, Vincenzo; De Marzo, Niccolo; Marino, Francesca; Guglielmi, Chiara; Lobascio, Andrea; Zanini, Cristina; Forni, Marco; Incarnato, Danny; Defilippi, Paola; Oliviero, Salvatore; Poli, Valeria			STAT3 induces breast cancer growth via ANGPTL4, MMP13 and STC1 secretion by cancer associated fibroblasts	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; STROMAL FIBROBLASTS; MONOCLONAL-ANTIBODY; TUMORS REVEALS; UP-REGULATION; METASTASIS; EXPRESSION; TRANSFORMATION; PROMOTES	In the tumor microenvironment, Cancer Associated Fibroblasts (CAFs) become activated by cancer cells and increase their secretory activity to produce soluble factors that contribute to tumor cells proliferation, invasion and dissemination to distant organs. The pro-tumorigenic transcription factor STAT3 and its canonical inducer, the pro-inflammatory cytokine IL-6, act conjunctly in a positive feedback loop that maintains high levels of IL-6 secretion and STAT3 activation in both tumor and stromal cells. Here, we demonstrate that STAT3 is essential for the pro-tumorigenic functions of murine breast cancer CAFs both in vitro and in vivo, and identify a STAT3 signature significantly enriched for genes encoding for secreted proteins. Among these, ANGPTL4, MMP13 and STC-1 were functionally validated as STAT3-dependent mediators of CAF pro-tumorigenic functions by different approaches. Both in vitro and in vivo CAFs activities were moreover impaired by MMP13 inhibition, supporting the feasibility of a therapeutic approach based on inhibiting STAT3-induced CAF-secreted proteins. The clinical potential of such an approach is supported by the observation that an equivalent CAF-STAT3 signature in humans is expressed at high levels in breast cancer stromal cells and characterizes patients with a shorter disease specific survival, including those with basal-like disease.	[Avalle, Lidia; Raggi, Laura; Monteleone, Emanuele; Savino, Aurora; Viavattene, Daniele; Statello, Luisa; Camperi, Andrea; Stabile, Simona Aversano; Salemme, Vincenzo; De Marzo, Niccolo; Marino, Francesca; Guglielmi, Chiara; Lobascio, Andrea; Defilippi, Paola; Poli, Valeria] Univ Torino, Dept Mol Biotechnol & Hlth Sci, Via Nizza 52, I-10126 Turin, Italy; [Zanini, Cristina; Forni, Marco] BioAir SPA Sci Dept, Via Nizza 52, I-10126 Turin, Italy; [Incarnato, Danny; Oliviero, Salvatore] Univ Torino, Dept Life Sci & Syst Biol, Via Nizza 52, I-10126 Turin, Italy; [Raggi, Laura] San Raffaele Telethon Inst Gene Therapy SR TIGET, Milan, Italy; [Monteleone, Emanuele] Univ Vita Salute San Raffaele, Milan, Italy; [Statello, Luisa] Univ Navarra, Ctr Appl Med Res, Pio XII 55 Ave, Pamplona 31008, Spain; [Guglielmi, Chiara] Univ Hosp Pisa, Dept Lab Med, Sect Mol Genet, Pisa, Italy; [Incarnato, Danny] Univ Groningen, Dept Mol Genet, Groningen Biomol Sci & Biotechnol Inst GBB, NL-9747 AG Groningen, Netherlands	University of Turin; University of Turin; Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; University of Navarra; University of Pisa; Azienda Ospedaliero Universitaria Pisana; University of Groningen	Avalle, L; Poli, V (corresponding author), Univ Torino, Dept Mol Biotechnol & Hlth Sci, Via Nizza 52, I-10126 Turin, Italy.	lidia.avalle@unito.it; valeria.poli@unito.it	Monteleone, Emanuele/AAC-4847-2022; AVALLE, Lidia/AAX-8735-2020	Monteleone, Emanuele/0000-0001-7440-900X; AVALLE, Lidia/0000-0002-5060-633X; Viavattene, Daniele/0000-0002-6216-3986; Aversano Stabile, Simona/0000-0003-0775-1774; Salemme, Vincenzo/0000-0001-9431-9693; Zanini, Cristina/0000-0002-6554-2113	Italian Cancer Research Association (AIRC) [IG16930, IG 20240]; Italian Ministry of University and Research (MIUR PRIN); Truus and Gerrit van Riemsdijk Foundation, Liechtenstein, donation; Piedmont Region (Deflect); Fondazione Umberto Veronesi	Italian Cancer Research Association (AIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of University and Research (MIUR PRIN)(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); Truus and Gerrit van Riemsdijk Foundation, Liechtenstein, donation; Piedmont Region (Deflect); Fondazione Umberto Veronesi(Fondazione Umberto Veronesi)	The authors wish to thank D. Taverna, C. Ambrogio, E. Calautti, M. Mazzone for critically reading the manuscript. This work was supported by the Italian Cancer Research Association (AIRC, IG16930 to V.P.; IG 20240 to S.O.); the Italian Ministry of University and Research (MIUR PRIN 2017 to V.P.); the Truus and Gerrit van Riemsdijk Foundation, Liechtenstein, donation to V.P.; Piedmont Region (Deflect). L. Avalle was supported by Fondazione Umberto Veronesi.	Albrengues J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10204; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Avalle L, 2020, MOL THER-METH CLIN D, V18, P62, DOI 10.1016/j.omtm.2020.05.023; Avalle L, 2017, CELL DEATH DIFFER, V24, P1750, DOI 10.1038/cdd.2017.103; Avalle L, 2017, CYTOKINE, V98, P42, DOI 10.1016/j.cyto.2017.03.018; Avalle Lidia, 2012, JAKSTAT, V1, P65, DOI 10.4161/jkst.20045; Folgueira MAAK, 2013, BIOSCIENCE REP, V33, P921, DOI 10.1042/BSR20130060; Barbieri I, 2010, CANCER RES, V70, P2558, DOI 10.1158/0008-5472.CAN-09-2840; Barbieri I, 2010, MOL CARCINOGEN, V49, P114, DOI 10.1002/mc.20605; Boye K, 2010, AM J PATHOL, V176, P528, DOI 10.2353/ajpath.2010.090526; Chang ACM, 2015, CLIN EXP METASTAS, V32, P15, DOI 10.1007/s10585-014-9687-9; Chong HC, 2014, MOL THER, V22, P1593, DOI 10.1038/mt.2014.102; Colaprico A, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1507; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Demaria M, 2012, CELL DEATH DIFFER, V19, P1390, DOI 10.1038/cdd.2012.20; Demaria M, 2010, AGING-US, V2, P823, DOI 10.18632/aging.100232; Dijkgraaf EM, 2015, ANN ONCOL, V26, P2141, DOI 10.1093/annonc/mdv309; Dumortier M, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-0992-0; Fan YC, 2015, ONCOTARGET, V6, P16120, DOI 10.18632/oncotarget.3878; Garner JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125838; Gendoo DMA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45165-4; Gong XH, 2019, NPJ PRECIS ONCOL, V3, DOI 10.1038/s41698-019-0094-1; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hendrayani SF, 2014, J BIOL CHEM, V289, P30962, DOI 10.1074/jbc.M114.594044; Huynh J, 2019, NAT REV CANCER, V19, P82, DOI 10.1038/s41568-018-0090-8; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Karaayvaz M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06052-0; Laklai H, 2016, NAT MED, V22, P497, DOI 10.1038/nm.4082; Li L, 2015, CELL REP, V10, P654, DOI 10.1016/j.celrep.2015.01.011; Lynch CC, 2002, DIFFERENTIATION, V70, P561, DOI 10.1046/j.1432-0436.2002.700909.x; NANNI P, 1983, CLIN EXP METASTAS, V1, P373, DOI 10.1007/BF00121199; Nielsen BS, 2001, CANCER RES, V61, P7091; Paek AR, 2017, BMB REP, V50, P621, DOI 10.5483/BMBRep.2017.50.12.177; Pena C, 2013, CANCER RES, V73, P1287, DOI 10.1158/0008-5472.CAN-12-1875; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; Quillard T, 2011, ARTERIOSCL THROM VAS, V31, P2464, DOI 10.1161/ATVBAHA.111.231563; Rossi JF, 2010, BRIT J CANCER, V103, P1154, DOI 10.1038/sj.bjc.6605872; Rovero S, 2000, J IMMUNOL, V165, P5133, DOI 10.4049/jimmunol.165.9.5133; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Savino A, 2021, CANCERS, V13, DOI 10.3390/cancers13133371; Schrors B, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01195; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Tell RW, 2014, P NATL ACAD SCI USA, V111, P12787, DOI 10.1073/pnas.1404881111; Teo Z, 2017, ONCOGENE, V36, P6408, DOI 10.1038/onc.2017.244; Vallania F, 2009, P NATL ACAD SCI USA, V106, P5117, DOI 10.1073/pnas.0900473106; Wang SW, 2014, INT J ONCOL, V44, P1032, DOI 10.3892/ijo.2014.2259; Yang XG, 2016, CANCER RES, V76, P4124, DOI 10.1158/0008-5472.CAN-15-2973; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Yu HX, 2018, ARTERIOSCL THROM VAS, V38, P555, DOI 10.1161/ATVBAHA.117.310502; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; ZHANG B, 2008, BMC CANCER, V8; Zhao FY, 2020, J CELL MOL MED, V24, P7686, DOI 10.1111/jcmm.15348; Zheng X, 2016, CELL SIGNAL, V28, P1314, DOI 10.1016/j.cellsig.2016.06.009	55	4	4	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2022	41	10					1456	1467		10.1038/s41388-021-02172-y	http://dx.doi.org/10.1038/s41388-021-02172-y		JAN 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN2JO	35042959	Green Published			2022-12-17	WOS:000744825500001
J	Cannistraci, A; Hascoet, P; Ali, A; Mundra, P; Clarke, NW; Pavet, V; Marais, R				Cannistraci, A.; Hascoet, P.; Ali, A.; Mundra, P.; Clarke, N. W.; Pavet, V; Marais, R.			MiR-378a inhibits glucose metabolism by suppressing GLUT1 in prostate cancer	ONCOGENE			English	Article							RADICAL PROSTATECTOMY; ANDROGEN RECEPTOR; CELL-GROWTH; IN-VITRO; EXPRESSION; TOMOGRAPHY; PLASTICITY; BIOMARKERS; MICRORNAS; SURVIVAL	Prostate cancer (PCa) is the fifth leading cause of cancer related deaths worldwide, in part due to a lack of molecular stratification tools that can distinguish primary tumours that will remain indolent from those that will metastasise. Amongst potential molecular biomarkers, microRNAs (miRs) have attracted particular interest because of their high stability in body fluids and fixed tissues. These small non-coding RNAs modulate several physiological and pathological processes, including cancer progression. Herein we explore the prognostic potential and the functional role of miRs in localised PCa and their relation to nodal metastasis. We define a 7-miR signature that is associated with poor survival independently of age, Gleason score, pathological T state, N stage and surgical margin status and that is also prognostic for disease-free survival in patients with intermediate-risk localised disease. Within our 7-miR signature, we show that miR-378a-3p (hereafter miR-378a) levels are low in primary tumours compared to benign prostate tissue, and also lower in Gleason score 8-9 compared to Gleason 6-7 PCa. We demonstrate that miR-378a impairs glucose metabolism and reduces proliferation in PCa cells through independent mechanisms, and we identify glucose transporter 1 (GLUT1) messenger RNA as a direct target of miR-378a. We show that GLUT1 inhibition hampers glycolysis, leading to cell death. Our data provides a rational for a new PCa stratification strategy based on miR expression, and it reveals that miR-378a and GLUT1 are potential therapeutic targets in highly aggressive glycolytic PCa.	[Cannistraci, A.; Hascoet, P.; Mundra, P.; Pavet, V; Marais, R.] Univ Manchester, Canc Res UK Manchester Inst, Mol Oncol Grp, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England; [Ali, A.; Clarke, N. W.] Univ Manchester, Genitourinary Canc Res Grp, Manchester Canc Res Ctr, Div Canc Sci, 555 Wilmslow Rd, Manchester M20 4GJ, Lancs, England; [Ali, A.; Clarke, N. W.] Univ Manchester, FASTMAN Prostate Canc Ctr Excellence, Manchester Canc Res Ctr, Div Canc Sci, 555 Wilmslow Rd, Manchester M20 4GJ, Lancs, England; [Clarke, N. W.] Christie NHS Fdn Trust, Wilmslow Rd, Manchester M20 4BX, Lancs, England	Cancer Research UK; University of Manchester; University of Manchester; University of Manchester; Christie NHS Foundation Trust	Pavet, V; Marais, R (corresponding author), Univ Manchester, Canc Res UK Manchester Inst, Mol Oncol Grp, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England.	valeria.pavet@cruk.manchester.ac.uk; richard.marais@cruk.manchester.ac.uk		Pavet, Valeria/0000-0002-4472-6503	Cancer Research UK [C5759/A27412, C5759/A20971]; Prostate Cancer UK [CE013_2-004]	Cancer Research UK(Cancer Research UK); Prostate Cancer UK	We thank the CRUK Manchester Institute core facilities, particularly Duncan Smith (Biological Mass Spectrometry), Steve Bagley and Kang Zeng (Visualisation, Irradiation & Analysis), Wolfgang Breitwieser and Sudhakar Sahoo (Molecular Biology and Computational Biology Support). We also thank Pedro Oliveira and Maximiliano Portal for helpful discussions, Ashwin Sachdeva for constructive comments on the manuscript and Nathalie Dhomen for initial administration of the project. The results published here are in whole or part based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga.This work was supported by a core grant from Cancer Research UK to the Cancer Research UK Manchester Institute (C5759/A27412 and C5759/A20971) to RM, and Prostate Cancer UK (CE013_2-004) to RM and NWC.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Aggarwal R, 2018, J CLIN ONCOL, V36, P2492, DOI 10.1200/JCO.2017.77.6880; Ancey PB, 2018, FEBS J, V285, P2926, DOI 10.1111/febs.14577; Arisan ED, 2020, BIOLOGY-BASEL, V9, DOI 10.3390/biology9030052; Bantscheff M, 2012, ANAL BIOANAL CHEM, V404, P939, DOI 10.1007/s00216-012-6203-4; Bartel DP, 2018, CELL, V173, P20, DOI 10.1016/j.cell.2018.03.006; Beg MS, 2017, INVEST NEW DRUG, V35, P180, DOI 10.1007/s10637-016-0407-y; Bonci D, 2016, ONCOGENE, V35, P1180, DOI 10.1038/onc.2015.176; Boorjian SA, 2007, J UROLOGY, V178, P864, DOI 10.1016/j.juro.2007.05.048; Boudreau A, 2016, NAT CHEM BIOL, V12, P779, DOI 10.1038/nchembio.2143; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Briganti A, 2009, EUR UROL, V55, P261, DOI 10.1016/j.eururo.2008.09.043; Carrer M, 2012, P NATL ACAD SCI USA, V109, P15330, DOI 10.1073/pnas.1207605109; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen QG, 2016, TUMOR BIOL, V37, P2095, DOI 10.1007/s13277-015-3996-8; Chen S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0376-5; Chen YH, 2020, NUCLEIC ACIDS RES, V48, pD127, DOI 10.1093/nar/gkz757; Choi SYC, 2016, CLIN CANCER RES, V22, P2721, DOI 10.1158/1078-0432.CCR-15-1624; Cooper CS, 2015, NAT GENET, V47, P367, DOI 10.1038/ng.3221; Coppola V, 2013, ONCOGENE, V32, P1843, DOI 10.1038/onc.2012.194; Coppola V, 2010, ENDOCR-RELAT CANCER, V17, pF1, DOI 10.1677/ERC-09-0172; de Padua MC, 2017, ONCOTARGET, V8, P87623, DOI 10.18632/oncotarget.21007; Ding NX, 2018, INT J MOL MED, V42, P381, DOI 10.3892/ijmm.2018.3639; Ell B, 2013, CANCER CELL, V24, P542, DOI 10.1016/j.ccr.2013.09.008; Erber J, 2019, CANCER RES, V79, P4855, DOI 10.1158/0008-5472.CAN-18-3959; Fox JJ, 2018, JAMA ONCOL, V4, P217, DOI 10.1001/jamaoncol.2017.3588; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gundem G, 2015, NATURE, V520, P353, DOI 10.1038/nature14347; Guo XB, 2019, ONCOL REP, V42, P1957, DOI 10.3892/or.2019.7283; Hatziapostolou M, 2013, TRENDS ENDOCRIN MET, V24, P361, DOI 10.1016/j.tem.2013.03.002; James ND, 2016, JAMA ONCOL, V2, P348, DOI 10.1001/jamaoncol.2015.4350; Jans J, 2010, UROLOGY, V75, P786, DOI 10.1016/j.urology.2009.08.024; Kane CJ, 2017, EUR UROL FOCUS, V3, P487, DOI 10.1016/j.euf.2016.10.010; Kawaguchi M, 2016, BIOCHEM BIOPH RES CO, V474, P188, DOI 10.1016/j.bbrc.2016.04.098; Lan HY, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/125094; Lehuede C, 2016, CANCER RES, V76, P5201, DOI 10.1158/0008-5472.CAN-16-0266; Liu W, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6684; Liu Y, 2012, MOL CANCER THER, V11, P1672, DOI 10.1158/1535-7163.MCT-12-0131; Machado IF, 2020, CELL MOL LIFE SCI, V77, P1947, DOI 10.1007/s00018-019-03375-z; McGuirk S, 2020, TRENDS CANCER, V6, P49, DOI 10.1016/j.trecan.2019.11.009; Meirelles GSP, 2010, CLIN CANCER RES, V16, P6093, DOI 10.1158/1078-0432.CCR-10-1357; Menendez JA, 2012, CELL CYCLE, V11, P2782, DOI 10.4161/cc.20948; Meziou S, 2020, PROSTATE CANCER P D, V23, P441, DOI 10.1038/s41391-020-0202-x; Mishra S, 2014, ONCOGENE, V33, P4097, DOI 10.1038/onc.2013.374; Pertega-Gomes N, 2015, J PATHOL, V236, P517, DOI 10.1002/path.4547; Preisser F, 2020, EUR UROL ONCOL, V3, P270, DOI 10.1016/j.euo.2020.03.002; Ramani R, 2017, BIOMARK INSIGHTS, V12, P1, DOI 10.1177/1177271917702895; Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448; Rickman DS, 2017, NAT MED, V23, P664, DOI 10.1038/nm.4341; Seto AG, 2018, BRIT J HAEMATOL, V183, P428, DOI 10.1111/bjh.15547; Shibuya K, 2015, ONCOTARGET, V6, P651, DOI 10.18632/oncotarget.2892; Shiratori R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55296-3; Siebeneicher H, 2016, CHEMMEDCHEM, V11, P2261, DOI 10.1002/cmdc.201600276; Slack FJ, 2019, CELL, V179, P1033, DOI 10.1016/j.cell.2019.10.017; Stewart GD, 2008, ONCOL REP, V20, P1561, DOI 10.3892/or_00000180; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thomson DW, 2011, NUCLEIC ACIDS RES, V39, P6845, DOI 10.1093/nar/gkr330; van Zandwijk N, 2017, LANCET ONCOL, V18, P1386, DOI 10.1016/S1470-2045(17)30621-6; Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039; Velazquez-Torres G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02851-7; Wani S, 2014, BIORXIV, DOI [10.1101/005439, DOI 10.1101/005439]; Williams KJ, 2002, ONCOGENE, V21, P282, DOI 10.1038/sj.onc.1205047; Xi Xiaochen, 2017, Non-Coding RNA, V3, P9, DOI 10.3390/ncrna3010009; Zhang YF, 2020, J AMB INTEL HUM COMP, V11, P4239, DOI 10.1007/s12652-020-01704-w; Ziegler A, 2012, HUM GENET, V131, P1627, DOI 10.1007/s00439-012-1188-9	65	4	4	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2022	41	10					1445	1455		10.1038/s41388-022-02178-0	http://dx.doi.org/10.1038/s41388-022-02178-0		JAN 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN2JO	35039635	hybrid, Green Published			2022-12-17	WOS:000743421700001
J	James, NE; Woodman, M; Ribeiro, JR				James, Nicole E.; Woodman, Morgan; Ribeiro, Jennifer R.			Prognostic immunologic signatures in epithelial ovarian cancer	ONCOGENE			English	Review							GENE-EXPRESSION; T-CELLS; CHEMOTHERAPY; SURVIVAL; MICROENVIRONMENT; CARCINOMA; BRCA1	Epithelial Ovarian Cancer (EOC) is a deadly gynecologic malignancy in which patients frequently develop recurrent disease following initial platinum-taxane chemotherapy. Analogous to many other cancer subtypes, EOC clinical trials have centered upon immunotherapeutic approaches, most notably programmed cell death 1 (PD-1) inhibitors. While response rates to these immunotherapies in EOC patients have been low, evidence suggests that ovarian tumors are immunogenic and that immune-related genomic profiles can serve as prognostic markers. This review will discuss recent advances in the development of immune-based prognostic signatures in EOC that predict patient clinical outcomes, as well as emphasize specific research areas that need to be addressed to drive this field forward.	[James, Nicole E.; Woodman, Morgan; Ribeiro, Jennifer R.] Women & Infants Hosp Rhode Isl, Program Womens Oncol, Dept Obstet & Gynecol, Providence, RI 02905 USA; [James, Nicole E.; Ribeiro, Jennifer R.] Brown Univ, Warren Alpert Sch Med, Providence, RI 02912 USA	Women & Infants Hospital Rhode Island; Brown University	Ribeiro, JR (corresponding author), Women & Infants Hosp Rhode Isl, Program Womens Oncol, Dept Obstet & Gynecol, Providence, RI 02905 USA.; Ribeiro, JR (corresponding author), Brown Univ, Warren Alpert Sch Med, Providence, RI 02912 USA.	Jrribeiro@wihri.org		Ribeiro, Jennifer/0000-0002-1685-8568				Bohm S, 2016, CLIN CANCER RES, V22, P3025, DOI 10.1158/1078-0432.CCR-15-2657; Brunekreeft KL, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1760705; Cao TF, 2021, J OVARIAN RES, V14, DOI 10.1186/s13048-021-00766-4; Chang CC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113311; Chang L, 2019, THERANOSTICS, V9, P4130, DOI 10.7150/thno.34692; Chifman J, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2948-z; Clarke B, 2009, MODERN PATHOL, V22, P393, DOI 10.1038/modpathol.2008.191; Cortez AJ, 2018, CANCER CHEMOTH PHARM, V81, P17, DOI 10.1007/s00280-017-3501-8; Ding Q, 2020, AGING-US, V12, P4879, DOI 10.18632/aging.102914; Farkkila A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15315-8; Foukakis T, 2018, BRIT J CANCER, V118, P480, DOI 10.1038/bjc.2017.446; Guo QY, 2015, SCI REP-UK, V5, DOI 10.1038/srep17683; Hamanishi J, 2015, J CLIN ONCOL, V33, P4015, DOI 10.1200/JCO.2015.62.3397; Hao DP, 2018, CLIN CANCER RES, V24, P3560, DOI 10.1158/1078-0432.CCR-17-3862; Harwood FC, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar3938; Honkala AT, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03139; James NE, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.622182; James NE, 2020, CANCERS, V12, DOI 10.3390/cancers12082150; Jimenez-Sanchez A, 2020, NAT GENET, V52, P582, DOI 10.1038/s41588-020-0630-5; Jones WD, 2020, CANCERS, V12, DOI 10.3390/cancers12030620; Khadirnaikar S, 2020, CANCER REP-US, V3, DOI 10.1002/cnr2.1166; Korsunsky I, 2017, J INVEST MED, V65, P1068, DOI 10.1136/jim-2017-000457; Koti M, 2015, BRIT J CANCER, V112, P1215, DOI 10.1038/bjc.2015.81; Li H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86294-z; Liu GY, 2012, PHARMACOGENOMICS, V13, P1523, DOI [10.2217/PGS.12.137, 10.2217/pgs.12.137]; Liu J, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20201431; Liu SY, 2020, ONCOTARGETS THER, V13, P6037, DOI 10.2147/OTT.S256708; Lu XF, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12979; Mairinger F, 2019, CANCER MANAG RES, V11, P9571, DOI 10.2147/CMAR.S219872; Mesnage SJL, 2017, ANN ONCOL, V28, P651, DOI 10.1093/annonc/mdw625; Mlynska A, 2019, ONCOL REP, V41, P1238, DOI 10.3892/or.2018.6886; Nixon AB, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0799-2; Olivier M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194781; Radestad E, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1535730; Ray M, 2019, GENE CHROMOSOME CANC, V58, P34, DOI 10.1002/gcc.22688; Rossi L, 2017, ONCOTARGET, V8, P12389, DOI 10.18632/oncotarget.13310; Shen SP, 2019, EBIOMEDICINE, V40, P318, DOI 10.1016/j.ebiom.2018.12.054; Siamakpour-Reihani S, 2020, GYNECOL ONCOL, V156, P662, DOI 10.1016/j.ygyno.2019.12.019; Talluri B, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8090360; Vankerckhoven A, 2021, TRANSL ONCOL, V14, DOI 10.1016/j.tranon.2021.101076; Weberpals JI, 2021, CANCER MED-US, V10, P3045, DOI 10.1002/cam4.3831; Wei Y., 2020, PEERJ, V8; Wu Y, 2020, AGING-US, V12, P11398, DOI 10.18632/aging.103199; Yan SB, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07695-3; Zhang B, 2021, J CELL MOL MED, V25, P2918, DOI 10.1111/jcmm.16327; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177; Zhang LY, 2019, ONCOTARGETS THER, V12, P7005, DOI 10.2147/OTT.S200191	47	4	4	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2022	41	10					1389	1396		10.1038/s41388-022-02181-5	http://dx.doi.org/10.1038/s41388-022-02181-5		JAN 2022	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN2JO	35031772				2022-12-17	WOS:000742613600001
J	Liu, YL; Ma, L; Hua, FL; Min, ZH; Zhan, YX; Zhang, W; Yao, JX				Liu, Yonglei; Ma, Li; Hua, Fanli; Min, Zhihui; Zhan, Yanxia; Zhang, Wei; Yao, Junxia			Exosomal circCARM1 from spheroids reprograms cell metabolism by regulating PFKFB2 in breast cancer	ONCOGENE			English	Article							STEM-CELLS; CIRCULAR RNA	Cancer stem cells (CSC) are the major obstacle for cancer therapy in clinic. Exosomes are one type of vesicles that containing circular RNA (circRNAs) involved in cell-cell communication. However, the roles of breast CSC (BCSC) exosomes are still unclear, and the purpose of the study was to investigate breast cancer cell metabolism reprogramming by circRNAs from BCSC exosomes. The circRNA array was performed in the exosomes secreted from spheroids of MDA-231 cells. circCARM1 was higher in BCSC exosomes than it in the parent breast cancer cells. Further investigation demonstrated that BCSC exosomes circCARM1 played an important role in breast cancer cell glycolysis by miR-1252-5p/PFKFB2. In a conclusion, BCSC exosome-derived circCARM1 played an important role in breast cancer cell glycolysis by sponging miR-1252-5p which regulated PFKFB2 expression.	[Liu, Yonglei; Ma, Li] Fudan Univ, Zhongshan Hosp, Med Res Ctr, Qingpu Branch, Shanghai, Peoples R China; [Hua, Fanli] Fudan Univ, Zhongshan Hosp, ChinaDept Hematol, Qingpu Branch, Shanghai, Peoples R China; [Min, Zhihui; Zhang, Wei] Fudan Univ, Zhongshan Hosp, Inst Clin Sci, Shanghai, Peoples R China; [Zhan, Yanxia] Fudan Univ, Zhongshan Hosp, Dept Pathol, Qingpu Branch, Shanghai, Peoples R China; [Yao, Junxia] Fudan Univ, Zhongshan Hosp, Dept Hematol, Shanghai, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University; Fudan University	Liu, YL (corresponding author), Fudan Univ, Zhongshan Hosp, Med Res Ctr, Qingpu Branch, Shanghai, Peoples R China.	yongleiliu@yeah.net			Shanghai Municipal Health Commission [202140454]; Shanghai Science and Technology Committee [19140901000]; National Natural Science Foundation of China [81502571]	Shanghai Municipal Health Commission; Shanghai Science and Technology Committee(Shanghai Science & Technology Committee); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by Shanghai Municipal Health Commission (No: 202140454), Shanghai Science and Technology Committee (No: 19140901000), and National Natural Science Foundation of China (No: 81502571).	Al-Sowayan BS, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00384; Chung IM, 2020, CLIN CHIM ACTA, V500, P226, DOI 10.1016/j.cca.2019.10.022; Clara JA, 2020, NAT REV CLIN ONCOL, V17, P204, DOI 10.1038/s41571-019-0293-2; Clayton SM, 2020, STEM CELLS DEV, V29, P327, DOI 10.1089/scd.2019.0197; El-Sahli S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21239125; Fanale D, 2018, ADV EXP MED BIOL, V1087, P109, DOI 10.1007/978-981-13-1426-1_9; Gabrusiewicz K, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1412909; Hardin H, 2018, LAB INVEST, V98, P1133, DOI 10.1038/s41374-018-0065-0; Hou J, 2018, CLIN TRANSL ONCOL, V20, P1109, DOI 10.1007/s12094-018-1839-y; Houles T, 2018, CANCER RES, V78, P2191, DOI 10.1158/0008-5472.CAN-17-2215; Hwang WL, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0699-4; Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977; Kristensen LS, 2018, ONCOGENE, V37, P555, DOI 10.1038/onc.2017.361; Li J, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0822-3; Li Y, 2015, CELL RES, V25, P981, DOI 10.1038/cr.2015.82; de Andres JL, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00966-3; Ozcan SC, 2020, MOL CELL BIOCHEM, V470, P115, DOI 10.1007/s11010-020-03751-5; Palacios-Ferrer JL, 2021, MOL ONCOL, V15, P407, DOI 10.1002/1878-0261.12823; Sharma A, 2018, INT J CANCER, V142, P1086, DOI 10.1002/ijc.31089; Taurin S, 2020, NEOPLASIA, V22, P663, DOI 10.1016/j.neo.2020.09.009; Wang L, 2020, J CELL MOL MED, V24, P6324, DOI 10.1111/jcmm.15274; Wang L, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0997-z; Wang YX, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1041-z; Yang LQ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0110-5; Yang ZY, 2020, CELL ONCOL, V43, P123, DOI 10.1007/s13402-019-00476-6; Yu T, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0776-8; Zeng XB, 2021, PHARMACOL RES, V163, DOI 10.1016/j.phrs.2020.105320; Zhao SJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0419-y	28	4	4	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2022	41	14					2012	2025		10.1038/s41388-021-02061-4	http://dx.doi.org/10.1038/s41388-021-02061-4		JAN 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0F2FY	35027669				2022-12-17	WOS:000742332100001
J	Byun, JY; Huang, K; Lee, JS; Huang, WJ; Hu, L; Zheng, XY; Tang, X; Li, FZ; Jo, DG; Song, XM; Huang, C				Byun, Joo-Yun; Huang, Kun; Lee, Jong Suk; Huang, Wenjie; Hu, Li; Zheng, Xuyu; Tang, Xin; Li, Fengzeng; Jo, Dong-Gyu; Song, Xinmao; Huang, Chuang			Targeting HIF-1 alpha/NOTCH1 pathway eliminates CD44(+) cancer stem-like cell phenotypes, malignancy, and resistance to therapy in head and neck squamous cell carcinoma	ONCOGENE			English	Article							HYPOXIA-INDUCIBLE FACTORS; EPITHELIAL-MESENCHYMAL TRANSITION; FACTOR 1-ALPHA; CHEMOTHERAPY RESISTANCE; BREAST-CANCER; EXPRESSION; PROGNOSIS; GROWTH; NOTCH; TH-302	Poor prognosis of head and neck squamous cell carcinomas (HNSCCs) results from resistance to chemotherapy and radiotherapy. To uncover the drivers of HNSCC resistance, including stemness and hypoxia, in this study, we compared the gene expression between CD44(+) and CD44(-) HNSCC cells and assessed the correlation of CD44 and hypoxia-inducible factor 1 alpha (HIF-1 alpha) expression with mouse features and outcomes of patients with HNSCC. We combined the knockdown or activation of HIF-1 alpha with in vitro and in vivo assays to evaluate effects on stemness and resistance of HNSCC cells. Analysis of clinical data showed that activation of HIF-1 alpha in CD44(+) patients with HNSCC was correlated with worse prognosis. Functional assays showed that HIF-1 alpha promoted stemness, resistance, and epithelial-mesenchymal transition in HNSCC CD44(+) cells. HIF-1 alpha activated NOTCH1 signaling in HNSCC stem-like cells characterized by CD44 expression. Moreover, inhibition of these signaling proteins using shRNA or Evofosfamide (Evo) development for cancer treatment, reversed chemoresistance in vitro and in vivo. Taken together, our results indicated that targeting HIF-1 alpha attenuated NOTCH1-induced stemness, which regulates responses to chemotherapy or radiotherapy and malignancy in CD44(+) HNSCCs. HIF-1 alpha/NOTCH1 signaling may represent a target for HNSCC treatment.	[Byun, Joo-Yun; Lee, Jong Suk; Jo, Dong-Gyu] Sungkyunkwan Univ, Sch Pharm, Suwon 16419, South Korea; [Huang, Kun; Hu, Li; Zheng, Xuyu; Tang, Xin; Li, Fengzeng] Chongqing Med Univ, Dept Dermatol, Affiliated Hosp 1, Chongqing, Peoples R China; [Huang, Wenjie] Chongqing Med Univ, Key Lab Diagnost Med, Minist Educ, Chongqing, Peoples R China; [Song, Xinmao] Fudan Univ, Dept Radiat Oncol, Eye Ear Nose & Throat Hosp, Shanghai, Peoples R China; [Huang, Chuang] Chongqing Univ, Canc Hosp, Chongqing Key Lab Translat Res Canc Metastasis &, Chongqing, Peoples R China; [Huang, Chuang] Chongqing Canc Inst, Chongqing, Peoples R China; [Huang, Chuang] Chongqing Canc Hosp, Chongqing, Peoples R China	Sungkyunkwan University (SKKU); Chongqing Medical University; Chongqing Medical University; Fudan University; Chongqing University	Jo, DG (corresponding author), Sungkyunkwan Univ, Sch Pharm, Suwon 16419, South Korea.; Song, XM (corresponding author), Fudan Univ, Dept Radiat Oncol, Eye Ear Nose & Throat Hosp, Shanghai, Peoples R China.; Huang, C (corresponding author), Chongqing Univ, Canc Hosp, Chongqing Key Lab Translat Res Canc Metastasis &, Chongqing, Peoples R China.; Huang, C (corresponding author), Chongqing Canc Inst, Chongqing, Peoples R China.; Huang, C (corresponding author), Chongqing Canc Hosp, Chongqing, Peoples R China.	jodg@skku.edu; muqinger@sina.com; huangchuang@126.com	Jo, Dong-Gyu/AAN-9278-2021; Song, Xinmao/AAP-9859-2021	Jo, Dong-Gyu/0000-0003-2271-1076; Song, Xinmao/0000-0002-4265-1851	MSKCC Senior Research Scientist Changhwan Yoon; National Natural Science Foundation grants of China [81972942]; Chongqing Science and Health Joint Medical Research Project [2020FYYX017]; Chongqing Innovative Support Program for Returned Overseas Chinese Scholars [cx2020103]; Natural Science Foundation grants of Chongqing [cstc2021jcyj-msxmX0009]; High-level Medical Reserved Personnel Training Project of Chongqing	MSKCC Senior Research Scientist Changhwan Yoon; National Natural Science Foundation grants of China(National Natural Science Foundation of China (NSFC)); Chongqing Science and Health Joint Medical Research Project; Chongqing Innovative Support Program for Returned Overseas Chinese Scholars; Natural Science Foundation grants of Chongqing; High-level Medical Reserved Personnel Training Project of Chongqing	We thank MSKCC Senior Research Scientist Changhwan Yoon for supporting Data and reviewing this manuscript. This study was supported by the National Natural Science Foundation grants of China (grant no. 81972942), the Chongqing Science and Health Joint Medical Research Project (grant no. 2020FYYX017), Chongqing Innovative Support Program for Returned Overseas Chinese Scholars (grant no. cx2020103), and the Natural Science Foundation grants of Chongqing (grant no. cstc2021jcyj-msxmX0009), and High-level Medical Reserved Personnel Training Project of Chongqing.	Acker T, 2005, CANCER CELL, V8, P131, DOI 10.1016/j.ccr.2005.07.003; Aebersold DM, 2001, CANCER RES, V61, P2911; Alison MR, 2012, CANCER TREAT REV, V38, P589, DOI 10.1016/j.ctrv.2012.03.003; Arumugam TV, 2018, PROG NEUROBIOL, V165, P103, DOI 10.1016/j.pneurobio.2018.03.002; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Birner P, 2000, CANCER RES, V60, P4693; Birner P, 2001, CLIN CANCER RES, V7, P1661; Bos R, 2003, CANCER, V97, P1573, DOI 10.1002/cncr.11246; Cheng YL, 2015, PHARMACOL THERAPEUT, V147, P80, DOI 10.1016/j.pharmthera.2014.11.005; Cho H, 2016, NATURE, V539, P107, DOI 10.1038/nature19795; Crowder Spencer W, 2014, Curr Pathobiol Rep, V2, P33; Duan JX, 2008, J MED CHEM, V51, P2412, DOI 10.1021/jm701028q; Fabbro D, 2020, CHIMIA, V74, P779, DOI 10.2533/chimia.2020.779; Farnie G, 2007, JNCI-J NATL CANCER I, V99, P616, DOI 10.1093/jnci/djk133; Favier J, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-139; Foster JG, 2014, FUTURE ONCOL, V10, P2659, DOI 10.2217/fon.14.201; Gammon L, 2016, J ORAL PATHOL MED, V45, P77, DOI 10.1111/jop.12327; Gao T, 2016, BIOMED PHARMACOTHER, V80, P393, DOI 10.1016/j.biopha.2016.02.044; Ghattass K, 2013, CURR CANCER DRUG TAR, V13, P670, DOI 10.2174/15680096113139990004; Guo M, 2006, APOPTOSIS, V11, P67, DOI 10.1007/s10495-005-3085-3; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Hashimoto O, 2011, PATHOBIOLOGY, V78, P181, DOI 10.1159/000325538; Huang C, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2448-6; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Kim NS, 2011, PATHOL ONCOL RES, V17, P493, DOI 10.1007/s12253-010-9327-x; Koukourakis MI, 2002, INT J RADIAT ONCOL, V53, P1192, DOI 10.1016/S0360-3016(02)02848-1; Krishnamachary B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044078; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Lee KE, 2012, CURR OPIN CELL BIOL, V24, P232, DOI 10.1016/j.ceb.2012.01.005; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Ma JH, 2010, J CLIN INVEST, V120, P103, DOI 10.1172/JCI37964; Medema JP, 2013, NAT CELL BIOL, V15, P338, DOI 10.1038/ncb2717; Mendez O, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-133; Mimeault M, 2013, J CELL MOL MED, V17, P30, DOI 10.1111/jcmm.12004; Murat A, 2008, J CLIN ONCOL, V26, P3015, DOI 10.1200/JCO.2007.15.7164; Putra AC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134496; Rawluszko-Wieczorek AA, 2014, MOL CANCER RES, V12, P1112, DOI 10.1158/1541-7786.MCR-14-0054; Rocco A, 2012, WORLD J GASTRO ONCOL, V4, P54, DOI 10.4251/wjgo.v4.i3.54; Saggar JK, 2014, INT J CANCER, V134, P2726, DOI 10.1002/ijc.28595; Samanta D, 2014, P NATL ACAD SCI USA, V111, pE5429, DOI 10.1073/pnas.1421438111; Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230; Sena JA, 2014, MOL CANCER RES, V12, P1233, DOI 10.1158/1541-7786.MCR-14-0149; Sindhu SK, 2019, ORAL MAXIL SURG CLIN, V31, P145, DOI 10.1016/j.coms.2018.09.003; Sivridis E, 2002, CANCER-AM CANCER SOC, V95, P1055, DOI 10.1002/cncr.10774; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Sun JD, 2012, CLIN CANCER RES, V18, P758, DOI 10.1158/1078-0432.CCR-11-1980; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Wang Y, 2011, CELL STEM CELL, V8, P399, DOI 10.1016/j.stem.2011.02.006; Welander J, 2014, ENDOCR-RELAT CANCER, V21, P495, DOI 10.1530/ERC-13-0384; Yang CF, 2014, CANCER LETT, V344, P260, DOI 10.1016/j.canlet.2013.11.006; Ye X, 2015, TRENDS CELL BIOL, V25, P675, DOI 10.1016/j.tcb.2015.07.012; Yoon C, 2015, BRIT J CANCER, V113, P46, DOI 10.1038/bjc.2015.186; Yoon C, 2016, CLIN CANCER RES, V22, P971, DOI 10.1158/1078-0432.CCR-15-1356; Zhong H, 1999, CANCER RES, V59, P5830	55	4	5	3	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2022	41	9					1352	1363		10.1038/s41388-021-02166-w	http://dx.doi.org/10.1038/s41388-021-02166-w		JAN 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZI1MQ	35013621				2022-12-17	WOS:000741571100001
J	King, RJ; Shukla, SK; He, CB; Vernucci, E; Thakur, R; Attri, KS; Dasgupta, A; Chaika, NV; Mulder, SE; Abrego, J; Murthy, D; Gunda, V; Pacheco, CG; Grandgenett, PM; Lazenby, AJ; Hollingsworth, MA; Yu, F; Mehla, K; Singh, PK				King, Ryan J.; Shukla, Surendra K.; He, Chunbo; Vernucci, Enza; Thakur, Ravi; Attri, Kuldeep S.; Dasgupta, Aneesha; Chaika, Nina V.; Mulder, Scott E.; Abrego, Jaime; Murthy, Divya; Gunda, Venugopal; Pacheco, Camila G.; Grandgenett, Paul M.; Lazenby, Audrey J.; Hollingsworth, Michael A.; Yu, Fang; Mehla, Kamiya; Singh, Pankaj K.			CD73 induces GM-CSF/MDSC-mediated suppression of T cells to accelerate pancreatic cancer pathogenesis	ONCOGENE			English	Article							TUMOR-GROWTH; TGF-BETA; ADENOSINE; PROMOTES; GEMCITABINE; GENERATION; TOLERANCE; ANTIBODY; IMMUNITY; BURDEN	Metabolic alterations regulate cancer aggressiveness and immune responses. Given the poor response of pancreatic ductal adenocarcinoma (PDAC) to conventional immunotherapies, we investigated the link between metabolic alterations and immunosuppression. Our metabolic enzyme screen indicated that elevated expression of CD73, an ecto-5'-nucleotidase that generates adenosine, correlates with increased aggressiveness. Correspondingly, we observed increased interstitial adenosine levels in tumors from spontaneous PDAC mouse models. Diminishing CD73 by genetic manipulations ablated in vivo tumor growth, and decreased myeloid-derived suppressor cells (MDSC) in orthotopic mouse models of PDAC. A high-throughput cytokine profiling demonstrated decreased GM-CSF in mice implanted with CD73 knockdowns. Furthermore, we noted increased IFN-gamma expression by intratumoral CD4(+) and CD8(+) T cells in pancreatic tumors with CD73 knockdowns. Depletion of CD4(+) T cells, but not CD8(+) T cells abrogated the beneficial effects of decreased CD73. We also observed that splenic MDSCs from Nt5e knockdown tumor-bearing mice were incompetent in suppressing T cell activation in the ex vivo assays. Replenishing GM-CSF restored tumor growth in Nt5e knockout tumors, which was reverted by MDSC depletion. Finally, anti-CD73 antibody treatment significantly improved gemcitabine efficacy in orthotopic models. Thus, targeting the adenosine axis presents a novel therapeutic opportunity for improving the anti-tumoral immune response against PDAC.	[King, Ryan J.; Shukla, Surendra K.; He, Chunbo; Vernucci, Enza; Thakur, Ravi; Attri, Kuldeep S.; Dasgupta, Aneesha; Chaika, Nina V.; Mulder, Scott E.; Abrego, Jaime; Murthy, Divya; Gunda, Venugopal; Pacheco, Camila G.; Grandgenett, Paul M.; Hollingsworth, Michael A.; Mehla, Kamiya; Singh, Pankaj K.] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; [Mulder, Scott E.; Hollingsworth, Michael A.; Singh, Pankaj K.] Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Lazenby, Audrey J.; Hollingsworth, Michael A.; Singh, Pankaj K.] Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; [Yu, Fang] Univ Nebraska, Med Ctr, Dept Biostat, Omaha, NE 68198 USA; [Singh, Pankaj K.] Univ Nebraska, Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Mehla, K; Singh, PK (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA.; Singh, PK (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.; Singh, PK (corresponding author), Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA.; Singh, PK (corresponding author), Univ Nebraska, Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA.	kamiya.mehla@unmc.edu; pankaj.singh@unmc.edu	Thakur, Ravi/AGH-8433-2022	Thakur, Ravi/0000-0003-2505-9757; Shukla, Surendra K/0000-0003-4490-8013	National Institutes of Health [R01CA163649, R01CA210439, R01CA216853]; Specialized Programs of Research Excellence (SPORE) [2P50 CA127297]; PCDC [U01CA210240]; NCI Research Specialist award [5R50CA211462]; Fred & Pamela Buffett Cancer Center Support Grant [P30CA036727]; SPORE Career Development Award (NCI) [2P50 CA127297]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Specialized Programs of Research Excellence (SPORE); PCDC; NCI Research Specialist award; Fred & Pamela Buffett Cancer Center Support Grant; SPORE Career Development Award (NCI)	This work was supported in part by funding from the National Institutes of Health grant (R01CA163649, R01CA210439, and R01CA216853, NCI) to PKS; the Specialized Programs of Research Excellence (SPORE, 2P50 CA127297, NCI) to PKS and MAH; SPORE Career Development Award (2P50 CA127297, NCI) to KM; the PCDC U01CA210240 to MAH; NCI Research Specialist award (5R50CA211462) to PMG. We would also like to acknowledge the Fred & Pamela Buffett Cancer Center Support Grant (P30CA036727, NCI) for supporting shared resources.	Allard B, 2017, IMMUNOL REV, V276, P121, DOI 10.1111/imr.12528; Andersson J, 2008, J EXP MED, V205, P1975, DOI 10.1084/jem.20080308; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025; Bhat P, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.67; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Condamine T, 2015, J LEUKOCYTE BIOL, V98, P913, DOI 10.1189/jlb.4RI0515-204R; Daniel SK, 2019, CLIN TRANSL MED, V8, DOI 10.1186/s40169-019-0226-9; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Dosch M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041222; Foley K, 2016, CANCER LETT, V381, P244, DOI 10.1016/j.canlet.2015.12.020; Gravett AM, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1438107; Gunda V, 2017, CLIN CANCER RES, V23, P5881, DOI 10.1158/1078-0432.CCR-17-1151; Gupta S, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00068; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Jackaman C, 2012, CANCER IMMUNOL IMMUN, V61, P2343, DOI 10.1007/s00262-012-1307-4; Jiang T, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4073-7; Johnson BA, 2017, CLIN CANCER RES, V23, P1656, DOI 10.1158/1078-0432.CCR-16-2318; Junger WG, 2011, NAT REV IMMUNOL, V11, P201, DOI 10.1038/nri2938; Kanehisa M, 2019, NUCLEIC ACIDS RES, V47, pD590, DOI 10.1093/nar/gky962; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; King RJ, 2017, ONCOTARGET, V8, P67152, DOI 10.18632/oncotarget.17934; Lee CR, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030869; Li CX, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01234-1; Linden J, 2012, ARTERIOSCL THROM VAS, V32, P2097, DOI 10.1161/ATVBAHA.111.226837; Looi CK, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1153-8; Lytle NK, 2019, CELL, V177, P572, DOI 10.1016/j.cell.2019.03.010; Ma N, 2017, INT J IMMUNOPATH PH, V30, P152, DOI 10.1177/0394632017711055; Masuda K, 2016, J EXP MED, V213, P605, DOI 10.1084/jem.20151289; Mauti LA, 2011, J CLIN INVEST, V121, P2794, DOI 10.1172/JCI41936; Molinier-Frenkel V, 2017, FEBS LETT, V591, P3135, DOI 10.1002/1873-3468.12784; MOSER GH, 1989, AM J PHYSIOL, V256, pC799, DOI 10.1152/ajpcell.1989.256.4.C799; O'Reilly EM, 2019, JAMA ONCOL, V5, P1431, DOI 10.1001/jamaoncol.2019.1588; O'Sullivan T, 2014, CELL REP, V7, P989, DOI 10.1016/j.celrep.2014.03.073; Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29; Ostrand-Rosenberg S, 2018, J IMMUNOL, V200, P422, DOI 10.4049/jimmunol.1701019; Plate JMD, 2005, CANCER IMMUNOL IMMUN, V54, P915, DOI 10.1007/s00262-004-0638-1; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Rivadeneira DB, 2018, CLIN CANCER RES, V24, P2473, DOI 10.1158/1078-0432.CCR-17-0894; Salminen A, 2019, CELL MOL LIFE SCI, V76, P1901, DOI 10.1007/s00018-019-03048-x; Shukla SK, 2017, CANCER CELL, V32, P71, DOI 10.1016/j.ccell.2017.06.004; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Srivastava MK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040677; Stagg J, 2011, CANCER RES, V71, P2892, DOI 10.1158/0008-5472.CAN-10-4246; Stagg J, 2010, P NATL ACAD SCI USA, V107, P1547, DOI 10.1073/pnas.0908801107; Sugiura A, 2018, J IMMUNOL, V200, P400, DOI 10.4049/jimmunol.1701041; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Szomolay B, 2012, J THEOR BIOL, V303, P141, DOI 10.1016/j.jtbi.2012.03.024; Tran DQ, 2012, J MOL CELL BIOL, V4, P29, DOI 10.1093/jmcb/mjr033; Vigano S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00925; Vijayan D, 2017, NAT REV CANCER, V17, P709, DOI 10.1038/nrc.2017.86; Wang L, 2011, J CLIN INVEST, V121, P2371, DOI 10.1172/JCI45559; Wang R, 2017, ONCOTARGET, V8, P57327, DOI 10.18632/oncotarget.16905; Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444; Zarek PE, 2008, BLOOD, V111, P251, DOI 10.1182/blood-2007-03-081646; Zarek PE, 2007, AUTOIMMUNITY, V40, P425, DOI 10.1080/08916930701464939; Zhang B, 2012, ONCOIMMUNOLOGY, V1, P67, DOI 10.4161/onci.1.1.18068; Zhao H, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01578; Zhou LJ, 2019, J MOL MED, V97, P803, DOI 10.1007/s00109-018-01742-0	63	4	4	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2022	41	7					971	982		10.1038/s41388-021-02132-6	http://dx.doi.org/10.1038/s41388-021-02132-6		JAN 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX7EK	35001076	Green Accepted			2022-12-17	WOS:000740643000001
J	Lin, JG; Xia, LZ; Oyang, LD; Liang, JX; Tan, SM; Wu, NY; Yi, P; Pan, Q; Rao, S; Han, YQ; Tang, YY; Su, M; Luo, X; Yang, YQ; Chen, XH; Yang, LX; Zhou, YJ; Liao, QJ				Lin, Jinguan; Xia, Longzheng; Oyang, Linda; Liang, Jiaxin; Tan, Shiming; Wu, Nayiyuan; Yi, Pin; Pan, Qing; Rao, Shan; Han, Yaqian; Tang, Yanyan; Su, Min; Luo, Xia; Yang, Yiqing; Chen, Xiaohui; Yang, Lixia; Zhou, Yujuan; Liao, Qianjin			The POU2F1-ALDOA axis promotes the proliferation and chemoresistance of colon cancer cells by enhancing glycolysis and the pentose phosphate pathway activity	ONCOGENE			English	Article							BREAST-CANCER; RESISTANCE; OXALIPLATIN; APOPTOSIS; TRANSCRIPTION; ALDOLASE; INSIGHTS	Cancer metabolic reprogramming enhances its malignant behaviors and drug resistance, which is regulated by POU domain transcription factors. This study explored the effect of POU domain class 2 transcription factor 1 (POU2F1) on metabolic reprogramming in colon cancer. The POU2F1 expression was analyzed in GEO dataset, TCGA cohorts and human colon cancer tissues by bioinformatics and immunohistochemistry. The effects of altered POU2F1 expression on proliferation, glucose metabolism and oxaliplatin sensitivity of colon cancer cells were tested. The impacts of POU2F1 on aldolase A (ALDOA) expression and malignant behaviors of colon cancer cells were examined. We found that up-regulated POU2F1 expression was associated with worse prognosis and oxaliplatin resistance in colon cancer. POU2F1 enhanced the proliferation, aerobic glycolysis and the pentose phosphate pathway (PPP) activity, but reduced oxidative stress and apoptosis in colon cancer cells, dependent on up-regulating ALDOA expression. Mechanistically, POU2F1 directly bound to the ALDOA promoter to enhance the ALDOA promoter activity in colon cancer cells. Moreover, activation of the POU2F1-ALDOA axis decreased the sensitivity to oxaliplatin in colon cancer cells. These data indicate that the POU2F1-ALDOA axis promotes the progression and oxaliplatin resistance by enhancing metabolic reprogramming in colon cancer. Our findings suggest that the POU2F1-ALDOA axis may be new therapeutic targets to overcome oxaliplatin resistance in colon cancer.	[Lin, Jinguan; Xia, Longzheng; Oyang, Linda; Liang, Jiaxin; Tan, Shiming; Wu, Nayiyuan; Yi, Pin; Pan, Qing; Rao, Shan; Han, Yaqian; Tang, Yanyan; Su, Min; Luo, Xia; Yang, Yiqing; Chen, Xiaohui; Yang, Lixia; Zhou, Yujuan; Liao, Qianjin] Cent South Univ, Hunan Canc Hosp, Hunan Key Lab Canc Metab, Changsha 410013, Hunan, Peoples R China; [Lin, Jinguan; Xia, Longzheng; Oyang, Linda; Liang, Jiaxin; Tan, Shiming; Wu, Nayiyuan; Yi, Pin; Pan, Qing; Rao, Shan; Han, Yaqian; Tang, Yanyan; Su, Min; Luo, Xia; Yang, Yiqing; Chen, Xiaohui; Yang, Lixia; Zhou, Yujuan; Liao, Qianjin] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Changsha 410013, Hunan, Peoples R China; [Yi, Pin; Pan, Qing] Univ South China, Hengyang 421001, Hunan, Peoples R China; [Zhou, Yujuan; Liao, Qianjin] Hunan Key Lab Translat Radiat Oncol, 283 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China	Central South University; Central South University; University of South China	Zhou, YJ; Liao, QJ (corresponding author), Cent South Univ, Hunan Canc Hosp, Hunan Key Lab Canc Metab, Changsha 410013, Hunan, Peoples R China.; Zhou, YJ; Liao, QJ (corresponding author), Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Changsha 410013, Hunan, Peoples R China.; Zhou, YJ; Liao, QJ (corresponding author), Hunan Key Lab Translat Radiat Oncol, 283 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.	yujany_zhou@163.com; march-on@126.com			National Natural Science Foundation of China [82173142, 81972636, 81872281, 81772842]; Natural Science Foundation of Hunan Province [2020JJ5336, 2019JJ40175, 2019JJ40183, 2018JJ1013]; Research Project of Health Commission of Hunan Province [202203034978, 202109031837, 20201020]; China Hunan Provincial Science and Technology Department [2018SK7005]; Ascend Foundation of National Cancer Center [NCC2018b68]; Hunan Cancer Hospital Climb Plan [ZX2020001-3, YF2020002]; Fundamental Research Funds for the Central Universities of Central South University [2019zzts832, 2019zzts833]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hunan Province(Natural Science Foundation of Hunan Province); Research Project of Health Commission of Hunan Province; China Hunan Provincial Science and Technology Department; Ascend Foundation of National Cancer Center; Hunan Cancer Hospital Climb Plan; Fundamental Research Funds for the Central Universities of Central South University	This work was supported in part by grants from the following sources: the National Natural Science Foundation of China (82173142, 81972636, 81872281, 81772842), the Natural Science Foundation of Hunan Province (2020JJ5336, 2019JJ40175, 2019JJ40183, 2018JJ1013), the Research Project of Health Commission of Hunan Province (202203034978, 202109031837, 20201020), China Hunan Provincial Science and Technology Department (2018SK7005), Ascend Foundation of National Cancer Center (NCC2018b68), and Supported By Hunan Cancer Hospital Climb Plan (ZX2020001-3, YF2020002) and By the Fundamental Research Funds for the Central Universities of Central South University (2019zzts832, 2019zzts833).	Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Benson AB, 2018, J NATL COMPR CANC NE, V16, P359, DOI 10.6004/jnccn.2018.0021; Bidkhori G, 2018, P NATL ACAD SCI USA, V115, pE11874, DOI 10.1073/pnas.1807305115; Blondy S, 2020, CANCER SCI, V111, P3142, DOI 10.1111/cas.14532; Bu PC, 2018, CELL METAB, V27, P1249, DOI 10.1016/j.cmet.2018.04.003; Cao PH, 2019, INT J BIOL SCI, V15, P1676, DOI 10.7150/ijbs.35265; Chen Q, 2020, LEUKEMIA, V34, P2736, DOI 10.1038/s41375-020-0801-5; Cheng CY, 2018, BIOMED PHARMACOTHER, V108, P194, DOI 10.1016/j.biopha.2018.09.031; Costanzo P, 1999, FEBS LETT, V454, P61, DOI 10.1016/S0014-5793(99)00775-9; Dai Ling, 2018, Cancer Manag Res, V10, P1799, DOI 10.2147/CMAR.S157925; Fan JJ, 2017, GENET MOL RES, V16, DOI 10.4238/gmr16039234; Fionda C, 2019, CANCERS, V11, DOI 10.3390/cancers11060810; Gold DA, 2014, MOL BIOL EVOL, V31, P3136, DOI 10.1093/molbev/msu243; Herbert K, 2019, GENE DEV, V33, P310, DOI 10.1101/gad.314633.118; Jiang ZH, 2018, J CELL MOL MED, V22, P4377, DOI 10.1111/jcmm.13732; Kawai K, 2017, INT J ONCOL, V50, P525, DOI 10.3892/ijo.2016.3814; Kondaveeti Y, 2015, CANCER LETT, V364, P44, DOI 10.1016/j.canlet.2015.04.025; Kuo CC, 2019, THERANOSTICS, V9, P2526, DOI 10.7150/thno.32915; Li QG, 2016, MOL CANCER RES, V14, P830, DOI 10.1158/1541-7786.MCR-16-0032; Lopez-Bertoni H, 2020, CANCER RES, V80, P1644, DOI 10.1158/0008-5472.CAN-19-1624; Maddox J, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003048; Mou JJ, 2018, BIOMED PHARMACOTHER, V103, P729, DOI 10.1016/j.biopha.2018.04.099; Ortmayr K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09695-9; Pages F, 2020, ANN ONCOL, V31, P921, DOI 10.1016/j.annonc.2020.03.310; Pankratova EV, 1998, FEBS LETT, V426, P81, DOI 10.1016/S0014-5793(98)00316-0; Park JS, 2020, NATURE, V578, P621, DOI 10.1038/s41586-020-1998-1; Petr MA, 2020, TRENDS CELL BIOL, V30, P117, DOI 10.1016/j.tcb.2019.12.001; Pierce CJ, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-00247-1; Ramanathan B, 2005, CANCER RES, V65, P8455, DOI 10.1158/0008-5472.CAN-05-1162; Sau A, 2018, ACS APPL MATER INTER, V10, P4582, DOI 10.1021/acsami.7b18837; Schworer S, 2019, CELL METAB, V29, P576, DOI 10.1016/j.cmet.2019.01.015; Shakya A, 2009, NAT CELL BIOL, V11, P320, DOI 10.1038/ncb1840; Sharpe DJ, 2014, ONCOTARGET, V5, P8803, DOI 10.18632/oncotarget.2492; Tantin D, 2013, DEVELOPMENT, V140, P2857, DOI 10.1242/dev.095927; Tharp ME, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14055-8; Vazquez-Arreguin K, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1007687; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wazir U, 2019, CANCER GENOM PROTEOM, V16, P121, DOI 10.21873/cgp.20117; Wu D, 2020, BIOCHEM BIOPH RES CO, V533, P533, DOI 10.1016/j.bbrc.2020.09.003; Yu JW, 2019, MED SCI MONITOR, V25, P1204, DOI 10.12659/MSM.912109; Yu LL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14437-3; Zheng PL, 2018, CELL RES, V28, P833, DOI 10.1038/s41422-018-0065-z; Zhu HY, 2017, AM J CANCER RES, V7, P1665	43	4	5	8	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2022	41	7					1024	1039		10.1038/s41388-021-02148-y	http://dx.doi.org/10.1038/s41388-021-02148-y		JAN 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX7EK	34997215	hybrid, Green Published			2022-12-17	WOS:000740148300001
J	Very, N; Hardiville, S; Decourcelle, A; Thevenet, J; Djouina, M; Page, A; Vergoten, G; Schulz, C; Kerr-Conte, J; Lefebvre, T; Dehennaut, V; El Yazidi-Belkoura, I				Very, Ninon; Hardiville, Stephan; Decourcelle, Amelie; Thevenet, Julien; Djouina, Madjid; Page, Adeline; Vergoten, Gerard; Schulz, Celine; Kerr-Conte, Julie; Lefebvre, Tony; Dehennaut, Vanessa; El Yazidi-Belkoura, Ikram			Thymidylate synthase O-GlcNAcylation: a molecular mechanism of 5-FU sensitization in colorectal cancer	ONCOGENE			English	Article							STRUCTURAL DETERMINANTS; FORCE-FIELD; 5-FLUOROURACIL; DEGRADATION; PHOSPHORYLATION; RESISTANCE; PURIFICATION; EXPRESSION; CISPLATIN; GLCNACASE	Alteration of O-GlcNAcylation, a dynamic posttranslational modification, is associated with tumorigenesis and tumor progression. Its role in chemotherapy response is poorly investigated. Standard treatment for colorectal cancer (CRC), 5-fluorouracil (5-FU), mainly targets Thymidylate Synthase (TS). TS O-GlcNAcylation was reported but not investigated yet. We hypothesize that O-GlcNAcylation interferes with 5-FU CRC sensitivity by regulating TS. In vivo, we observed that combined 5-FU with Thiamet-G (O-GlcNAcase (OGA) inhibitor) treatment had a synergistic inhibitory effect on grade and tumor progression. 5-FU decreased O-GlcNAcylation and, reciprocally, elevation of O-GlcNAcylation was associated with TS increase. In vitro in non-cancerous and cancerous colon cells, we showed that 5-FU impacts O-GlcNAcylation by decreasing O-GlcNAc Transferase (OGT) expression both at mRNA and protein levels. Reciprocally, OGT knockdown decreased 5-FU-induced cancer cell apoptosis by reducing TS protein level and activity. Mass spectrometry, mutagenesis and structural studies mapped O-GlcNAcylated sites on T251 and T306 residues and deciphered their role in TS proteasomal degradation. We reveal a crosstalk between O-GlcNAcylation and 5-FU metabolism in vitro and in vivo that converges to 5-FU CRC sensitization by stabilizing TS. Overall, our data propose that combining 5-FU-based chemotherapy with Thiamet-G could be a new way to enhance CRC response to 5-FU.	[Very, Ninon; Hardiville, Stephan; Schulz, Celine; Lefebvre, Tony; El Yazidi-Belkoura, Ikram] Univ Lille, CNRS, UMR 8576, UGSF,Unite Glycobiol Struct & Fonct, F-59000 Lille, France; [Decourcelle, Amelie; Dehennaut, Vanessa] Univ Lille, CNRS, INSERM, CHU Lille,UMR9020 U1277 CANTHER Canc Heterogene P, F-59000 Lille, France; [Thevenet, Julien; Kerr-Conte, Julie] Univ Lille, INSERM, CHU Lille, Inst Pasteur Lille,U1190,EGID, F-59000 Lille, France; [Djouina, Madjid; Vergoten, Gerard] Univ Lille, INSERM, CHU Lille, U1286,Inst Translat Res Inflammat,INFINITE, F-59000 Lille, France; [Page, Adeline] UCBL, SFR BioSci, Prot Sci Facil, CNRS UMS3444,INSERM US8,ENS Lyon, Lyon, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; CHU Lille; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm)	El Yazidi-Belkoura, I (corresponding author), Univ Lille, CNRS, UMR 8576, UGSF,Unite Glycobiol Struct & Fonct, F-59000 Lille, France.	ikram.el-yazidi@univ-lille.fr	DJOUINA, MADJID/GYV-1455-2022; El Yazidi-Belkoura, Ikram/AAE-8805-2022	DJOUINA, MADJID/0000-0003-3557-4103; EL YAZIDI-BELKOURA, IKRAM/0000-0002-5323-7509; page, adeline/0000-0001-7885-1014; Hardiville, Stephan/0000-0002-3554-277X	Ligue Contre le Cancer/Comite du Nord/Comite de la Somme; "Region Hauts-de-France" (Cancer Regional Program); University of Lille; Center National de la Recherche Scientifique; Ministere de l'Enseignement Superieur et de la Recherche; ITMO Cancer AVIESAN (Alliance Nationale pour les Sciences de la Vie et de la Sante, National Alliance for Life Sciences and Health)	Ligue Contre le Cancer/Comite du Nord/Comite de la Somme; "Region Hauts-de-France" (Cancer Regional Program); University of Lille; Center National de la Recherche Scientifique; Ministere de l'Enseignement Superieur et de la Recherche(Estonian Research CouncilEuropean Commission); ITMO Cancer AVIESAN (Alliance Nationale pour les Sciences de la Vie et de la Sante, National Alliance for Life Sciences and Health)	This work was supported by the "Ligue Contre le Cancer/Comite du Nord/Comite de la Somme", the "Region Hauts-de-France" (Cancer Regional Program), the University of Lille and the "Center National de la Recherche Scientifique". NV is the recipient of a fellowship from the "Ministere de l'Enseignement Superieur et de la Recherche". The authors acknowledge the financial support from ITMO Cancer AVIESAN (Alliance Nationale pour les Sciences de la Vie et de la Sante, National Alliance for Life Sciences and Health) within the framework of the cancer plan for Orbitrap mass spectrometer funding. We thank Dr. Guillemette Huet (CANTHER UMR9020 UMR1277, Lille, France) for HT-29 5F31 cell line [26], Dr. Matthew G. Alteen (Department of Chemistry, Simon Fraser University, Canada) for Thiamet-G and Dr. Cyril Couturier (UMR8090 IBL, Lille, France) for pcDNA3.1-Ub-HA plasmid gifts.	Almog R, 2001, PROTEIN SCI, V10, P988, DOI 10.1110/ps.47601; Anderson DD, 2007, CLIN CHEM LAB MED, V45, P1760, DOI 10.1515/CCLM.2007.355; Bai WQ, 2015, INT J CLIN EXP PATHO, V8, P12333; Barbour KW, 2013, BIOSCIENCE REP, V33, P165, DOI 10.1042/BSR20120112; Becker C, 2005, GUT, V54, P950, DOI 10.1136/gut.2004.061283; Chanama S, 2017, SE ASIAN J TROP MED, V48, P722; de Queiroz RM, 2016, J BIOL CHEM, V291, P18897, DOI 10.1074/jbc.M116.734533; Decourcelle A, 2020, CANCERS, V12, DOI 10.3390/cancers12113168; Decourcelle A, 2020, BIOCHEM BIOPH RES CO, V521, P125, DOI 10.1016/j.bbrc.2019.10.090; Etienne MC, 2004, BRIT J CANCER, V90, P526, DOI 10.1038/sj.bjc.6601523; Ferrara P, 2003, ONCOGENE, V22, P1461, DOI 10.1038/sj.onc.1206266; Forsthoefel AM, 2004, BIOCHEMISTRY-US, V43, P1972, DOI 10.1021/bi035894p; Fraczyk T, 2015, BBA-PROTEINS PROTEOM, V1854, P1922, DOI 10.1016/j.bbapap.2015.08.007; Fraczyk T, 2010, BIOORG CHEM, V38, P124, DOI 10.1016/j.bioorg.2010.02.001; Gajjar, 2021, INFL THYM SYNTH EXPR; Hahne H, 2013, J PROTEOME RES, V12, P927, DOI 10.1021/pr300967y; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Hanover JA, 2018, J BIOENERG BIOMEMBR, V50, P155, DOI 10.1007/s10863-018-9751-2; Hardiville S, 2020, MOL CELL, V77, P1143, DOI 10.1016/j.molcel.2019.11.022; Ishikawa M, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-188; Jorgensen WL, 2005, J COMPUT CHEM, V26, P1689, DOI 10.1002/jcc.20297; Kang KA, 2016, ONCOTARGET, V7, P40594, DOI 10.18632/oncotarget.9745; Kanwal S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069150; Kristensen MH, 2010, J INT MED RES, V38, P484, DOI 10.1177/147323001003800212; Lagant P, 2004, J PHYS CHEM A, V108, P4019, DOI 10.1021/jp0311781; Lam C, 2021, CANCER LETT, V503, P11, DOI 10.1016/j.canlet.2021.01.010; Lee H, 2019, CANCER RES, V79, P2839, DOI 10.1158/0008-5472.CAN-18-1991; LESUFFLEUR T, 1991, INT J CANCER, V49, P721, DOI 10.1002/ijc.2910490516; Luanpitpong S, 2018, MOL CANCER THER, V17, P484, DOI 10.1158/1535-7163.MCT-17-0390; Luanpitpong S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10886-x; Mi WY, 2011, BBA-MOL BASIS DIS, V1812, P514, DOI 10.1016/j.bbadis.2011.01.009; Nishiyama M, 1999, CLIN CANCER RES, V5, P2620; Olivier-Van Stichelen S, 2014, FASEB J, V28, P3325, DOI 10.1096/fj.13-243535; Palmirotta Raffaele, 2018, Oncotarget, V9, P25355, DOI 10.18632/oncotarget.25256; PEDERSON NV, 1994, MAGN RESON MED, V31, P224, DOI 10.1002/mrm.1910310217; Pena MMO, 2009, J BIOL CHEM, V284, P31597, DOI 10.1074/jbc.M109.038455; Pena MMO, 2006, BIOCHEM J, V394, P355, DOI 10.1042/BJ20051479; Peters GJ, 2002, BBA-MOL BASIS DIS, V1587, P194, DOI 10.1016/S0925-4439(02)00082-0; PETERS GJ, 1995, EUR J CANCER, V31A, P1299, DOI 10.1016/0959-8049(95)00172-F; Pozzi C, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9040134; Raab S, 2021, CELL MOL LIFE SCI, V78, P5397, DOI 10.1007/s00018-021-03857-z; Rahman L, 2004, CANCER CELL, V5, P341, DOI 10.1016/S1535-6108(04)00080-7; Ruan HB, 2013, MOL CELL PROTEOMICS, V12, P3489, DOI 10.1074/mcp.R113.029751; Samsonoff WA, 1997, J BIOL CHEM, V272, P13281, DOI 10.1074/jbc.272.20.13281; Sekine H, 2018, MOL CELL BIOL, V38, DOI 10.1128/MCB.00252-18; Singh JP, 2020, ONCOGENE, V39, P560, DOI 10.1038/s41388-019-0975-3; Sprung R, 2005, J PROTEOME RES, V4, P950, DOI 10.1021/pr050033j; Stastna M, 2019, GENES-BASEL, V10, DOI 10.3390/genes10100788; Steenackers A, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00046; SWAIN SM, 1989, J CLIN ONCOL, V7, P890, DOI 10.1200/JCO.1989.7.7.890; Vergoten G, 2003, BIOCHIMIE, V85, P65, DOI 10.1016/S0300-9084(03)00052-X; Very N, 2018, ONCOTARGET, V9, P1380, DOI 10.18632/oncotarget.22377; Wakasa K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123076; Xi YG, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-68; Xie X, O GLCNAC REGULATES M, V2021, DOI 10.1101/2021.02.08.430201; Yang SZ, 2020, LAB INVEST, V100, P777, DOI 10.1038/s41374-019-0365-z; Yang XY, 2017, NAT REV MOL CELL BIO, V18, P452, DOI 10.1038/nrm.2017.22; Yang YR, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.24; Yang YR, 2012, AGING CELL, V11, P439, DOI 10.1111/j.1474-9726.2012.00801.x; Yu M, 2019, EXP CELL RES, V382, DOI 10.1016/j.yexcr.2019.06.009; Yuzwa SA, 2008, NAT CHEM BIOL, V4, P483, DOI 10.1038/nchembio.96; Zhou FX, 2018, THERANOSTICS, V8, P5200, DOI 10.7150/thno.27806	62	4	4	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2022	41	5					745	756		10.1038/s41388-021-02121-9	http://dx.doi.org/10.1038/s41388-021-02121-9		NOV 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ4FN	34845374	Green Submitted			2022-12-17	WOS:000723571700002
J	Lu, YW; Wu, FY; Cao, QY; Sun, Y; Huang, ML; Xiao, J; Zhou, B; Zhang, L				Lu, Youwei; Wu, Fengying; Cao, Qiuyi; Sun, Yu; Huang, Moli; Xiao, Jing; Zhou, Bin; Zhang, Liang			B7-H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression	ONCOGENE			English	Article							IMMUNE MICROENVIRONMENT; CHECKPOINT INHIBITORS; PD-1 BLOCKADE; SOLID TUMORS; CANCER; PEMBROLIZUMAB; EXPRESSION; NIVOLUMAB; SENSITIVITY; DOCETAXEL	PD-1/PD-L1 inhibitors have shown clinical benefit in lung adenocarcinoma (LUAD). However, the immunotherapy strategy is less effective in patients with EGFR-activating mutations (EGFR MT). Studies showed that besides low expression of PD-L1, the absence of TILs and distinct expression profile of immune checkpoint molecules might be associated with low response of the patient subset. In this study, we first compared CD8A, GZMB and PRF1 mRNA levels in different LUAD subtypes harboring different driver mutations by dataset analyses and investigated the association between 15 well-defined B7-CD28 family members and driver mutations. The results showed that the decreases in the density and function of CD8(+) TILs, CD274 (PD-L1 gene), and CD86 and increases in VTCN1 (B7-H4 gene) and HHLA2 were associated with LUAD with EGFR-activating mutations. Immunohistochemical staining studies further supported that PD-L1 was downregulated and B7-H4 was upregulated in the subtype. Furthermore, PD-L1 expression was positively associated with levels of CD8A and granzyme B, while B7-H4 expression was negatively associated with granzyme B levels. In lung cancer cell lines, EGFR-activating mutations effectively upregulated B7-H4 and downregulated PD-L1. MEK/ERK-pathway activation upregulated B7-H4, and PI3K/Akt activation upregulated PD-L1. EGFR 19Del mutation was associated with inhibition of CD8(+) T-cell function, while knocking down B7-H4 could reverse the inhibition, and further showed tumor-growth inhibition and longer survival in vivo. Taken together, this study shed light on that B7-H4 might be an alternative immune-checkpoint molecule and a potential therapeutic target for LUAD with EGFR MT.	[Lu, Youwei; Cao, Qiuyi; Sun, Yu; Zhang, Liang] Soochow Univ, Coll Pharmaceut Sci, Suzhou, Jiangsu, Peoples R China; [Wu, Fengying] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China; [Huang, Moli] Soochow Univ, Sch Biol & Basic Med Sci, Dept Bioinformat, Suzhou, Peoples R China; [Xiao, Jing] Songgang Peoples Hosp Shenzhen Baoan Dist, Cent Lab, Shenzhen, Guangdong, Peoples R China; [Zhou, Bin; Zhang, Liang] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Clin Immunol, Suzhou, Jiangsu, Peoples R China; [Zhou, Bin; Zhang, Liang] Soochow Univ, Jiangsu Key Lab Clin Immunol, Suzhou, Jiangsu, Peoples R China; [Zhou, Bin; Zhang, Liang] Soochow Univ, Jiangsu Key Lab Gastrointestinal Tumor Immunol, Suzhou, Jiangsu, Peoples R China	Soochow University - China; Tongji University; Soochow University - China; Soochow University - China; Soochow University - China; Soochow University - China	Zhang, L (corresponding author), Soochow Univ, Coll Pharmaceut Sci, Suzhou, Jiangsu, Peoples R China.; Zhou, B; Zhang, L (corresponding author), Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Clin Immunol, Suzhou, Jiangsu, Peoples R China.; Zhou, B; Zhang, L (corresponding author), Soochow Univ, Jiangsu Key Lab Clin Immunol, Suzhou, Jiangsu, Peoples R China.; Zhou, B; Zhang, L (corresponding author), Soochow Univ, Jiangsu Key Lab Gastrointestinal Tumor Immunol, Suzhou, Jiangsu, Peoples R China.	karichou@163.com; zliang@suda.edu.cn		Zhang, Liang/0000-0002-5041-8005	National Nature Science Foundation of China [31370872, 81402381, 81502454]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by National Nature Science Foundation of China (Grant No. 31370872, No. 81402381, and No. 81502454).	Altan M, 2017, CLIN CANCER RES, V23, P5202, DOI 10.1158/1078-0432.CCR-16-3107; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Boussiotis VA, 2016, NEW ENGL J MED, V375, P1767, DOI 10.1056/NEJMra1514296; Brzezianska E, 2006, MUTAT RES-FUND MOL M, V599, P26, DOI 10.1016/j.mrfmmm.2005.12.013; Buder-Bakhaya K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01474; Chen JA, 2020, CURR TREAT OPTION ON, V21, DOI 10.1007/s11864-020-00750-y; Chen Q, 2018, ONCOTARGETS THER, V11, P4673, DOI 10.2147/OTT.S168313; Chen Y, 2020, PATHOL RES PRACT, V216, DOI 10.1016/j.prp.2020.153134; Cheng HY, 2018, CLIN CANCER RES, V24, P1954, DOI 10.1158/1078-0432.CCR-17-2924; D'Incecco A, 2015, BRIT J CANCER, V112, P95, DOI 10.1038/bjc.2014.555; Dong ZY, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1356145; Du HW, 2019, CANCER CELL, V35, P221, DOI 10.1016/j.ccell.2019.01.002; Gainor JF, 2016, CLIN CANCER RES, V22, P4585, DOI 10.1158/1078-0432.CCR-15-3101; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gruosso T, 2019, J CLIN INVEST, V129, P1785, DOI 10.1172/JCI96313; Hamid O, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-204; Haratani K, 2017, ANN ONCOL, V28, P1532, DOI 10.1093/annonc/mdx183; Harris-Bookman S, 2018, INT J CANCER, V143, P3201, DOI 10.1002/ijc.31661; Hatogai K, 2020, BRIT J CANCER, V122, P413, DOI 10.1038/s41416-019-0622-3; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Iizuka A, 2019, CLIN CANCER RES, V25, P2925, DOI 10.1158/1078-0432.CCR-17-3123; Janakiram M, 2017, IMMUNOL REV, V276, P26, DOI 10.1111/imr.12521; Jiang P, 2018, NAT MED, V24, P1550, DOI 10.1038/s41591-018-0136-1; John P, 2019, TRENDS PHARMACOL SCI, V40, P883, DOI 10.1016/j.tips.2019.09.008; Jung KH, 2019, CLIN CANCER RES, V25, P3220, DOI 10.1158/1078-0432.CCR-18-2740; Kasten BB, 2020, CURR MED CHEM, V27, P4016, DOI 10.2174/0929867326666190228120908; Krawczyk P, 2016, ANN ONCOL, V27, P358, DOI 10.1093/annonc/mdv553; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lee CK, 2017, J THORAC ONCOL, V12, P403, DOI 10.1016/j.jtho.2016.10.007; Leprieur EG, 2017, EUR J CANCER, V78, P16, DOI 10.1016/j.ejca.2016.12.041; Li J, 2018, IMMUNITY, V48, P773, DOI 10.1016/j.immuni.2018.03.018; Mazzaschi G, 2018, CLIN CANCER RES, V24, P407, DOI 10.1158/1078-0432.CCR-17-2156; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Ni L, 2017, MOL CANCER THER, V16, P1203, DOI 10.1158/1535-7163.MCT-16-0761; Oble Darryl A, 2009, Cancer Immun, V9, P3; Pai-Scherf L, 2017, ONCOLOGIST, V22, P1392, DOI 10.1634/theoncologist.2017-0078; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Rousalova I, 2010, INT J ONCOL, V37, P1361, DOI 10.3892/ijo_00000788; Schliekelman MJ, 2015, CANCER RES, V75, P1789, DOI 10.1158/0008-5472.CAN-14-2535; Sul J, 2016, ONCOLOGIST, V21, P643, DOI 10.1634/theoncologist.2015-0498; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Toki MI, 2018, J THORAC ONCOL, V13, P1884, DOI 10.1016/j.jtho.2018.09.012; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Westover D, 2018, ANN ONCOL, V29, pI10, DOI 10.1093/annonc/mdx703; Xing XF, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1356144; Yagi T, 2019, ANN SURG, V269, P471, DOI 10.1097/SLA.0000000000002616; Yoshida H, 2018, ANN ONCOL, V29, P777, DOI 10.1093/annonc/mdx745; Yu SR, 2020, ONCOGENE, V39, P2643, DOI 10.1038/s41388-020-1182-y; Zhao ZM, 2020, CANCER LETT, V485, P14, DOI 10.1016/j.canlet.2020.04.013	54	4	4	3	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2022	41	5					704	717		10.1038/s41388-021-02124-6	http://dx.doi.org/10.1038/s41388-021-02124-6		NOV 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ4FN	34839353				2022-12-17	WOS:000722970800001
J	Otani, S; Date, Y; Ueno, T; Ito, T; Kajikawa, S; Omori, K; Taniuchi, I; Umeda, M; Komori, T; Toguchida, J; Ito, K				Otani, Shohei; Date, Yuki; Ueno, Tomoya; Ito, Tomoko; Kajikawa, Shuhei; Omori, Keisuke; Taniuchi, Ichiro; Umeda, Masahiro; Komori, Toshihisa; Toguchida, Junya; Ito, Kosei			Runx3 is required for oncogenic Myc upregulation in p53-deficient osteosarcoma	ONCOGENE			English	Article							C-MYC; TRANSCRIPTIONAL REGULATION; TUMOR-SUPPRESSOR; P53 LOSS; CANCER; CELLS; EXPRESSION; REPRESSION; FAMILY; INACTIVATION	Osteosarcoma (OS) in human patients is characterized by genetic alteration of TP53. Osteoprogenitor-specific p53-deleted mice (OS mice) have been widely used to study the process of osteosarcomagenesis. However, the molecular mechanisms responsible for the development of OS upon p53 inactivation remain largely unknown. In this study, we detected prominent RUNX3/Runx3 expression in human and mouse p53-deficient OS. Myc was aberrantly upregulated by Runx3 via mR1, a consensus Runx site in the Myc promoter, in a manner dependent on p53 deficiency. Reduction of the Myc level by disruption of mR1 or Runx3 knockdown decreased the tumorigenicity of p53-deficient OS cells and effectively suppressed OS development in OS mice. Furthermore, Runx inhibitors exerted therapeutic effects on OS mice. Together, these results show that p53 deficiency promotes osteosarcomagenesis in human and mouse by allowing Runx3 to induce oncogenic Myc expression.	[Otani, Shohei; Date, Yuki; Ueno, Tomoya; Ito, Tomoko; Omori, Keisuke; Ito, Kosei] Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol Bone Biol, 1-7-1 Sakamoto, Nagasaki 8528588, Japan; [Otani, Shohei; Omori, Keisuke; Umeda, Masahiro] Nagasaki Univ, Grad Sch Biomed Sci, Dept Clin Oral Oncol, 1-7-1 Sakamoto, Nagasaki 8528588, Japan; [Date, Yuki] Japan Soc Promot Sci, Chiyoda Ku, 5-3-1 Kojimachi, Tokyo 1020083, Japan; [Kajikawa, Shuhei] Okayama Univ Sci, Dept Vet Med, Fac Vet Med, 1-3 Ikoinooka, Imabari, Ehime 7948555, Japan; [Taniuchi, Ichiro] RIKEN Ctr Integrat Med Sci, Lab Transcript Regulat, Tsurumi Ku, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan; [Komori, Toshihisa] Nagasaki Univ, Grad Sch Biomed Sci, Dept Cell Biol, 1-7-1 Sakamoto, Nagasaki 8528588, Japan; [Toguchida, Junya] Kyoto Univ, Inst Frontier Life & Med Sci, Sakyo Ku, Shogoin Kawahara Cho, Kyoto 6068507, Japan; [Toguchida, Junya] Kyoto Univ, Ctr iPS Cell Res & Applicat CiRA, Sakyo Ku, 53 Shogoin Kawahara Cho, Kyoto 6068507, Japan	Nagasaki University; Nagasaki University; Japan Society for the Promotion of Science; Okayama University of Science; RIKEN; Nagasaki University; Kyoto University; Kyoto University	Ito, K (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol Bone Biol, 1-7-1 Sakamoto, Nagasaki 8528588, Japan.	itok@nagasaki-u.ac.jp		Otani, Shohei/0000-0001-5474-2243	KAKENHI/Japan Society for the Promotion of Science (JSPS) [26290040, 18H02972, 19K22724]; JSPS Research Fellowship for Young Scientists [18J20543]; Funding Program for Next Generation World-Leading Researchers [LS097]	KAKENHI/Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); JSPS Research Fellowship for Young Scientists(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Funding Program for Next Generation World-Leading Researchers(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	We thank G. Huang for critical advice on the study; A. Berns and F. W. Alt for providing the p53 and Myc flox mouse lines, respectively; T. Kishino for generating genome-edited mouse lines; and all members of the Biomedical Research Center, Nagasaki University for maintaining mouse lines. This work was supported by KAKENHI/Japan Society for the Promotion of Science (JSPS) grants 26290040 (KI), 18H02972 (KI), and 19K22724 (KI); by the Funding Program for Next Generation World-Leading Researchers LS097 (KI); and by the JSPS Research Fellowship for Young Scientists 18J20543 (YD).	Bauer O, 2015, MOL CELL BIOL, V35, P1097, DOI 10.1128/MCB.01106-14; Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105; Bledsoe KL, 2014, J CELL PHYSIOL, V229, P2049, DOI 10.1002/jcp.24663; Bonev B, 2017, CELL, V171, P557, DOI 10.1016/j.cell.2017.09.043; Bouaoun L, 2016, HUM MUTAT, V37, P865, DOI 10.1002/humu.23035; Bougeard G, 2015, J CLIN ONCOL, V33, P2345, DOI 10.1200/JCO.2014.59.5728; Buenrostro Jason D, 2015, Curr Protoc Mol Biol, V109, DOI 10.1002/0471142727.mb2129s109; Bushweller JH, 2019, NAT REV CANCER, V19, P611, DOI 10.1038/s41568-019-0196-7; Chen SF, 2018, BIOINFORMATICS, V34, P884, DOI 10.1093/bioinformatics/bty560; Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003; Cho SW, 2018, CELL, V173, P1398, DOI 10.1016/j.cell.2018.03.068; Chuang LSH, 2017, ADV EXP MED BIOL, V962, P299, DOI 10.1007/978-981-10-3233-2_19; Chuang LSH, 2013, INT J CANCER, V132, P1260, DOI 10.1002/ijc.27964; Cunningham L, 2012, P NATL ACAD SCI USA, V109, P14592, DOI 10.1073/pnas.1200037109; Date Y, 2020, MOL CELLS, V43, P176, DOI 10.14348/molcells.2019.0285; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; Gabay M, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014241; Gamberi G, 1998, ONCOLOGY-BASEL, V55, P556, DOI 10.1159/000011912; Gilbert LA, 2013, CELL, V154, P442, DOI 10.1016/j.cell.2013.06.044; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; He YL, 2015, STEM CELLS, V33, P1304, DOI 10.1002/stem.1925; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hosoi H, 2021, GENE, V774, DOI 10.1016/j.gene.2021.145421; Illendula A, 2016, EBIOMEDICINE, V8, P117, DOI 10.1016/j.ebiom.2016.04.032; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Ito Y, 2015, NAT REV CANCER, V15, P81, DOI 10.1038/nrc3877; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lancho O, 2018, TRENDS CANCER, V4, P810, DOI 10.1016/j.trecan.2018.10.003; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lee TI, 2013, CELL, V152, P1237, DOI 10.1016/j.cell.2013.02.014; Levanon D, 2004, ONCOGENE, V23, P4211, DOI 10.1038/sj.onc.1207670; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Martin J. W., 2011, Sarcoma, V2011, P282745, DOI 10.1155/2011/282745; Morita K, 2017, J CLIN INVEST, V127, P2815, DOI 10.1172/JCI91788; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Naoe Y, 2007, J EXP MED, V204, P1749, DOI 10.1084/jem.20062456; Ottaviano L, 2010, GENE CHROMOSOME CANC, V49, P40, DOI 10.1002/gcc.20717; PORTER DE, 1992, J BONE JOINT SURG BR, V74, P883; Pulikkan JA, 2018, CELL, V174, P172, DOI 10.1016/j.cell.2018.05.048; Qin X, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1009169; Ramirez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257; Sabapathy K, 2018, NAT REV CLIN ONCOL, V15, P13, DOI 10.1038/nrclinonc.2017.151; Shin MH, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005884; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; van der Deen M, 2012, J BIOL CHEM, V287, P4503, DOI 10.1074/jbc.M111.287771; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; Walz S, 2014, NATURE, V511, P483, DOI 10.1038/nature13473; Whittle MC, 2015, CELL, V161, P1345, DOI 10.1016/j.cell.2015.04.048; Wierstra I, 2008, ADV CANCER RES, V99, P113, DOI 10.1016/S0065-230X(07)99004-1; Yamada C, 2010, J BIOL CHEM, V285, P16693, DOI 10.1074/jbc.M109.055525	54	4	4	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2022	41	5					683	691		10.1038/s41388-021-02120-w	http://dx.doi.org/10.1038/s41388-021-02120-w		NOV 2021	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ4FN	34803166				2022-12-17	WOS:000720812600001
J	Kong, Y; Zhang, YT; Wang, HL; Kan, WJ; Guo, HR; Liu, Y; Zang, Y; Li, J				Kong, Ya; Zhang, Yutian; Wang, Hanlin; Kan, Weijuan; Guo, Haoran; Liu, Yun; Zang, Yi; Li, Jia			Inner nuclear membrane protein TMEM201 promotes breast cancer metastasis by positive regulating TGF beta signaling	ONCOGENE			English	Article							INTEGRAL PROTEIN; MAN1; REVEALS; LAMINA; SAMP1	Emerging evidence shows the association between nuclear envelope and tumor progression, however, the functional contributions of specific constituents of the nuclear envelope remain largely unclear. We found that the expression level of transmembrane protein 201 (TMEM201), an integral inner nuclear membrane protein of unknown function, was significantly elevated in invasive breast cancer and predicted poor breast cancer prognosis. We showed that TMEM201, as a positive modulator, was both necessary and sufficient to regulate the migration and invasion of breast cancer cells in vitro and in vivo. Mechanistically, RNA-sequencing analysis and validation showed that TMEM201 deficiency inhibited epithelial-to-mesenchymal transition and transforming growth factor-beta signaling. Finally, we showed that TMEM201 physically interacted with SMAD2/3 and was required for the phosphorylation of SMAD2/3, nuclear translocation and transcriptional activation of the TGF beta. Thus, we demonstrated that specific inner nuclear membrane component mediated signal-dependent transcriptional effects to control breast cancer metastasis.	[Kong, Ya; Zhang, Yutian; Wang, Hanlin; Kan, Weijuan; Guo, Haoran; Zang, Yi; Li, Jia] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China; [Kong, Ya; Zhang, Yutian; Guo, Haoran; Zang, Yi; Li, Jia] Univ Chinese Acad Sci, Beijing 100049, Peoples R China; [Wang, Hanlin] Fudan Univ, Dept Pharmacol, Shanghai 201203, Peoples R China; [Liu, Yun] China Pharmaceut Univ, State Key Lab Nat Med, Jiangsu Key Lab Drug Screening, 24 Tong Jia Xiang St, Nanjing 210009, Peoples R China; [Zang, Yi; Li, Jia] UCAS, Hangzhou Inst Adv Study, Sch Pharmaceut Sci & Technol, Hangzhou, Peoples R China; [Li, Jia] Pilot Natl Lab Marine Sci & Technol Qingdao, Open Studio Druggabil Res Marine Nat Prod, Qingdao 266237, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Fudan University; China Pharmaceutical University; Qingdao National Laboratory for Marine Science & Technology	Zang, Y; Li, J (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China.; Zang, Y; Li, J (corresponding author), Univ Chinese Acad Sci, Beijing 100049, Peoples R China.; Zang, Y; Li, J (corresponding author), UCAS, Hangzhou Inst Adv Study, Sch Pharmaceut Sci & Technol, Hangzhou, Peoples R China.; Li, J (corresponding author), Pilot Natl Lab Marine Sci & Technol Qingdao, Open Studio Druggabil Res Marine Nat Prod, Qingdao 266237, Peoples R China.	yzang@simm.ac.cn; jli@simm.ac.cn	Li, Jia/F-9116-2011	Wang, Hanlin/0000-0003-0443-4378	National Natural Science Foundation of China [31871414, 81971265]; Science and Technology Commission of Shanghai Municipality [19JC1416300]; Shanghai Institute of Materia Medica [SIMM2004KF-01]; Shanghai Municipal Human Resources and Social Security Bureau [Y91204R]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Shanghai Institute of Materia Medica; Shanghai Municipal Human Resources and Social Security Bureau	This work is supported by the National Natural Science Foundation of China (Grant 31871414, 81971265), Science and Technology Commission of Shanghai Municipality (19JC1416300), Shanghai Institute of Materia Medica (SIMM2004KF-01), Shanghai Municipal Human Resources and Social Security Bureau (Y91204R).	Bell ES, 2016, EUR J CELL BIOL, V95, P449, DOI 10.1016/j.ejcb.2016.06.007; Bengtsson L, 2007, FEBS J, V274, P1374, DOI 10.1111/j.1742-4658.2007.05696.x; Borrego-Pinto J, 2012, J CELL SCI, V125, P1099, DOI 10.1242/jcs.087049; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Buch C, 2009, J CELL SCI, V122, P2100, DOI 10.1242/jcs.047373; Chow KH, 2012, NAT REV CANCER, V12, P196, DOI 10.1038/nrc3219; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; de las Heras JI, 2013, SEMIN CANCER BIOL, V23, P125, DOI 10.1016/j.semcancer.2012.01.008; Dephoure N, 2008, P NATL ACAD SCI USA, V105, P10762, DOI 10.1073/pnas.0805139105; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dreger M, 2001, P NATL ACAD SCI USA, V98, P11943, DOI 10.1073/pnas.211201898; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Goldberg M, 1998, MOL CELL BIOL, V18, P4315, DOI 10.1128/MCB.18.7.4315; Gruenbaum Y, 2005, NAT REV MOL CELL BIO, V6, P21, DOI 10.1038/nrm1550; Hetzer MW, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000539; Kao KJ, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-143; Karlsson G, 2005, PHYSIOL GENOMICS, V21, P396, DOI 10.1152/physiolgenomics.00303.2004; Korfali N, 2012, NUCLEUS-PHILA, V3, P552, DOI 10.4161/nucl.22257; Korfali N, 2010, MOL CELL PROTEOMICS, V9, P2571, DOI 10.1074/mcp.M110.002915; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Lin F, 2005, HUM MOL GENET, V14, P437, DOI 10.1093/hmg/ddi040; Liu C, 2019, ONCOTARGETS THER, V12, P3817, DOI 10.2147/OTT.S179870; Lu T, 2016, BIOCHEM BIOPH RES CO, V478, P1189, DOI 10.1016/j.bbrc.2016.08.093; Mansharamani M, 2005, J BIOL CHEM, V280, P13863, DOI 10.1074/jbc.M413020200; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Moustakas A, 2016, J CLIN MED, V5, DOI 10.3390/jcm5070063; Olsen JV, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000475; Osada SI, 2003, DEVELOPMENT, V130, P1783, DOI 10.1242/dev.00401; Pan D, 2005, J BIOL CHEM, V280, P15992, DOI 10.1074/jbc.M411234200; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Raju GP, 2003, J BIOL CHEM, V278, P428, DOI 10.1074/jbc.M210505200; Reis-Sobreiro M, 2018, CANCER RES, V78, P6086, DOI 10.1158/0008-5472.CAN-18-0608; Rodriguez-Bravo V, 2018, CELL, V174, P1200, DOI 10.1016/j.cell.2018.07.015; Schaffer BE, 2015, CELL METAB, V22, P907, DOI 10.1016/j.cmet.2015.09.009; Schirmer EC, 2003, SCIENCE, V301, P1380, DOI 10.1126/science.1088176; Schirmer EC, 2007, EXP CELL RES, V313, P2167, DOI 10.1016/j.yexcr.2007.03.012; Schreiber KH, 2013, CELL, V152, P1365, DOI 10.1016/j.cell.2013.02.015; Shi JL, 2019, AM J TRANSL RES, V11, P393; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Vijayaraghavan B, 2018, BBA-BIOMEMBRANES, V1860, P1326, DOI 10.1016/j.bbamem.2018.03.001; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Wilkie GS, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.003129; Wolff AC, 2018, ARCH PATHOL LAB MED, V142, P1364, DOI [10.5858/arpa.2018-0902-SA, 10.1200/JCO.2018.77.8738]; Yang YC, 2003, P NATL ACAD SCI USA, V100, P10269, DOI 10.1073/pnas.1834070100; Zhou HJ, 2013, J PROTEOME RES, V12, P260, DOI 10.1021/pr300630k	45	4	4	3	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2022	41	5					647	656		10.1038/s41388-021-02098-5	http://dx.doi.org/10.1038/s41388-021-02098-5		NOV 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ4FN	34799661				2022-12-17	WOS:000720611600002
J	Laut, AK; Dorneburg, C; Furstberger, A; Barth, TFE; Kestler, HA; Debatin, KM; Beltinger, C				Laut, Astrid K.; Dorneburg, Carmen; Furstberger, Axel; Barth, Thomas F. E.; Kestler, Hans A.; Debatin, Klaus-Michael; Beltinger, Christian			CHD5 inhibits metastasis of neuroblastoma	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENE; MOLECULAR ANALYSIS; BINDING-PROTEIN; DISTAL 1P; DELETION; REGION; EXPRESSION; INVASION; LOCI; MECHANISMS	CHD5, a tumor suppressor at 1p36, is frequently lost or silenced in poor prognosis neuroblastoma (NB) and many adult cancers. The role of CHD5 in metastasis is unknown. We confirm that low expression of CHD5 is associated with stage 4 NB. Forced expression of CHD5 in NB cell lines with 1p loss inhibited key aspects of the metastatic cascade in vitro: anchorage-independent growth, migration, and invasion. In vivo, formation of bone marrow and liver metastases developing from intravenously injected NB cells was delayed and decreased by forced CHD5 expression. Genome-wide mRNA sequencing revealed reduction of genes and gene sets associated with metastasis when CHD5 was overexpressed. Known metastasis-suppressing genes preferentially upregulated in CHD5-overexpressing NB cells included PLCL1. In patient NB, low expression of PLCL1was associated with metastatic disease and poor survival. Knockdown of PLCL1 and of p53 in IMR5 NB cells overexpressing CHD5 reversed CHD5-induced inhibition of invasion and migration in vitro. In summary, CHD5 is a metastasis suppressor in NB.	[Laut, Astrid K.; Dorneburg, Carmen; Beltinger, Christian] Univ Med Ctr Ulm, Dept Pediat & Adolescent Med, Sect Expt Pediat Oncol, Ulm, Germany; [Furstberger, Axel; Kestler, Hans A.] Ulm Univ, Inst Med Syst Biol, Ulm, Germany; [Barth, Thomas F. E.] Univ Med Ctr Ulm, Dept Pathol, Ulm, Germany; [Debatin, Klaus-Michael] Univ Med Ctr Ulm, Dept Pediat & Adolescent Med, Ulm, Germany	Ulm University; Ulm University; Ulm University; Ulm University	Beltinger, C (corresponding author), Univ Med Ctr Ulm, Dept Pediat & Adolescent Med, Sect Expt Pediat Oncol, Ulm, Germany.	Christian.Beltinger@uniklinik-ulm.de	Debatin, Klaus-Michael/J-9704-2014; Kestler, Hans A./D-5799-2012	Debatin, Klaus-Michael/0000-0002-8397-1886; Kestler, Hans A./0000-0002-4759-5254	Deutsche Forschungsgemeinschaft [GRK2254]; DFG	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); DFG(German Research Foundation (DFG))	The excellent technical assistance of Nicole Heymann, Helgard Knauss and Alix Otto is greatly appreciated. This work was supported by a grant of the Deutsche Forschungsgemeinschaft to CB (Project B1 within the GRK2254). AL was a member of the International Graduate School in Molecular Medicine, Ulm, that is funded by the DFG.	Ara T, 2006, CANCER METAST REV, V25, P645, DOI 10.1007/s10555-006-9028-9; Asano S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05908-7; Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052; Bauer A, 2001, GENE CHROMOSOME CANC, V31, P228, DOI 10.1002/gcc.1139; Bhoopathi P, 2019, ONCOGENE, V38, P6781, DOI 10.1038/s41388-019-0920-5; Botzer LE, 2016, BRIT J CANCER, V114, P759, DOI 10.1038/bjc.2016.26; Byrne FL, 2014, ONCOGENE, V33, P882, DOI 10.1038/onc.2013.11; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; Caron H, 2001, GENE CHROMOSOME CANC, V30, P168, DOI 10.1002/1098-2264(200102)30:2<168::AID-GCC1072>3.0.CO;2-E; Chen DD, 2020, NEOPLASIA, V22, P231, DOI 10.1016/j.neo.2020.04.001; CHENG NC, 1995, ONCOGENE, V10, P291; Chou RH, 2012, ONCOL REP, V27, P238, DOI 10.3892/or.2011.1497; Delloye-Bourgeois C, 2017, CANCER CELL, V32, P427, DOI 10.1016/j.ccell.2017.09.006; Dorneburg C, 2018, CLIN CANCER RES, V24, P5772, DOI 10.1158/1078-0432.CCR-17-2578; Egan CM, 2013, DEV CELL, V26, P223, DOI 10.1016/j.devcel.2013.07.008; Fabian J, 2016, ONCOTARGET, V7, P66344, DOI 10.18632/oncotarget.11662; Fife CM, 2017, ONCOGENE, V36, P501, DOI 10.1038/onc.2016.220; Fujita T, 2008, JNCI-J NATL CANCER I, V100, P940, DOI 10.1093/jnci/djn176; Garcia I, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-277; GEHRING M, 1995, CANCER RES, V55, P5366; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Kolla Venkatadri, 2014, Cancer Res, V74, P652, DOI 10.1158/0008-5472.CAN-13-3056; Kolla V, 2015, BIOCHEM J, V468, P345, DOI 10.1042/BJ20150030; Koyama H, 2012, CLIN CANCER RES, V18, P1588, DOI 10.1158/1078-0432.CCR-11-2644; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Maetani Y, 2021, BIOCHEM BIOPH RES CO, V552, P106, DOI 10.1016/j.bbrc.2021.03.045; Maris John M, 2010, N Engl J Med, V362, P2202, DOI 10.1056/NEJMra0804577; Martinsson T, 1997, EUR J CANCER, V33, P1997, DOI 10.1016/S0959-8049(97)00278-5; MARTINSSON T, 1995, CANCER RES, V55, P5681; Matthay KK, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.78; Naraparaju K, 2016, ONCOTARGET, V7, P15977, DOI 10.18632/oncotarget.7434; Okawa ER, 2008, ONCOGENE, V27, P803, DOI 10.1038/sj.onc.1210675; Paul S, 2013, CELL REP, V3, P92, DOI 10.1016/j.celrep.2012.12.009; Quan JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108066; Quan JH, 2014, J BIOL CHEM, V289, P20717, DOI 10.1074/jbc.M114.568568; Seong BKA, 2017, CANCER RES, V77, P696, DOI 10.1158/0008-5472.CAN-16-1502; Thompson PM, 2003, ONCOGENE, V22, P1002, DOI 10.1038/sj.onc.1206211; White PS, 2005, ONCOGENE, V24, P2684, DOI 10.1038/sj.onc.1208306; White PS, 1997, EUR J CANCER, V33, P1957, DOI 10.1016/S0959-8049(97)00311-0; White PS, 2001, MED PEDIATR ONCOL, V36, P37, DOI 10.1002/1096-911X(20010101)36:1<37::AID-MPO1010>3.0.CO;2-L; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; Wu PY, 2019, CANCER RES, V79, P5550, DOI 10.1158/0008-5472.CAN-18-3272; Xiang X, 2015, CANCER LETT, V359, P187, DOI 10.1016/j.canlet.2015.01.008; Xie CR, 2015, ONCOTARGET, V6, P40940, DOI 10.18632/oncotarget.5724; Zhu SZ, 2017, CANCER CELL, V32, P310, DOI 10.1016/j.ccell.2017.08.002	45	4	4	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2022	41	5					622	633		10.1038/s41388-021-02081-0	http://dx.doi.org/10.1038/s41388-021-02081-0		NOV 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ4FN	34789839	Green Published, hybrid			2022-12-17	WOS:000719713800001
J	Jin, X; Zhang, B; Zhang, H; Yu, HX				Jin, Xin; Zhang, Bin; Zhang, Hao; Yu, Haixin			Smoking-associated upregulation of CBX3 suppresses ARHGAP24 expression to activate Rac1 signaling and promote tumor progression in lung adenocarcinoma	ONCOGENE			English	Article							PANCREATIC-CANCER; RHO-GTPASES; METHYLATION; RESISTANCE; CELLS; BRD4	Although tobacco smoking is a risk factor for lung adenocarcinoma (LUAD), the mechanisms by which tobacco smoking induces LUAD development remain elusive. Histone methylation levels in human bronchial epithelial cells have been reported to increase after exposure to cigarettes. In this study, we explored the mechanisms regulating histone methylation in LUAD in response to smoking. We found that the histone H3K9 methylation reader CBX3 was upregulated in current smokers with LUAD, and that CBX3 overexpression promoted LUAD progression. Functional enrichment analyses revealed that CBX3 regulated the activation of Rho GTPases in LUAD. We also found that by forming a complex with TRIM28, TRIM24, and RBBP4, CBX3 repressed the expression of ARHGAP24 and increased the amount of active Rac1 in LUAD cells. Collectively, these results suggest that smoking associated upregulation of CBX3 promotes LUAD progression by activating the ARHGAP24/Rac1 pathway. Hence, the CBX3/ARHGAP24/Rac1 axis may represent a promising therapeutic target in smoking-induced LUAD.	[Jin, Xin] Cent South Univ, Xiangya Hosp 2, Dept Urol, Changsha 410011, Hunan, Peoples R China; [Jin, Xin] Cent South Univ, Urooncol Inst, Changsha 410011, Hunan, Peoples R China; [Zhang, Bin; Yu, Haixin] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan 430022, Peoples R China; [Zhang, Hao] Cent South Univ, Xiangya Hosp 2, Dept Cardiovasc Surg, Changsha 410011, Hunan, Peoples R China	Central South University; Central South University; Huazhong University of Science & Technology; Central South University	Yu, HX (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan 430022, Peoples R China.; Zhang, H (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Cardiovasc Surg, Changsha 410011, Hunan, Peoples R China.	zhanghao7106@csu.edu.cn; haixin.y@outlook.com		Yu, Haixin/0000-0002-0245-2102	Chinese National Natural Science Foundation [82073321]	Chinese National Natural Science Foundation(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the Chinese National Natural Science Foundation Grant No. 82073321 (XJ).	Abe K, 2011, BIOL REPROD, V85, P1013, DOI 10.1095/biolreprod.111.091512; Alam H, 2018, CANCER RES, V78, P3834, DOI 10.1158/0008-5472.CAN-17-3571; Bid HK, 2013, MOL CANCER THER, V12, P1925, DOI 10.1158/1535-7163.MCT-13-0164; Bot C, 2017, J CELL SCI, V130, P1134, DOI 10.1242/jcs.197236; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cai HP, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03247-6; Chang C, 2018, ONCOGENE, V37, P415, DOI 10.1038/onc.2017.332; Cho EJ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091037; Fong KW, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07475-5; Glancy E, 2021, CURR OPIN STRUC BIOL, V67, P135, DOI 10.1016/j.sbi.2020.10.017; Gray JL, 2020, ANGEW CHEM INT EDIT, V59, P6342, DOI 10.1002/anie.201900585; Haga Raquel B, 2016, Small GTPases, V7, P207; He X, 2017, INT J CHRONIC OBSTR, V12, P3245, DOI 10.2147/COPD.S144881; He ZS, 2021, J CELL PHYSIOL, V236, P107, DOI 10.1002/jcp.29631; Hodge RG, 2016, NAT REV MOL CELL BIO, V17, P496, DOI 10.1038/nrm.2016.67; Huang CY, 2017, GENE DEV, V31, P241, DOI 10.1101/gad.292169.116; Itsumi M, 2013, J MOL ENDOCRINOL, V50, P401, DOI 10.1530/JME-13-0024; Jin X, 2017, CANCER RES, V77, P4328, DOI 10.1158/0008-5472.CAN-16-3143; Jin X, 2017, J BIOL CHEM, V292, P6269, DOI 10.1074/jbc.M116.764407; Johan MZ, 2019, BIOCHEM SOC T, V47, P101, DOI 10.1042/BST20180334; Kang NX, 2015, INT IMMUNOPHARMACOL, V24, P95, DOI 10.1016/j.intimp.2014.10.029; Kaur G, 2019, ARCH TOXICOL, V93, P2715, DOI 10.1007/s00204-019-02562-y; Li H, 2015, LUNG CANCER, V88, P1, DOI 10.1016/j.lungcan.2015.01.017; Lin HX, 2020, DIS MARKERS, V2020, DOI 10.1155/2020/2412741; Liu HL, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-5000; Maeda T, 2018, CANCER RES, V78, P205, DOI 10.1158/0008-5472.CAN-17-1636; Nakamura F, 2013, BIOCHEM J, V453, P17, DOI 10.1042/BJ20130290; Oyama K, 2018, EPIGENET CHROMATIN, V11, DOI 10.1186/s13072-018-0187-z; Porazinski S, 2020, ADV EXP MED BIOL, V1223, P99, DOI 10.1007/978-3-030-35582-1_6; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Saini V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041401; Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028; Singh PB, 2010, RUSS J GENET+, V46, P1257, DOI 10.1134/S1022795410100297; Stueve TR, 2017, HUM MOL GENET, V26, P3014, DOI 10.1093/hmg/ddx188; Sundar IK, 2014, J PROTEOME RES, V13, P982, DOI 10.1021/pr400998n; Svensmark JH, 2019, ONCOGENE, V38, P7447, DOI 10.1038/s41388-019-0963-7; Tcherkezian J, 2007, BIOL CELL, V99, P67, DOI 10.1042/BC20060086; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Yang C, 2020, AM J CANCER RES, V10, P523; Yang JZ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1107-y; Yu HX, 2020, CLIN EPIGENETICS, V12, DOI 10.1186/s13148-020-00872-y; Zaidan NZ, 2020, NUCLEIC ACIDS RES, V48, P12660, DOI 10.1093/nar/gkaa1091; Zhang B, 2021, MOL ONCOL, V15, P3062, DOI 10.1002/1878-0261.12955; Zhang Y, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0292-4; Zhong XP, 2019, AGING-US, V11, P5483, DOI 10.18632/aging.102132	45	4	4	3	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2022	41	4					538	549		10.1038/s41388-021-02114-8	http://dx.doi.org/10.1038/s41388-021-02114-8		NOV 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK9PJ	34785774	hybrid, Green Published			2022-12-17	WOS:000719277200003
J	Liu, XQ; Shao, XR; Liu, Y; Dong, ZX; Chan, SH; Shi, YY; Chen, SN; Qi, L; Zhong, L; Yu, Y; Lv, T; Yang, PF; Li, LY; Wang, XB; Zhang, XD; Li, X; Zhao, WX; Sehgal, L; Li, M; Zhang, XD				Liu, Xue-Qi; Shao, Xin-Rong; Liu, Ye; Dong, Zhao-Xia; Chan, Sze-Hoi; Shi, Yuan-Yuan; Chen, Shu-Na; Qi, Lin; Zhong, Li; Yu, Yue; Lv, Ting; Yang, Peng-Fei; Li, Li-Yan; Wang, Xiao-Bin; Zhang, Xu-Dong; Li, Xin; Zhao, Wenxue; Sehgal, Lalit; Li, Miao; Zhang, Xing-Ding			Tight junction protein 1 promotes vasculature remodeling via regulating USP2/TWIST1 in bladder cancer	ONCOGENE			English	Article							TUMOR ANGIOGENESIS; MESENCHYMAL TRANSITION; VASCULOGENIC MIMICRY; BREAST-CANCER; GROWTH; MACROPHAGES; METASTASIS; TWIST1; PHOSPHORYLATION; MODEL	Bladder cancer (BLCA) is the most common malignant tumor of the urinary system and is characterized by high metastatic rates and poor prognosis. The expression of tight junction protein 1 (TJP1) is associated with bladder cancer invasion; however, the mechanism by which TJP1 affects vasculature remodeling remains unknown. In this study, we found that TJP1 expression correlated with tumor angiogenesis and poor overall survival in clinical samples. Furthermore, TJP1 overexpression promoted tumor angiogenesis in BLCA cells and stimulated recruitment of macrophages to tumors by upregulating CCL2 expression. Mechanistically, TJP1 interacted with TWIST1 and enhanced the transcriptional activity of CCL2. The impairment of tumor angiogenesis caused by knockdown of TJP1 was dramatically rescued by overexpression of TWIST1. Furthermore, TJP1 recruited USP2, which deubiquitinated TWIST1, thereby protecting TWIST1 from proteasome-mediated protein degradation. In conclusion, our results suggest that TJP1 controls angiogenesis in BLCA via TWIST1-dependent regulation of CCL2. We demonstrate that TJP1 functions as a scaffold for the interaction between USP2 and TWIST1 and this may provide potential therapeutic targets in bladder cancer.	[Liu, Xue-Qi; Shao, Xin-Rong; Dong, Zhao-Xia; Chan, Sze-Hoi; Shi, Yuan-Yuan; Chen, Shu-Na; Qi, Lin; Yu, Yue; Li, Li-Yan; Zhang, Xu-Dong; Li, Xin; Zhao, Wenxue; Zhang, Xing-Ding] Sun Yat Sen Univ, Mol Canc Res Ctr, Sch Med, Shenzhen Campus Sun Yat Sen Univ, Shenzhen, Peoples R China; [Liu, Ye; Lv, Ting; Yang, Peng-Fei] Sun Yat Sen Univ, Dept Pathol, Affiliated Hosp 5, Zhuhai, Peoples R China; [Zhong, Li] Sun Yat Sen Univ, Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China; [Wang, Xiao-Bin] China Med Univ, Ctr Reprod Med, Androl Sect, Shengjing Hosp, Shenyang, Peoples R China; [Sehgal, Lalit] Ohio State Univ, Dept Internal Med, Div Hematol, Comprehens Canc Ctr, Columbus, OH USA; [Li, Miao] Shenzhen Univ, Shenzhen Second Peoples Hosp, Affiliated Hosp 1, Shenzhen, Peoples R China; [Li, Miao] Shenzhen Univ, Sch Biomed Engn, Guangdong Key Lab Biomed Measurements & Ultrasoun, Hlth Sci Ctr, Shenzhen, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; China Medical University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Second People's Hospital of Shenzhen; Shenzhen University; Shenzhen University	Zhang, XD (corresponding author), Sun Yat Sen Univ, Mol Canc Res Ctr, Sch Med, Shenzhen Campus Sun Yat Sen Univ, Shenzhen, Peoples R China.; Li, M (corresponding author), Shenzhen Univ, Shenzhen Second Peoples Hosp, Affiliated Hosp 1, Shenzhen, Peoples R China.	limiao27@mail.sysu.edu.cn; zhangxd39@mail.sysu.edu.cn	; Li, Xin/A-4137-2011	Zhong, Li/0000-0002-1646-2862; Liu, Xueqi/0000-0002-8295-032X; Li, Xin/0000-0001-8328-4894; Yang, Pengfei/0000-0001-5266-2311	National Natural Science Foundation of China [81970191, 32170789, 3210050130]; Guangdong Natural Science Foundation of China [2018A0303130090]; Shenzhen Science and Technology Innovation Commission, China [JCYJ20190807160209294, JCYJ20190807160813467]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Foundation of China(National Natural Science Foundation of Guangdong Province); Shenzhen Science and Technology Innovation Commission, China	We thank Prof. Kang (Sun Yat-sen University Cancer Center) for kindly providing T24 and 5637 bladder cancer cells and the faculty (Fifth Affiliated Hospital of Sun Yat-sen University) for collecting the clinical samples. This work was supported in part by the National Natural Science Foundation of China (grant no. 81970191; 32170789; 3210050130); supported by Guangdong Natural Science Foundation of China (grant no. 2018A0303130090); supported by Shenzhen Science and Technology Innovation Commission, China (JCYJ20190807160209294, JCYJ20190807160813467).	Anghelina M, 2004, STEM CELLS DEV, V13, P665, DOI 10.1089/scd.2004.13.665; Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; Bauer H, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/402593; Beutel O, 2019, CELL, V179, P923, DOI 10.1016/j.cell.2019.10.011; Black PC, 2007, CANCER METAST REV, V26, P623, DOI 10.1007/s10555-007-9084-9; de Iongh RU, 2005, CELLS TISSUES ORGANS, V179, P43, DOI 10.1159/000084508; Dhanasekaran R, 2020, ELIFE, V9, DOI 10.7554/eLife.50731; Flamme I, 1997, J CELL PHYSIOL, V173, P206, DOI 10.1002/(SICI)1097-4652(199711)173:2<206::AID-JCP22>3.0.CO;2-C; He JB, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1512-6; HENRY N, 1983, FEBS LETT, V161, P243, DOI 10.1016/0014-5793(83)81017-5; Hsu YL, 2017, ONCOGENE, V36, P4929, DOI 10.1038/onc.2017.105; Hu L, 2008, CANCER RES, V68, P4296, DOI 10.1158/0008-5472.CAN-08-0067; Koga M, 2008, BIOCHEM BIOPH RES CO, V365, P279, DOI 10.1016/j.bbrc.2007.10.182; Laakkonen JP, 2017, ANGIOGENESIS, V20, P109, DOI 10.1007/s10456-016-9532-7; Lee KW, 2015, CANCER RES, V75, P73, DOI 10.1158/0008-5472.CAN-14-0350; Lesage J, 2017, FASEB J, V31, P1678, DOI 10.1096/fj.201600890R; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Li CW, 2016, CANCER RES, V76, P1451, DOI 10.1158/0008-5472.CAN-15-1941; Li FT, 2020, CANCERS, V12, DOI 10.3390/cancers12061582; Li TL, 2018, ONCOL LETT, V16, P687, DOI 10.3892/ol.2018.8733; Liu XW, 2016, AM J PATHOL, V186, P2486, DOI 10.1016/j.ajpath.2016.04.018; Low-Marchelli JM, 2013, CANCER RES, V73, P662, DOI 10.1158/0008-5472.CAN-12-0653; Martin TA, 2002, J CELL PHYSIOL, V192, P268, DOI 10.1002/jcp.10133; Meng J, 2019, ONCOGENE, V38, P228, DOI 10.1038/s41388-018-0428-4; Naito S, 2016, EUR UROL, V70, P506, DOI 10.1016/j.eururo.2016.03.053; Neufeld G, 2006, CANCER METAST REV, V25, P373, DOI 10.1007/s10555-006-9011-5; Ponce M. Lourdes, 2009, V467, P183, DOI 10.1007/978-1-59745-241-0_10; Rao Q, 2016, ONCOTARGET, V7, P7842, DOI 10.18632/oncotarget.5467; Ribatti D, 2007, CANCER LETT, V248, P18, DOI 10.1016/j.canlet.2006.06.007; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Roberts CM, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3169-9; Shibuya Masabumi, 2011, Genes Cancer, V2, P1097, DOI 10.1177/1947601911423031; Singh S, 2007, CANCER METAST REV, V26, P453, DOI 10.1007/s10555-007-9068-9; Sun T, 2011, HEPATOLOGY, V54, P1690, DOI 10.1002/hep.24543; Tornavaca O, 2015, J CELL BIOL, V208, P821, DOI 10.1083/jcb.201404140; Tran LD, 2021, NAT REV CANCER, V21, P104, DOI 10.1038/s41568-020-00313-1; Tsai KW, 2018, ANTICANCER RES, V38, P4607, DOI 10.21873/anticanres.12765; Wagenblast E, 2015, NATURE, V520, P358, DOI 10.1038/nature14403; Wang SY, 2012, BREAST CANCER RES TR, V133, P1037, DOI 10.1007/s10549-011-1902-7; Wang XS, 2015, FEBS J, V282, P4376, DOI 10.1111/febs.13502; Weis SM, 2011, NAT MED, V17, P1359, DOI 10.1038/nm.2537; Witjes JA, 2014, EUR UROL, V65, P778, DOI 10.1016/j.eururo.2013.11.046; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Yang WH, 2016, ONCOGENE, V35, P2287, DOI 10.1038/onc.2015.291; Yang Z, 2020, CANCER LETT, V473, P118, DOI 10.1016/j.canlet.2019.12.018; Zhao YJ, 2015, ONCOLOGIST, V20, P660, DOI 10.1634/theoncologist.2014-0465; Zhao ZX, 2017, ONCOTARGET, V8, P20380, DOI 10.18632/oncotarget.14608; Zhou L, 2016, ONCOTARGET, V7, P76214, DOI 10.18632/oncotarget.12775	49	4	4	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2022	41	4					502	514		10.1038/s41388-021-02112-w	http://dx.doi.org/10.1038/s41388-021-02112-w		NOV 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK9PJ	34782718				2022-12-17	WOS:000718778400002
J	Hao, XH; Bu, WQ; Lv, GS; Xu, LM; Hou, D; Wang, J; Liu, XJ; Yang, TT; Zhang, XY; Liu, Q; Gong, YQ; Shao, CS				Hao, Xiaohe; Bu, Wenqing; Lv, Guosheng; Xu, Limei; Hou, Dong; Wang, Jing; Liu, Xiaojie; Yang, Tingting; Zhang, Xiyu; Liu, Qiao; Gong, Yaoqin; Shao, Changshun			Disrupted mitochondrial homeostasis coupled with mitotic arrest generates antineoplastic oxidative stress	ONCOGENE			English	Article							CHECKPOINT KINASE 1; DNA-DAMAGE; CELL-CYCLE; CANCER-CELLS; CHK1; RESPIRATION; BIOGENESIS; METABOLISM; RESISTANCE; INHIBITION	Reactive oxygen species (ROS) serve as critical signals in various cellular processes. Excessive ROS cause cell death or senescence and mediates the therapeutic effect of many cancer drugs. Recent studies showed that ROS increasingly accumulate during G2/M arrest, the underlying mechanism, however, has not been fully elucidated. Here, we show that in cancer cells treated with anticancer agent TH287 or paclitaxel that causes M arrest, mitochondria accumulate robustly and produce excessive mitochondrial superoxide, which causes oxidative DNA damage and undermines cell survival and proliferation. While mitochondrial mass is greatly increased in cells arrested at M phase, the mitochondrial function is compromised, as reflected by reduced mitochondrial membrane potential, increased SUMOylation and acetylation of mitochondrial proteins, as well as an increased metabolic reliance on glycolysis. CHK1 functional disruption decelerates cell cycle, spares the M arrest and attenuates mitochondrial oxidative stress. Induction of mitophagy and blockade of mitochondrial biogenesis, measures that reduce mitochondrial accumulation, also decelerate cell cycle and abrogate M arrest-coupled mitochondrial oxidative stress. These results suggest that cell cycle progression and mitochondrial homeostasis are interdependent and coordinated, and that impairment of mitochondrial homeostasis and the associated redox signaling may mediate the antineoplastic effect of the M arrest-inducing chemotherapeutics. Our findings provide insights into the fate of cells arrested at M phase and have implications in cancer therapy.	[Hao, Xiaohe; Lv, Guosheng; Xu, Limei; Hou, Dong; Wang, Jing; Zhang, Xiyu; Liu, Qiao; Gong, Yaoqin; Shao, Changshun] Shandong Univ, Sch Basic Med Sci, Dept Genet, MOE Key Lab Expt Teratol, Jinan 250012, Shandong, Peoples R China; [Bu, Wenqing; Liu, Xiaojie; Yang, Tingting; Shao, Changshun] Soochow Univ, Inst Translat Med, State Key Lab Radiat Med & Protect, Suzhou 215123, Jiangsu, Peoples R China	Shandong University; Soochow University - China	Shao, CS (corresponding author), Shandong Univ, Sch Basic Med Sci, Dept Genet, MOE Key Lab Expt Teratol, Jinan 250012, Shandong, Peoples R China.; Shao, CS (corresponding author), Soochow Univ, Inst Translat Med, State Key Lab Radiat Med & Protect, Suzhou 215123, Jiangsu, Peoples R China.	shaoc@suda.edu.cn	Shao, Changshun/AAD-8977-2022	Shao, Changshun/0000-0003-2618-9342	National Natural Science Foundation of China [31771260, 81572785, 81372241]; State Key Laboratory of Radiation Medicine and Protection, Soochow University [GZN1201804]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); State Key Laboratory of Radiation Medicine and Protection, Soochow University	We thank Dr. Weihang Chai for critically reading and commenting on the manuscript. This study was supported by National Natural Science Foundation of China (31771260, 81572785 and 81372241), and the State Key Laboratory of Radiation Medicine and Protection, Soochow University (GZN1201804).	Busby EC, 2000, CANCER RES, V60, P2108; Carrassa L, 2009, J CELL MOL MED, V13, P1565, DOI [10.1111/j.1582-4934.2008.00362.x, 10.1111/j.1582-4934.2009.00362.x]; Chen C, 2008, J EXP MED, V205, P2397, DOI 10.1084/jem.20081297; Correia-Melo C, 2016, EMBO J, V35, P724, DOI 10.15252/embj.201592862; Dai Y, 2010, CLIN CANCER RES, V16, P376, DOI 10.1158/1078-0432.CCR-09-1029; Daud AI, 2015, J CLIN ONCOL, V33, P1060, DOI 10.1200/JCO.2014.57.5027; Dhimolea E, 2021, CANCER CELL, V39, P240, DOI 10.1016/j.ccell.2020.12.002; Fishler T, 2010, ONCOGENE, V29, P4007, DOI 10.1038/onc.2010.163; Fu XA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002009; Fujikawa K, 1999, J BIOL CHEM, V274, P18201, DOI 10.1074/jbc.274.26.18201; Funakoshi T, 2019, NEUROTOXICOLOGY, V75, P70, DOI 10.1016/j.neuro.2019.09.001; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gad H, 2014, NATURE, V508, P215, DOI 10.1038/nature13181; Glasauer A, 2014, BIOCHEM PHARMACOL, V92, P90, DOI 10.1016/j.bcp.2014.07.017; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Gul N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51205-w; Harbauer AB, 2014, SCIENCE, V346, P1109, DOI 10.1126/science.1261253; Havens CG, 2006, MOL CELL BIOL, V26, P4701, DOI 10.1128/MCB.00303-06; Hayes JD, 2020, CANCER CELL, V38, P167, DOI 10.1016/j.ccell.2020.06.001; Hou D, 2018, REDOX BIOL, V17, P99, DOI 10.1016/j.redox.2018.03.016; Kawamura T, 2016, SCI REP-UK, V6, DOI 10.1038/srep26521; Leach JK, 2001, CANCER RES, V61, P3894; Liu EY, 2015, P NATL ACAD SCI USA, V112, P773, DOI 10.1073/pnas.1409563112; Liu QH, 2000, GENE DEV, V14, P1448; Ma CX, 2012, J CLIN INVEST, V122, P1541, DOI 10.1172/JCI58765; Macip S, 2006, ONCOGENE, V25, P6037, DOI 10.1038/sj.onc.1209629; Manic G, 2018, GUT, V67, P903, DOI 10.1136/gutjnl-2016-312623; Marcar L, 2019, CELL REP, V27, P3422, DOI 10.1016/j.celrep.2019.05.058; Matassa DS, 2016, CELL DEATH DIFFER, V23, P1542, DOI 10.1038/cdd.2016.39; Myers K, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000324; Parmar K, 2019, CLIN CANCER RES, V25, P6127, DOI 10.1158/1078-0432.CCR-19-0448; Patterson JC, 2019, CELL SYST, V9, P74, DOI 10.1016/j.cels.2019.05.009; Patterson JC, 2019, CELL SYST, V8, P163, DOI 10.1016/j.cels.2019.01.005; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Pfanner N, 2019, NAT REV MOL CELL BIO, V20, P267, DOI 10.1038/s41580-018-0092-0; POSAKONY JW, 1977, J CELL BIOL, V74, P468, DOI 10.1083/jcb.74.2.468; Qian X, 2019, MOL CELL, V76, P885, DOI 10.1016/j.molcel.2019.09.019; Rehman SK, 2021, CELL, V184, P226, DOI 10.1016/j.cell.2020.11.018; Rudd SG, 2020, CANCER RES, V80, P3530, DOI 10.1158/0008-5472.CAN-19-0883; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Schwer B, 2006, P NATL ACAD SCI USA, V103, P10224, DOI 10.1073/pnas.0603968103; Schwer B, 2009, AGING CELL, V8, P604, DOI 10.1111/j.1474-9726.2009.00503.x; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Summer R, 2019, AM J PHYSIOL-LUNG C, V316, pL1049, DOI 10.1152/ajplung.00244.2018; Takai H, 2000, GENE DEV, V14, P1439; Tong LY, 2015, CANCER LETT, V367, P18, DOI 10.1016/j.canlet.2015.07.008; Tsai WB, 2008, NAT CELL BIOL, V10, P460, DOI 10.1038/ncb1709; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Wang TS, 2019, MOL CELL, V75, P823, DOI 10.1016/j.molcel.2019.06.008; Wang ZQ, 2014, DEV CELL, V29, P217, DOI 10.1016/j.devcel.2014.03.012; Willis J, 2013, P NATL ACAD SCI USA, V110, P10592, DOI 10.1073/pnas.1301445110; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Xu B, 2014, MUTAT RES-FUND MOL M, V770, P1, DOI 10.1016/j.mrfmmm.2014.08.004; Xu LM, 2020, REDOX BIOL, V36, DOI 10.1016/j.redox.2020.101604; Yamamori T, 2012, FREE RADICAL BIO MED, V53, P260, DOI 10.1016/j.freeradbiomed.2012.04.033; Yu D, 2020, P NATL ACAD SCI USA, V117, P9964, DOI 10.1073/pnas.1913633117; Zachos G, 2007, DEV CELL, V12, P247, DOI 10.1016/j.devcel.2007.01.003; Zasadil LM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007965; Zhang YW, 2014, INT J CANCER, V134, P1013, DOI 10.1002/ijc.28226; Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689	63	4	4	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2022	41	3					427	443		10.1038/s41388-021-02105-9	http://dx.doi.org/10.1038/s41388-021-02105-9		NOV 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YF8LK	34773075	Green Published, hybrid			2022-12-17	WOS:000717915200002
J	Arai, H; Elliott, A; Millstein, J; Xiu, J; Ou, FS; Innocenti, F; Wang, JY; Battaglin, F; Jayachandran, P; Kawanishi, N; Soni, S; Zhang, W; Sohal, D; Goldberg, RM; Hall, MJ; Scott, AJ; Khushman, M; Hwang, JJ; Lou, E; Weinberg, BA; Lockhart, AC; Shields, AF; Abraham, JP; Magee, D; Stafford, P; Zhang, J; Venook, AP; Korn, WM; Lenz, HJ				Arai, Hiroyuki; Elliott, Andrew; Millstein, Joshua; Xiu, Joanne; Ou, Fang-Shu; Innocenti, Federico; Wang, Jingyuan; Battaglin, Francesca; Jayachandran, Priya; Kawanishi, Natsuko; Soni, Shivani; Zhang, Wu; Sohal, Davendra; Goldberg, Richard M.; Hall, Michael J.; Scott, Aaron J.; Khushman, Mohd; Hwang, Jimmy J.; Lou, Emil; Weinberg, Benjamin A.; Lockhart, Albert Craig; Shields, Anthony Frank; Abraham, Jim P.; Magee, Daniel; Stafford, Phillip; Zhang, Jian; Venook, Alan P.; Korn, W. Michael; Lenz, Heinz-Josef			Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer	ONCOGENE			English	Article							EGFR INHIBITION; RESISTANCE; ACTIVATION; LANDSCAPE; CETUXIMAB; PATHWAY	Loss-of-function alterations of Neurofibromin 1 (NF1) activate RAS, a driver of colorectal cancer. However, the clinical implications of NF1 alterations are largely unknown. We performed a comprehensive molecular profiling of NF1-mutant colorectal cancer using data from 8150 patients included in a dataset of commercial CLIA-certified laboratory (Caris Life Sciences). In addition, NF1 expression levels were tested for associations with clinical outcomes using data from 431 patients in the CALGB/SWOG 80405 trial. In the Caris dataset, 2.2% of patients had pathogenic or presumed pathogenic NF1 mutations. NF1-mutant tumors more frequently harbored PIK3CA (25.0% vs. 16.7%) and PTEN mutations (24.0% vs. 4.2%) than wild type tumors. Gene set enrichment analysis revealed that MAPK and PI3K pathway signatures were enriched in NF1-mutant tumors. In the CALGB/SWOG 80405 cohort, low NF1 expression was associated with poor prognosis, and high NF1 expression was associated with better efficacy of cetuximab than bevacizumab. Together, we revealed concurrent genetic alterations in the PI3K pathways in NF1-mutant tumors, suggesting the need to simultaneously block MAPK and PI3K pathways in treatment. The potential of NF1 alteration as a novel biomarker for targeted therapy was highlighted, warranting further investigations in clinical settings.	[Arai, Hiroyuki; Wang, Jingyuan; Battaglin, Francesca; Jayachandran, Priya; Kawanishi, Natsuko; Soni, Shivani; Zhang, Wu; Lenz, Heinz-Josef] Univ Southern Calif, Div Med Oncol, Norris Comprehens Canc Ctr, Los Angeles, CA 90007 USA; [Elliott, Andrew; Xiu, Joanne; Abraham, Jim P.; Magee, Daniel; Stafford, Phillip; Zhang, Jian; Korn, W. Michael] Caris Life Sci, Med Affairs, Clin & Translat Res, Phoenix, AZ USA; [Millstein, Joshua] Univ Southern Calif, Dept Prevent Med, Norris Comprehens Canc Ctr, Los Angeles, CA 90007 USA; [Ou, Fang-Shu] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA; [Innocenti, Federico] Univ N Carolina, UNC Eshelman Sch Pharm, Chapel Hill, NC 27515 USA; [Sohal, Davendra] Univ Cincinnati, Div Hematol Oncol, Cincinnati, OH USA; [Goldberg, Richard M.] West Virginia Univ, Canc Inst, Morgantown, WV 26506 USA; [Hall, Michael J.] Fox Chase Canc Ctr, Dept Clin Genet, Philadelphia, PA 19111 USA; [Scott, Aaron J.] Banner Univ Arizona, Dept Med, Div Hematol & Oncol, Tucson, AZ USA; [Khushman, Mohd] Univ S Alabama, Mitchell Canc Inst, Med Oncol, Mobile, AL 36688 USA; [Hwang, Jimmy J.] Levine Canc Inst, GI Med Oncol, Dept Solid Tumor Oncol, Charlotte, NC USA; [Lou, Emil] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN USA; [Weinberg, Benjamin A.] Georgetown Univ, Lombardi Comprehens Canc Ctr, Ruesch Ctr Cure Gastrointestinal Canc, Washington, DC USA; [Lockhart, Albert Craig] Univ Miami, Miller Sch Med, Dept Med, Div Oncol, Miami, FL 33136 USA; [Shields, Anthony Frank] Wayne State Univ, Karmanos Canc Inst, Dept Oncol, Detroit, MI USA; [Venook, Alan P.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA	University of Southern California; University of Southern California; Mayo Clinic; University of North Carolina; University of North Carolina Chapel Hill; University System of Ohio; University of Cincinnati; West Virginia University; Fox Chase Cancer Center; University of Arizona; University of South Alabama; University of Minnesota System; University of Minnesota Twin Cities; Georgetown University; University of Miami; Barbara Ann Karmanos Cancer Institute; Wayne State University; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Lenz, HJ (corresponding author), Univ Southern Calif, Div Med Oncol, Norris Comprehens Canc Ctr, Los Angeles, CA 90007 USA.	lenz@usc.edu	Battaglin, Francesca/C-2746-2017	Battaglin, Francesca/0000-0002-9869-0163; Arai, Hiroyuki/0000-0002-1886-7070	National Cancer Institute of the National Institutes of Health [U10CA180821, U10CA180882, UG1CA233163, P30CA 014089]; Gloria Borges WunderGlo Foundation; Dhont Family Foundation; Victoria and Philip Wilson Research Fund; San Pedro Peninsula Cancer Guild; Daniel Butler Research Fund; Bristol-Myers Squibb; Genentech; Pfizer	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Gloria Borges WunderGlo Foundation; Dhont Family Foundation; Victoria and Philip Wilson Research Fund; San Pedro Peninsula Cancer Guild; Daniel Butler Research Fund; Bristol-Myers Squibb(Bristol-Myers Squibb); Genentech(Roche HoldingGenentech); Pfizer(Pfizer)	We thank all patients who contributed to this study. Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821 and U10CA180882 (to the Alliance for Clinical Trials in Oncology), UG1CA233163, P30CA 014089 [to H-JL], Gloria Borges WunderGlo Foundation, Dhont Family Foundation, Victoria and Philip Wilson Research Fund, San Pedro Peninsula Cancer Guild, and Daniel Butler Research Fund. Also supported in part by funds from Bristol-Myers Squibb, Genentech, and Pfizer. tThe content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310; Arai H, 2021, CLIN CANCER RES, V27, P3234, DOI 10.1158/1078-0432.CCR-20-3635; Bertotti A, 2015, NATURE, V526, P263, DOI 10.1038/nature14969; Campbell BB, 2017, CELL, V171, P1042, DOI 10.1016/j.cell.2017.09.048; de Bruin EC, 2014, CANCER DISCOV, V4, P606, DOI 10.1158/2159-8290.CD-13-0741; Diez D, 2011, NUCLEIC ACIDS RES, V39, P5526, DOI 10.1093/nar/gkr154; Georgiou A, 2020, MOL CANCER RES, V18, P835, DOI 10.1158/1541-7786.MCR-19-1201; Kumagai Shogo, 2021, Nat Rev Cancer, V21, P181, DOI 10.1038/s41568-020-00322-0; Loi S, 2016, CLIN CANCER RES, V22, P1499, DOI 10.1158/1078-0432.CCR-15-1125; Maertens O, 2014, CANCER DISCOV, V4, P519, DOI 10.1158/2159-8290.CD-14-0286; Magnuson AM, 2018, P NATL ACAD SCI USA, V115, pE10672, DOI 10.1073/pnas.1810580115; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Mauri G, 2020, ANN ONCOL, V31, P1135, DOI 10.1016/j.annonc.2020.05.027; Moore AR, 2020, NAT REV DRUG DISCOV, V19, P533, DOI 10.1038/s41573-020-0068-6; Post Jasmin B, 2019, Oncotarget, V10, P1440, DOI 10.18632/oncotarget.26677; Price TJ, 2014, LANCET ONCOL, V15, P569, DOI 10.1016/S1470-2045(14)70118-4; Rad E, 2016, SEMIN CELL DEV BIOL, V52, P39, DOI 10.1016/j.semcdb.2016.02.007; Riaz N, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00921-w; Sepulveda AR, 2017, J CLIN ONCOL, V35, P1453, DOI 10.1200/JCO.2016.71.9807; Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235; Vanderwalde A, 2018, CANCER MED-US, V7, P746, DOI 10.1002/cam4.1372; Venook AP, 2017, JAMA-J AM MED ASSOC, V317, P2392, DOI 10.1001/jama.2017.7105; Vidotto T, 2020, BRIT J CANCER, V122, P1732, DOI 10.1038/s41416-020-0834-6; Wagle MC, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0051-4; Woolston A, 2019, CANCER CELL, V36, P35, DOI 10.1016/j.ccell.2019.05.013	25	4	4	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2022	41	2					260	267		10.1038/s41388-021-02074-z	http://dx.doi.org/10.1038/s41388-021-02074-z		NOV 2021	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC1XK	34728807	Green Accepted			2022-12-17	WOS:000713936100002
J	Liu, WX; Gou, HY; Wang, XH; Li, XM; Hu, XX; Su, H; Li, SM; Yu, J				Liu, Wenxiu; Gou, Hongyan; Wang, Xiaohong; Li, Xiaoming; Hu, Xiaoxu; Su, Hao; Li, Shengmian; Yu, Jun			TTPAL promotes gastric tumorigenesis by directly targeting NNMT to activate PI3K/AKT signaling	ONCOGENE			English	Article							CANCER	Copy number alterations are crucial for gastric cancer (GC) development. In this study, Tocopherol alpha transfer protein-like (TTPAL) was identified to be highly amplified in our primary GC cohort (30/86). Multivariate analysis showed that high TTPAL expression was correlated with the poor prognosis of GC patients. Ectopic expression of TTPAL promoted GC cell proliferation, migration, and invasion in vitro and promoted murine xenograft tumor growth and lung metastasis in vivo. Conversely, silencing of TTPAL exerted significantly opposite effects in vitro. Moreover, RNA-sequencing and co-immunoprecipitation (Co-IP) followed by liquid chromatograph-mass spectrometry (LC-MS) identified that TTPAL exerted oncogenic functions via the interaction of Nicotinamide-N-methyl transferase (NNMT) and activated PI3K/AKT signaling pathway. Collectively, TTPAL plays a pivotal oncogenic role in gastric carcinogenesis through promoting PI3K/AKT pathway via cooperating with NNMT. TTPAL may serve as a prognostic biomarker of patients with GC.	[Liu, Wenxiu; Gou, Hongyan; Wang, Xiaohong; Hu, Xiaoxu; Su, Hao; Yu, Jun] Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China; [Liu, Wenxiu; Li, Xiaoming; Li, Shengmian] Hebei Med Univ, Dept Gastroenterol & Hepatol, Hosp 4, Shijiazhuang, Hebei, Peoples R China; [Gou, Hongyan; Yu, Jun] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Hong Kong, Peoples R China; [Gou, Hongyan; Yu, Jun] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut, State Key Lab Digest Dis, Hong Kong, Peoples R China	Chinese University of Hong Kong, Shenzhen; Hebei Medical University; Chinese University of Hong Kong; Chinese University of Hong Kong	Yu, J (corresponding author), Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China.; Li, SM (corresponding author), Hebei Med Univ, Dept Gastroenterol & Hepatol, Hosp 4, Shijiazhuang, Hebei, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut, State Key Lab Digest Dis, Hong Kong, Peoples R China.	shengmianli2013@163.com; junyu@cuhk.edu.hk	Jun, Yu/D-8569-2015	Jun, Yu/0000-0001-5008-2153	Science and Technology Program Grant Shenzhen [JCYJ20 180307151253271, JCY20190814170401660]; RGC Collaborative Research Fund [C4039-19GF, C7065-18GF]; Hebei province's special fund for introducing intelligence project [2527005]; RGC-GRF Hong Kong [14163817]; Natural Science Foundation of Guangdong Province [2019A1515011218]; Vice-Chancellor's Discretionary Fund Chinese University of Hong Kong	Science and Technology Program Grant Shenzhen; RGC Collaborative Research Fund(Hong Kong Research Grants Council); Hebei province's special fund for introducing intelligence project; RGC-GRF Hong Kong(Hong Kong Research Grants Council); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Vice-Chancellor's Discretionary Fund Chinese University of Hong Kong	Science and Technology Program Grant Shenzhen (JCYJ20 180307151253271 and JCY20190814170401660); RGC Collaborative Research Fund (C4039-19GF, C7065-18GF), Hebei province's special fund for introducing intelligence project (2527005); RGC-GRF Hong Kong (14163817); Natural Science Foundation of Guangdong Province (2019A1515011218). Vice-Chancellor's Discretionary Fund Chinese University of Hong Kong.	Akar S, 2019, TURK J MED SCI, V49, P1547, DOI 10.3906/sag-1907-166; Asplund J, 2018, ANN SURG ONCOL, V25, P2693, DOI 10.1245/s10434-018-6627-y; Belletti B, 2015, AGING-US, V7, P529, DOI 10.18632/aging.100786; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Calderwood SK, 2016, TRENDS BIOCHEM SCI, V41, P311, DOI 10.1016/j.tibs.2016.01.003; Cao HY, 2020, EUR REV MED PHARMACO, V24, P11468, DOI [10.26355/eurrev_202011_23761, 10.26355/eurrev_202011_23759]; Chen HR, 2019, THERANOSTICS, V9, P5246, DOI 10.7150/thno.34713; Chivu-Economescu M, 2018, WORLD J GASTROENTERO, V24, P1942, DOI 10.3748/wjg.v24.i18.1942; Della Peruta M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-61; Fatima V, 2020, CANCERS, V12, P880; Fu QF, 2017, CLIN CANCER RES, V23, P6336, DOI 10.1158/1078-0432.CCR-16-2813; Gou HY, 2019, CANCER RES, V79, P3332, DOI 10.1158/0008-5472.CAN-18-2986; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Jahn T, 2002, MOL CELL BIOL, V22, P979, DOI 10.1128/MCB.22.4.979-991.2002; Kimura Y, 2004, MODERN PATHOL, V17, P1328, DOI 10.1038/modpathol.3800180; Palanichamy K, 2017, CLIN CANCER RES, V23, P2325, DOI 10.1158/1078-0432.CCR-16-1323; Pentimalli F, 2018, ONCOGENE, V37, P3657, DOI 10.1038/s41388-018-0214-3; Qiao JL, 2016, ONCOTARGET, V7, P46088, DOI 10.18632/oncotarget.10024; Qin J, 2012, CURR OPIN CELL BIOL, V24, P607, DOI 10.1016/j.ceb.2012.06.003; Tang JT, 2018, ONCOGENE, V37, P3006, DOI 10.1038/s41388-018-0196-1; Zhang L, 2019, ONCOGENE, V38, P4590, DOI 10.1038/s41388-019-0743-4	21	4	4	2	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2021	40	49					6666	6679		10.1038/s41388-021-01838-x	http://dx.doi.org/10.1038/s41388-021-01838-x		OCT 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM1GJ	34642500	Green Published, hybrid			2022-12-17	WOS:000706593200002
J	Roukens, MG; Frederiks, CL; Seinstra, D; Braccioli, L; Khalil, AA; Pals, C; De Neck, S; Bornes, L; Beerling, E; Mokry, M; de Bruin, A; Westendorp, B; van Rheenen, J; Coffer, PJ				Roukens, M. Guy; Frederiks, Cynthia L.; Seinstra, Danielle; Braccioli, Luca; Khalil, Antoine A.; Pals, Cornelieke; De Neck, Simon; Bornes, Laura; Beerling, Evelyne; Mokry, Michal; de Bruin, Alain; Westendorp, Bart; van Rheenen, Jacco; Coffer, Paul J.			Regulation of a progenitor gene program by SOX4 is essential for mammary tumor proliferation	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER METASTASIS; ENRICHMENT ANALYSIS; EXPRESSION; REVEALS; CELLS; COLONIZATION; POPULATION; PLASTICITY; REQUIRES	In breast cancer the transcription factor SOX4 has been shown to be associated with poor survival, increased tumor size and metastasis formation. This has mostly been attributed to the ability of SOX4 to regulate Epithelial-to-Mesenchymal-Transition (EMT). However, SOX4 regulates target gene transcription in a context-dependent manner that is determined by the cellular and epigenetic state. In this study we have investigated the loss of SOX4 in mammary tumor development utilizing organoids derived from a PyMT genetic mouse model of breast cancer. Using CRISPR/Cas9 to abrogate SOX4 expression, we found that SOX4 is required for inhibiting differentiation by regulating a subset of genes that are highly activated in fetal mammary stem cells (fMaSC). In this way, SOX4 re-activates an oncogenic transcriptional program that is regulated in many progenitor cell-types during embryonic development. SOX4-knockout organoids are characterized by the presence of more differentiated cells that exhibit luminal or basal gene expression patterns, but lower expression of cell cycle genes. In agreement, primary tumor growth and metastatic outgrowth in the lungs are impaired in SOX4(KO) tumors. Finally, SOX4(KO) tumors show a severe loss in competitive capacity to grow out compared to SOX4-proficient cells in primary tumors. Our study identifies a novel role for SOX4 in maintaining mammary tumors in an undifferentiated and proliferative state. Therapeutic manipulation of SOX4 function could provide a novel strategy for cancer differentiation therapy, which would promote differentiation and inhibit cycling of tumor cells.	[Roukens, M. Guy; Frederiks, Cynthia L.; Braccioli, Luca; Pals, Cornelieke; Coffer, Paul J.] Univ Med Ctr Utrecht, Regenerat Med Ctr Utrecht, Utrecht, Netherlands; [Roukens, M. Guy; Frederiks, Cynthia L.; Braccioli, Luca; Khalil, Antoine A.; Pals, Cornelieke; Coffer, Paul J.] Univ Med Ctr Utrecht, Ctr Mol Med Utrecht, Utrecht, Netherlands; [Seinstra, Danielle; Bornes, Laura; Beerling, Evelyne; van Rheenen, Jacco] Netherlands Canc Inst, Oncode Inst, Dept Mol Pathol, Amsterdam, Netherlands; [De Neck, Simon; de Bruin, Alain; Westendorp, Bart] Univ Utrecht, Fac Vet Med, Dept Biomol Hlth Sci, Utrecht, Netherlands; [De Neck, Simon; de Bruin, Alain] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, Groningen, Netherlands; [Mokry, Michal] Univ Med Ctr Utrecht, Lab Expt Cardiol, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Netherlands Cancer Institute; Utrecht University; University of Groningen; Utrecht University; Utrecht University Medical Center	Roukens, MG; Coffer, PJ (corresponding author), Univ Med Ctr Utrecht, Regenerat Med Ctr Utrecht, Utrecht, Netherlands.; Roukens, MG; Coffer, PJ (corresponding author), Univ Med Ctr Utrecht, Ctr Mol Med Utrecht, Utrecht, Netherlands.	m.g.roukens2@umcutrecht.nl; pcoffer@umcutrecht.nl		Khalil, Antoine A./0000-0003-3469-0778; Westendorp, Bart/0000-0003-1043-3638; Roukens, Guy/0000-0002-4270-8678; Mokry, Michal/0000-0002-5298-4852; de Bruin, Alain/0000-0001-8579-2649; Bornes, Laura/0000-0001-9721-1223				Aiello NM, 2016, DIS MODEL MECH, V9, P105, DOI 10.1242/dmm.023184; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Beerling E, 2016, CELL REP, V14, P2281, DOI 10.1016/j.celrep.2016.02.034; Bornes L, 2019, CELL REP, V29, P2565, DOI 10.1016/j.celrep.2019.10.107; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Braccioli L, 2018, STEM CELL RES, V33, P110, DOI 10.1016/j.scr.2018.10.005; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dravis C, 2018, CANCER CELL, V34, P466, DOI 10.1016/j.ccell.2018.08.001; Driessens G, 2012, NATURE, V488, P527, DOI 10.1038/nature11344; Elso CM, 2004, GENES IMMUN, V5, P93, DOI 10.1038/sj.gene.6364042; Foronda M, 2014, CELL REP, V8, P486, DOI 10.1016/j.celrep.2014.06.031; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giraddi RR, 2018, CELL REP, V24, P1653, DOI 10.1016/j.celrep.2018.07.025; Gracz AD, 2018, GASTROENTEROLOGY, V155, P1508, DOI 10.1053/j.gastro.2018.07.023; Jechlinger M, 2003, ONCOGENE, V22, P7155, DOI 10.1038/sj.onc.1206887; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Pfefferle AD, 2015, BREAST CANCER RES TR, V149, P425, DOI 10.1007/s10549-014-3262-6; Schepers AG, 2012, SCIENCE, V337, P730, DOI 10.1126/science.1224676; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; Shimokawa M, 2017, NATURE, V545, P187, DOI 10.1038/nature22081; Spike BT, 2012, CELL STEM CELL, V10, P183, DOI 10.1016/j.stem.2011.12.018; Stankic M, 2013, CELL REP, V5, P1228, DOI 10.1016/j.celrep.2013.11.014; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Vervoort SJ, 2013, ONCOGENE, V32, P3397, DOI 10.1038/onc.2012.506; Vervoort SJ, 2018, ELIFE, V7, DOI 10.7554/eLife.27706; Vervoort SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053238; Wahl GM, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0012-z; Ye X, 2015, TRENDS CELL BIOL, V25, P675, DOI 10.1016/j.tcb.2015.07.012; Zhang H., 2014, BLOOD, V124, P1577, DOI DOI 10.1182/BLOOD.V124.21.1577.1577; Zhang H, 2013, CANCER CELL, V24, P575, DOI 10.1016/j.ccr.2013.09.018; Zhang JC, 2012, CANCER RES, V72, P4597, DOI 10.1158/0008-5472.CAN-12-1045	44	4	4	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2021	40	45					6343	6353		10.1038/s41388-021-02004-z	http://dx.doi.org/10.1038/s41388-021-02004-z		SEP 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW1BA	34584219	Green Published, hybrid			2022-12-17	WOS:000701638300002
J	Vafaizadeh, V; Buechel, D; Rubinstein, N; Kalathur, RKR; Bazzani, L; Saxena, M; Valenta, T; Hausmann, G; Cantu, C; Basler, K; Christofori, G				Vafaizadeh, Vida; Buechel, David; Rubinstein, Natalia; Kalathur, Ravi K. R.; Bazzani, Lorenzo; Saxena, Meera; Valenta, Tomas; Hausmann, George; Cantu, Claudio; Basler, Konrad; Christofori, Gerhard			The interactions of Bcl9/Bcl9L with beta-catenin and Pygopus promote breast cancer growth, invasion, and metastasis	ONCOGENE			English	Article							EXPRESSION; CELLS; GENE; INACTIVATION; TRANSITION; ONCOGENE; DELETION; BCL9-2; MODEL; B9L	Canonical Wnt/beta-catenin signaling is an established regulator of cellular state and its critical contributions to tumor initiation, malignant tumor progression and metastasis formation have been demonstrated in various cancer types. Here, we investigated how the binding of beta-catenin to the transcriptional coactivators B-cell CLL/lymphoma 9 (Bcl9) and Bcl9-Like (Bcl9L) affected mammary gland carcinogenesis in the MMTV-PyMT transgenic mouse model of metastatic breast cancer. Conditional knockout of both Bcl9 and Bcl9L resulted into tumor cell death. In contrast, disrupting the interaction of Bcl9/Bcl9L with beta-catenin, either by deletion of their HD2 domains or by a point mutation in the N-terminal domain of beta-catenin (D164A), diminished primary tumor growth and tumor cell proliferation and reduced tumor cell invasion and lung metastasis. In comparison, the disruption of HD1 domain-mediated binding of Bcl9/Bcl9L to Pygopus had only moderate effects. Interestingly, interfering with the beta-catenin-Bcl9/Bcl9L-Pygo chain of adapters only partially impaired the transcriptional response of mammary tumor cells to Wnt3a and TGF beta treatments. Together, the results indicate that Bcl9/Bcl9L modulate but are not critically required for canonical Wnt signaling in its contribution to breast cancer growth and malignant progression, a notion consistent with the "just-right" hypothesis of Wnt-driven tumor progression.	[Vafaizadeh, Vida; Buechel, David; Kalathur, Ravi K. R.; Bazzani, Lorenzo; Saxena, Meera; Christofori, Gerhard] Univ Basel, Dept Biomed, Basel, Switzerland; [Rubinstein, Natalia] Univ Buenos Aires, Inst Biociencias Biotecnol & Biol Traslac, Dept Fisiol Biol Mol & Celular, Fac Ciencias Exactas & Nat, Buenos Aires, DF, Argentina; [Kalathur, Ravi K. R.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Bazzani, Lorenzo] Univ Siena, Dept Life Sci, Siena, Italy; [Valenta, Tomas; Hausmann, George; Basler, Konrad] Univ Zurich, Dept Mol Life Sci, Zurich, Switzerland; [Cantu, Claudio] Linkoping Univ, Wallenberg Ctr Mol Med, Linkoping, Sweden; [Cantu, Claudio] Linkoping Univ, Fac Med & Hlth Sci, Dept Biomed & Clin Sci, Div Mol Med & Virol, Linkoping, Sweden	University of Basel; University of Buenos Aires; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Siena; University of Zurich; Linkoping University; Linkoping University	Vafaizadeh, V; Christofori, G (corresponding author), Univ Basel, Dept Biomed, Basel, Switzerland.	vidavafaizadeh@gmail.com; gerhard.christofori@unibas.ch		Rubinstein, Natalia/0000-0002-5690-1516; Hausmann, George/0000-0002-2146-6665; Cantu, Claudio/0000-0003-1547-5415; Vafaizadeh, Vida/0000-0002-0875-6246	SystemsX.ch MTD project MetastasiX [2014/268]; Swiss National Science Foundation [310030B_163471]; Swiss National Science Foundation Sinergia [CRSII3_136274]; Knut and Alice Wallenberg Foundation; Cancerfonden [CAN 2018/542]; Universitat Basel (Universitatsbibliothek Basel)	SystemsX.ch MTD project MetastasiX; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss National Science Foundation Sinergia(Swiss National Science Foundation (SNSF)); Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Cancerfonden(Swedish Cancer Society); Universitat Basel (Universitatsbibliothek Basel)	We acknowledge funding for this work by the SystemsX.ch MTD project MetastasiX (2014/268), a project grant by the Swiss National Science Foundation (310030B_163471), and the Swiss National Science Foundation Sinergia grant CRSII3_136274. CC is a WCMM fellow supported by the Knut and Alice Wallenberg Foundation and by Cancerfonden (CAN 2018/542). Open Access funding provided by Universitat Basel (Universitatsbibliothek Basel).	Andrews PGP, 2018, CELL REP, V23, P1516, DOI 10.1016/j.celrep.2018.04.020; Borrelli C, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21591-9; Brault V, 2001, DEVELOPMENT, V128, P1253; Cantu C, 2018, GENE DEV, V32, P1443, DOI 10.1101/gad.315531.118; Cantu C, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aah4598; Cantu C, 2014, GENE DEV, V28, P1879, DOI 10.1101/gad.246140.114; Chaffer CL, 2007, CELLS TISSUES ORGANS, V185, P7, DOI 10.1159/000101298; de la Roche M, 2014, CANCER RES, V74, P1495, DOI 10.1158/0008-5472.CAN-13-2682; Deka J, 2010, CANCER RES, V70, P6619, DOI 10.1158/0008-5472.CAN-10-0148; Derynck R, 2019, DEV CELL, V49, P313, DOI 10.1016/j.devcel.2019.04.026; El-Hage P, 2015, MOL CANCER RES, V13, P902, DOI 10.1158/1541-7786.MCR-14-0180; Elsarraj HS, 2020, NPJ BREAST CANCER, V6, DOI 10.1038/s41523-020-0157-z; Elsarraj HS, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0630-z; Feng M, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau5240; Fluck MM, 2009, MICROBIOL MOL BIOL R, V73, P542, DOI 10.1128/MMBR.00009-09; Gay DM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08586-3; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; He X, 2006, CELL, V127, P40, DOI 10.1016/j.cell.2006.09.016; Herr P, 2012, TRENDS MOL MED, V18, P483, DOI 10.1016/j.molmed.2012.06.008; Jia W, 2011, MOL CANCER RES, V9, P1732, DOI 10.1158/1541-7786.MCR-11-0245; Jiang M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13842-7; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Katoh M, 2018, INT J MOL MED, V42, P713, DOI 10.3892/ijmm.2018.3689; Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092-8674(02)00679-7; Li J, 2013, CELL REP, V5, P1650, DOI 10.1016/j.celrep.2013.11.037; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Liu X, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07193-w; Luna JM, 2017, MOL CELL, V67, P400, DOI 10.1016/j.molcel.2017.06.025; Mani M, 2009, CANCER RES, V69, P7577, DOI 10.1158/0008-5472.CAN-09-0773; Meyer-Schaller N, 2019, DEV CELL, V48, P539, DOI 10.1016/j.devcel.2018.12.023; Micalizzi DS, 2010, J MAMMARY GLAND BIOL, V15, P117, DOI 10.1007/s10911-010-9178-9; Mieszczanek J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08164-z; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Moor AE, 2015, EBIOMEDICINE, V2, P1932, DOI 10.1016/j.ebiom.2015.10.030; Moses H, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003277; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676; Parker DS, 2002, DEVELOPMENT, V129, P2565; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Sannino G, 2016, ONCOTARGET, V7, P73725, DOI 10.18632/oncotarget.12455; Saxena M, 2020, CANCER RES, V80, P3631, DOI 10.1158/0008-5472.CAN-19-2910; Saxena M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30640-1; Shang ZS, 2019, J BIOL CHEM, V294, P9844, DOI 10.1074/jbc.RA119.007655; Thompson B, 2002, NAT CELL BIOL, V4, P367, DOI 10.1038/ncb786; Toya H, 2007, CANCER SCI, V98, P484, DOI 10.1111/j.1349-7006.2007.00430.x; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Valenta T, 2011, GENE DEV, V25, P2631, DOI 10.1101/gad.181289.111; van Schie EH, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00025; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Waldmeier L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048651; Xie Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054507; Xu WQ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07978-z; Yang C, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.356; Yang G, 2020, NANOTECHNOLOGY, V31, DOI 10.1088/1361-6528/ab5a03; Yang J, 2020, NAT REV MOL CELL BIO, V21, P341, DOI 10.1038/s41580-020-0237-9; Zatula N, 2014, ONCOTARGET, V5, P6770, DOI 10.18632/oncotarget.2252; Zhang Y, 2018, LIFE SCI, V208, P284, DOI 10.1016/j.lfs.2018.07.023; Zimmerli D, 2020, ELIFE, V9, DOI 10.7554/eLife.58123	58	4	4	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2021	40	43					6195	6209		10.1038/s41388-021-02016-9	http://dx.doi.org/10.1038/s41388-021-02016-9		SEP 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WO5HW	34545187	Green Published, hybrid			2022-12-17	WOS:000698130400001
J	Singh, SK; Kumar, S; Viswakarma, N; Principe, DR; Das, S; Sondarva, G; Nair, RS; Srivastava, P; Sinha, SC; Grippo, PJ; Thatcher, GRJ; Rana, B; Rana, A				Singh, Sunil Kumar; Kumar, Sandeep; Viswakarma, Navin; Principe, Daniel R.; Das, Subhasis; Sondarva, Gautam; Nair, Rakesh Sathish; Srivastava, Piush; Sinha, Subhash C.; Grippo, Paul J.; Thatcher, Gregory R. J.; Rana, Basabi; Rana, Ajay			MAP4K4 promotes pancreatic tumorigenesis via phosphorylation and activation of mixed lineage kinase 3	ONCOGENE			English	Article							PROTEIN-KINASE; SCAFFOLD PROTEINS; FAMILY KINASES; STE20 KINASE; STRESS; CELLS; ADENOCARCINOMA; INHIBITOR; REGULATOR; APOPTOSIS	MAP4K4 is a Ste20 member and reported to play important roles in various pathologies, including in cancer. However, the mechanism by which MAP4K4 promotes pancreatic cancer is not fully understood. It is suggested that MAP4K4 might function as a cancer promoter via specific downstream target(s) in an organ-specific manner. Here we identified MLK3 as a direct downstream target of MAP4K4. The MAP4K4 and MLK3 associates with each other, and MAP4K4 phosphorylates MLK3 on Thr738 and increases MLK3 kinase activity and downstream signaling. The phosphorylation of MLK3 by MAP4K4 promotes pancreatic cancer cell proliferation, migration, and colony formation. Moreover, MAP4K4 is overexpressed in human pancreatic tumors and directly correlates with the disease progression. The MAP4K4-specific pharmacological inhibitor, GNE-495, impedes pancreatic cancer cell growth, migration, induces cell death, and arrests cell cycle progression. Additionally, the GNE-495 reduced the tumor burden and extended survival of the KPC mice with pancreatic cancer. The MAP4K4 inhibitor also reduced MAP4K4 protein expression, tumor stroma, and induced cell death in murine pancreatic tumors. These findings collectively suggest that MLK3 phosphorylation by MAP4K4 promotes pancreatic cancer, and therefore therapies targeting MAP4K4 might alleviate the pancreatic cancer tumor burden in patients.	[Singh, Sunil Kumar; Kumar, Sandeep; Viswakarma, Navin; Principe, Daniel R.; Das, Subhasis; Sondarva, Gautam; Nair, Rakesh Sathish; Srivastava, Piush; Rana, Basabi; Rana, Ajay] Univ Illinois, Dept Surg, Div Surg Oncol, Chicago, IL 60612 USA; [Sinha, Subhash C.] Weill Cornell Med, New York, NY 10021 USA; [Grippo, Paul J.] Univ Illinois, Dept Med, Chicago, IL 60612 USA; [Thatcher, Gregory R. J.] Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA; [Rana, Basabi; Rana, Ajay] Univ Illinois, Univ Illinois Hosp, Chicago, IL 60612 USA; [Rana, Basabi; Rana, Ajay] Univ Illinois, Hlth Sci Syst Canc Ctr, Chicago, IL 60612 USA; [Rana, Basabi; Rana, Ajay] Jesse Brown VA Med Ctr, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cornell University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Arizona; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Rana, A (corresponding author), Univ Illinois, Dept Surg, Div Surg Oncol, Chicago, IL 60612 USA.; Rana, A (corresponding author), Univ Illinois, Univ Illinois Hosp, Chicago, IL 60612 USA.; Rana, A (corresponding author), Univ Illinois, Hlth Sci Syst Canc Ctr, Chicago, IL 60612 USA.; Rana, A (corresponding author), Jesse Brown VA Med Ctr, Chicago, IL 60612 USA.	arana@uic.edu	Singh, Sunil/AAA-1630-2022; Das, Subhasis/O-8421-2017	Singh, Sunil/0000-0001-7639-9212; Principe, Daniel/0000-0003-4355-6597; Srivastava, Piush/0000-0003-4646-9392; Sinha, Subhash/0000-0001-8916-5677; Das, Subhasis/0000-0003-1032-4407	Veterans Affairs Merit Award [BX004903]; Career Scientist Award [BX004855]; VA-Merit [BX003296]; National Cancer Institute [CA216410, CA176846, CA178063, CA219764]; UIC-Cancer Center pilot grant; NIH shared instrument grant [S100D018445]	Veterans Affairs Merit Award(US Department of Veterans Affairs); Career Scientist Award; VA-Merit; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); UIC-Cancer Center pilot grant; NIH shared instrument grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We acknowledge funding support from Veterans Affairs Merit Award (BX004903) and Career Scientist Award (BX004855) to A.R., and VA-Merit to B.R. (BX003296). This work is partly supported through grants from the National Cancer Institute to A.R. (CA216410 and CA176846), and B.R. (CA178063 and CA219764), and UIC-Cancer Center pilot grant award to BR. We also acknowledge the NIH shared instrument grant # S100D018445, awarded to U.A.M.S. Proteomics Core Lab, Little Rock, Arkansas, USA. Per the funding policy of the Department of Veterans Affairs, we are required to state that these contents do not represent the views of the Department of Veterans Affairs or the United States Government.	Aouadi M, 2009, NATURE, V458, P1180, DOI 10.1038/nature07774; Bos PH, 2019, CELL CHEM BIOL, V26, P1703, DOI 10.1016/j.chembiol.2019.10.005; Chuang HC, 2016, ADV IMMUNOL, V129, P277, DOI 10.1016/bs.ai.2015.09.006; Chuang HC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5602; Collins CS, 2006, P NATL ACAD SCI USA, V103, P3775, DOI 10.1073/pnas.0600040103; Das S, 2020, ONCOGENE, V39, P722, DOI 10.1038/s41388-019-1011-3; Das S, 2015, J BIOL CHEM, V290, P21705, DOI 10.1074/jbc.M115.655563; Delpire E, 2009, PFLUG ARCH EUR J PHY, V458, P953, DOI 10.1007/s00424-009-0674-y; Dhanasekaran A, 2004, J BIOL CHEM, V279, P37575, DOI 10.1074/jbc.M404003200; Dhanasekaran DN, 2007, ONCOGENE, V26, P3185, DOI 10.1038/sj.onc.1210411; Egberts JH, 2008, CANCER RES, V68, P1443, DOI 10.1158/0008-5472.CAN-07-5704; Farrow B, 2002, SURG ONCOL, V10, P153, DOI 10.1016/S0960-7404(02)00015-4; Flach RJR, 2016, MOL CELL BIOL, V36, P1740, DOI 10.1128/MCB.01121-15; Flach RJR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9995; Gao X, 2017, MOL ONCOL, V11, P628, DOI 10.1002/1878-0261.12055; Gao X, 2016, CELL BIOSCI, V6, DOI 10.1186/s13578-016-0121-7; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Jin M, 2016, ENVIRON TOXICOL PHAR, V46, P246, DOI 10.1016/j.etap.2016.08.006; Kumar S, 2016, MOL ONCOL, V10, P949, DOI 10.1016/j.molonc.2016.03.007; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Larhammar M, 2017, J NEUROSCI, V37, P11074, DOI 10.1523/JNEUROSCI.0905-17.2017; Liang JJ, 2008, CLIN CANCER RES, V14, P7043, DOI 10.1158/1078-0432.CCR-08-0381; Liu HZ, 1999, CURR BIOL, V9, P101, DOI 10.1016/S0960-9822(99)80023-2; Maroney AC, 2001, J BIOL CHEM, V276, P25302, DOI 10.1074/jbc.M011601200; Ndubaku CO, 2015, ACS MED CHEM LETT, V6, P913, DOI 10.1021/acsmedchemlett.5b00174; Prolo LM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50160-w; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Rana Ajay, 2013, Genes Cancer, V4, P334, DOI 10.1177/1947601913485415; Rangasamy V, 2012, P NATL ACAD SCI USA, V109, P8149, DOI 10.1073/pnas.1200804109; Rangasamy V, 2010, CANCER RES, V70, P1731, DOI 10.1158/0008-5472.CAN-09-3492; Rattanasinchai C, 2016, CANCERS, V8, DOI 10.3390/cancers8050051; Sathyanarayana P, 2002, MOL CELL, V10, P1527, DOI 10.1016/S1097-2765(02)00734-7; Schroder P, 2015, ANGEW CHEM INT EDIT, V54, P12398, DOI 10.1002/anie.201501515; Schwaid AG, 2015, ACS CHEM BIOL, V10, P2667, DOI 10.1021/acschembio.5b00679; Tang XQ, 2006, P NATL ACAD SCI USA, V103, P2087, DOI 10.1073/pnas.0507660103; Torres MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080580; Vitorino P, 2015, NATURE, V519, P425, DOI 10.1038/nature14323; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Wright JH, 2003, MOL CELL BIOL, V23, P2068, DOI 10.1128/MCB.23.6.2068-2082.2003; Xue YZ, 2001, DEVELOPMENT, V128, P1559; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Yue JP, 2014, DEV CELL, V31, P572, DOI 10.1016/j.devcel.2014.10.025; Zhao XD, 2016, ONCOTARGET, V7, P81110, DOI 10.18632/oncotarget.13212	43	4	4	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2021	40	43					6153	6165		10.1038/s41388-021-02007-w	http://dx.doi.org/10.1038/s41388-021-02007-w		SEP 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WO5HW	34511598	hybrid, Green Published			2022-12-17	WOS:000695127400001
J	Chen, L; Jin, XH; Luo, J; Duan, JL; Cai, MY; Chen, JW; Feng, ZH; Guo, AM; Wang, FW; Xie, D				Chen, Li; Jin, Xiao-Han; Luo, Jie; Duan, Jin-Ling; Cai, Mu-Yan; Chen, Jie-Wei; Feng, Zi-Hao; Guo, Austin Meng; Wang, Feng-Wei; Xie, Dan			ITLN1 inhibits tumor neovascularization and myeloid derived suppressor cells accumulation in colorectal carcinoma	ONCOGENE			English	Article							ANGIOGENIC SWITCH; PROGENITOR CELLS; HUMAN INTELECTIN; PROMOTES; METASTASIS; VASCULOGENESIS; IDENTIFICATION; RECRUITMENT; EXPRESSION; GROWTH	Low levels of ITLN1 have been correlated with obesity-related colorectal carcinogenesis, however, the specific functions and underlying mechanisms remain unclear. Thus, we sought to explore the inhibitory role of ITLN1 in the tumor-permissive microenvironment that exists during the first occurrence and subsequent development of colorectal carcinoma (CRC). Results indicated that ITLN1 was frequently lost in CRC tissues and ITLN1 to be an independent prognostic predictor of CRC. Orthotopic and subcutaneous tumor xenograft approaches were then used to further confirm the protective role of ITLN1 during tumor progression. Increased ITLN1 expression in CRC cells significantly inhibited local pre-existing vessels sprouting, EPC recruitment and the infiltration of immunosuppressive myeloid-derived suppressor cells (MDSCs) into tumor tissues without affecting the behavior of CRC cells in vitro. Comparatively, ITLN1-derived MDSCs had a lower suppressive effect on T cell proliferation, NOS2 expression, and ROS production. In addition, ITLN1 overexpression markedly suppressed bone marrow (BM)-derived hematopoietic progenitor cells (HPC) differentiation into MDSCs as well as NOS2 activity on MDSCs. Using H-2b+YFP + chimerism through bone marrow transplantation, increased ITLN1 in HCT116 significantly reduced the BM-derived EPCs and MDSCs in vivo mobilization. Mechanistically, results indicated ITLN1 inhibited tumor-derived IL-17D and CXCL2 (MIP2) through the KEAP1/Nrf2/ROS/IL-17D and p65 NF-kappa B/CXCL2 signaling cascades dependent on PI3K/AKT/GSK3ss. This effect was reversed by the PI3K selective inhibitor LY294002. Collectively, ITLN1 synergistically suppressed IL-17D and CXCL2-mediated tumor vascularization, bone marrow derived EPC recruitment, as well as MDSCs generation and trafficking. Thus, ITLN1 potentially serves as a critical prognostic and therapeutic target for CRC.	[Chen, Li; Jin, Xiao-Han; Luo, Jie; Duan, Jin-Ling; Wang, Feng-Wei; Xie, Dan] Sun Yat Sen Univ Canc Ctr, State Key Lab Oncol South China, Guangzhou, Peoples R China; [Chen, Li; Jin, Xiao-Han; Luo, Jie; Duan, Jin-Ling; Wang, Feng-Wei; Xie, Dan] Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China; [Chen, Li] Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Guangzhou Inst Pediat, Guangzhou, Guangdong, Peoples R China; [Cai, Mu-Yan; Chen, Jie-Wei; Xie, Dan] Sun Yat Sen Univ Canc Ctr, Dept Pathol, Guangzhou, Peoples R China; [Feng, Zi-Hao] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Urol, Guangzhou, Peoples R China; [Guo, Austin Meng] New York Med Coll, Dept Pharmacol, New York, NY USA	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Guangzhou Medical University; Sun Yat Sen University; Sun Yat Sen University; New York Medical College	Xie, D (corresponding author), Sun Yat Sen Univ Canc Ctr, State Key Lab Oncol South China, Guangzhou, Peoples R China.; Xie, D (corresponding author), Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China.; Xie, D (corresponding author), Sun Yat Sen Univ Canc Ctr, Dept Pathol, Guangzhou, Peoples R China.	xiedan@sysucc.org.cn		jie, luo/0000-0002-0791-1419	National Key R&D Program of China [2017YFC1309000, 2016YFC1302305]; National Natural Science Foundation of China [81430055, 81572359, 81602063, 81730072, 81772595, 8197227]; National Natural Science Foundation for Youth [81502259]; Natural Science Foundation of Guangdong [S1014030001589]; 61th China Postdoctoral Science foundation [2017M612816]; Guangzhou Science and Technology Plan Projects [201803040019, 201904020044]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation for Youth; Natural Science Foundation of Guangdong(National Natural Science Foundation of Guangdong Province); 61th China Postdoctoral Science foundation(China Postdoctoral Science Foundation); Guangzhou Science and Technology Plan Projects	This work was supported by grants from the National Key R&D Program of China (No. 2017YFC1309000 and No. 2016YFC1302305); the National Natural Science Foundation of China (No.81430055, 81572359, 81602063, 81730072, 81772595, 8197227); the National Natural Science Foundation for Youth (No.81502259); the Natural Science Foundation of Guangdong (No. S1014030001589); the 61th China Postdoctoral Science foundation (2017M612816) and the Guangzhou Science and Technology Plan Projects (No. 201803040019, 201904020044).	Achyut BR, 2015, CANCER LETT, V369, P416, DOI 10.1016/j.canlet.2015.09.004; Aleksandrova K, 2016, CANCER RES, V76, P3862, DOI 10.1158/0008-5472.CAN-15-3464; Alissa EM, 2016, J CLIN TRANSL ENDOCR, V3, P7, DOI 10.1016/j.jcte.2015.12.001; Au-Yeung CL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17383-2; Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Cai MY, 2011, GUT, V60, P967, DOI 10.1136/gut.2010.231993; Caiado F, 2012, FIBROGENESIS TISSUE, V5, DOI 10.1186/1755-1536-5-4; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Chowdhry S, 2013, ONCOGENE, V32, P3765, DOI 10.1038/onc.2012.388; Chung AS, 2013, NAT MED, V19, P1114, DOI 10.1038/nm.3291; Condamine T, 2011, TRENDS IMMUNOL, V32, P19, DOI 10.1016/j.it.2010.10.002; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gao DC, 2008, SCIENCE, V319, P195, DOI 10.1126/science.1150224; Gonzalez-Donquiles C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177549; Hanrahan V, 2003, J PATHOL, V200, P183, DOI 10.1002/path.1339; Hempen PM, 2003, CANCER RES, V63, P994; Huang YJ, 2018, BIOCHEM CELL BIOL, V96, P475, DOI 10.1139/bcb-2017-0291; Isner JM, 1999, J CLIN INVEST, V103, P1231, DOI 10.1172/JCI6889; Jaramillo MC, 2013, GENE DEV, V27, P2179, DOI 10.1101/gad.225680.113; Kaplan RN, 2007, TRENDS MOL MED, V13, P72, DOI 10.1016/j.molmed.2006.12.003; Katoh H, 2013, CANCER CELL, V24, P631, DOI 10.1016/j.ccr.2013.10.009; Kim HJ, 2012, J PROTEOMICS, V75, P2983, DOI 10.1016/j.jprot.2011.12.002; Kim TH, 2011, CANCER RES, V71, P2260, DOI 10.1158/0008-5472.CAN-10-3007; Komiya T, 1998, BIOCHEM BIOPH RES CO, V251, P759, DOI 10.1006/bbrc.1998.9513; Lee JK, 2001, GLYCOBIOLOGY, V11, P65, DOI 10.1093/glycob/11.1.65; Li CQ, 2009, P NATL ACAD SCI USA, V106, P14547, DOI 10.1073/pnas.0907539106; Li D, 2015, ONCOTARGET, V6, P16168, DOI 10.18632/oncotarget.3753; Li D, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0320-6; Liu Y, 2016, CANCER CELL, V30, P668, DOI 10.1016/j.ccell.2016.09.011; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Maeda K, 2016, J CANCER, V7, P207, DOI 10.7150/jca.13732; Mancinelli R, 2018, BIOMETALS, V31, P369, DOI 10.1007/s10534-018-0094-6; Mody K, 2018, CANCER J, V24, P165, DOI 10.1097/PPO.0000000000000328; Moldogazieva NT, 2018, CANCER RES, V78, P6040, DOI 10.1158/0008-5472.CAN-18-0980; Morandi F, 2014, J IMMUNOL, V192, P2634, DOI 10.4049/jimmunol.1302656; Movahedi K, 2008, BLOOD, V111, P4233, DOI 10.1182/blood-2007-07-099226; Numasaki M, 2003, BLOOD, V101, P2620, DOI 10.1182/blood-2002-05-1461; Patan S, 2004, CANC TREAT, V117, P3; Paul J, 2017, CANCER CELL, V31, P64, DOI 10.1016/j.ccell.2016.12.003; Saddawi-Konefka R, 2016, CELL REP, V16, P2348, DOI 10.1016/j.celrep.2016.07.075; Schmidt A, 2007, CIRC RES, V101, P125, DOI 10.1161/CIRCRESAHA.107.148932; Shin K, 2008, BIOL PHARM BULL, V31, P1605, DOI 10.1248/bpb.31.1605; Starnes T, 2002, J IMMUNOL, V169, P642, DOI 10.4049/jimmunol.169.2.642; Suzuki YA, 2005, CELL MOL LIFE SCI, V62, P2560, DOI 10.1007/s00018-005-5371-1; Taki M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03966-7; Tanigawa N, 1996, CANCER RES, V56, P2671; Tanigawa N, 1997, CANCER RES, V57, P1043; Tepper OM, 2005, BLOOD, V105, P1068, DOI 10.1182/blood-2004-03-1051; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Tsuji S, 2001, J BIOL CHEM, V276, P23456, DOI 10.1074/jbc.M103162200; Wali A, 2005, LUNG CANCER, V48, P19, DOI 10.1016/j.lungcan.2004.10.011; Wang DZ, 2017, CANCER RES, V77, P3655, DOI 10.1158/0008-5472.CAN-16-3199; Washimi K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039889; Xie D, 2003, INT J CANCER, V107, P896, DOI 10.1002/ijc.11514; Xu HW, 2017, CARCINOGENESIS, V38, P281, DOI 10.1093/carcin/bgw121; Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031; Yang RZ, 2006, AM J PHYSIOL-ENDOC M, V290, pE1253, DOI 10.1152/ajpendo.00572.2004; Zhang C, 2014, CARCINOGENESIS, V35, P2771, DOI 10.1093/carcin/bgu192; Zhang H, 2017, ONCOGENE, V36, P2095, DOI 10.1038/onc.2016.367; Zhang YY, 2013, EUR J PHARMACOL, V698, P137, DOI 10.1016/j.ejphar.2012.11.016	63	4	4	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2021	40	40					5925	5937		10.1038/s41388-021-01965-5	http://dx.doi.org/10.1038/s41388-021-01965-5		AUG 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD5KT	34363021				2022-12-17	WOS:000682519100004
J	Jiang, CH; McKay, RM; Le, LQ				Jiang, Chunhui; McKay, Renee M.; Le, Lu Q.			Tumorigenesis in neurofibromatosis type 1: role of the microenvironment	ONCOGENE			English	Review							NERVE SHEATH TUMORS; PHASE-II TRIAL; SCHWANN-CELLS; NF1 LOSS; TGF-BETA; GROWTH; PLEXIFORM; EXPRESSION; DIFFERENTIATION; PROLIFERATION	Neurofibromatosis Type 1 (NF1) is one of the most common inherited neurological disorders and predisposes patients to develop benign and malignant tumors. Neurofibromas are NF1-associated benign tumors but can cause substantial discomfort and disfigurement. Numerous studies have shown that neurofibromas arise from the Schwann cell lineage but both preclinical mouse models and clinical trials have demonstrated that the neurofibroma tumor microenvironment contributes significantly to tumorigenesis. This offers the opportunity for targeting new therapeutic vulnerabilities to treat neurofibromas. However, a translational gap exists between deciphering the contribution of the neurofibroma tumor microenvironment and clinically applying this knowledge to treat neurofibromas. Here, we discuss the key cellular and molecular components in the neurofibroma tumor microenvironment that can potentially be targeted therapeutically to advance neurofibroma treatment.	[Jiang, Chunhui; McKay, Renee M.; Le, Lu Q.] Univ Texas Southwestern Med Ctr Dallas, Dept Dermatol, Dallas, TX USA; [Le, Lu Q.] Univ Texas Southwestern Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX USA; [Le, Lu Q.] Univ Texas Southwestern Med Ctr Dallas, UTSW Comprehens Neurofibromatosis Clin, Dallas, TX USA; [Le, Lu Q.] Univ Texas Southwestern Med Ctr Dallas, Hamon Ctr Regenerat Sci & Med, Dallas, TX USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Le, LQ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Dermatol, Dallas, TX USA.; Le, LQ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX USA.; Le, LQ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, UTSW Comprehens Neurofibromatosis Clin, Dallas, TX USA.; Le, LQ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Hamon Ctr Regenerat Sci & Med, Dallas, TX USA.	Lu.Le@UTSouthwestern.edu		Le, Lu/0000-0003-2817-5382; McKay, Renee/0000-0001-5976-1996	Burroughs Wellcome Fund; National Cancer Institute of the NIH [R01 CA166593]; Developmental and Hyperactive RAS Tumor SPORE [U54 CA196519]; US Department of Defense [W81XWH-21-1-0651]; Neurofibromatosis Therapeutic Acceleration Program; NF1 Research Consortium Fund; Giorgio Foundation	Burroughs Wellcome Fund(Burroughs Wellcome Fund); National Cancer Institute of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Developmental and Hyperactive RAS Tumor SPORE; US Department of Defense(United States Department of Defense); Neurofibromatosis Therapeutic Acceleration Program; NF1 Research Consortium Fund; Giorgio Foundation	LQL is the Thomas L. Shield, M.D. Endowed Professor in Dermatology. He held a Career Award for Medical Scientists from the Burroughs Wellcome Fund, and is supported by funding from the National Cancer Institute of the NIH (R01 CA166593) and the Developmental and Hyperactive RAS Tumor SPORE (U54 CA196519); the US Department of Defense (W81XWH-21-1-0651); the Neurofibromatosis Therapeutic Acceleration Program; the NF1 Research Consortium Fund; and the Giorgio Foundation.	Atit RP, 1999, J INVEST DERMATOL, V112, P835, DOI 10.1046/j.1523-1747.1999.00609.x; Babovic-Vuksanovic D, 2006, NEUROLOGY, V67, P1860, DOI 10.1212/01.wnl.0000243231.12248.67; Bergoug M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112365; Bonner JC, 2004, CYTOKINE GROWTH F R, V15, P255, DOI 10.1016/j.cytogfr.2004.03.006; Brosseau JP, 2021, ACTA NEUROPATHOL COM, V9, DOI 10.1186/s40478-020-01103-4; Brosseau JP, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07452-y; Brosseau JP, 2018, NEUROLOGY, V91, pS14, DOI 10.1212/WNL.0000000000005788; Chen ZG, 2019, CANCER DISCOV, V9, P114, DOI 10.1158/2159-8290.CD-18-0151; Chen ZG, 2014, CANCER CELL, V26, P695, DOI 10.1016/j.ccell.2014.09.009; Choi K, 2017, SCI REP-UK, V7, DOI 10.1038/srep43315; Dallas SL, 2005, J BIOL CHEM, V280, P18871, DOI 10.1074/jbc.M410762200; Dolivo DM, 2017, CYTOKINE GROWTH F R, V38, P49, DOI 10.1016/j.cytogfr.2017.09.003; Dombi E, 2007, NEUROLOGY, V68, P643, DOI 10.1212/01.wnl.0000250332.89420.e6; Driskell RR, 2013, NATURE, V504, P277, DOI 10.1038/nature12783; Dundr P, 2009, PATHOL INT, V59, P86, DOI 10.1111/j.1440-1827.2008.02333.x; Evans DGR, 2002, J MED GENET, V39, P311, DOI 10.1136/jmg.39.5.311; Fletcher Jonathan S, 2020, Neurooncol Adv, V2, pi23, DOI 10.1093/noajnl/vdz045; Fricker FR, 2011, FUTUR NEUROL, V6, P809, DOI 10.2217/FNL.11.45; Fricker FR, 2011, J NEUROSCI, V31, P3225, DOI 10.1523/JNEUROSCI.2568-10.2011; Gorlewicz A, 2009, NEUROBIOL DIS, V34, P245, DOI 10.1016/j.nbd.2009.01.011; Gross AM, 2020, NEW ENGL J MED, V382, P1430, DOI 10.1056/NEJMoa1912735; Hagel C, 2012, NEUROPATHOLOGY, V32, P406, DOI 10.1111/j.1440-1789.2011.01276.x; Harboe M, 2018, GLIA, V66, P934, DOI 10.1002/glia.23293; Harigai R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24484-y; Henderson NC, 2020, NATURE, V587, P555, DOI 10.1038/s41586-020-2938-9; Hirbe AC, 2014, LANCET NEUROL, V13, P834, DOI 10.1016/S1474-4422(14)70063-8; JAAKKOLA S, 1989, J CLIN INVEST, V84, P253, DOI 10.1172/JCI114148; Jessen KR, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020487; Joseph NM, 2008, CANCER CELL, V13, P129, DOI 10.1016/j.ccr.2008.01.003; KADONO T, 1994, BIOCHEM BIOPH RES CO, V198, P827, DOI 10.1006/bbrc.1994.1118; Kim Y, 2008, J BIOL CHEM, V283, P22513, DOI 10.1074/jbc.M708319200; Le LQ, 2007, ONCOGENE, V26, P4609, DOI 10.1038/sj.onc.1210261; Le LQ, 2011, CANCER RES, V71, P4686, DOI 10.1158/0008-5472.CAN-10-4577; Liao CP, 2018, J CLIN INVEST, V128, P2848, DOI 10.1172/JCI99424; Liao CP, 2016, ONCOTARGET, V7, P61500, DOI 10.18632/oncotarget.11133; Linneberg C, 2015, ASN NEURO, V7, DOI 10.1177/1759091415602859; Mascharak S, 2021, SCIENCE, V372, P362, DOI 10.1126/science.aba2374; Mashour GA, 2001, ONCOGENE, V20, P97, DOI 10.1038/sj.onc.1204026; Misa K, 2017, PHYSIOL REP, V5, DOI 10.14814/phy2.13383; Mo J, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI139807; Moleirinho S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060028; Park J, 2012, J CLIN INVEST, V122, P4243, DOI 10.1172/JCI63930; Parrinello S, 2010, CELL, V143, P145, DOI 10.1016/j.cell.2010.08.039; Parrinello S, 2008, GENE DEV, V22, P3335, DOI 10.1101/gad.490608; PELTONEN J, 1986, ANN NY ACAD SCI, V486, P260, DOI 10.1111/j.1749-6632.1986.tb48079.x; Piersma B, 2015, FRONT MED, V2, DOI 10.3389/fmed.2015.00059; Prada CE, 2013, ACTA NEUROPATHOL, V125, P159, DOI 10.1007/s00401-012-1056-7; Radomska KJ, 2019, CANCER DISCOV, V9, P130, DOI 10.1158/2159-8290.CD-18-0156; Ribeiro S, 2013, CELL REP, V5, P126, DOI 10.1016/j.celrep.2013.08.033; Riccardi VM, 2015, AM J MED GENET A, V167, P1570, DOI 10.1002/ajmg.a.37045; RICCARDI VM, 1987, ARCH DERMATOL, V123, P1011, DOI 10.1001/archderm.123.8.1011; Rice FL, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216527; Robertson KA, 2012, LANCET ONCOL, V13, P1218, DOI 10.1016/S1470-2045(12)70414-X; Ronellenfitsch MW, 2020, J CLIN INVEST, V130, P2488, DOI 10.1172/JCI130787; Saito H, 2007, ONCOGENE, V26, P4714, DOI 10.1038/sj.onc.1210250; Sottile J, 2002, MOL BIOL CELL, V13, P3546, DOI 10.1091/mbc.E02-01-0048; STREULI CH, 1995, J CELL BIOL, V129, P591, DOI 10.1083/jcb.129.3.591; Sun K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4485; Toole BP, 2009, CLIN CANCER RES, V15, P7462, DOI 10.1158/1078-0432.CCR-09-0479; Wang-Gillam A, 2019, J CLIN ONCOL, V37, P1041, DOI 10.1200/JCO.19.00056; Wehner D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00143-0; Widemann BC, 2014, PEDIATR BLOOD CANCER, V61, P1598, DOI 10.1002/pbc.25041; Wishart AL, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc3175; Woodhoo A, 2009, NAT NEUROSCI, V12, P839, DOI 10.1038/nn.2323; Wu JQ, 2008, CANCER CELL, V13, P105, DOI 10.1016/j.ccr.2007.12.027; Yang FC, 2003, J CLIN INVEST, V112, P1851, DOI 10.1172/JCI200319195; Yang FC, 2008, CELL, V135, P437, DOI 10.1016/j.cell.2008.08.041; Yang FC, 2006, HUM MOL GENET, V15, P2421, DOI 10.1093/hmg/ddl165; Zheng H, 2008, CANCER CELL, V13, P117, DOI 10.1016/j.ccr.2008.01.002; Zhu Y, 2002, SCIENCE, V296, P920, DOI 10.1126/science.1068452	70	4	4	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2021	40	39					5781	5787		10.1038/s41388-021-01979-z	http://dx.doi.org/10.1038/s41388-021-01979-z		AUG 2021	7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UZ8WB	34345017	Green Accepted			2022-12-17	WOS:000681523500002
J	Yan, Y; Narayan, A; Cho, S; Cheng, ZQ; Liu, JO; Zhu, H; Wang, GN; Wharram, B; Lisok, A; Brummet, M; Saeki, H; Huang, T; Gabrielson, K; Gabrielson, E; Cope, L; Kanaan, YM; Afsari, A; Naab, T; Yfantis, HG; Ambs, S; Pomper, MG; Sukumar, S; Merino, VF				Yan, Yu; Narayan, Athira; Cho, Soonweng; Cheng, Zhiqiang; Liu, Jun O.; Zhu, Heng; Wang, Guannan; Wharram, Bryan; Lisok, Ala; Brummet, Mary; Saeki, Harumi; Huang, Tao; Gabrielson, Kathleen; Gabrielson, Edward; Cope, Leslie; Kanaan, Yasmine M.; Afsari, Ali; Naab, Tammey; Yfantis, Harris G.; Ambs, Stefan; Pomper, Martin G.; Sukumar, Saraswati; Merino, Vanessa F.			CRY beta B2 enhances tumorigenesis through upregulation of nucleolin in triple negative breast cancer	ONCOGENE			English	Article							AFRICAN-AMERICAN; TRANSLATION; CELLS; DRUG; OVEREXPRESSION; STABILIZATION; PHENOTYPE; REGIONS; MODEL	Expression of beta-crystallin B2 (CRY beta B2) is elevated in African American (AA) breast tumors. The underlying mechanisms of CRY beta B2-induced malignancy and the association of CRY beta B2 protein expression with survival have not yet been described. Here, we report that the expression of CRY beta B2 in breast cancer cells increases stemness, growth, and metastasis. Transcriptomics data revealed that CRY beta B2 upregulates genes that are functionally associated with unfolded protein response, oxidative phosphorylation, and DNA repair, while down-regulating genes related to apoptosis. CRY beta B2 in tumors promotes de-differentiation, an increase in mesenchymal markers and cancer-associated fibroblasts, and enlargement of nucleoli. Proteome microarrays identified a direct interaction between CRY beta B2 and the nucleolar protein, nucleolin. CRY beta B2 induces nucleolin, leading to the activation of AKT and EGFR signaling. CRISPR studies revealed a dependency on nucleolin for the pro-tumorigenic effects of CRY beta B2. Triple-negative breast cancer (TNBC) xenografts with upregulated CRY beta B2 are distinctively sensitive to the nucleolin aptamer, AS-1411. Lastly, in AA patients, higher levels of nucleolar CRY beta B2 in primary TNBC correlates with decreased survival. In summary, CRY beta B2 is upregulated in breast tumors of AA patients and induces oncogenic alterations consistent with an aggressive cancer phenotype. CRY beta B2 increases sensitivity to nucleolin inhibitors and may promote breast cancer disparity.	[Yan, Yu; Narayan, Athira; Wharram, Bryan; Lisok, Ala; Brummet, Mary; Pomper, Martin G.; Merino, Vanessa F.] Johns Hopkins Univ, Dept Radiol & Radiol Sci, Sch Med, Baltimore, MD 21218 USA; [Yan, Yu; Huang, Tao] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Breast & Thyroid Surg, Wuhan, Peoples R China; [Yan, Yu; Cho, Soonweng; Liu, Jun O.; Wang, Guannan; Gabrielson, Kathleen; Cope, Leslie; Pomper, Martin G.; Sukumar, Saraswati] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; [Cheng, Zhiqiang; Liu, Jun O.; Zhu, Heng; Pomper, Martin G.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; [Saeki, Harumi; Gabrielson, Kathleen] Johns Hopkins Univ, Dept Mol & Comparat Pathobiol, Sch Med, Baltimore, MD USA; [Saeki, Harumi; Gabrielson, Kathleen; Gabrielson, Edward] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Kanaan, Yasmine M.] Howard Univ, Coll Med, Dept Microbiol, Washington, DC USA; [Afsari, Ali; Naab, Tammey] Howard Univ, Coll Med, Dept Pathol, Washington, DC USA; [Yfantis, Harris G.] Baltimore Vet Affairs Med Ctr, Pathol & Lab Med, Baltimore, MD USA; [Ambs, Stefan] NCI, Mol Epidemiol Sect, Lab Human Carcinogenesis, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; Huazhong University of Science & Technology; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard University; Howard University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Merino, VF (corresponding author), Johns Hopkins Univ, Dept Radiol & Radiol Sci, Sch Med, Baltimore, MD 21218 USA.; Sukumar, S (corresponding author), Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.	saras@jhmi.edu; vmerino1@jhmi.edu	; Cheng, Zhiqiang/F-5016-2016	Yan, Yu/0000-0003-2309-9464; Cheng, Zhiqiang/0000-0002-4371-0104	DOD BCRP Center of Excellence Grant [W81XWH-04-1-0595]; DOD BCRP [W81XWH-15-1-0017]; Division of Nuclear Medicine and Molecular Imaging	DOD BCRP Center of Excellence Grant; DOD BCRP(United States Department of Defense); Division of Nuclear Medicine and Molecular Imaging	This work was funded by the DOD BCRP Center of Excellence Grant W81XWH-04-1-0595 to S.S, DOD BCRP, W81XWH-15-1-0017 to V.M and the Division of Nuclear Medicine and Molecular Imaging.	Abdelmohsen K, 2011, NUCLEIC ACIDS RES, V39, P8513, DOI 10.1093/nar/gkr488; Alvandi F, 2014, ONCOLOGIST, V19, P94, DOI 10.1634/theoncologist.2013-0077; Anders F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175451; Atchley DP, 2008, J CLIN ONCOL, V26, P4282, DOI 10.1200/JCO.2008.16.6231; Barrow MA, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1191-3; Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618; BUGLER B, 1982, EUR J BIOCHEM, V128, P475; Carotenuto P, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091090; Chen CY, 2000, GENE DEV, V14, P1236; Chen Z, 2016, SAUDI MED J, V37, P1312, DOI 10.15537/smj.2016.12.15972; Cho B, 2021, JAMA ONCOL, V7, P1016, DOI 10.1001/jamaoncol.2021.1254; Churpek JE, 2015, BREAST CANCER RES TR, V149, P31, DOI 10.1007/s10549-014-3195-0; Dawson PJ, 1996, AM J PATHOL, V148, P313; Derenzini M, 1998, AM J PATHOL, V152, P1291; DERENZINI M, 1989, ACTA CYTOL, V33, P491; DeSantis CE, 2016, CA-CANCER J CLIN, V66, P31, DOI 10.3322/caac.21320; Di Segni A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002310; Dietze EC, 2015, NAT REV CANCER, V15, P248, DOI 10.1038/nrc3896; Field LA, 2012, CANCER-AM CANCER SOC, V118, P1334, DOI 10.1002/cncr.26405; Fonseca NA, 2015, BIOMATERIALS, V69, P76, DOI 10.1016/j.biomaterials.2015.08.007; Foss CA, 2019, MOL IMAGING BIOL, V21, P473, DOI 10.1007/s11307-018-1228-5; Gao Q, 2014, BIOCHEM BIOPH RES CO, V453, P37, DOI 10.1016/j.bbrc.2014.09.049; Gieniec KA, 2019, BRIT J CANCER, V121, P293, DOI 10.1038/s41416-019-0509-3; Graw J, 2009, EXP EYE RES, V88, P173, DOI 10.1016/j.exer.2008.10.011; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jovov B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030168; Konishi H, 2011, P NATL ACAD SCI USA, V108, P17773, DOI 10.1073/pnas.1110969108; Li L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18222-z; Liedtke T, 2007, MOL CELL PROTEOMICS, V6, P895, DOI 10.1074/mcp.M600245-MCP200; Lv YR, 2014, MOL CELL BIOL, V34, P4513, DOI 10.1128/MCB.00524-14; Mahotka C, 2018, LEUKEMIA, V32, P1865, DOI 10.1038/s41375-018-0090-4; Martin DN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004531; Menashe I, 2009, J NATL CANCER I, V101, P993, DOI 10.1093/jnci/djp176; Merino VF, 2016, CANCER RES, V76, P2013, DOI 10.1158/0008-5472.CAN-15-1619; Miller FR, 2000, J NATL CANCER I, V92, P1185, DOI 10.1093/jnci/92.14.1185A; Otake Y, 2007, BLOOD, V109, P3069, DOI 10.1182/blood-2006-08-043257; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Paulucci DJ, 2017, ONCOTARGET, V8, P5196, DOI 10.18632/oncotarget.14122; Pomper MG, 2009, CELL RES, V19, P370, DOI 10.1038/cr.2008.329; Rosenberg JE, 2014, INVEST NEW DRUG, V32, P178, DOI 10.1007/s10637-013-0045-6; Schmidt EK, 2009, NAT METHODS, V6, P275, DOI [10.1038/NMETH.1314, 10.1038/nmeth.1314]; Shin SH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06606-2; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Sturtz LA, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-62; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Tu Zhigang, 2012, Small GTPases, V3, P163, DOI 10.4161/sgtp.19884; Wallace TA, 2008, CANCER RES, V68, P927, DOI 10.1158/0008-5472.CAN-07-2608; Xie QP, 2016, ONCOTARGET, V7, P16636, DOI 10.18632/oncotarget.7674; Yakhni M, 2019, AM J CANCER RES, V9, P1043; Yang A, 2011, J BIOL CHEM, V286, P43370, DOI 10.1074/jbc.M111.225185; Yang YG, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0547-5; Zeng Sulin, 2018, Cancer Transl Med, V4, P70, DOI 10.4103/ctm.ctm_22_18	52	4	4	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2021	40	38					5752	5763		10.1038/s41388-021-01975-3	http://dx.doi.org/10.1038/s41388-021-01975-3		AUG 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UU4CG	34341513				2022-12-17	WOS:000680382100001
J	Fatima, I; Barman, S; Uppada, J; Chauhan, S; Rauth, S; Rachagani, S; Ponnusamy, MP; Smith, L; Talmon, G; Singh, AB; Batra, SK; Dhawan, P				Fatima, Iram; Barman, Susmita; Uppada, JayaPrakash; Chauhan, Shailender; Rauth, Sanchita; Rachagani, Satyanarayana; Ponnusamy, Moorthy Palanimuthu; Smith, Lynette; Talmon, Geoffrey; Singh, Amar B.; Batra, Surinder K.; Dhawan, Punita			MASTL regulates EGFR signaling to impact pancreatic cancer progression	ONCOGENE			English	Article							NUCLEAR-ENVELOPE BREAKDOWN; GREATWALL KINASE; CELL; GALECTIN-3; RECEPTOR; PROTEIN; EXPRESSION; PHOSPHORYLATION; GEMCITABINE; ACTIVATION	Pancreatic cancer (PC) remains a major cause of cancer-related deaths primarily due to its inherent potential of therapy resistance. Checkpoint inhibitors have emerged as promising anti-cancer agents when used in combination with conventional anti-cancer therapies. Recent studies have highlighted a critical role of the Greatwall kinase (microtubule-associated serine/threonine-protein kinase-like (MASTL)) in promoting oncogenic malignancy and resistance to anti-cancer therapies; however, its role in PC remains unknown. Based on a comprehensive investigation involving PC patient samples, murine models of PC progression (Kras;PdxCre-KC and Kras;p53;PdxCre-KPC), and loss and gain of function studies, we report a previously undescribed critical role of MASTL in promoting cancer malignancy and therapy resistance. Mechanistically, MASTL promotes PC by modulating the epidermal growth factor receptor protein stability and, thereupon, kinase signaling. We further demonstrate that combinatorial therapy targeting MASTL promotes the efficacy of the cell-killing effects of Gemcitabine using both genetic and pharmacological inhibitions. Taken together, this study identifies a key role of MASTL in promoting PC progression and its utility as a novel target in promoting sensitivity to the anti-PC therapies.	[Fatima, Iram; Barman, Susmita; Rauth, Sanchita; Rachagani, Satyanarayana; Ponnusamy, Moorthy Palanimuthu; Singh, Amar B.; Batra, Surinder K.; Dhawan, Punita] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Uppada, JayaPrakash] Univ Alabama, Alabama Life Res Inst, Coll Community Hlth Sci, Tuscaloosa, AL USA; [Chauhan, Shailender] Univ Arizona, Cellular & Mol Med, Canc Ctr UAHS, Tucson, AZ USA; [Smith, Lynette] Univ Nebraska Med Ctr, Dept Biostat, Omaha, NE USA; [Talmon, Geoffrey] Univ Nebraska Med Ctr, Dept Pathl, Omaha, NE USA; [Singh, Amar B.; Dhawan, Punita] VA Nebraska Western Iowa Hlth Care Syst, Omaha, NE 69101 USA; [Batra, Surinder K.; Dhawan, Punita] Univ Nebraska Med Ctr, Buffett Canc Ctr, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Alabama System; University of Alabama Tuscaloosa; University of Arizona; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System; University of Nebraska System; University of Nebraska Medical Center	Dhawan, P (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.; Dhawan, P (corresponding author), VA Nebraska Western Iowa Hlth Care Syst, Omaha, NE 69101 USA.; Dhawan, P (corresponding author), Univ Nebraska Med Ctr, Buffett Canc Ctr, Omaha, NE 68198 USA.	punita.dhawan@unmc.edu	Barman, Susmita/AAY-8311-2021; Chauhan, Shailender Singh/AAM-5269-2020	Chauhan, Shailender Singh/0000-0002-1975-2734; Barman, Susmita/0000-0002-0491-8498	VA merit [BX002086, DK124095, BX002761]; NIH/NCI [CA250383, CA216746]; Nebraska Research Initiative (NRI); NCI [P30 CA36727, NIH-1P50 CA 127297-01A2]	VA merit(US Department of Veterans Affairs); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Nebraska Research Initiative (NRI); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by BX002086 (VA merit), CA250383 (NIH/NCI), CA216746 (NIH/NCI), and Nebraska Research Initiative (NRI) to PD and DK124095 and BX002761 (VA merit) to ABS. We also acknowledge NCI Cancer Center Support Grant P30 CA36727, NIH-1P50 CA 127297-01A2 for tissue arrays obtained.	Alvarez-Fernandez M, 2018, CELL DEATH DIFFER, V25, P828, DOI 10.1038/s41418-017-0024-0; Alvarez-Fernandez M, 2014, BIOESSAYS, V36, P757, DOI 10.1002/bies.201400040; Alvarez-Fernandez M, 2013, P NATL ACAD SCI USA, V110, P17374, DOI 10.1073/pnas.1310745110; Ammarah U, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23246-0; Anania MC, 2015, ONCOTARGET, V6, P34629, DOI 10.18632/oncotarget.5282; Ardito CM, 2012, CANCER CELL, V22, P304, DOI 10.1016/j.ccr.2012.07.024; Barman S, 2018, J NUTR BIOCHEM, V54, P113, DOI 10.1016/j.jnutbio.2017.11.008; Cabrera M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136878; Castilho PV, 2009, MOL BIOL CELL, V20, P4777, DOI 10.1091/mbc.E09-07-0643; Chang WA, 2017, ONCOL LETT, V14, P5077, DOI 10.3892/ol.2017.6882; Chong CR, 2013, NAT MED, V19, P1389, DOI 10.1038/nm.3388; Cruz JJ, 2007, ANN ONCOL, V18, P421, DOI 10.1093/annonc/mdl175; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; El Ayachi I, 2019, CANCER RES, V79, P982, DOI 10.1158/0008-5472.CAN-18-1069; Fatima I, 2020, CANCER MED-US, V9, P6322, DOI 10.1002/cam4.3141; Fatima I, 2019, CANCERS, V11, DOI 10.3390/cancers11122039; Fatima Iram, 2018, PLoS One, V13, pe0197796, DOI 10.1371/journal.pone.0197796; Furukawa Y, 2000, J BIOL CHEM, V275, P21661, DOI 10.1074/jbc.M906893199; Gharbi-Ayachi A, 2010, SCIENCE, V330, P1673, DOI 10.1126/science.1197048; Gowrikumar S, 2019, ONCOGENE, V38, P6566, DOI 10.1038/s41388-019-0864-9; Heinemann V, 2002, SEMIN ONCOL, V29, P9, DOI 10.1053/sonc.2002.37372; Huch M, 2013, EMBO J, V32, P2708, DOI 10.1038/emboj.2013.204; Kleespies A, 2006, DRUG RESIST UPDATE, V9, P1, DOI 10.1016/j.drup.2006.02.002; Kucinska M, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0371-1; Kuo HY, 2016, GLYCOBIOLOGY, V26, P155, DOI 10.1093/glycob/cwv088; Lambert A, 2019, THER ADV MED ONCOL, V11, DOI 10.1177/1758835919875568; Li J, 2019, COMPUT STRUCT BIOTEC, V17, P498, DOI 10.1016/j.csbj.2019.03.016; Li PP, 2016, CELL, V167, P973, DOI 10.1016/j.cell.2016.10.025; Liu W, 2012, J INVEST DERMATOL, V132, P2828, DOI 10.1038/jid.2012.211; Lorca T, 2013, ONCOGENE, V32, P537, DOI 10.1038/onc.2012.79; Markowska AI, 2011, J BIOL CHEM, V286, P29913, DOI 10.1074/jbc.M111.226423; Martinez-Bosch N, 2014, CANCER RES, V74, P3512, DOI 10.1158/0008-5472.CAN-13-3013; Marzec K, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00162; Mizrahi JD, 2020, LANCET, V395, P2008, DOI 10.1016/S0140-6736(20)30974-0; Navas C, 2012, CANCER CELL, V22, P318, DOI 10.1016/j.ccr.2012.08.001; Nedaeinia R, 2014, CURR DRUG TARGETS, V15, P1293, DOI 10.2174/1389450115666141125123003; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Oberstein PE, 2013, THER ADV GASTROENTER, V6, P321, DOI 10.1177/1756283X13478680; Ocasio CA, 2016, ONCOTARGET, V7, P71182, DOI 10.18632/oncotarget.11511; Oliveira-Cunha Melissa, 2011, Cancers (Basel), V3, P1513, DOI 10.3390/cancers3021513; Orozco CA, 2018, P NATL ACAD SCI USA, V115, pE3769, DOI 10.1073/pnas.1722434115; Oyanadel C, 2018, MOL BIOL CELL, V29, P557, DOI 10.1091/mbc.E16-05-0301; Piyush T, 2017, CELL DEATH DIFFER, V24, P1937, DOI 10.1038/cdd.2017.119; Pryczynicz A, 2008, ANTICANCER RES, V28, P1399; R Core Team, 2022, R LANG ENV STAT COMP; Ren DP, 2017, J BIOL CHEM, V292, P10026, DOI 10.1074/jbc.M117.778233; Reshi I, 2020, MOL CELL BIOL, V40, DOI 10.1128/MCB.00366-18; Rogers S, 2018, ONCOGENE, V37, P4518, DOI 10.1038/s41388-018-0295-z; Roth Marc T, 2020, F1000Res, V9, DOI 10.12688/f1000research.21981.1; Ruess DA, 2017, DRUG AGING, V34, P331, DOI 10.1007/s40266-017-0453-y; Sun XJ, 2017, ONCOL LETT, V14, P7283, DOI 10.3892/ol.2017.7155; Torres MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080580; Uppada SB, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0848-3; Vera J, 2015, ELIFE, V4, DOI 10.7554/eLife.10115; Voets E, 2012, MOL CELL BIOL, V32, P1334, DOI 10.1128/MCB.00213-12; Voets E, 2010, CELL CYCLE, V9, P3591, DOI 10.4161/cc.9.17.12832; Wang L, 2014, ONCOTARGET, V5, P11479, DOI 10.18632/oncotarget.2565; Wee P, 2017, CANCERS, V9, DOI 10.3390/cancers9050052; Yao YL, 2019, CARBOHYD POLYM, V204, P111, DOI 10.1016/j.carbpol.2018.10.008; Yoon YN, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4600-6; Zaffaroni N, 2001, EUR J CANCER, V37, P1953, DOI 10.1016/S0959-8049(01)00227-1	61	4	4	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2021	40	38					5691	5704		10.1038/s41388-021-01951-x	http://dx.doi.org/10.1038/s41388-021-01951-x		JUL 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UU4CG	34331012	Green Accepted			2022-12-17	WOS:000679620500004
J	Kanda, M; Shimizu, D; Nakamura, S; Sawaki, K; Umeda, S; Miwa, T; Tanaka, H; Inokawa, Y; Hattori, N; Hayashi, M; Tanaka, C; Nakayama, G; Iguchi, Y; Katsuno, M; Kodera, Y				Kanda, Mitsuro; Shimizu, Dai; Nakamura, Shunsuke; Sawaki, Koichi; Umeda, Shinichi; Miwa, Takashi; Tanaka, Haruyoshi; Inokawa, Yoshikuni; Hattori, Norifumi; Hayashi, Masamichi; Tanaka, Chie; Nakayama, Goro; Iguchi, Yohei; Katsuno, Masahisa; Kodera, Yasuhiro			Blockade of CHRNB2 signaling with a therapeutic monoclonal antibody attenuates the aggressiveness of gastric cancer cells	ONCOGENE			English	Article							PERITONEAL METASTASIS; PROLIFERATION; RECEPTORS; SMOKING; GENES	Here, we evaluated the therapeutic potential of antibodies (Abs) targeting cholinergic receptor nicotinic beta 2 subunit (CHRNB2) in gastric cancer. To investigate the effects of these Abs on malignant phenotypes in vitro and in mouse xenograft models, we generated gene knockouts through genome editing, performed RNA interference-mediated knockdown of gene expression, and ectopically expressed CHRNB2 in gastric cancer cells. The effects of anti-CHRNB2 Abs on the proliferation of cancer cells were evaluated both in vitro and in vivo. We determined the effects of Chrnb2 deficiency on mice and the clinical significance of CHRNB2 expression in gastric cancer clinical specimens. Knockdown of CHRNB2 attenuated gastric cancer cell proliferation, whereas forced overexpression of CHRNB2 increased cell proliferation. Knockout of CHRNB2 significantly influenced cell survival and functions associated with metastasis. The effects of polyclonal Abs targeting the C- and N-termini of CHRNB2 guided the development of anti-CHRNB2 monoclonal Abs that inhibited the growth of gastric cancer cells in vitro and in vivo. Pathway analysis revealed that CHRNB2 interfered with signaling through the PI3K-AKT and JAK-STAT pathways. Chrnb2-deficient mice exhibited normal reproduction, organ functions, and motor functions. CHRNB2 regulates multiple oncological phenotypes associated with metastasis, and blockade of CHRNB2 expression using specific Abs shows promise for controlling metastasis in gastric cancer.	[Kanda, Mitsuro; Shimizu, Dai; Nakamura, Shunsuke; Sawaki, Koichi; Umeda, Shinichi; Miwa, Takashi; Tanaka, Haruyoshi; Inokawa, Yoshikuni; Hattori, Norifumi; Hayashi, Masamichi; Tanaka, Chie; Nakayama, Goro; Kodera, Yasuhiro] Nagoya Univ, Grad Sch Med, Dept Gastroenterol Surg Surg 2, Nagoya, Aichi, Japan; [Iguchi, Yohei; Katsuno, Masahisa] Nagoya Univ, Grad Sch Med, Dept Neurol, Nagoya, Aichi, Japan	Nagoya University; Nagoya University	Kanda, M (corresponding author), Nagoya Univ, Grad Sch Med, Dept Gastroenterol Surg Surg 2, Nagoya, Aichi, Japan.	m-kanda@med.nagoya-u.ac.jp	Kanda, Mitsuro/M-4891-2014; Hayashi, Masamichi/P-9743-2015	Kanda, Mitsuro/0000-0001-5464-3819; Hayashi, Masamichi/0000-0001-6875-2303; Tanaka, Haruyoshi/0000-0003-0079-8422	Japan Agency for Medical Research and Development [20H03750, 17lm0203005j0001]; Center for Advanced Medicine and Clinical Research at Nagoya University; Japan Research Foundation for Clinical Pharmacology; Foundation for Promotion of Cancer Research; Kobayashi Foundation for Cancer Research; Mochida Memorial Foundation for Medical and Pharmaceutical Research	Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED)); Center for Advanced Medicine and Clinical Research at Nagoya University; Japan Research Foundation for Clinical Pharmacology; Foundation for Promotion of Cancer Research; Kobayashi Foundation for Cancer Research(Kobayashi Foundation for Cancer Research); Mochida Memorial Foundation for Medical and Pharmaceutical Research	We thank Edanz Group (https://en-author-services.edanz.com/ac) and the SPRINGER NATURE English Language Editing service (https://authorservices.springernature.com/language-editing/) for editing a draft of this manuscript. This work was supported by a Grant-in-Aid for Scientific Research (B, 20H03750), the Japan Agency for Medical Research and Development (17lm0203005j0001, 2017); the Center for Advanced Medicine and Clinical Research at Nagoya University (2018); a grant (2018) from the Japan Research Foundation for Clinical Pharmacology, Foundation for Promotion of Cancer Research, Kobayashi Foundation for Cancer Research; and the Mochida Memorial Foundation for Medical and Pharmaceutical Research.	Ambrosi P, 2013, RECENT PAT ANTI-CANC, V8, P38; Bang YJ, 2010, LANCET, V376, P1302; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Calcagno DQ, 2013, WORLD J GASTROENTERO, V19, P1182, DOI 10.3748/wjg.v19.i8.1182; Chen JW, 2019, SURG ONCOL, V31, P46, DOI 10.1016/j.suronc.2019.09.003; Chen ZH, 2015, INT J CLIN EXP MED, V8, P9063; Cheng WL, 2020, J CANCER, V11, P1125, DOI 10.7150/jca.36359; Dasgupta P, 2009, INT J CANCER, V124, P36, DOI 10.1002/ijc.23894; Ehringer MA, 2007, AM J MED GENET B, V144B, P596, DOI 10.1002/ajmg.b.30464; Gao JF, 2014, CANCER CELL INT, V14, DOI 10.1186/s12935-014-0072-1; Ibrahim SM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35254-1; Janjigian YY, 2013, J SURG ONCOL, V107, P237, DOI 10.1002/jso.23263; Kanda M, 2020, MOL THER-NUCL ACIDS, V22, P791, DOI 10.1016/j.omtn.2020.10.001; Kanda M, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01251-0; Kanda M, 2020, GASTRIC CANCER, V23, P203, DOI 10.1007/s10120-019-00995-z; Kanda M, 2018, ONCOGENE, V37, P5355, DOI 10.1038/s41388-018-0335-8; Kanda M, 2018, ANN SURG, V267, P495, DOI 10.1097/SLA.0000000000002096; Kanda M, 2016, INT J CANCER, V138, P721, DOI 10.1002/ijc.29803; Katsuno M, 2002, NEURON, V35, P843, DOI 10.1016/S0896-6273(02)00834-6; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Miwa T, 2021, BRIT J CANCER, V124, P1449, DOI 10.1038/s41416-021-01271-7; Muro K, 2016, LANCET ONCOL, V17, P717, DOI 10.1016/S1470-2045(16)00175-3; Pedersen JE, 2019, BMC EVOL BIOL, V19, DOI 10.1186/s12862-018-1341-8; Perkins KA, 2009, CANCER EPIDEM BIOMAR, V18, P2608, DOI 10.1158/1055-9965.EPI-09-0166; Razzak Mina, 2014, Nat Rev Clin Oncol, V11, P499, DOI 10.1038/nrclinonc.2014.138; Schaal C, 2014, MOL CANCER RES, V12, P14, DOI 10.1158/1541-7786.MCR-13-0541; Shen Lin, 2013, Lancet Oncol, V14, pe535, DOI 10.1016/S1470-2045(13)70436-4; Shitara K, 2018, LANCET, V392, P123, DOI 10.1016/S0140-6736(18)31257-1; Smyth EC, 2020, LANCET, V396, P635, DOI 10.1016/S0140-6736(20)31288-5; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Thrift AP, 2020, CLIN GASTROENTEROL H, V18, P534, DOI 10.1016/j.cgh.2019.07.045; Umeda S, 2020, INT J CANCER, V146, P2865, DOI 10.1002/ijc.32705; Vandamme N, 2020, CANCER RES, V80, P2983, DOI 10.1158/0008-5472.CAN-19-2373; Velazquez EJ, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01198-8; Wadhwa R, 2013, NAT REV CLIN ONCOL, V10, P643, DOI 10.1038/nrclinonc.2013.170; Wang HY, 2013, CELL, V153, P910, DOI 10.1016/j.cell.2013.04.025; Zahavi D, 2020, ANTIBODIES, V9, DOI 10.3390/antib9030034; Zhang ZW, 2019, J CANCER, V10, P3860, DOI 10.7150/jca.31291; Zhao Rongqing, 2020, Antib Ther, V3, P63, DOI 10.1093/abt/tbaa004	39	4	4	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2021	40	36					5495	5504		10.1038/s41388-021-01945-9	http://dx.doi.org/10.1038/s41388-021-01945-9		JUL 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO7MC	34331011				2022-12-17	WOS:000679620500001
J	Liu, ZY; Wang, AQ; Pu, YY; Li, ZW; Xue, RD; Zhang, C; Xiang, X; Jian-Yu, E; Bu, ZD; Bai, F; Ji, JF				Liu, Ziyang; Wang, Anqiang; Pu, Yingying; Li, Zhongwu; Xue, Ruidong; Zhang, Chong; Xiang, Xiao; Jian-Yu, E.; Bu, Zhaode; Bai, Fan; Ji, Jiafu			Genomic and transcriptomic profiling of hepatoid adenocarcinoma of the stomach	ONCOGENE			English	Article							STEM-CELLS; TUMOR; CANCER; METASTASIS; METHIONINE; MUTATIONS; CARCINOMA; DIFFERENTIATION; HETEROGENEITY; TRANSITION	Hepatoid adenocarcinoma of the stomach (HAS), a rare subtype of gastric cancer (GC), has a low incidence but a high mortality rate. Little is known about the molecular features of HAS. Here we applied whole-exome sequencing (WES) on 58 tumours and the matched normal controls from 54 HAS patients, transcriptome sequencing on 30 HAS tumours, and single-cell RNA sequencing (scRNA-seq) on one HAS tumour. Our results reveal that the adenocarcinomatous component and hepatocellular-like component of the same HAS tumour originate monoclonally, and HAS is likely to initiate from pluripotent precursor cells. HAS has high stemness and high methionine cycle activity compared to classical GC. Two genes in the methionine cycle, MAT2A, and AHCY are potential targets for HAS treatments. We provide the first integrative genomic profiles of HAS, which may facilitate its diagnosis, prognosis, and treatment.	[Liu, Ziyang; Pu, Yingying; Xue, Ruidong; Zhang, Chong; Bai, Fan] Peking Univ, Biomed Pioneering Innovat Ctr BIOPIC, Sch Life Sci, Beijing, Peoples R China; [Wang, Anqiang; Bu, Zhaode; Ji, Jiafu] Peking Univ, Dept Gastrointestinal Surg, Canc Hosp & Inst, Minist Educ,Lab Carcinogenesis & Translat Res, Beijing, Peoples R China; [Pu, Yingying] Wuhan Univ, Frontier Sci Ctr Immunol & Metab, Sch Med, Med Res Inst, Wuhan, Peoples R China; [Pu, Yingying] Wuhan Univ, Sch & Hosp Stomatol, State Key Lab Breeding Base Basic Sci Stomatol Hu, Wuhan, Peoples R China; [Pu, Yingying] Wuhan Univ, Sch & Hosp Stomatol, Minist Educ KLOBM, Key Lab Oral Biomed, Wuhan, Peoples R China; [Li, Zhongwu] Peking Univ, Dept Pathol, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing, Peoples R China; [Xue, Ruidong] Peking Univ First Hosp, Translat Canc Res Ctr, Beijing, Peoples R China; [Xiang, Xiao] Peking Univ Peoples Hosp, Beijing Key Surg Basic Res Lab Liver Cirrhosis &, Dept Hepatobilliary Surg, Beijing, Peoples R China; [Jian-Yu, E.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Ji, Jiafu] Peking Univ, Dept Biobank, Minist Educ, Key Lab Carcinogenesis & Translat Res,Canc Hosp &, Beijing, Peoples R China	Peking University; Peking University; Wuhan University; Wuhan University; Wuhan University; Peking University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Peking University	Bai, F (corresponding author), Peking Univ, Biomed Pioneering Innovat Ctr BIOPIC, Sch Life Sci, Beijing, Peoples R China.; Bu, ZD; Ji, JF (corresponding author), Peking Univ, Dept Gastrointestinal Surg, Canc Hosp & Inst, Minist Educ,Lab Carcinogenesis & Translat Res, Beijing, Peoples R China.; Ji, JF (corresponding author), Peking Univ, Dept Biobank, Minist Educ, Key Lab Carcinogenesis & Translat Res,Canc Hosp &, Beijing, Peoples R China.	buzhaode@cjcrcn.org; jijiafu@hsc.pku.edu.cn		Liu, Ziyang/0000-0002-3067-9523; Bu, Zhaode/0000-0001-8728-9676; E, Jian-Yu/0000-0002-6175-6974; Xue, Ruidong/0000-0002-5743-805X; Zhang, Chong/0000-0001-5072-5219	National Science and Technology Major Project [2018ZX10302205, 2019YFC1315702]; Guangdong Province Key Research and Development Program [2019B020226002]; Peking University Clinical Scientist Program [BMU2019LCKXJ011]; National Science Foundation for Young Scientists of China [81802735]; Beijing Youth Talent Plan [QML20191101]; 'San Ming' Project of Shenzhen city, China [SZSM201612051]; Beijing Municipal Science and Technology Commission NOVA Program [2010B033]	National Science and Technology Major Project; Guangdong Province Key Research and Development Program; Peking University Clinical Scientist Program; National Science Foundation for Young Scientists of China; Beijing Youth Talent Plan; 'San Ming' Project of Shenzhen city, China; Beijing Municipal Science and Technology Commission NOVA Program	This work was financially supported by the National Science and Technology Major Project (2018ZX10302205, 2019YFC1315702), the Guangdong Province Key Research and Development Program (2019B020226002) to F. Bai; Peking University Clinical Scientist Program (BMU2019LCKXJ011); National Science Foundation for Young Scientists of China (No. 81802735); Beijing Youth Talent Plan (No. QML20191101); 'San Ming' Project of Shenzhen city, China (No. SZSM201612051) and Beijing Municipal Science and Technology Commission NOVA Program (2010B033).	Akazawa Y, 2018, HUM PATHOL, V78, P79, DOI 10.1016/j.humpath.2018.04.022; Alexandrov LB, 2013, CELL REP, V3, P246, DOI 10.1016/j.celrep.2012.12.008; Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021; Bort R, 2006, DEV BIOL, V290, P44, DOI 10.1016/j.ydbio.2005.11.006; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cancer Genome Atlas Research Network. Electronic address: wheeler@bcm.edu, 2017, Cell, V169, P1327, DOI 10.1016/j.cell.2017.05.046; Christenser S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12594-8; Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695; Comoglio PM, 2018, NAT REV CANCER, V18, P341, DOI 10.1038/s41568-018-0002-y; DeLaForest A, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00044; Ding X, 2019, BRAIN RES, V1717, P117, DOI 10.1016/j.brainres.2019.03.035; Favero F, 2015, ANN ONCOL, V26, P64, DOI 10.1093/annonc/mdu479; Fu DJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13847-2; Gao Q, 2019, CELL, V179, P561, DOI 10.1016/j.cell.2019.08.052; Gao X, 2019, NATURE, V572, P397, DOI 10.1038/s41586-019-1437-3; Gaude E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13041; Gibbons DL, 2018, DEV DYNAM, V247, P555, DOI 10.1002/dvdy.24485; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Harvey A, 2019, STEM CELL REP, V13, P573, DOI 10.1016/j.stemcr.2019.09.003; ISHIKURA H, 1986, CANCER, V58, P119, DOI 10.1002/1097-0142(19860701)58:1<119::AID-CNCR2820580121>3.0.CO;2-U; Jiang H, 2020, P NATL ACAD SCI USA, V117, P4770, DOI 10.1073/pnas.1914937117; Kan ZY, 2013, GENOME RES, V23, P1422, DOI 10.1101/gr.154492.113; Khemlina G, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0712-x; Kim E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09780-z; Kim JE, 2009, MODERN PATHOL, V22, P1312, DOI 10.1038/modpathol.2009.98; Kim KM, 2014, ASIA-PAC J CLIN ONCO, V10, P297, DOI 10.1111/ajco.12263; Kim S, 2018, NAT METHODS, V15, P591, DOI 10.1038/s41592-018-0051-x; Komninou D, 2006, NUTR CANCER, V54, P202, DOI 10.1207/s15327914nc5402_6; Krebs AM, 2017, NAT CELL BIOL, V19, P518, DOI 10.1038/ncb3513; Lan SW, 2019, LUNG CANCER, V132, P154, DOI 10.1016/j.lungcan.2019.04.025; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lin L, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1362-2; Liu PY, 2012, CARCINOGENESIS, V33, P1270, DOI 10.1093/carcin/bgs148; Liu XW, 2010, AM J SURG PATHOL, V34, P1465, DOI 10.1097/PAS.0b013e3181f0a873; Malta TM, 2018, CELL, V173, P338, DOI 10.1016/j.cell.2018.03.034; Martin M., 2011, EMBNET J, V17, P10, DOI 10.14806/ej.17.1.200; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Nakanishi Y, 2013, NAT GENET, V45, P98, DOI 10.1038/ng.2481; Newman AM, 2019, NAT BIOTECHNOL, V37, P773, DOI 10.1038/s41587-019-0114-2; Pastushenko I, 2019, TRENDS CELL BIOL, V29, P212, DOI 10.1016/j.tcb.2018.12.001; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044; Qing T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04221-7; Reid MA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07868-6; Roth A, 2014, NAT METHODS, V11, P396, DOI [10.1038/NMETH.2883, 10.1038/nmeth.2883]; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Scholnick SB, 2003, GENE CHROMOSOME CANC, V38, P281, DOI 10.1002/gcc.10279; Shafiei S, 2019, EXP MOL PATHOL, V108, P164, DOI 10.1016/j.yexmp.2019.04.015; Shiraki N, 2014, CELL METAB, V19, P780, DOI 10.1016/j.cmet.2014.03.017; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Su JS, 2013, WORLD J GASTROENTERO, V19, P321, DOI 10.3748/wjg.v19.i3.321; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Totoki Y, 2014, NAT GENET, V46, P1267, DOI 10.1038/ng.3126; Tschaharganeh DF, 2014, CELL, V158, P579, DOI 10.1016/j.cell.2014.05.051; Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983; Wang K, 2011, NAT GENET, V43, P1219, DOI 10.1038/ng.982; Wang Q, 2017, CELL STEM CELL, V20, P70, DOI 10.1016/j.stem.2016.10.002; Wang YK, 2019, GASTRIC CANCER, V22, P1183, DOI 10.1007/s10120-019-00965-5; Wang ZX, 2019, NAT MED, V25, P825, DOI 10.1038/s41591-019-0423-5; Xu W, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.27; Xue RD, 2019, CANCER CELL, V35, P932, DOI 10.1016/j.ccell.2019.04.007; Yonemura Y, 2002, EXP ONCOL, V24, P89; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang P, 2019, CELL REP, V27, P1934, DOI 10.1016/j.celrep.2019.04.052; Zheng CH, 2017, CELL, V169, P1342, DOI 10.1016/j.cell.2017.05.035	70	4	4	10	38	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2021	40	38					5705	5717		10.1038/s41388-021-01976-2	http://dx.doi.org/10.1038/s41388-021-01976-2		JUL 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UU4CG	34326469				2022-12-17	WOS:000679262800001
J	Rejeski, K; Duque-Afonso, J; Lubbert, M				Rejeski, Kai; Duque-Afonso, Jesus; Luebbert, Michael			AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms	ONCOGENE			English	Review							ACUTE MYELOID-LEUKEMIA; AML1-ETO FUSION PROTEIN; TARGET GENE; TUMOR-SUPPRESSOR; ASXL2 MUTATIONS; T(8/21) AML; GENOME-WIDE; MYELODYSPLASTIC SYNDROME; DIFFERENTIATION BLOCK; RETINOIC ACID	The chromosomal translocation t(8;21) and the resulting oncofusion gene AML1/ETO have long served as a prototypical genetic lesion to model and understand leukemogenesis. In this review, we describe the wide-ranging role of AML1/ETO in AML leukemogenesis, with a particular focus on the aberrant epigenetic regulation of gene transcription driven by this AML-defining mutation. We begin by analyzing how structural changes secondary to distinct genomic breakpoints and splice changes, as well as posttranscriptional modifications, influence AML1/ETO protein function. Next, we characterize how AML1/ETO recruits chromatin-modifying enzymes to target genes and how the oncofusion protein alters chromatin marks, transcription factor binding, and gene expression. We explore the specific impact of these global changes in the epigenetic network facilitated by the AML1/ETO oncofusion on cellular processes and leukemic growth. Furthermore, we define the genetic landscape of AML1/ETO-positive AML, presenting the current literature concerning the incidence of cooperating mutations in genes such as KIT, FLT3, and NRAS. Finally, we outline how alterations in transcriptional regulation patterns create potential vulnerabilities that may be exploited by epigenetically active agents and other therapeutics.	[Rejeski, Kai; Duque-Afonso, Jesus; Luebbert, Michael] Univ Freiburg, Med Ctr, Dept Hematol Oncol & Stem Cell Transplantat, Freiburg, Germany; [Rejeski, Kai] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Hematol & Oncol, Munich, Germany; [Rejeski, Kai; Luebbert, Michael] German Canc Res Ctr, German Canc Consortium DKTK Freiburg Partner Site, Heidelberg, Germany; [Duque-Afonso, Jesus; Luebbert, Michael] Univ Freiburg, Fac Med, Freiburg, Germany	University of Freiburg; University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg	Lubbert, M (corresponding author), Univ Freiburg, Med Ctr, Dept Hematol Oncol & Stem Cell Transplantat, Freiburg, Germany.; Lubbert, M (corresponding author), German Canc Res Ctr, German Canc Consortium DKTK Freiburg Partner Site, Heidelberg, Germany.; Lubbert, M (corresponding author), Univ Freiburg, Fac Med, Freiburg, Germany.	michael.luebbert@uniklinik-freiburg.de	Rejeski, Kai/AIE-6115-2022	Rejeski, Kai/0000-0003-3905-0251; Duque-Afonso, Jesus/0000-0002-8287-5673	Forschungskommission UKF [DUQ1106/16]; Berta Ottenstein-Program for Advanced Clinician Scientists, Faculty of Medicine, University of Freiburg; DFG [DU 1287/5-1, FOR 2674, CRC 992, 192904750]; Jose Carreras Leukemia Foundation [R14/25]; DKTK	Forschungskommission UKF; Berta Ottenstein-Program for Advanced Clinician Scientists, Faculty of Medicine, University of Freiburg; DFG(German Research Foundation (DFG)); Jose Carreras Leukemia Foundation; DKTK	JD receives research support from the Forschungskommission UKF (DUQ1106/16), Berta Ottenstein-Program for Advanced Clinician Scientists, Faculty of Medicine, University of Freiburg, and from the DFG (DU 1287/5-1). ML received funding by the Jose Carreras Leukemia Foundation (Project ID R14/25), the DFG (FOR 2674, Project ID A05, A09, CRC 992 Medical Epigenetics, Project ID 192904750), and DKTK. We thank Carlos Duque-Afonso for graphic design. The cloning experiments of the novel AML1 (exon 6)/ETO MigR1-overexpression plasmid outlined in Fig. 1C, D includes original work by KR with the help of Pia Veratti. We extend our gratitude to all co-workers from the Lubbert laboratory who have worked on cloning the AML1 exon 6 variant, especially Sandra Nitsch and Margit Sauer. We also thank Dr. Cornelius Miething for his advice and expertise during the cloning experiments.	Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Arora R, 2016, CURR CANCER DRUG TAR, V16, P215, DOI 10.2174/1568009616666151113120146; Ben-Ami O, 2013, CELL REP, V4, P1131, DOI 10.1016/j.celrep.2013.08.020; Berg T, 2007, LEUKEMIA RES, V31, P497, DOI 10.1016/j.leukres.2006.08.008; Berg T, 2008, HAEMATOL-HEMATOL J, V93, P1728, DOI 10.3324/haematol.13044; Bolouri H, 2018, NAT MED, V24, P103, DOI 10.1038/nm.4439; Bristow CAP, 2003, NUCLEIC ACIDS RES, V31, P2735, DOI 10.1093/nar/gkg401; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Buchi F, 2014, EPIGENETICS-US, V9, P387, DOI 10.4161/epi.27322; Cai ZL, 2000, IMMUNITY, V13, P423, DOI 10.1016/S1074-7613(00)00042-X; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chen GF, 2019, FEBS J, V286, P901, DOI 10.1111/febs.14751; Chevalier N, 2010, LEUKEMIA, V24, P1779, DOI 10.1038/leu.2010.151; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Christen F, 2019, BLOOD, V133, P1140, DOI 10.1182/blood-2018-05-852822; Claus R, 2006, J LEUKOCYTE BIOL, V80, P1462, DOI 10.1189/jlb.0106005; Craddock CF, 2017, CLIN CANCER RES, V23, P6430, DOI 10.1158/1078-0432.CCR-17-1423; De Braekeleer E, 2011, FUTURE ONCOL, V7, P77, DOI 10.2217/FON.10.158; DeKelver RC, 2014, LEUKEMIA LYMPHOMA, V55, P884, DOI 10.3109/10428194.2013.815351; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; DiNardo CD, 2018, NEW ENGL J MED, V378, P2386, DOI 10.1056/NEJMoa1716984; Dohner H, 2015, NEW ENGL J MED, V373, P1136, DOI 10.1056/NEJMra1406184; Dou LP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12960-6; Duncavage EJ, 2021, NEW ENGL J MED, V384, P924, DOI 10.1056/NEJMoa2024534; Dunne J, 2012, LEUKEMIA, V26, P1131, DOI 10.1038/leu.2011.316; Duque-Afonso J, 2011, ONCOGENE, V30, P3062, DOI 10.1038/onc.2011.32; Duque-Afonso J, 2011, BRIT J HAEMATOL, V153, P612, DOI 10.1111/j.1365-2141.2011.08586.x; Essig A, 2014, LEUKEMIA RES, V38, P340, DOI 10.1016/j.leukres.2013.12.014; Faber ZJ, 2016, NAT GENET, V48, P1551, DOI 10.1038/ng.3709; Fang HT, 2012, P NATL ACAD SCI USA, V109, P2521, DOI 10.1073/pnas.1121341109; Fazi F, 2007, BLOOD, V109, P4432, DOI 10.1182/blood-2006-09-045781; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Fliegauf M, 2004, ONCOGENE, V23, P9070, DOI 10.1038/sj.onc.1208042; Fortier JM, 2010, LEUKEMIA, V24, P950, DOI 10.1038/leu.2010.61; Frank R, 1995, ONCOGENE, V11, P2667; Gao XN, 2015, LEUKEMIA, V29, P1730, DOI 10.1038/leu.2015.56; Gardini A, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000275; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Grinev VV, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20848-z; Haferlach T, 2019, BLOOD, V133, P1006, DOI 10.1182/blood-2019-01-896076; Hartmann L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11733; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; Hollein A, 2019, HEMASPHERE, V3, DOI 10.1097/HS9.0000000000000178; Jahn N, 2017, LEUKEMIA, V31, P1012, DOI 10.1038/leu.2017.18; Jin W, 2013, ONCOGENE, V32, P1978, DOI 10.1038/onc.2012.204; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Kohrs N, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005946; Komeno Y, 2014, BLOOD, V123, P3760, DOI 10.1182/blood-2013-08-521252; Koschmieder S, 2009, J CLIN ONCOL, V27, P619, DOI 10.1200/JCO.2008.17.9812; Kozu T, 2005, GENE CHROMOSOME CANC, V43, P45, DOI 10.1002/gcc.20165; LaFiura KM, 2008, ONCOGENE, V27, P4933, DOI 10.1038/onc.2008.134; Lausten-Thomsen U, 2011, BLOOD, V117, P186, DOI 10.1182/blood-2010-05-282764; Lavallee VP, 2016, BLOOD, V127, P2498, DOI 10.1182/blood-2016-03-703868; LENNY N, 1995, ONCOGENE, V11, P1761; Li YZ, 2016, BLOOD, V127, P233, DOI 10.1182/blood-2015-03-626671; Licht JD, 2001, ONCOGENE, V20, P5660, DOI 10.1038/sj.onc.1204593; Liddiard K, 2010, ONCOGENE, V29, P2005, DOI 10.1038/onc.2009.462; Lin S, 2017, BLOOD, V130, P1213, DOI 10.1182/blood-2016-11-750976; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Liu SJ, 2007, J PHARMACOL EXP THER, V321, P953, DOI 10.1124/jpet.106.118406; Liu SJ, 2005, CANCER RES, V65, P1277, DOI 10.1158/0008-5472.CAN-04-4532; Liu XS, 2016, ONCOGENE, V35, P3071, DOI 10.1038/onc.2015.371; Liu XS, 2014, GENE DEV, V28, P1917, DOI 10.1101/gad.245910.114; Liu YZ, 2006, CANCER CELL, V9, P249, DOI 10.1016/j.ccr.2006.03.012; Loke J, 2017, CELL REP, V19, P1654, DOI 10.1016/j.celrep.2017.05.005; Lorsbach RB, 2004, BLOOD, V103, P2522, DOI 10.1182/blood-2003-07-2439; Lubbert M, 2020, J CLIN ONCOL, V38, P257, DOI 10.1200/JCO.19.01053; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; Maiques-Diaz A, 2012, LEUKEMIA, V26, P1329, DOI 10.1038/leu.2011.376; Mandoli A, 2016, CELL REP, V17, P2087, DOI 10.1016/j.celrep.2016.08.082; Mannari D, 2010, LEUKEMIA, V24, P891, DOI 10.1038/leu.2009.288; Marcucci G, 2020, BLOOD ADV, V4, P696, DOI 10.1182/bloodadvances.2019000492; Marneth AE, 2018, HAEMATOLOGICA, V103, pE395, DOI 10.3324/haematol.2017.180844; Martens JHA, 2012, BLOOD, V120, P4038, DOI 10.1182/blood-2012-05-429050; Martinez-Soria N, 2018, CANCER CELL, V34, P626, DOI 10.1016/j.ccell.2018.08.015; Meyer T, 2020, LEUKEMIA, V34, P404, DOI 10.1038/s41375-019-0578-6; Micol JB, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15429; Micol JB, 2014, BLOOD, V124, P1445, DOI 10.1182/blood-2014-04-571018; Ming Y, 2004, P NATL ACAD SCI USA, V101, P17186, DOI 10.1073/pnas.0406702101; Mulloy JC, 2005, P NATL ACAD SCI USA, V102, P4016, DOI 10.1073/pnas.0404701102; Nieborowska-Skorska M, 2019, BLOOD ADV, V3, P4050, DOI 10.1182/bloodadvances.2019000756; Oo ZM, 2018, LEUKEMIA LYMPHOMA, V59, P2188, DOI 10.1080/10428194.2017.1410882; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192; Paschka P, 2006, J CLIN ONCOL, V24, P3904, DOI 10.1200/JCO.2006.06.9500; Paschka P, 2018, LEUKEMIA, V32, P1621, DOI 10.1038/s41375-018-0129-6; Paschka P, 2013, BLOOD, V121, P170, DOI 10.1182/blood-2012-05-431486; Peterson LF, 2007, BLOOD, V109, P4392, DOI 10.1182/blood-2006-03-012575; Ponnusamy K, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.6; Ponnusamy K, 2014, HAEMATOLOGICA, V99, DOI 10.3324/haematol.2014.106088; Prebet T, 2014, J CLIN ONCOL, V32, P1242, DOI 10.1200/JCO.2013.50.3102; Ptasinska A, 2012, LEUKEMIA, V26, P1829, DOI 10.1038/leu.2012.49; Ptasinska A, 2019, CELL REP, V28, P3022, DOI 10.1016/j.celrep.2019.08.040; Ptasinska A, 2014, CELL REP, V8, P1974, DOI 10.1016/j.celrep.2014.08.024; Qi X, 2021, TOXICOL APPL PHARM, V417, DOI 10.1016/j.taap.2021.115459; Qiu JS, 2016, RNA, V22, P1535, DOI 10.1261/rna.056101.116; Monte ER, 2020, ONCOGENE, V39, P3195, DOI 10.1038/s41388-020-1209-4; ROWLEY JD, 1973, ANN GENET-PARIS, V16, P109; Saeed S, 2012, BLOOD, V120, P3058, DOI 10.1182/blood-2011-10-386086; Shia WJ, 2012, BLOOD, V119, P4953, DOI 10.1182/blood-2011-04-347476; Shimada H, 2000, BLOOD, V96, P655; Shimizu K, 2000, BLOOD, V96, P288, DOI 10.1182/blood.V96.1.288.013k05_288_296; Shiroma Y, 2020, CANCER SCI, V111, P1058, DOI 10.1111/cas.14355; Solari L, 2013, LEUKEMIA, V27, P1397, DOI 10.1038/leu.2013.53; Sood R, 2017, BLOOD, V129, P2070, DOI 10.1182/blood-2016-10-687830; Stein EM, 2017, BLOOD, V130, P722, DOI 10.1182/blood-2017-04-779405; Stoner SA, 2020, BLOOD CANCER J, V10, DOI 10.1038/s41408-020-0282-9; Sun XJ, 2013, NATURE, V500, P93, DOI 10.1038/nature12287; Tabe Y, 2007, CELL DEATH DIFFER, V14, P1443, DOI 10.1038/sj.cdd.4402139; Teppo S, 2016, GENOME RES, V26, P1468, DOI 10.1101/gr.193649.115; Thome CH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66223-2; Tiacci E, 2004, CANCER RES, V64, P7399, DOI 10.1158/0008-5472.CAN-04-1865; Tian WL, 2014, GENE, V542, P122, DOI 10.1016/j.gene.2014.03.046; Tian Y, 2018, J CELL BIOCHEM, V119, P3706, DOI 10.1002/jcb.26587; Tijchon E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226435; Tonks A, 2007, LEUKEMIA, V21, P2495, DOI 10.1038/sj.leu.2404961; Trombly DJ, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1445-0; Tyner JW, 2018, NATURE, V562, P526, DOI 10.1038/s41586-018-0623-z; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Vegi NM, 2016, CELL REP, V16, P498, DOI 10.1016/j.celrep.2016.05.094; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wang L, 2011, SCIENCE, V333, P765, DOI 10.1126/science.1201662; Wang ZD, 2021, LEUKEMIA LYMPHOMA, V62, P937, DOI 10.1080/10428194.2020.1849680; Wichmann C, 2015, LEUKEMIA, V29, P279, DOI 10.1038/leu.2014.179; Wolford JK, 1998, GENE, V212, P103, DOI 10.1016/S0378-1119(98)00141-3; Xu Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12735-z; Yamato G, 2017, GENE CHROMOSOME CANC, V56, P382, DOI 10.1002/gcc.22443; Yan M, 2006, NAT MED, V12, P945, DOI 10.1038/nm1443; Yang GY, 2005, MOL CELL BIOL, V25, P5869, DOI 10.1128/MCB.25.14.5869-5879.2005; Yang YX, 2020, J MED CHEM, V63, P1337, DOI 10.1021/acs.jmedchem.9b01721; Yin JAL, 2012, BLOOD, V120, P2826, DOI 10.1182/blood-2012-06-435669; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001; Zhang JS, 2004, SCIENCE, V305, P1286, DOI 10.1126/science.1097937; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhuang WY, 2013, ONCOL REP, V30, P185, DOI 10.3892/or.2013.2459	136	4	4	6	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2021	40	38					5665	5676		10.1038/s41388-021-01952-w	http://dx.doi.org/10.1038/s41388-021-01952-w		JUL 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UU4CG	34331016	Green Published, hybrid			2022-12-17	WOS:000679620500005
J	Huang, SB; Deng, WG; Wang, P; Yan, Y; Xie, CB; Cao, XL; Chen, M; Zhang, CL; Shi, DB; Dong, YX; Cheng, P; Xu, HL; Zhu, WK; Hu, ZC; Tang, B; Zhu, JY				Huang, Shaobin; Deng, Wuguo; Wang, Peng; Yan, Yue; Xie, Chuanbo; Cao, Xiaoling; Chen, Miao; Zhang, Changlin; Shi, Dingbo; Dong, Yunxian; Cheng, Pu; Xu, Hailin; Zhu, Wenkai; Hu, Zhicheng; Tang, Bing; Zhu, Jiayuan			Fermitin family member 2 promotes melanoma progression by enhancing the binding of p-alpha-Pix to Rac1 to activate the MAPK pathway	ONCOGENE			English	Article							STAGE-III MELANOMA; METASTATIC MELANOMA; KINDLIN-2 PROMOTES; CANCER CELLS; BRAF; INHIBITION; VEMURAFENIB; RESISTANCE; SURVIVAL; MORTALITY	We identified fermitin family member 2 (FERMT2, also known as kindlin-2) as a potential target in A375 cell line by siRNA library screening. Drugs that target mutant BRAF kinase lack durable efficacy in the treatment of melanoma because of acquired resistance, thus the identification of novel therapeutic targets is needed. Immunohistochemistry was used to identify kindlin-2 expression in melanoma samples. The interaction between kindlin-2 and Rac1 or p-Rac/Cdc42 guanine nucleotide exchange factor 6 (alpha-Pix) was investigated. Finally, the tumor suppressive role of kindlin-2 was validated in vitro and in vivo. Analysis of clinical samples and Oncomine data showed that higher levels of kindlin-2 predicted a more advanced T stage and M stage and facilitated metastasis and recurrence. Kindlin-2 knockdown significantly inhibited melanoma growth and migration, whereas kindlin-2 overexpression had the inverse effects. Further study showed that kindlin-2 could specifically bind to p-alpha-Pix(S13) and Rac1 to induce a switch from the inactive Rac1-GDP conformation to the active Rac1-GTP conformation and then stimulate the downstream MAPK pathway. Moreover, we revealed that a Rac1 inhibitor suppressed melanoma growth and metastasis and the combination of the Rac1 inhibitor and vemurafenib resulted in a better therapeutic outcome than monotherapy in melanoma with high kindlin-2 expression and BRAF mutation. Our results demonstrated that kindlin-2 promoted melanoma progression, which was attributed to specific binding to p-alpha-Pix(S13) and Rac1 to stimulate the downstream MAPK pathway. Thus, kindlin-2 could be a potential therapeutic target for treating melanoma.	[Huang, Shaobin; Wang, Peng; Cao, Xiaoling; Dong, Yunxian; Cheng, Pu; Xu, Hailin; Hu, Zhicheng; Tang, Bing; Zhu, Jiayuan] Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Peoples R China; [Huang, Shaobin; Deng, Wuguo; Yan, Yue; Xie, Chuanbo; Chen, Miao; Zhang, Changlin; Shi, Dingbo] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China; [Huang, Shaobin] Sun Yat Sen Univ, Affiliated Hosp 6, Guangzhou, Peoples R China; [Zhu, Wenkai] Portland State Univ, Dept Chem, Portland, OR 97207 USA	Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Portland State University	Hu, ZC; Tang, B; Zhu, JY (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Peoples R China.	huzhch5@mail.sysu.edu.cn; tangbing@mail.sysu.edu.cn; zhujiay@mail.sysu.edu.cn			National Natural Science Foundation of China [81702761, 81772925, 81871565]; Natural Science Foundation of Guangdong Province [2016A03031100, 2015A030313018]; Science and Technology Planning Project of Guangdong Province [2016B090916001]; Sun Yat-sen University Clinical Research 5010 Program [2013001, 2018003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Science and Technology Planning Project of Guangdong Province; Sun Yat-sen University Clinical Research 5010 Program	This work was supported in part by the National Natural Science Foundation of China (81702761, 81772925, 81871565), the Natural Science Foundation of Guangdong Province (2016A03031100, 2015A030313018), the Science and Technology Planning Project of Guangdong Province (2016B090916001), the Sun Yat-sen University Clinical Research 5010 Program (2013001, 2018003).	Amin MB., 2017, AJCC CANC STAGING MA, V8th, DOI DOI 10.1007/978-3-319-40618-3; Balch C, 1992, RADIOTHERAPY MELANOM; Barbaric J, 2016, EUR J CANCER, V55, P47, DOI 10.1016/j.ejca.2015.11.019; Bottcher RT, 2017, J CELL BIOL, V216, P3785, DOI 10.1083/jcb.201701176; Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10; Casado-Medrano V, 2018, BIOCHEM SOC T, V46, P1003, DOI 10.1042/BST20170519; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Ducreux M, 2019, THER ADV MED ONCOL, V11, DOI 10.1177/1758835919856494; Dudnik E, 2019, CLIN LUNG CANCER, V20, P278, DOI 10.1016/j.cllc.2019.03.007; Eggermont AMM, 2016, NEW ENGL J MED, V375, P1845, DOI 10.1056/NEJMoa1611299; Eggermont AMM, 2008, LANCET, V372, P117, DOI 10.1016/S0140-6736(08)61033-8; Falini B, 2019, HEMATOL ONCOL, V37, P30, DOI 10.1002/hon.2594; Fecher LA, 2008, CURR OPIN ONCOL, V20, P183, DOI 10.1097/CCO.0b013e3282f5271c; Feng JH, 2016, MOL CANCER THER, V15, P1163, DOI 10.1158/1535-7163.MCT-15-0973; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Guo L, 2018, J CELL BIOL, V217, P1431, DOI 10.1083/jcb.201612177; Guy GP, 2015, MMWR-MORBID MORTAL W, V64, P591; Haga Raquel B, 2016, Small GTPases, V7, P207; Halaban R, 2015, CLIN THER, V37, P682, DOI 10.1016/j.clinthera.2014.10.027; Hong M, 2019, CANCER MANAG RES, V11, P369, DOI 10.2147/CMAR.S186236; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; HUHN J, 2019, INT MICROBIOL; Joly MM, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0868-8; Kim G, 2014, CLIN CANCER RES, V20, P4994, DOI 10.1158/1078-0432.CCR-14-0776; KNIPPLER CM, 2019, ENDOCR RELAT CANC; Lin J, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0603-4; Long GV, 2017, ANN ONCOL, V28, P1631, DOI 10.1093/annonc/mdx176; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Long GV, 2011, J CLIN ONCOL, V29, P1239, DOI 10.1200/JCO.2010.32.4327; Ma J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066275; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Margiotta A, 2017, BBA-MOL CELL RES, V1864, P367, DOI 10.1016/j.bbamcr.2016.11.020; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Ou YW, 2016, ONCOTARGET, V7, P74872, DOI 10.18632/oncotarget.12439; Pedini F, 2019, MOL ONCOL, V13, P1836, DOI 10.1002/1878-0261.12506; Peng JX, 2019, ONCOL REP, V41, P224, DOI 10.3892/or.2018.6838; Pluskota E, 2017, J PHYSIOL-LONDON, V595, P6443, DOI 10.1113/JP274380; Qi LH, 2016, SCI CHINA LIFE SCI, V59, P1123, DOI 10.1007/s11427-016-0025-0; Qin Y, 2013, PIGM CELL MELANOMA R, V26, P97, DOI 10.1111/pcmr.12031; Robert C, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw435.37; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Sandru A, 2014, J Med Life, V7, P572; Shen ZL, 2013, J SURG ONCOL, V108, P106, DOI 10.1002/jso.23353; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Sossey-Alaoui K, 2017, CANCER RES, V77, P5129, DOI 10.1158/0008-5472.CAN-16-2337; Spagnolo F, 2015, ONCOTARGETS THER, V8, P157, DOI 10.2147/OTT.S39096; Sullivan RJ, 2019, NAT MED, V25, P929, DOI 10.1038/s41591-019-0474-7; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Wang P, 2018, INT J BIOCHEM CELL B, V105, P41, DOI 10.1016/j.biocel.2018.09.022; Wang P, 2017, SCI CHINA LIFE SCI, V60, P1214, DOI 10.1007/s11427-016-9044-5; Weber JS, 2015, LANCET ONCOL, V16, P375, DOI 10.1016/S1470-2045(15)70076-8; Wei CY, 2019, AGING-US, V11, P6273, DOI 10.18632/aging.102187; Wiebe CB, 2003, J PERIODONTOL, V74, P25, DOI 10.1902/jop.2003.74.1.25; Wu CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8531; Yang JR, 2016, GENE, V576, P571, DOI 10.1016/j.gene.2015.11.005; Yasuda-Yamahara M, 2018, MATRIX BIOL, V68-69, P263, DOI 10.1016/j.matbio.2018.01.003; Yoshida N, 2017, CANCER LETT, V390, P103, DOI 10.1016/j.canlet.2017.01.008; Zhou K, 2018, LAB INVEST, V98, P989, DOI 10.1038/s41374-018-0071-2	58	4	4	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2021	40	37					5626	5638		10.1038/s41388-021-01954-8	http://dx.doi.org/10.1038/s41388-021-01954-8		JUL 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UR2PS	34321603	hybrid, Green Published			2022-12-17	WOS:000678443300002
J	Seto-Tetsuo, F; Arioka, M; Miura, K; Inoue, T; Igawa, K; Tomooka, K; Takahashi-Yanaga, F; Sasaguri, T				Seto-Tetsuo, Fumi; Arioka, Masaki; Miura, Koichi; Inoue, Takeru; Igawa, Kazunobu; Tomooka, Katsuhiko; Takahashi-Yanaga, Fumi; Sasaguri, Toshiyuki			DIF-1 inhibits growth and metastasis of triple-negative breast cancer through AMPK-mediated inhibition of the mTORC1-S6K signaling pathway	ONCOGENE			English	Article							DIFFERENTIATION-INDUCING FACTOR; FACTOR-I; MESENCHYMAL TRANSITION; CYCLIN D1; PHOSPHORYLATION SITES; MTOR; EXPRESSION; MUTATIONS; SNAIL; P53	We have previously reported that the differentiation-inducing factor-1 (DIF-1), a compound identified in Dictyostelium discoideum, suppresses the growth of MCF-7 breast cancer cells by inactivating p70 ribosomal protein S6 kinase (p70(S6K)). Therefore, we first examined whether the same mechanism operates in other breast cancer cells, especially triple-negative breast cancer (TNBC), the most aggressive and refractory phenotype of breast cancer. We also investigated the mechanism by which DIF-1 suppresses p70(S6K) by focusing on the AMPK-mTORC1 system. We found that DIF-1 induces phosphorylation of AMPK and Raptor and dephosphorylation of p70(S6K) in multiple TNBC cell lines. Next, we examined whether AMPK-mediated inhibition of p70(S6K) leads to the suppression of proliferation and migration/infiltration of TNBC cells. DIF-1 significantly reduced the expression levels of cyclin D1 by suppressing the translation of STAT3 and strongly suppressed the expression levels of Snail, which led to the suppression of growth and motility, respectively. Finally, we investigated whether DIF-1 exerts anticancer effects on TNBC in vivo. Intragastric administration of DIF-1 suppressed tumor growth and spontaneous lung metastasis of 4T1-Luc cells injected into the mammary fat pad of BALB/c mice. DIF-1 is expected to lead to the development of anticancer drugs, including anti-TNBC, by a novel mechanism.	[Seto-Tetsuo, Fumi; Arioka, Masaki; Miura, Koichi; Inoue, Takeru; Sasaguri, Toshiyuki] Kyushu Univ, Fac Med Sci, Dept Clin Pharmacol, Fukuoka, Japan; [Igawa, Kazunobu; Tomooka, Katsuhiko] Kyushu Univ, Inst Mat Chem & Engn, Kasuga, Japan; [Takahashi-Yanaga, Fumi] Univ Occupat & Environm Hlth, Sch Med, Dept Pharmacol, Kitakyushu, Fukuoka, Japan	Kyushu University; Kyushu University; University of Occupational & Environmental Health - Japan	Arioka, M; Sasaguri, T (corresponding author), Kyushu Univ, Fac Med Sci, Dept Clin Pharmacol, Fukuoka, Japan.	arioka.masaki.118@m.kyushu-u.ac.jp; sasaguri.toshiyuki.922@m.kyushu-u.ac.jp		Tetsuo, Fumi/0000-0002-6443-9827	JSPS KAKENHI [JP17K15581, JP20K07292, JP20K22709]; Fukuoka Foundation for Sound Health Cancer Research Fund; Kaibara Morikazu Medical Science Promotion Foundation; Society for Women's Health Science Research	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Fukuoka Foundation for Sound Health Cancer Research Fund; Kaibara Morikazu Medical Science Promotion Foundation(Kaibara Morikazu Medical Science Promotion Foundation); Society for Women's Health Science Research	We appreciate the technical support provided by the Research Support Center at the Graduate School of Medical Sciences of Kyushu University. This study was supported by JSPS KAKENHI Grant Numbers JP17K15581, JP20K07292, JP20K22709, by Fukuoka Foundation for Sound Health Cancer Research Fund to MA, by Kaibara Morikazu Medical Science Promotion Foundation to MA, and by Society for Women's Health Science Research to FTY.	Agarwal S, 2016, MOL CANCER RES, V14, P66, DOI 10.1158/1541-7786.MCR-15-0159; Agarwal S, 2015, J BIOL CHEM, V290, P27473, DOI 10.1074/jbc.M115.665133; Arioka M, 2017, BIOCHEM PHARMACOL, V138, P31, DOI 10.1016/j.bcp.2017.05.004; Ban HS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162568; Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Burgstaller S, 2009, AMINO ACIDS, V36, P297, DOI 10.1007/s00726-008-0066-1; Campbell K, 2016, DEVELOPMENT, V143, P4291, DOI 10.1242/dev.139071; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Chen L, 2014, BREAST CANCER RES TR, V147, P609, DOI 10.1007/s10549-014-3112-6; Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751; DeSantis CE, 2016, CA-CANCER J CLIN, V66, P31, DOI 10.3322/caac.21320; Casas SD, 2019, CUREUS, V11, DOI 10.7759/cureus.4963; Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371; Faria J, 2019, J MAMMARY GLAND BIOL, V24, P111, DOI 10.1007/s10911-019-09429-z; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Figueiredo VC, 2017, CELL MOL LIFE SCI, V74, P2537, DOI 10.1007/s00018-017-2481-5; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Handa N, 2011, ACTA CRYSTALLOGR D, V67, P480, DOI 10.1107/S0907444911010201; He JC, 2019, BREAST CANCER RES TR, V178, P263, DOI 10.1007/s10549-019-05380-z; Hiraga T, 2004, CLIN CANCER RES, V10, P4559, DOI 10.1158/1078-0432.CCR-03-0325; Howlader NR, 2020, BREAST CANCER RES TR, V182, P739, DOI 10.1007/s10549-020-05738-8; Hua H, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0754-1; Hui L, 2006, ONCOGENE, V25, P7305, DOI 10.1038/sj.onc.1209735; Iriki T, 2017, LUNG CANCER, V106, P22, DOI 10.1016/j.lungcan.2017.01.003; Jhaveri K, 2016, CLIN BREAST CANCER, V16, P113, DOI 10.1016/j.clbc.2015.11.006; Jingushi K, 2013, J PHARMACOL SCI, V121, P103, DOI 10.1254/jphs.12204FP; Jingushi K, 2012, BIOCHEM PHARMACOL, V83, P47, DOI 10.1016/j.bcp.2011.10.001; Jiralerspong S, 2009, J CLIN ONCOL, V27, P3297, DOI 10.1200/JCO.2009.19.6410; Kubokura N, 2015, J PHARMACOL SCI, V127, P446, DOI 10.1016/j.jphs.2015.03.005; Lee JS, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1202-4; Liu QS, 2013, CANCER RES, V73, P2574, DOI 10.1158/0008-5472.CAN-12-1702; Ma JH, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-0527-z; Matsuda T, 2010, J PHARMACOL SCI, V112, P320, DOI 10.1254/jphs.09348FP; Mori J, 2005, EXP CELL RES, V310, P426, DOI 10.1016/j.yexcr.2005.07.024; MORRIS HR, 1987, NATURE, V328, P811, DOI 10.1038/328811a0; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; MUNDAY MR, 1988, EUR J BIOCHEM, V175, P331, DOI 10.1111/j.1432-1033.1988.tb14201.x; Nakamura K, 2017, J EPIDEMIOL, V27, pS58, DOI 10.1016/j.je.2016.12.009; Parajuli P, 2001, CANCER RES, V61, P8227; Pastushenko I, 2019, TRENDS CELL BIOL, V29, P212, DOI 10.1016/j.tcb.2018.12.001; Peart O, 2017, RADIOL TECHNOL, V88, p519M; Pon YL, 2008, CANCER RES, V68, P6524, DOI 10.1158/0008-5472.CAN-07-6302; Rosner M, 2010, AMINO ACIDS, V38, P223, DOI 10.1007/s00726-008-0230-7; Sabbatinelli J, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01523; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Schaffer BE, 2015, CELL METAB, V22, P907, DOI 10.1016/j.cmet.2015.09.009; Shimizu K, 2004, CANCER RES, V64, P2568, DOI 10.1158/0008-5472.CAN-03-3551; Son H, 2010, TOX RESEARCH, V26, P245, DOI 10.5487/TR.2010.26.4.245; Stevens KN, 2013, CANCER RES, V73, P2025, DOI 10.1158/0008-5472.CAN-12-1699; Sugden C, 2015, MOL BIOL CELL, V26, P805, DOI 10.1091/mbc.E14-08-1319; Takahashi-Yanaga F, 2006, J BIOL CHEM, V281, P38489, DOI 10.1074/jbc.M605205200; Takahashi-Yanaga F, 2014, BIOCHEM PHARMACOL, V89, P340, DOI 10.1016/j.bcp.2014.03.006; Tao K, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-228; Tetsuo F, 2019, CANCER SCI, V110, P3761, DOI 10.1111/cas.14204; Wang YF, 2013, CURR CANCER DRUG TAR, V13, P963, DOI 10.2174/15680096113136660102; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Yao H, 2017, ONCOTARGET, V8, P1913, DOI 10.18632/oncotarget.12284; Yin L, 2020, BREAST CANCER RES, V22, DOI 10.1186/s13058-020-01296-5; Yunokawa M, 2012, CANCER SCI, V103, P1665, DOI 10.1111/j.1349-7006.2012.02359.x; Zhang A, 2013, ONCOL LETT, V6, P339, DOI 10.3892/ol.2013.1385	63	4	4	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2021	40	37					5579	5589		10.1038/s41388-021-01958-4	http://dx.doi.org/10.1038/s41388-021-01958-4		JUL 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UR2PS	34304250				2022-12-17	WOS:000677232000001
J	Birladeanu, AM; Rogalska, M; Potiri, M; Papadaki, V; Andreadou, M; Kontoyiannis, DL; Lewis, JD; Erpapazoglou, Z; Kafasla, P				Birladeanu, Andrada-Maria; Rogalska, Malgorzata; Potiri, Myrto; Papadaki, Vasiliki; Andreadou, Margarita; Kontoyiannis, Dimitris L.; Lewis, Joe D.; Erpapazoglou, Zoi; Kafasla, Panagiota			The scaffold protein IQGAP1 links heat-induced stress signals to alternative splicing regulation in gastric cancer cells	ONCOGENE			English	Article							PRE-MESSENGER-RNA; SUMO MODIFICATION; NUCLEAR; HNRNP; SUMOYLATION; IDENTIFICATION; TRANSCRIPTOME; REVEALS; SITES; ASSOCIATION	In response to oncogenic signals, Alternative Splicing (AS) regulators such as SR and hnRNP proteins show altered expression levels, subnuclear distribution and/or post-translational modification status, but the link between signals and these changes remains unknown. Here, we report that a cytosolic scaffold protein, IQGAP1, performs this task in response to heat-induced signals. We show that in gastric cancer cells, a nuclear pool of IQGAP1 acts as a tethering module for a group of spliceosome components, including hnRNPM, a splicing factor critical for the response of the spliceosome to heat-shock. IQGAP1 controls hnRNPM's sumoylation, subnuclear localisation and the relevant response of the AS machinery to heat-induced stress. Genome-wide analyses reveal that IQGAP1 and hnRNPM co-regulate the AS of a cell cycle-related RNA regulon in gastric cancer cells, thus favouring the accelerated proliferation phenotype of gastric cancer cells. Overall, we reveal a missing link between stress signals and AS regulation.	[Birladeanu, Andrada-Maria; Potiri, Myrto; Papadaki, Vasiliki; Andreadou, Margarita; Kontoyiannis, Dimitris L.; Erpapazoglou, Zoi; Kafasla, Panagiota] BSRC Alexander Fleming, Inst Fundamental Biomed Res, 34 Fleming St, Athens 16672, Greece; [Rogalska, Malgorzata] Barcelona Inst Sci & Technol, Ctr Genom Regulat CRG, Dr Aiguader 88, Barcelona 08003, Spain; [Rogalska, Malgorzata] Univ Pompeu Fabra UPF, Barcelona 08003, Spain; [Kontoyiannis, Dimitris L.] Aristotle Univ Thessaloniki, Dept Biol, Thessaloniki, Greece; [Lewis, Joe D.] European Mol Biol Lab, D-69117 Heidelberg, Germany	Alexander Fleming Biomedical Sciences Research Center; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Pompeu Fabra University; Aristotle University of Thessaloniki; European Molecular Biology Laboratory (EMBL)	Kafasla, P (corresponding author), BSRC Alexander Fleming, Inst Fundamental Biomed Res, 34 Fleming St, Athens 16672, Greece.	kafasla@fleming.gr	, Panagiota/AAZ-2732-2021; Kafasla, Panagiota/GRR-3951-2022; Kafasla, Panagiota/B-9187-2009; Rogalska, Malgorzata Ewa/O-5962-2016	Kafasla, Panagiota/0000-0002-9730-0397; Potiri, Myrto/0000-0001-9051-5881; Rogalska, Malgorzata Ewa/0000-0002-6331-9815; Kontoyiannis, Dimitris/0000-0003-4682-9490; Lewis, Joe/0000-0002-9926-1328	European Union (European Regional Development Fund) [NSRF 2014-2020] [MIS 5002135]; Hellenic Foundation for Research & Innovation (HFRI); General Secretariat for Research and Technology (GSRT) [846]; European Research Council [ERC] [ERC AdvG 670146]; European Commission [274837]	European Union (European Regional Development Fund) [NSRF 2014-2020]; Hellenic Foundation for Research & Innovation (HFRI); General Secretariat for Research and Technology (GSRT)(Greek Ministry of Development-GSRT); European Research Council [ERC](European Research Council (ERC)European Commission); European Commission(European CommissionEuropean Commission Joint Research Centre)	InfrafrontierGR/Phenotypos Infrastructure, co-funded by Greece and the European Union (European Regional Development Fund) [NSRF 2014-2020, MIS 5002135]; Hellenic Foundation for Research & Innovation (HFRI) and the General Secretariat for Research and Technology (GSRT) [grant agreement 846 to ZE]; MR was supported by the European Research Council [ERC AdvG 670146]; European Commission Grant FP7PEOPLE-2010-IEF [274837] to PK; Stavros Niarchos Foundation (SNF) donation to BSRC "Al. Fleming".	Alfieri C, 2017, OPEN BIOL, V7, DOI 10.1098/rsob.170204; Biamonti G, 2009, TRENDS BIOCHEM SCI, V34, P146, DOI 10.1016/j.tibs.2008.11.004; Cherry S, 2020, GENE DEV, V34, P1005, DOI 10.1101/gad.338962.120; CHOI YD, 1984, P NATL ACAD SCI-BIOL, V81, P7471, DOI 10.1073/pnas.81.23.7471; Cvitkovic I, 2013, NUCLEIC ACIDS RES, V41, pD132, DOI 10.1093/nar/gks999; da Fonseca PCA, 2011, NATURE, V470, P274, DOI 10.1038/nature09625; Damianov A, 2016, CELL, V165, P606, DOI 10.1016/j.cell.2016.03.040; Denegri M, 2001, MOL BIOL CELL, V12, P3502, DOI 10.1091/mbc.12.11.3502; El Marabti E, 2018, FRONT MOL BIOSCI, V5, DOI 10.3389/fmolb.2018.00080; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; Gattoni R, 1996, NUCLEIC ACIDS RES, V24, P2535, DOI 10.1093/nar/24.13.2535; Gohr A, 2019, BIOINFORMATICS, V35, P130, DOI 10.1093/bioinformatics/bty606; Hendriks IA, 2017, NAT STRUCT MOL BIOL, V24, P325, DOI 10.1038/nsmb.3366; Hendriks IA, 2016, METHODS MOL BIOL, V1475, P171, DOI 10.1007/978-1-4939-6358-4_13; Hendriks IA, 2016, NAT REV MOL CELL BIO, V17, P581, DOI 10.1038/nrm.2016.81; Hendriks IA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8289; Hendriks IA, 2014, NAT STRUCT MOL BIOL, V21, P927, DOI 10.1038/nsmb.2890; Heyd F, 2011, TRENDS BIOCHEM SCI, V36, P397, DOI 10.1016/j.tibs.2011.04.003; Ho YD, 1999, J BIOL CHEM, V274, P464, DOI 10.1074/jbc.274.1.464; Hu W, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44048-y; Huelga SC, 2012, CELL REP, V1, P167, DOI 10.1016/j.celrep.2012.02.001; Irimia M, 2014, CELL, V159, P1511, DOI 10.1016/j.cell.2014.11.035; Johnson M, 2011, INT J BIOCHEM CELL B, V43, P65, DOI 10.1016/j.biocel.2010.09.014; Johnson MA, 2013, BBA-MOL CELL RES, V1833, P2334, DOI 10.1016/j.bbamcr.2013.06.002; Kafasla P, 2000, BIOCHEM J, V350, P495, DOI 10.1042/0264-6021:3500495; Kafasla P, 2002, BIOCHEM J, V363, P793, DOI 10.1042/0264-6021:3630793; Kahles A, 2018, CANCER CELL, V34, P211, DOI 10.1016/j.ccell.2018.07.001; Kim YS, 2014, BIOORG MED CHEM LETT, V24, P1094, DOI 10.1016/j.bmcl.2014.01.010; Lamm N, 2020, NAT CELL BIOL, V22, P1460, DOI 10.1038/s41556-020-00605-6; Langeberg LK, 2015, NAT REV MOL CELL BIO, V16, P232, DOI 10.1038/nrm3966; Li SH, 2000, MOL CELL BIOL, V20, P697, DOI 10.1128/MCB.20.2.697-701.2000; Lian ATY, 2015, CELL CYCLE, V14, P2058, DOI 10.1080/15384101.2015.1044168; Liang ZW, 2017, CANCER LETT, V411, P90, DOI 10.1016/j.canlet.2017.09.046; Liebelt F, 2019, CELL REP, V26, P236, DOI 10.1016/j.celrep.2018.12.027; Liu JQ, 2019, J CELL BIOCHEM, V120, P15790, DOI 10.1002/jcb.28849; Lleres D, 2010, EMBO REP, V11, P445, DOI 10.1038/embor.2010.64; MAHL P, 1989, J CELL BIOL, V109, P1921, DOI 10.1083/jcb.109.5.1921; Marko M, 2010, EXP CELL RES, V316, P390, DOI 10.1016/j.yexcr.2009.10.021; Matic I, 2010, MOL CELL, V39, P641, DOI 10.1016/j.molcel.2010.07.026; McQuin C, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2005970; Meissner M, 2000, J CELL BIOCHEM, V76, P559, DOI 10.1002/(SICI)1097-4644(20000315)76:4<559::AID-JCB4>3.0.CO;2-U; Neumayer G, 2014, CELL MOL LIFE SCI, V71, P3027, DOI 10.1007/s00018-014-1582-7; Oltean S, 2014, ONCOGENE, V33, P5311, DOI 10.1038/onc.2013.533; Osman MA, 2013, BBA-REV CANCER, V1836, P166, DOI 10.1016/j.bbcan.2013.04.005; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Passacantilli I, 2017, NUCLEIC ACIDS RES, V45, P12270, DOI 10.1093/nar/gkx831; Penas C, 2012, FRONT ONCOL, V1, DOI 10.3389/fonc.2011.00060; Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106; Popp MWL, 2013, ANNU REV GENET, V47, P139, DOI 10.1146/annurev-genet-111212-133424; Pozzi B, 2017, NUCLEIC ACIDS RES, V45, P6729, DOI 10.1093/nar/gkx213; Rando OJ, 2000, TRENDS CELL BIOL, V10, P92, DOI 10.1016/S0962-8924(99)01713-4; Rappsilber J, 2002, GENOME RES, V12, P1231, DOI 10.1101/gr.473902; Rosenbaum JC, 2011, MOL CELL, V41, P93, DOI 10.1016/j.molcel.2010.12.004; Santos A, 2015, NUCLEIC ACIDS RES, V43, pD1140, DOI 10.1093/nar/gku1092; Saraiva-Agostinho N, 2019, NUCLEIC ACIDS RES, V47, DOI 10.1093/nar/gky888; Sayedyahossein S, 2016, J BIOL CHEM, V291, P19261, DOI 10.1074/jbc.M116.732529; Shalgi R, 2014, CELL REP, V7, P1362, DOI 10.1016/j.celrep.2014.04.044; Sharma S, 2011, P NATL ACAD SCI USA, V108, P11381, DOI 10.1073/pnas.1019711108; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; Smith JM, 2015, TRENDS CELL BIOL, V25, P171, DOI 10.1016/j.tcb.2014.12.005; Suganuma T, 2010, CELL, V142, P726, DOI 10.1016/j.cell.2010.07.045; Sveen A, 2016, ONCOGENE, V35, P2413, DOI 10.1038/onc.2015.318; Tammsalu T, 2015, NAT PROTOC, V10, P1374, DOI 10.1038/nprot.2015.095; Van Nostrand EL, 2016, NAT METHODS, V13, P508, DOI [10.1038/NMETH.3810, 10.1038/nmeth.3810]; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; Vassileva MT, 2004, MOL CELL BIOL, V24, P3623, DOI 10.1128/MCB.24.9.3623-3632.2004; Vertegaal ACO, 2004, J BIOL CHEM, V279, P33791, DOI 10.1074/jbc.M404201200; Wang ZF, 2008, RNA, V14, P802, DOI 10.1261/rna.876308; White CD, 2009, FEBS LETT, V583, P1817, DOI 10.1016/j.febslet.2009.05.007; Yamano Hiroyuki, 2019, F1000Res, V8, DOI 10.12688/f1000research.18582.1; Zhong XY, 2009, GENE DEV, V23, P482, DOI 10.1101/gad.1752109; Zhou ZA, 2016, CELL DIV, V11, DOI 10.1186/s13008-016-0021-6	72	4	4	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2021	40	36					5518	5532		10.1038/s41388-021-01963-7	http://dx.doi.org/10.1038/s41388-021-01963-7		JUL 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO7MC	34294847	Green Accepted, Green Submitted			2022-12-17	WOS:000678016900001
J	Takagi, S; Sasaki, Y; Koike, S; Takemoto, A; Seto, Y; Haraguchi, M; Ukaji, T; Kawaguchi, T; Sugawara, M; Saito, M; Funauchi, Y; Ae, K; Matsumoto, S; Fujita, N; Katayama, R				Takagi, Satoshi; Sasaki, Yuki; Koike, Sumie; Takemoto, Ai; Seto, Yosuke; Haraguchi, Mizuki; Ukaji, Takao; Kawaguchi, Tokuichi; Sugawara, Minoru; Saito, Masanori; Funauchi, Yuki; Ae, Keisuke; Matsumoto, Seiichi; Fujita, Naoya; Katayama, Ryohei			Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis	ONCOGENE			English	Article							OSTEOGENIC-SARCOMA; CANCER; CHEMOTHERAPY; LPA(1); AGGRUS/PODOPLANIN; ANTAGONIST; MECHANISMS	Osteosarcoma is the most common primary malignant bone cancer, with high rates of pulmonary metastasis. Osteosarcoma patients with pulmonary metastasis have worse prognosis than those with localized disease, leading to dramatically reduced survival rates. Therefore, understanding the biological characteristics of metastatic osteosarcoma and the molecular mechanisms of invasion and metastasis of osteosarcoma cells will lead to the development of innovative therapeutic intervention for advanced osteosarcoma. Here, we identified that osteosarcoma cells commonly exhibit high platelet activation-inducing characteristics, and molecules released from activated platelets promote the invasiveness of osteosarcoma cells. Given that heat-denatured platelet releasate maintained the ability to promote osteosarcoma invasion, we focused on heat-tolerant molecules, such as lipid mediators in the platelet releasate. Osteosarcoma-induced platelet activation leads to abundant lysophosphatidic acid (LPA) release. Exposure to LPA or platelet releasate induced morphological changes and increased invasiveness of osteosarcoma cells. By analyzing publicly available transcriptome datasets and our in-house osteosarcoma patient-derived xenograft tumors, we found that LPA receptor 1 (LPAR1) is notably upregulated in osteosarcoma. LPAR1 gene KO in osteosarcoma cells abolished the platelet-mediated osteosarcoma invasion in vitro and the formation of early pulmonary metastatic foci in experimental pulmonary metastasis models. Of note, the pharmacological inhibition of LPAR1 by the orally available LPAR1 antagonist, ONO-7300243, prevented pulmonary metastasis of osteosarcoma in the mouse models. These results indicate that the LPA-LPAR1 axis is essential for the osteosarcoma invasion and metastasis, and targeting LPAR1 would be a promising therapeutic intervention for advanced osteosarcoma.	[Takagi, Satoshi; Sasaki, Yuki; Koike, Sumie; Takemoto, Ai; Seto, Yosuke; Haraguchi, Mizuki; Ukaji, Takao; Katayama, Ryohei] Japanese Fdn Canc Res, Canc Chemotherapy Ctr, Div Expt Chemotherapy, Tokyo, Japan; [Kawaguchi, Tokuichi; Sugawara, Minoru] Japanese Fdn Canc Res, Canc Precis Med Ctr, Project Dev Genom Based Canc Med, Tokyo, Japan; [Saito, Masanori; Funauchi, Yuki; Ae, Keisuke] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Orthoped Oncol, Tokyo, Japan; [Matsumoto, Seiichi] Japanese Fdn Canc Res, Canc Inst Hosp, Tarcoma Ctr, Tokyo, Japan; [Fujita, Naoya] Japanese Fdn Canc Res, Canc Chemotherapy Ctr, Tokyo, Japan	Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research	Katayama, R (corresponding author), Japanese Fdn Canc Res, Canc Chemotherapy Ctr, Div Expt Chemotherapy, Tokyo, Japan.	ryohei.katayama@jfcr.or.jp	Saito, Masanori/GRR-1714-2022; Katayama, Ryohei/K-8537-2014	Fujita, Naoya/0000-0002-9631-9264; Katayama, Ryohei/0000-0001-7394-895X; Saito, Masanori/0000-0002-4139-4013	MEXT/JSPS KAKENHI [JP18H06187, JP19K22572, JP17H06327, JP19H03524, JP20K21554]; Acceleration Transformative Research for Medical Innovation (ACT-M) from Japan Agency for Medical Research and Development (AMED) [JP20im0210110]; Nippon Foundation; Tokyo Biochemical Research Foundation; Project for Cancer Research and Therapeutic Evolution (P-CREATE) from the Japan Agency for Medical Research and Development (AMED) [JP21cm0106286, JP21cm0106205, JP21cm0106203]	MEXT/JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Acceleration Transformative Research for Medical Innovation (ACT-M) from Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Nippon Foundation(Nippon Foundation); Tokyo Biochemical Research Foundation; Project for Cancer Research and Therapeutic Evolution (P-CREATE) from the Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED))	We thank Mr. Yuki Shimizu, Ms. Miho Takami, Ms. Tomoko Oh-Hara, and Ms. Harumi Shibata from JFCR for technical assistance. This study was supported in part by MEXT/JSPS KAKENHI grant number JP18H06187 (to S Takagi), JP19K22572 (to S Takagi), JP17H06327 (to N Fujita), JP19H03524 (to R Katayama), and JP20K21554 (to R Katayama). This study was also supported in part by the Project for Cancer Research and Therapeutic Evolution (P-CREATE) grant number JP21cm0106286 (to S Takagi), JP21cm0106205 (to N Fujita) and JP21cm0106203 (to R Katayama), the Acceleration Transformative Research for Medical Innovation (ACT-M) grant number JP20im0210110 (to N Fujita) from the Japan Agency for Medical Research and Development (AMED), the grant from Nippon Foundation (to N Fujita), and Grant-inAid from the Tokyo Biochemical Research Foundation (to S Takagi).	Aljubran AH, 2009, ANN ONCOL, V20, P1136, DOI 10.1093/annonc/mdn731; Allanore Y, 2018, ARTHRITIS RHEUMATOL, V70, P1634, DOI 10.1002/art.40547; Anderson RL, 2019, NAT REV CLIN ONCOL, V16, P185, DOI 10.1038/s41571-018-0134-8; Aoki J, 2004, SEMIN CELL DEV BIOL, V15, P477, DOI 10.1016/j.semcdb.2004.05.001; Bacci G, 2001, EUR J CANCER, V37, P2030, DOI 10.1016/S0959-8049(01)00229-5; Baeyens AAL, 2020, ANNU REV IMMUNOL, V38, P759, DOI 10.1146/annurev-immunol-081519-083952; Bambace NM, 2011, J THROMB HAEMOST, V9, P237, DOI 10.1111/j.1538-7836.2010.04131.x; Boucharaba A, 2004, J CLIN INVEST, V114, P1714, DOI 10.1172/JCI200422123; Bousquet M, 2016, ANN ONCOL, V27, P738, DOI 10.1093/annonc/mdw009; Briccoli A, 2010, SURG ONCOL, V19, P193, DOI 10.1016/j.suronc.2009.05.002; Buergy D, 2012, INT J CANCER, V130, P2747, DOI 10.1002/ijc.27441; Casali PG, 2018, ANN ONCOL, V29, P79, DOI 10.1093/annonc/mdy310; Castelino FV, 2011, ARTHRITIS RHEUM-US, V63, P1405, DOI 10.1002/art.30262; Chatterjee M, 2020, J THROMB HAEMOST, V18, P543, DOI 10.1111/jth.14721; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; Durnali AG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152621; Franco AT, 2015, BLOOD, V126, P582, DOI 10.1182/blood-2014-08-531582; Fujita N, 2012, J BIOCHEM, V152, P407, DOI 10.1093/jb/mvs108; Gay LJ, 2011, NAT REV CANCER, V11, P123, DOI 10.1038/nrc3004; Haemmerle M, 2018, CANCER CELL, V33, P965, DOI 10.1016/j.ccell.2018.03.002; Iwano S, 2018, SCIENCE, V359, P935, DOI 10.1126/science.aaq1067; Kager L, 2003, J CLIN ONCOL, V21, P2011, DOI 10.1200/JCO.2003.08.132; Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838; Kempf-Bielack B, 2005, J CLIN ONCOL, V23, P559, DOI 10.1200/JCO.2005.04.063; Knowlden S, 2014, J IMMUNOL, V192, P851, DOI 10.4049/jimmunol.1302831; Labelle M, 2011, CANCER CELL, V20, P576, DOI 10.1016/j.ccr.2011.09.009; Leblanc R, 2018, BRIT J PHARMACOL, V175, P3100, DOI 10.1111/bph.14362; MEYERS PA, 1993, J CLIN ONCOL, V11, P449, DOI 10.1200/JCO.1993.11.3.449; Nagahashi M, 2018, CANCER SCI, V109, P3671, DOI 10.1111/cas.13802; Noguchi K, 2009, CURR OPIN PHARMACOL, V9, P15, DOI 10.1016/j.coph.2008.11.010; O'Donnell VB, 2014, CIRC RES, V114, P1185, DOI 10.1161/CIRCRESAHA.114.301597; Ohashi T, 2015, EXP DERMATOL, V24, P698, DOI 10.1111/exd.12752; Ohta H, 2003, MOL PHARMACOL, V64, P994, DOI 10.1124/mol.64.4.994; Overall CM, 2006, BRIT J CANCER, V94, P941, DOI 10.1038/sj.bjc.6603043; Palmer SM, 2018, CHEST, V154, P1061, DOI 10.1016/j.chest.2018.08.1058; Pradere JP, 2007, J AM SOC NEPHROL, V18, P3110, DOI 10.1681/ASN.2007020196; Riaz A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020215; Ribi S, 2015, ONCOTARGET, V6, P7727, DOI 10.18632/oncotarget.3115; Ritter J, 2010, ANN ONCOL, V21, P320, DOI 10.1093/annonc/mdq276; ROSEN G, 1979, CANCER-AM CANCER SOC, V43, P2163, DOI 10.1002/1097-0142(197906)43:6<2163::AID-CNCR2820430602>3.0.CO;2-S; Salah S, 2014, MOL CLIN ONCOL, V2, P811, DOI 10.3892/mco.2014.325; Sano T, 2002, J BIOL CHEM, V277, P21197, DOI 10.1074/jbc.M201289200; Stone RL, 2012, NEW ENGL J MED, V366, P610, DOI 10.1056/NEJMoa1110352; Tager AM, 2008, NAT MED, V14, P45, DOI 10.1038/nm1685; Takagi S, 2018, CLIN CANCER RES, V24, P2430, DOI 10.1158/1078-0432.CCR-17-2003; Takagi S, 2014, CANCER SCI, V105, P983, DOI 10.1111/cas.12464; Takagi S, 2014, INT J CANCER, V134, P2605, DOI 10.1002/ijc.28602; Takagi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073609; Takemoto A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42186; Xiang HJ, 2020, J CANCER, V11, P3519, DOI 10.7150/jca.41841; Zhang B, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018-020-1576-0	51	4	4	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2021	40	36					5548	5558		10.1038/s41388-021-01956-6	http://dx.doi.org/10.1038/s41388-021-01956-6		JUL 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO7MC	34302117	Green Published, hybrid			2022-12-17	WOS:000676064800003
J	Alfei, F; Ho, PC; Lo, WL				Alfei, Francesca; Ho, Ping-Chih; Lo, Wan-Lin			DCision-making in tumors governs T cell anti-tumor immunity	ONCOGENE			English	Review							PLASMACYTOID DENDRITIC CELLS; ENDOTHELIAL GROWTH-FACTOR; MELANOMA PROGRESSION; INHIBITORY RECEPTORS; DOWN-REGULATION; IFN-GAMMA; TGF-BETA; ANTIGEN; CANCER; CTLA-4	The exploitation of T cell-based immunotherapies and immune checkpoint blockade for cancer treatment has dramatically shifted oncological treatment paradigms and broadened the horizons of cancer immunology. Dendritic cells have emerged as the critical tailors of T cell immune responses, which initiate and coordinate anti-tumor immunity. Importantly, genetic alterations in cancer cells, cytokines and chemokines produced by cancer and stromal cells, and the process of tumor microenvironmental regulation can compromise dendritic cell-T cell cross-talk, thereby disrupting anti-tumor T cell responses. This review summarizes how T cell activation is controlled by dendritic cells and how the tumor microenvironment alters dendritic cell properties in the context of the anti-tumor immune cycle. Furthermore, we will highlight therapeutic options for tailoring dendritic cell-mediated decision-making in T cells for cancer treatment.	[Alfei, Francesca; Ho, Ping-Chih] Univ Lausanne, Dept Oncol, Lausanne, Switzerland; [Ho, Ping-Chih] Univ Lausanne, Ludwig Inst Canc Res, Lausanne, Switzerland; [Lo, Wan-Lin] Univ Calif San Francisco, Dept Med, Div Rheumatol, Rosalind Russell & Ephraim P Engleman Arthrit Res, San Francisco, CA 94143 USA; [Lo, Wan-Lin] Univ Utah, Dept Pathol, Div Microbiol & Immunol, Salt Lake City, UT 84112 USA	University of Lausanne; Ludwig Institute for Cancer Research; University of Lausanne; University of California System; University of California San Francisco; Utah System of Higher Education; University of Utah	Ho, PC (corresponding author), Univ Lausanne, Dept Oncol, Lausanne, Switzerland.; Ho, PC (corresponding author), Univ Lausanne, Ludwig Inst Canc Res, Lausanne, Switzerland.; Lo, WL (corresponding author), Univ Calif San Francisco, Dept Med, Div Rheumatol, Rosalind Russell & Ephraim P Engleman Arthrit Res, San Francisco, CA 94143 USA.; Lo, WL (corresponding author), Univ Utah, Dept Pathol, Div Microbiol & Immunol, Salt Lake City, UT 84112 USA.	ping-chih.ho@unil.ch; wan-lin.lo@path.utah.edu		Lo, Wan-Lin/0000-0002-9074-6847; Ho, Ping-Chih/0000-0003-3078-3774	Swiss Government Excellence Fellowship; EMBO Postdoctoral Fellowship; European Research Council [802773-MitoGuide]; SNSF [31003A_182470]; Cancer Research Institute (CLIP investigator award); Cancer Research Institute (Lloyd J. Old STAR award); NIH NIAID Career Transition Award [K22AI143960]; Ludwig Cancer Research	Swiss Government Excellence Fellowship; EMBO Postdoctoral Fellowship(European Molecular Biology Organization (EMBO)); European Research Council(European Research Council (ERC)European Commission); SNSF(Swiss National Science Foundation (SNSF)); Cancer Research Institute (CLIP investigator award); Cancer Research Institute (Lloyd J. Old STAR award); NIH NIAID Career Transition Award; Ludwig Cancer Research	We thank Matt Gubin (MD Anderson Cancer Center) and Haopeng Wang (ShanghaiTech University) for providing helpful feedback on the paper. FA is supported by a Swiss Government Excellence Fellowship and EMBO Postdoctoral Fellowship. P-CH is funded by Ludwig Cancer Research, the European Research Council Starting Grant (802773-MitoGuide), SNSF project grants (31003A_182470), and the Cancer Research Institute (CLIP investigator award and Lloyd J. Old STAR award). W-LL is supported by NIH NIAID Career Transition Award K22AI143960.	Abelin JG, 2019, IMMUNITY, V51, P766, DOI 10.1016/j.immuni.2019.08.012; Alspach E, 2019, NATURE, V574, P696, DOI 10.1038/s41586-019-1671-8; Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001; Arslan F, 2007, BRIT J CANCER, V96, P1560, DOI 10.1038/sj.bjc.6603766; Aspord C, 2013, CANCER IMMUNOL RES, V1, P402, DOI 10.1158/2326-6066.CIR-13-0114-T; Belladonna ML, 2008, J IMMUNOL, V181, P5194, DOI 10.4049/jimmunol.181.8.5194; Berdiaki A, 2008, BBA-GEN SUBJECTS, V1780, P194, DOI 10.1016/j.bbagen.2007.10.005; Binnewies M, 2019, CELL, V177, P556, DOI 10.1016/j.cell.2019.02.005; Bottcher JP, 2018, CELL, V172, P1022, DOI 10.1016/j.cell.2018.01.004; Borst J, 2018, NAT REV IMMUNOL, V18, P635, DOI 10.1038/s41577-018-0044-0; Brewitz A, 2017, IMMUNITY, V46, P205, DOI 10.1016/j.immuni.2017.01.003; Briukhovetska D, 2021, NAT REV CANCER, V21, P481, DOI 10.1038/s41568-021-00363-z; Brown RD, 2001, BLOOD, V98, P2992, DOI 10.1182/blood.V98.10.2992; Burbage M, 2020, NATURE, V584, P523, DOI 10.1038/d41586-020-02339-9; Cabrita R, 2020, NATURE, V577, P561, DOI 10.1038/s41586-019-1914-8; Cancel JC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00009; Cao W, 2014, J IMMUNOL, V192, P2920, DOI 10.4049/jimmunol.1302801; Caronni N, 2018, CANCER RES, V78, P1685, DOI 10.1158/0008-5472.CAN-17-1307; Chakraborty AK, 2014, NAT IMMUNOL, V15, P798, DOI 10.1038/ni.2940; Chen J, 2019, NATURE, V567, P530, DOI 10.1038/s41586-019-0985-x; Cheng WC, 2019, NAT IMMUNOL, V20, P206, DOI 10.1038/s41590-018-0290-0; Chomarat P, 2000, NAT IMMUNOL, V1, P510, DOI 10.1038/82763; Conrad C, 2012, CANCER RES, V72, P5240, DOI 10.1158/0008-5472.CAN-12-2271; Corthay A, 2009, CANCER RES, V69, P5901, DOI 10.1158/0008-5472.CAN-08-4816; Courtney AH, 2018, TRENDS BIOCHEM SCI, V43, P108, DOI 10.1016/j.tibs.2017.11.008; Cubillos-Ruiz JR, 2015, CELL, V161, P1527, DOI 10.1016/j.cell.2015.05.025; DALAL BI, 1993, AM J PATHOL, V143, P381; Diao J, 2011, J IMMUNOL, V186, P5058, DOI 10.4049/jimmunol.1004125; Dong R, 2020, EMBO J, V39, DOI 10.15252/embj.2020104730; Dudziak D, 2007, SCIENCE, V315, P107, DOI 10.1126/science.1136080; Fernandes RA, 2020, NATURE, V586, P779, DOI 10.1038/s41586-020-2851-2; Ferris ST, 2020, NATURE, V584, P624, DOI 10.1038/s41586-020-2611-3; FISCHER JR, 1994, EUR J CANCER, V30A, P2125, DOI 10.1016/0959-8049(94)00364-B; Flavell RA, 2010, NAT REV IMMUNOL, V10, P554, DOI 10.1038/nri2808; Fong L, 2001, P NATL ACAD SCI USA, V98, P8809, DOI 10.1073/pnas.141226398; Fourcade J, 2012, CANCER RES, V72, P887, DOI 10.1158/0008-5472.CAN-11-2637; Fu CM, 2020, P NATL ACAD SCI USA, V117, P23730, DOI 10.1073/pnas.2002345117; Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096; Gao JJ, 2017, NAT MED, V23, P551, DOI 10.1038/nm.4308; Gaud G, 2018, NAT REV IMMUNOL, V18, P485, DOI 10.1038/s41577-018-0020-8; Gee MH, 2018, CELL, V172, P549, DOI 10.1016/j.cell.2017.11.043; Giuffrida L, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23331-5; Gottfried E, 2006, BLOOD, V107, P2013, DOI 10.1182/blood-2005-05-1795; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; Gubin MM, 2018, CELL, V175, P1443, DOI 10.1016/j.cell.2018.11.003; Gubin MM, 2015, J CLIN INVEST, V125, P3413, DOI 10.1172/JCI80008; Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988; Gudipati V, 2020, NAT IMMUNOL, V21, P848, DOI 10.1038/s41590-020-0719-0; Hack K, 2012, CLIN EXP DERMATOL, V37, P557, DOI 10.1111/j.1365-2230.2012.04362.x; Herber DL, 2010, NAT MED, V16, P880, DOI 10.1038/nm.2172; Huang CY, 2020, TRANSL ONCOL, V13, DOI 10.1016/j.tranon.2020.100862; Imai K, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-3; Itakura E, 2011, MODERN PATHOL, V24, P801, DOI 10.1038/modpathol.2011.5; June CH, 2014, HUM GENE THER, V25, P779, DOI 10.1089/hum.2014.2533; Kel JM, 2010, J IMMUNOL, V185, P3248, DOI 10.4049/jimmunol.1000981; Khuu CH, 2007, MOL IMMUNOL, V44, P1598, DOI 10.1016/j.molimm.2006.08.006; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Le Bon A, 2003, NAT IMMUNOL, V4, P1009, DOI 10.1038/ni978; Li WT, 2020, IMMUNITY, V53, P456, DOI 10.1016/j.immuni.2020.07.011; Lindner SE, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz3223; Linsley PS, 1996, IMMUNITY, V4, P535, DOI 10.1016/S1074-7613(00)80480-X; Liu XD, 2019, NATURE, V567, P525, DOI 10.1038/s41586-019-0979-8; Lorenzi S, 2011, J IMMUNOL, V186, P5142, DOI 10.4049/jimmunol.1004163; Malissen B, 2020, CELL RES, V30, P948, DOI 10.1038/s41422-020-00420-6; Marzo AL, 2000, J IMMUNOL, V165, P6047, DOI 10.4049/jimmunol.165.11.6047; Matsushita H, 2012, NATURE, V482, P400, DOI 10.1038/nature10755; Montoya M, 2002, BLOOD, V99, P3263, DOI 10.1182/blood.V99.9.3263; Munoz-Erazo L, 2020, CELL MOL IMMUNOL, V17, P570, DOI 10.1038/s41423-020-0457-0; Nikitovic D, 2006, IUBMB LIFE, V58, P47, DOI 10.1080/15216540500531713; Nurieva R, 2006, EMBO J, V25, P2623, DOI 10.1038/sj.emboj.7601146; Oyama T, 1998, J IMMUNOL, V160, P1224; Qureshi OS, 2012, J BIOL CHEM, V287, P9429, DOI 10.1074/jbc.M111.304329; Qureshi OS, 2011, SCIENCE, V332, P600, DOI 10.1126/science.1202947; Ricciardelli C, 2002, CLIN CANCER RES, V8, P1054; Robert F, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.2511; Roth TL, 2020, CELL, V181, P728, DOI 10.1016/j.cell.2020.03.039; Rumpret M, 2020, NAT REV IMMUNOL, V20, P771, DOI 10.1038/s41577-020-0352-z; Salio M, 2003, EUR J IMMUNOL, V33, P1052, DOI 10.1002/eji.200323676; Salter AI, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aat6753; Scheper W, 2019, NAT MED, V25, P89, DOI 10.1038/s41591-018-0266-5; Schietinger A, 2016, IMMUNITY, V45, P389, DOI 10.1016/j.immuni.2016.07.011; Scott AC, 2019, NATURE, V571, P270, DOI 10.1038/s41586-019-1324-y; Shang WJ, 2018, P NATL ACAD SCI USA, V115, pE4051, DOI 10.1073/pnas.1801340115; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Sharma P, 2020, NAT REV IMMUNOL, V20, P75, DOI 10.1038/s41577-020-0275-8; Shifrut E, 2018, CELL, V175, P1958, DOI 10.1016/j.cell.2018.10.024; Sitkovsky MV, 2014, CANCER IMMUNOL RES, V2, P598, DOI 10.1158/2326-6066.CIR-14-0075; Sockolosky JT, 2018, SCIENCE, V359, P1037, DOI 10.1126/science.aar3246; Sockolosky JT, 2016, P NATL ACAD SCI USA, V113, pE2646, DOI 10.1073/pnas.1604268113; Spitzer MH, 2017, CELL, V168, P487, DOI 10.1016/j.cell.2016.12.022; Sugiura D, 2019, SCIENCE, V364, P558, DOI 10.1126/science.aav7062; Sun ZC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11782-w; Tang M, 2015, CELL REP, V13, P2851, DOI 10.1016/j.celrep.2015.11.053; Tel J, 2013, CANCER RES, V73, P1063, DOI 10.1158/0008-5472.CAN-12-2583; Terabe M, 2000, NAT IMMUNOL, V1, P515, DOI 10.1038/82771; Terra M, 2018, CANCER RES, V78, P3014, DOI 10.1158/0008-5472.CAN-17-2719; Theocharis AD, 2010, FEBS J, V277, P3904, DOI 10.1111/j.1742-4658.2010.07800.x; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Trendel N, 2021, SCI SIGNAL, V14, DOI 10.1126/scisignal.aay9363; Valk E, 2008, TRENDS IMMUNOL, V29, P272, DOI 10.1016/j.it.2008.02.011; vanderMerwe PA, 1997, J EXP MED, V185, P393, DOI 10.1084/jem.185.3.393; Veglia F, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02186-9; Vesely MD, 2011, ANNU REV IMMUNOL, V29, P235, DOI 10.1146/annurev-immunol-031210-101324; Vigano S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00925; von Rahden BHA, 2006, MOL CARCINOGEN, V45, P786, DOI 10.1002/mc.20259; Waickman AT, 2012, CANCER IMMUNOL IMMUN, V61, P917, DOI 10.1007/s00262-011-1155-7; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Weber EW, 2021, SCIENCE, V372, P49, DOI 10.1126/science.aba1786; Wehbi VL, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00222; Wei SC, 2017, CELL, V170, P1120, DOI 10.1016/j.cell.2017.07.024; Werfel TA, 2018, SEMIN IMMUNOPATHOL, V40, P545, DOI 10.1007/s00281-018-0698-5; Wu L, 2020, CELL MOL IMMUNOL, V17, P600, DOI 10.1038/s41423-020-0470-3; Wu W, 2020, CELL, V182, P855, DOI 10.1016/j.cell.2020.07.018; Xu MM, 2017, IMMUNITY, V47, P363, DOI 10.1016/j.immuni.2017.07.016; Xu XZ, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201905085; Yang YM, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag1209; Yarchoan M, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126908; Yost KE, 2019, NAT MED, V25, P1251, DOI 10.1038/s41591-019-0522-3; Zhao YL, 2019, IMMUNITY, V51, P1059, DOI 10.1016/j.immuni.2019.11.003	120	4	4	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2021	40	34					5253	5261		10.1038/s41388-021-01946-8	http://dx.doi.org/10.1038/s41388-021-01946-8		JUL 2021	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UJ0LG	34290401	hybrid, Green Published			2022-12-17	WOS:000677857200001
J	Clements, ME; Holtslander, L; Edwards, C; Todd, V; Dooyema, SDR; Bullock, K; Bergdorf, K; Zahnow, CA; Connolly, RM; Johnson, RW				Clements, Miranda E.; Holtslander, Lauren; Edwards, Courtney; Todd, Vera; Dooyema, Samuel D. R.; Bullock, Kennady; Bergdorf, Kensey; Zahnow, Cynthia A.; Connolly, Roisin M.; Johnson, Rachelle W.			HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer	ONCOGENE			English	Article							BONE METASTASIS; RECEPTOR; CELLS; PHOSPHORYLATION; DIFFERENTIATION; ACETYLATION; SURVIVAL	Despite advances in breast cancer treatment, residual disease driven by dormant tumor cells continues to be a significant clinical problem. Leukemia inhibitory factor receptor (LIFR) promotes a dormancy phenotype in breast cancer cells and LIFR loss is correlated with poor patient survival. Herein, we demonstrate that histone deacetylase inhibitors (HDACi), which are in phase III clinical trials for breast cancer, epigenetically induced LIFR and activated a pro-dormancy program in breast cancer cells. HDACi slowed breast cancer cell proliferation and reduced primary tumor growth. Primary breast tumors from HDACi-treated patients had increased LIFR levels and reduced proliferation rates compared to pre-treatment levels. Recent Phase II clinical trial data studying entinostat and azacitidine in metastatic breast cancer revealed that induction of several pro-dormancy genes post-treatment was associated with prolonged patient survival. Together, these findings suggest HDACi as a potential therapeutic avenue to promote dormancy, prevent recurrence, and improve patient outcomes in breast cancer.	[Clements, Miranda E.; Edwards, Courtney; Todd, Vera; Johnson, Rachelle W.] Vanderbilt Univ, Program Canc Biol, Nashville, TN 37235 USA; [Clements, Miranda E.; Holtslander, Lauren; Edwards, Courtney; Todd, Vera; Bullock, Kennady; Johnson, Rachelle W.] Vanderbilt Univ, Vanderbilt Ctr Bone Biol, Dept Med, Div Clin Pharmacol,Med Ctr, Nashville, TN 37235 USA; [Holtslander, Lauren; Johnson, Rachelle W.] Vanderbilt Univ, Dept Med, Div Clin Pharmacol, Med Ctr, Nashville, TN 37235 USA; [Dooyema, Samuel D. R.] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Nashville, TN USA; [Bullock, Kennady; Bergdorf, Kensey] Vanderbilt Univ, Dept Pharmacol, Nashville, TN USA; [Zahnow, Cynthia A.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Dept Oncol, Baltimore, MD USA; [Connolly, Roisin M.] Univ Coll Cork, Coll Med & Hlth, Canc Res UCC, Cork, Ireland; [Connolly, Roisin M.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Johns Hopkins University; Johns Hopkins Medicine; University College Cork; Johns Hopkins University; Johns Hopkins Medicine	Johnson, RW (corresponding author), Vanderbilt Univ, Program Canc Biol, Nashville, TN 37235 USA.; Johnson, RW (corresponding author), Vanderbilt Univ, Vanderbilt Ctr Bone Biol, Dept Med, Div Clin Pharmacol,Med Ctr, Nashville, TN 37235 USA.; Johnson, RW (corresponding author), Vanderbilt Univ, Dept Med, Div Clin Pharmacol, Med Ctr, Nashville, TN 37235 USA.	rachelle.johnson@vumc.org		Johnson, Rachelle/0000-0003-2755-9851	DoD Breakthrough Award [W81XWH-18-10029]; NIH [R00CA194198, P30CA068485]; Novartis; Puma Biotechnology; Merck; Genentech; Macrogenics	DoD Breakthrough Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Novartis(Novartis); Puma Biotechnology; Merck(Merck & Company); Genentech(Roche HoldingGenentech); Macrogenics	MEC, LH, CE, and RWJ are supported by DoD Breakthrough Award W81XWH-18-10029 (RWJ), and VT and RWJ are supported by NIH award R00CA194198 (RWJ). This project was also supported by scholarship funds from NIH award P30CA068485 Vanderbilt-Ingram Cancer Center Support Grant. RMC has received research grants to institution from Novartis, Puma Biotechnology, Merck, Genentech, and Macrogenics.	Abaza MSI, 2014, INT J MOL MED, V34, P513, DOI 10.3892/ijmm.2014.1795; Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Almog N, 2013, TRANSCR-AUSTIN, V4, P177, DOI 10.4161/trns.25558; Almog N, 2009, CANCER RES, V69, P836, DOI 10.1158/0008-5472.CAN-08-2590; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Bragado P, 2013, NAT CELL BIOL, V15, P1351, DOI 10.1038/ncb2861; Cackowski FC, 2017, J CELL BIOCHEM, V118, P891, DOI 10.1002/jcb.25768; Campbell JP, 2012, JOVE-J VIS EXP, DOI 10.3791/4260; Carlson P, 2019, NAT CELL BIOL, V21, P238, DOI 10.1038/s41556-018-0267-0; Chen DH, 2012, NAT MED, V18, P1511, DOI 10.1038/nm.2940; Clements ME, 2020, ONCOGENE, V39, P1318, DOI 10.1038/s41388-019-1064-3; Clements ME, 2019, CURR OSTEOPOROS REP, V17, P353, DOI 10.1007/s11914-019-00532-y; Cohen Adam L, 2017, JCO Precis Oncol, V1, DOI 10.1200/PO.16.00011; Connolly RM, 2017, CLIN CANCER RES, V23, P2691, DOI 10.1158/1078-0432.CCR-16-1729; Denoyer D, 2014, GROWTH FACTORS, V32, P63, DOI 10.3109/08977194.2014.894037; Douglas AM, 1998, INT J CANCER, V75, P64, DOI 10.1002/(SICI)1097-0215(19980105)75:1<64::AID-IJC11>3.0.CO;2-D; Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882; Eckschlager T, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071414; El Touny LH, 2014, J CLIN INVEST, V124, P156, DOI 10.1172/JCI70259; Falkenberg KJ, 2014, NAT REV DRUG DISCOV, V13, P673, DOI 10.1038/nrd4360; Formisano L, 2017, CLIN CANCER RES, V23, P6138, DOI 10.1158/1078-0432.CCR-17-1232; Gawrzak S, 2018, NAT CELL BIOL, V20, P211, DOI 10.1038/s41556-017-0021-z; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Gomis RR, 2017, MOL ONCOL, V11, P62, DOI 10.1016/j.molonc.2016.09.009; Harhous Z, 2019, FRONT CARDIOVASC MED, V6, DOI 10.3389/fcvm.2019.00150; Hosseini H, 2016, NATURE, V540, P552, DOI 10.1038/nature20785; Huang GY, 2014, STEM CELLS, V32, P1149, DOI 10.1002/stem.1609; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Iorns E, 2012, BREAST CANCER RES TR, V135, P79, DOI 10.1007/s10549-012-2068-7; Johnson RW, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00241; Johnson RW, 2016, NAT CELL BIOL, V18, P1078, DOI 10.1038/ncb3408; Kim RS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035569; MORRIS VL, 1993, CLIN EXP METASTAS, V11, P103, DOI 10.1007/BF00880071; Oki T, 2014, SCI REP-UK, V4, DOI 10.1038/srep04012; Onder TT, 2012, NATURE, V483, P598, DOI 10.1038/nature10953; Pernodet N, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3341; Sanger N, 2011, INT J CANCER, V129, P2522, DOI 10.1002/ijc.25895; Sosa MS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7170; Suraweera A, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00092; Wang XJ, 2017, CELL REP, V18, P933, DOI 10.1016/j.celrep.2016.12.081; West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738; YONEDA T, 1994, BREAST CANCER RES TR, V32, P73, DOI 10.1007/BF00666208; Yu-Lee LY, 2018, CANCER RES, V78, P2911, DOI 10.1158/0008-5472.CAN-17-1051; Yumoto K, 2016, SCI REP-UK, V6, DOI 10.1038/srep36520; Zeng HL, 2016, CANCER CELL, V30, P459, DOI 10.1016/j.ccell.2016.08.001; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017	48	4	4	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2021	40	34					5314	5326		10.1038/s41388-021-01931-1	http://dx.doi.org/10.1038/s41388-021-01931-1		JUL 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UJ0LG	34247191	Green Accepted			2022-12-17	WOS:000671644900002
J	Zhang, EB; Zhang, XP; Wang, K; Zhang, FK; Chen, TW; Ma, N; Ni, QZ; Wang, YK; Zheng, QW; Cao, HJ; Xia, J; Zhu, B; Xu, S; Ding, XF; Wang, X; Li, ZG; Cheng, SQ; Xie, D; Li, JJ				Zhang, Er-Bin; Zhang, Xiuping; Wang, Kang; Zhang, Fengkun; Chen, Tian-Wei; Ma, Ning; Ni, Qian-Zhi; Wang, Yi-Kang; Zheng, Qian-Wen; Cao, Hui-Jun; Xia, Ji; Zhu, Bing; Xu, Sheng; Ding, Xufen; Wang, Xiang; Li, Zhigang; Cheng, Shuqun; Xie, Dong; Li, Jing-Jing			Antifungal agent Terbinafine restrains tumor growth in preclinical models of hepatocellular carcinoma via AMPK-mTOR axis	ONCOGENE			English	Article							CELL-GROWTH; SORAFENIB; PATHWAY; PHOSPHORYLATION; SIROLIMUS; RAPAMYCIN; KINASE; CANCER; RAPTOR	The prognosis of hepatocellular carcinoma (HCC) remains unsatisfactory due to limited effective treatment options. In this work, we investigated the therapeutic efficacy of Terbinafine for HCC and the underlying mechanism. The influence of Terbinafine on cell growth, 3D spheroid formation, clonogenic survival, and protein synthesis was investigated in human HCC cell lines. Co-immunoprecipitation, immunofluorescence, and other techniques were employed to explore how Terbinafine exerts its anticancer effect. Subcutaneous tumorigenicity assay, orthotopic and patient-derived xenograft (PDX) HCC models were used to evaluate the anticancer effect of Terbinafine monotherapy and the combinatorial treatment with Terbinafine and sorafenib against HCC. The anticancer activity of Terbinafine was Squalene epoxidase (SQLE)-independent. Instead, Terbinafine robustly suppressed the proliferation of HCC cells by inhibiting mTORC1 signaling via activation of AMPK. Terbinafine alone or in combination with sorafenib delayed tumor progression and markedly prolonged the survival of tumor-bearing mice. The synergy between Terbinafine and sorafenib was due to concomitant inhibition of mTORC1 and induction of severe persistent DNA double-strand breaks (DSBs), which led to the delayed proliferation and accelerated cell death. Terbinafine showed promising anticancer efficacy in preclinical models of HCC and may serve as a potential therapeutic strategy for HCC.	[Zhang, Er-Bin; Zhang, Fengkun; Chen, Tian-Wei; Ma, Ning; Ni, Qian-Zhi; Wang, Yi-Kang; Zheng, Qian-Wen; Cao, Hui-Jun; Xia, Ji; Zhu, Bing; Xu, Sheng; Ding, Xufen; Xie, Dong; Li, Jing-Jing] Univ Chinese Acad Sci, Chinese Acad Sci, Shanghai Inst Nutr & Hlth, CAS Key Lab Nutr Metab & Food Safety, Shanghai 200031, Peoples R China; [Zhang, Xiuping; Wang, Kang; Cheng, Shuqun] Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 4, Shanghai 2000438, Peoples R China; [Zhang, Xiuping] Chinese People Liberat Army PLA, Fac Hepatopancreato Biliary Surg, Gen Hosp, Beijing 100853, Peoples R China; [Zhang, Xiuping] Inst Hepatobiliary Surg Chinese PLA, Beijing 100853, Peoples R China; [Zheng, Qian-Wen; Xie, Dong] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China; [Wang, Xiang] Huzhou Univ, Affiliated Hosp 1, Peoples Hosp Huzhou 1, Huzhou 313000, Zhejiang, Peoples R China; [Li, Zhigang] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Thorac Surg, Sect Esophageal Surg, Shanghai 200030, Peoples R China; [Xie, Dong] China Natl Ctr Food Safety Risk Assessment, NHC Key Lab Food Safety Risk Assessment, Beijing 100022, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Nutrition & Health, CAS; University of Chinese Academy of Sciences, CAS; Naval Medical University; ShanghaiTech University; Huzhou University; Shanghai Jiao Tong University	Xie, D; Li, JJ (corresponding author), Univ Chinese Acad Sci, Chinese Acad Sci, Shanghai Inst Nutr & Hlth, CAS Key Lab Nutr Metab & Food Safety, Shanghai 200031, Peoples R China.; Cheng, SQ (corresponding author), Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 4, Shanghai 2000438, Peoples R China.; Xie, D (corresponding author), ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China.; Xie, D (corresponding author), China Natl Ctr Food Safety Risk Assessment, NHC Key Lab Food Safety Risk Assessment, Beijing 100022, Peoples R China.	chengshuqun@aliyun.com; dxie@sibs.ac.cn; tide7@163.com	Cao, Huijun/HDM-1523-2022; cheng, sq/GPT-4112-2022; Li, Jing/GYU-5036-2022	, Ning/0000-0003-1825-8854	National Key R&D Program of China [2018YFC1603002, 2018YFC1604404]; National Natural Science Foundation of China [81730083, 82030084, 31771538, 81972757]; Youth Innovation Promotion Association of Chinese Academy of Sciences fund [2017324]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Youth Innovation Promotion Association of Chinese Academy of Sciences fund	This work was supported by the National Key R&D Program of China (2018YFC1603002 and 2018YFC1604404), National Natural Science Foundation of China (81730083 and 82030084) to Dong Xie; and National Natural Science Foundation of China (31771538 and 81972757), Youth Innovation Promotion Association of Chinese Academy of Sciences fund (2017324) to Jing-Jing Li.	Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Decaens T, 2012, DIGEST LIVER DIS, V44, P610, DOI 10.1016/j.dld.2012.02.005; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Ferrin G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041266; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Guan DX, 2015, HEPATOLOGY, V62, P1791, DOI 10.1002/hep.28117; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Humphreys, 2004, J DRUG EVALUATION, V2, P133, DOI DOI 10.3109/14791130500070064; Iavarone M, 2011, HEPATOLOGY, V54, P2055, DOI 10.1002/hep.24644; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Kudo M, 2018, LANCET, V391, P1163, DOI 10.1016/S0140-6736(18)30207-1; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Liu GY, 2020, NAT REV MOL CELL BIO, V21, P183, DOI 10.1038/s41580-019-0199-y; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Llovet JM, 2014, CLIN CANCER RES, V20, P2072, DOI 10.1158/1078-0432.CCR-13-0547; Matter MS, 2014, J HEPATOL, V60, P855, DOI 10.1016/j.jhep.2013.11.031; Menon S, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002739; Piguet AC, 2011, MOL CANCER THER, V10, P1007, DOI 10.1158/1535-7163.MCT-10-0666; Populo H, 2012, INT J MOL SCI, V13, P1886, DOI 10.3390/ijms13021886; Prieto J, 2015, NAT REV GASTRO HEPAT, V12, P681, DOI 10.1038/nrgastro.2015.173; Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168; Revankar SG, 2008, FUTURE MICROBIOL, V3, P9, DOI 10.2217/17460913.3.1.9; Rizell M, 2008, INT J CLIN ONCOL, V13, P66, DOI 10.1007/s10147-007-0733-3; Sahin F, 2004, CLIN CANCER RES, V10, P8421, DOI 10.1158/1078-0432.CCR-04-0941; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schmidt EK, 2009, NAT METHODS, V6, P275, DOI [10.1038/NMETH.1314, 10.1038/nmeth.1314]; Schoniger-Hekele M, 2010, ALIMENT PHARM THER, V32, P763, DOI 10.1111/j.1365-2036.2010.04404.x; Semela D, 2007, J HEPATOL, V46, P840, DOI 10.1016/j.jhep.2006.11.021; Sharpless NE, 2015, NAT REV CANCER, V15, P397, DOI 10.1038/nrc3960; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Thomas HE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003923; Tuominen VJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2615; Villanueva A, 2008, GASTROENTEROLOGY, V135, P1972, DOI 10.1053/j.gastro.2008.08.008; Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006	42	4	5	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2021	40	34					5302	5313		10.1038/s41388-021-01934-y	http://dx.doi.org/10.1038/s41388-021-01934-y		JUL 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UJ0LG	34247189				2022-12-17	WOS:000671644900003
J	Yu, P; Zhu, X; Zhu, JL; Han, YB; Zhang, H; Zhou, X; Yang, L; Xia, YZ; Zhang, C; Kong, LY				Yu, Pei; Zhu, Xiong; Zhu, Jia-Le; Han, Yu-Bao; Zhang, Hao; Zhou, Xiang; Yang, Lei; Xia, Yuan-Zheng; Zhang, Chao; Kong, Ling-Yi			The Chk2-PKM2 axis promotes metabolic control of vasculogenic mimicry formation in p53-mutated triple-negative breast cancer	ONCOGENE			English	Article							MUTANT P53; VASCULAR MIMICRY; CHK2; KINASE; EXPRESSION; CELLS; SENESCENCE; PROGRESSION; METASTASIS; ACTIVATION	Vasculogenic mimicry (VM) formation, which participates in the process of neovascularization, is highly activated in p53-mutated triple-negative breast cancer (TNBC). Here, we show that Chk2 is negatively correlated with VM formation in p53-mutated TNBC. Its activation by DNA-damaging agents such as cisplatin, etoposide, and DPT reduces VM formation. Mechanistically, the Chk2-PKM2 axis plays an important role in the inhibition of VM formation at the level of metabolic regulation. Chk2 promotes the Chk2-PKM2 interaction through the Chk2 SCD (SQ/TQ cluster domain) and the PKM2 C domain. Furthermore, Chk2 promotes the nuclear export of PKM2 by phosphorylating PKM2 at Ser100. P-PKM2 S100 reduces VM formation by decreasing glucose flux, and the PKM2 S100A mutation abolishes the inhibition of glucose flux and VM formation induced by Chk2 activation. Overall, this study proposes a novel strategy of VM suppression through Chk2 induction, which prevents PKM2-mediated glucose flux in p53-mutated TNBC.	[Yu, Pei; Zhu, Jia-Le; Han, Yu-Bao; Zhang, Hao; Yang, Lei; Xia, Yuan-Zheng; Zhang, Chao; Kong, Ling-Yi] China Pharmaceut Univ, Sch Tradit Chinese Pharm, Jiangsu Key Lab Bioact Nat Prod Res, Nanjing, Peoples R China; [Yu, Pei; Zhu, Jia-Le; Han, Yu-Bao; Zhang, Hao; Yang, Lei; Xia, Yuan-Zheng; Zhang, Chao; Kong, Ling-Yi] China Pharmaceut Univ, Sch Tradit Chinese Pharm, State Key Lab Nat Med, Nanjing, Peoples R China; [Zhu, Xiong] China Pharmaceut Univ, Med & Chem Inst, Nanjing, Peoples R China; [Zhou, Xiang] China Pharmaceut Univ, Dept Sci China, Nanjing, Peoples R China	China Pharmaceutical University; China Pharmaceutical University; China Pharmaceutical University; China Pharmaceutical University	Zhang, C; Kong, LY (corresponding author), China Pharmaceut Univ, Sch Tradit Chinese Pharm, Jiangsu Key Lab Bioact Nat Prod Res, Nanjing, Peoples R China.; Zhang, C; Kong, LY (corresponding author), China Pharmaceut Univ, Sch Tradit Chinese Pharm, State Key Lab Nat Med, Nanjing, Peoples R China.	zhangchao@cpu.edu.cn; cpu_lykong@126.com		Zhang, Chao/0000-0002-8163-9716; , Pei Yu/0000-0001-6729-4443	National Natural Science Foundation of China [81872986, 81872889]; "Double First-Class" University project [CPU2018GF03]; Ministry of Education of China, and the State Administration of Foreign Export Affairs of China [B18056]; Drug Innovation Major Project [2018ZX09711-001-007, 2018ZX09735002-003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); "Double First-Class" University project; Ministry of Education of China, and the State Administration of Foreign Export Affairs of China; Drug Innovation Major Project	This work was supported by the National Natural Science Foundation of China (81872986, 81872889), the "Double First-Class" University project (CPU2018GF03), the 111 Project from the Ministry of Education of China, and the State Administration of Foreign Export Affairs of China (B18056), the Drug Innovation Major Project (2018ZX09711-001-007, 2018ZX09735002-003).	Aliouat-Denis CM, 2005, MOL CANCER RES, V3, P627, DOI 10.1158/1541-7786.MCR-05-0121; Alkema NG, 2014, GYNECOL ONCOL, V133, P591, DOI 10.1016/j.ygyno.2014.03.557; Antoni L, 2007, NAT REV CANCER, V7, P925, DOI 10.1038/nrc2251; Ashwell S, 2008, CLIN CANCER RES, V14, P4032, DOI 10.1158/1078-0432.CCR-07-5138; Bartkova J, 2004, ONCOGENE, V23, P8545, DOI 10.1038/sj.onc.1207878; Carlessi L, 2007, MOL CANCER THER, V6, P935, DOI 10.1158/1535-7163.MCT-06-0567; Chen CR, 2005, CANCER RES, V65, P6017, DOI 10.1158/0008-5472.CAN-05-0677; Chen YP, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax5819; Cheng TY, 2018, ONCOGENE, V37, P1730, DOI 10.1038/s41388-017-0086-y; Dai BJ, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1404; Dando I, 2016, IUBMB LIFE, V68, P722, DOI 10.1002/iub.1534; Delgado-Bellido D, 2019, CELL DEATH DIFFER, V26, P348, DOI 10.1038/s41418-018-0125-4; Delgado-Bellido D, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0631-x; Fernandez-Cortes M, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00803; Gomez-Escudero J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50866-x; Gong C, 2015, J BIOL CHEM, V290, P14811, DOI 10.1074/jbc.M115.652628; Guo QQ, 2020, EMBO J, V39, DOI 10.15252/embj.2019103111; Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092; Hess AR, 2003, CANCER RES, V63, P4757; Hsu PC, 2019, ONCOGENE, V38, P1166, DOI 10.1038/s41388-018-0506-7; Kastenhuber ER, 2017, CELL, V170, P1062, DOI 10.1016/j.cell.2017.08.028; Kilpivaara O, 2005, INT J CANCER, V113, P575, DOI 10.1002/ijc.20638; Kwon Jiyun, 2019, Exp Mol Med, V51, P1, DOI 10.1038/s12276-019-0232-4; Langer EM, 2018, ONCOGENE, V37, P1005, DOI 10.1038/onc.2017.356; Lee JH, 2007, ONCOGENE, V26, P7741, DOI 10.1038/sj.onc.1210872; Li TB, 2017, NAT METHODS, V14, P61, DOI 10.1038/nmeth.4083; Liang J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12431; Liu K, 2017, P NATL ACAD SCI USA, V114, pE3766, DOI 10.1073/pnas.1619832114; Liu S, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1411-x; Liu TJ, 2013, ONCOGENE, V32, P544, DOI 10.1038/onc.2012.85; Lulli M, 2021, CANCER RES, V81, P2861, DOI 10.1158/0008-5472.CAN-20-3134; Ma CX, 2012, J CLIN INVEST, V122, P1541, DOI 10.1172/JCI58765; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Meng J, 2019, ONCOGENE, V38, P228, DOI 10.1038/s41388-018-0428-4; Mukhopadhyay UK, 2019, JNCI-J NATL CANCER I, V111, P1202, DOI 10.1093/jnci/djz051; Muller PAJ, 2013, ONCOGENE, V32, P1252, DOI 10.1038/onc.2012.148; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Nayak D, 2017, CELL DEATH DIFFER, V24, P1275, DOI 10.1038/cdd.2017.70; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; Perona R, 2008, CLIN TRANSL ONCOL, V10, P538, DOI 10.1007/s12094-008-0248-5; Pommier Y, 2006, CLIN CANCER RES, V12, P2657, DOI 10.1158/1078-0432.CCR-06-0743; Quiros-Gonzalez I, 2018, BRIT J CANCER, V118, P1098, DOI 10.1038/s41416-018-0033-x; Schneider JG, 2006, CELL METAB, V4, P377, DOI 10.1016/j.cmet.2006.10.002; Seo GJ, 2003, BIOCHEM BIOPH RES CO, V304, P339, DOI 10.1016/S0006-291X(03)00589-8; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Sullivan A, 2002, ONCOGENE, V21, P1316, DOI 10.1038/sj.onc.1205207; Sun T, 2010, HEPATOLOGY, V51, P545, DOI 10.1002/hep.23311; Sun Y, 1999, MOL CARCINOGEN, V24, P25, DOI 10.1002/(SICI)1098-2744(199901)24:1<25::AID-MC4>3.3.CO;2-J; Tang QS, 2020, TRENDS CANCER, V6, P62, DOI 10.1016/j.trecan.2019.11.004; Tat SK, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2782; Vogiatzi F, 2016, P NATL ACAD SCI USA, V113, pE8433, DOI 10.1073/pnas.1612711114; Wagenblast E, 2015, NATURE, V520, P358, DOI 10.1038/nature14403; Wang Y, 2018, J CELL MOL MED, V22, P3475, DOI 10.1111/jcmm.13625; Wei Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14041; Williamson SC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13322; Xiao Z, 2006, MOL CANCER THER, V5, P1935, DOI 10.1158/1535-7163.MCT-06-0077; Yan W, 2018, NAT CELL BIOL, V20, P597, DOI 10.1038/s41556-018-0083-6; Yang JN, 2016, CANCER LETT, V383, P18, DOI 10.1016/j.canlet.2016.09.012; Yang P, 2014, CELL SIGNAL, V26, P1853, DOI 10.1016/j.cellsig.2014.03.020; Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Yang ZH, 2015, EXP MOL PATHOL, V98, P352, DOI 10.1016/j.yexmp.2015.03.030; Yu WW, 2019, ONCOGENE, V38, P1225, DOI 10.1038/s41388-018-0463-1; Zhang Q, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1282-6; Zhang SW, 2007, CANCER LETT, V254, P157, DOI 10.1016/j.canlet.2006.12.036; Zhao N, 2012, MED ONCOL, V29, P3599, DOI 10.1007/s12032-012-0245-5; Zhao WJ, 2018, CELL PHYSIOL BIOCHEM, V45, P1590, DOI 10.1159/000487724	67	4	4	4	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2021	40	34					5262	5274		10.1038/s41388-021-01933-z	http://dx.doi.org/10.1038/s41388-021-01933-z		JUL 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UJ0LG	34244606				2022-12-17	WOS:000672114100002
J	Lyu, L; Lin, TC; McCarty, N				Lyu, Lin; Lin, Tsung-Chin; McCarty, Nami			TRIM44 mediated p62 deubiquitination enhances DNA damage repair by increasing nuclear FLNA and 53BP1 expression	ONCOGENE			English	Article							COMET ASSAY; PATHWAYS; PROLIFERATION; AUTOPHAGY; MIGRATION; UBIQUITIN; PROTEINS; INVASION; TARGETS; CELLS	Cancer cells show increases in protein degradation pathways, including autophagy, during progression to meet the increased protein degradation demand and support cell survival. On the other hand, reduced autophagy activity during aging is associated with a reduced DNA damage response and increased genomic instability. Therefore, it is a puzzling how DNA repair can be increased in cancer cells that are resistant to chemotherapies or during progression when autophagy activity is intact or increased. We discovered that tripartite motif containing 44 (TRIM44) is a pivotal element regulating the DNA damage response in cancer cells with intact autophagy. TRIM44 deubiquitinates p62, an autophagy substrate, which leads to its oligomerization. This prevents p62 localization to the nucleus upon irradiation. Increased cytoplasmic retention of p62 by TRIM44 prevents the degradation of FLNA and 53BP1, which increases DNA damage repair. Together, our data support TRIM44 a potential therapeutic target for therapy-resistant tumor cells with intact autophagy.	[Lyu, Lin; Lin, Tsung-Chin; McCarty, Nami] Univ Texas Hlth Sci Ctr Houston, Ctr Stem Cell & Regenerat Dis, Brown Fdn Inst Mol Med Prevent Human Dis IMM, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	McCarty, N (corresponding author), Univ Texas Hlth Sci Ctr Houston, Ctr Stem Cell & Regenerat Dis, Brown Fdn Inst Mol Med Prevent Human Dis IMM, Houston, TX 77030 USA.	nami.mccarty@uth.tmc.edu		Lyu, Lin/0000-0001-9771-0110	NIH [R01CA181319]; CPRIT grant [RP20093]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CPRIT grant	This work is supported by NIH grant (R01CA181319) and CPRIT grant (RP20093) given to NM.	Ahmed KM, 2018, MOL CELL BIOL, V38, DOI 10.1128/MCB.00672-17; Anderson KC., 2011, ONCOLOGY-BASEL, V25, pS3; Blanpain C, 2011, CELL STEM CELL, V8, P16, DOI 10.1016/j.stem.2010.12.012; Boehrer S, 2009, ONCOGENE, V28, P2205, DOI 10.1038/onc.2009.69; Cambiaghi V, 2012, ADV EXP MED BIOL, V770, P77; Chen Z, 2019, LEUKEMIA, V33, P469, DOI 10.1038/s41375-018-0222-x; Chen Z, 2014, BLOOD, V123, P2204, DOI 10.1182/blood-2013-07-517136; Dietlein F, 2014, TRENDS GENET, V30, P326, DOI 10.1016/j.tig.2014.06.003; Gogineni VR, 2011, CANCER LETT, V313, P64, DOI 10.1016/j.canlet.2011.08.022; Gourzones-Dmitriev C, 2013, CELL CYCLE, V12, P2760, DOI 10.4161/cc.25951; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Herrero AB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121581; Hewitt G, 2016, AUTOPHAGY, V12, P1917, DOI 10.1080/15548627.2016.1210368; Huen MSY, 2007, CELL, V131, P901, DOI 10.1016/j.cell.2007.09.041; Ichimura Y, 2008, J BIOL CHEM, V283, P22847, DOI 10.1074/jbc.M802182200; Jarvinen AK, 2008, GENE CHROMOSOME CANC, V47, P500, DOI 10.1002/gcc.20551; Kashimoto K, 2012, CANCER SCI, V103, P2021, DOI 10.1111/j.1349-7006.2012.02407.x; Kawabata H, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091931; Kawaguchi T, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317700409; Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026; Klaude M, 1996, MUTAT RES-DNA REPAIR, V363, P89, DOI 10.1016/0921-8777(95)00063-1; Kolas NK, 2007, SCIENCE, V318, P1637, DOI 10.1126/science.1150034; Lindahl T, 2004, NATURE, V427, P598, DOI 10.1038/427598a; Luo QQ, 2015, INT J CLIN ONCOL, V20, P508, DOI 10.1007/s10147-014-0752-9; Michels TC, 2017, AM FAM PHYSICIAN, V95, P373; Mirman Z, 2020, GENE DEV, V34, P7, DOI 10.1101/gad.333237.119; Munshi NC, 2013, CLIN CANCER RES, V19, P3337, DOI 10.1158/1078-0432.CCR-12-1881; Nisole S, 2005, NAT REV MICROBIOL, V3, P799, DOI 10.1038/nrmicro1248; Nubel U, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000855; Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5; Ong CAJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju050; Pan JA, 2016, MOL CELL, V62, P149, DOI 10.1016/j.molcel.2016.03.015; Panier S, 2014, NAT REV MOL CELL BIO, V15, P7, DOI 10.1038/nrm3719; Pankiv S, 2010, J BIOL CHEM, V285, P5941, DOI 10.1074/jbc.M109.039925; Petermann E, 2010, MOL CELL, V37, P492, DOI 10.1016/j.molcel.2010.01.021; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Rodgers K, 2016, J CELL PHYSIOL, V231, P15, DOI 10.1002/jcp.25053; Shammas MA, 2009, BLOOD, V113, P2290, DOI 10.1182/blood-2007-05-089193; Tan YY, 2017, ONCOL RES, V25, P1253, DOI 10.3727/096504017X14854310794561; Terry LJ, 2007, SCIENCE, V318, P1412, DOI 10.1126/science.1142204; Torgovnick A, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00157; Velkova A, 2010, CELL CYCLE, V9, P1421, DOI 10.4161/cc.9.7.11256; Walters DK, 2011, LEUKEMIA, V25, P1344, DOI 10.1038/leu.2011.94; Wang YN, 2016, MOL CELL, V63, P34, DOI 10.1016/j.molcel.2016.05.027; Yamada Y, 2017, CANCER SCI, V108, P32, DOI 10.1111/cas.13105	45	4	4	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2021	40	32					5116	5130		10.1038/s41388-021-01890-7	http://dx.doi.org/10.1038/s41388-021-01890-7		JUL 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA7OD	34211088				2022-12-17	WOS:000668832500001
J	Chen, CH; Wang, BW; Hsiao, YC; Wu, CY; Cheng, FJ; Hsia, TC; Chen, CY; Wang, YH; Weihua, Z; Chou, RH; Tang, CH; Chen, YJ; Wei, YL; Hsu, JL; Tu, CY; Hung, MC; Huang, WC				Chen, Chia-Hung; Wang, Bo-Wei; Hsiao, Yu-Chun; Wu, Chun-Yi; Cheng, Fang-Ju; Hsia, Te-Chun; Chen, Chih-Yi; Wang, Yihua; Weihua, Zhang; Chou, Ruey-Hwang; Tang, Chih-Hsin; Chen, Yun-Ju; Wei, Ya-Ling; Hsu, Jennifer L.; Tu, Chih-Yen; Hung, Mien-Chie; Huang, Wei-Chien			PKC delta-mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITOR; BREAST-CANCER CELLS; LUNG-CANCER; GLUCOSE-TRANSPORTER; EARLY PREDICTION; EXPRESSION; PROTEIN; PHOSPHORYLATION; OVEREXPRESSION	The tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) have been widely used for non-small cell lung cancer (NSCLC) patients, but the development of acquired resistance remains a therapeutic hurdle. The reduction of glucose uptake has been implicated in the anti-tumor activity of EGFR TKIs. In this study, the upregulation of the active sodium/glucose co-transporter 1 (SGLT1) was found to confer the development of acquired EGFR TKI resistance and was correlated with the poorer clinical outcome of the NSCLC patients who received EGFR TKI treatment. Blockade of SGLT1 overcame this resistance in vitro and in vivo by reducing glucose uptake in NSCLC cells. Mechanistically, SGLT1 protein was stabilized through the interaction with PKC delta-phosphorylated (Thr678) EGFR in the TKI-resistant cells. Our findings revealed that PKC delta/EGFR axis-dependent SGLT1 upregulation was a critical mechanism underlying the acquired resistance to EGFR TKIs. We suggest co-targeting PKC delta/SGLT1 as a potential strategy to improve the therapeutic efficacy of EGFR TKIs in NSCLC patients.	[Chen, Chia-Hung; Hsia, Te-Chun; Tu, Chih-Yen] China Med Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Taichung, Taiwan; [Chen, Chia-Hung; Tang, Chih-Hsin; Tu, Chih-Yen] China Med Univ, Sch Med, Taichung, Taiwan; [Chen, Chia-Hung; Hsia, Te-Chun] China Med Univ, Dept Resp Therapy, Taichung, Taiwan; [Wang, Bo-Wei; Hsiao, Yu-Chun; Chou, Ruey-Hwang; Wei, Ya-Ling; Hsu, Jennifer L.; Hung, Mien-Chie; Huang, Wei-Chien] China Med Univ, Ctr Mol Med, Res Ctr Canc Biol, Taichung, Taiwan; [Wang, Bo-Wei; Hsiao, Yu-Chun; Chou, Ruey-Hwang; Wei, Ya-Ling; Hsu, Jennifer L.; Hung, Mien-Chie; Huang, Wei-Chien] China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan; [Wang, Bo-Wei; Hsiao, Yu-Chun; Hung, Mien-Chie; Huang, Wei-Chien] China Med Univ, Drug Dev Ctr, Taichung, Taiwan; [Hsiao, Yu-Chun; Cheng, Fang-Ju; Chou, Ruey-Hwang; Hung, Mien-Chie; Huang, Wei-Chien] China Med Univ, PhD Program Canc Biol & Drug Discovery, Taichung, Taiwan; [Hsiao, Yu-Chun; Cheng, Fang-Ju; Chou, Ruey-Hwang; Hung, Mien-Chie; Huang, Wei-Chien] Acad Sinica, Taichung, Taiwan; [Wu, Chun-Yi] Natl Yang Ming Univ, Dept Biomed Imaging & Radiol Sci, Taipei, Taiwan; [Cheng, Fang-Ju; Tang, Chih-Hsin] China Med Univ, Grad Inst Basic Med Sci, Taichung, Taiwan; [Cheng, Fang-Ju; Hsu, Jennifer L.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Hsia, Te-Chun] China Med Univ Hosp, Hyperbar Oxygen Therapy Ctr, Dept Internal Med, Taichung, Taiwan; [Chen, Chih-Yi] Chung Shan Med Univ, Inst Med, Dept Surg, Div Thorac Surg, Taichung, Taiwan; [Wang, Yihua] Univ Southampton, Fac Environm & Life Sci, Biol Sci, Southampton, Hants, England; [Wang, Yihua] Univ Southampton, Inst Life Sci, Southampton, Hants, England; [Weihua, Zhang] Univ Houston, Dept Biol & Biochem, Houston, TX USA; [Chen, Yun-Ju] E Da Hosp, Dept Med Res, Kaohsiung, Taiwan; [Chen, Yun-Ju] I Shou Univ, Sch Med Int Students, Kaohsiung, Taiwan; [Chen, Yun-Ju] E Da Hosp, Dept Pharm, Kaohsiung, Taiwan; [Huang, Wei-Chien] Asia Univ, Dept Med Lab Sci & Biotechnol, Taichung, Taiwan	China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; Academia Sinica - Taiwan; National Yang Ming Chiao Tung University; China Medical University Taiwan; University of Texas System; UTMD Anderson Cancer Center; China Medical University Taiwan; China Medical University Hospital - Taiwan; Chung Shan Medical University; University of Southampton; University of Southampton; University of Houston System; University of Houston; E-Da Hospital; I Shou University; E-Da Hospital; Asia University Taiwan	Tu, CY (corresponding author), China Med Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Taichung, Taiwan.; Tu, CY (corresponding author), China Med Univ, Sch Med, Taichung, Taiwan.; Hung, MC; Huang, WC (corresponding author), China Med Univ, Ctr Mol Med, Res Ctr Canc Biol, Taichung, Taiwan.; Hung, MC; Huang, WC (corresponding author), China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan.; Hung, MC; Huang, WC (corresponding author), China Med Univ, Drug Dev Ctr, Taichung, Taiwan.; Hung, MC; Huang, WC (corresponding author), China Med Univ, PhD Program Canc Biol & Drug Discovery, Taichung, Taiwan.; Hung, MC; Huang, WC (corresponding author), Acad Sinica, Taichung, Taiwan.; Huang, WC (corresponding author), Asia Univ, Dept Med Lab Sci & Biotechnol, Taichung, Taiwan.	chesttu@gmail.com; mhung@cmu.edu.tw; whuang@mail.cmu.edu.tw	Chou, Ruey-Hwang/K-8541-2013; Hung, Mien-Chie/ABD-5911-2021; Wang, Bo/AAU-1329-2021	Chou, Ruey-Hwang/0000-0002-2297-2180; Hung, Mien-Chie/0000-0003-4317-4740; Wang, Bo/0000-0001-8947-8526; Cheng, Fang-Ju/0000-0001-6104-7185; Wang, Yihua/0000-0001-5561-0648	Ministry of Science Technology, Taiwan [MOST 108-2314-B-039-032]; China Medical University [CMU106-ASIA-18]; China Medical University Hospital [DMR-108-012, DMR-109-212, DMR-109-213]; "Drug Development Center, China Medical University" from The Featured Areas Research Center Program by the Ministry of Education (MOE) in Taiwan; Medical Research Council [MR/S025480/1]	Ministry of Science Technology, Taiwan; China Medical University(China Medical University); China Medical University Hospital; "Drug Development Center, China Medical University" from The Featured Areas Research Center Program by the Ministry of Education (MOE) in Taiwan; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Experiments and data analysis were performed in part through the use of the Medical Research Core Facilities in the Office of Research & Development at China Medical University, Taichung, Taiwan. This research was funded in part by the following: Ministry of Science Technology, Taiwan (grant number: MOST 108-2314-B-039-032), China Medical University (grant number: CMU106-ASIA-18), and China Medical University Hospital (DMR-108-012, DMR-109-212, DMR-109-213). This work was also financially supported by the "Drug Development Center, China Medical University" from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan. Y. Wang was supported by Medical Research Council (MR/S025480/1). We would like to thank Iona J. MacDonald from China Medical University, Taichung, Taiwan, for her English language revision of this manuscript.	Ancey PB, 2018, FEBS J, V285, P2926, DOI 10.1111/febs.14577; Apicella M, 2018, CELL METAB, V28, P848, DOI 10.1016/j.cmet.2018.08.006; Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Barrio JR, 2020, J NUCL MED, V61, P931, DOI 10.2967/jnumed.119.237446; Blodgett AB, 2011, DIABETES TECHNOL THE, V13, P743, DOI 10.1089/dia.2011.0041; Carey KD, 2006, CANCER RES, V66, P8163, DOI 10.1158/0008-5472.CAN-06-0453; Chen CH, 2017, MOL ONCOL, V11, P1273, DOI 10.1002/1878-0261.12102; Chen WS, 2015, ONCOTARGET, V6, P25962, DOI 10.18632/oncotarget.4504; Chen Y, 2017, ONCOTARGET, V8, P63813, DOI 10.18632/oncotarget.19130; Chen YJ, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/682380; Cheng FJ, 2021, ONCOGENE, V40, P1162, DOI 10.1038/s41388-020-01597-1; Chou YT, 2010, CANCER RES, V70, P8822, DOI 10.1158/0008-5472.CAN-10-0638; Dicembrini I, 2019, DIABETES OBES METAB, V21, P1871, DOI 10.1111/dom.13745; Dietrich M, 2019, EXP CELL RES, V382, DOI 10.1016/j.yexcr.2019.06.018; Feinmesser RL, 1999, J BIOL CHEM, V274, P16168, DOI 10.1074/jbc.274.23.16168; Gorzalczany Y, 2011, CANCER LETT, V310, P207, DOI 10.1016/j.canlet.2011.07.002; Guo GF, 2011, MED ONCOL, V28, pS197, DOI 10.1007/s12032-010-9696-8; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hachemi M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087629; Hsia TC, 2013, MOL PHARMACOL, V83, P857, DOI 10.1124/mol.112.082743; Hsiao YC, 2015, ONCOTARGET, V6, P37965, DOI 10.18632/oncotarget.5700; Hudson CD, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.125; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; Husain H, 2017, MOL CANCER THER, V16, P265, DOI 10.1158/1535-7163.MCT-16-0105; Hussein YR, 2011, TRANSL ONCOL, V4, P321, DOI 10.1593/tlo.11256; Janku F, 2013, ONCOTARGET, V4, P463, DOI 10.18632/oncotarget.886; Jia Y, 2016, NATURE, V534, P129, DOI 10.1038/nature17960; Jin N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10427-2; Kaida H, 2016, EUR J RADIOL, V85, P1804, DOI 10.1016/j.ejrad.2016.08.007; Kanwal A, 2012, ANAL BIOCHEM, V429, P70, DOI 10.1016/j.ab.2012.07.003; Ke EE, 2016, TRENDS PHARMACOL SCI, V37, P887, DOI 10.1016/j.tips.2016.09.003; Khuong HT, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-012-0322-3; Kim JH, 2018, CANCER RES, V78, P4482, DOI 10.1158/0008-5472.CAN-18-0117; Kim J, 2019, NAT CELL BIOL, V21, P63, DOI 10.1038/s41556-018-0205-1; Kluba M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139971; Kunimasa K, 2017, CANCER SCI, V108, P1368, DOI 10.1111/cas.13266; Lapuerta P, 2015, DIABETES VASC DIS RE, V12, P101, DOI 10.1177/1479164114563304; Lee PC, 2018, CANCER CELL, V34, P954, DOI 10.1016/j.ccell.2018.11.007; Li L, 2019, CANCER LETT, V452, P191, DOI 10.1016/j.canlet.2019.03.027; Lim SO, 2016, CANCER RES, V76, P1284, DOI 10.1158/0008-5472.CAN-15-2478; Lin HW, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/719578; Liu ML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080721; Liu TC, 2017, AM J CANCER RES, V7, P187; Llado A, 2004, MOL BIOL CELL, V15, P4877, DOI 10.1091/mbc.E04-02-0127; Lypova N, 2019, J BIOL CHEM, V294, P10530, DOI 10.1074/jbc.RA119.007784; Ma RS, 2019, CANCER BIOL THER, V20, P1206, DOI 10.1080/15384047.2019.1599665; Makinoshima H, 2014, J BIOL CHEM, V289, P20813, DOI 10.1074/jbc.M114.575464; Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314; McCracken AN, 2013, TRENDS ENDOCRIN MET, V24, P200, DOI 10.1016/j.tem.2013.01.002; Miller S, 2010, AUTOPHAGY, V6, P805, DOI 10.1126/science.1184429; Mok TS, 2017, NEW ENGL J MED, V376, P629, DOI 10.1056/NEJMoa1612674; Momcilovic M, 2017, CELL REP, V18, P601, DOI 10.1016/j.celrep.2016.12.061; Moruno Felix, 2012, Cells, V1, P372, DOI 10.3390/cells1030372; Murtuza A, 2019, CANCER RES, V79, P689, DOI 10.1158/0008-5472.CAN-18-1281; Musso G, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l1328; Nagarajan A, 2016, TRENDS CANCER, V2, P365, DOI 10.1016/j.trecan.2016.06.002; Recondo G, 2018, NAT REV CLIN ONCOL, V15, P694, DOI 10.1038/s41571-018-0081-4; Ren JG, 2013, PROSTATE, V73, P1453, DOI 10.1002/pros.22692; Rieg T, 2018, DIABETOLOGIA, V61, P2079, DOI 10.1007/s00125-018-4654-7; Sasaki H, 2012, MOL MED REP, V5, P599, DOI 10.3892/mmr.2011.736; Scafoglio C, 2015, P NATL ACAD SCI USA, V112, pE4111, DOI 10.1073/pnas.1511698112; Skoulidis F, 2019, NAT REV CANCER, V19, P495, DOI 10.1038/s41568-019-0179-8; Su H, 2006, CLIN CANCER RES, V12, P5659, DOI 10.1158/1078-0432.CCR-06-0368; Sunaga N, 2008, LUNG CANCER, V59, P203, DOI 10.1016/j.lungcan.2007.08.012; Suzuki Shuhei, 2018, Oncotarget, V9, P32667, DOI 10.18632/oncotarget.25994; Tu CY, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/168949; Wang CW, 2015, INT J BIOCHEM CELL B, V64, P239, DOI 10.1016/j.biocel.2015.04.006; Wang L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0242-x; Wang ZL, 2016, INT J ONCOL, V48, P2558, DOI 10.3892/ijo.2016.3468; Weihua Z, 2008, CANCER CELL, V13, P385, DOI 10.1016/j.ccr.2008.03.015; Wu SG, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0777-1; Xu QL, 2017, ONCOTARGET, V8, P9557, DOI 10.18632/oncotarget.13771; Yamazaki Y, 2018, EUR J PHARMACOL, V822, P25, DOI 10.1016/j.ejphar.2018.01.003; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Zambrowicz B, 2012, CLIN PHARMACOL THER, V92, P158, DOI 10.1038/clpt.2012.58; Zander T, 2011, J CLIN ONCOL, V29, P1701, DOI 10.1200/JCO.2010.32.4939; Zhang H, 2017, ONCOL REP, V37, P1765, DOI 10.3892/or.2017.5367	78	4	4	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2021	40	29					4796	4808		10.1038/s41388-021-01889-0	http://dx.doi.org/10.1038/s41388-021-01889-0		JUN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR9TO	34155348	hybrid, Green Accepted, Green Published			2022-12-17	WOS:000664006700005
J	Kim, SY; Shen, Q; Son, K; Kim, HS; Yang, HD; Na, MJ; Shin, E; Yu, S; Kang, K; You, JS; Yu, KR; Jeong, SM; Lee, EK; Ahn, YM; Park, WS; Nam, SW				Kim, Sang Yean; Shen, Qingyu; Son, Keunhong; Kim, Hyung Seok; Yang, Hee Doo; Na, Min Jeong; Shin, Eunbi; Yu, Suji; Kang, Keunsoo; You, Jueng Soo; Yu, Kyung-Rok; Jeong, Seung Min; Lee, Eun Kyung; Ahn, Young Min; Park, Won Sang; Nam, Suk Woo			SMARCA4 oncogenic potential via IRAK1 enhancer to activate Gankyrin and AKR1B10 in liver cancer	ONCOGENE			English	Article							COMPLEXES; ARID1A	SWItch/Sucrose Non-Fermentable (SWI/SNF) is a multiprotein complex essential for the regulation of eukaryotic gene expression. SWI/SNF complex genes are genetically altered in over 20% of human malignancies, but the aberrant regulation of the SWI/SNF subunit genes and subsequent dysfunction caused by abnormal expression of subunit gene in cancer, remain poorly understood. Among the SWI/SNF subunit genes, SMARCA4, SMARCC1, and SMARCA2 were identified to be overexpressed in human hepatocellular carcinoma (HCC). Modulation of SMARCA4, SMARCC1, and SMARCA2 inhibited in vitro tumorigenesis of HCC cells. However, SMARCA4-targeting elicited remarkable inhibition in an in vivo Ras-transgenic mouse HCC model (Ras-Tg), and high expression levels of SMARCA4 significantly associated with poor prognosis in HCC patients. Furthermore, most HCC patients (72-86%) showed SMARCA4 overexpression compared to healthy controls. To identify SMARCA4-specific active enhancers, mapping, and analysis of chromatin state in liver cancer cells were performed. Integrative analysis of SMARCA4-regulated genes and active chromatin enhancers suggested 37 genes that are strongly activated by SMARCA4 in HCC. Through chromatin immunoprecipitation-qPCR and luciferase assays, we demonstrated that SMARCA4 activates Interleukin-1 receptor-associated kinase 1 (IRAK1) expression through IRAK1 active enhancer in HCC. We then showed that transcriptional activation of IRAK1 induces oncoprotein Gankyrin and aldo-keto reductase family 1 member B10 (AKR1B10) in HCC. The regulatory mechanism of the SMARCA4-IRAK1-Gankyrin, AKR1B10 axis was further demonstrated in HCC cells and in vivo Ras-Tg mice. Our results suggest that aberrant overexpression of SMARCA4 causes SWI/SNF to promote IRAK1 enhancer to activate oncoprotein Gankyrin and AKR1B10, thereby contributing to hepatocarcinogenesis.	[Kim, Sang Yean; Shen, Qingyu; Na, Min Jeong; Shin, Eunbi; Yu, Suji; Park, Won Sang; Nam, Suk Woo] Catholic Univ Korea, Dept Pathol, Coll Med, 222 Banpo Daero, Seoul 06591, South Korea; [Kim, Sang Yean; Na, Min Jeong; Shin, Eunbi; Yu, Suji; Park, Won Sang; Nam, Suk Woo] Catholic Univ Korea, Funct RNom Res Ctr, 222 Banpo Daero, Seoul 06591, South Korea; [Kim, Sang Yean; Na, Min Jeong; Shin, Eunbi; Yu, Suji; Nam, Suk Woo] Catholic Univ Korea, Grad Sch Med, Dept Biomed Hlth Sci, 222 Banpo Daero, Seoul 06591, South Korea; [Son, Keunhong; Kang, Keunsoo] Dankook Univ, Dept Microbiol, Cheonan 31116, South Korea; [Kim, Hyung Seok; Yang, Hee Doo; Nam, Suk Woo] NEORNAT Inc, Rm 305 Med Sch Bldg,222 Banpo Daero, Seoul, South Korea; [You, Jueng Soo] Konkuk Univ, Res Inst Med Sci, Sch Med, Dept Biochem, Seoul 05029, South Korea; [Yu, Kyung-Rok] Seoul Natl Univ, Dept Agr Biotechnol, Seoul 08826, South Korea; [Jeong, Seung Min; Lee, Eun Kyung] Catholic Univ Korea, Dept Biochem, Coll Med, 222 Banpo Daero, Seoul 06591, South Korea; [Ahn, Young Min] Kyung Hee Univ, Dept Kidney Syst, Coll Oriental Med, Seoul 02447, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Dankook University; Konkuk University; Konkuk University Medical Center; Seoul National University (SNU); Catholic University of Korea; Kyung Hee University	Nam, SW (corresponding author), Catholic Univ Korea, Dept Pathol, Coll Med, 222 Banpo Daero, Seoul 06591, South Korea.; Nam, SW (corresponding author), Catholic Univ Korea, Funct RNom Res Ctr, 222 Banpo Daero, Seoul 06591, South Korea.; Nam, SW (corresponding author), Catholic Univ Korea, Grad Sch Med, Dept Biomed Hlth Sci, 222 Banpo Daero, Seoul 06591, South Korea.; Nam, SW (corresponding author), NEORNAT Inc, Rm 305 Med Sch Bldg,222 Banpo Daero, Seoul, South Korea.	swnam@catholic.ac.kr	SHEN, QINGYU/U-8848-2018	Kim, Hyung Seok/0000-0003-2784-0109	National Research Foundation (NRF) of Korea [2017R1A2B3002989, 2021M3E5E7021893]	National Research Foundation (NRF) of Korea(National Research Foundation of Korea)	We acknowledge support from the National Research Foundation (NRF) of Korea (2017R1A2B3002989 and 2021M3E5E7021893).	Alver BH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14648; Buscarlet M, 2014, BLOOD, V123, P1720, DOI 10.1182/blood-2013-02-483495; Cao DL, 1998, J BIOL CHEM, V273, P11429, DOI 10.1074/jbc.273.19.11429; Cheng BY, 2018, CANCER RES, V78, P2332, DOI 10.1158/0008-5472.CAN-17-2445; Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906; Hu B, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12791; Jubierre L, 2016, ONCOGENE, V35, P5179, DOI 10.1038/onc.2016.50; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; Mashtalir N, 2018, CELL, V175, P1272, DOI 10.1016/j.cell.2018.09.032; Mathur R, 2017, NAT GENET, V49, P296, DOI 10.1038/ng.3744; Michel BC, 2018, NAT CELL BIOL, V20, P1410, DOI 10.1038/s41556-018-0221-1; O'Neil NJ, 2017, NAT REV GENET, V18, P613, DOI 10.1038/nrg.2017.47; Saladi SV, 2017, CANCER CELL, V31, P35, DOI 10.1016/j.ccell.2016.12.001; Shlyueva D, 2014, NAT REV GENET, V15, P272, DOI 10.1038/nrg3682; Su B, 2015, HEPATOLOGY, V61, P585, DOI 10.1002/hep.27551; Sun XX, 2017, CANCER CELL, V32, P574, DOI 10.1016/j.ccell.2017.10.007; Wang AG, 2005, J HEPATOL, V43, P836, DOI 10.1016/j.jhep.2005.04.012; Wang P, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2289-3; Yang HD, 2019, HEPATOLOGY, V70, P1262, DOI 10.1002/hep.30657	19	4	4	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2021	40	28					4652	4662		10.1038/s41388-021-01875-6	http://dx.doi.org/10.1038/s41388-021-01875-6		JUN 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK8LG	34140644				2022-12-17	WOS:000662838900004
J	Zhu, HQ; Li, Q; Zhao, YL; Peng, H; Guo, LY; Zhu, J; Jiang, Z; Zeng, ZX; Xu, B; Chen, SS				Zhu, Hengqing; Li, Qing; Zhao, Yulan; Peng, Hong; Guo, Liangyun; Zhu, Jing; Jiang, Zi; Zeng, Zhaoxia; Xu, Bin; Chen, Sisi			Vaccinia-related kinase 2 drives pancreatic cancer progression by protecting Plk1 from Chfr-mediated degradation	ONCOGENE			English	Article							POLO-LIKE KINASES; VRK2; IDENTIFICATION; STABILIZATION; EPIDEMIOLOGY; ACCUMULATION; EXPRESSION; STABILITY; LIGASE; AURORA	As a key cell cycle regulator, polo-like kinase 1 (Plk1) has been recognized as a crucial factor involved in the progression of pancreatic cancer (PC). However, its regulatory mechanism is poorly understood. Here, we present evidence that Plk1 is a novel substrate of vaccinia-related kinase 2 (VRK2), a serine-threonine kinase that is highly expressed and predicts poor prognosis in PC. VRK2 phosphorylates Plk1 at threonine 210 and protects it from ubiquitin-dependent proteasomal degradation. We showed that mechanistically complement factor H-related protein (CFHR), as a major E3 ligase, promotes Plk1 degradation by ubiquitinating it at lysine 209. Phosphorylation of Plk1 at threonine 210 by VRK2 interferes with the interaction of Chfr with Plk1 and antagonizes Plk1 ubiquitination, thereby stabilizing the Plk1 protein. Taken together, our data reveal a mechanism of Plk1 overexpression in PC and provide evidence for targeting VRK2 as a potential therapeutic strategy.	[Zhu, Hengqing] Nanchang Univ, Dept Gen Surg, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China; [Zhu, Hengqing] Zhejiang Univ, Dept Thyroid Surg, Affiliated Hosp 2, Sch Med, Hangzhou, Peoples R China; [Li, Qing] Nanchang Univ, Dept Pathol, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China; [Zhao, Yulan] Zhejiang Univ, Dept Ultrasound Med, Affiliated Hosp 2, Sch Med, Hangzhou, Peoples R China; [Peng, Hong] 908th Hosp Chinese Peoples Liberat Army Joint, Dept Colorectal Surg, Nanchang, Jiangxi, Peoples R China; [Guo, Liangyun] Nanchang Univ, Dept Ultrasound, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China; [Zhu, Jing; Jiang, Zi] Nanchang Univ, Dept Pharm, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China; [Zeng, Zhaoxia] Nanchang Univ, Dept Radiol, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China; [Xu, Bin] Nanchang Univ, Dept Burns, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China; [Chen, Sisi] Nanchang Univ, Dept Neurol, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China	Nanchang University; Zhejiang University; Nanchang University; Zhejiang University; Nanchang University; Nanchang University; Nanchang University; Nanchang University; Nanchang University	Xu, B (corresponding author), Nanchang Univ, Dept Burns, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China.; Chen, SS (corresponding author), Nanchang Univ, Dept Neurol, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China.	bxu1990@126.com; Cheinsee@163.com		Chen, Sisi/0000-0002-1908-5054	Scientific research and cultivation project of talents in the First Affiliated Hospital of Nanchang University [YFYPY202015]	Scientific research and cultivation project of talents in the First Affiliated Hospital of Nanchang University	This study was supported by the Scientific research and cultivation project of talents in the First Affiliated Hospital of Nanchang University (YFYPY202015).	Archambault V, 2009, NAT REV MOL CELL BIO, V10, P265, DOI 10.1038/nrm2653; Blanco S, 2006, FEBS J, V273, P2487, DOI 10.1111/j.1742-4658.2006.05256.x; Chen B, 2018, MOL MED REP, V18, P105, DOI 10.3892/mmr.2018.8941; de Carcer G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05429-5; Eckerdt F, 2005, J BIOL CHEM, V280, P36575, DOI 10.1074/jbc.M504548200; Fernandez IF, 2010, MOL CELL BIOL, V30, P4687, DOI 10.1128/MCB.01581-09; Golsteyn R M, 1996, Prog Cell Cycle Res, V2, P107; Grimont A, 2015, GUT, V64, P1790, DOI 10.1136/gutjnl-2014-307075; Ilic M, 2016, WORLD J GASTROENTERO, V22, P9694, DOI 10.3748/wjg.v22.i44.9694; Jeong YH, 2018, J NEUROCHEM, V147, P609, DOI 10.1111/jnc.14562; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Kim JS, 2011, J BIOL CHEM, V286, P30615, DOI 10.1074/jbc.M111.231803; Kim S, 2015, MOL CELL BIOL, V35, P1754, DOI 10.1128/MCB.01325-14; Kim S, 2014, MOL CELL BIOL, V34, P643, DOI 10.1128/MCB.00756-13; Klerkx EPF, 2009, HISTOL HISTOPATHOL, V24, P749, DOI 10.14670/HH-24.749; Lens SMA, 2010, NAT REV CANCER, V10, P825, DOI 10.1038/nrc2964; Li J, 2016, CELL CYCLE, V15, P711, DOI 10.1080/15384101.2016.1148838; Lin QJ, 2015, WORLD J GASTROENTERO, V21, P7988, DOI 10.3748/wjg.v21.i26.7988; Liu ZX, 2017, TRANSL ONCOL, V10, P22, DOI 10.1016/j.tranon.2016.10.003; Mahajan UM, 2016, GUT, V65, P1838, DOI 10.1136/gutjnl-2016-311393; Mai J, 2019, THERANOSTICS, V9, P3541, DOI 10.7150/thno.32908; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; McGuigan A, 2018, WORLD J GASTROENTERO, V24, P4846, DOI 10.3748/wjg.v24.i43.4846; Monsalve DM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.40; Nezu J, 1997, GENOMICS, V45, P327, DOI 10.1006/geno.1997.4938; Nichols RJ, 2004, J BIOL CHEM, V279, P7934, DOI 10.1074/jbc.M310813200; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Sanz-Garcia M, 2008, MOL CELL PROTEOMICS, V7, P2199, DOI 10.1074/mcp.M700586-MCP200; Seki A, 2008, SCIENCE, V320, P1655, DOI 10.1126/science.1157425; Shin CH, 2017, CELL DEATH DIFFER, V24, P1861, DOI 10.1038/cdd.2017.106; Shin SB, 2020, ONCOGENE, V39, P767, DOI 10.1038/s41388-019-1023-z; Song B, 2013, MOL CANCER THER, V12, P58, DOI 10.1158/1535-7163.MCT-12-0632; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Tesli M, 2016, BRIT J PSYCHIAT, V209, P114, DOI 10.1192/bjp.bp.115.161950; Vazquez-Cedeira M, 2012, J BIOL CHEM, V287, P42739, DOI 10.1074/jbc.M112.404285; Wen DH, 2017, CELL REP, V21, P2147, DOI 10.1016/j.celrep.2017.10.085; Xiao DB, 2016, MOL CELL, V64, P493, DOI 10.1016/j.molcel.2016.09.016; Xin XF, 2019, ACS APPL MATER INTER, V11, P14647, DOI 10.1021/acsami.9b02756; Yabar CS, 2016, GASTROENTEROL CLIN N, V45, P429, DOI 10.1016/j.gtc.2016.04.003	39	4	4	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2021	40	28					4663	4674		10.1038/s41388-021-01893-4	http://dx.doi.org/10.1038/s41388-021-01893-4		JUN 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK8LG	34140642				2022-12-17	WOS:000662838900003
J	Kimura, H; Sada, R; Takada, N; Harada, A; Doki, Y; Eguchi, H; Yamamoto, H; Kikuchi, A				Kimura, Hirokazu; Sada, Ryota; Takada, Naoki; Harada, Akikazu; Doki, Yuichiro; Eguchi, Hidetoshi; Yamamoto, Hideki; Kikuchi, Akira			The Dickkopf1 and FOXM1 positive feedback loop promotes tumor growth in pancreatic and esophageal cancers	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; WNT; DKK1; LUNG; TARGET; GENE; CONTRIBUTES; SPECIFICITY; EXPRESSION; REGULATOR	Dickkopf1 (DKK1) is overexpressed in various cancers and promotes cancer cell proliferation by binding to cytoskeleton-associated protein 4 (CKAP4). However, the mechanisms underlying DKK1 expression are poorly understood. RNA sequence analysis revealed that expression of the transcription factor forkhead box M1 (FOXM1) and its target genes concordantly fluctuated with expression of DKK1 in pancreatic ductal adenocarcinoma (PDAC) cells. DKK1 knockdown decreased FOXM1 expression and vice versa in PDAC and esophageal squamous cell carcinoma (ESCC) cells. Inhibition of either the DKK1-CKAP4-AKT pathway or the ERK pathway suppressed FOXM1 expression, and simultaneous inhibition of both pathways showed synergistic effects. A FOXM1 binding site was identified in the 5MODIFIER LETTER PRIME-untranslated region of the DKK1 gene, and its depletion decreased DKK1 expression and cancer cell proliferation. Clinicopathological and database analysis revealed that PDAC and ESCC patients who simultaneously express DKK1 and FOXM1 have a poorer prognosis. Multivariate analysis demonstrated that expression of both DKK1 and FOXM1 is the independent prognostic factor in ESCC patients. Although it has been reported that FOXM1 enhances Wnt signaling, FOXM1 induced DKK1 expression independently of Wnt signaling in PDAC and ESCC cells. These results suggest that DKK1 and FOXM1 create a positive feedback loop to promote cancer cell proliferation.	[Kimura, Hirokazu; Sada, Ryota; Takada, Naoki; Harada, Akikazu; Yamamoto, Hideki; Kikuchi, Akira] Osaka Univ, Grad Sch Med, Dept Mol Biol & Biochem, Suita, Osaka, Japan; [Doki, Yuichiro; Eguchi, Hidetoshi] Osaka Univ, Grad Sch Med, Dept Gastroenterol Surg, Suita, Osaka, Japan	Osaka University; Osaka University	Kikuchi, A (corresponding author), Osaka Univ, Grad Sch Med, Dept Mol Biol & Biochem, Suita, Osaka, Japan.	akikuchi@molbiobc.med.osaka-u.ac.jp		Sada, Ryota/0000-0003-3403-0542; Kikuchi, Akira/0000-0003-3378-9522	Ministry of Education, Culture, Sports, Science and Technology of Japan [16H06374, 16H06944, 18K15064, 20K16330, 20K07311]; Japan Agency for Medical Research and development, AMED [18cm0106132h0001, 20cm0106152h0002]; Yasuda Memorial Foundation; Ichiro Kanehara Foundation of the Promotion of Medical Science Medical Care; Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Agency for Medical Research and development, AMED(Japan Agency for Medical Research and Development (AMED)); Yasuda Memorial Foundation; Ichiro Kanehara Foundation of the Promotion of Medical Science Medical Care; Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University	This work was supported by Grants-in-Aid for Scientific Research (2016-2021) (No. 16H06374) to AK, for Young Scientists (Start-up) (2016-2017) (No. 16H06944) to HK, for Early-Career Scientists (2018-2019) (No. 18K15064) to HK, for Early-Career Scientists (2020-2021) (No. 20K16330) to RS, for Scientific Research (C) (2020-2022) (No. 20K07311) to HY from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and also supported by the Project for Cancer Research And Therapeutic Evolution (P-CREATE) (2018) (18cm0106132h0001) and (2019-2021) (20cm0106152h0002) to AK from the Japan Agency for Medical Research and development, AMED, and by grants to AK from the Yasuda Memorial Foundation, the Ichiro Kanehara Foundation of the Promotion of Medical Science & Medical Care, and by Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University to AK.	Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; Aoyagi K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018196; Arensman MD, 2014, ONCOGENE, V33, P899, DOI 10.1038/onc.2013.23; Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008-5472.CAN-08-4135; Eisinger-Mathason TSK, 2015, P NATL ACAD SCI USA, V112, pE3402, DOI 10.1073/pnas.1420005112; Gartel AL, 2017, CANCER RES, V77, P3135, DOI 10.1158/0008-5472.CAN-16-3566; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Golson ML, 2016, DEVELOPMENT, V143, P4558, DOI 10.1242/dev.112672; Haeberle L, 2019, TRANSL GASTROENT HEP, V4, DOI 10.21037/tgh.2019.06.02; Han SX, 2015, ONCOTARGET, V6, P19907, DOI 10.18632/oncotarget.4529; Haniu M, 2011, PROTEIN SCI, V20, P1802, DOI 10.1002/pro.705; Hsu PD, 2013, NAT BIOTECHNOL, V31, P827, DOI 10.1038/nbt.2647; Hussain M, 2009, CANCER RES, V69, P3570, DOI 10.1158/0008-5472.CAN-08-2807; Jiang XM, 2013, P NATL ACAD SCI USA, V110, P12649, DOI 10.1073/pnas.1307218110; Kagey MH, 2017, BRIT J PHARMACOL, V174, P4637, DOI 10.1111/bph.13894; Kajiwara C, 2018, CANCER RES, V78, P6107, DOI 10.1158/0008-5472.CAN-18-1749; Kikuchi A, 2017, BRIT J PHARMACOL, V174, P4651, DOI 10.1111/bph.13863; Kimura H, 2019, CLIN CANCER RES, V25, P1936, DOI 10.1158/1078-0432.CCR-18-2124; Kimura H, 2016, J CLIN INVEST, V126, P2689, DOI 10.1172/JCI84658; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; Laoukili J, 2007, BBA-REV CANCER, V1775, P92, DOI 10.1016/j.bbcan.2006.08.006; Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017; Ma RYM, 2005, J CELL SCI, V118, P795, DOI 10.1242/jcs.01657; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mikheev AM, 2008, BREAST CANCER RES TR, V112, P263, DOI 10.1007/s10549-007-9867-2; Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311; Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054; Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892; Park HJ, 2009, EMBO J, V28, P2908, DOI 10.1038/emboj.2009.239; Peters CJ, 2010, GASTROENTEROLOGY, V139, P1995, DOI 10.1053/j.gastro.2010.05.080; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Renz BW, 2018, CANCER CELL, V33, P75, DOI 10.1016/j.ccell.2017.11.007; Rustgi AK, 2014, NEW ENGL J MED, V371, P2499, DOI 10.1056/NEJMra1314530; Sada R, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aat9519; Sakane H, 2010, J CELL SCI, V123, P360, DOI 10.1242/jcs.058008; Shinno N, 2018, ONCOGENE, V37, P3471, DOI 10.1038/s41388-018-0179-2; Suzuki R, 2007, BRIT J HAEMATOL, V138, P624, DOI 10.1111/j.1365-2141.2007.06702.x; Wang IC, 2014, ONCOGENE, V33, P5391, DOI 10.1038/onc.2013.475; Yamabuki T, 2007, CANCER RES, V67, P2517, DOI 10.1158/0008-5472.CAN-06-3369; Yamamoto H, 2008, DEV CELL, V15, P37, DOI 10.1016/j.devcel.2008.04.015; Yoshida Y, 2007, GASTROENTEROLOGY, V132, P1420, DOI 10.1053/j.gastro.2007.01.036; Zhang H, 2016, TUMOR BIOL, V37, P11321, DOI 10.1007/s13277-016-4995-0; Zhang N, 2011, CANCER CELL, V20, P427, DOI 10.1016/j.ccr.2011.08.016; Zhang YQ, 2013, CANCER RES, V73, P4909, DOI 10.1158/0008-5472.CAN-12-4384	45	4	4	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2021	40	26					4486	4502		10.1038/s41388-021-01860-z	http://dx.doi.org/10.1038/s41388-021-01860-z		JUN 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC8LA	34117362	Green Published, hybrid			2022-12-17	WOS:000660409400002
J	Liu, WB; Huang, YS; Wang, DD; Han, F; Chen, HQ; Chen, JP; Jiang, X; Cao, J; Liu, JY				Liu, Wenbin; Huang, Yongsheng; Wang, Dandan; Han, Fei; Chen, Hongqiang; Chen, Jianping; Jiang, Xiao; Cao, Jia; Liu, Jinyi			MPDZ as a novel epigenetic silenced tumor suppressor inhibits growth and progression of lung cancer through the Hippo-YAP pathway	ONCOGENE			English	Article							DNA METHYLATION; BREAST-CANCER; YAP/TAZ; MUPP1; PROTEIN; HYPERMETHYLATION; INACTIVATION; ANGIOMOTIN; DIAGNOSIS; PROGNOSIS	MPDZ also named MUPP1 is involved in signal transduction mediated by the formation of protein complexes. However, the expression regulation, clinical significance, potential function, and mechanism of this gene in lung cancer remain unclear. Methylation status of MPDZ was measured by methylation-specific PCR and bisulfite genomic sequencing. Kaplan-Meier and Cox regression analyses were performed to identify the prognostic value of MPDZ. The tumor suppressing effects of MPDZ were determined in vitro and in vivo. The target molecules and signaling pathway that mediated the function of MPDZ were also identified. MPDZ methylation was identified in 61.2% of primary lung cancer tissues and most lung cancer cell lines but not in normal lung tissues. MPDZ expression was significantly downregulated in lung cancer tissues and negatively associated with DNA hypermethylation, and attenuated MPDZ expression predicted a poor outcome. Furthermore, MPDZ overexpression prominently dampened cell growth, migration, and invasion of tumor cells. Conversely, MPDZ knockdown promoted cell proliferation, migration, and invasion in vitro and in vivo. Moreover, MPDZ deficiency promotes tumor metastasis and reduces the survival of MPDZ knockout mice. Importantly, MPDZ promotes tumor suppressor ability that depends on the Hippo pathway-mediated repression of YAP. MPDZ activates the phosphorylation of YAP (Ser127) and inhibits YAP expression through stabilizing MST1 and interaction with LATS1. We first identified and validated that MPDZ methylation and expression could be a good diagnostic marker and independent prognostic factor for lung cancer. MPDZ functions as a tumor suppressor by inhibiting cell proliferation, migration, and invasion through regulating the Hippo-YAP signaling pathway.	[Liu, Wenbin; Huang, Yongsheng; Wang, Dandan; Han, Fei; Chen, Hongqiang; Chen, Jianping; Jiang, Xiao; Cao, Jia; Liu, Jinyi] Third Mil Med Univ, Army Med Univ, Coll Prevent Med, Inst Toxicol, Chongqing, Peoples R China	Army Medical University	Liu, WB; Cao, J; Liu, JY (corresponding author), Third Mil Med Univ, Army Med Univ, Coll Prevent Med, Inst Toxicol, Chongqing, Peoples R China.	liuwenbin@tmmu.edu.cn; caojia1962@126.com; jinyiliutmmu@163.com	Han, Fei/AAG-9260-2020; liu, wen/HGE-3071-2022	Han, Fei/0000-0002-0265-5487; liu, jin-yi/0000-0003-1803-7752; Huang, Yongsheng/0000-0002-8449-7522	National Natural Science Foundation of China [81573179]; Natural Science Foundation Project of Chongqing CSTC of China [cstc2018jcyjAX0233]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation Project of Chongqing CSTC of China	This work was supported by grants from the National Natural Science Foundation of China (No. 81573179) and the Natural Science Foundation Project of Chongqing CSTC of China (No. cstc2018jcyjAX0233). The authors sincerely thank Yajing Li for technical help.	Belinsky SA, 2015, ANNU REV PHYSIOL, V77, P453, DOI 10.1146/annurev-physiol-021014-072018; Berger AH, 2016, CANCER CELL, V30, P214, DOI 10.1016/j.ccell.2016.06.022; Coyne CB, 2004, J BIOL CHEM, V279, P48079, DOI 10.1074/jbc.M409061200; De Carvalho DD, 2012, CANCER CELL, V21, P655, DOI 10.1016/j.ccr.2012.03.045; Feil R, 2012, NAT REV GENET, V13, P97, DOI 10.1038/nrg3142; Feldner A, 2017, EMBO MOL MED, V9, P890, DOI 10.15252/emmm.201606430; Guillaume JL, 2008, J BIOL CHEM, V283, P16762, DOI 10.1074/jbc.M802069200; Han F, 2015, ONCOGENE, V34, P4391, DOI 10.1038/onc.2014.370; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hsu YL, 2015, ONCOGENE, V34, P4056, DOI 10.1038/onc.2014.333; Hubers AJ, 2015, BRIT J CANCER, V112, P1105, DOI 10.1038/bjc.2014.636; Ishiuchi T, 2009, J CELL BIOL, V185, P959, DOI 10.1083/jcb.200811030; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Krapivinsky G, 2004, NEURON, V43, P563, DOI 10.1016/j.neuron.2004.08.003; Lanaspa MA, 2008, P NATL ACAD SCI USA, V105, P15797, DOI 10.1073/pnas.0805761105; Lanaspa MA, 2007, P NATL ACAD SCI USA, V104, P13672, DOI 10.1073/pnas.0702752104; Lee YS, 2013, CANCER CELL, V24, P603, DOI 10.1016/j.ccr.2013.10.003; Li E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a019133; Liu JL, 2018, J PATHOL, V244, P71, DOI 10.1002/path.4995; Liu W, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.65; Liu WB, 2015, ONCOTARGET, V6, P21225, DOI 10.18632/oncotarget.4237; Liu WB, 2015, MOL CARCINOGEN, V54, P312, DOI 10.1002/mc.22101; Liu WB, 2014, INT J CANCER, V134, P1311, DOI 10.1002/ijc.28472; Liu Y, 2003, CARCINOGENESIS, V24, P1897, DOI 10.1093/carcin/bgg169; Martin TA, 2004, EUR J CANCER, V40, P2717, DOI 10.1016/j.ejca.2004.08.008; Massimi P, 2004, ONCOGENE, V23, P8033, DOI 10.1038/sj.onc.1207977; Mohammad HP, 2015, CANCER CELL, V28, P57, DOI 10.1016/j.ccell.2015.06.002; Nawaz I, 2014, EPIGENETICS-US, V9, P1138, DOI 10.4161/epi.29499; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Sheu JJC, 2009, CANCER EPIDEM BIOMAR, V18, P2709, DOI 10.1158/1055-9965.EPI-09-0349; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Tetzlaff F, 2018, ELIFE, V7, DOI 10.7554/eLife.32860; Ullmer C, 1998, FEBS LETT, V424, P63, DOI 10.1016/S0014-5793(98)00141-0; Walko G, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14744; Wang J, 2016, J BIOL CHEM, V291, P17988, DOI 10.1074/jbc.M115.711275; Wen XL, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0170-6; Wrangle J, 2014, CLIN CANCER RES, V20, P1856, DOI 10.1158/1078-0432.CCR-13-2109; Yang JN, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201809540; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Yuan S, 2016, ONCOGENE, V35, P6120, DOI 10.1038/onc.2016.149; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhang X, 2011, ONCOGENE, V30, P2810, DOI 10.1038/onc.2011.8; Zhang YL, 2018, CANCER RES, V78, P2305, DOI 10.1158/0008-5472.CAN-17-2867; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2012, GENE DEV, V26, P54, DOI 10.1101/gad.173435.111; Zhao B, 2011, GENE DEV, V25, P51, DOI 10.1101/gad.2000111; Zhu HB, 2013, HEPATOLOGY, V58, P2012, DOI 10.1002/hep.26587	49	4	4	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2021	40	26					4468	4485		10.1038/s41388-021-01857-8	http://dx.doi.org/10.1038/s41388-021-01857-8		JUN 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC8LA	34108620				2022-12-17	WOS:000659470200001
J	Shariati, M; Evans, KW; Zheng, XF; Bristow, CA; Ng, PKS; Rizvi, YQ; Tapia, C; Yang, F; Carugo, A; Heffernan, TP; Peoples, MD; Tripathy, D; Meric-Bernstam, F				Shariati, Maryam; Evans, Kurt W.; Zheng, Xiaofeng; Bristow, Christopher A.; Ng, Patrick Kwok-Shing; Rizvi, Yasmeen Q.; Tapia, Coya; Yang, Fei; Carugo, Alessandro; Heffernan, Timothy P.; Peoples, Michael D.; Tripathy, Debu; Meric-Bernstam, Funda			Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations	ONCOGENE			English	Article							DOMAIN RECEPTOR 1; THERAPY; AKT; PHOSPHORYLATION; PALBOCICLIB; FULVESTRANT; COMBINATION; DISCOVERY; COMPLEX; POTENT	Molecular alterations in the PI3K/AKT pathway occur frequently in hormone receptor-positive breast tumors. Patients with ER-positive, HER2-negative metastatic breast cancer are often treated with CDK4/6 inhibitors such as palbociclib in combination with endocrine therapy. Although this is an effective regimen, most patients ultimately progress. The purpose of this study was identifying synthetic lethality partners that can enhance palbociclib's antitumor efficacy in the presence of PIK3CA/AKT1 mutations. We utilized a barcoded shRNA library to determine critical targets for survival in isogenic MCF7 cells with PIK3CA/AKT1 mutations. We demonstrated that the efficacy of palbociclib is reduced in the presence of PIK3CA/AKT1 mutations. We also identified that the downregulation of discoidin domain receptor 1 (DDR1) is synthetically lethal with palbociclib. DDR1 knockdown and DDR1 pharmacological inhibitor decreased cell growth and inhibited cell cycle progression in all cell lines, while enhanced the sensitivity of PIK3CA/AKT1 mutant cells to palbociclib. Combined treatment of palbociclib and 7rh further induced cell cycle arrest in PIK3CA/AKT1 mutant cell lines. In vivo, 7rh significantly enhanced palbociclib's antitumor efficacy. Our data indicates that DDR1 inhibition can augment cell cycle suppressive effect of palbociclib and could be effective strategy for targeted therapy of ER-positive, HER2-negative breast cancers with PI3K pathway activation.	[Shariati, Maryam; Evans, Kurt W.; Rizvi, Yasmeen Q.; Tapia, Coya; Yang, Fei; Meric-Bernstam, Funda] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA; [Zheng, Xiaofeng] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Bristow, Christopher A.; Carugo, Alessandro; Heffernan, Timothy P.; Peoples, Michael D.] Univ Texas MD Anderson Canc Ctr, Ctr Coclin Trials, Houston, TX 77030 USA; [Bristow, Christopher A.; Carugo, Alessandro; Heffernan, Timothy P.; Peoples, Michael D.] Univ Texas MD Anderson Canc Ctr, Inst Appl Canc Sci, Houston, TX 77030 USA; [Ng, Patrick Kwok-Shing; Meric-Bernstam, Funda] Univ Texas MD Anderson Canc Ctr, Sheikh Khalifa Bin Zayed Inst Personalized Canc T, Houston, TX 77030 USA; [Tapia, Coya; Yang, Fei] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Tripathy, Debu] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; [Meric-Bernstam, Funda] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Meric-Bernstam, F (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA.; Meric-Bernstam, F (corresponding author), Univ Texas MD Anderson Canc Ctr, Sheikh Khalifa Bin Zayed Inst Personalized Canc T, Houston, TX 77030 USA.; Meric-Bernstam, F (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX 77030 USA.	fmeric@mdanderson.org		Carugo, Alessandro/0000-0001-5182-3320	Nellie B. Connally Breast Cancer Research Endowment; Center for Clinical and Translational Sciences (CTSA-Informatics) [1UL1TR003167-01]; MD Anderson Cancer Center Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer; Cancer Prevention Institute of Texas [RP150535]; Cancer Center Support Grant (CCSG) by National Cancer Institute (NCI) [CA-16672]	Nellie B. Connally Breast Cancer Research Endowment; Center for Clinical and Translational Sciences (CTSA-Informatics); MD Anderson Cancer Center Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer; Cancer Prevention Institute of Texas; Cancer Center Support Grant (CCSG) by National Cancer Institute (NCI)	This work was funded in part by the Nellie B. Connally Breast Cancer Research Endowment, The Center for Clinical and Translational Sciences (CTSA-Informatics) #1UL1TR003167-01, the MD Anderson Cancer Center Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer, and the Cancer Prevention Institute of Texas Grant RP150535: Precision Oncology Decision Support Core. The MD Anderson Reverse Phase Protein Array Core Facility and Histology, Pathology, and Imaging Core were funded by the Cancer Center Support Grant (CCSG) funded by National Cancer Institute (NCI) #CA-16672.	Ambrogio C, 2016, NAT MED, V22, P270, DOI 10.1038/nm.4041; Anders L, 2011, CANCER CELL, V20, P620, DOI 10.1016/j.ccr.2011.10.001; Andre F., 2018, ANN ONCOL, V29, DOI 10.1093/annonc/mdy424.010; [Anonymous], 2018, N Engl J Med, V379, P2582, DOI 10.1056/NEJMx180043; [Anonymous], 2016, PALBOCICLIB PACKAGE; Assent D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116006; Beaver JA, 2013, CLIN CANCER RES, V19, P5413, DOI 10.1158/1078-0432.CCR-13-0884; Belfiore A, 2018, CELL ADHES MIGR, V12, P305, DOI 10.1080/19336918.2018.1445953; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cortes J, 2017, CANCER TREAT REV, V61, P53, DOI 10.1016/j.ctrv.2017.09.011; Cristofanilli M, 2018, EUR J CANCER, V104, P21, DOI 10.1016/j.ejca.2018.08.011; Cristofanilli M, 2016, LANCET ONCOL, V17, P425, DOI 10.1016/S1470-2045(15)00613-0; Das S, 2006, CANCER RES, V66, P8123, DOI 10.1158/0008-5472.CAN-06-1215; Day PJ, 2009, P NATL ACAD SCI USA, V106, P4166, DOI 10.1073/pnas.0809645106; Dean JL, 2010, ONCOGENE, V29, P4018, DOI 10.1038/onc.2010.154; Dogruluk T, 2015, CANCER RES, V75, P5341, DOI 10.1158/0008-5472.CAN-15-1654; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Franco J, 2014, ONCOTARGET, V5, P6512, DOI 10.18632/oncotarget.2270; Gadiya M, 2018, CELL ADHES MIGR, V12, P315, DOI 10.1080/19336918.2018.1520556; Gao MS, 2013, J MED CHEM, V56, P3281, DOI 10.1021/jm301824k; Gordus A, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2008.72; Herrera-Abreu MT, 2016, CANCER RES, V76, P2301, DOI 10.1158/0008-5472.CAN-15-0728; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; Hu J, 2007, BIOINFORMATICS, V23, P1986, DOI 10.1093/bioinformatics/btm283; Hyman DM, 2017, J CLIN ONCOL, V35, P2251, DOI 10.1200/JCO.2017.73.0143; Jansen VM, 2017, CANCER RES, V77, P2488, DOI 10.1158/0008-5472.CAN-16-2653; Ju ZL, 2015, BIOINFORMATICS, V31, P912, DOI 10.1093/bioinformatics/btu736; Juric D, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.SABCS15-P3-14-01; Koh M, 2015, INT J CANCER, V136, pE508, DOI 10.1002/ijc.29154; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Mata R, 2016, ONCOTARGET, V7, P7683, DOI 10.18632/oncotarget.6524; Meric-Bernstam F, 2018, JCO PRECIS ONCOL, V2, P1, DOI 10.1200/PO.17.00245; Miller TW, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3039; O'Leary B, 2018, CANCER DISCOV, V8, P1390, DOI 10.1158/2159-8290.CD-18-0264; Polyak K, 2011, J CLIN INVEST, V121, P3786, DOI 10.1172/JCI60534; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Saby C, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00462; Shariati M, 2019, EXPERT OPIN INV DRUG, V28, P977, DOI 10.1080/13543784.2019.1676726; Toogood PL, 2005, J MED CHEM, V48, P2388, DOI 10.1021/jm049354h; Vehlow A, 2019, CELL REP, V26, P3672, DOI 10.1016/j.celrep.2019.02.096; VILLALBA M, 2019, SCI REP-UK, V9; Vora SR, 2014, CANCER CELL, V26, P136, DOI 10.1016/j.ccr.2014.05.020; Wander SA, 2020, CANCER DISCOV, V10, P1174, DOI 10.1158/2159-8290.CD-19-1390	44	4	4	7	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2021	40	26					4425	4439		10.1038/s41388-021-01819-0	http://dx.doi.org/10.1038/s41388-021-01819-0		JUN 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC8LA	34108622	Green Submitted			2022-12-17	WOS:000659470200002
J	Thomson, CS; Pundavela, J; Perrino, MR; Coover, RA; Choi, K; Chaney, KE; Rizvi, TA; Largaespada, DA; Ratner, N				Thomson, Craig S.; Pundavela, Jay; Perrino, Melissa R.; Coover, Robert A.; Choi, Kwangmin; Chaney, Katherine E.; Rizvi, Tilat A.; Largaespada, David A.; Ratner, Nancy			WNT5A inhibition alters the malignant peripheral nerve sheath tumor microenvironment and enhances tumor growth	ONCOGENE			English	Article							BETA-CATENIN; SCHWANN-CELLS; STEM-CELLS; MECHANISMS; PROMOTES; TRANSFORMATION; PROGRESSION; ACTIVATION; INVASION; MITOGENS	Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft-tissue sarcomas that cause significant mortality in adults with neurofibromatosis type 1. We compared gene expression of growth factors in normal human nerves to MPNST and normal human Schwann cells to MPNST cell lines. We identified WNT5A as the most significantly upregulated ligand-coding gene and verified its protein expression in MPNST cell lines and tumors. In many contexts WNT5A acts as an oncogene. However, inhibiting WNT5A expression using shRNA did not alter MPNST cell proliferation, invasion, migration, or survival in vitro. Rather, shWNT5A-treated MPNST cells upregulated mRNAs associated with the remodeling of extracellular matrix and with immune cell communication. In addition, these cells secreted increased amounts of the proinflammatory cytokines CXCL1, CCL2, IL6, CXCL8, and ICAM1. Versus controls, shWNT5A-expressing MPNST cells formed larger tumors in vivo. Grafted tumors contained elevated macrophage/stromal cells, larger and more numerous blood vessels, and increased levels of Mmp9, Cxcl13, Lipocalin-1, and Ccl12. In some MPNST settings, these effects were mimicked by targeting the WNT5A receptor ROR2. These data suggest that the non-canonical Wnt ligand WNT5A inhibits MPNST tumor formation by modulating the MPNST microenvironment, so that blocking WNT5A accelerates tumor growth in vivo.	[Thomson, Craig S.] Univ Cincinnati, Coll Med, Dept Pharmacol & Syst Physiol, Cincinnati, OH 45220 USA; [Thomson, Craig S.; Pundavela, Jay; Perrino, Melissa R.; Coover, Robert A.; Choi, Kwangmin; Chaney, Katherine E.; Rizvi, Tilat A.; Ratner, Nancy] Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA; [Perrino, Melissa R.; Ratner, Nancy] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45220 USA; [Largaespada, David A.] Univ Minnesota, Coll Biol Sci, Dept Genet Cell Biol & Dev, Minneapolis, MN USA; [Coover, Robert A.] High Point Univ, Fred Wilson Sch Pharm, Dept Basic Pharmaceut Sci, High Point, NC USA	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of Minnesota System; University of Minnesota Twin Cities	Ratner, N (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA.; Ratner, N (corresponding author), Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45220 USA.	Nancy.ratner@cchmc.org		Perrino, Melissa/0000-0002-0598-7102; RATNER, NANCY/0000-0001-5030-9354; Pundavela, Jay/0000-0003-2861-4736	National Institute of Health (NIH) [5R01NS086219]	National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank the CCHMC research pathology core for tissue processing and embedding and the viral vector core for lentivirus preparation. This research was supported by the National Institute of Health (NIH) 5R01NS086219, to DAL and NR.	Ahsan S, 2016, ONCOTARGET, V7, P57171, DOI 10.18632/oncotarget.11036; Asem MS, 2016, CANCERS, V8, DOI 10.3390/cancers8090079; Banerjee J, 2020, GENES-BASEL, V11, DOI 10.3390/genes11020226; Berger H, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00031; Bi LQ, 2014, INT J CLIN EXP PATHO, V7, P987; Bos JL, 2007, CELL, V129, P865, DOI 10.1016/j.cell.2007.05.018; Brohl AS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15183-1; Brosseau JP, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07452-y; Cadigan KM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007906; Cho H, 2016, WOUND REPAIR REGEN, V24, P829, DOI 10.1111/wrr.12453; Choi K, 2017, SCI REP-UK, V7, DOI 10.1038/srep43315; DAVIS JB, 1990, J CELL BIOL, V110, P1353, DOI 10.1083/jcb.110.4.1353; DeLeon-Pennell KY, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.94207; Dong S, 2015, CLIN LAB, V61, P537, DOI 10.7754/Clin.Lab.2014.141127; Ekstrom EJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-88; Evans DG, 2010, AM J MED GENET A, V152A, P327, DOI 10.1002/ajmg.a.33139; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Green J, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a009175; Grigoryan T, 2013, P NATL ACAD SCI USA, V110, P18174, DOI 10.1073/pnas.1310490110; Handolias D, 2008, FUTURE ONCOL, V4, P211, DOI 10.2217/14796694.4.2.211; Huang L, 2016, EXP THER MED, V12, P3851, DOI 10.3892/etm.2016.3885; Huang TC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181034; Jang J, 2017, SCI REP-UK, V7, DOI 10.1038/srep41612; Jiang HJ, 2013, NEUROCHEM RES, V38, P346, DOI 10.1007/s11064-012-0925-8; Katoh M, 2017, INT J ONCOL, V51, P1357, DOI 10.3892/ijo.2017.4129; Katoh M, 2017, INT J MOL MED, V40, P587, DOI 10.3892/ijmm.2017.3071; Katoh M, 2009, INT J MOL MED, V23, P763, DOI 10.3892/ijmm_00000190; Khan AQ, 2019, SEMIN CANCER BIOL, V54, P1, DOI 10.1016/j.semcancer.2018.03.001; Kim J, 2010, J IMMUNOL, V185, P1274, DOI 10.4049/jimmunol.1000181; Kobayashi C, 2006, CANCER GENET CYTOGEN, V165, P98, DOI 10.1016/j.cancergencyto.2005.07.006; Largaespada D, 2013, CANCER CELL, V23, P269, DOI 10.1016/j.ccr.2013.03.001; Li H, 2016, LAB INVEST, V96, P1105, DOI 10.1038/labinvest.2016.88; Li ZQ, 2018, INT J MED SCI, V15, P1415, DOI 10.7150/ijms.26741; Liu AR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090229; Long HT, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1693-z; Lopez-Bergami P, 2020, CANCER METAST REV, V39, P933, DOI 10.1007/s10555-020-09878-7; Luo C, 2020, J CLIN INVEST, V130, P853, DOI 10.1172/JCI130038; Luscan A, 2014, CLIN CANCER RES, V20, P358, DOI 10.1158/1078-0432.CCR-13-0780; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Mahller YY, 2008, CANCER RES, V68, P1170, DOI 10.1158/0008-5472.CAN-07-2734; Mahller YY, 2006, PEDIATR BLOOD CANCER, V46, P745, DOI 10.1002/pbc.20565; McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042; Miettinen MM, 2017, HUM PATHOL, V67, P1, DOI 10.1016/j.humpath.2017.05.010; Miller SJ, 2009, EMBO MOL MED, V1, P236, DOI 10.1002/emmm.200900027; Miller SJ, 2006, CANCER RES, V66, P2584, DOI 10.1158/0008-5472.CAN-05-3330; O'Neil NJ, 2017, NAT REV GENET, V18, P613, DOI 10.1038/nrg.2017.47; Oishi I, 2003, GENES CELLS, V8, P645, DOI 10.1046/j.1365-2443.2003.00662.x; Prada CE, 2013, ACTA NEUROPATHOL, V125, P159, DOI 10.1007/s00401-012-1056-7; Prasad CP, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0421-0; Rauner M, 2012, J BONE MINER RES, V27, P575, DOI 10.1002/jbmr.1488; Rebalka IA, 2018, AM J PHYSIOL-CELL PH, V315, pC714, DOI 10.1152/ajpcell.00195.2017; Reilly KM, 2013, CANCER DISCOV, V3, P610, DOI 10.1158/2159-8290.CD-13-0192; RIDLEY AJ, 1989, J CELL BIOL, V109, P3419, DOI 10.1083/jcb.109.6.3419; Roman-Gomez J, 2007, EUR J CANCER, V43, P2736, DOI 10.1016/j.ejca.2007.10.004; Sapi Z, 2016, GENE CHROMOSOME CANC, V55, P786, DOI 10.1002/gcc.22379; Shurell E, 2016, ONCOTARGET, V7, P64300, DOI 10.18632/oncotarget.11734; Simanshu DK, 2017, CELL, V170, P17, DOI 10.1016/j.cell.2017.06.009; Sohier P, 2017, GENE CHROMOSOME CANC, V56, P421, DOI 10.1002/gcc.22446; Tian F, 2015, INT J MOL SCI, V16, P3178, DOI 10.3390/ijms16023178; de Vasconcelos RAT, 2019, CANCER MED-US, V8, P972, DOI 10.1002/cam4.1977; Tu B, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130811; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; Wang TX, 2019, J CANCER RES THER, V15, P904, DOI 10.4103/jcrt.JCRT_886_18; Wang ZG, 2015, ONCOL REP, V34, P391, DOI 10.3892/or.2015.3966; Watson AL, 2013, CANCER DISCOV, V3, P674, DOI 10.1158/2159-8290.CD-13-0081; Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558; Widemann BC, 2009, CURR ONCOL REP, V11, P322, DOI 10.1007/s11912-009-0045-z; Yamagata K, 2012, J BIOL CHEM, V287, P1588, DOI 10.1074/jbc.M111.315127; Yamamoto T, 1999, J BIOCHEM-TOKYO, V126, P799, DOI 10.1093/oxfordjournals.jbchem.a022519; Yamanaka H, 2002, EMBO REP, V3, P69, DOI 10.1093/embo-reports/kvf008; Yang FC, 2003, J CLIN INVEST, V112, P1851, DOI 10.1172/JCI200319195; Zhang C, 2017, CHIN J CANCER, V36, DOI 10.1186/s40880-017-0246-z; Zhang CY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10999-3; Zhao LY, 2017, EBIOMEDICINE, V16, P87, DOI 10.1016/j.ebiom.2017.01.021; Zhurinsky J, 2000, MOL CELL BIOL, V20, P4238, DOI 10.1128/MCB.20.12.4238-4252.2000	76	4	4	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2021	40	24					4229	4241		10.1038/s41388-021-01773-x	http://dx.doi.org/10.1038/s41388-021-01773-x		JUN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SU3OE	34079083	Green Accepted			2022-12-17	WOS:000657217400006
J	Ricordel, C; Chaillot, L; Blondel, A; Archambeau, J; Jouan, F; Mouche, A; Tiercin, M; Burel, A; Lena, H; Desrues, B; Guillaudeux, T; Pedeux, R				Ricordel, Charles; Chaillot, Laura; Blondel, Alice; Archambeau, Jerome; Jouan, Florence; Mouche, Audrey; Tiercin, Marie; Burel, Agnes; Lena, Herve; Desrues, Benoit; Guillaudeux, Thierry; Pedeux, Remy			ING2 tumor suppressive protein translocates into mitochondria and is involved in cellular metabolism homeostasis	ONCOGENE			English	Article							INTERMEMBRANE SPACE; CYTOPLASMIC EXPRESSION; DISULFIDE RELAY; PHD FINGER; NUCLEAR; PROGRESSION; P53; P33(ING1B); TUMORIGENESIS; GENES	ING2 (Inhibitor of Growth 2) is a tumor suppressor gene that has been implicated in critical biological functions (cell-cycle regulation, replicative senescence, DNA repair and DNA replication), most of which are recognized hallmarks of tumorigenesis occurring in the cell nucleus. As its close homolog ING1 has been recently observed in the mitochondrial compartment, we hypothesized that ING2 could also translocate into the mitochondria and be involved in new biological functions. In the present study, we demonstrate that ING2 is imported in the inner mitochondrial fraction in a redox-sensitive manner in human cells and that this mechanism is modulated by 14-3-3 eta protein expression. Remarkably, ING2 is necessary to maintain mitochondrial ultrastructure integrity without interfering with mitochondrial networks or polarization. We observed an interaction between ING2 and mtDNA under basal conditions. This interaction appears to be mediated by TFAM, a critical regulator of mtDNA integrity. The loss of mitochondrial ING2 does not impair mtDNA repair, replication or transcription but leads to a decrease in mitochondrial ROS production, suggesting a detrimental impact on OXPHOS activity. We finally show using multiple models that ING2 is involved in mitochondrial respiration and that its loss confers a protection against mitochondrial respiratory chain inhibition in vitro. Consequently, we propose a new tumor suppressor role for ING2 protein in the mitochondria as a metabolic shift gatekeeper during tumorigenesis.	[Ricordel, Charles; Chaillot, Laura; Blondel, Alice; Archambeau, Jerome; Jouan, Florence; Mouche, Audrey; Lena, Herve; Desrues, Benoit; Guillaudeux, Thierry; Pedeux, Remy] Univ Rennes 1, Chem Oncogenesis Stress & Signaling, INSERM, U1242,CLCC Eugene Marquis, Rennes, France; [Ricordel, Charles; Lena, Herve; Desrues, Benoit] Univ Rennes 1, Dept Pulm Med, CHU Pontchaillou, Rennes, France; [Tiercin, Marie] Hop St Malo, Dept Pulm Med, St Malo, France; [Burel, Agnes; Guillaudeux, Thierry] Univ Rennes 1, UMS 3480, BIOSIT, MRic, Rennes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Eugene Marquis; Universite de Rennes 1; CHU Rennes; Universite de Rennes 1; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Rennes 1	Pedeux, R (corresponding author), Univ Rennes 1, Chem Oncogenesis Stress & Signaling, INSERM, U1242,CLCC Eugene Marquis, Rennes, France.	remy.pedeux@univ-rennes1.fr	PEDEUX, Rémy M/I-2603-2014	PEDEUX, Rémy M/0000-0002-2553-7934	La Ligue Contre le Cancer; Nuovo-Soldati Fundation research grant; INSERM (Institut National de la Sante et de la Recherche Medicale); La Ligue Contre le Cancer (Grand Ouest); Association pour la Recherche sur le Cancer (ARC); Fondation pour la Recherche Medicale (FMR) [DEQ20180339169]; AIS Rennes Metropole; Biosit; Action Incitative Universite de Rennes 1; Region Bretagne; FHU Camin (CHU Rennes) doctoral followship	La Ligue Contre le Cancer(Ligue nationale contre le cancer); Nuovo-Soldati Fundation research grant; INSERM (Institut National de la Sante et de la Recherche Medicale)(Institut National de la Sante et de la Recherche Medicale (Inserm)); La Ligue Contre le Cancer (Grand Ouest); Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Fondation pour la Recherche Medicale (FMR)(Fondation pour la Recherche Medicale); AIS Rennes Metropole(Region Bretagne); Biosit; Action Incitative Universite de Rennes 1; Region Bretagne(Region Bretagne); FHU Camin (CHU Rennes) doctoral followship	We thank S.Manie for his participation and the technical support. We thank the photonic facility of the Microscopy Rennes Imaging Center (MRic-Photonics) of Biosit, Universite de Rennes 1. We thank Pr JA MacDonald and his team members as well as Pr K Riabowol (University of Calgary, Canada) for providing lentiviral vectors and technical support for the generation of the CrispR clones. AM was a recipient of a doctoral fellowship from La Ligue Contre le Cancer and Region Bretagne. C. Ricordel was a recipient of FHU Camin (CHU Rennes) doctoral followship and Nuovo-Soldati Fundation research grant. RP is supported by INSERM (Institut National de la Sante et de la Recherche Medicale). The work was supported by La Ligue Contre le Cancer (Grand Ouest), Association pour la Recherche sur le Cancer (ARC), Fondation pour la Recherche Medicale (FMR, DEQ20180339169), AIS Rennes Metropole, Biosit and Action Incitative Universite de Rennes 1.	Abdrabou A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010318; Achanta G, 2005, EMBO J, V24, P3482, DOI 10.1038/sj.emboj.7600819; Archambeau J, 2020, CANCERS, V12, DOI 10.3390/cancers12010058; Backes S, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00083; Bose P, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.321; Dabir DV, 2013, DEV CELL, V25, P81, DOI 10.1016/j.devcel.2013.03.006; Dantas A, 2019, CANCERS, V11, DOI 10.3390/cancers11111817; Dar S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09206-0; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Edwards R, 2020, BIOL CHEM, V401, P737, DOI 10.1515/hsz-2020-0114; Ferre F, 2006, NUCLEIC ACIDS RES, V34, pW182, DOI 10.1093/nar/gkl189; Furda A, 2014, METHODS MOL BIOL, V1105, P419, DOI 10.1007/978-1-62703-739-6_31; Gabriel K, 2007, J MOL BIOL, V365, P612, DOI 10.1016/j.jmb.2006.10.038; Gong W, 2006, MOL CELL BIOL, V26, P2947, DOI 10.1128/MCB.26.8.2947-2954.2006; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Guerillon C, 2014, CANCER LETT, V345, P1, DOI 10.1016/j.canlet.2013.11.016; Guerillon C, 2013, CELL MOL LIFE SCI, V70, P3753, DOI 10.1007/s00018-013-1270-z; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He GHY, 2005, MOL BIOL EVOL, V22, P104, DOI 10.1093/molbev/msh256; Hilgendorf KI, 2013, GENE DEV, V27, P1003, DOI 10.1101/gad.211326.112; Kaufman BA, 2007, MOL BIOL CELL, V18, P3225, DOI 10.1091/mbc.E07-05-0404; Krogan NJ, 2006, NATURE, V440, P637, DOI 10.1038/nature04670; Larrieu D, 2010, CELL CYCLE, V9, P3984, DOI 10.4161/cc.9.19.13208; Larrieu D, 2009, EMBO REP, V10, P1168, DOI 10.1038/embor.2009.180; Lee SR, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/8060949; Lehuede C, 2016, CANCER RES, V76, P5201, DOI 10.1158/0008-5472.CAN-16-0266; Li XH, 2010, J CANCER RES CLIN, V136, P1573, DOI 10.1007/s00432-010-0815-x; Longen S, 2014, DEV CELL, V28, P30, DOI 10.1016/j.devcel.2013.11.007; Ma Y, 2020, J PHYSIOL BIOCHEM, V76, P373, DOI 10.1007/s13105-020-00743-3; Marusich MF, 1997, BBA-MOL BASIS DIS, V1362, P145, DOI 10.1016/S0925-4439(97)00061-6; Mouche A, 2019, CELL DEATH DIFFER, V26, P2344, DOI 10.1038/s41418-019-0305-x; Neumann CA, 2003, NATURE, V424, P561, DOI 10.1038/nature01819; Nicolle O, 2015, TRAFFIC, V16, P893, DOI 10.1111/tra.12289; Pallotti F, 2007, METHOD CELL BIOL, V80, P3, DOI 10.1016/S0091-679X(06)80001-4; Pedeux R, 2005, MOL CELL BIOL, V25, P6639, DOI 10.1128/MCB.25.15.6639-6648.2005; Pile LA, 2003, J BIOL CHEM, V278, P37840, DOI 10.1074/jbc.M305996200; Puleston Daniel, 2015, Cold Spring Harb Protoc, V2015, DOI 10.1101/pdb.prot086298; Quispe-Tintaya W, 2013, BIOTECHNIQUES, V55, P133, DOI 10.2144/000114077; Rosivatz E, 2011, CELL SIGNAL, V23, P478, DOI 10.1016/j.cellsig.2010.10.025; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Satoh H, 2013, CANCER RES, V73, P4158, DOI 10.1158/0008-5472.CAN-12-4499; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Shiao YH, 2000, CANCER RES, V60, P2816; Steinmetz LM, 2002, NAT GENET, V31, P400, DOI 10.1038/ng929; Sullivan LB, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-17; Szczepanowska J, 2004, FEBS LETT, V578, P316, DOI 10.1016/j.febslet.2004.11.022; TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551; Valente AJ, 2017, ACTA HISTOCHEM, V119, P315, DOI 10.1016/j.acthis.2017.03.001; van Donselaar E, 2007, TRAFFIC, V8, P471, DOI 10.1111/j.1600-0854.2007.00552.x; Vogtle FN, 2012, MOL CELL PROTEOMICS, V11, P1840, DOI 10.1074/mcp.M112.021105; Vyas S, 2016, CELL, V166, P555, DOI 10.1016/j.cell.2016.07.002; Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365; Wang YM, 2007, CLIN CANCER RES, V13, P4111, DOI 10.1158/1078-0432.CCR-07-0408; Wang YE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074513; Weckbecker D, 2012, EMBO J, V31, P4348, DOI 10.1038/emboj.2012.263; Ythier D, 2010, ONCOGENE, V29, P5946, DOI 10.1038/onc.2010.325; Zhang JT, 2008, J CANCER RES CLIN, V134, P421, DOI 10.1007/s00432-007-0305-y; Zhu ZL, 2013, ONCOL LETT, V5, P161, DOI 10.3892/ol.2012.983; Zhuang J, 2013, P NATL ACAD SCI USA, V110, P17356, DOI 10.1073/pnas.1310908110; Zong WX, 2016, MOL CELL, V61, P667, DOI 10.1016/j.molcel.2016.02.011	60	4	4	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2021	40	24					4111	4123		10.1038/s41388-021-01832-3	http://dx.doi.org/10.1038/s41388-021-01832-3		MAY 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SU3OE	34017078				2022-12-17	WOS:000652439200004
J	Zhang, FF; Tang, XF; Fan, S; Liu, X; Sun, J; Ju, C; Liang, YP; Liu, RF; Zhou, RH; Yu, B; Zhang, CH; Zhang, ZP; Kang, TB; Huang, GF; Lv, XB				Zhang, Feifei; Tang, Xiaofeng; Fan, Song; Liu, Xia; Sun, Jun; Ju, Cheng; Liang, Yiping; Liu, Renfeng; Zhou, Ruihao; Yu, Bo; Zhang, Changhua; Zhang, Zhiping; Kang, Tiebang; Huang, Guofu; Lv, Xiao-Bin			Targeting the p300/NONO axis sensitizes melanoma cells to BRAF inhibitors	ONCOGENE			English	Article							STRAND BREAK REPAIR; ACQUIRED-RESISTANCE; DRIVES RESISTANCE; RAF KINASE; NONO; MECHANISM; P54(NRB); PROTEIN; GROWTH; SWITCH	BRAF inhibitors (BRAFi) that target BRAF V600E kinase, a driver mutation found in 50% of melanomas, show a significant antitumor response, but the common emergence of acquired resistance remains a challenge. Abnormal expression of RAF isoforms CRAF and ARAF reactivates pERK1/2, which plays crucial roles in the acquisition of resistance of melanoma cells. However, the mechanisms of dysregulation of RAF isoforms in resistant melanoma cells remain unknown. Here, we identified NONO interacted with and stabilized both CRAF and ARAF in melanoma cells, and that NONO was acetylated at 198K by p300 acetyltransferase, which stabilized NONO via antagonizing its ubiquitination/degradation mediated by RNF8. The upregulation of both p300 and NONO promoted the rebound of pERK1/2 and the subsequent resistance of melanoma cells to BRAFi, and the activation of ERK1/2 in turn induced p300 to form a positive feedback loop in resistant melanoma cells. There was a positive correlation between p300 and NONO in resistant melanoma cells and clinical samples, and p300 inhibitor C646 overcame the resistance of resistant melanoma cells to BRAF inhibitors in vitro and in vivo. Our findings reveal that targeting the positive feedback loop of p300-NONO-CRAF/ARAF-pERK1/2 may be excellent strategies to overcome the resistance of BRAF inhibitors for melanoma patients.	[Zhang, Feifei; Tang, Xiaofeng; Sun, Jun; Ju, Cheng; Liang, Yiping; Liu, Renfeng; Zhou, Ruihao; Yu, Bo; Zhang, Zhiping; Lv, Xiao-Bin] Nanchang Univ, Cent Lab, Jiangxi Key Lab Canc Metastasis & Precis Treatmen, Affiliated Hosp 3, Nanchang, Jiangxi, Peoples R China; [Fan, Song] Sun Yat Sen Univ, Dept Oral & Maxillofacial Surg, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China; [Liu, Xia] South China Univ Technol, Guangzhou Peoples Hosp 1, Sch Med, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China; [Sun, Jun; Zhang, Changhua] Jiangxi Univ Tradit Chinese Med, Coll Pharm, Nanchang, Jiangxi, Peoples R China; [Ju, Cheng; Liu, Renfeng; Yu, Bo; Zhang, Zhiping] Nanchang Univ, Dept Orthoped, Affiliated Hosp 3, Nanchang, Jiangxi, Peoples R China; [Kang, Tiebang] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Guangdong, Peoples R China; [Huang, Guofu] Nanchang Univ, Affiliated Hosp 3, Dept Ophthalmol, Nanchang, Jiangxi, Peoples R China	Nanchang University; Sun Yat Sen University; South China University of Technology; Jiangxi University of Traditional Chinese Medicine; Nanchang University; State Key Lab Oncology South China; Sun Yat Sen University; Nanchang University	Lv, XB (corresponding author), Nanchang Univ, Cent Lab, Jiangxi Key Lab Canc Metastasis & Precis Treatmen, Affiliated Hosp 3, Nanchang, Jiangxi, Peoples R China.; Huang, GF (corresponding author), Nanchang Univ, Affiliated Hosp 3, Dept Ophthalmol, Nanchang, Jiangxi, Peoples R China.	hgf2222@sina.com; nclvxiaobin@sina.cn			National Natural Science Foundation of China [81672866, 81960501, 81560452, 81760552]; Natural Science Foundation of Jiangxi Province [20202BAB206041, 20161BAB205192, 20171ACB21073]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangxi Province(Natural Science Foundation of Jiangxi Province)	This work was supported by grants from the National Natural Science Foundation of China (Nos. 81672866, 81960501 and 81560452 to XBL; No. 81760552 to XT); the Natural Science Foundation of Jiangxi Province (No. 20202BAB206041; Nos. 20161BAB205192 and 20171ACB21073 to XBL).	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Alfano L, 2016, ONCOGENE, V35, P567, DOI 10.1038/onc.2015.107; Alfano L, 2018, J CELL PHYSIOL, V233, P4338, DOI 10.1002/jcp.26269; Audrito V, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx198; Corre S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06951-2; Deshar R, 2019, NUCLEIC ACIDS RES, V47, P762, DOI 10.1093/nar/gky1166; Diaz-Martinez M, 2018, CANCER RES, V78, P1017, DOI 10.1158/0008-5472.CAN-17-1318; Feng PF, 2020, J CELL MOL MED, V24, P4368, DOI 10.1111/jcmm.15141; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Holderfield M, 2014, NAT REV CANCER, V14, P455, DOI 10.1038/nrc3760; Hu ZX, 2020, HEPATOLOGY, V72, P548, DOI 10.1002/hep.31062; Jaafar L, 2017, NUCLEIC ACIDS RES, V45, P1848, DOI 10.1093/nar/gkw1209; Janostiak R, 2019, ISCIENCE, V16, P453, DOI 10.1016/j.isci.2019.06.001; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Jun JH, 2010, J BIOL CHEM, V285, P36410, DOI 10.1074/jbc.M110.142307; Karoulia Z, 2017, NAT REV CANCER, V17, P676, DOI 10.1038/nrc.2017.79; Knott GJ, 2016, NUCLEIC ACIDS RES, V44, P3989, DOI 10.1093/nar/gkw271; Lavoie H, 2015, NAT REV MOL CELL BIO, V16, P281, DOI 10.1038/nrm3979; Li SY, 2014, NUCLEIC ACIDS RES, V42, P9771, DOI 10.1093/nar/gku650; Li SY, 2009, NUCLEIC ACIDS RES, V37, P6746, DOI 10.1093/nar/gkp741; Liu MH, 2016, ONCOTARGET, V7, P84951, DOI 10.18632/oncotarget.13069; Matallanas David, 2011, Genes Cancer, V2, P232, DOI 10.1177/1947601911407323; Montagut C, 2008, CANCER RES, V68, P4853, DOI 10.1158/0008-5472.CAN-07-6787; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Ohanna M, 2018, GENE DEV, V32, P448, DOI 10.1101/gad.305854.117; Parmenter TJ, 2014, CANCER DISCOV, V4, P423, DOI 10.1158/2159-8290.CD-13-0440; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Qin YY, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaw9960; Saei A, 2018, J EXP MED, V215, P1913, DOI 10.1084/jem.20171960; Schiffnery S, 2011, CARCINOGENESIS, V32, P1176, DOI 10.1093/carcin/bgr103; Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642; Talebi A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04664-0; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312; Yang H, 2010, CANCER RES, V70, P5518, DOI 10.1158/0008-5472.CAN-10-0646; Yao Z, 2015, CANCER CELL, V28, P370, DOI 10.1016/j.ccell.2015.08.001; Zhang KX, 2016, J CANCER RES THER, V12, pC131, DOI 10.4103/0973-1482.200613; Zhu Z, 2016, ONCOGENE, V35, P1399, DOI 10.1038/onc.2015.197	38	4	5	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2021	40	24					4137	4150		10.1038/s41388-021-01834-1	http://dx.doi.org/10.1038/s41388-021-01834-1		MAY 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SU3OE	34017080				2022-12-17	WOS:000652439200001
J	Tan, JH; Zheng, X; Li, MC; Ye, F; Song, CY; Xu, C; Zhang, XX; Li, WQ; Wang, Y; Zeng, SQ; Li, HY; Chen, G; Huang, XY; Ma, D; Liu, D; Gao, QL				Tan, Jiahong; Zheng, Xu; Li, Mengchen; Ye, Fei; Song, Chunyan; Xu, Cheng; Zhang, Xiaoxue; Li, Wenqian; Wang, Ya; Zeng, Shaoqing; Li, Huayi; Chen, Gang; Huang, Xiaoyuan; Ma, Ding; Liu, Dan; Gao, Qinglei			C/EBP beta promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer	ONCOGENE			English	Article							DNA MISMATCH REPAIR; PARP INHIBITORS; CELL-LINES; EXPRESSION; CISPLATIN; IDENTIFICATION; DEFICIENCY; TOXICITY; BREAST; DAMAGE	PARP inhibitors (PARPi) are efficacious in treating high-grade serous ovarian cancer (HG-SOC) with homologous recombination (HR) deficiency. However, they exhibit suboptimal efficiency in HR-proficient cancers. Here, we found that the expression of CCAAT/enhancer-binding protein beta (C/EBP beta), a transcription factor, was inversely correlated with PARPi sensitivity in vitro and in vivo, both in HR-proficient condition. High C/EBP beta expression enhanced PARPi tolerance; PARPi treatment in turn induced C/EBP beta expression. C/EBP beta directly targeted and upregulated multiple HR genes (BRCA1, BRIP1, BRIT1, and RAD51), thereby inducing restoration of HR capacity and mediating acquired PARPi resistance. C/EBP beta is a key regulator of the HR pathway and an indicator of PARPi responsiveness. Targeting C/EBP beta could induce HR deficiency and rescue PARPi sensitivity accordingly. Our findings indicate that HR-proficient patients may benefit from PARPi via targeting C/EBP beta, and C/EBP beta expression levels enable predicting and tracking PARPi responsiveness during treatment.	[Tan, Jiahong; Zheng, Xu; Li, Mengchen; Song, Chunyan; Xu, Cheng; Zhang, Xiaoxue; Li, Wenqian; Wang, Ya; Zeng, Shaoqing; Li, Huayi; Chen, Gang; Huang, Xiaoyuan; Ma, Ding; Liu, Dan; Gao, Qinglei] Huazhong Univ Sci & Technol, Tongji Med Coll, Canc Biol Res Ctr, Key Lab,Minist Educ,Tongji Hosp, Wuhan, Peoples R China; [Tan, Jiahong; Zheng, Xu; Song, Chunyan; Xu, Cheng; Zhang, Xiaoxue; Li, Wenqian; Wang, Ya; Zeng, Shaoqing; Li, Huayi; Chen, Gang; Huang, Xiaoyuan; Ma, Ding; Liu, Dan; Gao, Qinglei] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Obstet & Gynecol, Wuhan, Peoples R China; [Ye, Fei] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Neurosurg, Wuhan, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Liu, D; Gao, QL (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Canc Biol Res Ctr, Key Lab,Minist Educ,Tongji Hosp, Wuhan, Peoples R China.; Liu, D; Gao, QL (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Obstet & Gynecol, Wuhan, Peoples R China.	tj_liudan@tjh.tjmu.edu.cn; qingleigao@hotmail.com		Jiahong, Tan/0000-0002-5748-4697	National Sci-Tech Support Projects [2018ZX10301402-002]; National Key Basic Research Program of China [2015CB553903]; National Natural Science Foundation of China [82072889, 81974405, 81772787]; Chinese Society of Clinical Oncology [Y-2019AZZD-0359]; Leading Talents of Science and Technology Innovation in National Ten Thousand Talents Plan [[2019]252]; Tongji Hospital (HUST) Foundation for Excellent Young Scientist [2020YBKY024]	National Sci-Tech Support Projects; National Key Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese Society of Clinical Oncology; Leading Talents of Science and Technology Innovation in National Ten Thousand Talents Plan; Tongji Hospital (HUST) Foundation for Excellent Young Scientist	This work was supported by National Sci-Tech Support Projects (2018ZX10301402-002), National Key Basic Research Program of China (2015CB553903), National Natural Science Foundation of China (82072889, 81974405, and 81772787), Chinese Society of Clinical Oncology (Y-2019AZZD-0359), Leading Talents of Science and Technology Innovation in National Ten Thousand Talents Plan ([2019]252), and Tongji Hospital (HUST) Foundation for Excellent Young Scientist (2020YBKY024). We sincerely thank all participants in the study.	Aebi S, 1996, CANCER RES, V56, P3087; Bian L, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1100-5; Bian X, 2018, ONCOGENE, V37, P341, DOI 10.1038/onc.2017.326; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Ceccaldi R, 2016, TRENDS CELL BIOL, V26, P52, DOI 10.1016/j.tcb.2015.07.009; Cortez AJ, 2018, CANCER CHEMOTH PHARM, V81, P17, DOI 10.1007/s00280-017-3501-8; Curtin NJ, 2012, NAT REV CANCER, V12, P801, DOI 10.1038/nrc3399; Dhawan MS, 2017, CLIN CANCER RES, V23, P6400, DOI 10.1158/1078-0432.CCR-17-0703; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Dong QZ, 2019, CANCER RES, V79, P819, DOI 10.1158/0008-5472.CAN-18-1273; Fang Y, 2019, CANCER CELL, V35, P851, DOI 10.1016/j.ccell.2019.05.001; Fornes O, 2020, NUCLEIC ACIDS RES, V48, pD87, DOI 10.1093/nar/gkz1001; HE X, 2015, MOL CANCER, V14; Ji T, 2013, CANCER LETT, V341, P231, DOI 10.1016/j.canlet.2013.08.022; Kim H, 2017, CLIN CANCER RES, V23, P3097, DOI 10.1158/1078-0432.CCR-16-2273; Konecny GE, 2019, EBIOMEDICINE, V43, P9, DOI 10.1016/j.ebiom.2019.04.009; Korch C, 2012, GYNECOL ONCOL, V127, P241, DOI 10.1016/j.ygyno.2012.06.017; Kurbacher CM, 2011, METHODS MOL BIOL, V731, P161, DOI 10.1007/978-1-61779-080-5_15; Lee IC, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030290; Lheureux S, 2019, CA-CANCER J CLIN, V69, P280, DOI 10.3322/caac.21559; Lheureux S, 2019, LANCET, V393, P1240, DOI 10.1016/S0140-6736(18)32552-2; LI A, 2019, J HEMATOL ONCOL, V12; Liu DH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02627-5; Liu Q, 2018, ONCOGENE, V37, P2793, DOI 10.1038/s41388-018-0130-6; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21; Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760; Marques M, 2019, ONCOGENE, V38, P2177, DOI 10.1038/s41388-018-0568-6; McCabe N, 2006, CANCER RES, V66, P8109, DOI 10.1158/0008-5472.CAN-06-0140; Miller AL, 2019, EBIOMEDICINE, V44, P419, DOI 10.1016/j.ebiom.2019.05.035; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Papp E, 2018, CELL REP, V25, P2617, DOI 10.1016/j.celrep.2018.10.096; Peasland A, 2011, BRIT J CANCER, V105, P372, DOI 10.1038/bjc.2011.243; Penning TD, 2010, CURR OPIN DRUG DISC, V13, P577; Pignochino Y, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0652-5; Robinson LS, 2015, EBIOMEDICINE, V2, P1827, DOI 10.1016/j.ebiom.2015.10.022; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Sato Y, 2007, DIABETOLOGIA, V50, P481, DOI 10.1007/s00125-006-0480-4; Schurch NJ, 2016, RNA, V22, P839, DOI 10.1261/rna.053959.115; Shen YQ, 2015, J PHARMACOL EXP THER, V353, P446, DOI 10.1124/jpet.114.222448; Stewart RA, 2018, CANCER RES, V78, P6717, DOI 10.1158/0008-5472.CAN-18-2652; Sun CY, 2018, CANCER CELL, V33, P401, DOI 10.1016/j.ccell.2018.01.019; Sun CG, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-0844-0; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Taverna P, 2000, CANCER CHEMOTH PHARM, V46, P507, DOI 10.1007/s002800000186; Wang J, 2017, ONCOGENE, V36, P5939, DOI 10.1038/onc.2017.197; Wang ZH, 2019, CELL REP, V28, P655, DOI 10.1016/j.celrep.2019.06.054; Yamaguchi H, 2018, ONCOGENE, V37, P208, DOI 10.1038/onc.2017.311; Yasukawa M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030272; Yi JY, 2019, EBIOMEDICINE, V43, P225, DOI 10.1016/j.ebiom.2019.03.027; YU S, 2018, CLIN INFECT DIS, V9; Yuan Y, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756-8722-4-16; Zahnow CA, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001033; Zheng RB, 2019, NUCLEIC ACIDS RES, V47, pD729, DOI 10.1093/nar/gky1094; Zhu H, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01167-9	55	4	4	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2021	40	22					3845	3858		10.1038/s41388-021-01788-4	http://dx.doi.org/10.1038/s41388-021-01788-4		MAY 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SM7LL	33966038	hybrid, Green Published			2022-12-17	WOS:000648369800001
J	Sherman, J; Verstandig, G; Rowe, JW; Brumer, Y				Sherman, Jeff; Verstandig, Grant; Rowe, John W.; Brumer, Yisroel			Application of machine learning to large in vitro databases to identify drug-cancer cell interactions: azithromycin and KLK6 mutation status	ONCOGENE			English	Article							STEM-CELLS; MITOCHONDRIA	Recent advances in machine learning promise to yield novel insights by interrogation of large datasets ranging from gene expression and mutation data to CRISPR knockouts and drug screens. We combined existing and new algorithms with available experimental data to identify potentially clinically relevant relationships to provide a proof of principle for the promise of machine learning in oncological drug discovery. Specifically, we screened cell line data from the Cancer Dependency Map for the effects of azithromycin, which has been shown to kill cancer cells in vitro. Our findings demonstrate a strong relationship between Kallikrein Related Peptidase 6 (KLK6) mutation status and the ability of azithromycin to kill cancer cells in vitro. While the application of azithromycin showed no meaningful average effect in KLK6 wild-type cell lines, statistically significant enhancements of cell death are seen in multiple independent KLK6-mutated cancer cell lines. These findings suggest a potentially valuable clinical strategy in patients with KLK6-mutated malignancies.	[Sherman, Jeff; Verstandig, Grant; Brumer, Yisroel] Zephyr AI, Washington, DC 20010 USA; [Sherman, Jeff; Verstandig, Grant; Brumer, Yisroel] Red Cell Partners, Washington, DC 20549 USA; [Rowe, John W.] Columbia Univ, New York, NY USA	Columbia University	Sherman, J (corresponding author), Zephyr AI, Washington, DC 20010 USA.; Sherman, J (corresponding author), Red Cell Partners, Washington, DC 20549 USA.	sherman@redcellpartners.com		Rowe, John/0000-0002-3620-6612; Brumer, Yisroel/0000-0002-7046-0198; Sherman, Jeff/0000-0003-1377-0357				Ahmed N, 2016, BIOL CHEM, V397, P1265, DOI 10.1515/hsz-2016-0177; Bazaga A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67846-1; Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Corsello SM, 2020, NAT CANCER, V1, P235, DOI 10.1038/s43018-019-0018-6; DepMap, 2020, BROAD DEPMAP 21Q1 PU, DOI 10.6084/m9.figshare.13681534.v1; Dezso Z, 2020, BMC BIOINFORMATICS, V21, DOI 10.1186/s12859-020-3442-9; Fiorillo M, 2019, AGING-US, V11, P2202, DOI 10.18632/aging.101905; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Haritos C, 2018, CLIN EXP MED, V18, P203, DOI 10.1007/s10238-018-0487-4; Jiang XP, 2019, ANTIBIOTICS-BASEL, V8, DOI 10.3390/antibiotics8030110; Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829; Klikauer T, 2016, TRIPLEC-COMMUN CAPIT, V14, P260; Lamb R, 2015, ONCOTARGET, V6, P4569, DOI 10.18632/oncotarget.3174; Li FJ, 2017, ONCOL LETT, V14, P89, DOI 10.3892/ol.2017.6103; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Lundberg SM, 2017, ADV NEUR IN, V30; Lundberg SM, 2020, NAT MACH INTELL, V2, P56, DOI 10.1038/s42256-019-0138-9; Madhukar NS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12928-6; Qiao XR, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0309-9; Raileanu LE, 2004, ANN MATH ARTIF INTEL, V41, P77, DOI 10.1023/B:AMAI.0000018580.96245.c6; Schrader CH, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0381-6; Shimada K, 2019, TOOL BROWSING CANC D, DOI 10.1101/2019.12.13.874776v1; Tamir A, 2014, J OVARIAN RES, V7, DOI 10.1186/s13048-014-0109-z; Travis J, 2015, SCIENCE, V350, P1456, DOI 10.1126/science.350.6267.1456; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Wang HM, 2019, DEV DYNAM, V248, P10, DOI 10.1002/dvdy.24678; Wang Shou-man, 2008, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V24, P1087	28	4	4	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2021	40	21					3766	3770		10.1038/s41388-021-01807-4	http://dx.doi.org/10.1038/s41388-021-01807-4		MAY 2021	5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SI8ZW	33953352				2022-12-17	WOS:000647503300001
J	Billing, O; Holmgren, Y; Nosek, D; Hedman, H; Hemmingsson, O				Billing, Ola; Holmgren, Ylva; Nosek, Daniel; Hedman, Hakan; Hemmingsson, Oskar			LRIG1 is a conserved EGFR regulator involved in melanoma development, survival and treatment resistance	ONCOGENE			English	Article							NEGATIVE REGULATOR; BRAF(V600E) INHIBITION; RECEPTOR; GROWTH; CANCER; EXPRESSION; PROTEINS; GENES; LMO7; MUTATIONS	Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) is a pan-negative regulator of receptor tyrosine kinase (RTK) signaling and a tumor suppressor in several cancers, but its involvement in melanoma is largely unexplored. Here, we aim to determine the role of LRIG1 in melanoma tumorigenesis, RTK signaling, and BRAF inhibitor resistance. We find that LRIG1 is downregulated during early tumorigenesis and that LRIG1 affects activation of the epidermal growth factor receptor (EGFR) in melanoma cells. LRIG1-dependent regulation of EGFR signaling is evolutionary conserved to the roundworm C. elegans, where negative regulation of the EGFR-Ras-Raf pathway by sma-10/LRIG completely depends on presence of the receptor let-23/EGFR. In a cohort of metastatic melanoma patients, we observe an association between LRIG1 and survival in the triple wild-type subtype and in tumors with high EGFR expression. During in vitro development of BRAF inhibitor resistance, LRIG1 expression decreases; and mimics LRIG1 knockout cells for increased EGFR expression. Treating resistant cells with recombinant LRIG1 suppresses AKT activation and proliferation. Together, our results show that sma-10/LRIG is a conserved regulator of RTK signaling, add to our understanding of LRIG1 in melanoma and identifies recombinant LRIG1 as a potential therapeutic against BRAF inhibitor-resistant melanoma.	[Billing, Ola; Holmgren, Ylva; Hemmingsson, Oskar] Umea Univ, Dept Surg & Perioperat Sci Surg, Umea, Sweden; [Holmgren, Ylva; Hedman, Hakan] Umea Univ, Dept Radiat Sci Oncol, Umea, Sweden; [Nosek, Daniel] Umea Univ, Dept Med Biosci Pathol, Umea, Sweden; [Hemmingsson, Oskar] Umea Univ, Wallenberg Ctr Mol Med, Umea, Sweden	Umea University; Umea University; Umea University; Umea University	Billing, O (corresponding author), Umea Univ, Dept Surg & Perioperat Sci Surg, Umea, Sweden.	ola.billing@umu.se		Hemmingsson, Oskar/0000-0003-1732-168X; Billing, Ola/0000-0001-5824-6263	NIH Office of Research Infrastructure Programs [P40 OD010440]; Knut and Alice Wallenberg foundation; Wenner-Gren foundations; Swedish Society of Medicine [SLS-503511]; Cancer Research Foundation in Northern Sweden [LP 14-2059, LP 17-2151, LP 19-2207, LP 12-1936]; Region Vasterbotten [RV-371261, RV-644351, RV-762061]; Swedish Cancer Society [CAN 2018/546]; JC Kempe Memorial Foundation	NIH Office of Research Infrastructure Programs(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Knut and Alice Wallenberg foundation(Knut & Alice Wallenberg Foundation); Wenner-Gren foundations; Swedish Society of Medicine; Cancer Research Foundation in Northern Sweden; Region Vasterbotten; Swedish Cancer Society(Swedish Cancer Society); JC Kempe Memorial Foundation	We thank Carl Herdenberg, Lars Nilsson (Umea University) for discussions and Simon Tuck (Umea University) and Richard Padgett (Rutgers University, NJ, USA) for discussions and nematode strains. Some nematode strains were provided by the CGC, which is funded by NIH Office of Research Infrastructure Programs (P40 OD010440). We also thank Christina Lundin, Peter Hagglof, Annika Holmberg, Charlotte Nordstrom and Anette Berglund for technical assistance. This study was funded by the Knut and Alice Wallenberg foundation (OH), the Wenner-Gren foundations (OH), the Swedish Society of Medicine (OH, SLS-503511), Cancer Research Foundation in Northern Sweden (OH, LP 14-2059, LP 17-2151 and LP 19-2207; HH, LP 12-1936), Region Vasterbotten (OH, RV-371261, RV-644351, RV-762061), the Swedish Cancer Society (HH, CAN 2018/546) and JC Kempe Memorial Foundation (YH).	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dedeic Z, 2011, J CELL SCI, V124, P1691, DOI 10.1242/jcs.080259; FERGUSON EL, 1985, GENETICS, V110, P17; Gleason RJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180681; Goldman MJ, 2020, NAT BIOTECHNOL, V38, P675, DOI 10.1038/s41587-020-0546-8; Goldoni S, 2007, ONCOGENE, V26, P368, DOI 10.1038/sj.onc.1209803; Gumienny TL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000963; Guo DS, 2004, GENOMICS, V84, P157, DOI 10.1016/j.ygeno.2004.01.013; Gur G, 2004, EMBO J, V23, P3270, DOI 10.1038/sj.emboj.7600342; HAN M, 1990, GENETICS, V126, P899; Holaska JM, 2006, HUM MOL GENET, V15, P3459, DOI 10.1093/hmg/ddl423; Johansson M, 2013, NEURO-ONCOLOGY, V15, P1200, DOI 10.1093/neuonc/not054; Karlsson T, 2008, J INVEST DERMATOL, V128, P1192, DOI 10.1038/sj.jid.5701175; Karlsson T, 2018, LUNG CANCER, V125, P174, DOI 10.1016/j.lungcan.2018.09.017; Kvarnbrink S, 2015, ACTA ONCOL, V54, P1113, DOI 10.3109/0284186X.2015.1021427; Laederich MB, 2004, J BIOL CHEM, V279, P47050, DOI 10.1074/jbc.M409703200; Li W, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20181165; Lindquist D, 2014, ACTA ONCOL, V53, P1135, DOI 10.3109/0284186X.2014.953258; Maixner A, 1998, DEV GENET, V23, P347, DOI 10.1002/(SICI)1520-6408(1998)23:4<347::AID-DVG9>3.0.CO;2-C; Mao F, 2017, J NEUROL SCI, V383, P56, DOI 10.1016/j.jns.2017.10.025; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Nilsson J, 2001, BIOCHEM BIOPH RES CO, V284, P1155, DOI 10.1006/bbrc.2001.5092; Obenauf AC, 2015, NATURE, V520, P368, DOI 10.1038/nature14336; Oh YM, 2014, SCI REP-UK, V4, DOI 10.1038/srep04980; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Rouam S, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-150; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shah P, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080915; Shattuck DL, 2007, MOL CELL BIOL, V27, P1934, DOI 10.1128/MCB.00757-06; Shin SY, 2009, J CELL SCI, V122, P425, DOI 10.1242/jcs.036319; Stefansson K, 2019, ONCOL REP, V42, P142, DOI 10.3892/or.2019.7138; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Suzuki Y, 2002, FEBS LETT, V521, P67, DOI 10.1016/S0014-5793(02)02824-7; Takeda H, 2015, NAT GENET, V47, P142, DOI 10.1038/ng.3175; Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wang JX, 2016, J CELL COMMUN SIGNAL, V10, P191, DOI 10.1007/s12079-016-0349-3; Wang Y, 2013, BRIT J CANCER, V108, P1765, DOI 10.1038/bjc.2013.138; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Xiang SJ, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0844-x; Xiong J, 2019, CANCERS, V11, DOI 10.3390/cancers11030280; Xu YB, 2015, J MOL BIOL, V427, P1934, DOI 10.1016/j.jmb.2015.03.001; Yi W, 2011, EXP CELL RES, V317, P504, DOI 10.1016/j.yexcr.2010.11.005	50	4	4	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2021	40	21					3707	3718		10.1038/s41388-021-01808-3	http://dx.doi.org/10.1038/s41388-021-01808-3		MAY 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SI8ZW	33947959	hybrid, Green Published			2022-12-17	WOS:000647099200001
J	Papoutsoglou, P; Rodrigues, DM; Moren, A; Bergman, A; Ponten, F; Coulouarn, C; Caja, L; Heldin, CH; Moustakas, A				Papoutsoglou, Panagiotis; Rodrigues-Junior, Dorival Mendes; Moren, Anita; Bergman, Andrew; Ponten, Fredrik; Coulouarn, Cedric; Caja, Laia; Heldin, Carl-Henrik; Moustakas, Aristidis			The noncoding MIR100HG RNA enhances the autocrine function of transforming growth factor beta signaling	ONCOGENE			English	Article								Activation of the transforming growth factor beta (TGF beta) pathway modulates the expression of genes involved in cell growth arrest, motility, and embryogenesis. An expression screen for long noncoding RNAs indicated that TGF beta induced mir-100-let-7a-2-mir-125b-1 cluster host gene (MIR100HG) expression in diverse cancer types, thus confirming an earlier demonstration of TGF beta-mediated transcriptional induction of MIR100HG in pancreatic adenocarcinoma. MIR100HG depletion attenuated TGF beta signaling, expression of TGF beta-target genes, and TGF beta-mediated cell cycle arrest. Moreover, MIR100HG silencing inhibited both normal and cancer cell motility and enhanced the cytotoxicity of cytostatic drugs. MIR100HG overexpression had an inverse impact on TGF beta signaling responses. Screening for downstream effectors of MIR100HG identified the ligand TGF beta 1. MIR100HG and TGFB1 mRNA formed ribonucleoprotein complexes with the RNA-binding protein HuR, promoting TGF beta 1 cytokine secretion. In addition, TGF beta regulated let-7a-2-3p, miR-125b-5p, and miR-125b-1-3p expression, all encoded by MIR100HG intron-3. Certain intron-3 miRNAs may be involved in TGF beta/SMAD-mediated responses (let-7a-2-3p) and others (miR-100, miR-125b) in resistance to cytotoxic drugs mediated by MIR100HG. In support of a model whereby TGF beta induces MIR100HG, which then enhances TGF beta 1 secretion, analysis of human carcinomas showed that MIR100HG expression correlated with expression of TGFB1 and its downstream extracellular target TGFBI. Thus, MIR100HG controls the magnitude of TGF beta signaling via TGF beta 1 autoinduction and secretion in carcinomas.	[Papoutsoglou, Panagiotis; Rodrigues-Junior, Dorival Mendes; Moren, Anita; Bergman, Andrew; Caja, Laia; Heldin, Carl-Henrik; Moustakas, Aristidis] Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, Sci Life Lab, Box 582, Uppsala, Sweden; [Papoutsoglou, Panagiotis; Coulouarn, Cedric] Univ Rennes, Ctr Lutte Canc Eugene Marquis, InInserm, UMR S 1242,COSS Chem Oncogenesis Stress Signaling, Rennes, France; [Ponten, Fredrik] Uppsala Univ, Rudbeck Lab, Dept Immunol Genet & Pathol, Box 256, Uppsala, Sweden	Uppsala University; UNICANCER; Centre Eugene Marquis; Universite de Rennes 1; Uppsala University	Moustakas, A (corresponding author), Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, Sci Life Lab, Box 582, Uppsala, Sweden.	aris.moustakas@imbim.uu.se	Papoutsoglou, Panagiotis/AAF-8898-2019; Coulouarn, Cedric/E-5472-2011; Rodrigues, Dorival Mendes/E-1808-2011	Papoutsoglou, Panagiotis/0000-0003-2115-3500; Coulouarn, Cedric/0000-0002-5692-9586; Rodrigues, Dorival Mendes/0000-0002-8861-9240; Ponten, Fredrik/0000-0003-0703-3940; Caja Puigsubira, Laia/0000-0002-8786-8763	Cancerfonden [CAN2012/438, CAN2015/438, CAN2018/469]; Vetenskapsradet [K2013-66X-14936-10-5, 2017-01588-3, 2018-02757-3, 2015-02757, 2020-01291]; Barncancerfonden [PR2018-0091]; European Research Council [787472]; Bodossaki Foundation; Alexander Onassis Foundation, Greece; Inserm; Universite de Rennes-1; ITMO Cancer AVIESAN Plan Cancer [C18007NS]; Ludwig Cancer Research,	Cancerfonden(Swedish Cancer Society); Vetenskapsradet(Swedish Research Council); Barncancerfonden; European Research Council(European Research Council (ERC)European Commission); Bodossaki Foundation; Alexander Onassis Foundation, Greece; Inserm(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Universite de Rennes-1; ITMO Cancer AVIESAN Plan Cancer; Ludwig Cancer Research,	This work was supported by Ludwig Cancer Research, Cancerfonden [CAN2012/438, CAN2015/438, CAN2018/469] to ArM, Vetenskapsradet [K2013-66X-14936-10-5, 2017-01588-3, 2018-02757-3] to ArM, [2015-02757, 2020-01291] to CHH, Barncancerfonden [PR2018-0091] to ArM, European Research Council [787472] to CHH, Bodossaki Foundation and Alexander Onassis Foundation, Greece to PP, Inserm, Universite de Rennes-1, and ITMO Cancer AVIESAN Plan Cancer [C18007NS] to CC.	Anaya J, 2016, PEERJ COMPUT SCI, DOI 10.7717/peerj-cs.67; Bai DN, 2012, CELL SIGNAL, V24, P1426, DOI 10.1016/j.cellsig.2012.03.003; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen DH, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004177; David CJ, 2018, NAT REV MOL CELL BIO, V19, P419, DOI 10.1038/s41580-018-0007-0; David CJ, 2016, CELL, V164, P1015, DOI 10.1016/j.cell.2016.01.009; Davis BN, 2010, MOL CELL, V39, P373, DOI 10.1016/j.molcel.2010.07.011; Dews M, 2010, CANCER RES, V70, P8233, DOI 10.1158/0008-5472.CAN-10-2412; Emmrich S, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-171; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gordian Edna, 2019, Oncotarget, V10, P810, DOI 10.18632/oncotarget.26574; Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838; Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021; Hoadley KA, 2018, CELL, V173, P291, DOI 10.1016/j.cell.2018.03.022; Bueno MJ, 2011, BBA-MOL BASIS DIS, V1812, P592, DOI 10.1016/j.bbadis.2011.02.002; Li WH, 2019, ONCOL LETT, V18, P6483, DOI 10.3892/ol.2019.11060; Lu YY, 2017, NAT MED, V23, P1331, DOI 10.1038/nm.4424; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Maupin KA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013002; Merdrignac A, 2018, HEPATOL COMMUN, V2, P254, DOI 10.1002/hep4.1142; Montes M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7967; Nabors LB, 2001, CANCER RES, V61, P2154; Ottaviani S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03962-x; Pabis M, 2019, NUCLEIC ACIDS RES, V47, P1011, DOI 10.1093/nar/gky1138; Papoutsoglou P, 2020, CANCER SCI, V111, P2672, DOI 10.1111/cas.14509; Papoutsoglou P, 2019, CELL REP, V28, P3182, DOI 10.1016/j.celrep.2019.08.028; Pelechano V, 2013, NAT REV GENET, V14, P880, DOI 10.1038/nrg3594; Spangberg K, 2000, VIROLOGY, V274, P378, DOI 10.1006/viro.2000.0461; Su XC, 2019, BIOMED PHARMACOTHER, V109, P788, DOI 10.1016/j.biopha.2018.10.029; Sun QY, 2018, NUCLEIC ACIDS RES, V46, P10405, DOI 10.1093/nar/gky696; Tordonato C, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00072; Vlachos IS, 2017, METHODS MOL BIOL, V1517, P25, DOI 10.1007/978-1-4939-6563-2_2; Wang F, 2012, J MOL DIAGN, V14, P22, DOI 10.1016/j.jmoldx.2011.08.002; Wang SW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0869-2	35	4	4	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2021	40	21					3748	3765		10.1038/s41388-021-01803-8	http://dx.doi.org/10.1038/s41388-021-01803-8		MAY 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SI8ZW	33941855	hybrid, Green Published			2022-12-17	WOS:000646512300002
J	Richart, L; Bidard, FC; Margueron, R				Richart, Laia; Bidard, Francois-Clement; Margueron, Raphael			Enhancer rewiring in tumors: an opportunity for therapeutic intervention	ONCOGENE			English	Review							BET BROMODOMAIN INHIBITORS; SUPER-ENHANCER; GENE-EXPRESSION; TRANSCRIPTIONAL ADDICTION; SELECTIVE-INHIBITION; OVERCOME RESISTANCE; TARGETED THERAPY; BLADDER-CANCER; CELL IDENTITY; WHOLE-GENOME	Enhancers are cis-regulatory sequences that fine-tune expression of their target genes in a spatiotemporal manner. They are recognized by sequence-specific transcription factors, which in turn recruit transcriptional coactivators that facilitate transcription by promoting assembly and activation of the basal transcriptional machinery. Their functional importance is underscored by the fact that they are often the target of genetic and nongenetic events in human disease that disrupt their sequence, interactome, activation potential, and/or chromatin environment. Dysregulation of transcription and addiction to transcriptional effectors that interact with and modulate enhancer activity are common features of cancer cells and are amenable to therapeutic intervention. Here, we discuss the current knowledge on enhancer biology, the broad spectrum of mechanisms that lead to their malfunction in tumor cells, and recent progress in developing drugs that efficaciously target their dependencies.	[Richart, Laia; Margueron, Raphael] Paris Sci & Lettres Res Univ, Inst Curie, Paris, France; [Richart, Laia; Margueron, Raphael] CNRS, UMR3215, INSERM, U934/, Paris, France; [Bidard, Francois-Clement] Inst Curie, Dept Med Oncol, Paris, France; [Bidard, Francois-Clement] SIRIC2 Inst Curie, Circulating Tumor Biomarkers Lab, Paris, France; [Bidard, Francois-Clement] Univ Paris Saclay, UVSQ, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Universite Paris Saclay	Margueron, R (corresponding author), Paris Sci & Lettres Res Univ, Inst Curie, Paris, France.; Margueron, R (corresponding author), CNRS, UMR3215, INSERM, U934/, Paris, France.	raphael.margueron@curie.fr	Margueron, Raphael/B-9996-2015	Margueron, Raphael/0000-0002-9093-7977	Fondation pour la Recherche Medicale [Equipe FRM EQU202003010312]; Pfizer	Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Pfizer(Pfizer)	Work in the lab of RM is supported by the Fondation pour la Recherche Medicale (Equipe FRM EQU202003010312). LR work was partly supported by a research grant from Pfizer. We thank Daniel Holoch and Ming-Kang Lee for their critical review of the manuscript.	Abramson JS, 2015, BLOOD, V126; Affer M, 2014, LEUKEMIA, V28, P1725, DOI 10.1038/leu.2014.70; Akhtar MS, 2009, MOL CELL, V34, P387, DOI 10.1016/j.molcel.2009.04.016; Akhtar-Zaidi B, 2012, SCIENCE, V336, P736, DOI 10.1126/science.1217277; Albrecht BK, 2016, J MED CHEM, V59, P1330, DOI 10.1021/acs.jmedchem.5b01882; Alekseyenko AA, 2015, GENE DEV, V29, P1507, DOI 10.1101/gad.267583.115; Ali S, 2009, CANCER RES, V69, P6208, DOI 10.1158/0008-5472.CAN-09-0301; Ambrosini G, 2019, CANCER RES, V79, P2415, DOI 10.1158/0008-5472.CAN-18-3177; Amorim S, 2016, LANCET HAEMATOL, V3, pE196, DOI 10.1016/S2352-3026(16)00021-1; Andricovich J, 2018, CANCER CELL, V33, P512, DOI 10.1016/j.ccell.2018.02.003; Arfaoui A, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201809930; Bagratuni T, 2020, EUR J CANCER, V126, P125, DOI 10.1016/j.ejca.2019.11.017; Bahr C, 2018, NATURE, V553, P515, DOI 10.1038/nature25193; Balbas-Martinez C, 2013, NAT GENET, V45, P1464, DOI 10.1038/ng.2799; Bandopadhayay P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10307-9; Beauchamp EM, 2019, BLOOD, V133, P1171, DOI 10.1182/blood-2018-08-870089; Belakavadi M, 2008, MOL CELL BIOL, V28, P3932, DOI 10.1128/MCB.02191-07; Benabdallah NS, 2019, MOL CELL, V76, P473, DOI 10.1016/j.molcel.2019.07.038; Benabdallah NS, 2015, COLD SH Q B, V80, P45, DOI 10.1101/sqb.2015.80.027268; Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352-3026(15)00247-1; Bihani T, 2015, ONCOTARGET, V6, P2407, DOI 10.18632/oncotarget.2964; Boedicker C, 2020, ONCOGENE, V39, P3837, DOI 10.1038/s41388-020-1229-0; Boija A, 2018, CELL, V175, P1842, DOI 10.1016/j.cell.2018.10.042; Bolin S, 2018, ONCOGENE, V37, P2850, DOI 10.1038/s41388-018-0135-1; Bose DA, 2017, CELL, V168, P135, DOI 10.1016/j.cell.2016.12.020; Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013; Butler JEF, 2001, GENE DEV, V15, P2515, DOI 10.1101/gad.924301; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Calebiro D, 2016, J CLIN INVEST, V126, P3383, DOI 10.1172/JCI84894; Calo E, 2013, MOL CELL, V49, P825, DOI 10.1016/j.molcel.2013.01.038; Calvo-Vidal, 2017, NAT COMMUN, V8; Camero S, 2020, CANCER LETT, V479, P71, DOI 10.1016/j.canlet.2020.03.011; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; Casa V, 2020, GENOME RES, V30, P515, DOI 10.1101/gr.253211.119; Catarino RR, 2018, GENE DEV, V32, P202, DOI 10.1101/gad.310367.117; Chaidos A, 2014, BLOOD, V123, P697, DOI 10.1182/blood-2013-01-478420; Chapuy B, 2013, CANCER CELL, V24, P777, DOI 10.1016/j.ccr.2013.11.003; Chen H, 2018, CELL, V173, P386, DOI 10.1016/j.cell.2018.03.027; Chen JW, 2021, CLIN CANCER RES, V27, P1438, DOI 10.1158/1078-0432.CCR-20-3044; Chipumuro E, 2014, CELL, V159, P1126, DOI 10.1016/j.cell.2014.10.024; Cho WK, 2018, SCIENCE, V361, P412, DOI 10.1126/science.aar4199; Christensen CL, 2014, CANCER CELL, V26, P909, DOI 10.1016/j.ccell.2014.10.019; Chua V, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201809081; Clarke PA, 2016, ELIFE, V5, DOI 10.7554/eLife.20722; Cromm PM, 2017, CELL CHEM BIOL, V24, P1181, DOI 10.1016/j.chembiol.2017.05.024; Dai XP, 2017, NAT MED, V23, DOI 10.1038/nm.4378; Dale T, 2015, NAT CHEM BIOL, V11, P973, DOI 10.1038/nchembio.1952; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dave K, 2017, ELIFE, V6, DOI 10.7554/eLife.23382; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; De Koninck M, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026476; De Santa F, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000384; Debruyne DN, 2019, NATURE, V572, P676, DOI 10.1038/s41586-019-1472-0; Noblejas-Lopez MD, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1387-5; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Deng WL, 2014, CELL, V158, P849, DOI 10.1016/j.cell.2014.05.050; Dixon JR, 2012, NATURE, V485, P376, DOI 10.1038/nature11082; Donner AJ, 2010, NAT STRUCT MOL BIOL, V17, P194, DOI 10.1038/nsmb.1752; Drier Y, 2016, NAT GENET, V48, P265, DOI 10.1038/ng.3502; Edmondson SD, 2019, BIOORG MED CHEM LETT, V29, P1555, DOI 10.1016/j.bmcl.2019.04.030; El Khattabi L, 2019, CELL, V178, P1145, DOI 10.1016/j.cell.2019.07.011; Esnault C, 2008, MOL CELL, V31, P337, DOI 10.1016/j.molcel.2008.06.021; Fagan RJ, 2019, CANCER LETT, V458, P56, DOI 10.1016/j.canlet.2019.05.024; Faivre EJ, 2020, NATURE, V578, P306, DOI 10.1038/s41586-020-1930-8; Fant CB, 2019, TRANSCR-AUSTIN, V10, P76, DOI 10.1080/21541264.2018.1556915; Fehling SC, 2020, CANCER LETT, V468, P48, DOI 10.1016/j.canlet.2019.10.011; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Firestein R, 2008, NATURE, V455, P547, DOI 10.1038/nature07179; Fiskus W, 2021, LEUKEMIA, V35, P2621, DOI 10.1038/s41375-021-01181-w; Flavahan WA, 2019, NATURE, V575, P229, DOI 10.1038/s41586-019-1668-3; Flavahan WA, 2016, NATURE, V529, P110, DOI 10.1038/nature16490; Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888; Frankel N, 2010, NATURE, V466, P490, DOI 10.1038/nature09158; French CA, 2008, ONCOGENE, V27, P2237, DOI 10.1038/sj.onc.1210852; Fulco CP, 2019, NAT GENET, V51, P1664, DOI 10.1038/s41588-019-0538-0; Galbraith MD, 2019, TRANSCR-AUSTIN, V10, P118, DOI 10.1080/21541264.2018.1539615; Gilan O, 2020, SCIENCE, V368, P387, DOI 10.1126/science.aaz8455; Gollavilli PN, 2018, CANCER RES, V78, P4760, DOI 10.1158/0008-5472.CAN-18-0484; Groschel S, 2014, CELL, V157, P369, DOI 10.1016/j.cell.2014.02.019; Grubert F, 2015, CELL, V162, P1051, DOI 10.1016/j.cell.2015.07.048; Gu WT, 2013, CELL CYCLE, V12, P987, DOI 10.4161/cc.24003; Guerra SL, 2020, CANCER CELL, V37, P705, DOI 10.1016/j.ccell.2020.03.004; Guo GW, 2013, NAT GENET, V45, P1459, DOI 10.1038/ng.2798; Haller F, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08069-x; Hamilton WB, 2019, NATURE, V575, P355, DOI 10.1038/s41586-019-1732-z; Han XY, 2020, NAT STRUCT MOL BIOL, V27, P333, DOI 10.1038/s41594-020-0394-8; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harms PW., 2014, HUM PATHOL, V1, P21, DOI DOI 10.1016/J.EHPC.2014.07.002; Hnisz D, 2018, ANNU REV CANC BIOL, V2, P21, DOI 10.1146/annurev-cancerbio-030617-050134; Hnisz D, 2017, CELL, V169, P13, DOI 10.1016/j.cell.2017.02.007; Hnisz D, 2015, MOL CELL, V58, P362, DOI 10.1016/j.molcel.2015.02.014; Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053; Iniguez AB, 2018, CANCER CELL, V34, P922, DOI 10.1016/j.ccell.2018.11.005; Iniguez AB, 2018, CANCER CELL, V33, P202, DOI 10.1016/j.ccell.2017.12.009; Jiang YY, 2017, GUT, V66, P1358, DOI 10.1136/gutjnl-2016-311818; Jin X, 2018, MOL CELL, V71, P592, DOI 10.1016/j.molcel.2018.06.036; Kagey MH, 2010, NATURE, V467, P430, DOI 10.1038/nature09380; Kapoor A, 2010, NATURE, V468, P1105, DOI 10.1038/nature09590; Katainen R, 2015, NAT GENET, V47, P818, DOI 10.1038/ng.3335; Kelso TWR, 2014, MOL CELL BIOL, V34, P3675, DOI 10.1128/MCB.00595-14; Kim TK, 2010, NATURE, V465, P182, DOI 10.1038/nature09033; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Klein IA, 2020, SCIENCE, V368, P1386, DOI 10.1126/science.aaz4427; Knoechel B, 2014, NAT GENET, V46, P364, DOI 10.1038/ng.2913; Kojic A, 2018, NAT STRUCT MOL BIOL, V25, P496, DOI 10.1038/s41594-018-0070-4; Kurimchak AM, 2016, CELL REP, V16, P1273, DOI 10.1016/j.celrep.2016.06.091; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Lam FC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04315-4; Lambert JP, 2019, MOL CELL, V73, P621, DOI 10.1016/j.molcel.2018.11.006; Larochelle S, 2012, NAT STRUCT MOL BIOL, V19, P1108, DOI 10.1038/nsmb.2399; Latif AL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20378-8; Leal AS, 2017, CANCER LETT, V394, P76, DOI 10.1016/j.canlet.2017.02.021; Lewin J, 2018, J CLIN ONCOL, V36, P3007, DOI 10.1200/JCO.2018.78.2292; Li B, 2017, CANCER RES, V77, P3834, DOI 10.1158/0008-5472.CAN-16-2546; Li WP, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0761-2; Li WB, 2013, NATURE, V498, P516, DOI 10.1038/nature12210; Liao SD, 2018, GENE DEV, V32, P1188, DOI 10.1101/gad.315648.118; Liddicoat BJ, 2020, MOL CELL, V78, P991, DOI 10.1016/j.molcel.2020.05.026; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Lu HS, 2015, ELIFE, V4, DOI 10.7554/eLife.06535; Lu J, 2015, CHEM BIOL, V22, P755, DOI 10.1016/j.chembiol.2015.05.009; Lucking U, 2017, CHEMMEDCHEM, V12, P1776, DOI 10.1002/cmdc.201700447; Madsen JGS, 2020, NAT GENET, V52, P1227, DOI 10.1038/s41588-020-0709-z; Mahe M, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708163; Matkar S, 2015, CANCER CELL, V28, P472, DOI 10.1016/j.ccell.2015.09.005; Maurano MT, 2012, SCIENCE, V337, P1190, DOI 10.1126/science.1222794; Mazur PK, 2015, NAT MED, V21, P1163, DOI 10.1038/nm.3952; McDermott MSJ, 2017, ONCOTARGET, V8, P12558, DOI 10.18632/oncotarget.14894; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Mir M, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.182766; Moreno V, 2020, ANN ONCOL, V31, P780, DOI 10.1016/j.annonc.2020.03.294; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Morrison-Smiths CD, 2020, MOL CANCER THER, V19, P1406, DOI 10.1158/1535-7163.MCT-20-0087; Muller M, 2016, STEM CELL RES, V16, P349, DOI 10.1016/j.scr.2016.02.005; Nabet B, 2015, CELL REP, V12, P1300, DOI 10.1016/j.celrep.2015.06.078; Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589; Nora EP, 2012, NATURE, V485, P381, DOI 10.1038/nature11049; Northcott PA, 2017, NATURE, V547, P311, DOI 10.1038/nature22973; Nott A, 2019, SCIENCE, V366, P1134, DOI 10.1126/science.aay0793; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Olson CM, 2018, NAT CHEM BIOL, V14, P163, DOI [10.1038/NCHEMBIO.2538, 10.1038/nchembio.2538]; Ortega-Molina A, 2015, NAT MED, V21, P1199, DOI 10.1038/nm.3943; Ozer HG, 2018, CANCER DISCOV, V8, P458, DOI 10.1158/2159-8290.CD-17-0902; Pandey PK, 2005, MOL CELL BIOL, V25, P10695, DOI 10.1128/MCB.25.24.10695-10710.2005; Patel H, 2018, MOL CANCER THER, V17, P1156, DOI 10.1158/1535-7163.MCT-16-0847; Pelish HE, 2015, NATURE, V526, P273, DOI 10.1038/nature14904; Phillips-Cremins JE, 2013, CELL, V153, P1281, DOI 10.1016/j.cell.2013.04.053; Piha-Paul SA, 2020, JNCI CANCER SPECT, V4, DOI 10.1093/jncics/pkz093; Piunti A, 2017, NAT MED, V23, P493, DOI 10.1038/nm.4296; Piya S, 2019, J CLIN INVEST, V129, P1878, DOI 10.1172/JCI120654; Puente XS, 2015, NATURE, V526, P519, DOI 10.1038/nature14666; Pulikkan JA, 2018, CELL, V174, P172, DOI 10.1016/j.cell.2018.05.048; Quereda V, 2019, CANCER CELL, V36, P545, DOI 10.1016/j.ccell.2019.09.004; Raina K, 2016, P NATL ACAD SCI USA, V113, P7124, DOI 10.1073/pnas.1521738113; Rao SSP, 2017, CELL, V171, P305, DOI 10.1016/j.cell.2017.09.026; Rao SSP, 2014, CELL, V159, P1665, DOI 10.1016/j.cell.2014.11.021; Rathert P, 2015, NATURE, V525, P543, DOI 10.1038/nature14898; Rickels R, 2018, TRENDS CELL BIOL, V28, P608, DOI 10.1016/j.tcb.2018.04.003; Risom T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05729-w; Rusan M, 2018, CANCER DISCOV, V8, P59, DOI 10.1158/2159-8290.CD-17-0461; Sabari BR, 2018, SCIENCE, V361, DOI 10.1126/science.aar3958; Saenz DT, 2020, BLOOD, V135, P1255, DOI 10.1182/blood.2019002922; Sanborn AL, 2015, P NATL ACAD SCI USA, V112, pE6456, DOI 10.1073/pnas.1518552112; Schilbach S, 2017, NATURE, V551, P204, DOI 10.1038/nature24282; Segura MF, 2013, CANCER RES, V73, P6264, DOI 10.1158/0008-5472.CAN-13-0122-T; Sharko AC, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010144; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508; Sin-Chan P, 2019, CANCER CELL, V36, P51, DOI 10.1016/j.ccell.2019.06.002; Siu KT, 2017, LEUKEMIA, V31, P1760, DOI 10.1038/leu.2016.355; Spitz F, 2016, SEMIN CELL DEV BIOL, V57, P57, DOI 10.1016/j.semcdb.2016.06.017; Stathis A, 2016, CANCER DISCOV, V6, P492, DOI 10.1158/2159-8290.CD-15-1335; Stevens JL, 2002, SCIENCE, V296, P755, DOI 10.1126/science.1068943; Stratikopoulos EE, 2015, CANCER CELL, V27, P837, DOI 10.1016/j.ccell.2015.05.006; Stubbs MC, 2019, CLIN CANCER RES, V25, P300, DOI 10.1158/1078-0432.CCR-18-0098; Sun B, 2018, LEUKEMIA, V32, P343, DOI 10.1038/leu.2017.207; Sur I, 2016, NAT REV CANCER, V16, P483, DOI 10.1038/nrc.2016.62; Sze CC, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026427; Takahashi H, 2011, CELL, V146, P92, DOI 10.1016/j.cell.2011.06.005; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; Tothova Z, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.142149; van Arensbergen J, 2014, TRENDS CELL BIOL, V24, P695, DOI 10.1016/j.tcb.2014.07.004; Vazquez R, 2017, ONCOTARGET, V8, P7598, DOI 10.18632/oncotarget.13814; Walsh L, 2019, CLIN CANCER RES, V25, P7139, DOI 10.1158/1078-0432.CCR-19-0713; Wang YB, 2015, CELL, V163, P174, DOI 10.1016/j.cell.2015.08.063; Waring MJ, 2016, NAT CHEM BIOL, V12, P1097, DOI [10.1038/NCHEMBIO.2210, 10.1038/nchembio.2210]; Welch JS, 2012, CELL, V150, P264, DOI 10.1016/j.cell.2012.06.023; Welter Danielle, 2014, Nucleic Acids Res, V42, pD1001, DOI 10.1093/nar/gkt1229; Welti J, 2018, CLIN CANCER RES, V24, P3149, DOI 10.1158/1078-0432.CCR-17-3571; Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035; Wu WY, 2020, MOL CELL, V78, P1114, DOI 10.1016/j.molcel.2020.04.034; Yan LM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19770-1; Yang L, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal1645; Yang X, 2012, P NATL ACAD SCI USA, V109, pE2813, DOI 10.1073/pnas.1204311109; Yokoyama Y, 2016, CANCER RES, V76, P6320, DOI 10.1158/0008-5472.CAN-16-0854; Zawistowski JS, 2017, CANCER DISCOV, V7, P302, DOI 10.1158/2159-8290.CD-16-0653; Zengerle M, 2015, ACS CHEM BIOL, V10, P1770, DOI 10.1021/acschembio.5b00216; Zhang GT, 2013, J MED CHEM, V56, P9251, DOI 10.1021/jm401334s; Zhang HH, 2018, CELL, V175, P1244, DOI 10.1016/j.cell.2018.09.051; Zhang JJ, 2020, CLIN CANCER RES, V26, P2681, DOI 10.1158/1078-0432.CCR-19-1418; Zhang TH, 2016, NAT CHEM BIOL, V12, P876, DOI 10.1038/nchembio.2166; Zhang W, 2020, CANCER LETT, V469, P510, DOI 10.1016/j.canlet.2019.11.027; Zhang XH, 2018, LEUKEMIA, V32, P2224, DOI 10.1038/s41375-018-0044-x; Zhang XY, 2016, NAT GENET, V48, P176, DOI 10.1038/ng.3470; Zhou S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14318-9; Zimmerman MW, 2018, CANCER DISCOV, V8, P320, DOI 10.1158/2159-8290.CD-17-0993	206	4	4	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2021	40	20					3475	3491		10.1038/s41388-021-01793-7	http://dx.doi.org/10.1038/s41388-021-01793-7		MAY 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE7RS	33934105				2022-12-17	WOS:000645962300001
J	Woodley, CM; Romer, AS; Wang, J; Guarnaccia, AD; Elion, DL; Maxwell, JN; Guerrazzi, K; McCann, TS; Popay, TM; Matlock, BK; Flaherty, DK; Lorey, SL; Liu, Q; Tansey, WP; Weissmiller, AM				Woodley, Chase M.; Romer, Alexander S.; Wang, Jing; Guarnaccia, Alissa D.; Elion, David L.; Maxwell, Jack N.; Guerrazzi, Kiana; McCann, Tyler S.; Popay, Tessa M.; Matlock, Brittany K.; Flaherty, David K.; Lorey, Shelly L.; Liu, Qi; Tansey, William P.; Weissmiller, April M.			Multiple interactions of the oncoprotein transcription factor MYC with the SWI/SNF chromatin remodeler	ONCOGENE			English	Article							SANT DOMAIN; COMPLEX; TARGET	The SNF5 subunit of the SWI/SNF chromatin remodeling complex has been shown to act as a tumor suppressor through multiple mechanisms, including impairing the ability of the oncoprotein transcription factor MYC to bind chromatin. Beyond SNF5, however, it is unknown to what extent MYC can access additional SWI/SNF subunits or how these interactions affect the ability of MYC to drive transcription, particularly in SNF5-null cancers. Here, we report that MYC interacts with multiple SWI/SNF components independent of SNF5. We show that MYC binds the pan-SWI/SNF subunit BAF155 through the BAF155 SWIRM domain, an interaction that is inhibited by the presence of SNF5. In SNF5-null cells, MYC binds with remaining SWI/SNF components to essential genes, although for a purpose that is distinct from chromatin remodeling. Analysis of MYC-SWI/SNF target genes in SNF5-null cells reveals that they are associated with core biological functions of MYC linked to protein synthesis. These data reveal that MYC can bind SWI/SNF in an SNF5-independent manner and that SNF5 modulates access of MYC to core SWI/SNF complexes. This work provides a framework in which to interrogate the influence of SWI/SNF on MYC function in cancers in which SWI/SNF or MYC are altered.	[Woodley, Chase M.; Guarnaccia, Alissa D.; Elion, David L.; Guerrazzi, Kiana; McCann, Tyler S.; Popay, Tessa M.; Lorey, Shelly L.; Tansey, William P.] Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37212 USA; [Romer, Alexander S.; Maxwell, Jack N.; Weissmiller, April M.] Middle Tennessee State Univ, Dept Biol, Murfreesboro, TN 37130 USA; [Wang, Jing; Liu, Qi] Vanderbilt Univ, Med Ctr, Ctr Quantitat Sci, Nashville, TN USA; [Wang, Jing; Liu, Qi] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA; [Matlock, Brittany K.; Flaherty, David K.] Vanderbilt Univ, Med Ctr, Med Ctr Flow Cytometry Shared Resource, Nashville, TN USA; [Tansey, William P.] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37212 USA	Vanderbilt University; Middle Tennessee State University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Weissmiller, AM (corresponding author), Middle Tennessee State Univ, Dept Biol, Murfreesboro, TN 37130 USA.	april.weissmiller@mtsu.edu		Woodley, Chase/0000-0001-7121-7504; Popay, Tessa/0000-0002-4694-8804; Weissmiller, April/0000-0003-4505-0530; Wang, Jing/0000-0003-2775-9001; Guarnaccia, Alissa/0000-0003-4195-2158	NIH [CA68485, DK20593, DK58404, DK59637, EY08126]; Rally Foundation for Childhood Cancer Research Young Investigator Award [T32CA119925]; NIH/NCI [F31CA225065, T32CA009582, CA247833]; Alex's Lemonade Stand Foundation; St. Baldrick's Foundation; Robert J. Kleberg and Helen C. Kleberg Foundation	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rally Foundation for Childhood Cancer Research Young Investigator Award; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Alex's Lemonade Stand Foundation; St. Baldrick's Foundation; Robert J. Kleberg and Helen C. Kleberg Foundation	Special thanks to Dr. Scott Hiebert for his invaluable contributions. We would also like to thank the Vanderbilt University Medical Center Flow Cytometry Shared Resource, the Vanderbilt University Chemical Synthesis Core, the Vanderbilt Cell Imaging Shared Resource (CISR), and the Vanderbilt University Medical Center Technologies for Advanced Genomics (VANTAGE) Core for their critical assistance in this project. The Nikon Center of Excellence located in CISR is supported by NIH grants CA68485, DK20593, DK58404, DK59637, and EY08126. This work was supported by The Rally Foundation for Childhood Cancer Research Young Investigator Award and T32CA119925 to A.M.W, by the NIH/NCI, F31CA225065 and T32CA009582 to A.D.G, and grants from Alex's Lemonade Stand Foundation, St. Baldrick's Foundation, the Robert J. Kleberg and Helen C. Kleberg Foundation, and grant CA247833 from the NIH/NCI to W.P.T.	Alpsoy A, 2018, J BIOL CHEM, V293, P3892, DOI 10.1074/jbc.RA117.001065; Alver BH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14648; Boyer LA, 2004, NAT REV MOL CELL BIO, V5, P158, DOI 10.1038/nrm1314; Boyer LA, 2002, MOL CELL, V10, P935, DOI 10.1016/S1097-2765(02)00634-2; Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Feng JX, 2012, NAT PROTOC, V7, P1728, DOI 10.1038/nprot.2012.101; Gadd S, 2010, LAB INVEST, V90, P724, DOI 10.1038/labinvest.2010.66; Gatchalian J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07528-9; Genovese G, 2017, NATURE, V542, P362, DOI 10.1038/nature21064; Hohmann AF, 2014, TRENDS GENET, V30, P356, DOI 10.1016/j.tig.2014.05.001; JI H, 2011, PLOS ONE, V6; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Martin M., 2011, EMBNET J, V17, P10, DOI 10.14806/ej.17.1.200; Mashtalir N, 2018, CELL, V175, P1272, DOI 10.1016/j.cell.2018.09.032; McBride MJ, 2018, CANCER CELL, V33, P1128, DOI 10.1016/j.ccell.2018.05.002; Michel BC, 2018, NAT CELL BIOL, V20, P1410, DOI 10.1038/s41556-018-0221-1; Mittal P, 2020, NAT REV CLIN ONCOL, V17, P435, DOI 10.1038/s41571-020-0357-3; Nabet B, 2018, NAT CHEM BIOL, V14, P431, DOI 10.1038/s41589-018-0021-8; Nakayama RT, 2017, NAT GENET, V49, P1613, DOI 10.1038/ng.3958; Orlando KA, 2020, ELIFE, V9, DOI 10.7554/eLife.59073; Pan J, 2019, NAT GENET, V51, P618, DOI 10.1038/s41588-019-0363-5; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Reddy D, 2018, NAT CELL BIOL, V20, P1332, DOI 10.1038/s41556-018-0246-5; Shain AH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055119; Sohn DH, 2007, J BIOL CHEM, V282, P10614, DOI 10.1074/jbc.M610563200; Stark R, 2011, DIFFBIND DIFFERENTIA; Stojanova A, 2016, CELL CYCLE, V15, P1693, DOI 10.1080/15384101.2016.1146836; Tansey, 2015, OPEN ACCESS J SCI TE, V3, DOI [10.11131/2015/101124, DOI 10.11131/2015/101124]; Tansey W.P., 2014, NEW J SCI, V2014, P1; Thomas LR, 2016, ONCOGENE, V35, P3613, DOI 10.1038/onc.2015.416; Thomas LR, 2015, MOL CELL, V58, P440, DOI 10.1016/j.molcel.2015.02.028; Vierbuchen T, 2017, MOL CELL, V68, P1067, DOI 10.1016/j.molcel.2017.11.026; WANG J, 2018, BMC GENOMICS, V19; Wang L, 2014, CANCER CELL, V25, P21, DOI 10.1016/j.ccr.2013.12.007; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; WANG XF, 2017, NAT GENET, V49, P289, DOI [DOI 10.1038/NG.3746, 10.1038/ng.3746]; Wang X, 2011, J CLIN INVEST, V121, P3834, DOI 10.1172/JCI37210; Wang XY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08657-5; Weissmiller AM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10022-5; WILSON AC, 1995, GENE DEV, V9, P2445, DOI 10.1101/gad.9.20.2445	47	4	4	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2021	40	20					3593	3609		10.1038/s41388-021-01804-7	http://dx.doi.org/10.1038/s41388-021-01804-7		APR 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE7RS	33931740	Green Accepted			2022-12-17	WOS:000645887000004
J	Zhou, M; Zhang, XL; Liu, C; Nie, DN; Li, SY; Lai, PL; Jin, YL				Zhou, Min; Zhang, Xiuli; Liu, Chang; Nie, Danian; Li, Shuyi; Lai, Peilong; Jin, Yanli			Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogenous leukemia stem cells via upregulation of SOX6	ONCOGENE			English	Article							HISTONE METHYLTRANSFERASE; PHILADELPHIA-CHROMOSOME; MAINTENANCE; RESISTANCE; IMATINIB; THERAPY; HEAD; AXIS; CML	The application of tyrosine kinase inhibitors (TKIs) in clinic has revolutionized chronic myelogenous leukemia (CML) treatment, but fails to eliminate leukemia stem cells (LSCs), which are considered as roots of drug resistance and disease relapse. Thus, eradication of LSCs may be a promising strategy for curing CML. In this study, we found that protein lysine methyltransferase G9A was overexpressed in CML LSCs. The upregulation of G9A by BCR-ABL was independent on its tyrosine kinase activity. Knockdown of G9A by shRNAs or pharmacological inhibition of G9A by UNC0642 significantly suppressed survival and impaired self-renewal capacity of CML LSCs. Inhibition of G9a eradicated LSCs in CML mice driven by BCR-ABL gene and dramatically prolonged survival of the mice. Ex vivo treatment with G9A inhibitor inhibited long-term engraftment of CML CD34(+) cells in immunodeficient mice. Mechanically, tumor suppressor SOX6 was identified as a direct target of G9A in CML LSCs by RNA-seq analysis. Silencing Sox6 at least partially rescued G9a knockdown-mediated LSCs elimination in vivo. Our findings improve the understanding of LSC regulation network and validate G9A as a therapeutic target in CML LSCs. Targeting G9A may be considered as an additional strategy for the treatment of patients with CML.	[Zhou, Min; Zhang, Xiuli; Liu, Chang; Li, Shuyi; Jin, Yanli] Jinan Univ, Inst Tumor Pharmacol, Coll Pharm, Guangzhou, Peoples R China; [Liu, Chang] Jinan Univ, Integrated Chinese & Western Med Postdoctoral Res, Guangzhou, Peoples R China; [Nie, Danian] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Hematol, Guangzhou, Peoples R China; [Lai, Peilong] Guangdong Acad Med Sci, Dept Hematol, Guangdong Gen Hosp, Guangzhou, Peoples R China	Jinan University; Jinan University; Sun Yat Sen University; Guangdong Academy of Medical Sciences & Guangdong General Hospital	Jin, YL (corresponding author), Jinan Univ, Inst Tumor Pharmacol, Coll Pharm, Guangzhou, Peoples R China.	yanlijin2014@jnu.edu.cn			National Natural Science Funds [81922069, 81974505, 82003778]; Natural Science Funds of Guangdong Province for Distinguished Young Scholars [2016A030306036]; Young Scholar of Science and Technology of Guangdong Province [2016TQ03R926]	National Natural Science Funds(National Natural Science Foundation of China (NSFC)); Natural Science Funds of Guangdong Province for Distinguished Young Scholars; Young Scholar of Science and Technology of Guangdong Province	This study was supported by grants from the National Natural Science Funds (Nos. 81922069 and 81974505 to YJ; No. 82003778 to CL); the Natural Science Funds of Guangdong Province for Distinguished Young Scholars (Grant No. 2016A030306036 to YJ); the Young Scholar of Science and Technology of Guangdong Province (2016TQ03R926 to YJ).	Abraham SA, 2016, NATURE, V534, P341, DOI 10.1038/nature18288; Bhat AV, 2019, CANCER RES, V79, P2232, DOI 10.1158/0008-5472.CAN-18-2676; Bhatia R, 2003, BLOOD, V101, P4701, DOI 10.1182/blood-2002-09-2780; Cantu C, 2011, BLOOD, V117, P3669, DOI 10.1182/blood-2010-04-282350; Carter BZ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag1180; Casciello F, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00487; Chen YY, 2009, NAT GENET, V41, P783, DOI 10.1038/ng.389; Cortes JE, 2013, NEW ENGL J MED, V369, P1783, DOI 10.1056/NEJMoa1306494; Crews LA, 2013, CANCER LETT, V338, P15, DOI 10.1016/j.canlet.2012.08.006; Druker BJ, 2008, BLOOD, V112, P4808, DOI 10.1182/blood-2008-07-077958; Gehrmann U, 2019, P NATL ACAD SCI USA, V116, P25839, DOI 10.1073/pnas.1901639116; Holyoake TL, 2017, BLOOD, V129, P1595, DOI 10.1182/blood-2016-09-696013; Hu L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0322-6; Hua KT, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-189; Jain P, 2015, LANCET HAEMATOL, V2, pE376, DOI 10.1016/S2352-3026(15)00127-1; Jin YL, 2017, CLIN CANCER RES, V23, P2842, DOI 10.1158/1078-0432.CCR-16-1298; Jin YL, 2016, J CLIN INVEST, V126, P3961, DOI 10.1172/JCI85239; Jones PA, 2016, NAT REV GENET, V17, P630, DOI 10.1038/nrg.2016.93; Kalmanti L, 2015, LEUKEMIA, V29, P1123, DOI 10.1038/leu.2015.36; Lehnertz B, 2014, GENE DEV, V28, P317, DOI 10.1101/gad.236794.113; Liang ZX, 2020, SEMIN CANCER BIOL, V67, P83, DOI 10.1016/j.semcancer.2019.07.011; Liu C, 2018, CANCER RES, V78, P1522, DOI 10.1158/0008-5472.CAN-17-1733; Liu CW, 2017, MOL CANCER THER, V16, P1421, DOI 10.1158/1535-7163.MCT-16-0567-T; Liu F, 2013, J MED CHEM, V56, P8931, DOI 10.1021/jm401480r; Liu SL, 2015, ONCOTARGET, V6, P6887, DOI 10.18632/oncotarget.3159; Luo CW, 2017, RADIOTHER ONCOL, V124, P395, DOI 10.1016/j.radonc.2017.03.002; Ma L, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009587; O'Hare T, 2012, NAT REV CANCER, V12, P513, DOI 10.1038/nrc3317; Pan MR, 2016, ONCOTARGET, V7, P61136, DOI 10.18632/oncotarget.11256; Pfister SX, 2017, NAT REV DRUG DISCOV, V16, P241, DOI 10.1038/nrd.2016.256; Rowbotham SP, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07077-1; Saikia T, 2018, CURR ONCOL REP, V20, DOI 10.1007/s11912-018-0665-2; Segovia C, 2019, NAT MED, V25, P1073, DOI 10.1038/s41591-019-0499-y; Shinkai Y, 2011, GENE DEV, V25, P781, DOI 10.1101/gad.2027411; Tachibana M, 2005, GENE DEV, V19, P815, DOI 10.1101/gad.1284005; Tao H, 2014, MOL CELL BIOCHEM, V394, P23, DOI 10.1007/s11010-014-2077-4; Toh TB, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0596-9; Tu WB, 2018, CANCER CELL, V34, P579, DOI 10.1016/j.ccell.2018.09.001; Wang J, 2016, ONCOGENE, V35, P1692, DOI 10.1038/onc.2015.234; Wang LH, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0120-6; Wang YF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00350-9; Wei L, 2017, J HEPATOL, V67, P758, DOI 10.1016/j.jhep.2017.05.015; Xie HF, 2016, CANCER DISCOV, V6, P1237, DOI 10.1158/2159-8290.CD-15-1439; Zhang HJ, 2019, STEM CELL TRANSL MED, V8, P768, DOI 10.1002/sctm.18-0247; Zhang HJ, 2012, NAT GENET, V44, P861, DOI 10.1038/ng.2350; Zhao C, 2007, CANCER CELL, V12, P528, DOI 10.1016/j.ccr.2007.11.003; Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737; Zhou JF, 2018, CLIN CANCER RES, V24, P145, DOI 10.1158/1078-0432.CCR-17-1533	48	4	5	4	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2021	40	20					3564	3577		10.1038/s41388-021-01799-1	http://dx.doi.org/10.1038/s41388-021-01799-1		APR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE7RS	33931742				2022-12-17	WOS:000645887000003
J	Venugopalan, A; Lynberg, M; Cultraro, CM; Nguyen, KDP; Zhang, X; Waris, M; Dayal, N; Abebe, A; Maity, TK; Guha, U				Venugopalan, Abhilash; Lynberg, Matthew; Cultraro, Constance M.; Nguyen, Khoa Dang P.; Zhang, Xu; Waris, Maryam; Dayal, Noelle; Abebe, Asebot; Maity, Tapan K.; Guha, Udayan			SCAMP3 is a mutant EGFR phosphorylation target and a tumor suppressor in lung adenocarcinoma	ONCOGENE			English	Article								Mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase domain constitutively activate EGFR resulting in lung tumorigenesis. Activated EGFR modulates downstream signaling by altering phosphorylation-driven interactions that promote growth and survival. Secretory carrier membrane proteins (SCAMPs) are a family of transmembrane proteins that regulate recycling of receptor proteins, including EGFR. The potential role of SCAMPs in mutant EGFR function and tumorigenesis has not been elucidated. Using quantitative mass-spectrometry-based phosphoproteomics, we identified SCAMP3 as a target of mutant EGFRs in lung adenocarcinoma and sought to further investigate the role of SCAMP3 in the regulation of lung tumorigenesis. Here we show that activated EGFR, either directly or indirectly phosphorylates SCAMP3 at Y86 and this phosphorylation increases the interaction of SCAMP3 with both wild-type and mutant EGFRs. SCAMP3 knockdown increases lung adenocarcinoma cell survival and increases xenograft tumor growth in vivo, demonstrating a tumor suppressor role of SCAMP3 in lung tumorigenesis. The tumor suppressor function is a result of SCAMP3 promoting EGFR degradation and attenuating MAP kinase signaling pathways. SCAMP3 knockdown also increases multinucleated cells in culture, suggesting that SCAMP3 is required for efficient cytokinesis. The enhanced growth, increased colony formation, reduced EGFR degradation and multinucleation phenotype of SCAMP3-depleted cells were reversed by re-expression of wild-type SCAMP3, but not SCAMP3 Y86F, suggesting that Y86 phosphorylation is critical for SCAMP3 function. Taken together, the results of this study demonstrate that SCAMP3 functions as a novel tumor suppressor in lung cancer by modulating EGFR signaling and cytokinesis that is partly Y86 phosphorylation-dependent.	[Venugopalan, Abhilash; Lynberg, Matthew; Cultraro, Constance M.; Nguyen, Khoa Dang P.; Zhang, Xu; Waris, Maryam; Dayal, Noelle; Abebe, Asebot; Maity, Tapan K.; Guha, Udayan] NCI, Thorac & GI Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Guha, Udayan] Bristol Myers Squibb, Lawrenceville, NJ 08648 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Bristol-Myers Squibb	Venugopalan, A; Guha, U (corresponding author), NCI, Thorac & GI Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.; Guha, U (corresponding author), Bristol Myers Squibb, Lawrenceville, NJ 08648 USA.	abhilash.venugopalan@nih.gov; udayan.guha@nih.gov		Guha, Udayan/0000-0003-1087-9218; Nguyen, Khoa Dang/0000-0003-0888-304X	NIH Intramural Research Program, Center of Cancer Research, National Cancer Institute	NIH Intramural Research Program, Center of Cancer Research, National Cancer Institute	We thank Gaga Geneti for the assistance with the mice handling and treatments. This research was supported by the NIH Intramural Research Program, Center of Cancer Research, National Cancer Institute.	Aoh QL, 2009, MOL BIOL CELL, V20, P1816, DOI 10.1091/mbc.E08-09-0894; Avraham R, 2011, NAT REV MOL CELL BIO, V12, P104, DOI 10.1038/nrm3048; Awasthi S, 2018, DATA BRIEF, V19, P424, DOI 10.1016/j.dib.2018.04.086; Awasthi S, 2018, J PROTEOMICS, V189, P48, DOI 10.1016/j.jprot.2018.04.005; Beaumatin F, 2019, MOL CELL, V76, P163, DOI 10.1016/j.molcel.2019.07.021; Brose MS, 2002, CANCER RES, V62, P6997; Castle A, 2005, J CELL SCI, V118, P3769, DOI 10.1242/jcs.02503; Cheng KW, 2004, NAT MED, V10, P1251, DOI 10.1038/nm1125; Diaz-Carballo D, 2018, CANCER RES, V78, P2318, DOI 10.1158/0008-5472.CAN-17-1861; Falguieres T, 2012, TRAFFIC, V13, P131, DOI 10.1111/j.1600-0854.2011.01291.x; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gao S, 2020, BIORXIV, DOI [10.1101/2020.07.04.187617, DOI 10.1101/2020.07.04.187617]; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Ghosh D, 2016, STEM CELLS, V34, P2276, DOI 10.1002/stem.2411; Glubb DM, 2017, ONCOTARGET, V8, P64670, DOI 10.18632/oncotarget.18501; Kulyte A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50210-3; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maity TK, 2015, CANCER DISCOV, V5, P534, DOI 10.1158/2159-8290.CD-14-0750; Mittal K, 2017, BRIT J CANCER, V116, P1186, DOI 10.1038/bjc.2017.78; Murray D., 2018, CANCERS, V10, p118.; Padron D, 2007, CANCER RES, V67, P7695, DOI 10.1158/0008-5472.CAN-07-0484; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Parekh A, 2018, ONCOGENE, V37, P4546, DOI 10.1038/s41388-018-0272-6; Pinilla-Macua I, 2017, ELIFE, V6, DOI 10.7554/eLife.31993; Pinilla-Macua I, 2016, P NATL ACAD SCI USA, V113, P2122, DOI 10.1073/pnas.1520301113; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Schiel JA, 2012, NAT CELL BIOL, V14, P1068, DOI 10.1038/ncb2577; Singleton DR, 1997, J CELL SCI, V110, P2099; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Stewart EL, 2015, TRANSL LUNG CANCER R, V4, P67, DOI 10.3978/j.issn.2218-6751.2014.11.06; Suarez-Arroyo IJ, 2016, AM J CANCER RES, V6, P1720; Tabara K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041017; Thomas P, 2016, BIOCHEM BIOPH RES CO, V478, P1028, DOI 10.1016/j.bbrc.2016.08.012; Tomas A, 2014, TRENDS CELL BIOL, V24, P26, DOI 10.1016/j.tcb.2013.11.002; Venugopalan A, 2016, ONCOTARGET, V7, P54137, DOI 10.18632/oncotarget.11021; Walsh AM, 2014, INTEGR BIOL-UK, V6, P312, DOI 10.1039/c3ib40176f; Wei YJ, 2013, CELL, V154, P1269, DOI 10.1016/j.cell.2013.08.015; Wu TT, 1998, MOL BIOL CELL, V9, P1661, DOI 10.1091/mbc.9.7.1661; Zhang XY, 2017, ONCOTARGET, V8, P109247, DOI 10.18632/oncotarget.22665; Zhang X, 2017, MOL CELL PROTEOMICS, V16, P891, DOI 10.1074/mcp.M117.067439; Zhang X, 2015, PROTEOMICS, V15, P340, DOI 10.1002/pmic.201400315	45	4	4	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2021	40	18					3331	3346		10.1038/s41388-021-01764-y	http://dx.doi.org/10.1038/s41388-021-01764-y		APR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE1MB	33850265	Green Accepted			2022-12-17	WOS:000639730800001
J	Fang, R; Wang, XT; Xia, QY; Zhao, M; Zhang, H; Wang, X; Ye, SB; Cheng, K; Liang, Y; Cheng, Y; Gu, YY; Rao, Q				Fang, Ru; Wang, Xiaotong; Xia, Qiuyuan; Zhao, Ming; Zhang, Hao; Wang, Xuan; Ye, Shengbing; Cheng, Kai; Liang, Yan; Cheng, Yang; Gu, Yayun; Rao, Qiu			Nuclear translocation of ASPL-TFE3 fusion protein creates favorable metabolism by mediating autophagy in translocation renal cell carcinoma	ONCOGENE			English	Article								The ASPL-TFE3 fusion gene, resulting from t(X;17)(p11.2;q25.3), is one of the most commonly identified fusion genes in Xp11 translocation renal cell carcinoma (tRCC). However, its roles and underlying mechanism in RCC development are not yet clear. Here, we identified ASPL-TFE3 fusion as the most common tRCC subtype in a Chinese population (29/126, 23.03%). This fusion protein translocated into the nucleus and promoted RCC cell proliferation both in vitro and in vivo. Mechanistically, the fusion protein transcriptionally activated the lysosome-autophagy pathway by binding to the promoters of lysosome-related genes. Autophagy, activated by ASPL-TFE3, enabled RCC cells to escape energy stress by promoting the utilization of proteins and lipids. Moreover, we found that the ASPL-TFE3 fusion escaped regulation by the classic mTOR-TFE3 signal and instead activated phospho-mTOR and its downstream targets. Finally, targeting both autophagy and the mTOR axis resulted in a greater antiproliferative effect than single pathway inhibition. In summary, these results confirmed the ASPL-TFE3 fusion as a master regulator of metabolic adaptation mediated by autophagy in tRCC. The simultaneous manipulation of autophagy and the mTOR axis may represent a novel treatment strategy for ASPL-TFE3 fusion RCC.	[Fang, Ru; Wang, Xiaotong; Xia, Qiuyuan; Wang, Xuan; Ye, Shengbing; Cheng, Kai; Liang, Yan; Rao, Qiu] Nanjing Univ, Jinling Hosp, Dept Pathol, Sch Med, Nanjing, Jiangsu, Peoples R China; [Zhao, Ming] Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Peoples Hosp, Dept Pathol, Hangzhou, Zhejiang, Peoples R China; [Zhang, Hao] Nanjing Med Univ, Nanjing Hosp 1, Dept Nephrol, Nanjing, Jiangsu, Peoples R China; [Cheng, Yang] Nanjing Med Univ, Hlth Management Ctr, Geriatr Hosp, Nanjing, Jiangsu, Peoples R China; [Gu, Yayun] Nanjing Med Univ, Ctr Global Hlth, Sch Publ Hlth, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China	Nanjing University; Hangzhou Medical College; Zhejiang Provincial People's Hospital; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University	Rao, Q (corresponding author), Nanjing Univ, Jinling Hosp, Dept Pathol, Sch Med, Nanjing, Jiangsu, Peoples R China.; Cheng, Y (corresponding author), Nanjing Med Univ, Hlth Management Ctr, Geriatr Hosp, Nanjing, Jiangsu, Peoples R China.; Gu, YY (corresponding author), Nanjing Med Univ, Ctr Global Hlth, Sch Publ Hlth, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China.	yangchengjsnj@163.com; yayungu@njmu.edu.cn; raoqiu1103@126.com			National Natural Science Foundation of China [81872095, 81903385, 81902836, 81802557]; National Natural Science Foundation of Jiangsu Province [BK20180291]; Natural Science Foundation of Zhejiang Province [LY21H160052]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province)	This work was supported by the National Natural Science Foundation of China (81872095 to QR, 81903385 to YC, 81902836 to YG, and 81802557 to QX), the National Natural Science Foundation of Jiangsu Province (BK20180291 to QX), and Natural Science Foundation of Zhejiang Province (LY21H160052 to MZ).	Aquila S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071725; Argani P, 2002, AM J SURG PATHOL, V26, P1553, DOI 10.1097/00000478-200212000-00003; Argani P, 2001, AM J PATHOL, V159, P179, DOI 10.1016/S0002-9440(10)61684-7; Argani P, 2001, AM J PATHOL, V158, P2089, DOI 10.1016/S0002-9440(10)64680-9; Calio A, 2017, MODERN PATHOL, V30, P407, DOI 10.1038/modpathol.2016.200; Cheng J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15671-5; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; Damayanti NP, 2018, CLIN CANCER RES, V24, P5977, DOI 10.1158/1078-0432.CCR-18-0269; Di Malta C, 2017, SCIENCE, V356, P1188, DOI 10.1126/science.aag2553; Ellis CL, 2014, MODERN PATHOL, V27, P875, DOI 10.1038/modpathol.2013.208; Fang R, 2020, PATHOL RES PRACT, V216, DOI 10.1016/j.prp.2020.152867; Gao MQ, 2010, ONCOGENE, V29, P2672, DOI 10.1038/onc.2010.35; Goranov AI, 2009, GENE DEV, V23, P1408, DOI 10.1101/gad.1777309; Ho H, 2011, PIGM CELL MELANOMA R, V24, P595, DOI 10.1111/j.1755-148X.2011.00889.x; Ishiguro N, 2016, NEOPLASIA, V18, P626, DOI 10.1016/j.neo.2016.08.001; Jaksch M, 2008, CANCER RES, V68, P7882, DOI 10.1158/0008-5472.CAN-08-0723; Kepp O, 2020, AUTOPHAGY, V16, P1166, DOI 10.1080/15548627.2020.1758417; Komai Y, 2009, CLIN CANCER RES, V15, P1170, DOI 10.1158/1078-0432.CCR-08-1183; Lim CY, 2016, J CELL BIOL, V214, P653, DOI 10.1083/jcb.201607005; Lopez-Hernandez T, 2020, NAT CELL BIOL, V22, P815, DOI 10.1038/s41556-020-0535-7; Lu SY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173771; Martina JA, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004754; Martina JA, 2013, J CELL BIOL, V200, P475, DOI 10.1083/jcb.201209135; Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184; Napolitano G, 2020, NATURE, V585, P597, DOI 10.1038/s41586-020-2444-0; Ozturk DG, 2019, AUTOPHAGY, V15, P375, DOI 10.1080/15548627.2018.1531197; Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587; Rao Q, 2015, AM J SURG PATHOL, V39, P1181, DOI 10.1097/PAS.0000000000000502; Rao Q, 2012, AM J SURG PATHOL, V36, P1327, DOI 10.1097/PAS.0b013e31825aafb5; Roczniak-Ferguson A, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002790; Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32; Wang XT, 2018, MODERN PATHOL, V31, P1346, DOI 10.1038/s41379-018-0051-5; Wang XT, 2016, HISTOPATHOLOGY, V69, P450, DOI 10.1111/his.12949; Weterman MAJ, 2000, ONCOGENE, V19, P69, DOI 10.1038/sj.onc.1203255; Weterman MAJ, 2001, ONCOGENE, V20, P1414, DOI 10.1038/sj.onc.1204213; Xia QY, 2020, AM J SURG PATHOL, V44, P477, DOI 10.1097/PAS.0000000000001408; Xia QY, 2018, HISTOPATHOLOGY, V72, P786, DOI 10.1111/his.13439; Xia QY, 2017, MODERN PATHOL, V30, P416, DOI 10.1038/modpathol.2016.204; Yin QY, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201911036; Yin XQ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1101-7	40	4	5	1	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2021	40	18					3303	3317		10.1038/s41388-021-01776-8	http://dx.doi.org/10.1038/s41388-021-01776-8		APR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE1MB	33846569				2022-12-17	WOS:000639635100003
J	Watson, MJ; Berger, PL; Banerjee, K; Frank, SB; Tang, L; Ganguly, SS; Hostetter, G; Winn, M; Miranti, CK				Watson, M. J.; Berger, P. L.; Banerjee, K.; Frank, S. B.; Tang, L.; Ganguly, S. S.; Hostetter, G.; Winn, M.; Miranti, C. K.			Aberrant CREB1 activation in prostate cancer disrupts normal prostate luminal cell differentiation	ONCOGENE			English	Article								The molecular mechanisms of luminal cell differentiation are not understood well enough to determine how differentiation goes awry during oncogenesis. Using RNA-Seq analysis, we discovered that CREB1 plays a central role in maintaining new luminal cell survival and that oncogenesis dramatically changes the CREB1-induced transcriptome. CREB1 is active in luminal cells, but not basal cells. We identified ING4 and its E3 ligase, JFK, as CREB1 transcriptional targets in luminal cells. During luminal cell differentiation, transient induction of ING4 expression is followed by a peak in CREB1 activity, while JFK increases concomitantly with CREB1 activation. Transient expression of ING4 is required for luminal cell induction; however, failure to properly down-regulate ING4 leads to luminal cell death. Consequently, blocking CREB1 increased ING4 expression, suppressed JFK, and led to luminal cell death. Thus, CREB1 is responsible for the suppression of ING4 required for luminal cell survival and maintenance. Oncogenic transformation by suppressing PTEN resulted in constitutive activation of CREB1. However, the tumor cells could no longer fully differentiate into luminal cells, failed to express ING4, and displayed a unique CREB1 transcriptome. Blocking CREB1 in tumorigenic cells suppressed tumor growth in vivo, rescued ING4 expression, and restored luminal cell formation, but ultimately induced luminal cell death. IHC of primary prostate tumors demonstrated a strong correlation between loss of ING4 and loss of PTEN. This is the first study to define a molecular mechanism whereby oncogenic loss of PTEN, leading to aberrant CREB1 activation, suppresses ING4 expression causing disruption of luminal cell differentiation.	[Watson, M. J.; Berger, P. L.; Hostetter, G.; Winn, M.; Miranti, C. K.] Van Andel Res Inst, Ctr Canc & Cell Biol, Grand Rapids, MI 49503 USA; [Banerjee, K.; Frank, S. B.; Tang, L.; Ganguly, S. S.; Miranti, C. K.] Univ Arizona, Dept Cellular & Mol Med, Canc Ctr, Tucson, AZ 85724 USA	Van Andel Institute; University of Arizona	Miranti, CK (corresponding author), Van Andel Res Inst, Ctr Canc & Cell Biol, Grand Rapids, MI 49503 USA.; Miranti, CK (corresponding author), Univ Arizona, Dept Cellular & Mol Med, Canc Ctr, Tucson, AZ 85724 USA.	cmiranti@email.arizona.edu		Frank, Sander/0000-0001-7591-944X; Watson, McLane/0000-0001-5778-7690	DOD; VAI	DOD(United States Department of Defense); VAI	MJW, PLB, KB, SBF, TL, SSG CKM -2 grants from DOD; GH, MW -VAI.	Abate-Shen C, 2008, DIFFERENTIATION, V76, P717, DOI 10.1111/j.1432-0436.2008.00292.x; Berger PL, 2017, PROSTATE, V77, P49, DOI 10.1002/pros.23249; Berger PL, 2014, CANCER RES, V74, P3357, DOI 10.1158/0008-5472.CAN-13-3076; Bhat NR, 2007, NEUROCHEM RES, V32, P293, DOI 10.1007/s11064-006-9274-9; Brandi F, 2018, ONCOL LETT, V16, P6238, DOI 10.3892/ol.2018.9417; Burger PE, 2005, P NATL ACAD SCI USA, V102, P7180, DOI 10.1073/pnas.0502761102; Capaldo CT, 2015, SEMIN CELL DEV BIOL, V42, P22, DOI 10.1016/j.semcdb.2015.04.003; Chang H, 2015, ANN DIAGN PATHOL, V19, P330, DOI 10.1016/j.anndiagpath.2015.06.010; Cheng JC, 2008, BLOOD, V111, P1182, DOI 10.1182/blood-blood-2007-04-083600; Chhabra A, 2007, ONCOL REP, V18, P953; Cizmecioglu O, 2008, CELL CYCLE, V7, P3548, DOI 10.4161/cc.7.22.7071; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Edick MJ, 2007, MOL BIOL CELL, V18, P2481, DOI 10.1091/mbc.E06-04-0261; Fang ZJ, 2016, ONCOTARGET, V7, P78055, DOI 10.18632/oncotarget.12938; Frank SB, 2017, J CELL SCI, V130, P1952, DOI 10.1242/jcs.197152; Frank SB, 2017, BMC BIOTECHNOL, V17, DOI 10.1186/s12896-017-0341-x; Garcia GE, 2006, NEOPLASIA, V8, P523, DOI 10.1593/neo.05745; Garcia-Hernandez V, 2017, ANN NY ACAD SCI, V1397, P66, DOI 10.1111/nyas.13360; Gmyrek GA, 2001, AM J PATHOL, V159, P579, DOI 10.1016/S0002-9440(10)61729-4; Gu TT, 2011, CANCER RES, V71, P2821, DOI 10.1158/0008-5472.CAN-10-3399; Henry GH, 2018, CELL REP, V25, P3530, DOI 10.1016/j.celrep.2018.11.086; Hung T, 2009, MOL CELL, V33, P248, DOI 10.1016/j.molcel.2008.12.016; Jeong SG, 2017, BIOCHEM BIOPH RES CO, V482, P182, DOI 10.1016/j.bbrc.2016.11.031; Kim JH, 2018, BONE, V107, P188, DOI 10.1016/j.bone.2017.12.005; Kirschner N, 2013, J INVEST DERMATOL, V133, P1161, DOI 10.1038/jid.2012.507; Koh Cheryl M, 2010, Genes Cancer, V1, P617, DOI 10.1177/1947601910379132; Kwon OJ, 2016, STEM CELLS, V34, P191, DOI 10.1002/stem.2217; Lalonde ME, 2013, GENE DEV, V27, P2009, DOI 10.1101/gad.223396.113; Lamb LE, 2010, J CELL SCI, V123, P266, DOI 10.1242/jcs.054502; Landeira BS, 2018, CEREB CORTEX, V28, P538, DOI 10.1093/cercor/bhw387; Liu WN, 2013, CANCER-AM CANCER SOC, V119, P2405, DOI 10.1002/cncr.27954; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Magnusdottir E, 2007, P NATL ACAD SCI USA, V104, P14988, DOI 10.1073/pnas.0707323104; Martins G, 2008, ANNU REV IMMUNOL, V26, P133, DOI 10.1146/annurev.immunol.26.021607.090241; Melnikova VO, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012452; Mochizuki M, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.005920; Palacios A, 2010, J MOL BIOL, V396, P1117, DOI 10.1016/j.jmb.2009.12.049; Rahman F, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201600506; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; Ruan K, 2015, SCI REP-UK, V5, DOI 10.1038/srep12720; Shankar DB, 2005, CANCER CELL, V7, P351, DOI 10.1016/j.ccr.2005.02.018; Steven A, 2016, ONCOTARGET, V7, P35454, DOI 10.18632/oncotarget.7721; Sunkel B, 2016, NUCLEIC ACIDS RES, V44, P4105, DOI 10.1093/nar/gkv1528; Thangapazham R, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-16; Thway K, 2012, AM J SURG PATHOL, V36, pE1, DOI 10.1097/PAS.0b013e31825485c5; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Wang JN, 2012, CANCER RES, V72, P3786, DOI 10.1158/0008-5472.CAN-12-0523; Wang SY, 2006, P NATL ACAD SCI USA, V103, P1480, DOI 10.1073/pnas.0510652103; Xiao GQ, 2020, AM J CLIN PATHOL, V153, P407, DOI 10.1093/ajcp/aqz183; Yan JL, 2007, P NATL ACAD SCI USA, V104, P1841, DOI 10.1073/pnas.0605562104; Yan RR, 2015, GENE DEV, V29, P672, DOI 10.1101/gad.254292.114; Zhang Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06177-2; Zhu Q, 2017, ACTA BIOCH BIOPH SIN, V49, P609, DOI 10.1093/abbs/gmx053	54	4	4	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2021	40	18					3260	3272		10.1038/s41388-021-01772-y	http://dx.doi.org/10.1038/s41388-021-01772-y		APR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE1MB	33846571				2022-12-17	WOS:000639635100002
J	Lao, MY; Zhang, XZ; Ma, T; Xu, J; Yang, HS; Duan, Y; Ying, HG; Zhang, XY; Guo, CX; Qiu, JY; Bai, XL; Liang, TB				Lao, Mengyi; Zhang, Xiaozhen; Ma, Tao; Xu, Jian; Yang, Hanshen; Duan, Yi; Ying, Honggang; Zhang, Xiaoyu; Guo, Chengxiang; Qiu, Junyu; Bai, Xueli; Liang, Tingbo			Regulator of calcineurin 1 gene isoform 4 in pancreatic ductal adenocarcinoma regulates the progression of tumor cells	ONCOGENE			English	Article								Therapeutic strategies to treat pancreatic ductal adenocarcinoma (PDAC) remain unsatisfying and limited. Therefore, it is imperative to fully determine the mechanisms underlying PDAC progression. In the present study, we report a novel role of regulator of calcineurin 1, isoform 4 (RCAN1.4) in regulating PDAC progression. We demonstrated that RCAN1.4 expression was decreased significantly in PDAC tissues compared with that in para-cancerous tissues, and correlated with poor prognosis of patients with pancreatic cancer. In vitro, stable high expression of RCAN1.4 could suppress the metastasis and proliferation and angiogenesis of pancreatic tumor cells. In addition, interferon alpha inducible protein 27 (IFI27) was identified as having a functional role in RCAN1.4-mediated PDAC migration and invasion, while VEGFA play a vital role in RCAN1.4-mediated PDAC angiogenesis. Analysis of mice with subcutaneously/orthotopic implanted xenograft tumors and liver metastasis model confirmed that RCAN1.4 could modulate the growth, metastasis, and angiogenesis of tumors via IFI27/VEGFA in vivo. In conclusion, our results suggested that RCAN1.4 suppresses the growth, metastasis, and angiogenesis of PDAC, functioning partly via IFI27 and VEGFA. Importantly, our results provided possible diagnostic criteria and therapeutic targets for PDAC.	[Lao, Mengyi; Zhang, Xiaozhen; Ma, Tao; Xu, Jian; Yang, Hanshen; Duan, Yi; Ying, Honggang; Zhang, Xiaoyu; Guo, Chengxiang; Qiu, Junyu; Bai, Xueli; Liang, Tingbo] Zhejiang Univ, Dept Hepatobiliary & Pancreat Surg, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China; [Lao, Mengyi; Zhang, Xiaozhen; Ma, Tao; Xu, Jian; Yang, Hanshen; Duan, Yi; Ying, Honggang; Zhang, Xiaoyu; Guo, Chengxiang; Qiu, Junyu; Bai, Xueli; Liang, Tingbo] Zhejiang Prov Key Lab Pancreat Dis, Hangzhou, Peoples R China; [Lao, Mengyi; Zhang, Xiaozhen; Ma, Tao; Xu, Jian; Yang, Hanshen; Duan, Yi; Ying, Honggang; Zhang, Xiaoyu; Guo, Chengxiang; Qiu, Junyu; Bai, Xueli; Liang, Tingbo] Zhejiang Prov Innovat Ctr Study Pancreat Dis, Hangzhou, Peoples R China	Zhejiang University	Bai, XL; Liang, TB (corresponding author), Zhejiang Univ, Dept Hepatobiliary & Pancreat Surg, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China.; Bai, XL; Liang, TB (corresponding author), Zhejiang Prov Key Lab Pancreat Dis, Hangzhou, Peoples R China.; Bai, XL; Liang, TB (corresponding author), Zhejiang Prov Innovat Ctr Study Pancreat Dis, Hangzhou, Peoples R China.	shirleybai@zju.edu.cn; liangtingbo@zju.edu.cn	Zhang, xiaoyu/GXA-3206-2022	Zhang, Xiaozhen/0000-0003-3567-8789	National Natural Science Foundation of China [U20A20378, 81871925, 81672337, 82071867, 82071748]; National Key Research and Development Program [2019YFC1316000]; Key Research and Development Program of Zhejiang Province [2019C03019, 2020C03117]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program; Key Research and Development Program of Zhejiang Province	We thank Mr. Minghua Sun for his technical support during sample processing. This study was supported by the National Natural Science Foundation of China (U20A20378, to T-BL; 81871925, 81672337, and 82071867 to X-LB; 82071748 to TM), the National Key Research and Development Program (2019YFC1316000 to T-BL), and the Key Research and Development Program of Zhejiang Province (2019C03019 to T-BL; 2020C03117 to X-LB).	Baek KH, 2009, NATURE, V459, P1126, DOI 10.1038/nature08062; Cheriyath V, 2011, J INTERF CYTOK RES, V31, P173, DOI 10.1089/jir.2010.0105; Chiaravalli M, 2017, CANCER TREAT REV, V60, P32, DOI 10.1016/j.ctrv.2017.08.007; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Hampton T, 2005, JAMA-J AM MED ASSOC, V293, P284, DOI 10.1001/jama.293.3.284; Hasle H, 2000, LANCET, V355, P165, DOI 10.1016/S0140-6736(99)05264-2; Hasle H, 2001, LANCET ONCOL, V2, P429, DOI 10.1016/S1470-2045(00)00435-6; Jang C, 2011, KOREAN J PHYSIOL PHA, V15, P299, DOI 10.4196/kjpp.2011.15.5.299; Jin HJ, 2017, GASTROENTEROLOGY, V153, P799, DOI 10.1053/j.gastro.2017.05.045; Kleeff J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.22; Lee JC, 2013, BIOCHEM BIOPH RES CO, V440, P50, DOI 10.1016/j.bbrc.2013.09.033; Liu NL, 2014, ONCOTARGET, V5, P4959, DOI 10.18632/oncotarget.2067; Martinez-Martineza S, 2009, P NATL ACAD SCI USA, V106, P6117, DOI 10.1073/pnas.0812544106; Mihalich A, 2012, GYNECOL ENDOCRINOL, V28, P216, DOI 10.3109/09513590.2011.588746; Minami T, 2004, J BIOL CHEM, V279, P50537, DOI 10.1074/jbc.M406454200; Rosebeck S, 2008, APOPTOSIS, V13, P562, DOI 10.1007/s10495-008-0190-0; Ryeom S, 2008, CANCER CELL, V13, P420, DOI 10.1016/j.ccr.2008.02.018; Satge D, 2001, B ACAD NAT MED PARIS, V185, P1239, DOI 10.1016/S0001-4079(19)34447-4; Song ZS, 2018, EXP CELL RES, V372, P118, DOI 10.1016/j.yexcr.2018.09.017; Suomela S, 2004, J INVEST DERMATOL, V122, P717, DOI 10.1111/j.0022-202X.2004.22322.x; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Wang CJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90651; Wang H, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957-018-1371-0; Wang-Gillam A, 2016, LANCET, V387, P545, DOI 10.1016/S0140-6736(15)00986-1; Yang QH, 2002, LANCET, V359, P1019, DOI 10.1016/S0140-6736(02)08092-3	25	4	4	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2021	40	17					3136	3151		10.1038/s41388-021-01763-z	http://dx.doi.org/10.1038/s41388-021-01763-z		APR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RV2NJ	33824473	hybrid, Green Published			2022-12-17	WOS:000637478800004
J	Chueh, AC; Advani, G; Foroutan, M; Smith, J; Ng, N; Nandurkar, H; Lio, DS; Zhu, HJ; Chong, YP; Verkade, H; Fujita, DJ; Bjorge, J; Basheer, F; Lim, JP; Luk, I; Dhillon, A; Sakthianandeswaren, A; Mouradov, D; Sieber, O; Hollande, F; Mariadason, JM; Cheng, HC				Chueh, Anderly C.; Advani, Gahana; Foroutan, Momeneh; Smith, Jai; Ng, Nadia; Nandurkar, Harshal; Lio, Daisy S.; Zhu, Hong-Jian; Chong, Yuh-Ping; Verkade, Heather; Fujita, Donald J.; Bjorge, Jeffrey; Basheer, Faiza; Lim, Jet Phey; Luk, Ian; Dhillon, Amardeep; Sakthianandeswaren, Anuratha; Mouradov, Dmitri; Sieber, Oliver; Hollande, Frederic; Mariadason, John M.; Cheng, Heung-Chin			CSK-homologous kinase (CHK/MATK) is a potential colorectal cancer tumour suppressor gene epigenetically silenced by promoter methylation	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; SRC-FAMILY; C-SRC; HUMAN COLON; PHOSPHATASE-ACTIVITY; DNA METHYLATION; CELLS; EXPRESSION; ACTIVATION; CLONING	Hyperactivation of SRC-family protein kinases (SFKs) contributes to the initiation and progression of human colorectal cancer (CRC). Since oncogenic mutations of SFK genes are rare in human CRC, we investigated if SFK hyperactivation is linked to dysregulation of their upstream inhibitors, C-terminal SRC kinase (CSK) and its homolog CSK-homologous kinase (CHK/MATK). We demonstrate that expression of CHK/MATK but not CSK was significantly downregulated in CRC cell lines and primary tumours compared to normal colonic tissue. Investigation of the mechanism by which CHK/MATK expression is down-regulated in CRC cells uncovered hypermethylation of the CHK/MATK promoter in CRC cell lines and primary tumours. Promoter methylation of CHK/MATK was also observed in several other tumour types. Consistent with epigenetic silencing of CHK/MATK, genetic deletion or pharmacological inhibition of DNA methyltransferases increased CHK/MATK mRNA expression in CHK/MATK-methylated colon cancer cell lines. SFKs were hyperactivated in CHK/MATK-methylated CRC cells despite expressing enzymatically active CSK, suggesting loss of CHK/MATK contributes to SFK hyperactivation. Re-expression of CHK/MATK in CRC cell lines led to reduction in SFK activity via a non-catalytic mechanism, a reduction in anchorage-independent growth, cell proliferation and migration in vitro, and a reduction in tumour growth and metastasis in a zebrafish embryo xenotransplantation model in vivo, collectively identifying CHK/MATK as a novel putative tumour suppressor gene in CRC. Furthermore, our discovery that CHK/MATK hypermethylation occurs in the majority of tumours warrants its further investigation as a diagnostic marker of CRC.	[Chueh, Anderly C.; Luk, Ian; Mariadason, John M.] Austin Hosp, Olivia Newton John Canc Res Inst, Heidelberg, Vic, Australia; [Chueh, Anderly C.; Sakthianandeswaren, Anuratha; Mouradov, Dmitri; Sieber, Oliver] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia; [Chueh, Anderly C.; Sakthianandeswaren, Anuratha; Mouradov, Dmitri; Sieber, Oliver] Univ Melbourne, Dept Med Biol, Parkville, Vic, Australia; [Chueh, Anderly C.; Mariadason, John M.] Univ Melbourne, Austin Hosp, Dept Med, Heidelberg, Vic, Australia; [Chueh, Anderly C.; Sieber, Oliver] Monash Univ, Biomedicine Discovery Inst, Canc Program, Clayton, Vic, Australia; [Chueh, Anderly C.; Sieber, Oliver] Monash Univ, Biomedicine Discovery Inst, Dept Biochem & Mol Biol, Clayton, Vic, Australia; [Advani, Gahana; Ng, Nadia; Lio, Daisy S.; Verkade, Heather; Cheng, Heung-Chin] Univ Melbourne, Bio21 Inst, Dept Biochem & Pharmacol, Parkville, Vic, Australia; [Foroutan, Momeneh; Smith, Jai; Hollande, Frederic] Univ Melbourne, Dept Clin Pathol, Victorian Comprehens Canc Ctr, Parkville, Vic, Australia; [Foroutan, Momeneh; Smith, Jai; Hollande, Frederic] Univ Melbourne, Victorian Comprehens Canc Ctr, Ctr Canc Res, Parkville, Vic, Australia; [Nandurkar, Harshal] Monash Univ, Australian Ctr Blood Dis, Prahran, Vic, Australia; [Zhu, Hong-Jian; Sieber, Oliver] Univ Melbourne, Royal Melbourne Hosp, Dept Surg, Parkville, Vic, Australia; [Chong, Yuh-Ping] RMIT Univ, Sch Hlth & Biomed Sci, Discipline Lab Med, Bundoora, Vic, Australia; [Fujita, Donald J.; Bjorge, Jeffrey] Univ Calgary, Cumming Sch Med, Dept Biochem & Mol Biol, Calgary, AB, Canada; [Basheer, Faiza; Lim, Jet Phey; Dhillon, Amardeep] Deakin Univ, Inst Mental & Phys Hlth & Clin Translat, Sch Med, Geelong, Vic, Australia; [Mariadason, John M.] La Trobe Univ, Sch Canc Med, Heidelberg, Vic, Australia	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; La Trobe University; Olivia Newton-John Cancer Research Institute; Walter & Eliza Hall Institute; University of Melbourne; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Monash University; Monash University; University of Melbourne; University of Melbourne; University of Melbourne; Monash University; Royal Melbourne Hospital; University of Melbourne; Royal Melbourne Institute of Technology (RMIT); University of Calgary; Deakin University; La Trobe University	Chueh, AC (corresponding author), Austin Hosp, Olivia Newton John Canc Res Inst, Heidelberg, Vic, Australia.; Chueh, AC (corresponding author), Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia.; Chueh, AC (corresponding author), Univ Melbourne, Dept Med Biol, Parkville, Vic, Australia.; Chueh, AC (corresponding author), Univ Melbourne, Austin Hosp, Dept Med, Heidelberg, Vic, Australia.; Chueh, AC (corresponding author), Monash Univ, Biomedicine Discovery Inst, Canc Program, Clayton, Vic, Australia.; Chueh, AC (corresponding author), Monash Univ, Biomedicine Discovery Inst, Dept Biochem & Mol Biol, Clayton, Vic, Australia.; Cheng, HC (corresponding author), Univ Melbourne, Bio21 Inst, Dept Biochem & Pharmacol, Parkville, Vic, Australia.	Anderly.Chueh@monash.edu; heung@unimelb.edu.au	Chüeh, Anderly C/AFC-2076-2022; Sieber, Oliver/ABA-9211-2021; Nandurkar, Harshal/AAO-7443-2020; BASHEER, FAIZA/GPF-8188-2022; Basheer, Faiza/AAW-5083-2021; Hollande, Frederic/GLS-4120-2022; Chueh, Anderly/AAF-9375-2022	Chüeh, Anderly C/0000-0003-1140-5516; Sieber, Oliver/0000-0001-9480-0786; BASHEER, FAIZA/0000-0003-4850-2205; Basheer, Faiza/0000-0003-4850-2205; Hollande, Frederic/0000-0002-7046-8392; Smith, Jai/0000-0003-4997-6189; Chong, Yuh Ping/0000-0002-9596-3242; Narwani, Gahana/0000-0003-3129-6249; Dhillon, Amardeep/0000-0002-6065-663X; Zhu, Hong-Jian/0000-0002-1478-995X; Mouradov, Dmitri/0000-0001-8149-816X; Foroutan, Momeneh/0000-0002-1440-0457	NHMRC [GNT1136119, 628727, 1050486]; Australian Brain Foundation [1141906]; NHMRC Senior Research fellowship [GNT1046092]; Tour de Cure Foundation, Australia; National Health and Medical Research Council of Australia [1164081]	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Australian Brain Foundation; NHMRC Senior Research fellowship(National Health and Medical Research Council (NHMRC) of Australia); Tour de Cure Foundation, Australia; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	O. Sieber is a NHMRC Senior Research Fellow (GNT1136119); grant support to H.-J. Zhu: NHMRC project grant #628727, grant support to H.-C. Cheng: NHMRC project grant # 1050486 and Australian Brain Foundation, grant support to A. Dhillon: NHMRC project grants #1141906. J. Mariadason was supported by a NHMRC Senior Research fellowship (GNT1046092). F. Hollande received grants from the Tour de Cure Foundation, Australia (Senior Project grant) and the National Health and Medical Research Council of Australia (Grant #1164081).	Advani G, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0186-x; [Anonymous], 2014, JAMA, V312, P2566, DOI 10.1001/jama.2014.15746; AVRAHAM S, 1995, J BIOL CHEM, V270, P1833, DOI 10.1074/jbc.270.4.1833; Bjorge JD, 2000, J BIOL CHEM, V275, P41439, DOI 10.1074/jbc.M004852200; BJORGE JD, 1995, J BIOL CHEM, V270, P24222, DOI 10.1074/jbc.270.41.24222; Boczek EE, 2019, J BIOL CHEM, V294, P13186, DOI 10.1074/jbc.RA119.008199; Carethers JM, 2020, ANNU REV MED, V71, P59, DOI 10.1146/annurev-med-103018-123125; Chong YP, 2005, GROWTH FACTORS, V23, P233, DOI 10.1080/08977190500178877; Chong YP, 2004, J BIOL CHEM, V279, P20752, DOI 10.1074/jbc.M309865200; Chong YP, 2006, J BIOL CHEM, V281, P32988, DOI 10.1074/jbc.M602951200; CHOW LML, 1994, P NATL ACAD SCI USA, V91, P4975, DOI 10.1073/pnas.91.11.4975; Constancio-Lund SS, 2009, MOL CARCINOGEN, V48, P156, DOI 10.1002/mc.20466; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; Cordero JB, 2014, EMBO J, V33, P1474, DOI 10.1002/embj.201387454; Druliner BR, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21525-4; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; Haber AL, 2017, NATURE, V551, P333, DOI 10.1038/nature24489; Hesson LB, 2016, MOL CANCER RES, V14, P1217, DOI 10.1158/1541-7786.MCR-16-0175; Hoekstra E, 2016, ONCOTARGET, V7, P21922, DOI 10.18632/oncotarget.7829; Huang WY, 2015, NUCLEIC ACIDS RES, V43, pD856, DOI 10.1093/nar/gku1151; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Jones RJ, 2002, BRIT J CANCER, V87, P1128, DOI 10.1038/sj.bjc.6600594; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Kemble DJ, 2009, P NATL ACAD SCI USA, V106, P5070, DOI 10.1073/pnas.0806117106; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; Kong XQ, 2019, CANCER CELL, V35, P633, DOI 10.1016/j.ccell.2019.03.003; Lerner EC, 2005, J BIOL CHEM, V280, P40832, DOI 10.1074/jbc.M508782200; Lerner EC, 2002, NAT STRUCT BIOL, V9, P365, DOI 10.1038/nsb782; Luebeck GE, 2019, CANCER RES, V79, P495, DOI 10.1158/0008-5472.CAN-18-1682; Luo YX, 2014, GASTROENTEROLOGY, V147, P418, DOI 10.1053/j.gastro.2014.04.039; MCVICAR DW, 1994, ONCOGENE, V9, P2037; Mouradov D, 2014, CANCER RES, V74, P3238, DOI 10.1158/0008-5472.CAN-14-0013; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Oneyama C, 2008, MOL CELL, V30, P426, DOI 10.1016/j.molcel.2008.03.026; PARK JS, 1993, ONCOGENE, V8, P2627; Poh AR, 2017, CANCER CELL, V31, P563, DOI 10.1016/j.ccell.2017.03.006; PURCHIO AF, 1983, MOL CELL BIOL, V3, P1589, DOI 10.1128/MCB.3.9.1589; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Schneider C, 2019, NAT REV IMMUNOL, V19, P584, DOI 10.1038/s41577-019-0176-x; Scott A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177210; Shah NH, 2018, CRIT REV BIOCHEM MOL, V53, P535, DOI 10.1080/10409238.2018.1495173; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Sirvent A, 2012, AM J CANCER RES, V2, P357; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; The Cancer Genome Atlas Network, 2012, NATURE, V487, P330, DOI [DOI 10.1038/NATURE11252, 10.1038/nature11252]; Welman A, 2006, NEOPLASIA, V8, P905, DOI 10.1593/neo.06475; Westphalen CB, 2014, J CLIN INVEST, V124, P1283, DOI 10.1172/JCI73434; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yan KS, 2017, CELL STEM CELL, V21, P78, DOI 10.1016/j.stem.2017.06.014; Zhang B, 2014, NATURE, V513, P382, DOI 10.1038/nature13438; Zhu S, 2008, ONCOGENE, V27, P2027, DOI 10.1038/sj.onc.1210838; Zhu S, 2007, CANCER RES, V67, P10129, DOI 10.1158/0008-5472.CAN-06-4338	52	4	4	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2021	40	17					3015	3029		10.1038/s41388-021-01755-z	http://dx.doi.org/10.1038/s41388-021-01755-z		MAR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RV2NJ	33767439				2022-12-17	WOS:000632824700001
J	Wei, T; Ji, XW; Gao, Y; Zhu, XM; Xiao, GR				Wei, Tian; Ji, Xiaowen; Gao, Yan; Zhu, Xiaomei; Xiao, Guiran			ZnT7 RNAi favors Raf(GOF)scrib(-/-) -induced tumor growth and invasion in Drosophila through JNK signaling pathway	ONCOGENE			English	Article							ZINC TRANSPORTERS; CELL-DEATH; CANCER; AUTOPHAGY; TRAFFICKING; DEFICIENCY; HOMEOSTASIS; METABOLISM; ACTIVATION; INTERACTS	The disruption of zinc homeostasis has been identified in patients suffering from various cancers, but a causative relationship has not yet been established. Drosophila melanogaster has become a powerful model to study cancer biology. Here using a Drosophila model of malignant tumor Raf(GOF) scrib(-/-), we observed that the tumor growth, invasion and migration were enhanced by silencing dZnT7, a zinc transporter localized on the Golgi apparatus. Further study indicated that the zinc deficiency in Golgi of dZnT7 RNAi resulted in ER stress which could activate the c-Jun-N-terminal Kinase (JNK) signaling and this process is mediated by Atg9. Lastly, we demonstrated that the exacerbation of dZnT7 RNAi on tumor was promoted by JNK signaling-dependent cell autonomous and non-autonomous autophagy. These findings suggest that zinc homeostasis in secretory compartments may provide a new therapeutic target for tumor treatment.	[Wei, Tian; Ji, Xiaowen; Gao, Yan; Xiao, Guiran] Hefei Univ Technol, Sch Food & Biol Engn, Hefei 230009, Anhui, Peoples R China; [Zhu, Xiaomei] Anhui Med Univ, Sch Basic Med Sci, Hefei 230032, Anhui, Peoples R China	Hefei University of Technology; Anhui Medical University	Xiao, GR (corresponding author), Hefei Univ Technol, Sch Food & Biol Engn, Hefei 230009, Anhui, Peoples R China.	xiaoguiran@hfut.edu.cn		Xiao, Guiran/0000-0002-1238-1838; Wei, Tian/0000-0001-7270-0979	National Natural Science Foundation of China [31671284]; Fundamental Research Funds for the Central Universities [JZ2020HGPA0115]; Youth Science and Technology Talents Support Program (2020) by Anhui Association for Science and Technology [RCTJ202001]; National Postdoctoral Program for Innovative Talents [BX201600045]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Youth Science and Technology Talents Support Program (2020) by Anhui Association for Science and Technology; National Postdoctoral Program for Innovative Talents	This project was funded by the National Natural Science Foundation of China (31671284), the Fundamental Research Funds for the Central Universities (JZ2020HGPA0115), Youth Science and Technology Talents Support Program (2020) by Anhui Association for Science and Technology (RCTJ202001), and the National Postdoctoral Program for Innovative Talents (BX201600045). The authors appreciate the gifts of fly stocks from Dr. Bing Zhou and Dr. Jose C. PASTOR-PAREJA. The authors are also grateful to the Bloomington Drosophila Stock Center, the Vienna Drosophila RNAi Center and Tsinghua Fly Center for fly stocks.	Antoniou X, 2011, J ALZHEIMERS DIS, V24, P633, DOI 10.3233/JAD-2011-091567; Bafaro E, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.29; Bali A, 2017, INT J DEV BIOL, V61, P551, DOI 10.1387/ijdb.170077bs; Beira JV, 2016, CHROMOSOMA, V125, P573, DOI 10.1007/s00412-016-0595-4; Bin BH, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/9365747; Biteau B, 2011, EXP GERONTOL, V46, P349, DOI 10.1016/j.exger.2010.11.003; Bubici C, 2014, BRIT J PHARMACOL, V171, P24, DOI 10.1111/bph.12432; Calap-Quintana P, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071456; Cousins RJ, 2006, J BIOL CHEM, V281, P24085, DOI 10.1074/jbc.R600011200; Dechen KS, 2015, INT J BIOCHEM CELL B, V60, P23, DOI 10.1016/j.biocel.2014.12.017; Dhanasekaran Danny N, 2017, Genes Cancer, V8, P682, DOI 10.18632/genesandcancer.155; Doggett K, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-57; Eom SJ, 2001, MOL PHARMACOL, V59, P981, DOI 10.1124/mol.59.5.981; Franklin RB, 2007, ARCH BIOCHEM BIOPHYS, V463, P211, DOI 10.1016/j.abb.2007.02.033; Groth C, 2013, DEVELOPMENT, V140, P3018, DOI 10.1242/dev.088336; Hershfinkel M, 2007, MOL MED, V13, P331, DOI 10.2119/2006-00038.Hershfinkel; Hrabeta J, 2016, J MOL MED, V94, P1199, DOI 10.1007/s00109-016-1454-8; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Kambe T, 2015, PHYSIOL REV, V95, P749, DOI 10.1152/physrev.00035.2014; Katheder NS, 2017, NATURE, V541, P417, DOI 10.1038/nature20815; Kirschke CP, 2003, J BIOL CHEM, V278, P4096, DOI 10.1074/jbc.M207644200; Kolenko V, 2013, NAT REV UROL, V10, P219, DOI 10.1038/nrurol.2013.43; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Kushnir T, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006860; Lang ML, 2012, PLOS GENET, V8, P623, DOI 10.1371/journal.pgen.1002683; Lee H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021533; Li DD, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020667; Liang D, 2013, CELL SIGNAL, V25, P1126, DOI 10.1016/j.cellsig.2013.02.003; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Liu SN, 2016, SCI REP-UK, V6, DOI 10.1038/srep38003; Ma XJ, 2017, CELL REP, V19, P2657, DOI 10.1016/j.celrep.2017.05.092; Ma XJ, 2012, CELL RES, V22, P425, DOI 10.1038/cr.2011.135; MacDonald RS, 2000, J NUTR, V130, p1500S, DOI 10.1093/jn/130.5.1500S; Manic G, 2014, MOL CELL ONCOL, V1, DOI 10.4161/mco.29911; McCall KA, 2000, J NUTR, V130, p1437S, DOI 10.1093/jn/130.5.1437S; McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001; Mishra-Gorur K, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.039727; Missirlis F, 2007, GENETICS, V177, P89, DOI 10.1534/genetics.107.075150; Newsome TP, 2000, DEVELOPMENT, V127, P851; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Pan Z, 2017, FRONT BIOSCI-LANDMRK, V22, P623, DOI 10.2741/4507; Pastor-Pareja JC, 2013, ANNU REV GENET, V47, P51, DOI 10.1146/annurev-genet-110711-155414; Poillet-Perez L, 2019, GENE DEV, V33, P610, DOI 10.1101/gad.325514.119; Prasad AS, 2013, ADV NUTR, V4, P176, DOI 10.3945/an.112.003210; Qin QH, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-101; Richards CD, 2016, ARCH BIOCHEM BIOPHYS, V611, P142, DOI 10.1016/j.abb.2016.07.015; Richardson HE, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4258387; Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028; Schroeder MC, 2013, ONCOGENE, V32, P4471, DOI 10.1038/onc.2012.476; Sheng ZT, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008863; Sonoshita M, 2017, CURR TOP DEV BIOL, V121, P287, DOI 10.1016/bs.ctdb.2016.07.008; Sousa CM, 2016, NATURE, V536, P479, DOI 10.1038/nature19084; Sun YH, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1350-6; Takatani-Nakase T, 2018, BIOL PHARM BULL, V41, P1517, DOI 10.1248/bpb.b18-00086; Tang HW, 2013, DEV CELL, V27, P489, DOI 10.1016/j.devcel.2013.10.017; Tepaamorndech S, 2011, CANCER LETT, V308, P33, DOI 10.1016/j.canlet.2011.04.011; Troost T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049007; Uhlirova M, 2005, P NATL ACAD SCI USA, V102, P13123, DOI 10.1073/pnas.0504170102; Villegas SN, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.039032; Wang XX, 2009, FASEB J, V23, P2650, DOI 10.1096/fj.08-126649; Weber U, 2000, DEVELOPMENT, V127, P3619; Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001; Willsey HR, 2016, ELIFE, V5, DOI 10.7554/eLife.11491; Wu H, 2009, MECH DEVELOP, V126, P624, DOI 10.1016/j.mod.2009.06.1082; Wu M, 2010, NATURE, V463, P545, DOI 10.1038/nature08702; Xiao GR, 2019, CELL REP, V26, P748, DOI 10.1016/j.celrep.2018.12.053; Xiao GR, 2018, FRONT GENET, V8, DOI 10.3389/fgene.2017.00234; Xiao GR, 2016, ARCH BIOCHEM BIOPHYS, V611, P134, DOI 10.1016/j.abb.2016.04.016; Xiao GR, 2014, ELIFE, V3, DOI 10.7554/eLife.03191; Xu R, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012912; Xue J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109180; Yan M, 2008, J NUTR, V138, P667, DOI 10.1093/jn/138.4.667; Yu HJ, 2009, BIOCHEM J, V417, P133, DOI 10.1042/BJ20081421; Zang YR, 2015, ELIFE, V4, DOI 10.7554/eLife.07187; Zeke A, 2016, MICROBIOL MOL BIOL R, V80, P793, DOI 10.1128/MMBR.00043-14; Zhang L, 2007, BRAIN RES BULL, V74, P278, DOI 10.1016/j.brainresbull.2007.06.022; Zhang XL, 2018, KIDNEY BLOOD PRESS R, V43, P500, DOI 10.1159/000488697	77	4	4	1	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2217	2229		10.1038/s41388-021-01703-x	http://dx.doi.org/10.1038/s41388-021-01703-x			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33649534				2022-12-17	WOS:000746143800005
J	Song, D; Lan, JQ; Chen, YQ; Liu, AY; Wu, Q; Zhao, CC; Feng, YD; Wang, J; Luo, XL; Cao, ZX; Cao, XN; Hu, JB; Wang, GH				Song, Da; Lan, Jingqin; Chen, Yaqi; Liu, Anyi; Wu, Qi; Zhao, Chongchong; Feng, Yongdong; Wang, Jing; Luo, Xuelai; Cao, Zhixin; Cao, Xiaonian; Hu, Junbo; Wang, Guihua			NSD2 promotes tumor angiogenesis through methylating and activating STAT3 protein	ONCOGENE			English	Article								Tumor angiogenesis plays vital roles in tumorigenesis and development; regulatory mechanism of angiogenesis is still not been fully elucidated. NSD2, a histone methyltransferase catalyzing di-methylation of histone H3 at lysine 36, has been proved a critical molecule in proliferation, metastasis, and tumorigenesis. But its role in tumor angiogenesis remains unknown. Here we demonstrated that NSD2 promoted tumor angiogenesis in vitro and in vivo. Furthermore, we confirmed that the angiogenic function of NSD2 was mediated by STAT3. Momentously, we found that NSD2 promoted the methylation and activation of STAT3. In addition, mass spectrometry and site-directed mutagenesis assays revealed that NSD2 methylated STAT3 at lysine 163 (K163). Meanwhile, K to R mutant at K163 of STAT3 attenuated the activation and angiogenic function of STAT3. Taken together, we conclude that methylation of STAT3 catalyzed by NSD2 promotes the activation of STAT3 pathway and enhances the ability of tumor angiogenesis. Our findings investigate a NSD2-dependent methylation-phosphorylation regulation pattern of STAT3 and reveal that NSD2/STAT3/VEGFA axis might be a potential target for tumor therapy.	[Song, Da; Lan, Jingqin; Chen, Yaqi; Liu, Anyi; Wu, Qi; Feng, Yongdong; Luo, Xuelai; Cao, Zhixin; Cao, Xiaonian; Hu, Junbo; Wang, Guihua] Huazhong Univ Sci & Technol, Tongji Hosp, GI Canc Res Inst, Wuhan, Peoples R China; [Lan, Jingqin] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Thyroid & Breast Surg, Wuhan, Peoples R China; [Zhao, Chongchong] Tsinghua Univ, Technol Ctr Prot Sci, Prot Facil, Beijing, Peoples R China; [Wang, Jing] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Immunol, Wuhan, Peoples R China; [Cao, Xiaonian] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Thorac Surg, Wuhan, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Tsinghua University; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Hu, JB; Wang, GH (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, GI Canc Res Inst, Wuhan, Peoples R China.	jbhu@tjh.tjmu.edu.cn; ghwang@tjh.tjmu.edu.cn	Wang, Guihua/AAX-3130-2021		NSFC [81773113, 81922053, 81702264, 81974432, 81874186]	NSFC(National Natural Science Foundation of China (NSFC))	We are grateful to the members in Guihua Wang's lab and Junbo Hu's lab for the critical inputs and suggestions. This work is supported by NSFC (No. 81773113 GW, No. 81922053 GW, No.81702264 XC, No. 81974432 GW, and No. 81874186 JH).	Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183; Aytes A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07511-4; Bharadwaj U, 2020, PHARMACOL REV, V72, P486, DOI 10.1124/pr.119.018440; Biggar KK, 2015, NAT REV MOL CELL BIO, V16, P5, DOI 10.1038/nrm3915; Canavese M, 2017, INT J CANCER, V140, P2183, DOI 10.1002/ijc.30567; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Cheong CM, 2020, CANCER LETT, V475, P99, DOI 10.1016/j.canlet.2020.01.040; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dasgupta M, 2015, P NATL ACAD SCI USA, V112, P3985, DOI 10.1073/pnas.1503152112; de Palma M, 2017, NAT REV CANCER, V17, P457, DOI 10.1038/nrc.2017.51; Foltz SM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16434-y; Guo JP, 2019, NAT CELL BIOL, V21, P226, DOI 10.1038/s41556-018-0261-6; Haibe Y, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00221; Hamamoto R, 2015, NAT REV CANCER, V15, P110, DOI 10.1038/nrc3884; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He C, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1347-1; Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189; Hou ZL, 2020, CANCER LETT, V487, P63, DOI 10.1016/j.canlet.2020.05.029; Hudlebusch HR, 2011, CLIN CANCER RES, V17, P2919, DOI 10.1158/1078-0432.CCR-10-1302; Keats JJ, 2005, BLOOD, V105, P4060, DOI 10.1182/blood-2004-09-3704; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Kuo AJ, 2011, MOL CELL, V44, P609, DOI 10.1016/j.molcel.2011.08.042; Lhoumaud P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12811-4; Luo J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09784-9; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Nimura K, 2009, NATURE, V460, P287, DOI 10.1038/nature08086; Park JW, 2018, ONCOGENE, V37, P6212, DOI 10.1038/s41388-018-0393-y; Saltz LB, 2016, LANCET ONCOL, V17, P1469, DOI 10.1016/S1470-2045(16)30213-3; Smeets D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06567-6; Stec I, 1998, HUM MOL GENET, V7, P1071, DOI 10.1093/hmg/7.7.1071; Stratman AN, 2011, BLOOD, V117, P3709, DOI 10.1182/blood-2010-11-316752; Stratman AN, 2010, BLOOD, V116, P4720, DOI 10.1182/blood-2010-05-286872; Stubbs MC, 2019, CLIN CANCER RES, V25, P300, DOI 10.1158/1078-0432.CCR-18-0098; Swaroop A, 2019, ONCOGENE, V38, P671, DOI 10.1038/s41388-018-0474-y; Wang GH, 2019, NAT CELL BIOL, V21, P214, DOI 10.1038/s41556-018-0266-1; Wang JJ, 2019, ACTA PHARMACOL SIN, V40, P1067, DOI 10.1038/s41401-018-0199-z; Wang XW, 2012, NUCLEIC ACIDS RES, V40, pD1144, DOI 10.1093/nar/gkr1013; Xie ZG, 2019, LEUKEMIA, V33, P739, DOI 10.1038/s41375-018-0300-0; Yang JB, 2010, P NATL ACAD SCI USA, V107, P21499, DOI 10.1073/pnas.1016147107; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhang JF, 2019, CANCER DISCOV, V9, P1306, DOI 10.1158/2159-8290.CD-18-0083; Zhang X, 2015, CELL MOL LIFE SCI, V72, P4257, DOI 10.1007/s00018-015-2001-4	45	4	4	3	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2021	40	16					2952	2967		10.1038/s41388-021-01747-z	http://dx.doi.org/10.1038/s41388-021-01747-z		MAR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ5XW	33742125				2022-12-17	WOS:000630655600003
J	Voronina, N; Aichmuller, C; Kolb, T; Korshunov, A; Ryzhova, M; Barnholtz-Sloan, J; Cioffi, G; Sill, M; von Deimling, A; Pfister, SM; Gronych, J; Jones, DTW; Frisen, J; Zapatka, M; Ernst, A				Voronina, Natalia; Aichmueller, Christian; Kolb, Thorsten; Korshunov, Andrey; Ryzhova, Marina; Barnholtz-Sloan, Jill; Cioffi, Gino; Sill, Martin; von Deimling, Andreas; Pfister, Stefan M.; Gronych, Jan; Jones, David T. W.; Frisen, Jonas; Zapatka, Marc; Ernst, Aurelie			The age of adult pilocytic astrocytoma cells	ONCOGENE			English	Article								Adult pilocytic astrocytomas (PAs) have been regarded as indistinguishable from pediatric PAs in terms of genome-wide expression and methylation patterns. It has been unclear whether adult PAs arise early in life and remain asymptomatic until adulthood, or whether they develop during adulthood. We sought to determine the age and origin of adult human PAs using two types of "marks" in the genomic DNA. First, we analyzed the DNA methylation patterns of adult and pediatric PAs to distinguish between PAs of different anatomic locations (n = 257 PA and control brain tissues). Second, we measured the concentration of nuclear bomb test-derived C-14 in genomic DNA (n = 14 cases), which indicates the time point of the formation of human cell populations. Our data suggest that adult and pediatric PAs developing in the infratentorial brain are closely related and potentially develop from precursor cells early in life, whereas supratentorial PAs might show age and location-specific differences.	[Voronina, Natalia; Kolb, Thorsten; Ernst, Aurelie] DKFZ, Grp Genome Instabil Tumors, Heidelberg, Germany; [Aichmueller, Christian; Zapatka, Marc] DKFZ Heidelberg Ctr Personalized Oncol HIPO, DKFZ, Div Mol Genet, Heidelberg, Germany; [Aichmueller, Christian; Zapatka, Marc] German Canc Consortium DKTK, Heidelberg, Germany; [Korshunov, Andrey; von Deimling, Andreas] DKFZ, Heidelberg Univ Hosp, Dept Neuropathol, Heidelberg, Germany; [Korshunov, Andrey; von Deimling, Andreas] DKFZ, CCU Neuropathol, Heidelberg, Germany; [Ryzhova, Marina] NN Burdenko Inst Neurosurg, Moscow, Russia; [Barnholtz-Sloan, Jill; Cioffi, Gino] Case Western Reserve Univ, Sch Med, Dept Populat & Quantitat Hlth Sci, Cleveland, OH USA; [Barnholtz-Sloan, Jill; Cioffi, Gino] Cent Brain Tumor Registry US, Hinsdale, IL USA; [Sill, Martin; Pfister, Stefan M.] Hopp Childrens Canc Ctr Heidelberg KiTZ, Heidelberg, Germany; [Sill, Martin; Pfister, Stefan M.] DKFZ, Div Pediat Neurooncol, Heidelberg, Germany; [Sill, Martin; Pfister, Stefan M.] DKFZ, German Canc Consortium DKTK, Heidelberg, Germany; [Sill, Martin; Pfister, Stefan M.] Heidelberg Univ Hosp, Dept Pediat Oncol Hematol & Immunol, Heidelberg, Germany; [Gronych, Jan] DKFZ, Div Pediat Neurooncol, Hopp Childrens Canc Ctr Heidelberg KiTZ, Heidelberg, Germany; [Gronych, Jan] DKFZ, German Canc Consortium DKTK, Heidelberg, Germany; [Jones, David T. W.] Hopp Childrens Canc Ctr Heidelberg KiTZ, Pediat Glioma Res Grp, Heidelberg, Germany; [Frisen, Jonas] Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden; [Gronych, Jan] Roche Diagnost Deutschland GmbH, Mannheim, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Russian Academy of Medical Sciences; N.N.Burdenko National Medical Research Center of Neurosurgery; Case Western Reserve University; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Karolinska Institutet	Ernst, A (corresponding author), DKFZ, Grp Genome Instabil Tumors, Heidelberg, Germany.	a.ernst@dkfz.de	Barnholtz-Sloan, Jill/A-4817-2011; von Deimling, Andreas/F-7774-2013; Zapatka, Marc/G-9896-2013; Pfister, Stefan M/F-6860-2013	Barnholtz-Sloan, Jill/0000-0001-6190-9304; von Deimling, Andreas/0000-0002-5863-540X; Zapatka, Marc/0000-0001-8287-5967; Pfister, Stefan M/0000-0002-5447-5322	Else Kroner-Fresenius Foundation; Fritz Thyssen Foundation; Wilhelm Sander Foundation; Centers for Disease Control and Prevention (CDC) [75D30119C06056]; American Brain Tumor Association; Sontag Foundation; Musella Foundation; National Brain Tumor Society; Children's Brain Tumor Foundation; Uncle Kory Foundation; Zelda Dorin Tetenbaum Memorial Fund; Cancer Prevention and Research Institute of Texas (CPRIT) [RP160097T]; Novocure	Else Kroner-Fresenius Foundation; Fritz Thyssen Foundation; Wilhelm Sander Foundation; Centers for Disease Control and Prevention (CDC)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); American Brain Tumor Association; Sontag Foundation; Musella Foundation; National Brain Tumor Society; Children's Brain Tumor Foundation; Uncle Kory Foundation; Zelda Dorin Tetenbaum Memorial Fund; Cancer Prevention and Research Institute of Texas (CPRIT); Novocure(Novocure Limited)	We thank the Else Kroner-Fresenius Foundation, the Fritz Thyssen Foundation and the Wilhelm Sander Foundation for funding. We thank Peter Lichter for the discussions. We thank Helena Lonnqvist for support with the DNA extraction, Frauke Devens and Michaela Hergt for support with the immunohistology and Andrea Wittmann for help with tumor tissue collection. We thank the team of the Department of Physics of the Uppsala University for the AMS measurements, and Karl Hakansson and Lars Beckel in particular. We thank Nada Jabado and Almos Klekner for kindly searching for potentially suitable samples, even though the tissues did not meet the criteria for retrospective birth-dating, we are very grateful to both of them for trying to help. Funding for CBTRUS was provided by the Centers for Disease Control and Prevention (CDC) under contract no. 75D30119C06056, the American Brain Tumor Association, The Sontag Foundation, Novocure, the Musella Foundation, National Brain Tumor Society, the Children's Brain Tumor Foundation, the Uncle Kory Foundation, the Zelda Dorin Tetenbaum Memorial Fund, as well as private and in-kind donations. QTO is supported by a Research Training Grant from the Cancer Prevention and Research Institute of Texas (CPRIT; RP160097T). Contents are solely the responsibility of the authors and do not necessarily represent the official views of the CDC.	Aichmuller CF, 2020, NEURO-ONCOLOGY, V22, P1327, DOI 10.1093/neuonc/noaa035; Antonelli Manila, 2018, Oncotarget, V9, P13807, DOI 10.18632/oncotarget.24480; Bergmann O, 2009, SCIENCE, V324, P98, DOI 10.1126/science.1164680; Brokinkel B, 2015, NEUROPATH APPL NEURO, V41, P258, DOI 10.1111/nan.12145; Buhl JL, 2019, CLIN CANCER RES, V25, P1851, DOI 10.1158/1078-0432.CCR-18-1965; Capper D, 2018, NATURE, V555, P469, DOI 10.1038/nature26000; Ernst A, 2014, CELL, V156, P1072, DOI 10.1016/j.cell.2014.01.044; Fernandez AF, 2012, GENOME RES, V22, P407, DOI 10.1101/gr.119867.110; Gerstung M, 2020, NATURE, V578, P122, DOI 10.1038/s41586-019-1907-7; Hovestadt V, 2014, NATURE, V510, P537, DOI 10.1038/nature13268; Huttner HB, 2018, EBIOMEDICINE, V27, P176, DOI 10.1016/j.ebiom.2017.12.020; Janzarik WG, 2007, NEUROPEDIATRICS, V38, P61, DOI 10.1055/s-2007-984451; Korber V, 2019, CANCER CELL, V35, P692, DOI 10.1016/j.ccell.2019.02.007; Kratz CP, 2017, CLIN CANCER RES, V23, pE38, DOI 10.1158/1078-0432.CCR-17-0408; Lambert SR, 2013, ACTA NEUROPATHOL, V126, P291, DOI 10.1007/s00401-013-1124-7; Magrini S, 2013, J NEURO-ONCOL, V115, P103, DOI 10.1007/s11060-013-1200-9; Miller JA, 2014, NATURE, V508, P199, DOI 10.1038/nature13185; Mitoma H, 2020, CEREBELLUM, V19, P131, DOI 10.1007/s12311-019-01091-9; Moran S, 2016, LANCET ONCOL, V17, P1386, DOI 10.1016/S1470-2045(16)30297-2; Northcott PA, 2011, ACTA NEUROPATHOL, V122, P231, DOI 10.1007/s00401-011-0846-7; Sexton-Oates A, 2018, MOL ONCOL, V12, P1219, DOI 10.1002/1878-0261.12062; Sharma MK, 2007, CANCER RES, V67, P890, DOI 10.1158/0008-5472.CAN-06-0973; Spalding KL, 2008, NATURE, V453, P783, DOI 10.1038/nature06902; Spalding KL, 2013, CELL, V153, P1219, DOI 10.1016/j.cell.2013.05.002; Spalding KL, 2005, CELL, V122, P133, DOI 10.1016/j.cell.2005.04.028; Theeler BJ, 2014, NEURO-ONCOLOGY, V16, P841, DOI 10.1093/neuonc/not246; Vladoiu MC, 2019, NATURE, V572, P67, DOI 10.1038/s41586-019-1158-7; Yeung MSY, 2019, NATURE, V566, P538, DOI 10.1038/s41586-018-0842-3; Zheng SJC, 2018, NAT METHODS, V15, P1059, DOI 10.1038/s41592-018-0213-x	29	4	4	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2021	40	16					2830	2841		10.1038/s41388-021-01738-0	http://dx.doi.org/10.1038/s41388-021-01738-0		MAR 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ5XW	33731860	hybrid, Green Published			2022-12-17	WOS:000629880400001
J	Yu, ZY; Jiang, XY; Qin, L; Deng, HX; Wang, JL; Ren, W; Li, HB; Zhao, L; Liu, HX; Yan, H; Shi, WG; Wang, Q; Luo, CJ; Long, B; Zhou, HN; Sun, H; Jiao, ZY				Yu, Zeyuan; Jiang, Xiangyan; Qin, Long; Deng, Haixiao; Wang, Jianli; Ren, Wen; Li, Hongbin; Zhao, Lei; Liu, Huanxiang; Yan, Hong; Shi, Wengui; Wang, Qi; Luo, Changjiang; Long, Bo; Zhou, Huinian; Sun, Hui; Jiao, Zuoyi			A novel UBE2T inhibitor suppresses Wnt/beta-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination (vol 40, pg 1027, 2021)	ONCOGENE			English	Correction												yaohy04@126.com; jiaozy@lzu.edu.cn	ZHOU, Huinian/AAD-9279-2022	Liu, Huanxiang/0000-0002-9284-3667				Yu ZY, 2021, ONCOGENE, V40, P1027, DOI 10.1038/s41388-020-01572-w	1	4	4	2	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2021	40	14					2622	2623		10.1038/s41388-021-01717-5	http://dx.doi.org/10.1038/s41388-021-01717-5		MAR 2021	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK3YE	33707750	Bronze, Green Published			2022-12-17	WOS:000627660400001
J	Ali, MM; Di Marco, M; Mahale, S; Jachimowicz, D; Kosalai, ST; Reischl, S; Statello, L; Mishra, K; Darnfors, C; Kanduri, M; Kanduri, C				Ali, Mohamad Moustafa; Di Marco, Mirco; Mahale, Sagar; Jachimowicz, Daniel; Kosalai, Subazini Thankaswamy; Reischl, Silke; Statello, Luisa; Mishra, Kankadeb; Darnfors, Catarina; Kanduri, Meena; Kanduri, Chandrasekhar			LY6K-AS lncRNA is a lung adenocarcinoma prognostic biomarker and regulator of mitotic progression	ONCOGENE			English	Article							LONG NONCODING RNAS; 14-3-3 PROTEINS; GENE-EXPRESSION; HISTONE CODE; ORGANIZATION; PROTEOLYSIS; MECHANISMS; RESISTANCE; LANDSCAPE; IMPACT	Recent advances in genomics unraveled several actionable mutational drivers in lung cancer, leading to promising therapies such as tyrosine kinase inhibitors and immune checkpoint inhibitors. However, the tumors' acquired resistance to the newly-developed as well as existing therapies restricts life quality improvements. Therefore, we investigated the noncoding portion of the human transcriptome in search of alternative actionable targets. We identified an antisense transcript, LY6K-AS, with elevated expression in lung adenocarcinoma (LUAD) patients, and its higher expression in LUAD patients predicts poor survival outcomes. LY6K-AS abrogation interfered with the mitotic progression of lung cancer cells resulting in unfaithful chromosomal segregation. LY6K-AS interacts with and stabilizes 14-3-3 proteins to regulate the transcription of kinetochore and mitotic checkpoint proteins. We also show that LY6K-AS regulates the levels of histone H3 lysine 4 trimethylation (H3K4me3) at the promoters of kinetochore members. Cisplatin treatment and LY6K-AS silencing affect many common pathways enriched in cell cycle-related functions. LY6K-AS silencing affects the growth of xenografts derived from wildtype and cisplatin-resistant lung cancer cells. Collectively, these data indicate that LY6K-AS silencing is a promising therapeutic option for LUAD that inhibits oncogenic mitotic progression.	[Ali, Mohamad Moustafa; Di Marco, Mirco; Mahale, Sagar; Jachimowicz, Daniel; Kosalai, Subazini Thankaswamy; Reischl, Silke; Statello, Luisa; Mishra, Kankadeb; Kanduri, Chandrasekhar] Univ Gothenburg, Inst Biomed, Dept Med Biochem & Cell Biol, Gothenburg, Sweden; [Darnfors, Catarina] Sahlgrens Univ Hosp, Dept Clin Pathol & Genet, Gothenburg, Sweden; [Kanduri, Meena] Sahlgrens Univ Hosp, Dept Clin Chem & Transfus Med, Gothenburg, Sweden	University of Gothenburg; Sahlgrenska University Hospital; Sahlgrenska University Hospital	Kanduri, C (corresponding author), Univ Gothenburg, Inst Biomed, Dept Med Biochem & Cell Biol, Gothenburg, Sweden.	kanduri.chandrasekhar@gu.se	Ali, Mohamad Moustafa/ABF-5464-2020; Statello, Luisa/AAU-5115-2021	Ali, Mohamad Moustafa/0000-0002-4902-0550; Statello, Luisa/0000-0001-8261-4214; Kanduri, Chandrasekhar/0000-0001-6271-9078; Di Marco, Amerigo Mirco/0000-0001-8890-233X; Reischl, Silke/0000-0003-4822-4137	Knut and Alice Wallenberg Foundation [KAW2014.0057]; Swedish Foundation for Strategic Research [RB13-0204]; Swedish Cancer Research foundation [Cancerfonden] [CAN2018/591]; Swedish Research Council [2017-02834]; Barncancerfonden [PR2018-0090]; Ingabritt Och Arne Lundbergs forskningsstiftelse; LUA/ ALF	Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Swedish Cancer Research foundation [Cancerfonden](Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Barncancerfonden; Ingabritt Och Arne Lundbergs forskningsstiftelse; LUA/ ALF	This work was supported by the grants from Knut and Alice Wallenberg Foundation [KAW2014.0057]; Swedish Foundation for Strategic Research [RB13-0204]; Swedish Cancer Research foundation [Cancerfonden: Kontrakt no. CAN2018/591]; Swedish Research Council [2017-02834]; Barncancerfonden [PR2018-0090]; Ingabritt Och Arne Lundbergs forskningsstiftelse and LUA/ ALF (to CK). The Proteomics Core Facility at Gothenburg University, performed the analysis for protein identification. We acknowledge the Centre for Cellular Imaging at the University of Gothenburg for assisting in microscopy.	Akhade VS, 2017, ADV EXP MED BIOL, V1008, P47, DOI 10.1007/978-981-10-5203-3_2; Ali M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04082-2; Balbin OA, 2015, GENOME RES, V25, P1068, DOI 10.1101/gr.180596.114; Bose A, 2019, J BIOSCIENCES, V44, DOI 10.1007/s12038-019-9867-5; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen DY, 2015, INT J ONCOL, V46, P818, DOI 10.3892/ijo.2014.2740; de Groot PM, 2018, TRANSL LUNG CANCER R, V7, P220, DOI 10.21037/tlcr.2018.05.06; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dominguez-Brauer C, 2015, MOL CELL, V60, P524, DOI 10.1016/j.molcel.2015.11.006; Galluzzi L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.428; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gardino AK, 2011, SEMIN CELL DEV BIOL, V22, P688, DOI 10.1016/j.semcdb.2011.09.008; Gavet O, 2010, DEV CELL, V18, P533, DOI 10.1016/j.devcel.2010.02.013; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Gutschner T, 2013, CANCER RES, V73, P1180, DOI 10.1158/0008-5472.CAN-12-2850; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hirsch FR, 2017, LANCET, V389, P299, DOI 10.1016/S0140-6736(16)30958-8; Holland AJ, 2012, EMBO REP, V13, P501, DOI 10.1038/embor.2012.55; Hosing AS, 2008, CELL CYCLE, V7, P3171, DOI 10.4161/cc.7.20.6812; Isaka T, 2003, J HISTOCHEM CYTOCHEM, V51, P1343, DOI 10.1177/002215540305101011; Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192; Kasahara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2879; Kasahara K, 2010, EMBO J, V29, P2802, DOI 10.1038/emboj.2010.157; Kornienko AE, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0873-8; Lara-Gonzalez P, 2019, DEV CELL, V51, P313, DOI 10.1016/j.devcel.2019.09.005; Lassmann T, 2011, BIOINFORMATICS, V27, P130, DOI 10.1093/bioinformatics/btq614; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Lischetti T, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723548.2014.970484; MacDonald N, 2005, MOL CELL, V20, P199, DOI 10.1016/j.molcel.2005.08.032; Mahale S, 2016, SCI REP-UK, V6, DOI 10.1038/s41598-016-0030-3; Marchese FP, 2016, MOL CELL, V63, P397, DOI 10.1016/j.molcel.2016.06.031; Montes M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7967; NISHIMURA K, 2019, NAT COMMUN, V10; Nowicki TS, 2018, CANCER J, V24, P47, DOI 10.1097/PPO.0000000000000303; Ohhata T, 2011, GENE DEV, V25, P1702, DOI 10.1101/gad.16997911; Ooi AT, 2014, CANCER PREV RES, V7, P487, DOI 10.1158/1940-6207.CAPR-13-0372; Pandey GK, 2014, CANCER CELL, V26, P722, DOI 10.1016/j.ccell.2014.09.014; Pandey RR, 2008, MOL CELL, V32, P232, DOI 10.1016/j.molcel.2008.08.022; Qi WQ, 2005, INT J CANCER, V113, P359, DOI 10.1002/ijc.20492; Raungrut P, 2014, ASIAN PAC J CANCER P, V15, P3513, DOI 10.7314/APJCP.2014.15.8.3513; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Roeten MSF, 2018, CANCER CHEMOTH PHARM, V81, P227, DOI 10.1007/s00280-017-3489-0; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Siemeister G, 2019, CLIN CANCER RES, V25, P1404, DOI 10.1158/1078-0432.CCR-18-0628; Subhash S, 2018, NUCLEIC ACIDS RES, V46, P9384, DOI 10.1093/nar/gky635; Subhash S, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1250-z; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Uetake Y, 2010, CURR BIOL, V20, P1666, DOI 10.1016/j.cub.2010.08.018; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; Vedadi M, 2017, PROTEIN SCI, V26, P662, DOI 10.1002/pro.3129; White NM, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0429-8; Winter S, 2008, EMBO J, V27, P88, DOI 10.1038/sj.emboj.7601954; Wu H, 2017, TRENDS GENET, V33, P540, DOI 10.1016/j.tig.2017.05.004; Wu SG, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0777-1; Zippo A, 2009, CELL, V138, P1122, DOI 10.1016/j.cell.2009.07.031	57	4	4	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2021	40	13					2463	2478		10.1038/s41388-021-01696-7	http://dx.doi.org/10.1038/s41388-021-01696-7		MAR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RH1BQ	33674747				2022-12-17	WOS:000625607100003
J	Alasadi, A; Cao, B; Guo, JJ; Tao, HL; Collantes, J; Tan, V; Su, XY; Augeri, D; Jin, SK				Alasadi, Amer; Cao, Bin; Guo, Jingjing; Tao, Hanlin; Collantes, Juan; Tan, Victor; Su, Xiaoyang; Augeri, David; Jin, Shengkan			Mitochondrial uncoupler MB1-47 is efficacious in treating hepatic metastasis of pancreatic cancer in murine tumor transplantation models	ONCOGENE			English	Article							GROWTH	Pancreatic ductal adenocarcinoma (PDA) is aggressive cancer characterized by rapid progression, metastatic recurrence, and highly resistant to treatment. PDA cells exhibit aerobic glycolysis, or the Warburg effect, which reduces the flux of pyruvate into mitochondria. As a result, more glycolytic metabolites are shunted to pathways for the production of building blocks (e.g., ribose) and reducing agents (e.g., NADPH) for biosynthesis that are necessary for cell proliferation. In addition, PDA cells are highly addicted to glutamine for both maintaining biosynthetic pathways and achieving redox balance. Mitochondrial uncoupling facilitates proton influx across the mitochondrial inner membrane without generating ATP, leading to a futile cycle that consumes glucose metabolites and glutamine. We synthesized a new mitochondrial uncoupler MB1-47 and tested its effect on cancer cell metabolism and the anticancer activity in pancreatic cancer cell models and murine tumor transplantation models. MB1-47 uncouples mitochondria in the pancreatic cancer cells, resulting in: (1) the acceleration of pyruvate oxidation and TCA turnover; (2) increases in AMP/ATP and ADP/AMP ratios; and (3) a decrease in the synthesis rate of nucleotides and sugar nucleotides. Moreover, MB1-47 arrests cell cycle at G(0)-G(1) phase, reduces clonogenicity, and inhibits cell growth of murine and human pancreatic cancer cells. In vivo studies showed that MB1-47 inhibits tumor growth in murine tumor transplantation models, and inhibits the hepatic metastasis when tumor cells were transplanted intrasplenically. Our results provide proof of concept for a potentially new strategy of treating PDA, and a novel prototype experimental drug for future studies and development.	[Alasadi, Amer; Guo, Jingjing; Tao, Hanlin; Collantes, Juan; Tan, Victor; Jin, Shengkan] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; [Alasadi, Amer] Rutgers State Univ, Robert Wood Johnson Med Sch, Grad Program Physiol & Integrat Biol, Piscataway, NJ USA; [Cao, Bin; Augeri, David] Rutgers State Univ, Ernest Mario Sch Pharm, Med Chem Dept, Piscataway, NJ USA; [Su, Xiaoyang] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Med, Piscataway, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center	Jin, SK (corresponding author), Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA.	victor.jin@rutgers.edu		Collantes, Juan Carlos/0000-0002-0154-5075; Tan, Victor/0000-0001-5869-2773; Alasadi, Amer/0000-0001-6082-1597	Rutgers Busch Biomedical Award; HCED Iraq Scholarship program, New Jersey Cancer Commission Research (NJCCR) Fellowship; Mito BioPharma, LLC; HCED Iraq Scholarship program; NJCCR; NIH [1R21CA216604, 1R21 AA027050]	Rutgers Busch Biomedical Award; HCED Iraq Scholarship program, New Jersey Cancer Commission Research (NJCCR) Fellowship; Mito BioPharma, LLC; HCED Iraq Scholarship program; NJCCR; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors want to thank Frank Leu for reviewing and editing the paper. The project was partially funded by Rutgers Busch Biomedical Award (2014), HCED Iraq Scholarship program, New Jersey Cancer Commission Research (NJCCR) Fellowship, and Mito BioPharma, LLC. AA is supported by HCED Iraq Scholarship program. HT was supported in part by NJCCR. AA, HT, JG, and SJ are partially supported by NIH (1R21CA216604 and 1R21 AA027050).	Alasadi A, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0092-6; BLUM R, 2014, CELL, V5; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Efthimiou E, 2001, PANCREATOLOGY, V1, P571, DOI 10.1159/000055865; Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001; Frayha GJ, 1997, GEN PHARMACOL-VASC S, V28, P273, DOI 10.1016/S0306-3623(96)00149-8; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; GILLEN S, 2010, NAT REV CLIN ONCOL, V7; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harper J A, 2001, Obes Rev, V2, P255, DOI 10.1046/j.1467-789X.2001.00043.x; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Jastroch M, 2010, ESSAYS BIOCHEM, V47, P53, DOI [10.1042/BSE0470053, 10.1042/bse0470053]; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Mimeault M, 2005, PANCREAS, V31, P301, DOI 10.1097/01.mpa.0000175893.04660.1b; PARASCANDOLA J, 1974, MOL CELL BIOCHEM, V5, P69, DOI 10.1007/BF01874175; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; SHIMIZU M, 1986, MUTAT RES, V170, P11, DOI 10.1016/0165-1218(86)90077-7; Siegel R., 2015, CA-CANCER J CLIN, V65, P29, DOI [10.3322/caac.21254, DOI 10.3322/CAAC.21254, DOI 10.3322/caac.21208]; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Stathis A, 2010, NAT REV CLIN ONCOL, V7, P163, DOI 10.1038/nrclinonc.2009.236; Sun SY, 1997, CANCER RES, V57, P4931; Tao HL, 2014, NAT MED, V20, P1263, DOI 10.1038/nm.3699; TERADA H, 1990, ENVIRON HEALTH PERSP, V87, P213, DOI 10.2307/3431027; Wang W, 2009, ACTA PHYSIOL, V196, P55, DOI 10.1111/j.1748-1716.2009.01980.x; Wang YL, 2018, CELL REP, V24, P47, DOI 10.1016/j.celrep.2018.06.008; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Xu J, 2012, CRIT REV FOOD SCI, V52, P373, DOI 10.1080/10408398.2010.500245; Zhou WD, 2012, J PROTEOME RES, V11, P554, DOI 10.1021/pr2009274	37	4	4	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2285	2295		10.1038/s41388-021-01688-7	http://dx.doi.org/10.1038/s41388-021-01688-7		MAR 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33649533				2022-12-17	WOS:000623739900004
J	Blondel-Tepaz, E; Leverve, M; Sokrat, B; Paradis, JS; Kosic, M; Saha, K; Auffray, C; Lima-Fernandes, E; Zamborlini, A; Poupon, A; Gaboury, L; Findlay, J; Baillie, GS; Enslen, H; Bouvier, M; Angers, S; Marullo, S; Scott, MGH				Blondel-Tepaz, Elodie; Leverve, Marie; Sokrat, Badr; Paradis, Justine S.; Kosic, Milena; Saha, Kusumika; Auffray, Cedric; Lima-Fernandes, Evelyne; Zamborlini, Alessia; Poupon, Anne; Gaboury, Louis; Findlay, Jane; Baillie, George S.; Enslen, Herve; Bouvier, Michel; Angers, Stephane; Marullo, Stefano; Scott, Mark G. H.			The RanBP2/RanGAP1-SUMO complex gates beta-arrestin2 nuclear entry to regulate the Mdm2-p53 signaling axis	ONCOGENE			English	Article							BETA-ARRESTINS; SUMO MODIFICATION; EXPORT SIGNAL; BINDING-SITES; PROTEIN; SUMOYLATION; RECEPTOR; LOCALIZATION; RAN; PHOSPHORYLATION	Mdm2 antagonizes the tumor suppressor p53. Targeting the Mdm2-p53 interaction represents an attractive approach for the treatment of cancers with functional p53. Investigating mechanisms underlying Mdm2-p53 regulation is therefore important. The scaffold protein beta-arrestin2 (beta-arr2) regulates tumor suppressor p53 by counteracting Mdm2.beta-arr2 nucleocytoplasmic shuttling displaces Mdm2 from the nucleus to the cytoplasm resulting in enhanced p53 signaling. beta-arr2 is constitutively exported from the nucleus, via a nuclear export signal, but mechanisms regulating its nuclear entry are not completely elucidated. beta-arr2 can be SUMOylated, but no information is available on how SUMO may regulate beta-arr2 nucleocytoplasmic shuttling. While we found beta-arr2 SUMOylation to be dispensable for nuclear import, we identified a non-covalent interaction between SUMO and beta-arr2, via a SUMO interaction motif (SIM), that is required for beta-arr2 cytonuclear trafficking. This SIM promotes association of beta-arr2 with the multimolecular RanBP2/RanGAP1-SUMO nucleocytoplasmic transport hub that resides on the cytoplasmic filaments of the nuclear pore complex. Depletion of RanBP2/RanGAP1-SUMO levels result in defective beta-arr2 nuclear entry. Mutation of the SIM inhibits beta-arr2 nuclear import, its ability to delocalize Mdm2 from the nucleus to the cytoplasm and enhanced p53 signaling in lung and breast tumor cell lines. Thus, a beta-arr2 SIM nuclear entry checkpoint, coupled with active beta-arr2 nuclear export, regulates its cytonuclear trafficking function to control the Mdm2-p53 signaling axis.	[Blondel-Tepaz, Elodie; Leverve, Marie; Saha, Kusumika; Auffray, Cedric; Lima-Fernandes, Evelyne; Enslen, Herve; Marullo, Stefano; Scott, Mark G. H.] Inst Cochin, U1016, INSERM, Paris, France; [Blondel-Tepaz, Elodie; Leverve, Marie; Saha, Kusumika; Auffray, Cedric; Lima-Fernandes, Evelyne; Enslen, Herve; Marullo, Stefano; Scott, Mark G. H.] CNRS, UMR8104, Paris, France; [Blondel-Tepaz, Elodie; Leverve, Marie; Saha, Kusumika; Auffray, Cedric; Lima-Fernandes, Evelyne; Enslen, Herve; Marullo, Stefano; Scott, Mark G. H.] Univ Paris, Paris, France; [Sokrat, Badr] Univ Montreal, Inst Res Immunol & Canc IRIC, Montreal, PQ, Canada; [Sokrat, Badr; Paradis, Justine S.; Gaboury, Louis; Bouvier, Michel] Univ Montreal, Dept Biochem & Mol Med, Montreal, PQ, Canada; [Paradis, Justine S.; Bouvier, Michel] Univ Montreal, Mol Biol Program, Montreal, PQ, Canada; [Kosic, Milena; Angers, Stephane] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada; [Kosic, Milena; Angers, Stephane] Univ Toronto, Dept Biochem, Toronto, ON, Canada; [Zamborlini, Alessia] Univ Paris Saclay, Inst Integrat Biol Cell I2BC, CNRS, CEA, Gif Sur Yvette, France; [Poupon, Anne] Univ Tours, IFCE, CNRS, INRA,PRC, Nouzilly, France; [Gaboury, Louis] Univ Montreal, Dept Pathol & Cell Biol, IRIC, Montreal, PQ, Canada; [Findlay, Jane; Baillie, George S.] Univ Glasgow, Coll Vet Med & Life Sci, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Universite de Montreal; Universite de Montreal; Universite de Montreal; University of Toronto; University of Toronto; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); INRAE; Universite de Tours; Universite de Montreal; University of Glasgow	Scott, MGH (corresponding author), Inst Cochin, U1016, INSERM, Paris, France.; Scott, MGH (corresponding author), CNRS, UMR8104, Paris, France.; Scott, MGH (corresponding author), Univ Paris, Paris, France.	mark.scott@inserm.fr	Enslen, Hervé/AAH-4492-2021; Angers, Stephane/E-1432-2014; Zamborlini, Alessia/ABE-2256-2021; Marullo, Stefano/C-6142-2008; Bouvier, Michel/H-2758-2014	Enslen, Hervé/0000-0001-9741-5293; Angers, Stephane/0000-0001-7241-9044; Zamborlini, Alessia/0000-0002-8902-1996; Marullo, Stefano/0000-0001-9604-9973; Sokrat, Badr/0000-0002-5770-1858; Scott, Mark G.H./0000-0002-1557-1856; Bouvier, Michel/0000-0003-1128-0100	"Investments for the Future" program [ANR-11-LABX-0071, ANR-11-IDEX-0005-01]; Fondation ARC pour la Recherche sur le Cancer ("Projet ARC"); Ligue contre le Cancer; Royal Society; France Canada Research Fund; CNRS; INSERM; CIHR Foundation [FDN148431]; MESR; Fondation ARC pour la Recherche sur le Cancer doctoral fellowships	"Investments for the Future" program; Fondation ARC pour la Recherche sur le Cancer ("Projet ARC")(Fondation ARC pour la Recherche sur le Cancer); Ligue contre le Cancer(Ligue nationale contre le cancer); Royal Society(Royal Society of London); France Canada Research Fund; CNRS(Centre National de la Recherche Scientifique (CNRS)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); CIHR Foundation(Canadian Institutes of Health Research (CIHR)); MESR(Ministry of Research, France); Fondation ARC pour la Recherche sur le Cancer doctoral fellowships	We thank Dr. A. Benmerah for helpful discussion, Dr. J. Liotard for excellent technical assistance, and the Institut Cochin Imaging (IMAG'IC) and Sequencing platforms (GENOM'IC). The Institut Cochin lab is part of the Who am I? laboratory of excellence (grant ANR-11-LABX-0071), funded by the "Investments for the Future" program operated by The French National Research Agency (grant ANR-11-IDEX-0005-01). This work was funded by grants from the Fondation ARC pour la Recherche sur le Cancer ("Projet ARC" to MGHS), Ligue contre le Cancer (to MGHS), Royal Society ("International Joint Project Scheme" to MGHS and GSB), France Canada Research Fund (to MGHS and SA), CNRS, and INSERM. The work in the laboratory of M.B. was supported by a CIHR Foundation (FDN148431) grant. M.B. holds the Canada Research Chair in Signal transduction and Molecular Pharmacology. EBT was funded by MESR and Fondation ARC pour la Recherche sur le Cancer doctoral fellowships.	Alexander RA, 2020, CELL MOL LIFE SCI, V77, P5259, DOI 10.1007/s00018-020-03471-5; Beauclair G, 2015, BIOINFORMATICS, V31, P3483, DOI 10.1093/bioinformatics/btv403; Blondel-Tepaz E, 2019, METHODS MOL BIOL, V1957, P251, DOI 10.1007/978-1-4939-9158-7_16; Bolger GB, 2006, BIOCHEM J, V398, P23, DOI 10.1042/BJ20060423; Boularan C, 2007, P NATL ACAD SCI USA, V104, P18061, DOI 10.1073/pnas.0705550104; Brandariz-Nunez A, 2013, VIROLOGY, V435, P463, DOI 10.1016/j.virol.2012.09.042; Enslen Herve, 2014, Handb Exp Pharmacol, V219, P405, DOI 10.1007/978-3-642-41199-1_21; Flotho A, 2013, ANNU REV BIOCHEM, V82, P357, DOI 10.1146/annurev-biochem-061909-093311; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Gonzalez-Santamaria J, 2011, J VIROL, V85, P12890, DOI 10.1128/JVI.05628-11; Guo DH, 2004, NAT GENET, V36, P837, DOI 10.1038/ng1391; Hashizume C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.370; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hutten S, 2008, MOL BIOL CELL, V19, P2300, DOI 10.1091/mbc.E07-12-1279; Hutten S, 2009, J CELL SCI, V122, P1100, DOI 10.1242/jcs.040154; Jakobs A, 2007, NAT METHODS, V4, P245, DOI 10.1038/NMETH1006; Javadi A, 2017, ELIFE, V6, DOI 10.7554/eLife.24578; Kerscher O, 2007, EMBO REP, V8, P550, DOI 10.1038/sj.embor.7400980; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Laporte SA, 2019, METHODS MOL BIOL, V1957, P9, DOI 10.1007/978-1-4939-9158-7_2; Li RW, 2012, J VIROL, V86, P5412, DOI 10.1128/JVI.00314-12; Li X, 2010, BIOCHEM J, V428, P55, DOI 10.1042/BJ20091672; Lima-Fernandes E, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5431; Lima-Fernandes E, 2011, EMBO J, V30, P2557, DOI 10.1038/emboj.2011.178; Lin DY, 2006, MOL CELL, V24, P341, DOI 10.1016/j.molcel.2006.10.019; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aat7650; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Monteith JA, 2016, MOL ONCOL, V10, P1207, DOI 10.1016/j.molonc.2016.05.007; Namkung Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12178; Paradis JS, 2015, P NATL ACAD SCI USA, V112, pE5160, DOI 10.1073/pnas.1508836112; Peterson YK, 2017, PHARMACOL REV, V69, P256, DOI 10.1124/pr.116.013367; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Sakin V, 2015, J BIOL CHEM, V290, P23589, DOI 10.1074/jbc.M115.660118; Scott MGH, 2002, J BIOL CHEM, V277, P37693, DOI 10.1074/jbc.M207552200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Singh R, 2014, J BIOL CHEM, V289, P19383, DOI 10.1074/jbc.M114.575159; Walde S, 2012, TRAFFIC, V13, P218, DOI 10.1111/j.1600-0854.2011.01302.x; Wang P, 2003, J BIOL CHEM, V278, P11648, DOI 10.1074/jbc.M208109200; Wang PY, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092482; Werner A, 2012, MOL CELL, V46, P287, DOI 10.1016/j.molcel.2012.02.017; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; Wyatt D, 2011, J BIOL CHEM, V286, P3884, DOI 10.1074/jbc.M110.152116; Xiao N, 2015, J BIOL CHEM, V290, P1927, DOI 10.1074/jbc.M114.608703; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0; Zhang XH, 2020, BIOCHEM PHARMACOL, V178, DOI 10.1016/j.bcp.2020.114049	48	4	4	2	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2243	2257		10.1038/s41388-021-01704-w	http://dx.doi.org/10.1038/s41388-021-01704-w		MAR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33649538	Bronze, Green Accepted, Green Submitted			2022-12-17	WOS:000623739900002
J	Wei, T; Ji, XW; Gao, Y; Zhu, XM; Xiao, GR				Wei, Tian; Ji, Xiaowen; Gao, Yan; Zhu, Xiaomei; Xiao, Guiran			ZnT7 RNAi favors Raf(GOF)scrib(-/-)-induced tumor growth and invasion in Drosophila through JNK signaling pathway	ONCOGENE			English	Article; Early Access								The disruption of zinc homeostasis has been identified in patients suffering from various cancers, but a causative relationship has not yet been established. Drosophila melanogaster has become a powerful model to study cancer biology. Here using a Drosophila model of malignant tumor Raf(GOF)scrib(-/-), we observed that the tumor growth, invasion and migration were enhanced by silencing dZnT7, a zinc transporter localized on the Golgi apparatus. Further study indicated that the zinc deficiency in Golgi of dZnT7 RNAi resulted in ER stress which could activate the c-Jun-N-terminal Kinase (JNK) signaling and this process is mediated by Atg9. Lastly, we demonstrated that the exacerbation of dZnT7 RNAi on tumor was promoted by JNK signaling-dependent cell autonomous and non-autonomous autophagy. These findings suggest that zinc homeostasis in secretory compartments may provide a new therapeutic target for tumor treatment.	[Wei, Tian; Ji, Xiaowen; Gao, Yan; Xiao, Guiran] Hefei Univ Technol, Sch Food & Biol Engn, Hefei 230009, Anhui, Peoples R China; [Zhu, Xiaomei] Anhui Med Univ, Sch Basic Med Sci, Hefei 230032, Anhui, Peoples R China	Hefei University of Technology; Anhui Medical University	Xiao, GR (corresponding author), Hefei Univ Technol, Sch Food & Biol Engn, Hefei 230009, Anhui, Peoples R China.	xiaoguiran@hfut.edu.cn		Xiao, Guiran/0000-0002-1238-1838; Wei, Tian/0000-0001-7270-0979	National Natural Science Foundation of China [31671284]; Fundamental Research Funds for the Central Universities [JZ2020HGPA0115]; Youth Science and Technology Talents Support Program (2020) by Anhui Association for Science and Technology [RCTJ202001]; National Postdoctoral Program for Innovative Talents [BX201600045]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Youth Science and Technology Talents Support Program (2020) by Anhui Association for Science and Technology; National Postdoctoral Program for Innovative Talents	This project was funded by the National Natural Science Foundation of China (31671284), the Fundamental Research Funds for the Central Universities (JZ2020HGPA0115), Youth Science and Technology Talents Support Program (2020) by Anhui Association for Science and Technology (RCTJ202001), and the National Postdoctoral Program for Innovative Talents (BX201600045). The authors appreciate the gifts of fly stocks from Dr. Bing Zhou and Dr. Jose C. PASTOR-PAREJA. The authors are also grateful to the Bloomington Drosophila Stock Center, the Vienna Drosophila RNAi Center and Tsinghua Fly Center for fly stocks.	Antoniou X, 2011, J ALZHEIMERS DIS, V24, P633, DOI 10.3233/JAD-2011-091567; Bafaro E, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.29; Bali A, 2017, INT J DEV BIOL, V61, P551, DOI 10.1387/ijdb.170077bs; Beira JV, 2016, CHROMOSOMA, V125, P573, DOI 10.1007/s00412-016-0595-4; Bin BH, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/9365747; Biteau B, 2011, EXP GERONTOL, V46, P349, DOI 10.1016/j.exger.2010.11.003; Bubici C, 2014, BRIT J PHARMACOL, V171, P24, DOI 10.1111/bph.12432; Calap-Quintana P, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071456; Cousins RJ, 2006, J BIOL CHEM, V281, P24085, DOI 10.1074/jbc.R600011200; Dechen KS, 2015, INT J BIOCHEM CELL B, V60, P23, DOI 10.1016/j.biocel.2014.12.017; Dhanasekaran Danny N, 2017, Genes Cancer, V8, P682, DOI 10.18632/genesandcancer.155; Doggett K, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-57; Eom SJ, 2001, MOL PHARMACOL, V59, P981, DOI 10.1124/mol.59.5.981; Franklin RB, 2007, ARCH BIOCHEM BIOPHYS, V463, P211, DOI 10.1016/j.abb.2007.02.033; Groth C, 2013, DEVELOPMENT, V140, P3018, DOI 10.1242/dev.088336; Hershfinkel M, 2007, MOL MED, V13, P331, DOI 10.2119/2006-00038.Hershfinkel; Hrabeta J, 2016, J MOL MED, V94, P1199, DOI 10.1007/s00109-016-1454-8; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Kambe T, 2015, PHYSIOL REV, V95, P749, DOI 10.1152/physrev.00035.2014; Katheder NS, 2017, NATURE, V541, P417, DOI 10.1038/nature20815; Kirschke CP, 2003, J BIOL CHEM, V278, P4096, DOI 10.1074/jbc.M207644200; Kolenko V, 2013, NAT REV UROL, V10, P219, DOI 10.1038/nrurol.2013.43; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Kushnir T, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006860; Lang ML, 2012, PLOS GENET, V8, P623, DOI 10.1371/journal.pgen.1002683; Lee H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021533; Li DD, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020667; Liang D, 2013, CELL SIGNAL, V25, P1126, DOI 10.1016/j.cellsig.2013.02.003; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Liu SN, 2016, SCI REP-UK, V6, DOI 10.1038/srep38003; Ma XJ, 2017, CELL REP, V19, P2657, DOI 10.1016/j.celrep.2017.05.092; Ma XJ, 2012, CELL RES, V22, P425, DOI 10.1038/cr.2011.135; MacDonald RS, 2000, J NUTR, V130, p1500S, DOI 10.1093/jn/130.5.1500S; Manic G, 2014, MOL CELL ONCOL, V1, DOI 10.4161/mco.29911; McCall KA, 2000, J NUTR, V130, p1437S, DOI 10.1093/jn/130.5.1437S; McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001; Mishra-Gorur K, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.039727; Missirlis F, 2007, GENETICS, V177, P89, DOI 10.1534/genetics.107.075150; Newsome TP, 2000, DEVELOPMENT, V127, P851; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Pan Z, 2017, FRONT BIOSCI-LANDMRK, V22, P623, DOI 10.2741/4507; Pastor-Pareja JC, 2013, ANNU REV GENET, V47, P51, DOI 10.1146/annurev-genet-110711-155414; Poillet-Perez L, 2019, GENE DEV, V33, P610, DOI 10.1101/gad.325514.119; Prasad AS, 2013, ADV NUTR, V4, P176, DOI 10.3945/an.112.003210; Qin QH, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-101; Richards CD, 2016, ARCH BIOCHEM BIOPHYS, V611, P142, DOI 10.1016/j.abb.2016.07.015; Richardson HE, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4258387; Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028; Schroeder MC, 2013, ONCOGENE, V32, P4471, DOI 10.1038/onc.2012.476; Sheng ZT, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008863; Sonoshita M, 2017, CURR TOP DEV BIOL, V121, P287, DOI 10.1016/bs.ctdb.2016.07.008; Sousa CM, 2016, NATURE, V536, P479, DOI 10.1038/nature19084; Sun YH, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1350-6; Takatani-Nakase T, 2018, BIOL PHARM BULL, V41, P1517, DOI 10.1248/bpb.b18-00086; Tang HW, 2013, DEV CELL, V27, P489, DOI 10.1016/j.devcel.2013.10.017; Tepaamorndech S, 2011, CANCER LETT, V308, P33, DOI 10.1016/j.canlet.2011.04.011; Troost T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049007; Uhlirova M, 2005, P NATL ACAD SCI USA, V102, P13123, DOI 10.1073/pnas.0504170102; Villegas SN, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.039032; Wang XX, 2009, FASEB J, V23, P2650, DOI 10.1096/fj.08-126649; Weber U, 2000, DEVELOPMENT, V127, P3619; Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001; Willsey HR, 2016, ELIFE, V5, DOI 10.7554/eLife.11491; Wu H, 2009, MECH DEVELOP, V126, P624, DOI 10.1016/j.mod.2009.06.1082; Wu M, 2010, NATURE, V463, P545, DOI 10.1038/nature08702; Xiao GR, 2019, CELL REP, V26, P748, DOI 10.1016/j.celrep.2018.12.053; Xiao GR, 2018, FRONT GENET, V8, DOI 10.3389/fgene.2017.00234; Xiao GR, 2016, ARCH BIOCHEM BIOPHYS, V611, P134, DOI 10.1016/j.abb.2016.04.016; Xiao GR, 2014, ELIFE, V3, DOI 10.7554/eLife.03191; Xu R, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012912; Xue J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109180; Yan M, 2008, J NUTR, V138, P667, DOI 10.1093/jn/138.4.667; Yu HJ, 2009, BIOCHEM J, V417, P133, DOI 10.1042/BJ20081421; Zang YR, 2015, ELIFE, V4, DOI 10.7554/eLife.07187; Zeke A, 2016, MICROBIOL MOL BIOL R, V80, P793, DOI 10.1128/MMBR.00043-14; Zhang L, 2007, BRAIN RES BULL, V74, P278, DOI 10.1016/j.brainresbull.2007.06.022; Zhang XL, 2018, KIDNEY BLOOD PRESS R, V43, P500, DOI 10.1159/000488697	77	4	4	1	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-021-01703-x	http://dx.doi.org/10.1038/s41388-021-01703-x		MAR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QP3MA	33649534				2022-12-17	WOS:000623739900001
J	Feng, MX; Wang, YS; Bi, L; Zhang, PJ; Wang, HZ; Zhao, ZX; Mao, JH; Wei, GW				Feng, Maoxiao; Wang, Yunshan; Bi, Lei; Zhang, Pengju; Wang, Huaizhi; Zhao, Zhongxi; Mao, Jian-Hua; Wei, Guangwei			CRL4A(DTL) degrades DNA-PKcs to modulate NHEJ repair and induce genomic instability and subsequent malignant transformation	ONCOGENE			English	Article								Genomic instability induced by DNA damage and improper DNA damage repair is one of the main causes of malignant transformation and tumorigenesis. DNA double strand breaks (DSBs) are the most detrimental form of DNA damage, and nonhomologous end-joining (NHEJ) mechanisms play dominant and priority roles in initiating DSB repair. A well-studied oncogene, the ubiquitin ligase Cullin 4A (CUL4A), is reported to be recruited to DSB sites in genomic DNA, but whether it regulates NHEJ mechanisms of DSB repair is unclear. Here, we discovered that the CUL4A-DTL ligase complex targeted the DNA-PKcs protein in the NHEJ repair pathway for nuclear degradation. Overexpression of either CUL4A or DTL reduced NHEJ repair efficiency and subsequently increased the accumulation of DSBs. Moreover, we demonstrated that overexpression of either CUL4A or DTL in normal cells led to genomic instability and malignant proliferation. Consistent with the in vitro findings, in human precancerous lesions, CUL4A expression gradually increased with increasing malignant tendency and was negatively correlated with DNA-PKcs and positively correlated with gamma-H2AX expression. Collectively, this study provided strong evidence that the CUL4A-DTL axis increases genomic instability and enhances the subsequent malignant transformation of normal cells by inhibiting NHEJ repair. These results also suggested that CUL4A may be a prognostic marker of precancerous lesions and a potential therapeutic target in cancer.	[Feng, Maoxiao; Wei, Guangwei] Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Key Lab Expt Teratol,Minist Educ,Dept Cell Biol, Jinan, Shandong, Peoples R China; [Wang, Yunshan] Cheeloo Coll Med, Hosp 2, Dept Clin Lab, Jinan, Shandong, Peoples R China; [Wang, Yunshan; Bi, Lei; Zhang, Pengju; Mao, Jian-Hua] Lawrence Berkeley Natl Lab, Biol Syst & Engn Div, Berkeley, CA 94720 USA; [Bi, Lei] Nanjing Univ Chinese Med, Sch Preclin Med, Nanjing, Jiangsu, Peoples R China; [Zhang, Pengju] Shandong Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Key Lab Expt Teratol,Minist Educ, Jinan, Shandong, Peoples R China; [Wang, Huaizhi] Univ Chinese Acad Sci, Chongqing Gen Hosp, Inst Hepatopancreatobiliary Surg, Chongqing, Peoples R China; [Zhao, Zhongxi] Shandong Univ, Sch Pharmaceut Sci, Jinan, Shandong, Peoples R China	Shandong University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; Nanjing University of Chinese Medicine; Shandong University; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Shandong University	Wei, GW (corresponding author), Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Key Lab Expt Teratol,Minist Educ,Dept Cell Biol, Jinan, Shandong, Peoples R China.; Mao, JH (corresponding author), Lawrence Berkeley Natl Lab, Biol Syst & Engn Div, Berkeley, CA 94720 USA.	jhmao@lbl.gov; gwwei@email.sdu.edu.cn	Mao, Jian-Hua/EIZ-8595-2022	Mao, Jian-Hua/0000-0001-9320-6021; wang, yunshan/0000-0003-4873-054X	National Key R&D Program of China [2017YFC1308600]; National Natural Science Foundation of China [81872148, 81874040]; Natural Science Foundation of Shandong Province [ZR2019MH002]; Key Research and Development Projects in of Shandong Province [2019GSF108218]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Key Research and Development Projects in of Shandong Province	This work was supported by the National Key R&D Program of China (No.2017YFC1308600), National Natural Science Foundation of China (81872148, 81874040), Natural Science Foundation of Shandong Province (ZR2019MH002), and Key Research and Development Projects in of Shandong Province (2019GSF108218).	Abbas T, 2008, GENE DEV, V22, P2496, DOI 10.1101/gad.1676108; Abbas T, 2013, MOL CELL, V49, P1147, DOI 10.1016/j.molcel.2013.02.003; Abbas T, 2011, CELL CYCLE, V10, P241, DOI 10.4161/cc.10.2.14530; Abbas T, 2010, MOL CELL, V40, P9, DOI 10.1016/j.molcel.2010.09.014; Allen C, 2003, MOL CANCER RES, V1, P913; Arnoult N, 2017, NATURE, V549, P548, DOI 10.1038/nature24023; Baranes-Bachar K, 2018, MOL CELL, V69, P866, DOI 10.1016/j.molcel.2018.02.002; Batenburg NL, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02114-x; Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110; Beskow C, 2009, BRIT J CANCER, V101, P816, DOI 10.1038/sj.bjc.6605201; Bolzan AD, 2018, MUTAT RES-REV MUTAT, V775, P51, DOI 10.1016/j.mrrev.2018.02.003; Bondar T, 2006, MOL CELL BIOL, V26, P2531, DOI 10.1128/MCB.26.7.2531-2539.2006; Chang HHY, 2017, NAT REV MOL CELL BIO, V18, P495, DOI 10.1038/nrm.2017.48; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Davis AJ, 2014, NUCLEIC ACIDS RES, V42, P11487, DOI 10.1093/nar/gku824; Espejel S, 2004, J CELL BIOL, V167, P627, DOI 10.1083/jcb.200407178; Goodwin JF, 2015, CANCER CELL, V28, P97, DOI 10.1016/j.ccell.2015.06.004; Gupta A, 2002, INT J RADIAT ONCOL, V52, P822, DOI 10.1016/S0360-3016(01)02739-0; Hall JR, 2014, CELL CYCLE, V13, P3602, DOI 10.4161/15384101.2014.962957; Han CH, 2015, CELL CYCLE, V14, P1103, DOI 10.4161/15384101.2014.973740; Han JH, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01759-y; Han JH, 2013, CELL, V155, P817, DOI 10.1016/j.cell.2013.10.014; Hannah J, 2009, DNA REPAIR, V8, P536, DOI 10.1016/j.dnarep.2009.01.011; Higa LAA, 2003, NAT CELL BIOL, V5, P1008, DOI 10.1038/ncb1061; Higa LA, 2006, CELL CYCLE, V5, P1675, DOI 10.4161/cc.5.15.3149; Ihara M, 2019, J RADIAT RES, V60, P171, DOI 10.1093/jrr/rry097; Jhappan C, 1997, NAT GENET, V17, P483, DOI 10.1038/ng1297-483; Jin JP, 2006, MOL CELL, V23, P709, DOI 10.1016/j.molcel.2006.08.010; Kais Z, 2016, CELL REP, V15, P2488, DOI 10.1016/j.celrep.2016.05.031; Kim HB, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-46; Kurimasa A, 1999, P NATL ACAD SCI USA, V96, P1403, DOI 10.1073/pnas.96.4.1403; Lee J, 2007, MOL CELL, V26, P775, DOI 10.1016/j.molcel.2007.06.001; Lee J, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00021; Leung-Pineda V, 2009, CANCER RES, V69, P2630, DOI 10.1158/0008-5472.CAN-08-3382; Li BH, 2006, BLOOD, V107, P4291, DOI 10.1182/blood-2005-08-3349; Lieber MR, 2010, ANNU REV BIOCHEM, V79, P181, DOI 10.1146/annurev.biochem.052308.093131; Liu JF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4830; Liu LR, 2009, MOL CELL, V34, P451, DOI 10.1016/j.molcel.2009.04.020; Liu XS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9325; Lu HM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02146-3; Meir M, 2015, NUCLEIC ACIDS RES, V43, P4517, DOI 10.1093/nar/gkv270; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Mohiuddin IS, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00635; Moon JJ, 2019, EXP BIOL MED, V244, P227, DOI 10.1177/1535370219826031; Nishitani H, 2008, J BIOL CHEM, V283, P29045, DOI 10.1074/jbc.M806045200; Oda H, 2010, MOL CELL, V40, P364, DOI 10.1016/j.molcel.2010.10.011; Pastwa E, 2003, ACTA BIOCHIM POL, V50, P891; Pyun BJ, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.43; Rao F, 2014, MOL CELL, V54, P119, DOI 10.1016/j.molcel.2014.02.020; Reichermeier KM, 2020, MOL CELL, V77, P1092, DOI 10.1016/j.molcel.2019.12.013; Ren SC, 2012, J MOL MED, V90, P1121, DOI 10.1007/s00109-012-0885-0; Scherer PC, 2016, P NATL ACAD SCI USA, V113, P3503, DOI 10.1073/pnas.1525580113; Serrano MA, 2013, ONCOGENE, V32, P2452, DOI 10.1038/onc.2012.257; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; Sibanda BL, 2017, SCIENCE, V355, P520, DOI 10.1126/science.aak9654; Simsek D, 2010, NAT STRUCT MOL BIOL, V17, P410, DOI 10.1038/nsmb.1773; Srinivasan G, 2019, P NATL ACAD SCI USA, V116, P17438, DOI 10.1073/pnas.1903150116; Surucu B, 2008, J BIOL CHEM, V283, P30025, DOI 10.1074/jbc.M803053200; Wang YS, 2014, CANCER RES, V74, P520, DOI 10.1158/0008-5472.CAN-13-2182; Waning DL, 2008, BLOOD, V112, P320, DOI 10.1182/blood-2007-11-126300; Yang YF, 2016, MOL CELL, V62, P507, DOI 10.1016/j.molcel.2016.04.014; Zeng M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11364; Zhang Q, 2016, MOL CELL, V61, P419, DOI 10.1016/j.molcel.2015.12.010; Zhou Y, 2017, MOL CELL, V65, P91, DOI 10.1016/j.molcel.2016.11.004	64	4	4	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					2096	2111		10.1038/s41388-021-01690-z	http://dx.doi.org/10.1038/s41388-021-01690-z		FEB 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33627782	Green Published, hybrid, Green Submitted			2022-12-17	WOS:000621289100001
J	Netanely, D; Leibou, S; Parikh, R; Stern, N; Vaknine, H; Brenner, R; Amar, S; Factor, RH; Perluk, T; Frand, J; Nizri, E; Hershkovitz, D; Zemser-Werner, V; Levy, C; Shamir, R				Netanely, Dvir; Leibou, Stav; Parikh, Roma; Stern, Neta; Vaknine, Hananya; Brenner, Ronen; Amar, Sarah; Factor, Rivi Haiat; Perluk, Tomer; Frand, Jacob; Nizri, Eran; Hershkovitz, Dov; Zemser-Werner, Valentina; Levy, Carmit; Shamir, Ron			Classification of node-positive melanomas into prognostic subgroups using keratin, immune, and melanogenesis expression patterns	ONCOGENE			English	Article							GENE; CANCER; TOOL; CONTRIBUTES; DISCOVERY; DYNAMICS; EXPANDER; SUBTYPES; BIOLOGY	Cutaneous melanoma tumors are heterogeneous and show diverse responses to treatment. Identification of robust molecular biomarkers for classifying melanoma tumors into clinically distinct and homogenous subtypes is crucial for improving the diagnosis and treatment of the disease. In this study, we present a classification of melanoma tumors into four subtypes with different survival profiles based on three distinct gene expression signatures: keratin, immune, and melanogenesis. The melanogenesis expression pattern includes several genes that are characteristic of the melanosome organelle and correlates with worse survival, suggesting the involvement of melanosomes in melanoma aggression. We experimentally validated the secretion of melanosomes into surrounding tissues by melanoma tumors, which potentially affects the lethality of metastasis. We propose a simple molecular decision tree classifier for predicting a tumor's subtype based on representative genes from the three identified signatures. Key predictor genes were experimentally validated on melanoma samples taken from patients with varying survival outcomes. Our three-pattern approach for classifying melanoma tumors can contribute to advancing the understanding of melanoma variability and promote accurate diagnosis, prognostication, and treatment.	[Netanely, Dvir; Stern, Neta; Shamir, Ron] Tel Aviv Univ, Blavatnik Sch Comp Sci, Tel Aviv, Israel; [Leibou, Stav; Parikh, Roma; Nizri, Eran; Hershkovitz, Dov; Levy, Carmit] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Vaknine, Hananya; Brenner, Ronen; Amar, Sarah] Edith Wolfson Med Ctr, Dept Oncol, Holon, Israel; [Factor, Rivi Haiat; Perluk, Tomer; Frand, Jacob] Edith Wolfson Med Ctr, Dept Plast & Reconstruct Surg, Holon, Israel; [Nizri, Eran] Tel Aviv Sourasky Med Ctr, Dept Surg A, Tel Aviv, Israel; [Hershkovitz, Dov; Zemser-Werner, Valentina] Tel Aviv Sourasky Med Ctr, Inst Pathol, Tel Aviv, Israel	Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Shamir, R (corresponding author), Tel Aviv Univ, Blavatnik Sch Comp Sci, Tel Aviv, Israel.	rshamir@tau.ac.il	Shamir, Ron/E-6514-2011	Shamir, Ron/0000-0003-1889-9870; Netanely, Dvir/0000-0002-6861-2332	Israeli Science Foundation [1339/18]; GermanIsraeli Project DFG [RE 4193/1-1]; United States-Israel Binational Science Foundation, Jerusal em, Israel [2016694]; United States National Science Foundation; European Research Council under the European Union [726225]; Melanoma Research Alliance [402792]; Edmond J. Safra Center for Bioinformatics, Tel Aviv University	Israeli Science Foundation(Israel Science Foundation); GermanIsraeli Project DFG(German Research Foundation (DFG)); United States-Israel Binational Science Foundation, Jerusal em, Israel(US-Israel Binational Science Foundation); United States National Science Foundation(National Science Foundation (NSF)); European Research Council under the European Union(European Research Council (ERC)); Melanoma Research Alliance; Edmond J. Safra Center for Bioinformatics, Tel Aviv University	The results published here are based upon data generated by The Cancer Genome Atlas managed by the NCI and NHGRI. Information about TCGA can be found at http://ca ncergenome.nih.gov. The authors would like to thank Dr. Martin Lauss from Lund University for providing them with the assignment of TCGA melanoma samples to Lund subtypes. RS acknowledges the support of the Israeli Science Foundation (grant 1339/18), GermanIsraeli Project DFG RE 4193/1-1, and grant 2016694 from the United States-Israel Binational Science Foundation, Jerusal em, Israel, and the United States National Science Foundation. CL acknowledges grant support from the European Research Council under the European Union's Horizon 2020 research and innovation programme (grant agreement no. 726225) and Melanoma Research Alliance (402792). DN was supported in part by a fellowship from the Edmond J. Safra Center for Bioinformatics, Tel Aviv University.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Apalla Z., 2017, DERMATOL PRACT CONCE, V7, P1, DOI [DOI 10.5826/DPC.0702A01, https://doi.org/10.5826/dpc.0702a01]; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bell RE, 2016, GENOME RES, V26, P601, DOI 10.1101/gr.197194.115; Bellono NW, 2014, ELIFE, V3, DOI 10.7554/eLife.04543; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berson JF, 2001, MOL BIOL CELL, V12, P3451, DOI 10.1091/mbc.12.11.3451; Bland JM, 2004, BRIT MED J, V328, P1073, DOI 10.1136/bmj.328.7447.1073; Borgono CA, 2006, CLIN CANCER RES, V12, P1487, DOI 10.1158/1078-0432.CCR-05-2106; Chauvin JM, 2015, J CLIN INVEST, V125, P2046, DOI 10.1172/JCI80445; Chen KG, 2006, P NATL ACAD SCI USA, V103, P9903, DOI 10.1073/pnas.0600213103; Chen KG, 2009, PIGM CELL MELANOMA R, V22, P740, DOI 10.1111/j.1755-148X.2009.00630.x; Chen KG, 2009, JNCI-J NATL CANCER I, V101, P1259, DOI 10.1093/jnci/djp259; Chen KG, 2006, FROM MELANOCYTES TO MELANOMA: THE PROGRESSION TO MALIGNANCY, P591, DOI 10.1007/978-1-59259-994-3_33; Cirenajwis H, 2015, ONCOTARGET, V6, P12297, DOI 10.18632/oncotarget.3655; D'Mello SAN, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071144; Dror S, 2016, NAT CELL BIOL, V18, P1006, DOI 10.1038/ncb3399; Eckhart L, 2013, BBA-MOL CELL RES, V1833, P3471, DOI 10.1016/j.bbamcr.2013.06.010; Eden E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-48; Horwitz RI, 1979, J CHRON DIS, V32, pII; Houghton AN, 2002, CANCER CELL, V2, P275, DOI 10.1016/S1535-6108(02)00161-7; Jonsson G, 2010, CLIN CANCER RES, V16, P3356, DOI 10.1158/1078-0432.CCR-09-2509; Kabbarah O, 2005, CANCER CELL, V8, P439, DOI 10.1016/j.ccr.2005.11.008; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Lauss M, 2016, J INVEST DERMATOL, V136, P2502, DOI 10.1016/j.jid.2016.05.119; Lazova R, 2009, EXP DERMATOL, V18, P934, DOI 10.1111/j.1600-0625.2009.00933.x; Leonardi GC, 2018, INT J ONCOL, V52, P1071, DOI 10.3892/ijo.2018.4287; Levy C, 2006, TRENDS MOL MED, V12, P406, DOI 10.1016/j.molmed.2006.07.008; Lin JY, 2007, NATURE, V445, P843, DOI 10.1038/nature05660; Liu XW, 2017, BIOMED PHARMACOTHER, V88, P595, DOI 10.1016/j.biopha.2017.01.112; Loh WY, 1997, STAT SINICA, V7, P815; Manieri NA, 2017, TRENDS IMMUNOL, V38, P20, DOI 10.1016/j.it.2016.10.002; Martins WK, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-76; MATTHEWS NH, 2017, EPIDEMIOLOGY MELANOM, P3; Netanely D, 2019, PROMO INTERACTIVE TO, DOI 10.1101/629584; Netanely D, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-3142-5; Netanely D, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0724-2; Nsengimana J, 2015, ONCOTARGET, V6, P11683, DOI 10.18632/oncotarget.3549; Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29; Ossio R, 2017, NAT REV CANCER, V17, P393, DOI 10.1038/nrc.2017.43; Podgorelec Vili, 2002, J Med Syst, V26, P445, DOI 10.1023/A:1016409317640; PRAAGMAN J, 1985, EUR J OPER RES, V19, P144, DOI 10.1016/0377-2217(85)90321-2; Rajkumar S, 2016, BRIT J CANCER, V115, P145, DOI 10.1038/bjc.2016.195; Rambow F, 2015, CELL REP, V13, P840, DOI 10.1016/j.celrep.2015.09.037; Raposo G, 2007, NAT REV MOL CELL BIO, V8, P786, DOI 10.1038/nrm2258; Scolyer RA, 2011, MOL ONCOL, V5, P124, DOI 10.1016/j.molonc.2011.03.002; Shain AH, 2016, NAT REV CANCER, V16, P345, DOI 10.1038/nrc.2016.37; Shamir, PROMO PROFILER MULTI; Shamir R, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-232; Sher YP, 2006, CANCER RES, V66, P11763, DOI 10.1158/0008-5472.CAN-06-3165; Swetter SM, 2019, J AM ACAD DERMATOL, V80, P208, DOI 10.1016/j.jaad.2018.08.055; Tomihari M, 2009, EXP DERMATOL, V18, P586, DOI 10.1111/j.1600-0625.2008.00830.x; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Ulitsky I, 2010, NAT PROTOC, V5, P303, DOI 10.1038/nprot.2009.230; Ward WH, 2017, CUTANEOUS MELANOMA: ETIOLOGY AND THERAPY, P79, DOI 10.15586/codon.cutaneousmelanoma.2017.ch6	55	4	4	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2021	40	10					1792	1805		10.1038/s41388-021-01665-0	http://dx.doi.org/10.1038/s41388-021-01665-0		FEB 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU6VJ	33564068	Green Published, hybrid			2022-12-17	WOS:000616489100010
J	Bai, J; Yokomizo-Nakano, T; Kubota, S; Sun, YQ; Kanai, A; Iimori, M; Harada, H; Iwama, A; Sashida, G				Bai, Jie; Yokomizo-Nakano, Takako; Kubota, Sho; Sun, Yuqi; Kanai, Akinori; Iimori, Mihoko; Harada, Hironori; Iwama, Atsushi; Sashida, Goro			Overexpression of Hmga2 activates Igf2bp2 and remodels transcriptional program of Tet2-deficient stem cells in myeloid transformation	ONCOGENE			English	Article							SELF-RENEWAL; MYELOFIBROSIS; GENE; EZH2; MOUSE; PATHOGENESIS; MUTATIONS; PROTEINS; PROMOTES; BINDING	High Mobility Group AT-hook 2 (HMGA2) is a chromatin modifier and its overexpression has been found in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Level of Hmga2 expression is fine-tuned by Lin28b-Let-7 axis and Polycomb Repressive Complex 2, in which deletion of Ezh2 leads to activation of Hmga2 expression in hematopoietic stem cells. To elucidate the mechanisms by which the overexpression of HMGA2 helps transformation of stem cells harboring a driver mutation of TET2, we generated an Hmga2-expressing Tet2-deficient mouse model showing the progressive phenotypes of MDS and AML. The overexpression of Hmga2 remodeled the transcriptional program of Tet2-deficient stem and progenitor cells, leading to the impaired differentiation of myeloid cells. Furthermore, Hmga2 was bound to a proximal region of Igf2bp2 oncogene, and activated its transcription, leading to enhancing self-renewal of Tet2-deficient stem cells that was suppressed by inhibition of the DNA binding of Hmga2. These combinatory effects on the transcriptional program and cellular function were not redundant to those in Tet2-deficient cells. The present results elucidate that Hmga2 targets key oncogenic pathways during the transformation and highlight the Hmga2-Igf2bp2 axis as a potential target for therapeutic intervention.	[Bai, Jie; Yokomizo-Nakano, Takako; Kubota, Sho; Sun, Yuqi; Iimori, Mihoko; Sashida, Goro] Kumamoto Univ, Int Res Ctr Med Sci IRCMS, Lab Transcript Regulat Leukemogenesis, Kumamoto, Japan; [Kanai, Akinori] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Mol Oncol, Hiroshima, Japan; [Harada, Hironori] Tokyo Univ Pharm & Life Sci, Lab Oncol, Tokyo, Japan; [Iwama, Atsushi] Univ Tokyo, Ctr Stem Cell Biol & Regenerat Med, Inst Med Sci, Div Stem Cell & Mol Med, Tokyo, Japan	Kumamoto University; Hiroshima University; Tokyo University of Pharmacy & Life Sciences; University of Tokyo	Sashida, G (corresponding author), Kumamoto Univ, Int Res Ctr Med Sci IRCMS, Lab Transcript Regulat Leukemogenesis, Kumamoto, Japan.	sashidag@kumamoto-u.ac.jp	Sashida, Goro/N-5259-2014	Sashida, Goro/0000-0003-2318-5987; Kubota, Sho/0000-0001-6119-1259	Daiichi Sankyo Foundation of Life Science; Uehara Memorial Foundation; Princess Takamatsu Cancer Research Fund; Japanese Society of Hematology; International Joint Usage/Research Center, the Institute of Medical Science, the University of Tokyo; Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan [16KT0113, 18H02842, 19K22640, 19K08842]	Daiichi Sankyo Foundation of Life Science; Uehara Memorial Foundation(Uehara Memorial Foundation); Princess Takamatsu Cancer Research Fund; Japanese Society of Hematology; International Joint Usage/Research Center, the Institute of Medical Science, the University of Tokyo; Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	The authors thank the members of the Sashida Laboratory for their discussions during the preparation of this manuscript and Mr. Shinji Kudoh and Dr. Takaaki Ito for their technical help. This work was supported in part by a grant from the Daiichi Sankyo Foundation of Life Science (to GS), the Uehara Memorial Foundation (to GS), the Princess Takamatsu Cancer Research Fund (to GS), the Japanese Society of Hematology (to GS), International Joint Usage/Research Center, the Institute of Medical Science, the University of Tokyo (to GS), and Grants-in-Aid for Scientific Research (16KT0113, 18H02842, 19K22640 and 19K08842) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan.	Abdel-Wahab O, 2013, J EXP MED, V210, P2641, DOI 10.1084/jem.20131141; Cabezas-Wallscheid N, 2014, CELL STEM CELL, V15, P507, DOI 10.1016/j.stem.2014.07.005; Chin MT, 1998, J BIOL CHEM, V273, P9755, DOI 10.1074/jbc.273.16.9755; Cleynen I, 2007, MOL CANCER RES, V5, P363, DOI 10.1158/1541-7786.MCR-06-0331; Copley MR, 2013, NAT CELL BIOL, V15, P916, DOI 10.1038/ncb2783; Dai N, 2017, ELIFE, V6, DOI [10.7554/eLife.27155.001, 10.7554/eLife.27155]; Degrauwe N, 2016, CELL REP, V15, P1634, DOI 10.1016/j.celrep.2016.04.086; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Dutta A, 2017, BLOOD, V130, P920, DOI 10.1182/blood-2016-12-757344; Fusco A, 2007, NAT REV CANCER, V7, P899, DOI 10.1038/nrc2271; Guglielmelli P, 2007, STEM CELLS, V25, P165, DOI 10.1634/stemcells.2006-0351; Hasegawa N, 2017, LEUKEMIA, V31, P861, DOI 10.1038/leu.2016.268; He X, 2018, CELL PHYSIOL BIOCHEM, V51, P1945, DOI 10.1159/000495719; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Kishi Y, 2012, NAT NEUROSCI, V15, P1127, DOI 10.1038/nn.3165; Marquis M, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0103-6; Moran-Crusio K, 2011, CANCER CELL, V20, P11, DOI 10.1016/j.ccr.2011.06.001; Muto T, 2013, J EXP MED, V210, P2627, DOI 10.1084/jem.20131144; Nimer SD, 2008, BLOOD, V111, P4841, DOI 10.1182/blood-2007-08-078139; Nishino J, 2008, CELL, V135, P227, DOI 10.1016/j.cell.2008.09.017; Oguro H, 2012, J EXP MED, V209, P445, DOI 10.1084/jem.20111709; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Oshima M, 2016, EXP HEMATOL, V44, P282, DOI 10.1016/j.exphem.2015.12.009; Pellagatti A, 2010, LEUKEMIA, V24, P756, DOI 10.1038/leu.2010.31; Pellagatti A, 2018, BLOOD, V132, P1225, DOI 10.1182/blood-2018-04-843771; Platzbecker U, 2017, LANCET ONCOL, V18, P1338, DOI 10.1016/S1470-2045(17)30615-0; Quivoron C, 2011, CANCER CELL, V20, P25, DOI 10.1016/j.ccr.2011.06.003; Rowe RG, 2016, J EXP MED, V213, P1497, DOI 10.1084/jem.20151912; Sashida G, 2016, J EXP MED, V213, P1459, DOI 10.1084/jem.20151121; Shastri A, 2017, BLOOD, V129, P1586, DOI 10.1182/blood-2016-10-696062; Shih AH, 2012, NAT REV CANCER, V12, P599, DOI 10.1038/nrc3343; Shimizu T, 2016, J EXP MED, V213, P1479, DOI 10.1084/jem.20151136; Sperling AS, 2017, NAT REV CANCER, V17, P5, DOI 10.1038/nrc.2016.112; Sternberg A, 2005, BLOOD, V106, P2982, DOI 10.1182/blood-2005-04-1543; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Watanabe-Okochi N, 2008, BLOOD, V111, P4297, DOI 10.1182/blood-2007-01-068346; Yokomizo-Nakano T, 2020, CANCER RES, V80, P2523, DOI 10.1158/0008-5472.CAN-19-3167; Zhang XT, 2016, NAT GENET, V48, P1014, DOI 10.1038/ng.3610; Zhou T, 2015, BLOOD, V126, P1057, DOI 10.1182/blood-2015-01-624239	39	4	4	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2021	40	8					1531	1541		10.1038/s41388-020-01629-w	http://dx.doi.org/10.1038/s41388-020-01629-w		JAN 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QM6NM	33452460				2022-12-17	WOS:000607998600010
J	Cheng, FJ; Chen, CH; Tsai, WC; Wang, BW; Yu, MC; Hsia, TC; Wei, YL; Hsiao, YC; Hu, DW; Ho, CY; Li, TS; Wu, CY; Chou, WY; Yu, YL; Tang, CH; Chen, CY; Chen, CM; Hsu, JL; Chen, HF; Chen, Y; Tu, CY; Hung, MC; Huang, WC				Cheng, Fang-Ju; Chen, Chia-Hung; Tsai, Wen-Chen; Wang, Bo-Wei; Yu, Meng-Chieh; Hsia, Te-Chun; Wei, Ya-Ling; Hsiao, Yu-Chun; Hu, Dai-Wei; Ho, Chien-Yi; Li, Tzong-Shiun; Wu, Chun-Yi; Chou, Wen-Yu; Yu, Yung-Luen; Tang, Chih-Hsin; Chen, Chih-Yi; Chen, Chuan-Mu; Hsu, Jennifer L.; Chen, Hsiao-Fan; Chen, Yeh; Tu, Chih-Yen; Hung, Mien-Chie; Huang, Wei-Chien			Cigarette smoke-induced LKB1/AMPK pathway deficiency reduces EGFR TKI sensitivity in NSCLC	ONCOGENE			English	Article							CELL LUNG-CANCER; MUTATIONS; ERLOTINIB; PREDICTORS; EXPRESSION; SIGNATURE; GEFITINIB; LKB1; TRANSFORMATION; ACTIVATION	Smoker patients with non-small cell lung cancer (NSCLC) have poorer prognosis and survival than those without smoking history. However, the mechanisms underlying the low response rate of those patients to EGFR tyrosine kinase inhibitors (TKIs) are not well understood. Here we report that exposure to cigarette smoke extract enhances glycolysis and attenuates AMP-activated protein kinase (AMPK)-dependent inhibition of mTOR; this in turn reduces the sensitivity of NSCLC cells with wild-type EGFR (EGFR(WT)) to EGFR TKI by repressing expression of liver kinase B1 (LKB1), a master kinase of the AMPK subfamily, via CpG island methylation. In addition, LKB1 expression is correlated positively with sensitivity to TKI in patients with NSCLC. Moreover, combined treatment of EGFR TKI with AMPK activators synergistically increases EGFR TKI sensitivity. Collectively, the current study suggests that LKB1 may serve as a marker to predict EGFR TKI sensitivity in smokers with NSCLC carrying EGFR(WT) and that the combination of EGFR TKI and AMPK activator may be a potentially effective therapeutic strategy against NSCLC with EGFR(WT).	[Cheng, Fang-Ju; Tang, Chih-Hsin] China Med Univ, Grad Inst Basic Med Sci, Taichung 404, Taiwan; [Cheng, Fang-Ju; Hsu, Jennifer L.; Hung, Mien-Chie] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Cheng, Fang-Ju; Wang, Bo-Wei; Hu, Dai-Wei; Yu, Yung-Luen; Tang, Chih-Hsin; Hsu, Jennifer L.; Hung, Mien-Chie; Huang, Wei-Chien] China Med Univ, Grad Inst Biomed Sci, Taichung 404, Taiwan; [Chen, Chia-Hung; Hsia, Te-Chun; Tu, Chih-Yen] China Med Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Taichung 404, Taiwan; [Chen, Chia-Hung; Tang, Chih-Hsin; Tu, Chih-Yen] China Med Univ, Sch Med, Taichung 404, Taiwan; [Chen, Chia-Hung] China Med Univ, Dept Resp Therapy, Taichung 404, Taiwan; [Chen, Chia-Hung] Taiwan Clin Trial Consortium Lung Dis TCoC, Taichung 404, Taiwan; [Tsai, Wen-Chen; Chou, Wen-Yu] China Med Univ, Dept Hlth Serv Adm, Taichung 406, Taiwan; [Yu, Meng-Chieh; Wei, Ya-Ling; Hsiao, Yu-Chun; Yu, Yung-Luen; Chen, Hsiao-Fan; Hung, Mien-Chie; Huang, Wei-Chien] China Med Univ Hosp, Ctr Mol Med, Taichung 404, Taiwan; [Ho, Chien-Yi] China Med Univ, Dept Biomed Imaging & Radiol Sci, Taichung 404, Taiwan; [Ho, Chien-Yi] China Med Univ, Hsinchu Hosp, Phys Examinat Ctr, Div Family Med, Hsinchu 302, Taiwan; [Ho, Chien-Yi] China Med Univ, Hsinchu Hosp, Dept Med Res, Hsinchu 302, Taiwan; [Li, Tzong-Shiun] Show Chwan Mem Hosp, Dept Plast Surg, Changhua 500, Taiwan; [Li, Tzong-Shiun] Show Chwan Mem Hosp, Innovat Res Ctr, Changhua 500, Taiwan; [Wu, Chun-Yi] Natl Yang Ming Univ, Dept Biomed Imaging & Radiol Sci, Taipei 112, Taiwan; [Yu, Yung-Luen; Hung, Mien-Chie; Huang, Wei-Chien] China Med Univ, PhD Program Canc Biol & Drug Discovery, Taichung 404, Taiwan; [Yu, Yung-Luen; Chen, Hsiao-Fan; Chen, Yeh; Hung, Mien-Chie] China Med Univ, Inst New Drug Dev, Taichung 404, Taiwan; [Yu, Yung-Luen; Chen, Yeh; Huang, Wei-Chien] China Med Univ, Res Ctr Canc Biol, Drug Dev Ctr, Taichung 404, Taiwan; [Yu, Yung-Luen; Chen, Yeh; Hung, Mien-Chie; Huang, Wei-Chien] Asia Univ, Dept Biotechnol, Taichung 413, Taiwan; [Tang, Chih-Hsin] China Med Univ, Chinese Med Res Ctr, Taichung 404, Taiwan; [Chen, Chih-Yi] Chung Shan Med Univ, Inst Med, Taichung 402, Taiwan; [Chen, Chih-Yi] Chung Shan Med Univ Hosp, Dept Surg, Div Thorac Surg, Taichung 402, Taiwan; [Chen, Chuan-Mu] Natl Chung Hsing Univ, Dept Life Sci, Taichung 402, Taiwan; [Chen, Chuan-Mu] Natl Chung Hsing Univ, PhD Program Translat Med, Taichung 402, Taiwan; [Chen, Chuan-Mu] Natl Chung Hsing Univ, IEGG & Anim Biotechnol Ctr, Taichung 402, Taiwan	China Medical University Taiwan; University of Texas System; UTMD Anderson Cancer Center; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; Show Chwan Memorial Hospital; Show Chwan Memorial Hospital; National Yang Ming Chiao Tung University; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; Asia University Taiwan; China Medical University Taiwan; Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University Hospital; National Chung Hsing University; National Chung Hsing University; National Chung Hsing University	Hung, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.; Hung, MC; Huang, WC (corresponding author), China Med Univ, Grad Inst Biomed Sci, Taichung 404, Taiwan.; Tu, CY (corresponding author), China Med Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Taichung 404, Taiwan.; Tu, CY (corresponding author), China Med Univ, Sch Med, Taichung 404, Taiwan.; Hung, MC; Huang, WC (corresponding author), China Med Univ Hosp, Ctr Mol Med, Taichung 404, Taiwan.; Hung, MC; Huang, WC (corresponding author), China Med Univ, PhD Program Canc Biol & Drug Discovery, Taichung 404, Taiwan.; Hung, MC (corresponding author), China Med Univ, Inst New Drug Dev, Taichung 404, Taiwan.; Huang, WC (corresponding author), China Med Univ, Res Ctr Canc Biol, Drug Dev Ctr, Taichung 404, Taiwan.; Hung, MC; Huang, WC (corresponding author), Asia Univ, Dept Biotechnol, Taichung 413, Taiwan.	chesttu@gmail.com; mhung@cmu.edu.tw; whuang@mail.cmu.edu.tw	Wu, Chun-Yi/AAD-4184-2021; Hung, Mien-Chie/ABD-5911-2021; Wang, Bo/AAU-1329-2021; Chen, Chuan-Mu/K-7049-2013; Huang, Wei-Chien/D-1740-2012; Tsai, Wen-Chen/O-3095-2015	Wu, Chun-Yi/0000-0002-8217-1692; Hung, Mien-Chie/0000-0003-4317-4740; Wang, Bo/0000-0001-8947-8526; Chen, Chuan-Mu/0000-0003-2461-9150; Huang, Wei-Chien/0000-0001-6467-8716; Tsai, Wen-Chen/0000-0002-9684-0789; Cheng, Fang-Ju/0000-0001-6104-7185	Ministry of Science Technology, Taiwan [MOST 108-2314-B-039-056, MOST 108-2314-B-039-053]; Ministry of Education (The International Co-cultivation of Talent), China Medical University [CMU106-ASIA-18, CMU107-TU-06]; China Medical University Hospital [DMR-107-023, DMR-108-021]	Ministry of Science Technology, Taiwan; Ministry of Education (The International Co-cultivation of Talent), China Medical University; China Medical University Hospital	This study was supported in part by grants from the Ministry of Science Technology, Taiwan (MOST 108-2314-B-039-056 and MOST 108-2314-B-039-053), the Ministry of Education (The International Co-cultivation of Talent), China Medical University (CMU106-ASIA-18 and CMU107-TU-06), and China Medical University Hospital (DMR-107-023 and DMR-108-021). Experiments and data analysis were performed in part through the use of the Medical Research Core Facilities, Office of Research & Development at China Medical University, Taichung, Taiwan, R.O.C. We thank Chung Shan Medical University for the Seahorse XF24<SUP>e</SUP> Analysis and the Center for Advanced Molecular Imaging and Translation of Chang Gung Memorial Hospital for the analysis with Micro Positron Emission Tomography (MicroPET) system.	An Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047919; Arrieta O, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2658-6; Barupal DK, 2016, CHEM RES TOXICOL, V29, P1818, DOI 10.1021/acs.chemrestox.6b00187; Carey KD, 2006, CANCER RES, V66, P8163, DOI 10.1158/0008-5472.CAN-06-0453; Cha JH, 2018, MOL CELL, V71, P606, DOI 10.1016/j.molcel.2018.07.030; Clark GM, 2006, CLIN LUNG CANCER, V7, P389, DOI 10.3816/CLC.2006.n.022; Daijo H, 2016, SCI REP-UK, V6, DOI 10.1038/srep34424; Der SD, 2014, J THORAC ONCOL, V9, P59, DOI 10.1097/JTO.0000000000000042; Douillard JY, 2010, J CLIN ONCOL, V28, P744, DOI 10.1200/JCO.2009.24.3030; Filosto S, 2012, MOL CANCER THER, V11, P795, DOI 10.1158/1535-7163.MCT-11-0698; Fueger BJ, 2006, J NUCL MED, V47, P999; Gao B, 2010, J THORAC ONCOL, V5, P1130, DOI 10.1097/JTO.0b013e3181e05016; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Gleeson FC, 2015, J THORAC ONCOL, V10, P531, DOI 10.1097/JTO.0000000000000391; He TY, 2014, ANN SURG ONCOL, V21, pS703, DOI 10.1245/s10434-014-3824-1; Huang YH, 2013, ASIAN PAC J CANCER P, V14, P1985, DOI 10.7314/APJCP.2013.14.3.1985; Jorgensen E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-229; Kim MS, 2010, INT J CANCER, V127, P269, DOI 10.1002/ijc.25057; Koivunen JP, 2008, BRIT J CANCER, V99, P245, DOI 10.1038/sj.bjc.6604469; Li YY, 2018, J CELL BIOCHEM, V119, P8909, DOI 10.1002/jcb.27144; Midha A, 2015, AM J CANCER RES, V5, P2892; Min HY, 2017, CLIN CANCER RES, V23, P1299, DOI 10.1158/1078-0432.CCR-16-0534; Mitsudomi T, 2014, TRANSL LUNG CANCER R, V3, P205, DOI 10.3978/j.issn.2218-6751.2014.08.04; Morgillo F, 2017, ESMO OPEN, V2, DOI 10.1136/esmoopen-2016-000132; Nakamura Y, 2010, J THORAC ONCOL, V5, P1404, DOI 10.1097/JTO.0b013e3181e59a7b; Okayama H, 2012, CANCER RES, V72, P100, DOI 10.1158/0008-5472.CAN-11-1403; Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264-6021:3480607; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shiah SG, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00644-z; Siu LL, 2007, J CLIN ONCOL, V25, P2178, DOI 10.1200/JCO.2006.07.6547; Song M.A., 2017, JNCI-J NATL CANCER I, V109; Sun RJ, 2015, INT J CLIN EXP MED, V8, P14070; Suter M, 2006, J BIOL CHEM, V281, P32207, DOI 10.1074/jbc.M606357200; Tarca AL, 2013, BIOINFORMATICS, V29, P2892, DOI 10.1093/bioinformatics/btt492; Tennis MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032921; Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736; Tu CY, 2018, MOL ONCOL, V12, P705, DOI 10.1002/1878-0261.12193; Vanden Heuvel JP, 2018, ELIFE, V7; Vaz M, 2017, CANCER CELL, V32, P360, DOI 10.1016/j.ccell.2017.08.006; Wu JY, 2011, LUNG CANCER, V72, P205, DOI 10.1016/j.lungcan.2010.08.013; Xie Y, 2011, CLIN CANCER RES, V17, P5705, DOI 10.1158/1078-0432.CCR-11-0196; Zeng J, 2013, BIOMED RES INT, V2013, DOI DOI 10.1155/2013/658126; Zeng Q, 2019, THORAC CANCER, V10, P1717, DOI 10.1111/1759-7714.13141; Zhang HY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25702-3; Zhao Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.60	47	4	4	3	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2021	40	6					1162	1175		10.1038/s41388-020-01597-1	http://dx.doi.org/10.1038/s41388-020-01597-1		DEC 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QG0OL	33335306	Green Published, hybrid			2022-12-17	WOS:000599788200001
J	Luo, JH; Liu, S; Tao, JY; Ren, BG; Luo, K; Chen, ZH; Nalesnik, M; Cieply, K; Ma, TZ; Cheng, SY; Chen, Q; Michalopoulos, GK; Nelson, JB; Bhargava, R; Zhang, J; Ma, DQ; Jarrard, D; Pennathur, A; Luketich, JD; DeFranco, DB; Monga, SP; Tseng, G; Yu, YP				Luo, Jian-Hua; Liu, Silvia; Tao, Junyan; Ren, Bao-Guo; Luo, Katherine; Chen, Zhang-Hui; Nalesnik, Michael; Cieply, Kathleen; Ma, Tianzhou; Cheng, Shi-Yuan; Chen, Qi; Michalopoulos, George K.; Nelson, Joel B.; Bhargava, Rohit; Zhang, Jun; Ma, Deqin; Jarrard, David; Pennathur, Arjun; Luketich, James D.; DeFranco, Donald B.; Monga, Satdarshan Paul; Tseng, George; Yu, Yan-Ping			Pten-NOLC1 fusion promotes cancers involving MET and EGFR signalings	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; NF-KAPPA-B; TUMOR-SUPPRESSOR; ONCOGENIC ACTIVITY; PROSTATE-CANCER; PTEN; GENE; MAINTENANCE; NUCLEOLAR; NOPP140	Inactivation of Pten gene through deletions and mutations leading to excessive pro-growth signaling pathway activations frequently occurs in cancers. Here, we report a Pten derived pro-cancer growth gene fusion Pten-NOLC1 originated from a chr10 genome rearrangement and identified through a transcriptome sequencing analysis of human cancers. Pten-NOLC1 fusion is present in primary human cancer samples and cancer cell lines from different organs. The product of Pten-NOLC1 is a nuclear protein that interacts and activates promoters of EGFR, c-MET, and their signaling molecules. Pten-NOLC1 promotes cancer proliferation, growth, invasion, and metastasis, and reduces the survival of animals xenografted with Pten-NOLC1-expressing cancer cells. Genomic disruption of Pten-NOLC1 induces cancer cell death, while genomic integration of this fusion gene into the liver coupled with somatic Pten deletion produces spontaneous liver cancers in mice. Our studies indicate that Pten-NOLC1 gene fusion is a driver for human cancers.	[Luo, Jian-Hua; Liu, Silvia; Tao, Junyan; Ren, Bao-Guo; Chen, Zhang-Hui; Nalesnik, Michael; Cieply, Kathleen; Michalopoulos, George K.; Bhargava, Rohit; Monga, Satdarshan Paul; Yu, Yan-Ping] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; [Luo, Katherine; Tseng, George] Columbia Univ, Dept Biol, 1212 Amsterdam Ave, New York, NY 10027 USA; [Ma, Tianzhou] Univ Pittsburgh, Sch Med, Dept Biostat, Pittsburgh, PA 15261 USA; [Cheng, Shi-Yuan] Northwestern Univ, Sch Med, Dept Neurol, Chicago, IL 60611 USA; [Chen, Qi] Univ Kansas, Dept Pharmacol Toxicol & Therapeut, Kansas City, KS 66160 USA; [Nelson, Joel B.] Univ Pittsburgh, Sch Med, Dept Urol, Pittsburgh, PA 15261 USA; [Zhang, Jun] Univ Iowa, Dept Med, Iowa City, IA 52242 USA; [Ma, Deqin] Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA; [Jarrard, David] Univ Wisconsin, Dept Urol, Madison, WI 53792 USA; [Pennathur, Arjun; Luketich, James D.] Univ Pittsburgh, Sch Med, Dept Thorac Surg, Pittsburgh, PA 15261 USA; [DeFranco, Donald B.] Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; [Ma, Tianzhou] Univ Maryland, Sch Publ Hlth, Dept Epidemiol & Biostat, College Pk, MD 20742 USA; [Zhang, Jun] Univ Kansas, Med Ctr, Dept Med, Kansas City, KS 66160 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Columbia University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Northwestern University; University of Kansas; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Iowa; University of Iowa; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University System of Maryland; University of Maryland College Park; University of Kansas; University of Kansas Medical Center	Luo, JH; Yu, YP (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA.	luoj@msx.upmc.edu; ypyu@pitt.edu	Luo, jian/HGE-7331-2022; Ma, Tianzhou/AAC-8221-2021; Yu, Yan/GYV-4514-2022	Ma, Tianzhou/0000-0003-3605-0811; Luo, Jianhua/0000-0002-3189-4225; Cheng, Shiyuan/0000-0003-1737-0588; Zhang, Jun/0000-0001-7886-6187	NCI NIH HHS [P30 CA086862, R56 CA229262, R01 CA250227, R01 CA098249, R01 CA251155] Funding Source: Medline; NIDDK NIH HHS [P30 DK120531] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baker SJ, 2007, CELL, V128, P25, DOI 10.1016/j.cell.2006.12.023; BENSON ES, 1961, POSTGRAD MED, V30, pA22; Chen HK, 1999, MOL CELL BIOL, V19, P8536; Chen ZH, 2017, GASTROENTEROLOGY, V153, P1120, DOI 10.1053/j.gastro.2016.12.036; Chen ZH, 2017, NAT BIOTECHNOL, V35, P543, DOI 10.1038/nbt.3843; Chen ZH, 2015, J BIOL CHEM, V290, P1404, DOI 10.1074/jbc.M114.622761; Gao XS, 2011, BMB REP, V44, P70, DOI 10.5483/BMBRep.2011.44.1.70; Han YC, 2013, J PATHOL, V230, P184, DOI 10.1002/path.4169; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He DM, 2017, ONCOGENE, V36, P3629, DOI 10.1038/onc.2017.123; Hwang YC, 2009, AM J PATHOL, V175, P342, DOI 10.2353/ajpath.2009.080931; Isaac C, 1998, J CELL BIOL, V142, P319, DOI 10.1083/jcb.142.2.319; Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Lee YM, 1996, MOL CELL BIOL, V16, P4257; Li AG, 2006, MOL CELL, V23, P575, DOI 10.1016/j.molcel.2006.06.028; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Litovchick L, 2007, MOL CELL, V26, P539, DOI 10.1016/j.molcel.2007.04.015; Luo JH, 2015, AM J PATHOL, V185, P1834, DOI 10.1016/j.ajpath.2015.03.008; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; McCubrey JA, 2006, ADV ENZYME REGUL, V46, P249, DOI 10.1016/j.advenzreg.2006.01.004; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; PAI CY, 1995, J CELL SCI, V108, P1911; Ran FA, 2013, CELL, V154, P1380, DOI 10.1016/j.cell.2013.08.021; Renvoise B, 2009, HUM MOL GENET, V18, P1181, DOI 10.1093/hmg/ddp009; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Tsai YT, 2008, J BIOMED SCI, V15, P471, DOI 10.1007/s11373-007-9226-7; Wang X, 2002, MOL CELL, V9, P411, DOI 10.1016/S1097-2765(02)00439-2; Yan-Ping Y., 2019, ONCOTARGET; Yin Y, 2008, ONCOGENE, V27, P5443, DOI 10.1038/onc.2008.241; Yu GY, 2006, AM J PATHOL, V168, P597, DOI 10.2353/ajpath.2006.050620; Yu YP, 2014, AM J PATHOL, V184, P2840, DOI 10.1016/j.ajpath.2014.06.025; Yu YP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092820; Yu Yan-Ping, 2019, Oncotarget, V10, P3352; Yu YP, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38550-6; Zuo ZH, 2017, MOL CARCINOGEN, V56, P315, DOI 10.1002/mc.22494	40	4	4	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2021	40	6					1064	1076		10.1038/s41388-020-01582-8	http://dx.doi.org/10.1038/s41388-020-01582-8		DEC 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QG0OL	33323972	Green Accepted			2022-12-17	WOS:000599126500006
J	Na, YJ; Hall, A; Choi, KM; Hu, L; Rose, J; Coover, RA; Miller, A; Hennigan, RF; Dombi, E; Kim, MO; Subramanian, S; Ratner, N; Wu, JQ				Na, Youjin; Hall, Ashley; Choi, Kwangmin; Hu, Liang; Rose, Jonathan; Coover, Robert A.; Miller, Adam; Hennigan, Robert F.; Dombi, Eva; Kim, Mi-Ok; Subramanian, Subbaya; Ratner, Nancy; Wu, Jianqiang			MicroRNA-155 contributes to plexiform neurofibroma growth downstream of MEK	ONCOGENE			English	Article							IN-VIVO; SCHWANN-CELLS; MOUSE MODEL; MIR-155; CANCER; DIFFERENTIATION; INHIBITION; ACTIVATION; TYPE-1; ROLES	MicroRNAs (miRs) are small non-coding RNAs that can have large impacts on oncogenic pathways. Possible functions of dysregulated miRs have not been studied in neurofibromatosis type 1 (NF1) plexiform neurofibromas (PNFs). In PNFs, Schwann cells (SCs) have biallelic NF1 mutations necessary for tumorigenesis. We analyzed a miR microarray comparing with normal and PNF SCs and identified differences in miR expression, and we validated in mouse PNFs versus normal mouse SCs by qRT-PCR. Among these, miR-155 was a top overexpressed miR, and its expression was regulated by RAS/MAPK signaling. Overexpression of miR-155 increased mature Nf1(-/-) mouse SC proliferation. In SC precursors, which model tumor-initiating cells, pharmacological and genetic inhibition of miR-155 decreased PNF-derived sphere numbers in vitro, and we identified Maf as a miR-155 target. In vivo, global deletion of miR-155 significantly decreased tumor number and volume, increasing mouse survival. Fluorescent nanoparticles entered PNFs, suggesting that an anti-miR might have therapeutic potential. However, treatment of established PNFs using anti-miR-155 peptide nucleic acid-loaded nanoparticles marginally decreased tumor numbers and did not reduce tumor growth. These results suggest that miR-155 plays a functional role in PNF growth and/or SC proliferation, and that targeting neurofibroma miRs is feasible, and might provide novel therapeutic opportunities.	[Na, Youjin; Hall, Ashley; Choi, Kwangmin; Hu, Liang; Rose, Jonathan; Coover, Robert A.; Miller, Adam; Hennigan, Robert F.; Ratner, Nancy; Wu, Jianqiang] Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Div Expt Hematol & Canc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA; [Dombi, Eva] NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA; [Kim, Mi-Ok] UCSF, Dept Epidemiol & Biostat, Box 0128,1450 3rd St,Suite 285, San Francisco, CA 94143 USA; [Subramanian, Subbaya] Univ Minnesota, Dept Surg, Minneapolis, MN 55455 USA; [Ratner, Nancy; Wu, Jianqiang] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45267 USA; [Coover, Robert A.] High Point Univ, Fred Wilson Sch Pharm, Pharmaceut Sci, One Univ Pkwy, High Point, NC 27268 USA	Cincinnati Children's Hospital Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Francisco; University of Minnesota System; University of Minnesota Twin Cities; University System of Ohio; University of Cincinnati	Wu, JQ (corresponding author), Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Div Expt Hematol & Canc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.; Wu, JQ (corresponding author), Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45267 USA.	Jianqiang.wu@cchmc.org		Coover, Robert/0000-0001-8153-6912; RATNER, NANCY/0000-0001-5030-9354; Rose, Jonathan/0000-0002-6262-2433	NIH [R01 NS097233, NIH R0 NS28840, R37 NS096356]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Drs. Mark Saltzman and Christopher J. Cheng (Yale School of Engineering and Applied Science) for providing fluorescence-conjugated nanoparticles to fulfill part of the in vivo experiments. This work was supported by NIH R01 NS097233 to J.W. NIH R0 NS28840 and R37 NS096356 to N.R.	Babar IA, 2012, P NATL ACAD SCI USA, V109, pE1695, DOI 10.1073/pnas.1201516109; Banerjee A, 2010, EUR J IMMUNOL, V40, P225, DOI 10.1002/eji.200939381; Baulcombe D, 2002, SCIENCE, V297, P2002, DOI 10.1126/science.1077906; Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005; Boyd KP, 2009, J AM ACAD DERMATOL, V61, P1, DOI 10.1016/j.jaad.2008.12.051; Brundage ME, 2014, ONCOGENE, V33, P5626, DOI 10.1038/onc.2013.506; Chai GL, 2010, CANCER SCI, V101, P1997, DOI 10.1111/j.1349-7006.2010.01616.x; Chen ZG, 2019, CANCER DISCOV, V9, P114, DOI 10.1158/2159-8290.CD-18-0151; Chene CJ, 2011, BIOMATERIALS, V32, P6194, DOI 10.1016/j.biomaterials.2011.04.053; Dombi E, 2016, NEW ENGL J MED, V375, P2550, DOI 10.1056/NEJMoa1605943; Fabani MM, 2010, NUCLEIC ACIDS RES, V38, P4466, DOI 10.1093/nar/gkq160; Ganguly S, 2008, OLIGONUCLEOTIDES, V18, P277, DOI 10.1089/oli.2008.0140; Gong M, 2012, NEURO-ONCOLOGY, V14, P1007, DOI 10.1093/neuonc/nos124; Gordon JEA, 2013, BRIT J HAEMATOL, V162, P162, DOI 10.1111/bjh.12364; Gross AM, 2020, NEW ENGL J MED, V382, P1430, DOI 10.1056/NEJMoa1912735; Hall A, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau8389; Higgs Gadareth, 2013, J Clin Bioinforma, V3, P17, DOI 10.1186/2043-9113-3-17; Jessen WJ, 2013, J CLIN INVEST, V123, P340, DOI 10.1172/JCI60578; Jiang S, 2012, EMBO J, V31, P1985, DOI 10.1038/emboj.2012.45; John B, 2005, PLOS BIOL, V3, P1328, DOI 10.1371/journal.pbio.0030264; Jousma E, 2015, PEDIATR BLOOD CANCER, V62, P1709, DOI 10.1002/pbc.25546; Kim M, 2018, GENE DEV, V32, P645, DOI 10.1101/gad.310490.117; Kluiver J, 2005, J PATHOL, V207, P243, DOI 10.1002/path.1825; Kraniak JM, 2010, MOL CELL BIOCHEM, V344, P267, DOI 10.1007/s11010-010-0551-1; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Le LQ, 2007, ONCOGENE, V26, P4609, DOI 10.1038/sj.onc.1210261; Liu M, 2020, J CLIN INVEST, V130, P2081, DOI 10.1172/JCI131335; Ma L, 2010, NAT BIOTECHNOL, V28, P341, DOI 10.1038/nbt.1618; Martin Elizabeth C, 2014, Genes Cancer, V5, P353; MCCORMICK F, 1995, CURR OPIN GENET DEV, V5, P51, DOI 10.1016/S0959-437X(95)90053-5; Miller SJ, 2009, EMBO MOL MED, V1, P236, DOI 10.1002/emmm.200900027; Miller SJ, 2006, CANCER RES, V66, P2584, DOI 10.1158/0008-5472.CAN-05-3330; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; O'Connell RM, 2010, NAT REV IMMUNOL, V10, P111, DOI 10.1038/nri2708; Prada CE, 2013, ACTA NEUROPATHOL, V125, P159, DOI 10.1007/s00401-012-1056-7; Presneau N, 2013, BRIT J CANCER, V108, P964, DOI 10.1038/bjc.2012.518; Radomska KJ, 2019, CANCER DISCOV, V9, P130, DOI 10.1158/2159-8290.CD-18-0156; Ratner N, 2015, NAT REV CANCER, V15, P290, DOI 10.1038/nrc3911; Rice FL, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216527; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253; Sherman LS, 2001, METHOD ENZYMOL, V333, P348; Solomon J, 2004, COMPUT MED IMAG GRAP, V28, P257, DOI 10.1016/j.compmedimag.2004.03.002; Su W, 2014, J IMMUNOL, V192, P358, DOI 10.4049/jimmunol.1301397; Subramanian S, 2010, J PATHOL, V220, P58, DOI 10.1002/path.2633; Thai TH, 2007, SCIENCE, V316, P604, DOI 10.1126/science.1141229; Trotta R, 2013, BLOOD, V121, P3126, DOI 10.1182/blood-2012-12-467597; Varan A, 2016, CLIN GENET, V89, P341, DOI 10.1111/cge.12625; Vasilatou D, 2010, EUR J HAEMATOL, V84, P1, DOI 10.1111/j.1600-0609.2009.01348.x; Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]; Wu JQ, 2008, CANCER CELL, V13, P105, DOI 10.1016/j.ccr.2007.12.027; Wu JQ, 2016, CELL REP, V14, P1979, DOI 10.1016/j.celrep.2016.01.074; Wu JQ, 2012, PEDIATR BLOOD CANCER, V58, P173, DOI 10.1002/pbc.23015; Xiao CC, 2007, CELL, V131, P146, DOI 10.1016/j.cell.2007.07.021; Yin QY, 2008, J BIOL CHEM, V283, P2654, DOI 10.1074/jbc.M708218200; Zhang C, 2015, DIABETES-METAB RES, V31, P773, DOI 10.1002/dmrr.2676; Zhang Y, 2012, BLOOD, V120, P1678, DOI 10.1182/blood-2012-02-410647; Zheng H, 2008, CANCER CELL, V13, P117, DOI 10.1016/j.ccr.2008.01.002; Zhou Y, 2019, CLIN NEUROL NEUROSUR, V176, P103, DOI 10.1016/j.clineuro.2018.12.005; Zhu Y, 2002, SCIENCE, V296, P920, DOI 10.1126/science.1068452	60	4	4	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2021	40	5					951	963		10.1038/s41388-020-01581-9	http://dx.doi.org/10.1038/s41388-020-01581-9		DEC 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC5NB	33293695	Green Accepted			2022-12-17	WOS:000599053400002
J	Han, CH; Zhang, AL; Liu, ZD; Moore, C; Fu, YX				Han, Chuanhui; Zhang, Anli; Liu, Zhida; Moore, Casey; Fu, Yang-Xin			Small molecular drugs reshape tumor microenvironment to synergize with immunotherapy	ONCOGENE			English	Review							DEPENDENT ANTITUMOR IMMUNITY; ARYL-HYDROCARBON RECEPTOR; PD-L1 EXPRESSION; STING ACTIVATION; T-CELLS; INHIBITION; INDUCTION; BLOCKADE; CDK4/6; MERTK	Recently, immune checkpoint blockade (ICB), especially anti-programmed death 1 (anti-PD-1) and anti-programmed death-ligand 1 (anti-PD-L1) therapy, has become an increasingly appealing therapeutic strategy for cancer patients. However, only a small portion of patients responds to anti-PD treatment. Therefore, treatment strategies are urgently needed to reverse the ICB-resistant tumor microenvironment (TME). It has become clear that the TME has diminished innate sensing that is critical to activate adaptive immunity. In addition, tumor cells upregulate various immunosuppressive factors to diminish the immune response and resist immunotherapy. In this review, we briefly update the current small molecular drugs that could synergize with immunotherapy, especially anti-PD therapy. We will discuss the modes of action by those drugs including inducing innate sensing and limiting immunosuppressive factors in the TME.	[Han, Chuanhui; Zhang, Anli; Liu, Zhida; Moore, Casey; Fu, Yang-Xin] UT Southwestern Med Ctr, Dept Pathol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Fu, YX (corresponding author), UT Southwestern Med Ctr, Dept Pathol, Dallas, TX 75390 USA.	Yang-Xin.Fu@utsouthwestern.edu		fu, yang-xin/0000-0001-8441-6617; ZHANG, ANLI/0000-0001-7847-6541	Cancer Prevention and Research Institute of Texas (CPRIT) [RR150072]	Cancer Prevention and Research Institute of Texas (CPRIT)	We thank members of Prof. Yang-Xin Fu lab for fruitful discussions. This work was supported by Cancer Prevention and Research Institute of Texas (CPRIT) grant RR150072 given to Y-XF.	Ahn J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4723; Al-Obeidi FA, 2000, ONCOGENE, V19, P5690, DOI 10.1038/sj.onc.1203926; [Anonymous], 2020, J CLIN ONCOL, DOI DOI 10.1200/JCO.2020.38.15_suppl.1051; Antonioli L, 2013, TRENDS MOL MED, V19, P355, DOI 10.1016/j.molmed.2013.03.005; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Beaver JA, 2015, CLIN CANCER RES, V21, P4760, DOI 10.1158/1078-0432.CCR-15-1185; Bosurgi L, 2017, SCIENCE, V356, P1072, DOI 10.1126/science.aai8132; Botti G, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1150-7; Bryn T, 2008, INT IMMUNOL, V20, P235, DOI 10.1093/intimm/dxm134; Cheng BB, 2018, EUR J MED CHEM, V157, P582, DOI 10.1016/j.ejmech.2018.08.028; Cook RS, 2013, J CLIN INVEST, V123, P3231, DOI 10.1172/JCI67655; Corrales L, 2015, CELL REP, V11, P1018, DOI 10.1016/j.celrep.2015.04.031; Crittenden MR, 2016, ONCOTARGET, V7, P78653, DOI 10.18632/oncotarget.11823; Deng JH, 2018, CANCER DISCOV, V8, P216, DOI 10.1158/2159-8290.CD-17-0915; Deng LF, 2014, IMMUNITY, V41, P843, DOI 10.1016/j.immuni.2014.10.019; Di Virgilio F, 2018, NAT REV CANCER, V18, P601, DOI 10.1038/s41568-018-0037-0; Ding LY, 2018, CELL REP, V25, P2972, DOI 10.1016/j.celrep.2018.11.054; Du WT, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.124184; Galluzzi L, 2007, CELL DEATH DIFFER, V14, P1237, DOI 10.1038/sj.cdd.4402148; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Gandhi R, 2010, NAT IMMUNOL, V11, P846, DOI 10.1038/ni.1915; Giampazolias E, 2017, NAT CELL BIOL, V19, P1116, DOI 10.1038/ncb3596; Goel S, 2017, NATURE, V548, P471, DOI 10.1038/nature23465; Guo ZQ, 2017, ONCOTARGET, V8, P89761, DOI 10.18632/oncotarget.21125; Gutierrez-Vazquez C, 2018, IMMUNITY, V48, P19, DOI 10.1016/j.immuni.2017.12.012; Hamilton E, 2016, CANCER TREAT REV, V45, P129, DOI 10.1016/j.ctrv.2016.03.002; Han CH, 2020, NAT IMMUNOL, V21, P546, DOI 10.1038/s41590-020-0641-5; Heidegger S, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aau8943; Hoglen NC, 2004, J PHARMACOL EXP THER, V309, P634, DOI 10.1124/jpet.103.062034; Holmgaard RB, 2013, J EXP MED, V210, P1389, DOI 10.1084/jem.20130066; Holtzhausen A, 2019, CANCER IMMUNOL RES, V7, P1672, DOI 10.1158/2326-6066.CIR-19-0008; Huang Q, 2011, NAT MED, V17, P860, DOI 10.1038/nm.2385; Karavitis J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046342; Kasikara C, 2019, CANCER RES, V79, P2669, DOI 10.1158/0008-5472.CAN-18-2614; Kim H, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz5683; Kitai Y, 2017, J IMMUNOL, V198, P1649, DOI 10.4049/jimmunol.1601694; Kitanaka N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208955; Labadie BW, 2019, CLIN CANCER RES, V25, P1462, DOI 10.1158/1078-0432.CCR-18-2882; Lang XT, 2019, CANCER DISCOV, V9, P1673, DOI 10.1158/2159-8290.CD-19-0338; Lemke G, 2008, NAT REV IMMUNOL, V8, P327, DOI 10.1038/nri2303; Li XG, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11238-1; Li YK, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1074374; Liu YY, 2018, CANCER CELL, V33, P480, DOI 10.1016/j.ccell.2018.02.005; Liu ZD, 2020, CELL MOL IMMUNOL, V17, P13, DOI 10.1038/s41423-019-0341-y; Liu ZD, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aav6473; Long GV, 2019, LANCET ONCOL, V20, P1083, DOI 10.1016/S1470-2045(19)30274-8; Looby E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-190; Lu HL, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00083; Mahanonda R, 2007, J IMMUNOL, V178, P1151, DOI 10.4049/jimmunol.178.2.1151; Maj T, 2017, NAT IMMUNOL, V18, P1332, DOI 10.1038/ni.3868; Mangsbo SM, 2010, J IMMUNOTHER, V33, P225, DOI 10.1097/CJI.0b013e3181c01fcb; Mao YM, 2014, CLIN CANCER RES, V20, P4096, DOI 10.1158/1078-0432.CCR-14-0635; McKenzie JA, 2018, JNCI-J NATL CANCER I, V110, P777, DOI 10.1093/jnci/djx257; Mender I, 2020, CANCER CELL, V38, P400, DOI 10.1016/j.ccell.2020.05.020; Mender I, 2015, CANCER DISCOV, V5, P82, DOI 10.1158/2159-8290.CD-14-0609; Mezrich JD, 2010, J IMMUNOL, V185, P3190, DOI 10.4049/jimmunol.0903670; MINAKUCHI R, 1990, J IMMUNOL, V145, P2616; Munn DH, 2005, IMMUNITY, V22, P633, DOI 10.1016/j.immuni.2005.03.013; Myers KV, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1022-2; Nishii Naoto, 2018, Oncotarget, V9, P13301, DOI 10.18632/oncotarget.24327; Opitz CA, 2011, NATURE, V478, P197, DOI 10.1038/nature10491; Pantelidou C, 2019, CANCER DISCOV, V9, P722, DOI 10.1158/2159-8290.CD-18-1218; Prima V, 2017, P NATL ACAD SCI USA, V114, P1117, DOI 10.1073/pnas.1612920114; Qin X., 2010, CELL MOL BIOL, V56; Ramanjulu JM, 2018, NATURE, V564, P439, DOI 10.1038/s41586-018-0705-y; Rodriguez PC, 2002, J BIOL CHEM, V277, P21123, DOI 10.1074/jbc.M110675200; Rothlin CV, 2014, INFLAMM BOWEL DIS, V20, P1472, DOI 10.1097/MIB.0000000000000050; Sato-Kaneko F, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93397; Schaer DA, 2018, CELL REP, V22, P2978, DOI 10.1016/j.celrep.2018.02.053; Sen T, 2019, CANCER DISCOV, V9, P646, DOI 10.1158/2159-8290.CD-18-1020; Shae D, 2019, NAT NANOTECHNOL, V14, P269, DOI 10.1038/s41565-018-0342-5; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shimizu K, 2018, ANTICANCER RES, V38, P4637, DOI 10.21873/anticanres.12768; Shimizu K, 2017, CANCER MANAG RES, V9, P741, DOI 10.2147/CMAR.S146897; Sivick KE, 2018, CELL REP, V25, P3074, DOI 10.1016/j.celrep.2018.11.047; Spranger S, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/2051-1426-2-3; Steggerda SM, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0308-4; Tang HL, 2019, J PHARMACOL EXP THER, V368, P401, DOI 10.1124/jpet.118.254359; Tran L, 2017, CANCER IMMUNOL RES, V5, P1141, DOI 10.1158/2326-6066.CIR-17-0235; Tudor DV, 2020, CANCER BIOL MED, V17, P20, DOI 10.20892/j.issn.2095-3941.2019.0339; van der Zanden SY, 2020, TRENDS IMMUNOL, V41, P493, DOI 10.1016/j.it.2020.04.004; Wang ZN, 2019, J CLIN INVEST, V129, P4850, DOI 10.1172/JCI127471; Wei HF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084927; Wiemer AJ, 2011, J IMMUNOL, V187, P3663, DOI 10.4049/jimmunol.1100103; Wu JJ, 2020, IMMUNITY, V53, P115, DOI 10.1016/j.immuni.2020.06.009; Yang XB, 2020, ONCOLOGIST, V25, P470, DOI 10.1634/theoncologist.2019-0563; Yokoyama Y, 2019, CANCER RES, V79, P1996, DOI 10.1158/0008-5472.CAN-18-2022; Zhang JF, 2018, NATURE, V553, P91, DOI 10.1038/nature25015; Zhou Y, 2020, IMMUNITY, V52, P357, DOI 10.1016/j.immuni.2020.01.014; Zhu HF, 2018, NAT PRODUCT BIOPROSP, V8, P297, DOI 10.1007/s13659-018-0177-7; Zou WP, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7118	91	4	4	1	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2021	40	5					885	898		10.1038/s41388-020-01575-7	http://dx.doi.org/10.1038/s41388-020-01575-7		DEC 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC5NB	33288883				2022-12-17	WOS:000599011200002
J	Fountain, DM; Smith, MJ; O'Leary, C; Pathmanaban, ON; Roncaroli, F; Bobola, N; King, AT; Evans, DG				Fountain, Daniel M.; Smith, Miriam J.; O'Leary, Claire; Pathmanaban, Omar N.; Roncaroli, Federico; Bobola, Nicoletta; King, Andrew T.; Evans, Dafydd Gareth			The spatial phenotype of genotypically distinct meningiomas demonstrate potential implications of the embryology of the meninges	ONCOGENE			English	Review							GERMLINE SMARCB1 MUTATION; PROTEIN-KINASE-A; TUMOR-LOCALIZATION; TISSUE ORIGINS; CELL; CLASSIFICATION; HEDGEHOG; COMMON; FATE; BAP1	Meningiomas are the most common primary brain tumor and their incidence and prevalence is increasing. This review summarizes current evidence regarding the embryogenesis of the human meninges in the context of meningioma pathogenesis and anatomical distribution. Though not mutually exclusive, chromosomal instability and pathogenic variants affecting the long arm of chromosome 22 (22q) result in meningiomas in neural-crest cell-derived meninges, while variants affecting Hedgehog signaling, PI3K signaling, TRAF7, KLF4, and POLR2A result in meningiomas in the mesodermal-derived meninges of the midline and paramedian anterior, central, and ventral posterior skull base. Current evidence regarding the common pathways for genetic pathogenesis and the anatomical distribution of meningiomas is presented alongside existing understanding of the embryological origins for the meninges prior to proposing next steps for this work.	[Fountain, Daniel M.; O'Leary, Claire; Pathmanaban, Omar N.; Roncaroli, Federico; King, Andrew T.] Salford Royal NHS Fdn Trust, Geoffrey Jefferson Brain Res Ctr, Manchester, Lancs, England; [Fountain, Daniel M.; O'Leary, Claire; Pathmanaban, Omar N.; Roncaroli, Federico; King, Andrew T.] Univ Manchester, Manchester, Lancs, England; [Smith, Miriam J.; Evans, Dafydd Gareth] Univ Manchester, Manchester Acad Hlth Sci Ctr MAHSC, Manchester Ctr Genom Med, Sch Biol Sci,St Marys Hosp,Div Evolut & Genom Sci, Manchester, Lancs, England; [Bobola, Nicoletta] Univ Manchester, Fac Biol Med & Hlth, Sch Med Sci, Manchester, Lancs, England	Salford Royal NHS Foundation Trust; University of Manchester; University of Manchester; University of Manchester	Fountain, DM (corresponding author), Salford Royal NHS Fdn Trust, Geoffrey Jefferson Brain Res Ctr, Manchester, Lancs, England.; Fountain, DM (corresponding author), Univ Manchester, Manchester, Lancs, England.	Daniel.fountain@nhs.net	Evans, D Gareth/AAB-4308-2022	Evans, D Gareth/0000-0002-8482-5784; Pathmanaban, Omar/0000-0002-5083-9416; King, Andrew/0000-0002-6546-7248; Roncaroli, Federico/0000-0003-3650-5572; Fountain, Daniel/0000-0001-6227-9930				Aavikko M, 2012, AM J HUM GENET, V91, P520, DOI 10.1016/j.ajhg.2012.07.015; Abdel-Rahman MH, 2011, J MED GENET, V48, P856, DOI 10.1136/jmedgenet-2011-100156; Abedalthagafi M, 2016, NEURO-ONCOLOGY, V18, P649, DOI 10.1093/neuonc/nov316; Akhmametyeva EM, 2006, DEV DYNAM, V235, P2771, DOI 10.1002/dvdy.20883; ALMEFTY O, 1990, J NEUROSURG, V73, P840, DOI 10.3171/jns.1990.73.6.0840; Almefty R, 2014, J NEUROSURG, V120, P40, DOI 10.3171/2013.8.JNS13535; Batarfi M, 2017, BIOL COMMUN, V55, P6273; Belloni E, 1996, NAT GENET, V14, P353, DOI 10.1038/ng1196-353; Boetto J, 2018, ONCOGENE, V37, P4955, DOI 10.1038/s41388-018-0328-7; BONNAL J, 1980, J NEUROSURG, V53, P587, DOI 10.3171/jns.1980.53.5.0587; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Brastianos PK, 2017, VISMODEGIB FAK INHIB, P2; Brastianos PK, 2019, NEURO-ONCOLOGY, V21, pI18, DOI 10.1093/neuonc/noy136; Brastianos PK, 2013, NAT GENET, V45, P285, DOI 10.1038/ng.2526; Brodbelt AR, 2019, BRIT J NEUROSURG, V33, P641, DOI 10.1080/02688697.2019.1661965; Carbone M, 2013, NAT REV CANCER, V13, P153, DOI 10.1038/nrc3459; Catala M, 1998, EMBRYONIC FETAL DEV; Chen CM, 2011, NEUROSURG REV, V34, P281, DOI 10.1007/s10143-011-0321-x; Christiaans I, 2011, J MED GENET, V48, P93, DOI 10.1136/jmg.2010.082420; Clark VE, 2013, SCIENCE, V339, P1077, DOI 10.1126/science.1233009; Clarke VE, 2016, NAT GENET, V48, P1253, DOI 10.1038/ng.3651; COULY GF, 1992, DEVELOPMENT, V114, P1; Dasgupta K, 2019, GENESIS, V57, DOI 10.1002/dvg.23288; De Monte F, 2011, AL MEFTYS MENINGIOMA, V2nd; DeSisto J, 2020, DEV CELL, V54, P43, DOI 10.1016/j.devcel.2020.06.009; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; Fang L, IMMUNE CELL INFILTRA, DOI 10.1093/neuonc/not110; Goldbrunner R, 2016, LANCET ONCOL, V17, pE383, DOI 10.1016/S1470-2045(16)30321-7; Gutmann DH, 2002, NEOPLASIA, V4, P279, DOI 10.1038/sj.neo.7900249; Hadfield KD, 2010, J MED GENET, V47, P567, DOI 10.1136/jmg.2009.075721; HALATA Z, 1990, ANAT EMBRYOL, V182, P529; Hindley CJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep23208; Imlay SP, 1998, DIAGN CYTOPATHOL, V18, P131, DOI 10.1002/(SICI)1097-0339(199802)18:2<131::AID-DC9>3.0.CO;2-I; Jia JH, 2004, NATURE, V432, P1045, DOI 10.1038/nature03179; Jiang XB, 2000, DEVELOPMENT, V127, P1607; Jiang XB, 2002, DEV BIOL, V241, P106, DOI 10.1006/dbio.2001.0487; Kalamarides M, 2011, ONCOGENE, V30, P2333, DOI 10.1038/onc.2010.609; Kalamarides M, 2002, GENE DEV, V16, P1060, DOI 10.1101/gad.226302; Ketter R, 2008, NEUROSURGERY, V62, P61, DOI 10.1227/01.NEU.0000311062.72626.D6; Kros J, 2001, J PATHOL, V194, P367, DOI 10.1002/path.909; Kume T, 1998, CELL, V93, P985, DOI 10.1016/S0092-8674(00)81204-0; Langer LF, 2019, ELIFE, V8, DOI 10.7554/eLife.45672; Laulajainen M, 2008, ONCOGENE, V27, P3233, DOI 10.1038/sj.onc.1210988; Lopes MB., 2009, MENINGIOMAS, P25, DOI [10.1007/978-1-84628-784-8_4, DOI 10.1007/978-1-84628-784-8_4]; Magill S, 2019, NEURO-ONCOLOGY, V21, P268; Magill ST, 2019, J NEUROSURG, V131, P1179, DOI 10.3171/2018.6.JNS18118; Magill ST, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2018.1.FOCUS17753; Maguire LH, 2015, DEV DYNAM, V244, P311, DOI 10.1002/dvdy.24226; Mawrin C, 2010, J NEURO-ONCOL, V99, P379, DOI 10.1007/s11060-010-0342-2; McBratney-Owen B, 2008, DEV BIOL, V322, P121, DOI 10.1016/j.ydbio.2008.07.016; McClatchey AI, 1997, GENE DEV, V11, P1253, DOI 10.1101/gad.11.10.1253; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; Nanda A, 2008, SKULL BASE-INTERD AP, V18, P243, DOI 10.1055/s-2007-1016956; Nassiri F, 2019, NEURO-ONCOLOGY, V21, P901, DOI 10.1093/neuonc/noz061; Nie XG, 2005, ACTA ODONTOL SCAND, V63, P127, DOI 10.1080/00016350510019847; ORAHILLY R, 1986, J NEUROPATH EXP NEUR, V45, P588, DOI 10.1097/00005072-198609000-00008; Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223; Pan A, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00061; Patel AJ, 2019, P NATL ACAD SCI USA, V116, P21715, DOI 10.1073/pnas.1912858116; Petrilli AM, 2016, ONCOGENE, V35, P537, DOI 10.1038/onc.2015.125; Preusser M, 2018, NAT REV NEUROL, V14, P106, DOI 10.1038/nrneurol.2017.168; Proctor DT, 2019, NEURO-ONCOLOGY ADV, P1, DOI 10.1093/noajnl/vdz018; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Reuss DE, 2013, ACTA NEUROPATHOL, V125, P351, DOI 10.1007/s00401-013-1093-x; Riemenschneider MJ, 2006, LANCET NEUROL, V5, P1045, DOI 10.1016/S1474-4422(06)70625-1; Rowland BD, 2006, NAT REV CANCER, V6, P11, DOI 10.1038/nrc1780; Sahm F, 2017, LANCET ONCOL, V18, P682, DOI 10.1016/S1470-2045(17)30155-9; Sahm F, 2013, ACTA NEUROPATHOL, V126, P757, DOI 10.1007/s00401-013-1187-5; Schmitz U, 2001, BRIT J CANCER, V84, P199, DOI 10.1054/bjoc.2000.1583; Sensenig E, 1951, CONTR EMBRYOL, V228, P145; Shankar GM, 2017, NEURO-ONCOLOGY, V19, P535, DOI 10.1093/neuonc/now235; Siegenthaler JA, 2011, CURR OPIN GENET DEV, V21, P249, DOI 10.1016/j.gde.2010.12.005; Siegenthaler JA, 2009, CELL, V139, P597, DOI 10.1016/j.cell.2009.10.004; Smith MJ, 2017, HISTOPATHOLOGY, V70, P814, DOI 10.1111/his.13135; Smith MJ, 2015, CANCER GENET-NY, V208, P107, DOI 10.1016/j.cancergen.2015.02.003; Smith MJ, 2014, J PATHOL, V234, P436, DOI 10.1002/path.4427; Smith MJ, 2013, NAT GENET, V45, P295, DOI 10.1038/ng.2552; Smith MJ, 2012, NEUROGENETICS, V13, P141, DOI 10.1007/s10048-012-0319-8; Smith MJ, 2011, J MED GENET, V48, P261, DOI 10.1136/jmg.2010.085241; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Trainor P, 2000, NAT CELL BIOL, V2, P96, DOI 10.1038/35000051; van den Munckhof P, 2012, NEUROGENETICS, V13, P1, DOI 10.1007/s10048-011-0300-y; Vitte J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00346-5; Wada N, 2005, DEVELOPMENT, V132, P3977, DOI 10.1242/dev.01943; Wellenreuther R, 1995, ANAL NEUROFIBROMATOS; Yamashima T, 1997, J NEUROSCI, V17, P2376; Yamashima T, 2009, MENINGIOMAS, P15, DOI DOI 10.1007/978-1-84628-784-8_3; Yoshida T, 2008, MECH DEVELOP, V125, P797, DOI 10.1016/j.mod.2008.06.007; Youngblood MW, 2020, J NEUROSURG, V133, P1345, DOI 10.3171/2019.8.JNS191266; ZADOR Z, 2020, SCI REP UK, V10; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhang N, 2010, MERLIN NF2 TUMOR SUP	92	4	4	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2021	40	5					875	884		10.1038/s41388-020-01568-6	http://dx.doi.org/10.1038/s41388-020-01568-6		DEC 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC5NB	33262459	Green Published, hybrid			2022-12-17	WOS:000595928700006
J	Li, MD; Ma, DH; Chang, ZJ				Li, Mengdi; Ma, Danhui; Chang, Zhijie			Current understanding of CREPT and p15RS, carboxy-terminal domain (CTD)-interacting proteins, in human cancers	ONCOGENE			English	Review							RNA-POLYMERASE-II; PROMOTES TUMOR-GROWTH; CELL-CYCLE; TRANSCRIPTION TERMINATION; POOR-PROGNOSIS; PROLIFERATION; EXPRESSION; INTERACTS; GENE; IDENTIFICATION	CREPT and p15RS, also named RPRD1B and RPRD1A, are RPRD (regulation of nuclear pre-mRNA-domain-containing) proteins containing C-terminal domain (CTD)-interacting domain (CID), which mediates the binding to the CTD of Rpb1, the largest subunit of RNA polymerase II (RNAPII). CREPT and p15RS are highly conserved, with a common yeast orthologue Rtt103. Intriguingly, human CREPT and p15RS possess opposite functions in the regulation of cell proliferation and tumorigenesis. While p15RS inhibits cell proliferation, CREPT promotes cell cycle and tumor growth. Aberrant expression of both CREPT and p15RS was found in numerous types of cancers. At the molecular level, both CREPT and p15RS were reported to regulate gene transcription by interacting with RNAPII. However, CREPT also exerts a key function in the processes linked to DNA damage repairs. In this review, we summarized the recent studies regarding the biological roles of CREPT and p15RS, as well as the molecular mechanisms underlying their activities. Fully revealing the mechanisms of CREPT and p15RS functions will not only provide new insights into understanding gene transcription and maintenance of DNA stability in tumors, but also promote new approach development for tumor diagnosis and therapy.	[Li, Mengdi; Ma, Danhui; Chang, Zhijie] Tsinghua Univ, Sch Med, State Key Lab Membrane Biol, Beijing 100084, Peoples R China	Tsinghua University	Chang, ZJ (corresponding author), Tsinghua Univ, Sch Med, State Key Lab Membrane Biol, Beijing 100084, Peoples R China.	zhijiec@tsinghua.edu.cn		Ma, Danhui/0000-0002-0552-4300; Chang, Zhijie/0000-0003-1567-3227	Chinese National Major Scientific Research Program [2016YFA0500301]; National Natural Science Foundation of China [81830092, 81230044]	Chinese National Major Scientific Research Program; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the Chinese National Major Scientific Research Program (2016YFA0500301), and grants from the National Natural Science Foundation of China (81830092, 81230044).	Aguilera A, 2012, MOL CELL, V46, P115, DOI 10.1016/j.molcel.2012.04.009; Ali I, 2019, MOL CELL, V74, P1164, DOI 10.1016/j.molcel.2019.04.008; Barilla D, 2001, P NATL ACAD SCI USA, V98, P445, DOI 10.1073/pnas.021545298; Belotserkovskii BP, 2013, NUCLEIC ACIDS RES, V41, P1817, DOI 10.1093/nar/gks1333; Buratowski S, 2005, CURR OPIN CELL BIOL, V17, P257, DOI 10.1016/j.ceb.2005.04.003; Chapman RD, 2008, TRENDS GENET, V24, P289, DOI 10.1016/j.tig.2008.03.010; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Collin P, 2019, MOL CELL, V73, P655, DOI 10.1016/j.molcel.2018.12.002; Ding LD, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1211-8; Doerks T, 2002, GENOME RES, V12, P47, DOI 10.1101/gr.203201; Dolan ME, 2017, CLIN CANCER RES, V23, P5757, DOI 10.1158/1078-0432.CCR-16-3224; Egloff S, 2012, MOL CELL, V45, P111, DOI 10.1016/j.molcel.2011.11.006; Fan XZ, 2018, J BIOL CHEM, V293, P7618, DOI 10.1074/jbc.RA118.001969; Guhua JXY, 2003, J CHIN PATHOL, V19, P1300; Harlen KM, 2017, NAT REV MOL CELL BIO, V18, P263, DOI 10.1038/nrm.2017.10; Hsin JP, 2012, GENE DEV, V26, P2119, DOI 10.1101/gad.200303.112; Ingham RJ, 2005, MOL CELL BIOL, V25, P7092, DOI 10.1128/MCB.25.16.7092-7106.2005; Jasnovidova O, 2017, P NATL ACAD SCI USA, V114, P11133, DOI 10.1073/pnas.1712450114; Jasnovidova O, 2017, EMBO REP, V18, P906, DOI 10.15252/embr.201643723; Jiang J, 2019, CHEM-BIOL INTERACT, V302, P74, DOI 10.1016/j.cbi.2019.02.004; Jin K, 2018, J CELL BIOCHEM, V119, P1083, DOI 10.1002/jcb.26277; Jung HM, 2009, J CELL BIOCHEM, V106, P703, DOI 10.1002/jcb.22063; Kamieniarz-Gdula K, 2019, MOL CELL, V74, P158, DOI 10.1016/j.molcel.2019.01.027; Kim M, 2004, NATURE, V432, P517, DOI 10.1038/nature03041; Komor MA, 2020, INT J CANCER, V146, P1979, DOI 10.1002/ijc.32627; Kuang YS, 2018, WORLD J GASTROENTERO, V24, P475, DOI 10.3748/wjg.v24.i4.475; Li J, 2018, MOL CARCINOGEN, V57, P1408, DOI 10.1002/mc.22866; Li WM, 2018, CANCER SCI, V109, P1012, DOI 10.1111/cas.13524; Liang Z, 2017, BIOCHEM BIOPH RES CO, V493, P263, DOI 10.1016/j.bbrc.2017.09.033; Liu CX, 2015, J BIOL CHEM, V290, P9701, DOI 10.1074/jbc.M114.620872; Liu J, 2002, BIOCHEM BIOPH RES CO, V299, P880, DOI 10.1016/S0006-291X(02)02684-0; Liu T, 2016, AM J TRANSL RES, V8, P2097; Long L, 2018, J NUTR, V148, P834, DOI 10.1093/jn/nxy047; Lu DD, 2012, CANCER CELL, V21, P92, DOI 10.1016/j.ccr.2011.12.016; Lunde BM, 2010, NAT STRUCT MOL BIOL, V17, P1195, DOI 10.1038/nsmb.1893; Ma DH, 2020, THERANOSTICS, V10, P3708, DOI 10.7150/thno.41677; Ma JT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174309; Marechal A, 2014, MOL CELL, V53, P235, DOI 10.1016/j.molcel.2013.11.002; Mei KR, 2014, SCI CHINA LIFE SCI, V57, P97, DOI 10.1007/s11427-013-4589-7; Meinhart A, 2004, NATURE, V430, P223, DOI 10.1038/nature02679; Morales JC, 2014, NUCLEIC ACIDS RES, V42, P4996, DOI 10.1093/nar/gku160; Motea EA, 2018, CLIN CANCER RES, V24, P6459, DOI 10.1158/1078-0432.CCR-17-1118; Ni ZY, 2014, NAT STRUCT MOL BIOL, V21, P686, DOI 10.1038/nsmb.2853; Ni ZY, 2011, TRANSCR-AUSTIN, V2, P237, DOI 10.4161/trns.2.5.17803; Noble CG, 2005, NAT STRUCT MOL BIOL, V12, P144, DOI 10.1038/nsmb887; Park JS, 2004, CANCER LETT, V214, P19, DOI 10.1016/j.canlet.2004.04.012; Patidar PL, 2016, NUCLEIC ACIDS RES, V44, P1718, DOI 10.1093/nar/gkv1492; Patturajan M, 1998, MOL CELL BIOL, V18, P2406, DOI 10.1128/MCB.18.4.2406; Ren LL, 2019, THERANOSTICS, V9, P449, DOI 10.7150/thno.29055; Schroder S, 2013, MOL CELL, V52, P314, DOI 10.1016/j.molcel.2013.10.009; She YG, 2014, INT J CLIN EXP PATHO, V7, P6596; Srividya I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031288; STERNER DE, 1995, MOL CELL BIOL, V15, P5716; Stirling PC, 2012, GENE DEV, V26, P163, DOI 10.1101/gad.179721.111; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Sugiyama T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042962; Sun M, 2018, BIOCHEM BIOPH RES CO, V496, P1183, DOI 10.1016/j.bbrc.2018.01.167; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Tucker JF, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005873; Vasiljeva L, 2006, MOL CELL, V21, P239, DOI 10.1016/j.molcel.2005.11.028; Wang Y, 2014, ONCOL REP, V31, P1389, DOI 10.3892/or.2014.2990; Wei MH, 2019, BIOCHIMIE, V162, P116, DOI 10.1016/j.biochi.2019.04.014; Weintraub AS, 2017, CELL, V171, P1573, DOI 10.1016/j.cell.2017.11.008; Wen N, 2020, J INT MED RES, V48, DOI 10.1177/0300060519895089; Wu YY, 2010, J BIOL CHEM, V285, P34621, DOI 10.1074/jbc.M110.148791; Yu SX, 2019, INT J CLIN EXP PATHO, V12, P3301; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; Zhang XC, 2012, CELL CYCLE, V11, P1988, DOI 10.4161/cc.20400; Zhang XY, 2005, PROG BIOCHEM BIOPHYS, V32, P771; Zhang YQ, 2018, ONCOGENE, V37, P3485, DOI 10.1038/s41388-018-0161-z; Zhang YQ, 2014, J BIOL CHEM, V289, P22589, DOI 10.1074/jbc.M114.560979; Zhang ZH, 2019, BIOCHEM BIOPH RES CO, V509, P746, DOI 10.1016/j.bbrc.2018.12.176; Zheng GX, 2016, BIOCHEM BIOPH RES CO, V480, P436, DOI 10.1016/j.bbrc.2016.10.067	73	4	4	5	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2021	40	4					705	716		10.1038/s41388-020-01544-0	http://dx.doi.org/10.1038/s41388-020-01544-0		NOV 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA4GO	33239754				2022-12-17	WOS:000592629300001
J	Alula, KM; Delgado-Deida, Y; Jackson, DN; Venuprasad, K; Theiss, AL				Alula, Kibrom M.; Delgado-Deida, Yaritza; Jackson, Dakota N.; Venuprasad, K.; Theiss, Arianne L.			Nuclear partitioning of Prohibitin 1 inhibits Wnt/beta-catenin-dependent intestinal tumorigenesis	ONCOGENE			English	Article							BETA-CATENIN; PATHWAY; ACTIVATION; CELLS; AXIN; APC; EXPRESSION; CARCINOMA; PROTEINS; SURVIVAL	The Wnt/beta-catenin signaling pathway is aberrantly activated in the majority of colorectal cancer cases due to somatic mutations in the adenomatous polyposis coli (APC) gene. Prohibitin 1 (PHB1) serves pleiotropic cellular functions with dynamic subcellular trafficking, facilitating signaling crosstalk between organelles. Nuclear-localized PHB1 is an important regulator of gene transcription. Using mice with inducible intestinal epithelial cell (IEC)-specific deletion of Phb1 (Phb1(i Delta IEC)) and mice with IEC-specific overexpression of Phb1 (Phb1Tg), we demonstrate that IEC-specific PHB1 combats intestinal tumorigenesis in the Apc(Min/+) mouse model by inhibiting Wnt/beta-catenin signaling. Forced nuclear accumulation of PHB1 in human RKO or SW48 CRC cell lines increased AXIN1 expression and decreased cell viability. PHB1 deficiency in CRC cells decreased AXIN1 expression and increased beta-catenin activation that was abolished by XAV939, a pharmacological AXIN stabilizer. These results define a role of PHB1 in inhibiting the Wnt/beta-catenin pathway to influence the development of intestinal tumorigenesis. Induction of nuclear PHB1 trafficking provides a novel therapeutic option to influence AXIN1 expression and the beta-catenin destruction complex in Wnt-driven intestinal tumorigenesis.	[Alula, Kibrom M.; Delgado-Deida, Yaritza; Theiss, Arianne L.] Univ Colorado, Dept Med, Div Gastroenterol & Hepatol, Aurora, CO 80045 USA; [Jackson, Dakota N.] Baylor Univ, Med Ctr, Baylor Scott & White Res Inst, Dept Internal Med,Div Gastroenterol, Dallas, TX USA; [Venuprasad, K.] Univ Texas Southwestern Med Ctr Dallas, Coll Med, Dallas, TX 75390 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Baylor Health Care System; Baylor University; Baylor University Medical Center; University of Texas System; University of Texas Southwestern Medical Center Dallas	Theiss, AL (corresponding author), Univ Colorado, Dept Med, Div Gastroenterol & Hepatol, Aurora, CO 80045 USA.	arianne.theiss@cuanschutz.edu		poojary, venuprasd/0000-0001-8986-9092	National Institutes of Health [R01-DK117001]; Litwin IBD Pioneers Crohn's Colitis Foundation [301869]; GI & Liver Innate Immune Program (GALIIP)-University of Colorado Anschutz	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Litwin IBD Pioneers Crohn's Colitis Foundation; GI & Liver Innate Immune Program (GALIIP)-University of Colorado Anschutz	We thank Jie Han (Baylor Scott & White Research Institute) for technical assistance. This work was supported by National Institutes of Health grants R01-DK117001 (ALT), Litwin IBD Pioneers Crohn's Colitis Foundation 301869 (ALT), and GI & Liver Innate Immune Program (GALIIP)-University of Colorado Anschutz (ALT).	Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Basmadjian C, 2013, FUTURE MED CHEM, V5, P2185, DOI 10.4155/fmc.13.177; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bourges I, 2004, BIOCHEM J, V383, P491, DOI 10.1042/BJ20040256; Chen DB, 2010, INT J ONCOL, V37, P355, DOI 10.3892/ijo_00000684; Chia IV, 2005, MOL CELL BIOL, V25, P4371, DOI 10.1128/MCB.25.11.4371-4376.2005; Chiu CF, 2013, ONCOGENE, V32, P777, DOI 10.1038/onc.2012.86; Chowdhury D, 2017, CURR DRUG TARGETS, V18, P1836, DOI 10.2174/1389450117666160824161225; Cormier RT, 2000, ONCOGENE, V19, P3182, DOI 10.1038/sj.onc.1203646; Delgado-Deida Y, 2020, GASTROENTEROL REP, V8, P215, DOI 10.1093/gastro/goaa025; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Hammoudi A, 2013, BIOCHEM BIOPH RES CO, V440, P364, DOI 10.1016/j.bbrc.2013.08.076; Hsieh SY, 2006, PROTEOMICS, V6, P5322, DOI 10.1002/pmic.200500541; Jackson DN, 2020, CANCER RES, V80, P3519, DOI 10.1158/0008-5472.CAN-20-0216; Jackson DN, 2020, GUT, V69, P1928, DOI 10.1136/gutjnl-2019-319523; Jackson DN, 2020, GUT MICROBES, V11, P285, DOI 10.1080/19490976.2019.1592421; Kathiria AS, 2012, CANCER RES, V72, P5778, DOI 10.1158/0008-5472.CAN-12-0603; Kim DM, 2017, ONCOL REP, V37, P3201, DOI 10.3892/or.2017.5599; Ko KS, 2010, HEPATOLOGY, V52, P2096, DOI 10.1002/hep.23919; Krishnamurthy N, 2018, CANCER TREAT REV, V62, P50, DOI 10.1016/j.ctrv.2017.11.002; Lau T, 2013, CANCER RES, V73, P3132, DOI 10.1158/0008-5472.CAN-12-4562; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Ma LL, 2017, ONCOTARGET, V8, P76340, DOI 10.18632/oncotarget.19394; Mavila N, 2018, HEPATOL COMMUN, V2, P1583, DOI 10.1002/hep4.1257; Nenci A, 2007, NATURE, V446, P557, DOI 10.1038/nature05698; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Peng YT, 2015, APOPTOSIS, V20, P1135, DOI 10.1007/s10495-015-1143-z; Rastogi S, 2006, J BIOL CHEM, V281, P2951, DOI 10.1074/jbc.M508669200; Schatoff EM, 2017, CURR COLORECT CANC R, V13, P101, DOI 10.1007/s11888-017-0354-9; Theiss AL, 2007, FASEB J, V21, P197, DOI 10.1096/fj.06-6801com; Theiss AL, 2011, BBA-MOL CELL RES, V1813, P1137, DOI 10.1016/j.bbamcr.2011.01.033; Theiss AL, 2009, GASTROENTEROLOGY, V137, P199, DOI 10.1053/j.gastro.2009.03.033; Thuaud F, 2013, CHEM BIOL, V20, P316, DOI 10.1016/j.chembiol.2013.02.006; Tortelote GG, 2017, CELL SIGNAL, V40, P30, DOI 10.1016/j.cellsig.2017.08.008; Tsutsumi T, 2009, HEPATOLOGY, V50, P378, DOI 10.1002/hep.22998; Wang D, 2020, CELL MOL LIFE SCI, V77, P3525, DOI 10.1007/s00018-020-03475-1; Wang ZH, 2016, GENETICS, V203, P269, DOI 10.1534/genetics.115.183244; Yu LL, 2017, CANCER RES, V77, P1564, DOI 10.1158/0008-5472.CAN-16-2074; Zhou TB, 2013, J RECEPT SIG TRANSD, V33, P28, DOI 10.3109/10799893.2012.752006	41	4	4	3	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					369	383		10.1038/s41388-020-01538-y	http://dx.doi.org/10.1038/s41388-020-01538-y		NOV 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33144683	Green Accepted			2022-12-17	WOS:000585016500002
J	Lattier, JM; De, A; Chen, ZH; Morales, JE; Lang, FF; Huse, JT; McCarty, JH				Lattier, John M.; De, Arpan; Chen, Zhihua; Morales, John E.; Lang, Frederick F.; Huse, Jason T.; McCarty, Joseph H.			Megalencephalic leukoencephalopathy with subcortical cysts 1 (MLC1) promotes glioblastoma cell invasion in the brain microenvironment	ONCOGENE			English	Article							DYSTROPHIN-GLYCOPROTEIN COMPLEX; STEM-LIKE CELLS; GLIALCAM MUTATIONS; PROTEIN; ASTROCYTES; CHANNEL; INTERACTS; SUBUNIT; GROWTH; DEFECT	Glioblastoma (GBM), or grade IV astrocytoma, is a malignant brain cancer that contains subpopulations of proliferative and invasive cells that coordinately drive primary tumor growth, progression, and recurrence after therapy. Here, we have analyzed functions for megalencephalic leukoencephalopathy with subcortical cysts 1 (Mlc1), an eight-transmembrane protein normally expressed in perivascular brain astrocyte end feet that is essential for neurovascular development and physiology, in the pathogenesis of GBM. We show that Mlc1 is expressed in human stem-like GBM cells (GSCs) and is linked to the development of primary and recurrent GBM. Genetically inhibiting MLC1 in GSCs using RNAi-mediated gene silencing results in diminished growth and invasion in vitro as well as impaired tumor initiation and progression in vivo. Biochemical assays identify the receptor tyrosine kinase Axl and its intracellular signaling effectors as important for MLC1 control of GSC invasive growth. Collectively, these data reveal key functions for MLC1 in promoting GSC growth and invasion, and suggest that targeting the Mlc1 protein or its associated signaling effectors may be a useful therapy for blocking tumor progression in patients with primary or recurrent GBM.	[Lattier, John M.; De, Arpan; Chen, Zhihua; Morales, John E.; Lang, Frederick F.; McCarty, Joseph H.] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; [Huse, Jason T.] Univ Texas MD Anderson Canc Ctr, Translat Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	McCarty, JH (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA.	jhmccarty@mdanderson.org	De, Arpan/AAG-8512-2020	De, Arpan/0000-0001-8237-6703; Lattier, John/0000-0002-7680-668X	Cancer Prevention and Research Institute of Texas [RP180220]; National Institutes of Health [R01NS087635, R21NS103841, P50CA127001]; Brockman Foundation; Terry L. Chandler Foundation; NCI	Cancer Prevention and Research Institute of Texas; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Brockman Foundation; Terry L. Chandler Foundation; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the various members of the McCarty laboratory for insightful comments on the paper. This work was supported, in part, by grants to JHM from the Cancer Prevention and Research Institute of Texas (RP180220), the National Institutes of Health (R01NS087635, R21NS103841, and P50CA127001), the Brockman Foundation, and the Terry L. Chandler Foundation. The following NCI-funded Cancer Center Support Grant (CCSG) Core Facilities were instrumental in data acquisition: the shRNA and ORFeome Core, the Research Histopathology Facility, the Flow Cytometry and Cellular Imaging Facility, and the Sequencing and Microarray Facility.	Ambrosini E, 2008, MOL CELL NEUROSCI, V37, P480, DOI 10.1016/j.mcn.2007.11.003; Amiry-Moghaddam M, 2003, NAT REV NEUROSCI, V4, P991, DOI 10.1038/nrn1252; Amiry-Moghaddam M, 2019, CANCER RES, V79, P2810, DOI 10.1158/0008-5472.CAN-19-1185; Antony J, 2017, CANCER RES, V77, P3725, DOI 10.1158/0008-5472.CAN-17-0392; Antony J, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf8175; Balasubramaniyan V, 2015, ONCOTARGET, V6, P31007, DOI 10.18632/oncotarget.5219; Boor I, 2007, ACTA NEUROPATHOL, V114, P403, DOI 10.1007/s00401-007-0247-0; Boor PKI, 2005, J NEUROPATH EXP NEUR, V64, P412; Brignone MS, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00106; Brignone MS, 2011, HUM MOL GENET, V20, P90, DOI 10.1093/hmg/ddq435; Capdevila-Nortes X, 2015, J PHYSIOL-LONDON, V593, P4165, DOI 10.1113/JP270467; Chen ZH, 2018, CANCER RES, V78, P3809, DOI 10.1158/0008-5472.CAN-18-0085; Dundar B, 2020, GLIA, V68, P2173, DOI 10.1002/glia.23813; Elorza-Vidal X, 2020, HUM MOL GENET, V29, P1107, DOI 10.1093/hmg/ddaa009; Gaitan-Penas H, 2017, J PHYSIOL-LONDON, V595, P6993, DOI 10.1113/JP275087; Garcia J, 2020, CANCER TREAT REV, V86, DOI 10.1016/j.ctrv.2020.102017; Gilbert A, 2019, BRAIN STRUCT FUNCT, V224, P1267, DOI 10.1007/s00429-019-01832-w; Guerrero PA, 2017, ONCOGENE, V36, P6568, DOI 10.1038/onc.2017.248; Hara A, 2019, J ONCOL, V2019, DOI 10.1155/2019/2964783; Hoegg-Beiler MB, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4475; Hwang J, 2019, MOL BRAIN, V12, DOI 10.1186/s13041-019-0540-6; Jeworutzki E, 2012, NEURON, V73, P951, DOI 10.1016/j.neuron.2011.12.039; Jhaveri N, 2016, CANCER LETT, V380, P545, DOI 10.1016/j.canlet.2014.12.028; Lanciotti A, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061425; Lanciotti A, 2016, HUM MOL GENET, V25, P1543, DOI 10.1093/hmg/ddw032; Lanciotti A, 2012, HUM MOL GENET, V21, P2166, DOI 10.1093/hmg/dds032; Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115; Leegwater PAJ, 2002, HUM GENET, V110, P279, DOI 10.1007/s00439-002-0682-x; Leegwater PAJ, 2001, AM J HUM GENET, V68, P831, DOI 10.1086/319519; Leventoux N, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62145-1; Lewis-Tuffin LJ, 2015, MOL ONCOL, V9, P1783, DOI 10.1016/j.molonc.2015.06.001; Lopez-Hernandez T, 2011, HUM MOL GENET, V20, P3266, DOI 10.1093/hmg/ddr238; Lopez-Hernandez T, 2011, AM J HUM GENET, V88, P422, DOI 10.1016/j.ajhg.2011.02.009; Ma W, 2015, MOL MED REP, V12, P1050, DOI 10.3892/mmr.2015.3492; McCarty JH, 2020, J CELL SCI, V133, DOI 10.1242/jcs.239434; Minata M, 2019, CELL REP, V26, P1893, DOI 10.1016/j.celrep.2019.01.076; Muir M, 2020, EXPERT OPIN THER TAR, V24, P605, DOI 10.1080/14728222.2020.1762568; Nishizuka SS, 2016, DRUG METAB PHARMACOK, V31, P35, DOI 10.1016/j.dmpk.2015.11.009; Onken J, 2017, ONCOTARGET, V8, P50403, DOI 10.18632/oncotarget.18468; Peglion F, 2019, CURR OPIN CELL BIOL, V60, P121, DOI 10.1016/j.ceb.2019.05.002; Rao L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16061-7; Reyes SB, 2013, MOL BIOL CELL, V24, P474, DOI 10.1091/mbc.E12-07-0521; Sadahiro H, 2018, CANCER RES, V78, P3002, DOI 10.1158/0008-5472.CAN-17-2433; Turner KL, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0095; van der Knaap MS, 2012, LANCET NEUROL, V11, P973, DOI 10.1016/S1474-4422(12)70192-8; van der Knaap MS, 2010, ANN NEUROL, V67, P834, DOI 10.1002/ana.21980; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Waite A, 2012, TRENDS NEUROSCI, V35, P487, DOI 10.1016/j.tins.2012.04.004; Wen PY, 2020, NEURO-ONCOLOGY, V22, P1073, DOI 10.1093/neuonc/noaa106	49	4	4	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2020	39	50					7253	7264		10.1038/s41388-020-01503-9	http://dx.doi.org/10.1038/s41388-020-01503-9		OCT 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PD4HE	33040087	Green Accepted			2022-12-17	WOS:000576626800001
J	Shen, H; Wang, GC; Li, X; Ge, X; Wang, M; Shi, ZM; Bhardwaj, V; Wang, ZX; Zinner, RG; Peiper, SC; Aplin, AE; Jiang, BH; He, J				Shen, Hua; Wang, Gao-Chan; Li, Xiang; Ge, Xin; Wang, Meng; Shi, Zhu-Mei; Bhardwaj, Vikas; Wang, Zi-Xuan; Zinner, Ralph G.; Peiper, Stephen C.; Aplin, Andrew E.; Jiang, Bing-Hua; He, Jun			S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer	ONCOGENE			English	Article							TYROSINE KINASE INHIBITORS; DRUG-RESISTANCE; P70S6K1 ACTIVATION; MAMMALIAN TARGET; BREAST-CANCER; GROWTH; MDM2; EXPRESSION; GEFITINIB; PROMOTES	The development of resistance to EGFR Tyrosine kinase inhibitors (TKIs) in NSCLC with activating EGFR mutations is a critical limitation of this therapy. In addition to genetic alterations such as EGFR secondary mutation causing EGFR-TKI resistance, compensatory activation of signaling pathways without interruption of genome integrity remains to be defined. In this study, we identified S6K1/MDM2 signaling axis as a novel bypass mechanism for the development of EGFR-TKI resistance. The observation of S6K1 as a candidate mechanism for resistance to EGFR TKI therapy was investigated by interrogation of public databases and a clinical cohort to establish S6K1 expression as a prognostic/predictive biomarker. The role of S6K1 in TKI resistance was determined in in vitro gain-and-loss of function studies and confirmed in subcutaneous and orthotopic mouse lung cancer models. Blockade of S6K1 by a specific inhibitor PF-4708671 synergistically enhanced the efficacy of TKI without showing toxicity. The mechanistic study showed the inhibition of EGFR caused nuclear translocation of S6K1 for binding with MDM2 in resistant cells. MDM2 is a downstream effector of S6K1-mediated TKI resistance. Taken together, we present evidence for the reversal of resistance to EGFR TKI by the addition of small molecule S6K1/MDM2 antagonists that could have clinical benefit.	[Shen, Hua] Nanjing Med Univ, Sir Run Run Hosp, Dept Oncol, Nanjing, Peoples R China; [Shen, Hua] Nanjing Med Univ, Dept Oncol, Affiliated Hosp 1, Nanjing, Peoples R China; [Wang, Gao-Chan; Li, Xiang; Wang, Meng; Wang, Zi-Xuan; Peiper, Stephen C.; He, Jun] Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Li, Xiang] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Thorac Surg, Xian, Peoples R China; [Ge, Xin; Shi, Zhu-Mei] Nanjing Med Univ, State Key Lab Reprod Med, Dept Pathol, Nanjing, Peoples R China; [Bhardwaj, Vikas] Thomas Jefferson Univ, Coll Pharm, Philadelphia, PA 19107 USA; [Zinner, Ralph G.] Thomas Jefferson Univ, Dept Med Oncol, Philadelphia, PA 19107 USA; [Aplin, Andrew E.] Thomas Jefferson Univ, Dept Canc Biol, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Jiang, Bing-Hua] Univ Iowa, Dept Pathol, Carver Coll Med, Iowa City, IA USA	Nanjing Medical University; Nanjing Medical University; Jefferson University; Xi'an Jiaotong University; Nanjing Medical University; Jefferson University; Jefferson University; Jefferson University; University of Iowa	He, J (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA.	Jun.he@jefferson.edu		He, Jun/0000-0002-5162-6041; Bhardwaj, Vikas/0000-0003-3364-8711	National Cancer Institute [R00 CA 215316, R01 CA232587, R01 CA160495]; Natural Science Foundation of China [81874230]; Jiangsu Social Development Project (China) [BE2018726]; Natural Science Foundation of Jiangsu Province [BK20171484]; Project of Invigorating Health Care through Science, Technology, and Education (Jiangsu Provincial Medical Youth Talent) [QNRC2016856]; Summit of the Six Top Talents Program of Jiangsu Province [2017WSN-179]; NCI of the NIH [P30CA056036]	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Social Development Project (China); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Project of Invigorating Health Care through Science, Technology, and Education (Jiangsu Provincial Medical Youth Talent); Summit of the Six Top Talents Program of Jiangsu Province; NCI of the NIH	This work was supported by National Cancer Institute (R00 CA 215316, R01 CA232587, R01 CA160495), Natural Science Foundation of China (No. 81874230), Jiangsu Social Development Project (China, BE2018726), the Natural Science Foundation of Jiangsu Province (Grants No. BK20171484), the Project of Invigorating Health Care through Science, Technology, and Education (Jiangsu Provincial Medical Youth Talent QNRC2016856), the Summit of the Six Top Talents Program of Jiangsu Province (2017WSN-179). Research reported in this publication utilized the Flow Cytometry Facility at Sidney Kimmel Cancer Center at Jefferson Health, which was supported by the NCI of the NIH (P30CA056036).	Ashton JC, 2015, CANCER RES, V75, P2400, DOI 10.1158/0008-5472.CAN-14-3763; Bilanges Benoit, 2010, Biochem J, V431, pe1, DOI 10.1042/BJ20101445; Bostner J, 2015, ENDOCR-RELAT CANCER, V22, P331, DOI 10.1530/ERC-14-0513; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; Cappuzzo F, 2009, J CLIN ONCOL, V27, P1667, DOI 10.1200/JCO.2008.19.1635; de Bruin EC, 2014, CANCER DISCOV, V4, P606, DOI 10.1158/2159-8290.CD-13-0741; Desbois-Mouthon C, 2006, INT J CANCER, V119, P2557, DOI 10.1002/ijc.22221; Donev IS, 2011, CLIN CANCER RES, V17, P2260, DOI 10.1158/1078-0432.CCR-10-1993; Eischen CM, 2017, J MOL CELL BIOL, V9, P69, DOI 10.1093/jmcb/mjw052; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fang J, 2006, J CELL PHYSIOL, V209, P261, DOI 10.1002/jcp.20749; Feeley KP, 2017, CANCER RES, V77, P3823, DOI 10.1158/0008-5472.CAN-17-0809; Fenton TR, 2011, INT J BIOCHEM CELL B, V43, P47, DOI 10.1016/j.biocel.2010.09.018; Fujita Y, 2012, J THORAC ONCOL, V7, P1640, DOI 10.1097/JTO.0b013e3182653d7f; Grasso S, 2014, NEOPLASIA, V16, P845, DOI 10.1016/j.neo.2014.08.011; Gray JE, 2019, CLIN CANCER RES, V25, P6644, DOI 10.1158/1078-0432.CCR-19-1126; Guix M, 2008, J CLIN INVEST, V118, P2609, DOI 10.1172/JCI34588; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hollebecque A, 2014, EUR J CANCER, V50, P876, DOI 10.1016/j.ejca.2013.12.006; Ip CKM, 2014, ONCOTARGET, V5, P9133; Jacobsen K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00450-6; Jiang BH, 2008, DRUG RESIST UPDATE, V11, P63, DOI 10.1016/j.drup.2008.03.001; Jiang XH, 2009, BIOCHEM BIOPH RES CO, V387, P521, DOI 10.1016/j.bbrc.2009.07.060; Ju LX, 2010, J CELL BIOCHEM, V111, P1565, DOI 10.1002/jcb.22888; Juchum M, 2015, DRUG RESIST UPDATE, V20, P12, DOI 10.1016/j.drup.2015.05.002; Khotskaya YB, 2014, AM J TRANSL RES, V6, P361; Koizumi F, 2005, INT J CANCER, V116, P36, DOI 10.1002/ijc.20985; Lai KP, 2010, EMBO J, V29, P2994, DOI 10.1038/emboj.2010.166; Leonetti A, 2019, BRIT J CANCER, V121, P725, DOI 10.1038/s41416-019-0573-8; Lu QJ, 2015, ONCOL LETT, V10, P277, DOI 10.3892/ol.2015.3228; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; McIlwain DR, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008656; Oxnard GR, 2011, CLIN CANCER RES, V17, P5530, DOI 10.1158/1078-0432.CCR-10-2571; Park HS, 2014, INT J CLIN ONCOL, V19, P842, DOI 10.1007/s10147-013-0639-1; Pearce LR, 2010, BIOCHEM J, V431, P245, DOI 10.1042/BJ20101024; Phuchareon J, 2015, P NATL ACAD SCI USA, V112, pE3855, DOI 10.1073/pnas.1510733112; Qi HW, 2011, EXP THER MED, V2, P1091, DOI 10.3892/etm.2011.324; Qiu ZX, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147185; Rolfo C, 2014, CANCER TREAT REV, V40, P990, DOI 10.1016/j.ctrv.2014.05.009; Romaniello D, 2018, CLIN CANCER RES, V24, P5610, DOI 10.1158/1078-0432.CCR-18-0450; Shangary S, 2008, P NATL ACAD SCI USA, V105, P3933, DOI 10.1073/pnas.0708917105; Shin S, 2011, P NATL ACAD SCI USA, V108, pE1204, DOI 10.1073/pnas.1110195108; Tavares MR, 2015, LIFE SCI, V131, P1, DOI 10.1016/j.lfs.2015.03.001; Tolcher A, 2014, EUR J CANCER, V50, P867, DOI 10.1016/j.ejca.2013.11.039; Valovka T, 2003, MOL CELL BIOL, V23, P852, DOI 10.1128/MCB.23.3.852-863.2003; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990; Wang W, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6086; Wang Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0922-0; Wao H, 2013, SYST REV-LONDON, V2, DOI 10.1186/2046-4053-2-10; Wykosky J, 2015, CANCER RES, V75, P394, DOI 10.1158/0008-5472.CAN-14-2004; Yu HA, 2018, CLIN CANCER RES, V24, P3108, DOI 10.1158/1078-0432.CCR-17-2961; Zhang CH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-184; Zhang Y, 2015, MOL CANCER THER, V14, P799, DOI 10.1158/1535-7163.MCT-14-0648; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330	55	4	4	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2020	39	49					7181	7195		10.1038/s41388-020-01497-4	http://dx.doi.org/10.1038/s41388-020-01497-4		OCT 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PB0GA	33037411	Green Accepted			2022-12-17	WOS:000578440800004
J	Zhang, JQ; Bosbach, B; Loo, JK; Vitiello, GA; Zeng, S; Seifert, AM; Medina, BD; Param, NJ; Maltbaek, JH; Rossi, F; Antonescu, CR; Besmer, P; DeMatteo, RP				Zhang, Jennifer Q.; Bosbach, Benedikt; Loo, Jennifer K.; Vitiello, Gerardo A.; Zeng, Shan; Seifert, Adrian M.; Medina, Benjamin D.; Param, Nesteene J.; Maltbaek, Joanna H.; Rossi, Ferdinand; Antonescu, Cristina R.; Besmer, Peter; DeMatteo, Ronald P.			The V654A second-site KIT mutation increases tumor oncogenesis and STAT activation in a mouse model of gastrointestinal stromal tumor	ONCOGENE			English	Article							C-KIT; IMATINIB MESYLATE; SIGNAL-TRANSDUCTION; INTERSTITIAL-CELLS; TARGETED MUTATION; DRUG-RESISTANCE; TYROSINE KINASE; INHIBITION; MECHANISMS; EFFICACY	Gastrointestinal stromal tumor (GIST) is the most common human sarcoma and arises in the gastrointestinal tract. Most GISTs are caused by activating mutations in the KIT receptor tyrosine kinase, such as the exon 11KITV559 Delta mutation. The small molecule imatinib inhibits KIT and has been a mainstay of therapy in GIST. Unfortunately, imatinib-treated patients typically relapse, most often due to clonal emergence of the resistance-associatedKITV654A mutation. To determine the biologic impact of this second-site mutation in vivo, we created a mouse model with the corresponding V558 Delta;V653AKitdouble mutation restricted (a) spatially to ETV1(+)cells, which include the interstitial cells of Cajal (ICCs) from which GISTs presumably originate, and (b) temporally through tamoxifen treatment after birth. This resulted in the first in vivo model of the most common second-site mutation associated with imatinib resistance in GIST and the first in vivo demonstration that cell-autonomous expression of mutant KIT in the ICC lineage leads to GIST. GISTs driven by the V558 Delta;V653AKitdouble mutation were resistant to imatinib, while cabozantinib was more effective in overcoming resistance than sunitinib. Compared to control mice with a single V558 Delta Kitmutation, mice with a double V558 Delta; V653AKitmutation had increased tumor oncogenesis and associated KIT-dependent STAT activation. Our findings demonstrate that the biologic consequences of a second-site mutation in an oncogenic driver may include not only a mechanism for drug resistance, but changes in tumor oncogenic potential and differential activation of signaling pathways.	[Zhang, Jennifer Q.; Loo, Jennifer K.; Vitiello, Gerardo A.; Zeng, Shan; Seifert, Adrian M.; Medina, Benjamin D.; Param, Nesteene J.; Maltbaek, Joanna H.; Rossi, Ferdinand; DeMatteo, Ronald P.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA; [Bosbach, Benedikt; Besmer, Peter] Mem Sloan Kettering Canc Ctr, Dev Biol, New York, NY 10021 USA; [Bosbach, Benedikt] Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, New York, NY 10021 USA; [Rossi, Ferdinand; DeMatteo, Ronald P.] Hosp Univ Penn, Dept Surg, 3400 Spruce St, Philadelphia, PA 19104 USA; [Antonescu, Cristina R.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Pennsylvania; Pennsylvania Medicine; Memorial Sloan Kettering Cancer Center	DeMatteo, RP (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA.; DeMatteo, RP (corresponding author), Hosp Univ Penn, Dept Surg, 3400 Spruce St, Philadelphia, PA 19104 USA.	ronald.dematteo@pennmedicine.upenn.edu	Seifert, Adrian M./AAL-3453-2021	Seifert, Adrian M./0000-0002-5329-3164; Maltbaek, Joanna/0000-0003-3225-1843; Vitiello, Gerardo/0000-0002-7452-8903	NIH [R01 CA102613, T32 CA09501]; GIST Cancer Research Fund; Starr Cancer Consortium; Cancer Center Support Grant [P30 CA008748];  [F32 CA186534];  [P50 CA140146-01];  [R01 HL55748];  [CA102774]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); GIST Cancer Research Fund; Starr Cancer Consortium; Cancer Center Support Grant; ; ; ; 	The investigators were supported by NIH grants R01 CA102613 and T32 CA09501, and Betsy Levine-Brown and Marc Brown (RPD); GIST Cancer Research Fund (RPD and CRA); F32 CA186534 (JQZ); P50 CA140146-01 and the Starr Cancer Consortium (CRA and PB); and R01 HL55748 and CA102774 (PB). The Flow Cytometry and Molecular Cytology Core Facilities were supported by Cancer Center Support Grant P30 CA008748.	Antonescu CR, 2005, CLIN CANCER RES, V11, P4182, DOI 10.1158/1078-0432.CCR-04-2245; Bahlawane C, 2015, CELL COMMUN SIGNAL, V13, DOI 10.1186/s12964-015-0096-8; Balachandran VP, 2011, NAT MED, V17, P1094, DOI 10.1038/nm.2438; Beckett EAH, 2007, DEV DYNAM, V236, P60, DOI 10.1002/dvdy.20929; Blanke CD, 2008, J CLIN ONCOL, V26, P626, DOI 10.1200/JCO.2007.13.4452; Bosbach B, 2017, P NATL ACAD SCI USA, V114, pE8448, DOI 10.1073/pnas.1711449114; Bosbach B, 2012, P NATL ACAD SCI USA, V109, pE2276, DOI 10.1073/pnas.1115240109; Casteran N, 2003, ONCOGENE, V22, P4710, DOI 10.1038/sj.onc.1206587; Cavnar MJ, 2013, J EXP MED, V210, P2873, DOI 10.1084/jem.20130875; Chaix A, 2014, ONCOGENE, V33, P872, DOI 10.1038/onc.2013.12; Chaix A, 2011, J BIOL CHEM, V286, P5956, DOI 10.1074/jbc.M110.182642; Chi P, 2010, NATURE, V467, P849, DOI 10.1038/nature09409; Choudhary C, 2009, MOL CELL, V36, P326, DOI 10.1016/j.molcel.2009.09.019; Cohen NA, 2015, CANCER RES, V75, P2061, DOI 10.1158/0008-5472.CAN-14-2564; Debiec-Rychter M, 2005, GASTROENTEROLOGY, V128, P270, DOI 10.1053/j.gastro.2004.11.020; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Duensing A, 2004, ONCOGENE, V23, P3999, DOI 10.1038/sj.onc.1207525; Gajiwala KS, 2009, P NATL ACAD SCI USA, V106, P1542, DOI 10.1073/pnas.0812413106; Georgiades P, 2002, GENESIS, V34, P251, DOI 10.1002/gene.10161; Guo TH, 2009, CLIN CANCER RES, V15, P6862, DOI 10.1158/1078-0432.CCR-09-1315; Heinrich MC, 2008, J CLIN ONCOL, V26, P5360, DOI 10.1200/JCO.2008.17.4284; Heinrich MC, 2008, J CLIN ONCOL, V26, P5352, DOI 10.1200/JCO.2007.15.7461; Heydt C, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1311-0; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Joensuu H, 2012, ANNU REV MED, V63, P247, DOI 10.1146/annurev-med-043010-091813; Kim TS, 2014, CLIN CANCER RES, V20, P2350, DOI 10.1158/1078-0432.CCR-13-3033; Kluppel M, 1998, DEV DYNAM, V211, P60; Kwon JG, 2009, GASTROENTEROLOGY, V136, P630, DOI 10.1053/j.gastro.2008.10.031; Lorincz A, 2008, GASTROENTEROLOGY, V134, P1083, DOI 10.1053/j.gastro.2008.01.036; Miller CL, 1996, EXP HEMATOL, V24, P185; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; Prenen H, 2006, CLIN CANCER RES, V12, P2622, DOI 10.1158/1078-0432.CCR-05-2275; Ran LL, 2015, CANCER DISCOV, V5, P304, DOI 10.1158/2159-8290.CD-14-0985; Regales L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000810; Roberts KG, 2007, MOL CANCER THER, V6, P1159, DOI 10.1158/1535-7163.MCT-06-0641; Schoffski P, 2020, EUR J CANCER, V134, P62, DOI 10.1016/j.ejca.2020.04.021; Seifert AM, 2017, CLIN CANCER RES, V23, P454, DOI 10.1158/1078-0432.CCR-16-1163; Sommer G, 2003, P NATL ACAD SCI USA, V100, P6706, DOI 10.1073/pnas.1037763100; Spector MS, 2012, LEUKEMIA, V26, P1422, DOI 10.1038/leu.2011.354; Stadtfeld M, 2005, DEVELOPMENT, V132, P203, DOI 10.1242/dev.01558; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; Tamborini E, 2006, ONCOGENE, V25, P6140, DOI 10.1038/sj.onc.1209639; Torihashi S, 1997, GASTROENTEROLOGY, V112, P144, DOI 10.1016/S0016-5085(97)70229-4; Verweij J, 2004, LANCET, V364, P1127, DOI 10.1016/S0140-6736(04)17098-0; West RB, 2004, AM J PATHOL, V165, P107, DOI 10.1016/S0002-9440(10)63279-8; YEE NS, 1994, J EXP MED, V179, P1777, DOI 10.1084/jem.179.6.1777; Zhang JQ, 2018, CANCER IMMUNOL RES, V6, P434, DOI 10.1158/2326-6066.CIR-17-0345; Zhao J, 2014, CANCER SCI, V105, P117, DOI 10.1111/cas.12320; Zhu MJ, 2007, ONCOGENE, V26, P6386, DOI 10.1038/sj.onc.1210464	49	4	4	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2020	39	49					7153	7165		10.1038/s41388-020-01489-4	http://dx.doi.org/10.1038/s41388-020-01489-4		OCT 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PB0GA	33024275	Green Accepted			2022-12-17	WOS:000575700700003
J	Lopez, I; Chalatsi, E; Ellenbroek, SIJ; Andrieux, A; Roux, PF; Cerapio, JP; Jouvion, G; van Rheenen, J; Seeler, JS; Dejean, A				Lopez, Ignacio; Chalatsi, Eleftheria; Ellenbroek, Saskia I. J.; Andrieux, Alexandra; Roux, Pierre-Francois; Cerapio, Juan P.; Jouvion, Gregory; van Rheenen, Jacco; Seeler, Jacob-S.; Dejean, Anne			An unanticipated tumor-suppressive role of the SUMO pathway in the intestine unveiled by Ubc9 haploinsufficiency	ONCOGENE			English	Article							CRYPT STEM-CELLS; ENRICHMENT ANALYSIS; CONJUGATING ENZYME; DNA-DAMAGE; SUMOYLATION; EXPRESSION; INFLAMMATION; CANCER; UBIQUITIN; COLON	Sumoylation is an essential posttranslational modification in eukaryotes that has emerged as an important pathway in oncogenic processes. Most human cancers display hyperactivated sumoylation and many cancer cells are remarkably sensitive to its inhibition, thus supporting application of chemical sumoylation inhibitors in cancer treatment. Here we show, first, that transformed embryonic fibroblasts derived from mice haploinsufficient for Ubc9, the essential and unique gene encoding the SUMO E2 conjugating enzyme, exhibit enhanced proliferation and transformed phenotypes in vitro and as xenografts ex vivo. To then evaluate the possible impact of loss of oneUbc9allele in vivo, we used a mouse model of intestinal tumorigenesis. We crossedUbc9(+/-)mice with mice harboring a conditional ablation of Apc either all along the crypt-villus axis or only in Lgr5(+)crypt-based columnar (CBC) cells, the cell compartment that includes the intestinal stem cells proposed as cells-of-origin of intestinal cancer. WhileUbc9(+/-)mice display no overt phenotypes and no globally visible hyposumoylation in cells of the small intestine, we found, strikingly, that, upon loss of Apc in both models,Ubc9(+/-)mice develop more (>2-fold) intestinal adenomas and show significantly shortened survival. This is accompanied by reduced global sumoylation levels in the polyps, indicating that Ubc9 levels become critical upon oncogenic stress. Moreover, we found that, in normal conditions,Ubc9(+/-)mice show a moderate but robust (15%) increase in the number of Lgr5(+)CBC cells when compared to their wild-type littermates, and further, that these cells display higher degree of stemness and cancer-related and inflammatory gene expression signatures that, altogether, may contribute to enhanced intestinal tumorigenesis. The phenotypes of Ubc9 haploinsufficiency discovered here indicate an unanticipated tumor-suppressive role of sumoylation, one that may have important implications for optimal use of sumoylation inhibitors in the clinic.	[Lopez, Ignacio; Chalatsi, Eleftheria; Andrieux, Alexandra; Roux, Pierre-Francois; Cerapio, Juan P.; Seeler, Jacob-S.; Dejean, Anne] Inst Pasteur, Equipe Labellisee Ligue Natl Canc, INSERM, Nucl Org & Oncogenesis Unit,U993, F-75015 Paris, France; [Chalatsi, Eleftheria] Sorbonne Univ, Coll Doctoral, F-75005 Paris, France; [Ellenbroek, Saskia I. J.; van Rheenen, Jacco] Netherlands Canc Inst, Oncode Inst, Div Mol Pathol, Amsterdam, Netherlands; [Jouvion, Gregory] Inst Pasteur, Expt Neuropathol Unit, F-75015 Paris, France; [Chalatsi, Eleftheria] Biorad Labs, Marnes La Coquette, France; [Cerapio, Juan P.] Univ Toulouse, Ctr Rech Cancerol Toulouse, Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Sorbonne Universite; Netherlands Cancer Institute; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Seeler, JS; Dejean, A (corresponding author), Inst Pasteur, Equipe Labellisee Ligue Natl Canc, INSERM, Nucl Org & Oncogenesis Unit,U993, F-75015 Paris, France.	jacob.seeler@pasteur.fr; anne.dejean@pasteur.fr	Jouvion, Grégory/AAL-2620-2021; Dejean, Anne/L-5145-2018; Roux, Pierre-François/J-8875-2019	Roux, Pierre-François/0000-0002-0695-4206; Ellenbroek, Saskia/0000-0001-8007-2634; Cerapio Arroyo, Juan Pablo/0000-0002-3032-3180; Chalatsi, Eleftheria/0000-0003-2447-5572; Lopez, Ignacio/0000-0001-9669-8906	INCa; ANR; ERC-AdG "SUMOSTRESS"; Josef Steiner Cancer Foundation; ERC-CoG "Cancer Recurrence"; Fondation ARC [PDF20170505624]; LNCC (Equipe labellisee); Odyssey; ERC-AdG "SUMiDENTITY"	INCa(Institut National du Cancer (INCA) France); ANR(French National Research Agency (ANR)); ERC-AdG "SUMOSTRESS"; Josef Steiner Cancer Foundation; ERC-CoG "Cancer Recurrence"; Fondation ARC; LNCC (Equipe labellisee); Odyssey; ERC-AdG "SUMiDENTITY"	This work was supported by grants from INCa, LNCC (Equipe labellisee), Odyssey, ANR and ERC-AdG "SUMOSTRESS" and "SUMiDENTITY" to AD, and by the Josef Steiner Cancer Foundation and ERC-CoG "Cancer Recurrence" to JvR. IL was supported by Fondation ARC (PDF20170505624). We thank Dr. Giulia Nigro and the Institut Pasteur UTechS facility for technical input and Drs. Bob Weinberg, Maria Jasin, and Sergio F. de Almeida for providing reagents.	Alvarez A, 2014, JOVE-J VIS EXP, DOI 10.3791/51742; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Basak O, 2014, EMBO J, V33, P2057, DOI 10.15252/embj.201488017; Bettermann K, 2012, CANCER LETT, V316, P113, DOI 10.1016/j.canlet.2011.10.036; Borowicz S, 2014, JOVE-J VIS EXP, DOI 10.3791/51998; Bu PC, 2016, CELL STEM CELL, V18, P189, DOI 10.1016/j.stem.2016.01.006; Buczacki SJA, 2013, NATURE, V495, P65, DOI 10.1038/nature11965; Carbon S, 2019, NUCLEIC ACIDS RES, V47, pD330, DOI 10.1093/nar/gky1055; Carvalho BS, 2010, BIOINFORMATICS, V26, P2363, DOI 10.1093/bioinformatics/btq431; Cheloufi S, 2015, NATURE, V528, P218, DOI 10.1038/nature15749; Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427; Clevers H, 2013, CELL, V154, P274, DOI 10.1016/j.cell.2013.07.004; Colnot S, 2004, P NATL ACAD SCI USA, V101, P17216, DOI 10.1073/pnas.0404761101; Cossec JC, 2018, CELL STEM CELL, V23, P742, DOI 10.1016/j.stem.2018.10.001; Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI 10.1093/nar/gkt1102; Decque A, 2016, NAT IMMUNOL, V17, P140, DOI 10.1038/ni.3342; Demarque MD, 2011, GASTROENTEROLOGY, V140, P286, DOI 10.1053/j.gastro.2010.10.002; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Fevr T, 2007, MOL CELL BIOL, V27, P7551, DOI 10.1128/MCB.01034-07; Flotho A, 2013, ANNU REV BIOCHEM, V82, P357, DOI 10.1146/annurev-biochem-061909-093311; Golebiowski F, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000282; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Hayashi T, 2002, EXP CELL RES, V280, P212, DOI 10.1006/excr.2002.5634; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He XY, 2017, NAT CHEM BIOL, V13, P1164, DOI [10.1038/NCHEMBIO.2463, 10.1038/nchembio.2463]; Hendriks IA, 2016, NAT REV MOL CELL BIO, V17, P581, DOI 10.1038/nrm.2016.81; Jackson SP, 2013, MOL CELL, V49, P795, DOI 10.1016/j.molcel.2013.01.017; Jackstadt R, 2016, J PATHOL, V238, P141, DOI 10.1002/path.4645; Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092; Karin M, 2016, NATURE, V529, P307, DOI 10.1038/nature17039; Kessler JD, 2012, SCIENCE, V335, P348, DOI 10.1126/science.1212728; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lindemans CA, 2015, NATURE, V528, P560, DOI 10.1038/nature16460; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; MOLL R, 1993, DIFFERENTIATION, V53, P75, DOI 10.1111/j.1432-0436.1993.tb00648.x; Moschos SJ, 2010, HUM PATHOL, V41, P1286, DOI 10.1016/j.humpath.2010.02.007; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; Mustfa SA, 2017, OPEN BIOL, V7, DOI 10.1098/rsob.170024; Nacerddine K, 2005, DEV CELL, V9, P769, DOI 10.1016/j.devcel.2005.10.007; Nagel R, 2016, EMBO REP, V17, P1516, DOI 10.15252/embr.201643030; Neyret-Kahn H, 2013, GENOME RES, V23, P1563, DOI 10.1101/gr.154872.113; Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29; Ordonez-Moran P, 2015, CANCER CELL, V28, P815, DOI 10.1016/j.ccell.2015.11.001; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Pino MS, 2010, GASTROENTEROLOGY, V138, P2059, DOI 10.1053/j.gastro.2009.12.065; Rafehi H, 2011, JOVE-J VIS EXP, DOI 10.3791/2573; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Seeler JS, 2017, NAT REV CANCER, V17, P184, DOI 10.1038/nrc.2016.143; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Stankovic-Valentin N, 2018, MOL ASPECTS MED, V63, P3, DOI 10.1016/j.mam.2018.07.002; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suhail A, 2019, CELL REP, V29, P3522, DOI 10.1016/j.celrep.2019.11.028; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tetteh PW, 2016, CELL STEM CELL, V18, P203, DOI 10.1016/j.stem.2016.01.001; Tian H, 2011, NATURE, V478, P255, DOI 10.1038/nature10408; van Es JH, 2012, NAT CELL BIOL, V14, P1099, DOI 10.1038/ncb2581; Yu B, 2015, P NATL ACAD SCI USA, V112, pE1724, DOI 10.1073/pnas.1415569112	61	4	4	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2020	39	43					6692	6703		10.1038/s41388-020-01457-y	http://dx.doi.org/10.1038/s41388-020-01457-y		SEP 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OF2UT	32948837	Green Published, hybrid			2022-12-17	WOS:000570855500001
J	Bongiovanni, D; Tosello, V; Saccomani, V; Dalla Santa, S; Amadori, A; Zanovello, P; Piovan, E				Bongiovanni, Deborah; Tosello, Valeria; Saccomani, Valentina; Dalla Santa, Silvia; Amadori, Alberto; Zanovello, Paola; Piovan, Erich			Crosstalk between Hedgehog pathway and the glucocorticoid receptor pathway as a basis for combination therapy in T-cell acute lymphoblastic leukemia	ONCOGENE			English	Article							FLOOR PLATE; TRANSCRIPTION; ACTIVATION; MECHANISM; AGONISTS; ROLES; GLI2; HES1	Notwithstanding intensified therapy, a considerable fraction of T-cell acute lymphoblastic leukemia (T-ALL) patients face a dismal prognosis due to primary resistance to treatment and relapse, raising the need for more efficient and targeted therapies. Hedgehog (HH) signaling is a major developmental pathway frequently deregulated in cancer, for which a role in T-ALL is emerging. Mounting evidence suggests that ligand-independent activation of HH pathway occurs in cancer including T-ALL, emphasizing the necessity of dissecting the complex interplay between HH and other signaling pathways regulating activation. In this work, we present a therapeutically relevant crosstalk between HH signaling and the glucocorticoid receptor (NR3C1) pathway acting at the level of GLI1 transcription factor. GLI inhibitor GANT61 and dexamethasone were shown to exert a synergistic anti-leukemic effect in vitro in T-ALL cell lines and patient-derived xenografts. Mechanistically, dexamethasone-activated NR3C1 impaired GLI1 function by dynamically modulating the recruitment of PCAF acetyltransferase and HDAC1 deacetylase. Increased GLI1 acetylation was associated with compromised transcriptional activity and reduced protein stability. In summary, our study identifies a novel crosstalk between GLI1 and NR3C1 signaling pathway which could be exploited in HH-dependent malignancies to increase therapeutic efficacy.	[Bongiovanni, Deborah; Saccomani, Valentina; Dalla Santa, Silvia; Amadori, Alberto; Zanovello, Paola; Piovan, Erich] Univ Padua, Dipartimento Sci Chirurg Oncol & Gastroenterol, Padua, Italy; [Tosello, Valeria; Amadori, Alberto; Piovan, Erich] Ist Oncol Veneto IOV IRCCS, UOC Immunol & Diagnost Mol Oncol, Padua, Italy	University of Padua; IRCCS Istituto Oncologico Veneto (IOV)	Piovan, E (corresponding author), Univ Padua, Dipartimento Sci Chirurg Oncol & Gastroenterol, Padua, Italy.; Piovan, E (corresponding author), Ist Oncol Veneto IOV IRCCS, UOC Immunol & Diagnost Mol Oncol, Padua, Italy.	erich.piovan@unipd.it	Piovan, Erich/L-1444-2016	Piovan, Erich/0000-0002-4241-563X; Bongiovanni, Deborah/0000-0001-8693-4776	Italian Foundation for Cancer Research (Fondazione AIRC) [22233]; Progetto di Ricerca di Ateneo (Universita di Padova) [SID19_01]; Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR); Istituto Oncologico Veneto 5 x 1000 fund	Italian Foundation for Cancer Research (Fondazione AIRC); Progetto di Ricerca di Ateneo (Universita di Padova); Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR)(Ministry of Education, Universities and Research (MIUR)); Istituto Oncologico Veneto 5 x 1000 fund	This work was supported by the Italian Foundation for Cancer Research (Fondazione AIRC) grants to EP (IG2018#22233); Progetto di Ricerca di Ateneo (SID19_01; Universita di Padova) to EP. Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR) Ex 60% to EP; Istituto Oncologico Veneto 5 x 1000 fund to EP.	Amakye D, 2013, NAT MED, V19, P1410, DOI 10.1038/nm.3389; Belver L, 2016, NAT REV CANCER, V16, P494, DOI 10.1038/nrc.2016.63; Burns MA, 2018, LEUKEMIA, V32, P2126, DOI 10.1038/s41375-018-0097-x; Canettieri G, 2010, NAT CELL BIOL, V12, P132, DOI 10.1038/ncb2013; Chiang MY, 2008, J CLIN INVEST, V118, P3181, DOI 10.1172/JCI35090; Coni S, 2017, SCI REP-UK, V7, DOI 10.1038/srep44079; Coni S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065718; Crompton T, 2007, NAT REV IMMUNOL, V7, P726, DOI 10.1038/nri2151; Dagklis A, 2016, BLOOD, V128, P2642, DOI 10.1182/blood-2016-03-703454; Dagklis A, 2015, HAEMATOLOGICA, V100, pE102, DOI 10.3324/haematol.2014.119248; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Dierks C, 2007, NAT MED, V13, P944, DOI 10.1038/nm1614; Ding Q, 1998, DEVELOPMENT, V125, P2533; Fuccillo M, 2006, NAT REV NEUROSCI, V7, P772, DOI 10.1038/nrn1990; Gallet A, 2011, TRENDS CELL BIOL, V21, P238, DOI 10.1016/j.tcb.2010.12.005; Gruber W, 2018, INT J CANCER, V142, P968, DOI 10.1002/ijc.31117; Gulino A, 2012, VITAM HORM, V88, P211, DOI 10.1016/B978-0-12-394622-5.00009-2; Hegde GV, 2008, MOL CANCER RES, V6, P1928, DOI 10.1158/1541-7786.MCR-08-0142; Heine VM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002731; Heine VM, 2009, J CLIN INVEST, V119, P267, DOI 10.1172/JCI36376; HOECK W, 1989, J BIOL CHEM, V264, P14396; Hou XM, 2014, BIOCHIMIE, V101, P50, DOI 10.1016/j.biochi.2013.12.019; Hunger SP, 2015, NEW ENGL J MED, V373, P1541, DOI 10.1056/NEJMra1400972; Inaba H, 2010, LANCET ONCOL, V11, P1096, DOI 10.1016/S1470-2045(10)70114-5; Ingram WJ, 2008, ONCOGENE, V27, P1489, DOI 10.1038/sj.onc.1210767; Kassel O, 2007, MOL CELL ENDOCRINOL, V275, P13, DOI 10.1016/j.mce.2007.07.003; Malatesta M, 2013, CANCER RES, V73, P6323, DOI 10.1158/0008-5472.CAN-12-4660; Matise MP, 1998, DEVELOPMENT, V125, P2759; Newton R, 2007, MOL PHARMACOL, V72, P799, DOI 10.1124/mol.107.038794; Nieuwenhuis E, 2005, CLIN GENET, V67, P193, DOI 10.1111/j.1399-0004.2004.00360.x; Niewiadomski P, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020147; Pak E, 2016, DEV CELL, V38, P333, DOI 10.1016/j.devcel.2016.07.026; Pandolfi S, 2015, EXPERT REV MOL MED, V17, DOI 10.1017/erm.2015.3; Persson M, 2002, GENE DEV, V16, P2865, DOI 10.1101/gad.243402; Petrova R, 2014, DEVELOPMENT, V141, P3445, DOI 10.1242/dev.083691; Pietrobono S, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00556; Ramsbottom SA, 2016, J DEV BIOL, V4, DOI 10.3390/jdb4030023; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Rubin LL, 2006, NAT REV DRUG DISCOV, V5, P1026, DOI 10.1038/nrd2086; SCHMIDT TJ, 1994, RECEPTOR, V4, P229; Schrappe M, 2011, BLOOD, V118, P2077, DOI 10.1182/blood-2011-03-338707; Schreck KC, 2010, CLIN CANCER RES, V16, P6060, DOI 10.1158/1078-0432.CCR-10-1624; Schwartz JR, 2010, MOL CELL ENDOCRINOL, V320, P76, DOI 10.1016/j.mce.2010.02.014; Tosello V, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7100160; Wang JB, 2011, VITAM HORM, V87, P207, DOI 10.1016/B978-0-12-386015-6.00030-5; Wang JB, 2010, P NATL ACAD SCI USA, V107, P9323, DOI 10.1073/pnas.0910712107; Wang Y, 2012, CHEM BIOL, V19, P972, DOI 10.1016/j.chembiol.2012.06.012; Wu FJ, 2017, CELL CHEM BIOL, V24, P252, DOI 10.1016/j.chembiol.2017.02.010; Ying LT, 2000, NAT NEUROSCI, V3, P979, DOI 10.1038/79916	49	4	4	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2020	39	42					6544	6555		10.1038/s41388-020-01453-2	http://dx.doi.org/10.1038/s41388-020-01453-2		SEP 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA9HI	32917954				2022-12-17	WOS:000568475200003
J	Wang, J; Wang, GW; Cheng, DM; Huang, S; Chang, AT; Tan, XM; Wang, Q; Zhao, SR; Wu, D; Liu, AT; Yang, S; Xiang, R; Sun, PQ				Wang, Juan; Wang, Guanwen; Cheng, Dongmei; Huang, Shan; Chang, Antao; Tan, Xiaoming; Wang, Qiong; Zhao, Shaorong; Wu, Dan; Liu, Andy T.; Yang, Shuang; Xiang, Rong; Sun, Peiqing			Her2 promotes early dissemination of breast cancer by suppressing the p38-MK2-Hsp27 pathway that is targetable by Wip1 inhibition	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-SUPPRESSOR; CELL-ADHESION; E-CADHERIN; PHOSPHATASE; HSP27; GROWTH; METASTASIS; EXPRESSION	Cancer can metastasize from early lesions without detectable tumors. Despite extensive studies on metastasis in cancer cells from patients with detectable primary tumors, mechanisms for early metastatic dissemination are poorly understood. Her2 promotes breast cancer early dissemination by inhibiting p38, but the downstream pathway in this process was unknown. Using early lesion breast cancer models, we demonstrate that the effect of p38 suppression by Her2 on early dissemination is mediated by MK2 and heat shock protein 27 (Hsp27). The early disseminating cells in the MMTV-Her2 breast cancer model are Her2(high)p-p38(low)p-MK2(low)p-Hsp27(low), which also exist in human breast carcinoma tissues. Suppression of p38 and MK2 by Her2 reduces MK2-mediated Hsp27 phosphorylation, and unphosphorylated Hsp27 binds to beta-catenin and enhances its phosphorylation by Src, leading to beta-catenin activation and disseminating phenotypes in early lesion breast cancer cells. Pharmacological inhibition of MK2 promotes, while inhibition of a p38 phosphatase Wip1 suppresses, early dissemination in vivo. These findings identify Her2-mediated suppression of the p38-MK2-Hsp27 pathway as a novel mechanism for cancer early dissemination, and provide a basis for new therapies targeting early metastatic dissemination in Her2(+)breast cancer.	[Wang, Juan; Wang, Guanwen; Huang, Shan; Chang, Antao; Wang, Qiong; Zhao, Shaorong; Yang, Shuang; Xiang, Rong] Nankai Univ, Sch Med, Dept Immunol, Tianjin, Peoples R China; [Wang, Juan; Wang, Guanwen; Cheng, Dongmei; Huang, Shan; Chang, Antao; Tan, Xiaoming; Wu, Dan; Liu, Andy T.; Sun, Peiqing] Wake Forest Baptist Med Ctr, Dept Canc Biol, Winston Salem, NC 27006 USA; [Wang, Juan; Wang, Guanwen; Cheng, Dongmei; Huang, Shan; Chang, Antao; Tan, Xiaoming; Wu, Dan; Liu, Andy T.; Sun, Peiqing] Wake Forest Baptist Med Ctr, Comprehens Canc Ctr, Winston Salem, NC 27006 USA; [Tan, Xiaoming] Shanghai Jiao Tong Univ, Renji Hosp, Dept Resp Dis, Sch Med, South Campus, Shanghai, Peoples R China; [Liu, Andy T.] Univ N Carolina, Chapel Hill, NC 27515 USA	Nankai University; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Shanghai Jiao Tong University; University of North Carolina; University of North Carolina Chapel Hill	Xiang, R (corresponding author), Nankai Univ, Sch Med, Dept Immunol, Tianjin, Peoples R China.; Sun, PQ (corresponding author), Wake Forest Baptist Med Ctr, Dept Canc Biol, Winston Salem, NC 27006 USA.; Sun, PQ (corresponding author), Wake Forest Baptist Med Ctr, Comprehens Canc Ctr, Winston Salem, NC 27006 USA.	rxiang@nankai.edu.cn; psun@wakehealth.edu		Liu, Andy/0000-0002-9268-4272	NIH/NCI [CA131231, CA172115]; Bilateral Inter-Governmental S&T Cooperation Project grants from Ministry of Science and Technology of China [81972882, 2018YFE0114300]; Cell Engineering and Tumor Tissue and Pathology Shared Resources of WFBCCC - NCI's Cancer Center Support Grant [P30CA012197]; Anderson Oncology Research Professorship	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Bilateral Inter-Governmental S&T Cooperation Project grants from Ministry of Science and Technology of China; Cell Engineering and Tumor Tissue and Pathology Shared Resources of WFBCCC - NCI's Cancer Center Support Grant; Anderson Oncology Research Professorship	This study was supported by NIH/NCI grants CA131231, CA172115 (PS) and Bilateral Inter-Governmental S&T Cooperation Project grants from Ministry of Science and Technology of China (81972882 and 2018YFE0114300, RX), and by Cell Engineering and Tumor Tissue and Pathology Shared Resources of WFBCCC, supported by NCI's Cancer Center Support Grant (P30CA012197). PS is supported by the Anderson Oncology Research Professorship.	Brembeck FH, 2006, CURR OPIN GENET DEV, V16, P51, DOI 10.1016/j.gde.2005.12.007; Cardiff RD, 2001, MICROSC RES TECHNIQ, V52, P224, DOI 10.1002/1097-0029(20010115)52:2<224::AID-JEMT1007>3.3.CO;2-1; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen Z, 2016, SCI REP, P6; Collins NL, 2005, MOL CELL BIOL, V25, P5282, DOI 10.1128/MCB.25.12.5282-5291.2005; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Cordonnier T, 2015, INT J CANCER, V136, pE496, DOI 10.1002/ijc.29122; Demidov ON, 2007, ONCOGENE, V26, P2502, DOI 10.1038/sj.onc.1210032; Di KJ, 2007, EXP CELL RES, V313, P3983, DOI 10.1016/j.yexcr.2007.08.023; Dietlein F, 2015, CELL, V162, P146, DOI 10.1016/j.cell.2015.05.053; ENGEL K, 1995, J BIOL CHEM, V270, P27213, DOI 10.1074/jbc.270.45.27213; Esfandiari A, 2016, MOL CANCER THER, V15, P379, DOI 10.1158/1535-7163.MCT-15-0651; Eyles J, 2010, J CLIN INVEST, V120, P2030, DOI 10.1172/JCI42002; Fry EA, 2017, INT J CANCER, V140, P495, DOI 10.1002/ijc.30399; Gavert N, 2007, J CELL BIOCHEM, V102, P820, DOI 10.1002/jcb.21505; Gilmartin AG, 2014, NAT CHEM BIOL, V10, P181, DOI [10.1038/NCHEMBIO.1427, 10.1038/nchembio.1427]; Goloudina AR, 2016, ONCOTARGET, V7, P31563, DOI 10.18632/oncotarget.7325; Greco FA, 2009, SEMIN ONCOL, V36, P6, DOI 10.1053/j.seminoncol.2008.10.007; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Haeger A, 2015, TRENDS CELL BIOL, V25, P556, DOI 10.1016/j.tcb.2015.06.003; Hajra KM, 2002, CANCER RES, V62, P1613; Han JH, 2007, TRENDS BIOCHEM SCI, V32, P364, DOI 10.1016/j.tibs.2007.06.007; Han YC, 2017, ONCOL REP, V38, P3574, DOI 10.3892/or.2017.6017; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harper KL, 2016, NATURE, V540, P588, DOI 10.1038/nature20609; Huang S, 2000, J BIOL CHEM, V275, P12266, DOI 10.1074/jbc.275.16.12266; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Katsogiannou M, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00346; Koniali Lola, 2020, Oncotarget, V11, P650, DOI 10.18632/oncotarget.27453; Lee JS, 2014, J DERMATOL SCI, V73, P125, DOI 10.1016/j.jdermsci.2013.09.003; Lee JW, 2008, EUR J CELL BIOL, V87, P377, DOI 10.1016/j.ejcb.2008.03.006; Liu Y, 2018, NAT COMMUN, P9; Lu XB, 2008, CANCER METAST REV, V27, P123, DOI 10.1007/s10555-008-9127-x; Malladi S, 2016, CELL, V165, P45, DOI 10.1016/j.cell.2016.02.025; Matsushima-Nishiwaki R, 2008, J BIOL CHEM, V283, P18852, DOI 10.1074/jbc.M801301200; Montero L, 1999, CANCER RES, V59, P5286; Mourey RJ, 2010, J PHARMACOL EXP THER, V333, P797, DOI 10.1124/jpet.110.166173; Neviere Z, 2020, THER ADV MED ONCOL, V12, DOI 10.1177/1758835919897530; Orsulic S, 1999, J CELL SCI, V112, P1237; Pantel K, 2008, NAT REV CANCER, V8, P329, DOI 10.1038/nrc2375; Paul C, 2002, MOL CELL BIOL, V22, P816, DOI 10.1128/MCB.22.3.816-834.2002; Pechackova S, 2016, ONCOTARGET, V7, P14458, DOI 10.18632/oncotarget.7363; Polakis P, 2000, GENE DEV, V14, P1837; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Rocchi P, 2006, BJU INT, V98, P1082, DOI 10.1111/j.1464-410X.2006.06425.x; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Shi Y, 2002, BIOL CHEM, V383, P1519, DOI 10.1515/BC.2002.173; Shiota M, 2013, CANCER RES, V73, P3109, DOI 10.1158/0008-5472.CAN-12-3979; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Taneja P, 2010, CANCER RES, V70, P9084, DOI 10.1158/0008-5472.CAN-10-0159; Tian L, 2019, LIFE SCI, V239, DOI 10.1016/j.lfs.2019.117035; Wang SZE, 2007, J BIOL CHEM, V282, P5661, DOI 10.1074/jbc.M608499200; Xu L, 2006, ONCOGENE, V25, P2987, DOI 10.1038/sj.onc.1209337; Yamaguchi H, 2006, BIOCHEMISTRY-US, V45, P13193, DOI 10.1021/bi061356b; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257	58	4	4	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2020	39	40					6313	6326		10.1038/s41388-020-01437-2	http://dx.doi.org/10.1038/s41388-020-01437-2		AUG 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NV5JK	32848211	Green Accepted			2022-12-17	WOS:000563171800001
J	Chervo, MF; Russo, RIC; Petrillo, E; Izzo, F; De Martino, M; Bellora, N; Cenciarini, ME; Chiauzzi, VA; de la Parra, LS; Pereyra, MG; Guttlein, LN; Podhajcer, OL; Daniotti, JL; Dupont, A; Barchuk, S; Figurelli, S; Della Vecchia, DL; Roa, JC; Guzman, P; Proietti, CJ; Schillaci, R; Elizalde, PV				Chervo, Maria F.; Cordo Russo, Rosalia I.; Petrillo, Ezequiel; Izzo, Franco; De Martino, Mara; Bellora, Nicolas; Cenciarini, Mauro E.; Chiauzzi, Violeta A.; santa Maria de la Parra, Lucia; Pereyra, Matias G.; Guttlein, Leandro N.; Podhajcer, Osvaldo L.; Daniotti, Jose L.; Dupont, Agustina; Barchuk, Sabrina; Figurelli, Silvina; Lopez Della Vecchia, Daniel; Roa, Juan C.; Guzman, Pablo; Proietti, Cecilia J.; Schillaci, Roxana; Elizalde, Patricia V.			Canonical ErbB-2 isoform and ErbB-2 variant c located in the nucleus drive triple negative breast cancer growth	ONCOGENE			English	Article							PROGESTERONE-RECEPTOR; SPLICE VARIANT; EGF RECEPTOR; JUXTAMEMBRANE REGION; DOWN-REGULATION; BASAL-LIKE; HER2; ACTIVATION; EXPRESSION; DOMAIN	Triple negative breast cancer (TNBC) refers to tumors that do not express clinically significant levels of estrogen and progesterone receptors, and lack membrane overexpression or gene amplification of ErbB-2/HER2, a receptor tyrosine kinase. Transcriptome and proteome heterogeneity of TNBC poses a major challenge to precision medicine. Clinical biomarkers and targeted therapies for this disease remain elusive, so chemotherapy has been the standard of care for early and metastatic TNBC. Our present findings placed ErbB-2 in an unanticipated scenario: the nucleus of TNBC (NErbB-2). Our study on ErbB-2 alternative splicing events, using a PCR-sequencing approach combined with an RNA interference strategy, revealed that TNBC cells express either the canonical (wild-type) ErbB-2, encoded by transcript variant 1, or the non-canonical ErbB-2 isoform c, encoded by alternative variant 3 (RefSeq), or both. These ErbB-2 isoforms function in the nucleus as transcription factors. Evicting both from the nucleus or silencing isoform c only, blocks TN cell and tumor growth. This reveals not only NErbB-2 canonical and alternative isoforms role as targets of therapy in TNBC, but also isoform c dominant oncogenic potential. Furthermore, we validated our findings in the clinic and observed that NErbB-2 correlates with poor prognosis in primary TN tumors, disclosing NErbB-2 as a novel biomarker for TNBC. Our discoveries challenge the present scenario of drug development for personalized BC medicine that focuses on wild-type RefSeq proteins, which conserve the canonical domains and are located in their classical cellular compartments.	[Chervo, Maria F.; Cordo Russo, Rosalia I.; Izzo, Franco; De Martino, Mara; Cenciarini, Mauro E.; Chiauzzi, Violeta A.; santa Maria de la Parra, Lucia; Pereyra, Matias G.; Proietti, Cecilia J.; Schillaci, Roxana; Elizalde, Patricia V.] Consejo Nacl Invest Cient & Tecn, Inst Biol & Med Expt IBYME, Lab Mol Mech Carcinogenesis & Mol Endocrinol, Vuelta Obligado 2490,C1428ADN, Buenos Aires, DF, Argentina; [Petrillo, Ezequiel] Univ Buenos Aires UBA, Fac Ciencias Exactas & Nat, Dept Fisiol Biol Mol & Celular, C1428EHA, Buenos Aires, DF, Argentina; [Petrillo, Ezequiel] CONICET UBA, Inst Fisiol Biol Mol & Neurociencias IFIBYNE, C1428EHA, Buenos Aires, DF, Argentina; [Bellora, Nicolas] CONICET UNComahue, Inst Andinopatagon Tecnol Biol & Geoambientales I, Lab Microbiol Aplicada Biotecnol & Bioinformat Le, Quintral 1250, RA-8400 San Carlos De Bariloche, Rio Negro, Argentina; [Guttlein, Leandro N.; Podhajcer, Osvaldo L.] Consejo Nacl Invest Cient & Tecn, Leloir Inst, Lab Mol & Cellular Therapy, Ave Patricias Argentinas 435,C1405BWE, Buenos Aires, DF, Argentina; [Daniotti, Jose L.] Consejo Nacl Invest Cient & Tecn, CIQUIBIC, Ctr Invest Quim Biol Cordoba, Ciudad Univ,X5000HUA, Cordoba, Argentina; [Daniotti, Jose L.] Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol Ranwel Caputto, Ciudad Univ,X5000HUA, Cordoba, Argentina; [Dupont, Agustina; Barchuk, Sabrina; Figurelli, Silvina; Lopez Della Vecchia, Daniel] Hosp Gen Agudos Juan A Fernandez, Unidad Patol Mamaria, C1425AGP, Buenos Aires, DF, Argentina; [Roa, Juan C.; Guzman, Pablo] Univ La Frontera, Dept Anat Patol BIOREN, Casilla 54-D, Temuco, Chile; [Roa, Juan C.] Pontificia Univ Catolica Chile, Sch Med, Dept Pathol, Santiago 8330024, Chile; [Roa, Juan C.] Pontificia Univ Catolica Chile, Adv Ctr Chron Dis ACCDIS, Santiago, Chile	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine; University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Universidad Nacional del Comahue; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Leloir Institute; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Cordoba; University of Buenos Aires; Universidad de La Frontera; Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile	Elizalde, PV (corresponding author), Consejo Nacl Invest Cient & Tecn, Inst Biol & Med Expt IBYME, Lab Mol Mech Carcinogenesis & Mol Endocrinol, Vuelta Obligado 2490,C1428ADN, Buenos Aires, DF, Argentina.	patriciaelizalde@ibyme.conicet.gov.ar	Roa, Juan C./K-4749-2014; Russo, Rosalia Cordo/O-9149-2017; Bellora, Nicolas/E-6356-2014	Roa, Juan C./0000-0001-8313-8774; Russo, Rosalia Cordo/0000-0002-5984-9717; Santa Maria de la Parra, Lucia/0000-0002-4577-139X; De Martino, Mara/0000-0002-3049-6495; Bellora, Nicolas/0000-0001-6637-3465; Izzo, Franco/0000-0002-5813-6504; Chervo, Maria Florencia/0000-0001-8878-5591	National Agency of Scientific Promotion of Argentina [IDB/PICT 2012-668, PID 2012-066, PICT 2015-1587, PICT 2017-1072]; INC 2016 research grant from Nat. Cancer Institute of Argentina; Fondation Nelia et Amadeo Barletta Research Grant; Foundation Alberto J. Roemmers Research Grant	National Agency of Scientific Promotion of Argentina(ANPCyT); INC 2016 research grant from Nat. Cancer Institute of Argentina; Fondation Nelia et Amadeo Barletta Research Grant; Foundation Alberto J. Roemmers Research Grant	In memory of EH Charreau, our colleague and dear friend. We thank A Molinolo (UCSD, USA) and E Gil Deza (Instituto Oncologico Henry Moore, Argentina) for their advice. This work was supported by IDB/PICT 2012-668, PID 2012-066, PICT 2015-1587, PICT 2017-1072 from the National Agency of Scientific Promotion of Argentina, INC 2016 research grant from Nat. Cancer Institute of Argentina, and Fondation Nelia et Amadeo Barletta Research Grant, all awarded to PVE, and Foundation Alberto J. Roemmers Research Grant awarded to PVE and RICR.	Al-Ejeh F, 2014, ONCOTARGET, V5, P3145, DOI 10.18632/oncotarget.1865; Alajati A, 2013, CANCER RES, V73, P5320, DOI 10.1158/0008-5472.CAN-12-3186; Anido J, 2006, EMBO J, V25, P3234, DOI 10.1038/sj.emboj.7601191; Beguelin W, 2010, MOL CELL BIOL, V30, P5456, DOI 10.1128/MCB.00012-10; Brand TM, 2014, MOL CANCER THER, V13, P1356, DOI 10.1158/1535-7163.MCT-13-1021; Burstein MD, 2015, CLIN CANCER RES, V21, P1688, DOI 10.1158/1078-0432.CCR-14-0432; Castagnoli L, 2017, ONCOGENE, V36, P1721, DOI 10.1038/onc.2016.338; Castiglioni F, 2006, ENDOCR-RELAT CANCER, V13, P221, DOI 10.1677/erc.1.01047; Contessa JN, 2008, CANCER RES, V68, P3803, DOI 10.1158/0008-5472.CAN-07-6389; Russo RIC, 2015, ONCOGENE, V34, P3413, DOI 10.1038/onc.2014.272; Daemen A, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-0933-y; Flaque MCD, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3587; Flaque MCD, 2013, STEROIDS, V78, P559, DOI 10.1016/j.steroids.2012.11.003; Duarte HO, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112262; Elizalde PV, 2016, ENDOCR-RELAT CANCER, V23, pT243, DOI 10.1530/ERC-16-0360; Ferreira IG, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020580; Frei AP, 2012, NAT BIOTECHNOL, V30, P997, DOI 10.1038/nbt.2354; Garrido-Castro AC, 2019, CANCER DISCOV, V9, P176, DOI 10.1158/2159-8290.CD-18-1177; Gautrey H, 2015, RNA BIOL, V12, P1139, DOI 10.1080/15476286.2015.1076610; Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005; Grigoriadis A, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-619; Henderson IC, 1998, BREAST CANCER RES TR, V52, P261, DOI 10.1023/A:1006141703224; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Hsu YH, 2014, CANCER RES, V74, P4822, DOI 10.1158/0008-5472.CAN-14-0584; Ito K, 2016, CANCER RES, V76, P4406, DOI 10.1158/0008-5472.CAN-15-3445; Ortiz-Ruiz MJ, 2014, ONCOTARGET, V5, P11308, DOI 10.18632/oncotarget.2324; Jura N, 2011, MOL CELL, V42, P9, DOI 10.1016/j.molcel.2011.03.004; Jura N, 2009, CELL, V137, P1293, DOI 10.1016/j.cell.2009.04.025; Kelemen O, 2013, GENE, V514, P1, DOI 10.1016/j.gene.2012.07.083; Kim HM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004987; Kwong KY, 1998, MOL CARCINOGEN, V23, P62, DOI 10.1002/(SICI)1098-2744(199810)23:2<62::AID-MC2>3.0.CO;2-O; Le Du F, 2015, ONCOTARGET, V6, P12890, DOI 10.18632/oncotarget.3849; Lee CYF, 2014, CANCER RES, V74, P341, DOI 10.1158/0008-5472.CAN-13-1055; Lehmann BD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157368; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Li LY, 2011, CANCER RES, V71, P4269, DOI 10.1158/0008-5472.CAN-10-3504; Li X, 2012, J BIOL CHEM, V287, P83; LIN YZJ, 1991, ONCOGENE, V6, P639; Linggi B, 2006, ONCOGENE, V25, P160, DOI 10.1038/sj.onc.1209003; Menon R, 2014, J PROTEOME RES, V13, P212, DOI 10.1021/pr400773v; Mitra D, 2009, MOL CANCER THER, V8, P2152, DOI 10.1158/1535-7163.MCT-09-0295; Molina MA, 2002, CLIN CANCER RES, V8, P347; Paik S, 2008, NEW ENGL J MED, V358, P1409, DOI 10.1056/NEJMc0801440; Pal S, 2011, GENOME RES, V21, P1260, DOI 10.1101/gr.120535.111; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Prat A, 2013, BREAST CANCER RES TR, V142, P237, DOI 10.1007/s10549-013-2743-3; Prat A, 2013, ONCOLOGIST, V18, P123, DOI 10.1634/theoncologist.2012-0397; Proietti CJ, 2009, MOL CELL BIOL, V29, P1249, DOI 10.1128/MCB.00853-08; PUPA SM, 1993, ONCOGENE, V8, P2917; Red Brewer M, 2009, MOL CELL, V34, P641, DOI 10.1016/j.molcel.2009.04.034; Reyes A, 2018, NUCLEIC ACIDS RES, V46, P582, DOI 10.1093/nar/gkx1165; Ross JS, 2009, ONCOLOGIST, V14, P320, DOI 10.1634/theoncologist.2008-0230; Sasso Marianna, 2011, J NUCL ACIDS INVESTI, V2, pe9; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Schillaci R, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-74; Schmid P, 2018, NEW ENGL J MED, V379, P2108, DOI 10.1056/NEJMoa1809615; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Thiel KW, 2007, P NATL ACAD SCI USA, V104, P19238, DOI 10.1073/pnas.0703854104; Tilio M, 2016, CANCER LETT, V381, P76, DOI 10.1016/j.canlet.2016.07.028; Tryndyak VP, 2010, INT J CANCER, V126, P2575, DOI 10.1002/ijc.24972; Turpin J, 2016, ONCOGENE, V35, P6053, DOI 10.1038/onc.2016.129; Venturutti L, 2016, ONCOGENE, V35, P2208, DOI 10.1038/onc.2015.281; Wang SC, 2004, CANCER CELL, V6, P251, DOI 10.1016/j.ccr.2004.07.012; Warri AM, 1996, EUR J CANCER, V32A, P134, DOI 10.1016/0959-8049(95)00550-1; Watanabe M, 2013, ANAL BIOANAL CHEM, V405, P4289, DOI 10.1007/s00216-013-6771-y; Wood ER, 2008, P NATL ACAD SCI USA, V105, P2773, DOI 10.1073/pnas.0708281105; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yunokawa M, 2012, CANCER SCI, V103, P1665, DOI 10.1111/j.1349-7006.2012.02359.x; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	70	4	4	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2020	39	39					6245	6262		10.1038/s41388-020-01430-9	http://dx.doi.org/10.1038/s41388-020-01430-9		AUG 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NS8XO	32843720				2022-12-17	WOS:000562669100003
J	Ge, ML; Li, D; Qiao, Z; Sun, Y; Kang, T; Zhu, SH; Wang, SF; Xiao, H; Zhao, CJ; Shen, SH; Xu, ZS; Liu, H				Ge, Maolin; Li, Dan; Qiao, Zhi; Sun, Yan; Kang, Ting; Zhu, Shouhai; Wang, Shifen; Xiao, Hua; Zhao, Chunjun; Shen, Shuhong; Xu, Zhenshu; Liu, Han			Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors	ONCOGENE			English	Article							MULTIPLE-MYELOMA; METHYLTRANSFERASE ACTIVITY; FAMILY PROTEINS; CANCER; CELLS; GENE; BORTEZOMIB; MONOUBIQUITINATION; TRANSCRIPTION; DEGRADATION	MLL undergoes multiple distinct chromosomal translocations to yield aggressive leukemia with dismal outcomes. Besides their well-established role in leukemogenesis, MLL fusions also possess latent tumor-suppressive activity, which can be exploited as effective cancer treatment strategies using pharmacological means such as proteasome inhibitors (PIs). Here, using MLL-rearranged xenografts and MLL leukemic cells as models, we show that wild-type MLL is indispensable for the latent tumor-suppressive activity of MLL fusions. MLL dysfunction, shown as loss of the chromatin accumulation and subsequent degradation of MLL, compromises the latent tumor suppression of MLL-AF4 and is instrumental for the acquired PI resistance. Mechanistically, MLL dysfunction is caused by chronic PI treatment-induced epigenetic reprogramming through the H2Bub-ASH2L-MLL axis and can be specifically restored by histone deacetylase (HDAC) inhibitors, which induce histone acetylation and recruits MLL on chromatin to promote cell cycle gene expression. Our findings not only demonstrate the mechanism underlying the inevitable acquisition of PI resistance in MLL leukemic cells, but also illustrate that preventing the emergence of PI-resistant cells constitutes a novel rationale for combination therapy with PIs and HDAC inhibitors in MLL leukemias.	[Ge, Maolin; Li, Dan; Sun, Yan; Zhu, Shouhai; Zhao, Chunjun; Liu, Han] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Hematol,Ruijin Hosp, State Key Lab Med Genom,Natl Res Ctr Translat Med, Shanghai 200025, Peoples R China; [Qiao, Zhi; Xiao, Hua] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, State Key Lab Microbial Metab, Shanghai 200240, Peoples R China; [Kang, Ting] Shanghai Jiao Tong Univ, Sch Med, Xin Hua Hosp, Dept Oncol, Shanghai 200092, Peoples R China; [Wang, Shifen; Xu, Zhenshu] Fujian Med Univ, Union Hosp, Fujian Inst Hematol, Fujian Prov Key Lab Hematol, Fuzhou 350001, Peoples R China; [Shen, Shuhong] Shanghai Jiao Tong Univ, Key Lab Pediat Hematol & Oncol, Minist Hlth,Dept Hematol & Oncol,Sch Med, Pediat Translat Med Inst,Shanghai Childrens Med C, Shanghai 200127, Peoples R China	Chinese Academy of Sciences; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Fujian Medical University; Shanghai Jiao Tong University	Liu, H (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Hematol,Ruijin Hosp, State Key Lab Med Genom,Natl Res Ctr Translat Med, Shanghai 200025, Peoples R China.; Xu, ZS (corresponding author), Fujian Med Univ, Union Hosp, Fujian Inst Hematol, Fujian Prov Key Lab Hematol, Fuzhou 350001, Peoples R China.; Shen, SH (corresponding author), Shanghai Jiao Tong Univ, Key Lab Pediat Hematol & Oncol, Minist Hlth,Dept Hematol & Oncol,Sch Med, Pediat Translat Med Inst,Shanghai Childrens Med C, Shanghai 200127, Peoples R China.	shenshuhong@scmc.com.cn; zhenshuxu@yahoo.com; liuhan68@sjtu.edu.cn	Xiao, Hua/I-7429-2013	Xiao, Hua/0000-0002-2831-0436; Liu, Han/0000-0002-0022-1861	National Key Research and Development Program of China [2018YFA0107802]; National Natural Science Foundation of China [81973996, 81570119]; Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant [20161304]; Program of Shanghai Academic Research Leader [19XD1402500]; Shanghai Municipal Health Commission [2019CXJQ01]; Joint Funds for the Innovation of Science and Technology of Fujian Province of China [2017Y9005]; Collaborative Innovation Center of Hematology; Samuel Waxman Cancer Research Foundation	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant; Program of Shanghai Academic Research Leader; Shanghai Municipal Health Commission; Joint Funds for the Innovation of Science and Technology of Fujian Province of China; Collaborative Innovation Center of Hematology; Samuel Waxman Cancer Research Foundation	This work was supported by the National Key Research and Development Program of China (2018YFA0107802), the National Natural Science Foundation of China (81973996 and 81570119), the Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant (20161304), the Program of Shanghai Academic Research Leader (19XD1402500), the Shanghai Municipal Health Commission (2019CXJQ01), the Joint Funds for the Innovation of Science and Technology of Fujian Province of China (No.2017Y9005), the Collaborative Innovation Center of Hematology, and the Samuel Waxman Cancer Research Foundation.	Ahmad K, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.39; Allen MD, 2006, EMBO J, V25, P4503, DOI 10.1038/sj.emboj.7601340; Cao F, 2014, MOL CELL, V53, P247, DOI 10.1016/j.molcel.2013.12.001; Chen YF, 2017, CANCER CELL, V31, P755, DOI 10.1016/j.ccell.2017.05.002; Drexler HG, 2004, LEUKEMIA, V18, P227, DOI 10.1038/sj.leu.2403236; Espinosa JM, 2008, GENE DEV, V22, P2743, DOI 10.1101/gad.1732108; Flavahan WA, 2017, SCIENCE, V357, DOI 10.1126/science.aal2380; Glickman MS, 2012, CELL, V148, P1089, DOI 10.1016/j.cell.2012.02.015; Goldman A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7139; Hideshima T, 2005, P NATL ACAD SCI USA, V102, P8567, DOI 10.1073/pnas.0503221102; Hsieh JJD, 2003, CELL, V115, P293, DOI 10.1016/S0092-8674(03)00816-X; Kaldis P, 2007, CELL, V128, P241, DOI 10.1016/j.cell.2007.01.006; Koss C, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.972.972; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Lee JS, 2007, CELL, V131, P1084, DOI 10.1016/j.cell.2007.09.046; Li D, 2018, LEUKEMIA, V32, P2012, DOI 10.1038/s41375-018-0212-z; Liang KW, 2017, CELL, V168, P59, DOI 10.1016/j.cell.2016.12.011; Liau BB, 2017, CELL STEM CELL, V20, P233, DOI 10.1016/j.stem.2016.11.003; Liu H, 2014, CANCER CELL, V25, P530, DOI 10.1016/j.ccr.2014.03.008; Liu H, 2010, NATURE, V467, P343, DOI 10.1038/nature09350; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Manasanch EE, 2017, NAT REV CLIN ONCOL, V14, P417, DOI [10.1038/nrclinonc.2016.206, 10.1007/s12079-011-0121-7]; Mazur PK, 2015, NAT MED, V21, P1163, DOI 10.1038/nm.3952; McConkey D, 2010, BLOOD, V116, P308, DOI 10.1182/blood-2010-04-278507; Meyer C, 2018, LEUKEMIA, V32, P273, DOI 10.1038/leu.2017.213; Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102; Milne TA, 2010, MOL CELL, V38, P853, DOI 10.1016/j.molcel.2010.05.011; Mishra BP, 2014, CELL REP, V7, P1239, DOI 10.1016/j.celrep.2014.04.015; Moreau P, 2012, BLOOD, V120, P947, DOI 10.1182/blood-2012-04-403733; Mujtaba S, 2007, ONCOGENE, V26, P5521, DOI 10.1038/sj.onc.1210618; Muntean AG, 2012, ANNU REV PATHOL-MECH, V7, P283, DOI 10.1146/annurev-pathol-011811-132434; Nakanishi S, 2008, NAT STRUCT MOL BIOL, V15, P881, DOI 10.1038/nsmb.1454; Pei XY, 2004, CLIN CANCER RES, V10, P3839, DOI 10.1158/1078-0432.CCR-03-0561; Prenzel T, 2011, CANCER RES, V71, P5739, DOI 10.1158/0008-5472.CAN-11-1896; Rao RC, 2015, NAT REV CANCER, V15, P334, DOI 10.1038/nrc3929; Riedel SS, 2016, J CLIN INVEST, V126, P1438, DOI 10.1172/JCI80825; Rushworth SA, 2011, CANCER RES, V71, P1999, DOI 10.1158/0008-5472.CAN-10-3018; Salgia R, 2018, TRENDS CANCER, V4, P110, DOI 10.1016/j.trecan.2018.01.001; San-Miguel JF, 2014, LANCET ONCOL, V15, P1195, DOI 10.1016/S1470-2045(14)70440-1; Shaffer SM, 2017, NATURE, V546, P431, DOI 10.1038/nature22794; Shilatifard A, 2012, ANNU REV BIOCHEM, V81, P65, DOI 10.1146/annurev-biochem-051710-134100; Takeda S, 2006, GENE DEV, V20, P2397, DOI 10.1101/gad.1449406; Thiel AT, 2010, CANCER CELL, V17, P148, DOI 10.1016/j.ccr.2009.12.034; Wainwright EN, 2017, TRENDS CANCER, V3, P372, DOI 10.1016/j.trecan.2017.04.004; Wang E, 2013, P NATL ACAD SCI USA, V110, P3901, DOI 10.1073/pnas.1301045110; Wang ZX, 2010, CELL, V141, P1183, DOI 10.1016/j.cell.2010.05.016; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738; Wu LP, 2013, MOL CELL, V49, P1108, DOI 10.1016/j.molcel.2013.01.033; Xia ZB, 2005, P NATL ACAD SCI USA, V102, P14028, DOI 10.1073/pnas.0506464102; Xu HM, 2016, CANCER CELL, V30, P863, DOI 10.1016/j.ccell.2016.10.019; Zhang QL, 2009, LEUKEMIA, V23, P1507, DOI 10.1038/leu.2009.41; Zhao ZB, 2019, GENE DEV, V33, P61, DOI 10.1101/gad.319830.118	53	4	4	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2020	39	36					5888	5901		10.1038/s41388-020-01408-7	http://dx.doi.org/10.1038/s41388-020-01408-7		JUL 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NJ1HO	32733069	Green Published, hybrid			2022-12-17	WOS:000557084000001
J	Ko, KP; Jeong, SI; Lim, JS; Lee, KW; Lee, MG; Chi, SG				Ko, Kyung-Phil; Jeong, Seong-In; Lim, Ji-Sun; Lee, Kyung-Woo; Lee, Min-Goo; Chi, Sung-Gil			NORE1A directs apoptotic switch of TNF signaling through reciprocal modulation of ITCH-mediated destruction of TNFRI and BAX	ONCOGENE			English	Article							TUMOR-NECROSIS-FACTOR; E3 UBIQUITIN LIGASE; NF-KAPPA-B; SUPPRESSOR GENE; CONFORMATIONAL-CHANGE; RAS; ALPHA; EFFECTOR; RASSF1A; DEATH	NORE1A (RASSF5) is a tumor suppressor of the Ras-association domain family (RASSF) that is commonly inactivated in multiple human cancers. However, the molecular mechanism underlying its growth inhibition function remains largely undefined. Here we report that NORE1A antagonizes tumor necrosis factor receptor I (TNFRI) through the assembly of ITCH-mediated destruction complex to suppress TNF-NF-kappa B signaling and tumorigenesis. Moreover, NORE1A is identified as a transcription target of NF-kappa B, which directs an apoptotic switch of TNF effect by blocking ITCH interaction with and ubiquitination of BAX. Mechanistically, NORE1A binds directly to TNFRI and ITCH via the C1 and PPXY domains, respectively to facilitate the formation of ITCH-mediated destruction complex followed by ubiquitination-mediated lysosomal degradation of TNFRI. Through this function, NORE1A suppresses TNF-induced NF-kappa B-mediated transcription of pro-inflammatory and tumor-promoting genes, epithelial-to-mesenchymal transition, invasion and migration of tumor cells, and also debilitates tumor cell activation of macrophage and fibroblast. While NORE1A suppresses TNF receptor-mediated apoptosis, it activates TNF-induced apoptosis through BAX activation by protecting BAX from ITCH binding and ubiquitination. Cytotoxic response to TNF is substantially attenuated in NORE1A-depleted cells and tumors, and NORE1A-induced tumor regression is highly impeded in BAX-depleted tumors. An inverse correlation is shown between NORE1A and TNFRI expression in both cancer cell lines and primary tumors, and NORE1A effect on survival of cancer patients is strongly associated with expression status of ITCH. Collectively, this study uncovers that NORE1A directs a substrate switch of ITCH favoring TNFRI over BAX to terminate TNF signaling and accelerate apoptosis, illuminating the mechanistic consequence of NORE1A inactivation in tumorigenesis.	[Ko, Kyung-Phil; Jeong, Seong-In; Lim, Ji-Sun; Lee, Kyung-Woo; Lee, Min-Goo; Chi, Sung-Gil] Korea Univ, Dept Life Sci, Seoul 02841, South Korea	Korea University	Chi, SG (corresponding author), Korea Univ, Dept Life Sci, Seoul 02841, South Korea.	chi6302@korea.ac.kr		Chi, Sung-Gil/0000-0003-4643-9003	National Research Foundation of Korea, Republic of Korea [NRF-2018R1A2A1A05020236]; Korea University Grant, Republic of Korea [K1705811]	National Research Foundation of Korea, Republic of Korea(National Research Foundation of Korea); Korea University Grant, Republic of Korea	This work was supported in part by National Research Foundation of Korea (Grant numbers NRF-2018R1A2A1A05020236, SGC) and Korea University Grant (K1705811, SGC), Republic of Korea.	Avruch J, 2009, J BIOL CHEM, V284, P11001, DOI 10.1074/jbc.R800073200; Azakir BA, 2010, FEBS J, V277, P1319, DOI 10.1111/j.1742-4658.2010.07562.x; Baillat G, 2005, BBA-MOL CELL RES, V1745, P101, DOI 10.1016/j.bbamcr.2004.12.005; Baksh S, 2005, MOL CELL, V18, P637, DOI 10.1016/j.molcel.2005.05.010; Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628; Benard G, 2010, EMBO J, V29, P1458, DOI 10.1038/emboj.2010.39; Calvisi DF, 2009, CANCER RES, V69, P4629, DOI 10.1158/0008-5472.CAN-08-3672; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chen JD, 2003, CANCER CELL, V4, P405, DOI 10.1016/S1535-6108(03)00269-1; Choi YB, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00422-16; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; D'Alessio A, 2005, AM J PATHOL, V166, P1273, DOI 10.1016/S0002-9440(10)62346-2; Donninger H, 2015, J CELL BIOL, V208, P777, DOI 10.1083/jcb.201408087; Faustman D, 2010, NAT REV DRUG DISCOV, V9, P482, DOI 10.1038/nrd3030; Foley CJ, 2008, MOL CELL BIOL, V28, P4520, DOI 10.1128/MCB.02011-07; Fritsch J, 2014, MOL CELL BIOL, V34, P3214, DOI 10.1128/MCB.00048-14; Guan JJ, 2015, STEM CELL RES THER, V6, DOI 10.1186/scrt539; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hong IS, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.64; Irimia M, 2004, ONCOGENE, V23, P8695, DOI 10.1038/sj.onc.1207914; Johnson BN, 2012, P NATL ACAD SCI USA, V109, P6283, DOI 10.1073/pnas.1113248109; Jones SJ, 1999, J IMMUNOL, V162, P1042; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kim H, 2015, CELL REP, V11, P1151, DOI 10.1016/j.celrep.2015.04.048; Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623; Kraus S, 2009, CURR OPIN PHARMACOL, V9, P405, DOI 10.1016/j.coph.2009.06.006; Lee CK, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-577; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Martinez-Reza I, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0398-9; Matthews CP, 2007, CURR CANCER DRUG TAR, V7, P317, DOI 10.2174/156800907780809723; Ofengeim D, 2013, NAT REV MOL CELL BIO, V14, P727, DOI 10.1038/nrm3683; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Park J, 2010, J BIOL CHEM, V285, P35029, DOI 10.1074/jbc.M110.165506; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Prando ED, 2011, EPIGENETICS-US, V6, P1413, DOI 10.4161/epi.6.12.18271; Roussos ET, 2011, NAT REV CANCER, V11, P573, DOI 10.1038/nrc3078; Schneider-Brachert W, 2004, IMMUNITY, V21, P415, DOI 10.1016/j.immuni.2004.08.017; Schneider-Brachert W, 2013, INT J MOL SCI, V14, P14475, DOI 10.3390/ijms140714475; Shembade N, 2008, NAT IMMUNOL, V9, P254, DOI 10.1038/ni1563; Stieglitz B, 2008, EMBO J, V27, P1995, DOI 10.1038/emboj.2008.125; Suryaraja R, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.91; TALMADGE JE, 1988, CANCER RES, V48, P544; Tchikov V, 2011, EUR J CELL BIOL, V90, P467, DOI 10.1016/j.ejcb.2010.11.002; Tomita Y, 2004, INT J CANCER, V112, P927, DOI 10.1002/ijc.20493; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; van der Weyden L, 2007, BBA-REV CANCER, V1776, P58, DOI 10.1016/j.bbcan.2007.06.003; Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200; Vucic D, 2011, NAT REV MOL CELL BIO, V12, P439, DOI 10.1038/nrm3143; Wang P, 2009, CELL DEATH DIFFER, V16, P1192, DOI 10.1038/cdd.2009.51; Wertz IE, 2010, CELL DEATH DIFFER, V17, P14, DOI 10.1038/cdd.2009.168; Yau R, 2016, NAT CELL BIOL, V18, P579, DOI 10.1038/ncb3358; Zheng WW, 2016, INT J CLIN EXP MED, V9, P2027	53	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2020	39	34					5675	5689		10.1038/s41388-020-01392-y	http://dx.doi.org/10.1038/s41388-020-01392-y		JUL 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NE9FK	32690868				2022-12-17	WOS:000550641000001
J	Toda, J; Ichii, M; Oritani, K; Shibayama, H; Tanimura, A; Saito, H; Yokota, T; Motooka, D; Okuzaki, D; Kitai, Y; Muromoto, R; Kashiwakura, J; Matsuda, T; Hosen, N; Kanakura, Y				Toda, Jun; Ichii, Michiko; Oritani, Kenji; Shibayama, Hirohiko; Tanimura, Akira; Saito, Hideaki; Yokota, Takafumi; Motooka, Daisuke; Okuzaki, Daisuke; Kitai, Yuichi; Muromoto, Ryuta; Kashiwakura, Jun-ichi; Matsuda, Tadashi; Hosen, Naoki; Kanakura, Yuzuru			Signal-transducing adapter protein-1 is required for maintenance of leukemic stem cells in CML	ONCOGENE			English	Article							CHRONIC MYELOID-LEUKEMIA; BCR-ABL; MOLECULAR RESPONSE; TYROSINE KINASE; IN-VITRO; IMATINIB; CONTRIBUTES; ACTIVATION; NILOTINIB; SURVIVAL	The family of signal-transducing adapter proteins (STAPs) has been reported to be involved in a variety of intracellular signaling pathways and implicated as transcriptional factors. We previously cloned STAP-2 as a c-Fms interacting protein and explored its effects on chronic myeloid leukemia (CML) leukemogenesis. STAP-2 binds to BCR-ABL, upregulates BCR-ABL phosphorylation, and activates its downstream molecules. In this study, we evaluated the role of STAP-1, another member of the STAP family, in CML pathogenesis. We found that the expression of STAP-1 is aberrantly upregulated in CML stem cells (LSCs) in patients' bone marrow. Using experimental model mice, deletion of STAP-1 prolonged the survival of CML mice with inducing apoptosis of LSCs. The impaired phosphorylation status of STAT5 by STAP-1 ablation leads to downregulation of antiapoptotic genes, Bcl-2 and Bcl-xL. Interestingly, transcriptome analyses indicated that STAP-1 affects several signaling pathways related to BCR-ABL, JAK2, and PPAR gamma. This adapter protein directly binds to not only BCR-ABL, but also STAT5 proteins, showing synergistic effects of STAP-1 inhibition and BCR-ABL or JAK2 tyrosine kinase inhibition. Our results identified STAP-1 as a regulator of CML LSCs and suggested it to be a potential therapeutic target for CML.	[Toda, Jun; Ichii, Michiko; Oritani, Kenji; Shibayama, Hirohiko; Tanimura, Akira; Saito, Hideaki; Yokota, Takafumi; Hosen, Naoki; Kanakura, Yuzuru] Osaka Univ, Dept Hematol & Oncol, Grad Sch Med, Suita, Osaka, Japan; [Oritani, Kenji] Int Univ Hlth & Welf, Grad Sch Med Sci, Dept Hematol, Narita, Japan; [Motooka, Daisuke; Okuzaki, Daisuke] Osaka Univ, Genome Informat Res Ctr, Res Inst Microbial Dis, Suita, Osaka, Japan; [Kitai, Yuichi; Muromoto, Ryuta; Kashiwakura, Jun-ichi; Matsuda, Tadashi] Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Sapporo, Hokkaido, Japan; [Kanakura, Yuzuru] Sumitomo Hosp, Osaka, Japan	Osaka University; International University of Health & Welfare; Osaka University; Hokkaido University; Sumitomo Hospital	Ichii, M (corresponding author), Osaka Univ, Dept Hematol & Oncol, Grad Sch Med, Suita, Osaka, Japan.	michii@bldon.med.osaka-u.ac.jp	Matsuda, Tadashi/A-3835-2012; Muromoto, Ryuta/E-4203-2012; Okuzaki, Daisuke/AAN-5641-2020	Matsuda, Tadashi/0000-0002-3089-3757; Muromoto, Ryuta/0000-0002-7474-493X; Okuzaki, Daisuke/0000-0002-4552-783X; Shibayama, Hirohiko/0000-0003-4014-2815; ichii, michiko/0000-0002-0018-6656; /0000-0002-0297-5640	Japan Society for the Promotion of Science KAKENHI [16K09872, 19K17829]	Japan Society for the Promotion of Science KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors would like to thank the courageous patients for participation and contribution to this study. We are also grateful to Ms. Habuchi, Ms. Shih, and Mr. Takashima (Osaka University) for technical support. This work was supported in part by Japan Society for the Promotion of Science KAKENHI (Grant Nos 16K09872 and 19K17829).	Abraham SA, 2016, NATURE, V534, P341, DOI 10.1038/nature18288; Agarwal P, 2019, CELL STEM CELL, V24, P769, DOI 10.1016/j.stem.2019.02.018; Agerstam H, 2016, BLOOD, V128, P2683, DOI 10.1182/blood-2015-11-679985; Chomel JC, 2016, ONCOTARGET, V7, P35293, DOI 10.18632/oncotarget.9182; Chu S, 2011, BLOOD, V118, P5565, DOI 10.1182/blood-2010-12-327437; Copland M, 2006, BLOOD, V107, P4532, DOI 10.1182/blood-2005-07-2947; Corbin AS, 2011, J CLIN INVEST, V121, P396, DOI 10.1172/JCI35721; Diaz-Blanco E, 2007, LEUKEMIA, V21, P494, DOI 10.1038/sj.leu.2404549; Fujita N, 2014, EUR J IMMUNOL, V44, P1791, DOI 10.1002/eji.201344239; Gallipoli P, 2014, BLOOD, V124, P1492, DOI 10.1182/blood-2013-12-545640; Gallipoli P, 2013, BLOOD, V122, P3335, DOI 10.1182/blood-2013-02-485607; Giustacchini A, 2017, NAT MED, V23, P692, DOI 10.1038/nm.4336; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; Hamilton A, 2012, BLOOD, V119, P1501, DOI 10.1182/blood-2010-12-326843; Hoelbl A, 2010, EMBO MOL MED, V2, P98, DOI 10.1002/emmm.201000062; Hurtz C, 2011, J EXP MED, V208, P2163, DOI 10.1084/jem.20110304; Ikeda O, 2011, CANCER SCI, V102, P756, DOI 10.1111/j.1349-7006.2010.01842.x; Jiang XY, 2002, BLOOD, V100, P3731, DOI 10.1182/blood-2002-05-1324; Lemoli RM, 2009, BLOOD, V114, P5191, DOI 10.1182/blood-2008-08-176016; Liu X, 2017, LEUKEMIA, V31, P2376, DOI 10.1038/leu.2017.108; Mahon FX, 2010, LANCET ONCOL, V11, P1029, DOI 10.1016/S1470-2045(10)70233-3; Masuhara M, 2000, BIOCHEM BIOPH RES CO, V268, P697, DOI 10.1006/bbrc.2000.2223; Minoguchi M, 2003, J BIOL CHEM, V278, P11182, DOI 10.1074/jbc.M211230200; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734; Nelson EA, 2011, BLOOD, V117, P3421, DOI 10.1182/blood-2009-11-255232; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Ohya K, 1999, P NATL ACAD SCI USA, V96, P11976, DOI 10.1073/pnas.96.21.11976; Prost S, 2015, NATURE, V525, P380, DOI 10.1038/nature15248; Quintas-Cardama A, 2009, BLOOD, V113, P1619, DOI 10.1182/blood-2008-03-144790; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; Reynaud D, 2011, CANCER CELL, V20, P661, DOI 10.1016/j.ccr.2011.10.012; Ross DM, 2010, LEUKEMIA, V24, P1719, DOI 10.1038/leu.2010.185; Ross DM, 2013, BLOOD, V122, P515, DOI 10.1182/blood-2013-02-483750; Saussele S, 2018, LANCET ONCOL, V19, P747, DOI 10.1016/S1470-2045(18)30192-X; Sekine Y, 2005, J BIOL CHEM, V280, P8188, DOI 10.1074/jbc.M411692200; Sekine Y, 2012, ONCOGENE, V31, P4384, DOI 10.1038/onc.2011.604; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Steeghs EMP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-17704-4; Stoecker K, 2009, BIOCHEM BIOPH RES CO, V379, P121, DOI 10.1016/j.bbrc.2008.12.021; Sweet K, 2018, LEUKEMIA RES, V74, P89, DOI 10.1016/j.leukres.2018.10.002; Tokunaga M, 2010, J BIOL CHEM, V285, P31774, DOI 10.1074/jbc.M110.118653; Uchida N, 2019, MOL THER-METH CLIN D, V13, P187, DOI 10.1016/j.omtm.2019.01.005; Wang Y, 2007, BLOOD, V109, P2147, DOI 10.1182/blood-2006-08-040022; Warfvinge R, 2017, BLOOD, V129, P2384, DOI 10.1182/blood-2016-07-728873; Warsch W, 2012, ONCOTARGET, V3, P1669; Zhang B, 2012, CANCER CELL, V21, P577, DOI 10.1016/j.ccr.2012.02.018; Zhang HJ, 2012, BLOOD, V119, P2595, DOI 10.1182/blood-2011-10-387381; Zhao C, 2007, CANCER CELL, V12, P528, DOI 10.1016/j.ccr.2007.11.003; Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737	50	4	4	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2020	39	34					5601	5615		10.1038/s41388-020-01387-9	http://dx.doi.org/10.1038/s41388-020-01387-9		JUL 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NE9FK	32661325	Green Published, hybrid			2022-12-17	WOS:000548100200003
J	Kohvakka, A; Sattari, M; Shcherban, A; Annala, M; Urbanucci, A; Kesseli, J; Tammela, TLJ; Kivinummi, K; Latonen, L; Nykter, M; Visakorpi, T				Kohvakka, Annika; Sattari, Mina; Shcherban, Anastasia; Annala, Matti; Urbanucci, Alfonso; Kesseli, Juha; Tammela, Teuvo L. J.; Kivinummi, Kati; Latonen, Leena; Nykter, Matti; Visakorpi, Tapio			AR and ERG drive the expression of prostate cancer specific long noncoding RNAs	ONCOGENE			English	Article							ANDROGEN RECEPTOR CISTROME; TMPRSS2-ERG GENE FUSION; DNA ELEMENTS; OVEREXPRESSION; ENCYCLOPEDIA; PROGRESSION; BINDING; PTEN	Long noncoding RNAs (lncRNAs) play pivotal roles in cancer development and progression, and some function in a highly cancer-specific manner. However, whether the cause of their expression is an outcome of a specific regulatory mechanism or nonspecific transcription induced by genome reorganization in cancer remains largely unknown. Here, we investigated a group of lncRNAs that we previously identified to be aberrantly expressed in prostate cancer (PC), called TPCATs. Our high-throughput real-time PCR experiments were integrated with publicly available RNA-seq and ChIP-seq data and revealed that the expression of a subset of TPCATs is driven by PC-specific transcription factors (TFs), especially androgen receptor (AR) and ETS-related gene (ERG). Our in vitro validations confirmed that AR and ERG regulated a subset of TPCATs, most notably forEPCART. Knockout ofEPCARTwas found to reduce migration and proliferation of the PC cells in vitro. The high expression ofEPCARTand two other TPCATs (TPCAT-3-174133andTPCAT-18-31849) were also associated with the biochemical recurrence of PC in prostatectomy patients and were independent prognostic markers. Our findings suggest that the expression of numerous PC-associated lncRNAs is driven by PC-specific mechanisms and not by random cellular events that occur during cancer development. Furthermore, we report three prospective prognostic markers for the early detection of advanced PC and showEPCARTto be a functionally relevant lncRNA in PC.	[Kohvakka, Annika; Sattari, Mina; Shcherban, Anastasia; Annala, Matti; Kesseli, Juha; Tammela, Teuvo L. J.; Kivinummi, Kati; Nykter, Matti; Visakorpi, Tapio] Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland; [Kohvakka, Annika; Sattari, Mina; Shcherban, Anastasia; Annala, Matti; Kesseli, Juha; Tammela, Teuvo L. J.; Kivinummi, Kati; Nykter, Matti; Visakorpi, Tapio] Tampere Univ Hosp, Tays Canc Ctr, Tampere, Finland; [Urbanucci, Alfonso] Oslo Univ Hosp, Inst Canc Res, Dept Tumor Biol, Oslo, Norway; [Tammela, Teuvo L. J.] Tampere Univ Hosp, Dept Urol, Tampere, Finland; [Latonen, Leena] Univ Eastern Finland, Inst Biomed, Kuopio, Finland; [Visakorpi, Tapio] Fimlab Labs Ltd, Tampere Univ Hosp, Tampere, Finland	Tampere University; Tampere University; Tampere University Hospital; University of Oslo; Tampere University; Tampere University Hospital; University of Eastern Finland; Tampere University; Tampere University Hospital	Visakorpi, T (corresponding author), Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland.; Visakorpi, T (corresponding author), Tampere Univ Hosp, Tays Canc Ctr, Tampere, Finland.; Visakorpi, T (corresponding author), Fimlab Labs Ltd, Tampere Univ Hosp, Tampere, Finland.	tapio.visakorpi@tuni.fi	Urbanucci, Alfonso/S-4450-2019	Urbanucci, Alfonso/0000-0003-2931-3652; Sattari, Mina/0000-0001-7358-616X; Nykter, Matti/0000-0001-6956-2843	Academy of Finland [317755, 310829, 317871]; Sigrid Juselius Foundation; Cancer Society of Finland; Business Finland; Finnish Cultural Foundation; European Union [721746]; Norwegian Cancer Society [AU 198016-2018]; Research collegium of the University of Tampere/IASR	Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Cancer Society of Finland; Business Finland; Finnish Cultural Foundation(Finnish Cultural FoundationFinnish IT center for science); European Union(European Commission); Norwegian Cancer Society(Norwegian Cancer Society); Research collegium of the University of Tampere/IASR	This study was supported by grants from the Academy of Finland (TV 317755, MN 310829, and LL 317871), Sigrid Juselius Foundation (TV and LL), Cancer Society of Finland, Business Finland, the Finnish Cultural Foundation (AK), the European Union's Horizon 2020 (MS, TransPot - 721746), Norwegian Cancer Society grant (AU 198016-2018), Research collegium of the University of Tampere/IASR (KK). The authors want to thank Jenni Jouppila, Paula Kosonen, Riina Kylatie, Paivi Martikainen, Hanna Selin, and Marika Vaha-Jaakkola for their technical assistance and Tampere Imaging Facility (TIF) for their service. The results published here are in part based upon data generated by The Cancer Genome Atlas project (dbGaP Study Accession: phs000178.v9.p8) established by the NCI and NHGRI. Information about TCGA can be found at http://cancergenome.nih.gov. We acknowledge ENCODE Consortium and the ENCODE production laboratories for generating the DNase-seq data.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Boormans JL, 2011, EUR UROL, V60, P183, DOI 10.1016/j.eururo.2011.03.028; Bottcher R, 2015, ONCOTARGET, V6, P4036; Carver BS, 2009, NAT GENET, V41, P619, DOI 10.1038/ng.370; Cerveira N, 2006, NEOPLASIA, V8, P826, DOI 10.1593/neo.06427; Chawla K, 2013, BIOINFORMATICS, V29, P2519, DOI 10.1093/bioinformatics/btt432; Chen Y, 2013, NAT MED, V19, P1023, DOI 10.1038/nm.3216; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; Davis CA, 2018, NUCLEIC ACIDS RES, V46, pD794, DOI 10.1093/nar/gkx1081; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Hessels D, 2003, EUR UROL, V44, P8, DOI 10.1016/S0302-2838(03)00201-X; Kron KJ, 2017, NAT GENET, V49, P1336, DOI 10.1038/ng.3930; Linja MJ, 2001, CANCER RES, V61, P3550; Martens-Uzunova ES, 2014, EUR UROL, V65, P1140, DOI 10.1016/j.eururo.2013.12.003; Nam RK, 2007, CANCER BIOL THER, V6, P40, DOI 10.4161/cbt.6.1.3489; Perner S, 2007, AM J SURG PATHOL, V31, P882, DOI 10.1097/01.pas.0000213424.38503.aa; Perner S, 2006, CANCER RES, V66, P8337, DOI 10.1158/0008-5472.CAN-06-1482; Pomerantz MM, 2015, NAT GENET, V47, P1346, DOI 10.1038/ng.3419; Prensner JR, 2014, LANCET ONCOL, V15, P1469, DOI 10.1016/S1470-2045(14)71113-1; Prensner JR, 2011, NAT BIOTECHNOL, V29, P742, DOI 10.1038/nbt.1914; Sahu A, 2015, TRENDS CANCER, V1, P93, DOI 10.1016/j.trecan.2015.08.010; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Shukla S, 2016, NEOPLASIA, V18, P489, DOI 10.1016/j.neo.2016.07.001; Su XP, 2014, ONCOTARGET, V5, P9864, DOI 10.18632/oncotarget.2454; Takayama K, 2013, EMBO J, V32, P1665, DOI 10.1038/emboj.2013.99; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Urbanucci A, 2012, ONCOGENE, V31, P2153, DOI 10.1038/onc.2011.401; Waltering KK, 2009, CANCER RES, V69, P8141, DOI 10.1158/0008-5472.CAN-09-0919; Weischenfeldt J, 2013, CANCER CELL, V23, P159, DOI 10.1016/j.ccr.2013.01.002; White NM, 2017, EUR UROL, V71, P257, DOI 10.1016/j.eururo.2016.07.012; White NM, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0429-8; Yan XH, 2015, CANCER CELL, V28, P529, DOI 10.1016/j.ccell.2015.09.006; Yang LQ, 2013, NATURE, V500, P598, DOI 10.1038/nature12451; Ylipaa A, 2015, CANCER RES, V75, P4026, DOI 10.1158/0008-5472.CAN-15-0217; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Zhang A, 2015, CELL REP, V13, P209, DOI 10.1016/j.celrep.2015.08.069; Zhang YJ, 2018, NAT GENET, V50, P814, DOI 10.1038/s41588-018-0120-1	38	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 23	2020	39	30					5241	5251		10.1038/s41388-020-1365-6	http://dx.doi.org/10.1038/s41388-020-1365-6		JUN 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MO5BV	32555329	Green Accepted			2022-12-17	WOS:000545371000005
J	Okumura, K; Saito, M; Yoshizawa, Y; Ito, Y; Isogai, E; Araki, K; Wakabayashi, Y				Okumura, Kazuhiro; Saito, Megumi; Yoshizawa, Yasuhiro; Ito, Yuki; Isogai, Eriko; Araki, Kimi; Wakabayashi, Yuichi			Pak1 maintains epidermal stem cells by regulating Langerhans cells and is required for skin carcinogenesis	ONCOGENE			English	Article							P21-ACTIVATED KINASES; CHEMICAL CARCINOGENESIS; TUMOR PROGRESSION; CANCER; RECEPTOR; MICE; MECHANISMS; INHIBITION; ALPHA	Pak1 (serine/threonine p21-activated kinases) was previously reported to have oncogenic activity in several cancers. However, its roles in the cancer microenvironment are poorly understood. We demonstrated that Pak1 expression in Langerhans cells (LCs) is essential for the maintenance of epidermal stem cells and skin tumor development. We found that PAK1 is localized in LCs by immunohistochemistry. Furthermore, the number of LCs significantly decreased in MSM/Ms Pak1 homozygous knockout mice (MSM/Ms-Pak1(-/-)). F-1 hybrid (FVB/NxMSM/Ms) Pak1 heterozygous knockout mice (F-1-Pak1(+/-)) had increased numbers of Th17 cells in the skin. Therefore, Pak1 knockdown cells were prepared using LC-derived XS52 cells (XS52-Pak1KD) and co-cultured with keratinocyte-derived C5N cells. As a result, XS52-Pak1KD cell supernatants promoted C5N cell proliferation. We then carried out DMBA/TPA skin carcinogenesis experiments using F-1-Pak1(+/-) mice. Of note, F-1-Pak1(+/-) mice exhibited stronger resistance to skin tumors than control mice. F-1-Pak1(+/-) mice had fewer epidermal stem cells in the skin bulge. Our study suggested that Pak1 regulates the epidermal stem cell number by changing the properties of LCs and functions in skin carcinogenesis. We clarified a novel role of Pak1 in regulating LCs as a potential therapeutic target in skin immune disease and carcinogenesis.	[Okumura, Kazuhiro; Saito, Megumi; Yoshizawa, Yasuhiro; Ito, Yuki; Isogai, Eriko; Wakabayashi, Yuichi] Chiba Canc Ctr, Res Inst, Dept Carcinogenesis Res, Div Expt Anim Res,Chuo Ku, 666-2 Nitonacho, Chiba 2608717, Japan; [Araki, Kimi] Inst Resource Dev & Anal, Div Dev Genet, Chuo Ku, 2-2-1 Honjo, Kumamoto 8600811, Japan	Chiba Cancer Center	Wakabayashi, Y (corresponding author), Chiba Canc Ctr, Res Inst, Dept Carcinogenesis Res, Div Expt Anim Res,Chuo Ku, 666-2 Nitonacho, Chiba 2608717, Japan.	yuichi_wakabayashi@chiba-cc.jp			JSPS KAKENHI grant [JP19K07494, JP15K06817]	JSPS KAKENHI grant(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors thank Dr. Naoki Okada of Osaka university and Dr. Akira Takashima for providing XS52 and NS47 cells, and Dr. Allan Balmain of University of California, San Francisco for providing C5N cells. The authors also thank Mrs. Sakura Katori and Mrs. Akemi Hongu for their technical assistance. This study was supported by JSPS KAKENHI grant number JP19K07494. This work was supported by JSPS KAKENHI Grant Number JP15K06817 (AdAMS).	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Allen JD, 2009, BLOOD, V113, P2695, DOI 10.1182/blood-2008-06-160861; Aoto Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31349-x; Araki K, 2009, MAMM GENOME, V20, P14, DOI 10.1007/s00335-008-9160-7; Beesetti S, 2019, J CELL PHYSIOL, V234, P969, DOI 10.1002/jcp.26925; Cataisson C, 2012, J EXP MED, V209, P1689, DOI 10.1084/jem.20101355; Chow HY, 2012, CANCER RES, V72, P5966, DOI 10.1158/0008-5472.CAN-12-2246; Cipolat S, 2014, ELIFE, V3, DOI 10.7554/eLife.01888; Clausen BE, 2015, J INVEST DERMATOL, V135, P1218, DOI 10.1038/jid.2014.520; Di Cesare A, 2009, J INVEST DERMATOL, V129, P1339, DOI 10.1038/jid.2009.59; Eaton LH, 2018, BRIT J DERMATOL, V178, P1364, DOI 10.1111/bjd.16172; Forcales SV, 2012, EMBO J, V31, P301, DOI 10.1038/emboj.2011.391; Gan JF, 2016, P NATL ACAD SCI USA, V113, P14745, DOI 10.1073/pnas.1618582114; Garcia-Garcia E, 2002, J LEUKOCYTE BIOL, V72, P107; Go C, 1999, CANCER RES, V59, P2861; Gonzalez-Villasana V, 2015, CLIN CANCER RES, V21, P2127, DOI 10.1158/1078-0432.CCR-14-2279; Gorelik L, 2001, NAT MED, V7, P1118, DOI 10.1038/nm1001-1118; Guo FK, 2010, P NATL ACAD SCI USA, V107, P18505, DOI 10.1073/pnas.1010249107; Guo YX, 2017, J PATHOL, V243, P208, DOI 10.1002/path.4940; He H, 2013, BBA-MOL CELL RES, V1833, P33, DOI 10.1016/j.bbamcr.2012.10.015; Huynh N, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3432-0; Huynh N, 2016, CANCER BIOL THER, V17, P813, DOI 10.1080/15384047.2016.1195045; Jagadeeshan S, 2016, ANN ONCOL, V27, P1546, DOI 10.1093/annonc/mdw184; Jantschitsch C, 2012, J INVEST DERMATOL, V132, P1479, DOI 10.1038/jid.2011.469; Jensen KB, 2010, NAT PROTOC, V5, P898, DOI 10.1038/nprot.2010.39; Kaplan DH, 2017, NAT IMMUNOL, V18, P1068, DOI 10.1038/ni.3815; Kelly Mollie L, 2012, Cell Logist, V2, P84; Kemp CJ, 2005, SEMIN CANCER BIOL, V15, P460, DOI 10.1016/j.semcancer.2005.06.003; Kim E, 2014, CANCER RES, V74, P5520, DOI 10.1158/0008-5472.CAN-14-0735; Kumar R, 2017, GENE, V605, P20, DOI 10.1016/j.gene.2016.12.014; Langowski JL, 2006, NATURE, V442, P461, DOI 10.1038/nature04808; Lewis JM, 2015, J INVEST DERMATOL, V135, P1405, DOI 10.1038/jid.2014.411; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luckashenak N, 2013, J IMMUNOL, V190, P27, DOI 10.4049/jimmunol.1201082; Modi BG, 2012, SCIENCE, V335, P104, DOI 10.1126/science.1211600; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; Muller G, 2020, AUTOPHAGY, V16, P1380, DOI 10.1080/15548627.2019.1686728; Nagao K, 2012, NAT IMMUNOL, V13, P744, DOI 10.1038/ni.2353; Nardinocchi L, 2015, EUR J IMMUNOL, V45, P922, DOI 10.1002/eji.201445052; Okumura K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097201; Okumura K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102111; Ong CC, 2011, P NATL ACAD SCI USA, V108, P7177, DOI 10.1073/pnas.1103350108; Ortner D, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1260215; Schwarz T, 2011, EUR J CELL BIOL, V90, P560, DOI 10.1016/j.ejcb.2010.09.011; Seoane J, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022277; Singh A, 2016, CARCINOGENESIS, V37, P72, DOI 10.1093/carcin/bgv162; Tran G, 2018, J AM ACAD DERMATOL, V78, P579, DOI 10.1016/j.jaad.2017.09.022; van de Ven R, 2011, BLOOD, V118, P2502, DOI 10.1182/blood-2011-03-344838; Wang A, 2020, J DERMATOL, V47, P104, DOI 10.1111/1346-8138.15184; Wang K, 2018, INT J ONCOL, V52, P261, DOI 10.3892/ijo.2017.4193; Wang L, 2010, CANCER RES, V70, P10112, DOI 10.1158/0008-5472.CAN-10-0775; Wong LLY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068843; XU S, 1995, J IMMUNOL, V154, P2697; Yeo D, 2015, PANCREAS, V44, P363, DOI 10.1097/MPA.0000000000000276; Yi CL, 2008, CANCER RES, V68, P7932, DOI 10.1158/0008-5472.CAN-08-0866; YUSPA SH, 1994, J INVEST DERMATOL, V103, pS90, DOI 10.1111/1523-1747.ep12399255; Zhang W, 2015, CELL DEATH DIFFER, V22, P287, DOI 10.1038/cdd.2014.142; Zhu G, 2012, ONCOGENE, V31, P1001, DOI 10.1038/onc.2011.294; Zoumpourlis V, 2003, CARCINOGENESIS, V24, P1159, DOI 10.1093/carcin/bgg067	60	4	4	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	24					4756	4769		10.1038/s41388-020-1323-3	http://dx.doi.org/10.1038/s41388-020-1323-3		MAY 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LY0HO	32427988				2022-12-17	WOS:000534491700001
J	Arnal-Estape, A; Cai, WLL; Albert, AE; Zhao, MH; Stevens, LE; Lopez-Giraldez, F; Patel, KD; Tyagi, S; Schmitt, EM; Westbrook, TF; Nguyen, DX				Arnal-Estape, Anna; Cai, Wesley L.; Albert, Alexandra E.; Zhao, Minghui; Stevens, Laura E.; Lopez-Giraldez, Francesc; Patel, Kiran D.; Tyagi, Siddhartha; Schmitt, Earlene M.; Westbrook, Thomas F.; Nguyen, Don X.			Tumor progression and chromatin landscape of lung cancer are regulated by the lineage factor GATA6	ONCOGENE			English	Article							STEM-CELLS; ADENOCARCINOMA; DIFFERENTIATION; SUPPRESSION; EXPRESSION; ORIGIN; NKX2-1; MICE	Lineage selective transcription factors (TFs) are important regulators of tumorigenesis, but their biological functions are often context dependent with undefined epigenetic mechanisms of action. In this study, we uncover a conditional role for the endodermal and pulmonary specifying TF GATA6 in lung adenocarcinoma (LUAD) progression. Impairing Gata6 in genetically engineered mouse models reduces the proliferation and increases the differentiation of Kras mutant LUAD tumors. These effects are influenced by the epithelial cell type that is targeted for transformation and genetic context of Kras-mediated tumor initiation. In LUAD cells derived from surfactant protein C expressing progenitors, we identify multiple genomic loci that are bound by GATA6. Moreover, suppression of Gata6 in these cells significantly alters chromatin accessibility, particularly at distal enhancer elements. Analogous to its paradoxical activity in lung development, GATA6 expression fluctuates during different stages of LUAD progression and can epigenetically control diverse transcriptional programs associated with bone morphogenetic protein signaling, alveolar specification, and tumor suppression. These findings reveal how GATA6 can modulate the chromatin landscape of lung cancer cells to control their proliferation and divergent lineage dependencies during tumor progression.	[Arnal-Estape, Anna; Cai, Wesley L.; Zhao, Minghui; Stevens, Laura E.; Patel, Kiran D.; Nguyen, Don X.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Arnal-Estape, Anna; Nguyen, Don X.] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT 06510 USA; [Albert, Alexandra E.] Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; [Lopez-Giraldez, Francesc] Yale Univ, Sch Med, Yale Ctr Genome Anal, New Haven, CT USA; [Tyagi, Siddhartha; Schmitt, Earlene M.; Westbrook, Thomas F.] Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Tyagi, Siddhartha; Schmitt, Earlene M.; Westbrook, Thomas F.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Westbrook, Thomas F.] Baylor Coll Med, Therapeut Innovat Ctr THINC, Houston, TX 77030 USA; [Nguyen, Don X.] Yale Univ, Sch Med, Dept Med Med Oncol, New Haven, CT 06510 USA; [Stevens, Laura E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Yale University; Yale University; Yale University; Yale University; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Yale University; Harvard University; Dana-Farber Cancer Institute	Nguyen, DX (corresponding author), Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA.; Nguyen, DX (corresponding author), Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT 06510 USA.; Nguyen, DX (corresponding author), Yale Univ, Sch Med, Dept Med Med Oncol, New Haven, CT 06510 USA.	don.nguyen@yale.edu	López-Giráldez, Francesc/A-5251-2011	López-Giráldez, Francesc/0000-0001-7476-9822; , SIDDHARTHA/0000-0001-5543-4787; Cai, Wesley L/0000-0002-3871-5509	Lung Cancer Research Foundation; McNair Medical Institute [R01CA178039]; Cancer Research UK Grand Challenge; Mark Foundation for Cancer Research [R01CA166376, R01CA191489];  [DGE-1122492];  [T32GM007205];  [T32CA193200]	Lung Cancer Research Foundation; McNair Medical Institute; Cancer Research UK Grand Challenge(Cancer Research UK); Mark Foundation for Cancer Research; ; ; 	We thank Qin Yan for discussion. This work was funded by the Lung Cancer Research Foundation (AA-E), the McNair Medical Institute (TFW), R01CA178039 (TFW), Cancer Research UK Grand Challenge (TFW), Mark Foundation for Cancer Research (TFW), R01CA166376 (DXN), and R01CA191489 (DXN). WLC was supported by DGE-1122492, AEA by T32GM007205, and KDP by T32CA193200.	Atlasi Y, 2017, NAT REV GENET, V18, DOI 10.1038/nrg.2017.57; Barkauskas CE, 2013, J CLIN INVEST, V123, P3025, DOI 10.1172/JCI68782; Borczuk AC, 2003, AM J PATHOL, V163, P1949, DOI 10.1016/S0002-9440(10)63553-5; Chen TP, 2014, NAT REV GENET, V15, P93, DOI 10.1038/nrg3607; Chen Z, 2014, NAT REV CANCER, V14, P535, DOI 10.1038/nrc3775; Cheung WKC, 2015, ONCOGENE, V34, P5771, DOI 10.1038/onc.2015.85; Cheung WKC, 2013, CANCER CELL, V23, P725, DOI 10.1016/j.ccr.2013.04.009; Chung MI, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.163014; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Corces MR, 2017, NAT METHODS, V14, P959, DOI [10.1038/NMETH.4396, 10.1038/nmeth.4396]; David CJ, 2016, CELL, V164, P1015, DOI 10.1016/j.cell.2016.01.009; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Hirsch HA, 2010, CANCER CELL, V17, P348, DOI 10.1016/j.ccr.2010.01.022; Hu HC, 2016, J THORAC ONCOL, V11, P2161, DOI 10.1016/j.jtho.2016.07.016; IKEDA K, 1995, J BIOL CHEM, V270, P8108, DOI 10.1074/jbc.270.14.8108; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Kimura H, 2013, J HUM GENET, V58, P439, DOI 10.1038/jhg.2013.66; Kwei KA, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000081; Li CMC, 2015, GENE DEV, V29, P1850, DOI 10.1101/gad.267393.115; Liao CM, 2018, J CLIN INVEST, V128, P2944, DOI 10.1172/JCI96539; Lin L, 2012, P NATL ACAD SCI USA, V109, P4251, DOI 10.1073/pnas.1011989109; Liu C, 2002, AM J PHYSIOL-LUNG C, V283, pL468, DOI 10.1152/ajplung.00044.2002; Marino S, 2000, GENE DEV, V14, P994; Martinelli P, 2017, GUT, V66, P1665, DOI 10.1136/gutjnl-2015-311256; Martinelli P, 2016, GUT, V65, P476, DOI 10.1136/gutjnl-2014-308042; McCormack N, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-36; Mehta A, 2016, EMBO MOL MED, V8, P1380, DOI 10.15252/emmm.201606382; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Nakajima N, 2018, HISTOPATHOLOGY, V73, P38, DOI 10.1111/his.13500; Quinlan MP, 2008, CELL CYCLE, V7, P1332, DOI 10.4161/cc.7.10.5927; Sodhi CP, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-19; Stevens LE, 2017, CANCER RES, V77, P1905, DOI 10.1158/0008-5472.CAN-16-1978; Sutherland KD, 2014, P NATL ACAD SCI USA, V111, P4952, DOI 10.1073/pnas.1319963111; Whissell G, 2014, NAT CELL BIOL, V16, P695, DOI 10.1038/ncb2992; Whitsett JA, 2011, AM J RESP CRIT CARE, V184, P401, DOI 10.1164/rccm.201103-0495PP; Winslow MM, 2011, NATURE, V473, P101, DOI 10.1038/nature09881; Xu X, 2012, P NATL ACAD SCI USA, V109, P4910, DOI 10.1073/pnas.1112499109; Yang HH, 2002, DEVELOPMENT, V129, P2233; Yang YA, 2014, J CLIN INVEST, V124, P2696, DOI 10.1172/JCI72171; Zaret KS, 2011, GENE DEV, V25, P2227, DOI 10.1101/gad.176826.111; Zhang Y, 2008, NAT GENET, V40, P862, DOI 10.1038/ng.157	42	4	4	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	18					3726	3737		10.1038/s41388-020-1246-z	http://dx.doi.org/10.1038/s41388-020-1246-z		MAR 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LI5XR	32157212	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000518886000003
J	Rajan, SS; Amin, AD; Li, LX; Rolland, DC; Li, HQ; Kwon, D; Kweh, MF; Arumov, A; Roberts, ER; Yan, AM; Basrur, V; Elenitoba-Johnson, KSJ; Chen, XS; Puvvada, SD; Lussier, YA; Bilbao, D; Lim, MS; Schatz, JH				Rajan, Soumya S.; Amin, Amit Dipak; Li, Lingxiao; Rolland, Delphine C.; Li, Haiquan; Kwon, Deukwoo; Kweh, Mercedes F.; Arumov, Artavazd; Roberts, Evan R.; Yan, Aimin; Basrur, Venkatesha; Elenitoba-Johnson, Kojo S. J.; Chen, Xi Steven; Puvvada, Soham D.; Lussier, Yves A.; Bilbao, Daniel; Lim, Megan S.; Schatz, Jonathan H.			The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma	ONCOGENE			English	Article							NPM-ALK; ANAPLASTIC LYMPHOMA; TYROSINE PHOSPHORYLATION; KINASE INHIBITORS; APOPTOSIS; TUMOR; GENE; RESISTANCE; REVEALS; TARGET	Rational new strategies are needed to treat tumors resistant to kinase inhibitors. Mechanistic studies of resistance provide fertile ground for development of new approaches. Cancer drug addiction is a paradoxical resistance phenomenon, well-described in MEK-ERK-driven solid tumors, in which drug-target overexpression promotes resistance but a toxic overdose of signaling if the inhibitor is withdrawn. This can permit prolonged control of tumors through intermittent dosing. We and others showed previously that cancer drug addiction arises also in the hematologic malignancy ALK-positive anaplastic large-cell lymphoma (ALCL) resistant to ALK-specific tyrosine kinase inhibitors (TKIs). This is driven by the overexpression of the fusion kinase NPM1-ALK, but the mechanism by which ALK overactivity drives toxicity upon TKI withdrawal remained obscure. Here we reveal the mechanism of ALK-TKI addiction in ALCL. We interrogated the well-described mechanism of MEK/ERK pathway inhibitor addiction in solid tumors and found it does not apply to ALCL. Instead, phosphoproteomics and confirmatory functional studies revealed that the STAT1 overactivation is the key mechanism of ALK-TKI addiction in ALCL. The withdrawal of TKI from addicted tumors in vitro and in vivo leads to overwhelming phospho-STAT1 activation, turning on its tumor-suppressive gene-expression program and turning off STAT3's oncogenic program. Moreover, a novel NPM1-ALK-positive ALCL PDX model showed a significant survival benefit from intermittent compared with continuous TKI dosing. In sum, we reveal for the first time the mechanism of cancer drug addiction in ALK-positive ALCL and the benefit of scheduled intermittent dosing in high-risk patient-derived tumors in vivo.	[Rajan, Soumya S.; Arumov, Artavazd] Univ Miami, Miller Sch Med, Sheila & David Fuente Grad Program Canc Biol, Miami, FL 33136 USA; [Rajan, Soumya S.; Amin, Amit Dipak; Li, Lingxiao; Kwon, Deukwoo; Kweh, Mercedes F.; Arumov, Artavazd; Roberts, Evan R.; Yan, Aimin; Chen, Xi Steven; Bilbao, Daniel; Schatz, Jonathan H.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; [Amin, Amit Dipak; Li, Lingxiao; Kweh, Mercedes F.; Schatz, Jonathan H.] Univ Miami, Miller Sch Med, Dept Med, Div Hematol, Miami, FL 33136 USA; [Rolland, Delphine C.; Elenitoba-Johnson, Kojo S. J.; Lim, Megan S.] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA USA; [Li, Haiquan] Univ Arizona, Dept Biosyst Engn, Tucson, AZ USA; [Kwon, Deukwoo; Chen, Xi Steven] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA; [Basrur, Venkatesha] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Puvvada, Soham D.; Lussier, Yves A.] UA Canc Ctr, Bio5 Inst, Dept Med, Ann Arbor, MI USA; [Lussier, Yves A.] Univ Arizona, Interdisciplinary Program Stat, Tucson, AZ USA	University of Miami; University of Miami; University of Miami; University of Pennsylvania; Pennsylvania Medicine; University of Arizona; University of Miami; University of Michigan System; University of Michigan; University of Arizona	Schatz, JH (corresponding author), Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.; Schatz, JH (corresponding author), Univ Miami, Miller Sch Med, Dept Med, Div Hematol, Miami, FL 33136 USA.	jschatz@med.maimi.edu	Sundara Rajan, Soumya/GYJ-3752-2022; Rolland, Delphine/ABG-2497-2021	Schatz, Jonathan/0000-0003-1842-228X; Elenitoba-Johnson, Kojo/0000-0002-1082-1545; Amin, Amit Dipak/0000-0002-2613-2082; Bilbao Cortes, Daniel/0000-0003-1630-8811; Lim, Megan/0000-0002-0415-2867; Sundara Rajan, Soumya/0000-0001-8346-9741; Rolland, Delphine/0000-0002-7801-6534; Li, Haiquan/0000-0002-8049-0278; Arumov, Artavazd/0000-0002-9520-2777	National Institutes of Health/National Cancer Institute [1R01CA190696-01, 5R01CA190696-05]	National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a grant from National Institutes of Health/National Cancer Institute, 1R01CA190696-01 (JHS) and 5R01CA190696-05. We would also like to acknowledge the Sheila and David Fuente Graduate Program in Cancer Biology at University of Miami. SSR is a PhD candidate at University of Miami. This work is submitted in partial fulfillment of the requirement of the PhD. We would also like to thank Dr Izidore Lossos, University of Miami, for his input and suggestions in writing the manuscript.	Adam P, 2003, AM J SURG PATHOL, V27, P1473, DOI 10.1097/00000478-200311000-00012; Amin AD, 2015, CANCER RES, V75, P2916, DOI 10.1158/0008-5472.CAN-14-3437; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Beebe JD, 2018, PHARMACOL THERAPEUT, V191, P74, DOI 10.1016/j.pharmthera.2018.06.006; Bonvini P, 2004, CANCER RES, V64, P3256, DOI 10.1158/0008-5472.CAN-03-3531; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; BRUNET A, 1994, ONCOGENE, V9, P3379; Carpenter RL, 2014, CANCERS, V6, P897, DOI 10.3390/cancers6020897; Ceccon M, 2016, ONCOGENE, V35, P3854, DOI 10.1038/onc.2015.456; Chiarle R, 2005, NAT MED, V11, P623, DOI 10.1038/nm1249; Crockett DK, 2004, ONCOGENE, V23, P2617, DOI 10.1038/sj.onc.1207398; Croucher DR, 2013, CANCER RES, V73, P1969, DOI 10.1158/0008-5472.CAN-12-1472; Cui YX, 2009, BLOOD, V113, P5217, DOI 10.1182/blood-2008-06-160168; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Ferguson FM, 2018, NAT REV DRUG DISCOV, V17, P353, DOI 10.1038/nrd.2018.21; Gainor JF, 2016, CANCER DISCOV, V6, P1118, DOI 10.1158/2159-8290.CD-16-0596; Gambacorti-Passerini C, 2011, NEW ENGL J MED, V364, P775, DOI 10.1056/NEJMc1013224; Gardeux V, 2014, J AM MED INFORM ASSN, V21, P1015, DOI 10.1136/amiajnl-2013-002519; Haan S, 2005, CELL SIGNAL, V17, P1542, DOI 10.1016/j.cellsig.2005.03.010; Hong A, 2018, CANCER DISCOV, V8, P74, DOI 10.1158/2159-8290.CD-17-0682; Houghton PJ, 2014, PEDIATR BLOOD CANCER, V61, P1972, DOI 10.1002/pbc.25175; Johnson TW, 2014, J MED CHEM, V57, P4720, DOI 10.1021/jm500261q; Kameda H, 2009, BIOCHEM BIOPH RES CO, V378, P744, DOI 10.1016/j.bbrc.2008.11.102; Kodama T, 2014, CANCER LETT, V351, P215, DOI 10.1016/j.canlet.2014.05.020; Kong XJ, 2017, NATURE, V550, P270, DOI 10.1038/nature24037; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Lim MS, 2009, BLOOD, V114, P1585, DOI 10.1182/blood-2009-02-204735; Marzec M, 2007, ONCOGENE, V26, P813, DOI 10.1038/sj.onc.1209843; McDonnell SRP, 2012, ONCOGENE, V31, P3733, DOI 10.1038/onc.2011.542; McDonnell SRP, 2013, BLOOD, V122, P958, DOI 10.1182/blood-2013-01-482026; Moriceau G, 2015, CANCER CELL, V27, P240, DOI 10.1016/j.ccell.2014.11.018; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Mosse YP, 2017, J CLIN ONCOL, V35, P3215, DOI 10.1200/JCO.2017.73.4830; Onciu M, 2003, BLOOD, V102, P2642, DOI 10.1182/blood-2003-04-1095; Passerini CG, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt378; Pearson Joel D, 2012, J Signal Transduct, V2012, P123253, DOI 10.1155/2012/123253; Pensa S, 2013, MADAME CURIE BIOSCIE; Piva R, 2010, J CLIN ONCOL, V28, P1583, DOI 10.1200/JCO.2008.20.9759; Prutsch N, 2019, LEUKEMIA, V33, P696, DOI 10.1038/s41375-018-0239-1; Redaelli S, 2018, CANCER RES, V78, P6866, DOI 10.1158/0008-5472.CAN-18-1867; Rickert KW, 2011, J BIOL CHEM, V286, P11218, DOI 10.1074/jbc.M110.204404; Satoh JI, 2013, GENE REGUL SYST BIO, V7, P41, DOI 10.4137/GRSB.S11433; Sattu K, 2013, FEBS J, V280, P5269, DOI 10.1111/febs.12453; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; Sironi JJ, 2004, J BIOL CHEM, V279, P4066, DOI 10.1074/jbc.M307774200; Suda K, 2012, LUNG CANCER, V76, P292, DOI 10.1016/j.lungcan.2011.11.007; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Wu CS, 2015, BLOOD, V126, P336, DOI 10.1182/blood-2014-10-603738; Xiao Y, 2015, J IMMUNOL, V195, P4218, DOI 10.4049/jimmunol.1501200; Yokoyama K, 2011, EMBO J, V30, P4739, DOI 10.1038/emboj.2011.348	55	4	4	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2103	2117		10.1038/s41388-019-1136-4	http://dx.doi.org/10.1038/s41388-019-1136-4			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31804622	Green Accepted			2022-12-17	WOS:000518584000006
J	Qian, MY; Geng, JW; Luo, KL; Huang, Z; Zhang, QK; Zhang, JA; Ji, LY; Wu, JM				Qian, Mengyao; Geng, Jingwen; Luo, Kaili; Huang, Zheng; Zhang, Qinkai; Zhang, Jian-an; Ji, Liying; Wu, Jianmin			BCL11B regulates MICA/B-mediated immune response by acting as a competitive endogenous RNA	ONCOGENE			English	Article							NATURAL-KILLER-CELLS; HUMAN NKG2D; TUMOR; LIGANDS; CANCER; CYTOTOXICITY; RECEPTOR; EXPRESSION; MICB; IMMUNOBIOLOGY	Cancer immune surveillance is an important host protection process that inhibits carcinogenesis and maintains cellular homeostasis. The major histocompatibility complex class I-related molecules A and B (MICA and MICB) are NKG2D ligands that play important roles in tumor immune surveillance. In the present study, by a combined bioinformatics prediction and experimental approach, we identify BCL11B 3 '-UTR as a putative MICA and MICB ceRNA. We demonstrate in several human cell lines of different origins that the knockdown of BCL11B downregulates surface expression of MICA and MICB. Furthermore, we demonstrate miRNA dependency of BCL11B-mediated MICA and MICB regulation in Dicer knockdown HCT116 cells. In addition, MICA/B-targeting miRNAs (miR-17, miR-93, miR-20a, miR-20b, miR-106a, and miR-106b) repressed the expression of BCL11B by targeting its 3 '-UTR. Moreover, we showed that the BCL11B knockdown-mediated downregulation of MICA/B resulted in reduced NK cell elimination in vitro and in vivo through reduced recognition of NKG2D. Of particular significance, BCL11B displays tumor-suppressive properties. The expression of BCL11B is downregulated in colon cancer tissues and associated with a reduced median survival of colon cancer patients. Taken together, our study revealed a new mechanism of BCL11B that prevents immune evasion of cancerous cells by upregulation of the NKG2D ligands MICA and MICB in a ceRNA manner.	[Qian, Mengyao; Geng, Jingwen; Luo, Kaili; Huang, Zheng; Zhang, Qinkai; Ji, Liying; Wu, Jianmin] Wenzhou Med Univ, Inst Genom Med, Wenzhou 325000, Zhejiang, Peoples R China; [Zhang, Jian-an] Wenzhou Med Univ, Dept Obstet & Gynecol, Affiliated Hosp 2, Wenzhou 325027, Zhejiang, Peoples R China; [Zhang, Jian-an] Wenzhou Med Univ, Yuying Children, Wenzhou 325027, Zhejiang, Peoples R China	Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical University	Wu, JM (corresponding author), Wenzhou Med Univ, Inst Genom Med, Wenzhou 325000, Zhejiang, Peoples R China.	Jianminwu81@hotmail.com		Zhang, Qinkai/0000-0002-3709-2362; Wu, Jianmin/0000-0002-8223-1667	National Natural Sciences Foundation of China [NSFC-81472651, 81201589]	National Natural Sciences Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by National Natural Sciences Foundation of China (grant NSFC-81472651, 81201589).	Abel AM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01869; Aragon-Sanabria V, 2018, ADV EXP MED BIOL, V1092, P113, DOI 10.1007/978-3-319-95294-9_7; Arnon TI, 2006, SEMIN CANCER BIOL, V16, P348, DOI 10.1016/j.semcancer.2006.07.005; Breunig C, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.364; Bugide S, 2018, P NATL ACAD SCI USA, V115, pE3509, DOI 10.1073/pnas.1802691115; Cai S, 2017, CELL STEM CELL, V20, P247, DOI 10.1016/j.stem.2016.11.007; Cerwenka A, 2018, SCIENCE, V359, P1460, DOI 10.1126/science.aat2184; Chitadze G, 2013, SCAND J IMMUNOL, V78, P120, DOI 10.1111/sji.12072; Chitadze G, 2013, INT J CANCER, V133, P1557, DOI 10.1002/ijc.28174; Connell C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032442; de Andrade LF, 2018, SCIENCE, V359, P1537, DOI 10.1126/science.aao0505; Dhar P, 2018, CURR OPIN IMMUNOL, V51, P55, DOI 10.1016/j.coi.2018.02.004; Eichmuller SB, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx034; El-Gazzar A, 2013, J IMMUNOL, V191, P1509, DOI 10.4049/jimmunol.1301071; Fernandez-Messina L, 2010, J BIOL CHEM, V285, P8543, DOI 10.1074/jbc.M109.045906; Fu WJ, 2017, J INVEST DERMATOL, V137, P1523, DOI 10.1016/j.jid.2017.02.980; Gasser S, 2005, NATURE, V436, P1186, DOI 10.1038/nature03884; Gonzalez S, 2006, CURR TOP MICROBIOL, V298, P121; Guerra N, 2008, IMMUNITY, V28, P571, DOI 10.1016/j.immuni.2008.02.016; Halfteck GG, 2009, J IMMUNOL, V182, P2221, DOI 10.4049/jimmunol.0801878; Kaiser BK, 2007, NATURE, V447, P482, DOI 10.1038/nature05768; Kato N, 2007, LEUKEMIA, V21, P2103, DOI 10.1038/sj.leu.2404862; Kloess S, 2010, EUR J IMMUNOL, V40, P3255, DOI 10.1002/eji.201040568; Koch J, 2013, TRENDS IMMUNOL, V34, P182, DOI 10.1016/j.it.2013.01.003; Kumar MS, 2014, NATURE, V505, P212, DOI 10.1038/nature12785; Kumar S, 2018, IMMUNOLOGY, V154, P383, DOI 10.1111/imm.12921; Lanier LL, 2008, NAT IMMUNOL, V9, P495, DOI 10.1038/ni1581; Lennon MJ, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00089; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Lopez-Soto A, 2009, ONCOGENE, V28, P2370, DOI 10.1038/onc.2009.117; Lopez-Soto A, 2015, INT J CANCER, V136, P1741, DOI 10.1002/ijc.28775; Lopez-Soto A, 2013, J IMMUNOL, V190, P4408, DOI 10.4049/jimmunol.1202950; Lowry LE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01061; Min-Oo G, 2013, TRENDS IMMUNOL, V34, P251, DOI 10.1016/j.it.2013.02.005; Nachmani D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5186; Nishiguchi Y, 2016, DEV BIOL, V416, P98, DOI 10.1016/j.ydbio.2016.06.001; Punwani D, 2016, NEW ENGL J MED, V375, P2165, DOI 10.1056/NEJMoa1509164; Raulet DH, 2013, ANNU REV IMMUNOL, V31, P413, DOI 10.1146/annurev-immunol-032712-095951; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Sakamaki A, 2015, CARCINOGENESIS, V36, P622, DOI 10.1093/carcin/bgv044; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Schmiedel D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02040; Schmiedel D, 2016, ELIFE, V5, DOI 10.7554/eLife.13426; Seidel E, 2012, CELL MOL LIFE SCI, V69, P3911, DOI 10.1007/s00018-012-1001-x; Shen JY, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.158; Simon R, 2016, GENES BRAIN BEHAV, V15, P405, DOI 10.1111/gbb.12287; Smyth MJ, 2005, J EXP MED, V202, P583, DOI 10.1084/jem.20050994; Stern-Ginossar N, 2008, NAT IMMUNOL, V9, P1065, DOI 10.1038/ni.1642; Sumazin P, 2011, CELL, V147, P370, DOI 10.1016/j.cell.2011.09.041; Tam YK, 1999, HUM GENE THER, V10, P1359, DOI 10.1089/10430349950018030; Tay Y, 2014, CELL RES, V24, P259, DOI 10.1038/cr.2014.21; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Tay Y, 2011, CELL, V147, P344, DOI 10.1016/j.cell.2011.09.029; Toledano T, 2018, J IMMUNOL, V200, P2819, DOI 10.4049/jimmunol.1700968; Tsukerman P, 2012, CANCER RES, V72, P5463, DOI 10.1158/0008-5472.CAN-11-2671; Vesely MD, 2013, ANN NY ACAD SCI, V1284, P1, DOI 10.1111/nyas.12105; Vyas M, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1339854; Wu JM, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.289; Wu JM, 2014, CARCINOGENESIS, V35, P155, DOI 10.1093/carcin/bgt268	59	4	4	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1514	1526		10.1038/s41388-019-1083-0	http://dx.doi.org/10.1038/s41388-019-1083-0			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31673069				2022-12-17	WOS:000513289600009
J	Ji, DH; Zhang, PS; Ma, WJ; Fei, YW; Xue, W; Wang, Y; Zhang, XY; Zhou, HX; Zhao, Y				Ji, Dehuan; Zhang, Pengshan; Ma, Wenjuan; Fei, Yiwen; Xue, Wen; Wang, Yu; Zhang, Xiuyan; Zhou, Haixia; Zhao, Yun			Oncogenic heterogeneous nuclear ribonucleoprotein D-like modulates the growth and imatinib response of human chronic myeloid leukemia CD34(+) cells via pre-B-cell leukemia homeobox 1	ONCOGENE			English	Article							HEMATOPOIETIC STEM-CELLS; GENE-EXPRESSION; HNRNP PROTEINS; MESSENGER-RNA; PROLIFERATION; JKTBP1; PBX1; MICRODELETION; INSIGHTS; CLONING	Chronic myeloid leukemia (CML) originates from normal hematopoietic stem cells acquiring BCR-ABL fusion gene, specific BCR-ABL inhibitors (e.g., imatinib mesylate, IM) have greatly improved patient management. However, some patients are still suffering from relapse and drug resistance, which urges better understanding of the growth/survival mechanisms of CML stem/progenitor cells. In the present study, the role and its underlying mechanism of heterogeneous nuclear ribonucleoprotein D-like (HNRPDL) in CML cells were investigated. Firstly, overexpression of HNRPDL promoted the growth of murine BaF3 cells in vitro and induced leukemia in vivo, which was enhanced by co-expression of BCR-ABL. Conversely, HNRPDL silencing inhibited colony-forming cell (CFC) production of CML CD34(+) cells and attenuated BCR-ABL induced leukemia. In addition, HNRPDL modulated imatinib response of K562 cells and HNRPDL silencing sensitized CML CD34(+) cells to imatinib treatment. Mechanistically, we found the stability of pre-B-cell leukemia homeobox 1 (PBX1) mRNA was sustained by HNRPDL through its binding to a specific motif (ACUAGC) in 3 '-untranslated region (3 '-UTR) of PBX1. The expression of PBX1 was significantly higher in CML CD34(+) cells than that in control cells and PBX silencing inhibited the growth of CML cells and sensitized them to imatinib treatment. In contrast, overexpression of PBX1 elevated the CFC production of normal hematopoietic CD34(+) cells and "rescued" HNRPDL silencing induced growth inhibition and imatinib sensitization. Taken together, our data have demonstrated that HNRPDL transforms hematopoietic cells and a novel HNRPDL/PBX1 axis plays an important role in human CML CD34(+) cells.	[Ji, Dehuan; Zhang, Pengshan; Ma, Wenjuan; Fei, Yiwen; Xue, Wen; Wang, Yu; Zhang, Xiuyan; Zhao, Yun] Soochow Univ, Natl Clin Res Ctr Hematol Dis, Cyrus Tang Hematol Ctr, Suzhou 215123, Peoples R China; [Zhou, Haixia] Soochow Univ, Affiliated Hosp 1, Natl Clin Res Ctr Hematol Dis, Suzhou 215006, Peoples R China; [Zhao, Yun] Soochow Univ, Collaborat Innovat Ctr Hematol, Suzhou 215006, Peoples R China	Soochow University - China; Soochow University - China; Soochow University - China	Zhao, Y (corresponding author), Soochow Univ, Natl Clin Res Ctr Hematol Dis, Cyrus Tang Hematol Ctr, Suzhou 215123, Peoples R China.; Zhou, HX (corresponding author), Soochow Univ, Affiliated Hosp 1, Natl Clin Res Ctr Hematol Dis, Suzhou 215006, Peoples R China.; Zhao, Y (corresponding author), Soochow Univ, Collaborat Innovat Ctr Hematol, Suzhou 215006, Peoples R China.	zhouhaixia@suda.edu.cn; zhaoy@suda.edu.cn		, Yun/0000-0002-0065-4675	National Natural Science Foundation of China [31771579, 31371392, 81400113, 81500119, 81800151]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Innovation Capability Development Project of Jiangsu Province [BM2015004]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Innovation Capability Development Project of Jiangsu Province	This work was supported by National Natural Science Foundation of China (Nos. 31771579, 31371392 to YZ, 81400113 to HZ, 81500119 to XZ, and 81800151 to WM), the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), and the Innovation Capability Development Project of Jiangsu Province (No. BM2015004).	Akindahunsi AA, 2005, COMPUT BIOL CHEM, V29, P13, DOI 10.1016/j.compbiolchem.2004.11.002; Al-Ghoul M, 2008, J PROTEOME RES, V7, P4107, DOI 10.1021/pr800174k; Bandiera A, 2003, ARCH BIOCHEM BIOPHYS, V409, P305, DOI 10.1016/S0003-9861(02)00413-7; Bertagnolo V, 2011, J PROTEOMICS, V75, P398, DOI 10.1016/j.jprot.2011.08.005; Bonnet C, 2010, J MED GENET, V47, P377, DOI 10.1136/jmg.2009.071902; Boopathi E, 2004, J BIOL CHEM, V279, P35242, DOI 10.1074/jbc.M403160200; Corbin AS, 2011, J CLIN INVEST, V121, P396, DOI 10.1172/JCI35721; de Wit M, 2014, J PROTEOMICS, V99, P26, DOI 10.1016/j.jprot.2014.01.001; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; Deneault E, 2009, CELL, V137, P369, DOI 10.1016/j.cell.2009.03.026; Doi A, 1998, BBA-GENE STRUCT EXPR, V1396, P51, DOI 10.1016/S0167-4781(97)00223-6; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Ficara F, 2008, CELL STEM CELL, V2, P484, DOI 10.1016/j.stem.2008.03.004; Geuens T, 2016, HUM GENET, V135, P851, DOI 10.1007/s00439-016-1683-5; Golan-Gerstl R, 2011, CANCER RES, V71, P4464, DOI 10.1158/0008-5472.CAN-10-4410; Guo X, 2006, ONCOGENE, V25, P4241, DOI 10.1038/sj.onc.1209452; Hamilton A, 2012, BLOOD, V119, P1501, DOI 10.1182/blood-2010-12-326843; Hu XY, 2017, AM J MED GENET A, V173, P120, DOI 10.1002/ajmg.a.37965; HUNGER SP, 1991, BLOOD, V77, P687; Imasaki T, 2007, MOL CELL, V28, P57, DOI 10.1016/j.molcel.2007.08.006; Ito T, 2010, NATURE, V466, P765, DOI 10.1038/nature09171; Jiang XY, 2010, BLOOD, V116, P2112, DOI 10.1182/blood-2009-05-222471; Kamei D, 2002, GENE, V298, P49, DOI 10.1016/S0378-1119(02)00926-5; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; Kawamura H, 2002, J BIOL CHEM, V277, P2732, DOI 10.1074/jbc.M108477200; Kurokawa Y, 2003, J HEPATOL, V39, P1004, DOI 10.1016/S0168-8278(03)00473-2; Lai CK, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.86; Omnus DJ, 2011, J MOL BIOL, V407, P492, DOI 10.1016/j.jmb.2011.01.050; Peng XC, 2011, MOL CELL BIOCHEM, V351, P233, DOI 10.1007/s11010-011-0730-8; Perrotti D, 1998, EMBO J, V17, P4442, DOI 10.1093/emboj/17.15.4442; Perrotti D, 2007, CLIN CANCER RES, V13, P1638, DOI 10.1158/1078-0432.CCR-06-2320; Radich JP, 2006, P NATL ACAD SCI USA, V103, P2794, DOI 10.1073/pnas.0510423103; Reboll MR, 2007, RNA, V13, P1328, DOI 10.1261/rna.545407; Sherbenou DW, 2007, J CLIN INVEST, V117, P2067, DOI 10.1172/JCI31988; Shimabe M, 2009, ONCOGENE, V28, P4364, DOI 10.1038/onc.2009.288; Sloma I, 2010, LEUKEMIA, V24, P1823, DOI 10.1038/leu.2010.159; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; Tsuchiya N, 1998, J BIOCHEM-TOKYO, V123, P499; van Erk MJ, 2005, EUR J NUTR, V44, P143, DOI 10.1007/s00394-004-0503-1; Vegi NM, 2016, CELL REP, V16, P498, DOI 10.1016/j.celrep.2016.05.094; Vieira NM, 2014, HUM MOL GENET, V23, P4103, DOI 10.1093/hmg/ddu127; Wang Y, 2013, NAT STRUCT MOL BIOL, V20, P36, DOI 10.1038/nsmb.2459; Wu YY, 2008, CELL BIOCHEM FUNCT, V26, P467, DOI 10.1002/cbf.1468; Xu X, 2016, J BIOL CHEM, V291, P9617, DOI 10.1074/jbc.M115.701979; Zhang PS, 2018, ACTA BIOCH BIOPH SIN, V50, P880, DOI 10.1093/abbs/gmy085; Zhang X, 2015, ONCOGENE, V34, P3000, DOI 10.1038/onc.2014.241; Zhou HC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107606	47	4	4	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					443	453		10.1038/s41388-019-0998-9	http://dx.doi.org/10.1038/s41388-019-0998-9			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31488872				2022-12-17	WOS:000507766400014
J	Dupain, C; Gracia, C; Harttrampf, AC; Riviere, J; Geoerger, B; Massaad-Massade, L				Dupain, Celia; Gracia, Celine; Harttrampf, Anne C.; Riviere, Julie; Geoerger, Birgit; Massaad-Massade, Liliane			Newly identified LMO3-BORCS5 fusion oncogene in Ewing sarcoma at relapse is a driver of tumor progression	ONCOGENE			English	Article							GENE FUSIONS; GENOMIC LANDSCAPE; QUANTITATIVE PCR; CANCER; CELL; EXPRESSION; BORC; RHABDOMYOSARCOMAS; TUMORIGENICITY; PROLIFERATION	Recently, we detected a new fusion transcript LMO3-BORCS5 in a patient with Ewing sarcoma within a cohort of relapsed pediatric cancers. LMO3-BORCS5 was as highly expressed as the characteristic fusion oncogene EWS/FLI1. However, the expression level of LMO3-BORCS5 at diagnosis was very low. Sanger sequencing depicted two LMO3-BORCS5 variants leading to loss of the functional domain LIM2 in LMO3 gene, and disruption of BORCS5. In vitro studies showed that LMO3-BORCS5 (i) increases proliferation, (ii) decreases expression of apoptosis-related genes and treatment sensitivity, and (iii) downregulates genes involved in differentiation and upregulates proliferative and extracellular matrix-related pathways. Remarkably, in vivo LMO3-BORCS5 demonstrated its high oncogenic potential by inducing tumors in mouse fibroblastic NIH-3T3 cell line. Moreover, BORCS5 probably acts, in vivo, as a tumor-suppressor gene. In conclusion, functional studies of fusion oncogenes at relapse are of great importance to define mechanisms involved in tumor progression and resistance to conventional treatments.	[Dupain, Celia; Gracia, Celine; Harttrampf, Anne C.; Geoerger, Birgit; Massaad-Massade, Liliane] Univ Paris Sud 11, CNRS UMR 8203, Gustave Roussy Canc Ctr, Lab Vectorol & Therapeut Anticanc, F-94805 Villejuif, France; [Riviere, Julie] Gustave Roussy Canc Ctr, INSERM U1170, Villejuif, France; [Geoerger, Birgit] Gustave Roussy, Dept Pediat & Adolescent Oncol, Villejuif, France; [Massaad-Massade, Liliane] U1195 INSERM, 20 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm)	Massaad-Massade, L (corresponding author), Univ Paris Sud 11, CNRS UMR 8203, Gustave Roussy Canc Ctr, Lab Vectorol & Therapeut Anticanc, F-94805 Villejuif, France.; Massaad-Massade, L (corresponding author), U1195 INSERM, 20 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	liliane.massade@inserm.fr	; Massade, Liliane/O-7226-2017	Gracia, Celine/0000-0002-3312-6465; Massade, Liliane/0000-0002-9636-4559	Universite Paris-Sud; CNRS	Universite Paris-Sud; CNRS(Centre National de la Recherche Scientifique (CNRS))	This study was supported by Universite Paris-Sud (CD) and CNRS and microarray analysis was supported by the "Taxe d'apprentissage Gustave Roussy - 2017 - CD". We acknowledge Drs Nathalie Gaspar and Estelle Daudigeos-Dubus as well as the ITCC (Innovative Therapies for Children with Cancer) consortium for providing the pediatric cell lines and antineoplastic molecules used in the study, as well as Catherine Richon (technical assistance). We acknowledge Dr Giorgia Urbinati and Pr. Karim Benihoud for the valuable comments as well as Lena Zig and Linda Ramdani for their precious technical help for the cloning of LMO3-BORCS5. We also acknowledge Dr Guillaume Meurice for the analysis of microarray data. The animal studies were performed within the animal facility of Gustave Roussy and authors gratefully thank the technical support of Olivia Bawa and expertize of Dr Paule Opolon (histocytopathology platform) for the preparation and analysis of histological slides.	Abate F, 2014, BMC SYST BIOL, V8, DOI 10.1186/s12918-014-0097-z; Albanese A, 2012, ANNU REV BIOMED ENG, V14, P1, DOI [10.1146/annurev-bioeng-071811-150124, 10.1146/annurev.bioeng-071811-150124]; Ali HM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095964; Alves IT, 2015, ONCOGENE, V34, P568, DOI 10.1038/onc.2013.591; Anderson ND, 2018, SCIENCE, V361, DOI 10.1126/science.aam8419; Aoyama M, 2005, CANCER RES, V65, P4587, DOI 10.1158/0008-5472.CAN-04-4630; Arpinati M, 2013, BIOL BLOOD MARROW TR, V19, P735, DOI 10.1016/j.bbmt.2013.01.007; Bao JX, 2000, DEVELOPMENT, V127, P425; Barr FG, 2001, ONCOGENE, V20, P5736, DOI 10.1038/sj.onc.1204599; Benjamini Y, 2008, BIOMETRICS, V64, P1215, DOI 10.1111/j.1541-0420.2007.00984.x; Bridge JA, 2013, BRAIN PATHOL, V23, P121, DOI 10.1111/j.1750-3639.2012.00612.x; Brouwer-Visser J, 2015, CYTOKINE GROWTH F R, V26, P371, DOI 10.1016/j.cytogfr.2015.01.002; Buart S, 2017, ONCOTARGET, V8, P108786, DOI 10.18632/oncotarget.22150; Cachia D, 2015, BRAIN TUMOR PATHOL, V32, P105, DOI 10.1007/s10014-014-0205-1; Chaudhary B, 2014, CANCER IMMUNOL IMMUN, V63, P81, DOI 10.1007/s00262-013-1500-0; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Cooper GM, 2000, DEV CAUSES CANC CELL; Crompton BD, 2014, CANCER DISCOV, V4, P1326, DOI 10.1158/2159-8290.CD-13-1037; Dancey JE, 2012, CELL, V148, P409, DOI 10.1016/j.cell.2012.01.014; Daudigeos-Dubus E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142612; Duan C, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0521-3; Dupain C, 2019, MOL THER, V27, P200, DOI 10.1016/j.ymthe.2018.10.022; Dupain C, 2017, MOL THER-NUCL ACIDS, V6, P315, DOI 10.1016/j.omtn.2017.01.005; Dupain C, 2016, INT J ONCOL, V49, P1248, DOI 10.3892/ijo.2016.3617; Frenkel-Morgenstern M, 2012, GENOME RES, V22, P1231, DOI 10.1101/gr.130062.111; Gao QS, 2018, CELL REP, V23, P227, DOI 10.1016/j.celrep.2018.03.050; Goel RK, 2016, CANCER METAST REV, V35, P179, DOI 10.1007/s10555-016-9623-3; Graham RP, 2015, MODERN PATHOL, V28, P822, DOI 10.1038/modpathol.2015.4; Haeussler M, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1012-2; Han SM, 2013, NEOPLASIA, V15, P1193, DOI 10.1593/neo.131604; Hartmaier RJ, 2018, ANN ONCOL, V29, P872, DOI 10.1093/annonc/mdy025; Harttrampf AC, 2017, CLIN CANCER RES, V23, P6101, DOI 10.1158/1078-0432.CCR-17-0381; Isogai E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019297; Jeanmougin M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012336; Justilien V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035040; Kalinova M, 2008, LEUKEMIA RES, V32, P25, DOI 10.1016/j.leukres.2007.01.002; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Kim C, 2016, J CANCER, V7, P1550, DOI 10.7150/jca.15578; Kumar-Sinha C, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0252-1; Langemeyer L, 2015, DEV CELL, V33, P121, DOI 10.1016/j.devcel.2015.04.008; Larsen S, 2010, BIOCHEM BIOPH RES CO, V392, P252, DOI 10.1016/j.bbrc.2009.12.010; Latysheva NS, 2016, NUCLEIC ACIDS RES, V44, P4487, DOI 10.1093/nar/gkw282; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Li J, 2015, HUM PATHOL, V46, P1821, DOI 10.1016/j.humpath.2015.07.022; Lin PP, 2008, CANCER RES, V68, P8968, DOI 10.1158/0008-5472.CAN-08-0573; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Man JH, 2014, CELL REP, V9, P1812, DOI 10.1016/j.celrep.2014.10.055; Massard C, 2017, CANCER DISCOV, V7, P586, DOI 10.1158/2159-8290.CD-16-1396; Mertens F, 2015, NAT REV CANCER, V15, P371, DOI 10.1038/nrc3947; Mitelman F, 2007, NAT REV CANCER, V7, P233, DOI 10.1038/nrc2091; Montpetit A, 2002, EUR J HUM GENET, V10, P62, DOI 10.1038/sj.ejhg.5200766; Niwa S, 2017, CURR BIOL, V27, P2569, DOI 10.1016/j.cub.2017.07.013; Okada T, 2013, SCI REP-UK, V3, DOI 10.1038/srep02899; Panagopoulos I, 2014, ONCOL REP, V32, P40, DOI 10.3892/or.2014.3180; Parveen A, 2016, CRIT REV EUKAR GENE, V26, P49, DOI 10.1615/CritRevEukaryotGeneExpr.v26.i1.60; Pu J, 2015, DEV CELL, V33, P176, DOI 10.1016/j.devcel.2015.02.011; Qiu YS, 2018, INT J MOL MED, V41, P2755, DOI 10.3892/ijmm.2018.3476; Rekhi B, 2016, MODERN PATHOL, V29, P1532, DOI 10.1038/modpathol.2016.144; Sang MX, 2014, MOL BIOL REP, V41, P1067, DOI 10.1007/s11033-013-2952-1; Shugay M, 2013, BIOINFORMATICS, V29, P2539, DOI 10.1093/bioinformatics/btt445; Shugay M, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002797; Song YF, 2015, AM J TRANSL RES, V7, P1271; Stransky N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5846; Teranoa T, 2005, EXP HEMATOL, V33, P641, DOI 10.1016/j.exphem.2005.01.018; Tirode F, 2014, CANCER DISCOV, V4, P1342, DOI 10.1158/2159-8290.CD-14-0622; Tsubota Shoma, 2017, Oncoscience, V4, P70, DOI 10.18632/oncoscience.360; Urbinati G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125277; Vaishnavi A, 2013, NAT MED, V19, P1469, DOI 10.1038/nm.3352; Yau NKM, 2015, CURR CANCER DRUG TAR, V15, P327; Zhang L, 2015, INT J CLIN EXP PATHO, V8, P11421; Zhao YB, 2013, SCI REP-UK, V3, DOI 10.1038/srep03120; Zhou W, 2015, CANCER LETT, V360, P68, DOI 10.1016/j.canlet.2015.02.004	72	4	4	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2019	38	47					7200	7215		10.1038/s41388-019-0914-3	http://dx.doi.org/10.1038/s41388-019-0914-3			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP0UL	31488873	Green Published, hybrid			2022-12-17	WOS:000497989400002
J	Hu, YB; Yan, C; Mu, L; Mi, YL; Zhao, H; Hu, H; Li, XL; Tao, DD; Wu, YQ; Gong, JP; Qin, JC				Hu, Y. -B.; Yan, C.; Mu, L.; Mi, Y. -L.; Zhao, H.; Hu, H.; Li, X. -L.; Tao, D. -D.; Wu, Y. -Q.; Gong, J. -P.; Qin, J. -C.			Exosomal Wnt-induced dedifferentiation of colorectal cancer cells contributes to chemotherapy resistance (vol 38, pg 1951, 2019)	ONCOGENE			English	Correction									[Hu, Y. -B.; Yan, C.; Mu, L.; Mi, Y. -L.; Zhao, H.; Hu, H.; Li, X. -L.; Wu, Y. -Q.; Gong, J. -P.; Qin, J. -C.] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Surg, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China; [Hu, Y. -B.; Yan, C.; Mu, L.; Mi, Y. -L.; Zhao, H.; Hu, H.; Li, X. -L.; Tao, D. -D.; Gong, J. -P.; Qin, J. -C.] Huazhong Univ Sci & Technol, Tongji Hosp, Mol Med Ctr, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology	Gong, JP; Qin, JC (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Dept Surg, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China.; Gong, JP; Qin, JC (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Mol Med Ctr, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China.	jpgong@tjh.tjmu.edu.cn; jcqin@tjh.tjmu.edu.cn						Hu YB, 2019, ONCOGENE, V38, P1951, DOI 10.1038/s41388-018-0557-9	1	4	5	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2019	38	35					6319	6321		10.1038/s41388-019-0863-x	http://dx.doi.org/10.1038/s41388-019-0863-x			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IU9RZ	31366984	hybrid, Green Published			2022-12-17	WOS:000483919400006
J	Fu, QH; Zhang, Q; Lou, Y; Yang, JQ; Nie, G; Chen, Q; Chen, YW; Zhang, JY; Wang, JX; Wei, T; Qin, H; Dang, XW; Bai, XL; Liang, TB				Fu, Qihan; Zhang, Qi; Lou, Yu; Yang, Jiaqi; Nie, Gang; Chen, Qi; Chen, Yiwen; Zhang, Jingying; Wang, Jianxin; Wei, Tao; Qin, Hao; Dang, Xiaowei; Bai, Xueli; Liang, Tingbo			Primary tumor-derived exosomes facilitate metastasis by regulating adhesion of circulating tumor cells via SMAD3 in liver cancer (vol 37, pg 6105, 2018)	ONCOGENE			English	Correction									[Fu, Qihan; Zhang, Qi; Lou, Yu; Yang, Jiaqi; Nie, Gang; Chen, Qi; Chen, Yiwen; Zhang, Jingying; Wang, Jianxin; Wei, Tao; Qin, Hao; Bai, Xueli; Liang, Tingbo] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Hepatobiliary & Pancreat Surg, Hangzhou, Zhejiang, Peoples R China; [Fu, Qihan; Zhang, Qi; Lou, Yu; Yang, Jiaqi; Nie, Gang; Chen, Qi; Chen, Yiwen; Zhang, Jingying; Wang, Jianxin; Wei, Tao; Qin, Hao; Bai, Xueli; Liang, Tingbo] Zhejiang Prov Key Lab Pancreat Dis, Hangzhou, Zhejiang, Peoples R China; [Fu, Qihan] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China; [Dang, Xiaowei] Zhengzhou Univ, Affiliated Hosp 1, Dept Hepatopancreatobiliary Surg, Zhengzhou, Henan, Peoples R China	Zhejiang University; Zhejiang University; Zhengzhou University	Bai, XL; Liang, TB (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Hepatobiliary & Pancreat Surg, Hangzhou, Zhejiang, Peoples R China.; Bai, XL; Liang, TB (corresponding author), Zhejiang Prov Key Lab Pancreat Dis, Hangzhou, Zhejiang, Peoples R China.	liangtingbo@zju.edu.cn; shirleybai@zju.edu.cn						Fu QH, 2018, ONCOGENE, V37, P6105, DOI 10.1038/s41388-018-0391-0	1	4	5	3	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5740	5741		10.1038/s41388-019-0830-6	http://dx.doi.org/10.1038/s41388-019-0830-6			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	31068668	Green Published, hybrid			2022-12-17	WOS:000474845100014
J	Kang, MH; Jeong, KJ; Kim, WY; Lee, HJ; Gong, G; Suh, N; Gyorffy, B; Kim, S; Jeong, SY; Mills, GB; Park, YY				Kang, M. H.; Jeong, K. J.; Kim, W. Y.; Lee, H. J.; Gong, G.; Suh, N.; Gyorffy, B.; Kim, S.; Jeong, S. Y.; Mills, G. B.; Park, Y. -Y.			Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer (vol 36, pg 1745, 2017)	ONCOGENE			English	Correction									[Kang, M. H.; Jeong, S. Y.; Park, Y. -Y.] Ulsan Coll Med, Dept Convergence Med, Seoul, South Korea; [Jeong, K. J.; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Kim, W. Y.] Korea Univ, Guro Hosp, Dept Surg, Seoul, South Korea; [Lee, H. J.; Gong, G.] ASAN Med Ctr, Dept Pathol, Seoul, South Korea; [Suh, N.] Soon Chun Hyang Univ, Coll Med Sci, Dept Med Engn, Asan, South Korea; [Gyorffy, B.] Semmelweis Univ, Dept Pediat 2, MTA TTK Lendulet Canc Biomarker Res Grp, Budapest, Hungary; [Kim, S.] Korea Res Inst Biosci & Biotechnol, Anging Res Inst, Daejeon, South Korea; [Park, Y. -Y.] ASAN Med Ctr, ASAN Inst Life Sci, Seoul, South Korea	University of Ulsan; University of Texas System; UTMD Anderson Cancer Center; Korea University; Korea University Medicine (KU Medicine); University of Ulsan; Asan Medical Center; Soonchunhyang University; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences; Semmelweis University; Korea Research Institute of Bioscience & Biotechnology (KRIBB); University of Ulsan; Asan Medical Center	Park, YY (corresponding author), Ulsan Coll Med, Dept Convergence Med, Seoul, South Korea.; Park, YY (corresponding author), ASAN Med Ctr, ASAN Inst Life Sci, Seoul, South Korea.	yypark@amc.seoul.kr	Jeong, Kangjin/HGT-9268-2022; Gyorffy, Balazs/AAA-9135-2021	Gyorffy, Balazs/0000-0002-5772-3766; Mills, Gordon/0000-0002-0144-9614				Kang MH, 2017, ONCOGENE, V36, P1745, DOI 10.1038/onc.2016.327	1	4	4	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4427	4428		10.1038/s41388-019-0721-x	http://dx.doi.org/10.1038/s41388-019-0721-x			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30718918	Bronze			2022-12-17	WOS:000469339100018
J	Abdelwahab, EMM; Pal, S; Kvell, K; Sarosi, V; Bai, P; Rue, R; Krymskaya, V; McPhail, D; Porter, A; Pongracz, JE				Abdelwahab, E. M. M.; Pal, S.; Kvell, K.; Sarosi, V; Bai, P.; Rue, R.; Krymskaya, V; McPhail, D.; Porter, A.; Pongracz, J. E.			Mitochondrial dysfunction is a key determinant of the rare disease lymphangioleiomyomatosis and provides a novel therapeutic target	ONCOGENE			English	Article							CYTOCHROME-C; CELL; BIOGENESIS; TSC2; PHOSPHORYLATION; ESTROGEN; FEATURES; CHAIN; GENE	Lymphangioleiomyomatosis (LAM) is a rare and progressive systemic disease affecting mainly young women of childbearing age. A deterioration in lung function is driven by neoplastic growth of atypical smooth muscle-like LAM cells in the pulmonary interstitial space that leads to cystic lung destruction and spontaneous pneumothoraces. Therapeutic options for preventing disease progression are limited and often end with lung transplantation temporarily delaying an inevitable decline. To identify new therapeutic strategies for this crippling orphan disease, we have performed array based and metabolic molecular analysis on patient-derived cell lines. Our results point to the conclusion that mitochondrial biogenesis and mitochondrial dysfunction in LAM cells provide a novel target for treatment.	[Abdelwahab, E. M. M.; Kvell, K.; Pongracz, J. E.] Univ Pecs, Sch Pharm, Dept Pharmaceut Biotechnol, Pecs, Hungary; [Abdelwahab, E. M. M.; Kvell, K.; Pongracz, J. E.] Univ Pecs, Janos Szentagothai Res Ctr, Pecs, Hungary; [Pal, S.] Univ Pecs, Sch Pharm, Dept Pharmaceut Technol, Pecs, Hungary; [Sarosi, V] Univ Pecs, Sch Med, Dept Internal Med, Pecs, Hungary; [Sarosi, V] Univ Pecs, Clin Ctr, Pecs, Hungary; [Bai, P.] Univ Debrecen, Dept Med Chem, MTA DE Lendulet Lab Cellular Metab, Debrecen, Hungary; [Bai, P.] Univ Debrecen, Fac Med, Res Ctr Mol Med, Debrecen, Hungary; [Rue, R.; Krymskaya, V] Univ Penn, Dept Med, Pulm Allergy & Crit Care Div, Perelman Sch Med, Philadelphia, PA 19104 USA; [McPhail, D.; Porter, A.] Antoxis Ltd, Aberdeen, Scotland; [Porter, A.] Univ Aberdeen, Sch Med & Med Sci, Aberdeen, Scotland	University of Pecs; University of Pecs; University of Pecs; University of Pecs; University of Pecs; University of Debrecen; University of Debrecen; University of Pennsylvania; Pennsylvania Medicine; University of Aberdeen	Pongracz, JE (corresponding author), Univ Pecs, Sch Pharm, Dept Pharmaceut Biotechnol, Pecs, Hungary.; Pongracz, JE (corresponding author), Univ Pecs, Janos Szentagothai Res Ctr, Pecs, Hungary.	judit.e.pongracz@gmail.com	Pongracz, Judit E/N-7927-2018; Pongracz, Judit E/J-7517-2019	Pongracz, Judit E/0000-0002-0278-5556; Pongracz, Judit E/0000-0002-0278-5556; ELHUSSEINY, MOHAMED MAHMOUD ABDELWAHAB/0000-0003-4102-2233	European Union; State of Hungary - European Social Fund [TAMOP-4.2.4, A/2-11/1-2012-0001]	European Union(European Commission); State of Hungary - European Social Fund	JEP was supported by the European Union and the State of Hungary, co-financed by the European Social Fund in the framework of TAMOP-4.2.4.A/2-11/1-2012-0001 "National Excellence Program".	Astrinidis A, 2000, J MED GENET, V37, P55, DOI 10.1136/jmg.37.1.55; Barros RPA, 2011, CELL METAB, V14, P289, DOI 10.1016/j.cmet.2011.08.005; Bennett CJ, 2004, BIOORGAN MED CHEM, V12, P2079, DOI 10.1016/j.bmc.2004.02.031; Chang WYC, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-34; Drummond NJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12072-5; Fernandez-Vizarra E, 2009, BBA-MOL CELL RES, V1793, P200, DOI 10.1016/j.bbamcr.2008.05.028; Finck BN, 2007, CIRCULATION, V115, P2540, DOI 10.1161/CIRCULATIONAHA.107.670588; Goncharova EA, 2006, AM J RESP CELL MOL, V34, P473, DOI 10.1165/rcmb.2005-0374OC; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Gozuacik D, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00065; Gyftopoulos K, 2000, EUR UROL, V38, P323, DOI 10.1159/000020301; Hald SM, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1446-z; Harknett EC, 2011, QJM-INT J MED, V104, P971, DOI 10.1093/qjmed/hcr116; Hayashi K, 2001, JPN J CANCER RES, V92, P42, DOI 10.1111/j.1349-7006.2001.tb01046.x; Hayashida M, 2007, RESPIROLOGY, V12, P523, DOI 10.1111/j.1440-1843.2007.01101.x; Huttemann M, 2011, MITOCHONDRION, V11, P369, DOI 10.1016/j.mito.2011.01.010; Julian LM, 2017, CANCER RES, V77, P5491, DOI 10.1158/0008-5472.CAN-17-0925; Kovacs T, 2014, AGING CELL, V13, P838, DOI 10.1111/acel.12240; Krymskaya VP, 2017, ANNU REV MED, V68, P69, DOI 10.1146/annurev-med-050715-104245; Lawler PR, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006627; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Lu C, 2017, ANN AM THORAC SOC, V14, P919, DOI 10.1513/AnnalsATS.201610-824OC; MacKeigan JP, 2015, NEURO-ONCOLOGY, V17, P1550, DOI 10.1093/neuonc/nov152; Marin-Hernandez A, 2009, MINI-REV MED CHEM, V9, P1084, DOI 10.2174/138955709788922610; Mei LL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185636; Miglio G, 2009, NEUROCHEM INT, V55, P496, DOI 10.1016/j.neuint.2009.05.001; Moini H, 1999, REDOX REP, V4, P35, DOI 10.1179/135100099101534729; Motalleb G, 2014, CELL J, V15, P324; Rigobello MP, 2002, BRIT J PHARMACOL, V136, P1162, DOI 10.1038/sj.bjp.0704823; Shao D, 2010, MITOCHONDRION, V10, P516, DOI 10.1016/j.mito.2010.05.012; Simiantonaki N, 2008, INT J ONCOL, V32, P585; Uldry M, 2006, CELL METAB, V3, P333, DOI 10.1016/j.cmet.2006.04.002	33	4	4	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					3093	3101		10.1038/s41388-018-0625-1	http://dx.doi.org/10.1038/s41388-018-0625-1			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30573768	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000465167600015
J	Traxel, S; Schadt, L; Eyer, T; Mordasini, V; Gysin, C; Munthe, LA; Niggli, F; Nadal, D; Burgler, S				Traxel, Sabrina; Schadt, Linda; Eyer, Tatjana; Mordasini, Vanessa; Gysin, Claudine; Munthe, Ludvig A.; Niggli, Felix; Nadal, David; Burgler, Simone			Bone marrow T helper cells with a Th1 phenotype induce activation and proliferation of leukemic cells in precursor B acute lymphoblastic leukemia patients	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; CHILDHOOD LEUKEMIA; MULTIPLE-MYELOMA; GENE-EXPRESSION; IFN-GAMMA; TRANSCRIPTION FACTOR; CYTOKINE PRODUCTION; LYMPHOMA-CELLS; IN-VITRO; PRE-B	Precursor B cell acute lymphoblastic leukemia (BCP-ALL) constitutes the leading cause of cancer-related death in children. While chromosomal alterations contribute to BCP-ALL pathogenesis, they are insufficient for leukemia development. Epidemiological data and evidence from a mouse model suggest that immune responses to infections may trigger the emergence of leukemia, but the mechanisms remain unclear. Here, we show that T helper (Th) cells from bone marrow of pediatric BCP-ALL patients can be attracted and activated by autologous BCP-ALL cells. Bone-marrow Th cells supportively interacted with BCP-ALL cells, inducing upregulation of important surface molecules and BCP-ALL cell proliferation. These Th cells displayed a Th1-like phenotype and produced high levels of IFN-gamma. IFN-gamma was responsible for the upregulation of CD38 in BCP-ALL cells, a molecule which we found to be associated with early relapse, and accountable for the production of IP-10, a chemokine involved in BCP-ALL migration and drug resistance. Thus, our data provide mechanistic support for an involvement of Th cell immune responses in the propagation of BCP-ALL and suggest that BCP-ALL cell-supportive Th cells may serve as therapeutic target.	[Traxel, Sabrina; Schadt, Linda; Eyer, Tatjana; Mordasini, Vanessa; Niggli, Felix; Nadal, David; Burgler, Simone] Univ Childrens Hosp Zurich, Expt Infect Dis & Canc Res, Childrens Res Ctr, Zurich, Switzerland; [Gysin, Claudine] Univ Childrens Hosp Zurich, Div Otolaryngol, Childrens Res Ctr, Zurich, Switzerland; [Munthe, Ludvig A.] Univ Oslo, KG Jebsen Ctr B Cell Malignancies, Inst Clin Med, Oslo, Norway	University Children's Hospital Zurich; University Children's Hospital Zurich; University of Oslo	Burgler, S (corresponding author), Univ Childrens Hosp Zurich, Expt Infect Dis & Canc Res, Childrens Res Ctr, Zurich, Switzerland.	simone.buergler@kispi.uzh.ch	Munthe, Ludvig/GRJ-3355-2022	Traxel, Sabrina/0000-0002-9193-5586; Munthe, Ludvig A/0000-0002-0344-3654	Forschungskredit of the University of Zurich; Children's Research Center (CRC) of the Children's Hospital Zurich; Stiftung fur Krebsbekampfung; Krebsliga Schweiz/Swiss Cancer League [KLS 3189-02-2013]; Charles Meyer Cancer Research Initiative	Forschungskredit of the University of Zurich; Children's Research Center (CRC) of the Children's Hospital Zurich; Stiftung fur Krebsbekampfung; Krebsliga Schweiz/Swiss Cancer League; Charles Meyer Cancer Research Initiative	We thank the pediatric patients and donors who provided the clinical samples. This work was supported by the Forschungskredit of the University of Zurich, The Children's Research Center (CRC) of the Children's Hospital Zurich, the Stiftung fur Krebsbekampfung and the Krebsliga Schweiz/Swiss Cancer League (grant number KLS 3189-02-2013), the Krebsliga Schweiz/Swiss Cancer League (grant number KLS 3189-02-2013) and the Charles Meyer Cancer Research Initiative.	Baldridge MT, 2010, NATURE, V465, P793, DOI 10.1038/nature09135; Boyerinas B, 2013, BLOOD, V121, P4821, DOI 10.1182/blood-2012-12-475483; Burgler S, 2015, CRIT REV IMMUNOL, V35, P417, DOI 10.1615/CritRevImmunol.v35.i5.50; Burgler S, 2015, J IMMUNOL, V194, P827, DOI 10.4049/jimmunol.1401350; BUSCHLE M, 1993, J EXP MED, V177, P213, DOI 10.1084/jem.177.1.213; Buske C, 1997, EXP HEMATOL, V25, P329; Cardoso AA, 1996, BLOOD, V88, P41; Chen JJY, 2002, J LEUKOCYTE BIOL, V72, P271; Chillemi A, 2014, FRONT BIOSCI-LANDMRK, V19, P152, DOI 10.2741/4201; Deckert J, 2014, CLIN CANCER RES, V20, P4574, DOI 10.1158/1078-0432.CCR-14-0695; Dhodapkar MV, 2003, J EXP MED, V198, P1753, DOI 10.1084/jem.20031030; Duan CW, 2014, CANCER CELL, V25, P778, DOI 10.1016/j.ccr.2014.04.015; Einav U, 2005, ONCOGENE, V24, P6367, DOI 10.1038/sj.onc.1208797; Fei F, 2015, ONCOTARGET, V6, P11378, DOI 10.18632/oncotarget.3409; Feuerer M, 2001, NAT MED, V7, P452, DOI 10.1038/86523; FLUCKIGER AC, 1992, BLOOD, V80, P3173; Ford AM, 1998, P NATL ACAD SCI USA, V95, P4584, DOI 10.1073/pnas.95.8.4584; Fortney JE, 2001, LEUKEMIA RES, V25, P901, DOI 10.1016/S0145-2126(01)00051-0; Ghia P, 2001, BLOOD, V98, P533, DOI 10.1182/blood.V98.3.533; Gomez AM, 2015, BLOOD CELL MOL DIS, V55, P220, DOI 10.1016/j.bcmd.2015.07.001; Greaves M, 2006, NAT REV CANCER, V6, P193, DOI 10.1038/nrc1816; Greaves M, 2018, NAT REV CANCER, V18, P471, DOI 10.1038/s41568-018-0015-6; Herndler-Brandstetter D, 2011, J IMMUNOL, V186, P6965, DOI 10.4049/jimmunol.1100243; Hersher R, 2012, NAT MED, V18, P1446, DOI 10.1038/nm1012-1446a; Hogan LE, 2011, BLOOD, V118, P5218, DOI 10.1182/blood-2011-04-345595; Iwamoto S, 2007, J CLIN INVEST, V117, P1049, DOI 10.1172/JCI30235; JOHNSON PWM, 1993, BLOOD, V82, P1848, DOI 10.1182/blood.V82.6.1848.bloodjournal8261848; KINLEN L, 1988, LANCET, V2, P1323; Ko RH, 2010, J CLIN ONCOL, V28, P648, DOI 10.1200/JCO.2009.22.2950; Kreis C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170020; Lee Y, 2012, BLOOD, V119, P227, DOI 10.1182/blood-2011-06-357442; Liston A, 2014, NAT REV IMMUNOL, V14, P154, DOI 10.1038/nri3605; Liu ML, 2011, CYTOKINE GROWTH F R, V22, P121, DOI 10.1016/j.cytogfr.2011.06.001; Lokhorst HM, 2015, NEW ENGL J MED, V373, P1207, DOI 10.1056/NEJMoa1506348; MacKenzie J, 2006, HAEMATOL-HEMATOL J, V91, P240; Martin-Lorenzo A, 2015, CANCER DISCOV, V5, P1328, DOI 10.1158/2159-8290.CD-15-0892; McHeyzer-Williams LJ, 2006, CURR TOP MICROBIOL, V311, P59; Mori H, 2002, P NATL ACAD SCI USA, V99, P8242, DOI 10.1073/pnas.112218799; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Mudry RE, 2000, BLOOD, V96, P1926, DOI 10.1182/blood.V96.5.1926.h8001926_1926_1932; Nakase K, 2007, LEUKEMIA, V21, P326, DOI 10.1038/sj.leu.2404497; Nijhof IS, 2015, CLIN CANCER RES, V21, P2802, DOI 10.1158/1078-0432.CCR-14-1813; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Okhrimenko A, 2014, P NATL ACAD SCI USA, V111, P9229, DOI 10.1073/pnas.1318731111; Os A, 2013, CELL REP, V4, P566, DOI 10.1016/j.celrep.2013.07.011; Pai SY, 2004, P NATL ACAD SCI USA, V101, P1993, DOI 10.1073/pnas.0308697100; Pangault C, 2010, LEUKEMIA, V24, P2080, DOI 10.1038/leu.2010.223; Pui CH, 2008, LANCET, V371, P1030, DOI 10.1016/S0140-6736(08)60457-2; Purizaca J, 2012, ARCH MED RES, V43, P89, DOI 10.1016/j.arcmed.2012.03.005; Raetz EA, 2012, HEMATOL-AM SOC HEMAT, P129, DOI 10.1182/asheducation-2012.1.129; Rakoff-Nahoum Seth, 2006, Yale J Biol Med, V79, P123; Reid GSD, 2003, LEUKEMIA RES, V27, P1135, DOI 10.1016/S0145-2126(03)00106-1; Renard N, 1996, BLOOD, V87, P5162, DOI 10.1182/blood.V87.12.5162.bloodjournal87125162; Richardson RB, 2011, LEUKEMIA RES, V35, P1425, DOI 10.1016/j.leukres.2011.07.023; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Taylor GM, 2009, LEUKEMIA, V23, P863, DOI 10.1038/leu.2008.374; Thompson P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100480; Tokoyoda K, 2009, IMMUNITY, V30, P721, DOI 10.1016/j.immuni.2009.03.015; UMETSU DT, 1990, J IMMUNOL, V144, P2550; Vaisitti T, 2015, LEUKEMIA, V29, P356, DOI 10.1038/leu.2014.207; van der Veer MS, 2011, BLOOD CANCER J, V1, DOI 10.1038/bcj.2011.42; Wang D, 2017, LEUKEMIA, V31, P2114, DOI 10.1038/leu.2017.69; Wu SL, 2005, CANCER-AM CANCER SOC, V103, P1054, DOI 10.1002/cncr.20869; Yamashita M, 2004, J BIOL CHEM, V279, P26983, DOI 10.1074/jbc.M403688200; Zaki M, 2000, LEUKEMIA RES, V24, P611, DOI 10.1016/S0145-2126(00)00022-9; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	66	4	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2420	2431		10.1038/s41388-018-0594-4	http://dx.doi.org/10.1038/s41388-018-0594-4			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30532071				2022-12-17	WOS:000462588000014
J	Shmueli, MD; Levy-Kanfo, L; Haj, E; Schoenfeld, AR; Gazit, E; Segal, D				Shmueli, Merav D.; Levy-Kanfo, Limor; Haj, Esraa; Schoenfeld, Alan R.; Gazit, Ehud; Segal, Daniel			Arginine refolds, stabilizes, and restores function of mutant pVHL proteins in animal model of the VHL cancer syndrome	ONCOGENE			English	Article							TUMOR-SUPPRESSOR PROTEIN; HIF-ALPHA; LINDAU; DROSOPHILA; HIF-1-ALPHA; COMPLEX; BINDING; HYDROXYPROLINE; UBIQUITINATION; UBIQUITYLATION	The von Hippel-Lindau (VHL) syndrome is a rare inherited cancer, caused by mutations in the VHL gene, many of which render the VHL protein (pVHL) unstable. pVHL is a tumor-suppressor protein implicated in a variety of cellular processes, most notably in response to changes in oxygen availability, due to its role as part of an E3-ligase complex which targets the hypoxia-inducible factor (HIF) for degradation. Previously we reported, using in silico and in vitro analyses, that common oncogenic VHL mutations render pVHL less stable than the wild-type protein, distort its core domain and as a result reduce the ability of the protein to bind its target HIF-1 alpha. Among various chemical chaperones tested, arginine was the most effective in refolding mutant of pVHL. Here we examined the consequences of administering L- or D-arginine to a Drosophila VHL model and to human renal carcinoma cells, both expressing misfolded versions of human pVHL. Arginine treatment increased pVHL solubility in both models and increased the half-life of the mutant pVHL proteins in the cell culture. In both models, L- as well as D-arginine enhanced the ability of wild-type pVHL and certain misfolded mutant versions of pVHL to bind ODD, the HIF-derived target peptide, reflecting restoration of pVHL function. Moreover, continuous feeding of Drosophila expressing misfolded versions of pVHL either L- or D-arginine rich diet rescued their lethal phenotype. Collectively, these in vivo results suggest that arginine supplementation should be examined as a potential novel treatment for VHL cancer syndrome.	[Shmueli, Merav D.; Levy-Kanfo, Limor; Haj, Esraa; Gazit, Ehud; Segal, Daniel] Tel Aviv Univ, George S Wise Fac Life Sci, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel; [Schoenfeld, Alan R.] Adelphi Univ, Dept Biol, One South Ave,POB 701, Garden City, NY 11530 USA	Tel Aviv University; Adelphi University	Segal, D (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel.	dsegal@post.tau.ac.il	Shmueli, Merav/HDM-9859-2022; Gazit, Ehud/C-3715-2011; Gazit, Ehud/M-8026-2019; Gazit, Ehud/AHE-9332-2022	Shmueli, Merav/0000-0002-9196-7633; Gazit, Ehud/0000-0001-5764-1720; Gazit, Ehud/0000-0001-5764-1720; Segal, Daniel/0000-0002-6777-505X	Israel Cancer Association; Cancer Biology Research Center in Tel Aviv University; VHL Alliance	Israel Cancer Association; Cancer Biology Research Center in Tel Aviv University; VHL Alliance	This work was supported in part by the Israel Cancer Association, the Cancer Biology Research Center in Tel Aviv University, and the VHL Alliance (to DS).	Arakawa T, 2007, BIOPHYS CHEM, V127, P1, DOI 10.1016/j.bpc.2006.12.007; Arquier N, 2006, BIOCHEM J, V393, P471, DOI 10.1042/BJ20050675; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bangiyeva V, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-229; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P256, DOI 10.1093/nar/26.1.256; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Chen CH, 2009, LANGMUIR, V25, P6717, DOI 10.1021/la9002065; Cho NK, 2002, CELL, V108, P865, DOI 10.1016/S0092-8674(02)00676-1; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; D'Angelo G, 2003, J BIOL CHEM, V278, P38183, DOI 10.1074/jbc.M302244200; Ding ZY, 2012, J BIOMOL SCREEN, V17, P572, DOI 10.1177/1087057112436557; Duchi S, 2010, DEVELOPMENT, V137, P1493, DOI 10.1242/dev.042804; Gossage L, 2015, NAT REV CANCER, V15, P55, DOI 10.1038/nrc3844; Groth AC, 2004, GENETICS, V166, P1775, DOI 10.1534/genetics.166.4.1775; Guo Y, 2009, ONCOGENE, V28, P1864, DOI 10.1038/onc.2009.35; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Hsouna A, 2010, MOL CELL BIOL, V30, P3779, DOI 10.1128/MCB.01578-09; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Khan SH, 2010, IUBMB LIFE, V62, P891, DOI 10.1002/iub.406; Knauth K, 2006, ONCOGENE, V25, P370, DOI 10.1038/sj.onc.1209062; Kurban G, 2008, ONCOGENE, V27, P1004, DOI 10.1038/sj.onc.1210709; Li JG, 2010, J CHEM PHYS, V133, DOI 10.1063/1.3469790; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McNeal CJ, 2016, J NUTR, V146, P2587, DOI 10.3945/jn.116.234740; Miller F, 2005, J BIOL CHEM, V280, P7985, DOI 10.1074/jbc.M413160200; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Navarro E, 2005, BASIC CLIN PHARMACOL, V97, P149, DOI 10.1111/j.1742-7843.2005.pto_973110.x; Ohh M, 1999, J CLIN INVEST, V104, P1583, DOI 10.1172/JCI8161; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Shmueli MD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109864; Shmueli MD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066333; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Tabaro F, 2016, SCI REP-UK, V6, DOI 10.1038/srep31128; Tarade D, 2018, ONCOGENE, V37, P139, DOI 10.1038/onc.2017.338; Varshney N, 2017, J KIDNEY CANCER VHL, V4, P20, DOI 10.15586/jkcvhl.2017.88; Yang H, 2007, MOL CELL, V28, P15, DOI 10.1016/j.molcel.2007.09.010; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	43	4	5	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					1038	1049		10.1038/s41388-018-0491-x	http://dx.doi.org/10.1038/s41388-018-0491-x			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30194449				2022-12-17	WOS:000458624900008
J	He, TL; Jin, M; Xu, CX; Ma, ZJ; Wu, FF; Zhang, XB				He, Tianliang; Jin, Min; Xu, Chenxi; Ma, Zhongjun; Wu, Fufang; Zhang, Xiaobo			The homeostasis-maintaining metabolites from bacterial stress response to bacteriophage infection suppress tumor metastasis	ONCOGENE			English	Article							MICROBIAL NATURAL-PRODUCTS; DEEP-SEA FUNGUS; DRUG DISCOVERY; CELL-PROLIFERATION; MARINE-ENVIRONMENT; HYDROTHERMAL VENTS; BREAST-CANCER; DIVERSITY; ORIGIN; GENOME	The antiviral metabolites from bacterial stress response to bacteriophage infection can maintain homeostasis of host cells, while metabolism disorder is a remarkable characteristic of tumorigenesis. In the aspect of metabolic homeostasis, therefore, the antiviral homeostasis-maintaining metabolites of bacteria may possess anti-tumor activity. However, this issue has not been addressed. Here we show that the homeostasis-challenged maintaining metabolites from deep-sea bacteriophage-challenged thermophile can suppress tumor metastasis. The results indicated that the metabolic profiles of the bacteriophage GVE2-infected and virus-free thermophile Geobacillus sp. E263 from a deep-sea hydrothermal vent were remarkably different. Thirteen metabolites were significantly elevated and two metabolites were downregulated in thermophile stress response to GVE2 infection. As an example, the upregulated L-norleucine was characterized. The data showed that L-norleucine had antiviral activity in thermophile. Furthermore, the in vitro and in vivo assays revealed that L-norleucine, as well as its derivative, significantly suppressed metastasis of gastric and breast cancer cells. L-norleucine interacted with hnRNPA2/B1 protein to inhibit the expressions of Twist1 and Snail, two inhibitors of E-cadherin, and promote the E-cadherin expression, leading to the inhibition of tumor metastasis. Therefore, our study presented that antiviral homeostasis-maintaining metabolites of microbes might be a promising source for anti-tumor drugs.	[He, Tianliang; Jin, Min; Xu, Chenxi; Zhang, Xiaobo] Zhejiang Univ, Coll Life Sci, Hangzhou 310058, Zhejiang, Peoples R China; [Ma, Zhongjun] Zhejiang Univ, Inst Marine Biol & Nat Prod, Dept Ocean Sci & Engn, Hangzhou 310058, Zhejiang, Peoples R China; [Wu, Fufang] Fuyang Normal Univ, Sch Chem & Mat Engn, Fuyang 236037, Peoples R China	Zhejiang University; Zhejiang University; Fuyang Normal University	Zhang, XB (corresponding author), Zhejiang Univ, Coll Life Sci, Hangzhou 310058, Zhejiang, Peoples R China.	zxb0812@zju.edu.cn		He, Tianliang/0000-0003-4437-5309; Zhang, Xiaobo/0000-0003-4606-212X	China Ocean Mineral Resources R D Association [DY135-B-04]; National Program on the Key Basic Research Project [2015CB755903]	China Ocean Mineral Resources R D Association; National Program on the Key Basic Research Project	This work was supported by China Ocean Mineral Resources R & D Association (DY135-B-04) and National Program on the Key Basic Research Project (2015CB755903).	Ankrah NYD, 2014, ISME J, V8, P1089, DOI 10.1038/ismej.2013.216; Berdy J, 2005, J ANTIBIOT, V58, P1, DOI 10.1038/ja.2005.1; Brana AF, 2015, MICROB ECOL, V69, P512, DOI 10.1007/s00248-014-0508-0; Bristow RG, 2008, NAT REV CANCER, V8, P180, DOI 10.1038/nrc2344; Cairns R, 2006, MOL CANCER RES, V4, P61, DOI 10.1158/1541-7786.MCR-06-0002; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Ciavardelli D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.285; Ferronato MJ, 2015, J STEROID BIOCHEM, V154, P285, DOI 10.1016/j.jsbmb.2015.09.009; Geuens T, 2016, HUM GENET, V135, P851, DOI 10.1007/s00439-016-1683-5; Gulder TAM, 2009, CURR OPIN MICROBIOL, V12, P252, DOI 10.1016/j.mib.2009.05.002; Hanaford AR, 2014, CANCER RES, V74, DOI 10.1158/1538-7445.AM2014-3090; He TL, 2016, MAR BIOTECHNOL, V18, P232, DOI 10.1007/s10126-015-9683-3; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Jin M, 2015, APPL MICROBIOL BIOT, V99, P8101, DOI 10.1007/s00253-015-6674-2; Jin M, 2013, MICROBIOL-SGM, V159, P1597, DOI 10.1099/mic.0.067611-0; Katt WP, 2014, DRUG DISCOV TODAY, V19, P450, DOI 10.1016/j.drudis.2013.10.008; Knight V, 2003, APPL MICROBIOL BIOT, V62, P446, DOI 10.1007/s00253-003-1381-9; Krall AS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11457; Lam KS, 2007, TRENDS MICROBIOL, V15, P279, DOI 10.1016/j.tim.2007.04.001; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Li DH, 2007, ARCH PHARM RES, V30, P1051; Li DH, 2007, J ANTIBIOT, V60, P317, DOI 10.1038/ja.2007.40; Li X, 2005, TRENDS BIOTECHNOL, V23, P539, DOI 10.1016/j.tibtech.2005.08.006; Li Y, 2009, J NAT PROD, V72, P912, DOI 10.1021/np900116m; Liu B, 2006, CURR MICROBIOL, V53, P163, DOI 10.1007/s00284-005-0509-9; Loh TJ, 2015, ONCOL REP, V34, P1231, DOI 10.3892/or.2015.4110; Majeed R, 2012, J CANC SCI THER, V4; Martin W, 2008, NAT REV MICROBIOL, V6, P805, DOI 10.1038/nrmicro1991; Nastrucci C, 2012, RECENT PAT ANTI-CANC, V7, P218, DOI 10.2174/157489212799972963; NISHIO M, 1990, J GEN VIROL, V71, P61, DOI 10.1099/0022-1317-71-1-61; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pelaez F, 2006, BIOCHEM PHARMACOL, V71, P981, DOI 10.1016/j.bcp.2005.10.010; Pettit RK, 2011, MICROB BIOTECHNOL, V4, P471, DOI 10.1111/j.1751-7915.2010.00196.x; Qu XH, 2015, ONCOL LETT, V10, P1677, DOI 10.3892/ol.2015.3457; Remes C, 2012, BIOORG CHEM, V41-42, P6, DOI 10.1016/j.bioorg.2011.12.003; Rohwer F, 2009, NATURE, V459, P207, DOI 10.1038/nature08060; Salomon CE, 2004, NAT PROD REP, V21, P105, DOI 10.1039/b301384g; Sana Theodore R, 2008, J Biomol Tech, V19, P258; Sanchez EL, 2015, VIROLOGY, V479, P609, DOI 10.1016/j.virol.2015.02.038; Shi F, 2018, ONCOTARGET, V9, P706, DOI 10.18632/oncotarget.23091; Simmons TL, 2008, P NATL ACAD SCI USA, V105, P4587, DOI 10.1073/pnas.0709851105; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Tauler J, 2010, CANCER RES, V70, P7137, DOI 10.1158/0008-5472.CAN-10-0860; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wei DH, 2010, J VIROL, V84, P2365, DOI 10.1128/JVI.02182-09; Weitz Joshua S, 2012, F1000 Biol Rep, V4, P17; Xiong ZQ, 2013, MAR DRUGS, V11, P700, DOI 10.3390/md11030700; Yang CD, 2009, CANCER RES, V69, P7986, DOI 10.1158/0008-5472.CAN-09-2266; Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559	49	4	4	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2018	37	43					5766	5779		10.1038/s41388-018-0376-z	http://dx.doi.org/10.1038/s41388-018-0376-z			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY1KL	29925861				2022-12-17	WOS:000448288200005
J	Morris, SM; Mhyre, AJ; Carmack, SS; Myers, CH; Burns, C; Ye, WJ; Ferrer, M; Olson, JM; Klinghoffer, RA				Morris, Shelli M.; Mhyre, Andrew J.; Carmack, Savanna S.; Myers, Carrie H.; Burns, Connor; Ye, Wenjuan; Ferrer, Marc; Olson, James M.; Klinghoffer, Richard A.			A modified gene trap approach for improved high-throughput cancer drug discovery	ONCOGENE			English	Article							TYROSINE KINASE INHIBITOR; EMBRYONIC STEM-CELLS; EXPRESSION SIGNATURE; PROMOTER TRAPS; MELANOMA; BRAF; MUTAGENESIS; LEUKEMIA; TAK-632; DESIGN	While advances in laboratory automation has dramatically increased throughout of compound screening efforts, development of robust cell-based assays in relevant disease models remain resource-intensive and time-consuming, presenting a bottleneck to drug discovery campaigns. To address this issue, we present a modified gene trap approach to efficiently generate pathway-specific reporters that result in a robust "on" signal when the pathway of interest is inhibited. In this proof-of-concept study, we used vemurafenib and trametinib to identify traps that specifically detect inhibition of the mitogen-activated protein kinase (MAPK) pathway in a model of BRAFV600E driven human malignant melanoma. We demonstrate that insertion of our trap into particular loci results in remarkably specific detection of MAPK pathway inhibitors over compounds targeting any other pathway or cellular function. The accuracy of our approach was highlighted in a pilot screen of similar to 6000 compounds where 40 actives were detected, including 18 MEK, 10 RAF, and 3 ERK inhibitors along with a few compounds representing previously under-characterized inhibitors of the MAPK pathway. One such compound, bafetinib, a second generation BCR/ABL inhibitor, reduced phosphorylation of ERK and when combined with trametinib, both in vitro and in vivo, reduced growth of vemurafenib resistant melanoma cells. While piloted in a model of BRAF-driven melanoma, our results set the stage for using this approach to rapidly generate reporters against any transcriptionally active pathway across a wide variety of disease-relevant cell-based models to expedite drug discovery efforts.	[Morris, Shelli M.; Mhyre, Andrew J.; Carmack, Savanna S.; Myers, Carrie H.; Olson, James M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA; [Burns, Connor; Klinghoffer, Richard A.] Presage Biosci, Seattle, WA 98109 USA; [Ye, Wenjuan; Ferrer, Marc] NIH NCATS, Rockville, MD USA; [Olson, James M.] Univ Washington, Sch Med, Div Pediat Hematol Oncol, Seattle, WA 98195 USA; [Olson, James M.] Seattle Childrens Hosp, Seattle, WA 98105 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Seattle Children's Hospital	Olson, JM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.; Klinghoffer, RA (corresponding author), Presage Biosci, Seattle, WA 98109 USA.; Olson, JM (corresponding author), Univ Washington, Sch Med, Div Pediat Hematol Oncol, Seattle, WA 98195 USA.; Olson, JM (corresponding author), Seattle Childrens Hosp, Seattle, WA 98105 USA.	jolson@fredhutch.org; Rich.Klinghoffer@presagebio.com			National Cancer Institute of the National Institutes of Health [R43CA171366, RO1CA193841, RO1CA155360]; Seattle Children's Brain Tumor Research Endowment; NATIONAL CANCER INSTITUTE [R01CA193841, R43CA171366, R01CA114567, R01CA155360] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [ZIATR000363] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Seattle Children's Brain Tumor Research Endowment; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We would like to thank Jason Frazier, Robert Finney, Emily J. Girard, Madison W. Nakamoto and the staff of the Genomics Shared Resource and the Comparative Medicine Shared Resource at the Fred Hutchinson Cancer Research Center. This research was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers R43CA171366 (R.A.K.), RO1CA193841 (A.J.M. and J.M.O.), RO1CA155360 and the Seattle Children's Brain Tumor Research Endowment (J.M.O.).	Abe H, 2011, ACS MED CHEM LETT, V2, P320, DOI 10.1021/ml200004g; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Dang CV, 2017, NAT REV CANCER, V17, P502, DOI 10.1038/nrc.2017.36; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Friedel RH, 2010, METHOD ENZYMOL, V477, P243, DOI 10.1016/S0076-6879(10)77013-0; FRIEDRICH G, 1993, METHOD ENZYMOL, V225, P681; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Gilmartin AG, 2011, CLIN CANCER RES, V17, P989, DOI 10.1158/1078-0432.CCR-10-2200; Griner LAM, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.360; Inglese J, 2006, P NATL ACAD SCI USA, V103, P11473, DOI 10.1073/pnas.0604348103; Johansson P, 2007, PIGM CELL RES, V20, P216, DOI 10.1111/j.1600-0749.2007.00375.x; Kaelin WG, 2017, NAT REV CANCER, V17, P441, DOI 10.1038/nrc.2017.32; Kalkat M, 2017, GENES-BASEL, V8, DOI 10.3390/genes8060151; Kannengiesser C, 2008, MOL ONCOL, V1, P425, DOI 10.1016/j.molonc.2008.01.002; Kimura S, 2005, BLOOD, V106, P3948, DOI 10.1182/blood-2005-06-2209; Li YJ, 2015, INT J CLIN EXP PATHO, V8, P7818; Loboda A, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-26; Luke JJ, 2017, NAT REV CLIN ONCOL, V14, P463, DOI 10.1038/nrclinonc.2017.43; Medico E, 2001, NAT BIOTECHNOL, V19, P579, DOI 10.1038/89343; Monga M, 2002, LEUKEMIA, V16, P520, DOI 10.1038/sj.leu.2402464; Nakamura A, 2013, CANCER RES, V73, P7043, DOI 10.1158/0008-5472.CAN-13-1825; Okaniwa M, 2013, J MED CHEM, V56, P6478, DOI 10.1021/jm400778d; Okaniwa M, 2012, J MED CHEM, V55, P3452, DOI 10.1021/jm300126x; Pavey S, 2004, ONCOGENE, V23, P4060, DOI 10.1038/sj.onc.1207563; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Santos FPS, 2010, CURR OPIN INVEST DR, V11, P1450; Southall N. A., 2009, HDB DRUG SCREENING, P442; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Wang Yuhong, 2010, Curr Chem Genomics, V4, P57, DOI 10.2174/1875397301004010057; Yamaguchi T, 2011, INT J ONCOL, V39, P23, DOI 10.3892/ijo.2011.1015; Zhang F, 2014, HUM MOL GENET, V23, pR40, DOI 10.1093/hmg/ddu125	35	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2018	37	31					4226	4238		10.1038/s41388-018-0274-4	http://dx.doi.org/10.1038/s41388-018-0274-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP1HN	29717260	Green Accepted, hybrid			2022-12-17	WOS:000440566100003
J	Lee, S; Liu, P; Teinturier, R; Jakob, J; Tschaffon, M; Tasdogan, A; Wittig, R; Hoeller, S; Baumhoer, D; Frappart, L; Vettorazzi, S; Bertolino, P; Zhang, C; Tuckermann, J				Lee, S.; Liu, P.; Teinturier, R.; Jakob, J.; Tschaffon, M.; Tasdogan, A.; Wittig, R.; Hoeller, S.; Baumhoer, D.; Frappart, L.; Vettorazzi, S.; Bertolino, P.; Zhang, C.; Tuckermann, J.			Deletion of Menin in craniofacial osteogenic cells in mice elicits development of mandibular ossifying fibroma	ONCOGENE			English	Article							MESENCHYMAL STEM-CELLS; BENIGN FIBROOSSEOUS LESIONS; NEOPLASIA TYPE-1 MEN1; BONE; EXPRESSION; JAW; DIFFERENTIATION; SPECIFICATION; MAINTENANCE; PROGENITORS	Ossifying fibroma (OF) is a rare benign tumor of the craniofacial bones that can reach considerable and disfiguring dimensions if left untreated. Although the clinicopathological characteristics of OF are well established, the underlying etiology has remained largely unknown. Our work indicates that Men1-a tumor suppressor gene responsible of Multiple endocrine neoplasia type 1-is critical for OF formation and shows that mice with targeted disruption of Men1 in osteoblasts (Men1(Runx2Cre)) develop multifocal OF in the mandible with a 100% penetrance. Using lineage-tracing analysis, we demonstrate that loss of Men1 arrests stromal osteoprogenitors in OF at the osterix-positive pre-osteoblastic differentiation stage. Analysis of Men1-lacking stromal spindle cells isolated from OF (OF-derived MSCs (OFMSCs)) revealed a downregulation of the cyclin-dependent kinase (CDK) inhibitor Cdkn1a, consistent with an increased proliferation rate. Intriguingly, the re-expression of Men1 in Men1-deficient OFMSCs restored Cdkn1a expression and abrogated cellular proliferation supporting the tumor-suppressive role of Men1 in OF. Although our work presents the first evidence of Men1 in OF development, it further provides the first genetic mouse model of OF that can be used to better understand the molecular pathogenesis of these benign tumors and to potentially develop novel treatment strategies.	[Lee, S.; Liu, P.; Tschaffon, M.; Vettorazzi, S.; Tuckermann, J.] Univ Ulm, Inst Comparat Mol Endocrinol, Helmholtzstr 8-1, D-89081 Ulm, BW, Germany; [Teinturier, R.; Bertolino, P.; Zhang, C.] Univ Lyon 1, INSERM, Ctr Rech Cancerol Lyon, CNRS UMR5286,U1052, Lyon, France; [Jakob, J.; Frappart, L.] Leibniz Inst Aging, Fritz Lipmann Inst, Jena, Germany; [Tasdogan, A.] Univ Hosp Ulm, Inst Immunol, Ulm, Germany; [Wittig, R.] Ulm Univ, Inst Laser Technol Med & Metrol, Ulm, Germany; [Hoeller, S.; Baumhoer, D.] Univ Hosp, Bone Tumour Reference Ctr, Basel, Switzerland; [Hoeller, S.; Baumhoer, D.] Univ Hosp, DOESAK Registry, Inst Pathol, Basel, Switzerland; [Hoeller, S.; Baumhoer, D.] Univ Basel, Basel, Switzerland; [Frappart, L.] Univ Claude Bernard Lyon 1, INSERM, Oncogenese & Progress Tumorale, Lyon, France	Ulm University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard; Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); Ulm University; Ulm University; University of Basel; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Tuckermann, J (corresponding author), Univ Ulm, Inst Comparat Mol Endocrinol, Helmholtzstr 8-1, D-89081 Ulm, BW, Germany.	jan.tuckermann@uni-ulm.de	Bertolino, philippe/D-4072-2018; ZHANG, Chang Xian/G-2905-2013; Bertolino, philippe/M-8977-2019; Tasdogan, Alpaslan/U-5133-2017; Wittig, Rainer/AAT-5361-2021	Bertolino, philippe/0000-0001-8064-8269; Bertolino, philippe/0000-0001-8064-8269; Wittig, Rainer/0000-0002-3735-9370; Zhang, Chang Xian/0000-0002-5443-8951; Lee, Sooyeon/0000-0001-6244-4975; Holler, Sylvia/0000-0001-9277-7076; Vettorazzi, Dr. Sabine/0000-0001-8667-9488	Boehringer Ingelheim Foundation; Deutsche Forschungsgemeinschaft (DFG) [1468, Tu 220/6-1, Tu 220/6-2]; Deutsche Forschungsgemeinschaft (Collaborative Research Centre) [1149, C02/INST 40/492-1]; Deutsche Forschungsgemeinschaft (Trilateral Consortium) [Tu 220/12-1]; Leibniz Graduate School of Ageing from Fritz Lipmann Institute Jena	Boehringer Ingelheim Foundation(Boehringer Ingelheim); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Deutsche Forschungsgemeinschaft (Collaborative Research Centre)(German Research Foundation (DFG)); Deutsche Forschungsgemeinschaft (Trilateral Consortium)(German Research Foundation (DFG)); Leibniz Graduate School of Ageing from Fritz Lipmann Institute Jena	We are grateful to the staff of the animal facilities of the University of Ulm, led by Dr Petra Kirsch and in particular to Tobias Rappold. We thank Professor Dr Volker Rasche from the Core Facility Animal MRI, Ulm University and Dr Markus Rojewsky from the Institut fur Transfusionsmedizin Universitatsklinikum Ulm. We thank Dr Merle Stein and Dr Giorgio Caratti for critical reading of the manuscript. This study was supported by the Boehringer Ingelheim Foundation (to JT), Deutsche Forschungsgemeinschaft (DFG, Priority Program Immunobone 1468, Tu 220/6-1, 6-2, Collaborative Research Centre 1149, C02/INST 40/492-1, Trilateral Consortium Tu 220/12-1 to JT) and the Leibniz Graduate School of Ageing from Fritz Lipmann Institute Jena (to SL).	Bertolino P, 2003, CANCER RES, V63, P4836; Bhasin M, 2013, CASE REP DENT, V2013, DOI 10.1155/2013/497234; Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002; Chan CKF, 2015, CELL, V160, P285, DOI 10.1016/j.cell.2014.12.002; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Darling TN, 1997, ARCH DERMATOL, V133, P853, DOI 10.1001/archderm.133.7.853; Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805; Engleka KA, 2007, DEV BIOL, V311, P524, DOI 10.1016/j.ydbio.2007.08.057; Eversole R, 2008, HEAD NECK PATHOL, V2, P177, DOI 10.1007/s12105-008-0057-2; Falchetti A, 2009, GENET MED, V11, P825, DOI 10.1097/GIM.0b013e3181be5c97; Fauquier T, 2014, DEVELOPMENT, V141, P166, DOI 10.1242/dev.103226; Gherardi S, 2017, BBA-GENE REGUL MECH, V1860, P427, DOI 10.1016/j.bbagrm.2017.02.003; Houlihan DD, 2012, NAT PROTOC, V7, P2103, DOI 10.1038/nprot.2012.125; Isakov O, 2013, GENET RES, V95, P114, DOI 10.1017/S0016672313000141; JACKSON CE, 1990, SURGERY, V108, P1006; Franco-Barrera MJ, 2016, ORAL MAXILLOFAC SURG, V20, P1, DOI 10.1007/s10006-015-0535-0; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kanazawa I, 2015, J BIOL CHEM, V290, P3910, DOI 10.1074/jbc.M114.629899; Karnik SK, 2005, P NATL ACAD SCI USA, V102, P14659, DOI 10.1073/pnas.0503484102; KASSEM M, 1994, CLIN ENDOCRINOL, V41, P415, DOI 10.1111/j.1365-2265.1994.tb02570.x; Kim YS, 1999, ONCOGENE, V18, P5936, DOI 10.1038/sj.onc.1203005; Kottemann MC, 2009, DNA REPAIR, V8, P944, DOI 10.1016/j.dnarep.2009.06.001; Lemmens I, 1997, HUM MOL GENET, V6, P1177, DOI 10.1093/hmg/6.7.1177; Liu P, 2017, CELL DEATH DIFFER, V24, P672, DOI 10.1038/cdd.2016.165; Liu Y, 2010, DENTOMAXILLOFAC RAD, V39, P57, DOI 10.1259/dmfr/96330046; Matkar S, 2013, TRENDS BIOCHEM SCI, V38, P394, DOI [10.1016/j.tibs.2013.0S.005, 10.1016/j.tibs.2013.05.005]; Mendez-Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262; Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102; Mizoguchi T, 2014, DEV CELL, V29, P340, DOI 10.1016/j.devcel.2014.03.013; Morikawa S, 2009, J EXP MED, V206, P2483, DOI 10.1084/jem.20091046; Omatsu Y, 2010, IMMUNITY, V33, P387, DOI 10.1016/j.immuni.2010.08.017; Ono N, 2014, NAT CELL BIOL, V16, P1157, DOI 10.1038/ncb3067; Papagerakis P., 2013, DEV STRUCTURE TEETH; Park D, 2012, CELL STEM CELL, V10, P259, DOI 10.1016/j.stem.2012.02.003; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pinho S, 2013, J EXP MED, V210, P1351, DOI 10.1084/jem.20122252; Qin HY, 2013, CELL STEM CELL, V13, P577, DOI 10.1016/j.stem.2013.08.010; Ramaesh T, 2003, J ANAT, V203, P213, DOI 10.1046/j.1469-7580.2003.00210.x; Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005; Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480; Schnepp RW, 2006, CANCER RES, V66, P5707, DOI 10.1158/0008-5472.CAN-05-4518; Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140-6736(04)16627-0; Shibata S, 2008, J ANAT, V213, P274, DOI 10.1111/j.1469-7580.2008.00934.x; Slootweg PJ, 2017, WHO CLASSIFICATION H, P251; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Sung JH, 2008, TRANSPL P, V40, P2649, DOI 10.1016/j.transproceed.2008.08.009; Toyosawa S, 2007, MODERN PATHOL, V20, P389, DOI 10.1038/modpathol.3800753; Trijolet JP, 2011, EUR ANN OTORHINOLARY, V128, P30, DOI 10.1016/j.anorl.2010.06.005; WALDRON CA, 1973, ORAL SURG ORAL MED O, V35, P340, DOI 10.1016/0030-4220(73)90072-8; Woo SB, 2015, J ORAL MAXIL SURG, V73, pS87, DOI 10.1016/j.joms.2015.05.010; Worthley DL, 2015, CELL, V160, P269, DOI 10.1016/j.cell.2014.11.042; Yadav R., 2009, J ORAL SCI, V51, P151, DOI [10.2334/josnusd.51.151, DOI 10.2334/JOSNUSD.51.151]; Yamaza T, 2011, J DENT RES, V90, P317, DOI 10.1177/0022034510387796; Yang YJ, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.98; Zhang H, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/265380; Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008	56	4	4	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2018	37	5					616	626		10.1038/onc.2017.364	http://dx.doi.org/10.1038/onc.2017.364			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FU4GT	28991228				2022-12-17	WOS:000423812200007
J	De Melo, J; Kim, SS; Lourenco, C; Penn, LZ				De Melo, J.; Kim, S. S.; Lourenco, C.; Penn, L. Z.			Lysine-52 stabilizes the MYC oncoprotein through an SCFFbxw7-independent mechanism	ONCOGENE			English	Article							C-MYC; TUMOR-SUPPRESSOR; PROTEIN; DEGRADATION; PHOSPHORYLATION; DOMAIN; FBW7; UBIQUITYLATION; TUMORIGENESIS; TRANSCRIPTION	The oncogenic transcription factor c-MYC (MYC) is deregulated and often overexpressed in more than 50% of cancers. MYC deregulation is associated with poor prognosis and aggressive disease, suggesting that the development of therapeutic inhibitors targeting MYC would markedly impact patient outcome. MYC is highly regulated, with a protein and mRNA half-life of similar to 30 min. The most extensively studied pathway regulating MYC protein stability involves ubiquitylation and proteasomal degradation mediated by the E3-ligase, SCFFbxw7. Here we provide evidence for an SCFFbxw7-independent regulatory mechanism centred on the highly conserved lysine-52 (K52) within MYC Box I. This residue has been shown to be post-translationally modified by both ubiquitylation and SUMOylation, hinting at the interplay of post-translational modifications at this site and the importance of this residue. We demonstrate that mutation of K52 to arginine (R) renders the MYC protein more labile. Mechanistically, we show that the degradation pathway regulated by K52 is independent of the Cullin-RING ligase family of E3-ligases, which includes not only the canonical SCFFbxw7 but also other known MYC-targeting E3-ligases, such as SCFSkp2, SCF beta TCRP, SCFFbxo28 and DCXTRUSS. Taken together, our data identify a novel regulatory pathway centred on K52 that may be exploited for the development of anti-MYC therapeutics.	[De Melo, J.; Kim, S. S.; Lourenco, C.; Penn, L. Z.] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Lourenco, C.; Penn, L. Z.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Penn, LZ (corresponding author), Univ Hlth Network, Princess Margaret Canc Res Tower,101 Coll St, Toronto, ON M5G 1L7, Canada.	lpenn@uhnresearch.ca		Penn, Linda/0000-0001-8133-5459; De Melo, Jason/0000-0001-6519-4879	Canadian Institutes of Health Research [MOP275788]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	We thank Dr Bert Vogelstein for the HCT116 cells (wt/Fbxw7<SUP>-/-</SUP>) and all members of the Penn lab and especially the technical support of Aaliya Tamachi and Natasha Vitkin. LZP holds the Tier 1 Canada Research Chair in Molecular Oncology. This work was also supported by the Canadian Institutes of Health Research (MOP275788).	Adhikary S, 2005, CELL, V123, P409, DOI 10.1016/j.cell.2005.08.016; Akhoondi S, 2007, CANCER RES, V67, P9006, DOI 10.1158/0008-5472.CAN-07-1320; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Cepeda D, 2013, EMBO MOL MED, V5, P1067, DOI 10.1002/emmm.201202341; Chakraborty AA, 2014, ONCOGENE, V34, P1; Choi SH, 2010, GENE DEV, V24, P1236, DOI 10.1101/gad.1920310; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Diefenbacher ME, 2015, CANCER RES, V75, P1181, DOI 10.1158/0008-5472.CAN-14-1726; Fletcher S, 2015, BBA-GENE REGUL MECH, V1849, P525, DOI 10.1016/j.bbagrm.2014.03.005; Gonzalez-Prieto R, 2015, CELL CYCLE, V14, P1859, DOI 10.1080/15384101.2015.1040965; Grim JE, 2008, J CELL BIOL, V181, P913, DOI 10.1083/jcb.200802076; Gustafson WC, 2010, ONCOGENE, V29, P1249, DOI 10.1038/onc.2009.512; Hakem A, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002360; Helander S, 2015, STRUCTURE, V23, P2267, DOI 10.1016/j.str.2015.10.010; Herbst A, 2005, EMBO REP, V6, P177, DOI 10.1038/sj.embor.7400333; Inoue S, 2013, GENE DEV, V27, P1101, DOI 10.1101/gad.214577.113; Kalkat M, 2017, GENES-BASEL, V8, DOI 10.3390/genes8060151; Kalkat M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115337; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Kim W, 2011, MOL CELL, V44, P325, DOI 10.1016/j.molcel.2011.08.025; Kress TR, 2015, NAT REV CANCER, V15, P593, DOI 10.1038/nrc3984; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; McKeown MR, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014266; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Oster SK, 2003, ONCOGENE, V22, P1998, DOI 10.1038/sj.onc.1206228; Paul I, 2013, ONCOGENE, V32, P1284, DOI 10.1038/onc.2012.144; Popov N, 2010, NAT CELL BIOL, V12, P973, DOI 10.1038/ncb2104; Prochownik Edward V, 2010, Genes Cancer, V1, P650; PULVERER BJ, 1994, ONCOGENE, V9, P59; Rabellino A, 2016, CELL REP, V15, P2266, DOI 10.1016/j.celrep.2016.05.015; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Tang Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163324; Topham C, 2015, CANCER CELL, V28, P129, DOI 10.1016/j.ccell.2015.06.001; Tu W.B., 2014, BIOCHIM BIOPHYS ACTA, V1849, P469; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wasylishen AR, 2014, ONCOGENE, V33, P1066, DOI 10.1038/onc.2013.36; Wasylishen AR, 2011, ONCOGENE, V30, P3727, DOI 10.1038/onc.2011.88; Wasylishen AR, 2013, CANCER RES, V73, P6504, DOI 10.1158/0008-5472.CAN-12-4063; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Wolf E, 2015, TRENDS CELL BIOL, V25, P241, DOI 10.1016/j.tcb.2014.10.006; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Zhang Q, 2013, P NATL ACAD SCI USA, V110, P978, DOI 10.1073/pnas.1208334110; Zhao XD, 2008, NAT CELL BIOL, V10, P643, DOI 10.1038/ncb1727; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	53	4	4	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2017	36	49					6815	6822		10.1038/onc.2017.268	http://dx.doi.org/10.1038/onc.2017.268			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FP0IK	28806398				2022-12-17	WOS:000417282500007
J	Beesetti, S; Mavuluri, J; Surabhi, RP; Oberyszyn, TM; Tober, K; Pitani, RS; Joseph, LD; Venkatraman, G; Rayala, SK				Beesetti, S.; Mavuluri, J.; Surabhi, R. P.; Oberyszyn, T. M.; Tober, K.; Pitani, R. S.; Joseph, L. D.; Venkatraman, G.; Rayala, S. K.			Transcriptional regulation of ataxia-telangiectasia and Rad3-related protein by activated p21-activated kinase-1 protects keratinocytes in UV-B-induced premalignant skin lesions	ONCOGENE			English	Article							NF-KAPPA-B; GROWTH-FACTOR RECEPTOR; DNA-DAMAGE; CELLS; PAK1; IRRADIATION; CANCER; PATHWAYS; FOS; PHOSPHORYLATION	Sun-induced skin lesions, in particular actinic keratosis, are generally considered as premalignant skin lesions that can progress into squamous cell carcinoma (SCC) and invasive SCC if left untreated. Therefore, understanding the molecular mechanisms by which the ultraviolet-B (UV-B)-exposed cells are being protected and the signaling pathways that promote the progression of certain premalignant skin lesions to malignant lesions will permit us to prevent or cure skin cancers. In the current study, we found that phospho-p21-activated kinase-1 (Pak1) and Pak1 expression was high in clinical samples of sunlight-induced premalignant skin lesions assessed by immunohistochemistry. Further, we observed that phospho-Pak1 and Pak1 levels are high in UV-B-exposed hairless SKH mouse model skin samples as compared with unexposed skin tissue. Our results from cell line and animal models showed that Pak1 is activated in response to UV-B radiation, and this activated Pak1 translocates from the cytoplasm to the nucleus. Inside the nucleus, Pak1 via C-Fos binds to a specific promoter region of DNA repair kinase ATR (ataxia-telangiectasia and Rad3-related protein) and acts as a transcriptional regulator of ATR. Results from our analysis showed that Pak1 overexpression, knockdown and Pak1 knockout cell line models showed that Pak1 confers protection to keratinocytes from UV-B-induced apoptosis and DNA damage via ATR. To our knowledge, this is the first study that evaluates the functional and clinical significance of a signaling molecule, Pak1, in sun-induced premalignant skin lesions and indicates that increased Pak1 activation and expression could serve as an early warning sign of progression toward non-melanoma skin cancer, if ignored.	[Beesetti, S.; Mavuluri, J.; Surabhi, R. P.; Rayala, S. K.] IITM, Dept Biotechnol, Madras 600036, Tamil Nadu, India; [Oberyszyn, T. M.; Tober, K.] Ohio State Univ, Coll Med, Dept Pathol, Columbus, OH 43210 USA; [Pitani, R. S.] Sri Ramachandra Univ, Dept Community Med, Madras, Tamil Nadu, India; [Joseph, L. D.] Sri Ramachandra Univ, Dept Pathol, Madras, Tamil Nadu, India; [Venkatraman, G.] Sri Ramachandra Univ, Dept Human Genet, Madras 600116, Tamil Nadu, India	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Madras; University System of Ohio; Ohio State University; Sri Ramachandra Institute of Higher Education & Research; Sri Ramachandra Institute of Higher Education & Research; Sri Ramachandra Institute of Higher Education & Research	Rayala, SK (corresponding author), IITM, Dept Biotechnol, Madras 600036, Tamil Nadu, India.; Venkatraman, G (corresponding author), Sri Ramachandra Univ, Dept Human Genet, Madras 600116, Tamil Nadu, India.	ganeshv@sriramachandra.edu.in; rayala@iitm.ac.in	Venkatraman, Ganesh/AAB-1467-2020; beesetti, swarna/ABD-2044-2020; Joseph, Leena Dennis/AAS-9420-2020; Mavuluri, Jayadev/AAW-6724-2021	Venkatraman, Ganesh/0000-0003-0179-9785; Rayala, Suresh/0000-0003-4394-4450; Oberyszyn, Tatiana/0000-0002-5308-0855; Latha, B Swarna/0000-0001-7598-5607	DRDO-LSRB, Government of India [DLS/81/48222/XXIII/LSRB/2009]; NCI [R01CA133629]; NATIONAL CANCER INSTITUTE [R01CA133629] Funding Source: NIH RePORTER	DRDO-LSRB, Government of India; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Barathidasan, Veterinary Pathologist from Mahatma Gandhi Medical College and Research Institute (MGMCRI), Pondicherry for scoring the mice slides. We also thank Rahul and Venu for help with IHC and animal studies. We thank DRDO-LSRB, Government of India, for the financial support to SKR (Grant No: DLS/81/48222/XXIII/LSRB/2009), and NCI R01CA133629 (to TMO) and Indian Institute of Technology Madras (IITM) for all other facilities.	Anna Brozyna, 2007, Expert Rev Dermatol, V2, P451, DOI 10.1586/17469872.2.4.451; Auclair Y, 2009, CELL CYCLE, V8, P1865, DOI 10.4161/cc.8.12.8800; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Bhat M Ramesh, 2012, Indian J Dermatol, V57, P158, DOI 10.4103/0019-5154.94298; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Brzoska K, 2009, MUTAGENESIS, V24, P1, DOI 10.1093/mutage/gen056; Carr TD, 2012, CANCER PREV RES, V5, P1394, DOI 10.1158/1940-6207.CAPR-12-0272-T; Chow HY, 2012, CANCER RES, V72, P5966, DOI 10.1158/0008-5472.CAN-12-2246; Cooper SJ, 2007, CURR CANCER DRUG TAR, V7, P325, DOI 10.2174/156800907780809714; Corona R, 1996, Ann Ist Super Sanita, V32, P37; Criscione VD, 2009, CANCER-AM CANCER SOC, V115, P2523, DOI 10.1002/cncr.24284; Dore J F, 2001, IARC Sci Publ, V154, P81; El-Abaseri TB, 2007, J BIOMED BIOTECHNOL, DOI 10.1155/2007/97939; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Gan JF, 2015, INT J MOL SCI, V16, P12035, DOI 10.3390/ijms160612035; Ghosal G, 2013, TRANSL CANCER RES, V2, P107, DOI 10.3978/j.issn.2218-676X.2013.04.01; Gill Pavandeep, 2015, CMAJ Open, V3, pE258, DOI 10.9778/cmajo.20140037; HAAS S, 1995, CARCINOGENESIS, V16, P985, DOI 10.1093/carcin/16.5.985; Holm C, 2006, JNCI-J NATL CANCER I, V98, P671, DOI 10.1093/jnci/djj185; Ichihashi M, 2003, TOXICOLOGY, V189, P21, DOI 10.1016/S0300-483X(03)00150-1; Jagadeeshan S, 2015, ONCOGENE, V34, P455, DOI 10.1038/onc.2013.576; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Li DQ, 2012, CELL REP, V2, P1657, DOI 10.1016/j.celrep.2012.11.018; MARKS VJ, 1993, OTOLARYNG CLIN N AM, V26, P23; Motwani M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066585; Ong CC, 2013, JNCI-J NATL CANCER I, V105, P606, DOI 10.1093/jnci/djt054; Panda Saumya, 2010, Indian J Dermatol, V55, P373, DOI 10.4103/0019-5154.74551; Radu M, 2014, NAT REV CANCER, V14, P13, DOI 10.1038/nrc3645; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; Sanchez-Solana B, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.404061; Sato K, 2013, INT J MOL SCI, V14, P10761, DOI 10.3390/ijms140610761; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Singh RR, 2005, J BIOL CHEM, V280, P18130, DOI 10.1074/jbc.M412607200; Tai MH, 2012, INT J MOL SCI, V13, P4351, DOI 10.3390/ijms13044351; Tse E Y, 2014, J MOL SIGNALING, V9, P7, DOI [10.1186/1750-2187-9-7, DOI 10.1186/1750-2187-9-725093037]; Vodenicharov MD, 2005, COMP SER PHOTOCHEM, V5, P247; Wang N, 2015, ADV APPL BIOTECHNOLO, V65, P627; Wang Y, 2015, MED SCI MONIT BASIC, V21, P21, DOI 10.12659/MSMBR.893143; Ward IM, 2004, J BIOL CHEM, V279, P9677, DOI 10.1074/jbc.C300554200; Xu YR, 2006, J BIOL CHEM, V281, P27389, DOI 10.1074/jbc.M602355200; Xu YR, 2006, AM J PATHOL, V169, P823, DOI 10.2353/ajpath.2006.050449; Yang ZB, 2004, CLIN CANCER RES, V10, P658, DOI 10.1158/1078-0432.CCR-0382-03; Zhou MJ, 2012, BIOMED ENVIRON SCI, V25, P583, DOI 10.3967/0895-3988.2012.05.013	44	4	4	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2017	36	44					6154	6163		10.1038/onc.2017.218	http://dx.doi.org/10.1038/onc.2017.218			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FL5CU	28692051				2022-12-17	WOS:000414249800009
J	Manent, J; Banerjee, S; Simoes, RD; Zoranovic, T; Mitsiades, C; Penninger, JM; Simpson, KJ; Humbert, PO; Richardson, HE				Manent, J.; Banerjee, S.; Simoes, R. de Matos; Zoranovic, T.; Mitsiades, C.; Penninger, J. M.; Simpson, K. J.; Humbert, P. O.; Richardson, H. E.			Autophagy suppresses Ras-driven epithelial tumourigenesis by limiting the accumulation of reactive oxygen species (vol 36, pg 5576, 2017)	ONCOGENE			English	Correction													Penninger, Josef M/I-6860-2013; Pryjda, Tamara/O-5714-2019; Richardson, Helena E/A-8080-2013	Penninger, Josef M/0000-0002-8194-3777; Richardson, Helena E/0000-0003-3852-4953; Simpson, Kaylene/0000-0001-9136-1781				Manent J, 2017, ONCOGENE, V36, P5576, DOI 10.1038/onc.2017.175	1	4	4	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2017	36	40					5658	5660		10.1038/onc.2017.239	http://dx.doi.org/10.1038/onc.2017.239			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI8ZW	28980625	Green Published, Bronze			2022-12-17	WOS:000412293600010
J	Wu, DW; Lee, MC; Hsu, NY; Wu, TC; Wu, JY; Wang, YC; Cheng, YW; Chen, CY; Lee, H				Wu, D-W; Lee, M-C; Hsu, N-Y; Wu, T-C; Wu, J-Y; Wang, Y-C; Cheng, Y-W; Chen, C-Y; Lee, H.			FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-kappa B/Slug-mediated PUMA reduction (vol 34, pg 2505, 2015)	ONCOGENE			English	Correction																		Wu DW, 2015, ONCOGENE, V34, P2505, DOI 10.1038/onc.2014.184	1	4	4	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2017	36	38					5439	5439		10.1038/onc.2017.249	http://dx.doi.org/10.1038/onc.2017.249			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FH7PJ	28714963	Bronze			2022-12-17	WOS:000411382100010
J	Wu, TS; Tan, CT; Chang, CC; Lin, BR; Lai, WT; Chen, ST; Kuo, MYP; Rau, CL; Jaw, FS; Chang, HH				Wu, T-S; Tan, C-T; Chang, C-C; Lin, B-R; Lai, W-T; Chen, S-T; Kuo, M. Yen-Ping; Rau, C-L; Jaw, F-S; Chang, H-H			B-cell lymphoma/leukemia 10 promotes oral cancer progression through STAT1/ATF4/S100P signaling pathway (vol 34, pg 1207, 2015)	ONCOGENE			English	Correction									[Wu, T-S; Lai, W-T; Kuo, M. Yen-Ping; Chang, H-H] Natl Taiwan Univ, Grad Inst Clin Dent, Sch Dent, Taipei, Taiwan; [Tan, C-T] Natl Taiwan Univ Hosp, Dept Otolaryngol, Taipei, Taiwan; [Chang, C-C] Natl Taiwan Univ, Grad Inst Oral Biol, Sch Dent, Taipei, Taiwan; [Lin, B-R] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan; [Chen, S-T] Natl Taiwan Univ Hosp, Dept Pediat, Taipei, Taiwan; [Chen, S-T] Natl Taiwan Univ Hosp, YunLin Branch, Dept Pediat, Yunlin, Taiwan; [Rau, C-L; Jaw, F-S] Natl Taiwan Univ, Inst Biomed Engn, Taipei, Taiwan; [Rau, C-L] Taipei Med Univ, Shuang Ho Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan; [Chang, H-H] Natl Taiwan Univ, Sch Dent, Dept Dent, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; Taipei Medical University; Shuang Ho Hospital; National Taiwan University	Wu, TS (corresponding author), Natl Taiwan Univ, Grad Inst Clin Dent, Sch Dent, Taipei, Taiwan.			LIN, BEEN-REN/0000-0001-8354-1758				Wu TS, 2015, ONCOGENE, V34, P1207, DOI 10.1038/onc.2014.43	1	4	5	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2017	36	38					5440	5440		10.1038/onc.2017.250	http://dx.doi.org/10.1038/onc.2017.250			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FH7PJ	28714961	Bronze			2022-12-17	WOS:000411382100011
J	Goto, H; Kariya, R; Kudo, E; Okuno, Y; Ueda, K; Katano, H; Okada, S				Goto, H.; Kariya, R.; Kudo, E.; Okuno, Y.; Ueda, K.; Katano, H.; Okada, S.			Restoring PU.1 induces apoptosis and modulates viral transactivation via interferon-stimulated genes in primary effusion lymphoma	ONCOGENE			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; ACUTE MYELOID-LEUKEMIA; KAPOSIS-SARCOMA; CELL-LINE; TRANSCRIPTION FACTOR; REGULATED GENES; EXPRESSION; GROWTH; AIDS; ELEMENTS	Primary effusion lymphoma (PEL), which is an aggressive subgroup of B-cell lymphoma associated with Kaposi sarcoma-associated herpes virus/human herpes virus-8, is refractory to the standard treatment, and exhibits a poor survival. Although PU.1 is downregulated in PEL, the potential role of its reduction remains to be elucidated. In this investigation, we analyzed the DNA methylation of PU.1 cis-regulatory elements in PEL and the effect of restoring PU.1 on PEL cells. The mRNA level of PU.1 was downregulated in PEL cells. The methylated promoter and enhancer regions of the PU.1 gene were detected in PEL cells. Suppression of cell growth and apoptosis were caused by the restoration of PU.1 in PEL cells. A microarray analysis revealed that interferon-stimulated genes (ISGs) including pro-apoptotic ISGs were strongly increased in BCBL-1 cells after the induction of PU.1. Reporter assays showed that PU.1 transactivated pro-apoptotic ISG promoters, such as the XAF1, OAS1 and TRAIL promoters. Mutations at the PU.1 binding sequences suppressed its transactivation. We confirmed the binding of PU.1 to the XAF1, OAS1 and TRAIL promoters in a chromatin immunoprecipitation assay. PU.1 suppressed ORF57 activation by inducing IRF7. The reinduction of PU.1 reduced formation of ascites and lymphoma cell infiltration of distant organs in PEL xenograft model mice. Collectively, PU.1 has a role in tumor suppression in PEL and its down-regulation is associated with PEL development. Restoring PU.1 with demethylation agents may be a novel therapeutic approach for PEL.	[Goto, H.; Kariya, R.; Kudo, E.; Okada, S.] Kumamoto Univ, Div Hematopoiesis, Ctr AIDS Res, Honjo, Kumamoto, Japan; [Okuno, Y.] Kumamoto Univ, Grad Sch Med, Dept Hematol, Honjo, Kumamoto, Japan; [Okuno, Y.] Kumamoto Univ, Grad Sch Med, Dept Rheumatol, Honjo, Kumamoto, Japan; [Okuno, Y.] Kumamoto Univ, Grad Sch Med, Dept Infect Dis, Honjo, Kumamoto, Japan; [Ueda, K.] Osaka Univ, Grad Sch Med, Dept Microbiol & Immunol, Div Virol, Suita, Osaka, Japan; [Katano, H.] Natl Inst Infect Dis, Dept Pathol, Shinjuku Ku, Toyama, Tokyo, Japan	Kumamoto University; Kumamoto University; Kumamoto University; Kumamoto University; Osaka University; National Institute of Infectious Diseases (NIID)	Okada, S (corresponding author), Kumamoto Univ, Ctr AIDS Res, Div Hematopoiesis, Chuo Ku, 2-2-1 Honjo, Kumamoto 8600811, Japan.	okadas@kumamoto-u.ac.jp		Okada, Seiji/0000-0003-3124-5206	Japan Agency for Medical Research and Development, AMED [17fk0410208h0002]; Ministry of Education, Science, Sports, and Culture of Japan [16K08742]; Grants-in-Aid for Scientific Research [16H07080] Funding Source: KAKEN	Japan Agency for Medical Research and Development, AMED(Japan Agency for Medical Research and Development (AMED)); Ministry of Education, Science, Sports, and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by the Research program on HIV/AIDS (No. 17fk0410208h0002) from the Japan Agency for Medical Research and Development, AMED, and Grants-in-Aid for Science Research (No. 16K08742) from the Ministry of Education, Science, Sports, and Culture of Japan.	Ansari MQ, 1996, AM J CLIN PATHOL, V105, P221; Arguello M, 2003, ONCOGENE, V22, P964, DOI 10.1038/sj.onc.1206270; Boulanger E, 2005, J CLIN ONCOL, V23, P4372, DOI 10.1200/JCO.2005.07.084; Castelli JC, 1998, CELL DEATH DIFFER, V5, P313, DOI 10.1038/sj.cdd.4400352; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; Deng H, 2007, CURR TOP MICROBIOL, V312, P157; Domingo-Gil E, 2006, APOPTOSIS, V11, P725, DOI 10.1007/s10495-006-5541-0; DONG BH, 1995, J BIOL CHEM, V270, P4133, DOI 10.1074/jbc.270.8.4133; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; Fan W, 2005, J VIROL, V79, P1244, DOI 10.1128/JVI.79.2.1244-1251.2005; Goto H, 2015, J CANCER RES CLIN, V141, P465, DOI 10.1007/s00432-014-1842-9; Goto H, 2014, EUR J CANCER, V50, P1836, DOI 10.1016/j.ejca.2014.03.004; Goto H, 2013, INT J HEMATOL, V97, P624, DOI 10.1007/s12185-013-1339-3; Goto H, 2012, CANCER SCI, V103, P775, DOI 10.1111/j.1349-7006.2012.02212.x; Gradoville L, 2000, J VIROL, V74, P6207, DOI 10.1128/JVI.74.13.6207-6212.2000; Hussain AR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039945; Iwasaki H, 2005, BLOOD, V106, P1590, DOI 10.1182/blood-2005-03-0860; Katano H, 1999, J MED VIROL, V58, P394, DOI 10.1002/(SICI)1096-9071(199908)58:4&lt;394::AID-JMV12&gt;3.0.CO;2-H; Katano H, 1999, AM J PATHOL, V155, P47, DOI 10.1016/S0002-9440(10)65097-3; Leaman DW, 2002, J BIOL CHEM, V277, P28504, DOI 10.1074/jbc.M204851200; Li YL, 2001, BLOOD, V98, P2958, DOI 10.1182/blood.V98.10.2958; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Majerciak V, 2009, FRONT BIOSCI-LANDMRK, V14, P1516, DOI 10.2741/3322; Miyagi J, 2002, INT J HEMATOL, V76, P165, DOI 10.1007/BF02982580; Moore PS, 2001, PHILOS T R SOC B, V356, P499, DOI 10.1098/rstb.2000.0777; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; Nishiyama C, 2002, J IMMUNOL, V168, P4546, DOI 10.4049/jimmunol.168.9.4546; Nutt SL, 2005, J EXP MED, V201, P221, DOI 10.1084/jem.20041535; Okada S, 2014, INTRACTABLE RARE DIS, V3, P65, DOI 10.5582/irdr.2014.01010; Palmeri D, 2007, J VIROL, V81, P13299, DOI 10.1128/JVI.00732-07; Pang SHM, 2016, LEUKEMIA, V30, P1375, DOI 10.1038/leu.2016.27; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; Rosenbauer F, 2006, NAT GENET, V38, P27, DOI 10.1038/ng1679; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Rusinova I, 2013, NUCLEIC ACIDS RES, V41, pD1040, DOI 10.1093/nar/gks1215; Samarajiwa SA, 2009, NUCLEIC ACIDS RES, V37, pD852, DOI 10.1093/nar/gkn732; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Solomon LA, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1303-0; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Tatetsu H, 2007, CANCER RES, V67, P5328, DOI 10.1158/0008-5472.CAN-06-4265; Uddin S, 2005, ONCOGENE, V24, P7022, DOI 10.1038/sj.onc.1208864; Uddin S, 2005, CLIN CANCER RES, V11, P3102, DOI 10.1158/1078-0432.CCR-04-1857; Ueda K, 2002, J VIROL, V76, P12044, DOI 10.1128/JVI.76.23.12044-12054.2002; Ueno S, 2009, ONCOGENE, V28, P4116, DOI 10.1038/onc.2009.263; Wang JZ, 2005, J VIROL, V79, P2420, DOI 10.1128/JVI.79.4.2420-2431.2005; Wang S, 2001, ARCH VIROL, V146, P1415, DOI 10.1007/s007050170102; Will B, 2015, NAT MED, V21, P1172, DOI 10.1038/nm.3936; Yuki H, 2013, BLOOD, V121, P962, DOI 10.1182/blood-2012-05-431429; Zou B, 2012, MOL CARCINOGEN, V51, P422, DOI 10.1002/mc.20807	54	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2017	36	37					5252	5262		10.1038/onc.2017.138	http://dx.doi.org/10.1038/onc.2017.138			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FG8HT	28481873				2022-12-17	WOS:000410671700004
J	Ferreira, HJ; Heyn, H; Vizoso, M; Moutinho, C; Vidal, E; Gomez, A; Martinez-Cardus, A; Simo-Riudalbas, L; Moran, S; Jost, E; Esteller, M				Ferreira, H. J.; Heyn, H.; Vizoso, M.; Moutinho, C.; Vidal, E.; Gomez, A.; Martinez-Cardus, A.; Simo-Riudalbas, L.; Moran, S.; Jost, E.; Esteller, M.			DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia (vol 35, pg 3079, 2016)	ONCOGENE			English	Correction													Esteller, Manel/L-5956-2014; Martinez, Anna/AAA-4939-2020	Esteller, Manel/0000-0003-4490-6093; Vizoso, Miguel/0000-0002-9992-2851				Ferreira HJ, 2016, ONCOGENE, V35, P3079, DOI 10.1038/onc.2015.359	1	4	4	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4233	4233		10.1038/onc.2017.57	http://dx.doi.org/10.1038/onc.2017.57			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28288143	hybrid, Green Published			2022-12-17	WOS:000405835800014
J	Yang, YC; Cheng, TY; Huang, SM; Su, CY; Yang, PW; Lee, JM; Chen, CK; Hsiao, M; Hua, KT; Kuo, ML				Yang, Y-C; Cheng, T-Y; Huang, S-M; Su, C-Y; Yang, P-W; Lee, J-M; Chen, C-K; Hsiao, M.; Hua, K-T; Kuo, M-L			Cytosolic PKM2 stabilizes mutant EGFR protein expression through regulating HSP90-EGFR association (vol 35, pg 3387, 2016)	ONCOGENE			English	Correction														CHENG, TSU-YAO/0000-0002-7370-5605				Yang YC, 2016, ONCOGENE, V35, P3387, DOI 10.1038/onc.2015.397	1	4	4	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4234	4234		10.1038/onc.2017.18	http://dx.doi.org/10.1038/onc.2017.18			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28319058	Bronze			2022-12-17	WOS:000405835800015
J	Xu, Y; Miriyala, S; Fang, F; Bakthavatchalu, V; Noel, T; Schnell, DM; Wang, C; St Clair, WH; St Clair, DK				Xu, Y.; Miriyala, S.; Fang, F.; Bakthavatchalu, V.; Noel, T.; Schnell, D. M.; Wang, C.; St Clair, W. H.; St Clair, D. K.			Manganese superoxide dismutase deficiency triggers mitochondrial uncoupling and the Warburg effect (vol 34, pg 4229, 2015)	ONCOGENE			English	Correction														Miriyala, Sumitra/0000-0001-7158-9295				Xu Y, 2015, ONCOGENE, V34, P4229, DOI 10.1038/onc.2014.355	1	4	4	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					4087	4087		10.1038/onc.2016.513	http://dx.doi.org/10.1038/onc.2016.513			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28288137	Bronze			2022-12-17	WOS:000405379900014
J	Urbinati, C; Grillo, E; Chiodelli, P; Tobia, C; Caccuri, F; Fiorentini, S; David, G; Rusnati, M				Urbinati, C.; Grillo, E.; Chiodelli, P.; Tobia, C.; Caccuri, F.; Fiorentini, S.; David, G.; Rusnati, M.			Syndecan-1 increases B-lymphoid cell extravasation in response to HIV-1 Tat via alpha(v)beta(3)/pp60src/pp125FAK pathway	ONCOGENE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HEPARAN-SULFATE PROTEOGLYCANS; INTEGRIN-MEDIATED ADHESION; ENDOTHELIAL-CELLS; IN-VIVO; SIGNALING PATHWAY; VASCULAR-PERMEABILITY; CYTOPLASMIC DOMAINS; INDUCED CHEMOTAXIS; MULTIPLE-MYELOMA	Syndecan-1 is a heparan sulfate proteoglycan (HSPG) commonly upregulated in AIDS-related B lymphoid malignancies. Tat is the main HIV-1 transactivating factor that has a major role in the pathogenesis of AIDS-related lymphomas (ARL) by engaging heparan sulfate proteoglycans (HSPGs), chemokine receptors and integrins at the lymphoid cell (LC) surface. Here B-lymphoid Namalwa cell clones that do not express or overexpress syndecan-1 (EV-Ncs and SYN-Ncs, respectively) were compared for their responsiveness with Tat: in the absence of syndecan-1, Tat induces a limited EV-Nc migration via C-X-C motif chemokine receptor 4 (CXCR4), G-proteins and Rac. Syndecan-1 overexpression increases SYN-Nc responsiveness to Tat and makes this response independent from CXCR4 and G-protein and dependent instead on pp60src phosphorylation. Tat-induced SYN-Nc migration and pp60src phosphorylation require the engagement of alpha(v)beta(3) integrin and consequent pp125FAK phosphorylation. This complex set of Tat-driven activations is orchestrated by the direct interaction of syndecan-1 with pp60src and its simultaneous coupling with alpha(v)beta(3). The Tat/syndecan-1/alpha(v)beta(3) interplay is retained in vivo and is shared also by other syndecan-1(+) B-LCs, including BJAB cells, whose responsiveness to Tat is inhibited by syndecan-1 knockdown. In conclusion, overexpression of syndecan-1 confers to B-LCs an increased capacity to migrate in response to Tat, owing to a switch from a CXCR4/G-protein/Rac to a syndecan-1/alpha(v)beta(3)/pp60src/pp125FAK signal transduction pathway that depends on the formation of a complex in which syndecan-1 interacts with Tat via its HS-chains, with alpha(v)beta(3) via its core protein ectodomain and with pp60src via its intracellular tail. These findings have implications in ARL progression and may help in identifying new therapeutical targets for the treatment of AIDS-associated neoplasia.	[Urbinati, C.; Grillo, E.; Chiodelli, P.; Tobia, C.; Rusnati, M.] Univ Brescia, Dept Mol & Translat Med, Sect Expt Oncol & Immunol, Viale Europa 11, I-25123 Brescia, Italy; [Caccuri, F.; Fiorentini, S.] Univ Brescia, Dept Mol & Translat Med, Sect Microbiol, Brescia, Italy; [David, G.] Univ Leuven, Dept Human Genet, Leuven, Belgium; [David, G.] Flanders Inst Biotechnol, Leuven, Belgium	University of Brescia; University of Brescia; KU Leuven; Flanders Institute for Biotechnology (VIB)	Rusnati, M (corresponding author), Univ Brescia, Dept Mol & Translat Med, Sect Expt Oncol & Immunol, Viale Europa 11, I-25123 Brescia, Italy.	marco.rusnati@unibs.it	Rusnati, Marco/F-1168-2010; Grillo, Elisabetta/AAS-3884-2021; Caccuri, Francesca/AAC-1281-2022; Tobia, Chiara/ABA-5682-2021	Rusnati, Marco/0000-0001-9968-5908; Caccuri, Francesca/0000-0002-1923-9033; Tobia, Chiara/0000-0002-0985-7356; FIORENTINI, SIMONA/0000-0002-1866-314X; Urbinati, Chiara Eva/0000-0002-0138-7871; Grillo, Elisabetta/0000-0002-8403-0607	MIUR; Fondazione Italiana per la Ricerca sul Cancro Fellowship	MIUR(Ministry of Education, Universities and Research (MIUR)); Fondazione Italiana per la Ricerca sul Cancro Fellowship(Fondazione AIRC per la ricerca sul cancro)	We thank Professor Marco Presta (University of Brescia) for helpful discussion. This work was supported by grants from MIUR to MR. PC was supported by Fondazione Italiana per la Ricerca sul Cancro Fellowship.	Akula SM, 2001, VIROLOGY, V282, P245, DOI 10.1006/viro.2000.0851; Arai A, 2005, CELL SIGNAL, V17, P497, DOI 10.1016/j.cellsig.2004.09.007; Arai A, 2006, CELL SIGNAL, V18, P2162, DOI 10.1016/j.cellsig.2006.05.001; Arese M, 2001, J IMMUNOL, V166, P1380, DOI 10.4049/jimmunol.166.2.1380; Beauvais DLM, 2004, J CELL BIOL, V167, P171, DOI 10.1083/jcb.200404171; Bonnet F, 2008, CURR OPIN ONCOL, V20, P534, DOI 10.1097/CCO.0b013e32830a5080; Brule S, 2009, BBA-GEN SUBJECTS, V1790, P1643, DOI 10.1016/j.bbagen.2009.08.001; Calpe E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081221; Carbone A, 1999, INT J BIOL MARKER, V14, P144, DOI 10.1177/172460089901400304; Chirivi RGS, 1999, BLOOD, V94, P1747, DOI 10.1182/blood.V94.5.1747.417a02_1747_1754; Choi Y, 2010, BIOCHEM BIOPH RES CO, V391, P921, DOI 10.1016/j.bbrc.2009.11.165; Colombrino E, 2004, EXP CELL RES, V295, P539, DOI 10.1016/j.yexcr.2004.01.018; Cross LM, 2003, ARTERIOSCL THROM VAS, V23, P911, DOI 10.1161/01.ATV.0000068685.72914.7E; Dhawan S, 1997, BLOOD, V90, P1535; Dhodapkar MV, 1999, LEUKEMIA LYMPHOMA, V34, P35, DOI 10.3109/10428199909083378; Fadnes B, 2012, GLYCOCONJUGATE J, V29, P513, DOI 10.1007/s10719-012-9427-9; Feistritzer C, 2005, EXP CELL RES, V305, P214, DOI 10.1016/j.yexcr.2005.01.001; Gatignol A, 2000, Adv Pharmacol, V48, P209; Ghezzi S, 2000, BIOCHEM BIOPH RES CO, V270, P992, DOI 10.1006/bbrc.2000.2523; Hamon M, 2004, GLYCOBIOLOGY, V14, P311, DOI 10.1093/glycob/cwh038; Hatse S, 2002, FEBS LETT, V527, P255, DOI 10.1016/S0014-5793(02)03143-5; Hoffmann C, 2005, BLOOD, V106, P1762, DOI 10.1182/blood-2004-12-4631; Huang LL, 1997, BIOCHEM BIOPH RES CO, V237, P461, DOI 10.1006/bbrc.1997.7162; Ingold K, 2005, J EXP MED, V201, P1375, DOI 10.1084/jem.20042309; Jarousse N, 2011, J IMMUNOL, V187, P5540, DOI 10.4049/jimmunol.1003495; Jarousse N, 2008, J VIROL, V82, P12591, DOI 10.1128/JVI.01167-08; Kaneider NC, 2002, J CELL SCI, V115, P227; Kinnunen T, 1998, J BIOL CHEM, V273, P10702, DOI 10.1074/jbc.273.17.10702; Kundu RK, 1999, BLOOD, V94, P275, DOI 10.1182/blood.V94.1.275.413a30_275_282; Lafrenie RM, 1996, J IMMUNOL, V156, P1638; Lamorte S, 2012, LEUKEMIA, V26, P1081, DOI 10.1038/leu.2011.290; Lebakken CS, 2000, EXP CELL RES, V259, P315, DOI 10.1006/excr.2000.4981; Lebakken CS, 1996, J CELL BIOL, V132, P1209, DOI 10.1083/jcb.132.6.1209; LEVINE AM, 1992, BLOOD, V80, P8; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Martis N, 2012, CURR HEMATOL MALIG R, V7, P228, DOI 10.1007/s11899-012-0125-2; Mennerich D, 2004, EUR J CANCER, V40, P1373, DOI 10.1016/j.ejca.2004.01.038; Mitola S, 1997, BLOOD, V90, P1365, DOI 10.1182/blood.V90.4.1365.1365_1365_1372; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Montecucco F, 2006, ANN NY ACAD SCI, V1069, P463, DOI 10.1196/annals.1351.045; Mosheimer BA, 2005, J CLIN ENDOCR METAB, V90, P2964, DOI 10.1210/jc.2004-1895; Murphy JW, 2007, J BIOL CHEM, V282, P10018, DOI 10.1074/jbc.M608796200; Noonan D, 2000, Adv Pharmacol, V48, P229; Okabe S, 2002, J HEMATOTH STEM CELL, V11, P923, DOI 10.1089/152581602321080583; Ott VL, 1998, J BIOL CHEM, V273, P35291, DOI 10.1074/jbc.273.52.35291; Pals ST, 2007, BLOOD, V110, P3102, DOI 10.1182/blood-2007-05-075176; Rabkin CS, 2001, EUR J CANCER, V37, P1316, DOI 10.1016/S0959-8049(01)00104-6; Rapraeger AC, 2013, FEBS J, V280, P2207, DOI 10.1111/febs.12160; Reijmers RM, 2013, FEBS J, V280, P2180, DOI 10.1111/febs.12180; Renshaw SA, 2006, BLOOD, V108, P3976, DOI 10.1182/blood-2006-05-024075; Rusnati M, 1999, J BIOL CHEM, V274, P28198, DOI 10.1074/jbc.274.40.28198; Safaiyan F, 1999, J BIOL CHEM, V274, P36267, DOI 10.1074/jbc.274.51.36267; SALCEDO R, 1995, CELL IMMUNOL, V160, P165, DOI 10.1016/0008-8749(95)80023-C; Sanderson RD, 2002, ANN HEMATOL, V81, P125, DOI 10.1007/s00277-002-0437-8; Saphire ACS, 2001, J VIROL, V75, P9187, DOI 10.1128/JVI.75.19.9187-9200.2001; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Shah BK, 2010, J CLIN ONCOL, V28, pE459, DOI 10.1200/JCO.2010.28.3077; Toborek M, 2003, J NEUROCHEM, V84, P169, DOI 10.1046/j.1471-4159.2003.01543.x; Toschi E, 2001, MOL BIOL CELL, V12, P2934, DOI 10.1091/mbc.12.10.2934; Urbinati C, 2005, ARTERIOSCL THROM VAS, V25, P2315, DOI 10.1161/01.ATV.0000186182.14908.7b; Urbinati C, 2005, J CELL SCI, V118, P3949, DOI 10.1242/jcs.02518; Urbinati C, 2009, BLOOD, V114, P3335, DOI 10.1182/blood-2009-01-198945; Vacca A, 2001, EXP HEMATOL, V29, P993, DOI 10.1016/S0301-472X(01)00674-9; van der Voort R, 2000, J EXP MED, V192, P1115, DOI 10.1084/jem.192.8.1115; Volinsky N, 2006, BIOCHEM J, V397, P213, DOI 10.1042/BJ20051655; Wang HY, 2010, J BIOL CHEM, V285, P13569, DOI 10.1074/jbc.M110.102137; Westerfield M, 1995, ZEBRAFISH BOOK; Whiteford JR, 2007, EXP CELL RES, V313, P3902, DOI 10.1016/j.yexcr.2007.08.002; Yang Y, 2002, BLOOD, V100, P610, DOI 10.1182/blood.V100.2.610; Yarchoan R, 2005, NAT CLIN PRACT ONCOL, V2, P406, DOI 10.1038/ncponc0253; Zhang Z, 2001, J BIOL CHEM, V276, P41921, DOI 10.1074/jbc.M106608200	72	4	4	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2017	36	18					2609	2618		10.1038/onc.2016.420	http://dx.doi.org/10.1038/onc.2016.420			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET9AN	27819680				2022-12-17	WOS:000400597300011
J	Yigit, MV; Ghosh, SK; Kumar, M; Petkova, V; Kavishwar, A; Moore, A; Medarova, Z				Yigit, M. V.; Ghosh, S. K.; Kumar, M.; Petkova, V.; Kavishwar, A.; Moore, A.; Medarova, Z.			Context-dependent differences in miR-10b breast oncogenesis can be targeted for the prevention and arrest of lymph node metastasis (vol 32, pg 1530, 2012)	ONCOGENE			English	Correction																		YIGIT MV, 2012, ONCOGENE, V32, P1530, DOI DOI 10.1038/0NC.2016.413	1	4	4	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2017	36	18					2628	2628		10.1038/onc.2016.413	http://dx.doi.org/10.1038/onc.2016.413			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET9AN	27841862	Bronze			2022-12-17	WOS:000400597300013
J	Xue, Y; Raharja, A; Sim, W; Wong, ESM; Rahmat, SAB; Lane, DP				Xue, Y.; Raharja, A.; Sim, W.; Wong, E. S. M.; Rahmat, S. A. B.; Lane, D. P.			The hot-spot p53R172H mutant promotes formation of giant spermatogonia triggered by DNA damage	ONCOGENE			English	Article							LIGHT-MICROSCOPIC CHARACTERIZATION; GERM-CELL TUMORS; STEM-CELLS; PROLIFERATING CELLS; CERVICAL-CARCINOMA; SERTOLI-CELLS; IN-VITRO; P53; MOUSE; EXPRESSION	Overexpression of mutant p53 is a common finding in most cancers but testicular tumours accumulate wild-type p53 (wtp53). In contrast to the accepted concept that p53 homozygous mutant mice do not accumulate mutant p53 in normal cells, our study on a mutant p53 mouse model of Li-Fraumeni syndrome harbouring the hot-spot p53R172H mutation described an elevated level of mutant p53 in non-cancerous mouse tissues. Here we use detailed immunohistochemical analysis to document the expression of p53R172H in mouse testis. In developing and adult testes, p53R172H was expressed in gonocytes, type A, Int, B spermatogonia as well as in pre-Sertoli cells and Leydig cells but was undetectable in spermatocytes and spermatids. A similar staining pattern was demonstrated for wtp53. However, the intensity of wtp53 staining was generally weaker than that of p53R172H, which indicates that the expression of p53R172H can be a surrogate marker of p53 gene transcription. Comparing the responses of wtp53 and p53R172H to irradiation, we found persistent DNA double-strand breaks in p53R172H testes and the formation of giant spermatogonia (GSG) following persistent DNA damage in p53R172H and p53-null mice. Strikingly, we found that p53R172H promotes spontaneous formation of GSG in non-stressed p53R172H ageing mice. Two types of GSG: Viable and Degenerative GSG were defined. We elucidate the factors involved in the formation of GSG: the loss of p53 function is a requirement for the formation of GSG whereas DNA damage acts as a promoting trigger. The formation of GSG does not translate to higher efficacy of testicular tumorigenesis arising from mutant p53 cells, which might be due to the presence of delayed-onset of p53-independent apoptosis.	[Xue, Y.; Sim, W.; Rahmat, S. A. B.; Lane, D. P.] ASTAR, Lab p53, Singapore, Singapore; [Raharja, A.] Barts & London Queen Marys Sch Med & Dent, London, England; [Wong, E. S. M.] ASTAR, Inst Med Biol, Singapore, Singapore	Agency for Science Technology & Research (A*STAR); University of London; Queen Mary University London; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB)	Lane, DP (corresponding author), 8A Biomed Grove,Neuros Immunos 06-04-05, Singapore 138648, Singapore.	dplane@p53Lab.a-star.edu.sg	Raharja, Antony/AAR-6885-2020	Raharja, Antony/0000-0001-6163-7927; Lane, David/0000-0003-0551-3545	Agency for Science, Technology and Research (A*STAR) of Singapore	Agency for Science, Technology and Research (A*STAR) of Singapore(Agency for Science Technology & Research (A*STAR))	We thank Dr Farid John Ghadessy for critical reading of the manuscript. We thank Ms Sarah Binte Zulkifli for microscope technical assistance. This work was funded by the Agency for Science, Technology and Research (A*STAR) of Singapore.	Ahmed EA, 2009, BIOL REPROD, V80, P1084, DOI 10.1095/biolreprod.108.071662; ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; Ariizumi T, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-44; Barker Nick, 2010, Curr Protoc Stem Cell Biol, VChapter 5, DOI 10.1002/9780470151808.sc05a04s13; Beumer TL, 1998, CELL DEATH DIFFER, V5, P669, DOI 10.1038/sj.cdd.4400396; Chiarini-Garcia H, 2001, BIOL REPROD, V65, P1170, DOI 10.1095/biolreprod65.4.1170; Chiarini-Garcia Helio, 2008, V450, P95, DOI 10.1007/978-1-60327-214-8_6; Chung P, 2016, BMJ CLIN EVID, V2016; De Rooij DG, 1998, INT J EXP PATHOL, V79, P67, DOI 10.1046/j.1365-2613.1998.00057.x; de Rooij DG, 1998, CURR OPIN CELL BIOL, V10, P694, DOI 10.1016/S0955-0674(98)80109-9; DEROOIJ DG, 1988, J CELL SCI, P181; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ERICKSON BH, 1983, MUTAT RES, V108, P317, DOI 10.1016/0027-5107(83)90129-X; GINSBERG SS, 1992, CANCER-AM CANCER SOC, V70, P606, DOI 10.1002/1097-0142(19920801)70:3<606::AID-CNCR2820700311>3.0.CO;2-L; Goh AM, 2015, ONCOTARGET, V6, P17968, DOI 10.18632/oncotarget.4956; Guillou L, 1996, AM J PATHOL, V149, P1221; Hirota T, 2005, NATURE, V438, P1176, DOI 10.1038/nature04254; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Manecksha RP, 2009, BJU INT, V104, P1329, DOI 10.1111/j.1464-410X.2009.08854.x; Nagano M, 1998, TISSUE CELL, V30, P389, DOI 10.1016/S0040-8166(98)80053-0; OAKBERG EF, 1956, AM J ANAT, V99, P507, DOI 10.1002/aja.1000990307; OAKBERG EF, 1971, ANAT REC, V169, P515, DOI 10.1002/ar.1091690305; Oatley JA, 2008, ANNU REV CELL DEV BI, V24, P263, DOI 10.1146/annurev.cellbio.24.110707.175355; Oatley JM, 2012, PHYSIOL REV, V92, P577, DOI 10.1152/physrev.00025.2011; Okwun OE, 1996, J REPROD FERTIL, V107, P137, DOI 10.1530/jrf.0.1070137; PENG HQ, 1993, CANCER RES, V53, P3574; Rajpert-De Meyts E, 2016, LANCET, V387, P1762, DOI 10.1016/S0140-6736(15)00991-5; Raverot G, 2005, DEV BIOL, V283, P215, DOI 10.1016/j.ydbio.2005.04.013; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; Schrans-Stassen BHGJ, 1999, ENDOCRINOLOGY, V140, P5894, DOI 10.1210/en.140.12.5894; Stacey DW, 2003, CURR OPIN CELL BIOL, V15, P158, DOI 10.1016/S0955-0674(03)00008-5; VONHOCHSTETTER AR, 1985, VIRCHOWS ARCH A, V407, P309; Xue Y, 2015, ONCOTARGET, V6, P34979, DOI 10.18632/oncotarget.5512; Xue YZ, 2010, CANCER RES, V70, P5316, DOI 10.1158/0008-5472.CAN-09-3789; Yin YZ, 2002, J ANDROL, V23, P64, DOI 10.1002/jand.2002.23.1.64	35	4	4	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2017	36	14					2002	2013		10.1038/onc.2016.374	http://dx.doi.org/10.1038/onc.2016.374			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ER6EQ	27869164	Green Published, hybrid			2022-12-17	WOS:000398898500010
J	Tsuruyama, T; Hiratsuka, T; Yamada, N				Tsuruyama, T.; Hiratsuka, T.; Yamada, N.			Hotspots of MLV integration in the hematopoietic tumor genome	ONCOGENE			English	Review							MURINE LEUKEMIA-VIRUS; PRE-B LYMPHOMAS; GENE-THERAPY; INSERTIONAL MUTAGENESIS; RETROVIRAL INTEGRATION; SITE SELECTION; CELL EXPANSION; SL/KH STRAIN; N-MYC; C-MYC	Extensive research has been performed regarding the integration sites of murine leukemia retrovirus (MLV) for the identification of proto-oncogenes. To date, the overlap of mutations within specific oligonucleotides across different tumor genomes has been regarded as a rare event; however, a recent study of MLV integration into the oncogene Zfp521 suggested the existence of a hotspot oligonucleotide for MLV integration. In the current review, we discuss the hotspots of MLV integration into several genes: c-Myc, Stat5a and N-myc, as well as ZFP521, as examined in tumor genomes. From this, MLV integration convergence within specific oligonucleotides is not necessarily a rare event. This short review aims to promote re-consideration of MLV integration within the tumor genome, which involves both well-known and potentially newly identified and novel mechanisms and specifications.	[Tsuruyama, T.; Hiratsuka, T.] Kyoto Univ, Grad Sch Med, Dept Pathol, Sakyo Ku, Kyoto 6068501, Japan; [Tsuruyama, T.; Yamada, N.] Kyoto Univ, Ctr Anat Pathol & Forens Med Res, Grad Sch Med, Kyoto, Japan	Kyoto University; Kyoto University	Tsuruyama, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pathol, Sakyo Ku, Kyoto 6068501, Japan.	tsuruyam@kuhp.kyoto-u.ac.jp			 [2502]		This work was supported by a Grant-in-Aid for Scientific Research on Innovative Areas, MEXT, Japan (project title 'Synergy of Fluctuation and Structure' and number 2502). This funding agency had no role in the study design, data collection, analysis, decision to publish or preparation of the manuscript.	Abujiang P, 1996, LAB ANIM SCI, V46, P410; Aiyer S, 2014, NUCLEIC ACIDS RES, V42, P5917, DOI 10.1093/nar/gku175; Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; BAUMBACH WR, 1988, J VIROL, V62, P3151, DOI 10.1128/JVI.62.9.3151-3155.1988; Belkina AC, 2014, J LEUKOCYTE BIOL, V95, P451, DOI 10.1189/jlb.1112588; CORCORAN LM, 1985, CELL, V40, P71, DOI 10.1016/0092-8674(85)90310-1; Crowe BL, 2016, P NATL ACAD SCI USA, V113, P2086, DOI 10.1073/pnas.1516813113; Dave UP, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000491; De Ravin SS, 2014, J VIROL, V88, P4504, DOI 10.1128/JVI.00011-14; De Rijck J, 2013, CELL REP, V5, P886, DOI 10.1016/j.celrep.2013.09.040; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; Elis E, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003103; Felice B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004571; Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286; Gao FJ, 2015, CELL IMMUNOL, V294, P1, DOI 10.1016/j.cellimm.2015.01.010; Ginn SL, 2005, MED J AUSTRALIA, V182, P458, DOI 10.5694/j.1326-5377.2005.tb06785.x; Goldgur Y, 1999, P NATL ACAD SCI USA, V96, P13040, DOI 10.1073/pnas.96.23.13040; Gupta SS, 2013, J VIROL, V87, P12721, DOI 10.1128/JVI.01942-13; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hansen GM, 2000, GENOME RES, V10, P237, DOI 10.1101/gr.10.2.237; HARANGHERA N, 1995, LEUKEMIA, V9, P1199; Hiai H, 1999, Prog Exp Tumor Res, V35, P64; Hiai H, 2003, CANCER SCI, V94, P847, DOI 10.1111/j.1349-7006.2003.tb01365.x; Hiratsuka T, 2016, ONCOGENE, V35, P3227, DOI 10.1038/onc.2015.385; Hiratsuka T, 2008, LEUKEMIA RES, V32, P309, DOI 10.1016/j.leukres.2007.05.013; Holman AG, 2005, P NATL ACAD SCI USA, V102, P6103, DOI 10.1073/pnas.0501646102; Hwang HC, 2002, P NATL ACAD SCI USA, V99, P11293, DOI 10.1073/pnas.162356099; Jin G, 2003, CANCER SCI, V94, P791, DOI 10.1111/j.1349-7006.2003.tb01520.x; Kaszynski RH, 2010, CANCER SCI, V101, P800, DOI 10.1111/j.1349-7006.2009.01437.x; Katane M, 2004, J GENE MED, V6, P260, DOI 10.1002/jgm.487; Katz RA, 1998, J BIOL CHEM, V273, P24190, DOI 10.1074/jbc.273.37.24190; Kim R, 2003, J VIROL, V77, P2056, DOI 10.1128/JVI.77.3.2056-2062.2003; Kohn DB, 2003, NAT REV CANCER, V3, P477, DOI 10.1038/nrc1122; KURDIHAIDAR B, 1993, GENOMICS, V15, P305, DOI 10.1006/geno.1993.1061; Kvaratskhelia M, 2014, NUCLEIC ACIDS RES, V42, P10209, DOI 10.1093/nar/gku769; LaFave MC, 2014, NUCLEIC ACIDS RES, V42, P4257, DOI 10.1093/nar/gkt1399; LENZ J, 1982, J VIROL, V43, P943, DOI 10.1128/JVI.43.3.943-951.1982; LIAO XB, 1995, J VIROL, V69, P7132, DOI 10.1128/JVI.69.11.7132-7137.1995; Lu LM, 1999, CANCER RES, V59, P2593; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Mortuza GB, 2008, J MOL BIOL, V376, P1493, DOI 10.1016/j.jmb.2007.12.043; Muralidharan SV, 2016, ONCOGENE, V35, P4689, DOI 10.1038/onc.2015.521; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Nielsen AA, 2005, J VIROL, V79, P67, DOI 10.1128/JVI.79.1.67-78.2005; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270; Pike-Overzet K, 2007, MOL THER, V15, P1910, DOI 10.1038/sj.mt.6300297; RASSART E, 1986, J VIROL, V58, P96, DOI 10.1128/JVI.58.1.96-106.1986; Ruiz-Herguido C, 2012, J EXP MED, V209, P1457, DOI 10.1084/jem.20120225; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; SETOGUCHI M, 1989, MOL CELL BIOL, V9, P4515, DOI 10.1128/MCB.9.10.4515; Sharma A, 2013, P NATL ACAD SCI USA, V110, P12036, DOI 10.1073/pnas.1307157110; Shaughnessy JD, 1999, ONCOGENE, V18, P2069; SHIMADA MO, 1993, LEUKEMIA RES, V17, P573, DOI 10.1016/0145-2126(93)90087-2; Sorensen AB, 1996, J VIROL, V70, P4063; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Suzuki T, 2006, EMBO J, V25, P3422, DOI 10.1038/sj.emboj.7601215; Swazo NK, 2006, J MED PHILOS, V31, P533, DOI 10.1080/03605310600912709; TAMURA T, 1989, J CANCER RES CLIN, V115, P235, DOI 10.1007/BF00391695; Tsuruyama T, 2002, P NATL ACAD SCI USA, V99, P8253, DOI 10.1073/pnas.112202899; Tsuruyama T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031533; Tsuruyama T, 2011, AM J PATHOL, V178, P1374, DOI 10.1016/j.ajpath.2010.12.012; Tsuruyama T, 2010, J LEUKOCYTE BIOL, V88, P107, DOI 10.1189/jlb.1109748; Umehara T, 2010, J BIOL CHEM, V285, P7610, DOI 10.1074/jbc.M109.062422; VANBEVEREN C, 1980, P NATL ACAD SCI-BIOL, V77, P3307; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Vollmuth F, 2009, J BIOL CHEM, V284, P36547, DOI 10.1074/jbc.M109.033712; Wang GP, 2007, GENOME RES, V17, P1186, DOI 10.1101/gr.6286907; Warming S, 2003, BLOOD, V101, P1934, DOI 10.1182/blood-2002-08-2652; WITHERSWARD ES, 1994, GENE DEV, V8, P1473, DOI 10.1101/gad.8.12.1473; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; YAMADA Y, 1994, CANCER RES, V54, P403; Zhang WS, 2012, J BIOL CHEM, V287, P43137, DOI 10.1074/jbc.M112.413047	78	4	4	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1169	1175		10.1038/onc.2016.285	http://dx.doi.org/10.1038/onc.2016.285			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27721401	hybrid, Green Published			2022-12-17	WOS:000395861300001
J	Hsu, TI; Lin, SC; Lu, PS; Chang, WC; Hung, CY; Yeh, YM; Su, WC; Liao, PC; Hung, JJ				Hsu, T-I; Lin, S-C; Lu, P-S; Chang, W-C; Hung, C-Y; Yeh, Y-M; Su, W-C; Liao, P-C; Hung, J-J			MMP7-mediated cleavage of nucleolin at Asp255 induces MMP9 expression to promote tumor malignancy (vol 34, pg 826, 2015)	ONCOGENE			English	Correction													Hsu, Tsung-I/AAK-9942-2020	Hsu, Tsung-I/0000-0002-7524-7740				Hsu TI, 2015, ONCOGENE, V34, P826, DOI 10.1038/onc.2014.22	1	4	5	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 9	2017	36	6					875	876		10.1038/onc.2016.274	http://dx.doi.org/10.1038/onc.2016.274			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IX	27477695	Bronze			2022-12-17	WOS:000394168200014
J	Tumiati, M; Munne, PM; Edgren, H; Eldfors, S; Hemmes, A; Kuznetsov, SG				Tumiati, M.; Munne, P. M.; Edgren, H.; Eldfors, S.; Hemmes, A.; Kuznetsov, S. G.			Rad51c- and Trp53-double-mutant mouse model reveals common features of homologous recombination-deficient breast cancers	ONCOGENE			English	Article							MAMMARY-TUMORS; P53; GENE; BRCA1; REPAIR; CELLS; IDENTIFICATION; TUMORIGENESIS; RESISTANCE; SYNERGIZES	Almost half of all hereditary breast cancers (BCs) are associated with germ-line mutations in homologous recombination (HR) genes. However, the tumor phenotypes associated with different HR genes vary, making it difficult to define the role of HR in BC predisposition. To distinguish between HR-dependent and -independent features of BCs, we generated a mouse model in which an essential HR gene, Rad51c, is knocked-out specifically in epidermal tissues. Rad51c is one of the key mediators of HR and a well-known BC predisposition gene. Here, we demonstrate that deletion of Rad51c invariably requires inactivation of the Trp53 tumor suppressor (TP53 in humans) to produce mammary carcinomas in 63% of female mice. Nonetheless, loss of Rad51c shortens the latency of Trp53-deficient mouse tumors from 11 to 6 months. Remarkably, the histopathological features of Rad51c-deficient mammary carcinomas, such as expression of hormone receptors and luminal epithelial markers, faithfully recapitulate the histopathology of human RAD51C-mutated BCs. Similar to other BC models, Rad51c/p53 double-mutant mouse mammary tumors also reveal a propensity for genomic instability, but lack the focal amplification of the Met locus or distinct mutational signatures reported for other HR genes. Using the human mammary epithelial cell line MCF10A, we show that deletion of TP53 can rescue RAD51C-deficient cells from radiation-induced cellular senescence, whereas it exacerbates their centrosome amplification and nuclear abnormalities. Altogether, our data indicate that a trend for genomic instability and inactivation of Trp53 are common features of HR-mediated BCs, whereas histopathology and somatic mutation patterns are specific for different HR genes.	[Tumiati, M.; Munne, P. M.; Edgren, H.; Eldfors, S.; Hemmes, A.; Kuznetsov, S. G.] Univ Helsinki, Inst Mol Med Finland FIMM, Biomed Helsinki 2U,Room E303b,Tukholmankatu 8, FIN-00290 Helsinki, Finland; [Edgren, H.] MediSapiens Ltd, Erottajankatu 19B, Helsinki, Finland	University of Helsinki	Kuznetsov, SG (corresponding author), Univ Helsinki, Inst Mol Med Finland FIMM, Biomed Helsinki 2U,Room E303b,Tukholmankatu 8, FIN-00290 Helsinki, Finland.	sergey.kuznetsov@helsinki.fi	Munne, Pauliina/M-8629-2015; Eldfors, Samuli/AAB-3029-2019	Munne, Pauliina/0000-0002-9720-9964; Eldfors, Samuli/0000-0001-5056-4750; Kuznetsov, Sergey/0000-0002-5662-9700; Tumiati, Manuela/0000-0003-4889-3445	Academy of Finland; Finnish Medical Foundation; Sigrid Juselius Foundation; Cancer Society of Finland; Biocenter Finland; Helsinki Doctoral Program in Biomedicine (DPBM)	Academy of Finland(Academy of Finland); Finnish Medical Foundation; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Cancer Society of Finland; Biocenter Finland; Helsinki Doctoral Program in Biomedicine (DPBM)	We thank Pekka Ellonen, Maija Lepisto, Sonja Lagstrom, and the rest of the FIMM sequencing unit for advice and sequencing of tumor samples, the pathology unit of the Haartman Institute for histology services, Sami Blom and Dr Johan Lundin for scanning histological slides. We are grateful to Dr Shyam Sharan and Dr Madalena Tarsounas for providing critical comments on the manuscript. Financial support for the project was provided to SGK by the Academy of Finland, Finnish Medical Foundation, Sigrid Juselius Foundation, Cancer Society of Finland, and Biocenter Finland. MT was supported by a fellowship from the Helsinki Doctoral Program in Biomedicine (DPBM), and the Academy of Finland.	Arnes JB, 2005, CLIN CANCER RES, V11, P4003, DOI 10.1158/1078-0432.CCR-04-2064; Badie S, 2010, NAT STRUCT MOL BIOL, V17, P1461, DOI 10.1038/nsmb.1943; Badie S, 2009, J CELL BIOL, V185, P587, DOI 10.1083/jcb.200811079; Bogliolo M, 2013, AM J HUM GENET, V92, P800, DOI 10.1016/j.ajhg.2013.04.002; Bowman-Colin C, 2013, P NATL ACAD SCI USA, V110, P8632, DOI 10.1073/pnas.1305362110; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Chun J, 2013, MOL CELL BIOL, V33, P387, DOI 10.1128/MCB.00465-12; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dosanjh MK, 1998, NUCLEIC ACIDS RES, V26, P1179, DOI 10.1093/nar/26.5.1179; Fenech M, 2011, MUTAGENESIS, V26, P125, DOI 10.1093/mutage/geq052; Foulkes WD, 2004, J MED GENET, V41, P1, DOI 10.1136/jmg.2003.013805; Francis JC, 2015, J PATHOL, V236, P186, DOI 10.1002/path.4517; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Gevensleben H, 2014, VIRCHOWS ARCH, V465, P365, DOI 10.1007/s00428-014-1619-1; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jaspers JE, 2013, CANCER DISCOV, V3, P68, DOI 10.1158/2159-8290.CD-12-0049; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Katsura M, 2009, NUCLEIC ACIDS RES, V37, P3959, DOI 10.1093/nar/gkp262; Kee Y, 2012, J CLIN INVEST, V122, P3799, DOI 10.1172/JCI58321; Kee Y, 2010, GENE DEV, V24, P1680, DOI 10.1101/gad.1955310; Knight JF, 2013, P NATL ACAD SCI USA, V110, pE1301, DOI 10.1073/pnas.1210353110; Kuznetsov S, 2007, J CELL BIOL, V176, P581, DOI 10.1083/jcb.200608130; Kuznetsov SG, 2009, CANCER RES, V69, P863, DOI 10.1158/0008-5472.CAN-08-3057; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Lin ZG, 2006, P NATL ACAD SCI USA, V103, P10328, DOI 10.1073/pnas.0604232103; Lindh AR, 2007, CYTOGENET GENOME RES, V116, P38, DOI 10.1159/000097416; Liu S, 2008, P NATL ACAD SCI USA, V105, P1680, DOI 10.1073/pnas.0711613105; Liu X, 2007, P NATL ACAD SCI USA, V104, P12111, DOI 10.1073/pnas.0702969104; Masson JY, 2001, GENE DEV, V15, P3296, DOI 10.1101/gad.947001; Meindl A, 2010, NAT GENET, V42, P410, DOI 10.1038/ng.569; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Munne PM, 2014, SCI REP-UK, V4, DOI 10.1038/srep04663; Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024; Olivares-Illana V, 2010, ONCOGENE, V29, P5113, DOI 10.1038/onc.2010.266; Olopade OI, 2008, CLIN CANCER RES, V14, P7988, DOI 10.1158/1078-0432.CCR-08-1211; Oplustilova L, 2012, CELL CYCLE, V11, P3837, DOI 10.4161/cc.22026; Osorio A, 2012, HUM MOL GENET, V21, P2889, DOI 10.1093/hmg/dds115; Rodrigue A, 2013, J CELL SCI, V126, P348, DOI 10.1242/jcs.114595; Smolen GA, 2006, CANCER RES, V66, P3452, DOI 10.1158/0008-5472.CAN-05-4181; Somyajit K, 2012, J BIOL CHEM, V287, P3366, DOI 10.1074/jbc.M111.311241; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Stratton MR, 2008, NAT GENET, V40, P17, DOI 10.1038/ng.2007.53; Tacconi EMC, 2015, CHROMOSOMA, V124, P119, DOI 10.1007/s00412-014-0497-2; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Tumiati M, 2015, J PATHOL, V235, P136, DOI 10.1002/path.4455; Vaz F, 2010, NAT GENET, V42, P406, DOI 10.1038/ng.570; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Zhang F, 2009, CURR BIOL, V19, P524, DOI 10.1016/j.cub.2009.02.018	49	4	4	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2016	35	35					4601	4610		10.1038/onc.2015.528	http://dx.doi.org/10.1038/onc.2015.528			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU6PE	26820992				2022-12-17	WOS:000382336300006
J	Tie, SR; McCarthy, DJ; Kendrick, TS; Louw, A; Le, C; Satiaputra, J; Kucera, N; Phillips, M; Ingley, E				Tie, S. R.; McCarthy, D. J.; Kendrick, T. S.; Louw, A.; Le, C.; Satiaputra, J.; Kucera, N.; Phillips, M.; Ingley, E.			Regulation of sarcoma cell migration, invasion and invadopodia formation by AFAP1L1 through a phosphotyrosine-dependent pathway	ONCOGENE			English	Article							ERYTHROPOIETIN-INDUCED DIFFERENTIATION; PODOSOME FORMATION; ERYTHROID-CELLS; TYROSINE KINASE; ADAPTER PROTEIN; ACTIN DYNAMICS; SRC SUBSTRATE; TUMOR-CELLS; N-WASP; CORTACTIN	Invasion and metastasis are controlled by the invadopodia, which delivers matrix-degrading enzymes to the invasion interface permitting cancer cell penetration and spread into healthy tissue. We have identified a novel pathway that directs Lyn/Src family tyrosine kinase signals to the invadopodia to regulate sarcoma cell invasion via the molecule AFAP-1-like-1 (AFAP1L1), a new member of the AFAP (actin filament-associated protein) family. We show that AFAP1L1 can transform cells, promote migration and co-expression with active Lyn profoundly influences cell morphology and movement. AFAP1L1 intersects several invadopodia pathway components through its multiple domains and motifs, including the following (i) pleckstrin homology domains that bind phospholipids generated at the plasma membrane by phosphoinositide 3-kinase, (ii) a direct filamentous-actin binding domain and (iii) phospho-tyrosine motifs (pY136 and pY566) that specifically bind Vav2 and Nck2 SH2 domains, respectively. These phosphotyrosine motifs are essential for AFAP1L1-mediated cytoskeleton regulation. Through its interaction with Vav2, AFAP1L1 regulates Rac activity and downstream control of PAK1/2/3 (p21-activated kinases) phosphorylation of myosin light chain (MLC) kinase and MLC2. AFAP1L1 interaction with Nck2 recruits actin-nucleating complexes. Significantly, in osteosarcoma cell lines, knockdown of AFAP1L1 inhibits phosphorylated MLC2 recruitment to filamentous-actin structures, disrupts invadopodia formation, cell attachment, migration and invasion. These data define a novel pathway that directs Lyn/Src family tyrosine kinase signals to sarcoma cell invadopodia through specific recruitment of Vav2 and Nck2 to phosphorylated AFAP1L1, to control cell migration and invasion.	[Tie, S. R.; McCarthy, D. J.; Kendrick, T. S.; Louw, A.; Le, C.; Satiaputra, J.; Kucera, N.; Ingley, E.] Univ Western Australia, Harry Perkins Inst Med Res, Cell Signalling Grp, Nedlands, WA 6009, Australia; [Tie, S. R.; McCarthy, D. J.; Kendrick, T. S.; Louw, A.; Le, C.; Satiaputra, J.; Kucera, N.; Ingley, E.] Univ Western Australia, Med Res Ctr, Nedlands, WA 6009, Australia; [Louw, A.] Royal Perth Hosp, Med Res Fdn, Perth, WA 6001, Australia; [Phillips, M.] Univ Western Australia, Harry Perkins Inst Med Res, Perth, WA 6009, Australia; [Phillips, M.] Univ Western Australia, Med Res Ctr, Perth, WA 6009, Australia	Harry Perkins Institute of Medical Research; University of Western Australia; University of Western Australia; Royal Perth Hospital; Harry Perkins Institute of Medical Research; University of Western Australia; University of Western Australia	Ingley, E (corresponding author), Univ Western Australia, Harry Perkins Inst Med Res, Cell Signalling Grp, QEII Med Ctr, Level 7,QQ Block,6 Verdun St, Nedlands, WA 6009, Australia.; Ingley, E (corresponding author), Univ Western Australia, Med Res Ctr, QEII Med Ctr, Level 7,QQ Block,6 Verdun St, Nedlands, WA 6009, Australia.	evan.ingley@uwa.edu.au	Ingley, Evan/C-2401-2013	Ingley, Evan/0000-0002-8112-9134; Phillips, Michael/0000-0002-0252-9085	National Health and Medical Research Council [513714, 634352]; Medical Research Foundation of Royal Perth Hospital; Cancer Council of Western Australia; Harry Perkins Institute of Medical Research; Sock-it-to-Sarcoma; Hollywood Private Hospital Research Foundation	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Medical Research Foundation of Royal Perth Hospital; Cancer Council of Western Australia(Cancer Council Western Australia); Harry Perkins Institute of Medical Research; Sock-it-to-Sarcoma; Hollywood Private Hospital Research Foundation	We thank Janice Lam, Matt Lee, Rebecca Shapiro, Morgane Davies, Irma Larma and Kevin Li for technical assistance. This work was supported by grants from the National Health and Medical Research Council (513714 and 634352), the Medical Research Foundation of Royal Perth Hospital and the Cancer Council of Western Australia. EI received support from the Cancer Council of Western Australia, The Harry Perkins Institute of Medical Research, Sock-it-to-Sarcoma and the Hollywood Private Hospital Research Foundation.	Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Albiges-Rizo C, 2009, J CELL SCI, V122, P3037, DOI 10.1242/jcs.052704; Badowski C, 2008, MOL BIOL CELL, V19, P633, DOI 10.1091/mbc.E06-01-0088; Barrio-Real L, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003543; Buday L, 2002, CELL SIGNAL, V14, P723, DOI 10.1016/S0898-6568(02)00027-X; Bustelo XR, 2001, ONCOGENE, V20, P6372, DOI 10.1038/sj.onc.1204780; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; CHEN WT, 1985, NATURE, V316, P156, DOI 10.1038/316156a0; Courtneidge SA, 2005, COLD SH Q B, V70, P167, DOI 10.1101/sqb.2005.70.014; Crimaldi L, 2009, EXP CELL RES, V315, P2581, DOI 10.1016/j.yexcr.2009.06.012; Dang I, 2013, NATURE, V503, P281, DOI 10.1038/nature12611; Delorme-Walker VD, 2011, J CELL BIOL, V193, P1289, DOI 10.1083/jcb.201010059; DesMarais V, 2009, CELL MOTIL CYTOSKEL, V66, P303, DOI 10.1002/cm.20361; Dorfleutner A, 2008, J CELL SCI, V121, P2394, DOI 10.1242/jcs.026187; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Furu M, 2011, ONCOGENE, V30, P4015, DOI 10.1038/onc.2011.108; Gatesman A, 2004, MOL CELL BIOL, V24, P7578, DOI 10.1128/MCB.24.17.7578-7597.2004; Heo J, 2005, BIOCHEMISTRY-US, V44, P6573, DOI 10.1021/bi047443q; Huang CH, 2013, NAT CELL BIOL, V15, P1307, DOI 10.1038/ncb2859; Ingley E, 1999, FEBS LETT, V459, P69, DOI 10.1016/S0014-5793(99)01188-6; Ingley E, 2001, J BIOL CHEM, V276, P43428, DOI 10.1074/jbc.M106645200; Ingley E, 2000, J BIOL CHEM, V275, P7887, DOI 10.1074/jbc.275.11.7887; Ingley E, 2006, J BIOL CHEM, V281, P31920, DOI 10.1074/jbc.M602637200; Kaipparettu BA, 2008, BIOTECHNIQUES, V45, P165, DOI 10.2144/000112883; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; Li A, 2010, CURR BIOL, V20, P339, DOI 10.1016/j.cub.2009.12.035; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Lock P, 1998, EMBO J, V17, P4346, DOI 10.1093/emboj/17.15.4346; Lodyga M, 2010, J CELL SCI, V123, P4156, DOI 10.1242/jcs.071050; Mader CC, 2011, CANCER RES, V71, P1730, DOI 10.1158/0008-5472.CAN-10-1432; Moshfegh Y, 2014, NAT CELL BIOL, V16, P571, DOI 10.1038/ncb2972; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Nakahara H, 2003, GENES CELLS, V8, P1019, DOI 10.1111/j.1365-2443.2003.00695.x; Nurnberg A, 2011, NAT REV CANCER, V11, P177, DOI 10.1038/nrc3003; Oser M, 2009, J CELL BIOL, V186, P571, DOI 10.1083/jcb.200812176; Poincloux R, 2009, J CELL SCI, V122, P3015, DOI 10.1242/jcs.034561; Ridley AJ, 2011, CELL, V145, P1012, DOI 10.1016/j.cell.2011.06.010; Rivera GM, 2006, P NATL ACAD SCI USA, V103, P9536, DOI 10.1073/pnas.0603786103; Samuels AL, 2009, BLOOD, V113, P3845, DOI 10.1182/blood-2008-04-153452; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Schoumacher M, 2010, J CELL BIOL, V189, P541, DOI 10.1083/jcb.200909113; Seals DF, 2005, CANCER CELL, V7, P155, DOI 10.1016/j.ccr.2005.01.006; Snyder BN, 2011, EUR J CELL BIOL, V90, P376, DOI 10.1016/j.ejcb.2010.11.016; Stylli SS, 2008, J CLIN NEUROSCI, V15, P725, DOI 10.1016/j.jocn.2008.03.003; Stylli SS, 2009, J CELL SCI, V122, P2727, DOI 10.1242/jcs.046680; Takahashi R, 2014, CANCER MED-US, V3, P759, DOI 10.1002/cam4.237; Tehrani S, 2007, P NATL ACAD SCI USA, V104, P11933, DOI 10.1073/pnas.0701077104; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; Timpson P, 2001, CURR BIOL, V11, P1836, DOI 10.1016/S0960-9822(01)00583-8; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Weaver AM, 2006, CLIN EXP METASTAS, V23, P97, DOI 10.1007/s10585-006-9014-1; Wells CM, 2005, EXP CELL RES, V310, P303, DOI 10.1016/j.yexcr.2005.07.015; Xu J, 2007, J BIOL CHEM, V282, P16401, DOI 10.1074/jbc.M701684200; Yamaguchi H, 2011, J CELL BIOL, V193, P1275, DOI 10.1083/jcb.201009126	57	4	4	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2016	35	16					2098	2111		10.1038/onc.2015.272	http://dx.doi.org/10.1038/onc.2015.272			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ9AH	26212012	Green Submitted			2022-12-17	WOS:000374505600009
J	Lee, GH; Yan, C; Shin, SJ; Hong, SC; Ahn, T; Moon, A; Park, SJ; Lee, YC; Yoo, WH; Kim, HT; Kim, DS; Chae, SW; Kim, HR; Chae, HJ				Lee, G-H; Yan, C.; Shin, S-J; Hong, S-C; Ahn, T.; Moon, A.; Park, S. J.; Lee, Y. C.; Yoo, W. H.; Kim, H-T; Kim, D-S; Chae, S-W; Kim, H-R; Chae, H-J			BAX inhibitor-1 enhances cancer metastasis by altering glucose metabolism and activating the sodium-hydrogen exchanger: the alteration of mitochondrial function (vol 29, pg 2130, 2010)	ONCOGENE			English	Correction														HyoungTae, Kim/0000-0002-2482-6064				Lee GH, 2010, ONCOGENE, V29, P2130, DOI 10.1038/onc.2009.491	1	4	4	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					803	804		10.1038/onc.2015.421	http://dx.doi.org/10.1038/onc.2015.421			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	26865227	Bronze			2022-12-17	WOS:000370331300016
J	Sethi, G; Ahn, KS; Chaturvedi, MM; Aggarwal, BB				Sethi, G.; Ahn, K. S.; Chaturvedi, M. M.; Aggarwal, B. B.			Epidermal growth factor (EGF) activates nuclear factor-B-kappa through I kappa B alpha kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of I kappa B alpha (vol 26, pg 7324, 2007)	ONCOGENE			English	Correction													Sethi, Gautam/F-2372-2011	Sethi, Gautam/0000-0002-8677-8475				Sethi G, 2007, ONCOGENE, V26, P7324, DOI 10.1038/sj.onc.1210544	1	4	4	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2015	34	42					5407	5407		10.1038/onc.2015.313	http://dx.doi.org/10.1038/onc.2015.313			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EI	26473948	Bronze			2022-12-17	WOS:000363479200011
J	Vascotto, C; Lirussi, L; Poletto, M; Tiribelli, M; Damiani, D; Fabbro, D; Damante, G; Demple, B; Colombo, E; Tell, G				Vascotto, C.; Lirussi, L.; Poletto, M.; Tiribelli, M.; Damiani, D.; Fabbro, D.; Damante, G.; Demple, B.; Colombo, E.; Tell, G.			Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology (vol 33, pg 2876, 2014)	ONCOGENE			English	Correction									[Vascotto, C.; Lirussi, L.; Poletto, M.; Fabbro, D.; Damante, G.; Tell, G.] Univ Udine, Dept Med & Biol Sci, I-33100 Udine, Italy; [Tiribelli, M.; Damiani, D.] Univ Udine, Dept Expt & Clin Med Sci, I-33100 Udine, Italy; [Demple, B.] SUNY Stony Brook, Sch Med, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; [Colombo, E.] European Inst Oncol, Dept Expt Oncol, Milan, Italy; [Colombo, E.] Univ Milan, Dipartimento Sci Salute, Milan, Italy	University of Udine; University of Udine; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; IRCCS European Institute of Oncology (IEO); University of Milan	Vascotto, C (corresponding author), Univ Udine, Dept Med & Biol Sci, I-33100 Udine, Italy.		Damante, Giuseppe/AAC-5200-2022; Tiribelli, Mario/G-7989-2018; damiani, daniela/AAD-4629-2022	Tiribelli, Mario/0000-0001-9449-2621; damiani, daniela/0000-0002-1663-4468; Tell, Gianluca/0000-0001-8845-6448; Damante, Giuseppe/0000-0003-2312-4009; vascotto, carlo/0000-0003-4431-029X				Vascotto C, 2014, ONCOGENE, V33, P2876, DOI 10.1038/onc.2013.251	1	4	4	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	26					3482	3482		10.1038/onc.2015.191	http://dx.doi.org/10.1038/onc.2015.191			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CL3SU	26109248	Bronze			2022-12-17	WOS:000356871700013
J	Watnick, RS; Rodriguez, RK; Wang, S; Blois, AL; Rangarajan, A; Ince, T; Weinberg, RA				Watnick, R. S.; Rodriguez, R. K.; Wang, S.; Blois, A. L.; Rangarajan, A.; Ince, T.; Weinberg, R. A.			Thrombospondin-1 repression is mediated via distinct mechanisms in fibroblasts and epithelial cells (vol 34, pg 2823, 2015)	ONCOGENE			English	Correction														Ince, Tan/0000-0003-0315-6425				Watnick RS, 2015, ONCOGENE, V34, P2823, DOI 10.1038/onc.2014.228	1	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2015	34	22					2949	2950		10.1038/onc.2015.183	http://dx.doi.org/10.1038/onc.2015.183			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CJ2OM	26020734	Bronze			2022-12-17	WOS:000355324300014
J	Ng, KY; Yin, T; Machida, K; Wu, YI; Mayer, BJ				Ng, K. Y.; Yin, T.; Machida, K.; Wu, Y. I.; Mayer, B. J.			Phosphorylation of Dok1 by Abl family kinases inhibits CrkI transforming activity	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; FACTOR-INDUCED ACTIVATION; PROTEIN-TYROSINE KINASE; PROLINE-RICH SEQUENCES; V-CRK; ADAPTER PROTEIN; CELL-MIGRATION; NEGATIVE REGULATION; MOLECULAR RESPONSE; DOCKING PROTEIN	The Crk SH2/SH3 adaptor and the Abl nonreceptor tyrosine kinase were first identified as oncoproteins, and both can induce tumorigenesis when overexpressed or mutationally activated. We previously reported the surprising finding that inhibition or knockdown of Abl family kinases enhanced transformation of mouse fibroblasts by CrkI. Abl family inhibitors are currently used or are being tested for treatment of human malignancies, and our finding raised concerns that such inhibitors might actually promote the growth of tumors overexpressing CrkI. Here, we identify the Dok1 adaptor as the key effector for the enhancement of CrkI transformation by Abl inhibition. We show that phosphorylation of tyrosines 295 and 361 of Dok1 by Abl family kinases suppresses CrkI transforming activity, and that upon phosphorylation these tyrosines bind the SH2 domains of the Ras inhibitor p120 RasGAP. Knockdown of RasGAP resulted in a similar enhancement of CrkI transformation, consistent with a critical role for Ras activity. Imaging studies using a FRET sensor of Ras activation revealed alterations in the localization of activated Ras in CrkI-transformed cells. Our results support a model in which Dok1 phosphorylation normally suppresses localized Ras pathway activity in Crk-transformed cells via recruitment and/or activation of RasGAP, and that preventing this negative feedback mechanism by inhibiting Abl family kinases leads to enhanced transformation by Crk.	[Ng, K. Y.; Machida, K.; Mayer, B. J.] Univ Connecticut, Ctr Hlth, Raymond & Beverly Sackler Lab Genet & Mol Med, Dept Genet & Dev Biol, Farmington, CT 06030 USA; [Yin, T.; Wu, Y. I.; Mayer, B. J.] Univ Connecticut, Ctr Hlth, Richard D Berlin Ctr Cell Anal & Modeling, Dept Genet & Dev Biol, Farmington, CT 06030 USA	University of Connecticut; University of Connecticut	Mayer, BJ (corresponding author), Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, 263 Farmington Ave, Farmington, CT 06030 USA.	bmayer@uchc.edu			National Institutes of Health [CA82258, NS071216]; NATIONAL CANCER INSTITUTE [R01CA082258] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS071216] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Sofya Borinskaya for technical help in soft agar colony counting, Mari Ogiue-Ikeda for the preparation of the SH2 probes and Joshua Jadwin for critically reading this manuscript. In addition, we greatly appreciate Pier Paolo Pandolfi from Harvard Medical School for generously providing the human Dok1 cDNA. This study was supported by grants CA82258 (to BJM) and NS071216 (to YIW) from the National Institutes of Health.	ABELSON HT, 1970, CANCER RES, V30, P2213; Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; Akin C, 2004, BLOOD, V103, P3222, DOI 10.1182/blood-2003-11-3816; Allington TM, 2009, FASEB J, V23, P4231, DOI 10.1096/fj.09-138412; Apperley JF, 2002, NEW ENGL J MED, V347, P481, DOI 10.1056/NEJMoa020150; Ashman LK, 2013, EXPERT OPIN INV DRUG, V22, P103, DOI 10.1517/13543784.2013.740010; Bell Emily S, 2012, Genes Cancer, V3, P341, DOI 10.1177/1947601912459951; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Berger AH, 2010, NAT GENET, V42, P216, DOI 10.1038/ng.527; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Chodniewicz D, 2004, BBA-MOL CELL RES, V1692, P63, DOI 10.1016/j.bbamcr.2004.03.006; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; deJong R, 1997, ONCOGENE, V14, P507, DOI 10.1038/sj.onc.1200885; Downey C, 2008, CELL MOL LIFE SCI, V65, P1446, DOI 10.1007/s00018-008-8038-x; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Gil-Henn H, 2013, ONCOGENE, V32, P2622, DOI 10.1038/onc.2012.284; Greulich H, 1996, CELL GROWTH DIFFER, V7, P1443; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Hodgson L., 2010, CURR PROTOC CELL BIO, DOI [10.1002/0471143030.cb1411s46, DOI 10.1002/0471143030.CB1411S46]; Hughes TP, 2014, BLOOD, V123, P1353, DOI 10.1182/blood-2013-06-510396; Kain KH, 2003, ONCOGENE, V22, P6071, DOI 10.1038/sj.onc.1206930; Kain KH, 2001, J BIOL CHEM, V276, P16185, DOI 10.1074/jbc.M100095200; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Kunath T, 2003, NAT BIOTECHNOL, V21, P559, DOI 10.1038/nbt813; Lambert MP, 2011, J HEPATOL, V54, P705, DOI 10.1016/j.jhep.2010.07.027; Lee S, 2004, ONCOGENE, V23, P2287, DOI 10.1038/sj.onc.1207385; Linghu H, 2006, ONCOGENE, V25, P3547, DOI 10.1038/sj.onc.1209398; Machida K, 2007, MOL CELL, V26, P899, DOI 10.1016/j.molcel.2007.05.031; Mashima R, 2010, LAB INVEST, V90, P1357, DOI 10.1038/labinvest.2010.121; Mashima R, 2009, IMMUNOL REV, V232, P273, DOI 10.1111/j.1600-065X.2009.00844.x; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Mihrshahi R, 2009, J IMMUNOL, V183, P4879, DOI 10.4049/jimmunol.0901531; Miller CT, 2003, ONCOGENE, V22, P7950, DOI 10.1038/sj.onc.1206529; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Nelms K, 1998, GENOMICS, V53, P243, DOI 10.1006/geno.1998.5514; Neuzillet C, 2014, PHARMACOL THERAPEUT, V141, P160, DOI 10.1016/j.pharmthera.2013.10.001; Niki M, 2004, J EXP MED, V200, P1689, DOI 10.1084/jem.20041306; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Pertz O, 2006, NATURE, V440, P1069, DOI 10.1038/nature04665; Reichardt P, 2011, CURR CANCER DRUG TAR, V11, P688, DOI 10.2174/156800911796191042; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Rodrigues SP, 2005, MOL CANCER RES, V3, P183; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Saulnier A, 2012, INT J CANCER, V130, P2484, DOI 10.1002/ijc.26299; Scheffzek K, 2001, STRUCTURE, V9, P1043, DOI 10.1016/S0969-2126(01)00674-8; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082; Shinohara H, 2004, GENES CELLS, V9, P601, DOI 10.1111/j.1356-9597.2004.00748.x; Songyang Z, 2001, J BIOL CHEM, V276, P2459, DOI 10.1074/jbc.M005504200; Sriram Ganapathy, 2010, Genes Cancer, V1, P1132, DOI 10.1177/1947601910397188; Takino T, 2003, CANCER RES, V63, P2335; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Wagner MJ, 2013, COLD SPRING HARB PER, V5; Wang BL, 1996, ONCOGENE, V13, P1379; Watanabe T, 2009, CELL RES, V19, P638, DOI 10.1038/cr.2009.40; White D, 2005, BLOOD, V106, P2520, DOI 10.1182/blood-2005-03-1103; Yamanashi Y, 2000, GENE DEV, V14, P11; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yasuda T, 2004, J EXP MED, V200, P1681, DOI 10.1084/jem.20041247; Yasuda T, 2007, INT IMMUNOL, V19, P487, DOI 10.1093/intimm/dxm015; Yip SC, 2007, J CELL SCI, V120, P3138, DOI 10.1242/jcs.005298; Zheng J, 2010, ONCOGENE, V29, P6378, DOI 10.1038/onc.2010.369; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	68	4	4	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2015	34	20					2650	2659		10.1038/onc.2014.210	http://dx.doi.org/10.1038/onc.2014.210			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI1YN	25043303	Green Accepted			2022-12-17	WOS:000354541300011
J	Kountouras, J; Kapetanakis, N; Zavos, C; Polyzos, SA; Romiopoulos, I; Tsiaousi, E; Anastasiadou, K; Giorgakis, N; Vardaka, E; Nikolaidou, C; Venizelos, I; Katsinelos, P				Kountouras, J.; Kapetanakis, N.; Zavos, C.; Polyzos, S. A.; Romiopoulos, I.; Tsiaousi, E.; Anastasiadou, K.; Giorgakis, N.; Vardaka, E.; Nikolaidou, C.; Venizelos, I.; Katsinelos, P.			Helicobacter pylori might contribute to cancer and/or bone marrow-derived stem cell-related gastrointestinal oncogenesis	ONCOGENE			English	Letter							INFECTION		[Kountouras, J.; Kapetanakis, N.; Zavos, C.; Polyzos, S. A.; Romiopoulos, I.; Tsiaousi, E.; Anastasiadou, K.; Giorgakis, N.; Vardaka, E.; Nikolaidou, C.; Venizelos, I.; Katsinelos, P.] Aristotle Univ Thessaloniki, Dept Med, Med Clin 2, Ippokrat Hosp, GR-54006 Thessaloniki, Greece	Aristotle University of Thessaloniki	Kountouras, J (corresponding author), Aristotle Univ Thessaloniki, Dept Med, Med Clin 2, Ippokrat Hosp, GR-54006 Thessaloniki, Greece.	jannis@auth.gr	Polyzos, Stergios/H-2844-2019; VARDAKA, Elisabeth/ABD-1341-2020; Zavos, Christos/N-8618-2015	Polyzos, Stergios/0000-0001-9232-4042; Zavos, Christos/0000-0002-3443-7791; Vardaka, Elisabeth/0000-0002-3698-9135				Bessede E, 2014, ONCOGENE, V33, P4123, DOI 10.1038/onc.2013.380; Kapetanakis N, 2013, IMMUNOGASTROENTEROLO, V2, P47; Kapetanakis N, 2012, AM J EPIDEMIOL, V176, P566, DOI 10.1093/aje/kws302; Kountouras J, 2008, J SURG RES, V146, P149, DOI 10.1016/j.jss.2007.06.011; Kountouras J, 2013, AM J GASTROENTEROL, V108, P625, DOI 10.1038/ajg.2013.17	5	4	5	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2015	34	5					670	670		10.1038/onc.2013.602	http://dx.doi.org/10.1038/onc.2013.602			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DD	24469039				2022-12-17	WOS:000348853500014
J	Lindner, SE; Wissler, M; Grunder, A; Aumann, K; Ottina, E; Peintner, L; Brauns-Schubert, P; Preiss, F; Herzog, S; Borner, C; Charvet, C; Villunger, A; Pahl, HL; Maurer, U				Lindner, S. E.; Wissler, M.; Gruender, A.; Aumann, K.; Ottina, E.; Peintner, L.; Brauns-Schubert, P.; Preiss, F.; Herzog, S.; Borner, C.; Charvet, C.; Villunger, A.; Pahl, H. L.; Maurer, U.			Increased leukocyte survival and accelerated onset of lymphoma in the absence of MCL-1 S159-phosphorylation	ONCOGENE			English	Article						GSK-3; MCL-1; E mu-Myc; lymphoma; apoptosis	GLYCOGEN-SYNTHASE KINASE-3; APOPTOSIS; MYC; MEDIATE; PI3K	The antiapoptotic BCL-2 protein MCL-1, which opposes mitochondrial outer membrane permeabilization, was shown to have a crucial role in the survival of hematopoietic cells. We have previously shown that, upon loss of phosphatidylinositol 3-kinase signaling, S159 of MCL-1 is phosphorylated by glycogen synthase kinase-3 (GSK-3), earmarking MCL-1 for enhanced ubiquitylation and degradation. In this study, we introduced MCL-1(wt) or the phosphorylation-deficient mutant MCL-1(S159A) in mouse BM cells, followed by adoptive transfer to recipient mice. Mice expressing MCL-1(S159A) exhibited significantly elevated white blood cell and lymphocyte counts, whereas no effect was observed on the distribution of T and B lymphocyte subsets or the numbers of monocytes, red blood cells or platelets. Expression of MCL-1(S159A) in E mu-Myc transgenic bone marrow significantly accelerated the onset of disease, and these mice displayed increased spleen weights compared with E mu-Myc/MCL-1(wt) mice. Our data demonstrate that the absence of MCL-1 S159 phosphorylation provides a survival advantage for hematopoietic cells in vivo and facilitates oncogenesis.	[Lindner, S. E.; Wissler, M.; Brauns-Schubert, P.; Preiss, F.; Borner, C.; Maurer, U.] Univ Freiburg, Inst Mol Med & Cell Res, D-79104 Freiburg, Germany; [Lindner, S. E.; Brauns-Schubert, P.; Preiss, F.] Univ Freiburg, Fac Biol, D-79104 Freiburg, Germany; [Gruender, A.; Pahl, H. L.] Univ Hosp, Clin Res Ctr, Dept Mol Hematol, Freiburg, Germany; [Aumann, K.] Univ Med Ctr Freiburg, Inst Pathol, Freiburg, Germany; [Ottina, E.; Peintner, L.; Herzog, S.; Villunger, A.] Med Univ Innsbruck, Bioctr, Div Dev Immunol, A-6020 Innsbruck, Austria; [Brauns-Schubert, P.; Preiss, F.; Borner, C.; Maurer, U.] Univ Freiburg, Spemann Grad Sch Biol & Med SGBM, D-79104 Freiburg, Germany; [Borner, C.; Maurer, U.] Ctr Biol Signaling Studies, BIOSS, Freiburg, Germany; [Charvet, C.] Univ Paris 05, CNRS UMR 8104, INSERM U1016, Inst Cochin, Paris, France	University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; Medical University of Innsbruck; University of Freiburg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Maurer, U (corresponding author), Univ Freiburg, Inst Mol Med & Cell Res, Stefan Meier Str 17, D-79104 Freiburg, Germany.	ulrich.maurer@mol-med.uni-freiburg.de	Lindner, Silke/AAF-6063-2021; Pahl, Heike/AGM-5260-2022; Aumann, Konrad/GSN-1821-2022	Aumann, Konrad/0000-0001-8178-1571; Peintner, Lukas/0000-0002-0445-1445; Ottina, Eleonora/0000-0002-9630-496X; Herzog, Sebastian/0000-0001-7167-3489	Deutsche Forschungsgemeinschaft [Ma 1967/1, Ma 1967/2]; Deutsche Krebshilfe [109199, 107397]; Spemann Graduate School of Biology and Medicine (SGBM) - Excellence Initiative of the German Federal and State Governments, Germany [GSC-4]; Centre for Biological Signalling Studies (BIOSS) - Excellence Initiative, Germany [EXC-294]; Austrian Science Fund (FWF); NATIONAL CANCER INSTITUTE [P01CA108671] Funding Source: NIH RePORTER; Austrian Science Fund (FWF) [P 23510] Funding Source: researchfish	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe); Spemann Graduate School of Biology and Medicine (SGBM) - Excellence Initiative of the German Federal and State Governments, Germany; Centre for Biological Signalling Studies (BIOSS) - Excellence Initiative, Germany; Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	We thank Martin Brandenburg, Katharina Thumm, Heiko Bauer, Klaus Geiger, Jan Bodinek-Wersing and Karin Neubert. This study was supported by Grants Ma 1967/1 and Ma 1967/2 from the Deutsche Forschungsgemeinschaft to UM, Grants 109199 and 107397 from the Deutsche Krebshilfe to UM the Spemann Graduate School of Biology and Medicine (SGBM, GSC-4) funded by the Excellence Initiative of the German Federal and State Governments, Germany to PBS, FP and UM, by the Centre for Biological Signalling Studies (BIOSS, EXC-294) funded by the Excellence Initiative, Germany to UM and CB and a fellowship from the Dr Heinrich Kircher-Stiftung to SEL as well as the Austrian Science Fund (FWF) to AV.	Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Brunelle JK, 2009, J CELL BIOL, V187, P429, DOI 10.1083/jcb.200904049; Campbell KJ, 2010, BLOOD, V116, P3197, DOI 10.1182/blood-2010-04-281071; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Ding QQ, 2007, MOL CELL BIOL, V27, P4006, DOI 10.1128/MCB.00620-06; Dzhagalov I, 2007, BLOOD, V109, P1620, DOI 10.1182/blood-2006-03-013771; Gutierrez A, 2009, BLOOD, V114, P647, DOI 10.1182/blood-2009-02-206722; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Inuzuka H, 2011, NATURE, V471, P104, DOI 10.1038/nature09732; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Morel C, 2009, MOL CELL BIOL, V29, P3845, DOI 10.1128/MCB.00279-09; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; Sander S, 2012, CANCER CELL, V22, P167, DOI 10.1016/j.ccr.2012.06.012; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Steimer DA, 2009, BLOOD, V113, P2805, DOI 10.1182/blood-2008-05-159145; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Xiang ZF, 2010, J CLIN INVEST, V120, P2109, DOI 10.1172/JCI39964; Zhao Y, 2007, MOL CELL BIOL, V27, P4328, DOI 10.1128/MCB.00153-07	20	4	4	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2014	33	44					5221	5224		10.1038/onc.2013.469	http://dx.doi.org/10.1038/onc.2013.469			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR9RZ	24213575	Green Accepted			2022-12-17	WOS:000343914900009
J	Nguyen-Lefebvre, AT; Leprun, G; Morin, V; Vinuelas, J; Coute, Y; Madjar, JJ; Gandrillon, O; Gonin-Giraud, S				Nguyen-Lefebvre, A. T.; Leprun, G.; Morin, V.; Vinuelas, J.; Coute, Y.; Madjar, J-J; Gandrillon, O.; Gonin-Giraud, S.			V-erbA generates ribosomes devoid of RPL11 and regulates translational activity in avian erythroid progenitors	ONCOGENE			English	Article						v-erbA oncogene; ribosomal proteins; translational activity regulation; 2D-DIGE; proteomic	THYROID-HORMONE RECEPTOR; PROTEIN L11; TGF-BETA; EXPRESSION; CELLS; ONCOGENE; CANCER; DIFFERENTIATION; PROLIFERATION; GATA-1	The v-erbA oncogene transforms chicken erythrocytic progenitors (T2EC) by blocking their differentiation and freezing them in a state of self-renewal. Transcriptomes of T2EC, expressing either v-erbA or a non-transforming form of v-erbA (S61G), were compared using serial analysis of gene expression and some, but not all, mRNA-encoding ribosomal proteins were seen to be affected by v-erbA. These results suggest that this oncogene could modulate the composition of ribosomes. In the present study, we demonstrate, using two-dimensional difference in gel electrophoresis, that v-erbA-expressing cells have a lower amount of RPL11 associated with the ribosomes. The presence of ribosomes devoid of RPL11 in v-erbA-expressing cells was further confirmed by immunoprecipitation. In order to assess the possible impact of these specialized ribosomes on the translational activity, we analyzed proteomes of either v-erbA or S61G-expressing cells using 2D/mass spectrometry, and identified nine proteins present in differing amounts within these cells. Among these proteins, we focused on HSP70 because of its involvement in erythroid differentiation. Our results indicate that, in v-erbA-expressing cells, hsp70 is not only transcribed but also translated more efficiently, as shown by polyribosome fractionation experiments. We demonstrate here, for the first time, the existence of ribosomes with different protein components, notably ribosomes devoid of RPL11, and a regulation of mRNA translation depending on v-erbA oncogene expression.	[Nguyen-Lefebvre, A. T.; Leprun, G.; Morin, V.; Vinuelas, J.; Madjar, J-J; Gandrillon, O.; Gonin-Giraud, S.] Univ Lyon 1, Ctr Genet & Physiol Mol & Cellulaire, CNRS, UMR 5534, F-69622 Villeurbanne, France; [Coute, Y.] CEA, IRTSV, Lab Biol Grande Echelle, Grenoble, France; [Coute, Y.] INSERM, U1038, Grenoble, France; [Coute, Y.] Univ Grenoble 1, Grenoble, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Gonin-Giraud, S (corresponding author), Univ Lyon 1, Ctr Genet & Physiol Mol & Cellulaire, Team Bases Mol Autorenouvellement & Alterat, CNRS,UMR 5534, Batiment Gregor Mendel,16 Rue Raphael Dubois, F-69622 Villeurbanne, France.	sandrine.giraud@univ-lyon1.fr	Couté, Yohann/G-2695-2015	Couté, Yohann/0000-0003-3896-6196	Association pour la Recherche contre le Cancer; Ligue contre le Cancer (Comite Departemental du Rhone); Societe Francaise d'Hematologie (SFH); Region Rhone-Alpes; Universite Claude Bernard Lyon 1 (UCBL1); Centre National de la Recherche Scientifique (CNRS)	Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Ligue contre le Cancer (Comite Departemental du Rhone); Societe Francaise d'Hematologie (SFH); Region Rhone-Alpes(Region Auvergne-Rhone-Alpes); Universite Claude Bernard Lyon 1 (UCBL1); Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS))	We thank Dr Stephanie Gobert-Gosse (Universite Claude Bernard Lyon 1, Villeurbanne, France) for her expert advice on the two-dimensional electrophoresis experiments and Clement Soleilhavoup for his technical help in the analysis of total mRNA levels by RT-qPCR. This work received support from grants from Association pour la Recherche contre le Cancer, Ligue contre le Cancer (Comite Departemental du Rhone), Societe Francaise d'Hematologie (SFH), Region Rhone-Alpes, Universite Claude Bernard Lyon 1 (UCBL1) and Centre National de la Recherche Scientifique (CNRS).	Anh TNL, 2011, J PROTEOMICS, V74, P167, DOI 10.1016/j.jprot.2010.10.007; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BISTER K, 1979, P NATL ACAD SCI USA, V76, P5023, DOI 10.1073/pnas.76.10.5023; Bonamy GMC, 2005, MOL ENDOCRINOL, V19, P1213, DOI 10.1210/me.2004-0204; BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; Bresson C, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-390; Cardenas D, 2012, NUCLEIC ACIDS RES, V40, P1; Casabona MG, 2013, ENVIRON MICROBIOL, V15, P471, DOI 10.1111/j.1462-2920.2012.02816.x; Challagundla KB, 2011, MOL CELL BIOL, V31, P4007, DOI 10.1128/MCB.05810-11; Dai MS, 2007, EMBO J, V26, P3332, DOI 10.1038/sj.emboj.7601776; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; Gandrillon O, 1999, EMBO J, V18, P2764, DOI 10.1093/emboj/18.10.2764; GANDRILLON O, 1994, ONCOGENE, V9, P749; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GANDRILLON O, 1995, INT J ONCOL, V6, P215; Gandrillon O, 2012, PROG BIOPHYS MOL BIO, V110, P1, DOI 10.1016/j.pbiomolbio.2012.05.006; Gonin-Giraud S, 2008, LEUKEMIA RES, V32, P1878, DOI 10.1016/j.leukres.2008.05.010; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; Greco A, 1997, MOL GEN GENET, V256, P320, DOI 10.1007/s004380050575; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; Habif G, 2013, J PROTEOMICS, V78, P231, DOI 10.1016/j.jprot.2012.09.009; Hill WE, 1990, AM SOC MICROBIOLOGY, Vxxiii, P678; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Kaberdina AC, 2009, MOL CELL, V33, P227, DOI 10.1016/j.molcel.2008.12.014; Kiparisov S, 2005, MOL GENET GENOMICS, V274, P235, DOI 10.1007/s00438-005-0020-9; Komili S, 2007, CELL, V131, P557, DOI 10.1016/j.cell.2007.08.037; Madjar JJ, 1994, CELL BIOL LABORATORY, V1, P657; Marygold SJ, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r216; Meyuhas O, 2009, PROG MOL BIOL TRANSL, V90, P109, DOI 10.1016/S1877-1173(09)90003-5; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rabilloud T, 1999, METH MOL B, V112, P297; Rascle A, 1997, BASEL, V1, P119; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; Ribeil JA, 2007, NATURE, V445, P102, DOI 10.1038/nature05378; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; Sugihara Y, 2010, J PROTEOME RES, V9, P1351, DOI 10.1021/pr9008964; TILL JE, 1963, RADIAT RES, V18, P96, DOI 10.2307/3571429; Vandelkerckhove J, 2008, M S-MED SCI, V24, P37, DOI 10.1051/medsci/200824137; Vargas-Roig LM, 1998, INT J CANCER, V79, P468, DOI 10.1002/(SICI)1097-0215(19981023)79:5<468::AID-IJC4>3.0.CO;2-Z; VargasRoig LM, 1997, CANCER DETECT PREV, V21, P441; WALLER JP, 1961, P NATL ACAD SCI USA, V47, P18, DOI 10.1073/pnas.47.1.18; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; WOOL IG, 1979, ANNU REV BIOCHEM, V48, P719, DOI 10.1146/annurev.bi.48.070179.003443; Xue SF, 2012, NAT REV MOL CELL BIO, V13, P355, DOI 10.1038/nrm3359; YEN PM, 1994, J BIOL CHEM, V269, P903; Zhang JY, 2007, GENE DEV, V21, P2580, DOI 10.1101/gad.1569307; Zhang Q, 2011, J BIOL CHEM, V286, P38264, DOI 10.1074/jbc.M111.277012	49	4	4	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2014	33	12					1581	1589		10.1038/onc.2013.93	http://dx.doi.org/10.1038/onc.2013.93			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD4TS	23563180				2022-12-17	WOS:000333244200011
J	Zhang, S; Mercado-Uribe, I; Xing, Z; Sun, B; Kuang, J; Liu, J				Zhang, S.; Mercado-Uribe, I.; Xing, Z.; Sun, B.; Kuang, J.; Liu, J.			Generation of cancer stem-like cells through the formation of polyploid giant cancer cells (vol 33, pg 116, 2013)	ONCOGENE			English	Correction																		ZHANG S, 2013, GENERATION CANC STEM, DOI DOI 10.1038/ONC.2013.96	1	4	4	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					134	134		10.1038/onc.2013.318	http://dx.doi.org/10.1038/onc.2013.318			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU		Bronze			2022-12-17	WOS:000329212000015
J	Sampson, ER; McMurray, HR; Hassane, DC; Newman, L; Salzman, P; Jordan, CT; Land, H				Sampson, E. R.; McMurray, H. R.; Hassane, D. C.; Newman, L.; Salzman, P.; Jordan, C. T.; Land, H.			Gene signature critical to cancer phenotype as a paradigm for anticancer drug discovery	ONCOGENE			English	Article						oncogene cooperation; gene expression; driver genes	HISTONE DEACETYLASE INHIBITORS; SUBEROYLANILIDE HYDROXAMIC ACID; CELL-CYCLE ARREST; MYC-INDUCED PROLIFERATION; PHASE-I; VALPROIC ACID; SODIUM PHENYLBUTYRATE; EXPRESSION; APOPTOSIS; P53	Malignant cell transformation commonly results in the deregulation of thousands of cellular genes, an observation that suggests a complex biological process and an inherently challenging scenario for the development of effective cancer interventions. To better define the genes/pathways essential to regulating the malignant phenotype, we recently described a novel strategy based on the cooperative nature of carcinogenesis that focuses on genes synergistically deregulated in response to cooperating oncogenic mutations. These so-called 'cooperation response genes' (CRGs) are highly enriched for genes critical for the cancer phenotype, thereby suggesting their causal role in the malignant state. Here, we show that CRGs have an essential role in drug-mediated anticancer activity and that anticancer agents can be identified through their ability to antagonize the CRG expression profile. These findings provide proof-of-concept for the use of the CRG signature as a novel means of drug discovery with relevance to underlying anticancer drug mechanisms.	[Sampson, E. R.; McMurray, H. R.; Newman, L.; Land, H.] Univ Rochester, Med Ctr, Dept Biomed Genet, Rochester, NY 14642 USA; [Hassane, D. C.; Jordan, C. T.] Univ Rochester, Med Ctr, Dept Hematol & Oncol, Rochester, NY 14642 USA; [Hassane, D. C.] Weill Cornell Med Coll, Dept Pathol & Lab Med, Inst Computat Biomed, New York, NY USA; [Salzman, P.] Univ Rochester, Med Ctr, Dept Biostat & Computat Biol, Rochester, NY 14642 USA; [Land, H.] Univ Rochester, Med Ctr, James P Wilmot Canc Ctr, Rochester, NY 14642 USA	University of Rochester; University of Rochester; Cornell University; University of Rochester; University of Rochester	Land, H (corresponding author), Univ Rochester, Med Ctr, Dept Biomed Genet, 601 Elmwood Ave, Rochester, NY 14642 USA.	Land@urmc.rochester.edu	Hassane, Duane/AAA-3456-2021; jordan, craig/D-7666-2014	salzman, peter/0000-0001-8114-4863; McMurray, Helene/0000-0003-1738-8622; Hassane, Duane/0000-0002-0719-9572; jordan, craig/0000-0003-0869-3465	NIH [CA90663, CA120317, CA138249, GM075299, T32 CA09363, K99 LM009477]; James P Wilmot Cancer Center; NATIONAL CANCER INSTITUTE [R01CA120317, R01CA090663, R01CA138249, T32CA009363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075299] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [K99LM009477] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); James P Wilmot Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	We thank Drs D Bohmann and M Noble for discussion, Drs A Burgess and R Whitehead for materials. This work was supported in part by NIH grants CA90663, CA120317, CA138249, GM075299, and a James P Wilmot Cancer Center pilot grant. HRM was supported in part by NIH T32 CA09363, PS by NIH K99 LM009477.	Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Angelucci A, 2006, ANTI-CANCER DRUG, V17, P1141, DOI 10.1097/01.cad.0000236302.89843.fc; Atmaca A, 2007, BRIT J CANCER, V97, P177, DOI 10.1038/sj.bjc.6603851; Batty N, 2009, CANCER LETT, V280, P192, DOI 10.1016/j.canlet.2009.03.013; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bouchard C, 2004, EMBO J, V23, P2830, DOI 10.1038/sj.emboj.7600279; Braiteh F, 2008, CLIN CANCER RES, V14, P6296, DOI 10.1158/1078-0432.CCR-08-1247; Butler LM, 2000, CANCER RES, V60, P5165; Carducci MA, 2001, CLIN CANCER RES, V7, P3047; Corsello SM, 2009, BLOOD, V113, P6193, DOI 10.1182/blood-2008-07-166090; Fantin VR, 2007, CLIN CANCER RES, V13, P7237, DOI 10.1158/1078-0432.CCR-07-2114; Friedman DR, 2009, CLIN CANCER RES, V15, P6947, DOI 10.1158/1078-0432.CCR-09-1132; Fritsche P, 2009, GUT; Gilbert J, 2001, CLIN CANCER RES, V7, P2292; Gore SD, 2002, CLIN CANCER RES, V8, P963; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; Hassane DC, 2008, BLOOD; HEERDT BG, 1994, CANCER RES, V54, P3288; Hieronymus H, 2006, CANCER CELL, V10, P321, DOI 10.1016/j.ccr.2006.09.005; Huang E, 2003, NAT GENET, V34, P226, DOI 10.1038/ng1167; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Iizuka M, 2003, CURR OPIN GENET DEV, V13, P154, DOI 10.1016/S0959-437X(03)00020-0; Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kelly WK, 2005, J CLIN ONCOL, V23, P3923, DOI 10.1200/JCO.2005.14.167; Kelly WK, 2003, CLIN CANCER RES, V9, P3578; Kuendgen A, 2006, CANCER-AM CANCER SOC, V106, P112, DOI 10.1002/cncr.21552; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Li XN, 2005, MOL CANCER THER, V4, P1912, DOI 10.1158/1535-7163.MCT-05-0184; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; McMurray HR, 2008, NATURE, V453, P1112, DOI 10.1038/nature06973; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mori S, 2009, ONCOGENE, V28, P2796, DOI 10.1038/onc.2009.139; Mori S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006772; Munster P, 2007, J CLIN ONCOL, V25, P1979, DOI 10.1200/JCO.2006.08.6165; Patnaik A, 2002, CLIN CANCER RES, V8, P2142; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Rochette PJ, 2005, J MOL BIOL, V352, P44, DOI 10.1016/j.jmb.2005.06.033; Roper E, 2001, EMBO REP, V2, P145, DOI 10.1093/embo-reports/kve020; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stegmaier K, 2004, NAT GENET, V36, P257, DOI 10.1038/ng1305; Stegmaier K, 2007, PLOS MED, V4, P702, DOI 10.1371/journal.pmed.0040122; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takai N, 2004, CANCER-AM CANCER SOC, V101, P2760, DOI 10.1002/cncr.20709; Wei G, 2006, CANCER CELL, V10, P331, DOI 10.1016/j.ccr.2006.09.006; WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xia MX, 2007, NAT STRUCT MOL BIOL, V14, P215, DOI 10.1038/nsmb1208; Zhang HT, 2007, ACTA PHARMACOL SIN, V28, P1783, DOI 10.1111/j.1745-7254.2007.00660.x; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	59	4	4	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2013	32	33					3809	3818		10.1038/onc.2012.389	http://dx.doi.org/10.1038/onc.2012.389			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	22964631	Green Accepted			2022-12-17	WOS:000323210200003
J	Wang, Y; Wang, Z; Joshi, BH; Puri, RK; Stultz, B; Yuan, Q; Bai, Y; Zhou, P; Yuan, Z; Hursh, DA; Bi, X				Wang, Y.; Wang, Z.; Joshi, B. H.; Puri, R. K.; Stultz, B.; Yuan, Q.; Bai, Y.; Zhou, P.; Yuan, Z.; Hursh, D. A.; Bi, X.			The tumor suppressor Caliban regulates DNA damage-induced apoptosis through p53-dependent and -independent activity	ONCOGENE			English	Article						Apoptosis; Caliban; p53; tumor suppressor	CELL-DEATH; GENOMIC INSTABILITY; IONIZING-RADIATION; P53 FUNCTION; DROSOPHILA; ATM; SENESCENCE; PROTEIN; MAINTENANCE; RESTORATION	We previously identified Caliban (Clbn) as the Drosophila homolog of human Serologically defined colon cancer antigen 1 gene and demonstrated that it could function as a tumor suppressor in human non-small-cell lung cancer (NSCLC) cells, although its mode of action was unknown. Herein, we identify roles for Clbn in DNA damage response. We generate clbn knockout flies using homologous recombination and demonstrate that they have a heightened sensitivity to irradiation. We show that normal Clbn function facilitates both p53-dependent and -independent DNA damage-induced apoptosis. Clbn coordinates different apoptosis pathways, showing a two-stage upregulation following DNA damage. Clbn has proapoptotic functions, working with both caspase and the proapoptotic gene Hid. Finally, ecotopic expression of clbn(+) in NSCLC cells suppresses tumor formation in athymic nude mice. We conclude that Caliban is a regulator of DNA damage-induced apoptosis, functioning as a tumor suppressor in both p53-dependent and -independent pathways.	[Wang, Y.; Wang, Z.; Yuan, Q.; Bi, X.] Chinese Acad Sci, Inst High Energy Phys, CAS Key Lab Biol Effects Nanomat & Nanosafety, Beijing 100049, Peoples R China; [Wang, Z.; Bi, X.] Dalian Med Univ, Inst Canc Stem Cell, Ctr Canc, Dalian, Peoples R China; [Joshi, B. H.; Puri, R. K.; Stultz, B.; Hursh, D. A.] US FDA, Ctr Biol Evaluat & Res, Div Cellular & Gene Therapies, Bethesda, MD USA; [Bai, Y.; Yuan, Z.] Chinese Acad Sci, Inst Biophys, State Key Lab Brain & Cognit Sci, Beijing 100049, Peoples R China; [Zhou, P.] Beijing Inst Radiat Med, Dept Radiat Toxicol & Oncol, Beijing, Peoples R China	Chinese Academy of Sciences; Institute of High Energy Physics, CAS; Dalian Medical University; US Food & Drug Administration (FDA); Chinese Academy of Sciences; Institute of Biophysics, CAS; Academy of Military Medical Sciences - China	Bi, X (corresponding author), Chinese Acad Sci, Inst High Energy Phys, CAS Key Lab Biol Effects Nanomat & Nanosafety, Beijing 100049, Peoples R China.	bixl@ihep.ac.cn	Bi, Xiaolin/C-7038-2014; Yuan, Qing/ABF-3033-2020; Bi, Xiaolin/E-7469-2010	Bi, Xiaolin/0000-0003-2837-9457; Bi, Xiaolin/0000-0002-7172-7851; Hursh, Deborah/0000-0002-5614-7111	National Basic Research Program of China (973 Program) [2010CB934004]; National Natural Science Foundation of China [30871388]; CAS; Food and Drug Administration, Center for Biologics Evaluation and Research	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAS(Chinese Academy of Sciences); Food and Drug Administration, Center for Biologics Evaluation and Research	We thank Drs Hermann Steller, Laura Johnston and Tin Tin Su; the Bloomington Stock Center for fly stocks; Dr Dong Han at National Center for Nanoscience and Technology for help with the scanning electron microscope; and the members of the Bi laboratory for advice and discussions. We also thank Dr Mark Mortin for generating the knockout clbn flies and for critically reading this manuscript. We are grateful for comments on this manuscript from Tehyen Chu and Brent McCright. This work was supported by grants from National Basic Research Program of China (973 Program grant no. 2010CB934004), National Natural Science Foundation of China (grant no. 30871388) and CAS Knowledge Innovation Program to XB and by the Food and Drug Administration, Center for Biologics Evaluation and Research.	Akdemir F, 2007, ONCOGENE, V26, P5184, DOI 10.1038/sj.onc.1210328; Attardi LD, 2005, MUTAT RES-FUND MOL M, V569, P145, DOI 10.1016/j.mrfmmm.2004.04.019; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Baum JS, 2007, CELL DEATH DIFFER, V14, P1508, DOI 10.1038/sj.cdd.4402155; Bennett K, 2010, J PROTEOME RES, V9, P4289, DOI 10.1021/pr1003467; Bi XL, 2005, ONCOGENE, V24, P8229, DOI 10.1038/sj.onc.1208962; Bi XL, 2004, CURR BIOL, V14, P1348, DOI 10.1016/j.cub.2004.06.063; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Carbonnelle D, 2001, INT J CANCER, V92, P388, DOI 10.1002/ijc.1197; Chalastanis A, 2010, J NATL CANCER I, V102, P1731, DOI 10.1093/jnci/djq389; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Deuring R, 2000, MOL CELL, V5, P355, DOI 10.1016/S1097-2765(00)80430-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Duffy JB, 2002, GENESIS, V34, P1, DOI 10.1002/gene.10150; Fan Y, 2010, CELL DEATH DIFFER, V17, P912, DOI 10.1038/cdd.2009.182; Gong WJ, 2003, P NATL ACAD SCI USA, V100, P2556, DOI 10.1073/pnas.0535280100; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Kornbluth S, 2005, J CELL SCI, V118, P1779, DOI 10.1242/jcs.02377; Lannan E, 2007, J VIROL, V81, P9319, DOI 10.1128/JVI.00247-07; Lee JH, 2003, FEBS LETT, V550, P5, DOI 10.1016/S0014-5793(03)00771-3; Long SW, 2011, BIOSCIENCE REP, V31, P333, DOI 10.1042/BSR20100124; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; McKinnon PJ, 2004, EMBO REP, V5, P772, DOI 10.1038/sj.embor.7400210; McNamee LM, 2009, GENETICS, V182, P423, DOI 10.1534/genetics.109.102327; Moon NS, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000153; Oikemus SR, 2004, GENE DEV, V18, P1850, DOI 10.1101/gad.1202504; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; Papait R, 2009, BIOCHEM BIOPH RES CO, V379, P434, DOI 10.1016/j.bbrc.2008.12.091; Rasti M, 2012, PATHOL ONCOL RES, V18, P169, DOI 10.1007/s12253-011-9423-6; Sabourin M, 2008, TRENDS CELL BIOL, V18, P337, DOI 10.1016/j.tcb.2008.04.004; Scanlan MJ, 1998, INT J CANCER, V76, P652, DOI 10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.3.CO;2-9; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Silva E, 2004, CURR BIOL, V14, P1341, DOI 10.1016/j.cub.2004.06.056; Sogame N, 2003, P NATL ACAD SCI USA, V100, P4696, DOI 10.1073/pnas.0736384100; Song YH, 2004, CURR BIOL, V14, P1354, DOI 10.1016/j.cub.2004.06.064; Squillaro T, 2010, FASEB J, V24, P1593, DOI 10.1096/fj.09-143057; Steller H, 2008, CELL DEATH DIFFER, V15, P1132, DOI 10.1038/cdd.2008.50; Stultz BG, 2006, DEV BIOL, V296, P329, DOI 10.1016/j.ydbio.2006.05.034; Titen SWA, 2008, GENETICS, V180, P1821, DOI 10.1534/genetics.108.093625; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Wichmann A, 2006, P NATL ACAD SCI USA, V103, P9952, DOI 10.1073/pnas.0510528103; Wichmann A, 2010, DEV BIOL, V346, P80, DOI 10.1016/j.ydbio.2010.07.023; Xie GF, 1998, ONCOGENE, V16, P721, DOI 10.1038/sj.onc.1201793; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529	46	4	4	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2013	32	33					3857	3866		10.1038/onc.2012.395	http://dx.doi.org/10.1038/onc.2012.395			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	22964637				2022-12-17	WOS:000323210200008
J	Deng, W; Tsao, SW; Mak, GWY; Tsang, CM; Ching, YP; Guan, XY; Huen, MSY; Cheung, ALM				Deng, W.; Tsao, S. W.; Mak, G. W. Y.; Tsang, C. M.; Ching, Y. P.; Guan, X-Y; Huen, M. S. Y.; Cheung, A. L. M.			Impact of G(2) checkpoint defect on centromeric instability	ONCOGENE			English	Article						G(2) checkpoint; defect; centromere; instability	SQUAMOUS-CELL CARCINOMAS; CYCLIN B1; CHROMOSOMAL REARRANGEMENTS; HEPATOCELLULAR-CARCINOMA; ATAXIA-TELANGIECTASIA; GENOMIC INSTABILITY; EPITHELIAL-CELLS; ATM KINASE; CANCER; EXPRESSION	Centromeric instability is characterized by dynamic formation of centromeric breaks, deletions, isochromosomes and translocations, which are commonly observed in cancer. So far, however, the mechanisms of centromeric instability in cancer cells are still poorly understood. In this study, we tested the hypothesis that G(2) checkpoint defect promotes centromeric instability. Our observations from multiple approaches consistently support this hypothesis. We found that overexpression of cyclin B1, one of the pivotal genes driving G(2) to M phase transition, impaired G(2) checkpoint and promoted the formation of centromeric aberrations in telomerase-immortalized cell lines. Conversely, centromeric instability in cancer cells was ameliorated through reinforcement of G(2) checkpoint by cyclin B1 knockdown. Remarkably, treatment with KU55933 for only 2.5 h, which abrogated G(2) checkpoint, was sufficient to produce centromeric aberrations. Moreover, centromeric aberrations constituted the major form of structural abnormalities in G(2) checkpoint-defective ataxia telangiectasia cells. Statistical analysis showed that the frequencies of centromeric aberrations in G(2) checkpoint-defective cells were always significantly over-represented compared with random assumption. As there are multiple pathways leading to G(2) checkpoint defect, our finding offers a broad explanation for the common occurrence of centromeric aberrations in cancer cells. Oncogene (2011) 30, 1281-1289; doi:10.1038/onc.2010.508; published online 8 November 2010	[Deng, W.; Tsao, S. W.; Mak, G. W. Y.; Tsang, C. M.; Ching, Y. P.; Huen, M. S. Y.; Cheung, A. L. M.] Univ Hong Kong, Dept Anat, Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China; [Guan, X-Y] Univ Hong Kong, Dept Clin Oncol, Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Cheung, ALM (corresponding author), Univ Hong Kong, Fac Med Bldg, Dept Anat, 21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.	lmcheung@hkucc.hku.hk	Deng, Wen/C-4154-2009; Deng, Wen/M-5208-2019; /A-3639-2009; Guan, Xin-Yuan/A-3639-2009	/0000-0003-1874-9805; Guan, Xin-Yuan/0000-0002-4485-6017; CHING, Yick Pang/0000-0002-6461-8358	Research Grants Council of Hong Kong Special Administrative Region, China [HKU 7556/06M]	Research Grants Council of Hong Kong Special Administrative Region, China(Hong Kong Research Grants Council)	We thank Dr Prochownik, Children's Hospital of Pittsburgh, Pittsburgh, PA, for the kind gift of pApuro-CyclinB1 plasmids, and Department of Pediatrics and Adolescent Medicine, The University of Hong Kong for use of SKY facilities. We also thank Dr JC Tang (Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University) and Professor G Srivastava (Department of Pathology, The University of Hong Kong) for the SLMT-1 cell line, and Dr R Glaser (Department of Medical Microbiology and Immunology, Ohio State University Medical Center) for the HNE-1 cell line; T Chan, PY Cheung, CS Leung, P Mak, J Cheung, A Li and B Lai for technical assistance. This study was supported by a grant from the Research Grants Council of Hong Kong Special Administrative Region, China, Project No. HKU 7556/06M.	Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Beheshti B, 2000, MOL DIAGN, V5, P23, DOI 10.2165/00066982-200005010-00008; Cheung PY, 2010, CANCER LETT, V293, P41, DOI 10.1016/j.canlet.2009.12.015; Deckbar D, 2007, J CELL BIOL, V176, P749, DOI 10.1083/jcb.200612047; Deng W, 2007, CHROMOSOMA, V116, P557, DOI 10.1007/s00412-007-0120-x; Deng W, 2003, CYTOM PART A, V51A, P46, DOI 10.1002/cyto.a.10004; Deng W, 2008, CANCER RES, V68, P7200, DOI 10.1158/0008-5472.CAN-07-6569; Dillon N, 2002, TRENDS GENET, V18, P252, DOI 10.1016/S0168-9525(02)02648-3; Ehrlich M, 2002, J NUTR, V132, p2424S, DOI 10.1093/jn/132.8.2424S; Eichler EE, 2003, SCIENCE, V301, P793, DOI 10.1126/science.1086132; GLASER R, 1989, P NATL ACAD SCI USA, V86, P9524, DOI 10.1073/pnas.86.23.9524; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Ito Y, 2000, ONCOLOGY-BASEL, V59, P68, DOI 10.1159/000012140; JIN YS, 1995, CANCER RES, V55, P3204; JOHANSSON M, 1995, CANCER GENET CYTOGEN, V81, P46, DOI 10.1016/0165-4608(94)00207-X; Kaufmann WK, 1997, CELL GROWTH DIFFER, V8, P1105; KOJIS TL, 1989, HUM GENET, V83, P347, DOI 10.1007/BF00291379; Leach TJ, 2000, MOL CELL BIOL, V20, P6308, DOI 10.1128/MCB.20.17.6308-6316.2000; Li HM, 2006, INT J CANCER, V119, P1567, DOI 10.1002/ijc.22032; Lobrich M, 2007, NAT REV CANCER, V7, P861, DOI 10.1038/nrc2248; Nakamura N, 2005, HUM PATHOL, V36, P828, DOI 10.1016/j.humpath.2005.03.012; Padilla-Nash HM, 2001, GENE CHROMOSOME CANC, V30, P349, DOI 10.1002/gcc.1101; Pandita TK, 2002, ONCOGENE, V21, P611, DOI 10.1038/sj.onc.1205060; Perrod S, 2003, CELL MOL LIFE SCI, V60, P2303, DOI 10.1007/s00018-003-3246-x; PINCHEIRA J, 1991, MUTAT RES, V251, P71, DOI 10.1016/0027-5107(91)90216-B; Rainey MD, 2008, CANCER RES, V68, P7466, DOI 10.1158/0008-5472.CAN-08-0763; Santana C, 2002, MUTAT RES-FUND MOL M, V508, P49, DOI 10.1016/S0027-5107(02)00172-0; Stewenius Y, 2005, P NATL ACAD SCI USA, V102, P5541, DOI 10.1073/pnas.0408454102; Struski S, 2002, CANCER GENET CYTOGEN, V135, P63, DOI 10.1016/S0165-4608(01)00624-0; Suzuki T, 2007, CANCER SCI, V98, P644, DOI 10.1111/j.1349-7006.2007.00444.x; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takeno S, 2002, CANCER, V94, P2874, DOI 10.1002/cncr.10542; Tang JCO, 2001, CANCER GENET CYTOGEN, V124, P36, DOI 10.1016/S0165-4608(00)00317-4; Terzoudi GI, 2005, CANCER RES, V65, P11292, DOI 10.1158/0008-5472.CAN-05-2148; White JS, 2008, CELL CYCLE, V7, P1277, DOI 10.4161/cc.7.9.5961; Wong N, 2000, HEPATOLOGY, V32, P1060, DOI 10.1053/jhep.2000.19349; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Yin XY, 2001, CANCER RES, V61, P6487; Yoshida T, 2004, ANN ONCOL, V15, P252, DOI 10.1093/annonc/mdh073; ZHU D, 1995, CANCER GENET CYTOGEN, V80, P63, DOI 10.1016/0165-4608(94)00128-X	43	4	4	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	11					1281	1289		10.1038/onc.2010.508	http://dx.doi.org/10.1038/onc.2010.508			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	736JX	21057540	Green Submitted			2022-12-17	WOS:000288492100003
J	Luo, J; Yang, J; Yu, BY; Liu, W; Li, M; Zhuang, SM				Luo, J.; Yang, J.; Yu, B-Y; Liu, W.; Li, M.; Zhuang, S-M			Identification of Siah-interacting protein as a potential regulator of apoptosis and curcumin resistance	ONCOGENE			English	Article						Siah-interacting protein; SIP; curcumin; apoptosis	CALCYCLIN-BINDING-PROTEIN; KINASE-C; ACQUIRED-RESISTANCE; CANCER-THERAPY; UP-REGULATION; BETA-CATENIN; CELLS; PHOSPHORYLATION; TRANSLOCATION; S100A6	The mechanism underlying curcumin (diferuloylmethane) resistance is still largely unknown. Here we employed proteomic approach to identify the Siah-interacting protein (SIP) as a candidate for detailed study, because the spot intensity of SIP on a two-dimensional gel displayed 70-90% reduction in curcumin-sensitive cells, but remained unchanged in curcumin-resistant sublines, after curcumin treatment. Both gain-and loss-of-function studies revealed that SIP promoted curcumin-induced apoptosis. Moreover, SIP underwent phosphorylation and nuclear translocation in curcumin-sensitive but not resistant cells, upon curcumin exposure. The nuclear translocation of SIP was remarkably impaired when a putative nuclear localization sequence (NLS, amino acid (aa) 143-159) was deleted or the serine 141 was mutated into alanine, whereas truncation of the N-terminal region (aa 1-43) obviously increased the nuclear import of SIP. In accordance with their nuclear localization, N-terminal truncation significantly enhanced the proapoptotic effect of SIP, whereas NLS deletion or Ser141Ala mutation attenuated the apoptosis-promoting activity of both wild-type- and N-terminal truncated-SIP. These data suggest that SIP plays a role in apoptosis and curcumin resistance, and the function of SIP may be regulated by different motifs, such as the NLS, N-terminal region and serine 141. Our findings provide new insights into the biological significance of SIP and the mechanisms of drug resistance. Oncogene (2010) 29, 6357-6366; doi:10.1038/onc.2010.358; published online 23 August 2010	[Luo, J.; Yang, J.; Yu, B-Y; Zhuang, S-M] Sun Yat Sen Univ, Sch Life Sci, Minist Educ, Key Lab Gene Engn,State Key Lab Biocontrol, Guangzhou 510275, Guangdong, Peoples R China; [Liu, W.; Li, M.] Sun Yat Sen Univ, Zhongshan Sch Med, Prote Ctr, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University	Zhuang, SM (corresponding author), Sun Yat Sen Univ, Sch Life Sci, Minist Educ, Key Lab Gene Engn,State Key Lab Biocontrol, Guangzhou 510275, Guangdong, Peoples R China.	zhuangshimei@163.com		Yang, Jin-E/0000-0002-7511-1042; Zhuang, Shi-Mei/0000-0002-2512-3942	National Natural Science Foundation of China [30470664]; Ministry of Science and Technology of China [2010CB912803, 2005CB724600]; Ministry of Education of China [105136]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China); Ministry of Education of China(Ministry of Education, China)	This study was supported by grants from the National Natural Science Foundation of China (30470664), Ministry of Science and Technology of China (2010CB912803, 2005CB724600) and Ministry of Education of China (105136).	Aggarwal BB, 2005, CLIN CANCER RES, V11, P7490, DOI 10.1158/1078-0432.CCR-05-1192; Bhandarkar SS, 2007, ADV EXP MED BIOL, V595, P185; Bhattacharya S, 2005, BIOCHEMISTRY-US, V44, P9462, DOI 10.1021/bi0502689; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; Daouti S, 2009, CANCER RES, V69, P1924, DOI 10.1158/0008-5472.CAN-08-2627; Dhillon N, 2008, CLIN CANCER RES, V14, P4491, DOI 10.1158/1078-0432.CCR-08-0024; Filipek A, 1996, BIOCHEM J, V320, P585, DOI 10.1042/bj3200585; Filipek A, 2002, J BIOL CHEM, V277, P21103, DOI 10.1074/jbc.M111010200; Filipek A, 2002, J BIOL CHEM, V277, P28848, DOI 10.1074/jbc.M203602200; Gutcher I, 2003, CELL MOL LIFE SCI, V60, P1061, DOI 10.1007/s00018-003-2281-y; Hsieh HL, 2002, J CELL SCI, V115, P3149; Huang HD, 2005, NUCLEIC ACIDS RES, V33, pD80; Iakoucheva LM, 2004, NUCLEIC ACIDS RES, V32, P1037, DOI 10.1093/nar/gkh253; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Jin TR, 2008, CELL SIGNAL, V20, P1697, DOI 10.1016/j.cellsig.2008.04.014; Joo JH, 2008, J CELL BIOCHEM, V103, P1183, DOI 10.1002/jcb.21496; Karunagaran D, 2005, CURR CANCER DRUG TAR, V5, P117, DOI 10.2174/1568009053202081; Kawamori T, 1999, CANCER RES, V59, P597; Kilanczyk E, 2009, BIOCHEM BIOPH RES CO, V380, P54, DOI 10.1016/j.bbrc.2009.01.026; Knauf JA, 1999, J BIOL CHEM, V274, P23414, DOI 10.1074/jbc.274.33.23414; Lange A, 2007, J BIOL CHEM, V282, P5101, DOI 10.1074/jbc.R600026200; Li N, 2002, CARCINOGENESIS, V23, P1307, DOI 10.1093/carcin/23.8.1307; Lotfi K, 2002, BIOCHEM BIOPH RES CO, V293, P1489, DOI 10.1016/S0006-291X(02)00415-1; Mahmmoud YA, 2007, BRIT J PHARMACOL, V150, P200, DOI 10.1038/sj.bjp.0706970; Mansson E, 2002, BIOCHEM BIOPH RES CO, V298, P338, DOI 10.1016/S0006-291X(02)02471-3; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Ning XX, 2007, MOL CANCER RES, V5, P1254, DOI 10.1158/1541-7786.MCR-06-0426; O'Connor R, 2009, CURR CANCER DRUG TAR, V9, P273, DOI 10.2174/156800909788166583; Orre LM, 2007, MOL CELL PROTEOMICS, V6, P2122, DOI 10.1074/mcp.M700202-MCP200; Santelli E, 2005, J BIOL CHEM, V280, P34278, DOI 10.1074/jbc.M506707200; Shankar E, 2008, ONCOGENE, V27, P3957, DOI 10.1038/onc.2008.39; Sharma RA, 2004, CLIN CANCER RES, V10, P6847, DOI 10.1158/1078-0432.CCR-04-0744; Sun SR, 2007, BIOCHEM BIOPH RES CO, V356, P864, DOI 10.1016/j.bbrc.2007.03.080; Takigawa Y, 2008, CURR DRUG TARGETS, V9, P1013, DOI 10.2174/138945008786786127; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Wang WZ, 2008, FEBS LETT, V582, P2689, DOI 10.1016/j.febslet.2008.06.048; Wu J, 2003, J BIOCHEM MOL BIOL, V36, P354; Wu JH, 2004, CANCER RES, V64, P6461, DOI 10.1158/0008-5472.CAN-04-0866; Yang YJ, 2006, LIFE SCI, V78, P753, DOI 10.1016/j.lfs.2005.05.100	41	4	4	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	48					6357	6366		10.1038/onc.2010.358	http://dx.doi.org/10.1038/onc.2010.358			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	688SW	20729913				2022-12-17	WOS:000284874700006
J	Kralova, J; Sheely, JI; Liss, AS; Bose, HR				Kralova, J.; Sheely, J. I.; Liss, A. S.; Bose, H. R., Jr.			ERK and JNK activation is essential for oncogenic transformation by v-Rel	ONCOGENE			English	Article						v-Rel; NF-kappa B; transformation; oncogenesis; MAPK	NF-KAPPA-B; SIGNAL-REGULATED KINASE; CELL-CYCLE ARREST; C-REL; TRANSCRIPTION FACTOR; CANCER PROGRESSION; GENE-EXPRESSION; BREAST-CANCER; TUMOR-GROWTH; JUN KINASE	v-Rel is the acutely oncogenic member of the NF-kappa B family of transcription factors. Infection with retroviruses expressing v-Rel rapidly induces fatal lymphomas in birds and transforms primary lymphocytes and fibroblasts in vitro. We have previously shown that AP-1 transcriptional activity contributes to v-Rel-mediated transformation. Although v-Rel increases the expression of these factors, their activity may also be induced through phosphorylation by the mitogen-activated protein kinases (MAPKs). The expression of v-Rel results in the strong and sustained activation of the ERK and JNK MAPK pathways. This induction is critical for the v-Rel-transformed phenotype, as suppression of MAPK activity with chemical inhibitors or small interfering RNA severely impairs colony formation of v-Rel-transformed lymphoid cell lines. However, signaling must be maintained within an optimal range in these cells, as strong additional activation of either pathway beyond the levels induced by v-Rel through the expression of constitutively active MAPK proteins attenuates the transformed phenotype. MAPK signaling also has an important role in the initial transformation of primary spleen cells by v-Rel, although distinct requirements for MAPK activity at different stages of v-Rel-mediated transformation were identified. We also show that the ability of v-Rel to induce MAPK signaling more strongly than c-Rel contributes to its greater oncogenicity. Oncogene (2010) 29, 6267-6279; doi:10.1038/onc.2010.359; published online 30 August 2010	[Kralova, J.; Sheely, J. I.; Liss, A. S.; Bose, H. R., Jr.] Univ Texas Austin, Inst Mol & Cellular Biol, Sect Mol Genet & Microbiol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Bose, HR (corresponding author), Univ Texas Austin, Inst Mol & Cellular Biol, Sect Mol Genet & Microbiol, 1 Univ Stn A5000, Austin, TX 78712 USA.	bose@mail.utexas.edu	Liss, Andrew/L-9696-2019; Kralova, Jarmila/G-3834-2014	Kralova, Jarmila/0000-0002-4735-8857	National Cancer Institute [CA33192, CA098151]; Grant Agency of the Academy of Sciences of the Czech Republic [KAN200200651]; NATIONAL CANCER INSTITUTE [R01CA098151, R01CA033192] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Grant Agency of the Academy of Sciences of the Czech Republic(Czech Academy of SciencesGrant Agency of the Czech Republic); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the laboratories of Natalie Ahn and Aming Lin for generously providing the CA MKK constructs. This work was supported by Public Health Service grants CA33192 and CA098151 from the National Cancer Institute. Jarmila Kralova was supported, in part, by grant KAN200200651 from the Grant Agency of the Academy of Sciences of the Czech Republic. We also thank R Hrdlickova and J Nehyba for their critical reading of the manuscript.	Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bode AM, 2007, MOL CARCINOGEN, V46, P591, DOI 10.1002/mc.20348; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Bost F, 1999, MOL CELL BIOL, V19, P1938; Bubendorf L, 1999, CANCER RES, V59, P803; Bunting K, 2007, J IMMUNOL, V178, P7097, DOI 10.4049/jimmunol.178.11.7097; Chen NY, 2001, CANCER RES, V61, P3908; Corzo C, 2006, CANCER GENET CYTOGEN, V165, P151, DOI 10.1016/j.cancergencyto.2005.08.013; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Dutta J, 2006, ONCOGENE, V25, P6800, DOI 10.1038/sj.onc.1209938; Fujii M, 1996, ONCOGENE, V12, P2193; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; Gupta N, 2008, CANCER RES, V68, P808, DOI 10.1158/0008-5472.CAN-07-3169; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Houben R, 2008, J INVEST DERMATOL, V128, P2003, DOI 10.1038/jid.2008.30; Karakosta A, 2005, J EXP CLIN CANC RES, V24, P505; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kennedy NJ, 2003, GENE DEV, V17, P629, DOI 10.1101/gad.1062903; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; Kralova J, 1996, ONCOGENE, V12, P2595; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Liss AS, 2010, ONCOGENE, V29, P4925, DOI 10.1038/onc.2010.239; Majid SM, 2006, ONCOGENE, V25, P756, DOI 10.1038/sj.onc.1209107; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; Nehyba J, 1997, ONCOGENE, V14, P2881, DOI 10.1038/sj.onc.1201150; Nelson DM, 1998, HUM GENE THER, V9, P2401, DOI 10.1089/hum.1998.9.16-2401; Nielsen C, 2007, CANCER RES, V67, P178, DOI 10.1158/0008-5472.CAN-06-2801; OKUNO H, 1991, ONCOGENE, V6, P1491; Oleinik NV, 2007, ONCOGENE, V26, P7222, DOI 10.1038/sj.onc.1210526; Potapova O, 2002, CANCER RES, V62, P3257; Pratilas CA, 2009, P NATL ACAD SCI USA, V106, P4519, DOI 10.1073/pnas.0900780106; Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Skarpen E, 2008, FASEB J, V22, P466, DOI 10.1096/fj.07-8650com; Suzukawa K, 2002, ENVIRON HEALTH PERSP, V110, P865, DOI 10.1289/ehp.02110865; Tsavachidou D, 2004, CANCER RES, V64, P5556, DOI 10.1158/0008-5472.CAN-04-1669; Ussar S, 2004, J BIOL CHEM, V279, P43861, DOI 10.1074/jbc.M406240200; Whitmarsh AJ, 2007, ONCOGENE, V26, P3172, DOI 10.1038/sj.onc.1210410; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yang YM, 2003, CLIN CANCER RES, V9, P391; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966	50	4	4	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	47					6267	6279		10.1038/onc.2010.359	http://dx.doi.org/10.1038/onc.2010.359			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	685CG	20802521	Green Accepted			2022-12-17	WOS:000284601700008
J	Kotsinas, A; Pateras, IS; Galanos, PS; Karamouzis, MV; Sfikakis, PP; Gorgoulis, VG				Kotsinas, A.; Pateras, I. S.; Galanos, P. S.; Karamouzis, M. V.; Sfikakis, P. P.; Gorgoulis, V. G.			Why is p53-inducible gene 3 rarely affected in cancer?	ONCOGENE			English	Letter							PIG3; P53		[Kotsinas, A.; Pateras, I. S.; Galanos, P. S.; Gorgoulis, V. G.] Univ Athens, Sch Med, Mol Carcinogenesis Grp, Dept Histol & Embryol, GR-11527 Athens, Greece; [Karamouzis, M. V.] Univ Athens, Sch Med, Dept Biol Chem, GR-11527 Athens, Greece; [Sfikakis, P. P.] Univ Athens, Sch Med, Dept Propedeut & Internal Med 1, GR-11527 Athens, Greece	Athens Medical School; National & Kapodistrian University of Athens; Athens Medical School; National & Kapodistrian University of Athens; Athens Medical School; National & Kapodistrian University of Athens	Kotsinas, A (corresponding author), Univ Athens, Sch Med, Mol Carcinogenesis Grp, Dept Histol & Embryol, GR-11527 Athens, Greece.	vgorg@med.uoa.gr	Galanos, Panagiotis/AAR-7690-2021; Gorgoulis, Vassilis/AAD-3630-2019; Sfikakis, Petros/AAD-7289-2019; Karamouzis, Michalis/AAD-2860-2020	Galanos, Panagiotis/0000-0003-1403-4685; Gorgoulis, Vassilis/0000-0001-9001-4112; 				Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Gorgoulis VG, 2004, MUTAT RES-FUND MOL M, V556, P143, DOI 10.1016/j.mrfmmm.2004.07.008; Lee JH, 2010, ONCOGENE, V29, P1431, DOI 10.1038/onc.2009.438; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Nicholls CD, 2004, J BIOL CHEM, V279, P24171, DOI 10.1074/jbc.M401049200	5	4	4	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	37					5220	5220		10.1038/onc.2010.263	http://dx.doi.org/10.1038/onc.2010.263			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650QZ	20603616				2022-12-17	WOS:000281867200011
J	Song, J; Sandoval, R; Pilkinton, MA; Tian, X; Raychaudhuri, P; Colamonici, OR				Song, J.; Sandoval, R.; Pilkinton, M. A.; Tian, X.; Raychaudhuri, P.; Colamonici, O. R.			ARF-induced downregulation of Mip130/LIN-9 protein levels mediates a positive feedback that leads to increased expression of p16(Ink4a) and p19(Arf)	ONCOGENE			English	Article						LIN-9; ARF; p53; senescence and cell cycle	CELL-CYCLE ARREST; GROWTH SUPPRESSION; ONCOGENIC RAS; CDKN2A LOCUS; G(1) CONTROL; B-MYB; SENESCENCE; P53; P14(ARF); GENE	The ARF-MDM2-p53 pathway constitutes one of the most important mechanisms of surveillance against oncogenic transformation, and its inactivation occurs in a large proportion of cancers. Here, we show that ARF regulates Mip130/LIN-9 by inducing its translocation to the nucleolus and decreasing the expression of the Mip130/LIN-9 protein through a post-transcriptional mechanism. The knockdown of Mip130/LIN-9 in p53(-/-) and Arf(-/-) mouse embryonic fibroblasts (MEFs) mimics some effects of ARF, such as the downregulation of B-Myb, impaired induction of G2/M genes, and a decrease in cell proliferation. Importantly, although the knockdown of Mip130/LIN-9 reduced the proliferation of p53 or Arf-null MEFs, only p53(-/-) MEFs showed a senescence-like state and an increase in the expression of Arf and p16. Interestingly, the increase in p16 and ARF is indirect because the Mip130/LIN-9 knockdown decreased the transcription of negative regulators of the Ink4a/Arf locus, such as BUBR1 and CDC6. Chromatin immunoprecipitation assays also reveal that Mip130/LIN-9 occupies the promoters of the BubR1 and cdc6 genes, suggesting that Mip130/LIN-9 is necessary for the expression of these genes. Altogether, these results indicate that there is a feedback mechanism between ARF and Mip130/LIN-9 in which either the increase of ARF or the decrease in Mip130/LIN-9 causes a further increase in the expression of Arf and p16. Oncogene (2010) 29, 1976-1986; doi:10.1038/onc.2009.485; published online 18 January 2010	[Song, J.; Sandoval, R.; Pilkinton, M. A.; Colamonici, O. R.] Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA; [Tian, X.] Northwestern Univ, Feinberg Sch Med, Dept Physiol, Chicago, IL 60611 USA; [Raychaudhuri, P.] Univ Illinois, Dept Biochem Mol Genet, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Northwestern University; Feinberg School of Medicine; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Colamonici, OR (corresponding author), Univ Illinois, Dept Pharmacol, 835 S Wolcott Ave,MC868,Rm E403, Chicago, IL 60612 USA.	ocolamon@uic.edu			National Institutes of Health [RO1 GM81562, NCI-KO1CA127862, T32]; Ruth L Kirschstein National Research Service Award [NOT-OD-06-093]; Training Program in Signal Transduction and Cellular Endocrinology [DK07739]; NATIONAL CANCER INSTITUTE [K01CA127862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM081562] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ruth L Kirschstein National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Training Program in Signal Transduction and Cellular Endocrinology; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Drs Charles Sherr and Martine Roussel, St Jude Children's Research Hospital, for the Arf and p53 plasmid constructs and Arf<SUP>-/-</SUP> and p53<SUP>-/-</SUP> MEFs. This work was supported by Public Health Service Grants RO1 GM81562 (ORC) and NCI-KO1CA127862 (RS) from the National Institutes of Health. JS and MP were supported by NIH Institutional T32 training grants, Ruth L Kirschstein National Research Service Award NOT-OD-06-093 and Training Program in Signal Transduction and Cellular Endocrinology DK07739, respectively.	Baker DJ, 2008, CELL CYCLE, V7, P2795, DOI 10.4161/cc.7.18.6687; Baker DJ, 2008, NAT CELL BIOL, V10, P825, DOI 10.1038/ncb1744; Baker DJ, 2006, J CELL BIOL, V172, P529, DOI 10.1083/jcb.200507081; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Blagosklonny MV, 2006, J CELL PHYSIOL, V209, P592, DOI 10.1002/jcp.20750; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Datta A, 2005, MOL CELL BIOL, V25, P8024, DOI 10.1128/MCB.25.18.8024-8036.2005; Dimri GP, 2005, CANCER CELL, V7, P505, DOI 10.1016/j.ccr.2005.05.025; Du W, 2006, ONCOGENE, V25, P5190, DOI 10.1038/sj.onc.1209651; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Gazzeri S, 1998, CANCER RES, V58, P3926; Gil J, 2004, NAT CELL BIOL, V6, P67, DOI 10.1038/ncb1077; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Gonzalez S, 2006, NATURE, V440, P702, DOI 10.1038/nature04585; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Hartman TK, 2007, NEUROBIOL AGING, V28, P921, DOI 10.1016/j.neurobiolaging.2006.05.012; Hemmati PG, 2005, ONCOGENE, V24, P4114, DOI 10.1038/sj.onc.1208579; Hong Z, 2007, J CELL PHYSIOL, V210, P567, DOI 10.1002/jcp.20919; Isono K, 2005, MOL CELL BIOL, V25, P6694, DOI 10.1128/MCB.25.15.6694-6706.2005; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Kelly-Spratt KS, 2004, PLOS BIOL, V2, P1138, DOI 10.1371/journal.pbio.0020242; Leng XH, 2002, MOL CELL BIOL, V22, P2242, DOI 10.1128/MCB.22.7.2242-2254.2002; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Litovchick L, 2007, MOL CELL, V26, P539, DOI 10.1016/j.molcel.2007.04.015; Modestou M, 2001, CANCER RES, V61, P3145; Muller H, 1997, MOL CELL BIOL, V17, P5508; Normand G, 2005, J BIOL CHEM, V280, P7118, DOI 10.1074/jbc.M412330200; Osterloh L, 2007, EMBO J, V26, P144, DOI 10.1038/sj.emboj.7601478; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pilkinton M, 2007, ONCOGENE, V26, P7535, DOI 10.1038/sj.onc.1210562; Pilkinton M, 2007, J BIOL CHEM, V282, P168, DOI 10.1074/jbc.M609924200; QUELLE DE, 1995, CELL, V83, P993; Saadatmandi N, 2002, CANCER GENE THER, V9, P830, DOI 10.1038/sj.cgt.7700505; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Sandoval R, 2006, EXP CELL RES, V312, P2465, DOI 10.1016/j.yexcr.2006.04.002; Sandoval R, 2009, EXP CELL RES, V315, P2914, DOI 10.1016/j.yexcr.2009.07.014; Schmunis GA, 2007, ISBT SCI SERIES, V2, P6, DOI 10.1111/j.1751-2824.2007.00052.x; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharpless NE, 2004, EXP GERONTOL, V39, P1751, DOI 10.1016/j.exger.2004.06.025; Sharpless NE, 2004, J CLIN INVEST, V113, P160, DOI 10.1172/JCI200420761; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sotillo R, 2001, P NATL ACAD SCI USA, V98, P13312, DOI 10.1073/pnas.241338598; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Voncken JW, 2003, P NATL ACAD SCI USA, V100, P2468, DOI 10.1073/pnas.0434312100; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002	63	4	4	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	13					1976	1986		10.1038/onc.2009.485	http://dx.doi.org/10.1038/onc.2009.485			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	577CV	20101237	Green Accepted			2022-12-17	WOS:000276199600010
J	Dean, J; Hashimoto, K; Tsuji, T; Gautier, V; Hall, WW; Sheehy, N				Dean, J.; Hashimoto, K.; Tsuji, T.; Gautier, V.; Hall, W. W.; Sheehy, N.			Functional interaction of HTLV-1 Tax protein with the POZ domain of the transcriptional repressor BCL6	ONCOGENE			English	Article						HTLV-1; BCL6; Tax 1	T-CELL LEUKEMIA; VIRUS TYPE-I; CENTER B-CELLS; FINGER ENCODING GENE; NF-KAPPA-B; LAZ3/BCL6 ONCOPROTEIN; HISTONE DEACETYLASES; DOWN-REGULATION; TYPE-1 HTLV-1; PDCD2 GENE	The Tax protein encoded by human T-cell leukaemia virus type 1 (HTLV-1) has a pivotal role in T-cell transformation by deregulating cellular signalling pathways. Using the yeast two-hybrid system to screen a human leukocyte cDNA library, we identified BCL6 (B-cell lymphoma 6) as a cellular protein, which interacts with Tax 1. The BCL6 gene encodes a sequence-specific transcriptional repressor that contains a conserved N-terminal poxvirus and zinc finger (POZ) repressor domain and a C-terminal Kruppel-like zinc finger DNA binding domain. Using both in vivo and in vitro methods, we demonstrate that the POZ domain of BCL6 is sufficient for its interaction with Tax 1. Using functional assays, we demonstrate that Tax 1 enhanced the repressive activity of BCL6 and increased the levels of apoptosis induced by BCL6 in osteosarcoma cells indicating that both proteins cooperate in vivo to cause a physiological affect. Furthermore, BCL6 recruited Tax 1 into punctate nuclear structures, which suggests that Tax 1 colocalizes with BCL6 in repressor complexes in vivo. BCL6 expression significantly downregulated both basal and Tax-induced nuclear factor-kappa B and long terminal repeat activation. This suggests that the expression of BCL6 in HTLV infected cells may contribute to the silencing of viral gene expression and to the long clinical latency associated with HTLV infection. Oncogene (2009) 28, 3723-3734; doi: 10.1038/onc.2009.230;published online 24 August 2009	[Dean, J.; Hashimoto, K.; Tsuji, T.; Gautier, V.; Hall, W. W.; Sheehy, N.] Univ Coll Dublin, Sch Med & Med Sci, Ctr Res Infect Dis, Dublin D4, Ireland; [Hashimoto, K.] Itoh Hosp, Dept Neurol, Ibusuki City, Kagoshima, Japan; [Tsuji, T.] Natl Inst Infect Dis, Dept Pathol, Tokyo, Japan	University College Dublin; National Institute of Infectious Diseases (NIID)	Sheehy, N (corresponding author), Univ Coll Dublin, Sch Med & Med Sci, Ctr Res Infect Dis, Dublin D4, Ireland.	Noreen.sheehy@ucd.ie	Gautier, virginie/K-4057-2012	Gautier, virginie/0000-0003-1862-2644; Sheehy, Noreen/0000-0001-5004-0228				Albagli O, 1999, ONCOGENE, V18, P5063, DOI 10.1038/sj.onc.1202892; Albagli O, 2000, MOL CELL BIOL, V20, P8560, DOI 10.1128/MCB.20.22.8560-8570.2000; Albagli O, 1996, BIOCHEM BIOPH RES CO, V220, P911, DOI 10.1006/bbrc.1996.0505; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Baron BW, 2007, P NATL ACAD SCI USA, V104, P7449, DOI 10.1073/pnas.0701770104; Baron BW, 2002, P NATL ACAD SCI USA, V99, P2860, DOI 10.1073/pnas.042702599; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; Cheng J, 2007, BLOOD, V110, P2110, DOI 10.1182/blood-2006-11-058388; Delebecque F, 2002, J VIROL, V76, P7883, DOI 10.1128/JVI.76.15.7883-7889.2002; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; Dhordain P, 1995, ONCOGENE, V11, P2689; Dhordain P, 2000, ONCOGENE, V19, P6240, DOI 10.1038/sj.onc.1203976; Gabet AS, 2003, ONCOGENE, V22, P3734, DOI 10.1038/sj.onc.1206468; GAIDANO G, 1994, BLOOD, V84, P397; GESSAIN A, 1985, LANCET, V2, P407; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; Hasegawa H, 2006, NAT MED, V12, P466, DOI 10.1038/nm1389; Hironaka N, 2004, NEOPLASIA, V6, P266, DOI 10.1593/neo.03388; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; Huynh KD, 2000, GENE DEV, V14, P1810; Hyjek E, 2001, BLOOD, V97, P270, DOI 10.1182/blood.V97.1.270; Ichii H, 2002, NAT IMMUNOL, V3, P558, DOI 10.1038/ni802; Ichii H, 2007, INT IMMUNOL, V19, P427, DOI 10.1093/intimm/dxm007; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Kelly KF, 2006, TRENDS CELL BIOL, V16, P578, DOI 10.1016/j.tcb.2006.09.003; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Kibler KV, 2001, J VIROL, V75, P2161, DOI 10.1128/JVI.75.5.2161-2173.2001; Lemasson I, 2004, MOL CELL BIOL, V24, P6117, DOI 10.1128/MCB.24.14.6117-6126.2004; Lemercier C, 2002, J BIOL CHEM, V277, P22045, DOI 10.1074/jbc.M201736200; Li ZP, 2005, J IMMUNOL, V174, P205, DOI 10.4049/jimmunol.174.1.205; Lu HX, 2004, J VIROL, V78, P6735, DOI 10.1128/JVI.78.13.6735-6743.2004; Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; Mori N, 1999, BLOOD, V93, P2360; Nakayama T, 2008, ONCOGENE, V27, P3221, DOI 10.1038/sj.onc.1210984; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; OSAME M, 1986, LANCET, V1, P1031; Perez-Rosado A, 2008, J PATHOL, V214, P498, DOI 10.1002/path.2279; Phan RT, 2004, NATURE, V432, P635, DOI 10.1038/nature03147; Phan RT, 2005, NAT IMMUNOL, V6, P1054, DOI 10.1038/ni1245; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; Ranuncolo SM, 2008, J BIOL CHEM, V283, P22565, DOI 10.1074/jbc.M803490200; Ranuncolo SM, 2007, NAT IMMUNOL, V8, P705, DOI 10.1038/ni1478; Seyfert VL, 1996, ONCOGENE, V12, P2331; Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7; Sheehy N, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-20; Stogios PJ, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-10-r82; Sun SC, 2005, ONCOGENE, V24, P5952, DOI 10.1038/sj.onc.1208969; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Tsuji T, 2007, J BIOL CHEM, V282, P13875, DOI 10.1074/jbc.M611629200; Yamochi T, 1999, ONCOGENE, V18, P487, DOI 10.1038/sj.onc.1202334; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Zhang H, 2001, BBA-MOL CELL RES, V1540, P188, DOI 10.1016/S0167-4889(01)00128-8; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	64	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2009	28	42					3723	3734		10.1038/onc.2009.230	http://dx.doi.org/10.1038/onc.2009.230			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	509MY	19701248				2022-12-17	WOS:000271023200005
J	Herynk, MH; Lewis, MT; Hopp, TA; Medina, D; Corona-Rodriguez, A; Cui, Y; Beyer, AR; Fuqua, SAW				Herynk, M. H.; Lewis, M. T.; Hopp, T. A.; Medina, D.; Corona-Rodriguez, A.; Cui, Y.; Beyer, A. R.; Fuqua, S. A. W.			Accelerated mammary maturation and differentiation, and delayed MMTVneu-induced tumorigenesis of K303R mutant ER alpha transgenic mice	ONCOGENE			English	Article						breast cancer; estrogen receptor; K303R ER mutation; HER2/neu	ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER; GLAND DEVELOPMENT; HINGE REGION; MUTATION; TUMORS; TRANSACTIVATION; OVEREXPRESSION; ACETYLATION; EXPRESSION	We identified a somatic mutation in estrogen receptor-alpha (ER alpha) in breast cancer causing a lysine to arginine transition (K303R) resulting in hypersensitivity to estrogen, altered associations with coactivators and corepressors and altered posttranslational modifications of ER alpha. We have developed a transgenic mouse expressing the K303R mutant ER alpha under control of the mouse mammary tumor virus (MMTV) promoter. At 4 months of age, K303R ER alpha transgenic animals demonstrate precocious alveolar budding compared with wild-type ER alpha transgenic mice or nontransgenic littermates. Despite these morphologic differences, K303R ER alpha transgenic mice displayed no differences in levels of ER alpha, progesterone receptor or proliferation at this time-point. Pregnancy or chronic estrogen plus progesterone exposure in K303R ER alpha transgenic mice also resulted in significantly more alveolar budding, increased beta-casein production and dilated ducts when compared with nontransgenic littermates. To examine the effects of mutant expression on tumorigenesis, mutant ER alpha mice were crossed with FVB-MMTVneu mice and significantly delayed time to neu-mediated tumorigenesis in bigenic animals. In contrast, mutant expression did not affect carcinogen-induced tumorigenesis. Collectively, these data demonstrate that aberrant estrogenic signaling through the K303R ER alpha mutation may lead to precocious alveolar budding in virgin mice, and to an expedited maturation and differentiation phenotype in the mammary glands of hormonally stimulated animals. Oncogene (2009) 28, 3177-3187; doi: 10.1038/onc.2009.174; published online 29 June 2009	[Herynk, M. H.; Lewis, M. T.; Hopp, T. A.; Medina, D.; Corona-Rodriguez, A.; Cui, Y.; Beyer, A. R.; Fuqua, S. A. W.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA	Baylor College of Medicine	Fuqua, SAW (corresponding author), Baylor Coll Med, Lester & Sue Smith Breast Ctr, 1 Baylor Plaza,MS 600,N1200 Alkek, Houston, TX 77030 USA.	sfuqua@bcm.edu	Lewis, Michael T/A-9572-2009		NIH/NCI [CA72038, DAMD17-03-1-0417]; NATIONAL CANCER INSTITUTE [R01CA072038] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Gary Chamness for editorial assistance and Ms Robin Sample for administrative assistance. This work was supported by NIH/NCI CA72038 to SAWF, and by DAMD17-03-1-0417 to MHH.	Bershtein LM, 2003, B EXP BIOL MED+, V135, P580, DOI 10.1023/A:1025437620749; Bocchinfuso WP, 1997, J MAMMARY GLAND BIOL, V2, P323, DOI 10.1023/A:1026339111278; BORRAS M, 1994, J STEROID BIOCHEM, V48, P325, DOI 10.1016/0960-0760(94)90072-8; Conway K, 2005, BREAST CANCER RES, V7, pR871, DOI 10.1186/bcr1315; Cui Y, 2004, CANCER RES, V64, P9199, DOI 10.1158/0008-5472.CAN-04-2126; Cui YK, 2006, MOL ENDOCRINOL, V20, P2020, DOI 10.1210/me.2005-0063; Cullinane CA, 2005, INT J CANCER, V117, P988, DOI 10.1002/ijc.21273; Davies MPA, 2005, BREAST CANCER RES, V7, pR113, DOI 10.1186/bcr965; DURBAN EM, 1985, DEV BIOL, V109, P288, DOI 10.1016/0012-1606(85)90456-7; Frech MS, 2005, CANCER RES, V65, P681; Fuqua SAW, 2000, CANCER RES, V60, P4026; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Guzman RC, 1999, P NATL ACAD SCI USA, V96, P2520, DOI 10.1073/pnas.96.5.2520; Herynk MH, 2007, CLIN CANCER RES, V13, P3235, DOI 10.1158/1078-0432.CCR-06-2608; Herynk MH, 2004, ENDOCR REV, V25, P869, DOI 10.1210/er.2003-0010; IP MM, 2000, METHODS MAMMARY GLAN, V16; Jin ZM, 2002, J NUTR, V132, P3186, DOI 10.1093/jn/131.10.3186; Lavrovsky Y, 1998, TRANSGENIC RES, V7, P319, DOI 10.1023/A:1008838616203; MEDINA D, 1974, J NATL CANCER I, V53, P213, DOI 10.1093/jnci/53.1.213; Medina D, 2004, CLIN CANCER RES, V10, p380S, DOI 10.1158/1078-0432.CCR-031211; Mishra SK, 2003, J BIOL CHEM, V278, P19209, DOI 10.1074/jbc.M301968200; Rajkumar L, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1645; Richert MM, 2000, J MAMMARY GLAND BIOL, V5, P227, DOI 10.1023/A:1026499523505; Russo J, 2004, MATURITAS, V49, P2, DOI 10.1016/j.maturitas.2004.04.011; Sentis S, 2005, MOL ENDOCRINOL, V19, P2671, DOI 10.1210/me.2005-0042; Tekmal RR, 2007, J STEROID BIOCHEM, V106, P111, DOI 10.1016/j.jsbmb.2007.05.009; Tilli MT, 2003, AM J PATHOL, V163, P1713, DOI 10.1016/S0002-9440(10)63529-8; Tokunaga E, 2004, BREAST CANCER RES TR, V84, P289, DOI 10.1023/B:BREA.0000019963.67754.93; Wang CG, 2001, J BIOL CHEM, V276, P18375, DOI 10.1074/jbc.M100800200; Yang XH, 2003, CANCER RES, V63, P2425	30	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2009	28	36					3177	3187		10.1038/onc.2009.174	http://dx.doi.org/10.1038/onc.2009.174			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492QF	19561644	Green Accepted			2022-12-17	WOS:000269673400001
J	Klucky, B; Wintersberger, E				Klucky, B.; Wintersberger, E.			Polyomavirus small T antigen transactivates genes by its ability to provoke the synthesis and the stabilization of MYC	ONCOGENE			English	Article						polyomavirus; T antigens; MYC; S-phase induction	SIMIAN-VIRUS-40 SMALL-T; PROTEIN PHOSPHATASE 2A; HUMAN CELL-TRANSFORMATION; SMALL TUMOR-ANTIGEN; MOUSE FIBROBLASTS; CYCLIN-A; S-PHASE; C-MYC; INDUCTION; PATHWAY	DNA tumor viruses are capable of driving quiescent cells into the cell cycle. In case of polyomaviridae, two viral proteins, the large and the small ( ST) T antigens are responsible for this outcome. ST interacts with the protein phosphatase PP2A and with chaperons of the dnaK type and leads to the transactivation of several genes, which play a role in S-phase induction. One of these is the transcription factor myelocytomatosis ( MYC), which by itself is an important regulator of growth. Microarray analysis has revealed several ST-induced genes, which are also targets of MYC; hence, ST may induce these genes via MYC. Experiments shown here are in line with this assumption. MYC-regulated genes are induced by ST at later times than MYC and a MYC responsive promoter is stimulated by ST. Regulation of MYC occurs through signal transduction pathways, which are co-ordinated by PP2A suggesting that they may be targets of ST. Here, we show that this is the case as important kinases involved in these pathways appear in the active phosphorylated form in the presence of ST. Inhibition of these kinases interferes with MYC induction and inhibition of MYC activity blocks ST-mediated transactivation.	Med Univ Vienna, Dept Med Biochem, Div Mol Biol, MFPL, A-1030 Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Wintersberger, E (corresponding author), Med Univ Vienna, Dept Med Biochem, Div Mol Biol, MFPL, Dr Bohrgasse 9, A-1030 Vienna, Austria.	erhard.wintersberger@meduniwien.ac.at						Barker N, 2000, ADV CANCER RES, V77, P1; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Howe AK, 1998, J VIROL, V72, P9637, DOI 10.1128/JVI.72.12.9637-9644.1998; Klucky B, 2004, ONCOGENE, V23, P4707, DOI 10.1038/sj.onc.1207640; Levens DL, 2003, GENE DEV, V17, P1071, DOI 10.1101/gad.1095203; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Nemethova M, 2004, MOL CELL BIOL, V24, P10986, DOI 10.1128/MCB.24.24.10986-10994.2004; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; OGRIS E, 1992, J VIROL, V66, P53, DOI 10.1128/JVI.66.1.53-61.1992; PASSAMATO R, 2004, CANCER CELL, V5, P127; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; Pelengaris S, 2003, ARCH BIOCHEM BIOPHYS, V416, P129, DOI 10.1016/S0003-9861(03)00294-7; Porras A, 1996, J VIROL, V70, P6902; Porras A, 1999, J VIROL, V73, P3102; Reiss K, 2003, ONCOGENE, V22, P6517, DOI 10.1038/sj.onc.1206959; Schuchner S, 2001, J VIROL, V75, P6498, DOI 10.1128/JVI.75.14.6498-6507.2001; Schuchner S, 1999, J VIROL, V73, P9266; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Sullivan CS, 2002, MICROBIOL MOL BIOL R, V66, P179, DOI 10.1128/MMBR.66.2.179-202.2002; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yu J, 2001, VIROLOGY, V290, P192, DOI 10.1006/viro.2001.1204	28	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2007	26	43					6356	6360		10.1038/sj.onc.1210458	http://dx.doi.org/10.1038/sj.onc.1210458			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17438527				2022-12-17	WOS:000249583300012
J	Dow, LE; Kauffman, JS; Caddy, J; Zarbalis, K; Peterson, AS; Jane, SM; Russell, SM; Humbert, PO				Dow, L. E.; Kauffman, J. S.; Caddy, J.; Zarbalis, K.; Peterson, A. S.; Jane, S. M.; Russell, S. M.; Humbert, P. O.			The tumour-suppressor scribble dictates cell polarity during directed epithelial migration: regulation of Rho GTPase recruitment to the leading edge (vol 26, pg 2272, 2007)	ONCOGENE			English	Correction									Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Dow, LE (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.		Humbert, Patrick O/L-4264-2016; Jane, Stephen/D-6659-2011	Humbert, Patrick O/0000-0002-1366-6691; 				Dow LE, 2007, ONCOGENE, V26, P2272, DOI 10.1038/sj.onc.1210016	1	4	4	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	38					5692	5692		10.1038/sj.onc.1210639	http://dx.doi.org/10.1038/sj.onc.1210639			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS		Bronze			2022-12-17	WOS:000248801900016
J	Mayelzadeh, F; Martinez, JD				Mayelzadeh, F.; Martinez, J. D.			DNA binding and selective gene induction by different forms of the p53 protein	ONCOGENE			English	Article						conformation; transactivation; chromatin immunoprecipitation	WILD-TYPE P53; MUTANT P53; CELLS; LOCALIZATION; ACTIVATION; EXPRESSION; MUTATIONS; COMPLEX; GROWTH	P53 is a tumor suppressor gene that plays a crucial role in suppressing tumorigenesis by inducing either cell cycle arrest or apoptosis in cells with DNA damage. In more than 50% of tumors p53 is inactivated by gene mutations. However, there have also been reports of tumor cells in which p53 remains wild type and is present in elevated concentrations. Here we utilized a set of mutant cell lines, which, unlike the parental A1-5 cell line, which expresses a mouse tsp53 and becomes growth arrested at 32 degrees C, are capable of growth at this same incubation temperature. We found that the tsp53 in the two cell lines, ALTR-17 and ALTR-24, was identical to the parental A1-5s and concentrated in the nucleus at 32 degrees C. Examination of both lines revealed that p21 was induced at 32 degrees C, although to a lesser extent than in parental cells and that the p21 genes were not mutated. Interestingly, evaluation of the conformation of tsp53 using conformation-specific antibodies showed that the protein existed in different forms, which were found to bind DNA using chromatin immunoprecipitation assays and which we showed could induce expression of a p21 reporter construct. We conclude that the tsp53 may exist in various forms capable of binding DNA.	Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA; Univ Arizona, Genet Grad Interdisciplinary Program, Tucson, AZ USA; Univ Arizona, Dept Cell Biol & Anat, Tucson, AZ USA	Arizona Center Cancer Care; University of Arizona; University of Arizona; University of Arizona	Martinez, JD (corresponding author), Univ Arizona, Arizona Canc Ctr, 1515 N Campbell Ave,POB 245024, Tucson, AZ 85724 USA.	jmartinez@azcc.arizona.edu			NATIONAL CANCER INSTITUTE [R01CA090776] Funding Source: NIH RePORTER; NCI NIH HHS [CA090776] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARENJEE S, 2004, MOL CELL BIOL, V24, P2052; BARTEK J, 1990, ONCOGENE, V5, P893; Benchimol S, 2001, CELL DEATH DIFFER, V8, P1049, DOI 10.1038/sj.cdd.4400918; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gaitonde SV, 2000, ONCOGENE, V19, P4042, DOI 10.1038/sj.onc.1203756; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Martinez JD, 1997, ONCOGENE, V14, P2511, DOI 10.1038/sj.onc.1201095; McLure KG, 1999, EMBO J, V18, P763, DOI 10.1093/emboj/18.3.763; MOLL R, 1992, AM J PATHOL, V140, P427; Qiao DH, 2001, CARCINOGENESIS, V22, P957, DOI 10.1093/carcin/22.6.957; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Watts GS, 2004, NEOPLASIA, V6, P187, DOI 10.1593/neo.03292; Wolff A, 2001, ONCOGENE, V20, P1307, DOI 10.1038/sj.onc.1204251; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	24	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2007	26	21					2955	2963		10.1038/sj.onc.1210110	http://dx.doi.org/10.1038/sj.onc.1210110			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17130840	Green Accepted			2022-12-17	WOS:000246395400001
J	Nilsson, LM; Keller, UB; Yang, C; Nilsson, JA; CLeveland, JL; Roussel, MF				Nilsson, L. M.; Keller, U. B.; Yang, C.; Nilsson, J. A.; CLeveland, J. L.; Roussel, M. F.			Ink4c is dispensable for tumor suppression in Myc-induced B-cell lymphomagenesis	ONCOGENE			English	Article						p18(Ink4c); Arf; Myc; lymphomagenesis	CDK INHIBITOR P18(INK4C); INDUCED APOPTOSIS; CYCLE ARREST; EXPRESSION; MICE; INDUCTION; GROWTH; GENE; DIFFERENTIATION; PROLIFERATION	p18(Ink4c) functions as a dedicated inhibitor of cyclin-D-dependent kinases. Loss of Ink4c predisposes mice to tumor development and, in a dose-dependent manner, complements the tumor-promoting effects of various oncogenes. We have now addressed whether Ink4c loss impacts B-cell tumor development in the E mu-Myc transgenic mouse, a model of human Burkitt lymphoma. Loss of one or both alleles did not influence the onset of lymphoma in E mu-Myc transgenics, and did not appreciably affect Myc's proliferative or apoptotic responses in precancerous B cells. Nevertheless, Ink4c loss modulated the effects of Myc-induced transformation by decreasing the frequency of Arf loss, an ordinarily common event in E mu-Myc-induced lymphomas.	St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Umea Univ, Dept Mol Biol, Umea, Sweden	St Jude Children's Research Hospital; St Jude Children's Research Hospital; Umea University	Roussel, MF (corresponding author), St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, 332 N Lauderdale St, Memphis, TN 38105 USA.	martine.roussel@stjude.org	Nilsson, Jonas/E-5346-2013; Roussel, Martine F/F-1469-2016	Roussel, Martine F/0000-0002-1740-8139; Nilsson, Jonas/0000-0003-0346-6837	NCI NIH HHS [CA-21765, R01 CA-76379, CA-71907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, R01CA076379, P01CA071907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ASKEW DS, 1991, ONCOGENE, V6, P1915; Bai F, 2003, MOL CELL BIOL, V23, P1269, DOI 10.1128/MCB.23.4.1269-1277.2003; Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; CREWS S, 1982, SCIENCE, V218, P1319, DOI 10.1126/science.7146913; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Damo LA, 2005, MOL CARCINOGEN, V42, P109, DOI 10.1002/mc.20068; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2002, CANCER RES, V62, P2184; Eischen CM, 2001, MOL CELL BIOL, V21, P7653, DOI 10.1128/MCB.21.22.7653-7662.2001; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Franciotta D, 1998, CEPHALALGIA, V18, P4, DOI 10.1046/j.1468-2982.1998.1801001-5.x; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; JACOBSEN KA, 1994, BLOOD, V84, P2784; Kamijo T, 1999, CANCER RES, V59, P2464; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Knoepfler PS, 2002, GENE DEV, V16, P2699, DOI 10.1101/gad.1021202; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Kulkarni MS, 2002, LEUKEMIA, V16, P127, DOI 10.1038/sj.leu.2402328; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Maclean KH, 2003, MOL CELL BIOL, V23, P7256, DOI 10.1128/MCB.23.20.7256-7270.2003; Morishita A, 2004, HEPATOLOGY, V40, P677, DOI 10.1002/hep.20337; Morse L, 1997, IMMUNITY, V6, P47, DOI 10.1016/S1074-7613(00)80241-1; Nilsson JA, 2005, CANCER CELL, V7, P433, DOI 10.1016/j.ccr.2005.03.036; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; NOWAK NJ, 2005, CURRENT PROTOCOLS HU; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; QUELLE DE, 1995, CELL, V83, P993; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sanchez-Aguilera A, 2004, BLOOD, V103, P2351, DOI 10.1182/blood-2003-07-2356; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Snijders AM, 2005, GENOME RES, V15, P302, DOI 10.1101/gr.2902505; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Tourigny MR, 2002, IMMUNITY, V17, P179, DOI 10.1016/S1074-7613(02)00364-3; Uziel T, 2005, GENE DEV, V19, P2656, DOI 10.1101/gad.1368605; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Yang Y, 2001, BLOOD CELL MOL DIS, V27, P1, DOI 10.1006/bcmd.2000.0344; Zindy F, 2003, CANCER RES, V63, P5420	52	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2007	26	20					2833	2839		10.1038/sj.onc.1210104	http://dx.doi.org/10.1038/sj.onc.1210104			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17099725				2022-12-17	WOS:000246210800003
J	Rockstroh, A; Kleinert, A; Kramer, M; Grosse, F; Soe, K				Rockstroh, A.; Kleinert, A.; Kramer, M.; Grosse, F.; Soe, K.			Cellular stress triggers the human topoisomerase I damage response independently of DNA damage in a p53 controlled manner	ONCOGENE			English	Article						apoptosis; damage response; p53; topoisomerase I; colcemid; TNF alpha	CLEAVAGE COMPLEXES; HYDROGEN-PEROXIDE; INDUCED APOPTOSIS; INDUCTION; CELLS; FRAGMENTATION; POLYMERASE; CASPASE-3; ADDUCTS; REPAIR	The 'human topoisomerase I (htopoI) damage response' was reported to be triggered by various kinds of DNA lesions. Also, a high and persistent level of htopoI cleavage complexes correlated with apoptosis. In the present study, we demonstrate that DNA damage-independent induction of cell death using colcemid and tumor necrosis factor a is also accompanied by a strong htopoI response that correlates with the onset of apoptotic hallmarks. Consequently, these results suggest that htopoI cleavage complex formation may be caused by signaling pathways independent of the kind of cellular stress. Thus, protein interactions or signaling cascades induced by DNA damage or cellular stress might lead to the formation of stabilized cleavage complexes rather than the DNA lesion itself. Finally, we show that p53 not only plays a key role in the regulation of the htopoI response to UV-C irradiation but also to treatment with colcemid.	Fritz Lipmann Inst eV, Leibniz Inst Age Res, Biochem, D-07745 Jena, Germany	Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI)	Soe, K (corresponding author), Fritz Lipmann Inst eV, Leibniz Inst Age Res, Biochem, Beutenbergstr 11, D-07745 Jena, Germany.	kent@fli-leibniz.de	Soe, Kent/N-3618-2017	Soe, Kent/0000-0001-7402-314X				ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Daroui P, 2004, J BIOL CHEM, V279, P14587, DOI 10.1074/jbc.M311370200; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Huppertz B, 1999, ANAT EMBRYOL, V200, P1, DOI 10.1007/s004290050254; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Lanza A, 1996, J BIOL CHEM, V271, P6978, DOI 10.1074/jbc.271.12.6978; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Mao YH, 2000, CANCER RES, V60, P4538; Mao YH, 2003, DNA REPAIR, V2, P1115, DOI 10.1016/S1568-7864(03)00122-8; Pommier Y, 2002, J BIOL CHEM, V277, P13666, DOI 10.1074/jbc.M200209200; Pommier Y, 2000, P NATL ACAD SCI USA, V97, P2040, DOI 10.1073/pnas.040397497; Pourquier P, 2000, P NATL ACAD SCI USA, V97, P1885, DOI 10.1073/pnas.97.4.1885; Pourquier P, 2002, CLIN CANCER RES, V8, P2499; Pourquier P, 2001, CANCER RES, V61, P53; Pourquier P, 1997, J BIOL CHEM, V272, P26441, DOI 10.1074/jbc.272.42.26441; Pourquier P, 1999, J BIOL CHEM, V274, P8516, DOI 10.1074/jbc.274.13.8516; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; Pourquier P, 1998, J BIOL CHEM, V273, P27245, DOI 10.1074/jbc.273.42.27245; ROSEN A, 1995, J EXP MED, V181, P1557, DOI 10.1084/jem.181.4.1557; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Samejima K, 1999, J BIOL CHEM, V274, P4335, DOI 10.1074/jbc.274.7.4335; SHERWOOD SW, 1994, EXP CELL RES, V215, P373, DOI 10.1006/excr.1994.1354; Soe K, 2004, DNA REPAIR, V3, P387, DOI 10.1016/j.dnarep.2003.12.003; Sordet O, 2004, J BIOL CHEM, V279, P50499, DOI 10.1074/jbc.M410277200; Sordet O, 2004, J BIOL CHEM, V279, P33968, DOI 10.1074/jbc.M404620200; STEWART AF, 1990, CELL, V60, P141; Subramanian D, 1998, CANCER RES, V58, P976; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651	33	4	4	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					123	131		10.1038/sj.onc.1209766	http://dx.doi.org/10.1038/sj.onc.1209766			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799632				2022-12-17	WOS:000243236500012
J	Kiser, KF; Colombi, M; Moroni, C				Kiser, K. F.; Colombi, M.; Moroni, C.			Isolation and characterization of dominant and recessive IL-3-independent hematopoietic transformants	ONCOGENE			English	Article						mutagenesis; Raf-1; ICR191; mast cells; stat	COLONY-STIMULATING FACTOR; ABROGATE CYTOKINE DEPENDENCY; MESSENGER-RNA TURNOVER; BCR-ABL; AUTOCRINE TRANSFORMATION; DIFFERENTIAL ABILITIES; SIGNAL-TRANSDUCTION; FACTOR-INDEPENDENCE; PREVENT APOPTOSIS; BETA-SUBUNIT	Retroviral integration mutagenesis and treatment with the frameshift mutagen ICR191 were used to transform v-H-ras expressing PB-3c cells to interleukin-3 (IL-3) independence. Six clones displayed viral integrations into the 30 region of the IL-3 gene thus acting posttranscriptionally by disrupting the AU-rich instability element. Two clones contained reverse orientation integration into the raf-1 gene revealing an enhancer insertion mechanism. Growth by this mechanism was sensitive to the Raf-1 inhibitor BAY 43-9006 and the Mek inhibitor U0126. Following treatment with ICR191, IL-3-independent clones were recovered and studied by cell fusion. With 21/22 clones, IL-3 independence resulted from a recessive mechanism as cellular hybrids with parental cells reverted to IL-3 dependence. Recessive clone D2c displayed increased phospho-Erk1/2 levels and was growth sensitive to U0126, but not to BAY43-9006. The single dominant clone, D5a, showed no signs of mitogen-activated protein kinases pathway activation but displayed constitutive phosphorylation of Stat5. We conclude that PB-3c has several options to acquire IL-3 growth autonomy involving transcriptional or posttranscriptional mechanisms affecting the distal regulators Erk or Stat5. The reported panel of independent dominant and recessive transformants should provide a useful tool for inhibitor profiling.	Univ Basel, Dept Clin Biol Sci, Inst Med Microbiol, CH-4051 Basel, Switzerland	University of Basel	Moroni, C (corresponding author), Univ Basel, Dept Clin Biol Sci, Inst Med Microbiol, Peterspl 10, CH-4051 Basel, Switzerland.	christoph.moroni@unibas.ch						ALGATE PA, 1993, ONCOGENE, V8, P1221; ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; Benjamin D, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh086; Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; Blalock WL, 2000, ONCOGENE, V19, P526, DOI 10.1038/sj.onc.1203337; DANDREA R, 1994, BLOOD, V83, P2802, DOI 10.1182/blood.V83.10.2802.2802; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HANNEMANN J, 1995, MOL CELL BIOL, V15, P2402; Hayakawa F, 2000, ONCOGENE, V19, P624, DOI 10.1038/sj.onc.1203354; HIRSCH HH, 1993, J EXP MED, V178, P403, DOI 10.1084/jem.178.2.403; Hoyle PE, 2000, LEUKEMIA, V14, P642, DOI 10.1038/sj.leu.2401720; IHLE JN, 1981, J IMMUNOL, V127, P2565; Jiang XY, 2002, BLOOD, V100, P3731, DOI 10.1182/blood-2002-05-1324; Joung YH, 2003, EXP MOL MED, V35, P350, DOI 10.1038/emm.2003.46; Liu CB, 1999, J BIOL CHEM, V274, P6342, DOI 10.1074/jbc.274.10.6342; McCormack MP, 1997, BLOOD, V90, P1471, DOI 10.1182/blood.V90.4.1471.1471_1471_1481; McCubrey JA, 2004, ONCOGENE, V23, P7810, DOI 10.1038/sj.onc.1208055; McCubrey JA, 1998, LEUKEMIA, V12, P1903, DOI 10.1038/sj.leu.2401215; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Nagata Y, 1996, BIOCHEM BIOPH RES CO, V221, P785, DOI 10.1006/bbrc.1996.0674; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; Nosaka T, 2002, EXP HEMATOL, V30, P697, DOI 10.1016/S0301-472X(02)00808-1; Onishi M, 1996, BLOOD, V88, P1399, DOI 10.1182/blood.V88.4.1399.bloodjournal8841399; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Onishi M, 1996, EXP HEMATOL, V24, P324; OVERELL RW, 1987, MOL CELL BIOL, V7, P3394, DOI 10.1128/MCB.7.10.3394; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; Piao XH, 1996, BLOOD, V87, P3117, DOI 10.1182/blood.V87.8.3117.bloodjournal8783117; Shelton JG, 2003, ONCOGENE, V22, P2478, DOI 10.1038/sj.onc.1206321; SHOUNAN Y, 1995, EXP HEMATOL, V23, P492; Steelman LS, 2004, LEUKEMIA, V18, P189, DOI 10.1038/sj.leu.2403241; Stoecklin G, 2003, ONCOGENE, V22, P3554, DOI 10.1038/sj.onc.1206418; STOECKLIN G, 1994, J BIOL CHEM, V269, P28591; Stoecklin G, 2002, EMBO J, V21, P4709, DOI 10.1093/emboj/cdf444; Testa U, 2004, LEUKEMIA, V18, P219, DOI 10.1038/sj.leu.2403224; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0	38	4	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2006	25	50					6595	6603		10.1038/sj.onc.1209673	http://dx.doi.org/10.1038/sj.onc.1209673			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16702946				2022-12-17	WOS:000241569700004
J	Zhang, J; Lahti, JM; Bruce, A; He, L; Parihar, K; Fan, C; Grenet, J; Liu, L; Kidd, VJ; Cormier, S; Tang, D				Zhang, J.; Lahti, J. M.; Bruce, A.; He, L.; Parihar, K.; Fan, C.; Grenet, J.; Liu, L.; Kidd, V. J.; Cormier, S.; Tang, D.			Identification of an ataxia telangiectasia-mutated protein mediated surveillance system to regulate Bcl-2 overexpression	ONCOGENE			English	Article						Bcl-2; ATM; p53; oncogene surveillance system	CELL-CYCLE ENTRY; NEGATIVE BREAST-CANCER; DNA-DAMAGE; TUMOR-SUPPRESSOR; PARADOXICAL INHIBITION; PROGNOSTIC MARKERS; TRANSGENIC MICE; CYTOCHROME-C; P53; APOPTOSIS	Bcl-2 can both promote and attenuate tumorigenesis. Although the former function is relatively well characterized, the mechanism of the latter remains elusive. We report here that enforced Bcl-2 expression in MCF7 cells stabilizes p53, induces phosphorylation of p53 serine 15 (p53pSer15) and inhibits MCF7 cell growth. Consistent with p53 Ser15 being a target of ataxia telangiectasia mutated protein(ATM)/ATR (ATM- and rad3-related) in the DNA damage response, Bcl-2 activates ATM by inducing ATM Ser1981 phosphorylation, which is accompanied with the phosphorylaton of two additional ATM substrates, Chk2 Thr68 and H2AX Ser139. Downregulation of ATM using a specific small interference RNA fragment (ATMRNAi) abolished Bcl-2-induced p53pSer15 and Bcl-2-mediated growth inhibition of MCF7 cells. Ectopic expression of a dominant-negative p53 mutant, p53175H, partially rescued this growth inhibition. Taken together, these observations demonstrate the contribution of ATM-p53 function to Bcl-2-mediated inhibition of MCF7 cell growth, indicating an ATM- mediated surveillance system for regulating Bcl-2 overexpression. Consistent with this concept, we found that MCF7 cells express Bcl-2 heterogeneously with 34.5% of cells being Bcl-2 negative. In general, Bcl-2-positive MCF7 cells proliferate slower than those of Bcl-2 negative. Thus, we provide evidence suggesting that activation of ATM suppresses Bcl-2-induced tumorigenesis, and that attenuation of ATM function may be an important event in breast cancer progression.	St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA; McMaster Univ, Dept Med, Div Nephrol, Hamilton, ON, Canada; McMaster Univ, St Josephs Hosp, Father Sean OSullivan Res Inst, Hamilton, ON, Canada	St Jude Children's Research Hospital; McMaster University; McGill University; McMaster University	Lahti, JM (corresponding author), St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, 332 N Lauderdale, Memphis, TN 38105 USA.	jill.lahti@stjude.org.or; damut@mcmaster.ca	Tang, Damu/AAQ-1786-2021; Lahti, Jari/P-7987-2018	Tang, Damu/0000-0002-3282-9521; Lahti, Jari/0000-0002-4310-5297	NCI NIH HHS [CA67938] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA067938, R01CA067938] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; Chang J, 2003, CANCER-AM CANCER SOC, V97, P545, DOI 10.1002/cncr.11083; Charpin C, 1998, J CLIN ONCOL, V16, P2025, DOI 10.1200/JCO.1998.16.6.2025; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Cong F, 1999, ONCOGENE, V18, P7731, DOI 10.1038/sj.onc.1203290; Daidone MG, 1999, ENDOCR-RELAT CANCER, V6, P61, DOI 10.1677/erc.0.0060061; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; de la Coste A, 1999, CANCER RES, V59, P5017; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; GEE JMW, 1994, INT J CANCER, V59, P619, DOI 10.1002/ijc.2910590508; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; HELLEMANS P, 1995, BRIT J CANCER, V72, P354, DOI 10.1038/bjc.1995.338; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Jager JJ, 2002, APOPTOSIS, V7, P361, DOI 10.1023/A:1016179530785; JOENSUU H, 1994, AM J PATHOL, V145, P1191; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kirkin V, 2004, BBA-MOL CELL RES, V1644, P229, DOI 10.1016/j.bbamcr.2003.08.009; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Le MG, 1999, INT J CANCER, V84, P562, DOI 10.1002/(SICI)1097-0215(19991222)84:6<562::AID-IJC4>3.0.CO;2-0; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Li YX, 2004, ONCOGENE, V23, P7355, DOI 10.1038/sj.onc.1207957; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; LIPPONEN P, 1995, J PATHOL, V177, P49, DOI 10.1002/path.1711770109; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; Murphy KL, 1999, ONCOGENE, V18, P6597, DOI 10.1038/sj.onc.1203099; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; PIETENPOL JA, 1994, CANCER RES, V54, P3714; Saintigny Y, 2001, EMBO J, V20, P2596, DOI 10.1093/emboj/20.10.2596; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; TSUIMOTO Y, 1984, SCIENCE, V266, P1097; Vairo G, 1996, ONCOGENE, V13, P1511; vanSlooten HJ, 1996, BRIT J CANCER, V74, P78, DOI 10.1038/bjc.1996.319; YANG J, 1997, SCIENCE, V275, P1132; Youn CK, 2005, NAT CELL BIOL, V7, P137, DOI 10.1038/ncb1215; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	48	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2006	25	41					5601	5611		10.1038/sj.onc.1209565	http://dx.doi.org/10.1038/sj.onc.1209565			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16636671				2022-12-17	WOS:000240599100002
J	Shai, R; Shi, T; Kremen, TJ; Horvath, S; Liau, LM; Cloughesy, TF; Mischel, PS; Nelson, SF				Shai, R.; Shi, T.; Kremen, T. J.; Horvath, S.; Liau, L. M.; Cloughesy, T. F.; Mischel, P. S.; Nelson, S. F.			Gene expression profiling identifies molecular subtypes of gliomas (vol 22, pg 4918, 2003)	ONCOGENE			English	Correction													Cloughesy, Timothy Francis/AGV-1013-2022; Nelson, Stanley F/D-4771-2009	Nelson, Stanley F/0000-0002-2082-3114; Kremen, Thomas/0000-0003-1643-4869; Liau, Linda/0000-0002-4053-0052				YANG X, 2003, ONCOGENE, V22, P4918	1	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	30					4256	4256		10.1038/sj.onc.1209746	http://dx.doi.org/10.1038/sj.onc.1209746			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA		Bronze			2022-12-17	WOS:000239004800015
J	Fei, JW; Angel, P; Wei, QX; de Villiers, EM				Fei, J-W; Angel, P.; Wei, Q-X; de Villiers, E-M			TAp63 alpha indirectly regulates a cutaneous HPV promoter through complex formation with Jun family members	ONCOGENE			English	Article						TAp63 alpha; Jun; HPV 20; mtp53 R248W	C-JUN; HUMAN PAPILLOMAVIRUSES; AP-1 SUBUNITS; P53 HOMOLOG; P63; CELL; PROTEINS; DELTA-NP63-ALPHA; FOS; P73	The p63 alpha isoforms of the p53 family have been demonstrated to play a crucial role in the development and differentiation of the skin. We show that expression of the TAp63 alpha isoform leads to an upregulation of the cutaneous papillomavirus HPV 20 promoter, which is increased at least three-fold when c-Jun is co-expressed, in contrast to a minimal increase in activity in the presence of c-Jun alone. Co-expression of TAp63 alpha with JunB or JunD, respectively, and in combination, leads to a reduction in the viral promoter activation measured by the expression of TAp63 alpha alone. JunB and JunD also inhibits the additive effect exerted on the TAp63a activation by c-Jun. Co-immunoprecipitation assays demonstrate a complex formation of c-Jun, JunB and JunD with TAp 63 alpha through the SAM domain mediating protein-protein interactions, which is characteristic for p63 alpha. Co-expression of p53 mutant R248W not only downregulates the differential modulation of the viral promoter by TAp63 alpha alone and in the presence of the Jun family members, but leads to a reduction in the protein levels of the overexpressed c-Jun, JunB, JunD, as well as TAp63 alpha. This model system provides insight into yet unknown pathways through which TAp63 alpha and Jun may cooperate in the pathogenesis of HPV associated cutaneous lesions.	Deutsch Krebsforschungszentrum, Div Characterizat Tumorviruses, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	de Villiers, EM (corresponding author), Deutsch Krebsforschungszentrum, Div Characterizat Tumorviruses, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	e.devilliers@dkfz.de	Piris, Miguel A/AAP-1445-2020	Piris, Miguel A/0000-0001-5839-3634				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Angel P, 2002, BIOCHEM PHARMACOL, V64, P949, DOI 10.1016/S0006-2952(02)01158-9; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; BOSSYWETZEL E, 1992, GENE DEV, V6, P2340, DOI 10.1101/gad.6.12a.2340; Caldeira S, 2003, J VIROL, V77, P2195, DOI 10.1128/JVI.77.3.2195-2206.2003; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; de Villiers EM, 1999, SEMIN CANCER BIOL, V9, P413, DOI 10.1006/scbi.1999.0145; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Duijf PHG, 2002, HUM MOL GENET, V11, P799, DOI 10.1093/hmg/11.7.799; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Fehrmann F, 2003, ONCOGENE, V22, P5201, DOI 10.1038/sj.onc.1206554; Fei JW, 2005, CELL CYCLE, V4, P689, DOI 10.4161/cc.4.5.1653; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Ghioni P, 2002, MOL CELL BIOL, V22, P8659, DOI 10.1128/MCB.22.24.8659-8668.2002; Green H, 2003, P NATL ACAD SCI USA, V100, P15625, DOI 10.1073/pnas.0307226100; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Irwin MS, 2001, APOPTOSIS, V6, P17, DOI 10.1023/A:1009663809458; Jackson S, 2000, ONCOGENE, V19, P592, DOI 10.1038/sj.onc.1203339; Kim CA, 2003, TRENDS BIOCHEM SCI, V28, P625, DOI 10.1016/j.tibs.2003.11.001; King KE, 2003, ONCOGENE, V22, P3635, DOI 10.1038/sj.onc.1206536; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Koster MI, 2004, CELL CYCLE, V3, P411; Leaner VD, 2003, ONCOGENE, V22, P5619, DOI 10.1038/sj.onc.1206644; Lee H, 2002, DEV CELL, V2, P607, DOI 10.1016/S1534-5807(02)00166-1; Longworth MS, 2004, MICROBIOL MOL BIOL R, V68, P362, DOI 10.1128/MMBR.68.2.362-372.2004; MAJEWSKI S, 1995, ARCH DERMATOL, V131, P1312, DOI 10.1001/archderm.131.11.1312; McKeon F, 2004, GENE DEV, V18, P465, DOI 10.1101/gad.1190504; Mehic D, 2005, J INVEST DERMATOL, V124, P212, DOI 10.1111/j.0022-202X.2004.23558.x; Meixner A, 2004, EMBO J, V23, P1325, DOI 10.1038/sj.emboj.7600133; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Passegue E, 2002, NAT GENET, V30, P158, DOI 10.1038/ng790; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Ruhland A, 2001, INT J CANCER, V91, P828, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1129&gt;3.0.CO;2-B; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Vinciguerra M, 2004, J BIOL CHEM, V279, P9634, DOI 10.1074/jbc.M308721200; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Vogt PK, 2002, NAT REV CANCER, V2, P465, DOI 10.1038/nrc818; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Westfall MD, 2004, CARCINOGENESIS, V25, P857, DOI 10.1093/carcin/bgh148; Wu GJ, 2003, CANCER RES, V63, P2351; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	60	4	4	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3914	3923		10.1038/sj.onc.1209420	http://dx.doi.org/10.1038/sj.onc.1209420			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16474846				2022-12-17	WOS:000238668800004
J	Yue, J; Xiong, W; Ferrell, JE				Yue, J; Xiong, W; Ferrell, JE			B-Raf and C-Raf are required for Ras-stimulated p42 MAP kinase activation in Xenopus egg extracts	ONCOGENE			English	Article						B-Raf; C-Raf; Mos; Ras; p42; MAPK; MEK1	SPINDLE ASSEMBLY CHECKPOINT; MAMMALIAN SOMATIC-CELLS; PROTEIN-KINASE; OOCYTE MATURATION; A-RAF; MITOTIC PROGRESSION; SIGNALING PATHWAY; P34CDC2 KINASE; BRAF MUTATIONS; ONCOGENIC RAS	During mitosis, a select pool of MEK1 and p42/p44 MAPK becomes activated at the kinetochores and spindle poles, without substantial activation of the bulk of the cytoplasmic p42/p44 MAPK. Recently, we set out to identify the MAP kinase kinase kinase ( MAPKKK) responsible for this mitotic activation, using cyclin-treated Xenopus egg extracts as a model system, and presented evidence that Mos was the relevant MAPKKK. However, a second MAPKKK distinct from Mos was readily detectable as well. Here, we partially purify this second MAPKKK and identify it as B-Raf. No changes in the activity of B-Raf were detectable during progesterone-induced oocyte maturation, after egg fertilization, or during the early embryonic cell cycle, arguing against a role for B-Raf in the mitotic activation of MEK1 and p42 MAPK. Ras proteins can bring about activation of MEK1 and p42 MAPK in extracts, and Ras may contribute to signaling from the classical progesterone receptor during oocyte maturation and from receptor tyrosine kinases during early embryogenesis. We found that both B-Raf and C-Raf, but not Mos, are required for Ras-induced MEK1 and p42 MAPK activation. These data indicate that two upstream stimuli, active Ras and active Cdc2, utilize different MAPKKKs to activate MEK1 and p42 MAPK.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Yue, J (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, CCSR Room 3160,269 W Campus Dr, Stanford, CA 94305 USA.	jyue@stanford.edu	Yue, Jianbo/AAC-4588-2019; Yue, Jianbo/C-4463-2009; Yue, Jianbo/K-8002-2015	Yue, Jianbo/0000-0001-6384-5447	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046383] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46383] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; Bagowski CP, 2001, J BIOL CHEM, V276, P1459, DOI 10.1074/jbc.M008050200; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; Bayaa M, 2000, P NATL ACAD SCI USA, V97, P12607, DOI 10.1073/pnas.220302597; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; CATLING AD, 1994, J BIOL CHEM, V269, P30014; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Colanzi A, 2003, J CELL BIOL, V161, P27, DOI 10.1083/jcb.200208099; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; EYCHENE A, 1995, ONCOGENE, V10, P1159; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; Ferrell JE, 1999, BIOESSAYS, V21, P866, DOI 10.1002/(SICI)1521-1878(199910)21:10<866::AID-BIES9>3.0.CO;2-1; Ferrell JE, 1999, BIOESSAYS, V21, P833, DOI 10.1002/(SICI)1521-1878(199910)21:10<833::AID-BIES5>3.0.CO;2-P; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; FUKUDA M, 1994, J BIOL CHEM, V269, P33097; Guadagno TM, 1998, SCIENCE, V282, P1312, DOI 10.1126/science.282.5392.1312; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; HATTORI S, 1992, J BIOL CHEM, V267, P20346; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Maller JL, 2003, SCIENCE, V300, P594, DOI 10.1126/science.1083725; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; MURAKAMI MS, 2001, SCI STKE, pPE30; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; Nebreda AR, 2000, CURR OPIN CELL BIOL, V12, P666, DOI 10.1016/S0955-0674(00)00150-2; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; Park JY, 2004, SCIENCE, V303, P682, DOI 10.1126/science.1092463; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pollock PM, 2002, CANCER CELL, V2, P5, DOI 10.1016/S1535-6108(02)00089-2; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; SADLER SE, 1990, MOL CELL BIOL, V10, P1689, DOI 10.1128/MCB.10.4.1689; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; Sohaskey ML, 1999, MOL BIOL CELL, V10, P3729, DOI 10.1091/mbc.10.11.3729; Tian JD, 2000, P NATL ACAD SCI USA, V97, P14358, DOI 10.1073/pnas.250492197; VANRENTERGHEM B, 1993, J BIOL CHEM, V268, P19935; Walter SA, 1997, MOL BIOL CELL, V8, P2157, DOI 10.1091/mbc.8.11.2157; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; WANG XM, 1994, P NATL ACAD SCI USA, V91, P8329, DOI 10.1073/pnas.91.18.8329; Wang XM, 1997, J CELL BIOL, V137, P433, DOI 10.1083/jcb.137.2.433; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wu XY, 1996, J BIOL CHEM, V271, P3265, DOI 10.1074/jbc.271.6.3265; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; Yue JB, 2004, CURR BIOL, V14, P1581, DOI 10.1016/j.cub.2004.08.056; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547	64	4	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 1	2006	25	23					3307	3315		10.1038/sj.onc.1209354	http://dx.doi.org/10.1038/sj.onc.1209354			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16434971				2022-12-17	WOS:000237951200009
J	Mitsuuchi, Y; Powell, DR; Gallo, JM				Mitsuuchi, Y; Powell, DR; Gallo, JM			Adenoviral modification of mouse brain derived endothelial cells, bEnd3, to induce apoptosis by vascular endothelial growth factor	ONCOGENE			English	Article						endothelial cells; drug delivery; adenovirus; VEGF; apoptosis	ANGIOGENESIS; MECHANISMS; VEHICLES; PROTEIN; CANCER; DELIVERY; RECEPTOR; SYSTEM; DRUGS; GENE	A second generation genetically-engineered cell-based drug delivery system, referred to as apoptotic-induced drug delivery (AIDD), was developed using endothelial cells (ECs) that undergo apoptosis upon binding of vascular endothelial growth factor (VEGF) to a Flk-1: Fas fusion protein (FF). This new AIDD was redesigned using mouse brain derived ECs, bEnd3cells, and an adenovirus vector in order to enhance and control the expression of FF. The FF was tagged with a HA epitope (FFHA) and designed to be coexpressed with green. fluorescence protein (GFP) by the regulation of cytomegalovirus promoters in the adenovirus vector. bEnd3 ce lls showed favorable coexpression of FFHA and GFP consistent with the multiplicity of infection of the adenovirus. Immunofluorescence analysis demonstrated that FFHA was localized at the plasma membrane, whereas GFP was predominantly located in the cytoplasm of ECs. Cell death was induced by VEGF, but not by platelet derived growth factor or. fibroblast growth factor in a dose-dependent manner (range 2 - 20 ng/ml), and revealed caspase-dependent apoptotic profiles. The FFHA expressing bEnd3cells underwent apoptosis when cocultured with a glioma cell (SF188V +) line able to overexpress VEGF. The combined data indicated that the FFHA adenovirus system can induce apoptotic signaling in ECs in response to VEGF, and thus, is an instrumental modi. cation to the development of AIDD.	Fox Chase Canc Ctr, Dept Pharmacol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Gallo, JM (corresponding author), Fox Chase Canc Ctr, Dept Pharmacol, 333 Cottham Ave, Philadelphia, PA 19111 USA.	jmgallo@temple.edu			NATIONAL CANCER INSTITUTE [R01CA085577] Funding Source: NIH RePORTER; NCI NIH HHS [CA 085577] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; Carpenito C, 2002, INT J RADIAT ONCOL, V54, P1473, DOI 10.1016/S0360-3016(02)03921-4; CHINNAIYAN AM, 1995, CELL, V81, P512; Dass CR, 2002, J PHARM PHARMACOL, V54, P3, DOI 10.1211/0022357021771887; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; Hallmann R, 2000, ENDOTHELIUM-J ENDOTH, V7, P135, DOI 10.3109/10623320009072208; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; ITOH N, 1993, J BIOL CHEM, V268, P10932; Le Ricousse-Roussanne S, 2004, CARDIOVASC RES, V62, P176, DOI 10.1016/j.cardiores.2004.01.017; Ma J, 1998, APOPTOSIS, V3, P195, DOI 10.1023/A:1009603023214; Ma JG, 1998, CLIN EXP METASTAS, V16, P559, DOI 10.1023/A:1006598419541; Ma JG, 2002, CANCER RES, V62, P1382; Mitsuuchi Y, 1998, J CELL BIOCHEM, V70, P433, DOI 10.1002/(SICI)1097-4644(19980915)70:4<433::AID-JCB1>3.0.CO;2-K; NI R, 1994, EXP CELL RES, V215, P332, DOI 10.1006/excr.1994.1349; Pereboeva L, 2003, STEM CELLS, V21, P389, DOI 10.1634/stemcells.21-4-389; PLATE KH, 1994, INT J CANCER, V59, P520, DOI 10.1002/ijc.2910590415; Quinn TP, 2001, CANCER RES, V61, P8629; Scappaticci FA, 2002, J CLIN ONCOL, V20, P3906, DOI 10.1200/JCO.2002.01.033; Soga N, 2001, CELL COMMUN ADHES, V8, P1, DOI 10.3109/15419060109080703; ten Tije AJ, 2003, CLIN PHARMACOKINET, V42, P665, DOI 10.2165/00003088-200342070-00005; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wrede CE, 2002, J BIOL CHEM, V277, P49676, DOI 10.1074/jbc.M208756200	22	4	6	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					954	958		10.1038/sj.onc.1209142	http://dx.doi.org/10.1038/sj.onc.1209142			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16247462				2022-12-17	WOS:000235212700014
J	Mahon, FX				Mahon, FX			JAK the trigger	ONCOGENE			English	Editorial Material						tyrosine kinases; leukemia; JAK2	TYROSINE KINASE; MUTATION	A somatic mutation that leads to activation of the JAK2 tyrosine kinase has recently been identified as a recurrent genetic abnormality in several different myeloproliferative disorders. A translocation generating the constitutively activated fusion protein PCM1-JAK2 has also been recently found in atypical chronic myelogenous leukemia and acute leukemia. This recent spate of independent studies (one of which is published in this issue of Oncogene) establish abnormal JAK2 activation as the underlying defect in a significant number of cases of myeloproliferative disease, and JAK2 as an important new therapeutic target.	Univ Bordeaux 2, CHU Bordeau, INSERM, E0217,Serv Malad Sang,Lab Hematopoiese Leucem & C, F-33076 Bordeaux, France	CHU Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Mahon, FX (corresponding author), Univ Bordeaux 2, CHU Bordeau, INSERM, E0217,Serv Malad Sang,Lab Hematopoiese Leucem & C, 146 Rue Leo Saignat,Boite 50, F-33076 Bordeaux, France.	francois-xavier.mahon@umr5540.u-bordeaux2.fr						Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Reiter A, 2005, CANCER RES, V65, P2662, DOI 10.1158/0008-5472.CAN-04-4263	8	4	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7125	7126		10.1038/sj.onc.1208885	http://dx.doi.org/10.1038/sj.onc.1208885			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16007127				2022-12-17	WOS:000232990100001
J	Sato, M; Sasaki, H; Kazui, T; Yokota, J; Kohno, T				Sato, M; Sasaki, H; Kazui, T; Yokota, J; Kohno, T			Probing the chromosome 9p21 region susceptible to DNA double-strand breaks in human cells in vivo by restriction enzyme transfer	ONCOGENE			English	Article						DNA double-strand break; chromosome deletion; p16; tumor suppressor gene; restriction enzyme	BREAKPOINT-CLUSTER REGION; ALTERED CHROMATIN-STRUCTURE; HUMAN LUNG-CANCER; ALTERNATIVE MECHANISMS; MLL GENE; METHYLATION; DELETIONS; CLEAVAGE; LEUKEMIA; TRANSLOCATIONS	A restriction enzyme, MspI, was introduced into cultured human cells as a probe to detect genomic regions susceptible to DNA double-strand breaks ( DSBs). A 2 h exposure to MspI at a concentration of 8U/mu l produced DSBs at MspI sites in more than 80% of HeLa cells. The sensitivity to digestion was examined on chromosomal DNAs for the region containing the p16 tumor suppressor gene and two other related genes, p14ARF and p15, by Southern blot hybridization analysis and linker-mediated capture of DNA fragments digested in vivo. DNAs for the promoter regions of the three genes, respectively, were sensitive to MspI digestion in HeLa cells, while DNA for the p16 promoter region was less sensitive in lung cancer cells with hypermethylation of the region. Breakpoints for interstitial 9p21 deletions removing the p16/p14ARF/p15 locus in a variety of human cancers were significantly over-represented in the three sensitive regions. The results suggest that the MspI sensitivity in vivo of each genomic region reflects its susceptibility to DSBs that trigger chromosome aberrations in human cells. This method could help us understand the pathogenic significance of differential susceptibility to DSBs among genomic regions in human carcinogenesis.	Natl Canc Ctr, Div Biol, Chuo Ku, Tokyo 1040045, Japan; Hamamatsu Univ Sch Med, Dept Surg 1, Hamamatsu, Shizuoka 4313192, Japan; Natl Canc Ctr, Div Genet, Tokyo 1040045, Japan	National Cancer Center - Japan; Hamamatsu University School of Medicine; National Cancer Center - Japan	Yokota, J (corresponding author), Natl Canc Ctr, Div Biol, Chuo Ku, 1-1 Tsukiji 5-Chome,, Tokyo 1040045, Japan.	jyokota@gan2.ncc.go.jp						Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Broeker PLS, 1996, BLOOD, V87, P1912, DOI 10.1182/blood.V87.5.1912.bloodjournal8751912; Cayuela JM, 1997, BLOOD, V90, P3720, DOI 10.1182/blood.V90.9.3720; Costello JF, 1996, CANCER RES, V56, P2405; Daser A, 2004, GENE DEV, V18, P965, DOI 10.1101/gad.1195504; Elliott B, 2002, CELL MOL LIFE SCI, V59, P373, DOI 10.1007/s00018-002-8429-3; Florl AR, 2003, GENE CHROMOSOME CANC, V37, P141, DOI 10.1002/gcc.10192; Folle GA, 1998, MUTAT RES-FUND MOL M, V404, P17, DOI 10.1016/S0027-5107(98)00090-6; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; Hamada K, 2000, GENE CHROMOSOME CANC, V27, P308, DOI 10.1002/(SICI)1098-2264(200003)27:3<308::AID-GCC12>3.0.CO;2-W; Inoue H, 1997, P NATL ACAD SCI USA, V94, P14584, DOI 10.1073/pnas.94.26.14584; KAMB A, 1994, SCIENCE, V264, P440; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Khobta A, 2004, CANCER RES, V64, P2656, DOI 10.1158/0008-5472.CAN-03-1126; Kitagawa Y, 2002, J BIOL CHEM, V277, P46289, DOI 10.1074/jbc.M208353200; Kuwahara Y, 2004, GENE CHROMOSOME CANC, V41, P125, DOI 10.1002/gcc.20075; LAZARIDES E, 1974, P NATL ACAD SCI USA, V71, P4742, DOI 10.1073/pnas.71.12.4742; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Moiseenko VV, 1998, INT J RADIAT BIOL, V74, P533, DOI 10.1080/095530098141113; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Obe G, 2002, MUTAT RES-FUND MOL M, V504, P17, DOI 10.1016/S0027-5107(02)00076-3; Park MJ, 2003, CANCER GENET CYTOGEN, V141, P5, DOI 10.1016/S0165-4608(02)00645-3; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Raschke S, 2005, GENE CHROMOSOME CANC, V42, P58, DOI 10.1002/gcc.20119; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Rowley JD, 2001, NAT REV CANCER, V1, P245, DOI 10.1038/35106108; Sasaki S, 2003, ONCOGENE, V22, P3792, DOI 10.1038/sj.onc.1206589; Sato M, 2002, ONCOGENE, V21, P4822, DOI 10.1038/sj.onc.1205581; Sim SP, 2001, J BIOL CHEM, V276, P31590, DOI 10.1074/jbc.M103962200; Stanulla M, 2001, HUM MOL GENET, V10, P2481, DOI 10.1093/hmg/10.22.2481; Strissel PL, 1998, BLOOD, V92, P3793, DOI 10.1182/blood.V92.10.3793.422a24_3793_3803; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; WINEGAR RA, 1990, SOMAT CELL MOLEC GEN, V16, P251, DOI 10.1007/BF01233361; Xing EP, 1999, CLIN CANCER RES, V5, P2704	38	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 8	2005	24	40					6108	6118		10.1038/sj.onc.1208750	http://dx.doi.org/10.1038/sj.onc.1208750			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	16007206	Green Submitted			2022-12-17	WOS:000231718100005
J	Ruiz-Vela, A; Piqueras, R; Carvalho-Pinto, C; Gomez, L; Yaniz-Galende, E; Moreno-Ortiz, MC; Bernad, A; Harshman, K; Martinez, C				Ruiz-Vela, A; Piqueras, R; Carvalho-Pinto, C; Gomez, L; Yaniz-Galende, E; Moreno-Ortiz, MC; Bernad, A; Harshman, K; Martinez, C			ZAP-70 upregulation in transformed B cells after early pre-BI cell transplant into NOD/SCID mice	ONCOGENE			English	Article						pre-B cells; microarray; lineage; NOD/SCID; transplant	CHRONIC LYMPHOCYTIC-LEUKEMIA; TRANSCRIPTION FACTOR; MONOCLONAL-ANTIBODY; BONE-MARROW; EXPRESSION; GENE; DIFFERENTIATION; CD19; PHENOTYPE; PROTEINS	Understanding of the signal transduction pathways that lead to B cell development is of extreme interest to learn how alterations in these pathways might initiate malignant transformation. Long- term cultured early pre-BI cells can differentiate into IgM(+) B cells after transplant into NOD/SCID mice, offering the possibility to explore checkpoints in B cell development. Using DNA microarray and Western blot analysis of IgM(+)B cells vs parental early pre-BI cells, we demonstrated that zetaassociated protein 70 (ZAP-70) is upregulated in our B cell differentiation model. Unlike parental ZAP-70(-) early pre-BI cells, ZAP-70(+) IgM B cells exhibited a transformed phenotype, as indicated by BCL-6 expression, a high Ki-67 proliferation index, resistance to IL-7 deprivation-induced apoptosis, and an increased repopulation rate in NOD/SCID mice. These data show the characterization and generation of a novel murine leukemia model with many similarities to human ZAP70(+) B cell chronic lymphocytic leukemia.	Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Ruiz-Vela, A (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.	aruiz@cnb.uam.es	Bernad, Antonio/P-8573-2017; Carla, Carvalho-Pinto Eponina/GXG-7917-2022	Carla, Carvalho-Pinto Eponina/0000-0002-1815-8418; Ruiz-Vela, Antonio/0000-0002-4410-6208; Bernad, Antonio/0000-0003-0620-9668				Astsaturov IA, 1997, LEUKEMIA LYMPHOMA, V26, P337, DOI 10.3109/10428199709051783; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; CHAN AC, 1994, J IMMUNOL, V152, P4758; Chen LG, 2002, BLOOD, V100, P4609, DOI 10.1182/blood-2002-06-1683; CORDONE I, 1992, LEUKEMIA, V6, P902; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; Hunte BE, 1998, EUR J IMMUNOL, V28, P3850; Ibrahim S, 2001, BLOOD, V98, P181, DOI 10.1182/blood.V98.1.181; Klein U, 2001, J EXP MED, V194, P1625, DOI 10.1084/jem.194.11.1625; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; MUSTO P, 1990, HAEMATOLOGICA, V75, P583; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; O'Riordan M, 2000, IMMUNOL REV, V175, P94, DOI 10.1034/j.1600-065X.2000.017503.x; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; Orchard JA, 2004, LANCET, V363, P105, DOI 10.1016/S0140-6736(03)15260-9; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; RANHEIM EA, 1995, BLOOD, V85, P3556, DOI 10.1182/blood.V85.12.3556.bloodjournal85123556; Rolink A, 1996, J EXP MED, V183, P187, DOI 10.1084/jem.183.1.187; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROLINK A, 1994, INT IMMUNOL, V6, P1257, DOI 10.1093/intimm/6.8.1257; Rosenwald A, 2001, J EXP MED, V194, P1639, DOI 10.1084/jem.194.11.1639; Ruiz-Vela A, 2001, J EXP MED, V194, P247, DOI 10.1084/jem.194.3.247; STAMENKOVIC I, 1988, J EXP MED, V168, P1205, DOI 10.1084/jem.168.3.1205; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	27	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5119	5124		10.1038/sj.onc.1208706	http://dx.doi.org/10.1038/sj.onc.1208706			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15856008				2022-12-17	WOS:000230816900011
J	Liu, Y; Liu, ZG; Gao, H; Zhou, Y; Androphy, EJ; Chen, JJ				Liu, Y; Liu, ZG; Gao, H; Zhou, Y; Androphy, EJ; Chen, JJ			Opposing effects of bovine papillomavirus type 1 E6 and E7 genes on Fas-mediated apoptosis	ONCOGENE			English	Article						BPV-1; E6; E7; Fas; apoptosis; p53	TUMOR-NECROSIS-FACTOR; ALPHA-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; HUMAN KERATINOCYTES; CELL-DEATH; BINDING-PROTEIN; TRANSFORMING ACTIVITY; INHIBITS APOPTOSIS; INFECTED-CELLS; VIRUS DNA	Programmed cell death (PCD), best exemplified by apoptosis, is a genetically programmed process of cellular destruction that is indispensable for normal development and homeostasis of multicellular organisms. Tumor necrosis factor alpha (TNF) and related cytokines are employed by host defenses to eliminate virally infected cells through induction of apoptosis. Many viruses have evolved specific gene products to modulate this process. We have recently shown that the bovine papillomavirus type 1 (BPV-1) E6 and E7 genes independently sensitize mouse cells to TNF-induced apoptosis. In this report, we investigated the effect of E6 and E7 expression on Fas-mediated apoptosis. In contrast to TNF-mediated apoptosis, E6 and E7 demonstrated opposite effects: while E7 potentiated apoptosis triggered by an agonistic Fas antibody, E6 attenuated the effect. The mitochondrial pathway leading to the activation of caspases appears to be involved in Fas-mediated apoptosis in C127 cells. To further explore the mechanisms by which E6 and E7 modulate Fas-mediated apoptosis, we examined the surface expression of Fas in cells expressing E6 and E7. Significantly, levels of surface Fas expression correlated with the opposing effects of E6 and E7 on Fas-mediated apoptosis. Specifically, while E7 increased the surface expression of Fas, E6 reduced surface Fas expression. Mutational analysis demonstrated a correlation of E6's ability to downregulate surface Fas expression and apoptosis. Since the tumor suppressor p53 can be targeted for degradation by human papillomavirus and has been shown to induce apoptosis by upregulating surface Fas expression, we investigated the role of p53 in BPV-1 E6 and E7 modulation of Fas-mediated apoptosis. Our results demonstrated that the modulatory effects by E6 and E7 could occur in the absence of p53. Interestingly, the reduced Fas protein level on the cell surface is not accompanied by a decrease in total Fas levels in E6-expressing cells. Instead, considerably more Fas protein is found in the cytoplasm of cells expressing E6. These results highlight a novel activity of E6 and E7 that may be involved in viral pathogenesis.	Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA; Univ Nebraska, Ctr Biotechnol, Lincoln, NE 68588 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Nebraska System; University of Nebraska Lincoln	Chen, JJ (corresponding author), Univ Massachusetts, Sch Med, Dept Med, LRB Room 323,364 Plantat St, Worcester, MA 01605 USA.	jason.chen@umassmed.edu		Androphy, Elliot/0000-0002-8104-0703; liu, zhiguo/0000-0002-8485-7356	NATIONAL CANCER INSTITUTE [R01CA107394, F32CA069738] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 107394, F32 CA 69738, R01 CA107394] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguilar-Lemarroy A, 2002, ONCOGENE, V21, P165, DOI 10.1038/sj.onc.1204979; Alfandari J, 1999, VIROLOGY, V257, P383, DOI 10.1006/viro.1999.9675; Arnold R, 1999, J IMMUNOL, V162, P7140; Basile JR, 2001, J BIOL CHEM, V276, P22522, DOI 10.1074/jbc.M010505200; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bergqvist A, 1997, J VIROL, V71, P276, DOI 10.1128/JVI.71.1.276-283.1997; Bohl J, 2000, VIROLOGY, V271, P163, DOI 10.1006/viro.2000.0316; Boyer SN, 1996, CANCER RES, V56, P4620; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; Das K, 2000, J VIROL, V74, P812, DOI 10.1128/JVI.74.2.812-816.2000; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; DUERKSENHUGHES P, 1989, J IMMUNOL, V143, P4193; DVORETZKY I, 1980, VIROLOGY, V103, P369, DOI 10.1016/0042-6822(80)90195-6; Elsing A, 1998, P NATL ACAD SCI USA, V95, P10072, DOI 10.1073/pnas.95.17.10072; Fan XL, 2003, J BIOL CHEM, V278, P43163, DOI 10.1074/jbc.M306008200; Finzer P, 2002, CANCER LETT, V188, P15, DOI 10.1016/S0304-3835(02)00431-7; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; GROFF DE, 1986, VIROLOGY, V150, P221, DOI 10.1016/0042-6822(86)90281-3; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Hill LL, 1999, SCIENCE, V285, P898, DOI 10.1126/science.285.5429.898; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Howley M. P., 1996, FIELDS VIROLOGY, P2045; Iglesias M, 1998, ONCOGENE, V17, P1195, DOI 10.1038/sj.onc.1202054; Jaattela M, 2004, ONCOGENE, V23, P2746, DOI 10.1038/sj.onc.1207513; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; LAMBERTI C, 1990, EMBO J, V9, P1907, DOI 10.1002/j.1460-2075.1990.tb08317.x; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; LEITHAUSER F, 1993, LAB INVEST, V69, P415; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu Y, 2000, J BIOL CHEM, V275, P30894, DOI 10.1074/jbc.M000640200; Liu YM, 2000, J CELL BIOCHEM, V78, P334, DOI 10.1002/(SICI)1097-4644(20000801)78:2<334::AID-JCB15>3.3.CO;2-6; Liu ZG, 2002, VIROLOGY, V295, P230, DOI 10.1006/viro.2001.1351; LOCKSHIN RICHARD A., 1965, J INSECT PHYSIOL, V11, P123, DOI 10.1016/0022-1910(65)90099-5; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; LOWY DR, 1980, NATURE, V287, P72, DOI 10.1038/287072a0; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Magal SS, 1998, INT J CANCER, V75, P96; Mannhardt B, 2000, MOL CELL BIOL, V20, P6483, DOI 10.1128/MCB.20.17.6483-6495.2000; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; NEARY K, 1989, J VIROL, V63, P259, DOI 10.1128/JVI.63.1.259-266.1989; OGASAWARA J, 1995, J EXP MED, V181, P485, DOI 10.1084/jem.181.2.485; Peng SL, 1996, J EXP MED, V184, P1149, DOI 10.1084/jem.184.3.1149; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Proskuryakov SY, 2003, EXP CELL RES, V283, P1, DOI 10.1016/S0014-4827(02)00027-7; Puthenveettil JA, 1996, ONCOGENE, V13, P1123; Rapp L, 1999, ONCOGENE, V18, P607, DOI 10.1038/sj.onc.1202373; Rapp L, 1998, BBA-REV CANCER, V1378, pF1, DOI 10.1016/S0304-419X(98)00009-2; SAYAMA K, 1994, J INVEST DERMATOL, V103, P330, DOI 10.1111/1523-1747.ep12394858; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SCHILLER JT, 1986, CANC CELLS DNA TUMOR, V4, P571; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; Shisler J, 1997, J VIROL, V71, P8299, DOI 10.1128/JVI.71.11.8299-8306.1997; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Thompson DA, 2001, ONCOGENE, V20, P3629, DOI 10.1038/sj.onc.1204483; Tollefson AE, 1998, NATURE, V392, P726, DOI 10.1038/33712; Tong X, 1998, J VIROL, V72, P476, DOI 10.1128/JVI.72.1.476-482.1998; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Vande Pol SB, 1998, ONCOGENE, V16, P43, DOI 10.1038/sj.onc.1201504; Vanden Berghe Tom, 2004, Methods Mol Med, V98, P101; Wallach D, 1997, FEBS LETT, V410, P96, DOI 10.1016/S0014-5793(97)00553-X; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Wang XD, 2001, GENE DEV, V15, P2922; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOLD WSM, 1989, MOL BIOL MED, V6, P433; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yuste VJ, 2001, J BIOL CHEM, V276, P22323, DOI 10.1074/jbc.M100072200; Zimmermann H, 2000, J GEN VIROL, V81, P2617, DOI 10.1099/0022-1317-81-11-2617; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	81	4	4	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3942	3953		10.1038/sj.onc.1208542	http://dx.doi.org/10.1038/sj.onc.1208542			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15782122				2022-12-17	WOS:000229435300010
J	Winter, AG; Dorgan, C; Melton, DW				Winter, AG; Dorgan, C; Melton, DW			Expression of a splicing variant in the 5'-UTR of the human ERCC1 gene is not cancer related	ONCOGENE			English	Article						ERCC1; nucleotide excision repair; ovarian cancer; cisplatin; splicing	NUCLEOTIDE EXCISION-REPAIR; CELL LUNG-CANCER; OVARIAN-CANCER; MESSENGER-RNA; COMBINATION CHEMOTHERAPY; CISPLATIN RESISTANCE; LINES; POLYMORPHISMS; PLATINUM; REMOVAL	Cisplatin is the most commonly used chemotherapeutic agent in the treatment of ovarian cancer. One of the mechanisms of resistance of ovarian tumours to cisplatin is increased nucleotide excision repair activity, in particular increased levels of the endonuclease ERCC1. Since 30-40% of ovarian cancers develop resistance to cisplatin after treatment and these tumours are usually incurable, ERCC1 expression is potentially useful as a predictive marker for the effectiveness of cisplatin-based chemotherapy. Using RT-PCR and Northern blotting, we have examined the expression of a 42 bp differentially spliced sequence in exon 1 of the human ERCC1 gene, loss of which has previously been reported to be correlated with higher levels of ERCC1 mRNA in ovarian cancer cell lines. We report here that this alternate transcript is ubiquitous in human tissues and cancer cell lines, is absent in mouse and thus does not appear to be cancer related.	Univ Edinburgh, Western Gen Hosp, Sir Alastair Currie Canc Res UK Labs, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Melton, DW (corresponding author), Univ Edinburgh, Western Gen Hosp, Sir Alastair Currie Canc Res UK Labs, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland.	david.melton@ed.ac.uk						DABHOLKAR M, 1994, J CLIN INVEST, V94, P703, DOI 10.1172/JCI117388; Damia G, 1996, INT J CANCER, V66, P779, DOI 10.1002/(SICI)1097-0215(19960611)66:6<779::AID-IJC12>3.0.CO;2-Z; Ferry KV, 2000, BIOCHEM PHARMACOL, V60, P1305, DOI 10.1016/S0006-2952(00)00441-X; HOY CA, 1985, CANCER RES, V45, P1737; Isla D, 2004, ANN ONCOL, V15, P1194, DOI 10.1093/annonc/mdh319; JOHNSON SW, 1994, BIOCHEM PHARMACOL, V47, P689, DOI 10.1016/0006-2952(94)90132-5; LANGDON SP, 1988, CANCER RES, V48, P6166; Li QD, 1999, BIOCHEM PHARMACOL, V57, P347, DOI 10.1016/S0006-2952(98)00291-3; Li TY, 2004, INT J ONCOL, V25, P1105; MASUDA H, 1990, CANCER RES, V50, P1863; MASUDA H, 1988, CANCER RES, V48, P5713; McGuire WP, 1998, SEMIN ONCOL, V25, P340; PARKER RJ, 1991, J CLIN INVEST, V87, P772, DOI 10.1172/JCI115080; Ryu JS, 2004, LUNG CANCER, V44, P311, DOI 10.1016/j.lungcan.2003.11.019; Stoehlmacher J, 2004, BRIT J CANCER, V91, P344, DOI 10.1038/sj.bjc.6601975; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; Yu JJ, 2001, ONCOGENE, V20, P7694, DOI 10.1038/sj.onc.1204977	17	4	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					2110	2113		10.1038/sj.onc.1208400	http://dx.doi.org/10.1038/sj.onc.1208400			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688021				2022-12-17	WOS:000227681900016
J	Stoica, GE; Franke, TF; Wellstein, A; Morgan, E; Czubayko, F; List, HJ; Reiter, R; Martin, MB; Stoica, A				Stoica, GE; Franke, TF; Wellstein, A; Morgan, E; Czubayko, F; List, HJ; Reiter, R; Martin, MB; Stoica, A			Heregulin-beta 1 regulates the estrogen receptor-alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway (Retraction of vol 24, pg 1964, 2005)	ONCOGENE			English	Correction														Wellstein, Anton/0000-0002-0570-4950				Stoica GE, 2005, ONCOGENE, V24, P1964, DOI 10.1038/sj.onc.1208526	1	4	4	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 10	2005	24	11					1964	1964		10.1038/sj.onc.1208526	http://dx.doi.org/10.1038/sj.onc.1208526			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15759010	Bronze			2022-12-17	WOS:000227542000015
J	Kaur, GP; Reddy, DE; Zimonjic, DB; de Riel, JK; Athwal, RS				Kaur, GP; Reddy, DE; Zimonjic, DB; de Riel, JK; Athwal, RS			Functional identification of a BAC clone from 16q24 carrying a senescence gene SEN16 for breast cancer cells	ONCOGENE			English	Article						cell senescence; breast cancer; BAC contig; BAC transfer; functional complementation	CHROMOSOME ARM 16Q; TUMOR-SUPPRESSOR GENE; CARCINOMA IN-SITU; ALLELIC IMBALANCE; HETEROZYGOSITY REGION; CELLULAR SENESCENCE; FREQUENT LOSS; DELETION; PHENOTYPE; WFDC1	We have identified an 85 kb BAC clone, 346J21, that carries a cell senescence gene (SEN16), previously mapped to 16q24.3. Transfer and retention of 346J21 in breast cancer cell lines leads to growth arrest after 8-10 cell doublings, accompanied by the appearance of characteristic senescent cell morphology and senescence-associated acid beta-galactosidase activity. Loss of transferred BAC results in reversion to the immortal growth phenotype of the parental cancer cell lines. BAC 346J21 restores senescence in the human breast cancer cell lines, MCF.7 and MDA-MB468, and the rat mammary tumor cell line LA7, but not in the human glioblastoma cell line T98G. We postulate that inactivation of both copies of SEN16 is required for the immortalization of breast epithelial cells at an early stage of tumorigenesis. Positional mapping of 346J21 shows that SEN16 is distinct from other candidate tumor suppressor genes reported at 16q24.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; NCI, Expt Carcinogenesis Lab, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kaur, GP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res, 3307 N Broad St,AHB Room 201, Philadelphia, PA 19140 USA.	pkaur001@temple.edu	Zimonjic, Drazen/AAX-7513-2020		NATIONAL CANCER INSTITUTE [Z01BC010038, R01CA074983, ZIABC010038] Funding Source: NIH RePORTER; NCI NIH HHS [CA74983] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balsara BR, 2001, GENE CHROMOSOME CANC, V30, P245, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1083>3.0.CO;2-M; Bando K, 2000, GENE CHROMOSOME CANC, V28, P38, DOI 10.1002/(SICI)1098-2264(200005)28:1<38::AID-GCC5>3.0.CO;2-A; Bednarek AK, 2000, CANCER RES, V60, P2140; Bednarek AK, 2001, CANCER RES, V61, P8068; Bertram MJ, 1999, MOL CELL BIOL, V19, P1479; Callen DF, 2002, CANCER GENET CYTOGEN, V133, P76, DOI 10.1016/S0165-4608(01)00565-9; Campisi J, 2000, IN VIVO, V14, P183; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Chalmers IJ, 2001, CANCER GENET CYTOGEN, V126, P39, DOI 10.1016/S0165-4608(00)00376-9; Chin RK, 1998, CANCER GENET CYTOGEN, V103, P155, DOI 10.1016/S0165-4608(97)00407-X; Cleton-Jansen AM, 2001, CANCER RES, V61, P1171; CLETONJANSEN AM, 1994, GENE CHROMOSOME CANC, V9, P101, DOI 10.1002/gcc.2870090205; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Driouch K, 1997, GENE CHROMOSOME CANC, V19, P185, DOI 10.1002/(SICI)1098-2264(199707)19:3<185::AID-GCC8>3.0.CO;2-U; Godfrey TE, 1997, CANCER GENET CYTOGEN, V98, P36, DOI 10.1016/S0165-4608(96)00392-5; Hansen LL, 2002, CANCER GENET CYTOGEN, V139, P1, DOI 10.1016/S0165-4608(02)00620-9; Hansen LL, 1998, CANCER RES, V58, P2166; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HAYFLICK L, 1974, J AM GERIATR SOC, V22, P1; Huang Y, 2001, MOL BIOL REP, V28, P185, DOI 10.1023/A:1015726217890; HUBBARDSMITH K, 1992, MOL CELL BIOL, V12, P2273, DOI 10.1128/MCB.12.5.2273; Kawakami M, 1999, INT J ONCOL, V15, P715; Kochetkova M, 2002, CANCER RES, V62, P4599; LAKHANI SR, 1995, J CLIN PATHOL, V48, P611, DOI 10.1136/jcp.48.7.611; Larsen M, 2000, MAMM GENOME, V11, P767, DOI 10.1007/s003350010135; LINDBLOM A, 1993, CANCER RES, V53, P3707; Mejia JE, 1997, GENOME RES, V7, P179, DOI 10.1101/gr.7.2.179; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; Powell JA, 2002, GENOMICS, V80, P303, DOI 10.1006/geno.2002.6828; RADFORD DM, 1995, CANCER RES, V55, P3399; Reddy DE, 2000, ONCOGENE, V19, P217, DOI 10.1038/sj.onc.1203264; Reddy DE, 1999, ONCOGENE, V18, P5100, DOI 10.1038/sj.onc.1202888; Saffroy R, 2002, EUR J HUM GENET, V10, P239, DOI 10.1038/sj.ejhg.5200795; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Sandhu AK, 1996, ONCOGENE, V12, P247; Sato M, 1998, GENE CHROMOSOME CANC, V22, P1; Suzuki H, 1996, GENE CHROMOSOME CANC, V17, P225, DOI 10.1002/(SICI)1098-2264(199612)17:4<225::AID-GCC4>3.0.CO;2-5; Tominaga K, 2002, MECH AGEING DEV, V123, P927, DOI 10.1016/S0047-6374(02)00030-1; TSUDA H, 1994, CANCER RES, V54, P513; Vos CBJ, 1999, BRIT J CANCER, V81, P1410, DOI 10.1038/sj.bjc.6693372; Watson JEV, 2004, ONCOGENE, V23, P3487, DOI 10.1038/sj.onc.1207474; Whitmore SA, 1998, GENOMICS, V52, P325, DOI 10.1006/geno.1998.5457; Whitmore SA, 1998, GENOMICS, V50, P1, DOI 10.1006/geno.1998.5316; ZIMONJIC DB, 1995, CANCER GENET CYTOGEN, V82, P1, DOI 10.1016/0165-4608(95)91129-7	44	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					47	54		10.1038/sj.onc.1208175	http://dx.doi.org/10.1038/sj.onc.1208175			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15558027				2022-12-17	WOS:000226125800007
J	Edwards, KM; Munger, K				Edwards, KM; Munger, K			Make WARTS, not cancer!	ONCOGENE			English	Editorial Material							TUMOR-SUPPRESSOR; CELL-GROWTH; HOMOLOG	The WARTS gene encodes a kinase that localizes to the mitotic apparatus of a dividing cell. Named WARTS after the growths that develop in the eyes of Drosophila in which the gene is deleted. WARTS is also implicated as a tumor suppressor in mice and humans. In this issue of Oncogene, Iida et al. describe experiments suggesting that, in addition to a role in regulating mitosis, WARTS functions to prevent further rounds of DNA synthesis and mitosis in tetraploid cells. As well as opening up new possibilities of exploring the yet ill-defined mechanistic basis of the tetraploidy checkpoint, the involvement of a tumor-suppressor gene in this checkpoint supports its importance as a safeguard against the acquisition of genomic instability, a key event in the progression to cancer.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Munger, K (corresponding author), Harvard Univ, Sch Med, Dept Pathol, New Res Bldg 0958C,77 Ave Louis Pasteur, Boston, MA 02115 USA.	karl_munger@hms.harvard.edu		Munger, Karl/0000-0003-3288-9935				Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Duensing S, 2002, CANCER RES, V62, P7075; Duensing S, 2001, CANCER RES, V61, P2356; GATEFF E, 1994, ANN NY ACAD SCI, V712, P260, DOI 10.1111/j.1749-6632.1994.tb33578.x; Hay BA, 2003, DEV CELL, V5, P361, DOI 10.1016/S1534-5807(03)00270-3; Hisaoka M, 2002, LAB INVEST, V82, P1427, DOI 10.1097/01.LAB.0000032381.68634.CA; IIDA S, 2004, ONCOGENE A B, V10; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kamikubo Y, 2003, J BIOL CHEM, V278, P17609, DOI 10.1074/jbc.M211974200; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Weinberg R A, 1998, ONE RENEGADE CELL CA	14	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5263	5265		10.1038/sj.onc.1207686	http://dx.doi.org/10.1038/sj.onc.1207686			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15122320				2022-12-17	WOS:000222491600001
J	Kroemer, G				Kroemer, G			Cell death and cancer: an introduction	ONCOGENE			English	Editorial Material									Inst Gustave Roussy, CNRS, UMR 8125, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR 8125, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013	KROEMER, Guido/0000-0002-9334-4405				Blagosklonny MV, 2004, ONCOGENE, V23, P2967, DOI 10.1038/sj.onc.1207520; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Debatin KM, 2004, ONCOGENE, V23, P2950, DOI 10.1038/sj.onc.1207558; Distelhorst CW, 2004, ONCOGENE, V23, P2875, DOI 10.1038/sj.onc.1207519; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Guicciardi ME, 2004, ONCOGENE, V23, P2881, DOI 10.1038/sj.onc.1207512; Henry-Mowatt J, 2004, ONCOGENE, V23, P2850, DOI 10.1038/sj.onc.1207534; Jaattela M, 2004, ONCOGENE, V23, P2746, DOI 10.1038/sj.onc.1207513; Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514; MELINO G, 2004, ONCOGENE, V23, P2757; Mosser DD, 2004, ONCOGENE, V23, P2907, DOI 10.1038/sj.onc.1207529; Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Salvesen GS, 2004, ONCOGENE, V23, P2774, DOI 10.1038/sj.onc.1207522; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Takahashi Y, 2004, ONCOGENE, V23, P2819, DOI 10.1038/sj.onc.1207533; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556	21	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2004	23	16					2744	2745		10.1038/sj.onc.1207531	http://dx.doi.org/10.1038/sj.onc.1207531			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO					2022-12-17	WOS:000220799600001
J	Joseph, MK; Solomon, LR; Petros, AM; Cai, J; Simmer, RL; Zhang, HC; Rosenberg, S; Ng, SC				Joseph, MK; Solomon, LR; Petros, AM; Cai, J; Simmer, RL; Zhang, HC; Rosenberg, S; Ng, SC			Divergence of Genbank and human tumor Bcl-2 sequences and implications for binding affinity to key apoptotic proteins	ONCOGENE			English	Article						Bcl-2; apoptosis; BH3 region; fluorescence anisotropy; Genbank sequences	T(14-18) CHROMOSOMAL TRANSLOCATION; CELL-DEATH; ANTISENSE OLIGONUCLEOTIDES; FOLLICULAR LYMPHOMA; STRUCTURAL-ANALYSIS; DISTINCT; BCL-X(L); CANCER; FAMILY; DOMAIN	Heterodimerization of antiapoptotic and pro-apoptotic Bcl-2 family of proteins provides an important mechanism for apoptosis regulation. Knowledge about key amino acids in the binding groove of native Bcl-2 contributing to this interaction will greatly facilitate the design of Bcl-2-specific inhibitors. There are two different Bcl-2 sequences, M13994 and M14745, in Genbank. Chimeric proteins Bcl-2( 1) and Bcl-2( 2) derived from the above sequences, although similar in structure, showed different binding affinities to Bak and Bad BH3 peptides (Petros et al., 2001). In this study, we show that the Bcl-2( 1) sequence in normal and tumor human tissue samples differs from M13994 and M14745, and contains P59, T96, R110, S117 and G237. The actual sequence in the binding pocket matches the Bcl-2 - Ig fusion sequence X06487, originally identified in a t(14: 18) translocation of the Bcl-2 gene, associated with follicular lymphoma. The possible effects of the observed amino acid differences compared to M13994 and M14745 were investigated by combining structural data with fluorescence anisotropy. G110R substitution confers on Bcl-2( 1) substantially increased binding affinity to Bak, Bad and Bax BH3 peptides, demonstrating that R110 is a key contributor to the BH3 binding affinity of Bcl-2. Although NMR structure did not predict R110 involvement in binding to these BH3 peptides, fluorescence anisotropy data clearly points to a critical role for this residue in binding to proapoptotic Bcl-2 family members.	Abbott Labs, Global Pharmaceut Res Div, Canc Res, Abbott Pk, IL 60064 USA	Abbott Laboratories	Joseph, MK (corresponding author), Abbott Labs, Global Pharmaceut Res Div, Canc Res, Abbott Pk, IL 60064 USA.	mary.joseph@abbott.com						Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Antonsson B, 2001, CELL TISSUE RES, V306, P347, DOI 10.1007/s00441-001-0472-0; BAKHSHI A, 1987, P NATL ACAD SCI USA, V84, P2396, DOI 10.1073/pnas.84.8.2396; BELLI B, 2003, AACR ANN M WASH DC; Berghella AM, 1998, CANCER BIOTHER RADIO, V13, P225, DOI 10.1089/cbr.1998.13.225; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COTTER FE, 1994, ONCOGENE, V9, P3049; Dias N, 2002, EUR J PHARM BIOPHARM, V54, P263, DOI 10.1016/S0939-6411(02)00060-7; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NGAN BY, 1988, NEW ENGL J MED, V318, P1638, DOI 10.1056/NEJM198806233182502; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Petros AM, 2000, PROTEIN SCI, V9, P2528, DOI 10.1017/S096183680000331X; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; Petrovic AS, 1998, BLOOD, V91, P3952, DOI 10.1182/blood.V91.10.3952.3952_3952_3961; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; ZHANG HC, 1995, BIOCHEM BIOPH RES CO, V208, P950, DOI 10.1006/bbrc.1995.1426; Zhang HC, 2002, ANAL BIOCHEM, V307, P70, DOI 10.1016/S0003-2697(02)00028-3	23	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	2004	23	3					835	838		10.1038/sj.onc.1207141	http://dx.doi.org/10.1038/sj.onc.1207141			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737118				2022-12-17	WOS:000188304900022
J	Yam, JWP; Chan, KW; Hsiao, WLW				Yam, JWP; Chan, KW; Hsiao, WLW			Transcriptional regulation of the promoter of the rat frizzled related protein gene by CREB	ONCOGENE			English	Article						rat frizzled related protein (rFrp); transcriptional regulation; CREB	BETA-CATENIN; MOLECULAR-CLONING; SPEMANN ORGANIZER; COLON-CARCINOMA; BREAST-TUMORS; CYCLIN D1; C-MYC; BINDING; EXPRESSION; APOPTOSIS	Frizzled related proteins (Frps) are secreted proteins structurally similar to frizzled receptors; they bind Wnt via the cysteine-rich domain and antagonize the Wnt signaling pathway. In this study, we have investigated the mechanisms regulating the transcriptional regulation of rat Frp (rFrp) promoter. From previous findings, we know that the transcriptional activation domain of rFrp resides in the region -202 to -144 relative to the transcription start site, and that it is essential for efficient promoter activity. The study presented here was designed to identify trans-acting factors that bind to this critical domain of the rFrp promoter and to elucidate the pathway involved in the regulation of rFrp expression. Electrophoretic mobility shift assay (EMSA) demonstrated that specific DNA protein binding activities fall into two adjacent core sequences with (CTTTGGGGG) at -197 to -189 and (AGATGATGTAA) at -151 to -141 of the rFrp promoter. Reporter assay showed that these core sequences are both required for the activation of rFrp promoter. Mutation within either one or both core sequence drastically reduced the promoter activity. Southwestern blotting showed that the estimated molecular mass of the distinct binding protein to the (AGATGATGTAA) domain is about 43 kDa. Further EMSA suggested CREB as the trans-acting factor in the DNA-protein complex, which was out competed by CREB consensus oligonucleotides and supershifted by anti-CREB antibody. Overexpression of PKA and CREB also transactivated rFrp promoter, and dominant-negative CREB inhibited the promoter activity in transient reporter assays. More importantly, CREB, phosphorylated CREB and the adaptor protein CBP were found binding to the endogenous rFrp promoter using chromatin immunoprecipitation assay. Collectively, our results demonstrate the induction of rFrp promoter activity by PKA and CREB in vitro, and the binding of CREB and CBP to the rFrp promoter core motif in vivo.	Hong Kong Univ Sci & Technol, Dept Biol, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Hsiao, WLW (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Clear Water Bay, Hong Kong, Hong Kong, Peoples R China.		; Yam, Judy Wai Ping/C-4454-2009	Hsiao, W.L.Wendy/0000-0002-9113-8819; Yam, Judy Wai Ping/0000-0002-5637-121X				Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Brown JD, 1998, CURR OPIN CELL BIOL, V10, P182, DOI 10.1016/S0955-0674(98)80140-3; Bui TD, 1997, GENE, V189, P25, DOI 10.1016/S0378-1119(96)00808-6; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chang JHT, 1999, HUM MOL GENET, V8, P575, DOI 10.1093/hmg/8.4.575; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601; De Vos J, 2001, BLOOD, V98, P771, DOI 10.1182/blood.V98.3.771; Dennis S, 1999, J CELL SCI, V112, P3815; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Fukuhara K, 2002, J CLIN ENDOCR METAB, V87, P1729, DOI 10.1210/jc.87.4.1729; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hoang B, 1996, J BIOL CHEM, V271, P26131, DOI 10.1074/jbc.271.42.26131; James IE, 2000, OSTEOARTHR CARTILAGE, V8, P452, DOI 10.1053/joca.1999.0321; Katoh M, 2001, BIOCHEM BIOPH RES CO, V282, P116, DOI 10.1006/bbrc.2001.4551; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LeGros L, 2001, J BIOL CHEM, V276, P24918, DOI 10.1074/jbc.M102816200; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Preiherr J, 2000, ANTICANCER RES, V20, P2255; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; ROESLER WJ, 1995, J BIOL CHEM, V270, P8225, DOI 10.1074/jbc.270.14.8225; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Schumann H, 2000, CARDIOVASC RES, V45, P720, DOI 10.1016/S0008-6363(99)00376-4; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wolf V, 1997, FEBS LETT, V417, P385, DOI 10.1016/S0014-5793(97)01324-0; Wong SCC, 2002, J PATHOL, V196, P145, DOI 10.1002/path.1035; Xu LF, 2000, GENE DEV, V14, P585; Yam JWP, 2001, BIOCHEM BIOPH RES CO, V286, P94, DOI 10.1006/bbrc.2001.5349; Yam JWP, 1999, BIOCHEM BIOPH RES CO, V266, P472, DOI 10.1006/bbrc.1999.1852; Yeagley D, 1998, J BIOL CHEM, V273, P18743, DOI 10.1074/jbc.273.30.18743; Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4	50	4	4	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2003	22	25					3901	3910		10.1038/sj.onc.1206489	http://dx.doi.org/10.1038/sj.onc.1206489			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813463				2022-12-17	WOS:000183612000009
J	Sonderegger, CK; Narisawa-Saito, M; Vogt, PK				Sonderegger, CK; Narisawa-Saito, M; Vogt, PK			The C-terminal region of cellular Qin oligomerizes: correlation with oncogenic transformation and transcriptional repression	ONCOGENE			English	Article						FoxG1; oncogenic transformation; chicken embryo fibroblasts; oligomerization; transcriptional repression	DNA-RECOGNITION; ACUTE LEUKEMIAS; MLL GENE; PROTEIN; BF-1; CLONING; EXPRESSION; MEMBER; PAX3; CONVERSION	Expression of the oncoprotein Qin induces tumors in chickens and oncogenic transformation of chicken embryo fibroblasts in culture. We performed a detailed deletion analysis of the C-terminal region of Qin (amino acids 246-451, extending from the winged helix domain to the C-terminus) and identified amino acids 246-379 as important for transformation. The same region mediates homo-oligomerization of Qin as documented in vitro by GST pulldowns and in vivo by coimmunoprecipitation. A 60 amino-acid region within the oligomerization domain is necessary and sufficient for transcriptional repression induced by Qin.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	pkvogt@scripps.edu	Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500				Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BIEGEL JA, 1991, GENE CHROMOSOME CANC, V3, P483, DOI 10.1002/gcc.2870030612; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Bourguignon C, 1998, DEVELOPMENT, V125, P4889; Chang HW, 1996, ONCOGENE, V13, P441; CHANG HW, 1995, P NATL ACAD SCI USA, V92, P447, DOI 10.1073/pnas.92.2.447; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CORRAL J, 1993, P NATL ACAD SCI USA, V90, P8538, DOI 10.1073/pnas.90.18.8538; Dou CL, 2000, MOL CELL BIOL, V20, P6201, DOI 10.1128/MCB.20.17.6201-6211.2000; DOUGLASS EC, 1991, GENE CHROMOSOME CANC, V3, P480, DOI 10.1002/gcc.2870030611; Gajiwala KS, 2000, NATURE, V403, P916, DOI 10.1038/35002634; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; HATINI V, 1994, J NEUROBIOL, V25, P1293, DOI 10.1002/neu.480251010; JIANG J, 1993, EMBO J, V12, P3201, DOI 10.1002/j.1460-2075.1993.tb05989.x; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KIROV N, 1993, EMBO J, V12, P3193, DOI 10.1002/j.1460-2075.1993.tb05988.x; Li J, 1997, P NATL ACAD SCI USA, V94, P10885, DOI 10.1073/pnas.94.20.10885; LI J, 1995, CANCER RES, V55, P5540; Lu XY, 2000, P NATL ACAD SCI USA, V97, P1988, DOI 10.1073/pnas.040573197; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; Ma Y, 2000, ONCOGENE, V19, P4815, DOI 10.1038/sj.onc.1203834; MCCABE NR, 1992, P NATL ACAD SCI USA, V89, P11794, DOI 10.1073/pnas.89.24.11794; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; RAO A, 2001, SCI STKE, pE1; Rodriguez C, 2001, J BIOL CHEM, V276, P30224, DOI 10.1074/jbc.M102759200; SHAPIRO DN, 1993, CANCER RES, V53, P5108; SONDEREGGER CK, 2003, IN PRESS ONCOGENE; SONDEREGGER CK, 2001, UNPUB; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; WHANGPENG J, 1992, GENE CHROMOSOME CANC, V5, P299, DOI 10.1002/gcc.2870050405; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; Yao J, 2001, MOL CELL BIOL, V21, P1962, DOI 10.1128/MCB.21.6.1962-1972.2001; Yuasa J, 1996, NATURE, V382, P632, DOI 10.1038/382632a0; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666	38	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2003	22	13					1908	1915		10.1038/sj.onc.1206307	http://dx.doi.org/10.1038/sj.onc.1206307			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673196				2022-12-17	WOS:000181967700001
J	Fitzsimmons, S; Ireland, H; Barr, NI; Cuthbert, AP; Going, JJ; Newbold, R; Parkinson, EK				Fitzsimmons, S; Ireland, H; Barr, NI; Cuthbert, AP; Going, JJ; Newbold, R; Parkinson, EK			Human squamous cell carcinomas lose a mortality gene from chromosome 6q14.3 to q15	ONCOGENE			English	Article						chromosome 6; senescence; keratinocyte; squamous cancer	TUMOR-SUPPRESSOR GENE; FUNCTIONAL EVIDENCE; GROWTH-ARREST; NASOPHARYNGEAL CARCINOMA; INDEFINITE DIVISION; HIGH-FREQUENCY; HUMAN CANCERS; SENESCENCE; REGION; IDENTIFICATION	Normal human keratinocytes possess a finite replicative lifespan. Most advanced squamous cell carcinomas (SCCs), however, are immortal, a phenotype that is associated with p53 and INK4A dysfunction, high levels of telomerase and loss of heterozygosity (LOH) at several genetic loci, suggestive of the dysfunction of other mortality genes. We show here that human chromosome 6 specifically reduces the proliferation or viability of a human SCC line, BICR31, possessing LOH across the chromosome. This was determined by an 88% reduction in colony yield (P < 0.001), following the reintroduction of an intact normal chromosome 6 by monochromosome transfer. Deletion analysis of immortal segregants using polymorphic markers revealed the loss of a 2.9 Mbp interval, centred on marker D6S1045 at 6q14.3-q15, in 6/19 segregants. Crucially, allelic losses of this region were not identified in control hybrids constructed between chromosome 6 and the BICR6 SCC cell line that is heterozygous for chromosome 6 and which showed no reduction in colony formation relative to the control chromosome transfers. This indicates that the minimally deleted region at D6S1045 is not the result of fragile sites, a recombination hot spot, or a feature of the monochromosome transfer technique. LOH of D6S1045 was found in 2/9 immortal SCC lines and was part of a minimally deleted region of line BICR19. Furthermore, allelic imbalance, consistent with LOH, was detected in 31 17 advanced SCCs of the tongue. These results suggest the existence of a suppressor of SCC immortality and tumour development at chromosome 6q14.3-q15, which is important to a subset of human SCCs.	Beatson Inst Canc Res, Canc Res UK Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Brunel Univ, Dept Biol & Biochem, Uxbridge UBS 3PH, Middx, England; Univ Glasgow, Glasgow Royal Infirm, Dept Pathol, Glasgow G4 0SF, Lanark, Scotland	Beatson Institute; Brunel University; University of Glasgow	Parkinson, EK (corresponding author), Beatson Inst Canc Res, Canc Res UK Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.			Going, James/0000-0001-9120-919X				Azzalin CM, 1997, CYTOGENET CELL GENET, V78, P112, DOI 10.1159/000134640; Banga SS, 1997, ONCOGENE, V14, P313, DOI 10.1038/sj.onc.1200842; Benitez J, 1997, CANCER RES, V57, P4217; CASEY G, 1993, HUM MOL GENET, V2, P1921, DOI 10.1093/hmg/2.11.1921; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; CLARK LJ, 1993, BRIT J CANCER, V68, P617, DOI 10.1038/bjc.1993.396; Cooney KA, 1996, CANCER RES, V56, P4150; CUTHBERT AP, 1995, CYTOGENET CELL GENET, V71, P68, DOI 10.1159/000134066; Cuthbert AP, 1999, JNCI-J NATL CANCER I, V91, P37, DOI 10.1093/jnci/91.1.37; EDINGTON KG, 1995, MOL CARCINOGEN, V13, P254, DOI 10.1002/mc.2940130408; EDWARDS NL, 1978, SCIENCE, V201, P628, DOI 10.1126/science.27864; Engelman JA, 1998, FEBS LETT, V436, P403, DOI 10.1016/S0014-5793(98)01134-X; England NL, 1996, CARCINOGENESIS, V17, P1567, DOI 10.1093/carcin/17.8.1567; FANTES JA, 1995, GENOMICS, V25, P447, DOI 10.1016/0888-7543(95)80045-N; Forsyth NR, 2002, ONCOGENE, V21, P5135, DOI 10.1038/sj.onc.1205688; FUJIKAWAYAMAMOTO K, 1994, CELL STRUCT FUNCT, V19, P391, DOI 10.1247/csf.19.391; Going JJ, 1996, J PATHOL, V179, P121; GREEN RJ, 1988, HUM GENET, V81, P9, DOI 10.1007/BF00283720; Guan XY, 1996, BLOOD, V88, P1418, DOI 10.1182/blood.V88.4.1418.bloodjournal8841418; Hassfeld W, 1998, NUCLEIC ACIDS RES, V26, P439, DOI 10.1093/nar/26.2.439; Hatcher CJ, 2001, DEV BIOL, V230, P177, DOI 10.1006/dbio.2000.0134; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Karlsson C, 1996, CANCER RES, V56, P241; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; LEVY FO, 1994, GENOMICS, V22, P637, DOI 10.1006/geno.1994.1439; Lo KW, 2001, CANCER RES, V61, P3877; Loughran O, 1997, ONCOGENE, V14, P1955, DOI 10.1038/sj.onc.1201028; Morelli C, 1997, CANCER RES, V57, P4153; Nathrath MH, 2002, ONCOGENE, V21, P5975, DOI 10.1038/sj.onc.1205764; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; Parkinson EK, 1997, EUR J CANCER, V33, P727, DOI 10.1016/S0959-8049(97)00063-4; Resta R, 1998, IMMUNOL REV, V161, P95, DOI 10.1111/j.1600-065X.1998.tb01574.x; RIMESSI P, 1994, ONCOGENE, V9, P3467; Robertson GP, 1998, P NATL ACAD SCI USA, V95, P9418, DOI 10.1073/pnas.95.16.9418; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Sandhu AK, 1996, ONCOGENE, V12, P247; SASAKI M, 1994, CANCER RES, V54, P6090; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; STANTON P, 1994, BRIT J CANCER, V70, P427, DOI 10.1038/bjc.1994.322; Steenbergen RDM, 2001, JNCI-J NATL CANCER I, V93, P865, DOI 10.1093/jnci/93.11.865; Turker MS, 1999, CANCER RES, V59, P1837; UEJIMA H, 1995, GENE CHROMOSOME CANC, V14, P120, DOI 10.1002/gcc.2870140206; WANG XW, 1992, CARCINOGENESIS, V13, P555, DOI 10.1093/carcin/13.4.555; Wu CL, 1999, GENE CHROMOSOME CANC, V25, P16, DOI 10.1002/(SICI)1098-2264(199905)25:1<16::AID-GCC3>3.3.CO;2-U; Yi CH, 1999, GENOMICS, V55, P10, DOI 10.1006/geno.1998.5632; Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804; [No title captured]	49	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1737	1746		10.1038/sj.onc.1206295	http://dx.doi.org/10.1038/sj.onc.1206295			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642877				2022-12-17	WOS:000181580500016
J	Xi, YG; Ding, KY; Ren, YH; Shen, Y; Ke, Y				Xi, YG; Ding, KY; Ren, YH; Shen, Y; Ke, Y			Esophageal cancer in Chinese population: no polymorphism in codon 149 of P21(Waf1/Cip1) cyclin dependent kinase gene	ONCOGENE			English	Article						P21(Waf1/Cip1); esophageal cancer; single nucleotide polymorphism	DNA-REPLICATION; INHIBITOR GENE; CELL-CYCLE; EXPRESSION; P21; WAF1; P53; ASSOCIATION; WAF1/CIP1; SEQUENCE	It has recently been suggested that people of the Indian population who carried the codon 149 polymorphism (G (A) under barT-->G (G) under barT) of P21(Waf1/Cip1) gene were more susceptible to esophageal cancer and oral cancer than the individuals without that polymorphism. Since esophageal cancer is a high incident neoplasm in China, we analysed the same codon of P21(Waf1/Cip1) in the Chinese population. Blood samples from 80 esophageal cancer patients and 80 normal blood donors were collected for DNA extraction. Methods of Polymerase Chain Reaction (PCR) and direct sequencing were used for detection of the polymorphism in codon 149 of P21(Waf/Cip1). Bioinformatics analysis was also thoroughly performed for this gene. No polymorphism was found in all samples tested. Bioinformatics analysis revealed that the so-called polymorphism of codon 149 reported previously was a wrong one. In conclusion, no polymorphism exists in codon 149 of P21(Waf1/Cip1). It is not appropriate to use it as a susceptible site of the gene in cancer study.	Peking Univ, Sch Oncol, Beijing Inst Canc Res, Genet Lab, Beijing 100034, Peoples R China; Peking Union Med Coll, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China; Chinese Natl Human Genome Ctr, Beijing 100176, Peoples R China	Peking University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Ke, Y (corresponding author), Peking Univ, Sch Oncol, Beijing Inst Canc Res, Genet Lab, 1 Da Hong Luo Chang St,Western Dist, Beijing 100034, Peoples R China.			Xi, Yaguang/0000-0003-3681-9352; Ding, Keyue/0000-0002-3496-6415				Bahl R, 2000, ONCOGENE, V19, P323, DOI 10.1038/sj.onc.1203325; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; CHEDID M, 1994, ONCOGENE, V9, P3021; CHEN J, 1995, NATURE, V375, P386; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Florea L, 1998, GENOME RES, V8, P967, DOI 10.1101/gr.8.9.967; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; GOUBIN F, 1995, ONCOGENE, V10, P2281; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HUPPI K, 1994, ONCOGENE, V9, P3017; JIANG HP, 1994, ONCOGENE, V9, P3397; Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745; Ralhan R, 2000, CLIN CANCER RES, V6, P2440; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Zeng YX, 1996, ONCOGENE, V12, P1557	18	4	5	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7745	7748		10.1038/sj.onc.1205873	http://dx.doi.org/10.1038/sj.onc.1205873			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400017				2022-12-17	WOS:000178756200014
J	Evans, RL; Poe, BS; Goodrich, DW				Evans, RL; Poe, BS; Goodrich, DW			Nuclear localization is required for induction of apoptotic cell death by the Rb-associated p84N5 death domain protein	ONCOGENE			English	Article						apoptosis; death domain; nucleus; retinoblastoma; Rb	RETINOBLASTOMA GENE-PRODUCT; SUPPRESSION; ACTIVATION; SIGNAL; LIFE; P53	The mechanisms utilized to transduce apoptotic signals that originate from within the nucleus, in response to DNA damage for example, are not well understood. Identifying these mechanisms is important for predicting how tumor cells will respond to genotoxic radiation or chemotherapy. The Rb tumor suppressor protein can inhibit apoptosis triggered by DNA damage, but how it does so is unclear. We have previously characterized a death domain protein, p84N5, that specifically associates with an amino-terminal domain of Rb protein. The p84N5 death domain is required for its ability to trigger apoptotic cell death. Association with Rb protein inhibits p84N5-induced apoptosis suggesting that it may be a mediator of Rb's effects on apoptosis. Unlike other death domain-containing apoptotic signaling proteins, however, p84N5 is localized predominantly within the nucleus of interphase cells. Here we test whether p84N5 requires nuclear localization in order to trigger apoptosis. We identify the p84N5 nuclear localization signal and demonstrate that nuclear localization is required for p84N5-induced apoptosis. To our knowledge, this identifies p84N5 as the first death-domain containing apoptotic signaling protein that functions within the nucleus. By analogy to other death domain containing proteins, p84N5 may play some role in apoptotic signaling within the nucleus. Further, p84N5 is a potential mediator of Rb protein's effects on DNA damage induced apoptosis.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Goodrich, DW (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.				NCI NIH HHS [CA-70292] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070292] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Doostzadeh-Cizeron J, 2000, J BIOL CHEM, V275, P25336, DOI 10.1074/jbc.M000793200; Doostzadeh-Cizeron J, 1999, MOL BIOL CELL, V10, P3251, DOI 10.1091/mbc.10.10.3251; Doostzadeh-Cizeron J, 2001, J BIOL CHEM, V276, P1127, DOI 10.1074/jbc.M006944200; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fisher CL, 1997, BIOTECHNIQUES, V23, P570, DOI 10.2144/97234bm01; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Haimovitz-Friedman A, 1998, RADIAT RES, V150, pS102, DOI 10.2307/3579812; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Riley DJ, 1997, MOL CELL BIOL, V17, P7342, DOI 10.1128/MCB.17.12.7342; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5	21	4	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 11	2002	21	30					4691	4695		10.1038/sj.onc.1205583	http://dx.doi.org/10.1038/sj.onc.1205583			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	569WH	12096345				2022-12-17	WOS:000176625100010
J	Arlt, A; Vorndamm, J; Breitenbroich, M; Folsch, UR; Kalthoff, H; Schmidt, WE; Schafer, H				Arlt, A; Vorndamm, J; Breitenbroich, M; Folsch, UR; Kalthoff, H; Schmidt, WE; Schafer, H			Inhibition of NF-kappa B sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin (vol 20, pg 859, 2001)	ONCOGENE			English	Correction													Arlt, Alexander/G-7308-2019; Kalthoff, Holger/B-1618-2010	Arlt, Alexander/0000-0002-6160-1059; 				Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168	1	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2611	2611		10.1038/sj.onc.1205379	http://dx.doi.org/10.1038/sj.onc.1205379			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG		Bronze			2022-12-17	WOS:000174918400018
J	Le Bras, M; Delattre, V; Bensaad, K; Blandino, G; Soussi, T				Le Bras, M; Delattre, V; Bensaad, K; Blandino, G; Soussi, T			Monoclonal antibodies raised against Xenopus p53 interact with human p73	ONCOGENE			English	Article						p53; p73; antibodies; xenopus laevis	PROTEIN; MUTATIONS; DOMAIN	The p53 tumor suppressor gene belongs to a multigene family that includes two paralogues, p63 and p73. The structure of the p63 and p73 genes is quite similar, but both have common activities with p53, such as DNA binding and transactivation. Both p53 and p73 bind to mdm2, but only p53 is degraded through the activity of mdm2. p63 neither binds to nor is degraded by mdm2 despite important conservation in the key interacting residues. Using a panel of monoclonal antibodies raised against human and Xenopus p53, we have been able to find several antibodies that cross-react strongly with human p73. These antibodies react both with exogenous p73 expressed in mammalian cells and with endogenous p73. Interestingly, all these antibodies react with the same epitope localized in the amino-terminus of p53, but have no cross-reaction with p63. This epitope corresponds to the exact mdm2 binding site to p53. These antibodies inhibit the interaction between either p53 or p73 and mdm2, and may be useful tools for the study of these proteins. Furthermore, our studies suggest that there exist specific spatial requirements for the interaction between p53 or p73 and mdm2.	Inst Curie, Lab Genotoxicol Tumeurs, F-75005 Paris 05, France; Univ Paris 06, F-75005 Paris, France; Mol Oncogenesis Lab, I-00158 Rome, Italy	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Sorbonne Universite	Soussi, T (corresponding author), Inst Curie, Lab Genotoxicol Tumeurs, 26 Rue Ulm, F-75005 Paris 05, France.		Blandino, Giovanni/B-1137-2013	Blandino, Giovanni/0000-0002-6970-2241; soussi, thierry/0000-0001-8184-3293; LE BRAS, PhD, HDR, Morgane/0000-0003-4317-5591				Bensaad K, 2001, ONCOGENE, V20, P3766, DOI 10.1038/sj.onc.1204492; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; Kojima T, 2001, BIOCHEM BIOPH RES CO, V281, P1170, DOI 10.1006/bbrc.2001.4486; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEGROS Y, 1994, ONCOGENE, V9, P2071; LEGROS Y, 1994, ONCOGENE, V9, P3689; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Little NA, 2001, ONCOGENE, V20, P4576, DOI 10.1038/sj.onc.1204615; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Portefaix JM, 2000, J IMMUNOL METHODS, V244, P17, DOI 10.1016/S0022-1759(00)00246-5; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; Tominaga O, 2001, BRIT J CANCER, V84, P57, DOI 10.1054/bjoc.2000.1542; VOJTESEK B, 1995, ONCOGENE, V10, P389; Wang XQ, 2001, FEBS LETT, V490, P202, DOI 10.1016/S0014-5793(01)02124-X; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127	15	4	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2002	21	8					1304	1308		10.1038/sj.onc.1205189	http://dx.doi.org/10.1038/sj.onc.1205189			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850851				2022-12-17	WOS:000173729400019
J	Bradshaw, PS; Condie, A; Matutes, E; Catovsky, D; Yuille, MR				Bradshaw, PS; Condie, A; Matutes, E; Catovsky, D; Yuille, MR			Breakpoints in the ataxia telangiectasia gene arise at the RGYW somatic hypermutation motif	ONCOGENE			English	Article						ATM; rearrangement; somatic hypermutation; T-PLL; T-ALL	ACUTE LYMPHOBLASTIC-LEUKEMIA; ATM GENE; B-CELLS; PROLYMPHOCYTIC LEUKEMIA; MISSENSE MUTATIONS; BCL-6 MUTATIONS; BREAST-CANCER; LYMPHOMA	The mature sporadic T-cell malignancy, T-cell prolymphocytic leukemia (T-PLL) is remarkable for frequently harbouring somatic mutations of the Ataxia Telangiectasia (A-T) gene, ATM. Because some data suggest ATM is frequently rearranged in T-PLL, it was decided to investigate such rearrangements in detail by cloning breakpoints. Among 17 T-PLL tumour samples, three rearrangements were detected by Southern blotting. Two cases harboured a unique type of intragenic duplication in which breakpoints arose at the consensus sequence RGYW/WRCY. The third case harboured a large deletion terminating within the ATM gene. Also, 13 T-cell acute lymphoblastic leukemia (T-ALL) samples were examined and one sample harboured a deletion - insertion with the RGYW motif at the breakpoint in ATM. This is the first known deleterious mutation detected in ATM in T-ALL. Interestingly, the RGYW motif is the signal for a cell-cycle regulated DNA double strand break (DSB) that initiates somatic hypermutation of immunoglobulin and, probably, T-cell receptor genes. The structures of the ATM duplications suggest they may arise from an error in somatic hypermutation. We suggest that aberrant components of somatic hypermutation may contribute to the defective DSB repair characteristic of cancer.	Inst Canc Res, Acad Dept Haematol & Cytogenet, Sutton, Surrey, England	University of London; Institute of Cancer Research - UK	Yuille, MR (corresponding author), HGMP RC, MRC, Cambridge CB2 4AT, England.			Yuille, Martin/0000-0002-4992-5405				Hacia JC, 1998, GENOME RES, V8, P1245, DOI 10.1101/gr.8.12.1245; Haidar MA, 2000, CANCER-AM CANCER SOC, V88, P1057, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1057::AID-CNCR16>3.0.CO;2-6; HECHT F, 1990, CANCER GENET CYTOGEN, V46, P9, DOI 10.1016/0165-4608(90)90003-S; Izatt L, 1999, GENE CHROMOSOME CANC, V26, P286, DOI 10.1002/(SICI)1098-2264(199912)26:4<286::AID-GCC2>3.0.CO;2-X; Klein U, 1998, IMMUNOL REV, V162, P261; Luo LP, 1998, CANCER RES, V58, P2293; Meyn MS, 1999, CLIN GENET, V55, P289, DOI 10.1034/j.1399-0004.1999.550501.x; Papavasiliou FN, 2000, NATURE, V408, P216, DOI 10.1038/35041599; Pasqualucci L, 2000, CANCER RES, V60, P5644; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; RAVID Z, 1980, INT J CANCER, V25, P705, DOI 10.1002/ijc.2910250604; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; Stankovic T, 2001, BLOOD, V97, P1517, DOI 10.1182/blood.V97.5.1517; Stankovic T, 1998, AM J HUM GENET, V62, P334, DOI 10.1086/301706; Stilgenbauer S, 1997, NAT MED, V3, P1155, DOI 10.1038/nm1097-1155; Stoppa-Lyonnet D, 2000, BLOOD, V96, P374, DOI 10.1182/blood.V96.1.374a.013k56e_374_377; Takeuchi S, 1998, BRIT J HAEMATOL, V103, P536, DOI 10.1046/j.1365-2141.1998.00993.x; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Vanasse GJ, 1999, BLOOD, V94, P3997, DOI 10.1182/blood.V94.12.3997.424k44_3997_4010; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; Yuille MAR, 1998, ONCOGENE, V16, P789, DOI 10.1038/sj.onc.1201603; ZHENG B, 1994, NATURE, V372, P556, DOI 10.1038/372556a0	22	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2002	21	3					483	487		10.1038/sj.onc.1205105	http://dx.doi.org/10.1038/sj.onc.1205105			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821961				2022-12-17	WOS:000173311200017
J	Wadle, A; Thiel, G; Mischo, A; Jung, V; Pfreundschuh, M; Renner, C				Wadle, A; Thiel, G; Mischo, A; Jung, V; Pfreundschuh, M; Renner, C			Chromosomal localization and promoter analysis of the adenomatous polyposis coli binding protein RP1	ONCOGENE			English	Article						adenomatous polyposis coli tumour-suppressor; protein; tubulin binding proteins; RP1 protein; chromosomal localization; T-cell signalling	CAMP RESPONSE ELEMENT; APC GENE-PRODUCT; BETA-CATENIN; CYCLIN D1; YEAST; IDENTIFICATION; CANCER; CELLS; MICROTUBULES; EXPRESSION	characterized by the ability of its members to serve as interacting partners for the adenomatous polyposis coli (ADC) tumour suppressor protein and tubulin. Data obtained with highly conserved yeast homologues suggest that the EB1/RP1 protein family promotes cytoplasmic microtubule dynamics and contributes to the sensor mechanism controlling the cytokinesis checkpoint during mitosis. However, the precise function of this protein family in mammalian cells has not been elucidated so far and remains unclear. Here, we report on the genomic localization of the RP1 gene and the characterization of the corresponding promoter. The RP1 gene was found to be encoded on chromosome 18q21, a locus which is altered or deleted in up to 50% of all patients with colorectal cancer. Promoter analysis revealed that the RP1 gene is under the control of a strong promoter that was 10 times more active in mammalian cells when compared to SV40 promoter. Members of the cyclic AMP response element binding protein family (CREB1 and CREB2) could be identified as transcription factors binding specifically within the RP1 promoter sequence.	Univ Saarland, Sch Med, Dept Med 1, D-66421 Homburg, Germany; Univ Saarland, Sch Med, D-66421 Homburg, Germany; Univ Saarland, Sch Med, Inst Human Genet, D-66421 Homburg, Germany	Saarland University; Saarland University; Saarland University	Renner, C (corresponding author), Univ Saarland, Sch Med, Dept Med 1, D-66421 Homburg, Germany.							Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; Beinhauer JD, 1997, J CELL BIOL, V139, P717, DOI 10.1083/jcb.139.3.717; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; Butscher WG, 1998, J BIOL CHEM, V273, P552, DOI 10.1074/jbc.273.1.552; Cibelli G, 1999, EUR J CELL BIOL, V78, P642, DOI 10.1016/S0171-9335(99)80049-1; Cibelli G, 1996, EUR J BIOCHEM, V236, P171, DOI 10.1111/j.1432-1033.1996.00171.x; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; FEUERSTEIN N, 1995, J IMMUNOL, V154, P68; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hsueh YP, 1997, J IMMUNOL, V158, P85; Jernvall P, 1999, BRIT J CANCER, V79, P903, DOI 10.1038/sj.bjc.6690144; Juwana JP, 1999, INT J CANCER, V81, P275, DOI 10.1002/(SICI)1097-0215(19990412)81:2<275::AID-IJC18>3.0.CO;2-Z; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek WS, 2000, SCIENCE, V287, P2257, DOI 10.1126/science.287.5461.2257; Muhua L, 1998, NATURE, V393, P487, DOI 10.1038/31014; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Ogunbiyi OA, 1998, J CLIN ONCOL, V16, P427, DOI 10.1200/JCO.1998.16.2.427; Papadimitrakopoulou VA, 1998, CLIN CANCER RES, V4, P539; POLAKIS P, 1997, BIOCHIM BIOPHYS ACTA, V1332, P127; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Renner C, 1997, J IMMUNOL, V159, P1276; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Sambrook J., 1989, MOL CLONING LAB MANU; Schwartz K, 1997, MOL BIOL CELL, V8, P2677, DOI 10.1091/mbc.8.12.2677; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tarafa G, 2000, ONCOGENE, V19, P546, DOI 10.1038/sj.onc.1203353; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thiel G, 1996, GENE, V168, P173, DOI 10.1016/0378-1119(95)00739-3; Tirnauer JS, 1999, J CELL BIOL, V145, P993, DOI 10.1083/jcb.145.5.993; VANDERVELDE G, 1994, WATER SCI TECHNOL, V29, P1; Zhang YM, 1998, HUM GENET, V103, P727	33	4	4	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5920	5929		10.1038/sj.onc.1204797	http://dx.doi.org/10.1038/sj.onc.1204797			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593399				2022-12-17	WOS:000171037200017
J	Low, W; Olmos-Centenera, G; Madsen, C; Leverrier, Y; Collins, M				Low, W; Olmos-Centenera, G; Madsen, C; Leverrier, Y; Collins, M			Role of Bax in apoptosis of IL-3-dependent cells	ONCOGENE			English	Article						apoptosis; IL-3; Bax	COLONY-STIMULATING FACTOR; ACTIVATED PROTEIN-KINASE; COMMON BETA-SUBUNIT; CYTOCHROME-C; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC MALIGNANCIES; INTERLEUKIN-3 STIMULATION; CONFORMATIONAL-CHANGE; SIGNAL-TRANSDUCTION; FACTOR DEPRIVATION	IL-3 removal was reported to induce membrane association of the apoptotic effector Bax. This report demonstrates that IL-3-dependent cells from Bax-null mice failed to activate caspases after IL-3 removal and survived in an 10-fold lower concentration of IL-3. As IL-3 removal also down-regulates expression of Bcl-X, we examined the relationship between Bcl-X decrease and Bax membrane association. IL-3 removal from BAF-3 cells, followed by sorting caspase-active and caspase-inactive populations, showed that both expressed similar levels of Bcl-X. Inhibition of IL-3 signalling via PI-3 kinase and MEK1/2 resulted in cells with minimal Bcl-X, which remained viable with soluble Bax. However BAF-3-derived cells, which maintained Bcl-X expression without IL-3, also remained viable with soluble Bax on IL-3 removal. Therefore a decrease in Bcl-X is necessary, though not sufficient, for Bax membrane association on IL-3 removal. In contrast, treatment of BAF-3 cells with hydroxyurea induced apoptosis in the absence of a Bcl-X decrease. Furthermore, IL-3-dependent cells from Bax-null mice activated caspases after hydroxyurea treatment and show the same sensitivity to a variety of cytotoxic drugs. Thus, apoptosis after IL-3 removal requires a decrease in Bcl-X and Bax membrane association, whereas that induced by cytotoxic drugs does not.	UCL, Dept Immunol & Mol Pathol, Windeyer Inst Med Sci, London W1P 6DB, England; Ecole Normale Super Lyon, CNRS,INRA, UMR 49, Biol Cellulaire & Mol Lab, F-69364 Lyon 07, France	University of London; University College London; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); INRAE	Collins, M (corresponding author), UCL, Dept Immunol & Mol Pathol, Windeyer Inst Med Sci, 46 Cleveland St, London W1P 6DB, England.	mary.collins@ucl.ac.uk	LEVERRIER, Yann/M-3767-2014	LEVERRIER, Yann/0000-0002-4227-5446; Olmos Centenera, Gemma/0000-0003-4835-0846				Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Chong MJ, 2000, P NATL ACAD SCI USA, V97, P889, DOI 10.1073/pnas.97.2.889; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Furlong IJ, 1997, J CELL SCI, V110, P653; GonzalezGarcia A, 1997, J BIOL CHEM, V272, P10220; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hara T, 1996, STEM CELLS, V14, P605, DOI 10.1002/stem.140605; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; Johnson MD, 1998, J NEUROSCI RES, V54, P721, DOI 10.1002/(SICI)1097-4547(19981215)54:6<721::AID-JNR1>3.0.CO;2-1; JUCKER M, 1995, J BIOL CHEM, V270, P27817; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Maurer M, 2000, J INVEST DERMATOL, V114, P1205, DOI 10.1046/j.1523-1747.2000.00005.x; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; Mizuguchi R, 1998, J BIOL CHEM, V273, P32297, DOI 10.1074/jbc.273.48.32297; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Oliver FJ, 1997, J BIOL CHEM, V272, P10624; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Palacios C, 2000, ONCOGENE, V19, P3556, DOI 10.1038/sj.onc.1203683; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; Pratt JC, 1996, J BIOL CHEM, V271, P12137, DOI 10.1074/jbc.271.21.12137; Pritchard DM, 1999, ONCOGENE, V18, P7287, DOI 10.1038/sj.onc.1203150; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RAO P, 1995, J BIOL CHEM, V270, P6886, DOI 10.1074/jbc.270.12.6886; Sanz C, 2000, BLOOD, V95, P2742, DOI 10.1182/blood.V95.9.2742.009k24_2742_2747; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Shibata MA, 1999, EMBO J, V18, P2692, DOI 10.1093/emboj/18.10.2692; Silva A, 1997, BLOOD, V89, P2717, DOI 10.1182/blood.V89.8.2717; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; Thomas J, 1998, ONCOGENE, V16, P1399, DOI 10.1038/sj.onc.1201672; Vekrellis K, 1997, DEVELOPMENT, V124, P1239; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Xie ZH, 1998, BIOCHEMISTRY-US, V37, P6410, DOI 10.1021/bi973052i; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	59	4	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2001	20	33					4476	4483		10.1038/sj.onc.1204580	http://dx.doi.org/10.1038/sj.onc.1204580			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494143				2022-12-17	WOS:000170074900005
J	Hofmann, JFX; Sykora, M; Redemann, N; Beug, H				Hofmann, JFX; Sykora, M; Redemann, N; Beug, H			G1-Cdk activity is required for both proliferation and viability of cytokine-dependent myeloid and erythroid cells	ONCOGENE			English	Article						apoptosis; caspases; cell cycle; cytokines; hematopoiesis	BCL-X-L; APOPTOSIS; DEATH; SURVIVAL; ERYTHROPOIETIN; DIFFERENTIATION; GROWTH; MICE; RECEPTOR; PHOSPHORYLATION	Hematopoietic cytokines are critically required for survival and cell proliferation of myeloid and erythroid progenitors. It is poorly understood how the apoptotic machinery of progenitor cells senses the absence of specific cytokines, Here we show that G1-Cdk activity is essential for cytokine-mediated viability of myeloid and erythroid progenitors. Cytokine deprivation is associated with rapid downregulation of G1-Cdk activity, cell cycle arrest, and apoptosis, Specific inhibition of G1-Cdk activity results in apoptotic cell death in the presence of saturating cytokine levels. In contrast, specific cell cycle arrest in G2/M does not affect viability. When cell proliferation is arrested by cytokine withdrawal, primary erythroid progenitors expressing v-ErbA maintain G1-Cdk activity and undergo delayed apoptosis, Cdk-inhibitors strongly enhance apoptosis in starved v-ErbA cells, indicating that sustained Cdk activity is required for protection from apoptosis by v-ErbA.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Boehringer Ingelheim GmbH & Co KG, Onkol Forsch A, D-88400 Biberach, Germany	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Boehringer Ingelheim	Beug, H (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	beug@nt.imp.univie.ac.at						Akashi K, 1997, CELL, V89, P1033, DOI 10.1016/S0092-8674(00)80291-3; Alessi F, 1998, EXP CELL RES, V245, P8, DOI 10.1006/excr.1998.4216; ALLEN PD, 1993, BLOOD REV, V7, P63, DOI 10.1016/0268-960X(93)90025-Y; Antoku K, 1998, LEUKEMIA, V12, P682, DOI 10.1038/sj.leu.2400992; Barge RMY, 1997, FEBS LETT, V409, P207, DOI 10.1016/S0014-5793(97)00507-3; Bauer A, 1998, EMBO J, V17, P4291, DOI 10.1093/emboj/17.15.4291; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Colussi PA, 1999, IMMUNOL CELL BIOL, V77, P58, DOI 10.1046/j.1440-1711.1999.00788.x; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; Estrov Z, 1998, BLOOD, V92, P3090, DOI 10.1182/blood.V92.9.3090; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GANDRILLON O, 1994, ONCOGENE, V9, P749; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Gregoli PA, 1997, BLOOD, V90, P630, DOI 10.1182/blood.V90.2.630.630_630_640; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; Hetts SW, 1998, JAMA-J AM MED ASSOC, V279, P300, DOI 10.1001/jama.279.4.300; Hinton HJ, 1999, J IMMUNOL, V162, P7002; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KELLEY LL, 1993, BLOOD, V82, P2340; Kieslinger M, 2000, GENE DEV, V14, P232; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; Kumar S, 1999, TRENDS BIOCHEM SCI, V24, P1, DOI 10.1016/S0968-0004(98)01332-2; KUMAR S, 1995, FEBS LETT, V368, P69, DOI 10.1016/0014-5793(95)00602-6; Lagasse E, 1997, CELL, V89, P1021, DOI 10.1016/S0092-8674(00)80290-1; Lotem J, 1996, LEUKEMIA, V10, P925; Maraskovsky E, 1997, CELL, V89, P1011, DOI 10.1016/S0092-8674(00)80289-5; MARTIN SJ, 1995, CRIT REV ONCOL HEMAT, V18, P137, DOI 10.1016/1040-8428(94)00124-C; MARVEL J, 1994, ONCOGENE, V9, P1117; Mayor T, 1999, FEBS LETT, V452, P92, DOI 10.1016/S0014-5793(99)00534-7; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Motoyama N, 1999, J EXP MED, V189, P1691, DOI 10.1084/jem.189.11.1691; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Ohta T, 1997, J BIOL CHEM, V272, P23111, DOI 10.1074/jbc.272.37.23111; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Raff MC, 1996, CELL, V86, P173, DOI 10.1016/S0092-8674(00)80087-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Socolovsky M, 1997, J BIOL CHEM, V272, P14009, DOI 10.1074/jbc.272.22.14009; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Traver D, 1998, IMMUNITY, V9, P47, DOI 10.1016/S1074-7613(00)80587-7; Vander Heiden MG, 1999, MOL CELL, V3, P159; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; VONLINDERN M, 2001, IN PRESS ONCOGENE; WANG ZY, 1995, BLOOD, V86, P3783, DOI 10.1182/blood.V86.10.3783.bloodjournal86103783; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wu H, 1997, P NATL ACAD SCI USA, V94, P1806, DOI 10.1073/pnas.94.5.1806; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	59	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2001	20	31					4198	4208		10.1038/sj.onc.1204550	http://dx.doi.org/10.1038/sj.onc.1204550			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464286				2022-12-17	WOS:000169857200010
J	Law, W; Linial, ML				Law, W; Linial, ML			Transforming ability of Gag-Myc fusion proteins correlates with Gag-Myc protein stability and transcriptional repression	ONCOGENE			English	Article						myc; repression; avian retrovirus; Gag-Myc	ROUS-SARCOMA VIRUS; ORNITHINE DECARBOXYLASE GENE; UBIQUITIN-PROTEASOME PATHWAY; NUCLEOTIDE-SEQUENCE ANALYSIS; DNA-DAMAGING AGENTS; C-MYC; V-MYC; NEOPLASTIC TRANSFORMATION; NUCLEOCAPSID PROTEIN; CELL-TRANSFORMATION	Avian retroviruses that have transduced c-myc are useful tools to study the conditions necessary for cellular transformation. FH3, one such retrovirus which encodes a Gag-Myc fusion protein, is not transforming in quail embryonic fibroblasts, but a late variant of FH3 that arose after passaging FH3-infected cells is transforming. Mutational analysis of FH3 revealed that the presence of a portion of the retroviral protease in FH3 inhibited transformation and that this inhibition was transferable to more highly transforming retrovirus, MC29. Transforming and non-transforming FH3-derived and MC29-derived Gag-Myc proteins were used to further explore characteristics of Myc necessary for transformation. Gag-Myc proteins which were transforming were found to be the most stable in the cell, To distinguish whether transactivation and/or repression is correlated to transformation, the various Gag-Myc fusion proteins were tested for their ability to activate or repress c-Myc targets. Results indicated that a correlation exists between transforming Gag-Myc proteins and their ability to repress, whereas all Gag-Myc proteins could transactivate, regardless of their ability to transform, Taken together, these results suggest that protein stabilization of Myc and repression of target genes by Myc are important for cellular transformation.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Linial, ML (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, Mail Stop A3-015,1100 Fairview Ave N, Seattle, WA 98109 USA.				NATIONAL CANCER INSTITUTE [R01CA018282, T32CA009657, R01CA058809] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-18282, CA-58809, 5 T32 CA-09657] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P100, DOI 10.1073/pnas.80.1.100; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BIEGALKE BJ, 1990, VIROLOGY, V177, P657, DOI 10.1016/0042-6822(90)90531-U; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BRASIER AR, 1995, CURRENT PROTOCOLS MO; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CAMPBELL S, 1995, J VIROL, V69, P6487, DOI 10.1128/JVI.69.10.6487-6497.1995; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; CHEN C, 1989, J VIROL, V63, P5092, DOI 10.1128/JVI.63.12.5092-5100.1989; CHEN CA, 1996, CURRENT PROTOCOLS MO; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Coffin JM, 1996, VIROLOGY, P1767; COHN SL, 1990, ONCOGENE, V5, P1821; CROUCH DH, 1990, ONCOGENE, V5, P683; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DIBHAJJ F, 1993, PROTEIN SCI, V2, P231; DUPRAZ P, 1992, J VIROL, V66, P4662, DOI 10.1128/JVI.66.8.4662-4670.1992; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FRYKBERG L, 1987, ONCOGENE, V1, P415; FU XD, 1988, J BIOL CHEM, V263, P2140; Gavine PR, 1999, ONCOGENE, V18, P7552, DOI 10.1038/sj.onc.1203102; GELFAND CA, 1993, J BIOL CHEM, V268, P18450; GRINDE B, 1992, J BIOL CHEM, V267, P9481; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HAYFLICK J, 1985, P NATL ACAD SCI USA, V82, P2718, DOI 10.1073/pnas.82.9.2718; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; KARPEL RL, 1987, J BIOL CHEM, V262, P4961; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee CM, 1999, ONCOGENE, V18, P2997, DOI 10.1038/sj.onc.1202786; Lee LA, 1997, CURR TOP MICROBIOL, V224, P131; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LINIAL M, 1985, P NATL ACAD SCI USA, V82, P53, DOI 10.1073/pnas.82.1.53; LINIAL M, 1982, VIROLOGY, V119, P382, DOI 10.1016/0042-6822(82)90097-6; LOEB DD, 1989, NATURE, V340, P397, DOI 10.1038/340397a0; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MAO Y, 1993, BIOCHEM J, V295, P641, DOI 10.1042/bj2950641; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MIN SY, 1992, ONCOGENE, V7, P1531; MLADENOV Z, 1967, JNCI-J NATL CANCER I, V38, P251; MOSHIER JA, 1993, CANCER RES, V53, P2618; OERTLE S, 1992, J VIROL, V66, P3873, DOI 10.1128/JVI.66.6.3873-3878.1992; PENA A, 1993, J BIOL CHEM, V268, P27277; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P2500, DOI 10.1073/pnas.80.9.2500; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Schneider A, 1997, CURR TOP MICROBIOL, V224, P137; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; SHINDO H, 1993, ACTA NEUROPATHOL, V86, P345, DOI 10.1007/BF00369446; TIKHONENKO AT, 1992, J VIROL, V66, P946, DOI 10.1128/JVI.66.2.946-955.1992; TIKHONENKO AT, 1993, J VIROL, V67, P3635, DOI 10.1128/JVI.67.6.3635-3638.1993; Vairapandi M, 1996, ONCOGENE, V12, P2579; Vogt VM, 1996, CURR TOP MICROBIOL, V214, P95; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WALTHER N, 1986, VIROLOGY, V154, P219, DOI 10.1016/0042-6822(86)90444-7; WALTHER N, 1985, J VIROL, V54, P576, DOI 10.1128/JVI.54.2.576-585.1985; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P3642, DOI 10.1073/pnas.80.12.3642; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	74	4	5	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2001	20	9					1118	1127		10.1038/sj.onc.1204226	http://dx.doi.org/10.1038/sj.onc.1204226			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314049				2022-12-17	WOS:000167232100012
J	Provot, S; Pouponnot, C; Lecoq, O; Calothy, G; Felder-Schmittbuhl, MP				Provot, S; Pouponnot, C; Lecoq, O; Calothy, G; Felder-Schmittbuhl, MP			Characterization of a novel quiescence responsive element downregulated by v-Src in the promoter of the neuroretina specific QR1 gene	ONCOGENE			English	Article						growth arrest; differentiation; neuroretina; gene expression; oncogene; Maf	ROUS-SARCOMA VIRUS; EXTRACELLULAR-MATRIX PROTEIN; CHICKEN-EMBRYO FIBROBLASTS; TRANSCRIPTION FACTOR NRL; ARREST-SPECIFIC GENE; RETINA-SPECIFIC QR1; GROWTH-ARREST; CELL-PROLIFERATION; MAMMALIAN-CELLS; DOWN-REGULATION	The neuroretina is a functional unit of the central nervous system which arises through successive steps of division, growth arrest and differentiation of neuroectodermal precursors. Postmitotic quail neuroretina (QNR) cells are conditionally induced to divide upon infection with temperature sensitive mutants of Rous sarcoma virus (RSV), since QNR cell division can be arrested by either inactivating p60v-Src at the nonpermissive temperature (41 degrees C) or by serum deprivation at 37 degrees C. We are studying the transcriptional control of QR1, a neuroretina specific gene, whose expression is down-regulated in proliferating cells at 37 degrees C and is fully restored when these cells are made quiescent. We previously showed that this quiescence specific upregulation implicates a promoter region named A box, which binds Maf transcription factors. We report the identification of the C box, a second promoter sequence that activates QR1 transcription in non dividing cells. This sequence is able to form two DNA-protein complexes, one of which (C4) is predominantly detected in growth arrested NR cells. We identified the DNA binding site for C4 and described mutations that abolish both C4 binding and promoter activity in quiescent cells. Moreover, we show that a multimerized C box is able to stimulate a heterologous promoter in non dividing cells and constitutes, therefore, a novel quiescence responsive enhancer. Finally, me report that QR1 transcriptional response to cell quiescence requires cooperation between the C box and A box.	CNRS, UMR 146, Inst Curie, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Felder-Schmittbuhl, MP (corresponding author), CNRS, UMR 146, Inst Curie, Batiment 110 Ctr Univ, F-91405 Orsay, France.			PROVOT, SYLVAIN/0000-0003-4087-4450				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BEDARD PA, 1989, MOL CELL BIOL, V9, P1371, DOI 10.1128/MCB.9.3.1371; BEDDINGTON RSP, 1989, DEVELOPMENT, V106, P37; Bendik I, 1998, CANCER RES, V58, P626; Bradshaw AD, 1999, MOL BIOL CELL, V10, P1569, DOI 10.1091/mbc.10.5.1569; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; CALOTHY G, 1978, VIROLOGY, V89, P75, DOI 10.1016/0042-6822(78)90041-7; Casado FJ, 1996, MECH DEVELOP, V54, P237, DOI 10.1016/0925-4773(95)00482-3; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; COCCIA EM, 1992, MOL CELL BIOL, V12, P3514, DOI 10.1128/MCB.12.8.3514; DELSAL G, 1994, P NATL ACAD SCI USA, V91, P1848, DOI 10.1073/pnas.91.5.1848; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; FABBRETTI E, 1995, GENE DEV, V9, P1846, DOI 10.1101/gad.9.15.1846; Freund C, 1996, HUM MOL GENET, V5, P1471, DOI 10.1093/hmg/5.Supplement_1.1471; Fry CJ, 1999, J BIOL CHEM, V274, P29583, DOI 10.1074/jbc.274.42.29583; GILLET G, 1995, EMBO J, V14, P1372, DOI 10.1002/j.1460-2075.1995.tb07123.x; GILLET G, 1993, ONCOGENE, V8, P565; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Goruppi S, 1996, ONCOGENE, V12, P471; Grossi M, 1998, ONCOGENE, V17, P1629, DOI 10.1038/sj.onc.1202090; GUERMAH M, 1990, MOL CELL BIOL, V10, P3584, DOI 10.1128/MCB.10.7.3584; GUERMAH M, 1991, P NATL ACAD SCI USA, V88, P4503, DOI 10.1073/pnas.88.10.4503; JOHNSTON IG, 1990, NEURON, V4, P165, DOI 10.1016/0896-6273(90)90452-L; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KAWAI S, 1971, VIROLOGY, V46, P470, DOI 10.1016/0042-6822(71)90047-X; KERPPOLA TK, 1994, ONCOGENE, V9, P675; Kim S, 1999, MOL CELL BIOL, V19, P5718; Kumar R, 1996, J BIOL CHEM, V271, P29612, DOI 10.1074/jbc.271.47.29612; Kurschner C, 1997, BIOCHEM BIOPH RES CO, V231, P333, DOI 10.1006/bbrc.1997.6097; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Lih CJ, 1996, P NATL ACAD SCI USA, V93, P4617, DOI 10.1073/pnas.93.10.4617; MAO PL, 1993, J BIOL CHEM, V268, P8131; McKinnon PJ, 1996, GENOME RES, V6, P1077, DOI 10.1101/gr.6.11.1077; Nelson PS, 1998, CANCER RES, V58, P232; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PESSAC B, 1983, NATURE, V302, P616, DOI 10.1038/302616a0; PESSAC B, 1974, SCIENCE, V185, P709, DOI 10.1126/science.185.4152.709; PEYSSONNAUX C, 2000, IN PRESS MOL CELL BI; PIERANI A, 1993, MOL CELL BIOL, V13, P3401, DOI 10.1128/MCB.13.6.3401; POIRIER F, 1982, J VIROL, V42, P780, DOI 10.1128/JVI.42.3.780-789.1982; POUPONNOT C, 1995, MOL CELL BIOL, V15, P5563; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; Ring BZ, 2000, DEVELOPMENT, V127, P307; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; SIMONNEAU L, 1986, MOL CELL BIOL, V6, P3704, DOI 10.1128/MCB.6.11.3704; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; THIERRY F, 1990, MOL CELL BIOL, V10, P4431, DOI 10.1128/MCB.10.8.4431; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VARDIMON L, 1991, MOL CELL BIOL, V11, P5275, DOI 10.1128/MCB.11.10.5275; Zavitz KH, 1997, CURR OPIN CELL BIOL, V9, P773, DOI 10.1016/S0955-0674(97)80077-4; Zhang PM, 1999, CURR OPIN CELL BIOL, V11, P655, DOI 10.1016/S0955-0674(99)00032-0	58	4	4	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2000	19	41					4736	4745		10.1038/sj.onc.1203837	http://dx.doi.org/10.1038/sj.onc.1203837			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032024				2022-12-17	WOS:000089528800008
J	Chatterjee, D; Pantazis, P; Li, G; Bremner, TA; Hendrickson, EA; Wyche, JH				Chatterjee, D; Pantazis, P; Li, G; Bremner, TA; Hendrickson, EA; Wyche, JH			Susceptibility to apoptosis is restored in human leukemia HCW-2 cells following induction and stabilization of the apoptotic effector Bak	ONCOGENE			English	Article						apoptosis; Bak; leukemia cells; differentiation	ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; BCL-2 HOMOLOG BAK; CYTOCHROME-C; MYELOID-LEUKEMIA; HL-60 CELLS; TERMINAL DIFFERENTIATION; INHIBITS APOPTOSIS; MESSENGER-RNA; LINE HL-60	We demonstrate that treatment of HCW-2 cells, an apoptotic resistant variant of the human HL-60 promyelocytic leukemia cell line with phorbol-12-myristate acetate (PMA), induced differentiation along the monocytic lineage. During this process there was a dramatic increase in the mitochondrial levels of the apoptosis effector, Bail, due to the stabilization of bak mRNA, which was correlated with the sensitization of HCW-2 cells to respond to the apoptotic effect of staurosporine (STS), Treatment of PMA-differentiated, but not undifferentiated, HCW-2 cells induced processing of Bid, substantial efflux of cytochrome c from mitochondria to the cytosol, activation of caspase-3 and apoptosis, The biological significance of the increased mitochondrial Bak in differentiated HCW-2 cells mas supported by the finding that transient transfection of a bak cDNA into HCW-2 cells conferred sensitivity to STS-triggered apoptosis, as determined ba pro-caspase-3 processing, cytochrome c efflux and DNA fragmentation. Our results suggest that the induction of Bak, upon monocytic differentiation, may he a critical event that regulates the apoptotic sensitivity of differentiated HCW-2 cells.	Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02912 USA; Howard Univ, Dept Biol, Washington, DC 20059 USA	Brown University; Howard University	Chatterjee, D (corresponding author), Brown Univ, Dept Mol Biol Cell Biol & Biochem, 69 Brown St, Providence, RI 02912 USA.							BENITO A, 1995, AM J PATHOL, V146, P481; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1995, ONCOGENE, V11, P1921; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; BREITMAN TR, 1990, METHOD ENZYMOL, V190, P118; CAMPANA D, 1993, BLOOD, V81, P1025; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chang TC, 1997, FEBS LETT, V415, P11, DOI 10.1016/S0014-5793(97)01083-1; Chatterjee D, 1997, CELL GROWTH DIFFER, V8, P1083; CHATTERJEE D, 1989, CANCER RES, V49, P3910; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291; DELIA D, 1995, BLOOD, V85, P359, DOI 10.1182/blood.V85.2.359.bloodjournal852359; DEXTER DL, 1979, CANCER RES, V39, P1020; Doyle GAR, 1997, BIOCHEMISTRY-US, V36, P2492, DOI 10.1021/bi962161e; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FRANKEL SR, 1992, ANN INTERN MED, V117, P292, DOI 10.7326/0003-4819-117-4-292; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Han ZT, 1998, P NATL ACAD SCI USA, V95, P5357, DOI 10.1073/pnas.95.9.5357; HAN ZY, 1994, AM J PATHOL, V145, P423; Han ZY, 1998, CELL DEATH DIFFER, V5, P469, DOI 10.1038/sj.cdd.4400367; Han ZY, 1999, MOL CELL BIOL, V19, P1381; Han ZY, 1996, CANCER RES, V56, P1621; Hegde R, 1998, J BIOL CHEM, V273, P7783, DOI 10.1074/jbc.273.14.7783; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; HSU SY, 1997, P NATL ACAD SCI USA, V95, P4997; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Inohara N, 1998, J BIOL CHEM, V273, P8705, DOI 10.1074/jbc.273.15.8705; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Krajewski S, 1996, CANCER RES, V56, P2849; Kren BT, 1996, CELL GROWTH DIFFER, V7, P1633; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; MINN AJ, 1997, NATURE, V385, P853; MIYASHITA T, 1993, BLOOD, V81, P151; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; NAUMOVSKI L, 1994, BLOOD, V83, P2261; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Olsson I, 1996, EUR J HAEMATOL, V57, P1; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PANTAZIS P, 1994, EUR J HAEMATOL, V53, P135; Pantazis Panayotis, 1999, Neoplasia (New York), V1, P231, DOI 10.1038/sj.neo.7900025; PARK JR, 1994, BLOOD, V84, P440; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Rokhlin OW, 1997, CANCER RES, V57, P1758; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; Sanz C, 1997, BLOOD, V89, P3199, DOI 10.1182/blood.V89.9.3199; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Simonian PL, 1997, ONCOGENE, V15, P1871, DOI 10.1038/sj.onc.1201350; SOLARY E, 1993, BLOOD, V81, P1359; Sordet O, 1999, CELL DEATH DIFFER, V6, P351, DOI 10.1038/sj.cdd.4400499; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	71	4	4	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4108	4116		10.1038/sj.onc.1203757	http://dx.doi.org/10.1038/sj.onc.1203757			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962571				2022-12-17	WOS:000088955100004
J	Andersson, ML; Vennstrom, B				Andersson, ML; Vennstrom, B			A choice between transcriptional enhancement and repression by the v-erbA oncoprotein governed by one nucleotide in a thyroid hormone responsive half site	ONCOGENE			English	Article						thyroid hormone; receptor; P75(gag-v-erbA); corepressor; response element	RETINOIC ACID RECEPTORS; AVIAN ERYTHROBLASTOSIS VIRUS; DNA-SEQUENCE SPECIFICITY; C-ERBA; ERYTHROID-DIFFERENTIATION; BINDING DOMAIN; COREPRESSOR SMRT; A GENE; P-BOX; PROTEIN	The v-erbA oncoprotein (P75(gag-v-erbA)) can repress thyroid hormone receptor induced transcriptional activation of target genes. A central question is hom hormone responsive elements in a target gene determine the transcriptional regulation mediated by P75(gag-v-erbA). We addressed this with receptors chimeric between P75(gag-v-erbA) and thyroid hormone receptor (TR) by testing their regulatory activities on thyroid hormone response elements (TREs) differing in the sequence of the consensus core recognition motif AGGTCA. We report here that enhances, TR dependent transcriptional activation is conferred by P75(gag-v-erbA) when the thymidine in the half site recognition motif is exchanged for an adenosine. The enhancement mas independent of the DNA binding region of P75(gag-v-erbA), whereas increased expression of corepressor abolished the enhancing effect, The data indicate that the enhancement results from an impaired DNA binding by the oncoprotein combined with an effective scavenging of corepressors. Our data thus suggest the P75(gag-v-erbA) indirectly can contribute to enhancement of thyroid hormone induced gene expression.	Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Vennstrom, B (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Box 285, S-17177 Stockholm, Sweden.		Andersson Lendahl, Monika/ABE-5981-2021	Andersson Lendahl, Monika/0000-0002-5690-8515				ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; Baniahmad A, 1998, MOL ENDOCRINOL, V12, P504, DOI 10.1210/me.12.4.504; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; Bauer A, 1997, ONCOGENE, V15, P701, DOI 10.1038/sj.onc.1201208; BEUG H, 1994, CURR OPIN CELL BIOL, V6, P816, DOI 10.1016/0955-0674(94)90050-7; BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Ciana P, 1998, EMBO J, V17, P7382, DOI 10.1093/emboj/17.24.7382; DAMM K, 1993, FASEB J, V7, P904, DOI 10.1096/fasebj.7.10.8102105; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DESAIYAJNIK V, 1995, J VIROL, V69, P5103, DOI 10.1128/JVI.69.8.5103-5112.1995; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; FARSETTI A, 1992, J BIOL CHEM, V267, P15784; FUERSTENBERG S, 1990, J VIROL, V64, P5891, DOI 10.1128/JVI.64.12.5891-5902.1990; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Judelson C, 1996, J BIOL CHEM, V271, P10800, DOI 10.1074/jbc.271.18.10800; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LEE Y, 1993, J BIOL CHEM, V268, P2021; Li H, 1997, MOL ENDOCRINOL, V11, P2025, DOI 10.1210/me.11.13.2025; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAWAZ Z, 1995, P NATL ACAD SCI USA, V92, P11691, DOI 10.1073/pnas.92.25.11691; NELSON CC, 1994, MOL ENDOCRINOL, V8, P829, DOI 10.1210/me.8.7.829; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; RASCLE A, 1994, ONCOGENE, V9, P2853; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; Schmidt S, 1998, NUCLEIC ACIDS RES, V26, P1191, DOI 10.1093/nar/26.5.1191; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHROEDER C, 1992, ONCOGENE, V7, P217; SJOBERG M, 1995, MOL CELL BIOL, V15, P4718; SMITMCBRIDE Z, 1994, MOL ENDOCRINOL, V8, P819, DOI 10.1210/me.8.7.819; STEINLEIN P, 1995, CURR BIOL, V5, P191, DOI 10.1016/S0960-9822(95)00040-6; SUDOL M, 1986, NUCLEIC ACIDS RES, V14, P2391, DOI 10.1093/nar/14.5.2391; Tagami T, 1998, MOL ENDOCRINOL, V12, P1888, DOI 10.1210/me.12.12.1888; TSIKA RW, 1990, P NATL ACAD SCI USA, V87, P379, DOI 10.1073/pnas.87.1.379; UMESONO K, 1991, CELL, V65, P1; Wahlstrom GM, 1996, ONCOGENE, V13, P843; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; Wong JM, 1997, EMBO J, V16, P7130, DOI 10.1093/emboj/16.23.7130; YEN PM, 1992, J BIOL CHEM, V267, P3565; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	53	4	4	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3563	3569		10.1038/sj.onc.1203692	http://dx.doi.org/10.1038/sj.onc.1203692			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951561	Bronze			2022-12-17	WOS:000088568300001
J	Villalonga, P; Rius, E; Bachs, O; Agell, N				Villalonga, P; Rius, E; Bachs, O; Agell, N			[Lys(61)]N-Ras is able to induce full activation and nuclear accumulation of Cdk4 in NIH3T3 cells	ONCOGENE			English	Article						Ras; cdk4; cdk2; cell cycle; cell nucleus	CYCLIN-DEPENDENT KINASES; INHIBITOR P27(KIP1); RETINOBLASTOMA PROTEIN; SIGNAL-TRANSDUCTION; G(1) PROGRESSION; PHASE-TRANSITION; 3T3 FIBROBLASTS; RAS ACTIVITY; S-PHASE; GROWTH	The elements of the cell cycle regulatory machinery activated by the oncogenic form of Ras, [Lys(61)]N-Ras, have been analysed in NIH3T3 cells. We demonstrate that [Lys(61)]N-Ras expression is able to induce full cdk4 activation. As already reported, oncogenic Ras expression was sufficient to induce cyclin D1 and p21(cip1) expression and their association with cdk4. Furthermore, serum-starved [Lys(61)]N-Ras NIH3T3 cells showed nuclear accumulation of cyclin D1 and cdk4 not observed in serum-started NIH3T3 cells. This accumulation of cdk4 into the cell nucleus observed in serum-started [Lys(61)]N-Ras NIH3T3 cells was inhibited by a microinjection of neutralizing anti-Ras antibodies. Thus, active [Lys(61)]N-Ras was a sufficient signal to induce nuclear accumulation of cyclin D1/cdk4, leading to its full activation, Transfection of [Lys(61)]N-Ras NIH3T3 cells with an inactive form of MEK or their treatment with PD 98059, showed that nuclear translocation of cdk4 was MEK dependent. Interestingly, cells constitutively expressing [Lys(61)]N-Ras did not inactivate pRb and did not proliferate in the absence of serum. This may be due to the fact that although association of cdk2 with cyclin E and the translocation of those complexes to the nucleus were achieved, [Lys(61)]N-Ras expression was not sufficient to induce cdk2 activation. The high levels of p27(kip1) that were found in cyclin E/cdk2 complexes may be responsible for the inability of oncogenic Res to activate this kinase. In consequence, oncogenic alterations that lead to a decrease in p27(kip1) bound to cyclin E may cooperate with Ras to induce full cdk2 activation, pRb inactivation and thus cell proliferation.	Univ Barcelona, Fac Med, IDIBAPS, Dept Biol Cellular Anat Patol, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Agell, N (corresponding author), Univ Barcelona, Fac Med, IDIBAPS, Dept Biol Cellular Anat Patol, E-08036 Barcelona, Spain.		Agell, Neus/E-9640-2016; Villalonga, Priam/K-4350-2014	Agell, Neus/0000-0002-1205-6074; Villalonga, Priam/0000-0002-7190-6884				Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Arber N, 1997, CANCER RES, V57, P1569; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; BOS JL, 1989, CANCER RES, V49, P4682; Bosch M, 1998, J BIOL CHEM, V273, P22145, DOI 10.1074/jbc.273.34.22145; Botz J, 1996, MOL CELL BIOL, V16, P3401; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; Dong F, 1998, J BIOL CHEM, V273, P6190, DOI 10.1074/jbc.273.11.6190; DOU QP, 1994, J BIOL CHEM, V269, P1306; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Downward J, 1997, CURR BIOL, V7, P258; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; Geng Y, 1996, ONCOGENE, V12, P1173; GRANA X, 1995, ONCOGENE, V11, P211; HARPER JW, 1993, CELL, V75, P805; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; KEYOMARSI K, 1994, CANCER RES, V54, P380; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Liu Y, 1996, CANCER RES, V56, P31; Lloyd AC, 1998, CURR OPIN GENET DEV, V8, P43, DOI 10.1016/S0959-437X(98)80060-9; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; Mittnacht S, 1997, CURR BIOL, V7, P219, DOI 10.1016/S0960-9822(97)70094-0; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Peeper DS, 1997, FEBS LETT, V410, P11, DOI 10.1016/S0014-5793(97)00319-0; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QUELLE DE, 1995, ONCOGENE, V11, P635; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Roussel ME, 1998, ADV CANCER RES, V74, P1, DOI 10.1016/S0065-230X(08)60763-0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Taules M, 1998, J BIOL CHEM, V273, P33279, DOI 10.1074/jbc.273.50.33279; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Winston JT, 1996, ONCOGENE, V12, P127; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	71	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 3	2000	19	5					690	699		10.1038/sj.onc.1203341	http://dx.doi.org/10.1038/sj.onc.1203341			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZU	10698514				2022-12-17	WOS:000085192000011
J	Makarovskiy, AN; Pu, YS; Lo, P; Earley, K; Paglia, M; Hixson, DC; Lin, SH				Makarovskiy, AN; Pu, YS; Lo, P; Earley, K; Paglia, M; Hixson, DC; Lin, SH			Expression and androgen regulation of C-CAM cell adhesion molecule isoforms in rat dorsal and ventral prostate	ONCOGENE			English	Article						C-CAM; androgen regulation; prostate	TRANSGENIC MICE; BILIARY GLYCOPROTEIN; HEPATOCELLULAR CARCINOMAS; MESSENGER-RNA; ANTIGEN GENE; ECTO-ATPASE; E-CADHERIN; CANCER; PROGRESSION; PROBASIN	C-CAM is an epithelial cell adhesion molecule with two major splice variants that differ in the length of the cytoplasmic domain. C-CAM1 (long (L)-form) strongly suppresses the tumorigenicity of human prostate carcinoma cells. In contrast, C-CAM2 (short (S)-form) does not exhibit tumor-suppressive activity. In the present study we have investigated the functional significance of L-form and S-form C-CAM in rat prostate by examining their expression and distribution in different prostate lobes and their response to androgen deprivation, RNase protection assays with a probe for both C-CAM isoforms detected high levels of C-CAM messages in the rat dorso-lateral prostate (DLP), L- and S-form proteins, localized by indirect immunofluorescence using isoform-specific antipeptide antibodies, were co-expressed on the apical surface of prostate epithelial cells in normal DLP, Androgen depletion did not significantly change the steady state levels of C-CAM message and protein expression in the DLP, although there was a change in the pattern of protein expression in these lobes, In contrast, C-CAM isoform messages and proteins were undetectable in normal ventral prostate (VP) but increased markedly in this lobe in response to castration, producing isoform ratios similar to those in DLP, These results demonstrate that coordinate expression of C-CAM isoforms is maintained in the VP following androgen depletion and suggest that androgen suppresses C-CAM expression in VP but not in DLP, These results suggest that balanced expression of L- and S-form C-CAM is important for normal prostate growth and differentiation.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Brown Univ, Rhode Isl Hosp, Dept Med Oncol, Providence, RI 02903 USA; Brown Univ, Rhode Isl Hosp, Dept Urol, Providence, RI 02903 USA	University of Texas System; UTMD Anderson Cancer Center; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital	Lin, SH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Box 89,1515 Holcombe Blvd, Houston, TX 77030 USA.			PU, YEONG-SHIAU/0000-0002-2859-3966	NATIONAL CANCER INSTITUTE [P30CA016672, R01CA042714, R01CA064856] Funding Source: NIH RePORTER; NCI NIH HHS [CA64856, CA16672, CA42714] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOSTWICK DG, 1993, HUM PATHOL, V24, P298, DOI 10.1016/0046-8177(93)90041-E; BUSSEMAKERS MJG, 1992, CANCER RES, V52, P2916; CHEUNG PH, 1993, J BIOL CHEM, V268, P6139; CHEUNG PH, 1993, BIOCHEM J, V295, P427, DOI 10.1042/bj2950427; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P1256, DOI 10.1210/me.11.9.1256; CRESS AE, 1995, CANCER METAST REV, V14, P219, DOI 10.1007/BF00690293; Gingrich JR, 1996, CANCER RES, V56, P4096; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; HIXSON DC, 1989, CANCER RES, V49, P6788; HIXSON DC, 1985, CANCER RES, V45, P3742; HSIEH JT, 1995, CANCER RES, V55, P190; Kasper S, 1998, LAB INVEST, V78, P319; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; Kunath T, 1995, ONCOGENE, V11, P2375; LEE C, 1981, PROSTATIC CELL STRUC, P145; LIN SH, 1991, BIOCHEM J, V278, P155, DOI 10.1042/bj2780155; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; MATUO Y, 1985, BIOCHEM BIOPH RES CO, V130, P293, DOI 10.1016/0006-291X(85)90416-4; MCNEAL JE, 1988, AM J SURG PATHOL, V12, P897, DOI 10.1097/00000478-198812000-00001; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; PARKER MG, 1979, P NATL ACAD SCI USA, V76, P1580, DOI 10.1073/pnas.76.4.1580; PARKER MG, 1980, J BIOL CHEM, V255, P6996; PRICE D, 1963, NATL CANCER I MONOGR, V12, P351; THOMPSON NL, 1994, PATHOBIOLOGY, V62, P209, DOI 10.1159/000163912; Turbide C, 1997, CANCER RES, V57, P2781; UMBAS R, 1992, CANCER RES, V52, P5104; Wei CW, 1997, P NATL ACAD SCI USA, V94, P6369, DOI 10.1073/pnas.94.12.6369; Yan Y, 1997, PROSTATE, V32, P129	30	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 27	1999	18	21					3252	3260		10.1038/sj.onc.1202665	http://dx.doi.org/10.1038/sj.onc.1202665			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359531				2022-12-17	WOS:000080523800008
J	Kristjuhan, A; Jaks, V; Rimm, I; Tooming, T; Maimets, T				Kristjuhan, A; Jaks, V; Rimm, I; Tooming, T; Maimets, T			Oligomerization of p53 is necessary to inhibit its transcriptional transactivation property at high protein concentration	ONCOGENE			English	Article						p53; oligomerization; transactivation	WILD-TYPE P53; DOWN-REGULATES TRANSCRIPTION; TATA-BINDING PROTEIN; REPRESSION FUNCTIONS; ACTIVATION DOMAINS; DNA; PROMOTERS; GROWTH; SITE; REGIONS	We have previously shown that transactivation by tumor suppressor protein p53 can be inhibited in vivo at elevated protein concentrations. In this study we characterize the structural requirements of this function. We show that oligomerization domain of p53 is involved in loss of transactivation at high protein concentrations: mutants not able to oligomerize are neither able to suppress transactivation, although these transactivating properties can be untouched.	Tartu State Univ, Estonian Bioctr, Inst Mol & Cell Biol, EE-2400 Tartu, Estonia	Estonian Biocentre; University of Tartu	Maimets, T (corresponding author), Tartu State Univ, Estonian Bioctr, Inst Mol & Cell Biol, Riia 23, EE-2400 Tartu, Estonia.		Jaks, Viljar/H-2467-2012; Maimets, Toivo/E-9268-2017	Jaks, Viljar/0000-0002-2221-6262; Maimets, Toivo/0000-0001-6461-3365; Kristjuhan, Arnold/0000-0002-5842-4952				BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEB SP, 1994, ONCOGENE, V9, P1341; DESAINTES C, 1995, ONCOGENE, V10, P2155; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; JACKSON P, 1993, ONCOGENE, V8, P589; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kristjuhan A, 1995, EUR J BIOCHEM, V234, P827, DOI 10.1111/j.1432-1033.1995.827_a.x; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LIU X, 1995, MOL CELL BIOL, V15, P6474; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Lu X, 1996, ONCOGENE, V13, P413; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MIYASHITA T, 1995, CELL, V80, P293; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PELLEGATA NS, 1995, ONCOGENE, V11, P337; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SANG BC, 1994, ONCOGENE, V9, P853; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SOUSSI T, 1990, ONCOGENE, V5, P945; SPAETE RR, 1985, J VIROL, V56, P135, DOI 10.1128/JVI.56.1.135-143.1985; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TARUNINA M, 1993, ONCOGENE, V8, P3165; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013	45	4	4	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2413	2418		10.1038/sj.onc.1201749	http://dx.doi.org/10.1038/sj.onc.1201749			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620560				2022-12-17	WOS:000073428000015
J	Martinez, JD; Craven, MT; Pennington, ME				Martinez, JD; Craven, MT; Pennington, ME			Selective binding of different p53 response elements by p53 containing complexes	ONCOGENE			English	Article						p53; DNA binding; EMSA	TRANSFORMATION; MUTATIONS; SUPPRESSION; MUTANT; GENE	The p53 tumor suppressor protein binds two copies of a ten base pair motif that is degenerate in eight out of ten bases and conforms to the sequence, 5'PuPuPuC(A/T)(T/A)GPyPyPy-3'. As a consequence of this high degree of degeneracy, p53 response elements show a great deal of variation and it has been speculated that the variation aids in the selective activation of p53 responsive genes by specific stimuli. Here, we examined the DNA binding characteristics of several different p53 protein complexes present in nuclear extracts prepared from a cell line expressing the murine temperature sensitive p53 protein, p53(val135). Interestingly, the complexes exhibited a distinct preference for binding to some p53 response elements and not others, A critical determinant of this specificity was the sequence at the center of the ten base pair motif and alteration of a single base within this region mas sufficient to alter the set of complexes that associated with the oligonucleotide, In addition, thermal denaturation experiments demonstrated that some complexes could bind DIVA even though the p53(val135) protein had a mutant conformation, Our results are consistent with the hypothesis that p53 can distinguish between various response elements and suggest that this selectivity is manifested, in part, by the sequence of the motif and conformation of the p53 protein.	Univ Arizona, Dept Radiat Oncol, Tucson, AZ 85724 USA	University of Arizona	Martinez, JD (corresponding author), Univ Arizona, Dept Radiat Oncol, Tucson, AZ 85724 USA.				NCI NIH HHS [CA64842, CA-23074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064842, P30CA023074] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Martinez JD, 1997, ONCOGENE, V14, P2511, DOI 10.1038/sj.onc.1201095; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Nagaich AK, 1997, J BIOL CHEM, V272, P14830, DOI 10.1074/jbc.272.23.14830; Park DJ, 1996, MOL CARCINOGEN, V16, P101, DOI 10.1002/(SICI)1098-2744(199606)16:2<101::AID-MC6>3.0.CO;2-L; Smith ML, 1996, AM J PATHOL, V148, P1019; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	19	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					453	458		10.1038/sj.onc.1201565	http://dx.doi.org/10.1038/sj.onc.1201565			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484834				2022-12-17	WOS:000071739400003
J	Thatikunta, P; Raj, GV; Kundu, M; Khalili, K; Amini, S				Thatikunta, P; Raj, GV; Kundu, M; Khalili, K; Amini, S			The transcription factor E2F-1 modulates TGF-beta 1 RNA expression in glial cells	ONCOGENE			English	Article						E2F1; TGF-beta 1; gene expression; oncoproteins; central nervous system	RETINOBLASTOMA GENE-PRODUCT; GROWTH FACTOR-BETA-1 GENE; TGF-BETA; TUMOR-ANTIGEN; S-PHASE; PROTEIN; CYCLE; PROMOTER; BINDING; INHIBITION	The cell type specificity of the regulation of expression of the potent growth inhibitory cytokine transforming growth factor-beta (TGF-beta), prompted our analyses of the regulation of TGF-beta 1 gene expression in glial cells by viral and cellular oncoproteins. We have shown that SV40 T-antigen diminished TGF-beta 1 expression in glial cells and this repression was dependent on the ability of T-antigen to interact with the tumor suppressor protein, pRb, and two structurally related proteins, p107 and p130. The cellular transcription factor E2F-1, which is a downstream effector of T-antigen, was unable to influence expression from the TGF-beta 1 promoter by itself. Interestingly, E2F-1 could overcome viral T-antigen-mediated repression of the TGF-beta 1 promoter, suggesting potential feedback loop between TGF-beta and E2F in virally transformed glial cells. Using deletion analyses, we have mapped two E2F-1-responsive regions on the TGF-beta 1 promoter: a T-antigen-dependent negative regulatory sequence (TdNRS) between - 323 and - 175, and a T-antigen-independent positive regulatory sequence (TiPRS) between - 34 and + 10 on the TGF-beta 1 promoter, Further examination of TiPRS revealed the presence of a functional E2F binding site. Interestingly, the amino terminus of E2F-1 was required for its activation of TGF-beta 1 expression, as mutations in that domain abolished the ability of E2F-1 to increase TGF-beta 1 expression. These data suggest that yet-uncharacterized interaction between the amino terminus of E2F-1 and cellular proteins regulates TGF-beta 1 expression, The mechanism for E2F-1-mediated Tantigen-dependent regulation of TGF-beta 1 expression from TdNRS awaits further characterization.	ALLEGHENY UNIV HLTH SCI,CTR NEUROVIROL,PHILADELPHIA,PA 19107; ALLEGHENY UNIV HLTH SCI,DEPT NEUROL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,DEPT MICROBIOL & IMMUNOL,KIMMEL CANC INST,PHILADELPHIA,PA 19107	Drexel University; Drexel University; Jefferson University			Kundu, Mondira/N-8139-2018	Kundu, Mondira/0000-0001-9946-2472				BENZAKOUR O, 1994, B CANCER, V81, P1014; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; DATTA PK, 1994, J BIOL CHEM, V269, P25392; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FLANDERS KC, 1991, DEVELOPMENT, V113, P183; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KIM SJ, 1989, J BIOL CHEM, V264, P402; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LOGAN TJ, 1994, MOL BIOL CELL, V5, P667, DOI 10.1091/mbc.5.6.667; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; NEVINS JR, 1992, SCIENCE, V258, P424; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; RAJ GV, 1994, MOL CELL BIOL, V14, P7770, DOI 10.1128/MCB.14.12.7770; Raj GV, 1996, ONCOGENE, V12, P1279; ROBERTS AB, 1991, CANCER CELL-MON REV, V3, P19; ROBERTS AB, 1990, ANN NY ACAD SCI, V593, P43, DOI 10.1111/j.1749-6632.1990.tb16098.x; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; SALA A, 1994, CANCER RES, V54, P1402; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; TEVETHIA MJ, 1988, VIROLOGY, V162, P76, DOI 10.1016/0042-6822(88)90396-0; VERITY AN, 1993, J NEUROCHEM, V60, P577, DOI 10.1111/j.1471-4159.1993.tb03188.x; WALL NA, 1994, CURR OPIN GENET DEV, V4, P517, DOI 10.1016/0959-437X(94)90066-C; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0	42	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2959	2969		10.1038/sj.onc.1201129	http://dx.doi.org/10.1038/sj.onc.1201129			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205103				2022-12-17	WOS:A1997XF55500010
J	Tai, YT; Gould, MN				Tai, YT; Gould, MN			The genetic penetrance of the activated neu oncogene for the induction of mammary cancer in vivo	ONCOGENE			English	Article						neu; rat; mammary cancer; retroviral vector	SINGLE-STEP INDUCTION; TRANSGENIC MICE; EPITHELIAL-CELLS; COMPETITIVE PCR; FREQUENCY; CARCINOGENESIS; SUPPRESSION; INITIATION; NEOPLASIA; INVIVO	Carcinogeneis is most often viewed as a multistage disease process, An exception to this was suggested for neu transformation of mammary cells in a transgenic model (Muller et al., 1988); however, this interpretation is controversial (Bouchard et al., 1989), In order to better define nea mammary transformation in vivo, we directly measured the genetic penetrance of the nea oncogene, Mammary cells in situ were infected with replication-defective retroviral vectors carrying the activated nea oncogene (pJRneu). A limiting dilution in vivo transplantation assay was used to measure the percentage of mammary clonogenic (stem-like) cells that stably and functionally integrated this vector, Based on this, the percentage of clonogens integrating and expressing neu that could progress to mammary carcinomas was quantified to estimate the penetrance of this gene in mammary carcinogenesis, The genetic penetrance of neu was 3.6% (95% confidence interval 2.2%-5.8%), This high degree of genetic penetrance is compatible with the observations that certain neu-transgenic mice develop a very great number of mammary carcinomas (Muller et al., 1988), However, whether these data are compatible with a single-step transformation model (100% penetrance) is uncertain and is discussed.	UNIV WISCONSIN,DEPT HUMAN ONCOL,MADISON,WI 53792	University of Wisconsin System; University of Wisconsin Madison			Gould, Michael N/C-7414-2014		NCI NIH HHS [CA58328] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058328] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE K, 1995, BRAIN RES, V683, P251, DOI 10.1016/0006-8993(95)00272-R; Bauer G, 1996, HISTOL HISTOPATHOL, V11, P237; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CARDIFF RD, 1991, AM J PATHOL, V139, P495; Clifton K. H., 1985, CELL CLONES MANUAL M, P128; CLIFTON KH, 1986, CANCER RES, V46, P2390; DOMANN FE, 1994, RADIAT RES, V137, P330, DOI 10.2307/3578707; GOULD MN, 1977, RADIAT RES, V72, P343, DOI 10.2307/3574704; Hess S, 1996, J EXP MED, V183, P159, DOI 10.1084/jem.183.1.159; KAMIYA K, 1995, P NATL ACAD SCI USA, V92, P1332, DOI 10.1073/pnas.92.5.1332; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Langer C, 1996, EXP CELL RES, V222, P117, DOI 10.1006/excr.1996.0015; LEE WMF, 1985, MOL CELL BIOL, V5, P3345, DOI 10.1128/MCB.5.12.3345; Lenahan MK, 1996, ONCOGENE, V12, P1847; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MCCULLOCH RK, 1995, PCR METH APPL, V4, P219; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; SHEMESH J, 1993, J BIOL CHEM, V268, P15704; SIEBERT PD, 1993, BIOTECHNIQUES, V14, P244; SIEBERT PD, 1992, NATURE, V359, P557, DOI 10.1038/359557a0; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TAI YT, 1995, CARCINOGENESIS, V16, P1455, DOI 10.1093/carcin/16.7.1455; WANG BC, 1991, CANCER RES, V51, P2642; WANG BC, 1991, CANCER RES, V51, P5649	25	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 5	1997	14	22					2701	2707		10.1038/sj.onc.1201101	http://dx.doi.org/10.1038/sj.onc.1201101			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XB978	9178768				2022-12-17	WOS:A1997XB97800009
J	CollFresno, PM; Batoz, M; Tarquin, S; Birnbaum, D; Coulier, F				CollFresno, PM; Batoz, M; Tarquin, S; Birnbaum, D; Coulier, F			Cytotoxic activity of a diphtheria toxin/FGF6 mitotoxin on human tumour cell lines	ONCOGENE			English	Article						mitotoxin; fibroblast growth factor; tumour cell line; diphtheria toxin	FIBROBLAST GROWTH-FACTOR; FACTOR-PSEUDOMONAS EXOTOXIN; HEPARAN-SULFATE PROTEOGLYCANS; FACTOR-SAPORIN MITOTOXIN; BREAST-CARCINOMA CELLS; CYTO-TOXIC ACTIVITY; PHASE-I TRIAL; FUSION PROTEIN; SIGNAL TRANSDUCTION; MYCOSIS-FUNGOIDES	The FGFs constitute a family of, at least, 12 polypeptides (FGF1 to PGF12) implicated in a number of physiological and pathological processes throughout embryogenesis and adult life. They bind to at least three types of cell surface molecules, including four high affinity transmembrane tyrosine kinase receptors (FGFR1 to FGFR4). In addition to important roles during development, FGF involvement in pathological conditions, including tumour formation, has been suspected, and overexpression of FGFR in tumour specimens is well documented. Diphtheria Toxin/FGF6 (DT/FGF6) mitotoxin has been shown to selectively and effectively target FGFR1-expressing cells. We show here that DT/FGF6 targets myoblasts engineered to express either one of the four FGFR, as well as FGFR-expressing tumour cells.	INSERM,U119,MOL ONCOL LAB,F-13009 MARSEILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			Coulier, François/G-6098-2015	Coulier, François/0000-0002-6288-7773; Birnbaum, Daniel/0000-0001-7920-9883				ADELAIDE J, 1988, ONCOGENE, V2, P413; ADNANE J, 1991, ONCOGENE, V6, P659; AVIEZER D, 1994, J BIOL CHEM, V269, P114; BATOZ M, 1995, CELL GROWTH DIFFER, V6, P1143; BEITZ JG, 1992, CANCER RES, V52, P227; BIRNBAUM D, 1991, ANN NY ACAD SCI, V638, P409, DOI 10.1111/j.1749-6632.1991.tb49055.x; BURRUS LW, 1992, MOL CELL BIOL, V12, P5600, DOI 10.1128/MCB.12.12.5600; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; COULIER F, 1996, IN PRESS J MOL EVOL; Coulier Francois, 1994, Progress in Growth Factor Research, V5, P1, DOI 10.1016/0955-2235(94)90014-0; DELAPEYRIERE O, 1993, DEVELOPMENT, V118, P601; DELAPEYRIERE O, 1990, ONCOGENE, V5, P823; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ENSOLI B, 1989, CANCER CELL-MON REV, V1, P93; FOSS FM, 1994, BLOOD, V84, P1765; GALLAGHER JT, 1994, EUR J CLIN CHEM CLIN, V32, P239; GAWLAK SL, 1993, BIOCONJUGATE CHEM, V4, P483, DOI 10.1021/bc00024a010; HALABAN R, 1991, ANN NY ACAD SCI, V638, P232, DOI 10.1111/j.1749-6632.1991.tb49034.x; HORLICK RA, 1992, GENE, V120, P291, DOI 10.1016/0378-1119(92)90108-2; JACQUEMIER J, 1994, INT J CANCER, V59, P373, DOI 10.1002/ijc.2910590314; JAYE M, 1987, J BIOL CHEM, V262, P16612; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KIHARA A, 1995, CANCER RES, V55, P71; KUZEL TM, 1993, LEUKEMIA LYMPHOMA, V11, P369, DOI 10.3109/10428199309067928; LAPPI DA, 1989, BIOCHEM BIOPH RES CO, V160, P917, DOI 10.1016/0006-291X(89)92522-9; LORBERBOUMGALSKI H, 1988, P NATL ACAD SCI USA, V85, P1922, DOI 10.1073/pnas.85.6.1922; LUQMANI YA, 1995, INT J CANCER, V64, P274, DOI 10.1002/ijc.2910640411; MCLESKEY SW, 1994, CANCER RES, V54, P523; MERWIN JR, 1992, CANCER RES, V52, P4995; OGATA M, 1989, P NATL ACAD SCI USA, V86, P4215, DOI 10.1073/pnas.86.11.4215; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; Pai L H, 1994, Important Adv Oncol, P3; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; PLATANIAS LC, 1994, LEUKEMIA LYMPHOMA, V14, P257, DOI 10.3109/10428199409049676; QUARTO N, 1994, J CELL SCI, V107, P3201; RHOGANI M, 1994, J BIOL CHEM, V269, P3976; Siegall C B, 1990, Semin Cancer Biol, V1, P345; SIEGALL CB, 1988, P NATL ACAD SCI USA, V85, P9738, DOI 10.1073/pnas.85.24.9738; SIEGALL CB, 1994, CANCER-AM CANCER SOC, V74, P1006, DOI 10.1002/1097-0142(19940801)74:3+<1006::AID-CNCR2820741506>3.0.CO;2-V; SIEGALL CB, 1994, BIOCONJUGATE CHEM, V5, P77, DOI 10.1021/bc00025a010; TEPLER I, 1994, CANCER-AM CANCER SOC, V73, P1276, DOI 10.1002/1097-0142(19940215)73:4<1276::AID-CNCR2820730424>3.0.CO;2-D; THEILLET C, 1989, ONCOGENE, V4, P915; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; XERRI L, 1991, AM J PATHOL, V138, P9; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; YING WB, 1994, CANCER, V74, P848, DOI 10.1002/1097-0142(19940801)74:3<848::AID-CNCR2820740310>3.0.CO;2-J; ZHOU DJ, 1988, ONCOGENE, V2, P279	50	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					243	247		10.1038/sj.onc.1200826	http://dx.doi.org/10.1038/sj.onc.1200826			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010226				2022-12-17	WOS:A1997WC81800012
J	Gopalakrishnan, S; Fischer, RS; Quinlan, MP				Gopalakrishnan, S; Fischer, RS; Quinlan, MP			Induction of a complex between rasGAP and a novel 110 kD protein is required for immortalization of primary epithelial cells by the E1A 12S oncoprotein of adenovirus	ONCOGENE			English	Article						immortalization; adenovirus E1A 12S; protein complexes	GTPASE-ACTIVATING PROTEIN; EFFICIENT NUCLEAR-LOCALIZATION; GROWTH-FACTOR INDUCTION; C-TERMINAL REGION; TYROSINE PHOSPHORYLATION; COOPERATING ONCOGENES; CELLULAR PROTEIN; E1A-12S PROTEIN; TUMOR-ANTIGEN; EMBRYO CELLS	Although established cell lines can be transformed with oncogenic ras, primary epithelial cells cannot, but require the coexpression of an immortalizing oncogene, such as the E1A region of adenovirus. We have previously shown that immortalization of primary epithelial cells by E1A 12S requires the expression of five regions encoded by both the first and second exons of the gene, However, only three of these regions, located in the first exon, are required for cotransformation of primary cells with an activated ras oncogene, Thus, the expression of oncogenic ras is able to abrogate the need for the E1A function(s) encoded by the second exon that are required for immortalization, This suggested the possibility that the functions encoded by the second exon of E1A may involve or interact with the normal ras signal transduction pathway, The results described herein demonstrate that immortalization-competent 12S gene products induce the expression of a novel 110 kD protein, p110, that forms a stable complex with rasGAP. Failure to induce the p110-rasGAP complex results in the concomitant loss of ability of 12S to immortalize primary epithelial cells, The appearance of this complex parallels the expression of the 12S protein and is sensitive to the levels of E1A 12S, p110 induction is independent of the ability of 12S to activate the cell cycle and of the presence of adenovirus E1B and is not observed in the presence of the large T antigen of SV40, Thus, it is not a general response to proliferation or tumorigenic transformation, but rather seems to be specific to the immortalization function(s) of E1A 12S.	UNIV TENNESSEE, CTR HLTH SCI, DEPT MICROBIOL & IMMUNOL, MEMPHIS, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center				Fischer, Robert/0000-0003-0650-2696	NATIONAL CANCER INSTITUTE [R01CA050540] Funding Source: NIH RePORTER; NCI NIH HHS [CA50540] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; AMREIN KE, 1992, P NATL ACAD SCI USA, V89, P3343, DOI 10.1073/pnas.89.8.3343; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOLS BLMC, 1991, CANCER RES, V51, P1177; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; CERNI C, 1989, P NATL ACAD SCI USA, V86, P3266, DOI 10.1073/pnas.86.9.3266; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DOUGLAS JL, 1995, J VIROL, V69, P8061, DOI 10.1128/JVI.69.12.8061-8065.1995; DOUGLAS JL, 1994, CELL GROWTH DIFFER, V5, P475; DOUGLAS JL, 1991, ONCOGENE, V6, P2093; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Flint S. J, 1981, DNA TUMOR VIRUSES; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GALLIMORE PH, 1974, J MOL BIOL, V89, P49, DOI 10.1016/0022-2836(74)90162-4; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOTOH A, 1994, LEUKEMIA, V8, P115; GRAHAM FL, 1974, NATURE, V251, P687, DOI 10.1038/251687a0; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GSCHWENDT M, 1993, BIOCHEM BIOPH RES CO, V194, P571, DOI 10.1006/bbrc.1993.1858; HJERMSTAD SJ, 1993, BIOCHEMISTRY-US, V32, P10519, DOI 10.1021/bi00090a031; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KANNABIRAN C, 1993, J VIROL, V67, P507, DOI 10.1128/JVI.67.1.507-515.1993; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LINDER S, 1990, EXP CELL RES, V191, P1, DOI 10.1016/0014-4827(90)90027-8; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MCCORMICK F, 1990, ONCOGENE, V5, P1281; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; PRONK GJ, 1993, ONCOGENE, V8, P2773; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; QUINLAN MP, 1994, ONCOGENE, V9, P2639; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; QUINLAN MP, 1992, J VIROL, V66, P2020, DOI 10.1128/JVI.66.4.2020-2030.1992; QUINLAN MP, 1993, ONCOGENE, V8, P3289; QUINLAN MP, 1993, ONCOGENE, V8, P257; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHENK T, 1991, ADV CANCER RES, V57, P47; SJOLANDER A, 1992, BIOCHEM BIOPH RES CO, V189, P1503, DOI 10.1016/0006-291X(92)90245-G; STEPHENS C, 1987, EMBO J, V6, P2027, DOI 10.1002/j.1460-2075.1987.tb02467.x; SUBRAMANIAN T, 1991, ONCOGENE, V6, P1171; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; TAUB M, 1984, METHODS SERUM FREE C; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VANDOREN K, 1984, MOL CELL BIOL, V4, P1653, DOI 10.1128/MCB.4.8.1653; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEINSTEIN IB, 1991, SCIENCE, V251, P387, DOI 10.1126/science.1989073; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	75	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 19	1996	13	12					2659	2669						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000140				2022-12-17	WOS:A1996VZ65400016
J	Langenfeld, J				Langenfeld, J			Inhibited transformation of immortalized human bronchial epithelial cells by retinoic acid is linked to cyclin E down-regulation (vol 13, pg 1983, 1996)	ONCOGENE			English	Correction, Addition																		Langenfeld J, 1996, ONCOGENE, V13, P1983	1	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2743	2743						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654					2022-12-17	WOS:A1996VZ65400026
J	Tantravahi, R; Dudek, H; Patel, G; Reddy, EP				Tantravahi, R; Dudek, H; Patel, G; Reddy, EP			Murine myeloid leukemic cells with disrupted myb loci show splicing anomalies that account for heterogeneous sizes in myb proteins	ONCOGENE			English	Article						ABPL tumors; Myb protein heterogeneity; RNA splicing	C-MYB; NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; DNA-BINDING; V-MYB; DIFFERENTIAL EXPRESSION; STRUCTURAL ORGANIZATION; CELLULAR PROGENITOR; ONCOGENE ACTIVATION; GENE	The ABPL tumor cell lines represent a group of myeloid cell lines which contain an altered myb locus due viral insertional mutagenesis within the third exon of c-myb. Immunoprecipitation analysis of the proteins produced in three ABPL lines revealed an interesting anomaly. Despite the invariant position of the virus integration event, the three ABPL tumor cell lines me examined (ABPL-1, ABPL-2 and ABPL-4) produced three different sized proteins. In this report, we examined the molecular basis for this protein size heterogeneity. Molecular cloning and sequence analysis of the cDNAs derived from the myb transcripts show that ABPL-1 tumor produces a tripartate mRNA containing sequences derived from the viral gag and Env genes fused to the myb coding region. This results in the synthesis of a 74 kd protein. In the ABPL-2 tumor line, a gag-myb fusion protein is produced which is of 68 kd. In ABPL-4 cell line a gag-myb fusion protein is produced which contains an internal deletion of coding sequences derived from exons 13 and 14. This deletion results in the synthesis of a 59 kd protein in ABPL-4 tumor cell line,These observations were further confirmed by RNase protection assays which demonstrate the presence of aberrantly spliced mRNAs in ABPL-1 and ABPL-4 tumor cells but not in cells containing an undisrupted c-myb locus. In vitro translation and immuno-precipitation analysis of the cRNAs derived from the ABPL-1, ABPL-2 and ABPL-4 cDNAs show the synthesis of protein products that mere identical to Myb proteins produced by these tumors in vivo. These results suggest that integration of Mo-MuLV within the c-myb locus not only results in deletions of the 5' end of the transcript but splicing aberrations within the encoded mRNA, which results in the synthesis of a heterogeneous array of proteins, not seen in normal hematopoietic cells.	TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOL BIOL, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [P01CA052009] Funding Source: NIH RePORTER; NCI NIH HHS [CA52009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BADING H, 1987, ONCOGENE, V1, P395; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; CASTLE S, 1985, BIOCHEM BIOPH RES CO, V132, P688, DOI 10.1016/0006-291X(85)91187-8; CRAIG RW, 1984, CANCER RES, V44, P442; DUDEK H, 1989, ONCOGENE, V4, P1489; DUDEK H, 1989, ONCOGENE, V4, P1061; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GERWITZ AM, 1989, SCIENCE, V242, P1303; GILMAN M, 1988, CURRENT PROTOCOLS MO; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Kawasaki ES, 1990, PCR PROTOCOLS GUIDE; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; LAVU S, 1984, CURR TOP MICROBIOL, V113, P37; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; ROVERA G, 1987, ONCOGENE, V1, P29; RUSHLOW KE, 1982, SCIENCE, V216, P1421, DOI 10.1126/science.6283631; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; SHENONG GLC, 1987, J VIROL, V61, P3721, DOI 10.1128/JVI.61.12.3721-3725.1987; URBANEK P, 1988, NUCLEIC ACIDS RES, V16, P11521, DOI 10.1093/nar/16.24.11521; WATSON RJ, 1988, ONCOGENE, V2, P267; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	37	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	1996	13	6					1187	1196						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808693				2022-12-17	WOS:A1996VJ20200010
J	DUDLEY, ME; SUNDBERG, JP; ROOPENIAN, DC				DUDLEY, ME; SUNDBERG, JP; ROOPENIAN, DC			MOTIF-PRIMED POLYMERASE CHAIN REACTION-BASED ALLELOTYPE OF SARCOMAS INDUCED BY 3-METHYLCHOLANTHRENE IN INTERSPECIFIC HYBRID MICE	ONCOGENE			English	Article						LOSS OF HETEROZYGOSITY; GENOME FINGER-PRINTING; PCR; 3-METHYLCHOLANTHRENE	MINOR HISTOCOMPATIBILITY ANTIGENS; MOUSE SKIN; BREAST-CANCER; T-CELLS; TUMORS; CARCINOMAS; AMPLIFICATION; CHROMOSOME-7; RAS; CARCINOGENESIS	Loss of heterozygosity (LOH) occurs commonly in some human tumors and is thought to reflect the selective pressure exerted by tumor suppressor genes. The purpose of this study was to examine the genomic location and relative frequency of LOH of chemically induced tumors in an established mouse model for chemical carcinogenesis. Twenty-four tumors were induced by subcutaneous injection of 3-methylcholanthrene into inter-subspecific hybrid (C57BL/6J x SPRET/Ei)F1 mice. Tumors were diagnosed as poorly differentiated, spindle cell sarcomas. DNA isolated from cell cultures derived from the sarcomas was analysed for LOH using a multi-locus genome scanning technique, motif-primed PCR, followed by conventional simple sequence length polymorphism (SSLP) PCR markers. Ninety-one motif-primed PCR products and seven SSLP markers were evaluated, covering segments of 39 out of 41 chromosomes. LOH was extremely rare; average fractional allelic loss per tumor was less than 0.01 suggesting a remarkable genetic stability of the tumors and that genetic events leading to transformation are only rarely revealed as LOH. However, some regions exhibiting LOH were identified encompassing both known and hypothesized tumor suppressor loci such as Trp53. These data indicate that motif-primed PCR is an efficient method of scanning the genome of interspecific sarcomas for rare mutational events generating LOH during tumor induction. Cell lines derived from the sarcomas promise to be useful for identifying genes whose inactivation causes increased malignancy during tumor progression.			DUDLEY, ME (corresponding author), JACKSON LAB, 600 MAIN ST, BAR HARBOR, ME 04609 USA.				NCI NIH HHS [CA34196] Funding Source: Medline; NIAID NIH HHS [AI28802, AI24544] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA034196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028802, R29AI024544, R01AI024544] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBOR A, 1994, CANCER RES, V54, P4502; BARRIOS C, 1994, AM J CLIN ONCOL-CANC, V17, P273, DOI 10.1097/00000421-199406000-00019; BIRKENMEIER EH, 1992, MAMM GENOME, V3, P537, DOI 10.1007/BF00350618; BUCHMANN A, 1991, CANCER RES, V51, P4097; BURNS PA, 1991, ONCOGENE, V6, P2363; CAETANOANOLLES G, 1992, MOL GEN GENET, V235, P157, DOI 10.1007/BF00279356; CARBONE G, 1991, INT J CANCER, V47, P619, DOI 10.1002/ijc.2910470423; Coggin J H Jr, 1989, Mol Biother, V1, P223; CORNELISSE CJ, 1992, INT J CANCER, V50, P544, DOI 10.1002/ijc.2910500408; Davisson MT, 1989, GENETIC VARIANTS STR, P432; DIETRICH W, 1992, GENETICS, V131, P423; DIETRICH W, 1994, GENETICS, V91, P9451; EDWARDS RJ, 1994, CARCINOGENESIS, V15, P829, DOI 10.1093/carcin/15.5.829; FOLEY EJ, 1953, CANCER RES, V13, P835; Gross L, 1943, CANCER RES, V3, P326; HEGI ME, 1994, CANCER RES, V54, P6257; HONMA M, 1994, MUTAT RES, V304, P167, DOI 10.1016/0027-5107(94)90208-9; HOVIG E, 1993, GENOMICS, V17, P66, DOI 10.1006/geno.1993.1284; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KEMP CJ, 1993, CANCER RES, V53, P6022; KLEIN G, 1960, CANCER RES, V20, P1561; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; MULLAART E, 1993, NATURE, V365, P469, DOI 10.1038/365469a0; MULLAART E, 1993, GENES CHROMO CANCER, V6, P167; NAGAI H, 1993, CANCER DETECT PREV, V17, P399; NIWA O, 1992, JPN J CANCER RES, V83, P1192, DOI 10.1111/j.1349-7006.1992.tb02744.x; OLD LJ, 1962, ANN NY ACAD SCI, V101, P80, DOI 10.1111/j.1749-6632.1962.tb26446.x; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; PREHN RT, 1957, J NATL CANCER I, V18, P769; QUATTROCHI LC, 1994, J BIOL CHEM, V269, P6949; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RE FC, 1992, MOL CARCINOGEN, V5, P155, DOI 10.1002/mc.2940050211; ROOPENIAN DC, 1984, J IMMUNOL, V132, P1080; ROOPENIAN DC, 1983, J IMMUNOL, V131, P2135; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; SATO T, 1990, CANCER RES, V50, P7184; SHU S, 1985, CANCER RES, V45, P1657; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; SRIVASTAVA PK, 1986, P NATL ACAD SCI USA, V83, P3407, DOI 10.1073/pnas.83.10.3407; STEWART HL, 1979, PATHOLOGY TUMOURS LA, V2, P487; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; SUNDBERG JP, 1991, VET PATHOL, V28, P200, DOI 10.1177/030098589102800303; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; TAYLOR BA, 1984, MOL GEN GENET, V195, P491, DOI 10.1007/BF00341452; VISAKORPI T, 1995, CANCER RES, V55, P342; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WELSH J, 1991, NUCLEIC ACIDS RES, V19, P5275, DOI 10.1093/nar/19.19.5275; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; YAMAGUCHI T, 1992, CANCER RES, V52, P2419	52	4	4	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	1995	11	3					517	524						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630636				2022-12-17	WOS:A1995RN53000012
J	KATAHIRA, J; SIOMI, H; ISHIZAKI, T; UMEMOTO, T; TANAKA, Y; SHIDA, H				KATAHIRA, J; SIOMI, H; ISHIZAKI, T; UMEMOTO, T; TANAKA, Y; SHIDA, H			A CELLULAR PROTEIN WHICH IS COPRECIPITATED WITH HTLV-I REX PROTEIN IN THE PRESENCE OF THE TARGET MESSENGER-RNA	ONCOGENE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; RNA RESPONSE ELEMENTS; DOMINANT-NEGATIVE MUTANTS; LEUKEMIA-VIRUS; HIV-1 REV; GENE-EXPRESSION; MESSENGER-RNA; TYPE-1 REV; REGULATORY PROTEINS	We examined the cellular protein(s) which can associate with Rex protein of human T cell leukemia virus type I (HTLV-I), using Rex-maltose binding protein (MBP) fusion protein. Immunoprecipitation of RexMBP with anti-MBP antibody revealed that a 24 kD protein (p24) associated with RexMBP only in the presence of Rex-responsive mRNA. The fact that p24 was present in both the nucleus and the cytoplasm is consistent with a role of Rex in the nucleo-cytoplasmic transport of viral mRNAs. P24 did not interact with nonfunctional Rex mutant proteins even if they had RNA binding activity in vitro. These results suggest the possible involvement of p24 in the Rex function through a complex formation with Rex on Rex-responsive mRNA.	KYOTO UNIV,INST VIRUS RES,KYOTO 60601,JAPAN; UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104; KITASATO UNIV,SCH HYG SCI,DEPT IMMUNOL,SAGAMIHARA,KANAGAWA 228,JAPAN; UNIV OSAKA PREFECTURE,COLL AGR,VET PUBL HLTH LAB,SAKAI,OSAKA 591,JAPAN	Kyoto University; University of Pennsylvania; Kitasato University; Osaka Metropolitan University			Siomi, Haruhiko/A-7020-2015	Siomi, Haruhiko/0000-0001-8690-3822				AHMED YF, 1990, GENE DEV, V4, P1014, DOI 10.1101/gad.4.6.1014; ARRIGO SJ, 1991, GENE DEV, V5, P808, DOI 10.1101/gad.5.5.808; BALLAUN C, 1991, J VIROL, V65, P4408, DOI 10.1128/JVI.65.8.4408-4413.1991; BOGERD H, 1993, J VIROL, V67, P2496, DOI 10.1128/JVI.67.5.2496-2502.1993; BOGERD HP, 1991, P NATL ACAD SCI USA, V88, P5704, DOI 10.1073/pnas.88.13.5704; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; ETCHISON D, 1987, J VIROL, V61, P2702, DOI 10.1128/JVI.61.9.2702-2710.1987; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRASSMANN R, 1991, J VIROL, V65, P3721, DOI 10.1128/JVI.65.7.3721-3727.1991; HADZOPOULOUCLAD.M, 1989, J VIROL, V63, P1959; HAMMARSKJOLD ML, 1989, J VIROL, V63, P1959; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HOLLAND MJ, 1990, PCR PROTOCOLS GUIDE, P169; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; KJEMS J, 1992, EMBO J, V11, P1119, DOI 10.1002/j.1460-2075.1992.tb05152.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LU XB, 1990, P NATL ACAD SCI USA, V87, P7598, DOI 10.1073/pnas.87.19.7598; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; OHTANI K, 1987, EMBO J, V6, P389, DOI 10.1002/j.1460-2075.1987.tb04767.x; PETTERSSON I, 1984, J BIOL CHEM, V259, P5907; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; RIMSKY L, 1989, NATURE, V341, P453, DOI 10.1038/341453a0; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; SAKAI H, 1990, J VIROL, V64, P5833, DOI 10.1128/JVI.64.12.5833-5839.1990; SCHWARTZ S, 1992, J VIROL, V66, P7176, DOI 10.1128/JVI.66.12.7176-7182.1992; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SODROSKI JG, 1985, J VIROL, V55, P831, DOI 10.1128/JVI.55.3.831-835.1985; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOYOSHIMA H, 1990, J VIROL, V64, P2825, DOI 10.1128/JVI.64.6.2825-2832.1990; TRONO D, 1990, EMBO J, V9, P4155, DOI 10.1002/j.1460-2075.1990.tb07638.x; UNGE T, 1991, P NATL ACAD SCI USA, V88, P7145, DOI 10.1073/pnas.88.16.7145; WEICHSELBRAUN I, 1992, J VIROL, V66, P4540, DOI 10.1128/JVI.66.7.4540-4545.1992; WEICHSELBRAUN I, 1992, J VIROL, V66, P2583, DOI 10.1128/JVI.66.4.2583-2587.1992; WINSLOW BJ, 1993, J VIROL, V67, P2349, DOI 10.1128/JVI.67.4.2349-2354.1993; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	59	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3535	3544						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970714				2022-12-17	WOS:A1994PT39200016
J	DIECKMANN, A; KRIPPL, B				DIECKMANN, A; KRIPPL, B			THE E1A TRANSCRIPTIONAL CONTROL REGION IS EFFICIENTLY ACTIVATED IN PROLIFERATING TISSUES OF TRANSGENIC MICE	ONCOGENE			English	Article							EUKARYOTIC TRANSCRIPTION; DNA-REPLICATION; AUTO-REGULATION; GENE; CELLS; INITIATION; EXPRESSION; SEQUENCES; PROTEINS; PRODUCT	To study the in vivo regulation of the adenovirus E1A transcriptional regulatory region in transgenic mice, we have constructed two hybrid genes in which the viral control element regulates the expression of the CAT and the lacZ reporter gene. The fusion constructs were introduced into the mouse germline. The expression of the transgenes were monitored during embryogenesis and during postnatal development as web as in adult organs. We show that the E1A regulatory region is recognized and activated in undifferentiated cells during early embryonic cleavage, in the morula, in the inner cell mass and in the trophectoderm of the blastocyst. Transcription initiation at the E1A promoter leads to higher marker gene expression in proliferative centers in postimplantation embryos at the beginning of the neural tube closure. Analysing marker gene expression during postnatal development, a correlation of transcriptional activity of the E1A regulatory region and cell proliferation could be demonstrated. The expression profile of the transgene in different adult organs parallels with DNA synthesis. Marker gene expression was high in cells of organs known to have a high mitotic rate, such as the intestine, the stomach, the skin and the bone marrow, whereas little activity of the E1A control region was observed in the post-proliferative brain. These results are consistent with the finding that activation of the viral cis-regulating elements dramatically increased in the kidney after mitotic stimulation by folic acid. These observations strongly suggests a cell cycle regulated expression from the E1A enhancer/promoter in the absence of the E1A autoregulatory proteins in the living animal.	RUHR UNIV BOCHUM,FAK MED,INST PHYSIOL CHEM,D-44780 BOCHUM,GERMANY	Ruhr University Bochum								BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; CID A, 1993, J VIROL, V67, P6742, DOI 10.1128/JVI.67.11.6742-6752.1993; CLEAVER JE, 1967, THYMIDINE METABOLISM, P184; COGAN JD, 1992, J VIROL, V66, P3833, DOI 10.1128/JVI.66.6.3833-3845.1992; FUJITA S, 1964, J COMP NEUROL, V122, P311, DOI 10.1002/cne.901220303; GOSSLER A, 1989, SCIENCE, V244, P463, DOI 10.1126/science.2497519; GOSSLER A, 1993, GENE TARGETING PRACT, P181; GROSVELD F, 1992, TRANSGENIC ANIMALS, P79; HATFIELD L, 1993, J VIROL, V67, P3931, DOI 10.1128/JVI.67.7.3931-3939.1993; HEARING P, 1986, CELL, V45, P229, DOI 10.1016/0092-8674(86)90387-9; HEARING P, 1985, MOL CELL BIOL, V5, P3214, DOI 10.1128/MCB.5.11.3214; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; Hogan B., 1986, MANIPULATING MOUSE E; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; KRIPPL B, 1988, NUCLEIC ACIDS RES, V18, P8965; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; NEVINS JR, 1991, TRENDS BIOCHEM SCI, V16, P435, DOI 10.1016/0968-0004(91)90171-Q; OSBORNE TF, 1983, J VIROL, V45, P594, DOI 10.1128/JVI.45.2.594-599.1983; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SEIFERT R, 1992, ANAT EMBRYOL, V186, P601; SEISER C, 1989, NUCLEIC ACIDS RES, V17, P185, DOI 10.1093/nar/17.1.185; SNOW MHL, 1978, DEV MAMMALS, P337; TAYLOR DM, 1966, NATURE, V212, P472, DOI 10.1038/212472a0; TIBBETTS C, 1986, J VIROL, V57, P1055, DOI 10.1128/JVI.57.3.1055-1064.1986; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	31	4	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2227	2233						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036008				2022-12-17	WOS:A1994NX62900014
J	CHEN, SC; REDENIUS, D; YOUNG, JC; SCHWARTZ, RC				CHEN, SC; REDENIUS, D; YOUNG, JC; SCHWARTZ, RC			SYNERGY OF IL-7 AND V-HA-RAS IN THE IN-VITRO NEOPLASTIC PROGRESSION OF MURINE PRE-B CELLS	ONCOGENE			English	Article							STIMULATES TYROSINE PHOSPHORYLATION; INOSITOL PHOSPHOLIPID TURNOVER; LEUKEMIA-VIRUS; LYMPHOID-CELLS; INTERLEUKIN-7; CONSTRUCTION; EXPRESSION; ONCOGENES; GROWTH; DIFFERENTIATION	A recombinant retrovirus expressing IL-7 was super-infected into a murine pre-B cell line previously infected with a retrovirus expressing v-Ha-ras. Populations of cells polyclonal for integration of the IL-7 virus and independent of IL-7 for growth were generated. These cells were highly tumorigenic. Similarly, co-infection of murine bone marrow with retroviruses expressing IL-7 and v-Ha-ras generated a pre-B lymphoid outgrowth that was tumorigenic. While IL-7 and v-Ha-ras expression are not individually sufficient to induce tumorigenicity, their co-expression yields highly tumorigenic pre-B lymphoid cell lines. IL-7 expression may be equivalent to v-myc expression for synergy with v-H-ras in the neoplastic transformation of murine pre-B cells.	MICHIGAN STATE UNIV,DEPT MIKROBIOL,E LANSING,MI 48824; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024	Michigan State University; University of California System; University of California Los Angeles					NATIONAL CANCER INSTITUTE [R29CA045360] Funding Source: NIH RePORTER; NCI NIH HHS [CA45360] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHANG JM, 1989, BLOOD, V73, P1487; EARLY P, 1980, CELL, V19, P981, DOI 10.1016/0092-8674(80)90089-6; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MEEKER TC, 1990, BLOOD, V76, P285; MORRISSEY PJ, 1989, J EXP MED, V169, P707, DOI 10.1084/jem.169.3.707; MUIRHEAD M, 1990, INT J CELL CLONING, V8, P392, DOI 10.1002/stem.5530080643; MUIRHEAD M, 1992, LYMPHOKINE CYTOK RES, V11, P167; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; OVERELL RW, 1991, MOL CELL BIOL, V11, P1590, DOI 10.1128/MCB.11.3.1590; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RAVE N, 1979, NUCLEIC ACIDS RES, V6, P3559, DOI 10.1093/nar/6.11.3559; ROIFMAN CM, 1992, J IMMUNOL, V148, P1136; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHWARTZ RC, 1986, CURR TOP MICROBIOL, V132, P75; SCHWARTZ RC, 1981, J IMMUNOL, V126, P2104; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SCHWARTZ RC, 1988, MUTAT RES, V195, P245, DOI 10.1016/0165-1110(88)90003-6; SEIDMAN JG, 1978, NATURE, V276, P790, DOI 10.1038/276790a0; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P6323, DOI 10.1073/pnas.88.14.6323; VENKITARAMAN AR, 1992, P NATL ACAD SCI USA, V89, P12083, DOI 10.1073/pnas.89.24.12083; WHITLOCK CA, 1983, CELL, V32, P903, DOI 10.1016/0092-8674(83)90075-2; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608; WONG PMC, 1989, MOL CELL BIOL, V9, P797; YOUNG JC, 1991, MOL CELL BIOL, V11, P854, DOI 10.1128/MCB.11.2.854	31	4	4	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2119	2125						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336938				2022-12-17	WOS:A1993LP17100012
J	SMITH, KT; COGGINS, LW; DOHERTY, I; PENNIE, WD; CAIRNEY, M; CAMPO, MS				SMITH, KT; COGGINS, LW; DOHERTY, I; PENNIE, WD; CAIRNEY, M; CAMPO, MS			BPV-4 INDUCES AMPLIFICATION AND ACTIVATION OF SILENT BPV-1 IN A SUBLINE OF C127 CELLS	ONCOGENE			English	Article							BOVINE PAPILLOMAVIRUS TYPE-4; MOUSE CELLS; MORPHOLOGICAL TRANSFORMATION; TERMINAL DOMAIN; DNA-SEQUENCES; CATTLE; GENE; MAINTENANCE; REPLICATION; VIRUS	BPV4-induced malignant transformation of C127 mouse fibroblasts in vitro is the result of a 'hit and run' mechanism. Viral DNA is lost on continued subculture of transformed cell lines without loss of any malignant characteristics. The DNA from these cells harbours specific amplified sequences. Two such amplified fragments of approximately 10kb and 12kb were molecularly cloned and designated HL-10 and HL-12 respectively. HL-10 transformed C127 celts efficiently and therefore encodes a transforming function, whereas the 12 kb clone did not. Heteroduplexes showed that HL-12 was homologous to HL-10 except for two additional tandem copies of an approximately 1.7 kb sequence. Sequence analysis of HL-10 revealed that the clone contained a 5.2 kb region from BPV-1 including the transforming ORFs. Transformation studies have shown differences between HL-10 and BPV-1, indicating that the host flanking sequences may contribute to the transforming potential of the BPV-1 ORFs. The BPV-1 DNA was associated with sequences homologous to murine autonomously replicating sequences (ARS) implicated in the establishment of multiple tandem DNA repeats. As the parental cells contain the set of sequences amplified in transformed cells in single copy and show none of the characteristics of transformed cells, we conclude that BPV-4 has activated these sequences by amplification and rearrangement. These phenomena may be mediated through an interaction between BPV-4 proteins and the BPV-1 origin of DNA replication or via the ARS region.	BEATSON INST CANC RES, CRC BEATSON LABS, GLASGOW G61 1BD, SCOTLAND	Beatson Institute								AGRAWAL R, 1992, J GEN VIROL, V73, P201, DOI 10.1099/0022-1317-73-1-201; CAMPO MS, 1978, CELL, V15, P1411, DOI 10.1016/0092-8674(78)90065-X; CAMPO MS, 1985, EMBO J, V4, P1819, DOI 10.1002/j.1460-2075.1985.tb03856.x; CAMPO MS, 1990, ONCOGENE, V5, P303; CAMPO MS, 1982, J GEN VIROL, V63, P255, DOI 10.1099/0022-1317-63-2-255; CAMPO MS, 1986, CIBA F SYMP, V120, P117; CHEN EY, 1982, NATURE, V299, P529, DOI 10.1038/299529a0; Coggins LW, 1987, ELECTRON MICROS, P1; FERGUSON J, 1978, ADV TECHNIQUES BIOL, V2, P123; GAUKROGER J, 1991, J GEN VIROL, V72, P1165, DOI 10.1099/0022-1317-72-5-1165; GILBERT D, 1989, CELL, V56, P143, DOI 10.1016/0092-8674(89)90885-4; GREEN M, 1987, CELL, V51, P795, DOI 10.1016/0092-8674(87)90102-4; GRUMMT F, 1989, CELL, V56, P143, DOI 10.1016/0092-8674(89)90886-6; HOLST A, 1988, CELL, V52, P355; JACKSON ME, 1991, MOL CARCINOGEN, V4, P382, DOI 10.1002/mc.2940040510; JAGGAR RT, 1990, J GEN VIROL, V71, P3041, DOI 10.1099/0022-1317-71-12-3041; JARRETT WFH, 1978, NATURE, V274, P215, DOI 10.1038/274215a0; KLEINBERGER T, 1986, MOL CELL BIOL, V6, P1958, DOI 10.1128/MCB.6.6.1958; LAMBERT PF, 1987, CELL, V50, P69, DOI 10.1016/0092-8674(87)90663-5; LIU Y, 1990, J VIROL, V64, P5903, DOI 10.1128/JVI.64.12.5903-5911.1990; LUSKY M, 1986, P NATL ACAD SCI USA, V83, P3609, DOI 10.1073/pnas.83.11.3609; MACNAB JCM, 1987, J GEN VIROL, V68, P2525, DOI 10.1099/0022-1317-68-10-2525; MARSH JL, 1984, GENE, V32, P481, DOI 10.1016/0378-1119(84)90022-2; MORGAN D, 1990, J VIROL, V64, P969, DOI 10.1128/JVI.64.3.969-976.1990; POPESCU NC, 1990, CANCER RES, V50, P1316; SATO H, 1989, VIROLOGY, V168, P195, DOI 10.1016/0042-6822(89)90423-6; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SMITH KT, 1989, ONCOGENE, V4, P409; SMITH KT, 1988, VIROLOGY, V164, P39, DOI 10.1016/0042-6822(88)90617-4; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; STENLUND A, 1987, SCIENCE, V236, P1666, DOI 10.1126/science.3037693; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0	32	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1993	8	1					151	156						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380914				2022-12-17	WOS:A1993KN00500018
J	GEBERT				GEBERT			CORRECTION	ONCOGENE			English	Correction, Addition																		GEBERT, 1991, ONCOGENE, V6, P1859	1	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					821	821						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682					2022-12-17	WOS:A1992HQ68200030
J	KRAFT, AS; WANG, SS; XIANG, JL; POUNCEY, L; KIDD, VJ				KRAFT, AS; WANG, SS; XIANG, JL; POUNCEY, L; KIDD, VJ			REGULATION OF THE P58GTA CELL-DIVISION CONTROL-RELATED PROTEIN-KINASE DURING PHORBOL 12-MYRISTATE 13-ACETATE-INDUCED TERMINAL DIFFERENTIATION OF U937 CELLS	ONCOGENE			English	Article							PROMYELOCYTIC LEUKEMIA-CELLS; EXPRESSION; PHOSPHORYLATION; ONCOGENE; HL-60; INCREASE; CYCLE; AP-1	We describe the regulation of expression, activity and subcellular localization of a cell cycle control-related kinase, p58GTA, during the withdrawal from the cell cycle of U937 human leukemic cells induced by phorbol esters. Our studies indicate that steady-state mRNA, protein levels, transcription and subcellular localization of this kinase are affected in distinctly different manners by phorbol esters (phorbol 12-myristate 13-acetate, PMA). Steady-state mRNA levels increase dramatically within 1 h of PMA treatment, while steady-state protein levels increase only slightly. However, within 24 h of PMA treatment both steady-state p58GTA mRNA and protein levels decrease markedly. Assays of p58GTA protein kinase activity show that, even though steady-state protein levels are relatively constant, protein kinase activity increases within 30 min of PMA treatment, and then peaks at 2 h and 12 h after PMA treatment. Once again, p58GTA protein kinase activity decreases by 48 h to levels similar to unstimulated cells. These results suggest that the expression of the p58GTA protein kinase gene and, quite possibly, its post-translational modification are affected by phorbol esters in a complex manner.	UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NCI NIH HHS [CA42533] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; BUNNELL BA, 1990, SOMAT CELL MOLEC GEN, V16, P151, DOI 10.1007/BF01233045; BUNNELL BA, 1990, BIOCHEM BIOPH RES CO, V171, P196, DOI 10.1016/0006-291X(90)91376-4; EIPERS PG, 1991, GENOMICS, V11, P621, DOI 10.1016/0888-7543(91)90069-Q; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FIELDS AP, 1989, J BIOL CHEM, V264, P21896; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; KIDD VJ, 1991, CELL GROWTH DIFFER, V2, P85; KRAFT AS, 1987, ONCOGENE, V1, P111; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; POUNCEY L, 1991, SOMAT CELL MOLEC GEN, V17, P435, DOI 10.1007/BF01233167; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; THOMAS NSB, 1989, J BIOL CHEM, V264, P13697; WILLIAM F, 1990, J BIOL CHEM, V265, P18166; WILLIAM F, 1988, J CELL PHYSIOL, V137, P402, DOI 10.1002/jcp.1041370303; YEN A, 1987, CANCER RES, V47, P129	22	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					501	506						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549364				2022-12-17	WOS:A1992HK00500015
J	EISEMANN, A				EISEMANN, A			CORRECTION	ONCOGENE			English	Correction, Addition																		EISEMANN A, 1991, ONCOGENE, V6, P1195	1	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2379	2379						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735					2022-12-17	WOS:A1991GX73500031
J	DELSENNO, L; MAESTRI, I; PIVA, R; BIANCHINI, E; ROSSI, R; UBERTI, ED				DELSENNO, L; MAESTRI, I; PIVA, R; BIANCHINI, E; ROSSI, R; UBERTI, ED			A C-MYC GENE VARIANT WITHOUT EXON 1 AND WITH AN ABNORMAL METHYLATION PATTERN INHERITED IN A WOMAN WITH NO EVIDENCE OF MALIGNANCY	ONCOGENE			English	Note							TRANSLOCATION; ONCOGENES; LYMPHOMAS; CELLS; HYPOMETHYLATION; CHROMOSOME-8; ACTIVATION; CANCER	A c-myc DNA with a deletion which includes 5' flanking, exon 1 and intron I sequences has been found in normal white blood cells of a mother and one daughter in a Northern Italian family. In addition, the degree of methylation of specific CCGG sites in the truncated DNA is lower in both mother and daughter than that found in normal DNA. It is of interest that deletions of the first exon and hypomethylation of the c-myc gene have usually been observed only in some neoplasias. However, our results demonstrate that the c-myc truncated DNA with the abnormal methylation pattern here reported is a genomic variant which by itself is not related to neoplastic transformation.	UNIV FERRARA,CTR STUDI BIOCHIM PATHOL GENOMA UMANO,I-44100 FERRARA,ITALY; UNIV FERRARA,IST MED INTERNA,SEZ ENDOCRINOL,I-44100 FERRARA,ITALY	University of Ferrara; University of Ferrara	DELSENNO, L (corresponding author), UNIV FERRARA,IST CHIM BIOL,VL BORSARI 46,I-44100 FERRARA,ITALY.			degli Uberti, Ettore/0000-0002-9441-7223; Piva, Roberta/0000-0003-2663-6210; maestri, iva/0000-0002-3485-4640				ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; ALT FW, 1986, COLD SPRING HARB SYM, V1, P931; AVVEDIMENTO VE, 1985, HUM GENET, V71, P163, DOI 10.1007/BF00283375; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; CHEAH MSC, 1984, JNCI-J NATL CANCER I, V73, P1057; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DELSENNO L, 1986, FEBS LETT, V196, P296, DOI 10.1016/0014-5793(86)80266-6; DELSENNO L, 1989, J UROLOGY, V142, P146; DELSENNO L, 1984, NEW TRENDS EXPT HEMA, P230; DYSON PJ, 1985, P NATL ACAD SCI USA, V82, P1984, DOI 10.1073/pnas.82.7.1984; HALL JM, 1989, AM J HUM GENET, V44, P577; HALUSKA FG, 1989, NUCLEIC ACIDS RES, V15, P865; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; MIDDLETON PG, 1988, NUCLEIC ACIDS RES, V13, P5723; OCONNELL P, 1987, CYTOGENET CELL GENET, V46, P673; RABBITTS PH, 1985, EMBO J, V4, P3727, DOI 10.1002/j.1460-2075.1985.tb04141.x; RANZANI GN, 1989, ATTI ASS GENET ITA Y, V30, P295; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; SCHWAB M, 1984, NATURE, V308, P288, DOI 10.1038/308288a0; SILVA AJ, 1988, CELL, V54, P145, DOI 10.1016/0092-8674(88)90546-6	20	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1895	1898						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923512				2022-12-17	WOS:A1991GX11800024
J	GRANT, SG; CHAPMAN, VM				GRANT, SG; CHAPMAN, VM			DETAILED GENETIC-MAPPING OF THE A-RAF PROTOONCOGENE ON THE MOUSE X-CHROMOSOME	ONCOGENE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; GLYCEROL KINASE-DEFICIENCY; CHRONIC GRANULOMATOUS-DISEASE; ELECTROPHORETIC VARIATION; TRANSFORMING SEQUENCE; CARRYING RETROVIRUS; ADRENAL HYPOPLASIA; SYNOVIAL SARCOMA; FAMILY; EXPRESSION	The transcribed murine A-raf proto-oncogene has been localized to the proximal region of the mouse X chromosome, within the context of four other active genes in this region which together constitute a conserved linkage group between mouse and man. This localization has been accomplished using species-specific restriction fragment length variation and DNAs from a previously defined informative subset of progeny representative of a set of 100 progeny from an interspecific backcross between inbred C57BL/6JRos and wild-derived Mus spretus. This new data regionally orders the mouse A-raf locus relative to the 24 X-linked markers previously examined in this backcross. We find that A-raf co-localizes with two other active genes, tissue inhibitor of metalloproteinases (Timp) and synapsin (Syn-1), 4.0 +/- 2.0 cM distal to the Otc gene at the proximal end of the mouse X chromosome, for a partial gene order in this region of: centromere-Cybb-Otc-Timp/A-raf/Syn-1-Xlr-1-Hprt.	NEW YORK STATE DEPT HLTH, ROSWELL PK MEM INST, DEPT MOLEC & CELLULAR BIOL, BUFFALO, NY 14263 USA	Roswell Park Cancer Institute			Grant, Stephen G/D-6984-2014	Grant, Stephen G/0000-0002-9236-0913	NIGMS NIH HHS [GM24125, GM33160] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024125, R01GM033160] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVNER P, 1987, SOMAT CELL MOLEC GEN, V13, P267, DOI 10.1007/BF01535208; AVNER P, 1988, TRENDS GENET, V4, P18, DOI 10.1016/0168-9525(88)90123-0; BARTLEY JA, 1986, J PEDIATR-US, V108, P189, DOI 10.1016/S0022-3476(86)80980-5; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; BROWN SDM, 1985, TRENDS GENET, V1, P219, DOI 10.1016/0168-9525(85)90086-1; BURMEISTER M, 1988, Genomics, V2, P189, DOI 10.1016/0888-7543(88)90002-X; CAPECCHI MR, 1989, TRENDS GENET, V5, P70, DOI 10.1016/0168-9525(89)90029-2; CHAMBERLAIN JS, 1987, SOMAT CELL MOLEC GEN, V13, P671, DOI 10.1007/BF01534487; CHANG EH, 1982, P NATL ACAD SCI-BIOL, V79, P4848, DOI 10.1073/pnas.79.16.4848; CHAPMAN VM, 1983, GENETICS, V103, P785; CHELLY J, 1988, HUM GENET, V78, P222, DOI 10.1007/BF00291665; DAVIES KE, 1987, CYTOGENET CELL GENET, V46, P277, DOI 10.1159/000132481; DAVISSON M T, 1987, Genomics, V1, P213, DOI 10.1016/0888-7543(87)90047-4; DEFEO D, 1981, P NATL ACAD SCI-BIOL, V78, P3328, DOI 10.1073/pnas.78.6.3328; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; DEWALD GW, 1989, CANCER GENET CYTOGEN, V42, P173, DOI 10.1016/0165-4608(89)90085-X; DISTECHE CM, 1989, GENOMICS, V5, P177, DOI 10.1016/0888-7543(89)90044-X; ELLIOTT RW, 1990, GENOMICS, V6, P635, DOI 10.1016/0888-7543(90)90498-J; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVA A, 1987, ONCOGENE, V1, P355; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FRANCKE U, 1985, AM J HUM GENET, V37, P250; FRANCKE U, 1984, CYTOGENET CELL GENET, V38, P298, DOI 10.1159/000132078; FROHMAN MA, 1989, CELL, V56, P145, DOI 10.1016/0092-8674(89)90887-8; GEWERT DR, 1987, EMBO J, V6, P651, DOI 10.1002/j.1460-2075.1987.tb04804.x; GILGENKRANTZ S, 1989, CYTOGENET CELL GENET, V51, P1004; GRANT SG, 1990, IN PRESS CYTOGENET C; GUENET JL, 1986, CURR TOP MICROBIOL, V127, P109; HAMMOND J, 1985, LANCET, V1, P54; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HEIDECKER G, 1989, GENES SIGNAL TRANSDU, P339; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P3934, DOI 10.1073/pnas.83.11.3934; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; KENWRICK S, 1987, CELL, V48, P351, DOI 10.1016/0092-8674(87)90438-7; KILIMANN MW, 1985, EMBO J, V4, P1997, DOI 10.1002/j.1460-2075.1985.tb03883.x; KISS Z, 1988, FEBS LETT, V240, P221, DOI 10.1016/0014-5793(88)80372-7; KNUDSON AG, 1989, BRIT J CANCER, V59, P661, DOI 10.1038/bjc.1989.137; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; LAFRENIERE RG, 1989, CYTOGENET CELL GENET, V51, P1028; LALLEY PA, 1989, CYTOGENET CELL GENET, V51, P503, DOI 10.1159/000132806; LYON MF, 1988, AM J HUM GENET, V42, P8; MCCABE ERB, 1989, J CLIN INVEST, V83, P95, DOI 10.1172/JCI113890; MIYOSHI J, 1984, NUCLEIC ACIDS RES, V12, P1821, DOI 10.1093/nar/12.4.1821; MORTON CC, 1989, GENOMICS, V4, P367, DOI 10.1016/0888-7543(89)90344-3; MULLINS LJ, 1988, GENOMICS, V3, P187, DOI 10.1016/0888-7543(88)90078-X; MULLINS LJ, 1990, GENOMICS, V7, P19, DOI 10.1016/0888-7543(90)90514-U; NADEAU JH, 1984, P NATL ACAD SCI-BIOL, V81, P814, DOI 10.1073/pnas.81.3.814; NADEAU JH, 1989, TRENDS GENET, V5, P82, DOI 10.1016/0168-9525(89)90031-0; NIELSEN JT, 1977, GENETICS, V87, P319; NOGUCHI T, 1987, EMBO J, V6, P1301, DOI 10.1002/j.1460-2075.1987.tb02368.x; NOGUCHI T, 1988, ONCOGENE, V3, P709; OBRIEN SJ, 1983, NATURE, V302, P839, DOI 10.1038/302839a0; OBRIEN SJ, 1988, ANNU REV GENET, V22, P323, DOI 10.1146/annurev.ge.22.120188.001543; OHNO S, 1969, ANNU REV GENET, V3, P495, DOI 10.1146/annurev.ge.03.120169.002431; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; REEVES BR, 1989, ONCOGENE, V4, P373; SEARLE AG, 1989, ANN HUM GENET, V53, P89, DOI 10.1111/j.1469-1809.1989.tb01777.x; STEPHENSON DA, 1988, NUCLEIC ACIDS RES, V16, P1642, DOI 10.1093/nar/16.4.1642; STEPHENSON DA, 1988, CURR TOP MICROBIOL, V137, P18; STEPHENSON DA, 1991, IN PRESS MAMMALIAN G; STORM SM, 1990, ONCOGENE, V5, P345; SZPIRER J, 1985, SOMAT CELL MOLEC GEN, V11, P93, DOI 10.1007/BF01534739; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; TRONICK SR, 1989, GENOMICS, V5, P546, DOI 10.1016/0888-7543(89)90022-0; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; VANOMMEN GJB, 1986, CELL, V47, P499, DOI 10.1016/0092-8674(86)90614-8; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247	72	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1991	6	3					397	402						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	2011396				2022-12-17	WOS:A1991FT34400007
J	LORENZ, U; SOCK, E; GRUMMT, F; MOELLING, K				LORENZ, U; SOCK, E; GRUMMT, F; MOELLING, K			ANALYSIS OF DNA-SEQUENCES PRESENT IN COMPLEXES OF V-MYC AND CELLULAR DNA	ONCOGENE			English	Article							AVIAN MYELOCYTOMATOSIS VIRUS; TRANSCRIPTIONAL ENHANCER; TRANSFORMING ABILITY; GENE-PRODUCT; MOUSE CELLS; REPLICATION; LOCALIZATION; ONCOGENE; PROTEIN; BINDING	We have isolated cellular DNA sequences from the myelocytomatosis virus-transformed quail fibroblastic cell-line (MC29-Q8) by indirect immunoprecipitation of v-Myc-DNA complexes and subsequent cloning of the DNA. The v-Myc-DNA complexes were obtained from isolated nuclei pretreated with 150 mM salt and indirect immunoprecipitation of the p110 Gag-Myc protein with the IgG of a Gag-specific monoclonal antibody. A non-specific monoclonal IgG was used as control to account for non-specific interactions. The DNA from the precipitates was isolated, cloned and characterized. 21 positive and 13 control clones with inserts ranging in size from 25 to 330 nucleotides were sequenced and analysed for sequence homologies to known DNA-motives. Some of the sequences over-represented in the specific DNA fragments corresponded to elements which have been previously described to promote DNA amplification. Six of these DNA fragments were tested for their ability to promote DNA amplification by insertion into a plasmid containing the HSV-1 tk gene with a truncated promoter. These constructs were transfected into mouse Ltk- cells which grow under HAT selection only upon amplification of the tk-carrying plasmids. Two of the six DNA fragments showed the capability to amplify their plasmids in cis and create stable cellular clones. Copy numbers of the amplified plasmids in these Ltk+ clones ranged from 470 to 680 whereby the amplified sequences were integrated as large clusters of head-to-tail tandems. The data presented here suggest that the Myc protein may be involved in DNA amplification and therefore may play a role in DNA replication.	MAX PLANCK INST MOLEC GENET,ABT SCHUSTER,IHNESTR 73,W-1000 BERLIN 33,GERMANY; UNIV WURZBURG,INST BIOCHEM,W-8700 WURZBURG,GERMANY	Max Planck Society; University of Wurzburg				Lorenz, Ulrike/0000-0002-7933-6855; Sock, Elisabeth/0000-0001-9925-3136				ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; BADER JP, 1985, J VIROL, V53, P509, DOI 10.1128/JVI.53.2.509-514.1985; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BEIMLING P, 1985, BIOCHEMISTRY-US, V24, P6349, DOI 10.1021/bi00344a005; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BROACH JR, 1982, COLD SPRING HARB SYM, V47, P1165, DOI 10.1101/SQB.1983.047.01.132; CHURCHILL MEA, 1989, EMBO J, V8, P4189, DOI 10.1002/j.1460-2075.1989.tb08604.x; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DELUCIA AL, 1983, J VIROL, V46, P143, DOI 10.1128/JVI.46.1.143-150.1983; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DONNER P, 1983, P NATL ACAD SCI-BIOL, V80, P2861, DOI 10.1073/pnas.80.10.2861; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREISERWILKE I, 1981, J VIROL, V39, P325, DOI 10.1128/JVI.39.1.325-329.1981; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HOLST A, 1988, CELL, V52, P355; HOLST A, 1989, CELL, V56, P143; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; IGUCHIARIGA SMM, 1987, NUCLEIC ACIDS RES, V15, P4889, DOI 10.1093/nar/15.12.4889; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LAIMINS LA, 1984, J VIROL, V49, P183, DOI 10.1128/JVI.49.1.183-189.1984; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; Maniatis T., 1982, MOL CLONING; RAMSAY G, 1980, NATURE, V288, P170, DOI 10.1038/288170a0; RAMSAY G, 1982, EMBO J, V1, P1111, DOI 10.1002/j.1460-2075.1982.tb01305.x; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; RAMSAY GM, 1982, J VIROL, V41, P745, DOI 10.1128/JVI.41.3.745-753.1982; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIH CK, 1984, P NATL ACAD SCI-BIOL, V81, P4697, DOI 10.1073/pnas.81.15.4697; Stinchcomb D. T, 1981, INITIATION DNA REPLI, P473, DOI 10.1016/b978-0-12-583580-0.50036-4; VARMUS HE, 1987, MOL BASIS BLOOD DISE, P271; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WEGNER M, 1989, NUCLEIC ACIDS RES, V17, P9909, DOI 10.1093/nar/17.23.9909; WEGNER M, 1989, NUCLEIC ACIDS RES, V17, P8783, DOI 10.1093/nar/17.21.8783; ZASTROW G, 1989, NUCLEIC ACIDS RES, V17, P1867, DOI 10.1093/nar/17.5.1867	41	4	4	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					51	57						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1992445				2022-12-17	WOS:A1991EY03900007
J	BINETRUY, B; SCHILLER, J; LOWY, D; CERNI, C; CUZIN, F				BINETRUY, B; SCHILLER, J; LOWY, D; CERNI, C; CUZIN, F			NONSELECTIVE ANALYSIS OF THE TRANSFORMATION OF FR3T3 RAT-CELLS BY BOVINE PAPILLOMAVIRUS TYPE-1 - REGULATIONS OF VIRAL TRANSCRIPTION ASSOCIATED WITH PHENOTYPIC TRANSFORMATION	ONCOGENE			English	Article									NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892; UNIV VIENNA,INST TUMOR BIOL & CANC RES,A-1090 VIENNA,AUSTRIA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Vienna	BINETRUY, B (corresponding author), UNIV NICE,CTR BIOCHEM,INSERM,U273,F-06034 NICE,FRANCE.		Schiller, John/ABK-8287-2022; Binetruy, Bernard/S-2062-2019; Binetruy, Bernard/AFL-7188-2022; Binetruy, Bernard/A-6465-2009; Binetruy, Bernard/AAG-7139-2022	Binetruy, Bernard/0000-0001-8012-7092; 				AHOLA H, 1987, J VIROL, V61, P2240, DOI 10.1128/JVI.61.7.2240-2244.1987; BAKER CC, 1987, EMBO J, V6, P1027, DOI 10.1002/j.1460-2075.1987.tb04855.x; BINETRUY B, 1982, EMBO J, V1, P621, DOI 10.1002/j.1460-2075.1982.tb01218.x; BINETRUY B, 1987, CANCER CELL, V5, P223; BURKHARDT A, 1987, EMBO J, V6, P2381, DOI 10.1002/j.1460-2075.1987.tb02515.x; CHEN EY, 1982, NATURE, V299, P529, DOI 10.1038/299529a0; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; DIMAIO D, 1986, J VIROL, V57, P475, DOI 10.1128/JVI.57.2.475-480.1986; DIMAIO D, 1988, EMBO J, V7, P1197, DOI 10.1002/j.1460-2075.1988.tb02931.x; DIMAIO D, 1982, P NATL ACAD SCI-BIOL, V79, P4030, DOI 10.1073/pnas.79.13.4030; DIMAIO D, 1987, CANCER CELLS, V5, P187; GLAICHENHAUS N, 1987, CELL, V50, P1081, DOI 10.1016/0092-8674(87)90174-7; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRISONI M, 1984, VIROLOGY, V135, P406, DOI 10.1016/0042-6822(84)90196-X; HAUGEN TH, 1987, EMBO J, V6, P145, DOI 10.1002/j.1460-2075.1987.tb04732.x; HERMONAT PL, 1988, EMBO J, V7, P2815, DOI 10.1002/j.1460-2075.1988.tb03137.x; LAMBERT PF, 1988, ANNU REV GENET, V22, P235, DOI 10.1146/annurev.ge.22.120188.001315; LAMBERT PF, 1987, CELL, V50, P69, DOI 10.1016/0092-8674(87)90663-5; LAMBERT PF, 1988, J VIROL, V62, P4009, DOI 10.1128/JVI.62.11.4009-4015.1988; Maniatis T., 1982, MOL CLONING; MENEGUZZI G, 1984, EMBO J, V3, P365, DOI 10.1002/j.1460-2075.1984.tb01813.x; MOUGNEAU E, 1988, ONCOGENE RES, V2, P177; NEARY K, 1989, J VIROL, V63, P259, DOI 10.1128/JVI.63.1.259-266.1989; PRAKASH SS, 1988, J VIROL, V62, P3608, DOI 10.1128/JVI.62.10.3608-3613.1988; RISSER R, 1974, VIROLOGY, V59, P477, DOI 10.1016/0042-6822(74)90457-7; SARVER N, 1982, P NATL ACAD SCI-BIOL, V79, P7147, DOI 10.1073/pnas.79.23.7147; SARVER N, 1984, J VIROL, V52, P377, DOI 10.1128/JVI.52.2.377-388.1984; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SCHILLER JT, 1986, J VIROL, V57, P1; SEIF R, 1977, J VIROL, V24, P721, DOI 10.1128/JVI.24.3.721-728.1977; SPALHOLZ BA, 1987, J VIROL, V61, P2128, DOI 10.1128/JVI.61.7.2128-2137.1987; STENLUND A, 1985, J MOL BIOL, V182, P541, DOI 10.1016/0022-2836(85)90240-2; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; YANG YC, 1985, NATURE, V318, P575, DOI 10.1038/318575a0; ZERLIN M, 1987, ONCOGENE, V1, P19; ZHANG YL, 1987, J VIROL, V61, P2924, DOI 10.1128/JVI.61.9.2924-2928.1987	38	4	4	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1990	5	11					1645	1651						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EL401	2176280				2022-12-17	WOS:A1990EL40100005
J	SCHERDIN, U; STEFFEN, M; DIETEL, M; BOECKER, W; BREINDL, M; HOLZEL, F				SCHERDIN, U; STEFFEN, M; DIETEL, M; BOECKER, W; BREINDL, M; HOLZEL, F			ELEVATED EXPRESSION OF V-MOS IS CORRELATED WITH ALTERED DIFFERENTIATION OF CARCINOMA-CELLS	ONCOGENE			English	Article									UNIV HOSP EPPENDORF, DEPT INTERNAL MED, EPPENDORF, GERMANY; UNIV HOSP EPPENDORF, DEPT OBSTET, EPPENDORF, GERMANY; UNIV KIEL, INST PATHOL, W-2300 KIEL 1, GERMANY; UNIV MUNSTER, INST PATHOL, W-4400 MUNSTER, GERMANY; HEINRICH PETTE INST EXPTL VIROL & IMMUNOL, W-2000 HAMBURG 20, GERMANY	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Kiel; University of Munster; Heinrich Pette Institute	HOLZEL, F (corresponding author), UNIV HOSP EPPENDORF, INST PHYSIOL CHEM, EPPENDORF, GERMANY.							ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; BALL JK, 1973, VIROLOGY, V56, P268, DOI 10.1016/0042-6822(73)90305-X; BOETTIGER D, 1989, CURR TOP MICROBIOL, V147, P31; BRADBURY JM, 1988, INT J CANCER, V42, P923, DOI 10.1002/ijc.2910420623; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; CHISWELL DJ, 1982, NUCLEIC ACIDS RES, V10, P3967, DOI 10.1093/nar/10.13.3967; CHISWELL DJ, 1982, VIROLOGY, V116, P428, DOI 10.1016/0042-6822(82)90137-4; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLLETTA G, 1983, MOL CELL BIOL, V3, P2099, DOI 10.1128/MCB.3.11.2099; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DENIS N, 1987, EXP CELL RES, V172, P212, DOI 10.1016/0014-4827(87)90107-8; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DONNER L, 1980, J VIROL, V35, P129, DOI 10.1128/JVI.35.1.129-140.1980; DOUGHERTY JP, 1988, J VIROL, V62, P2817, DOI 10.1128/JVI.62.8.2817-2822.1988; DULBECCO R, 1983, P NATL ACAD SCI-BIOL, V80, P1033, DOI 10.1073/pnas.80.4.1033; DULBECCO R, 1986, CANCER RES, V46, P5144; DURBAN EM, 1981, P NATL ACAD SCI-BIOL, V78, P3600, DOI 10.1073/pnas.78.6.3600; DYSON PJ, 1985, EMBO J, V4, P413, DOI 10.1002/j.1460-2075.1985.tb03644.x; FEINSTEIN SC, 1982, J MOL BIOL, V156, P549, DOI 10.1016/0022-2836(82)90266-2; FUSCO A, 1985, J VIROL, V56, P284, DOI 10.1128/JVI.56.1.284-292.1985; FUSCO A, 1982, CANCER RES, V42, P618; GREEN AR, 1988, CANCER SURV, V7, P335; GROFFEN J, 1983, VIROLOGY, V126, P213, DOI 10.1016/0042-6822(83)90473-7; GUTANKA RV, 1980, J VIROL, V43, P569; HOLZEL F, 1983, CELL BIOL INT REP, V7, P555, DOI 10.1016/0309-1651(83)90175-3; INOUE H, 1983, VIROLOGY, V125, P242, DOI 10.1016/0042-6822(83)90078-8; ITO E, 1989, ONCOGENE, V4, P1193; JAMIESON S, 1986, J NATL CANCER I, V76, P247; KAZIKA S, 1989, MOL CELL BIOL, V9, P5669; KELLER JR, 1990, ONCOGENE, V5, P549; KURATA N, 1989, EMBO J, V8, P457, DOI 10.1002/j.1460-2075.1989.tb03398.x; LEIBOVITCH MP, 1987, EXP CELL RES, V170, P80, DOI 10.1016/0014-4827(87)90118-2; LEIDER JM, 1988, J VIROL, V62, P3084, DOI 10.1128/JVI.62.9.3084-3091.1988; LEMISCHKA IR, 1981, J MOL BIOL, V151, P101, DOI 10.1016/0022-2836(81)90223-0; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; MARUYAMA K, 1987, ONCOGENE, V1, P361; MATHEYPREVOT B, 1984, J VIROL, V50, P325, DOI 10.1128/JVI.50.2.325-334.1984; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; NAGLE RB, 1986, J HISTOCHEM CYTOCHEM, V34, P869, DOI 10.1177/34.7.2423579; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OGISO Y, 1986, BIOCHEM BIOPH RES CO, V140, P477, DOI 10.1016/0006-291X(86)90757-6; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; RUDLAND PS, 1987, CELLULAR MOL BIOL MA, P9; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SHTIVELMAN E, 1984, P NATL ACAD SCI-BIOL, V81, P294, DOI 10.1073/pnas.81.2.294; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEFFEN M, 1988, CANCER RES, V48, P7212; TROTTER J, 1989, ONCOGENE, V4, P457; TUREK LP, 1980, J VIROL, V35, P466, DOI 10.1128/JVI.35.2.466-478.1980; VANDERHOORN FA, 1985, MOL CELL BIOL, V5, P2204, DOI 10.1128/MCB.5.9.2204; VIAC J, 1983, J INVEST DERMATOL, V81, P351, DOI 10.1111/1523-1747.ep12519941; VOGT M, 1979, VIROLOGY, V93, P226, DOI 10.1016/0042-6822(79)90290-3; WARBURTON MJ, 1987, J NATL CANCER I, V78, P1191; WEBER K, 1984, EMBO J, V3, P2707, DOI 10.1002/j.1460-2075.1984.tb02198.x; WEINBERG RA, 1981, J GEN VIROL, V54, P1, DOI 10.1099/0022-1317-54-1-1; WEISSMAN B, 1985, MOL CELL BIOL, V5, P3386, DOI 10.1128/MCB.5.12.3386; WOOD TG, 1983, J VIROL, V46, P726, DOI 10.1128/JVI.46.3.726-736.1983; YU G, 1989, J BIOL CHEM, V264, P10276; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	70	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1990	5	11					1619	1627						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EL401	2148370				2022-12-17	WOS:A1990EL40100002
J	SHEPEL, LA; GORSKI, J				SHEPEL, LA; GORSKI, J			RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISMS IN THE RAT N-RAS AND RETINOBLASTOMA GENES - THEIR IDENTIFICATION AND CHARACTERIZATION	ONCOGENE			English	Article									UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD008192, R37HD008192] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA018110] Funding Source: NIH RePORTER; NCI NIH HHS [CA18110] Funding Source: Medline; NICHD NIH HHS [HD08192] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CLIFTON KH, 1956, ANAT REC, V125, P65, DOI 10.1002/ar.1091250106; CZERNILOFSKY AP, 1980, NATURE, V287, P198, DOI 10.1038/287198a0; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; DURRIN LK, 1985, ENDOCRINOLOGY, V117, P2098, DOI 10.1210/endo-117-5-2098; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4843; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUJIMOTO M, 1987, J NEURO-ONCOL, V5, P151, DOI 10.1007/BF02571303; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; HANSEN MF, 1988, CELL, V53, P172, DOI 10.1016/0092-8674(88)90376-5; HOLTZMAN S, 1979, CANCER RES, V39, P779; KITYAMA H, 1989, CELL, V556, P77; KRONTIRIS TG, 1985, NATURE, V313, P369, DOI 10.1038/313369a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LINGHAM RB, 1988, MOL ENDOCRINOL, V2, P230, DOI 10.1210/mend-2-3-230; LLOYD RV, 1983, AM J PATHOL, V113, P198; LOOSEMITCHELL DS, 1988, MOL ENDOCRINOL, V2, P926; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MALKOVA J, 1977, NEOPLASMA, V24, P277; MARX JL, 1983, SCIENCE, V222, P602, DOI 10.1126/science.6635658; MIDDLETONPRICE H, 1988, ANN HUM GENET, V52, P189, DOI 10.1111/j.1469-1809.1988.tb01096.x; MURPHY LJ, 1987, ENDOCRINOLOGY, V120, P1882, DOI 10.1210/endo-120-5-1882; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SHEPEL L A, 1988, Biofactors, V1, P71; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPANDIDOS DA, 1984, ANTICANCER RES, V4, P269; STONE JP, 1979, CANCER RES, V39, P773; SUMI C, 1984, JNCI-J NATL CANCER I, V73, P1229; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TRAVERS MT, 1987, FEBS LETT, V211, P27, DOI 10.1016/0014-5793(87)81267-X; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VENNSTROM B, 1980, J VIROL, V36, P575; WICKLUND JA, 1982, ENDOCRINOLOGY, V111, P1140; WIKLUND J, 1981, ENDOCRINOLOGY, V109, P1708, DOI 10.1210/endo-109-5-1708; WIKLUND J, 1981, ENDOCRINOLOGY, V109, P1700, DOI 10.1210/endo-109-5-1700	45	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1990	5	11					1675	1682						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EL401	1980008				2022-12-17	WOS:A1990EL40100010
J	ECCLES, MR; BAUMBACH, WR; COLE, MD				ECCLES, MR; BAUMBACH, WR; COLE, MD			EXAMINATION OF THE ROLE OF CSF-1 INDEPENDENCE IN MYC RETROVIRUS INDUCED MONOCYTE TUMORIGENESIS	ONCOGENE			English	Article									PRINCETON UNIV,LEWIS THOMAS LAB,DEPT BIOL,PRINCETON,NJ 08544; UNIV OTAGO,DEPT BIOCHEM,DUNEDIN,NEW ZEALAND; AMER CYANAMID CO,DEPT MOLEC BIOL,PRINCETON,NJ 08540	Princeton University; University of Otago; American Cyanamid Company					FOGARTY INTERNATIONAL CENTER [F05TW003942] Funding Source: NIH RePORTER; FIC NIH HHS [F05 TW03942] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BAUMBACH WR, 1988, J VIROL, V62, P3151, DOI 10.1128/JVI.62.9.3151-3155.1988; BAUMBACH WR, 1987, MOL CELL BIOL, V7, P664, DOI 10.1128/MCB.7.2.664; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; KELEKAR A, 1987, MOL CELL BIOL, V7, P3899, DOI 10.1128/MCB.7.11.3899; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; WHEELER EF, 1986, NATURE, V324, P377, DOI 10.1038/324377a0	16	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1990	5	10					1535	1539						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK502	2250911				2022-12-17	WOS:A1990EK50200013
J	ZHU, QS; HEISTERKAMP, N; GROFFEN, J				ZHU, QS; HEISTERKAMP, N; GROFFEN, J			CHARACTERIZATION OF THE HUMAN ABL PROMOTER REGIONS	ONCOGENE			English	Article									CHILDRENS HOSP LOS ANGELES,DEPT PATHOL,MOLEC DIAG SECT,4650 SUNSET BLVD,LOS ANGELES,CA 90027	Children's Hospital Los Angeles			Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273	NATIONAL CANCER INSTITUTE [R01CA047073, R55CA047456, R01CA047456] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47073, CA 47456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCOT SS, 1989, J BIOL CHEM, V264, P2343; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BERNARDS A, 1988, ONCOGENE, V2, P297; BERNARDS A, 1987, MOL CELL BIOL, V7, P3231, DOI 10.1128/MCB.7.9.3231; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRUNKE KJ, 1984, MOL CELL BIOL, V4, P1115, DOI 10.1128/MCB.4.6.1115; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DEPAGTERHOLTHUIZEN P, 1987, FEBS LETT, V214, P259, DOI 10.1016/0014-5793(87)80066-2; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FROMM M, 1982, Journal of Molecular and Applied Genetics, V1, P457; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GROSSCHEDL R, 1980, P NATL ACAD SCI-BIOL, V77, P1432, DOI 10.1073/pnas.77.3.1432; HEISTERKAMP N, 1983, Journal of Molecular and Applied Genetics, V2, P57; HENTZE MW, 1986, P NATL ACAD SCI USA, V83, P7226, DOI 10.1073/pnas.83.19.7226; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KIM SJ, 1989, J BIOL CHEM, V264, P7041; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; LEVANON D, 1985, EMBO J, V4, P77, DOI 10.1002/j.1460-2075.1985.tb02320.x; Maxam A M, 1980, Methods Enzymol, V65, P499; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MELTON DW, 1986, CELL, V44, P319, DOI 10.1016/0092-8674(86)90766-X; MERRILL GF, 1984, J BIOL CHEM, V264, P1769; MYERS RM, 1981, CELL, V25, P373, DOI 10.1016/0092-8674(81)90056-8; NOWELL PC, 1960, SCIENCE, V132, P1497; RYFFEL GU, 1989, NUCLEIC ACIDS RES, V17, P939, DOI 10.1093/nar/17.3.939; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHNEIDER R, 1986, NUCLEIC ACIDS RES, V14, P1303, DOI 10.1093/nar/14.3.1303; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; STAM K, 1985, NEW ENGL J MED, V313, P1429, DOI 10.1056/NEJM198512053132301; VALERIO D, 1985, EMBO J, V4, P437, DOI 10.1002/j.1460-2075.1985.tb03648.x	37	4	4	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1990	5	6					885	891						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP553	2163052				2022-12-17	WOS:A1990DP55300015
J	SHIGEOKA, H; YANG, HC				SHIGEOKA, H; YANG, HC			C-FOS REGULATION IN UNTRANSFORMED AS COMPARED TO TRANSFORMED BALB/C 3T3 FIBROBLASTS	ONCOGENE			English	Article									UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,DIV MED ONCOL,TORRANCE,CA 90509; UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,DEPT MED,TORRANCE,CA 90509	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center								BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BENJAMIN CW, 1988, P NATL ACAD SCI USA, V85, P4345, DOI 10.1073/pnas.85.12.4345; BENJAMIN CW, 1987, P NATL ACAD SCI USA, V84, P546, DOI 10.1073/pnas.84.2.546; Berridge M J, 1986, J Cell Sci Suppl, V4, P137; BRAVO R, 1987, CELL, V48, P251, DOI 10.1016/0092-8674(87)90428-4; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; CURRAN T, 1984, CELL, V36, P259; DUBROW R, 1979, CANCER RES, V39, P2718; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LIN AH, 1988, MOL CELL BIOL, V8, P5052, DOI 10.1128/MCB.8.11.5052; MATUOKA K, 1988, SCIENCE, V239, P640, DOI 10.1126/science.2829356; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; ROZENGURT E, 1986, SCIENCE, V234, P160; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SIEGFRIED Z, 1989, ONCOGENE, V4, P3; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; SUBRAMANIAM M, 1989, NATURE, V340, P64, DOI 10.1038/340064a0; TABAK HF, 1978, NUCLEIC ACIDS RES, V5, P2321, DOI 10.1093/nar/5.7.2321; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; VERMA IM, 1987, ADV CANCER RES, V49, P29, DOI 10.1016/S0065-230X(08)60793-9; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YANG HC, 1989, EXP CELL RES, V183, P36, DOI 10.1016/0014-4827(89)90416-3; YANG HC, 1987, J CELL PHYSIOL, V133, P377, DOI 10.1002/jcp.1041330224	40	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1990	5	5					741	745						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG374	1693185				2022-12-17	WOS:A1990DG37400015
J	RENZO, A; BOUCHARD, L; MONGEAU, CJ; BASTIN, M				RENZO, A; BOUCHARD, L; MONGEAU, CJ; BASTIN, M			EFFECT OF CPG-RICH SEQUENCES IN TRANSFORMATION AND TUMORIGENESIS BY POLYOMAVIRUS	ONCOGENE			English	Article									UNIV SHERBROOKE,DEPT MICROBIOL,SHERBROOKE J1H 5N4,QUEBEC,CANADA; UNIV SHERBROOKE,DEPT PATHOL,SHERBROOKE J1H 5N4,QUEBEC,CANADA	University of Sherbrooke; University of Sherbrooke								ADHYA S, 1982, CELL, V29, P939, DOI 10.1016/0092-8674(82)90456-1; ASSELIN C, 1983, MOL CELL BIOL, V3, P1451, DOI 10.1128/MCB.3.8.1451; ATWEH GF, 1988, MOL CELL BIOL, V8, P5047, DOI 10.1128/MCB.8.11.5047; BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; BIRD AP, 1987, EMBO J, V6, P999, DOI 10.1002/j.1460-2075.1987.tb04851.x; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOUCHARD L, 1984, VIROLOGY, V135, P53, DOI 10.1016/0042-6822(84)90116-8; BOUCHARD L, 1987, J VIROL, V61, P2448, DOI 10.1128/JVI.61.8.2448-2453.1987; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; BUSSLINGER M, 1983, CELL, V34, P197, DOI 10.1016/0092-8674(83)90150-2; CAZIN C, 1984, EMBO J, V3, P383; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; COLBY WW, 1983, NATURE, V301, P722, DOI 10.1038/301722a0; COMPERE SJ, 1981, CELL, V25, P233, DOI 10.1016/0092-8674(81)90248-8; COUREY AJ, 1986, CELL, V45, P567, DOI 10.1016/0092-8674(86)90288-6; CROCE CM, 1985, BLOOD, V65, P1; CULLEN BR, 1984, NATURE, V307, P241, DOI 10.1038/307241a0; EMERMAN M, 1984, CELL, V39, P459, DOI 10.1016/0092-8674(84)90453-7; GELINAS C, 1984, J VIROL, V51, P242, DOI 10.1128/JVI.51.1.242-246.1984; IVARIE RD, 1982, P NATL ACAD SCI-BIOL, V79, P2967, DOI 10.1073/pnas.79.9.2967; JONES PA, 1982, P NATL ACAD SCI-BIOL, V79, P1215, DOI 10.1073/pnas.79.4.1215; KAMEN R, 1980, COLD SPRING HARB SYM, V44, P63; KESHET I, 1985, P NATL ACAD SCI USA, V82, P2560, DOI 10.1073/pnas.82.9.2560; LAIMINS L, 1986, P NATL ACAD SCI USA, V83, P3151, DOI 10.1073/pnas.83.10.3151; LAN NC, 1984, J BIOL CHEM, V259, P1601; Luria SE, 1943, GENETICS, V28, P491; LUSKY M, 1981, NATURE, V289, P70; MATHEYPREVOT B, 1984, J VIROL, V50, P325, DOI 10.1128/JVI.50.2.325-334.1984; MOHANDAS T, 1981, SCIENCE, V211, P393, DOI 10.1126/science.6164095; PETERSON DO, 1987, MOL CELL BIOL, V7, P1563, DOI 10.1128/MCB.7.4.1563; RABBITTS TH, 1983, NATURE, V306, P806, DOI 10.1038/306806a0; ROGINSKI RS, 1983, CELL, V35, P149, DOI 10.1016/0092-8674(83)90217-9; RULEY HE, 1982, NUCLEIC ACIDS RES, V10, P4515, DOI 10.1093/nar/10.15.4515; SCANGOS GA, 1981, MOL CELL BIOL, V1, P111, DOI 10.1128/MCB.1.2.111; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P61, DOI 10.1073/pnas.79.1.61; WILSON JB, 1986, CELL, V44, P477, DOI 10.1016/0092-8674(86)90469-1	37	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1989	4	12					1469	1475						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2556676				2022-12-17	WOS:A1989CB65900008
J	CHALIFOUR, LE; GOMES, ML; MESMASSON, AM				CHALIFOUR, LE; GOMES, ML; MESMASSON, AM			MICROINJECTION OF METALLOTHIONEIN-ONCOMODULIN DNA INTO FERTILIZED MOUSE EMBRYOS IS CORRELATED WITH FETAL LETHALITY	ONCOGENE			English	Article									MCGILL UNIV,DEPT MICROBIOL & IMMUNOL,MONTREAL H3A 2B4,QUEBEC,CANADA	McGill University	CHALIFOUR, LE (corresponding author), NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,6100 ROYALMOUNT AVE,MONTREAL H4P 2R2,QUEBEC,CANADA.			Mes-Masson, Anne-Marie/0000-0002-6498-266X				ADAMS JM, 1987, CURRENT COMMUNICATIO, P212; ADAMSON ED, 1986, EXPT APPROACHES MAMM, P449; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; ANDREWS GK, 1984, DEV BIOL, V103, P294, DOI 10.1016/0012-1606(84)90317-8; ANDREWS GK, 1987, DEVELOPMENT, V100, P463; BEDDINGTON R, 1987, P43; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BREWER LM, 1987, PLACENTA, V8, P351, DOI 10.1016/0143-4004(87)90063-4; BREWER LM, 1985, DEV BIOL, V112, P49, DOI 10.1016/0012-1606(85)90117-4; BRINSTER RL, 1982, NATURE, V296, P39, DOI 10.1038/296039a0; CHALIFOUR LE, 1987, GENE DEV, V1, P1096, DOI 10.1101/gad.1.10.1096; CHALIFOUR LE, 1986, J VIROL, V59, P619, DOI 10.1128/JVI.59.3.619-627.1986; CHEN HY, 1986, MOL DEV BIOL, P149; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V13, P2633; COMPERE SJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P129, DOI 10.1016/0304-419X(88)90008-X; CORY S, 1988, ANNU REV IMMUNOL, V6, P25; DEPAMPHILIS ML, 1988, BIOTECHNIQUES, V6, P662; DURKIN JP, 1983, CANCER RES, V43, P5390; GILLEN MF, 1987, J BIOL CHEM, V262, P5308; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HANAHAN D, 1986, ONCOGENES GROWTH CON, P349; HEIZMANN CW, 1987, METHOD ENZYMOL, V139, P207; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; KLEE CB, 1984, BIOCHEM BIOPH RES CO, V125, P420, DOI 10.1016/S0006-291X(84)80384-8; MACMANUS JP, 1982, ONCODEV BIOL MED, V3, P79; MACMANUS JP, 1979, CANCER RES, V39, P3000; MACMANUS JP, 1983, CALCIUM CELL FUNCTIO, V4, P411; MESMASSON AM, 1989, IN PRESS J CELL SCI; MULLER R, 1986, TRENDS BIOCHEM SCI, V11, P129, DOI 10.1016/0968-0004(86)90066-6; MUTUS B, 1985, BIOCHEM BIOPH RES CO, V131, P500, DOI 10.1016/0006-291X(85)91830-3; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PALMITER RD, 1982, NATURE, V300, P611, DOI 10.1038/300611a0; PFYFFER GE, 1984, P NATL ACAD SCI-BIOL, V81, P6632, DOI 10.1073/pnas.81.21.6632; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; RUTHER U, 1988, CELL, V53, P847, DOI 10.1016/S0092-8674(88)90289-9; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; Shuster J, 1980, Prog Exp Tumor Res, V25, P89; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; WIRAK DO, 1985, MOL CELL BIOL, V5, P2924, DOI 10.1128/MCB.5.11.2924; ZAMCHEK N, 1983, ONCODEVELOPMENTAL MA, P335	44	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1989	4	10					1241	1246						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AU508	2477784				2022-12-17	WOS:A1989AU50800012
J	COLLEDGE, WH; GEBHARDT, A; EDGE, MD; BELL, JC				COLLEDGE, WH; GEBHARDT, A; EDGE, MD; BELL, JC			ANALYSIS OF A-MULV TRANSFORMED FIBROBLAST LINES FOR AMPLIFICATION OF THE C-MYC, P53 AND C-FOS NUCLEAR PROTO-ONCOGENES	ONCOGENE			English	Article									NATL INST MED RES,EUKARYOT MOLEC GENET LAB,LONDON NW7 1AA,ENGLAND; ICI PHARMACEUT,DIV BIOTECHNOL,ALDERLEY PK SK10 5TG,CHESHIRE,ENGLAND; MCGILL UNIV,DEPT BIOCHEM,MONTREAL H36 1Y6,QUEBEC,CANADA	MRC National Institute for Medical Research; McGill University			Colledge, William/X-4976-2019	Colledge, William/0000-0002-9603-4429				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GEBHARDT A, 1986, EMBO J, V5, P2191, DOI 10.1002/j.1460-2075.1986.tb04483.x; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; HEIGHWAY J, 1986, BRIT J CANCER, V53, P285, DOI 10.1038/bjc.1986.47; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MCKAY IA, 1986, MOL CELL BIOL, V6, P3382, DOI 10.1128/MCB.6.10.3382; NEPVEU A, 1985, NATURE, V317, P440, DOI 10.1038/317440a0; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; ROSENBERG N, 1980, J VIROL, V33, P340, DOI 10.1128/JVI.33.1.340-348.1980; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; SCHER CD, 1975, NATURE, V253, P729, DOI 10.1038/253729a0; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	31	4	4	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1989	4	6					753	757						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA660	2543944				2022-12-17	WOS:A1989AA66000011
J	SCHWAB, M; OEHLMANN, R; BRUDERLEIN, S; WAKAMATSU, Y				SCHWAB, M; OEHLMANN, R; BRUDERLEIN, S; WAKAMATSU, Y			AMPLIFIED DNA IN CELLS OF GENETIC MELANOMA OF XIPHOPHORUS	ONCOGENE			English	Article									KYOTO UNIV,YOSHIDA COLL,BIOL LAB,KYOTO 606,JAPAN	Kyoto University	SCHWAB, M (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM,INST EXPTL PATHOL,NEUENHEIMER FELD 280,D-6900 HEIDELBERG,FED REP GER.							ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ANDERS F, 1967, EXPERIENTIA, V23, P1, DOI 10.1007/BF02142235; ANDERS F, 1984, ADV CANCER RES, V42, P191, DOI 10.1016/S0065-230X(08)60459-5; Friedman B, 1934, AM NAT, V68, P446, DOI 10.1086/280562; Gordon M, 1928, J HERED, V19, P551, DOI 10.1093/oxfordjournals.jhered.a102942; Gordon M, 1927, GENETICS, V12, P253; OZATO K, 1983, DIFFERENTIATION, V24, P181, DOI 10.1111/j.1432-0436.1983.tb01318.x; RONINSON IB, 1983, NUCLEIC ACIDS RES, V11, P5413, DOI 10.1093/nar/11.16.5413; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SCHWAB M, 1987, TRENDS GENET, V3, P38, DOI 10.1016/0168-9525(87)90164-8; SCHWAB M, 1982, MOL GEN GENET, V188, P410, DOI 10.1007/BF00330042; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; SCHWAB M, 1985, NATURE, V315, P345, DOI 10.1038/315345a0; SCHWAB M, 1981, DIFFERENTIATION, V19, P77, DOI 10.1111/j.1432-0436.1981.tb01132.x; SCHWAB M, 1985, TRENDS GENET, V1, P271, DOI 10.1016/0168-9525(85)90103-9; SCHWAB M, 1986, ADV CANCER RES, V47, P63, DOI 10.1016/S0065-230X(08)60198-0; SCHWAB M, 1986, ONCOGENES GROWTH CON, P332; SCHWAB M, 1988, IN PRESS CIBA F S, V142; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; VIELKIND U, 1976, J EXP ZOOL, V196, P197, DOI 10.1002/jez.1401960207; WAKAMATSU Y, 1984, DEV GROWTH DIFFER, V26, P503; WEITH A, 1987, EMBO J, V6, P1295, DOI 10.1002/j.1460-2075.1987.tb02367.x	24	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1989	4	2					139	144						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5675	2927944				2022-12-17	WOS:A1989U567500003
J	KLEMPNAUER, KH				KLEMPNAUER, KH			ASSOCIATION OF V-MYC PROTEIN WITH CHROMATIN	ONCOGENE			English	Note											KLEMPNAUER, KH (corresponding author), UNIV HEIDELBERG,ZENTRUM MOLEK BIOL,NEUENHEIMER FELD 282,D-6900 HEIDELBERG,FED REP GER.							ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BISTER K, 1987, ONCOGENE, V1, P97; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOYLE WJ, 1985, MOL CELL BIOL, V5, P3017, DOI 10.1128/MCB.5.11.3017; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; EISENMAN RN, 1985, MOL CELL BIOL, V5, P114, DOI 10.1128/MCB.5.1.114; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; KLEMPNAUER KH, 1988, ONCOGENE, V2, P545; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SPECTOR DL, 1987, ONCOGENE, V1, P5; STUDZINSKI GP, 1986, SCIENCE, V234, P467, DOI 10.1126/science.3532322; SYMONDS G, 1986, MOL CELL BIOL, V6, P1796, DOI 10.1128/MCB.6.5.1796; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0	29	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1989	4	1					115	118						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5674	2644610				2022-12-17	WOS:A1989U567400018
J	SHORE, SK; HARD, GC; MAGEE, PN				SHORE, SK; HARD, GC; MAGEE, PN			DEREGULATION AND OVEREXPRESSION OF C-FOS PROTO-ONCOGENE IN RAT RENAL CELL-LINES AND PRIMARY TUMORS INDUCED BY DIMETHYLNITROSAMINE	ONCOGENE			English	Article									TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS RES INST,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NATIONAL CANCER INSTITUTE [T32CA009214] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09214] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARR FG, 1986, MOL CELL BIOL, V6, P3023, DOI 10.1128/MCB.6.9.3023; BRAVO R, 1986, EMBO J, V5, P695, DOI 10.1002/j.1460-2075.1986.tb04269.x; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CALABRETTA B, 1987, BIOCHEM BIOPH RES CO, V147, P716, DOI 10.1016/0006-291X(87)90989-2; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORRAL M, 1985, EXP CELL RES, V160, P427, DOI 10.1016/0014-4827(85)90190-9; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HARD GC, 1977, J NATL CANCER I, V58, P1377, DOI 10.1093/jnci/58.5.1377; HARD GC, 1975, JNCI-J NATL CANCER I, V54, P1085, DOI 10.1093/jnci/54.5.1085; HARD GC, 1970, CANCER RES, V30, P2796; HARD GC, 1974, ONCOLOGY, V30, P485, DOI 10.1159/000224992; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; Maniatis T., 1982, MOL CLONING; MCLEAN AEM, 1970, BRIT J EXP PATHOL, V51, P587; MILLER AD, 1984, CELL, V36, P51; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NICOLL JW, 1975, NATURE, V254, P261, DOI 10.1038/254261a0; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NISHIZAWA M, 1987, J VIROL, V61, P3733, DOI 10.1128/JVI.61.12.3733-3740.1987; PLUMB M, 1983, NUCLEIC ACIDS RES, V11, P2391, DOI 10.1093/nar/11.8.2391; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SUKUMAR S, 1986, MOL CELL BIOL, V6, P2716, DOI 10.1128/MCB.6.7.2716; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; VERMA IM, 1987, ADV CANCER RES, V49, P29, DOI 10.1016/S0065-230X(08)60793-9; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x	29	4	4	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					567	570						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	3152601				2022-12-17	WOS:A1988R516300013
J	HECKFORD, SE; GELMANN, EP; MATIS, LA				HECKFORD, SE; GELMANN, EP; MATIS, LA			DISTINCT MECHANISMS OF C-MYC AND LYMPHOKINE GENE-EXPRESSION IN AN ANTIGEN SPECIFIC T-CELL CLONE	ONCOGENE			English	Article									US FDA,CTR BIOL EVALUAT & RES,DIV BIOCHEM & BIOPHYS,BETHESDA,MD 20892; NCI,MED BRANCH,BETHESDA,MD 20892	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BROOME HE, 1987, MOL CELL BIOL, V7, P2988, DOI 10.1128/MCB.7.8.2988; CHUNG J, 1987, CELL, V51, P1001, DOI 10.1016/0092-8674(87)90586-1; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; DEPPER JM, 1984, J IMMUNOL, V133, P3054; EISENMAN RN, 1985, MOL CELL BIOL, V5, P114, DOI 10.1128/MCB.5.1.114; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GRAY PW, 1983, P NATL ACAD SCI-BIOL, V80, P5842, DOI 10.1073/pnas.80.19.5842; HECKFORD SE, 1986, J IMMUNOL, V137, P3652; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; KASHIMA N, 1985, NATURE, V313, P402, DOI 10.1038/313402a0; KATZEN D, 1985, J IMMUNOL, V135, P1840; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRONKE M, 1985, J EXP MED, V161, P1593, DOI 10.1084/jem.161.6.1593; LARN S, 1985, CANCER CELLS, V3; MANIATIS T, 1982, MOL CLONING LABORATO; MARTIN MB, 1986, J BIOL CHEM, V261, P2355; MATIS LA, 1983, J IMMUNOL, V130, P1527; MATIS LA, 1985, J IMMUNOL, V135, P703; MILLS GB, 1985, J IMMUNOL, V134, P1640; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; OETTGEN HC, 1985, CELL, V40, P583, DOI 10.1016/0092-8674(85)90206-5; PARNES JR, 1981, P NATL ACAD SCI-BIOL, V78, P2253, DOI 10.1073/pnas.78.4.2253; PAUZA CD, 1987, MOL CELL BIOL, V7, P342, DOI 10.1128/MCB.7.1.342; REED JC, 1987, ONCOGENE, V1, P223; REED JC, 1985, MOL CELL BIOL, V5, P3361, DOI 10.1128/MCB.5.12.3361; REED JC, 1985, P NATL ACAD SCI USA, V82, P4221, DOI 10.1073/pnas.82.12.4221; ROSENBERG SA, 1984, SCIENCE, V223, P1412, DOI 10.1126/science.6367046; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; SHAW J, 1987, MOL IMMUNOL, V24, P409, DOI 10.1016/0161-5890(87)90014-9; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; TORELLI G, 1985, MOL CELL BIOL, V5, P2874, DOI 10.1128/MCB.5.10.2874; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; WAHL GM, 1979, J BIOL CHEM, V254, P8679; WANG A, 1984, SCIENCE, V224, P1431, DOI 10.1126/science.6427925; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WEISS A, 1987, J IMMUNOL, V138, P2169; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510	45	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					415	421						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	3152599				2022-12-17	WOS:A1988Q773900009
J	PICHON, F; SEUWEN, K; POUYSSEGUR, J; LAGARDE, AE				PICHON, F; SEUWEN, K; POUYSSEGUR, J; LAGARDE, AE			PROGRESSIVE RELAXATION OF GO-ARREST CONTROLS AND ALTERED RESPONSIVENESS TO INSULIN, EGF AND THROMBIN IN CCL39 LUNG FIBROBLASTS OVER-EXPRESSING MYC AND RAS ONCOGENES	ONCOGENE			English	Article									MT SINAI HOSP,RES INST,DIV CANC & CELL BIOL,ROOM 876,600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV TORONTO,DEPT MED GENET,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV NICE,FAC SCI,CTR BIOCHIM,F-06034 NICE,FRANCE	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; UDICE-French Research Universities; Universite Cote d'Azur								ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BALK SD, 1985, P NATL ACAD SCI USA, V82, P5781, DOI 10.1073/pnas.82.17.5781; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BOWENPOPE DF, 1984, P NATL ACAD SCI-BIOL, V81, P2396, DOI 10.1073/pnas.81.8.2396; BUTNICK NZ, 1985, MOL CELL BIOL, V5, P3009, DOI 10.1128/MCB.5.11.3009; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHADWICK DE, 1988, J NATL CANCER I, V80, P318, DOI 10.1093/jnci/80.5.318; CHAMBARD JC, 1983, J BIOL CHEM, V258, P1706; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; COFFEY RJ, 1987, J CELL PHYSIOL, V132, P143, DOI 10.1002/jcp.1041320120; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CORY S, 1987, ONCOGENE RES, V1, P64; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DENHARDT DT, 1986, BIOCHIM BIOPHYS ACTA, V865, P83, DOI 10.1016/0304-419X(86)90024-7; DURKIN JP, 1986, MOL CELL BIOL, V6, P1386, DOI 10.1128/MCB.6.5.1386; DURNAM DM, 1984, MOL CELL BIOL, V4, P484, DOI 10.1128/MCB.4.3.484; FALCONE G, 1987, EXP CELL RES, V168, P273, DOI 10.1016/0014-4827(87)90435-6; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOSANG M, 1985, J CELL BIOCHEM, V29, P265, DOI 10.1002/jcb.240290310; HUME CR, 1988, ONCOGENE, V2, P223; JOHNSSON A, 1986, EMBO J, V5, P1535, DOI 10.1002/j.1460-2075.1986.tb04394.x; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KAPLAN PL, 1982, P NATL ACAD SCI-BIOL, V79, P485, DOI 10.1073/pnas.79.2.485; KARIN M, 1981, EUR J BIOCHEM, V118, P527, DOI 10.1111/j.1432-1033.1981.tb05551.x; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KELEKAR A, 1987, MOL CELL BIOL, V7, P3899, DOI 10.1128/MCB.7.11.3899; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LEOF EB, 1987, MOL CELL BIOL, V7, P2649, DOI 10.1128/MCB.7.7.2649; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NICOLAIEW N, 1986, EXP CELL RES, V166, P357, DOI 10.1016/0014-4827(86)90482-9; OWEN RD, 1987, MOL CELL BIOL, V7, P2512, DOI 10.1128/MCB.7.7.2512; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; PEREZRODRIGUEZ R, 1981, J CELL PHYSIOL, V109, P387, DOI 10.1002/jcp.1041090303; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; REIN A, 1985, MOL CELL BIOL, V5, P2257, DOI 10.1128/MCB.5.9.2257; RENWICK DE, 1986, JNCI-J NATL CANCER I, V77, P105; REYNOLDS VL, 1987, ONCOGENE, V1, P323; ROBERTS AB, 1985, NATURE, V315, P237, DOI 10.1038/315237a0; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SEUWEN K, 1988, EMBO J, V7, P161, DOI 10.1002/j.1460-2075.1988.tb02796.x; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; TRIMBLE WS, 1986, NATURE, V321, P782, DOI 10.1038/321782a0; TSUCHIDA N, 1982, SCIENCE, V217, P937, DOI 10.1126/science.6287573; VANOBBERGHENSCHILLING E, 1983, EXP CELL RES, V147, P369, DOI 10.1016/0014-4827(83)90219-7; VENNSTROM B, 1987, ONCOGENE, V1, P271; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; ZERLIN M, 1987, ONCOGENE, V1, P19; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541	60	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					373	381						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	3078948				2022-12-17	WOS:A1988Q773900004
J	OHARA, BM; BLAIR, DG				OHARA, BM; BLAIR, DG			A THRESHOLD EFFECT IN THE INDUCTION OF TUMORIGENICITY OF AN ESTABLISHED HUMAN CELL-LINE BY V-MOS	ONCOGENE			English	Article									NCI,FREDERICK CANC RES FACIL,MOLEC ONCOL LAB,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BLAIR DG, 1980, P NATL ACAD SCI-BIOL, V77, P3504, DOI 10.1073/pnas.77.6.3504; BLAIR DG, 1982, SCIENCE, V218, P1122, DOI 10.1126/science.6293052; BOREK C, 1982, ADV CANCER RES, V37, P159, DOI 10.1016/S0065-230X(08)60884-2; DIPAOLO JA, 1983, J NATL CANCER I, V70, P3; DONIGER J, 1983, SCIENCE, V222, P1144, DOI 10.1126/science.6648529; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FISCHINGER PJ, 1975, P NATL ACAD SCI USA, V72, P5150, DOI 10.1073/pnas.72.12.5150; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; HAAPALA DK, 1985, J VIROL, V53, P827, DOI 10.1128/JVI.53.3.827-833.1985; KLINGER HP, 1986, CYTOGENET CELL GENET, V42, P225, DOI 10.1159/000132283; KOUFOS A, 1985, NATURE, V316, P330, DOI 10.1038/316330a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LUNDBERG C, 1987, P NATL ACAD SCI USA, V84, P2372, DOI 10.1073/pnas.84.8.2372; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; OHARA BM, 1987, MOL CELL BIOL, V7, P2941, DOI 10.1128/MCB.7.8.2941; OSHIMURA M, 1985, NATURE, V316, P636, DOI 10.1038/316636a0; PAPKOFF J, 1984, J VIROL, V52, P420, DOI 10.1128/JVI.52.2.420-430.1984; ROBEY WG, 1977, CELL, V10, P79; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAGER R, 1983, P NATL ACAD SCI-BIOL, V80, P7601, DOI 10.1073/pnas.80.24.7601; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANBRIDGE EJ, 1981, SOMAT CELL GENET, V7, P699, DOI 10.1007/BF01538758; STEVENSON M, 1986, MOL CELL BIOL, V6, P3410, DOI 10.1128/MCB.6.10.3410; STILES CD, 1975, P NATL ACAD SCI USA, V72, P4971, DOI 10.1073/pnas.72.12.4971; TAINSKY MA, 1987, MOL CELL BIOL, V7, P1280, DOI 10.1128/MCB.7.3.1280; TODARO GJ, 1974, J NATL CANCER I, V52, P167, DOI 10.1093/jnci/52.1.167	30	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1988	3	3					295	299						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	2974527				2022-12-17	WOS:A1988Q436700008
J	BARKA, T; GUBITS, RM; VANDERNOEN, H				BARKA, T; GUBITS, RM; VANDERNOEN, H			ACCUMULATION OF C-FOS MESSENGER-RNA IN SLICES OF MOUSE SUBMANDIBULAR-GLAND INCUBATED INVITRO	ONCOGENE			English	Article									NATHAN KLINE INST PSYCHIAT RES, DIV MOLEC BIOL, ORANGEBURG, NY 10962 USA	Nathan Kline Institute for Psychiatric Research	BARKA, T (corresponding author), CUNY MT SINAI SCH MED, DEPT ANAT, NEW YORK, NY 10029 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE007637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019753] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038202] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE07637] Funding Source: Medline; NIDDK NIH HHS [DK19753] Funding Source: Medline; NIGMS NIH HHS [GM38202] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIAS IM, 1984, J BIOL CHEM, V259, P5406; BARKA T, 1986, MOL CELL BIOL, V6, P2984, DOI 10.1128/MCB.6.8.2984; BENOS DJ, 1982, AM J PHYSIOL, V242, pC131, DOI 10.1152/ajpcell.1982.242.3.C131; BENOS DJ, 1983, J CELL PHYSIOL, V116, P213, DOI 10.1002/jcp.1041160213; BESTERMAN JM, 1984, P NATL ACAD SCI-BIOL, V81, P6762, DOI 10.1073/pnas.81.21.6762; Borle A B, 1981, Rev Physiol Biochem Pharmacol, V90, P13; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1986, P NATL ACAD SCI USA, V83, P8521, DOI 10.1073/pnas.83.22.8521; CURRIE RW, 1981, SCIENCE, V214, P72, DOI 10.1126/science.7280681; DESCHAMPS J, 1985, COLD SPRING HARB SYM, V50, P733, DOI 10.1101/SQB.1985.050.01.091; GUBITS RM, 1984, J BIOL CHEM, V259, P2803; GUBITS RM, 1986, J CELL BIOL, V103, pA166; HIDAKA H, 1983, METHOD ENZYMOL, V102, P185; KANAMURA S, 1975, LAB INVEST, V32, P366; LALLEMAIN G, 1984, J BIOL CHEM, V259, P5809; LUBIN M, 1982, J CELL PHYSIOL, V113, P247, DOI 10.1002/jcp.1041130210; LUBIN M, 1985, J CELL PHYSIOL, V124, P539, DOI 10.1002/jcp.1041240325; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MULLER R, 1985, BIOCHIM BIOPHYS ACTA, V823, P207; NARAHASHI T, 1974, PHYSIOL REV, V54, P813, DOI 10.1152/physrev.1974.54.4.813; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PETERSEN OH, 1970, J PHYSIOL-LONDON, V208, P431, DOI 10.1113/jphysiol.1970.sp009129; PROZIALECK WC, 1982, J PHARMACOL EXP THER, V222, P509; QUISSELL DO, 1986, IN VITRO CELL DEV B, V22, P469; SARIBANSOHRABY S, 1986, AM J PHYSIOL, V250, pC175, DOI 10.1152/ajpcell.1986.250.2.C175; SHANES AM, 1958, PHARMACOL REV, V10, P165; SHANES AM, 1958, PHARMACOL REV, V10, P59; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; TSUDA T, 1986, FEBS LETT, V208, P39, DOI 10.1016/0014-5793(86)81527-7; VERMA IM, 1986, TRENDS GENET, V2, P93, DOI 10.1016/0168-9525(86)90191-5	31	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene		1987	1	3					297	300						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J9705	3133624				2022-12-17	WOS:A1987J970500010
J	Dutta, S; Polavaram, NS; Islam, R; Bhattacharya, S; Bodas, S; Mayr, T; Roy, S; Albala, SAY; Toma, MI; Darehshouri, A; Borkowetz, A; Conrad, S; Fuessel, S; Wirth, M; Baretton, GB; Hofbauer, LC; Ghosh, P; Pienta, KJ; Klinkebiel, DL; Batra, SK; Muders, MH; Datta, K				Dutta, Samikshan; Polavaram, Navatha Shree; Islam, Ridwan; Bhattacharya, Sreyashi; Bodas, Sanika; Mayr, Thomas; Roy, Sohini; Albala, Sophie Alvarez Y.; Toma, Marieta, I; Darehshouri, Anza; Borkowetz, Angelika; Conrad, Stefanie; Fuessel, Susanne; Wirth, Manfred; Baretton, Gustavo B.; Hofbauer, Lorenz C.; Ghosh, Paramita; Pienta, Kenneth J.; Klinkebiel, David L.; Batra, Surinder K.; Muders, Michael H.; Datta, Kaustubh			Neuropilin-2 regulates androgen-receptor transcriptional activity in advanced prostate cancer	ONCOGENE			English	Article							NUCLEAR-PORE COMPLEXES; PROTEINS; NUP98	Aberrant transcriptional activity of androgen receptor (AR) is one of the dominant mechanisms for developing of castration-resistant prostate cancer (CRPC). Analyzing AR-transcriptional complex related to CRPC is therefore important towards understanding the mechanism of therapy resistance. While studying its mechanism, we observed that a transmembrane protein called neuropilin-2 (NRP2) plays a contributory role in forming a novel AR-transcriptional complex containing nuclear pore proteins. Using immunogold electron microscopy, high-resolution confocal microscopy, chromatin immunoprecipitation, proteomics, and other biochemical techniques, we delineated the molecular mechanism of how a specific splice variant of NRP2 becomes sumoylated upon ligand stimulation and translocates to the inner nuclear membrane. This splice variant of NRP2 then stabilizes the complex between AR and nuclear pore proteins to promote CRPC specific gene expression. Both full-length and splice variants of AR have been identified in this specific transcriptional complex. In vitro cell line-based assays indicated that depletion of NRP2 not only destabilizes the AR-nuclear pore protein interaction but also inhibits the transcriptional activities of AR. Using an in vivo bone metastasis model, we showed that the inhibition of NRP2 led to the sensitization of CRPC cells toward established anti-AR therapies such as enzalutamide. Overall, our finding emphasize the importance of combinatorial inhibition of NRP2 and AR as an effective therapeutic strategy against treatment refractory prostate cancer.	[Dutta, Samikshan; Polavaram, Navatha Shree; Islam, Ridwan; Bhattacharya, Sreyashi; Bodas, Sanika; Roy, Sohini; Klinkebiel, David L.; Batra, Surinder K.; Datta, Kaustubh] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Mayr, Thomas; Muders, Michael H.] Univ Bonn, Med Fac, Rudolf Becker Lab Prostate Canc Res, Bonn, Germany; [Mayr, Thomas; Toma, Marieta, I; Muders, Michael H.] Univ Bonn, Med Fac, Inst Pathol, Bonn, Germany; [Mayr, Thomas; Toma, Marieta, I; Baretton, Gustavo B.; Muders, Michael H.] Tech Univ Dresden, Inst Pathol, Dresden, Germany; [Albala, Sophie Alvarez Y.] Univ Nebraska, Dept Agron & Hort, Lincoln, NE USA; [Darehshouri, Anza] UT Southwestern Med Ctr, Dept Cell Biol, Dallas, TX USA; [Borkowetz, Angelika; Fuessel, Susanne; Wirth, Manfred] Tech Univ Dresden, Dept Urol, Dresden, Germany; [Conrad, Stefanie; Hofbauer, Lorenz C.] Tech Univ Dresden, Dept Med 3, Div Endocrinol & Metab Bone Dis, Dresden, Germany; [Conrad, Stefanie; Hofbauer, Lorenz C.] Tech Univ Dresden, Ctr Hlth Aging, Dresden, Germany; [Baretton, Gustavo B.; Hofbauer, Lorenz C.] German Res Ctr DKFZ, German Canc Consortium DKTK, Partner Site Dresden, Heidelberg, Germany; [Baretton, Gustavo B.] Univ Hosp, Univ Canc Ctr UCC, Tumor & Normal Tissue Bank, Dresden, Germany; [Baretton, Gustavo B.] Tech Univ Dresden, Fac Med, Dresden, Germany; [Ghosh, Paramita] Univ Calif Davis, Dept Biochem & Mol Med, Davis, CA 95616 USA; [Pienta, Kenneth J.] Johns Hopkins Univ, Sch Med, Brady Urol Inst, Baltimore, MD USA	University of Nebraska System; University of Nebraska Medical Center; University of Bonn; University of Bonn; Technische Universitat Dresden; University of Nebraska System; University of Nebraska Lincoln; University of Texas System; University of Texas Southwestern Medical Center Dallas; Technische Universitat Dresden; Technische Universitat Dresden; Technische Universitat Dresden; Helmholtz Association; German Cancer Research Center (DKFZ); Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; University of California System; University of California Davis; Johns Hopkins University	Dutta, S; Datta, K (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.	samikshan.dutta@unmc.edu; kaustubh.datta@unmc.edu		Dutta, samikshan/0000-0002-4160-1422	Lageschulte Fund [1R21CA241234-01, NE-LB506]; DoD [W81XWH2110628]; DFG [273676790, 416001651]; Rudolf-Becker-Foundation; DFG;  [R01CA182435];  [R01CA239343]	Lageschulte Fund; DoD(United States Department of Defense); DFG(German Research Foundation (DFG)); Rudolf-Becker-Foundation; DFG(German Research Foundation (DFG)); ; 	This work was supported by grants for SD (1R21CA241234-01, NE-LB506, Lageschulte Fund), KD (R01CA182435, R01CA239343, DoD W81XWH2110628), MHM and LHH (DFG project number 273676790), and MHM (DFG project number 416001651). MM is funded by the Rudolf-Becker-Foundation for his professorship. The construction of the prostate cancer tissue microarray was funded by the DFG Forschergruppe-1586 SKELMET to LCH and SF.	Ark AV, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00180; Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Borkowetz A, 2020, INT J CANCER, V146, P2619, DOI 10.1002/ijc.32679; Coleman DJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40518-5; Coutinho I, 2016, ENDOCR-RELAT CANCER, V23, pT179, DOI 10.1530/ERC-16-0422; D'Angelo MA, 2018, NUCLEUS-PHILA, V9, P142, DOI 10.1080/19491034.2017.1395542; Dieppois G, 2010, J CELL SCI, V123, P1989, DOI 10.1242/jcs.053694; Drozdz MM, 2017, NUCLEUS-PHILA, V8, P34, DOI 10.1080/19491034.2016.1252893; Dutta S, 2016, SCI REP-UK, V6, DOI 10.1038/srep23588; Franks TM, 2013, TRENDS CELL BIOL, V23, P112, DOI 10.1016/j.tcb.2012.10.013; Fricker M, 1997, J CELL BIOL, V136, P531, DOI 10.1083/jcb.136.3.531; Garcia-Oliver E, 2012, BBA-GENE REGUL MECH, V1819, P555, DOI 10.1016/j.bbagrm.2011.11.011; Gemmill RM, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aag0528; Giacinti S, 2018, ANTICANCER RES, V38, P6029, DOI 10.21873/anticanres.12953; Gomez-Cavazos JS, 2015, J CELL BIOL, V208, P671, DOI 10.1083/jcb.201410047; He YD, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21860-7; Holzer K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10133-z; Ibarra A, 2016, GENE DEV, V30, P2253, DOI 10.1101/gad.287417.116; Ibarra A, 2015, GENE DEV, V29, P337, DOI 10.1101/gad.256495.114; Imamura Y, 2016, INT J UROL, V23, P654, DOI 10.1111/iju.13137; Kersemans V, 2013, J MAGN RESON IMAGING, V37, P1499, DOI 10.1002/jmri.23829; Kitazawa T, 2017, NEURON, V96, P259, DOI 10.1016/j.neuron.2017.09.059; Kuhn TM, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111414; Kuhn TM, 2019, J CELL BIOL, V218, P2945, DOI 10.1083/jcb.201807139; Labade AS, 2016, EPIGENET CHROMATIN, V9, DOI 10.1186/s13072-016-0106-0; Liang Y, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003308; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; Palancade B, 2007, MOL BIOL CELL, V18, P2912, DOI 10.1091/mbc.E07-02-0123; Parker MW, 2015, STRUCTURE, V23, P677, DOI 10.1016/j.str.2015.01.018; Polavaram NS, 2021, BONE RES, V9, DOI 10.1038/s41413-021-00136-2; Powers E, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00978-z; Ptak C, 2014, CURR OPIN CELL BIOL, V28, P46, DOI 10.1016/j.ceb.2014.02.001; Raices M, 2017, DEV CELL, V41, P540, DOI 10.1016/j.devcel.2017.05.007; Raices M, 2017, CURR OPIN CELL BIOL, V46, P26, DOI 10.1016/j.ceb.2016.12.006; Rodriguez-Bravo V, 2018, CELL, V174, P1200, DOI 10.1016/j.cell.2018.07.015; Rodriguez-Navarro S, 2004, CELL, V116, P75, DOI 10.1016/S0092-8674(03)01025-0; Rossignol M, 2000, GENOMICS, V70, P211, DOI 10.1006/geno.2000.6381; Roumiguie M, 2021, FUTURE ONCOL, V17, P1811, DOI 10.2217/fon-2020-1104; Ruben GJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021923; Savoy RM, 2015, ENDOCR-RELAT CANCER, V22, P369, DOI 10.1530/ERC-15-0021; Schmidt KT, 2021, NAT REV UROL, V18, P209, DOI 10.1038/s41585-021-00438-4; Schweizer MT, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198389; Shafran JS, 2019, MOL CANCER RES, V17, P1627, DOI 10.1158/1541-7786.MCR-18-1279; Sharma NL, 2013, CANCER CELL, V23, P35, DOI 10.1016/j.ccr.2012.11.010; Stanton MJ, 2013, CANCER RES, V73, P160, DOI 10.1158/0008-5472.CAN-11-3635; Su YL, 2018, GENE DEV, V32, P1398, DOI 10.1101/gad.314377.118; Sulpice E, 2008, BLOOD, V111, P2036, DOI 10.1182/blood-2007-04-084269; Sump B, 2017, GENE DEV, V31, P2201, DOI 10.1101/gad.310359.117; Tan KN, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186622; Tucci M, 2018, ONCOTARGETS THER, V11, P7353, DOI 10.2147/OTT.S153764; Tucci M, 2018, MINERVA UROL NEFROL, V70, P144, DOI 10.23736/S0393-2249.17.03066-1; Wang LM, 2020, J CLIN INVEST, V130, P1782, DOI 10.1172/JCI126327	52	3	3	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2022	41	30					3747	3760		10.1038/s41388-022-02382-y	http://dx.doi.org/10.1038/s41388-022-02382-y		JUN 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3D1SP	35754042				2022-12-17	WOS:000815742800001
J	Peng, W; Shi, S; Zhong, JC; Liang, HH; Hou, JB; Hu, XS; Wang, F; Zhang, JY; Geng, SJ; Sun, XC; Zhong, D; Cui, HJ				Peng, Wen; Shi, Shuang; Zhong, Jiacheng; Liang, Hanghua; Hou, Jianbin; Hu, Xiaosong; Wang, Feng; Zhang, Jiayi; Geng, Shengjun; Sun, Xiaochuan; Zhong, Dong; Cui, Hongjuan			CBX3 accelerates the malignant progression of glioblastoma multiforme by stabilizing EGFR expression	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; LUNG ADENOCARCINOMA; CANCER PROGRESSION; TUMOR-SUPPRESSOR; HISTONE H3; LYSINE 9; PARKIN; P53; PROLIFERATION; GENE	CBX3, also known as HP1 gamma, is a major isoform of heterochromatin protein 1, whose deregulation has been reported to promote the development of human cancers. However, the molecular mechanism of CBX3 in glioblastoma multiforme (GBM) are unclear. Our study reported the identification of CBX3 as a potential therapeutic target for GBM. Briefly, we found that, CBX3 is significantly upregulated in GBM and reduces patient survival. In addition, functional assays demonstrated that CBX3 significantly promote the proliferation, invasion and tumorigenesis of GBM cells in vitro and in vivo. Mechanistically, Erlotinib, a small molecule targeting epidermal growth factor receptor (EGFR) tyrosine kinase, was used to demonstrate that CBX3 direct the malignant progression of GBM are EGFR dependent. Previous studies have shown that PARK2(Parkin) and STUB1(Carboxy Terminus of Hsp70-Interacting Protein) are EGFR-specific E3 ligases. Notably, we verified that CBX3 directly suppressed PARK2 and STUB1 at the transcriptional level through its CD domain to reduce the ubiquitination of EGFR. Moreover, the CSD domain of CBX3 interacted with PARK2 and regulated its ubiquitination to further reduce its protein level. Collectively, these results revealed an unknown mechanism underlying the pathogenesis of GBM and confirmed that CBX3 is a promising therapeutic target.	[Peng, Wen; Liang, Hanghua; Hou, Jianbin; Hu, Xiaosong; Wang, Feng; Zhang, Jiayi; Geng, Shengjun; Cui, Hongjuan] Southwest Univ, State Key Lab Silkworm Genome Biol, Chongqing 400716, Peoples R China; [Peng, Wen; Liang, Hanghua; Hou, Jianbin; Hu, Xiaosong; Wang, Feng; Zhang, Jiayi; Geng, Shengjun; Cui, Hongjuan] Southwest Univ, Med Res Inst, Canc Ctr, Chongqing 400716, Peoples R China; [Shi, Shuang; Zhong, Jiacheng; Sun, Xiaochuan; Zhong, Dong] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China	Southwest University - China; Southwest University - China; Chongqing Medical University	Cui, HJ (corresponding author), Southwest Univ, State Key Lab Silkworm Genome Biol, Chongqing 400716, Peoples R China.; Cui, HJ (corresponding author), Southwest Univ, Med Res Inst, Canc Ctr, Chongqing 400716, Peoples R China.; Zhong, D (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China.	zhongdongdp@sina.com; hcui@swu.edu.cn	Hu, Xiao/GQI-0007-2022	Hu, Xiao/0000-0003-1128-4099	Natural Science Foundation of Chongqing [cstc2019jcyj-zdxmX0033]; Chongqing Doctoral Research and Innovation Project [CYB21131]	Natural Science Foundation of Chongqing(Natural Science Foundation of Chongqing); Chongqing Doctoral Research and Innovation Project	This research was supported by the Natural Science Foundation of Chongqing (cstc2019jcyj-zdxmX0033) and Chongqing Doctoral Research and Innovation Project (CYB21131).	Akaike Y, 2015, ONCOGENE, V34, P3463, DOI 10.1038/onc.2014.278; Alam H, 2018, CANCER RES, V78, P3834, DOI 10.1158/0008-5472.CAN-17-3571; Aldape K, 2015, ACTA NEUROPATHOL, V129, P829, DOI 10.1007/s00401-015-1432-1; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bhuripanyo K, 2018, SCI ADV, V4, DOI 10.1126/sciadv.1701393; Brandes AA, 2008, CLIN CANCER RES, V14, P957, DOI 10.1158/1078-0432.CCR-07-1810; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Cai HP, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03247-6; Caillier M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015507; Chakravarti A, 2013, INT J RADIAT ONCOL, V85, P1206, DOI 10.1016/j.ijrobp.2012.10.008; Chang SC, 2018, ASIA-PAC J CLIN ONCO, V14, pe283, DOI 10.1111/ajco.12820; Chen CY, 2013, CANCER RES, V73, P4009, DOI 10.1158/0008-5472.CAN-12-4066; Chen LY, 2018, BIOCHEM BIOPH RES CO, V500, P691, DOI 10.1016/j.bbrc.2018.04.137; Choi Jae Duk, 2013, Genomics & Informatics, V11, P164, DOI 10.5808/GI.2013.11.4.164; da Costa CA, 2009, NAT CELL BIOL, V11, P1370, DOI 10.1038/ncb1981; Dialynas GK, 2008, MUTAT RES-FUND MOL M, V647, P13, DOI 10.1016/j.mrfmmm.2008.09.007; England B, 2013, TUMOR BIOL, V34, P2063, DOI 10.1007/s13277-013-0871-3; Eskilsson E, 2018, NEURO-ONCOLOGY, V20, P743, DOI 10.1093/neuonc/nox191; Furnari FB, 2015, NAT REV CANCER, V15, P302, DOI 10.1038/nrc3918; Gao FQ, 2020, GENE, V726, DOI 10.1016/j.gene.2019.144196; Guimaraes DP, 2002, BIOCHIMIE, V84, P83, DOI 10.1016/S0300-9084(01)01356-6; Hegi ME, 2011, MOL CANCER THER, V10, P1102, DOI 10.1158/1535-7163.MCT-11-0048; Hou J, 2017, ONCOGENE, V36, P1134, DOI 10.1038/onc.2016.280; Karpel-Massler G, 2009, MOL CANCER RES, V7, P1000, DOI 10.1158/1541-7786.MCR-08-0479; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li Q, 2021, TRANSL LUNG CANCER R, V10, P936, DOI 10.21037/tlcr-21-147; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Lim M, 2018, NAT REV CLIN ONCOL, V15, P422, DOI 10.1038/s41571-018-0003-5; Lin DC, 2015, CANCER RES, V75, P1815, DOI 10.1158/0008-5472.CAN-14-1433; Liu M, 2015, CANCER RES, V75, P4593, DOI 10.1158/0008-5472.CAN-14-3735; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Maugeri G, 2015, INT J ONCOL, V47, P1282, DOI 10.3892/ijo.2015.3105; Okorokov AL, 2009, CURR OPIN STRUC BIOL, V19, P197, DOI 10.1016/j.sbi.2009.02.003; Osuka S, 2017, J CLIN INVEST, V127, P415, DOI 10.1172/JCI89587; Reardon DA, 2014, NEURO-ONCOLOGY, V16, pviii7, DOI 10.1093/neuonc/nou232; Roth P, 2014, NEURO-ONCOLOGY, V16, pviii14, DOI 10.1093/neuonc/nou222; Shao GB, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0784-2; Sridharan R, 2013, NAT CELL BIOL, V15, P872, DOI 10.1038/ncb2768; Stathias V, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07659-z; Sunico CR, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-29; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Viotti J, 2014, ONCOGENE, V33, P1764, DOI 10.1038/onc.2013.124; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang FM, 2021, MOL NEUROBIOL, V58, P3362, DOI 10.1007/s12035-021-02337-6; Wang SQ, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1930-3; Wang TX, 2014, ONCOTARGET, V5, P1969, DOI 10.18632/oncotarget.1890; Weisz L, 2007, ONCOGENE, V26, P2202, DOI 10.1038/sj.onc.1210294; Weller M, 2017, LANCET ONCOL, V18, pE315, DOI 10.1016/S1470-2045(17)30194-8; Wong SC, 2021, NUTRIENTS, V13, DOI 10.3390/nu13030950; Xuan F, 2016, NEURO-ONCOLOGY, V18, P819, DOI 10.1093/neuonc/nov281; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yeo CWS, 2012, CANCER RES, V72, P2543, DOI 10.1158/0008-5472.CAN-11-3060; Zhang C, 2011, P NATL ACAD SCI USA, V108, P16259, DOI 10.1073/pnas.1113884108; Zhang Y, 2018, CANCERS, V10, DOI 10.3390/cancers10090297; Zhao SP, 2019, J NEURO-ONCOL, V145, P35, DOI 10.1007/s11060-019-03286-w; Zhao YZ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0137-7; Zhong XP, 2019, AGING-US, V11, P5483, DOI 10.18632/aging.102132	58	3	3	11	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2022	41	22					3051	3063		10.1038/s41388-022-02296-9	http://dx.doi.org/10.1038/s41388-022-02296-9		APR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1U7PG	35459780				2022-12-17	WOS:000787474100005
J	Bernstock, JD; Kang, KD; Klinger, NV; Olsen, HE; Gary, S; Totsch, SK; Ghajar-Rahimi, G; Segar, D; Thompson, EM; Darley-Usmar, V; Mott, BT; Peruzzotti-Jametti, L; Friedman, GK				Bernstock, Joshua D.; Kang, Kyung-Don; Klinger, Neil, V; Olsen, Hannah E.; Gary, Sam; Totsch, Stacie K.; Ghajar-Rahimi, Gelare; Segar, David; Thompson, Eric M.; Darley-Usmar, Victor; Mott, Bryan T.; Peruzzotti-Jametti, Luca; Friedman, Gregory K.			Targeting oncometabolism to maximize immunotherapy in malignant brain tumors	ONCOGENE			English	Review							CENTRAL-NERVOUS-SYSTEM; REGULATORY T-CELLS; ADJUVANT TEMOZOLOMIDE; EMERGING HALLMARKS; GLIOBLASTOMA CELLS; IMMUNE RESISTANCE; POLY-ICLC; IN-VIVO; GLUCOSE; METABOLISM	Brain tumors result in significant morbidity and mortality in both children and adults. Recent data indicate that immunotherapies may offer a survival benefit after standard of care has failed for malignant brain tumors. Modest results from several late phase clinical trials, however, underscore the need for more refined, comprehensive strategies that incorporate new mechanistic and pharmacologic knowledge. Recently, oncometabolism has emerged as an adjunct modality for combinatorial treatment approaches necessitated by the aggressive, refractory nature of high-grade glioma and other progressive malignant brain tumors. Manipulation of metabolic processes in cancer and immune cells that comprise the tumor microenvironment through controlled targeting of oncogenic pathways may be utilized to maximize the efficacy of immunotherapy and improve patient outcomes. Herein, we summarize preclinical and early phase clinical trial research of oncometabolism-based therapeutics that may augment immunotherapy by exploiting the biochemical and genetic underpinnings of brain tumors. We also examine metabolic pathways related to immune cells that target tumor cells, termed "tumor immunometabolism". Specifically, we focus on glycolysis and altered glucose metabolism, including glucose transporters, hexokinase, pyruvate dehydrogenase, and lactate dehydrogenase, glutamine, and we discuss targeting arginase, adenosine, and indoleamine 2,3-dioxygenase, and toll-like receptors. Lastly, we summarize future directions targeting metabolism in combination with emerging therapies such as oncolytic virotherapy, vaccines, and chimeric antigen receptor T cells.	[Bernstock, Joshua D.; Klinger, Neil, V; Olsen, Hannah E.; Segar, David] Brigham & Womens Hosp, Harvard Med Sch, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA; [Kang, Kyung-Don; Totsch, Stacie K.; Friedman, Gregory K.] Univ Alabama Birmingham, Dept Pediat, Div Pediat Hematol & Oncol, Birmingham, AL 35294 USA; [Gary, Sam; Ghajar-Rahimi, Gelare] Univ Alabama Birmingham, Med Scientist Training Program, Birmingham, AL USA; [Thompson, Eric M.] Duke Univ, Dept Neurosurg, Durham, NC USA; [Darley-Usmar, Victor] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; [Mott, Bryan T.] Wake Forest Baptist Med Ctr, Dept Neurosurg, Winston Salem, NC USA; [Peruzzotti-Jametti, Luca] Univ Cambridge, Dept Clin Neurosci, Cambridge, England	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Duke University; University of Alabama System; University of Alabama Birmingham; Wake Forest University; Wake Forest Baptist Medical Center; University of Cambridge	Bernstock, JD (corresponding author), Brigham & Womens Hosp, Harvard Med Sch, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA.; Friedman, GK (corresponding author), Univ Alabama Birmingham, Dept Pediat, Div Pediat Hematol & Oncol, Birmingham, AL 35294 USA.	jbernstock@partners.org; gfriedman@peds.uab.edu		Bernstock, Joshua/0000-0002-7814-3867; Friedman, Gregory/0000-0002-6653-7420; Ghajar-Rahimi, Gelare/0000-0001-5089-7176	U.S. Food and Drug Administration [R01FD005379, R01FD006368]; Rally Foundation for Childhood Cancer Research; Hyundai Hope on Wheels; Andrew McDonough B+ Foundation; Cannonball Kids' cancer Foundation; FISM-Fondazione Italiana Sclerosi Multipla-cod [2017/B/5]; "5 per mille" public funding; Wellcome Trust CRCD Fellowship [RG G105713]; Addenbrooke's Charitable Trust [RG 97519]; Department of Defense [CA171067]; Musella Foundation for Brain Tumor Research and Information; Pediatric Brain Tumor Foundation	U.S. Food and Drug Administration; Rally Foundation for Childhood Cancer Research; Hyundai Hope on Wheels; Andrew McDonough B+ Foundation; Cannonball Kids' cancer Foundation; FISM-Fondazione Italiana Sclerosi Multipla-cod(Fondazione Italiana Sclerosi Multipla (FISM)); "5 per mille" public funding; Wellcome Trust CRCD Fellowship(Wellcome Trust); Addenbrooke's Charitable Trust; Department of Defense(United States Department of Defense); Musella Foundation for Brain Tumor Research and Information; Pediatric Brain Tumor Foundation	GKF is supported by grants from the U.S. Food and Drug Administration (R01FD005379 and R01FD006368), the Rally Foundation for Childhood Cancer Research, Hyundai Hope on Wheels, Andrew McDonough B+ Foundation, and Cannonball Kids' cancer Foundation. LP-J has been supported by a senior research fellowship FISM-Fondazione Italiana Sclerosi Multipla-cod. 2017/B/5 and financed or co financed with the "5 per mille" public funding, a Wellcome Trust CRCD Fellowship (RG G105713), and the Addenbrooke's Charitable Trust (RG 97519). EMT is supported by the Department of Defense (CA171067), The Musella Foundation for Brain Tumor Research and Information, and the Pediatric Brain Tumor Foundation. We thank Adam A. Dmytriw for reviewing the manuscript.	Angelin A, 2017, CELL METAB, V25, P1282, DOI 10.1016/j.cmet.2016.12.018; Bavaresco L, 2008, MOL CELL BIOCHEM, V319, P61, DOI 10.1007/s11010-008-9877-3; Bernstock JD, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1678921; Brand A, 2016, CELL METAB, V24, P657, DOI 10.1016/j.cmet.2016.08.011; Bullen JW, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf0583; Bunse L, 2018, NAT MED, V24, P1192, DOI 10.1038/s41591-018-0095-6; Cascone T, 2018, CELL METAB, V27, P977, DOI 10.1016/j.cmet.2018.02.024; Certo M, 2021, NAT REV IMMUNOL, V21, P151, DOI 10.1038/s41577-020-0406-2; Chang CH, 2015, CELL, V162, P1229, DOI 10.1016/j.cell.2015.08.016; Cohen KJ, 2011, NEURO-ONCOLOGY, V13, P317, DOI 10.1093/neuonc/noq191; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; Cosset E, 2017, CANCER CELL, V32, P856, DOI 10.1016/j.ccell.2017.10.016; Crane CA, 2014, P NATL ACAD SCI USA, V111, P12823, DOI 10.1073/pnas.1413933111; Dang L, 2010, NATURE, V465, P966, DOI 10.1038/nature09132; DANIELE S, 2015, SCI REP-UK, V5; De Waele J, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1407899; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Flavahan WA, 2013, NAT NEUROSCI, V16, P1373, DOI 10.1038/nn.3510; Frauwirth KA, 2002, IMMUNITY, V16, P769, DOI 10.1016/S1074-7613(02)00323-0; Friedman GK, 2021, NEW ENGL J MED, V384, P1613, DOI 10.1056/NEJMoa2024947; Galluzzi L, 2014, METHOD ENZYMOL, V542, pXIX, DOI 10.1016/B978-0-12-416618-9.10000-7; Galluzzi L, 2013, NAT REV DRUG DISCOV, V12, P829, DOI 10.1038/nrd4145; Geiger R, 2016, CELL, V167, P829, DOI 10.1016/j.cell.2016.09.031; Gielen PR, 2016, NEURO-ONCOLOGY, V18, P1253, DOI 10.1093/neuonc/now034; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Grzywa TM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00938; GUPTA S, 2017, CANCER RES, V77; Hanihara M, 2016, J NEUROSURG, V124, P1594, DOI 10.3171/2015.5.JNS141901; Hermans D, 2020, P NATL ACAD SCI USA, V117, P6047, DOI 10.1073/pnas.1920413117; Hill BG, 2020, BIOL CHEM, V401, P3, DOI 10.1515/hsz-2019-0268; Huang L, 2018, CELL MOL IMMUNOL, V15, P428, DOI 10.1038/cmi.2018.4; Jiang J, 2019, CANCERS, V11, DOI 10.3390/cancers11060804; Kareva I, 2013, CANCER RES, V73, P2737, DOI 10.1158/0008-5472.CAN-12-3696; Kathagen-Buhmann A, 2016, NEURO-ONCOLOGY, V18, P1219, DOI 10.1093/neuonc/now024; Kawalekar OU, 2016, IMMUNITY, V44, P380, DOI 10.1016/j.immuni.2016.01.021; Kees T, 2012, NEURO-ONCOLOGY, V14, P64, DOI 10.1093/neuonc/nor182; Kohanbash G, 2017, J CLIN INVEST, V127, P1425, DOI 10.1172/JCI90644; Krzak G, 2021, TRENDS IMMUNOL, V42, P45, DOI 10.1016/j.it.2020.11.004; Kuang R, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.88815; Kyi C, 2018, CLIN CANCER RES, V24, P4937, DOI 10.1158/1078-0432.CCR-17-1866; Le Calve B, 2010, NEOPLASIA, V12, P727, DOI 10.1593/neo.10526; Libby CJ, 2018, ACS CHEM BIOL, V13, P2048, DOI 10.1021/acschembio.8b00251; Libby CJ, 2018, BBA-REV CANCER, V1869, P175, DOI 10.1016/j.bbcan.2018.01.004; Lin H, 2017, NEURO-ONCOLOGY, V19, P43, DOI 10.1093/neuonc/now128; Liu FK, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-019-1085-6; Long GV, 2019, LANCET ONCOL, V20, P1083, DOI 10.1016/S1470-2045(19)30274-8; Louis DN, 2021, NEURO-ONCOLOGY, V23, P1231, DOI 10.1093/neuonc/noab106; Macintyre AN, 2014, CELL METAB, V20, P61, DOI 10.1016/j.cmet.2014.05.004; McBrayer SK, 2018, CELL, V175, P101, DOI 10.1016/j.cell.2018.08.038; Mehta MM, 2018, CANCER METAB, V6, DOI 10.1186/s40170-018-0184-5; Mellinghoff I, 2018, NEURO-ONCOLOGY, V20, P234; Metz R, 2012, ONCOIMMUNOLOGY, V1, P1460, DOI 10.4161/onci.21716; Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677; Mitsuka K, 2013, NEUROSURGERY, V72, P1031, DOI 10.1227/NEU.0b013e31828cf945; Moesta AK, 2020, NAT REV IMMUNOL, V20, P739, DOI 10.1038/s41577-020-0376-4; Moon YW, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0094-9; Mooney J, 2019, WORLD NEUROSURG, V129, P90, DOI 10.1016/j.wneu.2019.05.205; Muller S, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98791; Munn DH, 2016, TRENDS IMMUNOL, V37, P193, DOI 10.1016/j.it.2016.01.002; Nayak L, 2021, CLIN CANCER RES, V27, P1048, DOI 10.1158/1078-0432.CCR-20-2500; Ohta A, 2006, P NATL ACAD SCI USA, V103, P13132, DOI 10.1073/pnas.0605251103; Ohta A, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00304; Olsen Hannah E, 2021, Neurooncol Adv, V3, pvdab027, DOI 10.1093/noajnl/vdab027; Oshima N, 2020, CELL REP, V30, P1798, DOI 10.1016/j.celrep.2020.01.039; Ostrom Quinn T, 2019, Neuro Oncol, V21, pv1, DOI 10.1093/neuonc/noz150; Ott M, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.134386; PAPADOPOULOS KP, 2017, J CLIN ONCOL, V35; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; PEREZ RP, 2017, J CLIN ONCOL, V35; Pollack IF, 2016, NEURO-ONCOLOGY, V18, P1157, DOI 10.1093/neuonc/now026; Rai G, 2020, J MED CHEM, V63, P10984, DOI 10.1021/acs.jmedchem.0c00916; Raychaudhuri B, 2011, NEURO-ONCOLOGY, V13, P591, DOI 10.1093/neuonc/nor042; Reardon DA, 2020, JAMA ONCOL, V6, P1003, DOI 10.1001/jamaoncol.2020.1024; Reinfeld BI, 2021, NATURE, V593, P282, DOI 10.1038/s41586-021-03442-1; Rogers TW, 2018, J NEURO-ONCOL, V137, P181, DOI 10.1007/s11060-017-2710-7; Rosenfeld MR, 2010, NEURO-ONCOLOGY, V12, P1071, DOI 10.1093/neuonc/noq071; Sanzey M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123544; Sciacovelli M, 2017, CELL DEATH DIFFER, V24, P1, DOI 10.1038/cdd.2016.137; Shen H, 2015, MOL CANCER THER, V14, P1794, DOI 10.1158/1535-7163.MCT-15-0247; Sheth S, 2014, INT J MOL SCI, V15, P2024, DOI 10.3390/ijms15022024; Sinclair LV, 2013, NAT IMMUNOL, V14, P500, DOI 10.1038/ni.2556; Siu L, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001095; Steggerda SM, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0308-4; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tejera Dalissa, 2020, CNS Oncol, V9, pCNS62, DOI 10.2217/cns-2020-0014; Tonjes M, 2013, NAT MED, V19, P901, DOI 10.1038/nm.3217; Totsch SK, 2019, ONCOGENE, V38, P6159, DOI 10.1038/s41388-019-0870-y; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; Uyttenhove C, 2003, NAT MED, V9, P1269, DOI 10.1038/nm934; Velpula KK, 2017, ONCOTARGET, V8, P35639, DOI 10.18632/oncotarget.16767; Wainwright DA, 2012, CLIN CANCER RES, V18, P6110, DOI 10.1158/1078-0432.CCR-12-2130; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Weller M, 2017, LANCET ONCOL, V18, P1373, DOI 10.1016/S1470-2045(17)30517-X; Wicks RT, 2015, NEURO-ONCOLOGY, V17, P70, DOI 10.1093/neuonc/nou143; Wu JY, 2020, MOL CELL, V77, P213, DOI 10.1016/j.molcel.2019.10.023; Xu S, 2013, NEURO-ONCOLOGY, V15, P1160, DOI 10.1093/neuonc/not067; Yan A, 2019, J NEUROSCI, V39, P4387, DOI 10.1523/JNEUROSCI.1118-18.2019; Yuen Carlen A, 2016, CNS Oncol, V5, P101, DOI 10.2217/cns-2015-0006; Zappasodi R, 2021, NATURE, V591, P652, DOI 10.1038/s41586-021-03326-4; Zhai LJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01185; Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944; Zhou WH, 2019, CANCERS, V11, DOI 10.3390/cancers11091231; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212	105	3	3	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2022	41	19					2663	2671		10.1038/s41388-022-02312-y	http://dx.doi.org/10.1038/s41388-022-02312-y		APR 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1A5QI	35430605	Green Accepted			2022-12-17	WOS:000782888200001
J	Segeren, HA; van Liere, EA; Riemers, FM; de Bruin, A; Westendorp, B				Segeren, Hendrika A.; van Liere, Elsbeth A.; Riemers, Frank M.; de Bruin, Alain; Westendorp, Bart			Oncogenic RAS sensitizes cells to drug-induced replication stress via transcriptional silencing of P53	ONCOGENE			English	Article							DNA-DAMAGE; GENOMIC INSTABILITY; SIGNALING PATHWAYS; TGF-BETA; CANCER; EXPRESSION; CYCLE; ATR; ACTIVATION; DYNAMICS	Cancer cells often experience high basal levels of DNA replication stress (RS), for example due to hyperactivation of oncoproteins like MYC or RAS. Therefore, cancer cells are considered to be sensitive to drugs that exacerbate the level of RS or block the intra S-phase checkpoint. Consequently, RS-inducing drugs including ATR and CHK1 inhibitors are used or evaluated as anti-cancer therapies. However, drug resistance and lack of biomarkers predicting therapeutic efficacy limit efficient use. This raises the question what determines sensitivity of individual cancer cells to RS. Here, we report that oncogenic RAS does not only enhance the sensitivity to ATR/CHK1 inhibitors by directly causing RS. Instead, we observed that HRAS(G12V) dampens the activation of the P53-dependent transcriptional response to drug-induced RS, which in turn confers sensitivity to RS. We demonstrate that inducible expression of HRAS(G12V) sensitized cells to ATR and CHK1 inhibitors. Using RNA-sequencing of FACS-sorted cells we discovered that P53 signaling is the sole transcriptional response to RS. However, oncogenic RAS attenuates the transcription of P53 and TGF-beta pathway components which consequently dampens P53 target gene expression. Accordingly, live cell imaging showed that HRAS(G12V) exacerbates RS in S/G2-phase, which could be rescued by stabilization of P53. Thus, our results demonstrate that transcriptional control of P53 target genes is the prime determinant in the response to ATR/CHK1 inhibitors and show that hyperactivation of the MAPK pathway impedes this response. Our findings suggest that the level of oncogenic MAPK signaling could predict sensitivity to intra-S-phase checkpoint inhibition in cancers with intact P53.	[Segeren, Hendrika A.; van Liere, Elsbeth A.; Riemers, Frank M.; de Bruin, Alain; Westendorp, Bart] Univ Utrecht, Fac Vet Med, Dept Biomol Hlth Sci, Utrecht, Netherlands; [Riemers, Frank M.] Univ Utrecht, Fac Vet Med, Dept Clin Sci, Utrecht, Netherlands; [de Bruin, Alain] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, Groningen, Netherlands	Utrecht University; Utrecht University; University of Groningen	Westendorp, B (corresponding author), Univ Utrecht, Fac Vet Med, Dept Biomol Hlth Sci, Utrecht, Netherlands.	b.westendorp@uu.nl		Riemers, Frank/0000-0003-4732-9447; Westendorp, Bart/0000-0003-1043-3638	KWF Kankerbestrijding (Dutch Cancer Society) [11941-2018-II]; ZonMW [91116011]; Utrecht Life Sciences; University Medical Center Utrecht, Hubrecht Institute, Utrecht University; Netherlands X-omics Initiative (NWO) [184.034.019]	KWF Kankerbestrijding (Dutch Cancer Society); ZonMW(Netherlands Organization for Health Research and Development); Utrecht Life Sciences; University Medical Center Utrecht, Hubrecht Institute, Utrecht University; Netherlands X-omics Initiative (NWO)	This work is financially supported by the KWF Kankerbestrijding (Dutch Cancer Society, project grant 11941-2018-II) and ZonMW (grant 91116011). Further financial support was provided by research infrastructure grants from Utrecht Life Sciences to the Single Cell Analysis Center and the Center for Cell Imaging. Utrecht Sequencing Facility is subsidized by the University Medical Center Utrecht, Hubrecht Institute, Utrecht University and The Netherlands X-omics Initiative (NWO project 184.034.019).	Agarwal ML, 2001, ONCOGENE, V20, P2527, DOI 10.1038/sj.onc.1204353; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Andrews S., 2010, FASTQC QUALITY CONTR; Arora M, 2017, CELL REP, V19, P1351, DOI 10.1016/j.celrep.2017.04.055; Bacevic K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12868-5; Bajar BT, 2016, NAT METHODS, V13, P993, DOI [10.1038/NMETH.4045, 10.1038/nmeth.4045]; Barnes RP, 2018, CANCER RES, V78, P6549, DOI 10.1158/0008-5472.CAN-17-3931; Beck H, 2010, J CELL BIOL, V188, P629, DOI 10.1083/jcb.200905059; Buisson R, 2015, MOL CELL, V59, P1011, DOI 10.1016/j.molcel.2015.07.029; Chao HX, 2017, CELL SYST, V5, P445, DOI 10.1016/j.cels.2017.09.015; Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Cordenonsi M, 2007, SCIENCE, V315, P840, DOI 10.1126/science.1135961; Daigh LH, 2018, CELL SYST, V7, P17, DOI 10.1016/j.cels.2018.05.011; Daly AC, 2010, J BIOL CHEM, V285, P6489, DOI 10.1074/jbc.M109.043877; David L, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aac9704; De S, 2020, CELL REP, V30, P2083, DOI 10.1016/j.celrep.2020.01.074; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dietlein F, 2015, CELL, V162, P146, DOI 10.1016/j.cell.2015.05.053; Dillon MT, 2017, MOL CANCER THER, V16, P25, DOI 10.1158/1535-7163.MCT-16-0239; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Feringa FM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06308-9; FILMUS J, 1994, ONCOGENE, V9, P3627; Fischer M, 2017, ONCOGENE, V36, P3943, DOI 10.1038/onc.2016.502; Gaillard H, 2015, NAT REV CANCER, V15, P276, DOI 10.1038/nrc3916; Galanos P, 2016, NAT CELL BIOL, V18, P777, DOI 10.1038/ncb3378; Gilad O, 2010, CANCER RES, V70, P9693, DOI 10.1158/0008-5472.CAN-10-2286; Hamer PCD, 2011, CLIN CANCER RES, V17, P4200, DOI 10.1158/1078-0432.CCR-10-2537; Hamppa S, 2016, P NATL ACAD SCI USA, V113, pE4311, DOI 10.1073/pnas.1605828113; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Her J, 2018, MOL CELL BIOL, V38, DOI 10.1128/MCB.00472-17; Hong DS, 2018, CLIN CANCER RES, V24, P3263, DOI 10.1158/1078-0432.CCR-17-3347; Hornsveld M, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108675; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Hsu CH, 2019, CELL, V178, P361, DOI 10.1016/j.cell.2019.05.041; Italiano A, 2018, ANN ONCOL, V29, P1304, DOI 10.1093/annonc/mdy076; Kawarada Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep35483; Klusmann I, 2016, CELL REP, V17, P1845, DOI 10.1016/j.celrep.2016.10.036; Kotsantis P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13087; Koundrioukoff S, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003643; Kranz D, 2006, CANCER RES, V66, P10274, DOI 10.1158/0008-5472.CAN-06-1527; Krenning L, 2014, MOL CELL, V55, P59, DOI 10.1016/j.molcel.2014.05.007; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lerner LK, 2017, NUCLEIC ACIDS RES, V45, P1270, DOI 10.1093/nar/gkw1196; Liu HS, 2009, BIOCHEM J, V422, P543, DOI 10.1042/BJ20090342; Lloyd RL, 2021, NUCLEIC ACIDS RES, V49, P8665, DOI 10.1093/nar/gkab628; Lopez-Contreras AJ, 2012, J EXP MED, V209, P455, DOI 10.1084/jem.20112147; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Macheret M, 2018, NATURE, V555, P112, DOI 10.1038/nature25507; Macheret M, 2015, ANNU REV PATHOL-MECH, V10, P425, DOI 10.1146/annurev-pathol-012414-040424; Masamsetti VP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12255-w; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Moreno E, 2021, HEPATOLOGY, V73, P303, DOI 10.1002/hep.31259; Murga M, 2011, NAT STRUCT MOL BIOL, V18, P1331, DOI 10.1038/nsmb.2189; Oo ZY, 2018, CLIN CANCER RES, V24, P2901, DOI 10.1158/1078-0432.CCR-17-2701; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Patel PL, 2016, P NATL ACAD SCI USA, V113, pE5024, DOI 10.1073/pnas.1602379113; Pilie PG, 2019, NAT REV CLIN ONCOL, V16, P81, DOI 10.1038/s41571-018-0114-z; Purvis JE, 2012, SCIENCE, V336, P1440, DOI 10.1126/science.1218351; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Reaper PM, 2011, NAT CHEM BIOL, V7, P428, DOI [10.1038/NCHEMBIO.573, 10.1038/nchembio.573]; Reyes J, 2018, MOL CELL, V71, P581, DOI 10.1016/j.molcel.2018.06.031; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Roy S, 2018, ELIFE, V7, DOI 10.7554/eLife.31723; Sa G, 2004, EXP CELL RES, V300, P427, DOI 10.1016/j.yexcr.2004.07.032; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Scagliotti G, 2016, INVEST NEW DRUG, V34, P625, DOI 10.1007/s10637-016-0368-1; Schoppy DW, 2012, J CLIN INVEST, V122, P241, DOI 10.1172/JCI58928; Segeren HA, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108449; Su J, 2020, NATURE, V577, P566, DOI 10.1038/s41586-019-1897-5; Suram A, 2012, EMBO J, V31, P2839, DOI 10.1038/emboj.2012.132; Tarasov A, 2015, BIOINFORMATICS, V31, P2032, DOI 10.1093/bioinformatics/btv098; Taylor WR, 1999, ONCOGENE, V18, P283, DOI 10.1038/sj.onc.1202516; Techer H, 2017, NAT REV GENET, V18, P535, DOI 10.1038/nrg.2017.46; Toledo LI, 2013, CELL, V155, P1088, DOI 10.1016/j.cell.2013.10.043; Valente LJ, 2013, CELL REP, V3, P1339, DOI 10.1016/j.celrep.2013.04.012; Wang C, 2019, NATURE, V574, P268, DOI 10.1038/s41586-019-1607-3; Wei XY, 1998, SCIENCE, V281, P1502, DOI 10.1126/science.281.5382.1502; Weyemi U, 2012, ONCOGENE, V31, P1117, DOI 10.1038/onc.2011.327; Wilhelm T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11584-0; Xu YX, 2017, ELIFE, V6, DOI 10.7554/eLife.30523; Yang HW, 2017, NATURE, V549, P404, DOI 10.1038/nature23880	83	3	3	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2022	41	19					2719	2733		10.1038/s41388-022-02291-0	http://dx.doi.org/10.1038/s41388-022-02291-0		APR 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1A5QI	35393546	hybrid, Green Submitted, Green Published			2022-12-17	WOS:000779227700005
J	Garcia-Dominguez, DJ; Hajji, N; Lopez-Alemany, R; Sanchez-Molina, S; Figuerola-Bou, E; Civanto, FJM; Rello-Varona, S; Andres-Leon, E; Benito, A; Keun, HC; Mora, J; Tirado, OM; de Alava, E; Hontecillas-Prieto, L				Garcia-Dominguez, Daniel J.; Hajji, Nabil; Lopez-Alemany, Roser; Sanchez-Molina, Sara; Figuerola-Bou, Elisabet; Civanto, Francisco J. Moron; Rello-Varona, Santiago; Andres-Leon, Eduardo; Benito, Adrian; Keun, Hector C.; Mora, Jaume; Tirado, Oscar M.; de Alava, Enrique; Hontecillas-Prieto, Lourdes			Selective histone methyltransferase G9a inhibition reduces metastatic development of Ewing sarcoma through the epigenetic regulation of NEU1	ONCOGENE			English	Article							CANCER METASTASIS; SIALIDASE NEU1; METHYLATION; AUTOPHAGY; CELLS; OVEREXPRESSION; PROLIFERATION; APOPTOSIS; INVASION; MIMICRY	Ewing sarcoma (EWS) is an aggressive bone and soft tissue tumor with high susceptibility to metastasize. The underlying molecular mechanisms leading to EWS metastases remain poorly understood. Epigenetic changes have been implicated in EWS tumor growth and progression. Linking epigenetics and metastases may provide insight into novel molecular targets in EWS and improve its treatment. Here, we evaluated the effects of a selective G9a histone methyltransferase inhibitor (BIX01294) on EWS metastatic process. Our results showed that overexpression of G9a in tumors from EWS patients correlates with poor prognosis. Moreover, we observe a significantly higher expression of G9a in metastatic EWS tumor as compared to either primary or recurrent tumor. Using functional assays, we demonstrate that pharmacological G9a inhibition using BIX01294 disrupts several metastatic steps in vitro, such as migration, invasion, adhesion, colony formation and vasculogenic mimicry. Moreover, BIX01294 reduces tumor growth and metastases in two spontaneous metastases mouse models. We further identified the sialidase NEU1 as a direct target and effector of G9a in the metastatic process in EWS. NEU1 overexpression impairs migration, invasion and clonogenic capacity of EWS cell lines. Overall, G9a inhibition impairs metastases in vitro and in vivo through the overexpression of NEU1. G9a has strong potential as a prognostic marker and may be a promising therapeutic target for EWS patients.	[Garcia-Dominguez, Daniel J.; Civanto, Francisco J. Moron; de Alava, Enrique; Hontecillas-Prieto, Lourdes] Hosp Univ Virgen del Rocio, Inst Biomed Seville IBiS, CSIC, CIBERONC, Seville, Spain; [Hajji, Nabil] Imperial Coll London, Div Brain Sci, London, England; [Sanchez-Molina, Sara; Figuerola-Bou, Elisabet; Mora, Jaume] Hosp St Joan de Deu, Dev Tumour Biol Lab, Barcelona, Spain; [Andres-Leon, Eduardo] Consejo Super Invest Cient IPBLN CSIC, Bioinformat Unit, Inst Parasitol & Biomed Lopez Neyra, Granada, Spain; [Benito, Adrian; Keun, Hector C.] Imperial Coll London, Div Canc, Canc Metab & Syst Toxicol Grp, London, England; [de Alava, Enrique] Univ Seville, Pathol Unit, Univ Virgen del Rocio, CIBERONC,CSIC, Seville, Spain; [de Alava, Enrique] Univ Seville, Sch Med, Dept Normal & Pathol Cytol & Histol, Seville 41009, Spain; [Garcia-Dominguez, Daniel J.; Hontecillas-Prieto, Lourdes] Univ Seville, Sch Med, Dept Med Biochem & Mol Biol, Virgen Macarena Univ Hosp, Seville, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital; Imperial College London; University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Imperial College London; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; University of Sevilla; Hospital Universitario Virgen Macarena; University of Sevilla	Garcia-Dominguez, DJ; de Alava, E; Hontecillas-Prieto, L (corresponding author), Hosp Univ Virgen del Rocio, Inst Biomed Seville IBiS, CSIC, CIBERONC, Seville, Spain.; Garcia-Dominguez, DJ; Hontecillas-Prieto, L (corresponding author), Univ Seville, Sch Med, Dept Med Biochem & Mol Biol, Virgen Macarena Univ Hosp, Seville, Spain.	dgarcia-ibis@us.es; enrique.alava.sspa@juntadeandalucia.es; lhontecillas-ibis@us.es	de Alava, Enrique/GOH-0368-2022; Andrés-León., Eduardo/K-8944-2014; Rello-Varona, Santi/A-4882-2009; Sanchez-Molina, Sara/B-2148-2017	de Alava, Enrique/0000-0001-8400-046X; Andrés-León., Eduardo/0000-0002-0621-9914; Figuerola-Bou, Elisabet/0000-0002-6839-9586; Rello-Varona, Santi/0000-0002-7500-5522; Sanchez-Molina, Sara/0000-0002-1430-131X; Hajji, Nabil/0000-0002-0695-920X	Asociacion Espanola Contra el Cancer" (AECC); Ministry of Economy and Competitiveness of Spain-FEDER (CIBERONC) [PI2000003, RD06/0020/0059]; CIBERONC [CB16/12/00361]; Consejeria de Salud de la Junta de Andalucia [PI-0013-2018]; Asociacion Alba Perez lucha contra el cancer infantil"; Catalan Agency for the Management of University and Research Grants [AGAUR 2017 SGR 332]	Asociacion Espanola Contra el Cancer" (AECC); Ministry of Economy and Competitiveness of Spain-FEDER (CIBERONC); CIBERONC; Consejeria de Salud de la Junta de Andalucia(Junta de Andalucia); Asociacion Alba Perez lucha contra el cancer infantil"; Catalan Agency for the Management of University and Research Grants	Research in the EDA and OMT labs are supported by "Asociacion Espanola Contra el Cancer" (AECC). EDA lab is also supported by the Ministry of Economy and Competitiveness of Spain-FEDER (CIBERONC, PI2000003, RD06/0020/0059). DGD and LHP are supported by CIBERONC (CB16/12/00361)S. LHP is funded by the Consejeria de Salud de la Junta de Andalucia (PI-0013-2018). SRV is supported by "Asociacion Alba Perez lucha contra el cancer infantil". The OMT lab is supported by the Catalan Agency for the Management of University and Research Grants (AGAUR 2017 SGR 332).	Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Balamuth NJ, 2010, LANCET ONCOL, V11, P184, DOI 10.1016/S1470-2045(09)70286-4; Bergin CJ, 2021, ONCOGENE, V40, P1191, DOI 10.1038/s41388-020-01591-7; Boulias K, 2004, NUCLEIC ACIDS RES, V32, P6096, DOI 10.1093/nar/gkh947; Casciello F, 2017, P NATL ACAD SCI USA, V114, P7077, DOI 10.1073/pnas.1618706114; Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833; Chen RJ, 2017, ONCOTARGET, V8, P62081, DOI 10.18632/oncotarget.19060; Crompton BD, 2014, CANCER DISCOV, V4, P1326, DOI 10.1158/2159-8290.CD-13-1037; Dang NN, 2020, AGING-US, V12, P2393, DOI 10.18632/aging.102750; de Nigris F, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115605; Folberg R, 2000, AM J PATHOL, V156, P361, DOI 10.1016/S0002-9440(10)64739-6; Garcia-Dominguez DJ, 2021, ONCOGENE, V40, P5843, DOI 10.1038/s41388-021-01974-4; Garcia-Dominguez Daniel Jose, 2018, Oncotarget, V9, P31397, DOI 10.18632/oncotarget.25829; Gaspar N, 2015, J CLIN ONCOL, V33, P3036, DOI 10.1200/JCO.2014.59.5256; Gilmour AM, 2013, CELL SIGNAL, V25, P2587, DOI 10.1016/j.cellsig.2013.08.008; Grunewald TGP, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0003-x; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hontecillas-Prieto L, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.578011; Hou GJ, 2016, ONCOTARGET, V7, P64957, DOI 10.18632/oncotarget.11778; Hu L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0322-6; Kim K, 2018, BIOCHEM BIOPH RES CO, V496, P758, DOI 10.1016/j.bbrc.2018.01.074; Kim Y, 2013, AUTOPHAGY, V9, P2126, DOI 10.4161/auto.26308; Kramer JM, 2016, BIOCHEM CELL BIOL, V94, P26, DOI 10.1139/bcb-2015-0017; Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017; Li F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138390; Li XL, 2018, SPRINGERBRIEF MATH, P1, DOI 10.1007/978-3-319-89617-5_1; Liao HY, 2018, ONCOTARGETS THER, V11, P6947, DOI 10.2147/OTT.S172190; Lopez-Alemany R, 2021, METHODS MOL BIOL, V2226, P201, DOI 10.1007/978-1-0716-1020-6_16; Mabe NW, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108341; Mackintosh C, 2012, ONCOGENE, V31, P1287, DOI 10.1038/onc.2011.317; Oh SY, 2015, MOL CELLS, V38, P528, DOI 10.14348/molcells.2015.0026; Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P; Pang ALY, 2014, ONCOL LETT, V7, P1819, DOI 10.3892/ol.2014.2034; Papait R, 2017, CIRCULATION, V136, P1233, DOI 10.1161/CIRCULATIONAHA.117.028561; Qin J, 2018, ONCOL LETT, V15, P8611, DOI 10.3892/ol.2018.8446; Ren AS, 2015, BIOCHEM BIOPH RES CO, V459, P10, DOI 10.1016/j.bbrc.2015.01.068; Ren LR, 2016, MOL CELL BIOCHEM, V411, P213, DOI 10.1007/s11010-015-2583-z; Sechler M, 2017, ONCOGENE, V36, P4150, DOI 10.1038/onc.2017.44; Segovia C, 2019, NAT MED, V25, P1073, DOI 10.1038/s41591-019-0499-y; Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25; Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Uemura T, 2009, ONCOGENE, V28, P1218, DOI 10.1038/onc.2008.471; van der Schaft DWJ, 2005, CANCER RES, V65, P11520, DOI 10.1158/0008-5472.CAN-05-2468; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wagenblast E, 2015, NATURE, V520, P358, DOI 10.1038/nature14403; Wei L, 2017, J HEPATOL, V67, P758, DOI 10.1016/j.jhep.2017.05.015; Wozniak RJ, 2007, ONCOGENE, V26, P77, DOI 10.1038/sj.onc.1209763; Yin C, 2019, FASEB J, V33, P14036, DOI 10.1096/fj.201900233RR; Yokoyama M, 2017, ONCOTARGET, V8, P21315, DOI 10.18632/oncotarget.15528	51	3	3	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2022	41	18					2638	2650		10.1038/s41388-022-02279-w	http://dx.doi.org/10.1038/s41388-022-02279-w		MAR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0W4LA	35354905	Green Published, hybrid			2022-12-17	WOS:000775854600001
J	Tu, JJ; Fang, YL; Han, DF; Tan, XW; Xu, Z; Jiang, HF; Wang, XM; Hong, WM; Wei, W				Tu, Jiajie; Fang, Yilong; Han, Dafei; Tan, Xuewen; Xu, Zhen; Jiang, Haifeng; Wang, Xinming; Hong, Wenming; Wei, Wei			MicroRNA-22 represses glioma development via activation of macrophage-mediated innate and adaptive immune responses	ONCOGENE			English	Article							STEM-CELLS; OSTEOGENIC DIFFERENTIATION; PROLIFERATION; INVASION; INHIBITION; TEMOZOLOMIDE; SENSITIVITY; RECEPTOR; HEALTH	Macrophage-mediated tumor cell phagocytosis and subsequent neoantigen presentation are critical for generating anti-tumor immunity. This study aimed to uncover the potential clinical value and molecular mechanisms of miRNA-22 (miR-22) in tumor cell phagocytosis via macrophages and more efficient T cell priming. We found that miR-22 expression was markedly downregulated in primary macrophages from glioma tissue samples compared to adjacent tissues. miR-22-overexpressing macrophages inhibited glioma cell proliferation and migration, respectively. miR-22 upregulation stimulated the phagocytic ability of macrophages, enhanced tumor cell phagocytosis, antigen presentation, and efficient T cell priming. Additionally, our data revealed that miR-22-overexpressing macrophages inhibited glioma formation in vivo, HDAC6 was a target, and NF-kappa B signaling was a pathway closely associated with miR-22 in tumor-associated macrophages (TAMs) of glioma. Our findings revealed the essential roles of miR-22 in tumor cell phagocytosis by macrophages and more efficient T cell priming, facilitating further research on phagocytic regulation to enhance the response to tumor immunotherapy.	[Tu, Jiajie; Fang, Yilong; Han, Dafei; Tan, Xuewen; Xu, Zhen; Jiang, Haifeng; Wei, Wei] Anhui Med Univ, Inst Clin Pharmacol, Key Lab Antiinflammatory & Immune Med, Minist Educ,Anhui Collaborat Innovat Ctr Antiinfl, Hefei, Peoples R China; [Wang, Xinming; Hong, Wenming] Anhui Med Univ, Affiliated Hosp 1, Dept Neurosurg, Hefei, Peoples R China	Anhui Medical University; Anhui Medical University	Wei, W (corresponding author), Anhui Med Univ, Inst Clin Pharmacol, Key Lab Antiinflammatory & Immune Med, Minist Educ,Anhui Collaborat Innovat Ctr Antiinfl, Hefei, Peoples R China.; Hong, WM (corresponding author), Anhui Med Univ, Affiliated Hosp 1, Dept Neurosurg, Hefei, Peoples R China.	524594636@qq.com; wwei@ahmu.edu.cn		hong, wenming/0000-0002-1143-8046	National Natural Science Foundation of China [31900616, 81673444, 82003795]; project of improvement of the scientific ability of Anhui Medical University [2020xkjT009]; Natural Science Foundation of Anhui Province for young scholars [1908085QH379]; Open Fund of Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, P.R. China, Anhui Medical University [KFJJ-2021-01]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); project of improvement of the scientific ability of Anhui Medical University; Natural Science Foundation of Anhui Province for young scholars; Open Fund of Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, P.R. China, Anhui Medical University	This study was supported by the National Natural Science Foundation of China (31900616, 81673444, 82003795), The project of improvement of the scientific ability of Anhui Medical University (2020xkjT009), Natural Science Foundation of Anhui Province for young scholars (1908085QH379) and The Open Fund of Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, P.R. China, Anhui Medical University (KFJJ-2021-01).	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Chang SJ, 2009, MOL BIOL REP, V36, P2165, DOI 10.1007/s11033-008-9430-1; Chen HC, 2016, TUMOR BIOL, V37, P6761, DOI 10.1007/s13277-015-4575-8; Domingues P, 2016, BRAIN BEHAV IMMUN, V53, P1, DOI 10.1016/j.bbi.2015.07.019; Guerriero JL, 2019, INT REV CEL MOL BIO, V342, P73, DOI 10.1016/bs.ircmb.2018.07.001; Guo YW, 2019, FRONT MOL NEUROSCI, V12, DOI 10.3389/fnmol.2019.00125; Hambardzumyan D, 2016, NAT NEUROSCI, V19, P20, DOI 10.1038/nn.4185; Heimberger AB, 2003, CLIN CANCER RES, V9, P4247; Hu T, 2020, NEUROSCI LETT, V728, DOI 10.1016/j.neulet.2020.134896; Huang S, 2012, STEM CELLS DEV, V21, P2531, DOI 10.1089/scd.2012.0014; Hussain SF, 2006, NEURO-ONCOLOGY, V8, P261, DOI 10.1215/15228517-2006-008; Josephs Debra H, 2015, Front Biosci (Elite Ed), V7, P293; Kim GW, 2019, ANTICANCER RES, V39, P6731, DOI 10.21873/anticanres.13888; Knox T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42237-3; Kramer OH, 2014, TRENDS PHARMACOL SCI, V35, P501, DOI 10.1016/j.tips.2014.08.001; Krutzik SR, 2005, NAT MED, V11, P653, DOI 10.1038/nm1246; Kurynina AV, 2018, BIOCHEMISTRY-MOSCOW+, V83, P200, DOI 10.1134/S0006297918030021; Li S, 2018, ONCOGENE, V37, P884, DOI 10.1038/onc.2017.381; Lorenzi S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046928; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Lu W, 2015, NAT IMMUNOL, V16, P1185, DOI 10.1038/ni.3292; Medler TR, 2016, MOL CANCER RES, V14, P994, DOI 10.1158/1541-7786.MCR-16-0109; Park SJ, 2014, CANCER LETT, V354, P97, DOI 10.1016/j.canlet.2014.07.041; Pei XF, 2018, PATHOL RES PRACT, V214, P1095, DOI 10.1016/j.prp.2018.04.009; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Salmi Marko, 2017, Duodecim, V133, P829; Seidel C, 2015, EPIGENOMICS-UK, V7, P103, DOI [10.2217/EPI.14.69, 10.2217/epi.14.69]; Shen C, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006259; Sin WC, 2016, ONCOGENE, V35, P1504, DOI 10.1038/onc.2015.210; von Roemeling CA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15129-8; Wan SF, 2016, ONCOTARGET, V7, P76667, DOI 10.18632/oncotarget.12395; Wang B, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110395; Wang ZH, 2016, CANCER LETT, V379, P134, DOI 10.1016/j.canlet.2016.06.001; Wang ZH, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0765-5; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Wong MLH, 2009, J CLIN NEUROSCI, V16, P1119, DOI 10.1016/j.jocn.2009.02.009; Wongjampa W, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206644; Yan GQ, 2017, J CELL BIOCHEM, V118, P1653, DOI 10.1002/jcb.25931; Yang Q, 2019, ACM T INTEL SYST TEC, V10, DOI 10.1145/3298981; Yang W, 2018, CANCER LETT, V415, P164, DOI 10.1016/j.canlet.2017.12.005; Yang XM, 2014, CANCER CELL, V25, P37, DOI 10.1016/j.ccr.2013.12.004; Zhang K, 2017, EUR REV MED PHARMACO, V21, P3598; Zhang L, 2020, EUR REV MED PHARMACO, V24, P571, DOI 10.26355/eurrev_202001_20033; Zhang X, 2017, BIOL RES, V50, DOI 10.1186/s40659-017-0133-8; Zhang YQ, 2020, J BUON, V25, P491; Zhou WC, 2015, NAT CELL BIOL, V17, P170, DOI 10.1038/ncb3090	46	3	3	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2022	41	17					2444	2457		10.1038/s41388-022-02236-7	http://dx.doi.org/10.1038/s41388-022-02236-7		MAR 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0R6YF	35279703				2022-12-17	WOS:000767909000002
J	Srinivas, US; Tay, NSC; Jaynes, P; Anbuselvan, A; Ramachandran, GK; Wardyn, JD; Hoppe, MM; Hoang, PM; Peng, YF; Lim, S; Lee, MY; Peethala, PC; An, O; Shendre, A; Tan, BWQ; Jemimah, S; Lakshmanan, M; Hu, LY; Jakhar, R; Sachaphibulkij, K; Lim, LHK; Pervaiz, S; Crasta, K; Yang, H; Tan, P; Liang, C; Ho, LN; Khanchandani, V; Kappei, D; Yong, WP; Tan, DSP; Bordi, M; Campello, S; Tam, WL; Frezza, C; Jeyasekharan, AD				Srinivas, Upadhyayula S.; Tay, Norbert S. C.; Jaynes, Patrick; Anbuselvan, Akshaya; Ramachandran, Gokula K.; Wardyn, Joanna D.; Hoppe, Michal M.; Hoang, Phuong Mai; Peng, Yanfen; Lim, Sherlly; Lee, May Yin; Peethala, Praveen C.; An, Omer; Shendre, Akshay; Tan, Bryce W. Q.; Jemimah, Sherlyn; Lakshmanan, Manikandan; Hu, Longyu; Jakhar, Rekha; Sachaphibulkij, Karishma; Lim, Lina H. K.; Pervaiz, Shazib; Crasta, Karen; Yang, Henry; Tan, Patrick; Liang, Chao; Ho, Lena; Khanchandani, Vartika; Kappei, Dennis; Yong, Wei Peng; Tan, David S. P.; Bordi, Matteo; Campello, Silvia; Tam, Wai Leong; Frezza, Christian; Jeyasekharan, Anand D.			PLK1 inhibition selectively induces apoptosis in ARID1A deficient cells through uncoupling of oxygen consumption from ATP production	ONCOGENE			English	Article							POLO-LIKE KINASE-1; CLEAR-CELL; SWI/SNF COMPLEXES; TUMOR PROGRESSION; BI 6727; EXPRESSION; CANCER; DNA; PHOSPHORYLATION; TARGET	Inhibitors of the mitotic kinase PLK1 yield objective responses in a subset of refractory cancers. However, PLK1 overexpression in cancer does not correlate with drug sensitivity, and the clinical development of PLK1 inhibitors has been hampered by the lack of patient selection marker. Using a high-throughput chemical screen, we discovered that cells deficient for the tumor suppressor ARID1A are highly sensitive to PLK1 inhibition. Interestingly this sensitivity was unrelated to canonical functions of PLK1 in mediating G2/M cell cycle transition. Instead, a whole-genome CRISPR screen revealed PLK1 inhibitor sensitivity in ARID1A deficient cells to be dependent on the mitochondrial translation machinery. We find that ARID1A knock-out (KO) cells have an unusual mitochondrial phenotype with aberrant biogenesis, increased oxygen consumption/expression of oxidative phosphorylation genes, but without increased ATP production. Using expansion microscopy and biochemical fractionation, we see that a subset of PLK1 localizes to the mitochondria in interphase cells. Inhibition of PLK1 in ARID1A KO cells further uncouples oxygen consumption from ATP production, with subsequent membrane depolarization and apoptosis. Knockdown of specific subunits of the mitochondrial ribosome reverses PLK1-inhibitor induced apoptosis in ARID1A deficient cells, confirming specificity of the phenotype. Together, these findings highlight a novel interphase role for PLK1 in maintaining mitochondrial fitness under metabolic stress, and a strategy for therapeutic use of PLK1 inhibitors. To translate these findings, we describe a quantitative microscopy assay for assessment of ARID1A protein loss, which could offer a novel patient selection strategy for the clinical development of PLK1 inhibitors in cancer.	[Srinivas, Upadhyayula S.; Tay, Norbert S. C.; Jaynes, Patrick; Anbuselvan, Akshaya; Ramachandran, Gokula K.; Wardyn, Joanna D.; Hoppe, Michal M.; Hoang, Phuong Mai; Peng, Yanfen; Lim, Sherlly; Peethala, Praveen C.; An, Omer; Shendre, Akshay; Tan, Bryce W. Q.; Jemimah, Sherlyn; Yang, Henry; Khanchandani, Vartika; Kappei, Dennis; Yong, Wei Peng; Tan, David S. P.; Tam, Wai Leong; Jeyasekharan, Anand D.] Natl Univ Singapore NUS, Canc Sci Inst Singapore, Singapore, Singapore; [Lee, May Yin; Tan, Patrick; Tam, Wai Leong] ASTAR, Genome Inst Singapore GIS, Singapore, Singapore; [Lakshmanan, Manikandan] ASTAR, Inst Mol & Cell Biol IMCB, Singapore, Singapore; [Hu, Longyu; Tan, Patrick] Duke NUS Med Sch, Canc & Stem Cell Biol, Singapore, Singapore; [Jakhar, Rekha; Sachaphibulkij, Karishma; Lim, Lina H. K.; Pervaiz, Shazib; Crasta, Karen] Natl Univ Singapore NUS, Yong Loo Lin Sch Med, Dept Physiol, Singapore, Singapore; [Jakhar, Rekha; Crasta, Karen] Natl Univ Hlth Syst NUHS, Ctr Hlth Longev, Singapore, Singapore; [Liang, Chao; Ho, Lena] Duke NUS Med Sch, Cardiovasc & Metab Disorders, Singapore, Singapore; [Kappei, Dennis; Tam, Wai Leong] Natl Univ Singapore NUS, Yong Loo Lin Sch Med, Dept Biochem, Singapore, Singapore; [Kappei, Dennis; Jeyasekharan, Anand D.] Natl Univ Singapore NUS, NUS Ctr Canc Res N2CR, Yong Loo Lin Sch Med, Singapore, Singapore; [Yong, Wei Peng; Tan, David S. P.; Jeyasekharan, Anand D.] Natl Univ Hosp NUH, Natl Univ Canc Inst Singapore NCIS, Singapore, Singapore; [Bordi, Matteo; Campello, Silvia] Univ Roma Tor Vergata, Dept Biol, Rome, Italy; [Frezza, Christian] Univ Cambridge, MRC Canc Unit, Cambridge, England	Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore; University of Rome Tor Vergata; University of Cambridge	Jeyasekharan, AD (corresponding author), Natl Univ Singapore NUS, Canc Sci Inst Singapore, Singapore, Singapore.; Jeyasekharan, AD (corresponding author), Natl Univ Singapore NUS, NUS Ctr Canc Res N2CR, Yong Loo Lin Sch Med, Singapore, Singapore.; Jeyasekharan, AD (corresponding author), Natl Univ Hosp NUH, Natl Univ Canc Inst Singapore NCIS, Singapore, Singapore.	csiadj@nus.edu.sg	Lee, May Yin/AAB-3450-2021	Lee, May Yin/0000-0003-2366-9463; Tay, Norbert/0000-0002-4960-9250; Jemimah, Sherlyn/0000-0003-1974-5064; Hoppe, Michal Marek/0000-0002-0364-6080; Tam, Wai Leong/0000-0003-2365-5264; Peng, Yanfen/0000-0003-1753-8547	Singapore Ministry of Health's National Medical Research Council Transition Award [NMRC/TA/0052/2016]; Cancer Science Institute of Singapore; National University of Singapore, through the National Research Foundation Singapore; Singapore Ministry of Education under its Research Centers of Excellence initiative; Singapore Ministry of Health's National Medical Research Council [NMRC/CIRG/1400/2014]	Singapore Ministry of Health's National Medical Research Council Transition Award(Ministry of Health-SingaporeNational Medical Research Council, Singapore); Cancer Science Institute of Singapore; National University of Singapore, through the National Research Foundation Singapore; Singapore Ministry of Education under its Research Centers of Excellence initiative(Ministry of Education, Singapore); Singapore Ministry of Health's National Medical Research Council(National Medical Research Council, Singapore)	ADJ is supported by the Singapore Ministry of Health's National Medical Research Council Transition Award (NMRC/TA/0052/2016). Work in ADJ's and the Kappei laboratory is also funded by the Cancer Science Institute of Singapore, National University of Singapore, through the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centers of Excellence initiative. Part of this work was funded through a collaborative grant between ADJ and DSPT from the Singapore Ministry of Health's National Medical Research Council (NMRC/CIRG/1400/2014).	ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Ashizawa M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43293-5; Ayhan A, 2012, INT J GYNECOL CANCER, V22, P1310, DOI 10.1097/IGC.0b013e31826b5dcc; Bertolin G, 2018, ELIFE, V7, DOI 10.7554/eLife.38111; Bitler BG, 2015, NAT MED, V21, P231, DOI 10.1038/nm.3799; Bruinsma W, 2012, TRENDS BIOCHEM SCI, V37, P534, DOI 10.1016/j.tibs.2012.09.005; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Croucher PJP, 2020, CANCER RES, V80, DOI 10.1158/1538-7445.AM2020-2019; Deribe YL, 2018, NAT MED, V24, P1047, DOI 10.1038/s41591-018-0019-5; Doench JG, 2016, NAT BIOTECHNOL, V34, P184, DOI 10.1038/nbt.3437; Dykhuizen EC, 2013, NATURE, V497, P624, DOI 10.1038/nature12146; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Elsayed I, 2019, FUTURE MED CHEM, V11, P1383, DOI 10.4155/fmc-2019-0084; Fukumoto T, 2019, CANCER RES, V79, P5482, DOI 10.1158/0008-5472.CAN-19-1302; Gorlick R, 2014, PEDIATR BLOOD CANCER, V61, P158, DOI 10.1002/pbc.24616; Gutteridge REA, 2017, CANCER LETT, V394, P13, DOI 10.1016/j.canlet.2017.02.013; Gutteridge REA, 2016, MOL CANCER THER, V15, P1427, DOI 10.1158/1535-7163.MCT-15-0897; Helming KC, 2014, CANCER CELL, V26, P309, DOI 10.1016/j.ccr.2014.07.018; Hoppe MM, 2021, EMBO MOL MED, V13, DOI 10.15252/emmm.202013366; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Joukov V, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aar4195; Kadoch C, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500447; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; Koc EC, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00183; Li ZG, 2014, MOL CELL BIOL, V34, P3642, DOI 10.1128/MCB.00814-14; Liu CR, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09813-7; Liu WC, 2011, P NATL ACAD SCI USA, V108, P12920, DOI 10.1073/pnas.1107332108; Liu XQ, 2015, TRANSL ONCOL, V8, P185, DOI 10.1016/j.tranon.2015.03.010; Liu ZX, 2017, TRANSL ONCOL, V10, P22, DOI 10.1016/j.tranon.2016.10.003; Ma XY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01647-5; Mao TL, 2013, AM J SURG PATHOL, V37, P1342, DOI 10.1097/PAS.0b013e3182889dc3; Matsumoto T, 2009, P NATL ACAD SCI USA, V106, P14542, DOI 10.1073/pnas.0904229106; Mennuni M, 2022, EMBO REP, V23, DOI 10.15252/embr.202153054; Miller RE, 2016, MOL CANCER THER, V15, P1472, DOI 10.1158/1535-7163.MCT-15-0554; Nickerson JA, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00049; Ogiwara H, 2019, CANCER CELL, V35, P177, DOI 10.1016/j.ccell.2018.12.009; Perez-Riverol Y, 2022, NUCLEIC ACIDS RES, V50, pD543, DOI 10.1093/nar/gkab1038; Popov LD, 2020, J CELL MOL MED, V24, P4892, DOI 10.1111/jcmm.15194; Richter U, 2015, J CELL BIOL, V211, P373, DOI 10.1083/jcb.201504062; Rudolph D, 2009, CLIN CANCER RES, V15, P3094, DOI 10.1158/1078-0432.CCR-08-2445; Savas S, 2018, CRIT REV ONCOL HEMAT, V123, P114, DOI 10.1016/j.critrevonc.2018.01.009; Sharon D, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax2863; Shen JF, 2015, CANCER DISCOV, V5, P752, DOI 10.1158/2159-8290.CD-14-0849; Skrtic M, 2011, CANCER CELL, V20, P674, DOI 10.1016/j.ccr.2011.10.015; Tillberg PW, 2016, NAT BIOTECHNOL, V34, P987, DOI 10.1038/nbt.3625; Tolstorukov MY, 2013, P NATL ACAD SCI USA, V110, P10165, DOI 10.1073/pnas.1302209110; Trizzino M, 2018, CELL REP, V23, P3933, DOI 10.1016/j.celrep.2018.05.097; Valente AJ, 2017, ACTA HISTOCHEM, V119, P315, DOI 10.1016/j.acthis.2017.03.001; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; Wang K, 2011, NAT GENET, V43, P1219, DOI 10.1038/ng.982; Wardyn JD., 2021, CURR PROTOC, V1, P286; Williamson CT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13837; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Wu CJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05694-4; Wu JN, 2013, CANCER DISCOV, V3, P35, DOI 10.1158/2159-8290.CD-12-0361; Xing HL, 2014, BMC PLANT BIOL, V14, DOI 10.1186/s12870-014-0327-y; Yamamoto S, 2012, MODERN PATHOL, V25, P615, DOI 10.1038/modpathol.2011.189; Yao CH, 2019, ELIFE, V8, DOI 10.7554/eLife.41351; Yim H, 2013, ANTI-CANCER DRUG, V24, P999, DOI 10.1097/CAD.0000000000000007; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001	60	3	3	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2022	41	13					1986	2002		10.1038/s41388-022-02219-8	http://dx.doi.org/10.1038/s41388-022-02219-8		MAR 2022	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J9BT	35236967				2022-12-17	WOS:000763262700001
J	Ji, XY; Chen, XP; Zhang, BX; Xie, M; Zhang, TY; Luo, XY; Liu, DF; Feng, YY; Wang, YJ; Sun, MY; Li, CX; Huang, WJ; Xia, LM				Ji, Xiaoyu; Chen, Xiaoping; Zhang, Bixiang; Xie, Meng; Zhang, Tongyue; Luo, Xiangyuan; Liu, Danfei; Feng, Yangyang; Wang, Yijun; Sun, Mengyu; Li, Congxin; Huang, Wenjie; Xia, Limin			T-box transcription factor 19 promotes hepatocellular carcinoma metastasis through upregulating EGFR and RAC1	ONCOGENE			English	Article							PREDICTS POOR-PROGNOSIS; THERAPEUTIC TARGET; CELL-MIGRATION; CANCER; GENE; EXPRESSION; TBX3; DOWNSTREAM; INHIBITION; RESISTANCE	The effect of targeted therapy for metastatic hepatocellular carcinoma (HCC) is still unsatisfactory. Exploring the underlying mechanism of HCC metastasis is favorable to provide new therapeutic strategies. T-box (TBX) transcription factor family genes, which are crucial regulators in embryo and organ development, are vital for regulating tumor initiation, growth and metastasis. Here we explored the role of TBX19 in HCC metastasis, which is one of the most upregulated TBX family genes in human HCC tissues. TBX19 expression was markedly upregulated in HCC tissues and elevated TBX19 expression predicted poor prognosis. Overexpression of TBX19 enhanced HCC metastasis through upregulating epidermal growth factor receptor (EGFR) and Rac family small GTPase 1 (RAC1) expression. Downregulation of EGFR and RAC1 inhibited TBX19-mediated HCC metastasis, while upregulation of EGFR and RAC1 restored inhibition of HCC metastasis mediated by TBX19 knockdown. Furthermore, epidermal growth factor (EGF)/EGFR signaling upregulated TBX19 expression via the extracellular signal-regulated kinase (ERK)/nuclear factor (NF)-kB axis. Besides, the combined application of EGFR inhibitor Erlotinib and RAC1 inhibitor NSC23766 markedly inhibited TBX19-mediated HCC metastasis. In HCC cohorts, TBX19 expression was positively associated with EGFR and RAC1 expression. Patients with positive coexpression of TBX19/EGFR or TBX19/RAC1 displayed the poorest prognosis. In conclusion, EGF/EGFR signaling upregulated TBX19 expression via ERK/NF-kB pathway and TBX19 fostered HCC metastasis by enhancing EGFR and RAC1 expression, which formed an EGF-TBX19-EGFR positive feedback loop. Targeting this signaling pathway may offer a potential therapeutic strategy to efficiently restrain TBX19-mediated HCC metastasis.	[Ji, Xiaoyu; Xie, Meng; Zhang, Tongyue; Luo, Xiangyuan; Liu, Danfei; Feng, Yangyang; Wang, Yijun; Sun, Mengyu; Li, Congxin; Xia, Limin] Huazhong Univ Sci & Technol, Inst Liver & Gastrointestinal Dis, Tongji Hosp,Tongji Med Coll, Dept Gastroenterol,Hubei Key Lab HepatoPancreato, Wuhan 430030, Hubei, Peoples R China; [Chen, Xiaoping; Zhang, Bixiang; Huang, Wenjie] Huazhong Univ Sci & Technol, Hepat Surg Ctr,Hubei Key Lab HepatoPancreatobilia, Tongji Med Coll,Clin Med Res Ctr Hepat Surg Hubei, Tongji Hosp,Key Lab Organ Transplantat,Minist Edu, Wuhan 430030, Hubei, Peoples R China; [Chen, Xiaoping; Zhang, Bixiang; Huang, Wenjie] Huazhong Univ Sci & Technol, Hepat Surg Ctr,Hubei Key Lab HepatoPancreatobilia, Tongji Med Coll,Clin Med Res Ctr Hepat Surg Hubei, Tongji Hosp,Key Lab Organ Transplantat,Minist Pub, Wuhan 430030, Hubei, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Xia, LM (corresponding author), Huazhong Univ Sci & Technol, Inst Liver & Gastrointestinal Dis, Tongji Hosp,Tongji Med Coll, Dept Gastroenterol,Hubei Key Lab HepatoPancreato, Wuhan 430030, Hubei, Peoples R China.; Huang, WJ (corresponding author), Huazhong Univ Sci & Technol, Hepat Surg Ctr,Hubei Key Lab HepatoPancreatobilia, Tongji Med Coll,Clin Med Res Ctr Hepat Surg Hubei, Tongji Hosp,Key Lab Organ Transplantat,Minist Edu, Wuhan 430030, Hubei, Peoples R China.; Huang, WJ (corresponding author), Huazhong Univ Sci & Technol, Hepat Surg Ctr,Hubei Key Lab HepatoPancreatobilia, Tongji Med Coll,Clin Med Res Ctr Hepat Surg Hubei, Tongji Hosp,Key Lab Organ Transplantat,Minist Pub, Wuhan 430030, Hubei, Peoples R China.	huangwenjie@tjh.tjmu.edu.cn; xialimin@tjh.tjmu.edu.cn	Wang, Yijun/GXW-1763-2022	Danfei, Liu/0000-0002-2298-5520; Zhang, Bixiang/0000-0002-1609-7260; Huang, Wenjie/0000-0003-3182-8516	National Natural Science Foundation of China [81871911, 81972237, 81772623]; National Key Research and Development Program of China [2018YFC1312103]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China	Research was supported by grants from the National Natural Science Foundation of China No. 81871911 (WH), No. 81972237 (LX), No. 81772623 (LX), and National Key Research and Development Program of China 2018YFC1312103 (LX).	Abrahams A, 2010, IUBMB LIFE, V62, P92, DOI 10.1002/iub.275; Ando J, 2017, FUKUSHIMA J MED SCI, V63, P141, DOI 10.5387/fms.2017-08; Bayo J, 2021, GUT, V70, P1362, DOI 10.1136/gutjnl-2020-321454; Bid HK, 2013, MOL CANCER THER, V12, P1925, DOI 10.1158/1535-7163.MCT-13-0164; Buckley AF, 2008, AM J CLIN PATHOL, V129, P245, DOI 10.1309/WF10QAAED3PP93BH; Cannon AC, 2020, TRENDS CANCER, V6, P478, DOI 10.1016/j.trecan.2020.02.021; Cao XB, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-42; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chang FY, 2016, ONCOL LETT, V12, P4305, DOI 10.3892/ol.2016.5296; Chen J, 2020, HEPATOLOGY, V71, P1712, DOI 10.1002/hep.30951; Chong CR, 2013, NAT MED, V19, P1389, DOI 10.1038/nm.3388; Conlon FL, 2002, GENOME BIOL, V3; Cui J, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.616173; Dong L, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0025-6; Dong XB, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.590898; Feng XG, 2018, ONCOL RES, V26, P959, DOI 10.3727/096504017X15145624664031; Finn RS, 2021, HEPATOLOGY, V73, P150, DOI 10.1002/hep.31306; Furuse J, 2008, CRIT REV ONCOL HEMAT, V67, P8, DOI 10.1016/j.critrevonc.2008.02.009; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Gastonguay AJ, 2012, CANCER BIOL THER, V13, P647, DOI 10.4161/cbt.20082; Gordan JD, 2020, J CLIN ONCOL, V38, P4317, DOI 10.1200/JCO.20.02672; Gudino V, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22531-3; He Q, 2021, HEPATOLOGY, V74, P3174, DOI 10.1002/hep.32062; He Q, 2020, ONCOGENE, V39, P7279, DOI 10.1038/s41388-020-01500-y; Hu WW, 2021, HEPATOLOGY, V73, P674, DOI 10.1002/hep.31293; Huang PX, 2014, J CELL MOL MED, V18, P218, DOI 10.1111/jcmm.12153; Kaneto N, 2014, CANCER SCI, V105, P788, DOI 10.1111/cas.12425; Kang L, 2020, AM J TRANSL RES, V12, P7870; Karachaliou N, 2019, EXPERT REV RESP MED, V13, P1019, DOI 10.1080/17476348.2019.1656068; Koinis F, 2020, CANCERS, V12, DOI 10.3390/cancers12010244; Komposch K, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010030; Lamolet B, 2001, CELL, V104, P849, DOI 10.1016/S0092-8674(01)00282-3; Li DX, 2020, THERANOSTICS, V10, P3749, DOI 10.7150/thno.42596; Liang BY, 2021, J HEPATOL, V75, P120, DOI 10.1016/j.jhep.2021.01.044; Liang JX, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.674426; Liu JX, 2001, P NATL ACAD SCI USA, V98, P8674, DOI 10.1073/pnas.141234898; Liu SJ, 2008, HEPATOLOGY, V47, P1964, DOI 10.1002/hep.22240; Liu XY, 2019, EXP THER MED, V17, P723, DOI 10.3892/etm.2018.7028; Liu ZY, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1412-8; Liu ZC, 2018, J CELL BIOCHEM, V119, P4170, DOI 10.1002/jcb.26625; London M, 2020, CELL BIOL INT, V44, P1267, DOI 10.1002/cbin.11340; Lowery FJ, 2012, CANCER METAST REV, V31, P479, DOI 10.1007/s10555-012-9380-x; Papaioannou VE, 2014, DEVELOPMENT, V141, P3819, DOI 10.1242/dev.104471; Renard CA, 2007, CANCER RES, V67, P901, DOI 10.1158/0008-5472.CAN-06-2344; Roselli M, 2012, CLIN CANCER RES, V18, P3868, DOI 10.1158/1078-0432.CCR-11-3211; Sigismund S, 2018, MOL ONCOL, V12, P3, DOI 10.1002/1878-0261.12155; Tang ML, 2021, CANCER RES, V81, P3835, DOI 10.1158/0008-5472.CAN-21-0436; Thomas MB, 2007, CANCER-AM CANCER SOC, V110, P1059, DOI 10.1002/cncr.22886; Wang N, 2019, THYROID, V29, P378, DOI 10.1089/thy.2018.0312; Wansleben S, 2014, BBA-REV CANCER, V1846, P380, DOI 10.1016/j.bbcan.2014.08.004; Xu MJ, 2017, CANCER METAST REV, V36, P463, DOI 10.1007/s10555-017-9687-8; Yoneda N, 2011, LAB INVEST, V91, P262, DOI 10.1038/labinvest.2010.161; Yu J, 2010, ONCOGENE, V29, P6464, DOI 10.1038/onc.2010.370; Zhang J, 2016, SAUDI MED J, V37, P1184, DOI 10.15537/smj.2016.11.16267; Zhangyuan GY, 2020, ONCOGENE, V39, P1213, DOI 10.1038/s41388-019-1052-7; Zhao ST, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0820-6; Zhou K, 2018, LAB INVEST, V98, P989, DOI 10.1038/s41374-018-0071-2; Zhou QQ, 2020, ONCOGENE, V39, P2140, DOI 10.1038/s41388-019-1131-9; Zhu G, 2015, ONCOGENE, V34, P5971, DOI 10.1038/onc.2015.45; Zhu YJ, 2017, ACTA PHARMACOL SIN, V38, P614, DOI 10.1038/aps.2017.5; Zong MJ, 2011, INT J MOL SCI, V12, P4953, DOI 10.3390/ijms12084953	61	3	3	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2022	41	15					2225	2238		10.1038/s41388-022-02249-2	http://dx.doi.org/10.1038/s41388-022-02249-2		FEB 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J8DX	35217793				2022-12-17	WOS:000761868000001
J	Rammohan, M; Harris, E; Bhansali, RS; Zhao, E; Li, LS; Crispino, JD				Rammohan, Malini; Harris, Ethan; Bhansali, Rahul S.; Zhao, Emily; Li, Loretta S.; Crispino, John D.			The chromosome 21 kinase DYRK1A: emerging roles in cancer biology and potential as a therapeutic target	ONCOGENE			English	Review							TAU EXON 10; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; DOWN-SYNDROME; INCREASED DOSAGE; ONCOGENIC TRANSFORMATION; TRANSCRIPTION FACTORS; MARINE-INVERTEBRATES; SELECTIVE INHIBITOR; COGNITIVE DEFICITS	Dual-specificity tyrosine phosphorylation-regulated kinase 1 A (DYRK1A) is a serine/threonine kinase that belongs to the DYRK family of proteins, a subgroup of the evolutionarily conserved CMGC protein kinase superfamily. Due to its localization on chromosome 21, the biological significance of DYRK1A was initially characterized in the pathogenesis of Down syndrome (DS) and related neurodegenerative diseases. However, increasing evidence has demonstrated a prominent role in cancer through its ability to regulate biologic processes including cell cycle progression, DNA damage repair, transcription, ubiquitination, tyrosine kinase activity, and cancer stem cell maintenance. DYRK1A has been identified as both an oncogene and tumor suppressor in different models, underscoring the importance of cellular context in its function. Here, we review mechanistic contributions of DYRK1A to cancer biology and its role as a potential therapeutic target.	[Rammohan, Malini] Northwestern Univ, Driskill Grad Program Life Sci, Chicago, IL 60611 USA; [Harris, Ethan] Univ Illinois, Coll Med, Chicago, IL USA; [Harris, Ethan; Crispino, John D.] St Jude Childrens Res Hosp, Dept Hematol, Div Expt Hematol, 332 N Lauderdale St, Memphis, TN 38105 USA; [Bhansali, Rahul S.] Hosp Univ Penn, Div Hematol Oncol, Dept Med, 3400 Spruce St, Philadelphia, PA 19104 USA; [Zhao, Emily] Northwestern Univ, Weinberg Coll Arts & Sci, Chicago, IL 60611 USA; [Li, Loretta S.] Ann & Robert H Lurie Childrens Hosp Chicago, Stanley Manne Childrens Res Inst, Mol & Translat Canc Biol Program, Chicago, IL 60611 USA; [Li, Loretta S.] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol & Stem Cell Transplantat, Dept Pediat, Chicago, IL 60611 USA	Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; St Jude Children's Research Hospital; University of Pennsylvania; Pennsylvania Medicine; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine	Crispino, JD (corresponding author), St Jude Childrens Res Hosp, Dept Hematol, Div Expt Hematol, 332 N Lauderdale St, Memphis, TN 38105 USA.	john.crispino@stjude.org		Harris, Ethan/0000-0002-8735-1959; Bhansali, Rahul/0000-0002-3616-7393	NIH [R35 CA253096]; St. Jude/ALSAC; American Society of Hematology's Medical Student PhysicianScientist Award	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); St. Jude/ALSAC; American Society of Hematology's Medical Student PhysicianScientist Award	This review was supported in part by the NIH (R35 CA253096). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Additional support was provided St. Jude/ALSAC. EH is supported by the American Society of Hematology's Medical Student PhysicianScientist Award.	Almatroodi SA, 2020, MOLECULES, V25, DOI 10.3390/molecules25143146; Altafaj X, 2001, HUM MOL GENET, V10, P1915, DOI 10.1093/hmg/10.18.1915; Alvarez M, 2003, J CELL SCI, V116, P3099, DOI 10.1242/jcs.00618; An LW, 2018, P NATL ACAD SCI USA, V115, pEB286, DOI 10.1073/pnas.1804823115; Arron JR, 2006, NATURE, V441, P595, DOI 10.1038/nature04678; Aznar S, 2001, MOL BIOL CELL, V12, P3282, DOI 10.1091/mbc.12.10.3282; Baek KH, 2009, NATURE, V459, P1126, DOI 10.1038/nature08062; Balint B, 2017, CHEMMEDCHEM, V12, P932, DOI 10.1002/cmdc.201600539; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Becker W, 1999, PROG NUCLEIC ACID RE, V62, P1; Becker W, 2018, FEBS J, V285, P1203, DOI 10.1111/febs.14347; Bhansali RS, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI135937; Borad MJ, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.3_suppl.312; Buontempo F, 2014, LEUKEMIA, V28, P543, DOI 10.1038/leu.2013.349; Canzonetta C, 2008, AM J HUM GENET, V83, P388, DOI 10.1016/j.ajhg.2008.08.012; Chan KS, 2008, ONCOGENE, V27, P1087, DOI 10.1038/sj.onc.1210726; Chen B, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22084011; Chen JY, 2013, MOL CELL, V52, P87, DOI 10.1016/j.molcel.2013.09.009; Cho HJ, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.037044; Coombs TC, 2013, BIOORG MED CHEM LETT, V23, P3654, DOI 10.1016/j.bmcl.2013.02.096; Couly F, 2018, MOLECULES, V23, DOI 10.3390/molecules23092181; Coutadeur S, 2015, J NEUROCHEM, V133, P440, DOI 10.1111/jnc.13018; de Graaf Katrin, 2006, BMC Biochemistry, V7, DOI 10.1186/1471-2091-7-7; Delabar Jean-Maurice, 1993, European Journal of Human Genetics, V1, P114; Deng Xiaobing, 2014, Genes Cancer, V5, P337; Di Vona C, 2015, MOL CELL, V57, P506, DOI 10.1016/j.molcel.2014.12.026; Ding SH, 2012, NEUROBIOL AGING, V33, P1389, DOI 10.1016/j.neurobiolaging.2010.11.021; Djamshidian A, 2016, MOV DISORD CLIN PRAC, V3, P19, DOI 10.1002/mdc3.12242; Fan H, 2008, CHEM REV, V108, P264, DOI 10.1021/cr078199m; Feki A, 2018, BRAIN SCI, V8, DOI 10.3390/brainsci8100187; Ferron SR, 2010, CELL STEM CELL, V7, P367, DOI 10.1016/j.stem.2010.06.021; Fruit C, 2019, PHARMACEUTICALS-BASE, V12, DOI 10.3390/ph12040185; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; Galceran J, 2003, J NEURAL TRANSM-SUPP, P139; Guard SE, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42990-5; Guo XM, 2010, J BIOL CHEM, V285, P13223, DOI 10.1074/jbc.M110.102574; Henderson SH, 2021, J MED CHEM, V64, P11709, DOI 10.1021/acs.jmedchem.1c01115; Henderson SH, 2020, ACS MED CHEM LETT, V11, P1620, DOI 10.1021/acsmedchemlett.0c00279; Himpel S, 2001, BIOCHEM J, V359, P497, DOI 10.1042/0264-6021:3590497; Hurtz C, 2020, BLOOD, V136, DOI 10.1182/blood-2020-141258; Imperatore C, 2014, MOLECULES, V19, P20391, DOI 10.3390/molecules191220391; Iness AN, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00223; Jarry M, 2014, NEURO-ONCOLOGY, V16, P1484, DOI 10.1093/neuonc/nou102; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Ji JL, 2015, EUR J HUM GENET, V23, P1473, DOI 10.1038/ejhg.2015.71; Jin J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6930; Jin NN, 2015, J BIOL CHEM, V290, P15219, DOI 10.1074/jbc.M115.645507; Jiramongkol Y, 2020, CANCER METAST REV, V39, P681, DOI 10.1007/s10555-020-09883-w; Johnston PA, 2011, MOL INTERV, V11, P18, DOI 10.1124/mi.11.1.4; Kamal MM, 2012, STEM CELLS, V30, P405, DOI 10.1002/stem.1020; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Kim H, 1997, ARCH BIOCHEM BIOPHYS, V337, P137, DOI 10.1006/abbi.1996.9771; Kim HM, 2018, ANTICANCER RES, V38, P6171, DOI 10.21873/anticanres.12970; Kinstrie R, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000579; Kottakis F, 2011, MOL CELL, V43, P285, DOI 10.1016/j.molcel.2011.06.020; Kumar Nagi B, 2018, Oncotarget, V9, P37798, DOI 10.18632/oncotarget.26519; Kurabayashi N, 2015, EMBO REP, V16, P1548, DOI 10.15252/embr.201540374; Lamoral-Theys D, 2010, CURR MED CHEM, V17, P812, DOI 10.2174/092986710790712183; Lee SB, 2016, NATURE, V529, P172, DOI 10.1038/nature16475; Leontovich AA, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-1020-0; Lepagnol-Bestel AM, 2009, HUM MOL GENET, V18, P1405, DOI 10.1093/hmg/ddp047; Li D, 2010, J BIOL CHEM, V285, P35374, DOI 10.1074/jbc.M110.148445; Li MT, 2001, J NEUROSCI, V21, P6544, DOI 10.1523/JNEUROSCI.21-17-06544.2001; Li YC, 2021, BLOOD, V138, P2360, DOI 10.1182/blood.2021011247; Li YL, 2019, J CELL MOL MED, V23, P7427, DOI 10.1111/jcmm.14609; Li YL, 2020, CANCER BIOL MED, V17, P387, DOI 10.20892/j.issn.2095-3941.2019.0380; Litovchick L, 2011, GENE DEV, V25, P801, DOI 10.1101/gad.2034211; Liu N, 2014, P NATL ACAD SCI USA, V111, P4109, DOI 10.1073/pnas.1401732111; Liu Q, 2016, J BIOL CHEM, V291, P26399, DOI 10.1074/jbc.M116.717553; Liu Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097974; Lu HS, 2018, NATURE, V558, P318, DOI 10.1038/s41586-018-0174-3; Lu M, 2011, J BIOL CHEM, V286, P10755, DOI 10.1074/jbc.M110.174540; Luna J, 2019, GUT, V68, P1465, DOI 10.1136/gutjnl-2018-316128; MacDonald J, 2017, MOL CANCER RES, V15, P371, DOI 10.1158/1541-7786.MCR-16-0323-T; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; Malinge S, 2012, J CLIN INVEST, V122, P948, DOI 10.1172/JCI60455; Martin CE, 2021, EXP CELL RES, V405, DOI 10.1016/j.yexcr.2021.112656; Martins LR, 2014, LEUKEMIA, V28, P179, DOI 10.1038/leu.2013.232; Menon VR, 2019, CELL CYCLE, V18, P531, DOI 10.1080/15384101.2019.1577525; Miyata Y, 2011, BBA-MOL CELL RES, V1813, P1728, DOI 10.1016/j.bbamcr.2011.06.023; Naert G, 2015, EUR NEUROPSYCHOPHARM, V25, P2170, DOI 10.1016/j.euroneuro.2015.03.018; Navas C, 2012, CANCER CELL, V22, P318, DOI 10.1016/j.ccr.2012.08.001; Negrini S, 2013, TRENDS CELL BIOL, V23, P289, DOI 10.1016/j.tcb.2013.01.006; Okada Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20234-2; Papadopoulos C, 2011, J BIOL CHEM, V286, P5494, DOI 10.1074/jbc.M110.157909; Park J, 2010, J BIOL CHEM, V285, P31895, DOI 10.1074/jbc.M110.147520; Park NS, 2018, J CELL MOL MED, V22, P5833, DOI 10.1111/jcmm.13854; Pozo N, 2013, J CLIN INVEST, V123, P2475, DOI 10.1172/JCI63623; Prins RC, 2013, LEUKEMIA, V27, P2094, DOI 10.1038/leu.2013.228; Qian W, 2011, NUCLEIC ACIDS RES, V39, P6161, DOI 10.1093/nar/gkr195; Quang CT, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.14; Quesada AR, 1996, BRIT J CANCER, V74, P677, DOI 10.1038/bjc.1996.421; Radhakrishnan A, 2016, SCI REP-UK, V6, DOI 10.1038/srep36132; Recasens A, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00456-6; Roewenstrunk J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42445-x; Rossignol E, 2008, ANTI-CANCER DRUG, V19, P789, DOI 10.1097/CAD.0b013e32830ce4d8; Rozen EJ, 2018, CELL REP, V23, P1867, DOI 10.1016/j.celrep.2018.04.008; Ruben K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132453; Sakaguchi M, 2012, J INVEST DERMATOL, V132, P1877, DOI 10.1038/jid.2012.45; Senft D, 2018, NAT REV CANCER, V18, P69, DOI 10.1038/nrc.2017.105; Shi JH, 2008, J BIOL CHEM, V283, P28660, DOI 10.1074/jbc.M802645200; Shin CM, 2018, CLIN NUTR, V37, P452, DOI 10.1016/j.clnu.2017.01.014; Siddiqui-Jain A, 2010, CANCER RES, V70, P10288, DOI 10.1158/0008-5472.CAN-10-1893; Siveen KS, 2014, BBA-REV CANCER, V1845, P136, DOI 10.1016/j.bbcan.2013.12.005; Song WJ, 1996, GENOMICS, V38, P331, DOI 10.1006/geno.1996.0636; Soppa U, 2014, CELL CYCLE, V13, P2084, DOI 10.4161/cc.29104; Soundararajan M, 2013, STRUCTURE, V21, P986, DOI 10.1016/j.str.2013.03.012; Taira N, 2010, J BIOL CHEM, V285, P4909, DOI 10.1074/jbc.M109.042341; Tazarki H, 2019, EUR J MED CHEM, V166, P304, DOI 10.1016/j.ejmech.2019.01.052; TEJEDOR F, 1995, NEURON, V14, P287, DOI 10.1016/0896-6273(95)90286-4; Thompson BJ, 2015, J EXP MED, V212, P723, DOI 10.1084/jem.20150002; Tubi LQ, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-78; Walmsley DL, 2021, J MED CHEM, V64, P8971, DOI 10.1021/acs.jmedchem.1c00024; Wang E., 2021, BLOOD, V138, P507; Wang PF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12893-4; Wang P, 2021, J CELL MOL MED, V25, P6082, DOI 10.1111/jcmm.16505; Weber C, 2021, J MED CHEM, V64, P6745, DOI 10.1021/acs.jmedchem.1c00023; Wegiel J, 2011, J NEUROPATH EXP NEUR, V70, P36, DOI 10.1097/NEN.0b013e318202bfa1; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Westbrook TF, 2008, NATURE, V452, P370, DOI 10.1038/nature06780; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Wu P, 2016, ONCOTARGET, V7, P19863, DOI 10.18632/oncotarget.7887; Wurzlbauer A, 2020, MOLECULES, V25, DOI 10.3390/molecules25245962; Xu XY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1253-y; Yin WH, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-15; Yin XM, 2012, J BIOL CHEM, V287, P30497, DOI 10.1074/jbc.M112.355412; Yoon HR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186826; Yousefelahiyeh M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207779; Yu D, 2019, NUCLEIC ACIDS RES, V47, P4462, DOI 10.1093/nar/gkz162; Zhang L, 2020, ARCH PHARM RES, V43, P1259, DOI 10.1007/s12272-020-01283-6; Zhang P., 2021, CELL DEATH DIS, V12; Zhang YJ, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00486-7; Zhao C, 2020, CHEM-BIOL INTERACT, V316, DOI 10.1016/j.cbi.2019.108913; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	134	3	3	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2022	41	14					2003	2011		10.1038/s41388-022-02245-6	http://dx.doi.org/10.1038/s41388-022-02245-6		FEB 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0F2FY	35220406	Green Accepted			2022-12-17	WOS:000761854700001
J	Wu, SQ; Guo, BB; Zhang, LY; Zhu, X; Zhao, PP; Deng, JQ; Zheng, J; Li, F; Wang, YR; Zhang, SH; Zhang, Z; Lu, JC; Zhou, YF				Wu, Siqi; Guo, Binbin; Zhang, Liyuan; Zhu, Xun; Zhao, Peipei; Deng, Jieqiong; Zheng, Jian; Li, Fang; Wang, Yirong; Zhang, Shenghua; Zhang, Zheng; Lu, Jiachun; Zhou, Yifeng			A micropeptide XBP1SBM encoded by lncRNA promotes angiogenesis and metastasis of TNBC via XBP1s pathway	ONCOGENE			English	Article							NEGATIVE BREAST-CANCER; PROTEIN; METABOLISM; EXPRESSION	Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) with a poor prognosis. To date, the mechanism of TNBC's aggressive phenotype is still unclear. Based on metabolome analysis, we found that glutamine (Gln) metabolism plays a key role in the difference between TNBC and non-TNBC. We identified a 21-amino-acid survival-associated micropeptide XBP1SBM, encoded by the lncRNA MLLT4-AS1, which was upregulated in TNBC tissues and Gln-deprived TNBC cell lines. We showed that XBP1SBM expression was upregulated by Gln-deprivation-induced XBP1s transcriptional promotion, and in turn retained XBP1s in the nuclear to enhance the expression of VEGF. Using human endothelial cells, mouse xenograft models and mouse spontaneous BC models, we found that XBP1SBM improved Gln levels and promoted angiogenesis and metastasis in TNBC. Our study showed that a TNBC-specific nutrient deficiency adaption results in aggressive TNBC, and this mechanism provides a novel potential prognostic biomarker and therapeutic target in TNBC.	[Wu, Siqi; Guo, Binbin; Deng, Jieqiong; Li, Fang; Wang, Yirong; Zhang, Shenghua; Zhang, Zheng; Zhou, Yifeng] Soochow Univ, Dept Genet, Med Coll, Suzhou 215123, Peoples R China; [Zhang, Liyuan; Zhao, Peipei] Soochow Univ, Dept Radiotherapy & Oncol, Affiliated Hosp 2, San Xiang Rd 1055, Suzhou 215004, Peoples R China; [Zhu, Xun] Soochow Univ, Dept Gen Surg, Affiliated Hosp 2, San Xiang Rd 1055, Suzhou 215004, Peoples R China; [Zheng, Jian; Zhou, Yifeng] Sun Yat Sen Univ Canc Ctr, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China; [Zheng, Jian; Zhou, Yifeng] Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Peoples R China; [Lu, Jiachun] Guangzhou Med Univ, Affiliated Hosp 1, Sch Publ Hlth, Inst Chem Carcinogenesis, Guangzhou 510182, Peoples R China	Soochow University - China; Soochow University - China; Soochow University - China; State Key Lab Oncology South China; Sun Yat Sen University; Guangzhou Medical University	Zhou, YF (corresponding author), Soochow Univ, Dept Genet, Med Coll, Suzhou 215123, Peoples R China.; Zhou, YF (corresponding author), Sun Yat Sen Univ Canc Ctr, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China.; Zhou, YF (corresponding author), Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Peoples R China.	zhouyifeng@suda.edu.cn	zhang, zheng/HCH-9684-2022; Wu, Siqi/GVT-6711-2022	Wu, Siqi/0000-0002-5051-2923; Zheng, Jian/0000-0001-9831-7038	National Scientific Foundation of China [82103263, 81772544, 81972649]; National Science Fund for Distinguished Young Scholars [82125027]; Program for Guangdong Introducing Innovative and Entrepreneurial Teams [2017ZT07S096]	National Scientific Foundation of China(National Natural Science Foundation of China (NSFC)); National Science Fund for Distinguished Young Scholars(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); Program for Guangdong Introducing Innovative and Entrepreneurial Teams	This work was supported by The National Scientific Foundation of China grants 82103263, 81772544 and 81972649; The National Science Fund for Distinguished Young Scholars 82125027; Program for Guangdong Introducing Innovative and Entrepreneurial Teams (2017ZT07S096).	Anderson DM, 2015, CELL, V160, P595, DOI 10.1016/j.cell.2015.01.009; Bielenberg DR, 2015, CANCER J, V21, P267, DOI 10.1097/PPO.0000000000000138; Brown M, 2008, CANCER-AM CANCER SOC, V112, P737, DOI 10.1002/cncr.23243; Budczies J, 2015, INT J CANCER, V136, P1619, DOI 10.1002/ijc.29152; Carey L, 2010, NAT REV CLIN ONCOL, V7, P683, DOI 10.1038/nrclinonc.2010.154; Cech TR, 2014, CELL, V157, P77, DOI 10.1016/j.cell.2014.03.008; Chasse H, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkw907; Chen X, 2014, NATURE, V508, P103, DOI 10.1038/nature13119; Choi SW, 2019, BRIEF BIOINFORM, V20, P1853, DOI 10.1093/bib/bby055; Davies MPA, 2008, INT J CANCER, V123, P85, DOI 10.1002/ijc.23479; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Guo BB, 2020, EMBO J, V39, DOI 10.15252/embj.2019102190; Guttman M, 2013, CELL, V154, P240, DOI 10.1016/j.cell.2013.06.009; Hetz C, 2011, PHYSIOL REV, V91, P1219, DOI 10.1152/physrev.00001.2011; Hu R, 2015, MOL CELL BIOL, V35, P379, DOI 10.1128/MCB.00847-14; Huang JZ, 2017, MOL CELL, V68, P171, DOI 10.1016/j.molcel.2017.09.015; Jiang YZ, 2019, CANCER CELL, V35, P428, DOI 10.1016/j.ccell.2019.02.001; Karaayvaz M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06052-0; Kaser A, 2010, CELL RES, V20, P506, DOI 10.1038/cr.2010.61; Kim RS, 2016, SCI REP-UK, V6, DOI 10.1038/srep39342; Kung HN, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002229; Li F, 2019, INT J CANCER, V145, P927, DOI 10.1002/ijc.32166; Li HY, 2015, CELL SIGNAL, V27, P82, DOI 10.1016/j.cellsig.2014.09.018; Li W, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0949-7; Li W, 2017, J BIOL CHEM, V292, P5801, DOI 10.1074/jbc.M116.758508; Li W, 2014, GASTROENTEROLOGY, V146, P1714, DOI 10.1053/j.gastro.2014.03.002; Liu L, 2019, NAT CELL BIOL, V21, P328, DOI 10.1038/s41556-019-0285-6; Loayza-Puch F, 2016, NATURE, V530, P490, DOI 10.1038/nature16982; Martinez-Outschoorn UE, 2017, NAT REV CLIN ONCOL, V14, P11, DOI 10.1038/nrclinonc.2016.60; Mayers JR, 2015, TRENDS BIOCHEM SCI, V40, P130, DOI 10.1016/j.tibs.2015.01.004; Mohammed RAA, 2011, MODERN PATHOL, V24, P774, DOI 10.1038/modpathol.2011.4; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Shanware NP, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5900; Tajan M, 2018, CELL METAB, V28, P721, DOI 10.1016/j.cmet.2018.07.005; Tian J, 2018, BRIT J CANCER, V119, P1495, DOI 10.1038/s41416-018-0287-3; Timmerman LA, 2013, CANCER CELL, V24, P450, DOI 10.1016/j.ccr.2013.08.020; Wang YR, 2020, J EXP MED, V217, DOI 10.1084/jem.20190950; Wang YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08033-9; White E, 2013, GENE DEV, V27, P2065, DOI 10.1101/gad.228122.113; Wu H, 2015, ONCOGENE, V34, P4723, DOI 10.1038/onc.2014.400; Yoshida H, 2006, J CELL BIOL, V172, P565, DOI 10.1083/jcb.200508145; Zhang J, 2017, EMBO J, V36, P1302, DOI 10.15252/embj.201696151	42	3	3	10	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2022	41	15					2163	2172		10.1038/s41388-022-02229-6	http://dx.doi.org/10.1038/s41388-022-02229-6		FEB 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J8DX	35197570				2022-12-17	WOS:000760099800001
J	Baker, SC; Mason, AS; Slip, RG; Skinner, KT; Macdonald, A; Masood, O; Harris, RS; Fenton, TR; Periyasamy, M; Ali, S; Southgate, J				Baker, Simon C.; Mason, Andrew S.; Slip, Raphael G.; Skinner, Katie T.; Macdonald, Andrew; Masood, Omar; Harris, Reuben S.; Fenton, Tim R.; Periyasamy, Manikandan; Ali, Simak; Southgate, Jennifer			Induction of APOBEC3-mediated genomic damage in urothelium implicates BK polyomavirus (BKPyV) as a hit-and-run driver for bladder cancer	ONCOGENE			English	Article							TRANSPLANT RECIPIENTS; MUTATIONAL SIGNATURES; DEAMINASE APOBEC3B; GENE-EXPRESSION; JC VIRUS; RISK; PROLIFERATION; INFECTION; CELLS; REPLICATION	Limited understanding of bladder cancer aetiopathology hampers progress in reducing incidence. Mutational signatures show the anti-viral apolipoprotein B mRNA editing enzyme catalytic polypeptide (APOBEC) enzymes are responsible for the preponderance of mutations in bladder tumour genomes, but no causative viral agent has been identified. BK polyomavirus (BKPyV) is a common childhood infection that remains latent in the adult kidney, where reactivation leads to viruria. This study provides missing mechanistic evidence linking reactivated BKPyV-infection to bladder cancer risk. We used a mitotically-quiescent, functionally-differentiated model of normal human urothelium to examine BKPyV-infection. BKPyV-infection led to significantly elevated APOBEC3A and APOBEC3B protein, increased deaminase activity and greater numbers of apurinic/apyrimidinic sites in the host urothelial genome. BKPyV Large T antigen (LT-Ag) stimulated re-entry from G0 into the cell cycle through inhibition of retinoblastoma protein and activation of EZH2, E2F1 and FOXM1, with cells arresting in G2. The single-stranded DNA displacement loops formed in urothelial cells during BKPyV-infection interacted with LT-Ag to provide a substrate for APOBEC3-activity. Addition of interferon gamma (IFN gamma) to infected urothelium suppressed expression of the viral genome. These results support reactivated BKPyV infections in adults as a risk factor for bladder cancer in immune-insufficient populations.	[Baker, Simon C.; Mason, Andrew S.; Slip, Raphael G.; Skinner, Katie T.; Southgate, Jennifer] Univ York, Dept Biol, Jack Birch Unit Mol Carcinogenesis, York YO10 5DD, N Yorkshire, England; [Baker, Simon C.; Mason, Andrew S.; Slip, Raphael G.; Skinner, Katie T.; Southgate, Jennifer] Univ York, York Biomed Res Inst, York YO10 5DD, N Yorkshire, England; [Macdonald, Andrew] Univ Leeds, Fac Biol Sci, Sch Mol & Cellular Pathol, Leeds, W Yorkshire, England; [Masood, Omar] St James Univ Hosp, Leeds Kidney Unit, Leeds, W Yorkshire, England; [Harris, Reuben S.] Univ Minnesota, Coll Biol Sci, Minneapolis, MN 55455 USA; [Fenton, Tim R.] Univ Kent, Sch Biosci, Canterbury CT2 7NJ, Kent, England; [Periyasamy, Manikandan; Ali, Simak] Imperial Coll London, Fac Med, Dept Surg & Canc, London, England; [Fenton, Tim R.] Univ Southampton, Fac Med, Sch Canc Sci, Canc Res UK Ctr, Southampton SO16 6YD, Hants, England; [Periyasamy, Manikandan] Inst Mol & Cell Biol IMCB, Dis Intervent Technol Lab DITL, Neuros Immunos, 8A Biomedical Grove,Neuros Immunos 06-04-05, Singapore 060405, Singapore	University of York - UK; University of York - UK; University of Leeds; Saint James's University Hospital; University of Minnesota System; University of Minnesota Twin Cities; University of Kent; Imperial College London; Cancer Research UK; University of Southampton; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Baker, SC (corresponding author), Univ York, Dept Biol, Jack Birch Unit Mol Carcinogenesis, York YO10 5DD, N Yorkshire, England.; Baker, SC (corresponding author), Univ York, York Biomed Res Inst, York YO10 5DD, N Yorkshire, England.	simon.baker@york.ac.uk	Southgate, Jennifer/AAJ-9089-2021; Ali, Simak/M-6912-2018	Southgate, Jennifer/0000-0002-0135-480X; Fenton, Tim/0000-0002-4737-8233; Ali, Simak/0000-0002-1320-0816; Baker, Simon/0000-0002-2755-6012; Slip, Raphael Grettir/0000-0002-5218-2251; Harris, Reuben/0000-0002-9034-9112; Macdonald, Andrew/0000-0002-5978-4693	York Against Cancer	York Against Cancer	This study was funded by York Against Cancer.	Abend JR, 2007, J VIROL, V81, P272, DOI 10.1128/JVI.01571-06; Alexandrov LB, 2020, NATURE, V578, P94, DOI 10.1038/s41586-020-1943-3; Baker SC, 2020, EUR UROL, V78, P143, DOI 10.1016/j.eururo.2020.03.049; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Bray NL, 2016, NAT BIOTECHNOL, V34, P888, DOI 10.1038/nbt0816-888d; Caller LG, 2019, J VIROL, V93, DOI 10.1128/JVI.00595-19; Chen X, 2013, MOL CELL BIOL, V33, P227, DOI 10.1128/MCB.00881-12; CHESTERS PM, 1983, J INFECT DIS, V147, P676, DOI 10.1093/infdis/147.4.676; Cortez LM, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008545; Cross WR, 2005, AM J PHYSIOL-RENAL, V289, pF459, DOI 10.1152/ajprenal.00040.2005; CROW J F, 1970, P591, DOI 10.1093/bioinformatics/btr330; Engels EA, 2011, JAMA-J AM MED ASSOC, V306, P1891, DOI 10.1001/jama.2011.1592; Erickson KD, 2019, VIROLOGY, V528, P198, DOI 10.1016/j.virol.2018.12.014; Fischer M, 2017, ONCOGENE, V36, P3943, DOI 10.1038/onc.2016.502; Fulciniti M, 2018, CELL REP, V25, P3693, DOI 10.1016/j.celrep.2018.12.016; Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2; Gupta G, 2018, AM J TRANSPLANT, V18, P245, DOI 10.1111/ajt.14530; Jalili P, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16802-8; KATAJA V, 1993, AM J EPIDEMIOL, V138, P735, DOI 10.1093/oxfordjournals.aje.a116911; Kean JM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000363; Kesherwani V, 2019, VACCINE, V37, P3457, DOI 10.1016/j.vaccine.2019.04.096; Kim D, 2019, NAT BIOTECHNOL, V37, P907, DOI 10.1038/s41587-019-0201-4; Kim HY, 2001, EMBO J, V20, P295, DOI 10.1093/emboj/20.1.295; Lawson ARJ, 2020, SCIENCE, V370, P75, DOI 10.1126/science.aba8347; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Li RM, 2013, VIROLOGY, V440, P41, DOI 10.1016/j.virol.2013.01.024; Linke SP, 2003, CANCER RES, V63, P2596; Llewellyn MA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29438-y; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Middlebrooks CD, 2016, NAT GENET, V48, P1330, DOI 10.1038/ng.3670; Mohammadi MH, 2021, VIROL J, V18, DOI 10.1186/s12985-021-01582-4; Nickeleit V, 1999, J AM SOC NEPHROL, V10, P1080; Panou MM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030902; Periyasamy M, 2017, NUCLEIC ACIDS RES, V45, P11056, DOI 10.1093/nar/gkx721; Pimentel H, 2017, NAT METHODS, V14, P687, DOI 10.1038/nmeth.4324; Robertson AG, 2017, CELL, V171, P540, DOI 10.1016/j.cell.2017.09.007; Roelofs PA, 2020, ELIFE, V9, DOI 10.7554/eLife.61287; Solovjeva L, 2015, BMC MOL BIOL, V16, DOI 10.1186/s12867-015-0046-4; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; SOUTHGATE J, 1994, LAB INVEST, V71, P583; Starrett GJ, 2019, MBIO, V10, DOI 10.1128/mBio.02690-18; Thielen BK, 2010, J BIOL CHEM, V285, P27753, DOI 10.1074/jbc.M110.102822; Tokunaga R, 2018, CANCER TREAT REV, V63, P40, DOI 10.1016/j.ctrv.2017.11.007; Tylden GD, 2015, ANTIMICROB AGENTS CH, V59, P3306, DOI 10.1128/AAC.00238-15; Varley C, 2005, EXP CELL RES, V306, P216, DOI 10.1016/j.yexcr.2005.02.004; Verhalen B, 2016, J VIROL, V90, P6379, DOI 10.1128/JVI.00771-16; Weinreb DB, 2006, DIAGN CYTOPATHOL, V34, P201, DOI 10.1002/dc.20429; Xiao YF, 2014, BIOINFORMATICS, V30, P801, DOI 10.1093/bioinformatics/btr671; Yu J, 2019, CANCER MANAG RES, V11, P157, DOI 10.2147/CMAR.S185796; Zapatka M, 2020, NAT GENET, V52, P320, DOI 10.1038/s41588-019-0558-9; Zareei N, 2019, MICROB PATHOGENESIS, V129, P187, DOI 10.1016/j.micpath.2019.02.015	51	3	3	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2022	41	15					2139	2151		10.1038/s41388-022-02235-8	http://dx.doi.org/10.1038/s41388-022-02235-8		FEB 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J8DX	35194151	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000759404700002
J	Tsuboyama, N; Wang, R; Szczepanski, AP; Chen, HH; Zhao, ZB; Shi, L; Wang, L				Tsuboyama, Natsumi; Wang, Ru; Szczepanski, Aileen Patricia; Chen, Huanhuan; Zhao, Zibo; Shi, Lei; Wang, Lu			Therapeutic targeting of BAP1/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer	ONCOGENE			English	Article							BRCA1-ASSOCIATED PROTEIN-1; UVEAL MELANOMA; BAP1; MUTATIONS; ASSOCIATION; GAIN	Small cell lung cancer (SCLC) is an aggressive disease, with patients diagnosed with either early-stage, limited stage, or extensive stage of SCLC tumor progression. Discovering and targeting the functional biomarkers for SCLC will be crucial in understanding the molecular basis underlying SCLC tumorigenesis to better assist in improving clinical treatment. Emerging studies have demonstrated that dysregulations in BAP1 histone H2A deubiquitinase complex are collectively associated with pathogenesis in human SCLC. Here, we investigated the function of the oncogenic BAP1/ASXL3/BRD4 epigenetic axis in SCLC by developing a next-generation BAP1 inhibitor, iBAP-II, and focusing on the epigenetic balance established between BAP1 and non-canonical PRC1 complexes in regulating SCLC-specific transcriptional programming. We further demonstrated that pharmacologic inhibition of BAP1's catalytic activity disrupted BAP1/ASXL3/BRD4 epigenetic axis by inducing protein degradation of the ASXL3 scaffold protein, which bridges BRD4 and BAP1 at active enhancers. Furthermore, treatment of iBAP-II represses neuroendocrine lineage-specific ASCL1/MYCL/E2F signaling in SCLC cell lines, and dramatically inhibits SCLC cell viability and tumor growth in vivo. In summary, this study has provided mechanistic insight into the oncogenic function of BAP1 in SCLC and highlighted the potential of targeting BAP1's activity as a novel SCLC therapy.	[Tsuboyama, Natsumi; Szczepanski, Aileen Patricia; Zhao, Zibo; Wang, Lu] Northwestern Univ, Feinberg Sch Med, Dept Biochem & Mol Genet, Chicago, IL 60611 USA; [Tsuboyama, Natsumi; Szczepanski, Aileen Patricia; Zhao, Zibo; Wang, Lu] Northwestern Univ, Feinberg Sch Med, Simpson Querrey Ctr Epigenet, Chicago, IL 60611 USA; [Wang, Ru; Chen, Huanhuan; Shi, Lei] China Pharmaceut Univ, Dept Med Chem, Jiangsu Key Lab Drug Design & Optimizat, Nanjing 210009, Peoples R China	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; China Pharmaceutical University	Wang, L (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Biochem & Mol Genet, Chicago, IL 60611 USA.; Wang, L (corresponding author), Northwestern Univ, Feinberg Sch Med, Simpson Querrey Ctr Epigenet, Chicago, IL 60611 USA.; Shi, L (corresponding author), China Pharmaceut Univ, Dept Med Chem, Jiangsu Key Lab Drug Design & Optimizat, Nanjing 210009, Peoples R China.	shilei@cpu.edu.cn; lu.wang1@northwestern.edu	Zhao, Zibo/GWQ-3444-2022	Wang, Lu/0000-0003-0441-0747; , Aileen/0000-0002-4133-0634; Tsuboyama, Natsumi/0000-0002-8620-3479				Asada S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05085-9; Balasubramani A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8307; Baymaz HI, 2014, PROTEOMICS, V14, P2179, DOI 10.1002/pmic.201400013; Bononi A, 2017, NATURE, V546, P549, DOI 10.1038/nature22798; Borromeo MD, 2016, CELL REP, V16, P1259, DOI 10.1016/j.celrep.2016.06.081; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Campagne A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08255-x; Carbone M, 2020, CANCER DISCOV, V10, P1103, DOI 10.1158/2159-8290.CD-19-1220; Carbone M, 2020, NAT REV CANCER, V20, P533, DOI 10.1038/s41568-020-0265-y; Conway E, 2021, MOL CELL, V81, P3526, DOI 10.1016/j.molcel.2021.06.020; De I, 2019, STRUCTURE, V27, P528, DOI 10.1016/j.str.2018.11.013; Dey A, 2012, SCIENCE, V337, P1541, DOI 10.1126/science.1221711; Dobrinic P, 2021, NAT STRUCT MOL BIOL, V28, P811, DOI 10.1038/s41594-021-00661-y; Gardner EE, 2017, CANCER CELL, V31, P286, DOI 10.1016/j.ccell.2017.01.006; Gazdar AF, 2017, NAT REV CANCER, V17, P725, DOI 10.1038/nrc.2017.87; Guo Y, 2018, LEUKEMIA, V32, P1834, DOI 10.1038/s41375-018-0126-9; Harbour JW, 2010, SCIENCE, V330, P1410, DOI 10.1126/science.1194472; He M, 2019, SCIENCE, V364, P283, DOI 10.1126/science.aav4902; Jiang LY, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005895; Kalirai H, 2014, BRIT J CANCER, V111, P1373, DOI 10.1038/bjc.2014.417; Khan P, 2022, SEMIN CANCER BIOL, V83, P57, DOI 10.1016/j.semcancer.2020.11.006; Kim DW, 2016, GENE DEV, V30, P1289, DOI 10.1101/gad.279307.116; Krushkal J, 2020, CLIN EPIGENETICS, V12, DOI 10.1186/s13148-020-00876-8; Lee HS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6128; Machida YJ, 2009, J BIOL CHEM, V284, P34179, DOI 10.1074/jbc.M109.046755; Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565; Misaghi S, 2009, MOL CELL BIOL, V29, P2181, DOI 10.1128/MCB.01517-08; Novelli F, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2111946118; Okino Y, 2015, J BIOL CHEM, V290, P1580, DOI 10.1074/jbc.M114.609834; Piunti A, 2021, NAT REV MOL CELL BIO, V22, P326, DOI 10.1038/s41580-021-00341-1; Plass C, 2013, NAT REV GENET, V14, P765, DOI 10.1038/nrg3554; Qin JY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9471; Rotinen M, 2018, NAT MED, V24, P1887, DOI 10.1038/s41591-018-0241-1; Ruan HB, 2012, CELL METAB, V16, P226, DOI 10.1016/j.cmet.2012.07.006; Rudin CM, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-020-00235-0; Scheuermann JC, 2010, NATURE, V465, P243, DOI 10.1038/nature08966; Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220; Srivastava A, 2016, HUM MOL GENET, V25, P597, DOI 10.1093/hmg/ddv499; Stanton BZ, 2017, NAT GENET, V49, P282, DOI 10.1038/ng.3735; Szczepanski AP, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00760-3; Tavares L, 2012, CELL, V148, P664, DOI 10.1016/j.cell.2011.12.029; van Essen TH, 2014, BRIT J OPHTHALMOL, V98, P1738, DOI 10.1136/bjophthalmol-2014-305047; Wang L, 2021, NAT CANCER, V2, P515, DOI 10.1038/s43018-021-00199-4; Yang H, 2018, BLOOD, V131, P328, DOI 10.1182/blood-2017-06-789669; Yu L, 2018, GENE DEV, V32, P1537, DOI 10.1101/gad.318436.118; Zhao ZB, 2021, CANCER RES, V81, P4696, DOI 10.1158/0008-5472.CAN-21-1114	46	3	3	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2022	41	15					2152	2162		10.1038/s41388-022-02240-x	http://dx.doi.org/10.1038/s41388-022-02240-x		FEB 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J8DX	35194152	Green Published, hybrid			2022-12-17	WOS:000759404700003
J	Kwon, J; Choi, H; Ware, AD; Morillo, BC; Wang, HY; Bouker, KB; Lu, XB; Waldman, T; Han, C				Kwon, Juntae; Choi, Hyeongjwa; Ware, Anna D.; Morillo, Bernadette Cecilia; Wang, Haiyang; Bouker, Kerrie B.; Lu, Xiongbin; Waldman, Todd; Han, Cecil			USP13 promotes development and metastasis of high-grade serous ovarian carcinoma in a novel mouse model	ONCOGENE			English	Article							SURFACE EPITHELIUM; CANCER; AUTOPHAGY; ORIGIN; PTEN; P53; PACLITAXEL; PATHWAY; BIOLOGY; CELLS	Epithelial ovarian cancer is the most lethal gynecologic malignancy and one of the most common causes of cancer mortality among women worldwide. Ubiquitin-Specific Peptidase 13 (USP13) gene copy is strongly amplified in human epithelial ovarian cancer, and high USP13 expression is correlated with poor survival outcomes. Yet, its pathological contribution to ovarian tumorigenesis remains unknown. We crossed a conditional Usp13 overexpressing knock-in mouse with a conditional knockout of Trp53 and Pten mouse and generated a novel ovarian cancer genetically engineered mouse model (GEMM), which closely recapitulates the genetic changes driving ovarian cancer in humans. Overexpression of USP13 with deletion of Trp53 and Pten in murine ovarian surface epithelium accelerated ovarian tumorigenesis and led to decreased survival in mice. Notably, USP13 greatly enhanced peritoneal metastasis of ovarian tumors with frequent development of hemorrhagic ascites. The primary and metastatic tumors exhibited morphology and clinical behavior similar to human high-grade serous ovarian cancer. Co-inhibition of USP13 and AKT significantly decreased the viability of the primary murine ovarian cancer cells isolated from the GEMM. USP13 also increased the tumorigenic and metastatic abilities of primary murine ovarian cancer cells in a syngeneic mouse study. These findings suggest a critical role of USP13 in ovarian cancer development and reveal USP13 as a potential therapeutic target for ovarian cancer.	[Kwon, Juntae; Choi, Hyeongjwa; Ware, Anna D.; Wang, Haiyang; Waldman, Todd; Han, Cecil] Georgetown Univ, Dept Oncol, Sch Med, Washington, DC 20007 USA; [Morillo, Bernadette Cecilia; Waldman, Todd] Georgetown Univ, Biochem & Mol Biol, Sch Med, Washington, DC 20007 USA; [Bouker, Kerrie B.; Waldman, Todd; Han, Cecil] Georgetown Univ, Lombardi Comprehens Canc Ctr, Sch Med, Washington, DC 20007 USA; [Lu, Xiongbin] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA	Georgetown University; Georgetown University; Georgetown University; Indiana University System; Indiana University Bloomington	Han, C (corresponding author), Georgetown Univ, Dept Oncol, Sch Med, Washington, DC 20007 USA.; Han, C (corresponding author), Georgetown Univ, Lombardi Comprehens Canc Ctr, Sch Med, Washington, DC 20007 USA.	ch1182@georgetown.edu		Kwon, Juntae/0000-0002-5439-3239	Rivkin Center Foundation [616749]; Mary Kay Foundation [05-19]; American Cancer Society [RSG-21120-01-TBE]; National Institutes of Health [R01CA222251]	Rivkin Center Foundation; Mary Kay Foundation; American Cancer Society(American Cancer Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by grants to C.H. from the Rivkin Center Foundation (#616749), the Mary Kay Foundation (#05-19), the American Cancer Society (RSG-21120-01-TBE, Grant DOI #: doi.org/10.53354/pc.gr.151096), and to X.L. from the National Institutes of Health (R01CA222251).	Al Habyan S, 2018, ONCOGENE, V37, P5127, DOI 10.1038/s41388-018-0317-x; ANTON M, 1995, J VIROL, V69, P4600, DOI 10.1128/JVI.69.8.4600-4606.1995; Armstrong DK, 2006, NEW ENGL J MED, V354, P34, DOI 10.1056/NEJMoa052985; Auersperg N, 2008, GYNECOL ONCOL, V110, P452, DOI 10.1016/j.ygyno.2008.05.031; Auersperg N, 2013, GYNECOL ONCOL, V130, P246, DOI 10.1016/j.ygyno.2013.03.021; Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Bobbs AS, 2015, CANCER GROWTH METAST, P29, DOI 10.4137/CGM.S21221; Bowtell DD, 2015, NAT REV CANCER, V15, P668, DOI 10.1038/nrc4019; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Cho KR, 2009, ANNU REV PATHOL-MECH, V4, P287, DOI 10.1146/annurev.pathol.4.110807.092246; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; Coscia F, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12645; Dinulescu DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173; Dobbin ZC, 2013, INT J MOL SCI, V14, P8213, DOI 10.3390/ijms14048213; Flesken-Nikitin A, 2003, CANCER RES, V63, P3459; Gong C, 2013, ONCOGENE, V32, P2261, DOI 10.1038/onc.2012.252; Han C., 2016, NAT COMMUN, V7; Hanrahan AJ, 2012, CANCER DISCOV, V2, P56, DOI 10.1158/2159-8290.CD-11-0170; Hao DP, 2017, CLIN CANCER RES, V23, P7400, DOI 10.1158/1078-0432.CCR-17-0638; Karnezis AN, 2017, NAT REV CANCER, V17, P65, DOI 10.1038/nrc.2016.113; Kim J, 2018, CANCERS, V10; Kim O, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008808; Klotz DM, 2017, ARCH GYNECOL OBSTET, V296, P1055, DOI 10.1007/s00404-017-4529-z; Kobel M, 2010, INT J GYNECOL PATHOL, V29, P203, DOI 10.1097/PGP.0b013e3181c042b6; Kroeger PT, 2017, CURR OPIN OBSTET GYN, V29, P26, DOI 10.1097/GCO.0000000000000340; Labidi-Galy SI, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00962-1; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Lawrenson K, 2019, CELL REP, V29, P3726, DOI 10.1016/j.celrep.2019.10.122; Lheureux S, 2019, CA-CANCER J CLIN, V69, P280, DOI 10.3322/caac.21559; Li Y., 2017, NAT COMMUN, V8; Lisio MA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040952; Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037; Lo Riso P, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00786-7; Macintyre G, 2018, NAT GENET, V50, P1262, DOI 10.1038/s41588-018-0179-8; Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008; Mehra Karishma, 2011, Front Biosci (Elite Ed), V3, P625, DOI 10.2741/e275; Meidhof S, 2015, EMBO MOL MED, V7, P831, DOI 10.15252/emmm.201404396; Moss NM, 2009, CANCER RES, V69, P7121, DOI 10.1158/0008-5472.CAN-08-4151; Motohara T, 2019, ONCOGENE, V38, P2885, DOI 10.1038/s41388-018-0637-x; Nagy A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84787-5; Otsuka I, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094409; Patch AM, 2015, NATURE, V521, P489, DOI 10.1038/nature14410; Perets R, 2016, CANCER RES, V76, P10, DOI 10.1158/0008-5472.CAN-15-1382; Perets R, 2013, CANCER CELL, V24, P751, DOI 10.1016/j.ccr.2013.10.013; Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056; Reyes-Turcu FE, 2006, CELL, V124, P1197, DOI 10.1016/j.cell.2006.02.038; Sandercock J, 2002, BRIT J CANCER, V87, P815, DOI 10.1038/sj.bjc.6600567; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Stuckelberger S, 2018, J PATHOL, V245, P129, DOI 10.1002/path.5065; Sun H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15534; Szabova L, 2012, CANCER RES, V72, P4141, DOI 10.1158/0008-5472.CAN-11-3834; Tan DSP, 2006, LANCET ONCOL, V7, P925, DOI 10.1016/S1470-2045(06)70939-1; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; Wu R, 2016, J PATHOL, V240, P341, DOI 10.1002/path.4783; Xing DY, 2005, P NATL ACAD SCI USA, V102, P6936, DOI 10.1073/pnas.0502256102; Zhai YL, 2017, J PATHOL, V243, P16, DOI 10.1002/path.4927; Zhang JS, 2013, NAT CELL BIOL, V15, P1486, DOI 10.1038/ncb2874; Zhang L, 2016, ONCOGENE, V35, P5010, DOI 10.1038/onc.2016.53; Zhang SZ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02693-9; Zhang S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13116-2; Zhao XS, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1421	67	3	3	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2022	41	13					1974	1985		10.1038/s41388-022-02224-x	http://dx.doi.org/10.1038/s41388-022-02224-x		FEB 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J9BT	35173307	Green Published, hybrid			2022-12-17	WOS:000756457400002
J	Wu, HZ; Ding, XY; Hu, XY; Zhao, Q; Chen, QC; Sun, T; Li, YL; Guo, H; Li, M; Gao, ZM; Yao, WF; Zhao, L; Li, K; Wei, MJ				Wu, Huizhe; Ding, Xiangyu; Hu, Xiaoyun; Zhao, Qing; Chen, Qiuchen; Sun, Tong; Li, Yalun; Guo, Hao; Li, Meng; Gao, Ziming; Yao, Weifan; Zhao, Lin; Li, Kai; Wei, Minjie			LINC01021 maintains tumorigenicity by enhancing N6-methyladenosine reader IMP2 dependent stabilization of MSX1 and JARID2: implication in colorectal cancer	ONCOGENE			English	Article							RNA-BINDING PROTEINS; M(6)A MODIFICATION; MESSENGER-RNA; NONCODING RNAS; METHYLATION; CROSSTALK; ROLES	Insulin-like growth factor-2 mRNA-binding protein 2 (IGF2BP2, also known as IMP2), a novel class III N6-methyladenosine (m(6)A) reader, has recently gained attention due to its critical functions in recognizing and stabilizing m(6)A modified oncogenic transcripts. However, whether and how long non-coding RNAs (lncRNAs) facilitate IMP2's role as m(6)A "reader" remains elusive, particularly in colorectal cancer (CRC). Here, we demonstrated that oncogenic LINC021 specifically bound with the m(6)A "reader" IMP2 protein and enhanced the mRNA stability of MSX1 and JARID2 in an m(6)A regulatory manner during CRC tumorigenesis and pathogenesis. Specifically, a remarkable upregulation of LINC021 was confirmed in CRC cell lines and clinical tissues (n = 130). High level of LINC021acted as an independent prognostic predictor for CRC clinical outcomes. Functional assays demonstrated that LINC021 exerted its functions as an oncogene to aggravate CRC malignant phenotypes including enhanced cell proliferation, colony formation, migration capabilities, and reduced cell apoptosis. Mechanistically, LINC021 directly recognized IMP2 protein, the latter enhanced the mRNA stability of transcripts such as MSX1 and JARID2 by recognizing their m(6)A-modified element RGGAC. Thus, these findings uncovered an essential LINC021/IMP2/MSX1 and JARID2 signaling axis in CRC tumorigenesis, which provided profound insights into our understanding of m(6)A modification regulated by lncRNA in CRC initiation and progression and shed light on the targeting of this axis for CRC treatment.	[Wu, Huizhe; Ding, Xiangyu; Hu, Xiaoyun; Zhao, Qing; Chen, Qiuchen; Sun, Tong; Guo, Hao; Li, Meng; Yao, Weifan; Zhao, Lin; Wei, Minjie] China Med Univ, Sch Pharm, Dept Pharmacol, Shenyang 110122, Peoples R China; [Wu, Huizhe; Ding, Xiangyu; Hu, Xiaoyun; Zhao, Qing; Chen, Qiuchen; Sun, Tong; Guo, Hao; Li, Meng; Yao, Weifan; Zhao, Lin; Wei, Minjie] China Med Univ, Liaoning Key Lab Mol Targeted Antitumor Drug Dev, Shenyang 110122, Peoples R China; [Wu, Huizhe; Ding, Xiangyu; Hu, Xiaoyun; Zhao, Qing; Chen, Qiuchen; Sun, Tong; Guo, Hao; Li, Meng; Yao, Weifan; Zhao, Lin; Wei, Minjie] China Med Univ, Liaoning Canc Immune Peptide Drug Engn Technol Re, Shenyang 110122, Peoples R China; [Wu, Huizhe; Ding, Xiangyu; Hu, Xiaoyun; Zhao, Qing; Chen, Qiuchen; Sun, Tong; Guo, Hao; Li, Meng; Yao, Weifan; Zhao, Lin; Wei, Minjie] China Med Univ, Ctr Key Lab Precis Diag & Treatment Gastrointesti, Minist Educ, Shenyang 110122, Peoples R China; [Li, Yalun] China Med Univ, Affiliated Hosp 1, Dept Anorectal Surg, Shenyang 110001, Peoples R China; [Gao, Ziming; Li, Kai] China Med Univ, Affiliated Hosp 1, Dept Surg Oncol & Gen Surg, Minist Educ,Key Lab Precis Diag & Treatment Gastr, Shenyang 110001, Peoples R China; [Wei, Minjie] Liaoning Med Diag & Treatment Ctr, Shenyang, Peoples R China	China Medical University; China Medical University; China Medical University; China Medical University; China Medical University; China Medical University	Wei, MJ (corresponding author), China Med Univ, Sch Pharm, Dept Pharmacol, Shenyang 110122, Peoples R China.; Wei, MJ (corresponding author), China Med Univ, Liaoning Key Lab Mol Targeted Antitumor Drug Dev, Shenyang 110122, Peoples R China.; Wei, MJ (corresponding author), China Med Univ, Liaoning Canc Immune Peptide Drug Engn Technol Re, Shenyang 110122, Peoples R China.; Wei, MJ (corresponding author), China Med Univ, Ctr Key Lab Precis Diag & Treatment Gastrointesti, Minist Educ, Shenyang 110122, Peoples R China.; Li, K (corresponding author), China Med Univ, Affiliated Hosp 1, Dept Surg Oncol & Gen Surg, Minist Educ,Key Lab Precis Diag & Treatment Gastr, Shenyang 110001, Peoples R China.; Wei, MJ (corresponding author), Liaoning Med Diag & Treatment Ctr, Shenyang, Peoples R China.	cmu_likai@163.com; mjwei@cmu.edu.cn	Hu, Xiao/GQI-0007-2022	Hu, Xiao/0000-0003-1128-4099	National Natural Science Foundation of China [81872905, 82073884]; Science and Technology Innovative Foundation for Young and Middle-aged Scientists of Shenyang City [RC200382]; Shenyang High Level Talent Innovation and Entrepreneurship Team [2019-SYRCCY-B-01]; Major Special S&T Projects in Liaoning Province [2019JH1/10300005]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Innovative Foundation for Young and Middle-aged Scientists of Shenyang City; Shenyang High Level Talent Innovation and Entrepreneurship Team; Major Special S&T Projects in Liaoning Province	This work was supported by grants from the National Natural Science Foundation of China (81872905, 82073884), Science and Technology Innovative Foundation for Young and Middle-aged Scientists of Shenyang City (RC200382), Shenyang High Level Talent Innovation and Entrepreneurship Team (2019-SYRCCY-B-01), and Major Special S&T Projects in Liaoning Province [2019JH1/10300005].	Adhikari A, 2019, J BIOL CHEM, V294, P19451, DOI 10.1074/jbc.RA119.010060; Ban YY, 2020, MOL ONCOL, V14, P1282, DOI 10.1002/1878-0261.12676; Chatterji P, 2018, TRENDS MOL MED, V24, P490, DOI 10.1016/j.molmed.2018.03.008; Dai FS, 2020, MOL THER-NUCL ACIDS, V22, P62, DOI 10.1016/j.omtn.2020.08.004; Degrauwe N, 2016, GENE DEV, V30, P2459, DOI 10.1101/gad.287540.116; Deng XL, 2018, CELL RES, V28, P507, DOI 10.1038/s41422-018-0034-6; Ferre F, 2016, BRIEF BIOINFORM, V17, P106, DOI 10.1093/bib/bbv031; Francescangeli F, 2019, NUTRIENTS, V11, DOI 10.3390/nu11122936; He LE, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1109-9; Heppt MV, 2018, J INVEST DERMATOL, V138, P141, DOI 10.1016/j.jid.2017.05.038; Hou PF, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01857-2; Hu XG, 2020, CELL DEATH DIFFER, V27, P1782, DOI 10.1038/s41418-019-0461-z; Huang HL, 2020, CANCER CELL, V37, P270, DOI 10.1016/j.ccell.2020.02.004; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Hunten S, 2015, MOL CELL PROTEOMICS, V14, P2609, DOI 10.1074/mcp.M115.050237; Khan RIN, 2021, GENOMICS, V113, P2860, DOI 10.1016/j.ygeno.2021.06.013; Li T, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1038-7; Liu HM, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02833-y; Lu SX, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01204-0; Ma S, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0805-7; Marmol I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010197; Meyer J, 2019, CLIN GASTROENTEROL H, V17, P1448, DOI 10.1016/j.cgh.2018.07.031; Muller S, 2019, NUCLEIC ACIDS RES, V47, P375, DOI 10.1093/nar/gky1012; Ni W, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1079-y; Qu F, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.645823; Roignant JY, 2017, TRENDS GENET, V33, P380, DOI 10.1016/j.tig.2017.04.003; Shen CQ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01190-w; Shi HL, 2019, MOL CELL, V74, P640, DOI 10.1016/j.molcel.2019.04.025; Tong JY, 2018, FRONT MED-PRC, V12, P481, DOI 10.1007/s11684-018-0654-8; Wang LY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225758; Wang Q, 2020, GUT, V69, P1193, DOI 10.1136/gutjnl-2019-319639; Wang TY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01204-7; Wang YL, 2020, THERANOSTICS, V10, P9407, DOI 10.7150/thno.48520; Wang Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1105-0; Xiang Y, 2017, NATURE, V543, P573, DOI 10.1038/nature21671; Yang Y, 2018, CELL RES, V28, P616, DOI 10.1038/s41422-018-0040-8; Yi YC, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01233-2; Zaccara S, 2020, CELL, V181, P1582, DOI 10.1016/j.cell.2020.05.012; Zhang J., 2020, CELL DEATH DIS, V11; Zhang YH, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01706-8; Zhao W, 2020, MOL THER-NUCL ACIDS, V19, P405, DOI 10.1016/j.omtn.2019.11.022; Zhao YC, 2021, THERANOSTICS, V11, P4549, DOI 10.7150/thno.54967; Zhou B, 2021, CANCER LETT, V497, P89, DOI 10.1016/j.canlet.2020.10.002; Zhou DJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16777-6; Zhou ZJ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01216-3; Zhu PP, 2021, ONCOGENE, V40, P1609, DOI 10.1038/s41388-020-01638-9	46	3	3	5	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2022	41	13					1959	1973		10.1038/s41388-022-02189-x	http://dx.doi.org/10.1038/s41388-022-02189-x		FEB 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J9BT	35173309				2022-12-17	WOS:000756457400001
J	Liao, YD; Huang, JM; Liu, P; Zhang, CY; Liu, JX; Xia, M; Shang, CL; Ooi, SY; Chen, YL; Qin, SH; Du, QQ; Liu, TY; Xu, MM; Zou, QJ; Zhou, YJ; Huang, H; Pan, YW; Wang, W; Yao, SZ				Liao, Yuandong; Huang, Jiaming; Liu, Pan; Zhang, Chunyu; Liu, Junxiu; Xia, Meng; Shang, Chunliang; Ooi, Shiyin; Chen, Yili; Qin, Shuhang; Du, Qiqiao; Liu, Tianyu; Xu, Manman; Zou, Qiaojian; Zhou, Yijia; Huang, Hua; Pan, Yuwen; Wang, Wei; Yao, Shuzhong			Downregulation of LNMAS orchestrates partial EMT and immune escape from macrophage phagocytosis to promote lymph node metastasis of cervical cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH; MECHANISMS; EXPRESSION; RATIO	Epithelial-mesenchymal transition (EMT) is an essential step to drive the metastatic cascade to lymph nodes (LNs) in cervical cancer cells. However, few of them metastasize successfully partially due to increased susceptibility to immunosurveillance conferred by EMT. The precise mechanisms of cancer cells orchestrate EMT and immune evasion remain largely unexplored. In this study, we identified a lncRNA termed lymph node metastasis associated suppressor (LNMAS), which was downregulated in LN-positive cervical cancer patients and correlated with LN metastasis and prognosis. Functionally, LNMAS suppressed cervical cancer cells metastasis in vitro and in vivo. Mechanistically, LNMAS exerts its metastasis suppressive activity by competitively interacting with HMGB1 and abrogating the chromatin accessibility of TWIST1 and STC1, inhibiting TWIST1-mediated partial EMT and STC1-dependent immune escape from macrophage phagocytosis. We further demonstrated that the CpG sites in the promoter region of LNMAS was hypermethylated and contributed to the downregulation of LNMAS. Taken together, our results reveal the essential role of LNMAS in the LN metastasis of cervical cancer and provide mechanistic insights into the regulation of LNMAS in EMT and immune evasion.	[Liao, Yuandong; Huang, Jiaming; Liu, Pan; Zhang, Chunyu; Liu, Junxiu; Xia, Meng; Ooi, Shiyin; Chen, Yili; Qin, Shuhang; Du, Qiqiao; Liu, Tianyu; Xu, Manman; Zou, Qiaojian; Zhou, Yijia; Huang, Hua; Pan, Yuwen; Wang, Wei; Yao, Shuzhong] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Guangzhou 510080, Guangdong, Peoples R China; [Shang, Chunliang] Peking Univ Third Hosp, Dept Obstet & Gynecol, Beijing 100191, Peoples R China	Sun Yat Sen University; Peking University	Wang, W; Yao, SZ (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Guangzhou 510080, Guangdong, Peoples R China.	wangw245@mail.sysu.edu.cn; yaoshuzh@mail.sysu.edu.cn	Zhang, Chun-yu/HDP-5776-2022	Yao, Shuzhong/0000-0002-5145-5705	National Natural Science Foundation of China [81874102, 82072874, 81902627]; Guangzhou Science and Technology Programme [202002020043]; Sun Yat-sen University Clinical Research Foundation of 5010 Project [2017006]; Natural Science Foundation of Guangdong Province [2017A030313509]; Guangdong Basic and Applied Basic Research Foundation [2021A1515011776]; First Affiliated Hospital of Sun Yat-sen University Undergraduate Teaching Reform Research Project [31911130-200437]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangzhou Science and Technology Programme; Sun Yat-sen University Clinical Research Foundation of 5010 Project; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Guangdong Basic and Applied Basic Research Foundation; First Affiliated Hospital of Sun Yat-sen University Undergraduate Teaching Reform Research Project	This work was supported by the National Natural Science Foundation of China (No. 81874102, 82072874 to SZY; 81902627 to JMH), Guangzhou Science and Technology Programme (No. 202002020043 to SZY), Sun Yat-sen University Clinical Research Foundation of 5010 Project (No. 2017006 to SZY), Natural Science Foundation of Guangdong Province (No. 2017A030313509 to WW), Guangdong Basic and Applied Basic Research Foundation (No. 2021A1515011776 to WW) and the First Affiliated Hospital of Sun Yat-sen University Undergraduate Teaching Reform Research Project (No. 31911130-200437 to WW).	Advani R, 2018, NEW ENGL J MED, V379, P1711, DOI 10.1056/NEJMoa1807315; Aiello NM, 2019, J EXP MED, V216, P1016, DOI 10.1084/jem.20181827; Athie A, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201908078; Barkal AA, 2019, NATURE, V572, P392, DOI 10.1038/s41586-019-1456-0; Battistelli C, 2021, CANCER RES, V81, P103, DOI 10.1158/0008-5472.CAN-20-1764; Bejarano L, 2021, CANCER DISCOV, V11, P933, DOI 10.1158/2159-8290.CD-20-1808; Berger AC, 2018, CANCER CELL, V33, P690, DOI 10.1016/j.ccell.2018.03.014; Bhatla N, 2018, INT J GYNECOL OBSTET, V143, P22, DOI 10.1002/ijgo.12611; Blair RH, 2016, J MOL BIOL, V428, P4060, DOI 10.1016/j.jmb.2016.08.018; Brabletz S, 2021, EMBO J, V40, DOI 10.15252/embj.2021108647; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen Y, 2013, INT J GYNECOL CANCER, V23, P157, DOI 10.1097/IGC.0b013e3182778bcf; Chockley PJ, 2018, J CLIN INVEST, V128, P1384, DOI 10.1172/JCI97611; Chu Ci, 2012, J Vis Exp, DOI 10.3791/3912; Dong WH, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00340; Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017; Fan JY, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0705-2; Feng MY, 2019, NAT REV CANCER, V19, P568, DOI 10.1038/s41568-019-0183-z; Fleming ND, 2015, GYNECOL ONCOL, V136, P48, DOI 10.1016/j.ygyno.2014.11.010; Garner H, 2020, NAT REV IMMUNOL, V20, P483, DOI 10.1038/s41577-019-0271-z; Guo FJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053989; Huang D, 2018, NAT IMMUNOL, V19, P1112, DOI 10.1038/s41590-018-0207-y; Huang JM, 2018, ONCOL LETT, V15, P5584, DOI 10.3892/ol.2018.8037; Iurlaro M, 2021, NAT GENET, V53, P279, DOI 10.1038/s41588-020-00768-w; Kang R, 2014, MOL ASPECTS MED, V40, P1, DOI 10.1016/j.mam.2014.05.001; Karaman S, 2014, J CLIN INVEST, V124, P922, DOI 10.1172/JCI71606; Klein M, 1999, J ENDOCRINOL, V161, P41, DOI 10.1677/joe.0.1610041; Kong DG, 2021, ONCOGENE, V40, P964, DOI 10.1038/s41388-020-01539-x; Kozlova AL, 2018, MOL BIOL+, V52, P637, DOI 10.1134/S0026893318050096; Lee CK, 2019, SCIENCE, V363, P644, DOI 10.1126/science.aav0173; Lepique AP, 2009, CLIN CANCER RES, V15, P4391, DOI 10.1158/1078-0432.CCR-09-0489; LIN H, CANCER CELL, V2021; Liu F, 2018, ONCOGENE, V37, P2394, DOI 10.1038/s41388-017-0119-6; Liu JQ, 2020, LIFE SCI, V241, DOI 10.1016/j.lfs.2019.117134; Liu XS, 2016, CELL, V167, P233, DOI 10.1016/j.cell.2016.08.056; Long YC, 2017, SCI ADV, V3, DOI 10.1126/sciadv.aao2110; Lv DJ, 2019, THERANOSTICS, V9, P5166, DOI 10.7150/thno.33972; Mikheeva SA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-194; Mittal V, 2018, ANNU REV PATHOL-MECH, V13, P395, DOI 10.1146/annurev-pathol-020117-043854; Mohme M, 2017, NAT REV CLIN ONCOL, V14, P155, DOI 10.1038/nrclinonc.2016.144; Noman MZ, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1345415; Noordhuis MG, 2011, CLIN CANCER RES, V17, P1317, DOI 10.1158/1078-0432.CCR-10-2320; Oki S, 2018, EMBO REP, V19, DOI 10.15252/embr.201846255; Pan X, 2021, CANCER BIOTHER RADIO, V36, P501, DOI 10.1089/cbr.2019.3344; Quan YS, 2018, BIOCHEM BIOPH RES CO, V497, P527, DOI 10.1016/j.bbrc.2018.02.072; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Shang CL, 2018, CANCER RES, V78, P877, DOI 10.1158/0008-5472.CAN-17-2356; Shibata K, 2008, ANN ONCOL, V19, P81, DOI 10.1093/annonc/mdm344; Sikic BI, 2019, J CLIN ONCOL, V37, P946, DOI 10.1200/JCO.18.02018; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Vojta A, 2016, NUCLEIC ACIDS RES, V44, P5615, DOI 10.1093/nar/gkw159; Wang JB, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00444; Winkle M, 2021, NAT REV DRUG DISCOV, V20, P629, DOI 10.1038/s41573-021-00219-z; Wu N, 2021, CELL DEATH DIFFER, V28, P219, DOI 10.1038/s41418-020-0596-y; Wu YM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1014-2; Xia M., 2020, CELL DEATH DIS, V11; Xu LL, 2021, ONCOGENE, V40, P3578, DOI 10.1038/s41388-021-01760-2; Xu XX, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.9; Yu BY, 2020, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01575; Zeng YT, 2019, ONCOGENE, V38, P6940, DOI 10.1038/s41388-019-0906-3; Zhang CY, 2020, THERANOSTICS, V10, P6561, DOI 10.7150/thno.44868; Zhu CY, 2020, EUR REV MED PHARMACO, V24, P2321, DOI 10.26355/eurrev_202003_20498	63	3	3	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2022	41	13					1931	1943		10.1038/s41388-022-02202-3	http://dx.doi.org/10.1038/s41388-022-02202-3		FEB 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J9BT	35152264	hybrid, Green Published			2022-12-17	WOS:000754368500001
J	Guerra, E; Relli, V; Ceci, M; Tripaldi, R; Simeone, P; Aloisi, AL; Pantalone, L; La Sorda, R; Lattanzio, R; Sacchetti, A; Havas, K; Guarnieri, S; Vergara, D; Fournier, I; Salzet, M; Tinari, N; Piantelli, M; Trerotola, M; Alberti, S				Guerra, Emanuela; Relli, Valeria; Ceci, Martina; Tripaldi, Romina; Simeone, Pasquale; Aloisi, Anna Laura; Pantalone, Ludovica; La Sorda, Rossana; Lattanzio, Rossano; Sacchetti, Andrea; Havas, Kristina; Guarnieri, Simone; Vergara, Daniele; Fournier, Isabelle; Salzet, Michel; Tinari, Nicola; Piantelli, Mauro; Trerotola, Marco; Alberti, Saverio			Trop-2, Na+/K+ ATPase, CD9, PKC alpha, cofilin assemble a membrane signaling super-complex that drives colorectal cancer growth and invasion	ONCOGENE			English	Article							PROTEIN-KINASE-C; E-CADHERIN; TETRASPANIN CD9; CELL-ADHESION; PH DOMAINS; TUMOR; BINDING; OUABAIN; METASTASIS; CLEAVAGE	Trop-2 is a transmembrane signal transducer that is overexpressed in most human cancers, and drives malignant progression. To gain knowledge on the higher-order molecular mechanisms that drive Trop-2 signaling, we applied next-generation sequencing, proteomics, and high-resolution microscopy to models and primary cases of human colorectal cancer (CRC). We had previously shown that Trop-2 induces a Ca2+ signal. We reveal here that Trop-2 binds the cell membrane Na+/K+-ATPase, and that clustering of Trop-2 induces an intracellular Ca2+ rise followed by membrane translocation of PKC alpha, which in turn phosphorylates the Trop-2 cytoplasmic tail. This feed-forward signaling is promoted by the binding of Trop-2 to the PKC alpha membrane-anchor CD9. CRISPR-based inactivation of CD9 in CRC cells shows that CD9 is required by Trop-2 for recruiting PKC alpha and cofilin-1 to the cell membrane. This induces malignant progression through proteolytic cleavage of E-cadherin, remodeling of the beta-actin cytoskeleton, and activation of Akt and ERK. The interaction between Trop-2 and CD9 was validated in vivo in murine models of CRC growth and invasion. Overexpression of the components of this Trop-2-driven super-complex significantly worsened disease-free and overall survival of CRC patients, supporting a pivotal relevance in CRC malignant progression. Our findings demonstrate a previously unsuspected layer of cancer growth regulation, which is dormant in normal tissues, and is activated by Trop-2 in cancer cells.	[Guerra, Emanuela; Relli, Valeria; Ceci, Martina; Tripaldi, Romina; Simeone, Pasquale; Aloisi, Anna Laura; Pantalone, Ludovica; La Sorda, Rossana; Lattanzio, Rossano; Sacchetti, Andrea; Havas, Kristina; Piantelli, Mauro; Trerotola, Marco; Alberti, Saverio] Univ G DAnnunzio, Ctr Adv Studies & Technol CAST, Lab Canc Pathol, Chieti, Italy; [Guerra, Emanuela; Tinari, Nicola; Piantelli, Mauro; Trerotola, Marco] Univ G DAnnunzio, Dept Med Oral & Biotechnol Sci, Chieti, Italy; [Lattanzio, Rossano] Univ G DAnnunzio, Dept Innovat Technol Med & Dent, Chieti, Italy; [Guarnieri, Simone] Univ G DAnnunzio, Ctr Adv Studies & Technol CAST, Lab Cell Physiol, Chieti, Italy; [Guarnieri, Simone] Univ G DAnnunzio, Dept Neurosci Imaging & Clin Sci, Chieti, Italy; [Vergara, Daniele] Univ Salento, Dept Biol & Environm Sci & Technol, Lecce, Italy; [Fournier, Isabelle; Salzet, Michel] Univ Lille 1, INSERM, U1192, Lab Proteom Reponse Inflammatoire Spectrometrie M, Cite Sci, Villeneuve Dascq, France; [Alberti, Saverio] Univ Messina, Dept Biomed Sci, Unit Med Genet, Messina, Italy; [Simeone, Pasquale] Univ G DAnnunzio, Dept Med & Aging Sci, Chieti, Italy; [Simeone, Pasquale] Univ G DAnnunzio, Ctr Adv Studies & Technol CAST, Lab Cytomorphol, Chieti, Italy; [Sacchetti, Andrea] Erasmus MC, Josephine Nefkens Inst, Rotterdam, Netherlands; [Havas, Kristina] FIRC Inst Mol Oncol IFOM, Milan, Italy	G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; University of Salento; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; University of Messina; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; Erasmus University Rotterdam; Erasmus MC; IFOM - FIRC Institute of Molecular Oncology	Trerotola, M; Alberti, S (corresponding author), Univ G DAnnunzio, Ctr Adv Studies & Technol CAST, Lab Canc Pathol, Chieti, Italy.; Trerotola, M (corresponding author), Univ G DAnnunzio, Dept Med Oral & Biotechnol Sci, Chieti, Italy.; Alberti, S (corresponding author), Univ Messina, Dept Biomed Sci, Unit Med Genet, Messina, Italy.	marco.trerotola@unich.it; salberti@unime.it	Simeone, Pasquale/K-7549-2016; Alberti, Saverio/M-4511-2014; Salzet, Michel/A-7675-2011; Vergara, Daniele/K-3831-2014	Simeone, Pasquale/0000-0003-4430-480X; Alberti, Saverio/0000-0002-4647-6042; Salzet, Michel/0000-0003-4318-0817; Vergara, Daniele/0000-0002-2396-7674; Guerra, Emanuela/0000-0002-7091-8621; Ceci, Martina/0000-0002-4550-8823	Italian Ministry of Health [RicOncol RF-EMR-2006-361866]; Italian Ministry of Development-FESR; Region Abruzzo (POR FESR 2007-2013: Activity 1.1.1 line B) [C78C14000100005]; Oncoxx Biotech, Italy; Marie Curie Transfer of Knowledge Fellowship-EC VI Framework Program [014541]; Programma Per Giovani Ricercatori "Rita Levi Montalcini", Italian Ministry of University and Research [PGR12I7N1Z];  [SSI000651];  [1083/2006];  [1828/2006]	Italian Ministry of Health(Ministry of Health, Italy); Italian Ministry of Development-FESR; Region Abruzzo (POR FESR 2007-2013: Activity 1.1.1 line B); Oncoxx Biotech, Italy; Marie Curie Transfer of Knowledge Fellowship-EC VI Framework Program; Programma Per Giovani Ricercatori "Rita Levi Montalcini", Italian Ministry of University and Research; ; ; 	Italian Ministry of Health (RicOncol RF-EMR-2006-361866), Italian Ministry of Development-FESR 2016-2018. SSI000651, art. 69 Reg. (CE) n. 1083/2006 and Reg. (CE) n. 1828/2006, Region Abruzzo (POR FESR 2007-2013: Activity 1.1.1 line B) C78C14000100005, Oncoxx Biotech, Italy and Marie Curie Transfer of Knowledge Fellowship-EC VI Framework Program (Contract 014541) to SA. Programma Per Giovani Ricercatori "Rita Levi Montalcini", Italian Ministry of University and Research (Grant PGR12I7N1Z) to MT. EG is an inventor in patents WO201687651 and WO201784763, and a partner in Mediterranea Theranostic Srl. MT is an inventor in patent WO201784763. SA is an inventor in patents WO201089782, WO201687651, and WO201784763, and is founder and CEO of Oncoxx Biotech Srl and Mediterranea Theranostic Srl. VR was an employee of Oncoxx Biotech Srl. PS is an inventor in a patent application under consideration (EP3546948).	Agesen TH, 2012, GUT, V61, P1560, DOI 10.1136/gutjnl-2011-301179; Alberti S, 1999, PROTEINS, V35, P360; Alberti S, 1998, PROTEINS, V31, P1, DOI 10.1002/(SICI)1097-0134(19980401)31:1<1::AID-PROT1>3.0.CO;2-R; ALBERTI S, 1992, HYBRIDOMA, V11, P539, DOI 10.1089/hyb.1992.11.539; Ambrogi F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096993; Antal CE, 2015, CELL, V160, P489, DOI 10.1016/j.cell.2015.01.001; Bahmad HF, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00347; Bardia A, 2019, NEW ENGL J MED, V380, P741, DOI 10.1056/NEJMoa1814213; BASU A, 1995, INT J CANCER, V62, P472, DOI 10.1002/ijc.2910620419; Cabantous S, 2013, SCI REP-UK, V3, DOI 10.1038/srep02854; Chen DD, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-716; Choi CK, 2008, NAT CELL BIOL, V10, P1039, DOI 10.1038/ncb1763; Ciccarelli FD, 2000, HUM MOL GENET, V9, P1001, DOI 10.1093/hmg/9.6.1001; Di Baldassarre A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30537-z; El Sewedy T, 1998, INT J CANCER, V75, P324, DOI 10.1002/(SICI)1097-0215(19980119)75:2<324::AID-IJC24>3.3.CO;2-5; Farah CA, 2012, ADV EXP MED BIOL, V740, P663, DOI 10.1007/978-94-007-2888-2_29; FORNARO M, 1995, INT J CANCER, V62, P610, DOI 10.1002/ijc.2910620520; Freeley M, 2011, CELL SIGNAL, V23, P753, DOI 10.1016/j.cellsig.2010.10.013; Guerra E, 2013, ONCOGENE, V32, P1594, DOI 10.1038/onc.2012.151; Guerra E, 2008, CANCER RES, V68, P8113, DOI 10.1158/0008-5472.CAN-07-6135; Guerra E, 2021, NEOPLASIA, V23, P898, DOI 10.1016/j.neo.2021.07.002; Guerra E, 2016, CLIN CANCER RES, V22, P4197, DOI 10.1158/1078-0432.CCR-15-1701; Haas A, 2002, J BIOL CHEM, V277, P18694, DOI 10.1074/jbc.M111357200; Hoshino A, 2020, CELL, V182, P1044, DOI 10.1016/j.cell.2020.07.009; Jiang XP, 2020, BBA-MOL CELL RES, V1867, DOI 10.1016/j.bbamcr.2019.118574; Krishn SR, 2019, MATRIX BIOL, V77, P41, DOI 10.1016/j.matbio.2018.08.004; Larre I, 2010, P NATL ACAD SCI USA, V107, P11387, DOI 10.1073/pnas.1000500107; Liang M, 2007, J BIOL CHEM, V282, P10585, DOI 10.1074/jbc.M609181200; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Maretzky T, 2005, P NATL ACAD SCI USA, V102, P9182, DOI 10.1073/pnas.0500918102; Matchkov VV, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00179; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOORE EDW, 1993, NATURE, V365, P657, DOI 10.1038/365657a0; Mori Y, 2019, J BIOL CHEM, V294, P11513, DOI 10.1074/jbc.RA119.008084; MORIKAWA K, 1988, CANCER RES, V48, P6863; Murayama Y, 2008, J CELL PHYSIOL, V216, P135, DOI 10.1002/jcp.21384; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; Ninsontia C, 2014, ANTICANCER RES, V34, P5495; Powner D, 2011, BIOCHEM SOC T, V39, P563, DOI 10.1042/BST0390563; Rios-Doria J, 2003, J BIOL CHEM, V278, P1372, DOI 10.1074/jbc.M208772200; Ripani E, 1998, INT J CANCER, V76, P671; Saczko-Brack D, 2016, P NATL ACAD SCI USA, V113, pE8387, DOI 10.1073/pnas.1612719113; Sakuma M, 2012, MOL BIOL CELL, V23, P3707, DOI 10.1091/mbc.E12-01-0053; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Scott RW, 2010, J CELL BIOL, V191, P169, DOI 10.1083/jcb.201002041; Shen JJ, 2020, ACTA PHARMACOL SIN, V41, P110, DOI 10.1038/s41401-019-0290-0; Spratley SJ, 2011, J BIOL CHEM, V286, P34254, DOI 10.1074/jbc.M111.259424; Stoyanova T, 2012, GENE DEV, V26, P2271, DOI 10.1101/gad.196451.112; Sveen A, 2011, GENOME MED, V3, DOI 10.1186/gm248; Tanaka K, 2011, CANCER DISCOV, V1, P524, DOI 10.1158/2159-8290.CD-11-0124; Thomas A, 2019, CLIN CANCER RES, V25, P6581, DOI 10.1158/1078-0432.CCR-19-1089; Tian J, 2006, MOL BIOL CELL, V17, P317, DOI 10.1091/mbc.E05-08-0735; Tian J, 2008, PHYSIOLOGY, V23, P205, DOI 10.1152/physiol.00008.2008; Tian J, 2009, J BIOL CHEM, V284, P14921, DOI 10.1074/jbc.M808355200; Trerotola M, 2013, ONCOGENE, V32, P222, DOI 10.1038/onc.2012.36; Trerotola M, 2021, NEOPLASIA, V23, P415, DOI 10.1016/j.neo.2021.03.006; Trerotola M, 2015, ONCOTARGET, V6, P14318, DOI 10.18632/oncotarget.3960; Trerotola M, 2013, CANCER RES, V73, P3155, DOI 10.1158/0008-5472.CAN-12-3266; Trerotola M, 2012, J CELL PHYSIOL, V227, P3670, DOI 10.1002/jcp.24074; Van Rheenen J, 2007, J CELL BIOL, V179, P1247, DOI 10.1083/jcb.200706206; Wang HX, 2011, J CELL SCI, V124, P2702, DOI 10.1242/jcs.085449; Wanger TM, 2015, CELL SIGNAL, V27, P1325, DOI 10.1016/j.cellsig.2015.03.017; Watanabe T, 2007, MOL BIOL CELL, V18, P605, DOI 10.1091/mbc.E06-07-0590; Zanna P, 2007, CANCER-AM CANCER SOC, V110, P452, DOI 10.1002/cncr.22785; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200	66	3	3	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2022	41	12					1795	1808		10.1038/s41388-022-02220-1	http://dx.doi.org/10.1038/s41388-022-02220-1		FEB 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV6UV	35132180	Green Published			2022-12-17	WOS:000752288100002
J	Lin, LF; Shi, KX; Zhou, SQ; Cai, MC; Zhang, CY; Sun, YH; Zang, JY; Cheng, L; Ye, KY; Ma, PF; Shen, PY; Zhang, MY; Cheng, Y; Qi, CT; Li, Y; Yin, X; Zheng, YY; Tan, L; Zhuang, GL; Zang, RY				Lin, Lifeng; Shi, Kaixuan; Zhou, Shaoqing; Mei-Chun Cai; Zhang, Caiyan; Sun, Yunheng; Zang, Jingyu; Cheng, Lin; Ye, Kaiyan; Ma, Pengfei; Shen, Peiye; Zhang, Meiying; Cheng, Yan; Qi, Chunting; Li, Ying; Yin, Xia; Zheng, Yiyan; Tan, Li; Zhuang, Guanglei; Zang, Rongyu			SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer	ONCOGENE			English	Article							CELL; REGULATORS; ADDICTION; SPECIFICATION; DEPENDENCIES; BINDING	Mu''llerian tissue-specific oncogenes, prototyped by PAX8, underlie ovarian tumorigenesis and represent unique molecular vulnerabilities. Further delineating such lineage-dependency factors and associated therapeutic implications would provide valuable insights into ovarian cancer biology and treatment. In this study, we identified SOX17 as a new lineage-survival master transcription factor, which shared co-expression pattern with PAX8 in epithelial ovarian carcinoma. Genetic disruption of SOX17 or PAX8 analogously inhibited neoplastic cell viability and downregulated a spectrum of lineage-related transcripts. Mechanistically, we showed that SOX17 physically interacted with PAX8 in cultured cell lines and clinical tumor specimens. The two nuclear proteins bound to overlapping genomic regions and regulated a common set of downstream genes, including those involved in cell cycle and tissue morphogenesis. In addition, we revealed that small-molecule inhibitors of transcriptional cyclin-dependent kinases (CDKs) effectively reduced SOX17 and PAX8 expression. ZSQ1722, a novel orally bioavailable CDK12/13 covalent antagonist, exerted potent anti-tumor activity in xenograft models. These findings shed light on an actionable lineage-survival transcriptional complex in ovarian cancer, and facilitated drug discovery by generating a serial of candidate compounds to pharmacologically target this difficult-to-treat malignancy.	[Lin, Lifeng; Zheng, Yiyan; Zang, Rongyu] Fudan Univ, Zhongshan Hosp, Dept Gynecol Oncol, Ovarian Canc Program, Shanghai, Peoples R China; [Shi, Kaixuan; Sun, Yunheng; Zang, Jingyu; Cheng, Lin; Ye, Kaiyan; Ma, Pengfei; Shen, Peiye; Zhang, Meiying; Yin, Xia; Zhuang, Guanglei] Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes, Dept Obstet & Gynecol,Ren Ji Hosp, Shanghai, Peoples R China; [Shi, Kaixuan; Sun, Yunheng; Zang, Jingyu; Cheng, Lin; Ye, Kaiyan; Ma, Pengfei; Shen, Peiye; Zhang, Meiying; Yin, Xia; Zhuang, Guanglei] Shanghai Jiao Tong Univ, Ren Ji Hosp, Shanghai Key Lab Gynecol Oncol, Sch Med, Shanghai, Peoples R China; [Zhou, Shaoqing; Cheng, Yan; Qi, Chunting; Li, Ying; Tan, Li] Chinese Acad Sci, Interdisciplinary Res Ctr Biol & Chem, Shanghai Inst Organ Chem, Shanghai, Peoples R China; [Zhou, Shaoqing; Tan, Li] Univ Chinese Acad Sci, Beijing, Peoples R China; [Mei-Chun Cai; Zhang, Caiyan] Shanghai Jiao Tong Univ, Ren Ji Hosp, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai, Peoples R China	Fudan University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institute of Organic Chemistry, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Shanghai Jiao Tong University	Zang, RY (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Gynecol Oncol, Ovarian Canc Program, Shanghai, Peoples R China.; Zhuang, GL (corresponding author), Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes, Dept Obstet & Gynecol,Ren Ji Hosp, Shanghai, Peoples R China.; Zhuang, GL (corresponding author), Shanghai Jiao Tong Univ, Ren Ji Hosp, Shanghai Key Lab Gynecol Oncol, Sch Med, Shanghai, Peoples R China.; Tan, L (corresponding author), Chinese Acad Sci, Interdisciplinary Res Ctr Biol & Chem, Shanghai Inst Organ Chem, Shanghai, Peoples R China.; Tan, L (corresponding author), Univ Chinese Acad Sci, Beijing, Peoples R China.	tanli@sioc.ac.cn; zhuangguanglei@gmail.com; zang.rongyu@zs-hospital.sh.cn	张, 梅莹/GPC-5265-2022	lin, lifeng/0000-0002-5160-9145	National Natural Science Foundation of China [81972429, 81922047, 82172596, 82173077, 82173111]; Science and Technology Commission of Shanghai Municipality [18140902300, 18JC1420500]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20161313]; Shanghai Municipal Science and Technology Major Project [2019SHZDZX02]; Shanghai Natural Science Foundation [20ZR1433100]; Shanghai Shenkang Hospital Development Center [SHDC2020CR3057B]; Shanghai Collaborative Innovation Center for Translational Medicine [TM202004]; Beijing Kuanghua foundation for the development of Chinese and Western Medicine (BKF) [KH-2021-LLZX-018]; Shanghai Jiao Tong University School of Medicine [YG2021GD02, TMSK-2021-207]; Shanghai Key Laboratory of Gynecologic Oncology [FKZL-2018-02]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support; Shanghai Municipal Science and Technology Major Project; Shanghai Natural Science Foundation(Natural Science Foundation of Shanghai); Shanghai Shenkang Hospital Development Center; Shanghai Collaborative Innovation Center for Translational Medicine; Beijing Kuanghua foundation for the development of Chinese and Western Medicine (BKF); Shanghai Jiao Tong University School of Medicine; Shanghai Key Laboratory of Gynecologic Oncology	This work was supported by the National Natural Science Foundation of China (81972429 to RZ; 81922047 and 82172596 to GZ; 82173077 to XY; 82173111 to MZ), the Science and Technology Commission of Shanghai Municipality (18140902300 to RZ; 18JC1420500 to LT), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20161313 to GZ), Shanghai Municipal Science and Technology Major Project (Grant No. 2019SHZDZX02 to LT), Shanghai Natural Science Foundation (20ZR1433100 to XY), Shanghai Shenkang Hospital Development Center (SHDC2020CR3057B to XY), Shanghai Collaborative Innovation Center for Translational Medicine (TM202004 to XY), Beijing Kuanghua foundation for the development of Chinese and Western Medicine (BKF) (KH-2021-LLZX-018 to XY), Shanghai Jiao Tong University School of Medicine (YG2021GD02 and TMSK-2021-207 to XY), the grants from Shanghai Key Laboratory of Gynecologic Oncology (FKZL-2018-02 to PM).	Ashrafizadeh M, 2020, PHARMACOL RES, V161, DOI 10.1016/j.phrs.2020.105159; Augert A, 2014, CANCER CELL, V26, P783, DOI 10.1016/j.ccell.2014.11.012; Blake JA, 2014, DEVELOPMENT, V141, P737, DOI 10.1242/dev.091785; Bleu M, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22708-w; Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013; Brien GL, 2016, CANCER CELL, V29, P464, DOI 10.1016/j.ccell.2016.03.007; Cai MC, 2020, J PATHOL, V251, P147, DOI 10.1002/path.5435; Cai MC, 2019, INT J CANCER, V144, P788, DOI 10.1002/ijc.31975; Chapuy B, 2013, CANCER CELL, V24, P777, DOI 10.1016/j.ccr.2013.11.003; Chaves-Moreira D, 2020, BIORXIV, DOI [10.1101/2020.09.09.290387, DOI 10.1101/2020.09.09.290387]; Chaves-Moreira D, 2021, CANCER RES, V81, P806, DOI 10.1158/0008-5472.CAN-20-3173; Chen Y, 2020, ONCOGENE, V39, P6633, DOI 10.1038/s41388-020-01459-w; Cheung HW, 2011, P NATL ACAD SCI USA, V108, P12372, DOI 10.1073/pnas.1109363108; Ding L, 2018, CELL, V173, P305, DOI 10.1016/j.cell.2018.03.033; Dinh HQ, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.108978; Durbin AD, 2018, NAT GENET, V50, P1240, DOI 10.1038/s41588-018-0191-z; Elias KM, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87988; Garraway LA, 2006, NAT REV CANCER, V6, P593, DOI 10.1038/nrc1947; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Ghannam-Shahbari D, 2018, ONCOGENE, V37, P2213, DOI 10.1038/s41388-017-0040-z; Goldman MJ, 2020, NAT BIOTECHNOL, V38, P675, DOI 10.1038/s41587-020-0546-8; Gryder BE, 2019, NAT GENET, V51, P1714, DOI 10.1038/s41588-019-0534-4; Gryder BE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11046-7; Huang HT, 2018, CELL CHEM BIOL, V25, P88, DOI 10.1016/j.chembiol.2017.10.005; Jolma A, 2015, NATURE, V527, P384, DOI 10.1038/nature15518; Kamachi Y, 2013, DEVELOPMENT, V140, P4129, DOI 10.1242/dev.091793; Kaya-Okur HS, 2020, NAT PROTOC, V15, P3264, DOI 10.1038/s41596-020-0373-x; Kaya-Okur HS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09982-5; Kuroki L, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3773; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Lee TI, 2013, CELL, V152, P1237, DOI 10.1016/j.cell.2013.02.014; Lheureux S, 2019, LANCET, V393, P1240, DOI 10.1016/S0140-6736(18)32552-2; Lv L, 2020, ELIFE, V9, DOI 10.7554/eLife.59994; Matulonis UA, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.61; Mills Kathryn, 2017, F1000Res, V6, P84, DOI 10.12688/f1000research.9977.1; Parua PK, 2020, NAT CHEM BIOL, V16, P716, DOI 10.1038/s41589-020-0563-4; Quereda V, 2019, CANCER CELL, V36, P545, DOI 10.1016/j.ccell.2019.09.004; Reddy J, 2019, PREDICTING MASTER TR, DOI [10.1101/839142, DOI 10.1101/839142]; Richters A, 2021, CELL CHEM BIOL, V28, P134, DOI 10.1016/j.chembiol.2020.10.001; Sarkar A, 2013, CELL STEM CELL, V12, P15, DOI 10.1016/j.stem.2012.12.007; Sharifnia T, 2019, NAT MED, V25, P292, DOI 10.1038/s41591-018-0312-3; Shi KX, 2019, ELIFE, V8, DOI 10.7554/eLife.44306; Slabicki M, 2020, NATURE, V585, P293, DOI 10.1038/s41586-020-2374-x; Spitz F, 2012, NAT REV GENET, V13, P613, DOI 10.1038/nrg3207; Tan DS, 2020, SEMIN CANCER BIOL, V67, P65, DOI 10.1016/j.semcancer.2019.08.008; Wei W, 2013, J CLIN INVEST, V123, P4435, DOI 10.1172/JCI70625; Zaret KS, 2020, ANNU REV GENET, V54, P367, DOI 10.1146/annurev-genet-030220-015007; Zhang TH, 2016, NAT CHEM BIOL, V12, P876, DOI 10.1038/nchembio.2166; Zhang ZF, 2017, MOL CANCER THER, V16, P1739, DOI 10.1158/1535-7163.MCT-17-0078	49	3	3	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2022	41	12					1767	1779		10.1038/s41388-022-02210-3	http://dx.doi.org/10.1038/s41388-022-02210-3		FEB 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV6UV	35124696				2022-12-17	WOS:000751581600001
J	Zhang, YH; Mohibi, S; Vasilatis, DM; Chen, MY; Zhang, J; Chen, XB				Zhang, Yanhong; Mohibi, Shakur; Vasilatis, Demitria M.; Chen, Mingyi; Zhang, Jin; Chen, Xinbin			Ferredoxin reductase and p53 are necessary for lipid homeostasis and tumor suppression through the ABCA1-SREBP pathway	ONCOGENE			English	Article							LOW-DENSITY-LIPOPROTEIN; CHOLESTEROL-METABOLISM; ADRENODOXIN REDUCTASE; STEROID HYDROXYLASE; ELECTRON-TRANSFER; PROSTATE-CANCER; TRANSGENIC MICE; NILE RED; GENE; BINDING	p53 is known to modulate metabolism and FDXR is required for steroidogenesis. Given that FDXR is a target/regulator of p53, the FDXR-p53 axis may play a unique role in lipid metabolism. Here, we found that expression of ABCA1, a cholesterol-efflux pump, was suppressed by loss of FDXR and/or p53, leading to activation of master lipogenic regulators SREBP1/2. Accordingly, lipid droplets, cholesterol, and triglycerides were increased by loss of FDXR or p53, which were further increased by loss of both FDXR and p53. To explore the biological significance of the FDXR-p53 axis, we generated a cohort of mice deficient in Fdxr and/or Trp53. We found that Fdxr(+/-), Trp53(+/-), and Fdxr(+/-);Trp53(+/-) mice had a short life span and were prone to spontaneous tumors and liver steatosis. Moreover, the levels of serum cholesterol and triglycerides were significantly increased in Fdxr(+/-) and Trp53(+/-) mice, which were further increased in Fdxr(+/-);Trp53(+/-) mice. Interestingly, loss of Fdxr but not p53 led to accumulation of serum low-density lipoprotein. Together, our findings reveal that the FDXR-p53 axis plays a critical role in lipid homeostasis and tumor suppression.	[Zhang, Yanhong; Mohibi, Shakur; Vasilatis, Demitria M.; Zhang, Jin; Chen, Xinbin] Univ Calif Davis, Sch Vet Med, Comparat Oncol Lab, Davis, CA 95616 USA; [Zhang, Yanhong; Mohibi, Shakur; Vasilatis, Demitria M.; Zhang, Jin; Chen, Xinbin] Univ Calif Davis, Sch Med, Comparat Oncol Lab, Davis, CA 95616 USA; [Chen, Mingyi] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of Texas System; University of Texas Southwestern Medical Center Dallas	Zhang, J; Chen, XB (corresponding author), Univ Calif Davis, Sch Vet Med, Comparat Oncol Lab, Davis, CA 95616 USA.; Zhang, J; Chen, XB (corresponding author), Univ Calif Davis, Sch Med, Comparat Oncol Lab, Davis, CA 95616 USA.	jinzhang@ucdavis.edu; xbchen@ucdavis.edu		zhang, jin/0000-0002-6835-920X; chen, xinbin/0000-0002-4582-6506; Mohibi, Shakur/0000-0001-5539-0841	NIH [CA224433, CA250338]; UCD Cancer Center Core Support Grant [CA093373]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UCD Cancer Center Core Support Grant	This work is supported in part by NIH grant CA224433 and CA250338 and by UCD Cancer Center Core Support Grant CA093373.	Assaily W, 2011, MOL CELL, V44, P491, DOI 10.1016/j.molcel.2011.08.038; Basso K, 2005, NAT GENET, V37, P382, DOI 10.1038/ng1532; Beloribi-Djefaflia S, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.49; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; DESSI S, 1994, CANCER, V73, P253, DOI 10.1002/1097-0142(19940115)73:2<253::AID-CNCR2820730204>3.0.CO;2-F; DESSI S, 1992, BRIT J CANCER, V66, P787, DOI 10.1038/bjc.1992.361; Ettinger SL, 2004, CANCER RES, V64, P2212, DOI 10.1158/0008-5472.CAN-2148-2; Funauchi Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep16497; Genicot G, 2005, THERIOGENOLOGY, V63, P1181, DOI 10.1016/j.theriogenology.2004.06.006; Graziani SR, 2002, GYNECOL ONCOL, V85, P493, DOI 10.1006/gyno.2002.6654; GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965; Guo DL, 2014, CURR PHARM DESIGN, V20, P2619, DOI 10.2174/13816128113199990486; HANUKOGLU I, 1989, EUR J BIOCHEM, V180, P479, DOI 10.1111/j.1432-1033.1989.tb14671.x; Hinson DD, 1997, J LIPID RES, V38, P2216; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; Huang WC, 2012, MOL CANCER RES, V10, P133, DOI 10.1158/1541-7786.MCR-11-0206; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Ki DH, 2007, INT J CANCER, V121, P2005, DOI 10.1002/ijc.22975; KIMURA T, 1967, J BIOL CHEM, V242, P485; Kolanjiappan K, 2003, CLIN BIOCHEM, V36, P61, DOI 10.1016/S0009-9120(02)00421-6; Kubicka S, 1997, HEPATOLOGY, V25, P867, DOI 10.1002/hep.510250414; Lacroix M, 2020, MOL METAB, V33, P2, DOI 10.1016/j.molmet.2019.10.002; Lane-Donovan C, 2014, NEURON, V83, P771, DOI 10.1016/j.neuron.2014.08.005; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; Liu Y, 2014, P NATL ACAD SCI USA, V111, pE2414, DOI 10.1073/pnas.1315605111; Lochner M, 2015, TRENDS IMMUNOL, V36, P81, DOI 10.1016/j.it.2014.12.005; Ma WZ, 2007, J BIOENERG BIOMEMBR, V39, P243, DOI 10.1007/s10863-007-9083-0; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Michihara A, 2001, BIOL PHARM BULL, V24, P1231, DOI 10.1248/bpb.24.1231; Miller WL, 2011, J LIPID RES, V52, P2111, DOI 10.1194/jlr.R016675; Moon SH, 2019, CELL, V176, P564, DOI 10.1016/j.cell.2018.11.011; Moustafa MA, 2004, CANCER SCI, V95, P530, DOI 10.1111/j.1349-7006.2004.tb03244.x; Muller JJ, 2001, J BIOL CHEM, V276, P2786, DOI 10.1074/jbc.M008501200; OKAMURA T, 1985, P NATL ACAD SCI USA, V82, P5705, DOI 10.1073/pnas.82.17.5705; Osborne TF, 2009, GENE DEV, V23, P2578, DOI 10.1101/gad.1854309; Parrales A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122074; Paul A, 2017, AM J HUM GENET, V101, P630, DOI 10.1016/j.ajhg.2017.09.007; Peng YY, 2017, HUM MOL GENET, V26, P4937, DOI 10.1093/hmg/ddx377; Rudling M, 1996, BBA-LIPID LIPID MET, V1299, P75, DOI 10.1016/0005-2760(95)00195-6; Sanchez-Macedo N, 2013, CELL DEATH DIFFER, V20, P659, DOI 10.1038/cdd.2012.168; Santos CR, 2012, FEBS J, V279, P2610, DOI 10.1111/j.1742-4658.2012.08644.x; Schaffner C P, 1981, Prog Clin Biol Res, V75A, P279; Schimanski S, 2010, HORM METAB RES, V42, P102, DOI 10.1055/s-0029-1241859; Shao W, 2012, CELL METAB, V16, P414, DOI 10.1016/j.cmet.2012.09.002; Sheftel AD, 2010, P NATL ACAD SCI USA, V107, P11775, DOI 10.1073/pnas.1004250107; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Simabuco Fernando M, 2018, Oncotarget, V9, P23780, DOI 10.18632/oncotarget.25267; Stenton SL, 2021, HUM MUTAT, V42, P310, DOI 10.1002/humu.24160; Swinnen JV, 2006, CURR OPIN CLIN NUTR, V9, P358, DOI 10.1097/01.mco.0000232894.28674.30; Tatidis L, 2002, BIOCHEM PHARMACOL, V63, P2169, DOI 10.1016/S0006-2952(02)01018-3; Veldurthy V, 2016, VITAM HORM, V100, P137, DOI 10.1016/bs.vh.2015.10.005; Vickery LE, 1997, STEROIDS, V62, P124, DOI 10.1016/S0039-128X(96)00170-5; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Wang XW, 2013, J MOL CELL BIOL, V5, P147, DOI 10.1093/jmcb/mjs064; Wymann MP, 2008, NAT REV MOL CELL BIO, V9, P162, DOI 10.1038/nrm2335; Yahagi N, 2003, J BIOL CHEM, V278, P25395, DOI 10.1074/jbc.M302364200; Yamauchi Y, 2015, J BIOL CHEM, V290, P23464, DOI 10.1074/jbc.M115.662668; Yang HJ, 2017, P NATL ACAD SCI USA, V114, P11500, DOI 10.1073/pnas.1711814114; Yoshioka Y, 2000, NMR BIOMED, V13, P377, DOI 10.1002/1099-1492(200011)13:7<377::AID-NBM658>3.0.CO;2-E; Zhang J, 2020, J PATHOL, V251, P284, DOI 10.1002/path.5451; Zhang J, 2018, CANCER RES, V78, P1511, DOI 10.1158/0008-5472.CAN-17-2457; Zhang J, 2014, P NATL ACAD SCI USA, V111, P18637, DOI 10.1073/pnas.1415607112; Zhang YH, 2017, GENE DEV, V31, P1243, DOI 10.1101/gad.299388.117; Zhou S, 2003, MUTAGENESIS, V18, P287, DOI 10.1093/mutage/18.3.287; Zollner A, 2008, FEBS J, V275, P799, DOI 10.1111/j.1742-4658.2008.06253.x	68	3	3	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2022	41	12					1718	1726		10.1038/s41388-021-02100-0	http://dx.doi.org/10.1038/s41388-021-02100-0		FEB 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV6UV	35121827	Green Published, hybrid			2022-12-17	WOS:000751251500001
J	Llobet, SG; Bhattacharya, A; Everts, M; van der Vegt, B; Fehrmann, RSN; van Vugt, MATM; Kok, K				Llobet, Sergi Guerrero; Bhattacharya, Arkajyoti; Everts, Marieke; van der Vegt, Bert; Fehrmann, Rudolf S. N.; van Vugt, Marcel A. T. M.; Kok, Klaas			An mRNA expression-based signature for oncogene-induced replication-stress	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; OVARIAN-CANCER; GENOMIC INSTABILITY; INDUCED SENESCENCE; NAT10; CELLS; ACETYLATION; ACTIVATION; RESISTANT; BARRIER	Oncogene-induced replication stress characterizes many aggressive cancers. Several treatments are being developed that target replication stress, however, identification of tumors with high levels of replication stress remains challenging. We describe a gene expression signature of oncogene-induced replication stress. A panel of triple-negative breast cancer (TNBC) and non-transformed cell lines were engineered to overexpress CDC25A, CCNE1 or MYC, which resulted in slower replication kinetics. RNA sequencing analysis revealed a set of 52 commonly upregulated genes. In parallel, mRNA expression analysis of patient-derived tumor samples (TCGA, n = 10,592) also revealed differential gene expression in tumors with amplification of oncogenes that trigger replication stress (CDC25A, CCNE1, MYC, CCND1, MYB, MOS, KRAS, ERBB2, and E2F1). Upon integration, we identified a six-gene signature of oncogene-induced replication stress (NAT10, DDX27, ZNF48, C8ORF33, MOCS3, and MPP6). Immunohistochemical analysis of NAT10 in breast cancer samples (n = 330) showed strong correlation with expression of phospho-RPA (R = 0.451, p = 1.82 x 10(-20)) and gamma H2AX (R = 0.304, p = 2.95 x 10(-9)). Finally, we applied our oncogene-induced replication stress signature to patient samples from TCGA (n = 8,862) and GEO (n = 13,912) to define the levels of replication stress across 27 tumor subtypes, identifying diffuse large B cell lymphoma, ovarian cancer, TNBC and colorectal carcinoma as cancer subtypes with high levels of oncogene-induced replication stress.	[Llobet, Sergi Guerrero; Bhattacharya, Arkajyoti; Everts, Marieke; Fehrmann, Rudolf S. N.; van Vugt, Marcel A. T. M.] Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands; [Kok, Klaas] Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands; [van der Vegt, Bert] Univ Med Ctr Groningen, Dept Pathol, Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen	van Vugt, MATM (corresponding author), Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands.	m.vugt@umcg.nl	van der Vegt, Bert/G-5887-2014; Fehrmann, Rudolf/E-2551-2011	van der Vegt, Bert/0000-0002-2613-1506; Guerrero Llobet, Sergi/0000-0003-2776-8610; van Vugt, Marcel/0000-0002-3202-4678; Bhattacharya, Arkajyoti/0000-0003-1479-0739; Fehrmann, Rudolf/0000-0002-7516-315X	Netherlands Organization for Scientific Research (NWO-VIDI) [917.13334]; Netherlands Organization for Scientific Research (NWO-VENI) [916-16025]; Dutch Cancer Society [RUG 2013-5960, 11352]; European Research Council (ERC)	Netherlands Organization for Scientific Research (NWO-VIDI)(Netherlands Organization for Scientific Research (NWO)); Netherlands Organization for Scientific Research (NWO-VENI)(Netherlands Organization for Scientific Research (NWO)); Dutch Cancer Society(KWF Kankerbestrijding); European Research Council (ERC)(European Research Council (ERC)European Commission)	We thank members of the Medical Oncology laboratory for fruitful discussions. This work was financially supported by grant from the Netherlands Organization for Scientific Research (NWO-VIDI #917.13334 to M.A.T.M.v.V. and NWO-VENI #916-16025 to R.S.N.F.), the Dutch Cancer Society (RUG 2013-5960 to R.S.N.F and #11352 to M.A.T.M.v.V.) and from the European Research Council (ERC-Consolidator grant "TENSION" to M.A.T.M.v.V.).	Aarts M, 2012, CANCER DISCOV, V2, P524, DOI 10.1158/2159-8290.CD-11-0320; Aggarwal P, 2007, GENE DEV, V21, P2908, DOI 10.1101/gad.1586007; Arango D, 2018, CELL, V175, P1872, DOI 10.1016/j.cell.2018.10.030; Aziz K, 2019, GASTROENTEROLOGY, V157, P210, DOI 10.1053/j.gastro.2019.03.016; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Carlos AR, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3697; Chen X, 2018, CLIN CANCER RES, V24, P6594, DOI 10.1158/1078-0432.CCR-18-1446; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; de Jong MRW, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193098; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dominissini D, 2018, CELL, V175, P1725, DOI 10.1016/j.cell.2018.11.037; Espana-Agusti J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02245-1; Farshidfar F, 2017, CELL REP, V18, P2780, DOI 10.1016/j.celrep.2017.02.033; Ferrao PT, 2012, ONCOGENE, V31, P1661, DOI 10.1038/onc.2011.358; Gadhikar MA, 2018, CANCER RES, V78, P781, DOI 10.1158/0008-5472.CAN-17-2802; Gerlinger M, 2010, BRIT J CANCER, V103, P1139, DOI 10.1038/sj.bjc.6605912; Llobet SG, 2020, NPJ BREAST CANCER, V6, DOI 10.1038/s41523-020-00181-w; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Heijink AM, 2015, P NATL ACAD SCI USA, V112, P15160, DOI 10.1073/pnas.1505283112; Inoue S, 2016, CANCER CELL, V30, P337, DOI 10.1016/j.ccell.2016.05.018; Italiano A, 2018, ANN ONCOL, V29, P1304, DOI 10.1093/annonc/mdy076; Joseph NM, 2019, J PATHOL, V248, P164, DOI 10.1002/path.5243; Kanu N, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1042-9; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kok YP, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-00270-2; Konstantinopoulos PA, 2020, LANCET ONCOL, V21, P957, DOI 10.1016/S1470-2045(20)30180-7; Leijen S, 2016, J CLIN ONCOL, V34, P4354, DOI 10.1200/JCO.2016.67.5942; Liu HY, 2020, NUCLEIC ACIDS RES, V48, P3638, DOI 10.1093/nar/gkaa130; Liu XF, 2016, EMBO REP, V17, P349, DOI 10.15252/embr.201540505; Lopez-Contreras AJ, 2012, J EXP MED, V209, P455, DOI 10.1084/jem.20112147; Calzetta NL, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc8257; Macheret M, 2018, NATURE, V555, P112, DOI 10.1038/nature25507; Maya-Mendoza A, 2015, MOL ONCOL, V9, P601, DOI 10.1016/j.molonc.2014.11.001; Neelsen KJ, 2013, J CELL BIOL, V200, P699, DOI 10.1083/jcb.201212058; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Pillay N, 2019, CANCER CELL, V35, P519, DOI 10.1016/j.ccell.2019.02.004; Rajeshkumar NV, 2011, CLIN CANCER RES, V17, P2799, DOI 10.1158/1078-0432.CCR-10-2580; Reddy A, 2017, CELL, V171, P481, DOI 10.1016/j.cell.2017.09.027; Shen Q, 2009, EXP CELL RES, V315, P1653, DOI 10.1016/j.yexcr.2009.03.007; Shimura T, 2013, CELL CYCLE, V12, P773, DOI 10.4161/cc.23719; Tort F, 2006, CANCER RES, V66, P10258, DOI 10.1158/0008-5472.CAN-06-2178; Urzua-Traslavina CG, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21671-w; Wengner AM, 2020, MOL CANCER THER, V19, P26, DOI 10.1158/1535-7163.MCT-19-0019; Williamson CT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13837; Young LA, 2019, CANCER RES, V79, P3762, DOI 10.1158/0008-5472.CAN-18-2480; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897	50	3	3	3	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1216	1224		10.1038/s41388-021-02162-0	http://dx.doi.org/10.1038/s41388-021-02162-0		JAN 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	35091678	Green Submitted, Green Accepted			2022-12-17	WOS:000749073200001
J	Zhang, WY; Chen, SY; Du, Q; Bian, PP; Chen, YT; Liu, ZX; Zheng, J; Sai, K; Mou, YG; Chen, ZP; Fan, X; Jiang, XB				Zhang, Weiyu; Chen, Siyu; Du, Qiu; Bian, Piaopiao; Chen, Yutong; Liu, Zexian; Zheng, Jian; Sai, Ke; Mou, Yonggao; Chen, Zhongping; Fan, Xiang; Jiang, Xiaobing			CircVPS13C promotes pituitary adenoma growth by decreasing the stability of IFITM1 mRNA via interacting with RRBP1	ONCOGENE			English	Article							RIBOSOME-BINDING PROTEIN-1; CIRCULAR RNA; COLORECTAL-CANCER; TRANSLOCATION; EPIDEMIOLOGY; EXPRESSION; INDUCTION; APOPTOSIS; PATHWAY	CircRNAs play important roles in a variety of biological processes by acting as microRNA sponges and protein scaffolds or by encoding functional proteins. However, their functions and underlying mechanisms remain largely unknown. Distinctive circRNA patterns were explored by comparing nonfunctioning pituitary adenomas (NFPAs) and normal pituitary tissues with a circRNA array. The biological functions of selected circRNAs were determined in vitro and in vivo. RNA-seq and circRNA pulldown assays were applied to investigate the underlying mechanisms. The circRNA profile of NFPAs is tremendously different from that of normal pituitary tissues. CircVPS13C is significantly upregulated in NFPA samples and cell lines. Gain- and loss-of-function experiments demonstrate that silencing circVPS13C inhibits the proliferation of pituitary tumor cells in vitro and in vivo. Mechanistically, circVPS13C silencing increases the expression of IFITM1 and subsequently activates its downstream genes involved in MAPK- and apoptosis-associated signaling pathways. Rescue experiments show that IFITM1 overexpression partly reverses the biological effects of circVPS13C. Further studies reveal that circVPS13C inhibits IFITM1 expression through a novel mechanism mainly by competitively interacting with RRBP1, a ribosome-binding protein of the endoplasmic reticulum membrane, and thereby alleviating the stability of IFITM1 mRNA. Clinically, circVPS13C expression is markedly higher in high-risk NFPA samples and is downregulated in patient serum 7 days post-transsphenoidal adenoma resection. Our findings suggest that circVPS13C is a critical regulator in the proliferation and development of NFPAs through a novel mechanism, whereby regulating mRNA stability via interacting with ribosome-binding proteins on the endoplasmic reticulum membrane.	[Zhang, Weiyu; Chen, Siyu; Du, Qiu; Bian, Piaopiao; Sai, Ke; Mou, Yonggao; Chen, Zhongping; Jiang, Xiaobing] Sun Yat Sen Univ, Dept Neurosurg Neurooncol, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou, Peoples R China; [Zhang, Weiyu; Fan, Xiang] Sun Yat Sen Univ, Dept Neurosurg, Affiliated Hosp 5, Zhuhai, Peoples R China; [Du, Qiu] Yangzhou Univ, Dept Neurosurg, Affiliated Hosp, Yangzhou, Jiangsu, Peoples R China; [Bian, Piaopiao] Guangzhou Med Univ, Dept Pathol, Affiliated Hosp 3, Guangzhou, Peoples R China; [Chen, Yutong] Sun Yat Sen Univ, Affiliated Hosp 5, Canc Ctr, Dept Abdominal Oncol, Zhuhai, Peoples R China; [Liu, Zexian; Zheng, Jian] Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China; [Jiang, Xiaobing] Jiangmen Cent Hosp, Dept Neurosurg, Jiangmen, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Yangzhou University; Guangzhou Medical University; Sun Yat Sen University; State Key Lab Oncology South China	Jiang, XB (corresponding author), Sun Yat Sen Univ, Dept Neurosurg Neurooncol, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou, Peoples R China.; Fan, X (corresponding author), Sun Yat Sen Univ, Dept Neurosurg, Affiliated Hosp 5, Zhuhai, Peoples R China.; Jiang, XB (corresponding author), Jiangmen Cent Hosp, Dept Neurosurg, Jiangmen, Peoples R China.	xiangfan@msn.com; jiangxiaob1@sysucc.org.cn	CHEN, SI/GZL-4800-2022	Liu, Ze-Xian/0000-0001-9698-0610; Zheng, Jian/0000-0001-9831-7038; chen, zhongping/0000-0002-6226-5771; zhang, weiyu/0000-0002-8928-6636	National Natural Science Foundation of China for Young Scholars [81702479]; Guangdong Basic and Applied Basic Research Foundation [2020A151501281]; Science and Technology Program of Jiangmen, China [2018630100110019805]; Natural Science Foundation of Jiangsu Province [BK20200936]	National Natural Science Foundation of China for Young Scholars(National Natural Science Foundation of China (NSFC)); Guangdong Basic and Applied Basic Research Foundation; Science and Technology Program of Jiangmen, China; Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province)	This research was supported by the National Natural Science Foundation of China for Young Scholars (grant number 81702479 to XJ), Guangdong Basic and Applied Basic Research Foundation (grant number 2020A151501281 to XJ), Science and Technology Program of Jiangmen, China (grant number 2018630100110019805 to YM), and the Natural Science Foundation of Jiangsu Province (grant number BK20200936 to QD).	Abdelmohsen K, 2017, RNA BIOL, V14, P361, DOI 10.1080/15476286.2017.1279788; Abe N, 2015, SCI REP-UK, V5, DOI 10.1038/srep16435; Aflorei ED, 2014, J NEURO-ONCOL, V117, P379, DOI 10.1007/s11060-013-1354-5; Agustsson TT, 2015, EUR J ENDOCRINOL, V173, P655, DOI 10.1530/EJE-15-0189; Brass AL, 2009, CELL, V139, P1243, DOI 10.1016/j.cell.2009.12.017; Chen NF, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1594-y; Cui XYA, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001336; Danila DC, 2000, J CLIN ENDOCR METAB, V85, P1180, DOI 10.1210/jc.85.3.1180; DEBLANDRE GA, 1995, J BIOL CHEM, V270, P23860, DOI 10.1074/jbc.270.40.23860; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Du Q, 2019, J CLIN ENDOCR METAB, V104, P2419, DOI 10.1210/jc.2018-01851; Du WW, 2017, CELL DEATH DIFFER, V24, P357, DOI 10.1038/cdd.2016.133; Escher TE, 2019, MOL CANCER RES, V17, P1180, DOI 10.1158/1541-7786.MCR-18-0916; Esposito D, 2019, PITUITARY, V22, P422, DOI 10.1007/s11102-019-00960-0; Grow EJ, 2015, NATURE, V522, P221, DOI 10.1038/nature14308; Guo JU, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0409-z; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Hatano H, 2008, CLIN CANCER RES, V14, P6097, DOI 10.1158/1078-0432.CCR-07-4761; Huang AQ, 2020, THERANOSTICS, V10, P3503, DOI 10.7150/thno.42174; Hyde M, 2002, J CELL BIOL, V156, P993, DOI 10.1083/jcb.200112008; Jagannathan S, 2014, J BIOL CHEM, V289, P25907, DOI 10.1074/jbc.M114.580688; Jasim S, 2017, ENDOCRINE, V56, P33, DOI 10.1007/s12020-016-1159-3; Kristensen LS, 2019, NAT REV GENET, V20, P675, DOI 10.1038/s41576-019-0158-7; Legnini I, 2017, MOL CELL, V66, P22, DOI 10.1016/j.molcel.2017.02.017; Lei M, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1135-7; Liang XS, 2015, CANCER SCI, V106, P740, DOI 10.1111/cas.12666; Melmed S, 2020, NEW ENGL J MED, V382, P937, DOI 10.1056/NEJMra1810772; Mete O, 2017, ENDOCR PATHOL, V28, P228, DOI 10.1007/s12022-017-9498-z; Ng WL, 2018, RNA BIOL, V15, P995, DOI 10.1080/15476286.2018.1486659; Pan Y, 2015, BRIT J CANCER, V113, P763, DOI 10.1038/bjc.2015.260; Piovesan D, 2016, NUCLEIC ACIDS RES, V44, pW367, DOI 10.1093/nar/gkw315; SAVITZ AJ, 1993, J CELL BIOL, V120, P853, DOI 10.1083/jcb.120.4.853; Song ZJ, 2016, CELL RES, V26, P1255, DOI 10.1038/cr.2016.114; Tsai HY, 2013, ONCOGENE, V32, P4921, DOI 10.1038/onc.2012.514; Yacqub-Usman K, 2012, NAT REV ENDOCRINOL, V8, P486, DOI 10.1038/nrendo.2012.54; Yanez DC, 2020, IMMUNOLOGY, V159, P365, DOI 10.1111/imm.13163; Yang G, 2007, ONCOGENE, V26, P594, DOI 10.1038/sj.onc.1209807; Yang J, 2018, CANCER SCI, V109, P3115, DOI 10.1111/cas.13640; Yang Yibing, 2018, J Natl Cancer Inst, V110, DOI 10.1093/jnci/djx166; Yang ZG, 2017, MOL THER, V25, P2062, DOI 10.1016/j.ymthe.2017.05.022; Yu F, 2015, CANCER LETT, V368, P135, DOI 10.1016/j.canlet.2015.07.034; Zhang LL, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01224-3; Zhang SJ, 2012, EUR J CANCER, V48, P389, DOI 10.1016/j.ejca.2011.11.002	43	3	3	11	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2022	41	11					1550	1562		10.1038/s41388-022-02186-0	http://dx.doi.org/10.1038/s41388-022-02186-0		JAN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ8WH	35091683				2022-12-17	WOS:000749073300005
J	Zigrossi, A; Hong, LK; Ekyalongo, RC; Cruz-Alvarez, C; Gornick, E; Diamond, AM; Kastrati, I				Zigrossi, Alexandra; Hong, Lenny K.; Ekyalongo, Roudy C.; Cruz-Alvarez, Cindy; Gornick, Emily; Diamond, Alan M.; Kastrati, Irida			SELENOF is a new tumor suppressor in breast cancer	ONCOGENE			English	Article							15-KDA SELENOPROTEIN; SEP15; PROTEIN; ROLES	Epidemiological evidence has indicated an inverse association between selenium status and various types of cancer, including breast cancer. Selenoproteins are the primary mediators of selenium effects in human health. We have previously reported loss of heterozygosity in breast tumor samples of the gene for one of the selenoproteins, SELENOF. The function of SELENOF remains unclear and whether SELENOF levels impact breast cancer risk or outcome is unknown. The mining of breast cancer patient databases revealed that SELENOF mRNA is significantly lower in late-stage tumor samples and lower levels of SELENOF also predict poor patient outcome from breast cancer. Genetically manipulating SELENOF in human breast cancer cells or in the murine mammary gland by overexpression, silencing or knockout impacted cell viability by affecting both proliferation and cell death. Restoring SELENOF can attenuate a number of aggressive cancer phenotypes in breast cancer cells, including clonogenic survival, and enhance the response to drugs or radiation used in breast cancer therapy. Importantly, enhancing SELENOF expression reduced in vivo tumor growth in a murine xenograft model of breast cancer. These data indicate that SELENOF is a new tumor suppressor in breast cancer.	[Zigrossi, Alexandra; Ekyalongo, Roudy C.; Cruz-Alvarez, Cindy; Gornick, Emily; Kastrati, Irida] Loyola Univ Chicago, Dept Canc Biol, Maywood, IL 60153 USA; [Hong, Lenny K.; Diamond, Alan M.] Univ Illinois, Dept Pathol, Chicago, IL 60612 USA	Loyola University Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kastrati, I (corresponding author), Loyola Univ Chicago, Dept Canc Biol, Maywood, IL 60153 USA.	ikastrati@luc.edu		Kastrati, Irida/0000-0002-8086-1411	LUC funds; Office of the Assistant Secretary of Defense for Health Affairs through the Prostate Cancer Research Program [W81XWH-17-PCRP-HDRA]	LUC funds; Office of the Assistant Secretary of Defense for Health Affairs through the Prostate Cancer Research Program	This work was supported by LUC funds to IK and by the Office of the Assistant Secretary of Defense for Health Affairs through the Prostate Cancer Research Program under Award No. W81XWH-17-PCRP-HDRA to AMD. These funding sources had no involvement in the data presented here.	Apostolou S, 2004, ONCOGENE, V23, P5032, DOI 10.1038/sj.onc.1207683; Ekoue DN, 2018, PROSTATE, V78, P279, DOI 10.1002/pros.23471; El-Bayoumy K, 1991, ROLE SELENIUM CANC P; Gladyshev VN, 2016, J BIOL CHEM, V291, P24036, DOI 10.1074/jbc.M116.756155; Gladyshev VN, 1998, J BIOL CHEM, V273, P8910, DOI 10.1074/jbc.273.15.8910; Guzman C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092444; Hatfield DL, 2002, MOL CELL BIOL, V22, P3565, DOI 10.1128/MCB.22.11.3565-3576.2002; Hatfield DL, 2014, TRENDS BIOCHEM SCI, V39, P112, DOI 10.1016/j.tibs.2013.12.007; Hetz C, 2020, NAT REV MOL CELL BIO, V21, P421, DOI 10.1038/s41580-020-0250-z; Hong LK, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222112040; Hu YJ, 2001, CANCER RES, V61, P2307; Hudson TS, 2012, CARCINOGENESIS, V33, P1225, DOI 10.1093/carcin/bgs129; Irons R, 2010, CANCER PREV RES, V3, P630, DOI 10.1158/1940-6207.CAPR-10-0003; Kasaikina MV, 2011, J BIOL CHEM, V286, P33203, DOI 10.1074/jbc.M111.259218; Korotkov KV, 2001, J BIOL CHEM, V276, P15330, DOI 10.1074/jbc.M009861200; Kumaraswamy E, 2002, METHOD ENZYMOL, V347, P187; Labunskyy VM, 2007, IUBMB LIFE, V59, P1, DOI 10.1080/15216540601126694; Labunskyy VM, 2014, PHYSIOL REV, V94, P739, DOI 10.1152/physrev.00039.2013; Labunskyy VM, 2009, BIOCHEMISTRY-US, V48, P8458, DOI 10.1021/bi900717p; Penney KL, 2010, CANCER PREV RES, V3, P604, DOI 10.1158/1940-6207.CAPR-09-0216; Schomburg L, 2009, BBA-GEN SUBJECTS, V1790, P1453, DOI 10.1016/j.bbagen.2009.03.015; SCHRAUZER GN, 1977, BIOINORG CHEM, V7, P23, DOI 10.1016/S0006-3061(00)80126-X; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Stadtman TC, 2000, ANN NY ACAD SCI, V899, P399, DOI 10.1111/j.1749-6632.2000.tb06203.x; Tsuji PA, 2011, NUTRIENTS, V3, P805, DOI 10.3390/nu3090805; Xun PC, 2011, ENVIRON RES, V111, P514, DOI 10.1016/j.envres.2011.01.016; Yim SH, 2018, CELL REP, V23, P1387, DOI 10.1016/j.celrep.2018.04.009; Zhang Y, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9050383	28	3	3	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2022	41	9					1263	1268		10.1038/s41388-021-02158-w	http://dx.doi.org/10.1038/s41388-021-02158-w		JAN 2022	6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZI1MQ	35082382				2022-12-17	WOS:000749084700002
J	Flum, M; Dicks, S; Teng, YH; Schrempp, M; Nystrom, A; Boerries, M; Hecht, A				Flum, Marion; Dicks, Severin; Teng, Yu-Hsiang; Schrempp, Monika; Nystroem, Alexander; Boerries, Melanie; Hecht, Andreas			Canonical TGF beta signaling induces collective invasion in colorectal carcinogenesis through a Snail1-and Zeb1-independent partial EMT	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CONSENSUS MOLECULAR SUBTYPES; COMPETITIVE DISPLACEMENT; CANCER PROGRESSION; DRIVES METASTASIS; TUMOR-SUPPRESSOR; MOUSE MODELS; CELL; EXPRESSION; TRANSPLANTATION	Local invasion is the initial step towards metastasis, the main cause of cancer mortality. In human colorectal cancer (CRC), malignant cells predominantly invade as cohesive collectives and may undergo partial epithelial-mesenchymal transition (pEMT) at the invasive front. How this particular mode of stromal infiltration is generated is unknown. Here we investigated the impact of oncogenic transformation and the microenvironment on tumor cell invasion using genetically engineered organoids as CRC models. We found that inactivation of the Apc tumor suppressor combined with expression of oncogenic Kras(G12D) and dominant-negative Trp53(R172H) did not cell-autonomously induce invasion in vitro. However, oncogenic transformation primed organoids for activation of a collective invasion program upon exposure to the prototypical microenvironmental factor TGF beta 1. Execution of this program co-depended on a permissive extracellular matrix which was further actively remodeled by invading organoids. Although organoids shed some epithelial properties particularly at the invasive edge, TGF beta 1-stimulated organoids largely maintained epithelial gene expression while additionally implementing a mesenchymal transcription pattern, resulting in a pEMT phenotype that did not progress to a fully mesenchymal state. Notably, while TGF beta 1 induced pEMT and promoted collective invasion, it abrogated self-renewal capacity of TKA organoids which correlated with the downregulation of intestinal stem cell (ISC) marker genes. Mechanistically, induction of the non-progressive pEMT required canonical TGF beta signaling mediated by Smad transcription factors (TFs), whereas the EMT master regulators Snail1 and Zeb1 were dispensable. Gene expression profiling provided further evidence for pEMT of TGF beta 1-treated organoids and showed that their transcriptomes resemble those of human poor prognosis CMS4 cancers which likewise exhibit pEMT features. We propose that collective invasion in colorectal carcinogenesis is triggered by microenvironmental stimuli through activation of a novel, transcription-mediated form of non-progressive pEMT independently of classical EMT regulators.	[Flum, Marion; Teng, Yu-Hsiang; Schrempp, Monika; Hecht, Andreas] Univ Freiburg, Fac Med, Inst Mol Med & Cell Res, D-79104 Freiburg, Germany; [Flum, Marion] Univ Freiburg, Spemann Grad Sch Biol & Med SGBM, D-79104 Freiburg, Germany; [Flum, Marion; Dicks, Severin; Teng, Yu-Hsiang; Hecht, Andreas] Univ Freiburg, Fac Biol, D-79104 Freiburg, Germany; [Dicks, Severin; Boerries, Melanie] Univ Freiburg, Med Ctr Univ Freiburg, Fac Med, Inst Med Bioinformat & Syst Med, D-79110 Freiburg, Germany; [Nystroem, Alexander] Univ Freiburg, Med Ctr Univ Freiburg, Fac Med, Dept Dermatol, D-79104 Freiburg, Germany; [Nystroem, Alexander] Univ Freiburg, Freiburg Inst Adv Studies FRIAS, D-79104 Freiburg, Germany; [Boerries, Melanie] Univ Freiburg, German Canc Consortium DKTK, D-79104 Freiburg, Germany; [Boerries, Melanie] German Canc Res Ctr, D-69120 Heidelberg, Germany; [Hecht, Andreas] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, D-79104 Freiburg, Germany	University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg	Hecht, A (corresponding author), Univ Freiburg, Fac Med, Inst Mol Med & Cell Res, D-79104 Freiburg, Germany.; Hecht, A (corresponding author), Univ Freiburg, Fac Biol, D-79104 Freiburg, Germany.; Hecht, A (corresponding author), Univ Freiburg, BIOSS Ctr Biol Signalling Studies, D-79104 Freiburg, Germany.	andreas.hecht@mol-med.uni-freiburg.de		Nystrom, Alexander/0000-0002-4666-2240	Excellence Initiative of the German Research Foundation (GSC-4, Spemann Graduate School); Ministry for Science, Research and Arts of the State of Baden-Wuerttemberg; Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [322977937/GRK2344, CRC-850, CRC-1479, 441891347-S1, CRC-1160, CRC-1453, 431984000 -S1, TRR167]; German Federal Ministry of Education and Research (BMBF) [FKZ 01ZZ1801B]	Excellence Initiative of the German Research Foundation (GSC-4, Spemann Graduate School); Ministry for Science, Research and Arts of the State of Baden-Wuerttemberg; Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)(German Research Foundation (DFG)); German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF))	We are grateful to the team of the Genomics and Proteomics Core Facility, German Cancer Research Center/DKFZ, Heidelberg, Germany, for NGS services, and to the staff of the Life Imaging Center (LIC) at the Center for Biological Systems Analysis (ZBSA) of the Albert-Ludwigs-University Freiburg for help with confocal microscopy. We especially appreciate the excellent support in image recording and analysis. We thank Hecht lab members for critical reading of the manuscript and Vivien Freihen for her invaluable advice and initial introduction to the handling of intestinal organoids. This study was supported in part by the Excellence Initiative of the German Research Foundation (GSC-4, Spemann Graduate School) and in part by the Ministry for Science, Research and Arts of the State of Baden-Wuerttemberg. Additional financial support was obtained from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) (Grant number 322977937/GRK2344 to AH; CRC-850 subprojects B5 to AH, B11 to AN, and Z1 to MB; CRC-1479 project ID: 441891347-S1 to MB, CRC-1160 project Z02 to MB, CRC-1453 project ID 431984000 -S1 to MB, and TRR167 project Z01 to MB), and from the German Federal Ministry of Education and Research (BMBF) within the framework of the e:Med research and funding concept CoNfirm (FKZ 01ZZ1801B to MB).	Aiello NM, 2018, DEV CELL, V45, P681, DOI 10.1016/j.devcel.2018.05.027; Balwierz PJ, 2014, GENOME RES, V24, P869, DOI 10.1101/gr.169508.113; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Bays JL, 2017, CELL MOL LIFE SCI, V74, P2999, DOI 10.1007/s00018-017-2511-3; Beyes S, 2019, ONCOGENE, V38, P6647, DOI 10.1038/s41388-019-0905-4; Boutin AT, 2017, GENE DEV, V31, P370, DOI 10.1101/gad.293449.116; Bronsert P, 2014, J PATHOL, V234, P410, DOI 10.1002/path.4416; Brown KA, 2007, J CELL BIOCHEM, V101, P9, DOI 10.1002/jcb.21255; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Caravagna G, 2018, NAT METHODS, V15, P707, DOI 10.1038/s41592-018-0108-x; Carstens JL, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.108990; Celia-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Danen EHJ, 2002, J CELL BIOL, V159, P1071, DOI 10.1083/jcb.200205014; Dekkers JF, 2013, NAT MED, V19, P939, DOI 10.1038/nm.3201; Derynck R, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aav5183; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Drost J, 2015, NATURE, V521, P43, DOI 10.1038/nature14415; Eide PW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16747-x; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Feng Gang, 2010, BMC Res Notes, V3, P10, DOI 10.1186/1756-0500-3-10; Fessler E, 2016, EMBO MOL MED, V8, P745, DOI 10.15252/emmm.201606184; Fox J., 2011, R COMPANION APPL REG, V2; Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548; Fumagalli A, 2020, CELL STEM CELL, V26, P569, DOI 10.1016/j.stem.2020.02.008; Fumagalli A, 2017, P NATL ACAD SCI USA, V114, pE2357, DOI 10.1073/pnas.1701219114; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Gotzmann J, 2006, ONCOGENE, V25, P3170, DOI 10.1038/sj.onc.1209083; Groger CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051136; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Isella C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15107; Izumi D, 2015, J CANC METASTASIS TR, V1, P156, DOI DOI 10.4103/2394-4722.165532; Jechlinger M, 2003, ONCOGENE, V22, P7155, DOI 10.1038/sj.onc.1206887; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kariya Y, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02003-6; Kroger C, 2019, P NATL ACAD SCI USA, V116, P7353, DOI 10.1073/pnas.1812876116; Kuonen F, 2018, J INVEST DERMATOL, V138, P2432, DOI 10.1016/j.jid.2018.04.029; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Li XN, 2014, NAT MED, V20, P769, DOI 10.1038/nm.3585; Linnekamp JF, 2018, CELL DEATH DIFFER, V25, P616, DOI 10.1038/s41418-017-0011-5; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Mak MP, 2016, CLIN CANCER RES, V22, P609, DOI 10.1158/1078-0432.CCR-15-0876; Maschler S, 2005, ONCOGENE, V24, P2032, DOI 10.1038/sj.onc.1208423; Matano M, 2015, NAT MED, V21, P256, DOI 10.1038/nm.3802; McFaline-Figueroa JL, 2019, NAT GENET, V51, P1389, DOI 10.1038/s41588-019-0489-5; Mise N, 2012, J BIOL CHEM, V287, P31393, DOI 10.1074/jbc.M112.357624; Moren A, 2005, J BIOL CHEM, V280, P22115, DOI 10.1074/jbc.M414027200; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; Nissen NI, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1110-6; Nystrom A, 2015, EMBO MOL MED, V7, P1211, DOI 10.15252/emmm.201505061; O'Rourke KP, 2017, NAT BIOTECHNOL, V35, P577, DOI 10.1038/nbt.3837; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Pape J, 2020, BRIT J CANCER, V123, P1178, DOI 10.1038/s41416-020-0973-9; Pastushenko I, 2019, TRENDS CELL BIOL, V29, P212, DOI 10.1016/j.tcb.2018.12.001; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044; Ronsch K, 2015, MOL ONCOL, V9, P335, DOI 10.1016/j.molonc.2014.08.016; Roper J, 2017, NAT BIOTECHNOL, V35, P569, DOI 10.1038/nbt.3836; RStudio Team, 2017, RSTUDIO INT DEV R VE; Sakai E, 2018, CANCER RES, V78, P1334, DOI 10.1158/0008-5472.CAN-17-3303; Schnappauf O, 2016, BBA-GENE REGUL MECH, V1859, P1353, DOI 10.1016/j.bbagrm.2016.08.002; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Simeonov KP, 2021, CANCER CELL, V39, P1150, DOI 10.1016/j.ccell.2021.05.005; Singh P, 2010, ANNU REV CELL DEV BI, V26, P397, DOI 10.1146/annurev-cellbio-100109-104020; Stemmler MP, 2019, NAT CELL BIOL, V21, P102, DOI 10.1038/s41556-018-0196-y; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492; Tauriello DVF, 2017, MOL ONCOL, V11, P97, DOI 10.1002/1878-0261.12018; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Wenzel J, 2020, ONCOGENE, V39, P3893, DOI 10.1038/s41388-020-1259-7; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wiener Z, 2014, P NATL ACAD SCI USA, V111, pE2229, DOI 10.1073/pnas.1406444111; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004; Zhang JY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005304; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064; Zhou Yujuan, 2018, Oncotarget, V9, P33403, DOI 10.18632/oncotarget.23607	83	3	3	5	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2022	41	10					1492	1506		10.1038/s41388-022-02190-4	http://dx.doi.org/10.1038/s41388-022-02190-4		JAN 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN2JO	35075245	Green Published, Green Submitted, hybrid			2022-12-17	WOS:000746328800001
J	Chen, Q; Zhuang, SQ; Hong, YL; Yang, LT; Guo, P; Mo, PL; Peng, KS; Li, WG; Xiao, NM; Yu, CD				Chen, Qiang; Zhuang, Shuqing; Hong, Yilin; Yang, Lingtao; Guo, Peng; Mo, Pingli; Peng, Kesong; Li, Wengang; Xiao, Nengming; Yu, Chundong			Demethylase JMJD2D induces PD-L1 expression to promote colorectal cancer immune escape by enhancing IFNGR1-STAT3-IRF1 signaling	ONCOGENE			English	Article							IFN-GAMMA; MECHANISMS; PROGRESSION; PATHWAY	Programmed death-ligand 1 (PD-L1) is an important immunosuppressive molecule highly expressed on the surface of cancer cells. IFN gamma triggered cancer cell immunosuppression against CD8(+) T cell surveillance via up-regulation of PD-L1. Histone demethylase JMJD2D promotes colorectal cancer (CRC) progression; however, the role of JMJD2D in cancer immune escape is unknown. Here, we report that both PD-L1 and JMJD2D are frequently overexpressed in human CRC specimens with a significant positive correlation. Genetic ablation of JMJD2D in CRC cells attenuated the expression of PD-L1 and stalled tumor growth in mice, accompanied by the elevated number and effector function of tumor infiltrating CD8(+) T cells. Mechanistically, JMJD2D coactivated SP-1 to promote the expression of IFNGR1, which elevated STAT3-IRF1 signaling and promoted PD-L1 expression. Again, JMJD2D is a major coactivator for STAT3-IRF1 axis to enhance PD-L1 transcription in a demethylation activity dependent manner. Furthermore, pharmacological inhibition of JMJD2D conduced to improve the anti-tumor efficacy of PD-L1 antibody as demonstrated by slower tumor growth and higher infiltration and function of CD8(+) T cells in the combination of JMJD2D inhibitor 5-c-8HQ and PD-L1 antibody group compared with monotherapy with either agent. These results demonstrate that JMJD2D promotes CRC immune escape by enhancing PD-L1 expression to inhibit the activation and tumor infiltration of CD8(+) T cells; targeting JMJD2D has the potential role in promoting the efficacy of anti-PD-1/PD-L1 immunotherapy.	[Chen, Qiang; Zhuang, Shuqing; Hong, Yilin; Yang, Lingtao; Guo, Peng; Mo, Pingli; Xiao, Nengming; Yu, Chundong] Xiamen Univ, Innovat Ctr Cell Biol, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen, Peoples R China; [Peng, Kesong] Fudan Univ, Sch Basic Med Sci, Dept Cellular & Genet Med, Shanghai, Peoples R China; [Li, Wengang] Xiamen Univ, Canc Res Ctr, Sch Med, Xiamen, Peoples R China; [Li, Wengang] Xiamen Univ, Xiangan Hosp, Res Ctr Retroperitoneal Tumor Comm Oncol Soc, Chinese Med Assoc,Sch Med, Xiamen, Peoples R China	Xiamen University; Fudan University; Xiamen University; Xiamen University	Xiao, NM; Yu, CD (corresponding author), Xiamen Univ, Innovat Ctr Cell Biol, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen, Peoples R China.; Peng, KS (corresponding author), Fudan Univ, Sch Basic Med Sci, Dept Cellular & Genet Med, Shanghai, Peoples R China.; Li, WG (corresponding author), Xiamen Univ, Canc Res Ctr, Sch Med, Xiamen, Peoples R China.; Li, WG (corresponding author), Xiamen Univ, Xiangan Hosp, Res Ctr Retroperitoneal Tumor Comm Oncol Soc, Chinese Med Assoc,Sch Med, Xiamen, Peoples R China.	kesongpeng@fudan.edu.cn; lwgang@xmu.edu.cn; nengming@xmu.edu.cn; cdyu@xmu.edu.cn		Peng, Kesong/0000-0001-9035-3421	National Natural Science Foundation of China [81970485, 81772942, 31570883, 81972223]; Scientific Research Foundation for Advanced Talents, Xiang'an Hospital of Xiamen University [PM20180917008]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Scientific Research Foundation for Advanced Talents, Xiang'an Hospital of Xiamen University	This work was supported by the National Natural Science Foundation of China (No. 81970485 and No. 81772942 to Chundong Yu, No. 31570883 to Nengming Xiao, No. 81972223 to Wengang Li); Scientific Research Foundation for Advanced Talents, Xiang'an Hospital of Xiamen University (No. PM20180917008 to Wengang Li).	Abiko K, 2015, BRIT J CANCER, V112, P1501, DOI 10.1038/bjc.2015.101; Canedo P, 2008, GUT, V57, P1504, DOI 10.1136/gut.2007.143578; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; Cha JH, 2019, MOL CELL, V76, P359, DOI 10.1016/j.molcel.2019.09.030; Chen CG, 2012, AM J PATHOL, V180, P661, DOI 10.1016/j.ajpath.2011.10.040; Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0; Deng SY, 2019, MOL CANCER THER, V18, P900, DOI 10.1158/1535-7163.MCT-18-1068; Doi T, 2017, ONCOL REP, V37, P1545, DOI 10.3892/or.2017.5399; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Du LY, 2020, J EXP MED, V217, DOI 10.1084/jem.20191115; Garcia-Diaz A, 2017, CELL REP, V19, P1189, DOI 10.1016/j.celrep.2017.04.031; Guo R, 2019, CANCER SCI, V110, P1665, DOI 10.1111/cas.13989; Hogg SJ, 2017, CELL REP, V18, P2162, DOI 10.1016/j.celrep.2017.02.011; Kim EY, 2017, LUNG CANCER, V110, P63, DOI 10.1016/j.lungcan.2017.06.006; Lee HT, 2019, MOLECULES, V24, DOI 10.3390/molecules24061190; Lim SO, 2016, CANCER CELL, V30, P925, DOI 10.1016/j.ccell.2016.10.010; Lin CF, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0317-0; Lu CW, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw283; Luo N, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1438106; Mimura K, 2018, CANCER SCI, V109, P43, DOI 10.1111/cas.13424; Peng KS, 2020, ONCOGENE, V39, P7076, DOI 10.1038/s41388-020-01483-w; Peng KS, 2019, GASTROENTEROLOGY, V156, P1112, DOI 10.1053/j.gastro.2018.11.036; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Sheng Q, 2020, CLIN EXP IMMUNOL, V200, P45, DOI 10.1111/cei.13406; Singh S, 2020, NAT CELL BIOL, V22, P591, DOI 10.1038/s41556-020-0495-y; Sun L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0988-9; Tannenbaum CS, 2000, SEMIN CANCER BIOL, V10, P113, DOI 10.1006/scbi.2000.0314; Tong ZW, 2015, J BIOL CHEM, V290, P18596, DOI 10.1074/jbc.M115.640490; Vesely MD, 2011, ANNU REV IMMUNOL, V29, P235, DOI 10.1146/annurev-immunol-031210-101324; Walter MR, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.606489; Wang Y, 2018, CELL CYCLE, V17, P1457, DOI 10.1080/15384101.2018.1489177; Wang YH, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0346-6; Woods DM, 2015, CANCER IMMUNOL RES, V3, P1375, DOI 10.1158/2326-6066.CIR-15-0077-T; Xiao G, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0784-9; Zhao YT, 2019, BIOCHEM BIOPH RES CO, V517, P201, DOI 10.1016/j.bbrc.2019.07.039; Zhu HR, 2016, CELL REP, V16, P2829, DOI 10.1016/j.celrep.2016.08.032; Zhuo MH, 2020, ONCOGENE, V39, P3336, DOI 10.1038/s41388-020-1219-2; Zingg D, 2017, CELL REP, V20, P854, DOI 10.1016/j.celrep.2017.07.007	39	3	3	9	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2022	41	10					1421	1433		10.1038/s41388-021-02173-x	http://dx.doi.org/10.1038/s41388-021-02173-x		JAN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN2JO	35027670				2022-12-17	WOS:000742332000001
J	Shu, L; Chen, A; Li, LR; Yao, L; He, YD; Xu, JB; Gu, W; Li, Q; Wang, K; Zhang, TC; Liu, GQ				Shu, Le; Chen, Ao; Li, Linrui; Yao, Lun; He, Yiduo; Xu, Jianbo; Gu, Wei; Li, Qiang; Wang, Kun; Zhang, Tongcun; Liu, Guoquan			NRG1 regulates Fra-1 transcription and metastasis of triple-negative breast cancer cells via the c-Myc ubiquitination as manipulated by ERK1/2-mediated Fbxw7 phosphorylation	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; INVASIVENESS; EXPRESSION; HEREGULIN; MICROENVIRONMENT; PROTOONCOGENE; DEGRADATION; INDUCTION; MOTILITY; RNA	Neuregulin 1 (NRG1), an EGF family member, is expressed in most breast cancers. It promotes breast cancer growth and metastasis in HER2 receptor expressing breast cancer. However, its role in triple-negative breast cancer (TNBC) has not been extensively investigated. In this study, we observed that NRG1 knockdown resulted in the suppression of TNBC cells (MDA-MB-231 cell and MDA-MB-468 cell) metastasis and downregulation of Fra-1 (FOS-like 1, AP-1 transcription factor subunit, which is an overexpressed transcription factor in TNBC and acts as a coordinator of metastasis). In addition, the transcriptional regulation of Fra-1 by NRG1 was mediated by ERK1/2-induced recruitment of c-Myc (MYC proto-oncogene, transcription factor) to the promoter of Fra-1. Furthermore, c-Myc was targeted by an E3 ligase Fbxw7 and its ubiquitination and degradation by Fbxw7 was regulated by NRG1 expression and ERK1/2-mediated Fbxw7 phosphorylation that results in the dissociation and nuclear import of c-Myc. Taken together, the results of our study demonstrated that NRG1 regulates the Fra-1 expression to coordinate the TNBC metastasis via the novel ERK1/2-Fbxw7-c-Myc pathway and targeting NRG1 expression could be a potential therapeutic strategy for TNBC.	[Shu, Le; Gu, Wei; Li, Qiang; Liu, Guoquan] Bengbu Med Coll, Anhui Prov Key Lab Translat Canc Res, Bengbu 233030, Anhui, Peoples R China; [Chen, Ao; Zhang, Tongcun] Wuhan Univ Sci & Technol, Coll Life Sci & Hlth, Inst Biol & Med, Wuhan 430070, Hubei, Peoples R China; [Li, Linrui; Yao, Lun] Huazhong Agr Univ, Coll Anim Sci & Vet Med, Wuhan 430070, Hubei, Peoples R China; [He, Yiduo; Xu, Jianbo] Huazhong Agr Univ, Coll Life Sci & Technol, Wuhan 430070, Hubei, Peoples R China; [Gu, Wei; Liu, Guoquan] Bengbu Med Coll, Sch Lab Med, Dept Biochem & Mol Biol, Bengbu 233030, Anhui, Peoples R China; [Li, Qiang] Bengbu Med Coll, Sch Biol Sci, Dept Cell Biol, Bengbu 233030, Anhui, Peoples R China; [Wang, Kun] Hubei Univ Med, Coll Biomed Engn, Shiyan 442000, Hubei, Peoples R China; [Zhang, Tongcun] Tianjin Univ Sci & Technol, Coll Biotechnol, Key Lab Ind Fermentat Microbiol, Minist Educ & Tianjin, Tianjin 300457, Peoples R China	Bengbu Medical College; Wuhan University of Science & Technology; Huazhong Agricultural University; Huazhong Agricultural University; Bengbu Medical College; Bengbu Medical College; Hubei University of Medicine; Tianjin University Science & Technology	Shu, L; Liu, GQ (corresponding author), Bengbu Med Coll, Anhui Prov Key Lab Translat Canc Res, Bengbu 233030, Anhui, Peoples R China.; Liu, GQ (corresponding author), Bengbu Med Coll, Sch Lab Med, Dept Biochem & Mol Biol, Bengbu 233030, Anhui, Peoples R China.	Leshu0101@163.com; guoquanliu@bbmc.edu.cn	Zhang, Tong/HGC-1090-2022	Chen, Ao/0000-0002-2330-0650	National Natural Science Foundation of China [31372418]; Bengbu Medical College Scientific and Technology Self-Innovation Foundation Program [BYKC2003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Bengbu Medical College Scientific and Technology Self-Innovation Foundation Program	This study was partially supported financially by the National Natural Science Foundation of China (31372418, GL) and Bengbu Medical College Scientific and Technology Self-Innovation Foundation Program (No. BYKC2003, GL).	Adiseshaiah P, 2005, ONCOGENE, V24, P4193, DOI 10.1038/sj.onc.1208583; Adiseshaiah P, 2008, J CELL PHYSIOL, V216, P405, DOI 10.1002/jcp.21410; Asiedu MK, 2014, ONCOGENE, V33, P1316, DOI 10.1038/onc.2013.57; Bakiri L, 2015, CELL DEATH DIFFER, V22, P336, DOI 10.1038/cdd.2014.157; Basbous J, 2007, MOL CELL BIOL, V27, P3936, DOI 10.1128/MCB.01776-06; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Breuleux M, 2007, CELL MOL LIFE SCI, V64, P2358, DOI 10.1007/s00018-007-7120-0; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Cheng FF, 2016, CANCER LETT, V375, P274, DOI 10.1016/j.canlet.2016.03.010; Cheng LS, 2009, CANCER LETT, V280, P50, DOI 10.1016/j.canlet.2009.02.007; Cizmecioglu O, 2012, J CELL SCI, V125, P981, DOI 10.1242/jcs.095075; Debinski W, 2005, MOL CANCER RES, V3, P237; Desmet CJ, 2013, P NATL ACAD SCI USA, V110, P5139, DOI 10.1073/pnas.1222085110; Finigan JH, 2011, J BIOL CHEM, V286, P10660, DOI 10.1074/jbc.M110.208041; Hardy KM, 2010, J MAMMARY GLAND BIOL, V15, P191, DOI 10.1007/s10911-010-9172-2; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Leconet W, 2017, CLIN CANCER RES, V23, P2806, DOI 10.1158/1078-0432.CCR-16-1316; Liu GQ, 2012, BLOOD, V120, P1942, DOI 10.1182/blood-2011-12-397430; Luo YP, 2010, ONCOGENE, V29, P662, DOI 10.1038/onc.2009.308; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; Marino N, 2013, AM J PATHOL, V183, P1084, DOI 10.1016/j.ajpath.2013.06.012; Mizejewski G.J., 2019, J CANC METASTASIS TR, V5, P35, DOI [10.20517/2394-4722.2018.70, DOI 10.20517/2394-4722.2018.70]; Momeny M, 2015, ONCOTARGET, V6, P3932, DOI 10.18632/oncotarget.2846; Rakha EA, 2007, CANCER-AM CANCER SOC, V109, P25, DOI 10.1002/cncr.22381; Ramos-Nino ME, 2003, CANCER RES, V63, P3539; Rattanasinchai C, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.44; Rothschild E, 2015, BREAST CANCER-BASIC, V9, P7, DOI 10.4137/BCBCR.S29423; Sundqvist A, 2020, ONCOGENE, V39, P4436, DOI 10.1038/s41388-020-1299-z; Tsai MS, 2003, ONCOGENE, V22, P761, DOI 10.1038/sj.onc.1206130; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Zhang PF, 2016, EMBO REP, V17, P1204, DOI 10.15252/embr.201642067; Zhao CY, 2014, CANCER RES, V74, P3983, DOI 10.1158/0008-5472.CAN-13-3396	34	3	3	5	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2022	41	6					907	919		10.1038/s41388-021-02142-4	http://dx.doi.org/10.1038/s41388-021-02142-4		JAN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT5VS	34992218				2022-12-17	WOS:000739823800002
J	Han, WT; Liu, MY; Han, D; Li, MQ; Toure, AA; Wang, ZF; Besschetnova, A; Patalano, S; Macoska, JA; Gao, S; He, HH; Cai, CM				Han, Wanting; Liu, Mingyu; Han, Dong; Li, Muqing; Toure, Anthia A.; Wang, Zifeng; Besschetnova, Anna; Patalano, Susan; Macoska, Jill A.; Gao, Shuai; He, Housheng Hansen; Cai, Changmeng			RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition	ONCOGENE			English	Article							NEUROENDOCRINE PHENOTYPE; LINEAGE PLASTICITY; INCREASED SURVIVAL; MECHANISMS; PHOSPHORYLATION; DIFFERENTIATION; DEMETHYLATION; METASTASIS; EXPRESSION; GENOMICS	Genomic loss of RB1 is a common alteration in castration-resistant prostate cancer (CRPC) and is associated with poor patient outcomes. RB1 loss is also a critical event that promotes the neuroendocrine transdifferentiation of prostate cancer (PCa) induced by the androgen receptor (AR) signaling inhibition (ARSi). The loss of Rb protein disrupts the Rb-E2F repressor complex and thus hyperactivates E2F transcription activators. While the impact of Rb inactivation on PCa progression and linage plasticity has been previously studied, there is a pressing need to fully understand underlying mechanisms and identify vulnerabilities that can be therapeutically targeted in Rb-deficient CRPC. Using an integrated cistromic and transcriptomic analysis, we have characterized Rb activities in multiple CRPC models by identifying Rb-directly regulated genes and revealed that Rb has distinct binding sites and targets in CRPC with different genomic backgrounds. Significantly, we show that E2F1 chromatin binding and transcription activity in Rb-deficient CRPC are highly dependent on LSD1/KDM1A, and that Rb inactivation sensitizes CRPC tumor to the LSD1 inhibitor treatment. These results provide new molecular insights into Rb activity in PCa progression and suggest that targeting LSD1 activity with small molecule inhibitors may be a potential treatment strategy to treat Rb-deficient CRPC.	[Han, Wanting; Liu, Mingyu; Han, Dong; Li, Muqing; Toure, Anthia A.; Wang, Zifeng; Besschetnova, Anna; Patalano, Susan; Macoska, Jill A.; Gao, Shuai; Cai, Changmeng] Univ Massachusetts, Ctr Personalized Canc Therapy, Boston, MA 02125 USA; [Han, Wanting; Liu, Mingyu; Li, Muqing; Toure, Anthia A.; Wang, Zifeng; Besschetnova, Anna; Patalano, Susan; Macoska, Jill A.; Gao, Shuai; Cai, Changmeng] Univ Massachusetts, Dept Biol, Boston, MA 02125 USA; [He, Housheng Hansen] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [He, Housheng Hansen] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON M5G 1L7, Canada	University of Massachusetts System; University of Massachusetts Boston; University of Massachusetts System; University of Massachusetts Boston; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Cai, CM (corresponding author), Univ Massachusetts, Ctr Personalized Canc Therapy, Boston, MA 02125 USA.; Cai, CM (corresponding author), Univ Massachusetts, Dept Biol, Boston, MA 02125 USA.	changmeng.cai@umb.edu	Han, Wanting/GQA-5728-2022; Han, Wanting/AEX-5349-2022	Han, Wanting/0000-0002-2173-3647; Gao, Shuai/0000-0002-7304-8801; Besschetnova, Anna/0000-0003-3623-1997; Macoska, Jill/0000-0001-8471-2221; Han, Dong/0000-0002-6224-855X	NIH [R00 CA166507, R01 CA211350, U54 CA156734]; DOD [W81XWH-16-1-0445, W81XWH-19-1-0361, W81XWH-21-1-0267, W81XWH-19-1-0777]; CIHR [142246, 152863, 152864, 159567]; Terry Fox Frontiers Program [1090 P3]; Integrative Biosciences Program at the University of Massachusetts Boston; CSM (College of Science and Mathematics) Dean's Doctoral Research Fellowship from the University of Massachusetts Boston	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); CIHR(Canadian Institutes of Health Research (CIHR)); Terry Fox Frontiers Program; Integrative Biosciences Program at the University of Massachusetts Boston; CSM (College of Science and Mathematics) Dean's Doctoral Research Fellowship from the University of Massachusetts Boston	This work is supported by grants from NIH (R00 CA166507 and R01 CA211350 to CC, U54 CA156734 to JAM), DOD (W81XWH-16-1-0445, W81XWH-19-1-0361, and W81XWH-21-1-0267 to CC, W81XWH-19-1-0777 to SG), CIHR (142246, 152863, 152864, and 159567 to HHH), and Terry Fox Frontiers Program Project Grants (1090 P3 to HHH). MLiu was supported by the graduate fellowship from the Integrative Biosciences Program at the University of Massachusetts Boston. WH and ZW were supported by CSM (College of Science and Mathematics) Dean's Doctoral Research Fellowship from the University of Massachusetts Boston. HHH holds Joey and Toby Tanenbaum Brazilian Ball Chair in Prostate Cancer.	Abida W, 2019, P NATL ACAD SCI USA, V116, P11428, DOI 10.1073/pnas.1902651116; Beltran H, 2019, CLIN CANCER RES, V25, P6916, DOI 10.1158/1078-0432.CCR-19-1423; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Berger A, 2019, J CLIN INVEST, V129, P3924, DOI 10.1172/JCI127961; Cai CM, 2014, CELL REP, V9, P1618, DOI 10.1016/j.celrep.2014.11.008; Chen WS, 2019, CLIN CANCER RES, V25, P4290, DOI 10.1158/1078-0432.CCR-19-0404; Cho HS, 2011, CANCER RES, V71, P655, DOI 10.1158/0008-5472.CAN-10-2446; Coleman DJ, 2020, NEOPLASIA, V22, P253, DOI 10.1016/j.neo.2020.04.002; Conteduca V, 2019, EUR J CANCER, V121, P7, DOI 10.1016/j.ejca.2019.08.011; Danza G, 2012, MOL CANCER RES, V10, P230, DOI 10.1158/1541-7786.MCR-11-0296; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Dick FA, 2013, NAT REV MOL CELL BIO, V14, P297, DOI 10.1038/nrm3567; Fang Y, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0811-9; Gao S, 2020, NAT GENET, V52, P1011, DOI 10.1038/s41588-020-0681-7; Gao S, 2019, CELL RES, V29, P770, DOI 10.1038/s41422-019-0203-2; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guo HY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08133-6; He Y, 2018, ONCOGENE, V37, P534, DOI 10.1038/onc.2017.353; Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092; Kontaki H, 2010, MOL CELL, V39, P152, DOI 10.1016/j.molcel.2010.06.006; Korenchuk S, 2001, IN VIVO, V15, P163; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Laurent B, 2015, MOL CELL, V57, P957, DOI 10.1016/j.molcel.2015.01.010; Lin TP, 2016, ONCOTARGET, V7, P26137, DOI 10.18632/oncotarget.8433; Mandigo AC, 2021, CANCER DISCOV, V11, P2334, DOI 10.1158/2159-8290.CD-20-1114; Mateo J, 2020, J CLIN INVEST, V130, P1743, DOI [10.1172/JCl132031, 10.1172/JCI132031]; McNair C, 2018, J CLIN INVEST, V128, P341, DOI 10.1172/JCI93566; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Metzger E, 2008, NAT CELL BIOL, V10, P53, DOI 10.1038/ncb1668; Metzger E, 2010, NATURE, V464, P792, DOI 10.1038/nature08839; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Nyquist MD, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107669; Pfitzenmaier J, 2003, J BONE MINER RES, V18, P1882, DOI 10.1359/jbmr.2003.18.10.1882; Qi JF, 2010, CANCER CELL, V18, P23, DOI 10.1016/j.ccr.2010.05.024; Quigley DA, 2018, CELL, V174, P758, DOI 10.1016/j.cell.2018.06.039; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Rubin MA, 2020, MOL CELL, V80, P562, DOI 10.1016/j.molcel.2020.10.033; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Sehrawat A, 2018, P NATL ACAD SCI USA, V115, pE4179, DOI 10.1073/pnas.1719168115; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571; Wang S, 2013, NAT PROTOC, V8, P2502, DOI 10.1038/nprot.2013.150; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Yuan HR, 2020, CANCER CELL, V38, P350, DOI 10.1016/j.ccell.2020.05.022; Yuan X, 2014, ONCOGENE, V33, P2815, DOI 10.1038/onc.2013.235; Zhang XT, 2015, CLIN CANCER RES, V21, P4698, DOI 10.1158/1078-0432.CCR-15-0157; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhao Y, 2019, EMBO J, V38, DOI 10.15252/embj.201899599	51	3	3	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2022	41	6					852	864		10.1038/s41388-021-02135-3	http://dx.doi.org/10.1038/s41388-021-02135-3		JAN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT5VS	34975152	Green Accepted			2022-12-17	WOS:000737109100001
J	Coronel, L; Hackes, D; Schwab, K; Riege, K; Hoffmann, S; Fischer, M				Coronel, Luis; Haeckes, David; Schwab, Katjana; Riege, Konstantin; Hoffmann, Steve; Fischer, Martin			p53-mediated AKT and mTOR inhibition requires RFX7 and DDIT4 and depends on nutrient abundance	ONCOGENE			English	Article							P53; KINASE; CELL; TARGET; AMPK; TRANSCRIPTION; METABOLISM; ACTIVATION; NETWORK; PATHWAY	In recent years the tumor suppressor p53 has been increasingly recognized as a potent regulator of the cell metabolism and for its ability to inhibit the critical pro-survival kinases AKT and mTOR. The mechanisms through which p53 controls AKT and mTOR, however, are largely unclear. Here, we demonstrate that p53 activates the metabolic regulator DDIT4 indirectly through the regulatory factor X 7 (RFX7). We provide evidence that DDIT4 is required for p53 to inhibit mTOR complex 2 (mTORC2)-dependent AKT activation. Most strikingly, we also find that the DDIT4 regulator RFX7 is required for p53-mediated inhibition of mTORC1 and AKT. Our results suggest that AMPK activation plays no role and p53-mediated AKT inhibition is not critical for p53-mediated mTORC1 inhibition. Moreover, using recently developed physiological cell culture media we uncover that basal p53 and RFX7 activity can play a critical role in restricting mTORC1 activity under physiological nutrient conditions, and we propose a nutrient-dependent model for p53-RFX7-mediated mTORC1 inhibition. These results establish RFX7 and its downstream target DDIT4 as essential effectors in metabolic control elicited by p53.	[Coronel, Luis; Haeckes, David; Schwab, Katjana; Riege, Konstantin; Hoffmann, Steve; Fischer, Martin] Fritz Lipmann Inst FLI, Leibniz Inst Aging, Computat Biol Grp, Beutenbergstr 11, D-07745 Jena, Germany	Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI)	Hoffmann, S; Fischer, M (corresponding author), Fritz Lipmann Inst FLI, Leibniz Inst Aging, Computat Biol Grp, Beutenbergstr 11, D-07745 Jena, Germany.	Steve.Hoffmann@leibniz-fli.de; Martin.Fischer@leibniz-fli.de	Fischer, Martin/I-4825-2014	Fischer, Martin/0000-0002-3429-1876; Luis Eduardo, Coronel Carrion/0000-0001-7906-0732; Schwab, Katjana/0000-0002-6916-2900; Hackes, David/0000-0002-2177-5206	German Research Foundation (DFG) [FI 1993/2-1]; German Federal Ministry for Education and Research (BMBF) [031L016D]; Federal Government of Germany; State of Thuringia; Projekt DEAL	German Research Foundation (DFG)(German Research Foundation (DFG)); German Federal Ministry for Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Federal Government of Germany; State of Thuringia; Projekt DEAL	This work was supported by the German Research Foundation (DFG) [research grant FI 1993/2-1 to MF] and the German Federal Ministry for Education and Research (BMBF) [031L016D to SH]. The FLI is a member of the Leibniz Association and is financially supported by the Federal Government of Germany and the State of Thuringia. Open Access funding enabled and organized by Projekt DEAL.	Agarwal S, 2016, MOL CANCER RES, V14, P66, DOI 10.1158/1541-7786.MCR-15-0159; Akeno N, 2015, ONCOGENE, V34, P589, DOI 10.1038/onc.2013.589; Andrysik Z, 2017, GENOME RES, V27, P1645, DOI 10.1101/gr.220533.117; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Baum N, 2009, ONCOGENE, V28, P3915, DOI 10.1038/onc.2009.248; Ben Sahra I, 2011, CANCER RES, V71, P4366, DOI 10.1158/0008-5472.CAN-10-1769; Bowling S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04167-y; Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028; Cantor JR, 2017, CELL, V169, P258, DOI 10.1016/j.cell.2017.03.023; Castro W, 2018, NAT IMMUNOL, V19, P809, DOI 10.1038/s41590-018-0144-9; Coronel L, 2021, NUCLEIC ACIDS RES, V49, P7437, DOI 10.1093/nar/gkab575; Cui DR, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03185-3; Dennis MD, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005103; DeYoung MP, 2008, GENE DEV, V22, P239, DOI 10.1101/gad.1617608; Duan L, 2018, J MOL CELL BIOL, V10, P331, DOI 10.1093/jmcb/mjx051; Ellisen LW, 2002, MOL CELL, V10, P995, DOI 10.1016/S1097-2765(02)00706-2; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Feng ZH, 2007, CANCER RES, V67, P3043, DOI 10.1158/0008-5472.CAN-06-4149; Fischer BA, 2020, TRENDS CANCER, V6, P6, DOI 10.1016/j.trecan.2019.11.001; Fischer M, 2021, TRENDS CANCER, V7, P12, DOI 10.1016/j.trecan.2020.08.007; Fischer M, 2019, ONCOGENE, V38, P4095, DOI 10.1038/s41388-019-0706-9; Fischer M, 2016, NUCLEIC ACIDS RES, V44, P6070, DOI 10.1093/nar/gkw523; Grande BM, 2019, BLOOD, V133, P1313, DOI 10.1182/blood-2018-09-871418; Herzig S, 2018, NAT REV MOL CELL BIO, V19, P121, DOI 10.1038/nrm.2017.95; Horton LE, 2002, ONCOGENE, V21, P5325, DOI 10.1038/sj.onc.1205662; Kawase T, 2009, CELL, V136, P535, DOI 10.1016/j.cell.2008.12.002; Kon N, 2021, GENE DEV, V35, P59, DOI 10.1101/gad.340919.120; Liu GY, 2020, NAT REV MOL CELL BIO, V21, P183, DOI 10.1038/s41580-019-0199-y; Lopez C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08578-3; Luo YD, 2021, J HEPATOL, V74, P96, DOI 10.1016/j.jhep.2020.07.036; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Menendez D, 2013, NUCLEIC ACIDS RES, V41, P7286, DOI 10.1093/nar/gkt504; Miyamoto T, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1603204; Nicolay BN, 2015, GENE DEV, V29, P1875, DOI 10.1101/gad.264127.115; Parmigiani A, 2014, CELL REP, V9, P1281, DOI 10.1016/j.celrep.2014.10.019; Peng M, 2014, CELL, V159, P122, DOI 10.1016/j.cell.2014.08.038; Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Warden SM, 2001, BIOCHEM J, V354, P275, DOI 10.1042/0264-6021:3540275; Zheng RB, 2019, NUCLEIC ACIDS RES, V47, pD729, DOI 10.1093/nar/gky1094	40	3	3	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2022	41	7					1063	1069		10.1038/s41388-021-02147-z	http://dx.doi.org/10.1038/s41388-021-02147-z		DEC 2021	7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX7EK	34907345	Green Published, hybrid			2022-12-17	WOS:000730070200001
J	Singh, AP; Luo, HC; Matur, M; Eshelman, MA; Hamamoto, K; Sharma, A; Lesperance, J; Huang, SM				Singh, Ajeet P.; Luo, Huacheng; Matur, Meghana; Eshelman, Melanie A.; Hamamoto, Karina; Sharma, Arati; Lesperance, Julia; Huang, Suming			A coordinated function of lncRNA HOTTIP and miRNA-196b underpinning leukemogenesis by targeting FAS signaling	ONCOGENE			English	Article							NONCODING RNA; MICRORNA; TRANSCRIPTION; HOX; APOPTOSIS; CHROMATIN; LEUKEMIA; ELEMENTS; BINDING	MicroRNAs (miRNAs) may modulate more than 60% of human coding genes and act as negative regulators, whereas long noncoding RNAs (lncRNAs) regulate gene expression on multiple levels by interacting with chromatin, functional proteins, and RNAs such as mRNAs and microRNAs. However, the crosstalk between HOTTIP lncRNA and miRNAs in leukemogenesis remains elusive. Using combined integrated analyses of global miRNA expression profiling and state-of-the-art genomic analyses of chromatin such as ChIRP-seq (HOTTIP binding in genomewide), ChIP-seq, and ATAC-seq, we found that some miRNA genes are directly controlled by HOTTIP. Specifically, the HOX cluster miRNAs (miR-196a, miR-196b, miR-10a, and miR-10b), located cis and trans, were most dramatically regulated and significantly decreased in HOTTIP-/- AML cells. HOTTIP bound to the miR-196b promoter and HOTTIP deletion reduced chromatin accessibility and enrichment of active histone modifications at HOX cluster-associated miRNAs in AML cells, whereas reactivation of HOTTIP restored miR gene expression and chromatin accessibility in the CTCF-boundary-attenuated AML cells. Inactivation of HOTTIP or miR-196b promotes apoptosis by altering the chromatin signature at the FAS promoter and increasing FAS expression. Transplantation of miR-196b knockdown MOLM13 cells in NSG mice increased overall survival of mice compared to wild-type cells transplanted into mice. Thus, HOTTIP remodels the chromatin architecture around miRNAs to promote their transcription and consequently represses tumor suppressors and promotes leukemogenesis.	[Singh, Ajeet P.; Luo, Huacheng; Matur, Meghana; Eshelman, Melanie A.; Hamamoto, Karina; Lesperance, Julia; Huang, Suming] Penn State Univ, Dept Pediat, Coll Med, Div Pediat Hematol Oncol, Hershey, PA 17033 USA; [Singh, Ajeet P.] Penn State Univ, Dept Biochem & Mol Biol, Coll Med, Hershey, PA 17033 USA; [Singh, Ajeet P.] NCI, Thorac Surg Branch, NIH, Bethesda, MD 20892 USA; [Luo, Huacheng; Sharma, Arati; Huang, Suming] Penn State Univ, Coll Med, Penn State Canc Inst, Hershey, PA 17033 USA; [Sharma, Arati] Penn State Univ, Dept Med, Div Hematol & Oncol, Coll Med, Hershey, PA 17033 USA; [Sharma, Arati] Penn State Univ, Dept Pharmacol, Coll Med, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Singh, AP; Luo, HC; Huang, SM (corresponding author), Penn State Univ, Dept Pediat, Coll Med, Div Pediat Hematol Oncol, Hershey, PA 17033 USA.; Singh, AP (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Coll Med, Hershey, PA 17033 USA.; Singh, AP (corresponding author), NCI, Thorac Surg Branch, NIH, Bethesda, MD 20892 USA.; Luo, HC; Huang, SM (corresponding author), Penn State Univ, Coll Med, Penn State Canc Inst, Hershey, PA 17033 USA.	ajeet.singh@nih.gov; hluo1@pennstatehealth.psu.edu; shuang4@pennstatehealth.psu.edu	Singh, Ajeet/N-8092-2017	Singh, Ajeet/0000-0002-0318-2167; Eshelman, Melanie/0000-0002-3814-5286	National Institutes of Health [R01DK110108, R01CA204044, R01HL141950]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We are grateful to the Penn State College of Medicine Genome Science Facility for illumine sequencing core and the Flow Cytometry & Cell Sorting Core. We are grateful for helpful discussions from Dr. Yi Qiu (Penn State College of Medicine). We thank Dr. Sachin Singh (Center for Cellular and Molecular Biology, India) for helping the data analysis from the TCGA dataset. This work was supported by the grants from National Institutes of Health (S.H., R01DK110108, R01CA204044, and R01HL141950).	[Anonymous], 2014, GENOME BIOL, DOI DOI 10.1186/S13059-014-0550-8; Basta JM, 2020, DEV BIOL, V464, P176, DOI 10.1016/j.ydbio.2020.05.008; Chou CH, 2018, NUCLEIC ACIDS RES, V46, pD296, DOI 10.1093/nar/gkx1067; Collins CT, 2016, CURR OPIN HEMATOL, V23, P354, DOI 10.1097/MOH.0000000000000245; de Boer J, 2013, LEUKEMIA, V27, P1224, DOI 10.1038/leu.2013.78; De Kumar B, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501402; Denans N, 2015, ELIFE, V4, DOI 10.7554/eLife.04379; Dey BK, 2014, TRANSCR-AUSTIN, V5, DOI 10.4161/21541272.2014.944014; Dykes IM, 2017, GENOM PROTEOM BIOINF, V15, P177, DOI 10.1016/j.gpb.2016.12.005; Fernandes JCR, 2019, NON-CODING RNA, V5, DOI 10.3390/ncrna5010017; Furio-Tari P, 2016, NUCLEIC ACIDS RES, V44, pW176, DOI 10.1093/nar/gkw443; Garzon R, 2006, P NATL ACAD SCI USA, V103, P5078, DOI 10.1073/pnas.0600587103; Grossi E, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14623-3; He RZ, 2019, GENES DIS, V6, P6, DOI 10.1016/j.gendis.2019.01.003; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jonas S, 2015, NAT REV GENET, V16, P421, DOI 10.1038/nrg3965; Lambert M, 2019, CANCERS, V11, DOI 10.3390/cancers11060837; Li ZJ, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1681; Long YC, 2017, SCI ADV, V3, DOI 10.1126/sciadv.aao2110; Luo HC, 2019, CANCER CELL, V36, P645, DOI 10.1016/j.ccell.2019.10.011; Luo HC, 2018, BLOOD, V132, P837, DOI 10.1182/blood-2017-11-814319; McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630; Mo JS, 2015, ONCOTARGET, V6, P2843, DOI 10.18632/oncotarget.3066; Neijts R, 2016, GENE DEV, V30, P1937, DOI 10.1101/gad.285767.116; Qiu Yi, 2021, Blood, V138, P2327, DOI 10.1182/blood.2021011992; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Rodrigues AR, 2017, P NATL ACAD SCI USA, V114, P3139, DOI 10.1073/pnas.1620767114; Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730; Schep AN, 2017, NAT METHODS, V14, P975, DOI [10.1038/NMETH.4401, 10.1038/nmeth.4401]; Singh AP, 2020, CELL MOL GASTROENTER, V9, P447, DOI 10.1016/j.jcmgh.2019.11.001; Singh AP, 2016, MOL CELL BIOL, V36, P1990, DOI 10.1128/MCB.01101-15; Singh AP, 2017, ONCOTARGET, V8, P54925, DOI 10.18632/oncotarget.18976; Singh AP, 2014, NUCLEIC ACIDS RES, V42, P2958, DOI 10.1093/nar/gkt1232; Stadthagen G, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003913; Takacs-Vellai K, 2007, DEV BIOL, V302, P661, DOI 10.1016/j.ydbio.2006.09.049; Tan YL, 2009, BMC MOL BIOL, V10, DOI 10.1186/1471-2199-10-12; Wallace JA, 2017, BLOOD, V130, P1290, DOI 10.1182/blood-2016-10-697698; Wang KC, 2011, NATURE, V472, P120, DOI 10.1038/nature09819; Weiss FU, 2009, GASTROENTEROLOGY, V137, P2136, DOI 10.1053/j.gastro.2009.08.065; Yamamura S, 2018, CELL MOL LIFE SCI, V75, P467, DOI 10.1007/s00018-017-2626-6; Yendamuri S, 2009, LEUKEMIA, V23, P1257, DOI 10.1038/leu.2008.382	42	3	3	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2022	41	5					718	731		10.1038/s41388-021-02127-3	http://dx.doi.org/10.1038/s41388-021-02127-3		NOV 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ4FN	34845377	Green Submitted, Green Accepted			2022-12-17	WOS:000723571700004
J	Song, DW; Cismas, S; Crudden, C; Trocme, E; Worrall, C; Suleymanova, N; Lin, TT; Zheng, HY; Seregard, S; Girnita, A; Girnita, L				Song, Dawei; Cismas, Sonia; Crudden, Caitrin; Trocme, Eric; Worrall, Claire; Suleymanova, Naida; Lin, Tingting; Zheng, Huiyuan; Seregard, Stefan; Girnita, Ada; Girnita, Leonard			IGF-1R is a molecular determinant for response to p53 reactivation therapy in conjunctival melanoma	ONCOGENE			English	Article							FACTOR-I RECEPTOR; DOWN-REGULATION; BETA-ARRESTIN; MALIGNANT-MELANOMA; UVEAL MELANOMA; GROWTH; EXPRESSION; MDM2; UBIQUITINATION; ACTIVATION	As the p53 tumor suppressor is rarely mutated in conjunctival melanoma (CM), we investigated its activation as a potential therapeutic strategy. Preventing p53/Mdm2 interaction by Nutlin-3, the prototypical Mdm2 antagonist, or via direct siRNA Mdm2 depletion, increased p53 and inhibited viability in CM cell lines. The sensitivity to Nutlin-3 p53 reactivation with concomitant Mdm2 stabilization was higher than that achieved by siRNA, indicative of effects on alternative Mdm2 targets, identified as the cancer-protective IGF-1R. Nutlin-3 treatment increased the association between IGF-1R and beta-arrestin1, the adaptor protein that brings Mdm2 to the IGF-1R, initiating receptor degradation in a ligand-dependent manner. Controlled expression of beta-arrestin1 augmented inhibitory Nutlin-3 effects on CM survival through enhanced IGF-1R degradation. Yet, the effect of IGF-1R downregulation on cell proliferation is balanced by beta-arrestin1-induced p53 inhibition. As mitomycin (MMC) is a well-established adjuvant treatment for CM, and it triggers p53 activation through genotoxic stress, we evaluated how these alternative p53-targeting strategies alter the cancer-relevant bioactivities of CM. In 2D and 3D in vitro models, Nutlin-3 or MMC alone, or in combination, reduces the overall cell tumor growth similar to 30%, with double treatment inhibition rate only marginally higher than single-drug regimens. However, histopathological evaluation of the 3D models revealed that Nutlin-3 was the most effective, causing necrotic areas inside spheroids and complete loss of nuclear staining for the proliferative marker Ki67. These findings were further validated in vivo; zebrafish xenografts demonstrate that Nutlin-3 alone has higher efficacy in restraining CM tumor cell growth and preventing metastasis. Combined, these results reveal that beta-arrestin1 directs Mdm2 toward different substrates, thus balancing IGF-1R pro-tumorigenic and p53-tumor suppressive signals. This study defines a potent dual-hit strategy: simultaneous control of a tumor-promoter (IGF-1R) and tumor-suppressor (p53), which ultimately mitigates recurrent and metastatic potential, thus opening up targeted therapy to CM.	[Song, Dawei; Cismas, Sonia; Crudden, Caitrin; Trocme, Eric; Worrall, Claire; Suleymanova, Naida; Lin, Tingting; Zheng, Huiyuan; Girnita, Ada; Girnita, Leonard] Karolinska Inst, Dept Oncol & Pathol, BioClinicum, Stockholm, Sweden; [Song, Dawei; Cismas, Sonia; Crudden, Caitrin; Trocme, Eric; Worrall, Claire; Suleymanova, Naida; Lin, Tingting; Zheng, Huiyuan; Girnita, Ada; Girnita, Leonard] Karolinska Univ Hosp, Stockholm, Sweden; [Crudden, Caitrin] Vrije Univ Amsterdam, Canc Ctr Amsterdam, Dept Pathol, Amsterdam UMC, De Boelelaan 1117, Amsterdam, Netherlands; [Trocme, Eric; Seregard, Stefan; Girnita, Leonard] St Erik Eye Hosp, Ophthalm Pathol & Oncol Serv, Stockholm, Sweden; [Lin, Tingting] Tianjin Med Univ Eye Hosp, Tianjin Int Joint Res & Dev Ctr Ophthalmol & Vis, Eye Inst, Tianjin, Peoples R China; [Lin, Tingting] Tianjin Med Univ Eye Hosp, Sch Optometry, Tianjin, Peoples R China; [Zheng, Huiyuan] Karolinska Inst, Inst Environm Med, Stockholm, Sweden; [Seregard, Stefan] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Girnita, Ada] Karolinska Univ Hosp, Skin Canc Ctr, Theme Canc, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Vrije Universiteit Amsterdam; Tianjin Medical University; Tianjin Medical University; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Girnita, L (corresponding author), Karolinska Inst, Dept Oncol & Pathol, BioClinicum, Stockholm, Sweden.; Girnita, L (corresponding author), Karolinska Univ Hosp, Stockholm, Sweden.; Girnita, L (corresponding author), St Erik Eye Hosp, Ophthalm Pathol & Oncol Serv, Stockholm, Sweden.	leonard.girnita@ki.se	Song, Dawei/HGC-7852-2022; Crudden, Caitrin/Q-5172-2018	Crudden, Caitrin/0000-0002-7786-112X; Song, Dawei/0000-0001-7707-7207	Swedish Research Council; Swedish Cancer Society; Swedish Childhood Cancer Foundation; Crown Princess Margareta's Foundation for the Visually Impaired; Welander Finsen Foundation; King Gustaf V Jubilee Foundation; China Scholarship Council [201700260284]; Stockholm Cancer Society; Karolinska Institute	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Swedish Childhood Cancer Foundation(European Commission); Crown Princess Margareta's Foundation for the Visually Impaired; Welander Finsen Foundation; King Gustaf V Jubilee Foundation; China Scholarship Council(China Scholarship Council); Stockholm Cancer Society; Karolinska Institute(Karolinska Institutet)	We gratefully acknowledge Prof. Robert J Lefkowitz, Prof. Gerasimos Anastassiou, Prof. Rob J W de Keizer, Prof. Rolf Kiessling, and Prof. A. Ciechanover for providing cell lines and reagents. We thank Anna Malmerfelt at the histology core facility, Karolinska Institutet, for technical assistance. Research support was received from the Swedish Research Council, Swedish Cancer Society, The Swedish Childhood Cancer Foundation, Crown Princess Margareta's Foundation for the Visually Impaired, Welander Finsen Foundation, King Gustaf V Jubilee Foundation, China Scholarship Council (Grant no. 201700260284), Stockholm Cancer Society, Stockholm County and Karolinska Institute. Schematics were partially created with BioRender.com.	All-Ericsson C, 2002, INVEST OPHTH VIS SCI, V43, P1; Bankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Brenner M, 2008, PHOTOCHEM PHOTOBIOL, V84, P539, DOI 10.1111/j.1751-1097.2007.00226.x; Burkhart CG, 2005, INT J DERMATOL, V44, P340, DOI 10.1111/j.1365-4632.2004.02556.x; Charan J, 2013, J PHARMACOL PHARMACO, V4, P303, DOI 10.4103/0976-500X.119726; Cisarova K, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1009201; Crudden C, 2021, CANCER RES, V81, P501, DOI 10.1158/0008-5472.CAN-20-1662; Crudden C, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.abb7887; Crudden C, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101223; Crudden C, 2018, INT REV CEL MOL BIO, V339, P1, DOI 10.1016/bs.ircmb.2018.02.006; Crudden C, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00064; Crudden C, 2015, GROWTH HORM IGF RES, V25, P2, DOI 10.1016/j.ghir.2014.10.002; de Waard NE, 2015, INVEST OPHTH VIS SCI, V56, P2325, DOI 10.1167/iovs.14-15239; Dziadziuszko R, 2010, J CLIN ONCOL, V28, P2174, DOI 10.1200/JCO.2009.24.6611; Economou MA, 2005, INVEST OPHTH VIS SCI, V46, P4372, DOI 10.1167/iovs.05-0322; Economou MA, 2008, INVEST OPHTH VIS SCI, V49, P2337, DOI 10.1167/iovs.07-0819; Fiorentzis M, 2019, ACTA OPHTHALMOL, V97, pE632, DOI 10.1111/aos.13993; Froment P, 2008, CELL CYCLE, V7, P3098, DOI 10.4161/cc.7.19.6807; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Gardrat S, 2021, CANCERS, V13, DOI 10.3390/cancers13153836; Gaudy-Marqueste C, 2022, J AM ACAD DERMATOL, V86, P312, DOI 10.1016/j.jaad.2021.07.011; Girnita L, 2000, CANCER RES, V60, P5278; Girnita L, 2016, PROG MOL BIOL TRANSL, V141, P277, DOI 10.1016/bs.pmbts.2016.04.001; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Girnita L, 2005, J BIOL CHEM, V280, P24412, DOI 10.1074/jbc.M501129200; Girnita L, 2007, J BIOL CHEM, V282, P11329, DOI 10.1074/jbc.M611526200; Girnita L, 2014, CELL MOL LIFE SCI, V71, P2403, DOI 10.1007/s00018-013-1514-y; Hara MR, 2011, NATURE, V477, P349, DOI 10.1038/nature10368; Jain P, 2021, BRIT J OPHTHALMOL, V105, P1358, DOI 10.1136/bjophthalmol-2020-316293; Jay V, 1996, ARCH PATHOL LAB MED, V120, P378; JRC, 2020, 2020 CANC INC MORT E; Kanter-Lewensohn L, 1998, MELANOMA RES, V8, P389, DOI 10.1097/00008390-199810000-00002; Keijser S, 2007, BRIT J OPHTHALMOL, V91, P1566, DOI 10.1136/bjo.2006.110841; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Maures T, 2002, ENDOCRINOLOGY, V143, P1858, DOI 10.1210/en.143.5.1858; Mihajlovic M, 2012, INT J CLIN EXP PATHO, V5, P739; Mikkelsen LH, 2020, ACTA OPHTHALMOL, V98, P1, DOI 10.1111/aos.14536; Moll UM, 2003, MOL CANCER RES, V1, P1001; Mundra PA, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20432-5; Nareyeck G, 2005, EXP EYE RES, V81, P361, DOI 10.1016/j.exer.2005.04.018; Newel F, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11107-x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pacheco RR, 2022, EYE, V36, P603, DOI 10.1038/s41433-021-01508-y; Plonka PM, 2009, EXP DERMATOL, V18, P799, DOI 10.1111/j.1600-0625.2009.00912.x; Ren J, 2017, JOVE-J VIS EXP, DOI 10.3791/55459; Rivolta C, 2016, J HUM GENET, V61, P361, DOI 10.1038/jhg.2015.152; Sehat B, 2008, CANCER RES, V68, P5669, DOI 10.1158/0008-5472.CAN-07-6364; Sekulic A, 2008, MAYO CLIN PROC, V83, P825, DOI 10.4065/83.7.825; Seregard S, 1998, SURV OPHTHALMOL, V42, P321, DOI 10.1016/S0039-6257(97)00122-7; Seregard S, 1996, J CLIN PATHOL, V49, P338, DOI 10.1136/jcp.49.4.338; Shields CL, 2021, ASIA-PAC J OPHTHALMO, V10, P146, DOI 10.1097/APO.0000000000000343; Shields CL, 2020, JAMA OPHTHALMOL, V138, P608, DOI 10.1001/jamaophthalmol.2020.0522; Shields CL, 2000, ARCH OPHTHALMOL-CHIC, V118, P1497; Suleymanova N, 2017, ONCOGENE, V36, P5734, DOI 10.1038/onc.2017.179; Suleymanova N, 2017, ONCOTARGET, V8, P82256, DOI 10.18632/oncotarget.19286; Triay E, 2009, BRIT J OPHTHALMOL, V93, P1524, DOI 10.1136/bjo.2009.157933; Tuomaala S, 2002, INVEST OPHTH VIS SCI, V43, P3399; Vasilcanu D, 2006, ONCOGENE, V25, P3186, DOI 10.1038/sj.onc.1209339; Vasilcanu R, 2008, ONCOGENE, V27, P1629, DOI 10.1038/sj.onc.1210797; Vasilcanu R, 2008, MOL PHARMACOL, V73, P930, DOI 10.1124/mol.107.040014; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Virgili G, 2020, JAMA OPHTHALMOL, V138, P601, DOI 10.1001/jamaophthalmol.2020.0531; Wood JM, 1999, EXP DERMATOL, V8, P153, DOI 10.1111/j.1600-0625.1999.tb00365.x; Worrall C, 2017, ONCOGENE, V36, P3274, DOI 10.1038/onc.2016.472; Yang G, 2006, J INVEST DERMATOL, V126, P2490, DOI 10.1038/sj.jid.5700470; Yoshihara H, 2012, BIOCHEM BIOPH RES CO, V423, P122, DOI 10.1016/j.bbrc.2012.05.093	67	3	3	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2022	41	4					600	611		10.1038/s41388-021-02111-x	http://dx.doi.org/10.1038/s41388-021-02111-x		NOV 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK9PJ	34785779				2022-12-17	WOS:000719276900001
J	Shin, Y; Kim, S; Ghate, NB; Rhie, SK; An, W				Shin, Yonghwan; Kim, Sungmin; Ghate, Nikhil B.; Rhie, Suhn K.; An, Woojin			MMP-9 drives the melanomagenic transcription program through histone H3 tail proteolysis	ONCOGENE			English	Article							MATRIX METALLOPROTEINASES; MUTATIONS; INHIBITION; GENE; BRAF; PROGRESSION; CLEAVAGE; TRIGGERS; BIOLOGY; EZH2	Melanoma is a type of skin cancer that develops in pigment-producing melanocytes and often spreads to other parts of the body. Aberrant gene expression has been considered as a crucial step for increasing the risk of melanomagenesis, but how chromatin reorganization contributes to this pathogenic process is still not well understood. Here we report that matrix metalloproteinase 9 (MMP-9) localizes to the nucleus of melanoma cells and potentiates gene expression by proteolytically clipping the histone H3 N-terminal tail (H3NT). From genome-wide studies, we discovered that growth-regulatory genes are selectively targeted and activated by MMP-9-dependent H3NT proteolysis in melanoma cells. MMP-9 cooperates functionally with p300/CBP because MMP-9 cleaves H3NT in a manner that is dependent on p300/CBP-mediated acetylation of H3K18. The functional significance of MMP-9-dependent H3NT proteolysis is further underscored by the fact that RNAi knockdown and small-molecule inhibition of MMP-9 and p300/CBP impede melanomagenic gene expression and melanoma tumor growth. Together, our data establish new functions and mechanisms for nuclear MMP-9 in promoting melanomagenesis and demonstrate how MMP-9-dependent H3NT proteolysis can be exploited to prevent and treat melanoma skin cancer.	[Shin, Yonghwan; Kim, Sungmin; Ghate, Nikhil B.; Rhie, Suhn K.; An, Woojin] Univ Southern Calif, Norris Comprehens Canc Ctr, Dept Biochem & Mol Med, Los Angeles, CA 90033 USA	University of Southern California	An, W (corresponding author), Univ Southern Calif, Norris Comprehens Canc Ctr, Dept Biochem & Mol Med, Los Angeles, CA 90033 USA.	woojinan@usc.edu		Kim, Sungmin/0000-0001-5873-6430; Rhie, Suhn/0000-0002-5522-5296	NIH [AR073233, P30CA014089]; National Cancer Institute	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH Grant AR073233 awarded to WA. The study was also partly supported by award number P30CA014089 from the National Cancer Institute.	Agrawal A, 2008, CHEMMEDCHEM, V3, P812, DOI 10.1002/cmdc.200700290; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Boissy RE, 1997, PIGM CELL RES, V10, P12, DOI 10.1111/j.1600-0749.1997.tb00461.x; Bruschi F, 2013, PATHOGENS, V2, P105, DOI 10.3390/pathogens2010105; Chen HX, 2014, J INVEST DERMATOL, V134, P2080, DOI 10.1038/jid.2014.161; Daura E, 2021, NEUROBIOL DIS, V156, DOI 10.1016/j.nbd.2021.105418; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Ding L, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00417-z; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dong JL, 2003, CANCER RES, V63, P3883; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Faiao-Flores F, 2019, CLIN CANCER RES, V25, P5686, DOI 10.1158/1078-0432.CCR-18-3382; Ferrari KJ, 2021, NUCLEIC ACIDS RES, V49, DOI 10.1093/nar/gkaa1228; Frankish A, 2019, NUCLEIC ACIDS RES, V47, pD766, DOI 10.1093/nar/gky955; Fu CH, 2020, MOL MED REP, V21, P1421, DOI 10.3892/mmr.2020.10950; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Guarneri C, 2017, ONCOL REP, V37, P737, DOI 10.3892/or.2017.5362; Hoffmann F, 2020, CLIN EPIGENETICS, V12, DOI 10.1186/s13148-020-0818-7; Kim E, 2019, CANCER RES, V79, P2649, DOI 10.1158/0008-5472.CAN-18-2331; Kim JM, 2018, ONCOGENE, V37, P5749, DOI 10.1038/s41388-018-0356-3; Kim K, 2018, EPIGENET CHROMATIN, V11, DOI 10.1186/s13072-018-0193-1; Kim K, 2016, GENE DEV, V30, P208, DOI 10.1101/gad.268714.115; Kim K, 2013, MOL CELL, V52, P459, DOI 10.1016/j.molcel.2013.09.017; Klein T, 2011, AMINO ACIDS, V41, P271, DOI 10.1007/s00726-010-0689-x; KORNER A, 1982, SCIENCE, V217, P1163, DOI 10.1126/science.6810464; Krauthammer M, 2015, NAT GENET, V47, P996, DOI 10.1038/ng.3361; Lin WM, 2008, CANCER RES, V68, P664, DOI 10.1158/0008-5472.CAN-07-2615; Lue JK, 2019, CLIN CANCER RES, V25, P5271, DOI 10.1158/1078-0432.CCR-18-3989; Mahmoud F, 2016, CANCER BIOL THER, V17, P579, DOI 10.1080/15384047.2016.1167291; Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002; Napoli S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051151; Papazafiropoulou A, 2009, HIPPOKRATIA, V13, P76; Rangaswami H, 2007, ONCOL REP, V18, P909; Rice JC, 2021, EPIGENET CHROMATIN, V14, DOI 10.1186/s13072-021-00398-4; Santos MCLG, 2004, J ORAL REHABIL, V31, P660, DOI 10.1111/j.1365-2842.2004.01297.x; Shen J, 2017, EMBO REP, V18, P2131, DOI 10.15252/embr.201743892; Shin Y, 2019, EPIGENET CHROMATIN, V12, DOI 10.1186/s13072-019-0270-0; Slominski A, 2004, PHYSIOL REV, V84, P1155, DOI 10.1152/physrev.00044.2003; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; Vargova Viola, 2012, Exp Suppl, V103, P1, DOI 10.1007/978-3-0348-0364-9_1; Wang R, 2018, MOL CANCER THER, V17, P2543, DOI 10.1158/1535-7163.MCT-18-0511; Wilmott JS, 2015, MODERN PATHOL, V28, P884, DOI 10.1038/modpathol.2015.34; Zhang XW, 2012, CANCER CELL, V22, P506, DOI 10.1016/j.ccr.2012.09.003; Zhao XB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023409; Zhou SH, 2021, AGEING RES REV, V69, DOI 10.1016/j.arr.2021.101349	46	3	3	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2022	41	4					560	570		10.1038/s41388-021-02109-5	http://dx.doi.org/10.1038/s41388-021-02109-5		NOV 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK9PJ	34785776				2022-12-17	WOS:000719277200005
J	Zheng, YL; Wu, JJ; Deng, R; Lin, CS; Huang, YH; Yang, X; Wang, CH; Yang, MM; He, YF; Lu, JB; Su, XD; Yan, Q; Zhu, YH; Guan, XY; Li, Y; Yun, JP				Zheng, Yinli; Wu, Jinjun; Deng, Ru; Lin, Censhan; Huang, Yuhua; Yang, Xia; Wang, Chunhua; Yang, Mingming; He, Yangfan; Lu, Jiabin; Su, Xiaodong; Yan, Qian; Zhu, Yinghui; Guan, Xinyuan; Li, Yan; Yun, Jingping			G3BP2 regulated by the lncRNA LINC01554 facilitates esophageal squamous cell carcinoma metastasis through stabilizing HDGF transcript	ONCOGENE			English	Article							RNA-BINDING PROTEINS; HEPATOCELLULAR-CARCINOMA; CANCER; EXPRESSION; INVASION; LINK	Metastasis is the leading cause of death of patients with esophageal squamous cell carcinoma (ESCC). Although an increasing number of studies have demonstrated the involvement of G3BP2 in several human cancers, how G3BP2 interacts with long noncoding RNAs and regulates mRNA transcripts in mediating ESCC metastasis remains unclear. In this study, we uncovered that G3BP2 was upregulated in ESCC. Further analysis revealed that upregulation of G3BP2 was significantly correlated with lymph node metastasis, depth of tumor invasion and unfavorable outcomes in ESCC patients. Both in vitro and in vivo functional assays demonstrated that G3BP2 dramatically enhanced ESCC cell migration and invasion. Mechanistically, LINC01554 maintained the high G3BP2 expression in ESCC by protecting G3BP2 from degradation through ubiquitination and the interaction domains within LINC01554 and G3BP2 were identified. In addition, RNA-seq revealed that HDGF was regulated by G3BP2. G3BP2 bound to HDGF mRNA transcript to stabilize its expression. Ectopic expression of HDGF effectively abolished the G3BP2 depletion-mediated inhibitory effect on tumor cell migration. Intriguingly, introduction of compound C108 which can inhibit G3BP2 remarkedly suppressed ESCC cell metastasis in vitro and in vivo. Collectively, this study describes a newly discovered regulatory axis, LINC01554/G3BP2/HDGF, that facilitates ESCC metastasis and will provide novel therapeutic strategies for ESCC.	[Zheng, Yinli; Deng, Ru; Lin, Censhan; Huang, Yuhua; Yang, Xia; Wang, Chunhua; Yang, Mingming; He, Yangfan; Lu, Jiabin; Su, Xiaodong; Zhu, Yinghui; Guan, Xinyuan; Li, Yan; Yun, Jingping] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou 510060, Peoples R China; [Zheng, Yinli; Deng, Ru; Lin, Censhan; Huang, Yuhua; Yang, Xia; Wang, Chunhua; Yang, Mingming; He, Yangfan; Lu, Jiabin; Yun, Jingping] Sun Yat Sen Univ, Dept Pathol, Canc Ctr, Guangzhou 510060, Peoples R China; [Wu, Jinjun] Guangzhou Univ Chinese Med, Int Inst Translat Chinese Med, Joint Lab Translat Canc Res Chinese Med, Minist Educ Peoples Republ China, Guangzhou 510006, Peoples R China; [Su, Xiaodong] Sun Yat Sen Univ, Dept Thorac Surg, Canc Ctr, Guangzhou 510060, Peoples R China; [Yan, Qian] Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Inst Gastroenterol, Dept Colorectal Surg,Guangdong Prov Key Lab Color, Guangzhou 510000, Peoples R China; [Guan, Xinyuan] Univ Hong Kong, Dept Clin Oncol, State Key Lab Liver Res, Hong Kong 852, Peoples R China; [Guan, Xinyuan] Univ Hong Kong, Dept Clin Oncol, Shenzhen Hosp, Shenzhen 518053, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Guangzhou University of Chinese Medicine; Ministry of Education, China; Sun Yat Sen University; Sun Yat Sen University; University of Hong Kong; University of Hong Kong	Li, Y; Yun, JP (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou 510060, Peoples R China.; Yun, JP (corresponding author), Sun Yat Sen Univ, Dept Pathol, Canc Ctr, Guangzhou 510060, Peoples R China.	liy6@mail.sysu.edu.cn; yunjp@sysucc.org.cn			National Natural Science Foundation of Guangdong Province [2018B030311005]; National Natural Science Foundation of China [82003056, 82072611, 82072604]; Guangdong Basic and Applied Basic Research Foundation [2019A1515110054]; China Postdoctoral Science Foundation [2019M663307]; Young Talent Teachers Plan of Sun Yat-sen University [20YKPY183]	National Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Basic and Applied Basic Research Foundation; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Young Talent Teachers Plan of Sun Yat-sen University	This study was supported by The National Natural Science Foundation of Guangdong Province (No.2018B030311005), The National Natural Science Foundation of China (No.82003056, 82072611, 82072604), Guangdong Basic and Applied Basic Research Foundation (No. 2019A1515110054), China Postdoctoral Science Foundation (No. 2019M663307), and Young Talent Teachers Plan of Sun Yat-sen University (No.20YKPY183).	Alam U, 2019, BBA-MOL CELL RES, V1866, P360, DOI 10.1016/j.bbamcr.2018.09.001; Ashikari D, 2017, ONCOGENE, V36, P6272, DOI 10.1038/onc.2017.225; Azad TD, 2020, GASTROENTEROLOGY, V158, P494, DOI 10.1053/j.gastro.2019.10.039; Bao CH, 2014, FUTURE ONCOL, V10, P2675, DOI 10.2217/fon.14.194; Bikkavilli RK, 2011, J CELL SCI, V124, P2310, DOI 10.1242/jcs.084046; Chen XX, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00650-0; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Fu QF, 2017, CLIN CANCER RES, V23, P6336, DOI 10.1158/1078-0432.CCR-16-2813; Gallouzi IE, 1998, MOL CELL BIOL, V18, P3956, DOI 10.1128/MCB.18.7.3956; Gao YB, 2014, NAT GENET, V46, P1097, DOI 10.1038/ng.3076; Gao Y, 2013, HUM GENET, V132, P649, DOI 10.1007/s00439-013-1276-5; Gupta N, 2017, P NATL ACAD SCI USA, V114, P1033, DOI 10.1073/pnas.1525387114; Hao QY, 2020, EUR REV MED PHARMACO, V24, P12667, DOI 10.26355/eurrev_202012_24164; Heijink AM, 2019, CELL REP, V28, P2345, DOI 10.1016/j.celrep.2019.07.070; Hu XT, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1095-y; Hubner JM, 2019, NEURO-ONCOLOGY, V21, P878, DOI 10.1093/neuonc/noz058; Lin AF, 2016, NAT CELL BIOL, V18, P213, DOI 10.1038/ncb3295; Lin CH, 2020, CANCERS, V12, DOI 10.3390/cancers12092690; Lin YW, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6229-5; Liu HW, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01241-2; Liu X, 2017, GASTROENTEROLOGY, V153, P166, DOI 10.1053/j.gastro.2017.03.033; Matsuki H, 2013, GENES CELLS, V18, P135, DOI 10.1111/gtc.12023; Noh JH, 2018, WIRES RNA, V9, DOI 10.1002/wrna.1471; Pereira B, 2017, TRENDS CANCER, V3, P506, DOI 10.1016/j.trecan.2017.05.003; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Shih TC, 2012, J HEPATOL, V57, P584, DOI 10.1016/j.jhep.2012.04.031; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21601, 10.3322/caac.21590]; Takayama KI, 2018, MOL CANCER RES, V16, P846, DOI 10.1158/1541-7786.MCR-17-0471; Taniuchi K, 2011, MOL CANCER RES, V9, P856, DOI 10.1158/1541-7786.MCR-10-0574; Tian H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18929-0; Valiente-Echeverria F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5819; Wang Q, 2020, GUT, V69, P1193, DOI 10.1136/gutjnl-2019-319639; Wang Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1105-0; Wei SC, 2015, NAT CELL BIOL, V17, P678, DOI 10.1038/ncb3157; Yang Y, 2021, ONCOGENE, V40, P731, DOI 10.1038/s41388-020-01485-8; Yao RW, 2019, NAT CELL BIOL, V21, P542, DOI 10.1038/s41556-019-0311-8; Yuan YH, 2009, CIRC RES, V105, P1177, DOI 10.1161/CIRCRESAHA.109.204669; Zeng HM, 2018, LANCET GLOB HEALTH, V6, pE555, DOI 10.1016/S2214-109X(18)30127-X; Zheng YL, 2019, THERANOSTICS, V9, P796, DOI 10.7150/thno.28992; Zuo XL, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-019-0839-x	40	3	3	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2022	41	4					515	526		10.1038/s41388-021-02073-0	http://dx.doi.org/10.1038/s41388-021-02073-0		NOV 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK9PJ	34782720	hybrid, Green Published			2022-12-17	WOS:000718778400005
J	Wu, Q; Liu, FF; Ge, MM; Laster, KV; Wei, LX; Du, RJ; Jiang, M; Zhang, J; Zhi, YF; Jin, GG; Zhao, SM; Kim, DJ; Dong, ZG; Liu, KD				Wu, Qiong; Liu, Fangfang; Ge, Mengmeng; Laster, Kyle Vaughn; Wei, Lixiao; Du, Ruijuan; Jiang, Ming; Zhang, Jing; Zhi, Yafei; Jin, Guoguo; Zhao, Simin; Kim, Dong Joon; Dong, Zigang; Liu, Kangdong			BRD4 drives esophageal squamous cell carcinoma growth by promoting RCC2 expression	ONCOGENE			English	Article							GENOMIC LANDSCAPE; GENE-EXPRESSION; TARGETING MYCN; P73 ISOFORMS; CANCER; OVEREXPRESSION; TRANSCRIPTION; INHIBITION; P53; SENSITIVITY	The low survival rate of esophageal squamous cell carcinoma patients is primarily attributed to technical limitations and a lack of insight regarding the molecular mechanisms contributing to its progression. Alterations in epigenetic modulators are critical to cancer development and prognosis. BRD4, a chromatin reader protein, plays an essential role in regulating oncogene expression. Here, we investigated the contributing role of BRD4 and its related mechanisms in the context of ESCC tumor progression. Our observations showed that BRD4 transcript and protein expression levels are significantly increased in ESCC patient tissues. Genetic or pharmacological inhibition of BRD4 suppressed ESCC cell proliferation in vitro and in vivo. Proteomic and transcriptomic analyses were subsequently used to deduce the potential targets of BRD4. Mechanistic studies showed that RCC2 is a downstream target of BRD4. Inhibition of either BRD4 or RCC2 resulted in decreased ESCC cell proliferation. The BRD4-TP73 interaction facilitated the binding of BRD4 complex to the promoter region of RCC2, and subsequently modulated RCC2 transcription. Furthermore, targeting BRD4 with inhibitors significantly decreased tumor volume in ESCC PDX models, indicating that BRD4 expression may contribute to tumor progression. Collectively, these findings suggest that BRD4 inhibition could be a promising strategy to treat ESCC by downregulating RCC2.	[Wu, Qiong; Liu, Fangfang; Du, Ruijuan; Zhang, Jing; Zhi, Yafei; Kim, Dong Joon; Dong, Zigang; Liu, Kangdong] Zhengzhou Univ, Sch Basic Med Sci, Pathophysiol Dept, Zhengzhou 450000, Peoples R China; [Wu, Qiong; Liu, Fangfang; Ge, Mengmeng; Laster, Kyle Vaughn; Wei, Lixiao; Du, Ruijuan; Jiang, Ming; Zhang, Jing; Zhi, Yafei; Jin, Guoguo; Zhao, Simin; Kim, Dong Joon; Dong, Zigang; Liu, Kangdong] China US Henan Hormel Canc Inst, Zhengzhou 450000, Peoples R China; [Jin, Guoguo] Henan Luoyang Orthoped Hosp, Zhengzhou 450000, Henan, Peoples R China; [Zhao, Simin] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou 450000, Henan, Peoples R China; [Dong, Zigang; Liu, Kangdong] State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou 450000, Henan, Peoples R China; [Dong, Zigang; Liu, Kangdong] Zhengzhou Univ, Prov Cooperat Innovat Ctr Canc Chemoprevent, Zhengzhou 450000, Henan, Peoples R China; [Liu, Kangdong] Canc Chemoprevent Int Collaborat Lab, Zhengzhou 450000, Henan, Peoples R China	Zhengzhou University; Zhengzhou University; Zhengzhou University	Kim, DJ; Dong, ZG; Liu, KD (corresponding author), Zhengzhou Univ, Sch Basic Med Sci, Pathophysiol Dept, Zhengzhou 450000, Peoples R China.; Kim, DJ; Dong, ZG; Liu, KD (corresponding author), China US Henan Hormel Canc Inst, Zhengzhou 450000, Peoples R China.; Dong, ZG; Liu, KD (corresponding author), State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou 450000, Henan, Peoples R China.; Dong, ZG; Liu, KD (corresponding author), Zhengzhou Univ, Prov Cooperat Innovat Ctr Canc Chemoprevent, Zhengzhou 450000, Henan, Peoples R China.; Liu, KD (corresponding author), Canc Chemoprevent Int Collaborat Lab, Zhengzhou 450000, Henan, Peoples R China.	djkim@hci-cn.org; zgdong@hci-cn.org; kdliu@zzu.edu.cn			National Natural Science Foundations of China [81872335]; National Science & Technology Major Project Key New Drug Creation and Manufacturing Program, China [2018ZX09711002]; Central Plains Science and Technology Innovation Leading Talents (KL)	National Natural Science Foundations of China(National Natural Science Foundation of China (NSFC)); National Science & Technology Major Project Key New Drug Creation and Manufacturing Program, China; Central Plains Science and Technology Innovation Leading Talents (KL)	This research was funded by the National Natural Science Foundations of China (Grant no. 81872335), National Science & Technology Major Project Key New Drug Creation and Manufacturing Program, China (No. 2018ZX09711002) and Central Plains Science and Technology Innovation Leading Talents (KL). We thank all members of our team for critical input and suggestions.	Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352-3026(15)00247-1; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bruun J, 2015, CLIN CANCER RES, V21, P3759, DOI 10.1158/1078-0432.CCR-14-3294; Calderon-Aparicio A, 2020, MOL CANCER RES, V18, P1660, DOI 10.1158/1541-7786.MCR-19-1152; Cao W, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13797-9; Carrasco G, 2010, CLIN CANCER RES, V16, P3253, DOI 10.1158/1078-0432.CCR-09-2491; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chen QM, 2020, HUM CELL, V33, P709, DOI 10.1007/s13577-020-00353-7; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dominguez G, 2006, J CLIN ONCOL, V24, P805, DOI 10.1200/JCO.2005.02.2350; Dominguez G, 2001, BREAST CANCER RES TR, V66, P183, DOI 10.1023/A:1010624717311; Donati B, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0915-9; Dullo I, 2015, NAT CELL BIOL, V17, P511, DOI 10.1038/ncb3130; Dutton SJ, 2014, LANCET ONCOL, V15, P894, DOI 10.1016/S1470-2045(14)70024-5; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Faivre EJ, 2020, NATURE, V578, P306, DOI 10.1038/s41586-020-1930-8; Feng Q, 2014, CELL RES, V24, P809, DOI 10.1038/cr.2014.71; Fontanals-Cirera B, 2017, MOL CELL, V68, P731, DOI 10.1016/j.molcel.2017.11.004; Gao YB, 2014, NAT GENET, V46, P1097, DOI 10.1038/ng.3076; Henssen A, 2016, CLIN CANCER RES, V22, P2470, DOI 10.1158/1078-0432.CCR-15-1449; Hu N, 2016, CANCER RES, V76, P1714, DOI 10.1158/0008-5472.CAN-15-0338; Hu N, 2009, CANCER RES, V69, P5908, DOI 10.1158/0008-5472.CAN-08-4622; Hu XM, 2014, J BIOL CHEM, V289, P23154, DOI 10.1074/jbc.M114.570812; Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027; Jiang YA, 2016, ONCOL REP, V35, P785, DOI 10.3892/or.2015.4459; Kim J, 2017, NATURE, V541, P169, DOI 10.1038/nature20805; Li L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05231-3; Lin DC, 2018, GASTROENTEROLOGY, V154, P374, DOI 10.1053/j.gastro.2017.06.066; Liu KD, 2013, CANCER RES, V73, P2181, DOI 10.1158/0008-5472.CAN-12-3408; Lockwood WW, 2012, P NATL ACAD SCI USA, V109, P19408, DOI 10.1073/pnas.1216363109; Matsuo M, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-15; Mazur PK, 2015, NAT MED, V21, P1163, DOI 10.1038/nm.3952; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Mirguet O, 2013, J MED CHEM, V56, P7501, DOI 10.1021/jm401088k; Mollinari C, 2003, DEV CELL, V5, P295, DOI 10.1016/S1534-5807(03)00205-3; Nagarajan S, 2017, NUCLEIC ACIDS RES, V45, P3130, DOI 10.1093/nar/gkw1276; Nimura Y, 1998, INT J CANCER, V78, P437, DOI 10.1002/(SICI)1097-0215(19981109)78:4<437::AID-IJC8>3.0.CO;2-V; Novak U, 2001, ANN ONCOL, V12, P981, DOI 10.1023/A:1011153206003; Nozaki M, 2001, BRAIN PATHOL, V11, P296; Padmanabhan A, 2020, CIRCULATION, V142, P2338, DOI 10.1161/CIRCULATIONAHA.120.047753; Pang B, 2017, CLIN CANCER RES, V23, P5598, DOI 10.1158/1078-0432.CCR-16-2909; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Sawada G, 2016, GASTROENTEROLOGY, V150, P1171, DOI 10.1053/j.gastro.2016.01.035; Shah MA, 2015, J CLIN ONCOL, V33, P1760, DOI 10.1200/JCO.2014.60.1799; Sharif T, 2019, CLIN CANCER RES, V25, P2001, DOI 10.1158/1078-0432.CCR-17-3177; Siu KT, 2017, LEUKEMIA, V31, P1760, DOI 10.1038/leu.2016.355; Smyth EC, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.48; Soldevilla B, 2011, CLIN CANCER RES, V17, P6029, DOI 10.1158/1078-0432.CCR-10-2388; Song C, 2018, ONCOGENE, V37, P8, DOI 10.1038/onc.2017.306; Song YM, 2014, NATURE, V509, P91, DOI 10.1038/nature13176; Stiewe T, 2002, CELL DEATH DIFFER, V9, P237, DOI 10.1038/sj.cdd.4400995; Su H, 2011, CLIN CANCER RES, V17, P2955, DOI 10.1158/1078-0432.CCR-10-2724; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tannapfel A, 1999, J NATL CANCER I, V91, P1154, DOI 10.1093/jnci/91.13.1154; Thrumurthy SG, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4373; Tomkova K, 2004, CANCER RES, V64, P6390, DOI 10.1158/0008-5472.CAN-04-2176; Vikhanskaya F, 2007, NAT CELL BIOL, V9, P698, DOI 10.1038/ncb1598; Winter GE, 2017, MOL CELL, V67, P5, DOI 10.1016/j.molcel.2017.06.004; Yang H, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-06901-6; Yu H, 2019, BIOCHEM BIOPH RES CO, V516, P999, DOI 10.1016/j.bbrc.2019.06.097; Zaika AI, 1999, CANCER RES, V59, P3257; Zanconato F, 2018, NAT MED, V24, P1599, DOI 10.1038/s41591-018-0158-8; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	65	3	3	7	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2022	41	3					347	360		10.1038/s41388-021-02099-4	http://dx.doi.org/10.1038/s41388-021-02099-4		NOV 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YF8LK	34750516				2022-12-17	WOS:000715670800003
J	Ruiz-Torres, SJ; Bourn, JR; Benight, NM; Hunt, BG; Lester, C; Waltz, SE				Ruiz-Torres, Sasha J.; Bourn, Jennifer R.; Benight, Nancy M.; Hunt, Brian G.; Lester, Carissa; Waltz, Susan E.			Macrophage-mediated RON signaling supports breast cancer growth and progression through modulation of IL-35	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASE; STIMULATING PROTEIN; IFN-GAMMA; PERITONEAL-MACROPHAGES; TUMOR-GROWTH; ACTIVATION; EXPRESSION; CELLS; IL-12; INHIBITION	Tumor associated macrophages (TAMs) play a major role in regulating mammary tumor growth and in directing the responses of tumor infiltrating leukocytes in the microenvironment. However, macrophage-specific mechanisms regulating the interactions of macrophages with tumor cells and other leukocytes that support tumor progression have not been extensively studied. In this study, we show that the activation of the RON receptor tyrosine kinase signaling pathway specifically in macrophages supports breast cancer growth and metastasis. Using clinically relevant murine models of breast cancer, we demonstrate that loss of macrophage RON expression results in decreases in mammary tumor cell proliferation, survival, cancer stem cell self-renewal, and metastasis. Macrophage RON signaling modulates these phenotypes via direct effects on the tumor proper and indirectly by regulating leukocyte recruitment including macrophages, T-cells, and B-cells in the mammary tumor microenvironment. We further show that macrophage RON expression regulates the macrophage secretome including IL-35 and other immunosuppressive factors. Overall, our studies implicate activation of RON signaling in macrophages as a key player in supporting a thriving mammary pro-tumor microenvironment through novel mechanisms including the augmentation of tumor cell properties through IL-35.	[Ruiz-Torres, Sasha J.; Bourn, Jennifer R.; Benight, Nancy M.; Hunt, Brian G.; Lester, Carissa; Waltz, Susan E.] Univ Cincinnati, Dept Canc Biol, Coll Med, Cincinnati, OH 45267 USA; [Waltz, Susan E.] Cincinnati Vet Affairs Med Ctr, Res Serv, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center	Waltz, SE (corresponding author), Univ Cincinnati, Dept Canc Biol, Coll Med, Cincinnati, OH 45267 USA.; Waltz, SE (corresponding author), Cincinnati Vet Affairs Med Ctr, Res Serv, Cincinnati, OH 45267 USA.	susan.waltz@uc.edu		Bourn, Jennifer/0000-0002-0902-2850; Waltz, Susan/0000-0003-3572-4642; Hunt, Brian/0000-0003-4155-730X	US Department of Veterans Affairs [1IOBX000803]; National Institutes of Health [R01 CA239697, T32 CA117846, F31 CA228373]; National Institutes of Diabetes & Digestive & Kidney Diseases [P30 DK078392]	US Department of Veterans Affairs(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Diabetes & Digestive & Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We would like to thank Vidjaya L. Premkumar, Lennox Brooks, Rebekah Karns, James Davis, and Madison Nashu for their technical and bioinformatic assistance. US Department of Veterans Affairs research grant 1IOBX000803 (SEW); National Institutes of Health grants R01 CA239697 (SEW), T32 CA117846 (SEW, SJRT, NMB, JRB), F31 CA228373 (BGH, SEW), and National Institutes of Diabetes & Digestive & Kidney Diseases grant P30 DK078392.	Benight NM, 2015, ONCOTARGET, V6, P17445, DOI 10.18632/oncotarget.3641; Benight NM, 2012, EXPERT OPIN THER TAR, V16, P921, DOI 10.1517/14728222.2012.710200; Brunelleschi S, 2001, BRIT J PHARMACOL, V134, P1285, DOI 10.1038/sj.bjp.0704356; Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427; Chen YQ, 1998, J IMMUNOL, V161, P4950; Choi JJ, 2015, CLIN REV ALLERG IMMU, V49, P327, DOI 10.1007/s12016-015-8468-9; Dambuza IM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00838-4; De Nardo D, 2018, METHODS MOL BIOL, V1784, P35, DOI 10.1007/978-1-4939-7837-3_4; Eyob H, 2013, CANCER DISCOV, V3, P751, DOI 10.1158/2159-8290.CD-12-0480; Goodridge HS, 2003, IMMUNOLOGY, V109, P415, DOI 10.1046/j.1365-2567.2003.01689.x; Gurusamy D, 2013, CANCER RES, V73, P1752, DOI 10.1158/0008-5472.CAN-12-2474; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hunt BG, 2020, BREAST CANCER RES TR, V181, P529, DOI 10.1007/s10549-020-05653-y; Ito Y, 2010, J CLIN INVEST, V120, P1981, DOI 10.1172/JCI39650; IWAMA A, 1995, BLOOD, V86, P3394, DOI 10.1182/blood.V86.9.3394.bloodjournal8693394; Jadus MR, 1996, BLOOD, V87, P5232, DOI 10.1182/blood.V87.12.5232.bloodjournal87125232; Kollet JI, 2006, MOL IMMUNOL, V43, P623, DOI 10.1016/j.molimm.2005.04.004; Korkaya H, 2011, J CLIN INVEST, V121, P3804, DOI 10.1172/JCI57099; Kourko O, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00969; Kulkarni RM, 2014, HEPATOB PANCREAT DIS, V13, P281, DOI 10.1016/S1499-3872(14)60254-X; KULKARNI RM, 2014, AM J PHYSIOL-GASTR L, V306; Kurihara N, 1996, BLOOD, V87, P3704, DOI 10.1182/blood.V87.9.3704.bloodjournal8793704; Lee CC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06268-0; Lindsten T, 2017, INT J ONCOL, V51, P104, DOI 10.3892/ijo.2017.3996; Liu JG, 2004, J BIOL CHEM, V279, P55609, DOI 10.1074/jbc.M406565200; McClaine RJ, 2010, NEOPLASIA, V12, P650, DOI 10.1593/neo.10476; Morrison AC, 2004, J IMMUNOL, V172, P1825, DOI 10.4049/jimmunol.172.3.1825; Morrison AC, 2002, J IMMUNOL, V168, P853, DOI 10.4049/jimmunol.168.2.853; Nanney LB, 1998, J INVEST DERMATOL, V111, P573, DOI 10.1046/j.1523-1747.1998.00332.x; Nikolaidis NM, 2011, INNATE IMMUN-LONDON, V17, P499, DOI 10.1177/1753425910383725; Nikolaidis NM, 2010, SHOCK, V33, P197, DOI 10.1097/SHK.0b013e3181ae8155; Peace BE, 2005, CANCER RES, V65, P1285, DOI 10.1158/0008-5472.CAN-03-3580; Pylayeva-Gupta Y, 2016, CLIN CANCER RES, V22, P4973, DOI 10.1158/1078-0432.CCR-16-0743; Ray M, 2010, J IMMUNOL, V185, P7309, DOI 10.4049/jimmunol.1000095; Ruiz-Torres SJ, 2017, ONCOTARGET, V8, P58918, DOI 10.18632/oncotarget.19441; Sainz B, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9012369; Sawant DV, 2015, J INTERF CYTOK RES, V35, P499, DOI 10.1089/jir.2015.0015; Sharda DR, 2011, J IMMUNOL, V187, P2181, DOI 10.4049/jimmunol.1003460; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Singh Saroj, 2017, Biochim Open, V4, P8, DOI 10.1016/j.biopen.2016.11.002; Stuart WD, 2011, HEPATOLOGY, V53, P1618, DOI 10.1002/hep.24239; Sullivan C, 2020, MOL CANCER RES, V18, P1244, DOI 10.1158/1541-7786.MCR-20-0060; Vignali DAA, 2012, NAT IMMUNOL, V13, P722, DOI 10.1038/ni.2366; Wagh PK, 2008, ADV CANCER RES, V100, P1, DOI 10.1016/S0065-230X(08)00001-8; Waltz SE, 2001, J CLIN INVEST, V108, P567, DOI 10.1172/JCI200111881; WANG MH, 1994, J BIOL CHEM, V269, P14027; Wellenstein MD, 2018, IMMUNITY, V48, P399, DOI 10.1016/j.immuni.2018.03.004; Welm AL, 2007, P NATL ACAD SCI USA, V104, P7570, DOI 10.1073/pnas.0702095104; Wilson CB, 2008, J IMMUNOL, V181, P2303, DOI 10.4049/jimmunol.181.4.2303; Zinser GM, 2006, CANCER RES, V66, P11967, DOI 10.1158/0008-5472.CAN-06-2473	50	3	3	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2022	41	3					321	333		10.1038/s41388-021-02091-y	http://dx.doi.org/10.1038/s41388-021-02091-y		NOV 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YF8LK	34743208	Green Accepted			2022-12-17	WOS:000715015000002
J	Shin, DH; Kim, SH; Choi, M; Bae, YK; Han, C; Choi, BK; Kim, SS; Han, JY				Shin, Dong Hoon; Kim, Sun Ha; Choi, Minyoung; Bae, Young-Ki; Han, Chungyong; Choi, Beom K.; Kim, Sang Soo; Han, Ji-Youn			Oncogenic KRAS promotes growth of lung cancer cells expressing SLC3A2-NRG1 fusion via ADAM17-mediated shedding of NRG1	ONCOGENE			English	Article							FACTOR RECEPTOR; EGF RECEPTOR; RAS; ADAM17; CHEMOTHERAPY; ACTIVATION; PHYSIOLOGY; PATHWAYS; GENETICS; CLEAVAGE	We previously found the SLC3A2-NRG1 (S-N) fusion gene in a lung adenocarcinoma specimen without known driver mutations and validated this in 59 invasive mucinous adenocarcinoma (IMA) samples. Interestingly, KRAS mutation coexisted (62.5%) in 10 out of 16 NRG1 fusions. In this study, we examined the role of mutant KRAS in regulating the S-N fusion protein in KRAS mutant (H358) and wild-type (Calu-3) cells. KRAS mutation-mediated increase in MEK1/2 and ERK1/2 activity enhanced disintegrin and metalloproteinase (ADAM)17 activity, which increased the shedding of NRG1 from the S-N fusion protein. The cleavage of NRG1 also increased the phosphorylation of ERBB2-ERBB3 heterocomplex receptors and their downstream signalling pathways, including PI3K/Akt/mTOR, even under activated KRAS mutation signalling. The concurrence of S-N fusion and KRAS mutation synergistically increased cell proliferation, colony formation, tumour growth, and the cells' resistance to EGFR kinase inhibitors more than KRAS mutation alone. Targeted inhibition of MEK1/2, and ADAM17 significantly induced apoptosis singly and when combined with each mutation singly or with chemotherapy in both the concurrent KRAS mutant and S-N fusion xenograft and lung orthotopic models. Taken together, this is the first study to report that KRAS mutation increased NRG1 cleavage from the S-N fusion protein through ADAM17, thereby enhancing the Ras/Raf/MEK/ERK and ERBB/PI3K/Akt/mTOR pathways. Moreover, the coexistence of KRAS mutant and S-N fusion in lung tumours renders them vulnerable to MEK1/2 and/or ADAM17 inhibitors, at least in part, due to their dependency on the strong positive loop between KRAS mutation and S-N fusion.	[Shin, Dong Hoon; Kim, Sun Ha; Choi, Minyoung; Bae, Young-Ki; Han, Chungyong; Choi, Beom K.; Kim, Sang Soo; Han, Ji-Youn] Res Inst, Goyang S, South Korea; [Shin, Dong Hoon; Kim, Sun Ha] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Canc Biomed Sci, Goyang Si, Gyeonggi Do, South Korea	National Cancer Center - Korea (NCC)	Shin, DH; Han, JY (corresponding author), Res Inst, Goyang S, South Korea.; Shin, DH (corresponding author), Natl Canc Ctr, Grad Sch Canc Sci & Policy, Canc Biomed Sci, Goyang Si, Gyeonggi Do, South Korea.	dhshin@ncc.re.kr; jymama@ncc.re.kr			National Cancer Centre [NCC-2010070, 2110340]; National Research Fund [NRF-2021R1F1A1062721]	National Cancer Centre; National Research Fund(Luxembourg National Research Fund)	This work was supported by grants (NCC-2010070 and 2110340) funded by the National Cancer Centre, and NRF-2021R1F1A1062721 funded by the National Research Fund.	Ambrogio C, 2017, ONCOGENE, V36, P2309, DOI 10.1038/onc.2016.385; Ardito CM, 2012, CANCER CELL, V22, P304, DOI 10.1016/j.ccr.2012.07.024; Baumgart A, 2010, CANCER RES, V70, P5368, DOI 10.1158/0008-5472.CAN-09-3763; BOS JL, 1989, CANCER RES, V49, P4682; Burdett S, 2014, LANCET, V383, P1561, DOI 10.1016/S0140-6736(13)62159-5; Chang JC, 2021, CLIN CANCER RES, V27, P4066, DOI 10.1158/1078-0432.CCR-21-0423; Chen JC, 2016, PHYSIOL REV, V96, P1025, DOI 10.1152/physrev.00030.2015; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Cisowski J, 2016, ONCOGENE, V35, P1328, DOI 10.1038/onc.2015.186; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Freed DM, 2017, CELL, V171, P683, DOI 10.1016/j.cell.2017.09.017; Fridman JS, 2007, CLIN CANCER RES, V13, P1892, DOI 10.1158/1078-0432.CCR-06-2116; Greulich Heidi, 2010, Genes Cancer, V1, P1200, DOI 10.1177/1947601911407324; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; Hames ML, 2016, LUNG CANCER, V92, P29, DOI 10.1016/j.lungcan.2015.11.004; Itahana Koji, 2007, Methods Mol Biol, V371, P21; Janssens E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052915; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Jonna S, 2019, CLIN CANCER RES, V25, P4966, DOI 10.1158/1078-0432.CCR-19-0160; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kamb A, 2003, MOL BIOL CELL, V14, P2201, DOI 10.1091/mbc.E02-11-0732; Karreth FA, 2009, CURR OPIN GENET DEV, V19, P4, DOI 10.1016/j.gde.2008.12.006; Kim BM, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8275256; Kim TM, 2015, J THORAC ONCOL, V10, P1736, DOI 10.1097/JTO.0000000000000688; Kris MG, 2014, JAMA-J AM MED ASSOC, V311, P1998, DOI 10.1001/jama.2014.3741; Kwan JC, 2009, J MED CHEM, V52, P5732, DOI 10.1021/jm9009394; Ma SQ, 2021, ONCOGENE, V40, P2596, DOI 10.1038/s41388-021-01734-4; Ni SS, 2013, TUMOR BIOL, V34, P1813, DOI 10.1007/s13277-013-0721-3; Saad MI, 2019, CANCERS, V11, DOI 10.3390/cancers11091218; Saad MI, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201809976; Sharma A, 2016, CLIN CANCER RES, V22, P4428, DOI 10.1158/1078-0432.CCR-15-2449; Sharma SV, 2010, BIOCHEM PHARMACOL, V80, P666, DOI 10.1016/j.bcp.2010.03.001; Shin DH, 2018, MOL CANCER THER, V17, P2024, DOI 10.1158/1535-7163.MCT-17-1178; Shin DH, 2016, ONCOTARGET, V7, P69450, DOI 10.18632/oncotarget.11913; Torti D, 2011, EMBO MOL MED, V3, P623, DOI 10.1002/emmm.201100176; Travis WD, 2013, J CLIN ONCOL, V31, P992, DOI 10.1200/JCO.2012.46.9270; Unni AM, 2015, ELIFE, V4, DOI 10.7554/eLife.06907; Van Schaeybroeck S, 2011, CANCER RES, V71, P1071, DOI 10.1158/0008-5472.CAN-10-0714; Wennerberg K, 2005, J CELL SCI, V118, P843, DOI 10.1242/jcs.01660; Wong MCS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14513-7; Xu PL, 2010, MOL CELL, V37, P551, DOI 10.1016/j.molcel.2010.01.034; Ying HQ, 2016, GENE DEV, V30, P355, DOI 10.1101/gad.275776.115; You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008; Zheng ZY, 2020, CANCER CELL, V37, P387, DOI 10.1016/j.ccell.2020.02.003; Zhou BBS, 2006, CANCER CELL, V10, P39, DOI 10.1016/j.ccr.2006.05.024; Zunke F, 2017, BBA-MOL CELL RES, V1864, P2059, DOI 10.1016/j.bbamcr.2017.07.001	48	3	3	4	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2022	41	2					280	292		10.1038/s41388-021-02097-6	http://dx.doi.org/10.1038/s41388-021-02097-6		NOV 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC1XK	34743207				2022-12-17	WOS:000715015000001
J	Tang, SC; Lion, Q; Peulen, O; Chariot, P; Lavergne, A; Mayer, A; Fuster, PA; Close, P; Klein, S; Florin, A; Buttner, R; Nemazanyy, I; Shostak, K; Chariot, A				Tang, Seng Chuan; Lion, Quentin; Peulen, Olivier; Chariot, Philippe; Lavergne, Arnaud; Mayer, Alice; Fuster, Paula Allepuz; Close, Pierre; Klein, Sebastian; Florin, Alexandra; Buettner, Reinhard; Nemazanyy, Ivan; Shostak, Kateryna; Chariot, Alain			The E3 ligase COP1 promotes ER alpha signaling and suppresses EMT in breast cancer	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; REGULATES C-JUN; TUMOR-SUPPRESSOR; CELLS; EXPRESSION; TRANSCRIPTION; MECHANISMS; RESISTANCE; STABILITY; PHOSPHORYLATION	ER alpha signaling drives proliferation, survival and cancer initiation in the mammary gland. Therefore, it is critical to elucidate mechanisms by which ER alpha expression is regulated. We show that the tumor suppressor E3 ligase COP1 promotes the degradative polyubiquitination of the microtubule-associated protein HPIP. As such, COP1 negatively regulates estrogen-dependent AKT activation in breast cancer cells. However, COP1 also induces ER alpha expression and ER alpha-dependent gene transcription, at least through c-Jun degradation. COP1 and ER alpha levels are positively correlated in clinical cases of breast cancer. COP1 also supports the metabolic reprogramming by estrogens, including glycolysis. On the other hand, COP1 suppresses EMT in breast cancer cells. COP1 deficiency also contributes to Tamoxifen resistance, at least through protective autophagy. Therefore, COP1 acts as an oncogenic E3 ligase by promoting ER alpha signaling but also acts as a tumor suppressor candidate by preventing EMT, which reflects a dual role of COP1 in breast cancer.	[Tang, Seng Chuan; Lion, Quentin; Peulen, Olivier; Chariot, Philippe; Lavergne, Arnaud; Mayer, Alice; Fuster, Paula Allepuz; Close, Pierre; Shostak, Kateryna; Chariot, Alain] Univ Liege, Interdisciplinary Cluster Appl Genoprote, CHU, Liege, Belgium; [Tang, Seng Chuan; Lion, Quentin; Chariot, Philippe; Fuster, Paula Allepuz; Shostak, Kateryna; Chariot, Alain] Univ Liege, Lab Med Chem, GIGA Stem Cells, CHU, Liege, Belgium; [Peulen, Olivier] Univ Liege, Metastasis Res Lab, GIGA Canc, CHU, Liege, Belgium; [Lavergne, Arnaud; Mayer, Alice] Univ Liege, GIGA Genom Platform, CHU, Liege, Belgium; [Close, Pierre] Univ Liege, Lab Canc Signaling, GIGA Stem Cells, CHU, B-4000 Liege, Belgium; [Close, Pierre; Chariot, Alain] Walloon Excellence Life Sci & Biotechnol WELBIO, Wavres, Belgium; [Klein, Sebastian; Florin, Alexandra; Buettner, Reinhard] Univ Hosp Cologne, Inst Pathol, Cologne, Germany; [Nemazanyy, Ivan] INSERM, Platform Metab Anal, Struct Federat Rech Necker, US24 CNRS UMS 3633, Paris, France	University of Liege; University of Liege; University of Liege; University of Liege; University of Liege; WELBIO; University of Cologne; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Chariot, A (corresponding author), Univ Liege, Interdisciplinary Cluster Appl Genoprote, CHU, Liege, Belgium.; Chariot, A (corresponding author), Univ Liege, Lab Med Chem, GIGA Stem Cells, CHU, Liege, Belgium.; Chariot, A (corresponding author), Walloon Excellence Life Sci & Biotechnol WELBIO, Wavres, Belgium.	Alain.chariot@uliege.ac.be	Peulen, Olivier/C-1250-2018	Peulen, Olivier/0000-0002-6933-0134; LION, Quentin/0000-0002-9662-9318; Tang, Seng Chuan/0000-0002-8709-3531	Belgian National Funds for Scientific Research (FNRS); Special Research Funds (FSR) at the University of Liege; Belgian foundation against Cancer [FAF-F/2016/794]; Walloon Excellence in Life Sciences and Biotechnology [WELBIO-CR-2015A-02]; "Fondation Leon Fredericq" of the CHU Liege	Belgian National Funds for Scientific Research (FNRS)(Fonds de la Recherche Scientifique - FNRS); Special Research Funds (FSR) at the University of Liege; Belgian foundation against Cancer; Walloon Excellence in Life Sciences and Biotechnology; "Fondation Leon Fredericq" of the CHU Liege	The authors thank Arnaud Blomme (Laboratory of Cancer Signaling, University of Liege, Liege, Belgium) for the gift of PyMT cells. The authors also thank the GIGA Imaging and Flow Cytometry Facility as well as the GIGA Genomics Platform for RNA-Sequencing analyses. This study was supported by Grants from the Belgian National Funds for Scientific Research (FNRS) and from Special Research Funds (FSR) at the University of Liege, the Belgian foundation against Cancer (FAF-F/2016/794), as well as from the Walloon Excellence in Life Sciences and Biotechnology (WELBIO-CR-2015A-02). We are also grateful to the "Fondation Leon Fredericq" of the CHU Liege for its financial support. A. Chariot and P. Close are Research Director and Senior Research Associate at the FNRS, respectively. The authors declare no conflict of interest.	Allred DC, 2004, BREAST CANCER RES, V6, P240, DOI 10.1186/bcr938; Baert JL, 2010, ONCOGENE, V29, P1810, DOI 10.1038/onc.2009.471; Chan EYW, 2007, J BIOL CHEM, V282, P25464, DOI 10.1074/jbc.M703663200; Cook KL, 2012, CANCER RES, V72, P3337, DOI 10.1158/0008-5472.CAN-12-0269; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Ewels PA, 2020, NAT BIOTECHNOL, V38, P276, DOI 10.1038/s41587-020-0439-x; Folkerd EJ, 2010, J CLIN ONCOL, V28, P4038, DOI 10.1200/JCO.2009.27.4290; Gatot JS, 2007, J BIOL CHEM, V282, P31131, DOI 10.1074/jbc.M701690200; Grabinski N, 2014, CELL SIGNAL, V26, P1021, DOI 10.1016/j.cellsig.2014.01.018; Hawley SA, 2010, CELL METAB, V11, P554, DOI 10.1016/j.cmet.2010.04.001; Hendriks MMWB, 2007, PROTEOMICS, V7, P3672, DOI 10.1002/pmic.200700046; Ikeda K, 2015, ACTA PHARMACOL SIN, V36, P24, DOI 10.1038/aps.2014.123; Jia M, 2016, CANCER RES, V76, P5634, DOI 10.1158/0008-5472.CAN-15-2910; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Kos M, 2001, MOL ENDOCRINOL, V15, P2057, DOI 10.1210/me.15.12.2057; Lorent J, 2019, EMBO J, V38, DOI 10.15252/embj.2018101323; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Luque-Bolivar A, 2020, BREAST CANCER-TARGET, V12, P211, DOI 10.2147/BCTT.S270799; Madureira PA, 2006, J BIOL CHEM, V281, P25167, DOI 10.1074/jbc.M603906200; Manavathi B, 2006, P NATL ACAD SCI USA, V103, P15981, DOI 10.1073/pnas.0607445103; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marine JC, 2012, NAT REV CANCER, V12, P455, DOI 10.1038/nrc3271; Meley D, 2006, J BIOL CHEM, V281, P34870, DOI 10.1074/jbc.M605488200; Migliorini D, 2011, J CLIN INVEST, V121, P1329, DOI 10.1172/JCI45784; NEEMAN M, 1989, P NATL ACAD SCI USA, V86, P5585, DOI 10.1073/pnas.86.14.5585; NEEMAN M, 1989, CANCER RES, V49, P589; O'Mahony F, 2012, MOL ENDOCRINOL, V26, P2058, DOI 10.1210/me.2012-1191; Ouyang M, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1151-y; Rademaker G, 2018, ONCOGENE, V37, P4398, DOI 10.1038/s41388-018-0287-z; Rae JM, 2005, BREAST CANCER RES TR, V92, P141, DOI 10.1007/s10549-005-1483-4; Samaddar JS, 2008, MOL CANCER THER, V7, P2977, DOI 10.1158/1535-7163.MCT-08-0447; Shostak K, 2014, CELL DEATH DIFFER, V21, P811, DOI 10.1038/cdd.2014.2; Shostak K, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15003-7; Shostak K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6232; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; Tecalco-Cruz AC, 2017, CLIN BREAST CANCER, V17, P1, DOI 10.1016/j.clbc.2016.07.015; Turner BC, 1998, CANCER RES, V58, P5466; van Gastel N, 2020, NATURE, V579, P111, DOI 10.1038/s41586-020-2050-1; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Vitari AC, 2011, NATURE, V474, P403, DOI 10.1038/nature10005; Wang SC, 2015, BIOMED PHARMACOTHER, V75, P33, DOI 10.1016/j.biopha.2015.08.027; Welboren WJ, 2009, ENDOCR-RELAT CANCER, V16, P1073, DOI 10.1677/ERC-09-0086; Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88; Wertz IE, 2004, SCIENCE, V303, P1371, DOI 10.1126/science.1093549; Xia JG, 2015, NUCLEIC ACIDS RES, V43, pW251, DOI 10.1093/nar/gkv380; Yoshida T, 2000, CARCINOGENESIS, V21, P2193, DOI 10.1093/carcin/21.12.2193; Zou SS, 2017, MOL NEUROBIOL, V54, P5008, DOI 10.1007/s12035-016-0033-x	50	3	3	3	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2022	41	2					173	190		10.1038/s41388-021-02038-3	http://dx.doi.org/10.1038/s41388-021-02038-3		OCT 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC1XK	34716429				2022-12-17	WOS:000712720900001
J	Rasheed, SAK; Subramanyan, LV; Lim, WK; Udayappan, UK; Wang, M; Casey, PJ				Rasheed, Suhail Ahmed Kabeer; Subramanyan, Lalitha Vaishnavi; Lim, Wei Kiang; Udayappan, Udhaya Kumari; Wang, Mei; Casey, Patrick J.			The emerging roles of G alpha 12/13 proteins on the hallmarks of cancer in solid tumors	ONCOGENE			English	Review							HETEROTRIMERIC G-PROTEINS; EPITHELIAL-MESENCHYMAL TRANSITION; EMBRYONAL CARCINOMA-CELLS; COUPLED RECEPTORS; GEP ONCOGENE; G ALPHA(12); STEM-CELLS; COOPERATIVE TRANSFORMATION; HEPATOCELLULAR-CARCINOMA; SIGNALING PATHWAY	G12 proteins comprise a subfamily of G-alpha subunits of heterotrimeric GTP-binding proteins (G proteins) that link specific cell surface G protein-coupled receptors (GPCRs) to downstream signaling molecules and play important roles in human physiology. The G12 subfamily contains two family members: G alpha 12 and G alpha 13 (encoded by the GNA12 and GNA13 genes, respectively) and, as with all G proteins, their activity is regulated by their ability to bind to guanine nucleotides. Increased expression of both G alpha 12 and G alpha 13, and their enhanced signaling, has been associated with tumorigenesis and tumor progression of multiple cancer types over the past decade. Despite these strong associations, G alpha 12/13 proteins are underappreciated in the field of cancer. As our understanding of G protein involvement in oncogenic signaling has evolved, it has become clear that G alpha 12/13 signaling is pleotropic and activates specific downstream effectors in different tumor types. Further, the expression of G alpha 12/13 proteins is regulated through a series of transcriptional and post-transcriptional mechanisms, several of which are frequently deregulated in cancer. With the ever-increasing understanding of tumorigenic processes driven by G alpha 12/13 proteins, it is becoming clear that targeting G alpha 12/13 signaling in a context-specific manner could provide a new strategy to improve therapeutic outcomes in a number of solid tumors. In this review, we detail how G alpha 12/13 proteins, which were first discovered as proto-oncogenes, are now known to drive several "classical" hallmarks, and also play important roles in the "emerging" hallmarks, of cancer.	[Rasheed, Suhail Ahmed Kabeer; Subramanyan, Lalitha Vaishnavi; Lim, Wei Kiang; Udayappan, Udhaya Kumari; Wang, Mei; Casey, Patrick J.] Duke NUS Med Sch, Program Canc & Stem Cell Biol, Singapore 169857, Singapore; [Casey, Patrick J.] Duke Univ, Dept Pharmacol & Canc Biol, Med Ctr, Durham, NC 27710 USA	National University of Singapore; Duke University	Casey, PJ (corresponding author), Duke NUS Med Sch, Program Canc & Stem Cell Biol, Singapore 169857, Singapore.; Casey, PJ (corresponding author), Duke Univ, Dept Pharmacol & Canc Biol, Med Ctr, Durham, NC 27710 USA.	patrick.casey@duke.edu		Casey, Patrick/0000-0002-7366-9309; Rasheed, Suhail Ahmed Kabeer/0000-0002-7674-7560; Wang, Mei/0000-0001-6887-6840	Ministry of Education, Singapore [MOE2018-T2-1-147]	Ministry of Education, Singapore(Ministry of Education, Singapore)	We thank Ministry of Education, Singapore (PI: Patrick Casey; MOE2018-T2-1-147) for funding some of the work described in the manuscript. We declare that the authors do not have any conflict of interest.	Akhurst RJ, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022301; Alfaro C, 2017, CANCER TREAT REV, V60, P24, DOI 10.1016/j.ctrv.2017.08.004; Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; Annala S, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aau5948; Arang N, 2020, FEBS LETT, V594, P4201, DOI 10.1002/1873-3468.14017; Baillie R, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00112; Bartolome RA, 2008, CANCER RES, V68, P8221, DOI 10.1158/0008-5472.CAN-08-0561; Bian D, 2006, ONCOGENE, V25, P2234, DOI 10.1038/sj.onc.1209261; Buch TRH, 2014, ADV BIOSCI BIOTECHNO, V05, P73, DOI DOI 10.1007/JHEP09(2014)006; Cai H, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-31; Carloni V, 2013, ONCOGENE, V32, P2649, DOI 10.1038/onc.2012.268; Cerchio R, 2020, GPCRS: STRUCTURE, FUNCTION, AND DRUG DISCOVERY, P463, DOI 10.1016/B978-0-12-816228-6.00022-2; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Chang Q, 2014, SEMIN IMMUNOL, V26, P48, DOI 10.1016/j.smim.2014.01.007; Chen QY, 2016, ONCOTARGET, V7, P18247, DOI 10.18632/oncotarget.7570; Chiang CW, 2014, J HIGH ENERGY PHYS, DOI [10.1186/1750-2187-9-6, 10.1007/JHEP09(2014)006]; De Francesco EM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122713; Dermott JM, 1999, ONCOGENE, V18, P7185, DOI 10.1038/sj.onc.1203345; Dobashi A, 2016, J CLIN EXP HEMATOP, V56, P71; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Dougan M, 2009, ANNU REV IMMUNOL, V27, P83, DOI 10.1146/annurev.immunol.021908.132544; Fouad YA, 2017, AM J CANCER RES, V7, P1016; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fu XD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002790; Fulda S, 2009, INT J CANCER, V124, P511, DOI 10.1002/ijc.24064; Gan CP, 2014, ONCOTARGET, V5, P9626, DOI 10.18632/oncotarget.2437; Gantulga D, 2008, J BIOCHEM, V144, P693, DOI 10.1093/jb/mvn123; Gentzler R, 2016, IMMUNOTHERAPY-UK, V8, P583, DOI 10.2217/imt-2015-0029; Giretti MS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002238; Ha Ji Hee, 2015, Genes Cancer, V6, P356; Ha JH, 2014, CELL SIGNAL, V26, P122, DOI 10.1016/j.cellsig.2013.08.012; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hauser AS, 2017, NAT REV DRUG DISCOV, V16, P829, DOI 10.1038/nrd.2017.178; Heide T, 2019, J PATHOL, V248, P230, DOI 10.1002/path.5250; Hsu JM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04313-6; Hu YQ, 2015, ONCOL REP, V34, P2507, DOI 10.3892/or.2015.4209; Jho EH, 1997, J BIOL CHEM, V272, P24461, DOI 10.1074/jbc.272.39.24461; Jhun BS, 2018, J PHYSIOL-LONDON, V596, P827, DOI 10.1113/JP275418; Jian SL., 2013, PLOS ONE, V8, P1, DOI DOI 10.1016/j.cell.2008.03.027; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Joshi S, 2015, INT J CANCER, V137, P1503, DOI 10.1002/ijc.29506; Juneja J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026085; Juneja J, 2009, BRIT J PHARMACOL, V158, P32, DOI 10.1111/j.1476-5381.2009.00180.x; Jung HS, 2014, CELL SIGNAL, V26, P1456, DOI 10.1016/j.cellsig.2014.02.022; Kelley GG, 2004, BIOCHEM J, V378, P129, DOI 10.1042/BJ20031370; Kelly P, 2007, BIOCHEMISTRY-US, V46, P6677, DOI 10.1021/bi700235f; Kelly P, 2006, J BIOL CHEM, V281, P26483, DOI 10.1074/jbc.M604376200; Kelly P, 2006, P NATL ACAD SCI USA, V103, P8173, DOI 10.1073/pnas.0510254103; Kim ES, 2010, BREAST CANCER RES TR, V124, P49, DOI 10.1007/s10549-009-0697-2; Koundouros N, 2020, BRIT J CANCER, V122, P4, DOI 10.1038/s41416-019-0650-z; Kozasa T, 2011, J BIOCHEM, V150, P357, DOI 10.1093/jb/mvr105; Krawetz R, 2006, EXP CELL RES, V312, P3224, DOI 10.1016/j.yexcr.2006.06.016; Krawetz R, 2009, BIOCHEM CELL BIOL, V87, P567, DOI [10.1139/o09-014, 10.1139/O09-014]; Kumar RN, 2006, ONCOGENE, V25, P899, DOI 10.1038/sj.onc.1209132; Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lappano R, 2011, NAT REV DRUG DISCOV, V10, P47, DOI 10.1038/nrd3320; Lee SJ, 2009, ONCOGENE, V28, P1230, DOI 10.1038/onc.2008.488; Lee SY, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0577-4; Li HL, 2019, CANCER BIOL MED, V16, P79, DOI 10.20892/j.issn.2095-3941.2018.0170; Lim WK, 2019, J BIOL CHEM, V294, P18192, DOI 10.1074/jbc.RA119.010018; Liu SC, 2009, CANCER RES, V69, P6122, DOI 10.1158/0008-5472.CAN-08-3435; Liu WJ, 2017, GENE, V626, P275, DOI 10.1016/j.gene.2017.05.040; Love C, 2012, NAT GENET, V44, P1321, DOI 10.1038/ng.2468; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mariggio S, 2006, CELL SIGNAL, V18, P2200, DOI 10.1016/j.cellsig.2006.05.003; Mastop M, 2018, PLOS ONE, V13, P1, DOI DOI 10.1158/2159-8290.CD-15-0224; Meigs TE, 2002, J BIOL CHEM, V277, P24594, DOI 10.1074/jbc.M201984200; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Morin RD, 2013, BLOOD, V122, P1256, DOI 10.1182/blood-2013-02-483727; Mu GG, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0081-6; Muppidi JR, 2014, NATURE, V516, P254, DOI 10.1038/nature13765; Mutlu M, 2016, SCI REP-UK, V6, DOI 10.1038/srep32541; O'Hayre M, 2014, CURR OPIN CELL BIOL, V27, P126, DOI 10.1016/j.ceb.2014.01.005; Offermanns S, 2001, ONCOGENE, V20, P1635, DOI 10.1038/sj.onc.1204189; Oldham WM, 2008, NAT REV MOL CELL BIO, V9, P60, DOI 10.1038/nrm2299; Park HW, 2015, CELL, V162, P780, DOI 10.1016/j.cell.2015.07.013; Pietras K, 2010, EXP CELL RES, V316, P1324, DOI 10.1016/j.yexcr.2010.02.045; Prud'homme GJ, 2012, CURR PHARM DESIGN, V18, P2838; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Radhika V, 2005, ONCOGENE, V24, P4597, DOI 10.1038/sj.onc.1208665; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Rasheed SAK, 2018, ONCOGENE, V37, P1340, DOI 10.1038/s41388-017-0038-6; Rasheed SAK, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0337-x; Rasheed SAK, 2013, J BIOL CHEM, V288, P7986, DOI 10.1074/jbc.M112.437749; Rives ML, 2018, MOL PHARMACOL, V93, P581, DOI 10.1124/mol.117.111369; Rohrer DK, 1998, PHYSIOL REV, V78, P35, DOI 10.1152/physrev.1998.78.1.35; Sabbah M, 2008, DRUG RESIST UPDATE, V11, P123, DOI 10.1016/j.drup.2008.07.001; Sethi N, 2011, NAT REV CANCER, V11, P735, DOI 10.1038/nrc3125; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Singh JK, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3436; Sivaraj KK, 2013, DEV CELL, V25, P427, DOI 10.1016/j.devcel.2013.04.008; Solomon H, 2011, J PATHOL, V225, P475, DOI 10.1002/path.2988; Song YD, 2009, CLIN CANCER RES, V15, P492, DOI 10.1158/1078-0432.CCR-08-1945; Sonnenburg DW, 2018, CURR ONCOL REP, V20, DOI 10.1007/s11912-018-0692-z; Stark MS, 2016, ONCOTARGET, V7, P49677, DOI 10.18632/oncotarget.10109; Stecky RC, 2020, CELL SIGNAL, V72, DOI 10.1016/j.cellsig.2020.109653; Sutkeviciute I, 2020, J BIOL CHEM, V295, P11626, DOI 10.1074/jbc.REV120.009348; Suzuki N, 2009, NEUROSIGNALS, V17, P55, DOI 10.1159/000186690; Syrovatkina V, 2019, PROTEIN SCI, V28, P305, DOI 10.1002/pro.3531; Teo CR, 2016, CELL SIGNAL, V28, P1479, DOI 10.1016/j.cellsig.2016.07.001; Thiery JP, 2013, CANCER CELL, V23, P272, DOI 10.1016/j.ccr.2013.03.004; Tolkacheva T, 1997, ONCOGENE, V15, P727, DOI 10.1038/sj.onc.1201229; Tripathi P, 2012, INT J BIOCHEM CELL B, V44, P1852, DOI 10.1016/j.biocel.2012.06.025; Turm H, 2010, J BIOL CHEM, V285, P15137, DOI 10.1074/jbc.M109.072843; Udayappan UK, 2017, MOLECULES, V22, DOI 10.3390/molecules22040612; Wang GC, 2016, CANCER DISCOV, V6, P80, DOI 10.1158/2159-8290.CD-15-0224; Ward Y, 2011, CANCER RES, V71, P7301, DOI 10.1158/0008-5472.CAN-11-2381; Worzfeld T, 2008, TRENDS PHARMACOL SCI, V29, P582, DOI 10.1016/j.tips.2008.08.002; Wu V, 2019, J BIOL CHEM, V294, P11062, DOI 10.1074/jbc.REV119.005601; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; Xu Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep35948; Yagi H, 2016, ONCOGENE, V35, P4471, DOI 10.1038/onc.2015.505; Yagi H, 2019, FASEB J, V33, P13683, DOI 10.1096/fj.201901278R; Yagi H, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002221; Yan M, 2015, J MOL SIGNAL, V10, P1; Yang YM, 2015, ONCOGENE, V34, P2910, DOI 10.1038/onc.2014.218; Yang YM, 2015, ONCOTARGET, V6, P19055, DOI 10.18632/oncotarget.3957; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Yuan JZ, 2006, CELL SIGNAL, V18, P1051, DOI 10.1016/j.cellsig.2005.08.017; Zhang HH, 2013, INT J CLIN EXP PATHO, V6, P1734; Zhang JX, 2014, ANN ONCOL, V25, P2196, DOI 10.1093/annonc/mdu439; Zhang JX, 2016, ONCOTARGET, V7, P4414, DOI 10.18632/oncotarget.6780; Zhang YH, 1996, ONCOGENE, V12, P2377; Zhang ZQ, 2018, CANCER MED-US, V7, P5611, DOI 10.1002/cam4.1783	130	3	3	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2022	41	2					147	158		10.1038/s41388-021-02069-w	http://dx.doi.org/10.1038/s41388-021-02069-w		OCT 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC1XK	34689178	Green Published, hybrid			2022-12-17	WOS:000710613600001
J	Leon, F; Seshacharyulu, P; Nimmakayala, RK; Chugh, S; Karmakar, S; Nallasamy, P; Vengoji, R; Rachagani, S; Cox, JL; Mallya, K; Batra, SK; Ponnusamy, MP				Leon, Frank; Seshacharyulu, Parthasarathy; Nimmakayala, Rama K.; Chugh, Seema; Karmakar, Saswati; Nallasamy, Palanisamy; Vengoji, Raghupathy; Rachagani, Satyanarayana; Cox, Jesse L.; Mallya, Kavita; Batra, Surinder K.; Ponnusamy, Moorthy P.			Reduction in O-glycome induces differentially glycosylated CD44 to promote stemness and metastasis in pancreatic cancer	ONCOGENE			English	Article							SELF-RENEWAL; CELLS; BREAST; TUMORIGENICITY; PROGRESSION; EXPRESSION; RESISTANCE; INITIATION; NANOG	Aberrant protein glycosylation has been shown to have a significant contribution in aggressive cancer, including pancreatic cancer (PC). Emerging evidence has implicated the involvement of cancer stem cells (CSCs) in PC aggressiveness; however, the contribution of glycosylation on self-renewal properties and maintenance of CSC is understudied. Here, using several in vitro and in vivo models lacking C1GALT1 expression, we identified the role of aberrant O-glycosylation in stemness properties and aggressive PC metastasis. A loss in C1GALT1 was found to result in the truncation of O-glycosylation on several glycoproteins with an enrichment of Tn carbohydrate antigen. Mapping of Tn-bearing glycoproteins in C1GALT1 KO cells identified significant Tn enrichment on CSC glycoprotein CD44. Notably, a loss of C1GALT1 in PC cells was found to enhance CSC features (side population-SP, ALDH1+, and tumorspheres) and self-renewal markers NANOG, SOX9, and KLF4. Furthermore, a loss of CD44 in existing C1GALT1 KO cells decreased NANOG expression and CSC features. We determined that O-glycosylation of CD44 activates ERK/NF-kB signaling, which results in increased NANOG expression in PC cells that facilitated the alteration of CSC features, suggesting that NANOG is essential for PC stemness. Finally, we identified that loss of C1GALT1 expression was found to augment tumorigenic and metastatic potential, while an additional loss of CD44 in these cells reversed the effects. Overall, our results identified that truncation of O-glycans on CD44 increases NANOG activation that mediates increased CSC activation.	[Leon, Frank; Seshacharyulu, Parthasarathy; Nimmakayala, Rama K.; Chugh, Seema; Karmakar, Saswati; Nallasamy, Palanisamy; Vengoji, Raghupathy; Rachagani, Satyanarayana; Mallya, Kavita; Batra, Surinder K.; Ponnusamy, Moorthy P.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Cox, Jesse L.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA; [Batra, Surinder K.; Ponnusamy, Moorthy P.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; [Batra, Surinder K.; Ponnusamy, Moorthy P.] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Batra, SK; Ponnusamy, MP (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.; Batra, SK; Ponnusamy, MP (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA.; Batra, SK; Ponnusamy, MP (corresponding author), Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA.	sbatra@unmc.edu; mpalanim@unmc.edu	Nimmakayala, Rama Krishna/CAG-5670-2022; Seshacharyulu, Parthasarathy/AGL-7648-2022; Nallasamy, Palanisamy/AAH-7727-2021	Nimmakayala, Rama Krishna/0000-0003-4637-4828; Seshacharyulu, Parthasarathy/0000-0002-2348-3901; Nallasamy, Palanisamy/0000-0001-8962-2487	National Institutes of Health [R01 CA210637, R01 CA206444, P01 CA217798, U01 CA200466, U01 CA210240]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Craig Semerad, Victoria B. Smith, and Samantha Wall of the Flow Cytometry Research Facility, University of Nebraska Medical Center, for assisting with flow cytometry. We thank Janice A. Taylor and James R. Talaska of the Advanced Microscopy Core Facility at the University of Nebraska Medical Center for assisting with confocal microscopy. Further, we thank Dr. Vikas Kumar and Dr. Dragana Lagundin, of the Mass Spectrometry and Proteomics Core Facility at the University of Nebraska Medical Center, for assisting with proteomics. Lastly, we thank Corinn E. Grabow for assistance in technical support. We were supported primarily by the following grants from the National Institutes of Health R01 CA210637, R01 CA206444, P01 CA217798, U01 CA200466, and U01 CA210240. The authors/work in this article were supported, in parts, by the following grants from the National Institutes of Health (R01 CA210637, R01 CA206444, P01 CA217798, U01 CA200466, and U01 CA210240).	Abel EV, 2013, GASTROENTEROLOGY, V144, P1241, DOI 10.1053/j.gastro.2013.01.072; Alison MR, 2011, J PATHOL, V223, P147, DOI 10.1002/path.2793; Barkeer S, 2018, NEOPLASIA, V20, P813, DOI 10.1016/j.neo.2018.06.001; Bourguignon LYW, 2008, J BIOL CHEM, V283, P17635, DOI 10.1074/jbc.M800109200; Chia J, 2016, BBA-GEN SUBJECTS, V1860, P1623, DOI 10.1016/j.bbagen.2016.03.008; Chugh S, 2018, GASTROENTEROLOGY, V155, P1608, DOI 10.1053/j.gastro.2018.08.007; Chugh S, 2016, BRIT J CANCER, V114, P1376, DOI 10.1038/bjc.2016.116; Cummings RD, 2019, GLYCOCONJUGATE J, V36, P241, DOI 10.1007/s10719-019-09876-0; de Beca FF, 2013, J CLIN PATHOL, V66, P187, DOI 10.1136/jclinpath-2012-201169; Dorsett KA, 2019, J OVARIAN RES, V12, DOI 10.1186/s13048-019-0574-5; Es-haghi M, 2016, TUMOR BIOL, V37, P1559, DOI 10.1007/s13277-015-4690-6; Fang RP, 2020, ONCOGENE, V39, P2290, DOI 10.1038/s41388-019-1146-2; Feitelson MA, 2015, SEMIN CANCER BIOL, V35, pS25, DOI 10.1016/j.semcancer.2015.02.006; Freitas D, 2019, EBIOMEDICINE, V40, P349, DOI 10.1016/j.ebiom.2019.01.017; Ghantous A, 2013, DRUG DISCOV TODAY, V18, P894, DOI 10.1016/j.drudis.2013.05.005; Gill DJ, 2013, P NATL ACAD SCI USA, V110, pE3152, DOI 10.1073/pnas.1305269110; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Gupta R, 2020, BRIT J CANCER, V122, P1661, DOI 10.1038/s41416-020-0772-3; Ju TZ, 2011, ANGEW CHEM INT EDIT, V50, P1770, DOI 10.1002/anie.201002313; Kaltschmidt C, 2019, CANCERS, V11, DOI 10.3390/cancers11050655; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Li WZ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14364-2; Lonardo E, 2011, CELL STEM CELL, V9, P433, DOI 10.1016/j.stem.2011.10.001; Mimeault M, 2014, CANCER EPIDEM BIOMAR, V23, P234, DOI 10.1158/1055-9965.EPI-13-0785; Nimmakayala RK, 2019, BBA-REV CANCER, V1871, P50, DOI 10.1016/j.bbcan.2018.10.006; Nimmakayala RK, 2018, GASTROENTEROLOGY, V155, P892, DOI 10.1053/j.gastro.2018.05.041; Radhakrishnan P, 2014, P NATL ACAD SCI USA, V111, pE4066, DOI 10.1073/pnas.1406619111; Remmers N, 2013, CLIN CANCER RES, V19, P1981, DOI 10.1158/1078-0432.CCR-12-2662; Rinkenbaugh AL, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5020016; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Schultz MJ, 2016, CANCER RES, V76, P3978, DOI 10.1158/0008-5472.CAN-15-2834; Scott E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061389; Steentoft C, 2013, EMBO J, V32, P1478, DOI 10.1038/emboj.2013.79; Stowell SR, 2015, ANNU REV PATHOL-MECH, V10, P473, DOI 10.1146/annurev-pathol-012414-040438; Thomas D, 2019, J CELL MOL MED, V23, P6885, DOI 10.1111/jcmm.14572; Trinchera M, 2017, BIOLOGY-BASEL, V6, DOI 10.3390/biology6010016; Vaz AP, 2014, BRIT J CANCER, V111, P486, DOI 10.1038/bjc.2014.152; Vaz AP, 2016, ONCOTARGET, V7, P3307, DOI 10.18632/oncotarget.6580; Wang L, 2018, METHODS MOL BIOL, V1692, P31, DOI 10.1007/978-1-4939-7401-6_3; Zakaria N, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00166; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	42	3	3	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2022	41	1					57	71		10.1038/s41388-021-02047-2	http://dx.doi.org/10.1038/s41388-021-02047-2		OCT 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA0OI	34675409	Green Accepted			2022-12-17	WOS:000709687900002
J	Gravemeyer, J; Spassova, I; Verhaegen, ME; Dlugosz, AA; Hoffmann, D; Lange, A; Becker, JC				Gravemeyer, Jan; Spassova, Ivelina; Verhaegen, Monique E.; Dlugosz, Andrzej A.; Hoffmann, Daniel; Lange, Anja; Becker, Juergen C.			DNA-methylation patterns imply a common cellular origin of virus- and UV-associated Merkel cell carcinoma	ONCOGENE			English	Article							NEUROENDOCRINE CARCINOMA; EXPRESSION; EZH2; CANCER; CLASSIFICATION; MECHANISMS; SELECTION; TARGETS	Merkel cell carcinoma (MCC) is a neuroendocrine tumor either induced by integration of the Merkel cell polyomavirus into the cell genome or by accumulation of UV-light-associated mutations (VP-MCC and UV-MCC). Whether VP- and UV-MCC have the same or different cellular origins is unclear; with mesenchymal or epidermal origins discussed. DNA-methylation patterns have a proven utility in determining cellular origins of cancers. Therefore, we used this approach to uncover evidence regarding the cell of origin of classical VP- and UV-MCC cell lines, i.e., cell lines with a neuroendocrine growth pattern (n = 9 and n = 4, respectively). Surprisingly, we observed high global similarities in the DNA-methylation of UV- and VP-MCC cell lines. CpGs of lower methylation in VP-MCC cell lines were associated with neuroendocrine marker genes such as SOX2 and INSM1, or linked to binding sites of EZH2 and SUZ12 of the polycomb repressive complex 2, i.e., genes with an impact on carcinogenesis and differentiation of neuroendocrine cancers. Thus, the observed differences appear to be rooted in viral compared to mutation-driven carcinogenesis rather than distinct cells of origin. To test this hypothesis, we used principal component analysis, to compare DNA-methylation data from different epithelial and non-epithelial neuroendocrine cancers and established a scoring model for epithelial and neuroendocrine characteristics. Subsequently, we applied this scoring model to the DNA-methylation data of the VP- and UV-MCC cell lines, revealing that both clearly scored as epithelial cancers. In summary, our comprehensive analysis of DNA-methylation suggests a common epithelial origin of UV- and VP-MCC cell lines.	[Gravemeyer, Jan; Spassova, Ivelina; Becker, Juergen C.] Univ Duisburg Essen, Translat Skin Canc Res TSCR, Essen, Germany; [Gravemeyer, Jan; Becker, Juergen C.] German Canc Consortium DKTK, Heidelberg, Germany; [Gravemeyer, Jan; Becker, Juergen C.] German Canc Res Ctr, Heidelberg, Germany; [Spassova, Ivelina; Becker, Juergen C.] Univ Hosp Essen, Dept Dermatol, Essen, Germany; [Verhaegen, Monique E.; Dlugosz, Andrzej A.] Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA; [Dlugosz, Andrzej A.] Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; [Hoffmann, Daniel; Lange, Anja] Univ Duisburg Essen, Bioinformat & Computat Biophys, Essen, Germany	University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Duisburg Essen; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Duisburg Essen	Becker, JC (corresponding author), Univ Duisburg Essen, Translat Skin Canc Res TSCR, Essen, Germany.; Becker, JC (corresponding author), German Canc Consortium DKTK, Heidelberg, Germany.; Becker, JC (corresponding author), German Canc Res Ctr, Heidelberg, Germany.; Becker, JC (corresponding author), Univ Hosp Essen, Dept Dermatol, Essen, Germany.	j.becker@dkfz.de	Hoffmann, Daniel/P-5624-2019	Hoffmann, Daniel/0000-0003-2973-7869; Verhaegen, Monique/0000-0003-0229-5917; Spassova, Ivelina/0000-0003-4663-7966	German Cancer Consortium (DKTK) [ED003]	German Cancer Consortium (DKTK)	The project was funded by the German Cancer Consortium (DKTK) ED003. We thank the microarray unit of the DKFZ Genomics and Proteomics Core Facility for providing the Illumina Human Methylation arrays and related services.	Alharbi RA, 2013, LEUKEMIA, V27, P1000, DOI 10.1038/leu.2012.356; Augsburger D, 2017, ONCOTARGET, V8, P104638, DOI 10.18632/oncotarget.20136; Balanis NG, 2019, CANCER CELL, V36, P17, DOI 10.1016/j.ccell.2019.06.005; Battafarano RJ, 2005, J THORAC CARDIOV SUR, V130, P166, DOI 10.1016/j.jtcvs.2005.02.064; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bocchetta M, 2000, P NATL ACAD SCI USA, V97, P10214, DOI 10.1073/pnas.170207097; Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Esposti DD, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0419-z; Fan KJ, 2020, J INVEST DERMATOL, V140, P56, DOI 10.1016/j.jid.2019.06.135; Faviana P, 2019, APPL IMMUNOHISTO M M, V27, P689, DOI 10.1097/PAI.0000000000000647; Fehrmann RSN, 2015, NAT GENET, V47, P115, DOI 10.1038/ng.3173; Ferone G, 2020, GENE DEV, V34, P1017, DOI 10.1101/gad.338228.120; Fisseler-Eckhoff Annette, 2012, Cancers (Basel), V4, P777, DOI 10.3390/cancers4030777; Gravemeyer J, 2021, J INVEST DERMATOL, V141, P1675, DOI 10.1016/j.jid.2021.01.012; Gujar H, 2021, GENOME MED, V13, DOI 10.1186/s13073-021-00946-3; Guo HY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08133-6; Harms KL, 2017, HUM PATHOL, V67, P78, DOI 10.1016/j.humpath.2017.07.009; Harms PW, 2022, J INVEST DERMATOL, V142, P641, DOI 10.1016/j.jid.2021.07.173; Harms PW, 2015, CANCER RES, V75, P3720, DOI 10.1158/0008-5472.CAN-15-0702; Harold A, 2019, P NATL ACAD SCI USA, V116, P20104, DOI 10.1073/pnas.1907154116; Heinz S, 2015, NAT REV MOL CELL BIO, V16, P144, DOI 10.1038/nrm3949; Hesbacher S, 2016, ONCOTARGET, V7, P32956, DOI 10.18632/oncotarget.8793; Hoadley KA, 2018, CELL, V173, P291, DOI 10.1016/j.cell.2018.03.022; Hon GC, 2013, NAT GENET, V45, P1198, DOI 10.1038/ng.2746; Horny K, 2021, CANCERS, V13, DOI 10.3390/cancers13040649; Kervarrec T, 2022, J INVEST DERMATOL, V142, P516, DOI 10.1016/j.jid.2021.07.175; Kervarrec T, 2020, CANCERS, V12, DOI 10.3390/cancers12071989; Kervarrec T, 2020, J INVEST DERMATOL, V140, P976, DOI 10.1016/j.jid.2019.09.026; Kervarrec T, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00451; Khan SN, 2013, LEUKEMIA, V27, P1301, DOI 10.1038/leu.2013.80; Kim M, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.10; Knepper TC, 2019, CLIN CANCER RES, V25, P5961, DOI 10.1158/1078-0432.CCR-18-4159; Laga AC, 2010, AM J PATHOL, V176, P903, DOI 10.2353/ajpath.2010.090495; Lilo MT, 2018, AM J SURG PATHOL, V42, P1541, DOI 10.1097/PAS.0000000000001136; Liu W, 2016, CELL HOST MICROBE, V19, P775, DOI 10.1016/j.chom.2016.04.024; Llaguno SRA, 2016, BRIT J CANCER, V115, P1445, DOI 10.1038/bjc.2016.354; Maksimovic Jovana, 2016, F1000Res, V5, P1281, DOI 10.12688/f1000research.8839.3; Martincorena I, 2015, SCIENCE, V348, P880, DOI 10.1126/science.aaa6806; Matthay KK, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.78; Moran S, 2016, LANCET ONCOL, V17, P1386, DOI 10.1016/S1470-2045(16)30297-2; Nirenberg A, 2020, J EUR ACAD DERMATOL, V34, P1425, DOI 10.1111/jdv.16158; Ostrowski SM, 2015, DEVELOPMENT, V142, P2533, DOI 10.1242/dev.123141; Park DE, 2020, NAT CELL BIOL, V22, P603, DOI 10.1038/s41556-020-0503-2; Park JW, 2018, SCIENCE, V362, P91, DOI 10.1126/science.aat5749; Phipson B, 2016, BIOINFORMATICS, V32, P286, DOI 10.1093/bioinformatics/btv560; Pulitzer MP, 2015, MODERN PATHOL, V28, P1023, DOI 10.1038/modpathol.2015.60; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rodriguez-Paredes M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03025-1; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Sheffield NC, 2016, BIOINFORMATICS, V32, P587, DOI 10.1093/bioinformatics/btv612; Sunshine JC, 2018, ONCOGENE, V37, P1409, DOI 10.1038/s41388-017-0073-3; Tei S, 2009, J CELL SCI, V122, P3190, DOI 10.1242/jcs.049627; Tenjin Y, 2020, LAB INVEST, V100, P1575, DOI 10.1038/s41374-020-00479-0; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Town J, 2016, P NATL ACAD SCI USA, V113, P3603, DOI 10.1073/pnas.1521251113; Tu Jian, 2017, Cancer Rep Rev, V1, DOI 10.15761/CRR.1000111; Verhaegen ME, 2014, J INVEST DERMATOL, V134, P2241, DOI 10.1038/jid.2014.138; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Yan W, 2011, AM J CANCER RES, V1, P275; Zhang Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06177-2	62	3	3	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2022	41	1					37	45		10.1038/s41388-021-02064-1	http://dx.doi.org/10.1038/s41388-021-02064-1		OCT 2021	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA0OI	34667274	Green Published, hybrid			2022-12-17	WOS:000708806900001
J	Yan, H; Yu, CC; Fine, SA; Youssof, AL; Yang, YR; Yan, J; Karg, DC; Cheung, EC; Friedman, RA; Ying, HQ; Chen, EI; Luo, J; Miao, Y; Qiu, WL; Su, GH				Yan, Han; Yu, Chih-Chieh; Fine, Stuart A.; Youssof, Ayman Lee; Yang, Ye-Ran; Yan, Jun; Karg, Dillon C.; Cheung, Edwin C.; Friedman, Richard A.; Ying, Haoqiang; Chen, Emily, I; Luo, Ji; Miao, Yi; Qiu, Wanglong; Su, Gloria H.			Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1	ONCOGENE			English	Article							MUTANT K-RAS; HIPPO PATHWAY; IMBALANCE; TAZ; SPECIFICITY; MUTATIONS; CONVERGE; ROLES	Human pancreatic ductal adenocarcinoma (PDAC) harboring one KRAS mutant allele often displays increasing genomic loss of the remaining wild-type (WT) allele (known as LOH at KRAS) as tumors progress to metastasis, yet the molecular ramification of this WT allelic loss is unknown. In this study, we showed that the restoration of WT KRAS expression in human PDAC cell lines with LOH at KRAS significantly attenuated the malignancy of PDAC cells both in vitro and in vivo, demonstrating a tumor-suppressive role of the WT KRAS allele. Through RNA-Seq, we identified the HIPPO signaling pathway to be positively regulated by WT KRAS in PDAC cells. In accordance with this observation, PDAC cells with LOH at KRAS exhibited increased nuclear localization and activation of transcriptional co-activator YAP1. Mechanistically, we discovered that WT KRAS expression sequestered YAP1 from the nucleus, through enhanced 14-3-3zeta interaction with phosphorylated YAP1 at S127. Consistently, expression of a constitutively-active YAP1 mutant in PDAC cells bypassed the growth inhibitory effects of WT KRAS. In patient samples, we found that the YAP1-activation genes were significantly upregulated in tumors with LOH at KRAS, and YAP1 nuclear localization predicted poor survival for PDAC patients. Collectively, our results reveal that the WT allelic loss leads to functional activation of YAP1 and enhanced tumor malignancy, which explains the selection advantage of the tumor cells with LOH at KRAS during pancreatic cancer clonal evolution and progression to metastasis, and should be taken into consideration in future therapeutic strategies targeting KRAS.	[Yan, Han; Yu, Chih-Chieh; Yang, Ye-Ran; Qiu, Wanglong; Su, Gloria H.] Columbia Univ, Irving Med Ctr, Dept Pathol & Cell Biol, New York, NY 10027 USA; [Yan, Han; Yu, Chih-Chieh; Fine, Stuart A.; Youssof, Ayman Lee; Karg, Dillon C.; Cheung, Edwin C.; Friedman, Richard A.; Chen, Emily, I; Qiu, Wanglong; Su, Gloria H.] Columbia Univ, Irving Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10027 USA; [Yan, Han; Miao, Yi] Nanjing Med Univ, Pancreas Ctr, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China; [Yan, Han; Miao, Yi] Nanjing Med Univ, Dept Gen Surg, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China; [Yan, Jun] Tianjin First Ctr Hosp, Dept Pathol, Tianjin, TJ, Peoples R China; [Friedman, Richard A.] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Biomed Informat Shared Resource, Irving Med Ctr, New York, NY USA; [Friedman, Richard A.] Columbia Univ, Dept Biomed Informat, Biomed Informat Shared Resource, Irving Med Ctr, New York, NY USA; [Ying, Haoqiang] Univ Texas MD Anderson Canc Ctr, Mol & Cellular Oncol Dept, Houston, TX 77030 USA; [Chen, Emily, I] Columbia Univ, Dept Pharmacol, Irving Med Ctr, New York, NY USA; [Luo, Ji] NCI, Lab Canc Biol & Genet, Ctr Canc Res, Bethesda, MD 20892 USA; [Su, Gloria H.] Columbia Univ, Dept Otolaryngol & Head & Neck Surg, Irving Med Ctr, New York, NY 10027 USA; [Su, Gloria H.] Columbia Univ, Pancreas Ctr, Irving Med Ctr, New York, NY 10027 USA	Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Nanjing Medical University; Nanjing Medical University; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; University of Texas System; UTMD Anderson Cancer Center; Columbia University; NewYork-Presbyterian Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital	Su, GH (corresponding author), Columbia Univ, Irving Med Ctr, Dept Pathol & Cell Biol, New York, NY 10027 USA.; Su, GH (corresponding author), Columbia Univ, Irving Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10027 USA.; Su, GH (corresponding author), Columbia Univ, Dept Otolaryngol & Head & Neck Surg, Irving Med Ctr, New York, NY 10027 USA.; Su, GH (corresponding author), Columbia Univ, Pancreas Ctr, Irving Med Ctr, New York, NY 10027 USA.	gs2157@columbia.edu		Yan, Han/0000-0002-2041-3115; Yu, Chih-Chieh/0000-0002-6828-1764; Yang, Yeran/0000-0003-2189-2207; Ying, Haoqiang/0000-0003-0616-2310; Fine, Stuart/0000-0003-1213-1799	NIH/NCI [R01 CA217207, R01 CA178445]; NIH [P30CA013696]; CUIMC Irving Drug Discovery Pilot Award [HICCC_FY21IDD01]; China Scholarship Council; Morgan Stanley Children's Hospital-Beijing Children's Hospital Program; NCI-ICBP (Integrative Cancer Biology Program) Summer Research Program	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CUIMC Irving Drug Discovery Pilot Award; China Scholarship Council(China Scholarship Council); Morgan Stanley Children's Hospital-Beijing Children's Hospital Program; NCI-ICBP (Integrative Cancer Biology Program) Summer Research Program	This study was supported by NIH/NCI R01 CA178445, NIH/NCI R01 CA217207, CUIMC Irving Drug Discovery Pilot Award (HICCC_FY21IDD01), and NIH P30CA013696 for the HICCC. HYan was supported by the China Scholarship Council for research at the CUIMC. YY was supported by the Morgan Stanley Children's Hospital-Beijing Children's Hospital Program. DCK was supported by the NCI-ICBP (Integrative Cancer Biology Program) Summer Research Program.	Ahsan S., 2017, CURR PROTOC BIOINFOR, V57, p7.15.1, DOI 10.1002/cpbi.24; Alexa A, 2006, BIOINFORMATICS, V22, P1600, DOI 10.1093/bioinformatics/btl140; Ambrogio C, 2018, CELL, V172, P857, DOI 10.1016/j.cell.2017.12.020; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Avruch J, 2009, J BIOL CHEM, V284, P11001, DOI 10.1074/jbc.R800073200; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu, 2017, Cancer Cell, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Chiosea SI, 2011, MODERN PATHOL, V24, P1571, DOI 10.1038/modpathol.2011.109; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; EVERITT B, 1980, QUAL QUANT, V14, P75, DOI 10.1007/BF00154794; Gibson-Corley KN, 2013, VET PATHOL, V50, P1007, DOI 10.1177/0300985813485099; Grabocka E, 2014, CANCER CELL, V25, P243, DOI 10.1016/j.ccr.2014.01.005; Gruber R, 2016, GASTROENTEROLOGY, V151, P526, DOI 10.1053/j.gastro.2016.05.006; Hart SN, 2013, J COMPUT BIOL, V20, P970, DOI 10.1089/cmb.2012.0283; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hong X, 2014, EMBO J, V33, P2447, DOI 10.15252/embj.201489385; Hosseini P., 2010, BMC RES NOTES, V3; Kanehisa M, 2004, NUCLEIC ACIDS RES, V32, pD277, DOI 10.1093/nar/gkh063; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Kim NG, 2015, J CELL BIOL, V210, P503, DOI 10.1083/jcb.201501025; Krasinskas AM, 2013, MODERN PATHOL, V26, P1346, DOI 10.1038/modpathol.2013.71; Lampson BL, 2013, CURR BIOL, V23, P70, DOI 10.1016/j.cub.2012.11.031; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Liu RJ, 2015, NUCLEIC ACIDS RES, V43, pE97, DOI 10.1093/nar/gkv412; Makohon-Moore AP, 2017, NAT GENET, V49, P358, DOI 10.1038/ng.3764; Malapelle U, 2015, J CLIN PATHOL, V68, P265, DOI 10.1136/jclinpath-2014-202761; Matallanas D, 2011, MOL CELL, V44, P893, DOI 10.1016/j.molcel.2011.10.016; McDonald OG, 2017, NAT GENET, V49, P367, DOI 10.1038/ng.3753; Modrek B, 2009, MOL CANCER RES, V7, P1244, DOI 10.1158/1541-7786.MCR-08-0532; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Mueller S, 2018, NATURE, V554, P62, DOI 10.1038/nature25459; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Qiu WL, 2011, ONCOTARGET, V2, P862; R Core Team, 2022, R LANG ENV STAT COMP; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Rodriguez-Viciana P, 2004, MOL CELL BIOL, V24, P4943, DOI 10.1128/MCB.24.11.4943-4954.2004; Romano D, 2013, MOL CELL BIOL, V33, P1859, DOI 10.1128/MCB.01414-12; Allende MTS, 2017, PANCREAS, V46, P913, DOI 10.1097/MPA.0000000000000867; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Simon R, 2002, GENET EPIDEMIOL, V23, P21, DOI 10.1002/gepi.202; Singh A, 2005, FASEB J, V19, P161, DOI 10.1096/fj.04-2584hyp; Soh J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007464; Staffas A, 2015, LEUKEMIA, V29, P1032, DOI 10.1038/leu.2014.315; Stephen AG, 2014, CANCER CELL, V25, P272, DOI 10.1016/j.ccr.2014.02.017; Sun TAN, 2021, GENES DIS, V8, P241, DOI 10.1016/j.gendis.2020.05.004; To MD, 2013, ONCOGENE, V32, P4028, DOI 10.1038/onc.2012.404; To MD, 2008, NAT GENET, V40, P1240, DOI 10.1038/ng.211; Tu B, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130811; Vartanian S, 2013, J BIOL CHEM, V288, P2403, DOI 10.1074/jbc.M112.394130; Volodko N, 2014, FEBS LETT, V588, P2671, DOI 10.1016/j.febslet.2014.02.041; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Yan H, 2019, CANCER LETT, V442, P333, DOI 10.1016/j.canlet.2018.11.007; Young A, 2013, CANCER DISCOV, V3, P112, DOI 10.1158/2159-8290.CD-12-0231; Yu CC, 2017, CANCER LETT, V384, P86, DOI 10.1016/j.canlet.2016.10.013; Zhang WY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005049; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303; Zhou BY, 2016, SEMIN CELL DEV BIOL, V58, P60, DOI 10.1016/j.semcdb.2016.07.012	65	3	3	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2021	40	50					6759	6771		10.1038/s41388-021-02040-9	http://dx.doi.org/10.1038/s41388-021-02040-9		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP7IH	34663879	Green Accepted			2022-12-17	WOS:000708355700004
J	Pehkonen, H; de Curtis, I; Monni, O				Pehkonen, Henna; de Curtis, Ivan; Monni, Outi			Liprins in oncogenic signaling and cancer cell adhesion	ONCOGENE			English	Review							PROTEIN-TYROSINE-PHOSPHATASE; RESOLUTION COPY NUMBER; EXTRACELLULAR-MATRIX; ACTIVE ZONE; NEUROTRANSMITTER RELEASE; 11Q13 AMPLIFICATION; INTEGRIN ADHESOME; POOR-PROGNOSIS; ALPHA FAMILY; ORAL-CANCER	Liprins are a multifunctional family of scaffold proteins, identified by their involvement in several important neuronal functions related to signaling and organization of synaptic structures. More recently, the knowledge on the liprin family has expanded from neuronal functions to processes relevant to cancer progression, including cell adhesion, cell motility, cancer cell invasion, and signaling. These proteins consist of regions, which by prediction are intrinsically disordered, and may be involved in the assembly of supramolecular structures relevant for their functions. This review summarizes the current understanding of the functions of liprins in different cellular processes, with special emphasis on liprins in tumor progression. The available data indicate that liprins may be potential biomarkers for cancer progression and may have therapeutic importance.	[Pehkonen, Henna; Monni, Outi] Univ Helsinki, Fac Med, Appl Tumor Genom Res Program, Helsinki, Finland; [Pehkonen, Henna; Monni, Outi] Univ Helsinki, Fac Med, Dept Oncol, Helsinki, Finland; [de Curtis, Ivan] San Raffaele Vita Salute Univ, IRCSS, San Raffaele Sci Inst, Cell Adhes Unit,Div Neurosci, Milan, Italy; [Monni, Outi] iCAN Digital Precis Canc Med Flagship, Helsinki, Finland	University of Helsinki; University of Helsinki; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Monni, O (corresponding author), Univ Helsinki, Fac Med, Appl Tumor Genom Res Program, Helsinki, Finland.; Monni, O (corresponding author), Univ Helsinki, Fac Med, Dept Oncol, Helsinki, Finland.; Monni, O (corresponding author), iCAN Digital Precis Canc Med Flagship, Helsinki, Finland.	outi.monni@helsinki.fi		Monni, Outi/0000-0002-2319-8799	University of Helsinki including Helsinki University Central Hospital	University of Helsinki including Helsinki University Central Hospital	Open access funding provided by University of Helsinki including Helsinki University Central Hospital.	AKERVALL JA, 1995, CANCER, V76, P853, DOI 10.1002/1097-0142(19950901)76:5<853::AID-CNCR2820760520>3.0.CO;2-6; Alfarsi LH, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-06939-6; Asperti C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020757; Asperti C, 2010, EXP CELL RES, V316, P915, DOI 10.1016/j.yexcr.2010.01.017; Asperti C, 2009, J CELL SCI, V122, P3225, DOI 10.1242/jcs.054155; Astigarraga S, 2010, J NEUROSCI, V30, P15358, DOI 10.1523/JNEUROSCI.1862-10.2010; Astro V, 2011, ONCOGENE, V30, P1841, DOI 10.1038/onc.2010.562; Astro V, 2016, SCI REP-UK, V6, DOI 10.1038/srep33653; Astro V, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa3312; Astro V, 2014, J CELL SCI, V127, P3862, DOI 10.1242/jcs.155663; Banani SF, 2017, NAT REV MOL CELL BIO, V18, P285, DOI 10.1038/nrm.2017.7; Bari R, 2009, AM J PATHOL, V174, P647, DOI 10.2353/ajpath.2009.080685; Barros MC, 2018, ORAL ONCOL, V83, P81, DOI 10.1016/j.oraloncology.2018.06.010; Bera R, 2014, HEPATOLOGY, V59, P2238, DOI 10.1002/hep.27030; Bernadzki KM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09590-7; Boija A, 2021, CANCER CELL, V39, P174, DOI 10.1016/j.ccell.2020.12.003; Bomkamp C, 2019, FRONT SYNAPTIC NEURO, V11, DOI 10.3389/fnsyn.2019.00017; Branch KM, 2012, BIOL OPEN, V1, P711, DOI 10.1242/bio.20121867; Brenig J, 2015, J BIOL CHEM, V290, P14314, DOI 10.1074/jbc.M114.621946; Buccione R, 2004, NAT REV MOL CELL BIO, V5, P647, DOI 10.1038/nrm1436; Buraschi S, 2020, MATRIX BIOL, V93, P10, DOI 10.1016/j.matbio.2020.03.009; Cai DF, 2021, TRENDS BIOCHEM SCI, V46, P535, DOI 10.1016/j.tibs.2021.01.002; Carneiro A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-98; Chia PH, 2013, MOL CELL NEUROSCI, V56, P76, DOI 10.1016/j.mcn.2013.03.004; Chiaretti S, 2016, BIOL CELL, V108, P65, DOI 10.1111/boc.201500063; Chiaretti S, 2016, CURR CANCER DRUG TAR, V16, P238, DOI 10.2174/156800961603160206124103; Choe KM, 2006, P NATL ACAD SCI USA, V103, P11601, DOI 10.1073/pnas.0601185103; Colas E, 2011, INT J CANCER, V129, P2435, DOI 10.1002/ijc.25901; Dai Y, 2006, NAT NEUROSCI, V9, P1479, DOI 10.1038/nn1808; de Curtis I, 2021, TRENDS CELL BIOL, V31, P145, DOI 10.1016/j.tcb.2020.12.002; de Curtis I, 2011, EXP CELL RES, V317, P1, DOI 10.1016/j.yexcr.2010.09.014; Di Martino J, 2016, J CELL SCI, V129, P1759, DOI 10.1242/jcs.182329; Dickinson ME, 2016, NATURE, V537, P508, DOI 10.1038/nature19356; Emperador-Melero J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23116-w; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Geiger B, 2009, NAT REV MOL CELL BIO, V10, P21, DOI 10.1038/nrm2593; Gimona M, 2008, CURR OPIN CELL BIOL, V20, P235, DOI 10.1016/j.ceb.2008.01.005; Gligorijevic B, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001995; Gu CM, 2019, MOL THER-NUCL ACIDS, V16, P1, DOI 10.1016/j.omtn.2019.01.015; Hallam SJ, 2002, NAT NEUROSCI, V5, P1137, DOI 10.1038/nn959; Head BP, 2014, BBA-BIOMEMBRANES, V1838, P532, DOI 10.1016/j.bbamem.2013.07.018; Hoogenraad CC, 2007, DEV CELL, V12, P587, DOI 10.1016/j.devcel.2007.02.006; Horton ER, 2015, NAT CELL BIOL, V17, P1577, DOI 10.1038/ncb3257; Huang X, 2002, P NATL ACAD SCI USA, V99, P11369, DOI 10.1073/pnas.172285799; Huang X, 2006, GENE CHROMOSOME CANC, V45, P1058, DOI 10.1002/gcc.20371; Innocenti M, 2018, CELL ADHES MIGR, V12, P401, DOI 10.1080/19336918.2018.1448352; Iyama K, 2017, THYROID, V27, P811, DOI 10.1089/thy.2016.0673; Jakobsen Kristine Raaby, 2013, J Mol Signal, V8, P9, DOI 10.1186/1750-2187-8-9; Jarvinen AK, 2006, ONCOGENE, V25, P6997, DOI 10.1038/sj.onc.1209690; Jarvinen AK, 2008, GENE CHROMOSOME CANC, V47, P500, DOI 10.1002/gcc.20551; Johnson KG, 2003, PHYSIOL REV, V83, P1, DOI 10.1152/physrev.00016.2002; Kaufmann N, 2002, NEURON, V34, P27, DOI 10.1016/S0896-6273(02)00643-8; Kim S, 2003, J BIOL CHEM, V278, P6291, DOI 10.1074/jbc.M212287200; Kittelmann M, 2013, J CELL BIOL, V203, P849, DOI 10.1083/jcb.201302022; Ko J, 2003, J BIOL CHEM, V278, P42377, DOI 10.1074/jbc.M307561200; Ko J, 2003, J NEUROSCI, V23, P1667; Kriajevska M, 2002, J BIOL CHEM, V277, P5229, DOI 10.1074/jbc.M110976200; Laude AJ, 2004, MOL MEMBR BIOL, V21, P193, DOI 10.1080/09687680410001700517; LeVea CM, 2000, BREAST CANCER RES TR, V64, P221, DOI 10.1023/A:1006410509740; Linder S, 2005, J CELL SCI, V118, P2079, DOI 10.1242/jcs.02390; Linder S, 2007, TRENDS CELL BIOL, V17, P107, DOI 10.1016/j.tcb.2007.01.002; Linder S, 2009, J CELL SCI, V122, P3009, DOI 10.1242/jcs.032631; Linding R, 2003, STRUCTURE, V11, P1453, DOI 10.1016/j.str.2003.10.002; Liu WM, 2006, CANCER LETT, V240, P183, DOI 10.1016/j.canlet.2005.08.018; Liu YLC, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005608; Luo M, 2016, EXP DERMATOL, V25, P321, DOI 10.1111/exd.12933; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Mana G, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13546; Mattauch S, 2010, EXP CELL RES, V316, P2883, DOI 10.1016/j.yexcr.2010.06.022; Maturi V, 2018, MOL ONCOL, V12, P1153, DOI 10.1002/1878-0261.12317; McDonald NA, 2020, NATURE, V588, P454, DOI 10.1038/s41586-020-2942-0; Menzies AM, 2015, PIGM CELL MELANOMA R, V28, P607, DOI 10.1111/pcmr.12388; MEREDITH SD, 1995, ARCH OTOLARYNGOL, V121, P790; Miller KE, 2005, CURR BIOL, V15, P684, DOI 10.1016/j.cub.2005.02.061; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Nachat R, 2009, J CELL SCI, V122, P4035, DOI 10.1242/jcs.047266; Nam HJ, 1999, CELL, V97, P449, DOI 10.1016/S0092-8674(00)80755-2; Norrmen C, 2010, BLOOD, V115, P906, DOI 10.1182/blood-2009-03-212274; Oates ME, 2013, NUCLEIC ACIDS RES, V41, pD508, DOI 10.1093/nar/gks1226; Olsen O, 2006, CURR OPIN CELL BIOL, V18, P223, DOI 10.1016/j.ceb.2006.02.010; Olsen O, 2005, J CELL BIOL, V170, P1127, DOI 10.1083/jcb.200503011; Ono M, 1999, CANCER RES, V59, P2335; Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204; Owald D, 2010, J CELL BIOL, V188, P565, DOI 10.1083/jcb.200908055; Patel MR, 2006, NAT NEUROSCI, V9, P1488, DOI 10.1038/nn1806; Patel MR, 2009, SCIENCE, V323, P1500, DOI 10.1126/science.1169025; Pehkonen H, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0253-y; Pehkonen H, 2016, SCI REP-UK, V6, DOI 10.1038/srep24486; Petrie RJ, 2009, NAT REV MOL CELL BIO, V10, P538, DOI 10.1038/nrm2729; PULIDO R, 1995, P NATL ACAD SCI USA, V92, P11686, DOI 10.1073/pnas.92.25.11686; Ramos-Garcia P, 2017, ORAL ONCOL, V72, P7, DOI 10.1016/j.oraloncology.2017.04.016; Robertson J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7265; Sakamoto S, 2012, J CELL SCI, V125, P108, DOI 10.1242/jcs.087411; Sala K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49630-y; Sala K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19447-2; Sarhan AR, 2016, MOL CELL PROTEOMICS, V15, P1823, DOI 10.1074/mcp.M115.053652; Schoch S, 2002, NATURE, V415, P321, DOI 10.1038/415321a; SCHUURING E, 1992, CANCER RES, V52, P5229; Serra-Pages C, 2005, BIOCHEMISTRY-US, V44, P15715, DOI 10.1021/bi051434f; Serra-Pages C, 1998, J BIOL CHEM, V273, P15611, DOI 10.1074/jbc.273.25.15611; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Shen JC, 2007, CANCER RES, V67, P2552, DOI 10.1158/0008-5472.CAN-06-3870; Shin H, 2003, J BIOL CHEM, V278, P11393, DOI 10.1074/jbc.M211874200; Song JL, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1642-0; Spangler SA, 2007, BIOCHEM SOC T, V35, P1278, DOI 10.1042/BST0351278; Spangler SA, 2013, J CELL BIOL, V201, P915, DOI 10.1083/jcb.201301011; Spangler SA, 2011, J COMP NEUROL, V519, P3040, DOI 10.1002/cne.22665; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; Stryker E, 2007, J CELL SCI, V120, P3723, DOI 10.1242/jcs.03491; Stylli SS, 2008, J CLIN NEUROSCI, V15, P725, DOI 10.1016/j.jocn.2008.03.003; Sun ZQ, 2016, NAT CELL BIOL, V18, P941, DOI 10.1038/ncb3402; Takeuchi K, 2011, CLIN CANCER RES, V17, P3341, DOI 10.1158/1078-0432.CCR-11-0063; Takkunen M, 2010, J CELL MOL MED, V14, P1569, DOI 10.1111/j.1582-4934.2009.00868.x; Tan KD, 2008, GENE CHROMOSOME CANC, V47, P353, DOI 10.1002/gcc.20539; Taru H, 2011, J NEUROSCI, V31, P16261, DOI 10.1523/JNEUROSCI.0002-11.2011; van der Vaart B, 2013, DEV CELL, V27, P145, DOI 10.1016/j.devcel.2013.09.010; von Thun A, 2012, J CELL SCI, V125, P1465, DOI 10.1242/jcs.092916; Weaver AM, 2006, CLIN EXP METASTAS, V23, P97, DOI 10.1007/s10585-006-9014-1; Wei ZY, 2011, MOL CELL, V43, P586, DOI 10.1016/j.molcel.2011.07.021; Whitmore TE, 2012, J PROTEOME RES, V11, P2653, DOI 10.1021/pr201200n; Wiesner T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4116; Wilkerson PM, 2013, GENE CHROMOSOME CANC, V52, P333, DOI 10.1002/gcc.22037; Winograd-Katz SE, 2014, NAT REV MOL CELL BIO, V15, P273, DOI 10.1038/nrm3769; Wong MY, 2018, P NATL ACAD SCI USA, V115, P2234, DOI 10.1073/pnas.1719012115; Wu YS, 2018, PROSTATE, V78, P1222, DOI 10.1002/pros.23697; Wyszynski M, 2002, NEURON, V34, P39, DOI 10.1016/S0896-6273(02)00640-2; Xie XQ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13949-x; Xu C, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-143; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; YANG J, 2017, TUMOR BIOL, V39; Yeh I, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8174; Zhen M, 1999, NATURE, V401, P371, DOI 10.1038/43886; Zhou B, 2004, CANCER RES, V64, P7455, DOI 10.1158/0008-5472.CAN-04-1574; Zurner M, 2011, J COMP NEUROL, V519, P3019, DOI 10.1002/cne.22664; Zurner M, 2009, GENOMICS, V93, P243, DOI 10.1016/j.ygeno.2008.10.007	135	3	3	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2021	40	46					6406	6416		10.1038/s41388-021-02048-1	http://dx.doi.org/10.1038/s41388-021-02048-1		OCT 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA1UG	34654889	Green Published, hybrid			2022-12-17	WOS:000707986000001
J	Zheng, DD; Cao, M; Zuo, SY; Xia, X; Zhi, CC; Lin, YB; Deng, ST; Yuan, XQ				Zheng, Dandan; Cao, Meng; Zuo, Siyu; Xia, Xin; Zhi, Chunchun; Lin, Yanbing; Deng, Sitong; Yuan, Xiaoqin			RANBP1 promotes colorectal cancer progression by regulating pre-miRNA nuclear export via a positive feedback loop with YAP	ONCOGENE			English	Article							MICRORNA BIOGENESIS; PATHWAY; COMPLEX; STEP	Colorectal cancer (CRC) is among the top five most common malignant tumors worldwide and has a high mortality rate. Identification of the mechanism of CRC and potential therapeutic targets is critical for improving survival. In the present study, we observed high expression of RAN binding protein 1 (RANBP1) in CRC tissues. Upregulated RANBP1 expression was strongly associated with TNM stages and was an independent risk factor for poor prognosis. In vitro and in vivo functional experiments demonstrated that RANBP1 promoted the proliferation and invasion of CRC cells and inhibited the apoptosis of CRC cells. Low RANBP1 expression reduced the expression levels of hsa-miR-18a, hsa-miR-183, and hsa-miR-106 microRNAs (miRNAs) by inhibiting the nucleoplasmic transport of precursor miRNAs (pre-miRNAs), thereby promoting the accumulation of the latter in the nucleus and reducing the expression of mature miRNAs. Further experiments and bioinformatic analyses demonstrated that RANBP1 promoted the expression of YAP by regulating miRNAs and the Hippo pathway. We also found that YAP acted as a transcriptional cofactor to activate RANBP1 transcription in combination with TEAD4 transcription factor. Thus, RANBP1 further promoted the progression of CRC by forming a positive feedback loop with YAP. Our results revealed the biological role and mechanism of RANBP1 in CRC for the first time, suggesting that RANBP1 can be used as a diagnostic molecule and a potential therapeutic target in CRC.	[Zheng, Dandan; Zuo, Siyu; Xia, Xin; Lin, Yanbing; Deng, Sitong; Yuan, Xiaoqin] Nanjing Med Univ, Dept Anat Histol & Embryol, Nanjing 211166, Peoples R China; [Cao, Meng] Nanjing Univ, Dept Gen Surg, Nanjing Drum Tower Hosp, Affiliated Hosp,Med Sch, Nanjing 210008, Peoples R China; [Zuo, Siyu] Zhejiang Univ, Childrens Hosp, Natl Clin Res Ctr Child Hlth, Sch Med, Hangzhou 310003, Peoples R China; [Zhi, Chunchun] Nanjing Univ, Nanjing Jinling Hosp, Dept Pathol, Sch Med, Nanjing 210002, Peoples R China; [Yuan, Xiaoqin] Nanjing Med Univ, Key Lab Aging & Dis, Nanjing 211166, Peoples R China	Nanjing Medical University; Nanjing University; Zhejiang University; Nanjing University; Nanjing Medical University	Yuan, XQ (corresponding author), Nanjing Med Univ, Dept Anat Histol & Embryol, Nanjing 211166, Peoples R China.; Yuan, XQ (corresponding author), Nanjing Med Univ, Key Lab Aging & Dis, Nanjing 211166, Peoples R China.	yuanxq@njmu.edu.cn			National Natural Science Foundation of China [81972288]; General Project of the Natural Science Foundation of Jiangsu Province [BK20191353]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); General Project of the Natural Science Foundation of Jiangsu Province	This work was supported by the National Natural Science Foundation of China (no. 81972288) and the General Project of the Natural Science Foundation of Jiangsu Province (no. BK20191353).	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Budczies J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051862; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Dattilo V, 2017, SCI REP-UK, V7, DOI 10.1038/srep45361; Denli AM, 2004, NATURE, V432, P231, DOI 10.1038/nature03049; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; Di Fiore B, 2003, J CELL SCI, V116, P3399, DOI 10.1242/jcs.00624; Di Leva G, 2014, ANNU REV PATHOL-MECH, V9, P287, DOI 10.1146/annurev-pathol-012513-104715; Feng RM, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0368-6; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Kalab P, 2008, J CELL SCI, V121, P1577, DOI 10.1242/jcs.005959; Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645; Kim VN, 2004, TRENDS CELL BIOL, V14, P156, DOI 10.1016/j.tcb.2004.02.006; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385; Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932; Lu YY, 2017, NAT MED, V23, P1331, DOI 10.1038/nm.4424; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; Melo SA, 2010, CANCER CELL, V18, P303, DOI 10.1016/j.ccr.2010.09.007; Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Muralidhar B, 2011, J PATHOL, V224, P496, DOI 10.1002/path.2898; Nicoli S, 2010, NATURE, V464, P1196, DOI 10.1038/nature08889; Oh D, 2016, P NATL ACAD SCI USA, V113, P8729, DOI 10.1073/pnas.1607498113; Rensen WM, 2009, ONCOGENE, V28, P1748, DOI 10.1038/onc.2009.24; Shigeyasu K, 2017, CLIN CANCER RES, V23, P1312, DOI 10.1158/1078-0432.CCR-16-1023; Shu GS, 2012, PATHOL RES PRACT, V208, P392, DOI 10.1016/j.prp.2012.05.001; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Wagh PK, 2015, J PATHOL, V236, P41, DOI 10.1002/path.4500; Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803; Zhang L, 2015, CURR BIOL, V25, P296, DOI 10.1016/j.cub.2014.11.054; Zhang QM, 2017, AM J CANCER RES, V7, P935; Zhou QW, 2019, CANCER SCI, V110, P1194, DOI 10.1111/cas.13951	37	3	3	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2022	41	7					930	942		10.1038/s41388-021-02036-5	http://dx.doi.org/10.1038/s41388-021-02036-5		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX7EK	34615998				2022-12-17	WOS:000705759400003
J	Block, CJ; Mitchell, AV; Wu, L; Glassbrook, J; Craig, D; Chen, W; Dyson, G; DeGracia, D; Polin, L; Ratnam, M; Gibson, H; Wu, GJ				Block, C. James; Mitchell, Allison, V; Wu, Ling; Glassbrook, James; Craig, Douglas; Chen, Wei; Dyson, Gregory; DeGracia, Donald; Polin, Lisa; Ratnam, Manohar; Gibson, Heather; Wu, Guojun			RNA binding protein RBMS3 is a common EMT effector that modulates triple-negative breast cancer progression via stabilizing PRRX1 mRNA	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; POOR-PROGNOSIS; DOWN-REGULATION; EXPRESSION; METASTASIS; INDUCER; ROLES; CELLS	The epithelial-to-mesenchymal transition (EMT) has been recognized as a driving force for tumor progression in breast cancer. Recently, our group identified the RNA Binding Motif Single Stranded Interacting Protein 3 (RBMS3) to be significantly associated with an EMT transcriptional program in breast cancer. Additional expression profiling demonstrated that RBMS3 was consistently upregulated by multiple EMT transcription factors and correlated with mesenchymal gene expression in breast cancer cell lines. Functionally, RBMS3 was sufficient to induce EMT in two immortalized mammary epithelial cell lines. In triple-negative breast cancer (TNBC) models, RBMS3 was necessary for maintaining the mesenchymal phenotype and invasion and migration in vitro. Loss of RBMS3 significantly impaired both tumor progression and spontaneous metastasis in vivo. Using a genome-wide approach to interrogate mRNA stability, we found that ectopic expression of RBMS3 upregulates many genes that are resistant to degradation following transcriptional blockade by actinomycin D (ACTD). Specifically, RBMS3 was shown to interact with the mRNA of EMT transcription factor PRRX1 and promote PRRX1 mRNA stability. PRRX1 is required for RBMS3-mediated EMT and is partially sufficient to rescue the effect of RBMS3 knockdown in TNBC cell lines. Together, this study identifies RBMS3 as a novel and common effector of EMT, which could be a promising therapeutic target for TNBC treatment.	[Block, C. James; Mitchell, Allison, V; Wu, Ling; Glassbrook, James; Craig, Douglas; Chen, Wei; Dyson, Gregory; Polin, Lisa; Ratnam, Manohar; Gibson, Heather; Wu, Guojun] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Dept Oncol, Sch Med, 4100 John R, Detroit, MI 48201 USA; [Wu, Ling] Baylor Coll Med, McNair Med Inst, Dept Mol & Cellular Biol, One Baylor Plaza, Houston, TX 77030 USA; [DeGracia, Donald] Wayne State Univ, Dept Physiol, Sch Med, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Baylor College of Medicine; Wayne State University	Wu, GJ (corresponding author), Wayne State Univ, Barbara Ann Karmanos Canc Inst, Dept Oncol, Sch Med, 4100 John R, Detroit, MI 48201 USA.	wugu@karmanos.org	Gibson, Heather/GLV-4595-2022	Gibson, Heather/0000-0003-2652-8252; Wu, Ling/0000-0002-5786-4315	Wayne State University; KCI strategic plan cancer immunology and immunotherapy award;  [P30-CA022453-38]	Wayne State University; KCI strategic plan cancer immunology and immunotherapy award; 	This work is supported by Grant boost from Wayne State University (GW) and KCI strategic plan cancer immunology and immunotherapy award (GW and HG). The Biostatistics Core, AMTEC and the Biobanking and Correlative Sciences Core of KCI are supported by grant number P30-CA022453-38.	Addison JB, 2021, MOL CANCER RES, V19, P784, DOI 10.1158/1541-7786.MCR-20-0532; Aiello NM, 2019, J EXP MED, V216, P1016, DOI 10.1084/jem.20181827; Bagati A, 2017, CELL REP, V20, P2820, DOI 10.1016/j.celrep.2017.08.057; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Block CJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54282-z; Caramel J, 2013, CANCER CELL, V24, P466, DOI 10.1016/j.ccr.2013.08.018; Chen J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044636; Corley SM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55434-x; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Davis FM, 2014, TRENDS PHARMACOL SCI, V35, P479, DOI 10.1016/j.tips.2014.06.006; Fritz D, 2007, J MOL BIOL, V371, P585, DOI 10.1016/j.jmb.2007.06.006; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Iorns E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047995; Jayasena CS, 2012, J CELL BIOL, V199, P453, DOI 10.1083/jcb.201204138; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Li Y, 2011, CANCER RES, V71, P6106, DOI 10.1158/0008-5472.CAN-10-4291; Li Y, 2016, INT J ONCOL, V49, P51, DOI 10.3892/ijo.2016.3517; Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lu CK, 2012, DNA CELL BIOL, V31, P1245, DOI 10.1089/dna.2012.1619; Lv ZD, 2016, J CELL MOL MED, V20, P864, DOI 10.1111/jcmm.12770; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marcucci F, 2016, NAT REV DRUG DISCOV, V15, P311, DOI 10.1038/nrd.2015.13; McDowell IC, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1005896; Meng FY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13034-3; Meng FY, 2015, CANCER RES, V75, P584, DOI 10.1158/0008-5472.CAN-13-3029; Morel AP, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002723; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Orellana Esteban A, 2016, Bio Protoc, V6, DOI 10.21769/BioProtoc.1984; Park SY, 2015, ONCOTARGET, V6, P37535, DOI 10.18632/oncotarget.6063; Pasquier J, 2015, J ONCOL, V2015, DOI 10.1155/2015/792182; Penkov D, 2000, GENE, V243, P27, DOI 10.1016/S0378-1119(99)00515-6; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Puchalapalli M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163521; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Stemmler MP, 2019, NAT CELL BIOL, V21, P102, DOI 10.1038/s41556-018-0196-y; Takahashi Y, 2013, BRIT J CANCER, V109, P307, DOI 10.1038/bjc.2013.339; Takano S, 2016, GENE DEV, V30, P233, DOI 10.1101/gad.263327.115; Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Wang J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02243-3; Wu GY, 2019, CLIN CANCER RES, V25, P1022, DOI 10.1158/1078-0432.CCR-18-2554; Wu YL, 2020, ONCOL REP, V44, P55, DOI 10.3892/or.2020.7594; Yeung KT, 2017, MOL ONCOL, V11, P28, DOI 10.1002/1878-0261.12017; Zhang HJ, 2011, CANCER RES, V71, P4846, DOI 10.1158/0008-5472.CAN-11-0414; Zhang HJ, 2011, CANCER RES, V71, P1292, DOI 10.1158/0008-5472.CAN-10-2825; Zhang PJ, 2015, CELL CYCLE, V14, P481, DOI 10.1080/15384101.2015.1006048; Zhang T, 2016, AM J CANCER RES, V6, P2679; Zhu L, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1111-5	51	3	3	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2021	40	46					6430	6442		10.1038/s41388-021-02030-x	http://dx.doi.org/10.1038/s41388-021-02030-x		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA1UG	34608266	Green Accepted			2022-12-17	WOS:000703526900003
J	Tu, RF; Kang, WQ; Yang, MJ; Wang, LY; Bao, Q; Chen, Z; Dong, Y; Wang, JC; Jiang, J; Liu, HD; Qing, GL				Tu, Rongfu; Kang, Wenqian; Yang, Mengjie; Wang, Liyuan; Bao, Qing; Chen, Zhi; Dong, Yang; Wang, Jingchao; Jiang, Jue; Liu, Hudan; Qing, Guoliang			USP29 coordinates MYC and HIF1 alpha stabilization to promote tumor metabolism and progression	ONCOGENE			English	Article							CANCER METABOLISM; GLUTAMINE-METABOLISM; ONCOGENIC MYC; HIF-ALPHA; EXPRESSION; HYPOXIA; MUTATIONS; PHOSPHORYLATION; PROLIFERATION; KINASE-3	Tumor cells must rewire cellular metabolism to satisfy the demands of unbridled growth and proliferation. How these metabolic processes are integrated to fuel cancer cell growth remains largely unknown. Deciphering the regulatory mechanisms is vital to develop targeted strategies for tumor-selective therapies. We herein performed an unbiased and functional siRNA screen against 96 deubiquitinases, which play indispensable roles in cancer and are emerging as therapeutic targets, and identified USP29 as a top candidate essential for metabolic reprogramming that support biosynthesis and survival in tumor cells. Integrated metabolic flux analysis and molecular investigation reveal that USP29 directly deubiquitinates and stabilizes MYC and HIF1 alpha, two master regulators of metabolic reprogramming, enabling adaptive response of tumor cells in both normoxia and hypoxia. Systemic knockout of Usp29 depleted MYC and HIF1 alpha in MYC-driven neuroblastoma and B cell lymphoma, inhibited critical metabolic targets and significantly prolonged survival of tumor-bearing mice. Strikingly, mice homozygous null for the Usp29 gene are viable, fertile, and display no gross phenotypic abnormalities. Altogether, these results demonstrate that USP29 selectively coordinates MYC and HIF1 alpha to integrate metabolic processes critical for cancer cell growth, and therapeutic targeting of USP29, a potentially targetable enzyme, could create a unique vulnerability given deregulation of MYC and HIF1 alpha frequently occurs in human cancers.	[Tu, Rongfu; Kang, Wenqian; Qing, Guoliang] Wuhan Univ, Zhongnan Hosp, Dept Urol, Wuhan 430071, Peoples R China; [Tu, Rongfu; Kang, Wenqian; Yang, Mengjie; Wang, Liyuan; Bao, Qing; Chen, Zhi; Dong, Yang; Wang, Jingchao; Jiang, Jue; Liu, Hudan; Qing, Guoliang] Wuhan Univ, Frontier Sci Ctr Immunol & Metab, Med Res Inst, Wuhan 430071, Peoples R China	Wuhan University; Wuhan University	Qing, GL (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Urol, Wuhan 430071, Peoples R China.; Qing, GL (corresponding author), Wuhan Univ, Frontier Sci Ctr Immunol & Metab, Med Res Inst, Wuhan 430071, Peoples R China.	qingguoliang@whu.edu.cn			National Key R&D Program of China [2017YFA0505600]; National Natural Science Foundation of China [81970152, 81770177, 81830084]; National Science Foundation for Distinguished Young Scholar [81725013, 82025003]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science Foundation for Distinguished Young Scholar(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars)	We thank all members of the Qing lab for helpful suggestions, the Core Facility of Medical Research Institute at Wuhan University for providing hypoxia workstations and histology platform. We also thank Dr William A. Weiss (University of California, San Francisco) for providing transgenic TH-MYCN mice, Dr Wuhan Xiao (Institute of Hydrobiology, Chinese Academy of Sciences) for providing transgenic E mu-Myc mice. This study was supported by grants from National Key R&D Program of China (2017YFA0505600 to G.Q.), National Natural Science Foundation of China (81970152, 81770177 to H.L., 81830084 to G.Q.), National Science Foundation for Distinguished Young Scholar (81725013 to G.Q., 82025003 to H.L.).	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Cairns RA, 2013, CANCER DISCOV, V3, P730, DOI 10.1158/2159-8290.CD-13-0083; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Carracedo A, 2013, NAT REV CANCER, V13, P227, DOI 10.1038/nrc3483; Chandrasekaran AP, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115766; Cheng J, 2019, BBA-REV CANCER, V1872, DOI 10.1016/j.bbcan.2019.188312; Dang CV, 2016, COLD SH Q B, V81, P79, DOI 10.1101/sqb.2016.81.031153; Dang Chi Van, 2018, Biochim Biophys Acta Rev Cancer, V1870, P1, DOI 10.1016/j.bbcan.2018.07.006; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Dong Y, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00235-2; Faubert B, 2020, SCIENCE, V368, P152, DOI 10.1126/science.aaw5473; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Harrigan JA, 2018, NAT REV DRUG DISCOV, V17, P57, DOI 10.1038/nrd.2017.152; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang J, 2020, CANCER CELL, V37, P200, DOI 10.1016/j.ccell.2020.01.001; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Kloor M, 2002, BBA-GENE STRUCT EXPR, V1579, P219, DOI 10.1016/S0167-4781(02)00543-2; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Lane AN, 2015, NUCLEIC ACIDS RES, V43, P2466, DOI 10.1093/nar/gkv047; Le A, 2012, CELL METAB, V15, P110, DOI 10.1016/j.cmet.2011.12.009; Liu JH, 2011, EMBO J, V30, P846, DOI 10.1038/emboj.2011.11; Lu CW, 2008, J BIOL CHEM, V283, P28106, DOI 10.1074/jbc.M803508200; Luengo A, 2017, CELL CHEM BIOL, V24, P1161, DOI 10.1016/j.chembiol.2017.08.028; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Su HX, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06523-4; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun RC, 2014, CELL METAB, V19, P285, DOI 10.1016/j.cmet.2013.11.022; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Uchiyama K, 2002, J CELL BIOL, V159, P855, DOI 10.1083/jcb.200208112; Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; Wang YZ, 2004, J CELL BIOL, V164, P973, DOI 10.1083/jcb.200401010; WARBURG O, 1956, SCIENCE, V124, P269; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yuan M, 2012, NAT PROTOC, V7, P872, DOI 10.1038/nprot.2012.024; Yue M, 2017, CELL REP, V21, P3819, DOI 10.1016/j.celrep.2017.12.002; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099; Zhang Q, 2020, CELL RES, V30, P821, DOI 10.1038/s41422-020-0368-8; Zhu JJ, 2019, NAT REV MOL CELL BIO, V20, P436, DOI 10.1038/s41580-019-0123-5	50	3	3	2	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2021	40	46					6417	6429		10.1038/s41388-021-02031-w	http://dx.doi.org/10.1038/s41388-021-02031-w		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA1UG	34601505				2022-12-17	WOS:000702807100001
J	Garcia-Rendueles, AR; Chenlo, M; Oroz-Gonjar, F; Solomou, A; Mistry, A; Barry, S; Gaston-Massuet, C; Garcia-Lavandeira, M; Perez-Romero, S; Suarez-Farina, M; Pradilla-Dieste, A; Dieguez, C; Mehlen, P; Korbonits, M; Alvarez, CV				Garcia-Rendueles, Angela R.; Chenlo, Miguel; Oroz-Gonjar, Fernando; Solomou, Antonia; Mistry, Anisha; Barry, Sayka; Gaston-Massuet, Carles; Garcia-Lavandeira, Montserrat; Perez-Romero, Sihara; Suarez-Farina, Maria; Pradilla-Dieste, Alberto; Dieguez, Carlos; Mehlen, Patrick; Korbonits, Marta; Alvarez, Clara, V			RET signalling provides tumorigenic mechanism and tissue specificity for AIP-related somatotrophinomas	ONCOGENE			English	Article							RECEPTOR-INTERACTING-PROTEIN; PITUITARY-ADENOMA PREDISPOSITION; GENE-EXPRESSION; GROWTH-HORMONE; IN-SITU; MUTATIONS; CELLS; GH; APOPTOSIS; PATHWAY	It is unclear how loss-of-function germline mutations in the widely-expressed co-chaperone AIP, result in young-onset growth hormone secreting pituitary tumours. The RET receptor, uniquely co-expressed in somatotrophs with PIT1, induces apoptosis when unliganded, while RET supports cell survival when it is bound to its ligand. We demonstrate that at the plasma membrane, AIP is required to form a complex with monomeric-intracellular-RET, caspase-3 and PKC delta resulting in PIT1/CDKN2A-ARF/p53-apoptosis pathway activation. AIP-deficiency blocks RET/caspase-3/PKC delta activation preventing PIT1 accumulation and apoptosis. The presence or lack of the inhibitory effect on RET-induced apoptosis separated pathogenic AIP variants from non-pathogenic ones. We used virogenomics in neonatal rats to demonstrate the effect of mutant AIP protein on the RET apoptotic pathway in vivo. In adult male rats altered AIP induces elevated IGF-1 and gigantism, with pituitary hyperplasia through blocking the RET-apoptotic pathway. In females, pituitary hyperplasia is induced but IGF-1 rise and gigantism are blunted by puberty. Somatotroph adenomas from pituitary-specific Aip-knockout mice overexpress the RET-ligand GDNF, therefore, upregulating the survival pathway. Somatotroph adenomas from patients with or without AIP mutation abundantly express GDNF, but AIP-mutated tissues have less CDKN2A-ARF expression. Our findings explain the tissue-specific mechanism of AIP-induced somatotrophinomas and provide a previously unknown tumorigenic mechanism, opening treatment avenues for AIP-related tumours.	[Garcia-Rendueles, Angela R.; Chenlo, Miguel; Oroz-Gonjar, Fernando; Garcia-Lavandeira, Montserrat; Perez-Romero, Sihara; Suarez-Farina, Maria; Pradilla-Dieste, Alberto; Dieguez, Carlos; Alvarez, Clara, V] Univ Santiago de Compostela USC, Ctr Invest Med Mol & Enfermedades Cron CIMUS, Neoplasia & Endocrine Differentiat POL5, Santiago De Compostela, Spain; [Solomou, Antonia; Mistry, Anisha; Barry, Sayka; Gaston-Massuet, Carles; Korbonits, Marta] Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, Dept Endocrinol, London, England; [Mehlen, Patrick] Univ Lyon, Ctr Leon Berard, Patrick Mehlen Apoptosis Canc & Dev Lab Equipe La, INSERM U1052 CNRS UMR5286,LabEx DEVweCAN,Inst PLA, F-69008 Lyon, France	Universidade de Santiago de Compostela; University of London; Queen Mary University London; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Alvarez, CV (corresponding author), Univ Santiago de Compostela USC, Ctr Invest Med Mol & Enfermedades Cron CIMUS, Neoplasia & Endocrine Differentiat POL5, Santiago De Compostela, Spain.; Korbonits, M (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, Dept Endocrinol, London, England.	m.korbonits@qmul.ac.uk; clara.alvarez@usc.es	Alvarez, Clara V/AAN-4173-2020	Garcia Lavandeira, Montserrat/0000-0001-9208-2418; Chenlo, Miguel Angel/0000-0002-1802-0021; dieguez, carlos/0000-0002-0919-4337; Alvarez, Clara V/0000-0003-1500-4058	Medical Research Council UK [MR/M018539/1/010550]; Agencia Estatal de Investigacion (AEI, Spain); European FEDER funds [PID2019-110437RB-I00]; Xunta de Galicia (Centro singular de investigacion de Galicia accreditation 2019-2022); European Union (European Regional Development Fund -ERDF)	Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Agencia Estatal de Investigacion (AEI, Spain); European FEDER funds(European Commission); Xunta de Galicia (Centro singular de investigacion de Galicia accreditation 2019-2022); European Union (European Regional Development Fund -ERDF)	This work was supported by Medical Research Council UK MR/M018539/1/010550 QM project to MK (PI) and CVA, and by Agencia Estatal de Investigacion (AEI, Spain) with the participation of European FEDER funds PID2019-110437RB-I00 project to CVA. This work has received financial support from the Xunta de Galicia (Centro singular de investigacion de Galicia accreditation 2019-2022) and the European Union (European Regional Development Fund -ERDF).	Aflorei ED, 2018, J MED GENET, V55, P522, DOI 10.1136/jmedgenet-2017-105191; Andoniadou CL, 2013, CELL STEM CELL, V13, P433, DOI 10.1016/j.stem.2013.07.004; Awad S, 2018, END ABSTR, V59, pP127; Barry S, 2019, ONCOGENE, V38, P5381, DOI 10.1038/s41388-019-0779-5; Beckers A, 2013, ENDOCR REV, V34, P239, DOI 10.1210/er.2012-1013; Berger AH, 2011, NATURE, V476, P163, DOI 10.1038/nature10275; Bizzi MF, 2018, MOL CELL ENDOCRINOL, V476, P103, DOI 10.1016/j.mce.2018.04.014; Bogner EM, 2020, INT J CANCER, V147, P3523, DOI 10.1002/ijc.33268; Bolger GB, 2016, ENDOCR-RELAT CANCER, V23, P419, DOI 10.1530/ERC-15-0205; Bordeaux MC, 2000, EMBO J, V19, P4056, DOI 10.1093/emboj/19.15.4056; Cai F, 2013, EUR J ENDOCRINOL, V169, P867, DOI 10.1530/EJE-13-0442; Caimari, 2019, END ABSTR, V65; Canibano C, 2007, EMBO J, V26, P2015, DOI 10.1038/sj.emboj.7601636; Carty DM, 2021, PITUITARY, V24, P48, DOI 10.1007/s11102-020-01085-5; Cazabat L, 2012, J CLIN ENDOCR METAB, V97, pE663, DOI 10.1210/jc.2011-2291; Chen BJ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01704-z; Chenlo M, 2019, EBIOMEDICINE, V43, P537, DOI 10.1016/j.ebiom.2019.04.007; Colao A, 2011, ENDOCR REV, V32, P247, DOI 10.1210/er.2010-0002; Costantini F, 2010, ORGANOGENESIS, V6, P252, DOI 10.4161/org.6.4.12680; Denes J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117107; Diaz-Rodriguez E, 2012, ONCOGENE, V31, P2824, DOI 10.1038/onc.2011.458; Diaz-Rodriguez E, 2014, ENDOCRINOLOGY, V155, P4329, DOI 10.1210/en.2014-1034; Formosa R, 2017, HORM CANCER-US, V8, P174, DOI 10.1007/s12672-017-0288-3; Fredriksson S, 2002, NAT BIOTECHNOL, V20, P473, DOI 10.1038/nbt0502-473; Gadelha MR, 2019, ENDOCR REV, V40, P268, DOI 10.1210/er.2018-00115; Garcia A, 2001, MOL ENDOCRINOL, V15, P1484, DOI 10.1210/me.15.9.1484; Garcia-Lavandeira M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004815; Garcia-Lavandeira M, 2015, NEUROENDOCRINOLOGY, V101, P175, DOI 10.1159/000375502; Garcia-Rendueles AR, 2017, ONCOGENE, V36, P652, DOI 10.1038/onc.2016.233; Gaston-Massuet C, 2008, DEV BIOL, V324, P322, DOI 10.1016/j.ydbio.2008.08.008; Gillam MP, 2017, J ENDOCR SOC, V1, P78, DOI 10.1210/js.2016-1004; Giustina A, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgz096; Goddard TD, 2018, PROTEIN SCI, V27, P14, DOI 10.1002/pro.3235; Gremeaux L, 2012, STEM CELLS DEV, V21, P801, DOI 10.1089/scd.2011.0496; Guillou A, 2011, ENDOCRINOLOGY, V152, P515, DOI 10.1210/en.2010-0673; Hernandez-Ramirez Laura C, 2018, Oncotarget, V9, P9177, DOI 10.18632/oncotarget.24183; Hernandez-Ramirez LC, 2016, J CLIN ENDOCR METAB, V101, P3144, DOI 10.1210/jc.2016-1307; Hernandez-Ramirez LC, 2015, J CLIN ENDOCR METAB, V100, pE1242, DOI 10.1210/jc.2015-1869; Holden Paul, 2009, BMC Res Notes, V2, P243, DOI 10.1186/1756-0500-2-243; Hollingshead BD, 2004, J BIOL CHEM, V279, P45652, DOI 10.1074/jbc.M407840200; Igreja S, 2010, HUM MUTAT, V31, P950, DOI 10.1002/humu.21292; Iwata T, 2007, CLIN ENDOCRINOL, V66, P499, DOI 10.1111/j.1365-2265.2007.02758.x; Japon MA, 2002, J CLIN ENDOCR METAB, V87, P1879, DOI 10.1210/jc.87.4.1879; JAPON MA, 1994, J HISTOCHEM CYTOCHEM, V42, P1117, DOI 10.1177/42.8.8027530; Jayakody SA, 2012, J CLIN INVEST, V122, P3635, DOI 10.1172/JCI64311; Jones TR, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-482; Kasuki L, 2012, ENDOCR-RELAT CANCER, V19, pL25, DOI 10.1530/ERC-12-0020; Korbonits, 2017, END ABSTR, V50; Lecoq AL, 2016, J ENDOCRINOL, V231, P59, DOI 10.1530/JOE-16-0190; Leontiou CA, 2008, J CLIN ENDOCR METAB, V93, P2390, DOI 10.1210/jc.2007-2611; Li JC, 2018, NUCLEIC ACIDS RES, V46, P7793, DOI 10.1093/nar/gky678; Lin BC, 2007, J BIOL CHEM, V282, P35924, DOI 10.1074/jbc.M705471200; Marques P, 2020, J CLIN ENDOCR METAB, V105, pE2247, DOI 10.1210/clinem/dgaa040; Martin-Rodriguez JF, 2015, SCI REP-UK, V5, DOI 10.1038/srep16298; Melin AD, 2005, J MAMMAL, V86, P1042, DOI 10.1644/1545-1542(2005)86[1042:MPGETI]2.0.CO;2; Morgan RML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053339; Negulescu AM, 2018, FEBS J, V285, P3909, DOI 10.1111/febs.14507; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Raitila A, 2010, AM J PATHOL, V177, P1969, DOI 10.2353/ajpath.2010.100138; Ramirez-Yanez GO, 2005, EUR J ORTHODONT, V27, P494, DOI 10.1093/ejo/cji028; Reyland ME, 2007, BIOCHEM SOC T, V35, P1001, DOI 10.1042/BST0351001; Ritvonen E, 2017, EUR J ENDOCRINOL, V176, P243, DOI 10.1530/EJE-16-0620; Rizzoti K, 2013, CELL STEM CELL, V13, P419, DOI 10.1016/j.stem.2013.07.006; Rostomyan L, 2015, ENDOCR-RELAT CANCER, V22, P745, DOI 10.1530/ERC-15-0320; Salzer E, 2013, BLOOD, V121, P3112, DOI 10.1182/blood-2012-10-460741; SASAKI F, 1988, ENDOCRINOLOGY, V122, P1622, DOI 10.1210/endo-122-4-1622; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Solloso A, 2008, J CELL PHYSIOL, V215, P140, DOI 10.1002/jcp.21295; Sun DJ, 2019, CELL REP, V27, P1461, DOI 10.1016/j.celrep.2019.04.014; Tuominen I, 2015, ONCOGENE, V34, P1174, DOI 10.1038/onc.2014.50; Urbano AG, 2000, ENDOCRINOLOGY, V141, P1893, DOI 10.1210/en.141.5.1893; Vargiolu M, 2009, J CLIN ENDOCR METAB, V94, P2571, DOI 10.1210/jc.2008-1980; Vierimaa O, 2006, SCIENCE, V312, P1228, DOI 10.1126/science.1126100; Villa C, 2011, ENDOCR-RELAT CANCER, V18, P347, DOI 10.1530/ERC-11-0059; Wang J, 2004, J ENDOCRINOL, V180, P247, DOI 10.1677/joe.0.1800247; Xekouki P, 2013, ENDOCR-RELAT CANCER, V20, pL11, DOI 10.1530/ERC-13-0218; Yamashita M, 2006, VIROLOGY, V344, P88, DOI 10.1016/j.virol.2005.09.012; Zatelli MC, 2013, PITUITARY, V16, P238, DOI 10.1007/s11102-012-0409-5; Zorn JA, 2012, J BIOL CHEM, V287, P33781, DOI 10.1074/jbc.M112.386128	80	3	3	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2021	40	45					6354	6368		10.1038/s41388-021-02009-8	http://dx.doi.org/10.1038/s41388-021-02009-8		SEP 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW1BA	34588620	Green Published, hybrid			2022-12-17	WOS:000701380400003
J	Gillen, SL; Waldron, JA; Bushell, M				Gillen, Sarah L.; Waldron, Joseph A.; Bushell, Martin			Codon optimality in cancer	ONCOGENE			English	Review							POLYMERASE-III TRANSCRIPTION; TRANSFER-RNA MODIFICATION; 3' UNTRANSLATED REGIONS; GENE-EXPRESSION; TRANSLATION EFFICIENCY; IN-VIVO; ALTERNATIVE POLYADENYLATION; MESSENGER-RNAS; BREAST-CANCER; TUMOR-GROWTH	A key characteristic of cancer cells is their increased proliferative capacity, which requires elevated levels of protein synthesis. The process of protein synthesis involves the translation of codons within the mRNA coding sequence into a string of amino acids to form a polypeptide chain. As most amino acids are encoded by multiple codons, the nucleotide sequence of a coding region can vary dramatically without altering the polypeptide sequence of the encoded protein. Although mutations that do not alter the final amino acid sequence are often thought of as silent/synonymous, these can still have dramatic effects on protein output. Because each codon has a distinct translation elongation rate and can differentially impact mRNA stability, each codon has a different degree of 'optimality' for protein synthesis. Recent data demonstrates that the codon preference of a transcriptome matches the abundance of tRNAs within the cell and that this supply and demand between tRNAs and mRNAs varies between different cell types. The largest observed distinction is between mRNAs encoding proteins associated with proliferation or differentiation. Nevertheless, precisely how codon optimality and tRNA expression levels regulate cell fate decisions and their role in malignancy is not fully understood. This review describes the current mechanistic understanding on codon optimality, its role in malignancy and discusses the potential to target codon optimality therapeutically in the context of cancer.	[Gillen, Sarah L.; Waldron, Joseph A.; Bushell, Martin] Canc Res UK Beatson Inst, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland; [Bushell, Martin] Univ Glasgow, Inst Canc Sci, Glasgow G61 1QH, Lanark, Scotland	Beatson Institute; University of Glasgow	Gillen, SL; Bushell, M (corresponding author), Canc Res UK Beatson Inst, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.; Bushell, M (corresponding author), Univ Glasgow, Inst Canc Sci, Glasgow G61 1QH, Lanark, Scotland.	slg76@cam.ac.uk; martin.bushell@glasgow.ac.uk		Gillen, Sarah/0000-0002-0192-864X	Cancer Research UK (CRUK) [A29252] Funding Source: Medline; Medical Research Council [MC_UP_A600_1024, MC_EX_G0902052] Funding Source: Medline	Cancer Research UK (CRUK)(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aharon-Hefetz N, 2020, ELIFE, V9, DOI 10.7554/eLife.58461; Bazzini AA, 2016, EMBO J, V35, P2087, DOI 10.15252/embj.201694699; Begley U, 2013, EMBO MOL MED, V5, P366, DOI 10.1002/emmm.201201161; Behrens A, 2021, MOL CELL, V81, P1802, DOI 10.1016/j.molcel.2021.01.028; Benisty H, 2020, P NATL ACAD SCI USA, V117, P30848, DOI 10.1073/pnas.2016119117; Bhat M, 2015, NAT REV DRUG DISCOV, V14, P261, DOI 10.1038/nrd4505; Bin YN, 2019, BMC MED GENET, V20, DOI 10.1186/s12881-019-0926-4; Boel G, 2016, NATURE, V529, P358, DOI 10.1038/nature16509; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Bornelov S, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1726-z; Brule CE, 2017, TRENDS GENET, V33, P283, DOI 10.1016/j.tig.2017.02.001; Buhr F, 2016, MOL CELL, V61, P341, DOI 10.1016/j.molcel.2016.01.008; Burow DA, 2018, CELL REP, V24, P1704, DOI 10.1016/j.celrep.2018.07.039; Buschauer R, 2020, SCIENCE, V368, P281, DOI 10.1126/science.aay6912; Carneiro RL, 2019, NUCLEIC ACIDS RES, V47, P2216, DOI 10.1093/nar/gkz033; Chan PP, 2016, NUCLEIC ACIDS RES, V44, pD184, DOI 10.1093/nar/gkv1309; Chen Y, 2014, MOL CELL, V54, P737, DOI 10.1016/j.molcel.2014.03.034; Clarke CJ, 2016, CURR BIOL, V26, P755, DOI 10.1016/j.cub.2016.01.045; Collart MA, 2020, NUCLEIC ACIDS RES, V48, P1043, DOI 10.1093/nar/gkz763; Courel M, 2019, ELIFE, V8, DOI 10.7554/eLife.49708; Cozen AE, 2015, NAT METHODS, V12, P879, DOI [10.1038/NMETH.3508, 10.1038/nmeth.3508]; Crighton D, 2003, EMBO J, V22, P2810, DOI 10.1093/emboj/cdg265; Delaunay S, 2016, J EXP MED, V213, P2503, DOI 10.1084/jem.20160397; Deng WJ, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005706; Dhindsa RS, 2020, AM J HUM GENET, V107, P83, DOI 10.1016/j.ajhg.2020.05.011; Dittmar KA, 2006, PLOS GENET, V2, P2107, DOI 10.1371/journal.pgen.0020221; Dong C, 2016, BIOCHEM BIOPH RES CO, V476, P340, DOI 10.1016/j.bbrc.2016.05.124; dos Reis M, 2004, NUCLEIC ACIDS RES, V32, P5036, DOI 10.1093/nar/gkh834; Evans ME, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkx514; Fan SQ, 2009, CANCER BIOL THER, V8, P1463, DOI 10.4161/cbt.8.15.8960; Forrest ME, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228730; Frenkel-Morgenstern M, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2012.3; Frumkin I, 2018, P NATL ACAD SCI USA, V115, pE4940, DOI 10.1073/pnas.1719375115; Fu JJ, 2018, J BIOL CHEM, V293, P17929, DOI 10.1074/jbc.RA118.004908; Fu YG, 2011, GENOME RES, V21, P741, DOI 10.1101/gr.115295.110; Torres AG, 2014, FEBS LETT, V588, P4279, DOI 10.1016/j.febslet.2014.09.025; Gamble CE, 2016, CELL, V166, P679, DOI 10.1016/j.cell.2016.05.070; Gao NL, 2021, GENOM PROTEOM BIOINF, V19, P949, DOI 10.1016/j.gpb.2021.03.002; Gingold H, 2014, CELL, V158, P1281, DOI 10.1016/j.cell.2014.08.011; Gingold H, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.14; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Goodarzi H, 2016, CELL, V165, P1416, DOI 10.1016/j.cell.2016.05.046; Gorochowski TE, 2015, NUCLEIC ACIDS RES, V43, P3022, DOI 10.1093/nar/gkv199; Grandori C, 2005, NAT CELL BIOL, V7, P311, DOI 10.1038/ncb1224; Grewal SS, 2015, BBA-GENE REGUL MECH, V1849, P898, DOI 10.1016/j.bbagrm.2014.12.005; Griseri P, 2014, WORLD J CLIN ONCOL, V5, P323, DOI 10.5306/wjco.v5.i3.323; Gruber AR, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6465; Guimaraes JC, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-1943-5; Hanson G, 2018, NAT REV MOL CELL BIO, V19, P20, DOI 10.1038/nrm.2017.91; Harigaya Y, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3749-8; He Q, 2020, CELL DEATH DIS, V11, P1; Hernandez-Alias X, 2021, MOL SYST BIOL, V17, DOI 10.15252/msb.202010097; Hia FB, 2019, EMBO REP, V20, DOI 10.15252/embr.201948220; Hinnebusch AG, 2016, SCIENCE, V352, P1413, DOI 10.1126/science.aad9868; Hoffman Y, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005879; Ingolia NT, 2012, NAT PROTOC, V7, P1534, DOI 10.1038/nprot.2012.086; Ji Z, 2009, P NATL ACAD SCI USA, V106, P7028, DOI 10.1073/pnas.0900028106; Kantidakis T, 2010, P NATL ACAD SCI USA, V107, P11823, DOI 10.1073/pnas.1005188107; Komar AA, 2016, HUM MOL GENET, V25, pR77, DOI 10.1093/hmg/ddw207; Ladang A, 2015, J EXP MED, V212, P2057, DOI 10.1084/jem.20142288; Lambert M, 2018, MOLECULES, V23, DOI 10.3390/molecules23061479; Lampson BL, 2013, CURR BIOL, V23, P70, DOI 10.1016/j.cub.2012.11.031; Lee LJ, 2021, TRENDS CANCER, V7, P134, DOI 10.1016/j.trecan.2020.09.005; Leppek K, 2018, NAT REV MOL CELL BIO, V19, P158, DOI 10.1038/nrm.2017.103; Lewinson, RNA BIOL, V2021; Li QS, 2021, BMC GASTROENTEROL, V21, DOI 10.1186/s12876-020-01553-z; Li YK, 2012, CANCER BIOL THER, V13, P272, DOI 10.4161/cbt.18923; Liu Y, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-00642-6; Lorent J, 2019, EMBO J, V38, DOI 10.15252/embj.2018101323; Lu LG, 2018, CANCER INVEST, V36, P246, DOI 10.1080/07357907.2018.1466896; Mahlab S, 2012, RNA, V18, P640, DOI 10.1261/rna.030775.111; Makhtar WRW, 2017, ONCOGENE, V36, P6640, DOI 10.1038/onc.2017.273; Mauger DM, 2019, P NATL ACAD SCI USA, V116, P24075, DOI 10.1073/pnas.1908052116; Medina-Munoz SG, 2021, GENOME BIOL, V22, DOI 10.1186/s13059-020-02251-5; Mishima Y, 2016, MOL CELL, V61, P874, DOI 10.1016/j.molcel.2016.02.027; Modelska A, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.542; Najafabadi HS, 2009, NUCLEIC ACIDS RES, V37, P7014, DOI 10.1093/nar/gkp792; Novoa EM, 2019, MOL BIOL EVOL, V36, P2328, DOI 10.1093/molbev/msz124; Parmley JL, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000548; Pavon-Eternod M, 2009, NUCLEIC ACIDS RES, V37, P7268, DOI 10.1093/nar/gkp787; Peng Y, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2015.4; Perron G, 2018, CELL REP, V23, P1639, DOI 10.1016/j.celrep.2018.04.031; Pershing NLK, 2015, J CLIN INVEST, V125, P222, DOI 10.1172/JCI77627; Pinkard O, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17879-x; Plotkin JB, 2004, P NATL ACAD SCI USA, V101, P12588, DOI 10.1073/pnas.0404957101; Plotkin JB, 2011, NAT REV GENET, V12, P32, DOI 10.1038/nrg2899; Presnyak V, 2015, CELL, V160, P1111, DOI 10.1016/j.cell.2015.02.029; Radhakrishnan A, 2016, CELL, V167, P122, DOI 10.1016/j.cell.2016.08.053; Ranjan N, 2016, TRANSLATION, V4, DOI 10.1080/21690731.2016.1143076; Rapino F, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22254-5; Rapino F, 2018, NATURE, V558, P605, DOI 10.1038/s41586-018-0243-7; Rapino F, 2017, TRENDS CANCER, V3, P249, DOI 10.1016/j.trecan.2017.02.004; Rocha EPC, 2004, GENOME RES, V14, P2279, DOI 10.1101/gr.2896904; Rouya C, 2014, RNA, V20, P1398, DOI 10.1261/rna.045302.114; Rubio CA, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0476-1; Rudolph KLM, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006024; Rudorf S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134994; Rudorf S, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003909; Sandberg R, 2008, SCIENCE, V320, P1643, DOI 10.1126/science.1155390; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Schmidt EV, 2004, ONCOGENE, V23, P3217, DOI 10.1038/sj.onc.1207548; Schuster SL, 2019, TRENDS CANCER, V5, P245, DOI 10.1016/j.trecan.2019.02.011; Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098; Schwanhausser B, 2009, PROTEOMICS, V9, P205, DOI 10.1002/pmic.200800275; Sharma Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10489-2; SHARP PM, 1986, NUCLEIC ACIDS RES, V14, P5125, DOI 10.1093/nar/14.13.5125; Silvera D, 2009, NAT CELL BIOL, V11, P903, DOI 10.1038/ncb1900; Sommerkamp P, 2021, TRENDS MOL MED, V27, P660, DOI 10.1016/j.molmed.2021.04.006; Supek F, 2014, CELL, V156, P1324, DOI 10.1016/j.cell.2014.01.051; Tesina P, 2020, EMBO J, V39, DOI 10.15252/embj.2019103365; Torrent M, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aat6409; Trosemeier JH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43857-5; Vaklavas C, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00158; Waldman YY, 2010, NUCLEIC ACIDS RES, V38, P2964, DOI 10.1093/nar/gkq009; Walsh IM, 2020, P NATL ACAD SCI USA, V117, P3528, DOI 10.1073/pnas.1907126117; Wang YL, 2002, P NATL ACAD SCI USA, V99, P5860, DOI 10.1073/pnas.092538799; Webster MW, 2018, MOL CELL, V70, P1089, DOI 10.1016/j.molcel.2018.05.033; Weinberg DE, 2016, CELL REP, V14, P1787, DOI 10.1016/j.celrep.2016.01.043; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; White RJ, 2004, ONCOGENE, V23, P3208, DOI 10.1038/sj.onc.1207547; Wolfe AL, 2014, NATURE, V513, P65, DOI 10.1038/nature13485; Wu QS, 2019, ELIFE, V8, DOI 10.7554/eLife.45396; Wu XD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160463; Xu HY, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44457-z; Xu SQ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09235-5; Xu Y, 2013, NATURE, V495, P116, DOI 10.1038/nature11942; Yi J, 2017, ONCOTARGET, V8, P20751, DOI 10.18632/oncotarget.10612; Yu CH, 2015, MOL CELL, V59, P744, DOI 10.1016/j.molcel.2015.07.018; Zhang Z, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0239-8; Zhao FZ, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2022590118; Zhao F, 2017, NUCLEIC ACIDS RES, V45, P8484, DOI 10.1093/nar/gkx501; Zhou M, 2013, NATURE, V495, P111, DOI 10.1038/nature11833; Zhou ZP, 2016, P NATL ACAD SCI USA, V113, pE6117, DOI 10.1073/pnas.1606724113; Zou Q, 2019, THERANOSTICS, V9, P4141, DOI 10.7150/thno.35033	134	3	3	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2021	40	45					6309	6320		10.1038/s41388-021-02022-x	http://dx.doi.org/10.1038/s41388-021-02022-x		SEP 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW1BA	34584217	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000701638300005
J	Bolado-Carrancio, A; Lee, M; Ewing, A; Muir, M; Macleod, KG; Gallagher, WM; Nguyen, LK; Carragher, NO; Semple, CA; Brunton, VG; Caswell, PT; von Kriegsheim, A				Bolado-Carrancio, Alfonso; Lee, Martin; Ewing, Ailith; Muir, Morwenna; Macleod, Kenneth G.; Gallagher, William M.; Nguyen, Lan K.; Carragher, Neil O.; Semple, Colin A.; Brunton, Valerie G.; Caswell, Patrick T.; von Kriegsheim, Alex			ISGylation drives basal breast tumour progression by promoting EGFR recycling and Akt signalling	ONCOGENE			English	Article							UBIQUITIN-LIKE PROTEIN; ISG15 CONJUGATION; EARLY ENDOSOMES; 15-KDA PROTEIN; CELL-MIGRATION; IN-VITRO; CANCER; EXPRESSION; ACTIVATION; UBP43	ISG15 is an ubiquitin-like modifier that is associated with reduced survival rates in breast cancer patients. The mechanism by which ISG15 achieves this however remains elusive. We demonstrate that modification of Rab GDP-Dissociation Inhibitor Beta (GDI2) by ISG15 (ISGylation) alters endocytic recycling of the EGF receptor (EGFR) in non-interferon stimulated cells using CRISPR-knock out models for ISGylation. By regulating EGFR trafficking, ISGylation enhances EGFR recycling and sustains Akt-signalling. We further show that Akt signalling positively correlates with levels of ISG15 and its E2-ligase in basal breast cancer cohorts, confirming the link between ISGylation and Akt signalling in human tumours. Persistent and enhanced Akt activation explains the more aggressive tumour behaviour observed in human breast cancers. We show that ISGylation can act as a driver of tumour progression rather than merely being a bystander.	[Bolado-Carrancio, Alfonso; Lee, Martin; Muir, Morwenna; Macleod, Kenneth G.; Carragher, Neil O.; Brunton, Valerie G.; von Kriegsheim, Alex] Univ Edinburgh, Inst Genet & Canc, Edinburgh Canc Res Ctr, Crewe Rd South, Edinburgh EH4 2XU, Midlothian, Scotland; [Ewing, Ailith] Univ Edinburgh, Inst Genet & Canc, MRC Human Genet Unit, Crewe Rd South, Edinburgh EH4 2XU, Midlothian, Scotland; [Gallagher, William M.] Univ Coll Dublin, UCD Conway Inst, UCD Sch Biomol & Biomed Sci, Dublin D4, Ireland; [Nguyen, Lan K.] Monash Univ, Biomed Discovery Inst, Dept Biochem & Mol Biol, Melbourne, Vic 3800, Australia; [Caswell, Patrick T.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Wellcome Trust Ctr Cell Matrix Res, Fac Biol Med & Hlth,Sch Biol Sci, Manchester, Lancs, England	University of Edinburgh; University of Edinburgh; University College Dublin; Monash University; University of Manchester	von Kriegsheim, A (corresponding author), Univ Edinburgh, Inst Genet & Canc, Edinburgh Canc Res Ctr, Crewe Rd South, Edinburgh EH4 2XU, Midlothian, Scotland.	alex.vonkriegsheim@IGMM.ed.ac.uk	MacLeod, Kenneth/GWU-8940-2022; Lee, Martin/K-8682-2015	Bolado-Carrancio, Alfonso/0000-0003-2330-7489; Lee, Martin/0000-0001-6529-5784	Breast Cancer NOW [2013NovPR183]; Cancer Research UK (CRUK) [C157/A255140, C157/A24837]; Wellcome Trust [208402/Z/17/Z, 203128/A/16/Z]; MRC [MC_UU_00007/16, MR/R009376/1]; Worldwide Cancer Research [14-1226]; Australia's Victorian Cancer Agency [MCRF18026]; BREAST-PREDICT (CCRC13GAL); Science Foundation Ireland [15/IA/3104]	Breast Cancer NOW; Cancer Research UK (CRUK)(Cancer Research UK); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Worldwide Cancer Research; Australia's Victorian Cancer Agency; BREAST-PREDICT (CCRC13GAL); Science Foundation Ireland(Science Foundation IrelandEuropean Commission)	We thank Ana Herrero for help with the cellular fractionation method, Breast Cancer NOW (2013NovPR183), Cancer Research UK. Cancer Research UK (CRUK Edinburgh Centre C157/A255140 & C157/A24837), Wellcome Trust (Multiuser Equipment Grant, 208402/Z/17/Z & Centre for Cell-Matrix Research 203128/A/16/Z), MRC (core funding to the MRC Human Genetics Unit MRC grant MC_UU_00007/16 & MR/R009376/1), Worldwide Cancer Research (14-1226), Australia's Victorian Cancer Agency (MCRF18026), BREAST-PREDICT (CCRC13GAL) and Science Foundation Ireland (15/IA/3104) for funding.	Andersen JB, 2006, BRIT J CANCER, V94, P1465, DOI 10.1038/sj.bjc.6603099; Ankney JA, 2019, BMC MED GENOMICS, V12, DOI 10.1186/s12920-019-0530-7; Bektas N, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2117; Boelens MC, 2014, CELL, V159, P499, DOI 10.1016/j.cell.2014.09.051; Burks J, 2014, ONCOGENE, V33, P794, DOI 10.1038/onc.2012.633; Burks J, 2015, ONCOTARGET, V6, P7221, DOI 10.18632/oncotarget.3372; Butti R, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0797-x; Caswell PT, 2008, J CELL BIOL, V183, P143, DOI 10.1083/jcb.200804140; Cerikan B, 2016, DEV CELL, V39, P28, DOI 10.1016/j.devcel.2016.08.020; Creighton CJ, 2007, ONCOGENE, V26, P4648, DOI 10.1038/sj.onc.1210245; DCunha J, 1996, J IMMUNOL, V157, P4100; de Graauw M, 2014, ONCOGENE, V33, P2610, DOI 10.1038/onc.2013.219; Desai SD, 2006, CANCER RES, V66, P921, DOI 10.1158/0008-5472.CAN-05-1123; Desai SD, 2012, EXP BIOL MED, V237, P38, DOI 10.1258/ebm.2011.011236; Farrell J, 2014, J PROTEOME RES, V13, P2874, DOI 10.1021/pr5000285; Frittoli E, 2014, J CELL BIOL, V206, P307, DOI 10.1083/jcb.201403127; Giannakopoulos NV, 2005, BIOCHEM BIOPH RES CO, V336, P496, DOI 10.1016/j.bbrc.2005.08.132; Gilbert PM, 2001, J BIOL CHEM, V276, P8014, DOI 10.1074/jbc.M008845200; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; HAAS AL, 1987, J BIOL CHEM, V262, P11315; Hermann M, 2017, TRENDS IMMUNOL, V38, P79, DOI 10.1016/j.it.2016.11.001; Huang YF, 2014, CELL CYCLE, V13, P2200, DOI 10.4161/cc.29209; Jeon YJ, 2009, EMBO REP, V10, P374, DOI 10.1038/embor.2009.23; Kiessling A, 2009, ONCOGENE, V28, P2606, DOI 10.1038/onc.2009.115; KNIGHT E, 1991, J IMMUNOL, V146, P2280; KORANT BD, 1984, J BIOL CHEM, V259, P4835; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Li C, 2014, ONCOTARGET, V5, P8429, DOI 10.18632/oncotarget.2316; LOEB KR, 1992, J BIOL CHEM, V267, P7806; Luan P, 2000, TRAFFIC, V1, P270, DOI 10.1034/j.1600-0854.2000.010309.x; Mackenzie KJ, 2017, NATURE, V548, P461, DOI 10.1038/nature23449; Madden SF, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3444; Malakhov MP, 2002, J BIOL CHEM, V277, P9976, DOI 10.1074/jbc.M109078200; Malakhov MP, 2003, J BIOL CHEM, V278, P16608, DOI 10.1074/jbc.M208435200; Malakhova O, 2002, J BIOL CHEM, V277, P14703, DOI 10.1074/jbc.M111527200; Malakhova OA, 2003, GENE DEV, V17, P455, DOI 10.1101/gad.1056303; Malakhova OA, 2006, EMBO J, V25, P2358, DOI 10.1038/sj.emboj.7601149; Masuda H, 2012, BREAST CANCER RES TR, V136, P331, DOI 10.1007/s10549-012-2289-9; Morales DJ, 2013, J MOL BIOL, V425, P4995, DOI 10.1016/j.jmb.2013.09.041; Mustachio LM, 2017, ONCOTARGET, V8, P3, DOI 10.18632/oncotarget.13914; Nabet BY, 2017, CELL, V170, P352, DOI 10.1016/j.cell.2017.06.031; Nishimura Y, 2015, INT J ONCOL, V46, P1721, DOI 10.3892/ijo.2015.2871; Padovan E, 2002, CANCER RES, V62, P3453; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; Sainz B, 2014, CANCER RES, V74, P7309, DOI 10.1158/0008-5472.CAN-14-1354; Shin J, 2016, CANCER SCI, V107, P828, DOI 10.1111/cas.12935; Shisheva A, 1999, BIOCHEMISTRY-US, V38, P11711, DOI 10.1021/bi990200r; Sivan G, 2016, J VIROL, V90, P8891, DOI 10.1128/JVI.01114-16; Sooryanarain H, 2017, J VIROL, V91, DOI 10.1128/JVI.00621-17; Takeuchi T, 2005, J BIOCHEM, V138, P711, DOI 10.1093/jb/mvi172; Talvinen K, 2006, ANTICANCER RES, V26, P4745; Turriziani Benedetta, 2014, Biology (Basel), V3, P320, DOI 10.3390/biology3020320; Villarreal DO, 2015, MOL THER, V23, P1653, DOI 10.1038/mt.2015.120; Villarroya-Beltri C, 2017, J CELL SCI, V130, P2961, DOI 10.1242/jcs.205468; Weichselbaum RR, 2008, P NATL ACAD SCI USA, V105, P18490, DOI 10.1073/pnas.0809242105; Wilcke M, 2000, J CELL BIOL, V151, P1207, DOI 10.1083/jcb.151.6.1207; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/nmeth.1322, 10.1038/NMETH.1322]; Yang PS, 2011, CANCER SCI, V102, P2172, DOI 10.1111/j.1349-7006.2011.02089.x; Yanguez E, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003632; Ye QH, 2016, CANCER CELL, V30, P444, DOI 10.1016/j.ccell.2016.07.017; Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362; Zhang YF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13393-x; Zhao C, 2004, P NATL ACAD SCI USA, V101, P7578, DOI 10.1073/pnas.0402528101; Zhao C, 2005, P NATL ACAD SCI USA, V102, P10200, DOI 10.1073/pnas.0504754102	64	3	3	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2021	40	44					6235	6247		10.1038/s41388-021-02017-8	http://dx.doi.org/10.1038/s41388-021-02017-8		SEP 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR3FG	34556814	Green Submitted, Green Published, hybrid			2022-12-17	WOS:000698556400003
J	Moskovich, D; Finkelshtein, Y; Alfandari, A; Rosemarin, A; Lifschytz, T; Weisz, A; Mondal, S; Ungati, H; Katzav, A; Kidron, D; Mugesh, G; Ellis, M; Lerer, B; Ashur-Fabian, O				Moskovich, Dotan; Finkelshtein, Yael; Alfandari, Adi; Rosemarin, Amit; Lifschytz, Tzuri; Weisz, Avivit; Mondal, Santanu; Ungati, Harinarayana; Katzav, Aviva; Kidron, Debora; Mugesh, Govindasamy; Ellis, Martin; Lerer, Bernard; Ashur-Fabian, Osnat			Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment	ONCOGENE			English	Article							IODOTHYRONINE DEIODINASE MIMICS; THYROID-HORMONE-RECEPTOR; TYPE-3 DEIODINASE; MEDICINAL CHEMISTRY; KINASE INHIBITOR; GENE-EXPRESSION; PROLIFERATION; TRANSCRIPTION; MAPK; DIFFERENTIATION	The enzyme iodothyronine deiodinase type 3 (DIO3) contributes to cancer proliferation by inactivating the tumor-suppressive actions of thyroid hormone (T3). We recently established DIO3 involvement in the progression of high-grade serous ovarian cancer (HGSOC). Here we provide a link between high DIO3 expression and lower survival in patients, similar to common disease markers such as Ki67, PAX8, CA-125, and CCNE1. These observations suggest that DIO3 is a logical target for inhibition. Using a DIO3 mimic, we developed original DIO3 inhibitors that contain a core of dibromomaleic anhydride (DBRMD) as scaffold. Two compounds, PBENZ-DBRMD and ITYR-DBRMD, demonstrated attenuated cell counts, induction in apoptosis, and a reduction in cell proliferation in DIO3-positive HGSOC cells (OVCAR3 and KURAMOCHI), but not in DIO3-negative normal ovary cells (CHOK1) and OVCAR3 depleted for DIO3 or its substrate, T3. Potent tumor inhibition with a high safety profile was further established in HGSOC xenograft model, with no effect in DIO3-depleted tumors. The antitumor effects are mediated by downregulation in an array of pro-cancerous proteins, the majority of which known to be repressed by T3. To conclude, using small molecules that specifically target the DIO3 enzyme we present a new treatment paradigm for ovarian cancer and potentially other DIO3-dependent malignancies.	[Moskovich, Dotan; Finkelshtein, Yael; Alfandari, Adi; Ellis, Martin; Ashur-Fabian, Osnat] Meir Med Ctr, Hematol Inst, Translat Oncol Lab, Kefar Sava, Israel; [Moskovich, Dotan; Finkelshtein, Yael; Alfandari, Adi; Ellis, Martin; Ashur-Fabian, Osnat] Meir Med Ctr, Blood Bank, Kefar Sava, Israel; [Moskovich, Dotan; Finkelshtein, Yael; Alfandari, Adi; Ashur-Fabian, Osnat] Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, Tel Aviv, Israel; [Lifschytz, Tzuri; Lerer, Bernard] Hadassah Hebrew Univ, Med Ctr, Biol Psychiat Lab, Jerusalem, Israel; [Weisz, Avivit; Katzav, Aviva; Kidron, Debora] Meir Med Ctr, Dept Pathol, Kefar Sava, Israel; [Mondal, Santanu; Ungati, Harinarayana; Mugesh, Govindasamy] Indian Inst Sci, Dept Inorgan & Phys Chem, Bangalore, Karnataka, India; [Ellis, Martin] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem; Hadassah University Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Indian Institute of Science (IISC) - Bangalore; Tel Aviv University; Sackler Faculty of Medicine	Ashur-Fabian, O (corresponding author), Meir Med Ctr, Hematol Inst, Translat Oncol Lab, Kefar Sava, Israel.; Ashur-Fabian, O (corresponding author), Meir Med Ctr, Blood Bank, Kefar Sava, Israel.; Ashur-Fabian, O (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, Tel Aviv, Israel.	osnataf@gmail.com	Mondal, Santanu/L-9157-2015	Mondal, Santanu/0000-0002-7399-8364	Israel Innovation Authority, Nofar Program for Applied Research in Academia, Ministry of Economics [59435]	Israel Innovation Authority, Nofar Program for Applied Research in Academia, Ministry of Economics	The work of DM was done in partial fulfillment of the requirements for a PhD degree from the Sackler Faculty of Medicine, Tel Aviv University, Israel. OA-F and BL received support from the Israel Innovation Authority, Nofar Program for Applied Research in Academia, Ministry of Economics (Project 59435).	Bargonetti J, 2019, J MOL CELL BIOL, V11, P605, DOI 10.1093/jmcb/mjz067; Catalano V, 2016, CANCER RES, V76, P1237, DOI 10.1158/0008-5472.CAN-15-1542; Cheng SY, 2010, ENDOCR REV, V31, P139, DOI 10.1210/er.2009-0007; Cohen K, 2011, MOL CANCER RES, V9, P1385, DOI 10.1158/1541-7786.MCR-11-0187; Cole AJ., 2016, SCI REP-UK, V6, P1, DOI [10.1038/s41598-016-0001-8, DOI 10.1038/S41598-016-0001-8]; Contreras-Jurado C, 2016, SCI REP-UK, V6, DOI 10.1038/srep30990; Dentice M, 2007, P NATL ACAD SCI USA, V104, P14466, DOI 10.1073/pnas.0706754104; Dentice M, 2013, EXPERT OPIN THER TAR, V17, P1369, DOI 10.1517/14728222.2013.833189; Dentice M, 2012, GASTROENTEROLOGY, V143, P1037, DOI 10.1053/j.gastro.2012.06.042; Dhillon S, 2021, DRUGS, V81, P283, DOI 10.1007/s40265-020-01464-z; Di Girolamo D, 2016, J CLIN INVEST, V126, P2308, DOI 10.1172/JCI84465; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Flores-Morales A, 2002, MOL ENDOCRINOL, V16, P1257, DOI 10.1210/me.16.6.1257; Gagne R, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-341; Garcia-Silva S, 2004, MOL CELL BIOL, V24, P7514, DOI 10.1128/MCB.24.17.7514-7523.2004; Ghannam-Shahbari D, 2018, ONCOGENE, V37, P2213, DOI 10.1038/s41388-017-0040-z; Goemann IM, 2018, ENDOCR-RELAT CANCER, V25, pR625, DOI 10.1530/ERC-18-0097; Goemann IM, 2017, ENDOCR-RELAT CANCER, V24, pR367, DOI 10.1530/ERC-17-0192; Gyorffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329; Hernandes MZ, 2010, CURR DRUG TARGETS, V11, P303, DOI 10.2174/138945010790711996; Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075; Lheureux S, 2019, LANCET, V393, P1240, DOI 10.1016/S0140-6736(18)32552-2; Luongo C, 2019, NAT REV ENDOCRINOL, V15, P479, DOI 10.1038/s41574-019-0218-2; Manna D, 2012, J AM CHEM SOC, V134, P4269, DOI 10.1021/ja210478k; Manna D, 2011, J AM CHEM SOC, V133, P9980, DOI 10.1021/ja201657s; Manna D, 2010, ANGEW CHEM INT EDIT, V49, P9246, DOI 10.1002/anie.201005235; Mondal S, 2016, ORG BIOMOL CHEM, V14, P9490, DOI 10.1039/c6ob01375a; Moskovich D, 2021, CANCER LETT, V501, P224, DOI 10.1016/j.canlet.2020.11.011; Nappi A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22137175; Nappi A, 2021, ENDOCRINOLOGY, V162, DOI 10.1210/endocr/bqab016; Perez-Juste G, 2000, J BIOL CHEM, V275, P1307, DOI 10.1074/jbc.275.2.1307; Perez-Juste G, 1999, J BIOL CHEM, V274, P5026, DOI 10.1074/jbc.274.8.5026; Porlan E, 2008, ONCOGENE, V27, P2795, DOI 10.1038/sj.onc.1210936; Punchihewa C, 2012, J BIOL CHEM, V287, P14289, DOI 10.1074/jbc.M112.353201; Raja K, 2015, ANGEW CHEM INT EDIT, V54, P7674, DOI 10.1002/anie.201502762; Renko K, 2015, THYROID, V25, P962, DOI 10.1089/thy.2015.0058; Romitti M, 2016, ENDOCR-RELAT CANCER, V23, P135, DOI 10.1530/ERC-15-0162; Schweizer U, 2014, P NATL ACAD SCI USA, V111, P10526, DOI 10.1073/pnas.1323873111; Shinderman-Maman E, 2016, ONCOGENE, V35, P1977, DOI 10.1038/onc.2015.262; SIEGEL R, 2021 CA CANC J CLIN, V71, P33; Simpkins F, 2018, CLIN CANCER RES, V24, P4874, DOI 10.1158/1078-0432.CCR-17-3697; Smith BD, 2019, CANCER CELL, V35, P738, DOI 10.1016/j.ccell.2019.04.006; Steegborn C, 2020, EXP CLIN ENDOCR DIAB, V128, P375, DOI 10.1055/a-1022-9916; SUAREZ J, 2010, AM J PHYSIOL-CELL PH, V299; Voth AR, 2007, CURR TOP MED CHEM, V7, P1336; Nguyen VHL, 2019, J OVARIAN RES, V12, DOI 10.1186/s13048-019-0596-z; Wasik R, 2010, J PHYS CHEM B, V114, P10601, DOI 10.1021/jp102848y; Wilcken R, 2013, J MED CHEM, V56, P1363, DOI 10.1021/jm3012068; YAGINUMA Y, 1992, CANCER RES, V52, P4196	49	3	3	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2021	40	44					6248	6257		10.1038/s41388-021-02020-z	http://dx.doi.org/10.1038/s41388-021-02020-z		SEP 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR3FG	34556811				2022-12-17	WOS:000698556400005
J	Heltemes-Harris, LM; Hubbard, GK; LaRue, RS; Munro, SA; Yang, RD; Henzler, CM; Starr, TK; Sarver, AL; Kornblau, SM; Farrar, MA				Heltemes-Harris, Lynn M.; Hubbard, Gregory K.; LaRue, Rebecca S.; Munro, Sarah A.; Yang, Rendong; Henzler, Christine M.; Starr, Timothy K.; Sarver, Aaron L.; Kornblau, Steven M.; Farrar, Michael A.			Identification of mutations that cooperate with defects in B cell transcription factors to initiate leukemia	ONCOGENE			English	Article							STAT5 ACTIVATION; LYMPHOBLASTIC-LEUKEMIA; KAPPA-B; CBL-B; DIFFERENTIATION; GENE; TRANSFORMATION; RESISTANCE; DELETION; FAILURE	The transcription factors PAX5, IKZF1, and EBF1 are frequently mutated in B cell acute lymphoblastic leukemia (B-ALL). We demonstrate that compound heterozygous loss of multiple genes critical for B and T cell development drives transformation, including Pax5(+/-)xEbf1(+/-), Pax5(+/-)xikzf1(+/-), and Ebf1(+/-)xlkzf1(+/-) mice for B-ALL, or Tcf7(+/-)xlkzf1(+/-) mice for T-ALL. To identify genetic defects that cooperate with Pax5 and Ebf1 compound heterozygosity to initiate leukemia, we performed a Sleeping Beauty (SB) transposon screen that identified cooperating partners including gain-of-function mutations in Stat5b (similar to 65%) and Jak7 (similar to 68%), or loss-of-function mutations in Cblb (61%) and Myb (32%). These findings underscore the role of JAK/STAT5B signaling in B cell transformation and demonstrate roles for loss-of-function mutations in Cblb and Myb in transformation. RNA-Seq studies demonstrated upregulation of a PDK1>SGK3>MYC pathway; treatment of Pax5(+/-)xEbf1(+/- )leukemia cells with PDK1 inhibitors blocked proliferation in vitro. In addition, we identified a conserved transcriptional gene signature between human and murine leukemias characterized by upregulation of myeloid genes, most notably involving the GM-CSF pathway, that resemble a B cell/myeloid mixed-lineage leukemia. Thus, our findings identify multiple mechanisms that cooperate with defects in B cell transcription factors to generate either progenitor B cell or mixed B/myeloid-like leukemias.	[Heltemes-Harris, Lynn M.; Hubbard, Gregory K.; Farrar, Michael A.] Univ Minnesota, Ctr Immunol, Minneapolis, MN 55455 USA; [Heltemes-Harris, Lynn M.; Hubbard, Gregory K.; Starr, Timothy K.; Sarver, Aaron L.; Farrar, Michael A.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA; [Heltemes-Harris, Lynn M.; Hubbard, Gregory K.; Farrar, Michael A.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; [LaRue, Rebecca S.; Munro, Sarah A.; Yang, Rendong; Henzler, Christine M.] Univ Minnesota, Minnesota Supercomp Inst, Minneapolis, MN 55455 USA; [Starr, Timothy K.] Univ Minnesota, Dept Obstet Gynecol & Womens Hlth, Minneapolis, MN 55455 USA; [Kornblau, Steven M.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Yang, Rendong] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Texas System; UTMD Anderson Cancer Center; University of Minnesota System	Farrar, MA (corresponding author), Univ Minnesota, Ctr Immunol, Minneapolis, MN 55455 USA.; Farrar, MA (corresponding author), Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA.; Farrar, MA (corresponding author), Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.	farra005@umn.edu	; yang, rendong/I-5552-2014	Starr, Timothy/0000-0002-6308-3451; yang, rendong/0000-0002-9512-2240; Heltemes Harris, Lynn/0000-0002-2668-8005; Kornblau, Steven/0000-0002-5990-9548; Farrar, Michael/0000-0002-5569-0366	Cancer Research Institute Investigator award; Leukemia and Lymphoma Society Scholar award; UMN Masonic Cancer center; NIH [RO1 CA232317]; Randy Shaver Cancer Research and Community Fund; Masonic Cancer Center; NCI [CA211249]; Masonic Cancer Center Support Grant [CA077598]; CPRIT MIRA RP [160693]; NIH/NCI [P50 CA100632-09]; NIH NCI [R21 CA216652]	Cancer Research Institute Investigator award; Leukemia and Lymphoma Society Scholar award(Leukemia and Lymphoma Society); UMN Masonic Cancer center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Randy Shaver Cancer Research and Community Fund; Masonic Cancer Center; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Masonic Cancer Center Support Grant; CPRIT MIRA RP; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank A. Rost, for technical assistance with mouse breeding; the University of Minnesota's Supercomputing Institute for providing computing and bioinformatic resources; Dr. Meinrad Busslinger (Pax5+/-), Dr. Rudolf Grosschedl (Ebf1-/-), Dr. Peter Johnson (Cebpa-/-), Dr. Andrew Wells (Ikzf1-/-) and Dr. David Largaespada (Rosa26LSLSB11T2/OncxRosa26LSL-SB11) for providing the indicated mouse strains. The results published here are in part based upon data generated by the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative, phs000218, managed by the NCI. This work was supported by a Cancer Research Institute Investigator award, a Leukemia and Lymphoma Society Scholar award, funding from the UMN Masonic Cancer center and grants from the NIH (RO1 CA232317) to MAF. TKS was supported by grants from the Randy Shaver Cancer Research and Community Fund, NIH NCI (R21 CA216652), and the Masonic Cancer Center. ALS was supported by NCI (CA211249) and Masonic Cancer Center Support Grant (CA077598). SMK was supported by CPRIT MIRA RP 160693 and NIH/NCI P50 CA100632-09.	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Badger-Brown KM, 2013, LEUKEMIA, V27, P1146, DOI 10.1038/leu.2012.331; Beckmann PJ, 2019, CANCER RES, V79, P905, DOI 10.1158/0008-5472.CAN-18-1261; Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Chen F, 2007, CANCER RES, V67, P11093, DOI 10.1158/0008-5472.CAN-07-1576; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; Churchman ML, 2018, CANCER CELL, V33, P937, DOI 10.1016/j.ccell.2018.03.021; Dupuy AJ, 2009, CANCER RES, V69, P8150, DOI 10.1158/0008-5472.CAN-09-1135; Fahl SP, 2009, J IMMUNOL, V183, P5582, DOI 10.4049/jimmunol.0901187; Goetz CA, 2004, J IMMUNOL, V172, P4770, DOI 10.4049/jimmunol.172.8.4770; Heath V, 2004, BLOOD, V104, P1639, DOI 10.1182/blood-2003-11-3963; Heltemes-Harris LM, 2016, ONCOGENE, V35, P3454, DOI 10.1038/onc.2015.405; Heltemes-Harris LM, 2011, J EXP MED, V208, P1135, DOI 10.1084/jem.20101947; Katerndahl CDS, 2017, NAT IMMUNOL, V18, P694, DOI 10.1038/ni.3716; Kollmann S, 2019, LEUKEMIA, V33, P1583, DOI 10.1038/s41375-018-0369-5; Kornblau SM, 2009, BLOOD, V113, P154, DOI 10.1182/blood-2007-10-119438; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; Mullighan CG, 2008, NATURE, V453, P110, DOI 10.1038/nature06866; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Mullighan CG, 2014, HEMATOL-AM SOC HEMAT, P174, DOI 10.1182/asheducation-2014.1.174; Mullighan CG, 2009, NEW ENGL J MED, V360, P470, DOI 10.1056/NEJMoa0808253; Najafov A, 2011, BIOCHEM J, V433, P357, DOI 10.1042/BJ20101732; Oliveros JC, 2007, VENNY INTERACTIVE TO; Papathanasiou P, 2003, IMMUNITY, V19, P131, DOI 10.1016/S1074-7613(03)00168-7; Prasad MAJ, 2015, BLOOD, V125, P4052, DOI 10.1182/blood-2014-12-617282; Roberts KG, 2014, NEW ENGL J MED, V371, P1005, DOI 10.1056/NEJMoa1403088; Sarver AL, 2021, LAB INVEST, V101, P701, DOI 10.1038/s41374-021-00573-x; Scott MC, 2018, CANCER RES, V78, P326, DOI 10.1158/0008-5472.CAN-17-0576; Shah S, 2013, NAT GENET, V45, P1226, DOI 10.1038/ng.2754; Tan J, 2013, CANCER DISCOV, V3, P1156, DOI 10.1158/2159-8290.CD-12-0595; Temiz NA, 2016, GENOME RES, V26, P119, DOI 10.1101/gr.188649.114; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; van der Weyden L, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1586-1; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; Wang JH, 1996, IMMUNITY, V5, P537, DOI 10.1016/S1074-7613(00)80269-1; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; Xia YF, 2014, CANCER IMMUNOL RES, V2, P823, DOI 10.1158/2326-6066.CIR-14-0112; Xiao X, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2617-2; Zhou JJ, 2021, NAT IMMUNOL, V22, P460, DOI 10.1038/s41590-021-00888-3	43	3	3	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2021	40	43					6166	6179		10.1038/s41388-021-02012-z	http://dx.doi.org/10.1038/s41388-021-02012-z		SEP 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WO5HW	34535769	Green Accepted, Green Submitted			2022-12-17	WOS:000696766300001
J	Feng, HR; Jin, ZJ; Liang, JY; Zhao, QW; Zhan, L; Yang, ZY; Yan, JQ; Kuang, J; Cheng, X; Qiu, WH				Feng, Haoran; Jin, Zhijian; Liang, Juyong; Zhao, Qiwu; Zhan, Ling; Yang, Zheyu; Yan, Jiqi; Kuang, Jie; Cheng, Xi; Qiu, Weihua			FOXK2 transcriptionally activating VEGFA induces apatinib resistance in anaplastic thyroid cancer through VEGFA/VEGFR1 pathway	ONCOGENE			English	Article							COLORECTAL-CANCER; HEPATOCELLULAR-CARCINOMA; TYROSINE KINASE; INHIBITOR; CELLS; SUPPRESSES; EXPRESSION; PROGNOSIS; GROWTH	Anaplastic thyroid carcinoma (ATC) is a rare and extremely aggressive type of thyroid cancer, and the potential mechanisms involved in ATC progression remains unclarified. In this study, we found that forkhead box K2 (FOXK2) was upregulated in ATC tissues, and the expression of FOXK2 was associated with tumor size. Evidenced by RNA-seq and Chromatin immunoprecipitation (ChIP)-seq assays, FOXK2 positively regulated VEGF and VEGFR signaling network, among which only VEGFA could be noticed in both RNA-seq and ChIP-seq results. ChIP, dual-luciferase reporter system and functional experiments further confirmed that FOXK2 promoted angiogenesis by inducing the transcription of VEGFA. On VEGFR2 blockage by specific targeting agent, such as Apatinib, FOXK2 could rapidly trigger therapeutic resistance. Mechanical analyses revealed that VEGFA transcriptionally induced by FOXK2 could bind to VEGFR1 as a compensation for VEGFR2 blockage, which promoted angiogenesis by activating ERK, PI3K/AKT and P38/MAPK signaling in human umbilical vein endothelial cells (HUVECs). Synergic effect on anti-angiogenesis could be observed when VEGFR1 suppressor AF321 was included in VEGFR2 inhibition system, which clarified the pivot role of FOXK2 in VEGFR2 targeting therapy resistance. More importantly, the binding of VEGFA to VEGFR1 could further promoter FOXK2-mediated VEGFA transcription, which consequently constituted a positive feedback loop. Therefore, the novel loop VEGFA/VEGFR1/FOXK2 functioned importantly in resistance to VEGFR2 targeting therapy in FOXK2(+) ATCs. Altogether, FOXK2 plays critical roles in ATC angiogenesis and VEGFR2 blockage resistance by inducing VEGFA transcription. FOXK2 represents a potentially new therapeutic strategy and biomarker for anti-angiogenic therapy against ATC.	[Feng, Haoran; Jin, Zhijian; Liang, Juyong; Zhao, Qiwu; Zhan, Ling; Yang, Zheyu; Yan, Jiqi; Kuang, Jie; Cheng, Xi; Qiu, Weihua] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Gen Surg, Shanghai, Peoples R China; [Feng, Haoran] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai Inst Digest Surg, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Kuang, J; Cheng, X; Qiu, WH (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Gen Surg, Shanghai, Peoples R China.	kuangjie823@msn.com; drchengxi@126.com; qwh11072@rjh.com.cn			National Natural Science Foundation of China [82072948, 82003169, 82002475]; Shanghai Sailing Program [20YF1427700]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Sailing Program	The study was supported by the National Natural Science Foundation of China, 82072948 (WQ); National Natural Science Foundation of China, 82003169 (HF); National Natural Science Foundation of China, 82002475 (XC) and Shanghai Sailing Program, 20YF1427700 (XC).	Abbey CA, 2014, MATRIX BIOL, V38, P36, DOI 10.1016/j.matbio.2014.06.006; Bayless KJ, 2009, NAT PROTOC, V4, P1888, DOI 10.1038/nprot.2009.221; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; de Moraes GN, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.26; de Moraes GN, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0038-6; de Moraes GN, 2019, CANCERS, V11, DOI 10.3390/cancers11030393; Du F, 2019, THERANOSTICS, V9, P3879, DOI 10.7150/thno.31716; El Atat O, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020171; Fang ZJ, 2018, CANCER LETT, V415, P58, DOI 10.1016/j.canlet.2017.11.040; Feng HR, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1054-3; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Guo Y, 2016, BIOTECHNOL LETT, V38, P893, DOI 10.1007/s10529-016-2046-y; Hu XC, 2014, INT J CANCER, V135, P1961, DOI 10.1002/ijc.28829; Jin ZJ, 2017, CELL PHYSIOL BIOCHEM, V44, P1471, DOI 10.1159/000485583; Kebebew E, 2005, CANCER-AM CANCER SOC, V103, P1330, DOI 10.1002/cncr.20936; Lin MF, 2017, INT J BIOCHEM CELL B, V88, P155, DOI 10.1016/j.biocel.2017.05.019; Liu MT, 2019, THORAC CANCER, V10, P1868, DOI 10.1111/1759-7714.13162; Liu Y, 2019, CANCER LETT, V458, P1, DOI 10.1016/j.canlet.2019.05.030; Mesange P, 2014, ONCOTARGET, V5, P4709, DOI 10.18632/oncotarget.1671; Molinaro E, 2017, NAT REV ENDOCRINOL, V13, P644, DOI 10.1038/nrendo.2017.76; Nowak-Sliwinska P, 2018, ANGIOGENESIS, V21, P425, DOI 10.1007/s10456-018-9613-x; Qian Y, 2017, BIOCHEM BIOPH RES CO, V483, P475, DOI 10.1016/j.bbrc.2016.12.119; Rajabi S, 2019, ENDOCR J, V66, P277, DOI 10.1507/endocrj.EJ18-0537; Ramos-Vara JA, 2005, VET PATHOL, V42, P405, DOI 10.1354/vp.42-4-405; Roviello G, 2016, CANCER LETT, V372, P187, DOI 10.1016/j.canlet.2016.01.014; Scott LJ, 2018, DRUGS, V78, P747, DOI 10.1007/s40265-018-0903-9; Shan L, 2016, CANCER CELL, V30, P708, DOI 10.1016/j.ccell.2016.09.010; Shi ZY, 2016, ANN SURG ONCOL, V23, P211, DOI 10.1245/s10434-015-4515-2; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Smallridge RC, 2010, CLIN ONCOL-UK, V22, P486, DOI 10.1016/j.clon.2010.03.013; Statistisches Bundesamt (Destatis), 2020, CA-CANCER J CLIN, DOI DOI 10.3322/CAAC.21660; Sun TT, 2016, JPN J CLIN ONCOL, V46, P209, DOI 10.1093/jjco/hyv185; Taylor SC, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/361590; Tian S, 2011, CANCER SCI, V102, P1374, DOI 10.1111/j.1349-7006.2011.01939.x; Wang DN, 2019, J DIABETES COMPLICAT, V33, P374, DOI 10.1016/j.jdiacomp.2019.02.001; Wang SY, 2018, CANCER LETT, V439, P78, DOI 10.1016/j.canlet.2018.09.026; Wu L, 2017, IRAN J BASIC MED SCI, V20, P990, DOI 10.22038/IJBMS.2017.9263; Xu ZQ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1010-2; Xue JM, 2018, ONCOTARGETS THER, V11, P6119, DOI 10.2147/OTT.S172717; Zadeh MAH, 2015, MOL ONCOL, V9, P167, DOI 10.1016/j.molonc.2014.07.017; Zhang F, 2018, INT J CANCER, V142, P2543, DOI 10.1002/ijc.31278; Zhang X, 2018, J CLIN ENDOCR METAB, V103, P3640, DOI 10.1210/jc.2018-00381	42	3	3	5	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2021	40	42					6115	6129		10.1038/s41388-021-01830-5	http://dx.doi.org/10.1038/s41388-021-01830-5		SEP 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK6OK	34489549				2022-12-17	WOS:000692963000002
J	Feng, Q; Li, S; Ma, HM; Yang, WT; Zheng, PS				Feng, Qian; Li, Shan; Ma, Hong-Mei; Yang, Wen-Ting; Zheng, Peng-Sheng			LGR6 activates the Wnt/beta-catenin signaling pathway and forms a beta-catenin/TCF7L2/LGR6 feedback loop in LGR6(high) cervical cancer stem cells	ONCOGENE			English	Article							COMPARATIVE MODELING ANALYSIS; 78 LOW-INCOME; TUMOR-FORMATION; PROLIFERATION; ELIMINATION; REGULATOR; GENERATE; IMPACT	The leucine-rich repeat-containing G-protein-coupled receptor 6 (LGR6) is considered to be a stem cell marker in many normal tissues and promotes tissue development, regeneration, and repair. LGR6 is also related to the initiation and progression of some malignant tumors. However, the role of LGR6 in cervical cancer has not been reported. Here, immunohistochemistry and western blotting showed that LGR6 was significantly upregulated in cervical cancer, compared with the normal cervix. By analyzing The Cancer Genome Atlas database, LGR6 was found to be correlated with a poor prognosis of cervical cancer. Then, a small population of LGR6(high) cells isolated by using the fluorescence-activated cell sorting exhibited enhanced properties of cancer stem cells including self-renewal, differentiation, and tumorigenicity. Moreover, RNA sequencing revealed that LGR6 was correlated with the Wnt signaling pathway and TOP/FOP, reverse transcription-PCR, and western blotting further proved that LGR6 could activate the Wnt/beta-catenin signaling pathway. Interestingly, LGR6 upregulated the expression of TCF7L2 by activating the Wnt/beta-catenin pathway. Then, TCF7L2 combining with beta-catenin in the nucleus enhanced LGR6 transcription by binding the promoter of LGR6, which further activated the Wnt signaling to form a positive feedback loop. Thus, our study demonstrated that LGR6 activated a novel beta-catenin/TCF7L2/LGR6-positive feedback loop in LGR6(high) cervical cancer stem cells (CSCs), which provided a new therapeutic strategy for targeting cervical CSCs to improve the prognosis of cervical cancer patients.	[Feng, Qian; Li, Shan; Ma, Hong-Mei; Yang, Wen-Ting; Zheng, Peng-Sheng] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Reprod Med, Xian 710061, Shaanxi, Peoples R China; [Zheng, Peng-Sheng] Minist Educ Peoples Republ China, Key Lab Environm & Genes Related Dis, Sect Canc Stem Cell Res, Xian 710061, Shaanxi, Peoples R China	Xi'an Jiaotong University; Ministry of Education, China	Zheng, PS (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Reprod Med, Xian 710061, Shaanxi, Peoples R China.; Zheng, PS (corresponding author), Minist Educ Peoples Republ China, Key Lab Environm & Genes Related Dis, Sect Canc Stem Cell Res, Xian 710061, Shaanxi, Peoples R China.	zpsheng@mail.xjtu.edu.cn			Fundamental Research Funds for the Central Universities [xzy012020064]; National Natural Science Foundation of China [81472728, 81672910]	Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by a grant Dr. Wen-Ting Yang from the Fundamental Research Funds for the Central Universities (xzy012020064) and Prof. Peng-Sheng Zheng from the National Natural Science Foundation of China (Nos. 81472728 and 81672910).	Blaas L, 2016, NAT CELL BIOL, V18, P1346, DOI 10.1038/ncb3434; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brisson M, 2020, LANCET, V395, P575, DOI 10.1016/S0140-6736(20)30068-4; Canfell K, 2020, LANCET, V395, P591, DOI 10.1016/S0140-6736(20)30157-4; Cao HZ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.393; Carmon KS, 2011, P NATL ACAD SCI USA, V108, P11452, DOI 10.1073/pnas.1106083108; Chen Q, 2014, ONCOTARGET, V5, P9092, DOI 10.18632/oncotarget.2377; Chiang N, 2019, J CLIN INVEST, V129, P5294, DOI 10.1172/JCI129448; Clara JA, 2020, NAT REV CLIN ONCOL, V17, P204, DOI 10.1038/s41571-019-0293-2; Cohen PA, 2019, LANCET, V393, P169, DOI 10.1016/S0140-6736(18)32470-X; Cui L, 2013, J CLIN INVEST, V123, P1647, DOI 10.1172/JCI65048; da Costa SCS, 2019, J CLIN ONCOL, V37, P3124, DOI 10.1200/JCO.19.00674; Day BW, 2019, ACTA NEUROPATHOL, V138, P1033, DOI 10.1007/s00401-019-02069-x; de Lau W, 2014, GENE DEV, V28, P305, DOI 10.1101/gad.235473.113; Di Stefano B, 2018, NAT METHODS, V15, P732, DOI 10.1038/s41592-018-0104-1; Farias LMB, 2004, CANCER RES, V64, P6996, DOI 10.1158/0008-5472.CAN-04-1204; Grove EA, 2011, GENE DEV, V25, P1759, DOI 10.1101/gad.17594311; Guinot A, 2016, CANCER RES, V76, P4012, DOI 10.1158/0008-5472.CAN-15-3302; Hockel M, 2019, LANCET ONCOL, V20, P1316, DOI 10.1016/S1470-2045(19)30389-4; Lee JH, 2017, CELL, V170, P1149, DOI 10.1016/j.cell.2017.07.028; Lehoczky JA, 2015, P NATL ACAD SCI USA, V112, P13249, DOI 10.1073/pnas.1518874112; Lewis A, 2014, CELL REP, V8, P983, DOI 10.1016/j.celrep.2014.07.020; Li L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0782-8; Liu D., 2020, STEM CELLS; Liu SY, 2013, ONCOTARGET, V4, P2462, DOI 10.18632/oncotarget.1578; Liu XF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087092; Lv YP, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-019-0179-2; Lytle NK, 2018, NAT REV CANCER, V18, P669, DOI 10.1038/s41568-018-0056-x; Mazzoni SM, 2014, CANCER LETT, V355, P1, DOI 10.1016/j.canlet.2014.09.018; Mir R, 2016, ONCOGENE, V35, P1679, DOI 10.1038/onc.2015.232; Nguyen LV, 2012, NAT REV CANCER, V12, P133, DOI 10.1038/nrc3184; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; Powell AE, 2012, CELL, V149, P146, DOI 10.1016/j.cell.2012.02.042; Ravindranath A, 2008, CURR MOL MED, V8, P38; Ren WW, 2014, P NATL ACAD SCI USA, V111, P16401, DOI 10.1073/pnas.1409064111; Rodin D, 2019, LANCET ONCOL, V20, P915, DOI 10.1016/S1470-2045(19)30308-0; Ruan XH, 2019, MOL THER-ONCOLYTICS, V14, P94, DOI 10.1016/j.omto.2019.04.002; Ruiz EJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4175; Snippert HJ, 2010, SCIENCE, V327, P1385, DOI 10.1126/science.1184733; Song KH, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2016.87; Su PH, 2019, CANCER LETT, V450, P53, DOI 10.1016/j.canlet.2019.01.033; Sun Q, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-021-01749-7; Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61; Tammela T, 2017, NATURE, V545, P355, DOI 10.1038/nature22334; Valkenburg Kenneth C, 2011, Cancers (Basel), V3, P2050, DOI 10.3390/cancers3022050; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Viny AD, 2019, CELL STEM CELL, V25, P682, DOI 10.1016/j.stem.2019.08.003; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Wang L, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1109-z; Wang YD, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.272; Yi F, 2011, NAT CELL BIOL, V13, P762, DOI 10.1038/ncb2283; Yong X, 2016, CANCER LETT, V374, P292, DOI 10.1016/j.canlet.2016.02.032	52	3	3	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2021	40	42					6103	6114		10.1038/s41388-021-02002-1	http://dx.doi.org/10.1038/s41388-021-02002-1		SEP 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK6OK	34489551	hybrid, Green Published			2022-12-17	WOS:000692963000003
J	Zhu, M; Peng, RQ; Liang, X; Lan, ZD; Tang, M; Hou, PP; Song, JH; Mak, CSL; Park, J; Zheng, SE; Huang, AL; Ma, XD; Chen, RD; Chang, Q; Logothetis, CJ; Jain, AK; Lin, SH; Katayama, H; Hanash, S; Wang, GC				Zhu, Ming; Peng, Ruiqing; Liang, Xin; Lan, Zhengdao; Tang, Ming; Hou, Pingping; Song, Jian H.; Mak, Celia Sze Ling; Park, Jiwon; Zheng, Shui-er; Huang, Ailing; Ma, Xingdi; Chen, Ruidong; Chang, Qing; Logothetis, Christopher J.; Jain, Abhinav K.; Lin, Sue-Hwa; Katayama, Hiroyuki; Hanash, Samir; Wang, Guocan			P4HA2-induced prolyl hydroxylation suppresses YAP1-mediated prostate cancer cell migration, invasion, and metastasis	ONCOGENE			English	Article							HIPPO PATHWAY; TUMOR-SUPPRESSOR; SWI/SNF COMPLEX; YAP; GROWTH; COLLAGEN; KRAS; TRANSCRIPTION; APOPTOSIS; P73	Yes-associated protein 1 (YAP1), a key player in the Hippo pathway, has been shown to play a critical role in tumor progression. However, the role of YAP1 in prostate cancer cell invasion, migration, and metastasis is not well defined. Through functional, transcriptomic, epigenomic, and proteomic analyses, we showed that prolyl hydroxylation of YAP1 plays a critical role in the suppression of cell migration, invasion, and metastasis in prostate cancer. Knockdown (KD) or knockout (KO) of YAP1 led to an increase in cell migration, invasion, and metastasis in prostate cancer cells. Microarray analysis showed that the EMT pathway was activated in Yap1-KD cells. ChIP-seq analysis showed that YAP1 target genes are enriched in pathways regulating cell migration. Mass spectrometry analysis identified P4H prolyl hydroxylase in the YAP1 complex and YAP1 was hydroxylated at multiple proline residues. Proline-to-alanine mutations of YAP1 isoform 3 identified proline 174 as a critical residue, and its hydroxylation suppressed cell migration, invasion, and metastasis. KO of P4ha2 led to an increase in cell migration and invasion, which was reversed upon Yap1 KD. Our study identified a novel regulatory mechanism of YAP1 by which P4HA2-dependent prolyl hydroxylation of YAP1 determines its transcriptional activities and its function in prostate cancer metastasis.	[Zhu, Ming; Peng, Ruiqing; Liang, Xin; Song, Jian H.; Mak, Celia Sze Ling; Park, Jiwon; Zheng, Shui-er; Huang, Ailing; Chen, Ruidong; Logothetis, Christopher J.; Lin, Sue-Hwa; Wang, Guocan] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Zhu, Ming; Peng, Ruiqing; Liang, Xin; Song, Jian H.; Mak, Celia Sze Ling; Park, Jiwon; Zheng, Shui-er; Huang, Ailing; Chen, Ruidong; Logothetis, Christopher J.; Lin, Sue-Hwa; Wang, Guocan] Univ Texas MD Anderson Canc Ctr, David H Koch Ctr Appl Res Genitourinary Canc, Houston, TX 77030 USA; [Peng, Ruiqing] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China; [Lan, Zhengdao; Hou, Pingping; Ma, Xingdi; Wang, Guocan] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Tang, Ming; Chang, Qing] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Jain, Abhinav K.] Univ Texas MD Anderson Canc Ctr, Dept Epigenet & Mol Carcinogenesis & Epigen Profi, Houston, TX 77030 USA; [Lin, Sue-Hwa] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Katayama, Hiroyuki; Hanash, Samir] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; State Key Lab Oncology South China; Sun Yat Sen University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Wang, GC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.; Wang, GC (corresponding author), Univ Texas MD Anderson Canc Ctr, David H Koch Ctr Appl Res Genitourinary Canc, Houston, TX 77030 USA.; Wang, GC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA.	gwang6@mdanderson.org		Liang, Xin/0000-0001-7915-8094	MDACC (Moon Shot, IRG); UT STARs Award; NIH [R00 CA194289, P50 CA140388, R01CA174798, 5P50CA140388, P30CA016672]; Cancer Prevention Research Institute of Texas [RP150179, RP190252]	MDACC (Moon Shot, IRG); UT STARs Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention Research Institute of Texas	We thank Ronald DePinho and Haoqiang Ying for helpful discussions, Sarah E. Townsend for editing, and Dr Timothy C. Thompson for providing RM-1 cells. GW is supported by the funding from MDACC (Moon Shot, IRG, and PCRP), UT STARs Award, NIH R00 CA194289, and P50 CA140388. SHL is supported by grants from the NIH R01CA174798 (S.-H. Lin, L.-y. Yu-Lee), NIH 5P50CA140388 (C. Logothetis, S.-H. Lin), and Cancer Prevention Research Institute of Texas grants RP150179 & RP190252 (S.-H. Lin and L.-Y. Yu-Lee). This study is supported by NIH P30CA016672 for the use of Research Animal Support Facility, Flow Cytometry and Cellular Imaging Core Facility, and Functional Genomics Core.	Aro E, 2015, J BIOL CHEM, V290, P16964, DOI 10.1074/jbc.M115.662635; Becker JS, 2016, TRENDS GENET, V32, P29, DOI 10.1016/j.tig.2015.11.001; Calses PC, 2019, TRENDS CANCER, V5, P297, DOI 10.1016/j.trecan.2019.04.001; Chakravarthi BVSK, 2014, ONCOTARGET, V5, P6654, DOI 10.18632/oncotarget.2208; Chen YA, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00060; Cheng SY, 2020, PROSTATE CANCER P D, V23, P661, DOI 10.1038/s41391-020-0229-z; Cheung P, 2020, CELL STEM CELL, V27, P590, DOI 10.1016/j.stem.2020.07.003; Cottini F, 2014, NAT MED, V20, P599, DOI 10.1038/nm.3562; Discher DE, 2017, ANNU REV BIOPHYS, V46, P295, DOI 10.1146/annurev-biophys-062215-011206; Ehsanian R, 2010, ONCOGENE, V29, P6160, DOI 10.1038/onc.2010.339; Gilkes DM, 2013, CANCER RES, V73, P3285, DOI 10.1158/0008-5472.CAN-12-3963; Gorres KL, 2010, CRIT REV BIOCHEM MOL, V45, P106, DOI 10.3109/10409231003627991; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hiemer SE, 2014, J BIOL CHEM, V289, P13461, DOI 10.1074/jbc.M113.529115; Holster T, 2007, J BIOL CHEM, V282, P2512, DOI 10.1074/jbc.M606608200; Hoxha S, 2020, CANCER RES, V80, P2512, DOI 10.1158/0008-5472.CAN-19-2415; Isfort I, 2019, CLIN CANCER RES, V25, P3718, DOI 10.1158/1078-0432.CCR-17-3553; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Kim M, 2015, CELL REP, V11, P270, DOI 10.1016/j.celrep.2015.03.015; Kim TW, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9769; Kuser-Abali G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9126; Levy D, 2007, CELL DEATH DIFFER, V14, P743, DOI 10.1038/sj.cdd.4402063; Li SJ, 2019, NUCLEIC ACIDS RES, V47, pW206, DOI 10.1093/nar/gkz332; Ma SH, 2019, ANNU REV BIOCHEM, V88, P577, DOI 10.1146/annurev-biochem-013118-111829; Matallanas D, 2007, MOL CELL, V27, P962, DOI 10.1016/j.molcel.2007.08.008; Nagl NG, 2007, EMBO J, V26, P752, DOI 10.1038/sj.emboj.7601541; Nguyen LT, 2015, CANCER CELL, V27, P797, DOI 10.1016/j.ccell.2015.05.005; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Ou CL, 2017, ONCOTARGET, V8, P75727, DOI 10.18632/oncotarget.20155; Pekowska A, 2011, EMBO J, V30, P4198, DOI 10.1038/emboj.2011.295; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; Su WJ, 2019, CANCER CELL, V36, P139, DOI 10.1016/j.ccell.2019.06.009; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; van Huizen NA, 2019, J PROTEOME RES, V18, P2045, DOI 10.1021/acs.jproteome.8b00930; Wang GC, 2016, CANCER DISCOV, V6, P80, DOI 10.1158/2159-8290.CD-15-0224; Xiong GF, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-1; Yan FJ, 2020, BBA-GEN SUBJECTS, V1864, DOI 10.1016/j.bbagen.2019.07.006; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; Yu SJ, 2013, CLIN CANCER RES, V19, P1389, DOI 10.1158/1078-0432.CCR-12-1959; Yuan M, 2008, CELL DEATH DIFFER, V15, P1752, DOI 10.1038/cdd.2008.108; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhang B, 2007, ONCOGENE, V26, P7153, DOI 10.1038/sj.onc.1210509; Zhang L, 2015, MOL CELL BIOL, V35, P1350, DOI 10.1128/MCB.00102-15; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2009, CANCER RES, V69, P1089, DOI 10.1158/0008-5472.CAN-08-2997; Zurlo G, 2016, BBA-REV CANCER, V1866, P208, DOI 10.1016/j.bbcan.2016.09.004	47	3	5	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2021	40	41					6049	6056		10.1038/s41388-021-02000-3	http://dx.doi.org/10.1038/s41388-021-02000-3		SEP 2021	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WH0WV	34471235	Green Submitted, Green Accepted			2022-12-17	WOS:000691942100001
J	Lu, LQ; Zhang, J; Fan, W; Li, Y; Wang, JH; Li, TWH; Torres, LB; Mato, JM; Liu, T; Seki, E; Matsuda, M; Tomasi, ML; Bhowmick, NA; Yang, HP; Lu, SC				Lu, Liqing; Zhang, Jing; Fan, Wei; Li, Yuan; Wang, Jiaohong; Li, Tony W. H.; Torres, Lucia Barbier; Mato, Jose M.; Liu, Ting; Seki, Ekihiro; Matsuda, Michitaka; Tomasi, Maria Lauda; Bhowmick, Neil A.; Yang, Heping; Lu, Shelly C.			Deregulated 14-3-3 zeta and methionine adenosyltransferase alpha 1 interplay promotes liver cancer tumorigenesis in mice and humans	ONCOGENE			English	Article							EXPRESSION; CHOLANGIOCARCINOMA; TRANSCRIPTION; METHYLATION; PROTEINS; BINDING; GROWTH	Methionine adenosyltransferase 1A (MAT1A) is a tumor suppressor downregulated in hepatocellular carcinoma and cholangiocarcinoma, two of the fastest rising cancers worldwide. We compared MAT alpha 1 (protein encoded by MAT1A) interactome in normal versus cancerous livers by mass spectrometry to reveal interactions with 14-3-3 zeta. The MAT alpha 1/14-3-3 zeta complex was critical for the expression of 14-3-3 zeta. Similarly, the knockdown and small molecule inhibitor for 14-3-3 zeta (BV02), and ChIP analysis demonstrated the role of 14-3-3 zeta in suppressing MAT1A expression. Interaction between MAT alpha 1 and 14-3-3 zeta occurs directly and is enhanced by AKT2 phosphorylation of MAT alpha 1. Blocking their interaction enabled nuclear MAT alpha 1 translocation and inhibited tumorigenesis. In contrast, overexpressing 14-3-3 zeta lowered nuclear MAT alpha 1 levels and promoted tumor progression. However, tumor-promoting effects of 14-3-3 zeta were eliminated when liver cancer cells expressed mutant MAT alpha 1 unable to interact with 14-3-3 zeta. Taken together, the reciprocal negative regulation that MAT alpha 1 and 14-3-3 zeta exert is a key mechanism in liver tumorigenesis.	[Lu, Liqing; Zhang, Jing; Fan, Wei; Li, Yuan; Wang, Jiaohong; Li, Tony W. H.; Torres, Lucia Barbier; Seki, Ekihiro; Matsuda, Michitaka; Tomasi, Maria Lauda; Yang, Heping; Lu, Shelly C.] Cedars Sinai Med Ctr, Karsh Div Gastroenterol & Hepatol, Los Angeles, CA 90048 USA; [Lu, Liqing; Liu, Ting] Cent South Univ, Xiangya Hosp, Key Lab Canc Prote, Chinese Minist Hlth, Changsha, Hunan, Peoples R China; [Zhang, Jing] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Oncol, Wuhan, Peoples R China; [Li, Yuan; Liu, Ting] Cent South Univ, Xiangya Hosp, Dept Gastroenterol, Changsha, Hunan, Peoples R China; [Mato, Jose M.] Ctr Invest Biomed Red Enfermedades Hepat & Digest, CIC BioGUNE, Technol, Pk Bizkaia, Derio, Bizkaia, Spain; [Bhowmick, Neil A.] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA 90048 USA; [Bhowmick, Neil A.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Canc Biol Program, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; Central South University; Huazhong University of Science & Technology; Central South University; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; CIC bioGUNE; Cedars Sinai Medical Center; Cedars Sinai Medical Center	Yang, HP; Lu, SC (corresponding author), Cedars Sinai Med Ctr, Karsh Div Gastroenterol & Hepatol, Los Angeles, CA 90048 USA.	Heping.yang@cshs.org; shelly.lu@cshs.org	Torres, Lucia/GZM-2707-2022; Seki, Ekihiro/K-2481-2016; Mato, Jose/A-5187-2011	Seki, Ekihiro/0000-0002-9472-6085; Mato, Jose/0000-0003-1264-3153	NIH [DK123763, P01CA233452]; Natural Science Foundation General Program of Hunan Province [2018JJ2664]; Plan Nacional of I+D [SAF2017-88041-R]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Natural Science Foundation General Program of Hunan Province; Plan Nacional of I+D	This work was supported by NIH grants DK123763 (HP Yang, JM Mato and SC Lu), P01CA233452 (HP Yang, E Seki, ML Tomasi, N Bhowmick, and SC Lu), Natural Science Foundation General Program of Hunan Province NO.2018JJ2664 (T Liu), and Plan Nacional of I+D SAF2017-88041-R (JM Mato). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bergamaschi A, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2913; Ewald F, 2013, INT J CANCER, V133, P2065, DOI 10.1002/ijc.28214; Fan W, 2017, HEPATOLOGY, V65, P1249, DOI 10.1002/hep.28964; Frau M, 2013, J HEPATOL, V59, P830, DOI 10.1016/j.jhep.2013.04.031; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; Johnson C, 2010, BIOCHEM J, V427, P69, DOI 10.1042/BJ20091834; Li Y, 2020, HEPATOLOGY, V72, P1682, DOI 10.1002/hep.31196; Liu HY, 2011, AM J PATHOL, V178, P652, DOI 10.1016/j.ajpath.2010.10.023; Liu T, 2018, GASTROENTEROLOGY, V155, P557, DOI 10.1053/j.gastro.2018.04.032; Lu SC, 2012, PHYSIOL REV, V92, P1515, DOI 10.1152/physrev.00047.2011; Mroweh M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041794; Murray B, 2019, WORLD J GASTROENTERO, V25, P4300, DOI 10.3748/wjg.v25.i31.4300; Murray B, 2019, HEPATOLOGY, V70, P2018, DOI 10.1002/hep.30762; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Peng H, 2013, HEPATOLOGY, V57, P2299, DOI 10.1002/hep.26258; Perez C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161672; Reytor E, 2009, FASEB J, V23, P3347, DOI 10.1096/fj.09-130187; Ridder DA, 2021, CANCERS, V13, DOI 10.3390/cancers13040744; Root A, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0905-y; Su R, 2016, ONCOTARGET, V7, P77430, DOI 10.18632/oncotarget.12679; Tang YF, 2015, INT J CLIN EXP PATHO, V8, P15845; Tomasi ML, 2012, J CELL PHYSIOL, V227, P1583, DOI 10.1002/jcp.22875; Torres L, 2000, FASEB J, V14, P95, DOI 10.1096/fasebj.14.1.95; Vazquez-Chantada M, 2010, GASTROENTEROLOGY, V138, P1943, DOI 10.1053/j.gastro.2010.01.032; Wang C, 2016, LIVER INT, V36, P1176, DOI 10.1111/liv.13055; Xia QL, 2019, J CELL PHYSIOL, V234, P4851, DOI 10.1002/jcp.27283; Xu XD, 2004, ONCOL REP, V11, P25; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang HP, 2016, HEPATOLOGY, V64, P439, DOI 10.1002/hep.28541; Yang HP, 2013, J CLIN INVEST, V123, P285, DOI 10.1172/JCI63861; Yang HP, 2011, GASTROENTEROLOGY, V141, P378, DOI 10.1053/j.gastro.2011.03.044; Yu M, 2013, BBA-GENE REGUL MECH, V1829, P970, DOI 10.1016/j.bbagrm.2013.04.004	32	3	4	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2021	40	39					5866	5879		10.1038/s41388-021-01980-6	http://dx.doi.org/10.1038/s41388-021-01980-6		AUG 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UZ8WB	34349244	Green Accepted, Green Published			2022-12-17	WOS:000681143600001
J	Zhang, JN; Jiang, XY; Yin, J; Dou, SY; Xie, XL; Liu, T; Wang, YJ; Wang, SL; Zhou, X; Zhang, DX; Jiang, HQ				Zhang, Jiuna; Jiang, Xiaoyu; Yin, Jie; Dou, Shiying; Xie, Xiaoli; Liu, Ting; Wang, Yijun; Wang, Shuling; Zhou, Xue; Zhang, Dongxuan; Jiang, Huiqing			RNF141 interacts with KRAS to promote colorectal cancer progression	ONCOGENE			English	Article							K-RAS; HUMAN COLON; PROTEINS; MUTATIONS; GENE; LOCALIZATION; ASSOCIATION; EXPRESSION; LIGASES; GROWTH	RING finger proteins (RNFs) play a critical role in cancer initiation and progression. RNF141 is a member of RNFs family; however, its clinical significance, roles, and mechanism in colorectal cancer (CRC) remain poorly understood. Here, we examined the expression of RNF141 in 64 pairs of CRC and adjacent normal tissues by real-time PCR, Western blot, and immunohistochemical analysis. We found that there was more expression of RNF141 in CRC tissue compared with its adjacent normal tissue and high RNF141 expression associated with T stage. In vivo and in vitro functional experiments were conducted and revealed the oncogenic role of RNF141 in CRC. RNF141 knockdown suppressed proliferation, arrested the cell cycle in the G1 phase, inhibited migration, invasion and HUVEC tube formation but promoted apoptosis, whereas RNF141 overexpression exerted the opposite effects in CRC cells. The subcutaneous xenograft models showed that RNF141 knockdown reduced tumor growth, but its overexpression promoted tumor growth. Mechanistically, liquid chromatography-tandem mass spectrometry indicated RNF141 interacted with KRAS, which was confirmed by Co-immunoprecipitation, Immunofluorescence assay. Further analysis with bimolecular fluorescence complementation (BiFC) and Glutathione-S-transferase (GST) pull-down assays showed that RNF141 could directly bind to KRAS. Importantly, the upregulation of RNF141 increased GTP-bound KRAS, but its knockdown resulted in a reduction accordingly. Next, we demonstrated that RNF141 induced KRAS activation via increasing its enrichment on the plasma membrane not altering total KRAS expression, which was facilitated by the interaction with LYPLA1. Moreover, KRAS silencing partially abolished the effect of RNF141 on cell proliferation and apoptosis. In addition, our findings presented that RNF141 functioned as an oncogene by upregulating KRAS activity in a manner of promoting KRAS enrichment on the plasma membrane in CRC.	[Zhang, Jiuna; Jiang, Xiaoyu; Yin, Jie; Dou, Shiying; Xie, Xiaoli; Liu, Ting; Wang, Yijun; Wang, Shuling; Zhou, Xue; Zhang, Dongxuan; Jiang, Huiqing] Hebei Med Univ, Hosp 2, Hebei Inst Gastroenterol, Dept Gastroenterol,Hebei Key Lab Gastroenterol, Shijiazhuang, Hebei, Peoples R China; [Zhang, Jiuna] Hebei Engn Univ, Affiliated Hosp, Dept Gastroenterol, Handan, Peoples R China	Hebei Medical University	Jiang, HQ (corresponding author), Hebei Med Univ, Hosp 2, Hebei Inst Gastroenterol, Dept Gastroenterol,Hebei Key Lab Gastroenterol, Shijiazhuang, Hebei, Peoples R China.	jianghuiqing1959@sina.com	Wang, Yu/GZL-9655-2022; wang, yixuan/GXW-2866-2022; Wang, Yijun/GXW-1763-2022; Wang, Yixuan/GZK-6559-2022; Wang, Yin/HCI-9352-2022; wang, yi/GVT-8516-2022		National Natural Science Foundation of China [81702324, 81770601, 81602529]; Natural Science Foundation of Hebei Province, China [H2018206176, H2017206141]; Medical Science Research Project of Hebei Province, China [20190510]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hebei Province, China(Natural Science Foundation of Hebei Province); Medical Science Research Project of Hebei Province, China	This work was supported by the National Natural Science Foundation of China (81702324, 81770601, and 81602529), Natural Science Foundation of Hebei Province, China (H2018206176 and H2017206141); Medical Science Research Project of Hebei Province, China (20190510).	Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Baietti MF, 2016, EMBO MOL MED, V8, P288, DOI 10.15252/emmm.201505972; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Castagnola P, 2005, BBA-REV CANCER, V1756, P115, DOI 10.1016/j.bbcan.2005.06.003; Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0; Dekker FJ, 2010, NAT CHEM BIOL, V6, P449, DOI 10.1038/nchembio.362; Deng WQ, 2009, GENET MOL BIOL, V32, P594, DOI 10.1590/S1415-47572009005000062; Dohlman HG, 2019, J BIOL CHEM, V294, P18613, DOI 10.1074/jbc.REV119.011068; Donovan S, 2002, BBA-REV CANCER, V1602, P23, DOI 10.1016/S0304-419X(01)00041-5; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Friday BB, 2005, BBA-REV CANCER, V1756, P127, DOI 10.1016/j.bbcan.2005.08.001; Geng R, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.400; Geyer M, 1997, CURR OPIN STRUC BIOL, V7, P786, DOI 10.1016/S0959-440X(97)80147-9; Haigis KM, 2008, NAT GENET, V40, P600, DOI 10.1038/ng.115; Hobbs GA, 2016, J CELL SCI, V129, P1287, DOI 10.1242/jcs.182873; Hoeller D, 2009, NATURE, V458, P438, DOI 10.1038/nature07960; Inamura K, 2018, CANCERS, V10, DOI 10.3390/cancers10010026; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P12730, DOI 10.1073/pnas.91.26.12730; Jaworska AM, 2020, STEM CELLS, V38, P165, DOI 10.1002/stem.3109; Jiang XM, 2015, MOL CELL, V58, P522, DOI 10.1016/j.molcel.2015.03.015; Jura N, 2006, MOL CELL, V21, P679, DOI 10.1016/j.molcel.2006.02.011; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308; Koveitypour Z, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-019-0361-4; Lee DW, 2017, CANCER-AM CANCER SOC, V123, P3513, DOI 10.1002/cncr.30760; Levinson AM, 2017, J AM CHEM SOC, V139, P7632, DOI 10.1021/jacs.7b02988; Lieu CH, 2019, CLIN CANCER RES, V25, P5852, DOI 10.1158/1078-0432.CCR-19-0899; Liu L, 2018, ONCOGENE, V37, P148, DOI 10.1038/onc.2017.313; Martinelli E, 2020, ANN ONCOL, V31, P30, DOI 10.1016/j.annonc.2019.10.007; McCormick F, 2015, CLIN CANCER RES, V21, P1797, DOI 10.1158/1078-0432.CCR-14-2662; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Normanno N, 2009, NAT REV CLIN ONCOL, V6, P519, DOI 10.1038/nrclinonc.2009.111; Papke B, 2017, SCIENCE, V355, P1158, DOI 10.1126/science.aam7622; Prior IA, 2001, J CELL SCI, V114, P1603; Sasaki AT, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001518; Schmick M, 2015, TRENDS CELL BIOL, V25, P190, DOI 10.1016/j.tcb.2015.02.004; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Senft D, 2018, NAT REV CANCER, V18, P69, DOI 10.1038/nrc.2017.105; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Smakman N, 2005, BBA-REV CANCER, V1756, P103, DOI 10.1016/j.bbcan.2005.07.001; Song HX, 2008, BMB REP, V41, P664, DOI 10.5483/BMBRep.2008.41.9.664; Tan ZL, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax5576; Tsai FD, 2015, P NATL ACAD SCI USA, V112, P779, DOI 10.1073/pnas.1412811112; Veggiani G, 2019, PHARMACOL THERAPEUT, V199, P139, DOI 10.1016/j.pharmthera.2019.03.003; Venuto S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050510; Wang XW, 2014, GUT LIVER, V8, P487, DOI 10.5009/gnl13133; Wang YX, 2013, J MED CHEM, V56, P5219, DOI 10.1021/jm3017706; Zhu J, 2016, ONCOGENE, V35, P1955, DOI 10.1038/onc.2015.260	51	3	3	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2021	40	39					5829	5842		10.1038/s41388-021-01877-4	http://dx.doi.org/10.1038/s41388-021-01877-4		AUG 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UZ8WB	34345014	hybrid, Green Published			2022-12-17	WOS:000681523500006
J	Mecozzi, N; Vera, O; Karreth, FA				Mecozzi, Nicol; Vera, Olga; Karreth, Florian A.			Squaring the circle: circRNAs in melanoma	ONCOGENE			English	Review							CIRCULAR RNAS; CELL-PROLIFERATION; MALIGNANT-MELANOMA; CANCER; PROGRESSION; TRANSLATION; BIOGENESIS; REVEALS; MIR-135B-5P; EXPRESSION	Non-coding RNAs are emerging as critical molecules in the genesis, progression, and therapy resistance of cutaneous melanoma. This includes circular RNAs (circRNAs), a class of non-coding RNAs with distinct characteristics that forms through non-canonical back-splicing. In this review, we summarize the features and functions of circRNAs and introduce the current knowledge of the roles of circRNAs in melanoma. We also highlight the various mechanisms of action of the well-studied circRNA CDR1as and describe how it acts as a melanoma tumor suppressor. We further discuss the utility of circRNAs as biomarkers, therapeutic targets, and therapeutic agents in melanoma and outline challenges that must be overcome to comprehensively characterize circRNA functions.	[Mecozzi, Nicol; Vera, Olga; Karreth, Florian A.] H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute	Karreth, FA (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA.	florian.karreth@moffitt.org			NCI/NIH [R01 CA259046]; Harry J. Lloyd Charitable Foundation	NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Harry J. Lloyd Charitable Foundation	This work was supported by grants from the NCI/NIH (R01 CA259046) and the Harry J. Lloyd Charitable Foundation to FAK.	Abdelmohsen K, 2017, RNA BIOL, V14, P361, DOI 10.1080/15476286.2017.1279788; Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Ashwal-Fluss R, 2014, MOL CELL, V56, P55, DOI 10.1016/j.molcel.2014.08.019; Barrett SP, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007114; Begum S, 2018, ONCOGENE, V37, P4055, DOI 10.1038/s41388-018-0230-3; Bian DH, 2018, BIOMED PHARMACOTHER, V108, P165, DOI 10.1016/j.biopha.2018.08.152; CAPEL B, 1993, CELL, V73, P1019, DOI 10.1016/0092-8674(93)90279-Y; Chen H, 2019, ONCOTARGETS THER, V12, P3869, DOI 10.2147/OTT.S207938; Chen J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02799-x; Chen LL, 2020, NAT REV MOL CELL BIO, V21, P475, DOI 10.1038/s41580-020-0243-y; Chen LL, 2015, RNA BIOL, V12, P381, DOI 10.1080/15476286.2015.1020271; Chen YC, 2010, J INVEST DERMATOL, V130, P2790, DOI 10.1038/jid.2010.222; Chen ZB, 2020, LIFE SCI, V243, DOI 10.1016/j.lfs.2020.117323; Conn SJ, 2015, CELL, V160, P1125, DOI 10.1016/j.cell.2015.02.014; Conn VM, 2017, NAT PLANTS, V3, DOI 10.1038/nplants.2017.53; Du WW, 2017, CELL DEATH DIFFER, V24, P357, DOI 10.1038/cdd.2016.133; Du WW, 2016, NUCLEIC ACIDS RES, V44, P2846, DOI 10.1093/nar/gkw027; Errichelli L, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14741; Fang L, 2019, CANCER LETT, V459, P216, DOI 10.1016/j.canlet.2019.05.036; Fattore L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21061930; Giles KM, 2016, ONCOTARGET, V7, P31663, DOI 10.18632/oncotarget.9421; Giles KM, 2013, BIOCHEM BIOPH RES CO, V430, P706, DOI 10.1016/j.bbrc.2012.11.086; Guo JU, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0409-z; Hanniford D, 2020, CANCER CELL, V37, P55, DOI 10.1016/j.ccell.2019.12.007; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Hansen TB, 2011, EMBO J, V30, P4414, DOI 10.1038/emboj.2011.359; Hayward NK, 2017, NATURE, V545, P175, DOI 10.1038/nature22071; Holdt LM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12429; Horsham JL, 2015, J CLIN MED, V4, P1668, DOI 10.3390/jcm4091668; Hu Y, 2019, MELANOMA RES, V29, P119, DOI 10.1097/CMR.0000000000000524; Hung HX, 2020, NUCLEIC ACIDS RES, V48, P10368, DOI 10.1093/nar/gkaa704; Ivanov A, 2015, CELL REP, V10, P170, DOI 10.1016/j.celrep.2014.12.019; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Jin C, 2020, CELL BIOCHEM BIOPHYS, V78, P77, DOI 10.1007/s12013-019-00895-0; Karreth FA, 2020, P SINGAP NATL ACAD S, V14, P145, DOI [10.1142/S2591722620400104, DOI 10.1142/S2591722620400104]; Karreth FA, 2021, GENETIC TOOLS STABLE, DOI [10.1101/2021.05.27.446018, DOI 10.1101/2021.05.27.446018]; Karreth FA, 2013, CANCER DISCOV, V3, P1113, DOI 10.1158/2159-8290.CD-13-0202; Kleaveland B, 2018, CELL, V174, P350, DOI 10.1016/j.cell.2018.05.022; Kramer MC, 2015, GENE DEV, V29, P2168, DOI 10.1101/gad.270421.115; Kristensen LS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18355-2; Lasda E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148407; Legnini I, 2017, MOL CELL, V66, P22, DOI 10.1016/j.molcel.2017.02.017; Leucci E, 2016, NATURE, V531, P518, DOI 10.1038/nature17161; Li P, 2018, CELL PHYSIOL BIOCHEM, V46, P1606, DOI 10.1159/000489208; Li Y, 2015, CELL RES, V25, P981, DOI 10.1038/cr.2015.82; Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959; Liang DM, 2017, MOL CELL, V68, P940, DOI 10.1016/j.molcel.2017.10.034; Liang WC, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1685-4; Lou JC, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01253-y; Lu JJ, 2020, MOL CELL BIOCHEM, V475, P227, DOI 10.1007/s11010-020-03875-8; Lu RJ, 2020, INT J CLIN EXP PATHO, V13, P1791; Luan WK, 2018, BIOCHEM BIOPH RES CO, V502, P22, DOI 10.1016/j.bbrc.2018.05.114; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Nemlich Y, 2013, J CLIN INVEST, V123, P2703, DOI 10.1172/JCI62980; Pamudurti NR, 2017, MOL CELL, V66, P9, DOI 10.1016/j.molcel.2017.02.021; Piwecka M, 2017, SCIENCE, V357, DOI 10.1126/science.aam8526; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Qian P, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2444-x; Rambow F, 2019, GENE DEV, V33, P1295, DOI 10.1101/gad.329771.119; Ren JW, 2015, INT J CLIN EXP PATHO, V8, P6356; Rybak-Wolf A, 2015, MOL CELL, V58, P870, DOI 10.1016/j.molcel.2015.03.027; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Salzman J, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003777; Salzman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030733; Sarkar D, 2015, EPIGENETICS-US, V10, P103, DOI 10.1080/15592294.2014.1003746; Shain AH, 2018, CANCER CELL, V34, P45, DOI 10.1016/j.ccell.2018.06.005; Shain AH, 2015, NEW ENGL J MED, V373, P1926, DOI 10.1056/NEJMoa1502583; Szabo L, 2016, GENOME BIOL, V17, DOI [10.1186/s13059-016-1123-9, 10.1186/s13059-015-0690-5]; Tang WT, 2017, ONCOTARGETS THER, V10, P2045, DOI 10.2147/OTT.S131597; Tian S, 2020, WORLD J SURG ONCOL, V18, DOI 10.1186/s12957-020-01832-9; Turner N, 2018, CLIN EXP METASTAS, V35, P379, DOI 10.1007/s10585-018-9893-y; Ulitsky I, 2012, CELL, V151, P684, DOI 10.1016/j.cell.2012.10.002; Vendramin R, 2018, NAT STRUCT MOL BIOL, V25, P1035, DOI 10.1038/s41594-018-0143-4; Veno MT, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0801-3; Vera O, 2021, CANCERS, V13, DOI 10.3390/cancers13061408; Vergara IA, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21576-8; Wang Q, 2018, ONCOL REP, V39, P1813, DOI 10.3892/or.2018.6263; Wang Y, 2015, RNA, V21, P172, DOI 10.1261/rna.048272.114; Wei CY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01191-9; Westholm JO, 2014, CELL REP, V9, P1966, DOI 10.1016/j.celrep.2014.10.062; Xiao MS, 2020, TRENDS CELL BIOL, V30, P226, DOI 10.1016/j.tcb.2019.12.004; Xu LL, 2017, J CANCER RES CLIN, V143, P17, DOI 10.1007/s00432-016-2256-7; Yang Q, 2017, CELL DEATH DIFFER, V24, P1609, DOI 10.1038/cdd.2017.86; Yang Yibing, 2018, J Natl Cancer Inst, V110, DOI 10.1093/jnci/djx166; Yang Y, 2017, CELL RES, V27, P626, DOI 10.1038/cr.2017.31; Yang ZG, 2017, MOL THER, V25, P2062, DOI 10.1016/j.ymthe.2017.05.022; Yin D, 2021, HUM EXP TOXICOL, V40, P310, DOI 10.1177/0960327120950014; Yoshimoto R, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101345; You XT, 2015, NAT NEUROSCI, V18, P603, DOI 10.1038/nn.3975; Zhang ML, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06862-2; Zhang ML, 2018, ONCOGENE, V37, P1805, DOI 10.1038/s41388-017-0019-9; Zhang XH, 2020, EUR REV MED PHARMACO, V24, P1309, DOI 10.26355/eurrev_202002_20188; Zhang Y, 2021, GENOME BIOL, V22, DOI 10.1186/s13059-021-02263-9; Zhang Y, 2013, MOL CELL, V51, P792, DOI 10.1016/j.molcel.2013.08.017; Zheng X, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1010-6; Zhong Q, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0959-y; Zou Y, 2019, EUR REV MED PHARMACO, V23, P10918, DOI 10.26355/eurrev_201912_19795	99	3	3	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2021	40	37					5559	5566		10.1038/s41388-021-01977-1	http://dx.doi.org/10.1038/s41388-021-01977-1		JUL 2021	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UR2PS	34331015	Green Accepted			2022-12-17	WOS:000679620500006
J	Cheng, R; Xiao, LX; Zhou, WY; Jin, XY; Xu, ZC; Xu, C; Wang, PP; Luo, M; Wang, MY; Ma, KX; Cao, HM; Huang, Y; Lin, XY; Pang, FL; Li, YQ; Jiang, QH				Cheng, Rui; Xiao, Lixing; Zhou, Wenyang; Jin, Xiyun; Xu, Zhaochun; Xu, Chang; Wang, Pingping; Luo, Meng; Wang, Mengyun; Ma, Kexin; Cao, Huimin; Huang, Yan; Lin, Xiaoyu; Pang, Fenglan; Li, Yiqun; Jiang, Qinghua			A pan-cancer analysis of alternative splicing of splicing factors in 6904 patients	ONCOGENE			English	Article							PYRUVATE-KINASE; MUTATIONS; GENOME; TRANSCRIPTOME; APOPTOSIS; FAMILIES; M2	Great progress has been made in the investigation on mutation and expression of splicing factor. However, little is known on the role of alternative splicing of splicing factors across cancers. Here, we reported a pan-cancer analysis of alternative splicing of splicing factors spanning 6904 patients across 16 cancer types, and identified 167 splicing factors with implications regulating cancer-specific splicing patterns through alternative splicing. Furthermore, we found that abnormal splicing events of splicing factors could serve as potential common regulators for alternative splicing in different cancers. In addition, we developed a splicing-derived neoepitopes database (ASPNs), which provided the corresponding putative alternative splicing-derived neoepitopes of 16 cancer types. Our results suggested that alternative splicing of splicing factors involved in the pre-RNA splicing process was common across cancer types and may represent an underestimated hallmark of tumorigenesis.	[Cheng, Rui; Xiao, Lixing; Zhou, Wenyang; Jin, Xiyun; Xu, Zhaochun; Xu, Chang; Wang, Pingping; Luo, Meng; Wang, Mengyun; Ma, Kexin; Cao, Huimin; Huang, Yan; Lin, Xiaoyu; Pang, Fenglan; Li, Yiqun; Jiang, Qinghua] Harbin Inst Technol, Sch Life Sci & Technol, Harbin, Peoples R China; [Jiang, Qinghua] Harbin Inst Technol, Minist Educ, Key Lab Biol Big Data, Harbin, Peoples R China	Harbin Institute of Technology; Harbin Institute of Technology	Jiang, QH (corresponding author), Harbin Inst Technol, Sch Life Sci & Technol, Harbin, Peoples R China.; Jiang, QH (corresponding author), Harbin Inst Technol, Minist Educ, Key Lab Biol Big Data, Harbin, Peoples R China.	qhjiang@hit.edu.cm		cheng, rui/0000-0002-9398-3514; LUO, Meng/0000-0003-0622-9060; Wang, Pingping/0000-0001-8888-8005; Jin, Xiyun/0000-0003-2795-6451; Ma, Kexin/0000-0002-9930-0104; Xiao, Lixing/0000-0003-0929-0086; Zhou, Wenyang/0000-0002-3676-0584	National Natural Science Foundation of China [61822108, 62032007]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (Nos. 61822108 and 62032007 to QJ).	Anande G, 2020, CLIN CANCER RES, V26, P3597, DOI 10.1158/1078-0432.CCR-20-0184; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Bechara EG, 2013, MOL CELL, V52, P720, DOI 10.1016/j.molcel.2013.11.010; Biasini Marco, 2014, Nucleic Acids Res, V42, pW252, DOI 10.1093/nar/gku340; Black KL, 2018, NUCLEIC ACIDS RES, V46, P11357, DOI 10.1093/nar/gky946; Blencowe BJ, 2017, TRENDS BIOCHEM SCI, V42, P407, DOI 10.1016/j.tibs.2017.04.001; Brooks AN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087361; Chabot B, 2016, J CELL BIOL, V212, P13, DOI 10.1083/jcb.201510032; Chen M, 2010, CANCER RES, V70, P8977, DOI 10.1158/0008-5472.CAN-10-2513; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Cieslak MC, 2020, MAR GENOM, V51, DOI 10.1016/j.margen.2019.100723; Climente-Gonzalez H, 2017, CELL REP, V20, P2215, DOI 10.1016/j.celrep.2017.08.012; Coomer AO, 2019, BBA-GENE REGUL MECH, V1862, DOI 10.1016/j.bbagrm.2019.05.006; Davuluri RV, 2008, TRENDS GENET, V24, P167, DOI 10.1016/j.tig.2008.01.008; Dvinge H, 2019, GENOME RES, V29, P1591, DOI 10.1101/gr.246678.118; Dvinge H, 2016, NAT REV CANCER, V16, P413, DOI 10.1038/nrc.2016.51; Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143; Ferreira JA, 2006, ANN STAT, V34, P1827, DOI 10.1214/009053606000000425; Frankiw L, 2019, NAT REV IMMUNOL, V19, P675, DOI 10.1038/s41577-019-0195-7; Golan-Gerstl R, 2011, CANCER RES, V71, P4464, DOI 10.1158/0008-5472.CAN-10-4410; Gui XR, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09902-7; Hagen RM, 2012, BIOCHEM SOC T, V40, P870, DOI 10.1042/BST20120026; Hahn CN, 2015, IMMUNOL REV, V263, P257, DOI 10.1111/imr.12241; Hatcher JM, 2018, CELL CHEM BIOL, V25, P460, DOI 10.1016/j.chembiol.2018.01.013; Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q; Hollenbach JA, 2013, INT J IMMUNOGENET, V40, P46, DOI 10.1111/iji.12026; Howard JM, 2018, GENOME RES, V28, P689, DOI 10.1101/gr.229062.117; Hwang JY, 2020, NUCLEIC ACIDS RES, V48, pW300, DOI 10.1093/nar/gkaa237; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Janson G, 2017, BIOINFORMATICS, V33, P444, DOI 10.1093/bioinformatics/btw638; Jones P, 2014, BIOINFORMATICS, V30, P1236, DOI 10.1093/bioinformatics/btu031; Kahles A, 2018, CANCER CELL, V34, P211, DOI 10.1016/j.ccell.2018.07.001; Kedzierska H, 2017, CANCER LETT, V396, P53, DOI 10.1016/j.canlet.2017.03.013; Kim HJ, 2013, NATURE, V495, P467, DOI 10.1038/nature11922; Kim TK, 2015, KOREAN J ANESTHESIOL, V68, P540, DOI 10.4097/kjae.2015.68.6.540; Kobak D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13056-x; Lin JC, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122097; Maguire SL, 2015, J PATHOL, V235, P571, DOI 10.1002/path.4483; Martinez-Montiel N, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020545; Mayr C, 2019, CSH PERSPECT BIOL, V11, DOI 10.1101/cshperspect.a034728; Mazurek S, 2011, INT J BIOCHEM CELL B, V43, P969, DOI 10.1016/j.biocel.2010.02.005; Nilsen TW, 2010, NATURE, V463, P457, DOI 10.1038/nature08909; Norris AD, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00122; Otasek D, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1758-4; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Paschalis A, 2018, NAT REV CLIN ONCOL, V15, P663, DOI 10.1038/s41571-018-0085-0; Pradella D, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0579-2; Repana D, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-018-1612-0; Riley RS, 2019, NAT REV DRUG DISCOV, V18, P175, DOI 10.1038/s41573-018-0006-z; Ryan M, 2016, NUCLEIC ACIDS RES, V44, pD1018, DOI 10.1093/nar/gkv1288; Schwerk C, 2005, MOL CELL, V19, P1, DOI 10.1016/j.molcel.2005.05.026; Sebestyen E, 2016, GENOME RES, V26, P732, DOI 10.1101/gr.199935.115; Shah K, 2020, ONCOGENE, V39, P6172, DOI 10.1038/s41388-020-01429-2; Smart AC, 2018, NAT BIOTECHNOL, V36, P1056, DOI 10.1038/nbt.4239; van der Maaten L, 2014, J MACH LEARN RES, V15, P3221; Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910; von Mering C, 2003, NUCLEIC ACIDS RES, V31, P258, DOI 10.1093/nar/gkg034; Wagner KD, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8010041; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Xie RH, 2019, CANCER LETT, V449, P31, DOI 10.1016/j.canlet.2019.01.041; Zhang Y, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-40; Zhang YJ, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00486-7; Zhang ZB, 2020, AGING-US, V12, P14633, DOI 10.18632/aging.103516; Zhao M, 2013, NUCLEIC ACIDS RES, V41, pD970, DOI 10.1093/nar/gks937; Zhu H, 2014, CANCER LETT, V343, P51, DOI 10.1016/j.canlet.2013.09.014	66	3	4	13	33	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2021	40	35					5441	5450		10.1038/s41388-021-01947-7	http://dx.doi.org/10.1038/s41388-021-01947-7		JUL 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO0SJ	34285345				2022-12-17	WOS:000675072300001
J	Zhang, XQ; Dou, P; Akhtar, ML; Liu, F; Hu, XB; Yang, LJ; Yang, DP; Zhang, XH; Li, YQ; Qiao, SP; Li, K; Tang, R; Zhan, C; Ma, Y; Cheng, QX; Bai, Y; Han, F; Nie, H; Li, Y				Zhang, Xiaoqing; Dou, Peng; Akhtar, Muhammad Luqman; Liu, Fei; Hu, Xibo; Yang, Lijun; Yang, Depeng; Zhang, Xiaohan; Li, Yiqun; Qiao, Shupei; Li, Kai; Tang, Ran; Zhan, Chao; Ma, Yue; Cheng, Qixiang; Bai, Yan; Han, Fang; Nie, Huan; Li, Yu			NEU4 inhibits motility of HCC cells by cleaving sialic acids on CD44	ONCOGENE			English	Article							COLON-CANCER CELLS; MIGRATION; GLYCOSYLATION; EXPRESSION; ADHESION; BINDING; SURFACE; SIALYLATION; SUPPRESSION; RECOGNITION	Hepatocellular carcinoma (HCC) is an extremely metastatic tumor. Sialic acids (SAs) are associated with cancer development and metastasis. NEU4 is a sialidase that removes SAs from glycoconjugates, while the function of the NEU4 in HCC has not been clearly explored. In our research, we found the NEU4 expression was significantly down-regulated in HCC tissues, which was correlated with high grades and poor outcomes of HCC. The NEU4 expression could be regulated by histone acetylation. In the functional analysis of NEU4, the cell motility was inhibited when NEU4 was overexpressed, and restored when NEU4 expression was down-regulated. Similarly, NEU4 over-expressed HCC cells showed less metastasis in athymic nude mice. Further study revealed that NEU4 could inhibit cell migration by enzymatic decomposition of SAs. Our results verified a NEU4 active site (NEU4(E235)) and overexpressing inactivates NEU4(E235A) that weakens the inhibition ability to cell migration. Further, 70 kinds of specific interacting proteins of NEU4 including CD44 were identified through mass spectrum. Moreover, the alpha 2,3-linked SAs on CD44 were decreased and the hyaluronic acid (HA) binding ability was increased when NEU4 over-expressed or activated. Additionally, the mutation of CD44 with six N-glycosylation sites showed less sensibility to NEU4 on cell migration compared with wild-type CD44. In summary, our results revealed the mechanism of low expression of NEU4 in HCC and its inhibitory effect on cell migration by removal of SAs on CD44, which may provide new treatment strategies to control the motility and metastasis of HCC.	[Zhang, Xiaoqing; Dou, Peng; Akhtar, Muhammad Luqman; Liu, Fei; Hu, Xibo; Yang, Lijun; Yang, Depeng; Zhang, Xiaohan; Li, Yiqun; Qiao, Shupei; Li, Kai; Tang, Ran; Ma, Yue; Cheng, Qixiang; Bai, Yan; Han, Fang; Nie, Huan; Li, Yu] Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150008, Heilongjiang, Peoples R China; [Zhan, Chao] Harbin Med Univ, Affiliated Hosp 3, Harbin 150006, Heilongjiang, Peoples R China	Harbin Institute of Technology; Harbin Medical University	Nie, H; Li, Y (corresponding author), Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150008, Heilongjiang, Peoples R China.	nh1212@hit.edu.cn; liyugene@hit.edu.cn		Li, Kai/0000-0002-3062-3618; yang, depeng/0000-0001-8753-3106	National Natural Science Foundation of China [31771627]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (31771627).	Angata K, 2010, METHOD ENZYMOL, V479, P25, DOI 10.1016/S0076-6879(10)79002-9; Bassaganas S, 2014, PANCREAS, V43, P109, DOI 10.1097/MPA.0b013e31829d9090; BIRCH M, 1991, CANCER RES, V51, P6660; Borland G, 1998, IMMUNOLOGY, V93, P139; Chavas LMG, 2005, J BIOL CHEM, V280, P469, DOI 10.1074/jbc.M411506200; Comelli EM, 2003, GENE, V321, P155, DOI 10.1016/j.gene.2003.08.005; Finlay TM, 2010, GLYCOCONJUGATE J, V27, P329, DOI 10.1007/s10719-010-9281-6; Gong AH, 2020, J CELL SCI, V133, DOI 10.1242/jcs.244020; Grinchuk OV, 2018, MOL ONCOL, V12, P89, DOI 10.1002/1878-0261.12153; Guvench O, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00305; Harr JC, 2016, EMBO REP, V17, P139, DOI 10.15252/embr.201541809; Hou GJ, 2016, ONCOTARGET, V7, P64957, DOI 10.18632/oncotarget.11778; Katoh S, 1999, J IMMUNOL, V162, P5058; KATOH S, 1995, J EXP MED, V182, P419, DOI 10.1084/jem.182.2.419; Kongtawelert P, 2003, WORLD J GASTROENTERO, V9, P2178; Lagana A, 1995, CLIN CHIM ACTA, V243, P165, DOI 10.1016/0009-8981(95)06165-7; Lee M, 2010, INT J RADIAT ONCOL, V76, P1528, DOI 10.1016/j.ijrobp.2009.11.022; LESLEY J, 1995, J EXP MED, V182, P431, DOI 10.1084/jem.182.2.431; Li HY, 2018, CANCER LETT, V432, P121, DOI 10.1016/j.canlet.2018.06.009; Liu WZ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1027-6; Lv J, 2015, MED SCI MONIT BASIC, V21, P157, DOI 10.12659/MSMBR.893908; Lv Jun, 2015, Asian Pac J Cancer Prev, V16, P2693; Miyagi T, 2003, GLYCOCONJUGATE J, V20, P189, DOI 10.1023/B:GLYC.0000024250.48506.bf; Miyagi T, 2008, PROTEOMICS, V8, P3303, DOI 10.1002/pmic.200800248; Miyagi T, 2012, GLYCOBIOLOGY, V22, P880, DOI 10.1093/glycob/cws057; Monti E, 2004, GENOMICS, V83, P445, DOI 10.1016/j.ygeno.2003.08.019; Mozzi A, 2012, PROTEINS, V80, P1123, DOI 10.1002/prot.24013; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Nath S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0191-4; Ou LL, 2020, MOL MED REP, V21, P1449, DOI 10.3892/mmr.2020.10951; Painbeni T, 1997, EUR J CANCER, V33, P2216, DOI 10.1016/S0959-8049(97)00318-3; Quint K, 2011, VIRCHOWS ARCH, V459, P129, DOI 10.1007/s00428-011-1103-0; Rochman M, 2000, CELL ADHES COMMUN, V7, P331, DOI 10.3109/15419060009015004; Sano R, 2009, MOL CELL, V36, P500, DOI 10.1016/j.molcel.2009.10.021; Seyrantepe V, 2004, J BIOL CHEM, V279, P37021, DOI 10.1074/jbc.M404531200; Shiozaki K, 2015, FASEB J, V29, P2099, DOI 10.1096/fj.14-262543; Shiozaki K, 2011, J BIOL CHEM, V286, P21052, DOI 10.1074/jbc.M111.231191; Skelton TP, 1998, J CELL BIOL, V140, P431, DOI 10.1083/jcb.140.2.431; Sorice M, 2009, FASEB J, V23, P3298, DOI 10.1096/fj.08-128140; Sun HY, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00401; Sun TY, 2017, AM J TRANSL RES, V9, P103; Takahashi K, 2012, J BIOL CHEM, V287, P14816, DOI 10.1074/jbc.M111.324186; Uemura T, 2009, ONCOGENE, V28, P1218, DOI 10.1038/onc.2008.471; Ueno S, 2006, J BIOL CHEM, V281, P7756, DOI 10.1074/jbc.M509668200; Varki A, 2007, NATURE, V446, P1023, DOI 10.1038/nature05816; Villanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263; Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427; Wu LS, 2021, MOL MED REP, V23, DOI 10.3892/mmr.2020.11667; Yamaguchi K, 2005, BIOCHEM J, V390, P85, DOI 10.1042/BJ20050017; Yamaguchi K, 2006, BIOCHEM BIOPH RES CO, V346, P484, DOI 10.1016/j.bbrc.2006.05.136; Yamanami H, 2007, CANCER SCI, V98, P299, DOI 10.1111/j.1349-7006.2007.00403.x; Zong JB, 2013, ONCOL REP, V30, P3020, DOI 10.3892/or.2013.2742; Zong JB, 2009, ONCOL REP, V22, P953, DOI 10.3892/or_00000522	53	3	3	3	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2021	40	35					5427	5440		10.1038/s41388-021-01955-7	http://dx.doi.org/10.1038/s41388-021-01955-7		JUL 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO0SJ	34282273				2022-12-17	WOS:000674560900002
J	Fares, B; Berger, L; Bangiev-Girsh, E; Kakun, RR; Ghannam-Shahbari, D; Tabach, Y; Zohar, Y; Gottlieb, E; Perets, R				Fares, Basem; Berger, Liron; Bangiev-Girsh, Einav; Kakun, Reli Rachel; Ghannam-Shahbari, Dima; Tabach, Yuval; Zohar, Yaniv; Gottlieb, Eyal; Perets, Ruth			PAX8 plays an essential antiapoptotic role in uterine serous papillary cancer	ONCOGENE			English	Article							ENDOMETRIAL CANCER; INTRAEPITHELIAL CARCINOMA; HISTONE MODIFICATIONS; OVARIAN-CANCER; P53; EXPRESSION; PATHOGENESIS; INHIBITION; BINDING; PHOSPHORYLATION	Endometrial carcinoma (EC) is the fourth-most common cancer in women in the United States, and generally carries a favorable prognosis. However, about 10% of EC patients have a rare and aggressive form, uterine serous papillary carcinoma (USPC), which carries a much higher mortality rate. The developmental transcription factor PAX8 is expressed in nearly 100% of USPCs. We show that PAX8 plays a critical antiapoptotic role in USPC and this role is established via transcriptional activation of two aberrant signaling pathways. First, PAX8 positively regulates mutated p53, and missense p53 mutations have an oncogenic gain of function effect. Second, PAX8 directly transcriptionally regulates p21, in a p53-independent manner, and p21 acquires a growth promoting role that is mediated via cytoplasmic localization of the protein. We propose that mutated p53 and cytoplasmic p21 can independently mediate the pro-proliferative role of PAX8 in USPC. In addition, we performed a genome-wide transcriptome analysis to detect pathways that are regulated by PAX8, and propose that metabolism and HIF-1alpha -related pathways are potential candidates for mediating the role of PAX8 in USPC. Taken together our findings demonstrate for the first time that PAX8 is an essential lineage marker in USPC, and suggest its mechanism of action.	[Fares, Basem; Bangiev-Girsh, Einav; Kakun, Reli Rachel; Ghannam-Shahbari, Dima; Gottlieb, Eyal; Perets, Ruth] Technion Israel Inst Technol, Ruth & Bruce Rappaport Fac Med, Haifa, Israel; [Fares, Basem; Berger, Liron; Bangiev-Girsh, Einav; Kakun, Reli Rachel; Ghannam-Shahbari, Dima; Perets, Ruth] Clin Res Inst Rambam CRIR, Div Oncol, Rambam Hlth Care Campus, Haifa, Israel; [Tabach, Yuval] Hebrew Univ Jerusalem, Fac Med, Inst Med Res Israel Canada IMRIC, Dept Dev Biol & Canc Res, Jerusalem, Israel; [Zohar, Yaniv] Technion Israel Inst Technol, Dept Pathol, Rambam Hlth Care Campus, Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Rambam Health Care Campus; Hebrew University of Jerusalem; Rambam Health Care Campus; Technion Israel Institute of Technology	Perets, R (corresponding author), Technion Israel Inst Technol, Ruth & Bruce Rappaport Fac Med, Haifa, Israel.; Perets, R (corresponding author), Clin Res Inst Rambam CRIR, Div Oncol, Rambam Hlth Care Campus, Haifa, Israel.	Ru_Perets@RMC.gov.il	Gottlieb, Eyal/G-6450-2010	Gottlieb, Eyal/0000-0002-9770-0956; Perets, Ruth/0000-0001-7216-6577	Israel Science Foundation [1990/18]; Israel Cancer Research Fund's Len and Susan Mark Initiative for Ovarian and Uterine/MMMT Cancers; Israel Cancer Association's ICA USA Board of Directors; EU's Marie Curie Actions (FP7 People) program; Women's Health Fund at the Rambam Health Care Campus	Israel Science Foundation(Israel Science Foundation); Israel Cancer Research Fund's Len and Susan Mark Initiative for Ovarian and Uterine/MMMT Cancers; Israel Cancer Association's ICA USA Board of Directors; EU's Marie Curie Actions (FP7 People) program; Women's Health Fund at the Rambam Health Care Campus	RP is supported by grants from the Israel Science Foundation (1990/18), the Israel Cancer Research Fund's Len and Susan Mark Initiative for Ovarian and Uterine/MMMT Cancers, the Israel Cancer Association's ICA USA Board of Directors, the EU's Marie Curie Actions (FP7 People) program, and the Women's Health Fund at the Rambam Health Care Campus.	Adler EK, 2017, ONCOTARGET, V8, P108316, DOI 10.18632/oncotarget.22718; AMBROS RA, 1995, HUM PATHOL, V26, P1260, DOI 10.1016/0046-8177(95)90203-1; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Attias-Geva Z, 2012, EUR J CANCER, V48, P1570, DOI 10.1016/j.ejca.2011.09.014; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Ben-Ari Fuchs S, 2016, OMICS, V20, P139, DOI 10.1089/omi.2015.0168; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Bleu M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11672-1; BOKHMAN JV, 1983, GYNECOL ONCOL, V15, P10, DOI 10.1016/0090-8258(83)90111-7; Bouaoun L, 2016, HUM MUTAT, V37, P865, DOI 10.1002/humu.23035; Bowen NJ, 2007, GYNECOL ONCOL, V104, P331, DOI 10.1016/j.ygyno.2006.08.052; Brinton LA, 2013, GYNECOL ONCOL, V129, P277, DOI 10.1016/j.ygyno.2013.02.023; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Cheng Y, 2014, MOL CANCER THER, V13, P675, DOI 10.1158/1535-7163.MCT-13-0416; de Cristofaro T, 2016, ONCOTARGET, V7, P41929, DOI 10.18632/oncotarget.9740; de Jonge MM, 2019, CLIN CANCER RES, V25, P7517, DOI 10.1158/1078-0432.CCR-19-0848; de Renty C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097434; di Magliano MP, 2000, P NATL ACAD SCI USA, V97, P13144; Di Palma T, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-292; Dong PX, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-103; Elias KM, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87988; Fadare O, 2012, AM J CANCER RES, V2, P335; Fader AN, 2010, CURR OPIN OBSTET GYN, V22, P21, DOI 10.1097/GCO.0b013e328334d8a3; Fu DJ, 2020, DIS MODEL MECH, V13, DOI 10.1242/dmm.047035; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Ghannam-Shahbari D, 2018, ONCOGENE, V37, P2213, DOI 10.1038/s41388-017-0040-z; Goldman NA, 2006, MODERN PATHOL, V19, P1429, DOI 10.1038/modpathol.3800656; Gravina GL, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0085-1; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hardy LR, 2019, ONCOGENE, V38, P6003, DOI 10.1038/s41388-019-0842-2; Huang YF, 2014, J GASTROENTEROL, V49, P1441, DOI 10.1007/s00535-013-0900-4; Kotler E, 2018, MOL CELL, V71, P178, DOI 10.1016/j.molcel.2018.06.012; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Krzeslak A, 2012, PATHOL ONCOL RES, V18, P721, DOI 10.1007/s12253-012-9500-5; Kurman RJ, 2013, GYNECOL ONCOL, V129, P271, DOI 10.1016/j.ygyno.2013.03.029; Laury AR, 2011, AM J SURG PATHOL, V35, P816, DOI 10.1097/PAS.0b013e318216c112; Laury AR, 2010, AM J SURG PATHOL, V34, P627, DOI 10.1097/PAS.0b013e3181da7687; Lee S, 2004, J BIOL CHEM, V279, P1885, DOI 10.1074/jbc.M306968200; Lee Y, 2007, J PATHOL, V211, P26, DOI 10.1002/path.2091; Lee Y, 2006, ADV ANAT PATHOL, V13, P1, DOI 10.1097/01.pap.0000201826.46978.e5; Lin X, 2012, PLANT METHODS, V8, DOI 10.1186/1746-4811-8-48; Lotan TL, 2009, AM J SURG PATHOL, V33, P1037, DOI 10.1097/PAS.0b013e3181962dcd; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; Martinez JD, 1998, ONCOGENE, V16, P453, DOI 10.1038/sj.onc.1201565; Mayelzadeh F, 2007, ONCOGENE, V26, P2955, DOI 10.1038/sj.onc.1210110; Mittag J, 2007, ENDOCRINOLOGY, V148, P719, DOI 10.1210/en.2006-1054; Narlis M, 2007, J AM SOC NEPHROL, V18, P1121, DOI 10.1681/ASN.2006070739; Nonaka D, 2008, MODERN PATHOL, V21, P192, DOI 10.1038/modpathol.3801002; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Pennington KP, 2013, CANCER-AM CANCER SOC, V119, P332, DOI 10.1002/cncr.27720; Perets R, 2013, CANCER CELL, V24, P751, DOI 10.1016/j.ccr.2013.10.013; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; Rodriguez-Vilarrupla A, 2005, MOL CELL BIOL, V25, P7364, DOI 10.1128/MCB.25.16.7364-7374.2005; Santin AD, 2002, CLIN CANCER RES, V8, P1271; Sarfstein R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061537; Saule Claire, 2018, J Natl Cancer Inst, V110, DOI 10.1093/jnci/djx159; SHERMAN ME, 1995, HUM PATHOL, V26, P1268, DOI 10.1016/0046-8177(95)90204-X; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; SPIEGEL GW, 1995, AM J SURG PATHOL, V19, P417, DOI 10.1097/00000478-199504000-00003; Suarez AA, 2017, GYNECOL ONCOL, V144, P243, DOI 10.1016/j.ygyno.2016.12.010; Sun H, 2014, BRIT J CANCER, V111, P281, DOI 10.1038/bjc.2014.260; Tolcher MC, 2015, INT J GYNECOL PATHOL, V34, P57, DOI 10.1097/PGP.0000000000000109; Vergote IB, 2020, GYNECOL ONCOL, V156, P308, DOI 10.1016/j.ygyno.2019.11.012; Wettersten HI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113867; Winterhoff B, 2020, CURR OPIN OBSTET GYN, V32, P76, DOI 10.1097/GCO.0000000000000602; Zheng WX, 2005, GYNECOL ONCOL, V96, P579, DOI 10.1016/j.ygyno.2004.12.045; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	67	3	3	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2021	40	34					5275	5285		10.1038/s41388-021-01925-z	http://dx.doi.org/10.1038/s41388-021-01925-z		JUL 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UJ0LG	34244607				2022-12-17	WOS:000672114100001
J	Kaluz, S; Zhang, Q; Kuranaga, Y; Yang, H; Osuka, S; Bhattacharya, D; Devi, NS; Mun, J; Wang, W; Zhang, RW; Goodman, MM; Grossniklaus, HE; Van Meir, EG				Kaluz, Stefan; Zhang, Qing; Kuranaga, Yuki; Yang, Hua; Osuka, Satoru; Bhattacharya, Debanjan; Devi, Narra S.; Mun, Jiyoung; Wang, Wei; Zhang, Ruiwen; Goodman, Mark M.; Grossniklaus, Hans E.; Van Meir, Erwin G.			Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growth	ONCOGENE			English	Article							VEGF-A; CANCER; BREAST; MODEL; PEDF	Uveal melanoma (UM) is the most prevalent primary intraocular malignancy in adults, and patients that develop metastases (similar to 50%) survive <1 year, highlighting the urgent need for new therapies. TCGA has recently revealed that a hypoxia gene signature is associated with poor UM patient prognosis. Here we show that expression of hypoxia-regulated collagen prolyl-4-hydroxylase genes P4HA1 and P4HA2 is significantly upregulated in UM patients with metastatic disease and correlates with poor prognosis, suggesting these enzymes might be key tumor drivers. We targeted hypoxia-induced expression of P4HA1/2 in UM with KCN1, a hypoxia inducible factor-1 (HIF-1) pathway inhibitor and found potent inhibition of primary and metastatic disease and extension of animal survival, without overt side effects. At the molecular level, KCN1 antagonized hypoxia-induced expression of P4HA1 and P4HA2, which regulate collagen maturation and deposition in the extracellular matrix. The treatment decreased prolyl hydroxylation, induced proteolytic cleavage and rendered a disordered structure to collagen VI, the main collagen produced by UM, and reduced UM cell invasion. Together, these data demonstrate that extracellular collagen matrix formation can be targeted in UM by inhibiting hypoxia-induced P4HA1 and P4HA2 expression, warranting further development of this strategy in patients with uveal melanoma.	[Kaluz, Stefan; Osuka, Satoru; Bhattacharya, Debanjan; Devi, Narra S.; Van Meir, Erwin G.] Emory Univ, Dept Neurosurg, Atlanta, GA 30322 USA; [Kaluz, Stefan; Goodman, Mark M.; Grossniklaus, Hans E.; Van Meir, Erwin G.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA; [Zhang, Qing; Yang, Hua; Grossniklaus, Hans E.] Emory Univ, Dept Ophthalmol, Atlanta, GA 30322 USA; [Zhang, Qing] Cent South Univ, Xiangya Hosp 2, Dept Ophthalmol, Changsha, Hunan, Peoples R China; [Kuranaga, Yuki; Osuka, Satoru; Van Meir, Erwin G.] Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL USA; [Osuka, Satoru; Van Meir, Erwin G.] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL USA; [Mun, Jiyoung; Goodman, Mark M.] Emory Univ, Dept Radiol & Imaging Sci, Atlanta, GA 30322 USA; [Wang, Wei; Zhang, Ruiwen] Univ Houston, Dept Pharmacol & Pharmaceut Sci, Houston, TX USA; [Wang, Wei; Zhang, Ruiwen] Univ Houston, Coll Pharm, Drug Discovery Inst, Houston, TX 77030 USA; [Grossniklaus, Hans E.] Emory Univ, Dept Pathol, Atlanta, GA 30322 USA; [Van Meir, Erwin G.] Emory Univ, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University; Central South University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Emory University; University of Houston System; University of Houston; University of Houston System; University of Houston; Emory University; Emory University	Van Meir, EG (corresponding author), Emory Univ, Dept Neurosurg, Atlanta, GA 30322 USA.; Grossniklaus, HE; Van Meir, EG (corresponding author), Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.; Grossniklaus, HE (corresponding author), Emory Univ, Dept Ophthalmol, Atlanta, GA 30322 USA.; Van Meir, EG (corresponding author), Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL USA.; Van Meir, EG (corresponding author), Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL USA.; Grossniklaus, HE (corresponding author), Emory Univ, Dept Pathol, Atlanta, GA 30322 USA.; Van Meir, EG (corresponding author), Emory Univ, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA.	ophtheg@emory.edu; evanmeir@uab.edu			NIH [R01 CA116804, R01 CA176001, R01 CA180805, R24 EY017045, P30 EY06360, P30 CA138292, P30 CA13148]; National Natural Science Foundation of China [NNS81201808]; Fight For Sight Postdoctoral Award; Emory Melanoma Prevention and Research Discovery Fund; Winship Cancer Institute pilot grant; Central South University Lieying pilot grant; V Foundation; Max Cure Foundation; Samuel Waxman Cancer Research Foundation; Alan B. Slifka Foundation; Research to Prevent Blindness, Inc.	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fight For Sight Postdoctoral Award; Emory Melanoma Prevention and Research Discovery Fund; Winship Cancer Institute pilot grant; Central South University Lieying pilot grant; V Foundation; Max Cure Foundation; Samuel Waxman Cancer Research Foundation; Alan B. Slifka Foundation; Research to Prevent Blindness, Inc.(Research to Prevent Blindness (RPB))	This work was supported in part by grants from the NIH (R01 CA116804, R01 CA176001, R01 CA180805, R24 EY017045, P30 EY06360, P30 CA138292 and P30 CA13148), the National Natural Science Foundation of China (NNS81201808), the Fight For Sight Postdoctoral Award, the Emory Melanoma Prevention and Research Discovery Fund, a Winship Cancer Institute pilot grant, a Central South University Lieying pilot grant, the V Foundation, the Max Cure Foundation, the Samuel Waxman Cancer Research Foundation, the Alan B. Slifka Foundation, and an unrestricted grant from Research to Prevent Blindness, Inc.	Asnaghi L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105372; Canty EG, 2005, J CELL SCI, V118, P1341, DOI 10.1242/jcs.01731; Chattopadhyay C, 2016, CANCER-AM CANCER SOC, V122, P2299, DOI 10.1002/cncr.29727; Chen PW, 2013, TRENDS MOL MED, V19, P410, DOI 10.1016/j.molmed.2013.04.001; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; Dai X, 2017, ONCOTARGET, V8, P99245, DOI 10.18632/oncotarget.22104; Diener-West M, 2001, ARCH OPHTHALMOL-CHIC, V119, P969; Dogrusoz M, 2018, ACTA OPHTHALMOL, V96, P331, DOI 10.1111/aos.13580; Dong L, 2019, CLIN CANCER RES, V25, P2206, DOI 10.1158/1078-0432.CCR-18-1368; el Filali M, 2010, INVEST OPHTH VIS SCI, V51, P2329, DOI 10.1167/iovs.09-4739; Ferguson Jalisa H, 2017, J Enzyme Inhib Med Chem, V32, P992, DOI 10.1080/14756366.2017.1347784; Filleur S, 2009, J CELL BIOCHEM, V106, P769, DOI 10.1002/jcb.22072; Gangemi R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029989; Gelderblom H, 2001, EUR J CANCER, V37, P1590, DOI 10.1016/S0959-8049(01)00171-X; Gilkes DM, 2013, CANCER RES, V73, P3285, DOI 10.1158/0008-5472.CAN-12-3963; Gilkes DM, 2013, J BIOL CHEM, V288, P10819, DOI 10.1074/jbc.M112.442939; Goswami CP, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-970; Grimmer C, 2006, AM J PATHOL, V169, P491, DOI 10.2353/ajpath.2006.050738; Harbour JW, 2014, OPHTHALMOLOGY, V121, P1281, DOI 10.1016/j.ophtha.2013.12.014; Hofbauer KH, 2003, EUR J BIOCHEM, V270, P4515, DOI 10.1046/j.1432-1033.2003.03846.x; Hu K, 2016, ONCOTARGET, V7, P7816, DOI 10.18632/oncotarget.6868; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Klein CA, 2008, SCIENCE, V321, P1785, DOI 10.1126/science.1164853; Lattier JM, 2013, CLIN EXP METASTAS, V30, P969, DOI 10.1007/s10585-013-9596-3; Laurent C, 2011, CANCER RES, V71, P666, DOI 10.1158/0008-5472.CAN-10-0605; Mooring SR, 2011, J MED CHEM, V54, P8471, DOI 10.1021/jm201018g; Mouriaux F, 2014, INVEST OPHTH VIS SCI, V55, P1277, DOI 10.1167/iovs.13-13345; Mun JY, 2012, BIOORGAN MED CHEM, V20, P4590, DOI 10.1016/j.bmc.2012.04.064; Onken MD, 2006, J MOL DIAGN, V8, P567, DOI 10.2353/jmoldx.2006.060077; Provenzano PP, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-38; Rankin EB, 2016, SCIENCE, V352, P175, DOI 10.1126/science.aaf4405; Robertson AG, 2017, CANCER CELL, V32, P204, DOI 10.1016/j.ccell.2017.07.003; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Shi Q, 2012, ACS MED CHEM LETT, V3, P620, DOI 10.1021/ml300042k; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Stegen S, 2019, NATURE, V565, P511, DOI 10.1038/s41586-019-0874-3; Sullivan RJ, 2015, CLIN CANCER RES, V21, P2424, DOI 10.1158/1078-0432.CCR-14-1650; Tan C, 2011, BIOORG MED CHEM LETT, V21, P5528, DOI 10.1016/j.bmcl.2011.06.099; Van Meir EG, 1997, INT J CANCER, V71, P310; Walker C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103028; Wang W, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0044883, 10.1371/journal.pone.0052488]; Xiong GF, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-1; Yin SM, 2012, CLIN CANCER RES, V18, P6623, DOI 10.1158/1078-0432.CCR-12-0861; Zhang Q, 2011, INVEST OPHTH VIS SCI, V52, P2662, DOI 10.1167/iovs.10-6794	44	3	4	3	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2021	40	33					5182	5191		10.1038/s41388-021-01919-x	http://dx.doi.org/10.1038/s41388-021-01919-x		JUL 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC8LP	34218269	Green Accepted			2022-12-17	WOS:000669300400002
J	Casillas, AL; Chauhan, SS; Toth, RK; Sainz, AG; Clements, AN; Jensen, CC; Langlais, PR; Miranti, CK; Cress, AE; Warfel, NA				Casillas, Andrea L.; Chauhan, Shailender S.; Toth, Rachel K.; Sainz, Alva G.; Clements, Amber N.; Jensen, Corbin C.; Langlais, Paul R.; Miranti, Cindy K.; Cress, Anne E.; Warfel, Noel A.			Direct phosphorylation and stabilization of HIF-1 alpha by PIM1 kinase drives angiogenesis in solid tumors	ONCOGENE			English	Article							HYPOXIA-INDUCIBLE FACTOR-1; PROSTATE-CANCER CELLS; TRANSCRIPTION FACTOR; MEDIATES RESISTANCE; GROWTH; THERAPY; VHL; ACTIVATION; EXPRESSION; HYPOXIA-INDUCIBLE-FACTOR-1-ALPHA	Angiogenesis is essential for the sustained growth of solid tumors. Hypoxia-inducible factor 1 (HIF-1) is a master regulator of angiogenesis and constitutive activation of HIF-1 is frequently observed in human cancers. Therefore, understanding the mechanisms governing the activation of HIF-1 is critical for successful therapeutic targeting of tumor angiogenesis. Herein, we establish a new regulatory mechanism responsible for the constitutive activation of HIF-1 alpha in cancer, irrespective of oxygen tension. PIM1 kinase directly phosphorylates HIF-1 alpha at threonine 455, a previously uncharacterized site within its oxygen-dependent degradation domain. This phosphorylation event disrupts the ability of prolyl hydroxylases to bind and hydroxylate HIF-1 alpha, interrupting its canonical degradation pathway and promoting constitutive transcription of HIF-1 target genes. Moreover, phosphorylation of the analogous site in HIF-2 alpha (S435) stabilizes the protein through the same mechanism, indicating post-translational modification within the oxygen-dependent degradation domain as a mechanism of regulating the HIF-alpha subunits. In vitro and in vivo models demonstrate that expression of PIM1 is sufficient to stabilize HIF-1 alpha and HIF-2 alpha in normoxia and stimulate angiogenesis in a HIF-1-dependent manner. CRISPR mutants of HIF-1 alpha (Thr455D) promoted increased tumor growth, proliferation, and angiogenesis. Moreover, HIF-1 alpha-T455D xenograft tumors were refractory to the anti-angiogenic and cytotoxic effects of PIM inhibitors. These data identify a new signaling axis responsible for hypoxia-independent activation of HIF-1 and expand our understanding of the tumorigenic role of PIM1 in solid tumors.	[Casillas, Andrea L.; Clements, Amber N.; Jensen, Corbin C.] Univ Arizona, Canc Biol Grad Interdisciplinary Program, Tucson, AZ USA; [Chauhan, Shailender S.; Toth, Rachel K.; Miranti, Cindy K.; Cress, Anne E.; Warfel, Noel A.] Univ Arizona, Ctr Canc, Tucson, AZ 85724 USA; [Sainz, Alva G.] Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA; [Langlais, Paul R.] Univ Arizona, Dept Med, Tucson, AZ USA; [Miranti, Cindy K.; Cress, Anne E.; Warfel, Noel A.] Univ Arizona, Dept Cellular & Mol Med, Tucson, AZ 85724 USA	University of Arizona; University of Arizona; Salk Institute; University of Arizona; University of Arizona	Warfel, NA (corresponding author), Univ Arizona, Ctr Canc, Tucson, AZ 85724 USA.; Warfel, NA (corresponding author), Univ Arizona, Dept Cellular & Mol Med, Tucson, AZ 85724 USA.	warfelna@arizona.edu	Chauhan, Shailender Singh/AAM-5269-2020	Chauhan, Shailender Singh/0000-0002-1975-2734; Clements, Amber/0000-0002-6883-7558; Toth, Rachel/0000-0001-8897-5045; Warfel, Noel/0000-0001-6410-9011; Cress, Anne/0000-0001-6194-0061; Casillas, Andrea L/0000-0002-2059-3048	National Cancer Institute [T32CA009213]; American Cancer Society [RSG-16-159-01-CDD]; Department of Defense PCRP [W81XWH-19-1-0455]; National Institute of Health [P30CA023074]	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); Department of Defense PCRP(United States Department of Defense); National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We would like to thank the following shared resources at the University of Arizona Cancer Center for their help and support: EMSR, TACMASR, Gene Editing, and Biostatistics. We would also like to thank Dr. Dan Buster for performing in vitro kinase assays and Brenda Baggett and Dr. Marty Pagel for assisting with in vivo imaging. Studies were supported by funding from the National Cancer Institute (T32CA009213) on behalf of ALC, American Cancer Society (RSG-16-159-01-CDD) to NAW, and Department of Defense PCRP (W81XWH-19-1-0455) to NAW. A Cancer Center Support grant from the National Institute of Health (P30CA023074) also supported this research.	Baba Y, 2010, AM J PATHOL, V176, P2292, DOI 10.2353/ajpath.2010.090972; Baldewijns MM, 2010, J PATHOL, V221, P125, DOI 10.1002/path.2689; Bielenberg DR, 2015, CANCER J, V21, P267, DOI 10.1097/PPO.0000000000000138; Braso-Maristany F, 2017, NAT MED, V23, P526, DOI 10.1038/nm0417-526c; Brault L, 2010, HAEMATOL-HEMATOL J, V95, P1004, DOI 10.3324/haematol.2009.017079; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bullen JW, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf0583; Bullock AN, 2005, J BIOL CHEM, V280, P41675, DOI 10.1074/jbc.M510711200; Bushweller JH, 2019, NAT REV CANCER, V19, P611, DOI 10.1038/s41568-019-0196-7; Cam H, 2010, MOL CELL, V40, P509, DOI 10.1016/j.molcel.2010.10.030; Cardenas-Rodriguez J, 2013, MAGN RESON IMAGING, V31, P497, DOI 10.1016/j.mri.2012.10.008; Casillas AL, 2018, CLIN CANCER RES, V24, P169, DOI 10.1158/1078-0432.CCR-17-1318; Cen B, 2014, MOL CELL BIOL, V34, P2517, DOI 10.1128/MCB.00147-14; Chauhan SS, 2020, ONCOGENE, V39, P2597, DOI 10.1038/s41388-020-1168-9; Chauhan Shailender S, 2018, Oncoscience, V5, P254, DOI 10.18632/oncoscience.458; Chen WW, 2005, MOL CANCER RES, V3, P443, DOI 10.1158/1541-7786.MCR-05-0007; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Fallah J, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0752-z; Filtz TM, 2014, TRENDS PHARMACOL SCI, V35, P76, DOI 10.1016/j.tips.2013.11.005; Flugel D, 2007, MOL CELL BIOL, V27, P3253, DOI 10.1128/MCB.00015-07; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Gao XA, 2019, BREAST CANCER-TOKYO, V26, P663, DOI 10.1007/s12282-019-00966-3; Hammerman PS, 2005, BLOOD, V105, P4477, DOI 10.1182/blood-2004-09-3706; Hartwich J, 2013, J PEDIATR SURG, V48, P39, DOI 10.1016/j.jpedsurg.2012.10.016; Huang CY, 2013, J NUTR BIOCHEM, V24, P1596, DOI 10.1016/j.jnutbio.2013.01.010; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kettenbach AN, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001497; Kurmasheva RT, 2006, BRIT J CANCER, V95, P955, DOI 10.1038/sj.bjc.6603353; Lee S, 2007, GYNECOL ONCOL, V106, P311, DOI 10.1016/j.ygyno.2007.03.041; Liu ZJ, 2015, J ZHEJIANG UNIV-SC B, V16, P32, DOI 10.1631/jzus.B1400221; Malone T, 2020, PHARMACOL THERAPEUT, V207, DOI 10.1016/j.pharmthera.2019.107454; Markou A, 2020, CANCERS, V12, DOI 10.3390/cancers12051188; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Moody SE, 2015, ONCOGENE, V34, P2061, DOI 10.1038/onc.2014.153; Mylonis I, 2006, J BIOL CHEM, V281, P33095, DOI 10.1074/jbc.M605058200; Nawijn MC, 2011, NAT REV CANCER, V11, P23, DOI 10.1038/nrc2986; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Qu YC, 2016, MED SCI MONITOR, V22, P4254, DOI 10.12659/MSM.898223; Rapisarda A, 2002, CANCER RES, V62, P4316; Rebello Richard J., 2018, Advances in Biological Regulation, V67, P163, DOI 10.1016/j.jbior.2017.10.010; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Santio NM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130340; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; TANNOCK IF, 1968, BRIT J CANCER, V22, P258, DOI 10.1038/bjc.1968.34; Tong D, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.74; Wang C, 2013, J SURG RES, V185, P595, DOI 10.1016/j.jss.2013.06.004; Warfel NA, 2016, MOL CANCER THER, V15, P1637, DOI 10.1158/1535-7163.MCT-15-1018; Warfel NA, 2015, PHARMACOL THERAPEUT, V151, P41, DOI 10.1016/j.pharmthera.2015.03.001; Warfel NA, 2013, CELL CYCLE, V12, P3689, DOI 10.4161/cc.26930; Xie Y, 2006, ONCOGENE, V25, P70, DOI 10.1038/sj.onc.1209058; Xu DZ, 2010, J BIOL CHEM, V285, P38944, DOI 10.1074/jbc.M110.160325; Zhang M, 2018, CANCER SCI, V109, P1468, DOI 10.1111/cas.13562; Zhao W, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-0998-y; Zhong H, 2000, CANCER RES, V60, P1541	57	3	3	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2021	40	32					5142	5152		10.1038/s41388-021-01915-1	http://dx.doi.org/10.1038/s41388-021-01915-1		JUL 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA7OD	34211090	Green Submitted, Green Accepted			2022-12-17	WOS:000668832400001
J	Chen, TL; Zhang, FB; Liu, J; Huang, ZL; Zheng, YF; Deng, SK; Liu, Y; Wang, JH; Sun, XL				Chen, Taoliang; Zhang, Fabing; Liu, Jie; Huang, Zhilin; Zheng, Yaofeng; Deng, Shaokang; Liu, Yang; Wang, Jihui; Sun, Xinlin			Dual role of WNT5A in promoting endothelial differentiation of glioma stem cells and angiogenesis of glioma derived endothelial cells	ONCOGENE			English	Article							MALIGNANT GLIOMAS; GLIOBLASTOMA; PROLIFERATION; CANCER; OVEREXPRESSION; ACTIVATION; EXPRESSION; PROGNOSIS; THERAPY; PATHWAY	Glioma is a devastating cancer with a rich vascular network. No anti-angiogenic treatment is available for prolonging the overall survival of glioma patients. Recent studies have demonstrated that the endothelial differentiation of glioma stem cells (GSCs) into glioma-derived endothelial cells (GDECs) may be a novel target for anti-angiogenic therapy in glioma; however, the underlying mechanisms of this process remain unknown. Here, we report that wingless-related integration site (WNT) family member 5A (WNT5A) plays significant roles in GSC endothelial differentiation and GDECs angiogenesis. WNT5A is preferentially secreted by GDECs, and inhibition of WNT5A suppresses angiogenesis and tumorigenesis in GDECs. Silencing of WNT5A in GDECs also disrupts the impact of GDECs on stimulating GSC endothelial differentiation. Frizzled-4 is a receptor that mediates the effect of WNT5A on GSC endothelial differentiation and angiogenesis of GDECs via GSK3 beta/beta-catenin/epithelial-mesenchymal transition signalling. The shWNT5A@cRGD-DDD liposomes, targeting WNT5A, exert anti-angiogenic effects in vivo. In this study, we identified that WNT5A has a dual functional role in modulating the endothelial differentiation of GSCs and angiogenesis of GDECs, indicating that WNT5A is a potential target for anti-angiogenesis-based therapeutics in glioma.	[Chen, Taoliang; Zhang, Fabing; Liu, Jie; Huang, Zhilin; Zheng, Yaofeng; Deng, Shaokang; Liu, Yang; Wang, Jihui; Sun, Xinlin] Southern Med Univ, Zhujiang Hosp, Natl Key Clin Specialty,Dept Neurosurg, Engn Technol Res Ctr,Educ Minist China,Guangdong, Guangzhou, Peoples R China	Southern Medical University - China	Liu, Y; Wang, JH; Sun, XL (corresponding author), Southern Med Univ, Zhujiang Hosp, Natl Key Clin Specialty,Dept Neurosurg, Engn Technol Res Ctr,Educ Minist China,Guangdong, Guangzhou, Peoples R China.	lynanchang@hotmail.com; 346wangjihui@163.com; zjsunxinlin@163.com		Liu, Yang/0000-0001-9658-0000	Natural Science Foundation of China [81772652, 81802481]; Natural Science Foundation of Guangdong Province [2018A030310423]; China Postdoctoral Science Foundation [2020M672737]; President Foundation of ZhuJiang Hospital, Southern Medical University [jzjj2018rc04, yjjj2019qn14]; Guangzhou Science and Technology Planning Project [202102020015]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); President Foundation of ZhuJiang Hospital, Southern Medical University; Guangzhou Science and Technology Planning Project	Xinlin Sun received funding from the Natural Science Foundation of China (No. 81772652). Jihui Wang received funding from the Natural Science Foundation of China (No. 81802481), Natural Science Foundation of Guangdong Province (No. 2018A030310423), China Postdoctoral Science Foundation funded project (No. 2020M672737) and President Foundation of ZhuJiang Hospital, Southern Medical University (No. jzjj2018rc04). Taoliang Chen received funding from the President Foundation of ZhuJiang Hospital, Southern Medical University (No. yjjj2019qn14) and Guangzhou Science and Technology Planning Project (No. 202102020015)	Abdulkhalek S, 2014, CLIN TRANSL MED, V3, DOI 10.1186/s40169-014-0028-z; Akhtar N, 2018, DEV CELL, V47, P135, DOI 10.1016/j.devcel.2018.10.007; Carlson JC, 2021, NEURO-ONCOLOGY, V23, P932, DOI 10.1093/neuonc/noaa297; Chen TL, 2019, ONCOGENE, V38, P1183, DOI 10.1038/s41388-018-0515-6; Chen YL, 2020, CLIN NEUROL NEUROSUR, V198, DOI 10.1016/j.clineuro.2020.106239; Cheng CW, 2008, BIOCHEM BIOPH RES CO, V365, P285, DOI 10.1016/j.bbrc.2007.10.166; Deshors P, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2055-6; Ekstrom EJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-88; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Frenquelli M, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.615190; Habu M, 2014, J BIOCHEM, V156, P29, DOI 10.1093/jb/mvu015; Han S, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/7681926; Han Y, 2020, J DENT RES, V99, P804, DOI 10.1177/0022034520912190; Hardee ME, 2012, AM J PATHOL, V181, P1126, DOI 10.1016/j.ajpath.2012.06.030; Hu BL, 2016, CELL, V167, P1281, DOI 10.1016/j.cell.2016.10.039; Jiang X, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02978-w; Junge HJ, 2009, CELL, V139, P299, DOI 10.1016/j.cell.2009.07.048; Kamino M, 2011, CANCER SCI, V102, P540, DOI 10.1111/j.1349-7006.2010.01815.x; Kemper K, 2010, CANCER RES, V70, P719, DOI 10.1158/0008-5472.CAN-09-1820; Li XK, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.532581; Li ZT, 2020, MOL THER-NUCL ACIDS, V19, P827, DOI 10.1016/j.omtn.2019.09.034; Liu J, 2020, ACS APPL MATER INTER, V12, P52354, DOI 10.1021/acsami.0c14288; Liu ZY, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3578-9; Ma L, 2021, INT J MOL MED, V47, DOI 10.3892/ijmm.2021.4855; Masckauchan TNH, 2006, MOL BIOL CELL, V17, P5163, DOI 10.1091/mbc.E06-04-0320; Mei X, 2017, NEURO-ONCOLOGY, V19, P1109, DOI 10.1093/neuonc/nox016; Mooi J, 2021, CLIN CANCER RES, V27, P2159, DOI 10.1158/1078-0432.CCR-20-2714; Ostrom Quinn T, 2019, Neuro Oncol, V21, pv1, DOI 10.1093/neuonc/noz150; Piao Y, 2013, CLIN CANCER RES, V19, P4392, DOI 10.1158/1078-0432.CCR-12-1557; Plate KH, 2012, ACTA NEUROPATHOL, V124, P763, DOI 10.1007/s00401-012-1066-5; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Shi YN, 2017, CLIN CHIM ACTA, V471, P263, DOI 10.1016/j.cca.2017.06.017; Sun L, 2020, GENE, V747, DOI 10.1016/j.gene.2020.144657; Sun Z, 2020, MOL THER-NUCL ACIDS, V22, P1092, DOI 10.1016/j.omtn.2020.10.021; Suva ML, 2020, CANCER CELL, V37, P630, DOI 10.1016/j.ccell.2020.04.001; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Wei YC, 2019, AGING-US, V11, P8951, DOI 10.18632/aging.102359; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Wu HB, 2017, AUTOPHAGY, V13, P1528, DOI 10.1080/15548627.2017.1336277; Yang DH, 2009, CIRC RES, V104, P372, DOI 10.1161/CIRCRESAHA.108.185405; Yang XH, 2020, MOL MED REP, V22, P2981, DOI 10.3892/mmr.2020.11377; Yang Y, 2018, MOL CARCINOGEN, V57, P842, DOI 10.1002/mc.22805; Yin JL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16789-2; Ying M, 2011, ONCOGENE, V30, P3454, DOI 10.1038/onc.2011.58; Yu JM, 2007, CANCER LETT, V257, P172, DOI 10.1016/j.canlet.2007.07.011; Yu L, 2012, ONCOL REP, V27, P416, DOI 10.3892/or.2011.1481; Yu XL, 2021, EXP BIOL MED, V246, P20, DOI 10.1177/1535370220955139; Zeng Y, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.610661; Zhang L, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01589-8; Zhang XJ, 2018, TRENDS BIOCHEM SCI, V43, P1033, DOI 10.1016/j.tibs.2018.09.002; Zhang YK, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20182161; Zhang YH, 2017, ONCOL REP, V38, P1156, DOI 10.3892/or.2017.5728	52	3	3	3	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2021	40	32					5081	5094		10.1038/s41388-021-01922-2	http://dx.doi.org/10.1038/s41388-021-01922-2		JUN 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA7OD	34188250				2022-12-17	WOS:000668080200002
J	Melocchi, V; Dama, E; Mazzarelli, F; Cuttano, R; Colangelo, T; Di Candia, L; Lugli, E; Veronesi, G; Pelosi, G; Ferretti, GM; Taurchini, M; Graziano, P; Bianchi, F				Melocchi, Valentina; Dama, Elisa; Mazzarelli, Francesco; Cuttano, Roberto; Colangelo, Tommaso; Di Candia, Leonarda; Lugli, Enrico; Veronesi, Giulia; Pelosi, Giuseppe; Ferretti, Gian Maria; Taurchini, Marco; Graziano, Paolo; Bianchi, Fabrizio			Aggressive early-stage lung adenocarcinoma is characterized by epithelial cell plasticity with acquirement of stem-like traits and immune evasion phenotype	ONCOGENE			English	Article							INTRATUMORAL HETEROGENEITY; HEMATOPOIETIC STEM; GENE-EXPRESSION; IN-VITRO; CLASSIFICATION; METASTASIS; IDENTIFICATION; PROLIFERATION; PROGRESSION; ASSOCIATION	Lung adenocarcinoma (LUAD) is the main non-small-cell lung cancer diagnosed in similar to 40-50% of all lung cancer cases. Despite the improvements in early detection and personalized medicine, even a sizable fraction of patients with early-stage LUAD would experience disease relapses and adverse prognosis. Previous reports indicated the existence of LUAD molecular subtypes characterized by specific gene expression and mutational profiles, and correlating with prognosis. However, the biological and molecular features of such subtypes have not been further explored. Consequently, the mechanisms driving the emergence of aggressive LUAD remained unclear. Here, we adopted a multi-tiered approach ranging from molecular to functional characterization of LUAD and used it on multiple cohorts of patients (for a total of 1227 patients) and LUAD cell lines. We investigated the tumor transcriptome and the mutational and immune gene expression profiles, and we used LUAD cell lines for cancer cell phenotypic screening. We found that loss of lung cell lineage and gain of stem cell-like characteristics, along with mutator and immune evasion phenotypes, explain the aggressive behavior of a specific subset of lung adenocarcinoma that we called C1-LUAD, including early-stage disease. This subset can be identified using a 10-gene prognostic signature. Poor prognosis patients appear to have this specific molecular lung adenocarcinoma subtype which is characterized by peculiar molecular and biological features. Our data support the hypothesis that transformed lung stem/progenitor cells and/or reprogrammed epithelial cells with CSC characteristics are hallmarks of this aggressive disease. Such discoveries suggest alternative, more aggressive, therapeutic strategies for early-stage C1-LUAD.	[Melocchi, Valentina; Dama, Elisa; Mazzarelli, Francesco; Cuttano, Roberto; Colangelo, Tommaso; Bianchi, Fabrizio] Fdn IRCCS Casa Sollievo Sofferenza, Canc Biomarkers Unit, San Giovanni Rotondo, Italy; [Di Candia, Leonarda; Graziano, Paolo] Fdn IRCCS Casa Sollievo Sofferenza, Pathol Unit, San Giovanni Rotondo, Italy; [Lugli, Enrico] Humanitas Clin & Res Ctr IRCCS, Lab Translat Immunol, Milan, Italy; [Veronesi, Giulia] IRCCS San Raffaele Sci Inst, Div Thorac Surg, Milan, Italy; [Pelosi, Giuseppe] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy; [Pelosi, Giuseppe] IRCCS MultiMed, Interhosp Pathol Div, Milan, Italy; [Ferretti, Gian Maria; Taurchini, Marco] Fdn IRCCS Casa Sollievo Sofferenza, Thorac Surg Unit, San Giovanni Rotondo, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Milan; IRCCS Multimedica	Bianchi, F (corresponding author), Fdn IRCCS Casa Sollievo Sofferenza, Canc Biomarkers Unit, San Giovanni Rotondo, Italy.	f.bianchi@operapadrepio.it	Cuttano, Roberto/B-5884-2017; Bianchi, Fabrizio/W-7037-2019; Mazzarelli, Francesco/AAC-4749-2020; Graziano, Paolo/AAC-9802-2022; Lugli, Enrico/AAB-7933-2019; COLANGELO, TOMMASO/B-6119-2017; DAMA, ELISA/C-2709-2017; MELOCCHI, VALENTINA/B-5747-2017; Pelosi, Giuseppe/F-5073-2012	Cuttano, Roberto/0000-0003-4150-2114; Bianchi, Fabrizio/0000-0001-7412-8638; Mazzarelli, Francesco/0000-0002-9912-6820; Graziano, Paolo/0000-0001-7066-7896; Lugli, Enrico/0000-0002-1964-7678; COLANGELO, TOMMASO/0000-0002-6927-403X; DAMA, ELISA/0000-0001-6918-6577; MELOCCHI, VALENTINA/0000-0001-9656-3681; Pelosi, Giuseppe/0000-0003-4725-4692	Associazione Italiana Ricerca sul Cancro [MFAG-17568, IG-22827, IG-20676, 19548]; Italian Ministry of Health [GR-2016-02363975]; Umberto Veronesi Foundation; Pezcoller Foundation	Associazione Italiana Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health(Ministry of Health, Italy); Umberto Veronesi Foundation(Fondazione Umberto Veronesi); Pezcoller Foundation	We are grateful to Teresa Nittoli for technical assistance and Chiara Di Giorgio for critically editing the manuscript. This study was performed in accordance We are grateful to Teresa Nittoli for technical assistance and Chiara Di Giorgio for critically editing the manuscript. This study was performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the Fondazione IRCCS Casa Sollievo della Sofferenza (ref. number: BIO-POLMONE - V1.0_08 Giu 16). All authors gave their consent to publication. The gene expression data used in this study are publicly available as indicated in the "Methods" and Supplementary Information sections. This work was supported by the Associazione Italiana Ricerca sul Cancro [MFAG-17568 and IG-22827 to FB; IG-20676 to EL], the Italian Ministry of Health [GR-2016-02363975 and CLEARLY to FB]. RC was supported by a fellowship from the Umberto Veronesi Foundation and the Pezcoller Foundation. TC was supported by a fellowship from the Associazione Italiana Ricerca sul Cancro (#19548) and the Umberto Veronesi Foundation.with the Declaration of Helsinki and was approved by the Ethics Committee of the Fondazione IRCCS Casa Sollievo della Sofferenza (ref. number: BIO-POLMONE - V1.0_08 Giu 16). All authors gave their consent to publication. The gene expression data used in this study are publicly available as indicated in the "Methods" and Supplementary Information sections. This work was supported by the Associazione Italiana Ricerca sul Cancro [MFAG-17568 and IG-22827 to FB; IG-20676 to EL], the Italian Ministry of Health [GR-2016-02363975 and CLEARLY to FB]. RC was supported by a fellowship from the Umberto Veronesi Foundation and the Pezcoller Foundation. TC was supported by a fellowship from the Associazione Italiana Ricerca sul Cancro (#19548) and the Umberto Veronesi Foundation.	Aberle DR, 2011, NEW ENGL J MED, V365, P395, DOI 10.1056/NEJMoa1102873; Alexandrov LB, 2020, NATURE, V578, P94, DOI 10.1038/s41586-020-1943-3; Alvisi G, 2020, J CLIN INVEST, V130, P3137, DOI 10.1172/JCI130426; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bianchi F, 2007, J CLIN INVEST, V117, P3436, DOI 10.1172/JCI32007; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bremnes RM, 2016, J THORAC ONCOL, V11, P789, DOI 10.1016/j.jtho.2016.01.015; Bryant CM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011712; Burkholder B, 2014, BBA-REV CANCER, V1845, P182, DOI 10.1016/j.bbcan.2014.01.004; Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]; Care A, 1999, ONCOGENE, V18, P1993, DOI 10.1038/sj.onc.1202498; Chen F, 2017, ONCOGENE, V36, P1384, DOI 10.1038/onc.2016.303; Cheung WKC, 2015, ONCOGENE, V34, P5771, DOI 10.1038/onc.2015.85; Dama E, 2017, CLIN CANCER RES, V23, P62, DOI 10.1158/1078-0432.CCR-15-3005; de Bruin EC, 2014, SCIENCE, V346, P251, DOI 10.1126/science.1253462; de Koning HJ, 2020, NEW ENGL J MED, V382, P503, DOI 10.1056/NEJMoa1911793; Devarakonda S, 2015, LANCET ONCOL, V16, pE342, DOI 10.1016/S1470-2045(15)00077-7; Dolatshad H, 2015, LEUKEMIA, V29, P1092, DOI [10.1038/leu.2014.331, 10.1038/leu.2015.178]; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Fares J, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0134-x; Ferone G, 2016, CANCER CELL, V30, P519, DOI 10.1016/j.ccell.2016.09.001; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Grindel BJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25435-3; Han B, 2018, AM J CANCER RES, V8, P810; Jaillon S, 2020, NAT REV CANCER, V20, P485, DOI 10.1038/s41568-020-0281-y; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Kumar PA, 2011, CELL, V147, P525, DOI 10.1016/j.cell.2011.10.001; Lu HH, 2014, NAT CELL BIOL, V16, P1105, DOI 10.1038/ncb3041; Marjanovic ND, 2020, CANCER CELL, V38, P229, DOI 10.1016/j.ccell.2020.06.012; McCauley KB, 2018, STEM CELL REP, V10, P1579, DOI 10.1016/j.stemcr.2018.03.013; Miranda A, 2019, P NATL ACAD SCI USA, V116, P9020, DOI 10.1073/pnas.1818210116; Moises J, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-017-0542-z; Monterisi S, 2018, ONCOGENE, V37, P3575, DOI 10.1038/s41388-018-0229-9; Nazarov PV, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3819-y; Okayama H, 2012, CANCER RES, V72, P100, DOI 10.1158/0008-5472.CAN-11-1403; Orkin SH, 2011, CELL, V145, P835, DOI 10.1016/j.cell.2011.05.019; Prasetyanti PR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0600-4; Pribluda A, 2015, CLIN CANCER RES, V21, P2916, DOI 10.1158/1078-0432.CCR-14-1213; Reynolds SD, 2002, AM J RESP CRIT CARE, V166, P1498, DOI 10.1164/rccm.200204-285OC; Richards CH, 2011, FUTURE ONCOL, V7, P1223, DOI [10.2217/fon.11.99, 10.2217/FON.11.99]; Schabath MB, 2016, ONCOGENE, V35, P3209, DOI 10.1038/onc.2015.375; Schoenfeld A, 2020, CLIN CANCER RES, V26, P5701, DOI 10.1158/1078-0432.CCR-20-1825; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sonzogni A, 2017, J PATHOL CLIN RES, V3, P139, DOI 10.1002/cjp2.67; Staempfli MR, 2009, NAT REV IMMUNOL, V9, P377, DOI 10.1038/nri2530; Swanton C, 2015, CANCER DISCOV, V5, P704, DOI 10.1158/2159-8290.CD-15-0344; Takeuchi T, 2006, J CLIN ONCOL, V24, P1679, DOI 10.1200/JCO.2005.03.8224; Tammela T, 2017, NATURE, V545, P355, DOI 10.1038/nature22334; Tata PR, 2018, DEV CELL, V44, P679, DOI 10.1016/j.devcel.2018.02.024; Tate JG, 2019, NUCLEIC ACIDS RES, V47, pD941, DOI 10.1093/nar/gky1015; Thorsson V, 2018, IMMUNITY, V48, P812, DOI 10.1016/j.immuni.2018.03.023; Tian CX, 2020, CANCER RES, V80, P1461, DOI 10.1158/0008-5472.CAN-19-2578; Tokheim C, 2019, CELL SYST, V9, P9, DOI 10.1016/j.cels.2019.05.005; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Wolf J, 2020, NEW ENGL J MED, V383, P944, DOI 10.1056/NEJMoa2002787; Xu NZ, 2019, J HISTOCHEM CYTOCHEM, V67, P453, DOI 10.1369/0022155419829050; Yan XP, 2013, ONCOL REP, V30, P2733, DOI 10.3892/or.2013.2784; Yatabe Y, 2002, AM J SURG PATHOL, V26, P767, DOI 10.1097/00000478-200206000-00010; Yu H, 2016, J THORAC ONCOL, V11, P964, DOI 10.1016/j.jtho.2016.04.014; Zhang JJ, 2014, SCIENCE, V346, P256, DOI 10.1126/science.1256930; Zuo W, 2015, NATURE, V517, P616, DOI 10.1038/nature13903	62	3	3	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2021	40	31					4980	4991		10.1038/s41388-021-01909-z	http://dx.doi.org/10.1038/s41388-021-01909-z		JUN 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV5MG	34172935				2022-12-17	WOS:000667016100001
J	Wu, Y; Guo, QH; Ju, XZ; Hu, ZX; Xia, LF; Deng, Y; Zhao, P; Zhang, M; Shao, Y; Huang, SL; He, XH; Wen, H; Wu, XH				Wu, Yong; Guo, Qinhao; Ju, Xingzhu; Hu, Zhixiang; Xia, Lingfang; Deng, Yu; Zhao, Ping; Zhang, Meng; Shao, Yang; Huang, Shenglin; He, Xianghuo; Wen, Hao; Wu, Xiaohua			HNRNPH1-stabilized LINC00662 promotes ovarian cancer progression by activating the GRP78/p38 pathway	ONCOGENE			English	Article							NONCODING RNAS; PROTEINS; METASTASIS; BINDING; AXIS	Numerous studies suggest an important role for copy number alterations (CNAs) in cancer progression. However, CNAs of long intergenic noncoding RNAs (lincRNAs) in ovarian cancer (OC) and their potential functions have not been fully investigated. Here, based on analysis of The Cancer Genome Atlas (TCGA) database, we identified in this study an oncogenic lincRNA termed LINC00662 that exhibited a significant correlation between its CNA and its increased expression. LINC00662 overexpression is highly associated with malignant features in OC patients and is a prognostic indicator. LINC00662 significantly promotes OC cell proliferation and metastasis in vitro and in vivo. Mechanistically, LINC00662 is stabilized by heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1). Moreover, LINC00662 exerts oncogenic effects by interacting with glucose-regulated protein 78 (GRP78) and preventing its ubiquitination in OC cells, leading to activation of the oncogenic p38 MAPK signaling pathway. Taken together, our results define an oncogenic role for LINC00662 in OC progression mediated via GRP78/p38 signaling, with potential implications regarding therapeutic targets for OC.	[Wu, Yong; Guo, Qinhao; Ju, Xingzhu; Xia, Lingfang; Wen, Hao; Wu, Xiaohua] Fudan Univ, Dept Gynecol Oncol, Shanghai Canc Ctr, Shanghai 200032, Peoples R China; [Wu, Yong; Guo, Qinhao; Ju, Xingzhu; Xia, Lingfang; Zhang, Meng; Wen, Hao; Wu, Xiaohua] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Hu, Zhixiang; Huang, Shenglin; He, Xianghuo] Fudan Univ, Shanghai Canc Ctr, Inst Biomed Sci, Key Lab Med Epigenet & Metab, Shanghai 200032, Peoples R China; [Hu, Zhixiang; Shao, Yang; Huang, Shenglin; He, Xianghuo; Wu, Xiaohua] Fudan Univ, Canc Inst, Shanghai Canc Ctr, Shanghai 200032, Peoples R China; [Deng, Yu] Zhejiang Univ, Affiliated Hosp 1, Dept Pathol, Sch Med, Hangzhou 310000, Peoples R China; [Zhao, Ping] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Pathol, Sch Med, Shanghai 200001, Peoples R China; [Zhang, Meng; Shao, Yang] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai 200032, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University; Zhejiang University; Shanghai Jiao Tong University; Fudan University	Wen, H; Wu, XH (corresponding author), Fudan Univ, Dept Gynecol Oncol, Shanghai Canc Ctr, Shanghai 200032, Peoples R China.; Wen, H; Wu, XH (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.; Wu, XH (corresponding author), Fudan Univ, Canc Inst, Shanghai Canc Ctr, Shanghai 200032, Peoples R China.	wenhao_fdc@163.com; wu.xh@fudan.edu.cn	He, Xianghuo/I-1497-2014; Shao, Yang/AAH-1251-2020	He, Xianghuo/0000-0001-8872-668X; Shao, Yang/0000-0002-3239-4265	National Natural Science Foundation of China [81972431, 81902641, 82002747, 82002500]; Shanghai Sailing Program [20YF1408000]; Shanghai Anticancer Association EYAS PROJECT [SACA-CY19A07]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Sailing Program; Shanghai Anticancer Association EYAS PROJECT	This work was supported by grants from the National Natural Science Foundation of China (no. 81972431, 81902641, 82002747, 82002500), the Shanghai Sailing Program (no. 20YF1408000), and the Shanghai Anticancer Association EYAS PROJECT (no. SACA-CY19A07).	Andor N, 2017, CANCER RES, V77, P2179, DOI 10.1158/0008-5472.CAN-16-1553; Bailly C, 2019, BIOCHEM PHARMACOL, V163, P269, DOI 10.1016/j.bcp.2019.02.038; Beermann J, 2016, PHYSIOL REV, V96, P1297, DOI 10.1152/physrev.00041.2015; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bertone-Johnson ER, 2005, LANCET, V365, P101, DOI 10.1016/S0140-6736(05)17716-2; Bowtell DD, 2015, NAT REV CANCER, V15, P668, DOI 10.1038/nrc4019; Cao W, 2017, ORAL ONCOL, V65, P94, DOI 10.1016/j.oraloncology.2016.12.017; Cao XL, 2020, GENES GENOM, V42, P1361, DOI 10.1007/s13258-020-01001-y; Cerezo M, 2016, CANCER CELL, V29, P805, DOI 10.1016/j.ccell.2016.04.013; Chang YW, 2016, ONCOGENE, V35, P1517, DOI 10.1038/onc.2015.214; Cheng B, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-019-1510-7; Chu LZ, 2019, AGING-US, V11, P1456, DOI 10.18632/aging.101845; Cohen M, 2011, CANCER LETT, V309, P104, DOI 10.1016/j.canlet.2011.05.022; Decorsiere A, 2011, GENE DEV, V25, P220, DOI 10.1101/gad.607011; Diederichs S, 2016, EMBO MOL MED, V8, P442, DOI 10.15252/emmm.201506055; Du TD, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10824-7; Garneau D, 2005, J BIOL CHEM, V280, P22641, DOI 10.1074/jbc.M501070200; Gong WJ, 2018, J BIOCHEM, V164, P461, DOI 10.1093/jb/mvy078; Grammatikakis I, 2016, CELL REP, V15, P926, DOI 10.1016/j.celrep.2016.03.080; Grohar PJ, 2016, CELL REP, V14, P598, DOI 10.1016/j.celrep.2015.12.063; Guo T, 2020, CELL DEATH DIFFER, V27, P2191, DOI 10.1038/s41418-020-0494-3; Guo T, 2019, AGING-US, V11, P4890, DOI 10.18632/aging.102082; Indovina P, 2017, J CELL PHYSIOL, V232, P129, DOI 10.1002/jcp.25397; Jonas K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082969; Karst AM, 2014, CANCER RES, V74, P1141, DOI 10.1158/0008-5472.CAN-13-2247; Kneissig M, 2019, CURR OPIN GENET DEV, V54, P25, DOI 10.1016/j.gde.2019.02.005; Lauer S, 2019, CURR GENET, V65, P1287, DOI 10.1007/s00294-019-00980-0; Lheureux S, 2019, CA-CANCER J CLIN, V69, P280, DOI 10.3322/caac.21559; Li ZN, 2020, ORAL ONCOL, V103, DOI 10.1016/j.oraloncology.2020.104591; Liu Z, 2018, BIOCHEM BIOPH RES CO, V505, P843, DOI 10.1016/j.bbrc.2018.09.191; Marchese FP, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1348-2; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; Ransohoff JD, 2018, NAT REV MOL CELL BIO, V19, P143, DOI 10.1038/nrm.2017.104; Ried T, 2019, MOL ASPECTS MED, V69, P48, DOI 10.1016/j.mam.2019.07.007; Shaker OG, 2019, IUBMB LIFE, V71, P1322, DOI 10.1002/iub.2039; Shishkin SS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030745; Sun LL, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00137; Tan SS, 2011, J PATHOL, V223, P81, DOI 10.1002/path.2795; Thornton M, 2013, INT J CANCER, V133, P1408, DOI 10.1002/ijc.28137; Tian XH, 2020, MOL ONCOL, V14, P462, DOI 10.1002/1878-0261.12606; Topp MD, 2014, MOL ONCOL, V8, P656, DOI 10.1016/j.molonc.2014.01.008; Turunen JJ, 2013, RNA, V19, P380, DOI 10.1261/rna.036715.112; Wang HM, 2020, FRONT GENET, V10, DOI 10.3389/fgene.2019.01385; Watanabe T, 2009, MOL CANCER RES, V7, P1582, DOI 10.1158/1541-7786.MCR-09-0064; Xu D, 2019, CANCERS, V11, DOI 10.3390/cancers11101502; Zhao S, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1401-z; Zong L, 2019, ONCOGENE, V38, P5281, DOI 10.1038/s41388-019-0792-8	47	3	3	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2021	40	29					4770	4782		10.1038/s41388-021-01884-5	http://dx.doi.org/10.1038/s41388-021-01884-5		JUN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR9TO	34148056	Green Published, hybrid			2022-12-17	WOS:000663492900001
J	Shen, MQ; Zhang, RX; Jia, WZ; Zhu, ZP; Zhao, XP; Zhao, L; Huang, G; Liu, JJ				Shen, Mengqin; Zhang, Ruixue; Jia, Wenzhi; Zhu, Zongping; Zhao, Xiaoping; Zhao, Li; Huang, Gang; Liu, Jianjun			Nuclear scaffold protein p54(nrb)/NONO facilitates the hypoxia-enhanced progression of hepatocellular carcinoma	ONCOGENE			English	Article							LONG NONCODING RNA; LACTATE-DEHYDROGENASE; LUNG-CANCER; NONO; GROWTH	Hypoxia and related oxidative stress are closely related to the development and treatment of hepatocellular carcinoma (HCC). However, the mechanism mediated by hypoxia in HCC has not yet been elucidated. Here, we found multifunction scaffold protein p54(nrb)/NONO exerted pleiotropic effects to regulate hypoxia transcription signals, thereby enhancing the progression of liver cancer. Extensive analysis of clinical data demonstrated that NONO was significantly upregulated and represented as a poor prognostic indicator of HCC. The crucial role of NONO in driving angiogenesis and glycolysis, two well-known cancer phenotypes mediated by hypoxia, was examined in vitro an in vivo. Mechanistically, NONO interacted with and stabilized both HIF-1 and HIF-2 complexes thus activating the transcription of hypoxia-induced genes. Besides, NONO bound pre-mRNA and subsequent mRNA of these genes to facilitate them splicing and mRNA stability, respectively. Thus, NONO knockout seriously disrupted the expression of a cluster of HIF-1/2 targets and impeded hypoxia-enhanced progression in HCC. In conclusion, NONO functioned as a multipurpose scaffold that interacted with HIF-1/2 complex and their downstream transcripts to facilitate the expression of hypoxia-induced genes, allowing malignant proliferation, indicating that NONO might be a potential therapeutic target for HCC.	[Shen, Mengqin; Zhang, Ruixue; Jia, Wenzhi; Zhao, Xiaoping; Zhao, Li; Huang, Gang; Liu, Jianjun] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Inst Clin Nucl Med,Dept Nucl Med, Shanghai 200127, Peoples R China; [Zhu, Zongping] Qingdao Municipal Hosp Grp, Dept Nucl Med, Qingdao 266011, Peoples R China; [Huang, Gang] Shanghai Univ Med & Hlth Sci, Shanghai Key Lab Mol Imaging, Shanghai 201318, Peoples R China; [Liu, Jianjun] Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, Shanghai 200127, Peoples R China	Shanghai Jiao Tong University; Qingdao Municipal Hospital; Shanghai University of Medicine & Health Sciences; Shanghai Jiao Tong University	Huang, G; Liu, JJ (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Inst Clin Nucl Med,Dept Nucl Med, Shanghai 200127, Peoples R China.; Huang, G (corresponding author), Shanghai Univ Med & Hlth Sci, Shanghai Key Lab Mol Imaging, Shanghai 201318, Peoples R China.; Liu, JJ (corresponding author), Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, Shanghai 200127, Peoples R China.	huanggang2245@163.com; RInuclear@126.com		Huang, Gang/0000-0002-9245-1276	National Natural Science Foundation of China [81771858, 81530053, 81601524]; Shanghai Key Laboratory of Molecular Imaging [18DZ2260400]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Key Laboratory of Molecular Imaging	This study was supported by grants from the National Natural Science Foundation of China (81771858, 81530053, 81601524) and Shanghai Key Laboratory of Molecular Imaging (18DZ2260400).	Albadari N, 2019, EXPERT OPIN DRUG DIS, V14, P667, DOI 10.1080/17460441.2019.1613370; Benegiamo G, 2018, CELL METAB, V27, P404, DOI 10.1016/j.cmet.2017.12.010; Choudhry H, 2015, ONCOGENE, V34, P4482, DOI 10.1038/onc.2014.378; Custodio N, 2016, CRIT REV BIOCHEM MOL, V51, P395, DOI 10.1080/10409238.2016.1230086; DONG BH, 1993, NUCLEIC ACIDS RES, V21, P4085, DOI 10.1093/nar/21.17.4085; Feng PF, 2020, J CELL MOL MED, V24, P4368, DOI 10.1111/jcmm.15141; Fox AH, 2018, TRENDS BIOCHEM SCI, V43, P124, DOI 10.1016/j.tibs.2017.12.001; Hao XJ, 2013, HEPATOB PANCREAT DIS, V12, P617, DOI 10.1016/S1499-3872(13)60097-1; Hayashi Y, 2019, CANCER SCI, V110, P1510, DOI 10.1111/cas.13990; Hirose T, 2019, WIRES RNA, V10, DOI 10.1002/wrna.1545; Hu ZX, 2020, HEPATOLOGY, V72, P548, DOI 10.1002/hep.31062; Hua Q, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0773-y; Huang YH, 2016, CANCER RES, V76, P1549, DOI 10.1158/0008-5472.CAN-15-2073; Ippolito D, 2014, EUR J RADIOL, V83, P1665, DOI 10.1016/j.ejrad.2014.05.040; Jankowsky E, 2015, NAT REV MOL CELL BIO, V16, P533, DOI 10.1038/nrm4032; Jungermann K, 2000, HEPATOLOGY, V31, P255, DOI 10.1002/hep.510310201; Kessler Sonja M, 2019, Cell Physiol Biochem, V52, P787, DOI 10.33594/000000055; Kim SJ, 2020, THERANOSTICS, V10, P7974, DOI 10.7150/thno.45037; Knott GJ, 2016, NUCLEIC ACIDS RES, V44, P3989, DOI 10.1093/nar/gkw271; Lapenta F, 2018, CHEM SOC REV, V47, P3530, DOI 10.1039/c7cs00822h; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Mendez-Blanco C, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0159-1; Nobre AR, 2018, TRENDS CELL BIOL, V28, P941, DOI 10.1016/j.tcb.2018.06.008; Onodera T, 2019, CHEM PHARM BULL, V67, P186, DOI 10.1248/cpb.c18-00767; Pavao M, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-15; Pereira B, 2017, TRENDS CANCER, V3, P506, DOI 10.1016/j.trecan.2017.05.003; Qin H, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00927-w; Roos M, 2016, ACS CHEM BIOL, V11, P2773, DOI 10.1021/acschembio.6b00232; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 2014, ANNU REV PATHOL-MECH, V9, P47, DOI 10.1146/annurev-pathol-012513-104720; Severi T, 2010, ACTA PHARMACOL SIN, V31, P1409, DOI 10.1038/aps.2010.142; Shen MQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0839-4; Shibuya K, 2015, ONCOTARGET, V6, P651, DOI 10.18632/oncotarget.2892; Tang WD, 2020, BIOORGAN MED CHEM, V28, DOI 10.1016/j.bmc.2019.115235; Wang Y, 2009, NAT METHODS, V6, P825, DOI [10.1038/NMETH.1379, 10.1038/nmeth.1379]; Wu XQ, 2015, ACS CHEM BIOL, V10, P1476, DOI 10.1021/cb500851u; Xie H, 2014, CELL METAB, V19, P795, DOI 10.1016/j.cmet.2014.03.003; Xie RH, 2021, MOL THER, V29, P291, DOI 10.1016/j.ymthe.2020.08.018; Xiong XX, 2017, MOL PHARMACOL, V92, P246, DOI 10.1124/mol.116.107706; Yang JD, 2019, NAT REV GASTRO HEPAT, V16, P589, DOI 10.1038/s41575-019-0186-y; Zhu Z, 2016, ONCOGENE, V35, P1399, DOI 10.1038/onc.2015.197	41	3	3	3	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2021	40	24					4167	4183		10.1038/s41388-021-01848-9	http://dx.doi.org/10.1038/s41388-021-01848-9		JUN 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SU3OE	34079086	Green Published, hybrid			2022-12-17	WOS:000657217400003
J	Carotti, S; Zingariello, M; Francesconi, M; D'Andrea, L; Latasa, MU; Colyn, L; Fernandez-Barrena, MG; Flammia, RS; Falchi, M; Righi, D; Pedini, G; Pantano, F; Bagni, C; Perrone, G; Rana, RA; Avila, MA; Morini, S; Zalfa, F				Carotti, Simone; Zingariello, Maria; Francesconi, Maria; D'Andrea, Laura; Latasa, M. Ujue; Colyn, Leticia; Fernandez-Barrena, Maite G.; Flammia, Rocco Simone; Falchi, Mario; Righi, Daniela; Pedini, Giorgia; Pantano, Francesco; Bagni, Claudia; Perrone, Giuseppe; Rana, Rosa Alba; Avila, Matias A.; Morini, Sergio; Zalfa, Francesca			Fragile X mental retardation protein in intrahepatic cholangiocarcinoma: regulating the cancer cell behavior plasticity at the leading edge	ONCOGENE			English	Article							MESSENGER-RNA TRANSPORT; HEPATOCELLULAR-CARCINOMA; MYOSIN VA; FMRP; TRANSLATION; METASTASIS; EXPRESSION; ACTIN; IDENTIFICATION; ESTABLISHMENT	Intrahepatic cholangiocarcinoma (iCCA) is a rare malignancy of the intrahepatic biliary tract with a very poor prognosis. Although some clinicopathological parameters can be prognostic factors for iCCA, the molecular prognostic markers and potential mechanisms of iCCA have not been well investigated. Here, we report that the Fragile X mental retardation protein (FMRP), a RNA binding protein functionally absent in patients with the Fragile X syndrome (FXS) and also involved in several types of cancers, is overexpressed in human iCCA and its expression is significantly increased in iCCA metastatic tissues. The silencing of FMRP in metastatic iCCA cell lines affects cell migration and invasion, suggesting a role of FMRP in iCCA progression. Moreover, we show evidence that FMRP is localized at the invasive front of human iCCA neoplastic nests and in pseudopodia and invadopodia protrusions of migrating and invading iCCA cancer cells. Here FMRP binds several mRNAs encoding key proteins involved in the formation and/or function of these protrusions. In particular, we find that FMRP binds to and regulates the expression of Cortactin, a critical regulator of invadopodia formation. Altogether, our findings suggest that FMRP could promote cell invasiveness modulating membrane plasticity and invadopodia formation at the leading edges of invading iCCA cells.	[Carotti, Simone; Zingariello, Maria; Francesconi, Maria; D'Andrea, Laura; Flammia, Rocco Simone; Morini, Sergio; Zalfa, Francesca] Campus Biomed Univ, Dept Med, Res Unit Microscop & Ultrastruct Anat, Rome, Italy; [Carotti, Simone; Righi, Daniela; Perrone, Giuseppe; Zalfa, Francesca] Campus Biomed Univ Hosp, Dept Pathol, Predict Mol Diagnost Unit, Rome, Italy; [Latasa, M. Ujue; Colyn, Leticia; Fernandez-Barrena, Maite G.; Avila, Matias A.] Univ Navarra, Hepatol Program, Ctr Appl Med Res CIMA, Pamplona, Spain; [Latasa, M. Ujue; Colyn, Leticia; Fernandez-Barrena, Maite G.; Avila, Matias A.] IdiSNA, Pamplona, Spain; [Fernandez-Barrena, Maite G.] Ctr Investigac Biomed Red Enfermedades Hepat & Di, Madrid, Spain; [Falchi, Mario] Ist Super Sanita, Natl AIDS Ctr, Rome, Italy; [Pedini, Giorgia; Bagni, Claudia] Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy; [Pantano, Francesco] Campus Biomed Univ, Med Oncol Dept, Rome, Italy; [Bagni, Claudia] Univ Lausanne, Dept Fundamental Neurosci, Lausanne, Switzerland; [Perrone, Giuseppe] Campus Biomed Univ, Res Unit Pathol, Rome, Italy; [Rana, Rosa Alba] Univ G DAnnunzio, Med & Aging Sci Dept, Chieti, Italy	University Campus Bio-Medico - Rome Italy; University Campus Bio-Medico - Rome Italy; University of Navarra; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; Istituto Superiore di Sanita (ISS); University of Rome Tor Vergata; University Campus Bio-Medico - Rome Italy; University of Lausanne; University Campus Bio-Medico - Rome Italy; G d'Annunzio University of Chieti-Pescara	Morini, S; Zalfa, F (corresponding author), Campus Biomed Univ, Dept Med, Res Unit Microscop & Ultrastruct Anat, Rome, Italy.; Zalfa, F (corresponding author), Campus Biomed Univ Hosp, Dept Pathol, Predict Mol Diagnost Unit, Rome, Italy.	s.morini@unicampus.it; f.zalfa@unicampus.it	Flammia, Rocco Simone/ABC-2869-2021; Pantano, Francesco/D-8459-2012; Morini, Sergio/AAB-8540-2022; Perrone, Giuseppe/GLR-7098-2022; Avila, Matias A/Y-6342-2019	Flammia, Rocco Simone/0000-0002-3129-0544; Pantano, Francesco/0000-0002-2894-9686; Morini, Sergio/0000-0001-6137-2404; Avila, Matias A/0000-0001-6570-3557; Bagni, Claudia/0000-0002-4419-210X; D'Andrea, Laura/0000-0002-2042-9782; Colyn, Leticia/0000-0002-7403-9149; Falchi, Mario/0000-0002-8290-5406	FIRB 2010 funds [RBAP10447J_005]; Pathology Dept. and Predictive Molecular Diagnostic Division funds; Hepacare Project from Fundacion La Caixa; AECC Grant for Rare and Childhood cancers from Instituto de Salud Carlos III [FIS PI16/01126]; Gobierno de Navarra Salud [58/17]; FEDER/Ministerio de Ciencia, Innovacion y Universidades-Agencia Estatal de Investigacion [PID2019-104878RB-100/AEI/10.13039/501100011033]; Fundacion Eugenio Rodriguez Pascual; Italian Fragile X Association; PRIN2017 89LFKB; Etat de Vaud	FIRB 2010 funds; Pathology Dept. and Predictive Molecular Diagnostic Division funds; Hepacare Project from Fundacion La Caixa; AECC Grant for Rare and Childhood cancers from Instituto de Salud Carlos III; Gobierno de Navarra Salud; FEDER/Ministerio de Ciencia, Innovacion y Universidades-Agencia Estatal de Investigacion; Fundacion Eugenio Rodriguez Pascual; Italian Fragile X Association; PRIN2017 89LFKB; Etat de Vaud	This research was supported by FIRB 2010 funds (RBAP10447J_005) to RAR, by Pathology Dept. and Predictive Molecular Diagnostic Division funds to GP, by private funds to SM and by Hepacare Project from Fundacion La Caixa, AECC Grant for Rare and Childhood cancers 2017 call, grant FIS PI16/01126 from Instituto de Salud Carlos III, grant 58/17 from Gobierno de Navarra Salud, grant PID2019-104878RB-100/AEI/10.13039/501100011033 from FEDER/Ministerio de Ciencia, Innovacion y Universidades-Agencia Estatal de Investigacion, and Fundacion Eugenio Rodriguez Pascual to MAA and MGF-B. MGF-B is a Ramon y Cajal Fellow (RYC2018-00244475-1) and LC is a predoctoral fellow of the Gobierno de Navarra. GP was supported by the Italian Fragile X Association and PRIN2017 89LFKB and Etat de Vaud to CB. We thank Franca Abbruzzese for technical help with time lapse confocal acquisitions and Prof. R. Suzanne Zukin for the plasmid expressing human FMRP.	Arjonen A, 2011, CELL ADHES MIGR, V5, P421, DOI 10.4161/cam.5.5.17723; Ascano M, 2012, NATURE, V492, P382, DOI 10.1038/nature11737; Bagni C, 2019, NEURON, V101, P1070, DOI 10.1016/j.neuron.2019.02.041; Bagni C, 2013, AM J MED GENET A, V161, P2809, DOI 10.1002/ajmg.a.36241; Bagni C, 2012, J CLIN INVEST, V122, P4314, DOI 10.1172/JCI63141; Banales JM, 2016, NAT REV GASTRO HEPAT, V13, P261, DOI 10.1038/nrgastro.2016.51; Barcena-Varela M, 2019, HEPATOLOGY, V69, P587, DOI 10.1002/hep.30168; Beaty BT, 2014, EUR J CELL BIOL, V93, P438, DOI 10.1016/j.ejcb.2014.07.003; Bell JL, 2013, CELL MOL LIFE SCI, V70, P2657, DOI 10.1007/s00018-012-1186-z; Bhakar AL, 2012, ANNU REV NEUROSCI, V35, P417, DOI 10.1146/annurev-neuro-060909-153138; Bhogal B, 2011, NAT NEUROSCI, V14, P1517, DOI 10.1038/nn.2950; Bravo-Cordero JJ, 2012, CURR OPIN CELL BIOL, V24, P277, DOI 10.1016/j.ceb.2011.12.004; Chen WT, 1999, ANN NY ACAD SCI, V878, P361, DOI 10.1111/j.1749-6632.1999.tb07695.x; Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872; Clements O, 2020, J HEPATOL, V72, P95, DOI 10.1016/j.jhep.2019.09.007; D'Hulst C, 2006, BRAIN RES, V1121, P238, DOI 10.1016/j.brainres.2006.08.115; Darnell JC, 2011, CELL, V146, P247, DOI 10.1016/j.cell.2011.06.013; Davidovic L, 2007, HUM MOL GENET, V16, P3047, DOI 10.1093/hmg/ddm263; De Rubeis S, 2010, MOL CELL NEUROSCI, V43, P43, DOI 10.1016/j.mcn.2009.09.013; Di Grazia A., 2020, CELL MOL GASTROENTER, V20, P30172; Dianat N, 2014, HEPATOLOGY, V60, P700, DOI 10.1002/hep.27165; Dictenberg JB, 2008, DEV CELL, V14, P926, DOI 10.1016/j.devcel.2008.04.003; Didiot MC, 2008, NUCLEIC ACIDS RES, V36, P4902, DOI 10.1093/nar/gkn472; Eddy RJ, 2017, TRENDS CELL BIOL, V27, P595, DOI 10.1016/j.tcb.2017.03.003; Elizalde M, 2014, J CLIN INVEST, V124, P2909, DOI 10.1172/JCI74382; Ferrari F, 2007, MOL CELL NEUROSCI, V34, P343, DOI 10.1016/j.mcn.2006.11.015; Filippini A, 2017, RNA BIOL, V14, P1580, DOI 10.1080/15476286.2017.1338232; Gkogkas CG, 2014, CELL REP, V9, P1742, DOI 10.1016/j.celrep.2014.10.064; Gross C, 2012, NEUROPSYCHOPHARMACOL, V37, P178, DOI 10.1038/npp.2011.137; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Insall RH, 2009, DEV CELL, V17, P310, DOI 10.1016/j.devcel.2009.08.012; Janusz A, 2013, J NEUROSCI, V33, P18234, DOI 10.1523/JNEUROSCI.2207-13.2013; Kalkunte R, 2007, ARCH DIS CHILD, V92, P795, DOI 10.1136/adc.2006.103382; Kao DI, 2010, P NATL ACAD SCI USA, V107, P15601, DOI 10.1073/pnas.1010564107; Kurokawa Y, 2003, J HEPATOL, V39, P1004, DOI 10.1016/S0168-8278(03)00473-2; KUSAKA Y, 1988, RES EXP MED, V188, P367, DOI 10.1007/BF01851205; Li L, 2018, CANCER CELL, V33, P736, DOI 10.1016/j.ccell.2018.02.011; Li Y, 2003, J CANCER RES CLIN, V129, P43, DOI 10.1007/s00432-002-0396-4; Liao GN, 2015, WIRES RNA, V6, P1, DOI 10.1002/wrna.1265; Lindsay AJ, 2014, BIOL CELL, V106, P57, DOI 10.1111/boc.201200076; Liu YF, 2007, ONCOL REP, V18, P943; Luca R, 2013, EMBO MOL MED, V5, P1523, DOI 10.1002/emmm.201302847; MacGrath SM, 2012, J CELL SCI, V125, P1621, DOI 10.1242/jcs.093781; Maurin T, 2018, NUCLEIC ACIDS RES, V46, P6344, DOI 10.1093/nar/gky267; Mavros MN, 2014, JAMA SURG, V149, P565, DOI 10.1001/jamasurg.2013.5137; Mili S, 2008, NATURE, V453, P115, DOI 10.1038/nature06888; Miyashiro KY, 2003, NEURON, V37, P417, DOI 10.1016/S0896-6273(03)00034-5; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Napoli I, 2008, CELL, V134, P1042, DOI 10.1016/j.cell.2008.07.031; Ohashi S, 2002, J BIOL CHEM, V277, P37804, DOI 10.1074/jbc.M203608200; Pollard TD, 2009, SCIENCE, V326, P1208, DOI 10.1126/science.1175862; Ridley AJ, 2011, CELL, V145, P1012, DOI 10.1016/j.cell.2011.06.010; Rizvi S, 2018, NAT REV CLIN ONCOL, V15, P95, DOI 10.1038/nrclinonc.2017.157; Rizvi S, 2017, J HEPATOL, V67, P632, DOI 10.1016/j.jhep.2017.03.026; Schaeffer C, 2001, EMBO J, V20, P4803, DOI 10.1093/emboj/20.17.4803; Schultz-Pedersen S, 2001, AM J MED GENET, V103, P226, DOI 10.1002/ajmg.1533; Sidhu H, 2014, J NEUROSCI, V34, P9867, DOI 10.1523/JNEUROSCI.1162-14.2014; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; Sirica AE, 2019, HEPATOLOGY, V69, P1803, DOI 10.1002/hep.30289; Srivastava A, 2015, FEBS OPEN BIO, V5, P705, DOI 10.1016/j.fob.2015.07.005; Stumpf CR, 2011, CURR OPIN GENET DEV, V21, P474, DOI 10.1016/j.gde.2011.03.007; Taniuchi K, 2014, ONCOTARGET, V5, P6832, DOI 10.18632/oncotarget.2257; Vikesaa J, 2006, EMBO J, V25, P1456, DOI 10.1038/sj.emboj.7601039; Vira VA., 2009, EXTRACELL MATRIX PRO, V522, P211, DOI [10.1007/978-1-59745-413-1_15, DOI 10.1007/978-1-59745-413-1_15]; Wang YZ, 2013, J CLIN ONCOL, V31, P1188, DOI 10.1200/JCO.2012.41.5984; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Xing Z, 2016, ONCOTARGET, V7, P75394, DOI 10.18632/oncotarget.12215; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Zach S, 2015, J STEM CELL RES TRAN, V2, P1013; Zalfa F, 2003, CELL, V112, P317, DOI 10.1016/S0092-8674(03)00079-5; Zalfa F, 2007, NAT NEUROSCI, V10, P578, DOI 10.1038/nn1893; Zalfa F, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.521; Zhang MQ, 2007, P NATL ACAD SCI USA, V104, P10057, DOI 10.1073/pnas.0700169104	74	3	3	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2021	40	23					4033	4049		10.1038/s41388-021-01824-3	http://dx.doi.org/10.1038/s41388-021-01824-3		MAY 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SQ8GV	34017076	Green Published, hybrid			2022-12-17	WOS:000652439200002
J	Traphagen, NA; Hosford, SR; Jiang, A; Marotti, JD; Brauer, BL; Demidenko, E; Miller, TW				Traphagen, Nicole A.; Hosford, Sarah R.; Jiang, Amanda; Marotti, Jonathan D.; Brauer, Brooke L.; Demidenko, Eugene; Miller, Todd W.			High estrogen receptor alpha activation confers resistance to estrogen deprivation and is required for therapeutic response to estrogen in breast cancer	ONCOGENE			English	Article							POSTMENOPAUSAL WOMEN; ACQUIRED-RESISTANCE; RANDOMIZED-TRIAL; TAMOXIFEN; DIETHYLSTILBESTROL; ESR1; FULVESTRANT; ESTRADIOL; APOPTOSIS	Estrogen receptor alpha (ER)-positive breast cancer is commonly treated with endocrine therapies, including antiestrogens that bind and inhibit ER activity, and aromatase inhibitors that suppress estrogen biosynthesis to inhibit estrogen-dependent ER activity. Paradoxically, treatment with estrogens such as 17b-estradiol can also be effective against ER+ breast cancer. Despite the known efficacy of estrogen therapy, the lack of a predictive biomarker of response and understanding of the mechanism of action have contributed to its limited clinical use. Herein, we demonstrate that ER overexpression confers resistance to estrogen deprivation through ER activation in human ER+ breast cancer cells and xenografts grown in mice. However, ER overexpression and the associated high levels of ER transcriptional activation converted 17b-estradiol from a growth-promoter to a growth-suppressor, offering a targetable therapeutic vulnerability and a potential means of identifying patients likely to benefit from estrogen therapy. Since ER+ breast cancer cells and tumors ultimately developed resistance to continuous estrogen deprivation or continuous 17b-estradiol treatment, we tested schedules of alternating treatments. Oscillation of ER activity through cycling of 17b-estradiol and estrogen deprivation provided long-term control of patient-derived xenografts, offering a novel endocrine-only strategy to manage ER+ breast cancer.	[Traphagen, Nicole A.; Hosford, Sarah R.; Jiang, Amanda; Brauer, Brooke L.; Miller, Todd W.] Geisel Sch Med Dartmouth, Dept Mol & Syst Biol, Lebanon, NH 03755 USA; [Marotti, Jonathan D.] Dartmouth Hitchcock Med Ctr, Dept Pathol & Lab Med, Lebanon, NH USA; [Marotti, Jonathan D.] Geisel Sch Med Dartmouth, Lebanon, NH USA; [Marotti, Jonathan D.; Miller, Todd W.] Norris Cotton Canc Ctr, Comprehens Breast Program, Lebanon, NH 03527 USA; [Demidenko, Eugene] Geisel Sch Med Dartmouth, Dept Biomed Data Sci, Lebanon, NH USA	Dartmouth College; Dartmouth College; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College	Miller, TW (corresponding author), Geisel Sch Med Dartmouth, Dept Mol & Syst Biol, Lebanon, NH 03755 USA.; Miller, TW (corresponding author), Norris Cotton Canc Ctr, Comprehens Breast Program, Lebanon, NH 03527 USA.	Todd.W.Miller@dartmouth.edu		Miller, Todd/0000-0001-8912-2909; Jiang, Amanda/0000-0002-0327-6980	Susan G. Komen [CCR1533084]; NIH [R01CA200994, R01CA211869, F31CA243409]; NIH (Dartmouth College Norris Cotton Cancer Center Support Grant) [P30CA023108]	Susan G. Komen(Susan G. Komen Breast Cancer Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH (Dartmouth College Norris Cotton Cancer Center Support Grant)	This work was supported by Susan G. Komen (CCR1533084 to TWM) and NIH (R01CA200994 and R01CA211869 to TWM, F31CA243409 to NAT, Dartmouth College Norris Cotton Cancer Center Support Grant P30CA023108). We thank the following Norris Cotton Cancer Center Shared Resources for their support: Mouse Modeling; Pathology; Biostatistics; Microscopy; Genomics.	Agrawal Amit, 2006, World J Surg Oncol, V4, P44, DOI 10.1186/1477-7819-4-44; [Anonymous], 1960, JAMA-J AM MED ASSOC, V172, P1271; Ariazi EA, 2011, P NATL ACAD SCI USA, V108, P18879, DOI 10.1073/pnas.1115188108; Basudan A, 2019, MOL CANCER RES, V17, P457, DOI 10.1158/1541-7786.MCR-18-0946; BEEX L, 1981, CANCER TREAT REP, V65, P179; BERKENSTAM A, 1989, MOL ENDOCRINOL, V3, P22, DOI 10.1210/mend-3-1-22; CARTER AC, 1977, JAMA-J AM MED ASSOC, V237, P2079, DOI 10.1001/jama.237.19.2079; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chatterjee P, 2019, J CLIN INVEST, V129, P4245, DOI 10.1172/JCI127613; Cuzick J, 2010, LANCET ONCOL, V11, P1135, DOI 10.1016/S1470-2045(10)70257-6; Demidenko E., 2013, MIXED MODELS THEORY, Vxxvii; Demidenko E, 2020, ADV STAT APPL R; DeRose Yoko S, 2013, Curr Protoc Pharmacol, VChapter 14, DOI 10.1002/0471141755.ph1423s60; DeSantis CE, 2019, CA-CANCER J CLIN, V69, P438, DOI 10.3322/caac.21583; Desmedt C, 2016, J CLIN ONCOL, V34, P1872, DOI 10.1200/JCO.2015.64.0334; Ellis MJ, 2009, JAMA-J AM MED ASSOC, V302, P774, DOI 10.1001/jama.2009.1204; Ellison-Zelski SJ, 2009, MOL CELL BIOL, V29, P4949, DOI 10.1128/MCB.00383-09; Fan P, 2018, CELL DEATH DISCOV, V4, DOI 10.1038/s41420-017-0012-7; Fan P, 2015, MOL CANCER RES, V13, P1367, DOI 10.1158/1541-7786.MCR-14-0494; Fan P, 2013, CANCER RES, V73, P4510, DOI 10.1158/0008-5472.CAN-12-4152; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Haddow A, 1944, Br Med J, V2, P393; Hosford SR, 2019, MOL ONCOL, V13, P1778, DOI 10.1002/1878-0261.12528; Ingle JN, 2006, J CLIN ONCOL, V24, P1052, DOI 10.1200/JCO.2005.04.1053; INGLE JN, 1981, NEW ENGL J MED, V304, P16, DOI 10.1056/NEJM198101013040104; Iwase H, 2013, BRIT J CANCER, V109, P1537, DOI 10.1038/bjc.2013.520; Lee, 2017, CUREUS, V9; Li SQ, 2013, CELL REP, V4, P1116, DOI 10.1016/j.celrep.2013.08.022; Lonning PE, 2001, BREAST CANCER RES TR, V67, P111, DOI 10.1023/A:1010619225209; Ma R, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw236; MATELSKI H, 1985, AM J CLIN ONCOL-CANC, V8, P128, DOI 10.1097/00000421-198504000-00004; Mathew P, 2008, ANN ONCOL, V19, P395, DOI 10.1093/annonc/mdm568; Meerbrey KL, 2011, P NATL ACAD SCI USA, V108, P3665, DOI 10.1073/pnas.1019736108; Miller TW, 2010, J CLIN INVEST, V120, P2406, DOI 10.1172/JCI41680; Nielsen KV, 2011, BREAST CANCER RES TR, V127, P345, DOI 10.1007/s10549-010-0984-y; Peethambaram PP, 1999, BREAST CANCER RES TR, V54, P117, DOI 10.1023/A:1006185805079; PEREIRA B, 2016, P NATL ACAD SCI USA, V7; Perey L, 2007, ANN ONCOL, V18, P64, DOI 10.1093/annonc/mdl341; Robertson JFR, 2004, BRIT J CANCER, V90, pS7, DOI 10.1038/sj.bjc.6601630; Robertson JFR, 2009, J CLIN ONCOL, V27, P4530, DOI 10.1200/JCO.2008.21.1136; SACEDA M, 1988, MOL ENDOCRINOL, V2, P1157, DOI 10.1210/mend-2-12-1157; SANCHEZ C, 2011, MOL CELL BIOL, V13; SCHWEIZER M, 2015, LANCET ONCOL, V7; Schweizer MT, 2016, PROSTATE, V76, P1218, DOI 10.1002/pros.23209; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Simoes BM, 2015, CELL REP, V12, P1968, DOI 10.1016/j.celrep.2015.08.050; Szmulewitz R, 2009, EUR UROL, V56, P97, DOI 10.1016/j.eururo.2009.02.022; Teply BA, 2018, LANCET ONCOL, V19, P76, DOI 10.1016/S1470-2045(17)30906-3; Yu NY, 2019, JAMA ONCOL, V5, P1304, DOI 10.1001/jamaoncol.2019.1856; Zucchini G, 2015, EUR J CANCER, V51, P2725, DOI 10.1016/j.ejca.2015.08.028	51	3	3	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2021	40	19					3408	3421		10.1038/s41388-021-01782-w	http://dx.doi.org/10.1038/s41388-021-01782-w		APR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SB1JB	33875787	Green Accepted			2022-12-17	WOS:000641218600004
J	Fischietti, M; Eckerdt, F; Blyth, GT; Arslan, AD; Mati, WM; Oku, CV; Perez, RE; Lee-Chang, C; Kosciuczuk, EM; Saleiro, D; Beauchamp, EM; Lesniak, MS; Verzella, D; Sun, LY; Fish, EN; Yang, GY; Qiang, WA; Platanias, LC				Fischietti, Mariafausta; Eckerdt, Frank; Blyth, Gavin T.; Arslan, Ahmet D.; Mati, William M.; Oku, Chidera, V; Perez, Ricardo E.; Lee-Chang, Catalina; Kosciuczuk, Ewa M.; Saleiro, Diana; Beauchamp, Elspeth M.; Lesniak, Maciej S.; Verzella, Daniela; Sun, Leyu; Fish, Eleanor N.; Yang, Guang-Yu; Qiang, Wenan; Platanias, Leonidas C.			Schlafen 5 as a novel therapeutic target in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article								We provide evidence that a member of the human Schlafen (SLFN) family of proteins, SLFN5, is overexpressed in human pancreatic ductal adenocarcinoma (PDAC). Targeted deletion of SLFN5 results in decreased PDAC cell proliferation and suppresses PDAC tumorigenesis in in vivo PDAC models. Importantly, high expression levels of SLFN5 correlate with worse outcomes in PDAC patients, implicating SLFN5 in the pathophysiology of PDAC that leads to poor outcomes. Our studies establish novel regulatory effects of SLFN5 on cell cycle progression through binding/blocking of the transcriptional repressor E2F7, promoting transcription of key genes that stimulate S phase progression. Together, our studies suggest an essential role for SLFN5 in PDAC and support the potential for developing new therapeutic approaches for the treatment of pancreatic cancer through SLFN5 targeting.	[Fischietti, Mariafausta; Eckerdt, Frank; Blyth, Gavin T.; Arslan, Ahmet D.; Mati, William M.; Oku, Chidera, V; Perez, Ricardo E.; Lee-Chang, Catalina; Kosciuczuk, Ewa M.; Saleiro, Diana; Beauchamp, Elspeth M.; Lesniak, Maciej S.; Platanias, Leonidas C.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Fischietti, Mariafausta; Blyth, Gavin T.; Arslan, Ahmet D.; Mati, William M.; Oku, Chidera, V; Perez, Ricardo E.; Kosciuczuk, Ewa M.; Saleiro, Diana; Beauchamp, Elspeth M.; Platanias, Leonidas C.] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA; [Eckerdt, Frank; Lee-Chang, Catalina; Lesniak, Maciej S.] Northwestern Univ, Feinberg Sch Med, Dept Neurol Surg, Chicago, IL 60611 USA; [Kosciuczuk, Ewa M.; Beauchamp, Elspeth M.; Platanias, Leonidas C.] Jesse Brown Vet Affairs Med Ctr, Dept Med, Chicago, IL 60612 USA; [Verzella, Daniela] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy; [Sun, Leyu; Yang, Guang-Yu] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA; [Fish, Eleanor N.] Univ Hlth Network, Toronto Gen Hosp Res Inst, Toronto, ON, Canada; [Fish, Eleanor N.] Univ Toronto, Dept Immunol, Toronto, ON, Canada; [Qiang, Wenan] Northwestern Univ, Dept Obstet & Gynecol, Feinberg Sch Med, Evanston, IL USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center; University of L'Aquila; Northwestern University; Feinberg School of Medicine; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Northwestern University; Feinberg School of Medicine	Platanias, LC (corresponding author), Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.; Platanias, LC (corresponding author), Northwestern Univ, Dept Med, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA.; Platanias, LC (corresponding author), Jesse Brown Vet Affairs Med Ctr, Dept Med, Chicago, IL 60612 USA.	l-platanias@northwestern.edu	Kosciuczuk, Ewa Maria/AAD-2815-2022; Lee-Chang, Catalina/AAA-1808-2021	Lee-Chang, Catalina/0000-0002-7675-2124; Qiang, Wenan/0000-0001-5068-7128; Fischietti, Mariafausta/0000-0002-5691-689X	National Institutes of Health [R01-NS113352, R01CA77816, R01-CA121192]; Department of Veterans Affairs [I01-CX000916]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Veterans Affairs(US Department of Veterans Affairs)	National Institutes of Health [R01-NS113352, R01CA77816, R01-CA121192]; Department of Veterans Affairs [I01-CX000916]	Arslan AD, 2017, ONCOGENE, V36, P6006, DOI 10.1038/onc.2017.205; Back SA, 1999, J NEUROSCI METH, V91, P47, DOI 10.1016/S0165-0270(99)00062-X; Badea L, 2008, HEPATO-GASTROENTEROL, V55, P2016; Beauchamp EM, 2019, BLOOD, V133, P1171, DOI 10.1182/blood-2018-08-870089; Brown M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0226917; Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu, 2017, Cancer Cell, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Chen DT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133562; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Chung SJ, 2019, CLIN CANCER RES, V25, P2290, DOI 10.1158/1078-0432.CCR-18-1620; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Di Carlo C, 2018, WORLD J STEM CELLS, V10, P172, DOI 10.4252/wjsc.v10.i11.172; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Fischietti M, 2018, MOL CELL BIOL, V38, DOI 10.1128/MCB.00053-18; Fletcher SJ, 2015, J CLIN INVEST, V125, P3600, DOI 10.1172/JCI80347; Goswami CP, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-970; Grimont A, 2015, GUT, V64, P1790, DOI 10.1136/gutjnl-2014-307075; Guo LJ, 2019, EUR J PHARMACOL, V862, DOI 10.1016/j.ejphar.2019.172630; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Joukov V, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aar4195; Katsoulidis E, 2010, J BIOL CHEM, V285, P40333, DOI 10.1074/jbc.M110.151076; Katsoulidis E, 2009, J BIOL CHEM, V284, P25051, DOI 10.1074/jbc.M109.030445; Kent LN, 2016, J CLIN INVEST, V126, P2955, DOI 10.1172/JCI85506; Lee CJ, 2008, J CLIN ONCOL, V26, P2806, DOI 10.1200/JCO.2008.16.6702; Li J, 2008, DEV CELL, V14, P62, DOI 10.1016/j.devcel.2007.10.017; Li MQ, 2012, NATURE, V491, P125, DOI 10.1038/nature11433; Liu FR, 2018, CELL BIOL INT, V42, P2, DOI 10.1002/cbin.10778; Mavrommatis E, 2013, J BIOL CHEM, V288, P33006, DOI 10.1074/jbc.M113.460741; Mavrommatis E, 2013, J INTERF CYTOK RES, V33, P206, DOI 10.1089/jir.2012.0133; Mitxelena J, 2016, NUCLEIC ACIDS RES, V44, P5557, DOI 10.1093/nar/gkw146; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Napoles OC, 2017, J GASTROENTEROL, V52, P39, DOI 10.1007/s00535-016-1202-4; Petropoulos M, 2019, TRENDS BIOCHEM SCI, V44, P752, DOI 10.1016/j.tibs.2019.03.011; Razzak Mina, 2012, Nat Rev Urol, V9, P605, DOI 10.1038/nrurol.2012.188; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Sassano A, 2015, MOL CELL BIOL, V35, P2684, DOI 10.1128/MCB.00019-15; Seong RK, 2017, IMMUNOBIOLOGY, V222, P979, DOI 10.1016/j.imbio.2017.07.002; Soper A, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01823; Stewart ZA, 2003, TRENDS PHARMACOL SCI, V24, P139, DOI 10.1016/S0165-6147(03)00026-9; Thurlings I, 2017, ONCOGENE, V36, P829, DOI 10.1038/onc.2016.251; Wan GQ, 2019, CELL SIGNAL, V59, P1, DOI 10.1016/j.cellsig.2019.03.004; WEINERT T, 1993, SEMIN CANCER BIOL, V4, P129; Westendorp B, 2012, NUCLEIC ACIDS RES, V40, P3511, DOI 10.1093/nar/gkr1203; Xia ZQ, 2012, J IMMUNOL, V188, P3315, DOI 10.4049/jimmunol.1102775	44	3	3	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2021	40	18					3273	3286		10.1038/s41388-021-01761-1	http://dx.doi.org/10.1038/s41388-021-01761-1		APR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE1MB	33846574	Green Accepted			2022-12-17	WOS:000639635100001
J	Yang, WT; Chen, M; Xu, R; Zheng, PS				Yang, Wen-Ting; Chen, Mei; Xu, Rui; Zheng, Peng-Sheng			PRDM4 inhibits cell proliferation and tumorigenesis by inactivating the PI3K/AKT signaling pathway through targeting of PTEN in cervical carcinoma	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; TROPHOBLAST INVASION; STEM-CELLS; CANCER; GENE; METHYLATION; EXPRESSION; MUTATION; FAMILY	PR domain zinc finger protein 4 (PRDM4) is a transcription factor that plays key roles in stem cell self-renewal and tumorigenesis. However, its biological role and exact mechanism in cervical cancer remain unknown. Here, both immunohistochemistry (IHC) and Western blot assays demonstrated that the expression of PRDM4 in cervical cancer tissues was much lower than that in the normal cervix. A xenograft assay showed that PRDM4 overexpression in the cervical cancer cell lines SiHa and HeLa dramatically inhibited cell proliferation and tumorigenic potential in vivo. Conversely, the silencing of PRDM4 promoted cervical cancer cell proliferation and tumorigenic potential. Mechanistically, PRDM4 induced cell cycle arrest at the transition from G0/G1 phase to S phase by upregulating p27 and p21 expression and downregulating Cyclin D1 and CDK4 expression. Furthermore, the PI3K/AKT signaling pathway was inactivated in PRDM4-overexpressing cells, which decreased the levels of p-AKT and upregulated the expression of PTEN, an inhibitor of the PI3K/AKT signaling pathway, at both the transcriptional and translational levels. Dual-luciferase reporter assays and qChIP assays confirmed that PRDM4 transactivated the expression of PTEN by binding to two specific regions in the PTEN promoter. Furthermore, PTEN silencing or a PTEN inhibitor rescued the cell defects induced by PRDM4 overexpression. Therefore, our data suggest that PRDM4 inhibits cell proliferation and tumorigenesis by downregulating the activity of the PI3K/AKT signaling pathway by directly transactivating PTEN expression in cervical cancer.	[Yang, Wen-Ting; Chen, Mei; Zheng, Peng-Sheng] Xi An Jiao Tong Univ, Dept Reprod Med, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China; [Yang, Wen-Ting; Zheng, Peng-Sheng] Minist Educ Peoples Republ China, Key Lab Environm & Genes Related Dis, Xian, Shaanxi, Peoples R China; [Xu, Rui] Xi An Jiao Tong Univ, Shaanxi Canc Hosp, Coll Med, Dept Internal Med 1, Xian, Peoples R China	Xi'an Jiaotong University; Ministry of Education, China; Xi'an Jiaotong University	Zheng, PS (corresponding author), Xi An Jiao Tong Univ, Dept Reprod Med, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China.; Zheng, PS (corresponding author), Minist Educ Peoples Republ China, Key Lab Environm & Genes Related Dis, Xian, Shaanxi, Peoples R China.	zpsheng@mail.xjtu.edu.cn			National Natural Science Foundation of China [81472728, 81672910, 81602307]; Xi'an Municipal Science and Technology Bureau [2019115213YX007SF040(6)]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Xi'an Municipal Science and Technology Bureau	This work was supported by a grant from the National Natural Science Foundation of China (Nos 81472728, 81672910, and 81602307) and the Xi'an Municipal Science and Technology Bureau (No. 2019115213YX007SF040(6)).	Bikoff EK, 2008, NAT GENET, V40, P934, DOI 10.1038/ng0808-934; Bogani D, 2013, MOL CELL BIOL, V33, P3936, DOI 10.1128/MCB.00498-13; Carnero A, 2008, CURR CANCER DRUG TAR, V8, P187, DOI 10.2174/156800908784293659; Carnero A, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00252; Casamassimi A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072648; Chittka A, 2012, J BIOL CHEM, V287, P42995, DOI 10.1074/jbc.M112.392746; Cui N, 2016, ONCOTARGET, V7, P26152, DOI 10.18632/oncotarget.8434; de Sanjose S, 2010, LANCET ONCOL, V11, P1048, DOI 10.1016/S1470-2045(10)70230-8; Di Zazzo Erika, 2013, Biology (Basel), V2, P107, DOI 10.3390/biology2010107; Fog CK, 2012, BIOESSAYS, V34, P50, DOI 10.1002/bies.201100107; Hadziselimovic F, 2018, GENES-BASEL, V9, DOI 10.3390/genes9080391; Harima Y, 2001, INT J ONCOL, V18, P493; Hohenauer T, 2012, DEVELOPMENT, V139, P2267, DOI 10.1242/dev.070110; Kedde M, 2010, NAT CELL BIOL, V12, P1014, DOI 10.1038/ncb2105; LI L, 2018, CELL DEATH DIS, V9; Liu H, 2018, EMBO REP, V19, DOI 10.15252/embr.201745180; Liu XL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0081-9; Ma X, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171612; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Naseem A, 2019, J CELL BIOCHEM, V120, P15851, DOI 10.1002/jcb.28856; Orel N, 2007, J Stem Cells Regen Med, V2, P216; Rizvi MMA, 2011, J CANCER RES CLIN, V137, P1255, DOI 10.1007/s00432-011-0994-0; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Song NJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0904-3; Su TH, 2000, GYNECOL ONCOL, V76, P193, DOI 10.1006/gyno.1999.5659; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wang HY, 2015, ONCOTARGET, V6, P20711, DOI 10.18632/oncotarget.4133; Wen SY, 2015, ONCOGENE, V34, P717, DOI 10.1038/onc.2014.9; Yang WT, 2012, CANCER-AM CANCER SOC, V118, P3691, DOI 10.1002/cncr.26698; Yang XH, 1999, GENOMICS, V61, P319, DOI 10.1006/geno.1999.5967; Zeng YT, 2019, ONCOGENE, V38, P6940, DOI 10.1038/s41388-019-0906-3; Zhang J, 2018, BIOMED PHARMACOTHER, V100, P168, DOI 10.1016/j.biopha.2018.02.016; Zhang Y, 2020, MOL THER, V28, P631, DOI 10.1016/j.ymthe.2019.11.025; Zhang Y, 2017, MOL THER, V25, P2394, DOI 10.1016/j.ymthe.2017.06.028; Zhu Zhaohui, 2004, J Huazhong Univ Sci Technolog Med Sci, V24, P354	35	3	3	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2021	40	18					3318	3330		10.1038/s41388-021-01765-x	http://dx.doi.org/10.1038/s41388-021-01765-x		APR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE1MB	33846573	Green Published, hybrid			2022-12-17	WOS:000639635100004
J	Cingoz, A; Ozyerli-Goknar, E; Morova, T; Seker-Polat, F; Selvan, ME; Gumus, ZH; Bhere, D; Shah, KL; Solaroglu, I; Bagci-Onder, T				Cingoz, Ahmet; Ozyerli-Goknar, Ezgi; Morova, Tunc; Seker-Polat, Fidan; Esai Selvan, Myvizhi; Gumus, Zeynep Hulya; Bhere, Deepak; Shah, Khalid; Solaroglu, Ihsan; Bagci-Onder, Tugba			Generation of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization	ONCOGENE			English	Article								Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces tumor cell-specific apoptosis, making it a prime therapeutic candidate. However, many tumor cells are either innately TRAIL-resistant, or they acquire resistance with adaptive mechanisms that remain poorly understood. In this study, we generated acquired TRAIL resistance models using multiple glioblastoma (GBM) cell lines to assess the molecular alterations in the TRAIL-resistant state. We selected TRAIL-resistant cells through chronic and long-term TRAIL exposure and noted that they showed persistent resistance both in vitro and in vivo. Among known TRAIL-sensitizers, proteosome inhibitor Bortezomib, but not HDAC inhibitor MS-275, was effective in overcoming resistance in all cell models. This was partly achieved through upregulating death receptors and pro-apoptotic proteins, and downregulating major anti-apoptotic members, Bcl-2 and Bcl-xL. We showed that CRISPR/Cas9 mediated silencing of DR5 could block Bortezomib-mediated re-sensitization, demonstrating its critical role. While overexpression of Bcl-2 or Bcl-xL was sufficient to confer resistance to TRAIL-sensitive cells, it failed to override Bortezomib-mediated re-sensitization. With RNA sequencing in multiple paired TRAIL-sensitive and TRAIL-resistant cells, we identified major alterations in inflammatory signaling, particularly in the NF-kappa B pathway. Inhibiting NF-kappa B substantially sensitized the most resistant cells to TRAIL, however, the sensitization effect was not as great as what was observed with Bortezomib. Together, our findings provide new models of acquired TRAIL resistance, which will provide essential tools to gain further insight into the heterogeneous therapy responses within GBM tumors. Additionally, these findings emphasize the critical importance of combining proteasome inhibitors and pro-apoptotic ligands to overcome acquired resistance.	[Cingoz, Ahmet; Ozyerli-Goknar, Ezgi; Seker-Polat, Fidan; Bagci-Onder, Tugba] Koc Univ, Res Ctr Translat Med, Brain Canc Res & Therapy Lab, TR-34450 Istanbul, Turkey; [Cingoz, Ahmet; Ozyerli-Goknar, Ezgi; Morova, Tunc; Seker-Polat, Fidan; Gumus, Zeynep Hulya; Solaroglu, Ihsan; Bagci-Onder, Tugba] Koc Univ, Sch Med, TR-34450 Istanbul, Turkey; [Esai Selvan, Myvizhi; Gumus, Zeynep Hulya] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Esai Selvan, Myvizhi; Gumus, Zeynep Hulya] Icahn Sch Med Mt Sinai, Icahn Inst Data Sci & Genom Technol, New York, NY 10029 USA; [Bhere, Deepak; Shah, Khalid] Harvard Med Sch, Brigham & Womens Hosp, Ctr Stem Cell Therapeut & Imaging, Boston, MA 02115 USA; [Solaroglu, Ihsan] Koc Univ, Sch Med, Dept Neurosurg, TR-34010 Istanbul, Turkey	Koc University; Koc University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Koc University	Bagci-Onder, T (corresponding author), Koc Univ, Res Ctr Translat Med, Brain Canc Res & Therapy Lab, TR-34450 Istanbul, Turkey.; Bagci-Onder, T (corresponding author), Koc Univ, Sch Med, TR-34450 Istanbul, Turkey.	tuonder@ku.edu.tr	Cingoz, Ahmet/AAG-4228-2019; Selvan, Myvizhi Esai/AAC-9982-2020; Onder, Tugba Bagci/AAN-1392-2021	Cingoz, Ahmet/0000-0002-1111-7752; Selvan, Myvizhi Esai/0000-0003-4640-5727; Bagci Onder, Tugba/0000-0003-3646-2613; Ozyerli Goknar, Ezgi/0000-0003-0202-8165; Gumus, Zeynep/0000-0002-7364-2202; Bhere, Deepak/0000-0003-4142-5518	Scientific and Technological Research Council of Turkey (TUBITAK) [3501]; Marie Curie FP7 Career Reintegration Grant (EC) [618673]; BAGEP; NIH/NCI [U24 CA210993]; Icahn Institute; NIH [R01CA201148]; Presidency of Turkey, Presidency of Strategy and Budget	Scientific and Technological Research Council of Turkey (TUBITAK)(Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)); Marie Curie FP7 Career Reintegration Grant (EC); BAGEP; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Icahn Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Presidency of Turkey, Presidency of Strategy and Budget	Financial support was obtained from The Scientific and Technological Research Council of Turkey (TUBITAK) (3501), Marie Curie FP7 Career Reintegration Grant (EC Grant # 618673), and BAGEP. ZHG and ME acknowledge NIH/NCI U24 CA210993 and start-up funds from the Icahn Institute. KS acknowledges the NIH R01CA201148. The authors gratefully acknowledge the use of services and facilities of the Koc University Research Center for Translational Medicine (KUTTAM), funded by the Presidency of Turkey, Presidency of Strategy and Budget.	Albeck JG, 2008, MOL CELL, V30, P11, DOI 10.1016/j.molcel.2008.02.012; Ashkenazi A, 2008, NAT REV DRUG DISCOV, V7, P1001, DOI 10.1038/nrd2637; Bagci-Onder T, 2013, ONCOGENE, V32, P2818, DOI 10.1038/onc.2012.304; Bagci-Onder T, 2011, CANCER RES, V71, P154, DOI 10.1158/0008-5472.CAN-10-1601; Berens Michael E., 1999, Neoplasia (New York), V1, P208, DOI 10.1038/sj.neo.7900034; Bhere D, 2015, ADV CANCER RES, V127, P159, DOI 10.1016/bs.acr.2015.04.012; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; Bychkov ML, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109756; Chen GG, 2005, J CELL PHYSIOL, V203, P127, DOI 10.1002/jcp.20230; Chen KF, 2009, J BIOL CHEM, V284, P11121, DOI 10.1074/jbc.M806268200; Chen WJ, 2010, MOL PHARMACOL, V77, P416, DOI 10.1124/mol.109.061226; Corsten MF, 2007, CANCER RES, V67, P8994, DOI 10.1158/0008-5472.CAN-07-1045; Cristofanon S, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.163; de Wilt LHAM, 2013, CRIT REV ONCOL HEMAT, V85, P363, DOI 10.1016/j.critrevonc.2012.08.001; Delbridge ARD, 2015, CELL DEATH DIFFER, V22, P1071, DOI 10.1038/cdd.2015.50; Diessenbacher P, 2008, J INVEST DERMATOL, V128, P1134, DOI 10.1038/sj.jid.5701141; Falschlehner C, 2007, INT J BIOCHEM CELL B, V39, P1462, DOI 10.1016/j.biocel.2007.02.007; Flusberg DA, 2013, MOL BIOL CELL, V24, P2186, DOI 10.1091/mbc.E12-10-0737; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Fulda S, 2015, SEMIN CANCER BIOL, V31, P84, DOI 10.1016/j.semcancer.2014.05.002; Fulda S, 2011, ONCOTARGET, V2, P418; Ganten TM, 2005, HEPATOLOGY, V42, P588, DOI 10.1002/hep.20807; Han B, 2015, ONCOTARGET, V6, P17532, DOI 10.18632/oncotarget.3947; Hetschko H, 2008, J NEURO-ONCOL, V86, P265, DOI 10.1007/s11060-007-9472-6; Hoey T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001056; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Huang SB, 2008, CANCER RES, V68, P2944, DOI 10.1158/0008-5472.CAN-07-2508; Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818; Kandasamy K, 2008, MOL CANCER THER, V7, P1091, DOI 10.1158/1535-7163.MCT-07-2368; Kaya-Aksoy E, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0144-z; Khaw SL, 2009, LEUKEMIA LYMPHOMA, V50, P1069, DOI 10.1080/10428190903015644; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Koschny R, 2007, HEPATOLOGY, V45, P649, DOI 10.1002/hep.21555; Koschny R, 2014, J NEUROPATH EXP NEUR, V73, P1034, DOI 10.1097/NEN.0000000000000129; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Kurt IC, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.288; Lane D, 2006, MOL CANCER THER, V5, P509, DOI 10.1158/1535-7163.MCT-05-0362; Lee TJ, 2006, BIOCHEM BIOPH RES CO, V351, P1024, DOI 10.1016/j.bbrc.2006.10.163; Li Z, 2011, J BIOL CHEM, V286, P21164, DOI 10.1074/jbc.M110.207571; Lickliter JD, 2007, BRIT J CANCER, V96, P600, DOI 10.1038/sj.bjc.6603599; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Messaoudi K, 2015, DRUG DISCOV TODAY, V20, P899, DOI 10.1016/j.drudis.2015.02.011; Mitsiades N, 2002, BLOOD, V99, P2162, DOI 10.1182/blood.V99.6.2162; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Nakata S, 2004, ONCOGENE, V23, P6261, DOI 10.1038/sj.onc.1207830; Naumann I, 2011, CLIN CANCER RES, V17, P3204, DOI 10.1158/1078-0432.CCR-10-2451; Nikrad M, 2005, MOL CANCER THER, V4, P443; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Sasportas LS, 2009, P NATL ACAD SCI USA, V106, P4822, DOI 10.1073/pnas.0806647106; Seker F, 2019, CANCERS, V11, DOI 10.3390/cancers11111651; Senbabaoglu F, 2016, CANCER BIOL THER, V17, P546, DOI 10.1080/15384047.2016.1167292; Serrano-Saenz S, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1293-3; Siegmund D, 2002, MOL MED, V8, P725, DOI 10.1007/BF03402036; Singh TR, 2005, ONCOGENE, V24, P4609, DOI 10.1038/sj.onc.1208585; Song JJ, 2007, J BIOL CHEM, V282, P319, DOI 10.1074/jbc.M608065200; Song JH, 2008, J BIOL CHEM, V283, P25003, DOI 10.1074/jbc.M802511200; Spencer SL, 2009, NATURE, V459, P428, DOI 10.1038/nature08012; Stavrovskaya AA, 2016, BIOCHEMISTRY-MOSCOW+, V81, P91, DOI 10.1134/S0006297916020036; Stuckey DW, 2013, TRENDS MOL MED, V19, P685, DOI 10.1016/j.molmed.2013.08.007; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; Unterkircher T, 2011, CLIN CANCER RES, V17, P4019, DOI 10.1158/1078-0432.CCR-11-0075; von Karstedt S, 2017, NAT REV CANCER, V17, P352, DOI 10.1038/nrc.2017.28; Warren CFA, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1407-6; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wilting RH, 2012, DRUG RESIST UPDATE, V15, P21, DOI 10.1016/j.drup.2012.01.008; Wood TE, 2010, MOL CANCER THER, V9, P246, DOI 10.1158/1535-7163.MCT-09-0495	70	3	3	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2021	40	18					3201	3216		10.1038/s41388-021-01697-6	http://dx.doi.org/10.1038/s41388-021-01697-6		MAR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE1MB	33767436				2022-12-17	WOS:000632820300004
J	Yeo, AT; Jun, HJ; Appleman, VA; Zhang, PY; Varma, H; Sarkaria, JN; Charest, A				Yeo, Alan T.; Jun, Hyun Jung; Appleman, Vicky A.; Zhang, Piyan; Varma, Hemant; Sarkaria, Jann N.; Charest, Al			EGFRvIII tumorigenicity requires PDGFRA co-signaling and reveals therapeutic vulnerabilities in glioblastoma	ONCOGENE			English	Article								Focal amplification of epidermal growth factor receptor (EGFR) and its ligand-independent, constitutively active EGFRvIII mutant form are prominent oncogenic drivers in glioblastoma (GBM). The EGFRvIII gene rearrangement is considered to be an initiating event in the etiology of GBM, however, the mechanistic details of how EGFRvIII drives cellular transformation and tumor maintenance remain unclear. Here, we report that EGFRvIII demonstrates a reliance on PDGFRA co-stimulatory signaling during the tumorigenic process in a genetically engineered autochthonous GBM model. This dependency exposes liabilities that were leveraged using kinase inhibitors treatments in EGFRvIII-expressing GBM patient-derived xenografts (PDXs), where simultaneous pharmacological inhibition of EGFRvIII and PDGFRA kinase activities is necessary for anti-tumor efficacy. Our work establishes that EGFRvIII-positive tumors have unexplored vulnerabilities to targeted agents concomitant to the EGFR kinase inhibitor repertoire.	[Yeo, Alan T.; Jun, Hyun Jung; Appleman, Vicky A.; Zhang, Piyan; Charest, Al] Harvard Med Sch, Beth Israel Deaconess Med, Dept Med, Boston, MA 02115 USA; [Yeo, Alan T.] Tufts Univ, Sch Med, Sackler Sch Grad Studies, Boston, MA 02111 USA; [Varma, Hemant] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02115 USA; [Sarkaria, Jann N.] Mayo Clin, Dept Radiat Oncol, Rochester, MN USA; [Charest, Al] Beth Israel Deaconess Med Ctr, Canc Res Inst, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Tufts University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Mayo Clinic; Harvard University; Beth Israel Deaconess Medical Center	Charest, A (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med, Dept Med, Boston, MA 02115 USA.; Charest, A (corresponding author), Beth Israel Deaconess Med Ctr, Canc Res Inst, Boston, MA 02215 USA.	acharest@bidmc.harvard.edu			NIH [R01 CA229784, R21 CA245337]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by NIH grants R01 CA229784 and R21 CA245337 to AC and by internal funding to the Mayo Clinic GBM PDX National Resource to JNS.	Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Bedard PL, 2015, CLIN CANCER RES, V21, P730, DOI 10.1158/1078-0432.CCR-14-1814; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Brown AP, 2007, CANCER CHEMOTH PHARM, V59, P671, DOI 10.1007/s00280-006-0323-5; Chakravarty D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08940-9; Chen PH, 2013, BBA-PROTEINS PROTEOM, V1834, P2176, DOI 10.1016/j.bbapap.2012.10.015; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Darmanis S, 2017, CELL REP, V21, P1399, DOI 10.1016/j.celrep.2017.10.030; Davis MI, 2011, NAT BIOTECHNOL, V29, P1046, DOI 10.1038/nbt.1990; deCarvalho AC, 2018, NAT GENET, V50, P708, DOI 10.1038/s41588-018-0105-0; Ebbesen SH, 2016, P NATL ACAD SCI USA, V113, P3030, DOI 10.1073/pnas.1523693113; Fan QW, 2013, CANCER CELL, V24, P438, DOI 10.1016/j.ccr.2013.09.004; Felsberg J, 2017, CLIN CANCER RES, V23, P6846, DOI 10.1158/1078-0432.CCR-17-0890; Fernandes H, 2001, J BIOL CHEM, V276, P5375, DOI 10.1074/jbc.M005599200; Folkes AJ, 2008, J MED CHEM, V51, P5522, DOI 10.1021/jm800295d; Francis JM, 2014, CANCER DISCOV, V4, P956, DOI 10.1158/2159-8290.CD-13-0879; Gajadhar AS, 2012, MOL CANCER RES, V10, P428, DOI 10.1158/1541-7786.MCR-11-0531; Gan HK, 2013, FEBS J, V280, P5350, DOI 10.1111/febs.12393; Garnett J, 2013, NEOPLASIA, V15, P73, DOI 10.1593/neo.121536; Greenall SA, 2015, ONCOGENE, V34, P5277, DOI 10.1038/onc.2014.448; Grilley-Olson JE, 2016, INVEST NEW DRUG, V34, P740, DOI 10.1007/s10637-016-0377-0; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Heimberger AB, 2005, CLIN CANCER RES, V11, P1462, DOI 10.1158/1078-0432.CCR-04-1737; Hwang Y, 2011, MOL CANCER RES, V9, P1199, DOI 10.1158/1541-7786.MCR-11-0229; Jun HJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05036-4; Kancha RK, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-39; Kastenhuber ER, 2014, ACTA NEUROPATHOL, V127, P747, DOI 10.1007/s00401-013-1217-3; Lemmon MA, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a020768; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Luwor RB, 2004, ONCOGENE, V23, P6095, DOI 10.1038/sj.onc.1207870; Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467; McNeill RS, 2017, NEURO-ONCOLOGY, V19, P1469, DOI 10.1093/neuonc/nox044; Meyer M, 2015, P NATL ACAD SCI USA, V112, P851, DOI 10.1073/pnas.1320611111; Montano N, 2011, NEOPLASIA, V13, P1113, DOI 10.1593/neo.111338; Nathanson DA, 2014, SCIENCE, V343, P72, DOI 10.1126/science.1241328; Nishikawa Ryo, 2004, Brain Tumor Pathol, V21, P53, DOI 10.1007/BF02484510; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Paul MD, 2019, CHEM REV, V119, P5881, DOI 10.1021/acs.chemrev.8b00467; Reardon DA, 2014, NEURO-ONCOLOGY, V16, pviii7, DOI 10.1093/neuonc/nou232; Roskoski R, 2019, PHARMACOL RES, V139, P395, DOI 10.1016/j.phrs.2018.11.014; Roskoski R, 2018, PHARMACOL RES, V129, P65, DOI 10.1016/j.phrs.2018.01.021; Rutkowska A, 2019, J ONCOL, V2019, DOI 10.1155/2019/1092587; Sarkaria JN, 2007, MOL CANCER THER, V6, P1167, DOI 10.1158/1535-7163.MCT-06-0691; Sarkaria JN, 2006, CLIN CANCER RES, V12, P2264, DOI 10.1158/1078-0432.CCR-05-2510; Schram AM, 2018, BRIT J CANCER, V119, P1471, DOI 10.1038/s41416-018-0322-4; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shin KJ, 2006, P NATL ACAD SCI USA, V103, P13759, DOI 10.1073/pnas.0606179103; Shinojima N, 2003, CANCER RES, V63, P6962; Snuderl M, 2011, CANCER CELL, V20, P810, DOI 10.1016/j.ccr.2011.11.005; Stec W., 2018, ONCOTARGET, V9, P8560, DOI [DOI 10.18632/ONCOTARGET.24058, 10.18632/oncotarget.24058]; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Szerlip NJ, 2012, P NATL ACAD SCI USA, V109, P3041, DOI 10.1073/pnas.1114033109; Tolcher AW, 2015, CANCER CHEMOTH PHARM, V75, P183, DOI 10.1007/s00280-014-2615-5; Turner KM, 2017, NATURE, V543, P122, DOI 10.1038/nature21356; van den Bent MJ, 2015, NEURO-ONCOLOGY, V17, P935, DOI 10.1093/neuonc/nov013; Vaubel RA, 2020, CLIN CANCER RES, V26, P1094, DOI 10.1158/1078-0432.CCR-19-0909; Verhaak RGW, 2019, NAT REV CANCER, V19, P283, DOI 10.1038/s41568-019-0128-6; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wainberg ZA, 2017, TARGET ONCOL, V12, P775, DOI 10.1007/s11523-017-0530-5; Wee S, 2009, CANCER RES, V69, P4286, DOI 10.1158/0008-5472.CAN-08-4765; Weller M, 2009, J CLIN ONCOL, V27, P5743, DOI 10.1200/JCO.2009.23.0805; Weng LP, 2002, HUM MOL GENET, V11, P1687, DOI 10.1093/hmg/11.15.1687; Weng LP, 2001, HUM MOL GENET, V10, P605, DOI 10.1093/hmg/10.6.605; Xing YM, 2015, DEV BIOL, V408, P56, DOI 10.1016/j.ydbio.2015.10.002; Ymer Susie I, 2011, Cancers (Basel), V3, P2032, DOI 10.3390/cancers3022032; Zhou S, 2018, LIFE SCI ALLIANCE, V1, DOI 10.26508/lsa.201800029; Zhu H, 2009, P NATL ACAD SCI USA, V106, P2712, DOI 10.1073/pnas.0813314106	67	3	3	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2021	40	15					2682	2696		10.1038/s41388-021-01721-9	http://dx.doi.org/10.1038/s41388-021-01721-9		MAR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN8NW	33707748	Green Accepted			2022-12-17	WOS:000627660400002
J	Purayil, HT; Zhang, YS; Black, JB; Gharaibeh, R; Daaka, Y				Purayil, Hamsa Thayele; Zhang, Yushan; Black, Joseph B.; Gharaibeh, Raad; Daaka, Yehia			Nuclear beta Arrestin1 regulates androgen receptor function in castration resistant prostate cancer	ONCOGENE			English	Article							BETA-ARRESTIN 1; EMERGING MECHANISMS; ADRENERGIC-RECEPTOR; LINEAGE PLASTICITY; EXPORT SIGNAL; IDENTIFICATION; PROGRESSION; EXPRESSION; PROTEIN; KINASE	Progression of prostate cancer (PC) to terminal castration-resistant PC (CRPC) involves a diverse set of intermediates, and androgen receptor (AR) is the key mediator of PC initiation and progression to CRPC. Hence, identification of factors involved in the regulation of AR expression and function is a necessary first-step to improve disease outcome. In this study, we identified ubiquitous beta Arrestin 1 (beta Arr1) as a regulator of AR function in CRPC. Unbiased gene expression analysis of public datasets revealed increased levels of ARRB1 (the gene encoding beta Arr1) in CRPC when compared to normal tissue. Further, beta Arr1 expression correlated with enhanced AR transcriptional function in these datasets. The beta Arr1 partitions to both nucleus and cytosol and mechanistic studies showed that nuclear, and not cytosolic, beta Arr1 formed a complex with AR and AR-coregulator beta Catenin and that the heterotrimeric protein complex was recruited to androgen-response elements of AR-regulated genes. Functionally, we demonstrate that depletion of beta Arr1 attenuates PC cell and tumor growth and metastasis, and rescued expression of nuclear, but not cytosolic, beta Arr1 restores the PC colony growth and invasion of Matrigel in vitro and tumor growth and metastasis in mice. The targeting of beta Arr1-regulated AR transcriptional function may be used in the development of new drugs to treat lethal CRPC.	[Purayil, Hamsa Thayele; Zhang, Yushan; Black, Joseph B.; Daaka, Yehia] Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32611 USA; [Gharaibeh, Raad] Univ Florida, Coll Med, Dept Med, Gainesville, FL USA; [Zhang, Yushan] Univ Oklahoma, Hlth Sci Ctr, Stephen Canc Ctr, Norman, OK 73019 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma - Norman	Daaka, Y (corresponding author), Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32611 USA.	ydaaka@ufl.edu		THAYELE PURAYIL, HAMSA/0000-0002-7211-3659	Florida Academic Cancer Center Alliance	Florida Academic Cancer Center Alliance	This work was supported, in part, by the Florida Academic Cancer Center Alliance (to YD) and the UFHCC (to RG).	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012; Bao BY, 2008, PROSTATE, V68, P839, DOI 10.1002/pros.20749; Beltran H, 2019, CLIN CANCER RES, V25, P43, DOI 10.1158/1078-0432.CCR-18-1912; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; Buchanan FG, 2006, P NATL ACAD SCI USA, V103, P1492, DOI 10.1073/pnas.0510562103; Cianfrocca R, 2014, LIFE SCI, V118, P179, DOI 10.1016/j.lfs.2014.01.078; Claessens F, 2014, NAT REV UROL, V11, P712, DOI 10.1038/nrurol.2014.243; Dasgupta P, 2011, JNCI-J NATL CANCER I, V103, P317, DOI 10.1093/jnci/djq541; Dehm SM, 2011, ENDOCR-RELAT CANCER, V18, pR183, DOI 10.1530/ERC-11-0141; El-Khoury V, 2018, BRIT J CANCER, V119, P580, DOI 10.1038/s41416-018-0200-0; Fereshteha M, 2012, P NATL ACAD SCI USA, V109, P12532, DOI 10.1073/pnas.1209815109; Heemers HV, 2007, ENDOCR REV, V28, P778, DOI 10.1210/er.2007-0019; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Kang JH, 2005, CELL, V123, P833, DOI 10.1016/j.cell.2005.09.011; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Lakshmikanthan V, 2009, P NATL ACAD SCI USA, V106, P9379, DOI 10.1073/pnas.0900258106; Lee E, 2013, P NATL ACAD SCI USA, V110, P15710, DOI 10.1073/pnas.1218168110; Lefkowitz RJ, 2004, TRENDS PHARMACOL SCI, V25, P413, DOI 10.1016/j.tips.2004.06.006; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Ma L, 2007, J CELL SCI, V120, P213, DOI 10.1242/jcs.03338; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Nyquist MD, 2013, P NATL ACAD SCI USA, V110, P17492, DOI 10.1073/pnas.1308587110; Purayil HT, 2015, ONCOGENE, V34, P3144, DOI 10.1038/onc.2014.252; Rosano L, 2013, ONCOGENE, V32, P5066, DOI 10.1038/onc.2012.527; Rosano L, 2009, P NATL ACAD SCI USA, V106, P2806, DOI 10.1073/pnas.0807158106; Scott MGH, 2002, J BIOL CHEM, V277, P37693, DOI 10.1074/jbc.M207552200; Shenoy SK, 2012, ONCOGENE, V31, P282, DOI 10.1038/onc.2011.238; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Taplin ME, 2007, NAT CLIN PRACT ONCOL, V4, P236, DOI 10.1038/ncponc0765; Terada N, 2010, CANCER RES, V70, P1606, DOI 10.1158/0008-5472.CAN-09-2984; Titus MA, 2005, CLIN CANCER RES, V11, P4653, DOI 10.1158/1078-0432.CCR-05-0525; Tocci P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11045-8; Wang LG, 2012, ASIAN PAC J CANCER P, V13, P5671, DOI 10.7314/APJCP.2012.13.11.5671; Wang P, 2003, J BIOL CHEM, V278, P11648, DOI 10.1074/jbc.M208109200; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Xiao K, 2007, P NATL ACAD SCI USA, V104, P12011, DOI 10.1073/pnas.0704849104; Zecchini V, 2014, EMBO J, V33, P1365, DOI 10.15252/embj.201386874; Zhang X, 2017, NAT COMMUN, V8, P1, DOI [10.1038/ncomms14542, 10.1038/s41467-017-01968-5, 10.1038/s41467-017-00321-0]; Zhang YX, 2017, J BIOL CHEM, V292, P8933, DOI 10.1074/jbc.M116.770420; Zhang YS, 2017, CANCER LETT, V391, P50, DOI 10.1016/j.canlet.2017.01.007	42	3	3	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2021	40	14					2610	2620		10.1038/s41388-021-01730-8	http://dx.doi.org/10.1038/s41388-021-01730-8		MAR 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK3YE	33692468				2022-12-17	WOS:000627285600001
J	Mai, J; Peng, XD; Tang, J; Du, T; Chen, YH; Wang, ZF; Zhang, HL; Huang, JH; Zhong, ZY; Yang, D; Li, ZL; Huang, Y; Feng, GK; Zhu, XF; Deng, R				Mai, Jia; Peng, Xiao-Dan; Tang, Jun; Du, Tian; Chen, Yu-Hong; Wang, Zi-Feng; Zhang, Hai-Liang; Huang, Jun-Hao; Zhong, Zhuo-Yan; Yang, Dong; Li, Zhi-Ling; Huang, Yun; Feng, Gong-Kan; Zhu, Xiao-Feng; Deng, Rong			AKT-mediated regulation of chromatin ubiquitylation and tumorigenesis through Mel18 phosphorylation	ONCOGENE			English	Article							POLYCOMB GROUP GENE; HISTONE H2A UBIQUITINATION; BREAST-CANCER; GROUP PROTEIN; SELF-RENEWAL; MEL-18; PROLIFERATION; EXPRESSION; REPRESSION; COMPLEX	Polycomb repressor complex 1 (PRC1) is linked to the regulation of gene expression and histone ubiquitylation conformation, which contributes to carcinogenesis. However, the upstream regulators of PRC1 biogenesis machinery remain obscure. Here, we report that the polycomb group-related mammalian gene Mel18 is a target of the protein kinase AKT. AKT phosphorylates Mel18 at T334 to disrupt the interaction between Mel18 and other PRC1 members, leading to attenuated PRC1-dependent ubiquitylation of histone H2A at Lys119. As such, PRC1 target genes, many of which are known oncogenes, are derepressed upon T334-Mel18 phosphorylation, which promotes malignant behaviours, including cell proliferation, tumour formation, migration and invasion, bone and brain metastatic lesion formation. Notably, a positive correlation between AKT activity and pT334-Mel18 is observed, and prognostic models based on p-AKT and pT334-Mel18 that predicted overall survival and distant metastasis-free survival in breast cancer patients are established. These findings have implications for understanding the role of AKT and its associated proteins in chromatin ubiquitylation, and also indicate the AKT-Mel18-H2AK119ub axis as a novel prognostic biomarker and therapeutic target for cancer patients.	[Mai, Jia; Peng, Xiao-Dan; Tang, Jun; Du, Tian; Chen, Yu-Hong; Wang, Zi-Feng; Zhang, Hai-Liang; Huang, Jun-Hao; Zhong, Zhuo-Yan; Yang, Dong; Li, Zhi-Ling; Huang, Yun; Feng, Gong-Kan; Zhu, Xiao-Feng; Deng, Rong] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, Canc Ctr,State Key Lab Oncol South China, Guangzhou, Peoples R China; [Mai, Jia] Sichuan Univ, West China Univ Hosp 2, Key Lab Birth Defects & Related Dis Women & Child, Minist Educ,Dept Lab Med, Chengdu, Sichuan, Peoples R China; [Tang, Jun; Du, Tian; Huang, Jun-Hao] Sun Yat Sen Univ, Dept Breast Oncol, Canc Ctr, Guangzhou, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sichuan University; Sun Yat Sen University	Zhu, XF; Deng, R (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, Canc Ctr,State Key Lab Oncol South China, Guangzhou, Peoples R China.	zhuxfeng@mail.sysu.edu.cn; dengrong@sysucc.org.cn			Natural Science Foundation of China [81772624, 81572605, 81772835, 81972481, 81630079, 81972855]; Science and Technology Project of Guangzhou [201803010007]; China Postdoctoral Science Foundation [2020M683107]; Natural Science Foundation of Guangdong Province [2019A1515011209]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Project of Guangzhou; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province)	This study was supported by the Natural Science Foundation of China (81772624, 81572605, 81772835, 81972481, 81630079, and 81972855), the Science and Technology Project of Guangzhou (201803010007), China Postdoctoral Science Foundation (2020M683107) and the Natural Science Foundation of Guangdong Province (2019A1515011209).	Akasaka T, 1997, IMMUNITY, V7, P135, DOI 10.1016/S1074-7613(00)80516-6; Al-Zahrani KN, 2020, ONCOGENE, V39, P4592, DOI 10.1038/s41388-020-1315-3; Bhatnagar S, 2014, NATURE, V516, P116, DOI 10.1038/nature13955; Brown JS, 2017, PHARMACOL THERAPEUT, V172, P101, DOI 10.1016/j.pharmthera.2016.12.001; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Chun TH, 2005, FEBS LETT, V579, P5275, DOI 10.1016/j.febslet.2005.08.050; Deng R, 2021, AUTOPHAGY, V17, P3011, DOI 10.1080/15548627.2020.1850609; Elderkin S, 2007, MOL CELL, V28, P107, DOI 10.1016/j.molcel.2007.08.009; Fujisaki S, 2003, BIOCHEM BIOPH RES CO, V300, P135, DOI 10.1016/S0006-291X(02)02791-2; Gao ZH, 2012, MOL CELL, V45, P344, DOI 10.1016/j.molcel.2012.01.002; Ghosh JC, 2019, ONCOGENE, V38, P6926, DOI 10.1038/s41388-019-0939-7; Guo BH, 2010, ANN ONCOL, V21, P2361, DOI 10.1093/annonc/mdq241; Guo WJ, 2007, MOL BIOL CELL, V18, P536, DOI 10.1091/mbc.E06-05-0447; Kajiume T, 2004, EXP HEMATOL, V32, P571, DOI 10.1016/j.exphem.2004.03.001; KANNO M, 1995, EMBO J, V14, P5672, DOI 10.1002/j.1460-2075.1995.tb00254.x; Kimura M, 2001, IMMUNITY, V15, P275, DOI 10.1016/S1074-7613(01)00182-0; Klauke K, 2013, NAT CELL BIOL, V15, P353, DOI 10.1038/ncb2701; Kummar S, 2010, NAT REV DRUG DISCOV, V9, P843, DOI 10.1038/nrd3216; Lempiainen JK, 2020, ONCOGENE, V39, P2391, DOI 10.1038/s41388-020-1153-3; Li QQ, 2019, CELL REP, V28, P3406, DOI 10.1016/j.celrep.2019.08.066; Li X, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01272-2; Li ZL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17395-y; Liao SY, 2019, ONCOGENE, V38, P6723, DOI 10.1038/s41388-019-0928-x; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Mai J, 2019, THERANOSTICS, V9, P3541, DOI 10.7150/thno.32908; Marchi S, 2019, EMBO J, V38, DOI 10.15252/embj.201899435; Meng X, 2017, ONCOTARGET, V8, P72847, DOI 10.18632/oncotarget.20457; Morey L, 2015, CELL STEM CELL, V17, P300, DOI 10.1016/j.stem.2015.08.009; Nitulescu GM, 2018, INT J ONCOL, V53, P2319, DOI 10.3892/ijo.2018.4597; Nitulescu GM, 2016, INT J ONCOL, V48, P869, DOI 10.3892/ijo.2015.3306; Park JH, 2011, ONCOGENE, V30, P4578, DOI 10.1038/onc.2011.174; Perkail S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16589-8; Pietila M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10275-0; Scheuermann JC, 2010, NATURE, V465, P243, DOI 10.1038/nature08966; Su WJ, 2019, CANCER CELL, V36, P139, DOI 10.1016/j.ccell.2019.06.009; Tamburri S, 2020, MOL CELL, V77, P840, DOI 10.1016/j.molcel.2019.11.021; Uzawa K, 2013, CANCER MED-US, V2, P40, DOI 10.1002/cam4.56; Vidal M, 2017, EXP HEMATOL, V48, P12, DOI 10.1016/j.exphem.2016.12.006; Wan LX, 2018, MOL CELL, V69, P279, DOI 10.1016/j.molcel.2017.12.024; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wang W, 2011, UROL ONCOL-SEMIN ORI, V29, P244, DOI 10.1016/j.urolonc.2009.02.004; Wang YN, 2016, MOL CELL, V63, P34, DOI 10.1016/j.molcel.2016.05.027; Won HY, 2012, FASEB J, V26, P5002, DOI 10.1096/fj.12-209247; Xing Y, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1154-8; Zhang XW, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-40; Zhang YL, 2018, NAT CELL BIOL, V20, P1181, DOI 10.1038/s41556-018-0178-0; Zhang Z, 2017, P NATL ACAD SCI USA, V114, pE7949, DOI 10.1073/pnas.1711158114; Zhao ZB, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1870-5	48	3	3	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2021	40	13					2422	2436		10.1038/s41388-020-01602-7	http://dx.doi.org/10.1038/s41388-020-01602-7		MAR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RH1BQ	33664452				2022-12-17	WOS:000625833000003
J	Zheng, R; Du, ML; Ge, YQ; Gao, F; Xin, JY; Lv, Q; Qin, C; Zhu, Y; Gu, CY; Wang, MY; Zhu, QY; Guo, Z; Ben, S; Chu, HY; Ye, DW; Zhang, ZD; Wang, ML				Zheng, Rui; Du, Mulong; Ge, Yuqiu; Gao, Fang; Xin, Junyi; Lv, Qiang; Qin, Chao; Zhu, Yao; Gu, Chengyuan; Wang, Mengyun; Zhu, Qiuyuan; Guo, Zheng; Ben, Shuai; Chu, Haiyan; Ye, Dingwei; Zhang, Zhengdong; Wang, Meilin			Identification of low-frequency variants of UGT1A3 associated with bladder cancer risk by next-generation sequencing	ONCOGENE			English	Article							GENOME-WIDE ASSOCIATION; ANDROGEN RECEPTOR; GERMLINE MUTATIONS; CODING VARIANTS; RARE VARIANTS; MESSENGER-RNA; LUNG-CANCER; SUSCEPTIBILITY; POLYMORPHISMS; BREAST	Although genome-wide association studies (GWASs) have successfully revealed many common risk variants for bladder cancer, the heritability is still largely unexplained. We hypothesized that low-frequency variants involved in bladder cancer risk could reveal the unexplained heritability. Next-generation sequencing of 113 patients and 118 controls was conducted on 81 genes/regions of known bladder cancer GWAS loci. A two-stage validation comprising 3,350 cases and 4,005 controls was performed to evaluate the effects of low-frequency variants on bladder cancer risk. Biological experiments and techniques, including electrophoretic mobility shift assays, CRISPR/Cas9, RNA-Seq, and bioinformatics approaches, were performed to assess the potential functions of low-frequency variants. The low-frequency variant rs28898617 was located in the first exon of UGT1A3 and was significantly associated with increased bladder cancer risk (odds ratio = 1.50, P = 3.10 x 10(-6)). Intriguingly, rs28898617 was only observed in the Asian population, but monomorphism was observed in the European population. The risk-associated G allele of rs28898617 increased UGT1A3 expression, facilitated UGT1A3 transcriptional activity, and enhanced the binding activity. In addition, UGT1A3 deletion significantly inhibited the proliferation, invasion, and migration of bladder cancer cells and xenograft tumor growth. Mechanistically, UGT1A3 induced LAMC2 expression by binding CBP and promoting histone acetylation, which remarkably promoted the progression of bladder cancer. This is the first targeted sequencing study to reveal that the novel low-frequency variant rs28898617 and its associated gene UGT1A3 are involved in bladder cancer development, providing new insights into the genetic architecture of bladder cancer.	[Zheng, Rui; Du, Mulong; Ge, Yuqiu; Xin, Junyi; Zhu, Qiuyuan; Guo, Zheng; Ben, Shuai; Chu, Haiyan; Zhang, Zhengdong; Wang, Meilin] Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Dept Environm Genom, Nanjing, Peoples R China; [Zheng, Rui; Ge, Yuqiu; Gao, Fang; Xin, Junyi; Zhu, Qiuyuan; Guo, Zheng; Ben, Shuai; Chu, Haiyan; Zhang, Zhengdong; Wang, Meilin] Nanjing Med Univ, Dept Genet Toxicol, Key Lab Modern Toxicol, Minist Educ,Ctr Global Hlth,Sch Publ Hlth, Nanjing, Peoples R China; [Du, Mulong] Nanjing Med Univ, Sch Publ Hlth, Ctr Global Hlth, Dept Biostat, Nanjing, Peoples R China; [Gao, Fang] Southeast Univ, Key Lab Environm Med Engn, Minist Educ China, Sch Publ Hlth, Nanjing, Peoples R China; [Lv, Qiang; Qin, Chao] Nanjing Med Univ, Affiliated Hosp 1, Dept Urol, Nanjing, Peoples R China; [Zhu, Yao; Gu, Chengyuan; Wang, Mengyun; Ye, Dingwei] Fudan Univ, Shanghai Canc Ctr, Dept Urol, Shanghai, Peoples R China; [Wang, Meilin] Nanjing Med Univ, Affiliated Suzhou Hosp, Suzhou Municipal Hosp, Gusu Sch, Nanjing, Peoples R China; [Wang, Meilin] Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Inst Canc Res, Jiangsu Canc Hosp, Nanjing, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Ministry of Education, China; Southeast University - China; Nanjing Medical University; Fudan University; Nanjing Medical University; Nanjing Medical University	Zhang, ZD; Wang, ML (corresponding author), Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Dept Environm Genom, Nanjing, Peoples R China.; Zhang, ZD; Wang, ML (corresponding author), Nanjing Med Univ, Dept Genet Toxicol, Key Lab Modern Toxicol, Minist Educ,Ctr Global Hlth,Sch Publ Hlth, Nanjing, Peoples R China.; Wang, ML (corresponding author), Nanjing Med Univ, Affiliated Suzhou Hosp, Suzhou Municipal Hosp, Gusu Sch, Nanjing, Peoples R China.; Wang, ML (corresponding author), Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Inst Canc Res, Jiangsu Canc Hosp, Nanjing, Peoples R China.	drzdzhang@njmu.edu.cn; mwang@njmu.edu.cn	zhang, zheng/HCH-9684-2022	Xin, Junyi/0000-0001-6677-3936; Ye, Ding-wei/0000-0002-6761-5195	National Natural Science Foundation of China [81673264]; Priority Academic Program Development of Jiangsu Higher Education Institutions (Public Health and PreventiveMedicine)	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions (Public Health and PreventiveMedicine)	This study was supported in part by the National Natural Science Foundation of China (81673264) and the Priority Academic Program Development of Jiangsu Higher Education Institutions (Public Health and PreventiveMedicine). We are grateful to all the people who helped us accomplish this project. We thank Genesky Biotechnologies Inc. (Shanghai, China) for providing technical assistance.	1000 Genomes Project Consortium, 2012, Nature, V491, P56, DOI 10.1038/nature11632; Antoni S, 2017, EUR UROL, V71, P96, DOI 10.1016/j.eururo.2016.06.010; Bao LM, 2016, CELL BIOL TOXICOL, V32, P419, DOI 10.1007/s10565-016-9343-z; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen YK, 2006, DRUG METAB DISPOS, V34, P1462, DOI 10.1124/dmd.106.009761; Dobruch J, 2016, EUR UROL, V69, P300, DOI 10.1016/j.eururo.2015.08.037; Eichler EE, 2010, NAT REV GENET, V11, P446, DOI 10.1038/nrg2809; Ewing CM, 2012, NEW ENGL J MED, V366, P141, DOI 10.1056/NEJMoa1110000; Freedman ND, 2011, JAMA-J AM MED ASSOC, V306, P737, DOI 10.1001/jama.2011.1142; Fuchsberger C, 2016, NATURE, V536, P41, DOI 10.1038/nature18642; Ghasemzadeh A, 2016, CLIN CANCER RES, V22, P793, DOI 10.1158/1078-0432.CCR-15-1135; Gong QH, 2001, PHARMACOGENETICS, V11, P357, DOI 10.1097/00008571-200106000-00011; Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064; Gu JM, 2018, INT J MOL MED, V42, P1603, DOI 10.3892/ijmm.2018.3730; Gudmundsson J, 2012, NAT GENET, V44, P1326, DOI 10.1038/ng.2437; Hanioka N, 2012, BASIC CLIN PHARMACOL, V110, P253, DOI 10.1111/j.1742-7843.2011.00790.x; Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106; Hong SN, 2016, GUT, V65, P788, DOI 10.1136/gutjnl-2014-308617; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Inoue S, 2018, MOL CELL ENDOCRINOL, V465, P73, DOI 10.1016/j.mce.2017.06.021; Ionita-Laza I, 2013, AM J HUM GENET, V92, P841, DOI 10.1016/j.ajhg.2013.04.015; Iwai M, 2004, J HUM GENET, V49, P123, DOI 10.1007/s10038-003-0119-y; Izumi K, 2013, MOL CARCINOGEN, V52, P94, DOI 10.1002/mc.21833; Jin GF, 2015, AM J HUM GENET, V96, P832, DOI 10.1016/j.ajhg.2015.03.009; Jing YF, 2014, CANCER LETT, V348, P135, DOI 10.1016/j.canlet.2014.03.018; Kandimalla R, 2013, NAT REV UROL, V10, P327, DOI 10.1038/nrurol.2013.89; Khan A, 2018, NUCLEIC ACIDS RES, V46, pD260, DOI 10.1093/nar/gkx1126; Koutros S, 2016, INT J EPIDEMIOL, V45, P792, DOI 10.1093/ije/dyv195; Leslie EJ, 2015, AM J HUM GENET, V96, P397, DOI 10.1016/j.ajhg.2015.01.004; Li BS, 2008, AM J HUM GENET, V83, P311, DOI 10.1016/j.ajhg.2008.06.024; Liang Y, 2018, CELL DEATH DIFFER, V25, P1980, DOI 10.1038/s41418-018-0084-9; Lin DY, 2011, AM J HUM GENET, V89, P354, DOI [10.1016/j.ajhg.2011.07.015, 10.1016/j.ajhg.2011.07.015.]; Lombard AP, 2015, ENDOCR-RELAT CANCER, V22, pR265, DOI 10.1530/ERC-15-0209; Loveday C, 2011, NAT GENET, V43, P879, DOI 10.1038/ng.893; Ma Zhicheng, 2013, Mol Carcinog, V52, P916, DOI 10.1002/mc.21932; Mancuso N, 2016, NAT GENET, V48, P30, DOI 10.1038/ng.3446; Mucci LA, 2016, JAMA-J AM MED ASSOC, V315, P68, DOI 10.1001/jama.2015.17703; Nakamura A, 2008, DRUG METAB DISPOS, V36, P1461, DOI 10.1124/dmd.108.021428; Ockenga J, 2003, GASTROENTEROLOGY, V124, P1802, DOI 10.1016/S0016-5085(03)00294-4; Rothman N, 2010, NAT GENET, V42, P978, DOI 10.1038/ng.687; Ruark E, 2013, NATURE, V493, P406, DOI 10.1038/nature11725; Sathe A, 2018, METHODS MOL BIOL, V1655, P335, DOI 10.1007/978-1-4939-7234-0_23; Shyr D, 2013, BIOL PROCED ONLINE, V15, DOI 10.1186/1480-9222-15-4; Siegel RL, 2018, CA-CANCER J CLIN, V68, P30; Smith SC, 2009, AM J PATHOL, V174, P371, DOI 10.2353/ajpath.2009.080538; Strassburg CP, 1999, BIOCHEM J, V338, P489, DOI 10.1042/0264-6021:3380489; Stratton MR, 2008, NAT GENET, V40, P17, DOI 10.1038/ng.2007.53; Suer E, 2016, WORLD J UROL, V34, P847, DOI 10.1007/s00345-015-1710-5; Sun F, 2015, CARCINOGENESIS, V36, P757, DOI 10.1093/carcin/bgv040; Tukey RH, 2000, ANNU REV PHARMACOL, V40, P581, DOI 10.1146/annurev.pharmtox.40.1.581; Turati F, 2013, ANN ONCOL, V24, P2651, DOI 10.1093/annonc/mdt280; Vogel A, 2001, GASTROENTEROLOGY, V121, P1136, DOI 10.1053/gast.2001.28655; Wang L, 2018, XENOBIOTICA, V48, P357, DOI 10.1080/00498254.2017.1323139; Wang ML, 2016, CANCER RES, V76, P3277, DOI 10.1158/0008-5472.CAN-15-2564; Wang ML, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11478; Wang P, 2014, GENE CHROMOSOME CANC, V53, P98, DOI 10.1002/gcc.22121; Wang SY, 2013, GUT, V62, P496, DOI 10.1136/gutjnl-2011-301522; Wu JL, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00134; Yilmaz Latif, 2015, Asian Pac J Cancer Prev, V16, P1651; Yu XN, 2017, MOL VIS, V23, P296; Zhang YF, 2014, CANCER EPIDEM BIOMAR, V23, P622, DOI 10.1158/1055-9965.EPI-13-1043; Zhu M, 2017, GASTROENTEROLOGY, V152, P2011, DOI 10.1053/j.gastro.2017.02.017	62	3	3	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2021	40	13					2382	2394		10.1038/s41388-021-01672-1	http://dx.doi.org/10.1038/s41388-021-01672-1		MAR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RH1BQ	33658628	Green Published			2022-12-17	WOS:000625009600001
J	Ge, LP; Jin, X; Yang, YS; Liu, XY; Shao, ZM; Di, GH; Jiang, YZ				Ge, Li-Ping; Jin, Xi; Yang, Yun-Song; Liu, Xi-Yu; Shao, Zhi-Ming; Di, Gen-Hong; Jiang, Yi-Zhou			Tektin4 loss promotes triple-negative breast cancer metastasis through HDAC6-mediated tubulin deacetylation and increases sensitivity to HDAC6 inhibitor	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; MICROTUBULE-ASSOCIATED PROTEINS; DEXAMETHASONE; RICOLINOSTAT; COMBINATION; BORTEZOMIB; REGULATOR; DYNAMICS; STATHMIN	Progression of triple-negative breast cancer (TNBC) constitutes a major unresolved clinical challenge, and effective targeted therapies are lacking. Because microtubule dynamics play pivotal roles in breast cancer metastasis, we performed RNA sequencing on 245 samples from TNBC patients to characterize the landscape of microtubule-associated proteins (MAPs). Here, our transcriptome analyses revealed that low expression of one MAP, tektin4, indicated poor patient outcomes. Tektin4 loss led to a marked increase in TNBC migration, invasion, and metastasis and a decrease in microtubule stability. Mechanistically, we identified a novel microtubule-associated complex containing tektin4 and histone deacetylase 6 (HDAC6). Tektin4 loss increased the interaction between HDAC6 and alpha-tubulin, thus decreasing microtubule stability through HDAC6-mediated tubulin deacetylation. Significantly, we found that tektin4 loss sensitized TNBC cells, xenograft models, and patient-derived organoid models to the HDAC6-selective inhibitor ACY1215. Furthermore, tektin4 expression levels were positively correlated with microtubule stability levels in clinical samples. Together, our findings uncover a metastasis suppressor function of tektin4 and support clinical development of HDAC6 inhibition as a new therapeutic strategy for tektin4-deficient TNBC patients.	[Ge, Li-Ping; Jin, Xi; Yang, Yun-Song; Liu, Xi-Yu; Shao, Zhi-Ming; Di, Gen-Hong; Jiang, Yi-Zhou] Fudan Univ, Dept Breast Surg, Shanghai Canc Ctr, Shanghai, Peoples R China; [Ge, Li-Ping; Shao, Zhi-Ming] Fudan Univ, Human Phenome Inst, Shanghai, Peoples R China; [Ge, Li-Ping; Jin, Xi; Yang, Yun-Song; Liu, Xi-Yu; Shao, Zhi-Ming; Di, Gen-Hong; Jiang, Yi-Zhou] Fudan Univ, Canc Inst, Shanghai Canc Ctr, Shanghai, Peoples R China; [Ge, Li-Ping; Jin, Xi; Yang, Yun-Song; Liu, Xi-Yu; Shao, Zhi-Ming; Di, Gen-Hong; Jiang, Yi-Zhou] Key Lab Breast Canc Shanghai, Shanghai, Peoples R China; [Shao, Zhi-Ming; Di, Gen-Hong; Jiang, Yi-Zhou] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China; [Shao, Zhi-Ming; Di, Gen-Hong; Jiang, Yi-Zhou] Fudan Univ, Precis Canc Med Ctr, Shanghai Canc Ctr, Shanghai, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University; Fudan University	Di, GH; Jiang, YZ (corresponding author), Fudan Univ, Dept Breast Surg, Shanghai Canc Ctr, Shanghai, Peoples R China.; Di, GH; Jiang, YZ (corresponding author), Fudan Univ, Canc Inst, Shanghai Canc Ctr, Shanghai, Peoples R China.; Di, GH; Jiang, YZ (corresponding author), Key Lab Breast Canc Shanghai, Shanghai, Peoples R China.; Di, GH; Jiang, YZ (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China.; Di, GH; Jiang, YZ (corresponding author), Fudan Univ, Precis Canc Med Ctr, Shanghai Canc Ctr, Shanghai, Peoples R China.	genhongdi@163.com; yizhoujiang@fudan.edu.cn		Di, Genhong/0000-0003-1171-7907	National Natural Science Foundation of China [81874112, 91959207, 81922048, 81902684, 81874113]; Program of Shanghai Academic/Technology Research Leader [20XD1421100]; Fok Ying-Tong Education Foundation for College Young Teachers [171034]; Shanghai Sailing Program [19YF1409000]; Innovation Team of Ministry of Education [IRT1223]; Shanghai Key Laboratory of Breast Cancer [12DZ2260100]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program of Shanghai Academic/Technology Research Leader; Fok Ying-Tong Education Foundation for College Young Teachers; Shanghai Sailing Program; Innovation Team of Ministry of Education; Shanghai Key Laboratory of Breast Cancer	We would like to thank all the patients at Fudan University Shanghai Cancer Center for their support and commitment to tissue collection and banking. This work was supported by grants from the National Natural Science Foundation of China (81874112, 91959207, 81922048, 81902684, 81874113), the Program of Shanghai Academic/Technology Research Leader (20XD1421100), the Fok Ying-Tong Education Foundation for College Young Teachers (171034), the Shanghai Sailing Program (19YF1409000), the Innovation Team of Ministry of Education (IRT1223) and the Shanghai Key Laboratory of Breast Cancer (12DZ2260100).	Alesi GN, 2016, ONCOGENE, V35, P5412, DOI 10.1038/onc.2016.79; Amos LA, 2005, ADV PROTEIN CHEM, V71, P257, DOI 10.1016/S0065-3233(04)71007-4; Bhat KMR, 2007, CLIN CANCER RES, V13, P2849, DOI 10.1158/1078-0432.CCR-06-3040; Bitler BG, 2017, NAT CELL BIOL, V19, P962, DOI 10.1038/ncb3582; Cassimeris L, 2001, INT REV CYTOL, V210, P163; Chen JX, 2016, GUT, V65, P1522, DOI 10.1136/gutjnl-2015-310625; Collignon J, 2016, BREAST CANCER-TARGET, V8, P93, DOI 10.2147/BCTT.S69488; Costa RLB, 2017, J ONCOL PRACT, V13, P301, DOI 10.1200/JOP.2017.023333; Dai JL, 1996, MOL ENDOCRINOL, V10, P1582, DOI 10.1210/me.10.12.1582; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; DeSantis CE, 2019, CA-CANCER J CLIN, V69, P438, DOI 10.3322/caac.21583; Dong X, 2010, J PATHOL, V220, P361, DOI 10.1002/path.2662; Ell B, 2013, CANCER CELL, V24, P542, DOI 10.1016/j.ccr.2013.09.008; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Goodson HV, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a022608; Gradilone SA, 2013, CANCER RES, V73, P2259, DOI 10.1158/0008-5472.CAN-12-2938; Gu SC, 2016, J BIOL CHEM, V291, P5396, DOI 10.1074/jbc.M115.713123; Howlader N, 2018, CANCER EPIDEM BIOMAR, V27, P619, DOI 10.1158/1055-9965.EPI-17-0627; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Jacob F, 2020, CELL, V180, P188, DOI 10.1016/j.cell.2019.11.036; Jiang YY, 2016, ONCOGENE, V35, P4846, DOI 10.1038/onc.2016.17; Jiang YZ, 2019, CANCER CELL, V35, P428, DOI 10.1016/j.ccell.2019.02.001; Jiang YZ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4802; Laks DR, 2018, NEURO-ONCOLOGY, V20, P764, DOI 10.1093/neuonc/nox215; Le Large TYS, 2019, THER ADV MED ONCOL, V11, DOI 10.1177/1758835919841233; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; LHERNAULT SW, 1985, J CELL BIOL, V100, P457, DOI 10.1083/jcb.100.2.457; Li N, 2011, P NATL ACAD SCI USA, V108, P12851, DOI 10.1073/pnas.1017372108; Li T, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0654-9; Liu JR, 2019, BIOCHEM PHARMACOL, V163, P458, DOI 10.1016/j.bcp.2019.03.023; MACCIONI RB, 1995, PHYSIOL REV, V75, P835, DOI 10.1152/physrev.1995.75.4.835; Mak AB, 2012, CELL REP, V2, P951, DOI 10.1016/j.celrep.2012.09.016; Nakaya Y, 2008, NAT CELL BIOL, V10, P765, DOI 10.1038/ncb1739; Rey M, 2011, EUR J CELL BIOL, V90, P128, DOI 10.1016/j.ejcb.2010.09.004; Rodrigues-Ferreira S, 2020, BREAST CANCER RES TR, V179, P267, DOI 10.1007/s10549-019-05463-x; Santo L, 2012, BLOOD, V119, P2579, DOI 10.1182/blood-2011-10-387365; Tala, 2014, THERANOSTICS, V4, P1052, DOI 10.7150/thno.9727; Tran DD, 2011, MOL CANCER RES, V9, P1644, DOI 10.1158/1541-7786.MCR-11-0371; Valenzuela-Fernandez A, 2008, TRENDS CELL BIOL, V18, P291, DOI 10.1016/j.tcb.2008.04.003; Vogl DT, 2017, CLIN CANCER RES, V23, P3307, DOI 10.1158/1078-0432.CCR-16-2526; Wang J, 2017, ONCOTARGET, V8, P96215, DOI 10.18632/oncotarget.21894; Yang YF, 2014, P NATL ACAD SCI USA, V111, P2158, DOI 10.1073/pnas.1319341111; Yee AJ, 2016, LANCET ONCOL, V17, P1569, DOI 10.1016/S1470-2045(16)30375-8; Zhang Y, 2006, J BIOL CHEM, V281, P2401, DOI 10.1074/jbc.C500241200; Zhao L, 2019, ONCOGENE, V38, P935, DOI 10.1038/s41388-018-0493-8; Zheng ZC, 2018, ENDOCR PATHOL, V29, P310, DOI 10.1007/s12022-018-9549-0; Zilberman Y, 2009, J CELL SCI, V122, P3531, DOI 10.1242/jcs.046813	47	3	3	1	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2323	2334		10.1038/s41388-021-01655-2	http://dx.doi.org/10.1038/s41388-021-01655-2		MAR 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33654196				2022-12-17	WOS:000624398900003
J	Yamaguchi, J; Kokuryo, T; Yokoyama, Y; Ebata, T; Ochiai, Y; Nagino, M				Yamaguchi, Junpei; Kokuryo, Toshio; Yokoyama, Yukihiro; Ebata, Tomoki; Ochiai, Yosuke; Nagino, Masato			Premalignant pancreatic cells seed stealth metastasis in distant organs in mice	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; DISSEMINATED TUMOR-CELLS; EARLY DISSEMINATION; CANCER; MECHANISMS; EXPRESSION; INVASION; DORMANCY	Recent findings suggest that the dissemination of tumor cells occurs at the early stage of breast and pancreatic carcinogenesis, which is known as early dissemination. The evidence of early dissemination has been demonstrated predominantly in the bloodstream and bone marrow; however, limited evidence has revealed the existence and behavior of disseminated cells in distant organs. Here, we show that premalignant pancreatic cells seed distant stealth metastasis that eventually develops into manifest metastasis. By analyzing lineage-labeled pancreatic cancer mouse models (KPCT/TFF1KO; Pdx1-Cre/LSL-KRAS(G1)(2D)/LSL-p53(R172H)/LSL-tdTomato/TFF1KO), we found that premalignant pancreatic cells, rather than mature malignant cells, were prone to enter the bloodstream and reside in the bone marrow, liver, and lung. While these metastatic cells exhibited the characteristics of the cells of host organs and did not behave as malignant cells, they underwent malignant transformation and formed distinct tumors. Surprisingly, the manifestation of distant metastasis occurred even before tumor development in the primary site. Our data revealed that disseminated premalignant cells reside stealthily in distant organs and evolve in parallel with the progression of the primary tumor. These observations suggest that we must rebuild a therapeutic strategy for metastatic pancreatic cancer.	[Yamaguchi, Junpei; Kokuryo, Toshio; Yokoyama, Yukihiro; Ebata, Tomoki; Ochiai, Yosuke; Nagino, Masato] Nagoya Univ, Dept Surg, Div Surg Oncol, Grad Sch Med,Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668560, Japan	Nagoya University	Yamaguchi, J (corresponding author), Nagoya Univ, Dept Surg, Div Surg Oncol, Grad Sch Med,Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668560, Japan.	jumpei@med.nagoya-u.ac.jp	Nagino, Masato/I-7342-2014	Yamaguchi, Junpei/0000-0002-5892-5271	Japan Society for the Promotion of Science (JSPS) [17K10695, 20H03751]	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by the Japan Society for the Promotion of Science (JSPS) and Grants-in-Aid for Scientific Research (KAKENHI) (grant number 17K10695 and 20H03751).	Ao Z, 2015, CANCER RES, V75, P4681, DOI 10.1158/0008-5472.CAN-15-1633; Banys M, 2012, BREAST CANCER RES TR, V131, P801, DOI 10.1007/s10549-011-1478-2; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Clawson GA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184451; Fizazi K, 2015, ANN ONCOL, V26, pV133, DOI 10.1093/annonc/mdv305; Gast CE, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aat7828; Giancotti FG, 2013, CELL, V155, P750, DOI 10.1016/j.cell.2013.10.029; Greco FA, 2009, SEMIN ONCOL, V36, P6, DOI 10.1053/j.seminoncol.2008.10.007; Harper KL, 2016, NATURE, V540, P588, DOI 10.1038/nature20609; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hosseini H, 2016, NATURE, V540, P552, DOI 10.1038/nature20785; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Kang YB, 2013, CANCER CELL, V23, P573, DOI 10.1016/j.ccr.2013.04.017; Klein CA, 2002, LANCET, V360, P683, DOI 10.1016/S0140-6736(02)09838-0; Klein CA, 2009, NAT REV CANCER, V9, P302, DOI 10.1038/nrc2627; Kurashige M, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0137-0; Liu QF, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61487-0; Min S, 2013, CANCER GENE THER, V20, P379, DOI 10.1038/cgt.2013.36; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Ochiai Y, 2020, HEPATOLOGY, V72, P503, DOI 10.1002/hep.31039; Podsypanina K, 2008, SCIENCE, V321, P1841, DOI 10.1126/science.1161621; Rhim AD, 2014, GASTROENTEROLOGY, V146, P647, DOI 10.1053/j.gastro.2013.12.007; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Sanger N, 2011, INT J CANCER, V129, P2522, DOI 10.1002/ijc.25895; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; Soutto M, 2015, GUT, V64, P1028, DOI 10.1136/gutjnl-2014-307191; Sunagawa M, 2017, PANCREATOLOGY, V17, P782, DOI 10.1016/j.pan.2017.07.188; Sutton TL, 2019, CELL MOL GASTROENTER, V8, P595, DOI 10.1016/j.jcmgh.2019.07.002; Wang LD, 2015, GENE DEV, V29, P171, DOI 10.1101/gad.253591.114; Yamaguchi J, 2018, J CLIN INVEST, V128, P3619, DOI 10.1172/JCI97755; Yatabe Y, 2002, AM J SURG PATHOL, V26, P767, DOI 10.1097/00000478-200206000-00010	32	3	3	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2273	2284		10.1038/s41388-021-01706-8	http://dx.doi.org/10.1038/s41388-021-01706-8		MAR 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33649537				2022-12-17	WOS:000623739900003
J	Chen, L; Zhang, YA; Shu, X; Chen, Q; Wei, TT; Wang, HM; Wang, XR; Wu, QR; Zhang, XM; Liu, XY; Zheng, SY; Huang, L; Xiao, JY; Jiang, C; Yang, B; Wang, ZP; Guo, X				Chen, Lu; Zhang, Yanan; Shu, Xin; Chen, Qiong; Wei, Tiantian; Wang, Heman; Wang, Xiaorong; Wu, Qirou; Zhang, Xiaomei; Liu, Xiaoyan; Zheng, Suya; Huang, Lan; Xiao, Junyu; Jiang, Chao; Yang, Bing; Wang, Zhiping; Guo, Xing			Proteasome regulation by reversible tyrosine phosphorylation at the membrane	ONCOGENE			English	Article								Reversible phosphorylation has emerged as an important mechanism for regulating 26S proteasome function in health and disease. Over 100 phospho-tyrosine sites of the human proteasome have been detected, and yet their function and regulation remain poorly understood. Here we show that the 19S subunit Rpt2 is phosphorylated at Tyr439, a strictly conserved residue within the C-terminal HbYX motif of Rpt2 that is essential for 26S proteasome assembly. Unexpectedly, we found that Y439 phosphorylation depends on Rpt2 membrane localization mediated by its N-myristoylation. Multiple receptors tyrosine kinases can trigger Rpt2-Y439 phosphorylation by activating Src, a N-myristoylated tyrosine kinase. Src directly phosphorylates Rpt2-Y439 in vitro and negatively regulates 26S proteasome activity at cellular membranes, which can be reversed by the membrane-associated isoform of protein tyrosine phosphatase nonreceptor type 2 (PTPN2). In H1975 lung cancer cells with activated Src, blocking Rpt2-Y439 phosphorylation by the Y439F mutation conferred partial resistance to the Src inhibitor saracatinib both in vitro and in a mouse xenograft tumor model, and caused significant changes of cellular responses to saracatinib at the proteome level. Our study has defined a novel mechanism involved in the spatial regulation of proteasome function and provided new insights into tyrosine kinase inhibitor-based anticancer therapies.	[Chen, Lu; Zhang, Yanan; Shu, Xin; Chen, Qiong; Wang, Heman; Wu, Qirou; Zhang, Xiaomei; Liu, Xiaoyan; Zheng, Suya; Jiang, Chao; Yang, Bing; Guo, Xing] Zhejiang Univ, Inst Life Sci, Zhejiang Prov Key Lab Canc Mol Cell Biol, Hangzhou, Peoples R China; [Wei, Tiantian; Xiao, Junyu] Peking Univ, Acad Adv Interdisciplinary Studies, Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China; [Wang, Xiaorong; Huang, Lan] Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92717 USA; [Wang, Xiaorong; Huang, Lan] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92717 USA; [Wang, Zhiping] Zhejiang Univ, Sch Med, Ctr Neurosci, Hangzhou, Peoples R China; [Wang, Zhiping] Zhejiang Univ, Sch Med, Dept Neurol, NHC & CAMS Key Lab Med Neurobiol,Affiliated Hosp, Hangzhou, Peoples R China	Zhejiang University; Peking University; University of California System; University of California Irvine; University of California System; University of California Irvine; Zhejiang University; Zhejiang University	Guo, X (corresponding author), Zhejiang Univ, Inst Life Sci, Zhejiang Prov Key Lab Canc Mol Cell Biol, Hangzhou, Peoples R China.; Wang, ZP (corresponding author), Zhejiang Univ, Sch Med, Ctr Neurosci, Hangzhou, Peoples R China.; Wang, ZP (corresponding author), Zhejiang Univ, Sch Med, Dept Neurol, NHC & CAMS Key Lab Med Neurobiol,Affiliated Hosp, Hangzhou, Peoples R China.	z4wang@zju.edu.cn; xguo@zju.edu.cn	Liu, XiaoYan/GQA-7216-2022	Xiao, Junyu/0000-0003-1822-1701	Natural Science Foundation of China [31671391, 31870762, 91953103, 31671039]; Zhejiang Natural Science Foundation [LR18C050001]; Fundamental Research Funds for the Central Universities [2016QN81011]; Zhejiang University; National Key Research and Development Plan of the Ministry of Science and Technology of China [2016YF0501000]; NIH [R01GM074830]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Zhejiang Natural Science Foundation(Natural Science Foundation of Zhejiang Province); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Zhejiang University; National Key Research and Development Plan of the Ministry of Science and Technology of China; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Drs. Xin-Hua Feng, Hai Song, Bin Zhao (Life Sciences Institute, Zhejiang University, LSI-ZJU), Zhong-Yin Zhang (Purdue University), Shigeo Murata (The University of Tokyo), and Susan Lindquist (Massachusetts Institute of Technology) for crucial constructs, cell lines, and reagents. We are grateful for the critical and encouraging comments from Drs. Kun-Liang Guan, Anne-Claude Gingras, Benjamin Neel, Tony Hunter, and Tony Tiganis. We appreciate the technical assistance from Xiaorui Jiang, Fei Zhang, and the Core Facilities of LSI-ZJU. XG was supported by Natural Science Foundation of China (31671391, 31870762), Zhejiang Natural Science Foundation (LR18C050001), Fundamental Research Funds for the Central Universities (2016QN81011), and the startup funding from Zhejiang University. BY was funded by Natural Science Foundation of China (91953103). ZW was supported by Natural Science Foundation of China (31671039) and National Key Research and Development Plan of the Ministry of Science and Technology of China (2016YF0501000). LH was funded by NIH (R01GM074830).	Albert S, 2017, P NATL ACAD SCI USA, V114, P13726, DOI 10.1073/pnas.1716305114; Alevizopoulos K, 2014, CURR DRUG TARGETS, V15, P988, DOI 10.2174/1389450115666140908125025; Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Bard JAM, 2018, ANNU REV BIOCHEM, V87, P697, DOI 10.1146/annurev-biochem-062917-011931; Barr AJ, 2010, FUTURE MED CHEM, V2, P1563, DOI [10.4155/fmc.10.241, 10.4155/FMC.10.241]; Bose S, 2001, BIOCHEM J, V353, P291, DOI 10.1042/0264-6021:3530291; Budenholzer L, 2017, J MOL BIOL, V429, P3500, DOI 10.1016/j.jmb.2017.05.027; Casaletto JB, 2012, NAT REV CANCER, V12, P386, DOI 10.1038/nrc3277; Collins GA, 2017, CELL, V169, P792, DOI 10.1016/j.cell.2017.04.023; Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337; Eisele MR, 2018, CELL REP, V24, P1301, DOI 10.1016/j.celrep.2018.07.004; Feng Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00850-0; Finley D, 2020, CSH PERSPECT BIOL, V12, DOI 10.1101/cshperspect.a033985; Finley D, 2009, ANNU REV BIOCHEM, V78, P477, DOI 10.1146/annurev.biochem.78.081507.101607; Formisano L, 2015, ONCOTARGET, V6, P26090, DOI 10.18632/oncotarget.4636; Frankson R, 2017, CANCER RES, V77, P5701, DOI 10.1158/0008-5472.CAN-17-1510; Guerrero C, 2008, P NATL ACAD SCI USA, V105, P13333, DOI 10.1073/pnas.0801870105; Guo X, 2017, PROTEIN CELL, V8, P255, DOI 10.1007/s13238-017-0382-x; Guo X, 2016, NAT CELL BIOL, V18, P202, DOI 10.1038/ncb3289; Hein MY, 2015, CELL, V163, P712, DOI 10.1016/j.cell.2015.09.053; Hemmis CW, 2019, J BIOL CHEM, V294, P9659, DOI 10.1074/jbc.AC119.008881; Heun Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184404; Huang XL, 2016, NAT STRUCT MOL BIOL, V23, P778, DOI 10.1038/nsmb.3273; Hunter T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a020644; Julien SG, 2011, NAT REV CANCER, V11, P35, DOI 10.1038/nrc2980; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; Kikuchi J, 2010, PROTEOMICS, V10, P2769, DOI 10.1002/pmic.200900283; Kim YC, 2011, J BIOL CHEM, V286, P26652, DOI 10.1074/jbc.M111.246793; Kimura A, 2016, J PROTEOMICS, V130, P33, DOI 10.1016/j.jprot.2015.08.021; Kimura A, 2012, BIOCHEMISTRY-US, V51, P8856, DOI 10.1021/bi3007862; Kimura Y, 2003, ARCH BIOCHEM BIOPHYS, V409, P341, DOI 10.1016/S0003-9861(02)00639-2; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kolch W, 2010, NAT REV CANCER, V10, P618, DOI 10.1038/nrc2900; Kumar B, 2010, J BIOL CHEM, V285, P39523, DOI 10.1074/jbc.M110.153627; Kumar P, 2017, J PROTEOME RES, V16, P2789, DOI 10.1021/acs.jproteome.7b00065; Li DP, 2015, CELL REP, V10, P484, DOI 10.1016/j.celrep.2014.12.044; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; Liu XY, 2020, P NATL ACAD SCI USA, V117, P328, DOI 10.1073/pnas.1912531117; Liu X, 2006, MOL CELL, V22, P317, DOI 10.1016/j.molcel.2006.04.007; Lokireddy S, 2015, P NATL ACAD SCI USA, V112, pE7176, DOI 10.1073/pnas.1522332112; Manguso RT, 2017, NATURE, V547, P413, DOI 10.1038/nature23270; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Moritz A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000998; Muppirala M, 2013, BBA-MOL CELL RES, V1833, P1125, DOI 10.1016/j.bbamcr.2013.01.004; Murata S, 2018, NAT IMMUNOL, V19, P923, DOI 10.1038/s41590-018-0186-z; Murata S, 2009, NAT REV MOL CELL BIO, V10, P104, DOI 10.1038/nrm2630; Park S, 2013, NATURE, V497, P512, DOI 10.1038/nature12123; Park S, 2009, NATURE, V459, P866, DOI 10.1038/nature08065; Ramachandran KV, 2017, NAT STRUCT MOL BIOL, V24, P419, DOI 10.1038/nsmb.3389; RIVETT AJ, 1992, J HISTOCHEM CYTOCHEM, V40, P1165, DOI 10.1177/40.8.1619280; Satoh K, 2001, BIOCHEMISTRY-US, V40, P314, DOI 10.1021/bi001815n; Schmidt M, 2014, BBA-MOL CELL RES, V1843, P13, DOI 10.1016/j.bbamcr.2013.08.012; Scott JD, 2009, SCIENCE, V326, P1220, DOI 10.1126/science.1175668; Sharma K, 2014, CELL REP, V8, P1583, DOI 10.1016/j.celrep.2014.07.036; Shibahara T, 2002, EUR J BIOCHEM, V269, P1474, DOI 10.1046/j.1432-1033.2002.02792.x; Simanshu DK, 2017, CELL, V170, P17, DOI 10.1016/j.cell.2017.06.009; Smith DM, 2007, MOL CELL, V27, P731, DOI 10.1016/j.molcel.2007.06.033; St-Denis N, 2016, CELL REP, V17, P2488, DOI 10.1016/j.celrep.2016.10.078; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; TANAKA K, 1990, BIOCHEMISTRY-US, V29, P3777, DOI 10.1021/bi00467a026; Tang M, 2017, THERANOSTICS, V7, P1346, DOI 10.7150/thno.18804; Thinon E, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5919; Tibes R, 2005, ANNU REV PHARMACOL, V45, P357, DOI 10.1146/annurev.pharmtox.45.120403.100124; van Vliet C, 2005, NAT IMMUNOL, V6, P253, DOI 10.1038/ni1169; VerPlank JJS, 2017, BIOCHEM J, V474, P3355, DOI 10.1042/BCJ20160809; Wang JH, 2015, MOL CELL, V58, P710, DOI 10.1016/j.molcel.2015.05.002; Wang XR, 2007, BIOCHEMISTRY-US, V46, P3553, DOI 10.1021/bi061994u; Wei J, 2019, NATURE, V576, P471, DOI 10.1038/s41586-019-1821-z; Wiede F, 2020, EMBO J, V39, DOI 10.15252/embj.2019103637; Ye Diana Zi, 2012, Cell Logist, V2, P105; Ye Z, 2015, SCI REP-UK, V5, DOI 10.1038/srep16599; Zhang S, 2009, J AM CHEM SOC, V131, P13072, DOI 10.1021/ja903733z; Zhang ZY, 2017, ACCOUNTS CHEM RES, V50, P122, DOI 10.1021/acs.accounts.6b00537; Zong C, 2006, CIRC RES, V99, P372, DOI 10.1161/01.RES.0000237389.40000.02	74	3	3	1	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					1942	1956		10.1038/s41388-021-01674-z	http://dx.doi.org/10.1038/s41388-021-01674-z		FEB 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33603165	Green Submitted, Green Accepted			2022-12-17	WOS:000619433100003
J	Koschut, D; Ray, D; Li, ZH; Giarin, E; Groet, J; Alic, I; Kham, SKY; Chng, WJ; Ariffin, H; Weinstock, DM; Yeoh, AEJ; Basso, G; Nizetic, D				Koschut, David; Ray, Debleena; Li, Zhenhua; Giarin, Emanuela; Groet, Jurgen; Alic, Ivan; Kham, Shirley Kow-Yin; Chng, Wee Joo; Ariffin, Hany; Weinstock, David M.; Yeoh, Allen Eng-Juh; Basso, Giuseppe; Nizetic, Dean			RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia	ONCOGENE			English	Article								Leukemias are routinely sub-typed for risk/outcome prediction and therapy choice using acquired mutations and chromosomal rearrangements. Down syndrome acute lymphoblastic leukemia (DS-ALL) is characterized by high frequency of CRLF2-rearrangements, JAK2-mutations, or RAS-pathway mutations. Intriguingly, JAK2 and RAS-mutations are mutually exclusive in leukemic sub-clones, causing dichotomy in therapeutic target choices. We prove in a cell model that elevated CRLF2 in combination with constitutionally active JAK2 is sufficient to activate wtRAS. On primary clinical DSALL samples, we show that wtRAS-activation is an obligatory consequence of mutated/hyperphosphorylated JAK2. We further prove that CRLF2-ligand TSLP boosts the direct binding of active PTPN11 to wtRAS, providing the molecular mechanism for the wtRAS activation. Pre-inhibition of RAS or PTPN11, but not of PI3K or JAK-signaling, prevented TSLP-induced RAS-GTP boost. Cytotoxicity assays on primary clinical DS-ALL samples demonstrated that, regardless of mutation status, high-risk leukemic cells could only be killed using RAS-inhibitor or PTPN11-inhibitor, but not PI3K/JAK-inhibitors, suggesting a unified treatment target for up to 80% of DS-ALL. Importantly, protein activities-based principal-component-analysis multivariate clusters analyzed for independent outcome prediction using Cox proportional-hazards model showed that protein-activity (but not mutation-status) was independently predictive of outcome, demanding a paradigm-shift in patient-stratification strategy for precision therapy in high-risk ALL.	[Koschut, David; Ray, Debleena; Alic, Ivan; Nizetic, Dean] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore; [Li, Zhenhua; Kham, Shirley Kow-Yin] Natl Univ Singapore, Dept Paediat, Yong Loo Lin Sch Med, Singapore, Singapore; [Giarin, Emanuela; Basso, Giuseppe] Univ Padua, Dept Womens & Childrens Hlth SDB, Hematol Oncol Lab, Padua, Italy; [Groet, Jurgen; Nizetic, Dean] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England; [Alic, Ivan] Univ Zagreb, Fac Vet Med, Dept Anat Histol & Embryol, Zagreb, Croatia; [Chng, Wee Joo; Yeoh, Allen Eng-Juh] Natl Univ Canc Inst, Singapore, Singapore; [Ariffin, Hany] Univ Malaya, Med Ctr, Kuala Lumpur, Malaysia; [Weinstock, David M.] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Basso, Giuseppe] Italian Inst Genom Med, Turin, Italy	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; National University of Singapore; University of Padua; University of London; Queen Mary University London; University of Zagreb; National University of Singapore; Universiti Malaya; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Italian Institute for Genomic Medicine (IIGM)	Nizetic, D (corresponding author), Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore.	d.nizetic@qmul.ac.uk	ARIFFIN, HANY/B-8590-2010	ARIFFIN, HANY/0000-0002-4607-8837; Nizetic, Dean/0000-0001-5486-5761; Koschut, David/0000-0003-2204-5165; Ray, Debleena/0000-0002-8232-4062; Alic, Ivan/0000-0002-8125-8198; Li, Zhenhua/0000-0002-3623-6571	Singapore Ministry of Education Academic Research Funds Tier 2 grants [2015-T2-2-119, 2015-T2-1-023]; AIRC [IG 19186]; Fondazione Cariparo [17/07]	Singapore Ministry of Education Academic Research Funds Tier 2 grants; AIRC(Fondazione AIRC per la ricerca sul cancro); Fondazione Cariparo(Fondazione Cariparo)	Singapore Ministry of Education Academic Research Funds Tier 2 grants (2015-T2-2-119 and 2015-T2-1-023) to DN; AIRC IG 19186 and Fondazione Cariparo 17/07 to GB.	Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bercovich D, 2008, LANCET, V372, P1484, DOI 10.1016/S0140-6736(08)61341-0; Berger R, 1997, CANCER GENET CYTOGEN, V94, P8, DOI 10.1016/S0165-4608(96)00351-2; Bhojwani D, 2013, LANCET ONCOL, V14, pE205, DOI 10.1016/S1470-2045(12)70580-6; Buitenkamp TD, 2014, BLOOD, V123, P70, DOI 10.1182/blood-2013-06-509463; Bunda S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9859; Castellano Esther, 2011, Genes Cancer, V2, P261, DOI 10.1177/1947601911408079; De Vita S, 2007, BRIT J HAEMATOL, V137, P337, DOI 10.1111/j.1365-2141.2007.06574.x; Den Boer ML, 2009, LANCET ONCOL, V10, P125, DOI 10.1016/S1470-2045(08)70339-5; Groet J, 2003, LANCET, V361, P1617, DOI 10.1016/S0140-6736(03)13266-7; Harrison CJ, 2013, HEMATOL-AM SOC HEMAT, P118, DOI 10.1182/asheducation-2013.1.118; Hasle H, 2016, GENET MED, V18, P1151, DOI 10.1038/gim.2016.23; Hobbs GA, 2016, J CELL SCI, V129, P1287, DOI 10.1242/jcs.182873; Holmfeldt L, 2013, NAT GENET, V45, P242, DOI 10.1038/ng.2532; Hunger SP, 2015, BLOOD, V125, P3977, DOI 10.1182/blood-2015-02-580043; Inaba H, 2013, LANCET, V381, P1943, DOI 10.1016/S0140-6736(12)62187-4; Knight T, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00160; Laurent AP, 2020, CLIN CANCER RES, V26, P3307, DOI 10.1158/1078-0432.CCR-19-3519; Lee P, 2016, LEUKEMIA, V30, P1816, DOI 10.1038/leu.2016.164; McMahon LP, 2005, MOL ENDOCRINOL, V19, P175, DOI 10.1210/me.2004-0305; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; Mohi MG, 1998, MOL BIOL CELL, V9, P3299, DOI 10.1091/mbc.9.12.3299; Mullighan CG, 2009, NEW ENGL J MED, V360, P470, DOI 10.1056/NEJMoa0808253; Nguyen K, 2008, LEUKEMIA, V22, P2142, DOI 10.1038/leu.2008.251; Nikolaev SI, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5654; Nikolaev SI, 2013, BLOOD, V122, P554, DOI 10.1182/blood-2013-03-491936; Nizetic D, 2012, NAT REV CANCER, V12, P721, DOI 10.1038/nrc3355; Norton A, 2007, BLOOD, V110, P1077, DOI 10.1182/blood-2007-03-080374; Paulsson K, 2008, GENE CHROMOSOME CANC, V47, P26, DOI 10.1002/gcc.20502; Potter N, 2019, LEUKEMIA, V33, P893, DOI 10.1038/s41375-018-0297-4; Pui CH, 2008, LANCET, V371, P1030, DOI 10.1016/S0140-6736(08)60457-2; Pui CH, 2015, J CLIN ONCOL, V33, P2938, DOI 10.1200/JCO.2014.59.1636; Roberts KG, 2018, BEST PRACT RES CL HA, V31, P351, DOI 10.1016/j.beha.2018.09.003; Roberts KG, 2017, BLOOD ADV, V1, P1657, DOI 10.1182/bloodadvances.2017011296; Roberts KG, 2015, NAT REV CLIN ONCOL, V12, P344, DOI 10.1038/nrclinonc.2015.38; Roberts KG, 2012, CANCER CELL, V22, P153, DOI 10.1016/j.ccr.2012.06.005; Russell LJ, 2009, BLOOD, V114, P2688, DOI 10.1182/blood-2009-03-208397; Ryan SL, 2016, LEUKEMIA, V30, P1824, DOI 10.1038/leu.2016.80; Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557; Schwartzman O, 2017, P NATL ACAD SCI USA, V114, pE4030, DOI 10.1073/pnas.1702489114; Tasian SK, 2017, BLOOD, V130, P2064, DOI 10.1182/blood-2017-06-743252; Tasian SK, 2017, BLOOD, V129, P177, DOI 10.1182/blood-2016-05-707653; Tasian SK, 2012, BLOOD, V120, P833, DOI 10.1182/blood-2011-12-389932; Thompson BJ, 2015, J EXP MED, V212, P723, DOI 10.1084/jem.20150002; Vyas P, 2006, EARLY HUM DEV, V82, P767, DOI 10.1016/j.earlhumdev.2006.09.016; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; Yamamoto T, 2006, LEUKEMIA RES, V30, P1085, DOI 10.1016/j.leukres.2006.02.004; Yeoh AEJ, 2018, J CLIN ONCOL, V36, P2726, DOI 10.1200/JCO.2018.78.3050; Yeoh AEJ, 2012, J CLIN ONCOL, V30, P2384, DOI 10.1200/JCO.2011.40.5936; Yoda A, 2010, P NATL ACAD SCI USA, V107, P252, DOI 10.1073/pnas.0911726107	50	3	3	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2021	40	4					746	762		10.1038/s41388-020-01567-7	http://dx.doi.org/10.1038/s41388-020-01567-7			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RA8FZ	33247204	Green Published, hybrid, Green Submitted			2022-12-17	WOS:000631656200001
J	Kim, HJ; Kim, JY; Jung, CW; Lee, YS; An, JY; Kim, EH; Kim, KH; Lee, SP; Park, JY; Park, MJ				Kim, Hee-Jin; Kim, Jeong-Yub; Jung, Chan-Woong; Lee, Young-Sun; An, Joon-Yong; Kim, Eun Ho; Kim, Ki-Hong; Lee, Sang Pyung; Park, Jae-Yong; Park, Myung-Jin			ANO1 regulates the maintenance of stemness in glioblastoma stem cells by stabilizing EGFRvIII	ONCOGENE			English	Article							CHLORIDE CHANNEL TMEM16A; GROWTH-FACTOR RECEPTOR; TUMOR-GROWTH; CANCER; EXPRESSION; PROTEIN; CONTRIBUTES; GLIOMA; IDENTIFICATION; CONCOMITANT	Glioblastoma multiforme (GBM) or glioblastoma is the most deadly malignant brain tumor in adults. GBM is difficult to treat mainly due to the presence of glioblastoma stem cells (GSCs). Epidermal growth factor receptor variant III (EGFRvIII) has been linked to stemness and malignancy of GSCs; however, the regulatory mechanism of EGFRvIII is largely unknown. Here, we demonstrated that Anoctamin-1 (ANO1), a Ca2+-activated Cl- channel, interacts with EGFRvIII, increases its protein stability, and supports the maintenance of stemness and tumor progression in GSCs. Specifically, shRNA-mediated knockdown and pharmacological inhibition of ANO1 suppressed the self-renewal, invasion activities, and expression of EGFRvIII and related stem cell factors, including NOTCH1, nestin, and SOX2 in GSCs. Conversely, ANO1 overexpression enhanced the above phenomena. Mechanistically, ANO1 protected EGFRvIII from proteasomal degradation by directly binding to it. ANO1 knockdown significantly increased survival in mice and strongly suppressed local invasion of GSCs in an in vivo intracranial mouse model. Collectively, these results suggest that ANO1 plays a crucial role in the maintenance of stemness and invasiveness of GSCs by regulating the expression of EGFRvIII and related signaling molecules, and can be considered a promising therapeutic target for GBM treatment.	[Kim, Hee-Jin; Kim, Jeong-Yub; Jung, Chan-Woong; Park, Myung-Jin] Korea Inst Radiol & Med Sci, Radiat Therapeut Dev Team, Div Radiat Canc Sci, Seoul, South Korea; [Kim, Hee-Jin; Lee, Young-Sun; An, Joon-Yong; Park, Jae-Yong] Korea Univ, Sch Biosyst & Biomed Sci, Coll Hlth Sci, Seoul, South Korea; [Jung, Chan-Woong] Korea Univ, Dept Life Sci, Seoul, South Korea; [Kim, Eun Ho] Daegu Catholic Univ, Sch Med, Dept Biochem, Daegu, South Korea; [Kim, Ki-Hong] Daegu Catholic Univ, Dept Neurosurg, Sch Med, Daegu, South Korea; [Lee, Sang Pyung] Halla Gen Hosp, Dept Neurosurg, Jeju, South Korea	Korea Institute of Radiological & Medical Sciences; Korea University; Korea University; Catholic University of Daegu; Catholic University of Daegu	Park, MJ (corresponding author), Korea Inst Radiol & Med Sci, Radiat Therapeut Dev Team, Div Radiat Canc Sci, Seoul, South Korea.; Park, JY (corresponding author), Korea Univ, Sch Biosyst & Biomed Sci, Coll Hlth Sci, Seoul, South Korea.	jaeyong68@korea.ac.kr; mjpark@kirams.re.kr		An, Joon-Yong/0000-0001-8839-6297	National Research Foundation of Korea [NRF-2017M3A9C4092979]; Korea Institute of Radiological and Medical Sciences (KIRAMS) - Ministry of Science and ICT (MSIT), the Republic of Korea [50531-2019]	National Research Foundation of Korea(National Research Foundation of Korea); Korea Institute of Radiological and Medical Sciences (KIRAMS) - Ministry of Science and ICT (MSIT), the Republic of Korea	This work was supported by the Bio-Synergy Research Project (NRF-2017M3A9C4092979 to JYP) of the National Research Foundation of Korea, and by a grant from the Korea Institute of Radiological and Medical Sciences (KIRAMS), funded by the Ministry of Science and ICT (MSIT), the Republic of Korea (No. 50531-2019 to MJP).	Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bill A, 2015, ONCOTARGET, V6, P9173, DOI 10.18632/oncotarget.3277; Bill A, 2014, J BIOL CHEM, V289, P11029, DOI 10.1074/jbc.M114.549188; Bleeker FE, 2012, J NEURO-ONCOL, V108, P11, DOI 10.1007/s11060-011-0793-0; Britschgi A, 2013, P NATL ACAD SCI USA, V110, pE1026, DOI 10.1073/pnas.1217072110; Caputo A, 2008, SCIENCE, V322, P590, DOI 10.1126/science.1163518; Carles A, 2006, ONCOGENE, V25, P1821, DOI 10.1038/sj.onc.1209203; Carneiro A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-98; Cheng L, 2011, BIOCHEM BIOPH RES CO, V406, P643, DOI 10.1016/j.bbrc.2011.02.123; Cho H, 2012, NAT NEUROSCI, V15, P1015, DOI 10.1038/nn.3111; Crottes D, 2019, CELL CALCIUM, V82, DOI 10.1016/j.ceca.2019.06.004; Crottes D, 2019, P NATL ACAD SCI USA, V116, P13026, DOI 10.1073/pnas.1900703116; De la Fuente R, 2008, MOL PHARMACOL, V73, P758, DOI 10.1124/mol.107.043208; de la Iglesia N, 2009, CURR MOL MED, V9, P580; Del Vecchio CA, 2013, ONCOGENE, V32, P2670, DOI 10.1038/onc.2012.280; Duvvuri U, 2012, CANCER RES, V72, P3270, DOI 10.1158/0008-5472.CAN-12-0475-T; Emlet DR, 2014, CANCER RES, V74, P1238, DOI 10.1158/0008-5472.CAN-13-1407; Eskilsson E, 2016, NEURO-ONCOLOGY, V18, P1644, DOI 10.1093/neuonc/now113; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Gallego O, 2015, CURR ONCOL, V22, pE273, DOI 10.3747/co.22.2436; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Hatanpaa KJ, 2010, NEOPLASIA, V12, P675, DOI 10.1593/neo.10688; Huang F, 2012, P NATL ACAD SCI USA, V109, P16354, DOI 10.1073/pnas.1214596109; Huang PH, 2007, P NATL ACAD SCI USA, V104, P12867, DOI 10.1073/pnas.0705158104; Huang X, 2002, P NATL ACAD SCI USA, V99, P11369, DOI 10.1073/pnas.172285799; Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510; Ji QS, 2019, J CELL PHYSIOL, V234, P7856, DOI 10.1002/jcp.27865; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Katoh M, 2003, INT J ONCOL, V22, P1375; Lee YS, 2016, BIOCHEM BIOPH RES CO, V475, P216, DOI 10.1016/j.bbrc.2016.05.077; Lee YS, 2016, SCI REP-UK, V6, DOI 10.1038/srep26413; Liu F, 2015, ONCOTARGET, V6, P11585, DOI 10.18632/oncotarget.3412; Liu J, 2014, MOL MED REP, V9, P1068, DOI 10.3892/mmr.2014.1888; Liu W, 2012, CANCER LETT, V326, P41, DOI 10.1016/j.canlet.2012.07.015; Ma MM, 2017, HYPERTENSION, V69, P892, DOI 10.1161/HYPERTENSIONAHA.116.08874; Mukherjee B, 2009, CANCER RES, V69, P4252, DOI 10.1158/0008-5472.CAN-08-4853; Murat A, 2008, J CLIN ONCOL, V26, P3015, DOI 10.1200/JCO.2007.15.7164; Oh U, 2016, PFLUG ARCH EUR J PHY, V468, P443, DOI 10.1007/s00424-016-1790-0; Pedemonte N, 2014, PHYSIOL REV, V94, P419, DOI 10.1152/physrev.00039.2011; Sauter DRP, 2015, PFLUG ARCH EUR J PHY, V467, P1495, DOI 10.1007/s00424-014-1598-8; Schroeder BC, 2008, CELL, V134, P1019, DOI 10.1016/j.cell.2008.09.003; Shiwarski DJ, 2014, CLIN CANCER RES, V20, P4673, DOI 10.1158/1078-0432.CCR-14-0363; Simon S, 2013, CANCER RES, V73, P3661, DOI 10.1158/0008-5472.CAN-12-3839; Singh SK, 2003, CANCER RES, V63, P5821; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Sui YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115443; Wang H, 2019, CANCER LETT, V455, P48, DOI 10.1016/j.canlet.2019.04.027; Wang H, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0720-x; Yang YD, 2008, NATURE, V455, P1210, DOI 10.1038/nature07313; Yin J, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002152	50	3	3	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2021	40	8					1490	1502		10.1038/s41388-020-01612-5	http://dx.doi.org/10.1038/s41388-020-01612-5		JAN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QM6NM	33452454				2022-12-17	WOS:000607998600007
J	Chen, DJ; Parker, TM; Bhat-Nakshatri, P; Chu, XN; Liu, YL; Wang, Y; Nakshatri, H				Chen, Duojiao; Parker, Taylor M.; Bhat-Nakshatri, Poornima; Chu, Xiaona; Liu, Yunlong; Wang, Yue; Nakshatri, Harikrishna			Nonlinear relationship between chromatin accessibility and estradiol-regulated gene expression	ONCOGENE			English	Article							PIONEER TRANSCRIPTION FACTORS; BREAST-CANCER; ER-ALPHA; TAMOXIFEN RESISTANCE; DNA-BINDING; FOXA1; ENHANCERS; REVEALS; RECRUITMENT; REPRESSION	Chromatin accessibility is central to basal and inducible gene expression. Through ATAC-seq experiments in estrogen receptor-positive (ER+) breast cancer cell line MCF-7 and integration with multi-omics data, we found estradiol (E2) induced chromatin accessibility changes in a small number of breast cancer-relevant E2-regulated genes. As expected, open chromatin regions associated with E2-inducible gene expression showed enrichment of estrogen response element (ERE) and those associated with E2-repressible gene expression were enriched for ERE, PBX1, and PBX3. While a significant number of open chromatin regions showed pioneer factor FOXA1 occupancy in the absence of E2, E2-treatment further enhanced FOXA1 occupancy suggesting that ER-E2 enhances chromatin occupancy of FOXA1 to a subset of E2-regulated genes. Surprisingly, promoters of 80% and enhancers of 60% of E2-inducible genes displayed closed chromatin configuration both in the absence and presence of E2. Integration of ATAC-seq data with ER alpha ChIP-seq data revealed that similar to 40% ER alpha binding sites in the genome are found in chromatin regions that are not accessible as per ATAC-seq. Such ER alpha binding regions were enriched for binding sites of multiple nuclear receptors including ER, ESRRB, ERR gamma, COUP-TFII (NR2F2), RAR alpha, EAR2 as well as traditional pioneer factors FOXA1 and GATA3. Similar data were also obtained when ER alpha ChIP-seq data were integrated with MNase-seq and DNase-seq data sets. In summation, our results reveal complex mechanisms of ER-E2 interaction with nucleosomes. Notably, "closed chromatin" configuration as defined by ATAC-seq or by other techniques is not necessarily associated with lack of gene expression and technical limitations may preclude ATAC-seq to demonstrate accessibility of chromatin regions that are bound by ER alpha.	[Chen, Duojiao; Chu, Xiaona; Liu, Yunlong; Wang, Yue] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; [Parker, Taylor M.; Bhat-Nakshatri, Poornima; Nakshatri, Harikrishna] Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA; [Nakshatri, Harikrishna] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; [Nakshatri, Harikrishna] Roudebush VA Med Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	Wang, Y (corresponding author), Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.; Nakshatri, H (corresponding author), Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA.; Nakshatri, H (corresponding author), Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.; Nakshatri, H (corresponding author), Roudebush VA Med Ctr, Indianapolis, IN 46202 USA.	yuewang@iu.edu; hnakshat@iupui.edu	Chen, Duojiao/GRY-2410-2022	Wang, Yue/0000-0003-4671-8547; Nakshatri, Harikrishna/0000-0001-8876-0052	Susan G Komen for the Cure [SAC110025]	Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation)	Susan G Komen for the Cure (SAC110025 to HN) supported this work. We also thank the members of the Medical Genomics core for sequencing and help with data analyses.	Abba MC, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-37; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Andersson R, 2020, NAT REV GENET, V21, P71, DOI 10.1038/s41576-019-0173-8; Bhat-Nakshatri P, 2008, MOL CELL BIOL, V28, P7487, DOI 10.1128/MCB.00799-08; Brambati A, 2020, MUTAT RES-REV MUTAT, V784, DOI 10.1016/j.mrrev.2020.108300; Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Castellano-Pozo M, 2013, MOL CELL, V52, P583, DOI 10.1016/j.molcel.2013.10.006; Cheung E, 2010, ANNU REV PHYSIOL, V72, P191, DOI 10.1146/annurev-physiol-021909-135840; Chung CY, 2019, CELL REP, V29, P495, DOI 10.1016/j.celrep.2019.08.089; Cocce KJ, 2019, CELL REP, V29, P889, DOI 10.1016/j.celrep.2019.09.032; Costantino L, 2015, CURR OPIN CELL BIOL, V34, P39, DOI 10.1016/j.ceb.2015.04.008; D'Souza AD, 2018, BBA-GENE REGUL MECH, V1861, P158, DOI 10.1016/j.bbagrm.2017.12.008; De Bosscher K, 2020, NAT REV ENDOCRINOL, V16, P363, DOI 10.1038/s41574-020-0349-5; Drouin J, 2014, MOL ENDOCRINOL, V28, P989, DOI 10.1210/me.2014-1084; Dumelie JG, 2017, ELIFE, V6, DOI 10.7554/eLife.28306; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Pham D, 2019, CELL REP, V29, P1203, DOI 10.1016/j.celrep.2019.09.064; Esnault C, 2017, MOL CELL, V65, P1081, DOI 10.1016/j.molcel.2017.02.005; Fleming JD, 2013, GENOME RES, V23, P1195, DOI 10.1101/gr.148080.112; Gao TS, 2020, NUCLEIC ACIDS RES, V48, pD58, DOI 10.1093/nar/gkz980; Glont SE, 2019, CELL REP, V26, P2558, DOI 10.1016/j.celrep.2019.02.036; Goswami CP, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-970; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; Guertin MJ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004613; Hah N, 2011, CELL, V145, P622, DOI 10.1016/j.cell.2011.03.042; Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Iwafuchi-Doi M, 2016, MOL CELL, V62, P79, DOI 10.1016/j.molcel.2016.03.001; Jiang GJ, 2019, THERANOSTICS, V9, P6501, DOI 10.7150/thno.34874; Jozwik KM, 2012, NAT REV CANCER, V12, P381, DOI 10.1038/nrc3263; Liu Z, 2018, J CELL BIOL, V217, P1181, DOI 10.1083/jcb.201710038; Liu ZJ, 2014, CELL, V159, P358, DOI 10.1016/j.cell.2014.08.027; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; Magnani L, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002368; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; Meers MP, 2019, MOL CELL, V75, P562, DOI 10.1016/j.molcel.2019.05.025; Mueller B, 2017, GENE DEV, V31, P451, DOI 10.1101/gad.293118.116; Murakami S, 2019, MOL CANCER RES, V17, P2356, DOI 10.1158/1541-7786.MCR-19-0393; Nardini M, 2013, CELL, V152, P132, DOI 10.1016/j.cell.2012.11.047; Nardone V, 2017, BBA-GENE REGUL MECH, V1860, P571, DOI 10.1016/j.bbagrm.2016.09.006; Oldfield AJ, 2014, MOL CELL, V55, P708, DOI 10.1016/j.molcel.2014.07.005; Paakinaho V, 2019, CELL REP, V28, P3523, DOI 10.1016/j.celrep.2019.08.039; Sato S, 2019, OPEN BIOL, V9, DOI 10.1098/rsob.190116; Stork CT, 2016, ELIFE, V5, DOI 10.7554/eLife.17548; Swinstead EE, 2018, ENDOCR-RELAT CANCER, V25, pR385, DOI 10.1530/ERC-18-0033; Swinstead EE, 2016, CELL, V165, P593, DOI 10.1016/j.cell.2016.02.067; Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88; Wu YM, 2018, CANCER RES, V78, P671, DOI 10.1158/0008-5472.CAN-17-1327; Yang F, 2017, MOL CELL, V66, P321, DOI 10.1016/j.molcel.2017.03.019; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zaret KS, 2011, GENE DEV, V25, P2227, DOI 10.1101/gad.176826.111; Zhu C, 2019, MOL CELL, V75, P791, DOI 10.1016/j.molcel.2019.06.010; Zhuang T, 2015, ONCOTARGET, V6, P43853, DOI 10.18632/oncotarget.6081	55	3	3	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2021	40	7					1332	1346		10.1038/s41388-020-01607-2	http://dx.doi.org/10.1038/s41388-020-01607-2		JAN 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QK0LS	33420376				2022-12-17	WOS:000607346000007
J	Sharma, S; Pei, XH; Xing, F; Wu, SY; Wu, KR; Tyagi, A; Zhao, D; Deshpande, R; Ruiz, MG; Singh, R; Lyu, F; Watabe, K				Sharma, Sambad; Pei, Xinhong; Xing, Fei; Wu, Shih-Ying; Wu, Kerui; Tyagi, Abhishek; Zhao, Dan; Deshpande, Ravindra; Ruiz, Marco Gabriel; Singh, Ravi; Lyu, Feng; Watabe, Kounosuke			Regucalcin promotes dormancy of prostate cancer	ONCOGENE			English	Article							SMOOTH-MUSCLE; RADICAL PROSTATECTOMY; MAMMARY-GLAND; HUMAN BREAST; PROTEIN; CELLS; GENE; EXPRESSION; PROLIFERATION; REVEALS	Prostate cancer is one of the leading causes of mortality in men. The major cause of death in prostate cancer patients can be attributed to metastatic spread of disease or tumor recurrence after initial treatment. Prostate tumors are known to remain undetected or dormant for a long period of time before they progress locoregionally or at distant sites as overt tumors. However, the molecular mechanism of dormancy is yet poorly understood. In this study, we performed a differential gene expression analysis and identified a gene, Regucalcin (RGN), which promotes dormancy of prostate cancer. We found that cancer patients expressing higher level of RGN showed significantly longer recurrence-free and overall- survival. Using a doxycycline-inducible RGN expression system, we showed that ectopic expression of RGN in prostate tumor cells induced dormancy in vivo, while following suppression of RGN triggered recurrence of tumor growth. On the other hand, silencing RGN in LNCap cells promoted its outgrowth in the tibia of mice. Importantly, RGN promoted multiple known hallmarks of tumor dormancy including activation of p38 MAPK, decrease in Erk signaling and inhibition of FOXM1 expression. Furthermore, we found that RGN significantly suppressed angiogenesis by increasing secretory miR-23c level in the exosomes. Intriguingly, FOXM1 was found to negatively regulate miR-23c expression in prostate cancer. In addition, we identified 11 RGN downstream target genes that independently predicted longer recurrence-free survival in patients. We found that expression of these genes was regulated by FOXM1 and/or p38 MAPK. These findings suggest a critical role of RGN in prostate cancer dormancy, and the utility of RGN signaling and exosomal miR-23c as biomarkers for predicting recurrence.	[Sharma, Sambad; Xing, Fei; Wu, Shih-Ying; Wu, Kerui; Tyagi, Abhishek; Zhao, Dan; Deshpande, Ravindra; Ruiz, Marco Gabriel; Lyu, Feng; Watabe, Kounosuke] Wake Forest Baptist Med Ctr, Dept Canc Biol, Winston Salem, NC 27157 USA; [Pei, Xinhong] Zhengzhou Univ, Affiliated Hosp 1, Dept Breast Surg, Zhengzhou 450052, Henan, Peoples R China	Wake Forest University; Wake Forest Baptist Medical Center; Zhengzhou University	Watabe, K (corresponding author), Wake Forest Baptist Med Ctr, Dept Canc Biol, Winston Salem, NC 27157 USA.	kwatabe@wakehealth.edu	Deshpande, Ravindra/AAE-6392-2021; Tyagi, Abhishek/CAF-1274-2022; Singh, Ravi N/A-5740-2011; Tyagi, Abhishek/AFZ-6213-2022; Zhao, Dan/Y-8065-2019	Tyagi, Abhishek/0000-0002-0155-2099; Singh, Ravi N/0000-0003-0750-1804; Tyagi, Abhishek/0000-0002-0155-2099; Zhao, Dan/0000-0002-5120-6725	NIH [RO1CA173499, RO1CA185650, RO1CA205067]; China Scholarship Council [2014084100701, 2018093]; National Institutes of Health [P30CA012197]; comprehensive cancer center of Wake Forest University	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); China Scholarship Council(China Scholarship Council); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); comprehensive cancer center of Wake Forest University	This work was supported by NIH grant RO1CA173499, RO1CA185650, and RO1CA205067 to KW. XP was supported by State Scholarship fund (2014084100701) by China Scholarship Council. FL was supported by State Scholarship fund 2018093 by China Scholarship Council. The tumor tissue and pathology shared resources, biostatistics/bioinformatics shared resources, flow cytometry, and cell engineering shared resources are supported by comprehensive cancer center of Wake Forest University and, National Institutes of Health Grant (P30CA012197). The funding agency had no role in study design, data collection, data analysis, interpretation, and writing of the report. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute.	Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Amin KN, 2020, MICROVASC RES, V127, DOI 10.1016/j.mvr.2019.103924; Aslan C, 2019, J CELL PHYSIOL, V234, P16885, DOI 10.1002/jcp.28374; Ayala G, 2003, CLIN CANCER RES, V9, P4792; Aytes A, 2014, CANCER CELL, V25, P638, DOI 10.1016/j.ccr.2014.03.017; Boorjian SA, 2011, EUR UROL, V59, P893, DOI 10.1016/j.eururo.2011.02.026; Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698; Cackowski FC, 2019, PROSTATE, V79, P1715, DOI 10.1002/pros.23896; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chand V, 2019, MOL CANCER RES, V17, P1063, DOI 10.1158/1541-7786.MCR-18-0968; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Chen MH, 2011, CANCER CELL, V20, P173, DOI 10.1016/j.ccr.2011.07.013; Chery L, 2014, ONCOTARGET, V5, P9939, DOI 10.18632/oncotarget.2480; Corey E, 2002, PROSTATE, V52, P20, DOI 10.1002/pros.10091; Crumbaker M, 2017, CANCERS, V9, DOI 10.3390/cancers9040034; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Eckers JC, 2014, RADIAT RES, V182, P420, DOI 10.1667/RR13726.1; Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767; Henderson JR, 1999, DEV DYNAM, V214, P229, DOI 10.1002/(SICI)1097-0177(199903)214:3<229::AID-AJA6>3.0.CO;2-S; Huang W, 2012, ONCOGENE, V31, P4527, DOI 10.1038/onc.2011.573; Huang YQ, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0820-4; Ishigami A, 2015, GERIATR GERONTOL INT, V15, P804, DOI 10.1111/ggi.12347; Jones CU, 2011, NEW ENGL J MED, V365, P107, DOI 10.1056/NEJMoa1012348; Kalluri R, 2016, J CLIN INVEST, V126, P1208, DOI 10.1172/JCI81135; Kim MJ, 2002, P NATL ACAD SCI USA, V99, P2884, DOI 10.1073/pnas.042688999; Kobayashi A, 2011, J EXP MED, V208, P2641, DOI 10.1084/jem.20110840; Kupelian P, 1996, UROLOGY, V48, P249, DOI 10.1016/S0090-4295(96)00167-7; Long X, 2009, J BIOL CHEM, V284, P33671, DOI 10.1074/jbc.M109.050419; Lyu TJ, 2013, EPIGENETICS-US, V8, P1330, DOI 10.4161/epi.26675; Maia C, 2009, J CELL BIOCHEM, V107, P667, DOI 10.1002/jcb.22158; Maia CJB, 2008, MOL CELL BIOCHEM, V311, P81, DOI 10.1007/s11010-007-9697-x; Marques R, 2015, EXP CELL RES, V330, P325, DOI 10.1016/j.yexcr.2014.08.007; Marques R, 2014, CELL MOL LIFE SCI, V71, P93, DOI 10.1007/s00018-013-1323-3; MIWA T, 1991, MOL CELL BIOL, V11, P3296, DOI 10.1128/MCB.11.6.3296; Morgan TM, 2009, CLIN CANCER RES, V15, P677, DOI 10.1158/1078-0432.CCR-08-1754; Nakagawa T, 2008, INT J MOL MED, V21, P605; Paulin D, 2004, EXP CELL RES, V301, P1, DOI 10.1016/j.yexcr.2004.08.004; Petit I, 2007, TRENDS IMMUNOL, V28, P299, DOI 10.1016/j.it.2007.05.007; Ribeiro Mara Fernandes, 2013, Curr Angiogenes, V2, P54; Shaked Y, 2014, CURR PHARM DESIGN, V20, P4920; Sharma S, 2019, EBIOMEDICINE, V44, P194, DOI 10.1016/j.ebiom.2019.05.038; Sharma S, 2016, J BIOL CHEM, V291, P19351, DOI 10.1074/jbc.M116.737379; Sharma S, 2014, FRONT BIOSCI-LANDMRK, V19, P339, DOI 10.2741/4211; Sosa MS, 2011, CLIN CANCER RES, V17, P5850, DOI 10.1158/1078-0432.CCR-10-2574; Tanjore H, 2006, AM J PATHOL, V168, P715, DOI 10.2353/ajpath.2006.051321; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Varisli L, 2013, GENET TEST MOL BIOMA, V17, P562, DOI 10.1089/gtmb.2012.0524; Vaz CV, 2016, CURR MOL MED, V16, P607, DOI 10.2174/156652401666616; Vaz CV, 2015, TRANSL RES, V166, P693, DOI 10.1016/j.trsl.2015.08.009; Vaz CV, 2015, BBA-MOL CELL RES, V1853, P2621, DOI 10.1016/j.bbamcr.2015.07.006; Wang J, 2017, ONCOL LETT, V13, P4979, DOI 10.3892/ol.2017.6050; Wu KR, 2017, BBA-REV CANCER, V1868, P538, DOI 10.1016/j.bbcan.2017.10.001; Xing F, 2018, CANCER RES, V78, P4316, DOI 10.1158/0008-5472.CAN-18-1102; Yamaguchi M, 2005, INT J MOL MED, V15, P371; YAMAGUCHI M, 1990, BIOCHEM MED METAB B, V43, P140, DOI 10.1016/0885-4505(90)90019-W; Yamaguchi M, 2018, INT J ONCOL, V53, P1313, DOI 10.3892/ijo.2018.4458; Yamaguchi M, 2017, MOL CELL BIOCHEM, V430, P37, DOI 10.1007/s11010-017-2952-x; Yamaguchi M, 2016, INT J ONCOL, V49, P812, DOI 10.3892/ijo.2016.3538; Yamaguchi M, 2016, INT J ONCOL, V48, P1955, DOI 10.3892/ijo.2016.3409; Yamaguchi M, 2015, J CANCER RES CLIN, V141, P1333, DOI 10.1007/s00432-014-1831-z; Yamaguchi M, 2013, APOPTOSIS, V18, P1145, DOI 10.1007/s10495-013-0859-x; Yang ZH, 2017, DIS MODEL MECH, V10, P39, DOI 10.1242/dmm.027417	62	3	3	3	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2021	40	5					1012	1026		10.1038/s41388-020-01565-9	http://dx.doi.org/10.1038/s41388-020-01565-9		DEC 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC5NB	33323968	Green Accepted			2022-12-17	WOS:000599126500010
J	Teinturier, R; Luo, YK; Decaussin-Petrucci, M; Vlaeminck-Guillem, V; Vacherot, F; Firlej, V; Bonnavion, R; Abou Ziki, R; Gherardi, S; Goddard, I; Gadot, N; Bertolino, P; Le Romancer, M; Zhang, CX				Teinturier, Romain; Luo, Yakun; Decaussin-Petrucci, Myriam; Vlaeminck-Guillem, Virginie; Vacherot, Francis; Firlej, Virginie; Bonnavion, Remy; Abou Ziki, Razan; Gherardi, Samuele; Goddard, Isabelle; Gadot, Nicolas; Bertolino, Philippe; Le Romancer, Muriel; Zhang, Chang Xian			Men1 disruption in Nkx3.1-deficient mice results in AR(low)/CD44(+) microinvasive carcinoma development with the dysregulated AR pathway	ONCOGENE			English	Article							PROSTATE-CANCER; CELLS; GENE; MECHANISMS; COMPLEX	Dysregulated androgen receptor (AR) plays a crucial role in prostate cancer (PCa) development, though further factors involved in its regulation remain to be identified. Recently, paradoxical results were reported on the implication of the MEN1 gene in PCa. To dissect its role in prostate luminal cells, we generated a mouse model with inducible Men1 disruption in Nkx3.1-deficient mice in which mouse prostatic intraepithelial neoplasia (mPIN) occur. Prostate glands from mutant and control mice were analyzed pathologically and molecularly; cellular and molecular analyses were carried out in PCa cell lines after MEN1 knockdown (KD) by siRNA. Double-mutant mice developed accelerated mPIN and later displayed microinvasive adenocarcinoma. Markedly, early-stage lesions exhibited a decreased expression of AR and its target genes, accompanied by reduced CK18 and E-cadherin expression, suggesting a shift from a luminal to a dedifferentiated epithelial phenotype. Intriguingly, over 60% of menin-deficient cells expressed CD44 at a later stage. Furthermore, MEN1 KD led to the increase in CD44 expression in PC3 cells re-expressing AR. Menin bound to the proximal AR promoter and regulated AR transcription via the H3K4me3 histone mark. Interestingly, the cell proliferation of AR-dependent cells (LNCaP, 22Rv1, and VCaP), but not of AR-independent cells (DU145, PC3), responded strongly to MEN1 silencing. Finally, menin expression was found reduced in some human PCa. These findings highlight the regulation of the AR promoter by menin and the crosstalk between menin and the AR pathway. Our data could be useful for better understanding the increasingly reported AR-negative/NE-negative subtype of PCa and the mechanisms underlying its development.	[Teinturier, Romain; Luo, Yakun; Decaussin-Petrucci, Myriam; Vlaeminck-Guillem, Virginie; Bonnavion, Remy; Abou Ziki, Razan; Gherardi, Samuele; Bertolino, Philippe; Le Romancer, Muriel; Zhang, Chang Xian] Univ Claude Bernard Lyon 1, Univ Lyon, Ctr Rech Cancerol Lyon, Ctr Leon Berard,INSERM 1052,CNRS 5286, F-69008 Lyon, France; [Decaussin-Petrucci, Myriam; Vlaeminck-Guillem, Virginie] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Ctr Biol & Anatomopathol Sud, F-69495 Lyon, France; [Vacherot, Francis; Firlej, Virginie] Univ Paris Est Creteil, TRePCa, F-94010 Creteil, France; [Firlej, Virginie] Hop Univ Henri Mondor, Plateforme Ressources Biol, F-94000 Creteil, France; [Goddard, Isabelle] Univ Claude Bernard Lyon 1, Univ Lyon, Lab Modeles Tumoraux,INSERM 1052,CNRS 5286, Ctr Rech Cancerol Lyon CRCL,Fdn Synergie Lyon Can, F-69373 Lyon, France; [Gadot, Nicolas] Univ Claude Bernard Lyon 1, Univ Lyon, INSERM 1052,CNRS 5286,Ctr Leon Berard, Plateforme Anatomopathol Rech,Ctr Rech Cancerol L, F-69373 Lyon, France; [Teinturier, Romain] Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden; [Bonnavion, Remy] Max Planck Inst Heart & Lung Res, Bad Nauheim, Germany	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard; CHU Lyon; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard; Karolinska Institutet; Max Planck Society	Zhang, CX (corresponding author), Univ Claude Bernard Lyon 1, Univ Lyon, Ctr Rech Cancerol Lyon, Ctr Leon Berard,INSERM 1052,CNRS 5286, F-69008 Lyon, France.	chang.zhang@lyon.unicancer.fr	DECAUSSIN PETRUCCI, MYRIAM/GWZ-7373-2022; Bertolino, philippe/D-4072-2018; Firlej, Virginie/AFQ-6362-2022	Bertolino, philippe/0000-0001-8064-8269; Firlej, Virginie/0000-0003-4132-0695; Bonnavion, Remy/0000-0002-7389-4282; LUO, YAKUN/0000-0002-9644-5025	Epigenetics Cancer Program [ASC14092CSA]; Fondation de l'Association pour la Recherche contre le Cancer [SFI20101201530]; Ligue Inter-regionale contre le Cancer [R19040CC]; Association Le Cancer du Sein Parlons-en; Region Auvergne, Rhone-Alpes [SICORRA22425]; French Ministry of Higher Education and Research; Societe Francaise d'Endocrinologie; Fondation ARC, France; China Scholarship Council; Association "G04MEDIA S.A.R.L," Lebanon	Epigenetics Cancer Program; Fondation de l'Association pour la Recherche contre le Cancer; Ligue Inter-regionale contre le Cancer; Association Le Cancer du Sein Parlons-en; Region Auvergne, Rhone-Alpes(Region Auvergne-Rhone-Alpes); French Ministry of Higher Education and Research; Societe Francaise d'Endocrinologie; Fondation ARC, France; China Scholarship Council(China Scholarship Council); Association "G04MEDIA S.A.R.L," Lebanon	This study was supported by Epigenetics & Cancer Program (ASC14092CSA), the Fondation de l'Association pour la Recherche contre le Cancer (SFI20101201530), the Ligue Inter-regionale contre le Cancer (R19040CC), the Association Le Cancer du Sein Parlons-en, and the Region Auvergne, Rhone-Alpes, (SICORRA22425). RT and RB were the recipients of a PhD fellowship from French Ministry of Higher Education and Research, and of a 4th year doctoral fellowship from Societe Francaise d'Endocrinologie and the Fondation ARC, France, respectively. YL was the recipient of a PhD fellowship from China Scholarship Council. RAZ was the recipient of a PhD fellowship from Association "G04MEDIA S.A.R.L," Lebanon.	Abida W, 2019, P NATL ACAD SCI USA, V116, P11428, DOI 10.1073/pnas.1902651116; Altintas DM, 2011, MOL CELL ENDOCRINOL, V332, P149, DOI 10.1016/j.mce.2010.10.007; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Bertolino P, 2003, CANCER RES, V63, P4836; Bluemn EG, 2017, CANCER CELL, V32, P474, DOI 10.1016/j.ccell.2017.09.003; Dreijerink KMA, 2017, CELL REP, V18, P2359, DOI 10.1016/j.celrep.2017.02.025; Dreijerink KMA, 2014, NEW ENGL J MED, V371, P583, DOI 10.1056/NEJMc1406028; Floc'h N, 2012, CANCER RES, V72, P4483, DOI 10.1158/0008-5472.CAN-12-0283; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Li QH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06067-7; Liu X, 2015, ONCOTARGET, V6, P23959, DOI 10.18632/oncotarget.4260; Malik R, 2015, NAT MED, V21, P344, DOI 10.1038/nm.3830; Paris PL, 2009, PROSTATE CANCER P D, V12, P184, DOI 10.1038/pcan.2008.45; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Qin JC, 2012, CELL STEM CELL, V10, P556, DOI 10.1016/j.stem.2012.03.009; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Rybak AP, 2015, ONCOTARGET, V6, P1900, DOI 10.18632/oncotarget.2953; Seigne C, 2013, J PATHOL, V229, P546, DOI 10.1002/path.4146; Shilatifard A, 2012, ANNU REV BIOCHEM, V81, P65, DOI 10.1146/annurev-biochem-051710-134100; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Srinivasan D, 2019, J CELL BIOCHEM, V120, P2413, DOI 10.1002/jcb.27573; Thiel AT, 2012, BIOESSAYS, V34, P771, DOI 10.1002/bies.201200007; Wang X, 2009, NATURE, V461, P495, DOI 10.1038/nature08361; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004	25	3	3	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2021	40	6					1118	1127		10.1038/s41388-020-01589-1	http://dx.doi.org/10.1038/s41388-020-01589-1		DEC 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QG0OL	33323967				2022-12-17	WOS:000599126500008
J	Han, SS; Wen, KK; Vyas, YM				Han, Seong-Su; Wen, Kuo-Kuang; Vyas, Yatin M.			Deficiency of Wiskott-Aldrich syndrome protein has opposing effect on the pro-oncogenic pathway activation in nonmalignant versus malignant lymphocytes	ONCOGENE			English	Article							KAPPA-B; CANCER; WASP; CELLS; TRANSFORMATION; HALLMARKS; LYMPHOMA; INVASION; GENES; CDC42	Immunodeficiency is associated with cancer risk. Accordingly, hematolymphoid cancers develop in Wiskott-Aldrich syndrome (WAS), an X-linked primary immunodeficiency disorder (PID) resulting from the deficiency of WAS-protein (WASp) expressed predominantly in the hematolymphoid cell lineages. Despite the correlation between WASp deficiency and hematolymphoid cancers, the molecular mechanism underlying the oncogenic role of WASp is incompletely understood. Employing the WASp-sufficient and WASp-deficient cell-pair model of human T and B lymphocytes, we show that WASp deficiency differentially influences hyperactivation versus inhibition of both CDC42:ERK1/2 and NF-kappa B:AP-1 pro-oncogenic signaling pathways in nonmalignant versus malignant T and B lymphocytes. Furthermore, WASp deficiency induces a cell-type specific up/down-modulation of the DNA-binding activities of NF-kappa B, AP-1, and multiple other transcription factors with known roles in oncogenesis. We propose that WASp functions as a putative "tumor-suppressor" protein in normal T and B cells, and "oncoprotein" in a subset of established T and B cell malignancies that are not associated with the NPM-ALK fusion.	[Han, Seong-Su; Wen, Kuo-Kuang; Vyas, Yatin M.] Carver Coll Med, Div Pediat Hematol Oncol, Iowa City, IA 52242 USA; [Han, Seong-Su; Wen, Kuo-Kuang; Vyas, Yatin M.] Stead Family Univ Iowa, Childrens Hosp, Iowa City, IA 52242 USA		Vyas, YM (corresponding author), Carver Coll Med, Div Pediat Hematol Oncol, Iowa City, IA 52242 USA.; Vyas, YM (corresponding author), Stead Family Univ Iowa, Childrens Hosp, Iowa City, IA 52242 USA.	yatin-vyas@uiowa.edu		Han, Seong-Su/0000-0001-9824-6751; Vyas, Yatin/0000-0002-4595-0267	NIH [R21AI138051, R01AI146380]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported in part by the NIH grant R21AI138051 and R01AI146380 (to YMV).	Beishline K, 2015, FEBS J, V282, P224, DOI 10.1111/febs.13148; Bosticardo M, 2009, BLOOD, V113, P6288, DOI 10.1182/blood-2008-12-115253; Castellano G, 2010, CELL CYCLE, V9, P557, DOI 10.4161/cc.9.3.10554; Chaturvedi MM, 2011, ONCOGENE, V30, P1615, DOI 10.1038/onc.2010.566; Cheminant M, 2019, J ALLERGY CLIN IMMUN, V143, P2311, DOI 10.1016/j.jaci.2019.01.046; Davuluri G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110627; Escoll M, 2017, ONCOGENE, V36, P3515, DOI 10.1038/onc.2016.518; Etienne-Manneville S, 2004, J CELL SCI, V117, P1291, DOI 10.1242/jcs.01115; FARBER E, 1995, CANCER RES, V55, P3759; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hidalgo-Sastre A, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.127275; Hou JX, 2017, AM J TRANSL RES, V9, P403; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kawanishi S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081808; Keszei M, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1468954; Kurisu S, 2005, ONCOGENE, V24, P1309, DOI 10.1038/sj.onc.1208177; Lee EYHP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003236; Li H, 2019, CANCER RES, V79, P2167, DOI 10.1158/0008-5472.CAN-18-1253; Liu CH, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001704; Lopez-Bergami P, 2010, NAT REV CANCER, V10, P65, DOI 10.1038/nrc2681; Maldonado MD, 2018, CANCER RES, V78, P3101, DOI 10.1158/0008-5472.CAN-18-0619; Meacham CE, 2009, NAT GENET, V41, P1133, DOI 10.1038/ng.451; Menotti M, 2019, NAT MED, V25, P130, DOI 10.1038/s41591-018-0262-9; Morris HT, 2018, J PATHOL, V245, P337, DOI 10.1002/path.5086; Murga-Zamalloa CA, 2017, ONCOGENE, V36, P2085, DOI 10.1038/onc.2016.366; Ochs HD, 2006, J ALLERGY CLIN IMMUN, V117, P725, DOI 10.1016/j.jaci.2006.02.005; Ramkumar C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3598; Rey-Suarez I, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14335-8; Sadhukhan S, 2014, J IMMUNOL, V193, P150, DOI 10.4049/jimmunol.1302923; Sarkar K, 2018, J ALLERGY CLIN IMMUN, V142, P219, DOI 10.1016/j.jaci.2017.11.023; Sarkar K, 2015, BLOOD, V126, P1670, DOI 10.1182/blood-2015-05-646182; Sarkar K, 2014, BLOOD, V124, P3409, DOI 10.1182/blood-2014-07-587642; Schrank BR, 2018, NATURE, V559, P61, DOI 10.1038/s41586-018-0237-5; Shankar DB, 2005, CANCER CELL, V7, P351, DOI 10.1016/j.ccr.2005.02.018; Stengel K, 2011, CELL SIGNAL, V23, P1415, DOI 10.1016/j.cellsig.2011.04.001; Stieglitz E, 2015, NAT GENET, V47, P1326, DOI 10.1038/ng.3400; Taylor MD, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000813; Tong L, 2014, BIOSCIENCE REP, V34, P283, DOI 10.1042/BSR20140021; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wang Li-Hui, 2018, Cell Physiol Biochem, V51, P2647, DOI 10.1159/000495956; Wang Wenmeng, 2017, Critical Reviews in Oncogenesis, V22, P1, DOI 10.1615/CritRevOncog.2017021314; Wen KK, 2020, J ALLERGY CLIN IMMUN, V145, P324, DOI 10.1016/j.jaci.2019.09.026	44	3	3	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					345	354		10.1038/s41388-020-01533-3	http://dx.doi.org/10.1038/s41388-020-01533-3		NOV 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33139832	Green Accepted			2022-12-17	WOS:000584356100001
J	Alsafadi, S; Dayot, S; Tarin, M; Houy, A; Bellanger, D; Cornella, M; Wassef, M; Waterfall, JJ; Lehnert, E; Roman-Roman, S; Stern, MH; Popova, T				Alsafadi, Samar; Dayot, Stephane; Tarin, Malcy; Houy, Alexandre; Bellanger, Dorine; Cornella, Michele; Wassef, Michel; Waterfall, Joshua J.; Lehnert, Erik; Roman-Roman, Sergio; Stern, Marc-Henri; Popova, Tatiana			Genetic alterations ofSUGP1mimic mutant-SF3B1splice pattern in lung adenocarcinoma and other cancers	ONCOGENE			English	Article							SPLICING FACTOR SF3B1; MUTATIONS	Genes involved in 3 '-splice site recognition during mRNA splicing constitute an emerging class of oncogenes.SF3B1is the most frequently mutated splicing factor in cancer, and SF3B1 mutants corrupt branchpoint recognition leading to usage of cryptic 3 '-splice sites and subsequent aberrant junctions. For a comprehensive determination of alterations leading to this splicing pattern, we performed a pan-TCGA screening for SF3B1-specific aberrant acceptor usage. While the most of aberrant 3 '-splice patterns were explained bySF3B1mutations, we also detected nineSF3B1wild-type tumors (including five lung adenocarcinomas). Genomic profile analysis of these tumors identified somatic mutations combined with loss-of-heterozygosity in the splicing factorSUGP1in five of these cases. Modeling ofSUGP1loss and mutations in cell lines showed that both alterations induced mutant-SF3B1-like aberrant splicing. Our study provides definitive evidence that genetic alterations ofSUGP1genocopySF3B1mutations in lung adenocarcinoma and other cancers.	[Alsafadi, Samar; Tarin, Malcy; Waterfall, Joshua J.; Roman-Roman, Sergio] PSL Res Univ, Inst Curie, Translat Res Dept, Paris, France; [Alsafadi, Samar; Dayot, Stephane; Houy, Alexandre; Bellanger, Dorine; Cornella, Michele; Waterfall, Joshua J.; Stern, Marc-Henri; Popova, Tatiana] PSL Res Univ, Equipe Labellisee Ligue Natl Canc, DNA Repair & Uveal Melanoma DRUM, Inst Curie,INSERM U830, Paris, France; [Wassef, Michel] Sorbonne Univ, PSL Res Univ, Inst Curie, Paris, France; [Wassef, Michel] CNRS, UMR3215, INSERM, U934, Paris, France; [Lehnert, Erik] Seven Bridges Genom, Konigesberg, MA USA	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite	Stern, MH (corresponding author), PSL Res Univ, Equipe Labellisee Ligue Natl Canc, DNA Repair & Uveal Melanoma DRUM, Inst Curie,INSERM U830, Paris, France.	marc-henri.stern@curie.fr	Bellanger, Dorine/AAC-2235-2022; Alsafadi, Samar/C-4659-2017; Stern, Marc-Henri/A-2728-2011	Alsafadi, Samar/0000-0002-0060-1346; Stern, Marc-Henri/0000-0002-8100-2272; Wassef, Michel/0000-0003-3748-5112; Waterfall, Joshua/0000-0002-3762-5050; Tarin, Malcy/0000-0002-3865-9631	SIRIC Curie [INCa-DGOSInserm_12554]; European Union's Horizon 2020 project "UM Cure 2020" [667787]; Ligue Nationale Contre le Cancer (Labellisation); Canceropole Emergence from Canceropole Ile-de-France [EMERG-1 2017 ImmunSplice]; Federal funds from the National Cancer Institute, National Institutes of Health [HHSN261201400008C, HHSN261201500003I, 17x146]	SIRIC Curie; European Union's Horizon 2020 project "UM Cure 2020"; Ligue Nationale Contre le Cancer (Labellisation); Canceropole Emergence from Canceropole Ile-de-France; Federal funds from the National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The translational group of UM at Institut Curie is supported by SIRIC Curie (Grant INCa-DGOSInserm_12554) and the European Union's Horizon 2020 project "UM Cure 2020" (grant no. 667787). This work benefits also from financial support of the Ligue Nationale Contre le Cancer (Labellisation) and a grant from Canceropole Emergence from Canceropole Ile-de-France (EMERG-1 2017 ImmunSplice). The Seven Bridges Cancer Genomics Cloud has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, contract no. HHSN261201400008C and ID/IQ agreement no. 17x146 under contract no. HHSN261201500003I.	Agafonov DE, 2011, MOL CELL BIOL, V31, P2667, DOI 10.1128/MCB.05266-11; Agudelo D, 2017, NAT METHODS, V14, P615, DOI [10.1038/NMETH.4265, 10.1038/nmeth.4265]; Alsafadi S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10615; Bryant DW, 2010, BIOINFORMATICS, V26, P1500, DOI 10.1093/bioinformatics/btq206; Cretu C, 2016, MOL CELL, V64, P307, DOI 10.1016/j.molcel.2016.08.036; Darman RB, 2015, CELL REP, V13, P1033, DOI 10.1016/j.celrep.2015.09.053; DeBoever C, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004105; Dehghannasiri R, 2019, P NATL ACAD SCI USA, V116, P15524, DOI 10.1073/pnas.1900391116; Dvinge H, 2016, NAT REV CANCER, V16, P413, DOI 10.1038/nrc.2016.51; Furney SJ, 2013, CANCER DISCOV, V3, P1122, DOI 10.1158/2159-8290.CD-13-0330; Harbour JW, 2013, NAT GENET, V45, P133, DOI 10.1038/ng.2523; Ilagan JO, 2015, GENOME RES, V25, P14, DOI 10.1101/gr.181016.114; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Inoue D, 2019, NATURE, V574, P432, DOI 10.1038/s41586-019-1646-9; Kahles A, 2018, CANCER CELL, V34, P211, DOI 10.1016/j.ccell.2018.07.001; Kong Y, 2014, MELANOMA RES, V24, P332, DOI 10.1097/CMR.0000000000000071; Lau JW, 2017, CANCER RES, V77, pE3, DOI 10.1158/0008-5472.CAN-17-0387; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Liu ZQ, 2020, CANCER DISCOV, V10, P806, DOI 10.1158/2159-8290.CD-19-1330; Liu ZQ, 2020, P NATL ACAD SCI USA, V117, P10305, DOI 10.1073/pnas.1922622117; Maguire SL, 2015, J PATHOL, V235, P571, DOI 10.1002/path.4483; Martin M, 2013, NAT GENET, V45, P933, DOI 10.1038/ng.2674; Obeng EA, 2019, CANCER DISCOV, V9, P1493, DOI 10.1158/2159-8290.CD-19-0399; Papaemmanuil E, 2011, NEW ENGL J MED, V365, P1384, DOI 10.1056/NEJMoa1103283; Plaschka C, 2018, NATURE, V559, P420, DOI 10.1038/s41586-018-0323-8; Popova T, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r128; Quesada V, 2012, NAT GENET, V44, P47, DOI 10.1038/ng.1032; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Sampson ND, 2003, GENE, V305, P91, DOI 10.1016/S0378-1119(02)01230-1; Seiler M, 2018, CELL REP, V23, P282, DOI 10.1016/j.celrep.2018.01.088; Suzuki H, 2019, NATURE, V574, P707, DOI 10.1038/s41586-019-1650-0; van der Feltz C, 2019, CRIT REV BIOCHEM MOL, V54, P443, DOI 10.1080/10409238.2019.1691497; Wang LL, 2011, NEW ENGL J MED, V365, P2497, DOI 10.1056/NEJMoa1109016; Will CL, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003707; Xu XD, 2005, CELL, V120, P59, DOI 10.1016/j.cell.2004.11.036; Zhang J, 2019, MOL CELL, V76, P82, DOI 10.1016/j.molcel.2019.07.017	36	3	3	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					85	96		10.1038/s41388-020-01507-5	http://dx.doi.org/10.1038/s41388-020-01507-5		OCT 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33057152	Green Published, hybrid			2022-12-17	WOS:000577230500001
J	Jin, Y; Zhou, Y; Deng, WF; Wang, YC; Lee, RJ; Liu, YN; Elias, N; Hu, YC; Luo, MH; Liu, RM; Guan, BW; Geng, J; Xu, J; Ma, JF; Zhou, JP; Liu, N; Blute, ML; Colvin, RB; Wu, CL; Miao, Y				Jin, Yu; Zhou, Yi; Deng, Wenfeng; Wang, Yuchen; Lee, Richard J.; Liu, Yanna; Elias, Nahel; Hu, Yangcheng; Luo, Min-Hua; Liu, Rumin; Guan, Bowen; Geng, Jian; Xu, Jian; Ma, Junfeng; Zhou, Jiapeng; Liu, Na; Blute, Michael L.; Colvin, Robert B.; Wu, Chin-Lee; Miao, Yun			Genome-wide profiling of BK polyomavirus integration in bladder cancer of kidney transplant recipients reveals mechanisms of the integration at the nucleotide level	ONCOGENE			English	Article							INFECTION; VIRUS; MICROHOMOLOGY; REPLICATION; BLOOD	Chronic BK polyomavirus (BKPyV) infection is recognized as a potential oncogenic factor of urothelial carcinoma (UC) in renal transplant recipients. Recent studies have reported a positive correlation among BKPyV integration, persistent overexpression of viral large T antigen (TAg), and malignancy, yet little is known about the specific integration mechanisms and the impacts of viral integration. Here, we performed whole-genome sequencing (WGS) and viral capture-based sequencing on high-grade immunohistochemically TAg-positive UCs in two renal transplant recipients. A total of 181 integration sites, including the three found by WGS, were identified by viral capture-based sequencing, indicating its enhanced sensitivity and ability in identifying low-read integration sites in subpopulations of the tumor cells. The microhomologies between human and BKPyV genomes were significantly enriched in the flanking regions of 84.5% the integration sites, with a median length of 7 bp. Notably, 75 human genes formed fusion sequences due to viral insertional integration. Among them, the expression of 15 genes were statistically associated with UC based on GEO2R expression analysis. Our results indicated a multisite and multifragment linear integration pattern and a potential microhomology or nonhomologous end joining integration mechanism at the single-nucleotide level. We put forward a potential selection mechanism driven by immunity and centered on viral integration in the carcinogenesis of BKPyV.	[Jin, Yu; Zhou, Yi; Deng, Wenfeng; Wang, Yuchen; Liu, Yanna; Hu, Yangcheng; Liu, Rumin; Guan, Bowen; Geng, Jian; Xu, Jian; Miao, Yun] Southern Med Univ, Nanfang Hosp, Div Transplantat, Guangzhou, Peoples R China; [Lee, Richard J.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Boston, MA 02115 USA; [Elias, Nahel] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02115 USA; [Luo, Min-Hua] Wuhan Inst Virol, State Key Lab Virol, CAS Ctr Excellence Brain Sci & Intelligence Techn, Wuhan, Peoples R China; [Ma, Junfeng; Zhou, Jiapeng; Liu, Na] Mygenostics Co, Beijing, Peoples R China; [Blute, Michael L.; Wu, Chin-Lee] Harvard Med Sch, Massachusetts Gen Hosp, Dept Urol, Boston, MA 02115 USA; [Colvin, Robert B.; Wu, Chin-Lee] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA	Southern Medical University - China; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Chinese Academy of Sciences; Wuhan Institute of Virology, CAS; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Miao, Y (corresponding author), Southern Med Univ, Nanfang Hosp, Div Transplantat, Guangzhou, Peoples R China.; Wu, CL (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Urol, Boston, MA 02115 USA.; Wu, CL (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA.	cwu2@mgh.harvard.edu; miaoyunecho@126.com		Elias, Nahel/0000-0001-6466-7347	National Natural Science Foundation of China [81500573]; Science Foundation of Guangdong Province [2020A1515010674]; Science and Technology Planning Project of Guangzhou [201803010109]; President Funding of Nanfang Hospital [2018B009, 2018C003]; College Students' Innovative Entrepreneurial Training Plan Program [201812121148, X202012121239, 202012121046]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Science and Technology Planning Project of Guangzhou; President Funding of Nanfang Hospital; College Students' Innovative Entrepreneurial Training Plan Program	This work was funded by the National Natural Science Foundation of China (81500573), the Science Foundation of Guangdong Province (2020A1515010674), the Science and Technology Planning Project of Guangzhou (201803010109), the President Funding of Nanfang Hospital (2018B009, 2018C003) and College Students' Innovative Entrepreneurial Training Plan Program (201812121148, X202012121239, 202012121046).	Awan AA, 2018, AM J NEPHROL, V48, P472, DOI 10.1159/000495081; Billups K, 2015, PROG TRANSPLANT, V25, P182, DOI 10.7182/pit2015826; Cangemi M, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00160; Chang HHY, 2017, NAT REV MOL CELL BIO, V18, P495, DOI 10.1038/nrm.2017.48; Egli A, 2009, J INFECT DIS, V199, P837, DOI 10.1086/597126; Elfadawy N, 2018, INFECT DIS CLIN N AM, V32, P599, DOI 10.1016/j.idc.2018.04.009; Fu FX, 2018, CLIN SCI, V132, P1753, DOI 10.1042/CS20180443; Groves IJ, 2018, J PATHOL, V245, P9, DOI 10.1002/path.5058; Gupta G, 2018, AM J TRANSPLANT, V18, P245, DOI 10.1111/ajt.14530; Hesbacher S, 2016, ONCOTARGET, V7, P32956, DOI 10.18632/oncotarget.8793; Houben R, 2015, INT J CANCER, V136, pE290, DOI 10.1002/ijc.29200; Hu Z, 2015, NAT GENET, V47, P158, DOI 10.1038/ng.3178; Kean JM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000363; Kenan DJ, 2017, AM J TRANSPLANT, V17, P1674, DOI 10.1111/ajt.14191; Kenan DJ, 2015, J PATHOL, V237, P379, DOI 10.1002/path.4584; Lee YJ, 2014, BIOL BLOOD MARROW TR, V20, P1204, DOI 10.1016/j.bbmt.2014.04.017; Li WY, 2013, GENOMICS, V102, P338, DOI 10.1016/j.ygeno.2013.07.002; Lieber MR, 2010, ANNU REV BIOCHEM, V79, P181, DOI 10.1146/annurev.biochem.052308.093131; McCabe M, 2006, ONCOGENE, V25, P2727, DOI 10.1038/sj.onc.1209266; Michel Ortega Rosa M, 2016, J Immunother Cancer, V4, P63; Morrical SW, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016444; Muller DC, 2018, J PATHOL, V244, P265, DOI 10.1002/path.5012; Nickeleit V, 2018, J PATHOL, V246, P7, DOI 10.1002/path.5127; O'Neill JP, 2019, CLIN TRANSPLANT, V33, DOI 10.1111/ctr.13669; Ottaviani D, 2014, TRENDS GENET, V30, P85, DOI 10.1016/j.tig.2014.01.001; Papadimitriou JC, 2016, AM J TRANSPLANT, V16, P398, DOI 10.1111/ajt.13550; Pinto M, 2014, J INFECTION, V68, pS2, DOI 10.1016/j.jinf.2013.09.009; Roberts ISD, 2008, BRIT J CANCER, V99, P1383, DOI 10.1038/sj.bjc.6604711; Rosales BM, 2020, INT J CANCER, V146, P2703, DOI 10.1002/ijc.32585; Saribas AS, 2016, J CELL PHYSIOL, V231, P2115, DOI 10.1002/jcp.25329; Sirohi D, 2018, MODERN PATHOL, V31, P1429, DOI 10.1038/s41379-018-0065-z; Starrett GJ, 2019, CURR OPIN VIROL, V39, P8, DOI 10.1016/j.coviro.2019.06.009; Trofe-Clark J, 2016, SEMIN NEPHROL, V36, P372, DOI 10.1016/j.semnephrol.2016.05.014; Wang YC, 2020, ONCOGENE, V39, P5734, DOI 10.1038/s41388-020-01398-6; Yi K, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0112-3; Zhang F, 2009, NAT GENET, V41, P849, DOI 10.1038/ng.399; Zhou XS, 2015, MOL MED REP, V11, P910, DOI 10.3892/mmr.2014.2861	37	3	4	0	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					46	54		10.1038/s41388-020-01502-w	http://dx.doi.org/10.1038/s41388-020-01502-w		OCT 2020	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33051598				2022-12-17	WOS:000577556100003
J	Wang, YA; Sfakianos, J; Tewari, AK; Cordon-cardo, C; Kyprianou, N				Wang, Yuanshuo Alice; Sfakianos, John; Tewari, Ashutosh K.; Cordon-cardo, Carlos; Kyprianou, Natasha			Molecular tracing of prostate cancer lethality	ONCOGENE			English	Review							EXPRESSION SIGNATURE; PRECISION MEDICINE; TUMOR-SUPPRESSOR; CROSS-RESISTANCE; DNA METHYLATION; LARGE ONCOSOMES; POOR-PROGNOSIS; GENOME-WIDE; CABAZITAXEL; DOCETAXEL	Prostate cancer is diagnosed mostly in men over the age of 50 years, and has favorable 5-year survival rates due to early cancer detection and availability of curative surgical management. However, progression to metastasis and emergence of therapeutic resistance are responsible for the majority of prostate cancer mortalities. Recent advancement in sequencing technologies and computational capabilities have improved the ability to organize and analyze large data, thus enabling the identification of novel biomarkers for survival, metastatic progression and patient prognosis. Large-scale sequencing studies have also uncovered genetic and epigenetic signatures associated with prostate cancer molecular subtypes, supporting the development of personalized targeted-therapies. However, the current state of mainstream prostate cancer management does not take full advantage of the personalized diagnostic and treatment modalities available. This review focuses on interrogating biomarkers of prostate cancer progression, including gene signatures that correspond to the acquisition of tumor lethality and those of predictive and prognostic value in progression to advanced disease, and suggest how we can use our knowledge of biomarkers and molecular subtypes to improve patient treatment and survival outcomes.	[Wang, Yuanshuo Alice; Sfakianos, John; Tewari, Ashutosh K.; Kyprianou, Natasha] Icahn Sch Med Mt Sinai, Dept Urol, New York, NY 10029 USA; [Sfakianos, John; Tewari, Ashutosh K.; Cordon-cardo, Carlos; Kyprianou, Natasha] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA; [Cordon-cardo, Carlos; Kyprianou, Natasha] Icahn Sch Med Mt Sinai, Dept Pathol & Lab Med, New York, NY 10029 USA; [Kyprianou, Natasha] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Kyprianou, N (corresponding author), Icahn Sch Med Mt Sinai, Dept Urol, New York, NY 10029 USA.; Kyprianou, N (corresponding author), Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.; Kyprianou, N (corresponding author), Icahn Sch Med Mt Sinai, Dept Pathol & Lab Med, New York, NY 10029 USA.; Kyprianou, N (corresponding author), Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA.	natasha.kyprianou@mountsinai.org			NIH/NCI [R01 CA232574]	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	NIH/NCI R01 CA232574.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Agell L, 2012, AM J PATHOL, V181, P1585, DOI 10.1016/j.ajpath.2012.08.005; Akamatsu S, 2015, CELL REP, V12, P922, DOI 10.1016/j.celrep.2015.07.012; Al Nakouzi N, 2015, EUR UROL, V68, P228, DOI 10.1016/j.eururo.2014.04.015; Almassi N, 2018, JAMA ONCOL, V4, P554, DOI 10.1001/jamaoncol.2017.3159; Bauman DR, 2006, MOL ENDOCRINOL, V20, P444, DOI 10.1210/me.2005-0287; Beltran H, 2019, CLIN CANCER RES, V25, P43, DOI 10.1158/1078-0432.CCR-18-1912; Beltran H, 2017, CLIN CANCER RES, V23, P6802, DOI 10.1158/1078-0432.CCR-17-1034; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Beltran H, 2013, EUR UROL, V63, P920, DOI 10.1016/j.eururo.2012.08.053; Berney DM, 2009, BRIT J CANCER, V100, P888, DOI 10.1038/sj.bjc.6604951; Bilir B, 2016, CANCER RES, V76, P1112, DOI 10.1158/0008-5472.CAN-15-1868; Borno ST, 2012, CANCER DISCOV, V2, P1024, DOI 10.1158/2159-8290.CD-12-0041; Bougen NM, 2013, CANCER LETT, V332, P19, DOI 10.1016/j.canlet.2012.12.012; Boutros PC, 2015, NAT GENET, V47, P736, DOI 10.1038/ng.3315; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Broustas CG, 2012, J BIOL CHEM, V287, P41324, DOI 10.1074/jbc.M112.402784; Bu HJ, 2011, PROSTATE, V71, P575, DOI 10.1002/pros.21273; Buchheit CL, 2014, NAT REV CANCER, V14, P632, DOI 10.1038/nrc3789; Cajigas-Du Ross Christina K, 2018, Oncotarget, V9, P30363, DOI 10.18632/oncotarget.25744; Canovas V, 2017, ONCOTARGET, V8, P59165, DOI 10.18632/oncotarget.19467; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chang KH, 2013, CELL, V154, P1074, DOI 10.1016/j.cell.2013.07.029; Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028552; Chen X, 2016, CLIN CANCER RES, V22, P4505, DOI 10.1158/1078-0432.CCR-15-2956; Chien MH, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1247-3; Ciardiello C, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1317-6; Clarke NW, 2009, ASIAN J ANDROL, V11, P57, DOI 10.1038/aja.2008.29; Conteduca V, 2019, EUR J CANCER, V116, P158, DOI 10.1016/j.ejca.2019.05.007; Copeland BT, 2013, MOL CANCER RES, V11, P95, DOI 10.1158/1541-7786.MCR-12-0468; Cuzick J, 2011, LANCET ONCOL, V12, P245, DOI 10.1016/S1470-2045(10)70295-3; Dardenne E, 2016, CANCER CELL, V30, P563, DOI 10.1016/j.ccell.2016.09.005; Dey P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128239; Di Vizio D, 2012, AM J PATHOL, V181, P1573, DOI 10.1016/j.ajpath.2012.07.030; Di Vizio D, 2009, CANCER RES, V69, P5601, DOI 10.1158/0008-5472.CAN-08-3860; Ding ZH, 2011, NATURE, V470, P269, DOI 10.1038/nature09677; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Erho N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066855; Figiel S, 2017, HUM PATHOL, V61, P26, DOI 10.1016/j.humpath.2016.10.013; Fisher G, 2013, BRIT J CANCER, V108, P271, DOI 10.1038/bjc.2012.598; Formosa A, 2013, ONCOGENE, V32, P127, DOI 10.1038/onc.2012.14; Forshew T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003726; Fraser JA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55665-y; Fraser M, 2015, UROL ONCOL-SEMIN ORI, V33, P85, DOI 10.1016/j.urolonc.2013.10.020; Gajula RP, 2013, MOL CANCER RES, V11, P1387, DOI 10.1158/1541-7786.MCR-13-0218-T; Galletti G, 2017, CANCER TREAT REV, V57, P16, DOI 10.1016/j.ctrv.2017.04.008; Giri VN, 2020, J CLIN ONCOL; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Gorges TM, 2016, CLIN CHEM, V62, P1504, DOI 10.1373/clinchem.2016.260299; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guan B, 2017, ONCOTARGET, V8, P8162, DOI 10.18632/oncotarget.14131; Han RB, 2020, AM J TRANSL RES, V12, P1428; Harris KS, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/8629234; Hearn JWD, 2016, LANCET ONCOL, V17, P1435, DOI 10.1016/S1470-2045(16)30227-3; Helpap B, 2009, HISTOL HISTOPATHOL, V24, P661, DOI 10.14670/HH-24.661; Howlader N., 2021, SEER CANC STAT REV 1; Hudson BD, 2013, BRIEF FUNCT GENOMICS, V12, P397, DOI 10.1093/bfgp/elt021; Kalin M, 2011, EUR UROL, V60, P1235, DOI 10.1016/j.eururo.2011.06.038; Kamoun A, 2018, ANN ONCOL, V29, P1814, DOI 10.1093/annonc/mdy224; Kanwal R, 2018, CANCER LETT, V430, P25, DOI 10.1016/j.canlet.2018.05.014; Karanikolas BDW, 2010, PROSTATE, V70, P675, DOI 10.1002/pros.21112; Ketola K, 2017, CLIN CANCER RES, V23, P6923, DOI 10.1158/1078-0432.CCR-17-0901; Kim W, 2014, CLIN CANCER RES, V20, P6269, DOI 10.1158/1078-0432.CCR-14-1595; Ku SY, 2019, NAT REV UROL, V16, P645, DOI 10.1038/s41585-019-0237-8; Kwon OJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5416; Labrecque MP, 2016, ONCOTARGET, V7, P24284, DOI 10.18632/oncotarget.8301; Lambros MB, 2018, CLIN CANCER RES, V24, P5635, DOI 10.1158/1078-0432.CCR-18-0862; Larkin SET, 2012, BRIT J CANCER, V106, P157, DOI 10.1038/bjc.2011.490; Lassi K, 2010, CURR OPIN ONCOL, V22, P263, DOI 10.1097/CCO.0b013e3283380939; Lee JW, 2013, J BIOL CHEM, V288, P30054, DOI 10.1074/jbc.M113.481283; Lee YC, 2013, MOL CANCER RES, V11, P405, DOI 10.1158/1541-7786.MCR-12-0551; Leon-Mateos L, 2017, ONCOTARGET, V8, P54708, DOI 10.18632/oncotarget.18025; Li MF, 2018, J CANCER RES THER, V14, P864, DOI 10.4103/jcrt.JCRT_734_17; Lin ZY, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0615-x; Lindberg J, 2013, EUR UROL, V63, P347, DOI 10.1016/j.eururo.2012.03.050; Liu CF, 2019, MOL CANCER THER, V18, P1875, DOI 10.1158/1535-7163.MCT-18-1322; Liu CF, 2017, MOL CANCER THER, V16, P35, DOI 10.1158/1535-7163.MCT-16-0186; Liu CF, 2016, ONCOTARGET, V7, P32210, DOI 10.18632/oncotarget.8493; Liu CF, 2015, CANCER RES, V75, P1413, DOI 10.1158/0008-5472.CAN-14-3080; Lombard AP, 2017, MOL CANCER THER, V16, P2257, DOI 10.1158/1535-7163.MCT-17-0179; Long Q, 2014, CANCER RES, V74, P3228, DOI 10.1158/0008-5472.CAN-13-2699; Lotan TL, 2011, MODERN PATHOL, V24, P820, DOI 10.1038/modpathol.2011.7; Luo Y, 2015, ONCOTARGET, V6, P22564, DOI 10.18632/oncotarget.4197; Magadoux L, 2014, INT J ONCOL, V45, P919, DOI 10.3892/ijo.2014.2517; Majid S, 2013, CLIN CANCER RES, V19, P73, DOI 10.1158/1078-0432.CCR-12-2952; Majid S, 2012, CANCER RES, V72, P6435, DOI 10.1158/0008-5472.CAN-12-2181; Mak P, 2010, CANCER CELL, V17, P319, DOI 10.1016/j.ccr.2010.02.030; Marin-Aguilera M, 2019, INT J CANCER, V145, P1970, DOI 10.1002/ijc.32238; Martin SK, 2016, CANCER RES, V76, P912, DOI 10.1158/0008-5472.CAN-15-2078; Merrill RM, 2000, UROLOGY, V55, P730, DOI 10.1016/S0090-4295(99)00564-6; Minciacchi VR, 2017, CANCER RES, V77, P2306, DOI 10.1158/0008-5472.CAN-16-2942; Minciacchi VR, 2015, ONCOTARGET, V6, P11327, DOI 10.18632/oncotarget.3598; Miyamoto DT, 2015, SCIENCE, V349, P1351, DOI 10.1126/science.aab0917; Modena A, 2016, TARGET ONCOL, V11, P569, DOI 10.1007/s11523-016-0450-9; Mosquera JM, 2013, NEOPLASIA, V15, P1, DOI 10.1593/neo.121550; Mostaghel EA, 2019, CLIN CANCER RES, V25, P426, DOI 10.1158/1078-0432.CCR-18-1431; Mout L, 2018, EBIOMEDICINE, V27, P182, DOI 10.1016/j.ebiom.2017.12.024; Munkley J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05489-5; Murphy AB, 2020, UROLOGY, V142, P166, DOI 10.1016/j.urology.2020.01.052; Nilsson EM, 2015, ONCOTARGET, V6, P35710, DOI 10.18632/oncotarget.5958; Nolan KD, 2015, J BIOL CHEM, V290, P8271, DOI 10.1074/jbc.M115.637496; Nordstrom T, 2017, BMC UROL, V17, DOI 10.1186/s12894-017-0281-8; O'Reilly E, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.18.00134; Oh JJ, 2015, KOREAN J UROL, V56, P109, DOI 10.4111/kju.2015.56.2.109; Ok S, 2012, IMMUNOPHARM IMMUNOT, V34, P768, DOI 10.3109/08923973.2012.654494; Oliveira KCS, 2020, MOL CANCER RES, V18, P517, DOI 10.1158/1541-7786.MCR-19-0768; Olson A, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008451; Oon SF, 2011, NAT REV UROL, V8, P131, DOI 10.1038/nrurol.2011.11; Osorio LA, 2016, MOL MED REP, V13, P778, DOI 10.3892/mmr.2015.4585; Pal SK, 2018, UROL ONCOL-SEMIN ORI, V36, DOI 10.1016/j.urolonc.2017.12.006; Penney KL, 2011, J CLIN ONCOL, V29, P2391, DOI 10.1200/JCO.2010.32.6421; Pettersson A, 2013, JNCI-J NATL CANCER I, V105, P1881, DOI 10.1093/jnci/djt332; Pezaro CJ, 2014, EUR UROL, V66, P459, DOI 10.1016/j.eururo.2013.11.044; Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039; Pound CR, 1999, JAMA-J AM MED ASSOC, V281, P1591, DOI 10.1001/jama.281.17.1591; Rajasekhar VK, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1159; Ramachandran K, 2016, ANTICANCER RES, V36, P161; Ramalho-Carvalho J, 2017, CANCER LETT, V385, P150, DOI 10.1016/j.canlet.2016.10.028; Ramalinga M, 2015, ONCOTARGET, V6, P34446, DOI 10.18632/oncotarget.5920; Reyes Edwin E, 2015, J Transl Sci, V1; Reyes EE, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0313-z; Ross RW, 2012, LANCET ONCOL, V13, P1105, DOI 10.1016/S1470-2045(12)70263-2; Saal LH, 2007, P NATL ACAD SCI USA, V104, P7564, DOI 10.1073/pnas.0702507104; Salinas CA, 2014, NAT REV UROL, V11, P317, DOI 10.1038/nrurol.2014.91; Santoni M, 2016, EUR UROL, V69, P186, DOI 10.1016/j.eururo.2015.05.041; Sekino Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163936; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Skvortsova K, 2019, CANCER CELL, V35, P297, DOI 10.1016/j.ccell.2019.01.004; Spratt DE, 2019, CLIN CANCER RES, V25, P6721, DOI 10.1158/1078-0432.CCR-19-1587; Stephenson AJ, 2005, CANCER-AM CANCER SOC, V104, P290, DOI 10.1002/cncr.21157; Sun YF, 2011, J CANCER RES CLIN, V137, P1151, DOI 10.1007/s00432-011-0988-y; Tan HL, 2014, CLIN CANCER RES, V20, P890, DOI 10.1158/1078-0432.CCR-13-1982; Tan SH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041255; Tomlins SA, 2015, EUR UROL, V68, P555, DOI 10.1016/j.eururo.2015.04.033; Tzelepi V, 2011, J CLIN ONCOL, V29, P2574, DOI 10.1200/JCO.2010.33.2999; van Soest RJ, 2015, EUR J CANCER, V51, P2562, DOI 10.1016/j.ejca.2015.07.037; van Soest RJ, 2015, EUR UROL, V67, P981, DOI 10.1016/j.eururo.2014.11.033; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Wang L, 2018, ANN ONCOL, V29, P352, DOI 10.1093/annonc/mdx689; Wang X, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007609; Wang ZG, 2016, SCI REP-UK, V6, DOI 10.1038/srep25602; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Williams LV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083991; Wu YM, 2018, CELL, V173, P1770, DOI 10.1016/j.cell.2018.04.034; Xu S, 2016, ONCOL REP, V36, P10, DOI 10.3892/or.2016.4791; Yang L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00872-8; Yang YJ, 2019, BJU INT, V124, P258, DOI 10.1111/bju.14642; Yepuru M, 2013, CLIN CANCER RES, V19, P5613, DOI 10.1158/1078-0432.CCR-13-1151; Yi CY, 2018, INT J BIOCHEM CELL B, V102, P138, DOI 10.1016/j.biocel.2018.07.009; You SY, 2016, CANCER RES, V76, P4948, DOI 10.1158/0008-5472.CAN-16-0902; Zhang K, 2017, ONCOGENE, V36, P5681, DOI 10.1038/onc.2017.177; Zhang T, 2020, CLIN GENITOURIN CANC, V18, P1, DOI 10.1016/j.clgc.2019.09.015; Zhao JG, 2020, MOL CANCER THER, V19, P1708, DOI 10.1158/1535-7163.MCT-20-0015; Zhao LY, 2014, CANCER EPIDEM BIOMAR, V23, P1047, DOI 10.1158/1055-9965.EPI-13-0696; Zheng JF, 2016, BIOCHEM BIOPH RES CO, V480, P508, DOI 10.1016/j.bbrc.2016.08.120	155	3	3	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2020	39	50					7225	7238		10.1038/s41388-020-01496-5	http://dx.doi.org/10.1038/s41388-020-01496-5		OCT 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PD4HE	33046797	Green Accepted			2022-12-17	WOS:000578784100004
J	Jin, GG; Yan, MY; Liu, KD; Yao, K; Chen, HY; Zhang, CJ; Yi, Y; Reddy, K; Gorja, DR; Laster, KV; Guo, ZP; Dong, ZG				Jin, Guoguo; Yan, Mingyang; Liu, Kangdong; Yao, Ke; Chen, Hanyong; Zhang, Chengjuan; Yi, Yang; Reddy, Kanamata; Gorja, Dhilli Rao; Laster, Kyle Vaughn; Guo, Zhiping; Dong, Zigang			Discovery of a novel dual-target inhibitor against RSK1 and MSK2 to suppress growth of human colon cancer	ONCOGENE			English	Article							RIBOSOMAL S6 KINASE; PROTEIN; ACTIVATION; FAMILY; PHOSPHORYLATION; MAPK	Colon cancer is the most aggressive tumor in both men and women globally. As many the chemotherapeutic regimens have adverse side effects and contribute to the resistance and recurrence, therefore, finding novel therapeutic targets and developing effective agents are urgent. Based on the TCGA and GTEx database analysis, RSK1 and MSK2 were found abnormal expressed in colon cancer. RSK1 and MSK2 were overexpressed in colon cancer tissues confirmed by western blot and IHC. After knocking down RSK1 or MSK2, cell proliferation and anchorage-independent cell growth were markedly inhibited. Using a computer docking model, we identified a novel dual-target inhibitor, APIO-EE-07, that could block both RSK1 and MSK2 kinase activity in a dose-dependent manner. APIO-EE-07 inhibited cell growth and induced apoptosis and also increased expression of Bax as well as cleaved caspase-3 and -PARP in colon cancer cells by downregulating RSK1 and MSK2 downstream targets, including CREB and ATF1. Furthermore, APIO-EE-07 decreased tumor volume and weight in human patient-derived xenografts tumors implanted in SCID mice. In summary, our results demonstrate that RSK1 and MSK2 are the potential targets for the treatment of colon cancer. APIO-EE-07, a novel dual-target inhibitor of RSK1 and MSK2, can suppress the growth of colon cancer by attenuating RSK1 and MSK2 signaling.	[Jin, Guoguo; Guo, Zhiping] Henan Luoyang Orthoped Hosp, Zhengzhou, Henan, Peoples R China; [Jin, Guoguo; Yan, Mingyang; Liu, Kangdong; Gorja, Dhilli Rao; Laster, Kyle Vaughn; Dong, Zigang] China US Henan Hormel Canc Inst, Zhengzhou, Peoples R China; [Jin, Guoguo; Liu, Kangdong] Zhengzhou Univ, Henan Prov Cooperat Innovat Ctr Canc Chemoprevent, Zhengzhou, Henan, Peoples R China; [Liu, Kangdong; Dong, Zigang] Zhengzhou Univ, Coll Med, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou, Henan, Peoples R China; [Yao, Ke; Chen, Hanyong; Reddy, Kanamata] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA; [Zhang, Chengjuan] Zhengzhou Univ, Affiliated Tumor Hosp, Ctr Bio Repository, Zhengzhou, Henan, Peoples R China; [Yi, Yang] Henan Univ Chinese Med, Sch Basic Med Sci, Dept Pathol & Pathophysiol, Zhengzhou, Henan, Peoples R China	Zhengzhou University; Zhengzhou University; University of Minnesota System; Zhengzhou University; Henan University of Traditional Chinese Medicine	Guo, ZP (corresponding author), Henan Luoyang Orthoped Hosp, Zhengzhou, Henan, Peoples R China.; Dong, ZG (corresponding author), China US Henan Hormel Canc Inst, Zhengzhou, Peoples R China.; Dong, ZG (corresponding author), Zhengzhou Univ, Coll Med, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou, Henan, Peoples R China.	Zhiping74@hotmail.com; zgdong@hci-cn.org			Key Science and Technology Program of Henan Province, China [182102310125]; Key program of TCM research in Henan Province, China [2018ZY1016, 2019ZY1037]	Key Science and Technology Program of Henan Province, China; Key program of TCM research in Henan Province, China	This work was supported by the Key Science and Technology Program of Henan Province, China (182102310125) and the Key program of TCM research in Henan Province, China (2018ZY1016, 2019ZY1037).	Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; [Anonymous], 2019, SCHROD SUIT 2019; Arthur JSC, 2004, J NEUROSCI, V24, P4324, DOI 10.1523/JNEUROSCI.5227-03.2004; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bode AM, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0055-0; Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10; Clark DE, 2005, CANCER RES, V65, P3108; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Doehn U, 2009, MOL CELL, V35, P511, DOI 10.1016/j.molcel.2009.08.002; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Giselle R, 2002, MOL CELL BIOL, V8, P2871; Hidalgo M, 2014, CANCER DISCOV, V4, P998, DOI 10.1158/2159-8290.CD-14-0001; Houles T, 2018, SEMIN CANCER BIOL, V48, P53, DOI 10.1016/j.semcancer.2017.04.016; Hutchinson L, 2011, NAT REV CLIN ONCOL, V8, P189, DOI [10.1038/nrclinonc.2010.204, 10.1038/nrclinonc.2011.34]; Jideh B, 2018, MED J AUSTRALIA, V208, P483, DOI 10.5694/mja18.00279; Jin GG, 2017, ONCOTARGET, V8, P53387, DOI 10.18632/oncotarget.18508; Lara R, 2013, CANCER RES, V73, P5301, DOI 10.1158/0008-5472.CAN-12-4448; Lee YT, 2018, EUR J PHARMACOL, V834, P188, DOI 10.1016/j.ejphar.2018.07.034; Liu HY, 2014, NEUROCHEM RES, V39, P2479, DOI 10.1007/s11064-014-1452-6; Liu KD, 2011, J BIOL CHEM, V286, P2057, DOI 10.1074/jbc.M110.147306; Ludwik KA, 2016, MOL CANCER THER, V15, P2598, DOI 10.1158/1535-7163.MCT-16-0106; Markad SB, 2014, ORG LETT, V16, P5470, DOI 10.1021/ol502721r; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Reyskens KMSE, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00056; Rodriguez-Antona C, 2010, ENDOCR-RELAT CANCER, V17, P7, DOI 10.1677/ERC-08-0304; Roig AI, 2010, GASTROENTEROLOGY, V138, P1012, DOI 10.1053/j.gastro.2009.11.052; Romeo Y, 2012, BIOCHEM J, V441, P553, DOI 10.1042/BJ20110289; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Smith JA, 2005, CANCER RES, V65, P1027; Strelkov IS, 2002, CANCER RES, V62, P75; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Xian W, 2009, CANCER RES, V69, P2244, DOI 10.1158/0008-5472.CAN-08-3398; Yao K, 2014, CANCER PREV RES, V7, P958, DOI 10.1158/1940-6207.CAPR-14-0126; Ye D, 2019, J MOL NEUROSCI, V68, P475, DOI 10.1007/s12031-019-01309-9	35	3	3	2	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2020	39	43					6733	6746		10.1038/s41388-020-01467-w	http://dx.doi.org/10.1038/s41388-020-01467-w		SEP 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OF2UT	32963350				2022-12-17	WOS:000572030400002
J	Huang, QB; Sun, Y; Zhai, W; Ma, X; Shen, DL; Du, SL; You, BS; Niu, YJ; Huang, CP; Zhang, X; Chang, C				Huang, Qingbo; Sun, Yin; Zhai, Wei; Ma, Xin; Shen, Donglai; Du, Songliang; You, Bosen; Niu, Yuanjie; Huang, Chi-Ping; Zhang, Xu; Chang, Chawnshang			Androgen receptor modulates metastatic routes of VHL wild-type clear cell renal cell carcinoma in an oxygen-dependent manner	ONCOGENE			English	Article							HYPOXIA-INDUCIBLE FACTORS; TUMOR-SUPPRESSOR PROTEIN; CANCER; PROGRESSION; AXIS	Recent studies indicated that the androgen receptor (AR) plays important roles in modulating metastasis of VHL-mutant clear cell renal cell carcinoma (ccRCC). However, the precise mechanisms of AR roles in VHL wild-type (VHL-wt) ccRCC, remain unclear. Here we found that AR interacted with VHL to modulate the metastasis of VHL-wt ccRCC via an oxygen-dependent manner. Mechanism dissection revealed that AR could transcriptionally suppress the miR-185-5p expression in the presence of functional VHL-wt protein under a normoxic condition, which might then result in increasing the expression of VEGF-A and VEGF-C via targeting the 3 ' UTR of mRNAs at a post-transcriptional level. In contrast, under a hypoxic condition, AR could increase miR-185-5p expression to suppress VEGF-C expression, yet this miR-185-5p effect on VEGF-A was reversed via AR's positive regulation on the HIF2 alpha-increased VEGF-A expression that resulted in increasing VEGF-A in the VHL-wt RCC cells. These distinct AR functions under different oxygen conditions may involve the VHL-impacted ubiquitination and nuclear localization of AR. The differential regulation of VEGF-A vs VEGF-C by AR may then result in differential impacts on the ccRCC metastatic destinations of VHL-wt ccRCC cells under different oxygen conditions. These finer mechanisms may help in the development of a novel therapy to better suppress the ccRCC progression under different oxygenization conditions.	[Huang, Qingbo; Ma, Xin; Shen, Donglai; Du, Songliang; Zhang, Xu] Chinese Peoples Liberat Army Gen Hosp, Dept Urol, Beijing 100853, Peoples R China; [Huang, Qingbo; Sun, Yin; Zhai, Wei; You, Bosen; Niu, Yuanjie; Chang, Chawnshang] Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; [Huang, Qingbo; Sun, Yin; Zhai, Wei; You, Bosen; Niu, Yuanjie; Chang, Chawnshang] Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; [Huang, Qingbo; Sun, Yin; Zhai, Wei; You, Bosen; Niu, Yuanjie; Chang, Chawnshang] Univ Rochester, Med Ctr, Dept Radiat Oncol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; [Huang, Qingbo; Sun, Yin; Zhai, Wei; You, Bosen; Niu, Yuanjie; Chang, Chawnshang] Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY 14642 USA; [Zhai, Wei] Jiao Tong Univ, Renji Hosp, Dept Urol, Shanghai 200127, Peoples R China; [Huang, Chi-Ping; Chang, Chawnshang] China Med Univ Hosp, Dept Urol, Sex Hormone Res Ctr, Taichung 404, Taiwan	Chinese People's Liberation Army General Hospital; University of Rochester; University of Rochester; University of Rochester; University of Rochester; Shanghai Jiao Tong University; China Medical University Taiwan; China Medical University Hospital - Taiwan	Zhang, X (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Dept Urol, Beijing 100853, Peoples R China.; Chang, C (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.; Chang, C (corresponding author), Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.; Chang, C (corresponding author), Univ Rochester, Med Ctr, Dept Radiat Oncol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.; Chang, C (corresponding author), Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY 14642 USA.; Chang, C (corresponding author), China Med Univ Hosp, Dept Urol, Sex Hormone Res Ctr, Taichung 404, Taiwan.	xzhang@foxmail.com; chang@urmc.rochester.edu	zhang, xu/GYE-3558-2022; You, Bosen/AHC-2523-2022	Huang, Qingbo/0000-0003-2894-0187; Zhai, Wei/0000-0001-6274-6404; Chang, Chawnshang/0000-0001-8510-3516	George Whipple Professorship Endowment; Beijing Natural Science Foundation [7194319]; National Nature Science Foundation [81972389]	George Whipple Professorship Endowment; Beijing Natural Science Foundation(Beijing Natural Science Foundation); National Nature Science Foundation(National Natural Science Foundation of China (NSFC))	This work was supported by George Whipple Professorship Endowment, and Beijing Natural Science Foundation (No. 7194319), and National Nature Science Foundation (No. 81972389).	Arjumand W, 2012, TUMOR BIOL, V33, P9, DOI 10.1007/s13277-011-0257-3; Baran N, 2017, CLIN CANCER RES, V23, P2382, DOI 10.1158/1078-0432.CCR-16-0895; Bosson AD, 2014, MOL CELL, V56, P347, DOI 10.1016/j.molcel.2014.09.018; Bukowski RM, 1997, CANCER-AM CANCER SOC, V80, P1198, DOI 10.1002/(SICI)1097-0142(19971001)80:7<1198::AID-CNCR3>3.0.CO;2-H; Chen SL, 2013, BIOCHEM J, V456, P55, DOI 10.1042/BJ20121711; Chen Y, 2015, ONCOTARGET, V6, P31203, DOI 10.18632/oncotarget.4522; Chymkowitch P, 2011, EMBO J, V30, P468, DOI 10.1038/emboj.2010.337; Coffey K, 2012, J ENDOCRINOL, V215, P221, DOI 10.1530/JOE-12-0238; Gossage L, 2010, NAT REV CLIN ONCOL, V7, P277, DOI 10.1038/nrclinonc.2010.42; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; He DL, 2014, CANCER RES, V74, P4420, DOI 10.1158/0008-5472.CAN-13-2681; Huang QB, 2014, ONCOTARGET, V5, P3066, DOI 10.18632/oncotarget.1827; Huang QB, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00701-6; Kim W, 2003, CURR OPIN GENET DEV, V13, P55, DOI 10.1016/S0959-437X(02)00010-2; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Linehan WM, 2010, NAT REV UROL, V7, P277, DOI 10.1038/nrurol.2010.47; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Oudard S, 2007, ANN ONCOL, V18, P25, DOI 10.1093/annonc/mdm411; Petrova V, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-017-0011-9; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Qi JF, 2013, CANCER CELL, V23, P332, DOI 10.1016/j.ccr.2013.02.016; Qu B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041504; Sayeed A, 2012, J CELL PHYSIOL, V227, P751, DOI 10.1002/jcp.22784; Shen C, 2013, SEMIN CANCER BIOL, V23, P18, DOI 10.1016/j.semcancer.2012.06.001; Tomasetti C, 2015, SCIENCE, V347, P78, DOI 10.1126/science.1260825; Wang J, 2014, MOL ENDOCRINOL, V28, P239, DOI 10.1210/me.2013-1258; Wong SC, 2018, MOL CANCER THER, V17, P140, DOI 10.1158/1535-7163.MCT-17-0471; Xu KX, 2009, CANCER CELL, V15, P270, DOI 10.1016/j.ccr.2009.02.021; Yang OCY, 2013, KIDNEY INT, V84, P667, DOI 10.1038/ki.2013.245; Zhai W, 2016, ONCOGENE, V35, P4866, DOI 10.1038/onc.2016.19	31	3	3	4	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2020	39	43					6677	6691		10.1038/s41388-020-01455-0	http://dx.doi.org/10.1038/s41388-020-01455-0		SEP 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OF2UT	32943729				2022-12-17	WOS:000571161500002
J	Goodsell, DS; Burley, SK				Goodsell, David S.; Burley, Stephen K.			RCSB Protein Data Bank tools for 3D structure-guided cancer research: human papillomavirus (HPV) case study	ONCOGENE			English	Review							CRYSTAL-STRUCTURES; MECHANISM; VALIDATION	Atomic-level three-dimensional (3D) structure data for biological macromolecules often prove critical to dissecting and understanding the precise mechanisms of action of cancer-related proteins and their diverse roles in oncogenic transformation, proliferation, and metastasis. They are also used extensively to identify potentially druggable targets and facilitate discovery and development of both small-molecule and biologic drugs that are today benefiting individuals diagnosed with cancer around the world. 3D structures of biomolecules (including proteins, DNA, RNA, and their complexes with one another, drugs, and other small molecules) are freely distributed by the open-access Protein Data Bank (PDB). This global data repository is used by millions of scientists and educators working in the areas of drug discovery, vaccine design, and biomedical and biotechnology research. The US Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB) provides an integrated portal to the PDB archive that streamlines access for millions of worldwide PDB data consumers worldwide. Herein, we review online resources made available free of charge by the RCSB PDB to basic and applied researchers, healthcare providers, educators and their students, patients and their families, and the curious public. We exemplify the value of understanding cancer-related proteins in 3D with a case study focused on human papillomavirus.	[Goodsell, David S.; Burley, Stephen K.] Rutgers State Univ, Res Collaboratory Struct Bioinformat Prot Data Ba, Piscataway, NJ 08854 USA; [Goodsell, David S.; Burley, Stephen K.] Rutgers State Univ, Inst Quantitat Biomed, Piscataway, NJ 08854 USA; [Goodsell, David S.] Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA; [Burley, Stephen K.] Rutgers State Univ, Dept Chem & Chem Biol, Piscataway, NJ 08854 USA; [Burley, Stephen K.] Univ Calif San Diego, San Diego Supercomp Ctr, Res Collaboratory Struct Bioinformat Prot Data Ba, La Jolla, CA 92093 USA; [Burley, Stephen K.] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA; [Burley, Stephen K.] Rutgers State Univ, Rutgers Canc Inst New Jersey, New Brunswick, NJ 08903 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Scripps Research Institute; Rutgers State University New Brunswick; University of California System; University of California San Diego; University of California System; University of California San Diego; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Goodsell, DS; Burley, SK (corresponding author), Rutgers State Univ, Res Collaboratory Struct Bioinformat Prot Data Ba, Piscataway, NJ 08854 USA.; Goodsell, DS; Burley, SK (corresponding author), Rutgers State Univ, Inst Quantitat Biomed, Piscataway, NJ 08854 USA.; Goodsell, DS (corresponding author), Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA.; Burley, SK (corresponding author), Rutgers State Univ, Dept Chem & Chem Biol, Piscataway, NJ 08854 USA.; Burley, SK (corresponding author), Univ Calif San Diego, San Diego Supercomp Ctr, Res Collaboratory Struct Bioinformat Prot Data Ba, La Jolla, CA 92093 USA.; Burley, SK (corresponding author), Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA.; Burley, SK (corresponding author), Rutgers State Univ, Rutgers Canc Inst New Jersey, New Brunswick, NJ 08903 USA.	David.Goodsell@rcsb.org; Stephen.Burley@rcsb.org		Burley, Stephen K./0000-0002-2487-9713	National Science Foundation [DBI-1832184]; US Department of Energy [DE-SC0019749]; National Cancer Institute of the National Institutes of Health [R01GM133198]; National Institute of General Medical Sciences of the National Institutes of Health [R01GM133198]; National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R01GM133198]	National Science Foundation(National Science Foundation (NSF)); US Department of Energy(United States Department of Energy (DOE)); National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of General Medical Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institute of Allergy and Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We gratefully acknowledge discussions with Drs. X.F. Steven Zheng and Shridar Ganesan and other members of the Rutgers Cancer Institute of New Jersey, and contributions from all members of the RCSB PDB and our wwPDB partners around the world. RCSB PDB is jointly funded by grants to SKB from the National Science Foundation (DBI-1832184), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.	Adams PD, 2019, ACTA CRYSTALLOGR D, V75, P451, DOI 10.1107/S2059798319004522; [Anonymous], 2017, Wkly Epidemiol Rec, V92, P241; [Anonymous], 2018, DATABASE; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bishop B, 2007, J BIOL CHEM, V282, P31803, DOI 10.1074/jbc.M706380200; Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD464, DOI 10.1093/nar/gky1004; Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD520, DOI 10.1093/nar/gky949; Cardone G, 2014, MBIO, V5, DOI 10.1128/mBio.01104-14; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; Castellano GM, 2019, J THORAC ONCOL, V14, P1982, DOI 10.1016/j.jtho.2019.06.015; Charbonnier S, 2011, J MOL BIOL, V406, P745, DOI 10.1016/j.jmb.2011.01.015; Dasgupta J, 2011, J BIOL CHEM, V286, P2617, DOI 10.1074/jbc.M110.160184; Dutta S, 2010, J APPL CRYSTALLOGR, V43, P1224, DOI 10.1107/S002188981002371X; Enemark EJ, 2006, NATURE, V442, P270, DOI 10.1038/nature04943; Goddard TD, 2018, PROTEIN SCI, V27, P14, DOI 10.1002/pro.3235; Goodsell DS, 2020, PROTEIN SCI, V29, P52, DOI 10.1002/pro.3730; Goodsell DS, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002140; Gore S, 2017, STRUCTURE, V25, P1916, DOI 10.1016/j.str.2017.10.009; Graham SV, 2010, FUTURE MICROBIOL, V5, P1493, DOI [10.2217/fmb.10.107, 10.2217/FMB.10.107]; Guan J, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9120374; Guiley KZ, 2015, GENE DEV, V29, P961, DOI 10.1101/gad.257568.114; Hanson RM, 2010, J APPL CRYSTALLOGR, V43, P1250, DOI 10.1107/S0021889810030256; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KENDREW JC, 1958, NATURE, V181, P662, DOI 10.1038/181662a0; Kobayashi K, 2018, J CLIN MED, V7, DOI 10.3390/jcm7090241; Korkmaz S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197176; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; Martinez-Zapien D, 2016, NATURE, V529, P541, DOI 10.1038/nature16481; McBride AA, 2017, BIOL CHEM, V398, P919, DOI 10.1515/hsz-2017-0113; Mittal S, 2017, MUTAT RES-REV MUTAT, V772, P23, DOI 10.1016/j.mrrev.2016.08.001; RAO ST, 1973, J MOL BIOL, V76, P241, DOI 10.1016/0022-2836(73)90388-4; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Sehnal D., 2018, WORKSH MOL GRAPH VIS, DOI [/10.5555/3293503.3293509, DOI 10.5555/3293503.3293509, 10.2312/molva.20181103]; Shao CH, 2017, STRUCTURE, V25, P458, DOI 10.1016/j.str.2017.01.013; Watson H.C., 1969, PROGR STEREOCHEM, V4, P229; Westbrook JD, 2020, DRUG DISCOV TODAY, V25, P837, DOI 10.1016/j.drudis.2020.02.002; Westbrook JD, 2019, STRUCTURE, V27, P211, DOI 10.1016/j.str.2018.11.007; Wilkinson MD, 2016, SCI DATA, V3, DOI 10.1038/sdata.2016.18; Young JY, 2017, STRUCTURE, V25, P536, DOI 10.1016/j.str.2017.01.004	41	3	3	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2020	39	43					6623	6632		10.1038/s41388-020-01461-2	http://dx.doi.org/10.1038/s41388-020-01461-2		SEP 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OF2UT	32939013	Green Published, hybrid			2022-12-17	WOS:000570051900002
J	Tian, YR; Ma, RR; Sun, YJ; Liu, HT; Zhang, H; Sun, YY; Liu, L; Li, YH; Song, L; Gao, P				Tian, Yaru; Ma, Ranran; Sun, Yujing; Liu, Haiting; Zhang, Hui; Sun, Yiyuan; Liu, Lei; Li, Yuhong; Song, Lin; Gao, Peng			SP1-activated long noncoding RNA lncRNA GCMA functions as a competing endogenous RNA to promote tumor metastasis by sponging miR-124 and miR-34a in gastric cancer (vol 38, pg 4854, 2020)	ONCOGENE			English	Correction								An amendment to this paper has been published and can be accessed via a link at the top of the paper.				gaopeng@sdu.edu.cn						Tian YR, 2020, ONCOGENE, V39, P4854, DOI 10.1038/s41388-020-1330-4	1	3	3	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2020	39	42					6621	6621		10.1038/s41388-020-1377-2	http://dx.doi.org/10.1038/s41388-020-1377-2		SEP 2020	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA9HI	32913198	Bronze			2022-12-17	WOS:000568145400001
J	Zhou, QQ; Huang, TT; Jiang, ZY; Ge, C; Chen, XX; Zhang, LL; Zhao, FY; Zhu, MX; Chen, TY; Cui, Y; Li, H; Yao, M; Li, JJ; Tian, H				Zhou, Qingqing; Huang, Tingting; Jiang, Zhiyuan; Ge, Chao; Chen, Xiaoxia; Zhang, Lili; Zhao, Fangyu; Zhu, Miaoxin; Chen, Taoyang; Cui, Ying; Li, Hong; Yao, Ming; Li, Jinjun; Tian, Hua			Upregulation of SNX5 predicts poor prognosis and promotes hepatocellular carcinoma progression by modulating the EGFR-ERK1/2 signaling pathway (vol 39, pg 2140, 2019)	ONCOGENE			English	Correction												htian@shsci.org	huang, ting/GRR-3141-2022					Zhou QQ, 2020, ONCOGENE, V39, P2140, DOI 10.1038/s41388-019-1131-9	1	3	3	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2020	39	41					6511	6511		10.1038/s41388-020-01440-7	http://dx.doi.org/10.1038/s41388-020-01440-7		SEP 2020	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA1JL	32895479	Bronze			2022-12-17	WOS:000566854200001
J	Wang, Z; Li, YJ; Wu, DL; Yu, S; Wang, YL; Chan, FL				Wang, Zhu; Li, Youjia; Wu, Dinglan; Yu, Shan; Wang, Yuliang; Chan, Franky Leung			Nuclear receptor HNF4 alpha performs a tumor suppressor function in prostate cancer via its induction of p21-driven cellular senescence (vol 39, 1572, 2020)	ONCOGENE			English	Correction								The original version of this Article contained an error in the spelling of the author Chan FL, which was incorrectly given as leung Chan F. This has now been corrected in both the PDF and HTML versions of the Article.				yuliang.wang816@gmail.com; franky-chan@cuhk.edu.hk		Wu, Dinglan/0000-0002-5057-9626; Wang, Zhu/0000-0002-5457-3731				Wang Z, 2020, ONCOGENE, V39, P1572, DOI 10.1038/s41388-019-1080-3	1	3	3	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2020	39	39					6263	6263		10.1038/s41388-020-1290-8	http://dx.doi.org/10.1038/s41388-020-1290-8		AUG 2020	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NS8XO	32820251	Bronze, Green Published			2022-12-17	WOS:000561253800002
J	Vantaku, V; Putluri, V; Bader, DA; Maity, S; Ma, J; Arnold, JM; Rajapakshe, K; Donepudi, SR; von Rundstedt, FC; Devarakonda, V; Dubrulle, J; Karanam, B; McGuire, SE; Stossi, F; Jain, AK; Coarfa, C; Cao, Q; Sikora, AG; Villanueva, H; Kavuri, SM; Lotan, Y; Sreekumar, A; Putluri, N				Vantaku, Venkatrao; Putluri, Vasanta; Bader, David A.; Maity, Suman; Ma, Jing; Arnold, James M.; Rajapakshe, Kimal; Donepudi, Sri Ramya; von Rundstedt, Friedrich-Carl; Devarakonda, Vaishnavi; Dubrulle, Julien; Karanam, Balasubramanyam; McGuire, Sean E.; Stossi, Fabio; Jain, Abhinav K.; Coarfa, Cristian; Cao, Qi; Sikora, Andrew G.; Villanueva, Hugo; Kavuri, Shyam M.; Lotan, Yair; Sreekumar, Arun; Putluri, Nagireddy			Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression (Aug, 10.1038/S41388-019-0902-7, 2019)	ONCOGENE			English	Correction												putluri@bcm.edu		Bader, David/0000-0003-0514-7346				Vantaku V, 2020, ONCOGENE, V39, P6265, DOI 10.1038/s41388-019-0902-7	1	3	3	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2020	39	40					6387	6392		10.1038/s41388-020-1283-7	http://dx.doi.org/10.1038/s41388-020-1283-7		AUG 2020	6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NV5JK	32820250	Bronze			2022-12-17	WOS:000561253300001
J	Kohno, S; Linn, P; Nagatani, N; Watanabe, Y; Kumar, S; Soga, T; Takahashi, C				Kohno, Susumu; Linn, Paing; Nagatani, Naoko; Watanabe, Yoshihiro; Kumar, Sharad; Soga, Tomoyoshi; Takahashi, Chiaki			Pharmacologically targetable vulnerability in prostate cancer carrying RB1-SUCLA2 deletion	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; MUTATIONAL LANDSCAPE; COLLATERAL LETHALITY; RB; CELLS; EXPRESSION; SUCLA2; ENCEPHALOMYOPATHY; DIFFERENTIATION; DEFICIENCY	RB1gene is often homozygously deleted or mutated in prostate adenocarcinomas following acquirement of castration resistance and/or metastatic ability. We found thatSUCLA2gene is frequently involved in the deletion of theRB1gene region in advanced prostate cancer. SUCLA2 constitutes the beta-subunit of succinate CoA ligase heterodimer that reversibly converts succinyl CoA into succinate. We sought the possibility that deletion ofSUCLA2gives rise to a metabolic vulnerability that could be targeted therapeutically. We found a significant metabolic shift inSUCLA2-deleted prostate cancer cells, including lower mitochondrial respiratory activity. By screening a number of libraries for compounds that induce cell death selectively inSUCLA2-deficient prostate cancer cells, we identified thymoquinone (2-isopropyl-5-methylbenzo-1,4-quinone) and PMA (phorbol-12-myristate-13-acetate) from a natural compound library. These findings indicate that the metabolic vulnerability inSUCLA2-deficient prostate cancer cells is pharmacologically targetable.	[Kohno, Susumu; Linn, Paing; Nagatani, Naoko; Takahashi, Chiaki] Kanazawa Univ, Canc Res Inst, Div Oncol & Mol Biol, Kakuma Machi, Kanazawa, Ishikawa 9201192, Japan; [Watanabe, Yoshihiro] Kanazawa Univ Hosp, iCREK, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan; [Kumar, Sharad] Univ South Australia, Ctr Canc Biol, Adelaide, SA 5001, Australia; [Soga, Tomoyoshi] Keio Univ, Inst Adv Biosci, Tsuruoka, Yamagata 9970052, Japan	Kanazawa University; Kanazawa University; Centre for Cancer Biology; University of South Australia; Keio University	Kohno, S; Takahashi, C (corresponding author), Kanazawa Univ, Canc Res Inst, Div Oncol & Mol Biol, Kakuma Machi, Kanazawa, Ishikawa 9201192, Japan.	skohno@staff.kanazawa-u.ac.jp; chtakaha@staff.kanazawa-u.ac.jp	Kumar, Sharad/AAX-7787-2020	Kumar, Sharad/0000-0001-7126-9814; Linn, Paing/0000-0001-9525-7041; Takahashi, Chiaki/0000-0003-3390-9563	Funding Program for Next Generation World-Leading Researchers from cabinet office of Japan [LS049]; MEXT [17H03576, 17K19586, 19K22555, 17K14992, 20K07612]; Japan Agency for Medical Research and Development (AMED) [19cm0106164h0001]; Daiichi-Sankyo Co. Ltd. [C1010568, C1010818]; National Health & Medical Research Council of Australia [GNT 1103006]	Funding Program for Next Generation World-Leading Researchers from cabinet office of Japan; MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Daiichi-Sankyo Co. Ltd.(Daiichi Sankyo Company Limited); National Health & Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	We thank Drs. Y. Hirota and S. Tsutsumi for the substantial contribution to the initiation of work, Dr. A. Mizokami for helpful discussion, and Dr. Y. Watanabe for suggestion on research direction. This study was supported by Funding Program for Next Generation World-Leading Researchers (LS049) from cabinet office of Japan, Grant-in-Aid for Scientific Research (17H03576, 17K19586 and 19K22555 to CT, and 17K14992 and 20K07612 to SK) from MEXT, Project for Cancer Research and Therapeutic (P-CREATE) (19cm0106164h0001) from Japan Agency for Medical Research and Development (AMED), and TaNeDS (C1010568) and a collaborative research fund (C1010818) from Daiichi-Sankyo Co. Ltd. SK was supported by a Senior Principal Research Fellowship from the National Health & Medical Research Council of Australia (GNT 1103006).	Abida W, 2019, P NATL ACAD SCI USA, V116, P11428, DOI 10.1073/pnas.1902651116; Abou-Kheir WG, 2010, STEM CELLS, V28, P2129, DOI 10.1002/stem.538; Al-Amri A. M., 2009, Shiraz E Medical Journal, V10, P107; Aparicio A, 2011, NAT REV UROL, V8, P562, DOI 10.1038/nrurol.2011.107; Barbieri CE, 2013, EUR UROL, V64, P567, DOI 10.1016/j.eururo.2013.05.029; Beltran H, 2013, EUR UROL, V63, P920, DOI 10.1016/j.eururo.2012.08.053; Besse A, 2015, CELL METAB, V21, P417, DOI 10.1016/j.cmet.2015.02.008; Bignell GR, 2010, NATURE, V463, P893, DOI 10.1038/nature08768; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOUTAGY NE, 2015, JOVE J VIS EXP OCT, V105, DOI DOI 10.3791/53216; Brough R, 2018, ONCOGENE, V37, P5701, DOI 10.1038/s41388-018-0368-z; Carrozzo R, 2007, BRAIN, V130, P862, DOI 10.1093/brain/awl389; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Crumbaker M, 2017, CANCERS, V9, DOI 10.3390/cancers9040034; Dey P, 2017, NATURE, V542, P119, DOI 10.1038/nature21052; Dobolyi A, 2015, BRAIN STRUCT FUNCT, V220, P135, DOI 10.1007/s00429-013-0643-2; Donti TR, 2014, DIS MODEL MECH, V7, P271, DOI 10.1242/dmm.013466; Dyson NJ, 2016, GENE DEV, V30, P1492, DOI 10.1101/gad.282145.116; El-Hattab A, 2013, NEUROTHERAPEUTICS, V10, P186, DOI 10.1007/s13311-013-0177-6; Frank Sander, 2018, F1000Res, V7, DOI 10.12688/f1000research.14499.1; Frezza C, 2007, NAT PROTOC, V2, P287, DOI 10.1038/nprot.2006.478; Frezza C, 2011, NATURE, V477, P225, DOI 10.1038/nature10363; Gao S, 2016, CELL REP, V17, P966, DOI 10.1016/j.celrep.2016.09.064; Gong XQ, 2019, CANCER DISCOV, V9, P248, DOI 10.1158/2159-8290.CD-18-0469; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; HECKER E, 1967, NATURWISSENSCHAFTEN, V54, P282, DOI 10.1007/BF00620887; Hirotsu T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118699; Huang L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088893; Huang YQ, 2018, ONCOL LETT, V15, P6063, DOI 10.3892/ol.2018.8123; Huggins C, 1943, SCIENCE, V97, P541, DOI 10.1126/science.97.2529.541; Johnson JD, 1998, J BIOL CHEM, V273, P27580, DOI 10.1074/jbc.273.42.27580; Jones RA, 2016, J CLIN INVEST, V126, P3739, DOI 10.1172/JCI81568; Kadota K, 2008, ALGORITHM MOL BIOL, V3, DOI 10.1186/1748-7188-3-8; Kirby M, 2011, INT J CLIN PRACT, V65, P1180, DOI 10.1111/j.1742-1241.2011.02799.x; Knudsen Erik S, 2018, Oncotarget, V9, P30940, DOI 10.18632/oncotarget.25797; Kundu J, 2014, FOOD CHEM TOXICOL, V65, P18, DOI 10.1016/j.fct.2013.12.015; Li FK, 2019, CANCER RES, V79, P3903, DOI 10.1158/0008-5472.CAN-18-3604; Manning AL, 2012, NAT REV CANCER, V12, P220, DOI 10.1038/nrc3216; Matilainen S, 2015, EUR J HUM GENET, V23, P325, DOI 10.1038/ejhg.2014.128; Miller C, 2011, BBA-MOL BASIS DIS, V1812, P625, DOI 10.1016/j.bbadis.2011.01.013; Mostofa AGM, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00295; Muller FL, 2015, TRENDS CANCER, V1, P161, DOI 10.1016/j.trecan.2015.10.002; Muller FL, 2012, NATURE, V488, P337, DOI 10.1038/nature11331; Nicolay BN, 2015, GENE DEV, V29, P1875, DOI 10.1101/gad.264127.115; Ohmiya H, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-269; Oser MG, 2019, CANCER DISCOV, V9, P230, DOI 10.1158/2159-8290.CD-18-0389; Patel AB, 2005, P NATL ACAD SCI USA, V102, P5588, DOI 10.1073/pnas.0501703102; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Salah M, 2016, MOL CARCINOGEN, V55, P1974, DOI 10.1002/mc.22444; SALOMI MJ, 1991, NUTR CANCER, V16, P67, DOI 10.1080/01635589109514142; Sankaran VG, 2008, GENE DEV, V22, P463, DOI 10.1101/gad.1627208; Scime A, 2005, CELL METAB, V2, P283, DOI 10.1016/j.cmet.2005.10.002; Sharma A, 2010, J CLIN INVEST, V120, P4478, DOI 10.1172/JCI44239; Soga T, 2006, J BIOL CHEM, V281, P16768, DOI 10.1074/jbc.M601876200; Soga T, 2009, ANAL CHEM, V81, P6165, DOI 10.1021/ac900675k; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tort F, 2006, CANCER RES, V66, P10258, DOI 10.1158/0008-5472.CAN-06-2178; Ueda Yuji, 2019, Oncotarget, V10, P5412, DOI 10.18632/oncotarget.27124; VANDUUREN BL, 1969, PROG EXP TUMOR RES, V11, P31; Varaljai R, 2015, GENE DEV, V29, P1817, DOI 10.1101/gad.264036.115; Witkiewicz AK, 2018, CELL REP, V22, P1185, DOI 10.1016/j.celrep.2018.01.022; Yi TF, 2008, MOL CANCER THER, V7, P1789, DOI 10.1158/1535-7163.MCT-08-0124; Zacksenhaus E, 2018, MOL CELL ONCOL, V5, DOI 10.1080/23723556.2018.1481814; Zhang LD, 2016, ONCOL LETT, V12, P2840, DOI 10.3892/ol.2016.4971; Zhao YJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05168-5; Zhou ZX, 2006, CANCER RES, V66, P7889, DOI 10.1158/0008-5472.CAN-06-0486	66	3	3	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2020	39	34					5690	5707		10.1038/s41388-020-1381-6	http://dx.doi.org/10.1038/s41388-020-1381-6		JUL 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NE9FK	32694611				2022-12-17	WOS:000551055100001
J	Meyer-Schaller, N; Tiede, S; Ivanek, R; Diepenbruck, M; Christofori, G				Meyer-Schaller, Nathalie; Tiede, Stefanie; Ivanek, Robert; Diepenbruck, Maren; Christofori, Gerhard			A dual role of Irf1 in maintaining epithelial identity but also enabling EMT and metastasis formation of breast cancer cells	ONCOGENE			English	Article							REGULATORY FACTOR-I; INTERFERON; INDUCTION; PATHWAY; FAMILY; TARGET	An epithelial to mesenchymal transition (EMT) is an embryonic dedifferentiation program which is aberrantly activated in cancer cells to acquire cellular plasticity. This plasticity increases the ability of breast cancer cells to invade into surrounding tissue, to seed metastasis at distant sites and to resist to chemotherapy. In this study, we have observed a higher expression of interferon-related factors in basal-like and claudin-low subtypes of breast cancer in patients, known to be associated with EMT. Notably, Irf1 exerts essential functions during the EMT process, yet it is also required for the maintenance of an epithelial differentiation status of mammary gland epithelial cells: RNAi-mediated ablation of Irf1 in mammary epithelial cells results in the expression of mesenchymal factors and Smad transcriptional activity. Conversely, ablation of Irf1 during TGF beta-induced EMT prevents a mesenchymal transition and stabilizes the expression of E-cadherin. In the basal-like murine breast cancer cell line 4T1, RNAi-mediated ablation of Irf1 reduces colony formation and cell migration in vitro and shedding of circulating tumor cells and metastasis formation in vivo. This context-dependent dual role of Irf1 in the regulation of epithelial-mesenchymal plasticity provides important new insights into the functional contribution and therapeutic potential of interferon-regulated factors in breast cancer.	[Meyer-Schaller, Nathalie; Tiede, Stefanie; Ivanek, Robert; Diepenbruck, Maren; Christofori, Gerhard] Univ Basel, Dept Biomed, CH-4058 Basel, Switzerland; [Ivanek, Robert] Swiss Inst Bioinformat, CH-4058 Basel, Switzerland	University of Basel; Swiss Institute of Bioinformatics	Meyer-Schaller, N; Christofori, G (corresponding author), Univ Basel, Dept Biomed, CH-4058 Basel, Switzerland.	nathalie.meyer-schaller@unibas.ch; gerhard.christofori@unibas.ch			Swiss National Science Foundation [310030B_163471]; SystemsX.ch RTD Cellplasticity; Swiss Cancer League [KFS-3479-08-2014]; Krebsliga Beider Basel [03-2013]; Marie-Heim Vogtlin grant from the Swiss National Science Foundation	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); SystemsX.ch RTD Cellplasticity; Swiss Cancer League; Krebsliga Beider Basel; Marie-Heim Vogtlin grant from the Swiss National Science Foundation	We thank Petra Schmidt for technical assistance with immunoblotting and quantitative RT-PCR, Helena Antoniadis for help with mouse work, Christian Beisel and the D-BSSE sequencing facility for RNA-sequencing, Pascal Lorenz and the DBM Mattenstrasse microscopy facility for microscopy and image quantification support. This work was supported by the Swiss National Science Foundation (310030B_163471), the SystemsX.ch RTD Cellplasticity, the Swiss Cancer League (KFS-3479-08-2014), the Krebsliga Beider Basel (03-2013) (all GC) and by a Marie-Heim Vogtlin grant from the Swiss National Science Foundation (NM-S).	Alsamman K, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171672; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bouker KB, 2005, CARCINOGENESIS, V26, P1527, DOI 10.1093/carcin/bgi113; Bouker KB, 2004, CANCER RES, V64, P4030, DOI 10.1158/0008-5472.CAN-03-3602; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dror N, 2007, MOL IMMUNOL, V44, P338, DOI 10.1016/j.molimm.2006.02.026; Dvinge H, 2013, NATURE, V497, P378, DOI 10.1038/nature12108; Garcia-Diaz A, 2017, CELL REP, V19, P1189, DOI 10.1016/j.celrep.2017.04.031; Guerrero Michael S, 2012, Genes Cancer, V3, P371, DOI 10.1177/1947601912458585; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; Honda K, 2006, IMMUNITY, V25, P349, DOI 10.1016/j.immuni.2006.08.009; Huang RYJ, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.442; Irudayam JI, 2015, STEM CELL RES, V15, P354, DOI 10.1016/j.scr.2015.08.003; Jiang L, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1186-z; Jiang YY, 2020, CANCER LETT, V468, P72, DOI 10.1016/j.canlet.2019.10.013; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lehembre F, 2008, EMBO J, V27, P2603, DOI 10.1038/emboj.2008.178; Lotz-Jenne C, 2016, ONCOTARGET, V7, P25983, DOI 10.18632/oncotarget.8418; Maeda M, 2005, J CELL SCI, V118, P873, DOI 10.1242/jcs.01634; Meyer-Schaller N, 2019, DEV CELL, V48, P539, DOI 10.1016/j.devcel.2018.12.023; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Pavan S, 2018, ONCOGENE, V37, P4197, DOI 10.1038/s41388-018-0270-8; Pavan S, 2013, EUR J CANCER, V49, P964, DOI 10.1016/j.ejca.2012.09.024; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Stemmler MP, 2019, NAT CELL BIOL, V21, P102, DOI 10.1038/s41556-018-0196-y; Waldmeier L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048651; Yanai H, 2012, ONCOIMMUNOLOGY, V1, P1376, DOI 10.4161/onci.22475; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; You FP, 2013, NAT IMMUNOL, V14, P1237, DOI 10.1038/ni.2756; Yu M, 2017, INT J ONCOL, V50, P975, DOI 10.3892/ijo.2017.3852	34	3	3	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	24					4728	4740		10.1038/s41388-020-1326-0	http://dx.doi.org/10.1038/s41388-020-1326-0		MAY 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LY0HO	32404986				2022-12-17	WOS:000532807900001
J	Yin, HJ; Jiang, ZY; Feng, X; Ji, ZD; Jin, W				Yin, Huijing; Jiang, Zhengyu; Feng, Xu; Ji, Zhaodong; Jin, Wei			Identification of Sca-1(+)Abcg1(+) bronchioalveolar epithelial cells as the origin of lung adenocarcinoma in Gprc5a-knockout mouse model through the interaction between lung progenitor AT2 and Lgr5 cells	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GPRC5A; STEM-CELLS; EXTRACELLULAR-MATRIX; CHOLESTEROL EFFLUX; CANCER; GENE; ACTIVATION; EXPRESSION; POPULATION; PROMOTES	The reason for the reduced efficacy of lung cancer therapy is the existence of lung cancer stem cells (CSCs). Targeting CSCs results in evolved phenotypes with increased malignancy, leading to therapy failure. Here, we propose a new therapeutic strategy: investigating the "transitional" cells that represent the stage between normal lung stem cells and lung CSCs. Identifying and targeting the key molecule that drives carcinogenesis to inhibit or reverse this process would thus provide new perspectives for early diagnosis and intervention in lung cancer. We used Gprc5a-knockout (KO) mice, the first animal model of spontaneous lung adenocarcinoma established by the deletion of a single lung tumor suppressor gene. We investigated the interaction of lung progenitor cells AT2 with Lgr5 cells in the generation of CSCs and related signaling mechanism. In the present study, using Gprc5a-KO mice, we found the initiator Sca-1(+)Abcg1(+) subset with a CSC-like phenotype within the lung progenitor AT2 cell population in mice that had not yet developed tumors. We confirmed the self-renewal and tumor initiation capacities of this subset in vitro, in vivo, and clinical samples. Mechanistically, we found that the generation of Sca-1(+)Abcg1(+) cells was associated with an interaction between AT2 and Lgr5 cells and the subsequent activation of the ECM1-alpha 6 beta 4-ABCG1 axis. Importantly, Sca-1(+)Abcg1(+) and SPA(+)ABCG1(+) cells specifically existed in the small bronchioles of Gprc5a-KO mice and patients with pneumonia, respectively. Thus, the present study unveiled a new kind of lung cancer-initiating cells (LCICs) and provided potential markers for the early diagnosis of lung cancer.	[Yin, Huijing; Feng, Xu; Ji, Zhaodong] Fudan Univ, Inst Canc, Shanghai Canc Ctr, Shanghai 200032, Peoples R China; [Yin, Huijing; Feng, Xu; Ji, Zhaodong] Fudan Univ, Shanghai Med Sch, Dept Oncol, Shanghai 200032, Peoples R China; [Jiang, Zhengyu] Second Mil Med Univ, PLA, Dept Anesthesiol, Naval Med Ctr,Naval Med Univ, Shanghai 200052, Peoples R China; [Jiang, Zhengyu] Second Mil Med Univ, Changhai Hosp, Fac Anesthesiol, Naval Med Univ,PLA, Shanghai 200433, Peoples R China; [Jin, Wei] Shanghai Jiao Tong Univ, Dept Immunol & Microbiol, Sch Med,Chinese Minist Educ, Shanghai Inst Immunol,Key Lab Cell Differentiat &, Shanghai 200025, Peoples R China	Fudan University; Fudan University; Naval Medical University; Naval Medical University; Chinese Academy of Sciences; Shanghai Jiao Tong University	Yin, HJ (corresponding author), Fudan Univ, Inst Canc, Shanghai Canc Ctr, Shanghai 200032, Peoples R China.; Yin, HJ (corresponding author), Fudan Univ, Shanghai Med Sch, Dept Oncol, Shanghai 200032, Peoples R China.	yinhuijing@fudan.edu.cn			National Natural Science Foundation of China [81601985]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by grants from the National Natural Science Foundation of China (No. 81601985 for HY). We appreciate all the members in our lab and co-authors' contribution in encouraging discussion and suggestions.	Adorno-Cruz V, 2015, CANCER RES, V75, P924, DOI 10.1158/0008-5472.CAN-14-3225; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Cabezas-Wallscheid N, 2017, CELL, V169, P807, DOI 10.1016/j.cell.2017.04.018; Chapman HA, 2011, J CLIN INVEST, V121, P2855, DOI 10.1172/JCI57673; Cheng YJ, 1998, J BIOL CHEM, V273, P35008, DOI 10.1074/jbc.273.52.35008; Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012; COSTANTINI RM, 1990, CANCER RES, V50, P6107; Deng JO, 2010, CANCER PREV RES, V3, P424, DOI 10.1158/1940-6207.CAPR-10-0032; El Roz A, 2012, ANTICANCER RES, V32, P3007; Eramo A, 2010, ONCOGENE, V29, P4625, DOI 10.1038/onc.2010.207; Fujimoto J, 2012, J THORAC ONCOL, V7, P1747, DOI 10.1097/JTO.0b013e31826bb1ff; Grepmeier U, 2005, INT J ONCOL, V27, P481; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hantgan RR, 2003, J BIOL CHEM, V278, P3417, DOI 10.1074/jbc.M208869200; Hoye AM, 2016, AM J PHYSIOL-CELL PH, V310, pC955, DOI 10.1152/ajpcell.00326.2015; Hu L, 2010, BRIT J CANCER, V102, P1276, DOI 10.1038/sj.bjc.6605626; Huch M, 2013, NATURE, V494, P247, DOI 10.1038/nature11826; Hynes RO, 2009, SCIENCE, V326, P1216, DOI 10.1126/science.1176009; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jaks V, 2008, NAT GENET, V40, P1291, DOI 10.1038/ng.239; Kennedy MA, 2005, CELL METAB, V1, P121, DOI 10.1016/j.cmet.2005.01.002; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Kobayashi Y, 2011, GYNECOL ONCOL, V121, P390, DOI 10.1016/j.ygyno.2010.12.366; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Lee JH, 2017, CELL, V170, P1149, DOI 10.1016/j.cell.2017.07.028; Lee KM, 2015, ONCOGENE, V34, P6055, DOI 10.1038/onc.2015.54; Lee KM, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0479-6; Lee KM, 2015, CELL SIGNAL, V27, P228, DOI 10.1016/j.cellsig.2014.11.004; Leeman KT, 2014, CURR TOP DEV BIOL, V107, P207, DOI 10.1016/B978-0-12-416022-4.00008-1; Lin CW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053817; Lipscomb EA, 2005, CANCER METAST REV, V24, P413, DOI 10.1007/s10555-005-5133-4; Love Michael I, 2018, F1000Res, V7, P952, DOI 10.12688/f1000research.15398.1; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Matsuura F, 2006, J CLIN INVEST, V116, P1435, DOI 10.1172/JCI27602; Morrison BJ, 2013, TARGET ONCOL, V8, P159, DOI 10.1007/s11523-012-0247-4; Roberts A, 2013, NAT METHODS, V10, P71, DOI [10.1038/nmeth.2251, 10.1038/NMETH.2251]; Roberts A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-3-r22; Song JH, 2007, CANCER RES, V67, P6946, DOI 10.1158/0008-5472.CAN-06-3896; Sturek JM, 2010, J CLIN INVEST, V120, P2575, DOI 10.1172/JCI41280; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Takeuchi S, 1996, CANCER RES, V56, P738; Tammela T, 2017, NATURE, V545, P355, DOI 10.1038/nature22334; Tao QG, 2007, JNCI-J NATL CANCER I, V99, P1668, DOI 10.1093/jnci/djm208; Wang X, 2007, J CLIN INVEST, V117, P2216, DOI 10.1172/JCI32057; Yang Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002220; Ye XF, 2009, CANCER BIOL THER, V8, P951, DOI 10.4161/cbt.8.10.8244; Ye Xiaofeng, 2008, Briefings in Functional Genomics & Proteomics, V7, P322, DOI 10.1093/bfgp/eln021; Zhong SS, 2015, CANCER RES, V75, P1801, DOI 10.1158/0008-5472.CAN-14-2005	52	3	3	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	18					3754	3773		10.1038/s41388-020-1251-2	http://dx.doi.org/10.1038/s41388-020-1251-2		MAR 2020	20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LI5XR	32157214	Green Published, hybrid			2022-12-17	WOS:000518886000006
J	Oshikawa, K; Matsumoto, M; Kodama, M; Shimizu, H; Nakayama, KI				Oshikawa, Kiyotaka; Matsumoto, Masaki; Kodama, Manabu; Shimizu, Hideyuki; Nakayama, Keiichi I.			A fail-safe system to prevent oncogenesis by senescence is targeted by SV40 small T antigen	ONCOGENE			English	Article							CANCER; CELLS; TRANSFORMATION; ONCOPROTEINS; PATHWAY; BTG2; P53; FIBROBLASTS; MIGRATION; VACCINES	Whereas large T antigen (LT) of simian virus 40 (SV40) promotes oncogenesis by inactivating the tumor suppressor proteins p53 and pRb, SV40 small T antigen (ST) has been thought to be dispensable for this process. However, here we show that LT promotes both oncogenic growth and senescence in human cells expressing oncogenic Ras and that this latter effect is antagonized by ST. Inactivation of p53 by LT alone promoted the senescence-associated secretory phenotype (SASP), whereas the additional expression of ST attenuated this phenotype, allowing cells to avoid oncogene-induced senescence (OIS) and thereby promoting efficient oncogenesis. ST interacts with and inhibits the function of heterochromatin protein 1-binding protein 3 (HP1BP3), a positive regulator of global microRNA biogenesis, and it thereby triggers aberrant upregulation of B-cell translocation gene 2 (BTG2), which is essential for prevention of SASP and OIS by ST. Collectively, our results indicate that the HP1BP3-BTG2 axis constitutes a fail-safe system to prevent oncogenesis by means of OIS induction, and that this system is hijacked by ST.	[Oshikawa, Kiyotaka; Kodama, Manabu; Shimizu, Hideyuki; Nakayama, Keiichi I.] Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka, Japan; [Matsumoto, Masaki; Nakayama, Keiichi I.] Kyushu Univ, Med Inst Bioregulat, Div Prote, Fukuoka, Japan	Kyushu University; Kyushu University	Nakayama, KI (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka, Japan.; Matsumoto, M; Nakayama, KI (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Prote, Fukuoka, Japan.	masakim@bioreg.kyushu-u.ac.jp; nakayak1@bioreg.kyushu-u.ac.jp		Matsumoto, Masaki/0000-0002-6987-0288; Shimizu, Hideyuki/0000-0002-0772-2204	KAKENHI grants from Japan Society for the Promotion of Science (JSPS); Ministry of Education, Culture, Sports, Science, and Technology of Japan [18H05215, 17H06301, 25221303, 17K19606, 17H05534, 17H06011]; Project for Cancer Research and Therapeutic Evolution (P-CREATE) of the Japan Agency for Medical Research and Development (AMED); Core Research for Evolutionary Science and Technology (CREST) of the Japan Science and Technology Agency (JST) [JPMJCR15G4]	KAKENHI grants from Japan Society for the Promotion of Science (JSPS); Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Project for Cancer Research and Therapeutic Evolution (P-CREATE) of the Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Core Research for Evolutionary Science and Technology (CREST) of the Japan Science and Technology Agency (JST)(Japan Science & Technology Agency (JST))	We thank T. Akagi for the pCX4 system as well as hTERT, SV40 ER, and H-RasG12V expression vectors; A. Sakiyama and K. Tsunematsu for technical assistance; members of our laboratories for comments on the manuscript; and A. Ohta for help in preparation of the manuscript. This work was supported in part by KAKENHI grants from Japan Society for the Promotion of Science (JSPS) and the Ministry of Education, Culture, Sports, Science, and Technology of Japan to KIN (18H05215, 17H06301, and 25221303) and to MM (17K19606, 17H05534, and 17H06011) as well as by the Project for Cancer Research and Therapeutic Evolution (P-CREATE) of the Japan Agency for Medical Research and Development (AMED). MM is also supported by Core Research for Evolutionary Science and Technology (CREST, JPMJCR15G4) of the Japan Science and Technology Agency (JST).	Akagi T, 2003, P NATL ACAD SCI USA, V100, P13567, DOI 10.1073/pnas.1834876100; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013; Boiko AD, 2006, GENE DEV, V20, P236, DOI 10.1101/gad.1372606; Buganim Y, 2010, CANCER RES, V70, P2274, DOI 10.1158/0008-5472.CAN-09-2661; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen W, 2003, HISTOL HISTOPATHOL, V18, P541, DOI 10.14670/HH-18.541; Chien YC, 2011, GENE DEV, V25, P2125, DOI 10.1101/gad.17276711; Choi OR, 2016, CELL SIGNAL, V28, P1172, DOI 10.1016/j.cellsig.2016.05.014; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; de Boer E, 2003, P NATL ACAD SCI USA, V100, P7480, DOI 10.1073/pnas.1332608100; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Nguyen HT, 2014, CELL REP, V8, P707, DOI 10.1016/j.celrep.2014.06.062; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Li WQ, 2015, INT J ONCOL, V46, P1601, DOI 10.3892/ijo.2015.2843; Lim IK, 2017, CELL SIGNAL, V30, P179, DOI 10.1016/j.cellsig.2016.12.001; Liu HM, 2016, MOL CELL, V63, P420, DOI 10.1016/j.molcel.2016.06.014; Mao BJ, 2015, INT J ONCOL, V46, P459, DOI 10.3892/ijo.2014.2765; Matsumoto M, 2017, NAT METHODS, V14, P251, DOI [10.1038/NMETH.4116, 10.1038/nmeth.4116]; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Olin P, 1998, DEV BIOL STAND, V94, P227; Qi F, 2011, EXPERT REV RESP MED, V5, P683, DOI [10.1586/ERS.11.51, 10.1586/ers.11.51]; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Strickler HD, 1998, JAMA-J AM MED ASSOC, V279, P292, DOI 10.1001/jama.279.4.292; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tong ZY, 2015, INT J MOL SCI, V16, P14511, DOI 10.3390/ijms160714511; Uren A, 2005, CANCER RES, V65, P6199, DOI 10.1158/0008-5472.CAN-05-0455; Wagener N, 2013, BRIT J CANCER, V108, P973, DOI 10.1038/bjc.2012.573; Yang G, 2006, P NATL ACAD SCI USA, V103, P16472, DOI 10.1073/pnas.0605752103; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110	36	3	4	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2170	2186		10.1038/s41388-019-1139-1	http://dx.doi.org/10.1038/s41388-019-1139-1			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31819167				2022-12-17	WOS:000518584000011
J	Hayashi, T; Sano, K; Aburatani, H; Yaegashi, N; Konishi, I				Hayashi, Takuma; Sano, Kenji; Aburatani, Hiroyuki; Yaegashi, Nobuo; Konishi, Ikuo			Initialization of epithelial cells by tumor cells in a metastatic microenvironment	ONCOGENE			English	Letter							S100A4		[Hayashi, Takuma; Konishi, Ikuo] Natl Hosp Org Kyoto Med Ctr, Kyoto, Kyoto, Japan; [Hayashi, Takuma; Sano, Kenji] Shinshu Univ Hosp, Dept Med Lab, Nagano, Japan; [Aburatani, Hiroyuki] Univ Tokyo, Res Ctr Adv Sci & Technol, Genome Sci Lab, Tokyo, Japan; [Aburatani, Hiroyuki] ICGC, Hobart, Australia; [Yaegashi, Nobuo] Tohoku Univ, Sch Med, Dept Obstet & Gynecol, Sendai, Miyagi, Japan; [Konishi, Ikuo] Asian Soc Gynecol Oncol, Tokyo, Japan	Shinshu University; University of Tokyo; Tohoku University	Hayashi, T (corresponding author), Natl Hosp Org Kyoto Med Ctr, Kyoto, Kyoto, Japan.; Hayashi, T (corresponding author), Shinshu Univ Hosp, Dept Med Lab, Nagano, Japan.	yoyoyo224@hotmail.com			Japan Ministry of Education, Culture, Science and Technology [24592510, 15K1079, 19K09840]; Foundation of Osaka Cancer Research; Ichiro Kanehara Foundation of the Promotion of Medical Science and Medical Care; Foundation for the Promotion of Cancer Research; Kanzawa Medical Research Foundation; Takeda Foundation for Medical Science	Japan Ministry of Education, Culture, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Foundation of Osaka Cancer Research; Ichiro Kanehara Foundation of the Promotion of Medical Science and Medical Care; Foundation for the Promotion of Cancer Research; Kanzawa Medical Research Foundation(Kanzawa Medical Research Foundation); Takeda Foundation for Medical Science	This study was supported in part by grants from the Japan Ministry of Education, Culture, Science and Technology (nos. 24592510, 15K1079, and 19K09840), The Foundation of Osaka Cancer Research, The Ichiro Kanehara Foundation of the Promotion of Medical Science and Medical Care, The Foundation for the Promotion of Cancer Research, The Kanzawa Medical Research Foundation, and The Takeda Foundation for Medical Science.	Asselin-Labat ML, 2019, NATURE, V572, P589, DOI 10.1038/d41586-019-02399-6; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Cho RW, 2008, STEM CELLS, V26, P364, DOI 10.1634/stemcells.2007-0440; Herwig N, 2016, J CELL MOL MED, V20, P825, DOI 10.1111/jcmm.12808; Horiuchi A, 2012, INT J CANCER, V131, P1755, DOI 10.1002/ijc.27448; Liu LL, 2019, J BIOL CHEM, V294, P7516, DOI 10.1074/jbc.RA118.004365; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Ombrato L, 2019, NATURE, V572, P603, DOI 10.1038/s41586-019-1487-6; Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414	9	3	3	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	12					2638	2640		10.1038/s41388-020-1171-1	http://dx.doi.org/10.1038/s41388-020-1171-1		FEB 2020	3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KW4HU	32015485				2022-12-17	WOS:000510820900002
J	Zhangyuan, GY; Wang, F; Zhang, HT; Jiang, RQ; Tao, XW; Yu, DC; Jin, KP; Yu, WW; Liu, Y; Yin, Y; Shen, JT; Xu, QF; Zhang, WJ; Sun, BC				Zhangyuan, Guangyan; Wang, Fei; Zhang, Haitian; Jiang, Runqiu; Tao, Xuewen; Yu, Decai; Jin, Kangpeng; Yu, WeiWei; Liu, Yang; Yin, Yin; Shen, Jintao; Xu, Qinfeng; Zhang, Wenjie; Sun, Beicheng			VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR-PI3K-AKT pathway (vol 39, pg 1213, 2020)	ONCOGENE			English	Correction									[Zhangyuan, Guangyan; Wang, Fei; Zhang, Haitian; Jiang, Runqiu; Tao, Xuewen; Zhang, Wenjie; Sun, Beicheng] Nanjing Med Univ, Drum Tower Clin Med Coll, Dept Hepatobiliary Surg, Nanjing, Peoples R China; [Zhangyuan, Guangyan; Wang, Fei; Zhang, Haitian; Jiang, Runqiu; Tao, Xuewen; Yu, Decai; Jin, Kangpeng; Yu, WeiWei; Liu, Yang; Yin, Yin; Zhang, Wenjie; Sun, Beicheng] Nanjing Univ, Med Sch, Affiliated Drum Tower Hosp, Dept Hepatobiliary Surg, Nanjing, Jiangsu, Peoples R China; [Wang, Fei; Zhang, Haitian; Jiang, Runqiu; Jin, Kangpeng; Liu, Yang; Zhang, Wenjie; Sun, Beicheng] Nanjing Med Univ, Affiliated Hosp 1, Liver Transplantat Ctr, Nanjing, Jiangsu, Peoples R China; [Wang, Fei; Zhang, Haitian; Jiang, Runqiu; Jin, Kangpeng; Liu, Yang; Zhang, Wenjie; Sun, Beicheng] Nanjing Med Univ, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China; [Shen, Jintao; Xu, Qinfeng] Nanjing Univ, Med Sch, Affiliated Drum Tower Hosp, Dept Nucl Med, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing University; Nanjing Medical University; Nanjing Medical University; Nanjing University	Zhang, WJ; Sun, BC (corresponding author), Nanjing Med Univ, Drum Tower Clin Med Coll, Dept Hepatobiliary Surg, Nanjing, Peoples R China.; Zhang, WJ; Sun, BC (corresponding author), Nanjing Univ, Med Sch, Affiliated Drum Tower Hosp, Dept Hepatobiliary Surg, Nanjing, Jiangsu, Peoples R China.; Zhang, WJ; Sun, BC (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Liver Transplantat Ctr, Nanjing, Jiangsu, Peoples R China.; Zhang, WJ; Sun, BC (corresponding author), Nanjing Med Univ, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China.	drzhangwj@163.com; sunbc@nju.edu.cn		YU, Decai/0000-0002-3006-2531; Yin, Yin/0000-0001-8113-4278				Zhangyuan GY, 2020, ONCOGENE, V39, P1213, DOI 10.1038/s41388-019-1052-7	1	3	3	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1388	1388		10.1038/s41388-019-1095-9	http://dx.doi.org/10.1038/s41388-019-1095-9			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31700153	Bronze			2022-12-17	WOS:000526714600016
J	Adler, AJ; Mittal, P; Hagymasi, AT; Menoret, A; Shen, C; Agliano, F; Wright, KT; Grady, JJ; Kuo, CL; Ballesteros, E; Claffey, KP; Vella, AT				Adler, Adam J.; Mittal, Payal; Hagymasi, Adam T.; Menoret, Antoine; Shen, Chen; Agliano, Federica; Wright, Kyle T.; Grady, James J.; Kuo, Chia-Ling; Ballesteros, Enrique; Claffey, Kevin P.; Vella, Anthony T.			GRK2 enforces androgen receptor dependence in the prostate and prostate tumors	ONCOGENE			English	Article							PROTEIN-COUPLED RECEPTOR; RAF KINASE INHIBITOR; MOUSE MODEL; NEUROENDOCRINE DIFFERENTIATION; REGULATED EXPRESSION; CANCER; PTEN; GENE; ADENOCARCINOMA; METASTASIS	Metastatic tumors that have become resistant to androgen deprivation therapy represent the major challenge in treating prostate cancer. Although these recurrent tumors typically remain dependent on the androgen receptor (AR), non-AR-driven tumors that also emerge are particularly deadly and becoming more prevalent. Here, we present a new genetically engineered mouse model for non-AR-driven prostate cancer that centers on a negative regulator of G protein-coupled receptors that is downregulated in aggressive human prostate tumors. Thus, prostate-specific expression of a dominant-negative G protein-coupled receptor kinase 2 (GRK2-DN) transgene diminishes AR and AR target gene expression in the prostate, and confers resistance to castration-induced involution. Further, the GRK2-DN transgene dramatically accelerates oncogene-initiated prostate tumorigenesis by increasing primary tumor size, potentiating visceral organ metastasis, suppressing AR, and inducing neuroendocrine marker mRNAs. In summary, GRK2 enforces AR-dependence in the prostate, and the loss of GRK2 function in prostate tumors accelerates disease progression toward the deadliest stage.	[Adler, Adam J.; Mittal, Payal; Hagymasi, Adam T.; Menoret, Antoine; Shen, Chen; Agliano, Federica; Wright, Kyle T.; Vella, Anthony T.] UConn Hlth, Dept Immunol, Sch Med, Farmington, CT 06030 USA; [Grady, James J.; Kuo, Chia-Ling] UConn Hlth, Sch Med, Dept Community Med & Hlth Care, Farmington, CT USA; [Ballesteros, Enrique] UConn Hlth, Sch Med, Dept Pathol & Lab Med, Farmington, CT USA; [Claffey, Kevin P.] UConn Hlth, Sch Med, Dept Cell Biol, Farmington, CT USA; [Mittal, Payal] Merck Res Labs, Oncol Dept, Boston, MA 02115 USA; [Hagymasi, Adam T.] Univ Connecticut, Sch Med, Carole & Ray Neag Comprehens Canc Ctr, Farmington, CT USA	Merck & Company; University of Connecticut	Adler, AJ; Vella, AT (corresponding author), UConn Hlth, Dept Immunol, Sch Med, Farmington, CT 06030 USA.	aadler@uchc.edu; vella@uchc.edu		Agliano, Federica/0000-0002-1093-171X	National Institutes of Health [R01CA109339, R01AI094640]; Carole and Ray Neag Comprehensive Cancer Center	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Carole and Ray Neag Comprehensive Cancer Center	This work was supported by National Institutes of Health Grants R01CA109339 and R01AI094640 (to AJA and ATV) and by the Carole and Ray Neag Comprehensive Cancer Center. The authors thank Dr. Jeffrey Benovic for providing the GRK2-DN (beta ARK-K220R) construct, Dr. Robert Matusik for providing the ARR<INF>2</INF>PB construct as well as helpful discussions and critical reading of the paper, Dr. Stefan Brocke for advice regarding in vitro forskolin stimulations, and Dr. Christopher Bonin for editing the paper.	Abate-Shen C, 2003, CANCER RES, V63, P3886; Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Aggarwal R, 2018, J CLIN ONCOL, V36, P2492, DOI 10.1200/JCO.2017.77.6880; Alanee S, 2015, ANTICANCER RES, V35, P4145; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Bethel CR, 2006, CANCER RES, V66, P10683, DOI 10.1158/0008-5472.CAN-06-0963; Bishop JL, 2017, CANCER DISCOV, V7, P54, DOI 10.1158/2159-8290.CD-15-1263; Bluemn EG, 2017, CANCER CELL, V32, P474, DOI 10.1016/j.ccell.2017.09.003; Bookout AL, 2003, J BIOL CHEM, V278, P37569, DOI 10.1074/jbc.M306276200; Cai JA, 2010, TRANSL ONCOL, V3, P195, DOI 10.1593/tlo.09328; Carver BS, 2016, CANCER CELL, V29, P431, DOI 10.1016/j.ccell.2016.03.023; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chang KH, 2013, CELL, V154, P1074, DOI 10.1016/j.cell.2013.07.029; Chang KH, 2011, P NATL ACAD SCI USA, V108, P13728, DOI 10.1073/pnas.1107898108; Chiaverotti T, 2008, AM J PATHOL, V172, P236, DOI 10.2353/ajpath.2008.070602; Daaka Y., 2004, SCI STKE, V2004, pre2, DOI [10.1126/stke.2162004re2, DOI 10.1126/STKE.2162004RE2]; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Denmeade SR, 2002, NAT REV CANCER, V2, P389, DOI 10.1038/nrc801; Ding ZH, 2012, CELL, V148, P896, DOI 10.1016/j.cell.2012.01.039; Ding ZH, 2011, NATURE, V470, P269, DOI 10.1038/nature09677; Drake CG, 2005, CANCER CELL, V7, P239, DOI 10.1016/j.ccr.2005.01.027; Drake CG, 2014, ONCOLOGY-NY, V28, P974; Escara-Wilke J, 2015, PROSTATE, V75, P292, DOI 10.1002/pros.22915; Fu XB, 2013, J BIOL CHEM, V288, P7738, DOI 10.1074/jbc.M112.428078; Fu Z, 2003, J NATL CANCER I, V95, P878, DOI 10.1093/jnci/95.12.878; Furusato B, 2010, PATHOL INT, V60, P497, DOI 10.1111/j.1440-1827.2010.02548.x; Gandaglia G, 2015, EUR UROL, V68, P325, DOI 10.1016/j.eururo.2014.07.020; Gingrich J, 1999, PROSTATE CANCER P D, V6, P1; Gingrich JR, 1996, CANCER RES, V56, P4096; Gingrich JR, 1997, CANCER RES, V57, P4687; Grabowska MM, 2014, CANCER METAST REV, V33, P377, DOI 10.1007/s10555-013-9487-8; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; Han GZ, 2001, J BIOL CHEM, V276, P11204, DOI 10.1074/jbc.M008207200; He WW, 1997, GENOMICS, V43, P69, DOI 10.1006/geno.1997.4715; Hirano D, 2004, EUR UROL, V45, P586, DOI 10.1016/j.eururo.2003.11.032; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hu MM, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005171; Hurwitz AA, 2000, CANCER RES, V60, P2444; Kaplan-Lefko PJ, 2003, PROSTATE, V55, P219, DOI 10.1002/pros.10215; Kasbohm EA, 2005, J BIOL CHEM, V280, P11583, DOI 10.1074/jbc.M414423200; Khasnavis S, 2013, J BIOL CHEM, V288, P20843, DOI 10.1074/jbc.M112.443556; Komolov KE, 2017, CELL SIGNAL, V41, P17, DOI 10.1016/j.cellsig.2017.07.004; KONG GH, 1994, J BIOL CHEM, V269, P13084; Kwon ED, 2014, LANCET ONCOL, V15, P700, DOI 10.1016/S1470-2045(14)70189-5; Lee H, 2010, NAT MED, V16, P1421, DOI 10.1038/nm.2250; Lee JK, 2016, CANCER CELL, V29, P536, DOI 10.1016/j.ccell.2016.03.001; Lin BY, 1999, CANCER RES, V59, P4180; Lonergan Peter E, 2011, J Carcinog, V10, P20, DOI 10.4103/1477-3163.83937; Lorenz K, 2003, NATURE, V426, P574, DOI 10.1038/nature02158; Malchow S, 2013, SCIENCE, V339, P1219, DOI 10.1126/science.1233913; Metaye T, 2008, J ENDOCRINOL, V198, P101, DOI 10.1677/JOE-07-0562; Mulholland DJ, 2012, CANCER RES, V72, P1878, DOI 10.1158/0008-5472.CAN-11-3132; Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006; Nogues L, 2017, MOL PHARMACOL, V91, P220, DOI 10.1124/mol.116.107185; Palmgren JS, 2007, SEMIN ONCOL, V34, P22, DOI 10.1053/j.seminoncol.2006.10.026; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Prowatke I, 2007, BRIT J CANCER, V96, P82, DOI 10.1038/sj.bjc.6603490; Purayil HT, 2015, ONCOGENE, V34, P3144, DOI 10.1038/onc.2014.252; Qiao JB, 2016, ONCOTARGET, V7, P61955, DOI 10.18632/oncotarget.11326; Savage PA, 2008, SCIENCE, V319, P215, DOI 10.1126/science.1148886; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; SUGIMURA Y, 1986, BIOL REPROD, V34, P973, DOI 10.1095/biolreprod34.5.973; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tsurutani N, 2016, J IMMUNOL, V196, P124, DOI 10.4049/jimmunol.1501217; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang ZQ, 2017, CANCER LETT, V408, P10, DOI 10.1016/j.canlet.2017.08.013; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wright KT, 2013, J IMMUNOL, V191, P708, DOI 10.4049/jimmunol.1203486; Xu LL, 2000, CANCER RES, V60, P6568; Xu ZW, 2017, CANCER CHEMOTH PHARM, V79, P747, DOI 10.1007/s00280-017-3267-z; Yowell Charles W, 2002, Clin Prostate Cancer, V1, P177, DOI 10.3816/CGC.2002.n.020; Zhang JF, 2000, ENDOCRINOLOGY, V141, P4698, DOI 10.1210/en.141.12.4698; Zhou ZX, 2006, CANCER RES, V66, P7889, DOI 10.1158/0008-5472.CAN-06-0486; Zou M, 2017, CANCER DISCOV, V7, P736, DOI 10.1158/2159-8290.CD-16-1174	77	3	3	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2424	2436		10.1038/s41388-020-1159-x	http://dx.doi.org/10.1038/s41388-020-1159-x		JAN 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31959897	Green Accepted			2022-12-17	WOS:000508322900002
J	Champagne, J; Linares, LK; Maurel, B; Zampieri, A; Moreno, M; Fuentes, I; Dubois, E; Severac, D; Decorsiere, A; Bienvenu, F				Champagne, Julien; Linares, Laetitia K.; Maurel, Benjamin; Zampieri, Alexandre; Moreno, Maeva; Fuentes, Ivanna; Dubois, Emeric; Severac, Dany; Decorsiere, Adrien; Bienvenu, Frederic			TAG-RNAi overcomes off-target effects in cancer models	ONCOGENE			English	Article							CYCLIN D1; TRANSCRIPTIONAL ROLE; LARGE-SCALE; INTERFERENCE; REVEALS; DRIVE	RNA interference offers therapeutic opportunities for the clinical targeting of otherwise undruggable oncogenes. However RNAi can have off-target effects that considerably increase treatment risks. To manage these side effects and allow an easy subtraction of their activity in healthy tissues, we present here the TAG-RNAi approach where cells that are not designated targets do not have the mRNA tag. Using TAG-RNAi we first established the off-target signatures of three different siRNAs specific to the Cyclin D1 oncogene by RNA-sequencing of cultured cancer cells expressing a FLAG-HA-tagged-Cyclin D1. Then, by symmetrical allografts of tagged-cancer cells and untagged controls on the left and right flanks of model mice, we demonstrate that TAG-RNAi is a reliable approach to study the functional impact of any oncogene without off-target bias. Finally we show, as examples, that mutation-specific TAG-RNAi can be applied to downregulate two oncogenic mutants, KRAS-G12V or BRAF-V600E, while sparing the expression of the wild-type proteins. TAG-RNAi will thus avoid the traditional off-target limitations of RNAi in future experimental approaches.	[Champagne, Julien; Maurel, Benjamin; Zampieri, Alexandre; Moreno, Maeva; Fuentes, Ivanna; Decorsiere, Adrien; Bienvenu, Frederic] CNRS, Inst Genom Fonct, UMR 5203, F-34094 Montpellier, France; [Champagne, Julien; Maurel, Benjamin; Zampieri, Alexandre; Moreno, Maeva; Fuentes, Ivanna; Decorsiere, Adrien; Bienvenu, Frederic] INSERM, U1191, F-34094 Montpellier, France; [Champagne, Julien; Maurel, Benjamin; Zampieri, Alexandre; Moreno, Maeva; Fuentes, Ivanna; Decorsiere, Adrien; Bienvenu, Frederic] Univ Montpellier, UMR 5203, F-34094 Montpellier, France; [Linares, Laetitia K.] Univ Montpellier, IRCM, INSERM U896, Inst Reg Canc Montpellier, F-34298 Montpellier, France; [Dubois, Emeric; Severac, Dany] Inst Genom Fonct, MGX Montpellier GenomiX, 141 Rue Cardonille, F-34094 Montpellier 5, France; [Bienvenu, Frederic] Lab Excellence Genome & Epigenome Mol Med EpiGenM, F-34094 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM)	Bienvenu, F (corresponding author), CNRS, Inst Genom Fonct, UMR 5203, F-34094 Montpellier, France.; Bienvenu, F (corresponding author), INSERM, U1191, F-34094 Montpellier, France.; Bienvenu, F (corresponding author), Univ Montpellier, UMR 5203, F-34094 Montpellier, France.; Bienvenu, F (corresponding author), Lab Excellence Genome & Epigenome Mol Med EpiGenM, F-34094 Montpellier, France.	frederic.bienvenu@igf.cnrs.fr	Linares, Laetitia LKL/F-9901-2018	Linares, Laetitia LKL/0000-0003-1661-2119; Dubois, Emeric/0000-0002-6052-4178; bienvenu, frederic/0000-0003-2914-4051; decorsiere, adrien/0000-0002-5716-6154; CHAMPAGNE, Julien/0000-0001-8460-858X	Atip-Avenir program [RSE11003FSA]; Merieux Research Grant [060805]; FP7 Marie-Curie European IRG [277118]; EpiGenMed LabEx ("investissements d'avenir") [ANR-10-LABX-12-01]; Fondation pour la Recherche Medicale; Ligue Nationale contre le Cancer; University of Montpellier; SATT AxLR; Montpellier SIRIC; Canceropole GSO; Ligue Regionale contre le Cancer	Atip-Avenir program; Merieux Research Grant; FP7 Marie-Curie European IRG; EpiGenMed LabEx ("investissements d'avenir")(French National Research Agency (ANR)); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); University of Montpellier; SATT AxLR; Montpellier SIRIC; Canceropole GSO; Ligue Regionale contre le Cancer(Ligue nationale contre le cancer)	This work was supported by the Atip-Avenir program (RSE11003FSA), the Merieux Research Grant (060805), the FP7 Marie-Curie European IRG (277118), the EpiGenMed LabEx ("investissements d'avenir" reference ANR-10-LABX-12-01), the Fondation pour la Recherche Medicale, the Ligue Nationale and Regionale contre le Cancer, the University of Montpellier, the SATT AxLR, the Montpellier SIRIC, and the Canceropole GSO, all to FB. JC is the recipient of a Ligue Nationale contre le Cancer Ph.D. fellowship.	Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Anderson KR, 2018, NAT METHODS, V15, P512, DOI 10.1038/s41592-018-0011-5; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Bienvenu F, 2010, NATURE, V463, P374, DOI 10.1038/nature08684; Birmingham A, 2006, NAT METHODS, V3, P199, DOI 10.1038/NMETH854; Cantwell-Dorris ER, 2011, MOL CANCER THER, V10, P385, DOI 10.1158/1535-7163.MCT-10-0799; Casimiro MC, 2012, J CLIN INVEST, V122, P833, DOI 10.1172/JCI60256; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Guo RL, 2017, TRANSCRIPTOMICS, P5; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Iribe H, 2017, ACS OMEGA, V2, P2055, DOI 10.1021/acsomega.7b00291; Jackson AL, 2010, NAT REV DRUG DISCOV, V9, P57, DOI 10.1038/nrd3010; Kanasty R, 2013, NAT MATER, V12, P967, DOI [10.1038/NMAT3765, 10.1038/nmat3765]; Khan AA, 2009, NAT BIOTECHNOL, V27, P549, DOI 10.1038/nbt.1543; Kirk R., 2011, NAT REV CLIN ONCOL, V8, P691; Kok FO, 2015, DEV CELL, V32, P97, DOI 10.1016/j.devcel.2014.11.018; Lander E, 2019, NATURE, V567, P165, DOI 10.1038/d41586-019-00726-5; Lehmann S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088797; McDonald ER, 2017, CELL, V170, P577, DOI 10.1016/j.cell.2017.07.005; McFarland JM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06916-5; Mohr SE, 2014, NAT REV MOL CELL BIO, V15, P591, DOI 10.1038/nrm3860; Morrison C, 2018, NAT REV DRUG DISCOV, V17, P156, DOI 10.1038/nrd.2018.20; Pasquinelli AE, 2012, NAT REV GENET, V13, P271, DOI 10.1038/nrg3162; Prenen H, 2010, CLIN CANCER RES, V16, P2921, DOI 10.1158/1078-0432.CCR-09-2029; Rossi A, 2015, NATURE, V524, P230, DOI 10.1038/nature14580; Setten RL, 2019, NAT REV DRUG DISCOV, V18, P421, DOI 10.1038/s41573-019-0017-4; Sheridan C., 2019, NAT BIOTECHNOL; Stainier DYR, 2015, DEV CELL, V32, P7, DOI 10.1016/j.devcel.2014.12.012; Tabernero J, 2013, CANCER DISCOV, V3, P406, DOI 10.1158/2159-8290.CD-12-0429; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Wu SY, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008362; Xue W, 2014, P NATL ACAD SCI USA, V111, pE3553, DOI 10.1073/pnas.1412686111; Yin H, 2019, NAT REV CLIN ONCOL, V16, P281, DOI 10.1038/s41571-019-0166-8; Yu QY, 2006, CANCER CELL, V9, P23, DOI 10.1016/j.ccr.2005.12.012; Yu QY, 2005, ONCOGENE, V24, P7114, DOI 10.1038/sj.onc.1208853; Zampieri A, 2015, SCI REP-UK, V5, DOI 10.1038/srep15739; Zhou CY, 2019, NATURE, V571, P275, DOI 10.1038/s41586-019-1314-0; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	38	3	4	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					935	945		10.1038/s41388-019-1020-2	http://dx.doi.org/10.1038/s41388-019-1020-2			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31558799				2022-12-17	WOS:000509197200014
J	Liu, X; Huang, QL; Chen, LH; Zhang, HL; Schonbrunn, E; Chen, JD				Liu, Xia; Huang, Qingling; Chen, Lihong; Zhang, Huilai; Schonbrunn, Ernst; Chen, Jiandong			Tumor-derived CK1 alpha mutations enhance MDMX inhibition of p53	ONCOGENE			English	Article							CASEIN KINASE 1-ALPHA; MYELODYSPLASTIC SYNDROME; BETA-CATENIN; DEGRADATION; UBIQUITINATION; IDENTIFICATION; DESTRUCTION; DELETION; COMPLEX; SWITCH	Somatic missense mutations of the CSNK1A1 gene encoding casein kinase 1 alpha (CK1 alpha) occur in a subset of myelodysplastic syndrome (MDS) with del(5q) karyotype. The chromosomal deletion causes CSNK1A1 haplo-insufficiency. CK1 alpha mutations have also been observed in a variety of solid and hematopoietic tumors at low frequency. The functional consequence of CK1 alpha mutation remains unknown. Here we show that tumor-associated CK1 alpha mutations exclusively localize to the substrate-binding cleft. Functional analysis of recurrent mutants E98K and D140A revealed enhanced binding to the p53 inhibitor MDMX, increased ability to stimulate MDMX-p53 binding, and increased suppression of p21 expression. Furthermore, E98K and D140A mutants have reduced ability to promote phosphorylation of beta-catenin, resulting in enhanced Wnt signaling. The results suggest that the CK1 alpha mutations observed in tumors cause gain-of-function in cooperating with MDMX and inhibiting p53, and partial loss-of-function in suppressing Wnt signaling. These functional changes may promote expansion of abnormal myeloid progenitors in del(5q) MDS, and in rare cases drive the progression of other tumors.	[Liu, Xia; Huang, Qingling; Chen, Lihong; Chen, Jiandong] H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Dept, 12902 Magnolia Dr, Tampa, FL 33612 USA; [Liu, Xia; Zhang, Huilai] Tianjin Med Univ Canc Inst & Hosp, Tianjin Clin Res Ctr Canc, Sino US Ctr Lymphoma & Leukemia Res,Dept Lymphoma, Natl Clin Res Ctr Canc,Key Lab Canc Prevent & The, Tianjin 300060, Peoples R China; [Schonbrunn, Ernst] H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Dept, 12902 Magnolia Dr, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; Tianjin Medical University; H Lee Moffitt Cancer Center & Research Institute	Chen, JD (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Dept, 12902 Magnolia Dr, Tampa, FL 33612 USA.	Jiandong.chen@moffitt.org	Huang, Qingling/AAO-1728-2021	Huang, Qingling/0000-0002-0538-8249; Zhang, Huilai/0000-0002-8558-3131; Schonbrunn, Ernst/0000-0002-3589-3510	National Institutes of Health [CA141244, CA186917]; NCI Cancer Center Support Grant [P30-CA076292]; Tianjin Medical University Cancer Institute and Hospital	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Tianjin Medical University Cancer Institute and Hospital	We would like to thank the Moffitt Flow Cytometry Core. This work was supported in part by grants from the National Institutes of Health (CA141244, CA186917) (JC), and by the NCI Cancer Center Support Grant P30-CA076292. XL was partly supported by Tianjin Medical University Cancer Institute and Hospital.	Bello E, 2015, BRIT J HAEMATOL, V171, P210, DOI 10.1111/bjh.13563; Chen LH, 2005, MOL CELL BIOL, V25, P6509, DOI 10.1128/MCB.25.15.6509-6520.2005; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Drexler HG, 2009, LEUKEMIA RES, V33, P1011, DOI 10.1016/j.leukres.2009.03.005; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Elyada E, 2011, NATURE, V470, P409, DOI 10.1038/nature09673; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Heuser M, 2015, LEUKEMIA, V29, P1942, DOI 10.1038/leu.2015.49; Huart AS, 2009, J BIOL CHEM, V284, P32384, DOI 10.1074/jbc.M109.052647; Jaras M, 2014, J EXP MED, V211, P605, DOI 10.1084/jem.20131033; Knippschild U, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00096; Komrokji RS, 2013, BEST PRACT RES CL HA, V26, P365, DOI 10.1016/j.beha.2013.10.013; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kronke J, 2015, NATURE, V523, P183, DOI 10.1038/nature14610; Kronke J, 2014, SCIENCE, V343, P301, DOI 10.1126/science.1244851; Kulasekararaj AG, 2013, BRIT J HAEMATOL, V160, P660, DOI 10.1111/bjh.12203; Lu G, 2014, SCIENCE, V343, P305, DOI 10.1126/science.1244917; Petzold G, 2016, NATURE, V532, P127, DOI 10.1038/nature16979; Pribluda A, 2013, CANCER CELL, V24, P242, DOI 10.1016/j.ccr.2013.06.005; Schneider RK, 2016, NAT MED, V22, P288, DOI 10.1038/nm.4047; Schneider RK, 2014, CANCER CELL, V26, P509, DOI 10.1016/j.ccr.2014.08.001; Sinnberg T, 2010, CANCER RES, V70, P6999, DOI 10.1158/0008-5472.CAN-10-0645; Smith AE, 2015, LANCET HAEMATOL, V2, pE212, DOI 10.1016/S2352-3026(15)00050-2; Sobrado P, 2005, J CELL BIOCHEM, V94, P217, DOI 10.1002/jcb.20350; Starczynowski DT, 2010, NAT MED, V16, P49, DOI 10.1038/nm.2054; Tsujioka T, 2013, EXP HEMATOL, V41, P189, DOI 10.1016/j.exphem.2012.10.006; Wang L, 2008, HAEMATOL-HEMATOL J, V93, P994, DOI 10.3324/haematol.12603; Wei X, 2016, P NATL ACAD SCI USA, V113, pE2558, DOI 10.1073/pnas.1603838113; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wu SF, 2012, MOL CELL BIOL, V32, P4821, DOI 10.1128/MCB.00851-12	30	3	4	3	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					176	186		10.1038/s41388-019-0979-z	http://dx.doi.org/10.1038/s41388-019-0979-z			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31462704	Green Accepted			2022-12-17	WOS:000509849200012
J	Smeester, BA; Slipek, NJ; Pomeroy, EJ; Bomberger, HE; Shamsan, GA; Peterson, JJ; Crosby, MR; Draper, GM; Becklin, KL; Rahrmann, EP; McCarthy, JB; Odde, DJ; Wood, DK; Largaespada, DA; Moriarity, BS				Smeester, Branden A.; Slipek, Nicholas J.; Pomeroy, Emily J.; Bomberger, Heather E.; Shamsan, Ghaidan A.; Peterson, Joseph J.; Crosby, Margaret R.; Draper, Garrett M.; Becklin, Kelsie L.; Rahrmann, Eric P.; McCarthy, James B.; Odde, David J.; Wood, David K.; Largaespada, David A.; Moriarity, Branden S.			SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; GENETIC SCREEN; CELL-GROWTH; TUMOR; SEMAPHORINS; EXPRESSION; PLEXIN-B2	Semaphorins, specifically type IV, are important regulators of axonal guidance and have been increasingly implicated in poor prognoses in a number of different solid cancers. In conjunction with their cognate PLXNB family receptors, type IV members have been increasingly shown to mediate oncogenic functions necessary for tumor development and malignant spread. In this study, we investigated the role of semaphorin 4C (SEMA4C) in osteosarcoma growth, progression, and metastasis. We investigated the expression and localization of SEMA4C in primary osteosarcoma patient tissues and its tumorigenic functions in these malignancies. We demonstrate that overexpression of SEMA4C promotes properties of cellular transformation, while RNAi knockdown of SEMA4C promotes adhesion and reduces cellular proliferation, colony formation, migration, wound healing, tumor growth, and lung metastasis. These phenotypic changes were accompanied by reductions in activated AKT signaling, G1 cell cycle delay, and decreases in expression of mesenchymal marker genes SNAI1, SNAI2, and TWIST1. Lastly, monoclonal antibody blockade of SEMA4C in vitro mirrored that of the genetic studies. Together, our results indicate a multi-dimensional oncogenic role for SEMA4C in metastatic osteosarcoma and more importantly that SEMA4C has actionable clinical potential.	[Smeester, Branden A.; Slipek, Nicholas J.; Pomeroy, Emily J.; Peterson, Joseph J.; Crosby, Margaret R.; Draper, Garrett M.; Becklin, Kelsie L.; Largaespada, David A.; Moriarity, Branden S.] Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA; [Smeester, Branden A.; Slipek, Nicholas J.; Pomeroy, Emily J.; Peterson, Joseph J.; Crosby, Margaret R.; Draper, Garrett M.; Becklin, Kelsie L.; Largaespada, David A.; Moriarity, Branden S.] Univ Minnesota, Ctr Genome Engn, Minneapolis, MN 55455 USA; [Smeester, Branden A.; Slipek, Nicholas J.; Pomeroy, Emily J.; Shamsan, Ghaidan A.; Peterson, Joseph J.; Crosby, Margaret R.; Draper, Garrett M.; Becklin, Kelsie L.; McCarthy, James B.; Odde, David J.; Largaespada, David A.; Moriarity, Branden S.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA; [Bomberger, Heather E.; Shamsan, Ghaidan A.; Odde, David J.; Wood, David K.] Univ Minnesota, Dept Biomed Engn, Minneapolis, MN USA; [Rahrmann, Eric P.] Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge, England; [McCarthy, James B.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of Minnesota System; University of Minnesota Twin Cities	Moriarity, BS (corresponding author), Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA.; Moriarity, BS (corresponding author), Univ Minnesota, Ctr Genome Engn, Minneapolis, MN 55455 USA.; Moriarity, BS (corresponding author), Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA.	mori0164@umn.edu	Shamsan, Ghaidan A./X-3338-2019; Smeester, Branden A/E-7655-2013; Odde, David/AAY-1720-2020	Shamsan, Ghaidan A./0000-0003-0884-7540; Smeester, Branden A/0000-0001-9421-1711; Odde, David/0000-0001-7731-2799; Pomeroy, Emily/0000-0001-7690-3570	NIH NIAMS [T32 AR050938]; NIH NIAID [T32 AI997313]; Sobiech Osteosarcoma Fund Award; Randy Shaver Cancer and Community Fund; University of Minnesota Foundation; Rein in Sarcoma Foundation; Aflac-AACR Career Development Award; Children's Cancer Research Fund; National Science Foundation through the National Nano Coordinated Infrastructure Network (NNCI) [ECCS-1542202]	NIH NIAMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIH NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Sobiech Osteosarcoma Fund Award; Randy Shaver Cancer and Community Fund; University of Minnesota Foundation(University of Minnesota System); Rein in Sarcoma Foundation; Aflac-AACR Career Development Award; Children's Cancer Research Fund; National Science Foundation through the National Nano Coordinated Infrastructure Network (NNCI)	The authors would like to thank Dr. Kyle Williams for helpful discussion throughout the study, Dr. Sterbs for her intoxicating enthusiasm during the preparation of this paper, Dr. Juan Abrahante for statistical advice, and the Clinical and Translational Science Institute (CSTI) Histology and Research Laboratory team members Dr. Colleen Forester and Lori Holm for tissue preparation and histology services. Author BAS is supported by an NIH NIAMS T32 AR050938 Musculoskeletal Training Grant. Author EJP is supported by an NIH NIAID T32 AI997313 Immunology Training Grant. This work was made possible through funding from the Sobiech Osteosarcoma Fund Award, Randy Shaver Cancer and Community Fund, University of Minnesota Foundation, Rein in Sarcoma Foundation, Aflac-AACR Career Development Award, and the Children's Cancer Research Fund to author BSM Portions of this work were conducted in the Minnesota Nano Center, which is supported by the National Science Foundation through the National Nano Coordinated Infrastructure Network (NNCI) under Award Number ECCS-1542202. SEMA4C RNA expression results in data set #2 were in whole or part based upon data generated by the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative, phs000218, managed by the NCI. The data used are available (dbGaP accession phs000218.v21.p7). Information about TARGET can be found at http://ocg.cancer.gov/programs/target.	Abarrategi A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/3631764; Alto LT, 2017, METHODS MOL BIOL, V1493, P1, DOI 10.1007/978-1-4939-6448-2_1; Brett ME, 2018, INTEGR BIOL-UK, V10, P242, DOI 10.1039/c7ib00173h; Butti R, 2018, BREAST CANCER-TARGET, V10, P79, DOI 10.2147/BCTT.S135753; Chan CKF, 2018, CELL, V175, P43, DOI 10.1016/j.cell.2018.07.029; Choo S, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.26721; Clavijo PE, 2019, CANCER IMMUNOL RES, V7, P282, DOI 10.1158/2326-6066.CIR-18-0156; Deng SH, 2007, J NEUROSCI, V27, P6333, DOI 10.1523/JNEUROSCI.5381-06.2007; Evans EE, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1054599; Evans EE, 2015, CANCER IMMUNOL RES, V3, P689, DOI 10.1158/2326-6066.CIR-14-0171; Faustino-Rocha A, 2013, LAB ANIMAL, V42, P217, DOI 10.1038/laban.254; Garcia Z, 2006, EMBO J, V25, P655, DOI 10.1038/sj.emboj.7600967; Gianferante DM, 2017, NAT REV ENDOCRINOL, V13, P480, DOI 10.1038/nrendo.2017.16; Gurrapu S, 2018, CELL DEATH DIFFER, V25, P1259, DOI 10.1038/s41418-018-0097-4; Horvai AE, 2012, MODERN PATHOL, V25, P1452, DOI 10.1038/modpathol.2012.110; Jiang WG, 2015, SEMIN CANCER BIOL, V35, pS244, DOI 10.1016/j.semcancer.2015.03.008; Khanna C, 2000, CLIN EXP METASTAS, V18, P261, DOI 10.1023/A:1006767007547; Kumar S, 2014, MOL BIOSYST, V10, P838, DOI 10.1039/c3mb70431a; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Le AP, 2015, ONCOTARGET, V6, P7293, DOI 10.18632/oncotarget.3421; Leder K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014366; Lee KW, 2014, CANCER LETT, V343, P62, DOI 10.1016/j.canlet.2013.09.013; Lu J, 2018, FASEB J, V32, pfj201800113R; Marko TA, 2016, SCI REP-UK, V6, DOI 10.1038/srep39059; Meazza C, 2016, EXPERT REV ANTICANC, V16, P543, DOI 10.1586/14737140.2016.1168697; Meyer LAT, 2016, CELL ADHES MIGR, V10, P700, DOI 10.1080/19336918.2016.1261785; Mirabello L, 2009, CANCER-AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121; Mori S, 2009, ONCOGENE, V28, P2796, DOI 10.1038/onc.2009.139; Moriarity BS, 2015, NAT GENET, V47, P615, DOI 10.1038/ng.3293; Moriarity BS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096114; Morrow James J., 2015, Critical Reviews in Oncogenesis, V20, P173, DOI 10.1615/CritRevOncog.2015013713; Negishi-Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489; Paldy E, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00341-w; Poleszczuk J, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/3923527; Rahrmann EP, 2013, NAT GENET, V45, P756, DOI 10.1038/ng.2641; Rickel K, 2017, BONE, V102, P69, DOI 10.1016/j.bone.2016.10.017; Roche J, 2018, CANCERS, V10, DOI 10.3390/cancers10020052; Smeester BA, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/387169; Smeester BA, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/671386; Swiercz JM, 2008, J BIOL CHEM, V283, P1893, DOI 10.1074/jbc.M706822200; Tamagnone L, 2012, CANCER CELL, V22, P145, DOI 10.1016/j.ccr.2012.06.031; Wei JC, 2017, CLIN CANCER RES, V23, P214, DOI 10.1158/1078-0432.CCR-16-0741; Worzfeld T, 2014, NAT REV DRUG DISCOV, V13, P603, DOI 10.1038/nrd4337; Xue D, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00558; Yan GN, 2016, CANCER LETT, V370, P268, DOI 10.1016/j.canlet.2015.11.003; Yang QL, 2015, ONCOTARGET, V6, P3268, DOI 10.18632/oncotarget.3065; Ye X, 2015, TRENDS CELL BIOL, V25, P675, DOI 10.1016/j.tcb.2015.07.012; Yin K, 2012, MED ONCOL, V29, P3449, DOI 10.1007/s12032-012-0317-6; Zhou QD, 2013, J HUAZHONG U SCI-MED, V33, P672, DOI 10.1007/s11596-013-1179-7	49	3	4	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					1049	1062		10.1038/s41388-019-1041-x	http://dx.doi.org/10.1038/s41388-019-1041-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31582836	Green Submitted			2022-12-17	WOS:000511209700008
J	Verrico, A; Rovella, P; Di Francesco, L; Damizia, M; Staid, DS; Le Pera, L; Schinina, ME; Lavia, P				Verrico, Annalisa; Rovella, Paola; Di Francesco, Laura; Damizia, Michela; Staid, David Sasah; Le Pera, Loredana; Schinina, M. Eugenia; Lavia, Patrizia			Importin-beta/karyopherin-beta 1 modulates mitotic microtubule function and taxane sensitivity in cancer cells via its nucleoporin-binding region	ONCOGENE			English	Article							IMPORT RECEPTOR KPN-BETA-1; SPINDLE ASSEMBLY FACTORS; UP-REGULATION; AURORA-A; HURP; BETA; PROLIFERATION; INHIBITOR; TRANSPORT; PROTEIN	The nuclear transport receptor importin-beta/karyopherin-beta 1 is overexpressed in cancers that display genomic instability. It is regarded as a promising cancer target and inhibitors are being developed. In addition to its role in nucleo-cytoplasmic transport, importin-beta regulates mitosis, but the programmes and pathways in which it operates are defined only in part. To unravel importin-beta's mitotic functions we have developed cell lines expressing either wild-type or a mutant importin-beta form in characterised residues required for nucleoporin binding. Both forms similarly disrupted spindle pole organisation, while only wild-type importin-beta affected microtubule plus-end function and microtubule stability. A proteome-wide search for differential interactors identified a set of spindle regulators sensitive to mutations in the nucleoporin-binding region. Among those, HURP (hepatoma up-regulated protein) is an importin-beta interactor and a microtubule-stabilising factor. We found that induction of wild type, but not mutant importin-beta, under the same conditions that destabilise mitotic microtubules, delocalised HURP, indicating that the spatial distribution of HURP along the spindle requires importin-beta's nucleoporin-binding residues. Concomitantly, importin-beta overexpression sensitises cells to taxanes and synergistically increases mitotic cell death. Thus, the nucleoporin-binding domain is dispensable for importin-beta function in spindle pole organisation, but regulates microtubule stability, at least in part via HURP, and renders cells vulnerable to certain microtubule-targeting drugs.	[Verrico, Annalisa; Rovella, Paola; Damizia, Michela; Staid, David Sasah; Le Pera, Loredana; Lavia, Patrizia] CNR, Inst Mol Biol & Pathol IBPM, I-00185 Rome, Italy; [Di Francesco, Laura; Staid, David Sasah; Schinina, M. Eugenia] Sapienza Univ Rome, Dept Biochem Sci Alessandro Rossi Fanelli, I-00185 Rome, Italy; [Damizia, Michela; Lavia, Patrizia] Sapienza Univ Rome, Dept Biol & Biotechnol Charles Darwin, I-00185 Rome, Italy; [Le Pera, Loredana] CNR, Inst Biomembranes Bioenerget & Mol Biotechnol IBI, I-70126 Bari, Italy; [Verrico, Annalisa] Univ Paris Diderot, Sorbonne Paris Cite, CNRS, Inst Jacques Monod,UMR7592, F-75205 Paris, France	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Lavia, P (corresponding author), CNR, Inst Mol Biol & Pathol IBPM, I-00185 Rome, Italy.; Lavia, P (corresponding author), Sapienza Univ Rome, Dept Biol & Biotechnol Charles Darwin, I-00185 Rome, Italy.	patrizia.lavia@uniroma1.it	Le Pera, Loredana/ABD-3398-2020; Lavia, Patrizia/AAL-3982-2021	Le Pera, Loredana/0000-0002-0076-9878; Lavia, Patrizia/0000-0003-3310-6701; VERRICO, ANNALISA/0000-0002-1458-2545	AIRC (Associazione Italiana per la Ricerca sul Cancro) [IG14534]; CNR Flagship programme InterOmics (project SYNLETHER); MIUR	AIRC (Associazione Italiana per la Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro); CNR Flagship programme InterOmics (project SYNLETHER); MIUR(Ministry of Education, Universities and Research (MIUR))	This work was supported by grants from AIRC (Associazione Italiana per la Ricerca sul Cancro IG14534) and the CNR Flagship programme InterOmics (project SYNLETHER). MD was supported by a PhD fellowship from MIUR. We are grateful to our colleagues Alessandro Rosa (Department of Biology and Biotechnology, University La Sapienza, Rome) for the design and engineering of inducible expression vectors, to Enrico Cundari and Daniela Trisciuoglio (IBPM-CNR, Rome) for help with FACS experiments, to Maria Giubettini (Joint Lab CrestOptics/IIT CLNS@Sapienza, Rome) for contributing to early stages of this work, and to Veronica Morea and Andrea Ilari (IBPM-CNR and Biocrystal Facility, Rome) for insightful discussions and suggestions. We wish to dedicate this paper to our late Director and founder, Prof. Emilia Chiancone.	Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; Bayliss R, 2002, J BIOL CHEM, V277, P50597, DOI 10.1074/jbc.M209037200; Cagatay T, 2018, CURR OPIN CELL BIOL, V52, P30, DOI 10.1016/j.ceb.2018.01.006; Christie M, 2016, J MOL BIOL, V428, P2060, DOI 10.1016/j.jmb.2015.10.023; Ciciarello M, 2004, J CELL SCI, V117, P6511, DOI 10.1242/jcs.01569; Di Cesare E, 2017, ONCOTARGET, V8, P19738, DOI 10.18632/oncotarget.14980; Di Francesco L, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19351-9; Eifler K, 2015, TRENDS BIOCHEM SCI, V40, P779, DOI 10.1016/j.tibs.2015.09.006; Forbes DJ, 2015, CURR OPIN CELL BIOL, V35, P78, DOI 10.1016/j.ceb.2015.04.012; Forwood JK, 2010, STRUCTURE, V18, P1171, DOI 10.1016/j.str.2010.06.015; Gilistro E, 2017, J CELL SCI, V130, P2564, DOI 10.1242/jcs.197905; Gorlich D, 2003, EMBO J, V22, P1088, DOI 10.1093/emboj/cdg113; Ha S, 2017, ANTICANCER RES, V37, P2373, DOI 10.21873/anticanres.11575; Haschka MD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7891; He S, 2016, J CANCER RES CLIN, V142, P561, DOI 10.1007/s00432-015-2057-4; Hezwani M, 2017, SEMIN CELL DEV BIOL, V68, P2, DOI 10.1016/j.semcdb.2017.05.004; Jiang H, 2015, J CELL BIOL, V211, P7, DOI 10.1083/jcb.201503122; Joseph J, 2004, CURR BIOL, V14, P611, DOI 10.1016/j.cub.2004.03.031; Kimura M, 2017, ELIFE, V6, DOI 10.7554/eLife.21184; Kimura M, 2013, J BIOL CHEM, V288, P24540, DOI 10.1074/jbc.M113.489286; Koffa MD, 2006, CURR BIOL, V16, P743, DOI 10.1016/j.cub.2006.03.056; Kosyna FK, 2015, BIOL CHEM, V396, P1357, DOI 10.1515/hsz-2015-0171; Kuo TC, 2011, BIOCHEM PHARMACOL, V82, P184, DOI 10.1016/j.bcp.2011.04.008; Lavia P, 2016, CHROMOSOME RES, V24, P53, DOI 10.1007/s10577-015-9514-4; Lee MS, 2009, BBA-MOL CELL RES, V1793, P1571, DOI 10.1016/j.bbamcr.2009.07.005; Linder MI, 2017, DEV CELL, V43, P141, DOI 10.1016/j.devcel.2017.08.020; Lu T, 2016, BIOCHEM BIOPH RES CO, V478, P1189, DOI 10.1016/j.bbrc.2016.08.093; Martens-de Kemp SR, 2013, CLIN CANCER RES, V19, P1994, DOI 10.1158/1078-0432.CCR-12-2539; Ritterhoff T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11482; Rosa A, 2014, DEV BIOL, V391, P81, DOI 10.1016/j.ydbio.2014.03.020; Roscioli E, 2012, J CELL BIOL, V196, P435, DOI 10.1083/jcb.201109104; Santarella RA, 2007, J MOL BIOL, V365, P1587, DOI 10.1016/j.jmb.2006.10.064; Schmitz MHA, 2010, NAT CELL BIOL, V12, P886, DOI 10.1038/ncb2092; Sillje HHW, 2006, CURR BIOL, V16, P731, DOI 10.1016/j.cub.2006.02.070; Sloss O, 2016, ONCOTARGET, V7, P5176, DOI 10.18632/oncotarget.6894; Smith AE, 2002, SCIENCE, V295, P488, DOI 10.1126/science.1064732; Soderholm JF, 2011, ACS CHEM BIOL, V6, P700, DOI 10.1021/cb2000296; Song L, 2010, MOL CELL, V38, P369, DOI 10.1016/j.molcel.2010.02.038; Stelma T, 2016, IUBMB LIFE, V68, P268, DOI 10.1002/iub.1484; Tedeschi A, 2007, J CELL SCI, V120, P3748, DOI 10.1242/jcs.009308; Tsou AP, 2003, ONCOGENE, V22, P298, DOI 10.1038/sj.onc.1206129; van der Watt PJ, 2016, MOL CANCER THER, V15, P560, DOI 10.1158/1535-7163.MCT-15-0052; van der Watt PJ, 2013, CRIT REV EUKAR GENE, V23, P1; van der Watt PJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027723; Van der Watt PJ, 2009, INT J CANCER, V124, P1829, DOI 10.1002/ijc.24146; Wang CX, 2017, BIOCHEM BIOPH RES CO, V493, P1555, DOI 10.1016/j.bbrc.2017.10.016; Wong J, 2008, MOL BIOL CELL, V19, P2083, DOI 10.1091/mbc.E07-10-1088; Wong J, 2006, J CELL BIOL, V173, P879, DOI 10.1083/jcb.200511132; Wu JM, 2013, P NATL ACAD SCI USA, V110, pE1779, DOI 10.1073/pnas.1220523110; Yan WQ, 2015, CELL SIGNAL, V27, P851, DOI 10.1016/j.cellsig.2015.01.013; Yang J, 2019, ONCOGENE, V38, P4700, DOI 10.1038/s41388-019-0745-2; Yang LL, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0559-1; Yu CTR, 2005, MOL CELL BIOL, V25, P5789, DOI 10.1128/MCB.25.14.5789-5800.2005; Zhu J, 2016, TUMOR BIOL, V37, P661, DOI 10.1007/s13277-015-3839-7	54	3	4	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					454	468		10.1038/s41388-019-0989-x	http://dx.doi.org/10.1038/s41388-019-0989-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31492900				2022-12-17	WOS:000507766400015
J	Zhang, HW; Zhu, D; Zhang, ZB; Kaluz, S; Yu, B; Devi, NS; Olson, JJ; Van Meir, EG				Zhang, Hanwen; Zhu, Dan; Zhang, Zhaobin; Kaluz, Stefan; Yu, Bing; Devi, Narra S.; Olson, Jeffrey J.; Van Meir, Erwin G.			EZH2 targeting reduces medulloblastoma growth through epigenetic reactivation of the BAI1/p53 tumor suppressor pathway (vol 39, pg 1041, 2019)	ONCOGENE			English	Correction								An amendment to this paper has been published and can be accessed via a link at the top of the paper.	[Zhang, Hanwen; Zhu, Dan; Zhang, Zhaobin; Kaluz, Stefan; Yu, Bing; Devi, Narra S.; Olson, Jeffrey J.; Van Meir, Erwin G.] Emory Univ, Sch Med, Dept Neurosurg & Hematol & Med Oncol, Lab Mol Neurooncol, Atlanta, GA 30322 USA; [Zhang, Hanwen] Cent S Univ, Xiangya Hosp, Dept Neurosurg, Changsha 410013, Hunan, Peoples R China; [Zhang, Hanwen] Cent S Univ, Sch Med, Changsha 410013, Hunan, Peoples R China; [Olson, Jeffrey J.; Van Meir, Erwin G.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA; [Van Meir, Erwin G.] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA; [Van Meir, Erwin G.] UAB, Dept Neurosurg, WTI 520E,1720 2nd Ave, South Birmingham, AL 35294 USA; [Van Meir, Erwin G.] UAB, ONeal Comprehens Canc Ctr, WTI 520E,1720 2nd Ave, South Birmingham, AL 35294 USA	Emory University; Central South University; Central South University; Emory University; Emory University	Van Meir, EG (corresponding author), Emory Univ, Sch Med, Dept Neurosurg & Hematol & Med Oncol, Lab Mol Neurooncol, Atlanta, GA 30322 USA.; Van Meir, EG (corresponding author), Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.; Van Meir, EG (corresponding author), Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA.; Van Meir, EG (corresponding author), UAB, Dept Neurosurg, WTI 520E,1720 2nd Ave, South Birmingham, AL 35294 USA.; Van Meir, EG (corresponding author), UAB, ONeal Comprehens Canc Ctr, WTI 520E,1720 2nd Ave, South Birmingham, AL 35294 USA.	evanmeir@uab.edu	Zhang, Hanwen/AFK-2928-2022	Zhang, Hanwen/0000-0001-8955-7494; ZHU, DAN/0000-0003-2735-8996; Van Meir, Erwin G./0000-0003-2444-7707	NINDS NIH HHS [R01 NS096236] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Zhang HW, 2020, ONCOGENE, V39, P1041, DOI 10.1038/s41388-019-1036-7	1	3	3	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					1165	1165		10.1038/s41388-019-1067-0	http://dx.doi.org/10.1038/s41388-019-1067-0			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31676871	Bronze			2022-12-17	WOS:000511209700016
J	Hu, JM; Xia, XQ; Gorlick, R; Li, SL				Hu, Jiemiao; Xia, Xueqing; Gorlick, Richard; Li, Shulin			Induction of NKG2D ligand expression on tumor cells by CD8(+) T-cell engagement-mediated activation of nuclear factor-kappa B and p300/CBP-associated factor	ONCOGENE			English	Article							IFN-GAMMA; CARCINOMA CELLS; 4-1BB CD137; RECEPTOR; TRANSCRIPTION; MODULATION; CHEMOATTRACTANT; COSTIMULATION; CHEMOKINES; MECHANISM	The ligands for the natural killer group 2 (NKG2D) protein render tumor cells susceptible to NKG2D-dependent immune cell attack. However, cancer cells escape from immune surveillance by downregulating NKG2D ligands. We previously discovered that engagement of activated CD8(+) T cells and tumor cells induces NKG2D ligands on tumor cells, but the underlying mechanism remains to be defined. Both in vivo mouse tumor models and in vitro cell assays were performed to study the downstream signaling. Our results supported the notion that, upon engagement with the cognate receptors, CD137 ligand and CD40 initiates activation of nuclear factor-kappa B (NF-kappa B) signaling in tumor cells even in the absence of CD8(+) T cells. Like tumor and CD8(+) T cell contact-dependent NKG2D ligand induction, this CD137L/CD40-mediated signaling activation was associated with elevated levels of acetyltransferase P300/CBP-associated factor (PCAF), whereas inhibition of phosphorylated NF-kappa B abrogated PCAF induction. Although stimulation of CD137L/CD40-mediated signaling is vital, inflammatory cytokines, including interferon gamma (IFN gamma) and TNF alpha, also facilitate NKG2D ligand-induced immune surveillance via both facilitating T-cell chemotaxis and CD137L/CD40 induced NF-kappa B/PCAF activation. Collectively, our results unveil a novel mechanism of NKG2D ligand upregulation involving reverse signaling of CD40 and CD137L on tumor cells which, along with inflammatory cytokines IFN gamma and TNF alpha, stimulate downstream NF-kappa B and PCAF activation. Understanding this mechanism may help in development of induced NKG2D ligand-dependent T-cell therapy against cancers.	[Hu, Jiemiao; Xia, Xueqing; Gorlick, Richard; Li, Shulin] Univ Texas MD Anderson Canc Ctr, Div Pediat, Dept Pediat Res, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Li, SL (corresponding author), Univ Texas MD Anderson Canc Ctr, Div Pediat, Dept Pediat Res, Houston, TX 77030 USA.	Sli4@mdanderson.org	Li, Shulin/D-6478-2011		Cancer Center Support Grant [P30 CA016672]; NATIONAL CANCER INSTITUTE [R01CA120895, P30CA016672, R01CA200574] Funding Source: NIH RePORTER	Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The following Cancer Center Support Grant core resources were used: Genetically Engineered Mouse Facility and Monoclonal Antibody Core Facility with Cancer Center Support Grant P30 CA016672. The authors would like to thank Ms. Kathryn L Hale from the Department of Scientific Publications for editing the manuscript.	Altenburg A, 1999, J IMMUNOL, V162, P4140; Antonelli A, 2009, J CLIN ENDOCR METAB, V94, P1803, DOI 10.1210/jc.2008-2450; Arch RH, 1998, MOL CELL BIOL, V18, P558, DOI 10.1128/MCB.18.1.558; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Bartkowiak T, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00117; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Bui JD, 2006, J IMMUNOL, V176, P905, DOI 10.4049/jimmunol.176.2.905; Cannons JL, 2000, J IMMUNOL, V165, P6193, DOI 10.4049/jimmunol.165.11.6193; Carayannopoulos LN, 2002, J IMMUNOL, V169, P4079, DOI 10.4049/jimmunol.169.8.4079; Cerwenka A, 2000, IMMUNITY, V12, P721, DOI 10.1016/S1074-7613(00)80222-8; Cooke PW, 1999, J PATHOL, V188, P38; Elgueta R, 2009, IMMUNOL REV, V229, P152, DOI 10.1111/j.1600-065X.2009.00782.x; Gallagher NJ, 2002, J CLIN PATHOL-MOL PA, V55, P110, DOI 10.1136/mp.55.2.110; Gasser S, 2005, NATURE, V436, P1186, DOI 10.1038/nature03884; Gasser S, 2006, SEMIN CANCER BIOL, V16, P344, DOI 10.1016/j.semcancer.2006.07.004; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Han S, 2014, BRIT J CANCER, V110, P2560, DOI 10.1038/bjc.2014.162; Hauer J, 2005, P NATL ACAD SCI USA, V102, P2874, DOI 10.1073/pnas.0500187102; Held-Feindt J, 2002, INT J CANCER, V98, P352, DOI 10.1002/ijc.10207; Hu J, 2017, ENVIRON SCI POLLUT R, V24, P17090, DOI 10.1007/s11356-017-9057-7; Hu JM, 2017, CANCER IMMUNOL RES, V5, P300, DOI 10.1158/2326-6066.CIR-16-0234; Hu JB, 2017, DRUG DELIV, V24, P1856, DOI 10.1080/10717544.2017.1410258; Jung H, 2012, J EXP MED, V209, P2409, DOI 10.1084/jem.20120565; Kelly JM, 2002, NAT IMMUNOL, V3, P83, DOI 10.1038/ni746; Kim HH, 2000, MOL CELLS, V10, P247; Lanier LL, 2015, CANCER IMMUNOL RES, V3, P575, DOI 10.1158/2326-6066.CIR-15-0098; Lee DS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058748; Lin D, 2012, J BIOL CHEM, V287, P4299, DOI 10.1074/jbc.M111.282152; Martinez-Forero I, 2013, J IMMUNOL, V190, P6694, DOI 10.4049/jimmunol.1203010; Mohan K, 2002, J IMMUNOL, V168, P6420, DOI 10.4049/jimmunol.168.12.6420; Molinero LL, 2004, J IMMUNOL, V173, P5583, DOI 10.4049/jimmunol.173.9.5583; Moser B, 1998, Int Rev Immunol, V16, P323, DOI 10.3109/08830189809043000; Murdoch C, 2000, BLOOD, V95, P3032; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Sabbagh L, 2008, J IMMUNOL, V180, P8093, DOI 10.4049/jimmunol.180.12.8093; Salih HR, 2000, J IMMUNOL, V165, P2903, DOI 10.4049/jimmunol.165.5.2903; Saoulli K, 1998, J EXP MED, V187, P1849, DOI 10.1084/jem.187.11.1849; Sauer M, 2017, ONCOGENE, V36, P933, DOI 10.1038/onc.2016.259; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Tirapu I, 2006, CANCER RES, V66, P2442, DOI 10.1158/0008-5472.CAN-05-1681; Trebing J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.555; Werbajh S, 2000, FEBS LETT, V485, P195, DOI 10.1016/S0014-5793(00)02223-7; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhu S, 2007, CLIN CANCER RES, V13, P4252, DOI 10.1158/1078-0432.CCR-06-2894	47	3	3	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2019	38	49					7433	7446		10.1038/s41388-019-0960-x	http://dx.doi.org/10.1038/s41388-019-0960-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JT4BN	31427736	Green Accepted			2022-12-17	WOS:000500936600005
J	Li, DK; Tian, Y; Hu, Y; Qi, YJ; Tian, NY; Li, SS; Hu, PS; Wu, F; Wei, QF; Wei, ZZ; Wang, SS; Yin, B; Jiang, T; Yuan, JG; Qiang, BQ; Han, W; Peng, XZ				Li, Dengke; Tian, Yuan; Hu, Yan; Qi, Yingjiao; Tian, Ningyu; Li, Shanshan; Hu, Peishan; Wu, Fan; Wei, Qunfang; Wei, Zhizhong; Wang, Shanshan; Yin, Bin; Jiang, Tao; Yuan, Jiangang; Qiang, Boqin; Han, Wei; Peng, Xiaozhong			Glioma-associated human endothelial cell-derived extracellular vesicles specifically promote the tumourigenicity of glioma stem cells via CD9 (vol 38, pg 6898, 2019)	ONCOGENE			English	Correction									[Li, Dengke; Tian, Yuan; Hu, Yan; Qi, Yingjiao; Tian, Ningyu; Li, Shanshan; Hu, Peishan; Wu, Fan; Wei, Qunfang; Wei, Zhizhong; Wang, Shanshan; Yin, Bin; Yuan, Jiangang; Qiang, Boqin; Han, Wei; Peng, Xiaozhong] Chinese Acad Med Sci, Sch Basic Med,Peking Union Med Coll, State Key Lab Med Mol Biol,Dept Mol Biol & Bioche, Inst Basic Med Sci,Med Primate Res Ctr,Neurosci C, Beijing, Peoples R China; [Wu, Fan; Jiang, Tao] Capital Med Univ, Beijing Neurosurg Inst, Dept Mol Neuropathol, Beijing, Peoples R China; [Wei, Zhizhong; Peng, Xiaozhong] Chinese Acad Med Sci, Peking Union Med Coll, Inst Med Biol, Kunming, Yunnan, Peoples R China; [Jiang, Tao] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Beijing Neurosurgical Institute; Capital Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Medical Biology - CAMS; Peking Union Medical College; Capital Medical University	Han, W; Peng, XZ (corresponding author), Chinese Acad Med Sci, Sch Basic Med,Peking Union Med Coll, State Key Lab Med Mol Biol,Dept Mol Biol & Bioche, Inst Basic Med Sci,Med Primate Res Ctr,Neurosci C, Beijing, Peoples R China.; Peng, XZ (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll, Inst Med Biol, Kunming, Yunnan, Peoples R China.	hanwei2012@ibms.pumc.edu.cn; pengxiaozhong@pumc.edu.cn	jiang, tao/GWC-7108-2022					Li DK, 2019, ONCOGENE, V38, P6898, DOI 10.1038/s41388-019-0903-6	1	3	3	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2019	38	43					6958	6958		10.1038/s41388-019-1018-9	http://dx.doi.org/10.1038/s41388-019-1018-9			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JH4GX	31537903	Bronze			2022-12-17	WOS:000492728000006
J	Gowrikumar, S; Ahmad, R; Uppada, SB; Washington, MK; Shi, CJ; Singh, AB; Dhawan, P				Gowrikumar, Saiprasad; Ahmad, Rizwan; Uppada, Srijayaprakash Babu; Washington, Mary K.; Shi, Chanjuan; Singh, Amar B.; Dhawan, Punita			Upregulated claudin-1 expression promotes colitis-associated cancer by promoting beta-catenin phosphorylation and activation in Notch/p-AKT-dependent manner (vol 38, pg 5337, 2019)	ONCOGENE			English	Correction									[Gowrikumar, Saiprasad; Ahmad, Rizwan; Uppada, Srijayaprakash Babu; Singh, Amar B.; Dhawan, Punita] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Washington, Mary K.; Shi, Chanjuan] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; [Singh, Amar B.; Dhawan, Punita] VA Nebraska Western Iowa Hlth Care Syst, Omaha, NE 68105 USA; [Singh, Amar B.; Dhawan, Punita] Univ Nebraska Med Ctr, Buffet Canc Ctr, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System; University of Nebraska System; University of Nebraska Medical Center	Dhawan, P (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.; Dhawan, P (corresponding author), VA Nebraska Western Iowa Hlth Care Syst, Omaha, NE 68105 USA.; Dhawan, P (corresponding author), Univ Nebraska Med Ctr, Buffet Canc Ctr, Omaha, NE 68198 USA.	punita.dhawan@unmc.edu	Uppada, Srijayaprakash/AAD-7728-2021					Gowrikumar S, 2019, ONCOGENE, V38, P5321, DOI 10.1038/s41388-019-0795-5	1	3	3	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2019	38	38					6566	6566		10.1038/s41388-019-0864-9	http://dx.doi.org/10.1038/s41388-019-0864-9			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IY7XR	31417178	Bronze			2022-12-17	WOS:000486609000007
J	Guo, Y; Zhang, XJ; Xu, QB; Gong, FX; Shi, XQ; Li, CK; Huang, R; Nie, FY; Zhu, W; Li, JJ; Tang, JB; Li, RT; Zhang, LM; Chen, LX; Ma, RLZ				Guo, Yu; Zhang, Xiaojuan; Xu, Quanbin; Gong, Fuxing; Shi, Xiaoqian; Li, Chaokun; Huang, Rui; Nie, Fangyuan; Zhu, Wen; Li, Jiujie; Tang, Junbo; Li, Runting; Zhang, Limeng; Chen, Longxin; Ma, Runlin Z.			Human Papillomavirus 16 oncoprotein E7 retards mitotic progression by blocking Mps1-MAP4 signaling cascade	ONCOGENE			English	Article							MICROTUBULES; MAP4; MPS1; NEOPLASIA; TUBULIN; EXPRESSION; STABILITY; INFECTION; CELLS	Human epithelial cells can be infected by more than 200 types of human papilloma viruses (HPVs), and persistent HPV infections lead to cervical cancer or other deadly cancers. It has been established that mitotic progression is critical for HPV16 infection, but the underlying mechanism remains unknown. Here, we report that oncoprotein E7 of HPV16 but not HPV18 retards mitotic progression in host cell by direct binding to the C terminus of Microtubule-Associated Protein 4 (MAP4). MAP4 is a novel bona fide target of HPV16E7 protein which binds and recruits the latter to spindle microtubule in mitosis. HPV16E7 protein promotes MAP4 stability by inhibiting MAP4 phosphorylation- mediated degradation to increase the stability of microtubule polymerization and cause an extend mitotic progression. We further uncovered that Mps1 is a kinase of MAP4, and E7MAP4 binding blocks Mps1 phosphorylation of MAP4, thereby interrupting phosphorylation-dependent MAP4 degradation. Mutations of MAP4 at T927ES928E partially abolished E7-binding capacity and rescued mitotic progression in host cells. In conclusion, our study reveals a molecular mechanism by which HPV16E7 perturbs host mitotic progression by interfering Mps1MAP4 signaling cascade, which results in an extended infection window and may facilitate the persistent HPV16 infection.	[Guo, Yu; Gong, Fuxing; Shi, Xiaoqian; Li, Chaokun; Huang, Rui; Nie, Fangyuan; Zhu, Wen; Li, Jiujie; Ma, Runlin Z.] Univ Chinese Acad Sci, Sch Life Sci, Beijing 100049, Peoples R China; [Guo, Yu; Zhang, Xiaojuan; Gong, Fuxing; Shi, Xiaoqian; Li, Chaokun; Huang, Rui; Nie, Fangyuan; Ma, Runlin Z.] Chinese Acad Sci, Inst Genet & Dev Biol, State Key Lab Mol Dev Biol, Beijing 100101, Peoples R China; [Xu, Quanbin] Univ Colorado, Dept Biochem, Boulder, CO 80309 USA; [Tang, Junbo] China Agr Univ, Coll Food Sci & Nutr Engn, Beijing 100083, Peoples R China; [Li, Runting; Zhang, Limeng; Chen, Longxin; Ma, Runlin Z.] Zhengzhou Normal Univ, Zhengzhou City Key Lab Mol Biol, Zhengzhou 450044, Henan, Peoples R China	Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; Institute of Genetics & Developmental Biology, CAS; University of Colorado System; University of Colorado Boulder; China Agricultural University; Zhengzhou Normal University	Ma, RLZ (corresponding author), Univ Chinese Acad Sci, Sch Life Sci, Beijing 100049, Peoples R China.; Ma, RLZ (corresponding author), Chinese Acad Sci, Inst Genet & Dev Biol, State Key Lab Mol Dev Biol, Beijing 100101, Peoples R China.; Ma, RLZ (corresponding author), Zhengzhou Normal Univ, Zhengzhou City Key Lab Mol Biol, Zhengzhou 450044, Henan, Peoples R China.	rlma@genetics.ac.cn	gong, fuxing/GXF-5949-2022; Chen, Longxin/HGD-3900-2022	Li, Chaokun/0000-0001-9037-488X; Xu, Quanbin/0000-0002-2833-9773	National Basic Research Program of China [2014CB138505]; National Natural Science Foundation of China [81871130]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported in part by grants from National Basic Research Program of China (2014CB138505) and National Natural Science Foundation of China (81871130).	Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; Bosch FX, 2002, VIRUS RES, V89, P183, DOI 10.1016/S0168-1702(02)00187-9; Burger MPM, 1997, INT J GYNECOL PATHOL, V16, P10, DOI 10.1097/00004347-199701000-00002; DiGiuseppe S, 2016, P NATL ACAD SCI USA, V113, P6289, DOI 10.1073/pnas.1600638113; Dou Z, 2003, CELL RES, V13, P443, DOI 10.1038/sj.cr.7290186; Frisch M, 1999, LANCET, V354, P1442, DOI 10.1016/S0140-6736(99)92824-6; Gallo DE, 2012, VIROLOGY, V422, P13, DOI 10.1016/j.virol.2011.09.015; Hiruma Y, 2015, SCIENCE, V348, P1264, DOI 10.1126/science.aaa4055; Holmfeldt P, 2003, J CELL SCI, V116, P3701, DOI 10.1242/jcs.00685; Holmfeldt P, 2002, CURR BIOL, V12, P1034, DOI 10.1016/S0960-9822(02)00897-7; Jiang YY, 2016, ONCOGENE, V35, P4846, DOI 10.1038/onc.2016.17; Koshiol J, 2008, AM J EPIDEMIOL, V168, P123, DOI 10.1093/aje/kwn036; Kremer BE, 2005, MOL BIOL CELL, V16, P4648, DOI 10.1091/mbc.E05-03-0267; LAUZE E, 1995, EMBO J, V14, P1655, DOI 10.1002/j.1460-2075.1995.tb07154.x; Maciejowski J, 2017, DEV CELL, V41, P143, DOI 10.1016/j.devcel.2017.03.025; MANDELKOW E, 1995, CURR OPIN CELL BIOL, V7, P72, DOI 10.1016/0955-0674(95)80047-6; Espinosa AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055975; Marur S, 2010, LANCET ONCOL, V11, P781, DOI 10.1016/S1470-2045(10)70017-6; Mirabello L, 2017, CELL, V170, P1164, DOI 10.1016/j.cell.2017.08.001; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Ou Y, 2014, UROL ONCOL, V32, P21; PIPERNO G, 1987, J CELL BIOL, V104, P289, DOI 10.1083/jcb.104.2.289; Pyeon D, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000318; Shaw R, 2011, BRIT J ORAL MAX SURG, V49, P423, DOI 10.1016/j.bjoms.2010.06.023; STEINMANN KE, 1994, ONCOGENE, V9, P387; Takahashi M, 2003, AM J PHYSIOL-HEART C, V285, pH2072, DOI 10.1152/ajpheart.00396.2003; Thomas LK, 2014, EUR J CANCER, V50, P85, DOI 10.1016/j.ejca.2013.08.022; WEST RR, 1991, J BIOL CHEM, V266, P21886; Bosch FX, 2008, VACCINE, V26, pK1, DOI 10.1016/j.vaccine.2008.05.064; Xu QB, 2009, MOL BIOL CELL, V20, P10, DOI 10.1091/mbc.E08-03-0324; Zahnleiter D, 2015, HUM MUTAT, V36, P87, DOI 10.1002/humu.22711	32	3	5	4	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2019	38	31					5959	5970		10.1038/s41388-019-0851-1	http://dx.doi.org/10.1038/s41388-019-0851-1			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IT3GE	31253867				2022-12-17	WOS:000482740000004
J	Jeong, KJ; Park, SY; Cho, KH; Sohn, JS; Lee, J; Kim, YK; Kang, J; Park, CG; Han, JW; Lee, HY				Jeong, K. J.; Park, S. Y.; Cho, K. H.; Sohn, J. S.; Lee, J.; Kim, Y. K.; Kang, J.; Park, C. G.; Han, J. W.; Lee, H. Y.			The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion (vol 31, pg 4279, 2012)	ONCOGENE			English	Correction									[Jeong, K. J.; Park, S. Y.; Cho, K. H.; Kang, J.; Park, C. G.; Lee, H. Y.] Konyang Univ, Coll Med, Myunggok Med Res Inst, Dept Pharmacol, Daejeon, South Korea; [Sohn, J. S.] Konyang Univ, Coll Med, Myunggok Med Res Inst, Dept Pathol, Daejeon, South Korea; [Lee, J.] Konyang Univ, Coll Med, Myunggok Med Res Inst, Dept Microbiol, Daejeon, South Korea; [Kim, Y. K.] Sookmyung Womens Univ, Coll Pharm, Dept Pharmacol, Seoul, South Korea; [Han, J. W.] Sungkyunkwan Univ, Sch Pharm, Dept Biochem & Mol Biol, Suwon, South Korea	Konyang University; Konyang University Hospital; Konyang University; Konyang University Hospital; Konyang University; Konyang University Hospital; Sookmyung Women's University; Sungkyunkwan University (SKKU)	Lee, HY (corresponding author), Konyang Univ, Coll Med, Myunggok Med Res Inst, Dept Pharmacol, Daejeon, South Korea.	hoi@konyang.ac.kr	Jeong, Kangjin/HGT-9268-2022					Jeong KJ, 2012, ONCOGENE, V31, P4279, DOI 10.1038/onc.2011.595	1	3	3	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					5108	5110		10.1038/s41388-019-0769-7	http://dx.doi.org/10.1038/s41388-019-0769-7			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30926886	Bronze			2022-12-17	WOS:000472145900017
